{"generated":"2026-09-28T07:13:49.830Z","today":"2026-09-28","total":19147,"findings":[{"check":"future-year","severity":"high","id":"mountaineer-03","kind":"trial","name":"MOUNTAINEER-03","route":"/trials/mountaineer-03/","detail":"yearReported 2027 is in the future"},{"check":"soc-cites-dead","severity":"high","id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","detail":"standard-of-care row \"Treating less than the whole breast\" cites NSABP B-39/RTOG 0413 (status negative) without saying so in the text; explain the negative result or drop the reference"},{"check":"soc-cites-dead","severity":"high","id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","detail":"standard-of-care row \"Radiotherapy after mastectomy, and to the nodes\" cites NSABP B-51 / RTOG 1304 (status negative) without saying so in the text; explain the negative result or drop the reference"},{"check":"soc-cites-dead","severity":"high","id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","detail":"standard-of-care row \"Stage III colon cancer, mismatch-repair proficient\" cites Alliance N0147 (status negative) without saying so in the text; explain the negative result or drop the reference"},{"check":"soc-cites-dead","severity":"high","id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","detail":"standard-of-care row \"Peritoneal metastases\" cites PROPHYLOCHIP-PRODIGE 15 (status negative) without saying so in the text; explain the negative result or drop the reference"},{"check":"soc-cites-dead","severity":"high","id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","detail":"standard-of-care row \"The failed and stopped programmes\" cites Alliance N0147 (status negative) without saying so in the text; explain the negative result or drop the reference"},{"check":"soc-cites-dead","severity":"high","id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","detail":"standard-of-care row \"The failed and stopped programmes\" cites PROPHYLOCHIP-PRODIGE 15 (status negative) without saying so in the text; explain the negative result or drop the reference"},{"check":"soc-cites-dead","severity":"high","id":"corticotroph-pitnet","kind":"cancer","name":"Corticotroph pituitary neuroendocrine tumour (Cushing disease and silent corticotroph tumour)","route":"/cancers/corticotroph-pitnet/","detail":"standard-of-care row \"Persistent or recurrent\" cites Mifepristone (status negative) without saying so in the text; explain the negative result or drop the reference"},{"check":"soc-cites-dead","severity":"high","id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/","detail":"standard-of-care row \"Brain\" cites Takahashi trial: prophylactic cranial irradiation with MRI surveillance in extensive-stage small-cell lung cancer (status negative) without saying so in the text; explain the negative result or drop the reference"},{"check":"soc-cites-dead","severity":"high","id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","detail":"standard-of-care row \"Extensive-stage small-cell lung cancer, first line\" cites Takahashi trial: prophylactic cranial irradiation with MRI surveillance in extensive-stage small-cell lung cancer (status negative) without saying so in the text; explain the negative result or drop the reference"},{"check":"soc-cites-dead","severity":"high","id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","detail":"standard-of-care row \"Relapsed small-cell lung cancer\" cites ATLANTIS (status negative) without saying so in the text; explain the negative result or drop the reference"},{"check":"soc-cites-dead","severity":"high","id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","detail":"standard-of-care row \"The failed or stopped programmes\" cites AMPLIFY-7P (status negative) without saying so in the text; explain the negative result or drop the reference"},{"check":"soc-cites-dead","severity":"high","id":"gist-pdgfra-d842v","kind":"cancer","name":"PDGFRA D842V-mutant GIST","route":"/cancers/gist-pdgfra-d842v/","detail":"standard-of-care row \"Progression on avapritinib\" cites VOYAGER (status negative) without saying so in the text; explain the negative result or drop the reference"},{"check":"soc-cites-dead","severity":"high","id":"poorly-differentiated-chordoma","kind":"cancer","name":"Poorly differentiated chordoma (SMARCB1-deficient)","route":"/cancers/poorly-differentiated-chordoma/","detail":"standard-of-care row \"All cases\" cites Tazemetostat (status withdrawn) without saying so in the text; explain the negative result or drop the reference"},{"check":"soc-cites-dead","severity":"high","id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","detail":"standard-of-care row \"Screening\" cites PLCO, prostate component (Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial) (status negative) without saying so in the text; explain the negative result or drop the reference"},{"check":"soc-cites-dead","severity":"high","id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","detail":"standard-of-care row \"Hormone-relapsed (castration-resistant) metastatic prostate cancer: the order the approved treatments are given in\" cites FIRSTANA (status negative) without saying so in the text; explain the negative result or drop the reference"},{"check":"soc-cites-dead","severity":"high","id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","detail":"standard-of-care row \"Combinations and strategies that were tested and abandoned\" cites READY (status negative) without saying so in the text; explain the negative result or drop the reference"},{"check":"soc-cites-dead","severity":"high","id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","detail":"standard-of-care row \"Residual disease after chemotherapy: capecitabine or olaparib\" cites ECOG-ACRIN EA1131 (status negative) without saying so in the text; explain the negative result or drop the reference"},{"check":"soc-cites-dead","severity":"high","id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","detail":"standard-of-care row \"Residual disease after chemotherapy: capecitabine or olaparib\" cites BRE12-158 (Hoosier Oncology Group) (status negative) without saying so in the text; explain the negative result or drop the reference"},{"check":"approvals-vs-regional","severity":"medium","id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","detail":"EU first approval year 2019 in approvals but 2017 in regional-approvals.ts"},{"check":"approvals-vs-regional","severity":"medium","id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","detail":"UK first approval year 2020 in approvals but 2017 in regional-approvals.ts"},{"check":"approvals-vs-regional","severity":"medium","id":"catumaxomab","kind":"drug","name":"Catumaxomab","route":"/drugs/catumaxomab/","detail":"EU first approval year 2009 in approvals but 2025 in regional-approvals.ts"},{"check":"approvals-vs-regional","severity":"medium","id":"denosumab","kind":"drug","name":"Denosumab","route":"/drugs/denosumab/","detail":"EU first approval year 2011 in approvals but 2010 in regional-approvals.ts"},{"check":"approvals-vs-regional","severity":"medium","id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","detail":"UK first approval year 2024 in approvals but 2018 in regional-approvals.ts"},{"check":"approvals-vs-regional","severity":"medium","id":"erlotinib","kind":"drug","name":"Erlotinib","route":"/drugs/erlotinib/","detail":"EU first approval year 2007 in approvals but 2005 in regional-approvals.ts"},{"check":"approvals-vs-regional","severity":"medium","id":"futibatinib","kind":"drug","name":"Futibatinib","route":"/drugs/futibatinib/","detail":"UK first approval year 2024 in approvals but 2023 in regional-approvals.ts"},{"check":"approvals-vs-regional","severity":"medium","id":"ivosidenib","kind":"drug","name":"Ivosidenib","route":"/drugs/ivosidenib/","detail":"UK first approval year 2024 in approvals but 2023 in regional-approvals.ts"},{"check":"approvals-vs-regional","severity":"medium","id":"larotrectinib","kind":"drug","name":"Larotrectinib","route":"/drugs/larotrectinib/","detail":"UK first approval year 2020 in approvals but 2019 in regional-approvals.ts"},{"check":"approvals-vs-regional","severity":"medium","id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","detail":"EU first approval year 2019 in approvals but 2014 in regional-approvals.ts"},{"check":"approvals-vs-regional","severity":"medium","id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","detail":"UK first approval year 2023 in approvals but 2014 in regional-approvals.ts"},{"check":"approvals-vs-regional","severity":"medium","id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","detail":"EU first approval year 2021 in approvals but 2015 in regional-approvals.ts"},{"check":"approvals-vs-regional","severity":"medium","id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","detail":"UK first approval year 2022 in approvals but 2015 in regional-approvals.ts"},{"check":"approvals-vs-regional","severity":"medium","id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/","detail":"UK first approval year 2022 in approvals but 2021 in regional-approvals.ts"},{"check":"approvals-vs-regional","severity":"medium","id":"talazoparib","kind":"drug","name":"Talazoparib","route":"/drugs/talazoparib/","detail":"UK first approval year 2024 in approvals but 2019 in regional-approvals.ts"},{"check":"approvals-vs-regional","severity":"medium","id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","detail":"EU first approval year 2023 in approvals but 2021 in regional-approvals.ts"},{"check":"approvals-vs-regional","severity":"medium","id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","detail":"UK first approval year 2024 in approvals but 2021 in regional-approvals.ts"},{"check":"asof-before-regulatory-event","severity":"medium","id":"galleri","kind":"drug","name":"Galleri","route":"/drugs/galleri/","detail":"asOf 2026-09-04 predates the advisory-committee dated 2026-09-23 (US): FDA Molecular and Clinical Genetics Panel meeting"},{"check":"asof-before-regulatory-event","severity":"medium","id":"sevabertinib","kind":"drug","name":"Sevabertinib","route":"/drugs/sevabertinib/","detail":"asOf 2026-09-06 predates the accelerated-approval dated 2026-09-09 (US): FDA grants accelerated approval to sevabertinib for locally advanced or metastat"},{"check":"duplicate-name","severity":"medium","id":"1p19q-codeletion","kind":"term","name":"1p/19q codeletion","route":"/terms/1p19q-codeletion/","detail":"same normalised name as 1p19q-codeletion-readout (biomarker)"},{"check":"duplicate-name","severity":"medium","id":"1p19q-codeletion-readout","kind":"biomarker","name":"1p/19q codeletion","route":"/biomarkers/1p19q-codeletion-readout/","detail":"same normalised name as 1p19q-codeletion (term)"},{"check":"duplicate-name","severity":"medium","id":"nct06223841","kind":"trial","name":"A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors","route":"/trials/nct06223841/","detail":"same normalised name as nct06581419 (trial)"},{"check":"duplicate-name","severity":"medium","id":"nct06581419","kind":"trial","name":"A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors","route":"/trials/nct06581419/","detail":"same normalised name as nct06223841 (trial)"},{"check":"duplicate-name","severity":"medium","id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/","detail":"same normalised name as aml-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"aml-signalling","kind":"pathway","name":"Acute myeloid leukaemia (KEGG map)","route":"/pathways/aml-signalling/","detail":"same normalised name as aml (cancer)"},{"check":"duplicate-name","severity":"medium","id":"nct07744256","kind":"trial","name":"Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)","route":"/trials/nct07744256/","detail":"same normalised name as nct07480213 (trial)"},{"check":"duplicate-name","severity":"medium","id":"nct07480213","kind":"trial","name":"Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)","route":"/trials/nct07480213/","detail":"same normalised name as nct07744256 (trial)"},{"check":"duplicate-name","severity":"medium","id":"paper-gatenby-cancer-res","kind":"paper","name":"Adaptive therapy","route":"/key-papers/paper-gatenby-cancer-res/","detail":"same normalised name as adaptive-therapy-dynamics (technology)"},{"check":"duplicate-name","severity":"medium","id":"adaptive-therapy-dynamics","kind":"technology","name":"Adaptive therapy (evolution-based dosing)","route":"/technologies/adaptive-therapy-dynamics/","detail":"same normalised name as paper-gatenby-cancer-res (paper)"},{"check":"duplicate-name","severity":"medium","id":"nct00576914","kind":"trial","name":"Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer","route":"/trials/nct00576914/","detail":"same normalised name as nct01124253 (trial)"},{"check":"duplicate-name","severity":"medium","id":"nct01124253","kind":"trial","name":"Adjuvant Vinorelbine Plus Cisplatin(NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer(NSCLC)","route":"/trials/nct01124253/","detail":"same normalised name as nct00576914 (trial)"},{"check":"duplicate-name","severity":"medium","id":"alsf","kind":"institution","name":"Alex's Lemonade Stand Foundation","route":"/institutions/alsf/","detail":"same normalised name as alexs-lemonade-stand (collection)"},{"check":"duplicate-name","severity":"medium","id":"alexs-lemonade-stand","kind":"collection","name":"Alex's Lemonade Stand Foundation (ALSF)","route":"/collections/alexs-lemonade-stand/","detail":"same normalised name as alsf (institution)"},{"check":"duplicate-name","severity":"medium","id":"angiosarcoma","kind":"cancer","name":"Angiosarcoma","route":"/cancers/angiosarcoma/","detail":"same normalised name as paper-young-angiosarcoma-review-lancet-oncol-2010 (paper)"},{"check":"duplicate-name","severity":"medium","id":"paper-young-angiosarcoma-review-lancet-oncol-2010","kind":"paper","name":"Angiosarcoma (review)","route":"/key-papers/paper-young-angiosarcoma-review-lancet-oncol-2010/","detail":"same normalised name as angiosarcoma (cancer)"},{"check":"duplicate-name","severity":"medium","id":"ar-v7","kind":"term","name":"AR-V7 splice variant","route":"/terms/ar-v7/","detail":"same normalised name as ar-v7-splice-variant (biomarker)"},{"check":"duplicate-name","severity":"medium","id":"ar-v7-splice-variant","kind":"biomarker","name":"AR-V7 splice variant","route":"/biomarkers/ar-v7-splice-variant/","detail":"same normalised name as ar-v7 (term)"},{"check":"duplicate-name","severity":"medium","id":"autologous-transplant","kind":"term","name":"Autologous stem cell transplant (ASCT)","route":"/terms/autologous-transplant/","detail":"same normalised name as autologous-stem-cell-transplant (technology)"},{"check":"duplicate-name","severity":"medium","id":"autologous-stem-cell-transplant","kind":"technology","name":"Autologous stem cell transplant (high-dose therapy)","route":"/technologies/autologous-stem-cell-transplant/","detail":"same normalised name as autologous-transplant (term)"},{"check":"duplicate-name","severity":"medium","id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","detail":"same normalised name as basal-cell-carcinoma-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"basal-cell-carcinoma-signalling","kind":"pathway","name":"Basal cell carcinoma (KEGG map)","route":"/pathways/basal-cell-carcinoma-signalling/","detail":"same normalised name as basal-cell-carcinoma (cancer)"},{"check":"duplicate-name","severity":"medium","id":"bcr-abl","kind":"target","name":"BCR::ABL1 (Philadelphia chromosome)","route":"/targets/bcr-abl/","detail":"same normalised name as bcr-abl1-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"bcr-abl1-signalling","kind":"pathway","name":"BCR::ABL1 (Philadelphia chromosome)","route":"/pathways/bcr-abl1-signalling/","detail":"same normalised name as bcr-abl (target)"},{"check":"duplicate-name","severity":"medium","id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/","detail":"same normalised name as bevacizumab-glioma (drug)"},{"check":"duplicate-name","severity":"medium","id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/","detail":"same normalised name as bevacizumab (drug)"},{"check":"duplicate-name","severity":"medium","id":"biliary-tract-cancer","kind":"cancer","name":"Biliary tract cancer (all types)","route":"/cancers/biliary-tract-cancer/","detail":"same normalised name as cholangiocarcinoma (cancer)"},{"check":"duplicate-name","severity":"medium","id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/","detail":"same normalised name as biliary-tract-cancer (cancer)"},{"check":"duplicate-name","severity":"medium","id":"brachytherapy","kind":"technology","name":"Brachytherapy","route":"/technologies/brachytherapy/","detail":"same normalised name as brachytherapy-term (term)"},{"check":"duplicate-name","severity":"medium","id":"brachytherapy-term","kind":"term","name":"Brachytherapy (internal radiotherapy)","route":"/terms/brachytherapy-term/","detail":"same normalised name as brachytherapy (technology)"},{"check":"duplicate-name","severity":"medium","id":"paper-achrol-nat-rev-dis-primers","kind":"paper","name":"Brain metastases","route":"/key-papers/paper-achrol-nat-rev-dis-primers/","detail":"same normalised name as brain-metastases (term), secondary-brain-tumours (cancer)"},{"check":"duplicate-name","severity":"medium","id":"brain-metastases","kind":"term","name":"Brain metastases (intracranial disease)","route":"/terms/brain-metastases/","detail":"same normalised name as paper-achrol-nat-rev-dis-primers (paper), secondary-brain-tumours (cancer)"},{"check":"duplicate-name","severity":"medium","id":"secondary-brain-tumours","kind":"cancer","name":"Brain metastases (secondary brain tumours)","route":"/cancers/secondary-brain-tumours/","detail":"same normalised name as paper-achrol-nat-rev-dis-primers (paper), brain-metastases (term)"},{"check":"duplicate-name","severity":"medium","id":"paper-harbeck-nat-rev-dis-primers","kind":"paper","name":"Breast cancer","route":"/key-papers/paper-harbeck-nat-rev-dis-primers/","detail":"same normalised name as breast-cancer-signalling (pathway), breast-cancer-jbcs (journal), breast-cancer (cancer)"},{"check":"duplicate-name","severity":"medium","id":"breast-cancer-jbcs","kind":"journal","name":"Breast cancer","route":"/journals/breast-cancer-jbcs/","detail":"same normalised name as paper-harbeck-nat-rev-dis-primers (paper), breast-cancer-signalling (pathway), breast-cancer (cancer)"},{"check":"duplicate-name","severity":"medium","id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","detail":"same normalised name as paper-harbeck-nat-rev-dis-primers (paper), breast-cancer-signalling (pathway), breast-cancer-jbcs (journal)"},{"check":"duplicate-name","severity":"medium","id":"breast-cancer-signalling","kind":"pathway","name":"Breast cancer (KEGG map)","route":"/pathways/breast-cancer-signalling/","detail":"same normalised name as paper-harbeck-nat-rev-dis-primers (paper), breast-cancer-jbcs (journal), breast-cancer (cancer)"},{"check":"duplicate-name","severity":"medium","id":"src-bcrf","kind":"collection","name":"Breast Cancer Research Foundation","route":"/collections/src-bcrf/","detail":"same normalised name as bcrf (institution)"},{"check":"duplicate-name","severity":"medium","id":"bcrf","kind":"institution","name":"Breast Cancer Research Foundation","route":"/institutions/bcrf/","detail":"same normalised name as src-bcrf (collection)"},{"check":"duplicate-name","severity":"medium","id":"cachexia-biology","kind":"pathway","name":"Cancer cachexia","route":"/pathways/cachexia-biology/","detail":"same normalised name as cachexia (term)"},{"check":"duplicate-name","severity":"medium","id":"cachexia","kind":"term","name":"Cancer cachexia","route":"/terms/cachexia/","detail":"same normalised name as cachexia-biology (pathway)"},{"check":"duplicate-name","severity":"medium","id":"carers-gallbladder-cancer-uk","kind":"term","name":"Carers: what you can do and UK carer support","route":"/terms/carers-gallbladder-cancer-uk/","detail":"same normalised name as carers-pancreatic-cancer-uk (term), carers-breast-cancer-uk (term), carers-bowel-cancer-uk (term)"},{"check":"duplicate-name","severity":"medium","id":"carers-bowel-cancer-uk","kind":"term","name":"Carers: what you can do and UK carer support (bowel cancer)","route":"/terms/carers-bowel-cancer-uk/","detail":"same normalised name as carers-pancreatic-cancer-uk (term), carers-breast-cancer-uk (term), carers-gallbladder-cancer-uk (term)"},{"check":"duplicate-name","severity":"medium","id":"carers-breast-cancer-uk","kind":"term","name":"Carers: what you can do and UK carer support (breast cancer)","route":"/terms/carers-breast-cancer-uk/","detail":"same normalised name as carers-pancreatic-cancer-uk (term), carers-bowel-cancer-uk (term), carers-gallbladder-cancer-uk (term)"},{"check":"duplicate-name","severity":"medium","id":"carers-pancreatic-cancer-uk","kind":"term","name":"Carers: what you can do and UK carer support (pancreatic cancer)","route":"/terms/carers-pancreatic-cancer-uk/","detail":"same normalised name as carers-breast-cancer-uk (term), carers-bowel-cancer-uk (term), carers-gallbladder-cancer-uk (term)"},{"check":"duplicate-name","severity":"medium","id":"cell","kind":"journal","name":"Cell","route":"/journals/cell/","detail":"same normalised name as cell-term (term)"},{"check":"duplicate-name","severity":"medium","id":"cell-term","kind":"term","name":"Cell","route":"/terms/cell-term/","detail":"same normalised name as cell (journal)"},{"check":"duplicate-name","severity":"medium","id":"chemotherapy","kind":"section","name":"Chemotherapy","route":"/fronts/chemotherapy/","detail":"same normalised name as chemotherapy-term (term)"},{"check":"duplicate-name","severity":"medium","id":"chemotherapy-term","kind":"term","name":"Chemotherapy","route":"/terms/chemotherapy-term/","detail":"same normalised name as chemotherapy (section)"},{"check":"duplicate-name","severity":"medium","id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/","detail":"same normalised name as cml-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"cml-signalling","kind":"pathway","name":"Chronic myeloid leukaemia (KEGG map)","route":"/pathways/cml-signalling/","detail":"same normalised name as cml (cancer)"},{"check":"duplicate-name","severity":"medium","id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","detail":"same normalised name as paper-dekker-lancet (paper), colorectal-cancer-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"paper-dekker-lancet","kind":"paper","name":"Colorectal cancer","route":"/key-papers/paper-dekker-lancet/","detail":"same normalised name as colorectal (cancer), colorectal-cancer-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"colorectal-cancer-signalling","kind":"pathway","name":"Colorectal cancer (KEGG map)","route":"/pathways/colorectal-cancer-signalling/","detail":"same normalised name as colorectal (cancer), paper-dekker-lancet (paper)"},{"check":"duplicate-name","severity":"medium","id":"efflux-pump","kind":"term","name":"Drug efflux pumps (ABC transporters)","route":"/terms/efflux-pump/","detail":"same normalised name as drug-efflux-pumps (pathway)"},{"check":"duplicate-name","severity":"medium","id":"drug-efflux-pumps","kind":"pathway","name":"Drug efflux pumps (ABC transporters)","route":"/pathways/drug-efflux-pumps/","detail":"same normalised name as efflux-pump (term)"},{"check":"duplicate-name","severity":"medium","id":"dcis","kind":"term","name":"Ductal carcinoma in situ (DCIS)","route":"/terms/dcis/","detail":"same normalised name as ductal-carcinoma-in-situ (cancer)"},{"check":"duplicate-name","severity":"medium","id":"ductal-carcinoma-in-situ","kind":"cancer","name":"Ductal carcinoma in situ (DCIS)","route":"/cancers/ductal-carcinoma-in-situ/","detail":"same normalised name as dcis (term)"},{"check":"duplicate-name","severity":"medium","id":"eclipse-psma","kind":"trial","name":"ECLIPSE","route":"/trials/eclipse-psma/","detail":"same normalised name as eclipse (trial), eclipse-shield (trial)"},{"check":"duplicate-name","severity":"medium","id":"eclipse","kind":"trial","name":"ECLIPSE (GVAX pancreas and CRS-207)","route":"/trials/eclipse/","detail":"same normalised name as eclipse-psma (trial), eclipse-shield (trial)"},{"check":"duplicate-name","severity":"medium","id":"eclipse-shield","kind":"trial","name":"ECLIPSE (Shield blood test)","route":"/trials/eclipse-shield/","detail":"same normalised name as eclipse-psma (trial), eclipse (trial)"},{"check":"duplicate-name","severity":"medium","id":"c797s","kind":"term","name":"EGFR C797S","route":"/terms/c797s/","detail":"same normalised name as egfr-c797s (biomarker)"},{"check":"duplicate-name","severity":"medium","id":"egfr-c797s","kind":"biomarker","name":"EGFR C797S (and its phase with T790M)","route":"/biomarkers/egfr-c797s/","detail":"same normalised name as c797s (term)"},{"check":"duplicate-name","severity":"medium","id":"egfr-exon20-insertion","kind":"term","name":"EGFR exon 20 insertion","route":"/terms/egfr-exon20-insertion/","detail":"same normalised name as egfr-exon-20-insertion (biomarker)"},{"check":"duplicate-name","severity":"medium","id":"egfr-exon-20-insertion","kind":"biomarker","name":"EGFR exon 20 insertion","route":"/biomarkers/egfr-exon-20-insertion/","detail":"same normalised name as egfr-exon20-insertion (term)"},{"check":"duplicate-name","severity":"medium","id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/","detail":"same normalised name as paper-crosbie-lancet (paper), endometrial-cancer-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"paper-crosbie-lancet","kind":"paper","name":"Endometrial cancer","route":"/key-papers/paper-crosbie-lancet/","detail":"same normalised name as endometrial (cancer), endometrial-cancer-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"endometrial-cancer-signalling","kind":"pathway","name":"Endometrial cancer (KEGG map)","route":"/pathways/endometrial-cancer-signalling/","detail":"same normalised name as endometrial (cancer), paper-crosbie-lancet (paper)"},{"check":"duplicate-name","severity":"medium","id":"esr1-mutation","kind":"term","name":"ESR1 mutation","route":"/terms/esr1-mutation/","detail":"same normalised name as esr1-mutation-ctdna (biomarker)"},{"check":"duplicate-name","severity":"medium","id":"esr1-mutation-ctdna","kind":"biomarker","name":"ESR1 mutation (ligand-binding domain, usually in ctDNA)","route":"/biomarkers/esr1-mutation-ctdna/","detail":"same normalised name as esr1-mutation (term)"},{"check":"duplicate-name","severity":"medium","id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","detail":"same normalised name as paper-roa-gallbladder-cancer-primer-nat-rev-dis-primers-2022 (paper)"},{"check":"duplicate-name","severity":"medium","id":"paper-roa-gallbladder-cancer-primer-nat-rev-dis-primers-2022","kind":"paper","name":"Gallbladder cancer","route":"/key-papers/paper-roa-gallbladder-cancer-primer-nat-rev-dis-primers-2022/","detail":"same normalised name as gallbladder (cancer)"},{"check":"duplicate-name","severity":"medium","id":"paper-smyth-lancet","kind":"paper","name":"Gastric cancer","route":"/key-papers/paper-smyth-lancet/","detail":"same normalised name as gastric-cancer-signalling (pathway), gastric-cancer (journal)"},{"check":"duplicate-name","severity":"medium","id":"gastric-cancer","kind":"journal","name":"Gastric cancer","route":"/journals/gastric-cancer/","detail":"same normalised name as paper-smyth-lancet (paper), gastric-cancer-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"gastric-cancer-signalling","kind":"pathway","name":"Gastric cancer (KEGG map)","route":"/pathways/gastric-cancer-signalling/","detail":"same normalised name as paper-smyth-lancet (paper), gastric-cancer (journal)"},{"check":"duplicate-name","severity":"medium","id":"paper-weller-nat-rev-dis-primers","kind":"paper","name":"Glioma","route":"/key-papers/paper-weller-nat-rev-dis-primers/","detail":"same normalised name as glioma-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"glioma-signalling","kind":"pathway","name":"Glioma (KEGG map)","route":"/pathways/glioma-signalling/","detail":"same normalised name as paper-weller-nat-rev-dis-primers (paper)"},{"check":"duplicate-name","severity":"medium","id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/","detail":"same normalised name as paper-llovet-nat-rev-dis-primers (paper), hepatocellular-carcinoma-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"paper-llovet-nat-rev-dis-primers","kind":"paper","name":"Hepatocellular carcinoma","route":"/key-papers/paper-llovet-nat-rev-dis-primers/","detail":"same normalised name as hcc (cancer), hepatocellular-carcinoma-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"hepatocellular-carcinoma-signalling","kind":"pathway","name":"Hepatocellular carcinoma (KEGG map)","route":"/pathways/hepatocellular-carcinoma-signalling/","detail":"same normalised name as hcc (cancer), paper-llovet-nat-rev-dis-primers (paper)"},{"check":"duplicate-name","severity":"medium","id":"nct06770439","kind":"trial","name":"IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer","route":"/trials/nct06770439/","detail":"same normalised name as nct07692750 (trial)"},{"check":"duplicate-name","severity":"medium","id":"nct07692750","kind":"trial","name":"IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer","route":"/trials/nct07692750/","detail":"same normalised name as nct06770439 (trial)"},{"check":"duplicate-name","severity":"medium","id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/","detail":"same normalised name as immunotherapy-term (term)"},{"check":"duplicate-name","severity":"medium","id":"immunotherapy-term","kind":"term","name":"Immunotherapy","route":"/terms/immunotherapy-term/","detail":"same normalised name as immunotherapy (section)"},{"check":"duplicate-name","severity":"medium","id":"impact-bcc","kind":"trial","name":"IMPACT (cemiplimab in advanced basal cell carcinoma)","route":"/trials/impact-bcc/","detail":"same normalised name as impact-sipuleucel-t (trial)"},{"check":"duplicate-name","severity":"medium","id":"impact-sipuleucel-t","kind":"trial","name":"IMPACT (sipuleucel-T)","route":"/trials/impact-sipuleucel-t/","detail":"same normalised name as impact-bcc (trial)"},{"check":"duplicate-name","severity":"medium","id":"inc-colombia","kind":"institution","name":"Instituto Nacional de Cancerología (Colombia)","route":"/institutions/inc-colombia/","detail":"same normalised name as incan-mexico (institution)"},{"check":"duplicate-name","severity":"medium","id":"incan-mexico","kind":"institution","name":"Instituto Nacional de Cancerología (Mexico)","route":"/institutions/incan-mexico/","detail":"same normalised name as inc-colombia (institution)"},{"check":"duplicate-name","severity":"medium","id":"inc-argentina","kind":"institution","name":"Instituto Nacional del Cáncer (Argentina)","route":"/institutions/inc-argentina/","detail":"same normalised name as inca-uruguay (institution), inc-chile (institution)"},{"check":"duplicate-name","severity":"medium","id":"inc-chile","kind":"institution","name":"Instituto Nacional del Cáncer (Chile)","route":"/institutions/inc-chile/","detail":"same normalised name as inc-argentina (institution), inca-uruguay (institution)"},{"check":"duplicate-name","severity":"medium","id":"inca-uruguay","kind":"institution","name":"Instituto Nacional del Cáncer (Uruguay)","route":"/institutions/inca-uruguay/","detail":"same normalised name as inc-argentina (institution), inc-chile (institution)"},{"check":"duplicate-name","severity":"medium","id":"intravesical-therapy","kind":"term","name":"Intravesical therapy (BCG and bladder instillations)","route":"/terms/intravesical-therapy/","detail":"same normalised name as bcg-and-intravesical-therapy (technology)"},{"check":"duplicate-name","severity":"medium","id":"bcg-and-intravesical-therapy","kind":"technology","name":"Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy)","route":"/technologies/bcg-and-intravesical-therapy/","detail":"same normalised name as intravesical-therapy (term)"},{"check":"duplicate-name","severity":"medium","id":"paper-keynote-a18-os-lancet-2024","kind":"paper","name":"KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer (overall survival)","route":"/key-papers/paper-keynote-a18-os-lancet-2024/","detail":"same normalised name as paper-keynote-a18-pfs-lancet-2024 (paper)"},{"check":"duplicate-name","severity":"medium","id":"paper-keynote-a18-pfs-lancet-2024","kind":"paper","name":"KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer (progression-free survival)","route":"/key-papers/paper-keynote-a18-pfs-lancet-2024/","detail":"same normalised name as paper-keynote-a18-os-lancet-2024 (paper)"},{"check":"duplicate-name","severity":"medium","id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/","detail":"same normalised name as leukaemia-type (term)"},{"check":"duplicate-name","severity":"medium","id":"leukaemia-type","kind":"term","name":"Leukaemia (tissue type)","route":"/terms/leukaemia-type/","detail":"same normalised name as leukaemia (cancer)"},{"check":"duplicate-name","severity":"medium","id":"lgr5","kind":"term","name":"LGR5","route":"/terms/lgr5/","detail":"same normalised name as lgr5-gene (target)"},{"check":"duplicate-name","severity":"medium","id":"lgr5-gene","kind":"target","name":"LGR5","route":"/targets/lgr5-gene/","detail":"same normalised name as lgr5 (term)"},{"check":"duplicate-name","severity":"medium","id":"low-grade-serous-ovarian-cancer","kind":"cancer","name":"Low-grade serous ovarian cancer","route":"/cancers/low-grade-serous-ovarian-cancer/","detail":"same normalised name as lgsoc (term)"},{"check":"duplicate-name","severity":"medium","id":"lgsoc","kind":"term","name":"Low-grade serous ovarian cancer (LGSOC)","route":"/terms/lgsoc/","detail":"same normalised name as low-grade-serous-ovarian-cancer (cancer)"},{"check":"duplicate-name","severity":"medium","id":"lung-cancer-journal","kind":"journal","name":"Lung cancer","route":"/journals/lung-cancer-journal/","detail":"same normalised name as lung-cancer (cancer)"},{"check":"duplicate-name","severity":"medium","id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","detail":"same normalised name as lung-cancer-journal (journal)"},{"check":"duplicate-name","severity":"medium","id":"breast-cancer-related-lymphoedema","kind":"term","name":"Lymphoedema after breast cancer treatment","route":"/terms/breast-cancer-related-lymphoedema/","detail":"same normalised name as lymphoedema-after-breast-cancer (term)"},{"check":"duplicate-name","severity":"medium","id":"lymphoedema-after-breast-cancer","kind":"term","name":"Lymphoedema after breast cancer treatment","route":"/terms/lymphoedema-after-breast-cancer/","detail":"same normalised name as breast-cancer-related-lymphoedema (term)"},{"check":"duplicate-name","severity":"medium","id":"src-macmillan","kind":"collection","name":"Macmillan Cancer Support","route":"/collections/src-macmillan/","detail":"same normalised name as macmillan-cancer-support (institution)"},{"check":"duplicate-name","severity":"medium","id":"macmillan-cancer-support","kind":"institution","name":"Macmillan Cancer Support","route":"/institutions/macmillan-cancer-support/","detail":"same normalised name as src-macmillan (collection)"},{"check":"duplicate-name","severity":"medium","id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/","detail":"same normalised name as melanoma-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"melanoma-signalling","kind":"pathway","name":"Melanoma (KEGG map)","route":"/pathways/melanoma-signalling/","detail":"same normalised name as melanoma (cancer)"},{"check":"duplicate-name","severity":"medium","id":"mra","kind":"institution","name":"Melanoma Research Alliance","route":"/institutions/mra/","detail":"same normalised name as melanoma-research-alliance (collection)"},{"check":"duplicate-name","severity":"medium","id":"melanoma-research-alliance","kind":"collection","name":"Melanoma Research Alliance (MRA)","route":"/collections/melanoma-research-alliance/","detail":"same normalised name as mra (institution)"},{"check":"duplicate-name","severity":"medium","id":"met-amplification","kind":"term","name":"MET amplification (bypass resistance)","route":"/terms/met-amplification/","detail":"same normalised name as met-amplification-readout (biomarker)"},{"check":"duplicate-name","severity":"medium","id":"met-amplification-readout","kind":"biomarker","name":"MET amplification (gene copy number)","route":"/biomarkers/met-amplification-readout/","detail":"same normalised name as met-amplification (term)"},{"check":"duplicate-name","severity":"medium","id":"met-exon-14-skipping","kind":"term","name":"MET exon 14 skipping mutation","route":"/terms/met-exon-14-skipping/","detail":"same normalised name as met-ex14 (biomarker)"},{"check":"duplicate-name","severity":"medium","id":"met-ex14","kind":"biomarker","name":"MET exon 14 skipping mutation","route":"/biomarkers/met-ex14/","detail":"same normalised name as met-exon-14-skipping (term)"},{"check":"duplicate-name","severity":"medium","id":"paper-gerstberger-cell","kind":"paper","name":"Metastasis","route":"/key-papers/paper-gerstberger-cell/","detail":"same normalised name as metastasis (term)"},{"check":"duplicate-name","severity":"medium","id":"metastasis","kind":"term","name":"Metastasis","route":"/terms/metastasis/","detail":"same normalised name as paper-gerstberger-cell (paper)"},{"check":"duplicate-name","severity":"medium","id":"mgmt","kind":"term","name":"MGMT promoter methylation","route":"/terms/mgmt/","detail":"same normalised name as mgmt-promoter-methylation (biomarker)"},{"check":"duplicate-name","severity":"medium","id":"mgmt-promoter-methylation","kind":"biomarker","name":"MGMT promoter methylation","route":"/biomarkers/mgmt-promoter-methylation/","detail":"same normalised name as mgmt (term)"},{"check":"duplicate-name","severity":"medium","id":"microsoft","kind":"company","name":"Microsoft (Health & Life Sciences)","route":"/companies/microsoft/","detail":"same normalised name as microsoft-research (company)"},{"check":"duplicate-name","severity":"medium","id":"microsoft-research","kind":"company","name":"Microsoft (Research and Health AI)","route":"/companies/microsoft-research/","detail":"same normalised name as microsoft (company)"},{"check":"duplicate-name","severity":"medium","id":"myc","kind":"pathway","name":"MYC","route":"/pathways/myc/","detail":"same normalised name as myc-gene (target)"},{"check":"duplicate-name","severity":"medium","id":"myc-gene","kind":"target","name":"MYC","route":"/targets/myc-gene/","detail":"same normalised name as myc (pathway)"},{"check":"duplicate-name","severity":"medium","id":"mycn-amplification","kind":"term","name":"MYCN amplification","route":"/terms/mycn-amplification/","detail":"same normalised name as mycn-amp (biomarker)"},{"check":"duplicate-name","severity":"medium","id":"mycn-amp","kind":"biomarker","name":"MYCN amplification","route":"/biomarkers/mycn-amp/","detail":"same normalised name as mycn-amplification (term)"},{"check":"duplicate-name","severity":"medium","id":"nsclc-signalling","kind":"pathway","name":"Non-small cell lung cancer (KEGG map)","route":"/pathways/nsclc-signalling/","detail":"same normalised name as nsclc (cancer)"},{"check":"duplicate-name","severity":"medium","id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","detail":"same normalised name as nsclc-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"npm1","kind":"target","name":"NPM1 mutation","route":"/targets/npm1/","detail":"same normalised name as npm1-mutation (biomarker)"},{"check":"duplicate-name","severity":"medium","id":"npm1-mutation","kind":"biomarker","name":"NPM1 mutation","route":"/biomarkers/npm1-mutation/","detail":"same normalised name as npm1 (target)"},{"check":"duplicate-name","severity":"medium","id":"oncogene","kind":"term","name":"Oncogene","route":"/terms/oncogene/","detail":"same normalised name as oncogene-journal (journal)"},{"check":"duplicate-name","severity":"medium","id":"oncogene-journal","kind":"journal","name":"Oncogene","route":"/journals/oncogene-journal/","detail":"same normalised name as oncogene (term)"},{"check":"duplicate-name","severity":"medium","id":"oncology-karger","kind":"journal","name":"Oncology","route":"/journals/oncology-karger/","detail":"same normalised name as oncology-williston-park (journal)"},{"check":"duplicate-name","severity":"medium","id":"oncology-williston-park","kind":"journal","name":"Oncology (Williston Park)","route":"/journals/oncology-williston-park/","detail":"same normalised name as oncology-karger (journal)"},{"check":"duplicate-name","severity":"medium","id":"paper-hidalgo-pancreatic-cancer-review-nejm-2010","kind":"paper","name":"Pancreatic cancer","route":"/key-papers/paper-hidalgo-pancreatic-cancer-review-nejm-2010/","detail":"same normalised name as paper-kleeff-nat-rev-dis-primers (paper), pancreatic-cancer-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"paper-kleeff-nat-rev-dis-primers","kind":"paper","name":"Pancreatic cancer","route":"/key-papers/paper-kleeff-nat-rev-dis-primers/","detail":"same normalised name as paper-hidalgo-pancreatic-cancer-review-nejm-2010 (paper), pancreatic-cancer-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"pancreatic-cancer-signalling","kind":"pathway","name":"Pancreatic cancer (KEGG map)","route":"/pathways/pancreatic-cancer-signalling/","detail":"same normalised name as paper-hidalgo-pancreatic-cancer-review-nejm-2010 (paper), paper-kleeff-nat-rev-dis-primers (paper)"},{"check":"duplicate-name","severity":"medium","id":"prospect-prostvac","kind":"trial","name":"PROSPECT","route":"/trials/prospect-prostvac/","detail":"same normalised name as prospect (trial)"},{"check":"duplicate-name","severity":"medium","id":"prospect","kind":"trial","name":"PROSPECT (Alliance N1048)","route":"/trials/prospect/","detail":"same normalised name as prospect-prostvac (trial)"},{"check":"duplicate-name","severity":"medium","id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","detail":"same normalised name as prostate-cancer-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"prostate-cancer-signalling","kind":"pathway","name":"Prostate cancer (KEGG map)","route":"/pathways/prostate-cancer-signalling/","detail":"same normalised name as prostate (cancer)"},{"check":"duplicate-name","severity":"medium","id":"pcf","kind":"institution","name":"Prostate Cancer Foundation","route":"/institutions/pcf/","detail":"same normalised name as prostate-cancer-foundation (collection)"},{"check":"duplicate-name","severity":"medium","id":"prostate-cancer-foundation","kind":"collection","name":"Prostate Cancer Foundation (PCF)","route":"/collections/prostate-cancer-foundation/","detail":"same normalised name as pcf (institution)"},{"check":"duplicate-name","severity":"medium","id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/","detail":"same normalised name as paper-hsieh-nat-rev-dis-primers (paper), renal-cell-carcinoma-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"paper-hsieh-nat-rev-dis-primers","kind":"paper","name":"Renal cell carcinoma","route":"/key-papers/paper-hsieh-nat-rev-dis-primers/","detail":"same normalised name as rcc (cancer), renal-cell-carcinoma-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"renal-cell-carcinoma-signalling","kind":"pathway","name":"Renal cell carcinoma (KEGG map)","route":"/pathways/renal-cell-carcinoma-signalling/","detail":"same normalised name as rcc (cancer), paper-hsieh-nat-rev-dis-primers (paper)"},{"check":"duplicate-name","severity":"medium","id":"sclc-signalling","kind":"pathway","name":"Small cell lung cancer (KEGG map)","route":"/pathways/sclc-signalling/","detail":"same normalised name as sclc (cancer), paper-rudin-nat-rev-dis-primers (paper)"},{"check":"duplicate-name","severity":"medium","id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/","detail":"same normalised name as paper-rudin-nat-rev-dis-primers (paper), sclc-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"paper-rudin-nat-rev-dis-primers","kind":"paper","name":"Small-cell lung cancer","route":"/key-papers/paper-rudin-nat-rev-dis-primers/","detail":"same normalised name as sclc (cancer), sclc-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"st-baldricks","kind":"collection","name":"St. Baldrick's Foundation","route":"/collections/st-baldricks/","detail":"same normalised name as st-baldricks-foundation (institution)"},{"check":"duplicate-name","severity":"medium","id":"st-baldricks-foundation","kind":"institution","name":"St. Baldrick's Foundation","route":"/institutions/st-baldricks-foundation/","detail":"same normalised name as st-baldricks (collection)"},{"check":"duplicate-name","severity":"medium","id":"stellar","kind":"trial","name":"STELLAR","route":"/trials/stellar/","detail":"same normalised name as stellar-rectal (trial)"},{"check":"duplicate-name","severity":"medium","id":"stellar-rectal","kind":"trial","name":"STELLAR (rectal cancer)","route":"/trials/stellar-rectal/","detail":"same normalised name as stellar (trial)"},{"check":"duplicate-name","severity":"medium","id":"radiosurgery-srs","kind":"technology","name":"Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS)","route":"/technologies/radiosurgery-srs/","detail":"same normalised name as stereotactic-radiosurgery (term)"},{"check":"duplicate-name","severity":"medium","id":"stereotactic-radiosurgery","kind":"term","name":"Stereotactic radiosurgery (SRS)","route":"/terms/stereotactic-radiosurgery/","detail":"same normalised name as radiosurgery-srs (technology)"},{"check":"duplicate-name","severity":"medium","id":"nct06191744","kind":"trial","name":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease ","route":"/trials/nct06191744/","detail":"same normalised name as nct05409066 (trial)"},{"check":"duplicate-name","severity":"medium","id":"nct05409066","kind":"trial","name":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease ","route":"/trials/nct05409066/","detail":"same normalised name as nct06191744 (trial)"},{"check":"duplicate-name","severity":"medium","id":"nct05548127","kind":"trial","name":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)","route":"/trials/nct05548127/","detail":"same normalised name as nct06125522 (trial), nct05573555 (trial)"},{"check":"duplicate-name","severity":"medium","id":"nct05573555","kind":"trial","name":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)","route":"/trials/nct05573555/","detail":"same normalised name as nct06125522 (trial), nct05548127 (trial)"},{"check":"duplicate-name","severity":"medium","id":"nct06125522","kind":"trial","name":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)","route":"/trials/nct06125522/","detail":"same normalised name as nct05548127 (trial), nct05573555 (trial)"},{"check":"duplicate-name","severity":"medium","id":"targeted-axillary-dissection","kind":"term","name":"Targeted axillary dissection","route":"/terms/targeted-axillary-dissection/","detail":"same normalised name as targeted-axillary-dissection-md-anderson (trial)"},{"check":"duplicate-name","severity":"medium","id":"targeted-axillary-dissection-md-anderson","kind":"trial","name":"Targeted axillary dissection (MD Anderson prospective study)","route":"/trials/targeted-axillary-dissection-md-anderson/","detail":"same normalised name as targeted-axillary-dissection (term)"},{"check":"duplicate-name","severity":"medium","id":"targeted-oncology","kind":"journal","name":"Targeted oncology","route":"/journals/targeted-oncology/","detail":"same normalised name as src-targeted-oncology (collection)"},{"check":"duplicate-name","severity":"medium","id":"src-targeted-oncology","kind":"collection","name":"Targeted Oncology","route":"/collections/src-targeted-oncology/","detail":"same normalised name as targeted-oncology (journal)"},{"check":"duplicate-name","severity":"medium","id":"targeted-therapy-term","kind":"term","name":"Targeted therapy","route":"/terms/targeted-therapy-term/","detail":"same normalised name as targeted-therapy (section)"},{"check":"duplicate-name","severity":"medium","id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/","detail":"same normalised name as targeted-therapy-term (term)"},{"check":"duplicate-name","severity":"medium","id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/","detail":"same normalised name as paper-cabanillas-lancet (paper), thyroid-cancer-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"paper-cabanillas-lancet","kind":"paper","name":"Thyroid cancer","route":"/key-papers/paper-cabanillas-lancet/","detail":"same normalised name as thyroid (cancer), thyroid-cancer-signalling (pathway)"},{"check":"duplicate-name","severity":"medium","id":"thyroid-cancer-signalling","kind":"pathway","name":"Thyroid cancer (KEGG map)","route":"/pathways/thyroid-cancer-signalling/","detail":"same normalised name as thyroid (cancer), paper-cabanillas-lancet (paper)"},{"check":"duplicate-name","severity":"medium","id":"transform","kind":"trial","name":"TRANSFORM","route":"/trials/transform/","detail":"same normalised name as transform-prostate (trial)"},{"check":"duplicate-name","severity":"medium","id":"transform-prostate","kind":"trial","name":"TRANSFORM","route":"/trials/transform-prostate/","detail":"same normalised name as transform (trial)"},{"check":"duplicate-name","severity":"medium","id":"ventana-pd-l1-sp142","kind":"drug","name":"VENTANA PD-L1 (SP142) Assay","route":"/drugs/ventana-pd-l1-sp142/","detail":"same normalised name as ventana-pd-l1-sp263 (drug)"},{"check":"duplicate-name","severity":"medium","id":"ventana-pd-l1-sp263","kind":"drug","name":"VENTANA PD-L1 (SP263) Assay","route":"/drugs/ventana-pd-l1-sp263/","detail":"same normalised name as ventana-pd-l1-sp142 (drug)"},{"check":"duplicate-name","severity":"medium","id":"vision","kind":"trial","name":"VISION","route":"/trials/vision/","detail":"same normalised name as nct02864992 (trial)"},{"check":"duplicate-name","severity":"medium","id":"nct02864992","kind":"trial","name":"VISION (tepotinib)","route":"/trials/nct02864992/","detail":"same normalised name as vision (trial)"},{"check":"future-year-in-text","severity":"medium","id":"paper-shuch-lancet-oncol","kind":"paper","name":"[ 89 Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial","route":"/key-papers/paper-shuch-lancet-oncol/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"paper-neosphere-lancet-oncol-2016-update","kind":"paper","name":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial","route":"/key-papers/paper-neosphere-lancet-oncol-2016-update/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"paper-persephone-lancet-2019","kind":"paper","name":"6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial","route":"/key-papers/paper-persephone-lancet-2019/","detail":"mentions 2045, 2044, 2043"},{"check":"future-year-in-text","severity":"medium","id":"paper-latitude-lancet-oncol-2019-update","kind":"paper","name":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","route":"/key-papers/paper-latitude-lancet-oncol-2019-update/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"paper-abiraterone-acetate-prostate-lancet-oncol-2015","kind":"paper","name":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","route":"/key-papers/paper-abiraterone-acetate-prostate-lancet-oncol-2015/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"acns1422","kind":"trial","name":"ACNS1422","route":"/trials/acns1422/","detail":"mentions 2028"},{"check":"future-year-in-text","severity":"medium","id":"paper-capstone-1-lancet-oncol-2022","kind":"paper","name":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-capstone-1-lancet-oncol-2022/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"adiuvo-2","kind":"trial","name":"ADIUVO-2","route":"/trials/adiuvo-2/","detail":"mentions 2029"},{"check":"future-year-in-text","severity":"medium","id":"paper-apt-trial-lancet-oncol-2023-update","kind":"paper","name":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial","route":"/key-papers/paper-apt-trial-lancet-oncol-2023-update/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"paper-nct02362594-lancet-oncol-2021-update","kind":"paper","name":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","route":"/key-papers/paper-nct02362594-lancet-oncol-2021-update/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"agct1531","kind":"trial","name":"AGCT1531","route":"/trials/agct1531/","detail":"mentions 2027"},{"check":"future-year-in-text","severity":"medium","id":"alcohol-reduction-labelling","kind":"technology","name":"Alcohol reduction, pricing and cancer warning labels","route":"/technologies/alcohol-reduction-labelling/","detail":"mentions 2028"},{"check":"future-year-in-text","severity":"medium","id":"a071401","kind":"trial","name":"Alliance A071401","route":"/trials/a071401/","detail":"mentions 2027"},{"check":"future-year-in-text","severity":"medium","id":"amnog","kind":"term","name":"AMNOG (Germany, 2011)","route":"/terms/amnog/","detail":"mentions 2030"},{"check":"future-year-in-text","severity":"medium","id":"idea-acc-open-oncology-workforce-model","kind":"idea","name":"An open global model of cancer workforce supply and demand by country","route":"/ideas/idea-acc-open-oncology-workforce-model/","detail":"mentions 2040"},{"check":"future-year-in-text","severity":"medium","id":"paper-romana-1-2-lancet-oncol-2016","kind":"paper","name":"Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials","route":"/key-papers/paper-romana-1-2-lancet-oncol-2016/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"paper-kindler-lancet-oncol","kind":"paper","name":"Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial","route":"/key-papers/paper-kindler-lancet-oncol/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"idea-cost-real-time-pa-fhir","kind":"idea","name":"Answer prior authorisation requests in seconds from the medical record","route":"/ideas/idea-cost-real-time-pa-fhir/","detail":"mentions 2027"},{"check":"future-year-in-text","severity":"medium","id":"idea-reg-biosimilar-no-efficacy-trial","kind":"idea","name":"Approve cancer biosimilars on analytics and pharmacokinetics, no efficacy trials","route":"/ideas/idea-reg-biosimilar-no-efficacy-trial/","detail":"mentions 2028"},{"check":"future-year-in-text","severity":"medium","id":"atnec","kind":"trial","name":"ATNEC","route":"/trials/atnec/","detail":"mentions 2030"},{"check":"future-year-in-text","severity":"medium","id":"beth-devine","kind":"person","name":"Beth Devine","route":"/people/beth-devine/","detail":"mentions 2027"},{"check":"future-year-in-text","severity":"medium","id":"paper-villani-lancet-oncol","kind":"paper","name":"Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study","route":"/key-papers/paper-villani-lancet-oncol/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"bpifrance","kind":"company","name":"Bpifrance","route":"/companies/bpifrance/","detail":"mentions 2030"},{"check":"future-year-in-text","severity":"medium","id":"paper-stacchiotti-lancet-oncol","kind":"paper","name":"Building a global consensus approach to chordoma: a position paper from the medical and patient community","route":"/key-papers/paper-stacchiotti-lancet-oncol/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"paper-florence-duffaud-lancet-oncol-2020","kind":"paper","name":"Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial","route":"/key-papers/paper-florence-duffaud-lancet-oncol-2020/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"paper-bouvard-lancet-oncol","kind":"paper","name":"Carcinogenicity of consumption of red and processed meat","route":"/key-papers/paper-bouvard-lancet-oncol/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"paper-loomis-lancet-oncol","kind":"paper","name":"Carcinogenicity of drinking coffee, mate, and very hot beverages","route":"/key-papers/paper-loomis-lancet-oncol/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"paper-iarc-monographs-vol-124-group-lancet-oncol","kind":"paper","name":"Carcinogenicity of night shift work","route":"/key-papers/paper-iarc-monographs-vol-124-group-lancet-oncol/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"paper-empower-cscc-1-lancet-oncol-2020","kind":"paper","name":"Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial","route":"/key-papers/paper-empower-cscc-1-lancet-oncol-2020/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"paper-guckenberger-lancet-oncol","kind":"paper","name":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","route":"/key-papers/paper-guckenberger-lancet-oncol/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"circulate-us","kind":"trial","name":"CIRCULATE-US","route":"/trials/circulate-us/","detail":"mentions 2029, 2030"},{"check":"future-year-in-text","severity":"medium","id":"paper-pramesh-lancet-oncol","kind":"paper","name":"Delivery of affordable and equitable cancer care in India","route":"/key-papers/paper-pramesh-lancet-oncol/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"paper-henricks-lancet-oncol","kind":"paper","name":"DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis","route":"/key-papers/paper-henricks-lancet-oncol/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"drammatic","kind":"trial","name":"DRAMMATIC","route":"/trials/drammatic/","detail":"mentions 2032"},{"check":"future-year-in-text","severity":"medium","id":"paper-qian-lancet-oncol","kind":"paper","name":"Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study","route":"/key-papers/paper-qian-lancet-oncol/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"paper-sjostrom-lancet-oncol","kind":"paper","name":"Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial","route":"/key-papers/paper-sjostrom-lancet-oncol/","detail":"mentions 2037, 2045"},{"check":"future-year-in-text","severity":"medium","id":"paper-neosphere-lancet-oncol-2012","kind":"paper","name":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","route":"/key-papers/paper-neosphere-lancet-oncol-2012/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"ellison-institute","kind":"institution","name":"Ellison Institute of Technology","route":"/institutions/ellison-institute/","detail":"mentions 2027"},{"check":"future-year-in-text","severity":"medium","id":"european-health-data-space","kind":"term","name":"European Health Data Space Regulation (EU) 2025/327","route":"/terms/european-health-data-space/","detail":"mentions 2029"},{"check":"future-year-in-text","severity":"medium","id":"ficerafusp-alfa","kind":"drug","name":"Ficerafusp alfa","route":"/drugs/ficerafusp-alfa/","detail":"mentions 2027"},{"check":"future-year-in-text","severity":"medium","id":"paper-stummer-lancet-oncol","kind":"paper","name":"Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial","route":"/key-papers/paper-stummer-lancet-oncol/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"foxtrot","kind":"trial","name":"FOxTROT","route":"/trials/foxtrot/","detail":"mentions 2027"},{"check":"future-year-in-text","severity":"medium","id":"idea-tnbc-de-escalation-for-exceptional-responders","kind":"idea","name":"Give exceptional responders less: pembrolizumab omission after complete response, anthracycline-free regimens and chemotherapy omission in lymphocyte-rich stage I disease","route":"/ideas/idea-tnbc-de-escalation-for-exceptional-responders/","detail":"mentions 2033"},{"check":"future-year-in-text","severity":"medium","id":"hyperthermia-systems","kind":"technology","name":"Hyperthermia systems (BSD-2000, EHY-2000, superficial and interstitial applicators)","route":"/technologies/hyperthermia-systems/","detail":"mentions 2030"},{"check":"future-year-in-text","severity":"medium","id":"paper-shi-lancet-oncol","kind":"paper","name":"Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial","route":"/key-papers/paper-shi-lancet-oncol/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"inpact","kind":"trial","name":"InPACT","route":"/trials/inpact/","detail":"mentions 2027"},{"check":"future-year-in-text","severity":"medium","id":"paper-pace-b-lancet-oncol-2022-update","kind":"paper","name":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","route":"/key-papers/paper-pace-b-lancet-oncol-2022-update/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"paper-kumar-lancet-oncol","kind":"paper","name":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","route":"/key-papers/paper-kumar-lancet-oncol/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"paper-senft-lancet-oncol","kind":"paper","name":"Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial","route":"/key-papers/paper-senft-lancet-oncol/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"julio-oliveira","kind":"person","name":"Júlio Oliveira","route":"/people/julio-oliveira/","detail":"mentions 2027"},{"check":"future-year-in-text","severity":"medium","id":"karim-vermaelen","kind":"person","name":"Karim Vermaelen","route":"/people/karim-vermaelen/","detail":"mentions 2028"},{"check":"future-year-in-text","severity":"medium","id":"kenneth-tanabe","kind":"person","name":"Kenneth K. Tanabe","route":"/people/kenneth-tanabe/","detail":"mentions 2027"},{"check":"future-year-in-text","severity":"medium","id":"larry-ellison","kind":"person","name":"Larry Ellison","route":"/people/larry-ellison/","detail":"mentions 2027"},{"check":"future-year-in-text","severity":"medium","id":"paper-checkmate-204-lancet-oncol-2021-update","kind":"paper","name":"Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study","route":"/key-papers/paper-checkmate-204-lancet-oncol-2021-update/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"paper-nsabp-b39-lancet-2019","kind":"paper","name":"Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial","route":"/key-papers/paper-nsabp-b39-lancet-2019/","detail":"mentions 2039, 2093, 2036, 2089"},{"check":"future-year-in-text","severity":"medium","id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/","detail":"mentions 2028"},{"check":"future-year-in-text","severity":"medium","id":"mersana","kind":"company","name":"Mersana Therapeutics","route":"/companies/mersana/","detail":"mentions 2056"},{"check":"future-year-in-text","severity":"medium","id":"mevrometostat","kind":"drug","name":"Mevrometostat","route":"/drugs/mevrometostat/","detail":"mentions 2028"},{"check":"future-year-in-text","severity":"medium","id":"paper-issels-lancet-oncol","kind":"paper","name":"Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study","route":"/key-papers/paper-issels-lancet-oncol/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"paper-nala-j-clin-oncol-2020","kind":"paper","name":"Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial","route":"/key-papers/paper-nala-j-clin-oncol-2020/","detail":"mentions 2098"},{"check":"future-year-in-text","severity":"medium","id":"nhs-galleri","kind":"trial","name":"NHS-Galleri","route":"/trials/nhs-galleri/","detail":"mentions 2031"},{"check":"future-year-in-text","severity":"medium","id":"ninewells-dundee","kind":"institution","name":"Ninewells Hospital, Dundee","route":"/institutions/ninewells-dundee/","detail":"mentions 2027"},{"check":"future-year-in-text","severity":"medium","id":"paper-propel-lancet-oncol-2023","kind":"paper","name":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","route":"/key-papers/paper-propel-lancet-oncol-2023/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"oncotherm","kind":"company","name":"Oncotherm","route":"/companies/oncotherm/","detail":"mentions 2030"},{"check":"future-year-in-text","severity":"medium","id":"oscar-arrieta-rodriguez","kind":"person","name":"Óscar Gerardo Arrieta Rodríguez","route":"/people/oscar-arrieta-rodriguez/","detail":"mentions 2028"},{"check":"future-year-in-text","severity":"medium","id":"pancreatic-roadmap","kind":"roadmap","name":"Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question","route":"/roadmaps/pancreatic-roadmap/","detail":"mentions 2031"},{"check":"future-year-in-text","severity":"medium","id":"paper-keynote-716-lancet-oncol-2022-update","kind":"paper","name":"Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial","route":"/key-papers/paper-keynote-716-lancet-oncol-2022-update/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"paper-cleopatra-lancet-oncol-2013-update","kind":"paper","name":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study","route":"/key-papers/paper-cleopatra-lancet-oncol-2013-update/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"pierre-laurent-puig","kind":"person","name":"Pierre Laurent-Puig","route":"/people/pierre-laurent-puig/","detail":"mentions 2027"},{"check":"future-year-in-text","severity":"medium","id":"precede","kind":"trial","name":"PRECEDE","route":"/trials/precede/","detail":"mentions 2030"},{"check":"future-year-in-text","severity":"medium","id":"paper-alyami-lancet-oncol","kind":"paper","name":"Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications","route":"/key-papers/paper-alyami-lancet-oncol/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"paper-prado-lancet-oncol","kind":"paper","name":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study","route":"/key-papers/paper-prado-lancet-oncol/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"paper-vokinger-lancet-oncol","kind":"paper","name":"Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis","route":"/key-papers/paper-vokinger-lancet-oncol/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"paper-anthony-nichols-lancet-oncol-2019","kind":"paper","name":"Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial","route":"/key-papers/paper-anthony-nichols-lancet-oncol-2019/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"idea-pdac-ras-inhibitor-combinations-and-sequencing","kind":"idea","name":"RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression","route":"/ideas/idea-pdac-ras-inhibitor-combinations-and-sequencing/","detail":"mentions 2028, 2029"},{"check":"future-year-in-text","severity":"medium","id":"sandra-nolte","kind":"person","name":"Sandra Nolte","route":"/people/sandra-nolte/","detail":"mentions 2027"},{"check":"future-year-in-text","severity":"medium","id":"sichuan-huiyu-pharmaceutical","kind":"company","name":"Sichuan Huiyu Pharmaceutical","route":"/companies/sichuan-huiyu-pharmaceutical/","detail":"mentions 2090"},{"check":"future-year-in-text","severity":"medium","id":"stanislaw-klek","kind":"person","name":"Stanislaw Klek","route":"/people/stanislaw-klek/","detail":"mentions 2028"},{"check":"future-year-in-text","severity":"medium","id":"star-trec","kind":"trial","name":"STAR-TREC","route":"/trials/star-trec/","detail":"mentions 2027"},{"check":"future-year-in-text","severity":"medium","id":"sting-agonist","kind":"technology","name":"STING & innate immune agonists","route":"/technologies/sting-agonist/","detail":"mentions 2056"},{"check":"future-year-in-text","severity":"medium","id":"idea-pdac-surveillance-for-every-germline-carrier","kind":"idea","name":"Surveillance for every germline carrier found by universal testing, inside a registry rather than a research exception","route":"/ideas/idea-pdac-surveillance-for-every-germline-carrier/","detail":"mentions 2030"},{"check":"future-year-in-text","severity":"medium","id":"paper-ranganathan-lancet-oncol","kind":"paper","name":"The International Collaboration for Research methods Development in Oncology (CReDO) workshops: shaping the future of global oncology research","route":"/key-papers/paper-ranganathan-lancet-oncol/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"paper-haviland-lancet-oncol","kind":"paper","name":"The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials","route":"/key-papers/paper-haviland-lancet-oncol/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"theryq","kind":"company","name":"THERYQ","route":"/companies/theryq/","detail":"mentions 2030"},{"check":"future-year-in-text","severity":"medium","id":"paper-horizon-breast01-lancet-oncol-2026","kind":"paper","name":"Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial","route":"/key-papers/paper-horizon-breast01-lancet-oncol-2026/","detail":"mentions 2045"},{"check":"future-year-in-text","severity":"medium","id":"trips-doha","kind":"term","name":"TRIPS Agreement and the Doha Declaration","route":"/terms/trips-doha/","detail":"mentions 2033"},{"check":"future-year-in-text","severity":"medium","id":"vadims-beluns","kind":"person","name":"Vadims Beļuns","route":"/people/vadims-beluns/","detail":"mentions 2031"},{"check":"future-year-in-text","severity":"medium","id":"vasanta-nanduri","kind":"person","name":"Vasanta Nanduri","route":"/people/vasanta-nanduri/","detail":"mentions 2028"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"arhgef10","kind":"target","name":"ARHGEF10","route":"/targets/arhgef10/","detail":"\"ARHGEF10\" and \"ARHGEF10L\" (arhgef10l) differ by at most two characters; if they are one thing, keep arhgef10, move \"ARHGEF10L\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"cargo-therapeutics","kind":"company","name":"CARGO Therapeutics","route":"/companies/cargo-therapeutics/","detail":"\"CARGO Therapeutics\" and \"CARTx Therapeutics\" (cartx-therapeutics) differ by at most two characters; if they are one thing, keep cargo-therapeutics, move \"CARTx Therapeutics\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"checkmate-9dw","kind":"trial","name":"CheckMate 9DW","route":"/trials/checkmate-9dw/","detail":"\"CheckMate 9DW\" and \"CheckMate 9ER\" (checkmate-9er) differ by at most two characters; if they are one thing, keep checkmate-9dw, move \"CheckMate 9ER\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"checkmate-9dw","kind":"trial","name":"CheckMate 9DW","route":"/trials/checkmate-9dw/","detail":"\"CheckMate 9DW\" and \"CheckMate 9LA\" (checkmate-9la) differ by at most two characters; if they are one thing, keep checkmate-9dw, move \"CheckMate 9LA\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"checkmate-9er","kind":"trial","name":"CheckMate 9ER","route":"/trials/checkmate-9er/","detail":"\"CheckMate 9ER\" and \"CheckMate 9LA\" (checkmate-9la) differ by at most two characters; if they are one thing, keep checkmate-9er, move \"CheckMate 9LA\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"corbus-pharmaceuticals","kind":"company","name":"Corbus Pharmaceuticals","route":"/companies/corbus-pharmaceuticals/","detail":"\"Corbus Pharmaceuticals\" and \"Corvus Pharmaceuticals\" (corvus-pharmaceuticals) differ by at most two characters; if they are one thing, keep corbus-pharmaceuticals, move \"Corvus Pharmaceuticals\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"paper-planchard-dabrafenib-trametinib-braf-nsclc-lancet-oncol-2016","kind":"paper","name":"Dabrafenib plus trametinib in previously treated BRAF V600E-mutant metastatic non-small-cell lung cancer","route":"/key-papers/paper-planchard-dabrafenib-trametinib-braf-nsclc-lancet-oncol-2016/","detail":"\"Dabrafenib plus trametinib in previously treated BRAF V600E-mutant metastatic non-small-cell lung cancer\" and \"Dabrafenib plus trametinib in previously untreated BRAF V600E-mutant metastatic non-small-cell lung cancer\" (paper-planchard-dabrafenib-trametinib-first-line-lancet-oncol-2017) differ by at most two characters; if they are one thing, keep paper-planchard-dabrafenib-trametinib-braf-nsclc-lancet-oncol-2016, move \"Dabrafenib plus trametinib in previously untreated BRAF V600E-mutant metastatic non-small-cell lung cancer\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"dysphagia","kind":"term","name":"Dysphagia (difficulty swallowing)","route":"/terms/dysphagia/","detail":"\"Dysphagia (difficulty swallowing)\" and \"Dysplasia (pre-cancerous change)\" (dysplasia) differ by at most two characters; if they are one thing, keep dysphagia, move \"Dysplasia (pre-cancerous change)\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"feng-zhang","kind":"person","name":"Feng Zhang","route":"/people/feng-zhang/","detail":"\"Feng Zhang\" and \"Feng Wang\" (wang-feng-sysucc) differ by at most two characters; if they are one thing, keep feng-zhang, move \"Feng Wang\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"flt3-itd","kind":"biomarker","name":"FLT3-ITD (internal tandem duplication)","route":"/biomarkers/flt3-itd/","detail":"\"FLT3-ITD (internal tandem duplication)\" and \"FLT3-TKD (D835 and I836 tyrosine kinase domain mutations)\" (flt3-tkd) differ by at most two characters; if they are one thing, keep flt3-itd, move \"FLT3-TKD (D835 and I836 tyrosine kinase domain mutations)\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"hsp90aa1","kind":"target","name":"HSP90AA1","route":"/targets/hsp90aa1/","detail":"\"HSP90AA1\" and \"HSP90AB1\" (hsp90ab1) differ by at most two characters; if they are one thing, keep hsp90aa1, move \"HSP90AB1\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"inca-brazil","kind":"institution","name":"Instituto Nacional de Câncer (INCA)","route":"/institutions/inca-brazil/","detail":"\"Instituto Nacional de Câncer (INCA)\" and \"Instituto Nacional del Cáncer (Uruguay)\" (inca-uruguay) differ by at most two characters; if they are one thing, keep inca-brazil, move \"Instituto Nacional del Cáncer (Uruguay)\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"inc-argentina","kind":"institution","name":"Instituto Nacional del Cáncer (Argentina)","route":"/institutions/inc-argentina/","detail":"\"Instituto Nacional del Cáncer (Argentina)\" and \"Instituto Nacional de Câncer (INCA)\" (inca-brazil) differ by at most two characters; if they are one thing, keep inc-argentina, move \"Instituto Nacional de Câncer (INCA)\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"inc-chile","kind":"institution","name":"Instituto Nacional del Cáncer (Chile)","route":"/institutions/inc-chile/","detail":"\"Instituto Nacional del Cáncer (Chile)\" and \"Instituto Nacional de Câncer (INCA)\" (inca-brazil) differ by at most two characters; if they are one thing, keep inc-chile, move \"Instituto Nacional de Câncer (INCA)\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"interaact","kind":"trial","name":"InterAACT","route":"/trials/interaact/","detail":"\"InterAACT\" and \"INTERLACE\" (interlace) differ by at most two characters; if they are one thing, keep interaact, move \"INTERLACE\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"kras-g12c","kind":"biomarker","name":"KRAS G12C","route":"/biomarkers/kras-g12c/","detail":"\"KRAS G12C\" and \"KRAS G12D (and other non-G12C KRAS mutations)\" (kras-g12d) differ by at most two characters; if they are one thing, keep kras-g12c, move \"KRAS G12D (and other non-G12C KRAS mutations)\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"majic-et","kind":"trial","name":"MAJIC-ET","route":"/trials/majic-et/","detail":"\"MAJIC-ET\" and \"MAJIC-PV\" (majic-pv) differ by at most two characters; if they are one thing, keep majic-et, move \"MAJIC-PV\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"navigate","kind":"trial","name":"NAVIGATE","route":"/trials/navigate/","detail":"\"NAVIGATE\" and \"NAVIGATOR\" (navigator) differ by at most two characters; if they are one thing, keep navigate, move \"NAVIGATOR\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"neoplasia","kind":"journal","name":"Neoplasia","route":"/journals/neoplasia/","detail":"\"Neoplasia\" and \"Neoplasma\" (neoplasma) differ by at most two characters; if they are one thing, keep neoplasia, move \"Neoplasma\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"myeloma-transplant-eligible","kind":"cancer","name":"Newly diagnosed multiple myeloma, transplant-eligible","route":"/cancers/myeloma-transplant-eligible/","detail":"\"Newly diagnosed multiple myeloma, transplant-eligible\" and \"Newly diagnosed multiple myeloma, transplant-ineligible\" (myeloma-transplant-ineligible) differ by at most two characters; if they are one thing, keep myeloma-transplant-eligible, move \"Newly diagnosed multiple myeloma, transplant-ineligible\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"nicolas-penel","kind":"person","name":"Nicolas Penel","route":"/people/nicolas-penel/","detail":"\"Nicolas Penel\" and \"Nicolas Revel\" (nicolas-revel) differ by at most two characters; if they are one thing, keep nicolas-penel, move \"Nicolas Revel\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"pd-l1-cps","kind":"biomarker","name":"PD-L1 CPS (combined positive score)","route":"/biomarkers/pd-l1-cps/","detail":"\"PD-L1 CPS (combined positive score)\" and \"PD-L1 TPS (tumour proportion score)\" (pd-l1-tps) differ by at most two characters; if they are one thing, keep pd-l1-cps, move \"PD-L1 TPS (tumour proportion score)\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"pd-l1-ic-score","kind":"biomarker","name":"PD-L1 IC score (immune-cell score, SP142)","route":"/biomarkers/pd-l1-ic-score/","detail":"\"PD-L1 IC score (immune-cell score, SP142)\" and \"PD-L1 TC score (tumour-cell score, SP263 and 28-8)\" (pd-l1-tc-score) differ by at most two characters; if they are one thing, keep pd-l1-ic-score, move \"PD-L1 TC score (tumour-cell score, SP263 and 28-8)\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"radicals-hd","kind":"trial","name":"RADICALS-HD","route":"/trials/radicals-hd/","detail":"\"RADICALS-HD\" and \"RADICALS-RT\" (radicals-rt) differ by at most two characters; if they are one thing, keep radicals-hd, move \"RADICALS-RT\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"relevance","kind":"trial","name":"RELEVANCE","route":"/trials/relevance/","detail":"\"RELEVANCE\" and \"RELIANCE\" (reliance) differ by at most two characters; if they are one thing, keep relevance, move \"RELIANCE\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"kim-tae-won","kind":"person","name":"Tae Won Kim","route":"/people/kim-tae-won/","detail":"\"Tae Won Kim\" and \"Tae-You Kim\" (kim-tae-you) differ by at most two characters; if they are one thing, keep kim-tae-won, move \"Tae-You Kim\" into its aka and repoint links"},{"check":"near-duplicate-levenshtein","severity":"medium","id":"nct05955391","kind":"trial","name":"TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct05955391/","detail":"\"TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)\" and \"TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)\" (nsclc-3) differ by at most two characters; if they are one thing, keep nct05955391, move \"TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)\" into its aka and repoint links"},{"check":"outcome-no-source","severity":"medium","id":"alliance-n0574","kind":"trial","name":"Alliance N0574 (NCCTG N0574)","route":"/trials/alliance-n0574/","detail":"1 of 1 structured outcome carry numbers without a source: Cognitive deterioration at 3 months"},{"check":"outcome-no-source","severity":"medium","id":"ascent-03","kind":"trial","name":"ASCENT-03","route":"/trials/ascent-03/","detail":"1 of 3 structured outcomes carry numbers without a source: Objective response rate"},{"check":"outcome-no-source","severity":"medium","id":"bl-b01d1-307","kind":"trial","name":"BL-B01D1-307","route":"/trials/bl-b01d1-307/","detail":"1 of 3 structured outcomes carry numbers without a source: Confirmed objective response rate (BICR)"},{"check":"outcome-no-source","severity":"medium","id":"bonner-cetuximab-rt","kind":"trial","name":"Bonner trial (cetuximab plus radiotherapy)","route":"/trials/bonner-cetuximab-rt/","detail":"1 of 1 structured outcome carry numbers without a source: Locoregional control (primary) and overall survival"},{"check":"outcome-no-source","severity":"medium","id":"calgb-9343","kind":"trial","name":"CALGB 9343","route":"/trials/calgb-9343/","detail":"1 of 1 structured outcome carry numbers without a source: Locoregional recurrence at 10 years"},{"check":"outcome-no-source","severity":"medium","id":"cao-aro-aio-94","kind":"trial","name":"CAO/ARO/AIO-94 (German Rectal Cancer Study)","route":"/trials/cao-aro-aio-94/","detail":"1 of 1 structured outcome carry numbers without a source: Local recurrence at 5 years"},{"check":"outcome-no-source","severity":"medium","id":"captain-1st","kind":"trial","name":"CAPTAIN-1st","route":"/trials/captain-1st/","detail":"1 of 1 structured outcome carry numbers without a source: Progression-free survival"},{"check":"outcome-no-source","severity":"medium","id":"chhip","kind":"trial","name":"CHHiP","route":"/trials/chhip/","detail":"1 of 4 structured outcomes carry numbers without a source: Biochemical or clinical failure-free survival at 5 years"},{"check":"outcome-no-source","severity":"medium","id":"cyto-pv","kind":"trial","name":"CYTO-PV","route":"/trials/cyto-pv/","detail":"1 of 1 structured outcome carry numbers without a source: Cardiovascular death or major thrombosis"},{"check":"outcome-no-source","severity":"medium","id":"dahanca-5","kind":"trial","name":"DAHANCA 5","route":"/trials/dahanca-5/","detail":"1 of 1 structured outcome carry numbers without a source: Locoregional control at 5 years"},{"check":"outcome-no-source","severity":"medium","id":"dbcg-82bc","kind":"trial","name":"DBCG 82b and 82c","route":"/trials/dbcg-82bc/","detail":"1 of 1 structured outcome carry numbers without a source: Overall survival at 10 years (82b)"},{"check":"outcome-no-source","severity":"medium","id":"ecog-e3311","kind":"trial","name":"ECOG-ACRIN E3311","route":"/trials/ecog-e3311/","detail":"1 of 1 structured outcome carry numbers without a source: Progression-free survival at 2 years"},{"check":"outcome-no-source","severity":"medium","id":"emerald-1","kind":"trial","name":"EMERALD-1","route":"/trials/emerald-1/","detail":"2 of 2 structured outcomes carry numbers without a source: Progression-free survival; Overall survival"},{"check":"outcome-no-source","severity":"medium","id":"slotman-pci-es-sclc","kind":"trial","name":"EORTC 08993 (Slotman): prophylactic cranial irradiation in extensive-stage small-cell lung cancer","route":"/trials/slotman-pci-es-sclc/","detail":"1 of 1 structured outcome carry numbers without a source: Symptomatic brain metastases within 1 year"},{"check":"outcome-no-source","severity":"medium","id":"eortc-22922","kind":"trial","name":"EORTC 22922/10925","route":"/trials/eortc-22922/","detail":"1 of 1 structured outcome carry numbers without a source: Overall survival at 10 years"},{"check":"outcome-no-source","severity":"medium","id":"epcore-dlbcl-1","kind":"trial","name":"EPCORE DLBCL-1","route":"/trials/epcore-dlbcl-1/","detail":"1 of 2 structured outcomes carry numbers without a source: Progression-free survival"},{"check":"outcome-no-source","severity":"medium","id":"ev-303","kind":"trial","name":"EV-303 / KEYNOTE-905","route":"/trials/ev-303/","detail":"2 of 3 structured outcomes carry numbers without a source: Overall survival; Pathologic complete response"},{"check":"outcome-no-source","severity":"medium","id":"evera","kind":"trial","name":"evERA","route":"/trials/evera/","detail":"1 of 2 structured outcomes carry numbers without a source: Progression-free survival (ESR1-mutant)"},{"check":"outcome-no-source","severity":"medium","id":"fast-forward","kind":"trial","name":"FAST-Forward","route":"/trials/fast-forward/","detail":"1 of 1 structured outcome carry numbers without a source: Ipsilateral breast tumour relapse at 5 years"},{"check":"outcome-no-source","severity":"medium","id":"hypo-rt-pc","kind":"trial","name":"HYPO-RT-PC","route":"/trials/hypo-rt-pc/","detail":"1 of 3 structured outcomes carry numbers without a source: Failure-free survival at 5 years"},{"check":"outcome-no-source","severity":"medium","id":"immagine-1","kind":"trial","name":"iMMagine-1","route":"/trials/immagine-1/","detail":"1 of 1 structured outcome carry numbers without a source: Objective response rate"},{"check":"outcome-no-source","severity":"medium","id":"import-low","kind":"trial","name":"IMPORT LOW","route":"/trials/import-low/","detail":"1 of 1 structured outcome carry numbers without a source: Local relapse at 5 years"},{"check":"outcome-no-source","severity":"medium","id":"int-0116","kind":"trial","name":"INT-0116 (Macdonald trial)","route":"/trials/int-0116/","detail":"1 of 1 structured outcome carry numbers without a source: Median overall survival"},{"check":"outcome-no-source","severity":"medium","id":"komet-001","kind":"trial","name":"KOMET-001","route":"/trials/komet-001/","detail":"2 of 3 structured outcomes carry numbers without a source: Overall response rate; Overall survival (median)"},{"check":"outcome-no-source","severity":"medium","id":"leap-012","kind":"trial","name":"LEAP-012","route":"/trials/leap-012/","detail":"2 of 2 structured outcomes carry numbers without a source: Progression-free survival; Overall survival (final)"},{"check":"outcome-no-source","severity":"medium","id":"low-pv","kind":"trial","name":"Low-PV","route":"/trials/low-pv/","detail":"1 of 1 structured outcome carry numbers without a source: Response at 12 months"},{"check":"outcome-no-source","severity":"medium","id":"lumina","kind":"trial","name":"LUMINA","route":"/trials/lumina/","detail":"1 of 1 structured outcome carry numbers without a source: Local recurrence at 5 years"},{"check":"outcome-no-source","severity":"medium","id":"majic-pv","kind":"trial","name":"MAJIC-PV","route":"/trials/majic-pv/","detail":"1 of 1 structured outcome carry numbers without a source: Complete response within 1 year"},{"check":"outcome-no-source","severity":"medium","id":"naliricc","kind":"trial","name":"NALIRICC (AIO)","route":"/trials/naliricc/","detail":"1 of 1 structured outcome carry numbers without a source: Overall survival"},{"check":"outcome-no-source","severity":"medium","id":"ma-20","kind":"trial","name":"NCIC MA.20","route":"/trials/ma-20/","detail":"1 of 1 structured outcome carry numbers without a source: Disease-free survival at 10 years"},{"check":"outcome-no-source","severity":"medium","id":"nivopostop","kind":"trial","name":"NIVOPOSTOP (GORTEC 2018-01)","route":"/trials/nivopostop/","detail":"1 of 1 structured outcome carry numbers without a source: Disease-free survival at 3 years"},{"check":"outcome-no-source","severity":"medium","id":"nsabp-b39","kind":"trial","name":"NSABP B-39/RTOG 0413","route":"/trials/nsabp-b39/","detail":"1 of 1 structured outcome carry numbers without a source: Ipsilateral breast tumour recurrence at 10 years"},{"check":"outcome-no-source","severity":"medium","id":"pace-b","kind":"trial","name":"PACE-B","route":"/trials/pace-b/","detail":"1 of 4 structured outcomes carry numbers without a source: Freedom from biochemical or clinical failure at 5 years"},{"check":"outcome-no-source","severity":"medium","id":"pop-rt","kind":"trial","name":"POP-RT","route":"/trials/pop-rt/","detail":"1 of 1 structured outcome carry numbers without a source: Biochemical failure-free survival at 5 years"},{"check":"outcome-no-source","severity":"medium","id":"prime-ii","kind":"trial","name":"PRIME II","route":"/trials/prime-ii/","detail":"1 of 1 structured outcome carry numbers without a source: Ipsilateral breast tumour recurrence at 10 years"},{"check":"outcome-no-source","severity":"medium","id":"prodige-23","kind":"trial","name":"PRODIGE 23","route":"/trials/prodige-23/","detail":"1 of 1 structured outcome carry numbers without a source: Disease-free survival at 3 years"},{"check":"outcome-no-source","severity":"medium","id":"rapido","kind":"trial","name":"RAPIDO","route":"/trials/rapido/","detail":"1 of 1 structured outcome carry numbers without a source: Disease-related treatment failure at 3 years"},{"check":"outcome-no-source","severity":"medium","id":"response","kind":"trial","name":"RESPONSE","route":"/trials/response/","detail":"1 of 1 structured outcome carry numbers without a source: Haematocrit control plus 35% spleen reduction at week 32"},{"check":"outcome-no-source","severity":"medium","id":"response-2","kind":"trial","name":"RESPONSE-2","route":"/trials/response-2/","detail":"1 of 1 structured outcome carry numbers without a source: Haematocrit control at week 28"},{"check":"outcome-no-source","severity":"medium","id":"rtog-0617","kind":"trial","name":"RTOG 0617","route":"/trials/rtog-0617/","detail":"1 of 1 structured outcome carry numbers without a source: Median overall survival"},{"check":"outcome-no-source","severity":"medium","id":"rtog-1016","kind":"trial","name":"RTOG 1016","route":"/trials/rtog-1016/","detail":"1 of 1 structured outcome carry numbers without a source: Overall survival at 5 years"},{"check":"outcome-no-source","severity":"medium","id":"rtog-91-11","kind":"trial","name":"RTOG 91-11","route":"/trials/rtog-91-11/","detail":"1 of 1 structured outcome carry numbers without a source: Laryngectomy-free survival driver: larynx preservation at 2 years"},{"check":"outcome-no-source","severity":"medium","id":"rtog-9402","kind":"trial","name":"RTOG 9402","route":"/trials/rtog-9402/","detail":"1 of 1 structured outcome carry numbers without a source: Median overall survival, 1p/19q co-deleted"},{"check":"outcome-no-source","severity":"medium","id":"rtog-9601","kind":"trial","name":"RTOG 9601","route":"/trials/rtog-9601/","detail":"1 of 1 structured outcome carry numbers without a source: Overall survival at 12 years"},{"check":"outcome-no-source","severity":"medium","id":"start-b","kind":"trial","name":"START-B (UK Standardisation of Breast Radiotherapy)","route":"/trials/start-b/","detail":"1 of 1 structured outcome carry numbers without a source: Local-regional relapse at 10 years"},{"check":"outcome-no-source","severity":"medium","id":"sunrise-1","kind":"trial","name":"SunRISe-1","route":"/trials/sunrise-1/","detail":"2 of 2 structured outcomes carry numbers without a source: Complete response rate (CIS); Duration of CR ≥12 months"},{"check":"outcome-no-source","severity":"medium","id":"verify","kind":"trial","name":"VERIFY","route":"/trials/verify/","detail":"1 of 1 structured outcome carry numbers without a source: Clinical response weeks 20 to 32"},{"check":"pipeline-cites-dead","severity":"medium","id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/","detail":"pipeline lists Fianlimab + cemiplimab phase 3 (first-line melanoma) (status negative)"},{"check":"pipeline-cites-dead","severity":"medium","id":"hcc-early","kind":"cancer","name":"Early hepatocellular carcinoma (BCLC 0 and A)","route":"/cancers/hcc-early/","detail":"pipeline lists IMbrave050 (status negative)"},{"check":"pipeline-cites-dead","severity":"medium","id":"endometrial-nsmp","kind":"cancer","name":"Endometrial cancer with no specific molecular profile","route":"/cancers/endometrial-nsmp/","detail":"pipeline lists XPORT-EC-042 / ENGOT-EN20 / GOG-3083 (status negative)"},{"check":"pipeline-cites-dead","severity":"medium","id":"epithelioid-sarcoma","kind":"cancer","name":"Epithelioid sarcoma","route":"/cancers/epithelioid-sarcoma/","detail":"pipeline lists Tazemetostat with doxorubicin as front-line therapy for advanced epithelioid sarcoma (EZH-301 run-in) (status withdrawn)"},{"check":"pipeline-cites-dead","severity":"medium","id":"epithelioid-sarcoma","kind":"cancer","name":"Epithelioid sarcoma","route":"/cancers/epithelioid-sarcoma/","detail":"pipeline lists Tazemetostat (status withdrawn)"},{"check":"pipeline-cites-dead","severity":"medium","id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/","detail":"pipeline lists Anetumab ravtansine (status negative)"},{"check":"pipeline-cites-dead","severity":"medium","id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/","detail":"pipeline lists Anetumab ravtansine versus vinorelbine in relapsed mesothelin-positive pleural mesothelioma (status negative)"},{"check":"pipeline-cites-dead","severity":"medium","id":"oropharyngeal-cancer","kind":"cancer","name":"Oropharyngeal cancer (tonsil and base of tongue)","route":"/cancers/oropharyngeal-cancer/","detail":"pipeline lists De-ESCALaTE HPV (status negative)"},{"check":"pipeline-cites-dead","severity":"medium","id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/","detail":"pipeline lists AMPLIFY-7P (status negative)"},{"check":"pipeline-cites-dead","severity":"medium","id":"stage-iii-melanoma","kind":"cancer","name":"Stage III melanoma (after surgery)","route":"/cancers/stage-iii-melanoma/","detail":"pipeline lists RELATIVITY-098 (status negative)"},{"check":"positive-hr-ge-1","severity":"medium","id":"eortc-22881-boost","kind":"trial","name":"EORTC 22881-10882 (boost against no boost)","route":"/trials/eortc-22881-boost/","detail":"status positive but primary endpoint hazard ratio 1.05 (Overall survival at 20 years); not described as a non-inferiority or de-escalation trial"},{"check":"positive-hr-ge-1","severity":"medium","id":"nsabp-b32","kind":"trial","name":"NSABP B-32","route":"/trials/nsabp-b32/","detail":"status positive but primary endpoint hazard ratio 1.2 (Overall survival at 8 years (sentinel node-negative patients)); not described as a non-inferiority or de-escalation trial"},{"check":"positive-hr-ge-1","severity":"medium","id":"rtog-9408","kind":"trial","name":"RTOG 94-08","route":"/trials/rtog-9408/","detail":"status positive but primary endpoint hazard ratio 1.17 (Overall survival at 10 years); not described as a non-inferiority or de-escalation trial"},{"check":"positive-hr-ge-1","severity":"medium","id":"sequoia","kind":"trial","name":"SEQUOIA","route":"/trials/sequoia/","detail":"status positive but primary endpoint hazard ratio 1.045 (Overall survival); not described as a non-inferiority or de-escalation trial"},{"check":"positive-hr-ge-1","severity":"medium","id":"triangle","kind":"trial","name":"TRIANGLE","route":"/trials/triangle/","detail":"status positive but primary endpoint hazard ratio 1.77 (Failure-free survival at 3 years, arm A against arm I (superiority of transplant not shown)); not described as a non-inferiority or de-escalation trial"},{"check":"spike-scalar-divergence","severity":"medium","id":"breast-reconstruction","kind":"term","name":"Breast reconstruction","route":"/terms/breast-reconstruction/","detail":"defined in the breast-cancer spikes with different values; the first wins and hides the rest: tldr: \"Rebuilding the shape of a breast after a mastectomy, eith...\" vs \"Surgery to make a breast shape after a mastectomy, using ...\"; summary: \"There are two families of technique. Implant-based recons...\" vs \"NICE NG101 says to offer breast reconstruction to people ...\""},{"check":"spike-scalar-divergence","severity":"medium","id":"curettage-and-cautery","kind":"term","name":"Curettage and cautery","route":"/terms/curettage-and-cautery/","detail":"defined in the skin-cancer spikes with different values; the first wins and hides the rest: tldr: \"Scraping a small, low-risk skin cancer away with a spoon-...\" vs \"The tumour is scraped out with a sharp spoon-shaped instr...\"; summary: \"The British Association of Dermatologists describes curet...\" vs \"Curettage with or without electrodesiccation is the faste...\""},{"check":"spike-scalar-divergence","severity":"medium","id":"paper-kobayashi-egfr-t790m-gefitinib-resistance-nejm-2005","kind":"paper","name":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","route":"/key-papers/paper-kobayashi-egfr-t790m-gefitinib-resistance-nejm-2005/","detail":"defined in the lung-cancer and nsclc spikes with different values; the first wins and hides the rest: tldr: \"One patient, two years in complete remission on gefitinib...\" vs \"One patient whose lung cancer had disappeared for two yea...\"; summary: \"Kobayashi, Boggon, Dayaram and colleagues at Beth Israel ...\" vs \"A patient with EGFR-mutant, gefitinib-responsive advanced...\"; whatItMeans: \"Resistance to a targeted drug usually has a cause you can...\" vs \"It established that acquired resistance to a targeted dru...\""},{"check":"spike-scalar-divergence","severity":"medium","id":"paper-soda-eml4-alk-fusion-nature-2007","kind":"paper","name":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","route":"/key-papers/paper-soda-eml4-alk-fusion-nature-2007/","detail":"defined in the lung-cancer and nsclc spikes with different values; the first wins and hides the rest: tldr: \"A small inversion on chromosome 2 fuses two genes and mak...\" vs \"A small inversion on chromosome 2 was found to weld two g...\"; summary: \"Soda, Choi, Enomoto and colleagues, with Mano as senior a...\" vs \"A small inversion within chromosome 2p was shown to form ...\"; whatItMeans: \"The second driver in lung cancer, and the one that proved...\" vs \"It created the second targetable class in lung cancer and...\""},{"check":"spike-scalar-divergence","severity":"medium","id":"paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019","kind":"paper","name":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","route":"/key-papers/paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019/","detail":"defined in the lung-cancer and nsclc spikes with different values; the first wins and hides the rest: tldr: \"Small-cell lung cancer, treated as one disease for fifty ...\" vs \"Small-cell lung cancer has been treated as a single disea...\"; summary: \"Rudin, Poirier, Byers, Dive and eighteen colleagues propo...\" vs \"Evidence from primary human tumours, patient-derived xeno...\"; whatItMeans: \"The organising framework for every small-cell lung cancer...\" vs \"It reorganised a disease that had no molecular classifica...\""},{"check":"spike-scalar-divergence","severity":"medium","id":"sequoia","kind":"trial","name":"SEQUOIA","route":"/trials/sequoia/","detail":"defined in the cll and pancreatic spikes with different values; the first wins and hides the rest: name: \"SEQUOIA\" vs \"SEQUOIA (pancreatic cancer)\"; nct: \"NCT03336333\" vs \"NCT02923921\"; status: \"positive\" vs \"negative\"; yearReported: \"2022\" vs \"2021\"; sponsor: \"BeOne (BeiGene)\" vs \"Eli Lilly (ARMO BioSciences)\"; enrolled: \"590\" vs \"567\"; setting: \"Previously untreated CLL/SLL unsuitable for FCR: zanubrut...\" vs \"Metastatic pancreatic ductal adenocarcinoma progressing a...\"; tldr: \"Zanubrutinib beat chemoimmunotherapy in untreated CLL and...\" vs \"SEQUOIA added the immune cytokine pegilodecakin to second...\"; summary: \"SEQUOIA, trial NCT03336333 sponsored by BeOne, formerly B...\" vs \"SEQUOIA randomised 567 patients between March 2017 and Se...\"; result: \"PFS HR 0.42 vs BR; 5-year PFS 72.2% in del(17p).\" vs \"Median overall survival 5.8 months with pegilodecakin plu...\""},{"check":"status-vs-approvals","severity":"medium","id":"i131-mibg","kind":"drug","name":"131I-MIBG (iobenguane I-131) therapy","route":"/drugs/i131-mibg/","detail":"US/EU approvals recorded (US 2018) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"alitretinoin","kind":"drug","name":"Alitretinoin","route":"/drugs/alitretinoin/","detail":"US/EU approvals recorded (US 1999) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"altretamine","kind":"drug","name":"Altretamine","route":"/drugs/altretamine/","detail":"US/EU approvals recorded (US 1990) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"choline-c11","kind":"drug","name":"Choline C-11","route":"/drugs/choline-c11/","detail":"US/EU approvals recorded (US 2012) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"cinacalcet","kind":"drug","name":"Cinacalcet","route":"/drugs/cinacalcet/","detail":"US/EU approvals recorded (US 2004) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"dolasetron","kind":"drug","name":"Dolasetron","route":"/drugs/dolasetron/","detail":"US/EU approvals recorded (US 1997) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"dronabinol","kind":"drug","name":"Dronabinol","route":"/drugs/dronabinol/","detail":"US/EU approvals recorded (US 1985) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"eltrombopag","kind":"drug","name":"Eltrombopag","route":"/drugs/eltrombopag/","detail":"US/EU approvals recorded (US 2008) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"emapalumab","kind":"drug","name":"Emapalumab","route":"/drugs/emapalumab/","detail":"US/EU approvals recorded (US 2018) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"estramustine","kind":"drug","name":"Estramustine","route":"/drugs/estramustine/","detail":"US/EU approvals recorded (US 1981) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"ethiodized-oil","kind":"drug","name":"Ethiodized oil","route":"/drugs/ethiodized-oil/","detail":"US/EU approvals recorded (US 1954) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"floxuridine","kind":"drug","name":"Floxuridine","route":"/drugs/floxuridine/","detail":"US/EU approvals recorded (US 1970) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"fostamatinib","kind":"drug","name":"Fostamatinib","route":"/drugs/fostamatinib/","detail":"US/EU approvals recorded (US 2018) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"methoxsalen-ecp","kind":"drug","name":"Methoxsalen (extracorporeal photopheresis)","route":"/drugs/methoxsalen-ecp/","detail":"US/EU approvals recorded (US 1999) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"methyl-aminolevulinate","kind":"drug","name":"Methyl aminolevulinate","route":"/drugs/methyl-aminolevulinate/","detail":"US/EU approvals recorded (US 2004) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"nabilone","kind":"drug","name":"Nabilone","route":"/drugs/nabilone/","detail":"US/EU approvals recorded (US 1985) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"nbtxr3","kind":"drug","name":"NBTXR3 (hafnium oxide nanoparticles)","route":"/drugs/nbtxr3/","detail":"US/EU approvals recorded (EU 2019) but status is \"phase-3\""},{"check":"status-vs-approvals","severity":"medium","id":"peginterferon-alfa-2b","kind":"drug","name":"Peginterferon alfa-2b","route":"/drugs/peginterferon-alfa-2b/","detail":"US/EU approvals recorded (US 2011) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"porfimer-sodium","kind":"drug","name":"Porfimer sodium","route":"/drugs/porfimer-sodium/","detail":"US/EU approvals recorded (US 1995) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"propranolol-hemangeol","kind":"drug","name":"Propranolol (Hemangeol)","route":"/drugs/propranolol-hemangeol/","detail":"US/EU approvals recorded (US 2014) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"ravulizumab","kind":"drug","name":"Ravulizumab","route":"/drugs/ravulizumab/","detail":"US/EU approvals recorded (US 2018) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"romiplostim","kind":"drug","name":"Romiplostim","route":"/drugs/romiplostim/","detail":"US/EU approvals recorded (US 2008) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"sargramostim","kind":"drug","name":"Sargramostim","route":"/drugs/sargramostim/","detail":"US/EU approvals recorded (US 1991) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"streptozocin","kind":"drug","name":"Streptozocin","route":"/drugs/streptozocin/","detail":"US/EU approvals recorded (US 1982) but status is \"established\""},{"check":"status-vs-approvals","severity":"medium","id":"teniposide","kind":"drug","name":"Teniposide","route":"/drugs/teniposide/","detail":"US/EU approvals recorded (US 1992) but status is \"established\""},{"check":"text-vs-structured","severity":"medium","id":"anchor","kind":"trial","name":"ANCHOR","route":"/trials/anchor/","detail":"text says randomised 4,459 but enrolled is 4446"},{"check":"text-vs-structured","severity":"medium","id":"ck-301-101","kind":"trial","name":"CK-301-101","route":"/trials/ck-301-101/","detail":"text says enrolled 109 but enrolled is 272"},{"check":"text-vs-structured","severity":"medium","id":"conko-007","kind":"trial","name":"CONKO-007","route":"/trials/conko-007/","detail":"text says enrolled 525 but enrolled is 336"},{"check":"text-vs-structured","severity":"medium","id":"cross","kind":"trial","name":"CROSS","route":"/trials/cross/","detail":"text says randomised 368 but enrolled is 366"},{"check":"text-vs-structured","severity":"medium","id":"destiny-crc01","kind":"trial","name":"DESTINY-CRC01","route":"/trials/destiny-crc01/","detail":"text says enrolled 78 but enrolled is 86"},{"check":"text-vs-structured","severity":"medium","id":"fort","kind":"trial","name":"FoRT","route":"/trials/fort/","detail":"text says randomised 614 but enrolled is 548"},{"check":"text-vs-structured","severity":"medium","id":"halo-301","kind":"trial","name":"HALO 109-301","route":"/trials/halo-301/","detail":"text says randomised 494 but enrolled is 492"},{"check":"text-vs-structured","severity":"medium","id":"keynote-158","kind":"trial","name":"KEYNOTE-158","route":"/trials/keynote-158/","detail":"text says enrolled 104 but enrolled is 1609"},{"check":"text-vs-structured","severity":"medium","id":"neotrip","kind":"trial","name":"NeoTRIP (NeoTRIPaPDL1)","route":"/trials/neotrip/","detail":"text says randomised 280 but enrolled is 278"},{"check":"text-vs-structured","severity":"medium","id":"roar","kind":"trial","name":"ROAR (Rare Oncology Agnostic Research) basket: BRAF V600E biliary tract cancer cohort","route":"/trials/roar/","detail":"text says enrolled 43 but enrolled is 206"},{"check":"text-vs-structured","severity":"medium","id":"swog-9346","kind":"trial","name":"SWOG 9346 (intermittent androgen deprivation)","route":"/trials/swog-9346/","detail":"text says enrolled 3,040 but enrolled is 1535"},{"check":"text-vs-structured","severity":"medium","id":"trophimmun","kind":"trial","name":"TROPHIMMUN","route":"/trials/trophimmun/","detail":"text says enrolled 15 but enrolled is 24"},{"check":"unsourced-numbers","severity":"medium","id":"aml-myelodysplasia-related","kind":"term","name":"AML with myelodysplasia-related gene mutations (AML-MR)","route":"/terms/aml-myelodysplasia-related/","detail":"1 number in the text (9.6 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"b-all-cytogenetic-risk","kind":"term","name":"B-ALL risk groups (NCI criteria, ETV6::RUNX1, hyperdiploidy, hypodiploidy, iAMP21, IKZF1, CNS status)","route":"/terms/b-all-cytogenetic-risk/","detail":"5 numbers in the text (0.01 percent, 95 percent, 2 percent, 15 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"abl1-kinase-domain-mutations","kind":"term","name":"BCR::ABL1 kinase domain mutations (T315I and others)","route":"/terms/abl1-kinase-domain-mutations/","detail":"2 numbers in the text (3 percent, 20 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"brca-reversion-mutations","kind":"term","name":"BRCA reversion mutations","route":"/terms/brca-reversion-mutations/","detail":"1 number in the text (40 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"btki-bcl2i-resistance-mutations","kind":"term","name":"BTK C481S, PLCG2 and BCL2 G101V resistance mutations","route":"/terms/btki-bcl2i-resistance-mutations/","detail":"1 number in the text (80 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"cll-ipi","kind":"term","name":"CLL-IPI (chronic lymphocytic leukaemia prognostic index)","route":"/terms/cll-ipi/","detail":"2 numbers in the text (23 percent, 98 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-lung-screening-eligibility-by-risk-not-pack-years","kind":"idea","name":"Decide who is screened for lung cancer by individual risk, not by pack-years","route":"/ideas/idea-lung-screening-eligibility-by-risk-not-pack-years/","detail":"2 numbers in the text (31 percent, 17 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"dipss-mipss70","kind":"term","name":"DIPSS, DIPSS-plus and MIPSS70 (myelofibrosis risk scores)","route":"/terms/dipss-mipss70/","detail":"1 number in the text (1 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"foxo1-fusion-status","kind":"term","name":"FOXO1 fusion status and IRS group (rhabdomyosarcoma)","route":"/terms/foxo1-fusion-status/","detail":"2 numbers in the text (60 percent, 20 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"gist-risk-stratification","kind":"term","name":"GIST risk stratification (mitotic count, size, site; Miettinen and modified NIH criteria)","route":"/terms/gist-risk-stratification/","detail":"3 numbers in the text (2 percent, 90 percent, 82 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"gracell-biotechnologies","kind":"company","name":"Gracell Biotechnologies","route":"/companies/gracell-biotechnologies/","detail":"1 number in the text (1.2 billion) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"herve-dombret","kind":"person","name":"Hervé Dombret","route":"/people/herve-dombret/","detail":"1 number in the text (30 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"histological-response-induction","kind":"term","name":"Histological response to induction chemotherapy (osteosarcoma and Ewing sarcoma)","route":"/terms/histological-response-induction/","detail":"7 numbers in the text (90 percent, 50 percent, 75 percent, 57 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"inge-van-der-sluis","kind":"person","name":"Inge M. van der Sluis","route":"/people/inge-van-der-sluis/","detail":"1 number in the text (80 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-lung-resistance-directed-sequencing-at-every-progression","kind":"idea","name":"Make resistance a diagnosis: sequence at every progression and choose the next line from what the tumour became","route":"/ideas/idea-lung-resistance-directed-sequencing-at-every-progression/","detail":"1 number in the text (14 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"met-exon-14-skipping","kind":"term","name":"MET exon 14 skipping mutation","route":"/terms/met-exon-14-skipping/","detail":"5 numbers in the text (3 percent, 20 percent, 4 percent, 30 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"curie-siopen-score","kind":"term","name":"MIBG Curie and SIOPEN scores","route":"/terms/curie-siopen-score/","detail":"1 number in the text (10 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"mipi","kind":"term","name":"MIPI (Mantle Cell Lymphoma International Prognostic Index)","route":"/terms/mipi/","detail":"4 numbers in the text (30 percent, 51 months, 29 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"mlh1-promoter-methylation","kind":"term","name":"MLH1 promoter methylation (sporadic versus Lynch mismatch repair loss)","route":"/terms/mlh1-promoter-methylation/","detail":"2 numbers in the text (70 percent, 90 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"mpn-driver-mutations","kind":"term","name":"MPN driver mutations (JAK2 V617F, CALR, MPL) and allele burden","route":"/terms/mpn-driver-mutations/","detail":"4 numbers in the text (95 percent, 3 percent, 60 percent, 50 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"patidegib","kind":"drug","name":"Patidegib","route":"/drugs/patidegib/","detail":"1 number in the text (2 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"ph-like-all","kind":"term","name":"Ph-like (BCR::ABL1-like) acute lymphoblastic leukaemia","route":"/terms/ph-like-all/","detail":"3 numbers in the text (15 percent, 30 percent, 20 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"psa-kinetics","kind":"term","name":"PSA kinetics: PSA doubling time and PSA density","route":"/terms/psa-kinetics/","detail":"1 number in the text (50 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-prostate-per-lesion-mri-audit-before-focal-treatment","kind":"idea","name":"Publish a per-lesion miss rate for every prostate MRI service before it is allowed to guide focal treatment","route":"/ideas/idea-prostate-per-lesion-mri-audit-before-focal-treatment/","detail":"6 numbers in the text (93 percent, 41 percent, 45 percent, 65 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-prostate-randomise-the-sequence-not-only-the-drugs","kind":"idea","name":"Randomise the order of treatment, not only the drugs: a strategy platform for metastatic prostate cancer","route":"/ideas/idea-prostate-randomise-the-sequence-not-only-the-drugs/","detail":"4 numbers in the text (hazard ratio of 0.44, 8.6 months, 3.8 months, 10.9 months) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"sdh-deficiency","kind":"term","name":"SDH deficiency (SDHB immunohistochemistry loss)","route":"/terms/sdh-deficiency/","detail":"2 numbers in the text (7 percent, 40 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"segmental-chromosomal-aberrations","kind":"term","name":"Segmental chromosomal aberrations and ploidy (neuroblastoma)","route":"/terms/segmental-chromosomal-aberrations/","detail":"1 number in the text (40 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"sclc-molecular-subtypes","kind":"term","name":"Small-cell lung cancer transcription-factor subtypes (SCLC-A, SCLC-N, SCLC-P, SCLC-I) and SLFN11","route":"/terms/sclc-molecular-subtypes/","detail":"1 number in the text (15 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"sokal-elts-scores","kind":"term","name":"Sokal and ELTS risk scores (chronic myeloid leukaemia)","route":"/terms/sokal-elts-scores/","detail":"4 numbers in the text (12 percent, 10 percent, 1 percent, 0.1 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"ss18-ssx-fusion","kind":"term","name":"SS18::SSX fusion (synovial sarcoma)","route":"/terms/ss18-ssx-fusion/","detail":"4 numbers in the text (95 percent, 100 percent, 70 percent, 80 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-prostate-bipolar-androgen-therapy-phase-3-on-pfs2","kind":"idea","name":"Take high-dose testosterone to phase 3, with progression-free survival through the second line as the primary endpoint","route":"/ideas/idea-prostate-bipolar-androgen-therapy-phase-3-on-pfs2/","detail":"8 numbers in the text (30 percent, 50 percent, 52 percent, hazard ratio 0.44) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-prostate-hrr-testing-at-metastatic-diagnosis","kind":"idea","name":"Test every man for DNA repair faults on the day his prostate cancer is found to have spread, not three treatments later","route":"/ideas/idea-prostate-hrr-testing-at-metastatic-diagnosis/","detail":"5 numbers in the text (11.8 percent, 4.6 percent, 2.7 percent, 19.3 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"tk216","kind":"drug","name":"TK216","route":"/drugs/tk216/","detail":"1 number in the text (85 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-lung-never-smoker-disease-its-own-programme","kind":"idea","name":"Treat lung cancer in never-smokers as its own disease, with its own detection programme","route":"/ideas/idea-lung-never-smoker-disease-its-own-programme/","detail":"1 number in the text (53 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"uveal-melanoma-prognostic-markers","kind":"term","name":"Uveal melanoma prognostic markers (GNAQ/GNA11, monosomy 3, gene-expression class)","route":"/terms/uveal-melanoma-prognostic-markers/","detail":"3 numbers in the text (90 percent, 70 percent, 5 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"idea-prostate-plasticity-surveillance-before-it-is-neuroendocrine","kind":"idea","name":"Watch for the cancer changing cell type before the biopsy says neuroendocrine, and act on it","route":"/ideas/idea-prostate-plasticity-surveillance-before-it-is-neuroendocrine/","detail":"1 number in the text (17 percent) but no link, Wikipedia page or registry id"},{"check":"unsourced-numbers","severity":"medium","id":"wilms-risk-markers","kind":"term","name":"Wilms tumour risk markers (anaplasia, 1p/16q loss, 1q gain, SIOP and COG risk groups)","route":"/terms/wilms-risk-markers/","detail":"1 number in the text (30 percent) but no link, Wikipedia page or registry id"},{"check":"approvals-vs-regional","severity":"low","id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/","detail":"regional-approvals.ts records EU approved 2018 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/","detail":"regional-approvals.ts records EU approved 2011 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"acalabrutinib","kind":"drug","name":"Acalabrutinib","route":"/drugs/acalabrutinib/","detail":"regional-approvals.ts records EU approved 2020 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"alectinib","kind":"drug","name":"Alectinib","route":"/drugs/alectinib/","detail":"regional-approvals.ts records EU approved 2017 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"alpelisib","kind":"drug","name":"Alpelisib","route":"/drugs/alpelisib/","detail":"regional-approvals.ts records EU approved 2020 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"apalutamide","kind":"drug","name":"Apalutamide","route":"/drugs/apalutamide/","detail":"regional-approvals.ts records EU approved 2019 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"asciminib","kind":"drug","name":"Asciminib","route":"/drugs/asciminib/","detail":"regional-approvals.ts records EU approved 2022 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"avelumab","kind":"drug","name":"Avelumab","route":"/drugs/avelumab/","detail":"regional-approvals.ts records EU approved 2017 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"axicabtagene-ciloleucel","kind":"drug","name":"Axicabtagene ciloleucel","route":"/drugs/axicabtagene-ciloleucel/","detail":"regional-approvals.ts records EU approved 2018 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"axitinib","kind":"drug","name":"Axitinib","route":"/drugs/axitinib/","detail":"regional-approvals.ts records EU approved 2012 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"azacitidine","kind":"drug","name":"Azacitidine","route":"/drugs/azacitidine/","detail":"regional-approvals.ts records EU approved 2008 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"binimetinib","kind":"drug","name":"Binimetinib","route":"/drugs/binimetinib/","detail":"regional-approvals.ts records EU approved 2018 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/","detail":"regional-approvals.ts records EU approved 2015 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"bortezomib","kind":"drug","name":"Bortezomib","route":"/drugs/bortezomib/","detail":"regional-approvals.ts records EU approved 2004 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/","detail":"regional-approvals.ts records EU approved 2012 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"cabazitaxel","kind":"drug","name":"Cabazitaxel","route":"/drugs/cabazitaxel/","detail":"regional-approvals.ts records EU approved 2011 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"capmatinib","kind":"drug","name":"Capmatinib","route":"/drugs/capmatinib/","detail":"regional-approvals.ts records EU approved 2022 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/","detail":"regional-approvals.ts records EU approved 1986 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"carfilzomib","kind":"drug","name":"Carfilzomib","route":"/drugs/carfilzomib/","detail":"regional-approvals.ts records EU approved 2015 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"carmustine","kind":"drug","name":"Carmustine","route":"/drugs/carmustine/","detail":"regional-approvals.ts records EU approved 2018 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"cemiplimab","kind":"drug","name":"Cemiplimab","route":"/drugs/cemiplimab/","detail":"regional-approvals.ts records EU approved 2019 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"ciltacabtagene-autoleucel","kind":"drug","name":"Ciltacabtagene autoleucel","route":"/drugs/ciltacabtagene-autoleucel/","detail":"regional-approvals.ts records EU approved 2022 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/","detail":"regional-approvals.ts records EU approved 1979 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"cobimetinib","kind":"drug","name":"Cobimetinib","route":"/drugs/cobimetinib/","detail":"regional-approvals.ts records EU approved 2015 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"cpx-351","kind":"drug","name":"CPX-351 (liposomal daunorubicin-cytarabine)","route":"/drugs/cpx-351/","detail":"regional-approvals.ts records EU approved 2018 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"dabrafenib-trametinib","kind":"drug","name":"Dabrafenib + trametinib","route":"/drugs/dabrafenib-trametinib/","detail":"regional-approvals.ts records EU approved 2013 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"daratumumab","kind":"drug","name":"Daratumumab","route":"/drugs/daratumumab/","detail":"regional-approvals.ts records EU approved 2016 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"darolutamide","kind":"drug","name":"Darolutamide","route":"/drugs/darolutamide/","detail":"regional-approvals.ts records EU approved 2020 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"dasatinib","kind":"drug","name":"Dasatinib","route":"/drugs/dasatinib/","detail":"regional-approvals.ts records EU approved 2006 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"daunorubicin","kind":"drug","name":"Daunorubicin","route":"/drugs/daunorubicin/","detail":"regional-approvals.ts records EU approved 2018 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/","detail":"regional-approvals.ts records EU approved 1995 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"dostarlimab","kind":"drug","name":"Dostarlimab","route":"/drugs/dostarlimab/","detail":"regional-approvals.ts records EU approved 2021 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/","detail":"regional-approvals.ts records EU approved 1971 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","detail":"regional-approvals.ts records EU approved 2018 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"elacestrant","kind":"drug","name":"Elacestrant","route":"/drugs/elacestrant/","detail":"regional-approvals.ts records EU approved 2023 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"elotuzumab","kind":"drug","name":"Elotuzumab","route":"/drugs/elotuzumab/","detail":"regional-approvals.ts records EU approved 2016 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"elranatamab","kind":"drug","name":"Elranatamab","route":"/drugs/elranatamab/","detail":"regional-approvals.ts records EU conditional 2023 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/","detail":"regional-approvals.ts records EU approved 2013 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"erdafitinib","kind":"drug","name":"Erdafitinib","route":"/drugs/erdafitinib/","detail":"regional-approvals.ts records EU approved 2024 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"everolimus","kind":"drug","name":"Everolimus","route":"/drugs/everolimus/","detail":"regional-approvals.ts records EU approved 2009 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"exemestane","kind":"drug","name":"Exemestane","route":"/drugs/exemestane/","detail":"regional-approvals.ts records EU approved 1999 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"fulvestrant","kind":"drug","name":"Fulvestrant","route":"/drugs/fulvestrant/","detail":"regional-approvals.ts records EU approved 2004 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"ga68-psma-11","kind":"drug","name":"Gallium-68 gozetotide (PSMA-11)","route":"/drugs/ga68-psma-11/","detail":"regional-approvals.ts records EU approved 2022 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"gemtuzumab-ozogamicin","kind":"drug","name":"Gemtuzumab ozogamicin","route":"/drugs/gemtuzumab-ozogamicin/","detail":"regional-approvals.ts records EU approved 2018 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"gilteritinib","kind":"drug","name":"Gilteritinib","route":"/drugs/gilteritinib/","detail":"regional-approvals.ts records EU approved 2019 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"glofitamab","kind":"drug","name":"Glofitamab","route":"/drugs/glofitamab/","detail":"regional-approvals.ts records EU conditional 2023 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"goserelin","kind":"drug","name":"Goserelin / leuprolide (ovarian function suppression)","route":"/drugs/goserelin/","detail":"regional-approvals.ts records EU approved 1987 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"idecabtagene-vicleucel","kind":"drug","name":"Idecabtagene vicleucel","route":"/drugs/idecabtagene-vicleucel/","detail":"regional-approvals.ts records EU approved 2021 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"ifosfamide","kind":"drug","name":"Ifosfamide","route":"/drugs/ifosfamide/","detail":"regional-approvals.ts records EU approved 1980 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"imatinib","kind":"drug","name":"Imatinib","route":"/drugs/imatinib/","detail":"regional-approvals.ts records EU approved 2001 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"inotuzumab-ozogamicin","kind":"drug","name":"Inotuzumab ozogamicin","route":"/drugs/inotuzumab-ozogamicin/","detail":"regional-approvals.ts records EU approved 2017 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/","detail":"regional-approvals.ts records EU approved 2011 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"isatuximab","kind":"drug","name":"Isatuximab","route":"/drugs/isatuximab/","detail":"regional-approvals.ts records EU approved 2020 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"ivosidenib","kind":"drug","name":"Ivosidenib","route":"/drugs/ivosidenib/","detail":"regional-approvals.ts records EU approved 2023 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"lapatinib","kind":"drug","name":"Lapatinib","route":"/drugs/lapatinib/","detail":"regional-approvals.ts records EU approved 2008 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/","detail":"regional-approvals.ts records EU approved 2007 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"lenvatinib","kind":"drug","name":"Lenvatinib","route":"/drugs/lenvatinib/","detail":"regional-approvals.ts records EU approved 2015 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"letrozole","kind":"drug","name":"Letrozole (and other aromatase inhibitors)","route":"/drugs/letrozole/","detail":"regional-approvals.ts records EU approved 1996 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"lisocabtagene-maraleucel","kind":"drug","name":"Lisocabtagene maraleucel","route":"/drugs/lisocabtagene-maraleucel/","detail":"regional-approvals.ts records EU approved 2022 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"lorlatinib","kind":"drug","name":"Lorlatinib","route":"/drugs/lorlatinib/","detail":"regional-approvals.ts records EU approved 2019 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"melflufen","kind":"drug","name":"Melphalan flufenamide","route":"/drugs/melflufen/","detail":"regional-approvals.ts records EU approved 2022 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"midostaurin","kind":"drug","name":"Midostaurin","route":"/drugs/midostaurin/","detail":"regional-approvals.ts records EU approved 2017 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"mosunetuzumab","kind":"drug","name":"Mosunetuzumab","route":"/drugs/mosunetuzumab/","detail":"regional-approvals.ts records EU conditional 2022 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"neratinib","kind":"drug","name":"Neratinib","route":"/drugs/neratinib/","detail":"regional-approvals.ts records EU approved 2018 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/","detail":"regional-approvals.ts records EU approved 2017 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","detail":"regional-approvals.ts records EU approved 2015 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"gardasil-9","kind":"drug","name":"Nonavalent HPV vaccine","route":"/drugs/gardasil-9/","detail":"regional-approvals.ts records EU approved 2015 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"obinutuzumab","kind":"drug","name":"Obinutuzumab","route":"/drugs/obinutuzumab/","detail":"regional-approvals.ts records EU approved 2014 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/","detail":"regional-approvals.ts records EU approved 2016 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/","detail":"regional-approvals.ts records EU approved 1993 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/","detail":"regional-approvals.ts records EU approved 2016 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"pazopanib","kind":"drug","name":"Pazopanib","route":"/drugs/pazopanib/","detail":"regional-approvals.ts records EU approved 2010 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"pegylated-liposomal-doxorubicin","kind":"drug","name":"Pegylated liposomal doxorubicin","route":"/drugs/pegylated-liposomal-doxorubicin/","detail":"regional-approvals.ts records EU approved 1996 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/","detail":"regional-approvals.ts records EU approved 2004 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"pertuzumab","kind":"drug","name":"Pertuzumab","route":"/drugs/pertuzumab/","detail":"regional-approvals.ts records EU approved 2013 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"pirtobrutinib","kind":"drug","name":"Pirtobrutinib","route":"/drugs/pirtobrutinib/","detail":"regional-approvals.ts records EU conditional 2023 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"polatuzumab-vedotin","kind":"drug","name":"Polatuzumab vedotin","route":"/drugs/polatuzumab-vedotin/","detail":"regional-approvals.ts records EU approved 2020 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"ponatinib","kind":"drug","name":"Ponatinib","route":"/drugs/ponatinib/","detail":"regional-approvals.ts records EU approved 2013 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"megestrol-progestins","kind":"drug","name":"Progestins (megestrol acetate, medroxyprogesterone, levonorgestrel IUD)","route":"/drugs/megestrol-progestins/","detail":"regional-approvals.ts records EU approved 1970 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"quizartinib","kind":"drug","name":"Quizartinib","route":"/drugs/quizartinib/","detail":"regional-approvals.ts records EU approved 2023 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"radioactive-iodine","kind":"drug","name":"Radioactive iodine (I-131)","route":"/drugs/radioactive-iodine/","detail":"regional-approvals.ts records EU approved 1990 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"radium-223","kind":"drug","name":"Radium-223 dichloride","route":"/drugs/radium-223/","detail":"regional-approvals.ts records EU approved 2013 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"ramucirumab","kind":"drug","name":"Ramucirumab","route":"/drugs/ramucirumab/","detail":"regional-approvals.ts records EU approved 2014 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"relugolix","kind":"drug","name":"Relugolix","route":"/drugs/relugolix/","detail":"regional-approvals.ts records EU approved 2022 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/","detail":"regional-approvals.ts records EU approved 2017 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"ripretinib","kind":"drug","name":"Ripretinib","route":"/drugs/ripretinib/","detail":"regional-approvals.ts records EU approved 2021 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/","detail":"regional-approvals.ts records EU approved 1998 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"rucaparib","kind":"drug","name":"Rucaparib","route":"/drugs/rucaparib/","detail":"regional-approvals.ts records EU approved 2018 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"octreotide-lanreotide","kind":"drug","name":"Somatostatin analogues (octreotide, lanreotide)","route":"/drugs/octreotide-lanreotide/","detail":"regional-approvals.ts records EU approved 1988 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"sorafenib","kind":"drug","name":"Sorafenib","route":"/drugs/sorafenib/","detail":"regional-approvals.ts records EU approved 2006 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"sunitinib","kind":"drug","name":"Sunitinib","route":"/drugs/sunitinib/","detail":"regional-approvals.ts records EU approved 2006 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"tagraxofusp","kind":"drug","name":"Tagraxofusp","route":"/drugs/tagraxofusp/","detail":"regional-approvals.ts records EU approved 2021 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"talimogene-laherparepvec","kind":"drug","name":"Talimogene laherparepvec","route":"/drugs/talimogene-laherparepvec/","detail":"regional-approvals.ts records EU approved 2015 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"talquetamab","kind":"drug","name":"Talquetamab","route":"/drugs/talquetamab/","detail":"regional-approvals.ts records EU conditional 2023 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"tamoxifen","kind":"drug","name":"Tamoxifen","route":"/drugs/tamoxifen/","detail":"regional-approvals.ts records EU approved 1973 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"tebentafusp","kind":"drug","name":"Tebentafusp","route":"/drugs/tebentafusp/","detail":"regional-approvals.ts records EU approved 2022 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"tisagenlecleucel","kind":"drug","name":"Tisagenlecleucel","route":"/drugs/tisagenlecleucel/","detail":"regional-approvals.ts records EU approved 2018 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/","detail":"regional-approvals.ts records EU approved 2023 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"topotecan","kind":"drug","name":"Topotecan","route":"/drugs/topotecan/","detail":"regional-approvals.ts records EU approved 1996 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/","detail":"regional-approvals.ts records EU approved 2024 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/","detail":"regional-approvals.ts records EU approved 2000 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/","detail":"regional-approvals.ts records EU approved 2013 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"tremelimumab","kind":"drug","name":"Tremelimumab","route":"/drugs/tremelimumab/","detail":"regional-approvals.ts records EU approved 2023 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"tucatinib","kind":"drug","name":"Tucatinib","route":"/drugs/tucatinib/","detail":"regional-approvals.ts records EU approved 2021 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"vandetanib","kind":"drug","name":"Vandetanib","route":"/drugs/vandetanib/","detail":"regional-approvals.ts records EU conditional 2012 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"vemurafenib","kind":"drug","name":"Vemurafenib","route":"/drugs/vemurafenib/","detail":"regional-approvals.ts records EU approved 2012 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/","detail":"regional-approvals.ts records EU approved 2016 but approvals[] has no EU row"},{"check":"approvals-vs-regional","severity":"low","id":"zanubrutinib","kind":"drug","name":"Zanubrutinib","route":"/drugs/zanubrutinib/","detail":"regional-approvals.ts records EU approved 2021 but approvals[] has no EU row"},{"check":"approved-only-live-trials","severity":"low","id":"aminolevulinic-acid-gleolan","kind":"drug","name":"5-Aminolevulinic acid (oral, for glioma surgery)","route":"/drugs/aminolevulinic-acid-gleolan/","detail":"status \"approved\" but every linked trial is still running (Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302): recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"afamitresgene-autoleucel","kind":"drug","name":"Afamitresgene autoleucel","route":"/drugs/afamitresgene-autoleucel/","detail":"status \"approved\" but every linked trial is still running (SPEARHEAD-3 Pediatric Study: recruiting, Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"alemtuzumab","kind":"drug","name":"Alemtuzumab","route":"/drugs/alemtuzumab/","detail":"status \"approved\" but every linked trial is still running (Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"tregzi","kind":"drug","name":"Allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq","route":"/drugs/tregzi/","detail":"status \"approved\" but every linked trial is still running (Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"amifostine","kind":"drug","name":"Amifostine","route":"/drugs/amifostine/","detail":"status \"approved\" but every linked trial is still running (A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"aprepitant","kind":"drug","name":"Aprepitant (and fosaprepitant)","route":"/drugs/aprepitant/","detail":"status \"approved\" but every linked trial is still running (Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC): recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"asciminib","kind":"drug","name":"Asciminib","route":"/drugs/asciminib/","detail":"status \"approved\" but every linked trial is still running (Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP: recruiting, Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.: recruiting, A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP: active, Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia: recruiting, Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia: active, A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP): active, Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL): recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"belinostat","kind":"drug","name":"Belinostat","route":"/drugs/belinostat/","detail":"status \"approved\" but every linked trial is still running (Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL: recruiting, To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"benmelstobart","kind":"drug","name":"Benmelstobart","route":"/drugs/benmelstobart/","detail":"status \"approved\" but every linked trial is still running (Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy: recruiting, The Safety and Efficacy of Benmelstobart Injection in Patients With Advanced Biliary Tract Malignant Tumors: planned, Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations: planned, A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients: planned, A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer: planned, Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma: recruiting, An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"bosutinib","kind":"drug","name":"Bosutinib","route":"/drugs/bosutinib/","detail":"status \"approved\" but every linked trial is still running (TAPUR (Targeted Agent and Profiling Utilization Registry): recruiting, A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"carfilzomib","kind":"drug","name":"Carfilzomib","route":"/drugs/carfilzomib/","detail":"status \"approved\" but every linked trial is still running (A Study of Daratumumab: active, A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With: active, MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other: recruiting, Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto: active, A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Rela: recruiting, A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants W: active, A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Tre: active, A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-spe: recruiting, A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory: active, A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Mult: recruiting, Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM): active, A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Darat: recruiting, A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"cetuximab-sarotalocan","kind":"drug","name":"Cetuximab sarotalocan","route":"/drugs/cetuximab-sarotalocan/","detail":"status \"approved\" but every linked trial is still running (A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of : recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"clonoseq","kind":"drug","name":"clonoSEQ","route":"/drugs/clonoseq/","detail":"status \"approved\" but every linked trial is still running (Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance: recruiting, A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP: recruiting, Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"decitabine","kind":"drug","name":"Decitabine","route":"/drugs/decitabine/","detail":"status \"approved\" but every linked trial is still running (Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic P: recruiting, Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）: planned, A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia: active, Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2: active, Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML: recruiting, Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"disitamab-vedotin","kind":"drug","name":"Disitamab vedotin","route":"/drugs/disitamab-vedotin/","detail":"status \"approved\" but every linked trial is still running (Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer: planned, RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure: planned, A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent o: recruiting, Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.: recruiting, Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer: recruiting, To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer: recruiting, A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2: active, DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy: recruiting, DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer: recruiting, To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2: recruiting, A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors: active, A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.: recruiting, Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2: active, A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors: recruiting, A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer: active, Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer: recruiting, A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"dordaviprone","kind":"drug","name":"Dordaviprone","route":"/drugs/dordaviprone/","detail":"status \"approved\" but every linked trial is still running (ACTION: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"duvelisib","kind":"drug","name":"Duvelisib","route":"/drugs/duvelisib/","detail":"status \"approved\" but every linked trial is still running (A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"eflapegrastim","kind":"drug","name":"Eflapegrastim","route":"/drugs/eflapegrastim/","detail":"status \"approved\" but every linked trial is still running (A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"elotuzumab","kind":"drug","name":"Elotuzumab","route":"/drugs/elotuzumab/","detail":"status \"approved\" but every linked trial is still running (A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Re: recruiting, MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other: recruiting, Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto: active, A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortez: active, A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Tre: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"enasidenib","kind":"drug","name":"Enasidenib","route":"/drugs/enasidenib/","detail":"status \"approved\" but every linked trial is still running (Beat AML Master Trial: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"envafolimab","kind":"drug","name":"Envafolimab","route":"/drugs/envafolimab/","detail":"status \"approved\" but every linked trial is still running (A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Col: planned, Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer: planned, Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma: recruiting, Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers: planned, Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer: planned, Gemcitabine-Cisplatin Plus Envafolimab in Resectable Biliary Tract Malignancies: planned, A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy.: planned, Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer: recruiting, Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer: recruiting, Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors: recruiting, Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC: recruiting, ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors: recruiting, Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC: active, KN035 for dMMR/MSI-H Advanced Solid Tumors: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"fedratinib","kind":"drug","name":"Fedratinib","route":"/drugs/fedratinib/","detail":"status \"approved\" but every linked trial is still running (A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis): active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"flotufolastat","kind":"drug","name":"Flotufolastat F-18","route":"/drugs/flotufolastat/","detail":"status \"approved\" but every linked trial is still running (Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance: recruiting, Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT: recruiting, PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"fludeoxyglucose-f18","kind":"drug","name":"Fludeoxyglucose F-18 (FDG)","route":"/drugs/fludeoxyglucose-f18/","detail":"status \"approved\" but every linked trial is still running (AHOD2131 (COG / NCTN): recruiting, Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer: active, Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer: recruiting, A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations: recruiting, Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer: recruiting, Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"fulzerasib","kind":"drug","name":"Fulzerasib","route":"/drugs/fulzerasib/","detail":"status \"approved\" but every linked trial is still running (IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation: recruiting, Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC: recruiting, A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment: planned, Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases: recruiting, A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation: planned); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"garsorasib","kind":"drug","name":"Garsorasib","route":"/drugs/garsorasib/","detail":"status \"approved\" but every linked trial is still running (A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment: planned, D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standar: recruiting, Study to Evaluate D-1553 in Subjects With Solid Tumors: active, Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"gedatolisib","kind":"drug","name":"Gedatolisib","route":"/drugs/gedatolisib/","detail":"status \"approved\" but every linked trial is still running (Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer: recruiting, Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1): active, Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2): recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"glecirasib","kind":"drug","name":"Glecirasib","route":"/drugs/glecirasib/","detail":"status \"approved\" but every linked trial is still running (A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer: planned, A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment: planned, JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation: active, Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation: recruiting, A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib: recruiting, A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1: recruiting, A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China: active, A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.: recruiting, JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"glumetinib","kind":"drug","name":"Glumetinib","route":"/drugs/glumetinib/","detail":"status \"approved\" but every linked trial is still running (A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in N: recruiting, Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors: recruiting, Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"golidocitinib","kind":"drug","name":"Golidocitinib","route":"/drugs/golidocitinib/","detail":"status \"approved\" but every linked trial is still running (Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC): planned, Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC: recruiting, A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19): recruiting, Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3): recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"hpv-quadrivalent-vaccine","kind":"drug","name":"HPV quadrivalent vaccine (types 6, 11, 16 and 18)","route":"/drugs/hpv-quadrivalent-vaccine/","detail":"status \"approved\" but every linked trial is still running (Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females: recruiting, A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"human-normal-immunoglobulin","kind":"drug","name":"Human normal immunoglobulin (IVIg)","route":"/drugs/human-normal-immunoglobulin/","detail":"status \"approved\" but every linked trial is still running (LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"iberdomide","kind":"drug","name":"Iberdomide","route":"/drugs/iberdomide/","detail":"status \"approved\" but every linked trial is still running (A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly: active, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants : active, A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma: recruiting, A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-spe: recruiting, A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"icotinib","kind":"drug","name":"Icotinib","route":"/drugs/icotinib/","detail":"status \"approved\" but every linked trial is still running (Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations: planned, Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"idelalisib","kind":"drug","name":"Idelalisib","route":"/drugs/idelalisib/","detail":"status \"approved\" but every linked trial is still running (Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer: recruiting, A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors: recruiting, A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"inaticabtagene-autoleucel","kind":"drug","name":"Inaticabtagene autoleucel","route":"/drugs/inaticabtagene-autoleucel/","detail":"status \"approved\" but every linked trial is still running (A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric): recruiting, Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia: recruiting, Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"iparomlimab-tuvonralimab","kind":"drug","name":"Iparomlimab and tuvonralimab","route":"/drugs/iparomlimab-tuvonralimab/","detail":"status \"approved\" but every linked trial is still running (Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Secon: planned, QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC.: planned, Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent: planned, QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC: recruiting, QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDAC: planned, QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer: recruiting, QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer: recruiting, A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line: planned, Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC: planned, Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer: recruiting, CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal C: planned, PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC: planned, QLS5132 Combination Therapy in Advanced Solid Tumors: planned, QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer: planned, a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy: planned, Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC: recruiting, A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer: planned); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"ixazomib","kind":"drug","name":"Ixazomib","route":"/drugs/ixazomib/","detail":"status \"approved\" but every linked trial is still running (Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"limertinib","kind":"drug","name":"Limertinib","route":"/drugs/limertinib/","detail":"status \"approved\" but every linked trial is still running (A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.: planned, ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC: active, ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"mecapegfilgrastim","kind":"drug","name":"Mecapegfilgrastim","route":"/drugs/mecapegfilgrastim/","detail":"status \"approved\" but every linked trial is still running (Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer: active, Reverse Triple Negative Immune Resistant Breast Cancer: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"megestrol","kind":"drug","name":"Megestrol acetate","route":"/drugs/megestrol/","detail":"status \"approved\" but every linked trial is still running (RAINBO: recruiting, A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015): recruiting, Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"mesna","kind":"drug","name":"Mesna","route":"/drugs/mesna/","detail":"status \"approved\" but every linked trial is still running (A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC: recruiting, IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"mirdametinib","kind":"drug","name":"Mirdametinib","route":"/drugs/mirdametinib/","detail":"status \"approved\" but every linked trial is still running (Mirdametinib in Histiocytic Disorders: recruiting, Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia: recruiting, Mirdametinib in Patients With Advanced NF1-mutant Melanoma: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"motixafortide","kind":"drug","name":"Motixafortide","route":"/drugs/motixafortide/","detail":"status \"approved\" but every linked trial is still running (Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"nadofaragene-firadenovec","kind":"drug","name":"Nadofaragene firadenovec","route":"/drugs/nadofaragene-firadenovec/","detail":"status \"approved\" but every linked trial is still running (Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer: recruiting, A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"odronextamab","kind":"drug","name":"Odronextamab","route":"/drugs/odronextamab/","detail":"status \"approved\" but every linked trial is still running (A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemo: active, A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participant: recruiting, A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell : active, A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Pa: recruiting, A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy : recruiting, A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treat: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"olutasidenib","kind":"drug","name":"Olutasidenib","route":"/drugs/olutasidenib/","detail":"status \"approved\" but every linked trial is still running (Study of Olutasidenib and Temozolomide in HGG: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"olverembatinib","kind":"drug","name":"Olverembatinib","route":"/drugs/olverembatinib/","detail":"status \"approved\" but every linked trial is still running (Study of Olverembatinib (HQP1351) in Patients With CML-CP: recruiting, A Study of Olverembatinib in SDH-deficient GIST.: recruiting, A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1): recruiting, Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"omacetaxine","kind":"drug","name":"Omacetaxine mepesuccinate","route":"/drugs/omacetaxine/","detail":"status \"approved\" but every linked trial is still running (Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"ondansetron","kind":"drug","name":"Ondansetron","route":"/drugs/ondansetron/","detail":"status \"approved\" but every linked trial is still running (Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC): recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"orelabrutinib","kind":"drug","name":"Orelabrutinib","route":"/drugs/orelabrutinib/","detail":"status \"approved\" but every linked trial is still running (A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL: recruiting, Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma: recruiting, A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"pacritinib","kind":"drug","name":"Pacritinib","route":"/drugs/pacritinib/","detail":"status \"approved\" but every linked trial is still running (Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"paltusotine","kind":"drug","name":"Paltusotine","route":"/drugs/paltusotine/","detail":"status \"approved\" but every linked trial is still running (Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"penpulimab","kind":"drug","name":"Penpulimab","route":"/drugs/penpulimab/","detail":"status \"approved\" but every linked trial is still running (SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer: recruiting, Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (A: planned, A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs W: planned, Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.: recruiting, A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma: active, Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C: recruiting, Clinical Studies for the Treatment of Advanced Solid Tumors: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"pivekimab-sunirine","kind":"drug","name":"Pivekimab sunirine","route":"/drugs/pivekimab-sunirine/","detail":"status \"approved\" but every linked trial is still running (Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN: active, A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML): recruiting, IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"pralatrexate","kind":"drug","name":"Pralatrexate","route":"/drugs/pralatrexate/","detail":"status \"approved\" but every linked trial is still running (Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL: recruiting, To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"prosigna","kind":"drug","name":"Prosigna (PAM50)","route":"/drugs/prosigna/","detail":"status \"approved\" but every linked trial is still running (The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"pucotenlimab","kind":"drug","name":"Pucotenlimab","route":"/drugs/pucotenlimab/","detail":"status \"approved\" but every linked trial is still running (LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study: recruiting, Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer: recruiting, Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for: planned, Pucotenlimab Plus Radiotherapy and Chemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cance(PUCRT): recruiting, Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations: planned, Exploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Advanced Cholangiocarcinoma: recruiting, The Efficacy and Safety of Pucotenlimab (PD-1) Combined With Becotatugvedotin (EGFR-ADC) in Advanced Cholangiocarcinoma: planned, Becotatug Vedotin Plus Pucotenlimab for Advanced Biliary Tract Cancer, Phase II: planned, A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer: active, A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcin: recruiting, MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II): recruiting, Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma: recruiting, OH2 Injection in Combination With HX008 for Melanoma.: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"raloxifene","kind":"drug","name":"Raloxifene","route":"/drugs/raloxifene/","detail":"status \"approved\" but every linked trial is still running (Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"rezvilutamide","kind":"drug","name":"Rezvilutamide","route":"/drugs/rezvilutamide/","detail":"status \"approved\" but every linked trial is still running (A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer: recruiting, A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer: recruiting, A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/","detail":"status \"approved\" but every linked trial is still running (Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC: planned, HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer: planned, A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Ca: planned, Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations: planned, Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer: planned, Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC: planned, Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer: planned, Sac-TMT for Active TNBC Brain Metastases: planned, Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer: recruiting, Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases: recruiting, Sacituzumab Tirumotecan for Pancreatic Cancer: planned, Exploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Advanced Cholangiocarcinoma: recruiting, Sacituzumab Tirumotecan in Previously Treated TROP2-Positive Advanced Biliary Tract Cancer: planned, A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy.: planned, Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC): planned, Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis: planned, Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases: planned, Toripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable NSCLC: planned, A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advan: active, Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, A: active, A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: active, A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Canc: recruiting, A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021): recruiting, A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Pl: recruiting, A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015): active, Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With P: recruiting, A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With: active, Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287: recruiting, A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative P: active, A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Sm: recruiting, A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participan: recruiting, Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005): active, A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients: active, Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With: active, Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01): active, SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.: recruiting, A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-: active, Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Facto: recruiting, A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A): recruiting, A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04): active, Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012): recruiting, Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06): recruiting, KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J): recruiting, A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010): recruiting, A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031): recruiting, A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032): recruiting, A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F): recruiting, A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B): recruiting, A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027): recruiting, Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma: recruiting, Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06): recruiting, Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06): recruiting, Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01): recruiting, A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011): recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"siltuximab","kind":"drug","name":"Siltuximab","route":"/drugs/siltuximab/","detail":"status \"approved\" but every linked trial is still running (A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant: recruiting, Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis: active, A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005): recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"sonrotoclax","kind":"drug","name":"Sonrotoclax","route":"/drugs/sonrotoclax/","detail":"status \"approved\" but every linked trial is still running (CELESTIAL-TNCLL: active, A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refrac: recruiting, A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.: recruiting, Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma: active, A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Darat: recruiting, A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL): recruiting, A Study of BGB-11417 in Participants With Myeloid Malignancies: recruiting, A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia: recruiting, Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: active, A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies: recruiting, A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia: active, A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"sunvozertinib","kind":"drug","name":"Sunvozertinib","route":"/drugs/sunvozertinib/","detail":"status \"approved\" but every linked trial is still running (Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC: recruiting, A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Ins: recruiting, A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28): active, Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6): active, Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1): active, Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8): recruiting, A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21): recruiting, DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29): recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"tabelecleucel","kind":"drug","name":"Tabelecleucel","route":"/drugs/tabelecleucel/","detail":"status \"approved\" but every linked trial is still running (A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failu: recruiting, A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"tagraxofusp","kind":"drug","name":"Tagraxofusp","route":"/drugs/tagraxofusp/","detail":"status \"approved\" but every linked trial is still running (A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"taletrectinib","kind":"drug","name":"Taletrectinib","route":"/drugs/taletrectinib/","detail":"status \"approved\" but every linked trial is still running (Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV): recruiting, A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients: recruiting, Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"therascreen-cdx","kind":"drug","name":"therascreen companion diagnostic kits (KRAS, EGFR, PIK3CA, FGFR, BRAF)","route":"/drugs/therascreen-cdx/","detail":"status \"approved\" but every linked trial is still running (EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"tocilizumab","kind":"drug","name":"Tocilizumab","route":"/drugs/tocilizumab/","detail":"status \"approved\" but every linked trial is still running (Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers: recruiting, Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based T: recruiting, A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relaps: recruiting, A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combi: active, Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent: recruiting, A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma: recruiting, A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multi: active, A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokineti: active, A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies: active, A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treat: active, A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma: active, A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Li: active, A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma: recruiting, An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma: active, A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"trilaciclib","kind":"drug","name":"Trilaciclib","route":"/drugs/trilaciclib/","detail":"status \"approved\" but every linked trial is still running (The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC: planned, Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer): planned, the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib: recruiting, Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and C: recruiting, Study of Trilaciclib and Lurbinectidin: recruiting, Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"tucidinostat","kind":"drug","name":"Tucidinostat (chidamide)","route":"/drugs/tucidinostat/","detail":"status \"approved\" but every linked trial is still running (QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer: recruiting, A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Micro: planned, A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal C: recruiting, HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer: recruiting, Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer: recruiting, A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients: recruiting, A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma: recruiting, Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL): recruiting, Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"tunlametinib","kind":"drug","name":"Tunlametinib","route":"/drugs/tunlametinib/","detail":"status \"approved\" but every linked trial is still running (Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma: recruiting, Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"utidelone","kind":"drug","name":"Utidelone","route":"/drugs/utidelone/","detail":"status \"approved\" but every linked trial is still running (Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients: planned, Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy: recruiting, The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospec: recruiting, Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases: planned, Phase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid Tumors: active, A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"vebreltinib","kind":"drug","name":"Vebreltinib","route":"/drugs/vebreltinib/","detail":"status \"approved\" but every linked trial is still running (Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failur: planned, Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: recruiting, A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).: active, A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2): recruiting, Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI: recruiting, APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors: recruiting, Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.: recruiting, A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"vinflunine","kind":"drug","name":"Vinflunine","route":"/drugs/vinflunine/","detail":"status \"approved\" but every linked trial is still running (A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031): recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"vusolimogene-oderparepvec","kind":"drug","name":"Vusolimogene oderparepvec","route":"/drugs/vusolimogene-oderparepvec/","detail":"status \"approved\" but every linked trial is still running (VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]: recruiting, Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma: recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"zenocutuzumab","kind":"drug","name":"Zenocutuzumab","route":"/drugs/zenocutuzumab/","detail":"status \"approved\" but every linked trial is still running (A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy): active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"zidesamtinib","kind":"drug","name":"Zidesamtinib","route":"/drugs/zidesamtinib/","detail":"status \"approved\" but every linked trial is still running (A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1): recruiting); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"approved-only-live-trials","severity":"low","id":"zimberelimab","kind":"drug","name":"Zimberelimab","route":"/drugs/zimberelimab/","detail":"status \"approved\" but every linked trial is still running (Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases: recruiting, SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study): planned, Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer: planned, A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for: recruiting, Domvanalimab and Zimberelimab in Advanced Liver Cancers: active, Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC): active, Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.: recruiting, A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervic: recruiting, Study of Novel Treatment Combinations in Patients With Lung Cancer: active, Study With Various Immunotherapy Treatments in Participants With Lung Cancer: active, Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer: active, Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Subst: active, A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent o: recruiting, Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors: recruiting, Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer: recruiting, Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread: active, A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies: active); link the pivotal trial or note that the approval was accelerated on earlier data"},{"check":"future-year-in-text","severity":"low","id":"nct06856837","kind":"trial","name":"- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorec","route":"/trials/nct06856837/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04910685","kind":"trial","name":"(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis","route":"/trials/nct04910685/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05907954","kind":"trial","name":"(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma","route":"/trials/nct05907954/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03731260","kind":"trial","name":"(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo ","route":"/trials/nct03731260/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07432633","kind":"trial","name":"[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications","route":"/trials/nct07432633/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07702292","kind":"trial","name":"[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications","route":"/trials/nct07702292/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07333651","kind":"trial","name":"125I Seed Implantation Plus Systemic Therapy for Oligoprogressive NSCLC or Colorectal Cancer","route":"/trials/nct07333651/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07779694","kind":"trial","name":"16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal Cancer","route":"/trials/nct07779694/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07189871","kind":"trial","name":"177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors","route":"/trials/nct07189871/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06503146","kind":"trial","name":"18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection","route":"/trials/nct06503146/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"2027","kind":"year","name":"2027 in oncology","route":"/years/2027/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"2028","kind":"year","name":"2028 in oncology","route":"/years/2028/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"2029","kind":"year","name":"2029 in oncology","route":"/years/2029/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"2030","kind":"year","name":"2030 in oncology","route":"/years/2030/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"2031","kind":"year","name":"2031 in oncology","route":"/years/2031/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"2032","kind":"year","name":"2032 in oncology","route":"/years/2032/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"2033","kind":"year","name":"2033 in oncology","route":"/years/2033/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07043270","kind":"trial","name":"24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC","route":"/trials/nct07043270/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07124884","kind":"trial","name":"5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemother","route":"/trials/nct07124884/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06887218","kind":"trial","name":"5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer","route":"/trials/nct06887218/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-piccart-lancet-oncol","kind":"paper","name":"70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age","route":"/key-papers/paper-piccart-lancet-oncol/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07314723","kind":"trial","name":"9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer","route":"/trials/nct07314723/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06592326","kind":"trial","name":"9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer","route":"/trials/nct06592326/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07563738","kind":"trial","name":"A 2-part Phase 1/2 Open-label Trial on ODM-212","route":"/trials/nct07563738/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07332000","kind":"trial","name":"A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec","route":"/trials/nct07332000/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07078604","kind":"trial","name":"A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer","route":"/trials/nct07078604/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06508983","kind":"trial","name":"A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients","route":"/trials/nct06508983/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07578337","kind":"trial","name":"A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease.","route":"/trials/nct07578337/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07414927","kind":"trial","name":"A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following E","route":"/trials/nct07414927/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07454720","kind":"trial","name":"A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer","route":"/trials/nct07454720/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06922383","kind":"trial","name":"A Clinical Study of Arfolitixorin in Patients With mCRC","route":"/trials/nct06922383/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07489495","kind":"trial","name":"A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)","route":"/trials/nct07489495/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07227402","kind":"trial","name":"A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)","route":"/trials/nct07227402/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07190248","kind":"trial","name":"A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)","route":"/trials/nct07190248/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07209111","kind":"trial","name":"A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)","route":"/trials/nct07209111/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06997497","kind":"trial","name":"A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)","route":"/trials/nct06997497/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07227597","kind":"trial","name":"A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)","route":"/trials/nct07227597/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07446153","kind":"trial","name":"A Clinical Study of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects","route":"/trials/nct07446153/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06925737","kind":"trial","name":"A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)","route":"/trials/nct06925737/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06863272","kind":"trial","name":"A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)","route":"/trials/nct06863272/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06833073","kind":"trial","name":"A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)","route":"/trials/nct06833073/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06961006","kind":"trial","name":"A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)","route":"/trials/nct06961006/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06305767","kind":"trial","name":"A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)","route":"/trials/nct06305767/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07446387","kind":"trial","name":"A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer","route":"/trials/nct07446387/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07502014","kind":"trial","name":"A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line","route":"/trials/nct07502014/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06208410","kind":"trial","name":"A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors","route":"/trials/nct06208410/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07585279","kind":"trial","name":"A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer","route":"/trials/nct07585279/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06398444","kind":"trial","name":"A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms","route":"/trials/nct06398444/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05579132","kind":"trial","name":"A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)","route":"/trials/nct05579132/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07519772","kind":"trial","name":"A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)","route":"/trials/nct07519772/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07286149","kind":"trial","name":"A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)","route":"/trials/nct07286149/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06428409","kind":"trial","name":"A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)","route":"/trials/nct06428409/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07222488","kind":"trial","name":"A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)","route":"/trials/nct07222488/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07043725","kind":"trial","name":"A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer","route":"/trials/nct07043725/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07060807","kind":"trial","name":"A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)","route":"/trials/nct07060807/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06843447","kind":"trial","name":"A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)","route":"/trials/nct06843447/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07216703","kind":"trial","name":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Canc","route":"/trials/nct07216703/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06637423","kind":"trial","name":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)","route":"/trials/nct06637423/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06966700","kind":"trial","name":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","route":"/trials/nct06966700/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07609251","kind":"trial","name":"A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study","route":"/trials/nct07609251/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06643754","kind":"trial","name":"A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors","route":"/trials/nct06643754/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07407283","kind":"trial","name":"A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer","route":"/trials/nct07407283/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07676162","kind":"trial","name":"A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal","route":"/trials/nct07676162/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06778031","kind":"trial","name":"A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer","route":"/trials/nct06778031/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07597629","kind":"trial","name":"A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer","route":"/trials/nct07597629/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07714668","kind":"trial","name":"A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer","route":"/trials/nct07714668/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06340568","kind":"trial","name":"A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer","route":"/trials/nct06340568/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07003074","kind":"trial","name":"A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer","route":"/trials/nct07003074/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06459973","kind":"trial","name":"A Clinical Study of YL205 in Patients With Advanced Solid Tumors","route":"/trials/nct06459973/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06890884","kind":"trial","name":"A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)","route":"/trials/nct06890884/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06962267","kind":"trial","name":"A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)","route":"/trials/nct06962267/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07395063","kind":"trial","name":"A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.","route":"/trials/nct07395063/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06931717","kind":"trial","name":"A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Re","route":"/trials/nct06931717/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07483684","kind":"trial","name":"A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxal","route":"/trials/nct07483684/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06959693","kind":"trial","name":"A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Col","route":"/trials/nct06959693/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07222969","kind":"trial","name":"A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors","route":"/trials/nct07222969/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06827236","kind":"trial","name":"A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer","route":"/trials/nct06827236/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06892548","kind":"trial","name":"A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer","route":"/trials/nct06892548/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05755113","kind":"trial","name":"A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma","route":"/trials/nct05755113/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07079631","kind":"trial","name":"A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT3","route":"/trials/nct07079631/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07070232","kind":"trial","name":"A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors","route":"/trials/nct07070232/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07113275","kind":"trial","name":"A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course R","route":"/trials/nct07113275/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04183166","kind":"trial","name":"A Clinical Trial Evaluating TG4050 in Head and Neck Cancer","route":"/trials/nct04183166/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05890742","kind":"trial","name":"A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer","route":"/trials/nct05890742/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07258407","kind":"trial","name":"A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer","route":"/trials/nct07258407/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07653685","kind":"trial","name":"A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advan","route":"/trials/nct07653685/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04534205","kind":"trial","name":"A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1","route":"/trials/nct04534205/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07513376","kind":"trial","name":"A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I ","route":"/trials/nct07513376/","detail":"mentions 2034 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07554339","kind":"trial","name":"A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)","route":"/trials/nct07554339/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07032077","kind":"trial","name":"A Clinical Trial of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid Tumors","route":"/trials/nct07032077/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07405151","kind":"trial","name":"A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)","route":"/trials/nct07405151/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07111546","kind":"trial","name":"A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]","route":"/trials/nct07111546/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07791758","kind":"trial","name":"A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma","route":"/trials/nct07791758/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07634471","kind":"trial","name":"A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)","route":"/trials/nct07634471/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07570173","kind":"trial","name":"A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)","route":"/trials/nct07570173/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07318558","kind":"trial","name":"A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)","route":"/trials/nct07318558/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07419295","kind":"trial","name":"A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)","route":"/trials/nct07419295/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07111832","kind":"trial","name":"A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer","route":"/trials/nct07111832/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06561607","kind":"trial","name":"A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer","route":"/trials/nct06561607/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07367529","kind":"trial","name":"A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection","route":"/trials/nct07367529/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07255404","kind":"trial","name":"A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have N","route":"/trials/nct07255404/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07297212","kind":"trial","name":"A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma","route":"/trials/nct07297212/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07049055","kind":"trial","name":"A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer","route":"/trials/nct07049055/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06581419","kind":"trial","name":"A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors","route":"/trials/nct06581419/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06292208","kind":"trial","name":"A Clinical Trial to Evaluate Effect of IBD0333 in Patients With Advanced Malignant Tumors","route":"/trials/nct06292208/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07582432","kind":"trial","name":"A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma","route":"/trials/nct07582432/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06888921","kind":"trial","name":"A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer","route":"/trials/nct06888921/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07111520","kind":"trial","name":"A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced ","route":"/trials/nct07111520/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07186842","kind":"trial","name":"A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9","route":"/trials/nct07186842/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04529772","kind":"trial","name":"A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)","route":"/trials/nct04529772/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06835530","kind":"trial","name":"A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)","route":"/trials/nct06835530/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05359393","kind":"trial","name":"A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis","route":"/trials/nct05359393/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06184035","kind":"trial","name":"A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer","route":"/trials/nct06184035/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03075696","kind":"trial","name":"A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treat","route":"/trials/nct03075696/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07692204","kind":"trial","name":"A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer","route":"/trials/nct07692204/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07231068","kind":"trial","name":"A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation","route":"/trials/nct07231068/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07255664","kind":"trial","name":"A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC","route":"/trials/nct07255664/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06413680","kind":"trial","name":"A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Hav","route":"/trials/nct06413680/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06188520","kind":"trial","name":"A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With ","route":"/trials/nct06188520/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07354711","kind":"trial","name":"A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors","route":"/trials/nct07354711/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07439094","kind":"trial","name":"A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer","route":"/trials/nct07439094/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06253130","kind":"trial","name":"A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors","route":"/trials/nct06253130/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06921837","kind":"trial","name":"A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer","route":"/trials/nct06921837/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07629960","kind":"trial","name":"A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations","route":"/trials/nct07629960/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07220616","kind":"trial","name":"A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies","route":"/trials/nct07220616/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05908643","kind":"trial","name":"A First-In-Human Trial of pTTL in Advanced Colorectal Cancer","route":"/trials/nct05908643/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05584670","kind":"trial","name":"A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors","route":"/trials/nct05584670/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07147348","kind":"trial","name":"A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors","route":"/trials/nct07147348/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04686682","kind":"trial","name":"A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors","route":"/trials/nct04686682/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06363994","kind":"trial","name":"A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL","route":"/trials/nct06363994/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07459751","kind":"trial","name":"A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer","route":"/trials/nct07459751/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06868277","kind":"trial","name":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer","route":"/trials/nct06868277/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06627647","kind":"trial","name":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous N","route":"/trials/nct06627647/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06692738","kind":"trial","name":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-s","route":"/trials/nct06692738/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03591510","kind":"trial","name":"A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML","route":"/trials/nct03591510/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05984277","kind":"trial","name":"A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung","route":"/trials/nct05984277/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05120349","kind":"trial","name":"A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection","route":"/trials/nct05120349/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07796763","kind":"trial","name":"A Global Trial of Trastuzumab Rezetecan (SHR-A1811) in Combination With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Colorecta","route":"/trials/nct07796763/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07105215","kind":"trial","name":"A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors","route":"/trials/nct07105215/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07229638","kind":"trial","name":"A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors","route":"/trials/nct07229638/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05999994","kind":"trial","name":"A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer","route":"/trials/nct05999994/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06630234","kind":"trial","name":"A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)","route":"/trials/nct06630234/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06600789","kind":"trial","name":"A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies","route":"/trials/nct06600789/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07681596","kind":"trial","name":"A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07681596/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04256317","kind":"trial","name":"A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)","route":"/trials/nct04256317/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06412198","kind":"trial","name":"A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations","route":"/trials/nct06412198/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07333287","kind":"trial","name":"A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With Arterial Infusion Chemotherapy and Emboli","route":"/trials/nct07333287/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02448173","kind":"trial","name":"A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer","route":"/trials/nct02448173/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"g-hope-002","kind":"trial","name":"A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)","route":"/trials/g-hope-002/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06838546","kind":"trial","name":"A Multicenter, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Colorectal Cancer","route":"/trials/nct06838546/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07814066","kind":"trial","name":"A Multicenter, Open-label, Phase II Umbrella Study to Evaluate the Efficacy and Safety of the Investigational Product in Participants With Advanced or Metastati","route":"/trials/nct07814066/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07591597","kind":"trial","name":"A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus F","route":"/trials/nct07591597/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06878625","kind":"trial","name":"A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer","route":"/trials/nct06878625/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07632235","kind":"trial","name":"A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma","route":"/trials/nct07632235/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07669220","kind":"trial","name":"A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Cours","route":"/trials/nct07669220/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07579234","kind":"trial","name":"A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07579234/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06936644","kind":"trial","name":"A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation","route":"/trials/nct06936644/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04669171","kind":"trial","name":"A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma","route":"/trials/nct04669171/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07736612","kind":"trial","name":"A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer","route":"/trials/nct07736612/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07636785","kind":"trial","name":"A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors","route":"/trials/nct07636785/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07157033","kind":"trial","name":"A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.","route":"/trials/nct07157033/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05593094","kind":"trial","name":"A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced So","route":"/trials/nct05593094/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06163430","kind":"trial","name":"A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)","route":"/trials/nct06163430/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06956690","kind":"trial","name":"A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing ","route":"/trials/nct06956690/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06427941","kind":"trial","name":"A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Sol","route":"/trials/nct06427941/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06384807","kind":"trial","name":"A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors","route":"/trials/nct06384807/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05886920","kind":"trial","name":"A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations","route":"/trials/nct05886920/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04988555","kind":"trial","name":"A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)","route":"/trials/nct04988555/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07328217","kind":"trial","name":"A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors","route":"/trials/nct07328217/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07629726","kind":"trial","name":"A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms","route":"/trials/nct07629726/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06480240","kind":"trial","name":"A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors","route":"/trials/nct06480240/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07491497","kind":"trial","name":"A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC","route":"/trials/nct07491497/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07020221","kind":"trial","name":"A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors","route":"/trials/nct07020221/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06265727","kind":"trial","name":"A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors","route":"/trials/nct06265727/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07109726","kind":"trial","name":"A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations","route":"/trials/nct07109726/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06725758","kind":"trial","name":"A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours","route":"/trials/nct06725758/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06616766","kind":"trial","name":"A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946","route":"/trials/nct06616766/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05150691","kind":"trial","name":"A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors","route":"/trials/nct05150691/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05914116","kind":"trial","name":"A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors","route":"/trials/nct05914116/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07160725","kind":"trial","name":"A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors","route":"/trials/nct07160725/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06939283","kind":"trial","name":"A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma","route":"/trials/nct06939283/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06785636","kind":"trial","name":"A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC","route":"/trials/nct06785636/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07766018","kind":"trial","name":"A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer","route":"/trials/nct07766018/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06632262","kind":"trial","name":"A Phase 2 Clinical Study of ABSK061 and ABSK043","route":"/trials/nct06632262/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06668103","kind":"trial","name":"A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib","route":"/trials/nct06668103/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07164170","kind":"trial","name":"A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib","route":"/trials/nct07164170/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07623616","kind":"trial","name":"A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia","route":"/trials/nct07623616/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07102381","kind":"trial","name":"A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer","route":"/trials/nct07102381/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07133425","kind":"trial","name":"A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer","route":"/trials/nct07133425/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07710612","kind":"trial","name":"A Phase 2 Study of ABSK043 Combined With Osimertinib","route":"/trials/nct07710612/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05548296","kind":"trial","name":"A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma","route":"/trials/nct05548296/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07562581","kind":"trial","name":"A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC","route":"/trials/nct07562581/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07743112","kind":"trial","name":"A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia","route":"/trials/nct07743112/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05060016","kind":"trial","name":"A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)","route":"/trials/nct05060016/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07659795","kind":"trial","name":"A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer","route":"/trials/nct07659795/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07659782","kind":"trial","name":"A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer","route":"/trials/nct07659782/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07644559","kind":"trial","name":"A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer","route":"/trials/nct07644559/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07005154","kind":"trial","name":"A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer","route":"/trials/nct07005154/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06985147","kind":"trial","name":"A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)","route":"/trials/nct06985147/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06745323","kind":"trial","name":"A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC","route":"/trials/nct06745323/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06710288","kind":"trial","name":"A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In P","route":"/trials/nct06710288/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04485949","kind":"trial","name":"A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma","route":"/trials/nct04485949/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06929624","kind":"trial","name":"A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma","route":"/trials/nct06929624/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06007690","kind":"trial","name":"A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma","route":"/trials/nct06007690/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06774131","kind":"trial","name":"A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer","route":"/trials/nct06774131/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03459534","kind":"trial","name":"A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs","route":"/trials/nct03459534/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06601335","kind":"trial","name":"A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)","route":"/trials/nct06601335/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07174908","kind":"trial","name":"A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation","route":"/trials/nct07174908/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07833202","kind":"trial","name":"A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutatio","route":"/trials/nct07833202/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07182682","kind":"trial","name":"A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Ins","route":"/trials/nct07182682/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06496178","kind":"trial","name":"A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma P","route":"/trials/nct06496178/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05862272","kind":"trial","name":"A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis","route":"/trials/nct05862272/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06971523","kind":"trial","name":"A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies","route":"/trials/nct06971523/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07136142","kind":"trial","name":"A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors","route":"/trials/nct07136142/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07229612","kind":"trial","name":"A Phase I/II Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors","route":"/trials/nct07229612/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07253116","kind":"trial","name":"A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors","route":"/trials/nct07253116/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04685226","kind":"trial","name":"A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors","route":"/trials/nct04685226/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07069062","kind":"trial","name":"A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors","route":"/trials/nct07069062/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06922357","kind":"trial","name":"A Phase I/II of HRS-6719 in Patients With Advanced/Metastatic Solid Tumors","route":"/trials/nct06922357/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07417189","kind":"trial","name":"A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )","route":"/trials/nct07417189/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06245330","kind":"trial","name":"A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors","route":"/trials/nct06245330/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07123454","kind":"trial","name":"A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphom","route":"/trials/nct07123454/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06741644","kind":"trial","name":"A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors","route":"/trials/nct06741644/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05415072","kind":"trial","name":"A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas","route":"/trials/nct05415072/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07083323","kind":"trial","name":"A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors","route":"/trials/nct07083323/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06712680","kind":"trial","name":"A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes","route":"/trials/nct06712680/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05615974","kind":"trial","name":"A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors","route":"/trials/nct05615974/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06682780","kind":"trial","name":"A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours","route":"/trials/nct06682780/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07075328","kind":"trial","name":"A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma","route":"/trials/nct07075328/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06953323","kind":"trial","name":"A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors","route":"/trials/nct06953323/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06084884","kind":"trial","name":"A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma","route":"/trials/nct06084884/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05315167","kind":"trial","name":"A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors","route":"/trials/nct05315167/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06380816","kind":"trial","name":"A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer","route":"/trials/nct06380816/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06247995","kind":"trial","name":"A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.","route":"/trials/nct06247995/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07362940","kind":"trial","name":"A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib","route":"/trials/nct07362940/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07811037","kind":"trial","name":"A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, Immunogenicity, and Preliminary Efficacy of SGT003 in Patients With Advanced Solid Tumors","route":"/trials/nct07811037/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06797986","kind":"trial","name":"A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC.","route":"/trials/nct06797986/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07392736","kind":"trial","name":"A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.","route":"/trials/nct07392736/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05123482","kind":"trial","name":"A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies","route":"/trials/nct05123482/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07243340","kind":"trial","name":"A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor","route":"/trials/nct07243340/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04381130","kind":"trial","name":"A Phase I/IIa Study of EF-009 in Patients With Pancreatic Cancer","route":"/trials/nct04381130/","detail":"mentions 2027, 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07777211","kind":"trial","name":"A Phase I/IIa Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer","route":"/trials/nct07777211/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07228247","kind":"trial","name":"A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors","route":"/trials/nct07228247/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07744763","kind":"trial","name":"A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors","route":"/trials/nct07744763/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05133882","kind":"trial","name":"A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML","route":"/trials/nct05133882/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07040228","kind":"trial","name":"A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer","route":"/trials/nct07040228/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06474455","kind":"trial","name":"A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors","route":"/trials/nct06474455/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07501559","kind":"trial","name":"A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)","route":"/trials/nct07501559/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07226986","kind":"trial","name":"A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA","route":"/trials/nct07226986/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07466160","kind":"trial","name":"A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors","route":"/trials/nct07466160/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05910827","kind":"trial","name":"A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers","route":"/trials/nct05910827/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07621159","kind":"trial","name":"A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal Cancer","route":"/trials/nct07621159/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07750041","kind":"trial","name":"A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer","route":"/trials/nct07750041/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07358585","kind":"trial","name":"A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal Cancer","route":"/trials/nct07358585/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07002177","kind":"trial","name":"A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC","route":"/trials/nct07002177/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07283367","kind":"trial","name":"A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.","route":"/trials/nct07283367/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07547553","kind":"trial","name":"A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC","route":"/trials/nct07547553/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07361003","kind":"trial","name":"A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer","route":"/trials/nct07361003/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07052253","kind":"trial","name":"A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.","route":"/trials/nct07052253/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07241767","kind":"trial","name":"A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer","route":"/trials/nct07241767/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07331155","kind":"trial","name":"A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]","route":"/trials/nct07331155/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06889610","kind":"trial","name":"A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.","route":"/trials/nct06889610/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07798947","kind":"trial","name":"A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC","route":"/trials/nct07798947/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07308106","kind":"trial","name":"A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities","route":"/trials/nct07308106/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07253142","kind":"trial","name":"A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer","route":"/trials/nct07253142/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06907615","kind":"trial","name":"A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct06907615/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07301229","kind":"trial","name":"A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic Cancer","route":"/trials/nct07301229/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07283198","kind":"trial","name":"A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer","route":"/trials/nct07283198/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07390383","kind":"trial","name":"A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]","route":"/trials/nct07390383/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07489716","kind":"trial","name":"A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer","route":"/trials/nct07489716/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07729033","kind":"trial","name":"A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy.","route":"/trials/nct07729033/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07058012","kind":"trial","name":"A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal","route":"/trials/nct07058012/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07604909","kind":"trial","name":"A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy","route":"/trials/nct07604909/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07248020","kind":"trial","name":"A Phase II Single-Arm Study of High-Bioavailability Curcumin as Neoadjuvant Chemoradiotherapy in Mid-to-Low Rectal Cancer: Integrated Clinical and Translational","route":"/trials/nct07248020/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07283705","kind":"trial","name":"A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer","route":"/trials/nct07283705/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07405801","kind":"trial","name":"A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer","route":"/trials/nct07405801/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07679399","kind":"trial","name":"A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.","route":"/trials/nct07679399/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07591090","kind":"trial","name":"A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer","route":"/trials/nct07591090/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07669779","kind":"trial","name":"A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer","route":"/trials/nct07669779/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07474727","kind":"trial","name":"A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer","route":"/trials/nct07474727/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07743190","kind":"trial","name":"A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) P","route":"/trials/nct07743190/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07560111","kind":"trial","name":"A Phase II Study of GC101 in NSCLC","route":"/trials/nct07560111/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07784374","kind":"trial","name":"A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 Monotherapy in Patients With Previously Treated Locally Advanced Unresectable or Metast","route":"/trials/nct07784374/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07623642","kind":"trial","name":"A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.","route":"/trials/nct07623642/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06832202","kind":"trial","name":"A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients","route":"/trials/nct06832202/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07438106","kind":"trial","name":"A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer","route":"/trials/nct07438106/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07824882","kind":"trial","name":"A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamo","route":"/trials/nct07824882/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06728410","kind":"trial","name":"A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement","route":"/trials/nct06728410/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07644286","kind":"trial","name":"A Phase II Study of Pirfenidone Plus PD-1 Inhibitor With or Without Hypofractionated Radiotherapy for Refractory pMMR/MSS Colorectal Cancer","route":"/trials/nct07644286/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07071714","kind":"trial","name":"A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer","route":"/trials/nct07071714/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07506109","kind":"trial","name":"A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colo","route":"/trials/nct07506109/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07230405","kind":"trial","name":"A Phase II Study of SKB571 in Patients With Lung Cancer","route":"/trials/nct07230405/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07815223","kind":"trial","name":"A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC","route":"/trials/nct07815223/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06241846","kind":"trial","name":"A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC","route":"/trials/nct06241846/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07444437","kind":"trial","name":"A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer","route":"/trials/nct07444437/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07310784","kind":"trial","name":"A Phase II Trial of LM103 in Advanced Melanoma","route":"/trials/nct07310784/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03301805","kind":"trial","name":"A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer","route":"/trials/nct03301805/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07441512","kind":"trial","name":"A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer","route":"/trials/nct07441512/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07318883","kind":"trial","name":"A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab","route":"/trials/nct07318883/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07462143","kind":"trial","name":"A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer","route":"/trials/nct07462143/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06335355","kind":"trial","name":"A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients","route":"/trials/nct06335355/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07761429","kind":"trial","name":"A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP)","route":"/trials/nct07761429/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07076095","kind":"trial","name":"A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer","route":"/trials/nct07076095/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06844357","kind":"trial","name":"A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.","route":"/trials/nct06844357/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06361888","kind":"trial","name":"A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer","route":"/trials/nct06361888/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07521852","kind":"trial","name":"A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Part","route":"/trials/nct07521852/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07269158","kind":"trial","name":"A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer","route":"/trials/nct07269158/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07168200","kind":"trial","name":"A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the","route":"/trials/nct07168200/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07023315","kind":"trial","name":"A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma","route":"/trials/nct07023315/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06532006","kind":"trial","name":"A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer","route":"/trials/nct06532006/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07011056","kind":"trial","name":"A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma","route":"/trials/nct07011056/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05262010","kind":"trial","name":"A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years","route":"/trials/nct05262010/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06112379","kind":"trial","name":"A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer","route":"/trials/nct06112379/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07103668","kind":"trial","name":"A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients","route":"/trials/nct07103668/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07311694","kind":"trial","name":"A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct07311694/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06564324","kind":"trial","name":"A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients","route":"/trials/nct06564324/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06464991","kind":"trial","name":"A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)","route":"/trials/nct06464991/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06383767","kind":"trial","name":"A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer","route":"/trials/nct06383767/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06732323","kind":"trial","name":"A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer","route":"/trials/nct06732323/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07409428","kind":"trial","name":"A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL","route":"/trials/nct07409428/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07464327","kind":"trial","name":"A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-S","route":"/trials/nct07464327/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06953999","kind":"trial","name":"A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer","route":"/trials/nct06953999/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07533123","kind":"trial","name":"A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care","route":"/trials/nct07533123/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07441460","kind":"trial","name":"A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer","route":"/trials/nct07441460/","detail":"mentions 2034 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06764875","kind":"trial","name":"A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer","route":"/trials/nct06764875/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07229625","kind":"trial","name":"A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)","route":"/trials/nct07229625/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"taishan-301","kind":"trial","name":"A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma(TAISHAN-301)","route":"/trials/taishan-301/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06612151","kind":"trial","name":"A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer（TAISHAN-302）","route":"/trials/nct06612151/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07816380","kind":"trial","name":"A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer","route":"/trials/nct07816380/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06465914","kind":"trial","name":"A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males","route":"/trials/nct06465914/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06908304","kind":"trial","name":"A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC","route":"/trials/nct06908304/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07349069","kind":"trial","name":"A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer","route":"/trials/nct07349069/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05888493","kind":"trial","name":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","route":"/trials/nct05888493/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07365995","kind":"trial","name":"A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer","route":"/trials/nct07365995/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06126640","kind":"trial","name":"A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy","route":"/trials/nct06126640/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06564844","kind":"trial","name":"A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following C","route":"/trials/nct06564844/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07336953","kind":"trial","name":"A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic P","route":"/trials/nct07336953/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07647328","kind":"trial","name":"A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer","route":"/trials/nct07647328/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06764186","kind":"trial","name":"A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain","route":"/trials/nct06764186/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06247605","kind":"trial","name":"A Phase IIII Study of AL8326 in Small Cell Lung Cancer","route":"/trials/nct06247605/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07689955","kind":"trial","name":"A Phase-II Clinical Trial of Radiotherapy to the Coeliac Plexus to Help Pain in Advanced Pancreatic Cancer","route":"/trials/nct07689955/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06764940","kind":"trial","name":"A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases","route":"/trials/nct06764940/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06389292","kind":"trial","name":"A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia","route":"/trials/nct06389292/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06996782","kind":"trial","name":"A Platform Study in Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct06996782/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06140524","kind":"trial","name":"A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With H","route":"/trials/nct06140524/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05955508","kind":"trial","name":"A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Deve","route":"/trials/nct05955508/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06972498","kind":"trial","name":"A Prospective Multicenter Study: Ivosimab + Chemotherapy as Neoadjuvant for Resectable pMMR/MSS CRC Liver Mets","route":"/trials/nct06972498/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07101627","kind":"trial","name":"A Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer Therapy","route":"/trials/nct07101627/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07543848","kind":"trial","name":"A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemot","route":"/trials/nct07543848/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04501523","kind":"trial","name":"A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC","route":"/trials/nct04501523/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07471165","kind":"trial","name":"A Prospective, Single-Arm, Phase II Study: PD-L1 Monoclonal Antibody + Chemoradiotherapy as Bridge Therapy to Liver Transplantation for Locally Advanced Perihilar Cholangiocarcinoma (ACHIEVE-LT)","route":"/trials/nct07471165/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07809256","kind":"trial","name":"A Prospective, Single-center, Non-randomized, Interventional Study on the Effectiveness and Safety of Combined Immunotargeted Therapy in Patients With Metastati","route":"/trials/nct07809256/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05085028","kind":"trial","name":"A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung","route":"/trials/nct05085028/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06717126","kind":"trial","name":"A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma","route":"/trials/nct06717126/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07207070","kind":"trial","name":"A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer","route":"/trials/nct07207070/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07562490","kind":"trial","name":"A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer","route":"/trials/nct07562490/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06992258","kind":"trial","name":"A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer","route":"/trials/nct06992258/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04188145","kind":"trial","name":"A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Meta","route":"/trials/nct04188145/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07101614","kind":"trial","name":"A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy fo","route":"/trials/nct07101614/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06776952","kind":"trial","name":"A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma","route":"/trials/nct06776952/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06581406","kind":"trial","name":"A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult P","route":"/trials/nct06581406/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07099794","kind":"trial","name":"A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen","route":"/trials/nct07099794/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07172919","kind":"trial","name":"A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation","route":"/trials/nct07172919/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05862285","kind":"trial","name":"A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study","route":"/trials/nct05862285/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07569042","kind":"trial","name":"A Rollover Study of NBM-BMX in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma","route":"/trials/nct07569042/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05643742","kind":"trial","name":"A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies","route":"/trials/nct05643742/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06150885","kind":"trial","name":"A Safety And Efficacy Study Of Allogeneic CAR Gamma-Delta T Cells in Subjects With Relapsed/Refractory Solid Tumors","route":"/trials/nct06150885/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07365319","kind":"trial","name":"A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer","route":"/trials/nct07365319/","detail":"mentions 2035 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05329766","kind":"trial","name":"A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies","route":"/trials/nct05329766/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03930953","kind":"trial","name":"A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory No","route":"/trials/nct03930953/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct00781612","kind":"trial","name":"A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies","route":"/trials/nct00781612/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06822543","kind":"trial","name":"A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cance","route":"/trials/nct06822543/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07527026","kind":"trial","name":"A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS","route":"/trials/nct07527026/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07321015","kind":"trial","name":"A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance","route":"/trials/nct07321015/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07728955","kind":"trial","name":"A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as First-line Therapy for","route":"/trials/nct07728955/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07622550","kind":"trial","name":"A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated A","route":"/trials/nct07622550/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07135544","kind":"trial","name":"A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer","route":"/trials/nct07135544/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07198321","kind":"trial","name":"A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors","route":"/trials/nct07198321/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07797244","kind":"trial","name":"A Single-Arm, Phase II Study of Retlirafusp Alfa in Combination With XELOX and Bevacizumab for the First-Line Treatment of Advanced RAS-Mutated Colorectal Cance","route":"/trials/nct07797244/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07789210","kind":"trial","name":"A Single-Arm, Phase II, Multicenter Clinical Study of Neoadjuvant Encorafenib Plus Cetuximab N01 and mFOLFOX6 in Patients With Locally Advanced BRAF V600E-Mutan","route":"/trials/nct07789210/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07229846","kind":"trial","name":"A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatme","route":"/trials/nct07229846/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07347951","kind":"trial","name":"A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer","route":"/trials/nct07347951/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07415031","kind":"trial","name":"A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies","route":"/trials/nct07415031/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06614192","kind":"trial","name":"A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer","route":"/trials/nct06614192/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06228326","kind":"trial","name":"A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs","route":"/trials/nct06228326/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05970497","kind":"trial","name":"A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct05970497/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06413706","kind":"trial","name":"A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy","route":"/trials/nct06413706/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06413498","kind":"trial","name":"A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma","route":"/trials/nct06413498/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07391657","kind":"trial","name":"A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Rela","route":"/trials/nct07391657/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07502300","kind":"trial","name":"A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Pa","route":"/trials/nct07502300/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07640789","kind":"trial","name":"A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-s","route":"/trials/nct07640789/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07739199","kind":"trial","name":"A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line","route":"/trials/nct07739199/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06857175","kind":"trial","name":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)","route":"/trials/nct06857175/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07648914","kind":"trial","name":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)","route":"/trials/nct07648914/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06994195","kind":"trial","name":"A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANK","route":"/trials/nct06994195/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07582315","kind":"trial","name":"A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)","route":"/trials/nct07582315/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07518147","kind":"trial","name":"A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment","route":"/trials/nct07518147/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07678957","kind":"trial","name":"A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer","route":"/trials/nct07678957/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07730489","kind":"trial","name":"A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, F","route":"/trials/nct07730489/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07258511","kind":"trial","name":"A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07258511/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07518186","kind":"trial","name":"A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07518186/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07138846","kind":"trial","name":"A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer","route":"/trials/nct07138846/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"mountaintap-30","kind":"trial","name":"A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)","route":"/trials/mountaintap-30/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07802821","kind":"trial","name":"A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Sm","route":"/trials/nct07802821/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07138209","kind":"trial","name":"A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07138209/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07217301","kind":"trial","name":"A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer","route":"/trials/nct07217301/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05455320","kind":"trial","name":"A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination Wi","route":"/trials/nct05455320/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07005128","kind":"trial","name":"A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small","route":"/trials/nct07005128/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06435429","kind":"trial","name":"A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment o","route":"/trials/nct06435429/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07711067","kind":"trial","name":"A Study Comparing Whole-Body Heat Treatment Plus Systemic Therapy to Systemic Therapy Alone, for Advanced Pancreatic Cancer","route":"/trials/nct07711067/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07541079","kind":"trial","name":"A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)","route":"/trials/nct07541079/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06096779","kind":"trial","name":"A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirr","route":"/trials/nct06096779/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07739186","kind":"trial","name":"A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment f","route":"/trials/nct07739186/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07807163","kind":"trial","name":"A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC","route":"/trials/nct07807163/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06244771","kind":"trial","name":"A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors","route":"/trials/nct06244771/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06970639","kind":"trial","name":"A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases","route":"/trials/nct06970639/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07822542","kind":"trial","name":"A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Pat","route":"/trials/nct07822542/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07124117","kind":"trial","name":"A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors","route":"/trials/nct07124117/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05920356","kind":"trial","name":"A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants Wi","route":"/trials/nct05920356/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07321574","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors","route":"/trials/nct07321574/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04873362","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy","route":"/trials/nct04873362/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04931342","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","route":"/trials/nct04931342/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05535244","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multi","route":"/trials/nct05535244/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06793215","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Particip","route":"/trials/nct06793215/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06790693","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer","route":"/trials/nct06790693/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04524871","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Li","route":"/trials/nct04524871/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05170204","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small C","route":"/trials/nct05170204/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04802759","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","route":"/trials/nct04802759/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03424005","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","route":"/trials/nct03424005/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06588478","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","route":"/trials/nct06588478/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07602777","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)","route":"/trials/nct07602777/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07589634","kind":"trial","name":"A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relaps","route":"/trials/nct07589634/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05583617","kind":"trial","name":"A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma","route":"/trials/nct05583617/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05789082","kind":"trial","name":"A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Par","route":"/trials/nct05789082/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05207670","kind":"trial","name":"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies","route":"/trials/nct05207670/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04774718","kind":"trial","name":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors","route":"/trials/nct04774718/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04246086","kind":"trial","name":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokineti","route":"/trials/nct04246086/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07567846","kind":"trial","name":"A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer","route":"/trials/nct07567846/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06314373","kind":"trial","name":"A Study for HSK39775 in Participants With Solid Tumors","route":"/trials/nct06314373/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02960022","kind":"trial","name":"A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study","route":"/trials/nct02960022/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07541430","kind":"trial","name":"A Study in Adults With Desmoid Tumors","route":"/trials/nct07541430/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07280377","kind":"trial","name":"A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab","route":"/trials/nct07280377/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04471727","kind":"trial","name":"A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)","route":"/trials/nct04471727/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03768063","kind":"trial","name":"A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study","route":"/trials/nct03768063/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05142696","kind":"trial","name":"A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab","route":"/trials/nct05142696/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04939610","kind":"trial","name":"A Study of 177Lu-FAP-2286 in Advanced Solid Tumors","route":"/trials/nct04939610/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06378593","kind":"trial","name":"A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations","route":"/trials/nct06378593/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05526755","kind":"trial","name":"A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)","route":"/trials/nct05526755/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07831863","kind":"trial","name":"A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy","route":"/trials/nct07831863/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07556848","kind":"trial","name":"A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer","route":"/trials/nct07556848/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05141721","kind":"trial","name":"A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer","route":"/trials/nct05141721/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05592626","kind":"trial","name":"A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors","route":"/trials/nct05592626/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07299825","kind":"trial","name":"A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer","route":"/trials/nct07299825/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07244705","kind":"trial","name":"A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC","route":"/trials/nct07244705/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05951959","kind":"trial","name":"A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma","route":"/trials/nct05951959/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05057494","kind":"trial","name":"A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","route":"/trials/nct05057494/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06875310","kind":"trial","name":"A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)","route":"/trials/nct06875310/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04557059","kind":"trial","name":"A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer","route":"/trials/nct04557059/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06307431","kind":"trial","name":"A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).","route":"/trials/nct06307431/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05142423","kind":"trial","name":"A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors","route":"/trials/nct05142423/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07010263","kind":"trial","name":"A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemor","route":"/trials/nct07010263/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07357220","kind":"trial","name":"A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases","route":"/trials/nct07357220/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06938321","kind":"trial","name":"A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer","route":"/trials/nct06938321/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07114315","kind":"trial","name":"A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer","route":"/trials/nct07114315/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07623356","kind":"trial","name":"A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer","route":"/trials/nct07623356/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06860971","kind":"trial","name":"A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma","route":"/trials/nct06860971/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07465757","kind":"trial","name":"A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)","route":"/trials/nct07465757/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06369285","kind":"trial","name":"A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer","route":"/trials/nct06369285/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06095505","kind":"trial","name":"A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer","route":"/trials/nct06095505/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06385080","kind":"trial","name":"A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer","route":"/trials/nct06385080/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05488314","kind":"trial","name":"A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer","route":"/trials/nct05488314/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06750094","kind":"trial","name":"A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy","route":"/trials/nct06750094/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06662786","kind":"trial","name":"A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","route":"/trials/nct06662786/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07227025","kind":"trial","name":"A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer","route":"/trials/nct07227025/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07276399","kind":"trial","name":"A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer","route":"/trials/nct07276399/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06667076","kind":"trial","name":"A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct06667076/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05498428","kind":"trial","name":"A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer","route":"/trials/nct05498428/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05379595","kind":"trial","name":"A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer","route":"/trials/nct05379595/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06777316","kind":"trial","name":"A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors","route":"/trials/nct06777316/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04657068","kind":"trial","name":"A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors","route":"/trials/nct04657068/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05067140","kind":"trial","name":"A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer","route":"/trials/nct05067140/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06699212","kind":"trial","name":"A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of ","route":"/trials/nct06699212/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07673887","kind":"trial","name":"A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer","route":"/trials/nct07673887/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07287995","kind":"trial","name":"A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors","route":"/trials/nct07287995/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07730021","kind":"trial","name":"A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors","route":"/trials/nct07730021/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07488676","kind":"trial","name":"A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors","route":"/trials/nct07488676/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06977737","kind":"trial","name":"A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours","route":"/trials/nct06977737/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06072781","kind":"trial","name":"A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer","route":"/trials/nct06072781/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06564038","kind":"trial","name":"A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies","route":"/trials/nct06564038/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06130553","kind":"trial","name":"A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors","route":"/trials/nct06130553/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07546500","kind":"trial","name":"A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression","route":"/trials/nct07546500/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07544056","kind":"trial","name":"A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer","route":"/trials/nct07544056/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06679101","kind":"trial","name":"A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethas","route":"/trials/nct06679101/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07538271","kind":"trial","name":"A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer","route":"/trials/nct07538271/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04771130","kind":"trial","name":"A Study of BGB-11417 in Participants With Myeloid Malignancies","route":"/trials/nct04771130/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06970743","kind":"trial","name":"A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors","route":"/trials/nct06970743/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06706076","kind":"trial","name":"A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations","route":"/trials/nct06706076/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04219254","kind":"trial","name":"A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors","route":"/trials/nct04219254/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03526835","kind":"trial","name":"A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors","route":"/trials/nct03526835/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07054567","kind":"trial","name":"A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer","route":"/trials/nct07054567/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05880706","kind":"trial","name":"A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung ","route":"/trials/nct05880706/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07827261","kind":"trial","name":"A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer","route":"/trials/nct07827261/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07642024","kind":"trial","name":"A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU","route":"/trials/nct07642024/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06838273","kind":"trial","name":"A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metas","route":"/trials/nct06838273/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07554456","kind":"trial","name":"A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)","route":"/trials/nct07554456/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06787664","kind":"trial","name":"A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma","route":"/trials/nct06787664/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07729956","kind":"trial","name":"A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inopera","route":"/trials/nct07729956/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06475300","kind":"trial","name":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and ","route":"/trials/nct06475300/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06437522","kind":"trial","name":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors","route":"/trials/nct06437522/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06978114","kind":"trial","name":"A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer","route":"/trials/nct06978114/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06962787","kind":"trial","name":"A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer","route":"/trials/nct06962787/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07518173","kind":"trial","name":"A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or M","route":"/trials/nct07518173/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07264816","kind":"trial","name":"A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NS","route":"/trials/nct07264816/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06957886","kind":"trial","name":"A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer","route":"/trials/nct06957886/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07606599","kind":"trial","name":"A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure","route":"/trials/nct07606599/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06830889","kind":"trial","name":"A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy","route":"/trials/nct06830889/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07178795","kind":"trial","name":"A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC","route":"/trials/nct07178795/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06891833","kind":"trial","name":"A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Brea","route":"/trials/nct06891833/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07255872","kind":"trial","name":"A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia","route":"/trials/nct07255872/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07654400","kind":"trial","name":"A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer","route":"/trials/nct07654400/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06852222","kind":"trial","name":"A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)","route":"/trials/nct06852222/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04895709","kind":"trial","name":"A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors","route":"/trials/nct04895709/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06697197","kind":"trial","name":"A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors","route":"/trials/nct06697197/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07492680","kind":"trial","name":"A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)","route":"/trials/nct07492680/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07227636","kind":"trial","name":"A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy","route":"/trials/nct07227636/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06843434","kind":"trial","name":"A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma","route":"/trials/nct06843434/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05608044","kind":"trial","name":"A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer","route":"/trials/nct05608044/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02972840","kind":"trial","name":"A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL","route":"/trials/nct02972840/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06345729","kind":"trial","name":"A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)","route":"/trials/nct06345729/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05774951","kind":"trial","name":"A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy","route":"/trials/nct05774951/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06915246","kind":"trial","name":"A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma","route":"/trials/nct06915246/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05849480","kind":"trial","name":"A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)","route":"/trials/nct05849480/","detail":"mentions 2040 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06465329","kind":"trial","name":"A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Ce","route":"/trials/nct06465329/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07000305","kind":"trial","name":"A Study of Cetuximabβ Combined With Envolimab and mFOLFOX6 in Subjects With Advanced Colorectal Cancer","route":"/trials/nct07000305/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07412262","kind":"trial","name":"A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and Hig","route":"/trials/nct07412262/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06550895","kind":"trial","name":"A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma","route":"/trials/nct06550895/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05263960","kind":"trial","name":"A Study of CM350 in Patients With Advanced Solid Tumors","route":"/trials/nct05263960/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05759728","kind":"trial","name":"A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer","route":"/trials/nct05759728/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05908734","kind":"trial","name":"A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer","route":"/trials/nct05908734/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03314181","kind":"trial","name":"A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractor","route":"/trials/nct03314181/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06246643","kind":"trial","name":"A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies","route":"/trials/nct06246643/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07070219","kind":"trial","name":"A Study of CTD402 in T-ALL/LBL Patients","route":"/trials/nct07070219/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"companion-002","kind":"trial","name":"A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)","route":"/trials/companion-002/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05732103","kind":"trial","name":"A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes","route":"/trials/nct05732103/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07768436","kind":"trial","name":"A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer","route":"/trials/nct07768436/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05410145","kind":"trial","name":"A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation","route":"/trials/nct05410145/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06978400","kind":"trial","name":"A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer","route":"/trials/nct06978400/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05438043","kind":"trial","name":"A Study of Daratumumab","route":"/trials/nct05438043/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07205822","kind":"trial","name":"A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer","route":"/trials/nct07205822/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05785741","kind":"trial","name":"A Study of DB-1310 in Advanced/Metastatic Solid Tumors","route":"/trials/nct05785741/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07263594","kind":"trial","name":"A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors","route":"/trials/nct07263594/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06873555","kind":"trial","name":"A Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors","route":"/trials/nct06873555/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05765812","kind":"trial","name":"A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma","route":"/trials/nct05765812/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07807800","kind":"trial","name":"A Study of DES-1357 in People With Deficient Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer (mCRC)","route":"/trials/nct07807800/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02151084","kind":"trial","name":"A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer","route":"/trials/nct02151084/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06577025","kind":"trial","name":"A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Ind","route":"/trials/nct06577025/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07315750","kind":"trial","name":"A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.","route":"/trials/nct07315750/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06966453","kind":"trial","name":"A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer","route":"/trials/nct06966453/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06157892","kind":"trial","name":"A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors","route":"/trials/nct06157892/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06751329","kind":"trial","name":"A Study of DM002 in Patients With Advanced Solid Tumors","route":"/trials/nct06751329/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06515990","kind":"trial","name":"A Study of DM005 in Patients With Advanced Solid Tumors","route":"/trials/nct06515990/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07108270","kind":"trial","name":"A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)","route":"/trials/nct07108270/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06640049","kind":"trial","name":"A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China","route":"/trials/nct06640049/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06256588","kind":"trial","name":"A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma","route":"/trials/nct06256588/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07739966","kind":"trial","name":"A Study of DS-3939a in Participants With Solid Tumors","route":"/trials/nct07739966/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06522737","kind":"trial","name":"A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype","route":"/trials/nct06522737/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07559929","kind":"trial","name":"A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.","route":"/trials/nct07559929/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07154264","kind":"trial","name":"A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)","route":"/trials/nct07154264/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tai-shan6","kind":"trial","name":"A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)","route":"/trials/tai-shan6/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04008797","kind":"trial","name":"A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor","route":"/trials/nct04008797/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04078295","kind":"trial","name":"A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor","route":"/trials/nct04078295/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05845814","kind":"trial","name":"A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)","route":"/trials/nct05845814/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06483334","kind":"trial","name":"A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)","route":"/trials/nct06483334/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06492616","kind":"trial","name":"A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence","route":"/trials/nct06492616/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07271667","kind":"trial","name":"A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies","route":"/trials/nct07271667/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05377996","kind":"trial","name":"A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors","route":"/trials/nct05377996/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06099769","kind":"trial","name":"A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer","route":"/trials/nct06099769/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05443126","kind":"trial","name":"A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies","route":"/trials/nct05443126/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06623136","kind":"trial","name":"A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer","route":"/trials/nct06623136/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03980054","kind":"trial","name":"A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer","route":"/trials/nct03980054/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06782555","kind":"trial","name":"A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab","route":"/trials/nct06782555/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07312188","kind":"trial","name":"A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07312188/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06842498","kind":"trial","name":"A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","route":"/trials/nct06842498/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07383922","kind":"trial","name":"A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer","route":"/trials/nct07383922/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06064877","kind":"trial","name":"A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma","route":"/trials/nct06064877/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06119581","kind":"trial","name":"A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer","route":"/trials/nct06119581/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07011576","kind":"trial","name":"A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)","route":"/trials/nct07011576/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06980480","kind":"trial","name":"A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma","route":"/trials/nct06980480/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07678593","kind":"trial","name":"A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation","route":"/trials/nct07678593/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07259590","kind":"trial","name":"A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation","route":"/trials/nct07259590/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06500676","kind":"trial","name":"A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations","route":"/trials/nct06500676/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07172802","kind":"trial","name":"A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors","route":"/trials/nct07172802/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05520567","kind":"trial","name":"A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia","route":"/trials/nct05520567/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07101679","kind":"trial","name":"A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer","route":"/trials/nct07101679/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06464055","kind":"trial","name":"A Study of GQ1010 in Subjects With Advanced Solid Tumors","route":"/trials/nct06464055/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07452198","kind":"trial","name":"A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07452198/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06990880","kind":"trial","name":"A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer","route":"/trials/nct06990880/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07099898","kind":"trial","name":"A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)","route":"/trials/nct07099898/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07376629","kind":"trial","name":"A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC","route":"/trials/nct07376629/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07124936","kind":"trial","name":"A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma","route":"/trials/nct07124936/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07805551","kind":"trial","name":"A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer","route":"/trials/nct07805551/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06172478","kind":"trial","name":"A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct06172478/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07678684","kind":"trial","name":"A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma","route":"/trials/nct07678684/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06453486","kind":"trial","name":"A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment","route":"/trials/nct06453486/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07140393","kind":"trial","name":"A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor","route":"/trials/nct07140393/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06520488","kind":"trial","name":"A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors","route":"/trials/nct06520488/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07389733","kind":"trial","name":"A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer","route":"/trials/nct07389733/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06147570","kind":"trial","name":"A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer","route":"/trials/nct06147570/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07468851","kind":"trial","name":"A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy","route":"/trials/nct07468851/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06526624","kind":"trial","name":"A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer","route":"/trials/nct06526624/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06081920","kind":"trial","name":"A Study of IBI363 in Subjects With Advanced Melanoma","route":"/trials/nct06081920/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07174583","kind":"trial","name":"A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer","route":"/trials/nct07174583/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07602842","kind":"trial","name":"A Study of IDP-001 in Advanced or Metastatic Solid Tumors","route":"/trials/nct07602842/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07218926","kind":"trial","name":"A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy","route":"/trials/nct07218926/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07630974","kind":"trial","name":"A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)","route":"/trials/nct07630974/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06644781","kind":"trial","name":"A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)","route":"/trials/nct06644781/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06365840","kind":"trial","name":"A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor","route":"/trials/nct06365840/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07287098","kind":"trial","name":"A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer","route":"/trials/nct07287098/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05514054","kind":"trial","name":"A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer","route":"/trials/nct05514054/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07023627","kind":"trial","name":"A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression","route":"/trials/nct07023627/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05957367","kind":"trial","name":"A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies","route":"/trials/nct05957367/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06077760","kind":"trial","name":"A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (","route":"/trials/nct06077760/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07221474","kind":"trial","name":"A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)","route":"/trials/nct07221474/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07122414","kind":"trial","name":"A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer","route":"/trials/nct07122414/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07424287","kind":"trial","name":"A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC","route":"/trials/nct07424287/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06780085","kind":"trial","name":"A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)","route":"/trials/nct06780085/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06827613","kind":"trial","name":"A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors","route":"/trials/nct06827613/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07743723","kind":"trial","name":"A Study of IOV-5001 in Adults With Advanced Solid Tumors","route":"/trials/nct07743723/","detail":"mentions 2034 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07535437","kind":"trial","name":"A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer","route":"/trials/nct07535437/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07815665","kind":"trial","name":"A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma","route":"/trials/nct07815665/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07245446","kind":"trial","name":"A Study of Ivonescimab in First-Line ES-SCLC","route":"/trials/nct07245446/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07535463","kind":"trial","name":"A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer","route":"/trials/nct07535463/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05276726","kind":"trial","name":"A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1","route":"/trials/nct05276726/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06868849","kind":"trial","name":"A Study of JMT203 in Patients With Cancer Cachexia","route":"/trials/nct06868849/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04133636","kind":"trial","name":"A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Mul","route":"/trials/nct04133636/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07266441","kind":"trial","name":"A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07266441/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05421663","kind":"trial","name":"A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma","route":"/trials/nct05421663/","detail":"mentions 2041 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06667908","kind":"trial","name":"A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct06667908/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07047118","kind":"trial","name":"A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)","route":"/trials/nct07047118/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06564272","kind":"trial","name":"A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma","route":"/trials/nct06564272/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07609823","kind":"trial","name":"A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL","route":"/trials/nct07609823/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07042802","kind":"trial","name":"A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer","route":"/trials/nct07042802/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07752875","kind":"trial","name":"A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation","route":"/trials/nct07752875/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06481592","kind":"trial","name":"A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.","route":"/trials/nct06481592/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07288203","kind":"trial","name":"A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma","route":"/trials/nct07288203/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07359820","kind":"trial","name":"A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement","route":"/trials/nct07359820/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06868199","kind":"trial","name":"A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours","route":"/trials/nct06868199/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07669415","kind":"trial","name":"A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors","route":"/trials/nct07669415/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07112222","kind":"trial","name":"A Study of LM-350 in Subjects With Advanced Solid Tumours","route":"/trials/nct07112222/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06730347","kind":"trial","name":"A Study of Lorigerlimab in Participants With Advanced Solid Tumors","route":"/trials/nct06730347/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07459634","kind":"trial","name":"A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC","route":"/trials/nct07459634/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06378177","kind":"trial","name":"A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)","route":"/trials/nct06378177/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06679829","kind":"trial","name":"A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant","route":"/trials/nct06679829/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06952803","kind":"trial","name":"A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation","route":"/trials/nct06952803/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07326488","kind":"trial","name":"A Study of MHB009C in Patients With Advanced Solid Tumors","route":"/trials/nct07326488/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07229599","kind":"trial","name":"A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer","route":"/trials/nct07229599/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07130383","kind":"trial","name":"A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors","route":"/trials/nct07130383/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06345482","kind":"trial","name":"A Study of MHB039A for Advanced Solid Tumor","route":"/trials/nct06345482/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07192107","kind":"trial","name":"A Study of MHB042C in Patients With Advanced Solid Tumors","route":"/trials/nct07192107/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06985355","kind":"trial","name":"A Study of MHB046C Injection in Patients With Advanced Solid Tumors","route":"/trials/nct06985355/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07192120","kind":"trial","name":"A Study of MHB048C in Patients With Advanced Solid Tumors","route":"/trials/nct07192120/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07126665","kind":"trial","name":"A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors","route":"/trials/nct07126665/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06954246","kind":"trial","name":"A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer","route":"/trials/nct06954246/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06979596","kind":"trial","name":"A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)","route":"/trials/nct06979596/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06796907","kind":"trial","name":"A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)","route":"/trials/nct06796907/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07701486","kind":"trial","name":"A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer","route":"/trials/nct07701486/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07208149","kind":"trial","name":"A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)","route":"/trials/nct07208149/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06976190","kind":"trial","name":"A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcin","route":"/trials/nct06976190/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05688605","kind":"trial","name":"A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors","route":"/trials/nct05688605/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07093970","kind":"trial","name":"A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors","route":"/trials/nct07093970/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07737600","kind":"trial","name":"A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer","route":"/trials/nct07737600/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07116616","kind":"trial","name":"A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07116616/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05658562","kind":"trial","name":"A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL","route":"/trials/nct05658562/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06943521","kind":"trial","name":"A Study of MT-4561 in Patients With Various Advanced Solid Tumors","route":"/trials/nct06943521/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03862430","kind":"trial","name":"A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM","route":"/trials/nct03862430/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07026279","kind":"trial","name":"A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer","route":"/trials/nct07026279/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06855771","kind":"trial","name":"A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)","route":"/trials/nct06855771/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03162536","kind":"trial","name":"A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)","route":"/trials/nct03162536/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05947851","kind":"trial","name":"A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).","route":"/trials/nct05947851/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05624554","kind":"trial","name":"A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)","route":"/trials/nct05624554/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07586202","kind":"trial","name":"A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC","route":"/trials/nct07586202/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06686576","kind":"trial","name":"A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer","route":"/trials/nct06686576/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05751928","kind":"trial","name":"A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma","route":"/trials/nct05751928/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07170644","kind":"trial","name":"A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)","route":"/trials/nct07170644/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03873402","kind":"trial","name":"A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer","route":"/trials/nct03873402/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07069712","kind":"trial","name":"A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma","route":"/trials/nct07069712/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07098338","kind":"trial","name":"A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct07098338/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06792695","kind":"trial","name":"A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer","route":"/trials/nct06792695/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05624918","kind":"trial","name":"A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma","route":"/trials/nct05624918/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07450859","kind":"trial","name":"A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","route":"/trials/nct07450859/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07221500","kind":"trial","name":"A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)","route":"/trials/nct07221500/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06365853","kind":"trial","name":"A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer Wit","route":"/trials/nct06365853/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07814417","kind":"trial","name":"A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation","route":"/trials/nct07814417/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07734116","kind":"trial","name":"A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma.","route":"/trials/nct07734116/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06136650","kind":"trial","name":"A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)","route":"/trials/nct06136650/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06362369","kind":"trial","name":"A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy","route":"/trials/nct06362369/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07058519","kind":"trial","name":"A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC","route":"/trials/nct07058519/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07266428","kind":"trial","name":"A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors","route":"/trials/nct07266428/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06987500","kind":"trial","name":"A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment","route":"/trials/nct06987500/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06907043","kind":"trial","name":"A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.","route":"/trials/nct06907043/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07225946","kind":"trial","name":"A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct07225946/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"mcrpc","kind":"trial","name":"A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)","route":"/trials/mcrpc/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06941272","kind":"trial","name":"A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)","route":"/trials/nct06941272/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05334823","kind":"trial","name":"A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents","route":"/trials/nct05334823/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05652686","kind":"trial","name":"A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)","route":"/trials/nct05652686/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06041802","kind":"trial","name":"A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)","route":"/trials/nct06041802/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02332668","kind":"trial","name":"A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)","route":"/trials/nct02332668/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06623422","kind":"trial","name":"A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)","route":"/trials/nct06623422/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07302347","kind":"trial","name":"A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)","route":"/trials/nct07302347/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06731907","kind":"trial","name":"A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-34","route":"/trials/nct06731907/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05254743","kind":"trial","name":"A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","route":"/trials/nct05254743/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05879055","kind":"trial","name":"A Study of PM8002 in Combination With Chemotherapy in Patients With NEN","route":"/trials/nct05879055/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"proceade-crc-03","kind":"trial","name":"A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)","route":"/trials/proceade-crc-03/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06914128","kind":"trial","name":"A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors","route":"/trials/nct06914128/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05487391","kind":"trial","name":"A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection","route":"/trials/nct05487391/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05690945","kind":"trial","name":"A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer","route":"/trials/nct05690945/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06789796","kind":"trial","name":"a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy","route":"/trials/nct06789796/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06911827","kind":"trial","name":"A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients","route":"/trials/nct06911827/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04683679","kind":"trial","name":"A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negat","route":"/trials/nct04683679/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06504147","kind":"trial","name":"A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery","route":"/trials/nct06504147/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06660654","kind":"trial","name":"A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)","route":"/trials/nct06660654/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06155396","kind":"trial","name":"A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent o","route":"/trials/nct06155396/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05745740","kind":"trial","name":"A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation","route":"/trials/nct05745740/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06678659","kind":"trial","name":"A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer","route":"/trials/nct06678659/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04077099","kind":"trial","name":"A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer","route":"/trials/nct04077099/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03093116","kind":"trial","name":"A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements","route":"/trials/nct03093116/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07221253","kind":"trial","name":"A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)","route":"/trials/nct07221253/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07602855","kind":"trial","name":"A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)","route":"/trials/nct07602855/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07609862","kind":"trial","name":"A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies","route":"/trials/nct07609862/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07189065","kind":"trial","name":"A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma","route":"/trials/nct07189065/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07377578","kind":"trial","name":"A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma","route":"/trials/nct07377578/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06879717","kind":"trial","name":"A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients","route":"/trials/nct06879717/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07648030","kind":"trial","name":"A Study of Rusfertide in Japanese Adults With Polycythemia Vera","route":"/trials/nct07648030/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06926920","kind":"trial","name":"A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer","route":"/trials/nct06926920/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07040644","kind":"trial","name":"A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC","route":"/trials/nct07040644/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06312176","kind":"trial","name":"A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)","route":"/trials/nct06312176/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06841354","kind":"trial","name":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","route":"/trials/nct06841354/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07060989","kind":"trial","name":"A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation","route":"/trials/nct07060989/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05570253","kind":"trial","name":"A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer","route":"/trials/nct05570253/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04414475","kind":"trial","name":"A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refrac","route":"/trials/nct04414475/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07726992","kind":"trial","name":"A Study of SHR-1501 Combination With BCG Versus Placebo Combined With BCG in Subjects With Papillary-Only NMIBC","route":"/trials/nct07726992/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06754930","kind":"trial","name":"A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC","route":"/trials/nct06754930/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06764628","kind":"trial","name":"A Study of SHR-4375 in Subjects With Solid Tumors","route":"/trials/nct06764628/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07298772","kind":"trial","name":"A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors","route":"/trials/nct07298772/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07229586","kind":"trial","name":"A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors","route":"/trials/nct07229586/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06828354","kind":"trial","name":"A Study of SHR-A1811 in Subjects With Ovarian Cancer","route":"/trials/nct06828354/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07450976","kind":"trial","name":"A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer","route":"/trials/nct07450976/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07183189","kind":"trial","name":"A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC","route":"/trials/nct07183189/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07418749","kind":"trial","name":"A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer","route":"/trials/nct07418749/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07230106","kind":"trial","name":"A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer","route":"/trials/nct07230106/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"simrise","kind":"trial","name":"A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)","route":"/trials/simrise/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07241936","kind":"trial","name":"A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors","route":"/trials/nct07241936/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06670196","kind":"trial","name":"A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advan","route":"/trials/nct06670196/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07071337","kind":"trial","name":"A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy","route":"/trials/nct07071337/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07448922","kind":"trial","name":"A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors","route":"/trials/nct07448922/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07019675","kind":"trial","name":"A Study of SKB518 in Patients With Lung Cancer","route":"/trials/nct07019675/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07622186","kind":"trial","name":"A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct07622186/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04521231","kind":"trial","name":"A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL","route":"/trials/nct04521231/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07134088","kind":"trial","name":"A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia","route":"/trials/nct07134088/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06508658","kind":"trial","name":"A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcita","route":"/trials/nct06508658/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06549595","kind":"trial","name":"A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients","route":"/trials/nct06549595/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06533644","kind":"trial","name":"A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct06533644/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07672223","kind":"trial","name":"A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct07672223/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06271837","kind":"trial","name":"A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors","route":"/trials/nct06271837/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06971614","kind":"trial","name":"A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC","route":"/trials/nct06971614/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06846671","kind":"trial","name":"A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors","route":"/trials/nct06846671/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04712643","kind":"trial","name":"A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma","route":"/trials/nct04712643/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06456463","kind":"trial","name":"A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy","route":"/trials/nct06456463/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07205718","kind":"trial","name":"A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors","route":"/trials/nct07205718/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07436728","kind":"trial","name":"A Study of TAK-505 in Adults With Solid Tumors","route":"/trials/nct07436728/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"hr-nmibc","kind":"trial","name":"A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)","route":"/trials/hr-nmibc/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06211764","kind":"trial","name":"A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)","route":"/trials/nct06211764/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05552222","kind":"trial","name":"A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal","route":"/trials/nct05552222/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07259213","kind":"trial","name":"A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC","route":"/trials/nct07259213/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"pik3ca-2","kind":"trial","name":"A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)","route":"/trials/pik3ca-2/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06134375","kind":"trial","name":"A Study of Tetrathiomolybdate (TM) Plus Capecitabine","route":"/trials/nct06134375/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07740720","kind":"trial","name":"A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer","route":"/trials/nct07740720/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05968326","kind":"trial","name":"A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC","route":"/trials/nct05968326/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07742215","kind":"trial","name":"A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)","route":"/trials/nct07742215/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07015242","kind":"trial","name":"A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma","route":"/trials/nct07015242/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07439653","kind":"trial","name":"A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma","route":"/trials/nct07439653/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06431490","kind":"trial","name":"A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer","route":"/trials/nct06431490/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07691489","kind":"trial","name":"A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer","route":"/trials/nct07691489/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07428044","kind":"trial","name":"A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer","route":"/trials/nct07428044/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07679360","kind":"trial","name":"A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer","route":"/trials/nct07679360/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07567521","kind":"trial","name":"A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC","route":"/trials/nct07567521/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05382338","kind":"trial","name":"A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss","route":"/trials/nct05382338/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05423262","kind":"trial","name":"A Study of TRK-950 in Patients With Advanced Solid Tumors","route":"/trials/nct05423262/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05440708","kind":"trial","name":"A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma","route":"/trials/nct05440708/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05672524","kind":"trial","name":"A Study of Tucatinib and Trastuzumab in People With Rectal Cancer","route":"/trials/nct05672524/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06497985","kind":"trial","name":"A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients","route":"/trials/nct06497985/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04104776","kind":"trial","name":"A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas","route":"/trials/nct04104776/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06672068","kind":"trial","name":"A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC","route":"/trials/nct06672068/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06644768","kind":"trial","name":"A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations","route":"/trials/nct06644768/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06930794","kind":"trial","name":"A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive","route":"/trials/nct06930794/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07689201","kind":"trial","name":"A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib","route":"/trials/nct07689201/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02966756","kind":"trial","name":"A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","route":"/trials/nct02966756/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07218380","kind":"trial","name":"A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract","route":"/trials/nct07218380/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06943833","kind":"trial","name":"A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)","route":"/trials/nct06943833/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07699328","kind":"trial","name":"A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer","route":"/trials/nct07699328/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07093814","kind":"trial","name":"A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma","route":"/trials/nct07093814/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07589257","kind":"trial","name":"A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine Glioma","route":"/trials/nct07589257/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07213674","kind":"trial","name":"A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate ","route":"/trials/nct07213674/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07208773","kind":"trial","name":"A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors","route":"/trials/nct07208773/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07407933","kind":"trial","name":"A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors","route":"/trials/nct07407933/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07739758","kind":"trial","name":"A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer","route":"/trials/nct07739758/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07258979","kind":"trial","name":"A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.","route":"/trials/nct07258979/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05434234","kind":"trial","name":"A Study of YL201 in Patients With Advanced Solid Tumors","route":"/trials/nct05434234/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07197827","kind":"trial","name":"A Study of YL242 in Subjects With Advanced Solid Tumors","route":"/trials/nct07197827/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05100862","kind":"trial","name":"A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphom","route":"/trials/nct05100862/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05607108","kind":"trial","name":"A Study of ZEN003694 in People With Squamous Cell Lung Cancer","route":"/trials/nct05607108/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05118789","kind":"trial","name":"A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)","route":"/trials/nct05118789/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05458297","kind":"trial","name":"A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-","route":"/trials/nct05458297/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05406401","kind":"trial","name":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)","route":"/trials/nct05406401/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05967689","kind":"trial","name":"A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.","route":"/trials/nct05967689/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07796100","kind":"trial","name":"A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Ther","route":"/trials/nct07796100/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06885281","kind":"trial","name":"A Study of ZL-1310 in Participants With Selected Solid Tumors","route":"/trials/nct06885281/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"dllevate","kind":"trial","name":"A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)","route":"/trials/dllevate/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03505320","kind":"trial","name":"A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer","route":"/trials/nct03505320/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06901531","kind":"trial","name":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","route":"/trials/nct06901531/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07123441","kind":"trial","name":"A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer","route":"/trials/nct07123441/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06590259","kind":"trial","name":"A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM","route":"/trials/nct06590259/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07525206","kind":"trial","name":"A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer","route":"/trials/nct07525206/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07095452","kind":"trial","name":"A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lena","route":"/trials/nct07095452/","detail":"mentions 2042 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06833008","kind":"trial","name":"A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours","route":"/trials/nct06833008/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07023289","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone o","route":"/trials/nct07023289/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07196644","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan","route":"/trials/nct07196644/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07155187","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer","route":"/trials/nct07155187/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07059845","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult","route":"/trials/nct07059845/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06953960","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma ","route":"/trials/nct06953960/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07581002","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)","route":"/trials/nct07581002/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07769502","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatob","route":"/trials/nct07769502/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06568939","kind":"trial","name":"A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult ","route":"/trials/nct06568939/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07005102","kind":"trial","name":"A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer","route":"/trials/nct07005102/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06890338","kind":"trial","name":"A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Fo","route":"/trials/nct06890338/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06090539","kind":"trial","name":"A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas","route":"/trials/nct06090539/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06892522","kind":"trial","name":"A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-spe","route":"/trials/nct06892522/","detail":"mentions 2035 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07024784","kind":"trial","name":"A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN1","route":"/trials/nct07024784/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06312137","kind":"trial","name":"A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Sm","route":"/trials/nct06312137/","detail":"mentions 2034 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07821684","kind":"trial","name":"A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanc","route":"/trials/nct07821684/","detail":"mentions 2027, 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07756645","kind":"trial","name":"A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advan","route":"/trials/nct07756645/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06305247","kind":"trial","name":"A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours","route":"/trials/nct06305247/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"seacraft-2","kind":"trial","name":"A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)","route":"/trials/seacraft-2/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07693751","kind":"trial","name":"A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer","route":"/trials/nct07693751/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05706129","kind":"trial","name":"A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct05706129/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05428969","kind":"trial","name":"A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies","route":"/trials/nct05428969/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06109272","kind":"trial","name":"A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)","route":"/trials/nct06109272/","detail":"mentions 2030, 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05503797","kind":"trial","name":"A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations","route":"/trials/nct05503797/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06631989","kind":"trial","name":"A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer","route":"/trials/nct06631989/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06868485","kind":"trial","name":"A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer","route":"/trials/nct06868485/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04224493","kind":"trial","name":"A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus ","route":"/trials/nct04224493/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06669247","kind":"trial","name":"A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Mult","route":"/trials/nct06669247/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04817007","kind":"trial","name":"A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)","route":"/trials/nct04817007/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07325136","kind":"trial","name":"A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung ","route":"/trials/nct07325136/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06969430","kind":"trial","name":"A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)","route":"/trials/nct06969430/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07680764","kind":"trial","name":"A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pu","route":"/trials/nct07680764/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06898450","kind":"trial","name":"A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.","route":"/trials/nct06898450/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06035497","kind":"trial","name":"A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)","route":"/trials/nct06035497/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07213817","kind":"trial","name":"A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours","route":"/trials/nct07213817/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07213830","kind":"trial","name":"A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies","route":"/trials/nct07213830/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07128199","kind":"trial","name":"A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection","route":"/trials/nct07128199/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07178717","kind":"trial","name":"A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy W","route":"/trials/nct07178717/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06311721","kind":"trial","name":"A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer","route":"/trials/nct06311721/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05794906","kind":"trial","name":"A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer","route":"/trials/nct05794906/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06939595","kind":"trial","name":"A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer","route":"/trials/nct06939595/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06091865","kind":"trial","name":"A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Pa","route":"/trials/nct06091865/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05827016","kind":"trial","name":"A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly","route":"/trials/nct05827016/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07393282","kind":"trial","name":"A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)","route":"/trials/nct07393282/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06952478","kind":"trial","name":"A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone","route":"/trials/nct06952478/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07079228","kind":"trial","name":"A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer","route":"/trials/nct07079228/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06952504","kind":"trial","name":"A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participan","route":"/trials/nct06952504/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06459180","kind":"trial","name":"A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With","route":"/trials/nct06459180/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07566052","kind":"trial","name":"A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation","route":"/trials/nct07566052/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04293562","kind":"trial","name":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","route":"/trials/nct04293562/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07063745","kind":"trial","name":"A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion","route":"/trials/nct07063745/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06764485","kind":"trial","name":"A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer","route":"/trials/nct06764485/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"quintessential-2","kind":"trial","name":"A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)","route":"/trials/quintessential-2/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06646276","kind":"trial","name":"A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS)","route":"/trials/nct06646276/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06911502","kind":"trial","name":"A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Rela","route":"/trials/nct06911502/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07803783","kind":"trial","name":"A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based","route":"/trials/nct07803783/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06561386","kind":"trial","name":"A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous N","route":"/trials/nct06561386/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06847334","kind":"trial","name":"A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in the First-Line Treatment of Advanced Non-squamous","route":"/trials/nct06847334/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06984588","kind":"trial","name":"A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer","route":"/trials/nct06984588/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05963074","kind":"trial","name":"A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia","route":"/trials/nct05963074/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06598007","kind":"trial","name":"A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors","route":"/trials/nct06598007/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06988488","kind":"trial","name":"A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatama","route":"/trials/nct06988488/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06692166","kind":"trial","name":"A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer","route":"/trials/nct06692166/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06054555","kind":"trial","name":"A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma","route":"/trials/nct06054555/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07029737","kind":"trial","name":"A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain","route":"/trials/nct07029737/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07365241","kind":"trial","name":"A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer","route":"/trials/nct07365241/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05283720","kind":"trial","name":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neopl","route":"/trials/nct05283720/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05451810","kind":"trial","name":"A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refr","route":"/trials/nct05451810/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07285148","kind":"trial","name":"A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer","route":"/trials/nct07285148/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07749586","kind":"trial","name":"A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors","route":"/trials/nct07749586/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06590246","kind":"trial","name":"A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)","route":"/trials/nct06590246/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07522073","kind":"trial","name":"A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma","route":"/trials/nct07522073/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07460375","kind":"trial","name":"A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors","route":"/trials/nct07460375/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07564401","kind":"trial","name":"A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy","route":"/trials/nct07564401/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07149857","kind":"trial","name":"A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel","route":"/trials/nct07149857/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06065748","kind":"trial","name":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","route":"/trials/nct06065748/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07554521","kind":"trial","name":"A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States","route":"/trials/nct07554521/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05645107","kind":"trial","name":"A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma","route":"/trials/nct05645107/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07668752","kind":"trial","name":"A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation","route":"/trials/nct07668752/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06084936","kind":"trial","name":"A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma","route":"/trials/nct06084936/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05533775","kind":"trial","name":"A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Matu","route":"/trials/nct05533775/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07294508","kind":"trial","name":"A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer","route":"/trials/nct07294508/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06387069","kind":"trial","name":"A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia","route":"/trials/nct06387069/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07823322","kind":"trial","name":"A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection a","route":"/trials/nct07823322/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05319730","kind":"trial","name":"A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)","route":"/trials/nct05319730/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04064060","kind":"trial","name":"A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials","route":"/trials/nct04064060/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05519085","kind":"trial","name":"A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Re","route":"/trials/nct05519085/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05751512","kind":"trial","name":"A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN","route":"/trials/nct05751512/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06500884","kind":"trial","name":"A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events","route":"/trials/nct06500884/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07361497","kind":"trial","name":"A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell","route":"/trials/nct07361497/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06356311","kind":"trial","name":"A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)","route":"/trials/nct06356311/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06351631","kind":"trial","name":"A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)","route":"/trials/nct06351631/","detail":"mentions 2034 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07206498","kind":"trial","name":"A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC","route":"/trials/nct07206498/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05318573","kind":"trial","name":"A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer","route":"/trials/nct05318573/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06542250","kind":"trial","name":"A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.","route":"/trials/nct06542250/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04554914","kind":"trial","name":"A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases","route":"/trials/nct04554914/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06919965","kind":"trial","name":"A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer","route":"/trials/nct06919965/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06319820","kind":"trial","name":"A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer","route":"/trials/nct06319820/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06820463","kind":"trial","name":"A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil,","route":"/trials/nct06820463/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06284317","kind":"trial","name":"A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Canc","route":"/trials/nct06284317/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07100106","kind":"trial","name":"A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer","route":"/trials/nct07100106/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07409272","kind":"trial","name":"A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer","route":"/trials/nct07409272/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07227311","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Mult","route":"/trials/nct07227311/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07541170","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Rese","route":"/trials/nct07541170/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05296798","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","route":"/trials/nct05296798/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07490262","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment","route":"/trials/nct07490262/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07082686","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)","route":"/trials/nct07082686/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06330064","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)","route":"/trials/nct06330064/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04245839","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)","route":"/trials/nct04245839/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03178552","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct03178552/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06824467","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Pl","route":"/trials/nct06824467/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07284849","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer","route":"/trials/nct07284849/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06010329","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC","route":"/trials/nct06010329/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06010342","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients","route":"/trials/nct06010342/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07284758","kind":"trial","name":"A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct07284758/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07361510","kind":"trial","name":"A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and P","route":"/trials/nct07361510/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07811193","kind":"trial","name":"A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum","route":"/trials/nct07811193/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06828991","kind":"trial","name":"A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP","route":"/trials/nct06828991/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07155174","kind":"trial","name":"A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus St","route":"/trials/nct07155174/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06428019","kind":"trial","name":"A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)","route":"/trials/nct06428019/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06682793","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression","route":"/trials/nct06682793/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06166836","kind":"trial","name":"a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors","route":"/trials/nct06166836/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06780137","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensiv","route":"/trials/nct06780137/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06051695","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression","route":"/trials/nct06051695/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06818643","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)","route":"/trials/nct06818643/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06663137","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC","route":"/trials/nct06663137/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07221357","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Parti","route":"/trials/nct07221357/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07221149","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)","route":"/trials/nct07221149/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07570823","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","route":"/trials/nct07570823/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07562022","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma","route":"/trials/nct07562022/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07297329","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant","route":"/trials/nct07297329/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06973187","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","route":"/trials/nct06973187/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06948448","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard ","route":"/trials/nct06948448/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04570423","kind":"trial","name":"A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy","route":"/trials/nct04570423/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06116136","kind":"trial","name":"A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.","route":"/trials/nct06116136/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07291076","kind":"trial","name":"A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unres","route":"/trials/nct07291076/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07362459","kind":"trial","name":"A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer","route":"/trials/nct07362459/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04077723","kind":"trial","name":"A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combi","route":"/trials/nct04077723/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06609005","kind":"trial","name":"A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer","route":"/trials/nct06609005/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07498725","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors","route":"/trials/nct07498725/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07223047","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advance","route":"/trials/nct07223047/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04300556","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types","route":"/trials/nct04300556/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07293351","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal ","route":"/trials/nct07293351/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06618287","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors","route":"/trials/nct06618287/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06656390","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors","route":"/trials/nct06656390/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07612891","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor","route":"/trials/nct07612891/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07610798","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations","route":"/trials/nct07610798/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06746116","kind":"trial","name":"A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment","route":"/trials/nct06746116/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05941507","kind":"trial","name":"A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors","route":"/trials/nct05941507/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06946797","kind":"trial","name":"A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Pre","route":"/trials/nct06946797/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06717347","kind":"trial","name":"A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituxi","route":"/trials/nct06717347/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07354022","kind":"trial","name":"A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy","route":"/trials/nct07354022/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06349980","kind":"trial","name":"A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.","route":"/trials/nct06349980/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04590326","kind":"trial","name":"A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamata","route":"/trials/nct04590326/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07475806","kind":"trial","name":"A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder","route":"/trials/nct07475806/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06747585","kind":"trial","name":"A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors","route":"/trials/nct06747585/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07169734","kind":"trial","name":"A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors","route":"/trials/nct07169734/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07538804","kind":"trial","name":"A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer","route":"/trials/nct07538804/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06399757","kind":"trial","name":"A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors","route":"/trials/nct06399757/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"invincible-3","kind":"trial","name":"A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)","route":"/trials/invincible-3/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07286331","kind":"trial","name":"A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)","route":"/trials/nct07286331/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07286266","kind":"trial","name":"A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)","route":"/trials/nct07286266/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06943872","kind":"trial","name":"A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)","route":"/trials/nct06943872/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07188558","kind":"trial","name":"A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy","route":"/trials/nct07188558/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07129252","kind":"trial","name":"A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors","route":"/trials/nct07129252/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06634589","kind":"trial","name":"A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies","route":"/trials/nct06634589/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05801029","kind":"trial","name":"A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth","route":"/trials/nct05801029/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07055594","kind":"trial","name":"A Study to Investigate Safety and Preliminary Efficacy of SOA101 in Adult Subjects With Advanced Solid Tumors","route":"/trials/nct07055594/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05081609","kind":"trial","name":"A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other","route":"/trials/nct05081609/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07115043","kind":"trial","name":"A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors","route":"/trials/nct07115043/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07277231","kind":"trial","name":"A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia","route":"/trials/nct07277231/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05361174","kind":"trial","name":"A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer","route":"/trials/nct05361174/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06742996","kind":"trial","name":"A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refrac","route":"/trials/nct06742996/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04002297","kind":"trial","name":"A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantl","route":"/trials/nct04002297/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05714839","kind":"trial","name":"A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatme","route":"/trials/nct05714839/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06940739","kind":"trial","name":"A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel","route":"/trials/nct06940739/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07213609","kind":"trial","name":"A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors","route":"/trials/nct07213609/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06697184","kind":"trial","name":"A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.","route":"/trials/nct06697184/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07154290","kind":"trial","name":"A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct07154290/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07585266","kind":"trial","name":"A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)","route":"/trials/nct07585266/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05623020","kind":"trial","name":"A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide","route":"/trials/nct05623020/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"himalayas-1","kind":"trial","name":"A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)","route":"/trials/himalayas-1/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06989437","kind":"trial","name":"A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue","route":"/trials/nct06989437/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05262400","kind":"trial","name":"A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors","route":"/trials/nct05262400/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07062965","kind":"trial","name":"A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment","route":"/trials/nct07062965/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nsclc-4","kind":"trial","name":"A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)","route":"/trials/nsclc-4/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07192614","kind":"trial","name":"A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Pr","route":"/trials/nct07192614/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07450599","kind":"trial","name":"A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have Hi","route":"/trials/nct07450599/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05785767","kind":"trial","name":"A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small","route":"/trials/nct05785767/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06452277","kind":"trial","name":"A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-sma","route":"/trials/nct06452277/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06760819","kind":"trial","name":"A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)","route":"/trials/nct06760819/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05748171","kind":"trial","name":"A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL","route":"/trials/nct05748171/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06769698","kind":"trial","name":"A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous ","route":"/trials/nct06769698/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07265674","kind":"trial","name":"A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer","route":"/trials/nct07265674/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07287150","kind":"trial","name":"A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct07287150/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07054190","kind":"trial","name":"A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer","route":"/trials/nct07054190/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06619509","kind":"trial","name":"A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine","route":"/trials/nct06619509/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06885034","kind":"trial","name":"A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)","route":"/trials/nct06885034/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06246916","kind":"trial","name":"A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)","route":"/trials/nct06246916/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05562830","kind":"trial","name":"A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)","route":"/trials/nct05562830/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07213804","kind":"trial","name":"A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer","route":"/trials/nct07213804/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07673029","kind":"trial","name":"A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer","route":"/trials/nct07673029/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02301286","kind":"trial","name":"A Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients","route":"/trials/nct02301286/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03634540","kind":"trial","name":"A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)","route":"/trials/nct03634540/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06632405","kind":"trial","name":"A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC","route":"/trials/nct06632405/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06679985","kind":"trial","name":"A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepat","route":"/trials/nct06679985/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07232849","kind":"trial","name":"A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct07232849/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07003321","kind":"trial","name":"A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct07003321/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06555068","kind":"trial","name":"A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients","route":"/trials/nct06555068/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07601048","kind":"trial","name":"A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment","route":"/trials/nct07601048/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07281976","kind":"trial","name":"A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer","route":"/trials/nct07281976/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06624644","kind":"trial","name":"A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma","route":"/trials/nct06624644/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07028281","kind":"trial","name":"A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors","route":"/trials/nct07028281/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07268040","kind":"trial","name":"A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors","route":"/trials/nct07268040/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07196774","kind":"trial","name":"A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer","route":"/trials/nct07196774/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07393542","kind":"trial","name":"A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma","route":"/trials/nct07393542/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07059221","kind":"trial","name":"A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer","route":"/trials/nct07059221/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06639347","kind":"trial","name":"A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma","route":"/trials/nct06639347/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06417554","kind":"trial","name":"A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors","route":"/trials/nct06417554/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06895928","kind":"trial","name":"A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors","route":"/trials/nct06895928/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07203053","kind":"trial","name":"A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2","route":"/trials/nct07203053/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07497386","kind":"trial","name":"A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer","route":"/trials/nct07497386/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02346747","kind":"trial","name":"A Trial of Vigil for Participants With Ovarian Cancer","route":"/trials/nct02346747/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06505395","kind":"trial","name":"A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)","route":"/trials/nct06505395/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06545955","kind":"trial","name":"A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer","route":"/trials/nct06545955/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06149286","kind":"trial","name":"A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participant","route":"/trials/nct06149286/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05125016","kind":"trial","name":"A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer","route":"/trials/nct05125016/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03972657","kind":"trial","name":"A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metasta","route":"/trials/nct03972657/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06230224","kind":"trial","name":"A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell ","route":"/trials/nct06230224/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07336446","kind":"trial","name":"A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs","route":"/trials/nct07336446/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05557591","kind":"trial","name":"A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small ","route":"/trials/nct05557591/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05800015","kind":"trial","name":"A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult ","route":"/trials/nct05800015/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05730036","kind":"trial","name":"A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Re","route":"/trials/nct05730036/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06097364","kind":"trial","name":"A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemo","route":"/trials/nct06097364/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06091254","kind":"trial","name":"A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy ","route":"/trials/nct06091254/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07455851","kind":"trial","name":"A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct07455851/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07721259","kind":"trial","name":"A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden","route":"/trials/nct07721259/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05828511","kind":"trial","name":"A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnose","route":"/trials/nct05828511/","detail":"mentions 2035 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"aaa817","kind":"drug","name":"AAA817","route":"/drugs/aaa817/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07285694","kind":"trial","name":"AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)","route":"/trials/nct07285694/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"abbv-706","kind":"drug","name":"ABBV-706","route":"/drugs/abbv-706/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07441369","kind":"trial","name":"Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer","route":"/trials/nct07441369/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-nct03706365-lancet-oncol-2025","kind":"paper","name":"Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-nct03706365-lancet-oncol-2025/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-monarche-lancet-oncol-2023","kind":"paper","name":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","route":"/key-papers/paper-monarche-lancet-oncol-2023/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-abiraterone-acetate-prostate-lancet-oncol-2012","kind":"paper","name":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","route":"/key-papers/paper-abiraterone-acetate-prostate-lancet-oncol-2012/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-attard-lancet-oncol","kind":"paper","name":"Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol","route":"/key-papers/paper-attard-lancet-oncol/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05422911","kind":"trial","name":"Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.","route":"/trials/nct05422911/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07158918","kind":"trial","name":"ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors","route":"/trials/nct07158918/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07327034","kind":"trial","name":"ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression","route":"/trials/nct07327034/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"absk061","kind":"drug","name":"ABSK061","route":"/drugs/absk061/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"abt-301","kind":"drug","name":"ABT-301","route":"/drugs/abt-301/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"acasunlimab","kind":"drug","name":"Acasunlimab","route":"/drugs/acasunlimab/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05355298","kind":"trial","name":"ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer","route":"/trials/nct05355298/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03686124","kind":"trial","name":"ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors","route":"/trials/nct03686124/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07272109","kind":"trial","name":"Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes","route":"/trials/nct07272109/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06911333","kind":"trial","name":"AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct06911333/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06248606","kind":"trial","name":"Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases","route":"/trials/nct06248606/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06844422","kind":"trial","name":"Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)","route":"/trials/nct06844422/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07746388","kind":"trial","name":"Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial","route":"/trials/nct07746388/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07523555","kind":"trial","name":"Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies","route":"/trials/nct07523555/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06545747","kind":"trial","name":"Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI","route":"/trials/nct06545747/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07744256","kind":"trial","name":"Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)","route":"/trials/nct07744256/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07480213","kind":"trial","name":"Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)","route":"/trials/nct07480213/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07516210","kind":"trial","name":"Adaptive Radiotherapy for Safe Hypofractionation","route":"/trials/nct07516210/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07802626","kind":"trial","name":"Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing","route":"/trials/nct07802626/","detail":"mentions 2034 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06616584","kind":"trial","name":"Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemoth","route":"/trials/nct06616584/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06728072","kind":"trial","name":"Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer","route":"/trials/nct06728072/","detail":"mentions 2035 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06141070","kind":"trial","name":"Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease","route":"/trials/nct06141070/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07715396","kind":"trial","name":"Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden","route":"/trials/nct07715396/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-brightness-lancet-oncol-2018","kind":"paper","name":"Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial","route":"/key-papers/paper-brightness-lancet-oncol-2018/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06719336","kind":"trial","name":"Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001)","route":"/trials/nct06719336/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06916975","kind":"trial","name":"Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer","route":"/trials/nct06916975/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07560358","kind":"trial","name":"Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer","route":"/trials/nct07560358/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06672133","kind":"trial","name":"Adebrelimab Combined with Chemotherapy and Thoracic Radiotherapy for First-line Treatment of ES-SCLC","route":"/trials/nct06672133/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06177522","kind":"trial","name":"Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer","route":"/trials/nct06177522/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07392541","kind":"trial","name":"Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer","route":"/trials/nct07392541/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07230301","kind":"trial","name":"Adebrelimab Infusion Plus Standard Care for Pancreatic Cancer With Pleural or Peritoneal Effusions","route":"/trials/nct07230301/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07561775","kind":"trial","name":"Adebrelimab Plus S-1 for Resected Cholangiocarcinoma","route":"/trials/nct07561775/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"adg126","kind":"drug","name":"ADG126","route":"/drugs/adg126/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04587830","kind":"trial","name":"ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme","route":"/trials/nct04587830/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"adi-peg20","kind":"drug","name":"ADI-PEG20","route":"/drugs/adi-peg20/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06041776","kind":"trial","name":"Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations","route":"/trials/nct06041776/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06427447","kind":"trial","name":"Adjuvant Chemoradiotherapy Versus Chemotherapy for Pancreatic Cancer (ADJUPANC)","route":"/trials/nct06427447/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07149363","kind":"trial","name":"Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer","route":"/trials/nct07149363/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05797467","kind":"trial","name":"Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients","route":"/trials/nct05797467/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07296666","kind":"trial","name":"Adjuvant Chemotherapy for BTC Based on 3D-PTA","route":"/trials/nct07296666/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07802834","kind":"trial","name":"Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC","route":"/trials/nct07802834/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05270044","kind":"trial","name":"Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.","route":"/trials/nct05270044/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06501482","kind":"trial","name":"Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI","route":"/trials/nct06501482/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07407517","kind":"trial","name":"Adjuvant Intensification for LAR","route":"/trials/nct07407517/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05179889","kind":"trial","name":"Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer","route":"/trials/nct05179889/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-checkmate-238-lancet-oncol-2020-update","kind":"paper","name":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","route":"/key-papers/paper-checkmate-238-lancet-oncol-2020-update/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06520683","kind":"trial","name":"Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer","route":"/trials/nct06520683/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04317534","kind":"trial","name":"Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm","route":"/trials/nct04317534/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07225621","kind":"trial","name":"Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma","route":"/trials/nct07225621/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06780839","kind":"trial","name":"Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD","route":"/trials/nct06780839/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02455141","kind":"trial","name":"Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer","route":"/trials/nct02455141/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02830724","kind":"trial","name":"Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers","route":"/trials/nct02830724/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03190941","kind":"trial","name":"Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients","route":"/trials/nct03190941/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03801083","kind":"trial","name":"Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers","route":"/trials/nct03801083/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06938503","kind":"trial","name":"AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer","route":"/trials/nct06938503/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"agex","kind":"trial","name":"AgeX","route":"/trials/agex/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"aglatimagene-besadenovec","kind":"drug","name":"Aglatimagene besadenovec","route":"/drugs/aglatimagene-besadenovec/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-nct01436968-lancet-oncol-2026","kind":"paper","name":"Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial","route":"/key-papers/paper-nct01436968-lancet-oncol-2026/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"aurora","kind":"trial","name":"Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)","route":"/trials/aurora/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ai-081","kind":"drug","name":"AI-081","route":"/drugs/ai-081/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06600022","kind":"trial","name":"Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.","route":"/trials/nct06600022/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07544784","kind":"trial","name":"AK104 Plus Radiotherapy Combined With Standard Therapy Versus Standard Therapy as First-Line Treatment for pMMR/MSS CRLM (APSOC)","route":"/trials/nct07544784/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06951503","kind":"trial","name":"AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer","route":"/trials/nct06951503/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07767994","kind":"trial","name":"AK112 Combined With GAP Conversion Therapy for Locally Advanced Gallbladder Cancer","route":"/trials/nct07767994/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07158840","kind":"trial","name":"AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor","route":"/trials/nct07158840/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07021950","kind":"trial","name":"AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer","route":"/trials/nct07021950/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ak117","kind":"drug","name":"AK117","route":"/drugs/ak117/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03386617","kind":"trial","name":"AKY15-HK-301_NEPA Study","route":"/trials/nct03386617/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"al2846","kind":"drug","name":"AL2846","route":"/drugs/al2846/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"al8326","kind":"drug","name":"AL8326","route":"/drugs/al8326/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07831330","kind":"trial","name":"Albumin-bound Paclitaxel (II) in Combination With Gemcitabine as First Line Therapy for Metastatic Pancreatic Cancer","route":"/trials/nct07831330/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07828756","kind":"trial","name":"Albumin-bound Paclitaxel (II)-Combined Regimens for Pancreatic Cancer","route":"/trials/nct07828756/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05192798","kind":"trial","name":"Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC","route":"/trials/nct05192798/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06636981","kind":"trial","name":"All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi","route":"/trials/nct06636981/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"alliance-a021806","kind":"trial","name":"Alliance A021806","route":"/trials/alliance-a021806/","detail":"mentions 2028, 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"allo-647","kind":"drug","name":"ALLO-647","route":"/drugs/allo-647/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07551778","kind":"trial","name":"Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors","route":"/trials/nct07551778/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04616209","kind":"trial","name":"Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients","route":"/trials/nct04616209/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05948943","kind":"trial","name":"Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.","route":"/trials/nct05948943/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"alpha-9-oncology","kind":"company","name":"Alpha-9 Oncology","route":"/companies/alpha-9-oncology/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07780838","kind":"trial","name":"Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma","route":"/trials/nct07780838/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07569679","kind":"trial","name":"Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer","route":"/trials/nct07569679/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07130903","kind":"trial","name":"Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer","route":"/trials/nct07130903/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07590531","kind":"trial","name":"AMT-116 in Combination With AK112 in Patients With Lung Cancer","route":"/trials/nct07590531/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"idea-reg-pd1-biosimilar-advance-commitment","kind":"idea","name":"An advance market commitment for PD-1 biosimilars for lower-income countries","route":"/ideas/idea-reg-pd1-biosimilar-advance-commitment/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05876754","kind":"trial","name":"An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma","route":"/trials/nct05876754/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07293754","kind":"trial","name":"An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors","route":"/trials/nct07293754/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02531516","kind":"trial","name":"An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS","route":"/trials/nct02531516/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03897881","kind":"trial","name":"An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYN","route":"/trials/nct03897881/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07033026","kind":"trial","name":"An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.","route":"/trials/nct07033026/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06938282","kind":"trial","name":"An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer","route":"/trials/nct06938282/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07631871","kind":"trial","name":"An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy","route":"/trials/nct07631871/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06401356","kind":"trial","name":"An Extension Study for Patients Previously Enrolled in Studies With Pelabresib","route":"/trials/nct06401356/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05112965","kind":"trial","name":"An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)","route":"/trials/nct05112965/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03844048","kind":"trial","name":"An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial","route":"/trials/nct03844048/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07604766","kind":"trial","name":"An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Can","route":"/trials/nct07604766/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06557733","kind":"trial","name":"An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis","route":"/trials/nct06557733/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06447103","kind":"trial","name":"An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer","route":"/trials/nct06447103/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06634849","kind":"trial","name":"An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1).","route":"/trials/nct06634849/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07206056","kind":"trial","name":"An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)","route":"/trials/nct07206056/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05907057","kind":"trial","name":"An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.","route":"/trials/nct05907057/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05939414","kind":"trial","name":"An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.","route":"/trials/nct05939414/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06991556","kind":"trial","name":"An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Canc","route":"/trials/nct06991556/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02955940","kind":"trial","name":"An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib","route":"/trials/nct02955940/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07720284","kind":"trial","name":"An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC","route":"/trials/nct07720284/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07359066","kind":"trial","name":"An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors","route":"/trials/nct07359066/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07806058","kind":"trial","name":"An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors","route":"/trials/nct07806058/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07589569","kind":"trial","name":"An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer","route":"/trials/nct07589569/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07668453","kind":"trial","name":"An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies","route":"/trials/nct07668453/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06855849","kind":"trial","name":"An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients","route":"/trials/nct06855849/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07371663","kind":"trial","name":"An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors","route":"/trials/nct07371663/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07398326","kind":"trial","name":"Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer","route":"/trials/nct07398326/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04322617","kind":"trial","name":"Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer","route":"/trials/nct04322617/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06662877","kind":"trial","name":"Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment","route":"/trials/nct06662877/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07443397","kind":"trial","name":"Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.","route":"/trials/nct07443397/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07635290","kind":"trial","name":"Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer","route":"/trials/nct07635290/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07444541","kind":"trial","name":"ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer","route":"/trials/nct07444541/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07537998","kind":"trial","name":"Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a Single-Center, Prospective Randomized Co","route":"/trials/nct07537998/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05296564","kind":"trial","name":"Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers","route":"/trials/nct05296564/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07686796","kind":"trial","name":"Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A P","route":"/trials/nct07686796/","detail":"mentions 2027, 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-nct02257736-lancet-oncol-2021","kind":"paper","name":"Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study","route":"/key-papers/paper-nct02257736-lancet-oncol-2021/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05701306","kind":"trial","name":"APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors","route":"/trials/nct05701306/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07160686","kind":"trial","name":"Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment","route":"/trials/nct07160686/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04858334","kind":"trial","name":"APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a","route":"/trials/nct04858334/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ariceum-therapeutics","kind":"company","name":"Ariceum Therapeutics","route":"/companies/ariceum-therapeutics/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"arlocabtagene-autoleucel","kind":"drug","name":"Arlocabtagene Autoleucel","route":"/drugs/arlocabtagene-autoleucel/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05800223","kind":"trial","name":"Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer","route":"/trials/nct05800223/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ascent-05","kind":"trial","name":"ASCENT-05 / OptimICE-RD (AFT-65, GBG 119, NSABP B-63)","route":"/trials/ascent-05/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07109531","kind":"trial","name":"ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy","route":"/trials/nct07109531/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"asp2138","kind":"drug","name":"ASP2138","route":"/drugs/asp2138/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07007559","kind":"trial","name":"ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer","route":"/trials/nct07007559/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03464305","kind":"trial","name":"ASPIRIN Trial Belgium","route":"/trials/nct03464305/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05794750","kind":"trial","name":"Assess the Efficacy of Radiotherapy and Sequential Chemotherapy and AK104 Before TME Surgery for Local CRC（AK104-IIT-13）","route":"/trials/nct05794750/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07455903","kind":"trial","name":"Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT","route":"/trials/nct07455903/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07496229","kind":"trial","name":"Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)","route":"/trials/nct07496229/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07015853","kind":"trial","name":"ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation","route":"/trials/nct07015853/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05969860","kind":"trial","name":"At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer","route":"/trials/nct05969860/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"at101","kind":"drug","name":"AT101","route":"/drugs/at101/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07374419","kind":"trial","name":"Atamparib in Patients With Advanced Solid Tumors","route":"/trials/nct07374419/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"atebimetinib","kind":"drug","name":"Atebimetinib","route":"/drugs/atebimetinib/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07562152","kind":"trial","name":"Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","route":"/trials/nct07562152/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06663098","kind":"trial","name":"Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).","route":"/trials/nct06663098/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-impassion130-lancet-oncol-2020-update","kind":"paper","name":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-impassion130-lancet-oncol-2020-update/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"atigotatug","kind":"drug","name":"Atigotatug","route":"/drugs/atigotatug/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-nct04687241-lancet-oncol-2026","kind":"paper","name":"Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial","route":"/key-papers/paper-nct04687241-lancet-oncol-2026/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-nct04923906-lancet-oncol-2026","kind":"paper","name":"Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial","route":"/key-papers/paper-nct04923906-lancet-oncol-2026/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04614103","kind":"trial","name":"Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer","route":"/trials/nct04614103/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06241781","kind":"trial","name":"Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer","route":"/trials/nct06241781/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-javelin-merkel-200-lancet-oncol-2016","kind":"paper","name":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial","route":"/key-papers/paper-javelin-merkel-200-lancet-oncol-2016/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07038343","kind":"trial","name":"AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)","route":"/trials/nct07038343/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"avzo-021","kind":"drug","name":"AVZO-021","route":"/drugs/avzo-021/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07354919","kind":"trial","name":"Axelopran for Advanced Cancer in Patients Receiving Opioids","route":"/trials/nct07354919/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05850234","kind":"trial","name":"AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)","route":"/trials/nct05850234/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06106945","kind":"trial","name":"AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma","route":"/trials/nct06106945/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"azd0486","kind":"drug","name":"AZD0486","route":"/drugs/azd0486/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07215585","kind":"trial","name":"AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL","route":"/trials/nct07215585/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06137118","kind":"trial","name":"AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia","route":"/trials/nct06137118/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07611110","kind":"trial","name":"AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)","route":"/trials/nct07611110/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"azd3470","kind":"drug","name":"AZD3470","route":"/drugs/azd3470/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06137144","kind":"trial","name":"AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.","route":"/trials/nct06137144/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"azd4045","kind":"drug","name":"AZD4045","route":"/drugs/azd4045/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"azd4360","kind":"drug","name":"AZD4360","route":"/drugs/azd4360/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"azd4512","kind":"drug","name":"AZD4512","route":"/drugs/azd4512/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"azd5335","kind":"drug","name":"AZD5335","route":"/drugs/azd5335/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07218809","kind":"trial","name":"AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer","route":"/trials/nct07218809/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"azd5492","kind":"drug","name":"AZD5492","route":"/drugs/azd5492/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"azd5863","kind":"drug","name":"AZD5863","route":"/drugs/azd5863/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"azd6621","kind":"drug","name":"AZD6621","route":"/drugs/azd6621/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"azd9750","kind":"drug","name":"AZD9750","route":"/drugs/azd9750/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"azd9793","kind":"drug","name":"AZD9793","route":"/drugs/azd9793/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"azenosertib","kind":"drug","name":"Azenosertib","route":"/drugs/azenosertib/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"azur-1","kind":"trial","name":"AZUR-1","route":"/trials/azur-1/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07550088","kind":"trial","name":"BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases","route":"/trials/nct07550088/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06483555","kind":"trial","name":"Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel","route":"/trials/nct06483555/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02568267","kind":"trial","name":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangeme","route":"/trials/nct02568267/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07469774","kind":"trial","name":"BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct07469774/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"bcb-276","kind":"drug","name":"BCB-276","route":"/drugs/bcb-276/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"bcd-217","kind":"drug","name":"BCD-217","route":"/drugs/bcd-217/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"bdc-4182","kind":"drug","name":"BDC-4182","route":"/drugs/bdc-4182/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07193511","kind":"trial","name":"BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)","route":"/trials/nct07193511/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07486817","kind":"trial","name":"Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab","route":"/trials/nct07486817/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06324357","kind":"trial","name":"Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People Wit","route":"/trials/nct06324357/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07195695","kind":"trial","name":"Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutati","route":"/trials/nct07195695/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06581432","kind":"trial","name":"Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations","route":"/trials/nct06581432/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"bebt-209","kind":"drug","name":"BEBT-209","route":"/drugs/bebt-209/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07490119","kind":"trial","name":"Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer","route":"/trials/nct07490119/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07649980","kind":"trial","name":"Becotatug Vedotin Plus Pucotenlimab for Advanced Biliary Tract Cancer, Phase II","route":"/trials/nct07649980/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07629609","kind":"trial","name":"BEFAST Study, [68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer","route":"/trials/nct07629609/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07195591","kind":"trial","name":"Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care","route":"/trials/nct07195591/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07449754","kind":"trial","name":"Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma","route":"/trials/nct07449754/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04924075","kind":"trial","name":"Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL","route":"/trials/nct04924075/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07071844","kind":"trial","name":"BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients","route":"/trials/nct07071844/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07481786","kind":"trial","name":"Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases","route":"/trials/nct07481786/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06642844","kind":"trial","name":"Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment","route":"/trials/nct06642844/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07722754","kind":"trial","name":"Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial","route":"/trials/nct07722754/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"bexobrutideg","kind":"drug","name":"Bexobrutideg","route":"/drugs/bexobrutideg/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"bgb-43395","kind":"drug","name":"BGB-43395","route":"/drugs/bgb-43395/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07492641","kind":"trial","name":"BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease","route":"/trials/nct07492641/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06205706","kind":"trial","name":"BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors","route":"/trials/nct06205706/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06365788","kind":"trial","name":"Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer","route":"/trials/nct06365788/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"bicara-therapeutics","kind":"company","name":"Bicara Therapeutics","route":"/companies/bicara-therapeutics/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06159478","kind":"trial","name":"Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)","route":"/trials/nct06159478/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-redman-lancet-oncol","kind":"paper","name":"Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol","route":"/key-papers/paper-redman-lancet-oncol/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07410494","kind":"trial","name":"Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors","route":"/trials/nct07410494/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07523529","kind":"trial","name":"Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors","route":"/trials/nct07523529/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07625644","kind":"trial","name":"BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)","route":"/trials/nct07625644/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"bleximenib","kind":"drug","name":"Bleximenib","route":"/drugs/bleximenib/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07610525","kind":"trial","name":"Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial","route":"/trials/nct07610525/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05317858","kind":"trial","name":"Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets","route":"/trials/nct05317858/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07226856","kind":"trial","name":"BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma","route":"/trials/nct07226856/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"bms-986365","kind":"drug","name":"BMS-986365","route":"/drugs/bms-986365/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07594626","kind":"trial","name":"BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion","route":"/trials/nct07594626/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"bnt113","kind":"drug","name":"BNT113","route":"/drugs/bnt113/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"bnt324","kind":"drug","name":"BNT324","route":"/drugs/bnt324/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"bomedemstat","kind":"drug","name":"Bomedemstat","route":"/drugs/bomedemstat/","detail":"mentions 2034 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07485452","kind":"trial","name":"Boosting Osimertinib Blood Brain Barrier Penetration","route":"/trials/nct07485452/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06709144","kind":"trial","name":"Borderline of CME/D3 Dissection for Local Advanced Right-sided Colon Cancer","route":"/trials/nct06709144/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"botensilimab","kind":"drug","name":"Botensilimab","route":"/drugs/botensilimab/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05393466","kind":"trial","name":"BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct05393466/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07645118","kind":"trial","name":"Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer","route":"/trials/nct07645118/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-bray-globocan-2022-cacancer-2024","kind":"paper","name":"Bray 2024: GLOBOCAN 2022, the world's cancer count for 36 cancers in 185 countries","route":"/key-papers/paper-bray-globocan-2022-cacancer-2024/","detail":"mentions 2050 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"budigalimab","kind":"drug","name":"Budigalimab","route":"/drugs/budigalimab/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct01639508","kind":"trial","name":"Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or A","route":"/trials/nct01639508/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-nct04446117-lancet-oncol-2025","kind":"paper","name":"Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial","route":"/key-papers/paper-nct04446117-lancet-oncol-2025/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03539822","kind":"trial","name":"Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies","route":"/trials/nct03539822/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"cadance-304","kind":"trial","name":"CaDAnCe-304","route":"/trials/cadance-304/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"zhou-caicun","kind":"person","name":"Caicun Zhou","route":"/people/zhou-caicun/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"calderasib","kind":"drug","name":"Calderasib","route":"/drugs/calderasib/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-nct04214288-lancet-oncol-2024","kind":"paper","name":"Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial","route":"/key-papers/paper-nct04214288-lancet-oncol-2024/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02945566","kind":"trial","name":"Can we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer?","route":"/trials/nct02945566/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-han-j-natl-cancer-cent","kind":"paper","name":"Cancer incidence and mortality in China, 2022","route":"/key-papers/paper-han-j-natl-cancer-cent/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"candel-therapeutics","kind":"company","name":"Candel Therapeutics","route":"/companies/candel-therapeutics/","detail":"mentions 2027, 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06787339","kind":"trial","name":"Capecitabine in Low Risk Triple Negative Breast Cancer","route":"/trials/nct06787339/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05973864","kind":"trial","name":"Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery","route":"/trials/nct05973864/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07281768","kind":"trial","name":"Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer","route":"/trials/nct07281768/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04862663","kind":"trial","name":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)","route":"/trials/nct04862663/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-geometry-mono-1-lancet-oncol-2024-update","kind":"paper","name":"Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial","route":"/key-papers/paper-geometry-mono-1-lancet-oncol-2024-update/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07383285","kind":"trial","name":"CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal C","route":"/trials/nct07383285/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07257523","kind":"trial","name":"Carbon Ion Radiotherapy in Frail Patients With Pancreatic Cancer","route":"/trials/nct07257523/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07087054","kind":"trial","name":"Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen","route":"/trials/nct07087054/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"cart84","kind":"drug","name":"CART84","route":"/drugs/cart84/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06690775","kind":"trial","name":"CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.","route":"/trials/nct06690775/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07322094","kind":"trial","name":"CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ov","route":"/trials/nct07322094/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"cd19-t-hank","kind":"drug","name":"CD19 t-haNK","route":"/drugs/cd19-t-hank/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07153289","kind":"trial","name":"CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa)","route":"/trials/nct07153289/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06538857","kind":"trial","name":"CEB-01 in Locally Resectable Pancreatic Cancer","route":"/trials/nct06538857/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06986811","kind":"trial","name":"CEB-01 in Paediatrics With Locally Resectable Abdominal Tumours","route":"/trials/nct06986811/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06790602","kind":"trial","name":"Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma","route":"/trials/nct06790602/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07224022","kind":"trial","name":"Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer","route":"/trials/nct07224022/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06205836","kind":"trial","name":"Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer","route":"/trials/nct06205836/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"century-therapeutics","kind":"company","name":"Century Therapeutics","route":"/companies/century-therapeutics/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/","detail":"mentions 2035 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-tamrakar-cancer","kind":"paper","name":"Cervical cancer elimination in India: Repurposing diagnostics, vaccination, and accelerating policy for the 2030 target","route":"/key-papers/paper-tamrakar-cancer/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"cetrelimab","kind":"drug","name":"Cetrelimab","route":"/drugs/cetrelimab/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"cevostamab","kind":"drug","name":"Cevostamab","route":"/drugs/cevostamab/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07555938","kind":"trial","name":"Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma","route":"/trials/nct07555938/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06665087","kind":"trial","name":"CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC","route":"/trials/nct06665087/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06652412","kind":"trial","name":"CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC","route":"/trials/nct06652412/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"cgt4859","kind":"drug","name":"CGT4859","route":"/drugs/cgt4859/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"idea-pdac-neoadjuvant-chemotherapy-for-all-resectable-disease","kind":"idea","name":"Chemotherapy before surgery for every resectable pancreatic cancer, settled by the two perioperative trials rather than assumed","route":"/ideas/idea-pdac-neoadjuvant-chemotherapy-for-all-resectable-disease/","detail":"mentions 2027, 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"idea-gbc-neoadjuvant-for-high-risk-incidental-cancer","kind":"idea","name":"Chemotherapy before the second operation for high-risk incidental gallbladder cancer","route":"/ideas/idea-gbc-neoadjuvant-for-high-risk-incidental-cancer/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06280508","kind":"trial","name":"Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer","route":"/trials/nct06280508/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06096844","kind":"trial","name":"Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial","route":"/trials/nct06096844/","detail":"mentions 2039 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-phergain-lancet-oncol-2021","kind":"paper","name":"Chemotherapy de-escalation using an 18 F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial","route":"/key-papers/paper-phergain-lancet-oncol-2021/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07570849","kind":"trial","name":"Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma","route":"/trials/nct07570849/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05833724","kind":"trial","name":"Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)","route":"/trials/nct05833724/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"childhood-cancers","kind":"cancer","name":"Childhood cancers (all types)","route":"/cancers/childhood-cancers/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04120701","kind":"trial","name":"CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II","route":"/trials/nct04120701/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06992336","kind":"trial","name":"Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy","route":"/trials/nct06992336/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05770531","kind":"trial","name":"Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy","route":"/trials/nct05770531/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-plasmamatch-lancet-oncol-2020","kind":"paper","name":"Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial","route":"/key-papers/paper-plasmamatch-lancet-oncol-2020/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06037980","kind":"trial","name":"CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence","route":"/trials/nct06037980/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"clifutinib","kind":"drug","name":"Clifutinib","route":"/drugs/clifutinib/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07197853","kind":"trial","name":"Clinical Efficacy and Safety of Microwave Ablation Combined With Huaier Granules in Patients With Inoperable Stage IA Non-Small Cell Lung Cancer: A Prospective,","route":"/trials/nct07197853/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03093688","kind":"trial","name":"Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor","route":"/trials/nct03093688/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07512583","kind":"trial","name":"Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors","route":"/trials/nct07512583/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06821503","kind":"trial","name":"Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C","route":"/trials/nct06821503/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07522151","kind":"trial","name":"Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer","route":"/trials/nct07522151/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06680752","kind":"trial","name":"Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS","route":"/trials/nct06680752/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06767514","kind":"trial","name":"Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1","route":"/trials/nct06767514/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04668690","kind":"trial","name":"Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL","route":"/trials/nct04668690/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07005583","kind":"trial","name":"Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent","route":"/trials/nct07005583/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07827053","kind":"trial","name":"Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer","route":"/trials/nct07827053/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07036250","kind":"trial","name":"Clinical Study of U32 in Patients With Acute Myeloid Leukemia","route":"/trials/nct07036250/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07730515","kind":"trial","name":"Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma","route":"/trials/nct07730515/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07545603","kind":"trial","name":"Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma","route":"/trials/nct07545603/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06961188","kind":"trial","name":"Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis","route":"/trials/nct06961188/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05009836","kind":"trial","name":"Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC","route":"/trials/nct05009836/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07385703","kind":"trial","name":"Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma","route":"/trials/nct07385703/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07391618","kind":"trial","name":"Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU","route":"/trials/nct07391618/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06879145","kind":"trial","name":"Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)","route":"/trials/nct06879145/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03067051","kind":"trial","name":"Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System","route":"/trials/nct03067051/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07122063","kind":"trial","name":"Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors","route":"/trials/nct07122063/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06233877","kind":"trial","name":"Clinical Trial Evaluating Low Dose G-FLIP Plus Mitomycin C for Stage IV Pancreatic Cancer","route":"/trials/nct06233877/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07192068","kind":"trial","name":"Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.","route":"/trials/nct07192068/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07683949","kind":"trial","name":"Clinical Trial Evaluating the Efficacy of Capecitabine Plus Lenvatinib in Patients With Advanced Colorectal Cancer Refractory to Irinotecan, Oxaliplatin, and Fl","route":"/trials/nct07683949/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07367516","kind":"trial","name":"Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer","route":"/trials/nct07367516/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06255912","kind":"trial","name":"Clinical Trial for Advanced or Metastatic Pancreatic Cancer","route":"/trials/nct06255912/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02781883","kind":"trial","name":"Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML","route":"/trials/nct02781883/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07656376","kind":"trial","name":"Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation","route":"/trials/nct07656376/","detail":"mentions 2027, 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06781567","kind":"trial","name":"Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma","route":"/trials/nct06781567/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06745908","kind":"trial","name":"Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In","route":"/trials/nct06745908/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07176182","kind":"trial","name":"Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression","route":"/trials/nct07176182/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06400160","kind":"trial","name":"Clinical Trial of TB511 in Advanced Solid Tumors","route":"/trials/nct06400160/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07008976","kind":"trial","name":"Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer","route":"/trials/nct07008976/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07299747","kind":"trial","name":"Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors","route":"/trials/nct07299747/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06975410","kind":"trial","name":"Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors","route":"/trials/nct06975410/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05523947","kind":"trial","name":"Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor","route":"/trials/nct05523947/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07548177","kind":"trial","name":"Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma","route":"/trials/nct07548177/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06699836","kind":"trial","name":"CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen","route":"/trials/nct06699836/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-cobrim-lancet-oncol-2016-update","kind":"paper","name":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","route":"/key-papers/paper-cobrim-lancet-oncol-2016-update/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05692024","kind":"trial","name":"COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER","route":"/trials/nct05692024/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"anbl1531","kind":"trial","name":"COG ANBL1531","route":"/trials/anbl1531/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06185556","kind":"trial","name":"COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases","route":"/trials/nct06185556/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05861505","kind":"trial","name":"COLLISION RELAPSE Trial","route":"/trials/nct05861505/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","detail":"mentions 2038, 2040, 2027, 2028, 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"colorectal-roadmap","kind":"roadmap","name":"Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation","route":"/roadmaps/colorectal-roadmap/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03919461","kind":"trial","name":"Colorectal Metastasis Prevention International Trial 2","route":"/trials/nct03919461/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07281716","kind":"trial","name":"Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC","route":"/trials/nct07281716/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07762703","kind":"trial","name":"Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Incl","route":"/trials/nct07762703/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05874414","kind":"trial","name":"Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma","route":"/trials/nct05874414/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07467590","kind":"trial","name":"Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Study","route":"/trials/nct07467590/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06411600","kind":"trial","name":"Combination Therapy for BRAF-V600E Metastatic CRCm","route":"/trials/nct06411600/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06686030","kind":"trial","name":"Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer","route":"/trials/nct06686030/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07580339","kind":"trial","name":"Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer","route":"/trials/nct07580339/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07371273","kind":"trial","name":"Comparative Study on the Short- and Long-term Efficacy of Q-ISR, Traditional Sub-ISR, and t-ISR","route":"/trials/nct07371273/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06234072","kind":"trial","name":"Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients","route":"/trials/nct06234072/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07595276","kind":"trial","name":"Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Stat","route":"/trials/nct07595276/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06632327","kind":"trial","name":"Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer","route":"/trials/nct06632327/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06782932","kind":"trial","name":"Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer","route":"/trials/nct06782932/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct01993810","kind":"trial","name":"Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer","route":"/trials/nct01993810/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04333537","kind":"trial","name":"Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer","route":"/trials/nct04333537/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07021261","kind":"trial","name":"Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients","route":"/trials/nct07021261/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06119867","kind":"trial","name":"CompariSon Between the EuroPeAn and Japanese pathologiCal InvEstigation for Colon Cancer (SPACE)","route":"/trials/nct06119867/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-marina-lancet-oncol","kind":"paper","name":"Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial","route":"/key-papers/paper-marina-lancet-oncol/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07554846","kind":"trial","name":"Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC","route":"/trials/nct07554846/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"compass-therapeutics","kind":"company","name":"Compass Therapeutics","route":"/companies/compass-therapeutics/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-convert-lancet-oncol-2017","kind":"paper","name":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial","route":"/key-papers/paper-convert-lancet-oncol-2017/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06500273","kind":"trial","name":"Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL","route":"/trials/nct06500273/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06502080","kind":"trial","name":"Consolidative Radiotherapy (CSRT) in Patients With Oligometastatic/Locally Advanced Unresectable Bilary Tract Cancer (BTC)","route":"/trials/nct06502080/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07389265","kind":"trial","name":"Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer","route":"/trials/nct07389265/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07004413","kind":"trial","name":"Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients","route":"/trials/nct07004413/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06690528","kind":"trial","name":"Conversion Surgery Vs. Palliative Care in Pancreatic Cancer Oligometastatic to the Liver","route":"/trials/nct06690528/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07398339","kind":"trial","name":"Cosiporfin Sodium for Injection Photodynamic Therapy","route":"/trials/nct07398339/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05733000","kind":"trial","name":"CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors","route":"/trials/nct05733000/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07335497","kind":"trial","name":"CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct07335497/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"crb-701","kind":"drug","name":"CRB-701","route":"/drugs/crb-701/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"crc01","kind":"drug","name":"CRC01","route":"/drugs/crc01/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07829874","kind":"trial","name":"Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer.","route":"/trials/nct07829874/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07306286","kind":"trial","name":"Cryoablation Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy","route":"/trials/nct07306286/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07483996","kind":"trial","name":"Cryoablation Versus Lumpectomy in Early-Stage Breast Cancer","route":"/trials/nct07483996/","detail":"mentions 2035 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07188025","kind":"trial","name":"ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer","route":"/trials/nct07188025/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05815082","kind":"trial","name":"ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer","route":"/trials/nct05815082/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07012954","kind":"trial","name":"ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC","route":"/trials/nct07012954/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06609551","kind":"trial","name":"ctDNA-guided Selection of Adjuvant Chemotherapy Regimens for Elderly Colon Cancer Patients After Surgery: A Single-center, Randomized, Controlled Study","route":"/trials/nct06609551/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07209215","kind":"trial","name":"ctDNA-Informed Management of Early-Stage Rectal Cancer","route":"/trials/nct07209215/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06951646","kind":"trial","name":"ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)","route":"/trials/nct06951646/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06548412","kind":"trial","name":"CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers","route":"/trials/nct06548412/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ctx112","kind":"drug","name":"CTX112","route":"/drugs/ctx112/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"cullinan-therapeutics","kind":"company","name":"Cullinan Therapeutics","route":"/companies/cullinan-therapeutics/","detail":"mentions 2027, 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"cusatuzumab","kind":"drug","name":"Cusatuzumab","route":"/drugs/cusatuzumab/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06659705","kind":"trial","name":"Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)","route":"/trials/nct06659705/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07664150","kind":"trial","name":"CW-301 FIH Study of CAN016","route":"/trials/nct07664150/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07016126","kind":"trial","name":"D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC","route":"/trials/nct07016126/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"d07001","kind":"drug","name":"D07001","route":"/drugs/d07001/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06622057","kind":"trial","name":"D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer","route":"/trials/nct06622057/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-roar-lancet-oncol-2020","kind":"paper","name":"Dabrafenib plus trametinib in patients with BRAF V600E -mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","route":"/key-papers/paper-roar-lancet-oncol-2020/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07288879","kind":"trial","name":"DALY II Japan/MB-CART2019.1 for DLBCL","route":"/trials/nct07288879/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07472517","kind":"trial","name":"DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment","route":"/trials/nct07472517/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07707895","kind":"trial","name":"DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers","route":"/trials/nct07707895/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07544654","kind":"trial","name":"DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy","route":"/trials/nct07544654/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05882058","kind":"trial","name":"DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers","route":"/trials/nct05882058/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"darovasertib","kind":"drug","name":"Darovasertib","route":"/drugs/darovasertib/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06176261","kind":"trial","name":"DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs","route":"/trials/nct06176261/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05555732","kind":"trial","name":"Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)","route":"/trials/nct05555732/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05566795","kind":"trial","name":"DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)","route":"/trials/nct05566795/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06953089","kind":"trial","name":"DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors","route":"/trials/nct06953089/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07705919","kind":"trial","name":"DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer","route":"/trials/nct07705919/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06446557","kind":"trial","name":"De-scalation or swItch of Treatment According to Circulating tuMOr DNA Variation After 2 Cycles of Doublet Chemotherapy Plus Targeted Agent in Metastatic Unrese","route":"/trials/nct06446557/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06555003","kind":"trial","name":"DEBIRI Plus Chemotherapy vs. Chemotherapy Alone in Colorectal Cancer Liver Metastases","route":"/trials/nct06555003/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-fearon-lancet-oncol","kind":"paper","name":"Definition and classification of cancer cachexia: an international consensus","route":"/key-papers/paper-fearon-lancet-oncol/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05987644","kind":"trial","name":"Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements","route":"/trials/nct05987644/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06989112","kind":"trial","name":"DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC","route":"/trials/nct06989112/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"determine-arm04","kind":"trial","name":"DETERMINE arm 04: trastuzumab with pertuzumab in HER2-amplified or mutated rare cancers","route":"/trials/determine-arm04/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05770102","kind":"trial","name":"DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Mi","route":"/trials/nct05770102/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05768178","kind":"trial","name":"DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.","route":"/trials/nct05768178/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07440290","kind":"trial","name":"DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positi","route":"/trials/nct07440290/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07285057","kind":"trial","name":"Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance","route":"/trials/nct07285057/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"diamond","kind":"trial","name":"DIAMOND","route":"/trials/diamond/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07755124","kind":"trial","name":"Dietary Arginine Deprivation Combined With Chemoradiotherapy for Neoadjuvant Treatment of Rectal Cancer: A Randomized Controlled Trial","route":"/trials/nct07755124/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06698757","kind":"trial","name":"Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instability-high, Locally Advanced Colorectal Cancer","route":"/trials/nct06698757/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07646639","kind":"trial","name":"Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC","route":"/trials/nct07646639/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07159217","kind":"trial","name":"Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer","route":"/trials/nct07159217/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05911295","kind":"trial","name":"Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2","route":"/trials/nct05911295/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"dji136","kind":"drug","name":"DJI136","route":"/drugs/dji136/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04567420","kind":"trial","name":"DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)","route":"/trials/nct04567420/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07288112","kind":"trial","name":"DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma","route":"/trials/nct07288112/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06805305","kind":"trial","name":"DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)","route":"/trials/nct06805305/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07361484","kind":"trial","name":"Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)","route":"/trials/nct07361484/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"domvanalimab","kind":"drug","name":"Domvanalimab","route":"/drugs/domvanalimab/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05724563","kind":"trial","name":"Domvanalimab and Zimberelimab in Advanced Liver Cancers","route":"/trials/nct05724563/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06275958","kind":"trial","name":"DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer","route":"/trials/nct06275958/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06239194","kind":"trial","name":"Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors","route":"/trials/nct06239194/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07249905","kind":"trial","name":"Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma","route":"/trials/nct07249905/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04140500","kind":"trial","name":"Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors","route":"/trials/nct04140500/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05431270","kind":"trial","name":"Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy","route":"/trials/nct05431270/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06630624","kind":"trial","name":"Dose Finding, Efficacy and Immunological Response of IP-001 Following MWA or IRE for CRLM","route":"/trials/nct06630624/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06475352","kind":"trial","name":"Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme","route":"/trials/nct06475352/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02174549","kind":"trial","name":"Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer","route":"/trials/nct02174549/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07015892","kind":"trial","name":"Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized Trial","route":"/trials/nct07015892/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05751798","kind":"trial","name":"Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas","route":"/trials/nct05751798/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06333314","kind":"trial","name":"Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI","route":"/trials/nct06333314/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06757244","kind":"trial","name":"DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer","route":"/trials/nct06757244/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07411599","kind":"trial","name":"Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Rela","route":"/trials/nct07411599/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07059338","kind":"trial","name":"Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer","route":"/trials/nct07059338/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07467863","kind":"trial","name":"Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC","route":"/trials/nct07467863/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07486089","kind":"trial","name":"Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)","route":"/trials/nct07486089/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07510802","kind":"trial","name":"Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC","route":"/trials/nct07510802/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07462650","kind":"trial","name":"Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer","route":"/trials/nct07462650/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07589543","kind":"trial","name":"Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer","route":"/trials/nct07589543/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07627711","kind":"trial","name":"Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma","route":"/trials/nct07627711/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07641023","kind":"trial","name":"Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC","route":"/trials/nct07641023/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07551349","kind":"trial","name":"Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma","route":"/trials/nct07551349/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07551362","kind":"trial","name":"Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer","route":"/trials/nct07551362/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07627698","kind":"trial","name":"Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma","route":"/trials/nct07627698/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07502287","kind":"trial","name":"Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma","route":"/trials/nct07502287/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07500220","kind":"trial","name":"Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC","route":"/trials/nct07500220/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07641036","kind":"trial","name":"Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer","route":"/trials/nct07641036/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07510815","kind":"trial","name":"Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma","route":"/trials/nct07510815/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07480954","kind":"trial","name":"Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)","route":"/trials/nct07480954/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07617753","kind":"trial","name":"Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2","route":"/trials/nct07617753/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07589517","kind":"trial","name":"Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer","route":"/trials/nct07589517/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07480928","kind":"trial","name":"Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma","route":"/trials/nct07480928/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06992609","kind":"trial","name":"Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.","route":"/trials/nct06992609/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04597671","kind":"trial","name":"Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28)","route":"/trials/nct04597671/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04499053","kind":"trial","name":"Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer","route":"/trials/nct04499053/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03833154","kind":"trial","name":"Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation","route":"/trials/nct03833154/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-caspian-lancet-oncol-2021-update","kind":"paper","name":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial","route":"/key-papers/paper-caspian-lancet-oncol-2021-update/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07070440","kind":"trial","name":"DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)","route":"/trials/nct07070440/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"dzd8586","kind":"drug","name":"DZD8586","route":"/drugs/dzd8586/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07059650","kind":"trial","name":"DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)","route":"/trials/nct07059650/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06539182","kind":"trial","name":"DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)","route":"/trials/nct06539182/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"e-edv-d682","kind":"drug","name":"E-EDV-D682","route":"/drugs/e-edv-d682/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ea2197-ivonescimab","kind":"trial","name":"EA2197 ivonescimab: ivonescimab with gemcitabine and cisplatin versus standard chemo-immunotherapy in advanced biliary tract cancer","route":"/trials/ea2197-ivonescimab/","detail":"mentions 2027, 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06926075","kind":"trial","name":"Early Phase Study of KESONOTIDE™in Participants With Solid Tumours","route":"/trials/nct06926075/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07455734","kind":"trial","name":"Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors","route":"/trials/nct07455734/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"eb-car30-nk","kind":"drug","name":"EB-CAR30-NK","route":"/drugs/eb-car30-nk/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"eb-mf-car-nk-01","kind":"drug","name":"EB-MF-CAR-NK-01","route":"/drugs/eb-mf-car-nk-01/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"eb-nk-301","kind":"drug","name":"EB-NK-301","route":"/drugs/eb-nk-301/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07410676","kind":"trial","name":"EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors","route":"/trials/nct07410676/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"eclipse-psma","kind":"trial","name":"ECLIPSE","route":"/trials/eclipse-psma/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06556563","kind":"trial","name":"EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma","route":"/trials/nct06556563/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07251582","kind":"trial","name":"Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer","route":"/trials/nct07251582/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06923787","kind":"trial","name":"Effect of Perioperative Intravenous Infusion of Lidocaine on the Postoperative Course and the Immune Response in Patients Undergoing Surgery for Colon Cancer -","route":"/trials/nct06923787/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07432399","kind":"trial","name":"Effect of Perioperative Lidocaine or High-Dose Dexamethasone on Immune Response in Colon Cancer Surgery (PILDI Study)","route":"/trials/nct07432399/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07473128","kind":"trial","name":"Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer","route":"/trials/nct07473128/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07520578","kind":"trial","name":"EFFECTIVENESS OF EARLY INFORMATION AND ENDORSMENT BY GP TO INCREASE COLONOSCOPY FOLLOW-UP AND REDUCE DELAYS IN PEOPLE WITH A POSITIVE COLORECTAL CANCER SCREENIN","route":"/trials/nct07520578/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06463665","kind":"trial","name":"Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL ","route":"/trials/nct06463665/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07505472","kind":"trial","name":"Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuva","route":"/trials/nct07505472/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06281964","kind":"trial","name":"Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.","route":"/trials/nct06281964/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06959082","kind":"trial","name":"Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer","route":"/trials/nct06959082/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05304481","kind":"trial","name":"Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma","route":"/trials/nct05304481/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04465968","kind":"trial","name":"Efficacy and Safety of CRT, Durvalumab and Surgery for SST","route":"/trials/nct04465968/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07401537","kind":"trial","name":"Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer","route":"/trials/nct07401537/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06698965","kind":"trial","name":"Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and C","route":"/trials/nct06698965/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07070713","kind":"trial","name":"Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC","route":"/trials/nct07070713/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06949982","kind":"trial","name":"Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Co","route":"/trials/nct06949982/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07480356","kind":"trial","name":"Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer","route":"/trials/nct07480356/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07379047","kind":"trial","name":"Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)","route":"/trials/nct07379047/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04728893","kind":"trial","name":"Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)","route":"/trials/nct04728893/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06082102","kind":"trial","name":"Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma","route":"/trials/nct06082102/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04241185","kind":"trial","name":"Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)","route":"/trials/nct04241185/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07636824","kind":"trial","name":"Efficacy and Safety of Postoperative Concurrent Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma: A Multicenter Prospective Phase II Study","route":"/trials/nct07636824/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05918302","kind":"trial","name":"Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.","route":"/trials/nct05918302/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-florence-duffaud-lancet-oncol-2019","kind":"paper","name":"Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study","route":"/key-papers/paper-florence-duffaud-lancet-oncol-2019/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07728019","kind":"trial","name":"Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM","route":"/trials/nct07728019/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07638501","kind":"trial","name":"Efficacy and Safety of SBRT Plus Gemcitabine, Cisplatin, and Sintilimab as First-Line Treatment for Unresectable Biliary Tract Cancer","route":"/trials/nct07638501/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07545213","kind":"trial","name":"Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis","route":"/trials/nct07545213/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07498478","kind":"trial","name":"Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment","route":"/trials/nct07498478/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05116072","kind":"trial","name":"Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula","route":"/trials/nct05116072/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07714447","kind":"trial","name":"Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer","route":"/trials/nct07714447/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06995677","kind":"trial","name":"Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer","route":"/trials/nct06995677/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03567889","kind":"trial","name":"Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients","route":"/trials/nct03567889/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05821686","kind":"trial","name":"Efficacy of Interleukin-2 in Triple Negative Breast Cancer","route":"/trials/nct05821686/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07600268","kind":"trial","name":"Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Maintenance Therapy Compared to Maintenance Therapy Alone in Advanced Pancreatic Cancer","route":"/trials/nct07600268/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06783491","kind":"trial","name":"Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer","route":"/trials/nct06783491/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07446270","kind":"trial","name":"Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies","route":"/trials/nct07446270/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07025850","kind":"trial","name":"Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer","route":"/trials/nct07025850/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07698613","kind":"trial","name":"EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer","route":"/trials/nct07698613/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06486142","kind":"trial","name":"EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study","route":"/trials/nct06486142/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07617805","kind":"trial","name":"EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC","route":"/trials/nct07617805/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"eik1001","kind":"drug","name":"EIK1001","route":"/drugs/eik1001/","detail":"mentions 2035 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07262619","kind":"trial","name":"EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Partic","route":"/trials/nct07262619/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06525298","kind":"trial","name":"EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors","route":"/trials/nct06525298/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07034326","kind":"trial","name":"Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer","route":"/trials/nct07034326/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"elenestinib","kind":"drug","name":"Elenestinib","route":"/drugs/elenestinib/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"emactuzumab","kind":"drug","name":"Emactuzumab","route":"/drugs/emactuzumab/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07567014","kind":"trial","name":"Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS","route":"/trials/nct07567014/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06940947","kind":"trial","name":"Endoscopic Therapy Or Surgery for Early Colon Cancer","route":"/trials/nct06940947/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06831136","kind":"trial","name":"Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma","route":"/trials/nct06831136/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07429643","kind":"trial","name":"Endoscopic Ultrasound-Guided Loco-regional Chemotherapy Injection as Adjuvant Therapy for Locally Advanced Pancreatic Cancer.","route":"/trials/nct07429643/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07566156","kind":"trial","name":"Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)","route":"/trials/nct07566156/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"englumafusp-alfa","kind":"drug","name":"Englumafusp alfa","route":"/drugs/englumafusp-alfa/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06120140","kind":"trial","name":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib","route":"/trials/nct06120140/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07698106","kind":"trial","name":"Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC","route":"/trials/nct07698106/","detail":"mentions 2034 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"env-501","kind":"drug","name":"ENV-501","route":"/drugs/env-501/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04891198","kind":"trial","name":"ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors","route":"/trials/nct04891198/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ep0031","kind":"drug","name":"EP0031","route":"/drugs/ep0031/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ep0062","kind":"drug","name":"EP0062","route":"/drugs/ep0062/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03516708","kind":"trial","name":"Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer","route":"/trials/nct03516708/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06810375","kind":"trial","name":"Erector Spinae Versus Intercostal Nerve Blocks With Liposomal Bupivacaine for Analgesia in Thoracic Surgery","route":"/trials/nct06810375/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-egfr-nsclc-lancet-oncol-2012","kind":"paper","name":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","route":"/key-papers/paper-egfr-nsclc-lancet-oncol-2012/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"esg401","kind":"drug","name":"ESG401","route":"/drugs/esg401/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-rahib-projection-us-cancer-2040-jama-netw-open-2021","kind":"paper","name":"Estimated Projection of US Cancer Incidence and Death to 2040","route":"/key-papers/paper-rahib-projection-us-cancer-2040-jama-netw-open-2021/","detail":"mentions 2040 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-wouters-jama","kind":"paper","name":"Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018","route":"/key-papers/paper-wouters-jama/","detail":"mentions 2051 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04634357","kind":"trial","name":"ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma","route":"/trials/nct04634357/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"eu-hta-regulation","kind":"term","name":"EU HTA Regulation (EU) 2021/2282: joint clinical assessments","route":"/terms/eu-hta-regulation/","detail":"mentions 2028, 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"europac","kind":"trial","name":"EUROPAC","route":"/trials/europac/","detail":"mentions 2039 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"estro","kind":"institution","name":"European Society for Radiotherapy and Oncology","route":"/institutions/estro/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06806033","kind":"trial","name":"Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL","route":"/trials/nct06806033/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04422366","kind":"trial","name":"Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females","route":"/trials/nct04422366/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04390737","kind":"trial","name":"Evaluate the Safety and Clinical Activity of HH2853","route":"/trials/nct04390737/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05764928","kind":"trial","name":"Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin Therapy","route":"/trials/nct05764928/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07095868","kind":"trial","name":"Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors","route":"/trials/nct07095868/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"src-evaluate","kind":"collection","name":"Evaluate Vantage","route":"/collections/src-evaluate/","detail":"mentions 2036 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04645160","kind":"trial","name":"Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers","route":"/trials/nct04645160/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05037279","kind":"trial","name":"Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)","route":"/trials/nct05037279/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06596343","kind":"trial","name":"Evaluating the Benefits of Personalized Traditional Chinese Medicine in Postoperative Treatment for Locally Advanced Colorectal Cancer","route":"/trials/nct06596343/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07314528","kind":"trial","name":"Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal Cancer","route":"/trials/nct07314528/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06840821","kind":"trial","name":"Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptor","route":"/trials/nct06840821/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07018869","kind":"trial","name":"Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors","route":"/trials/nct07018869/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07617493","kind":"trial","name":"Evaluation of ICP-B208 in Patients With Advanced Solid Tumors","route":"/trials/nct07617493/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06775483","kind":"trial","name":"Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study","route":"/trials/nct06775483/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05696626","kind":"trial","name":"Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation","route":"/trials/nct05696626/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07669519","kind":"trial","name":"Evaluation of NuvastaticTM in Reducing Cancer-Related Fatigue in Colon Cancer Patients Undergoing First-Line Chemotherapy","route":"/trials/nct07669519/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04485286","kind":"trial","name":"Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury","route":"/trials/nct04485286/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06824064","kind":"trial","name":"Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer","route":"/trials/nct06824064/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06944548","kind":"trial","name":"Evaluation of the Effect of Adapted Physical Activity on the Modification of Lipid Metabolism During Chemotherapy for Metastatic COLorectal Cancer","route":"/trials/nct06944548/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07056777","kind":"trial","name":"Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer","route":"/trials/nct07056777/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07787429","kind":"trial","name":"Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma","route":"/trials/nct07787429/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07136181","kind":"trial","name":"Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma","route":"/trials/nct07136181/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07097064","kind":"trial","name":"Evaluation of the Stereotactic MR-guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancers","route":"/trials/nct07097064/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07407803","kind":"trial","name":"Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas","route":"/trials/nct07407803/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06824168","kind":"trial","name":"Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission","route":"/trials/nct06824168/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07670312","kind":"trial","name":"Evaluation of XYA02 in Patients With Advanced Solid Tumors","route":"/trials/nct07670312/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"evaxion","kind":"company","name":"Evaxion","route":"/companies/evaxion/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07340541","kind":"trial","name":"Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies","route":"/trials/nct07340541/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06448572","kind":"trial","name":"EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy.","route":"/trials/nct06448572/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-atun-lancet-oncol","kind":"paper","name":"Expanding global access to radiotherapy","route":"/key-papers/paper-atun-lancet-oncol/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06440902","kind":"trial","name":"Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNA","route":"/trials/nct06440902/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06427239","kind":"trial","name":"Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma","route":"/trials/nct06427239/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06547736","kind":"trial","name":"Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer","route":"/trials/nct06547736/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07631884","kind":"trial","name":"Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor","route":"/trials/nct07631884/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07105852","kind":"trial","name":"Exploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Advanced Cholangiocarcinoma","route":"/trials/nct07105852/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06593431","kind":"trial","name":"Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial","route":"/trials/nct06593431/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07405164","kind":"trial","name":"Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)","route":"/trials/nct07405164/","detail":"mentions 2034 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06465433","kind":"trial","name":"Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab","route":"/trials/nct06465433/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04930653","kind":"trial","name":"Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma","route":"/trials/nct04930653/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"f182112","kind":"drug","name":"F182112","route":"/drugs/f182112/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07705074","kind":"trial","name":"FAPI PET Imaging - An Exploratory Study","route":"/trials/nct07705074/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07815834","kind":"trial","name":"FAPI-Guided Radiotherapy With Cadonilimab and Standard Chemotherapy for Colorectal Peritoneal Metastasis: A Phase III Randomized Controlled Trial (TORHC-PM02)","route":"/trials/nct07815834/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07478523","kind":"trial","name":"FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers","route":"/trials/nct07478523/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"farletuzumab-exatecan","kind":"drug","name":"Farletuzumab-exatecan","route":"/drugs/farletuzumab-exatecan/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ficlatuzumab","kind":"drug","name":"Ficlatuzumab","route":"/drugs/ficlatuzumab/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06303505","kind":"trial","name":"FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC","route":"/trials/nct06303505/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06669117","kind":"trial","name":"FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations","route":"/trials/nct06669117/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02497820","kind":"trial","name":"Finding the Best Dose of Aspirin to Prevent Lynch Syndrome Cancers","route":"/trials/nct02497820/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06956001","kind":"trial","name":"Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation","route":"/trials/nct06956001/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05647122","kind":"trial","name":"First in Human Study of AZD9592 in Solid Tumors","route":"/trials/nct05647122/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05120596","kind":"trial","name":"First in Human Study of T3P-Y058-739 (T3P)","route":"/trials/nct05120596/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06657222","kind":"trial","name":"First in Human Study of TUB-030 in Patients With Advanced Solid Tumors","route":"/trials/nct06657222/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06795022","kind":"trial","name":"First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours","route":"/trials/nct06795022/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06877650","kind":"trial","name":"First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors","route":"/trials/nct06877650/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07216560","kind":"trial","name":"First-in-human Study of 7MW4911 in GI Cancer","route":"/trials/nct07216560/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07265622","kind":"trial","name":"First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors","route":"/trials/nct07265622/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06797999","kind":"trial","name":"First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma","route":"/trials/nct06797999/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05438329","kind":"trial","name":"First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors","route":"/trials/nct05438329/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06554795","kind":"trial","name":"First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors","route":"/trials/nct06554795/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04243499","kind":"trial","name":"First-in-Human Study of ICT01 in Patients With Advanced Cancer","route":"/trials/nct04243499/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06043817","kind":"trial","name":"First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations","route":"/trials/nct06043817/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05768139","kind":"trial","name":"First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors","route":"/trials/nct05768139/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04725474","kind":"trial","name":"First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)","route":"/trials/nct04725474/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07529717","kind":"trial","name":"First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer","route":"/trials/nct07529717/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06622486","kind":"trial","name":"First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors","route":"/trials/nct06622486/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06934538","kind":"trial","name":"First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer","route":"/trials/nct06934538/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07136779","kind":"trial","name":"First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies","route":"/trials/nct07136779/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07700160","kind":"trial","name":"First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors","route":"/trials/nct07700160/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-empower-lung-1-lancet-oncol-2023-update","kind":"paper","name":"First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial","route":"/key-papers/paper-empower-lung-1-lancet-oncol-2023-update/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06840782","kind":"trial","name":"First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.","route":"/trials/nct06840782/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07355205","kind":"trial","name":"First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer","route":"/trials/nct07355205/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-pembrolizumab-urothelial-lancet-oncol-2017","kind":"paper","name":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","route":"/key-papers/paper-pembrolizumab-urothelial-lancet-oncol-2017/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07299409","kind":"trial","name":"First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.","route":"/trials/nct07299409/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06616259","kind":"trial","name":"First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Contro","route":"/trials/nct06616259/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07332455","kind":"trial","name":"First-Time-in-Human Study of GSK5471713 in Adults With mCRPC","route":"/trials/nct07332455/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07235930","kind":"trial","name":"Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer","route":"/trials/nct07235930/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06636682","kind":"trial","name":"FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer","route":"/trials/nct06636682/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07455331","kind":"trial","name":"Flash Radiotherapy for Skin Cancer","route":"/trials/nct07455331/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06307548","kind":"trial","name":"Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurre","route":"/trials/nct06307548/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07060443","kind":"trial","name":"Fluorescence Lymph Node Mapping for Colon Cancer Surgery","route":"/trials/nct07060443/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06385418","kind":"trial","name":"Fluorouracil Treatment Via Colon for Colorectal Cancer","route":"/trials/nct06385418/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07378306","kind":"trial","name":"FMD and Neoadjuvant Chemo-immunotherapy in TNBC","route":"/trials/nct07378306/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07509398","kind":"trial","name":"FMT Combined With Standard First-Line Therapy in Initially Unresectable Colorectal Cancer","route":"/trials/nct07509398/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07292142","kind":"trial","name":"FMT in Triple Negative Breast Cancer Guided by ctDNA","route":"/trials/nct07292142/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06801665","kind":"trial","name":"FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colorectal Cancer With Liver Metastasis","route":"/trials/nct06801665/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05919264","kind":"trial","name":"FOG-001 in Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct05919264/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"foghorn-therapeutics","kind":"company","name":"Foghorn Therapeutics","route":"/companies/foghorn-therapeutics/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07446322","kind":"trial","name":"FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer","route":"/trials/nct07446322/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07729605","kind":"trial","name":"FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC","route":"/trials/nct07729605/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06780787","kind":"trial","name":"FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery","route":"/trials/nct06780787/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07621497","kind":"trial","name":"FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)","route":"/trials/nct07621497/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06733038","kind":"trial","name":"FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.","route":"/trials/nct06733038/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07558083","kind":"trial","name":"FOLICOLOR TRIAL: Following Therapy Response Through Liquid Biopsy in Metatstatic Colorectal Cancer Patients","route":"/trials/nct07558083/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"fortifi-hn01","kind":"trial","name":"FORTIFI-HN01","route":"/trials/fortifi-hn01/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06909825","kind":"trial","name":"FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","route":"/trials/nct06909825/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"frontier-medicines","kind":"company","name":"Frontier Medicines","route":"/companies/frontier-medicines/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07286695","kind":"trial","name":"Fruquintinib Combined With Trifluridine/Tipiracil Versus Bevacizumab Combined With Trifluridine/Tipiracil for Advanced Metastatic Colorectal Cancer","route":"/trials/nct07286695/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07510932","kind":"trial","name":"Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients (FIRST-K)","route":"/trials/nct07510932/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07724223","kind":"trial","name":"Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC","route":"/trials/nct07724223/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07362836","kind":"trial","name":"Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS)","route":"/trials/nct07362836/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07051785","kind":"trial","name":"Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer","route":"/trials/nct07051785/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06563986","kind":"trial","name":"FTD-TPI, Bevacizumab, and Radioembolization With 166Ho-microspheres in Refractory Metastatic Colorectal Cancer","route":"/trials/nct06563986/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07515963","kind":"trial","name":"FULIRI Plus Targeted Therapy for First-line Conversion Therapy of Colorectal Cancer Liver Metastases.","route":"/trials/nct07515963/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-capivasertib-breast-hr-positive-lancet-oncol-2022","kind":"paper","name":"Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial","route":"/key-papers/paper-capivasertib-breast-hr-positive-lancet-oncol-2022/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07492342","kind":"trial","name":"Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC","route":"/trials/nct07492342/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07289646","kind":"trial","name":"Functional Lung Avoidance Planning Guided by Lung Perfusion PET/CT Versus Anatomical Planning for Lung Stereotactic Body Radiotherapy","route":"/trials/nct07289646/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05749588","kind":"trial","name":"FUSCC Refractory TNBC Platform Study (FUTURE2.0)","route":"/trials/nct05749588/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"fusion-pharma","kind":"company","name":"Fusion Pharmaceuticals (AstraZeneca)","route":"/companies/fusion-pharma/","detail":"mentions 2068 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07710885","kind":"trial","name":"Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer","route":"/trials/nct07710885/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06722183","kind":"trial","name":"Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities","route":"/trials/nct06722183/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06506955","kind":"trial","name":"Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.","route":"/trials/nct06506955/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05438459","kind":"trial","name":"GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites","route":"/trials/nct05438459/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","detail":"mentions 2038, 2040, 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07294261","kind":"trial","name":"Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC","route":"/trials/nct07294261/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06190899","kind":"trial","name":"Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct06190899/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06963060","kind":"trial","name":"Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)","route":"/trials/nct06963060/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-seddon-lancet-oncol","kind":"paper","name":"Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial","route":"/key-papers/paper-seddon-lancet-oncol/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07310069","kind":"trial","name":"Gemcitabine and Nab-Paclitaxel Combined With Iparomlimab and Tuvorilimab for Advanced Gallbladder Cancer","route":"/trials/nct07310069/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06897644","kind":"trial","name":"Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic C","route":"/trials/nct06897644/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07599995","kind":"trial","name":"Gemcitabine-Cisplatin Plus Envafolimab in Resectable Biliary Tract Malignancies","route":"/trials/nct07599995/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07433673","kind":"trial","name":"Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)","route":"/trials/nct07433673/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06576115","kind":"trial","name":"Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer","route":"/trials/nct06576115/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06533579","kind":"trial","name":"Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)","route":"/trials/nct06533579/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07192432","kind":"trial","name":"Gene Therapy for HER-Positive Cancer (SENTRY-HER2)","route":"/trials/nct07192432/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07730125","kind":"trial","name":"Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies","route":"/trials/nct07730125/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05528133","kind":"trial","name":"Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer","route":"/trials/nct05528133/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"gfh375","kind":"drug","name":"GFH375","route":"/drugs/gfh375/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07554859","kind":"trial","name":"GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer","route":"/trials/nct07554859/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04977453","kind":"trial","name":"GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors","route":"/trials/nct04977453/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07432295","kind":"trial","name":"Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)","route":"/trials/nct07432295/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07209813","kind":"trial","name":"GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma","route":"/trials/nct07209813/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05804370","kind":"trial","name":"Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)","route":"/trials/nct05804370/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04121455","kind":"trial","name":"Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients","route":"/trials/nct04121455/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-sullivan-lancet-oncol","kind":"paper","name":"Global cancer surgery: delivering safe, affordable, and timely cancer surgery","route":"/key-papers/paper-sullivan-lancet-oncol/","detail":"mentions 2030, 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"global-oncology-access","kind":"technology","name":"Global oncology and access in low- and middle-income countries","route":"/technologies/global-oncology-access/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07718737","kind":"trial","name":"Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Can","route":"/trials/nct07718737/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06252675","kind":"trial","name":"Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma","route":"/trials/nct06252675/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"glsi-100","kind":"drug","name":"GLSI-100","route":"/drugs/glsi-100/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06980532","kind":"trial","name":"Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer","route":"/trials/nct06980532/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06908772","kind":"trial","name":"Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients","route":"/trials/nct06908772/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07802184","kind":"trial","name":"GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC","route":"/trials/nct07802184/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"golcadomide","kind":"drug","name":"Golcadomide","route":"/drugs/golcadomide/","detail":"mentions 2027, 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07110103","kind":"trial","name":"Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC","route":"/trials/nct07110103/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"golseek-1","kind":"trial","name":"GOLSEEK-1","route":"/trials/golseek-1/","detail":"mentions 2027, 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07337551","kind":"trial","name":"Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive","route":"/trials/nct07337551/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04864054","kind":"trial","name":"GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC","route":"/trials/nct04864054/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"gq1005","kind":"drug","name":"GQ1005","route":"/drugs/gq1005/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"gr1803","kind":"drug","name":"GR1803","route":"/drugs/gr1803/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06566547","kind":"trial","name":"GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct06566547/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"grade-3-net","kind":"cancer","name":"Grade 3 well-differentiated neuroendocrine tumour","route":"/cancers/grade-3-net/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05806385","kind":"trial","name":"Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers","route":"/trials/nct05806385/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"grt-c901","kind":"drug","name":"GRT-C901","route":"/drugs/grt-c901/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"grt-r902","kind":"drug","name":"GRT-R902","route":"/drugs/grt-r902/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06558773","kind":"trial","name":"GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.","route":"/trials/nct06558773/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06948981","kind":"trial","name":"GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies","route":"/trials/nct06948981/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07398664","kind":"trial","name":"H101 Plus TACE for r/m HNSCC","route":"/trials/nct07398664/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06389500","kind":"trial","name":"HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer","route":"/trials/nct06389500/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"hb1801","kind":"drug","name":"HB1801","route":"/drugs/hb1801/","detail":"mentions 2034 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"hdm2017","kind":"drug","name":"HDM2017","route":"/drugs/hdm2017/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07528768","kind":"trial","name":"HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry.","route":"/trials/nct07528768/","detail":"mentions 2027, 2034 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05586074","kind":"trial","name":"HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML","route":"/trials/nct05586074/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07764497","kind":"trial","name":"Hepatic Arterial Infusion Chemotherapy in Patients With Inoperable Colorectal Cancer Liver Metastasis","route":"/trials/nct07764497/","detail":"mentions 2036 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07636798","kind":"trial","name":"Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer","route":"/trials/nct07636798/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07570914","kind":"trial","name":"Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases","route":"/trials/nct07570914/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"herizon-btc-302","kind":"trial","name":"HERIZON-BTC-302","route":"/trials/herizon-btc-302/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06492759","kind":"trial","name":"High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer","route":"/trials/nct06492759/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06849492","kind":"trial","name":"HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer","route":"/trials/nct06849492/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05810792","kind":"trial","name":"Histamine Dihydrochloride and Interleukin-2 in Primary Resectable Pancreatic Cancer","route":"/trials/nct05810792/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"hitoshi-ishikawa","kind":"person","name":"Hitoshi Ishikawa","route":"/people/hitoshi-ishikawa/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"hlx22","kind":"drug","name":"HLX22","route":"/drugs/hlx22/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"hlx43","kind":"drug","name":"HLX43","route":"/drugs/hlx43/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"hmbd-001","kind":"drug","name":"HMBD-001","route":"/drugs/hmbd-001/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"hmpl-306","kind":"drug","name":"HMPL-306","route":"/drugs/hmpl-306/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"hmpl-453","kind":"drug","name":"HMPL-453","route":"/drugs/hmpl-453/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04353375","kind":"trial","name":"HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma","route":"/trials/nct04353375/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"hmpl-760","kind":"drug","name":"HMPL-760","route":"/drugs/hmpl-760/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07396584","kind":"trial","name":"HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor","route":"/trials/nct07396584/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06217042","kind":"trial","name":"HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer","route":"/trials/nct06217042/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06383078","kind":"trial","name":"HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer","route":"/trials/nct06383078/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07232875","kind":"trial","name":"HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer","route":"/trials/nct07232875/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"hrs-4357","kind":"drug","name":"HRS-4357","route":"/drugs/hrs-4357/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07296341","kind":"trial","name":"HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors","route":"/trials/nct07296341/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06587061","kind":"trial","name":"HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer","route":"/trials/nct06587061/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07131514","kind":"trial","name":"HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer","route":"/trials/nct07131514/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07240766","kind":"trial","name":"HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation","route":"/trials/nct07240766/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06770452","kind":"trial","name":"HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients","route":"/trials/nct06770452/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"hrs-8080","kind":"drug","name":"HRS-8080","route":"/drugs/hrs-8080/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07612007","kind":"trial","name":"HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization","route":"/trials/nct07612007/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"hs-20089","kind":"drug","name":"HS-20089","route":"/drugs/hs-20089/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06855069","kind":"trial","name":"HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer","route":"/trials/nct06855069/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07790510","kind":"trial","name":"HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer","route":"/trials/nct07790510/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05944237","kind":"trial","name":"HTL0039732 in Participants With Advanced Solid Tumours","route":"/trials/nct05944237/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06708663","kind":"trial","name":"HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours","route":"/trials/nct06708663/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04858009","kind":"trial","name":"Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis","route":"/trials/nct04858009/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06635980","kind":"trial","name":"Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer","route":"/trials/nct06635980/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07183865","kind":"trial","name":"Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)","route":"/trials/nct07183865/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06928584","kind":"trial","name":"Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer","route":"/trials/nct06928584/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07052669","kind":"trial","name":"Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC","route":"/trials/nct07052669/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"iah0968","kind":"drug","name":"IAH0968","route":"/drugs/iah0968/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ibi310","kind":"drug","name":"IBI310","route":"/drugs/ibi310/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ibi343","kind":"drug","name":"IBI343","route":"/drugs/ibi343/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07415525","kind":"trial","name":"IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer","route":"/trials/nct07415525/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06770439","kind":"trial","name":"IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer","route":"/trials/nct06770439/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07692750","kind":"trial","name":"IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer","route":"/trials/nct07692750/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07483554","kind":"trial","name":"IBI343 in Combination Therapy for Advanced Malignant Solid Tumors","route":"/trials/nct07483554/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07198841","kind":"trial","name":"IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation","route":"/trials/nct07198841/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ibi354","kind":"drug","name":"IBI354","route":"/drugs/ibi354/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07377643","kind":"trial","name":"IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer","route":"/trials/nct07377643/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07722494","kind":"trial","name":"IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer","route":"/trials/nct07722494/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07487805","kind":"trial","name":"ICONIC: ivermectin combined with immune checkpoint inhibition in cancer (University of Florida phase 2)","route":"/trials/nct07487805/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"icp-248","kind":"drug","name":"ICP-248","route":"/drugs/icp-248/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"apex-03","kind":"trial","name":"ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)","route":"/trials/apex-03/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05987332","kind":"trial","name":"IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma","route":"/trials/nct05987332/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"idrx-42","kind":"drug","name":"IDRX-42","route":"/drugs/idrx-42/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03608631","kind":"trial","name":"iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation","route":"/trials/nct03608631/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ifupinostat","kind":"drug","name":"Ifupinostat","route":"/drugs/ifupinostat/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07452224","kind":"trial","name":"ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer","route":"/trials/nct07452224/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07680439","kind":"trial","name":"Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).","route":"/trials/nct07680439/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ima203","kind":"drug","name":"IMA203","route":"/drugs/ima203/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05958121","kind":"trial","name":"IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors","route":"/trials/nct05958121/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04086264","kind":"trial","name":"IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia","route":"/trials/nct04086264/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"immatics","kind":"company","name":"Immatics","route":"/companies/immatics/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07260058","kind":"trial","name":"Immune Cell Therapy for Advanced Solid Tumors","route":"/trials/nct07260058/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06580574","kind":"trial","name":"Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers","route":"/trials/nct06580574/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07011823","kind":"trial","name":"Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC","route":"/trials/nct07011823/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"immune-stimulating-adc","kind":"technology","name":"Immune-stimulating antibody conjugate (ISAC)","route":"/technologies/immune-stimulating-adc/","detail":"mentions 2056 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-sankaranarayanan-lancet-oncol","kind":"paper","name":"Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study","route":"/key-papers/paper-sankaranarayanan-lancet-oncol/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07140679","kind":"trial","name":"Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer","route":"/trials/nct07140679/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06498635","kind":"trial","name":"Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial","route":"/trials/nct06498635/","detail":"mentions 2039 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05732389","kind":"trial","name":"Immunotherapy in Patients With Early dMMR Rectal Cancer","route":"/trials/nct05732389/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct01174121","kind":"trial","name":"Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer","route":"/trials/nct01174121/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07718490","kind":"trial","name":"Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancer","route":"/trials/nct07718490/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"impact-bcc","kind":"trial","name":"IMPACT (cemiplimab in advanced basal cell carcinoma)","route":"/trials/impact-bcc/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06999512","kind":"trial","name":"Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing Major Hepatectomy and Pancreaticoduodenectomy for C","route":"/trials/nct06999512/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"impactmf","kind":"trial","name":"IMpactMF","route":"/trials/impactmf/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06044623","kind":"trial","name":"Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients","route":"/trials/nct06044623/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05744219","kind":"trial","name":"Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial","route":"/trials/nct05744219/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07548736","kind":"trial","name":"Improvement Effect of Dexamethasone Enema for Acute Radiation-induced Rectal Injury","route":"/trials/nct07548736/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06936774","kind":"trial","name":"Improving Functional Outcomes and Quality of Life in Patients With Rectal Cancer After Surgery With Intensified Follow-up & Surveillance","route":"/trials/nct06936774/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"in10018","kind":"drug","name":"IN10018","route":"/drugs/in10018/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07441174","kind":"trial","name":"IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct07441174/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"inbrx-106","kind":"drug","name":"INBRX-106","route":"/drugs/inbrx-106/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06295731","kind":"trial","name":"INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC","route":"/trials/nct06295731/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"inca33890","kind":"drug","name":"INCA33890","route":"/drugs/inca33890/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"incb123667","kind":"drug","name":"INCB123667","route":"/drugs/incb123667/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"incb161734","kind":"drug","name":"INCB161734","route":"/drugs/incb161734/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-schuetz-lancet","kind":"paper","name":"Individualised nutritional support in medical inpatients at nutritional risk: a randomised clinical trial","route":"/key-papers/paper-schuetz-lancet/","detail":"mentions 2088 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06857773","kind":"trial","name":"Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy With Systemic Therapy","route":"/trials/nct06857773/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"inflation-reduction-act","kind":"term","name":"Inflation Reduction Act 2022: Medicare drug price negotiation","route":"/terms/inflation-reduction-act/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02843945","kind":"trial","name":"Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source","route":"/trials/nct02843945/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07321847","kind":"trial","name":"Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases","route":"/trials/nct07321847/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03150693","kind":"trial","name":"Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia","route":"/trials/nct03150693/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"insight-gist","kind":"trial","name":"INSIGHT","route":"/trials/insight-gist/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"int230-6","kind":"drug","name":"INT230-6","route":"/drugs/int230-6/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-pace-b-lancet-oncol-2019","kind":"paper","name":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","route":"/key-papers/paper-pace-b-lancet-oncol-2019/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06123156","kind":"trial","name":"Interest of Early Erectile Rehabilitation With Sildenafil After Radiotherapy and Proctectomy for Rectal Cancer","route":"/trials/nct06123156/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06509126","kind":"trial","name":"Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer","route":"/trials/nct06509126/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-eortc-22922-lancet-oncol-2020-update","kind":"paper","name":"Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial","route":"/key-papers/paper-eortc-22922-lancet-oncol-2020-update/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06478108","kind":"trial","name":"Interventional Software for Multi-immunotherapy of Solid Tumors","route":"/trials/nct06478108/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03257033","kind":"trial","name":"Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC","route":"/trials/nct03257033/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-orecchia-lancet-oncol","kind":"paper","name":"Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial","route":"/key-papers/paper-orecchia-lancet-oncol/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06358573","kind":"trial","name":"Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK","route":"/trials/nct06358573/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07539155","kind":"trial","name":"Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer","route":"/trials/nct07539155/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07339176","kind":"trial","name":"Intratumoral N17350 in Advanced Solid Tumors","route":"/trials/nct07339176/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06898970","kind":"trial","name":"Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma","route":"/trials/nct06898970/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07429266","kind":"trial","name":"INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)","route":"/trials/nct07429266/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06197425","kind":"trial","name":"Investigate the Efficacy of Chemotherapy in Patients With Positive ctDNA After Surgery and Adjuvant Chemotherapy for a Stage III Colorectal Cancer","route":"/trials/nct06197425/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07745296","kind":"trial","name":"Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer","route":"/trials/nct07745296/","detail":"mentions 2027, 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07718243","kind":"trial","name":"Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC","route":"/trials/nct07718243/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03808337","kind":"trial","name":"Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Origina","route":"/trials/nct03808337/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04273061","kind":"trial","name":"Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity","route":"/trials/nct04273061/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07615101","kind":"trial","name":"Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.","route":"/trials/nct07615101/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04851717","kind":"trial","name":"Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures","route":"/trials/nct04851717/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07430696","kind":"trial","name":"INVESTIGATION OF THE ANTI-NEOPLASTIC EFFECT OF TRISHUL (AYURVEDIC AGENT) ON TUMOUR REGRESSION OF RECTAL CANCER- A PILOT STUDY","route":"/trials/nct07430696/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03878849","kind":"trial","name":"Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer","route":"/trials/nct03878849/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06787612","kind":"trial","name":"Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer","route":"/trials/nct06787612/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05518903","kind":"trial","name":"Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma","route":"/trials/nct05518903/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07161115","kind":"trial","name":"Involve-site Radiotherapy Combined With Chemotherapy and Immunotherapy as Neoadjuvant Treatment for Locally Advanced Rectal Cancer","route":"/trials/nct07161115/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07263360","kind":"trial","name":"Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer","route":"/trials/nct07263360/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07447570","kind":"trial","name":"Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC","route":"/trials/nct07447570/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ipatasertib","kind":"drug","name":"Ipatasertib","route":"/drugs/ipatasertib/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07508761","kind":"trial","name":"IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors","route":"/trials/nct07508761/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05742607","kind":"trial","name":"IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)","route":"/trials/nct05742607/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07306273","kind":"trial","name":"IRE Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy","route":"/trials/nct07306273/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07238283","kind":"trial","name":"Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer","route":"/trials/nct07238283/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06513455","kind":"trial","name":"Irinotecan Liposome，Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer","route":"/trials/nct06513455/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07074353","kind":"trial","name":"Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer","route":"/trials/nct07074353/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07356973","kind":"trial","name":"Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma","route":"/trials/nct07356973/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06047015","kind":"trial","name":"Irreversible Electroporation (NanoKnife ®) and Immunotherapy for the Treatment of Stage IV Colorectal Cancer","route":"/trials/nct06047015/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04270409","kind":"trial","name":"Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma","route":"/trials/nct04270409/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ivdr","kind":"term","name":"IVDR (EU In Vitro Diagnostic Regulation 2017/746)","route":"/terms/ivdr/","detail":"mentions 2029, 2027, 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07405190","kind":"trial","name":"Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC","route":"/trials/nct07405190/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06928389","kind":"trial","name":"Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer","route":"/trials/nct06928389/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06848842","kind":"trial","name":"Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases","route":"/trials/nct06848842/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-nct06396065-lancet-oncol-2026","kind":"paper","name":"Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial","route":"/key-papers/paper-nct06396065-lancet-oncol-2026/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06127407","kind":"trial","name":"Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen","route":"/trials/nct06127407/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07809893","kind":"trial","name":"Ivosidenib Plus mFOLFOXIRI and Celecoxib for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer Patients","route":"/trials/nct07809893/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06549946","kind":"trial","name":"Ixovex-1 Single Agent and Combination Therapy","route":"/trials/nct06549946/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06416410","kind":"trial","name":"JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation","route":"/trials/nct06416410/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06973564","kind":"trial","name":"JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration","route":"/trials/nct06973564/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06386146","kind":"trial","name":"JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation","route":"/trials/nct06386146/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06731153","kind":"trial","name":"JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC","route":"/trials/nct06731153/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07175389","kind":"trial","name":"JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure","route":"/trials/nct07175389/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"jdq443","kind":"drug","name":"JDQ443","route":"/drugs/jdq443/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06581380","kind":"trial","name":"JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer","route":"/trials/nct06581380/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06380348","kind":"trial","name":"JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Chara","route":"/trials/nct06380348/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"jnj-79635322","kind":"drug","name":"JNJ-79635322","route":"/drugs/jnj-79635322/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"jnj-87189401","kind":"drug","name":"JNJ-87189401","route":"/drugs/jnj-87189401/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"jnj-90014496","kind":"drug","name":"JNJ-90014496","route":"/drugs/jnj-90014496/","detail":"mentions 2041 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"jnj-90301900","kind":"drug","name":"JNJ-90301900","route":"/drugs/jnj-90301900/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04892173","kind":"trial","name":"JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC","route":"/trials/nct04892173/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02468024","kind":"trial","name":"JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer","route":"/trials/nct02468024/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"journal-of-cancer-survivorship","kind":"journal","name":"Journal of cancer survivorship","route":"/journals/journal-of-cancer-survivorship/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"js105","kind":"drug","name":"JS105","route":"/drugs/js105/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"js111","kind":"drug","name":"JS111","route":"/drugs/js111/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06940401","kind":"trial","name":"JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations","route":"/trials/nct06940401/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07045311","kind":"trial","name":"JS207 Combination Therapy in Triple-negative Breast Cancer","route":"/trials/nct07045311/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07503756","kind":"trial","name":"JS212 Combination Therapies in Metastatic Colorectal Cancer","route":"/trials/nct07503756/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07384377","kind":"trial","name":"JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Iri","route":"/trials/nct07384377/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"jskn016","kind":"drug","name":"JSKN016","route":"/drugs/jskn016/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07154368","kind":"trial","name":"JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs.","route":"/trials/nct07154368/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07481058","kind":"trial","name":"KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer","route":"/trials/nct07481058/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04165070","kind":"trial","name":"KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)","route":"/trials/nct04165070/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07252739","kind":"trial","name":"KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)","route":"/trials/nct07252739/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07232602","kind":"trial","name":"KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)","route":"/trials/nct07232602/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"kl-a167","kind":"drug","name":"KL-A167","route":"/drugs/kl-a167/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05294172","kind":"trial","name":"KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma","route":"/trials/nct05294172/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"kn026","kind":"drug","name":"KN026","route":"/drugs/kn026/","detail":"mentions 2034 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07622017","kind":"trial","name":"KORTUC (KRC-01) Plus Radiotherapy for Organ Preservation in Rectal Cancer","route":"/trials/nct07622017/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07406633","kind":"trial","name":"KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)","route":"/trials/nct07406633/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07353645","kind":"trial","name":"KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer","route":"/trials/nct07353645/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-pik3ca-colorectal-lancet-oncol-2011","kind":"paper","name":"KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer","route":"/key-papers/paper-pik3ca-colorectal-lancet-oncol-2011/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06788756","kind":"trial","name":"L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Re","route":"/trials/nct06788756/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07227350","kind":"trial","name":"L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)","route":"/trials/nct07227350/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07227870","kind":"trial","name":"L19IL2/TNF in Patients With Basal Cell Carcinoma","route":"/trials/nct07227870/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06807437","kind":"trial","name":"Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula","route":"/trials/nct06807437/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07620548","kind":"trial","name":"Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas","route":"/trials/nct07620548/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"lcb02a","kind":"drug","name":"LCB02A","route":"/drugs/lcb02a/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"lcb84","kind":"drug","name":"LCB84","route":"/drugs/lcb84/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06710756","kind":"trial","name":"Lead-212 PSV359 Therapy for Patients With Solid Tumors","route":"/trials/nct06710756/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04752722","kind":"trial","name":"LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve","route":"/trials/nct04752722/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05170438","kind":"trial","name":"Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment","route":"/trials/nct05170438/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06193902","kind":"trial","name":"LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.","route":"/trials/nct06193902/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06831955","kind":"trial","name":"LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer","route":"/trials/nct06831955/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06789848","kind":"trial","name":"Ligufalimab and Cadonilimab in Advanced Liver Cancers","route":"/trials/nct06789848/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06571461","kind":"trial","name":"Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Canc","route":"/trials/nct06571461/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07797816","kind":"trial","name":"Liposomal Irinotecan Plus 5-FU/LV and Sintilimab With Sequential SBRT for Locally Advanced Biliary Tract Cancer","route":"/trials/nct07797816/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05854498","kind":"trial","name":"Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer","route":"/trials/nct05854498/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07281157","kind":"trial","name":"Liposomal Irinotecan, Capecitabine and Enlonstobart With Short-Course Radiotherapy for Locally Advanced Rectal Cancer","route":"/trials/nct07281157/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"lirafugratinib","kind":"drug","name":"Lirafugratinib","route":"/drugs/lirafugratinib/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04586231","kind":"trial","name":"LITESPARK-011","route":"/trials/nct04586231/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07284394","kind":"trial","name":"Liver-directed Chemotherapy After Surgery of Liver Metastases of Colorectal Cancer in Patients With High Risk of Recurrence of Their Disease","route":"/trials/nct07284394/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"livmoniplimab","kind":"drug","name":"Livmoniplimab","route":"/drugs/livmoniplimab/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"lm-108","kind":"drug","name":"LM-108","route":"/drugs/lm-108/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07362186","kind":"trial","name":"LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma","route":"/trials/nct07362186/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"lm-302","kind":"drug","name":"LM-302","route":"/drugs/lm-302/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"lns8801","kind":"drug","name":"LNS8801","route":"/drugs/lns8801/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07833319","kind":"trial","name":"Local Methylene Blue Injection for Prevention of Anastomotic Leakage and Permanent Stoma After Low Anterior Resection for Rectal Cancer","route":"/trials/nct07833319/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06208371","kind":"trial","name":"Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM","route":"/trials/nct06208371/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07150949","kind":"trial","name":"Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC","route":"/trials/nct07150949/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07620574","kind":"trial","name":"Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study","route":"/trials/nct07620574/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06652633","kind":"trial","name":"Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies","route":"/trials/nct06652633/","detail":"mentions 2039 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03435796","kind":"trial","name":"Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells","route":"/trials/nct03435796/","detail":"mentions 2036 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07162181","kind":"trial","name":"Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers","route":"/trials/nct07162181/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"lorigerlimab","kind":"drug","name":"Lorigerlimab","route":"/drugs/lorigerlimab/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06858410","kind":"trial","name":"Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma","route":"/trials/nct06858410/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07050043","kind":"trial","name":"Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC","route":"/trials/nct07050043/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07576725","kind":"trial","name":"Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial","route":"/trials/nct07576725/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07561060","kind":"trial","name":"Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy","route":"/trials/nct07561060/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07542262","kind":"trial","name":"Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR Cancers","route":"/trials/nct07542262/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07448142","kind":"trial","name":"Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer","route":"/trials/nct07448142/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07085169","kind":"trial","name":"Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC","route":"/trials/nct07085169/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07391566","kind":"trial","name":"LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation","route":"/trials/nct07391566/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07357519","kind":"trial","name":"Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)","route":"/trials/nct07357519/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07405736","kind":"trial","name":"Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer","route":"/trials/nct07405736/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06216301","kind":"trial","name":"LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC","route":"/trials/nct06216301/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"lung-cancer-evidence-roadmap","kind":"roadmap","name":"Lung cancer roadmap: from Doll and Hill and the naming of tobacco, through the cytotoxic plateau, computed tomography screening, EGFR and ALK, immunotherapy by PD-L1, the perioperative trials and PACIFIC, to DLL3 in small-cell disease and a 2032 registry watch","route":"/roadmaps/lung-cancer-evidence-roadmap/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07355231","kind":"trial","name":"Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI","route":"/trials/nct07355231/","detail":"mentions 2027, 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06496048","kind":"trial","name":"Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC","route":"/trials/nct06496048/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07153055","kind":"trial","name":"Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer","route":"/trials/nct07153055/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04919226","kind":"trial","name":"Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE","route":"/trials/nct04919226/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"lyell-immunopharma","kind":"company","name":"Lyell Immunopharma","route":"/companies/lyell-immunopharma/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05319314","kind":"trial","name":"LYL273 for Patients With Relapsed or Refractory mCRC","route":"/trials/nct05319314/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"m108","kind":"drug","name":"M108","route":"/drugs/m108/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06177041","kind":"trial","name":"M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma","route":"/trials/nct06177041/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"maat-pharma","kind":"company","name":"MaaT Pharma","route":"/companies/maat-pharma/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07149649","kind":"trial","name":"Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct07149649/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07199764","kind":"trial","name":"Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer","route":"/trials/nct07199764/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06747845","kind":"trial","name":"Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy","route":"/trials/nct06747845/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05692999","kind":"trial","name":"Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study","route":"/trials/nct05692999/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"idea-cost-biosimilar-default-substitution","kind":"idea","name":"Make the biosimilar the default at the pharmacy for trastuzumab, bevacizumab and rituximab","route":"/ideas/idea-cost-biosimilar-default-substitution/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"masked-adc","kind":"technology","name":"Masked / conditionally active ADC","route":"/technologies/masked-adc/","detail":"mentions 2051 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"mavrostobart","kind":"drug","name":"Mavrostobart","route":"/drugs/mavrostobart/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06534060","kind":"trial","name":"MB-105 in Patients With CD5 Positive T-cell Lymphoma","route":"/trials/nct06534060/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05655312","kind":"trial","name":"MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma","route":"/trials/nct05655312/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"mcla-129","kind":"drug","name":"MCLA-129","route":"/drugs/mcla-129/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06483100","kind":"trial","name":"Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance","route":"/trials/nct06483100/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03925662","kind":"trial","name":"Mebendazole as Adjuvant Treatment for Colon Cancer","route":"/trials/nct03925662/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06097728","kind":"trial","name":"MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma","route":"/trials/nct06097728/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07477808","kind":"trial","name":"Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer","route":"/trials/nct07477808/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06998758","kind":"trial","name":"Megestrol Acetate in Improving Neoadjuvant Chemotherapy-Related Weight Loss in Locally Advanced CRC","route":"/trials/nct06998758/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04920149","kind":"trial","name":"Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome","route":"/trials/nct04920149/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07066995","kind":"trial","name":"Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer","route":"/trials/nct07066995/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06134232","kind":"trial","name":"Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T","route":"/trials/nct06134232/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07344220","kind":"trial","name":"Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate","route":"/trials/nct07344220/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06759090","kind":"trial","name":"Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer","route":"/trials/nct06759090/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05929885","kind":"trial","name":"Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients","route":"/trials/nct05929885/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"mevpro-1","kind":"trial","name":"MEVPRO-1","route":"/trials/mevpro-1/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06761027","kind":"trial","name":"mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer","route":"/trials/nct06761027/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07062536","kind":"trial","name":"mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line","route":"/trials/nct07062536/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06791512","kind":"trial","name":"mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC","route":"/trials/nct06791512/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07817888","kind":"trial","name":"mFOLFOXIRI Plus Bevacizumab for Organ Preservation in Locally Advanced Rectal Cancer","route":"/trials/nct07817888/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06890624","kind":"trial","name":"mFOLFOXIRI Plus PD-1 Inhibitor vs mFOLFOX6 as Neoadjuvant Therapy for Locally Advanced Colon Cancer","route":"/trials/nct06890624/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04771871","kind":"trial","name":"MicroRNA Profiles in Triple Negative Breast Cancer","route":"/trials/nct04771871/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06153173","kind":"trial","name":"Mirdametinib in Histiocytic Disorders","route":"/trials/nct06153173/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07237100","kind":"trial","name":"Mirdametinib in Patients With Advanced NF1-mutant Melanoma","route":"/trials/nct07237100/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05445778","kind":"trial","name":"Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal C","route":"/trials/nct05445778/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"mk-1045","kind":"drug","name":"MK-1045","route":"/drugs/mk-1045/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07431827","kind":"trial","name":"MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)","route":"/trials/nct07431827/","detail":"mentions 2039 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07723482","kind":"trial","name":"ML-016 in Advanced Cancer With Lung and/or Liver Involvement","route":"/trials/nct07723482/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05429632","kind":"trial","name":"Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT","route":"/trials/nct05429632/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06923345","kind":"trial","name":"Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I)","route":"/trials/nct06923345/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05228431","kind":"trial","name":"Modified Sandwich Therapeutic Regimen for Locally Advanced Rectal Cancer","route":"/trials/nct05228431/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06493552","kind":"trial","name":"Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors","route":"/trials/nct06493552/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07372300","kind":"trial","name":"Modulated Electro-Hyperthermia in Combination With Multimodal Therapy for Locally Advanced Rectal Cancer","route":"/trials/nct07372300/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05462496","kind":"trial","name":"Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer","route":"/trials/nct05462496/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07802418","kind":"trial","name":"Molecularly Tailored Therapy in Advanced Pancreatic Cancer","route":"/trials/nct07802418/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05903092","kind":"trial","name":"MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer","route":"/trials/nct05903092/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"mountaineer","kind":"trial","name":"MOUNTAINEER","route":"/trials/mountaineer/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"mountaineer-03","kind":"trial","name":"MOUNTAINEER-03","route":"/trials/mountaineer-03/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07036380","kind":"trial","name":"MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma","route":"/trials/nct07036380/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07479485","kind":"trial","name":"MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)","route":"/trials/nct07479485/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07174427","kind":"trial","name":"Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma","route":"/trials/nct07174427/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04910386","kind":"trial","name":"Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers","route":"/trials/nct04910386/","detail":"mentions 2027, 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06782412","kind":"trial","name":"Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Dif","route":"/trials/nct06782412/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07371208","kind":"trial","name":"Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer","route":"/trials/nct07371208/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04146298","kind":"trial","name":"Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer","route":"/trials/nct04146298/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07639450","kind":"trial","name":"N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors","route":"/trials/nct07639450/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06061809","kind":"trial","name":"N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma","route":"/trials/nct06061809/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04605913","kind":"trial","name":"Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC","route":"/trials/nct04605913/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06662006","kind":"trial","name":"Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic","route":"/trials/nct06662006/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06669078","kind":"trial","name":"NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX as Conversion Therapy of Locally Advanced Pancreatic Cancer","route":"/trials/nct06669078/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07309289","kind":"trial","name":"NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer","route":"/trials/nct07309289/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07595172","kind":"trial","name":"NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer","route":"/trials/nct07595172/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04789486","kind":"trial","name":"Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer","route":"/trials/nct04789486/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07150663","kind":"trial","name":"Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer","route":"/trials/nct07150663/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"naporafenib","kind":"drug","name":"Naporafenib","route":"/drugs/naporafenib/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"navlimetostat","kind":"drug","name":"Navlimetostat","route":"/drugs/navlimetostat/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nb003","kind":"drug","name":"NB003","route":"/drugs/nb003/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06012695","kind":"trial","name":"NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma","route":"/trials/nct06012695/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07224152","kind":"trial","name":"NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer","route":"/trials/nct07224152/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06941857","kind":"trial","name":"NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer","route":"/trials/nct06941857/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07765667","kind":"trial","name":"NCT + PD1 + Ketogenic Diet and/or Vitamin C for LARC","route":"/trials/nct07765667/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ndi-219216","kind":"drug","name":"NDI-219216","route":"/drugs/ndi-219216/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06765109","kind":"trial","name":"Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC","route":"/trials/nct06765109/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07306624","kind":"trial","name":"Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer","route":"/trials/nct07306624/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06081244","kind":"trial","name":"NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)","route":"/trials/nct06081244/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06846268","kind":"trial","name":"Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer","route":"/trials/nct06846268/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05061550","kind":"trial","name":"Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer","route":"/trials/nct05061550/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07743632","kind":"trial","name":"Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC","route":"/trials/nct07743632/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07824960","kind":"trial","name":"Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma","route":"/trials/nct07824960/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07595874","kind":"trial","name":"Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3","route":"/trials/nct07595874/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06790212","kind":"trial","name":"Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer","route":"/trials/nct06790212/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07132008","kind":"trial","name":"Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer","route":"/trials/nct07132008/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07528209","kind":"trial","name":"Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer","route":"/trials/nct07528209/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-geparsixto-lancet-oncol-2014","kind":"paper","name":"Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial","route":"/key-papers/paper-geparsixto-lancet-oncol-2014/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06449313","kind":"trial","name":"Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features","route":"/trials/nct06449313/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07134218","kind":"trial","name":"Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer","route":"/trials/nct07134218/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07132463","kind":"trial","name":"Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study","route":"/trials/nct07132463/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07458529","kind":"trial","name":"Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer","route":"/trials/nct07458529/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07351487","kind":"trial","name":"Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)","route":"/trials/nct07351487/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06107920","kind":"trial","name":"Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy","route":"/trials/nct06107920/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07365592","kind":"trial","name":"Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC","route":"/trials/nct07365592/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06205485","kind":"trial","name":"Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer","route":"/trials/nct06205485/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07016399","kind":"trial","name":"Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC","route":"/trials/nct07016399/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07015190","kind":"trial","name":"Neoadjuvant Darovasertib in Primary Uveal Melanoma","route":"/trials/nct07015190/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07277322","kind":"trial","name":"Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases","route":"/trials/nct07277322/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06812728","kind":"trial","name":"Neoadjuvant FOLFIRINOX and Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer Patients","route":"/trials/nct06812728/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05132504","kind":"trial","name":"Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer","route":"/trials/nct05132504/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03426904","kind":"trial","name":"Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer","route":"/trials/nct03426904/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07472868","kind":"trial","name":"Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk","route":"/trials/nct07472868/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07691593","kind":"trial","name":"Neoadjuvant HRS-4642 Plus Chemotherapy With or Without Immunotherapy for Pancreatic Cancer","route":"/trials/nct07691593/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07403877","kind":"trial","name":"Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer","route":"/trials/nct07403877/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07409844","kind":"trial","name":"Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer","route":"/trials/nct07409844/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06734702","kind":"trial","name":"Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Ca","route":"/trials/nct06734702/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06353997","kind":"trial","name":"Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients","route":"/trials/nct06353997/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07381400","kind":"trial","name":"Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Study)","route":"/trials/nct07381400/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07527520","kind":"trial","name":"Neoadjuvant Moderately Hypofractionated Radiotherapy Combined With Chemotherapy and Immunotherapy for High-risk pMMR/MSS Locally Advanced Rectal Cancer: A Prosp","route":"/trials/nct07527520/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07808151","kind":"trial","name":"Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer","route":"/trials/nct07808151/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06646445","kind":"trial","name":"Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study.","route":"/trials/nct06646445/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06407310","kind":"trial","name":"Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer","route":"/trials/nct06407310/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07622771","kind":"trial","name":"Neoadjuvant Radiotherapy Combined With NALIRIFOX and Adebrelimab in pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Randomized, Phase II Clinical Trial","route":"/trials/nct07622771/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06850090","kind":"trial","name":"Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial","route":"/trials/nct06850090/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07608159","kind":"trial","name":"Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC.","route":"/trials/nct07608159/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07509424","kind":"trial","name":"Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Ca","route":"/trials/nct07509424/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07478731","kind":"trial","name":"Neoadjuvant SHR-1701 Plus Chemoradiotherapy for Locally Advanced Rectal Cancer","route":"/trials/nct07478731/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06987734","kind":"trial","name":"Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients","route":"/trials/nct06987734/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07178730","kind":"trial","name":"NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer","route":"/trials/nct07178730/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07372079","kind":"trial","name":"Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemoth","route":"/trials/nct07372079/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07134101","kind":"trial","name":"Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)","route":"/trials/nct07134101/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06437977","kind":"trial","name":"Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)","route":"/trials/nct06437977/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"neoadjuvant-versus-upfront-surgery-pancreatic","kind":"term","name":"Neoadjuvant therapy versus surgery first for resectable and borderline resectable pancreatic cancer","route":"/terms/neoadjuvant-versus-upfront-surgery-pancreatic/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06977542","kind":"trial","name":"Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer","route":"/trials/nct06977542/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06903273","kind":"trial","name":"Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma","route":"/trials/nct06903273/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07457359","kind":"trial","name":"Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer","route":"/trials/nct07457359/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03926338","kind":"trial","name":"Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer","route":"/trials/nct03926338/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-kristine-lancet-oncol-2018","kind":"paper","name":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial","route":"/key-papers/paper-kristine-lancet-oncol-2018/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07581912","kind":"trial","name":"Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases","route":"/trials/nct07581912/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06691594","kind":"trial","name":"Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy","route":"/trials/nct06691594/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07155629","kind":"trial","name":"Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer","route":"/trials/nct07155629/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06384560","kind":"trial","name":"Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)","route":"/trials/nct06384560/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07081360","kind":"trial","name":"Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer","route":"/trials/nct07081360/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05765877","kind":"trial","name":"Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer","route":"/trials/nct05765877/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07188246","kind":"trial","name":"Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer","route":"/trials/nct07188246/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07412613","kind":"trial","name":"Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer","route":"/trials/nct07412613/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05562297","kind":"trial","name":"Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer","route":"/trials/nct05562297/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06845319","kind":"trial","name":"NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients","route":"/trials/nct06845319/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"neogb","kind":"trial","name":"NEOGB","route":"/trials/neogb/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07504198","kind":"trial","name":"Neuroprotection of Memantine and Rosuvastatin","route":"/trials/nct07504198/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04564157","kind":"trial","name":"New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy","route":"/trials/nct04564157/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07559760","kind":"trial","name":"New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer","route":"/trials/nct07559760/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nhs-targeted-lung-health-check","kind":"technology","name":"NHS Targeted Lung Health Check (lung cancer screening programme)","route":"/technologies/nhs-targeted-lung-health-check/","detail":"mentions 2029, 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07677579","kind":"trial","name":"NIMBLE-CRC: NeoImmunoModulation Before Leveraging Excision in Colorectal Rectal Cancer","route":"/trials/nct07677579/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06409429","kind":"trial","name":"Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer","route":"/trials/nct06409429/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07277452","kind":"trial","name":"Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer","route":"/trials/nct07277452/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06343116","kind":"trial","name":"Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer","route":"/trials/nct06343116/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03391869","kind":"trial","name":"Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer","route":"/trials/nct03391869/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-brentuximab-vedotin-hodgkin-lymphoma-lancet-oncol-2016","kind":"paper","name":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","route":"/key-papers/paper-brentuximab-vedotin-hodgkin-lymphoma-lancet-oncol-2016/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07674732","kind":"trial","name":"Nodal-Region Sparing Short-Course RT With Chemo-PD-1/Bevacizumab vs. Short-Course RT With Chemotherapy as TNT in pMMR/MSS Locally Advanced Rectal Cancer","route":"/trials/nct07674732/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07230639","kind":"trial","name":"Node-Sparing Hypofractionated Radiotherapy Plus Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A Prospective, Randomized,","route":"/trials/nct07230639/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07279077","kind":"trial","name":"Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A Prospective, Single-Ar","route":"/trials/nct07279077/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06204094","kind":"trial","name":"Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer","route":"/trials/nct06204094/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06958419","kind":"trial","name":"Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorectal Cancer (MODIFI-CRC)","route":"/trials/nct06958419/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06958432","kind":"trial","name":"Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II)","route":"/trials/nct06958432/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06795503","kind":"trial","name":"Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients","route":"/trials/nct06795503/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","detail":"mentions 2038, 2040, 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04335669","kind":"trial","name":"NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC","route":"/trials/nct04335669/","detail":"mentions 2035 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05702229","kind":"trial","name":"Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","route":"/trials/nct05702229/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05485766","kind":"trial","name":"Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer","route":"/trials/nct05485766/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nucleus-radiopharma","kind":"company","name":"Nucleus RadioPharma","route":"/companies/nucleus-radiopharma/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07324304","kind":"trial","name":"NWRD06 DNA Plasmid for HCC After Curative Resection.","route":"/trials/nct07324304/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"obsidian-therapeutics","kind":"company","name":"Obsidian Therapeutics","route":"/companies/obsidian-therapeutics/","detail":"mentions 2027, 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07382531","kind":"trial","name":"OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors","route":"/trials/nct07382531/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05705492","kind":"trial","name":"Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer","route":"/trials/nct05705492/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-nct02734004-lancet-oncol-2020","kind":"paper","name":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study","route":"/key-papers/paper-nct02734004-lancet-oncol-2020/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05522491","kind":"trial","name":"Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer","route":"/trials/nct05522491/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04901741","kind":"trial","name":"Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer","route":"/trials/nct04901741/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07008716","kind":"trial","name":"Omitting CTV for Primary Tumor in LS-SCLC","route":"/trials/nct07008716/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05671510","kind":"trial","name":"ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors","route":"/trials/nct05671510/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05271318","kind":"trial","name":"Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) ","route":"/trials/nct05271318/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07381309","kind":"trial","name":"Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM","route":"/trials/nct07381309/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06919848","kind":"trial","name":"Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)","route":"/trials/nct06919848/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06196671","kind":"trial","name":"Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer","route":"/trials/nct06196671/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06904378","kind":"trial","name":"ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma","route":"/trials/nct06904378/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06369259","kind":"trial","name":"Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-R","route":"/trials/nct06369259/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06780670","kind":"trial","name":"Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy","route":"/trials/nct06780670/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04975997","kind":"trial","name":"Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants ","route":"/trials/nct04975997/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06514534","kind":"trial","name":"Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.","route":"/trials/nct06514534/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05735080","kind":"trial","name":"Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer","route":"/trials/nct05735080/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05491525","kind":"trial","name":"Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC","route":"/trials/nct05491525/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06318897","kind":"trial","name":"Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T","route":"/trials/nct06318897/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"opevesostat","kind":"drug","name":"Opevesostat","route":"/drugs/opevesostat/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"opt-in","kind":"trial","name":"OPT-IN (EA2197)","route":"/trials/opt-in/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07527806","kind":"trial","name":"Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging","route":"/trials/nct07527806/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04680260","kind":"trial","name":"OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer","route":"/trials/nct04680260/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07040098","kind":"trial","name":"Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer","route":"/trials/nct07040098/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06558214","kind":"trial","name":"OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial","route":"/trials/nct06558214/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05438420","kind":"trial","name":"Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors","route":"/trials/nct05438420/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07001618","kind":"trial","name":"Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiot","route":"/trials/nct07001618/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07581314","kind":"trial","name":"Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)","route":"/trials/nct07581314/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05969847","kind":"trial","name":"Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer","route":"/trials/nct05969847/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06991465","kind":"trial","name":"Organ Preservation in Rectal AdenoCa Using Hypofractionated Pelvic RT(Hypo-OPRA)","route":"/trials/nct06991465/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07337876","kind":"trial","name":"Organ Preservation in Rectal Cancer by Dose Escalated MR Guided Adaptive Radiotherapy","route":"/trials/nct07337876/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07106528","kind":"trial","name":"Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer","route":"/trials/nct07106528/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06998407","kind":"trial","name":"ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors","route":"/trials/nct06998407/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ose2101","kind":"drug","name":"OSE2101","route":"/drugs/ose2101/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04410796","kind":"trial","name":"Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers","route":"/trials/nct04410796/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07295821","kind":"trial","name":"Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study","route":"/trials/nct07295821/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07738172","kind":"trial","name":"Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung Cancer","route":"/trials/nct07738172/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-menon-lancet","kind":"paper","name":"Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial","route":"/key-papers/paper-menon-lancet/","detail":"mentions 2055 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-columbus-lancet-oncol-2018-update","kind":"paper","name":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial","route":"/key-papers/paper-columbus-lancet-oncol-2018-update/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-pishvaian-lancet-oncol","kind":"paper","name":"Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial","route":"/key-papers/paper-pishvaian-lancet-oncol/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-therap-lancet-oncol-2024-update","kind":"paper","name":"Overall survival with [ 177 Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","route":"/key-papers/paper-therap-lancet-oncol-2024-update/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-imspire150-lancet-oncol-2023-update","kind":"paper","name":"Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF V600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study","route":"/key-papers/paper-imspire150-lancet-oncol-2023-update/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06468033","kind":"trial","name":"P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk","route":"/trials/nct06468033/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07739485","kind":"trial","name":"Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study","route":"/trials/nct07739485/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06910072","kind":"trial","name":"Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer（UPGRADE-TN","route":"/trials/nct06910072/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07819591","kind":"trial","name":"Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC","route":"/trials/nct07819591/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07033598","kind":"trial","name":"Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia","route":"/trials/nct07033598/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"palacaparib","kind":"drug","name":"Palacaparib","route":"/drugs/palacaparib/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07085767","kind":"trial","name":"Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer","route":"/trials/nct07085767/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-pallas-penelope-b-lancet-oncol-2021","kind":"paper","name":"Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study","route":"/key-papers/paper-pallas-penelope-b-lancet-oncol-2021/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03899155","kind":"trial","name":"Pan Tumor Rollover Study","route":"/trials/nct03899155/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03322995","kind":"trial","name":"Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial","route":"/trials/nct03322995/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","detail":"mentions 2040, 2038, 2028, 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07230509","kind":"trial","name":"Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate","route":"/trials/nct07230509/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03384238","kind":"trial","name":"Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery","route":"/trials/nct03384238/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07043907","kind":"trial","name":"PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA NSCLC","route":"/trials/nct07043907/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07028424","kind":"trial","name":"PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment","route":"/trials/nct07028424/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07223424","kind":"trial","name":"Patient Preference for Subcutaneous vs. Intravenous Immune Therapy","route":"/trials/nct07223424/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07761533","kind":"trial","name":"PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS","route":"/trials/nct07761533/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06391905","kind":"trial","name":"PCSK9 Inhibitors in Combination With Advanced Treatment Strategies for the Treatment of Advanced Colorectal Cancer With pMMR/MSS","route":"/trials/nct06391905/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07277842","kind":"trial","name":"PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer","route":"/trials/nct07277842/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07477418","kind":"trial","name":"PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)","route":"/trials/nct07477418/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05286814","kind":"trial","name":"PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarc","route":"/trials/nct05286814/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07214298","kind":"trial","name":"Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma","route":"/trials/nct07214298/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"pelabresib","kind":"drug","name":"Pelabresib","route":"/drugs/pelabresib/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"peluntamig","kind":"drug","name":"Peluntamig","route":"/drugs/peluntamig/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06788912","kind":"trial","name":"Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)","route":"/trials/nct06788912/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06976944","kind":"trial","name":"Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer","route":"/trials/nct06976944/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07486687","kind":"trial","name":"Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy","route":"/trials/nct07486687/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06078384","kind":"trial","name":"Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC","route":"/trials/nct06078384/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05623319","kind":"trial","name":"Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)","route":"/trials/nct05623319/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05903833","kind":"trial","name":"Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surge","route":"/trials/nct05903833/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-nct02332668-lancet-oncol-2020","kind":"paper","name":"Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial","route":"/key-papers/paper-nct02332668-lancet-oncol-2020/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-blay-lancet-oncol","kind":"paper","name":"Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial","route":"/key-papers/paper-blay-lancet-oncol/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04976634","kind":"trial","name":"Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)","route":"/trials/nct04976634/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-keynote-177-lancet-oncol-2022-update","kind":"paper","name":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","route":"/key-papers/paper-keynote-177-lancet-oncol-2022-update/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05093231","kind":"trial","name":"Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer","route":"/trials/nct05093231/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06422143","kind":"trial","name":"Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287","route":"/trials/nct06422143/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07786766","kind":"trial","name":"Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive Cholangiocarcinoma","route":"/trials/nct07786766/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05950139","kind":"trial","name":"Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC","route":"/trials/nct05950139/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07450183","kind":"trial","name":"Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1","route":"/trials/nct07450183/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06960577","kind":"trial","name":"Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)","route":"/trials/nct06960577/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06001658","kind":"trial","name":"Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers","route":"/trials/nct06001658/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05637567","kind":"trial","name":"Perioperative Platelet Inhibition With Acetylsalicylic Acid in Patients With Resectable Tumors of the Pancreatic Head","route":"/trials/nct05637567/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07458204","kind":"trial","name":"Peritumoral and Periganglionic Infiltration of Levobupivacaine Prior to Conservative Surgery for Triple-negative Breast Cancer","route":"/trials/nct07458204/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"personalis","kind":"company","name":"Personalis (Tempus)","route":"/companies/personalis/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06631092","kind":"trial","name":"Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer","route":"/trials/nct06631092/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06293625","kind":"trial","name":"Personalising and Refining Neo-adjuvant Chemotherapy in Locally Advanced but Resecable Colon Cancer in the Elderly of 70 Years Old or More","route":"/trials/nct06293625/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07020247","kind":"trial","name":"Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study","route":"/trials/nct07020247/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07121595","kind":"trial","name":"Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial","route":"/trials/nct07121595/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07002203","kind":"trial","name":"Personalized Neoantigen Peptide Vaccines for Solid Tumors","route":"/trials/nct07002203/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05269381","kind":"trial","name":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","route":"/trials/nct05269381/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06888674","kind":"trial","name":"Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.","route":"/trials/nct06888674/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06888648","kind":"trial","name":"Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.","route":"/trials/nct06888648/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07340567","kind":"trial","name":"Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test","route":"/trials/nct07340567/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06606730","kind":"trial","name":"Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer","route":"/trials/nct06606730/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-mypathway-lancet-oncol-2019","kind":"paper","name":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study","route":"/key-papers/paper-mypathway-lancet-oncol-2019/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06245889","kind":"trial","name":"PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC","route":"/trials/nct06245889/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06617481","kind":"trial","name":"PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence","route":"/trials/nct06617481/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06057831","kind":"trial","name":"PET/MRI in Rectal Cancer","route":"/trials/nct06057831/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"petosemtamab","kind":"drug","name":"Petosemtamab","route":"/drugs/petosemtamab/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"pf-07248144","kind":"drug","name":"PF-07248144","route":"/drugs/pf-07248144/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"pf-08046054","kind":"drug","name":"PF-08046054","route":"/drugs/pf-08046054/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"pf-08634404","kind":"drug","name":"PF-08634404","route":"/drugs/pf-08634404/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04910022","kind":"trial","name":"Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma","route":"/trials/nct04910022/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07795749","kind":"trial","name":"Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B)","route":"/trials/nct07795749/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06553885","kind":"trial","name":"Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC","route":"/trials/nct06553885/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05671822","kind":"trial","name":"Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer","route":"/trials/nct05671822/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04379596","kind":"trial","name":"Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)","route":"/trials/nct04379596/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07612280","kind":"trial","name":"Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis","route":"/trials/nct07612280/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07145255","kind":"trial","name":"Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors","route":"/trials/nct07145255/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07529808","kind":"trial","name":"Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma","route":"/trials/nct07529808/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07589530","kind":"trial","name":"Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors","route":"/trials/nct07589530/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06993844","kind":"trial","name":"Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors","route":"/trials/nct06993844/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06249048","kind":"trial","name":"Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab","route":"/trials/nct06249048/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07751042","kind":"trial","name":"Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab","route":"/trials/nct07751042/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06795412","kind":"trial","name":"Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors","route":"/trials/nct06795412/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07605962","kind":"trial","name":"Phase 1/2 Study of UI-102 in Selected Advanced Cancers","route":"/trials/nct07605962/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05573126","kind":"trial","name":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer","route":"/trials/nct05573126/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05786924","kind":"trial","name":"Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies","route":"/trials/nct05786924/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05288205","kind":"trial","name":"Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation","route":"/trials/nct05288205/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07504263","kind":"trial","name":"Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies","route":"/trials/nct07504263/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07148128","kind":"trial","name":"Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.","route":"/trials/nct07148128/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07415863","kind":"trial","name":"Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors","route":"/trials/nct07415863/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06162572","kind":"trial","name":"Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct06162572/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07168226","kind":"trial","name":"Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101","route":"/trials/nct07168226/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07413601","kind":"trial","name":"Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Secon","route":"/trials/nct07413601/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07292298","kind":"trial","name":"Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation","route":"/trials/nct07292298/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05363280","kind":"trial","name":"Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment","route":"/trials/nct05363280/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07793253","kind":"trial","name":"Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer","route":"/trials/nct07793253/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07024706","kind":"trial","name":"Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab","route":"/trials/nct07024706/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06589440","kind":"trial","name":"Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Can","route":"/trials/nct06589440/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06567743","kind":"trial","name":"Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC","route":"/trials/nct06567743/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04613596","kind":"trial","name":"Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G","route":"/trials/nct04613596/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07106762","kind":"trial","name":"Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy","route":"/trials/nct07106762/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05864534","kind":"trial","name":"Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma","route":"/trials/nct05864534/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06030622","kind":"trial","name":"Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer","route":"/trials/nct06030622/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06757634","kind":"trial","name":"Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)","route":"/trials/nct06757634/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06982521","kind":"trial","name":"Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer","route":"/trials/nct06982521/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06467357","kind":"trial","name":"Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer","route":"/trials/nct06467357/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07154706","kind":"trial","name":"Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)","route":"/trials/nct07154706/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07197580","kind":"trial","name":"Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC","route":"/trials/nct07197580/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05232916","kind":"trial","name":"Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects","route":"/trials/nct05232916/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06915025","kind":"trial","name":"Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Pat","route":"/trials/nct06915025/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07242274","kind":"trial","name":"Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC","route":"/trials/nct07242274/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07723469","kind":"trial","name":"Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery","route":"/trials/nct07723469/","detail":"mentions 2034 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07778316","kind":"trial","name":"Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)","route":"/trials/nct07778316/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06118788","kind":"trial","name":"Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","route":"/trials/nct06118788/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06735144","kind":"trial","name":"Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors","route":"/trials/nct06735144/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06144671","kind":"trial","name":"Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors","route":"/trials/nct06144671/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07073534","kind":"trial","name":"Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors","route":"/trials/nct07073534/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06212076","kind":"trial","name":"Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients","route":"/trials/nct06212076/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07063329","kind":"trial","name":"Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive","route":"/trials/nct07063329/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03960840","kind":"trial","name":"Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL","route":"/trials/nct03960840/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07050641","kind":"trial","name":"Phase I/II Study of SCTB39-1 in Advanced Solid Tumours","route":"/trials/nct07050641/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06149481","kind":"trial","name":"Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Can","route":"/trials/nct06149481/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06730009","kind":"trial","name":"Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients","route":"/trials/nct06730009/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06110572","kind":"trial","name":"Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation","route":"/trials/nct06110572/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02802423","kind":"trial","name":"Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.","route":"/trials/nct02802423/","detail":"mentions 2027, 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05797168","kind":"trial","name":"Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors","route":"/trials/nct05797168/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06861452","kind":"trial","name":"Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients With Locally Advanced Pancreatic Carcinoma","route":"/trials/nct06861452/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07235176","kind":"trial","name":"Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients","route":"/trials/nct07235176/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07239596","kind":"trial","name":"Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom","route":"/trials/nct07239596/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07590934","kind":"trial","name":"Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer","route":"/trials/nct07590934/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05503888","kind":"trial","name":"Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer","route":"/trials/nct05503888/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07353268","kind":"trial","name":"Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerabil","route":"/trials/nct07353268/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07342725","kind":"trial","name":"Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Met","route":"/trials/nct07342725/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05720130","kind":"trial","name":"Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).","route":"/trials/nct05720130/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07243938","kind":"trial","name":"Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)","route":"/trials/nct07243938/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07175220","kind":"trial","name":"Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects","route":"/trials/nct07175220/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07742956","kind":"trial","name":"Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab In","route":"/trials/nct07742956/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07603791","kind":"trial","name":"Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC","route":"/trials/nct07603791/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07003022","kind":"trial","name":"Phase II Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC","route":"/trials/nct07003022/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06771609","kind":"trial","name":"Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy fo","route":"/trials/nct06771609/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05739981","kind":"trial","name":"Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer","route":"/trials/nct05739981/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07154316","kind":"trial","name":"Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer","route":"/trials/nct07154316/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06959550","kind":"trial","name":"Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer","route":"/trials/nct06959550/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07314294","kind":"trial","name":"Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients","route":"/trials/nct07314294/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07487519","kind":"trial","name":"Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Br","route":"/trials/nct07487519/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07530445","kind":"trial","name":"Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer","route":"/trials/nct07530445/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07387081","kind":"trial","name":"Phase II Study of LM-24C5","route":"/trials/nct07387081/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06830239","kind":"trial","name":"Phase II Study of Neoadjuvant Dostarlimab in Patients With Untreated T3-4N0-2 or Stage III pMMR/MSS Resectable Colon Cancer","route":"/trials/nct06830239/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07057791","kind":"trial","name":"Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer","route":"/trials/nct07057791/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07724756","kind":"trial","name":"Phase II Study of QLC2519 in Pediatric Solid Tumor Participants","route":"/trials/nct07724756/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07018050","kind":"trial","name":"Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma","route":"/trials/nct07018050/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07329322","kind":"trial","name":"Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Facto","route":"/trials/nct07329322/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07670273","kind":"trial","name":"Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer","route":"/trials/nct07670273/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07704177","kind":"trial","name":"Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer","route":"/trials/nct07704177/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07234877","kind":"trial","name":"Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets","route":"/trials/nct07234877/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07017673","kind":"trial","name":"Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer","route":"/trials/nct07017673/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05672108","kind":"trial","name":"Phase II Trial of Lung Chemoemobolization","route":"/trials/nct05672108/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07552181","kind":"trial","name":"Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer","route":"/trials/nct07552181/","detail":"mentions 2035 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06121505","kind":"trial","name":"Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer","route":"/trials/nct06121505/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07232290","kind":"trial","name":"Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera","route":"/trials/nct07232290/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07310173","kind":"trial","name":"Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma","route":"/trials/nct07310173/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07360132","kind":"trial","name":"Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous","route":"/trials/nct07360132/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07383116","kind":"trial","name":"Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous No","route":"/trials/nct07383116/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07291037","kind":"trial","name":"Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Acti","route":"/trials/nct07291037/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06123754","kind":"trial","name":"Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC","route":"/trials/nct06123754/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07754123","kind":"trial","name":"Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC","route":"/trials/nct07754123/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07228832","kind":"trial","name":"Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer","route":"/trials/nct07228832/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07829549","kind":"trial","name":"Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Act","route":"/trials/nct07829549/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06921785","kind":"trial","name":"Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma","route":"/trials/nct06921785/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07170995","kind":"trial","name":"Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Adva","route":"/trials/nct07170995/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07262567","kind":"trial","name":"Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer","route":"/trials/nct07262567/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03016819","kind":"trial","name":"Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)","route":"/trials/nct03016819/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06889688","kind":"trial","name":"Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer","route":"/trials/nct06889688/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06350097","kind":"trial","name":"Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell L","route":"/trials/nct06350097/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05687266","kind":"trial","name":"Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations","route":"/trials/nct05687266/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06357533","kind":"trial","name":"Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥","route":"/trials/nct06357533/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06632912","kind":"trial","name":"Phase IIIb Clinical Trial of Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) for Age/Immunization Schedule Bridging","route":"/trials/nct06632912/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05827081","kind":"trial","name":"Phase IIIb Study of Ribociclib + ET in Early Breast Cancer","route":"/trials/nct05827081/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07619898","kind":"trial","name":"PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure","route":"/trials/nct07619898/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07416058","kind":"trial","name":"PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC","route":"/trials/nct07416058/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06807359","kind":"trial","name":"Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System","route":"/trials/nct06807359/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06519266","kind":"trial","name":"PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases","route":"/trials/nct06519266/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06731894","kind":"trial","name":"Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors","route":"/trials/nct06731894/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07416994","kind":"trial","name":"Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer","route":"/trials/nct07416994/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06947928","kind":"trial","name":"Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Car","route":"/trials/nct06947928/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04624204","kind":"trial","name":"Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-","route":"/trials/nct04624204/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07070622","kind":"trial","name":"Planed Organ Preservation for Low Rectal Cancer After Neoadjuvant Chemotherapy (OPLAR)","route":"/trials/nct07070622/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05534087","kind":"trial","name":"Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)","route":"/trials/nct05534087/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"pm8002","kind":"drug","name":"PM8002","route":"/drugs/pm8002/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07133750","kind":"trial","name":"PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer","route":"/trials/nct07133750/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06616532","kind":"trial","name":"PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer","route":"/trials/nct06616532/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06419621","kind":"trial","name":"PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC","route":"/trials/nct06419621/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06634056","kind":"trial","name":"Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation","route":"/trials/nct06634056/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"polcagb","kind":"trial","name":"POLCAGB","route":"/trials/polcagb/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06752811","kind":"trial","name":"Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer","route":"/trials/nct06752811/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05008809","kind":"trial","name":"Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)","route":"/trials/nct05008809/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04365374","kind":"trial","name":"Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)","route":"/trials/nct04365374/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05797077","kind":"trial","name":"Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA","route":"/trials/nct05797077/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05868226","kind":"trial","name":"PRE-ISPY Phase I/II Oncology Platform Program","route":"/trials/nct05868226/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05845450","kind":"trial","name":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","route":"/trials/nct05845450/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06899477","kind":"trial","name":"Pre-Operative Treatment in REseCTable COlon CanceR","route":"/trials/nct06899477/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"precemtabart-tocentecan","kind":"drug","name":"Precemtabart tocentecan","route":"/drugs/precemtabart-tocentecan/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06227065","kind":"trial","name":"Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids","route":"/trials/nct06227065/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07729917","kind":"trial","name":"Precision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform Study","route":"/trials/nct07729917/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07069595","kind":"trial","name":"PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease","route":"/trials/nct07069595/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"preopanc-3","kind":"trial","name":"PREOPANC-3","route":"/trials/preopanc-3/","detail":"mentions 2027, 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06784791","kind":"trial","name":"Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mut","route":"/trials/nct06784791/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06751394","kind":"trial","name":"Preoperative Chemoradiotherapy and Toripalimab in Locally Recurrent Rectal Cancer","route":"/trials/nct06751394/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07276880","kind":"trial","name":"Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer","route":"/trials/nct07276880/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04495088","kind":"trial","name":"Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer","route":"/trials/nct04495088/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05083247","kind":"trial","name":"Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma","route":"/trials/nct05083247/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07271355","kind":"trial","name":"Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases,","route":"/trials/nct07271355/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06220032","kind":"trial","name":"Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma","route":"/trials/nct06220032/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06616987","kind":"trial","name":"Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer","route":"/trials/nct06616987/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07135882","kind":"trial","name":"Primary Radiotherapy In MEtastatic Lung Cancer","route":"/trials/nct07135882/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07510828","kind":"trial","name":"PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors","route":"/trials/nct07510828/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06460298","kind":"trial","name":"ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer","route":"/trials/nct06460298/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07605728","kind":"trial","name":"Probiotics for Abemaciclib-Induced Abdominal Discomfort.","route":"/trials/nct07605728/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06762405","kind":"trial","name":"PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-defi","route":"/trials/nct06762405/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-takahashi-lancet-oncol","kind":"paper","name":"Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial","route":"/key-papers/paper-takahashi-lancet-oncol/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05939687","kind":"trial","name":"Prophylactic Mesh Placement During Stoma Closure After Low Anterior Resection","route":"/trials/nct05939687/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06839092","kind":"trial","name":"Prophylactic PIPAC in Patients With High-risk Colorectal Cancer","route":"/trials/nct06839092/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05741164","kind":"trial","name":"Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer","route":"/trials/nct05741164/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07103447","kind":"trial","name":"Prospective Multicenter Single-arm Trial: AK112 + Nab-paclitaxel/Carboplatin Neoadjuvant for TNBC","route":"/trials/nct07103447/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06745882","kind":"trial","name":"Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC","route":"/trials/nct06745882/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"prostate-roadmap","kind":"roadmap","name":"Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch","route":"/roadmaps/prostate-roadmap/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07825753","kind":"trial","name":"Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer","route":"/trials/nct07825753/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02598349","kind":"trial","name":"Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas","route":"/trials/nct02598349/","detail":"mentions 2039 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07052214","kind":"trial","name":"PSMA PET Combined With MRI for the Detection of PCa","route":"/trials/nct07052214/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05381103","kind":"trial","name":"PSMA-PET to Guide Prostatectomy","route":"/trials/nct05381103/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06244992","kind":"trial","name":"PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct06244992/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07586124","kind":"trial","name":"Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma","route":"/trials/nct07586124/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06770270","kind":"trial","name":"Pucotenlimab Plus Radiotherapy and Chemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cance(PUCRT)","route":"/trials/nct06770270/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06665100","kind":"trial","name":"PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)","route":"/trials/nct06665100/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03965234","kind":"trial","name":"Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases","route":"/trials/nct03965234/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07269626","kind":"trial","name":"PULSAR in Systemic Therapy for Pancreatic Cancer","route":"/trials/nct07269626/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"purinostat","kind":"drug","name":"Purinostat","route":"/drugs/purinostat/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04683315","kind":"trial","name":"PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples","route":"/trials/nct04683315/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07044336","kind":"trial","name":"Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)","route":"/trials/nct07044336/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ql1706","kind":"drug","name":"QL1706","route":"/drugs/ql1706/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07649473","kind":"trial","name":"QL1706 Combined With Standard Therapy for Conversion Therapy of Synchronous Liver Metastases From Colon Cancer: a Multicenter, Single-arm, Exploratory Study","route":"/trials/nct07649473/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07025239","kind":"trial","name":"QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer","route":"/trials/nct07025239/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07636226","kind":"trial","name":"QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer","route":"/trials/nct07636226/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07342283","kind":"trial","name":"QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer","route":"/trials/nct07342283/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06951997","kind":"trial","name":"QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer","route":"/trials/nct06951997/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07156682","kind":"trial","name":"QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer","route":"/trials/nct07156682/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07733115","kind":"trial","name":"QL1706（Iparomlimab/Tuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line Treatment for PD-L1-Positive Biliary Tract Cancer","route":"/trials/nct07733115/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07110064","kind":"trial","name":"QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer","route":"/trials/nct07110064/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07463573","kind":"trial","name":"QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma","route":"/trials/nct07463573/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07509515","kind":"trial","name":"QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC.","route":"/trials/nct07509515/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"qls31905","kind":"drug","name":"QLS31905","route":"/drugs/qls31905/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"qls32015","kind":"drug","name":"QLS32015","route":"/drugs/qls32015/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07453394","kind":"trial","name":"QLS5132 Combination Therapy in Advanced Solid Tumors","route":"/trials/nct07453394/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05703971","kind":"trial","name":"Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients","route":"/trials/nct05703971/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04486833","kind":"trial","name":"Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib","route":"/trials/nct04486833/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07601178","kind":"trial","name":"QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride","route":"/trials/nct07601178/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"quemliclustat","kind":"drug","name":"Quemliclustat","route":"/drugs/quemliclustat/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03228667","kind":"trial","name":"QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors","route":"/trials/nct03228667/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"radcomp","kind":"trial","name":"RADCOMP","route":"/trials/radcomp/","detail":"mentions 2036 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06814496","kind":"trial","name":"Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors","route":"/trials/nct06814496/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07808138","kind":"trial","name":"RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung Cancer","route":"/trials/nct07808138/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06949111","kind":"trial","name":"Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）","route":"/trials/nct06949111/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07116577","kind":"trial","name":"Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC","route":"/trials/nct07116577/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07774754","kind":"trial","name":"Radiotherapy Combined With Capeox Chemotherapy, Sintilimab and Suvemcitug in Locally Advanced pMMR Rectal Cancer:a Prospective Clinical Trial","route":"/trials/nct07774754/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"idea-moon-radiotherapy-for-everyone-2040","kind":"idea","name":"Radiotherapy for everyone who needs it by 2040","route":"/ideas/idea-moon-radiotherapy-for-everyone-2040/","detail":"mentions 2040 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07291401","kind":"trial","name":"Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARC","route":"/trials/nct07291401/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06686771","kind":"trial","name":"Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer","route":"/trials/nct06686771/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06250972","kind":"trial","name":"Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer","route":"/trials/nct06250972/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-parker-lancet","kind":"paper","name":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","route":"/key-papers/paper-parker-lancet/","detail":"mentions 2061 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07632118","kind":"trial","name":"Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery","route":"/trials/nct07632118/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-rahib-projecting-cancer-deaths-2030-cancerres-2014","kind":"paper","name":"Rahib 2014: projecting US cancer incidence and deaths to 2030","route":"/key-papers/paper-rahib-projecting-cancer-deaths-2030-cancerres-2014/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"rainbo","kind":"trial","name":"RAINBO","route":"/trials/rainbo/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"rainfol-01","kind":"trial","name":"RAINFOL-01 (Rina-S)","route":"/trials/rainfol-01/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-nct02411448-lancet-oncol-2019","kind":"paper","name":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-nct02411448-lancet-oncol-2019/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07562659","kind":"trial","name":"Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer","route":"/trials/nct07562659/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06867705","kind":"trial","name":"Randomized Controlled Trial of Remote Symptoms Monitoring With Resilience PRO Compared to Care As Usual Only","route":"/trials/nct06867705/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04747236","kind":"trial","name":"Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL","route":"/trials/nct04747236/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07562711","kind":"trial","name":"Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer","route":"/trials/nct07562711/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07562503","kind":"trial","name":"Randomized Trial of Plasma ctDNA Methylation-Guided Adjuvant Therapy in T4N0 and Low-Risk Stage III Colorectal Cancer","route":"/trials/nct07562503/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03051464","kind":"trial","name":"Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery","route":"/trials/nct03051464/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"rc148","kind":"drug","name":"RC148","route":"/drugs/rc148/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"sqnsclc","kind":"trial","name":"RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)","route":"/trials/sqnsclc/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07366840","kind":"trial","name":"RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure","route":"/trials/nct07366840/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07419880","kind":"trial","name":"Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer","route":"/trials/nct07419880/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07006077","kind":"trial","name":"Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer","route":"/trials/nct07006077/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07735624","kind":"trial","name":"RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer","route":"/trials/nct07735624/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06411795","kind":"trial","name":"Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy","route":"/trials/nct06411795/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07594106","kind":"trial","name":"REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate ","route":"/trials/nct07594106/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07071961","kind":"trial","name":"Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Di","route":"/trials/nct07071961/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05794971","kind":"trial","name":"Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases","route":"/trials/nct05794971/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06425133","kind":"trial","name":"Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers","route":"/trials/nct06425133/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05462613","kind":"trial","name":"Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer","route":"/trials/nct05462613/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"rejoice-ovarian01","kind":"trial","name":"REJOICE-Ovarian01","route":"/trials/rejoice-ovarian01/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07259317","kind":"trial","name":"Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma","route":"/trials/nct07259317/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-sonabend-lancet-oncol","kind":"paper","name":"Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial","route":"/key-papers/paper-sonabend-lancet-oncol/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05796375","kind":"trial","name":"Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance","route":"/trials/nct05796375/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06315010","kind":"trial","name":"Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis","route":"/trials/nct06315010/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06580002","kind":"trial","name":"Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial","route":"/trials/nct06580002/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05632809","kind":"trial","name":"REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)","route":"/trials/nct05632809/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05582538","kind":"trial","name":"Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel","route":"/trials/nct05582538/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07219576","kind":"trial","name":"Retifanlimab and Ruxolitinib In Solid Malignancies","route":"/trials/nct07219576/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06679634","kind":"trial","name":"Retinoblastoma Phase II Expanded Access Clinical Trial","route":"/trials/nct06679634/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07752550","kind":"trial","name":"Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer","route":"/trials/nct07752550/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07814859","kind":"trial","name":"Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic Cancer","route":"/trials/nct07814859/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07773363","kind":"trial","name":"Retlirafusp Alfa Plus Apatinib and Chemotherapy as Second-Line Treatment for Pancreatic Cancer","route":"/trials/nct07773363/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07815288","kind":"trial","name":"Retlirafusp Alfa Plus Targeted Therapy and Chemotherapy for Unresectable Colorectal Liver-Limited Metastases","route":"/trials/nct07815288/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05973773","kind":"trial","name":"REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)","route":"/trials/nct05973773/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02934568","kind":"trial","name":"Ribociclib (LEE011) Rollover Study for Continued Access","route":"/trials/nct02934568/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07447050","kind":"trial","name":"Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial","route":"/trials/nct07447050/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06109779","kind":"trial","name":"Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)","route":"/trials/nct06109779/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06999252","kind":"trial","name":"Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer Patients","route":"/trials/nct06999252/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"rinzimetostat","kind":"drug","name":"Rinzimetostat","route":"/drugs/rinzimetostat/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07044453","kind":"trial","name":"Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX","route":"/trials/nct07044453/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ro7771950","kind":"drug","name":"RO7771950","route":"/drugs/ro7771950/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07413939","kind":"trial","name":"RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive","route":"/trials/nct07413939/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"rocbrutinib","kind":"drug","name":"Rocbrutinib","route":"/drugs/rocbrutinib/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07342478","kind":"trial","name":"ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL","route":"/trials/nct07342478/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04421963","kind":"trial","name":"Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib","route":"/trials/nct04421963/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05629234","kind":"trial","name":"Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)","route":"/trials/nct05629234/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05201066","kind":"trial","name":"Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.","route":"/trials/nct05201066/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07468071","kind":"trial","name":"Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other","route":"/trials/nct07468071/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07381764","kind":"trial","name":"ROMANCE: \"Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer\"","route":"/trials/nct07381764/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07586813","kind":"trial","name":"Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors","route":"/trials/nct07586813/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"rondecabtagene-autoleucel","kind":"drug","name":"Rondecabtagene autoleucel","route":"/drugs/rondecabtagene-autoleucel/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07173751","kind":"trial","name":"ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer","route":"/trials/nct07173751/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05966194","kind":"trial","name":"RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer","route":"/trials/nct05966194/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07662278","kind":"trial","name":"rSIFN-co in Combination With Total Neo-adjuvant Therapy in Subjects With Mid-low Locally Advanced Rectal Cancer","route":"/trials/nct07662278/","detail":"mentions 2027, 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"rugb","kind":"trial","name":"RUGB","route":"/trials/rugb/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05101070","kind":"trial","name":"S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors","route":"/trials/nct05101070/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct01349881","kind":"trial","name":"S0820, Adenoma and Second Primary Prevention Trial","route":"/trials/nct01349881/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06188702","kind":"trial","name":"S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP","route":"/trials/nct06188702/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07623577","kind":"trial","name":"Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases","route":"/trials/nct07623577/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07244874","kind":"trial","name":"Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC","route":"/trials/nct07244874/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07458113","kind":"trial","name":"Sac-TMT for Active TNBC Brain Metastases","route":"/trials/nct07458113/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07628504","kind":"trial","name":"Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations","route":"/trials/nct07628504/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06963905","kind":"trial","name":"Saci Nivo Rela for TNBC","route":"/trials/nct06963905/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04468061","kind":"trial","name":"Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC","route":"/trials/nct04468061/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07788222","kind":"trial","name":"Sacituzumab Govitecan and Q901 in Advanced TNBC","route":"/trials/nct07788222/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06238921","kind":"trial","name":"Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases","route":"/trials/nct06238921/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06243393","kind":"trial","name":"Sacituzumab Govitecan in Metastatic Colorectal Cancer","route":"/trials/nct06243393/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04595565","kind":"trial","name":"Sacituzumab Govitecan in Primary HER2-negative Breast Cancer","route":"/trials/nct04595565/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04230109","kind":"trial","name":"Sacituzumab Govitecan In TNBC","route":"/trials/nct04230109/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06170788","kind":"trial","name":"Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With P","route":"/trials/nct06170788/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06132958","kind":"trial","name":"Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)","route":"/trials/nct06132958/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06393374","kind":"trial","name":"Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)","route":"/trials/nct06393374/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06074588","kind":"trial","name":"Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With","route":"/trials/nct06074588/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06305754","kind":"trial","name":"Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, A","route":"/trials/nct06305754/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07561463","kind":"trial","name":"Sacituzumab Tirumotecan for Pancreatic Cancer","route":"/trials/nct07561463/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07501169","kind":"trial","name":"Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)","route":"/trials/nct07501169/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07324629","kind":"trial","name":"Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma","route":"/trials/nct07324629/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07701122","kind":"trial","name":"Sacituzumab Tirumotecan in Previously Treated TROP2-Positive Advanced Biliary Tract Cancer","route":"/trials/nct07701122/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07139470","kind":"trial","name":"Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer","route":"/trials/nct07139470/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07343479","kind":"trial","name":"Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases","route":"/trials/nct07343479/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06937177","kind":"trial","name":"Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy","route":"/trials/nct06937177/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-blinatumomab-all-leukemia-lancet-oncol-2015","kind":"paper","name":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","route":"/key-papers/paper-blinatumomab-all-leukemia-lancet-oncol-2015/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06474806","kind":"trial","name":"Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer","route":"/trials/nct06474806/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07095309","kind":"trial","name":"Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/ III Colorectal Cancer","route":"/trials/nct07095309/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04416984","kind":"trial","name":"Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)","route":"/trials/nct04416984/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07387926","kind":"trial","name":"Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)","route":"/trials/nct07387926/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06712355","kind":"trial","name":"Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer","route":"/trials/nct06712355/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06697301","kind":"trial","name":"Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma","route":"/trials/nct06697301/","detail":"mentions 2035 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05704244","kind":"trial","name":"Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)","route":"/trials/nct05704244/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06947291","kind":"trial","name":"Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors","route":"/trials/nct06947291/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07471789","kind":"trial","name":"Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).","route":"/trials/nct07471789/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06771622","kind":"trial","name":"Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors","route":"/trials/nct06771622/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07150247","kind":"trial","name":"Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer","route":"/trials/nct07150247/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06506643","kind":"trial","name":"Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms","route":"/trials/nct06506643/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07745790","kind":"trial","name":"Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer","route":"/trials/nct07745790/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06047379","kind":"trial","name":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","route":"/trials/nct06047379/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06060613","kind":"trial","name":"Safety and Efficacy of OBX-115 in Advanced Solid Tumors","route":"/trials/nct06060613/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06002789","kind":"trial","name":"Safety and Efficacy of PD-1 ± mFOLFOX6 Neoadjuvant Therapy in Local Advanced sMPCC","route":"/trials/nct06002789/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03934372","kind":"trial","name":"Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors","route":"/trials/nct03934372/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03793478","kind":"trial","name":"Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood","route":"/trials/nct03793478/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06191263","kind":"trial","name":"Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML","route":"/trials/nct06191263/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07102901","kind":"trial","name":"Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma","route":"/trials/nct07102901/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07463599","kind":"trial","name":"Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma","route":"/trials/nct07463599/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06016920","kind":"trial","name":"Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma","route":"/trials/nct06016920/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04623541","kind":"trial","name":"Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome","route":"/trials/nct04623541/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05951179","kind":"trial","name":"Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer","route":"/trials/nct05951179/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04938817","kind":"trial","name":"Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)","route":"/trials/nct04938817/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06334432","kind":"trial","name":"Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors","route":"/trials/nct06334432/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06508931","kind":"trial","name":"Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms","route":"/trials/nct06508931/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04663347","kind":"trial","name":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","route":"/trials/nct04663347/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07575191","kind":"trial","name":"Safety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer","route":"/trials/nct07575191/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07463235","kind":"trial","name":"Safety and Potency of a High Cabergoline Dosage in Microprolactinomas","route":"/trials/nct07463235/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06750185","kind":"trial","name":"Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors","route":"/trials/nct06750185/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06449222","kind":"trial","name":"Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy","route":"/trials/nct06449222/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06841055","kind":"trial","name":"Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Che","route":"/trials/nct06841055/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06810544","kind":"trial","name":"Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss","route":"/trials/nct06810544/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05732831","kind":"trial","name":"Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors","route":"/trials/nct05732831/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06274879","kind":"trial","name":"Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer","route":"/trials/nct06274879/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06638502","kind":"trial","name":"Safety of HRX215 in Patients After Minor and Major Liver Resection","route":"/trials/nct06638502/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06712316","kind":"trial","name":"Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer","route":"/trials/nct06712316/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06087653","kind":"trial","name":"Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)","route":"/trials/nct06087653/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06635785","kind":"trial","name":"Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors","route":"/trials/nct06635785/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06449209","kind":"trial","name":"Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy","route":"/trials/nct06449209/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05338931","kind":"trial","name":"Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma","route":"/trials/nct05338931/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"safir-abc10","kind":"trial","name":"SAFIR-ABC10","route":"/trials/safir-abc10/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"safusidenib","kind":"drug","name":"Safusidenib","route":"/drugs/safusidenib/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04589234","kind":"trial","name":"Saltikva for Metastatic Pancreatic Cancer","route":"/trials/nct04589234/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06258525","kind":"trial","name":"SAMe in Prevention of Oxaliplatin-associated Liver Injury","route":"/trials/nct06258525/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07665684","kind":"trial","name":"Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer","route":"/trials/nct07665684/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"sapanisertib","kind":"drug","name":"Sapanisertib","route":"/drugs/sapanisertib/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07558733","kind":"trial","name":"Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer","route":"/trials/nct07558733/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06463028","kind":"trial","name":"Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial ","route":"/trials/nct06463028/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"saruparib","kind":"drug","name":"Saruparib","route":"/drugs/saruparib/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06380751","kind":"trial","name":"Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer","route":"/trials/nct06380751/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06120491","kind":"trial","name":"Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents","route":"/trials/nct06120491/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05374603","kind":"trial","name":"Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC","route":"/trials/nct05374603/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07683403","kind":"trial","name":"Savolitinib Plus Cetuximab and FOLFOX Chemotherapy for RAS/BRAF Wild-type Metastatic Colorectal Cancer","route":"/trials/nct07683403/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06835179","kind":"trial","name":"SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.","route":"/trials/nct06835179/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06627712","kind":"trial","name":"SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC","route":"/trials/nct06627712/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07683221","kind":"trial","name":"SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer","route":"/trials/nct07683221/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07535632","kind":"trial","name":"SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer","route":"/trials/nct07535632/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05775146","kind":"trial","name":"SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases","route":"/trials/nct05775146/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04986579","kind":"trial","name":"Scalp Cooling in MBC","route":"/trials/nct04986579/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"scan-b","kind":"trial","name":"SCAN-B (Sweden Cancerome Analysis Network - Breast)","route":"/trials/scan-b/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"scc-after","kind":"trial","name":"SCC-AFTER","route":"/trials/scc-after/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04079166","kind":"trial","name":"SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)","route":"/trials/nct04079166/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07549399","kind":"trial","name":"SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC","route":"/trials/nct07549399/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07551479","kind":"trial","name":"SCRT Based iTNT vs. LCRT Based TNT for MSS Locally Advanced Rectal Cancer","route":"/trials/nct07551479/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07837362","kind":"trial","name":"SCRT Combined With CAPOX and PD-1/CTLA4 Antibody for Early-stage Low Rectal Cancer","route":"/trials/nct07837362/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06864013","kind":"trial","name":"SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer","route":"/trials/nct06864013/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07162714","kind":"trial","name":"SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer","route":"/trials/nct07162714/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07198165","kind":"trial","name":"SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC","route":"/trials/nct07198165/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07284992","kind":"trial","name":"SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC","route":"/trials/nct07284992/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06850103","kind":"trial","name":"SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases","route":"/trials/nct06850103/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"sctb14","kind":"drug","name":"SCTB14","route":"/drugs/sctb14/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"sctb35","kind":"drug","name":"SCTB35","route":"/drugs/sctb35/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"sctb41","kind":"drug","name":"SCTB41","route":"/drugs/sctb41/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07662395","kind":"trial","name":"SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer","route":"/trials/nct07662395/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"sctc21c","kind":"drug","name":"SCTC21C","route":"/drugs/sctc21c/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07150403","kind":"trial","name":"Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal","route":"/trials/nct07150403/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05717803","kind":"trial","name":"Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012)","route":"/trials/nct05717803/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07169903","kind":"trial","name":"Segmentectomy vs Lobectomy for 2 - 3cm IASLC Grade 1-2 Lung Adenocarcinoma: A Multi-center RCT","route":"/trials/nct07169903/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07617389","kind":"trial","name":"Selective Mediastinal Lymph Node Sampling Versus Systematic medIastinal Lymph Node Dissection After Neoadjuvant Chemoimmunotherapy for Non-small Cell Lung Cance","route":"/trials/nct07617389/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04428905","kind":"trial","name":"Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer","route":"/trials/nct04428905/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05035745","kind":"trial","name":"Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)","route":"/trials/nct05035745/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02343042","kind":"trial","name":"Selinexor and Backbone Treatments of Multiple Myeloma Patients","route":"/trials/nct02343042/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06946420","kind":"trial","name":"SENECA: First Line metaStatic pancrEatic caNcer Primary and Distant (if Oligometastatic) lEsion direCted rAdiotherapy","route":"/trials/nct06946420/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"senticol-iii","kind":"trial","name":"SENTICOL III","route":"/trials/senticol-iii/","detail":"mentions 2027, 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07181499","kind":"trial","name":"Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI","route":"/trials/nct07181499/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04570943","kind":"trial","name":"Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer","route":"/trials/nct04570943/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-trappe-lancet-oncol","kind":"paper","name":"Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial","route":"/key-papers/paper-trappe-lancet-oncol/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"serabelisib","kind":"drug","name":"Serabelisib","route":"/drugs/serabelisib/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07811076","kind":"trial","name":"Serine/Glycine-Restricted Diet With Chemoradiotherapy for Rectal Cancer","route":"/trials/nct07811076/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07819604","kind":"trial","name":"Serplulimab Combined With CAPOX and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer","route":"/trials/nct07819604/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05742425","kind":"trial","name":"Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases","route":"/trials/nct05742425/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07691632","kind":"trial","name":"Serplulimab Plus Decitabine and CAPOX Before Surgery for Locally Advanced Colorectal Cancer","route":"/trials/nct07691632/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"setidegrasib","kind":"drug","name":"Setidegrasib","route":"/drugs/setidegrasib/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"sevilla","kind":"trial","name":"SEVILLA","route":"/trials/sevilla/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07131319","kind":"trial","name":"SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC","route":"/trials/nct07131319/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"sg301","kind":"drug","name":"SG301","route":"/drugs/sg301/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06080776","kind":"trial","name":"SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations","route":"/trials/nct06080776/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07059949","kind":"trial","name":"Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer","route":"/trials/nct07059949/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07581626","kind":"trial","name":"Short-Course Online Adaptive Radiotherapy Combined With Chemotherapy, Targeted Therapy and Immunotherapy as Total Neoadjuvant Therapy (TNT) for Locally Advanced","route":"/trials/nct07581626/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06832917","kind":"trial","name":"Short-course Radiation (SCRT) Followed by 6 Cycles of Cadonilimab Plus MFOLFOX6 As Neoadjuvant Therapy for Patients with Locally Advanced Rectal Cancer (LARC):","route":"/trials/nct06832917/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07397442","kind":"trial","name":"Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer","route":"/trials/nct07397442/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06014944","kind":"trial","name":"Short-course Radiotherapy Combined With Furoquintinib and PD-1 Monoclonal Antibody","route":"/trials/nct06014944/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06760520","kind":"trial","name":"Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer","route":"/trials/nct06760520/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07686640","kind":"trial","name":"Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR/MSS Locally Advanced Rectal Cancer","route":"/trials/nct07686640/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05484024","kind":"trial","name":"Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer","route":"/trials/nct05484024/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07594925","kind":"trial","name":"Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer: A Prospective, Randomiz","route":"/trials/nct07594925/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07005570","kind":"trial","name":"Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS","route":"/trials/nct07005570/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07394192","kind":"trial","name":"Short-Course Radiotherapy With Tumor-Draining Lymph Node Preservation Followed by PD-1 Inhibitors in pMMR/MSS Stage II-III Rectal Cancer","route":"/trials/nct07394192/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07521605","kind":"trial","name":"Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer","route":"/trials/nct07521605/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07651007","kind":"trial","name":"Short-course RT Followed by NALIRIFOX Plus Pucotenlimab as Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer With MSS/pMMR","route":"/trials/nct07651007/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07469306","kind":"trial","name":"Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer","route":"/trials/nct07469306/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"shr-1501","kind":"drug","name":"SHR-1501","route":"/drugs/shr-1501/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07515820","kind":"trial","name":"SHR-3821 in Advanced Colorectal Cancer: an Exploratory Study","route":"/trials/nct07515820/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06666166","kind":"trial","name":"SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer","route":"/trials/nct06666166/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06123494","kind":"trial","name":"SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen","route":"/trials/nct06123494/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07700719","kind":"trial","name":"SHR-A1904 in Advanced Colorectal Cancer: an Exploratory Study","route":"/trials/nct07700719/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"shr-a1912","kind":"drug","name":"SHR-A1912","route":"/drugs/shr-a1912/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"shr-a2102","kind":"drug","name":"SHR-A2102","route":"/drugs/shr-a2102/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05303519","kind":"trial","name":"SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)","route":"/trials/nct05303519/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"sim0270","kind":"drug","name":"SIM0270","route":"/drugs/sim0270/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05239546","kind":"trial","name":"Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers","route":"/trials/nct05239546/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06680739","kind":"trial","name":"Single cEll pRofiling PErsistaNce To ImmuNothErapy","route":"/trials/nct06680739/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07039526","kind":"trial","name":"Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer","route":"/trials/nct07039526/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07648264","kind":"trial","name":"Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies","route":"/trials/nct07648264/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07654530","kind":"trial","name":"Sintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC.","route":"/trials/nct07654530/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-ren-lancet-oncol","kind":"paper","name":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study","route":"/key-papers/paper-ren-lancet-oncol/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07656766","kind":"trial","name":"Sintilimab Plus Gossypol Acetate in Advanced Colorectal Cancer","route":"/trials/nct07656766/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07831993","kind":"trial","name":"Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer","route":"/trials/nct07831993/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07165886","kind":"trial","name":"Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors","route":"/trials/nct07165886/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"sitneprotafib","kind":"drug","name":"Sitneprotafib","route":"/drugs/sitneprotafib/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"sjmb12","kind":"trial","name":"SJMB12","route":"/trials/sjmb12/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07459998","kind":"trial","name":"SKB103 for Injection in Advanced Solid Tumors","route":"/trials/nct07459998/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07380386","kind":"trial","name":"SKB105 for Injection in Advanced Solid Tumors","route":"/trials/nct07380386/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07586943","kind":"trial","name":"SKB118 Injection in Advanced Solid Tumors","route":"/trials/nct07586943/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05642780","kind":"trial","name":"SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors","route":"/trials/nct05642780/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07697586","kind":"trial","name":"SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer","route":"/trials/nct07697586/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07700667","kind":"trial","name":"SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma","route":"/trials/nct07700667/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07296809","kind":"trial","name":"SKB500 Combinations in Patients With Small Cell Lung Cancer","route":"/trials/nct07296809/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07545265","kind":"trial","name":"SKB565 for Injection in Advanced Solid Tumors","route":"/trials/nct07545265/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07341737","kind":"trial","name":"SL-28 for Advanced Solid Tumours","route":"/trials/nct07341737/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07748611","kind":"trial","name":"SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial","route":"/trials/nct07748611/","detail":"mentions 2027, 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07155200","kind":"trial","name":"Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)","route":"/trials/nct07155200/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07551635","kind":"trial","name":"SMARCA4/2 Inhibitor for POU2F3-Positive SCLC","route":"/trials/nct07551635/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06526819","kind":"trial","name":"SMP-3124LP in Adults With Advanced Solid Tumors","route":"/trials/nct06526819/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07391813","kind":"trial","name":"SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer","route":"/trials/nct07391813/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06736704","kind":"trial","name":"SNV4818 in Participants With Advanced Solid Tumors","route":"/trials/nct06736704/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"sofetabart-mipitecan","kind":"drug","name":"Sofetabart Mipitecan","route":"/drugs/sofetabart-mipitecan/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07431281","kind":"trial","name":"Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2","route":"/trials/nct07431281/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05902169","kind":"trial","name":"Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM","route":"/trials/nct05902169/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"soquelitinib","kind":"drug","name":"Soquelitinib","route":"/drugs/soquelitinib/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06561048","kind":"trial","name":"Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma","route":"/trials/nct06561048/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"spevatamig","kind":"drug","name":"Spevatamig","route":"/drugs/spevatamig/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05482893","kind":"trial","name":"Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junct","route":"/trials/nct05482893/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"spot-it","kind":"trial","name":"SPOT-IT","route":"/trials/spot-it/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06457906","kind":"trial","name":"SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC","route":"/trials/nct06457906/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ssgj-612","kind":"drug","name":"SSGJ-612","route":"/drugs/ssgj-612/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07646626","kind":"trial","name":"SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors","route":"/trials/nct07646626/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06714604","kind":"trial","name":"Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC","route":"/trials/nct06714604/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07106034","kind":"trial","name":"Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial","route":"/trials/nct07106034/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03678025","kind":"trial","name":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer","route":"/trials/nct03678025/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-rtog-0617-lancet-oncol-2015","kind":"paper","name":"Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study","route":"/key-papers/paper-rtog-0617-lancet-oncol-2015/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07076693","kind":"trial","name":"Standard-of-care Systemic Therapy With or Without Local Therapy in Patients With Oligoprogressive Non-Small Cell Lung Cancer(NSCLC）","route":"/trials/nct07076693/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"starpac2","kind":"trial","name":"STARPAC2","route":"/trials/starpac2/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06975293","kind":"trial","name":"STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas","route":"/trials/nct06975293/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06563388","kind":"trial","name":"Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial","route":"/trials/nct06563388/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-chisel-lancet-oncol-2019","kind":"paper","name":"Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial","route":"/key-papers/paper-chisel-lancet-oncol-2019/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06598527","kind":"trial","name":"Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant The","route":"/trials/nct06598527/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06523673","kind":"trial","name":"Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer","route":"/trials/nct06523673/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07126158","kind":"trial","name":"Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma","route":"/trials/nct07126158/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04899908","kind":"trial","name":"Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases","route":"/trials/nct04899908/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07132190","kind":"trial","name":"Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction","route":"/trials/nct07132190/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07007312","kind":"trial","name":"Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML","route":"/trials/nct07007312/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06158841","kind":"trial","name":"Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto","route":"/trials/nct06158841/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04524000","kind":"trial","name":"Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer","route":"/trials/nct04524000/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04544189","kind":"trial","name":"Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer","route":"/trials/nct04544189/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06225596","kind":"trial","name":"Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)","route":"/trials/nct06225596/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06855277","kind":"trial","name":"Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC","route":"/trials/nct06855277/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06792253","kind":"trial","name":"Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","route":"/trials/nct06792253/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05917405","kind":"trial","name":"Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT","route":"/trials/nct05917405/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05078047","kind":"trial","name":"Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO","route":"/trials/nct05078047/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07189455","kind":"trial","name":"Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer","route":"/trials/nct07189455/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06549465","kind":"trial","name":"Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)","route":"/trials/nct06549465/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04736173","kind":"trial","name":"Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer","route":"/trials/nct04736173/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06117774","kind":"trial","name":"Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)","route":"/trials/nct06117774/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04749108","kind":"trial","name":"Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma","route":"/trials/nct04749108/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07118800","kind":"trial","name":"Study Evaluating Two Treatment Strategies for Rectal Cancer in Patients ≥75 Years Old","route":"/trials/nct07118800/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05607420","kind":"trial","name":"Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma","route":"/trials/nct05607420/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06921928","kind":"trial","name":"Study for AZD4360 in Participants With Advanced Solid Tumours","route":"/trials/nct06921928/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05226871","kind":"trial","name":"Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies","route":"/trials/nct05226871/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07300943","kind":"trial","name":"Study in Advanced Solid Tumor Patients","route":"/trials/nct07300943/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07483983","kind":"trial","name":"Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Bi","route":"/trials/nct07483983/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07016230","kind":"trial","name":"Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocri","route":"/trials/nct07016230/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07278479","kind":"trial","name":"Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors","route":"/trials/nct07278479/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03600441","kind":"trial","name":"Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma","route":"/trials/nct03600441/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05952024","kind":"trial","name":"Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL","route":"/trials/nct05952024/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06380660","kind":"trial","name":"Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors","route":"/trials/nct06380660/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05317819","kind":"trial","name":"Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma","route":"/trials/nct05317819/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07804186","kind":"trial","name":"Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma","route":"/trials/nct07804186/","detail":"mentions 2034 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06722911","kind":"trial","name":"Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer","route":"/trials/nct06722911/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07284433","kind":"trial","name":"Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies","route":"/trials/nct07284433/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04208178","kind":"trial","name":"Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation","route":"/trials/nct04208178/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05776524","kind":"trial","name":"Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer","route":"/trials/nct05776524/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07287917","kind":"trial","name":"Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors","route":"/trials/nct07287917/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07346144","kind":"trial","name":"Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma","route":"/trials/nct07346144/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06710132","kind":"trial","name":"Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)","route":"/trials/nct06710132/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05909332","kind":"trial","name":"Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)","route":"/trials/nct05909332/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05898399","kind":"trial","name":"Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)","route":"/trials/nct05898399/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05267626","kind":"trial","name":"Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Ca","route":"/trials/nct05267626/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05867251","kind":"trial","name":"Study of AVZO-021 in Patients With Advanced Solid Tumors","route":"/trials/nct05867251/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05371093","kind":"trial","name":"Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma","route":"/trials/nct05371093/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07764978","kind":"trial","name":"Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT","route":"/trials/nct07764978/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07181161","kind":"trial","name":"Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer","route":"/trials/nct07181161/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07155226","kind":"trial","name":"Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression","route":"/trials/nct07155226/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07109219","kind":"trial","name":"Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia","route":"/trials/nct07109219/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07446855","kind":"trial","name":"Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours","route":"/trials/nct07446855/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04644068","kind":"trial","name":"Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies","route":"/trials/nct04644068/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05367440","kind":"trial","name":"Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer","route":"/trials/nct05367440/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06005493","kind":"trial","name":"Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors","route":"/trials/nct06005493/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05417594","kind":"trial","name":"Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies","route":"/trials/nct05417594/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06514027","kind":"trial","name":"Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations","route":"/trials/nct06514027/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07598318","kind":"trial","name":"Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations","route":"/trials/nct07598318/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06428396","kind":"trial","name":"Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)","route":"/trials/nct06428396/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07435038","kind":"trial","name":"Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","route":"/trials/nct07435038/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04662255","kind":"trial","name":"Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)","route":"/trials/nct04662255/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06313463","kind":"trial","name":"Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy","route":"/trials/nct06313463/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07011719","kind":"trial","name":"Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma","route":"/trials/nct07011719/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04195347","kind":"trial","name":"Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase","route":"/trials/nct04195347/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07019779","kind":"trial","name":"Study of CM518D1 in Patients With Advanced Solid Tumors","route":"/trials/nct07019779/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07030257","kind":"trial","name":"Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors","route":"/trials/nct07030257/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07283835","kind":"trial","name":"Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin","route":"/trials/nct07283835/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06881784","kind":"trial","name":"Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)","route":"/trials/nct06881784/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07252232","kind":"trial","name":"Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)","route":"/trials/nct07252232/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07491445","kind":"trial","name":"Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","route":"/trials/nct07491445/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05489211","kind":"trial","name":"Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)","route":"/trials/nct05489211/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05215340","kind":"trial","name":"Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionab","route":"/trials/nct05215340/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07129993","kind":"trial","name":"Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma","route":"/trials/nct07129993/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05651022","kind":"trial","name":"Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors","route":"/trials/nct05651022/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07527858","kind":"trial","name":"Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer","route":"/trials/nct07527858/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05320198","kind":"trial","name":"Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia","route":"/trials/nct05320198/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06819735","kind":"trial","name":"Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors","route":"/trials/nct06819735/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04550260","kind":"trial","name":"Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC","route":"/trials/nct04550260/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06726148","kind":"trial","name":"Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors","route":"/trials/nct06726148/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04836507","kind":"trial","name":"Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients","route":"/trials/nct04836507/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04417621","kind":"trial","name":"Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma","route":"/trials/nct04417621/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03876769","kind":"trial","name":"Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients","route":"/trials/nct03876769/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06726265","kind":"trial","name":"Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy ","route":"/trials/nct06726265/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06479239","kind":"trial","name":"Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer","route":"/trials/nct06479239/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06128551","kind":"trial","name":"Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors","route":"/trials/nct06128551/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05316155","kind":"trial","name":"Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer","route":"/trials/nct05316155/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06567015","kind":"trial","name":"Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs","route":"/trials/nct06567015/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06255379","kind":"trial","name":"Study of Fruquintinib Combined With Tegafur Gimeracil Oteracil in Patients With Metastatic Colorectal Cancer","route":"/trials/nct06255379/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06584032","kind":"trial","name":"Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer","route":"/trials/nct06584032/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07070518","kind":"trial","name":"Study of GV20-0251 in Participants With Solid Tumor Malignancies","route":"/trials/nct07070518/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07288359","kind":"trial","name":"Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors","route":"/trials/nct07288359/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06800313","kind":"trial","name":"Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer","route":"/trials/nct06800313/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06834672","kind":"trial","name":"Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","route":"/trials/nct06834672/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05745623","kind":"trial","name":"Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors","route":"/trials/nct05745623/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03947385","kind":"trial","name":"Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions","route":"/trials/nct03947385/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04145622","kind":"trial","name":"Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors","route":"/trials/nct04145622/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04198766","kind":"trial","name":"Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalen","route":"/trials/nct04198766/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06585410","kind":"trial","name":"Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma","route":"/trials/nct06585410/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05862012","kind":"trial","name":"Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)","route":"/trials/nct05862012/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06414460","kind":"trial","name":"Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors","route":"/trials/nct06414460/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06566079","kind":"trial","name":"Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors","route":"/trials/nct06566079/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07680790","kind":"trial","name":"Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based C","route":"/trials/nct07680790/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07100080","kind":"trial","name":"Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy","route":"/trials/nct07100080/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07640295","kind":"trial","name":"Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations","route":"/trials/nct07640295/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04699188","kind":"trial","name":"Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","route":"/trials/nct04699188/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06667960","kind":"trial","name":"Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer","route":"/trials/nct06667960/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06942234","kind":"trial","name":"Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer","route":"/trials/nct06942234/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06253663","kind":"trial","name":"Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic L","route":"/trials/nct06253663/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct01872260","kind":"trial","name":"Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer","route":"/trials/nct01872260/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04501120","kind":"trial","name":"Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML","route":"/trials/nct04501120/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06088290","kind":"trial","name":"Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)","route":"/trials/nct06088290/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05734066","kind":"trial","name":"Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma","route":"/trials/nct05734066/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06128837","kind":"trial","name":"Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer","route":"/trials/nct06128837/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04956640","kind":"trial","name":"Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)","route":"/trials/nct04956640/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07448116","kind":"trial","name":"Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.","route":"/trials/nct07448116/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06885840","kind":"trial","name":"Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.","route":"/trials/nct06885840/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04930432","kind":"trial","name":"Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors","route":"/trials/nct04930432/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05533697","kind":"trial","name":"Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors","route":"/trials/nct05533697/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06783140","kind":"trial","name":"Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer","route":"/trials/nct06783140/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07011654","kind":"trial","name":"Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)","route":"/trials/nct07011654/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06727565","kind":"trial","name":"Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Subst","route":"/trials/nct06727565/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05633667","kind":"trial","name":"Study of Novel Treatment Combinations in Patients With Lung Cancer","route":"/trials/nct05633667/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07520006","kind":"trial","name":"Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies","route":"/trials/nct07520006/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07516093","kind":"trial","name":"Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL","route":"/trials/nct07516093/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06890598","kind":"trial","name":"Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer","route":"/trials/nct06890598/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06161974","kind":"trial","name":"Study of Olutasidenib and Temozolomide in HGG","route":"/trials/nct06161974/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07282587","kind":"trial","name":"Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma","route":"/trials/nct07282587/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06136624","kind":"trial","name":"Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)","route":"/trials/nct06136624/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07079475","kind":"trial","name":"Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)","route":"/trials/nct07079475/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07745361","kind":"trial","name":"Study of Oral MRT-2359 With Apalutamide in Prostate Cancer","route":"/trials/nct07745361/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05287945","kind":"trial","name":"Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma","route":"/trials/nct05287945/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04094311","kind":"trial","name":"Study of Out of Specification for Tisagenlecleucel","route":"/trials/nct04094311/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06596694","kind":"trial","name":"Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)","route":"/trials/nct06596694/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06797635","kind":"trial","name":"Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)","route":"/trials/nct06797635/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06686394","kind":"trial","name":"Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)","route":"/trials/nct06686394/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02861573","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)","route":"/trials/nct02861573/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05609968","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)","route":"/trials/nct05609968/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05239741","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)","route":"/trials/nct05239741/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05173987","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)","route":"/trials/nct05173987/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03725059","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)","route":"/trials/nct03725059/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07777822","kind":"trial","name":"Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mu","route":"/trials/nct07777822/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04380636","kind":"trial","name":"Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)","route":"/trials/nct04380636/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05855200","kind":"trial","name":"Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer","route":"/trials/nct05855200/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07775287","kind":"trial","name":"Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metast","route":"/trials/nct07775287/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07702032","kind":"trial","name":"Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorecta","route":"/trials/nct07702032/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06760637","kind":"trial","name":"Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease","route":"/trials/nct06760637/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04606446","kind":"trial","name":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors","route":"/trials/nct04606446/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07499362","kind":"trial","name":"Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)","route":"/trials/nct07499362/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05450965","kind":"trial","name":"Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer","route":"/trials/nct05450965/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07644039","kind":"trial","name":"Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies","route":"/trials/nct07644039/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06608927","kind":"trial","name":"Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma","route":"/trials/nct06608927/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07638852","kind":"trial","name":"Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.","route":"/trials/nct07638852/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07397338","kind":"trial","name":"Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors","route":"/trials/nct07397338/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06162221","kind":"trial","name":"Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC","route":"/trials/nct06162221/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06445062","kind":"trial","name":"Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors","route":"/trials/nct06445062/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03564340","kind":"trial","name":"Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent","route":"/trials/nct03564340/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07125872","kind":"trial","name":"Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma","route":"/trials/nct07125872/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06118086","kind":"trial","name":"Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma","route":"/trials/nct06118086/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04683250","kind":"trial","name":"Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities","route":"/trials/nct04683250/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07211958","kind":"trial","name":"Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation","route":"/trials/nct07211958/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05379985","kind":"trial","name":"Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","route":"/trials/nct05379985/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05826535","kind":"trial","name":"Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma","route":"/trials/nct05826535/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03767348","kind":"trial","name":"Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)","route":"/trials/nct03767348/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05733598","kind":"trial","name":"Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC","route":"/trials/nct05733598/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05101096","kind":"trial","name":"Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors","route":"/trials/nct05101096/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05186974","kind":"trial","name":"Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)","route":"/trials/nct05186974/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03547973","kind":"trial","name":"Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread","route":"/trials/nct03547973/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06801834","kind":"trial","name":"Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer","route":"/trials/nct06801834/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06486441","kind":"trial","name":"Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Im","route":"/trials/nct06486441/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05840211","kind":"trial","name":"Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy","route":"/trials/nct05840211/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07339059","kind":"trial","name":"Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer","route":"/trials/nct07339059/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07473167","kind":"trial","name":"Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients","route":"/trials/nct07473167/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07201519","kind":"trial","name":"Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy","route":"/trials/nct07201519/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07326566","kind":"trial","name":"Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII","route":"/trials/nct07326566/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07765446","kind":"trial","name":"Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel","route":"/trials/nct07765446/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06252649","kind":"trial","name":"Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal","route":"/trials/nct06252649/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06359847","kind":"trial","name":"Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer","route":"/trials/nct06359847/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05098132","kind":"trial","name":"Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers","route":"/trials/nct05098132/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06191744","kind":"trial","name":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease ","route":"/trials/nct06191744/","detail":"mentions 2037 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05409066","kind":"trial","name":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease ","route":"/trials/nct05409066/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06228053","kind":"trial","name":"Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer","route":"/trials/nct06228053/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03155191","kind":"trial","name":"Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia","route":"/trials/nct03155191/","detail":"mentions 2035 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06731478","kind":"trial","name":"Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer","route":"/trials/nct06731478/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06072612","kind":"trial","name":"Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.","route":"/trials/nct06072612/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06284590","kind":"trial","name":"Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients","route":"/trials/nct06284590/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06726161","kind":"trial","name":"Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC","route":"/trials/nct06726161/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03967977","kind":"trial","name":"Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma","route":"/trials/nct03967977/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07100730","kind":"trial","name":"Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma","route":"/trials/nct07100730/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07022483","kind":"trial","name":"Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer","route":"/trials/nct07022483/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06819007","kind":"trial","name":"Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-","route":"/trials/nct06819007/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06899126","kind":"trial","name":"Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer","route":"/trials/nct06899126/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06431633","kind":"trial","name":"Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.","route":"/trials/nct06431633/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07736937","kind":"trial","name":"Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer","route":"/trials/nct07736937/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07806773","kind":"trial","name":"Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer","route":"/trials/nct07806773/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02899052","kind":"trial","name":"Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)","route":"/trials/nct02899052/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03069469","kind":"trial","name":"Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor","route":"/trials/nct03069469/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06535607","kind":"trial","name":"Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors","route":"/trials/nct06535607/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06079671","kind":"trial","name":"Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)","route":"/trials/nct06079671/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07823049","kind":"trial","name":"Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy","route":"/trials/nct07823049/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06082167","kind":"trial","name":"Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","route":"/trials/nct06082167/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06840483","kind":"trial","name":"Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer","route":"/trials/nct06840483/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06903377","kind":"trial","name":"Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer","route":"/trials/nct06903377/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07080216","kind":"trial","name":"Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer","route":"/trials/nct07080216/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06883526","kind":"trial","name":"Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma","route":"/trials/nct06883526/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06927687","kind":"trial","name":"Study of ZG005 in Patients With Advanced Solid Tumors","route":"/trials/nct06927687/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06938880","kind":"trial","name":"Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors","route":"/trials/nct06938880/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07258121","kind":"trial","name":"Study of ZGGS34 in Participants With Advanced Solid Tumors","route":"/trials/nct07258121/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07805954","kind":"trial","name":"Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mut","route":"/trials/nct07805954/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07621718","kind":"trial","name":"Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-muta","route":"/trials/nct07621718/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02945033","kind":"trial","name":"Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk","route":"/trials/nct02945033/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07726446","kind":"trial","name":"Study on Sequential Cryoablation, Relaforp Alpha, and Chemotherapy for Bile Duct Tumors","route":"/trials/nct07726446/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07104604","kind":"trial","name":"Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Tislelizumab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally","route":"/trials/nct07104604/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07471776","kind":"trial","name":"Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer","route":"/trials/nct07471776/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03040973","kind":"trial","name":"Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone","route":"/trials/nct03040973/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07387471","kind":"trial","name":"Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobu","route":"/trials/nct07387471/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05985655","kind":"trial","name":"Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors","route":"/trials/nct05985655/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04879043","kind":"trial","name":"Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma","route":"/trials/nct04879043/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05546866","kind":"trial","name":"Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm","route":"/trials/nct05546866/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05038735","kind":"trial","name":"Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.","route":"/trials/nct05038735/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07166094","kind":"trial","name":"Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer","route":"/trials/nct07166094/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07288177","kind":"trial","name":"Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer","route":"/trials/nct07288177/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07225270","kind":"trial","name":"Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Re","route":"/trials/nct07225270/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07564141","kind":"trial","name":"Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or","route":"/trials/nct07564141/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06619236","kind":"trial","name":"Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer","route":"/trials/nct06619236/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05257993","kind":"trial","name":"Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Adv","route":"/trials/nct05257993/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07221734","kind":"trial","name":"Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma","route":"/trials/nct07221734/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04464226","kind":"trial","name":"Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer","route":"/trials/nct04464226/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04925479","kind":"trial","name":"Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia","route":"/trials/nct04925479/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07354074","kind":"trial","name":"Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP","route":"/trials/nct07354074/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06632951","kind":"trial","name":"Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)","route":"/trials/nct06632951/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06772623","kind":"trial","name":"Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations","route":"/trials/nct06772623/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nsclc-2","kind":"trial","name":"Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nsclc-2/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04068597","kind":"trial","name":"Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies","route":"/trials/nct04068597/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05379946","kind":"trial","name":"Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors","route":"/trials/nct05379946/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07185997","kind":"trial","name":"Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants W","route":"/trials/nct07185997/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07214779","kind":"trial","name":"Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression","route":"/trials/nct07214779/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05168566","kind":"trial","name":"Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct05168566/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07219238","kind":"trial","name":"Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, o","route":"/trials/nct07219238/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06784752","kind":"trial","name":"Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET","route":"/trials/nct06784752/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06207656","kind":"trial","name":"Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initial","route":"/trials/nct06207656/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07341100","kind":"trial","name":"Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC","route":"/trials/nct07341100/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07427394","kind":"trial","name":"Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer","route":"/trials/nct07427394/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04581512","kind":"trial","name":"Study to Evaluate the Safety and Tolerability of EP0042","route":"/trials/nct04581512/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06922591","kind":"trial","name":"Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients","route":"/trials/nct06922591/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06888843","kind":"trial","name":"Study to Evaluate the Use of Capecitabine in Monotherapy and in Combination With Oxaliplatin in Elderly Patients as Adjuvant Chemotherapy for Locally Advanced C","route":"/trials/nct06888843/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04665206","kind":"trial","name":"Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors","route":"/trials/nct04665206/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05727904","kind":"trial","name":"Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.","route":"/trials/nct05727904/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05725200","kind":"trial","name":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer","route":"/trials/nct05725200/","detail":"mentions 2038 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04349436","kind":"trial","name":"Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies","route":"/trials/nct04349436/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05317416","kind":"trial","name":"Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant","route":"/trials/nct05317416/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06904235","kind":"trial","name":"Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)","route":"/trials/nct06904235/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05676931","kind":"trial","name":"Study With Various Immunotherapy Treatments in Participants With Lung Cancer","route":"/trials/nct05676931/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06998940","kind":"trial","name":"Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations","route":"/trials/nct06998940/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06353386","kind":"trial","name":"Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)","route":"/trials/nct06353386/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06395103","kind":"trial","name":"Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)","route":"/trials/nct06395103/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06780098","kind":"trial","name":"Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)","route":"/trials/nct06780098/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07049926","kind":"trial","name":"Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (","route":"/trials/nct07049926/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06469944","kind":"trial","name":"Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)","route":"/trials/nct06469944/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06445972","kind":"trial","name":"Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)","route":"/trials/nct06445972/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06780111","kind":"trial","name":"Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)","route":"/trials/nct06780111/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-gemstone-302-lancet-oncol-2022","kind":"paper","name":"Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial","route":"/key-papers/paper-gemstone-302-lancet-oncol-2022/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-sung-globocan-2020-cacancer-2021","kind":"paper","name":"Sung 2021: GLOBOCAN 2020, the year breast cancer overtook lung cancer as the most diagnosed cancer","route":"/key-papers/paper-sung-globocan-2020-cacancer-2021/","detail":"mentions 2040 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06743126","kind":"trial","name":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","route":"/trials/nct06743126/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06526793","kind":"trial","name":"Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL","route":"/trials/nct06526793/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07509151","kind":"trial","name":"Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin He","route":"/trials/nct07509151/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06531291","kind":"trial","name":"Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation","route":"/trials/nct06531291/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07833241","kind":"trial","name":"Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC","route":"/trials/nct07833241/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07436741","kind":"trial","name":"Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable P","route":"/trials/nct07436741/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07469956","kind":"trial","name":"Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer","route":"/trials/nct07469956/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06338683","kind":"trial","name":"Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer","route":"/trials/nct06338683/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07322341","kind":"trial","name":"SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer","route":"/trials/nct07322341/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05570825","kind":"trial","name":"SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer","route":"/trials/nct05570825/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07662811","kind":"trial","name":"SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer","route":"/trials/nct07662811/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"symbiotic-gi-03","kind":"trial","name":"Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer","route":"/trials/symbiotic-gi-03/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07227012","kind":"trial","name":"Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a","route":"/trials/nct07227012/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"symbiotic-gi-16","kind":"trial","name":"Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer","route":"/trials/symbiotic-gi-16/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07421700","kind":"trial","name":"Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer","route":"/trials/nct07421700/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07227415","kind":"trial","name":"Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With ","route":"/trials/nct07227415/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"symbiotic-lung-01","kind":"trial","name":"Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","route":"/trials/symbiotic-lung-01/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"symbiotic-lung-04","kind":"trial","name":"Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer","route":"/trials/symbiotic-lung-04/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07489066","kind":"trial","name":"Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC","route":"/trials/nct07489066/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07476287","kind":"trial","name":"Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed","route":"/trials/nct07476287/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07227298","kind":"trial","name":"Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers","route":"/trials/nct07227298/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"sys6010","kind":"drug","name":"SYS6010","route":"/drugs/sys6010/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07633873","kind":"trial","name":"SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNST","route":"/trials/nct07633873/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07442565","kind":"trial","name":"SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase III","route":"/trials/nct07442565/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"sys6023","kind":"drug","name":"SYS6023","route":"/drugs/sys6023/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07472647","kind":"trial","name":"SYS6090 Combination Therapy in Advanced Lung Cancer","route":"/trials/nct07472647/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06681038","kind":"trial","name":"Systemic Antitumor Treatment with or Without Pressurized Intraperitoneal Aerosol Chemotherapy for Colon Peritoneal Metastases (PIPOX02)","route":"/trials/nct06681038/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02885753","kind":"trial","name":"Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal C","route":"/trials/nct02885753/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06045767","kind":"trial","name":"T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer","route":"/trials/nct06045767/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"t3011","kind":"drug","name":"T3011","route":"/drugs/t3011/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05862324","kind":"trial","name":"TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)","route":"/trials/nct05862324/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tac01-cldn18-2","kind":"drug","name":"TAC01-CLDN18.2","route":"/drugs/tac01-cldn18-2/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05548127","kind":"trial","name":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)","route":"/trials/nct05548127/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07786428","kind":"trial","name":"Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC","route":"/trials/nct07786428/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tak-928","kind":"drug","name":"TAK-928","route":"/drugs/tak-928/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06434064","kind":"trial","name":"Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer","route":"/trials/nct06434064/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06914674","kind":"trial","name":"Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas","route":"/trials/nct06914674/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tar-210","kind":"drug","name":"TAR-210","route":"/drugs/tar-210/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tara-002","kind":"drug","name":"TARA-002","route":"/drugs/tara-002/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07598955","kind":"trial","name":"Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma","route":"/trials/nct07598955/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05636618","kind":"trial","name":"Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors","route":"/trials/nct05636618/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"targeted-lung-health-check","kind":"term","name":"Targeted lung health check","route":"/terms/targeted-lung-health-check/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07637513","kind":"trial","name":"Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer","route":"/trials/nct07637513/","detail":"mentions 2027, 2037 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07423585","kind":"trial","name":"Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer","route":"/trials/nct07423585/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05343013","kind":"trial","name":"TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy","route":"/trials/nct05343013/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04701476","kind":"trial","name":"TATE and Pembrolizumab (MK3475) in mCRC and NSCLC","route":"/trials/nct04701476/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-gounder-lancet-oncol","kind":"paper","name":"Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study","route":"/key-papers/paper-gounder-lancet-oncol/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tbi-1301","kind":"drug","name":"TBI-1301","route":"/drugs/tbi-1301/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tbi-1501","kind":"drug","name":"TBI-1501","route":"/drugs/tbi-1501/","detail":"mentions 2035 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tc011","kind":"drug","name":"TC011","route":"/drugs/tc011/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05549297","kind":"trial","name":"Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)","route":"/trials/nct05549297/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05913674","kind":"trial","name":"Technical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC)","route":"/trials/nct05913674/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04851119","kind":"trial","name":"Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors","route":"/trials/nct04851119/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05836870","kind":"trial","name":"Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer","route":"/trials/nct05836870/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06528990","kind":"trial","name":"Telehealth Intervention for Ostomy Self-Management","route":"/trials/nct06528990/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"telisotuzumab-adizutecan","kind":"drug","name":"Telisotuzumab adizutecan","route":"/drugs/telisotuzumab-adizutecan/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07323641","kind":"trial","name":"Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer","route":"/trials/nct07323641/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04919382","kind":"trial","name":"Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer","route":"/trials/nct04919382/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-baumert-lancet-oncol","kind":"paper","name":"Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study","route":"/key-papers/paper-baumert-lancet-oncol/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05128734","kind":"trial","name":"Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)","route":"/trials/nct05128734/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-malmstrom-lancet-oncol","kind":"paper","name":"Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial","route":"/key-papers/paper-malmstrom-lancet-oncol/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07583511","kind":"trial","name":"Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study","route":"/trials/nct07583511/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06908993","kind":"trial","name":"Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated","route":"/trials/nct06908993/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tersolisib","kind":"drug","name":"Tersolisib","route":"/drugs/tersolisib/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tesla-rct","kind":"trial","name":"TESLA RCT","route":"/trials/tesla-rct/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06907342","kind":"trial","name":"Testing a Functional Precision Medicine Approach to Select Chemotherapy for Metastatic Colorectal Cancer (COSENSE-1)","route":"/trials/nct06907342/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05053971","kind":"trial","name":"Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors","route":"/trials/nct05053971/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06958328","kind":"trial","name":"Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer","route":"/trials/nct06958328/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07359456","kind":"trial","name":"Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases","route":"/trials/nct07359456/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06500455","kind":"trial","name":"Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain","route":"/trials/nct06500455/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07437287","kind":"trial","name":"Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers","route":"/trials/nct07437287/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06500481","kind":"trial","name":"Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial","route":"/trials/nct06500481/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05863195","kind":"trial","name":"Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial","route":"/trials/nct05863195/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04172532","kind":"trial","name":"Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer","route":"/trials/nct04172532/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04267848","kind":"trial","name":"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Ch","route":"/trials/nct04267848/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04092283","kind":"trial","name":"Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Anti","route":"/trials/nct04092283/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02997228","kind":"trial","name":"Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study","route":"/trials/nct02997228/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06732401","kind":"trial","name":"Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer","route":"/trials/nct06732401/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05624996","kind":"trial","name":"Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer","route":"/trials/nct05624996/","detail":"mentions 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04929041","kind":"trial","name":"Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Pati","route":"/trials/nct04929041/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05673148","kind":"trial","name":"Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial","route":"/trials/nct05673148/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07551596","kind":"trial","name":"Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial","route":"/trials/nct07551596/","detail":"mentions 2027, 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07619521","kind":"trial","name":"Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma","route":"/trials/nct07619521/","detail":"mentions 2027, 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04068194","kind":"trial","name":"Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies","route":"/trials/nct04068194/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05691491","kind":"trial","name":"Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness","route":"/trials/nct05691491/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07147231","kind":"trial","name":"Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refracto","route":"/trials/nct07147231/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07061951","kind":"trial","name":"Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia","route":"/trials/nct07061951/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07388524","kind":"trial","name":"Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial","route":"/trials/nct07388524/","detail":"mentions 2027, 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03793179","kind":"trial","name":"Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer","route":"/trials/nct03793179/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05710406","kind":"trial","name":"Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer","route":"/trials/nct05710406/","detail":"mentions 2034 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05096663","kind":"trial","name":"Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer","route":"/trials/nct05096663/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07151586","kind":"trial","name":"Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Lo","route":"/trials/nct07151586/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06930118","kind":"trial","name":"The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advan","route":"/trials/nct06930118/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02000089","kind":"trial","name":"The Cancer of the Pancreas Screening-5 CAPS5)Study","route":"/trials/nct02000089/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07704645","kind":"trial","name":"The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer","route":"/trials/nct07704645/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06851299","kind":"trial","name":"The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast","route":"/trials/nct06851299/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-palbociclib-breast-hr-positive-lancet-oncol-2015","kind":"paper","name":"The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study","route":"/key-papers/paper-palbociclib-breast-hr-positive-lancet-oncol-2015/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06355427","kind":"trial","name":"The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma","route":"/trials/nct06355427/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06861088","kind":"trial","name":"The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer","route":"/trials/nct06861088/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06959589","kind":"trial","name":"The Efficacy and Safety of IBI351, Cetuximab β Combined With FOLFIRI as First-line /IBI351, Cetuximab β as Second-line in the Treatment of KRAS G12C-mutated Met","route":"/trials/nct06959589/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07565285","kind":"trial","name":"The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma","route":"/trials/nct07565285/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07514533","kind":"trial","name":"The Efficacy and Safety of Pucotenlimab (PD-1) Combined With Becotatugvedotin (EGFR-ADC) in Advanced Cholangiocarcinoma","route":"/trials/nct07514533/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07160283","kind":"trial","name":"The Efficacy and Safety of Trilaciclib in Bone Marrow Protection Before Chemotherapy for Advanced Bile Duct Cancer and Pancreatic Cancer","route":"/trials/nct07160283/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05984485","kind":"trial","name":"The Efficacy of Primary Total Mesorectal Excision (TME) Surgery Versus Neoadjuvant Chemotherapy Combined With TME Surgery in Low-risk Locally Advanced Rectal Ca","route":"/trials/nct05984485/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05496166","kind":"trial","name":"The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Canc","route":"/trials/nct05496166/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05776381","kind":"trial","name":"The Impact of a Patient Decision Aid on Treatment Choices for Patients With an Unexpected Malignant Colorectal Polyp","route":"/trials/nct05776381/","detail":"mentions 2028, 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07114861","kind":"trial","name":"The KN510713 Study in Combination With mFOLFIRINOX","route":"/trials/nct07114861/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06843551","kind":"trial","name":"The Miami \"EMPIRE\" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation","route":"/trials/nct06843551/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04329728","kind":"trial","name":"The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies","route":"/trials/nct04329728/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06115499","kind":"trial","name":"The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer","route":"/trials/nct06115499/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct02653755","kind":"trial","name":"The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer","route":"/trials/nct02653755/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05422690","kind":"trial","name":"The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer","route":"/trials/nct05422690/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07146230","kind":"trial","name":"The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2","route":"/trials/nct07146230/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06520345","kind":"trial","name":"The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)","route":"/trials/nct06520345/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07134205","kind":"trial","name":"The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer","route":"/trials/nct07134205/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04871412","kind":"trial","name":"The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial - Stage III","route":"/trials/nct04871412/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05771584","kind":"trial","name":"Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer","route":"/trials/nct05771584/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05063565","kind":"trial","name":"TheraSphere With Durvalumab and Tremelimumab for HCC","route":"/trials/nct05063565/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05208944","kind":"trial","name":"THIO Sequenced With Cemiplimab in Advanced NSCLC","route":"/trials/nct05208944/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06758401","kind":"trial","name":"This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lu","route":"/trials/nct06758401/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07649122","kind":"trial","name":"This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.","route":"/trials/nct07649122/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07028853","kind":"trial","name":"This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking En","route":"/trials/nct07028853/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06865339","kind":"trial","name":"Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer","route":"/trials/nct06865339/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05086614","kind":"trial","name":"Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer","route":"/trials/nct05086614/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07074106","kind":"trial","name":"TIL-Driven De-escalated Chemotherapy in Stage I-II TNBC","route":"/trials/nct07074106/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-cho-lancet-oncol","kind":"paper","name":"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study","route":"/key-papers/paper-cho-lancet-oncol/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06332274","kind":"trial","name":"tislelizUMaB in canceR Patients With molEcuLar residuaL Disease","route":"/trials/nct06332274/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07681297","kind":"trial","name":"Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Dis","route":"/trials/nct07681297/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06529523","kind":"trial","name":"Tislelizumab in People With Colorectal Cancer","route":"/trials/nct06529523/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07155525","kind":"trial","name":"Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas","route":"/trials/nct07155525/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tng456","kind":"drug","name":"TNG456","route":"/drugs/tng456/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tng462","kind":"drug","name":"TNG462","route":"/drugs/tng462/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05646511","kind":"trial","name":"TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer","route":"/trials/nct05646511/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06072131","kind":"trial","name":"To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL","route":"/trials/nct06072131/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06504732","kind":"trial","name":"To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer","route":"/trials/nct06504732/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06478719","kind":"trial","name":"To Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization","route":"/trials/nct06478719/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07795034","kind":"trial","name":"To Evaluate the Efficacy and Safety of Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) Combined With NBB-001 and NBB-002 for Patients With Recurrent Head and Neck Malignancies","route":"/trials/nct07795034/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05541822","kind":"trial","name":"To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation","route":"/trials/nct05541822/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07454187","kind":"trial","name":"To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct07454187/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06378242","kind":"trial","name":"To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2","route":"/trials/nct06378242/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07368998","kind":"trial","name":"To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer","route":"/trials/nct07368998/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06290869","kind":"trial","name":"Tobacco Education and Lung Health Study (TEAL)","route":"/trials/nct06290869/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05846789","kind":"trial","name":"Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers","route":"/trials/nct05846789/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07256964","kind":"trial","name":"Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer","route":"/trials/nct07256964/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06903858","kind":"trial","name":"Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer","route":"/trials/nct06903858/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07819578","kind":"trial","name":"Toripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable NSCLC","route":"/trials/nct07819578/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07810114","kind":"trial","name":"Total Neoadjuvant mFOLFOX6 Plus Suvemcitug and Enlonstobart With Selective Omission of Pelvic Radiotherapy for High-Risk Mid-Rectal Locally Advanced Rectal Canc","route":"/trials/nct07810114/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06758830","kind":"trial","name":"Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.","route":"/trials/nct06758830/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04643366","kind":"trial","name":"Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer","route":"/trials/nct04643366/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07214142","kind":"trial","name":"Total Neoadjuvant Therapy With PD-1 for Locally Advcancer Rectal Cancer","route":"/trials/nct07214142/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06229041","kind":"trial","name":"Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi)","route":"/trials/nct06229041/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06940388","kind":"trial","name":"Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer.","route":"/trials/nct06940388/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tovecimig","kind":"drug","name":"Tovecimig","route":"/drugs/tovecimig/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07662031","kind":"trial","name":"Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer","route":"/trials/nct07662031/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tq-b3234","kind":"drug","name":"TQ-B3234","route":"/drugs/tq-b3234/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tqb2102","kind":"drug","name":"TQB2102","route":"/drugs/tqb2102/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tqb2930","kind":"drug","name":"TQB2930","route":"/drugs/tqb2930/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07047365","kind":"trial","name":"TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer","route":"/trials/nct07047365/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tqb6411","kind":"drug","name":"TQB6411","route":"/drugs/tqb6411/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tracc","kind":"trial","name":"TRACC","route":"/trials/tracc/","detail":"mentions 2029, 2031 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06951399","kind":"trial","name":"Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer","route":"/trials/nct06951399/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03755739","kind":"trial","name":"Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors","route":"/trials/nct03755739/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"transcend","kind":"trial","name":"TRANSCEND","route":"/trials/transcend/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"transform-prostate","kind":"trial","name":"TRANSFORM","route":"/trials/transform-prostate/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"transgene","kind":"company","name":"Transgene","route":"/companies/transgene/","detail":"mentions 2027, 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05950945","kind":"trial","name":"Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer","route":"/trials/nct05950945/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-destiny-crc02-lancet-oncol-2024","kind":"paper","name":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial","route":"/key-papers/paper-destiny-crc02-lancet-oncol-2024/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-nct04639219-lancet-oncol-2024","kind":"paper","name":"Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study","route":"/key-papers/paper-nct04639219-lancet-oncol-2024/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07506057","kind":"trial","name":"Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy","route":"/trials/nct07506057/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07062263","kind":"trial","name":"Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients","route":"/trials/nct07062263/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07129018","kind":"trial","name":"Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer","route":"/trials/nct07129018/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05965531","kind":"trial","name":"Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy","route":"/trials/nct05965531/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04423211","kind":"trial","name":"Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging","route":"/trials/nct04423211/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05294731","kind":"trial","name":"Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader","route":"/trials/nct05294731/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03206671","kind":"trial","name":"Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents","route":"/trials/nct03206671/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07271992","kind":"trial","name":"TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer","route":"/trials/nct07271992/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tri-611","kind":"drug","name":"TRI-611","route":"/drugs/tri-611/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07282912","kind":"trial","name":"Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels","route":"/trials/nct07282912/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05988814","kind":"trial","name":"Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Li","route":"/trials/nct05988814/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07246863","kind":"trial","name":"Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC","route":"/trials/nct07246863/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07098988","kind":"trial","name":"Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC","route":"/trials/nct07098988/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06590857","kind":"trial","name":"Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.","route":"/trials/nct06590857/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07042685","kind":"trial","name":"Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer","route":"/trials/nct07042685/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06617858","kind":"trial","name":"Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment","route":"/trials/nct06617858/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07689539","kind":"trial","name":"Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation","route":"/trials/nct07689539/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06510374","kind":"trial","name":"Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer","route":"/trials/nct06510374/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07109414","kind":"trial","name":"Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)","route":"/trials/nct07109414/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07216443","kind":"trial","name":"Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome","route":"/trials/nct07216443/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07064018","kind":"trial","name":"Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies","route":"/trials/nct07064018/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05254327","kind":"trial","name":"Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001","route":"/trials/nct05254327/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04542824","kind":"trial","name":"Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)","route":"/trials/nct04542824/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06618235","kind":"trial","name":"Trial of THEO-260 in Ovarian Cancer Patients","route":"/trials/nct06618235/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06472245","kind":"trial","name":"Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor","route":"/trials/nct06472245/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06291064","kind":"trial","name":"Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer","route":"/trials/nct06291064/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06635824","kind":"trial","name":"Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)","route":"/trials/nct06635824/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07805252","kind":"trial","name":"Trial to Study the Safety, Pharmacokinetics and Preliminary Antitumour Activity of ODM-216 in Patients With Cancer","route":"/trials/nct07805252/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06569368","kind":"trial","name":"Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy","route":"/trials/nct06569368/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05007132","kind":"trial","name":"Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer","route":"/trials/nct05007132/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07146646","kind":"trial","name":"Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer","route":"/trials/nct07146646/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07261709","kind":"trial","name":"Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-","route":"/trials/nct07261709/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06992648","kind":"trial","name":"Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer","route":"/trials/nct06992648/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07104266","kind":"trial","name":"Triple Negative Breast Cancer and Celecoxib. Pilot Study","route":"/trials/nct07104266/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","detail":"mentions 2038, 2040, 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05187338","kind":"trial","name":"Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors","route":"/trials/nct05187338/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06851663","kind":"trial","name":"Trop2-targeted immunoPET Imaging of Solid Tumors","route":"/trials/nct06851663/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tropion-breast03","kind":"trial","name":"TROPION-Breast03","route":"/trials/tropion-breast03/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tropion-breast05","kind":"trial","name":"TROPION-Breast05","route":"/trials/tropion-breast05/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"tscan","kind":"company","name":"TScan Therapeutics","route":"/companies/tscan/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04969315","kind":"trial","name":"TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma","route":"/trials/nct04969315/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07284277","kind":"trial","name":"TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)","route":"/trials/nct07284277/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05458674","kind":"trial","name":"Tucatinib+Trastuzumab+Eribulin in HER2+ MBC","route":"/trials/nct05458674/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06947967","kind":"trial","name":"Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype","route":"/trials/nct06947967/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-jiang-lancet-oncol","kind":"paper","name":"Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-jiang-lancet-oncol/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07190300","kind":"trial","name":"TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in ","route":"/trials/nct07190300/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06949098","kind":"trial","name":"Tumor Local Excision +Postoperative Adjuvant Chemoradiotherapy for T1-2N0M0 Low/Ultra-Low Rectal Cancer","route":"/trials/nct06949098/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03977233","kind":"trial","name":"Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer","route":"/trials/nct03977233/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04589845","kind":"trial","name":"Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study","route":"/trials/nct04589845/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07267078","kind":"trial","name":"Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer","route":"/trials/nct07267078/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04513717","kind":"trial","name":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial","route":"/trials/nct04513717/","detail":"mentions 2033 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"ugn-104","kind":"drug","name":"UGN-104","route":"/drugs/ugn-104/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"uliledlimab","kind":"drug","name":"Uliledlimab","route":"/drugs/uliledlimab/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06955325","kind":"trial","name":"Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations","route":"/trials/nct06955325/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07503639","kind":"trial","name":"Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer","route":"/trials/nct07503639/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07407465","kind":"trial","name":"Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.","route":"/trials/nct07407465/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07217704","kind":"trial","name":"Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.","route":"/trials/nct07217704/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06813079","kind":"trial","name":"Using Tumor Models to Determine Treatments","route":"/trials/nct06813079/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"vanguard-study","kind":"trial","name":"Vanguard Study (NCI Cancer Screening Research Network)","route":"/trials/vanguard-study/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07472933","kind":"trial","name":"Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies","route":"/trials/nct07472933/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07655622","kind":"trial","name":"Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression","route":"/trials/nct07655622/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06970782","kind":"trial","name":"Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failur","route":"/trials/nct06970782/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"velzatinib","kind":"drug","name":"Velzatinib","route":"/drugs/velzatinib/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06127654","kind":"trial","name":"Ventilation Imaging to Improve the Quality of Life for Patients With Lung Cancer Treated With Radiation Therapy","route":"/trials/nct06127654/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"vepugratinib","kind":"drug","name":"Vepugratinib","route":"/drugs/vepugratinib/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07765836","kind":"trial","name":"Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC","route":"/trials/nct07765836/","detail":"mentions 2027, 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-bisogno-lancet-oncol","kind":"paper","name":"Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial","route":"/key-papers/paper-bisogno-lancet-oncol/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07219459","kind":"trial","name":"Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)","route":"/trials/nct07219459/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct03556228","kind":"trial","name":"VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma","route":"/trials/nct03556228/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06264180","kind":"trial","name":"VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]","route":"/trials/nct06264180/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06448754","kind":"trial","name":"Volrustomig Priming Regimens Exploratory Phase II Platform Study","route":"/trials/nct06448754/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07047001","kind":"trial","name":"Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma","route":"/trials/nct07047001/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"vrn110755","kind":"drug","name":"VRN110755","route":"/drugs/vrn110755/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"vs-7375","kind":"drug","name":"VS-7375","route":"/drugs/vs-7375/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06222489","kind":"trial","name":"Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT","route":"/trials/nct06222489/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"wisdom-trial","kind":"trial","name":"WISDOM (Women Informed to Screen Depending on Measures of Risk)","route":"/trials/wisdom-trial/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct04644289","kind":"trial","name":"WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC","route":"/trials/nct04644289/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07381777","kind":"trial","name":"XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC)","route":"/trials/nct07381777/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"xencor","kind":"company","name":"Xencor","route":"/companies/xencor/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05709249","kind":"trial","name":"Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer","route":"/trials/nct05709249/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"xilio-therapeutics","kind":"company","name":"Xilio Therapeutics","route":"/companies/xilio-therapeutics/","detail":"mentions 2027, 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05275374","kind":"trial","name":"XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation","route":"/trials/nct05275374/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06936527","kind":"trial","name":"XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation","route":"/trials/nct06936527/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05684965","kind":"trial","name":"XTX301 in Patients With Advanced Solid Tumors","route":"/trials/nct05684965/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07688577","kind":"trial","name":"XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors","route":"/trials/nct07688577/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07596290","kind":"trial","name":"Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC","route":"/trials/nct07596290/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06662669","kind":"trial","name":"YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer","route":"/trials/nct06662669/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"yl202","kind":"drug","name":"YL202","route":"/drugs/yl202/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07461454","kind":"trial","name":"YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer","route":"/trials/nct07461454/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07405476","kind":"trial","name":"Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment","route":"/trials/nct07405476/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-harding-lancet-oncol","kind":"paper","name":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","route":"/key-papers/paper-harding-lancet-oncol/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-zanubrutinib-cll-lancet-oncol-2022","kind":"paper","name":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","route":"/key-papers/paper-zanubrutinib-cll-lancet-oncol-2022/","detail":"mentions 2045 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"zanzalintinib","kind":"drug","name":"Zanzalintinib","route":"/drugs/zanzalintinib/","detail":"mentions 2032 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07750158","kind":"trial","name":"Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease","route":"/trials/nct07750158/","detail":"mentions 2030 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06943755","kind":"trial","name":"Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors","route":"/trials/nct06943755/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct06933329","kind":"trial","name":"Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct06933329/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"zg006","kind":"drug","name":"ZG006","route":"/drugs/zg006/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07038096","kind":"trial","name":"ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma","route":"/trials/nct07038096/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct05502237","kind":"trial","name":"Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer","route":"/trials/nct05502237/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"zipalertinib","kind":"drug","name":"Zipalertinib","route":"/drugs/zipalertinib/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07229339","kind":"trial","name":"Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer","route":"/trials/nct07229339/","detail":"mentions 2027, 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"zl-1310","kind":"drug","name":"ZL-1310","route":"/drugs/zl-1310/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07723534","kind":"trial","name":"Zolbetuximab With mFOLFOX6 or CAPOX in Claudin 18.2 Overexpressed Advanced or Metastatic Biliary Tract Cancers","route":"/trials/nct07723534/","detail":"mentions 2029 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"nct07551414","kind":"trial","name":"Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI","route":"/trials/nct07551414/","detail":"mentions 2027 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"zovegalisib","kind":"drug","name":"Zovegalisib","route":"/drugs/zovegalisib/","detail":"mentions 2028 (looks forward-looking)"},{"check":"future-year-in-text","severity":"low","id":"paper-cowan-lancet-oncol","kind":"paper","name":"γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial","route":"/key-papers/paper-cowan-lancet-oncol/","detail":"mentions 2045 (looks forward-looking)"},{"check":"name-collision-across-kinds","severity":"low","id":"seven-plus-three","kind":"term","name":"7+3 induction chemotherapy","route":"/terms/seven-plus-three/","detail":"\"cytarabine anthracycline\" is also Cytarabine + anthracycline ('7+3') (cytarabine-7-3, drug); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"seven-plus-three","kind":"term","name":"7+3 induction chemotherapy","route":"/terms/seven-plus-three/","detail":"\"cpx 351\" is also CPX-351 (liposomal daunorubicin-cytarabine) (cpx-351, drug); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"nct04501523","kind":"trial","name":"A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC","route":"/trials/nct04501523/","detail":"\"apollo\" is also DCLRE1B (dclre1b, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"nct02489318","kind":"trial","name":"A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC","route":"/trials/nct02489318/","detail":"\"titan\" is also TITAN (whole-slide multimodal model) (titan, technology); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"nct03862430","kind":"trial","name":"A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM","route":"/trials/nct03862430/","detail":"\"restore\" is also RESTORE: bipolar androgen therapy after progression on enzalutamide in metastatic castration-resistant prostate cancer (paper-teply-restore-bipolar-androgen-therapy-lancet-oncol-2018, paper); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"adenocarcinoma","kind":"term","name":"Adenocarcinoma","route":"/terms/adenocarcinoma/","detail":"\"ductal adenocarcinoma\" is also Ductal adenocarcinoma of the prostate (prostate-ductal-adenocarcinoma, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"adenocarcinoma","kind":"term","name":"Adenocarcinoma","route":"/terms/adenocarcinoma/","detail":"\"adenocarcinoma\" is also Adenocarcinoma of the urethra (including clear cell adenocarcinoma) (urethral-adenocarcinoma, cancer), Adenocarcinoma of the lung (lung-adenocarcinoma, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"adenocarcinoma","kind":"term","name":"Adenocarcinoma","route":"/terms/adenocarcinoma/","detail":"\"invasive lobular carcinoma\" is also Invasive lobular carcinoma of the breast (invasive-lobular-carcinoma, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"lung-adenocarcinoma","kind":"cancer","name":"Adenocarcinoma of the lung","route":"/cancers/lung-adenocarcinoma/","detail":"\"adenocarcinoma\" is also Adenocarcinoma (adenocarcinoma, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"urethral-adenocarcinoma","kind":"cancer","name":"Adenocarcinoma of the urethra (including clear cell adenocarcinoma)","route":"/cancers/urethral-adenocarcinoma/","detail":"\"adenocarcinoma\" is also Adenocarcinoma (adenocarcinoma, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"affirm","kind":"trial","name":"AFFIRM","route":"/trials/affirm/","detail":"\"affirm\" is also AFFIRM: increased survival with enzalutamide in prostate cancer after chemotherapy (paper-scher-affirm-enzalutamide-nejm-2012, paper); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"paper-scher-affirm-enzalutamide-nejm-2012","kind":"paper","name":"AFFIRM: increased survival with enzalutamide in prostate cancer after chemotherapy","route":"/key-papers/paper-scher-affirm-enzalutamide-nejm-2012/","detail":"\"affirm\" is also AFFIRM (affirm, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"anvisa","kind":"institution","name":"Agência Nacional de Vigilância Sanitária","route":"/institutions/anvisa/","detail":"\"anvisa\" is also Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA) (regulatory-agencies, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"alk-resistance-mutation","kind":"biomarker","name":"ALK kinase-domain resistance mutation (G1202R and the rest)","route":"/biomarkers/alk-resistance-mutation/","detail":"\"g1202r\" is also On-target resistance mutations (gatekeeper, solvent-front, compound) (gatekeeper-mutation, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"allogeneic-transplant","kind":"term","name":"Allogeneic stem cell transplant (allo-SCT)","route":"/terms/allogeneic-transplant/","detail":"\"allogeneic stem cell transplantation\" is also Allogeneic stem cell transplantation (allogeneic-hsct, technology); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"allogeneic-hsct","kind":"technology","name":"Allogeneic stem cell transplantation","route":"/technologies/allogeneic-hsct/","detail":"\"allogeneic stem cell transplantation\" is also Allogeneic stem cell transplant (allo-SCT) (allogeneic-transplant, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"nct02531516","kind":"trial","name":"An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS","route":"/trials/nct02531516/","detail":"\"atlas\" is also Atlas (Aignostics, Mayo Clinic, Charité) (atlas-aignostics, technology); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"anaemia","kind":"term","name":"Anaemia","route":"/terms/anaemia/","detail":"\"erythropoiesis stimulating agent\" is also Epoetin alfa (epoetin-alfa, drug); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"arpi","kind":"term","name":"Androgen receptor pathway inhibitor (ARPI)","route":"/terms/arpi/","detail":"\"ar v7\" is also AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer (paper-antonarakis-ar-v7-resistance-nejm-2014, paper), AR-V7 splice variant (ar-v7-splice-variant, biomarker); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"paper-young-angiosarcoma-review-lancet-oncol-2010","kind":"paper","name":"Angiosarcoma (review)","route":"/key-papers/paper-young-angiosarcoma-review-lancet-oncol-2010/","detail":"\"angiosarcoma\" is also Vascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma) (vascular-tumours, cancer), Angiosarcoma (angiosarcoma, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"paper-antonarakis-ar-v7-resistance-nejm-2014","kind":"paper","name":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","route":"/key-papers/paper-antonarakis-ar-v7-resistance-nejm-2014/","detail":"\"ar v7\" is also Androgen receptor pathway inhibitor (ARPI) (arpi, term), AR-V7 splice variant (ar-v7-splice-variant, biomarker); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"ar-v7-splice-variant","kind":"biomarker","name":"AR-V7 splice variant","route":"/biomarkers/ar-v7-splice-variant/","detail":"\"ar v7\" is also AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer (paper-antonarakis-ar-v7-resistance-nejm-2014, paper), Androgen receptor pathway inhibitor (ARPI) (arpi, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"ascl1","kind":"target","name":"ASCL1","route":"/targets/ascl1/","detail":"\"ascl1\" is also Small-cell lung cancer transcription-factor subtypes (SCLC-A, SCLC-N, SCLC-P, SCLC-I) and SLFN11 (sclc-molecular-subtypes, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"atlas-aignostics","kind":"technology","name":"Atlas (Aignostics, Mayo Clinic, Charité)","route":"/technologies/atlas-aignostics/","detail":"\"atlas\" is also An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS (nct02531516, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"autologous-transplant","kind":"term","name":"Autologous stem cell transplant (ASCT)","route":"/terms/autologous-transplant/","detail":"\"autologous stem cell transplant\" is also Autologous stem cell transplant (high-dose therapy) (autologous-stem-cell-transplant, technology); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"autologous-stem-cell-transplant","kind":"technology","name":"Autologous stem cell transplant (high-dose therapy)","route":"/technologies/autologous-stem-cell-transplant/","detail":"\"autologous stem cell transplant\" is also Autologous stem cell transplant (ASCT) (autologous-transplant, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"b2m","kind":"target","name":"B2M","route":"/targets/b2m/","detail":"\"beta 2 microglobulin\" is also R-ISS / R2-ISS staging (r-iss, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"bap1","kind":"target","name":"BAP1","route":"/targets/bap1/","detail":"\"bap1\" is also BAP1 loss (bap1-loss, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"bap1-loss","kind":"term","name":"BAP1 loss","route":"/terms/bap1-loss/","detail":"\"bap1\" is also BAP1 (bap1, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"basaloid-squamous-cell-carcinoma-lung","kind":"cancer","name":"Basaloid squamous cell carcinoma of the lung","route":"/cancers/basaloid-squamous-cell-carcinoma-lung/","detail":"\"basaloid squamous cell carcinoma\" is also The subtype and grade on a cutaneous squamous cell carcinoma report (cscc-subtype-and-grade, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"bcr-abl","kind":"target","name":"BCR::ABL1 (Philadelphia chromosome)","route":"/targets/bcr-abl/","detail":"\"bcr abl1\" is also BCR::ABL1 (Philadelphia chromosome) (bcr-abl1-signalling, pathway), Philadelphia chromosome (Ph+, BCR::ABL1) (philadelphia-chromosome, term), BCR::ABL1 transcript (Philadelphia chromosome, quantitative PCR) (bcr-abl1-transcript, biomarker); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"bcr-abl1-signalling","kind":"pathway","name":"BCR::ABL1 (Philadelphia chromosome)","route":"/pathways/bcr-abl1-signalling/","detail":"\"bcr abl1\" is also BCR::ABL1 (Philadelphia chromosome) (bcr-abl, target), Philadelphia chromosome (Ph+, BCR::ABL1) (philadelphia-chromosome, term), BCR::ABL1 transcript (Philadelphia chromosome, quantitative PCR) (bcr-abl1-transcript, biomarker); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"bcr-abl1-transcript","kind":"biomarker","name":"BCR::ABL1 transcript (Philadelphia chromosome, quantitative PCR)","route":"/biomarkers/bcr-abl1-transcript/","detail":"\"bcr abl1\" is also BCR::ABL1 (Philadelphia chromosome) (bcr-abl, target), BCR::ABL1 (Philadelphia chromosome) (bcr-abl1-signalling, pathway), Philadelphia chromosome (Ph+, BCR::ABL1) (philadelphia-chromosome, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"prostate-bcr","kind":"cancer","name":"Biochemical recurrence of prostate cancer","route":"/cancers/prostate-bcr/","detail":"\"psa recurrence\" is also mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer) (mcrpc-mhspc, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"bladder-cancer-signalling","kind":"pathway","name":"Bladder cancer (KEGG map)","route":"/pathways/bladder-cancer-signalling/","detail":"\"urothelial carcinoma\" is also Urothelial carcinoma of the urethra (urethral-urothelial-carcinoma, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"paper-achrol-nat-rev-dis-primers","kind":"paper","name":"Brain metastases","route":"/key-papers/paper-achrol-nat-rev-dis-primers/","detail":"\"brain metastases\" is also Brain metastases (intracranial disease) (brain-metastases, term), Brain metastases (secondary brain tumours) (secondary-brain-tumours, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"brain-metastases","kind":"term","name":"Brain metastases (intracranial disease)","route":"/terms/brain-metastases/","detail":"\"brain metastases\" is also Brain metastases (paper-achrol-nat-rev-dis-primers, paper), Brain metastases (secondary brain tumours) (secondary-brain-tumours, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"secondary-brain-tumours","kind":"cancer","name":"Brain metastases (secondary brain tumours)","route":"/cancers/secondary-brain-tumours/","detail":"\"brain metastases\" is also Brain metastases (paper-achrol-nat-rev-dis-primers, paper), Brain metastases (intracranial disease) (brain-metastases, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"paper-harbeck-nat-rev-dis-primers","kind":"paper","name":"Breast cancer","route":"/key-papers/paper-harbeck-nat-rev-dis-primers/","detail":"\"breast cancer\" is also Breast cancer (KEGG map) (breast-cancer-signalling, pathway), Breast cancer (breast-cancer-jbcs, journal), Breast cancer (all types) (breast-cancer, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"breast-cancer-jbcs","kind":"journal","name":"Breast cancer","route":"/journals/breast-cancer-jbcs/","detail":"\"breast cancer\" is also Breast cancer (paper-harbeck-nat-rev-dis-primers, paper), Breast cancer (KEGG map) (breast-cancer-signalling, pathway), Breast cancer (all types) (breast-cancer, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","detail":"\"breast cancer\" is also Breast cancer (paper-harbeck-nat-rev-dis-primers, paper), Breast cancer (KEGG map) (breast-cancer-signalling, pathway), Breast cancer (breast-cancer-jbcs, journal); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"breast-cancer-signalling","kind":"pathway","name":"Breast cancer (KEGG map)","route":"/pathways/breast-cancer-signalling/","detail":"\"breast cancer\" is also Breast cancer (paper-harbeck-nat-rev-dis-primers, paper), Breast cancer (breast-cancer-jbcs, journal), Breast cancer (all types) (breast-cancer, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"btki-bcl2i-resistance-mutations","kind":"term","name":"BTK C481S, PLCG2 and BCL2 G101V resistance mutations","route":"/terms/btki-bcl2i-resistance-mutations/","detail":"\"plcg2\" is also PLCG2 (plcg2, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"met-overexpression","kind":"biomarker","name":"c-Met protein overexpression (IHC 3+ in >= 50% of tumour cells)","route":"/biomarkers/met-overexpression/","detail":"\"met overexpression\" is also MET exon 14 skipping mutation (met-exon-14-skipping, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"calr","kind":"target","name":"CALR","route":"/targets/calr/","detail":"\"calr\" is also MPN driver mutations (JAK2 V617F, CALR, MPL) and allele burden (mpn-driver-mutations, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"camel","kind":"trial","name":"CameL","route":"/trials/camel/","detail":"\"camel\" is also CTAG2 (ctag2, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"cancer-of-unknown-primary","kind":"cancer","name":"Cancer of unknown primary (CUP)","route":"/cancers/cancer-of-unknown-primary/","detail":"\"cancer of unknown primary\" is also Primary tumour (primary-tumour, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/","detail":"\"capox\" is also FOLFOX, FOLFIRI, FOLFIRINOX and CAPOX (folfox-family, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"caps-consortium-pancreatic-screening","kind":"term","name":"CAPS: the Cancer of the Pancreas Screening consortium and its surveillance studies (CAPS1 to CAPS5)","route":"/terms/caps-consortium-pancreatic-screening/","detail":"\"caps5\" is also The Cancer of the Pancreas Screening-5 CAPS5)Study (nct02000089, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"carers-breast-cancer-uk","kind":"term","name":"Carers: what you can do and UK carer support (breast cancer)","route":"/terms/carers-breast-cancer-uk/","detail":"\"caregiver\" is also Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a \"Window of Opportunity\" Study (nct05067530, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"carers-pancreatic-cancer-uk","kind":"term","name":"Carers: what you can do and UK carer support (pancreatic cancer)","route":"/terms/carers-pancreatic-cancer-uk/","detail":"\"caregiver\" is also Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a \"Window of Opportunity\" Study (nct05067530, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"ccnd1","kind":"target","name":"CCND1","route":"/targets/ccnd1/","detail":"\"cyclin d1\" is also t(11;14), cyclin D1 and SOX11 (cyclin-d1-t11-14, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"cell","kind":"journal","name":"Cell","route":"/journals/cell/","detail":"\"cell\" is also Cell (cell-term, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"cell-term","kind":"term","name":"Cell","route":"/terms/cell-term/","detail":"\"cell\" is also Cell (cell, journal); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"central-venous-access","kind":"term","name":"Central venous access (port, PICC line)","route":"/terms/central-venous-access/","detail":"\"picc\" is also Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer (nct03926338, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"celmods","kind":"technology","name":"Cereblon E3 ligase modulators (CELMoDs)","route":"/technologies/celmods/","detail":"\"cereblon e3 ligase modulators\" is also Immunomodulatory drugs (IMiDs) and CELMoDs (imid, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"chan-zuckerberg-initiative","kind":"company","name":"Chan Zuckerberg Initiative (Biohub)","route":"/companies/chan-zuckerberg-initiative/","detail":"\"chan zuckerberg initiative\" is also Priscilla Chan (priscilla-chan, person); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"chemoprevention-and-er-negative-breast-cancer","kind":"term","name":"Chemoprevention (tamoxifen, anastrozole, raloxifene) and ER-negative breast cancer","route":"/terms/chemoprevention-and-er-negative-breast-cancer/","detail":"\"ibis i\" is also IBIS-I (International Breast Intervention Study I) (ibis-i, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"chemoprevention-and-er-negative-breast-cancer","kind":"term","name":"Chemoprevention (tamoxifen, anastrozole, raloxifene) and ER-negative breast cancer","route":"/terms/chemoprevention-and-er-negative-breast-cancer/","detail":"\"ibis ii\" is also IBIS-II (International Breast Intervention Study II) (ibis-ii, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","detail":"\"colorectal cancer\" is also Colorectal cancer (paper-dekker-lancet, paper), Colorectal cancer (KEGG map) (colorectal-cancer-signalling, pathway); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"paper-dekker-lancet","kind":"paper","name":"Colorectal cancer","route":"/key-papers/paper-dekker-lancet/","detail":"\"colorectal cancer\" is also Colorectal cancer (colorectal, cancer), Colorectal cancer (KEGG map) (colorectal-cancer-signalling, pathway); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"cpx-351","kind":"drug","name":"CPX-351 (liposomal daunorubicin-cytarabine)","route":"/drugs/cpx-351/","detail":"\"cpx 351\" is also 7+3 induction chemotherapy (seven-plus-three, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"crc01","kind":"drug","name":"CRC01","route":"/drugs/crc01/","detail":"\"crc01\" is also Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer (nct06226857, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"cribriform-prostate-cancer","kind":"term","name":"Cribriform growth pattern in prostate cancer","route":"/terms/cribriform-prostate-cancer/","detail":"\"invasive cribriform carcinoma\" is also Invasive cribriform carcinoma of the breast (invasive-cribriform-carcinoma-breast, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"ctag2","kind":"target","name":"CTAG2","route":"/targets/ctag2/","detail":"\"camel\" is also CameL (camel, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"nct05067530","kind":"trial","name":"Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a \"Window of Opportunity\" Study","route":"/trials/nct05067530/","detail":"\"caregiver\" is also Carers: what you can do and UK carer support (pancreatic cancer) (carers-pancreatic-cancer-uk, term), Carers: what you can do and UK carer support (breast cancer) (carers-breast-cancer-uk, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"cysltr2","kind":"target","name":"CYSLTR2","route":"/targets/cysltr2/","detail":"\"cysltr2\" is also Uveal melanoma prognostic markers (GNAQ/GNA11, monosomy 3, gene-expression class) (uveal-melanoma-prognostic-markers, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"cytarabine-7-3","kind":"drug","name":"Cytarabine + anthracycline ('7+3')","route":"/drugs/cytarabine-7-3/","detail":"\"cytarabine anthracycline\" is also 7+3 induction chemotherapy (seven-plus-three, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"cytogenetics","kind":"term","name":"Cytogenetics and karyotype","route":"/terms/cytogenetics/","detail":"\"translocation\" is also TFE3-rearranged (translocation) renal cell carcinoma (tfe3-rearranged-renal-cell-carcinoma, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"dclre1b","kind":"target","name":"DCLRE1B","route":"/targets/dclre1b/","detail":"\"apollo\" is also A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC (nct04501523, trial), Study of AZD0754 in Participants With Metastatic Prostate Cancer (nct06267729, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"deletion","kind":"term","name":"Deletion","route":"/terms/deletion/","detail":"\"exon 19 deletion\" is also EGFR exon 19 deletion (egfr-exon-19-deletion, biomarker); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"staging-systems","kind":"term","name":"Disease-specific staging and risk systems (FIGO, Ann Arbor, IPI, R-ISS, ELN, IMDC)","route":"/terms/staging-systems/","detail":"\"uicc\" is also Union for International Cancer Control (uicc, institution); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"nct06275958","kind":"trial","name":"DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer","route":"/trials/nct06275958/","detail":"\"dosage\" is also Dose (dose, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"dose","kind":"term","name":"Dose","route":"/terms/dose/","detail":"\"dosage\" is also DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer (nct06275958, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"prostate-ductal-adenocarcinoma","kind":"cancer","name":"Ductal adenocarcinoma of the prostate","route":"/cancers/prostate-ductal-adenocarcinoma/","detail":"\"ductal adenocarcinoma\" is also Adenocarcinoma (adenocarcinoma, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"ductal-carcinoma-in-situ","kind":"cancer","name":"Ductal carcinoma in situ (DCIS)","route":"/cancers/ductal-carcinoma-in-situ/","detail":"\"intraductal carcinoma\" is also Intraductal carcinoma of the prostate (IDC-P) (intraductal-carcinoma-prostate, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"ecog-acrin","kind":"company","name":"ECOG-ACRIN Cancer Research Group","route":"/companies/ecog-acrin/","detail":"\"ecog\" is also Quality of life (quality-of-life, term), Performance status (ECOG, Karnofsky) (performance-status, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"egf","kind":"target","name":"EGF","route":"/targets/egf/","detail":"\"epidermal growth factor\" is also Growth factor (growth-factor, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"c797s","kind":"term","name":"EGFR C797S","route":"/terms/c797s/","detail":"\"egfr c797s\" is also EGFR C797S (and its phase with T790M) (egfr-c797s, biomarker); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"egfr-c797s","kind":"biomarker","name":"EGFR C797S (and its phase with T790M)","route":"/biomarkers/egfr-c797s/","detail":"\"egfr c797s\" is also EGFR C797S (c797s, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"egfr-exon-19-deletion","kind":"biomarker","name":"EGFR exon 19 deletion","route":"/biomarkers/egfr-exon-19-deletion/","detail":"\"exon 19 deletion\" is also Deletion (deletion, term), EGFR mutation subtypes (exon 19 deletion, L858R, exon 20 insertion, T790M) (egfr-mutation-subtypes, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"eif1ax","kind":"target","name":"EIF1AX","route":"/targets/eif1ax/","detail":"\"eif1ax\" is also Uveal melanoma prognostic markers (GNAQ/GNA11, monosomy 3, gene-expression class) (uveal-melanoma-prognostic-markers, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/","detail":"\"endometrial cancer\" is also Endometrial cancer (paper-crosbie-lancet, paper), Endometrial cancer (KEGG map) (endometrial-cancer-signalling, pathway); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"paper-crosbie-lancet","kind":"paper","name":"Endometrial cancer","route":"/key-papers/paper-crosbie-lancet/","detail":"\"endometrial cancer\" is also Endometrial cancer (endometrial, cancer), Endometrial cancer (KEGG map) (endometrial-cancer-signalling, pathway); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"epoetin-alfa","kind":"drug","name":"Epoetin alfa","route":"/drugs/epoetin-alfa/","detail":"\"erythropoiesis stimulating agent\" is also Anaemia (anaemia, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"er-pr-negative-threshold","kind":"term","name":"ER and PR negative under 1 percent (the triple-negative threshold, and ER-low)","route":"/terms/er-pr-negative-threshold/","detail":"\"er low positive\" is also ER status (oestrogen receptor by IHC) (er-status, biomarker); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"er-pr-negative-threshold","kind":"term","name":"ER and PR negative under 1 percent (the triple-negative threshold, and ER-low)","route":"/terms/er-pr-negative-threshold/","detail":"\"pr negative\" is also PR status (progesterone receptor by IHC) (pr-status, biomarker); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"er-status","kind":"biomarker","name":"ER status (oestrogen receptor by IHC)","route":"/biomarkers/er-status/","detail":"\"er low positive\" is also ER and PR negative under 1 percent (the triple-negative threshold, and ER-low) (er-pr-negative-threshold, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"erspc","kind":"trial","name":"ERSPC (European Randomized Study of Screening for Prostate Cancer)","route":"/trials/erspc/","detail":"\"erspc\" is also ERSPC: screening and prostate cancer mortality in a randomised European study (paper-schroder-erspc-screening-mortality-nejm-2009, paper); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"paper-schroder-erspc-screening-mortality-nejm-2009","kind":"paper","name":"ERSPC: screening and prostate cancer mortality in a randomised European study","route":"/key-papers/paper-schroder-erspc-screening-mortality-nejm-2009/","detail":"\"erspc\" is also ERSPC (European Randomized Study of Screening for Prostate Cancer) (erspc, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"ema","kind":"institution","name":"European Medicines Agency","route":"/institutions/ema/","detail":"\"chmp\" is also Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA) (regulatory-agencies, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"fast-track-rmat","kind":"term","name":"Fast Track and RMAT designations","route":"/terms/fast-track-rmat/","detail":"\"prime\" is also PRIME (prime, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"flot-term","kind":"term","name":"FLOT regimen (perioperative chemotherapy for gastric cancer)","route":"/terms/flot-term/","detail":"\"flot4\" is also FLOT4-AIO (flot4, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"flot4","kind":"trial","name":"FLOT4-AIO","route":"/trials/flot4/","detail":"\"flot4\" is also FLOT regimen (perioperative chemotherapy for gastric cancer) (flot-term, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/","detail":"\"folfiri\" is also FOLFOX, FOLFIRI, FOLFIRINOX and CAPOX (folfox-family, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/","detail":"\"folfox\" is also FOLFOX, FOLFIRI, FOLFIRINOX and CAPOX (folfox-family, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"folfox-family","kind":"term","name":"FOLFOX, FOLFIRI, FOLFIRINOX and CAPOX","route":"/terms/folfox-family/","detail":"\"nalirifox\" is also NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV) (nalirifox, drug), NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX as Conversion Therapy of Locally Advanced Pancreatic Cancer (nct06669078, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"folfox-family","kind":"term","name":"FOLFOX, FOLFIRI, FOLFIRINOX and CAPOX","route":"/terms/folfox-family/","detail":"\"folfox\" is also FOLFOX (5-FU, leucovorin, oxaliplatin) (folfox, drug); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"folfox-family","kind":"term","name":"FOLFOX, FOLFIRI, FOLFIRINOX and CAPOX","route":"/terms/folfox-family/","detail":"\"folfiri\" is also FOLFIRI (5-FU, leucovorin, irinotecan) (folfiri, drug); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"folfox-family","kind":"term","name":"FOLFOX, FOLFIRI, FOLFIRINOX and CAPOX","route":"/terms/folfox-family/","detail":"\"capox\" is also CAPOX (capecitabine, oxaliplatin) (capox, drug); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"folfox-family","kind":"term","name":"FOLFOX, FOLFIRI, FOLFIRINOX and CAPOX","route":"/terms/folfox-family/","detail":"\"folfoxiri\" is also FOLFOXIRI (5-FU, leucovorin, oxaliplatin, irinotecan) (folfoxiri, drug); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"folfoxiri","kind":"drug","name":"FOLFOXIRI (5-FU, leucovorin, oxaliplatin, irinotecan)","route":"/drugs/folfoxiri/","detail":"\"folfoxiri\" is also FOLFOX, FOLFIRI, FOLFIRINOX and CAPOX (folfox-family, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"paper-smyth-lancet","kind":"paper","name":"Gastric cancer","route":"/key-papers/paper-smyth-lancet/","detail":"\"gastric cancer\" is also Gastric cancer (KEGG map) (gastric-cancer-signalling, pathway), Gastric cancer (gastric-cancer, journal); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"gastric-cancer","kind":"journal","name":"Gastric cancer","route":"/journals/gastric-cancer/","detail":"\"gastric cancer\" is also Gastric cancer (paper-smyth-lancet, paper), Gastric cancer (KEGG map) (gastric-cancer-signalling, pathway); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"gastric-cancer-signalling","kind":"pathway","name":"Gastric cancer (KEGG map)","route":"/pathways/gastric-cancer-signalling/","detail":"\"gastric cancer\" is also Gastric cancer (paper-smyth-lancet, paper), Gastric cancer (gastric-cancer, journal); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"gemcitabine-nab-paclitaxel","kind":"drug","name":"Gemcitabine + nab-paclitaxel","route":"/drugs/gemcitabine-nab-paclitaxel/","detail":"\"gemcitabine nab paclitaxel\" is also Taxanes (paclitaxel, docetaxel, nab-paclitaxel) (taxane, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"nct07599995","kind":"trial","name":"Gemcitabine-Cisplatin Plus Envafolimab in Resectable Biliary Tract Malignancies","route":"/trials/nct07599995/","detail":"\"gene\" is also Gene (gene, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"g-ba-iqwig","kind":"institution","name":"Gemeinsamer Bundesausschuss / IQWiG","route":"/institutions/g-ba-iqwig/","detail":"\"g ba\" is also Health technology assessment (HTA), reimbursement and QALYs (hta, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"gene","kind":"term","name":"Gene","route":"/terms/gene/","detail":"\"gene\" is also Gemcitabine-Cisplatin Plus Envafolimab in Resectable Biliary Tract Malignancies (nct07599995, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"genome-builds","kind":"term","name":"Genome builds: GRCh38 versus hg19 (GRCh37)","route":"/terms/genome-builds/","detail":"\"hg38\" is also LGR5 (lgr5-gene, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"genome-wide-loss-of-heterozygosity","kind":"term","name":"Genome-wide loss of heterozygosity (gLOH)","route":"/terms/genome-wide-loss-of-heterozygosity/","detail":"\"loh score\" is also HRD genomic scar scores (GIS, LOH, HRDetect) (hrd-genomic-scar-scores, technology); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"gbrca-mutation","kind":"term","name":"Germline BRCA mutation (gBRCA)","route":"/terms/gbrca-mutation/","detail":"\"hrrm\" is also Homologous recombination repair gene mutation in prostate cancer (hrr-gene-mutation, biomarker), Tumour (somatic or germline) BRCA1/2 mutation and HRR gene alterations (brca-somatic, biomarker); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"gbrca-mutation","kind":"term","name":"Germline BRCA mutation (gBRCA)","route":"/terms/gbrca-mutation/","detail":"\"brca mutated\" is also Tumour (somatic or germline) BRCA1/2 mutation and HRR gene alterations (brca-somatic, biomarker); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"gbrca-mutation","kind":"term","name":"Germline BRCA mutation (gBRCA)","route":"/terms/gbrca-mutation/","detail":"\"palb2\" is also PALB2 (palb2, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"getug-afu-15","kind":"trial","name":"GETUG-AFU 15","route":"/trials/getug-afu-15/","detail":"\"getug afu 15\" is also GETUG-AFU 15: androgen deprivation alone or with docetaxel in non-castrate metastatic prostate cancer (paper-gravis-getug-afu-15-docetaxel-lancet-oncol-2013, paper); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"paper-gravis-getug-afu-15-docetaxel-lancet-oncol-2013","kind":"paper","name":"GETUG-AFU 15: androgen deprivation alone or with docetaxel in non-castrate metastatic prostate cancer","route":"/key-papers/paper-gravis-getug-afu-15-docetaxel-lancet-oncol-2013/","detail":"\"getug afu 15\" is also GETUG-AFU 15 (getug-afu-15, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"gna11","kind":"target","name":"GNA11","route":"/targets/gna11/","detail":"\"gna11\" is also Uveal melanoma prognostic markers (GNAQ/GNA11, monosomy 3, gene-expression class) (uveal-melanoma-prognostic-markers, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"gnaq","kind":"target","name":"GNAQ","route":"/targets/gnaq/","detail":"\"gnaq\" is also Uveal melanoma prognostic markers (GNAQ/GNA11, monosomy 3, gene-expression class) (uveal-melanoma-prognostic-markers, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"growth-factor","kind":"term","name":"Growth factor","route":"/terms/growth-factor/","detail":"\"epidermal growth factor\" is also EGF (egf, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"health-canada","kind":"institution","name":"Health Canada","route":"/institutions/health-canada/","detail":"\"health canada\" is also Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA) (regulatory-agencies, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"hta","kind":"term","name":"Health technology assessment (HTA), reimbursement and QALYs","route":"/terms/hta/","detail":"\"g ba\" is also Gemeinsamer Bundesausschuss / IQWiG (g-ba-iqwig, institution); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"hta","kind":"term","name":"Health technology assessment (HTA), reimbursement and QALYs","route":"/terms/hta/","detail":"\"pbac\" is also Pharmaceutical Benefits Advisory Committee (pbac, institution); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/","detail":"\"hepatocellular carcinoma\" is also Hepatocellular carcinoma (paper-llovet-nat-rev-dis-primers, paper), Hepatocellular carcinoma (KEGG map) (hepatocellular-carcinoma-signalling, pathway); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"paper-llovet-nat-rev-dis-primers","kind":"paper","name":"Hepatocellular carcinoma","route":"/key-papers/paper-llovet-nat-rev-dis-primers/","detail":"\"hepatocellular carcinoma\" is also Hepatocellular carcinoma (hcc, cancer), Hepatocellular carcinoma (KEGG map) (hepatocellular-carcinoma-signalling, pathway); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"her2-ihc-2-plus","kind":"biomarker","name":"HER2 IHC 2+ (equivocal, reflex to ISH)","route":"/biomarkers/her2-ihc-2-plus/","detail":"\"her2 ihc 2\" is also HER2 testing in the UK: reflex ISH, the ratio against the copy number, and where the UK differs from ASCO/CAP (her2-testing-uk-breast, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"her2-testing-uk-breast","kind":"term","name":"HER2 testing in the UK: reflex ISH, the ratio against the copy number, and where the UK differs from ASCO/CAP","route":"/terms/her2-testing-uk-breast/","detail":"\"her2 ihc 2\" is also HER2 IHC 2+ (equivocal, reflex to ISH) (her2-ihc-2-plus, biomarker); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"hormonal","kind":"section","name":"Hormonal Therapy","route":"/fronts/hormonal/","detail":"\"hormonal therapy\" is also Hormone therapy (hormone-therapy, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"hormone-receptor-status","kind":"term","name":"Hormone receptor status (ER / PR)","route":"/terms/hormone-receptor-status/","detail":"\"progesterone receptor\" is also Progesterone receptor (PGR) (pgr, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"hormone-therapy","kind":"term","name":"Hormone therapy","route":"/terms/hormone-therapy/","detail":"\"hormonal therapy\" is also Hormonal Therapy (hormonal, section); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"hpv-p16","kind":"term","name":"HPV-positive (p16) head and neck cancer","route":"/terms/hpv-p16/","detail":"\"hpv positive head and neck cancer\" is also Oropharyngeal cancer (tonsil and base of tongue) (oropharyngeal-cancer, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"hrd-genomic-scar-scores","kind":"technology","name":"HRD genomic scar scores (GIS, LOH, HRDetect)","route":"/technologies/hrd-genomic-scar-scores/","detail":"\"loh score\" is also Genome-wide loss of heterozygosity (gLOH) (genome-wide-loss-of-heterozygosity, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"hrd-genomic-scar-scores","kind":"technology","name":"HRD genomic scar scores (GIS, LOH, HRDetect)","route":"/technologies/hrd-genomic-scar-scores/","detail":"\"genomic instability score\" is also HRD-positive (genomic instability score) (hrd-positive, biomarker); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"hrd-positive","kind":"biomarker","name":"HRD-positive (genomic instability score)","route":"/biomarkers/hrd-positive/","detail":"\"genomic instability score\" is also HRD genomic scar scores (GIS, LOH, HRDetect) (hrd-genomic-scar-scores, technology); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"human-normal-immunoglobulin","kind":"drug","name":"Human normal immunoglobulin (IVIg)","route":"/drugs/human-normal-immunoglobulin/","detail":"\"ivig\" is also Hypogammaglobulinaemia and infection risk after B-cell therapies (hypogammaglobulinaemia, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"hypogammaglobulinaemia","kind":"term","name":"Hypogammaglobulinaemia and infection risk after B-cell therapies","route":"/terms/hypogammaglobulinaemia/","detail":"\"ivig\" is also Human normal immunoglobulin (IVIg) (human-normal-immunoglobulin, drug); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"ibis-i","kind":"trial","name":"IBIS-I (International Breast Intervention Study I)","route":"/trials/ibis-i/","detail":"\"ibis i\" is also Chemoprevention (tamoxifen, anastrozole, raloxifene) and ER-negative breast cancer (chemoprevention-and-er-negative-breast-cancer, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"ibis-ii","kind":"trial","name":"IBIS-II (International Breast Intervention Study II)","route":"/trials/ibis-ii/","detail":"\"ibis ii\" is also Chemoprevention (tamoxifen, anastrozole, raloxifene) and ER-negative breast cancer (chemoprevention-and-er-negative-breast-cancer, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"icans","kind":"term","name":"ICANS (neurotoxicity)","route":"/terms/icans/","detail":"\"icans\" is also Institut Strauss (institut-strauss, institution); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"immuno-oncology","kind":"term","name":"Immuno-oncology (IO) and checkpoint blockade","route":"/terms/immuno-oncology/","detail":"\"pd 1\" is also PD-1 (pd1, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"imid","kind":"term","name":"Immunomodulatory drugs (IMiDs) and CELMoDs","route":"/terms/imid/","detail":"\"cereblon e3 ligase modulators\" is also Cereblon E3 ligase modulators (CELMoDs) (celmods, technology); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"imid","kind":"term","name":"Immunomodulatory drugs (IMiDs) and CELMoDs","route":"/terms/imid/","detail":"\"imid\" is also Institute of Mother and Child, Warsaw (institute-of-mother-and-child, institution); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"in-vitro-in-vivo","kind":"term","name":"In vitro and in vivo","route":"/terms/in-vitro-in-vivo/","detail":"\"in vivo\" is also In vivo (in-vivo, journal); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"in-vivo","kind":"journal","name":"In vivo","route":"/journals/in-vivo/","detail":"\"in vivo\" is also In vitro and in vivo (in-vitro-in-vivo, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"inherited-skin-cancer-syndromes","kind":"term","name":"Inherited syndromes that cause skin cancer: Gorlin syndrome and xeroderma pigmentosum","route":"/terms/inherited-skin-cancer-syndromes/","detail":"\"nbccs\" is also PTCH1 (Patched 1) (ptch1, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"inherited-skin-cancer-syndromes","kind":"term","name":"Inherited syndromes that cause skin cancer: Gorlin syndrome and xeroderma pigmentosum","route":"/terms/inherited-skin-cancer-syndromes/","detail":"\"sufu\" is also SUFU (sufu, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"institut-strauss","kind":"institution","name":"Institut Strauss","route":"/institutions/institut-strauss/","detail":"\"icans\" is also ICANS (neurotoxicity) (icans, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"institute-of-mother-and-child","kind":"institution","name":"Institute of Mother and Child, Warsaw","route":"/institutions/institute-of-mother-and-child/","detail":"\"imid\" is also Immunomodulatory drugs (IMiDs) and CELMoDs (imid, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"intracholecystic-papillary-tubular-neoplasm","kind":"term","name":"Intracholecystic papillary-tubular neoplasm (ICPN)","route":"/terms/intracholecystic-papillary-tubular-neoplasm/","detail":"\"icpn\" is also Papillary carcinoma of the gallbladder (gallbladder-papillary-carcinoma, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"intraductal-carcinoma-prostate","kind":"term","name":"Intraductal carcinoma of the prostate (IDC-P)","route":"/terms/intraductal-carcinoma-prostate/","detail":"\"intraductal carcinoma\" is also Ductal carcinoma in situ (DCIS) (ductal-carcinoma-in-situ, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"bcg-intravesical","kind":"drug","name":"Intravesical BCG","route":"/drugs/bcg-intravesical/","detail":"\"intravesical bcg\" is also Intravesical therapy (BCG and bladder instillations) (intravesical-therapy, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"intravesical-therapy","kind":"term","name":"Intravesical therapy (BCG and bladder instillations)","route":"/terms/intravesical-therapy/","detail":"\"intravesical bcg\" is also Intravesical BCG (bcg-intravesical, drug); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"intravesical-therapy","kind":"term","name":"Intravesical therapy (BCG and bladder instillations)","route":"/terms/intravesical-therapy/","detail":"\"intravesical therapy\" is also Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy) (bcg-and-intravesical-therapy, technology); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"bcg-and-intravesical-therapy","kind":"technology","name":"Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy)","route":"/technologies/bcg-and-intravesical-therapy/","detail":"\"intravesical therapy\" is also Intravesical therapy (BCG and bladder instillations) (intravesical-therapy, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"invasive-cribriform-carcinoma-breast","kind":"cancer","name":"Invasive cribriform carcinoma of the breast","route":"/cancers/invasive-cribriform-carcinoma-breast/","detail":"\"invasive cribriform carcinoma\" is also Cribriform growth pattern in prostate cancer (cribriform-prostate-cancer, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"invasive-lobular-carcinoma","kind":"cancer","name":"Invasive lobular carcinoma of the breast","route":"/cancers/invasive-lobular-carcinoma/","detail":"\"invasive lobular carcinoma\" is also Adenocarcinoma (adenocarcinoma, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"lacc","kind":"trial","name":"LACC (Laparoscopic Approach to Cervical Cancer)","route":"/trials/lacc/","detail":"\"lacc\" is also Locally advanced cervical cancer (locally-advanced-cervical-cancer, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"nct06229340","kind":"trial","name":"Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations","route":"/trials/nct06229340/","detail":"\"n ras\" is also NRAS (nras, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/","detail":"\"leukemia\" is also Leukemia (leukemia, journal), Leukaemia (tissue type) (leukaemia-type, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/","detail":"\"leukaemia\" is also Leukaemia (tissue type) (leukaemia-type, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"leukaemia-type","kind":"term","name":"Leukaemia (tissue type)","route":"/terms/leukaemia-type/","detail":"\"leukemia\" is also Leukemia (leukemia, journal), Leukaemia (all types) (leukaemia, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"leukaemia-type","kind":"term","name":"Leukaemia (tissue type)","route":"/terms/leukaemia-type/","detail":"\"leukaemia\" is also Leukaemia (all types) (leukaemia, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"leukemia","kind":"journal","name":"Leukemia","route":"/journals/leukemia/","detail":"\"leukemia\" is also Leukaemia (tissue type) (leukaemia-type, term), Leukaemia (all types) (leukaemia, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"lgr5","kind":"term","name":"LGR5","route":"/terms/lgr5/","detail":"\"lgr5\" is also LGR5 (lgr5-gene, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"lgr5-gene","kind":"target","name":"LGR5","route":"/targets/lgr5-gene/","detail":"\"lgr5\" is also LGR5 (lgr5, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"lgr5-gene","kind":"target","name":"LGR5","route":"/targets/lgr5-gene/","detail":"\"hg38\" is also Genome builds: GRCh38 versus hg19 (GRCh37) (genome-builds, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"locally-advanced-cervical-cancer","kind":"cancer","name":"Locally advanced cervical cancer","route":"/cancers/locally-advanced-cervical-cancer/","detail":"\"lacc\" is also LACC (Laparoscopic Approach to Cervical Cancer) (lacc, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"low-grade-serous-ovarian-cancer","kind":"cancer","name":"Low-grade serous ovarian cancer","route":"/cancers/low-grade-serous-ovarian-cancer/","detail":"\"low grade serous ovarian cancer\" is also Low-grade serous ovarian cancer (LGSOC) (lgsoc, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"lgsoc","kind":"term","name":"Low-grade serous ovarian cancer (LGSOC)","route":"/terms/lgsoc/","detail":"\"low grade serous ovarian cancer\" is also Low-grade serous ovarian cancer (low-grade-serous-ovarian-cancer, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"lung-cancer-journal","kind":"journal","name":"Lung cancer","route":"/journals/lung-cancer-journal/","detail":"\"lung cancer\" is also Lung cancer (all types) (lung-cancer, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","detail":"\"lung cancer\" is also Lung cancer (lung-cancer-journal, journal); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"lymphoma-type","kind":"term","name":"Lymphoma (tissue type)","route":"/terms/lymphoma-type/","detail":"\"lymphoma\" is also Non-Hodgkin lymphoma (all types) (non-hodgkin-lymphoma, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"lynch-associated-colorectal-cancer","kind":"cancer","name":"Lynch syndrome-associated colorectal cancer","route":"/cancers/lynch-associated-colorectal-cancer/","detail":"\"hnpcc\" is also MLH1 (mlh1, target), MSH2 (msh2, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"mcrpc-mhspc","kind":"term","name":"mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer)","route":"/terms/mcrpc-mhspc/","detail":"\"mcrpc\" is also Metastatic castration-resistant prostate cancer (prostate-mcrpc, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"mcrpc-mhspc","kind":"term","name":"mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer)","route":"/terms/mcrpc-mhspc/","detail":"\"mhspc\" is also Metastatic hormone-sensitive prostate cancer (prostate-mhspc, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"mcrpc-mhspc","kind":"term","name":"mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer)","route":"/terms/mcrpc-mhspc/","detail":"\"psa recurrence\" is also Biochemical recurrence of prostate cancer (prostate-bcr, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"mhra","kind":"institution","name":"Medicines and Healthcare products Regulatory Agency","route":"/institutions/mhra/","detail":"\"mhra\" is also Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA) (regulatory-agencies, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"merlin-ct","kind":"technology","name":"Merlin (Stanford abdominal CT vision-language model)","route":"/technologies/merlin-ct/","detail":"\"merlin\" is also NF2 (nf2, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"met-exon-14-skipping","kind":"term","name":"MET exon 14 skipping mutation","route":"/terms/met-exon-14-skipping/","detail":"\"met overexpression\" is also c-Met protein overexpression (IHC 3+ in >= 50% of tumour cells) (met-overexpression, biomarker); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"paper-gerstberger-cell","kind":"paper","name":"Metastasis","route":"/key-papers/paper-gerstberger-cell/","detail":"\"metastasis\" is also Metastasis (metastasis, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"metastasis","kind":"term","name":"Metastasis","route":"/terms/metastasis/","detail":"\"metastasis\" is also Metastasis (paper-gerstberger-cell, paper); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/","detail":"\"mcrpc\" is also mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer) (mcrpc-mhspc, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"prostate-mhspc","kind":"cancer","name":"Metastatic hormone-sensitive prostate cancer","route":"/cancers/prostate-mhspc/","detail":"\"mhspc\" is also mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer) (mcrpc-mhspc, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"mlh1","kind":"target","name":"MLH1","route":"/targets/mlh1/","detail":"\"hnpcc\" is also Lynch syndrome-associated colorectal cancer (lynch-associated-colorectal-cancer, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"mpn-driver-mutations","kind":"term","name":"MPN driver mutations (JAK2 V617F, CALR, MPL) and allele burden","route":"/terms/mpn-driver-mutations/","detail":"\"calr\" is also CALR (calr, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"msh2","kind":"target","name":"MSH2","route":"/targets/msh2/","detail":"\"hnpcc\" is also Lynch syndrome-associated colorectal cancer (lynch-associated-colorectal-cancer, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"muscle-invasive-bladder-cancer","kind":"cancer","name":"Muscle-invasive and advanced bladder cancer","route":"/cancers/muscle-invasive-bladder-cancer/","detail":"\"mibc\" is also Non-muscle-invasive vs muscle-invasive bladder cancer (NMIBC / MIBC) (nmibc-vs-mibc, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"myd88","kind":"target","name":"MYD88","route":"/targets/myd88/","detail":"\"myd88\" is also MYD88 L265P and CXCR4 mutations (myd88-l265p, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"myd88-l265p","kind":"term","name":"MYD88 L265P and CXCR4 mutations","route":"/terms/myd88-l265p/","detail":"\"myd88\" is also MYD88 (myd88, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"nalirifox","kind":"drug","name":"NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV)","route":"/drugs/nalirifox/","detail":"\"nalirifox\" is also NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX as Conversion Therapy of Locally Advanced Pancreatic Cancer (nct06669078, trial), FOLFOX, FOLFIRI, FOLFIRINOX and CAPOX (folfox-family, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"nct06669078","kind":"trial","name":"NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX as Conversion Therapy of Locally Advanced Pancreatic Cancer","route":"/trials/nct06669078/","detail":"\"nalirifox\" is also NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV) (nalirifox, drug), FOLFOX, FOLFIRI, FOLFIRINOX and CAPOX (folfox-family, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"nmpa-cde","kind":"institution","name":"National Medical Products Administration / Center for Drug Evaluation","route":"/institutions/nmpa-cde/","detail":"\"nmpa\" is also Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA) (regulatory-agencies, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"nct03926338","kind":"trial","name":"Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer","route":"/trials/nct03926338/","detail":"\"picc\" is also Central venous access (port, PICC line) (central-venous-access, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"nf2","kind":"target","name":"NF2","route":"/targets/nf2/","detail":"\"merlin\" is also Merlin (Stanford abdominal CT vision-language model) (merlin-ct, technology); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"nkx2-1","kind":"target","name":"NKX2-1","route":"/targets/nkx2-1/","detail":"\"ttf 1\" is also TTF-1 and p40 (how lung histology is decided) (ttf1-p40, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/","detail":"\"lymphoma\" is also Lymphoma (tissue type) (lymphoma-type, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"non-muscle-invasive-bladder-cancer","kind":"cancer","name":"Non-muscle-invasive bladder cancer","route":"/cancers/non-muscle-invasive-bladder-cancer/","detail":"\"nmibc\" is also Non-muscle-invasive vs muscle-invasive bladder cancer (NMIBC / MIBC) (nmibc-vs-mibc, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"nmibc-vs-mibc","kind":"term","name":"Non-muscle-invasive vs muscle-invasive bladder cancer (NMIBC / MIBC)","route":"/terms/nmibc-vs-mibc/","detail":"\"mibc\" is also Muscle-invasive and advanced bladder cancer (muscle-invasive-bladder-cancer, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"nmibc-vs-mibc","kind":"term","name":"Non-muscle-invasive vs muscle-invasive bladder cancer (NMIBC / MIBC)","route":"/terms/nmibc-vs-mibc/","detail":"\"nmibc\" is also Non-muscle-invasive bladder cancer (non-muscle-invasive-bladder-cancer, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"nras","kind":"target","name":"NRAS","route":"/targets/nras/","detail":"\"n ras\" is also Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations (nct06229340, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"nct04901741","kind":"trial","name":"Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer","route":"/trials/nct04901741/","detail":"\"optimus\" is also Project Optimus (project-optimus, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"gatekeeper-mutation","kind":"term","name":"On-target resistance mutations (gatekeeper, solvent-front, compound)","route":"/terms/gatekeeper-mutation/","detail":"\"g1202r\" is also ALK kinase-domain resistance mutation (G1202R and the rest) (alk-resistance-mutation, biomarker); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"oncogene","kind":"term","name":"Oncogene","route":"/terms/oncogene/","detail":"\"oncogene\" is also Oncogene (oncogene-journal, journal); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"oncogene-journal","kind":"journal","name":"Oncogene","route":"/journals/oncogene-journal/","detail":"\"oncogene\" is also Oncogene (oncogene, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"oral-serds","kind":"technology","name":"Oral SERDs","route":"/technologies/oral-serds/","detail":"\"oral serds\" is also Selective oestrogen receptor degrader (SERD) (serd, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"oropharyngeal-cancer","kind":"cancer","name":"Oropharyngeal cancer (tonsil and base of tongue)","route":"/cancers/oropharyngeal-cancer/","detail":"\"hpv positive head and neck cancer\" is also HPV-positive (p16) head and neck cancer (hpv-p16, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"nct06226857","kind":"trial","name":"Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer","route":"/trials/nct06226857/","detail":"\"crc01\" is also CRC01 (crc01, drug); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"palb2","kind":"target","name":"PALB2","route":"/targets/palb2/","detail":"\"palb2\" is also Germline BRCA mutation (gBRCA) (gbrca-mutation, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"paper-hidalgo-pancreatic-cancer-review-nejm-2010","kind":"paper","name":"Pancreatic cancer","route":"/key-papers/paper-hidalgo-pancreatic-cancer-review-nejm-2010/","detail":"\"pancreatic cancer\" is also Pancreatic ductal adenocarcinoma (pancreatic, cancer), Pancreatic cancer (KEGG map) (pancreatic-cancer-signalling, pathway); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"paper-kleeff-nat-rev-dis-primers","kind":"paper","name":"Pancreatic cancer","route":"/key-papers/paper-kleeff-nat-rev-dis-primers/","detail":"\"pancreatic cancer\" is also Pancreatic ductal adenocarcinoma (pancreatic, cancer), Pancreatic cancer (KEGG map) (pancreatic-cancer-signalling, pathway); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"pancreatic-cancer-signalling","kind":"pathway","name":"Pancreatic cancer (KEGG map)","route":"/pathways/pancreatic-cancer-signalling/","detail":"\"pancreatic cancer\" is also Pancreatic ductal adenocarcinoma (pancreatic, cancer), Pancreatic cancer (paper-hidalgo-pancreatic-cancer-review-nejm-2010, paper), Pancreatic cancer (paper-kleeff-nat-rev-dis-primers, paper); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","detail":"\"pancreatic cancer\" is also Pancreatic cancer (paper-hidalgo-pancreatic-cancer-review-nejm-2010, paper), Pancreatic cancer (paper-kleeff-nat-rev-dis-primers, paper), Pancreatic cancer (KEGG map) (pancreatic-cancer-signalling, pathway); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"pancreatic-enzyme-replacement","kind":"term","name":"Pancreatic enzyme replacement therapy (PERT, pancreatin, Creon) for pancreatic exocrine insufficiency: why and how to take it","route":"/terms/pancreatic-enzyme-replacement/","detail":"\"pert\" is also Pancrelipase (pancreatic enzyme replacement therapy) (pancrelipase, drug); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"pancrelipase","kind":"drug","name":"Pancrelipase (pancreatic enzyme replacement therapy)","route":"/drugs/pancrelipase/","detail":"\"pert\" is also Pancreatic enzyme replacement therapy (PERT, pancreatin, Creon) for pancreatic exocrine insufficiency: why and how to take it (pancreatic-enzyme-replacement, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"gallbladder-papillary-carcinoma","kind":"cancer","name":"Papillary carcinoma of the gallbladder","route":"/cancers/gallbladder-papillary-carcinoma/","detail":"\"icpn\" is also Intracholecystic papillary-tubular neoplasm (ICPN) (intracholecystic-papillary-tubular-neoplasm, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"papillary-rcc","kind":"cancer","name":"Papillary renal cell carcinoma","route":"/cancers/papillary-rcc/","detail":"\"prcc\" is also PRCC (prcc, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/","detail":"\"pd 1\" is also Immune checkpoint (immune-checkpoint, term), Immuno-oncology (IO) and checkpoint blockade (immuno-oncology, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"performance-status","kind":"term","name":"Performance status (ECOG, Karnofsky)","route":"/terms/performance-status/","detail":"\"ecog\" is also ECOG-ACRIN Cancer Research Group (ecog-acrin, company); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"pbac","kind":"institution","name":"Pharmaceutical Benefits Advisory Committee","route":"/institutions/pbac/","detail":"\"pbac\" is also Health technology assessment (HTA), reimbursement and QALYs (hta, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"pmda","kind":"institution","name":"Pharmaceuticals and Medical Devices Agency","route":"/institutions/pmda/","detail":"\"pmda\" is also Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA) (regulatory-agencies, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"philadelphia-chromosome","kind":"term","name":"Philadelphia chromosome (Ph+, BCR::ABL1)","route":"/terms/philadelphia-chromosome/","detail":"\"bcr abl1\" is also BCR::ABL1 (Philadelphia chromosome) (bcr-abl, target), BCR::ABL1 (Philadelphia chromosome) (bcr-abl1-signalling, pathway), BCR::ABL1 transcript (Philadelphia chromosome, quantitative PCR) (bcr-abl1-transcript, biomarker); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"pi-rads","kind":"term","name":"PI-RADS (Prostate Imaging Reporting and Data System)","route":"/terms/pi-rads/","detail":"\"pi rads\" is also Quantitative imaging biomarkers (RECIST, PERCIST, SUV, ADC) (quantitative-imaging-biomarkers, technology); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"pivot","kind":"trial","name":"PIVOT (Prostate Cancer Intervention Versus Observation Trial)","route":"/trials/pivot/","detail":"\"pivot\" is also PIVOT: follow-up of prostatectomy versus observation for early prostate cancer (paper-wilt-pivot-prostatectomy-observation-nejm-2017, paper); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"paper-wilt-pivot-prostatectomy-observation-nejm-2017","kind":"paper","name":"PIVOT: follow-up of prostatectomy versus observation for early prostate cancer","route":"/key-papers/paper-wilt-pivot-prostatectomy-observation-nejm-2017/","detail":"\"pivot\" is also PIVOT (Prostate Cancer Intervention Versus Observation Trial) (pivot, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"platinum-etoposide","kind":"drug","name":"Platinum + etoposide (EP / CE)","route":"/drugs/platinum-etoposide/","detail":"\"platinum etoposide\" is also Platinum-sensitive / platinum-resistant (platinum-sensitivity, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"platinum-sensitivity","kind":"term","name":"Platinum-sensitive / platinum-resistant","route":"/terms/platinum-sensitivity/","detail":"\"platinum etoposide\" is also Platinum + etoposide (EP / CE) (platinum-etoposide, drug); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"plcg2","kind":"target","name":"PLCG2","route":"/targets/plcg2/","detail":"\"plcg2\" is also BTK C481S, PLCG2 and BCL2 G101V resistance mutations (btki-bcl2i-resistance-mutations, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"plco-prostate","kind":"trial","name":"PLCO, prostate component (Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial)","route":"/trials/plco-prostate/","detail":"\"plco prostate\" is also PLCO: mortality results from a randomised prostate cancer screening trial (paper-andriole-plco-prostate-screening-nejm-2009, paper); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"paper-andriole-plco-prostate-screening-nejm-2009","kind":"paper","name":"PLCO: mortality results from a randomised prostate cancer screening trial","route":"/key-papers/paper-andriole-plco-prostate-screening-nejm-2009/","detail":"\"plco prostate\" is also PLCO, prostate component (Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial) (plco-prostate, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"pr-status","kind":"biomarker","name":"PR status (progesterone receptor by IHC)","route":"/biomarkers/pr-status/","detail":"\"pr negative\" is also ER and PR negative under 1 percent (the triple-negative threshold, and ER-low) (er-pr-negative-threshold, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"prcc","kind":"target","name":"PRCC","route":"/targets/prcc/","detail":"\"prcc\" is also Papillary renal cell carcinoma (papillary-rcc, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"prevail","kind":"trial","name":"PREVAIL","route":"/trials/prevail/","detail":"\"prevail\" is also PREVAIL: enzalutamide in metastatic prostate cancer before chemotherapy (paper-beer-prevail-enzalutamide-nejm-2014, paper); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"paper-beer-prevail-enzalutamide-nejm-2014","kind":"paper","name":"PREVAIL: enzalutamide in metastatic prostate cancer before chemotherapy","route":"/key-papers/paper-beer-prevail-enzalutamide-nejm-2014/","detail":"\"prevail\" is also PREVAIL (prevail, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"primary-tumour","kind":"term","name":"Primary tumour","route":"/terms/primary-tumour/","detail":"\"cancer of unknown primary\" is also Cancer of unknown primary (CUP) (cancer-of-unknown-primary, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"prime","kind":"trial","name":"PRIME","route":"/trials/prime/","detail":"\"prime\" is also Fast Track and RMAT designations (fast-track-rmat, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"priscilla-chan","kind":"person","name":"Priscilla Chan","route":"/people/priscilla-chan/","detail":"\"chan zuckerberg initiative\" is also Chan Zuckerberg Initiative (Biohub) (chan-zuckerberg-initiative, company); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"prodige-23","kind":"trial","name":"PRODIGE 23","route":"/trials/prodige-23/","detail":"\"prodige 23\" is also Total neoadjuvant therapy (TNT, rectal cancer) (total-neoadjuvant-therapy, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"pgr","kind":"target","name":"Progesterone receptor (PGR)","route":"/targets/pgr/","detail":"\"progesterone receptor\" is also Hormone receptor status (ER / PR) (hormone-receptor-status, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"project-optimus","kind":"term","name":"Project Optimus","route":"/terms/project-optimus/","detail":"\"optimus\" is also Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer (nct04901741, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"promis","kind":"trial","name":"PROMIS","route":"/trials/promis/","detail":"\"promis\" is also PROMIS: diagnostic accuracy of multiparametric MRI and TRUS biopsy in prostate cancer (paper-ahmed-promis-multiparametric-mri-lancet-2017, paper); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"paper-ahmed-promis-multiparametric-mri-lancet-2017","kind":"paper","name":"PROMIS: diagnostic accuracy of multiparametric MRI and TRUS biopsy in prostate cancer","route":"/key-papers/paper-ahmed-promis-multiparametric-mri-lancet-2017/","detail":"\"promis\" is also PROMIS (promis, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"psma-pet-expression","kind":"biomarker","name":"PSMA expression by PET (PSMA-positive)","route":"/biomarkers/psma-pet-expression/","detail":"\"psma pet\" is also PSMA PET (psma-pet, technology); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"psma-pet","kind":"technology","name":"PSMA PET","route":"/technologies/psma-pet/","detail":"\"psma pet\" is also PSMA expression by PET (PSMA-positive) (psma-pet-expression, biomarker); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"ptch1","kind":"target","name":"PTCH1 (Patched 1)","route":"/targets/ptch1/","detail":"\"nbccs\" is also Inherited syndromes that cause skin cancer: Gorlin syndrome and xeroderma pigmentosum (inherited-skin-cancer-syndromes, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"quality-of-life","kind":"term","name":"Quality of life","route":"/terms/quality-of-life/","detail":"\"ecog\" is also ECOG-ACRIN Cancer Research Group (ecog-acrin, company); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"quantitative-imaging-biomarkers","kind":"technology","name":"Quantitative imaging biomarkers (RECIST, PERCIST, SUV, ADC)","route":"/technologies/quantitative-imaging-biomarkers/","detail":"\"pi rads\" is also PI-RADS (Prostate Imaging Reporting and Data System) (pi-rads, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"quantitative-imaging-biomarkers","kind":"technology","name":"Quantitative imaging biomarkers (RECIST, PERCIST, SUV, ADC)","route":"/technologies/quantitative-imaging-biomarkers/","detail":"\"standardised uptake value\" is also Standardised uptake value (SUV) (suv, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"r-iss","kind":"term","name":"R-ISS / R2-ISS staging","route":"/terms/r-iss/","detail":"\"beta 2 microglobulin\" is also B2M (b2m, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"radiation-oncology","kind":"journal","name":"Radiation oncology","route":"/journals/radiation-oncology/","detail":"\"radiation oncology\" is also Radiotherapy (radiotherapy, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"radiation","kind":"section","name":"Radiation Therapy","route":"/fronts/radiation/","detail":"\"radiation therapy\" is also Radiotherapy (radiotherapy, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"radioembolisation-tare","kind":"technology","name":"Radioembolisation (TARE / SIRT, yttrium-90)","route":"/technologies/radioembolisation-tare/","detail":"\"radioembolisation\" is also TARE / SIRT (radioembolisation with yttrium-90) (tare, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"radiosensitisers","kind":"technology","name":"Radiosensitisers","route":"/technologies/radiosensitisers/","detail":"\"radiosensitisers\" is also Radiotherapy (radiotherapy, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"radiotherapy","kind":"term","name":"Radiotherapy","route":"/terms/radiotherapy/","detail":"\"radiation therapy\" is also Radiation Therapy (radiation, section); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"radiotherapy","kind":"term","name":"Radiotherapy","route":"/terms/radiotherapy/","detail":"\"radiation oncology\" is also Radiation oncology (radiation-oncology, journal); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"radiotherapy","kind":"term","name":"Radiotherapy","route":"/terms/radiotherapy/","detail":"\"radiosensitisers\" is also Radiosensitisers (radiosensitisers, technology); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"rapido","kind":"trial","name":"RAPIDO","route":"/trials/rapido/","detail":"\"rapido\" is also Total neoadjuvant therapy (TNT, rectal cancer) (total-neoadjuvant-therapy, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"regulatory-agencies","kind":"term","name":"Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA)","route":"/terms/regulatory-agencies/","detail":"\"chmp\" is also European Medicines Agency (ema, institution); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"regulatory-agencies","kind":"term","name":"Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA)","route":"/terms/regulatory-agencies/","detail":"\"mhra\" is also Medicines and Healthcare products Regulatory Agency (mhra, institution); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"regulatory-agencies","kind":"term","name":"Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA)","route":"/terms/regulatory-agencies/","detail":"\"pmda\" is also Pharmaceuticals and Medical Devices Agency (pmda, institution); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"regulatory-agencies","kind":"term","name":"Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA)","route":"/terms/regulatory-agencies/","detail":"\"nmpa\" is also National Medical Products Administration / Center for Drug Evaluation (nmpa-cde, institution); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"regulatory-agencies","kind":"term","name":"Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA)","route":"/terms/regulatory-agencies/","detail":"\"health canada\" is also Health Canada (health-canada, institution); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"regulatory-agencies","kind":"term","name":"Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA)","route":"/terms/regulatory-agencies/","detail":"\"swissmedic\" is also Swissmedic (swissmedic, institution); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"regulatory-agencies","kind":"term","name":"Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA)","route":"/terms/regulatory-agencies/","detail":"\"anvisa\" is also Agência Nacional de Vigilância Sanitária (anvisa, institution); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/","detail":"\"renal cell carcinoma\" is also Renal cell carcinoma (paper-hsieh-nat-rev-dis-primers, paper), Renal cell carcinoma (KEGG map) (renal-cell-carcinoma-signalling, pathway); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"paper-hsieh-nat-rev-dis-primers","kind":"paper","name":"Renal cell carcinoma","route":"/key-papers/paper-hsieh-nat-rev-dis-primers/","detail":"\"renal cell carcinoma\" is also Renal cell carcinoma (rcc, cancer), Renal cell carcinoma (KEGG map) (renal-cell-carcinoma-signalling, pathway); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"resectability-lung-cancer","kind":"term","name":"Resectability in lung cancer","route":"/terms/resectability-lung-cancer/","detail":"\"operable lung cancer\" is also Resectable stage I to III non-small-cell lung cancer (resectable-nsclc, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/","detail":"\"operable lung cancer\" is also Resectability in lung cancer (resectability-lung-cancer, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"paper-teply-restore-bipolar-androgen-therapy-lancet-oncol-2018","kind":"paper","name":"RESTORE: bipolar androgen therapy after progression on enzalutamide in metastatic castration-resistant prostate cancer","route":"/key-papers/paper-teply-restore-bipolar-androgen-therapy-lancet-oncol-2018/","detail":"\"restore\" is also A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM (nct03862430, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"retroperitoneal-sarcoma","kind":"cancer","name":"Retroperitoneal sarcoma","route":"/cancers/retroperitoneal-sarcoma/","detail":"\"retroperitoneal sarcoma\" is also Retroperitoneum (retroperitoneum, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"retroperitoneum","kind":"term","name":"Retroperitoneum","route":"/terms/retroperitoneum/","detail":"\"retroperitoneal sarcoma\" is also Retroperitoneal sarcoma (retroperitoneal-sarcoma, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"sdh-deficiency","kind":"term","name":"SDH deficiency (SDHB immunohistochemistry loss)","route":"/terms/sdh-deficiency/","detail":"\"sdha\" is also SDHA (sdha, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"sdh-deficiency","kind":"term","name":"SDH deficiency (SDHB immunohistochemistry loss)","route":"/terms/sdh-deficiency/","detail":"\"sdh deficient renal cell carcinoma\" is also Succinate dehydrogenase-deficient renal cell carcinoma (sdh-deficient-renal-cell-carcinoma, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"sdha","kind":"target","name":"SDHA","route":"/targets/sdha/","detail":"\"sdha\" is also SDH deficiency (SDHB immunohistochemistry loss) (sdh-deficiency, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"serd","kind":"term","name":"Selective oestrogen receptor degrader (SERD)","route":"/terms/serd/","detail":"\"oral serds\" is also Oral SERDs (oral-serds, technology); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"serum-tumour-markers","kind":"technology","name":"Serum tumour markers: proper use and misuse","route":"/technologies/serum-tumour-markers/","detail":"\"thyroglobulin\" is also Tumour markers (CEA, LDH, chromogranin, thyroglobulin) (tumour-markers, term), TG (tg, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"sf3b1","kind":"target","name":"SF3B1","route":"/targets/sf3b1/","detail":"\"sf3b1\" is also SF3B1 mutation (sf3b1-mutation, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"sf3b1-mutation","kind":"term","name":"SF3B1 mutation","route":"/terms/sf3b1-mutation/","detail":"\"sf3b1\" is also SF3B1 (sf3b1, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"sharp","kind":"trial","name":"SHARP","route":"/trials/sharp/","detail":"\"sharp\" is also SPEN (spen, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"shield","kind":"drug","name":"Shield","route":"/drugs/shield/","detail":"\"shield\" is also Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy (nct07506057, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"nct07750951","kind":"trial","name":"Single-arm, Phase II Clinical Study Evaluating the Safety and Efficacy of Sintilimab Combined With IBI-310 and Chemotherapy as Neoadjuvant Therapy for Locally A","route":"/trials/nct07750951/","detail":"\"sintilimab\" is also Sintilimab (sintilimab, drug); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/","detail":"\"sintilimab\" is also Single-arm, Phase II Clinical Study Evaluating the Safety and Efficacy of Sintilimab Combined With IBI-310 and Chemotherapy as Neoadjuvant Therapy for Locally A (nct07750951, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"slfn11","kind":"target","name":"SLFN11","route":"/targets/slfn11/","detail":"\"slfn11\" is also Small-cell lung cancer transcription-factor subtypes (SCLC-A, SCLC-N, SCLC-P, SCLC-I) and SLFN11 (sclc-molecular-subtypes, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/","detail":"\"small cell lung cancer\" is also Small-cell lung cancer (paper-rudin-nat-rev-dis-primers, paper), Small cell lung cancer (KEGG map) (sclc-signalling, pathway); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"paper-rudin-nat-rev-dis-primers","kind":"paper","name":"Small-cell lung cancer","route":"/key-papers/paper-rudin-nat-rev-dis-primers/","detail":"\"small cell lung cancer\" is also Small-cell lung cancer (sclc, cancer), Small cell lung cancer (KEGG map) (sclc-signalling, pathway); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/","detail":"\"sclc\" is also A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as First-line Therapy for (nct07728955, trial), Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell (nct06441344, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"sclc-molecular-subtypes","kind":"term","name":"Small-cell lung cancer transcription-factor subtypes (SCLC-A, SCLC-N, SCLC-P, SCLC-I) and SLFN11","route":"/terms/sclc-molecular-subtypes/","detail":"\"ascl1\" is also ASCL1 (ascl1, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"sclc-molecular-subtypes","kind":"term","name":"Small-cell lung cancer transcription-factor subtypes (SCLC-A, SCLC-N, SCLC-P, SCLC-I) and SLFN11","route":"/terms/sclc-molecular-subtypes/","detail":"\"slfn11\" is also SLFN11 (slfn11, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"smarca4","kind":"target","name":"SMARCA4","route":"/targets/smarca4/","detail":"\"smarca4\" is also STK11 / KEAP1 co-mutations (stk11-keap1, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"spcg-4","kind":"trial","name":"SPCG-4 (Scandinavian Prostate Cancer Group Study 4)","route":"/trials/spcg-4/","detail":"\"spcg 4\" is also SPCG-4: radical prostatectomy or watchful waiting in prostate cancer, 29-year follow-up (paper-bill-axelson-spcg-4-29-year-nejm-2018, paper); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"paper-bill-axelson-spcg-4-29-year-nejm-2018","kind":"paper","name":"SPCG-4: radical prostatectomy or watchful waiting in prostate cancer, 29-year follow-up","route":"/key-papers/paper-bill-axelson-spcg-4-29-year-nejm-2018/","detail":"\"spcg 4\" is also SPCG-4 (Scandinavian Prostate Cancer Group Study 4) (spcg-4, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"spen","kind":"target","name":"SPEN","route":"/targets/spen/","detail":"\"sharp\" is also SHARP (sharp, trial), SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC (nct06457906, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"squamous-cell-carcinoma","kind":"term","name":"Squamous cell carcinoma","route":"/terms/squamous-cell-carcinoma/","detail":"\"squamous cell carcinoma\" is also Squamous cell carcinoma of the urethra (urethral-squamous-cell-carcinoma, cancer), Squamous cell carcinoma of the lung (lung-squamous-cell-carcinoma, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"squamous-cell-carcinoma","kind":"term","name":"Squamous cell carcinoma","route":"/terms/squamous-cell-carcinoma/","detail":"\"squamous\" is also Squamous cell carcinoma of the lung (lung-squamous-cell-carcinoma, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"lung-squamous-cell-carcinoma","kind":"cancer","name":"Squamous cell carcinoma of the lung","route":"/cancers/lung-squamous-cell-carcinoma/","detail":"\"squamous cell carcinoma\" is also Squamous cell carcinoma (squamous-cell-carcinoma, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"urethral-squamous-cell-carcinoma","kind":"cancer","name":"Squamous cell carcinoma of the urethra","route":"/cancers/urethral-squamous-cell-carcinoma/","detail":"\"squamous cell carcinoma\" is also Squamous cell carcinoma (squamous-cell-carcinoma, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"nct06457906","kind":"trial","name":"SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC","route":"/trials/nct06457906/","detail":"\"sharp\" is also SPEN (spen, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"suv","kind":"term","name":"Standardised uptake value (SUV)","route":"/terms/suv/","detail":"\"standardised uptake value\" is also Quantitative imaging biomarkers (RECIST, PERCIST, SUV, ADC) (quantitative-imaging-biomarkers, technology); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"stk11-keap1","kind":"term","name":"STK11 / KEAP1 co-mutations","route":"/terms/stk11-keap1/","detail":"\"smarca4\" is also SMARCA4 (smarca4, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"nct06267729","kind":"trial","name":"Study of AZD0754 in Participants With Metastatic Prostate Cancer","route":"/trials/nct06267729/","detail":"\"apollo\" is also DCLRE1B (dclre1b, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"sdh-deficient-renal-cell-carcinoma","kind":"cancer","name":"Succinate dehydrogenase-deficient renal cell carcinoma","route":"/cancers/sdh-deficient-renal-cell-carcinoma/","detail":"\"sdh deficient renal cell carcinoma\" is also SDH deficiency (SDHB immunohistochemistry loss) (sdh-deficiency, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"sufu","kind":"target","name":"SUFU","route":"/targets/sufu/","detail":"\"sufu\" is also Inherited syndromes that cause skin cancer: Gorlin syndrome and xeroderma pigmentosum (inherited-skin-cancer-syndromes, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"swissmedic","kind":"institution","name":"Swissmedic","route":"/institutions/swissmedic/","detail":"\"swissmedic\" is also Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA) (regulatory-agencies, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"swog-9346","kind":"trial","name":"SWOG 9346 (intermittent androgen deprivation)","route":"/trials/swog-9346/","detail":"\"swog 9346\" is also SWOG 9346: intermittent versus continuous androgen deprivation in metastatic prostate cancer (paper-hussain-swog-9346-intermittent-androgen-deprivation-nejm-2013, paper); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"paper-hussain-swog-9346-intermittent-androgen-deprivation-nejm-2013","kind":"paper","name":"SWOG 9346: intermittent versus continuous androgen deprivation in metastatic prostate cancer","route":"/key-papers/paper-hussain-swog-9346-intermittent-androgen-deprivation-nejm-2013/","detail":"\"swog 9346\" is also SWOG 9346 (intermittent androgen deprivation) (swog-9346, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"swog-9916","kind":"trial","name":"SWOG 9916","route":"/trials/swog-9916/","detail":"\"swog 9916\" is also SWOG 9916: docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer (paper-petrylak-swog-9916-docetaxel-estramustine-nejm-2004, paper); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"paper-petrylak-swog-9916-docetaxel-estramustine-nejm-2004","kind":"paper","name":"SWOG 9916: docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","route":"/key-papers/paper-petrylak-swog-9916-docetaxel-estramustine-nejm-2004/","detail":"\"swog 9916\" is also SWOG 9916 (swog-9916, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"t-cell","kind":"term","name":"T cell","route":"/terms/t-cell/","detail":"\"t cell exhaustion\" is also T-cell exhaustion (t-cell-exhaustion, pathway); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"t-cell-exhaustion","kind":"pathway","name":"T-cell exhaustion","route":"/pathways/t-cell-exhaustion/","detail":"\"t cell exhaustion\" is also T cell (t-cell, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"cyclin-d1-t11-14","kind":"term","name":"t(11;14), cyclin D1 and SOX11","route":"/terms/cyclin-d1-t11-14/","detail":"\"cyclin d1\" is also CCND1 (ccnd1, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"tare","kind":"term","name":"TARE / SIRT (radioembolisation with yttrium-90)","route":"/terms/tare/","detail":"\"radioembolisation\" is also Radioembolisation (TARE / SIRT, yttrium-90) (radioembolisation-tare, technology); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"targeted-oncology","kind":"journal","name":"Targeted oncology","route":"/journals/targeted-oncology/","detail":"\"targeted oncology\" is also Targeted Oncology (src-targeted-oncology, collection); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"src-targeted-oncology","kind":"collection","name":"Targeted Oncology","route":"/collections/src-targeted-oncology/","detail":"\"targeted oncology\" is also Targeted oncology (targeted-oncology, journal); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"tax-327","kind":"trial","name":"TAX 327","route":"/trials/tax-327/","detail":"\"tax 327\" is also TAX 327: docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer (paper-tannock-tax-327-docetaxel-prednisone-nejm-2004, paper); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"paper-tannock-tax-327-docetaxel-prednisone-nejm-2004","kind":"paper","name":"TAX 327: docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","route":"/key-papers/paper-tannock-tax-327-docetaxel-prednisone-nejm-2004/","detail":"\"tax 327\" is also TAX 327 (tax-327, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"taxane","kind":"term","name":"Taxanes (paclitaxel, docetaxel, nab-paclitaxel)","route":"/terms/taxane/","detail":"\"gemcitabine nab paclitaxel\" is also Gemcitabine + nab-paclitaxel (gemcitabine-nab-paclitaxel, drug); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"tfe3-rearranged-renal-cell-carcinoma","kind":"cancer","name":"TFE3-rearranged (translocation) renal cell carcinoma","route":"/cancers/tfe3-rearranged-renal-cell-carcinoma/","detail":"\"translocation\" is also Cytogenetics and karyotype (cytogenetics, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"tg","kind":"target","name":"TG","route":"/targets/tg/","detail":"\"thyroglobulin\" is also Tumour markers (CEA, LDH, chromogranin, thyroglobulin) (tumour-markers, term), Serum tumour markers: proper use and misuse (serum-tumour-markers, technology), Thyroglobulin, calcitonin and CEA in thyroid cancer follow-up (thyroid-cancer-markers, technology); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"nct02000089","kind":"trial","name":"The Cancer of the Pancreas Screening-5 CAPS5)Study","route":"/trials/nct02000089/","detail":"\"caps5\" is also CAPS: the Cancer of the Pancreas Screening consortium and its surveillance studies (CAPS1 to CAPS5) (caps-consortium-pancreatic-screening, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"cscc-subtype-and-grade","kind":"term","name":"The subtype and grade on a cutaneous squamous cell carcinoma report","route":"/terms/cscc-subtype-and-grade/","detail":"\"basaloid squamous cell carcinoma\" is also Basaloid squamous cell carcinoma of the lung (basaloid-squamous-cell-carcinoma-lung, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"thyroid-cancer-markers","kind":"technology","name":"Thyroglobulin, calcitonin and CEA in thyroid cancer follow-up","route":"/technologies/thyroid-cancer-markers/","detail":"\"thyroglobulin\" is also Tumour markers (CEA, LDH, chromogranin, thyroglobulin) (tumour-markers, term), TG (tg, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/","detail":"\"thyroid cancer\" is also Thyroid cancer (paper-cabanillas-lancet, paper), Thyroid cancer (KEGG map) (thyroid-cancer-signalling, pathway); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"paper-cabanillas-lancet","kind":"paper","name":"Thyroid cancer","route":"/key-papers/paper-cabanillas-lancet/","detail":"\"thyroid cancer\" is also Thyroid cancer (thyroid, cancer), Thyroid cancer (KEGG map) (thyroid-cancer-signalling, pathway); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"titan","kind":"technology","name":"TITAN (whole-slide multimodal model)","route":"/technologies/titan/","detail":"\"titan\" is also A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC (nct02489318, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"nct06441344","kind":"trial","name":"Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell","route":"/trials/nct06441344/","detail":"\"sclc\" is also Small-cell lung cancer (sclc, cancer); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"total-neoadjuvant-therapy","kind":"term","name":"Total neoadjuvant therapy (TNT, rectal cancer)","route":"/terms/total-neoadjuvant-therapy/","detail":"\"rapido\" is also RAPIDO (rapido, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"total-neoadjuvant-therapy","kind":"term","name":"Total neoadjuvant therapy (TNT, rectal cancer)","route":"/terms/total-neoadjuvant-therapy/","detail":"\"prodige 23\" is also PRODIGE 23 (prodige-23, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"nct07506057","kind":"trial","name":"Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy","route":"/trials/nct07506057/","detail":"\"shield\" is also Shield (shield, drug); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"triton3","kind":"trial","name":"TRITON3","route":"/trials/triton3/","detail":"\"triton3\" is also TRITON3: rucaparib or physician's choice in metastatic castration-resistant prostate cancer (paper-fizazi-triton3-rucaparib-nejm-2023, paper); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"paper-fizazi-triton3-rucaparib-nejm-2023","kind":"paper","name":"TRITON3: rucaparib or physician's choice in metastatic castration-resistant prostate cancer","route":"/key-papers/paper-fizazi-triton3-rucaparib-nejm-2023/","detail":"\"triton3\" is also TRITON3 (triton3, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"tropic","kind":"trial","name":"TROPIC","route":"/trials/tropic/","detail":"\"tropic\" is also TROPIC: prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel (paper-de-bono-tropic-cabazitaxel-lancet-2010, paper); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"paper-de-bono-tropic-cabazitaxel-lancet-2010","kind":"paper","name":"TROPIC: prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel","route":"/key-papers/paper-de-bono-tropic-cabazitaxel-lancet-2010/","detail":"\"tropic\" is also TROPIC (tropic, trial); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"ttf1-p40","kind":"term","name":"TTF-1 and p40 (how lung histology is decided)","route":"/terms/ttf1-p40/","detail":"\"ttf 1\" is also NKX2-1 (nkx2-1, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"ttf1-p40","kind":"term","name":"TTF-1 and p40 (how lung histology is decided)","route":"/terms/ttf1-p40/","detail":"\"ttf1\" is also TTF1 (ttf1, target), NKX2-1 (nkx2-1, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"ttf1","kind":"target","name":"TTF1","route":"/targets/ttf1/","detail":"\"ttf1\" is also TTF-1 and p40 (how lung histology is decided) (ttf1-p40, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"brca-somatic","kind":"biomarker","name":"Tumour (somatic or germline) BRCA1/2 mutation and HRR gene alterations","route":"/biomarkers/brca-somatic/","detail":"\"hrrm\" is also Germline BRCA mutation (gBRCA) (gbrca-mutation, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"tumour-markers","kind":"term","name":"Tumour markers (CEA, LDH, chromogranin, thyroglobulin)","route":"/terms/tumour-markers/","detail":"\"thyroglobulin\" is also TG (tg, target), Serum tumour markers: proper use and misuse (serum-tumour-markers, technology), Thyroglobulin, calcitonin and CEA in thyroid cancer follow-up (thyroid-cancer-markers, technology); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"uicc","kind":"institution","name":"Union for International Cancer Control","route":"/institutions/uicc/","detail":"\"uicc\" is also Disease-specific staging and risk systems (FIGO, Ann Arbor, IPI, R-ISS, ELN, IMDC) (staging-systems, term); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"urethral-urothelial-carcinoma","kind":"cancer","name":"Urothelial carcinoma of the urethra","route":"/cancers/urethral-urothelial-carcinoma/","detail":"\"urothelial carcinoma\" is also Bladder cancer (KEGG map) (bladder-cancer-signalling, pathway); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"uveal-melanoma-prognostic-markers","kind":"term","name":"Uveal melanoma prognostic markers (GNAQ/GNA11, monosomy 3, gene-expression class)","route":"/terms/uveal-melanoma-prognostic-markers/","detail":"\"gnaq\" is also GNAQ (gnaq, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"uveal-melanoma-prognostic-markers","kind":"term","name":"Uveal melanoma prognostic markers (GNAQ/GNA11, monosomy 3, gene-expression class)","route":"/terms/uveal-melanoma-prognostic-markers/","detail":"\"gna11\" is also GNA11 (gna11, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"uveal-melanoma-prognostic-markers","kind":"term","name":"Uveal melanoma prognostic markers (GNAQ/GNA11, monosomy 3, gene-expression class)","route":"/terms/uveal-melanoma-prognostic-markers/","detail":"\"eif1ax\" is also EIF1AX (eif1ax, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"uveal-melanoma-prognostic-markers","kind":"term","name":"Uveal melanoma prognostic markers (GNAQ/GNA11, monosomy 3, gene-expression class)","route":"/terms/uveal-melanoma-prognostic-markers/","detail":"\"cysltr2\" is also CYSLTR2 (cysltr2, target); cross-link them with `related` or merge if they describe one thing"},{"check":"name-collision-across-kinds","severity":"low","id":"vascular-tumours","kind":"cancer","name":"Vascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma)","route":"/cancers/vascular-tumours/","detail":"\"angiosarcoma\" is also Angiosarcoma (review) (paper-young-angiosarcoma-review-lancet-oncol-2010, paper); cross-link them with `related` or merge if they describe one thing"},{"check":"near-duplicate-name","severity":"low","id":"aldoxorubicin","kind":"drug","name":"Aldoxorubicin","route":"/drugs/aldoxorubicin/","detail":"name overlaps with Doxorubicin (doxorubicin)"},{"check":"near-duplicate-name","severity":"low","id":"aminolevulinic-acid","kind":"drug","name":"Aminolevulinic acid (topical, for photodynamic therapy)","route":"/drugs/aminolevulinic-acid/","detail":"name overlaps with 5-Aminolevulinic acid (oral, for glioma surgery) (aminolevulinic-acid-gleolan)"},{"check":"near-duplicate-name","severity":"low","id":"comfort-i","kind":"trial","name":"COMFORT-I","route":"/trials/comfort-i/","detail":"name overlaps with COMFORT-II (comfort-ii)"},{"check":"near-duplicate-name","severity":"low","id":"lipegfilgrastim","kind":"drug","name":"Lipegfilgrastim","route":"/drugs/lipegfilgrastim/","detail":"name overlaps with Pegfilgrastim (pegfilgrastim)"},{"check":"near-duplicate-name","severity":"low","id":"peginterferon-alfa-2b","kind":"drug","name":"Peginterferon alfa-2b","route":"/drugs/peginterferon-alfa-2b/","detail":"name overlaps with Ropeginterferon alfa-2b (ropeginterferon-alfa-2b)"},{"check":"near-duplicate-name","severity":"low","id":"nct06735144","kind":"trial","name":"Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors","route":"/trials/nct06735144/","detail":"name overlaps with A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors (nct07136142)"},{"check":"near-duplicate-name","severity":"low","id":"nct06079671","kind":"trial","name":"Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)","route":"/trials/nct06079671/","detail":"name overlaps with A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA) (nct06943833)"},{"check":"near-duplicate-name","severity":"low","id":"tumour-marker","kind":"term","name":"Tumour marker","route":"/terms/tumour-marker/","detail":"name overlaps with Tumour markers (CEA, LDH, chromogranin, thyroglobulin) (tumour-markers)"},{"check":"orphan","severity":"low","id":"nct07222969","kind":"trial","name":"A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors","route":"/trials/nct07222969/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct05908643","kind":"trial","name":"A First-In-Human Trial of pTTL in Advanced Colorectal Cancer","route":"/trials/nct05908643/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06277219","kind":"trial","name":"A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)","route":"/trials/nct06277219/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06600789","kind":"trial","name":"A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies","route":"/trials/nct06600789/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07185880","kind":"trial","name":"A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients","route":"/trials/nct07185880/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06971523","kind":"trial","name":"A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies","route":"/trials/nct06971523/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07253116","kind":"trial","name":"A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors","route":"/trials/nct07253116/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07811037","kind":"trial","name":"A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, Immunogenicity, and Preliminary Efficacy of SGT003 in Patients With Advanced Solid Tumors","route":"/trials/nct07811037/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07501559","kind":"trial","name":"A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)","route":"/trials/nct07501559/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06810804","kind":"trial","name":"A Phase IIa Study to Evaluate NBQ72S","route":"/trials/nct06810804/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06150885","kind":"trial","name":"A Safety And Efficacy Study Of Allogeneic CAR Gamma-Delta T Cells in Subjects With Relapsed/Refractory Solid Tumors","route":"/trials/nct06150885/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07321574","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors","route":"/trials/nct07321574/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06314373","kind":"trial","name":"A Study for HSK39775 in Participants With Solid Tumors","route":"/trials/nct06314373/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06977737","kind":"trial","name":"A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours","route":"/trials/nct06977737/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07192588","kind":"trial","name":"A Study of GR1014 Cutaneous Gel for the Prevention of Skin Reactions Caused by Radiation Therapy for Breast Cancer","route":"/trials/nct07192588/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07678684","kind":"trial","name":"A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma","route":"/trials/nct07678684/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct05710848","kind":"trial","name":"A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer","route":"/trials/nct05710848/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06656390","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors","route":"/trials/nct06656390/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07055594","kind":"trial","name":"A Study to Investigate Safety and Preliminary Efficacy of SOA101 in Adult Subjects With Advanced Solid Tumors","route":"/trials/nct07055594/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct02346747","kind":"trial","name":"A Trial of Vigil for Participants With Ovarian Cancer","route":"/trials/nct02346747/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"acs-brightedge","kind":"company","name":"ACS BrightEdge (American Cancer Society)","route":"/companies/acs-brightedge/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06911333","kind":"trial","name":"AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct06911333/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"alexandria-venture-investments","kind":"company","name":"Alexandria Venture Investments","route":"/companies/alexandria-venture-investments/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct04616209","kind":"trial","name":"Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients","route":"/trials/nct04616209/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07033026","kind":"trial","name":"An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.","route":"/trials/nct07033026/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06634849","kind":"trial","name":"An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1).","route":"/trials/nct06634849/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07359066","kind":"trial","name":"An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors","route":"/trials/nct07359066/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"andera-partners","kind":"company","name":"Andera Partners","route":"/companies/andera-partners/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"a16z-bio-health","kind":"company","name":"Andreessen Horowitz Bio + Health","route":"/companies/a16z-bio-health/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"arch-venture-partners","kind":"company","name":"ARCH Venture Partners","route":"/companies/arch-venture-partners/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"arden-bio","kind":"company","name":"Arden Bio","route":"/companies/arden-bio/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"atlas-venture","kind":"company","name":"Atlas Venture","route":"/companies/atlas-venture/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct04807257","kind":"trial","name":"Auger Molecular Therapy (AMT) for Malignant Cutaneous Lesions Treatment","route":"/trials/nct04807257/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct05261750","kind":"trial","name":"Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer","route":"/trials/nct05261750/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"bpifrance","kind":"company","name":"Bpifrance","route":"/companies/bpifrance/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"center-for-metabolic-oncology","kind":"institution","name":"Center for Metabolic Oncology","route":"/institutions/center-for-metabolic-oncology/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06126510","kind":"trial","name":"Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma","route":"/trials/nct06126510/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"cormorant-asset-management","kind":"company","name":"Cormorant Asset Management","route":"/companies/cormorant-asset-management/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07335497","kind":"trial","name":"CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct07335497/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07664150","kind":"trial","name":"CW-301 FIH Study of CAN016","route":"/trials/nct07664150/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"dcvc","kind":"company","name":"DCVC","route":"/companies/dcvc/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"deerfield-management","kind":"company","name":"Deerfield Management","route":"/companies/deerfield-management/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"ecor1-capital","kind":"company","name":"EcoR1 Capital","route":"/companies/ecor1-capital/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07276789","kind":"trial","name":"Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer","route":"/trials/nct07276789/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct05304481","kind":"trial","name":"Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma","route":"/trials/nct05304481/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct05374915","kind":"trial","name":"Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)","route":"/trials/nct05374915/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"eqt-life-sciences","kind":"company","name":"EQT Life Sciences","route":"/companies/eqt-life-sciences/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06262139","kind":"trial","name":"Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients","route":"/trials/nct06262139/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06612281","kind":"trial","name":"Evaluation of Gixam's Performance in a FIT Negative Population","route":"/trials/nct06612281/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06824064","kind":"trial","name":"Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer","route":"/trials/nct06824064/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07136181","kind":"trial","name":"Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma","route":"/trials/nct07136181/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"f-prime-capital","kind":"company","name":"F-Prime Capital","route":"/companies/f-prime-capital/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06154291","kind":"trial","name":"FIH XON7 in Advanced/Metastatic Solid Tumors","route":"/trials/nct06154291/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06622486","kind":"trial","name":"First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors","route":"/trials/nct06622486/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06934538","kind":"trial","name":"First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer","route":"/trials/nct06934538/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"flagship-pioneering","kind":"company","name":"Flagship Pioneering","route":"/companies/flagship-pioneering/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"forbion","kind":"company","name":"Forbion","route":"/companies/forbion/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"foresite-capital","kind":"company","name":"Foresite Capital","route":"/companies/foresite-capital/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"founders-fund","kind":"company","name":"Founders Fund","route":"/companies/founders-fund/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"frazier-life-sciences","kind":"company","name":"Frazier Life Sciences","route":"/companies/frazier-life-sciences/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"gilde-healthcare","kind":"company","name":"Gilde Healthcare","route":"/companies/gilde-healthcare/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"ignitus-bio","kind":"company","name":"Ignitus Bio","route":"/companies/ignitus-bio/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06687681","kind":"trial","name":"Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas","route":"/trials/nct06687681/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct03096093","kind":"trial","name":"Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer","route":"/trials/nct03096093/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct03878849","kind":"trial","name":"Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer","route":"/trials/nct03878849/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"jeito-capital","kind":"company","name":"Jeito Capital","route":"/companies/jeito-capital/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06193902","kind":"trial","name":"LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.","route":"/trials/nct06193902/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"lightspeed-venture-partners","kind":"company","name":"Lightspeed Venture Partners","route":"/companies/lightspeed-venture-partners/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"logos-capital","kind":"company","name":"Logos Capital","route":"/companies/logos-capital/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"longwood-fund","kind":"company","name":"Longwood Fund","route":"/companies/longwood-fund/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"mckesson-ventures","kind":"company","name":"McKesson Ventures","route":"/companies/mckesson-ventures/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct04651634","kind":"trial","name":"MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients","route":"/trials/nct04651634/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"novo-holdings","kind":"company","name":"Novo Holdings","route":"/companies/novo-holdings/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"orbimed","kind":"company","name":"OrbiMed","route":"/companies/orbimed/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct04974008","kind":"trial","name":"Osteosarcoma Maintenance Therapy With OST31-164","route":"/trials/nct04974008/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct05801237","kind":"trial","name":"PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor","route":"/trials/nct05801237/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"perceptive-advisors","kind":"company","name":"Perceptive Advisors","route":"/companies/perceptive-advisors/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"perita-bio","kind":"company","name":"Perita Bio","route":"/companies/perita-bio/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07002203","kind":"trial","name":"Personalized Neoantigen Peptide Vaccines for Solid Tumors","route":"/trials/nct07002203/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"pfizer-ventures","kind":"company","name":"Pfizer Ventures","route":"/companies/pfizer-ventures/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06139575","kind":"trial","name":"Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer","route":"/trials/nct06139575/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct04643418","kind":"trial","name":"Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors","route":"/trials/nct04643418/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06938867","kind":"trial","name":"Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant","route":"/trials/nct06938867/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07168226","kind":"trial","name":"Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101","route":"/trials/nct07168226/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06118788","kind":"trial","name":"Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","route":"/trials/nct06118788/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct05720130","kind":"trial","name":"Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).","route":"/trials/nct05720130/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07314294","kind":"trial","name":"Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients","route":"/trials/nct07314294/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct04165590","kind":"trial","name":"Plasmodium Immunotherapy for Advanced Malignant Solid Tumors","route":"/trials/nct04165590/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"polaris-partners","kind":"company","name":"Polaris Partners","route":"/companies/polaris-partners/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06665100","kind":"trial","name":"PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)","route":"/trials/nct06665100/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"ra-capital","kind":"company","name":"RA Capital Management","route":"/companies/ra-capital/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"rarivive","kind":"company","name":"Rarivive","route":"/companies/rarivive/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06937177","kind":"trial","name":"Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy","route":"/trials/nct06937177/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct05558007","kind":"trial","name":"Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients","route":"/trials/nct05558007/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06506643","kind":"trial","name":"Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms","route":"/trials/nct06506643/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct04959903","kind":"trial","name":"Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT","route":"/trials/nct04959903/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06737081","kind":"trial","name":"SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies","route":"/trials/nct06737081/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"samsara-biocapital","kind":"company","name":"Samsara BioCapital","route":"/companies/samsara-biocapital/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"sanofi-ventures","kind":"company","name":"Sanofi Ventures","route":"/companies/sanofi-ventures/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"sante-ventures","kind":"company","name":"Sante Ventures","route":"/companies/sante-ventures/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"section-32","kind":"company","name":"Section 32 (S32)","route":"/companies/section-32/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06819735","kind":"trial","name":"Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors","route":"/trials/nct06819735/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06616389","kind":"trial","name":"Study of ODX (OsteoDex) in Multiple Myeloma","route":"/trials/nct06616389/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct07765446","kind":"trial","name":"Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel","route":"/trials/nct07765446/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06260774","kind":"trial","name":"Study of TTX-MC138 in Subjects With Advanced Solid Tumors","route":"/trials/nct06260774/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06580301","kind":"trial","name":"Study of YK012 in B-cell Acute Lymphoblastic Leukemia","route":"/trials/nct06580301/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct05499013","kind":"trial","name":"Study to Assess SLN124 in Patients With Polycythemia Vera","route":"/trials/nct05499013/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"nct06234098","kind":"trial","name":"Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors","route":"/trials/nct06234098/","detail":"no incoming links and 1 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"sv-health-investors","kind":"company","name":"SV Health Investors","route":"/companies/sv-health-investors/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"tcgx","kind":"company","name":"TCGX (TCG Crossover)","route":"/companies/tcgx/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"venrock","kind":"company","name":"Venrock","route":"/companies/venrock/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"orphan","severity":"low","id":"versant-ventures","kind":"company","name":"Versant Ventures","route":"/companies/versant-ventures/","detail":"no incoming links and 0 outgoing; link it from a cancer, target, technology or company page, or merge it into an existing record"},{"check":"regional-approval-only","severity":"low","id":"amrubicin","kind":"drug","name":"Amrubicin","route":"/drugs/amrubicin/","detail":"approved only outside US/EU (JP 2002); status \"established\" describes the global stage"},{"check":"text-says-approved","severity":"low","id":"i131-mibg","kind":"drug","name":"131I-MIBG (iobenguane I-131) therapy","route":"/drugs/i131-mibg/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"alitretinoin","kind":"drug","name":"Alitretinoin","route":"/drugs/alitretinoin/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"altretamine","kind":"drug","name":"Altretamine","route":"/drugs/altretamine/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"aminoglutethimide","kind":"drug","name":"Aminoglutethimide","route":"/drugs/aminoglutethimide/","detail":"text mentions approval but status is \"historic\""},{"check":"text-says-approved","severity":"low","id":"amsacrine","kind":"drug","name":"Amsacrine","route":"/drugs/amsacrine/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"cam2029","kind":"drug","name":"CAM2029 (octreotide subcutaneous depot)","route":"/drugs/cam2029/","detail":"text mentions approval but status is \"phase-3\""},{"check":"text-says-approved","severity":"low","id":"choline-c11","kind":"drug","name":"Choline C-11","route":"/drugs/choline-c11/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"cinacalcet","kind":"drug","name":"Cinacalcet","route":"/drugs/cinacalcet/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"dronabinol","kind":"drug","name":"Dronabinol","route":"/drugs/dronabinol/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"eltrombopag","kind":"drug","name":"Eltrombopag","route":"/drugs/eltrombopag/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"estramustine","kind":"drug","name":"Estramustine","route":"/drugs/estramustine/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"ethiodized-oil","kind":"drug","name":"Ethiodized oil","route":"/drugs/ethiodized-oil/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"fenbendazole","kind":"drug","name":"Fenbendazole (veterinary anthelmintic)","route":"/drugs/fenbendazole/","detail":"text mentions approval but status is \"preclinical\""},{"check":"text-says-approved","severity":"low","id":"floxuridine","kind":"drug","name":"Floxuridine","route":"/drugs/floxuridine/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"fostamatinib","kind":"drug","name":"Fostamatinib","route":"/drugs/fostamatinib/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","detail":"text mentions approval but status is \"phase-2\""},{"check":"text-says-approved","severity":"low","id":"methoxsalen-ecp","kind":"drug","name":"Methoxsalen (extracorporeal photopheresis)","route":"/drugs/methoxsalen-ecp/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"methyl-aminolevulinate","kind":"drug","name":"Methyl aminolevulinate","route":"/drugs/methyl-aminolevulinate/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"metyrapone","kind":"drug","name":"Metyrapone","route":"/drugs/metyrapone/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"peginterferon-alfa-2b","kind":"drug","name":"Peginterferon alfa-2b","route":"/drugs/peginterferon-alfa-2b/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"pipobroman","kind":"drug","name":"Pipobroman","route":"/drugs/pipobroman/","detail":"text mentions approval but status is \"historic\""},{"check":"text-says-approved","severity":"low","id":"plicamycin","kind":"drug","name":"Plicamycin","route":"/drugs/plicamycin/","detail":"text mentions approval but status is \"historic\""},{"check":"text-says-approved","severity":"low","id":"propranolol-hemangeol","kind":"drug","name":"Propranolol (Hemangeol)","route":"/drugs/propranolol-hemangeol/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"raltitrexed","kind":"drug","name":"Raltitrexed","route":"/drugs/raltitrexed/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"romiplostim","kind":"drug","name":"Romiplostim","route":"/drugs/romiplostim/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"sargramostim","kind":"drug","name":"Sargramostim","route":"/drugs/sargramostim/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"streptozocin","kind":"drug","name":"Streptozocin","route":"/drugs/streptozocin/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"teniposide","kind":"drug","name":"Teniposide","route":"/drugs/teniposide/","detail":"text mentions approval but status is \"established\""},{"check":"text-says-approved","severity":"low","id":"uracil-mustard","kind":"drug","name":"Uracil mustard","route":"/drugs/uracil-mustard/","detail":"text mentions approval but status is \"historic\""},{"check":"text-vs-structured","severity":"low","id":"peginterferon-alfa-2b","kind":"drug","name":"Peginterferon alfa-2b","route":"/drugs/peginterferon-alfa-2b/","detail":"text mentions approval in 2000 but the earliest recorded approval is 2011; add the missing approvals[] row or correct the year"},{"check":"unsourced","severity":"low","id":"1746","kind":"year","name":"1746 in oncology","route":"/years/1746/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1775","kind":"year","name":"1775 in oncology","route":"/years/1775/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1777","kind":"year","name":"1777 in oncology","route":"/years/1777/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1806","kind":"year","name":"1806 in oncology","route":"/years/1806/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1809","kind":"year","name":"1809 in oncology","route":"/years/1809/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1812","kind":"year","name":"1812 in oncology","route":"/years/1812/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1814","kind":"year","name":"1814 in oncology","route":"/years/1814/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1823","kind":"year","name":"1823 in oncology","route":"/years/1823/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1832","kind":"year","name":"1832 in oncology","route":"/years/1832/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1834","kind":"year","name":"1834 in oncology","route":"/years/1834/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1838","kind":"year","name":"1838 in oncology","route":"/years/1838/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1840","kind":"year","name":"1840 in oncology","route":"/years/1840/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1842","kind":"year","name":"1842 in oncology","route":"/years/1842/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1844","kind":"year","name":"1844 in oncology","route":"/years/1844/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1845","kind":"year","name":"1845 in oncology","route":"/years/1845/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1855","kind":"year","name":"1855 in oncology","route":"/years/1855/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1857","kind":"year","name":"1857 in oncology","route":"/years/1857/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1859","kind":"year","name":"1859 in oncology","route":"/years/1859/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1869","kind":"year","name":"1869 in oncology","route":"/years/1869/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1870","kind":"year","name":"1870 in oncology","route":"/years/1870/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1872","kind":"year","name":"1872 in oncology","route":"/years/1872/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1873","kind":"year","name":"1873 in oncology","route":"/years/1873/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1874","kind":"year","name":"1874 in oncology","route":"/years/1874/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1875","kind":"year","name":"1875 in oncology","route":"/years/1875/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1878","kind":"year","name":"1878 in oncology","route":"/years/1878/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1879","kind":"year","name":"1879 in oncology","route":"/years/1879/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1880","kind":"year","name":"1880 in oncology","route":"/years/1880/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1881","kind":"year","name":"1881 in oncology","route":"/years/1881/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1882","kind":"year","name":"1882 in oncology","route":"/years/1882/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1883","kind":"year","name":"1883 in oncology","route":"/years/1883/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1884","kind":"year","name":"1884 in oncology","route":"/years/1884/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1886","kind":"year","name":"1886 in oncology","route":"/years/1886/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1887","kind":"year","name":"1887 in oncology","route":"/years/1887/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1888","kind":"year","name":"1888 in oncology","route":"/years/1888/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1889","kind":"year","name":"1889 in oncology","route":"/years/1889/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1892","kind":"year","name":"1892 in oncology","route":"/years/1892/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1894","kind":"year","name":"1894 in oncology","route":"/years/1894/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1896","kind":"year","name":"1896 in oncology","route":"/years/1896/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1898","kind":"year","name":"1898 in oncology","route":"/years/1898/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1899","kind":"year","name":"1899 in oncology","route":"/years/1899/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1900","kind":"year","name":"1900 in oncology","route":"/years/1900/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1901","kind":"year","name":"1901 in oncology","route":"/years/1901/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1902","kind":"year","name":"1902 in oncology","route":"/years/1902/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1903","kind":"year","name":"1903 in oncology","route":"/years/1903/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1904","kind":"year","name":"1904 in oncology","route":"/years/1904/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1905","kind":"year","name":"1905 in oncology","route":"/years/1905/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1906","kind":"year","name":"1906 in oncology","route":"/years/1906/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1907","kind":"year","name":"1907 in oncology","route":"/years/1907/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1908","kind":"year","name":"1908 in oncology","route":"/years/1908/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1909","kind":"year","name":"1909 in oncology","route":"/years/1909/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1910","kind":"year","name":"1910 in oncology","route":"/years/1910/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1911","kind":"year","name":"1911 in oncology","route":"/years/1911/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1912","kind":"year","name":"1912 in oncology","route":"/years/1912/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1913","kind":"year","name":"1913 in oncology","route":"/years/1913/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1914","kind":"year","name":"1914 in oncology","route":"/years/1914/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1915","kind":"year","name":"1915 in oncology","route":"/years/1915/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1916","kind":"year","name":"1916 in oncology","route":"/years/1916/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1917","kind":"year","name":"1917 in oncology","route":"/years/1917/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1918","kind":"year","name":"1918 in oncology","route":"/years/1918/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1919","kind":"year","name":"1919 in oncology","route":"/years/1919/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1920","kind":"year","name":"1920 in oncology","route":"/years/1920/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1921","kind":"year","name":"1921 in oncology","route":"/years/1921/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1922","kind":"year","name":"1922 in oncology","route":"/years/1922/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1923","kind":"year","name":"1923 in oncology","route":"/years/1923/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1924","kind":"year","name":"1924 in oncology","route":"/years/1924/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1925","kind":"year","name":"1925 in oncology","route":"/years/1925/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1926","kind":"year","name":"1926 in oncology","route":"/years/1926/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1927","kind":"year","name":"1927 in oncology","route":"/years/1927/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1928","kind":"year","name":"1928 in oncology","route":"/years/1928/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1929","kind":"year","name":"1929 in oncology","route":"/years/1929/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1930","kind":"year","name":"1930 in oncology","route":"/years/1930/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1931","kind":"year","name":"1931 in oncology","route":"/years/1931/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1932","kind":"year","name":"1932 in oncology","route":"/years/1932/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1933","kind":"year","name":"1933 in oncology","route":"/years/1933/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1934","kind":"year","name":"1934 in oncology","route":"/years/1934/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1935","kind":"year","name":"1935 in oncology","route":"/years/1935/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1936","kind":"year","name":"1936 in oncology","route":"/years/1936/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1937","kind":"year","name":"1937 in oncology","route":"/years/1937/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1938","kind":"year","name":"1938 in oncology","route":"/years/1938/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1939","kind":"year","name":"1939 in oncology","route":"/years/1939/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1940","kind":"year","name":"1940 in oncology","route":"/years/1940/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1941","kind":"year","name":"1941 in oncology","route":"/years/1941/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1942","kind":"year","name":"1942 in oncology","route":"/years/1942/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1943","kind":"year","name":"1943 in oncology","route":"/years/1943/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1944","kind":"year","name":"1944 in oncology","route":"/years/1944/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1945","kind":"year","name":"1945 in oncology","route":"/years/1945/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1946","kind":"year","name":"1946 in oncology","route":"/years/1946/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1947","kind":"year","name":"1947 in oncology","route":"/years/1947/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1948","kind":"year","name":"1948 in oncology","route":"/years/1948/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1949","kind":"year","name":"1949 in oncology","route":"/years/1949/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1950","kind":"year","name":"1950 in oncology","route":"/years/1950/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1951","kind":"year","name":"1951 in oncology","route":"/years/1951/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1952","kind":"year","name":"1952 in oncology","route":"/years/1952/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1953","kind":"year","name":"1953 in oncology","route":"/years/1953/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1954","kind":"year","name":"1954 in oncology","route":"/years/1954/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1955","kind":"year","name":"1955 in oncology","route":"/years/1955/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1956","kind":"year","name":"1956 in oncology","route":"/years/1956/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1957","kind":"year","name":"1957 in oncology","route":"/years/1957/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1958","kind":"year","name":"1958 in oncology","route":"/years/1958/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1959","kind":"year","name":"1959 in oncology","route":"/years/1959/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1960","kind":"year","name":"1960 in oncology","route":"/years/1960/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1961","kind":"year","name":"1961 in oncology","route":"/years/1961/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1962","kind":"year","name":"1962 in oncology","route":"/years/1962/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1963","kind":"year","name":"1963 in oncology","route":"/years/1963/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1964","kind":"year","name":"1964 in oncology","route":"/years/1964/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1965","kind":"year","name":"1965 in oncology","route":"/years/1965/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1966","kind":"year","name":"1966 in oncology","route":"/years/1966/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1967","kind":"year","name":"1967 in oncology","route":"/years/1967/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1968","kind":"year","name":"1968 in oncology","route":"/years/1968/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1969","kind":"year","name":"1969 in oncology","route":"/years/1969/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1970","kind":"year","name":"1970 in oncology","route":"/years/1970/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1971","kind":"year","name":"1971 in oncology","route":"/years/1971/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1972","kind":"year","name":"1972 in oncology","route":"/years/1972/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1973","kind":"year","name":"1973 in oncology","route":"/years/1973/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1974","kind":"year","name":"1974 in oncology","route":"/years/1974/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1975","kind":"year","name":"1975 in oncology","route":"/years/1975/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1976","kind":"year","name":"1976 in oncology","route":"/years/1976/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1977","kind":"year","name":"1977 in oncology","route":"/years/1977/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1978","kind":"year","name":"1978 in oncology","route":"/years/1978/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1979","kind":"year","name":"1979 in oncology","route":"/years/1979/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1980","kind":"year","name":"1980 in oncology","route":"/years/1980/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1981","kind":"year","name":"1981 in oncology","route":"/years/1981/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1982","kind":"year","name":"1982 in oncology","route":"/years/1982/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1983","kind":"year","name":"1983 in oncology","route":"/years/1983/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1984","kind":"year","name":"1984 in oncology","route":"/years/1984/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1985","kind":"year","name":"1985 in oncology","route":"/years/1985/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1986","kind":"year","name":"1986 in oncology","route":"/years/1986/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1987","kind":"year","name":"1987 in oncology","route":"/years/1987/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1988","kind":"year","name":"1988 in oncology","route":"/years/1988/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1989","kind":"year","name":"1989 in oncology","route":"/years/1989/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1990","kind":"year","name":"1990 in oncology","route":"/years/1990/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1991","kind":"year","name":"1991 in oncology","route":"/years/1991/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1992","kind":"year","name":"1992 in oncology","route":"/years/1992/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1993","kind":"year","name":"1993 in oncology","route":"/years/1993/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1994","kind":"year","name":"1994 in oncology","route":"/years/1994/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1995","kind":"year","name":"1995 in oncology","route":"/years/1995/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1996","kind":"year","name":"1996 in oncology","route":"/years/1996/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1997","kind":"year","name":"1997 in oncology","route":"/years/1997/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1998","kind":"year","name":"1998 in oncology","route":"/years/1998/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1999","kind":"year","name":"1999 in oncology","route":"/years/1999/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"1p19q-codeletion","kind":"term","name":"1p/19q codeletion","route":"/terms/1p19q-codeletion/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"2000","kind":"year","name":"2000 in oncology","route":"/years/2000/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"2001","kind":"year","name":"2001 in oncology","route":"/years/2001/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"2002","kind":"year","name":"2002 in oncology","route":"/years/2002/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"2003","kind":"year","name":"2003 in oncology","route":"/years/2003/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"2004","kind":"year","name":"2004 in oncology","route":"/years/2004/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"2005","kind":"year","name":"2005 in oncology","route":"/years/2005/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"2006","kind":"year","name":"2006 in oncology","route":"/years/2006/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"2007","kind":"year","name":"2007 in oncology","route":"/years/2007/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"2008","kind":"year","name":"2008 in oncology","route":"/years/2008/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"2009","kind":"year","name":"2009 in oncology","route":"/years/2009/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"2010","kind":"year","name":"2010 in oncology","route":"/years/2010/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"2011","kind":"year","name":"2011 in oncology","route":"/years/2011/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"2012","kind":"year","name":"2012 in oncology","route":"/years/2012/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"2013","kind":"year","name":"2013 in oncology","route":"/years/2013/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"2014","kind":"year","name":"2014 in oncology","route":"/years/2014/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"2015","kind":"year","name":"2015 in oncology","route":"/years/2015/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"2016","kind":"year","name":"2016 in oncology","route":"/years/2016/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"2017","kind":"year","name":"2017 in oncology","route":"/years/2017/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"2018","kind":"year","name":"2018 in oncology","route":"/years/2018/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"2019","kind":"year","name":"2019 in oncology","route":"/years/2019/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"2020","kind":"year","name":"2020 in oncology","route":"/years/2020/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"2021","kind":"year","name":"2021 in oncology","route":"/years/2021/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"2022","kind":"year","name":"2022 in oncology","route":"/years/2022/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"2023","kind":"year","name":"2023 in oncology","route":"/years/2023/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"2024","kind":"year","name":"2024 in oncology","route":"/years/2024/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"2025","kind":"year","name":"2025 in oncology","route":"/years/2025/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"2026","kind":"year","name":"2026 in oncology","route":"/years/2026/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"2027","kind":"year","name":"2027 in oncology","route":"/years/2027/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"2028","kind":"year","name":"2028 in oncology","route":"/years/2028/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"2029","kind":"year","name":"2029 in oncology","route":"/years/2029/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"2030","kind":"year","name":"2030 in oncology","route":"/years/2030/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"2031","kind":"year","name":"2031 in oncology","route":"/years/2031/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"2032","kind":"year","name":"2032 in oncology","route":"/years/2032/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"2033","kind":"year","name":"2033 in oncology","route":"/years/2033/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ai-compute-platforms","kind":"technology","name":"AI compute and model platforms for oncology","route":"/technologies/ai-compute-platforms/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"aleksandar-sekulic","kind":"person","name":"Aleksandar Sekulic","route":"/people/aleksandar-sekulic/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"alexander-stratigos","kind":"person","name":"Alexander J. Stratigos","route":"/people/alexander-stratigos/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"alice-chen","kind":"person","name":"Alice P. Chen","route":"/people/alice-chen/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"alice-shaw","kind":"person","name":"Alice T. Shaw","route":"/people/alice-shaw/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-alpha-after-adc","kind":"idea","name":"Alpha radioligands after ADC failure","route":"/ideas/idea-alpha-after-adc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"amanda-fader","kind":"person","name":"Amanda Nickles Fader","route":"/people/amanda-fader/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"amer-zeidan","kind":"person","name":"Amer M. Zeidan","route":"/people/amer-zeidan/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"aml-myelodysplasia-related","kind":"term","name":"AML with myelodysplasia-related gene mutations (AML-MR)","route":"/terms/aml-myelodysplasia-related/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ana-oaknin","kind":"person","name":"Ana Oaknin","route":"/people/ana-oaknin/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"andrea-decensi","kind":"person","name":"Andrea DeCensi","route":"/people/andrea-decensi/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"andrea-sartore-bianchi","kind":"person","name":"Andrea Sartore-Bianchi","route":"/people/andrea-sartore-bianchi/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"andrew-lassman","kind":"person","name":"Andrew B. Lassman","route":"/people/andrew-lassman/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"andrew-wagner","kind":"person","name":"Andrew J. Wagner","route":"/people/andrew-wagner/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"andrew-zhu","kind":"person","name":"Andrew X. Zhu","route":"/people/andrew-zhu/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"angela-lamarca","kind":"person","name":"Angela Lamarca","route":"/people/angela-lamarca/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"anthony-nichols","kind":"person","name":"Anthony C. Nichols","route":"/people/anthony-nichols/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"antoine-italiano","kind":"person","name":"Antoine Italiano","route":"/people/antoine-italiano/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"b-all-cytogenetic-risk","kind":"term","name":"B-ALL risk groups (NCI criteria, ETV6::RUNX1, hyperdiploidy, hypodiploidy, iAMP21, IKZF1, CNS status)","route":"/terms/b-all-cytogenetic-risk/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"abl1-kinase-domain-mutations","kind":"term","name":"BCR::ABL1 kinase domain mutations (T315I and others)","route":"/terms/abl1-kinase-domain-mutations/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"brca-reversion-mutations","kind":"term","name":"BRCA reversion mutations","route":"/terms/brca-reversion-mutations/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"brigimadlin","kind":"drug","name":"Brigimadlin","route":"/drugs/brigimadlin/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"bryan-haugen","kind":"person","name":"Bryan R. Haugen","route":"/people/bryan-haugen/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"btki-bcl2i-resistance-mutations","kind":"term","name":"BTK C481S, PLCG2 and BCL2 G101V resistance mutations","route":"/terms/btki-bcl2i-resistance-mutations/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"cancer-ai-vocabulary","kind":"term","name":"Cancer AI vocabulary (CanSim terms map)","route":"/terms/cancer-ai-vocabulary/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"caron-jacobson","kind":"person","name":"Caron A. Jacobson","route":"/people/caron-jacobson/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"carotuximab","kind":"drug","name":"Carotuximab","route":"/drugs/carotuximab/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"checkpoint","kind":"term","name":"Checkpoint (two meanings)","route":"/terms/checkpoint/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"china-hgr-rules","kind":"term","name":"China Human Genetic Resources rules (2019, 2023)","route":"/terms/china-hgr-rules/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"chris-parker","kind":"person","name":"Chris C. Parker","route":"/people/chris-parker/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-pv-clone-directed-therapy","kind":"idea","name":"Clearing the JAK2 clone in polycythaemia vera: interferon plus mutant-selective inhibitors as a route to treatment-free remission","route":"/ideas/idea-pv-clone-directed-therapy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"cll-ipi","kind":"term","name":"CLL-IPI (chronic lymphocytic leukaemia prognostic index)","route":"/terms/cll-ipi/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"danny-rischin","kind":"person","name":"Danny Rischin","route":"/people/danny-rischin/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"daromun","kind":"drug","name":"Daromun","route":"/drugs/daromun/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"darren-hargrave","kind":"person","name":"Darren R. Hargrave","route":"/people/darren-hargrave/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"david-dearnaley","kind":"person","name":"David Dearnaley","route":"/people/david-dearnaley/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"david-gershenson","kind":"person","name":"David M. Gershenson","route":"/people/david-gershenson/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-lung-screening-eligibility-by-risk-not-pack-years","kind":"idea","name":"Decide who is screened for lung cancer by individual risk, not by pack-years","route":"/ideas/idea-lung-screening-eligibility-by-risk-not-pack-years/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"depth-of-invasion","kind":"term","name":"Depth of invasion (DOI)","route":"/terms/depth-of-invasion/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"dipss-mipss70","kind":"term","name":"DIPSS, DIPSS-plus and MIPSS70 (myelofibrosis risk scores)","route":"/terms/dipss-mipss70/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"disease-volume-chaarted","kind":"term","name":"Disease volume (CHAARTED high-volume versus low-volume) and LATITUDE risk","route":"/terms/disease-volume-chaarted/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"shelley-hwang","kind":"person","name":"E. Shelley Hwang","route":"/people/shelley-hwang/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-efflux-agnostic","kind":"idea","name":"Efflux-agnostic therapy for mesenchymal TNBC","route":"/ideas/idea-efflux-agnostic/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ependymoma-molecular-groups","kind":"term","name":"Ependymoma molecular groups (PF-A, PF-B, ZFTA, YAP1, MYCN)","route":"/terms/ependymoma-molecular-groups/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"eric-jonasch","kind":"person","name":"Eric Jonasch","route":"/people/eric-jonasch/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"extranodal-extension","kind":"term","name":"Extranodal extension (ENE)","route":"/terms/extranodal-extension/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"florence-duffaud","kind":"person","name":"Florence Duffaud","route":"/people/florence-duffaud/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"foxo1-fusion-status","kind":"term","name":"FOXO1 fusion status and IRS group (rhabdomyosarcoma)","route":"/terms/foxo1-fusion-status/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"francesco-lo-coco","kind":"person","name":"Francesco Lo-Coco","route":"/people/francesco-lo-coco/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"fred-saad","kind":"person","name":"Fred Saad","route":"/people/fred-saad/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"gerald-prager","kind":"person","name":"Gerald W. Prager","route":"/people/gerald-prager/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"gerhardt-attard","kind":"person","name":"Gerhardt Attard","route":"/people/gerhardt-attard/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"gi-6301","kind":"drug","name":"GI-6301","route":"/drugs/gi-6301/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"giles-robinson","kind":"person","name":"Giles W. Robinson","route":"/people/giles-robinson/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"gist-risk-stratification","kind":"term","name":"GIST risk stratification (mitotic count, size, site; Miettinen and modified NIH criteria)","route":"/terms/gist-risk-stratification/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"graded-prognostic-assessment","kind":"term","name":"Graded Prognostic Assessment (GPA) for brain metastases","route":"/terms/graded-prognostic-assessment/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"gregory-riely","kind":"person","name":"Gregory J. Riely","route":"/people/gregory-riely/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"miles-prince","kind":"person","name":"H. Miles Prince","route":"/people/miles-prince/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"hansjochen-wilke","kind":"person","name":"Hansjochen Wilke","route":"/people/hansjochen-wilke/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"hb-200","kind":"drug","name":"HB-200","route":"/drugs/hb-200/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"heikki-joensuu","kind":"person","name":"Heikki Joensuu","route":"/people/heikki-joensuu/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-pv-hepcidin-first","kind":"idea","name":"Hepcidin-based control as first-line treatment in low-risk polycythaemia vera","route":"/ideas/idea-pv-hepcidin-first/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"herve-dombret","kind":"person","name":"Hervé Dombret","route":"/people/herve-dombret/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"histological-response-induction","kind":"term","name":"Histological response to induction chemotherapy (osteosarcoma and Ewing sarcoma)","route":"/terms/histological-response-induction/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ihc-autostainers-histology-automation","kind":"technology","name":"Histology automation and IHC autostainers","route":"/technologies/ihc-autostainers-histology-automation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"hitoshi-katai","kind":"person","name":"Hitoshi Katai","route":"/people/hitoshi-katai/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"hyung-ho-kim","kind":"person","name":"Hyung-Ho Kim","route":"/people/hyung-ho-kim/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"inca033989","kind":"drug","name":"INCA033989","route":"/drugs/inca033989/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"inge-van-der-sluis","kind":"person","name":"Inge M. van der Sluis","route":"/people/inge-van-der-sluis/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"interferon-gamma-signature","kind":"term","name":"Interferon-gamma gene signature (T-cell-inflamed signature)","route":"/terms/interferon-gamma-signature/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ipset-thrombosis","kind":"term","name":"IPSET-thrombosis score (essential thrombocythaemia)","route":"/terms/ipset-thrombosis/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"jacques-grill","kind":"person","name":"Jacques Grill","route":"/people/jacques-grill/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"jan-burger","kind":"person","name":"Jan A. Burger","route":"/people/jan-burger/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"jan-buckner","kind":"person","name":"Jan C. Buckner","route":"/people/jan-buckner/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"jean-jacques-grob","kind":"person","name":"Jean-Jacques Grob","route":"/people/jean-jacques-grob/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"jean-pascal-machiels","kind":"person","name":"Jean-Pascal Machiels","route":"/people/jean-pascal-machiels/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"jeffrey-gershenwald","kind":"person","name":"Jeffrey E. Gershenwald","route":"/people/jeffrey-gershenwald/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"jeffrey-lancet","kind":"person","name":"Jeffrey E. Lancet","route":"/people/jeffrey-lancet/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"jennifer-chan","kind":"person","name":"Jennifer A. Chan","route":"/people/jennifer-chan/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"jens-hoeppner","kind":"person","name":"Jens Höppner","route":"/people/jens-hoeppner/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"joel-guigay","kind":"person","name":"Joël Guigay","route":"/people/joel-guigay/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"john-strickler","kind":"person","name":"John H. Strickler","route":"/people/john-strickler/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"john-kirkwood","kind":"person","name":"John M. Kirkwood","route":"/people/john-kirkwood/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"john-primrose","kind":"person","name":"John N. Primrose","route":"/people/john-primrose/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"john-leonard","kind":"person","name":"John P. Leonard","route":"/people/john-leonard/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"jong-mu-sun","kind":"person","name":"Jong-Mu Sun","route":"/people/jong-mu-sun/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"jordi-bruix","kind":"person","name":"Jordi Bruix","route":"/people/jordi-bruix/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prostate-metastatic-presentation-as-the-screening-endpoint","kind":"idea","name":"Judge a prostate screening programme on metastatic presentation, not on incidence or mortality","route":"/ideas/idea-prostate-metastatic-presentation-as-the-screening-endpoint/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"julien-hadoux","kind":"person","name":"Julien Hadoux","route":"/people/julien-hadoux/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"keith-bible","kind":"person","name":"Keith C. Bible","route":"/people/keith-bible/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"keunchil-park","kind":"person","name":"Keunchil Park","route":"/people/keunchil-park/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"kimberly-dunsmore","kind":"person","name":"Kimberly P. Dunsmore","route":"/people/kimberly-dunsmore/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"krishnansu-tewari","kind":"person","name":"Krishnansu S. Tewari","route":"/people/krishnansu-tewari/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"luca-gianni","kind":"person","name":"Luca Gianni","route":"/people/luca-gianni/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-lung-resistance-directed-sequencing-at-every-progression","kind":"idea","name":"Make resistance a diagnosis: sequence at every progression and choose the next line from what the tumour became","route":"/ideas/idea-lung-resistance-directed-sequencing-at-every-progression/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"manish-shah","kind":"person","name":"Manish A. Shah","route":"/people/manish-shah/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"maria-de-santis","kind":"person","name":"Maria De Santis","route":"/people/maria-de-santis/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"marie-plante","kind":"person","name":"Marie Plante","route":"/people/marie-plante/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"mark-robson","kind":"person","name":"Mark E. Robson","route":"/people/mark-robson/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"matthew-hellmann","kind":"person","name":"Matthew D. Hellmann","route":"/people/matthew-hellmann/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-lung-brain-metastasis-prevention-as-a-primary-endpoint","kind":"idea","name":"Measure brain metastasis prevention as a primary endpoint, not as a secondary one","route":"/ideas/idea-lung-brain-metastasis-prevention-as-a-primary-endpoint/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"met-exon-14-skipping","kind":"term","name":"MET exon 14 skipping mutation","route":"/terms/met-exon-14-skipping/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"curie-siopen-score","kind":"term","name":"MIBG Curie and SIOPEN scores","route":"/terms/curie-siopen-score/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"michael-atkins","kind":"person","name":"Michael B. Atkins","route":"/people/michael-atkins/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"michael-heinrich","kind":"person","name":"Michael C. Heinrich","route":"/people/michael-heinrich/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"michael-migden","kind":"person","name":"Michael R. Migden","route":"/people/michael-migden/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"michel-attal","kind":"person","name":"Michel Attal","route":"/people/michel-attal/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"miguel-sanz","kind":"person","name":"Miguel A. Sanz","route":"/people/miguel-sanz/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"mipi","kind":"term","name":"MIPI (Mantle Cell Lymphoma International Prognostic Index)","route":"/terms/mipi/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"mlh1-promoter-methylation","kind":"term","name":"MLH1 promoter methylation (sporadic versus Lynch mismatch repair loss)","route":"/terms/mlh1-promoter-methylation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"mpn-driver-mutations","kind":"term","name":"MPN driver mutations (JAK2 V617F, CALR, MPL) and allele burden","route":"/terms/mpn-driver-mutations/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"neil-gross","kind":"person","name":"Neil D. Gross","route":"/people/neil-gross/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"neovax","kind":"drug","name":"NeoVax","route":"/drugs/neovax/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"nsmp","kind":"term","name":"No specific molecular profile (NSMP) endometrial cancer","route":"/terms/nsmp/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"obrixtamig","kind":"drug","name":"Obrixtamig","route":"/drugs/obrixtamig/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"olivier-chinot","kind":"person","name":"Olivier L. Chinot","route":"/people/olivier-chinot/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"pharmacy-automation","kind":"technology","name":"Oncology pharmacy automation and compounding robots","route":"/technologies/pharmacy-automation/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"paltusotine","kind":"drug","name":"Paltusotine","route":"/drugs/paltusotine/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"cure-paths","kind":"roadmap","name":"Paths to cures: interception, eradication, control","route":"/roadmaps/cure-paths/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"patidegib","kind":"drug","name":"Patidegib","route":"/drugs/patidegib/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-organoid-guided-adc","kind":"idea","name":"Patient-derived organoids to pick ADC payloads","route":"/ideas/idea-organoid-guided-adc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"patricia-pautier","kind":"person","name":"Patricia Pautier","route":"/people/patricia-pautier/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"paul-chapman","kind":"person","name":"Paul B. Chapman","route":"/people/paul-chapman/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"paul-brown","kind":"person","name":"Paul D. Brown","route":"/people/paul-brown/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"paul-paik","kind":"person","name":"Paul K. Paik","route":"/people/paul-paik/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"peter-thuss-patience","kind":"person","name":"Peter Thuss-Patience","route":"/people/peter-thuss-patience/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ph-like-all","kind":"term","name":"Ph-like (BCR::ABL1-like) acute lymphoblastic leukaemia","route":"/terms/ph-like-all/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"philippe-armand","kind":"person","name":"Philippe Armand","route":"/people/philippe-armand/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"piotr-rutkowski","kind":"person","name":"Piotr Rutkowski","route":"/people/piotr-rutkowski/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"pretext-chic","kind":"term","name":"PRETEXT and CHIC risk groups (hepatoblastoma)","route":"/terms/pretext-chic/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"psa-kinetics","kind":"term","name":"PSA kinetics: PSA doubling time and PSA density","route":"/terms/psa-kinetics/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prostate-per-lesion-mri-audit-before-focal-treatment","kind":"idea","name":"Publish a per-lesion miss rate for every prostate MRI service before it is allowed to guide focal treatment","route":"/ideas/idea-prostate-per-lesion-mri-audit-before-focal-treatment/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-lung-uk-screening-testing-and-access-gaps","kind":"idea","name":"Publish the four numbers the NHS lung cancer pathway does not currently measure: reflex testing rate, genomic turnaround, surgical access and a lung-specific waiting time in every nation","route":"/ideas/idea-lung-uk-screening-testing-and-access-gaps/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"quincy-chu","kind":"person","name":"Quincy Chu","route":"/people/quincy-chu/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"raajit-rampal","kind":"person","name":"Raajit K. Rampal","route":"/people/raajit-rampal/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"frontier-2035","kind":"roadmap","name":"Radical oncology: what could change the war by 2035","route":"/roadmaps/frontier-2035/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ralf-gutzmer","kind":"person","name":"Ralf Gutzmer","route":"/people/ralf-gutzmer/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prostate-randomise-the-sequence-not-only-the-drugs","kind":"idea","name":"Randomise the order of treatment, not only the drugs: a strategy platform for metastatic prostate cancer","route":"/ideas/idea-prostate-randomise-the-sequence-not-only-the-drugs/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"rashmi-murthy","kind":"person","name":"Rashmi K. Murthy","route":"/people/rashmi-murthy/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"registry-based-trial","kind":"term","name":"Registry-based randomised trial","route":"/terms/registry-based-trial/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"remi-nout","kind":"person","name":"Remi A. Nout","route":"/people/remi-nout/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prostate-other-cause-mortality-as-a-reported-service-outcome","kind":"idea","name":"Report death from other causes as an outcome of the prostate cancer service, split by deprivation and ethnicity","route":"/ideas/idea-prostate-other-cause-mortality-as-a-reported-service-outcome/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"rob-pieters","kind":"person","name":"Rob Pieters","route":"/people/rob-pieters/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"robert-doebele","kind":"person","name":"Robert C. Doebele","route":"/people/robert-doebele/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"robert-ferris","kind":"person","name":"Robert L. Ferris","route":"/people/robert-ferris/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"robin-kate-kelley","kind":"person","name":"Robin Kate Kelley","route":"/people/robin-kate-kelley/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"robin-jones","kind":"person","name":"Robin L. Jones","route":"/people/robin-jones/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"rona-yaeger","kind":"person","name":"Rona Yaeger","route":"/people/rona-yaeger/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"rossella-elisei","kind":"person","name":"Rossella Elisei","route":"/people/rossella-elisei/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-lung-small-cell-platform-with-shared-controls-and-subtypes","kind":"idea","name":"Run small-cell lung cancer as one platform with shared controls and subtype stratification","route":"/ideas/idea-lung-small-cell-platform-with-shared-controls-and-subtypes/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"rupert-bartsch","kind":"person","name":"Rupert Bartsch","route":"/people/rupert-bartsch/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"salah-eddin-al-batran","kind":"person","name":"Salah-Eddin Al-Batran","route":"/people/salah-eddin-al-batran/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"samuel-wells","kind":"person","name":"Samuel A. Wells Jr.","route":"/people/samuel-wells/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"sarah-leary","kind":"person","name":"Sarah E. S. Leary","route":"/people/sarah-leary/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"scott-plotkin","kind":"person","name":"Scott R. Plotkin","route":"/people/scott-plotkin/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"sdh-deficiency","kind":"term","name":"SDH deficiency (SDHB immunohistochemistry loss)","route":"/terms/sdh-deficiency/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"sebastian-bauer","kind":"person","name":"Sebastian Bauer","route":"/people/sebastian-bauer/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"segmental-chromosomal-aberrations","kind":"term","name":"Segmental chromosomal aberrations and ploidy (neuroblastoma)","route":"/terms/segmental-chromosomal-aberrations/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"tarlatamab-vs-idxd-sequence","kind":"pairing","name":"Sequencing DLL3 engager and B7-H3 ADC in relapsed SCLC","route":"/pairings/tarlatamab-vs-idxd-sequence/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"shailender-bhatia","kind":"person","name":"Shailender Bhatia","route":"/people/shailender-bhatia/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"shannon-westin","kind":"person","name":"Shannon N. Westin","route":"/people/shannon-westin/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"sclc-molecular-subtypes","kind":"term","name":"Small-cell lung cancer transcription-factor subtypes (SCLC-A, SCLC-N, SCLC-P, SCLC-I) and SLFN11","route":"/terms/sclc-molecular-subtypes/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"sokal-elts-scores","kind":"term","name":"Sokal and ELTS risk scores (chronic myeloid leukaemia)","route":"/terms/sokal-elts-scores/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"srdan-verstovsek","kind":"person","name":"Srdan Verstovsek","route":"/people/srdan-verstovsek/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"ss18-ssx-fusion","kind":"term","name":"SS18::SSX fusion (synovial sarcoma)","route":"/terms/ss18-ssx-fusion/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"stephen-boorjian","kind":"person","name":"Stephen A. Boorjian","route":"/people/stephen-boorjian/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"stephen-freedland","kind":"person","name":"Stephen J. Freedland","route":"/people/stephen-freedland/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"sylvie-bonvalot","kind":"person","name":"Sylvie Bonvalot","route":"/people/sylvie-bonvalot/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prostate-bipolar-androgen-therapy-phase-3-on-pfs2","kind":"idea","name":"Take high-dose testosterone to phase 3, with progression-free survival through the second line as the primary endpoint","route":"/ideas/idea-prostate-bipolar-androgen-therapy-phase-3-on-pfs2/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prame-tcr-beyond-a02","kind":"idea","name":"TCR therapeutics for non-HLA-A*02 patients","route":"/ideas/idea-prame-tcr-beyond-a02/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prostate-hrr-testing-at-metastatic-diagnosis","kind":"idea","name":"Test every man for DNA repair faults on the day his prostate cancer is found to have spread, not three treatments later","route":"/ideas/idea-prostate-hrr-testing-at-metastatic-diagnosis/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"tk216","kind":"drug","name":"TK216","route":"/drugs/tk216/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-lung-never-smoker-disease-its-own-programme","kind":"idea","name":"Treat lung cancer in never-smokers as its own disease, with its own detection programme","route":"/ideas/idea-lung-never-smoker-disease-its-own-programme/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-lung-deprivation-gradient-treated-as-a-defect-in-delivery","kind":"idea","name":"Treat the deprivation gradient in lung cancer as a defect in delivery that can be fixed and measured","route":"/ideas/idea-lung-deprivation-gradient-treated-as-a-defect-in-delivery/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"trop2-pet","kind":"technology","name":"TROP2 PET","route":"/technologies/trop2-pet/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"trop2-pet-to-adc","kind":"pairing","name":"TROP2 PET → TROP2 ADC selection","route":"/pairings/trop2-pet-to-adc/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"uveal-melanoma-prognostic-markers","kind":"term","name":"Uveal melanoma prognostic markers (GNAQ/GNA11, monosomy 3, gene-expression class)","route":"/terms/uveal-melanoma-prognostic-markers/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"vicky-makker","kind":"person","name":"Vicky Makker","route":"/people/vicky-makker/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"vivek-subbiah","kind":"person","name":"Vivek Subbiah","route":"/people/vivek-subbiah/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"idea-prostate-plasticity-surveillance-before-it-is-neuroendocrine","kind":"idea","name":"Watch for the cancer changing cell type before the biopsy says neuroendocrine, and act on it","route":"/ideas/idea-prostate-plasticity-surveillance-before-it-is-neuroendocrine/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"wilms-risk-markers","kind":"term","name":"Wilms tumour risk markers (anaplasia, 1p/16q loss, 1q gain, SIOP and COG risk groups)","route":"/terms/wilms-risk-markers/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"youn-kim","kind":"person","name":"Youn H. Kim","route":"/people/youn-kim/","detail":"no external link or Wikipedia reference"},{"check":"unsourced","severity":"low","id":"yuichiro-doki","kind":"person","name":"Yuichiro Doki","route":"/people/yuichiro-doki/","detail":"no external link or Wikipedia reference"}],"staleness":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/","asOf":"2026-09-04","days":24},{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/","asOf":"2026-09-04","days":24},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/","asOf":"2026-09-04","days":24},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/","asOf":"2026-09-04","days":24},{"id":"thyroid","kind":"cancer","name":"Thyroid cancer","route":"/cancers/thyroid/","asOf":"2026-09-04","days":24},{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/","asOf":"2026-09-04","days":24},{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/","asOf":"2026-09-04","days":24},{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/","asOf":"2026-09-04","days":24},{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/","asOf":"2026-09-04","days":24},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/","asOf":"2026-09-04","days":24},{"id":"brain-tumours","kind":"cancer","name":"Brain and spinal cord tumours (all types)","route":"/cancers/brain-tumours/","asOf":"2026-09-04","days":24},{"id":"childhood-cancers","kind":"cancer","name":"Childhood cancers (all types)","route":"/cancers/childhood-cancers/","asOf":"2026-09-04","days":24},{"id":"extragonadal-germ-cell-tumour","kind":"cancer","name":"Extragonadal germ cell tumour","route":"/cancers/extragonadal-germ-cell-tumour/","asOf":"2026-09-04","days":24},{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/","asOf":"2026-09-04","days":24},{"id":"imaging","kind":"section","name":"Imaging","route":"/fronts/imaging/","asOf":"2026-09-04","days":24},{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/","asOf":"2026-09-04","days":24},{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/","asOf":"2026-09-04","days":24},{"id":"surgery","kind":"section","name":"Surgery & Interventional","route":"/fronts/surgery/","asOf":"2026-09-04","days":24},{"id":"radiation","kind":"section","name":"Radiation Therapy","route":"/fronts/radiation/","asOf":"2026-09-04","days":24},{"id":"chemotherapy","kind":"section","name":"Chemotherapy","route":"/fronts/chemotherapy/","asOf":"2026-09-04","days":24},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/","asOf":"2026-09-04","days":24},{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/","asOf":"2026-09-04","days":24},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/","asOf":"2026-09-04","days":24},{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/","asOf":"2026-09-04","days":24},{"id":"radiopharma","kind":"section","name":"Radiopharmaceuticals & Theranostics","route":"/fronts/radiopharma/","asOf":"2026-09-04","days":24},{"id":"hormonal","kind":"section","name":"Hormonal Therapy","route":"/fronts/hormonal/","asOf":"2026-09-04","days":24},{"id":"epigenetics","kind":"section","name":"Epigenetic & Transcriptional Therapy","route":"/fronts/epigenetics/","asOf":"2026-09-04","days":24},{"id":"supportive-care","kind":"section","name":"Supportive Care & Survivorship","route":"/fronts/supportive-care/","asOf":"2026-09-04","days":24},{"id":"ai-computation","kind":"section","name":"AI & Computation","route":"/fronts/ai-computation/","asOf":"2026-09-04","days":24},{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/","asOf":"2026-09-04","days":24},{"id":"prevention","kind":"section","name":"Prevention & Risk","route":"/fronts/prevention/","asOf":"2026-09-04","days":24},{"id":"nutrition-lifestyle","kind":"section","name":"Diet, Exercise & Lifestyle","route":"/fronts/nutrition-lifestyle/","asOf":"2026-09-04","days":24},{"id":"devices","kind":"section","name":"Devices & Physical Therapies","route":"/fronts/devices/","asOf":"2026-09-04","days":24},{"id":"ct","kind":"technology","name":"CT (computed tomography)","route":"/technologies/ct/","asOf":"2026-09-04","days":24},{"id":"mri","kind":"technology","name":"MRI","route":"/technologies/mri/","asOf":"2026-09-04","days":24},{"id":"ultrasound","kind":"technology","name":"Ultrasound","route":"/technologies/ultrasound/","asOf":"2026-09-04","days":24},{"id":"mammography","kind":"technology","name":"Mammography & tomosynthesis","route":"/technologies/mammography/","asOf":"2026-09-04","days":24},{"id":"pet","kind":"technology","name":"PET (positron emission tomography)","route":"/technologies/pet/","asOf":"2026-09-04","days":24},{"id":"pet-ct","kind":"technology","name":"PET/CT","route":"/technologies/pet-ct/","asOf":"2026-09-04","days":24},{"id":"pet-mri","kind":"technology","name":"PET/MRI","route":"/technologies/pet-mri/","asOf":"2026-09-04","days":24},{"id":"fdg-pet","kind":"technology","name":"FDG PET","route":"/technologies/fdg-pet/","asOf":"2026-09-04","days":24},{"id":"psma-pet","kind":"technology","name":"PSMA PET","route":"/technologies/psma-pet/","asOf":"2026-09-04","days":24},{"id":"fapi-pet","kind":"technology","name":"FAPI PET","route":"/technologies/fapi-pet/","asOf":"2026-09-04","days":24},{"id":"trop2-pet","kind":"technology","name":"TROP2 PET","route":"/technologies/trop2-pet/","asOf":"2026-09-04","days":24},{"id":"her2-pet","kind":"technology","name":"HER2 PET","route":"/technologies/her2-pet/","asOf":"2026-09-04","days":24},{"id":"immuno-pet","kind":"technology","name":"Immuno-PET","route":"/technologies/immuno-pet/","asOf":"2026-09-04","days":24},{"id":"parp-pet","kind":"technology","name":"PARP PET","route":"/technologies/parp-pet/","asOf":"2026-09-04","days":24},{"id":"spect","kind":"technology","name":"SPECT & bone scan","route":"/technologies/spect/","asOf":"2026-09-04","days":24},{"id":"whole-body-mri","kind":"technology","name":"Whole-body MRI","route":"/technologies/whole-body-mri/","asOf":"2026-09-04","days":24},{"id":"radiology-ai-screening","kind":"technology","name":"AI in radiology","route":"/technologies/radiology-ai-screening/","asOf":"2026-09-04","days":24},{"id":"optical-imaging","kind":"technology","name":"Optical & fluorescence imaging","route":"/technologies/optical-imaging/","asOf":"2026-09-04","days":24},{"id":"histopathology-ihc","kind":"technology","name":"Histopathology & immunohistochemistry","route":"/technologies/histopathology-ihc/","asOf":"2026-09-04","days":24},{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/","asOf":"2026-09-04","days":24},{"id":"wes-wgs","kind":"technology","name":"Whole-exome & whole-genome sequencing","route":"/technologies/wes-wgs/","asOf":"2026-09-04","days":24},{"id":"rna-seq","kind":"technology","name":"RNA sequencing & expression profiling","route":"/technologies/rna-seq/","asOf":"2026-09-04","days":24},{"id":"single-cell-spatial","kind":"technology","name":"Single-cell & spatial profiling","route":"/technologies/single-cell-spatial/","asOf":"2026-09-04","days":24},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/","asOf":"2026-09-04","days":24},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/","asOf":"2026-09-04","days":24},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/","asOf":"2026-09-04","days":24},{"id":"digital-pathology-ai","kind":"technology","name":"Digital pathology & AI","route":"/technologies/digital-pathology-ai/","asOf":"2026-09-04","days":24},{"id":"companion-diagnostic","kind":"technology","name":"Companion diagnostics","route":"/technologies/companion-diagnostic/","asOf":"2026-09-04","days":24},{"id":"hrd-testing","kind":"technology","name":"HRD & BRCA testing","route":"/technologies/hrd-testing/","asOf":"2026-09-04","days":24},{"id":"germline-testing","kind":"technology","name":"Germline (hereditary) testing","route":"/technologies/germline-testing/","asOf":"2026-09-04","days":24},{"id":"functional-drug-testing","kind":"technology","name":"Functional (ex vivo) drug testing","route":"/technologies/functional-drug-testing/","asOf":"2026-09-04","days":24},{"id":"organoids","kind":"technology","name":"Patient-derived organoids","route":"/technologies/organoids/","asOf":"2026-09-04","days":24},{"id":"pdx-models","kind":"technology","name":"Patient-derived xenografts","route":"/technologies/pdx-models/","asOf":"2026-09-04","days":24},{"id":"proteomics","kind":"technology","name":"Proteomics & phosphoproteomics","route":"/technologies/proteomics/","asOf":"2026-09-04","days":24},{"id":"methylation-profiling","kind":"technology","name":"DNA methylation profiling","route":"/technologies/methylation-profiling/","asOf":"2026-09-04","days":24},{"id":"robotic-surgery","kind":"technology","name":"Robotic & minimally invasive surgery","route":"/technologies/robotic-surgery/","asOf":"2026-09-04","days":24},{"id":"fluorescence-guided-surgery","kind":"technology","name":"Fluorescence-guided surgery","route":"/technologies/fluorescence-guided-surgery/","asOf":"2026-09-04","days":24},{"id":"sentinel-node","kind":"technology","name":"Sentinel lymph node biopsy","route":"/technologies/sentinel-node/","asOf":"2026-09-04","days":24},{"id":"thermal-ablation","kind":"technology","name":"Thermal ablation (RFA, microwave, cryo)","route":"/technologies/thermal-ablation/","asOf":"2026-09-04","days":24},{"id":"hifu-histotripsy","kind":"technology","name":"Focused ultrasound & histotripsy","route":"/technologies/hifu-histotripsy/","asOf":"2026-09-04","days":24},{"id":"irreversible-electroporation","kind":"technology","name":"Irreversible electroporation (NanoKnife)","route":"/technologies/irreversible-electroporation/","asOf":"2026-09-04","days":24},{"id":"sbrt","kind":"technology","name":"SBRT / SABR (stereotactic radiotherapy)","route":"/technologies/sbrt/","asOf":"2026-09-04","days":24},{"id":"brachytherapy","kind":"technology","name":"Brachytherapy","route":"/technologies/brachytherapy/","asOf":"2026-09-04","days":24},{"id":"mr-linac","kind":"technology","name":"MR-guided adaptive radiotherapy","route":"/technologies/mr-linac/","asOf":"2026-09-04","days":24},{"id":"flash-rt","kind":"technology","name":"FLASH radiotherapy","route":"/technologies/flash-rt/","asOf":"2026-09-04","days":24},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/","asOf":"2026-09-04","days":24},{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/","asOf":"2026-09-04","days":24},{"id":"radioimmunotherapy","kind":"technology","name":"Radio-antibody & radio-ADC","route":"/technologies/radioimmunotherapy/","asOf":"2026-09-04","days":24},{"id":"bnct","kind":"technology","name":"Boron neutron capture therapy","route":"/technologies/bnct/","asOf":"2026-09-04","days":24},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/","asOf":"2026-09-04","days":24},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/","asOf":"2026-09-04","days":24},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/","asOf":"2026-09-04","days":24},{"id":"hipec","kind":"technology","name":"HIPEC / PIPAC (intraperitoneal chemotherapy)","route":"/technologies/hipec/","asOf":"2026-09-04","days":24},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/","asOf":"2026-09-04","days":24},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/","asOf":"2026-09-04","days":24},{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/","asOf":"2026-09-04","days":24},{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/","asOf":"2026-09-04","days":24},{"id":"cdk46-inhibitor","kind":"technology","name":"CDK4/6 inhibitors","route":"/technologies/cdk46-inhibitor/","asOf":"2026-09-04","days":24},{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/","asOf":"2026-09-04","days":24},{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/","asOf":"2026-09-04","days":24},{"id":"antisense-sirna","kind":"technology","name":"Oligonucleotide therapeutics","route":"/technologies/antisense-sirna/","asOf":"2026-09-04","days":24},{"id":"synthetic-lethality-approaches","kind":"technology","name":"Synthetic lethality approaches","route":"/technologies/synthetic-lethality-approaches/","asOf":"2026-09-04","days":24},{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/","asOf":"2026-09-04","days":24},{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/","asOf":"2026-09-04","days":24},{"id":"bispecific-adc","kind":"technology","name":"Bispecific ADC","route":"/technologies/bispecific-adc/","asOf":"2026-09-04","days":24},{"id":"dual-payload-adc","kind":"technology","name":"Dual-payload ADC","route":"/technologies/dual-payload-adc/","asOf":"2026-09-04","days":24},{"id":"degrader-antibody-conjugate","kind":"technology","name":"Degrader-antibody conjugate (DAC)","route":"/technologies/degrader-antibody-conjugate/","asOf":"2026-09-04","days":24},{"id":"immune-stimulating-adc","kind":"technology","name":"Immune-stimulating antibody conjugate (ISAC)","route":"/technologies/immune-stimulating-adc/","asOf":"2026-09-04","days":24},{"id":"masked-adc","kind":"technology","name":"Masked / conditionally active ADC","route":"/technologies/masked-adc/","asOf":"2026-09-04","days":24},{"id":"site-specific-conjugation","kind":"technology","name":"Site-specific conjugation & linker chemistry","route":"/technologies/site-specific-conjugation/","asOf":"2026-09-04","days":24},{"id":"peptide-drug-conjugate","kind":"technology","name":"Peptide-drug & small-molecule-drug conjugates","route":"/technologies/peptide-drug-conjugate/","asOf":"2026-09-04","days":24},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/","asOf":"2026-09-04","days":24},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/","asOf":"2026-09-04","days":24},{"id":"neoantigen-mrna-vaccine","kind":"technology","name":"Personalised neoantigen (mRNA) vaccines","route":"/technologies/neoantigen-mrna-vaccine/","asOf":"2026-09-04","days":24},{"id":"shared-antigen-vaccine","kind":"technology","name":"Off-the-shelf cancer vaccines","route":"/technologies/shared-antigen-vaccine/","asOf":"2026-09-04","days":24},{"id":"oncolytic-virus","kind":"technology","name":"Oncolytic viruses","route":"/technologies/oncolytic-virus/","asOf":"2026-09-04","days":24},{"id":"cytokine-therapy","kind":"technology","name":"Cytokines & engineered cytokines","route":"/technologies/cytokine-therapy/","asOf":"2026-09-04","days":24},{"id":"sting-agonist","kind":"technology","name":"STING & innate immune agonists","route":"/technologies/sting-agonist/","asOf":"2026-09-04","days":24},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/","asOf":"2026-09-04","days":24},{"id":"in-vivo-car-t","kind":"technology","name":"In vivo CAR-T","route":"/technologies/in-vivo-car-t/","asOf":"2026-09-04","days":24},{"id":"til-therapy","kind":"technology","name":"TIL therapy","route":"/technologies/til-therapy/","asOf":"2026-09-04","days":24},{"id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/","asOf":"2026-09-04","days":24},{"id":"car-nk-macrophage","kind":"technology","name":"CAR-NK & CAR-macrophage","route":"/technologies/car-nk-macrophage/","asOf":"2026-09-04","days":24},{"id":"allogeneic-cell-therapy","kind":"technology","name":"Allogeneic (off-the-shelf) cell therapy","route":"/technologies/allogeneic-cell-therapy/","asOf":"2026-09-04","days":24},{"id":"armored-car","kind":"technology","name":"Armoured, logic-gated & next-gen CARs","route":"/technologies/armored-car/","asOf":"2026-09-04","days":24},{"id":"endocrine-therapy","kind":"technology","name":"Endocrine therapy (SERMs, AIs, SERDs)","route":"/technologies/endocrine-therapy/","asOf":"2026-09-04","days":24},{"id":"androgen-deprivation","kind":"technology","name":"Androgen deprivation & AR pathway inhibitors","route":"/technologies/androgen-deprivation/","asOf":"2026-09-04","days":24},{"id":"epigenetic-drugs","kind":"technology","name":"Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)","route":"/technologies/epigenetic-drugs/","asOf":"2026-09-04","days":24},{"id":"scalp-cooling","kind":"technology","name":"Scalp cooling (cold caps: DigniCap, Paxman)","route":"/technologies/scalp-cooling/","asOf":"2026-09-04","days":24},{"id":"cardio-oncology","kind":"technology","name":"Cardio-oncology","route":"/technologies/cardio-oncology/","asOf":"2026-09-04","days":24},{"id":"exercise-oncology","kind":"technology","name":"Exercise & lifestyle oncology","route":"/technologies/exercise-oncology/","asOf":"2026-09-04","days":24},{"id":"geriatric-assessment","kind":"technology","name":"Geriatric assessment","route":"/technologies/geriatric-assessment/","asOf":"2026-09-04","days":24},{"id":"pathology-foundation-model","kind":"technology","name":"Pathology & radiology foundation models","route":"/technologies/pathology-foundation-model/","asOf":"2026-09-04","days":24},{"id":"ai-trial-matching","kind":"technology","name":"AI trial matching & clinical decision support","route":"/technologies/ai-trial-matching/","asOf":"2026-09-04","days":24},{"id":"ai-drug-design","kind":"technology","name":"AI-driven drug & target discovery","route":"/technologies/ai-drug-design/","asOf":"2026-09-04","days":24},{"id":"crispr-screens","kind":"technology","name":"CRISPR functional genomics","route":"/technologies/crispr-screens/","asOf":"2026-09-04","days":24},{"id":"hpv-vaccine","kind":"technology","name":"HPV & HBV vaccination","route":"/technologies/hpv-vaccine/","asOf":"2026-09-04","days":24},{"id":"chemoprevention","kind":"technology","name":"Chemoprevention & risk-reducing surgery","route":"/technologies/chemoprevention/","asOf":"2026-09-04","days":24},{"id":"ttfields","kind":"technology","name":"Tumour treating fields (TTFields)","route":"/technologies/ttfields/","asOf":"2026-09-04","days":24},{"id":"photoimmunotherapy","kind":"technology","name":"Photoimmunotherapy & photodynamic therapy","route":"/technologies/photoimmunotherapy/","asOf":"2026-09-04","days":24},{"id":"hyperthermia","kind":"technology","name":"Hyperthermia","route":"/technologies/hyperthermia/","asOf":"2026-09-04","days":24},{"id":"spatial-transcriptomics","kind":"technology","name":"Spatial transcriptomics","route":"/technologies/spatial-transcriptomics/","asOf":"2026-09-04","days":24},{"id":"imaging-mass-cytometry","kind":"technology","name":"Imaging mass cytometry","route":"/technologies/imaging-mass-cytometry/","asOf":"2026-09-04","days":24},{"id":"multiplex-immunofluorescence","kind":"technology","name":"Multiplex immunofluorescence","route":"/technologies/multiplex-immunofluorescence/","asOf":"2026-09-04","days":24},{"id":"ai-pathology-scoring","kind":"technology","name":"AI scoring of biomarkers and grade on pathology slides","route":"/technologies/ai-pathology-scoring/","asOf":"2026-09-04","days":24},{"id":"radiomics","kind":"technology","name":"Radiomics","route":"/technologies/radiomics/","asOf":"2026-09-04","days":24},{"id":"ctc-capture","kind":"technology","name":"Circulating tumour cell capture","route":"/technologies/ctc-capture/","asOf":"2026-09-04","days":24},{"id":"cfdna-methylation-testing","kind":"technology","name":"Cell-free DNA methylation tests","route":"/technologies/cfdna-methylation-testing/","asOf":"2026-09-04","days":24},{"id":"gene-expression-prognostic-assays","kind":"technology","name":"Gene-expression prognostic assays","route":"/technologies/gene-expression-prognostic-assays/","asOf":"2026-09-04","days":24},{"id":"oncology-pharmacogenomics","kind":"technology","name":"Pharmacogenomic testing before chemotherapy","route":"/technologies/oncology-pharmacogenomics/","asOf":"2026-09-04","days":24},{"id":"ai-mammography-screening","kind":"technology","name":"AI-assisted mammography screening","route":"/technologies/ai-mammography-screening/","asOf":"2026-09-04","days":24},{"id":"ai-endoscopy-detection","kind":"technology","name":"AI polyp detection in colonoscopy","route":"/technologies/ai-endoscopy-detection/","asOf":"2026-09-04","days":24},{"id":"cns-tumour-methylation-classifier","kind":"technology","name":"Methylation classifier for brain tumours","route":"/technologies/cns-tumour-methylation-classifier/","asOf":"2026-09-04","days":24},{"id":"clonal-evolution-tracking","kind":"technology","name":"Tumour clonal evolution tracking","route":"/technologies/clonal-evolution-tracking/","asOf":"2026-09-04","days":24},{"id":"tigit-blockade","kind":"technology","name":"TIGIT blockade","route":"/technologies/tigit-blockade/","asOf":"2026-09-04","days":24},{"id":"lag3-blockade","kind":"technology","name":"LAG-3 blockade","route":"/technologies/lag3-blockade/","asOf":"2026-09-04","days":24},{"id":"tim3-blockade","kind":"technology","name":"TIM-3 blockade","route":"/technologies/tim3-blockade/","asOf":"2026-09-04","days":24},{"id":"cd47-blockade","kind":"technology","name":"CD47 and SIRP-alpha blockade","route":"/technologies/cd47-blockade/","asOf":"2026-09-04","days":24},{"id":"cd40-agonists","kind":"technology","name":"CD40 agonist antibodies","route":"/technologies/cd40-agonists/","asOf":"2026-09-04","days":24},{"id":"immunocytokines","kind":"technology","name":"Immunocytokines (antibody-cytokine fusions)","route":"/technologies/immunocytokines/","asOf":"2026-09-04","days":24},{"id":"nk-cell-engagers","kind":"technology","name":"NK cell engagers","route":"/technologies/nk-cell-engagers/","asOf":"2026-09-04","days":24},{"id":"trispecific-antibodies","kind":"technology","name":"Trispecific antibodies","route":"/technologies/trispecific-antibodies/","asOf":"2026-09-04","days":24},{"id":"dendritic-cell-vaccines","kind":"technology","name":"Dendritic cell vaccines","route":"/technologies/dendritic-cell-vaccines/","asOf":"2026-09-04","days":24},{"id":"bacterial-vector-vaccines","kind":"technology","name":"Bacterial vector cancer vaccines","route":"/technologies/bacterial-vector-vaccines/","asOf":"2026-09-04","days":24},{"id":"gamma-delta-t-cell-therapy","kind":"technology","name":"Gamma-delta T cell therapy","route":"/technologies/gamma-delta-t-cell-therapy/","asOf":"2026-09-04","days":24},{"id":"nk-cell-therapy","kind":"technology","name":"NK cell therapy and CAR-NK","route":"/technologies/nk-cell-therapy/","asOf":"2026-09-04","days":24},{"id":"virus-specific-t-cells","kind":"technology","name":"Virus-specific T cells","route":"/technologies/virus-specific-t-cells/","asOf":"2026-09-04","days":24},{"id":"lu177-radioligand-therapy","kind":"technology","name":"Lutetium-177 radioligand therapy","route":"/technologies/lu177-radioligand-therapy/","asOf":"2026-09-04","days":24},{"id":"astatine-211-alpha-therapy","kind":"technology","name":"Astatine-211 alpha therapy","route":"/technologies/astatine-211-alpha-therapy/","asOf":"2026-09-04","days":24},{"id":"radioligand-dosimetry","kind":"technology","name":"Radioligand dosimetry","route":"/technologies/radioligand-dosimetry/","asOf":"2026-09-04","days":24},{"id":"menin-inhibitors","kind":"technology","name":"Menin inhibitors","route":"/technologies/menin-inhibitors/","asOf":"2026-09-04","days":24},{"id":"bcl2-inhibitors","kind":"technology","name":"BCL-2 inhibitors","route":"/technologies/bcl2-inhibitors/","asOf":"2026-09-04","days":24},{"id":"idh-inhibitors","kind":"technology","name":"IDH inhibitors","route":"/technologies/idh-inhibitors/","asOf":"2026-09-04","days":24},{"id":"pi3k-akt-mtor-inhibitors","kind":"technology","name":"PI3K, AKT and mTOR inhibitors","route":"/technologies/pi3k-akt-mtor-inhibitors/","asOf":"2026-09-04","days":24},{"id":"mdm2-inhibitors","kind":"technology","name":"MDM2 inhibitors","route":"/technologies/mdm2-inhibitors/","asOf":"2026-09-04","days":24},{"id":"her2-tyrosine-kinase-inhibitors","kind":"technology","name":"HER2 tyrosine kinase inhibitors","route":"/technologies/her2-tyrosine-kinase-inhibitors/","asOf":"2026-09-04","days":24},{"id":"oral-serds","kind":"technology","name":"Oral SERDs","route":"/technologies/oral-serds/","asOf":"2026-09-04","days":24},{"id":"hedgehog-inhibitors","kind":"technology","name":"Hedgehog pathway inhibitors","route":"/technologies/hedgehog-inhibitors/","asOf":"2026-09-04","days":24},{"id":"gamma-secretase-inhibitors","kind":"technology","name":"Gamma-secretase inhibitors","route":"/technologies/gamma-secretase-inhibitors/","asOf":"2026-09-04","days":24},{"id":"celmods","kind":"technology","name":"Cereblon E3 ligase modulators (CELMoDs)","route":"/technologies/celmods/","asOf":"2026-09-04","days":24},{"id":"lsd1-inhibitors","kind":"technology","name":"LSD1 inhibitors","route":"/technologies/lsd1-inhibitors/","asOf":"2026-09-04","days":24},{"id":"atr-chk1-inhibitors","kind":"technology","name":"ATR and CHK1 inhibitors","route":"/technologies/atr-chk1-inhibitors/","asOf":"2026-09-04","days":24},{"id":"kat6-inhibitors","kind":"technology","name":"KAT6 inhibitors","route":"/technologies/kat6-inhibitors/","asOf":"2026-09-04","days":24},{"id":"genetically-engineered-mouse-models","kind":"technology","name":"Genetically engineered mouse models","route":"/technologies/genetically-engineered-mouse-models/","asOf":"2026-09-04","days":24},{"id":"humanised-mouse-models","kind":"technology","name":"Humanised mouse models","route":"/technologies/humanised-mouse-models/","asOf":"2026-09-04","days":24},{"id":"cancer-cell-line-encyclopedias","kind":"technology","name":"Cancer cell line encyclopedias and dependency maps","route":"/technologies/cancer-cell-line-encyclopedias/","asOf":"2026-09-04","days":24},{"id":"tumour-on-chip","kind":"technology","name":"Tumour-on-a-chip","route":"/technologies/tumour-on-chip/","asOf":"2026-09-04","days":24},{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/","asOf":"2026-09-04","days":24},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/","asOf":"2026-09-04","days":24},{"id":"her3","kind":"target","name":"HER3","route":"/targets/her3/","asOf":"2026-09-04","days":24},{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/","asOf":"2026-09-04","days":24},{"id":"nectin4","kind":"target","name":"Nectin-4","route":"/targets/nectin4/","asOf":"2026-09-04","days":24},{"id":"b7h3","kind":"target","name":"B7-H3","route":"/targets/b7h3/","asOf":"2026-09-04","days":24},{"id":"cldn18-2","kind":"target","name":"Claudin 18.2","route":"/targets/cldn18-2/","asOf":"2026-09-04","days":24},{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/","asOf":"2026-09-04","days":24},{"id":"fap","kind":"target","name":"FAP","route":"/targets/fap/","asOf":"2026-09-04","days":24},{"id":"sstr2","kind":"target","name":"Somatostatin receptor 2","route":"/targets/sstr2/","asOf":"2026-09-04","days":24},{"id":"dll3","kind":"target","name":"DLL3","route":"/targets/dll3/","asOf":"2026-09-04","days":24},{"id":"folr1","kind":"target","name":"Folate receptor alpha","route":"/targets/folr1/","asOf":"2026-09-04","days":24},{"id":"tissue-factor","kind":"target","name":"Tissue factor","route":"/targets/tissue-factor/","asOf":"2026-09-04","days":24},{"id":"cdh6","kind":"target","name":"CDH6","route":"/targets/cdh6/","asOf":"2026-09-04","days":24},{"id":"ceacam5","kind":"target","name":"CEACAM5","route":"/targets/ceacam5/","asOf":"2026-09-04","days":24},{"id":"gpc3","kind":"target","name":"Glypican-3","route":"/targets/gpc3/","asOf":"2026-09-04","days":24},{"id":"mesothelin","kind":"target","name":"Mesothelin","route":"/targets/mesothelin/","asOf":"2026-09-04","days":24},{"id":"cd70","kind":"target","name":"CD70","route":"/targets/cd70/","asOf":"2026-09-04","days":24},{"id":"ror1","kind":"target","name":"ROR1","route":"/targets/ror1/","asOf":"2026-09-04","days":24},{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/","asOf":"2026-09-04","days":24},{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/","asOf":"2026-09-04","days":24},{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/","asOf":"2026-09-04","days":24},{"id":"gprc5d","kind":"target","name":"GPRC5D","route":"/targets/gprc5d/","asOf":"2026-09-04","days":24},{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/","asOf":"2026-09-04","days":24},{"id":"cd38","kind":"target","name":"CD38","route":"/targets/cd38/","asOf":"2026-09-04","days":24},{"id":"cd33","kind":"target","name":"CD33","route":"/targets/cd33/","asOf":"2026-09-04","days":24},{"id":"cd123","kind":"target","name":"CD123","route":"/targets/cd123/","asOf":"2026-09-04","days":24},{"id":"mage-a4","kind":"target","name":"MAGE-A4","route":"/targets/mage-a4/","asOf":"2026-09-04","days":24},{"id":"gp100","kind":"target","name":"gp100 (PMEL)","route":"/targets/gp100/","asOf":"2026-09-04","days":24},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/","asOf":"2026-09-04","days":24},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/","asOf":"2026-09-04","days":24},{"id":"ctla4","kind":"target","name":"CTLA-4","route":"/targets/ctla4/","asOf":"2026-09-04","days":24},{"id":"lag3","kind":"target","name":"LAG-3","route":"/targets/lag3/","asOf":"2026-09-04","days":24},{"id":"tigit","kind":"target","name":"TIGIT","route":"/targets/tigit/","asOf":"2026-09-04","days":24},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/","asOf":"2026-09-04","days":24},{"id":"braf","kind":"target","name":"BRAF","route":"/targets/braf/","asOf":"2026-09-04","days":24},{"id":"alk","kind":"target","name":"ALK","route":"/targets/alk/","asOf":"2026-09-04","days":24},{"id":"met","kind":"target","name":"MET","route":"/targets/met/","asOf":"2026-09-04","days":24},{"id":"ret","kind":"target","name":"RET","route":"/targets/ret/","asOf":"2026-09-04","days":24},{"id":"ntrk","kind":"target","name":"NTRK","route":"/targets/ntrk/","asOf":"2026-09-04","days":24},{"id":"fgfr2","kind":"target","name":"FGFR2","route":"/targets/fgfr2/","asOf":"2026-09-04","days":24},{"id":"kit","kind":"target","name":"KIT","route":"/targets/kit/","asOf":"2026-09-04","days":24},{"id":"flt3","kind":"target","name":"FLT3","route":"/targets/flt3/","asOf":"2026-09-04","days":24},{"id":"pik3ca","kind":"target","name":"PIK3CA / PI3K-alpha","route":"/targets/pik3ca/","asOf":"2026-09-04","days":24},{"id":"akt","kind":"target","name":"AKT","route":"/targets/akt/","asOf":"2026-09-04","days":24},{"id":"cdk4-6","kind":"target","name":"CDK4/6","route":"/targets/cdk4-6/","asOf":"2026-09-04","days":24},{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/","asOf":"2026-09-04","days":24},{"id":"atr","kind":"target","name":"ATR","route":"/targets/atr/","asOf":"2026-09-04","days":24},{"id":"wee1","kind":"target","name":"WEE1","route":"/targets/wee1/","asOf":"2026-09-04","days":24},{"id":"idh","kind":"target","name":"IDH1 / IDH2","route":"/targets/idh/","asOf":"2026-09-04","days":24},{"id":"menin","kind":"target","name":"Menin","route":"/targets/menin/","asOf":"2026-09-04","days":24},{"id":"ezh2","kind":"target","name":"EZH2","route":"/targets/ezh2/","asOf":"2026-09-04","days":24},{"id":"bcl2","kind":"target","name":"BCL-2","route":"/targets/bcl2/","asOf":"2026-09-04","days":24},{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/","asOf":"2026-09-04","days":24},{"id":"hif2a","kind":"target","name":"HIF-2α","route":"/targets/hif2a/","asOf":"2026-09-04","days":24},{"id":"estrogen-receptor","kind":"target","name":"Estrogen receptor (ERα)","route":"/targets/estrogen-receptor/","asOf":"2026-09-04","days":24},{"id":"androgen-receptor","kind":"target","name":"Androgen receptor","route":"/targets/androgen-receptor/","asOf":"2026-09-04","days":24},{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/","asOf":"2026-09-04","days":24},{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/","asOf":"2026-09-04","days":24},{"id":"cd47","kind":"target","name":"CD47","route":"/targets/cd47/","asOf":"2026-09-04","days":24},{"id":"cyp17a1","kind":"target","name":"CYP17A1 (17-alpha-hydroxylase/17,20-lyase)","route":"/targets/cyp17a1/","asOf":"2026-09-04","days":24},{"id":"aromatase","kind":"target","name":"Aromatase (CYP19A1)","route":"/targets/aromatase/","asOf":"2026-09-04","days":24},{"id":"proteasome","kind":"target","name":"Proteasome (PSMB5)","route":"/targets/proteasome/","asOf":"2026-09-04","days":24},{"id":"cereblon","kind":"target","name":"Cereblon (CRBN)","route":"/targets/cereblon/","asOf":"2026-09-04","days":24},{"id":"top1","kind":"target","name":"Topoisomerase I (TOP1)","route":"/targets/top1/","asOf":"2026-09-04","days":24},{"id":"top2a","kind":"target","name":"Topoisomerase II alpha (TOP2A)","route":"/targets/top2a/","asOf":"2026-09-04","days":24},{"id":"tyms","kind":"target","name":"Thymidylate synthase (TYMS)","route":"/targets/tyms/","asOf":"2026-09-04","days":24},{"id":"dhfr","kind":"target","name":"Dihydrofolate reductase (DHFR)","route":"/targets/dhfr/","asOf":"2026-09-04","days":24},{"id":"gnrhr","kind":"target","name":"GnRH receptor (GNRHR)","route":"/targets/gnrhr/","asOf":"2026-09-04","days":24},{"id":"xpo1","kind":"target","name":"Exportin-1 (XPO1)","route":"/targets/xpo1/","asOf":"2026-09-04","days":24},{"id":"slamf7","kind":"target","name":"SLAMF7 (CS1)","route":"/targets/slamf7/","asOf":"2026-09-04","days":24},{"id":"tubulin","kind":"target","name":"Tubulin (microtubules)","route":"/targets/tubulin/","asOf":"2026-09-04","days":24},{"id":"dnmt1","kind":"target","name":"DNMT1 (DNA methyltransferase 1)","route":"/targets/dnmt1/","asOf":"2026-09-04","days":24},{"id":"rrm1","kind":"target","name":"Ribonucleotide reductase (RRM1)","route":"/targets/rrm1/","asOf":"2026-09-04","days":24},{"id":"pik3cd","kind":"target","name":"PI3K delta (PIK3CD)","route":"/targets/pik3cd/","asOf":"2026-09-04","days":24},{"id":"rara","kind":"target","name":"Retinoic acid receptor alpha (RARA)","route":"/targets/rara/","asOf":"2026-09-04","days":24},{"id":"fgfr3-receptor","kind":"target","name":"FGFR3","route":"/targets/fgfr3-receptor/","asOf":"2026-09-04","days":24},{"id":"pdgfrb","kind":"target","name":"PDGFRB","route":"/targets/pdgfrb/","asOf":"2026-09-04","days":24},{"id":"src","kind":"target","name":"SRC family kinases","route":"/targets/src/","asOf":"2026-09-04","days":24},{"id":"ifnar1","kind":"target","name":"Interferon alpha receptor (IFNAR1)","route":"/targets/ifnar1/","asOf":"2026-09-04","days":24},{"id":"csf3r","kind":"target","name":"G-CSF receptor (CSF3R)","route":"/targets/csf3r/","asOf":"2026-09-04","days":24},{"id":"htr3a","kind":"target","name":"5-HT3 receptor (HTR3A)","route":"/targets/htr3a/","asOf":"2026-09-04","days":24},{"id":"tacr1","kind":"target","name":"NK1 receptor (TACR1)","route":"/targets/tacr1/","asOf":"2026-09-04","days":24},{"id":"epor","kind":"target","name":"Erythropoietin receptor (EPOR)","route":"/targets/epor/","asOf":"2026-09-04","days":24},{"id":"axl","kind":"target","name":"AXL","route":"/targets/axl/","asOf":"2026-09-04","days":24},{"id":"glucocorticoid-receptor","kind":"target","name":"Glucocorticoid receptor (NR3C1)","route":"/targets/glucocorticoid-receptor/","asOf":"2026-09-04","days":24},{"id":"gamma-secretase","kind":"target","name":"Gamma-secretase (PSEN1)","route":"/targets/gamma-secretase/","asOf":"2026-09-04","days":24},{"id":"fgfr1","kind":"target","name":"FGFR1","route":"/targets/fgfr1/","asOf":"2026-09-04","days":24},{"id":"erbb4","kind":"target","name":"HER4 (ERBB4)","route":"/targets/erbb4/","asOf":"2026-09-04","days":24},{"id":"ada","kind":"target","name":"Adenosine deaminase (ADA)","route":"/targets/ada/","asOf":"2026-09-04","days":24},{"id":"pgr","kind":"target","name":"Progesterone receptor (PGR)","route":"/targets/pgr/","asOf":"2026-09-04","days":24},{"id":"eef2","kind":"target","name":"Elongation factor 2 (EEF2)","route":"/targets/eef2/","asOf":"2026-09-04","days":24},{"id":"fkbp12","kind":"target","name":"FKBP12 (FKBP1A)","route":"/targets/fkbp12/","asOf":"2026-09-04","days":24},{"id":"dnmt3a","kind":"target","name":"DNA methyltransferase 3A (DNMT3A)","route":"/targets/dnmt3a/","asOf":"2026-09-04","days":24},{"id":"gart","kind":"target","name":"GART (trifunctional purine synthesis enzyme)","route":"/targets/gart/","asOf":"2026-09-04","days":24},{"id":"tlr7","kind":"target","name":"Toll-like receptor 7 (TLR7)","route":"/targets/tlr7/","asOf":"2026-09-04","days":24},{"id":"pap","kind":"target","name":"Prostatic acid phosphatase (ACP3, PAP)","route":"/targets/pap/","asOf":"2026-09-04","days":24},{"id":"ron","kind":"target","name":"RON receptor (MST1R)","route":"/targets/ron/","asOf":"2026-09-04","days":24},{"id":"ddr2","kind":"target","name":"DDR2 receptor kinase","route":"/targets/ddr2/","asOf":"2026-09-04","days":24},{"id":"epha2","kind":"target","name":"EphA2 receptor","route":"/targets/epha2/","asOf":"2026-09-04","days":24},{"id":"raf1","kind":"target","name":"CRAF (RAF1)","route":"/targets/raf1/","asOf":"2026-09-04","days":24},{"id":"pkc","kind":"target","name":"Protein kinase C family (PKC)","route":"/targets/pkc/","asOf":"2026-09-04","days":24},{"id":"cox2","kind":"target","name":"COX-2 (PTGS2)","route":"/targets/cox2/","asOf":"2026-09-04","days":24},{"id":"tshr","kind":"target","name":"TSH receptor (TSHR)","route":"/targets/tshr/","asOf":"2026-09-04","days":24},{"id":"igf1r","kind":"target","name":"IGF-1 receptor (IGF1R)","route":"/targets/igf1r/","asOf":"2026-09-04","days":24},{"id":"tie2","kind":"target","name":"TIE2 receptor (TEK)","route":"/targets/tie2/","asOf":"2026-09-04","days":24},{"id":"il11ra","kind":"target","name":"IL-11 receptor alpha","route":"/targets/il11ra/","asOf":"2026-09-04","days":24},{"id":"csf2ra","kind":"target","name":"GM-CSF receptor (CSF2RA)","route":"/targets/csf2ra/","asOf":"2026-09-04","days":24},{"id":"lyn","kind":"target","name":"LYN kinase","route":"/targets/lyn/","asOf":"2026-09-04","days":24},{"id":"hck","kind":"target","name":"HCK kinase","route":"/targets/hck/","asOf":"2026-09-04","days":24},{"id":"ptk6","kind":"target","name":"PTK6 (BRK)","route":"/targets/ptk6/","asOf":"2026-09-04","days":24},{"id":"frk","kind":"target","name":"FRK kinase","route":"/targets/frk/","asOf":"2026-09-04","days":24},{"id":"xdh","kind":"target","name":"Xanthine oxidase (XDH)","route":"/targets/xdh/","asOf":"2026-09-04","days":24},{"id":"txnrd1","kind":"target","name":"Thioredoxin reductase 1","route":"/targets/txnrd1/","asOf":"2026-09-04","days":24},{"id":"gsr","kind":"target","name":"Glutathione reductase","route":"/targets/gsr/","asOf":"2026-09-04","days":24},{"id":"pola1","kind":"target","name":"DNA polymerase alpha (POLA1)","route":"/targets/pola1/","asOf":"2026-09-04","days":24},{"id":"cyp11a1","kind":"target","name":"CYP11A1 (cholesterol side-chain cleavage enzyme)","route":"/targets/cyp11a1/","asOf":"2026-09-04","days":24},{"id":"srd5a2","kind":"target","name":"5-alpha-reductase type 2 (SRD5A2)","route":"/targets/srd5a2/","asOf":"2026-09-04","days":24},{"id":"drd2","kind":"target","name":"Dopamine D2 receptor","route":"/targets/drd2/","asOf":"2026-09-04","days":24},{"id":"oprm1","kind":"target","name":"Mu-opioid receptor","route":"/targets/oprm1/","asOf":"2026-09-04","days":24},{"id":"cnr1","kind":"target","name":"Cannabinoid receptor 1","route":"/targets/cnr1/","asOf":"2026-09-04","days":24},{"id":"tph1","kind":"target","name":"Tryptophan hydroxylase 1","route":"/targets/tph1/","asOf":"2026-09-04","days":24},{"id":"impdh2","kind":"target","name":"IMP dehydrogenase (IMPDH2)","route":"/targets/impdh2/","asOf":"2026-09-04","days":24},{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/","asOf":"2026-09-04","days":24},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/","asOf":"2026-09-04","days":24},{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/","asOf":"2026-09-04","days":24},{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/","asOf":"2026-09-04","days":24},{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/","asOf":"2026-09-04","days":24},{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/","asOf":"2026-09-04","days":24},{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/","asOf":"2026-09-04","days":24},{"id":"mirvetuximab-soravtansine","kind":"drug","name":"Mirvetuximab soravtansine","route":"/drugs/mirvetuximab-soravtansine/","asOf":"2026-09-04","days":24},{"id":"tisotumab-vedotin","kind":"drug","name":"Tisotumab vedotin","route":"/drugs/tisotumab-vedotin/","asOf":"2026-09-04","days":24},{"id":"telisotuzumab-vedotin","kind":"drug","name":"Telisotuzumab vedotin","route":"/drugs/telisotuzumab-vedotin/","asOf":"2026-09-04","days":24},{"id":"zynlonta","kind":"drug","name":"Loncastuximab tesirine","route":"/drugs/zynlonta/","asOf":"2026-09-04","days":24},{"id":"gemtuzumab-ozogamicin","kind":"drug","name":"Gemtuzumab ozogamicin","route":"/drugs/gemtuzumab-ozogamicin/","asOf":"2026-09-04","days":24},{"id":"belantamab-mafodotin","kind":"drug","name":"Belantamab mafodotin","route":"/drugs/belantamab-mafodotin/","asOf":"2026-09-04","days":24},{"id":"izalontamab-brengitecan","kind":"drug","name":"Izalontamab brengitecan","route":"/drugs/izalontamab-brengitecan/","asOf":"2026-09-04","days":24},{"id":"patritumab-deruxtecan","kind":"drug","name":"Patritumab deruxtecan","route":"/drugs/patritumab-deruxtecan/","asOf":"2026-09-04","days":24},{"id":"ifinatamab-deruxtecan","kind":"drug","name":"Ifinatamab deruxtecan","route":"/drugs/ifinatamab-deruxtecan/","asOf":"2026-09-04","days":24},{"id":"raludotatug-deruxtecan","kind":"drug","name":"Raludotatug deruxtecan","route":"/drugs/raludotatug-deruxtecan/","asOf":"2026-09-04","days":24},{"id":"tilatamig-samrotecan","kind":"drug","name":"Tilatamig samrotecan","route":"/drugs/tilatamig-samrotecan/","asOf":"2026-09-04","days":24},{"id":"ak146d1","kind":"drug","name":"AK146D1","route":"/drugs/ak146d1/","asOf":"2026-09-04","days":24},{"id":"disitamab-vedotin","kind":"drug","name":"Disitamab vedotin","route":"/drugs/disitamab-vedotin/","asOf":"2026-09-04","days":24},{"id":"zilovertamab-vedotin","kind":"drug","name":"Zilovertamab vedotin","route":"/drugs/zilovertamab-vedotin/","asOf":"2026-09-04","days":24},{"id":"cmg901","kind":"drug","name":"Sonesitatug vedotin","route":"/drugs/cmg901/","asOf":"2026-09-04","days":24},{"id":"puxitatug-samrotecan","kind":"drug","name":"Puxitatug samrotecan","route":"/drugs/puxitatug-samrotecan/","asOf":"2026-09-04","days":24},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","asOf":"2026-09-04","days":24},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/","asOf":"2026-09-04","days":24},{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/","asOf":"2026-09-04","days":24},{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/","asOf":"2026-09-04","days":24},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","asOf":"2026-09-04","days":24},{"id":"relatlimab-nivolumab","kind":"drug","name":"Relatlimab + nivolumab","route":"/drugs/relatlimab-nivolumab/","asOf":"2026-09-04","days":24},{"id":"dostarlimab","kind":"drug","name":"Dostarlimab","route":"/drugs/dostarlimab/","asOf":"2026-09-04","days":24},{"id":"cemiplimab","kind":"drug","name":"Cemiplimab","route":"/drugs/cemiplimab/","asOf":"2026-09-04","days":24},{"id":"tarlatamab","kind":"drug","name":"Tarlatamab","route":"/drugs/tarlatamab/","asOf":"2026-09-04","days":24},{"id":"teclistamab","kind":"drug","name":"Teclistamab","route":"/drugs/teclistamab/","asOf":"2026-09-04","days":24},{"id":"glofitamab","kind":"drug","name":"Glofitamab","route":"/drugs/glofitamab/","asOf":"2026-09-04","days":24},{"id":"tebentafusp","kind":"drug","name":"Tebentafusp","route":"/drugs/tebentafusp/","asOf":"2026-09-04","days":24},{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/","asOf":"2026-09-04","days":24},{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/","asOf":"2026-09-04","days":24},{"id":"zanidatamab","kind":"drug","name":"Zanidatamab","route":"/drugs/zanidatamab/","asOf":"2026-09-04","days":24},{"id":"zenocutuzumab","kind":"drug","name":"Zenocutuzumab","route":"/drugs/zenocutuzumab/","asOf":"2026-09-04","days":24},{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/","asOf":"2026-09-04","days":24},{"id":"ciltacabtagene-autoleucel","kind":"drug","name":"Ciltacabtagene autoleucel","route":"/drugs/ciltacabtagene-autoleucel/","asOf":"2026-09-04","days":24},{"id":"axicabtagene-ciloleucel","kind":"drug","name":"Axicabtagene ciloleucel","route":"/drugs/axicabtagene-ciloleucel/","asOf":"2026-09-04","days":24},{"id":"lifileucel","kind":"drug","name":"Lifileucel","route":"/drugs/lifileucel/","asOf":"2026-09-04","days":24},{"id":"afamitresgene-autoleucel","kind":"drug","name":"Afamitresgene autoleucel","route":"/drugs/afamitresgene-autoleucel/","asOf":"2026-09-04","days":24},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","asOf":"2026-09-04","days":24},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","asOf":"2026-09-04","days":24},{"id":"pylarify","kind":"drug","name":"Piflufolastat F-18 / Pylarify TruVu","route":"/drugs/pylarify/","asOf":"2026-09-04","days":24},{"id":"ryz101","kind":"drug","name":"Actinium-225 DOTATATE","route":"/drugs/ryz101/","asOf":"2026-09-04","days":24},{"id":"ac225-psma","kind":"drug","name":"Actinium-225 PSMA agents","route":"/drugs/ac225-psma/","asOf":"2026-09-04","days":24},{"id":"fap-2286","kind":"drug","name":"FAP-2286 (177Lu / 68Ga)","route":"/drugs/fap-2286/","asOf":"2026-09-04","days":24},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/","asOf":"2026-09-04","days":24},{"id":"lorlatinib","kind":"drug","name":"Lorlatinib","route":"/drugs/lorlatinib/","asOf":"2026-09-04","days":24},{"id":"sotorasib","kind":"drug","name":"Sotorasib","route":"/drugs/sotorasib/","asOf":"2026-09-04","days":24},{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/","asOf":"2026-09-04","days":24},{"id":"daraxonrasib","kind":"drug","name":"Daraxonrasib","route":"/drugs/daraxonrasib/","asOf":"2026-09-04","days":24},{"id":"encorafenib","kind":"drug","name":"Encorafenib","route":"/drugs/encorafenib/","asOf":"2026-09-04","days":24},{"id":"selpercatinib","kind":"drug","name":"Selpercatinib","route":"/drugs/selpercatinib/","asOf":"2026-09-04","days":24},{"id":"zongertinib","kind":"drug","name":"Zongertinib","route":"/drugs/zongertinib/","asOf":"2026-09-04","days":24},{"id":"zidesamtinib","kind":"drug","name":"Zidesamtinib","route":"/drugs/zidesamtinib/","asOf":"2026-09-04","days":24},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","asOf":"2026-09-04","days":24},{"id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/","asOf":"2026-09-04","days":24},{"id":"talazoparib","kind":"drug","name":"Talazoparib","route":"/drugs/talazoparib/","asOf":"2026-09-04","days":24},{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/","asOf":"2026-09-04","days":24},{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/","asOf":"2026-09-04","days":24},{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/","asOf":"2026-09-04","days":24},{"id":"capivasertib","kind":"drug","name":"Capivasertib","route":"/drugs/capivasertib/","asOf":"2026-09-04","days":24},{"id":"inavolisib","kind":"drug","name":"Inavolisib","route":"/drugs/inavolisib/","asOf":"2026-09-04","days":24},{"id":"gedatolisib","kind":"drug","name":"Gedatolisib","route":"/drugs/gedatolisib/","asOf":"2026-09-04","days":24},{"id":"vepdegestrant","kind":"drug","name":"Vepdegestrant","route":"/drugs/vepdegestrant/","asOf":"2026-09-04","days":24},{"id":"elacestrant","kind":"drug","name":"Elacestrant","route":"/drugs/elacestrant/","asOf":"2026-09-04","days":24},{"id":"belzutifan","kind":"drug","name":"Belzutifan","route":"/drugs/belzutifan/","asOf":"2026-09-04","days":24},{"id":"relacorilant","kind":"drug","name":"Relacorilant","route":"/drugs/relacorilant/","asOf":"2026-09-04","days":24},{"id":"revumenib","kind":"drug","name":"Revumenib","route":"/drugs/revumenib/","asOf":"2026-09-04","days":24},{"id":"vorasidenib","kind":"drug","name":"Vorasidenib","route":"/drugs/vorasidenib/","asOf":"2026-09-04","days":24},{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/","asOf":"2026-09-04","days":24},{"id":"imatinib","kind":"drug","name":"Imatinib","route":"/drugs/imatinib/","asOf":"2026-09-04","days":24},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/","asOf":"2026-09-04","days":24},{"id":"tucatinib","kind":"drug","name":"Tucatinib","route":"/drugs/tucatinib/","asOf":"2026-09-04","days":24},{"id":"intismeran-autogene","kind":"drug","name":"Intismeran autogene","route":"/drugs/intismeran-autogene/","asOf":"2026-09-04","days":24},{"id":"autogene-cevumeran","kind":"drug","name":"Autogene cevumeran","route":"/drugs/autogene-cevumeran/","asOf":"2026-09-04","days":24},{"id":"vusolimogene-oderparepvec","kind":"drug","name":"Vusolimogene oderparepvec","route":"/drugs/vusolimogene-oderparepvec/","asOf":"2026-09-04","days":24},{"id":"talimogene-laherparepvec","kind":"drug","name":"Talimogene laherparepvec","route":"/drugs/talimogene-laherparepvec/","asOf":"2026-09-04","days":24},{"id":"optune","kind":"drug","name":"Optune / Optune Pax (TTFields)","route":"/drugs/optune/","asOf":"2026-09-04","days":24},{"id":"galleri","kind":"drug","name":"Galleri","route":"/drugs/galleri/","asOf":"2026-09-04","days":24},{"id":"shield","kind":"drug","name":"Shield","route":"/drugs/shield/","asOf":"2026-09-04","days":24},{"id":"signatera","kind":"drug","name":"Signatera","route":"/drugs/signatera/","asOf":"2026-09-04","days":24},{"id":"foundationone-cdx","kind":"drug","name":"FoundationOne CDx / Liquid CDx","route":"/drugs/foundationone-cdx/","asOf":"2026-09-04","days":24},{"id":"oncotype-dx","kind":"drug","name":"Oncotype DX","route":"/drugs/oncotype-dx/","asOf":"2026-09-04","days":24},{"id":"artera-ai-prostate","kind":"drug","name":"ArteraAI Prostate","route":"/drugs/artera-ai-prostate/","asOf":"2026-09-04","days":24},{"id":"artera-ai-breast","kind":"drug","name":"ArteraAI Breast","route":"/drugs/artera-ai-breast/","asOf":"2026-09-04","days":24},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/","asOf":"2026-09-04","days":24},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/","asOf":"2026-09-04","days":24},{"id":"omidubicel","kind":"drug","name":"Omidubicel","route":"/drugs/omidubicel/","asOf":"2026-09-04","days":24},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/","asOf":"2026-09-04","days":24},{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/","asOf":"2026-09-04","days":24},{"id":"daiichi-sankyo","kind":"company","name":"Daiichi Sankyo","route":"/companies/daiichi-sankyo/","asOf":"2026-09-04","days":24},{"id":"gilead","kind":"company","name":"Gilead Sciences (incl. Kite)","route":"/companies/gilead/","asOf":"2026-09-04","days":24},{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/","asOf":"2026-09-04","days":24},{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/","asOf":"2026-09-04","days":24},{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/","asOf":"2026-09-04","days":24},{"id":"pfizer","kind":"company","name":"Pfizer (incl. Seagen)","route":"/companies/pfizer/","asOf":"2026-09-04","days":24},{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/","asOf":"2026-09-04","days":24},{"id":"abbvie","kind":"company","name":"AbbVie (incl. ImmunoGen, Capstan)","route":"/companies/abbvie/","asOf":"2026-09-04","days":24},{"id":"amgen","kind":"company","name":"Amgen","route":"/companies/amgen/","asOf":"2026-09-04","days":24},{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/","asOf":"2026-09-04","days":24},{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/","asOf":"2026-09-04","days":24},{"id":"bayer","kind":"company","name":"Bayer","route":"/companies/bayer/","asOf":"2026-09-04","days":24},{"id":"astellas","kind":"company","name":"Astellas","route":"/companies/astellas/","asOf":"2026-09-04","days":24},{"id":"takeda","kind":"company","name":"Takeda","route":"/companies/takeda/","asOf":"2026-09-04","days":24},{"id":"boehringer-ingelheim","kind":"company","name":"Boehringer Ingelheim","route":"/companies/boehringer-ingelheim/","asOf":"2026-09-04","days":24},{"id":"sanofi","kind":"company","name":"Sanofi","route":"/companies/sanofi/","asOf":"2026-09-04","days":24},{"id":"regeneron","kind":"company","name":"Regeneron","route":"/companies/regeneron/","asOf":"2026-09-04","days":24},{"id":"servier","kind":"company","name":"Servier","route":"/companies/servier/","asOf":"2026-09-04","days":24},{"id":"kelun-biotech","kind":"company","name":"Sichuan Kelun-Biotech","route":"/companies/kelun-biotech/","asOf":"2026-09-04","days":24},{"id":"systimmune","kind":"company","name":"SystImmune / Sichuan Biokin","route":"/companies/systimmune/","asOf":"2026-09-04","days":24},{"id":"akeso","kind":"company","name":"Akeso","route":"/companies/akeso/","asOf":"2026-09-04","days":24},{"id":"summit-therapeutics","kind":"company","name":"Summit Therapeutics","route":"/companies/summit-therapeutics/","asOf":"2026-09-04","days":24},{"id":"adc-therapeutics","kind":"company","name":"ADC Therapeutics","route":"/companies/adc-therapeutics/","asOf":"2026-09-04","days":24},{"id":"zymeworks","kind":"company","name":"Zymeworks","route":"/companies/zymeworks/","asOf":"2026-09-04","days":24},{"id":"jazz","kind":"company","name":"Jazz Pharmaceuticals","route":"/companies/jazz/","asOf":"2026-09-04","days":24},{"id":"beone","kind":"company","name":"BeOne Medicines (formerly BeiGene)","route":"/companies/beone/","asOf":"2026-09-04","days":24},{"id":"remegen","kind":"company","name":"RemeGen","route":"/companies/remegen/","asOf":"2026-09-04","days":24},{"id":"dualitybio","kind":"company","name":"Duality Biotherapeutics","route":"/companies/dualitybio/","asOf":"2026-09-04","days":24},{"id":"medilink","kind":"company","name":"MediLink Therapeutics","route":"/companies/medilink/","asOf":"2026-09-04","days":24},{"id":"avenzo","kind":"company","name":"Avenzo Therapeutics","route":"/companies/avenzo/","asOf":"2026-09-04","days":24},{"id":"merus","kind":"company","name":"Merus","route":"/companies/merus/","asOf":"2026-09-04","days":24},{"id":"genmab","kind":"company","name":"Genmab","route":"/companies/genmab/","asOf":"2026-09-04","days":24},{"id":"revolution-medicines","kind":"company","name":"Revolution Medicines","route":"/companies/revolution-medicines/","asOf":"2026-09-04","days":24},{"id":"arvinas","kind":"company","name":"Arvinas","route":"/companies/arvinas/","asOf":"2026-09-04","days":24},{"id":"nuvalent","kind":"company","name":"Nuvalent","route":"/companies/nuvalent/","asOf":"2026-09-04","days":24},{"id":"celcuity","kind":"company","name":"Celcuity","route":"/companies/celcuity/","asOf":"2026-09-04","days":24},{"id":"menarini","kind":"company","name":"Menarini / Stemline","route":"/companies/menarini/","asOf":"2026-09-04","days":24},{"id":"corcept","kind":"company","name":"Corcept Therapeutics","route":"/companies/corcept/","asOf":"2026-09-04","days":24},{"id":"syndax","kind":"company","name":"Syndax Pharmaceuticals","route":"/companies/syndax/","asOf":"2026-09-04","days":24},{"id":"moderna","kind":"company","name":"Moderna","route":"/companies/moderna/","asOf":"2026-09-04","days":24},{"id":"biontech","kind":"company","name":"BioNTech","route":"/companies/biontech/","asOf":"2026-09-04","days":24},{"id":"replimune","kind":"company","name":"Replimune","route":"/companies/replimune/","asOf":"2026-09-04","days":24},{"id":"immunocore","kind":"company","name":"Immunocore","route":"/companies/immunocore/","asOf":"2026-09-04","days":24},{"id":"iovance","kind":"company","name":"Iovance Biotherapeutics","route":"/companies/iovance/","asOf":"2026-09-04","days":24},{"id":"legend-biotech","kind":"company","name":"Legend Biotech","route":"/companies/legend-biotech/","asOf":"2026-09-04","days":24},{"id":"carsgen","kind":"company","name":"CARsgen Therapeutics","route":"/companies/carsgen/","asOf":"2026-09-04","days":24},{"id":"adaptimmune","kind":"company","name":"Adaptimmune","route":"/companies/adaptimmune/","asOf":"2026-09-04","days":24},{"id":"lantheus","kind":"company","name":"Lantheus","route":"/companies/lantheus/","asOf":"2026-09-04","days":24},{"id":"telix","kind":"company","name":"Telix Pharmaceuticals","route":"/companies/telix/","asOf":"2026-09-04","days":24},{"id":"rayzebio","kind":"company","name":"RayzeBio (BMS)","route":"/companies/rayzebio/","asOf":"2026-09-04","days":24},{"id":"fusion-pharma","kind":"company","name":"Fusion Pharmaceuticals (AstraZeneca)","route":"/companies/fusion-pharma/","asOf":"2026-09-04","days":24},{"id":"itm","kind":"company","name":"ITM Isotope Technologies Munich","route":"/companies/itm/","asOf":"2026-09-04","days":24},{"id":"terrapower-isotopes","kind":"company","name":"TerraPower Isotopes","route":"/companies/terrapower-isotopes/","asOf":"2026-09-04","days":24},{"id":"orano-med","kind":"company","name":"Orano Med","route":"/companies/orano-med/","asOf":"2026-09-04","days":24},{"id":"foundation-medicine","kind":"company","name":"Foundation Medicine (Roche)","route":"/companies/foundation-medicine/","asOf":"2026-09-04","days":24},{"id":"guardant-health","kind":"company","name":"Guardant Health","route":"/companies/guardant-health/","asOf":"2026-09-04","days":24},{"id":"natera","kind":"company","name":"Natera","route":"/companies/natera/","asOf":"2026-09-04","days":24},{"id":"grail","kind":"company","name":"GRAIL","route":"/companies/grail/","asOf":"2026-09-04","days":24},{"id":"exact-sciences","kind":"company","name":"Exact Sciences (Abbott)","route":"/companies/exact-sciences/","asOf":"2026-09-04","days":24},{"id":"tempus","kind":"company","name":"Tempus AI","route":"/companies/tempus/","asOf":"2026-09-04","days":24},{"id":"caris","kind":"company","name":"Caris Life Sciences","route":"/companies/caris/","asOf":"2026-09-04","days":24},{"id":"bostongene","kind":"company","name":"BostonGene","route":"/companies/bostongene/","asOf":"2026-09-04","days":24},{"id":"illumina","kind":"company","name":"Illumina","route":"/companies/illumina/","asOf":"2026-09-04","days":24},{"id":"10x-genomics","kind":"company","name":"10x Genomics","route":"/companies/10x-genomics/","asOf":"2026-09-04","days":24},{"id":"artera","kind":"company","name":"Artera","route":"/companies/artera/","asOf":"2026-09-04","days":24},{"id":"paige","kind":"company","name":"Paige AI","route":"/companies/paige/","asOf":"2026-09-04","days":24},{"id":"pathai","kind":"company","name":"PathAI","route":"/companies/pathai/","asOf":"2026-09-04","days":24},{"id":"owkin","kind":"company","name":"Owkin","route":"/companies/owkin/","asOf":"2026-09-04","days":24},{"id":"novocure","kind":"company","name":"Novocure","route":"/companies/novocure/","asOf":"2026-09-04","days":24},{"id":"intuitive-surgical","kind":"company","name":"Intuitive Surgical","route":"/companies/intuitive-surgical/","asOf":"2026-09-04","days":24},{"id":"histosonics","kind":"company","name":"HistoSonics","route":"/companies/histosonics/","asOf":"2026-09-04","days":24},{"id":"insightec","kind":"company","name":"Insightec","route":"/companies/insightec/","asOf":"2026-09-04","days":24},{"id":"varian","kind":"company","name":"Varian (Siemens Healthineers)","route":"/companies/varian/","asOf":"2026-09-04","days":24},{"id":"elekta","kind":"company","name":"Elekta","route":"/companies/elekta/","asOf":"2026-09-04","days":24},{"id":"reflexion","kind":"company","name":"RefleXion Medical","route":"/companies/reflexion/","asOf":"2026-09-04","days":24},{"id":"iba","kind":"company","name":"IBA (Ion Beam Applications)","route":"/companies/iba/","asOf":"2026-09-04","days":24},{"id":"mevion","kind":"company","name":"Mevion Medical Systems","route":"/companies/mevion/","asOf":"2026-09-04","days":24},{"id":"ge-healthcare","kind":"company","name":"GE HealthCare","route":"/companies/ge-healthcare/","asOf":"2026-09-04","days":24},{"id":"siemens-healthineers","kind":"company","name":"Siemens Healthineers","route":"/companies/siemens-healthineers/","asOf":"2026-09-04","days":24},{"id":"united-imaging","kind":"company","name":"United Imaging","route":"/companies/united-imaging/","asOf":"2026-09-04","days":24},{"id":"cancer-commons","kind":"company","name":"Cancer Commons","route":"/companies/cancer-commons/","asOf":"2026-09-04","days":24},{"id":"celldex","kind":"company","name":"Celldex Therapeutics","route":"/companies/celldex/","asOf":"2026-09-04","days":24},{"id":"debiopharm","kind":"company","name":"Debiopharm","route":"/companies/debiopharm/","asOf":"2026-09-04","days":24},{"id":"keymed","kind":"company","name":"Keymed Biosciences (KYM Biosciences)","route":"/companies/keymed/","asOf":"2026-09-04","days":24},{"id":"morphosys","kind":"company","name":"MorphoSys (Novartis)","route":"/companies/morphosys/","asOf":"2026-09-04","days":24},{"id":"gritstone","kind":"company","name":"Gritstone bio","route":"/companies/gritstone/","asOf":"2026-09-04","days":24},{"id":"serova","kind":"company","name":"Serova","route":"/companies/serova/","asOf":"2026-09-04","days":24},{"id":"bulsara-bioworks","kind":"company","name":"Bulsara Bioworks","route":"/companies/bulsara-bioworks/","asOf":"2026-09-04","days":24},{"id":"circle-pharma","kind":"company","name":"Circle Pharma","route":"/companies/circle-pharma/","asOf":"2026-09-04","days":24},{"id":"valius","kind":"company","name":"Valius Sciences","route":"/companies/valius/","asOf":"2026-09-04","days":24},{"id":"elucidate-bio","kind":"company","name":"Elucidate Bio","route":"/companies/elucidate-bio/","asOf":"2026-09-04","days":24},{"id":"sengine","kind":"company","name":"SEngine Precision Medicine","route":"/companies/sengine/","asOf":"2026-09-04","days":24},{"id":"champions-oncology","kind":"company","name":"Champions Oncology","route":"/companies/champions-oncology/","asOf":"2026-09-04","days":24},{"id":"navexio","kind":"company","name":"Navexio","route":"/companies/navexio/","asOf":"2026-09-04","days":24},{"id":"patient-data-vault","kind":"company","name":"Patient Data Vault (data-vault.health)","route":"/companies/patient-data-vault/","asOf":"2026-09-04","days":24},{"id":"more-health","kind":"company","name":"MORE Health","route":"/companies/more-health/","asOf":"2026-09-04","days":24},{"id":"finaldose","kind":"company","name":"FinalDose","route":"/companies/finaldose/","asOf":"2026-09-04","days":24},{"id":"orna-therapeutics","kind":"company","name":"Orna Therapeutics (Eli Lilly)","route":"/companies/orna-therapeutics/","asOf":"2026-09-04","days":24},{"id":"umoja-biopharma","kind":"company","name":"Umoja Biopharma","route":"/companies/umoja-biopharma/","asOf":"2026-09-04","days":24},{"id":"interius","kind":"company","name":"Interius BioTherapeutics","route":"/companies/interius/","asOf":"2026-09-04","days":24},{"id":"insilico-medicine","kind":"company","name":"Insilico Medicine","route":"/companies/insilico-medicine/","asOf":"2026-09-04","days":24},{"id":"recursion","kind":"company","name":"Recursion Pharmaceuticals","route":"/companies/recursion/","asOf":"2026-09-04","days":24},{"id":"isomorphic-labs","kind":"company","name":"Isomorphic Labs","route":"/companies/isomorphic-labs/","asOf":"2026-09-04","days":24},{"id":"generate-biomedicines","kind":"company","name":"Generate:Biomedicines","route":"/companies/generate-biomedicines/","asOf":"2026-09-04","days":24},{"id":"perspective-therapeutics","kind":"company","name":"Perspective Therapeutics","route":"/companies/perspective-therapeutics/","asOf":"2026-09-04","days":24},{"id":"clarity-pharmaceuticals","kind":"company","name":"Clarity Pharmaceuticals","route":"/companies/clarity-pharmaceuticals/","asOf":"2026-09-04","days":24},{"id":"aktis-oncology","kind":"company","name":"Aktis Oncology","route":"/companies/aktis-oncology/","asOf":"2026-09-04","days":24},{"id":"radiomedix","kind":"company","name":"RadioMedix","route":"/companies/radiomedix/","asOf":"2026-09-04","days":24},{"id":"sutro-biopharma","kind":"company","name":"Sutro Biopharma","route":"/companies/sutro-biopharma/","asOf":"2026-09-04","days":24},{"id":"mersana","kind":"company","name":"Mersana Therapeutics","route":"/companies/mersana/","asOf":"2026-09-04","days":24},{"id":"tubulis","kind":"company","name":"Tubulis (Gilead)","route":"/companies/tubulis/","asOf":"2026-09-04","days":24},{"id":"araris","kind":"company","name":"Araris Biotech (Taiho)","route":"/companies/araris/","asOf":"2026-09-04","days":24},{"id":"synaffix","kind":"company","name":"Synaffix (Lonza)","route":"/companies/synaffix/","asOf":"2026-09-04","days":24},{"id":"kymera","kind":"company","name":"Kymera Therapeutics","route":"/companies/kymera/","asOf":"2026-09-04","days":24},{"id":"nurix","kind":"company","name":"Nurix Therapeutics","route":"/companies/nurix/","asOf":"2026-09-04","days":24},{"id":"c4-therapeutics","kind":"company","name":"C4 Therapeutics","route":"/companies/c4-therapeutics/","asOf":"2026-09-04","days":24},{"id":"monte-rosa","kind":"company","name":"Monte Rosa Therapeutics","route":"/companies/monte-rosa/","asOf":"2026-09-04","days":24},{"id":"verastem","kind":"company","name":"Verastem Oncology","route":"/companies/verastem/","asOf":"2026-09-04","days":24},{"id":"frontier-medicines","kind":"company","name":"Frontier Medicines","route":"/companies/frontier-medicines/","asOf":"2026-09-04","days":24},{"id":"quanta-therapeutics","kind":"company","name":"Quanta Therapeutics","route":"/companies/quanta-therapeutics/","asOf":"2026-09-04","days":24},{"id":"arsenal-bio","kind":"company","name":"Arsenal Biosciences","route":"/companies/arsenal-bio/","asOf":"2026-09-04","days":24},{"id":"sana-biotechnology","kind":"company","name":"Sana Biotechnology","route":"/companies/sana-biotechnology/","asOf":"2026-09-04","days":24},{"id":"allogene","kind":"company","name":"Allogene Therapeutics","route":"/companies/allogene/","asOf":"2026-09-04","days":24},{"id":"caribou","kind":"company","name":"Caribou Biosciences","route":"/companies/caribou/","asOf":"2026-09-04","days":24},{"id":"nkarta","kind":"company","name":"Nkarta","route":"/companies/nkarta/","asOf":"2026-09-04","days":24},{"id":"fate-therapeutics","kind":"company","name":"Fate Therapeutics","route":"/companies/fate-therapeutics/","asOf":"2026-09-04","days":24},{"id":"freenome","kind":"company","name":"Freenome","route":"/companies/freenome/","asOf":"2026-09-04","days":24},{"id":"delfi-diagnostics","kind":"company","name":"DELFI Diagnostics","route":"/companies/delfi-diagnostics/","asOf":"2026-09-04","days":24},{"id":"harbinger-health","kind":"company","name":"Harbinger Health","route":"/companies/harbinger-health/","asOf":"2026-09-04","days":24},{"id":"personalis","kind":"company","name":"Personalis (Tempus)","route":"/companies/personalis/","asOf":"2026-09-04","days":24},{"id":"foresight-diagnostics","kind":"company","name":"Foresight Diagnostics","route":"/companies/foresight-diagnostics/","asOf":"2026-09-04","days":24},{"id":"lunit","kind":"company","name":"Lunit","route":"/companies/lunit/","asOf":"2026-09-04","days":24},{"id":"aidoc","kind":"company","name":"Aidoc","route":"/companies/aidoc/","asOf":"2026-09-04","days":24},{"id":"xilis","kind":"company","name":"Xilis","route":"/companies/xilis/","asOf":"2026-09-04","days":24},{"id":"curesponse","kind":"company","name":"Curesponse","route":"/companies/curesponse/","asOf":"2026-09-04","days":24},{"id":"compugen","kind":"company","name":"Compugen","route":"/companies/compugen/","asOf":"2026-09-04","days":24},{"id":"immatics","kind":"company","name":"Immatics","route":"/companies/immatics/","asOf":"2026-09-04","days":24},{"id":"tscan","kind":"company","name":"TScan Therapeutics","route":"/companies/tscan/","asOf":"2026-09-04","days":24},{"id":"xencor","kind":"company","name":"Xencor","route":"/companies/xencor/","asOf":"2026-09-04","days":24},{"id":"sofie-biosciences","kind":"company","name":"SOFIE Biosciences","route":"/companies/sofie-biosciences/","asOf":"2026-09-04","days":24},{"id":"nouscom","kind":"company","name":"Nouscom","route":"/companies/nouscom/","asOf":"2026-09-04","days":24},{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/","asOf":"2026-09-04","days":24},{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/","asOf":"2026-09-04","days":24},{"id":"samsung-medical-center","kind":"institution","name":"Samsung Medical Center","route":"/institutions/samsung-medical-center/","asOf":"2026-09-04","days":24},{"id":"asan-medical-center","kind":"institution","name":"Asan Medical Center","route":"/institutions/asan-medical-center/","asOf":"2026-09-04","days":24},{"id":"mayo-clinic","kind":"institution","name":"Mayo Clinic","route":"/institutions/mayo-clinic/","asOf":"2026-09-04","days":24},{"id":"gustave-roussy","kind":"institution","name":"Gustave Roussy","route":"/institutions/gustave-roussy/","asOf":"2026-09-04","days":24},{"id":"royal-marsden","kind":"institution","name":"The Royal Marsden","route":"/institutions/royal-marsden/","asOf":"2026-09-04","days":24},{"id":"snuh","kind":"institution","name":"Seoul National University Hospital","route":"/institutions/snuh/","asOf":"2026-09-04","days":24},{"id":"princess-margaret","kind":"institution","name":"Princess Margaret Cancer Centre","route":"/institutions/princess-margaret/","asOf":"2026-09-04","days":24},{"id":"johns-hopkins","kind":"institution","name":"Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center","route":"/institutions/johns-hopkins/","asOf":"2026-09-04","days":24},{"id":"ieo-milan","kind":"institution","name":"IEO (European Institute of Oncology)","route":"/institutions/ieo-milan/","asOf":"2026-09-04","days":24},{"id":"charite","kind":"institution","name":"Charité Universitätsmedizin Berlin","route":"/institutions/charite/","asOf":"2026-09-04","days":24},{"id":"ncc-japan","kind":"institution","name":"National Cancer Center Hospital","route":"/institutions/ncc-japan/","asOf":"2026-09-04","days":24},{"id":"peter-mac","kind":"institution","name":"Peter MacCallum Cancer Centre","route":"/institutions/peter-mac/","asOf":"2026-09-04","days":24},{"id":"dana-farber","kind":"institution","name":"Dana-Farber Brigham Cancer Center","route":"/institutions/dana-farber/","asOf":"2026-09-04","days":24},{"id":"mgh","kind":"institution","name":"Massachusetts General Hospital Cancer Center","route":"/institutions/mgh/","asOf":"2026-09-04","days":24},{"id":"einstein-sao-paulo","kind":"institution","name":"Hospital Israelita Albert Einstein","route":"/institutions/einstein-sao-paulo/","asOf":"2026-09-04","days":24},{"id":"heidelberg-nct","kind":"institution","name":"Heidelberg University Hospital / NCT / DKFZ","route":"/institutions/heidelberg-nct/","asOf":"2026-09-04","days":24},{"id":"sirio-libanes","kind":"institution","name":"Hospital Sírio-Libanês","route":"/institutions/sirio-libanes/","asOf":"2026-09-04","days":24},{"id":"cleveland-clinic","kind":"institution","name":"Cleveland Clinic Taussig Cancer Institute","route":"/institutions/cleveland-clinic/","asOf":"2026-09-04","days":24},{"id":"institut-curie","kind":"institution","name":"Institut Curie","route":"/institutions/institut-curie/","asOf":"2026-09-04","days":24},{"id":"severance","kind":"institution","name":"Severance Hospital, Yonsei University","route":"/institutions/severance/","asOf":"2026-09-04","days":24},{"id":"the-christie","kind":"institution","name":"The Christie NHS Foundation Trust","route":"/institutions/the-christie/","asOf":"2026-09-04","days":24},{"id":"uke-hamburg","kind":"institution","name":"Universitätsklinikum Hamburg-Eppendorf","route":"/institutions/uke-hamburg/","asOf":"2026-09-04","days":24},{"id":"jfcr","kind":"institution","name":"Cancer Institute Hospital of JFCR","route":"/institutions/jfcr/","asOf":"2026-09-04","days":24},{"id":"int-milan","kind":"institution","name":"Fondazione IRCCS Istituto Nazionale dei Tumori","route":"/institutions/int-milan/","asOf":"2026-09-04","days":24},{"id":"vall-dhebron","kind":"institution","name":"Vall d'Hebron University Hospital / VHIO","route":"/institutions/vall-dhebron/","asOf":"2026-09-04","days":24},{"id":"gemelli","kind":"institution","name":"Policlinico Universitario A. Gemelli","route":"/institutions/gemelli/","asOf":"2026-09-04","days":24},{"id":"stanford","kind":"institution","name":"Stanford Health Care / Stanford Cancer Institute","route":"/institutions/stanford/","asOf":"2026-09-04","days":24},{"id":"lmu-munich","kind":"institution","name":"LMU Klinikum München","route":"/institutions/lmu-munich/","asOf":"2026-09-04","days":24},{"id":"uniklinik-koeln","kind":"institution","name":"Uniklinik Köln (CIO)","route":"/institutions/uniklinik-koeln/","asOf":"2026-09-04","days":24},{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/","asOf":"2026-09-04","days":24},{"id":"mount-sinai","kind":"institution","name":"The Mount Sinai Hospital / Tisch Cancer Institute","route":"/institutions/mount-sinai/","asOf":"2026-09-04","days":24},{"id":"la-paz","kind":"institution","name":"Hospital Universitario La Paz","route":"/institutions/la-paz/","asOf":"2026-09-04","days":24},{"id":"karolinska","kind":"institution","name":"Karolinska University Hospital","route":"/institutions/karolinska/","asOf":"2026-09-04","days":24},{"id":"gregorio-maranon","kind":"institution","name":"Hospital General Universitario Gregorio Marañón","route":"/institutions/gregorio-maranon/","asOf":"2026-09-04","days":24},{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/","asOf":"2026-09-04","days":24},{"id":"fred-hutch","kind":"institution","name":"Fred Hutchinson Cancer Center","route":"/institutions/fred-hutch/","asOf":"2026-09-04","days":24},{"id":"penn-abramson","kind":"institution","name":"Abramson Cancer Center, University of Pennsylvania","route":"/institutions/penn-abramson/","asOf":"2026-09-04","days":24},{"id":"city-of-hope","kind":"institution","name":"City of Hope","route":"/institutions/city-of-hope/","asOf":"2026-09-04","days":24},{"id":"moffitt","kind":"institution","name":"Moffitt Cancer Center","route":"/institutions/moffitt/","asOf":"2026-09-04","days":24},{"id":"michigan-rogel","kind":"institution","name":"University of Michigan Rogel Cancer Center","route":"/institutions/michigan-rogel/","asOf":"2026-09-04","days":24},{"id":"wustl-siteman","kind":"institution","name":"Siteman Cancer Center, Washington University","route":"/institutions/wustl-siteman/","asOf":"2026-09-04","days":24},{"id":"ucla-jonsson","kind":"institution","name":"UCLA Jonsson Comprehensive Cancer Center","route":"/institutions/ucla-jonsson/","asOf":"2026-09-04","days":24},{"id":"roswell-park","kind":"institution","name":"Roswell Park Comprehensive Cancer Center","route":"/institutions/roswell-park/","asOf":"2026-09-04","days":24},{"id":"broad-institute","kind":"institution","name":"Broad Institute of MIT and Harvard","route":"/institutions/broad-institute/","asOf":"2026-09-04","days":24},{"id":"cold-spring-harbor","kind":"institution","name":"Cold Spring Harbor Laboratory","route":"/institutions/cold-spring-harbor/","asOf":"2026-09-04","days":24},{"id":"francis-crick","kind":"institution","name":"The Francis Crick Institute","route":"/institutions/francis-crick/","asOf":"2026-09-04","days":24},{"id":"icr-london","kind":"institution","name":"The Institute of Cancer Research","route":"/institutions/icr-london/","asOf":"2026-09-04","days":24},{"id":"cruk","kind":"institution","name":"Cancer Research UK","route":"/institutions/cruk/","asOf":"2026-09-04","days":24},{"id":"nki","kind":"institution","name":"Netherlands Cancer Institute (NKI-AvL)","route":"/institutions/nki/","asOf":"2026-09-04","days":24},{"id":"dkfz","kind":"institution","name":"German Cancer Research Center (DKFZ)","route":"/institutions/dkfz/","asOf":"2026-09-04","days":24},{"id":"sysucc","kind":"institution","name":"Sun Yat-sen University Cancer Center","route":"/institutions/sysucc/","asOf":"2026-09-04","days":24},{"id":"fuscc","kind":"institution","name":"Fudan University Shanghai Cancer Center","route":"/institutions/fuscc/","asOf":"2026-09-04","days":24},{"id":"west-china","kind":"institution","name":"West China Hospital, Sichuan University","route":"/institutions/west-china/","asOf":"2026-09-04","days":24},{"id":"cams-cancer-hospital","kind":"institution","name":"Cancer Hospital, Chinese Academy of Medical Sciences","route":"/institutions/cams-cancer-hospital/","asOf":"2026-09-04","days":24},{"id":"tata-memorial","kind":"institution","name":"Tata Memorial Centre","route":"/institutions/tata-memorial/","asOf":"2026-09-04","days":24},{"id":"asco","kind":"institution","name":"American Society of Clinical Oncology (ASCO)","route":"/institutions/asco/","asOf":"2026-09-04","days":24},{"id":"esmo","kind":"institution","name":"European Society for Medical Oncology (ESMO)","route":"/institutions/esmo/","asOf":"2026-09-04","days":24},{"id":"aacr","kind":"institution","name":"American Association for Cancer Research (AACR)","route":"/institutions/aacr/","asOf":"2026-09-04","days":24},{"id":"iarc","kind":"institution","name":"International Agency for Research on Cancer (IARC / WHO)","route":"/institutions/iarc/","asOf":"2026-09-04","days":24},{"id":"pi3k-akt-mtor","kind":"pathway","name":"PI3K / AKT / mTOR","route":"/pathways/pi3k-akt-mtor/","asOf":"2026-09-04","days":24},{"id":"ras-mapk","kind":"pathway","name":"RAS / RAF / MEK / ERK (MAPK)","route":"/pathways/ras-mapk/","asOf":"2026-09-04","days":24},{"id":"p53-cell-cycle","kind":"pathway","name":"p53 / RB / cell-cycle checkpoint","route":"/pathways/p53-cell-cycle/","asOf":"2026-09-04","days":24},{"id":"ddr","kind":"pathway","name":"DNA damage response & homologous recombination","route":"/pathways/ddr/","asOf":"2026-09-04","days":24},{"id":"pd1-checkpoint","kind":"pathway","name":"PD-1 / PD-L1 immune checkpoint & T-cell activation","route":"/pathways/pd1-checkpoint/","asOf":"2026-09-04","days":24},{"id":"cgas-sting","kind":"pathway","name":"cGAS-STING innate sensing","route":"/pathways/cgas-sting/","asOf":"2026-09-04","days":24},{"id":"er-signaling","kind":"pathway","name":"Oestrogen receptor signalling","route":"/pathways/er-signaling/","asOf":"2026-09-04","days":24},{"id":"ar-signaling","kind":"pathway","name":"Androgen receptor signalling","route":"/pathways/ar-signaling/","asOf":"2026-09-04","days":24},{"id":"apoptosis-bcl2","kind":"pathway","name":"Intrinsic apoptosis (BCL-2 family)","route":"/pathways/apoptosis-bcl2/","asOf":"2026-09-04","days":24},{"id":"vegf-angiogenesis","kind":"pathway","name":"VEGF angiogenesis","route":"/pathways/vegf-angiogenesis/","asOf":"2026-09-04","days":24},{"id":"hif-vhl","kind":"pathway","name":"VHL / HIF oxygen sensing","route":"/pathways/hif-vhl/","asOf":"2026-09-04","days":24},{"id":"wnt","kind":"pathway","name":"Wnt / β-catenin","route":"/pathways/wnt/","asOf":"2026-09-04","days":24},{"id":"emt","kind":"pathway","name":"Epithelial-mesenchymal transition & drug efflux","route":"/pathways/emt/","asOf":"2026-09-04","days":24},{"id":"bcr-signalling","kind":"pathway","name":"B-cell receptor / BTK signalling (to NF-κB)","route":"/pathways/bcr-signalling/","asOf":"2026-09-04","days":24},{"id":"idh-2hg","kind":"pathway","name":"Mutant IDH / 2-hydroxyglutarate","route":"/pathways/idh-2hg/","asOf":"2026-09-04","days":24},{"id":"fgfr-signalling","kind":"pathway","name":"FGF / FGFR signalling","route":"/pathways/fgfr-signalling/","asOf":"2026-09-04","days":24},{"id":"menin-kmt2a","kind":"pathway","name":"Menin / KMT2A (HOXA9-MEIS1 axis)","route":"/pathways/menin-kmt2a/","asOf":"2026-09-04","days":24},{"id":"bcr-abl1-signalling","kind":"pathway","name":"BCR::ABL1 (Philadelphia chromosome)","route":"/pathways/bcr-abl1-signalling/","asOf":"2026-09-04","days":24},{"id":"cd47-sirpa","kind":"pathway","name":"CD47 / SIRPα (the 'don't eat me' signal)","route":"/pathways/cd47-sirpa/","asOf":"2026-09-04","days":24},{"id":"payload","kind":"term","name":"Payload (ADC)","route":"/terms/payload/","asOf":"2026-09-04","days":24},{"id":"linker","kind":"term","name":"Linker (ADC)","route":"/terms/linker/","asOf":"2026-09-04","days":24},{"id":"dar","kind":"term","name":"Drug-to-antibody ratio (DAR)","route":"/terms/dar/","asOf":"2026-09-04","days":24},{"id":"bystander-effect","kind":"term","name":"Bystander effect (ADC)","route":"/terms/bystander-effect/","asOf":"2026-09-04","days":24},{"id":"ild","kind":"term","name":"Interstitial lung disease (ILD) / pneumonitis","route":"/terms/ild/","asOf":"2026-09-04","days":24},{"id":"efflux-pump","kind":"term","name":"Drug efflux pumps (ABC transporters)","route":"/terms/efflux-pump/","asOf":"2026-09-04","days":24},{"id":"resistance","kind":"term","name":"Drug resistance (primary and acquired)","route":"/terms/resistance/","asOf":"2026-09-04","days":24},{"id":"orr","kind":"term","name":"Objective response rate (ORR)","route":"/terms/orr/","asOf":"2026-09-04","days":24},{"id":"recist","kind":"term","name":"RECIST","route":"/terms/recist/","asOf":"2026-09-04","days":24},{"id":"pfs","kind":"term","name":"Progression-free survival (PFS)","route":"/terms/pfs/","asOf":"2026-09-04","days":24},{"id":"os","kind":"term","name":"Overall survival (OS)","route":"/terms/os/","asOf":"2026-09-04","days":24},{"id":"efs","kind":"term","name":"Event-free / disease-free survival (EFS, DFS, iDFS, RFS)","route":"/terms/efs/","asOf":"2026-09-04","days":24},{"id":"hazard-ratio","kind":"term","name":"Hazard ratio (HR)","route":"/terms/hazard-ratio/","asOf":"2026-09-04","days":24},{"id":"pcr","kind":"term","name":"Pathologic complete response (pCR)","route":"/terms/pcr/","asOf":"2026-09-04","days":24},{"id":"rcb","kind":"term","name":"Residual cancer burden (RCB)","route":"/terms/rcb/","asOf":"2026-09-04","days":24},{"id":"ppv","kind":"term","name":"Positive predictive value (PPV)","route":"/terms/ppv/","asOf":"2026-09-04","days":24},{"id":"stage-shift","kind":"term","name":"Stage shift","route":"/terms/stage-shift/","asOf":"2026-09-04","days":24},{"id":"suv","kind":"term","name":"Standardised uptake value (SUV)","route":"/terms/suv/","asOf":"2026-09-04","days":24},{"id":"ihc","kind":"term","name":"Immunohistochemistry (IHC)","route":"/terms/ihc/","asOf":"2026-09-04","days":24},{"id":"her2-low","kind":"term","name":"HER2-low and HER2-ultralow","route":"/terms/her2-low/","asOf":"2026-09-04","days":24},{"id":"cps","kind":"term","name":"Combined positive score (CPS)","route":"/terms/cps/","asOf":"2026-09-04","days":24},{"id":"tils","kind":"term","name":"Tumour-infiltrating lymphocytes (TILs)","route":"/terms/tils/","asOf":"2026-09-04","days":24},{"id":"tmb","kind":"term","name":"Tumour mutational burden (TMB)","route":"/terms/tmb/","asOf":"2026-09-04","days":24},{"id":"msi","kind":"term","name":"Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR)","route":"/terms/msi/","asOf":"2026-09-04","days":24},{"id":"hrd","kind":"term","name":"Homologous recombination deficiency (HRD)","route":"/terms/hrd/","asOf":"2026-09-04","days":24},{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/","asOf":"2026-09-04","days":24},{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/","asOf":"2026-09-04","days":24},{"id":"vaf","kind":"term","name":"Variant allele frequency (VAF)","route":"/terms/vaf/","asOf":"2026-09-04","days":24},{"id":"vus","kind":"term","name":"Variant of uncertain significance (VUS)","route":"/terms/vus/","asOf":"2026-09-04","days":24},{"id":"founder-variant","kind":"term","name":"Founder variant","route":"/terms/founder-variant/","asOf":"2026-09-04","days":24},{"id":"ngs","kind":"term","name":"Next-generation sequencing (NGS)","route":"/terms/ngs/","asOf":"2026-09-04","days":24},{"id":"gene-fusion","kind":"term","name":"Gene fusion","route":"/terms/gene-fusion/","asOf":"2026-09-04","days":24},{"id":"mutational-signature","kind":"term","name":"Mutational signature","route":"/terms/mutational-signature/","asOf":"2026-09-04","days":24},{"id":"pam50","kind":"term","name":"PAM50 / intrinsic subtypes","route":"/terms/pam50/","asOf":"2026-09-04","days":24},{"id":"neoantigen","kind":"term","name":"Neoantigen","route":"/terms/neoantigen/","asOf":"2026-09-04","days":24},{"id":"oncogene-addiction","kind":"term","name":"Oncogene addiction","route":"/terms/oncogene-addiction/","asOf":"2026-09-04","days":24},{"id":"synthetic-lethality","kind":"term","name":"Synthetic lethality","route":"/terms/synthetic-lethality/","asOf":"2026-09-04","days":24},{"id":"crs","kind":"term","name":"Cytokine release syndrome (CRS)","route":"/terms/crs/","asOf":"2026-09-04","days":24},{"id":"icans","kind":"term","name":"ICANS (neurotoxicity)","route":"/terms/icans/","asOf":"2026-09-04","days":24},{"id":"irae","kind":"term","name":"Immune-related adverse events (irAEs)","route":"/terms/irae/","asOf":"2026-09-04","days":24},{"id":"abscopal-effect","kind":"term","name":"Abscopal effect","route":"/terms/abscopal-effect/","asOf":"2026-09-04","days":24},{"id":"immunogenic-cell-death","kind":"term","name":"Immunogenic cell death","route":"/terms/immunogenic-cell-death/","asOf":"2026-09-04","days":24},{"id":"adcc","kind":"term","name":"ADCC (antibody-dependent cellular cytotoxicity)","route":"/terms/adcc/","asOf":"2026-09-04","days":24},{"id":"fc-effector","kind":"term","name":"Fc engineering / effector function","route":"/terms/fc-effector/","asOf":"2026-09-04","days":24},{"id":"oligometastatic","kind":"term","name":"Oligometastatic disease","route":"/terms/oligometastatic/","asOf":"2026-09-04","days":24},{"id":"neoadjuvant-adjuvant","kind":"term","name":"Neoadjuvant / adjuvant / perioperative","route":"/terms/neoadjuvant-adjuvant/","asOf":"2026-09-04","days":24},{"id":"first-line","kind":"term","name":"Lines of therapy","route":"/terms/first-line/","asOf":"2026-09-04","days":24},{"id":"standard-of-care","kind":"term","name":"Standard of care","route":"/terms/standard-of-care/","asOf":"2026-09-04","days":24},{"id":"accelerated-approval","kind":"term","name":"Accelerated approval","route":"/terms/accelerated-approval/","asOf":"2026-09-04","days":24},{"id":"breakthrough-designation","kind":"term","name":"Breakthrough Therapy / Priority Review / Priority Voucher","route":"/terms/breakthrough-designation/","asOf":"2026-09-04","days":24},{"id":"companion-diagnostic-term","kind":"term","name":"Companion diagnostic","route":"/terms/companion-diagnostic-term/","asOf":"2026-09-04","days":24},{"id":"tumour-agnostic","kind":"term","name":"Tumour-agnostic (tissue-agnostic) approval","route":"/terms/tumour-agnostic/","asOf":"2026-09-04","days":24},{"id":"basket-umbrella-platform","kind":"term","name":"Basket, umbrella, and platform trials","route":"/terms/basket-umbrella-platform/","asOf":"2026-09-04","days":24},{"id":"real-world-evidence","kind":"term","name":"Real-world evidence","route":"/terms/real-world-evidence/","asOf":"2026-09-04","days":24},{"id":"theranostics","kind":"term","name":"Theranostics","route":"/terms/theranostics/","asOf":"2026-09-04","days":24},{"id":"alpha-vs-beta","kind":"term","name":"Alpha vs beta emitters","route":"/terms/alpha-vs-beta/","asOf":"2026-09-04","days":24},{"id":"dosimetry","kind":"term","name":"Dosimetry","route":"/terms/dosimetry/","asOf":"2026-09-04","days":24},{"id":"germline-vs-somatic","kind":"term","name":"Germline vs somatic mutations","route":"/terms/germline-vs-somatic/","asOf":"2026-09-04","days":24},{"id":"tnm-staging","kind":"term","name":"TNM staging","route":"/terms/tnm-staging/","asOf":"2026-09-04","days":24},{"id":"cold-vs-hot","kind":"term","name":"Hot vs cold tumours","route":"/terms/cold-vs-hot/","asOf":"2026-09-04","days":24},{"id":"adc-sequencing","kind":"term","name":"ADC sequencing","route":"/terms/adc-sequencing/","asOf":"2026-09-04","days":24},{"id":"netter-1","kind":"trial","name":"NETTER-1","route":"/trials/netter-1/","asOf":"2026-09-04","days":24},{"id":"luminosity","kind":"trial","name":"LUMINOSITY","route":"/trials/luminosity/","asOf":"2026-09-04","days":24},{"id":"navigate","kind":"trial","name":"NAVIGATE","route":"/trials/navigate/","asOf":"2026-09-04","days":24},{"id":"keynote-522","kind":"trial","name":"KEYNOTE-522","route":"/trials/keynote-522/","asOf":"2026-09-04","days":24},{"id":"keynote-355","kind":"trial","name":"KEYNOTE-355","route":"/trials/keynote-355/","asOf":"2026-09-04","days":24},{"id":"impassion130","kind":"trial","name":"IMpassion130","route":"/trials/impassion130/","asOf":"2026-09-04","days":24},{"id":"ascent","kind":"trial","name":"ASCENT","route":"/trials/ascent/","asOf":"2026-09-04","days":24},{"id":"ascent-03","kind":"trial","name":"ASCENT-03","route":"/trials/ascent-03/","asOf":"2026-09-04","days":24},{"id":"ascent-04","kind":"trial","name":"ASCENT-04 / KEYNOTE-D19","route":"/trials/ascent-04/","asOf":"2026-09-04","days":24},{"id":"tropion-breast01","kind":"trial","name":"TROPION-Breast01","route":"/trials/tropion-breast01/","asOf":"2026-09-04","days":24},{"id":"tropion-breast02","kind":"trial","name":"TROPION-Breast02","route":"/trials/tropion-breast02/","asOf":"2026-09-04","days":24},{"id":"tropion-breast05","kind":"trial","name":"TROPION-Breast05","route":"/trials/tropion-breast05/","asOf":"2026-09-04","days":24},{"id":"bl-b01d1-307","kind":"trial","name":"BL-B01D1-307","route":"/trials/bl-b01d1-307/","asOf":"2026-09-04","days":24},{"id":"izabright-breast01","kind":"trial","name":"IZABRIGHT-Breast01","route":"/trials/izabright-breast01/","asOf":"2026-09-04","days":24},{"id":"optimice-pcr","kind":"trial","name":"OptimICE-pCR (A012103)","route":"/trials/optimice-pcr/","asOf":"2026-09-04","days":24},{"id":"scarlet-s2212","kind":"trial","name":"SCARLET (SWOG S2212)","route":"/trials/scarlet-s2212/","asOf":"2026-09-04","days":24},{"id":"olympia","kind":"trial","name":"OlympiA","route":"/trials/olympia/","asOf":"2026-09-04","days":24},{"id":"destiny-breast03","kind":"trial","name":"DESTINY-Breast03","route":"/trials/destiny-breast03/","asOf":"2026-09-04","days":24},{"id":"destiny-breast04","kind":"trial","name":"DESTINY-Breast04","route":"/trials/destiny-breast04/","asOf":"2026-09-04","days":24},{"id":"destiny-breast06","kind":"trial","name":"DESTINY-Breast06","route":"/trials/destiny-breast06/","asOf":"2026-09-04","days":24},{"id":"destiny-breast09","kind":"trial","name":"DESTINY-Breast09","route":"/trials/destiny-breast09/","asOf":"2026-09-04","days":24},{"id":"destiny-breast11","kind":"trial","name":"DESTINY-Breast11","route":"/trials/destiny-breast11/","asOf":"2026-09-04","days":24},{"id":"natalee","kind":"trial","name":"NATALEE","route":"/trials/natalee/","asOf":"2026-09-04","days":24},{"id":"monarche","kind":"trial","name":"monarchE","route":"/trials/monarche/","asOf":"2026-09-04","days":24},{"id":"veritac-2","kind":"trial","name":"VERITAC-2","route":"/trials/veritac-2/","asOf":"2026-09-04","days":24},{"id":"adaura","kind":"trial","name":"ADAURA","route":"/trials/adaura/","asOf":"2026-09-04","days":24},{"id":"flaura2","kind":"trial","name":"FLAURA2","route":"/trials/flaura2/","asOf":"2026-09-04","days":24},{"id":"mariposa","kind":"trial","name":"MARIPOSA","route":"/trials/mariposa/","asOf":"2026-09-04","days":24},{"id":"tropion-lung01","kind":"trial","name":"TROPION-Lung01","route":"/trials/tropion-lung01/","asOf":"2026-09-04","days":24},{"id":"codebreak-300","kind":"trial","name":"CodeBreaK 300","route":"/trials/codebreak-300/","asOf":"2026-09-04","days":24},{"id":"dellphi-304","kind":"trial","name":"DeLLphi-304","route":"/trials/dellphi-304/","asOf":"2026-09-04","days":24},{"id":"checkmate-067","kind":"trial","name":"CheckMate 067","route":"/trials/checkmate-067/","asOf":"2026-09-04","days":24},{"id":"interpath-001","kind":"trial","name":"INTerpath-001 (V940-001)","route":"/trials/interpath-001/","asOf":"2026-09-04","days":24},{"id":"ev-302","kind":"trial","name":"EV-302 / KEYNOTE-A39","route":"/trials/ev-302/","asOf":"2026-09-04","days":24},{"id":"imvigor011","kind":"trial","name":"IMvigor011","route":"/trials/imvigor011/","asOf":"2026-09-04","days":24},{"id":"vision","kind":"trial","name":"VISION","route":"/trials/vision/","asOf":"2026-09-04","days":24},{"id":"psmafore","kind":"trial","name":"PSMAfore","route":"/trials/psmafore/","asOf":"2026-09-04","days":24},{"id":"nhs-galleri","kind":"trial","name":"NHS-Galleri","route":"/trials/nhs-galleri/","asOf":"2026-09-04","days":24},{"id":"pathfinder-2","kind":"trial","name":"PATHFINDER 2","route":"/trials/pathfinder-2/","asOf":"2026-09-04","days":24},{"id":"dynamic","kind":"trial","name":"DYNAMIC","route":"/trials/dynamic/","asOf":"2026-09-04","days":24},{"id":"adc-plus-io","kind":"pairing","name":"ADC + checkpoint inhibitor","route":"/pairings/adc-plus-io/","asOf":"2026-09-04","days":24},{"id":"cdk46-plus-endocrine","kind":"pairing","name":"CDK4/6 inhibitor + endocrine therapy","route":"/pairings/cdk46-plus-endocrine/","asOf":"2026-09-04","days":24},{"id":"braf-plus-mek","kind":"pairing","name":"BRAF inhibitor + MEK inhibitor","route":"/pairings/braf-plus-mek/","asOf":"2026-09-04","days":24},{"id":"kras-plus-egfr-crc","kind":"pairing","name":"KRAS G12C inhibitor + anti-EGFR antibody (colorectal)","route":"/pairings/kras-plus-egfr-crc/","asOf":"2026-09-04","days":24},{"id":"io-plus-vegf","kind":"pairing","name":"PD-1 blockade + VEGF inhibition","route":"/pairings/io-plus-vegf/","asOf":"2026-09-04","days":24},{"id":"parp-plus-arpi","kind":"pairing","name":"PARP inhibitor + AR pathway inhibitor (prostate)","route":"/pairings/parp-plus-arpi/","asOf":"2026-09-04","days":24},{"id":"vaccine-plus-pd1","kind":"pairing","name":"Personalised neoantigen vaccine + PD-1 blockade","route":"/pairings/vaccine-plus-pd1/","asOf":"2026-09-04","days":24},{"id":"radiation-plus-io","kind":"pairing","name":"Radiotherapy + immunotherapy","route":"/pairings/radiation-plus-io/","asOf":"2026-09-04","days":24},{"id":"oncolytic-plus-pd1","kind":"pairing","name":"Oncolytic virus + PD-1 blockade","route":"/pairings/oncolytic-plus-pd1/","asOf":"2026-09-04","days":24},{"id":"platinum-plus-hrd","kind":"pairing","name":"Platinum chemotherapy in HRD tumours","route":"/pairings/platinum-plus-hrd/","asOf":"2026-09-04","days":24},{"id":"psma-pet-to-rlt","kind":"pairing","name":"PSMA PET → PSMA radioligand therapy","route":"/pairings/psma-pet-to-rlt/","asOf":"2026-09-04","days":24},{"id":"trop2-pet-to-adc","kind":"pairing","name":"TROP2 PET → TROP2 ADC selection","route":"/pairings/trop2-pet-to-adc/","asOf":"2026-09-04","days":24},{"id":"ctdna-mrd-to-adjuvant","kind":"pairing","name":"ctDNA MRD → adjuvant therapy decision","route":"/pairings/ctdna-mrd-to-adjuvant/","asOf":"2026-09-04","days":24},{"id":"her2-low-to-tdxd","kind":"pairing","name":"HER2-low scoring → T-DXd","route":"/pairings/her2-low-to-tdxd/","asOf":"2026-09-04","days":24},{"id":"germline-to-parp","kind":"pairing","name":"Germline BRCA test → adjuvant PARP inhibitor","route":"/pairings/germline-to-parp/","asOf":"2026-09-04","days":24},{"id":"ai-pathology-to-adt","kind":"pairing","name":"AI pathology → androgen deprivation duration","route":"/pairings/ai-pathology-to-adt/","asOf":"2026-09-04","days":24},{"id":"tki-then-adc-lung","kind":"pairing","name":"EGFR TKI → ADC on progression","route":"/pairings/tki-then-adc-lung/","asOf":"2026-09-04","days":24},{"id":"io-then-til","kind":"pairing","name":"PD-1 failure → TIL therapy","route":"/pairings/io-then-til/","asOf":"2026-09-04","days":24},{"id":"beta-then-alpha","kind":"pairing","name":"Beta radioligand → alpha radioligand","route":"/pairings/beta-then-alpha/","asOf":"2026-09-04","days":24},{"id":"adc-after-adc-caution","kind":"pairing","name":"Caution: TOP1 ADC immediately after TOP1 ADC","route":"/pairings/adc-after-adc-caution/","asOf":"2026-09-04","days":24},{"id":"tigit-plus-pd1-caution","kind":"pairing","name":"Caution: TIGIT + PD-(L)1 blockade","route":"/pairings/tigit-plus-pd1-caution/","asOf":"2026-09-04","days":24},{"id":"ild-overlap-caution","kind":"pairing","name":"Caution: DXd ADC + agents with pneumonitis risk","route":"/pairings/ild-overlap-caution/","asOf":"2026-09-04","days":24},{"id":"proton-vs-imrt","kind":"pairing","name":"Caution: proton therapy vs IMRT","route":"/pairings/proton-vs-imrt/","asOf":"2026-09-04","days":24},{"id":"adc-generations","kind":"roadmap","name":"ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs","route":"/roadmaps/adc-generations/","asOf":"2026-09-04","days":24},{"id":"trop2-adc-roadmap","kind":"roadmap","name":"TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET","route":"/roadmaps/trop2-adc-roadmap/","asOf":"2026-09-04","days":24},{"id":"tnbc-history","kind":"roadmap","name":"TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line","route":"/roadmaps/tnbc-history/","asOf":"2026-09-04","days":24},{"id":"radiopharma-roadmap","kind":"roadmap","name":"Radiopharmaceutical roadmap: iodine → lutetium → actinium","route":"/roadmaps/radiopharma-roadmap/","asOf":"2026-09-04","days":24},{"id":"cell-therapy-roadmap","kind":"roadmap","name":"Cell therapy roadmap: CD19 CAR-T → solid tumours → in vivo CAR","route":"/roadmaps/cell-therapy-roadmap/","asOf":"2026-09-04","days":24},{"id":"molecular-imaging-roadmap","kind":"roadmap","name":"Molecular imaging roadmap: FDG → PSMA → FAP → antigen and immune PET","route":"/roadmaps/molecular-imaging-roadmap/","asOf":"2026-09-04","days":24},{"id":"early-detection-roadmap","kind":"roadmap","name":"Early detection roadmap: organ screening → blood tests for many cancers","route":"/roadmaps/early-detection-roadmap/","asOf":"2026-09-04","days":24},{"id":"immunotherapy-roadmap","kind":"roadmap","name":"Immunotherapy roadmap: Coley's toxins → checkpoint inhibitors → engineered immunity","route":"/roadmaps/immunotherapy-roadmap/","asOf":"2026-09-04","days":24},{"id":"kras-roadmap","kind":"roadmap","name":"KRAS roadmap: undruggable → G12C → pan-RAS","route":"/roadmaps/kras-roadmap/","asOf":"2026-09-04","days":24},{"id":"idea-trop2-pet-selection","kind":"idea","name":"TROP2 PET to choose and sequence TROP2 ADCs","route":"/ideas/idea-trop2-pet-selection/","asOf":"2026-09-04","days":24},{"id":"idea-payload-switching","kind":"idea","name":"Payload-class switching as the rule for ADC sequencing","route":"/ideas/idea-payload-switching/","asOf":"2026-09-04","days":24},{"id":"idea-post-neoadjuvant-adc","kind":"idea","name":"ADC for residual disease after KEYNOTE-522","route":"/ideas/idea-post-neoadjuvant-adc/","asOf":"2026-09-04","days":24},{"id":"idea-ctdna-escalation-tnbc","kind":"idea","name":"ctDNA-triggered escalation in early TNBC","route":"/ideas/idea-ctdna-escalation-tnbc/","asOf":"2026-09-04","days":24},{"id":"idea-efflux-agnostic","kind":"idea","name":"Efflux-agnostic therapy for mesenchymal TNBC","route":"/ideas/idea-efflux-agnostic/","asOf":"2026-09-04","days":24},{"id":"idea-fap-theranostics-pancancer","kind":"idea","name":"FAP theranostics as a pan-cancer stromal strategy","route":"/ideas/idea-fap-theranostics-pancancer/","asOf":"2026-09-04","days":24},{"id":"idea-in-vivo-car-solid","kind":"idea","name":"In vivo CAR-T against solid-tumour antigens","route":"/ideas/idea-in-vivo-car-solid/","asOf":"2026-09-04","days":24},{"id":"idea-neoadjuvant-adc-io","kind":"idea","name":"Neoadjuvant ADC + IO replacing anthracycline chemotherapy in TNBC","route":"/ideas/idea-neoadjuvant-adc-io/","asOf":"2026-09-04","days":24},{"id":"idea-til-guided-deescalation","kind":"idea","name":"TIL-based omission of chemotherapy in stage I TNBC","route":"/ideas/idea-til-guided-deescalation/","asOf":"2026-09-04","days":24},{"id":"idea-ai-her2-low-scoring","kind":"idea","name":"AI quantification of HER2-low and HER2-ultralow","route":"/ideas/idea-ai-her2-low-scoring/","asOf":"2026-09-04","days":24},{"id":"idea-alpha-after-adc","kind":"idea","name":"Alpha radioligands after ADC failure","route":"/ideas/idea-alpha-after-adc/","asOf":"2026-09-04","days":24},{"id":"idea-shared-kras-vaccine-adjuvant","kind":"idea","name":"Off-the-shelf KRAS vaccines after pancreatic cancer surgery","route":"/ideas/idea-shared-kras-vaccine-adjuvant/","asOf":"2026-09-04","days":24},{"id":"idea-mced-plus-fapi","kind":"idea","name":"FAPI PET as the workup for MCED positives","route":"/ideas/idea-mced-plus-fapi/","asOf":"2026-09-04","days":24},{"id":"idea-total-body-pet-dosimetry","kind":"idea","name":"Total-body PET for personalised radioligand dosing","route":"/ideas/idea-total-body-pet-dosimetry/","asOf":"2026-09-04","days":24},{"id":"idea-organoid-guided-adc","kind":"idea","name":"Patient-derived organoids to pick ADC payloads","route":"/ideas/idea-organoid-guided-adc/","asOf":"2026-09-04","days":24},{"id":"idea-dual-payload-first","kind":"idea","name":"Dual-payload ADCs in first line to prevent resistance","route":"/ideas/idea-dual-payload-first/","asOf":"2026-09-04","days":24},{"id":"idea-cd8-pet-io","kind":"idea","name":"CD8 PET to stop or switch immunotherapy early","route":"/ideas/idea-cd8-pet-io/","asOf":"2026-09-04","days":24},{"id":"idea-exercise-as-adjuvant","kind":"idea","name":"Structured exercise prescribed like a drug in all curative-intent cancer care","route":"/ideas/idea-exercise-as-adjuvant/","asOf":"2026-09-04","days":24},{"id":"idea-multimodal-foundation-model","kind":"idea","name":"Patient-level multimodal foundation models for treatment selection","route":"/ideas/idea-multimodal-foundation-model/","asOf":"2026-09-04","days":24},{"id":"idea-interception-vaccines","kind":"idea","name":"Cancer interception vaccines for high-risk carriers","route":"/ideas/idea-interception-vaccines/","asOf":"2026-09-04","days":24},{"id":"intogen","kind":"collection","name":"IntOGen","route":"/collections/intogen/","asOf":"2026-09-04","days":24},{"id":"clinicaltrials-gov","kind":"collection","name":"ClinicalTrials.gov","route":"/collections/clinicaltrials-gov/","asOf":"2026-09-04","days":24},{"id":"oncokb","kind":"collection","name":"OncoKB","route":"/collections/oncokb/","asOf":"2026-09-04","days":24},{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/","asOf":"2026-09-04","days":24},{"id":"cbioportal","kind":"collection","name":"cBioPortal for Cancer Genomics","route":"/collections/cbioportal/","asOf":"2026-09-04","days":24},{"id":"tcga-gdc","kind":"collection","name":"TCGA / NCI Genomic Data Commons","route":"/collections/tcga-gdc/","asOf":"2026-09-04","days":24},{"id":"depmap","kind":"collection","name":"DepMap (Cancer Dependency Map)","route":"/collections/depmap/","asOf":"2026-09-04","days":24},{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/","asOf":"2026-09-04","days":24},{"id":"cosmic","kind":"collection","name":"COSMIC (Catalogue of Somatic Mutations in Cancer)","route":"/collections/cosmic/","asOf":"2026-09-04","days":24},{"id":"clinvar","kind":"collection","name":"ClinVar","route":"/collections/clinvar/","asOf":"2026-09-04","days":24},{"id":"drugbank-chembl","kind":"collection","name":"DrugBank & ChEMBL","route":"/collections/drugbank-chembl/","asOf":"2026-09-04","days":24},{"id":"ttd","kind":"collection","name":"Therapeutic Target Database (TTD)","route":"/collections/ttd/","asOf":"2026-09-04","days":24},{"id":"adcdb","kind":"collection","name":"ADCdb / ADC Review","route":"/collections/adcdb/","asOf":"2026-09-04","days":24},{"id":"nccn","kind":"collection","name":"NCCN Guidelines","route":"/collections/nccn/","asOf":"2026-09-04","days":24},{"id":"esmo-guidelines","kind":"collection","name":"ESMO Clinical Practice Guidelines & MCBS","route":"/collections/esmo-guidelines/","asOf":"2026-09-04","days":24},{"id":"fda-approvals","kind":"collection","name":"FDA Oncology Approvals (OCE) & Novel Drug Approvals","route":"/collections/fda-approvals/","asOf":"2026-09-04","days":24},{"id":"seer","kind":"collection","name":"SEER (Surveillance, Epidemiology, and End Results)","route":"/collections/seer/","asOf":"2026-09-04","days":24},{"id":"globocan","kind":"collection","name":"GLOBOCAN / Global Cancer Observatory","route":"/collections/globocan/","asOf":"2026-09-04","days":24},{"id":"cancer-gov-pdq","kind":"collection","name":"NCI PDQ Cancer Information Summaries","route":"/collections/cancer-gov-pdq/","asOf":"2026-09-04","days":24},{"id":"awesome-cancer-variant-resources","kind":"collection","name":"awesome-cancer-variant-resources","route":"/collections/awesome-cancer-variant-resources/","asOf":"2026-09-04","days":24},{"id":"genie","kind":"collection","name":"AACR Project GENIE","route":"/collections/genie/","asOf":"2026-09-04","days":24},{"id":"hpa","kind":"collection","name":"Human Protein Atlas","route":"/collections/hpa/","asOf":"2026-09-04","days":24},{"id":"cptac","kind":"collection","name":"CPTAC (Clinical Proteomic Tumor Analysis Consortium)","route":"/collections/cptac/","asOf":"2026-09-04","days":24},{"id":"cellxgene-hca","kind":"collection","name":"CZ CELLxGENE / Human Cell Atlas","route":"/collections/cellxgene-hca/","asOf":"2026-09-04","days":24},{"id":"cancer-models","kind":"collection","name":"Cancer Models (PDCM Finder) & HCMI","route":"/collections/cancer-models/","asOf":"2026-09-04","days":24},{"id":"pubmed-europepmc","kind":"collection","name":"PubMed & Europe PMC","route":"/collections/pubmed-europepmc/","asOf":"2026-09-04","days":24},{"id":"eudract-ctis","kind":"collection","name":"EU Clinical Trials Register / CTIS","route":"/collections/eudract-ctis/","asOf":"2026-09-04","days":24},{"id":"newsweek-hospitals","kind":"collection","name":"Newsweek/Statista World's Best Specialized Hospitals: Oncology","route":"/collections/newsweek-hospitals/","asOf":"2026-09-04","days":24},{"id":"nature-index","kind":"collection","name":"Nature Index: Healthcare and Cancer institutions","route":"/collections/nature-index/","asOf":"2026-09-04","days":24},{"id":"scimago-oncology","kind":"collection","name":"SCImago Institutions Rankings: Oncology","route":"/collections/scimago-oncology/","asOf":"2026-09-04","days":24},{"id":"nci-cancer-centers","kind":"collection","name":"NCI-Designated Cancer Centers","route":"/collections/nci-cancer-centers/","asOf":"2026-09-04","days":24},{"id":"curie-nki-eortc","kind":"company","name":"EORTC","route":"/companies/curie-nki-eortc/","asOf":"2026-09-04","days":24},{"id":"nlst-nelson","kind":"trial","name":"NLST & NELSON (low-dose CT screening)","route":"/trials/nlst-nelson/","asOf":"2026-09-06","days":22},{"id":"crown","kind":"trial","name":"CROWN","route":"/trials/crown/","asOf":"2026-09-06","days":22},{"id":"alina","kind":"trial","name":"ALINA","route":"/trials/alina/","asOf":"2026-09-06","days":22},{"id":"pacific","kind":"trial","name":"PACIFIC","route":"/trials/pacific/","asOf":"2026-09-06","days":22},{"id":"laura","kind":"trial","name":"LAURA","route":"/trials/laura/","asOf":"2026-09-06","days":22},{"id":"checkmate-816","kind":"trial","name":"CheckMate 816","route":"/trials/checkmate-816/","asOf":"2026-09-06","days":22},{"id":"keynote-671","kind":"trial","name":"KEYNOTE-671","route":"/trials/keynote-671/","asOf":"2026-09-06","days":22},{"id":"keynote-024-189","kind":"trial","name":"KEYNOTE-024 & KEYNOTE-189","route":"/trials/keynote-024-189/","asOf":"2026-09-06","days":22},{"id":"harmoni-2","kind":"trial","name":"HARMONi-2","route":"/trials/harmoni-2/","asOf":"2026-09-06","days":22},{"id":"harmoni-3","kind":"trial","name":"HARMONi-3","route":"/trials/harmoni-3/","asOf":"2026-09-06","days":22},{"id":"herthena-lung02","kind":"trial","name":"HERTHENA-Lung02","route":"/trials/herthena-lung02/","asOf":"2026-09-06","days":22},{"id":"tropion-lung05","kind":"trial","name":"TROPION-Lung05","route":"/trials/tropion-lung05/","asOf":"2026-09-06","days":22},{"id":"krystal-12","kind":"trial","name":"KRYSTAL-12","route":"/trials/krystal-12/","asOf":"2026-09-06","days":22},{"id":"codebreak-200","kind":"trial","name":"CodeBreaK 200","route":"/trials/codebreak-200/","asOf":"2026-09-06","days":22},{"id":"krascendo-1","kind":"trial","name":"Krascendo 1","route":"/trials/krascendo-1/","asOf":"2026-09-06","days":22},{"id":"libretto-431","kind":"trial","name":"LIBRETTO-431","route":"/trials/libretto-431/","asOf":"2026-09-06","days":22},{"id":"telimet-nsclc-01","kind":"trial","name":"TeliMET NSCLC-01","route":"/trials/telimet-nsclc-01/","asOf":"2026-09-06","days":22},{"id":"alkove-1","kind":"trial","name":"ALKOVE-1","route":"/trials/alkove-1/","asOf":"2026-09-06","days":22},{"id":"soho-01","kind":"trial","name":"SOHO-01","route":"/trials/soho-01/","asOf":"2026-09-06","days":22},{"id":"alectinib","kind":"drug","name":"Alectinib","route":"/drugs/alectinib/","asOf":"2026-09-06","days":22},{"id":"lazertinib","kind":"drug","name":"Lazertinib","route":"/drugs/lazertinib/","asOf":"2026-09-06","days":22},{"id":"repotrectinib","kind":"drug","name":"Repotrectinib","route":"/drugs/repotrectinib/","asOf":"2026-09-06","days":22},{"id":"capmatinib-tepotinib","kind":"drug","name":"Capmatinib & tepotinib","route":"/drugs/capmatinib-tepotinib/","asOf":"2026-09-06","days":22},{"id":"pralsetinib","kind":"drug","name":"Pralsetinib","route":"/drugs/pralsetinib/","asOf":"2026-09-06","days":22},{"id":"dabrafenib-trametinib","kind":"drug","name":"Dabrafenib + trametinib","route":"/drugs/dabrafenib-trametinib/","asOf":"2026-09-06","days":22},{"id":"sevabertinib","kind":"drug","name":"Sevabertinib","route":"/drugs/sevabertinib/","asOf":"2026-09-06","days":22},{"id":"divarasib","kind":"drug","name":"Divarasib","route":"/drugs/divarasib/","asOf":"2026-09-06","days":22},{"id":"olomorasib","kind":"drug","name":"Olomorasib","route":"/drugs/olomorasib/","asOf":"2026-09-06","days":22},{"id":"neladalkib","kind":"drug","name":"Neladalkib","route":"/drugs/neladalkib/","asOf":"2026-09-06","days":22},{"id":"tremelimumab","kind":"drug","name":"Tremelimumab","route":"/drugs/tremelimumab/","asOf":"2026-09-06","days":22},{"id":"ros1","kind":"target","name":"ROS1","route":"/targets/ros1/","asOf":"2026-09-06","days":22},{"id":"low-dose-ct-screening","kind":"technology","name":"Low-dose CT lung screening","route":"/technologies/low-dose-ct-screening/","asOf":"2026-09-06","days":22},{"id":"robotic-bronchoscopy","kind":"technology","name":"Robotic and navigational bronchoscopy","route":"/technologies/robotic-bronchoscopy/","asOf":"2026-09-06","days":22},{"id":"tps","kind":"term","name":"Tumour proportion score (TPS)","route":"/terms/tps/","asOf":"2026-09-06","days":22},{"id":"egfr-exon19-l858r","kind":"term","name":"EGFR exon 19 deletion & L858R","route":"/terms/egfr-exon19-l858r/","asOf":"2026-09-06","days":22},{"id":"egfr-exon20-insertion","kind":"term","name":"EGFR exon 20 insertion","route":"/terms/egfr-exon20-insertion/","asOf":"2026-09-06","days":22},{"id":"c797s","kind":"term","name":"EGFR C797S","route":"/terms/c797s/","asOf":"2026-09-06","days":22},{"id":"met-amplification","kind":"term","name":"MET amplification (bypass resistance)","route":"/terms/met-amplification/","asOf":"2026-09-06","days":22},{"id":"histologic-transformation","kind":"term","name":"Histologic transformation","route":"/terms/histologic-transformation/","asOf":"2026-09-06","days":22},{"id":"oligoprogression","kind":"term","name":"Oligoprogression","route":"/terms/oligoprogression/","asOf":"2026-09-06","days":22},{"id":"amivantamab-plus-lazertinib","kind":"pairing","name":"Amivantamab + lazertinib (first-line EGFR NSCLC)","route":"/pairings/amivantamab-plus-lazertinib/","asOf":"2026-09-06","days":22},{"id":"pd1-plus-chemo-pdl1-low","kind":"pairing","name":"PD-1 blockade + chemotherapy in PD-L1-low NSCLC","route":"/pairings/pd1-plus-chemo-pdl1-low/","asOf":"2026-09-06","days":22},{"id":"targeted-before-io-nsclc","kind":"pairing","name":"Sequence: targeted therapy before immunotherapy in driver-positive NSCLC","route":"/pairings/targeted-before-io-nsclc/","asOf":"2026-09-06","days":22},{"id":"curium","kind":"company","name":"Curium","route":"/companies/curium/","asOf":"2026-09-06","days":22},{"id":"sumitomo-pharma","kind":"company","name":"Sumitomo Pharma (Myovant)","route":"/companies/sumitomo-pharma/","asOf":"2026-09-06","days":22},{"id":"veracyte","kind":"company","name":"Veracyte (Decipher)","route":"/companies/veracyte/","asOf":"2026-09-06","days":22},{"id":"blue-earth-diagnostics","kind":"company","name":"Blue Earth Diagnostics (Bracco)","route":"/companies/blue-earth-diagnostics/","asOf":"2026-09-06","days":22},{"id":"essa-pharma","kind":"company","name":"ESSA Pharma","route":"/companies/essa-pharma/","asOf":"2026-09-06","days":22},{"id":"steap1","kind":"target","name":"STEAP1","route":"/targets/steap1/","asOf":"2026-09-06","days":22},{"id":"klk2","kind":"target","name":"KLK2 (kallikrein-2)","route":"/targets/klk2/","asOf":"2026-09-06","days":22},{"id":"grpr","kind":"target","name":"GRPR (gastrin-releasing peptide receptor)","route":"/targets/grpr/","asOf":"2026-09-06","days":22},{"id":"active-surveillance","kind":"technology","name":"Active surveillance","route":"/technologies/active-surveillance/","asOf":"2026-09-06","days":22},{"id":"mp-mri","kind":"technology","name":"Multiparametric prostate MRI (PI-RADS)","route":"/technologies/mp-mri/","asOf":"2026-09-06","days":22},{"id":"psa","kind":"term","name":"PSA (prostate-specific antigen)","route":"/terms/psa/","asOf":"2026-09-06","days":22},{"id":"gleason-grade-group","kind":"term","name":"Gleason score / Grade Group","route":"/terms/gleason-grade-group/","asOf":"2026-09-06","days":22},{"id":"castration-resistance","kind":"term","name":"Castration-resistant prostate cancer (CRPC)","route":"/terms/castration-resistance/","asOf":"2026-09-06","days":22},{"id":"biochemical-recurrence","kind":"term","name":"Biochemical recurrence (BCR)","route":"/terms/biochemical-recurrence/","asOf":"2026-09-06","days":22},{"id":"psa50","kind":"term","name":"PSA50 / PSA90 response","route":"/terms/psa50/","asOf":"2026-09-06","days":22},{"id":"ar-v7","kind":"term","name":"AR-V7 splice variant","route":"/terms/ar-v7/","asOf":"2026-09-06","days":22},{"id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/","asOf":"2026-09-06","days":22},{"id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/","asOf":"2026-09-06","days":22},{"id":"apalutamide","kind":"drug","name":"Apalutamide","route":"/drugs/apalutamide/","asOf":"2026-09-06","days":22},{"id":"darolutamide","kind":"drug","name":"Darolutamide","route":"/drugs/darolutamide/","asOf":"2026-09-06","days":22},{"id":"relugolix","kind":"drug","name":"Relugolix","route":"/drugs/relugolix/","asOf":"2026-09-06","days":22},{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/","asOf":"2026-09-06","days":22},{"id":"cabazitaxel","kind":"drug","name":"Cabazitaxel","route":"/drugs/cabazitaxel/","asOf":"2026-09-06","days":22},{"id":"radium-223","kind":"drug","name":"Radium-223 dichloride","route":"/drugs/radium-223/","asOf":"2026-09-06","days":22},{"id":"lu177-psma-it","kind":"drug","name":"177Lu-PSMA-I&T","route":"/drugs/lu177-psma-it/","asOf":"2026-09-06","days":22},{"id":"xaluritamig","kind":"drug","name":"Xaluritamig","route":"/drugs/xaluritamig/","asOf":"2026-09-06","days":22},{"id":"pasritamig","kind":"drug","name":"Pasritamig","route":"/drugs/pasritamig/","asOf":"2026-09-06","days":22},{"id":"ga68-psma-11","kind":"drug","name":"Gallium-68 gozetotide (PSMA-11)","route":"/drugs/ga68-psma-11/","asOf":"2026-09-06","days":22},{"id":"flotufolastat","kind":"drug","name":"Flotufolastat F-18","route":"/drugs/flotufolastat/","asOf":"2026-09-06","days":22},{"id":"mevrometostat","kind":"drug","name":"Mevrometostat","route":"/drugs/mevrometostat/","asOf":"2026-09-06","days":22},{"id":"masofaniten","kind":"drug","name":"Masofaniten","route":"/drugs/masofaniten/","asOf":"2026-09-06","days":22},{"id":"decipher-prostate","kind":"drug","name":"Decipher Prostate","route":"/drugs/decipher-prostate/","asOf":"2026-09-06","days":22},{"id":"protect","kind":"trial","name":"ProtecT","route":"/trials/protect/","asOf":"2026-09-06","days":22},{"id":"precision-mri","kind":"trial","name":"PRECISION","route":"/trials/precision-mri/","asOf":"2026-09-06","days":22},{"id":"stampede","kind":"trial","name":"STAMPEDE","route":"/trials/stampede/","asOf":"2026-09-06","days":22},{"id":"chaarted","kind":"trial","name":"CHAARTED (E3805)","route":"/trials/chaarted/","asOf":"2026-09-06","days":22},{"id":"latitude","kind":"trial","name":"LATITUDE","route":"/trials/latitude/","asOf":"2026-09-06","days":22},{"id":"arches","kind":"trial","name":"ARCHES","route":"/trials/arches/","asOf":"2026-09-06","days":22},{"id":"arasens","kind":"trial","name":"ARASENS","route":"/trials/arasens/","asOf":"2026-09-06","days":22},{"id":"peace-1","kind":"trial","name":"PEACE-1","route":"/trials/peace-1/","asOf":"2026-09-06","days":22},{"id":"embark","kind":"trial","name":"EMBARK","route":"/trials/embark/","asOf":"2026-09-06","days":22},{"id":"profound","kind":"trial","name":"PROfound","route":"/trials/profound/","asOf":"2026-09-06","days":22},{"id":"propel","kind":"trial","name":"PROpel","route":"/trials/propel/","asOf":"2026-09-06","days":22},{"id":"talapro-2","kind":"trial","name":"TALAPRO-2","route":"/trials/talapro-2/","asOf":"2026-09-06","days":22},{"id":"magnitude","kind":"trial","name":"MAGNITUDE","route":"/trials/magnitude/","asOf":"2026-09-06","days":22},{"id":"capitello-281","kind":"trial","name":"CAPItello-281","route":"/trials/capitello-281/","asOf":"2026-09-06","days":22},{"id":"alsympca","kind":"trial","name":"ALSYMPCA","route":"/trials/alsympca/","asOf":"2026-09-06","days":22},{"id":"propsma","kind":"trial","name":"proPSMA","route":"/trials/propsma/","asOf":"2026-09-06","days":22},{"id":"therap","kind":"trial","name":"TheraP (ANZUP 1603)","route":"/trials/therap/","asOf":"2026-09-06","days":22},{"id":"psmaddition","kind":"trial","name":"PSMAddition","route":"/trials/psmaddition/","asOf":"2026-09-06","days":22},{"id":"splash","kind":"trial","name":"SPLASH","route":"/trials/splash/","asOf":"2026-09-06","days":22},{"id":"eclipse-psma","kind":"trial","name":"ECLIPSE","route":"/trials/eclipse-psma/","asOf":"2026-09-06","days":22},{"id":"alphabreak","kind":"trial","name":"AlphaBreak (FPI-2265) & AcTION (225Ac-PSMA-617)","route":"/trials/alphabreak/","asOf":"2026-09-06","days":22},{"id":"xalute","kind":"trial","name":"XALute","route":"/trials/xalute/","asOf":"2026-09-06","days":22},{"id":"mevpro-1","kind":"trial","name":"MEVPRO-1","route":"/trials/mevpro-1/","asOf":"2026-09-06","days":22},{"id":"idea-psma-pet-guided-mdt","kind":"idea","name":"PSMA-PET-guided metastasis-directed therapy as a curative strategy in oligorecurrent prostate cancer","route":"/ideas/idea-psma-pet-guided-mdt/","asOf":"2026-09-06","days":22},{"id":"idea-alpha-first-mhspc","kind":"idea","name":"Alpha-emitting PSMA therapy at first metastatic diagnosis","route":"/ideas/idea-alpha-first-mhspc/","asOf":"2026-09-06","days":22},{"id":"folfirinox","kind":"drug","name":"FOLFIRINOX / mFOLFIRINOX","route":"/drugs/folfirinox/","asOf":"2026-09-06","days":22},{"id":"nalirifox","kind":"drug","name":"NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV)","route":"/drugs/nalirifox/","asOf":"2026-09-06","days":22},{"id":"gemcitabine-nab-paclitaxel","kind":"drug","name":"Gemcitabine + nab-paclitaxel","route":"/drugs/gemcitabine-nab-paclitaxel/","asOf":"2026-09-06","days":22},{"id":"zoldonrasib","kind":"drug","name":"Zoldonrasib","route":"/drugs/zoldonrasib/","asOf":"2026-09-06","days":22},{"id":"elironrasib","kind":"drug","name":"Elironrasib","route":"/drugs/elironrasib/","asOf":"2026-09-06","days":22},{"id":"mrtx1133","kind":"drug","name":"MRTX1133","route":"/drugs/mrtx1133/","asOf":"2026-09-06","days":22},{"id":"eli-002-7p","kind":"drug","name":"ELI-002 7P","route":"/drugs/eli-002-7p/","asOf":"2026-09-06","days":22},{"id":"rasolute-302","kind":"trial","name":"RASolute 302","route":"/trials/rasolute-302/","asOf":"2026-09-06","days":22},{"id":"napoli-3","kind":"trial","name":"NAPOLI 3","route":"/trials/napoli-3/","asOf":"2026-09-06","days":22},{"id":"prodige-24","kind":"trial","name":"PRODIGE 24 / CCTG PA6","route":"/trials/prodige-24/","asOf":"2026-09-06","days":22},{"id":"preopanc","kind":"trial","name":"PREOPANC-1","route":"/trials/preopanc/","asOf":"2026-09-06","days":22},{"id":"polo","kind":"trial","name":"POLO","route":"/trials/polo/","asOf":"2026-09-06","days":22},{"id":"panova-3","kind":"trial","name":"PANOVA-3","route":"/trials/panova-3/","asOf":"2026-09-06","days":22},{"id":"amplify-7p","kind":"trial","name":"AMPLIFY-7P","route":"/trials/amplify-7p/","asOf":"2026-09-06","days":22},{"id":"pancreatic-surveillance","kind":"technology","name":"High-risk pancreatic surveillance (CAPS / PRECEDE)","route":"/technologies/pancreatic-surveillance/","asOf":"2026-09-06","days":22},{"id":"pdac-organoid-pharmacotyping","kind":"technology","name":"PDAC organoid pharmacotyping","route":"/technologies/pdac-organoid-pharmacotyping/","asOf":"2026-09-06","days":22},{"id":"ca19-9","kind":"term","name":"CA 19-9","route":"/terms/ca19-9/","asOf":"2026-09-06","days":22},{"id":"desmoplasia","kind":"term","name":"Desmoplasia (tumour stroma)","route":"/terms/desmoplasia/","asOf":"2026-09-06","days":22},{"id":"ipsen","kind":"company","name":"Ipsen","route":"/companies/ipsen/","asOf":"2026-09-06","days":22},{"id":"elicio-therapeutics","kind":"company","name":"Elicio Therapeutics","route":"/companies/elicio-therapeutics/","asOf":"2026-09-06","days":22},{"id":"idea-ras-inhibitor-neoadjuvant-pdac","kind":"idea","name":"RAS(ON) inhibitors to convert unresectable pancreatic cancer to resectable","route":"/ideas/idea-ras-inhibitor-neoadjuvant-pdac/","asOf":"2026-09-06","days":22},{"id":"idea-mced-new-onset-diabetes","kind":"idea","name":"Blood-based pancreatic cancer detection in new-onset diabetes","route":"/ideas/idea-mced-new-onset-diabetes/","asOf":"2026-09-06","days":22},{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/","asOf":"2026-09-06","days":22},{"id":"lomustine","kind":"drug","name":"Lomustine (CCNU)","route":"/drugs/lomustine/","asOf":"2026-09-06","days":22},{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/","asOf":"2026-09-06","days":22},{"id":"dordaviprone","kind":"drug","name":"Dordaviprone","route":"/drugs/dordaviprone/","asOf":"2026-09-06","days":22},{"id":"tovorafenib","kind":"drug","name":"Tovorafenib","route":"/drugs/tovorafenib/","asOf":"2026-09-06","days":22},{"id":"dcvax-l","kind":"drug","name":"DCVax-L","route":"/drugs/dcvax-l/","asOf":"2026-09-06","days":22},{"id":"rindopepimut","kind":"drug","name":"Rindopepimut","route":"/drugs/rindopepimut/","asOf":"2026-09-06","days":22},{"id":"eortc-26981","kind":"trial","name":"EORTC 26981 / NCIC CE.3 (Stupp trial)","route":"/trials/eortc-26981/","asOf":"2026-09-06","days":22},{"id":"ef-14","kind":"trial","name":"EF-14","route":"/trials/ef-14/","asOf":"2026-09-06","days":22},{"id":"indigo","kind":"trial","name":"INDIGO","route":"/trials/indigo/","asOf":"2026-09-06","days":22},{"id":"act-iv","kind":"trial","name":"ACT IV","route":"/trials/act-iv/","asOf":"2026-09-06","days":22},{"id":"litt","kind":"technology","name":"Laser interstitial thermal therapy (LITT)","route":"/technologies/litt/","asOf":"2026-09-06","days":22},{"id":"bbb-focused-ultrasound","kind":"technology","name":"Focused-ultrasound blood-brain barrier opening","route":"/technologies/bbb-focused-ultrasound/","asOf":"2026-09-06","days":22},{"id":"glioma-car-t","kind":"technology","name":"CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target)","route":"/technologies/glioma-car-t/","asOf":"2026-09-06","days":22},{"id":"mgmt","kind":"term","name":"MGMT promoter methylation","route":"/terms/mgmt/","asOf":"2026-09-06","days":22},{"id":"h3k27m","kind":"term","name":"H3 K27M (diffuse midline glioma)","route":"/terms/h3k27m/","asOf":"2026-09-06","days":22},{"id":"egfrviii","kind":"term","name":"EGFRvIII","route":"/terms/egfrviii/","asOf":"2026-09-06","days":22},{"id":"blood-brain-barrier","kind":"term","name":"Blood-brain barrier (BBB)","route":"/terms/blood-brain-barrier/","asOf":"2026-09-06","days":22},{"id":"day-one-biopharmaceuticals","kind":"company","name":"Day One Biopharmaceuticals","route":"/companies/day-one-biopharmaceuticals/","asOf":"2026-09-06","days":22},{"id":"northwest-biotherapeutics","kind":"company","name":"Northwest Biotherapeutics","route":"/companies/northwest-biotherapeutics/","asOf":"2026-09-06","days":22},{"id":"idea-neoadjuvant-io-glioblastoma","kind":"idea","name":"Neoadjuvant immunotherapy with surgical window for glioblastoma","route":"/ideas/idea-neoadjuvant-io-glioblastoma/","asOf":"2026-09-06","days":22},{"id":"idea-fus-plus-adc-glioma","kind":"idea","name":"Focused-ultrasound BBB opening to deliver ADCs and radioligands to glioma","route":"/ideas/idea-fus-plus-adc-glioma/","asOf":"2026-09-06","days":22},{"id":"tiragolumab","kind":"drug","name":"Tiragolumab","route":"/drugs/tiragolumab/","asOf":"2026-09-06","days":22},{"id":"magrolimab","kind":"drug","name":"Magrolimab","route":"/drugs/magrolimab/","asOf":"2026-09-06","days":22},{"id":"rovalpituzumab-tesirine","kind":"drug","name":"Rovalpituzumab tesirine","route":"/drugs/rovalpituzumab-tesirine/","asOf":"2026-09-06","days":22},{"id":"iniparib","kind":"drug","name":"Iniparib","route":"/drugs/iniparib/","asOf":"2026-09-06","days":22},{"id":"bempegaldesleukin","kind":"drug","name":"Bempegaldesleukin","route":"/drugs/bempegaldesleukin/","asOf":"2026-09-06","days":22},{"id":"adu-s100","kind":"drug","name":"ADU-S100 (MIW815)","route":"/drugs/adu-s100/","asOf":"2026-09-06","days":22},{"id":"eprenetapopt","kind":"drug","name":"Eprenetapopt","route":"/drugs/eprenetapopt/","asOf":"2026-09-06","days":22},{"id":"tusamitamab-ravtansine","kind":"drug","name":"Tusamitamab ravtansine","route":"/drugs/tusamitamab-ravtansine/","asOf":"2026-09-06","days":22},{"id":"impassion131","kind":"trial","name":"IMpassion131","route":"/trials/impassion131/","asOf":"2026-09-06","days":22},{"id":"epacadostat","kind":"drug","name":"Epacadostat","route":"/drugs/epacadostat/","asOf":"2026-09-06","days":22},{"id":"trastuzumab-duocarmazine","kind":"drug","name":"Trastuzumab duocarmazine","route":"/drugs/trastuzumab-duocarmazine/","asOf":"2026-09-06","days":22},{"id":"melflufen","kind":"drug","name":"Melphalan flufenamide","route":"/drugs/melflufen/","asOf":"2026-09-06","days":22},{"id":"tropion-breast03","kind":"trial","name":"TROPION-Breast03","route":"/trials/tropion-breast03/","asOf":"2026-09-06","days":22},{"id":"nccn-org","kind":"institution","name":"National Comprehensive Cancer Network (NCCN)","route":"/institutions/nccn-org/","asOf":"2026-09-06","days":22},{"id":"programmable-dna-targeting-therapeutics","kind":"technology","name":"Programmable DNA-targeting therapeutics","route":"/technologies/programmable-dna-targeting-therapeutics/","asOf":"2026-09-06","days":22},{"id":"fragmentomics","kind":"technology","name":"cfDNA fragmentomics","route":"/technologies/fragmentomics/","asOf":"2026-09-06","days":22},{"id":"adc-payload-neutralizer","kind":"technology","name":"ADC payload neutralisers","route":"/technologies/adc-payload-neutralizer/","asOf":"2026-09-06","days":22},{"id":"swog","kind":"company","name":"SWOG Cancer Research Network","route":"/companies/swog/","asOf":"2026-09-06","days":22},{"id":"nrg-oncology","kind":"company","name":"NRG Oncology","route":"/companies/nrg-oncology/","asOf":"2026-09-06","days":22},{"id":"alliance-oncology","kind":"company","name":"Alliance for Clinical Trials in Oncology","route":"/companies/alliance-oncology/","asOf":"2026-09-06","days":22},{"id":"ecog-acrin","kind":"company","name":"ECOG-ACRIN Cancer Research Group","route":"/companies/ecog-acrin/","asOf":"2026-09-06","days":22},{"id":"childrens-oncology-group","kind":"company","name":"Children's Oncology Group (COG)","route":"/companies/childrens-oncology-group/","asOf":"2026-09-06","days":22},{"id":"cctg","kind":"company","name":"Canadian Cancer Trials Group (CCTG)","route":"/companies/cctg/","asOf":"2026-09-06","days":22},{"id":"big","kind":"company","name":"Breast International Group (BIG)","route":"/companies/big/","asOf":"2026-09-06","days":22},{"id":"gbg","kind":"company","name":"German Breast Group (GBG)","route":"/companies/gbg/","asOf":"2026-09-06","days":22},{"id":"jcog","kind":"company","name":"Japan Clinical Oncology Group (JCOG)","route":"/companies/jcog/","asOf":"2026-09-06","days":22},{"id":"unicancer","kind":"company","name":"UNICANCER","route":"/companies/unicancer/","asOf":"2026-09-06","days":22},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/","asOf":"2026-09-07","days":21},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/","asOf":"2026-09-07","days":21},{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/","asOf":"2026-09-07","days":21},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/","asOf":"2026-09-07","days":21},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/","asOf":"2026-09-07","days":21},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/","asOf":"2026-09-07","days":21},{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/","asOf":"2026-09-07","days":21},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/","asOf":"2026-09-07","days":21},{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/","asOf":"2026-09-07","days":21},{"id":"neuroblastoma","kind":"cancer","name":"Neuroblastoma (paediatric)","route":"/cancers/neuroblastoma/","asOf":"2026-09-07","days":21},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/","asOf":"2026-09-07","days":21},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/","asOf":"2026-09-07","days":21},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/","asOf":"2026-09-07","days":21},{"id":"monaleesa-2","kind":"trial","name":"MONALEESA-2","route":"/trials/monaleesa-2/","asOf":"2026-09-07","days":21},{"id":"monarch-3","kind":"trial","name":"MONARCH 3","route":"/trials/monarch-3/","asOf":"2026-09-07","days":21},{"id":"paloma-2","kind":"trial","name":"PALOMA-2","route":"/trials/paloma-2/","asOf":"2026-09-07","days":21},{"id":"solar-1","kind":"trial","name":"SOLAR-1","route":"/trials/solar-1/","asOf":"2026-09-07","days":21},{"id":"capitello-291","kind":"trial","name":"CAPItello-291","route":"/trials/capitello-291/","asOf":"2026-09-07","days":21},{"id":"inavo120","kind":"trial","name":"INAVO120","route":"/trials/inavo120/","asOf":"2026-09-07","days":21},{"id":"emerald","kind":"trial","name":"EMERALD","route":"/trials/emerald/","asOf":"2026-09-07","days":21},{"id":"ember-3","kind":"trial","name":"EMBER-3","route":"/trials/ember-3/","asOf":"2026-09-07","days":21},{"id":"serena-6","kind":"trial","name":"SERENA-6","route":"/trials/serena-6/","asOf":"2026-09-07","days":21},{"id":"evera","kind":"trial","name":"evERA","route":"/trials/evera/","asOf":"2026-09-07","days":21},{"id":"persevera","kind":"trial","name":"persevERA","route":"/trials/persevera/","asOf":"2026-09-07","days":21},{"id":"lidera","kind":"trial","name":"lidERA","route":"/trials/lidera/","asOf":"2026-09-07","days":21},{"id":"postmonarch","kind":"trial","name":"postMONARCH","route":"/trials/postmonarch/","asOf":"2026-09-07","days":21},{"id":"tailorx","kind":"trial","name":"TAILORx","route":"/trials/tailorx/","asOf":"2026-09-07","days":21},{"id":"rxponder","kind":"trial","name":"RxPONDER (SWOG S1007)","route":"/trials/rxponder/","asOf":"2026-09-07","days":21},{"id":"soft-text","kind":"trial","name":"SOFT & TEXT","route":"/trials/soft-text/","asOf":"2026-09-07","days":21},{"id":"pallas-penelope-b","kind":"trial","name":"PALLAS & PENELOPE-B","route":"/trials/pallas-penelope-b/","asOf":"2026-09-07","days":21},{"id":"tropics-02","kind":"trial","name":"TROPiCS-02","route":"/trials/tropics-02/","asOf":"2026-09-07","days":21},{"id":"fourlight-1","kind":"trial","name":"FOURLIGHT-1","route":"/trials/fourlight-1/","asOf":"2026-09-07","days":21},{"id":"cambria","kind":"trial","name":"CAMBRIA-1 & CAMBRIA-2","route":"/trials/cambria/","asOf":"2026-09-07","days":21},{"id":"letrozole","kind":"drug","name":"Letrozole (and other aromatase inhibitors)","route":"/drugs/letrozole/","asOf":"2026-09-07","days":21},{"id":"exemestane","kind":"drug","name":"Exemestane","route":"/drugs/exemestane/","asOf":"2026-09-07","days":21},{"id":"tamoxifen","kind":"drug","name":"Tamoxifen","route":"/drugs/tamoxifen/","asOf":"2026-09-07","days":21},{"id":"fulvestrant","kind":"drug","name":"Fulvestrant","route":"/drugs/fulvestrant/","asOf":"2026-09-07","days":21},{"id":"camizestrant","kind":"drug","name":"Camizestrant","route":"/drugs/camizestrant/","asOf":"2026-09-07","days":21},{"id":"imlunestrant","kind":"drug","name":"Imlunestrant","route":"/drugs/imlunestrant/","asOf":"2026-09-07","days":21},{"id":"giredestrant","kind":"drug","name":"Giredestrant","route":"/drugs/giredestrant/","asOf":"2026-09-07","days":21},{"id":"alpelisib","kind":"drug","name":"Alpelisib","route":"/drugs/alpelisib/","asOf":"2026-09-07","days":21},{"id":"everolimus","kind":"drug","name":"Everolimus","route":"/drugs/everolimus/","asOf":"2026-09-07","days":21},{"id":"atirmociclib","kind":"drug","name":"Atirmociclib","route":"/drugs/atirmociclib/","asOf":"2026-09-07","days":21},{"id":"goserelin","kind":"drug","name":"Goserelin / leuprolide (ovarian function suppression)","route":"/drugs/goserelin/","asOf":"2026-09-07","days":21},{"id":"mammaprint","kind":"drug","name":"MammaPrint (70-gene signature)","route":"/drugs/mammaprint/","asOf":"2026-09-07","days":21},{"id":"esr1-mutation","kind":"term","name":"ESR1 mutation","route":"/terms/esr1-mutation/","asOf":"2026-09-07","days":21},{"id":"oral-serd","kind":"term","name":"Oral SERD","route":"/terms/oral-serd/","asOf":"2026-09-07","days":21},{"id":"endocrine-resistance","kind":"term","name":"Endocrine resistance","route":"/terms/endocrine-resistance/","asOf":"2026-09-07","days":21},{"id":"ovarian-function-suppression","kind":"term","name":"Ovarian function suppression (OFS)","route":"/terms/ovarian-function-suppression/","asOf":"2026-09-07","days":21},{"id":"late-recurrence","kind":"term","name":"Late recurrence","route":"/terms/late-recurrence/","asOf":"2026-09-07","days":21},{"id":"oral-serd-plus-cdk46-after-esr1","kind":"pairing","name":"Oral SERD + CDK4/6 inhibitor after ESR1 emergence","route":"/pairings/oral-serd-plus-cdk46-after-esr1/","asOf":"2026-09-07","days":21},{"id":"pi3k-pathway-plus-endocrine","kind":"pairing","name":"PI3K/AKT-pathway inhibitor + endocrine therapy (± CDK4/6)","route":"/pairings/pi3k-pathway-plus-endocrine/","asOf":"2026-09-07","days":21},{"id":"genomic-assay-to-chemo-omission","kind":"pairing","name":"Gene-expression assay → chemotherapy omission","route":"/pairings/genomic-assay-to-chemo-omission/","asOf":"2026-09-07","days":21},{"id":"idea-ctdna-switch-generalised","kind":"idea","name":"Molecular-progression switching beyond ESR1","route":"/ideas/idea-ctdna-switch-generalised/","asOf":"2026-09-07","days":21},{"id":"idea-cdk4-selective-first-line","kind":"idea","name":"CDK4-selective inhibitors as the new first-line backbone","route":"/ideas/idea-cdk4-selective-first-line/","asOf":"2026-09-07","days":21},{"id":"idea-late-recurrence-interception","kind":"idea","name":"Intercepting late recurrence with ctDNA surveillance and oral SERDs","route":"/ideas/idea-late-recurrence-interception/","asOf":"2026-09-07","days":21},{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/","asOf":"2026-09-07","days":21},{"id":"puma-biotechnology","kind":"company","name":"Puma Biotechnology","route":"/companies/puma-biotechnology/","asOf":"2026-09-07","days":21},{"id":"macrogenics","kind":"company","name":"MacroGenics","route":"/companies/macrogenics/","asOf":"2026-09-07","days":21},{"id":"hera-b31-n9831","kind":"trial","name":"HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab)","route":"/trials/hera-b31-n9831/","asOf":"2026-09-07","days":21},{"id":"cleopatra","kind":"trial","name":"CLEOPATRA","route":"/trials/cleopatra/","asOf":"2026-09-07","days":21},{"id":"aphinity","kind":"trial","name":"APHINITY","route":"/trials/aphinity/","asOf":"2026-09-07","days":21},{"id":"katherine","kind":"trial","name":"KATHERINE","route":"/trials/katherine/","asOf":"2026-09-07","days":21},{"id":"destiny-breast05","kind":"trial","name":"DESTINY-Breast05","route":"/trials/destiny-breast05/","asOf":"2026-09-07","days":21},{"id":"her2climb","kind":"trial","name":"HER2CLIMB","route":"/trials/her2climb/","asOf":"2026-09-07","days":21},{"id":"her2climb-02","kind":"trial","name":"HER2CLIMB-02","route":"/trials/her2climb-02/","asOf":"2026-09-07","days":21},{"id":"her2climb-05","kind":"trial","name":"HER2CLIMB-05","route":"/trials/her2climb-05/","asOf":"2026-09-07","days":21},{"id":"destiny-breast12","kind":"trial","name":"DESTINY-Breast12","route":"/trials/destiny-breast12/","asOf":"2026-09-07","days":21},{"id":"phergain","kind":"trial","name":"PHERGain","route":"/trials/phergain/","asOf":"2026-09-07","days":21},{"id":"persephone","kind":"trial","name":"PERSEPHONE","route":"/trials/persephone/","asOf":"2026-09-07","days":21},{"id":"apt-trial","kind":"trial","name":"APT (adjuvant paclitaxel-trastuzumab)","route":"/trials/apt-trial/","asOf":"2026-09-07","days":21},{"id":"horizon-breast01","kind":"trial","name":"HORIZON-Breast01","route":"/trials/horizon-breast01/","asOf":"2026-09-07","days":21},{"id":"ace-breast-02","kind":"trial","name":"ACE-Breast-02","route":"/trials/ace-breast-02/","asOf":"2026-09-07","days":21},{"id":"pertuzumab","kind":"drug","name":"Pertuzumab","route":"/drugs/pertuzumab/","asOf":"2026-09-07","days":21},{"id":"neratinib","kind":"drug","name":"Neratinib","route":"/drugs/neratinib/","asOf":"2026-09-07","days":21},{"id":"lapatinib","kind":"drug","name":"Lapatinib","route":"/drugs/lapatinib/","asOf":"2026-09-07","days":21},{"id":"pyrotinib","kind":"drug","name":"Pyrotinib","route":"/drugs/pyrotinib/","asOf":"2026-09-07","days":21},{"id":"margetuximab","kind":"drug","name":"Margetuximab","route":"/drugs/margetuximab/","asOf":"2026-09-07","days":21},{"id":"trastuzumab-rezetecan","kind":"drug","name":"Trastuzumab rezetecan","route":"/drugs/trastuzumab-rezetecan/","asOf":"2026-09-07","days":21},{"id":"trastuzumab-brengitecan","kind":"drug","name":"Trastuzumab brengitecan","route":"/drugs/trastuzumab-brengitecan/","asOf":"2026-09-07","days":21},{"id":"arx788","kind":"drug","name":"ARX788","route":"/drugs/arx788/","asOf":"2026-09-07","days":21},{"id":"trastuzumab-biosimilars","kind":"drug","name":"Trastuzumab biosimilars","route":"/drugs/trastuzumab-biosimilars/","asOf":"2026-09-07","days":21},{"id":"dual-her2-blockade","kind":"term","name":"Dual HER2 blockade","route":"/terms/dual-her2-blockade/","asOf":"2026-09-07","days":21},{"id":"her2-brain-metastases","kind":"term","name":"HER2-positive brain metastases","route":"/terms/her2-brain-metastases/","asOf":"2026-09-07","days":21},{"id":"trastuzumab-cardiotoxicity","kind":"term","name":"Trastuzumab cardiotoxicity","route":"/terms/trastuzumab-cardiotoxicity/","asOf":"2026-09-07","days":21},{"id":"biosimilar","kind":"term","name":"Biosimilar","route":"/terms/biosimilar/","asOf":"2026-09-07","days":21},{"id":"tucatinib-triplet-brain-mets","kind":"pairing","name":"Tucatinib + trastuzumab + capecitabine for brain metastases","route":"/pairings/tucatinib-triplet-brain-mets/","asOf":"2026-09-07","days":21},{"id":"pet-adapted-her2-deescalation","kind":"pairing","name":"Early FDG-PET response → chemotherapy omission (HER2+)","route":"/pairings/pet-adapted-her2-deescalation/","asOf":"2026-09-07","days":21},{"id":"idea-tdxd-first-then-nothing","kind":"idea","name":"Can T-DXd alone cure early HER2-positive disease?","route":"/ideas/idea-tdxd-first-then-nothing/","asOf":"2026-09-07","days":21},{"id":"idea-cns-first-adc-strategy","kind":"idea","name":"Systemic-first management of HER2-positive brain metastases","route":"/ideas/idea-cns-first-adc-strategy/","asOf":"2026-09-07","days":21},{"id":"idea-her2-adc-sequencing-payload","kind":"idea","name":"Sequencing HER2 ADCs by payload after T-DXd","route":"/ideas/idea-her2-adc-sequencing-payload/","asOf":"2026-09-07","days":21},{"id":"eisai","kind":"company","name":"Eisai","route":"/companies/eisai/","asOf":"2026-09-07","days":21},{"id":"exelixis","kind":"company","name":"Exelixis","route":"/companies/exelixis/","asOf":"2026-09-07","days":21},{"id":"elevar-therapeutics","kind":"company","name":"Elevar Therapeutics (HLB)","route":"/companies/elevar-therapeutics/","asOf":"2026-09-07","days":21},{"id":"sirtex","kind":"company","name":"Sirtex Medical","route":"/companies/sirtex/","asOf":"2026-09-07","days":21},{"id":"boston-scientific","kind":"company","name":"Boston Scientific","route":"/companies/boston-scientific/","asOf":"2026-09-07","days":21},{"id":"tace","kind":"technology","name":"Transarterial chemoembolisation (TACE)","route":"/technologies/tace/","asOf":"2026-09-07","days":21},{"id":"radioembolisation-tare","kind":"technology","name":"Radioembolisation (TARE / SIRT, yttrium-90)","route":"/technologies/radioembolisation-tare/","asOf":"2026-09-07","days":21},{"id":"liver-transplant-oncology","kind":"technology","name":"Liver transplantation for cancer (Milan criteria and beyond)","route":"/technologies/liver-transplant-oncology/","asOf":"2026-09-07","days":21},{"id":"hcc-surveillance","kind":"technology","name":"HCC surveillance in cirrhosis (ultrasound + AFP)","route":"/technologies/hcc-surveillance/","asOf":"2026-09-07","days":21},{"id":"afp","kind":"term","name":"Alpha-fetoprotein (AFP)","route":"/terms/afp/","asOf":"2026-09-07","days":21},{"id":"child-pugh-albi","kind":"term","name":"Child-Pugh and ALBI liver-function scores","route":"/terms/child-pugh-albi/","asOf":"2026-09-07","days":21},{"id":"bclc-staging","kind":"term","name":"BCLC staging","route":"/terms/bclc-staging/","asOf":"2026-09-07","days":21},{"id":"hbv-hcv","kind":"term","name":"Hepatitis B and C as cancer causes","route":"/terms/hbv-hcv/","asOf":"2026-09-07","days":21},{"id":"sorafenib","kind":"drug","name":"Sorafenib","route":"/drugs/sorafenib/","asOf":"2026-09-07","days":21},{"id":"lenvatinib","kind":"drug","name":"Lenvatinib","route":"/drugs/lenvatinib/","asOf":"2026-09-07","days":21},{"id":"regorafenib","kind":"drug","name":"Regorafenib","route":"/drugs/regorafenib/","asOf":"2026-09-07","days":21},{"id":"cabozantinib","kind":"drug","name":"Cabozantinib","route":"/drugs/cabozantinib/","asOf":"2026-09-07","days":21},{"id":"camrelizumab-rivoceranib","kind":"drug","name":"Camrelizumab + rivoceranib","route":"/drugs/camrelizumab-rivoceranib/","asOf":"2026-09-07","days":21},{"id":"ramucirumab","kind":"drug","name":"Ramucirumab","route":"/drugs/ramucirumab/","asOf":"2026-09-07","days":21},{"id":"sharp","kind":"trial","name":"SHARP","route":"/trials/sharp/","asOf":"2026-09-07","days":21},{"id":"reflect","kind":"trial","name":"REFLECT","route":"/trials/reflect/","asOf":"2026-09-07","days":21},{"id":"resorce","kind":"trial","name":"RESORCE","route":"/trials/resorce/","asOf":"2026-09-07","days":21},{"id":"celestial","kind":"trial","name":"CELESTIAL","route":"/trials/celestial/","asOf":"2026-09-07","days":21},{"id":"imbrave150","kind":"trial","name":"IMbrave150","route":"/trials/imbrave150/","asOf":"2026-09-07","days":21},{"id":"himalaya","kind":"trial","name":"HIMALAYA","route":"/trials/himalaya/","asOf":"2026-09-07","days":21},{"id":"checkmate-9dw","kind":"trial","name":"CheckMate 9DW","route":"/trials/checkmate-9dw/","asOf":"2026-09-07","days":21},{"id":"leap-002","kind":"trial","name":"LEAP-002","route":"/trials/leap-002/","asOf":"2026-09-07","days":21},{"id":"cares-310","kind":"trial","name":"CARES-310","route":"/trials/cares-310/","asOf":"2026-09-07","days":21},{"id":"imbrave050","kind":"trial","name":"IMbrave050","route":"/trials/imbrave050/","asOf":"2026-09-07","days":21},{"id":"emerald-1","kind":"trial","name":"EMERALD-1","route":"/trials/emerald-1/","asOf":"2026-09-07","days":21},{"id":"leap-012","kind":"trial","name":"LEAP-012","route":"/trials/leap-012/","asOf":"2026-09-07","days":21},{"id":"emerald-3","kind":"trial","name":"EMERALD-3","route":"/trials/emerald-3/","asOf":"2026-09-07","days":21},{"id":"sarah-sirvenib","kind":"trial","name":"SARAH and SIRveNIB","route":"/trials/sarah-sirvenib/","asOf":"2026-09-07","days":21},{"id":"tace-plus-systemic","kind":"pairing","name":"TACE + immunotherapy/anti-VEGF","route":"/pairings/tace-plus-systemic/","asOf":"2026-09-07","days":21},{"id":"io-varices-caution","kind":"pairing","name":"Caution: bevacizumab-based regimens with untreated varices","route":"/pairings/io-varices-caution/","asOf":"2026-09-07","days":21},{"id":"idea-hcc-io-before-transplant","kind":"idea","name":"Immunotherapy downstaging to transplant with a safe washout","route":"/ideas/idea-hcc-io-before-transplant/","asOf":"2026-09-07","days":21},{"id":"idea-hcc-blood-surveillance","kind":"idea","name":"Blood-based HCC surveillance to replace six-monthly ultrasound","route":"/ideas/idea-hcc-blood-surveillance/","asOf":"2026-09-07","days":21},{"id":"incyte","kind":"company","name":"Incyte","route":"/companies/incyte/","asOf":"2026-09-07","days":21},{"id":"taiho","kind":"company","name":"Taiho Pharmaceutical (Otsuka)","route":"/companies/taiho/","asOf":"2026-09-07","days":21},{"id":"transthera","kind":"company","name":"TransThera Sciences","route":"/companies/transthera/","asOf":"2026-09-07","days":21},{"id":"biliary-stenting-drainage","kind":"technology","name":"Biliary stenting and drainage","route":"/technologies/biliary-stenting-drainage/","asOf":"2026-09-07","days":21},{"id":"biliary-anatomy-subtypes","kind":"term","name":"Intrahepatic, perihilar, distal and gallbladder cancer","route":"/terms/biliary-anatomy-subtypes/","asOf":"2026-09-07","days":21},{"id":"fgfr2-fusion","kind":"term","name":"FGFR2 fusions and rearrangements","route":"/terms/fgfr2-fusion/","asOf":"2026-09-07","days":21},{"id":"gemcitabine-cisplatin","kind":"drug","name":"Gemcitabine + cisplatin","route":"/drugs/gemcitabine-cisplatin/","asOf":"2026-09-07","days":21},{"id":"pemigatinib","kind":"drug","name":"Pemigatinib","route":"/drugs/pemigatinib/","asOf":"2026-09-07","days":21},{"id":"futibatinib","kind":"drug","name":"Futibatinib","route":"/drugs/futibatinib/","asOf":"2026-09-07","days":21},{"id":"ivosidenib","kind":"drug","name":"Ivosidenib","route":"/drugs/ivosidenib/","asOf":"2026-09-07","days":21},{"id":"tinengotinib","kind":"drug","name":"Tinengotinib","route":"/drugs/tinengotinib/","asOf":"2026-09-07","days":21},{"id":"abc-02","kind":"trial","name":"ABC-02","route":"/trials/abc-02/","asOf":"2026-09-07","days":21},{"id":"bilcap","kind":"trial","name":"BILCAP","route":"/trials/bilcap/","asOf":"2026-09-07","days":21},{"id":"topaz-1","kind":"trial","name":"TOPAZ-1","route":"/trials/topaz-1/","asOf":"2026-09-07","days":21},{"id":"keynote-966","kind":"trial","name":"KEYNOTE-966","route":"/trials/keynote-966/","asOf":"2026-09-07","days":21},{"id":"fight-202","kind":"trial","name":"FIGHT-202","route":"/trials/fight-202/","asOf":"2026-09-07","days":21},{"id":"foenix-cca2","kind":"trial","name":"FOENIX-CCA2","route":"/trials/foenix-cca2/","asOf":"2026-09-07","days":21},{"id":"claridhy","kind":"trial","name":"ClarIDHy","route":"/trials/claridhy/","asOf":"2026-09-07","days":21},{"id":"herizon-btc-302","kind":"trial","name":"HERIZON-BTC-302","route":"/trials/herizon-btc-302/","asOf":"2026-09-07","days":21},{"id":"first-308","kind":"trial","name":"FIRST-308","route":"/trials/first-308/","asOf":"2026-09-07","days":21},{"id":"naliricc","kind":"trial","name":"NALIRICC (AIO)","route":"/trials/naliricc/","asOf":"2026-09-07","days":21},{"id":"gemcis-plus-io-btc","kind":"pairing","name":"Gemcitabine-cisplatin + PD-(L)1 blockade in biliary cancer","route":"/pairings/gemcis-plus-io-btc/","asOf":"2026-09-07","days":21},{"id":"idea-btc-ctdna-fgfr-resistance","kind":"idea","name":"ctDNA-guided switching among FGFR inhibitors","route":"/ideas/idea-btc-ctdna-fgfr-resistance/","asOf":"2026-09-07","days":21},{"id":"sstr-pet","kind":"technology","name":"Somatostatin receptor PET (68Ga/64Cu-DOTATATE)","route":"/technologies/sstr-pet/","asOf":"2026-09-07","days":21},{"id":"prrt","kind":"technology","name":"Peptide receptor radionuclide therapy (PRRT)","route":"/technologies/prrt/","asOf":"2026-09-07","days":21},{"id":"net-grade-ki67","kind":"term","name":"Neuroendocrine tumour grade (Ki-67) and WHO classification","route":"/terms/net-grade-ki67/","asOf":"2026-09-07","days":21},{"id":"chromogranin-a","kind":"term","name":"Chromogranin A","route":"/terms/chromogranin-a/","asOf":"2026-09-07","days":21},{"id":"carcinoid-syndrome","kind":"term","name":"Carcinoid syndrome and carcinoid heart disease","route":"/terms/carcinoid-syndrome/","asOf":"2026-09-07","days":21},{"id":"men1-hereditary-net","kind":"term","name":"MEN1 and hereditary neuroendocrine syndromes","route":"/terms/men1-hereditary-net/","asOf":"2026-09-07","days":21},{"id":"octreotide-lanreotide","kind":"drug","name":"Somatostatin analogues (octreotide, lanreotide)","route":"/drugs/octreotide-lanreotide/","asOf":"2026-09-07","days":21},{"id":"sunitinib","kind":"drug","name":"Sunitinib","route":"/drugs/sunitinib/","asOf":"2026-09-07","days":21},{"id":"itm-11","kind":"drug","name":"177Lu-edotreotide","route":"/drugs/itm-11/","asOf":"2026-09-07","days":21},{"id":"alphamedix","kind":"drug","name":"212Pb-DOTAMTATE","route":"/drugs/alphamedix/","asOf":"2026-09-07","days":21},{"id":"capecitabine-temozolomide","kind":"drug","name":"Capecitabine + temozolomide (CAPTEM)","route":"/drugs/capecitabine-temozolomide/","asOf":"2026-09-07","days":21},{"id":"promid","kind":"trial","name":"PROMID","route":"/trials/promid/","asOf":"2026-09-07","days":21},{"id":"clarinet","kind":"trial","name":"CLARINET","route":"/trials/clarinet/","asOf":"2026-09-07","days":21},{"id":"radiant-3-4","kind":"trial","name":"RADIANT-3 and RADIANT-4","route":"/trials/radiant-3-4/","asOf":"2026-09-07","days":21},{"id":"cabinet","kind":"trial","name":"CABINET (Alliance A021602)","route":"/trials/cabinet/","asOf":"2026-09-07","days":21},{"id":"compete","kind":"trial","name":"COMPETE","route":"/trials/compete/","asOf":"2026-09-07","days":21},{"id":"alphamedix-02","kind":"trial","name":"ALPHAMEDIX-02","route":"/trials/alphamedix-02/","asOf":"2026-09-07","days":21},{"id":"action-1","kind":"trial","name":"ACTION-1","route":"/trials/action-1/","asOf":"2026-09-07","days":21},{"id":"sanet","kind":"trial","name":"SANET-ep and SANET-p","route":"/trials/sanet/","asOf":"2026-09-07","days":21},{"id":"sstr-pet-to-prrt","kind":"pairing","name":"SSTR PET → PRRT","route":"/pairings/sstr-pet-to-prrt/","asOf":"2026-09-07","days":21},{"id":"prrt-then-alpha-net","kind":"pairing","name":"Beta PRRT → alpha PRRT","route":"/pairings/prrt-then-alpha-net/","asOf":"2026-09-07","days":21},{"id":"idea-net-dosimetry-prrt","kind":"idea","name":"Dosimetry-personalised PRRT instead of four fixed cycles","route":"/ideas/idea-net-dosimetry-prrt/","asOf":"2026-09-07","days":21},{"id":"idea-net-antagonist-ligands","kind":"idea","name":"SSTR antagonist radioligands to increase tumour dose","route":"/ideas/idea-net-antagonist-ligands/","asOf":"2026-09-07","days":21},{"id":"keynote-006","kind":"trial","name":"KEYNOTE-006","route":"/trials/keynote-006/","asOf":"2026-09-07","days":21},{"id":"relativity-047","kind":"trial","name":"RELATIVITY-047","route":"/trials/relativity-047/","asOf":"2026-09-07","days":21},{"id":"nadina","kind":"trial","name":"NADINA","route":"/trials/nadina/","asOf":"2026-09-07","days":21},{"id":"swog-s1801","kind":"trial","name":"SWOG S1801","route":"/trials/swog-s1801/","asOf":"2026-09-07","days":21},{"id":"keynote-716","kind":"trial","name":"KEYNOTE-716","route":"/trials/keynote-716/","asOf":"2026-09-07","days":21},{"id":"combi-ad","kind":"trial","name":"COMBI-AD","route":"/trials/combi-ad/","asOf":"2026-09-07","days":21},{"id":"columbus","kind":"trial","name":"COLUMBUS","route":"/trials/columbus/","asOf":"2026-09-07","days":21},{"id":"dreamseq","kind":"trial","name":"DREAMseq (ECOG-ACRIN EA6134)","route":"/trials/dreamseq/","asOf":"2026-09-07","days":21},{"id":"c-144-01","kind":"trial","name":"C-144-01","route":"/trials/c-144-01/","asOf":"2026-09-07","days":21},{"id":"imcgp100-202","kind":"trial","name":"IMCgp100-202","route":"/trials/imcgp100-202/","asOf":"2026-09-07","days":21},{"id":"mslt-ii","kind":"trial","name":"MSLT-II","route":"/trials/mslt-ii/","asOf":"2026-09-07","days":21},{"id":"prism-mel-301","kind":"trial","name":"PRISM-MEL-301","route":"/trials/prism-mel-301/","asOf":"2026-09-07","days":21},{"id":"fianlimab-phase3-melanoma","kind":"trial","name":"Fianlimab + cemiplimab phase 3 (first-line melanoma)","route":"/trials/fianlimab-phase3-melanoma/","asOf":"2026-09-07","days":21},{"id":"relativity-098","kind":"trial","name":"RELATIVITY-098","route":"/trials/relativity-098/","asOf":"2026-09-07","days":21},{"id":"vemurafenib","kind":"drug","name":"Vemurafenib","route":"/drugs/vemurafenib/","asOf":"2026-09-07","days":21},{"id":"binimetinib","kind":"drug","name":"Binimetinib","route":"/drugs/binimetinib/","asOf":"2026-09-07","days":21},{"id":"cobimetinib","kind":"drug","name":"Cobimetinib","route":"/drugs/cobimetinib/","asOf":"2026-09-07","days":21},{"id":"brenetafusp","kind":"drug","name":"Brenetafusp","route":"/drugs/brenetafusp/","asOf":"2026-09-07","days":21},{"id":"fianlimab","kind":"drug","name":"Fianlimab","route":"/drugs/fianlimab/","asOf":"2026-09-07","days":21},{"id":"dermoscopy-ai","kind":"technology","name":"Dermoscopy, total-body photography & AI skin analysis","route":"/technologies/dermoscopy-ai/","asOf":"2026-09-07","days":21},{"id":"breslow-thickness","kind":"term","name":"Breslow thickness","route":"/terms/breslow-thickness/","asOf":"2026-09-07","days":21},{"id":"ulceration-melanoma","kind":"term","name":"Ulceration (melanoma)","route":"/terms/ulceration-melanoma/","asOf":"2026-09-07","days":21},{"id":"major-pathological-response","kind":"term","name":"Major pathological response (MPR)","route":"/terms/major-pathological-response/","asOf":"2026-09-07","days":21},{"id":"hla-a02-restriction","kind":"term","name":"HLA-A*02:01 restriction","route":"/terms/hla-a02-restriction/","asOf":"2026-09-07","days":21},{"id":"io-first-then-braf-mek","kind":"pairing","name":"Immunotherapy first, then BRAF/MEK (BRAF-mutant melanoma)","route":"/pairings/io-first-then-braf-mek/","asOf":"2026-09-07","days":21},{"id":"neoadjuvant-io-response-adapted","kind":"pairing","name":"Neoadjuvant immunotherapy → response-adapted adjuvant","route":"/pairings/neoadjuvant-io-response-adapted/","asOf":"2026-09-07","days":21},{"id":"lag3-adjuvant-caution","kind":"pairing","name":"Caution: LAG-3 blockade outside active disease","route":"/pairings/lag3-adjuvant-caution/","asOf":"2026-09-07","days":21},{"id":"idea-ctdna-guided-adjuvant-melanoma","kind":"idea","name":"ctDNA-guided adjuvant therapy in stage II-III melanoma","route":"/ideas/idea-ctdna-guided-adjuvant-melanoma/","asOf":"2026-09-07","days":21},{"id":"idea-prame-tcr-beyond-a02","kind":"idea","name":"TCR therapeutics for non-HLA-A*02 patients","route":"/ideas/idea-prame-tcr-beyond-a02/","asOf":"2026-09-07","days":21},{"id":"prame","kind":"target","name":"PRAME","route":"/targets/prame/","asOf":"2026-09-07","days":21},{"id":"keynote-048","kind":"trial","name":"KEYNOTE-048","route":"/trials/keynote-048/","asOf":"2026-09-07","days":21},{"id":"keynote-689","kind":"trial","name":"KEYNOTE-689","route":"/trials/keynote-689/","asOf":"2026-09-07","days":21},{"id":"extreme","kind":"trial","name":"EXTREME","route":"/trials/extreme/","asOf":"2026-09-07","days":21},{"id":"checkmate-141","kind":"trial","name":"CheckMate 141","route":"/trials/checkmate-141/","asOf":"2026-09-07","days":21},{"id":"rtog-0129","kind":"trial","name":"RTOG 0129 (HPV analysis)","route":"/trials/rtog-0129/","asOf":"2026-09-07","days":21},{"id":"nrg-hn002-hn005","kind":"trial","name":"NRG-HN002 & NRG-HN005 (HPV+ de-escalation)","route":"/trials/nrg-hn002-hn005/","asOf":"2026-09-07","days":21},{"id":"javelin-hn-100","kind":"trial","name":"JAVELIN Head and Neck 100","route":"/trials/javelin-hn-100/","asOf":"2026-09-07","days":21},{"id":"trilynx","kind":"trial","name":"TrilynX","route":"/trials/trilynx/","asOf":"2026-09-07","days":21},{"id":"jupiter-02","kind":"trial","name":"JUPITER-02","route":"/trials/jupiter-02/","asOf":"2026-09-07","days":21},{"id":"liger-hn1","kind":"trial","name":"LiGeR-HN1","route":"/trials/liger-hn1/","asOf":"2026-09-07","days":21},{"id":"fortifi-hn01","kind":"trial","name":"FORTIFI-HN01","route":"/trials/fortifi-hn01/","asOf":"2026-09-07","days":21},{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/","asOf":"2026-09-07","days":21},{"id":"petosemtamab","kind":"drug","name":"Petosemtamab","route":"/drugs/petosemtamab/","asOf":"2026-09-07","days":21},{"id":"ficerafusp-alfa","kind":"drug","name":"Ficerafusp alfa","route":"/drugs/ficerafusp-alfa/","asOf":"2026-09-07","days":21},{"id":"cetuximab-sarotalocan","kind":"drug","name":"Cetuximab sarotalocan","route":"/drugs/cetuximab-sarotalocan/","asOf":"2026-09-07","days":21},{"id":"tors","kind":"technology","name":"Transoral robotic surgery (TORS)","route":"/technologies/tors/","asOf":"2026-09-07","days":21},{"id":"cthpv-dna","kind":"technology","name":"Circulating tumour HPV DNA (ctHPV-DNA)","route":"/technologies/cthpv-dna/","asOf":"2026-09-07","days":21},{"id":"hpv-p16","kind":"term","name":"HPV-positive (p16) head and neck cancer","route":"/terms/hpv-p16/","asOf":"2026-09-07","days":21},{"id":"lgr5","kind":"term","name":"LGR5","route":"/terms/lgr5/","asOf":"2026-09-07","days":21},{"id":"io-before-surgery-hnscc","kind":"pairing","name":"Immunotherapy before surgery rather than with chemoradiation (HNSCC)","route":"/pairings/io-before-surgery-hnscc/","asOf":"2026-09-07","days":21},{"id":"egfr-bispecific-plus-pd1-hnscc","kind":"pairing","name":"EGFR-directed bispecific + PD-1 blockade","route":"/pairings/egfr-bispecific-plus-pd1-hnscc/","asOf":"2026-09-07","days":21},{"id":"hpv-deescalation-caution","kind":"pairing","name":"Caution: de-escalating radiation on HPV status alone","route":"/pairings/hpv-deescalation-caution/","asOf":"2026-09-07","days":21},{"id":"idea-cthpv-adapted-deescalation","kind":"idea","name":"ctHPV-DNA-adapted de-escalation of chemoradiation","route":"/ideas/idea-cthpv-adapted-deescalation/","asOf":"2026-09-07","days":21},{"id":"idea-photoimmunotherapy-plus-pd1","kind":"idea","name":"Photoimmunotherapy as an in situ vaccine with PD-1 blockade","route":"/ideas/idea-photoimmunotherapy-plus-pd1/","asOf":"2026-09-07","days":21},{"id":"select-lenvatinib","kind":"trial","name":"SELECT","route":"/trials/select-lenvatinib/","asOf":"2026-09-07","days":21},{"id":"decision-sorafenib","kind":"trial","name":"DECISION","route":"/trials/decision-sorafenib/","asOf":"2026-09-07","days":21},{"id":"libretto-531","kind":"trial","name":"LIBRETTO-531","route":"/trials/libretto-531/","asOf":"2026-09-07","days":21},{"id":"arrow-thyroid","kind":"trial","name":"ARROW (thyroid cohorts)","route":"/trials/arrow-thyroid/","asOf":"2026-09-07","days":21},{"id":"estimabl2","kind":"trial","name":"ESTIMABL2","route":"/trials/estimabl2/","asOf":"2026-09-07","days":21},{"id":"ion-trial","kind":"trial","name":"IoN","route":"/trials/ion-trial/","asOf":"2026-09-07","days":21},{"id":"hilo","kind":"trial","name":"HiLo","route":"/trials/hilo/","asOf":"2026-09-07","days":21},{"id":"roar-atc","kind":"trial","name":"ROAR (anaplastic thyroid cancer cohort)","route":"/trials/roar-atc/","asOf":"2026-09-07","days":21},{"id":"astra","kind":"trial","name":"ASTRA","route":"/trials/astra/","asOf":"2026-09-07","days":21},{"id":"radioactive-iodine","kind":"drug","name":"Radioactive iodine (I-131)","route":"/drugs/radioactive-iodine/","asOf":"2026-09-07","days":21},{"id":"vandetanib","kind":"drug","name":"Vandetanib","route":"/drugs/vandetanib/","asOf":"2026-09-07","days":21},{"id":"radioiodine-therapy","kind":"technology","name":"Radioiodine therapy and whole-body iodine scanning","route":"/technologies/radioiodine-therapy/","asOf":"2026-09-07","days":21},{"id":"thyroid-fna-molecular","kind":"technology","name":"Thyroid nodule FNA, Bethesda cytology & molecular classifiers","route":"/technologies/thyroid-fna-molecular/","asOf":"2026-09-07","days":21},{"id":"active-surveillance-thyroid","kind":"technology","name":"Active surveillance of papillary microcarcinoma","route":"/technologies/active-surveillance-thyroid/","asOf":"2026-09-07","days":21},{"id":"rai-refractory","kind":"term","name":"Radioiodine-refractory (RAI-R) thyroid cancer","route":"/terms/rai-refractory/","asOf":"2026-09-07","days":21},{"id":"low-risk-dtc","kind":"term","name":"Low-risk differentiated thyroid cancer (ATA risk)","route":"/terms/low-risk-dtc/","asOf":"2026-09-07","days":21},{"id":"bethesda-category","kind":"term","name":"Bethesda category (thyroid cytology)","route":"/terms/bethesda-category/","asOf":"2026-09-07","days":21},{"id":"tsh-suppression","kind":"term","name":"TSH suppression","route":"/terms/tsh-suppression/","asOf":"2026-09-07","days":21},{"id":"tert-promoter","kind":"term","name":"TERT promoter mutation","route":"/terms/tert-promoter/","asOf":"2026-09-07","days":21},{"id":"braf-mek-neoadjuvant-atc","kind":"pairing","name":"BRAF/MEK inhibition → surgery in anaplastic thyroid cancer","route":"/pairings/braf-mek-neoadjuvant-atc/","asOf":"2026-09-07","days":21},{"id":"redifferentiation-rai","kind":"pairing","name":"MAPK inhibitor redifferentiation → radioiodine","route":"/pairings/redifferentiation-rai/","asOf":"2026-09-07","days":21},{"id":"idea-thyroid-overdiagnosis-reversal","kind":"idea","name":"Ultrasound restraint and surveillance to reverse thyroid cancer overdiagnosis","route":"/ideas/idea-thyroid-overdiagnosis-reversal/","asOf":"2026-09-07","days":21},{"id":"idea-atc-triplet-io","kind":"idea","name":"BRAF/MEK plus PD-1 blockade as standard for BRAF-mutant anaplastic thyroid cancer","route":"/ideas/idea-atc-triplet-io/","asOf":"2026-09-07","days":21},{"id":"keynote-177","kind":"trial","name":"KEYNOTE-177","route":"/trials/keynote-177/","asOf":"2026-09-07","days":21},{"id":"checkmate-8hw","kind":"trial","name":"CheckMate 8HW","route":"/trials/checkmate-8hw/","asOf":"2026-09-07","days":21},{"id":"niche-2","kind":"trial","name":"NICHE-2","route":"/trials/niche-2/","asOf":"2026-09-07","days":21},{"id":"atomic","kind":"trial","name":"ATOMIC (Alliance A021502)","route":"/trials/atomic/","asOf":"2026-09-07","days":21},{"id":"azur-1","kind":"trial","name":"AZUR-1","route":"/trials/azur-1/","asOf":"2026-09-07","days":21},{"id":"breakwater","kind":"trial","name":"BREAKWATER","route":"/trials/breakwater/","asOf":"2026-09-07","days":21},{"id":"paradigm","kind":"trial","name":"PARADIGM","route":"/trials/paradigm/","asOf":"2026-09-07","days":21},{"id":"crystal-fire3","kind":"trial","name":"CRYSTAL & FIRE-3","route":"/trials/crystal-fire3/","asOf":"2026-09-07","days":21},{"id":"mountaineer","kind":"trial","name":"MOUNTAINEER","route":"/trials/mountaineer/","asOf":"2026-09-07","days":21},{"id":"destiny-crc02","kind":"trial","name":"DESTINY-CRC02","route":"/trials/destiny-crc02/","asOf":"2026-09-07","days":21},{"id":"sunlight","kind":"trial","name":"SUNLIGHT","route":"/trials/sunlight/","asOf":"2026-09-07","days":21},{"id":"fresco-2","kind":"trial","name":"FRESCO-2","route":"/trials/fresco-2/","asOf":"2026-09-07","days":21},{"id":"circulate-japan","kind":"trial","name":"CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)","route":"/trials/circulate-japan/","asOf":"2026-09-07","days":21},{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/","asOf":"2026-09-07","days":21},{"id":"panitumumab","kind":"drug","name":"Panitumumab","route":"/drugs/panitumumab/","asOf":"2026-09-07","days":21},{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/","asOf":"2026-09-07","days":21},{"id":"trifluridine-tipiracil","kind":"drug","name":"Trifluridine/tipiracil","route":"/drugs/trifluridine-tipiracil/","asOf":"2026-09-07","days":21},{"id":"fruquintinib","kind":"drug","name":"Fruquintinib","route":"/drugs/fruquintinib/","asOf":"2026-09-07","days":21},{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/","asOf":"2026-09-07","days":21},{"id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/","asOf":"2026-09-07","days":21},{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/","asOf":"2026-09-07","days":21},{"id":"colorectal-screening","kind":"technology","name":"Colorectal cancer screening (colonoscopy, FIT, stool DNA, blood)","route":"/technologies/colorectal-screening/","asOf":"2026-09-07","days":21},{"id":"sidedness","kind":"term","name":"Sidedness (left vs right colon)","route":"/terms/sidedness/","asOf":"2026-09-07","days":21},{"id":"cms-subtypes","kind":"term","name":"Consensus molecular subtypes (CMS1-4)","route":"/terms/cms-subtypes/","asOf":"2026-09-07","days":21},{"id":"lynch-syndrome","kind":"term","name":"Lynch syndrome","route":"/terms/lynch-syndrome/","asOf":"2026-09-07","days":21},{"id":"fit-test","kind":"term","name":"Faecal immunochemical test (FIT)","route":"/terms/fit-test/","asOf":"2026-09-07","days":21},{"id":"clinical-complete-response","kind":"term","name":"Clinical complete response (cCR)","route":"/terms/clinical-complete-response/","asOf":"2026-09-07","days":21},{"id":"anti-egfr-left-sided","kind":"pairing","name":"Anti-EGFR antibody + chemotherapy in left-sided RAS/BRAF wild-type mCRC","route":"/pairings/anti-egfr-left-sided/","asOf":"2026-09-07","days":21},{"id":"neoadjuvant-io-dmmr","kind":"pairing","name":"Neoadjuvant checkpoint inhibitor → surgery (or no surgery) in dMMR colorectal cancer","route":"/pairings/neoadjuvant-io-dmmr/","asOf":"2026-09-07","days":21},{"id":"idea-ctdna-guided-adjuvant-crc","kind":"idea","name":"ctDNA-guided adjuvant therapy as the default in stage II-III colon cancer","route":"/ideas/idea-ctdna-guided-adjuvant-crc/","asOf":"2026-09-07","days":21},{"id":"idea-immunotherapy-mss-crc","kind":"idea","name":"Making microsatellite-stable colorectal cancer immunotherapy-responsive","route":"/ideas/idea-immunotherapy-mss-crc/","asOf":"2026-09-07","days":21},{"id":"toga","kind":"trial","name":"ToGA","route":"/trials/toga/","asOf":"2026-09-07","days":21},{"id":"checkmate-649","kind":"trial","name":"CheckMate 649","route":"/trials/checkmate-649/","asOf":"2026-09-07","days":21},{"id":"keynote-859","kind":"trial","name":"KEYNOTE-859","route":"/trials/keynote-859/","asOf":"2026-09-07","days":21},{"id":"spotlight-glow","kind":"trial","name":"SPOTLIGHT & GLOW","route":"/trials/spotlight-glow/","asOf":"2026-09-07","days":21},{"id":"matterhorn","kind":"trial","name":"MATTERHORN","route":"/trials/matterhorn/","asOf":"2026-09-07","days":21},{"id":"fortitude-101","kind":"trial","name":"FORTITUDE-101","route":"/trials/fortitude-101/","asOf":"2026-09-07","days":21},{"id":"herizon-gea-01","kind":"trial","name":"HERIZON-GEA-01","route":"/trials/herizon-gea-01/","asOf":"2026-09-07","days":21},{"id":"destiny-gastric04","kind":"trial","name":"DESTINY-Gastric04","route":"/trials/destiny-gastric04/","asOf":"2026-09-07","days":21},{"id":"rainbow","kind":"trial","name":"RAINBOW","route":"/trials/rainbow/","asOf":"2026-09-07","days":21},{"id":"clarity-gastric01","kind":"trial","name":"CLARITY-Gastric 01","route":"/trials/clarity-gastric01/","asOf":"2026-09-07","days":21},{"id":"zolbetuximab","kind":"drug","name":"Zolbetuximab","route":"/drugs/zolbetuximab/","asOf":"2026-09-07","days":21},{"id":"bemarituzumab","kind":"drug","name":"Bemarituzumab","route":"/drugs/bemarituzumab/","asOf":"2026-09-07","days":21},{"id":"flot","kind":"drug","name":"FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)","route":"/drugs/flot/","asOf":"2026-09-07","days":21},{"id":"siewert-classification","kind":"term","name":"Siewert classification (GEJ tumours)","route":"/terms/siewert-classification/","asOf":"2026-09-07","days":21},{"id":"lauren-classification","kind":"term","name":"Lauren classification (intestinal vs diffuse)","route":"/terms/lauren-classification/","asOf":"2026-09-07","days":21},{"id":"peritoneal-metastasis","kind":"term","name":"Peritoneal metastasis","route":"/terms/peritoneal-metastasis/","asOf":"2026-09-07","days":21},{"id":"her2-gastric-sequence","kind":"pairing","name":"HER2 sequence in gastric cancer: zanidatamab/trastuzumab + chemo ± PD-1 → T-DXd","route":"/pairings/her2-gastric-sequence/","asOf":"2026-09-07","days":21},{"id":"cldn18-antibody-then-adc","kind":"pairing","name":"CLDN18.2 antibody first line → CLDN18.2 ADC or CAR-T on progression","route":"/pairings/cldn18-antibody-then-adc/","asOf":"2026-09-07","days":21},{"id":"idea-biomarker-quadruplet-gastric","kind":"idea","name":"Biomarker-directed first-line quadruplets in gastric cancer","route":"/ideas/idea-biomarker-quadruplet-gastric/","asOf":"2026-09-07","days":21},{"id":"idea-peritoneal-directed-gastric","kind":"idea","name":"Peritoneal-directed therapy for gastric cancer","route":"/ideas/idea-peritoneal-directed-gastric/","asOf":"2026-09-07","days":21},{"id":"cross","kind":"trial","name":"CROSS","route":"/trials/cross/","asOf":"2026-09-07","days":21},{"id":"sano","kind":"trial","name":"SANO","route":"/trials/sano/","asOf":"2026-09-07","days":21},{"id":"checkmate-577","kind":"trial","name":"CheckMate 577","route":"/trials/checkmate-577/","asOf":"2026-09-07","days":21},{"id":"keynote-590","kind":"trial","name":"KEYNOTE-590","route":"/trials/keynote-590/","asOf":"2026-09-07","days":21},{"id":"checkmate-648","kind":"trial","name":"CheckMate 648","route":"/trials/checkmate-648/","asOf":"2026-09-07","days":21},{"id":"rationale-306","kind":"trial","name":"RATIONALE-306","route":"/trials/rationale-306/","asOf":"2026-09-07","days":21},{"id":"escort-1st","kind":"trial","name":"ESCORT-1st","route":"/trials/escort-1st/","asOf":"2026-09-07","days":21},{"id":"panku-esophagus01","kind":"trial","name":"PANKU-Esophagus01 (BL-B01D1-305)","route":"/trials/panku-esophagus01/","asOf":"2026-09-07","days":21},{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/","asOf":"2026-09-07","days":21},{"id":"camrelizumab","kind":"drug","name":"Camrelizumab","route":"/drugs/camrelizumab/","asOf":"2026-09-07","days":21},{"id":"endoscopic-resection","kind":"technology","name":"Endoscopic resection (EMR / ESD)","route":"/technologies/endoscopic-resection/","asOf":"2026-09-07","days":21},{"id":"barretts-esophagus","kind":"term","name":"Barrett's oesophagus","route":"/terms/barretts-esophagus/","asOf":"2026-09-07","days":21},{"id":"escc-vs-eac","kind":"term","name":"Squamous cell carcinoma vs adenocarcinoma of the oesophagus","route":"/terms/escc-vs-eac/","asOf":"2026-09-07","days":21},{"id":"cross-then-nivolumab","kind":"pairing","name":"CROSS chemoradiation → surgery → adjuvant nivolumab if residual disease","route":"/pairings/cross-then-nivolumab/","asOf":"2026-09-07","days":21},{"id":"idea-organ-preservation-esophageal","kind":"idea","name":"Organ preservation as the default after complete response in oesophageal cancer","route":"/ideas/idea-organ-preservation-esophageal/","asOf":"2026-09-07","days":21},{"id":"idea-non-endoscopic-barretts-screening","kind":"idea","name":"Non-endoscopic screening for Barrett's oesophagus and early adenocarcinoma","route":"/ideas/idea-non-endoscopic-barretts-screening/","asOf":"2026-09-07","days":21},{"id":"impower133","kind":"trial","name":"IMpower133","route":"/trials/impower133/","asOf":"2026-09-07","days":21},{"id":"caspian","kind":"trial","name":"CASPIAN","route":"/trials/caspian/","asOf":"2026-09-07","days":21},{"id":"adriatic","kind":"trial","name":"ADRIATIC","route":"/trials/adriatic/","asOf":"2026-09-07","days":21},{"id":"imforte","kind":"trial","name":"IMforte","route":"/trials/imforte/","asOf":"2026-09-07","days":21},{"id":"atlantis","kind":"trial","name":"ATLANTIS","route":"/trials/atlantis/","asOf":"2026-09-07","days":21},{"id":"dellphi-305","kind":"trial","name":"DeLLphi-305","route":"/trials/dellphi-305/","asOf":"2026-09-07","days":21},{"id":"ideate-lung02","kind":"trial","name":"IDeate-Lung02","route":"/trials/ideate-lung02/","asOf":"2026-09-07","days":21},{"id":"astrum-005","kind":"trial","name":"ASTRUM-005","route":"/trials/astrum-005/","asOf":"2026-09-07","days":21},{"id":"convert","kind":"trial","name":"CONVERT","route":"/trials/convert/","asOf":"2026-09-07","days":21},{"id":"platinum-etoposide","kind":"drug","name":"Platinum + etoposide (EP / CE)","route":"/drugs/platinum-etoposide/","asOf":"2026-09-07","days":21},{"id":"lurbinectedin","kind":"drug","name":"Lurbinectedin","route":"/drugs/lurbinectedin/","asOf":"2026-09-07","days":21},{"id":"topotecan","kind":"drug","name":"Topotecan","route":"/drugs/topotecan/","asOf":"2026-09-07","days":21},{"id":"serplulimab","kind":"drug","name":"Serplulimab","route":"/drugs/serplulimab/","asOf":"2026-09-07","days":21},{"id":"prophylactic-cranial-irradiation","kind":"technology","name":"Prophylactic cranial irradiation vs MRI surveillance","route":"/technologies/prophylactic-cranial-irradiation/","asOf":"2026-09-07","days":21},{"id":"pharmamar","kind":"company","name":"PharmaMar","route":"/companies/pharmamar/","asOf":"2026-09-07","days":21},{"id":"henlius","kind":"company","name":"Shanghai Henlius Biotech","route":"/companies/henlius/","asOf":"2026-09-07","days":21},{"id":"chemo-io-then-maintenance-sclc","kind":"pairing","name":"Chemo-immunotherapy induction → maintenance intensification (SCLC)","route":"/pairings/chemo-io-then-maintenance-sclc/","asOf":"2026-09-07","days":21},{"id":"tarlatamab-vs-idxd-sequence","kind":"pairing","name":"Sequencing DLL3 engager and B7-H3 ADC in relapsed SCLC","route":"/pairings/tarlatamab-vs-idxd-sequence/","asOf":"2026-09-07","days":21},{"id":"idea-sclc-subtype-directed","kind":"idea","name":"Subtype-directed therapy for SCLC (ASCL1 / NEUROD1 / POU2F3 / inflamed)","route":"/ideas/idea-sclc-subtype-directed/","asOf":"2026-09-07","days":21},{"id":"idea-mri-surveillance-replaces-pci","kind":"idea","name":"MRI surveillance replaces prophylactic cranial irradiation in SCLC","route":"/ideas/idea-mri-surveillance-replaces-pci/","asOf":"2026-09-07","days":21},{"id":"checkmate-743","kind":"trial","name":"CheckMate 743","route":"/trials/checkmate-743/","asOf":"2026-09-07","days":21},{"id":"keynote-483","kind":"trial","name":"IND.227 / KEYNOTE-483","route":"/trials/keynote-483/","asOf":"2026-09-07","days":21},{"id":"maps","kind":"trial","name":"MAPS","route":"/trials/maps/","asOf":"2026-09-07","days":21},{"id":"mars-2","kind":"trial","name":"MARS 2","route":"/trials/mars-2/","asOf":"2026-09-07","days":21},{"id":"lume-meso","kind":"trial","name":"LUME-Meso","route":"/trials/lume-meso/","asOf":"2026-09-07","days":21},{"id":"beat-meso","kind":"trial","name":"BEAT-meso (ETOP 13-18)","route":"/trials/beat-meso/","asOf":"2026-09-07","days":21},{"id":"dream3r","kind":"trial","name":"DREAM3R","route":"/trials/dream3r/","asOf":"2026-09-07","days":21},{"id":"stellar","kind":"trial","name":"STELLAR","route":"/trials/stellar/","asOf":"2026-09-07","days":21},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/","asOf":"2026-09-07","days":21},{"id":"nintedanib","kind":"drug","name":"Nintedanib","route":"/drugs/nintedanib/","asOf":"2026-09-07","days":21},{"id":"pleurectomy-decortication","kind":"technology","name":"Extended pleurectomy/decortication & radical mesothelioma surgery","route":"/technologies/pleurectomy-decortication/","asOf":"2026-09-07","days":21},{"id":"epithelioid-vs-sarcomatoid","kind":"term","name":"Epithelioid vs sarcomatoid (biphasic) mesothelioma","route":"/terms/epithelioid-vs-sarcomatoid/","asOf":"2026-09-07","days":21},{"id":"histology-directs-first-line-meso","kind":"pairing","name":"Histology → first-line choice in mesothelioma","route":"/pairings/histology-directs-first-line-meso/","asOf":"2026-09-07","days":21},{"id":"idea-adc-for-mesothelioma","kind":"idea","name":"Antibody-drug conjugates for mesothelioma: why they have failed so far and how they could work","route":"/ideas/idea-adc-for-mesothelioma/","asOf":"2026-09-07","days":21},{"id":"idea-mtap-prmt5-mesothelioma","kind":"idea","name":"PRMT5/MAT2A synthetic lethality for MTAP-deleted mesothelioma","route":"/ideas/idea-mtap-prmt5-mesothelioma/","asOf":"2026-09-07","days":21},{"id":"idea-mesothelin-car-t-regional","kind":"idea","name":"Regionally delivered mesothelin CAR-T with PD-1 blockade","route":"/ideas/idea-mesothelin-car-t-regional/","asOf":"2026-09-07","days":21},{"id":"niagara","kind":"trial","name":"NIAGARA","route":"/trials/niagara/","asOf":"2026-09-07","days":21},{"id":"ev-303","kind":"trial","name":"EV-303 / KEYNOTE-905","route":"/trials/ev-303/","asOf":"2026-09-07","days":21},{"id":"ev-304","kind":"trial","name":"EV-304 / KEYNOTE-B15","route":"/trials/ev-304/","asOf":"2026-09-07","days":21},{"id":"checkmate-274","kind":"trial","name":"CheckMate 274","route":"/trials/checkmate-274/","asOf":"2026-09-07","days":21},{"id":"potomac","kind":"trial","name":"POTOMAC","route":"/trials/potomac/","asOf":"2026-09-07","days":21},{"id":"sunrise-1","kind":"trial","name":"SunRISe-1","route":"/trials/sunrise-1/","asOf":"2026-09-07","days":21},{"id":"bond-003","kind":"trial","name":"BOND-003","route":"/trials/bond-003/","asOf":"2026-09-07","days":21},{"id":"quilt-3-032","kind":"trial","name":"QUILT 3.032","route":"/trials/quilt-3-032/","asOf":"2026-09-07","days":21},{"id":"thor","kind":"trial","name":"THOR","route":"/trials/thor/","asOf":"2026-09-07","days":21},{"id":"javelin-bladder-100","kind":"trial","name":"JAVELIN Bladder 100","route":"/trials/javelin-bladder-100/","asOf":"2026-09-07","days":21},{"id":"bcg-intravesical","kind":"drug","name":"Intravesical BCG","route":"/drugs/bcg-intravesical/","asOf":"2026-09-07","days":21},{"id":"tar-200","kind":"drug","name":"Gemcitabine intravesical system (TAR-200)","route":"/drugs/tar-200/","asOf":"2026-09-07","days":21},{"id":"cretostimogene","kind":"drug","name":"Cretostimogene grenadenorepvec","route":"/drugs/cretostimogene/","asOf":"2026-09-07","days":21},{"id":"nogapendekin-alfa","kind":"drug","name":"Nogapendekin alfa inbakicept","route":"/drugs/nogapendekin-alfa/","asOf":"2026-09-07","days":21},{"id":"nadofaragene-firadenovec","kind":"drug","name":"Nadofaragene firadenovec","route":"/drugs/nadofaragene-firadenovec/","asOf":"2026-09-07","days":21},{"id":"erdafitinib","kind":"drug","name":"Erdafitinib","route":"/drugs/erdafitinib/","asOf":"2026-09-07","days":21},{"id":"avelumab","kind":"drug","name":"Avelumab","route":"/drugs/avelumab/","asOf":"2026-09-07","days":21},{"id":"zelenectide-pevedotin","kind":"drug","name":"Zelenectide pevedotin","route":"/drugs/zelenectide-pevedotin/","asOf":"2026-09-07","days":21},{"id":"bcg-and-intravesical-therapy","kind":"technology","name":"Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy)","route":"/technologies/bcg-and-intravesical-therapy/","asOf":"2026-09-07","days":21},{"id":"cystoscopy-turbt","kind":"technology","name":"Cystoscopy, blue-light imaging & TURBT","route":"/technologies/cystoscopy-turbt/","asOf":"2026-09-07","days":21},{"id":"nmibc-vs-mibc","kind":"term","name":"Non-muscle-invasive vs muscle-invasive bladder cancer (NMIBC / MIBC)","route":"/terms/nmibc-vs-mibc/","asOf":"2026-09-07","days":21},{"id":"bcg-unresponsive","kind":"term","name":"BCG-unresponsive","route":"/terms/bcg-unresponsive/","asOf":"2026-09-07","days":21},{"id":"fgfr3","kind":"term","name":"FGFR3 alterations (bladder cancer)","route":"/terms/fgfr3/","asOf":"2026-09-07","days":21},{"id":"cg-oncology","kind":"company","name":"CG Oncology","route":"/companies/cg-oncology/","asOf":"2026-09-07","days":21},{"id":"immunitybio","kind":"company","name":"ImmunityBio","route":"/companies/immunitybio/","asOf":"2026-09-07","days":21},{"id":"ferring","kind":"company","name":"Ferring Pharmaceuticals","route":"/companies/ferring/","asOf":"2026-09-07","days":21},{"id":"bicycle-therapeutics","kind":"company","name":"Bicycle Therapeutics","route":"/companies/bicycle-therapeutics/","asOf":"2026-09-07","days":21},{"id":"ev-pembro-continuum","kind":"pairing","name":"Enfortumab vedotin + pembrolizumab across the bladder cancer continuum","route":"/pairings/ev-pembro-continuum/","asOf":"2026-09-07","days":21},{"id":"durvalumab-plus-bcg","kind":"pairing","name":"Durvalumab + BCG in BCG-naive high-risk NMIBC","route":"/pairings/durvalumab-plus-bcg/","asOf":"2026-09-07","days":21},{"id":"idea-bladder-preservation-mibc","kind":"idea","name":"Bladder preservation for MIBC after perioperative EV + pembrolizumab complete response","route":"/ideas/idea-bladder-preservation-mibc/","asOf":"2026-09-07","days":21},{"id":"idea-urine-ctdna-surveillance","kind":"idea","name":"Urine tumour DNA to replace surveillance cystoscopy in NMIBC","route":"/ideas/idea-urine-ctdna-surveillance/","asOf":"2026-09-07","days":21},{"id":"checkmate-214","kind":"trial","name":"CheckMate 214","route":"/trials/checkmate-214/","asOf":"2026-09-07","days":21},{"id":"keynote-426","kind":"trial","name":"KEYNOTE-426","route":"/trials/keynote-426/","asOf":"2026-09-07","days":21},{"id":"checkmate-9er","kind":"trial","name":"CheckMate 9ER","route":"/trials/checkmate-9er/","asOf":"2026-09-07","days":21},{"id":"clear","kind":"trial","name":"CLEAR (KEYNOTE-581)","route":"/trials/clear/","asOf":"2026-09-07","days":21},{"id":"keynote-564","kind":"trial","name":"KEYNOTE-564","route":"/trials/keynote-564/","asOf":"2026-09-07","days":21},{"id":"litespark-022","kind":"trial","name":"LITESPARK-022","route":"/trials/litespark-022/","asOf":"2026-09-07","days":21},{"id":"litespark-005","kind":"trial","name":"LITESPARK-005","route":"/trials/litespark-005/","asOf":"2026-09-07","days":21},{"id":"litespark-012","kind":"trial","name":"LITESPARK-012","route":"/trials/litespark-012/","asOf":"2026-09-07","days":21},{"id":"cosmic-313","kind":"trial","name":"COSMIC-313","route":"/trials/cosmic-313/","asOf":"2026-09-07","days":21},{"id":"contact-03","kind":"trial","name":"CONTACT-03","route":"/trials/contact-03/","asOf":"2026-09-07","days":21},{"id":"tinivo-2","kind":"trial","name":"TiNivo-2","route":"/trials/tinivo-2/","asOf":"2026-09-07","days":21},{"id":"axitinib","kind":"drug","name":"Axitinib","route":"/drugs/axitinib/","asOf":"2026-09-07","days":21},{"id":"tivozanib","kind":"drug","name":"Tivozanib","route":"/drugs/tivozanib/","asOf":"2026-09-07","days":21},{"id":"partial-nephrectomy-active-surveillance","kind":"technology","name":"Partial nephrectomy, ablation & active surveillance of small renal masses","route":"/technologies/partial-nephrectomy-active-surveillance/","asOf":"2026-09-07","days":21},{"id":"caix-pet","kind":"technology","name":"CAIX PET (89Zr-girentuximab)","route":"/technologies/caix-pet/","asOf":"2026-09-07","days":21},{"id":"imdc-risk","kind":"term","name":"IMDC risk groups (favourable / intermediate / poor)","route":"/terms/imdc-risk/","asOf":"2026-09-07","days":21},{"id":"sarcomatoid-rcc","kind":"term","name":"Sarcomatoid differentiation (RCC)","route":"/terms/sarcomatoid-rcc/","asOf":"2026-09-07","days":21},{"id":"aveo","kind":"company","name":"AVEO Oncology (LG Chem)","route":"/companies/aveo/","asOf":"2026-09-07","days":21},{"id":"io-rechallenge-caution-rcc","kind":"pairing","name":"Caution: PD-1 rechallenge after progression on immunotherapy (RCC)","route":"/pairings/io-rechallenge-caution-rcc/","asOf":"2026-09-07","days":21},{"id":"risk-directed-first-line-rcc","kind":"pairing","name":"IMDC risk → first-line regimen choice (RCC)","route":"/pairings/risk-directed-first-line-rcc/","asOf":"2026-09-07","days":21},{"id":"idea-adjuvant-selection-rcc","kind":"idea","name":"Biomarker-selected adjuvant therapy in RCC (ctDNA, CAIX PET, gene signatures)","route":"/ideas/idea-adjuvant-selection-rcc/","asOf":"2026-09-07","days":21},{"id":"idea-caix-theranostics","kind":"idea","name":"CAIX theranostics: 89Zr-girentuximab PET and 177Lu/225Ac-girentuximab therapy","route":"/ideas/idea-caix-theranostics/","asOf":"2026-09-07","days":21},{"id":"solo-1","kind":"trial","name":"SOLO-1","route":"/trials/solo-1/","asOf":"2026-09-07","days":21},{"id":"prima","kind":"trial","name":"PRIMA / ENGOT-OV26","route":"/trials/prima/","asOf":"2026-09-07","days":21},{"id":"paola-1","kind":"trial","name":"PAOLA-1 / ENGOT-ov25","route":"/trials/paola-1/","asOf":"2026-09-07","days":21},{"id":"athena-mono","kind":"trial","name":"ATHENA-MONO / GOG-3020","route":"/trials/athena-mono/","asOf":"2026-09-07","days":21},{"id":"duo-o","kind":"trial","name":"DUO-O / ENGOT-ov46","route":"/trials/duo-o/","asOf":"2026-09-07","days":21},{"id":"gog-0218-icon7","kind":"trial","name":"GOG-0218 & ICON7 (bevacizumab)","route":"/trials/gog-0218-icon7/","asOf":"2026-09-07","days":21},{"id":"ovhipec-1","kind":"trial","name":"OVHIPEC-1","route":"/trials/ovhipec-1/","asOf":"2026-09-07","days":21},{"id":"desktop-iii","kind":"trial","name":"DESKTOP III / ENGOT-ov20","route":"/trials/desktop-iii/","asOf":"2026-09-07","days":21},{"id":"mirasol","kind":"trial","name":"MIRASOL / GOG-3045","route":"/trials/mirasol/","asOf":"2026-09-07","days":21},{"id":"rosella","kind":"trial","name":"ROSELLA / GOG-3073","route":"/trials/rosella/","asOf":"2026-09-07","days":21},{"id":"keynote-b96","kind":"trial","name":"KEYNOTE-B96 / ENGOT-ov65","route":"/trials/keynote-b96/","asOf":"2026-09-07","days":21},{"id":"ramp-201","kind":"trial","name":"RAMP 201","route":"/trials/ramp-201/","asOf":"2026-09-07","days":21},{"id":"rejoice-ovarian01","kind":"trial","name":"REJOICE-Ovarian01","route":"/trials/rejoice-ovarian01/","asOf":"2026-09-07","days":21},{"id":"rainfol-01","kind":"trial","name":"RAINFOL-01 (Rina-S)","route":"/trials/rainfol-01/","asOf":"2026-09-07","days":21},{"id":"ukctocs","kind":"trial","name":"UKCTOCS","route":"/trials/ukctocs/","asOf":"2026-09-07","days":21},{"id":"rucaparib","kind":"drug","name":"Rucaparib","route":"/drugs/rucaparib/","asOf":"2026-09-07","days":21},{"id":"avutometinib-defactinib","kind":"drug","name":"Avutometinib + defactinib","route":"/drugs/avutometinib-defactinib/","asOf":"2026-09-07","days":21},{"id":"trabectedin","kind":"drug","name":"Trabectedin","route":"/drugs/trabectedin/","asOf":"2026-09-07","days":21},{"id":"pegylated-liposomal-doxorubicin","kind":"drug","name":"Pegylated liposomal doxorubicin","route":"/drugs/pegylated-liposomal-doxorubicin/","asOf":"2026-09-07","days":21},{"id":"luveltamab-tazevibulin","kind":"drug","name":"Luveltamab tazevibulin","route":"/drugs/luveltamab-tazevibulin/","asOf":"2026-09-07","days":21},{"id":"rinatabart-sesutecan","kind":"drug","name":"Rinatabart sesutecan","route":"/drugs/rinatabart-sesutecan/","asOf":"2026-09-07","days":21},{"id":"karyopharm","kind":"company","name":"Karyopharm Therapeutics","route":"/companies/karyopharm/","asOf":"2026-09-07","days":21},{"id":"ca-125","kind":"term","name":"CA-125","route":"/terms/ca-125/","asOf":"2026-09-07","days":21},{"id":"lgsoc","kind":"term","name":"Low-grade serous ovarian cancer (LGSOC)","route":"/terms/lgsoc/","asOf":"2026-09-07","days":21},{"id":"hgsoc","kind":"term","name":"High-grade serous ovarian carcinoma (HGSOC)","route":"/terms/hgsoc/","asOf":"2026-09-07","days":21},{"id":"risk-reducing-salpingectomy","kind":"technology","name":"Risk-reducing and opportunistic salpingectomy","route":"/technologies/risk-reducing-salpingectomy/","asOf":"2026-09-07","days":21},{"id":"parp-plus-bevacizumab","kind":"pairing","name":"PARP inhibitor + bevacizumab maintenance (HRD-positive)","route":"/pairings/parp-plus-bevacizumab/","asOf":"2026-09-07","days":21},{"id":"hipec-at-interval-surgery","kind":"pairing","name":"HIPEC at interval cytoreductive surgery","route":"/pairings/hipec-at-interval-surgery/","asOf":"2026-09-07","days":21},{"id":"caution-pd1-first-line-ovarian","kind":"pairing","name":"Caution: checkpoint inhibitors in first-line ovarian cancer","route":"/pairings/caution-pd1-first-line-ovarian/","asOf":"2026-09-07","days":21},{"id":"idea-fra-adc-sequencing-ovarian","kind":"idea","name":"Sequence folate-receptor ADCs by payload class","route":"/ideas/idea-fra-adc-sequencing-ovarian/","asOf":"2026-09-07","days":21},{"id":"idea-ctdna-guided-parp-duration","kind":"idea","name":"ctDNA-guided duration of PARP maintenance","route":"/ideas/idea-ctdna-guided-parp-duration/","asOf":"2026-09-07","days":21},{"id":"ruby","kind":"trial","name":"RUBY / ENGOT-EN6 / GOG-3031","route":"/trials/ruby/","asOf":"2026-09-07","days":21},{"id":"nrg-gy018-keynote-868","kind":"trial","name":"NRG-GY018 / KEYNOTE-868","route":"/trials/nrg-gy018-keynote-868/","asOf":"2026-09-07","days":21},{"id":"duo-e","kind":"trial","name":"DUO-E / GOG-3041 / ENGOT-EN10","route":"/trials/duo-e/","asOf":"2026-09-07","days":21},{"id":"keynote-775","kind":"trial","name":"KEYNOTE-775 / Study 309","route":"/trials/keynote-775/","asOf":"2026-09-07","days":21},{"id":"portec-3","kind":"trial","name":"PORTEC-3","route":"/trials/portec-3/","asOf":"2026-09-07","days":21},{"id":"destiny-pantumor02","kind":"trial","name":"DESTINY-PanTumor02","route":"/trials/destiny-pantumor02/","asOf":"2026-09-07","days":21},{"id":"xport-ec-042","kind":"trial","name":"XPORT-EC-042 / ENGOT-EN20 / GOG-3083","route":"/trials/xport-ec-042/","asOf":"2026-09-07","days":21},{"id":"fires-sentor","kind":"trial","name":"FIRES & SENTOR (sentinel node mapping)","route":"/trials/fires-sentor/","asOf":"2026-09-07","days":21},{"id":"selinexor","kind":"drug","name":"Selinexor","route":"/drugs/selinexor/","asOf":"2026-09-07","days":21},{"id":"megestrol-progestins","kind":"drug","name":"Progestins (megestrol acetate, medroxyprogesterone, levonorgestrel IUD)","route":"/drugs/megestrol-progestins/","asOf":"2026-09-07","days":21},{"id":"endometrial-molecular-classes","kind":"term","name":"Endometrial cancer molecular classes (POLEmut, MMRd, p53abn, NSMP)","route":"/terms/endometrial-molecular-classes/","asOf":"2026-09-07","days":21},{"id":"fertility-sparing-endometrial","kind":"technology","name":"Fertility-sparing hormonal treatment of early endometrial cancer","route":"/technologies/fertility-sparing-endometrial/","asOf":"2026-09-07","days":21},{"id":"chemo-io-first-line-endometrial","kind":"pairing","name":"Chemotherapy + PD-1/PD-L1 blockade, first-line advanced endometrial cancer","route":"/pairings/chemo-io-first-line-endometrial/","asOf":"2026-09-07","days":21},{"id":"lenvatinib-plus-pembrolizumab","kind":"pairing","name":"Lenvatinib + pembrolizumab (pMMR endometrial cancer after platinum)","route":"/pairings/lenvatinib-plus-pembrolizumab/","asOf":"2026-09-07","days":21},{"id":"idea-molecular-class-adjuvant-endometrial","kind":"idea","name":"Molecular-class-directed adjuvant therapy in endometrial cancer","route":"/ideas/idea-molecular-class-adjuvant-endometrial/","asOf":"2026-09-07","days":21},{"id":"idea-her2-adc-serous-endometrial","kind":"idea","name":"HER2 ADCs as standard for HER2-positive serous endometrial cancer","route":"/ideas/idea-her2-adc-serous-endometrial/","asOf":"2026-09-07","days":21},{"id":"keynote-a18","kind":"trial","name":"KEYNOTE-A18 / ENGOT-cx11 / GOG-3047","route":"/trials/keynote-a18/","asOf":"2026-09-07","days":21},{"id":"interlace","kind":"trial","name":"INTERLACE","route":"/trials/interlace/","asOf":"2026-09-07","days":21},{"id":"keynote-826","kind":"trial","name":"KEYNOTE-826","route":"/trials/keynote-826/","asOf":"2026-09-07","days":21},{"id":"beatcc","kind":"trial","name":"BEATcc / ENGOT-Cx10 / GOG-3030","route":"/trials/beatcc/","asOf":"2026-09-07","days":21},{"id":"compassion-16","kind":"trial","name":"COMPASSION-16 / AK104-303","route":"/trials/compassion-16/","asOf":"2026-09-07","days":21},{"id":"innovatv-301","kind":"trial","name":"innovaTV 301 / ENGOT-cx12 / GOG-3057","route":"/trials/innovatv-301/","asOf":"2026-09-07","days":21},{"id":"empower-cervical-1","kind":"trial","name":"EMPOWER-Cervical 1 / GOG-3016 / ENGOT-cx9","route":"/trials/empower-cervical-1/","asOf":"2026-09-07","days":21},{"id":"outback","kind":"trial","name":"OUTBACK / ANZGOG 0902 / GOG-0274","route":"/trials/outback/","asOf":"2026-09-07","days":21},{"id":"lacc","kind":"trial","name":"LACC (Laparoscopic Approach to Cervical Cancer)","route":"/trials/lacc/","asOf":"2026-09-07","days":21},{"id":"ken-she","kind":"trial","name":"KEN SHE (single-dose HPV vaccine)","route":"/trials/ken-she/","asOf":"2026-09-07","days":21},{"id":"senticol-iii","kind":"trial","name":"SENTICOL III","route":"/trials/senticol-iii/","asOf":"2026-09-07","days":21},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/","asOf":"2026-09-07","days":21},{"id":"cadonilimab","kind":"drug","name":"Cadonilimab","route":"/drugs/cadonilimab/","asOf":"2026-09-07","days":21},{"id":"gardasil-9","kind":"drug","name":"Nonavalent HPV vaccine","route":"/drugs/gardasil-9/","asOf":"2026-09-07","days":21},{"id":"cin-hsil","kind":"term","name":"Cervical precancer (CIN, HSIL/LSIL)","route":"/terms/cin-hsil/","asOf":"2026-09-07","days":21},{"id":"hpv-testing","kind":"technology","name":"HPV DNA testing and self-sampling","route":"/technologies/hpv-testing/","asOf":"2026-09-07","days":21},{"id":"colposcopy-excision","kind":"technology","name":"Colposcopy and excisional treatment (LEEP/LLETZ, cone)","route":"/technologies/colposcopy-excision/","asOf":"2026-09-07","days":21},{"id":"precancer-ablation","kind":"technology","name":"Thermal ablation and cryotherapy for cervical precancer","route":"/technologies/precancer-ablation/","asOf":"2026-09-07","days":21},{"id":"induction-chemo-then-crt","kind":"pairing","name":"Induction chemotherapy → chemoradiation (locally advanced cervical cancer)","route":"/pairings/induction-chemo-then-crt/","asOf":"2026-09-07","days":21},{"id":"io-plus-crt-cervical","kind":"pairing","name":"PD-1 blockade + chemoradiation (locally advanced cervical cancer)","route":"/pairings/io-plus-crt-cervical/","asOf":"2026-09-07","days":21},{"id":"caution-mis-radical-hysterectomy","kind":"pairing","name":"Caution: minimally invasive radical hysterectomy for early cervical cancer","route":"/pairings/caution-mis-radical-hysterectomy/","asOf":"2026-09-07","days":21},{"id":"idea-single-dose-hpv-self-sampling-elimination","kind":"idea","name":"Single-dose HPV vaccination plus HPV self-sampling to reach WHO elimination in low-income countries","route":"/ideas/idea-single-dose-hpv-self-sampling-elimination/","asOf":"2026-09-07","days":21},{"id":"idea-hpv-ctdna-cervical","kind":"idea","name":"HPV circulating tumour DNA to guide cervical cancer therapy","route":"/ideas/idea-hpv-ctdna-cervical/","asOf":"2026-09-07","days":21},{"id":"kura-oncology","kind":"company","name":"Kura Oncology","route":"/companies/kura-oncology/","asOf":"2026-09-07","days":21},{"id":"taiho-oncology","kind":"company","name":"Taiho Oncology (Otsuka)","route":"/companies/taiho-oncology/","asOf":"2026-09-07","days":21},{"id":"rigel-pharmaceuticals","kind":"company","name":"Rigel Pharmaceuticals","route":"/companies/rigel-pharmaceuticals/","asOf":"2026-09-07","days":21},{"id":"kmt2a","kind":"target","name":"KMT2A (MLL) rearrangement","route":"/targets/kmt2a/","asOf":"2026-09-07","days":21},{"id":"npm1","kind":"target","name":"NPM1 mutation","route":"/targets/npm1/","asOf":"2026-09-07","days":21},{"id":"cd22","kind":"target","name":"CD22","route":"/targets/cd22/","asOf":"2026-09-07","days":21},{"id":"btk","kind":"target","name":"BTK (Bruton tyrosine kinase)","route":"/targets/btk/","asOf":"2026-09-07","days":21},{"id":"bcr-abl","kind":"target","name":"BCR::ABL1 (Philadelphia chromosome)","route":"/targets/bcr-abl/","asOf":"2026-09-07","days":21},{"id":"allogeneic-hsct","kind":"technology","name":"Allogeneic stem cell transplantation","route":"/technologies/allogeneic-hsct/","asOf":"2026-09-07","days":21},{"id":"flow-cytometry-mrd","kind":"technology","name":"Multiparameter flow cytometry MRD","route":"/technologies/flow-cytometry-mrd/","asOf":"2026-09-07","days":21},{"id":"ngs-mrd-clonoseq","kind":"technology","name":"NGS-based MRD (clonoSEQ and molecular MRD)","route":"/technologies/ngs-mrd-clonoseq/","asOf":"2026-09-07","days":21},{"id":"cytogenetics-fish","kind":"technology","name":"Cytogenetics and FISH","route":"/technologies/cytogenetics-fish/","asOf":"2026-09-07","days":21},{"id":"bh3-profiling","kind":"technology","name":"BH3 profiling (functional apoptosis testing)","route":"/technologies/bh3-profiling/","asOf":"2026-09-07","days":21},{"id":"eln-risk","kind":"term","name":"ELN 2022 risk classification","route":"/terms/eln-risk/","asOf":"2026-09-07","days":21},{"id":"flt3-itd-allelic-ratio","kind":"term","name":"FLT3-ITD allelic ratio","route":"/terms/flt3-itd-allelic-ratio/","asOf":"2026-09-07","days":21},{"id":"ighv-status","kind":"term","name":"IGHV mutational status","route":"/terms/ighv-status/","asOf":"2026-09-07","days":21},{"id":"del17p-tp53","kind":"term","name":"del(17p) / TP53 aberration in CLL","route":"/terms/del17p-tp53/","asOf":"2026-09-07","days":21},{"id":"richter-transformation","kind":"term","name":"Richter transformation","route":"/terms/richter-transformation/","asOf":"2026-09-07","days":21},{"id":"mrd-negative-cr","kind":"term","name":"MRD-negative complete remission","route":"/terms/mrd-negative-cr/","asOf":"2026-09-07","days":21},{"id":"tumor-lysis-syndrome","kind":"term","name":"Tumour lysis syndrome (TLS)","route":"/terms/tumor-lysis-syndrome/","asOf":"2026-09-07","days":21},{"id":"differentiation-syndrome","kind":"term","name":"Differentiation syndrome","route":"/terms/differentiation-syndrome/","asOf":"2026-09-07","days":21},{"id":"ph-positive-all","kind":"term","name":"Ph-positive ALL","route":"/terms/ph-positive-all/","asOf":"2026-09-07","days":21},{"id":"azacitidine","kind":"drug","name":"Azacitidine","route":"/drugs/azacitidine/","asOf":"2026-09-07","days":21},{"id":"decitabine-cedazuridine","kind":"drug","name":"Decitabine + cedazuridine (oral)","route":"/drugs/decitabine-cedazuridine/","asOf":"2026-09-07","days":21},{"id":"cytarabine-7-3","kind":"drug","name":"Cytarabine + anthracycline ('7+3')","route":"/drugs/cytarabine-7-3/","asOf":"2026-09-07","days":21},{"id":"cpx-351","kind":"drug","name":"CPX-351 (liposomal daunorubicin-cytarabine)","route":"/drugs/cpx-351/","asOf":"2026-09-07","days":21},{"id":"midostaurin","kind":"drug","name":"Midostaurin","route":"/drugs/midostaurin/","asOf":"2026-09-07","days":21},{"id":"quizartinib","kind":"drug","name":"Quizartinib","route":"/drugs/quizartinib/","asOf":"2026-09-07","days":21},{"id":"gilteritinib","kind":"drug","name":"Gilteritinib","route":"/drugs/gilteritinib/","asOf":"2026-09-07","days":21},{"id":"enasidenib","kind":"drug","name":"Enasidenib","route":"/drugs/enasidenib/","asOf":"2026-09-07","days":21},{"id":"olutasidenib","kind":"drug","name":"Olutasidenib","route":"/drugs/olutasidenib/","asOf":"2026-09-07","days":21},{"id":"ziftomenib","kind":"drug","name":"Ziftomenib","route":"/drugs/ziftomenib/","asOf":"2026-09-07","days":21},{"id":"tagraxofusp","kind":"drug","name":"Tagraxofusp","route":"/drugs/tagraxofusp/","asOf":"2026-09-07","days":21},{"id":"ratify","kind":"trial","name":"RATIFY (CALGB 10603)","route":"/trials/ratify/","asOf":"2026-09-07","days":21},{"id":"viale-a","kind":"trial","name":"VIALE-A","route":"/trials/viale-a/","asOf":"2026-09-07","days":21},{"id":"quantum-first","kind":"trial","name":"QuANTUM-First","route":"/trials/quantum-first/","asOf":"2026-09-07","days":21},{"id":"admiral","kind":"trial","name":"ADMIRAL","route":"/trials/admiral/","asOf":"2026-09-07","days":21},{"id":"agile","kind":"trial","name":"AGILE","route":"/trials/agile/","asOf":"2026-09-07","days":21},{"id":"alfa-0701","kind":"trial","name":"ALFA-0701","route":"/trials/alfa-0701/","asOf":"2026-09-07","days":21},{"id":"augment-101","kind":"trial","name":"AUGMENT-101","route":"/trials/augment-101/","asOf":"2026-09-07","days":21},{"id":"komet-001","kind":"trial","name":"KOMET-001","route":"/trials/komet-001/","asOf":"2026-09-07","days":21},{"id":"cpx-351-301","kind":"trial","name":"CPX-351 Study 301","route":"/trials/cpx-351-301/","asOf":"2026-09-07","days":21},{"id":"ascertain-v","kind":"trial","name":"ASCERTAIN-V","route":"/trials/ascertain-v/","asOf":"2026-09-07","days":21},{"id":"myelomatch","kind":"trial","name":"myeloMATCH","route":"/trials/myelomatch/","asOf":"2026-09-07","days":21},{"id":"venetoclax-plus-hma","kind":"pairing","name":"Venetoclax + hypomethylating agent","route":"/pairings/venetoclax-plus-hma/","asOf":"2026-09-07","days":21},{"id":"flt3i-plus-7-3","kind":"pairing","name":"FLT3 inhibitor + intensive chemotherapy","route":"/pairings/flt3i-plus-7-3/","asOf":"2026-09-07","days":21},{"id":"menin-plus-venetoclax-hma","kind":"pairing","name":"Menin inhibitor + venetoclax + azacitidine","route":"/pairings/menin-plus-venetoclax-hma/","asOf":"2026-09-07","days":21},{"id":"idea-mrd-guided-transplant-aml","kind":"idea","name":"MRD-guided transplant decisions in intermediate-risk AML","route":"/ideas/idea-mrd-guided-transplant-aml/","asOf":"2026-09-07","days":21},{"id":"idea-shortened-venetoclax","kind":"idea","name":"Shorter venetoclax courses in unfit AML","route":"/ideas/idea-shortened-venetoclax/","asOf":"2026-09-07","days":21},{"id":"autolus","kind":"company","name":"Autolus Therapeutics","route":"/companies/autolus/","asOf":"2026-09-07","days":21},{"id":"adaptive-biotechnologies","kind":"company","name":"Adaptive Biotechnologies","route":"/companies/adaptive-biotechnologies/","asOf":"2026-09-07","days":21},{"id":"inotuzumab-ozogamicin","kind":"drug","name":"Inotuzumab ozogamicin","route":"/drugs/inotuzumab-ozogamicin/","asOf":"2026-09-07","days":21},{"id":"tisagenlecleucel","kind":"drug","name":"Tisagenlecleucel","route":"/drugs/tisagenlecleucel/","asOf":"2026-09-07","days":21},{"id":"obecabtagene-autoleucel","kind":"drug","name":"Obecabtagene autoleucel","route":"/drugs/obecabtagene-autoleucel/","asOf":"2026-09-07","days":21},{"id":"ponatinib","kind":"drug","name":"Ponatinib","route":"/drugs/ponatinib/","asOf":"2026-09-07","days":21},{"id":"dasatinib","kind":"drug","name":"Dasatinib","route":"/drugs/dasatinib/","asOf":"2026-09-07","days":21},{"id":"asciminib","kind":"drug","name":"Asciminib","route":"/drugs/asciminib/","asOf":"2026-09-07","days":21},{"id":"e1910","kind":"trial","name":"ECOG-ACRIN E1910","route":"/trials/e1910/","asOf":"2026-09-07","days":21},{"id":"aall1731","kind":"trial","name":"COG AALL1731","route":"/trials/aall1731/","asOf":"2026-09-07","days":21},{"id":"tower","kind":"trial","name":"TOWER","route":"/trials/tower/","asOf":"2026-09-07","days":21},{"id":"ino-vate","kind":"trial","name":"INO-VATE ALL","route":"/trials/ino-vate/","asOf":"2026-09-07","days":21},{"id":"eliana","kind":"trial","name":"ELIANA","route":"/trials/eliana/","asOf":"2026-09-07","days":21},{"id":"felix","kind":"trial","name":"FELIX","route":"/trials/felix/","asOf":"2026-09-07","days":21},{"id":"phallcon","kind":"trial","name":"PhALLCON","route":"/trials/phallcon/","asOf":"2026-09-07","days":21},{"id":"d-alba","kind":"trial","name":"D-ALBA (GIMEMA LAL2116)","route":"/trials/d-alba/","asOf":"2026-09-07","days":21},{"id":"interfant-06","kind":"trial","name":"Interfant-06","route":"/trials/interfant-06/","asOf":"2026-09-07","days":21},{"id":"tki-plus-blinatumomab-ph-all","kind":"pairing","name":"BCR::ABL1 TKI + blinatumomab (chemotherapy-free Ph+ ALL)","route":"/pairings/tki-plus-blinatumomab-ph-all/","asOf":"2026-09-07","days":21},{"id":"blinatumomab-frontline-consolidation","kind":"pairing","name":"Blinatumomab added to frontline chemotherapy","route":"/pairings/blinatumomab-frontline-consolidation/","asOf":"2026-09-07","days":21},{"id":"inotuzumab-then-transplant-caution","kind":"pairing","name":"Caution: inotuzumab before transplant (veno-occlusive disease)","route":"/pairings/inotuzumab-then-transplant-caution/","asOf":"2026-09-07","days":21},{"id":"idea-transplant-free-ph-all","kind":"idea","name":"Transplant-free Ph-positive ALL for MRD-negative adults","route":"/ideas/idea-transplant-free-ph-all/","asOf":"2026-09-07","days":21},{"id":"idea-menin-infant-all","kind":"idea","name":"Menin inhibitors for infant KMT2A-rearranged ALL","route":"/ideas/idea-menin-infant-all/","asOf":"2026-09-07","days":21},{"id":"ibrutinib","kind":"drug","name":"Ibrutinib","route":"/drugs/ibrutinib/","asOf":"2026-09-07","days":21},{"id":"acalabrutinib","kind":"drug","name":"Acalabrutinib","route":"/drugs/acalabrutinib/","asOf":"2026-09-07","days":21},{"id":"zanubrutinib","kind":"drug","name":"Zanubrutinib","route":"/drugs/zanubrutinib/","asOf":"2026-09-07","days":21},{"id":"pirtobrutinib","kind":"drug","name":"Pirtobrutinib","route":"/drugs/pirtobrutinib/","asOf":"2026-09-07","days":21},{"id":"obinutuzumab","kind":"drug","name":"Obinutuzumab","route":"/drugs/obinutuzumab/","asOf":"2026-09-07","days":21},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/","asOf":"2026-09-07","days":21},{"id":"lisocabtagene-maraleucel","kind":"drug","name":"Lisocabtagene maraleucel","route":"/drugs/lisocabtagene-maraleucel/","asOf":"2026-09-07","days":21},{"id":"sonrotoclax","kind":"drug","name":"Sonrotoclax","route":"/drugs/sonrotoclax/","asOf":"2026-09-07","days":21},{"id":"bgb-16673","kind":"drug","name":"BGB-16673","route":"/drugs/bgb-16673/","asOf":"2026-09-07","days":21},{"id":"nemtabrutinib","kind":"drug","name":"Nemtabrutinib","route":"/drugs/nemtabrutinib/","asOf":"2026-09-07","days":21},{"id":"resonate","kind":"trial","name":"RESONATE","route":"/trials/resonate/","asOf":"2026-09-07","days":21},{"id":"cll14","kind":"trial","name":"CLL14","route":"/trials/cll14/","asOf":"2026-09-07","days":21},{"id":"cll13-gaia","kind":"trial","name":"CLL13 / GAIA","route":"/trials/cll13-gaia/","asOf":"2026-09-07","days":21},{"id":"elevate-tn","kind":"trial","name":"ELEVATE-TN","route":"/trials/elevate-tn/","asOf":"2026-09-07","days":21},{"id":"sequoia","kind":"trial","name":"SEQUOIA","route":"/trials/sequoia/","asOf":"2026-09-07","days":21},{"id":"alpine","kind":"trial","name":"ALPINE","route":"/trials/alpine/","asOf":"2026-09-07","days":21},{"id":"captivate","kind":"trial","name":"CAPTIVATE","route":"/trials/captivate/","asOf":"2026-09-07","days":21},{"id":"glow","kind":"trial","name":"GLOW","route":"/trials/glow/","asOf":"2026-09-07","days":21},{"id":"amplify","kind":"trial","name":"AMPLIFY","route":"/trials/amplify/","asOf":"2026-09-07","days":21},{"id":"bruin-cll-321","kind":"trial","name":"BRUIN CLL-321","route":"/trials/bruin-cll-321/","asOf":"2026-09-07","days":21},{"id":"transcend-cll-004","kind":"trial","name":"TRANSCEND CLL 004","route":"/trials/transcend-cll-004/","asOf":"2026-09-07","days":21},{"id":"celestial-tncll","kind":"trial","name":"CELESTIAL-TNCLL","route":"/trials/celestial-tncll/","asOf":"2026-09-07","days":21},{"id":"cadance-304","kind":"trial","name":"CaDAnCe-304","route":"/trials/cadance-304/","asOf":"2026-09-07","days":21},{"id":"bellwave-011","kind":"trial","name":"BELLWAVE-011","route":"/trials/bellwave-011/","asOf":"2026-09-07","days":21},{"id":"btki-plus-venetoclax-fixed-duration","kind":"pairing","name":"BTK inhibitor + venetoclax, fixed duration","route":"/pairings/btki-plus-venetoclax-fixed-duration/","asOf":"2026-09-07","days":21},{"id":"venetoclax-plus-obinutuzumab","kind":"pairing","name":"Venetoclax + obinutuzumab (12 months)","route":"/pairings/venetoclax-plus-obinutuzumab/","asOf":"2026-09-07","days":21},{"id":"cit-in-del17p-caution","kind":"pairing","name":"Caution: chemoimmunotherapy in del(17p)/TP53 CLL","route":"/pairings/cit-in-del17p-caution/","asOf":"2026-09-07","days":21},{"id":"btki-ibrutinib-cardiac-caution","kind":"pairing","name":"Caution: ibrutinib in patients with cardiac risk","route":"/pairings/btki-ibrutinib-cardiac-caution/","asOf":"2026-09-07","days":21},{"id":"idea-mrd-guided-stop-cll","kind":"idea","name":"MRD-guided treatment duration in CLL","route":"/ideas/idea-mrd-guided-stop-cll/","asOf":"2026-09-07","days":21},{"id":"idea-btk-degrader-frontline","kind":"idea","name":"BTK degraders to pre-empt resistance in frontline CLL","route":"/ideas/idea-btk-degrader-frontline/","asOf":"2026-09-07","days":21},{"id":"ctdna-lymphoma-monitoring","kind":"technology","name":"ctDNA monitoring in lymphoma (PhasED-seq, clonoSEQ)","route":"/technologies/ctdna-lymphoma-monitoring/","asOf":"2026-09-07","days":21},{"id":"ipi-score","kind":"term","name":"International Prognostic Index (IPI)","route":"/terms/ipi-score/","asOf":"2026-09-07","days":21},{"id":"cell-of-origin","kind":"term","name":"Cell of origin (GCB vs ABC)","route":"/terms/cell-of-origin/","asOf":"2026-09-07","days":21},{"id":"double-hit-lymphoma","kind":"term","name":"Double-hit / high-grade B-cell lymphoma","route":"/terms/double-hit-lymphoma/","asOf":"2026-09-07","days":21},{"id":"lugano-classification","kind":"term","name":"Lugano classification / Ann Arbor staging","route":"/terms/lugano-classification/","asOf":"2026-09-07","days":21},{"id":"polatuzumab-vedotin","kind":"drug","name":"Polatuzumab vedotin","route":"/drugs/polatuzumab-vedotin/","asOf":"2026-09-07","days":21},{"id":"epcoritamab","kind":"drug","name":"Epcoritamab","route":"/drugs/epcoritamab/","asOf":"2026-09-07","days":21},{"id":"tafasitamab","kind":"drug","name":"Tafasitamab","route":"/drugs/tafasitamab/","asOf":"2026-09-07","days":21},{"id":"mosunetuzumab","kind":"drug","name":"Mosunetuzumab","route":"/drugs/mosunetuzumab/","asOf":"2026-09-07","days":21},{"id":"odronextamab","kind":"drug","name":"Odronextamab","route":"/drugs/odronextamab/","asOf":"2026-09-07","days":21},{"id":"golcadomide","kind":"drug","name":"Golcadomide","route":"/drugs/golcadomide/","asOf":"2026-09-07","days":21},{"id":"polarix","kind":"trial","name":"POLARIX","route":"/trials/polarix/","asOf":"2026-09-07","days":21},{"id":"zuma-7","kind":"trial","name":"ZUMA-7","route":"/trials/zuma-7/","asOf":"2026-09-07","days":21},{"id":"transform","kind":"trial","name":"TRANSFORM","route":"/trials/transform/","asOf":"2026-09-07","days":21},{"id":"starglo","kind":"trial","name":"STARGLO","route":"/trials/starglo/","asOf":"2026-09-07","days":21},{"id":"epcore-nhl-1","kind":"trial","name":"EPCORE NHL-1","route":"/trials/epcore-nhl-1/","asOf":"2026-09-07","days":21},{"id":"epcore-dlbcl-1","kind":"trial","name":"EPCORE DLBCL-1","route":"/trials/epcore-dlbcl-1/","asOf":"2026-09-07","days":21},{"id":"epcore-dlbcl-2","kind":"trial","name":"EPCORE DLBCL-2","route":"/trials/epcore-dlbcl-2/","asOf":"2026-09-07","days":21},{"id":"frontmind","kind":"trial","name":"frontMIND","route":"/trials/frontmind/","asOf":"2026-09-07","days":21},{"id":"l-mind","kind":"trial","name":"L-MIND","route":"/trials/l-mind/","asOf":"2026-09-07","days":21},{"id":"lotis-2","kind":"trial","name":"LOTIS-2","route":"/trials/lotis-2/","asOf":"2026-09-07","days":21},{"id":"waveline-003","kind":"trial","name":"waveLINE-003","route":"/trials/waveline-003/","asOf":"2026-09-07","days":21},{"id":"sunmo","kind":"trial","name":"SUNMO","route":"/trials/sunmo/","asOf":"2026-09-07","days":21},{"id":"golseek-1","kind":"trial","name":"GOLSEEK-1","route":"/trials/golseek-1/","asOf":"2026-09-07","days":21},{"id":"belinda","kind":"trial","name":"BELINDA","route":"/trials/belinda/","asOf":"2026-09-07","days":21},{"id":"bispecific-plus-adc-lymphoma","kind":"pairing","name":"CD20 bispecific + CD79b ADC (mosunetuzumab + polatuzumab)","route":"/pairings/bispecific-plus-adc-lymphoma/","asOf":"2026-09-07","days":21},{"id":"car-t-before-transplant-lbcl","kind":"pairing","name":"Early relapse: CAR-T before transplant","route":"/pairings/car-t-before-transplant-lbcl/","asOf":"2026-09-07","days":21},{"id":"idea-ctdna-guided-dlbcl-frontline","kind":"idea","name":"ctDNA-guided escalation and de-escalation in frontline DLBCL","route":"/ideas/idea-ctdna-guided-dlbcl-frontline/","asOf":"2026-09-07","days":21},{"id":"idea-bispecific-vs-car-t-second-line","kind":"idea","name":"Head-to-head bispecific vs CAR-T in second-line LBCL","route":"/ideas/idea-bispecific-vs-car-t-second-line/","asOf":"2026-09-07","days":21},{"id":"autologous-stem-cell-transplant","kind":"technology","name":"Autologous stem cell transplant (high-dose therapy)","route":"/technologies/autologous-stem-cell-transplant/","asOf":"2026-09-07","days":21},{"id":"r-iss","kind":"term","name":"R-ISS / R2-ISS staging","route":"/terms/r-iss/","asOf":"2026-09-07","days":21},{"id":"high-risk-myeloma","kind":"term","name":"High-risk cytogenetics (myeloma)","route":"/terms/high-risk-myeloma/","asOf":"2026-09-07","days":21},{"id":"mrd-negativity-myeloma","kind":"term","name":"MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶)","route":"/terms/mrd-negativity-myeloma/","asOf":"2026-09-07","days":21},{"id":"smoldering-myeloma","kind":"term","name":"Smouldering myeloma / MGUS","route":"/terms/smoldering-myeloma/","asOf":"2026-09-07","days":21},{"id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/","asOf":"2026-09-07","days":21},{"id":"bortezomib","kind":"drug","name":"Bortezomib","route":"/drugs/bortezomib/","asOf":"2026-09-07","days":21},{"id":"carfilzomib","kind":"drug","name":"Carfilzomib","route":"/drugs/carfilzomib/","asOf":"2026-09-07","days":21},{"id":"daratumumab","kind":"drug","name":"Daratumumab","route":"/drugs/daratumumab/","asOf":"2026-09-07","days":21},{"id":"isatuximab","kind":"drug","name":"Isatuximab","route":"/drugs/isatuximab/","asOf":"2026-09-07","days":21},{"id":"idecabtagene-vicleucel","kind":"drug","name":"Idecabtagene vicleucel","route":"/drugs/idecabtagene-vicleucel/","asOf":"2026-09-07","days":21},{"id":"anitocabtagene-autoleucel","kind":"drug","name":"Anitocabtagene autoleucel","route":"/drugs/anitocabtagene-autoleucel/","asOf":"2026-09-07","days":21},{"id":"elranatamab","kind":"drug","name":"Elranatamab","route":"/drugs/elranatamab/","asOf":"2026-09-07","days":21},{"id":"talquetamab","kind":"drug","name":"Talquetamab","route":"/drugs/talquetamab/","asOf":"2026-09-07","days":21},{"id":"linvoseltamab","kind":"drug","name":"Linvoseltamab","route":"/drugs/linvoseltamab/","asOf":"2026-09-07","days":21},{"id":"iberdomide","kind":"drug","name":"Iberdomide","route":"/drugs/iberdomide/","asOf":"2026-09-07","days":21},{"id":"mezigdomide","kind":"drug","name":"Mezigdomide","route":"/drugs/mezigdomide/","asOf":"2026-09-07","days":21},{"id":"perseus","kind":"trial","name":"PERSEUS","route":"/trials/perseus/","asOf":"2026-09-07","days":21},{"id":"cepheus","kind":"trial","name":"CEPHEUS","route":"/trials/cepheus/","asOf":"2026-09-07","days":21},{"id":"imroz","kind":"trial","name":"IMROZ","route":"/trials/imroz/","asOf":"2026-09-07","days":21},{"id":"cartitude-1","kind":"trial","name":"CARTITUDE-1","route":"/trials/cartitude-1/","asOf":"2026-09-07","days":21},{"id":"cartitude-4","kind":"trial","name":"CARTITUDE-4","route":"/trials/cartitude-4/","asOf":"2026-09-07","days":21},{"id":"karmma-3","kind":"trial","name":"KarMMa-3","route":"/trials/karmma-3/","asOf":"2026-09-07","days":21},{"id":"majestec-1","kind":"trial","name":"MajesTEC-1","route":"/trials/majestec-1/","asOf":"2026-09-07","days":21},{"id":"majestec-3","kind":"trial","name":"MajesTEC-3","route":"/trials/majestec-3/","asOf":"2026-09-07","days":21},{"id":"magnetismm-3","kind":"trial","name":"MagnetisMM-3","route":"/trials/magnetismm-3/","asOf":"2026-09-07","days":21},{"id":"monumental-1","kind":"trial","name":"MonumenTAL-1","route":"/trials/monumental-1/","asOf":"2026-09-07","days":21},{"id":"linker-mm1","kind":"trial","name":"LINKER-MM1","route":"/trials/linker-mm1/","asOf":"2026-09-07","days":21},{"id":"dreamm-7","kind":"trial","name":"DREAMM-7","route":"/trials/dreamm-7/","asOf":"2026-09-07","days":21},{"id":"dreamm-8","kind":"trial","name":"DREAMM-8","route":"/trials/dreamm-8/","asOf":"2026-09-07","days":21},{"id":"immagine-1","kind":"trial","name":"iMMagine-1","route":"/trials/immagine-1/","asOf":"2026-09-07","days":21},{"id":"cartitude-5","kind":"trial","name":"CARTITUDE-5","route":"/trials/cartitude-5/","asOf":"2026-09-07","days":21},{"id":"istopmm","kind":"trial","name":"iStopMM","route":"/trials/istopmm/","asOf":"2026-09-07","days":21},{"id":"cd38-plus-triplet","kind":"pairing","name":"CD38 antibody added to PI-IMiD-dex (quadruplet induction)","route":"/pairings/cd38-plus-triplet/","asOf":"2026-09-07","days":21},{"id":"bcma-then-gprc5d","kind":"pairing","name":"BCMA-directed therapy → GPRC5D-directed therapy","route":"/pairings/bcma-then-gprc5d/","asOf":"2026-09-07","days":21},{"id":"bispecific-infection-prophylaxis","kind":"pairing","name":"Caution: T-cell redirectors and infections","route":"/pairings/bispecific-infection-prophylaxis/","asOf":"2026-09-07","days":21},{"id":"idea-mrd-guided-stop-myeloma","kind":"idea","name":"MRD-guided treatment-free intervals in myeloma","route":"/ideas/idea-mrd-guided-stop-myeloma/","asOf":"2026-09-07","days":21},{"id":"idea-car-t-replaces-transplant","kind":"idea","name":"One CAR-T infusion instead of autologous transplant","route":"/ideas/idea-car-t-replaces-transplant/","asOf":"2026-09-07","days":21},{"id":"cd30","kind":"target","name":"CD30","route":"/targets/cd30/","asOf":"2026-09-07","days":21},{"id":"pet-adapted-therapy","kind":"technology","name":"PET-adapted (response-adapted) therapy","route":"/technologies/pet-adapted-therapy/","asOf":"2026-09-07","days":21},{"id":"deauville-score","kind":"term","name":"Deauville five-point scale","route":"/terms/deauville-score/","asOf":"2026-09-07","days":21},{"id":"reed-sternberg-cell","kind":"term","name":"Reed-Sternberg cell","route":"/terms/reed-sternberg-cell/","asOf":"2026-09-07","days":21},{"id":"echelon-1","kind":"trial","name":"ECHELON-1","route":"/trials/echelon-1/","asOf":"2026-09-07","days":21},{"id":"swog-s1826","kind":"trial","name":"SWOG S1826","route":"/trials/swog-s1826/","asOf":"2026-09-07","days":21},{"id":"hd21","kind":"trial","name":"GHSG HD21","route":"/trials/hd21/","asOf":"2026-09-07","days":21},{"id":"rathl","kind":"trial","name":"RATHL","route":"/trials/rathl/","asOf":"2026-09-07","days":21},{"id":"keynote-204","kind":"trial","name":"KEYNOTE-204","route":"/trials/keynote-204/","asOf":"2026-09-07","days":21},{"id":"checkmate-205","kind":"trial","name":"CheckMate 205","route":"/trials/checkmate-205/","asOf":"2026-09-07","days":21},{"id":"ahod2131","kind":"trial","name":"AHOD2131 (COG / NCTN)","route":"/trials/ahod2131/","asOf":"2026-09-07","days":21},{"id":"aethera","kind":"trial","name":"AETHERA","route":"/trials/aethera/","asOf":"2026-09-07","days":21},{"id":"pd1-plus-avd-hodgkin","kind":"pairing","name":"PD-1 blockade + AVD chemotherapy","route":"/pairings/pd1-plus-avd-hodgkin/","asOf":"2026-09-07","days":21},{"id":"bleomycin-omission-caution","kind":"pairing","name":"Caution: bleomycin lung toxicity, especially with brentuximab or G-CSF","route":"/pairings/bleomycin-omission-caution/","asOf":"2026-09-07","days":21},{"id":"idea-chemo-free-hodgkin","kind":"idea","name":"Chemotherapy-free Hodgkin lymphoma: brentuximab + PD-1 in early stage","route":"/ideas/idea-chemo-free-hodgkin/","asOf":"2026-09-07","days":21},{"id":"idea-cd30-car-t-hodgkin","kind":"idea","name":"CD30 CAR-T for multiply relapsed Hodgkin lymphoma","route":"/ideas/idea-cd30-car-t-hodgkin/","asOf":"2026-09-07","days":21},{"id":"deciphera","kind":"company","name":"Deciphera Pharmaceuticals (Ono)","route":"/companies/deciphera/","asOf":"2026-09-07","days":21},{"id":"springworks","kind":"company","name":"SpringWorks Therapeutics (Merck KGaA)","route":"/companies/springworks/","asOf":"2026-09-07","days":21},{"id":"us-worldmeds","kind":"company","name":"US WorldMeds","route":"/companies/us-worldmeds/","asOf":"2026-09-07","days":21},{"id":"limb-salvage-surgery","kind":"technology","name":"Limb-salvage surgery and endoprosthetic reconstruction","route":"/technologies/limb-salvage-surgery/","asOf":"2026-09-07","days":21},{"id":"fnclcc-grade","kind":"term","name":"FNCLCC grade (soft-tissue sarcoma)","route":"/terms/fnclcc-grade/","asOf":"2026-09-07","days":21},{"id":"sarcoma-histotype-tailoring","kind":"term","name":"Histotype-tailored therapy","route":"/terms/sarcoma-histotype-tailoring/","asOf":"2026-09-07","days":21},{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/","asOf":"2026-09-07","days":21},{"id":"ifosfamide","kind":"drug","name":"Ifosfamide","route":"/drugs/ifosfamide/","asOf":"2026-09-07","days":21},{"id":"pazopanib","kind":"drug","name":"Pazopanib","route":"/drugs/pazopanib/","asOf":"2026-09-07","days":21},{"id":"ripretinib","kind":"drug","name":"Ripretinib","route":"/drugs/ripretinib/","asOf":"2026-09-07","days":21},{"id":"avapritinib","kind":"drug","name":"Avapritinib","route":"/drugs/avapritinib/","asOf":"2026-09-07","days":21},{"id":"nirogacestat","kind":"drug","name":"Nirogacestat","route":"/drugs/nirogacestat/","asOf":"2026-09-07","days":21},{"id":"vimseltinib","kind":"drug","name":"Vimseltinib","route":"/drugs/vimseltinib/","asOf":"2026-09-07","days":21},{"id":"letetresgene-autoleucel","kind":"drug","name":"Letetresgene autoleucel","route":"/drugs/letetresgene-autoleucel/","asOf":"2026-09-07","days":21},{"id":"isg-sts-1001","kind":"trial","name":"ISG-STS 1001","route":"/trials/isg-sts-1001/","asOf":"2026-09-07","days":21},{"id":"announce","kind":"trial","name":"ANNOUNCE","route":"/trials/announce/","asOf":"2026-09-07","days":21},{"id":"invictus","kind":"trial","name":"INVICTUS","route":"/trials/invictus/","asOf":"2026-09-07","days":21},{"id":"insight-gist","kind":"trial","name":"INSIGHT","route":"/trials/insight-gist/","asOf":"2026-09-07","days":21},{"id":"voyager","kind":"trial","name":"VOYAGER","route":"/trials/voyager/","asOf":"2026-09-07","days":21},{"id":"defi","kind":"trial","name":"DeFi","route":"/trials/defi/","asOf":"2026-09-07","days":21},{"id":"motion","kind":"trial","name":"MOTION","route":"/trials/motion/","asOf":"2026-09-07","days":21},{"id":"ignyte-eso","kind":"trial","name":"IGNYTE-ESO","route":"/trials/ignyte-eso/","asOf":"2026-09-07","days":21},{"id":"euro-ewing-2012","kind":"trial","name":"Euro Ewing 2012","route":"/trials/euro-ewing-2012/","asOf":"2026-09-07","days":21},{"id":"int-0091","kind":"trial","name":"INT-0091 (Ewing sarcoma)","route":"/trials/int-0091/","asOf":"2026-09-07","days":21},{"id":"ssgxviii","kind":"trial","name":"SSGXVIII/AIO (adjuvant imatinib in GIST)","route":"/trials/ssgxviii/","asOf":"2026-09-07","days":21},{"id":"ctdna-genotype-gist-tki","kind":"pairing","name":"ctDNA KIT genotyping → TKI selection in GIST","route":"/pairings/ctdna-genotype-gist-tki/","asOf":"2026-09-07","days":21},{"id":"doxorubicin-cardio-caution","kind":"pairing","name":"Caution: cumulative anthracycline dose and the heart","route":"/pairings/doxorubicin-cardio-caution/","asOf":"2026-09-07","days":21},{"id":"idea-tcr-t-beyond-hla-a2","kind":"idea","name":"Extending sarcoma TCR-T beyond HLA-A*02","route":"/ideas/idea-tcr-t-beyond-hla-a2/","asOf":"2026-09-07","days":21},{"id":"idea-desmoid-intermittent-dosing","kind":"idea","name":"Intermittent or stop-and-restart nirogacestat in desmoid tumours","route":"/ideas/idea-desmoid-intermittent-dosing/","asOf":"2026-09-07","days":21},{"id":"y-mabs","kind":"company","name":"Y-mAbs Therapeutics","route":"/companies/y-mabs/","asOf":"2026-09-07","days":21},{"id":"gd2","kind":"target","name":"GD2 (disialoganglioside)","route":"/targets/gd2/","asOf":"2026-09-07","days":21},{"id":"tandem-transplant","kind":"technology","name":"Tandem autologous transplant","route":"/technologies/tandem-transplant/","asOf":"2026-09-07","days":21},{"id":"mibg-theranostics","kind":"technology","name":"MIBG imaging and 131I-MIBG therapy","route":"/technologies/mibg-theranostics/","asOf":"2026-09-07","days":21},{"id":"inrg-staging","kind":"term","name":"INRG staging and risk groups","route":"/terms/inrg-staging/","asOf":"2026-09-07","days":21},{"id":"mycn-amplification","kind":"term","name":"MYCN amplification","route":"/terms/mycn-amplification/","asOf":"2026-09-07","days":21},{"id":"dinutuximab","kind":"drug","name":"Dinutuximab (ch14.18) / dinutuximab beta","route":"/drugs/dinutuximab/","asOf":"2026-09-07","days":21},{"id":"naxitamab","kind":"drug","name":"Naxitamab","route":"/drugs/naxitamab/","asOf":"2026-09-07","days":21},{"id":"eflornithine","kind":"drug","name":"Eflornithine (DFMO)","route":"/drugs/eflornithine/","asOf":"2026-09-07","days":21},{"id":"i131-mibg","kind":"drug","name":"131I-MIBG (iobenguane I-131) therapy","route":"/drugs/i131-mibg/","asOf":"2026-09-07","days":21},{"id":"anbl0032","kind":"trial","name":"COG ANBL0032","route":"/trials/anbl0032/","asOf":"2026-09-07","days":21},{"id":"anbl0532","kind":"trial","name":"COG ANBL0532","route":"/trials/anbl0532/","asOf":"2026-09-07","days":21},{"id":"hr-nbl1","kind":"trial","name":"SIOPEN HR-NBL1","route":"/trials/hr-nbl1/","asOf":"2026-09-07","days":21},{"id":"anbl1531","kind":"trial","name":"COG ANBL1531","route":"/trials/anbl1531/","asOf":"2026-09-07","days":21},{"id":"gd2-cart01","kind":"trial","name":"GD2-CART01 (Bambino Gesù phase 1/2)","route":"/trials/gd2-cart01/","asOf":"2026-09-07","days":21},{"id":"naxitamab-201","kind":"trial","name":"Naxitamab Study 201","route":"/trials/naxitamab-201/","asOf":"2026-09-07","days":21},{"id":"nmtrc003","kind":"trial","name":"NMTRC003/003B (DFMO maintenance)","route":"/trials/nmtrc003/","asOf":"2026-09-07","days":21},{"id":"anti-gd2-plus-chemo-relapse","kind":"pairing","name":"Anti-GD2 antibody + irinotecan-temozolomide (chemoimmunotherapy)","route":"/pairings/anti-gd2-plus-chemo-relapse/","asOf":"2026-09-07","days":21},{"id":"il2-anti-gd2-caution","kind":"pairing","name":"Caution: IL-2 added to anti-GD2 therapy","route":"/pairings/il2-anti-gd2-caution/","asOf":"2026-09-07","days":21},{"id":"idea-gd2-car-t-frontline-consolidation","kind":"idea","name":"GD2 CAR-T as consolidation in high-risk neuroblastoma","route":"/ideas/idea-gd2-car-t-frontline-consolidation/","asOf":"2026-09-07","days":21},{"id":"idea-mfbg-pet-replaces-mibg","kind":"idea","name":"18F-MFBG PET replacing 123I-MIBG scintigraphy","route":"/ideas/idea-mfbg-pet-replaces-mibg/","asOf":"2026-09-07","days":21},{"id":"in-vivo-gene-editing-cancer","kind":"technology","name":"In vivo base and prime editing for cancer","route":"/technologies/in-vivo-gene-editing-cancer/","asOf":"2026-09-08","days":20},{"id":"epigenetic-editing","kind":"technology","name":"Epigenetic editing (durable gene silencing)","route":"/technologies/epigenetic-editing/","asOf":"2026-09-08","days":20},{"id":"self-amplifying-rna","kind":"technology","name":"Self-amplifying and circular RNA therapeutics","route":"/technologies/self-amplifying-rna/","asOf":"2026-09-08","days":20},{"id":"stroma-directed-car","kind":"technology","name":"CAR-T against stroma: fibroblasts and myeloid cells","route":"/technologies/stroma-directed-car/","asOf":"2026-09-08","days":20},{"id":"engineered-bacteria-therapy","kind":"technology","name":"Engineered bacteria as living cancer drugs","route":"/technologies/engineered-bacteria-therapy/","asOf":"2026-09-08","days":20},{"id":"phage-delivery","kind":"technology","name":"Bacteriophage-based tumour delivery","route":"/technologies/phage-delivery/","asOf":"2026-09-08","days":20},{"id":"microbiome-modulation-io","kind":"technology","name":"Microbiome modulation to unlock immunotherapy","route":"/technologies/microbiome-modulation-io/","asOf":"2026-09-08","days":20},{"id":"tumour-microbiome-targeting","kind":"technology","name":"Targeting the tumour's own microbes","route":"/technologies/tumour-microbiome-targeting/","asOf":"2026-09-08","days":20},{"id":"dna-origami-nanorobots","kind":"technology","name":"DNA origami nanorobots","route":"/technologies/dna-origami-nanorobots/","asOf":"2026-09-08","days":20},{"id":"magnetic-nanoparticle-hyperthermia","kind":"technology","name":"Magnetic nanoparticle hyperthermia","route":"/technologies/magnetic-nanoparticle-hyperthermia/","asOf":"2026-09-08","days":20},{"id":"photothermal-nanoparticles","kind":"technology","name":"Photothermal (plasmonic) nanoparticle ablation","route":"/technologies/photothermal-nanoparticles/","asOf":"2026-09-08","days":20},{"id":"sonodynamic-therapy","kind":"technology","name":"Sonodynamic therapy","route":"/technologies/sonodynamic-therapy/","asOf":"2026-09-08","days":20},{"id":"radiodynamic-therapy","kind":"technology","name":"Radiodynamic therapy and radiosensitising nanoparticles","route":"/technologies/radiodynamic-therapy/","asOf":"2026-09-08","days":20},{"id":"vhee-radiotherapy","kind":"technology","name":"Very-high-energy electron therapy","route":"/technologies/vhee-radiotherapy/","asOf":"2026-09-08","days":20},{"id":"proton-arc-therapy","kind":"technology","name":"Proton arc therapy","route":"/technologies/proton-arc-therapy/","asOf":"2026-09-08","days":20},{"id":"lattice-radiotherapy","kind":"technology","name":"Lattice and GRID radiotherapy","route":"/technologies/lattice-radiotherapy/","asOf":"2026-09-08","days":20},{"id":"auger-electron-therapy","kind":"technology","name":"Auger-electron therapy","route":"/technologies/auger-electron-therapy/","asOf":"2026-09-08","days":20},{"id":"alpha-nanogenerators","kind":"technology","name":"Alpha-emitter nanogenerators and daughter trapping","route":"/technologies/alpha-nanogenerators/","asOf":"2026-09-08","days":20},{"id":"radionuclide-parp-combination","kind":"technology","name":"Radioligand plus DNA-repair inhibitor combinations","route":"/technologies/radionuclide-parp-combination/","asOf":"2026-09-08","days":20},{"id":"nerve-tumour-denervation","kind":"technology","name":"Cancer neuroscience: cutting the nerve supply","route":"/technologies/nerve-tumour-denervation/","asOf":"2026-09-08","days":20},{"id":"cachexia-therapy","kind":"technology","name":"Cachexia-directed therapy (GDF-15 blockade)","route":"/technologies/cachexia-therapy/","asOf":"2026-09-08","days":20},{"id":"chronotherapy","kind":"technology","name":"Chronotherapy: timing treatment to the body clock","route":"/technologies/chronotherapy/","asOf":"2026-09-08","days":20},{"id":"metabolic-therapy","kind":"technology","name":"Metabolic therapy: starving the tumour of a nutrient","route":"/technologies/metabolic-therapy/","asOf":"2026-09-08","days":20},{"id":"senescence-targeting","kind":"technology","name":"Senolytics and senescence-directed therapy","route":"/technologies/senescence-targeting/","asOf":"2026-09-08","days":20},{"id":"il12-electroporation","kind":"technology","name":"Intratumoural gene electrotransfer (IL-12 plasmid)","route":"/technologies/il12-electroporation/","asOf":"2026-09-08","days":20},{"id":"de-novo-protein-design","kind":"technology","name":"De novo designed protein binders","route":"/technologies/de-novo-protein-design/","asOf":"2026-09-08","days":20},{"id":"molecular-glue-platforms","kind":"technology","name":"Molecular glue discovery platforms","route":"/technologies/molecular-glue-platforms/","asOf":"2026-09-08","days":20},{"id":"antibody-oligonucleotide-conjugates","kind":"technology","name":"Antibody-oligonucleotide conjugates","route":"/technologies/antibody-oligonucleotide-conjugates/","asOf":"2026-09-08","days":20},{"id":"logic-gated-therapeutics","kind":"technology","name":"Logic-gated therapeutics (AND, NOT gates)","route":"/technologies/logic-gated-therapeutics/","asOf":"2026-09-08","days":20},{"id":"in-situ-vaccination","kind":"technology","name":"In situ vaccination","route":"/technologies/in-situ-vaccination/","asOf":"2026-09-08","days":20},{"id":"interception-vaccination","kind":"technology","name":"Cancer interception vaccines","route":"/technologies/interception-vaccination/","asOf":"2026-09-08","days":20},{"id":"trained-innate-immunity","kind":"technology","name":"Trained innate immunity","route":"/technologies/trained-innate-immunity/","asOf":"2026-09-08","days":20},{"id":"histotripsy-immune-priming","kind":"technology","name":"Histotripsy as an immune primer","route":"/technologies/histotripsy-immune-priming/","asOf":"2026-09-08","days":20},{"id":"mechanobiology-therapy","kind":"technology","name":"Targeting tumour mechanics and pressure","route":"/technologies/mechanobiology-therapy/","asOf":"2026-09-08","days":20},{"id":"hypoxia-activated-therapy","kind":"technology","name":"Hypoxia-activated prodrugs","route":"/technologies/hypoxia-activated-therapy/","asOf":"2026-09-08","days":20},{"id":"digital-twins-trials","kind":"technology","name":"Digital twins and virtual control arms","route":"/technologies/digital-twins-trials/","asOf":"2026-09-08","days":20},{"id":"n-of-1-platforms","kind":"technology","name":"N-of-1 and rapid platform trials","route":"/technologies/n-of-1-platforms/","asOf":"2026-09-08","days":20},{"id":"continuous-ctdna-monitoring","kind":"technology","name":"Continuous and near-continuous ctDNA monitoring","route":"/technologies/continuous-ctdna-monitoring/","asOf":"2026-09-08","days":20},{"id":"breath-vocs","kind":"technology","name":"Breath and volatile-organic-compound detection","route":"/technologies/breath-vocs/","asOf":"2026-09-08","days":20},{"id":"drug-repurposing","kind":"technology","name":"Systematic drug repurposing","route":"/technologies/drug-repurposing/","asOf":"2026-09-08","days":20},{"id":"total-body-pet-screening","kind":"technology","name":"Total-body PET for screening and ultra-low-dose imaging","route":"/technologies/total-body-pet-screening/","asOf":"2026-09-08","days":20},{"id":"quantum-dot-imaging","kind":"technology","name":"Quantum-dot and molecular ultrasound imaging agents","route":"/technologies/quantum-dot-imaging/","asOf":"2026-09-08","days":20},{"id":"organoid-guided-therapy-scale","kind":"technology","name":"Organoid-guided therapy at scale","route":"/technologies/organoid-guided-therapy-scale/","asOf":"2026-09-08","days":20},{"id":"spatial-omics-guided-therapy","kind":"technology","name":"Spatial-omics-guided treatment selection","route":"/technologies/spatial-omics-guided-therapy/","asOf":"2026-09-08","days":20},{"id":"exosome-therapeutics","kind":"technology","name":"Engineered exosomes as drug carriers","route":"/technologies/exosome-therapeutics/","asOf":"2026-09-08","days":20},{"id":"fabrice-barlesi","kind":"person","name":"Fabrice Barlesi","route":"/people/fabrice-barlesi/","asOf":"2026-09-08","days":20},{"id":"fabrice-andre","kind":"person","name":"Fabrice André","route":"/people/fabrice-andre/","asOf":"2026-09-08","days":20},{"id":"jean-charles-soria","kind":"person","name":"Jean-Charles Soria","route":"/people/jean-charles-soria/","asOf":"2026-09-08","days":20},{"id":"benjamin-besse","kind":"person","name":"Benjamin Besse","route":"/people/benjamin-besse/","asOf":"2026-09-08","days":20},{"id":"aurelien-marabelle","kind":"person","name":"Aurélien Marabelle","route":"/people/aurelien-marabelle/","asOf":"2026-09-08","days":20},{"id":"karim-fizazi","kind":"person","name":"Karim Fizazi","route":"/people/karim-fizazi/","asOf":"2026-09-08","days":20},{"id":"laurence-zitvogel","kind":"person","name":"Laurence Zitvogel","route":"/people/laurence-zitvogel/","asOf":"2026-09-08","days":20},{"id":"nicholas-turner","kind":"person","name":"Nicholas Turner","route":"/people/nicholas-turner/","asOf":"2026-09-08","days":20},{"id":"johann-de-bono","kind":"person","name":"Johann de Bono","route":"/people/johann-de-bono/","asOf":"2026-09-08","days":20},{"id":"andrew-tutt","kind":"person","name":"Andrew Tutt","route":"/people/andrew-tutt/","asOf":"2026-09-08","days":20},{"id":"nicholas-james","kind":"person","name":"Nicholas James","route":"/people/nicholas-james/","asOf":"2026-09-08","days":20},{"id":"david-cunningham","kind":"person","name":"David Cunningham","route":"/people/david-cunningham/","asOf":"2026-09-08","days":20},{"id":"james-larkin","kind":"person","name":"James Larkin","route":"/people/james-larkin/","asOf":"2026-09-08","days":20},{"id":"uwe-oelfke","kind":"person","name":"Uwe Oelfke","route":"/people/uwe-oelfke/","asOf":"2026-09-08","days":20},{"id":"kristian-helin","kind":"person","name":"Kristian Helin","route":"/people/kristian-helin/","asOf":"2026-09-08","days":20},{"id":"paul-workman","kind":"person","name":"Paul Workman","route":"/people/paul-workman/","asOf":"2026-09-08","days":20},{"id":"chris-lord","kind":"person","name":"Christopher Lord","route":"/people/chris-lord/","asOf":"2026-09-08","days":20},{"id":"kevin-harrington","kind":"person","name":"Kevin Harrington","route":"/people/kevin-harrington/","asOf":"2026-09-08","days":20},{"id":"mel-greaves","kind":"person","name":"Mel Greaves","route":"/people/mel-greaves/","asOf":"2026-09-08","days":20},{"id":"charles-swanton","kind":"person","name":"Charles Swanton","route":"/people/charles-swanton/","asOf":"2026-09-08","days":20},{"id":"paul-nurse","kind":"person","name":"Paul Nurse","route":"/people/paul-nurse/","asOf":"2026-09-08","days":20},{"id":"caetano-reis-e-sousa","kind":"person","name":"Caetano Reis e Sousa","route":"/people/caetano-reis-e-sousa/","asOf":"2026-09-08","days":20},{"id":"erik-sahai","kind":"person","name":"Erik Sahai","route":"/people/erik-sahai/","asOf":"2026-09-08","days":20},{"id":"michelle-mitchell","kind":"person","name":"Michelle Mitchell","route":"/people/michelle-mitchell/","asOf":"2026-09-08","days":20},{"id":"iain-foulkes","kind":"person","name":"Iain Foulkes","route":"/people/iain-foulkes/","asOf":"2026-09-08","days":20},{"id":"ruth-plummer","kind":"person","name":"Ruth Plummer","route":"/people/ruth-plummer/","asOf":"2026-09-08","days":20},{"id":"caroline-dive","kind":"person","name":"Caroline Dive","route":"/people/caroline-dive/","asOf":"2026-09-08","days":20},{"id":"fiona-blackhall","kind":"person","name":"Fiona Blackhall","route":"/people/fiona-blackhall/","asOf":"2026-09-08","days":20},{"id":"andrew-wardley","kind":"person","name":"Andrew Wardley","route":"/people/andrew-wardley/","asOf":"2026-09-08","days":20},{"id":"ananya-choudhury","kind":"person","name":"Ananya Choudhury","route":"/people/ananya-choudhury/","asOf":"2026-09-08","days":20},{"id":"uwe-haberkorn","kind":"person","name":"Uwe Haberkorn","route":"/people/uwe-haberkorn/","asOf":"2026-09-08","days":20},{"id":"frederik-giesel","kind":"person","name":"Frederik Giesel","route":"/people/frederik-giesel/","asOf":"2026-09-08","days":20},{"id":"clemens-kratochwil","kind":"person","name":"Clemens Kratochwil","route":"/people/clemens-kratochwil/","asOf":"2026-09-08","days":20},{"id":"stefan-froehling","kind":"person","name":"Stefan Fröhling","route":"/people/stefan-froehling/","asOf":"2026-09-08","days":20},{"id":"juergen-debus","kind":"person","name":"Jürgen Debus","route":"/people/juergen-debus/","asOf":"2026-09-08","days":20},{"id":"andreas-von-deimling","kind":"person","name":"Andreas von Deimling","route":"/people/andreas-von-deimling/","asOf":"2026-09-08","days":20},{"id":"michael-baumann","kind":"person","name":"Michael Baumann","route":"/people/michael-baumann/","asOf":"2026-09-08","days":20},{"id":"stefan-pfister","kind":"person","name":"Stefan Pfister","route":"/people/stefan-pfister/","asOf":"2026-09-08","days":20},{"id":"hermann-brenner","kind":"person","name":"Hermann Brenner","route":"/people/hermann-brenner/","asOf":"2026-09-08","days":20},{"id":"andreas-trumpp","kind":"person","name":"Andreas Trumpp","route":"/people/andreas-trumpp/","asOf":"2026-09-08","days":20},{"id":"steven-le-gouill","kind":"person","name":"Steven Le Gouill","route":"/people/steven-le-gouill/","asOf":"2026-09-08","days":20},{"id":"francois-clement-bidard","kind":"person","name":"François-Clément Bidard","route":"/people/francois-clement-bidard/","asOf":"2026-09-08","days":20},{"id":"sergio-roman-roman","kind":"person","name":"Sergio Roman-Roman","route":"/people/sergio-roman-roman/","asOf":"2026-09-08","days":20},{"id":"olivier-delattre","kind":"person","name":"Olivier Delattre","route":"/people/olivier-delattre/","asOf":"2026-09-08","days":20},{"id":"eliane-piaggio","kind":"person","name":"Eliane Piaggio","route":"/people/eliane-piaggio/","asOf":"2026-09-08","days":20},{"id":"giuseppe-curigliano","kind":"person","name":"Giuseppe Curigliano","route":"/people/giuseppe-curigliano/","asOf":"2026-09-08","days":20},{"id":"paolo-veronesi","kind":"person","name":"Paolo Veronesi","route":"/people/paolo-veronesi/","asOf":"2026-09-08","days":20},{"id":"roberto-orecchia","kind":"person","name":"Roberto Orecchia","route":"/people/roberto-orecchia/","asOf":"2026-09-08","days":20},{"id":"pier-giuseppe-pelicci","kind":"person","name":"Pier Giuseppe Pelicci","route":"/people/pier-giuseppe-pelicci/","asOf":"2026-09-08","days":20},{"id":"alessandro-gronchi","kind":"person","name":"Alessandro Gronchi","route":"/people/alessandro-gronchi/","asOf":"2026-09-08","days":20},{"id":"filippo-de-braud","kind":"person","name":"Filippo de Braud","route":"/people/filippo-de-braud/","asOf":"2026-09-08","days":20},{"id":"marco-guzzo","kind":"person","name":"Marco Guzzo","route":"/people/marco-guzzo/","asOf":"2026-09-08","days":20},{"id":"josep-tabernero","kind":"person","name":"Josep Tabernero","route":"/people/josep-tabernero/","asOf":"2026-09-08","days":20},{"id":"javier-cortes","kind":"person","name":"Javier Cortés","route":"/people/javier-cortes/","asOf":"2026-09-08","days":20},{"id":"elena-garralda","kind":"person","name":"Elena Garralda","route":"/people/elena-garralda/","asOf":"2026-09-08","days":20},{"id":"enriqueta-felip","kind":"person","name":"Enriqueta Felip","route":"/people/enriqueta-felip/","asOf":"2026-09-08","days":20},{"id":"elena-elez","kind":"person","name":"Elena Élez","route":"/people/elena-elez/","asOf":"2026-09-08","days":20},{"id":"joaquin-arribas","kind":"person","name":"Joaquín Arribas","route":"/people/joaquin-arribas/","asOf":"2026-09-08","days":20},{"id":"ulrich-keilholz","kind":"person","name":"Ulrich Keilholz","route":"/people/ulrich-keilholz/","asOf":"2026-09-08","days":20},{"id":"lars-bullinger","kind":"person","name":"Lars Bullinger","route":"/people/lars-bullinger/","asOf":"2026-09-08","days":20},{"id":"angelika-eggert","kind":"person","name":"Angelika Eggert","route":"/people/angelika-eggert/","asOf":"2026-09-08","days":20},{"id":"christof-von-kalle","kind":"person","name":"Christof von Kalle","route":"/people/christof-von-kalle/","asOf":"2026-09-08","days":20},{"id":"markus-graefen","kind":"person","name":"Markus Graefen","route":"/people/markus-graefen/","asOf":"2026-09-08","days":20},{"id":"carsten-bokemeyer","kind":"person","name":"Carsten Bokemeyer","route":"/people/carsten-bokemeyer/","asOf":"2026-09-08","days":20},{"id":"klaus-pantel","kind":"person","name":"Klaus Pantel","route":"/people/klaus-pantel/","asOf":"2026-09-08","days":20},{"id":"volker-heinemann","kind":"person","name":"Volker Heinemann","route":"/people/volker-heinemann/","asOf":"2026-09-08","days":20},{"id":"peter-bartenstein","kind":"person","name":"Peter Bartenstein","route":"/people/peter-bartenstein/","asOf":"2026-09-08","days":20},{"id":"michael-von-bergwelt","kind":"person","name":"Michael von Bergwelt","route":"/people/michael-von-bergwelt/","asOf":"2026-09-08","days":20},{"id":"claus-belka","kind":"person","name":"Claus Belka","route":"/people/claus-belka/","asOf":"2026-09-08","days":20},{"id":"michael-hallek","kind":"person","name":"Michael Hallek","route":"/people/michael-hallek/","asOf":"2026-09-08","days":20},{"id":"juergen-wolf","kind":"person","name":"Jürgen Wolf","route":"/people/juergen-wolf/","asOf":"2026-09-08","days":20},{"id":"reinhard-buettner","kind":"person","name":"Reinhard Büttner","route":"/people/reinhard-buettner/","asOf":"2026-09-08","days":20},{"id":"roman-thomas","kind":"person","name":"Roman Thomas","route":"/people/roman-thomas/","asOf":"2026-09-08","days":20},{"id":"giovanni-scambia","kind":"person","name":"Giovanni Scambia","route":"/people/giovanni-scambia/","asOf":"2026-09-08","days":20},{"id":"anna-fagotti","kind":"person","name":"Anna Fagotti","route":"/people/anna-fagotti/","asOf":"2026-09-08","days":20},{"id":"giampaolo-tortora","kind":"person","name":"Giampaolo Tortora","route":"/people/giampaolo-tortora/","asOf":"2026-09-08","days":20},{"id":"vincenzo-valentini","kind":"person","name":"Vincenzo Valentini","route":"/people/vincenzo-valentini/","asOf":"2026-09-08","days":20},{"id":"jonas-bergh","kind":"person","name":"Jonas Bergh","route":"/people/jonas-bergh/","asOf":"2026-09-08","days":20},{"id":"per-hall","kind":"person","name":"Per Hall","route":"/people/per-hall/","asOf":"2026-09-08","days":20},{"id":"rolf-kiessling","kind":"person","name":"Rolf Kiessling","route":"/people/rolf-kiessling/","asOf":"2026-09-08","days":20},{"id":"hans-gustaf-ljunggren","kind":"person","name":"Hans-Gustaf Ljunggren","route":"/people/hans-gustaf-ljunggren/","asOf":"2026-09-08","days":20},{"id":"christian-blank","kind":"person","name":"Christian Blank","route":"/people/christian-blank/","asOf":"2026-09-08","days":20},{"id":"myriam-chalabi","kind":"person","name":"Myriam Chalabi","route":"/people/myriam-chalabi/","asOf":"2026-09-08","days":20},{"id":"john-haanen","kind":"person","name":"John Haanen","route":"/people/john-haanen/","asOf":"2026-09-08","days":20},{"id":"emile-voest","kind":"person","name":"Emile Voest","route":"/people/emile-voest/","asOf":"2026-09-08","days":20},{"id":"ton-schumacher","kind":"person","name":"Ton Schumacher","route":"/people/ton-schumacher/","asOf":"2026-09-08","days":20},{"id":"rene-bernards","kind":"person","name":"René Bernards","route":"/people/rene-bernards/","asOf":"2026-09-08","days":20},{"id":"sabine-linn","kind":"person","name":"Sabine Linn","route":"/people/sabine-linn/","asOf":"2026-09-08","days":20},{"id":"jaime-feliu","kind":"person","name":"Jaime Feliu","route":"/people/jaime-feliu/","asOf":"2026-09-08","days":20},{"id":"enrique-espinosa","kind":"person","name":"Enrique Espinosa","route":"/people/enrique-espinosa/","asOf":"2026-09-08","days":20},{"id":"beatriz-castelo","kind":"person","name":"Beatriz Castelo","route":"/people/beatriz-castelo/","asOf":"2026-09-08","days":20},{"id":"miguel-martin","kind":"person","name":"Miguel Martín","route":"/people/miguel-martin/","asOf":"2026-09-08","days":20},{"id":"sara-lopez-tarruella","kind":"person","name":"Sara López-Tarruella","route":"/people/sara-lopez-tarruella/","asOf":"2026-09-08","days":20},{"id":"pilar-garrido","kind":"person","name":"Pilar Garrido","route":"/people/pilar-garrido/","asOf":"2026-09-08","days":20},{"id":"denis-lacombe","kind":"person","name":"Denis Lacombe","route":"/people/denis-lacombe/","asOf":"2026-09-08","days":20},{"id":"alexander-eggermont","kind":"person","name":"Alexander Eggermont","route":"/people/alexander-eggermont/","asOf":"2026-09-08","days":20},{"id":"martine-piccart","kind":"person","name":"Martine Piccart","route":"/people/martine-piccart/","asOf":"2026-09-08","days":20},{"id":"michael-weller","kind":"person","name":"Michael Weller","route":"/people/michael-weller/","asOf":"2026-09-08","days":20},{"id":"roger-stupp","kind":"person","name":"Roger Stupp","route":"/people/roger-stupp/","asOf":"2026-09-08","days":20},{"id":"nathan-cherny","kind":"person","name":"Nathan Cherny","route":"/people/nathan-cherny/","asOf":"2026-09-08","days":20},{"id":"andres-cervantes","kind":"person","name":"Andrés Cervantes","route":"/people/andres-cervantes/","asOf":"2026-09-08","days":20},{"id":"solange-peters","kind":"person","name":"Solange Peters","route":"/people/solange-peters/","asOf":"2026-09-08","days":20},{"id":"david-cameron","kind":"person","name":"David Cameron","route":"/people/david-cameron/","asOf":"2026-09-08","days":20},{"id":"evandro-de-azambuja","kind":"person","name":"Evandro de Azambuja","route":"/people/evandro-de-azambuja/","asOf":"2026-09-08","days":20},{"id":"sibylle-loibl","kind":"person","name":"Sibylle Loibl","route":"/people/sibylle-loibl/","asOf":"2026-09-08","days":20},{"id":"gunter-von-minckwitz","kind":"person","name":"Gunter von Minckwitz","route":"/people/gunter-von-minckwitz/","asOf":"2026-09-08","days":20},{"id":"carsten-denkert","kind":"person","name":"Carsten Denkert","route":"/people/carsten-denkert/","asOf":"2026-09-08","days":20},{"id":"jean-yves-blay","kind":"person","name":"Jean-Yves Blay","route":"/people/jean-yves-blay/","asOf":"2026-09-08","days":20},{"id":"thomas-bachelot","kind":"person","name":"Thomas Bachelot","route":"/people/thomas-bachelot/","asOf":"2026-09-08","days":20},{"id":"christophe-le-tourneau","kind":"person","name":"Christophe Le Tourneau","route":"/people/christophe-le-tourneau/","asOf":"2026-09-08","days":20},{"id":"anthony-goncalves","kind":"person","name":"Anthony Gonçalves","route":"/people/anthony-goncalves/","asOf":"2026-09-08","days":20},{"id":"ahn-myung-ju","kind":"person","name":"Myung-Ju Ahn","route":"/people/ahn-myung-ju/","asOf":"2026-09-08","days":20},{"id":"park-yeon-hee","kind":"person","name":"Yeon Hee Park","route":"/people/park-yeon-hee/","asOf":"2026-09-08","days":20},{"id":"lee-jeeyun","kind":"person","name":"Jeeyun Lee","route":"/people/lee-jeeyun/","asOf":"2026-09-08","days":20},{"id":"kang-won-ki","kind":"person","name":"Won Ki Kang","route":"/people/kang-won-ki/","asOf":"2026-09-08","days":20},{"id":"lim-ho-yeong","kind":"person","name":"Ho Yeong Lim","route":"/people/lim-ho-yeong/","asOf":"2026-09-08","days":20},{"id":"park-woong-yang","kind":"person","name":"Woong-Yang Park","route":"/people/park-woong-yang/","asOf":"2026-09-08","days":20},{"id":"kim-sung-bae","kind":"person","name":"Sung-Bae Kim","route":"/people/kim-sung-bae/","asOf":"2026-09-08","days":20},{"id":"kang-yoon-koo","kind":"person","name":"Yoon-Koo Kang","route":"/people/kang-yoon-koo/","asOf":"2026-09-08","days":20},{"id":"ryu-min-hee","kind":"person","name":"Min-Hee Ryu","route":"/people/ryu-min-hee/","asOf":"2026-09-08","days":20},{"id":"kim-tae-won","kind":"person","name":"Tae Won Kim","route":"/people/kim-tae-won/","asOf":"2026-09-08","days":20},{"id":"lee-jae-lyun","kind":"person","name":"Jae Lyun Lee","route":"/people/lee-jae-lyun/","asOf":"2026-09-08","days":20},{"id":"lee-dae-ho","kind":"person","name":"Dae Ho Lee","route":"/people/lee-dae-ho/","asOf":"2026-09-08","days":20},{"id":"lee-sung-gyu","kind":"person","name":"Sung-Gyu Lee","route":"/people/lee-sung-gyu/","asOf":"2026-09-08","days":20},{"id":"bang-yung-jue","kind":"person","name":"Yung-Jue Bang","route":"/people/bang-yung-jue/","asOf":"2026-09-08","days":20},{"id":"im-seock-ah","kind":"person","name":"Seock-Ah Im","route":"/people/im-seock-ah/","asOf":"2026-09-08","days":20},{"id":"oh-do-youn","kind":"person","name":"Do-Youn Oh","route":"/people/oh-do-youn/","asOf":"2026-09-08","days":20},{"id":"kim-tae-you","kind":"person","name":"Tae-You Kim","route":"/people/kim-tae-you/","asOf":"2026-09-08","days":20},{"id":"kim-dong-wan","kind":"person","name":"Dong-Wan Kim","route":"/people/kim-dong-wan/","asOf":"2026-09-08","days":20},{"id":"lee-se-hoon","kind":"person","name":"Se-Hoon Lee","route":"/people/lee-se-hoon/","asOf":"2026-09-08","days":20},{"id":"cho-byoung-chul","kind":"person","name":"Byoung Chul Cho","route":"/people/cho-byoung-chul/","asOf":"2026-09-08","days":20},{"id":"rha-sun-young","kind":"person","name":"Sun Young Rha","route":"/people/rha-sun-young/","asOf":"2026-09-08","days":20},{"id":"kim-hye-ryun","kind":"person","name":"Hye Ryun Kim","route":"/people/kim-hye-ryun/","asOf":"2026-09-08","days":20},{"id":"shin-sang-joon","kind":"person","name":"Sang Joon Shin","route":"/people/shin-sang-joon/","asOf":"2026-09-08","days":20},{"id":"sohn-joohyuk","kind":"person","name":"Joohyuk Sohn","route":"/people/sohn-joohyuk/","asOf":"2026-09-08","days":20},{"id":"nakagama-hitoshi","kind":"person","name":"Hitoshi Nakagama","route":"/people/nakagama-hitoshi/","asOf":"2026-09-08","days":20},{"id":"ohe-yuichiro","kind":"person","name":"Yuichiro Ohe","route":"/people/ohe-yuichiro/","asOf":"2026-09-08","days":20},{"id":"yamamoto-noboru","kind":"person","name":"Noboru Yamamoto","route":"/people/yamamoto-noboru/","asOf":"2026-09-08","days":20},{"id":"yonemori-kan","kind":"person","name":"Kan Yonemori","route":"/people/yonemori-kan/","asOf":"2026-09-08","days":20},{"id":"kohno-takashi","kind":"person","name":"Takashi Kohno","route":"/people/kohno-takashi/","asOf":"2026-09-08","days":20},{"id":"goto-koichi","kind":"person","name":"Koichi Goto","route":"/people/goto-koichi/","asOf":"2026-09-08","days":20},{"id":"yoshino-takayuki","kind":"person","name":"Takayuki Yoshino","route":"/people/yoshino-takayuki/","asOf":"2026-09-08","days":20},{"id":"shitara-kohei","kind":"person","name":"Kohei Shitara","route":"/people/shitara-kohei/","asOf":"2026-09-08","days":20},{"id":"doi-toshihiko","kind":"person","name":"Toshihiko Doi","route":"/people/doi-toshihiko/","asOf":"2026-09-08","days":20},{"id":"sano-takeshi","kind":"person","name":"Takeshi Sano","route":"/people/sano-takeshi/","asOf":"2026-09-08","days":20},{"id":"takahashi-shunji","kind":"person","name":"Shunji Takahashi","route":"/people/takahashi-shunji/","asOf":"2026-09-08","days":20},{"id":"ohno-shinji","kind":"person","name":"Shinji Ohno","route":"/people/ohno-shinji/","asOf":"2026-09-08","days":20},{"id":"ueno-takayuki","kind":"person","name":"Takayuki Ueno","route":"/people/ueno-takayuki/","asOf":"2026-09-08","days":20},{"id":"fukuda-haruhiko","kind":"person","name":"Haruhiko Fukuda","route":"/people/fukuda-haruhiko/","asOf":"2026-09-08","days":20},{"id":"kitagawa-yuko","kind":"person","name":"Yuko Kitagawa","route":"/people/kitagawa-yuko/","asOf":"2026-09-08","days":20},{"id":"hofman-michael","kind":"person","name":"Michael Hofman","route":"/people/hofman-michael/","asOf":"2026-09-08","days":20},{"id":"mcarthur-grant","kind":"person","name":"Grant McArthur","route":"/people/mcarthur-grant/","asOf":"2026-09-08","days":20},{"id":"loi-sherene","kind":"person","name":"Sherene Loi","route":"/people/loi-sherene/","asOf":"2026-09-08","days":20},{"id":"solomon-benjamin","kind":"person","name":"Benjamin Solomon","route":"/people/solomon-benjamin/","asOf":"2026-09-08","days":20},{"id":"sandhu-shahneen","kind":"person","name":"Shahneen Sandhu","route":"/people/sandhu-shahneen/","asOf":"2026-09-08","days":20},{"id":"dawson-sarah-jane","kind":"person","name":"Sarah-Jane Dawson","route":"/people/dawson-sarah-jane/","asOf":"2026-09-08","days":20},{"id":"trapani-joseph","kind":"person","name":"Joseph Trapani","route":"/people/trapani-joseph/","asOf":"2026-09-08","days":20},{"id":"kaliks-rafael","kind":"person","name":"Rafael Kaliks","route":"/people/kaliks-rafael/","asOf":"2026-09-08","days":20},{"id":"hoff-paulo","kind":"person","name":"Paulo Hoff","route":"/people/hoff-paulo/","asOf":"2026-09-08","days":20},{"id":"katz-artur","kind":"person","name":"Artur Katz","route":"/people/katz-artur/","asOf":"2026-09-08","days":20},{"id":"barrios-carlos","kind":"person","name":"Carlos Barrios","route":"/people/barrios-carlos/","asOf":"2026-09-08","days":20},{"id":"ma-jun","kind":"person","name":"Jun Ma","route":"/people/ma-jun/","asOf":"2026-09-08","days":20},{"id":"xu-rui-hua","kind":"person","name":"Rui-Hua Xu","route":"/people/xu-rui-hua/","asOf":"2026-09-08","days":20},{"id":"zhang-li-sysucc","kind":"person","name":"Li Zhang","route":"/people/zhang-li-sysucc/","asOf":"2026-09-08","days":20},{"id":"fang-wenfeng","kind":"person","name":"Wenfeng Fang","route":"/people/fang-wenfeng/","asOf":"2026-09-08","days":20},{"id":"zeng-mu-sheng","kind":"person","name":"Mu-Sheng Zeng","route":"/people/zeng-mu-sheng/","asOf":"2026-09-08","days":20},{"id":"wang-feng-sysucc","kind":"person","name":"Feng Wang","route":"/people/wang-feng-sysucc/","asOf":"2026-09-08","days":20},{"id":"shao-zhi-ming","kind":"person","name":"Zhi-Ming Shao","route":"/people/shao-zhi-ming/","asOf":"2026-09-08","days":20},{"id":"jiang-yi-zhou","kind":"person","name":"Yi-Zhou Jiang","route":"/people/jiang-yi-zhou/","asOf":"2026-09-08","days":20},{"id":"hu-xichun","kind":"person","name":"Xichun Hu","route":"/people/hu-xichun/","asOf":"2026-09-08","days":20},{"id":"song-shaoli","kind":"person","name":"Shaoli Song","route":"/people/song-shaoli/","asOf":"2026-09-08","days":20},{"id":"ye-dingwei","kind":"person","name":"Dingwei Ye","route":"/people/ye-dingwei/","asOf":"2026-09-08","days":20},{"id":"li-jin-fuscc","kind":"person","name":"Jin Li","route":"/people/li-jin-fuscc/","asOf":"2026-09-08","days":20},{"id":"wei-yuquan","kind":"person","name":"Yuquan Wei","route":"/people/wei-yuquan/","asOf":"2026-09-08","days":20},{"id":"lu-you","kind":"person","name":"You Lu","route":"/people/lu-you/","asOf":"2026-09-08","days":20},{"id":"li-weimin","kind":"person","name":"Weimin Li","route":"/people/li-weimin/","asOf":"2026-09-08","days":20},{"id":"he-jie","kind":"person","name":"Jie He","route":"/people/he-jie/","asOf":"2026-09-08","days":20},{"id":"shi-yuankai","kind":"person","name":"Yuankai Shi","route":"/people/shi-yuankai/","asOf":"2026-09-08","days":20},{"id":"xu-binghe","kind":"person","name":"Binghe Xu","route":"/people/xu-binghe/","asOf":"2026-09-08","days":20},{"id":"wang-jie-cams","kind":"person","name":"Jie Wang","route":"/people/wang-jie-cams/","asOf":"2026-09-08","days":20},{"id":"ma-fei","kind":"person","name":"Fei Ma","route":"/people/ma-fei/","asOf":"2026-09-08","days":20},{"id":"huang-jing-cams","kind":"person","name":"Jing Huang","route":"/people/huang-jing-cams/","asOf":"2026-09-08","days":20},{"id":"zhou-caicun","kind":"person","name":"Caicun Zhou","route":"/people/zhou-caicun/","asOf":"2026-09-08","days":20},{"id":"shen-lin","kind":"person","name":"Lin Shen","route":"/people/shen-lin/","asOf":"2026-09-08","days":20},{"id":"qi-changsong","kind":"person","name":"Changsong Qi","route":"/people/qi-changsong/","asOf":"2026-09-08","days":20},{"id":"wu-yi-long","kind":"person","name":"Yi-Long Wu","route":"/people/wu-yi-long/","asOf":"2026-09-08","days":20},{"id":"lu-shun","kind":"person","name":"Shun Lu","route":"/people/lu-shun/","asOf":"2026-09-08","days":20},{"id":"gupta-sudeep","kind":"person","name":"Sudeep Gupta","route":"/people/gupta-sudeep/","asOf":"2026-09-08","days":20},{"id":"badwe-rajendra","kind":"person","name":"Rajendra Badwe","route":"/people/badwe-rajendra/","asOf":"2026-09-08","days":20},{"id":"patil-vijay","kind":"person","name":"Vijay Patil","route":"/people/patil-vijay/","asOf":"2026-09-08","days":20},{"id":"prabhash-kumar","kind":"person","name":"Kumar Prabhash","route":"/people/prabhash-kumar/","asOf":"2026-09-08","days":20},{"id":"noronha-vanita","kind":"person","name":"Vanita Noronha","route":"/people/noronha-vanita/","asOf":"2026-09-08","days":20},{"id":"chaturvedi-pankaj","kind":"person","name":"Pankaj Chaturvedi","route":"/people/chaturvedi-pankaj/","asOf":"2026-09-08","days":20},{"id":"shastri-surendra","kind":"person","name":"Surendra Shastri","route":"/people/shastri-surendra/","asOf":"2026-09-08","days":20},{"id":"dancey-janet","kind":"person","name":"Janet Dancey","route":"/people/dancey-janet/","asOf":"2026-09-08","days":20},{"id":"tu-dongsheng","kind":"person","name":"Dongsheng Tu","route":"/people/tu-dongsheng/","asOf":"2026-09-08","days":20},{"id":"parulekar-wendy","kind":"person","name":"Wendy Parulekar","route":"/people/parulekar-wendy/","asOf":"2026-09-08","days":20},{"id":"weiderpass-elisabete","kind":"person","name":"Elisabete Weiderpass","route":"/people/weiderpass-elisabete/","asOf":"2026-09-08","days":20},{"id":"bray-freddie","kind":"person","name":"Freddie Bray","route":"/people/bray-freddie/","asOf":"2026-09-08","days":20},{"id":"basu-partha","kind":"person","name":"Partha Basu","route":"/people/basu-partha/","asOf":"2026-09-08","days":20},{"id":"cree-ian","kind":"person","name":"Ian Cree","route":"/people/cree-ian/","asOf":"2026-09-08","days":20},{"id":"ilbawi-andre","kind":"person","name":"André Ilbawi","route":"/people/ilbawi-andre/","asOf":"2026-09-08","days":20},{"id":"selwyn-vickers","kind":"person","name":"Selwyn M. Vickers","route":"/people/selwyn-vickers/","asOf":"2026-09-08","days":20},{"id":"andrea-cercek","kind":"person","name":"Andrea Cercek","route":"/people/andrea-cercek/","asOf":"2026-09-08","days":20},{"id":"luis-diaz","kind":"person","name":"Luis A. Diaz Jr.","route":"/people/luis-diaz/","asOf":"2026-09-08","days":20},{"id":"charles-sawyers","kind":"person","name":"Charles L. Sawyers","route":"/people/charles-sawyers/","asOf":"2026-09-08","days":20},{"id":"howard-scher","kind":"person","name":"Howard I. Scher","route":"/people/howard-scher/","asOf":"2026-09-08","days":20},{"id":"michael-morris","kind":"person","name":"Michael J. Morris","route":"/people/michael-morris/","asOf":"2026-09-08","days":20},{"id":"bob-li","kind":"person","name":"Bob T. Li","route":"/people/bob-li/","asOf":"2026-09-08","days":20},{"id":"alexander-drilon","kind":"person","name":"Alexander Drilon","route":"/people/alexander-drilon/","asOf":"2026-09-08","days":20},{"id":"helena-yu","kind":"person","name":"Helena A. Yu","route":"/people/helena-yu/","asOf":"2026-09-08","days":20},{"id":"yelena-janjigian","kind":"person","name":"Yelena Y. Janjigian","route":"/people/yelena-janjigian/","asOf":"2026-09-08","days":20},{"id":"eileen-oreilly","kind":"person","name":"Eileen M. O'Reilly","route":"/people/eileen-oreilly/","asOf":"2026-09-08","days":20},{"id":"ross-levine","kind":"person","name":"Ross L. Levine","route":"/people/ross-levine/","asOf":"2026-09-08","days":20},{"id":"jae-park","kind":"person","name":"Jae H. Park","route":"/people/jae-park/","asOf":"2026-09-08","days":20},{"id":"saad-usmani","kind":"person","name":"Saad Z. Usmani","route":"/people/saad-usmani/","asOf":"2026-09-08","days":20},{"id":"david-solit","kind":"person","name":"David B. Solit","route":"/people/david-solit/","asOf":"2026-09-08","days":20},{"id":"benjamin-ebert","kind":"person","name":"Benjamin L. Ebert","route":"/people/benjamin-ebert/","asOf":"2026-09-08","days":20},{"id":"sara-tolaney","kind":"person","name":"Sara M. Tolaney","route":"/people/sara-tolaney/","asOf":"2026-09-08","days":20},{"id":"nancy-lin","kind":"person","name":"Nancy U. Lin","route":"/people/nancy-lin/","asOf":"2026-09-08","days":20},{"id":"pasi-janne","kind":"person","name":"Pasi A. Jänne","route":"/people/pasi-janne/","asOf":"2026-09-08","days":20},{"id":"kenneth-anderson","kind":"person","name":"Kenneth C. Anderson","route":"/people/kenneth-anderson/","asOf":"2026-09-08","days":20},{"id":"paul-richardson","kind":"person","name":"Paul G. Richardson","route":"/people/paul-richardson/","asOf":"2026-09-08","days":20},{"id":"ursula-matulonis","kind":"person","name":"Ursula A. Matulonis","route":"/people/ursula-matulonis/","asOf":"2026-09-08","days":20},{"id":"toni-choueiri","kind":"person","name":"Toni K. Choueiri","route":"/people/toni-choueiri/","asOf":"2026-09-08","days":20},{"id":"f-stephen-hodi","kind":"person","name":"F. Stephen Hodi","route":"/people/f-stephen-hodi/","asOf":"2026-09-08","days":20},{"id":"william-kaelin","kind":"person","name":"William G. Kaelin Jr.","route":"/people/william-kaelin/","asOf":"2026-09-08","days":20},{"id":"eliezer-van-allen","kind":"person","name":"Eliezer M. Van Allen","route":"/people/eliezer-van-allen/","asOf":"2026-09-08","days":20},{"id":"judy-garber","kind":"person","name":"Judy E. Garber","route":"/people/judy-garber/","asOf":"2026-09-08","days":20},{"id":"ann-partridge","kind":"person","name":"Ann H. Partridge","route":"/people/ann-partridge/","asOf":"2026-09-08","days":20},{"id":"daniel-haber","kind":"person","name":"Daniel A. Haber","route":"/people/daniel-haber/","asOf":"2026-09-08","days":20},{"id":"keith-flaherty","kind":"person","name":"Keith T. Flaherty","route":"/people/keith-flaherty/","asOf":"2026-09-08","days":20},{"id":"lecia-sequist","kind":"person","name":"Lecia V. Sequist","route":"/people/lecia-sequist/","asOf":"2026-09-08","days":20},{"id":"justin-gainor","kind":"person","name":"Justin F. Gainor","route":"/people/justin-gainor/","asOf":"2026-09-08","days":20},{"id":"ryan-corcoran","kind":"person","name":"Ryan B. Corcoran","route":"/people/ryan-corcoran/","asOf":"2026-09-08","days":20},{"id":"ryan-sullivan","kind":"person","name":"Ryan J. Sullivan","route":"/people/ryan-sullivan/","asOf":"2026-09-08","days":20},{"id":"theodore-hong","kind":"person","name":"Theodore S. Hong","route":"/people/theodore-hong/","asOf":"2026-09-08","days":20},{"id":"leif-ellisen","kind":"person","name":"Leif W. Ellisen","route":"/people/leif-ellisen/","asOf":"2026-09-08","days":20},{"id":"william-nelson","kind":"person","name":"William G. Nelson","route":"/people/william-nelson/","asOf":"2026-09-08","days":20},{"id":"bert-vogelstein","kind":"person","name":"Bert Vogelstein","route":"/people/bert-vogelstein/","asOf":"2026-09-08","days":20},{"id":"kenneth-kinzler","kind":"person","name":"Kenneth W. Kinzler","route":"/people/kenneth-kinzler/","asOf":"2026-09-08","days":20},{"id":"drew-pardoll","kind":"person","name":"Drew M. Pardoll","route":"/people/drew-pardoll/","asOf":"2026-09-08","days":20},{"id":"suzanne-topalian","kind":"person","name":"Suzanne L. Topalian","route":"/people/suzanne-topalian/","asOf":"2026-09-08","days":20},{"id":"julie-brahmer","kind":"person","name":"Julie R. Brahmer","route":"/people/julie-brahmer/","asOf":"2026-09-08","days":20},{"id":"dung-le","kind":"person","name":"Dung T. Le","route":"/people/dung-le/","asOf":"2026-09-08","days":20},{"id":"elizabeth-jaffee","kind":"person","name":"Elizabeth M. Jaffee","route":"/people/elizabeth-jaffee/","asOf":"2026-09-08","days":20},{"id":"patrick-forde","kind":"person","name":"Patrick M. Forde","route":"/people/patrick-forde/","asOf":"2026-09-08","days":20},{"id":"stephen-baylin","kind":"person","name":"Stephen B. Baylin","route":"/people/stephen-baylin/","asOf":"2026-09-08","days":20},{"id":"kellie-smith","kind":"person","name":"Kellie N. Smith","route":"/people/kellie-smith/","asOf":"2026-09-08","days":20},{"id":"robert-vonderheide","kind":"person","name":"Robert H. Vonderheide","route":"/people/robert-vonderheide/","asOf":"2026-09-08","days":20},{"id":"carl-june","kind":"person","name":"Carl H. June","route":"/people/carl-june/","asOf":"2026-09-08","days":20},{"id":"bruce-levine","kind":"person","name":"Bruce L. Levine","route":"/people/bruce-levine/","asOf":"2026-09-08","days":20},{"id":"drew-weissman","kind":"person","name":"Drew Weissman","route":"/people/drew-weissman/","asOf":"2026-09-08","days":20},{"id":"susan-domchek","kind":"person","name":"Susan M. Domchek","route":"/people/susan-domchek/","asOf":"2026-09-08","days":20},{"id":"angela-demichele","kind":"person","name":"Angela DeMichele","route":"/people/angela-demichele/","asOf":"2026-09-08","days":20},{"id":"charu-aggarwal","kind":"person","name":"Charu Aggarwal","route":"/people/charu-aggarwal/","asOf":"2026-09-08","days":20},{"id":"robert-mach","kind":"person","name":"Robert H. Mach","route":"/people/robert-mach/","asOf":"2026-09-08","days":20},{"id":"david-porter","kind":"person","name":"David L. Porter","route":"/people/david-porter/","asOf":"2026-09-08","days":20},{"id":"anthony-letai","kind":"person","name":"Anthony Letai","route":"/people/anthony-letai/","asOf":"2026-09-08","days":20},{"id":"douglas-lowy","kind":"person","name":"Douglas R. Lowy","route":"/people/douglas-lowy/","asOf":"2026-09-08","days":20},{"id":"steven-rosenberg","kind":"person","name":"Steven A. Rosenberg","route":"/people/steven-rosenberg/","asOf":"2026-09-08","days":20},{"id":"louis-staudt","kind":"person","name":"Louis M. Staudt","route":"/people/louis-staudt/","asOf":"2026-09-08","days":20},{"id":"james-gulley","kind":"person","name":"James L. Gulley","route":"/people/james-gulley/","asOf":"2026-09-08","days":20},{"id":"brigitte-widemann","kind":"person","name":"Brigitte C. Widemann","route":"/people/brigitte-widemann/","asOf":"2026-09-08","days":20},{"id":"nirali-shah","kind":"person","name":"Nirali N. Shah","route":"/people/nirali-shah/","asOf":"2026-09-08","days":20},{"id":"raffit-hassan","kind":"person","name":"Raffit Hassan","route":"/people/raffit-hassan/","asOf":"2026-09-08","days":20},{"id":"ramon-parsons","kind":"person","name":"Ramon E. Parsons","route":"/people/ramon-parsons/","asOf":"2026-09-08","days":20},{"id":"miriam-merad","kind":"person","name":"Miriam Merad","route":"/people/miriam-merad/","asOf":"2026-09-08","days":20},{"id":"sundar-jagannath","kind":"person","name":"Sundar Jagannath","route":"/people/sundar-jagannath/","asOf":"2026-09-08","days":20},{"id":"joshua-brody","kind":"person","name":"Joshua Brody","route":"/people/joshua-brody/","asOf":"2026-09-08","days":20},{"id":"matthew-galsky","kind":"person","name":"Matthew D. Galsky","route":"/people/matthew-galsky/","asOf":"2026-09-08","days":20},{"id":"nina-bhardwaj","kind":"person","name":"Nina Bhardwaj","route":"/people/nina-bhardwaj/","asOf":"2026-09-08","days":20},{"id":"thomas-marron","kind":"person","name":"Thomas U. Marron","route":"/people/thomas-marron/","asOf":"2026-09-08","days":20},{"id":"candace-johnson","kind":"person","name":"Candace S. Johnson","route":"/people/candace-johnson/","asOf":"2026-09-08","days":20},{"id":"renier-brentjens","kind":"person","name":"Renier J. Brentjens","route":"/people/renier-brentjens/","asOf":"2026-09-08","days":20},{"id":"igor-puzanov","kind":"person","name":"Igor Puzanov","route":"/people/igor-puzanov/","asOf":"2026-09-08","days":20},{"id":"robert-fenstermaker","kind":"person","name":"Robert A. Fenstermaker","route":"/people/robert-fenstermaker/","asOf":"2026-09-08","days":20},{"id":"eunice-wang","kind":"person","name":"Eunice S. Wang","route":"/people/eunice-wang/","asOf":"2026-09-08","days":20},{"id":"pawel-kalinski","kind":"person","name":"Pawel Kalinski","route":"/people/pawel-kalinski/","asOf":"2026-09-08","days":20},{"id":"todd-golub","kind":"person","name":"Todd R. Golub","route":"/people/todd-golub/","asOf":"2026-09-08","days":20},{"id":"gad-getz","kind":"person","name":"Gad Getz","route":"/people/gad-getz/","asOf":"2026-09-08","days":20},{"id":"matthew-meyerson","kind":"person","name":"Matthew Meyerson","route":"/people/matthew-meyerson/","asOf":"2026-09-08","days":20},{"id":"francisca-vazquez","kind":"person","name":"Francisca Vazquez","route":"/people/francisca-vazquez/","asOf":"2026-09-08","days":20},{"id":"andrew-aguirre","kind":"person","name":"Andrew J. Aguirre","route":"/people/andrew-aguirre/","asOf":"2026-09-08","days":20},{"id":"feng-zhang","kind":"person","name":"Feng Zhang","route":"/people/feng-zhang/","asOf":"2026-09-08","days":20},{"id":"bradley-bernstein","kind":"person","name":"Bradley E. Bernstein","route":"/people/bradley-bernstein/","asOf":"2026-09-08","days":20},{"id":"bruce-stillman","kind":"person","name":"Bruce W. Stillman","route":"/people/bruce-stillman/","asOf":"2026-09-08","days":20},{"id":"david-tuveson","kind":"person","name":"David A. Tuveson","route":"/people/david-tuveson/","asOf":"2026-09-08","days":20},{"id":"christopher-vakoc","kind":"person","name":"Christopher R. Vakoc","route":"/people/christopher-vakoc/","asOf":"2026-09-08","days":20},{"id":"adrian-krainer","kind":"person","name":"Adrian R. Krainer","route":"/people/adrian-krainer/","asOf":"2026-09-08","days":20},{"id":"tobias-janowitz","kind":"person","name":"Tobias Janowitz","route":"/people/tobias-janowitz/","asOf":"2026-09-08","days":20},{"id":"semir-beyaz","kind":"person","name":"Semir Beyaz","route":"/people/semir-beyaz/","asOf":"2026-09-08","days":20},{"id":"timothy-eberlein","kind":"person","name":"Timothy J. Eberlein","route":"/people/timothy-eberlein/","asOf":"2026-09-08","days":20},{"id":"timothy-ley","kind":"person","name":"Timothy J. Ley","route":"/people/timothy-ley/","asOf":"2026-09-08","days":20},{"id":"li-ding","kind":"person","name":"Li Ding","route":"/people/li-ding/","asOf":"2026-09-08","days":20},{"id":"malachi-griffith","kind":"person","name":"Malachi Griffith","route":"/people/malachi-griffith/","asOf":"2026-09-08","days":20},{"id":"obi-griffith","kind":"person","name":"Obi L. Griffith","route":"/people/obi-griffith/","asOf":"2026-09-08","days":20},{"id":"john-dipersio","kind":"person","name":"John F. DiPersio","route":"/people/john-dipersio/","asOf":"2026-09-08","days":20},{"id":"ramaswamy-govindan","kind":"person","name":"Ramaswamy Govindan","route":"/people/ramaswamy-govindan/","asOf":"2026-09-08","days":20},{"id":"robert-schreiber","kind":"person","name":"Robert D. Schreiber","route":"/people/robert-schreiber/","asOf":"2026-09-08","days":20},{"id":"eric-fearon","kind":"person","name":"Eric R. Fearon","route":"/people/eric-fearon/","asOf":"2026-09-08","days":20},{"id":"arul-chinnaiyan","kind":"person","name":"Arul M. Chinnaiyan","route":"/people/arul-chinnaiyan/","asOf":"2026-09-08","days":20},{"id":"shaomeng-wang","kind":"person","name":"Shaomeng Wang","route":"/people/shaomeng-wang/","asOf":"2026-09-08","days":20},{"id":"max-wicha","kind":"person","name":"Max S. Wicha","route":"/people/max-wicha/","asOf":"2026-09-08","days":20},{"id":"weiping-zou","kind":"person","name":"Weiping Zou","route":"/people/weiping-zou/","asOf":"2026-09-08","days":20},{"id":"theodore-lawrence","kind":"person","name":"Theodore S. Lawrence","route":"/people/theodore-lawrence/","asOf":"2026-09-08","days":20},{"id":"costas-lyssiotis","kind":"person","name":"Costas A. Lyssiotis","route":"/people/costas-lyssiotis/","asOf":"2026-09-08","days":20},{"id":"vincent-tuohy","kind":"person","name":"Vincent K. Tuohy","route":"/people/vincent-tuohy/","asOf":"2026-09-08","days":20},{"id":"timothy-chan","kind":"person","name":"Timothy A. Chan","route":"/people/timothy-chan/","asOf":"2026-09-08","days":20},{"id":"jame-abraham","kind":"person","name":"Jame Abraham","route":"/people/jame-abraham/","asOf":"2026-09-08","days":20},{"id":"justin-lathia","kind":"person","name":"Justin D. Lathia","route":"/people/justin-lathia/","asOf":"2026-09-08","days":20},{"id":"jaroslaw-maciejewski","kind":"person","name":"Jaroslaw P. Maciejewski","route":"/people/jaroslaw-maciejewski/","asOf":"2026-09-08","days":20},{"id":"shilpa-gupta","kind":"person","name":"Shilpa Gupta","route":"/people/shilpa-gupta/","asOf":"2026-09-08","days":20},{"id":"nathan-pennell","kind":"person","name":"Nathan A. Pennell","route":"/people/nathan-pennell/","asOf":"2026-09-08","days":20},{"id":"patrick-hwu","kind":"person","name":"Patrick Hwu","route":"/people/patrick-hwu/","asOf":"2026-09-08","days":20},{"id":"amod-sarnaik","kind":"person","name":"Amod A. Sarnaik","route":"/people/amod-sarnaik/","asOf":"2026-09-08","days":20},{"id":"frederick-locke","kind":"person","name":"Frederick L. Locke","route":"/people/frederick-locke/","asOf":"2026-09-08","days":20},{"id":"robert-gatenby","kind":"person","name":"Robert A. Gatenby","route":"/people/robert-gatenby/","asOf":"2026-09-08","days":20},{"id":"eric-haura","kind":"person","name":"Eric B. Haura","route":"/people/eric-haura/","asOf":"2026-09-08","days":20},{"id":"hatem-soliman","kind":"person","name":"Hatem Soliman","route":"/people/hatem-soliman/","asOf":"2026-09-08","days":20},{"id":"christine-chung","kind":"person","name":"Christine H. Chung","route":"/people/christine-chung/","asOf":"2026-09-08","days":20},{"id":"shari-pilon-thomas","kind":"person","name":"Shari Pilon-Thomas","route":"/people/shari-pilon-thomas/","asOf":"2026-09-08","days":20},{"id":"keith-stewart","kind":"person","name":"A. Keith Stewart","route":"/people/keith-stewart/","asOf":"2026-09-08","days":20},{"id":"john-dick","kind":"person","name":"John E. Dick","route":"/people/john-dick/","asOf":"2026-09-08","days":20},{"id":"lillian-siu","kind":"person","name":"Lillian L. Siu","route":"/people/lillian-siu/","asOf":"2026-09-08","days":20},{"id":"tak-mak","kind":"person","name":"Tak W. Mak","route":"/people/tak-mak/","asOf":"2026-09-08","days":20},{"id":"pamela-ohashi","kind":"person","name":"Pamela S. Ohashi","route":"/people/pamela-ohashi/","asOf":"2026-09-08","days":20},{"id":"aaron-schimmer","kind":"person","name":"Aaron D. Schimmer","route":"/people/aaron-schimmer/","asOf":"2026-09-08","days":20},{"id":"natasha-leighl","kind":"person","name":"Natasha B. Leighl","route":"/people/natasha-leighl/","asOf":"2026-09-08","days":20},{"id":"amit-oza","kind":"person","name":"Amit M. Oza","route":"/people/amit-oza/","asOf":"2026-09-08","days":20},{"id":"trevor-pugh","kind":"person","name":"Trevor J. Pugh","route":"/people/trevor-pugh/","asOf":"2026-09-08","days":20},{"id":"eric-winer","kind":"person","name":"Eric P. Winer","route":"/people/eric-winer/","asOf":"2026-09-08","days":20},{"id":"peter-pisters","kind":"person","name":"Peter W. T. Pisters","route":"/people/peter-pisters/","asOf":"2026-09-08","days":20},{"id":"giulio-draetta","kind":"person","name":"Giulio Draetta","route":"/people/giulio-draetta/","asOf":"2026-09-08","days":20},{"id":"james-allison","kind":"person","name":"James P. Allison","route":"/people/james-allison/","asOf":"2026-09-08","days":20},{"id":"padmanee-sharma","kind":"person","name":"Padmanee Sharma","route":"/people/padmanee-sharma/","asOf":"2026-09-08","days":20},{"id":"christopher-flowers","kind":"person","name":"Christopher R. Flowers","route":"/people/christopher-flowers/","asOf":"2026-09-08","days":20},{"id":"debu-tripathy","kind":"person","name":"Debu Tripathy","route":"/people/debu-tripathy/","asOf":"2026-09-08","days":20},{"id":"john-heymach","kind":"person","name":"John V. Heymach","route":"/people/john-heymach/","asOf":"2026-09-08","days":20},{"id":"hagop-kantarjian","kind":"person","name":"Hagop M. Kantarjian","route":"/people/hagop-kantarjian/","asOf":"2026-09-08","days":20},{"id":"funda-meric-bernstam","kind":"person","name":"Funda Meric-Bernstam","route":"/people/funda-meric-bernstam/","asOf":"2026-09-08","days":20},{"id":"anirban-maitra","kind":"person","name":"Anirban Maitra","route":"/people/anirban-maitra/","asOf":"2026-09-08","days":20},{"id":"jennifer-litton","kind":"person","name":"Jennifer K. Litton","route":"/people/jennifer-litton/","asOf":"2026-09-08","days":20},{"id":"albert-koong","kind":"person","name":"Albert C. Koong","route":"/people/albert-koong/","asOf":"2026-09-08","days":20},{"id":"mariana-chavez-macgregor","kind":"person","name":"Mariana Chavez-MacGregor","route":"/people/mariana-chavez-macgregor/","asOf":"2026-09-08","days":20},{"id":"cheryl-willman","kind":"person","name":"Cheryl L. Willman","route":"/people/cheryl-willman/","asOf":"2026-09-08","days":20},{"id":"evanthia-galanis","kind":"person","name":"Evanthia Galanis","route":"/people/evanthia-galanis/","asOf":"2026-09-08","days":20},{"id":"vincent-rajkumar","kind":"person","name":"S. Vincent Rajkumar","route":"/people/vincent-rajkumar/","asOf":"2026-09-08","days":20},{"id":"shaji-kumar","kind":"person","name":"Shaji K. Kumar","route":"/people/shaji-kumar/","asOf":"2026-09-08","days":20},{"id":"matthew-goetz","kind":"person","name":"Matthew P. Goetz","route":"/people/matthew-goetz/","asOf":"2026-09-08","days":20},{"id":"tanios-bekaii-saab","kind":"person","name":"Tanios Bekaii-Saab","route":"/people/tanios-bekaii-saab/","asOf":"2026-09-08","days":20},{"id":"alan-ashworth","kind":"person","name":"Alan Ashworth","route":"/people/alan-ashworth/","asOf":"2026-09-08","days":20},{"id":"eric-small","kind":"person","name":"Eric J. Small","route":"/people/eric-small/","asOf":"2026-09-08","days":20},{"id":"rahul-aggarwal","kind":"person","name":"Rahul Aggarwal","route":"/people/rahul-aggarwal/","asOf":"2026-09-08","days":20},{"id":"alan-venook","kind":"person","name":"Alan P. Venook","route":"/people/alan-venook/","asOf":"2026-09-08","days":20},{"id":"laura-esserman","kind":"person","name":"Laura J. Esserman","route":"/people/laura-esserman/","asOf":"2026-09-08","days":20},{"id":"thomas-hope","kind":"person","name":"Thomas A. Hope","route":"/people/thomas-hope/","asOf":"2026-09-08","days":20},{"id":"kevan-shokat","kind":"person","name":"Kevan M. Shokat","route":"/people/kevan-shokat/","asOf":"2026-09-08","days":20},{"id":"frank-mccormick","kind":"person","name":"Frank McCormick","route":"/people/frank-mccormick/","asOf":"2026-09-08","days":20},{"id":"emily-bergsland","kind":"person","name":"Emily K. Bergsland","route":"/people/emily-bergsland/","asOf":"2026-09-08","days":20},{"id":"katherine-matthay","kind":"person","name":"Katherine K. Matthay","route":"/people/katherine-matthay/","asOf":"2026-09-08","days":20},{"id":"steven-artandi","kind":"person","name":"Steven E. Artandi","route":"/people/steven-artandi/","asOf":"2026-09-08","days":20},{"id":"crystal-mackall","kind":"person","name":"Crystal L. Mackall","route":"/people/crystal-mackall/","asOf":"2026-09-08","days":20},{"id":"irving-weissman","kind":"person","name":"Irving L. Weissman","route":"/people/irving-weissman/","asOf":"2026-09-08","days":20},{"id":"ronald-levy","kind":"person","name":"Ronald Levy","route":"/people/ronald-levy/","asOf":"2026-09-08","days":20},{"id":"heather-wakelee","kind":"person","name":"Heather A. Wakelee","route":"/people/heather-wakelee/","asOf":"2026-09-08","days":20},{"id":"ash-alizadeh","kind":"person","name":"Ash A. Alizadeh","route":"/people/ash-alizadeh/","asOf":"2026-09-08","days":20},{"id":"maximilian-diehn","kind":"person","name":"Maximilian Diehn","route":"/people/maximilian-diehn/","asOf":"2026-09-08","days":20},{"id":"michael-teitell","kind":"person","name":"Michael A. Teitell","route":"/people/michael-teitell/","asOf":"2026-09-08","days":20},{"id":"antoni-ribas","kind":"person","name":"Antoni Ribas","route":"/people/antoni-ribas/","asOf":"2026-09-08","days":20},{"id":"dennis-slamon","kind":"person","name":"Dennis J. Slamon","route":"/people/dennis-slamon/","asOf":"2026-09-08","days":20},{"id":"johannes-czernin","kind":"person","name":"Johannes Czernin","route":"/people/johannes-czernin/","asOf":"2026-09-08","days":20},{"id":"jeremie-calais","kind":"person","name":"Jeremie Calais","route":"/people/jeremie-calais/","asOf":"2026-09-08","days":20},{"id":"owen-witte","kind":"person","name":"Owen N. Witte","route":"/people/owen-witte/","asOf":"2026-09-08","days":20},{"id":"amar-kishan","kind":"person","name":"Amar U. Kishan","route":"/people/amar-kishan/","asOf":"2026-09-08","days":20},{"id":"robert-stone","kind":"person","name":"Robert W. Stone","route":"/people/robert-stone/","asOf":"2026-09-08","days":20},{"id":"steven-rosen","kind":"person","name":"Steven T. Rosen","route":"/people/steven-rosen/","asOf":"2026-09-08","days":20},{"id":"michael-caligiuri","kind":"person","name":"Michael A. Caligiuri","route":"/people/michael-caligiuri/","asOf":"2026-09-08","days":20},{"id":"christine-brown","kind":"person","name":"Christine E. Brown","route":"/people/christine-brown/","asOf":"2026-09-08","days":20},{"id":"behnam-badie","kind":"person","name":"Behnam Badie","route":"/people/behnam-badie/","asOf":"2026-09-08","days":20},{"id":"hope-rugo","kind":"person","name":"Hope S. Rugo","route":"/people/hope-rugo/","asOf":"2026-09-08","days":20},{"id":"alex-herrera","kind":"person","name":"Alex F. Herrera","route":"/people/alex-herrera/","asOf":"2026-09-08","days":20},{"id":"virginia-sun","kind":"person","name":"Virginia Sun","route":"/people/virginia-sun/","asOf":"2026-09-08","days":20},{"id":"stephen-forman","kind":"person","name":"Stephen J. Forman","route":"/people/stephen-forman/","asOf":"2026-09-08","days":20},{"id":"thomas-lynch","kind":"person","name":"Thomas J. Lynch Jr.","route":"/people/thomas-lynch/","asOf":"2026-09-08","days":20},{"id":"stanley-riddell","kind":"person","name":"Stanley R. Riddell","route":"/people/stanley-riddell/","asOf":"2026-09-08","days":20},{"id":"sara-hurvitz","kind":"person","name":"Sara A. Hurvitz","route":"/people/sara-hurvitz/","asOf":"2026-09-08","days":20},{"id":"michael-leblanc","kind":"person","name":"Michael LeBlanc","route":"/people/michael-leblanc/","asOf":"2026-09-08","days":20},{"id":"philip-greenberg","kind":"person","name":"Philip D. Greenberg","route":"/people/philip-greenberg/","asOf":"2026-09-08","days":20},{"id":"denise-galloway","kind":"person","name":"Denise A. Galloway","route":"/people/denise-galloway/","asOf":"2026-09-08","days":20},{"id":"hans-peter-kiem","kind":"person","name":"Hans-Peter Kiem","route":"/people/hans-peter-kiem/","asOf":"2026-09-08","days":20},{"id":"gary-lyman","kind":"person","name":"Gary H. Lyman","route":"/people/gary-lyman/","asOf":"2026-09-08","days":20},{"id":"dawn-hershman","kind":"person","name":"Dawn L. Hershman","route":"/people/dawn-hershman/","asOf":"2026-09-08","days":20},{"id":"primo-lara","kind":"person","name":"Primo N. Lara Jr.","route":"/people/primo-lara/","asOf":"2026-09-08","days":20},{"id":"charles-blanke","kind":"person","name":"Charles D. Blanke","route":"/people/charles-blanke/","asOf":"2026-09-08","days":20},{"id":"neeraj-agarwal","kind":"person","name":"Neeraj Agarwal","route":"/people/neeraj-agarwal/","asOf":"2026-09-08","days":20},{"id":"kathy-albain","kind":"person","name":"Kathy S. Albain","route":"/people/kathy-albain/","asOf":"2026-09-08","days":20},{"id":"priyanka-sharma","kind":"person","name":"Priyanka Sharma","route":"/people/priyanka-sharma/","asOf":"2026-09-08","days":20},{"id":"anne-chiang","kind":"person","name":"Anne C. Chiang","route":"/people/anne-chiang/","asOf":"2026-09-08","days":20},{"id":"hagen-kennecke","kind":"person","name":"Hagen F. Kennecke","route":"/people/hagen-kennecke/","asOf":"2026-09-08","days":20},{"id":"charles-geyer","kind":"person","name":"Charles E. Geyer Jr.","route":"/people/charles-geyer/","asOf":"2026-09-08","days":20},{"id":"lori-pierce","kind":"person","name":"Lori J. Pierce","route":"/people/lori-pierce/","asOf":"2026-09-08","days":20},{"id":"deborah-bruner","kind":"person","name":"Deborah Watkins Bruner","route":"/people/deborah-bruner/","asOf":"2026-09-08","days":20},{"id":"peter-odwyer","kind":"person","name":"Peter J. O'Dwyer","route":"/people/peter-odwyer/","asOf":"2026-09-08","days":20},{"id":"mitchell-schnall","kind":"person","name":"Mitchell D. Schnall","route":"/people/mitchell-schnall/","asOf":"2026-09-08","days":20},{"id":"mark-litzow","kind":"person","name":"Mark R. Litzow","route":"/people/mark-litzow/","asOf":"2026-09-08","days":20},{"id":"douglas-hawkins","kind":"person","name":"Douglas S. Hawkins","route":"/people/douglas-hawkins/","asOf":"2026-09-08","days":20},{"id":"rachel-rau","kind":"person","name":"Rachel E. Rau","route":"/people/rachel-rau/","asOf":"2026-09-08","days":20},{"id":"susan-cohn","kind":"person","name":"Susan L. Cohn","route":"/people/susan-cohn/","asOf":"2026-09-08","days":20},{"id":"julie-park","kind":"person","name":"Julie R. Park","route":"/people/julie-park/","asOf":"2026-09-08","days":20},{"id":"alice-yu","kind":"person","name":"Alice L. Yu","route":"/people/alice-yu/","asOf":"2026-09-08","days":20},{"id":"clifford-hudis","kind":"person","name":"Clifford A. Hudis","route":"/people/clifford-hudis/","asOf":"2026-09-08","days":20},{"id":"robin-zon","kind":"person","name":"Robin T. Zon","route":"/people/robin-zon/","asOf":"2026-09-08","days":20},{"id":"lynn-schuchter","kind":"person","name":"Lynn M. Schuchter","route":"/people/lynn-schuchter/","asOf":"2026-09-08","days":20},{"id":"everett-vokes","kind":"person","name":"Everett E. Vokes","route":"/people/everett-vokes/","asOf":"2026-09-08","days":20},{"id":"margaret-foti","kind":"person","name":"Margaret Foti","route":"/people/margaret-foti/","asOf":"2026-09-08","days":20},{"id":"b-tumor-heterogeneity","kind":"bottleneck","name":"Tumour heterogeneity and clonal evolution","route":"/bottlenecks/b-tumor-heterogeneity/","asOf":"2026-09-08","days":20},{"id":"b-undruggable-targets","kind":"bottleneck","name":"The undruggable drivers","route":"/bottlenecks/b-undruggable-targets/","asOf":"2026-09-08","days":20},{"id":"b-preclinical-models","kind":"bottleneck","name":"Lab models that fail to predict what happens in patients","route":"/bottlenecks/b-preclinical-models/","asOf":"2026-09-08","days":20},{"id":"b-metastasis-biology","kind":"bottleneck","name":"Metastasis is understood least and studied last","route":"/bottlenecks/b-metastasis-biology/","asOf":"2026-09-08","days":20},{"id":"b-dormancy-mrd","kind":"bottleneck","name":"Dormant cells and minimal residual disease","route":"/bottlenecks/b-dormancy-mrd/","asOf":"2026-09-08","days":20},{"id":"b-resistance","kind":"bottleneck","name":"Acquired resistance to every therapy","route":"/bottlenecks/b-resistance/","asOf":"2026-09-08","days":20},{"id":"b-tme-immunosuppression","kind":"bottleneck","name":"Cold tumours and the immunosuppressive microenvironment","route":"/bottlenecks/b-tme-immunosuppression/","asOf":"2026-09-08","days":20},{"id":"b-brain-delivery","kind":"bottleneck","name":"The brain: barrier and sanctuary","route":"/bottlenecks/b-brain-delivery/","asOf":"2026-09-08","days":20},{"id":"b-cachexia-supportive","kind":"bottleneck","name":"Cachexia, toxicity and the limits of the patient","route":"/bottlenecks/b-cachexia-supportive/","asOf":"2026-09-08","days":20},{"id":"b-rare-cancers","kind":"bottleneck","name":"Rare and paediatric cancers without markets","route":"/bottlenecks/b-rare-cancers/","asOf":"2026-09-08","days":20},{"id":"b-immunotherapy-response","kind":"bottleneck","name":"No one can predict who responds to immunotherapy","route":"/bottlenecks/b-immunotherapy-response/","asOf":"2026-09-08","days":20},{"id":"b-early-detection","kind":"bottleneck","name":"The hardest cancers are found late","route":"/bottlenecks/b-early-detection/","asOf":"2026-09-08","days":20},{"id":"b-overdiagnosis","kind":"bottleneck","name":"Overdiagnosis and false alarms","route":"/bottlenecks/b-overdiagnosis/","asOf":"2026-09-08","days":20},{"id":"b-prevention-adoption","kind":"bottleneck","name":"Prevention we already have is not deployed","route":"/bottlenecks/b-prevention-adoption/","asOf":"2026-09-08","days":20},{"id":"b-hereditary-risk","kind":"bottleneck","name":"Inherited risk is mostly unidentified","route":"/bottlenecks/b-hereditary-risk/","asOf":"2026-09-08","days":20},{"id":"b-trial-enrolment","kind":"bottleneck","name":"Trials enrol too few, too slowly","route":"/bottlenecks/b-trial-enrolment/","asOf":"2026-09-08","days":20},{"id":"b-trial-design","kind":"bottleneck","name":"Trial design, endpoints and cost","route":"/bottlenecks/b-trial-design/","asOf":"2026-09-08","days":20},{"id":"b-trial-diversity","kind":"bottleneck","name":"Trials do not represent the people who get cancer","route":"/bottlenecks/b-trial-diversity/","asOf":"2026-09-08","days":20},{"id":"b-dose-optimisation","kind":"bottleneck","name":"Wrong doses","route":"/bottlenecks/b-dose-optimisation/","asOf":"2026-09-08","days":20},{"id":"b-combination-space","kind":"bottleneck","name":"Too many combinations to test","route":"/bottlenecks/b-combination-space/","asOf":"2026-09-08","days":20},{"id":"b-negative-results","kind":"bottleneck","name":"Failures are hidden","route":"/bottlenecks/b-negative-results/","asOf":"2026-09-08","days":20},{"id":"b-biomarker-validation","kind":"bottleneck","name":"Biomarkers are not validated or standardised","route":"/bottlenecks/b-biomarker-validation/","asOf":"2026-09-08","days":20},{"id":"b-regulatory-fragmentation","kind":"bottleneck","name":"Regulatory divergence between regions","route":"/bottlenecks/b-regulatory-fragmentation/","asOf":"2026-09-08","days":20},{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/","asOf":"2026-09-08","days":20},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/","asOf":"2026-09-08","days":20},{"id":"b-generic-repurposing","kind":"bottleneck","name":"No incentive to repurpose cheap drugs","route":"/bottlenecks/b-generic-repurposing/","asOf":"2026-09-08","days":20},{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/","asOf":"2026-09-08","days":20},{"id":"b-workforce","kind":"bottleneck","name":"Not enough oncologists, nurses, pathologists, physicists","route":"/bottlenecks/b-workforce/","asOf":"2026-09-08","days":20},{"id":"b-care-fragmentation","kind":"bottleneck","name":"Fragmented care and guideline gaps","route":"/bottlenecks/b-care-fragmentation/","asOf":"2026-09-08","days":20},{"id":"b-survivorship","kind":"bottleneck","name":"Survivorship and late effects are neglected","route":"/bottlenecks/b-survivorship/","asOf":"2026-09-08","days":20},{"id":"b-palliative","kind":"bottleneck","name":"Pain relief and palliative care are unavailable to most","route":"/bottlenecks/b-palliative/","asOf":"2026-09-08","days":20},{"id":"b-aging-comorbidity","kind":"bottleneck","name":"Older and multimorbid patients are excluded and undertreated","route":"/bottlenecks/b-aging-comorbidity/","asOf":"2026-09-08","days":20},{"id":"b-data-silos","kind":"bottleneck","name":"Data silos","route":"/bottlenecks/b-data-silos/","asOf":"2026-09-08","days":20},{"id":"b-real-world-evidence","kind":"bottleneck","name":"Weak real-world evidence and registries","route":"/bottlenecks/b-real-world-evidence/","asOf":"2026-09-08","days":20},{"id":"b-reproducibility","kind":"bottleneck","name":"Preclinical results do not reproduce","route":"/bottlenecks/b-reproducibility/","asOf":"2026-09-08","days":20},{"id":"b-knowledge-diffusion","kind":"bottleneck","name":"Knowledge reaches practice too slowly","route":"/bottlenecks/b-knowledge-diffusion/","asOf":"2026-09-08","days":20},{"id":"b-ai-validation","kind":"bottleneck","name":"AI that is built but not validated or deployed","route":"/bottlenecks/b-ai-validation/","asOf":"2026-09-08","days":20},{"id":"b-funding-allocation","kind":"bottleneck","name":"Funding follows fashion, not burden","route":"/bottlenecks/b-funding-allocation/","asOf":"2026-09-08","days":20},{"id":"b-incentive-misalignment","kind":"bottleneck","name":"Incentives reward me-too drugs and marginal gains","route":"/bottlenecks/b-incentive-misalignment/","asOf":"2026-09-08","days":20},{"id":"b-translational-valley","kind":"bottleneck","name":"The valley of death between lab and product","route":"/bottlenecks/b-translational-valley/","asOf":"2026-09-08","days":20},{"id":"b-ip-collaboration","kind":"bottleneck","name":"Secrecy and intellectual property block collaboration","route":"/bottlenecks/b-ip-collaboration/","asOf":"2026-09-08","days":20},{"id":"b-surgery-radiation-innovation","kind":"bottleneck","name":"Surgery and radiotherapy cure most, get least","route":"/bottlenecks/b-surgery-radiation-innovation/","asOf":"2026-09-08","days":20},{"id":"b-patient-voice","kind":"bottleneck","name":"Patients lack understanding, navigation and agency","route":"/bottlenecks/b-patient-voice/","asOf":"2026-09-08","days":20},{"id":"b-toxicity-qol","kind":"bottleneck","name":"Toxicity and quality of life are undervalued","route":"/bottlenecks/b-toxicity-qol/","asOf":"2026-09-08","days":20},{"id":"b-misinformation","kind":"bottleneck","name":"Misinformation and unproven therapies","route":"/bottlenecks/b-misinformation/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-multiregion-blocks-default","kind":"idea","name":"Bank three spatially separate tumour blocks from every resection","route":"/ideas/idea-bio1-multiregion-blocks-default/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-rapid-autopsy-network","kind":"idea","name":"A national rapid research autopsy network for end-stage cancer","route":"/ideas/idea-bio1-rapid-autopsy-network/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-ctdna-clone-report","kind":"idea","name":"A clone report from blood at every treatment cycle","route":"/ideas/idea-bio1-ctdna-clone-report/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-truncal-branch-labelling","kind":"idea","name":"Label every targetable mutation as truncal or branch on the report","route":"/ideas/idea-bio1-truncal-branch-labelling/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-outlier-lesion-biopsy","kind":"idea","name":"Biopsy the one lesion that is growing while the others shrink","route":"/ideas/idea-bio1-outlier-lesion-biopsy/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-barcoded-avatars-clonal-fitness","kind":"idea","name":"Barcode patient-derived tumours to watch which clones win under each drug","route":"/ideas/idea-bio1-barcoded-avatars-clonal-fitness/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-evolvability-index","kind":"idea","name":"A standard evolvability score for every tumour","route":"/ideas/idea-bio1-evolvability-index/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-adaptive-therapy-platform","kind":"idea","name":"A multi-cancer platform trial of adaptive (dose-holiday) therapy","route":"/ideas/idea-bio1-adaptive-therapy-platform/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-ctdna-adaptive-tki","kind":"idea","name":"ctDNA-guided dose holidays for lung cancer targeted therapy","route":"/ideas/idea-bio1-ctdna-adaptive-tki/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-first-strike-second-strike","kind":"idea","name":"Switch drugs at maximum response, not at relapse","route":"/ideas/idea-bio1-first-strike-second-strike/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-collateral-sensitivity-atlas","kind":"idea","name":"An open atlas of collateral sensitivity for every approved targeted drug","route":"/ideas/idea-bio1-collateral-sensitivity-atlas/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-evolutionary-double-bind","kind":"idea","name":"Design drug pairs where resisting one makes you vulnerable to the other","route":"/ideas/idea-bio1-evolutionary-double-bind/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-spatial-clone-immune-map","kind":"idea","name":"Map which tumour clones sit next to which immune cells before choosing therapy","route":"/ideas/idea-bio1-spatial-clone-immune-map/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-methylation-clone-tracking","kind":"idea","name":"Track clones in blood with methylation patterns instead of mutations","route":"/ideas/idea-bio1-methylation-clone-tracking/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-clonal-clearance-endpoint","kind":"idea","name":"Make clonal clearance, not tumour shrinkage, a trial endpoint","route":"/ideas/idea-bio1-clonal-clearance-endpoint/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-evolution-forecasting","kind":"idea","name":"Forecast the next resistance mutation like the weather","route":"/ideas/idea-bio1-evolution-forecasting/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-baseline-ultradeep-resistant-clones","kind":"idea","name":"Look for the resistant sub-population before the first dose","route":"/ideas/idea-bio1-baseline-ultradeep-resistant-clones/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-cfrna-plasticity-tracking","kind":"idea","name":"Detect tumours changing cell type from RNA in the blood","route":"/ideas/idea-bio1-cfrna-plasticity-tracking/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-evolutionary-tumour-boards","kind":"idea","name":"Evolutionary tumour boards with a modeller in the room","route":"/ideas/idea-bio1-evolutionary-tumour-boards/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-apobec-inhibitor-adjunct","kind":"idea","name":"Slow the tumour's mutation engine with APOBEC inhibitors during targeted therapy","route":"/ideas/idea-bio1-apobec-inhibitor-adjunct/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-cin-vulnerability-kif18a","kind":"idea","name":"Turn chromosomal chaos into a weakness with KIF18A inhibitors","route":"/ideas/idea-bio1-cin-vulnerability-kif18a/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-federated-evolution-atlas","kind":"idea","name":"Pool every multi-sample tumour genome into one open evolution atlas","route":"/ideas/idea-bio1-federated-evolution-atlas/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-clone-to-lesion-mapping","kind":"idea","name":"Match each blood-detected clone to the lesion it comes from on the scan","route":"/ideas/idea-bio1-clone-to-lesion-mapping/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-rebiopsy-before-switch","kind":"idea","name":"Re-test the metastasis, not the old primary, before every change of treatment","route":"/ideas/idea-bio1-rebiopsy-before-switch/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-clonal-neoantigen-vaccines","kind":"idea","name":"Vaccines aimed only at mutations shared by every tumour cell","route":"/ideas/idea-bio1-clonal-neoantigen-vaccines/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-myc-max-molecular-glue","kind":"idea","name":"Molecular glues that break the MYC-MAX partnership","route":"/ideas/idea-bio1-myc-max-molecular-glue/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-omomyc-mrna","kind":"idea","name":"mRNA-delivered MYC decoy proteins instead of MYC inhibitors","route":"/ideas/idea-bio1-omomyc-mrna/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-p53-mutant-reactivator-expansion","kind":"idea","name":"Extend p53 reactivation beyond the Y220C mutation","route":"/ideas/idea-bio1-p53-mutant-reactivator-expansion/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-mutant-p53-degrader","kind":"idea","name":"Degrade the damaged p53 protein rather than trying to repair it","route":"/ideas/idea-bio1-mutant-p53-degrader/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-pan-ras-covalent-g12d","kind":"idea","name":"Covalent chemistry for the RAS mutations that still have no drug","route":"/ideas/idea-bio1-pan-ras-covalent-g12d/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-covalent-ligandability-atlas","kind":"idea","name":"An open map of which cancer proteins any drug can stick to","route":"/ideas/idea-bio1-covalent-ligandability-atlas/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-glue-degrader-atlas","kind":"idea","name":"Screen glue-like compounds against every cancer cell line and publish it","route":"/ideas/idea-bio1-glue-degrader-atlas/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-fusion-tf-degraders","kind":"idea","name":"Degraders for the fusion proteins that drive childhood sarcomas","route":"/ideas/idea-bio1-fusion-tf-degraders/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-condensate-disruptors","kind":"idea","name":"Break up the liquid droplets where oncogenic transcription happens","route":"/ideas/idea-bio1-condensate-disruptors/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-tumour-restricted-e3-atlas","kind":"idea","name":"Find E3 ligases that only tumours have, and build degraders around them","route":"/ideas/idea-bio1-tumour-restricted-e3-atlas/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-antibody-degrader-conjugates","kind":"idea","name":"Use antibodies to deliver protein-destroying drugs into the right cells","route":"/ideas/idea-bio1-antibody-degrader-conjugates/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-lytac-surface-degraders","kind":"idea","name":"Drag cancer's surface and secreted proteins to the cell's recycling bin","route":"/ideas/idea-bio1-lytac-surface-degraders/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-rna-targeting-small-molecules","kind":"idea","name":"Small molecules that cut the RNA message of an undruggable oncogene","route":"/ideas/idea-bio1-rna-targeting-small-molecules/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-epigenetic-silencing-in-vivo","kind":"idea","name":"Switch off an undruggable oncogene permanently with epigenetic editing","route":"/ideas/idea-bio1-epigenetic-silencing-in-vivo/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-paralog-synthetic-lethality","kind":"idea","name":"Attack the backup copy when a tumour has lost the original gene","route":"/ideas/idea-bio1-paralog-synthetic-lethality/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-pp2a-activators","kind":"idea","name":"Turn a brake back on: drugs that reactivate the PP2A phosphatase","route":"/ideas/idea-bio1-pp2a-activators/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-wrn-msi-programme","kind":"idea","name":"WRN inhibitors: a second synthetic-lethal win for mismatch-repair cancers","route":"/ideas/idea-bio1-wrn-msi-programme/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-macrocycle-ppi-campaign","kind":"idea","name":"Macrocyclic peptides to cover protein surfaces that pills cannot","route":"/ideas/idea-bio1-macrocycle-ppi-campaign/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-arv7-degrader","kind":"idea","name":"Destroy the truncated androgen receptor that hormone drugs cannot touch","route":"/ideas/idea-bio1-arv7-degrader/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-ai-binders-disordered-regions","kind":"idea","name":"AI-designed proteins that grip the floppy parts of cancer drivers","route":"/ideas/idea-bio1-ai-binders-disordered-regions/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-pmhc-bispecifics-public-drivers","kind":"idea","name":"Antibodies that see mutant KRAS and p53 fragments displayed on the cell surface","route":"/ideas/idea-bio1-pmhc-bispecifics-public-drivers/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-mrna-intrabodies","kind":"idea","name":"Instruct tumour cells to make antibodies against their own oncoprotein","route":"/ideas/idea-bio1-mrna-intrabodies/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-translation-dependency-myc","kind":"idea","name":"Starve MYC-driven tumours by blocking protein production machinery","route":"/ideas/idea-bio1-translation-dependency-myc/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-undruggable-open-consortium","kind":"idea","name":"A precompetitive consortium for the twenty hardest cancer targets","route":"/ideas/idea-bio1-undruggable-open-consortium/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-undruggable-market-commitment","kind":"idea","name":"A guaranteed purchase prize for the first drug against a named hard target","route":"/ideas/idea-bio1-undruggable-market-commitment/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-immune-matched-humanised-mice","kind":"idea","name":"Humanised mice with an immune system matched to the tumour donor","route":"/ideas/idea-bio1-immune-matched-humanised-mice/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-co-clinical-avatar-trials","kind":"idea","name":"Run the mouse or organoid trial at the same time as the human trial","route":"/ideas/idea-bio1-co-clinical-avatar-trials/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-organoid-immune-coculture","kind":"idea","name":"Grow tumour organoids together with the patient's own immune cells","route":"/ideas/idea-bio1-organoid-immune-coculture/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-tumour-on-chip-penetration","kind":"idea","name":"Tumour-on-a-chip with blood flow to test whether big drugs actually get in","route":"/ideas/idea-bio1-tumour-on-chip-penetration/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-in-silico-trials-dose","kind":"idea","name":"In silico trials to choose the dose before the first patient","route":"/ideas/idea-bio1-in-silico-trials-dose/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-preclinical-preregistration","kind":"idea","name":"Pre-register animal efficacy studies like clinical trials","route":"/ideas/idea-bio1-preclinical-preregistration/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-multicentre-mouse-trials","kind":"idea","name":"Multi-centre randomised animal trials before committing to a human trial","route":"/ideas/idea-bio1-multicentre-mouse-trials/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-model-predictivity-benchmark","kind":"idea","name":"Score every model system on how well it predicted real trial results","route":"/ideas/idea-bio1-model-predictivity-benchmark/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-negative-preclinical-repository","kind":"idea","name":"A home for the animal and organoid experiments that failed","route":"/ideas/idea-bio1-negative-preclinical-repository/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-tumour-slice-cultures","kind":"idea","name":"Test drugs on freshly cut slices of the patient's own tumour","route":"/ideas/idea-bio1-tumour-slice-cultures/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-metastatic-niche-models","kind":"idea","name":"Build laboratory models of the organs cancer spreads to","route":"/ideas/idea-bio1-metastatic-niche-models/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-aged-comorbid-models","kind":"idea","name":"Test cancer drugs in old and unhealthy animals, not just young fit ones","route":"/ideas/idea-bio1-aged-comorbid-models/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-comparative-oncology-dogs","kind":"idea","name":"Pet dogs with spontaneous cancer as a bridge before human trials","route":"/ideas/idea-bio1-comparative-oncology-dogs/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-zebrafish-avatars","kind":"idea","name":"Zebrafish avatars for a drug answer within a week","route":"/ideas/idea-bio1-zebrafish-avatars/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-multi-organ-chip-tox","kind":"idea","name":"Linked human organ chips to predict side effects before people are dosed","route":"/ideas/idea-bio1-multi-organ-chip-tox/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-rare-cancer-organoid-bank","kind":"idea","name":"An open organoid bank for cancers too rare to have models","route":"/ideas/idea-bio1-rare-cancer-organoid-bank/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-organoid-assay-clinical-validation","kind":"idea","name":"Hold organoid drug tests to the same standard as a diagnostic test","route":"/ideas/idea-bio1-organoid-assay-clinical-validation/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-organoid-cell-therapy-potency","kind":"idea","name":"Use patient organoids to check a cell therapy will work before infusing it","route":"/ideas/idea-bio1-organoid-cell-therapy-potency/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-somatic-crispr-gemms","kind":"idea","name":"Make bespoke mouse cancer models in weeks with in vivo gene editing","route":"/ideas/idea-bio1-somatic-crispr-gemms/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-ctc-derived-explants","kind":"idea","name":"Grow models from tumour cells in the blood when a biopsy is impossible","route":"/ideas/idea-bio1-ctc-derived-explants/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-model-authentication-mandate","kind":"idea","name":"Prove the cell line is what you say it is, or the paper does not run","route":"/ideas/idea-bio1-model-authentication-mandate/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-reverse-translation-resistance-models","kind":"idea","name":"Every resistance mechanism found in a patient must be rebuilt in the laboratory","route":"/ideas/idea-bio1-reverse-translation-resistance-models/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-ex-vivo-perfused-tumour","kind":"idea","name":"Keep a freshly removed tumour alive on a pump and test drugs in it","route":"/ideas/idea-bio1-ex-vivo-perfused-tumour/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-model-patient-matching","kind":"idea","name":"Pick the laboratory model that matches the patient, not the one to hand","route":"/ideas/idea-bio1-model-patient-matching/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-virtual-cell-perturbation","kind":"idea","name":"A virtual cancer cell that predicts what a drug will do before you test it","route":"/ideas/idea-bio1-virtual-cell-perturbation/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-mandatory-progression-biopsy","kind":"idea","name":"Fund a biopsy at progression, every time, as standard care","route":"/ideas/idea-bio1-mandatory-progression-biopsy/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-open-resistance-atlas","kind":"idea","name":"One open atlas of how tumours escape every drug","route":"/ideas/idea-bio1-open-resistance-atlas/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-upfront-bypass-combination","kind":"idea","name":"Add the second drug on day one when the escape route is predictable","route":"/ideas/idea-bio1-upfront-bypass-combination/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-pre-randomised-sequencing-trials","kind":"idea","name":"Randomise the next line of treatment before the first one fails","route":"/ideas/idea-bio1-pre-randomised-sequencing-trials/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-antigen-mapping-at-progression","kind":"idea","name":"Re-map the tumour's surface proteins before choosing the next antibody drug","route":"/ideas/idea-bio1-antigen-mapping-at-progression/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-dual-antigen-adc-escape","kind":"idea","name":"Two-target antibody drugs to close the antigen escape route","route":"/ideas/idea-bio1-dual-antigen-adc-escape/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-adaptive-car-antigen-switch","kind":"idea","name":"Plan the second CAR-T target before the first one is lost","route":"/ideas/idea-bio1-adaptive-car-antigen-switch/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-drug-holiday-resensitisation","kind":"idea","name":"Pause a failed drug so the tumour becomes sensitive to it again","route":"/ideas/idea-bio1-drug-holiday-resensitisation/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-persister-ferroptosis","kind":"idea","name":"Kill the sleeping survivor cells with iron-dependent cell death","route":"/ideas/idea-bio1-persister-ferroptosis/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-epigenetic-persister-blockade","kind":"idea","name":"Block the chemical switch that lets cells hide from treatment","route":"/ideas/idea-bio1-epigenetic-persister-blockade/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-mutagenesis-blockade-rev1","kind":"idea","name":"Turn off the error-prone repair that manufactures resistance mutations","route":"/ideas/idea-bio1-mutagenesis-blockade-rev1/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-stress-response-blockade","kind":"idea","name":"Cut off the emergency programme cancer cells use to survive treatment","route":"/ideas/idea-bio1-stress-response-blockade/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-senolytics-after-therapy","kind":"idea","name":"Clear the zombie cells left behind by chemotherapy and radiotherapy","route":"/ideas/idea-bio1-senolytics-after-therapy/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-persister-metabolic-vulnerability","kind":"idea","name":"Starve the survivors: target the energy pathway drug-tolerant cells switch to","route":"/ideas/idea-bio1-persister-metabolic-vulnerability/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-molecular-progression-add-on","kind":"idea","name":"Add a drug when the blood test turns, without stopping the one that works","route":"/ideas/idea-bio1-molecular-progression-add-on/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-alternating-schedules","kind":"idea","name":"Rotate between drugs on a fixed schedule instead of waiting for failure","route":"/ideas/idea-bio1-alternating-schedules/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-resistance-mutation-vaccine","kind":"idea","name":"Vaccinate against the resistance mutation before it takes over","route":"/ideas/idea-bio1-resistance-mutation-vaccine/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-mechanism-matched-access","kind":"idea","name":"A fast route to the matched drug when it is licensed for another cancer","route":"/ideas/idea-bio1-mechanism-matched-access/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-resistance-platform-trial","kind":"idea","name":"A standing platform trial that assigns treatment by how the tumour escaped","route":"/ideas/idea-bio1-resistance-platform-trial/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-slfn11-payload-guidance","kind":"idea","name":"Use SLFN11 status to decide which antibody-drug payload to give next","route":"/ideas/idea-bio1-slfn11-payload-guidance/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-stromal-resistance-blockade","kind":"idea","name":"Block the survival signals the tumour's neighbours provide","route":"/ideas/idea-bio1-stromal-resistance-blockade/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-real-world-resistance-surveillance","kind":"idea","name":"Treat resistance like an infectious disease and run national surveillance","route":"/ideas/idea-bio1-real-world-resistance-surveillance/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-approval-linked-progression-sampling","kind":"idea","name":"Make post-progression sampling a condition of accelerated approval","route":"/ideas/idea-bio1-approval-linked-progression-sampling/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-drug-exposure-sanctuary-mapping","kind":"idea","name":"Find the parts of a tumour the drug never reaches","route":"/ideas/idea-bio1-drug-exposure-sanctuary-mapping/","asOf":"2026-09-08","days":20},{"id":"idea-bio1-immunopeptidome-timing","kind":"idea","name":"Time immunotherapy to the moment targeted drugs make tumours visible","route":"/ideas/idea-bio1-immunopeptidome-timing/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-antimetastatic-endpoint","kind":"idea","name":"A regulatory endpoint for drugs that block spread, not tumours","route":"/ideas/idea-bio2-antimetastatic-endpoint/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-ctc-clearance-go-nogo","kind":"idea","name":"Circulating tumour cell clearance as the phase 2 gate for anti-metastatic drugs","route":"/ideas/idea-bio2-ctc-clearance-go-nogo/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-net-blockade-perioperative","kind":"idea","name":"Break the neutrophil DNA nets that catch tumour cells after surgery","route":"/ideas/idea-bio2-net-blockade-perioperative/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-perioperative-betablocker-nsaid","kind":"idea","name":"Cheap perioperative beta-blocker plus anti-inflammatory to blunt surgical stress","route":"/ideas/idea-bio2-perioperative-betablocker-nsaid/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-premetastatic-niche-assay","kind":"idea","name":"A blood test for the pre-metastatic niche","route":"/ideas/idea-bio2-premetastatic-niche-assay/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-inhaled-lung-niche-immunotherapy","kind":"idea","name":"Inhaled immune therapy to make the lung hostile to arriving tumour cells","route":"/ideas/idea-bio2-inhaled-lung-niche-immunotherapy/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-liver-niche-kupffer-reprogramming","kind":"idea","name":"Reprogramme the liver's own immune cells to refuse metastases","route":"/ideas/idea-bio2-liver-niche-kupffer-reprogramming/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-cxcr4-mobilise-then-kill","kind":"idea","name":"Flush dormant cells out of bone marrow, then kill them","route":"/ideas/idea-bio2-cxcr4-mobilise-then-kill/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-platelet-cloak-aspirin-mrd","kind":"idea","name":"Strip the platelet coat off travelling tumour cells in ctDNA-positive patients","route":"/ideas/idea-bio2-platelet-cloak-aspirin-mrd/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-rapid-autopsy-commons","kind":"idea","name":"A global rapid tissue donation network for metastatic disease","route":"/ideas/idea-bio2-rapid-autopsy-commons/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-metastasis-screen-standard","kind":"idea","name":"Make in vivo metastasis screens a required step in drug discovery","route":"/ideas/idea-bio2-metastasis-screen-standard/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-ctc-culture-functional-testing","kind":"idea","name":"Grow blood-borne tumour cells to test drugs on the cells that actually spread","route":"/ideas/idea-bio2-ctc-culture-functional-testing/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-lymph-node-immune-priming","kind":"idea","name":"Treat the draining lymph node before removing it","route":"/ideas/idea-bio2-lymph-node-immune-priming/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-organotropism-atlas","kind":"idea","name":"An organotropism atlas that predicts where a cancer will spread","route":"/ideas/idea-bio2-organotropism-atlas/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-metastasis-funding-floor","kind":"idea","name":"Ring-fence a fifth of national cancer research money for metastasis","route":"/ideas/idea-bio2-metastasis-funding-floor/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-matrix-stiffness-prevention","kind":"idea","name":"Soften the tissue that new metastases need in order to grow","route":"/ideas/idea-bio2-matrix-stiffness-prevention/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-brain-met-prevention-trials","kind":"idea","name":"Prevention trials aimed only at brain metastasis","route":"/ideas/idea-bio2-brain-met-prevention-trials/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-oligometastatic-signature","kind":"idea","name":"A test to tell true oligometastatic disease from hidden widespread spread","route":"/ideas/idea-bio2-oligometastatic-signature/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-dormancy-selective-screen","kind":"idea","name":"A drug screen that only rewards killing sleeping cancer cells","route":"/ideas/idea-bio2-dormancy-selective-screen/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-autophagy-block-mrd","kind":"idea","name":"Block the recycling that keeps dormant cells alive","route":"/ideas/idea-bio2-autophagy-block-mrd/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-pro-dormancy-therapy","kind":"idea","name":"Keep dormant cells asleep instead of trying to kill them","route":"/ideas/idea-bio2-pro-dormancy-therapy/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-il1-awakening-blockade","kind":"idea","name":"Blunt the inflammation that wakes sleeping cancer cells","route":"/ideas/idea-bio2-il1-awakening-blockade/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-national-mrd-platform","kind":"idea","name":"A national platform trial that every ctDNA-positive patient can join","route":"/ideas/idea-bio2-national-mrd-platform/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-mrd-reference-standards","kind":"idea","name":"Reference materials and open proficiency testing for residual disease tests","route":"/ideas/idea-bio2-mrd-reference-standards/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-mrd-triggered-neoantigen-vaccine","kind":"idea","name":"Personalised vaccines given only when the blood test turns positive","route":"/ideas/idea-bio2-mrd-triggered-neoantigen-vaccine/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-nk-cells-for-mrd","kind":"idea","name":"Off-the-shelf natural killer cells to sweep up residual disease","route":"/ideas/idea-bio2-nk-cells-for-mrd/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-whole-genome-mrd-depth","kind":"idea","name":"Push residual disease detection a hundredfold deeper with whole-genome methods","route":"/ideas/idea-bio2-whole-genome-mrd-depth/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-marrow-niche-on-chip","kind":"idea","name":"A bone marrow niche on a chip to study human dormancy","route":"/ideas/idea-bio2-marrow-niche-on-chip/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-localise-the-mrd","kind":"idea","name":"When the blood test is positive, hunt for the lesion with sensitive imaging","route":"/ideas/idea-bio2-localise-the-mrd/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-circadian-mrd-sampling","kind":"idea","name":"Take the blood test, and give the drug, at the right time of day","route":"/ideas/idea-bio2-circadian-mrd-sampling/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-mrd-guided-endocrine-duration","kind":"idea","name":"Use residual disease tests to decide who needs ten years of hormone therapy","route":"/ideas/idea-bio2-mrd-guided-endocrine-duration/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-mrd-coverage-with-evidence","kind":"idea","name":"Pay for residual disease tests only inside a trial or registry","route":"/ideas/idea-bio2-mrd-coverage-with-evidence/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-mrd-clinic-service","kind":"idea","name":"A dedicated clinic for people whose blood test says the cancer is back","route":"/ideas/idea-bio2-mrd-clinic-service/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-survivor-plasma-biobank","kind":"idea","name":"Bank yearly blood from cancer survivors so future tests can be validated","route":"/ideas/idea-bio2-survivor-plasma-biobank/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-trem2-myeloid-reprogramming","kind":"idea","name":"Reprogramme suppressive macrophages instead of trying to delete them","route":"/ideas/idea-bio2-trem2-myeloid-reprogramming/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-in-situ-vaccination-solid","kind":"idea","name":"Turn one tumour into a vaccine to treat all the others","route":"/ideas/idea-bio2-in-situ-vaccination-solid/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-oncolytic-regulated-il12","kind":"idea","name":"Oncolytic viruses that make interleukin-12 only inside the tumour","route":"/ideas/idea-bio2-oncolytic-regulated-il12/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-engineered-bacteria-payloads","kind":"idea","name":"Engineered bacteria that live in tumours and manufacture drugs there","route":"/ideas/idea-bio2-engineered-bacteria-payloads/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-tumour-anchored-tgfbeta-trap","kind":"idea","name":"Anchor a TGF-beta trap in the tumour stroma so it cannot act everywhere","route":"/ideas/idea-bio2-tumour-anchored-tgfbeta-trap/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-lactate-acid-axis","kind":"idea","name":"De-acidify the tumour so T cells can work in it","route":"/ideas/idea-bio2-lactate-acid-axis/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-radiotherapy-sting-fractionation","kind":"idea","name":"Pick the radiation dose that switches the immune alarm on, not off","route":"/ideas/idea-bio2-radiotherapy-sting-fractionation/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-let-rbe-ab-selects-protons","kind":"idea","name":"Use LET, RBE and alpha/beta to decide when protons beat IMRT","route":"/ideas/idea-bio2-let-rbe-ab-selects-protons/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-tertiary-lymphoid-induction","kind":"idea","name":"Grow immune command posts inside tumours","route":"/ideas/idea-bio2-tertiary-lymphoid-induction/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-cxcr2-neutrophil-blockade","kind":"idea","name":"Clear the suppressive neutrophils out of pancreatic tumours first","route":"/ideas/idea-bio2-cxcr2-neutrophil-blockade/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-caf-subtype-assignment","kind":"idea","name":"Match therapy to the type of scar-forming cell in the tumour","route":"/ideas/idea-bio2-caf-subtype-assignment/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-implantable-microdevice-screen","kind":"idea","name":"Implant a tiny device that tests twenty drugs inside the patient's own tumour","route":"/ideas/idea-bio2-implantable-microdevice-screen/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-vascular-normalisation-window","kind":"idea","name":"Use imaging to find the window when tumour blood vessels are working properly","route":"/ideas/idea-bio2-vascular-normalisation-window/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-complement-c5ar-blockade","kind":"idea","name":"Block the complement signal that recruits tumour-protecting cells","route":"/ideas/idea-bio2-complement-c5ar-blockade/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-intracavitary-immunotherapy","kind":"idea","name":"Treat the body cavity, not the bloodstream, for surface spread","route":"/ideas/idea-bio2-intracavitary-immunotherapy/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-myeloid-engager-bispecific","kind":"idea","name":"Bispecific antibodies that engage macrophages instead of T cells","route":"/ideas/idea-bio2-myeloid-engager-bispecific/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-hypoxia-guided-adenosine","kind":"idea","name":"Use a hypoxia scan to pick patients for adenosine-pathway drugs","route":"/ideas/idea-bio2-hypoxia-guided-adenosine/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-histotripsy-immune-priming","kind":"idea","name":"Mechanically pulverise one tumour with ultrasound to wake the immune system","route":"/ideas/idea-bio2-histotripsy-immune-priming/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-trained-immunity-priming","kind":"idea","name":"Train the bone marrow to make better anti-tumour immune cells","route":"/ideas/idea-bio2-trained-immunity-priming/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-sonobiopsy","kind":"idea","name":"Ultrasound-assisted blood test instead of a brain biopsy","route":"/ideas/idea-bio2-sonobiopsy/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-intraventricular-car-t","kind":"idea","name":"Deliver CAR-T cells straight into the fluid around the brain","route":"/ideas/idea-bio2-intraventricular-car-t/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-robotic-convection-delivery","kind":"idea","name":"Robot-placed catheters and live imaging for drug infusion into brain tumours","route":"/ideas/idea-bio2-robotic-convection-delivery/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-transferrin-shuttle-adc","kind":"idea","name":"Use the brain's own transport door to carry antibody drugs across","route":"/ideas/idea-bio2-transferrin-shuttle-adc/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-implanted-ultrasound-repeat-dosing","kind":"idea","name":"A skull ultrasound implant that opens the barrier at every cycle","route":"/ideas/idea-bio2-implanted-ultrasound-repeat-dosing/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-cns-cohort-mandate","kind":"idea","name":"Stop excluding brain metastases from cancer trials","route":"/ideas/idea-bio2-cns-cohort-mandate/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-csf-ctdna-monitoring","kind":"idea","name":"Read the spinal fluid to track brain tumours without opening the skull","route":"/ideas/idea-bio2-csf-ctdna-monitoring/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-brain-exposure-disclosure","kind":"idea","name":"Require every oncology candidate to publish how much reaches the brain","route":"/ideas/idea-bio2-brain-exposure-disclosure/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-intranasal-delivery","kind":"idea","name":"Deliver drugs and cells to the brain through the nose","route":"/ideas/idea-bio2-intranasal-delivery/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-blood-csf-barrier-model","kind":"idea","name":"Build a human model of the barrier that guards the brain fluid","route":"/ideas/idea-bio2-blood-csf-barrier-model/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-fus-for-cell-entry","kind":"idea","name":"Open the barrier so engineered immune cells can enter the brain","route":"/ideas/idea-bio2-fus-for-cell-entry/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-brain-penetrant-glue-degraders","kind":"idea","name":"Design protein degraders small enough to get into the brain","route":"/ideas/idea-bio2-brain-penetrant-glue-degraders/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-gdf15-plus-exercise","kind":"idea","name":"Combine the new anti-wasting antibody with exercise and protein","route":"/ideas/idea-bio2-gdf15-plus-exercise/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-gdf15-stratified-enrolment","kind":"idea","name":"Select cachexia trial patients by the hormone driving their wasting","route":"/ideas/idea-bio2-gdf15-stratified-enrolment/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-cachexia-function-endpoint","kind":"idea","name":"Qualify a physical function endpoint so anti-wasting drugs can be approved","route":"/ideas/idea-bio2-cachexia-function-endpoint/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-prehabilitation-standard","kind":"idea","name":"Four weeks of training and nutrition before major cancer surgery, as standard","route":"/ideas/idea-bio2-prehabilitation-standard/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-exercise-reimbursement","kind":"idea","name":"Pay for supervised exercise the way we pay for drugs","route":"/ideas/idea-bio2-exercise-reimbursement/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-anamorelin-access","kind":"idea","name":"Get the one approved appetite drug licensed beyond a single country","route":"/ideas/idea-bio2-anamorelin-access/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-ai-sarcopenia-from-ct","kind":"idea","name":"Read muscle loss automatically from scans patients already have","route":"/ideas/idea-bio2-ai-sarcopenia-from-ct/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-lean-mass-dosing","kind":"idea","name":"Dose chemotherapy by muscle mass, not body surface area","route":"/ideas/idea-bio2-lean-mass-dosing/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-low-dose-olanzapine-appetite","kind":"idea","name":"A cheap old tablet to restore appetite","route":"/ideas/idea-bio2-low-dose-olanzapine-appetite/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-cachexia-pathway-code","kind":"idea","name":"Treat wasting like sepsis: a trigger, a bundle, an audit","route":"/ideas/idea-bio2-cachexia-pathway-code/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-protein-plus-training-during-io","kind":"idea","name":"Test protein and resistance training during immunotherapy","route":"/ideas/idea-bio2-protein-plus-training-during-io/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-remote-weight-step-monitoring","kind":"idea","name":"Catch wasting early with a smart scale and a step counter","route":"/ideas/idea-bio2-remote-weight-step-monitoring/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-rare-cancer-umbrella-platform","kind":"idea","name":"One standing umbrella trial for all rare cancers in a country","route":"/ideas/idea-bio2-rare-cancer-umbrella-platform/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-n-of-1-framework","kind":"idea","name":"A standing rulebook for one-patient treatments","route":"/ideas/idea-bio2-n-of-1-framework/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-paediatric-first-development","kind":"idea","name":"Develop drugs in children first when the target is a children's target","route":"/ideas/idea-bio2-paediatric-first-development/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-rare-cancer-telepathology-network","kind":"idea","name":"A same-week expert second opinion for every rare cancer diagnosis","route":"/ideas/idea-bio2-rare-cancer-telepathology-network/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-functional-precision-rare","kind":"idea","name":"Test drugs on the patient's own cancer cells when there is no trial to join","route":"/ideas/idea-bio2-functional-precision-rare/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-rare-cancer-prize-fund","kind":"idea","name":"Pay a prize for rare cancer drugs instead of hoping for a market","route":"/ideas/idea-bio2-rare-cancer-prize-fund/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-registry-embedded-randomisation","kind":"idea","name":"Randomise inside the registry that already follows every patient","route":"/ideas/idea-bio2-registry-embedded-randomisation/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-patient-partnered-rare-commons","kind":"idea","name":"Let patients themselves donate their records and samples for ultra-rare cancers","route":"/ideas/idea-bio2-patient-partnered-rare-commons/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-mechanism-defined-baskets","kind":"idea","name":"Group trials by broken mechanism, not by organ or single mutation","route":"/ideas/idea-bio2-mechanism-defined-baskets/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-shared-compound-access-pool","kind":"idea","name":"A shared compound library that rare cancer researchers can actually use","route":"/ideas/idea-bio2-shared-compound-access-pool/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-bayesian-borrowing-acceptance","kind":"idea","name":"Agree in advance how to borrow evidence between similar rare cancers","route":"/ideas/idea-bio2-bayesian-borrowing-acceptance/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-rare-tumour-model-bank","kind":"idea","name":"An open model bank for the rare tumours nobody has models for","route":"/ideas/idea-bio2-rare-tumour-model-bank/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-tcr-repertoire-early-readout","kind":"idea","name":"Watch the immune system's response in the blood three weeks in","route":"/ideas/idea-bio2-tcr-repertoire-early-readout/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-fmt-plus-checkpoint-phase3","kind":"idea","name":"Take faecal transplant plus immunotherapy to a definitive trial","route":"/ideas/idea-bio2-fmt-plus-checkpoint-phase3/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-antibiotic-stewardship-io","kind":"idea","name":"Protect the gut flora of patients about to start immunotherapy","route":"/ideas/idea-bio2-antibiotic-stewardship-io/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-spatial-signature-cdx","kind":"idea","name":"Turn the map of immune cells inside a tumour into a standardised test","route":"/ideas/idea-bio2-spatial-signature-cdx/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-ctdna-six-week-io-switch","kind":"idea","name":"Use a blood test at six weeks to decide whether to keep going","route":"/ideas/idea-bio2-ctdna-six-week-io-switch/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-io-biomarker-data-commons","kind":"idea","name":"Pool every immunotherapy trial's biomarker data into one commons","route":"/ideas/idea-bio2-io-biomarker-data-commons/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-til-reactivity-selection","kind":"idea","name":"Select patients for cell therapy by whether their tumour holds reactive T cells","route":"/ideas/idea-bio2-til-reactivity-selection/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-antigen-presentation-triage","kind":"idea","name":"Check whether a tumour can still show itself to the immune system","route":"/ideas/idea-bio2-antigen-presentation-triage/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-epigenetic-priming-cold-tumours","kind":"idea","name":"Unmask hidden antigens with a short epigenetic course before immunotherapy","route":"/ideas/idea-bio2-epigenetic-priming-cold-tumours/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-neoadjuvant-biomarker-engine","kind":"idea","name":"Use pre-surgery immunotherapy windows as the field's biomarker engine","route":"/ideas/idea-bio2-neoadjuvant-biomarker-engine/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-steroid-sparing-irae","kind":"idea","name":"Treat immunotherapy side-effects without wiping out the response","route":"/ideas/idea-bio2-steroid-sparing-irae/","asOf":"2026-09-08","days":20},{"id":"idea-bio2-fibre-diet-io-trial","kind":"idea","name":"Test a high-fibre diet as an immunotherapy adjunct","route":"/ideas/idea-bio2-fibre-diet-io-trial/","asOf":"2026-09-08","days":20},{"id":"idea-prev-mced-stage-endpoint-surrogate","kind":"idea","name":"Let MCED trials read out on late-stage incidence, with mortality follow-up mandated","route":"/ideas/idea-prev-mced-stage-endpoint-surrogate/","asOf":"2026-09-08","days":20},{"id":"idea-prev-mced-registry-randomised","kind":"idea","name":"Registry-based randomised MCED trial: a million people, no study visits","route":"/ideas/idea-prev-mced-registry-randomised/","asOf":"2026-09-08","days":20},{"id":"idea-prev-mced-change-control-plan","kind":"idea","name":"Pre-agreed update rules so an MCED test is not obsolete when its trial reads out","route":"/ideas/idea-prev-mced-change-control-plan/","asOf":"2026-09-08","days":20},{"id":"idea-prev-mced-positive-resolution-pathway","kind":"idea","name":"A 28-day national pathway for people with a positive multi-cancer blood test","route":"/ideas/idea-prev-mced-positive-resolution-pathway/","asOf":"2026-09-08","days":20},{"id":"idea-prev-interval-cancer-audit-blood-tests","kind":"idea","name":"Mandatory interval-cancer audit for every blood-based screening test","route":"/ideas/idea-prev-interval-cancer-audit-blood-tests/","asOf":"2026-09-08","days":20},{"id":"idea-prev-ai-mammogram-risk-intervals","kind":"idea","name":"Set each woman's mammogram interval from her last mammogram, using AI risk","route":"/ideas/idea-prev-ai-mammogram-risk-intervals/","asOf":"2026-09-08","days":20},{"id":"idea-prev-lung-screening-risk-model-eligibility","kind":"idea","name":"Lung screening eligibility by risk score, not pack-years, including high-risk never-smokers","route":"/ideas/idea-prev-lung-screening-risk-model-eligibility/","asOf":"2026-09-08","days":20},{"id":"idea-prev-ldct-ai-negative-triage","kind":"idea","name":"AI clears the normal lung screening scans so radiologists read only the suspicious ones","route":"/ideas/idea-prev-ldct-ai-negative-triage/","asOf":"2026-09-08","days":20},{"id":"idea-prev-mammography-ai-stepped-wedge","kind":"idea","name":"Roll out AI-supported mammography nationally as a stepped-wedge trial","route":"/ideas/idea-prev-mammography-ai-stepped-wedge/","asOf":"2026-09-08","days":20},{"id":"idea-prev-opportunistic-ct-ai-registry","kind":"idea","name":"Every routine CT scan checked by AI for early cancer signs, with a tracked follow-up pathway","route":"/ideas/idea-prev-opportunistic-ct-ai-registry/","asOf":"2026-09-08","days":20},{"id":"idea-prev-pancreas-ai-prediagnostic-ct","kind":"idea","name":"AI that spots pancreatic cancer on scans taken a year before diagnosis","route":"/ideas/idea-prev-pancreas-ai-prediagnostic-ct/","asOf":"2026-09-08","days":20},{"id":"idea-prev-new-onset-diabetes-pancreas-pathway","kind":"idea","name":"New diabetes after 50 plus weight loss triggers a pancreatic cancer check","route":"/ideas/idea-prev-new-onset-diabetes-pancreas-pathway/","asOf":"2026-09-08","days":20},{"id":"idea-prev-breath-voc-symptomatic-ruleout","kind":"idea","name":"A breath test to rule out cancer in people with vague symptoms","route":"/ideas/idea-prev-breath-voc-symptomatic-ruleout/","asOf":"2026-09-08","days":20},{"id":"idea-prev-urine-dna-haematuria-triage","kind":"idea","name":"A urine DNA test to decide who with blood in the urine needs a camera test","route":"/ideas/idea-prev-urine-dna-haematuria-triage/","asOf":"2026-09-08","days":20},{"id":"idea-prev-weight-loss-auto-alert","kind":"idea","name":"Smart scales and health records flag unexplained weight loss for a cancer check","route":"/ideas/idea-prev-weight-loss-auto-alert/","asOf":"2026-09-08","days":20},{"id":"idea-prev-cgm-glycaemic-drift-pancreas","kind":"idea","name":"Glucose monitor data as an early pancreatic cancer signal","route":"/ideas/idea-prev-cgm-glycaemic-drift-pancreas/","asOf":"2026-09-08","days":20},{"id":"idea-prev-ehr-symptom-signature-prompts","kind":"idea","name":"Cancer risk scores running automatically in GP records to prompt urgent referral","route":"/ideas/idea-prev-ehr-symptom-signature-prompts/","asOf":"2026-09-08","days":20},{"id":"idea-prev-mced-non-specific-symptom-triage","kind":"idea","name":"Multi-cancer blood test as the first step for patients with non-specific symptoms","route":"/ideas/idea-prev-mced-non-specific-symptom-triage/","asOf":"2026-09-08","days":20},{"id":"idea-prev-blood-count-trend-flags","kind":"idea","name":"Use the trend in routine blood counts, not a single threshold, to spot cancer","route":"/ideas/idea-prev-blood-count-trend-flags/","asOf":"2026-09-08","days":20},{"id":"idea-prev-fit-risk-adapted-thresholds","kind":"idea","name":"Personalised stool-test cut-offs by age, sex and prior results","route":"/ideas/idea-prev-fit-risk-adapted-thresholds/","asOf":"2026-09-08","days":20},{"id":"idea-prev-blood-crc-test-for-non-responders","kind":"idea","name":"Offer the blood test for bowel cancer only to people who refuse stool tests or colonoscopy","route":"/ideas/idea-prev-blood-crc-test-for-non-responders/","asOf":"2026-09-08","days":20},{"id":"idea-prev-capsule-sponge-pharmacy","kind":"idea","name":"A swallowable sponge test for reflux patients, offered in pharmacies","route":"/ideas/idea-prev-capsule-sponge-pharmacy/","asOf":"2026-09-08","days":20},{"id":"idea-prev-gastric-serology-migrant-screening","kind":"idea","name":"Stomach cancer serology screening for high-risk migrant communities in low-incidence countries","route":"/ideas/idea-prev-gastric-serology-migrant-screening/","asOf":"2026-09-08","days":20},{"id":"idea-prev-hcc-blood-surveillance-cirrhosis","kind":"idea","name":"Replace six-monthly ultrasound with a blood test for liver cancer in cirrhosis","route":"/ideas/idea-prev-hcc-blood-surveillance-cirrhosis/","asOf":"2026-09-08","days":20},{"id":"idea-prev-mri-first-prostate-screening-prs","kind":"idea","name":"MRI-first prostate screening with genetic pre-selection","route":"/ideas/idea-prev-mri-first-prostate-screening-prs/","asOf":"2026-09-08","days":20},{"id":"idea-prev-oral-cancer-community-smartphone-ai","kind":"idea","name":"Community health workers with smartphone AI screen for mouth cancer in South Asia","route":"/ideas/idea-prev-oral-cancer-community-smartphone-ai/","asOf":"2026-09-08","days":20},{"id":"idea-prev-lmic-five-cancer-methylation-test","kind":"idea","name":"A ten-dollar blood test for the five cancers that kill most people in poorer countries","route":"/ideas/idea-prev-lmic-five-cancer-methylation-test/","asOf":"2026-09-08","days":20},{"id":"idea-prev-fragmentomics-first-tier","kind":"idea","name":"Cheap DNA fragment-pattern blood test as a first sieve before expensive cancer tests","route":"/ideas/idea-prev-fragmentomics-first-tier/","asOf":"2026-09-08","days":20},{"id":"idea-prev-live-stage-dashboard","kind":"idea","name":"A live national dashboard of stage at diagnosis as the scorecard for early detection","route":"/ideas/idea-prev-live-stage-dashboard/","asOf":"2026-09-08","days":20},{"id":"idea-prev-open-stage-shift-microsimulation","kind":"idea","name":"Open-source models that translate stage shift into lives saved, for every cancer","route":"/ideas/idea-prev-open-stage-shift-microsimulation/","asOf":"2026-09-08","days":20},{"id":"idea-prev-emergency-department-cancer-test","kind":"idea","name":"A cancer blood test for older people arriving at A&E with unexplained symptoms","route":"/ideas/idea-prev-emergency-department-cancer-test/","asOf":"2026-09-08","days":20},{"id":"idea-prev-mobile-lung-screening-deprived-areas","kind":"idea","name":"Take lung screening scanners to supermarket car parks in the poorest areas","route":"/ideas/idea-prev-mobile-lung-screening-deprived-areas/","asOf":"2026-09-08","days":20},{"id":"idea-prev-ebv-dna-npc-screening-scaleup","kind":"idea","name":"Blood EBV DNA screening for nasopharyngeal cancer across southern China and Southeast Asia","route":"/ideas/idea-prev-ebv-dna-npc-screening-scaleup/","asOf":"2026-09-08","days":20},{"id":"idea-prev-dental-oral-exam-standard","kind":"idea","name":"Make a two-minute mouth cancer check part of every dental visit","route":"/ideas/idea-prev-dental-oral-exam-standard/","asOf":"2026-09-08","days":20},{"id":"idea-prev-bundled-cancer-check-at-60","kind":"idea","name":"A single 'cancer check at 60' appointment bundling all screening tests","route":"/ideas/idea-prev-bundled-cancer-check-at-60/","asOf":"2026-09-08","days":20},{"id":"idea-prev-thyroid-no-screening-no-small-biopsy","kind":"idea","name":"Stop biopsying small thyroid nodules and never screen the thyroid","route":"/ideas/idea-prev-thyroid-no-screening-no-small-biopsy/","asOf":"2026-09-08","days":20},{"id":"idea-prev-ptmc-active-surveillance-default","kind":"idea","name":"Active surveillance as the default for tiny papillary thyroid cancers","route":"/ideas/idea-prev-ptmc-active-surveillance-default/","asOf":"2026-09-08","days":20},{"id":"idea-prev-low-risk-dcis-surveillance-pathway","kind":"idea","name":"After the COMET trial: surveillance pathways and a new name for low-risk DCIS","route":"/ideas/idea-prev-low-risk-dcis-surveillance-pathway/","asOf":"2026-09-08","days":20},{"id":"idea-prev-indolent-lesion-nomenclature-body","kind":"idea","name":"An international body to rename indolent lesions so 'cancer' means something","route":"/ideas/idea-prev-indolent-lesion-nomenclature-body/","asOf":"2026-09-08","days":20},{"id":"idea-prev-gleason6-terminology-rct","kind":"idea","name":"Test whether calling Gleason 6 'not cancer' changes what men choose","route":"/ideas/idea-prev-gleason6-terminology-rct/","asOf":"2026-09-08","days":20},{"id":"idea-prev-prostate-as-triggered-biopsy","kind":"idea","name":"Prostate active surveillance without scheduled biopsies: MRI and blood tests decide","route":"/ideas/idea-prev-prostate-as-triggered-biopsy/","asOf":"2026-09-08","days":20},{"id":"idea-prev-small-renal-mass-surveillance","kind":"idea","name":"Watch small kidney tumours rather than remove them, with a national registry","route":"/ideas/idea-prev-small-renal-mass-surveillance/","asOf":"2026-09-08","days":20},{"id":"idea-prev-lung-nodule-ai-discharge","kind":"idea","name":"AI malignancy scores to end repeat scans and biopsies for benign lung nodules","route":"/ideas/idea-prev-lung-nodule-ai-discharge/","asOf":"2026-09-08","days":20},{"id":"idea-prev-blood-precursor-watch-registry","kind":"idea","name":"A watch-and-wait registry for blood precursor conditions found by chance","route":"/ideas/idea-prev-blood-precursor-watch-registry/","asOf":"2026-09-08","days":20},{"id":"idea-prev-annual-overdiagnosis-reporting","kind":"idea","name":"Every screening programme must publish its overdiagnosis rate each year","route":"/ideas/idea-prev-annual-overdiagnosis-reporting/","asOf":"2026-09-08","days":20},{"id":"idea-prev-screening-stop-by-life-expectancy","kind":"idea","name":"Stop screening by life expectancy, not birthday, with a tool in the record","route":"/ideas/idea-prev-screening-stop-by-life-expectancy/","asOf":"2026-09-08","days":20},{"id":"idea-prev-mced-pretest-decision-aid","kind":"idea","name":"A mandatory decision aid before any multi-cancer blood test","route":"/ideas/idea-prev-mced-pretest-decision-aid/","asOf":"2026-09-08","days":20},{"id":"idea-prev-barrett-surveillance-deescalation","kind":"idea","name":"Stop routine endoscopies for non-dysplastic Barrett's oesophagus","route":"/ideas/idea-prev-barrett-surveillance-deescalation/","asOf":"2026-09-08","days":20},{"id":"idea-prev-melanoma-ai-thick-melanoma-metric","kind":"idea","name":"Judge skin cancer AI by the thick melanomas it prevents, not the thin ones it finds","route":"/ideas/idea-prev-melanoma-ai-thick-melanoma-metric/","asOf":"2026-09-08","days":20},{"id":"idea-prev-incidentaloma-natural-history-cohort","kind":"idea","name":"A ten-year cohort of incidental findings to calibrate follow-up guidelines","route":"/ideas/idea-prev-incidentaloma-natural-history-cohort/","asOf":"2026-09-08","days":20},{"id":"idea-prev-ipmn-surveillance-stop-rule","kind":"idea","name":"Stop watching stable low-risk pancreatic cysts after five years","route":"/ideas/idea-prev-ipmn-surveillance-stop-rule/","asOf":"2026-09-08","days":20},{"id":"idea-prev-pathology-ai-borderline-anchor","kind":"idea","name":"AI second reads to stop borderline lesions being upgraded to cancer","route":"/ideas/idea-prev-pathology-ai-borderline-anchor/","asOf":"2026-09-08","days":20},{"id":"idea-prev-frail-elderly-primary-endocrine-breast","kind":"idea","name":"Hormone tablets instead of surgery for small breast cancers in the frail over-80s","route":"/ideas/idea-prev-frail-elderly-primary-endocrine-breast/","asOf":"2026-09-08","days":20},{"id":"idea-prev-omit-radiotherapy-low-risk-breast-default","kind":"idea","name":"Make skipping radiotherapy the default for very low-risk breast cancer","route":"/ideas/idea-prev-omit-radiotherapy-low-risk-breast-default/","asOf":"2026-09-08","days":20},{"id":"idea-prev-modern-autopsy-reservoir-studies","kind":"idea","name":"Modern autopsy studies to measure how much silent cancer people carry","route":"/ideas/idea-prev-modern-autopsy-reservoir-studies/","asOf":"2026-09-08","days":20},{"id":"idea-prev-hpv-single-dose-switch-catchup","kind":"idea","name":"Switch every country to single-dose HPV vaccination and add catch-up to age 26","route":"/ideas/idea-prev-hpv-single-dose-switch-catchup/","asOf":"2026-09-08","days":20},{"id":"idea-prev-hpv-vaccinate-at-screening","kind":"idea","name":"Offer HPV vaccination to women when they come for cervical screening or treatment","route":"/ideas/idea-prev-hpv-vaccinate-at-screening/","asOf":"2026-09-08","days":20},{"id":"idea-prev-hpv-self-sampling-mailed-default","kind":"idea","name":"Post every woman an HPV self-test kit instead of asking her to book a smear","route":"/ideas/idea-prev-hpv-self-sampling-mailed-default/","asOf":"2026-09-08","days":20},{"id":"idea-prev-hpv-same-day-screen-and-treat","kind":"idea","name":"Same-day HPV test and heat treatment of precancer by nurses in low-income settings","route":"/ideas/idea-prev-hpv-same-day-screen-and-treat/","asOf":"2026-09-08","days":20},{"id":"idea-prev-therapeutic-hpv-vaccine-cin","kind":"idea","name":"A therapeutic vaccine to clear cervical precancer without surgery","route":"/ideas/idea-prev-therapeutic-hpv-vaccine-cin/","asOf":"2026-09-08","days":20},{"id":"idea-prev-hbv-treat-all-hcc","kind":"idea","name":"Treat everyone with chronic hepatitis B to prevent liver cancer","route":"/ideas/idea-prev-hbv-treat-all-hcc/","asOf":"2026-09-08","days":20},{"id":"idea-prev-hcv-test-treat-surveillance-linkage","kind":"idea","name":"Cure hepatitis C in prisons and drug services, and enrol the cured in liver cancer surveillance","route":"/ideas/idea-prev-hcv-test-treat-surveillance-linkage/","asOf":"2026-09-08","days":20},{"id":"idea-prev-hpylori-family-test-and-treat","kind":"idea","name":"Family-based H. pylori test-and-treat to prevent stomach cancer","route":"/ideas/idea-prev-hpylori-family-test-and-treat/","asOf":"2026-09-08","days":20},{"id":"idea-prev-hpylori-stool-resistance-guided","kind":"idea","name":"Antibiotic-resistance testing from a stool sample before treating H. pylori","route":"/ideas/idea-prev-hpylori-stool-resistance-guided/","asOf":"2026-09-08","days":20},{"id":"idea-prev-hpylori-childhood-vaccine","kind":"idea","name":"A vaccine against H. pylori for children in high-risk regions","route":"/ideas/idea-prev-hpylori-childhood-vaccine/","asOf":"2026-09-08","days":20},{"id":"idea-prev-smokefree-generation-evaluation","kind":"idea","name":"Smoke-free generation laws with a built-in evaluation across countries","route":"/ideas/idea-prev-smokefree-generation-evaluation/","asOf":"2026-09-08","days":20},{"id":"idea-prev-very-low-nicotine-mandate","kind":"idea","name":"Make cigarettes non-addictive by capping their nicotine","route":"/ideas/idea-prev-very-low-nicotine-mandate/","asOf":"2026-09-08","days":20},{"id":"idea-prev-opt-out-cessation-in-lung-screening","kind":"idea","name":"Every lung screening visit includes stop-smoking medicine, opt-out","route":"/ideas/idea-prev-opt-out-cessation-in-lung-screening/","asOf":"2026-09-08","days":20},{"id":"idea-prev-cytisine-essential-medicine","kind":"idea","name":"Put cytisine, a cheap plant-based quit-smoking pill, on every essential medicines list","route":"/ideas/idea-prev-cytisine-essential-medicine/","asOf":"2026-09-08","days":20},{"id":"idea-prev-alcohol-cancer-warning-labels","kind":"idea","name":"Cancer warnings on alcohol labels, evaluated as a natural experiment","route":"/ideas/idea-prev-alcohol-cancer-warning-labels/","asOf":"2026-09-08","days":20},{"id":"idea-prev-minimum-unit-pricing-cancer-endpoints","kind":"idea","name":"Minimum alcohol pricing evaluated with cancer endpoints","route":"/ideas/idea-prev-minimum-unit-pricing-cancer-endpoints/","asOf":"2026-09-08","days":20},{"id":"idea-prev-glp1-cancer-prevention-rct","kind":"idea","name":"A trial of GLP-1 weight-loss drugs with cancer as the primary outcome","route":"/ideas/idea-prev-glp1-cancer-prevention-rct/","asOf":"2026-09-08","days":20},{"id":"idea-prev-glp1-endometrial-hyperplasia","kind":"idea","name":"GLP-1 drugs to reverse endometrial precancer in women with obesity","route":"/ideas/idea-prev-glp1-endometrial-hyperplasia/","asOf":"2026-09-08","days":20},{"id":"idea-prev-chemoprevention-master-protocol","kind":"idea","name":"One master trial for cancer prevention drugs across many precancers","route":"/ideas/idea-prev-chemoprevention-master-protocol/","asOf":"2026-09-08","days":20},{"id":"idea-prev-low-dose-tamoxifen-uptake","kind":"idea","name":"Low-dose tamoxifen for high-risk women, prescribed by pharmacists and nurses","route":"/ideas/idea-prev-low-dose-tamoxifen-uptake/","asOf":"2026-09-08","days":20},{"id":"idea-prev-opportunistic-salpingectomy-default","kind":"idea","name":"Remove the fallopian tubes during any pelvic surgery once childbearing is finished","route":"/ideas/idea-prev-opportunistic-salpingectomy-default/","asOf":"2026-09-08","days":20},{"id":"idea-prev-commercial-sunbed-ban","kind":"idea","name":"Ban commercial sunbeds","route":"/ideas/idea-prev-commercial-sunbed-ban/","asOf":"2026-09-08","days":20},{"id":"idea-prev-radon-testing-at-property-sale","kind":"idea","name":"Mandatory radon testing when homes are sold, with subsidised mitigation","route":"/ideas/idea-prev-radon-testing-at-property-sale/","asOf":"2026-09-08","days":20},{"id":"idea-prev-clean-air-never-smoker-endpoints","kind":"idea","name":"Evaluate clean-air policies using lung cancer in never-smokers","route":"/ideas/idea-prev-clean-air-never-smoker-endpoints/","asOf":"2026-09-08","days":20},{"id":"idea-prev-screening-default-appointments","kind":"idea","name":"Send screening invitations with a pre-booked time, not a request to call","route":"/ideas/idea-prev-screening-default-appointments/","asOf":"2026-09-08","days":20},{"id":"idea-prev-pharmacy-prevention-hub","kind":"idea","name":"Community pharmacies as one-stop cancer prevention hubs","route":"/ideas/idea-prev-pharmacy-prevention-hub/","asOf":"2026-09-08","days":20},{"id":"idea-prev-pay-for-prevention-outcomes","kind":"idea","name":"Pay insurers and health systems for cancers prevented and caught early","route":"/ideas/idea-prev-pay-for-prevention-outcomes/","asOf":"2026-09-08","days":20},{"id":"idea-prev-precursor-endpoints-for-approval","kind":"idea","name":"Regulators accept shrinking of precancer as the endpoint for prevention drug approval","route":"/ideas/idea-prev-precursor-endpoints-for-approval/","asOf":"2026-09-08","days":20},{"id":"idea-prev-hpv-male-catchup-oropharynx","kind":"idea","name":"Catch-up HPV vaccination for men to prevent throat cancer","route":"/ideas/idea-prev-hpv-male-catchup-oropharynx/","asOf":"2026-09-08","days":20},{"id":"idea-prev-ebv-vaccine","kind":"idea","name":"An Epstein-Barr virus vaccine to prevent nasopharyngeal cancer and lymphomas","route":"/ideas/idea-prev-ebv-vaccine/","asOf":"2026-09-08","days":20},{"id":"idea-prev-cascade-direct-contact-relatives","kind":"idea","name":"Let clinics contact relatives directly when a cancer gene is found","route":"/ideas/idea-prev-cascade-direct-contact-relatives/","asOf":"2026-09-08","days":20},{"id":"idea-prev-population-germline-screening-at-30","kind":"idea","name":"Offer everyone at 30 a test for the cancer genes that matter","route":"/ideas/idea-prev-population-germline-screening-at-30/","asOf":"2026-09-08","days":20},{"id":"idea-prev-deferred-disclosure-newborn-genomes","kind":"idea","name":"Store adult-onset cancer gene results from newborn genomes and disclose at 18","route":"/ideas/idea-prev-deferred-disclosure-newborn-genomes/","asOf":"2026-09-08","days":20},{"id":"idea-prev-prs-screening-start-age","kind":"idea","name":"Use a polygenic risk score to set when screening starts","route":"/ideas/idea-prev-prs-screening-start-age/","asOf":"2026-09-08","days":20},{"id":"idea-prev-prs-ancestry-portability-standard","kind":"idea","name":"Build polygenic scores that work in every ancestry before deploying any","route":"/ideas/idea-prev-prs-ancestry-portability-standard/","asOf":"2026-09-08","days":20},{"id":"idea-prev-lynch-frameshift-vaccine-rct","kind":"idea","name":"A randomised trial of a shared-antigen vaccine to prevent Lynch syndrome cancers","route":"/ideas/idea-prev-lynch-frameshift-vaccine-rct/","asOf":"2026-09-08","days":20},{"id":"idea-prev-brca1-denosumab-prevention","kind":"idea","name":"A bone drug to prevent breast cancer in BRCA1 carriers","route":"/ideas/idea-prev-brca1-denosumab-prevention/","asOf":"2026-09-08","days":20},{"id":"idea-prev-lynch-aspirin-implementation","kind":"idea","name":"Get every Lynch syndrome carrier onto the right dose of aspirin","route":"/ideas/idea-prev-lynch-aspirin-implementation/","asOf":"2026-09-08","days":20},{"id":"idea-prev-reflex-germline-testing","kind":"idea","name":"Automatic germline testing for every cancer type where it changes care","route":"/ideas/idea-prev-reflex-germline-testing/","asOf":"2026-09-08","days":20},{"id":"idea-prev-traceback-deceased-probands","kind":"idea","name":"Go back to families of women who died of ovarian cancer and offer BRCA testing","route":"/ideas/idea-prev-traceback-deceased-probands/","asOf":"2026-09-08","days":20},{"id":"idea-prev-vus-saturation-editing-consortium","kind":"idea","name":"Test every possible mutation in every cancer gene so no result is 'uncertain'","route":"/ideas/idea-prev-vus-saturation-editing-consortium/","asOf":"2026-09-08","days":20},{"id":"idea-prev-li-fraumeni-mri-plus-cfdna","kind":"idea","name":"Whole-body MRI plus blood DNA surveillance for people with Li-Fraumeni syndrome","route":"/ideas/idea-prev-li-fraumeni-mri-plus-cfdna/","asOf":"2026-09-08","days":20},{"id":"idea-prev-genetic-counselling-chatbot","kind":"idea","name":"A chatbot for pre-test genetic counselling so counsellors see only who needs them","route":"/ideas/idea-prev-genetic-counselling-chatbot/","asOf":"2026-09-08","days":20},{"id":"idea-prev-family-history-auto-match","kind":"idea","name":"Family history collected by app and matched to testing criteria automatically","route":"/ideas/idea-prev-family-history-auto-match/","asOf":"2026-09-08","days":20},{"id":"idea-prev-genetic-non-discrimination-insurance","kind":"idea","name":"Ban life and disability insurers from using genetic results","route":"/ideas/idea-prev-genetic-non-discrimination-insurance/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-justify-every-exclusion","kind":"idea","name":"Default-inclusive eligibility: sponsors must justify every exclusion criterion","route":"/ideas/idea-tr1-justify-every-exclusion/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-brain-mets-default-included","kind":"idea","name":"Brain metastases included by default in every solid-tumour trial","route":"/ideas/idea-tr1-brain-mets-default-included/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-pk-informed-organ-thresholds","kind":"idea","name":"Replace fixed kidney and liver cut-offs with drug-specific, pharmacology-based thresholds","route":"/ideas/idea-tr1-pk-informed-organ-thresholds/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-prior-cancer-hiv-hepatitis-inclusion","kind":"idea","name":"Stop excluding people with a prior cancer, controlled HIV, or treated hepatitis","route":"/ideas/idea-tr1-prior-cancer-hiv-hepatitis-inclusion/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-ehr-point-of-care-trial-alert","kind":"idea","name":"Trial matching inside the electronic record at the moment a treatment is chosen","route":"/ideas/idea-tr1-ehr-point-of-care-trial-alert/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-tumour-board-trial-line-item","kind":"idea","name":"A mandatory trial line in every tumour board recommendation","route":"/ideas/idea-tr1-tumour-board-trial-line-item/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-ngs-report-live-trial-match","kind":"idea","name":"Every tumour sequencing report lists open, nearby, matched trials pulled live","route":"/ideas/idea-tr1-ngs-report-live-trial-match/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-just-in-time-site-network","kind":"idea","name":"Just-in-time site activation: open a site in two weeks when a patient appears","route":"/ideas/idea-tr1-just-in-time-site-network/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-national-master-trial-agreement","kind":"idea","name":"One national master contract and budget template for all cancer trials","route":"/ideas/idea-tr1-national-master-trial-agreement/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-mutual-recognition-ethics-review","kind":"idea","name":"Mutual recognition of ethics review across countries","route":"/ideas/idea-tr1-mutual-recognition-ethics-review/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-home-infusion-trial-drugs","kind":"idea","name":"Home infusion and local blood draws for trial drugs after the first cycles","route":"/ideas/idea-tr1-home-infusion-trial-drugs/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-remote-consent-tele-screening","kind":"idea","name":"Remote consent and tele-screening so the first trial visit is a video call","route":"/ideas/idea-tr1-remote-consent-tele-screening/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-community-site-quota","kind":"idea","name":"At least a third of pivotal-trial sites in community and rural settings","route":"/ideas/idea-tr1-community-site-quota/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-travel-lodging-in-every-budget","kind":"idea","name":"Travel, lodging and meals reimbursed as a standard line in every trial budget","route":"/ideas/idea-tr1-travel-lodging-in-every-budget/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-pay-participants-for-time","kind":"idea","name":"Pay trial participants for their time, not only their expenses","route":"/ideas/idea-tr1-pay-participants-for-time/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-lay-trial-navigators","kind":"idea","name":"Lay trial navigators funded per centre, evaluated in a randomised trial","route":"/ideas/idea-tr1-lay-trial-navigators/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-opt-out-research-contact-register","kind":"idea","name":"Every patient is asked once at diagnosis whether researchers may contact them","route":"/ideas/idea-tr1-opt-out-research-contact-register/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-registry-embedded-randomisation","kind":"idea","name":"Randomise inside the cancer registry: registry-based trials for everyday questions","route":"/ideas/idea-tr1-registry-embedded-randomisation/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-rare-cancer-trial-in-a-box","kind":"idea","name":"Trial-in-a-box: a preconfigured protocol kit any hospital can open for a rare cancer","route":"/ideas/idea-tr1-rare-cancer-trial-in-a-box/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-pre-consented-cohort-randomisation","kind":"idea","name":"Pre-consented cohorts that can be randomised to future trials (TwiCs)","route":"/ideas/idea-tr1-pre-consented-cohort-randomisation/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-public-screen-fail-reasons","kind":"idea","name":"Publish why patients were screened out of each trial","route":"/ideas/idea-tr1-public-screen-fail-reasons/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-eligibility-impact-statement","kind":"idea","name":"Simulate eligibility against real-world data before every protocol is locked","route":"/ideas/idea-tr1-eligibility-impact-statement/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-live-trial-slot-api","kind":"idea","name":"A live 'seats available' feed for trial slots, like airline inventory","route":"/ideas/idea-tr1-live-trial-slot-api/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-pathology-triggered-referral","kind":"idea","name":"The pathology lab triggers a trial referral the day a rare cancer is diagnosed","route":"/ideas/idea-tr1-pathology-triggered-referral/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-evening-weekend-trial-clinics","kind":"idea","name":"Evening and weekend trial clinics for working-age patients","route":"/ideas/idea-tr1-evening-weekend-trial-clinics/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-universal-routine-cost-coverage","kind":"idea","name":"Every payer covers routine care costs for trial participants, in every country","route":"/ideas/idea-tr1-universal-routine-cost-coverage/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-protected-physician-time-for-enrolment","kind":"idea","name":"Pay oncologists for the time it takes to enrol a patient","route":"/ideas/idea-tr1-protected-physician-time-for-enrolment/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-open-trials-inside-guidelines","kind":"idea","name":"Guidelines list the open trials at every decision point, updated monthly","route":"/ideas/idea-tr1-open-trials-inside-guidelines/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-mobile-research-units","kind":"idea","name":"Mobile research units bring trial visits to rural towns","route":"/ideas/idea-tr1-mobile-research-units/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-drop-non-essential-biopsies","kind":"idea","name":"Drop mandatory fresh biopsies where blood or archival tissue would do","route":"/ideas/idea-tr1-drop-non-essential-biopsies/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-external-control-rulebook","kind":"idea","name":"A public rulebook for when an external or synthetic control arm is acceptable","route":"/ideas/idea-tr1-external-control-rulebook/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-bayesian-borrowing-smaller-controls","kind":"idea","name":"Borrow from past control arms to shrink the control group in phase 3","route":"/ideas/idea-tr1-bayesian-borrowing-smaller-controls/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-seamless-2-3-with-prespecified-go","kind":"idea","name":"Seamless phase 2/3 with pre-registered go rules as the default for new agents","route":"/ideas/idea-tr1-seamless-2-3-with-prespecified-go/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-standing-platform-per-cancer","kind":"idea","name":"A standing platform trial for every major cancer, funded as infrastructure","route":"/ideas/idea-tr1-standing-platform-per-cancer/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-surrogate-validation-programme","kind":"idea","name":"An independent programme that validates surrogate endpoints, setting by setting","route":"/ideas/idea-tr1-surrogate-validation-programme/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-crossover-adjusted-survival-standard","kind":"idea","name":"Pre-specified crossover-adjusted survival in every trial that allows crossover","route":"/ideas/idea-tr1-crossover-adjusted-survival-standard/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-ttf-and-qol-coprimary","kind":"idea","name":"Time to treatment failure and quality of life as co-primary endpoints in non-curative trials","route":"/ideas/idea-tr1-ttf-and-qol-coprimary/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-win-ratio-net-benefit-endpoint","kind":"idea","name":"Win-ratio endpoints that weigh survival, toxicity and quality of life together","route":"/ideas/idea-tr1-win-ratio-net-benefit-endpoint/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-public-de-escalation-trial-fund","kind":"idea","name":"A public fund for trials that test less treatment","route":"/ideas/idea-tr1-public-de-escalation-trial-fund/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-immunotherapy-stop-trials","kind":"idea","name":"Randomised trials of stopping immunotherapy after one year versus continuing","route":"/ideas/idea-tr1-immunotherapy-stop-trials/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-ctdna-guided-stop-in-metastatic-disease","kind":"idea","name":"Use tumour DNA in blood to decide when to pause treatment in metastatic cancer","route":"/ideas/idea-tr1-ctdna-guided-stop-in-metastatic-disease/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-mams-for-sequencing-questions","kind":"idea","name":"Multi-arm, multi-stage trials to answer which order to give approved drugs","route":"/ideas/idea-tr1-mams-for-sequencing-questions/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-post-approval-pragmatic-trial-in-excluded","kind":"idea","name":"After approval, a pragmatic trial in the patients the pivotal trial excluded","route":"/ideas/idea-tr1-post-approval-pragmatic-trial-in-excluded/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-shared-control-arms-across-sponsors","kind":"idea","name":"Competing sponsors share one control arm in the same indication","route":"/ideas/idea-tr1-shared-control-arms-across-sponsors/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-tolerability-estimands","kind":"idea","name":"Define tolerability endpoints as rigorously as efficacy endpoints","route":"/ideas/idea-tr1-tolerability-estimands/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-power-for-meaningful-benefit","kind":"idea","name":"Power trials to detect a benefit patients would value, not the smallest detectable one","route":"/ideas/idea-tr1-power-for-meaningful-benefit/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-registry-linked-os-followup","kind":"idea","name":"Cheap long-term survival follow-up by linking trial participants to registries","route":"/ideas/idea-tr1-registry-linked-os-followup/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-shrinkage-subgroup-analysis","kind":"idea","name":"Bayesian shrinkage for subgroup claims to stop false 'works in this group' stories","route":"/ideas/idea-tr1-shrinkage-subgroup-analysis/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-ai-central-imaging-reads","kind":"idea","name":"AI-assisted central imaging reads to cut endpoint cost and variability","route":"/ideas/idea-tr1-ai-central-imaging-reads/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-public-trial-cost-benchmarks","kind":"idea","name":"Publish per-patient trial cost benchmarks and target halving them","route":"/ideas/idea-tr1-public-trial-cost-benchmarks/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-esource-ehr-to-edc","kind":"idea","name":"Direct record-to-database data capture: no manual transcription, no full source verification","route":"/ideas/idea-tr1-esource-ehr-to-edc/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-aggregated-n-of-1-supportive-care","kind":"idea","name":"Aggregated single-patient crossover trials for symptom and supportive treatments","route":"/ideas/idea-tr1-aggregated-n-of-1-supportive-care/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-aggressive-futility-boundaries","kind":"idea","name":"Stop failing trials earlier with pre-registered aggressive futility rules","route":"/ideas/idea-tr1-aggressive-futility-boundaries/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-window-of-opportunity-default","kind":"idea","name":"A short pre-surgery drug window as the default early test of new agents","route":"/ideas/idea-tr1-window-of-opportunity-default/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-randomised-phase-2-before-phase-3","kind":"idea","name":"Require a randomised phase 2 before any phase 3","route":"/ideas/idea-tr1-randomised-phase-2-before-phase-3/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-smart-designs-for-adaptive-strategies","kind":"idea","name":"SMART designs to test treatment strategies, not just single drugs","route":"/ideas/idea-tr1-smart-designs-for-adaptive-strategies/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-target-trial-emulation-to-prioritise-rcts","kind":"idea","name":"Emulate the trial in real-world data first to decide which trials to run","route":"/ideas/idea-tr1-target-trial-emulation-to-prioritise-rcts/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-tumour-agnostic-approval-standard","kind":"idea","name":"A standard for tumour-agnostic approvals: minimum histologies and hierarchical modelling","route":"/ideas/idea-tr1-tumour-agnostic-approval-standard/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-open-protocol-and-sap-library","kind":"idea","name":"Open-source protocol and statistical analysis plan templates with runnable code","route":"/ideas/idea-tr1-open-protocol-and-sap-library/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-validate-real-world-progression-endpoints","kind":"idea","name":"Validate real-world progression endpoints so pragmatic trials can use them","route":"/ideas/idea-tr1-validate-real-world-progression-endpoints/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-diversity-plans-with-consequences","kind":"idea","name":"Diversity action plans with consequences: unmet targets trigger post-approval requirements","route":"/ideas/idea-tr1-diversity-plans-with-consequences/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-incidence-weighted-enrolment-targets","kind":"idea","name":"Set trial enrolment targets from who actually gets the disease, and publish progress live","route":"/ideas/idea-tr1-incidence-weighted-enrolment-targets/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-ancestry-aware-pharmacology-programme","kind":"idea","name":"Ancestry-aware pharmacology: drug-level sub-studies across populations before approval","route":"/ideas/idea-tr1-ancestry-aware-pharmacology-programme/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-duffy-null-neutrophil-threshold","kind":"idea","name":"Fix the neutrophil count rule that excludes many people of African ancestry","route":"/ideas/idea-tr1-duffy-null-neutrophil-threshold/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-mandatory-older-adult-cohort","kind":"idea","name":"A mandatory over-70s cohort with geriatric assessment in every pivotal trial","route":"/ideas/idea-tr1-mandatory-older-adult-cohort/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-parallel-comorbidity-cohorts","kind":"idea","name":"Parallel real-world cohorts for sicker patients alongside every pivotal trial","route":"/ideas/idea-tr1-parallel-comorbidity-cohorts/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-lmic-sites-in-pivotal-trials","kind":"idea","name":"Pivotal trials include sites in Africa, South Asia and Latin America, sponsor-funded","route":"/ideas/idea-tr1-lmic-sites-in-pivotal-trials/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-community-health-worker-recruitment","kind":"idea","name":"Community health workers and trusted local organisations paid to recruit for trials","route":"/ideas/idea-tr1-community-health-worker-recruitment/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-language-access-in-trials","kind":"idea","name":"Drop the 'must speak English' rule: translated consent and questionnaires as standard","route":"/ideas/idea-tr1-language-access-in-trials/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-site-equity-index","kind":"idea","name":"A public equity index for trial sites and sponsors, tied to funding","route":"/ideas/idea-tr1-site-equity-index/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-include-pregnancy-capable-people-sensibly","kind":"idea","name":"Stop over-excluding people who could become pregnant; study pregnancy exposure","route":"/ideas/idea-tr1-include-pregnancy-capable-people-sensibly/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-age-floor-twelve-for-adult-trials","kind":"idea","name":"Let adolescents from age 12 into adult trials when the cancer biology is the same","route":"/ideas/idea-tr1-age-floor-twelve-for-adult-trials/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-sex-stratified-pk-and-dosing","kind":"idea","name":"Analyse and dose by sex: women get more toxicity from many cancer drugs at the same dose","route":"/ideas/idea-tr1-sex-stratified-pk-and-dosing/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-disability-and-mental-illness-inclusion","kind":"idea","name":"Remove blanket exclusions for mental illness and dementia; support consent instead","route":"/ideas/idea-tr1-disability-and-mental-illness-inclusion/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-representativeness-in-the-label","kind":"idea","name":"Print the participation-to-prevalence ratio in every drug label and assessment report","route":"/ideas/idea-tr1-representativeness-in-the-label/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-diverse-investigator-pipeline","kind":"idea","name":"Fund investigators from under-represented communities and community sites to lead trials","route":"/ideas/idea-tr1-diverse-investigator-pipeline/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-paid-community-advisory-boards","kind":"idea","name":"Paid community advisory boards with power to change protocol burden","route":"/ideas/idea-tr1-paid-community-advisory-boards/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-post-marketing-safety-by-ancestry-and-sex","kind":"idea","name":"Post-marketing safety monitoring stratified by ancestry and sex, with label updates","route":"/ideas/idea-tr1-post-marketing-safety-by-ancestry-and-sex/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-ecog-2-dedicated-cohorts","kind":"idea","name":"Dedicated cohorts for patients with performance status 2 in first-line trials","route":"/ideas/idea-tr1-ecog-2-dedicated-cohorts/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-trial-desert-map","kind":"idea","name":"A public map of trial deserts to steer where new sites open","route":"/ideas/idea-tr1-trial-desert-map/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-randomised-dose-comparison-before-pivotal","kind":"idea","name":"Randomise at least two doses in phase 2 before any pivotal trial","route":"/ideas/idea-tr1-randomised-dose-comparison-before-pivotal/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-exposure-response-before-dose-selection","kind":"idea","name":"Exposure-response modelling with a pre-set target exposure before any dose is chosen","route":"/ideas/idea-tr1-exposure-response-before-dose-selection/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-public-dose-reduction-trials-of-approved-drugs","kind":"idea","name":"Publicly funded dose-reduction trials of expensive approved drugs","route":"/ideas/idea-tr1-public-dose-reduction-trials-of-approved-drugs/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-weight-based-vs-flat-dosing-trials","kind":"idea","name":"Test flat versus weight-based dosing of antibodies, and use dose banding to cut waste","route":"/ideas/idea-tr1-weight-based-vs-flat-dosing-trials/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-extended-interval-checkpoint-dosing","kind":"idea","name":"Extended-interval immunotherapy: give checkpoint inhibitors every 8-12 weeks once stable","route":"/ideas/idea-tr1-extended-interval-checkpoint-dosing/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-therapeutic-drug-monitoring-for-oral-tkis","kind":"idea","name":"Measure blood levels of oral targeted drugs and adjust doses to a target range","route":"/ideas/idea-tr1-therapeutic-drug-monitoring-for-oral-tkis/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-intermittent-dosing-to-delay-resistance","kind":"idea","name":"Test intermittent dosing of targeted drugs to delay resistance, with honest priors","route":"/ideas/idea-tr1-intermittent-dosing-to-delay-resistance/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-adaptive-therapy-randomised-phase-2","kind":"idea","name":"Evolution-guided 'adaptive therapy' dosing tested in randomised phase 2 trials","route":"/ideas/idea-tr1-adaptive-therapy-randomised-phase-2/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-start-low-titrate-up-oral-agents","kind":"idea","name":"Start low and step up: individualised titration of oral cancer drugs, randomised","route":"/ideas/idea-tr1-start-low-titrate-up-oral-agents/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-pre-emptive-pharmacogenomic-testing","kind":"idea","name":"Test DPYD, UGT1A1 and TPMT/NUDT15 before the first dose, everywhere","route":"/ideas/idea-tr1-pre-emptive-pharmacogenomic-testing/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-geriatric-dose-finding-cohorts","kind":"idea","name":"Dose-finding in older and frail patients, not extrapolation from fit ones","route":"/ideas/idea-tr1-geriatric-dose-finding-cohorts/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-model-based-dose-finding-with-late-toxicity","kind":"idea","name":"Retire the 3+3: model-based dose finding that counts late and chronic side effects","route":"/ideas/idea-tr1-model-based-dose-finding-with-late-toxicity/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-adc-dose-and-schedule-optimisation","kind":"idea","name":"Dose and schedule optimisation trials specific to antibody-drug conjugates","route":"/ideas/idea-tr1-adc-dose-and-schedule-optimisation/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-dose-evidence-statement-in-label","kind":"idea","name":"A 'dose evidence' panel in every label: how many doses were tested, and how","route":"/ideas/idea-tr1-dose-evidence-statement-in-label/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-patient-reported-toxicity-dose-algorithms","kind":"idea","name":"Dose adjustments driven by patients' own symptom reports, tested against clinician judgement","route":"/ideas/idea-tr1-patient-reported-toxicity-dose-algorithms/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-food-effect-dose-reduction","kind":"idea","name":"Use food effects to cut the dose and cost of oral drugs that absorb better with meals","route":"/ideas/idea-tr1-food-effect-dose-reduction/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-factorial-dose-finding-for-combinations","kind":"idea","name":"Factorial dose finding for drug combinations instead of full dose of everything","route":"/ideas/idea-tr1-factorial-dose-finding-for-combinations/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-organ-impairment-pk-before-approval","kind":"idea","name":"Kidney and liver impairment dosing studies completed before approval, not years after","route":"/ideas/idea-tr1-organ-impairment-pk-before-approval/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-low-dose-immunotherapy-for-lmic","kind":"idea","name":"Confirm ultra-low-dose immunotherapy so it can be afforded where most patients live","route":"/ideas/idea-tr1-low-dose-immunotherapy-for-lmic/","asOf":"2026-09-08","days":20},{"id":"idea-tr1-response-adapted-dose-reduction","kind":"idea","name":"Reduce the dose once the cancer responds: response-adapted de-escalation trials","route":"/ideas/idea-tr1-response-adapted-dose-reduction/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-perpetual-platforms","kind":"idea","name":"A perpetual platform trial in every major cancer, funded as infrastructure","route":"/ideas/idea-tr2-perpetual-platforms/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-shared-control-network","kind":"idea","name":"Shared concurrent control arms across sponsors' trials in the same setting","route":"/ideas/idea-tr2-shared-control-network/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-synergy-ranking-engine","kind":"idea","name":"An open engine that ranks every drug pair by predicted synergy before anyone runs a trial","route":"/ideas/idea-tr2-synergy-ranking-engine/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-combination-template-agreement","kind":"idea","name":"A standard cross-company combination agreement that takes weeks, not years, to sign","route":"/ideas/idea-tr2-combination-template-agreement/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-public-combination-formulary","kind":"idea","name":"A publicly held library of investigational drugs available for academic combination trials","route":"/ideas/idea-tr2-public-combination-formulary/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-smart-sequencing-adc","kind":"idea","name":"Sequential multiple-assignment randomised trials to find the best order of ADCs","route":"/ideas/idea-tr2-smart-sequencing-adc/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-organoid-coclinical-arms","kind":"idea","name":"Grow each trial patient's tumour as organoids to decide which platform arm opens next","route":"/ideas/idea-tr2-organoid-coclinical-arms/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-organoid-matrix-atlas","kind":"idea","name":"A public atlas of drug-pair responses across a thousand patient-derived organoids","route":"/ideas/idea-tr2-organoid-matrix-atlas/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-combo-dose-matrix","kind":"idea","name":"Find the lowest effective doses of both drugs in a combination, not the highest tolerated","route":"/ideas/idea-tr2-combo-dose-matrix/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-neoadjuvant-combo-platform","kind":"idea","name":"Pre-surgery platform trials that test combinations on pathological response in months","route":"/ideas/idea-tr2-neoadjuvant-combo-platform/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-pragmatic-sequence-randomisation","kind":"idea","name":"Registry-embedded randomisation of treatment order in routine care","route":"/ideas/idea-tr2-pragmatic-sequence-randomisation/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-alternating-vs-concurrent","kind":"idea","name":"Test alternating drug schedules against giving both drugs at once","route":"/ideas/idea-tr2-alternating-vs-concurrent/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-rwe-combination-emulation","kind":"idea","name":"Emulate combination trials from real-world data to triage which ones to run","route":"/ideas/idea-tr2-rwe-combination-emulation/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-factorial-adjuvant-generics","kind":"idea","name":"Factorial trials that test several cheap generics at once in the adjuvant setting","route":"/ideas/idea-tr2-factorial-adjuvant-generics/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-ctdna-futility-gates","kind":"idea","name":"Kill combination arms early using circulating tumour DNA, before waiting for scans","route":"/ideas/idea-tr2-ctdna-futility-gates/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-platform-single-ethics","kind":"idea","name":"One ethics approval and one consent form for a platform trial across countries","route":"/ideas/idea-tr2-platform-single-ethics/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-resistance-mechanism-baskets","kind":"idea","name":"Combination baskets defined by resistance mechanism rather than by cancer type","route":"/ideas/idea-tr2-resistance-mechanism-baskets/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-combination-utility","kind":"idea","name":"A non-profit phase 1b combination unit that any drug owner can use","route":"/ideas/idea-tr2-combination-utility/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-combination-patent-pool","kind":"idea","name":"A patent pool for combination method-of-use claims","route":"/ideas/idea-tr2-combination-patent-pool/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-sequence-registry","kind":"idea","name":"A registry of every treatment sequence patients actually receive, with outcomes","route":"/ideas/idea-tr2-sequence-registry/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-bandit-allocation","kind":"idea","name":"Let the trial learn: response-adaptive allocation across many combination arms","route":"/ideas/idea-tr2-bandit-allocation/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-qsp-combo-dosing","kind":"idea","name":"Mechanistic computer models to pick combination doses before dosing patients","route":"/ideas/idea-tr2-qsp-combo-dosing/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-combo-readiness-dossier","kind":"idea","name":"Every approved cancer drug ships with a public combination-readiness data pack","route":"/ideas/idea-tr2-combo-readiness-dossier/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-rt-drug-platform","kind":"idea","name":"A standing platform for testing new drugs with radiotherapy","route":"/ideas/idea-tr2-rt-drug-platform/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-paediatric-combo-prea","kind":"idea","name":"Make paediatric combination studies part of every relevant adult cancer drug approval","route":"/ideas/idea-tr2-paediatric-combo-prea/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-payer-combo-cwe","kind":"idea","name":"Payers cover off-label combinations only inside registry-randomised trials","route":"/ideas/idea-tr2-payer-combo-cwe/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-combination-forecast-tournament","kind":"idea","name":"An open forecasting tournament on which combination trials will succeed","route":"/ideas/idea-tr2-combination-forecast-tournament/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-antagonism-surveillance","kind":"idea","name":"Watch routine care for drug combinations that quietly make cancer treatment worse","route":"/ideas/idea-tr2-antagonism-surveillance/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-contribution-of-components-mandate","kind":"idea","name":"No accelerated approval for a combination without proof each part contributes","route":"/ideas/idea-tr2-contribution-of-components-mandate/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-window-of-opportunity-triplets","kind":"idea","name":"Two-week pre-operative windows to compare combination biology head to head","route":"/ideas/idea-tr2-window-of-opportunity-triplets/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-preclinical-negative-registry","kind":"idea","name":"A registry for preclinical experiments that did not work","route":"/ideas/idea-tr2-preclinical-negative-registry/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-negative-results-journal","kind":"idea","name":"A funder-backed, indexed journal of negative and inconclusive cancer results","route":"/ideas/idea-tr2-negative-results-journal/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-fdaaa-enforcement","kind":"idea","name":"Actually fine sponsors who do not post trial results","route":"/ideas/idea-tr2-fdaaa-enforcement/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-irb-results-gate","kind":"idea","name":"No new trial approval until the sponsor has reported its old ones","route":"/ideas/idea-tr2-irb-results-gate/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-termination-reports","kind":"idea","name":"Public post-mortem reports when a cancer drug programme is stopped","route":"/ideas/idea-tr2-termination-reports/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-shelved-asset-commons","kind":"idea","name":"A commons of shelved cancer drugs with their full data, open to new hypotheses","route":"/ideas/idea-tr2-shelved-asset-commons/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-outcome-switching-monitor","kind":"idea","name":"Automatically detect when a trial changes its outcomes after the fact","route":"/ideas/idea-tr2-outcome-switching-monitor/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-material-failure-disclosure","kind":"idea","name":"Listed companies must disclose top-line data, not just 'did not meet endpoint'","route":"/ideas/idea-tr2-material-failure-disclosure/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-failed-trial-biobank","kind":"idea","name":"Rescue the biological samples from failed trials for biomarker research","route":"/ideas/idea-tr2-failed-trial-biobank/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-failed-trial-ipd-default","kind":"idea","name":"Patient-level data from failed trials becomes open by default after two years","route":"/ideas/idea-tr2-failed-trial-ipd-default/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-writeup-grants","kind":"idea","name":"Small grants that pay scientists to write up abandoned projects","route":"/ideas/idea-tr2-writeup-grants/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-null-result-reporting","kind":"idea","name":"Grant progress reports must list what did not work","route":"/ideas/idea-tr2-null-result-reporting/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-negative-plenaries","kind":"idea","name":"Give negative trials plenary slots at the big cancer conferences","route":"/ideas/idea-tr2-negative-plenaries/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-failure-taxonomy","kind":"idea","name":"A machine-readable taxonomy of why cancer drugs fail","route":"/ideas/idea-tr2-failure-taxonomy/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-model-report-cards","kind":"idea","name":"Score every preclinical model by how often it predicted the clinical result","route":"/ideas/idea-tr2-model-report-cards/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-off-label-outcome-registry","kind":"idea","name":"Record what happens when doctors use cancer drugs off-label","route":"/ideas/idea-tr2-off-label-outcome-registry/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-retraction-propagation","kind":"idea","name":"Alert guidelines and trials when a paper they rely on is retracted","route":"/ideas/idea-tr2-retraction-propagation/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-reversal-registry","kind":"idea","name":"A public registry of cancer treatments that were later shown not to work","route":"/ideas/idea-tr2-reversal-registry/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-sponsor-transparency-score","kind":"idea","name":"A public transparency score for every trial sponsor, used by sites and patients","route":"/ideas/idea-tr2-sponsor-transparency-score/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-target-failure-index","kind":"idea","name":"A target de-risking index that counts failures as well as successes","route":"/ideas/idea-tr2-target-failure-index/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-her2-low-reference-materials","kind":"idea","name":"Calibrated reference slides so every lab scores HER2-low the same way","route":"/ideas/idea-tr2-her2-low-reference-materials/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-pdl1-digital-calibration","kind":"idea","name":"One digital PD-L1 scale that maps across all the competing assays","route":"/ideas/idea-tr2-pdl1-digital-calibration/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-marker-stratified-default","kind":"idea","name":"Test the drug in biomarker-negative patients too, so the biomarker can be validated","route":"/ideas/idea-tr2-marker-stratified-default/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-cdx-mutual-recognition","kind":"idea","name":"Regulators recognise each other's companion diagnostic approvals","route":"/ideas/idea-tr2-cdx-mutual-recognition/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-open-cdx-validation-sets","kind":"idea","name":"Public gold-standard datasets for validating every cancer biomarker test","route":"/ideas/idea-tr2-open-cdx-validation-sets/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-ctdna-mrd-qualification","kind":"idea","name":"Formally qualify tumour-DNA blood tests as a surrogate endpoint for adjuvant trials","route":"/ideas/idea-tr2-ctdna-mrd-qualification/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-psma-volume-qualification","kind":"idea","name":"Qualify PSMA PET tumour volume as a validated imaging biomarker","route":"/ideas/idea-tr2-psma-volume-qualification/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-bicr-discordance-public","kind":"idea","name":"Publish the disagreement between trial doctors and independent reviewers for every trial","route":"/ideas/idea-tr2-bicr-discordance-public/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-biomarker-evidence-grading","kind":"idea","name":"Label every biomarker claim with an evidence phase, like drugs","route":"/ideas/idea-tr2-biomarker-evidence-grading/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-eqa-public-results","kind":"idea","name":"Publish each laboratory's biomarker proficiency results","route":"/ideas/idea-tr2-eqa-public-results/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-ctdna-reference-plasma","kind":"idea","name":"Certified reference samples to benchmark every tumour-DNA blood test","route":"/ideas/idea-tr2-ctdna-reference-plasma/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-tmb-calibration-standard","kind":"idea","name":"A single calibrated tumour mutational burden across all sequencing panels","route":"/ideas/idea-tr2-tmb-calibration-standard/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-hrd-functional-standard","kind":"idea","name":"A functional test for homologous recombination deficiency validated across laboratories","route":"/ideas/idea-tr2-hrd-functional-standard/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-preanalytics-in-report","kind":"idea","name":"Record how long tissue waited before fixation in every pathology report","route":"/ideas/idea-tr2-preanalytics-in-report/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-cutpoint-lock","kind":"idea","name":"Lock the biomarker cut-off before phase 3, and publish it","route":"/ideas/idea-tr2-cutpoint-lock/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-prospective-retrospective-path","kind":"idea","name":"A formal regulatory route for validating a biomarker on archived trial samples","route":"/ideas/idea-tr2-prospective-retrospective-path/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-spatial-biomarker-standards","kind":"idea","name":"Standards for spatial and multiplex tissue biomarkers before they reach the clinic","route":"/ideas/idea-tr2-spatial-biomarker-standards/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-liquid-biopsy-challenge","kind":"idea","name":"An annual blinded shoot-out for liquid biopsy tests","route":"/ideas/idea-tr2-liquid-biopsy-challenge/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-radiomics-ibsi-mandate","kind":"idea","name":"No clinical claims for imaging-derived biomarkers without phantom and standards compliance","route":"/ideas/idea-tr2-radiomics-ibsi-mandate/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-biomarker-study-registry","kind":"idea","name":"Pre-register biomarker validation studies the way trials are registered","route":"/ideas/idea-tr2-biomarker-study-registry/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-biomarker-cwe","kind":"idea","name":"Pay for new biomarker tests only while evidence of clinical utility is being collected","route":"/ideas/idea-tr2-biomarker-cwe/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-ai-cdx-change-control","kind":"idea","name":"Version control and locked reference sets for AI algorithms used as companion diagnostics","route":"/ideas/idea-tr2-ai-cdx-change-control/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-label-assay-concordance","kind":"idea","name":"Drug labels must state which biomarker assays were validated and how they compare","route":"/ideas/idea-tr2-label-assay-concordance/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-biomarker-negative-arms","kind":"idea","name":"Randomised trials to test whether biomarker-negative patients really do not benefit","route":"/ideas/idea-tr2-biomarker-negative-arms/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-positivity-rate-surveillance","kind":"idea","name":"Monitor biomarker positivity rates across labs in real time to catch assay drift","route":"/ideas/idea-tr2-positivity-rate-surveillance/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-cell-line-authentication-mandate","kind":"idea","name":"Prove your cell lines are what you say they are, or the paper is not published","route":"/ideas/idea-tr2-cell-line-authentication-mandate/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-cell-line-passport","kind":"idea","name":"A digital passport for every cell culture: identity, contamination status, passage number","route":"/ideas/idea-tr2-cell-line-passport/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-preclinical-registered-reports","kind":"idea","name":"Registered reports for cancer biology: the plan is peer-reviewed before the result","route":"/ideas/idea-tr2-preclinical-registered-reports/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-replication-set-aside","kind":"idea","name":"Funders set aside a fixed share of budget for independent replication","route":"/ideas/idea-tr2-replication-set-aside/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-replication-before-ind","kind":"idea","name":"Independent replication of the key experiment before first-in-human academic trials","route":"/ideas/idea-tr2-replication-before-ind/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-automated-stats-check","kind":"idea","name":"Run automated statistics and image checks on every cancer manuscript before review","route":"/ideas/idea-tr2-automated-stats-check/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-raw-image-deposit","kind":"idea","name":"Deposit the raw blots, gels and microscopy images behind every figure","route":"/ideas/idea-tr2-raw-image-deposit/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-arrive-audit","kind":"idea","name":"Audit animal studies for randomisation and blinding, published by institution","route":"/ideas/idea-tr2-arrive-audit/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-multilab-preclinical","kind":"idea","name":"Multi-laboratory preclinical trials as the standard for go/no-go decisions","route":"/ideas/idea-tr2-multilab-preclinical/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-replication-bounties","kind":"idea","name":"Bounties for documented failed replications of high-impact findings","route":"/ideas/idea-tr2-replication-bounties/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-antibody-validation-mandate","kind":"idea","name":"Only use antibodies proven to hit their target with knockout controls","route":"/ideas/idea-tr2-antibody-validation-mandate/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-reference-compound-panels","kind":"idea","name":"Every drug screen includes standard reference compounds whose performance is published","route":"/ideas/idea-tr2-reference-compound-panels/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-timestamped-eln","kind":"idea","name":"Time-stamped electronic lab notebooks submitted with the paper","route":"/ideas/idea-tr2-timestamped-eln/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-animal-power-mandate","kind":"idea","name":"Pre-specified sample sizes for animal studies; no more 'representative' experiments","route":"/ideas/idea-tr2-animal-power-mandate/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-tenure-replication-credit","kind":"idea","name":"Count replications and open data in hiring and promotion","route":"/ideas/idea-tr2-tenure-replication-credit/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-random-audit","kind":"idea","name":"Random audits of published, funded research, like tax audits","route":"/ideas/idea-tr2-random-audit/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-replication-status-badge","kind":"idea","name":"A replication status badge on every cancer paper, visible in PubMed","route":"/ideas/idea-tr2-replication-status-badge/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-data-link-enforcement","kind":"idea","name":"Journals check that data links actually work, and flag papers whose data vanish","route":"/ideas/idea-tr2-data-link-enforcement/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-paid-statistical-review","kind":"idea","name":"Paid independent statistical review for preclinical papers that inform trials","route":"/ideas/idea-tr2-paid-statistical-review/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-reference-model-panels","kind":"idea","name":"Shared reference organoid and PDX panels that every lab can test against","route":"/ideas/idea-tr2-reference-model-panels/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-ai-external-validation-registry","kind":"idea","name":"A registry of external validation datasets for cancer AI models, with mandatory reporting","route":"/ideas/idea-tr2-ai-external-validation-registry/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-two-lab-rule","kind":"idea","name":"Top journals require an independent lab to reproduce key findings before publication","route":"/ideas/idea-tr2-two-lab-rule/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-preclinical-living-reviews","kind":"idea","name":"Living systematic reviews of animal and organoid evidence before every new trial","route":"/ideas/idea-tr2-preclinical-living-reviews/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-reagent-lot-ledger","kind":"idea","name":"Barcode every reagent lot so batch effects can be traced across experiments and labs","route":"/ideas/idea-tr2-reagent-lot-ledger/","asOf":"2026-09-08","days":20},{"id":"idea-tr2-phd-replication-year","kind":"idea","name":"Every cancer biology PhD begins with a funded replication of a published finding","route":"/ideas/idea-tr2-phd-replication-year/","asOf":"2026-09-08","days":20},{"id":"idea-reg-orbis-work-sharing","kind":"idea","name":"Turn Project Orbis into a work-sharing review with one shared assessment report","route":"/ideas/idea-reg-orbis-work-sharing/","asOf":"2026-09-08","days":20},{"id":"idea-reg-reliance-90-day-lmic","kind":"idea","name":"90-day reliance approval for cancer drugs cleared by two stringent regulators","route":"/ideas/idea-reg-reliance-90-day-lmic/","asOf":"2026-09-08","days":20},{"id":"idea-reg-single-global-dossier","kind":"idea","name":"One structured global dossier: submit the cancer drug file once, to a shared cloud","route":"/ideas/idea-reg-single-global-dossier/","asOf":"2026-09-08","days":20},{"id":"idea-reg-joint-scientific-advice-default","kind":"idea","name":"Joint FDA-EMA-MHRA-PMDA scientific advice by default before pivotal cancer trials","route":"/ideas/idea-reg-joint-scientific-advice-default/","asOf":"2026-09-08","days":20},{"id":"idea-reg-realtime-streaming-submission","kind":"idea","name":"Stream trial data to regulators as it accrues; review starts at last patient visit","route":"/ideas/idea-reg-realtime-streaming-submission/","asOf":"2026-09-08","days":20},{"id":"idea-reg-conditional-approval-sunset","kind":"idea","name":"Conditional approvals that lapse automatically if the confirmatory trial is late","route":"/ideas/idea-reg-conditional-approval-sunset/","asOf":"2026-09-08","days":20},{"id":"idea-reg-confirmatory-trial-escrow","kind":"idea","name":"Sponsors deposit the confirmatory trial budget in escrow at accelerated approval","route":"/ideas/idea-reg-confirmatory-trial-escrow/","asOf":"2026-09-08","days":20},{"id":"idea-reg-public-assessment-reports-all","kind":"idea","name":"Every regulator publishes its full assessment report so others can rely on it","route":"/ideas/idea-reg-public-assessment-reports-all/","asOf":"2026-09-08","days":20},{"id":"idea-reg-mutual-recognition-inspections-atmp","kind":"idea","name":"Mutual recognition of GMP inspections for cell, gene and radiopharmaceutical plants","route":"/ideas/idea-reg-mutual-recognition-inspections-atmp/","asOf":"2026-09-08","days":20},{"id":"idea-reg-global-trial-application-portal","kind":"idea","name":"One clinical trial application accepted by regulators in every major region","route":"/ideas/idea-reg-global-trial-application-portal/","asOf":"2026-09-08","days":20},{"id":"idea-reg-diagnostic-reliance-pathway","kind":"idea","name":"A reliance pathway for companion diagnostics so the test arrives with the drug","route":"/ideas/idea-reg-diagnostic-reliance-pathway/","asOf":"2026-09-08","days":20},{"id":"idea-reg-single-paediatric-plan","kind":"idea","name":"One global paediatric cancer development plan instead of separate FDA and EMA plans","route":"/ideas/idea-reg-single-paediatric-plan/","asOf":"2026-09-08","days":20},{"id":"idea-reg-tumour-agnostic-reliance","kind":"idea","name":"Adopt tumour-agnostic cancer drug labels across regions by reliance, not re-review","route":"/ideas/idea-reg-tumour-agnostic-reliance/","asOf":"2026-09-08","days":20},{"id":"idea-reg-label-divergence-index","kind":"idea","name":"A public index of how the same cancer drug's label differs between countries","route":"/ideas/idea-reg-label-divergence-index/","asOf":"2026-09-08","days":20},{"id":"idea-reg-approval-access-lag-tracker","kind":"idea","name":"Live tracker of the lag from first approval to real availability in every country","route":"/ideas/idea-reg-approval-access-lag-tracker/","asOf":"2026-09-08","days":20},{"id":"idea-reg-joint-regulator-hta-plan","kind":"idea","name":"One evidence plan agreed by regulator and payer before the pivotal trial","route":"/ideas/idea-reg-joint-regulator-hta-plan/","asOf":"2026-09-08","days":20},{"id":"idea-reg-mrct-no-bridging","kind":"idea","name":"One multiregional trial, no bridging studies: enforce ICH E17 in Japan and China","route":"/ideas/idea-reg-mrct-no-bridging/","asOf":"2026-09-08","days":20},{"id":"idea-reg-african-medicines-agency-oncology","kind":"idea","name":"Fund an oncology joint assessment unit inside the African Medicines Agency","route":"/ideas/idea-reg-african-medicines-agency-oncology/","asOf":"2026-09-08","days":20},{"id":"idea-reg-open-source-dossier-tools","kind":"idea","name":"Open-source dossier-building software for academic sponsors and generic makers","route":"/ideas/idea-reg-open-source-dossier-tools/","asOf":"2026-09-08","days":20},{"id":"idea-reg-shared-ai-review-assistant","kind":"idea","name":"A shared AI review assistant that maps one dossier to every regulator's questions","route":"/ideas/idea-reg-shared-ai-review-assistant/","asOf":"2026-09-08","days":20},{"id":"idea-reg-shared-postmarketing-registry-condition","kind":"idea","name":"One international registry, not one per country, for conditional approvals","route":"/ideas/idea-reg-shared-postmarketing-registry-condition/","asOf":"2026-09-08","days":20},{"id":"idea-reg-manufacturing-change-passport","kind":"idea","name":"Manufacturing-change passport: one approved CMC change accepted everywhere in 30 days","route":"/ideas/idea-reg-manufacturing-change-passport/","asOf":"2026-09-08","days":20},{"id":"idea-reg-orphan-designation-reciprocity","kind":"idea","name":"Automatic reciprocity of orphan and rare-paediatric designations between regulators","route":"/ideas/idea-reg-orphan-designation-reciprocity/","asOf":"2026-09-08","days":20},{"id":"idea-reg-publish-all-rejections","kind":"idea","name":"Publish every complete response letter and negative opinion across all regulators","route":"/ideas/idea-reg-publish-all-rejections/","asOf":"2026-09-08","days":20},{"id":"idea-reg-global-dose-optimisation-guideline","kind":"idea","name":"Make pre-approval dose optimisation an ICH standard so it is done once worldwide","route":"/ideas/idea-reg-global-dose-optimisation-guideline/","asOf":"2026-09-08","days":20},{"id":"idea-reg-point-of-care-cart-network","kind":"idea","name":"Hospital-made CAR-T under one shared regulatory master file","route":"/ideas/idea-reg-point-of-care-cart-network/","asOf":"2026-09-08","days":20},{"id":"idea-reg-in-vivo-cart-off-the-shelf-vial","kind":"idea","name":"In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma","route":"/ideas/idea-reg-in-vivo-cart-off-the-shelf-vial/","asOf":"2026-09-08","days":20},{"id":"idea-reg-two-day-cart-rapid-release","kind":"idea","name":"Two-day CAR-T manufacture paired with rapid release tests that regulators accept","route":"/ideas/idea-reg-two-day-cart-rapid-release/","asOf":"2026-09-08","days":20},{"id":"idea-reg-ipsc-master-bank-qualified-once","kind":"idea","name":"Qualify one iPSC master cell bank once for many off-the-shelf cell products","route":"/ideas/idea-reg-ipsc-master-bank-qualified-once/","asOf":"2026-09-08","days":20},{"id":"idea-reg-closed-manufacturing-interop-standard","kind":"idea","name":"An open interoperability standard for closed automated cell-processing machines","route":"/ideas/idea-reg-closed-manufacturing-interop-standard/","asOf":"2026-09-08","days":20},{"id":"idea-reg-cart-potency-reference-standards","kind":"idea","name":"Public reference standards and potency assays for CAR-T so every lab measures alike","route":"/ideas/idea-reg-cart-potency-reference-standards/","asOf":"2026-09-08","days":20},{"id":"idea-reg-vein-to-vein-public-benchmark","kind":"idea","name":"Mandatory public reporting of vein-to-vein time and failure rate per CAR-T product","route":"/ideas/idea-reg-vein-to-vein-public-benchmark/","asOf":"2026-09-08","days":20},{"id":"idea-reg-legacy-radium-recovery-ac225","kind":"idea","name":"Recover legacy radium-226 sources worldwide as the feedstock for actinium-225","route":"/ideas/idea-reg-legacy-radium-recovery-ac225/","asOf":"2026-09-08","days":20},{"id":"idea-reg-ac225-accelerator-pharmacopoeia","kind":"idea","name":"Regional cyclotron hubs for actinium-225 with an agreed actinium-227 impurity limit","route":"/ideas/idea-reg-ac225-accelerator-pharmacopoeia/","asOf":"2026-09-08","days":20},{"id":"idea-reg-yb176-enrichment-capacity","kind":"idea","name":"Build Western ytterbium-176 enrichment so lutetium-177 has more than one supplier","route":"/ideas/idea-reg-yb176-enrichment-capacity/","asOf":"2026-09-08","days":20},{"id":"idea-reg-medical-isotope-reactor-reserve","kind":"idea","name":"A coordinated reserve and shared schedule for the world's medical isotope reactors","route":"/ideas/idea-reg-medical-isotope-reactor-reserve/","asOf":"2026-09-08","days":20},{"id":"idea-reg-alpha-emitter-portfolio","kind":"idea","name":"Fund alpha emitters beyond actinium-225: lead-212, terbium-149 and astatine-211","route":"/ideas/idea-reg-alpha-emitter-portfolio/","asOf":"2026-09-08","days":20},{"id":"idea-reg-regional-radiopharmacy-hubs","kind":"idea","name":"Regional radiopharmacy hubs and harmonised transport rules for short-lived isotopes","route":"/ideas/idea-reg-regional-radiopharmacy-hubs/","asOf":"2026-09-08","days":20},{"id":"idea-reg-adc-platform-designation","kind":"idea","name":"Platform designation for ADC linker-payloads so manufacturing data carry across","route":"/ideas/idea-reg-adc-platform-designation/","asOf":"2026-09-08","days":20},{"id":"idea-reg-hpapi-continuous-flow","kind":"idea","name":"Continuous-flow synthesis of ultra-potent ADC payloads to ease the capacity squeeze","route":"/ideas/idea-reg-hpapi-continuous-flow/","asOf":"2026-09-08","days":20},{"id":"idea-reg-open-source-lentiviral-vectors","kind":"idea","name":"Non-profit, open-licence lentiviral vectors and producer cell lines for CAR-T","route":"/ideas/idea-reg-open-source-lentiviral-vectors/","asOf":"2026-09-08","days":20},{"id":"idea-reg-non-viral-cart-manufacturing","kind":"idea","name":"Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route","route":"/ideas/idea-reg-non-viral-cart-manufacturing/","asOf":"2026-09-08","days":20},{"id":"idea-reg-manufacturing-slot-exchange","kind":"idea","name":"A neutral slot exchange so unused CAR-T manufacturing slots go to the next patient","route":"/ideas/idea-reg-manufacturing-slot-exchange/","asOf":"2026-09-08","days":20},{"id":"idea-reg-hospital-exemption-harmonised","kind":"idea","name":"Harmonise Europe's hospital exemption for academic cell therapies, with one registry","route":"/ideas/idea-reg-hospital-exemption-harmonised/","asOf":"2026-09-08","days":20},{"id":"idea-reg-lmic-public-cart-manufacturing","kind":"idea","name":"Public-sector CAR-T manufacturing in India, Brazil and South Africa under $50,000","route":"/ideas/idea-reg-lmic-public-cart-manufacturing/","asOf":"2026-09-08","days":20},{"id":"idea-reg-ai-process-control-cell-manufacturing","kind":"idea","name":"Digital batch records and AI process control to halve cell therapy batch failures","route":"/ideas/idea-reg-ai-process-control-cell-manufacturing/","asOf":"2026-09-08","days":20},{"id":"idea-reg-early-apheresis-banking","kind":"idea","name":"Collect and freeze T cells at diagnosis for high-risk patients, before chemotherapy","route":"/ideas/idea-reg-early-apheresis-banking/","asOf":"2026-09-08","days":20},{"id":"idea-reg-public-cell-therapy-foundries","kind":"idea","name":"Public cell-therapy foundries at cancer centres for academics and start-ups","route":"/ideas/idea-reg-public-cell-therapy-foundries/","asOf":"2026-09-08","days":20},{"id":"idea-reg-comparability-by-design-digital-twin","kind":"idea","name":"Comparability by design: a digital twin and sentinel panel for cell process changes","route":"/ideas/idea-reg-comparability-by-design-digital-twin/","asOf":"2026-09-08","days":20},{"id":"idea-reg-isotope-supply-observatory","kind":"idea","name":"A global medical isotope supply observatory with forecasts and shortage alerts","route":"/ideas/idea-reg-isotope-supply-observatory/","asOf":"2026-09-08","days":20},{"id":"idea-reg-cart-outcomes-refund","kind":"idea","name":"Full refund for CAR-T if the patient has not responded at three months","route":"/ideas/idea-reg-cart-outcomes-refund/","asOf":"2026-09-08","days":20},{"id":"idea-reg-io-subscription-national","kind":"idea","name":"Subscription pricing for checkpoint inhibitors: fixed national fee, unlimited use","route":"/ideas/idea-reg-io-subscription-national/","asOf":"2026-09-08","days":20},{"id":"idea-reg-indication-specific-pricing","kind":"idea","name":"Pay a different price for the same cancer drug depending on the indication","route":"/ideas/idea-reg-indication-specific-pricing/","asOf":"2026-09-08","days":20},{"id":"idea-reg-pooled-procurement-adult-essentials","kind":"idea","name":"Pooled international procurement of essential adult cancer medicines","route":"/ideas/idea-reg-pooled-procurement-adult-essentials/","asOf":"2026-09-08","days":20},{"id":"idea-reg-biosimilar-no-efficacy-trial","kind":"idea","name":"Approve cancer biosimilars on analytics and pharmacokinetics, no efficacy trials","route":"/ideas/idea-reg-biosimilar-no-efficacy-trial/","asOf":"2026-09-08","days":20},{"id":"idea-reg-pd1-biosimilar-advance-commitment","kind":"idea","name":"An advance market commitment for PD-1 biosimilars for lower-income countries","route":"/ideas/idea-reg-pd1-biosimilar-advance-commitment/","asOf":"2026-09-08","days":20},{"id":"idea-reg-patent-pool-oncology-eml","kind":"idea","name":"Medicines Patent Pool licences for every patented cancer drug on the WHO list","route":"/ideas/idea-reg-patent-pool-oncology-eml/","asOf":"2026-09-08","days":20},{"id":"idea-reg-price-anchored-to-mcbs","kind":"idea","name":"Cap public prices for new cancer drugs to tiers of the ESMO and ASCO value scales","route":"/ideas/idea-reg-price-anchored-to-mcbs/","asOf":"2026-09-08","days":20},{"id":"idea-reg-weight-based-io-dosing-label","kind":"idea","name":"Restore weight-based dosing and vial sharing for immunotherapy in the label","route":"/ideas/idea-reg-weight-based-io-dosing-label/","asOf":"2026-09-08","days":20},{"id":"idea-reg-public-deescalation-trials-for-cost","kind":"idea","name":"Publicly funded trials of lower and less frequent doses of expensive cancer drugs","route":"/ideas/idea-reg-public-deescalation-trials-for-cost/","asOf":"2026-09-08","days":20},{"id":"idea-reg-financial-toxicity-vital-sign","kind":"idea","name":"Screen every cancer patient for financial toxicity as a vital sign, with navigation","route":"/ideas/idea-reg-financial-toxicity-vital-sign/","asOf":"2026-09-08","days":20},{"id":"idea-reg-net-price-transparency-registry","kind":"idea","name":"An international registry of real (net) cancer drug prices paid by public payers","route":"/ideas/idea-reg-net-price-transparency-registry/","asOf":"2026-09-08","days":20},{"id":"idea-reg-rd-cost-disclosure-condition","kind":"idea","name":"Disclose R&D and manufacturing costs of publicly funded cancer drugs to get coverage","route":"/ideas/idea-reg-rd-cost-disclosure-condition/","asOf":"2026-09-08","days":20},{"id":"idea-reg-provisional-price-until-os","kind":"idea","name":"Provisional prices for surrogate-endpoint approvals, reset when survival data arrive","route":"/ideas/idea-reg-provisional-price-until-os/","asOf":"2026-09-08","days":20},{"id":"idea-reg-patent-buyout-prize","kind":"idea","name":"Buy out the patent on a curative cancer drug and sell it at generic prices","route":"/ideas/idea-reg-patent-buyout-prize/","asOf":"2026-09-08","days":20},{"id":"idea-reg-secondary-patent-thicket-limits","kind":"idea","name":"Limit secondary patents and pay-for-delay so cancer generics arrive on time","route":"/ideas/idea-reg-secondary-patent-thicket-limits/","asOf":"2026-09-08","days":20},{"id":"idea-reg-nonprofit-generic-chemo-manufacturer","kind":"idea","name":"A non-profit manufacturer for generic cancer drugs in chronic shortage","route":"/ideas/idea-reg-nonprofit-generic-chemo-manufacturer/","asOf":"2026-09-08","days":20},{"id":"idea-reg-academic-cart-at-cost-coverage","kind":"idea","name":"Public payers cover academic CAR-T at cost as a benchmark for commercial prices","route":"/ideas/idea-reg-academic-cart-at-cost-coverage/","asOf":"2026-09-08","days":20},{"id":"idea-reg-combination-price-attribution","kind":"idea","name":"A combination pricing rule so two-drug regimens are not priced as two monopolies","route":"/ideas/idea-reg-combination-price-attribution/","asOf":"2026-09-08","days":20},{"id":"idea-reg-middle-income-negotiation-bloc","kind":"idea","name":"A joint price negotiation bloc for middle-income countries, modelled on Beneluxa","route":"/ideas/idea-reg-middle-income-negotiation-bloc/","asOf":"2026-09-08","days":20},{"id":"idea-reg-tiered-pricing-for-exclusivity","kind":"idea","name":"Grant extra exclusivity only in exchange for binding low prices in poorer countries","route":"/ideas/idea-reg-tiered-pricing-for-exclusivity/","asOf":"2026-09-08","days":20},{"id":"idea-reg-biosimilar-first-default-switching","kind":"idea","name":"Biosimilar-first defaults and payment parity in every cancer day unit","route":"/ideas/idea-reg-biosimilar-first-default-switching/","asOf":"2026-09-08","days":20},{"id":"idea-reg-annuity-payment-durable-therapies","kind":"idea","name":"Pay for one-time curative therapies as an annuity that stops at relapse","route":"/ideas/idea-reg-annuity-payment-durable-therapies/","asOf":"2026-09-08","days":20},{"id":"idea-reg-social-impact-bond-switching","kind":"idea","name":"Social impact bonds that fund biosimilar switching, repaid from payer savings","route":"/ideas/idea-reg-social-impact-bond-switching/","asOf":"2026-09-08","days":20},{"id":"idea-reg-market-expansion-repricing","kind":"idea","name":"Automatic price cuts when a cancer drug's approved indications and volumes expand","route":"/ideas/idea-reg-market-expansion-repricing/","asOf":"2026-09-08","days":20},{"id":"idea-reg-global-repurposing-fund","kind":"idea","name":"A public fund that pays for phase 3 trials of cheap, off-patent drugs against cancer","route":"/ideas/idea-reg-global-repurposing-fund/","asOf":"2026-09-08","days":20},{"id":"idea-reg-third-party-label-update","kind":"idea","name":"Let non-profits and academics add a cancer indication to an off-patent drug's label","route":"/ideas/idea-reg-third-party-label-update/","asOf":"2026-09-08","days":20},{"id":"idea-reg-repurposing-prize","kind":"idea","name":"A $50 million prize for the first off-patent drug proven to extend cancer survival","route":"/ideas/idea-reg-repurposing-prize/","asOf":"2026-09-08","days":20},{"id":"idea-reg-repurposing-social-impact-bond","kind":"idea","name":"A social impact bond: investors fund a repurposing trial, payers repay from savings","route":"/ideas/idea-reg-repurposing-social-impact-bond/","asOf":"2026-09-08","days":20},{"id":"idea-reg-aspirin-pik3ca-implementation","kind":"idea","name":"Get biomarker-directed aspirin after colorectal surgery into labels and guidelines","route":"/ideas/idea-reg-aspirin-pik3ca-implementation/","asOf":"2026-09-08","days":20},{"id":"idea-reg-recovery-style-platform-repurposing","kind":"idea","name":"A RECOVERY-style permanent platform trial of cheap drugs added to cancer care","route":"/ideas/idea-reg-recovery-style-platform-repurposing/","asOf":"2026-09-08","days":20},{"id":"idea-reg-perioperative-propranolol-etodolac","kind":"idea","name":"Perioperative beta-blocker plus COX-2 inhibitor to reduce metastasis after surgery","route":"/ideas/idea-reg-perioperative-propranolol-etodolac/","asOf":"2026-09-08","days":20},{"id":"idea-reg-statin-hcc-prevention-trial","kind":"idea","name":"A pragmatic trial of statins to prevent liver cancer in people with cirrhosis","route":"/ideas/idea-reg-statin-hcc-prevention-trial/","asOf":"2026-09-08","days":20},{"id":"idea-reg-evidence-gate-before-repurposing-phase3","kind":"idea","name":"Require genetic and target-trial evidence before funding any repurposing phase 3","route":"/ideas/idea-reg-evidence-gate-before-repurposing-phase3/","asOf":"2026-09-08","days":20},{"id":"idea-reg-target-trial-emulation-pipeline","kind":"idea","name":"An automated pipeline emulating trials of every common drug against every cancer","route":"/ideas/idea-reg-target-trial-emulation-pipeline/","asOf":"2026-09-08","days":20},{"id":"idea-reg-new-indication-exclusivity-off-patent","kind":"idea","name":"Three years of indication-specific exclusivity for proving a new cancer use of an old drug","route":"/ideas/idea-reg-new-indication-exclusivity-off-patent/","asOf":"2026-09-08","days":20},{"id":"idea-reg-delinked-market-entry-reward","kind":"idea","name":"A delinked market-entry reward paid by payers when a repurposed generic wins approval","route":"/ideas/idea-reg-delinked-market-entry-reward/","asOf":"2026-09-08","days":20},{"id":"idea-reg-generic-targeted-therapy-drup","kind":"idea","name":"A DRUP-style protocol for off-label generic targeted drugs in rare tumours","route":"/ideas/idea-reg-generic-targeted-therapy-drup/","asOf":"2026-09-08","days":20},{"id":"idea-reg-antihistamine-plus-io-trial","kind":"idea","name":"Randomise a cheap antihistamine alongside immunotherapy","route":"/ideas/idea-reg-antihistamine-plus-io-trial/","asOf":"2026-09-08","days":20},{"id":"idea-reg-vitamin-d-digestive-cancer-biomarker-trial","kind":"idea","name":"A biomarker-directed trial of vitamin D after surgery for digestive tract cancers","route":"/ideas/idea-reg-vitamin-d-digestive-cancer-biomarker-trial/","asOf":"2026-09-08","days":20},{"id":"idea-reg-losartan-pancreatic-stroma","kind":"idea","name":"Losartan to loosen the stroma of pancreatic cancer before chemotherapy: a phase 3","route":"/ideas/idea-reg-losartan-pancreatic-stroma/","asOf":"2026-09-08","days":20},{"id":"idea-reg-regulator-ready-repurposing-dossiers","kind":"idea","name":"Fund regulator-ready evidence dossiers for the 20 best-supported off-patent drugs","route":"/ideas/idea-reg-regulator-ready-repurposing-dossiers/","asOf":"2026-09-08","days":20},{"id":"idea-reg-guideline-fast-track-repurposed","kind":"idea","name":"A guideline fast track for repurposed drugs with phase 3 evidence but no manufacturer","route":"/ideas/idea-reg-guideline-fast-track-repurposed/","asOf":"2026-09-08","days":20},{"id":"idea-reg-payer-coverage-off-label-generic-commitment","kind":"idea","name":"Payers pre-commit to cover off-label generics when a definitive trial is positive","route":"/ideas/idea-reg-payer-coverage-off-label-generic-commitment/","asOf":"2026-09-08","days":20},{"id":"idea-reg-nonprofit-marketing-authorisation-holder","kind":"idea","name":"A non-profit company to hold marketing authorisations for repurposed cancer drugs","route":"/ideas/idea-reg-nonprofit-marketing-authorisation-holder/","asOf":"2026-09-08","days":20},{"id":"idea-reg-metronomic-lmic-phase3-to-label","kind":"idea","name":"Validate low-cost metronomic oral regimens in phase 3 and carry them into guidelines","route":"/ideas/idea-reg-metronomic-lmic-phase3-to-label/","asOf":"2026-09-08","days":20},{"id":"idea-reg-generic-chemo-strategic-reserve","kind":"idea","name":"A strategic reserve of essential generic cancer drugs to end recurring shortages","route":"/ideas/idea-reg-generic-chemo-strategic-reserve/","asOf":"2026-09-08","days":20},{"id":"idea-reg-factorial-addon-arms-cooperative-trials","kind":"idea","name":"Add a cheap-drug factorial arm to every cooperative-group adjuvant cancer trial","route":"/ideas/idea-reg-factorial-addon-arms-cooperative-trials/","asOf":"2026-09-08","days":20},{"id":"idea-reg-olanzapine-cachexia-global-confirmation","kind":"idea","name":"Confirm low-dose olanzapine for appetite and weight in advanced cancer worldwide","route":"/ideas/idea-reg-olanzapine-cachexia-global-confirmation/","asOf":"2026-09-08","days":20},{"id":"idea-reg-preregistered-ai-repurposing-scoring","kind":"idea","name":"Pre-registered, publicly scored AI ranking of repurposing candidates for cancer","route":"/ideas/idea-reg-preregistered-ai-repurposing-scoring/","asOf":"2026-09-08","days":20},{"id":"idea-acc-open-hardware-linac","kind":"idea","name":"An open-hardware radiotherapy machine built for unreliable power and dust","route":"/ideas/idea-acc-open-hardware-linac/","asOf":"2026-09-08","days":20},{"id":"idea-acc-linac-uptime-contracts","kind":"idea","name":"Pay for radiotherapy machine uptime, not for the machine","route":"/ideas/idea-acc-linac-uptime-contracts/","asOf":"2026-09-08","days":20},{"id":"idea-acc-hypofractionation-default-lmic","kind":"idea","name":"Make one-week radiotherapy the default in overloaded systems","route":"/ideas/idea-acc-hypofractionation-default-lmic/","asOf":"2026-09-08","days":20},{"id":"idea-acc-remote-planning-hubs","kind":"idea","name":"Round-the-clock remote treatment-planning hubs for clinics without physicists","route":"/ideas/idea-acc-remote-planning-hubs/","asOf":"2026-09-08","days":20},{"id":"idea-acc-modern-cobalt-bridge","kind":"idea","name":"Modernised cobalt-60 machines as a deliberate bridge where linacs cannot be kept running","route":"/ideas/idea-acc-modern-cobalt-bridge/","asOf":"2026-09-08","days":20},{"id":"idea-acc-pooled-procurement-radiotherapy","kind":"idea","name":"A Gavi-style pooled purchaser for radiotherapy equipment and service","route":"/ideas/idea-acc-pooled-procurement-radiotherapy/","asOf":"2026-09-08","days":20},{"id":"idea-acc-telepathology-district-network","kind":"idea","name":"Slide scanners in district hospitals wired to pathologists anywhere","route":"/ideas/idea-acc-telepathology-district-network/","asOf":"2026-09-08","days":20},{"id":"idea-acc-ai-first-pathology-common-cases","kind":"idea","name":"AI-first reading for high-volume common cancer diagnoses, pathologist for the exceptions","route":"/ideas/idea-acc-ai-first-pathology-common-cases/","asOf":"2026-09-08","days":20},{"id":"idea-acc-nurse-led-chemotherapy-units","kind":"idea","name":"Nurse-led chemotherapy day units with a doctor on a screen","route":"/ideas/idea-acc-nurse-led-chemotherapy-units/","asOf":"2026-09-08","days":20},{"id":"idea-acc-eml-listing-price-commitments","kind":"idea","name":"Tie WHO essential-medicines listing to a published tiered price and supply pledge","route":"/ideas/idea-acc-eml-listing-price-commitments/","asOf":"2026-09-08","days":20},{"id":"idea-acc-biosimilar-prequalification-pool","kind":"idea","name":"WHO prequalification plus pooled demand to push biosimilar prices below 10% of the originator","route":"/ideas/idea-acc-biosimilar-prequalification-pool/","asOf":"2026-09-08","days":20},{"id":"idea-acc-chemo-stockout-early-warning","kind":"idea","name":"A live stock-out map for essential chemotherapy drugs","route":"/ideas/idea-acc-chemo-stockout-early-warning/","asOf":"2026-09-08","days":20},{"id":"idea-acc-childhood-medicines-platform-scale","kind":"idea","name":"Guaranteed-quality childhood cancer medicines free of charge in 50 countries","route":"/ideas/idea-acc-childhood-medicines-platform-scale/","asOf":"2026-09-08","days":20},{"id":"idea-acc-hub-spoke-national-networks","kind":"idea","name":"National hub-and-spoke cancer networks with defined referral tiers","route":"/ideas/idea-acc-hub-spoke-national-networks/","asOf":"2026-09-08","days":20},{"id":"idea-acc-mobile-see-and-treat-units","kind":"idea","name":"Mobile diagnostic units that biopsy, scan and treat on the same visit","route":"/ideas/idea-acc-mobile-see-and-treat-units/","asOf":"2026-09-08","days":20},{"id":"idea-acc-hpv-self-sample-same-day-ablation","kind":"idea","name":"HPV self-testing with same-day treatment as the national cervical programme","route":"/ideas/idea-acc-hpv-self-sample-same-day-ablation/","asOf":"2026-09-08","days":20},{"id":"idea-acc-gbci-country-dashboards","kind":"idea","name":"Public country dashboards for the three WHO breast cancer targets","route":"/ideas/idea-acc-gbci-country-dashboards/","asOf":"2026-09-08","days":20},{"id":"idea-acc-infusion-sparing-regimens","kind":"idea","name":"Choose regimens by infusion-chair hours, not just efficacy, where chairs are the constraint","route":"/ideas/idea-acc-infusion-sparing-regimens/","asOf":"2026-09-08","days":20},{"id":"idea-acc-metronomic-lmic-platform-trial","kind":"idea","name":"A platform trial of very-low-cost metronomic chemotherapy in LMIC common cancers","route":"/ideas/idea-acc-metronomic-lmic-platform-trial/","asOf":"2026-09-08","days":20},{"id":"idea-acc-global-cancer-financing-window","kind":"idea","name":"A dedicated global financing window for cancer, modelled on the Global Fund","route":"/ideas/idea-acc-global-cancer-financing-window/","asOf":"2026-09-08","days":20},{"id":"idea-acc-frugal-hdr-brachytherapy","kind":"idea","name":"Low-cost cobalt-60 brachytherapy for cervical cancer in every regional centre","route":"/ideas/idea-acc-frugal-hdr-brachytherapy/","asOf":"2026-09-08","days":20},{"id":"idea-acc-registries-as-aid-condition","kind":"idea","name":"Make a population cancer registry a condition of every cancer aid programme","route":"/ideas/idea-acc-registries-as-aid-condition/","asOf":"2026-09-08","days":20},{"id":"idea-acc-abandonment-stipends","kind":"idea","name":"Cash for transport and food to stop families abandoning curative treatment","route":"/ideas/idea-acc-abandonment-stipends/","asOf":"2026-09-08","days":20},{"id":"idea-acc-diaspora-tele-tumour-boards","kind":"idea","name":"Credentialed diaspora oncologists staffing remote tumour boards for home-country hospitals","route":"/ideas/idea-acc-diaspora-tele-tumour-boards/","asOf":"2026-09-08","days":20},{"id":"idea-acc-solar-microgrids-for-cancer-units","kind":"idea","name":"Solar microgrids so radiotherapy, pathology and drug fridges never lose power","route":"/ideas/idea-acc-solar-microgrids-for-cancer-units/","asOf":"2026-09-08","days":20},{"id":"idea-acc-clinical-officer-oncology-track","kind":"idea","name":"An 18-month oncology track for clinical officers and physician associates","route":"/ideas/idea-acc-clinical-officer-oncology-track/","asOf":"2026-09-08","days":20},{"id":"idea-acc-oncology-pharmacist-prescribing","kind":"idea","name":"Oncology pharmacists as protocol prescribers for supportive care and dose adjustments","route":"/ideas/idea-acc-oncology-pharmacist-prescribing/","asOf":"2026-09-08","days":20},{"id":"idea-acc-remote-medical-physics-qa","kind":"idea","name":"One medical physicist covering many radiotherapy machines through remote quality assurance","route":"/ideas/idea-acc-remote-medical-physics-qa/","asOf":"2026-09-08","days":20},{"id":"idea-acc-echo-tele-mentoring-oncology","kind":"idea","name":"Project ECHO tele-mentoring for district clinicians managing cancer","route":"/ideas/idea-acc-echo-tele-mentoring-oncology/","asOf":"2026-09-08","days":20},{"id":"idea-acc-retention-packages-oncology","kind":"idea","name":"Retention packages so trained oncology staff stay: bonds, top-ups, working equipment","route":"/ideas/idea-acc-retention-packages-oncology/","asOf":"2026-09-08","days":20},{"id":"idea-acc-regional-oncology-training-hubs","kind":"idea","name":"Regional training hubs that produce oncologists, physicists and radiographers in-region","route":"/ideas/idea-acc-regional-oncology-training-hubs/","asOf":"2026-09-08","days":20},{"id":"idea-acc-ambient-ai-documentation-oncology","kind":"idea","name":"Ambient AI note-taking to give oncologists back a day a week","route":"/ideas/idea-acc-ambient-ai-documentation-oncology/","asOf":"2026-09-08","days":20},{"id":"idea-acc-advanced-practice-radiation-therapists","kind":"idea","name":"Advanced-practice radiation therapists doing contouring and on-treatment reviews","route":"/ideas/idea-acc-advanced-practice-radiation-therapists/","asOf":"2026-09-08","days":20},{"id":"idea-acc-nurse-led-follow-up-clinics","kind":"idea","name":"Nurse-led follow-up clinics for survivors, freeing oncologists for active treatment","route":"/ideas/idea-acc-nurse-led-follow-up-clinics/","asOf":"2026-09-08","days":20},{"id":"idea-acc-pathologist-assistants-and-ai-triage","kind":"idea","name":"Pathologist assistants plus AI triage to multiply pathologist capacity","route":"/ideas/idea-acc-pathologist-assistants-and-ai-triage/","asOf":"2026-09-08","days":20},{"id":"idea-acc-open-oncology-workforce-model","kind":"idea","name":"An open global model of cancer workforce supply and demand by country","route":"/ideas/idea-acc-open-oncology-workforce-model/","asOf":"2026-09-08","days":20},{"id":"idea-acc-fast-track-relicensing-oncologists","kind":"idea","name":"Fast-track relicensing for refugee, migrant and returning oncology professionals","route":"/ideas/idea-acc-fast-track-relicensing-oncologists/","asOf":"2026-09-08","days":20},{"id":"idea-acc-mainstream-tele-genetic-counselling","kind":"idea","name":"Oncology teams order germline tests; tele-genetic counsellors handle the results","route":"/ideas/idea-acc-mainstream-tele-genetic-counselling/","asOf":"2026-09-08","days":20},{"id":"idea-acc-community-health-workers-oncology","kind":"idea","name":"Community health workers trained in cancer triage, navigation and home palliative care","route":"/ideas/idea-acc-community-health-workers-oncology/","asOf":"2026-09-08","days":20},{"id":"idea-acc-district-surgeon-oncology-mentorship","kind":"idea","name":"Structured mentorship so district general surgeons perform common cancer operations safely","route":"/ideas/idea-acc-district-surgeon-oncology-mentorship/","asOf":"2026-09-08","days":20},{"id":"idea-acc-one-stop-breast-diagnostic-clinic","kind":"idea","name":"One-stop breast clinics: imaging, biopsy and a preliminary answer in a single visit","route":"/ideas/idea-acc-one-stop-breast-diagnostic-clinic/","asOf":"2026-09-08","days":20},{"id":"idea-acc-28-day-diagnosis-standard","kind":"idea","name":"A legislated, publicly reported 28-day standard from urgent referral to diagnosis","route":"/ideas/idea-acc-28-day-diagnosis-standard/","asOf":"2026-09-08","days":20},{"id":"idea-acc-funded-navigator-per-diagnosis","kind":"idea","name":"A paid patient navigator for every new cancer diagnosis, reimbursed as a service","route":"/ideas/idea-acc-funded-navigator-per-diagnosis/","asOf":"2026-09-08","days":20},{"id":"idea-acc-reflex-genomic-profiling-at-diagnosis","kind":"idea","name":"Pathologists order genomic profiling automatically at diagnosis of advanced cancer","route":"/ideas/idea-acc-reflex-genomic-profiling-at-diagnosis/","asOf":"2026-09-08","days":20},{"id":"idea-acc-guideline-concordance-dashboards","kind":"idea","name":"Live guideline-concordance dashboards for every tumour board, generated from the record","route":"/ideas/idea-acc-guideline-concordance-dashboards/","asOf":"2026-09-08","days":20},{"id":"idea-acc-national-virtual-mdt-rare-complex","kind":"idea","name":"Mandatory national virtual tumour boards for rare and complex cancers","route":"/ideas/idea-acc-national-virtual-mdt-rare-complex/","asOf":"2026-09-08","days":20},{"id":"idea-acc-portable-treatment-summary","kind":"idea","name":"A machine-readable treatment summary handed to every patient and readable by any hospital","route":"/ideas/idea-acc-portable-treatment-summary/","asOf":"2026-09-08","days":20},{"id":"idea-acc-primary-care-shared-care-agreements","kind":"idea","name":"Formal shared-care agreements between oncology and family doctors, with same-day e-consult","route":"/ideas/idea-acc-primary-care-shared-care-agreements/","asOf":"2026-09-08","days":20},{"id":"idea-acc-electronic-pro-monitoring-standard","kind":"idea","name":"Weekly electronic symptom reporting as a standard of care during systemic therapy","route":"/ideas/idea-acc-electronic-pro-monitoring-standard/","asOf":"2026-09-08","days":20},{"id":"idea-acc-tumour-board-implementation-audit","kind":"idea","name":"Audit whether tumour board recommendations were actually carried out","route":"/ideas/idea-acc-tumour-board-implementation-audit/","asOf":"2026-09-08","days":20},{"id":"idea-acc-acute-oncology-assessment-units","kind":"idea","name":"Acute oncology assessment units so sick cancer patients bypass the emergency department","route":"/ideas/idea-acc-acute-oncology-assessment-units/","asOf":"2026-09-08","days":20},{"id":"idea-acc-diagnostic-interval-public-registry","kind":"idea","name":"Record and publish the symptom-to-diagnosis interval for every cancer, by hospital","route":"/ideas/idea-acc-diagnostic-interval-public-registry/","asOf":"2026-09-08","days":20},{"id":"idea-acc-reflex-biomarker-panels-by-tumour","kind":"idea","name":"Standing reflex biomarker panels per tumour type, run without an oncologist's order","route":"/ideas/idea-acc-reflex-biomarker-panels-by-tumour/","asOf":"2026-09-08","days":20},{"id":"idea-acc-rapid-diagnostic-centres-vague-symptoms","kind":"idea","name":"Rapid diagnostic centres for people with vague but worrying symptoms","route":"/ideas/idea-acc-rapid-diagnostic-centres-vague-symptoms/","asOf":"2026-09-08","days":20},{"id":"idea-acc-embedded-decision-aids","kind":"idea","name":"Decision aids built into the record for every preference-sensitive cancer choice","route":"/ideas/idea-acc-embedded-decision-aids/","asOf":"2026-09-08","days":20},{"id":"idea-acc-financial-toxicity-screening-at-diagnosis","kind":"idea","name":"Screen every patient for financial hardship at diagnosis and connect them to help","route":"/ideas/idea-acc-financial-toxicity-screening-at-diagnosis/","asOf":"2026-09-08","days":20},{"id":"idea-acc-universal-asynchronous-second-opinion","kind":"idea","name":"An asynchronous expert second opinion for every new advanced-cancer diagnosis","route":"/ideas/idea-acc-universal-asynchronous-second-opinion/","asOf":"2026-09-08","days":20},{"id":"idea-acc-episode-payment-tied-to-concordance","kind":"idea","name":"Bundled episode payments for cancer care with bonuses for guideline concordance","route":"/ideas/idea-acc-episode-payment-tied-to-concordance/","asOf":"2026-09-08","days":20},{"id":"idea-acc-transition-handoff-medication-reconciliation","kind":"idea","name":"A standard handoff with medication reconciliation at every cancer care transition","route":"/ideas/idea-acc-transition-handoff-medication-reconciliation/","asOf":"2026-09-08","days":20},{"id":"idea-acc-pathway-capacity-simulation","kind":"idea","name":"Simulate each hospital's cancer pathway as a queue to find and remove the waits","route":"/ideas/idea-acc-pathway-capacity-simulation/","asOf":"2026-09-08","days":20},{"id":"idea-acc-auto-generated-survivorship-plans","kind":"idea","name":"Survivorship care plans generated automatically from the treatment record","route":"/ideas/idea-acc-auto-generated-survivorship-plans/","asOf":"2026-09-08","days":20},{"id":"idea-acc-risk-stratified-cardio-oncology-pathway","kind":"idea","name":"A risk-stratified cardio-oncology pathway for everyone receiving heart-toxic cancer therapy","route":"/ideas/idea-acc-risk-stratified-cardio-oncology-pathway/","asOf":"2026-09-08","days":20},{"id":"idea-acc-default-fertility-preservation-referral","kind":"idea","name":"Default fertility preservation referral for every patient under 40 before treatment","route":"/ideas/idea-acc-default-fertility-preservation-referral/","asOf":"2026-09-08","days":20},{"id":"idea-acc-national-late-effects-registry","kind":"idea","name":"A national late-effects registry linking treatment exposures to outcomes decades later","route":"/ideas/idea-acc-national-late-effects-registry/","asOf":"2026-09-08","days":20},{"id":"idea-acc-risk-stratified-follow-up","kind":"idea","name":"Risk-stratified follow-up: low-risk survivors to primary care with fast re-entry","route":"/ideas/idea-acc-risk-stratified-follow-up/","asOf":"2026-09-08","days":20},{"id":"idea-acc-tailored-second-cancer-screening","kind":"idea","name":"Tailored screening for second cancers in survivors with known high-risk exposures","route":"/ideas/idea-acc-tailored-second-cancer-screening/","asOf":"2026-09-08","days":20},{"id":"idea-acc-return-to-work-rehabilitation","kind":"idea","name":"Vocational rehabilitation integrated into cancer care so survivors can return to work","route":"/ideas/idea-acc-return-to-work-rehabilitation/","asOf":"2026-09-08","days":20},{"id":"idea-acc-cognitive-rehabilitation-after-chemotherapy","kind":"idea","name":"Trials of structured cognitive rehabilitation for cancer-related cognitive impairment","route":"/ideas/idea-acc-cognitive-rehabilitation-after-chemotherapy/","asOf":"2026-09-08","days":20},{"id":"idea-acc-cardiometabolic-clinic-hormone-therapy","kind":"idea","name":"Cardiometabolic screening and treatment for survivors on long-term hormone therapy","route":"/ideas/idea-acc-cardiometabolic-clinic-hormone-therapy/","asOf":"2026-09-08","days":20},{"id":"idea-acc-aya-survivorship-passport","kind":"idea","name":"A survivorship passport app for adolescent and young adult survivors","route":"/ideas/idea-acc-aya-survivorship-passport/","asOf":"2026-09-08","days":20},{"id":"idea-acc-survivor-biobank-late-effect-prediction","kind":"idea","name":"A survivor biobank to find who will develop late effects before they do","route":"/ideas/idea-acc-survivor-biobank-late-effect-prediction/","asOf":"2026-09-08","days":20},{"id":"idea-acc-lymphoedema-prospective-surveillance","kind":"idea","name":"Prospective arm-volume surveillance to catch and reverse lymphoedema early","route":"/ideas/idea-acc-lymphoedema-prospective-surveillance/","asOf":"2026-09-08","days":20},{"id":"idea-acc-automatic-early-palliative-triggers","kind":"idea","name":"Automatic palliative care referral triggered by diagnosis, not by decline","route":"/ideas/idea-acc-automatic-early-palliative-triggers/","asOf":"2026-09-08","days":20},{"id":"idea-acc-balanced-opioid-policy-reform","kind":"idea","name":"National opioid quota reform so morphine reaches cancer patients","route":"/ideas/idea-acc-balanced-opioid-policy-reform/","asOf":"2026-09-08","days":20},{"id":"idea-acc-local-oral-morphine-production","kind":"idea","name":"Locally prepared oral morphine solution, licensed for nurse prescribing","route":"/ideas/idea-acc-local-oral-morphine-production/","asOf":"2026-09-08","days":20},{"id":"idea-acc-neighbourhood-palliative-networks","kind":"idea","name":"Volunteer-led neighbourhood palliative networks, the Kerala model, adapted elsewhere","route":"/ideas/idea-acc-neighbourhood-palliative-networks/","asOf":"2026-09-08","days":20},{"id":"idea-acc-tele-palliative-care-default","kind":"idea","name":"Video palliative care as an equivalent default option for patients far from a team","route":"/ideas/idea-acc-tele-palliative-care-default/","asOf":"2026-09-08","days":20},{"id":"idea-acc-earmarked-palliative-budget-share","kind":"idea","name":"Earmark a fixed share of every national cancer budget for palliative care","route":"/ideas/idea-acc-earmarked-palliative-budget-share/","asOf":"2026-09-08","days":20},{"id":"idea-acc-pain-control-public-audit","kind":"idea","name":"Measure and publish pain control rates in every cancer centre","route":"/ideas/idea-acc-pain-control-public-audit/","asOf":"2026-09-08","days":20},{"id":"idea-acc-serious-illness-conversation-prompts","kind":"idea","name":"Train every oncology team in serious-illness conversations and prompt them in the record","route":"/ideas/idea-acc-serious-illness-conversation-prompts/","asOf":"2026-09-08","days":20},{"id":"idea-acc-single-fraction-palliative-radiotherapy-default","kind":"idea","name":"Single-fraction radiotherapy as the default for painful bone metastases","route":"/ideas/idea-acc-single-fraction-palliative-radiotherapy-default/","asOf":"2026-09-08","days":20},{"id":"idea-acc-essential-palliative-package-in-uhc","kind":"idea","name":"Put the essential palliative care package into every universal health coverage benefit list","route":"/ideas/idea-acc-essential-palliative-package-in-uhc/","asOf":"2026-09-08","days":20},{"id":"idea-acc-paediatric-palliative-in-every-childhood-unit","kind":"idea","name":"A paediatric palliative care team in every childhood cancer unit","route":"/ideas/idea-acc-paediatric-palliative-in-every-childhood-unit/","asOf":"2026-09-08","days":20},{"id":"idea-acc-home-based-end-of-life-kits","kind":"idea","name":"Home end-of-life care kits and trained family carers where no hospice exists","route":"/ideas/idea-acc-home-based-end-of-life-kits/","asOf":"2026-09-08","days":20},{"id":"idea-acc-methadone-and-alternatives-where-morphine-fails","kind":"idea","name":"Trials of low-cost opioid alternatives where morphine supply is unreliable","route":"/ideas/idea-acc-methadone-and-alternatives-where-morphine-fails/","asOf":"2026-09-08","days":20},{"id":"idea-acc-geriatric-assessment-by-default","kind":"idea","name":"Geriatric assessment by default for every patient over 70 starting cancer treatment","route":"/ideas/idea-acc-geriatric-assessment-by-default/","asOf":"2026-09-08","days":20},{"id":"idea-acc-broad-eligibility-as-regulatory-default","kind":"idea","name":"Make sponsors justify every trial exclusion of older and multimorbid patients","route":"/ideas/idea-acc-broad-eligibility-as-regulatory-default/","asOf":"2026-09-08","days":20},{"id":"idea-acc-pragmatic-trials-over-75-function-endpoints","kind":"idea","name":"Pragmatic trials in patients over 75 with function, not just survival, as the primary endpoint","route":"/ideas/idea-acc-pragmatic-trials-over-75-function-endpoints/","asOf":"2026-09-08","days":20},{"id":"idea-acc-structured-deprescribing-at-diagnosis","kind":"idea","name":"Structured deprescribing review at cancer diagnosis and again at transition to palliative care","route":"/ideas/idea-acc-structured-deprescribing-at-diagnosis/","asOf":"2026-09-08","days":20},{"id":"idea-acc-home-chemotherapy-older-patients","kind":"idea","name":"Home administration of selected chemotherapy and immunotherapy for older and frail patients","route":"/ideas/idea-acc-home-chemotherapy-older-patients/","asOf":"2026-09-08","days":20},{"id":"idea-acc-hospital-at-home-oncology","kind":"idea","name":"Hospital-at-home for oncology: treating low-risk febrile neutropenia and dehydration at home","route":"/ideas/idea-acc-hospital-at-home-oncology/","asOf":"2026-09-08","days":20},{"id":"idea-acc-upfront-reduced-dose-trials-frail","kind":"idea","name":"Upfront reduced-dose regimens tested head-to-head in frail older patients","route":"/ideas/idea-acc-upfront-reduced-dose-trials-frail/","asOf":"2026-09-08","days":20},{"id":"idea-acc-electronic-frailty-index-oncology","kind":"idea","name":"An automatic electronic frailty index inside the oncology record","route":"/ideas/idea-acc-electronic-frailty-index-oncology/","asOf":"2026-09-08","days":20},{"id":"idea-acc-geriatric-co-management-surgery","kind":"idea","name":"Geriatrician co-management for older patients having cancer surgery","route":"/ideas/idea-acc-geriatric-co-management-surgery/","asOf":"2026-09-08","days":20},{"id":"idea-acc-post-approval-evidence-over-75","kind":"idea","name":"Require post-approval evidence in patients over 75 and update labels accordingly","route":"/ideas/idea-acc-post-approval-evidence-over-75/","asOf":"2026-09-08","days":20},{"id":"idea-acc-caregiver-training-as-covered-service","kind":"idea","name":"Caregiver training and respite as a covered service in cancer care for older patients","route":"/ideas/idea-acc-caregiver-training-as-covered-service/","asOf":"2026-09-08","days":20},{"id":"idea-acc-pharmacist-interaction-review-oral-anticancer","kind":"idea","name":"Pharmacist interaction check before every oral cancer-drug prescription","route":"/ideas/idea-acc-pharmacist-interaction-review-oral-anticancer/","asOf":"2026-09-08","days":20},{"id":"idea-acc-time-toxicity-reporting","kind":"idea","name":"Report time toxicity, the days spent in healthcare, as a standard outcome for older patients","route":"/ideas/idea-acc-time-toxicity-reporting/","asOf":"2026-09-08","days":20},{"id":"idea-acc-prehabilitation-older-surgery","kind":"idea","name":"Multimodal prehabilitation for older patients before major cancer surgery","route":"/ideas/idea-acc-prehabilitation-older-surgery/","asOf":"2026-09-08","days":20},{"id":"idea-acc-dementia-and-cancer-pathway","kind":"idea","name":"A defined pathway for patients with both dementia and cancer","route":"/ideas/idea-acc-dementia-and-cancer-pathway/","asOf":"2026-09-08","days":20},{"id":"idea-data-mcode-payment-condition","kind":"idea","name":"No mCODE, no payment: tie oncology reimbursement to a minimal structured record","route":"/ideas/idea-data-mcode-payment-condition/","asOf":"2026-09-08","days":20},{"id":"idea-data-oncology-api-certification","kind":"idea","name":"Certify every oncology software product for a standard bulk data export","route":"/ideas/idea-data-oncology-api-certification/","asOf":"2026-09-08","days":20},{"id":"idea-data-national-cancer-data-space","kind":"idea","name":"A national cancer data space with one legal front door","route":"/ideas/idea-data-national-cancer-data-space/","asOf":"2026-09-08","days":20},{"id":"idea-data-federated-analytics-network","kind":"idea","name":"Send the code to the data: a federated analytics network of cancer centres","route":"/ideas/idea-data-federated-analytics-network/","asOf":"2026-09-08","days":20},{"id":"idea-data-federated-learning-imaging","kind":"idea","name":"Federated training of pathology and radiology models across hospitals","route":"/ideas/idea-data-federated-learning-imaging/","asOf":"2026-09-08","days":20},{"id":"idea-data-donor-card","kind":"idea","name":"A cancer data donor card: patient-controlled donation of records for research","route":"/ideas/idea-data-donor-card/","asOf":"2026-09-08","days":20},{"id":"idea-data-dynamic-consent-app","kind":"idea","name":"Dynamic consent with usage receipts","route":"/ideas/idea-data-dynamic-consent-app/","asOf":"2026-09-08","days":20},{"id":"idea-data-consent-in-the-pathway","kind":"idea","name":"Broad research consent as a routine step of the cancer pathway","route":"/ideas/idea-data-consent-in-the-pathway/","asOf":"2026-09-08","days":20},{"id":"idea-data-accredited-tre-network","kind":"idea","name":"Accredited trusted research environments with curated cancer tables","route":"/ideas/idea-data-accredited-tre-network/","asOf":"2026-09-08","days":20},{"id":"idea-data-synthetic-companion-datasets","kind":"idea","name":"A synthetic twin of every restricted cancer dataset for code development","route":"/ideas/idea-data-synthetic-companion-datasets/","asOf":"2026-09-08","days":20},{"id":"idea-data-open-deidentification-pipeline","kind":"idea","name":"One certified open-source de-identification pipeline for scans and slides","route":"/ideas/idea-data-open-deidentification-pipeline/","asOf":"2026-09-08","days":20},{"id":"idea-data-national-slide-archive","kind":"idea","name":"Digitise the nation's pathology slides and link them to outcomes","route":"/ideas/idea-data-national-slide-archive/","asOf":"2026-09-08","days":20},{"id":"idea-data-structured-genomic-reports","kind":"idea","name":"Every tumour genomic report machine-readable and deposited nationally","route":"/ideas/idea-data-structured-genomic-reports/","asOf":"2026-09-08","days":20},{"id":"idea-data-automatic-outcome-linkage","kind":"idea","name":"Automatic weekly linkage of cancer registries to deaths, prescriptions and imaging","route":"/ideas/idea-data-automatic-outcome-linkage/","asOf":"2026-09-08","days":20},{"id":"idea-data-pro-as-structured-standard","kind":"idea","name":"Patient-reported symptoms captured as standard structured data in every clinic","route":"/ideas/idea-data-pro-as-structured-standard/","asOf":"2026-09-08","days":20},{"id":"idea-data-open-line-of-therapy-algorithms","kind":"idea","name":"Open, benchmarked algorithms for lines of therapy and progression from routine data","route":"/ideas/idea-data-open-line-of-therapy-algorithms/","asOf":"2026-09-08","days":20},{"id":"idea-data-point-of-care-randomisation","kind":"idea","name":"Point-of-care randomisation built into the oncology record","route":"/ideas/idea-data-point-of-care-randomisation/","asOf":"2026-09-08","days":20},{"id":"idea-data-procurement-open-api-clauses","kind":"idea","name":"Public procurement clauses banning data export fees and lock-in","route":"/ideas/idea-data-procurement-open-api-clauses/","asOf":"2026-09-08","days":20},{"id":"idea-data-privacy-preserving-linkage-tokens","kind":"idea","name":"Privacy-preserving linkage tokens for every cancer data holder","route":"/ideas/idea-data-privacy-preserving-linkage-tokens/","asOf":"2026-09-08","days":20},{"id":"idea-data-registry-in-a-box","kind":"idea","name":"Open-source cancer registry-in-a-box for low-resource settings","route":"/ideas/idea-data-registry-in-a-box/","asOf":"2026-09-08","days":20},{"id":"idea-data-trial-to-registry-bridge","kind":"idea","name":"Map trial case report forms to the registry standard so trial and routine data join","route":"/ideas/idea-data-trial-to-registry-bridge/","asOf":"2026-09-08","days":20},{"id":"idea-data-atlas-to-outcome-linkage","kind":"idea","name":"Link single-cell and spatial tumour atlases to clinical outcomes","route":"/ideas/idea-data-atlas-to-outcome-linkage/","asOf":"2026-09-08","days":20},{"id":"idea-data-radiotherapy-dose-repository","kind":"idea","name":"A national repository of radiotherapy dose plans linked to outcomes","route":"/ideas/idea-data-radiotherapy-dose-repository/","asOf":"2026-09-08","days":20},{"id":"idea-data-surgical-video-commons","kind":"idea","name":"A consented commons of surgical video linked to pathology and outcomes","route":"/ideas/idea-data-surgical-video-commons/","asOf":"2026-09-08","days":20},{"id":"idea-data-ipd-deposit-enforcement","kind":"idea","name":"Enforce individual participant data sharing as a condition of publication and funding","route":"/ideas/idea-data-ipd-deposit-enforcement/","asOf":"2026-09-08","days":20},{"id":"idea-data-common-biobank-consent-mta","kind":"idea","name":"A common consent and material transfer template for tumour biobanks","route":"/ideas/idea-data-common-biobank-consent-mta/","asOf":"2026-09-08","days":20},{"id":"idea-data-patient-held-cancer-record","kind":"idea","name":"A patient-held cancer record that travels across providers and borders","route":"/ideas/idea-data-patient-held-cancer-record/","asOf":"2026-09-08","days":20},{"id":"idea-data-cross-border-rare-cancer-pool","kind":"idea","name":"One legal framework for pooling rare cancer data across borders","route":"/ideas/idea-data-cross-border-rare-cancer-pool/","asOf":"2026-09-08","days":20},{"id":"idea-data-quality-scorecards","kind":"idea","name":"Public data-quality scorecards for every cancer centre","route":"/ideas/idea-data-quality-scorecards/","asOf":"2026-09-08","days":20},{"id":"idea-data-structured-radiology-response","kind":"idea","name":"Structured, coded radiology reports for cancer response instead of free text","route":"/ideas/idea-data-structured-radiology-response/","asOf":"2026-09-08","days":20},{"id":"idea-data-target-trial-emulation-standard","kind":"idea","name":"A pre-registered standard for emulating trials with real-world data","route":"/ideas/idea-data-target-trial-emulation-standard/","asOf":"2026-09-08","days":20},{"id":"idea-data-rwe-rct-calibration-library","kind":"idea","name":"An open library pairing completed cancer trials with real-world emulations","route":"/ideas/idea-data-rwe-rct-calibration-library/","asOf":"2026-09-08","days":20},{"id":"idea-data-accelerated-approval-registry-condition","kind":"idea","name":"Every patient on an accelerated-approval drug enrolled in a registry until confirmation","route":"/ideas/idea-data-accelerated-approval-registry-condition/","asOf":"2026-09-08","days":20},{"id":"idea-data-rwpfs-validation-programme","kind":"idea","name":"Validate real-world progression against central imaging review","route":"/ideas/idea-data-rwpfs-validation-programme/","asOf":"2026-09-08","days":20},{"id":"idea-data-registry-based-rcts","kind":"idea","name":"Registry-based randomised trials for oncology comparative effectiveness","route":"/ideas/idea-data-registry-based-rcts/","asOf":"2026-09-08","days":20},{"id":"idea-data-coverage-with-evidence-development","kind":"idea","name":"Payers fund cancer drugs conditionally on a registry with a pre-specified analysis","route":"/ideas/idea-data-coverage-with-evidence-development/","asOf":"2026-09-08","days":20},{"id":"idea-data-off-label-outcomes-registry","kind":"idea","name":"A structured registry for every off-label cancer drug use","route":"/ideas/idea-data-off-label-outcomes-registry/","asOf":"2026-09-08","days":20},{"id":"idea-data-real-world-dose-intensity","kind":"idea","name":"Real-world dose intensity and toxicity monitoring to revise labelled doses","route":"/ideas/idea-data-real-world-dose-intensity/","asOf":"2026-09-08","days":20},{"id":"idea-data-excluded-populations-rwe-mandate","kind":"idea","name":"Mandatory real-world reporting for patients excluded from pivotal trials","route":"/ideas/idea-data-excluded-populations-rwe-mandate/","asOf":"2026-09-08","days":20},{"id":"idea-data-linked-pharmacovigilance-interactions","kind":"idea","name":"Linked prescribing and outcome data to find drug interactions with cancer therapy","route":"/ideas/idea-data-linked-pharmacovigilance-interactions/","asOf":"2026-09-08","days":20},{"id":"idea-data-access-programme-outcomes","kind":"idea","name":"One outcome record for every donated or discounted cancer drug pack","route":"/ideas/idea-data-access-programme-outcomes/","asOf":"2026-09-08","days":20},{"id":"idea-data-registry-genomics-linkage-programme","kind":"idea","name":"Link every national cancer registry to tumour genomics","route":"/ideas/idea-data-registry-genomics-linkage-programme/","asOf":"2026-09-08","days":20},{"id":"idea-data-observational-study-registration","kind":"idea","name":"Pre-registration and results reporting for real-world cancer studies","route":"/ideas/idea-data-observational-study-registration/","asOf":"2026-09-08","days":20},{"id":"idea-data-gcp-for-real-world-data","kind":"idea","name":"Good practice standards and inspection for real-world data sources","route":"/ideas/idea-data-gcp-for-real-world-data/","asOf":"2026-09-08","days":20},{"id":"idea-data-registry-follow-up-of-trial-participants","kind":"idea","name":"Follow every trial participant for 30 years through registry linkage","route":"/ideas/idea-data-registry-follow-up-of-trial-participants/","asOf":"2026-09-08","days":20},{"id":"idea-data-wearable-endpoints-validation","kind":"idea","name":"Wearable activity data as a validated real-world endpoint","route":"/ideas/idea-data-wearable-endpoints-validation/","asOf":"2026-09-08","days":20},{"id":"idea-data-external-control-arm-standard","kind":"idea","name":"Standards for external control arms built from federated real-world data","route":"/ideas/idea-data-external-control-arm-standard/","asOf":"2026-09-08","days":20},{"id":"idea-data-paediatric-rwe-consortium","kind":"idea","name":"An international consortium pooling the outcome of every treated child with cancer","route":"/ideas/idea-data-paediatric-rwe-consortium/","asOf":"2026-09-08","days":20},{"id":"idea-data-sequencing-analysis-per-approval","kind":"idea","name":"A real-world sequencing analysis within a year of every new approval","route":"/ideas/idea-data-sequencing-analysis-per-approval/","asOf":"2026-09-08","days":20},{"id":"idea-data-outcome-based-price-reassessment","kind":"idea","name":"Reassess cancer drug prices at three years using real-world outcomes","route":"/ideas/idea-data-outcome-based-price-reassessment/","asOf":"2026-09-08","days":20},{"id":"idea-data-computable-living-guidelines","kind":"idea","name":"Living guidelines published as versioned, computable rules","route":"/ideas/idea-data-computable-living-guidelines/","asOf":"2026-09-08","days":20},{"id":"idea-data-open-evidence-knowledge-graph","kind":"idea","name":"An open knowledge graph linking trials, results, biomarkers, drugs and recommendations","route":"/ideas/idea-data-open-evidence-knowledge-graph/","asOf":"2026-09-08","days":20},{"id":"idea-data-funded-living-systematic-reviews","kind":"idea","name":"Funded living systematic reviews for every major cancer indication","route":"/ideas/idea-data-funded-living-systematic-reviews/","asOf":"2026-09-08","days":20},{"id":"idea-data-plain-language-summary-mandate","kind":"idea","name":"A plain-language summary of every cancer trial result within a year","route":"/ideas/idea-data-plain-language-summary-mandate/","asOf":"2026-09-08","days":20},{"id":"idea-data-structured-trial-results-deposit","kind":"idea","name":"Deposit trial results as structured data, not just PDFs","route":"/ideas/idea-data-structured-trial-results-deposit/","asOf":"2026-09-08","days":20},{"id":"idea-data-provenance-first-decision-support","kind":"idea","name":"Decision support that cites the exact trial and guideline line it relies on","route":"/ideas/idea-data-provenance-first-decision-support/","asOf":"2026-09-08","days":20},{"id":"idea-data-tumour-board-evidence-assistant","kind":"idea","name":"A tumour board assistant that cites its evidence and tracks outcomes","route":"/ideas/idea-data-tumour-board-evidence-assistant/","asOf":"2026-09-08","days":20},{"id":"idea-data-guideline-concordance-dashboards","kind":"idea","name":"Real-time guideline-concordance feedback for every cancer centre","route":"/ideas/idea-data-guideline-concordance-dashboards/","asOf":"2026-09-08","days":20},{"id":"idea-data-thirty-day-practice-change-learning","kind":"idea","name":"Micro-learning pushed to community oncologists within 30 days of a practice change","route":"/ideas/idea-data-thirty-day-practice-change-learning/","asOf":"2026-09-08","days":20},{"id":"idea-data-patient-explainers-per-recommendation","kind":"idea","name":"A plain-language explainer for every guideline recommendation, in every major language","route":"/ideas/idea-data-patient-explainers-per-recommendation/","asOf":"2026-09-08","days":20},{"id":"idea-data-evidence-to-adoption-tracker","kind":"idea","name":"A public tracker of how long each country takes to adopt new evidence","route":"/ideas/idea-data-evidence-to-adoption-tracker/","asOf":"2026-09-08","days":20},{"id":"idea-data-retraction-propagation","kind":"idea","name":"Automatic flagging of retracted or corrected evidence in guidelines and decision support","route":"/ideas/idea-data-retraction-propagation/","asOf":"2026-09-08","days":20},{"id":"idea-data-open-licensed-guidelines","kind":"idea","name":"Open licences for publicly funded cancer guidelines","route":"/ideas/idea-data-open-licensed-guidelines/","asOf":"2026-09-08","days":20},{"id":"idea-data-unanswered-questions-registry","kind":"idea","name":"A public registry of unanswered clinical questions linked to funding calls","route":"/ideas/idea-data-unanswered-questions-registry/","asOf":"2026-09-08","days":20},{"id":"idea-data-living-llm-oncology-benchmark","kind":"idea","name":"A monthly-updated benchmark for AI answers to oncology questions with citation accuracy","route":"/ideas/idea-data-living-llm-oncology-benchmark/","asOf":"2026-09-08","days":20},{"id":"idea-data-rapid-guideline-translation","kind":"idea","name":"Expert-verified translation of guideline updates into 20 languages within 30 days","route":"/ideas/idea-data-rapid-guideline-translation/","asOf":"2026-09-08","days":20},{"id":"idea-data-offline-cds-lmic-generalists","kind":"idea","name":"Offline decision support for generalists treating common cancers in low-resource settings","route":"/ideas/idea-data-offline-cds-lmic-generalists/","asOf":"2026-09-08","days":20},{"id":"idea-data-toxicity-cds-for-nurses","kind":"idea","name":"Toxicity-management decision support for nurses and pharmacists","route":"/ideas/idea-data-toxicity-cds-for-nurses/","asOf":"2026-09-08","days":20},{"id":"idea-data-72-hour-second-opinion-network","kind":"idea","name":"A digital second-opinion network answering community oncologists within 72 hours","route":"/ideas/idea-data-72-hour-second-opinion-network/","asOf":"2026-09-08","days":20},{"id":"idea-data-standard-of-care-change-alerts","kind":"idea","name":"Subscribable alerts when the standard of care changes for a patient's situation","route":"/ideas/idea-data-standard-of-care-change-alerts/","asOf":"2026-09-08","days":20},{"id":"idea-data-full-data-with-abstract","kind":"idea","name":"End the abstract-to-paper gap: require full results with any conference presentation","route":"/ideas/idea-data-full-data-with-abstract/","asOf":"2026-09-08","days":20},{"id":"idea-data-implementation-trials-programme","kind":"idea","name":"Randomised trials of how to spread proven cancer treatments, not just what works","route":"/ideas/idea-data-implementation-trials-programme/","asOf":"2026-09-08","days":20},{"id":"idea-data-wikipedia-oncology-editors","kind":"idea","name":"Fund expert editors for the cancer pages of Wikipedia and Wikidata","route":"/ideas/idea-data-wikipedia-oncology-editors/","asOf":"2026-09-08","days":20},{"id":"idea-data-order-set-defaults-30-days","kind":"idea","name":"Update hospital order sets within 30 days of a guideline change","route":"/ideas/idea-data-order-set-defaults-30-days/","asOf":"2026-09-08","days":20},{"id":"idea-data-standard-of-care-api","kind":"idea","name":"A public API serving the current standard of care for any cancer, stage and biomarker","route":"/ideas/idea-data-standard-of-care-api/","asOf":"2026-09-08","days":20},{"id":"idea-data-prospective-ai-trials-fund","kind":"idea","name":"A dedicated fund for randomised trials of cancer AI with patient outcomes","route":"/ideas/idea-data-prospective-ai-trials-fund/","asOf":"2026-09-08","days":20},{"id":"idea-data-clinical-ai-model-registry","kind":"idea","name":"A public registry of every AI model used in cancer care","route":"/ideas/idea-data-clinical-ai-model-registry/","asOf":"2026-09-08","days":20},{"id":"idea-data-ai-post-market-performance-reporting","kind":"idea","name":"Mandatory post-market performance reporting for cancer AI","route":"/ideas/idea-data-ai-post-market-performance-reporting/","asOf":"2026-09-08","days":20},{"id":"idea-data-drift-monitoring-standard","kind":"idea","name":"A standard for monitoring AI performance drift with pause thresholds","route":"/ideas/idea-data-drift-monitoring-standard/","asOf":"2026-09-08","days":20},{"id":"idea-data-sequestered-prospective-benchmarks","kind":"idea","name":"Sequestered, prospectively collected benchmark datasets that no one can train on","route":"/ideas/idea-data-sequestered-prospective-benchmarks/","asOf":"2026-09-08","days":20},{"id":"idea-data-neutral-ai-evaluator","kind":"idea","name":"A neutral public evaluator for cancer AI, on the model of NIST","route":"/ideas/idea-data-neutral-ai-evaluator/","asOf":"2026-09-08","days":20},{"id":"idea-data-regulatory-sandbox-adaptive-ai","kind":"idea","name":"A regulatory sandbox for continuously learning cancer AI","route":"/ideas/idea-data-regulatory-sandbox-adaptive-ai/","asOf":"2026-09-08","days":20},{"id":"idea-data-ai-liability-safe-harbour","kind":"idea","name":"A liability framework for clinical AI: safe harbour for clinicians, liability for makers","route":"/ideas/idea-data-ai-liability-safe-harbour/","asOf":"2026-09-08","days":20},{"id":"idea-data-ai-reimbursement-tied-to-outcomes","kind":"idea","name":"Pay for cancer AI only when it has outcome evidence, then pay properly","route":"/ideas/idea-data-ai-reimbursement-tied-to-outcomes/","asOf":"2026-09-08","days":20},{"id":"idea-data-silent-trial-before-deployment","kind":"idea","name":"A mandatory silent (shadow) trial before any cancer AI goes live","route":"/ideas/idea-data-silent-trial-before-deployment/","asOf":"2026-09-08","days":20},{"id":"idea-data-subgroup-performance-reporting-mandate","kind":"idea","name":"Mandatory subgroup performance reporting for cancer AI","route":"/ideas/idea-data-subgroup-performance-reporting-mandate/","asOf":"2026-09-08","days":20},{"id":"idea-data-open-cell-foundation-model","kind":"idea","name":"An open foundation model of the cancer cell trained on perturbation data","route":"/ideas/idea-data-open-cell-foundation-model/","asOf":"2026-09-08","days":20},{"id":"idea-data-precompetitive-cancer-foundation-model","kind":"idea","name":"A pre-competitive consortium to train a shared multimodal cancer foundation model","route":"/ideas/idea-data-precompetitive-cancer-foundation-model/","asOf":"2026-09-08","days":20},{"id":"idea-data-open-weights-for-public-funded-ai","kind":"idea","name":"Publicly funded cancer AI must release open weights and model cards","route":"/ideas/idea-data-open-weights-for-public-funded-ai/","asOf":"2026-09-08","days":20},{"id":"idea-data-digital-twin-predict-then-observe","kind":"idea","name":"Digital twins for treatment selection, validated by predicting before observing","route":"/ideas/idea-data-digital-twin-predict-then-observe/","asOf":"2026-09-08","days":20},{"id":"idea-data-in-silico-trials-calibrated","kind":"idea","name":"In silico trials to prioritise combinations, scored against later real trials","route":"/ideas/idea-data-in-silico-trials-calibrated/","asOf":"2026-09-08","days":20},{"id":"idea-data-ai-pathology-evaluation-standard","kind":"idea","name":"A standard evaluation pathway for AI-assisted pathology, from reader study to deployment","route":"/ideas/idea-data-ai-pathology-evaluation-standard/","asOf":"2026-09-08","days":20},{"id":"idea-data-ai-screening-endpoints","kind":"idea","name":"Require stage-shift or interval-cancer endpoints for AI in cancer screening","route":"/ideas/idea-data-ai-screening-endpoints/","asOf":"2026-09-08","days":20},{"id":"idea-data-multisite-validation-precondition","kind":"idea","name":"External validation at five or more sites in two countries before clearance","route":"/ideas/idea-data-multisite-validation-precondition/","asOf":"2026-09-08","days":20},{"id":"idea-data-patient-facing-model-cards","kind":"idea","name":"Patients told which AI is used in their care, in plain language","route":"/ideas/idea-data-patient-facing-model-cards/","asOf":"2026-09-08","days":20},{"id":"idea-data-ai-red-team-programme","kind":"idea","name":"Red-team programmes that attack cancer AI before patients do","route":"/ideas/idea-data-ai-red-team-programme/","asOf":"2026-09-08","days":20},{"id":"idea-data-ai-audit-trail-in-ehr","kind":"idea","name":"Every AI output logged in the record with input hash, version and clinician response","route":"/ideas/idea-data-ai-audit-trail-in-ehr/","asOf":"2026-09-08","days":20},{"id":"idea-data-ai-decommissioning-rules","kind":"idea","name":"Rules for retiring cancer AI when performance drops or the standard of care moves","route":"/ideas/idea-data-ai-decommissioning-rules/","asOf":"2026-09-08","days":20},{"id":"idea-data-llm-documentation-rct-oncology","kind":"idea","name":"A randomised trial of AI scribes in oncology clinics measuring errors and time","route":"/ideas/idea-data-llm-documentation-rct-oncology/","asOf":"2026-09-08","days":20},{"id":"idea-data-ai-vs-tumour-board-rct","kind":"idea","name":"A randomised trial of AI-generated treatment recommendations versus tumour boards","route":"/ideas/idea-data-ai-vs-tumour-board-rct/","asOf":"2026-09-08","days":20},{"id":"idea-fund-burden-weighted-portfolio","kind":"idea","name":"Burden-weighted portfolio targets for every major cancer funder","route":"/ideas/idea-fund-burden-weighted-portfolio/","asOf":"2026-09-08","days":20},{"id":"idea-fund-metastasis-moonshot","kind":"idea","name":"A ring-fenced metastasis programme with metastasis-specific endpoints","route":"/ideas/idea-fund-metastasis-moonshot/","asOf":"2026-09-08","days":20},{"id":"idea-fund-prevention-moonshot","kind":"idea","name":"A delivery-science moonshot for prevention we already own","route":"/ideas/idea-fund-prevention-moonshot/","asOf":"2026-09-08","days":20},{"id":"idea-fund-dollars-per-death-dashboard","kind":"idea","name":"A public dashboard of research money per death for every cancer","route":"/ideas/idea-fund-dollars-per-death-dashboard/","asOf":"2026-09-08","days":20},{"id":"idea-fund-implementation-quota","kind":"idea","name":"A fixed share of trial-group funding for getting proven care to patients","route":"/ideas/idea-fund-implementation-quota/","asOf":"2026-09-08","days":20},{"id":"idea-fund-lmic-burden-match","kind":"idea","name":"Burden-matched funding for trials led in low- and middle-income countries","route":"/ideas/idea-fund-lmic-burden-match/","asOf":"2026-09-08","days":20},{"id":"idea-fund-neglected-cancer-lottery","kind":"idea","name":"Partial lottery funding for good proposals in under-funded cancers","route":"/ideas/idea-fund-neglected-cancer-lottery/","asOf":"2026-09-08","days":20},{"id":"idea-fund-ten-year-hard-problem-awards","kind":"idea","name":"Ten-year awards for scientists who commit to one hard problem","route":"/ideas/idea-fund-ten-year-hard-problem-awards/","asOf":"2026-09-08","days":20},{"id":"idea-fund-survivorship-endowment-levy","kind":"idea","name":"A survivorship research endowment funded by a levy on curative therapy prices","route":"/ideas/idea-fund-survivorship-endowment-levy/","asOf":"2026-09-08","days":20},{"id":"idea-fund-non-drug-trial-quota","kind":"idea","name":"A statutory minimum share of public trial money for surgery and radiotherapy","route":"/ideas/idea-fund-non-drug-trial-quota/","asOf":"2026-09-08","days":20},{"id":"idea-fund-replication-set-aside","kind":"idea","name":"Set aside 3% of grant budgets to replicate findings before translation","route":"/ideas/idea-fund-replication-set-aside/","asOf":"2026-09-08","days":20},{"id":"idea-fund-white-space-map","kind":"idea","name":"An annual map of high-burden questions that nobody is funding","route":"/ideas/idea-fund-white-space-map/","asOf":"2026-09-08","days":20},{"id":"idea-fund-programme-officer-incentives","kind":"idea","name":"Judge funding programme officers on burden alignment and trials completed","route":"/ideas/idea-fund-programme-officer-incentives/","asOf":"2026-09-08","days":20},{"id":"idea-fund-patient-burden-review-criterion","kind":"idea","name":"A formal patient-burden score in grant peer review","route":"/ideas/idea-fund-patient-burden-review-criterion/","asOf":"2026-09-08","days":20},{"id":"idea-fund-global-cancer-fund","kind":"idea","name":"A Global Fund for cancer care in low- and middle-income countries","route":"/ideas/idea-fund-global-cancer-fund/","asOf":"2026-09-08","days":20},{"id":"idea-fund-cachexia-programme","kind":"idea","name":"A dedicated programme for cachexia and treatment toxicity research","route":"/ideas/idea-fund-cachexia-programme/","asOf":"2026-09-08","days":20},{"id":"idea-fund-cross-funder-portfolio-registry","kind":"idea","name":"Mandatory machine-readable portfolio reporting for all large cancer funders","route":"/ideas/idea-fund-cross-funder-portfolio-registry/","asOf":"2026-09-08","days":20},{"id":"idea-fund-older-patients-trial-fund","kind":"idea","name":"A trials fund reserved for older and multimorbid patients","route":"/ideas/idea-fund-older-patients-trial-fund/","asOf":"2026-09-08","days":20},{"id":"idea-fund-fast-grants-oncology","kind":"idea","name":"Forty-eight-hour small grants for bold experiments in neglected cancers","route":"/ideas/idea-fund-fast-grants-oncology/","asOf":"2026-09-08","days":20},{"id":"idea-fund-brain-metastases-programme","kind":"idea","name":"Treat brain metastases as a disease with its own trials programme","route":"/ideas/idea-fund-brain-metastases-programme/","asOf":"2026-09-08","days":20},{"id":"idea-fund-cure-prize","kind":"idea","name":"A billion-dollar prize for the first durable cure of a lethal metastatic cancer","route":"/ideas/idea-fund-cure-prize/","asOf":"2026-09-08","days":20},{"id":"idea-fund-first-in-class-prize","kind":"idea","name":"Milestone prizes for first-in-class mechanisms reaching human proof of concept","route":"/ideas/idea-fund-first-in-class-prize/","asOf":"2026-09-08","days":20},{"id":"idea-fund-amc-paediatric-rare","kind":"idea","name":"Advance market commitments for paediatric and rare cancer drugs","route":"/ideas/idea-fund-amc-paediatric-rare/","asOf":"2026-09-08","days":20},{"id":"idea-fund-conditional-transferable-voucher","kind":"idea","name":"Transferable priority vouchers for first-in-class drugs, with price conditions","route":"/ideas/idea-fund-conditional-transferable-voucher/","asOf":"2026-09-08","days":20},{"id":"idea-fund-value-based-patent-extension","kind":"idea","name":"Patent term extension scaled to proven survival gain","route":"/ideas/idea-fund-value-based-patent-extension/","asOf":"2026-09-08","days":20},{"id":"idea-fund-benefit-indexed-exclusivity","kind":"idea","name":"Shorter exclusivity for later-in-class drugs without added benefit","route":"/ideas/idea-fund-benefit-indexed-exclusivity/","asOf":"2026-09-08","days":20},{"id":"idea-fund-pay-for-cure-annuities","kind":"idea","name":"Outcome-based annuity payments for potentially curative one-time therapies","route":"/ideas/idea-fund-pay-for-cure-annuities/","asOf":"2026-09-08","days":20},{"id":"idea-fund-nonprofit-pharma","kind":"idea","name":"A non-profit pharmaceutical company for the cancers markets ignore","route":"/ideas/idea-fund-nonprofit-pharma/","asOf":"2026-09-08","days":20},{"id":"idea-fund-public-option-generic-oncology","kind":"idea","name":"Public-option manufacturing for essential generic cancer drugs in shortage","route":"/ideas/idea-fund-public-option-generic-oncology/","asOf":"2026-09-08","days":20},{"id":"idea-fund-public-car-t-manufacturing","kind":"idea","name":"Hospital-based CAR-T manufacturing at cost through a public network","route":"/ideas/idea-fund-public-car-t-manufacturing/","asOf":"2026-09-08","days":20},{"id":"idea-fund-mcbs-linked-pricing","kind":"idea","name":"Launch prices indexed to the ESMO benefit scale, revisited when survival matures","route":"/ideas/idea-fund-mcbs-linked-pricing/","asOf":"2026-09-08","days":20},{"id":"idea-fund-head-to-head-mandate","kind":"idea","name":"Require head-to-head trials against the best in class for later entrants","route":"/ideas/idea-fund-head-to-head-mandate/","asOf":"2026-09-08","days":20},{"id":"idea-fund-health-impact-fund-oncology","kind":"idea","name":"A Health Impact Fund pilot that pays for measured health gain instead of price","route":"/ideas/idea-fund-health-impact-fund-oncology/","asOf":"2026-09-08","days":20},{"id":"idea-fund-sovereign-first-in-class-coinvestment","kind":"idea","name":"Public co-investment in first-in-class phase 1 with a royalty return","route":"/ideas/idea-fund-sovereign-first-in-class-coinvestment/","asOf":"2026-09-08","days":20},{"id":"idea-fund-academic-promotion-reform","kind":"idea","name":"Promote academics for trials completed, data shared and findings replicated","route":"/ideas/idea-fund-academic-promotion-reform/","asOf":"2026-09-08","days":20},{"id":"idea-fund-trial-completion-bonus","kind":"idea","name":"Pay investigators for finishing and publishing trials, not for enrolling patients","route":"/ideas/idea-fund-trial-completion-bonus/","asOf":"2026-09-08","days":20},{"id":"idea-fund-payer-funded-pragmatic-trials","kind":"idea","name":"Payers fund trials of cheaper, shorter or lower-dose versions of expensive treatments","route":"/ideas/idea-fund-payer-funded-pragmatic-trials/","asOf":"2026-09-08","days":20},{"id":"idea-fund-duration-trial-exclusivity","kind":"idea","name":"Extra exclusivity for sponsors who run treatment-duration and de-escalation trials","route":"/ideas/idea-fund-duration-trial-exclusivity/","asOf":"2026-09-08","days":20},{"id":"idea-fund-paediatric-deferral-escrow","kind":"idea","name":"Escrow a share of adult revenue until the paediatric study is done","route":"/ideas/idea-fund-paediatric-deferral-escrow/","asOf":"2026-09-08","days":20},{"id":"idea-fund-abbreviated-pathway-me-too-biologics","kind":"idea","name":"An abbreviated approval path for follow-on antibodies within a validated class","route":"/ideas/idea-fund-abbreviated-pathway-me-too-biologics/","asOf":"2026-09-08","days":20},{"id":"idea-fund-open-source-repurposing-leads","kind":"idea","name":"Patent-free open-source development of repurposed and off-patent cancer drugs","route":"/ideas/idea-fund-open-source-repurposing-leads/","asOf":"2026-09-08","days":20},{"id":"idea-fund-repurposing-indication-exclusivity","kind":"idea","name":"A repurposing label pathway with short exclusivity that non-profits can hold","route":"/ideas/idea-fund-repurposing-indication-exclusivity/","asOf":"2026-09-08","days":20},{"id":"idea-fund-social-impact-bonds-prevention","kind":"idea","name":"Social impact bonds for cancer prevention, repaid from avoided treatment costs","route":"/ideas/idea-fund-social-impact-bonds-prevention/","asOf":"2026-09-08","days":20},{"id":"idea-fund-global-access-licensing-royalties","kind":"idea","name":"University licences with royalties indexed to benefit and global access","route":"/ideas/idea-fund-global-access-licensing-royalties/","asOf":"2026-09-08","days":20},{"id":"idea-fund-phase-two-failure-reinsurance","kind":"idea","name":"Government reinsurance for phase 2 failures of first-in-class cancer drugs","route":"/ideas/idea-fund-phase-two-failure-reinsurance/","asOf":"2026-09-08","days":20},{"id":"idea-fund-translational-institutes-gmp","kind":"idea","name":"Regional translational institutes with academic GMP suites and IND teams","route":"/ideas/idea-fund-translational-institutes-gmp/","asOf":"2026-09-08","days":20},{"id":"idea-fund-ind-enabling-fund","kind":"idea","name":"A fast IND-enabling fund that pays for toxicology and manufacturing in eight weeks","route":"/ideas/idea-fund-ind-enabling-fund/","asOf":"2026-09-08","days":20},{"id":"idea-fund-milestone-venture-philanthropy","kind":"idea","name":"Milestone-based venture philanthropy with royalties recycled into the pipeline","route":"/ideas/idea-fund-milestone-venture-philanthropy/","asOf":"2026-09-08","days":20},{"id":"idea-fund-phase-zero-fund","kind":"idea","name":"A phase 0 fund to test academic compounds in humans with microdoses and imaging","route":"/ideas/idea-fund-phase-zero-fund/","asOf":"2026-09-08","days":20},{"id":"idea-fund-public-nonprofit-cro","kind":"idea","name":"A national non-profit contract research organisation for academic oncology trials","route":"/ideas/idea-fund-public-nonprofit-cro/","asOf":"2026-09-08","days":20},{"id":"idea-fund-translational-fellowships","kind":"idea","name":"Two-year translational fellowships that pay scientists to develop their own discovery","route":"/ideas/idea-fund-translational-fellowships/","asOf":"2026-09-08","days":20},{"id":"idea-fund-target-validation-consortium","kind":"idea","name":"A pre-competitive consortium to validate or kill academic targets before licensing","route":"/ideas/idea-fund-target-validation-consortium/","asOf":"2026-09-08","days":20},{"id":"idea-fund-academic-adc-bispecific-platform","kind":"idea","name":"An open engineering platform for academic ADCs and bispecifics","route":"/ideas/idea-fund-academic-adc-bispecific-platform/","asOf":"2026-09-08","days":20},{"id":"idea-fund-hospital-exemption-registry","kind":"idea","name":"Hospital-exemption cell therapies at scale, backed by a shared registry","route":"/ideas/idea-fund-hospital-exemption-registry/","asOf":"2026-09-08","days":20},{"id":"idea-fund-academic-radiopharma-pipeline","kind":"idea","name":"A university cyclotron network with shared regulatory files for new tracers","route":"/ideas/idea-fund-academic-radiopharma-pipeline/","asOf":"2026-09-08","days":20},{"id":"idea-fund-stalled-asset-registry","kind":"idea","name":"A public registry of stalled academic assets and shelved company compounds","route":"/ideas/idea-fund-stalled-asset-registry/","asOf":"2026-09-08","days":20},{"id":"idea-fund-national-drug-development-office","kind":"idea","name":"Scale up public drug development that takes academic assets to phase 1","route":"/ideas/idea-fund-national-drug-development-office/","asOf":"2026-09-08","days":20},{"id":"idea-fund-device-and-technique-translation-fund","kind":"idea","name":"A translation fund for academic surgical devices and radiotherapy technology","route":"/ideas/idea-fund-device-and-technique-translation-fund/","asOf":"2026-09-08","days":20},{"id":"idea-fund-biomarker-validation-fund","kind":"idea","name":"A fund for prospective validation of academic biomarkers and companion diagnostics","route":"/ideas/idea-fund-biomarker-validation-fund/","asOf":"2026-09-08","days":20},{"id":"idea-fund-organoid-translation-gate","kind":"idea","name":"A funded organoid and PDX panel as the go/no-go gate before IND-enabling money","route":"/ideas/idea-fund-organoid-translation-gate/","asOf":"2026-09-08","days":20},{"id":"idea-fund-shared-personalised-therapy-gmp","kind":"idea","name":"Shared modular GMP facilities for academic personalised vaccines and cell products","route":"/ideas/idea-fund-shared-personalised-therapy-gmp/","asOf":"2026-09-08","days":20},{"id":"idea-fund-protected-time-physician-scientists","kind":"idea","name":"Hospital-funded protected time for clinician-scientists, repaid by trial revenue","route":"/ideas/idea-fund-protected-time-physician-scientists/","asOf":"2026-09-08","days":20},{"id":"idea-fund-royalty-pool-academic-assets","kind":"idea","name":"A diversified royalty pool that finances academic phase 1 trials across fifty assets","route":"/ideas/idea-fund-royalty-pool-academic-assets/","asOf":"2026-09-08","days":20},{"id":"idea-fund-global-academic-phase-one-network","kind":"idea","name":"A global first-in-human network for academic cancer trials with single ethics review","route":"/ideas/idea-fund-global-academic-phase-one-network/","asOf":"2026-09-08","days":20},{"id":"idea-fund-academic-sponsor-indemnity-pool","kind":"idea","name":"A public indemnity pool so universities can sponsor first-in-human cancer trials","route":"/ideas/idea-fund-academic-sponsor-indemnity-pool/","asOf":"2026-09-08","days":20},{"id":"idea-fund-combination-patent-pool","kind":"idea","name":"An oncology patent pool for combination trials across companies","route":"/ideas/idea-fund-combination-patent-pool/","asOf":"2026-09-08","days":20},{"id":"idea-fund-compulsory-combination-access","kind":"idea","name":"A legal right to obtain marketed cancer drugs at cost for combination trials","route":"/ideas/idea-fund-compulsory-combination-access/","asOf":"2026-09-08","days":20},{"id":"idea-fund-standard-combination-agreement","kind":"idea","name":"A regulator-endorsed standard contract for inter-company combination trials","route":"/ideas/idea-fund-standard-combination-agreement/","asOf":"2026-09-08","days":20},{"id":"idea-fund-precompetitive-undruggable-consortium","kind":"idea","name":"An open-science consortium on the undruggable drivers, open until a candidate","route":"/ideas/idea-fund-precompetitive-undruggable-consortium/","asOf":"2026-09-08","days":20},{"id":"idea-fund-trial-data-trust","kind":"idea","name":"A single oncology trial data trust with mandatory deposit within eighteen months","route":"/ideas/idea-fund-trial-data-trust/","asOf":"2026-09-08","days":20},{"id":"idea-fund-control-arm-commons","kind":"idea","name":"A shared library of pooled control arms to shrink and speed future trials","route":"/ideas/idea-fund-control-arm-commons/","asOf":"2026-09-08","days":20},{"id":"idea-fund-universal-mta-fast-lane","kind":"idea","name":"A universal material transfer agreement with a thirty-day default","route":"/ideas/idea-fund-universal-mta-fast-lane/","asOf":"2026-09-08","days":20},{"id":"idea-fund-antitrust-safe-harbour","kind":"idea","name":"An antitrust safe harbour for cross-company combination trials and data pooling","route":"/ideas/idea-fund-antitrust-safe-harbour/","asOf":"2026-09-08","days":20},{"id":"idea-fund-open-results-bonus","kind":"idea","name":"Funder bonuses for releasing results and data within six months, negatives included","route":"/ideas/idea-fund-open-results-bonus/","asOf":"2026-09-08","days":20},{"id":"idea-fund-shelved-asset-escrow","kind":"idea","name":"Automatic offer of shelved cancer assets to non-profits after two years","route":"/ideas/idea-fund-shelved-asset-escrow/","asOf":"2026-09-08","days":20},{"id":"idea-fund-federated-learning-consortium","kind":"idea","name":"A federated learning consortium of cancer centres that jointly own the models","route":"/ideas/idea-fund-federated-learning-consortium/","asOf":"2026-09-08","days":20},{"id":"idea-fund-trial-biospecimen-commons","kind":"idea","name":"A commons for leftover trial biospecimens with standard access for approved research","route":"/ideas/idea-fund-trial-biospecimen-commons/","asOf":"2026-09-08","days":20},{"id":"idea-fund-neutral-platform-sponsor","kind":"idea","name":"A permanent neutral non-profit sponsor for multi-company platform trials","route":"/ideas/idea-fund-neutral-platform-sponsor/","asOf":"2026-09-08","days":20},{"id":"idea-fund-portable-patient-consent","kind":"idea","name":"Patient-held portable consent for reusing samples and data across studies","route":"/ideas/idea-fund-portable-patient-consent/","asOf":"2026-09-08","days":20},{"id":"idea-fund-scoop-protection-policy","kind":"idea","name":"Scoop protection and co-publication norms to reduce academic secrecy","route":"/ideas/idea-fund-scoop-protection-policy/","asOf":"2026-09-08","days":20},{"id":"idea-fund-surgical-trials-network","kind":"idea","name":"A permanently funded international network for randomised cancer surgery trials","route":"/ideas/idea-fund-surgical-trials-network/","asOf":"2026-09-08","days":20},{"id":"idea-fund-radiotherapy-trials-infrastructure","kind":"idea","name":"Core-funded radiotherapy trials infrastructure with central quality assurance","route":"/ideas/idea-fund-radiotherapy-trials-infrastructure/","asOf":"2026-09-08","days":20},{"id":"idea-fund-device-technique-registry","kind":"idea","name":"Mandatory staged registries for new surgical techniques before wide adoption","route":"/ideas/idea-fund-device-technique-registry/","asOf":"2026-09-08","days":20},{"id":"idea-fund-surgical-ai-robotics-evaluation","kind":"idea","name":"An independent evaluation unit for surgical robots and AI, paid on evidence","route":"/ideas/idea-fund-surgical-ai-robotics-evaluation/","asOf":"2026-09-08","days":20},{"id":"idea-fund-flash-evidence-programme","kind":"idea","name":"A coordinated FLASH radiotherapy evidence programme with shared dose-rate standards","route":"/ideas/idea-fund-flash-evidence-programme/","asOf":"2026-09-08","days":20},{"id":"idea-fund-proton-coverage-with-evidence","kind":"idea","name":"Pooled coverage-with-evidence for proton therapy across all centres","route":"/ideas/idea-fund-proton-coverage-with-evidence/","asOf":"2026-09-08","days":20},{"id":"idea-fund-surgeon-scientist-pathway","kind":"idea","name":"Funded research pathways for surgeon-scientists and radiation oncologist-scientists","route":"/ideas/idea-fund-surgeon-scientist-pathway/","asOf":"2026-09-08","days":20},{"id":"idea-fund-course-based-radiotherapy-payment","kind":"idea","name":"Pay per course of radiotherapy, not per session, so short courses are not penalised","route":"/ideas/idea-fund-course-based-radiotherapy-payment/","asOf":"2026-09-08","days":20},{"id":"idea-fund-surgical-video-registry","kind":"idea","name":"A video-based surgical quality registry linking assessed skill to cancer outcomes","route":"/ideas/idea-fund-surgical-video-registry/","asOf":"2026-09-08","days":20},{"id":"idea-fund-organ-preservation-programme","kind":"idea","name":"A funded programme of organ-preservation trials to avoid radical surgery","route":"/ideas/idea-fund-organ-preservation-programme/","asOf":"2026-09-08","days":20},{"id":"idea-fund-omission-deescalation-trials","kind":"idea","name":"Payer-funded trials that omit surgery or radiotherapy in low-risk patients","route":"/ideas/idea-fund-omission-deescalation-trials/","asOf":"2026-09-08","days":20},{"id":"idea-fund-lmic-radiotherapy-finance","kind":"idea","name":"Blended finance and a low-cost linac to close the global radiotherapy gap","route":"/ideas/idea-fund-lmic-radiotherapy-finance/","asOf":"2026-09-08","days":20},{"id":"idea-fund-intraoperative-imaging-trials","kind":"idea","name":"A pragmatic trial network for intraoperative margin tools, paid on margin reduction","route":"/ideas/idea-fund-intraoperative-imaging-trials/","asOf":"2026-09-08","days":20},{"id":"idea-fund-rt-io-platform","kind":"idea","name":"A neutral platform trial for radiotherapy plus immunotherapy combinations","route":"/ideas/idea-fund-rt-io-platform/","asOf":"2026-09-08","days":20},{"id":"idea-fund-adaptive-radiotherapy-evidence","kind":"idea","name":"Coverage-with-evidence registries for MR-guided and adaptive radiotherapy","route":"/ideas/idea-fund-adaptive-radiotherapy-evidence/","asOf":"2026-09-08","days":20},{"id":"idea-fund-surgical-outcomes-public-reporting","kind":"idea","name":"Public risk-adjusted outcome reporting for cancer surgery to drive centralisation","route":"/ideas/idea-fund-surgical-outcomes-public-reporting/","asOf":"2026-09-08","days":20},{"id":"idea-fund-rt-planning-ai-capacity","kind":"idea","name":"Validate and reimburse AI contouring and planning to expand radiotherapy capacity","route":"/ideas/idea-fund-rt-planning-ai-capacity/","asOf":"2026-09-08","days":20},{"id":"idea-fund-ablation-versus-surgery-trials","kind":"idea","name":"Device-agnostic public trials of ablation technologies against surgery","route":"/ideas/idea-fund-ablation-versus-surgery-trials/","asOf":"2026-09-08","days":20},{"id":"idea-fund-radiotherapy-innovation-pathway","kind":"idea","name":"A regulatory pathway for new radiotherapy techniques modelled on drug development","route":"/ideas/idea-fund-radiotherapy-innovation-pathway/","asOf":"2026-09-08","days":20},{"id":"idea-fund-technique-innovation-prize","kind":"idea","name":"Prizes for unpatentable surgical and radiotherapy techniques proven in trials","route":"/ideas/idea-fund-technique-innovation-prize/","asOf":"2026-09-08","days":20},{"id":"idea-moon-navigation-as-a-right","kind":"idea","name":"Patient navigation as a legal entitlement from the day of diagnosis","route":"/ideas/idea-moon-navigation-as-a-right/","asOf":"2026-09-08","days":20},{"id":"idea-moon-plain-language-consent","kind":"idea","name":"Two-page plain-language consent with teach-back for every cancer trial and treatment","route":"/ideas/idea-moon-plain-language-consent/","asOf":"2026-09-08","days":20},{"id":"idea-moon-results-in-plain-words","kind":"idea","name":"Every pathology and genomic report ships with a signed plain-language version","route":"/ideas/idea-moon-results-in-plain-words/","asOf":"2026-09-08","days":20},{"id":"idea-moon-pro-monitoring-standard","kind":"idea","name":"Weekly symptom check-ins with automatic alerts as standard of care on treatment","route":"/ideas/idea-moon-pro-monitoring-standard/","asOf":"2026-09-08","days":20},{"id":"idea-moon-certified-decision-aids","kind":"idea","name":"Certified decision aids required for every preference-sensitive cancer decision","route":"/ideas/idea-moon-certified-decision-aids/","asOf":"2026-09-08","days":20},{"id":"idea-moon-patient-designed-trials","kind":"idea","name":"Patient panels approve trial burden and endpoints as a condition of funding","route":"/ideas/idea-moon-patient-designed-trials/","asOf":"2026-09-08","days":20},{"id":"idea-moon-financial-toxicity-screening","kind":"idea","name":"Screen every patient for financial toxicity at diagnosis and refer like any other symptom","route":"/ideas/idea-moon-financial-toxicity-screening/","asOf":"2026-09-08","days":20},{"id":"idea-moon-goals-conversation-trigger","kind":"idea","name":"Algorithm-triggered goals-of-care conversations before crisis","route":"/ideas/idea-moon-goals-conversation-trigger/","asOf":"2026-09-08","days":20},{"id":"idea-moon-patient-held-cancer-record","kind":"idea","name":"A patient-owned, portable complete cancer record in a standard format","route":"/ideas/idea-moon-patient-held-cancer-record/","asOf":"2026-09-08","days":20},{"id":"idea-moon-funded-second-opinion","kind":"idea","name":"A funded expert second opinion for every new high-stakes or rare cancer diagnosis","route":"/ideas/idea-moon-funded-second-opinion/","asOf":"2026-09-08","days":20},{"id":"idea-moon-recorded-consultations","kind":"idea","name":"Recorded, AI-summarised consultations given to patients by default","route":"/ideas/idea-moon-recorded-consultations/","asOf":"2026-09-08","days":20},{"id":"idea-moon-question-prompt-lists","kind":"idea","name":"Question prompt lists sent to patients before every major consultation","route":"/ideas/idea-moon-question-prompt-lists/","asOf":"2026-09-08","days":20},{"id":"idea-moon-patient-experience-label","kind":"idea","name":"A mandatory patient-experience section in every cancer drug label and approval","route":"/ideas/idea-moon-patient-experience-label/","asOf":"2026-09-08","days":20},{"id":"idea-moon-results-back-to-participants","kind":"idea","name":"Plain-language trial results returned to every participant within a year","route":"/ideas/idea-moon-results-back-to-participants/","asOf":"2026-09-08","days":20},{"id":"idea-moon-peer-navigator-workforce","kind":"idea","name":"Paid survivor peer-navigators as a recognised health workforce role","route":"/ideas/idea-moon-peer-navigator-workforce/","asOf":"2026-09-08","days":20},{"id":"idea-moon-time-toxicity-reporting","kind":"idea","name":"Report time toxicity, the days a treatment consumes, in every trial and decision aid","route":"/ideas/idea-moon-time-toxicity-reporting/","asOf":"2026-09-08","days":20},{"id":"idea-moon-preference-studies-before-phase3","kind":"idea","name":"Quantitative patient preference studies set the benefit-risk bar before phase 3","route":"/ideas/idea-moon-preference-studies-before-phase3/","asOf":"2026-09-08","days":20},{"id":"idea-moon-caregiver-in-the-plan","kind":"idea","name":"Formal caregiver assessment and training written into every treatment plan","route":"/ideas/idea-moon-caregiver-in-the-plan/","asOf":"2026-09-08","days":20},{"id":"idea-moon-literacy-first-design-standard","kind":"idea","name":"A health-literacy certification standard for oncology portals, letters and apps","route":"/ideas/idea-moon-literacy-first-design-standard/","asOf":"2026-09-08","days":20},{"id":"idea-moon-trial-eligibility-at-every-decision","kind":"idea","name":"Patients are told which trials they qualify for at every treatment decision, in writing","route":"/ideas/idea-moon-trial-eligibility-at-every-decision/","asOf":"2026-09-08","days":20},{"id":"idea-moon-toxicity-first-endpoints","kind":"idea","name":"Tolerability as a co-primary endpoint with its own label claim","route":"/ideas/idea-moon-toxicity-first-endpoints/","asOf":"2026-09-08","days":20},{"id":"idea-moon-pro-ctcae-in-every-pivotal-trial","kind":"idea","name":"Patient-reported side-effects (PRO-CTCAE) collected and published in every registrational trial","route":"/ideas/idea-moon-pro-ctcae-in-every-pivotal-trial/","asOf":"2026-09-08","days":20},{"id":"idea-moon-supportive-care-arpa","kind":"idea","name":"An ARPA-style programme to develop supportive-care drugs nobody else will","route":"/ideas/idea-moon-supportive-care-arpa/","asOf":"2026-09-08","days":20},{"id":"idea-moon-neuropathy-prevention-programme","kind":"idea","name":"A prevention programme for chemotherapy nerve damage: SARM1 inhibitors, cooling and compression","route":"/ideas/idea-moon-neuropathy-prevention-programme/","asOf":"2026-09-08","days":20},{"id":"idea-moon-cardioprotection-by-default","kind":"idea","name":"Biomarker-guided cardioprotection for everyone on cardiotoxic cancer therapy","route":"/ideas/idea-moon-cardioprotection-by-default/","asOf":"2026-09-08","days":20},{"id":"idea-moon-olanzapine-antiemetic-everywhere","kind":"idea","name":"Low-dose olanzapine and generic antiemetic bundles in every guideline and formulary","route":"/ideas/idea-moon-olanzapine-antiemetic-everywhere/","asOf":"2026-09-08","days":20},{"id":"idea-moon-post-approval-dose-deescalation","kind":"idea","name":"Randomised lower-dose trials for approved drugs with quality of life as the primary endpoint","route":"/ideas/idea-moon-post-approval-dose-deescalation/","asOf":"2026-09-08","days":20},{"id":"idea-moon-quality-adjusted-pricing","kind":"idea","name":"Payers price drugs on quality-adjusted benefit, so toxicity costs the manufacturer","route":"/ideas/idea-moon-quality-adjusted-pricing/","asOf":"2026-09-08","days":20},{"id":"idea-moon-adult-late-effects-registry","kind":"idea","name":"A lifelong late-effects registry linked to every treatment for adult survivors","route":"/ideas/idea-moon-adult-late-effects-registry/","asOf":"2026-09-08","days":20},{"id":"idea-moon-cognitive-toxicity-programme","kind":"idea","name":"Measure and treat chemo brain with objective digital cognitive testing","route":"/ideas/idea-moon-cognitive-toxicity-programme/","asOf":"2026-09-08","days":20},{"id":"idea-moon-irae-prediction-and-prevention","kind":"idea","name":"Predict immune side-effects before they happen and pre-empt them","route":"/ideas/idea-moon-irae-prediction-and-prevention/","asOf":"2026-09-08","days":20},{"id":"idea-moon-fertility-preservation-default","kind":"idea","name":"Fertility preservation offered and funded by default before gonadotoxic treatment","route":"/ideas/idea-moon-fertility-preservation-default/","asOf":"2026-09-08","days":20},{"id":"idea-moon-hearing-protection-cisplatin","kind":"idea","name":"Protect hearing from cisplatin in adults as we now do in children","route":"/ideas/idea-moon-hearing-protection-cisplatin/","asOf":"2026-09-08","days":20},{"id":"idea-moon-hair-preservation-for-all","kind":"idea","name":"Fund scalp cooling and hair-preserving measures for every alopecia-inducing regimen","route":"/ideas/idea-moon-hair-preservation-for-all/","asOf":"2026-09-08","days":20},{"id":"idea-moon-oncology-hospital-at-home","kind":"idea","name":"Oncology hospital-at-home with remote monitoring for toxicity","route":"/ideas/idea-moon-oncology-hospital-at-home/","asOf":"2026-09-08","days":20},{"id":"idea-moon-supportive-care-platform-trial","kind":"idea","name":"A permanent platform trial for supportive-care interventions inside cooperative groups","route":"/ideas/idea-moon-supportive-care-platform-trial/","asOf":"2026-09-08","days":20},{"id":"idea-moon-open-pro-data-commons","kind":"idea","name":"An open commons of patient-reported outcome data from cancer trials","route":"/ideas/idea-moon-open-pro-data-commons/","asOf":"2026-09-08","days":20},{"id":"idea-moon-mucositis-taste-programme","kind":"idea","name":"Photobiomodulation and a taste and swallowing programme for mouth and throat toxicity","route":"/ideas/idea-moon-mucositis-taste-programme/","asOf":"2026-09-08","days":20},{"id":"idea-moon-sexual-health-as-toxicity-domain","kind":"idea","name":"Sexual health assessed and treated as a standard toxicity domain","route":"/ideas/idea-moon-sexual-health-as-toxicity-domain/","asOf":"2026-09-08","days":20},{"id":"idea-moon-quality-adjusted-survival-standard","kind":"idea","name":"Quality-adjusted survival reported in every trial publication and label","route":"/ideas/idea-moon-quality-adjusted-survival-standard/","asOf":"2026-09-08","days":20},{"id":"idea-moon-misinformation-rapid-response","kind":"idea","name":"A cancer misinformation rapid-response unit that rebuts within 48 hours","route":"/ideas/idea-moon-misinformation-rapid-response/","asOf":"2026-09-08","days":20},{"id":"idea-moon-verified-information-layer","kind":"idea","name":"A verified information layer that labels and links cancer content across platforms","route":"/ideas/idea-moon-verified-information-layer/","asOf":"2026-09-08","days":20},{"id":"idea-moon-clinician-creator-programme","kind":"idea","name":"Train and fund oncology clinicians as public content creators","route":"/ideas/idea-moon-clinician-creator-programme/","asOf":"2026-09-08","days":20},{"id":"idea-moon-prebunking-at-diagnosis","kind":"idea","name":"Inoculate newly diagnosed patients against common cancer scams","route":"/ideas/idea-moon-prebunking-at-diagnosis/","asOf":"2026-09-08","days":20},{"id":"idea-moon-unproven-clinic-registry","kind":"idea","name":"A public registry of unproven cancer clinics and reported outcomes","route":"/ideas/idea-moon-unproven-clinic-registry/","asOf":"2026-09-08","days":20},{"id":"idea-moon-supplement-interaction-database","kind":"idea","name":"An open supplement-drug interaction checker built into oncology prescribing","route":"/ideas/idea-moon-supplement-interaction-database/","asOf":"2026-09-08","days":20},{"id":"idea-moon-ban-unproven-therapy-ads","kind":"idea","name":"Ban and enforce against paid advertising of unproven cancer treatments","route":"/ideas/idea-moon-ban-unproven-therapy-ads/","asOf":"2026-09-08","days":20},{"id":"idea-moon-integrative-oncology-bridge","kind":"idea","name":"Evidence-based integrative oncology in every cancer centre to meet demand safely","route":"/ideas/idea-moon-integrative-oncology-bridge/","asOf":"2026-09-08","days":20},{"id":"idea-moon-ai-cancer-answer-audit","kind":"idea","name":"A public benchmark and audit of chatbot answers to cancer questions","route":"/ideas/idea-moon-ai-cancer-answer-audit/","asOf":"2026-09-08","days":20},{"id":"idea-moon-wikipedia-oncology-fellowships","kind":"idea","name":"Fund oncologists to maintain cancer articles on Wikipedia in many languages","route":"/ideas/idea-moon-wikipedia-oncology-fellowships/","asOf":"2026-09-08","days":20},{"id":"idea-moon-hpv-vaccine-confidence","kind":"idea","name":"Community-tailored HPV vaccine confidence campaigns with school-based delivery","route":"/ideas/idea-moon-hpv-vaccine-confidence/","asOf":"2026-09-08","days":20},{"id":"idea-moon-hype-index","kind":"idea","name":"An independent hype index grading cancer press releases and news stories","route":"/ideas/idea-moon-hype-index/","asOf":"2026-09-08","days":20},{"id":"idea-moon-patient-community-moderators","kind":"idea","name":"Trained moderators with evidence tools in online patient communities","route":"/ideas/idea-moon-patient-community-moderators/","asOf":"2026-09-08","days":20},{"id":"idea-moon-living-plain-evidence-summaries","kind":"idea","name":"Living plain-language evidence summaries for every common cancer question in 20 languages","route":"/ideas/idea-moon-living-plain-evidence-summaries/","asOf":"2026-09-08","days":20},{"id":"idea-moon-treatment-refusal-pathway","kind":"idea","name":"A structured pathway for patients declining proven treatment","route":"/ideas/idea-moon-treatment-refusal-pathway/","asOf":"2026-09-08","days":20},{"id":"idea-moon-population-interception","kind":"idea","name":"A whole-population cancer interception programme: risk-stratify every adult, detect and intercept early","route":"/ideas/idea-moon-population-interception/","asOf":"2026-09-08","days":20},{"id":"idea-moon-universal-sequencing-learning-system","kind":"idea","name":"Universal tumour and germline sequencing at diagnosis feeding a shared learning system","route":"/ideas/idea-moon-universal-sequencing-learning-system/","asOf":"2026-09-08","days":20},{"id":"idea-moon-lynch-vaccine-phase3","kind":"idea","name":"A frameshift neoantigen vaccine for Lynch syndrome carriers as the first preventive cancer vaccine approval","route":"/ideas/idea-moon-lynch-vaccine-phase3/","asOf":"2026-09-08","days":20},{"id":"idea-moon-in-vivo-cart-generic-price","kind":"idea","name":"In vivo CAR-T manufactured and priced like a generic biologic","route":"/ideas/idea-moon-in-vivo-cart-generic-price/","asOf":"2026-09-08","days":20},{"id":"idea-moon-closed-loop-adaptive-therapy","kind":"idea","name":"Autonomous closed-loop adaptive therapy driven by blood tests and evolutionary models","route":"/ideas/idea-moon-closed-loop-adaptive-therapy/","asOf":"2026-09-08","days":20},{"id":"idea-moon-global-open-trials-os","kind":"idea","name":"A global open trials operating system any hospital can plug into","route":"/ideas/idea-moon-global-open-trials-os/","asOf":"2026-09-08","days":20},{"id":"idea-moon-open-cancer-cell-state-model","kind":"idea","name":"An open model of every cancer cell state, built from perturbation atlases","route":"/ideas/idea-moon-open-cancer-cell-state-model/","asOf":"2026-09-08","days":20},{"id":"idea-moon-cure-prizes","kind":"idea","name":"Cure-focused prizes: pay for verified long-term cures, not for drugs","route":"/ideas/idea-moon-cure-prizes/","asOf":"2026-09-08","days":20},{"id":"idea-moon-engineered-immune-surveillance","kind":"idea","name":"Engineered immune surveillance: long-lived programmed immune cells that patrol for early cancer","route":"/ideas/idea-moon-engineered-immune-surveillance/","asOf":"2026-09-08","days":20},{"id":"idea-moon-synthetic-lethality-map-every-driver","kind":"idea","name":"A synthetic lethality map for every cancer driver in every tissue context","route":"/ideas/idea-moon-synthetic-lethality-map-every-driver/","asOf":"2026-09-08","days":20},{"id":"idea-moon-radiotherapy-for-everyone-2040","kind":"idea","name":"Radiotherapy for everyone who needs it by 2040","route":"/ideas/idea-moon-radiotherapy-for-everyone-2040/","asOf":"2026-09-08","days":20},{"id":"idea-moon-eliminate-infection-cancers","kind":"idea","name":"Eliminate infection-caused cancers: HPV, hepatitis B and C, H. pylori and EBV","route":"/ideas/idea-moon-eliminate-infection-cancers/","asOf":"2026-09-08","days":20},{"id":"idea-moon-mrd-weather-service","kind":"idea","name":"A national residual-disease weather service: serial blood tests for every curatively treated patient, pooled","route":"/ideas/idea-moon-mrd-weather-service/","asOf":"2026-09-08","days":20},{"id":"idea-moon-dormancy-eradication-programme","kind":"idea","name":"Eradicate dormant cancer cells: a programme to wake and kill or lock asleep disseminated cells","route":"/ideas/idea-moon-dormancy-eradication-programme/","asOf":"2026-09-08","days":20},{"id":"idea-moon-validated-digital-twins","kind":"idea","name":"Whole-patient digital twins validated in prospective randomised trials","route":"/ideas/idea-moon-validated-digital-twins/","asOf":"2026-09-08","days":20},{"id":"idea-moon-negative-results-ledger","kind":"idea","name":"A global ledger of negative results and failed compounds with mandatory deposition","route":"/ideas/idea-moon-negative-results-ledger/","asOf":"2026-09-08","days":20},{"id":"idea-moon-generics-for-cancer-fund","kind":"idea","name":"A public fund and label pathway to trial generic drugs against cancer","route":"/ideas/idea-moon-generics-for-cancer-fund/","asOf":"2026-09-08","days":20},{"id":"idea-moon-pooled-procurement-licensing-pool","kind":"idea","name":"Pooled procurement and voluntary licensing for essential cancer medicines in low-income countries","route":"/ideas/idea-moon-pooled-procurement-licensing-pool/","asOf":"2026-09-08","days":20},{"id":"idea-moon-brain-delivery-platform","kind":"idea","name":"A standard platform to get drugs into the brain: focused ultrasound plus shuttle-engineered therapeutics","route":"/ideas/idea-moon-brain-delivery-platform/","asOf":"2026-09-08","days":20},{"id":"idea-moon-rare-cancer-global-network","kind":"idea","name":"One global rare cancer network with n-of-1 and Bayesian trial frameworks","route":"/ideas/idea-moon-rare-cancer-global-network/","asOf":"2026-09-08","days":20},{"id":"idea-moon-cold-to-hot-programme","kind":"idea","name":"Make every cold tumour hot: a coordinated programme to reprogramme immune-excluded tumours","route":"/ideas/idea-moon-cold-to-hot-programme/","asOf":"2026-09-08","days":20},{"id":"idea-moon-cachexia-as-treatable-disease","kind":"idea","name":"Treat cachexia as a disease: GDF-15 blockade plus anabolic and nutrition bundles","route":"/ideas/idea-moon-cachexia-as-treatable-disease/","asOf":"2026-09-08","days":20},{"id":"idea-moon-individualised-dosing-all-oral-drugs","kind":"idea","name":"Model-informed individual dosing with drug-level monitoring for every oral cancer drug","route":"/ideas/idea-moon-individualised-dosing-all-oral-drugs/","asOf":"2026-09-08","days":20},{"id":"idea-moon-automated-combination-discovery","kind":"idea","name":"Automated combination discovery: patient-sample screens feeding Bayesian platform trials","route":"/ideas/idea-moon-automated-combination-discovery/","asOf":"2026-09-08","days":20},{"id":"idea-moon-indolence-classifiers-with-screening","kind":"idea","name":"Molecular indolence classifiers bundled with every screening programme","route":"/ideas/idea-moon-indolence-classifiers-with-screening/","asOf":"2026-09-08","days":20},{"id":"idea-moon-biomarker-validation-utility","kind":"idea","name":"A public biomarker validation utility with pre-diagnostic biobanks and blinded testing","route":"/ideas/idea-moon-biomarker-validation-utility/","asOf":"2026-09-08","days":20},{"id":"idea-moon-open-degrader-consortium","kind":"idea","name":"An open degrader consortium against every undruggable driver transcription factor","route":"/ideas/idea-moon-open-degrader-consortium/","asOf":"2026-09-08","days":20},{"id":"idea-moon-metastasis-prevention-indication","kind":"idea","name":"Metastasis prevention as a formal indication with its own trials and regulatory pathway","route":"/ideas/idea-moon-metastasis-prevention-indication/","asOf":"2026-09-08","days":20},{"id":"idea-moon-survivor-lifelong-care-model","kind":"idea","name":"Risk-stratified lifelong care for tens of millions of survivors, automated and shared with primary care","route":"/ideas/idea-moon-survivor-lifelong-care-model/","asOf":"2026-09-08","days":20},{"id":"idea-moon-palliative-care-from-diagnosis-everywhere","kind":"idea","name":"Palliative care from diagnosis for every advanced cancer, including opioid access, worldwide","route":"/ideas/idea-moon-palliative-care-from-diagnosis-everywhere/","asOf":"2026-09-08","days":20},{"id":"idea-moon-geriatric-assessment-default","kind":"idea","name":"Geriatric assessment by default for every older patient, and trials that admit them","route":"/ideas/idea-moon-geriatric-assessment-default/","asOf":"2026-09-08","days":20},{"id":"idea-moon-self-driving-cancer-labs","kind":"idea","name":"Self-driving laboratories that run the cancer biology hypothesis loop autonomously","route":"/ideas/idea-moon-self-driving-cancer-labs/","asOf":"2026-09-08","days":20},{"id":"idea-moon-task-shifting-ai-oncology-capacity","kind":"idea","name":"Double oncology capacity in low-resource settings with task-shifting and AI decision support","route":"/ideas/idea-moon-task-shifting-ai-oncology-capacity/","asOf":"2026-09-08","days":20},{"id":"idea-moon-federated-rwe-network","kind":"idea","name":"A global federated real-world evidence network at regulatory grade","route":"/ideas/idea-moon-federated-rwe-network/","asOf":"2026-09-08","days":20},{"id":"idea-moon-pay-for-cure-contracts","kind":"idea","name":"Pay-for-cure contracts: instalment payments for curative therapies contingent on durable remission","route":"/ideas/idea-moon-pay-for-cure-contracts/","asOf":"2026-09-08","days":20},{"id":"idea-moon-open-source-oncology-drug-discovery","kind":"idea","name":"Open-source drug discovery to clinical proof of concept for neglected cancers","route":"/ideas/idea-moon-open-source-oncology-drug-discovery/","asOf":"2026-09-08","days":20},{"id":"idea-moon-public-phase1-factory","kind":"idea","name":"A public-benefit phase 1 factory that takes academic discoveries into first-in-human trials","route":"/ideas/idea-moon-public-phase1-factory/","asOf":"2026-09-08","days":20},{"id":"idea-moon-neoantigen-vaccines-at-scale","kind":"idea","name":"Personalised cancer vaccines at commodity cost through fully automated manufacturing","route":"/ideas/idea-moon-neoantigen-vaccines-at-scale/","asOf":"2026-09-08","days":20},{"id":"idea-moon-image-guided-surgery-everywhere","kind":"idea","name":"Real-time margin assessment and image-guided surgery as the global standard","route":"/ideas/idea-moon-image-guided-surgery-everywhere/","asOf":"2026-09-08","days":20},{"id":"idea-moon-compact-flash-proton","kind":"idea","name":"Compact FLASH and proton systems at the price of a conventional linac","route":"/ideas/idea-moon-compact-flash-proton/","asOf":"2026-09-08","days":20},{"id":"idea-moon-population-germline-screening","kind":"idea","name":"Population germline screening for hereditary cancer genes with cascade testing","route":"/ideas/idea-moon-population-germline-screening/","asOf":"2026-09-08","days":20},{"id":"idea-moon-living-machine-readable-guidelines","kind":"idea","name":"Living, machine-readable guidelines pushed to the point of care in every country","route":"/ideas/idea-moon-living-machine-readable-guidelines/","asOf":"2026-09-08","days":20},{"id":"idea-moon-continuous-ai-validation-registry","kind":"idea","name":"Continuous prospective validation for every oncology AI tool after deployment","route":"/ideas/idea-moon-continuous-ai-validation-registry/","asOf":"2026-09-08","days":20},{"id":"idea-moon-reciprocal-tumour-agnostic-approvals","kind":"idea","name":"Reciprocal recognition of tumour-agnostic and rare-indication approvals across regulators","route":"/ideas/idea-moon-reciprocal-tumour-agnostic-approvals/","asOf":"2026-09-08","days":20},{"id":"idea-moon-independent-replication-institute","kind":"idea","name":"An independent replication institute that re-tests key preclinical cancer findings before trials","route":"/ideas/idea-moon-independent-replication-institute/","asOf":"2026-09-08","days":20},{"id":"src-npj-precision-oncology","kind":"collection","name":"npj Precision Oncology","route":"/collections/src-npj-precision-oncology/","asOf":"2026-09-08","days":20},{"id":"src-ema-chmp","kind":"collection","name":"EMA news and CHMP meeting highlights","route":"/collections/src-ema-chmp/","asOf":"2026-09-08","days":20},{"id":"src-nice-ta","kind":"collection","name":"NICE technology appraisals","route":"/collections/src-nice-ta/","asOf":"2026-09-08","days":20},{"id":"src-asco-post","kind":"collection","name":"The ASCO Post","route":"/collections/src-asco-post/","asOf":"2026-09-08","days":20},{"id":"src-onclive","kind":"collection","name":"OncLive","route":"/collections/src-onclive/","asOf":"2026-09-08","days":20},{"id":"src-targeted-oncology","kind":"collection","name":"Targeted Oncology","route":"/collections/src-targeted-oncology/","asOf":"2026-09-08","days":20},{"id":"src-cancer-network","kind":"collection","name":"CancerNetwork (ONCOLOGY)","route":"/collections/src-cancer-network/","asOf":"2026-09-08","days":20},{"id":"src-cancer-letter","kind":"collection","name":"The Cancer Letter","route":"/collections/src-cancer-letter/","asOf":"2026-09-08","days":20},{"id":"src-endpoints-news","kind":"collection","name":"Endpoints News","route":"/collections/src-endpoints-news/","asOf":"2026-09-08","days":20},{"id":"src-fierce-biotech","kind":"collection","name":"Fierce Biotech","route":"/collections/src-fierce-biotech/","asOf":"2026-09-08","days":20},{"id":"src-stat-news","kind":"collection","name":"STAT News","route":"/collections/src-stat-news/","asOf":"2026-09-08","days":20},{"id":"src-biocentury","kind":"collection","name":"BioCentury","route":"/collections/src-biocentury/","asOf":"2026-09-08","days":20},{"id":"src-evaluate","kind":"collection","name":"Evaluate Vantage","route":"/collections/src-evaluate/","asOf":"2026-09-08","days":20},{"id":"src-adc-review","kind":"collection","name":"ADC Review","route":"/collections/src-adc-review/","asOf":"2026-09-08","days":20},{"id":"src-urotoday","kind":"collection","name":"UroToday","route":"/collections/src-urotoday/","asOf":"2026-09-08","days":20},{"id":"src-oncodaily","kind":"collection","name":"OncoDaily","route":"/collections/src-oncodaily/","asOf":"2026-09-08","days":20},{"id":"src-healio-hemonc","kind":"collection","name":"Healio Hematology/Oncology","route":"/collections/src-healio-hemonc/","asOf":"2026-09-08","days":20},{"id":"src-medscape-oncology","kind":"collection","name":"Medscape Oncology","route":"/collections/src-medscape-oncology/","asOf":"2026-09-08","days":20},{"id":"src-biopharma-dive","kind":"collection","name":"BioPharma Dive","route":"/collections/src-biopharma-dive/","asOf":"2026-09-08","days":20},{"id":"src-asco-meeting-library","kind":"collection","name":"ASCO Meeting Library","route":"/collections/src-asco-meeting-library/","asOf":"2026-09-08","days":20},{"id":"src-esmo-congress","kind":"collection","name":"ESMO Congress","route":"/collections/src-esmo-congress/","asOf":"2026-09-08","days":20},{"id":"src-aacr-annual","kind":"collection","name":"AACR Annual Meeting","route":"/collections/src-aacr-annual/","asOf":"2026-09-08","days":20},{"id":"src-ash-annual","kind":"collection","name":"ASH Annual Meeting","route":"/collections/src-ash-annual/","asOf":"2026-09-08","days":20},{"id":"src-sabcs","kind":"collection","name":"San Antonio Breast Cancer Symposium","route":"/collections/src-sabcs/","asOf":"2026-09-08","days":20},{"id":"src-astro","kind":"collection","name":"ASTRO Annual Meeting","route":"/collections/src-astro/","asOf":"2026-09-08","days":20},{"id":"src-snmmi","kind":"collection","name":"SNMMI Annual Meeting","route":"/collections/src-snmmi/","asOf":"2026-09-08","days":20},{"id":"src-asco-daily-news","kind":"collection","name":"ASCO Daily News","route":"/collections/src-asco-daily-news/","asOf":"2026-09-08","days":20},{"id":"src-nature-briefing-cancer","kind":"collection","name":"Nature Briefing: Cancer","route":"/collections/src-nature-briefing-cancer/","asOf":"2026-09-08","days":20},{"id":"src-cruk-about-cancer","kind":"collection","name":"Cancer Research UK: About Cancer","route":"/collections/src-cruk-about-cancer/","asOf":"2026-09-08","days":20},{"id":"src-macmillan","kind":"collection","name":"Macmillan Cancer Support","route":"/collections/src-macmillan/","asOf":"2026-09-08","days":20},{"id":"src-lbbc","kind":"collection","name":"Living Beyond Breast Cancer","route":"/collections/src-lbbc/","asOf":"2026-09-08","days":20},{"id":"src-bcrf","kind":"collection","name":"Breast Cancer Research Foundation","route":"/collections/src-bcrf/","asOf":"2026-09-08","days":20},{"id":"src-tnbc-foundation","kind":"collection","name":"Triple Negative Breast Cancer Foundation","route":"/collections/src-tnbc-foundation/","asOf":"2026-09-08","days":20},{"id":"src-semantic-scholar","kind":"collection","name":"Semantic Scholar","route":"/collections/src-semantic-scholar/","asOf":"2026-09-08","days":20},{"id":"src-dimensions","kind":"collection","name":"Dimensions","route":"/collections/src-dimensions/","asOf":"2026-09-08","days":20},{"id":"metastatic-cascade","kind":"pathway","name":"The metastatic cascade","route":"/pathways/metastatic-cascade/","asOf":"2026-09-08","days":20},{"id":"tumor-microenvironment","kind":"pathway","name":"Tumour microenvironment (TME)","route":"/pathways/tumor-microenvironment/","asOf":"2026-09-08","days":20},{"id":"antigen-presentation-immunoediting","kind":"pathway","name":"Antigen presentation & immune editing","route":"/pathways/antigen-presentation-immunoediting/","asOf":"2026-09-08","days":20},{"id":"cancer-metabolism","kind":"pathway","name":"Cancer metabolism","route":"/pathways/cancer-metabolism/","asOf":"2026-09-08","days":20},{"id":"replication-stress","kind":"pathway","name":"DNA replication stress","route":"/pathways/replication-stress/","asOf":"2026-09-08","days":20},{"id":"chromosomal-instability","kind":"pathway","name":"Chromosomal instability & aneuploidy","route":"/pathways/chromosomal-instability/","asOf":"2026-09-08","days":20},{"id":"telomere-maintenance","kind":"pathway","name":"Telomere maintenance & replicative immortality","route":"/pathways/telomere-maintenance/","asOf":"2026-09-08","days":20},{"id":"autophagy","kind":"pathway","name":"Autophagy","route":"/pathways/autophagy/","asOf":"2026-09-08","days":20},{"id":"ferroptosis-cell-death","kind":"pathway","name":"Ferroptosis & regulated cell death","route":"/pathways/ferroptosis-cell-death/","asOf":"2026-09-08","days":20},{"id":"senescence","kind":"pathway","name":"Cellular senescence","route":"/pathways/senescence/","asOf":"2026-09-08","days":20},{"id":"cancer-stem-cells-plasticity","kind":"pathway","name":"Cancer stem cells & phenotypic plasticity","route":"/pathways/cancer-stem-cells-plasticity/","asOf":"2026-09-08","days":20},{"id":"clonal-evolution","kind":"pathway","name":"Clonal evolution & minimal residual disease","route":"/pathways/clonal-evolution/","asOf":"2026-09-08","days":20},{"id":"inflammation-nfkb","kind":"pathway","name":"Inflammation & NF-κB","route":"/pathways/inflammation-nfkb/","asOf":"2026-09-08","days":20},{"id":"hedgehog","kind":"pathway","name":"Hedgehog signalling","route":"/pathways/hedgehog/","asOf":"2026-09-08","days":20},{"id":"notch","kind":"pathway","name":"Notch signalling","route":"/pathways/notch/","asOf":"2026-09-08","days":20},{"id":"jak-stat","kind":"pathway","name":"JAK-STAT signalling","route":"/pathways/jak-stat/","asOf":"2026-09-08","days":20},{"id":"tgf-beta","kind":"pathway","name":"TGF-β signalling","route":"/pathways/tgf-beta/","asOf":"2026-09-08","days":20},{"id":"hippo-yap","kind":"pathway","name":"Hippo-YAP/TAZ","route":"/pathways/hippo-yap/","asOf":"2026-09-08","days":20},{"id":"myc","kind":"pathway","name":"MYC","route":"/pathways/myc/","asOf":"2026-09-08","days":20},{"id":"keap1-nrf2","kind":"pathway","name":"KEAP1-NRF2 antioxidant pathway","route":"/pathways/keap1-nrf2/","asOf":"2026-09-08","days":20},{"id":"swi-snf-chromatin","kind":"pathway","name":"SWI/SNF chromatin remodelling","route":"/pathways/swi-snf-chromatin/","asOf":"2026-09-08","days":20},{"id":"epigenetic-reprogramming","kind":"pathway","name":"Epigenetic reprogramming","route":"/pathways/epigenetic-reprogramming/","asOf":"2026-09-08","days":20},{"id":"rna-splicing","kind":"pathway","name":"RNA splicing","route":"/pathways/rna-splicing/","asOf":"2026-09-08","days":20},{"id":"mrna-translation-eif4f","kind":"pathway","name":"mRNA translation (eIF4F / mTOR)","route":"/pathways/mrna-translation-eif4f/","asOf":"2026-09-08","days":20},{"id":"circadian-control","kind":"pathway","name":"Circadian control","route":"/pathways/circadian-control/","asOf":"2026-09-08","days":20},{"id":"microbiome-tumour","kind":"pathway","name":"Microbiome-tumour interactions","route":"/pathways/microbiome-tumour/","asOf":"2026-09-08","days":20},{"id":"cancer-neuroscience","kind":"pathway","name":"Cancer neuroscience (nerve-tumour signalling)","route":"/pathways/cancer-neuroscience/","asOf":"2026-09-08","days":20},{"id":"cachexia-biology","kind":"pathway","name":"Cancer cachexia","route":"/pathways/cachexia-biology/","asOf":"2026-09-08","days":20},{"id":"clonal-haematopoiesis","kind":"pathway","name":"Clonal haematopoiesis (CHIP)","route":"/pathways/clonal-haematopoiesis/","asOf":"2026-09-08","days":20},{"id":"field-cancerisation","kind":"pathway","name":"Field cancerisation","route":"/pathways/field-cancerisation/","asOf":"2026-09-08","days":20},{"id":"tumor-dormancy","kind":"pathway","name":"Tumour dormancy","route":"/pathways/tumor-dormancy/","asOf":"2026-09-08","days":20},{"id":"hallmarks-of-cancer","kind":"term","name":"Hallmarks of Cancer","route":"/terms/hallmarks-of-cancer/","asOf":"2026-09-08","days":20},{"id":"sustaining-proliferative-signaling","kind":"term","name":"Hallmark: sustaining proliferative signalling","route":"/terms/sustaining-proliferative-signaling/","asOf":"2026-09-08","days":20},{"id":"evading-growth-suppressors","kind":"term","name":"Hallmark: evading growth suppressors","route":"/terms/evading-growth-suppressors/","asOf":"2026-09-08","days":20},{"id":"resisting-cell-death","kind":"term","name":"Hallmark: resisting cell death","route":"/terms/resisting-cell-death/","asOf":"2026-09-08","days":20},{"id":"enabling-replicative-immortality","kind":"term","name":"Hallmark: enabling replicative immortality","route":"/terms/enabling-replicative-immortality/","asOf":"2026-09-08","days":20},{"id":"inducing-angiogenesis","kind":"term","name":"Hallmark: inducing or accessing vasculature","route":"/terms/inducing-angiogenesis/","asOf":"2026-09-08","days":20},{"id":"activating-invasion-metastasis","kind":"term","name":"Hallmark: activating invasion and metastasis","route":"/terms/activating-invasion-metastasis/","asOf":"2026-09-08","days":20},{"id":"deregulating-cellular-energetics","kind":"term","name":"Hallmark: reprogramming cellular metabolism","route":"/terms/deregulating-cellular-energetics/","asOf":"2026-09-08","days":20},{"id":"avoiding-immune-destruction","kind":"term","name":"Hallmark: avoiding immune destruction","route":"/terms/avoiding-immune-destruction/","asOf":"2026-09-08","days":20},{"id":"genome-instability-mutation","kind":"term","name":"Enabling characteristic: genome instability and mutation","route":"/terms/genome-instability-mutation/","asOf":"2026-09-08","days":20},{"id":"tumor-promoting-inflammation","kind":"term","name":"Enabling characteristic: tumour-promoting inflammation","route":"/terms/tumor-promoting-inflammation/","asOf":"2026-09-08","days":20},{"id":"unlocking-phenotypic-plasticity","kind":"term","name":"Hallmark (2022): unlocking phenotypic plasticity","route":"/terms/unlocking-phenotypic-plasticity/","asOf":"2026-09-08","days":20},{"id":"nonmutational-epigenetic-reprogramming","kind":"term","name":"Hallmark (2022): non-mutational epigenetic reprogramming","route":"/terms/nonmutational-epigenetic-reprogramming/","asOf":"2026-09-08","days":20},{"id":"polymorphic-microbiomes","kind":"term","name":"Hallmark (2022): polymorphic microbiomes","route":"/terms/polymorphic-microbiomes/","asOf":"2026-09-08","days":20},{"id":"senescent-cells","kind":"term","name":"Hallmark (2022): senescent cells","route":"/terms/senescent-cells/","asOf":"2026-09-08","days":20},{"id":"disseminated-tumor-cells","kind":"term","name":"Disseminated tumour cells (DTCs)","route":"/terms/disseminated-tumor-cells/","asOf":"2026-09-08","days":20},{"id":"warburg-effect","kind":"term","name":"Warburg effect","route":"/terms/warburg-effect/","asOf":"2026-09-08","days":20},{"id":"immune-exclusion","kind":"term","name":"Immune exclusion","route":"/terms/immune-exclusion/","asOf":"2026-09-08","days":20},{"id":"cancer-associated-fibroblasts","kind":"term","name":"Cancer-associated fibroblasts (CAFs)","route":"/terms/cancer-associated-fibroblasts/","asOf":"2026-09-08","days":20},{"id":"tumor-associated-macrophages","kind":"term","name":"Tumour-associated macrophages (TAMs)","route":"/terms/tumor-associated-macrophages/","asOf":"2026-09-08","days":20},{"id":"myeloid-derived-suppressor-cells","kind":"term","name":"Myeloid-derived suppressor cells (MDSCs)","route":"/terms/myeloid-derived-suppressor-cells/","asOf":"2026-09-08","days":20},{"id":"whole-genome-doubling","kind":"term","name":"Whole-genome doubling (WGD)","route":"/terms/whole-genome-doubling/","asOf":"2026-09-08","days":20},{"id":"idea-dtc-colonisation-determinants","kind":"idea","name":"What decides which disseminated cells ever colonise?","route":"/ideas/idea-dtc-colonisation-determinants/","asOf":"2026-09-08","days":20},{"id":"idea-immune-exclusion-drivers","kind":"idea","name":"What actually holds T cells at the tumour border?","route":"/ideas/idea-immune-exclusion-drivers/","asOf":"2026-09-08","days":20},{"id":"idea-drugging-myc","kind":"idea","name":"Can MYC be drugged directly, and will patients tolerate it?","route":"/ideas/idea-drugging-myc/","asOf":"2026-09-08","days":20},{"id":"idea-targeting-aneuploidy","kind":"idea","name":"Is aneuploidy itself a druggable vulnerability?","route":"/ideas/idea-targeting-aneuploidy/","asOf":"2026-09-08","days":20},{"id":"idea-neoantigen-immunogenicity-rules","kind":"idea","name":"What makes a neoantigen actually immunogenic?","route":"/ideas/idea-neoantigen-immunogenicity-rules/","asOf":"2026-09-08","days":20},{"id":"idea-dormancy-maintenance-therapy","kind":"idea","name":"Keep them asleep: dormancy maintenance as adjuvant therapy","route":"/ideas/idea-dormancy-maintenance-therapy/","asOf":"2026-09-08","days":20},{"id":"idea-metabolic-vulnerability-mapping","kind":"idea","name":"Map metabolic dependencies in the patient, not the dish","route":"/ideas/idea-metabolic-vulnerability-mapping/","asOf":"2026-09-08","days":20},{"id":"idea-senolytics-after-chemo","kind":"idea","name":"One-two punch: clear senescent cells after chemotherapy","route":"/ideas/idea-senolytics-after-chemo/","asOf":"2026-09-08","days":20},{"id":"idea-microbiome-io-fmt","kind":"idea","name":"Microbiome transplant as a routine immunotherapy adjunct","route":"/ideas/idea-microbiome-io-fmt/","asOf":"2026-09-08","days":20},{"id":"idea-nerve-tumour-blockade","kind":"idea","name":"Cut the nerve supply to tumours with old drugs","route":"/ideas/idea-nerve-tumour-blockade/","asOf":"2026-09-08","days":20},{"id":"idea-cachexia-gdf15-prevention","kind":"idea","name":"Treat cachexia before it starts","route":"/ideas/idea-cachexia-gdf15-prevention/","asOf":"2026-09-08","days":20},{"id":"idea-chip-risk-modifiers","kind":"idea","name":"Which patients' blood clones will become leukaemia after treatment?","route":"/ideas/idea-chip-risk-modifiers/","asOf":"2026-09-08","days":20},{"id":"idea-field-interception","kind":"idea","name":"Intercept cancer at the field stage","route":"/ideas/idea-field-interception/","asOf":"2026-09-08","days":20},{"id":"idea-ferroptosis-persisters","kind":"idea","name":"Kill drug-tolerant persisters through ferroptosis","route":"/ideas/idea-ferroptosis-persisters/","asOf":"2026-09-08","days":20},{"id":"idea-splice-neoantigens","kind":"idea","name":"Shared splice-derived neoantigens as off-the-shelf vaccine targets","route":"/ideas/idea-splice-neoantigens/","asOf":"2026-09-08","days":20},{"id":"idea-chronotherapy-immunotherapy","kind":"idea","name":"Give immunotherapy in the morning","route":"/ideas/idea-chronotherapy-immunotherapy/","asOf":"2026-09-08","days":20},{"id":"idea-ecdna-targeting","kind":"idea","name":"Attack extrachromosomal DNA, the engine of oncogene amplification","route":"/ideas/idea-ecdna-targeting/","asOf":"2026-09-08","days":20},{"id":"frontier-2035","kind":"roadmap","name":"Radical oncology: what could change the war by 2035","route":"/roadmaps/frontier-2035/","asOf":"2026-09-08","days":20},{"id":"cure-paths","kind":"roadmap","name":"Paths to cures: interception, eradication, control","route":"/roadmaps/cure-paths/","asOf":"2026-09-08","days":20},{"id":"closed-automated-cell-manufacturing","kind":"technology","name":"Closed automated cell-therapy manufacturing","route":"/technologies/closed-automated-cell-manufacturing/","asOf":"2026-09-08","days":20},{"id":"point-of-care-cell-manufacturing","kind":"technology","name":"Point-of-care and decentralised cell manufacturing","route":"/technologies/point-of-care-cell-manufacturing/","asOf":"2026-09-08","days":20},{"id":"viral-vector-manufacturing","kind":"technology","name":"Viral vector manufacturing (lentiviral, retroviral, AAV)","route":"/technologies/viral-vector-manufacturing/","asOf":"2026-09-08","days":20},{"id":"plasmid-dna-manufacturing","kind":"technology","name":"Plasmid DNA and mRNA raw-material manufacturing","route":"/technologies/plasmid-dna-manufacturing/","asOf":"2026-09-08","days":20},{"id":"adc-cdmo-manufacturing","kind":"technology","name":"ADC bioconjugation manufacturing (CDMOs)","route":"/technologies/adc-cdmo-manufacturing/","asOf":"2026-09-08","days":20},{"id":"radiopharmacy-network","kind":"technology","name":"Radiopharmacy and cyclotron networks","route":"/technologies/radiopharmacy-network/","asOf":"2026-09-08","days":20},{"id":"therapy-isotope-supply-chain","kind":"technology","name":"Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225)","route":"/technologies/therapy-isotope-supply-chain/","asOf":"2026-09-08","days":20},{"id":"long-read-sequencing","kind":"technology","name":"Long-read sequencing (PacBio, Oxford Nanopore)","route":"/technologies/long-read-sequencing/","asOf":"2026-09-08","days":20},{"id":"next-gen-short-read-platforms","kind":"technology","name":"New short-read sequencing platforms","route":"/technologies/next-gen-short-read-platforms/","asOf":"2026-09-08","days":20},{"id":"spatial-biology-instruments","kind":"technology","name":"Spatial biology instruments","route":"/technologies/spatial-biology-instruments/","asOf":"2026-09-08","days":20},{"id":"whole-slide-scanners","kind":"technology","name":"Whole-slide scanners and image management","route":"/technologies/whole-slide-scanners/","asOf":"2026-09-08","days":20},{"id":"treatment-planning-systems","kind":"technology","name":"Radiotherapy treatment planning and QA software","route":"/technologies/treatment-planning-systems/","asOf":"2026-09-08","days":20},{"id":"auto-contouring-ai","kind":"technology","name":"AI auto-contouring and adaptive planning","route":"/technologies/auto-contouring-ai/","asOf":"2026-09-08","days":20},{"id":"oncology-real-world-data","kind":"technology","name":"Oncology EHR and real-world data platforms","route":"/technologies/oncology-real-world-data/","asOf":"2026-09-08","days":20},{"id":"clinical-trial-software","kind":"technology","name":"Clinical trial software (EDC, eCOA, CTMS, RTSM)","route":"/technologies/clinical-trial-software/","asOf":"2026-09-08","days":20},{"id":"decentralised-clinical-trials","kind":"technology","name":"Decentralised and hybrid clinical trials","route":"/technologies/decentralised-clinical-trials/","asOf":"2026-09-08","days":20},{"id":"community-oncology-networks","kind":"technology","name":"Community oncology and site networks","route":"/technologies/community-oncology-networks/","asOf":"2026-09-08","days":20},{"id":"contract-research-organisations","kind":"technology","name":"Contract research organisations (CROs)","route":"/technologies/contract-research-organisations/","asOf":"2026-09-08","days":20},{"id":"imaging-core-labs","kind":"technology","name":"Imaging core labs and central review","route":"/technologies/imaging-core-labs/","asOf":"2026-09-08","days":20},{"id":"biobanking","kind":"technology","name":"Biobanking and tissue procurement","route":"/technologies/biobanking/","asOf":"2026-09-08","days":20},{"id":"reference-laboratories","kind":"technology","name":"Reference laboratories and companion-diagnostic testing","route":"/technologies/reference-laboratories/","asOf":"2026-09-08","days":20},{"id":"pet-tracer-manufacturing","kind":"technology","name":"PET tracer manufacturing and distribution","route":"/technologies/pet-tracer-manufacturing/","asOf":"2026-09-08","days":20},{"id":"nuclear-medicine-hardware","kind":"technology","name":"Nuclear medicine and total-body PET hardware","route":"/technologies/nuclear-medicine-hardware/","asOf":"2026-09-08","days":20},{"id":"remote-patient-monitoring","kind":"technology","name":"Electronic patient-reported outcomes and remote monitoring","route":"/technologies/remote-patient-monitoring/","asOf":"2026-09-08","days":20},{"id":"pharmacy-automation","kind":"technology","name":"Oncology pharmacy automation and compounding robots","route":"/technologies/pharmacy-automation/","asOf":"2026-09-08","days":20},{"id":"ai-compute-platforms","kind":"technology","name":"AI compute and model platforms for oncology","route":"/technologies/ai-compute-platforms/","asOf":"2026-09-08","days":20},{"id":"sterile-fill-finish","kind":"technology","name":"Sterile fill-finish and lyophilisation","route":"/technologies/sterile-fill-finish/","asOf":"2026-09-08","days":20},{"id":"generic-drug-shortage-response","kind":"technology","name":"Generic oncology drug supply and shortage mitigation","route":"/technologies/generic-drug-shortage-response/","asOf":"2026-09-08","days":20},{"id":"hospital-information-systems-oncology","kind":"technology","name":"Oncology EHR modules and treatment pathways","route":"/technologies/hospital-information-systems-oncology/","asOf":"2026-09-08","days":20},{"id":"high-potency-payload-synthesis","kind":"technology","name":"Payload-linker synthesis (high-potency API)","route":"/technologies/high-potency-payload-synthesis/","asOf":"2026-09-08","days":20},{"id":"apheresis-starting-material","kind":"technology","name":"Apheresis and starting-material collection","route":"/technologies/apheresis-starting-material/","asOf":"2026-09-08","days":20},{"id":"cell-therapy-cold-chain","kind":"technology","name":"Cryopreservation and cell-therapy cold chain","route":"/technologies/cell-therapy-cold-chain/","asOf":"2026-09-08","days":20},{"id":"cell-therapy-orchestration-software","kind":"technology","name":"Cell-therapy orchestration and chain-of-identity software","route":"/technologies/cell-therapy-orchestration-software/","asOf":"2026-09-08","days":20},{"id":"cell-therapy-release-testing","kind":"technology","name":"Cell-therapy release and potency testing","route":"/technologies/cell-therapy-release-testing/","asOf":"2026-09-08","days":20},{"id":"allogeneic-cell-banking","kind":"technology","name":"Allogeneic donor and iPSC master cell banks","route":"/technologies/allogeneic-cell-banking/","asOf":"2026-09-08","days":20},{"id":"monoclonal-antibody-manufacturing","kind":"technology","name":"Antibody manufacturing (CHO bioprocessing)","route":"/technologies/monoclonal-antibody-manufacturing/","asOf":"2026-09-08","days":20},{"id":"medical-cyclotrons-synthesis-modules","kind":"technology","name":"Medical cyclotrons, hot cells, and synthesis modules","route":"/technologies/medical-cyclotrons-synthesis-modules/","asOf":"2026-09-08","days":20},{"id":"radionuclide-generators-kits","kind":"technology","name":"Radionuclide generators and cold kits","route":"/technologies/radionuclide-generators-kits/","asOf":"2026-09-08","days":20},{"id":"ngs-bioinformatics-software","kind":"technology","name":"Clinical NGS bioinformatics and variant interpretation","route":"/technologies/ngs-bioinformatics-software/","asOf":"2026-09-08","days":20},{"id":"genomics-cloud-platforms","kind":"technology","name":"Genomics cloud and secure research environments","route":"/technologies/genomics-cloud-platforms/","asOf":"2026-09-08","days":20},{"id":"variant-knowledgebases","kind":"technology","name":"Cancer variant knowledgebases and molecular tumour boards","route":"/technologies/variant-knowledgebases/","asOf":"2026-09-08","days":20},{"id":"cancer-registries-surveillance","kind":"technology","name":"Cancer registries and population surveillance","route":"/technologies/cancer-registries-surveillance/","asOf":"2026-09-08","days":20},{"id":"proteomics-platforms","kind":"technology","name":"Proteomics instruments and affinity platforms","route":"/technologies/proteomics-platforms/","asOf":"2026-09-08","days":20},{"id":"structural-biology-infrastructure","kind":"technology","name":"Structural biology infrastructure (cryo-EM, synchrotrons, AlphaFold)","route":"/technologies/structural-biology-infrastructure/","asOf":"2026-09-08","days":20},{"id":"high-throughput-screening-libraries","kind":"technology","name":"High-throughput screening and DNA-encoded libraries","route":"/technologies/high-throughput-screening-libraries/","asOf":"2026-09-08","days":20},{"id":"preanalytics-sample-stabilisation","kind":"technology","name":"Pre-analytics: blood-collection tubes and tissue fixation","route":"/technologies/preanalytics-sample-stabilisation/","asOf":"2026-09-08","days":20},{"id":"ihc-autostainers-histology-automation","kind":"technology","name":"Histology automation and IHC autostainers","route":"/technologies/ihc-autostainers-histology-automation/","asOf":"2026-09-08","days":20},{"id":"infusion-devices-vascular-access","kind":"technology","name":"Infusion pumps, ports, and ambulatory chemotherapy devices","route":"/technologies/infusion-devices-vascular-access/","asOf":"2026-09-08","days":20},{"id":"federated-learning-medical-ai","kind":"technology","name":"Federated learning and privacy-preserving AI","route":"/technologies/federated-learning-medical-ai/","asOf":"2026-09-08","days":20},{"id":"telemedicine-teleoncology","kind":"technology","name":"Telemedicine, teleoncology, and telepathology","route":"/technologies/telemedicine-teleoncology/","asOf":"2026-09-08","days":20},{"id":"miltenyi-biotec","kind":"company","name":"Miltenyi Biotec","route":"/companies/miltenyi-biotec/","asOf":"2026-09-08","days":20},{"id":"lonza","kind":"company","name":"Lonza","route":"/companies/lonza/","asOf":"2026-09-08","days":20},{"id":"cellares","kind":"company","name":"Cellares","route":"/companies/cellares/","asOf":"2026-09-08","days":20},{"id":"cytiva","kind":"company","name":"Cytiva (Danaher)","route":"/companies/cytiva/","asOf":"2026-09-08","days":20},{"id":"galapagos","kind":"company","name":"Galapagos","route":"/companies/galapagos/","asOf":"2026-09-08","days":20},{"id":"oxford-biomedica","kind":"company","name":"OXB (Oxford Biomedica)","route":"/companies/oxford-biomedica/","asOf":"2026-09-08","days":20},{"id":"thermo-fisher","kind":"company","name":"Thermo Fisher Scientific","route":"/companies/thermo-fisher/","asOf":"2026-09-08","days":20},{"id":"charles-river","kind":"company","name":"Charles River Laboratories","route":"/companies/charles-river/","asOf":"2026-09-08","days":20},{"id":"aldevron","kind":"company","name":"Aldevron (Danaher)","route":"/companies/aldevron/","asOf":"2026-09-08","days":20},{"id":"touchlight","kind":"company","name":"Touchlight","route":"/companies/touchlight/","asOf":"2026-09-08","days":20},{"id":"wuxi-xdc","kind":"company","name":"WuXi XDC","route":"/companies/wuxi-xdc/","asOf":"2026-09-08","days":20},{"id":"samsung-biologics","kind":"company","name":"Samsung Biologics","route":"/companies/samsung-biologics/","asOf":"2026-09-08","days":20},{"id":"piramal-pharma-solutions","kind":"company","name":"Piramal Pharma Solutions","route":"/companies/piramal-pharma-solutions/","asOf":"2026-09-08","days":20},{"id":"abzena","kind":"company","name":"Abzena","route":"/companies/abzena/","asOf":"2026-09-08","days":20},{"id":"catalent","kind":"company","name":"Catalent (Novo Holdings)","route":"/companies/catalent/","asOf":"2026-09-08","days":20},{"id":"petnet-solutions","kind":"company","name":"PETNET Solutions (Siemens Healthineers)","route":"/companies/petnet-solutions/","asOf":"2026-09-08","days":20},{"id":"cardinal-health","kind":"company","name":"Cardinal Health Nuclear & Precision Health Solutions","route":"/companies/cardinal-health/","asOf":"2026-09-08","days":20},{"id":"jubilant-radiopharma","kind":"company","name":"Jubilant Radiopharma","route":"/companies/jubilant-radiopharma/","asOf":"2026-09-08","days":20},{"id":"northstar-medical-radioisotopes","kind":"company","name":"NorthStar Medical Radioisotopes","route":"/companies/northstar-medical-radioisotopes/","asOf":"2026-09-08","days":20},{"id":"shine-technologies","kind":"company","name":"SHINE Technologies","route":"/companies/shine-technologies/","asOf":"2026-09-08","days":20},{"id":"eckert-ziegler","kind":"company","name":"Eckert & Ziegler","route":"/companies/eckert-ziegler/","asOf":"2026-09-08","days":20},{"id":"pacbio","kind":"company","name":"PacBio","route":"/companies/pacbio/","asOf":"2026-09-08","days":20},{"id":"oxford-nanopore","kind":"company","name":"Oxford Nanopore Technologies","route":"/companies/oxford-nanopore/","asOf":"2026-09-08","days":20},{"id":"ultima-genomics","kind":"company","name":"Ultima Genomics","route":"/companies/ultima-genomics/","asOf":"2026-09-08","days":20},{"id":"element-biosciences","kind":"company","name":"Element Biosciences","route":"/companies/element-biosciences/","asOf":"2026-09-08","days":20},{"id":"mgi-tech","kind":"company","name":"MGI Tech","route":"/companies/mgi-tech/","asOf":"2026-09-08","days":20},{"id":"bruker","kind":"company","name":"Bruker (Bruker Spatial Biology)","route":"/companies/bruker/","asOf":"2026-09-08","days":20},{"id":"vizgen","kind":"company","name":"Vizgen","route":"/companies/vizgen/","asOf":"2026-09-08","days":20},{"id":"akoya-biosciences","kind":"company","name":"Akoya Biosciences","route":"/companies/akoya-biosciences/","asOf":"2026-09-08","days":20},{"id":"leica-biosystems","kind":"company","name":"Leica Biosystems (Danaher)","route":"/companies/leica-biosystems/","asOf":"2026-09-08","days":20},{"id":"hamamatsu","kind":"company","name":"Hamamatsu Photonics","route":"/companies/hamamatsu/","asOf":"2026-09-08","days":20},{"id":"3dhistech","kind":"company","name":"3DHISTECH","route":"/companies/3dhistech/","asOf":"2026-09-08","days":20},{"id":"philips","kind":"company","name":"Philips","route":"/companies/philips/","asOf":"2026-09-08","days":20},{"id":"sectra","kind":"company","name":"Sectra","route":"/companies/sectra/","asOf":"2026-09-08","days":20},{"id":"proscia","kind":"company","name":"Proscia","route":"/companies/proscia/","asOf":"2026-09-08","days":20},{"id":"indica-labs","kind":"company","name":"Indica Labs","route":"/companies/indica-labs/","asOf":"2026-09-08","days":20},{"id":"raysearch","kind":"company","name":"RaySearch Laboratories","route":"/companies/raysearch/","asOf":"2026-09-08","days":20},{"id":"sun-nuclear","kind":"company","name":"Sun Nuclear (Mirion)","route":"/companies/sun-nuclear/","asOf":"2026-09-08","days":20},{"id":"brainlab","kind":"company","name":"Brainlab","route":"/companies/brainlab/","asOf":"2026-09-08","days":20},{"id":"limbus-ai","kind":"company","name":"Limbus AI","route":"/companies/limbus-ai/","asOf":"2026-09-08","days":20},{"id":"mim-software","kind":"company","name":"MIM Software (GE HealthCare)","route":"/companies/mim-software/","asOf":"2026-09-08","days":20},{"id":"therapanacea","kind":"company","name":"TheraPanacea","route":"/companies/therapanacea/","asOf":"2026-09-08","days":20},{"id":"mvision-ai","kind":"company","name":"MVision AI","route":"/companies/mvision-ai/","asOf":"2026-09-08","days":20},{"id":"flatiron-health","kind":"company","name":"Flatiron Health (Roche)","route":"/companies/flatiron-health/","asOf":"2026-09-08","days":20},{"id":"concertai","kind":"company","name":"ConcertAI","route":"/companies/concertai/","asOf":"2026-09-08","days":20},{"id":"cota-healthcare","kind":"company","name":"COTA","route":"/companies/cota-healthcare/","asOf":"2026-09-08","days":20},{"id":"trinetx","kind":"company","name":"TriNetX","route":"/companies/trinetx/","asOf":"2026-09-08","days":20},{"id":"komodo-health","kind":"company","name":"Komodo Health","route":"/companies/komodo-health/","asOf":"2026-09-08","days":20},{"id":"datavant","kind":"company","name":"Datavant","route":"/companies/datavant/","asOf":"2026-09-08","days":20},{"id":"medidata","kind":"company","name":"Medidata (Dassault Systèmes)","route":"/companies/medidata/","asOf":"2026-09-08","days":20},{"id":"veeva-systems","kind":"company","name":"Veeva Systems","route":"/companies/veeva-systems/","asOf":"2026-09-08","days":20},{"id":"oracle-health-sciences","kind":"company","name":"Oracle Health (Cerner) & Oracle Life Sciences","route":"/companies/oracle-health-sciences/","asOf":"2026-09-08","days":20},{"id":"epic-systems","kind":"company","name":"Epic Systems","route":"/companies/epic-systems/","asOf":"2026-09-08","days":20},{"id":"medable","kind":"company","name":"Medable","route":"/companies/medable/","asOf":"2026-09-08","days":20},{"id":"science-37","kind":"company","name":"Science 37 (eMed)","route":"/companies/science-37/","asOf":"2026-09-08","days":20},{"id":"mckesson-us-oncology","kind":"company","name":"McKesson / The US Oncology Network","route":"/companies/mckesson-us-oncology/","asOf":"2026-09-08","days":20},{"id":"oneoncology","kind":"company","name":"OneOncology","route":"/companies/oneoncology/","asOf":"2026-09-08","days":20},{"id":"florida-cancer-specialists","kind":"company","name":"Florida Cancer Specialists & Research Institute","route":"/companies/florida-cancer-specialists/","asOf":"2026-09-08","days":20},{"id":"sarah-cannon-research-institute","kind":"company","name":"Sarah Cannon Research Institute","route":"/companies/sarah-cannon-research-institute/","asOf":"2026-09-08","days":20},{"id":"iqvia","kind":"company","name":"IQVIA","route":"/companies/iqvia/","asOf":"2026-09-08","days":20},{"id":"icon-plc","kind":"company","name":"ICON plc","route":"/companies/icon-plc/","asOf":"2026-09-08","days":20},{"id":"parexel","kind":"company","name":"Parexel","route":"/companies/parexel/","asOf":"2026-09-08","days":20},{"id":"fortrea","kind":"company","name":"Fortrea","route":"/companies/fortrea/","asOf":"2026-09-08","days":20},{"id":"medpace","kind":"company","name":"Medpace","route":"/companies/medpace/","asOf":"2026-09-08","days":20},{"id":"calyx","kind":"company","name":"Calyx","route":"/companies/calyx/","asOf":"2026-09-08","days":20},{"id":"clario","kind":"company","name":"Clario","route":"/companies/clario/","asOf":"2026-09-08","days":20},{"id":"discovery-life-sciences","kind":"company","name":"Discovery Life Sciences","route":"/companies/discovery-life-sciences/","asOf":"2026-09-08","days":20},{"id":"indivumed","kind":"company","name":"Indivumed","route":"/companies/indivumed/","asOf":"2026-09-08","days":20},{"id":"hub-organoids","kind":"company","name":"HUB Organoids","route":"/companies/hub-organoids/","asOf":"2026-09-08","days":20},{"id":"labcorp","kind":"company","name":"Labcorp","route":"/companies/labcorp/","asOf":"2026-09-08","days":20},{"id":"quest-diagnostics","kind":"company","name":"Quest Diagnostics","route":"/companies/quest-diagnostics/","asOf":"2026-09-08","days":20},{"id":"neogenomics","kind":"company","name":"NeoGenomics","route":"/companies/neogenomics/","asOf":"2026-09-08","days":20},{"id":"agilent","kind":"company","name":"Agilent Technologies (Dako)","route":"/companies/agilent/","asOf":"2026-09-08","days":20},{"id":"canon-medical","kind":"company","name":"Canon Medical Systems","route":"/companies/canon-medical/","asOf":"2026-09-08","days":20},{"id":"kaiku-health","kind":"company","name":"Kaiku Health (Elekta)","route":"/companies/kaiku-health/","asOf":"2026-09-08","days":20},{"id":"omnicell","kind":"company","name":"Omnicell","route":"/companies/omnicell/","asOf":"2026-09-08","days":20},{"id":"becton-dickinson","kind":"company","name":"BD (Becton, Dickinson and Company)","route":"/companies/becton-dickinson/","asOf":"2026-09-08","days":20},{"id":"microsoft","kind":"company","name":"Microsoft (Health & Life Sciences)","route":"/companies/microsoft/","asOf":"2026-09-08","days":20},{"id":"google-health","kind":"company","name":"Google (Health, DeepMind, Verily)","route":"/companies/google-health/","asOf":"2026-09-08","days":20},{"id":"civica-rx","kind":"company","name":"Civica Rx","route":"/companies/civica-rx/","asOf":"2026-09-08","days":20},{"id":"terumo-bct","kind":"company","name":"Terumo Blood and Cell Technologies","route":"/companies/terumo-bct/","asOf":"2026-09-08","days":20},{"id":"fresenius-kabi","kind":"company","name":"Fresenius Kabi","route":"/companies/fresenius-kabi/","asOf":"2026-09-08","days":20},{"id":"cryoport","kind":"company","name":"Cryoport","route":"/companies/cryoport/","asOf":"2026-09-08","days":20},{"id":"biolife-solutions","kind":"company","name":"BioLife Solutions","route":"/companies/biolife-solutions/","asOf":"2026-09-08","days":20},{"id":"fujifilm-diosynth","kind":"company","name":"FUJIFILM Diosynth Biotechnologies","route":"/companies/fujifilm-diosynth/","asOf":"2026-09-08","days":20},{"id":"boehringer-ingelheim-biox","kind":"company","name":"Boehringer Ingelheim BioXcellence","route":"/companies/boehringer-ingelheim-biox/","asOf":"2026-09-08","days":20},{"id":"trasis","kind":"company","name":"Trasis","route":"/companies/trasis/","asOf":"2026-09-08","days":20},{"id":"comecer","kind":"company","name":"Comecer (ATS)","route":"/companies/comecer/","asOf":"2026-09-08","days":20},{"id":"sophia-genetics","kind":"company","name":"SOPHiA GENETICS","route":"/companies/sophia-genetics/","asOf":"2026-09-08","days":20},{"id":"qiagen","kind":"company","name":"QIAGEN","route":"/companies/qiagen/","asOf":"2026-09-08","days":20},{"id":"velsera","kind":"company","name":"Velsera (Seven Bridges and Pierian)","route":"/companies/velsera/","asOf":"2026-09-08","days":20},{"id":"dnanexus","kind":"company","name":"DNAnexus","route":"/companies/dnanexus/","asOf":"2026-09-08","days":20},{"id":"standard-biotools","kind":"company","name":"Standard BioTools (SomaLogic)","route":"/companies/standard-biotools/","asOf":"2026-09-08","days":20},{"id":"streck","kind":"company","name":"Streck","route":"/companies/streck/","asOf":"2026-09-08","days":20},{"id":"sakura-finetek","kind":"company","name":"Sakura Finetek","route":"/companies/sakura-finetek/","asOf":"2026-09-08","days":20},{"id":"baxter","kind":"company","name":"Baxter International","route":"/companies/baxter/","asOf":"2026-09-08","days":20},{"id":"b-braun","kind":"company","name":"B. Braun","route":"/companies/b-braun/","asOf":"2026-09-08","days":20},{"id":"project-optimus","kind":"term","name":"Project Optimus","route":"/terms/project-optimus/","asOf":"2026-09-08","days":20},{"id":"project-orbis","kind":"term","name":"Project Orbis","route":"/terms/project-orbis/","asOf":"2026-09-08","days":20},{"id":"real-time-oncology-review","kind":"term","name":"Real-Time Oncology Review (RTOR) and Assessment Aid","route":"/terms/real-time-oncology-review/","asOf":"2026-09-08","days":20},{"id":"project-frontrunner","kind":"term","name":"Project FrontRunner","route":"/terms/project-frontrunner/","asOf":"2026-09-08","days":20},{"id":"340b-program","kind":"term","name":"340B Drug Pricing Program","route":"/terms/340b-program/","asOf":"2026-09-08","days":20},{"id":"nccn-compendium","kind":"term","name":"NCCN Compendium and drug compendia","route":"/terms/nccn-compendium/","asOf":"2026-09-08","days":20},{"id":"icer-value-assessment","kind":"term","name":"ICER and health technology assessment","route":"/terms/icer-value-assessment/","asOf":"2026-09-08","days":20},{"id":"omop-ohdsi","kind":"term","name":"OMOP common data model and OHDSI","route":"/terms/omop-ohdsi/","asOf":"2026-09-08","days":20},{"id":"mcode","kind":"term","name":"mCODE (minimal Common Oncology Data Elements)","route":"/terms/mcode/","asOf":"2026-09-08","days":20},{"id":"bicr","kind":"term","name":"Blinded independent central review (BICR)","route":"/terms/bicr/","asOf":"2026-09-08","days":20},{"id":"cdmo","kind":"term","name":"CDMO (contract development and manufacturing organisation)","route":"/terms/cdmo/","asOf":"2026-09-08","days":20},{"id":"biosecure-act","kind":"term","name":"BIOSECURE Act","route":"/terms/biosecure-act/","asOf":"2026-09-08","days":20},{"id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/","asOf":"2026-09-08","days":20},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/","asOf":"2026-09-08","days":20},{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/","asOf":"2026-09-08","days":20},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/","asOf":"2026-09-08","days":20},{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/","asOf":"2026-09-08","days":20},{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/","asOf":"2026-09-08","days":20},{"id":"primary-cns-lymphoma","kind":"cancer","name":"Primary CNS lymphoma","route":"/cancers/primary-cns-lymphoma/","asOf":"2026-09-08","days":20},{"id":"waldenstrom","kind":"cancer","name":"Waldenström macroglobulinaemia","route":"/cancers/waldenstrom/","asOf":"2026-09-08","days":20},{"id":"hairy-cell-leukemia","kind":"cancer","name":"Hairy cell leukaemia","route":"/cancers/hairy-cell-leukemia/","asOf":"2026-09-08","days":20},{"id":"bpdcn","kind":"cancer","name":"Blastic plasmacytoid dendritic cell neoplasm (BPDCN)","route":"/cancers/bpdcn/","asOf":"2026-09-08","days":20},{"id":"uveal-melanoma","kind":"cancer","name":"Uveal melanoma","route":"/cancers/uveal-melanoma/","asOf":"2026-09-08","days":20},{"id":"testicular","kind":"cancer","name":"Testicular germ cell tumours","route":"/cancers/testicular/","asOf":"2026-09-08","days":20},{"id":"anal","kind":"cancer","name":"Anal cancer (squamous cell carcinoma)","route":"/cancers/anal/","asOf":"2026-09-08","days":20},{"id":"gist","kind":"cancer","name":"Gastrointestinal stromal tumour (GIST)","route":"/cancers/gist/","asOf":"2026-09-08","days":20},{"id":"appendiceal","kind":"cancer","name":"Appendiceal cancer and pseudomyxoma peritonei","route":"/cancers/appendiceal/","asOf":"2026-09-08","days":20},{"id":"vulvar","kind":"cancer","name":"Vulvar cancer","route":"/cancers/vulvar/","asOf":"2026-09-08","days":20},{"id":"gestational-trophoblastic","kind":"cancer","name":"Gestational trophoblastic neoplasia","route":"/cancers/gestational-trophoblastic/","asOf":"2026-09-08","days":20},{"id":"medulloblastoma","kind":"cancer","name":"Medulloblastoma","route":"/cancers/medulloblastoma/","asOf":"2026-09-08","days":20},{"id":"osteosarcoma","kind":"cancer","name":"Osteosarcoma","route":"/cancers/osteosarcoma/","asOf":"2026-09-08","days":20},{"id":"ewing-sarcoma","kind":"cancer","name":"Ewing sarcoma","route":"/cancers/ewing-sarcoma/","asOf":"2026-09-08","days":20},{"id":"wilms-tumor","kind":"cancer","name":"Wilms tumour (nephroblastoma)","route":"/cancers/wilms-tumor/","asOf":"2026-09-08","days":20},{"id":"retinoblastoma","kind":"cancer","name":"Retinoblastoma","route":"/cancers/retinoblastoma/","asOf":"2026-09-08","days":20},{"id":"rhabdomyosarcoma","kind":"cancer","name":"Rhabdomyosarcoma","route":"/cancers/rhabdomyosarcoma/","asOf":"2026-09-08","days":20},{"id":"hepatoblastoma","kind":"cancer","name":"Hepatoblastoma","route":"/cancers/hepatoblastoma/","asOf":"2026-09-08","days":20},{"id":"cancer-of-unknown-primary","kind":"cancer","name":"Cancer of unknown primary (CUP)","route":"/cancers/cancer-of-unknown-primary/","asOf":"2026-09-08","days":20},{"id":"nasopharyngeal","kind":"cancer","name":"Nasopharyngeal carcinoma","route":"/cancers/nasopharyngeal/","asOf":"2026-09-08","days":20},{"id":"thymic-epithelial","kind":"cancer","name":"Thymoma and thymic carcinoma","route":"/cancers/thymic-epithelial/","asOf":"2026-09-08","days":20},{"id":"adrenocortical","kind":"cancer","name":"Adrenocortical carcinoma","route":"/cancers/adrenocortical/","asOf":"2026-09-08","days":20},{"id":"salivary-gland","kind":"cancer","name":"Salivary gland cancers","route":"/cancers/salivary-gland/","asOf":"2026-09-08","days":20},{"id":"kaposi-sarcoma","kind":"cancer","name":"Kaposi sarcoma","route":"/cancers/kaposi-sarcoma/","asOf":"2026-09-08","days":20},{"id":"nilotinib","kind":"drug","name":"Nilotinib","route":"/drugs/nilotinib/","asOf":"2026-09-08","days":20},{"id":"bosutinib","kind":"drug","name":"Bosutinib","route":"/drugs/bosutinib/","asOf":"2026-09-08","days":20},{"id":"luspatercept","kind":"drug","name":"Luspatercept","route":"/drugs/luspatercept/","asOf":"2026-09-08","days":20},{"id":"imetelstat","kind":"drug","name":"Imetelstat","route":"/drugs/imetelstat/","asOf":"2026-09-08","days":20},{"id":"ruxolitinib","kind":"drug","name":"Ruxolitinib","route":"/drugs/ruxolitinib/","asOf":"2026-09-08","days":20},{"id":"fedratinib","kind":"drug","name":"Fedratinib","route":"/drugs/fedratinib/","asOf":"2026-09-08","days":20},{"id":"pacritinib","kind":"drug","name":"Pacritinib","route":"/drugs/pacritinib/","asOf":"2026-09-08","days":20},{"id":"momelotinib","kind":"drug","name":"Momelotinib","route":"/drugs/momelotinib/","asOf":"2026-09-08","days":20},{"id":"hydroxyurea","kind":"drug","name":"Hydroxyurea (hydroxycarbamide)","route":"/drugs/hydroxyurea/","asOf":"2026-09-08","days":20},{"id":"ropeginterferon-alfa-2b","kind":"drug","name":"Ropeginterferon alfa-2b","route":"/drugs/ropeginterferon-alfa-2b/","asOf":"2026-09-08","days":20},{"id":"rusfertide","kind":"drug","name":"Rusfertide","route":"/drugs/rusfertide/","asOf":"2026-09-08","days":20},{"id":"glasdegib","kind":"drug","name":"Glasdegib","route":"/drugs/glasdegib/","asOf":"2026-09-08","days":20},{"id":"arsenic-trioxide","kind":"drug","name":"Arsenic trioxide","route":"/drugs/arsenic-trioxide/","asOf":"2026-09-08","days":20},{"id":"tretinoin-atra","kind":"drug","name":"Tretinoin (all-trans retinoic acid, ATRA)","route":"/drugs/tretinoin-atra/","asOf":"2026-09-08","days":20},{"id":"bendamustine","kind":"drug","name":"Bendamustine","route":"/drugs/bendamustine/","asOf":"2026-09-08","days":20},{"id":"tazemetostat","kind":"drug","name":"Tazemetostat","route":"/drugs/tazemetostat/","asOf":"2026-09-08","days":20},{"id":"brexucabtagene-autoleucel","kind":"drug","name":"Brexucabtagene autoleucel","route":"/drugs/brexucabtagene-autoleucel/","asOf":"2026-09-08","days":20},{"id":"pralatrexate","kind":"drug","name":"Pralatrexate","route":"/drugs/pralatrexate/","asOf":"2026-09-08","days":20},{"id":"romidepsin","kind":"drug","name":"Romidepsin","route":"/drugs/romidepsin/","asOf":"2026-09-08","days":20},{"id":"belinostat","kind":"drug","name":"Belinostat","route":"/drugs/belinostat/","asOf":"2026-09-08","days":20},{"id":"mogamulizumab","kind":"drug","name":"Mogamulizumab","route":"/drugs/mogamulizumab/","asOf":"2026-09-08","days":20},{"id":"cladribine","kind":"drug","name":"Cladribine","route":"/drugs/cladribine/","asOf":"2026-09-08","days":20},{"id":"leucovorin","kind":"drug","name":"Leucovorin (folinic acid)","route":"/drugs/leucovorin/","asOf":"2026-09-08","days":20},{"id":"capmatinib","kind":"drug","name":"Capmatinib","route":"/drugs/capmatinib/","asOf":"2026-09-08","days":20},{"id":"tepotinib","kind":"drug","name":"Tepotinib","route":"/drugs/tepotinib/","asOf":"2026-09-08","days":20},{"id":"pentostatin","kind":"drug","name":"Pentostatin","route":"/drugs/pentostatin/","asOf":"2026-09-08","days":20},{"id":"moxetumomab-pasudotox","kind":"drug","name":"Moxetumomab pasudotox","route":"/drugs/moxetumomab-pasudotox/","asOf":"2026-09-08","days":20},{"id":"interferon-alfa","kind":"drug","name":"Interferon alfa-2a/2b","route":"/drugs/interferon-alfa/","asOf":"2026-09-08","days":20},{"id":"pivekimab-sunirine","kind":"drug","name":"Pivekimab sunirine","route":"/drugs/pivekimab-sunirine/","asOf":"2026-09-08","days":20},{"id":"idelalisib","kind":"drug","name":"Idelalisib","route":"/drugs/idelalisib/","asOf":"2026-09-08","days":20},{"id":"duvelisib","kind":"drug","name":"Duvelisib","route":"/drugs/duvelisib/","asOf":"2026-09-08","days":20},{"id":"copanlisib","kind":"drug","name":"Copanlisib","route":"/drugs/copanlisib/","asOf":"2026-09-08","days":20},{"id":"umbralisib","kind":"drug","name":"Umbralisib","route":"/drugs/umbralisib/","asOf":"2026-09-08","days":20},{"id":"ixazomib","kind":"drug","name":"Ixazomib","route":"/drugs/ixazomib/","asOf":"2026-09-08","days":20},{"id":"elotuzumab","kind":"drug","name":"Elotuzumab","route":"/drugs/elotuzumab/","asOf":"2026-09-08","days":20},{"id":"pomalidomide","kind":"drug","name":"Pomalidomide","route":"/drugs/pomalidomide/","asOf":"2026-09-08","days":20},{"id":"thalidomide","kind":"drug","name":"Thalidomide","route":"/drugs/thalidomide/","asOf":"2026-09-08","days":20},{"id":"panobinostat","kind":"drug","name":"Panobinostat","route":"/drugs/panobinostat/","asOf":"2026-09-08","days":20},{"id":"asparaginase","kind":"drug","name":"Asparaginase (pegaspargase, calaspargase pegol, Erwinia asparaginase)","route":"/drugs/asparaginase/","asOf":"2026-09-08","days":20},{"id":"treosulfan","kind":"drug","name":"Treosulfan","route":"/drugs/treosulfan/","asOf":"2026-09-08","days":20},{"id":"retifanlimab","kind":"drug","name":"Retifanlimab","route":"/drugs/retifanlimab/","asOf":"2026-09-08","days":20},{"id":"penpulimab","kind":"drug","name":"Penpulimab","route":"/drugs/penpulimab/","asOf":"2026-09-08","days":20},{"id":"vismodegib","kind":"drug","name":"Vismodegib","route":"/drugs/vismodegib/","asOf":"2026-09-08","days":20},{"id":"sonidegib","kind":"drug","name":"Sonidegib","route":"/drugs/sonidegib/","asOf":"2026-09-08","days":20},{"id":"erlotinib","kind":"drug","name":"Erlotinib","route":"/drugs/erlotinib/","asOf":"2026-09-08","days":20},{"id":"gefitinib","kind":"drug","name":"Gefitinib","route":"/drugs/gefitinib/","asOf":"2026-09-08","days":20},{"id":"afatinib","kind":"drug","name":"Afatinib","route":"/drugs/afatinib/","asOf":"2026-09-08","days":20},{"id":"mobocertinib","kind":"drug","name":"Mobocertinib","route":"/drugs/mobocertinib/","asOf":"2026-09-08","days":20},{"id":"sunvozertinib","kind":"drug","name":"Sunvozertinib","route":"/drugs/sunvozertinib/","asOf":"2026-09-08","days":20},{"id":"crizotinib","kind":"drug","name":"Crizotinib","route":"/drugs/crizotinib/","asOf":"2026-09-08","days":20},{"id":"taletrectinib","kind":"drug","name":"Taletrectinib","route":"/drugs/taletrectinib/","asOf":"2026-09-08","days":20},{"id":"larotrectinib","kind":"drug","name":"Larotrectinib","route":"/drugs/larotrectinib/","asOf":"2026-09-08","days":20},{"id":"entrectinib","kind":"drug","name":"Entrectinib","route":"/drugs/entrectinib/","asOf":"2026-09-08","days":20},{"id":"temsirolimus","kind":"drug","name":"Temsirolimus","route":"/drugs/temsirolimus/","asOf":"2026-09-08","days":20},{"id":"pexidartinib","kind":"drug","name":"Pexidartinib","route":"/drugs/pexidartinib/","asOf":"2026-09-08","days":20},{"id":"sipuleucel-t","kind":"drug","name":"Sipuleucel-T","route":"/drugs/sipuleucel-t/","asOf":"2026-09-08","days":20},{"id":"aldesleukin","kind":"drug","name":"Aldesleukin (high-dose IL-2)","route":"/drugs/aldesleukin/","asOf":"2026-09-08","days":20},{"id":"leuprolide","kind":"drug","name":"Leuprolide (leuprorelin) and GnRH agonists","route":"/drugs/leuprolide/","asOf":"2026-09-08","days":20},{"id":"degarelix","kind":"drug","name":"Degarelix","route":"/drugs/degarelix/","asOf":"2026-09-08","days":20},{"id":"bicalutamide","kind":"drug","name":"Bicalutamide","route":"/drugs/bicalutamide/","asOf":"2026-09-08","days":20},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/","asOf":"2026-09-08","days":20},{"id":"vincristine","kind":"drug","name":"Vincristine","route":"/drugs/vincristine/","asOf":"2026-09-08","days":20},{"id":"vinblastine","kind":"drug","name":"Vinblastine","route":"/drugs/vinblastine/","asOf":"2026-09-08","days":20},{"id":"vinorelbine","kind":"drug","name":"Vinorelbine","route":"/drugs/vinorelbine/","asOf":"2026-09-08","days":20},{"id":"methotrexate","kind":"drug","name":"Methotrexate","route":"/drugs/methotrexate/","asOf":"2026-09-08","days":20},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/","asOf":"2026-09-08","days":20},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/","asOf":"2026-09-08","days":20},{"id":"oxaliplatin","kind":"drug","name":"Oxaliplatin","route":"/drugs/oxaliplatin/","asOf":"2026-09-08","days":20},{"id":"irinotecan","kind":"drug","name":"Irinotecan (and liposomal irinotecan)","route":"/drugs/irinotecan/","asOf":"2026-09-08","days":20},{"id":"etoposide","kind":"drug","name":"Etoposide","route":"/drugs/etoposide/","asOf":"2026-09-08","days":20},{"id":"bleomycin","kind":"drug","name":"Bleomycin","route":"/drugs/bleomycin/","asOf":"2026-09-08","days":20},{"id":"dactinomycin","kind":"drug","name":"Dactinomycin (actinomycin D)","route":"/drugs/dactinomycin/","asOf":"2026-09-08","days":20},{"id":"mitomycin","kind":"drug","name":"Mitomycin C","route":"/drugs/mitomycin/","asOf":"2026-09-08","days":20},{"id":"melphalan","kind":"drug","name":"Melphalan (including hepatic delivery system)","route":"/drugs/melphalan/","asOf":"2026-09-08","days":20},{"id":"eribulin","kind":"drug","name":"Eribulin","route":"/drugs/eribulin/","asOf":"2026-09-08","days":20},{"id":"mitotane","kind":"drug","name":"Mitotane","route":"/drugs/mitotane/","asOf":"2026-09-08","days":20},{"id":"mifamurtide","kind":"drug","name":"Mifamurtide","route":"/drugs/mifamurtide/","asOf":"2026-09-08","days":20},{"id":"sodium-thiosulfate","kind":"drug","name":"Sodium thiosulfate (otoprotectant)","route":"/drugs/sodium-thiosulfate/","asOf":"2026-09-08","days":20},{"id":"pafolacianine","kind":"drug","name":"Pafolacianine","route":"/drugs/pafolacianine/","asOf":"2026-09-08","days":20},{"id":"aminolevulinic-acid-gleolan","kind":"drug","name":"5-Aminolevulinic acid (oral, for glioma surgery)","route":"/drugs/aminolevulinic-acid-gleolan/","asOf":"2026-09-08","days":20},{"id":"fluciclovine-f18","kind":"drug","name":"Fluciclovine F-18","route":"/drugs/fluciclovine-f18/","asOf":"2026-09-08","days":20},{"id":"fluoroestradiol-f18","kind":"drug","name":"Fluoroestradiol F-18 (FES PET)","route":"/drugs/fluoroestradiol-f18/","asOf":"2026-09-08","days":20},{"id":"ga68-dotatate","kind":"drug","name":"Gallium-68 DOTATATE (and Cu-64 DOTATATE)","route":"/drugs/ga68-dotatate/","asOf":"2026-09-08","days":20},{"id":"tilmanocept-tc99m","kind":"drug","name":"Technetium-99m tilmanocept","route":"/drugs/tilmanocept-tc99m/","asOf":"2026-09-08","days":20},{"id":"eltrombopag","kind":"drug","name":"Eltrombopag","route":"/drugs/eltrombopag/","asOf":"2026-09-08","days":20},{"id":"romiplostim","kind":"drug","name":"Romiplostim","route":"/drugs/romiplostim/","asOf":"2026-09-08","days":20},{"id":"emapalumab","kind":"drug","name":"Emapalumab","route":"/drugs/emapalumab/","asOf":"2026-09-08","days":20},{"id":"fostamatinib","kind":"drug","name":"Fostamatinib","route":"/drugs/fostamatinib/","asOf":"2026-09-08","days":20},{"id":"ravulizumab","kind":"drug","name":"Ravulizumab","route":"/drugs/ravulizumab/","asOf":"2026-09-08","days":20},{"id":"propranolol-hemangeol","kind":"drug","name":"Propranolol (Hemangeol)","route":"/drugs/propranolol-hemangeol/","asOf":"2026-09-08","days":20},{"id":"raltitrexed","kind":"drug","name":"Raltitrexed","route":"/drugs/raltitrexed/","asOf":"2026-09-08","days":20},{"id":"vindesine","kind":"drug","name":"Vindesine","route":"/drugs/vindesine/","asOf":"2026-09-08","days":20},{"id":"pixantrone","kind":"drug","name":"Pixantrone","route":"/drugs/pixantrone/","asOf":"2026-09-08","days":20},{"id":"abarelix","kind":"drug","name":"Abarelix","route":"/drugs/abarelix/","asOf":"2026-09-08","days":20},{"id":"alitretinoin","kind":"drug","name":"Alitretinoin","route":"/drugs/alitretinoin/","asOf":"2026-09-08","days":20},{"id":"aminoglutethimide","kind":"drug","name":"Aminoglutethimide","route":"/drugs/aminoglutethimide/","asOf":"2026-09-08","days":20},{"id":"diethylstilbestrol","kind":"drug","name":"Diethylstilbestrol","route":"/drugs/diethylstilbestrol/","asOf":"2026-09-08","days":20},{"id":"estramustine","kind":"drug","name":"Estramustine","route":"/drugs/estramustine/","asOf":"2026-09-08","days":20},{"id":"floxuridine","kind":"drug","name":"Floxuridine","route":"/drugs/floxuridine/","asOf":"2026-09-08","days":20},{"id":"fluoxymesterone","kind":"drug","name":"Fluoxymesterone","route":"/drugs/fluoxymesterone/","asOf":"2026-09-08","days":20},{"id":"porfimer-sodium","kind":"drug","name":"Porfimer sodium","route":"/drugs/porfimer-sodium/","asOf":"2026-09-08","days":20},{"id":"sargramostim","kind":"drug","name":"Sargramostim","route":"/drugs/sargramostim/","asOf":"2026-09-08","days":20},{"id":"lenograstim","kind":"drug","name":"Lenograstim","route":"/drugs/lenograstim/","asOf":"2026-09-08","days":20},{"id":"eflapegrastim","kind":"drug","name":"Eflapegrastim","route":"/drugs/eflapegrastim/","asOf":"2026-09-08","days":20},{"id":"histrelin","kind":"drug","name":"Histrelin","route":"/drugs/histrelin/","asOf":"2026-09-08","days":20},{"id":"buserelin","kind":"drug","name":"Buserelin","route":"/drugs/buserelin/","asOf":"2026-09-08","days":20},{"id":"infigratinib","kind":"drug","name":"Infigratinib","route":"/drugs/infigratinib/","asOf":"2026-09-08","days":20},{"id":"olaratumab","kind":"drug","name":"Olaratumab","route":"/drugs/olaratumab/","asOf":"2026-09-08","days":20},{"id":"hexaminolevulinate","kind":"drug","name":"Hexaminolevulinate","route":"/drugs/hexaminolevulinate/","asOf":"2026-09-08","days":20},{"id":"peginterferon-alfa-2b","kind":"drug","name":"Peginterferon alfa-2b","route":"/drugs/peginterferon-alfa-2b/","asOf":"2026-09-08","days":20},{"id":"ethiodized-oil","kind":"drug","name":"Ethiodized oil","route":"/drugs/ethiodized-oil/","asOf":"2026-09-08","days":20},{"id":"technetium-sulfur-colloid","kind":"drug","name":"Technetium Tc-99m sulfur colloid","route":"/drugs/technetium-sulfur-colloid/","asOf":"2026-09-08","days":20},{"id":"choline-c11","kind":"drug","name":"Choline C-11","route":"/drugs/choline-c11/","asOf":"2026-09-08","days":20},{"id":"streptozocin","kind":"drug","name":"Streptozocin","route":"/drugs/streptozocin/","asOf":"2026-09-08","days":20},{"id":"olmutinib","kind":"drug","name":"Olmutinib","route":"/drugs/olmutinib/","asOf":"2026-09-08","days":20},{"id":"methyl-aminolevulinate","kind":"drug","name":"Methyl aminolevulinate","route":"/drugs/methyl-aminolevulinate/","asOf":"2026-09-08","days":20},{"id":"trilaciclib","kind":"drug","name":"Trilaciclib","route":"/drugs/trilaciclib/","asOf":"2026-09-08","days":20},{"id":"teniposide","kind":"drug","name":"Teniposide","route":"/drugs/teniposide/","asOf":"2026-09-08","days":20},{"id":"altretamine","kind":"drug","name":"Altretamine","route":"/drugs/altretamine/","asOf":"2026-09-08","days":20},{"id":"plicamycin","kind":"drug","name":"Plicamycin","route":"/drugs/plicamycin/","asOf":"2026-09-08","days":20},{"id":"formestane","kind":"drug","name":"Formestane","route":"/drugs/formestane/","asOf":"2026-09-08","days":20},{"id":"amsacrine","kind":"drug","name":"Amsacrine","route":"/drugs/amsacrine/","asOf":"2026-09-08","days":20},{"id":"uracil-mustard","kind":"drug","name":"Uracil mustard","route":"/drugs/uracil-mustard/","asOf":"2026-09-08","days":20},{"id":"mitobronitol","kind":"drug","name":"Mitobronitol","route":"/drugs/mitobronitol/","asOf":"2026-09-08","days":20},{"id":"pipobroman","kind":"drug","name":"Pipobroman","route":"/drugs/pipobroman/","asOf":"2026-09-08","days":20},{"id":"oprelvekin","kind":"drug","name":"Oprelvekin","route":"/drugs/oprelvekin/","asOf":"2026-09-08","days":20},{"id":"motixafortide","kind":"drug","name":"Motixafortide","route":"/drugs/motixafortide/","asOf":"2026-09-08","days":20},{"id":"dronabinol","kind":"drug","name":"Dronabinol","route":"/drugs/dronabinol/","asOf":"2026-09-08","days":20},{"id":"nabilone","kind":"drug","name":"Nabilone","route":"/drugs/nabilone/","asOf":"2026-09-08","days":20},{"id":"dolasetron","kind":"drug","name":"Dolasetron","route":"/drugs/dolasetron/","asOf":"2026-09-08","days":20},{"id":"methoxsalen-ecp","kind":"drug","name":"Methoxsalen (extracorporeal photopheresis)","route":"/drugs/methoxsalen-ecp/","asOf":"2026-09-08","days":20},{"id":"cinacalcet","kind":"drug","name":"Cinacalcet","route":"/drugs/cinacalcet/","asOf":"2026-09-08","days":20},{"id":"nedaplatin","kind":"drug","name":"Nedaplatin","route":"/drugs/nedaplatin/","asOf":"2026-09-08","days":20},{"id":"doxifluridine","kind":"drug","name":"Doxifluridine","route":"/drugs/doxifluridine/","asOf":"2026-09-08","days":20},{"id":"nimotuzumab","kind":"drug","name":"Nimotuzumab","route":"/drugs/nimotuzumab/","asOf":"2026-09-08","days":20},{"id":"plitidepsin","kind":"drug","name":"Plitidepsin","route":"/drugs/plitidepsin/","asOf":"2026-09-08","days":20},{"id":"aldoxorubicin","kind":"drug","name":"Aldoxorubicin","route":"/drugs/aldoxorubicin/","asOf":"2026-09-08","days":20},{"id":"anetumab-ravtansine","kind":"drug","name":"Anetumab ravtansine","route":"/drugs/anetumab-ravtansine/","asOf":"2026-09-08","days":20},{"id":"zen-3694","kind":"drug","name":"ZEN-3694","route":"/drugs/zen-3694/","asOf":"2026-09-08","days":20},{"id":"jak2","kind":"target","name":"JAK2","route":"/targets/jak2/","asOf":"2026-09-08","days":20},{"id":"cd79b","kind":"target","name":"CD79b","route":"/targets/cd79b/","asOf":"2026-09-08","days":20},{"id":"cxcr4","kind":"target","name":"CXCR4","route":"/targets/cxcr4/","asOf":"2026-09-08","days":20},{"id":"ccr4","kind":"target","name":"CCR4","route":"/targets/ccr4/","asOf":"2026-09-08","days":20},{"id":"tim3","kind":"target","name":"TIM-3","route":"/targets/tim3/","asOf":"2026-09-08","days":20},{"id":"smoothened","kind":"target","name":"Smoothened (hedgehog pathway)","route":"/targets/smoothened/","asOf":"2026-09-08","days":20},{"id":"pdgfra","kind":"target","name":"PDGFRA","route":"/targets/pdgfra/","asOf":"2026-09-08","days":20},{"id":"csf1r","kind":"target","name":"CSF1R","route":"/targets/csf1r/","asOf":"2026-09-08","days":20},{"id":"ewsr1-fli1","kind":"target","name":"EWSR1-FLI1 fusion","route":"/targets/ewsr1-fli1/","asOf":"2026-09-08","days":20},{"id":"epcam","kind":"target","name":"EpCAM","route":"/targets/epcam/","asOf":"2026-09-08","days":20},{"id":"cldn6","kind":"target","name":"Claudin 6","route":"/targets/cldn6/","asOf":"2026-09-08","days":20},{"id":"cd73-adenosine","kind":"target","name":"CD73 / adenosine axis","route":"/targets/cd73-adenosine/","asOf":"2026-09-08","days":20},{"id":"vista","kind":"target","name":"VISTA","route":"/targets/vista/","asOf":"2026-09-08","days":20},{"id":"liv1","kind":"target","name":"LIV-1 (SLC39A6)","route":"/targets/liv1/","asOf":"2026-09-08","days":20},{"id":"mdm2","kind":"target","name":"MDM2","route":"/targets/mdm2/","asOf":"2026-09-08","days":20},{"id":"prmt5-mtap","kind":"target","name":"PRMT5 (MTAP-deleted cancers)","route":"/targets/prmt5-mtap/","asOf":"2026-09-08","days":20},{"id":"wrn","kind":"target","name":"WRN helicase (MSI-high cancers)","route":"/targets/wrn/","asOf":"2026-09-08","days":20},{"id":"cd52","kind":"target","name":"CD52","route":"/targets/cd52/","asOf":"2026-09-08","days":20},{"id":"cd7","kind":"target","name":"CD7","route":"/targets/cd7/","asOf":"2026-09-08","days":20},{"id":"palliative-care","kind":"technology","name":"Early integrated palliative care","route":"/technologies/palliative-care/","asOf":"2026-09-08","days":20},{"id":"hospice-end-of-life","kind":"technology","name":"Hospice and end-of-life care","route":"/technologies/hospice-end-of-life/","asOf":"2026-09-08","days":20},{"id":"pain-management","kind":"technology","name":"Cancer pain management","route":"/technologies/pain-management/","asOf":"2026-09-08","days":20},{"id":"palliative-radiotherapy","kind":"technology","name":"Palliative radiotherapy","route":"/technologies/palliative-radiotherapy/","asOf":"2026-09-08","days":20},{"id":"psycho-oncology","kind":"technology","name":"Psycho-oncology and distress screening","route":"/technologies/psycho-oncology/","asOf":"2026-09-08","days":20},{"id":"oncology-nutrition","kind":"technology","name":"Nutrition support and cachexia management","route":"/technologies/oncology-nutrition/","asOf":"2026-09-08","days":20},{"id":"prehabilitation","kind":"technology","name":"Prehabilitation before cancer surgery","route":"/technologies/prehabilitation/","asOf":"2026-09-08","days":20},{"id":"financial-navigation","kind":"technology","name":"Financial toxicity and financial navigation","route":"/technologies/financial-navigation/","asOf":"2026-09-08","days":20},{"id":"survivorship-care-plan","kind":"technology","name":"Survivorship care and late-effects surveillance","route":"/technologies/survivorship-care-plan/","asOf":"2026-09-08","days":20},{"id":"fertility-preservation","kind":"technology","name":"Oncofertility and fertility preservation","route":"/technologies/fertility-preservation/","asOf":"2026-09-08","days":20},{"id":"oncology-nursing","kind":"technology","name":"Oncology nursing and nurse-led care","route":"/technologies/oncology-nursing/","asOf":"2026-09-08","days":20},{"id":"integrative-oncology","kind":"technology","name":"Evidence-based integrative oncology","route":"/technologies/integrative-oncology/","asOf":"2026-09-08","days":20},{"id":"antiemetic-therapy","kind":"technology","name":"Antiemetics for chemotherapy-induced nausea and vomiting","route":"/technologies/antiemetic-therapy/","asOf":"2026-09-08","days":20},{"id":"bone-modifying-agents","kind":"technology","name":"Bone-modifying agents (bisphosphonates, denosumab)","route":"/technologies/bone-modifying-agents/","asOf":"2026-09-08","days":20},{"id":"g-csf-growth-factors","kind":"technology","name":"Growth factors: G-CSF and febrile neutropenia prevention","route":"/technologies/g-csf-growth-factors/","asOf":"2026-09-08","days":20},{"id":"transfusion-support","kind":"technology","name":"Transfusion support and anaemia management","route":"/technologies/transfusion-support/","asOf":"2026-09-08","days":20},{"id":"cancer-associated-thrombosis","kind":"technology","name":"Cancer-associated thrombosis prevention and treatment","route":"/technologies/cancer-associated-thrombosis/","asOf":"2026-09-08","days":20},{"id":"epro-symptom-monitoring","kind":"technology","name":"Electronic patient-reported outcome (ePRO) symptom monitoring","route":"/technologies/epro-symptom-monitoring/","asOf":"2026-09-08","days":20},{"id":"multidisciplinary-tumour-board","kind":"technology","name":"Multidisciplinary tumour boards","route":"/technologies/multidisciplinary-tumour-board/","asOf":"2026-09-08","days":20},{"id":"telehealth-oncology","kind":"technology","name":"Telehealth and hospital-at-home in oncology","route":"/technologies/telehealth-oncology/","asOf":"2026-09-08","days":20},{"id":"electrochemotherapy","kind":"technology","name":"Electrochemotherapy","route":"/technologies/electrochemotherapy/","asOf":"2026-09-08","days":20},{"id":"isolated-limb-perfusion","kind":"technology","name":"Isolated limb perfusion and infusion","route":"/technologies/isolated-limb-perfusion/","asOf":"2026-09-08","days":20},{"id":"percutaneous-hepatic-perfusion","kind":"technology","name":"Percutaneous hepatic perfusion (chemosaturation)","route":"/technologies/percutaneous-hepatic-perfusion/","asOf":"2026-09-08","days":20},{"id":"intraoperative-radiotherapy","kind":"technology","name":"Intraoperative radiotherapy (IORT)","route":"/technologies/intraoperative-radiotherapy/","asOf":"2026-09-08","days":20},{"id":"global-oncology-access","kind":"technology","name":"Global oncology and access in low- and middle-income countries","route":"/technologies/global-oncology-access/","asOf":"2026-09-08","days":20},{"id":"rare-cancers","kind":"term","name":"Rare cancers","route":"/terms/rare-cancers/","asOf":"2026-09-08","days":20},{"id":"cancer-health-disparities","kind":"term","name":"Cancer health disparities and equity","route":"/terms/cancer-health-disparities/","asOf":"2026-09-08","days":20},{"id":"aya-oncology","kind":"term","name":"Adolescent and young adult (AYA) oncology","route":"/terms/aya-oncology/","asOf":"2026-09-08","days":20},{"id":"cancer-in-pregnancy","kind":"term","name":"Cancer during pregnancy","route":"/terms/cancer-in-pregnancy/","asOf":"2026-09-08","days":20},{"id":"hereditary-cancer-syndromes","kind":"term","name":"Hereditary cancer syndromes","route":"/terms/hereditary-cancer-syndromes/","asOf":"2026-09-08","days":20},{"id":"li-fraumeni","kind":"term","name":"Li-Fraumeni syndrome (germline TP53)","route":"/terms/li-fraumeni/","asOf":"2026-09-08","days":20},{"id":"vhl-disease","kind":"term","name":"Von Hippel-Lindau disease","route":"/terms/vhl-disease/","asOf":"2026-09-08","days":20},{"id":"drug-price-transparency","kind":"term","name":"Oncology drug pricing and price transparency","route":"/terms/drug-price-transparency/","asOf":"2026-09-08","days":20},{"id":"financial-toxicity","kind":"term","name":"Financial toxicity","route":"/terms/financial-toxicity/","asOf":"2026-09-08","days":20},{"id":"oncology-workforce","kind":"term","name":"Oncology workforce","route":"/terms/oncology-workforce/","asOf":"2026-09-08","days":20},{"id":"who-essential-medicines","kind":"term","name":"WHO Essential Medicines List for cancer","route":"/terms/who-essential-medicines/","asOf":"2026-09-08","days":20},{"id":"plasma-ebv-dna","kind":"term","name":"Plasma EBV DNA","route":"/terms/plasma-ebv-dna/","asOf":"2026-09-08","days":20},{"id":"nice-guidance","kind":"collection","name":"NICE cancer guidance and technology appraisals (UK)","route":"/collections/nice-guidance/","asOf":"2026-09-08","days":20},{"id":"asco-guidelines","kind":"collection","name":"ASCO clinical practice guidelines","route":"/collections/asco-guidelines/","asOf":"2026-09-08","days":20},{"id":"csco-guidelines","kind":"collection","name":"CSCO guidelines (China)","route":"/collections/csco-guidelines/","asOf":"2026-09-08","days":20},{"id":"jsmo-jsco-guidelines","kind":"collection","name":"Japanese oncology guidelines (JSMO, JSCO and organ societies)","route":"/collections/jsmo-jsco-guidelines/","asOf":"2026-09-08","days":20},{"id":"american-cancer-society","kind":"collection","name":"American Cancer Society (ACS)","route":"/collections/american-cancer-society/","asOf":"2026-09-08","days":20},{"id":"leukemia-lymphoma-society","kind":"collection","name":"Leukemia & Lymphoma Society (LLS)","route":"/collections/leukemia-lymphoma-society/","asOf":"2026-09-08","days":20},{"id":"pancan","kind":"collection","name":"Pancreatic Cancer Action Network (PanCAN)","route":"/collections/pancan/","asOf":"2026-09-08","days":20},{"id":"mmrf","kind":"collection","name":"Multiple Myeloma Research Foundation (MMRF)","route":"/collections/mmrf/","asOf":"2026-09-08","days":20},{"id":"lymphoma-research-foundation","kind":"collection","name":"Lymphoma Research Foundation (LRF)","route":"/collections/lymphoma-research-foundation/","asOf":"2026-09-08","days":20},{"id":"national-brain-tumor-society","kind":"collection","name":"National Brain Tumor Society (NBTS)","route":"/collections/national-brain-tumor-society/","asOf":"2026-09-08","days":20},{"id":"alexs-lemonade-stand","kind":"collection","name":"Alex's Lemonade Stand Foundation (ALSF)","route":"/collections/alexs-lemonade-stand/","asOf":"2026-09-08","days":20},{"id":"st-baldricks","kind":"collection","name":"St. Baldrick's Foundation","route":"/collections/st-baldricks/","asOf":"2026-09-08","days":20},{"id":"colorectal-cancer-alliance","kind":"collection","name":"Colorectal Cancer Alliance","route":"/collections/colorectal-cancer-alliance/","asOf":"2026-09-08","days":20},{"id":"lungevity","kind":"collection","name":"LUNGevity Foundation (and GO2 for Lung Cancer)","route":"/collections/lungevity/","asOf":"2026-09-08","days":20},{"id":"melanoma-research-alliance","kind":"collection","name":"Melanoma Research Alliance (MRA)","route":"/collections/melanoma-research-alliance/","asOf":"2026-09-08","days":20},{"id":"ovarian-cancer-research-alliance","kind":"collection","name":"Ovarian Cancer Research Alliance (OCRA)","route":"/collections/ovarian-cancer-research-alliance/","asOf":"2026-09-08","days":20},{"id":"susan-g-komen","kind":"collection","name":"Susan G. Komen","route":"/collections/susan-g-komen/","asOf":"2026-09-08","days":20},{"id":"prostate-cancer-foundation","kind":"collection","name":"Prostate Cancer Foundation (PCF)","route":"/collections/prostate-cancer-foundation/","asOf":"2026-09-08","days":20},{"id":"paper-keynote-522-nejm-2022","kind":"paper","name":"KEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer","route":"/key-papers/paper-keynote-522-nejm-2022/","asOf":"2026-09-08","days":20},{"id":"paper-destiny-breast03-nejm-2022","kind":"paper","name":"DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer","route":"/key-papers/paper-destiny-breast03-nejm-2022/","asOf":"2026-09-08","days":20},{"id":"paper-destiny-breast04-nejm-2022","kind":"paper","name":"DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group","route":"/key-papers/paper-destiny-breast04-nejm-2022/","asOf":"2026-09-08","days":20},{"id":"paper-destiny-breast06-nejm-2024","kind":"paper","name":"DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer","route":"/key-papers/paper-destiny-breast06-nejm-2024/","asOf":"2026-09-08","days":20},{"id":"paper-monarche-jco-2020","kind":"paper","name":"monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer","route":"/key-papers/paper-monarche-jco-2020/","asOf":"2026-09-08","days":20},{"id":"paper-natalee-nejm-2024","kind":"paper","name":"NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer","route":"/key-papers/paper-natalee-nejm-2024/","asOf":"2026-09-08","days":20},{"id":"paper-olympia-nejm-2021","kind":"paper","name":"OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer","route":"/key-papers/paper-olympia-nejm-2021/","asOf":"2026-09-08","days":20},{"id":"paper-katherine-nejm-2019","kind":"paper","name":"KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment","route":"/key-papers/paper-katherine-nejm-2019/","asOf":"2026-09-08","days":20},{"id":"paper-tropion-breast01-jco-2024","kind":"paper","name":"TROPION-Breast01: datopotamab deruxtecan versus chemotherapy in pretreated hormone-receptor-positive breast cancer, and why a PFS win did not translate to survival","route":"/key-papers/paper-tropion-breast01-jco-2024/","asOf":"2026-09-08","days":20},{"id":"paper-ascent-nejm-2021","kind":"paper","name":"ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer","route":"/key-papers/paper-ascent-nejm-2021/","asOf":"2026-09-08","days":20},{"id":"paper-flaura-nejm-2018","kind":"paper","name":"FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer","route":"/key-papers/paper-flaura-nejm-2018/","asOf":"2026-09-08","days":20},{"id":"paper-mariposa-nejm-2024","kind":"paper","name":"MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer","route":"/key-papers/paper-mariposa-nejm-2024/","asOf":"2026-09-08","days":20},{"id":"paper-adaura-nejm-2020","kind":"paper","name":"ADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancer","route":"/key-papers/paper-adaura-nejm-2020/","asOf":"2026-09-08","days":20},{"id":"paper-keynote-189-nejm-2018","kind":"paper","name":"KEYNOTE-189: pembrolizumab plus chemotherapy as first treatment for non-squamous lung cancer without a driver mutation","route":"/key-papers/paper-keynote-189-nejm-2018/","asOf":"2026-09-08","days":20},{"id":"paper-checkmate-816-nejm-2022","kind":"paper","name":"CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery","route":"/key-papers/paper-checkmate-816-nejm-2022/","asOf":"2026-09-08","days":20},{"id":"paper-pacific-nejm-2017","kind":"paper","name":"PACIFIC: a year of durvalumab after chemoradiotherapy for stage III lung cancer","route":"/key-papers/paper-pacific-nejm-2017/","asOf":"2026-09-08","days":20},{"id":"paper-adriatic-nejm-2024","kind":"paper","name":"ADRIATIC: durvalumab after chemoradiotherapy for limited-stage small-cell lung cancer","route":"/key-papers/paper-adriatic-nejm-2024/","asOf":"2026-09-08","days":20},{"id":"paper-dellphi-301-nejm-2023","kind":"paper","name":"DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer","route":"/key-papers/paper-dellphi-301-nejm-2023/","asOf":"2026-09-08","days":20},{"id":"paper-codebreak-200-lancet-2023","kind":"paper","name":"CodeBreaK 200: sotorasib versus docetaxel in KRAS G12C-mutated lung cancer, a modest win for the first KRAS drug","route":"/key-papers/paper-codebreak-200-lancet-2023/","asOf":"2026-09-08","days":20},{"id":"paper-harmoni-2-lancet-2025","kind":"paper","name":"HARMONi-2: ivonescimab, a PD-1 x VEGF bispecific, beats pembrolizumab head-to-head in PD-L1-positive lung cancer","route":"/key-papers/paper-harmoni-2-lancet-2025/","asOf":"2026-09-08","days":20},{"id":"paper-napoli-3-lancet-2023","kind":"paper","name":"NAPOLI-3: NALIRIFOX versus gemcitabine plus nab-paclitaxel as first treatment for metastatic pancreatic cancer","route":"/key-papers/paper-napoli-3-lancet-2023/","asOf":"2026-09-08","days":20},{"id":"paper-spotlight-lancet-2023","kind":"paper","name":"SPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer","route":"/key-papers/paper-spotlight-lancet-2023/","asOf":"2026-09-08","days":20},{"id":"paper-checkmate-649-lancet-2021","kind":"paper","name":"CheckMate 649: nivolumab plus chemotherapy as first treatment for advanced gastric, gastro-oesophageal junction and oesophageal adenocarcinoma","route":"/key-papers/paper-checkmate-649-lancet-2021/","asOf":"2026-09-08","days":20},{"id":"paper-imbrave150-nejm-2020","kind":"paper","name":"IMbrave150: atezolizumab plus bevacizumab replaces sorafenib as first treatment for advanced liver cancer","route":"/key-papers/paper-imbrave150-nejm-2020/","asOf":"2026-09-08","days":20},{"id":"paper-keynote-177-nejm-2020","kind":"paper","name":"KEYNOTE-177: pembrolizumab instead of chemotherapy as first treatment for mismatch-repair-deficient metastatic colorectal cancer","route":"/key-papers/paper-keynote-177-nejm-2020/","asOf":"2026-09-08","days":20},{"id":"paper-breakwater-nejm-2025","kind":"paper","name":"BREAKWATER: encorafenib plus cetuximab with chemotherapy as first treatment for BRAF V600E-mutated colorectal cancer","route":"/key-papers/paper-breakwater-nejm-2025/","asOf":"2026-09-08","days":20},{"id":"paper-codebreak-300-nejm-2023","kind":"paper","name":"CodeBreaK 300: sotorasib plus panitumumab in chemotherapy-refractory KRAS G12C colorectal cancer","route":"/key-papers/paper-codebreak-300-nejm-2023/","asOf":"2026-09-08","days":20},{"id":"paper-niche-2-nejm-2024","kind":"paper","name":"NICHE-2: a month of nivolumab and ipilimumab before surgery clears mismatch-repair-deficient colon cancer in most patients","route":"/key-papers/paper-niche-2-nejm-2024/","asOf":"2026-09-08","days":20},{"id":"paper-vision-nejm-2021","kind":"paper","name":"VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer","route":"/key-papers/paper-vision-nejm-2021/","asOf":"2026-09-08","days":20},{"id":"paper-stampede-abiraterone-nejm-2017","kind":"paper","name":"STAMPEDE: adding abiraterone to hormone therapy at diagnosis of advanced prostate cancer","route":"/key-papers/paper-stampede-abiraterone-nejm-2017/","asOf":"2026-09-08","days":20},{"id":"paper-ev-302-nejm-2024","kind":"paper","name":"EV-302: enfortumab vedotin plus pembrolizumab replaces chemotherapy as first treatment for advanced bladder cancer","route":"/key-papers/paper-ev-302-nejm-2024/","asOf":"2026-09-08","days":20},{"id":"paper-niagara-nejm-2024","kind":"paper","name":"NIAGARA: durvalumab before and after cystectomy for muscle-invasive bladder cancer","route":"/key-papers/paper-niagara-nejm-2024/","asOf":"2026-09-08","days":20},{"id":"paper-clear-nejm-2021","kind":"paper","name":"CLEAR: lenvatinib plus pembrolizumab versus sunitinib as first treatment for advanced kidney cancer","route":"/key-papers/paper-clear-nejm-2021/","asOf":"2026-09-08","days":20},{"id":"paper-keynote-564-nejm-2021","kind":"paper","name":"KEYNOTE-564: a year of pembrolizumab after kidney cancer surgery","route":"/key-papers/paper-keynote-564-nejm-2021/","asOf":"2026-09-08","days":20},{"id":"paper-sunrise-1-jco-2025","kind":"paper","name":"SunRISe-1: TAR-200, a gemcitabine-releasing device placed in the bladder, for BCG-unresponsive non-muscle-invasive bladder cancer","route":"/key-papers/paper-sunrise-1-jco-2025/","asOf":"2026-09-08","days":20},{"id":"paper-paola-1-nejm-2019","kind":"paper","name":"PAOLA-1: olaparib added to bevacizumab maintenance in newly diagnosed ovarian cancer, with benefit confined to HRD-positive tumours","route":"/key-papers/paper-paola-1-nejm-2019/","asOf":"2026-09-08","days":20},{"id":"paper-solo-1-nejm-2018","kind":"paper","name":"SOLO-1: two years of olaparib maintenance after first-line chemotherapy for BRCA-mutated ovarian cancer","route":"/key-papers/paper-solo-1-nejm-2018/","asOf":"2026-09-08","days":20},{"id":"paper-keynote-a18-pfs-lancet-2024","kind":"paper","name":"KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer (progression-free survival)","route":"/key-papers/paper-keynote-a18-pfs-lancet-2024/","asOf":"2026-09-08","days":20},{"id":"paper-keynote-a18-os-lancet-2024","kind":"paper","name":"KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer (overall survival)","route":"/key-papers/paper-keynote-a18-os-lancet-2024/","asOf":"2026-09-08","days":20},{"id":"paper-ruby-nejm-2023","kind":"paper","name":"RUBY: dostarlimab with chemotherapy for advanced or recurrent endometrial cancer","route":"/key-papers/paper-ruby-nejm-2023/","asOf":"2026-09-08","days":20},{"id":"paper-checkmate-067-10-year-nejm-2025","kind":"paper","name":"CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma","route":"/key-papers/paper-checkmate-067-10-year-nejm-2025/","asOf":"2026-09-08","days":20},{"id":"paper-nadina-nejm-2024","kind":"paper","name":"NADINA: two doses of ipilimumab plus nivolumab before surgery beat a year of nivolumab after surgery in stage III melanoma","route":"/key-papers/paper-nadina-nejm-2024/","asOf":"2026-09-08","days":20},{"id":"paper-relativity-047-nejm-2022","kind":"paper","name":"RELATIVITY-047: relatlimab plus nivolumab, the first LAG-3 checkpoint combination, in untreated advanced melanoma","route":"/key-papers/paper-relativity-047-nejm-2022/","asOf":"2026-09-08","days":20},{"id":"paper-keynote-942-lancet-2024","kind":"paper","name":"KEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery","route":"/key-papers/paper-keynote-942-lancet-2024/","asOf":"2026-09-08","days":20},{"id":"paper-indigo-nejm-2023","kind":"paper","name":"INDIGO: vorasidenib, the first targeted drug for IDH-mutant low-grade glioma","route":"/key-papers/paper-indigo-nejm-2023/","asOf":"2026-09-08","days":20},{"id":"paper-stupp-temozolomide-nejm-2005","kind":"paper","name":"Stupp 2005: temozolomide added to radiotherapy for newly diagnosed glioblastoma","route":"/key-papers/paper-stupp-temozolomide-nejm-2005/","asOf":"2026-09-08","days":20},{"id":"paper-netter-2-lancet-2024","kind":"paper","name":"NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours","route":"/key-papers/paper-netter-2-lancet-2024/","asOf":"2026-09-08","days":20},{"id":"paper-spearhead-1-lancet-2024","kind":"paper","name":"SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma","route":"/key-papers/paper-spearhead-1-lancet-2024/","asOf":"2026-09-08","days":20},{"id":"paper-keynote-048-lancet-2019","kind":"paper","name":"KEYNOTE-048: pembrolizumab, alone or with chemotherapy, as first treatment for recurrent or metastatic head and neck cancer","route":"/key-papers/paper-keynote-048-lancet-2019/","asOf":"2026-09-08","days":20},{"id":"paper-slamon-trastuzumab-nejm-2001","kind":"paper","name":"Slamon 2001: adding trastuzumab to chemotherapy for HER2-positive metastatic breast cancer","route":"/key-papers/paper-slamon-trastuzumab-nejm-2001/","asOf":"2026-09-08","days":20},{"id":"paper-hurwitz-bevacizumab-crc-nejm-2004","kind":"paper","name":"Hurwitz 2004: bevacizumab with chemotherapy for metastatic colorectal cancer, the first anti-angiogenic drug to extend life","route":"/key-papers/paper-hurwitz-bevacizumab-crc-nejm-2004/","asOf":"2026-09-08","days":20},{"id":"paper-keynote-024-nejm-2016","kind":"paper","name":"KEYNOTE-024: pembrolizumab alone beats chemotherapy in PD-L1-high lung cancer","route":"/key-papers/paper-keynote-024-nejm-2016/","asOf":"2026-09-08","days":20},{"id":"paper-checkmate-057-nejm-2015","kind":"paper","name":"CheckMate 057: nivolumab beats docetaxel after chemotherapy in non-squamous lung cancer","route":"/key-papers/paper-checkmate-057-nejm-2015/","asOf":"2026-09-08","days":20},{"id":"paper-checkmate-017-nejm-2015","kind":"paper","name":"CheckMate 017: nivolumab beats docetaxel in squamous lung cancer after chemotherapy","route":"/key-papers/paper-checkmate-017-nejm-2015/","asOf":"2026-09-08","days":20},{"id":"paper-conroy-folfirinox-pancreatic-nejm-2011","kind":"paper","name":"Conroy 2011: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer (PRODIGE 4/ACCORD 11)","route":"/key-papers/paper-conroy-folfirinox-pancreatic-nejm-2011/","asOf":"2026-09-08","days":20},{"id":"paper-mpact-nab-paclitaxel-gemcitabine-nejm-2013","kind":"paper","name":"MPACT (Von Hoff 2013): nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer","route":"/key-papers/paper-mpact-nab-paclitaxel-gemcitabine-nejm-2013/","asOf":"2026-09-08","days":20},{"id":"paper-keynote-001-pembrolizumab-nsclc-nejm-2015","kind":"paper","name":"KEYNOTE-001 (Garon 2015): pembrolizumab in non-small-cell lung cancer and the 50% PD-L1 cut-off","route":"/key-papers/paper-keynote-001-pembrolizumab-nsclc-nejm-2015/","asOf":"2026-09-08","days":20},{"id":"paper-keynote-010-lancet-2016","kind":"paper","name":"KEYNOTE-010 (Herbst 2016): pembrolizumab versus docetaxel in previously treated PD-L1-positive lung cancer","route":"/key-papers/paper-keynote-010-lancet-2016/","asOf":"2026-09-08","days":20},{"id":"paper-keynote-006-pembrolizumab-ipilimumab-melanoma-nejm-2015","kind":"paper","name":"KEYNOTE-006 (Robert 2015): pembrolizumab versus ipilimumab in advanced melanoma","route":"/key-papers/paper-keynote-006-pembrolizumab-ipilimumab-melanoma-nejm-2015/","asOf":"2026-09-08","days":20},{"id":"paper-sauer-preoperative-chemoradiotherapy-rectal-nejm-2004","kind":"paper","name":"Sauer 2004: chemoradiotherapy before rather than after surgery for rectal cancer (CAO/ARO/AIO-94)","route":"/key-papers/paper-sauer-preoperative-chemoradiotherapy-rectal-nejm-2004/","asOf":"2026-09-08","days":20},{"id":"paper-burris-gemcitabine-pancreatic-jco-1997","kind":"paper","name":"Burris 1997: gemcitabine becomes the first standard treatment for advanced pancreatic cancer","route":"/key-papers/paper-burris-gemcitabine-pancreatic-jco-1997/","asOf":"2026-09-08","days":20},{"id":"paper-toga-trastuzumab-gastric-lancet-2010","kind":"paper","name":"ToGA (Bang 2010): trastuzumab with chemotherapy for HER2-positive advanced gastric cancer","route":"/key-papers/paper-toga-trastuzumab-gastric-lancet-2010/","asOf":"2026-09-08","days":20},{"id":"paper-druker-imatinib-phase1-nejm-2001","kind":"paper","name":"First imatinib trial: a pill that switched off the enzyme driving chronic myeloid leukaemia","route":"/key-papers/paper-druker-imatinib-phase1-nejm-2001/","asOf":"2026-09-08","days":20},{"id":"paper-iris-imatinib-nejm-2003","kind":"paper","name":"IRIS: imatinib versus interferon plus cytarabine as first treatment for chronic myeloid leukaemia","route":"/key-papers/paper-iris-imatinib-nejm-2003/","asOf":"2026-09-08","days":20},{"id":"paper-cll14-venetoclax-obinutuzumab-nejm-2019","kind":"paper","name":"CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients","route":"/key-papers/paper-cll14-venetoclax-obinutuzumab-nejm-2019/","asOf":"2026-09-08","days":20},{"id":"paper-elevate-tn-acalabrutinib-lancet-2020","kind":"paper","name":"ELEVATE-TN: acalabrutinib, alone or with obinutuzumab, against chemo-immunotherapy in untreated CLL","route":"/key-papers/paper-elevate-tn-acalabrutinib-lancet-2020/","asOf":"2026-09-08","days":20},{"id":"paper-amplify-acalabrutinib-venetoclax-nejm-2025","kind":"paper","name":"AMPLIFY: fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, versus chemo-immunotherapy in fit CLL patients","route":"/key-papers/paper-amplify-acalabrutinib-venetoclax-nejm-2025/","asOf":"2026-09-08","days":20},{"id":"paper-murano-venetoclax-rituximab-nejm-2018","kind":"paper","name":"MURANO: two years of venetoclax plus rituximab versus chemo-immunotherapy in relapsed CLL","route":"/key-papers/paper-murano-venetoclax-rituximab-nejm-2018/","asOf":"2026-09-08","days":20},{"id":"paper-maia-daratumumab-rd-nejm-2019","kind":"paper","name":"MAIA: adding daratumumab to lenalidomide-dexamethasone for older patients with newly diagnosed myeloma who cannot have a transplant","route":"/key-papers/paper-maia-daratumumab-rd-nejm-2019/","asOf":"2026-09-08","days":20},{"id":"paper-perseus-dara-vrd-transplant-nejm-2024","kind":"paper","name":"PERSEUS: daratumumab added to bortezomib-lenalidomide-dexamethasone around autologous transplant in newly diagnosed myeloma","route":"/key-papers/paper-perseus-dara-vrd-transplant-nejm-2024/","asOf":"2026-09-08","days":20},{"id":"paper-cepheus-dara-vrd-natmed-2025","kind":"paper","name":"CEPHEUS: daratumumab quadruplet for newly diagnosed myeloma patients not having a transplant, with MRD-negativity as the main endpoint","route":"/key-papers/paper-cepheus-dara-vrd-natmed-2025/","asOf":"2026-09-08","days":20},{"id":"paper-cartitude-1-cilta-cel-lancet-2021","kind":"paper","name":"CARTITUDE-1: cilta-cel, a BCMA CAR-T, in heavily pretreated myeloma","route":"/key-papers/paper-cartitude-1-cilta-cel-lancet-2021/","asOf":"2026-09-08","days":20},{"id":"paper-cartitude-4-cilta-cel-nejm-2023","kind":"paper","name":"CARTITUDE-4: cilta-cel CAR-T versus standard combinations after one to three prior lines of myeloma therapy","route":"/key-papers/paper-cartitude-4-cilta-cel-nejm-2023/","asOf":"2026-09-08","days":20},{"id":"paper-karmma-3-ide-cel-nejm-2023","kind":"paper","name":"KarMMa-3: ide-cel CAR-T versus standard regimens in triple-class-exposed relapsed myeloma","route":"/key-papers/paper-karmma-3-ide-cel-nejm-2023/","asOf":"2026-09-08","days":20},{"id":"paper-majestec-1-teclistamab-nejm-2022","kind":"paper","name":"MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma","route":"/key-papers/paper-majestec-1-teclistamab-nejm-2022/","asOf":"2026-09-08","days":20},{"id":"paper-magnetismm-3-elranatamab-natmed-2023","kind":"paper","name":"MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response","route":"/key-papers/paper-magnetismm-3-elranatamab-natmed-2023/","asOf":"2026-09-08","days":20},{"id":"paper-zuma-7-axi-cel-second-line-nejm-2022","kind":"paper","name":"ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early","route":"/key-papers/paper-zuma-7-axi-cel-second-line-nejm-2022/","asOf":"2026-09-08","days":20},{"id":"paper-transform-liso-cel-lancet-2022","kind":"paper","name":"TRANSFORM: liso-cel CAR-T versus salvage chemotherapy and transplant in early-relapsing large B-cell lymphoma","route":"/key-papers/paper-transform-liso-cel-lancet-2022/","asOf":"2026-09-08","days":20},{"id":"paper-polarix-polatuzumab-rchp-nejm-2022","kind":"paper","name":"POLARIX: swapping vincristine for the antibody-drug conjugate polatuzumab vedotin in first-line treatment of diffuse large B-cell lymphoma","route":"/key-papers/paper-polarix-polatuzumab-rchp-nejm-2022/","asOf":"2026-09-08","days":20},{"id":"paper-echelon-1-brentuximab-avd-nejm-2018","kind":"paper","name":"ECHELON-1: brentuximab vedotin replacing bleomycin in first-line chemotherapy for advanced Hodgkin lymphoma","route":"/key-papers/paper-echelon-1-brentuximab-avd-nejm-2018/","asOf":"2026-09-08","days":20},{"id":"paper-swog-s1826-nivolumab-avd-nejm-2024","kind":"paper","name":"SWOG S1826: nivolumab plus AVD chemotherapy versus brentuximab-AVD for advanced Hodgkin lymphoma in adolescents and adults","route":"/key-papers/paper-swog-s1826-nivolumab-avd-nejm-2024/","asOf":"2026-09-08","days":20},{"id":"paper-epcore-nhl-1-epcoritamab-jco-2023","kind":"paper","name":"EPCORE NHL-1: epcoritamab, a subcutaneous CD20 x CD3 bispecific, in relapsed large B-cell lymphoma including after CAR-T","route":"/key-papers/paper-epcore-nhl-1-epcoritamab-jco-2023/","asOf":"2026-09-08","days":20},{"id":"paper-zuma-2-brexu-cel-mantle-cell-nejm-2020","kind":"paper","name":"ZUMA-2: brexu-cel CAR-T for mantle cell lymphoma that has failed BTK inhibitors","route":"/key-papers/paper-zuma-2-brexu-cel-mantle-cell-nejm-2020/","asOf":"2026-09-08","days":20},{"id":"paper-viale-a-venetoclax-azacitidine-nejm-2020","kind":"paper","name":"VIALE-A: venetoclax plus azacitidine for older adults with acute myeloid leukaemia who cannot have intensive chemotherapy","route":"/key-papers/paper-viale-a-venetoclax-azacitidine-nejm-2020/","asOf":"2026-09-08","days":20},{"id":"paper-admiral-gilteritinib-flt3-nejm-2019","kind":"paper","name":"ADMIRAL: gilteritinib pills versus chemotherapy for relapsed FLT3-mutated acute myeloid leukaemia","route":"/key-papers/paper-admiral-gilteritinib-flt3-nejm-2019/","asOf":"2026-09-08","days":20},{"id":"paper-quantum-first-quizartinib-lancet-2023","kind":"paper","name":"QuANTUM-First: quizartinib added to intensive chemotherapy and continued as maintenance in newly diagnosed FLT3-ITD AML","route":"/key-papers/paper-quantum-first-quizartinib-lancet-2023/","asOf":"2026-09-08","days":20},{"id":"paper-agile-ivosidenib-azacitidine-nejm-2022","kind":"paper","name":"AGILE: ivosidenib plus azacitidine for newly diagnosed IDH1-mutated AML in patients unfit for intensive chemotherapy","route":"/key-papers/paper-agile-ivosidenib-azacitidine-nejm-2022/","asOf":"2026-09-08","days":20},{"id":"paper-augment-101-revumenib-menin-nature-2023","kind":"paper","name":"AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation","route":"/key-papers/paper-augment-101-revumenib-menin-nature-2023/","asOf":"2026-09-08","days":20},{"id":"paper-e1910-blinatumomab-mrd-negative-all-nejm-2024","kind":"paper","name":"ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission","route":"/key-papers/paper-e1910-blinatumomab-mrd-negative-all-nejm-2024/","asOf":"2026-09-08","days":20},{"id":"paper-aall1731-blinatumomab-children-nejm-2025","kind":"paper","name":"Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL","route":"/key-papers/paper-aall1731-blinatumomab-children-nejm-2025/","asOf":"2026-09-08","days":20},{"id":"paper-ino-vate-inotuzumab-all-nejm-2016","kind":"paper","name":"INO-VATE: inotuzumab ozogamicin, a CD22 antibody-drug conjugate, versus chemotherapy for relapsed adult B-cell ALL","route":"/key-papers/paper-ino-vate-inotuzumab-all-nejm-2016/","asOf":"2026-09-08","days":20},{"id":"paper-commands-luspatercept-mds-lancet-2023","kind":"paper","name":"COMMANDS: luspatercept versus epoetin alfa as first treatment for anaemia in lower-risk MDS needing transfusions","route":"/key-papers/paper-commands-luspatercept-mds-lancet-2023/","asOf":"2026-09-08","days":20},{"id":"paper-imerge-imetelstat-mds-lancet-2024","kind":"paper","name":"IMerge: imetelstat, a telomerase inhibitor, for transfusion-dependent lower-risk MDS after erythropoietin has failed","route":"/key-papers/paper-imerge-imetelstat-mds-lancet-2024/","asOf":"2026-09-08","days":20},{"id":"paper-comfort-1-ruxolitinib-myelofibrosis-nejm-2012","kind":"paper","name":"COMFORT-I: ruxolitinib, the first JAK inhibitor, versus placebo for myelofibrosis","route":"/key-papers/paper-comfort-1-ruxolitinib-myelofibrosis-nejm-2012/","asOf":"2026-09-08","days":20},{"id":"paper-momentum-momelotinib-lancet-2023","kind":"paper","name":"MOMENTUM: momelotinib versus danazol for myelofibrosis patients with anaemia after a prior JAK inhibitor","route":"/key-papers/paper-momentum-momelotinib-lancet-2023/","asOf":"2026-09-08","days":20},{"id":"paper-maude-ctl019-all-nejm-2014","kind":"paper","name":"Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL","route":"/key-papers/paper-maude-ctl019-all-nejm-2014/","asOf":"2026-09-08","days":20},{"id":"paper-eliana-tisagenlecleucel-nejm-2018","kind":"paper","name":"ELIANA: the global trial that made tisagenlecleucel the first approved CAR-T therapy for children and young adults with relapsed ALL","route":"/key-papers/paper-eliana-tisagenlecleucel-nejm-2018/","asOf":"2026-09-08","days":20},{"id":"paper-juliet-tisagenlecleucel-dlbcl-nejm-2019","kind":"paper","name":"JULIET: tisagenlecleucel for adults with relapsed or refractory diffuse large B-cell lymphoma","route":"/key-papers/paper-juliet-tisagenlecleucel-dlbcl-nejm-2019/","asOf":"2026-09-08","days":20},{"id":"paper-zuma-1-axi-cel-nejm-2017","kind":"paper","name":"ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma","route":"/key-papers/paper-zuma-1-axi-cel-nejm-2017/","asOf":"2026-09-08","days":20},{"id":"paper-ucart19-allogeneic-car-t-lancet-2020","kind":"paper","name":"UCART19: the first gene-edited, donor-derived CAR-T cells in children and adults with relapsed B-cell ALL","route":"/key-papers/paper-ucart19-allogeneic-car-t-lancet-2020/","asOf":"2026-09-08","days":20},{"id":"paper-c-144-01-lifileucel-melanoma-jco-2021","kind":"paper","name":"C-144-01: lifileucel, tumour-infiltrating lymphocytes grown from a patient's own tumour, in melanoma after checkpoint inhibitors have failed","route":"/key-papers/paper-c-144-01-lifileucel-melanoma-jco-2021/","asOf":"2026-09-08","days":20},{"id":"paper-rohaas-til-vs-ipilimumab-nejm-2022","kind":"paper","name":"Rohaas 2022: the first randomised trial of TIL therapy, against ipilimumab, in advanced melanoma","route":"/key-papers/paper-rohaas-til-vs-ipilimumab-nejm-2022/","asOf":"2026-09-08","days":20},{"id":"paper-hodi-ipilimumab-melanoma-nejm-2010","kind":"paper","name":"Hodi 2010: ipilimumab, the first checkpoint inhibitor, extends survival in metastatic melanoma","route":"/key-papers/paper-hodi-ipilimumab-melanoma-nejm-2010/","asOf":"2026-09-08","days":20},{"id":"paper-topalian-anti-pd1-nejm-2012","kind":"paper","name":"Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer","route":"/key-papers/paper-topalian-anti-pd1-nejm-2012/","asOf":"2026-09-08","days":20},{"id":"paper-le-mmr-deficiency-pd1-nejm-2015","kind":"paper","name":"Le 2015: PD-1 blockade works in tumours with mismatch-repair deficiency, whatever the organ","route":"/key-papers/paper-le-mmr-deficiency-pd1-nejm-2015/","asOf":"2026-09-08","days":20},{"id":"paper-le-mmr-deficiency-science-2017","kind":"paper","name":"Le 2017: mismatch-repair deficiency predicts response to PD-1 blockade across twelve tumour types, leading to the first tissue-agnostic drug approval","route":"/key-papers/paper-le-mmr-deficiency-science-2017/","asOf":"2026-09-08","days":20},{"id":"paper-cercek-dostarlimab-rectal-nejm-2022","kind":"paper","name":"Cercek 2022: six months of dostarlimab alone made rectal cancer disappear in every patient with mismatch-repair deficiency","route":"/key-papers/paper-cercek-dostarlimab-rectal-nejm-2022/","asOf":"2026-09-08","days":20},{"id":"paper-rojas-mrna-neoantigen-vaccine-pancreatic-nature-2023","kind":"paper","name":"Rojas 2023: a personalised mRNA vaccine trained T cells against each patient's pancreatic cancer, and those who responded stayed cancer-free longer","route":"/key-papers/paper-rojas-mrna-neoantigen-vaccine-pancreatic-nature-2023/","asOf":"2026-09-08","days":20},{"id":"paper-asco-irae-guideline-jco-2021","kind":"paper","name":"ASCO 2021 guideline: how to recognise and manage the immune-related side effects of checkpoint inhibitors","route":"/key-papers/paper-asco-irae-guideline-jco-2021/","asOf":"2026-09-08","days":20},{"id":"paper-pardoll-immune-checkpoint-blockade-nrc-2012","kind":"paper","name":"Pardoll 2012: the blockade of immune checkpoints in cancer immunotherapy","route":"/key-papers/paper-pardoll-immune-checkpoint-blockade-nrc-2012/","asOf":"2026-09-08","days":20},{"id":"paper-rizvi-mutational-landscape-pd1-science-2015","kind":"paper","name":"Rizvi 2015: the mutational landscape determines who responds to PD-1 blockade in lung cancer","route":"/key-papers/paper-rizvi-mutational-landscape-pd1-science-2015/","asOf":"2026-09-08","days":20},{"id":"paper-galon-immune-contexture-colorectal-science-2006","kind":"paper","name":"Galon 2006: the type, density and location of immune cells in colorectal tumours predict outcome","route":"/key-papers/paper-galon-immune-contexture-colorectal-science-2006/","asOf":"2026-09-08","days":20},{"id":"paper-schreiber-cancer-immunoediting-science-2011","kind":"paper","name":"Schreiber, Old and Smyth 2011: cancer immunoediting","route":"/key-papers/paper-schreiber-cancer-immunoediting-science-2011/","asOf":"2026-09-08","days":20},{"id":"paper-tumeh-pd1-adaptive-immune-resistance-nature-2014","kind":"paper","name":"Tumeh 2014: PD-1 blockade works by releasing T cells already present at the tumour edge","route":"/key-papers/paper-tumeh-pd1-adaptive-immune-resistance-nature-2014/","asOf":"2026-09-08","days":20},{"id":"paper-thorsson-immune-landscape-of-cancer-immunity-2018","kind":"paper","name":"Thorsson 2018: the immune landscape of cancer across 10,000 tumours","route":"/key-papers/paper-thorsson-immune-landscape-of-cancer-immunity-2018/","asOf":"2026-09-08","days":20},{"id":"paper-darnell-jak-stat-science-1994","kind":"paper","name":"Darnell, Kerr and Stark 1994: JAK-STAT pathways and transcriptional activation by interferons","route":"/key-papers/paper-darnell-jak-stat-science-1994/","asOf":"2026-09-08","days":20},{"id":"paper-binnewies-tumor-immune-microenvironment-natmed-2018","kind":"paper","name":"Binnewies 2018: understanding the tumour immune microenvironment for effective therapy","route":"/key-papers/paper-binnewies-tumor-immune-microenvironment-natmed-2018/","asOf":"2026-09-08","days":20},{"id":"paper-li-timer-tumour-infiltrating-immune-cells-cancerres-2017","kind":"paper","name":"Li 2017: TIMER, a web server for estimating immune cells in tumour genomic data","route":"/key-papers/paper-li-timer-tumour-infiltrating-immune-cells-cancerres-2017/","asOf":"2026-09-08","days":20},{"id":"paper-cella-fact-g-jco-1993","kind":"paper","name":"Cella 1993: the Functional Assessment of Cancer Therapy (FACT-G) quality of life scale","route":"/key-papers/paper-cella-fact-g-jco-1993/","asOf":"2026-09-08","days":20},{"id":"paper-chen-mellman-cancer-immunity-cycle-immunity-2013","kind":"paper","name":"Chen and Mellman 2013: the cancer-immunity cycle","route":"/key-papers/paper-chen-mellman-cancer-immunity-cycle-immunity-2013/","asOf":"2026-09-08","days":20},{"id":"paper-ribas-wolchok-checkpoint-blockade-science-2018","kind":"paper","name":"Ribas and Wolchok 2018: cancer immunotherapy using checkpoint blockade","route":"/key-papers/paper-ribas-wolchok-checkpoint-blockade-science-2018/","asOf":"2026-09-08","days":20},{"id":"paper-li-timer2-nar-2020","kind":"paper","name":"Li 2020: TIMER2.0 for analysis of tumour-infiltrating immune cells","route":"/key-papers/paper-li-timer2-nar-2020/","asOf":"2026-09-08","days":20},{"id":"paper-nlst-nejm-2011","kind":"paper","name":"NLST: yearly low-dose CT scans cut lung cancer deaths in heavy smokers","route":"/key-papers/paper-nlst-nejm-2011/","asOf":"2026-09-08","days":20},{"id":"paper-nelson-nejm-2020","kind":"paper","name":"NELSON: volume-based CT screening reduces lung cancer deaths with fewer false alarms","route":"/key-papers/paper-nelson-nejm-2020/","asOf":"2026-09-08","days":20},{"id":"paper-nordicc-nejm-2022","kind":"paper","name":"NordICC: inviting people to a screening colonoscopy reduced bowel cancer, but less than expected","route":"/key-papers/paper-nordicc-nejm-2022/","asOf":"2026-09-08","days":20},{"id":"paper-minnesota-fobt-nejm-1993","kind":"paper","name":"Minnesota trial: a yearly stool blood test cuts bowel cancer deaths by a third","route":"/key-papers/paper-minnesota-fobt-nejm-1993/","asOf":"2026-09-08","days":20},{"id":"paper-hpv-vaccine-sweden-nejm-2020","kind":"paper","name":"Swedish registry study: HPV vaccination almost eliminates cervical cancer when given before 17","route":"/key-papers/paper-hpv-vaccine-sweden-nejm-2020/","asOf":"2026-09-08","days":20},{"id":"paper-hpv-vaccine-england-lancet-2021","kind":"paper","name":"England's HPV programme: cervical cancer down 87% in the first cohort vaccinated at 12-13","route":"/key-papers/paper-hpv-vaccine-england-lancet-2021/","asOf":"2026-09-08","days":20},{"id":"paper-hpv-self-sampling-bmj-2018","kind":"paper","name":"Self-collected HPV samples are as accurate as clinician samples and reach women who never attend screening","route":"/key-papers/paper-hpv-self-sampling-bmj-2018/","asOf":"2026-09-08","days":20},{"id":"paper-masai-lancet-oncol-2023","kind":"paper","name":"MASAI: AI-supported mammography screening finds more cancers with half the radiologist workload","route":"/key-papers/paper-masai-lancet-oncol-2023/","asOf":"2026-09-08","days":20},{"id":"paper-pathfinder-lancet-2023","kind":"paper","name":"PATHFINDER: the first prospective test of a multi-cancer blood test in people without symptoms","route":"/key-papers/paper-pathfinder-lancet-2023/","asOf":"2026-09-08","days":20},{"id":"paper-nhs-galleri-design-cancers-2022","kind":"paper","name":"NHS-Galleri: design of the largest randomised trial of a multi-cancer blood test","route":"/key-papers/paper-nhs-galleri-design-cancers-2022/","asOf":"2026-09-08","days":20},{"id":"paper-detect-a-science-2020","kind":"paper","name":"DETECT-A: a blood test plus PET-CT found treatable cancers in 10,000 women with no symptoms","route":"/key-papers/paper-detect-a-science-2020/","asOf":"2026-09-08","days":20},{"id":"paper-imvigor011-nejm-2025","kind":"paper","name":"IMvigor011: using a blood test for leftover cancer to decide who gets immunotherapy after bladder surgery","route":"/key-papers/paper-imvigor011-nejm-2025/","asOf":"2026-09-08","days":20},{"id":"paper-dynamic-nejm-2022","kind":"paper","name":"DYNAMIC: a blood test safely halved chemotherapy use after surgery for stage II colon cancer","route":"/key-papers/paper-dynamic-nejm-2022/","asOf":"2026-09-08","days":20},{"id":"paper-galaxy-signatera-nat-med-2023","kind":"paper","name":"GALAXY: tumour DNA in blood four weeks after bowel cancer surgery predicts relapse tenfold","route":"/key-papers/paper-galaxy-signatera-nat-med-2023/","asOf":"2026-09-08","days":20},{"id":"paper-challenge-exercise-nejm-2025","kind":"paper","name":"CHALLENGE: a structured exercise programme after chemotherapy improves survival in colon cancer","route":"/key-papers/paper-challenge-exercise-nejm-2025/","asOf":"2026-09-08","days":20},{"id":"paper-predimed-breast-jama-im-2015","kind":"paper","name":"PREDIMED: a Mediterranean diet with extra-virgin olive oil and fewer breast cancers","route":"/key-papers/paper-predimed-breast-jama-im-2015/","asOf":"2026-09-08","days":20},{"id":"paper-body-fatness-iarc-nejm-2016","kind":"paper","name":"IARC verdict: excess body fat causes 13 cancers","route":"/key-papers/paper-body-fatness-iarc-nejm-2016/","asOf":"2026-09-08","days":20},{"id":"paper-capp2-aspirin-lynch-lancet-2020","kind":"paper","name":"CAPP2: two years of aspirin cuts bowel cancer in Lynch syndrome by more than a third over 10 years","route":"/key-papers/paper-capp2-aspirin-lynch-lancet-2020/","asOf":"2026-09-08","days":20},{"id":"paper-ibis-i-tamoxifen-lancet-oncol-2015","kind":"paper","name":"IBIS-I: five years of tamoxifen keeps preventing breast cancer for at least 20 years","route":"/key-papers/paper-ibis-i-tamoxifen-lancet-oncol-2015/","asOf":"2026-09-08","days":20},{"id":"paper-brca-risk-reducing-surgery-jama-2010","kind":"paper","name":"PROSE consortium: preventive surgery lowers cancer and death in BRCA1 and BRCA2 carriers","route":"/key-papers/paper-brca-risk-reducing-surgery-jama-2010/","asOf":"2026-09-08","days":20},{"id":"paper-lynch-frameshift-vaccine-ccr-2020","kind":"paper","name":"First trial of a vaccine against the shared neoantigens of mismatch-repair-deficient cancers","route":"/key-papers/paper-lynch-frameshift-vaccine-ccr-2020/","asOf":"2026-09-08","days":20},{"id":"paper-doll-hill-smoking-lung-cancer-bmj-1950","kind":"paper","name":"Doll and Hill 1950: the case-control study that tied smoking to lung cancer","route":"/key-papers/paper-doll-hill-smoking-lung-cancer-bmj-1950/","asOf":"2026-09-08","days":20},{"id":"paper-doll-peto-50-year-doctors-bmj-2004","kind":"paper","name":"Fifty years of the British Doctors Study: smokers lose ten years of life, quitting gives most of it back","route":"/key-papers/paper-doll-peto-50-year-doctors-bmj-2004/","asOf":"2026-09-08","days":20},{"id":"paper-alcohol-cancer-burden-lancet-oncol-2021","kind":"paper","name":"Alcohol caused an estimated 741,000 cancers worldwide in 2020","route":"/key-papers/paper-alcohol-cancer-burden-lancet-oncol-2021/","asOf":"2026-09-08","days":20},{"id":"paper-basch-epro-survival-jama-2017","kind":"paper","name":"Basch: asking patients to report symptoms online during chemotherapy improved survival","route":"/key-papers/paper-basch-epro-survival-jama-2017/","asOf":"2026-09-08","days":20},{"id":"paper-temel-early-palliative-care-nejm-2010","kind":"paper","name":"Temel: early palliative care alongside chemotherapy improved quality of life, mood and survival in lung cancer","route":"/key-papers/paper-temel-early-palliative-care-nejm-2010/","asOf":"2026-09-08","days":20},{"id":"paper-gap70-geriatric-assessment-lancet-2021","kind":"paper","name":"GAP70+: a geriatric assessment before chemotherapy cut serious toxicity in older adults by a fifth","route":"/key-papers/paper-gap70-geriatric-assessment-lancet-2021/","asOf":"2026-09-08","days":20},{"id":"paper-drug-dosing-conundrum-nejm-2021","kind":"paper","name":"FDA's Project Optimus manifesto: cancer drugs are approved at doses that are too high","route":"/key-papers/paper-drug-dosing-conundrum-nejm-2021/","asOf":"2026-09-08","days":20},{"id":"paper-hallmarks-of-cancer-cell-2000","kind":"paper","name":"The Hallmarks of Cancer: six capabilities every tumour must acquire","route":"/key-papers/paper-hallmarks-of-cancer-cell-2000/","asOf":"2026-09-08","days":20},{"id":"paper-hallmarks-new-dimensions-cancer-discov-2022","kind":"paper","name":"Hallmarks of Cancer 2022: adding phenotypic plasticity, epigenetic reprogramming, microbiomes and senescent cells","route":"/key-papers/paper-hallmarks-new-dimensions-cancer-discov-2022/","asOf":"2026-09-08","days":20},{"id":"paper-tcga-pancancer-atlas-cell-2018","kind":"paper","name":"TCGA Pan-Cancer Atlas: 10,000 tumours across 33 cancer types, classified by molecular features","route":"/key-papers/paper-tcga-pancancer-atlas-cell-2018/","asOf":"2026-09-08","days":20},{"id":"paper-vogelstein-cancer-genome-landscapes-science-2013","kind":"paper","name":"Cancer genome landscapes: about 140 driver genes, and each tumour needs only a handful","route":"/key-papers/paper-vogelstein-cancer-genome-landscapes-science-2013/","asOf":"2026-09-08","days":20},{"id":"paper-gerlinger-intratumour-heterogeneity-nejm-2012","kind":"paper","name":"Gerlinger: a single biopsy misses most of the mutations in a kidney tumour","route":"/key-papers/paper-gerlinger-intratumour-heterogeneity-nejm-2012/","asOf":"2026-09-08","days":20},{"id":"paper-tracerx-100-nejm-2017","kind":"paper","name":"TRACERx first 100: tracking how lung cancers evolve, and how chromosomal chaos predicts relapse","route":"/key-papers/paper-tracerx-100-nejm-2017/","asOf":"2026-09-08","days":20},{"id":"paper-tracerx-evolution-nature-2023","kind":"paper","name":"TRACERx 421: the full-cohort picture of how lung cancer evolves and which subclones drive relapse","route":"/key-papers/paper-tracerx-evolution-nature-2023/","asOf":"2026-09-08","days":20},{"id":"paper-martincorena-somatic-mutations-normal-skin-science-2015","kind":"paper","name":"Martincorena: normal sun-exposed skin is a patchwork of cancer-mutation clones","route":"/key-papers/paper-martincorena-somatic-mutations-normal-skin-science-2015/","asOf":"2026-09-08","days":20},{"id":"paper-jaiswal-chip-nejm-2014","kind":"paper","name":"Jaiswal: clonal haematopoiesis, the pre-leukaemic clones in most people over 70","route":"/key-papers/paper-jaiswal-chip-nejm-2014/","asOf":"2026-09-08","days":20},{"id":"paper-depmap-tsherniak-cell-2017","kind":"paper","name":"Defining a Cancer Dependency Map: which genes each cancer cell line cannot live without","route":"/key-papers/paper-depmap-tsherniak-cell-2017/","asOf":"2026-09-08","days":20},{"id":"paper-alphafold2-jumper-nature-2021","kind":"paper","name":"AlphaFold 2: predicting protein structures to near-experimental accuracy","route":"/key-papers/paper-alphafold2-jumper-nature-2021/","asOf":"2026-09-08","days":20},{"id":"paper-ostrem-kras-g12c-nature-2013","kind":"paper","name":"Ostrem and Shokat: the hidden pocket that made KRAS G12C druggable","route":"/key-papers/paper-ostrem-kras-g12c-nature-2013/","asOf":"2026-09-08","days":20},{"id":"paper-protac-concept-sakamoto-pnas-2001","kind":"paper","name":"The first PROTAC: a chimeric molecule that tags a protein for destruction","route":"/key-papers/paper-protac-concept-sakamoto-pnas-2001/","asOf":"2026-09-08","days":20},{"id":"paper-leach-allison-ctla4-blockade-science-1996","kind":"paper","name":"Leach, Krummel and Allison: releasing the CTLA-4 brake makes mice reject tumours","route":"/key-papers/paper-leach-allison-ctla4-blockade-science-1996/","asOf":"2026-09-08","days":20},{"id":"paper-iwai-pdl1-tumour-escape-pnas-2002","kind":"paper","name":"Iwai and Honjo: tumours use PD-L1 to escape T cells, and blocking it restores attack","route":"/key-papers/paper-iwai-pdl1-tumour-escape-pnas-2002/","asOf":"2026-09-08","days":20},{"id":"paper-reproducibility-project-cancer-biology-elife-2021","kind":"paper","name":"Reproducibility Project: Cancer Biology found that landmark preclinical results mostly shrank or vanished on replication","route":"/key-papers/paper-reproducibility-project-cancer-biology-elife-2021/","asOf":"2026-09-08","days":20},{"id":"paper-prasad-surrogate-endpoints-jama-im-2015","kind":"paper","name":"Prasad: most surrogate endpoints in cancer trials correlate poorly with survival","route":"/key-papers/paper-prasad-surrogate-endpoints-jama-im-2015/","asOf":"2026-09-08","days":20},{"id":"paper-unger-trial-participation-barriers-jnci-2019","kind":"paper","name":"Unger: most patients never get the chance to join a cancer trial, and when offered, half say yes","route":"/key-papers/paper-unger-trial-participation-barriers-jnci-2019/","asOf":"2026-09-08","days":20},{"id":"paper-bray-globocan-2022-cacancer-2024","kind":"paper","name":"Bray 2024: GLOBOCAN 2022, the world's cancer count for 36 cancers in 185 countries","route":"/key-papers/paper-bray-globocan-2022-cacancer-2024/","asOf":"2026-09-08","days":20},{"id":"paper-slamon-her2-amplification-science-1987","kind":"paper","name":"Slamon 1987: HER2 gene amplification marks an aggressive form of breast cancer","route":"/key-papers/paper-slamon-her2-amplification-science-1987/","asOf":"2026-09-08","days":20},{"id":"paper-coussens-werb-inflammation-cancer-nature-2002","kind":"paper","name":"Coussens and Werb 2002: inflammation and cancer","route":"/key-papers/paper-coussens-werb-inflammation-cancer-nature-2002/","asOf":"2026-09-08","days":20},{"id":"paper-reya-cancer-stem-cells-nature-2001","kind":"paper","name":"Reya 2001: stem cells, cancer and cancer stem cells","route":"/key-papers/paper-reya-cancer-stem-cells-nature-2001/","asOf":"2026-09-08","days":20},{"id":"paper-esteva-skin-cancer-deep-learning-nature-2017","kind":"paper","name":"Esteva 2017: a deep neural network classifies skin cancer at dermatologist level","route":"/key-papers/paper-esteva-skin-cancer-deep-learning-nature-2017/","asOf":"2026-09-08","days":20},{"id":"paper-therasse-recist-jnci-2000","kind":"paper","name":"Therasse 2000: RECIST, the standard rules for measuring whether a tumour responds","route":"/key-papers/paper-therasse-recist-jnci-2000/","asOf":"2026-09-08","days":20},{"id":"paper-aaronson-eortc-qlq-c30-jnci-1993","kind":"paper","name":"Aaronson 1993: the EORTC QLQ-C30 quality of life questionnaire","route":"/key-papers/paper-aaronson-eortc-qlq-c30-jnci-1993/","asOf":"2026-09-08","days":20},{"id":"paper-sung-globocan-2020-cacancer-2021","kind":"paper","name":"Sung 2021: GLOBOCAN 2020, the year breast cancer overtook lung cancer as the most diagnosed cancer","route":"/key-papers/paper-sung-globocan-2020-cacancer-2021/","asOf":"2026-09-08","days":20},{"id":"paper-bray-globocan-2018-cacancer-2018","kind":"paper","name":"Bray 2018: GLOBOCAN 2018, worldwide incidence and mortality for 36 cancers","route":"/key-papers/paper-bray-globocan-2018-cacancer-2018/","asOf":"2026-09-08","days":20},{"id":"paper-siegel-cancer-statistics-2024-cacancer-2024","kind":"paper","name":"Siegel 2024: Cancer statistics, 2024, the American Cancer Society's annual US report","route":"/key-papers/paper-siegel-cancer-statistics-2024-cacancer-2024/","asOf":"2026-09-08","days":20},{"id":"paper-chen-cancer-statistics-china-2015-cacancer-2016","kind":"paper","name":"Chen 2016: Cancer statistics in China, 2015","route":"/key-papers/paper-chen-cancer-statistics-china-2015-cacancer-2016/","asOf":"2026-09-08","days":20},{"id":"paper-calle-obesity-cancer-mortality-nejm-2003","kind":"paper","name":"Calle 2003: overweight, obesity and death from cancer in 900,000 US adults","route":"/key-papers/paper-calle-obesity-cancer-mortality-nejm-2003/","asOf":"2026-09-08","days":20},{"id":"paper-hollstein-p53-mutations-science-1991","kind":"paper","name":"Hollstein 1991: p53 mutations in human cancers","route":"/key-papers/paper-hollstein-p53-mutations-science-1991/","asOf":"2026-09-08","days":20},{"id":"paper-al-hajj-breast-cancer-stem-cells-pnas-2003","kind":"paper","name":"Al-Hajj 2003: prospective identification of tumorigenic breast cancer cells","route":"/key-papers/paper-al-hajj-breast-cancer-stem-cells-pnas-2003/","asOf":"2026-09-08","days":20},{"id":"paper-bao-glioma-stem-cells-radioresistance-nature-2006","kind":"paper","name":"Bao 2006: glioma stem cells resist radiotherapy by activating the DNA damage response","route":"/key-papers/paper-bao-glioma-stem-cells-radioresistance-nature-2006/","asOf":"2026-09-08","days":20},{"id":"paper-slamon-her2-breast-ovarian-science-1989","kind":"paper","name":"Slamon 1989: HER2/neu in human breast and ovarian cancer","route":"/key-papers/paper-slamon-her2-breast-ovarian-science-1989/","asOf":"2026-09-08","days":20},{"id":"paper-allemani-concord-3-lancet-2018","kind":"paper","name":"Allemani 2018: CONCORD-3, global surveillance of cancer survival 2000 to 2014","route":"/key-papers/paper-allemani-concord-3-lancet-2018/","asOf":"2026-09-08","days":20},{"id":"paper-fitzmaurice-gbd-cancer-2015-jamaoncol-2017","kind":"paper","name":"Fitzmaurice 2017: the Global Burden of Disease estimate of cancer in 2015","route":"/key-papers/paper-fitzmaurice-gbd-cancer-2015-jamaoncol-2017/","asOf":"2026-09-08","days":20},{"id":"paper-torre-global-cancer-statistics-2012-cacancer-2015","kind":"paper","name":"Torre 2015: Global cancer statistics, 2012","route":"/key-papers/paper-torre-global-cancer-statistics-2012-cacancer-2015/","asOf":"2026-09-08","days":20},{"id":"paper-kalluri-weinberg-emt-basics-jci-2009","kind":"paper","name":"Kalluri and Weinberg 2009: the basics of epithelial-mesenchymal transition","route":"/key-papers/paper-kalluri-weinberg-emt-basics-jci-2009/","asOf":"2026-09-08","days":20},{"id":"paper-mani-emt-stem-cell-properties-cell-2008","kind":"paper","name":"Mani 2008: the epithelial-mesenchymal transition generates cells with properties of stem cells","route":"/key-papers/paper-mani-emt-stem-cell-properties-cell-2008/","asOf":"2026-09-08","days":20},{"id":"paper-thiery-emt-tumour-progression-nrc-2002","kind":"paper","name":"Thiery 2002: epithelial-mesenchymal transitions in tumour progression","route":"/key-papers/paper-thiery-emt-tumour-progression-nrc-2002/","asOf":"2026-09-08","days":20},{"id":"paper-quail-joyce-microenvironment-metastasis-natmed-2013","kind":"paper","name":"Quail and Joyce 2013: microenvironmental regulation of tumour progression and metastasis","route":"/key-papers/paper-quail-joyce-microenvironment-metastasis-natmed-2013/","asOf":"2026-09-08","days":20},{"id":"paper-grivennikov-immunity-inflammation-cancer-cell-2010","kind":"paper","name":"Grivennikov, Greten and Karin 2010: immunity, inflammation and cancer","route":"/key-papers/paper-grivennikov-immunity-inflammation-cancer-cell-2010/","asOf":"2026-09-08","days":20},{"id":"paper-balkwill-mantovani-inflammation-virchow-lancet-2001","kind":"paper","name":"Balkwill and Mantovani 2001: inflammation and cancer, back to Virchow?","route":"/key-papers/paper-balkwill-mantovani-inflammation-virchow-lancet-2001/","asOf":"2026-09-08","days":20},{"id":"paper-levine-p53-gatekeeper-cell-1997","kind":"paper","name":"Levine 1997: p53, the cellular gatekeeper for growth and division","route":"/key-papers/paper-levine-p53-gatekeeper-cell-1997/","asOf":"2026-09-08","days":20},{"id":"paper-el-deiry-waf1-p21-cell-1993","kind":"paper","name":"El-Deiry 1993: WAF1, the gene through which p53 stops cell division","route":"/key-papers/paper-el-deiry-waf1-p21-cell-1993/","asOf":"2026-09-08","days":20},{"id":"paper-lamouille-emt-molecular-mechanisms-nrmcb-2014","kind":"paper","name":"Lamouille 2014: molecular mechanisms of epithelial-mesenchymal transition","route":"/key-papers/paper-lamouille-emt-molecular-mechanisms-nrmcb-2014/","asOf":"2026-09-08","days":20},{"id":"paper-lemmon-schlessinger-rtk-signalling-cell-2010","kind":"paper","name":"Lemmon and Schlessinger 2010: cell signalling by receptor tyrosine kinases","route":"/key-papers/paper-lemmon-schlessinger-rtk-signalling-cell-2010/","asOf":"2026-09-08","days":20},{"id":"paper-vogelstein-surfing-p53-network-nature-2000","kind":"paper","name":"Vogelstein, Lane and Levine 2000: surfing the p53 network","route":"/key-papers/paper-vogelstein-surfing-p53-network-nature-2000/","asOf":"2026-09-08","days":20},{"id":"paper-sherr-roberts-cdk-inhibitors-genesdev-1999","kind":"paper","name":"Sherr and Roberts 1999: CDK inhibitors as regulators of the G1 phase","route":"/key-papers/paper-sherr-roberts-cdk-inhibitors-genesdev-1999/","asOf":"2026-09-08","days":20},{"id":"paper-jemal-global-cancer-statistics-2011-cacancer","kind":"paper","name":"Jemal 2011: Global cancer statistics (GLOBOCAN 2008)","route":"/key-papers/paper-jemal-global-cancer-statistics-2011-cacancer/","asOf":"2026-09-08","days":20},{"id":"paper-parkin-global-cancer-statistics-2002-cacancer-2005","kind":"paper","name":"Parkin 2005: Global cancer statistics, 2002","route":"/key-papers/paper-parkin-global-cancer-statistics-2002-cacancer-2005/","asOf":"2026-09-08","days":20},{"id":"paper-ferlay-globocan-2012-methods-ijc-2015","kind":"paper","name":"Ferlay 2015: sources, methods and major patterns in GLOBOCAN 2012","route":"/key-papers/paper-ferlay-globocan-2012-methods-ijc-2015/","asOf":"2026-09-08","days":20},{"id":"paper-ferlay-globocan-2018-methods-ijc-2019","kind":"paper","name":"Ferlay 2019: GLOBOCAN 2018 sources and methods","route":"/key-papers/paper-ferlay-globocan-2018-methods-ijc-2019/","asOf":"2026-09-08","days":20},{"id":"paper-ferlay-cancer-statistics-2020-overview-ijc-2021","kind":"paper","name":"Ferlay 2021: cancer statistics for the year 2020, an overview","route":"/key-papers/paper-ferlay-cancer-statistics-2020-overview-ijc-2021/","asOf":"2026-09-08","days":20},{"id":"paper-siegel-cancer-statistics-2019-cacancer-2019","kind":"paper","name":"Siegel 2019: Cancer statistics, 2019","route":"/key-papers/paper-siegel-cancer-statistics-2019-cacancer-2019/","asOf":"2026-09-08","days":20},{"id":"paper-siegel-cancer-statistics-2022-cacancer-2022","kind":"paper","name":"Siegel 2022: Cancer statistics, 2022","route":"/key-papers/paper-siegel-cancer-statistics-2022-cacancer-2022/","asOf":"2026-09-08","days":20},{"id":"paper-siegel-cancer-statistics-2023-cacancer-2023","kind":"paper","name":"Siegel 2023: Cancer statistics, 2023","route":"/key-papers/paper-siegel-cancer-statistics-2023-cacancer-2023/","asOf":"2026-09-08","days":20},{"id":"paper-siegel-cancer-statistics-2012-cacancer-2012","kind":"paper","name":"Siegel 2012: Cancer statistics, 2012","route":"/key-papers/paper-siegel-cancer-statistics-2012-cacancer-2012/","asOf":"2026-09-08","days":20},{"id":"paper-siegel-cancer-statistics-2015-cacancer-2015","kind":"paper","name":"Siegel 2015: Cancer statistics, 2015","route":"/key-papers/paper-siegel-cancer-statistics-2015-cacancer-2015/","asOf":"2026-09-08","days":20},{"id":"paper-siegel-cancer-statistics-2016-cacancer-2016","kind":"paper","name":"Siegel 2016: Cancer statistics, 2016","route":"/key-papers/paper-siegel-cancer-statistics-2016-cacancer-2016/","asOf":"2026-09-08","days":20},{"id":"paper-siegel-cancer-statistics-2017-cacancer-2017","kind":"paper","name":"Siegel 2017: Cancer statistics, 2017","route":"/key-papers/paper-siegel-cancer-statistics-2017-cacancer-2017/","asOf":"2026-09-08","days":20},{"id":"paper-siegel-cancer-statistics-2018-cacancer-2018","kind":"paper","name":"Siegel 2018: Cancer statistics, 2018","route":"/key-papers/paper-siegel-cancer-statistics-2018-cacancer-2018/","asOf":"2026-09-08","days":20},{"id":"paper-siegel-cancer-statistics-2021-cacancer-2021","kind":"paper","name":"Siegel 2021: Cancer statistics, 2021","route":"/key-papers/paper-siegel-cancer-statistics-2021-cacancer-2021/","asOf":"2026-09-08","days":20},{"id":"paper-veber-oral-bioavailability-jmedchem-2002","kind":"paper","name":"Veber 2002: molecular properties that influence the oral bioavailability of drug candidates","route":"/key-papers/paper-veber-oral-bioavailability-jmedchem-2002/","asOf":"2026-09-08","days":20},{"id":"paper-singh-brain-tumour-initiating-cells-nature-2004","kind":"paper","name":"Singh 2004: identification of human brain tumour initiating cells","route":"/key-papers/paper-singh-brain-tumour-initiating-cells-nature-2004/","asOf":"2026-09-08","days":20},{"id":"paper-rahib-projecting-cancer-deaths-2030-cancerres-2014","kind":"paper","name":"Rahib 2014: projecting US cancer incidence and deaths to 2030","route":"/key-papers/paper-rahib-projecting-cancer-deaths-2030-cancerres-2014/","asOf":"2026-09-08","days":20},{"id":"paper-sato-lgr5-organoids-nature-2009","kind":"paper","name":"Sato 2009: single Lgr5 stem cells build crypt-villus organoids","route":"/key-papers/paper-sato-lgr5-organoids-nature-2009/","asOf":"2026-09-08","days":20},{"id":"paper-yarden-sliwkowski-erbb-network-nrmcb-2001","kind":"paper","name":"Yarden and Sliwkowski 2001: untangling the ErbB signalling network","route":"/key-papers/paper-yarden-sliwkowski-erbb-network-nrmcb-2001/","asOf":"2026-09-08","days":20},{"id":"paper-jemal-cancer-statistics-2007-cacancer-2007","kind":"paper","name":"Jemal 2007: Cancer statistics, 2007","route":"/key-papers/paper-jemal-cancer-statistics-2007-cacancer-2007/","asOf":"2026-09-08","days":20},{"id":"paper-jemal-cancer-statistics-2008-cacancer-2008","kind":"paper","name":"Jemal 2008: Cancer statistics, 2008","route":"/key-papers/paper-jemal-cancer-statistics-2008-cacancer-2008/","asOf":"2026-09-08","days":20},{"id":"paper-jemal-cancer-statistics-2009-cacancer-2009","kind":"paper","name":"Jemal 2009: Cancer statistics, 2009","route":"/key-papers/paper-jemal-cancer-statistics-2009-cacancer-2009/","asOf":"2026-09-08","days":20},{"id":"paper-jemal-cancer-statistics-2010-cacancer-2010","kind":"paper","name":"Jemal 2010: Cancer statistics, 2010","route":"/key-papers/paper-jemal-cancer-statistics-2010-cacancer-2010/","asOf":"2026-09-08","days":20},{"id":"paper-siegel-cancer-statistics-2013-cacancer-2013","kind":"paper","name":"Siegel 2013: Cancer statistics, 2013","route":"/key-papers/paper-siegel-cancer-statistics-2013-cacancer-2013/","asOf":"2026-09-08","days":20},{"id":"paper-siegel-cancer-statistics-2014-cacancer-2014","kind":"paper","name":"Siegel 2014: Cancer statistics, 2014","route":"/key-papers/paper-siegel-cancer-statistics-2014-cacancer-2014/","asOf":"2026-09-08","days":20},{"id":"structured-exercise-survivorship","kind":"technology","name":"Structured exercise programmes after curative treatment","route":"/technologies/structured-exercise-survivorship/","asOf":"2026-09-08","days":20},{"id":"exercise-during-chemotherapy","kind":"technology","name":"Exercise during chemotherapy and radiotherapy","route":"/technologies/exercise-during-chemotherapy/","asOf":"2026-09-08","days":20},{"id":"resistance-training-cachexia","kind":"technology","name":"Resistance training and protein for cachexia and sarcopenia","route":"/technologies/resistance-training-cachexia/","asOf":"2026-09-08","days":20},{"id":"eras-perioperative-nutrition","kind":"technology","name":"Enhanced recovery (ERAS) and perioperative nutrition","route":"/technologies/eras-perioperative-nutrition/","asOf":"2026-09-08","days":20},{"id":"nutrition-screening-mnt","kind":"technology","name":"Oncology nutrition assessment and medical nutrition therapy","route":"/technologies/nutrition-screening-mnt/","asOf":"2026-09-08","days":20},{"id":"enteral-parenteral-nutrition","kind":"technology","name":"Enteral and parenteral nutrition support","route":"/technologies/enteral-parenteral-nutrition/","asOf":"2026-09-08","days":20},{"id":"immunonutrition-perioperative","kind":"technology","name":"Immunonutrition before cancer surgery","route":"/technologies/immunonutrition-perioperative/","asOf":"2026-09-08","days":20},{"id":"fasting-mimicking-diet","kind":"technology","name":"Fasting and fasting-mimicking diets around chemotherapy","route":"/technologies/fasting-mimicking-diet/","asOf":"2026-09-08","days":20},{"id":"ketogenic-diet-glioblastoma","kind":"technology","name":"Ketogenic diets in glioblastoma","route":"/technologies/ketogenic-diet-glioblastoma/","asOf":"2026-09-08","days":20},{"id":"time-restricted-eating","kind":"technology","name":"Time-restricted eating in cancer prevention and survivorship","route":"/technologies/time-restricted-eating/","asOf":"2026-09-08","days":20},{"id":"mediterranean-plant-forward-diet","kind":"technology","name":"Mediterranean and plant-forward dietary patterns","route":"/technologies/mediterranean-plant-forward-diet/","asOf":"2026-09-08","days":20},{"id":"dietary-fibre-microbiome-io","kind":"technology","name":"Dietary fibre and the gut microbiome for immunotherapy response","route":"/technologies/dietary-fibre-microbiome-io/","asOf":"2026-09-08","days":20},{"id":"fmt-checkpoint-nonresponders","kind":"technology","name":"Faecal microbiota transplantation for PD-1 non-responders","route":"/technologies/fmt-checkpoint-nonresponders/","asOf":"2026-09-08","days":20},{"id":"probiotics-antibiotic-stewardship-io","kind":"technology","name":"Probiotics, antibiotics and stewardship around immunotherapy","route":"/technologies/probiotics-antibiotic-stewardship-io/","asOf":"2026-09-08","days":20},{"id":"glp1-agonists-cancer-risk","kind":"technology","name":"GLP-1 receptor agonists and obesity-related cancer risk","route":"/technologies/glp1-agonists-cancer-risk/","asOf":"2026-09-08","days":20},{"id":"bariatric-surgery-cancer-incidence","kind":"technology","name":"Bariatric surgery and cancer incidence","route":"/technologies/bariatric-surgery-cancer-incidence/","asOf":"2026-09-08","days":20},{"id":"alcohol-reduction-labelling","kind":"technology","name":"Alcohol reduction, pricing and cancer warning labels","route":"/technologies/alcohol-reduction-labelling/","asOf":"2026-09-08","days":20},{"id":"vitamin-d-omega3-supplementation","kind":"technology","name":"Vitamin D and omega-3 supplementation","route":"/technologies/vitamin-d-omega3-supplementation/","asOf":"2026-09-08","days":20},{"id":"aspirin-cancer-prevention","kind":"technology","name":"Aspirin for cancer prevention and adjuvant therapy","route":"/technologies/aspirin-cancer-prevention/","asOf":"2026-09-08","days":20},{"id":"coffee-intake-cancer","kind":"technology","name":"Coffee and tea intake","route":"/technologies/coffee-intake-cancer/","asOf":"2026-09-08","days":20},{"id":"red-processed-meat-reduction","kind":"technology","name":"Red and processed meat reduction","route":"/technologies/red-processed-meat-reduction/","asOf":"2026-09-08","days":20},{"id":"ultra-processed-food-ssb","kind":"technology","name":"Ultra-processed food and sugar-sweetened drinks","route":"/technologies/ultra-processed-food-ssb/","asOf":"2026-09-08","days":20},{"id":"smoking-cessation-after-diagnosis","kind":"technology","name":"Smoking cessation in cancer patients","route":"/technologies/smoking-cessation-after-diagnosis/","asOf":"2026-09-08","days":20},{"id":"sleep-circadian-interventions","kind":"technology","name":"Sleep and circadian interventions in cancer","route":"/technologies/sleep-circadian-interventions/","asOf":"2026-09-08","days":20},{"id":"cachexia-appetite-pharmacotherapy","kind":"technology","name":"Cachexia pharmacotherapy: GDF-15 blockade, anamorelin, olanzapine","route":"/technologies/cachexia-appetite-pharmacotherapy/","asOf":"2026-09-08","days":20},{"id":"dietitian-led-weight-loss-breast","kind":"technology","name":"Dietitian-led weight-loss programmes in HR-positive breast cancer","route":"/technologies/dietitian-led-weight-loss-breast/","asOf":"2026-09-08","days":20},{"id":"soy-breast-cancer","kind":"technology","name":"Soy foods and breast cancer","route":"/technologies/soy-breast-cancer/","asOf":"2026-09-08","days":20},{"id":"dietary-supplements-treatment-interactions","kind":"technology","name":"Dietary supplements during cancer treatment: interactions and harms","route":"/technologies/dietary-supplements-treatment-interactions/","asOf":"2026-09-08","days":20},{"id":"cachexia","kind":"term","name":"Cancer cachexia","route":"/terms/cachexia/","asOf":"2026-09-08","days":20},{"id":"sarcopenia","kind":"term","name":"Sarcopenia","route":"/terms/sarcopenia/","asOf":"2026-09-08","days":20},{"id":"immunonutrition","kind":"term","name":"Immunonutrition","route":"/terms/immunonutrition/","asOf":"2026-09-08","days":20},{"id":"glycaemic-index","kind":"term","name":"Glycaemic index and glycaemic load","route":"/terms/glycaemic-index/","asOf":"2026-09-08","days":20},{"id":"warburg-effect-diet-claims","kind":"term","name":"Warburg-effect diet claims ('sugar feeds cancer')","route":"/terms/warburg-effect-diet-claims/","asOf":"2026-09-08","days":20},{"id":"unproven-diet-claims","kind":"term","name":"Unproven diet claims (alkaline, juice, 'anti-cancer' diets)","route":"/terms/unproven-diet-claims/","asOf":"2026-09-08","days":20},{"id":"ultra-processed-food","kind":"term","name":"Ultra-processed food (NOVA group 4)","route":"/terms/ultra-processed-food/","asOf":"2026-09-08","days":20},{"id":"metabolic-syndrome","kind":"term","name":"Metabolic syndrome and insulin resistance","route":"/terms/metabolic-syndrome/","asOf":"2026-09-08","days":20},{"id":"prehabilitation-term","kind":"term","name":"Prehabilitation (the pre-treatment window)","route":"/terms/prehabilitation-term/","asOf":"2026-09-08","days":20},{"id":"met-hours","kind":"term","name":"MET-hours per week","route":"/terms/met-hours/","asOf":"2026-09-08","days":20},{"id":"body-composition","kind":"term","name":"Body composition (lean mass, fat mass, visceral fat)","route":"/terms/body-composition/","asOf":"2026-09-08","days":20},{"id":"gut-microbiome-diversity","kind":"term","name":"Gut microbiome diversity and composition","route":"/terms/gut-microbiome-diversity/","asOf":"2026-09-08","days":20},{"id":"dietary-pattern-scores","kind":"term","name":"Dietary pattern scores (Mediterranean, HEI, AHEI, DASH, WCRF/AICR)","route":"/terms/dietary-pattern-scores/","asOf":"2026-09-08","days":20},{"id":"nutrition-impact-symptoms","kind":"term","name":"Nutrition impact symptoms","route":"/terms/nutrition-impact-symptoms/","asOf":"2026-09-08","days":20},{"id":"malnutrition-screening","kind":"term","name":"Malnutrition screening tools (MUST, NRS-2002, MST, PG-SGA)","route":"/terms/malnutrition-screening/","asOf":"2026-09-08","days":20},{"id":"obesity-related-cancers","kind":"term","name":"Obesity-related cancers (IARC list of 13)","route":"/terms/obesity-related-cancers/","asOf":"2026-09-08","days":20},{"id":"energy-balance","kind":"term","name":"Energy balance","route":"/terms/energy-balance/","asOf":"2026-09-08","days":20},{"id":"alcohol-attributable-cancer","kind":"term","name":"Alcohol-attributable cancer","route":"/terms/alcohol-attributable-cancer/","asOf":"2026-09-08","days":20},{"id":"challenge","kind":"trial","name":"CHALLENGE (CCTG CO.21)","route":"/trials/challenge/","asOf":"2026-09-08","days":20},{"id":"bwel","kind":"trial","name":"BWEL (Breast Cancer Weight Loss, Alliance A011401)","route":"/trials/bwel/","asOf":"2026-09-08","days":20},{"id":"vital","kind":"trial","name":"VITAL (VITamin D and OmegA-3 TriaL)","route":"/trials/vital/","asOf":"2026-09-08","days":20},{"id":"aspree","kind":"trial","name":"ASPREE (ASPirin in Reducing Events in the Elderly)","route":"/trials/aspree/","asOf":"2026-09-08","days":20},{"id":"alascca","kind":"trial","name":"ALASCCA","route":"/trials/alascca/","asOf":"2026-09-08","days":20},{"id":"add-aspirin","kind":"trial","name":"Add-Aspirin","route":"/trials/add-aspirin/","asOf":"2026-09-08","days":20},{"id":"romana-1-2","kind":"trial","name":"ROMANA 1 and ROMANA 2","route":"/trials/romana-1-2/","asOf":"2026-09-08","days":20},{"id":"ponsegromab-phase-2","kind":"trial","name":"Ponsegromab phase 2 in cancer cachexia","route":"/trials/ponsegromab-phase-2/","asOf":"2026-09-08","days":20},{"id":"olanzapine-appetite-tmh","kind":"trial","name":"Low-dose olanzapine for cancer anorexia (Tata Memorial)","route":"/trials/olanzapine-appetite-tmh/","asOf":"2026-09-08","days":20},{"id":"fmt-pd1-refractory-melanoma-pitt","kind":"trial","name":"FMT plus pembrolizumab in anti-PD-1-refractory melanoma (Pittsburgh)","route":"/trials/fmt-pd1-refractory-melanoma-pitt/","asOf":"2026-09-08","days":20},{"id":"mimic-01","kind":"trial","name":"MIMic-01: healthy-donor FMT plus anti-PD-1, first-line melanoma","route":"/trials/mimic-01/","asOf":"2026-09-08","days":20},{"id":"ergo2","kind":"trial","name":"ERGO2: ketogenic diet and fasting during re-irradiation of recurrent glioma","route":"/trials/ergo2/","asOf":"2026-09-08","days":20},{"id":"prehab-trial","kind":"trial","name":"PREHAB: multimodal prehabilitation before colorectal cancer surgery","route":"/trials/prehab-trial/","asOf":"2026-09-08","days":20},{"id":"whel","kind":"trial","name":"WHEL (Women's Healthy Eating and Living)","route":"/trials/whel/","asOf":"2026-09-08","days":20},{"id":"idea-nl-exercise-dose-finding","kind":"idea","name":"A dose-finding trial for exercise after cancer","route":"/ideas/idea-nl-exercise-dose-finding/","asOf":"2026-09-08","days":20},{"id":"idea-nl-glp1-adjuvant-hr-breast","kind":"idea","name":"GLP-1 receptor agonists as adjuvant weight-loss therapy in HR-positive breast cancer","route":"/ideas/idea-nl-glp1-adjuvant-hr-breast/","asOf":"2026-09-08","days":20},{"id":"idea-nl-ketogenic-gbm-definitive-trial","kind":"idea","name":"One definitive ketogenic diet trial in glioblastoma, then stop","route":"/ideas/idea-nl-ketogenic-gbm-definitive-trial/","asOf":"2026-09-08","days":20},{"id":"idea-nl-diet-covariates-io-trials","kind":"idea","name":"Capture diet, fibre and antibiotic exposure in every immunotherapy pivotal trial","route":"/ideas/idea-nl-diet-covariates-io-trials/","asOf":"2026-09-08","days":20},{"id":"idea-nl-alcohol-minimum-pricing-cancer-endpoints","kind":"idea","name":"Evaluate alcohol minimum unit pricing against cancer incidence","route":"/ideas/idea-nl-alcohol-minimum-pricing-cancer-endpoints/","asOf":"2026-09-08","days":20},{"id":"idea-nl-upf-controlled-feeding-trial","kind":"idea","name":"Controlled feeding trials to separate ultra-processing from calories","route":"/ideas/idea-nl-upf-controlled-feeding-trial/","asOf":"2026-09-08","days":20},{"id":"idea-nl-antioxidant-supplement-harm-confirmation","kind":"idea","name":"Confirm or refute the harm of antioxidant supplements during chemotherapy","route":"/ideas/idea-nl-antioxidant-supplement-harm-confirmation/","asOf":"2026-09-08","days":20},{"id":"idea-nl-bariatric-cancer-registry-linkage","kind":"idea","name":"Link bariatric and GLP-1 registries to cancer registries in every country that has both","route":"/ideas/idea-nl-bariatric-cancer-registry-linkage/","asOf":"2026-09-08","days":20},{"id":"idea-nl-sleep-circadian-survivorship-rct","kind":"idea","name":"Treat insomnia in survivors and measure whether the cancer notices","route":"/ideas/idea-nl-sleep-circadian-survivorship-rct/","asOf":"2026-09-08","days":20},{"id":"idea-nl-dietitian-in-every-mdt","kind":"idea","name":"A dietitian in every gastrointestinal and head and neck tumour board","route":"/ideas/idea-nl-dietitian-in-every-mdt/","asOf":"2026-09-08","days":20},{"id":"idea-nl-ask-about-diet-prebunking","kind":"idea","name":"Ask about diet at diagnosis, and prebunk the myths before the internet does","route":"/ideas/idea-nl-ask-about-diet-prebunking/","asOf":"2026-09-08","days":20},{"id":"arc-institute","kind":"institution","name":"Arc Institute","route":"/institutions/arc-institute/","asOf":"2026-09-08","days":20},{"id":"institute-for-protein-design","kind":"institution","name":"Institute for Protein Design (University of Washington)","route":"/institutions/institute-for-protein-design/","asOf":"2026-09-08","days":20},{"id":"providence-health","kind":"institution","name":"Providence Health & Services","route":"/institutions/providence-health/","asOf":"2026-09-08","days":20},{"id":"yale-school-of-medicine","kind":"institution","name":"Yale School of Medicine / Yale Cancer Center","route":"/institutions/yale-school-of-medicine/","asOf":"2026-09-08","days":20},{"id":"google-deepmind","kind":"company","name":"Google DeepMind (and Google Research)","route":"/companies/google-deepmind/","asOf":"2026-09-08","days":20},{"id":"microsoft-research","kind":"company","name":"Microsoft (Research and Health AI)","route":"/companies/microsoft-research/","asOf":"2026-09-08","days":20},{"id":"nvidia","kind":"company","name":"NVIDIA","route":"/companies/nvidia/","asOf":"2026-09-08","days":20},{"id":"evolutionaryscale","kind":"company","name":"EvolutionaryScale","route":"/companies/evolutionaryscale/","asOf":"2026-09-08","days":20},{"id":"vevo-therapeutics","kind":"company","name":"Vevo Therapeutics","route":"/companies/vevo-therapeutics/","asOf":"2026-09-08","days":20},{"id":"bioptimus","kind":"company","name":"Bioptimus","route":"/companies/bioptimus/","asOf":"2026-09-08","days":20},{"id":"aignostics","kind":"company","name":"Aignostics","route":"/companies/aignostics/","asOf":"2026-09-08","days":20},{"id":"kaiko-ai","kind":"company","name":"kaiko.ai","route":"/companies/kaiko-ai/","asOf":"2026-09-08","days":20},{"id":"histai","kind":"company","name":"HistAI","route":"/companies/histai/","asOf":"2026-09-08","days":20},{"id":"chai-discovery","kind":"company","name":"Chai Discovery","route":"/companies/chai-discovery/","asOf":"2026-09-08","days":20},{"id":"xaira-therapeutics","kind":"company","name":"Xaira Therapeutics","route":"/companies/xaira-therapeutics/","asOf":"2026-09-08","days":20},{"id":"lila-sciences","kind":"company","name":"Lila Sciences","route":"/companies/lila-sciences/","asOf":"2026-09-08","days":20},{"id":"cradle-bio","kind":"company","name":"Cradle","route":"/companies/cradle-bio/","asOf":"2026-09-08","days":20},{"id":"profluent-bio","kind":"company","name":"Profluent","route":"/companies/profluent-bio/","asOf":"2026-09-08","days":20},{"id":"latent-labs","kind":"company","name":"Latent Labs","route":"/companies/latent-labs/","asOf":"2026-09-08","days":20},{"id":"genesis-molecular-ai","kind":"company","name":"Genesis Molecular AI (formerly Genesis Therapeutics)","route":"/companies/genesis-molecular-ai/","asOf":"2026-09-08","days":20},{"id":"iambic-therapeutics","kind":"company","name":"Iambic Therapeutics","route":"/companies/iambic-therapeutics/","asOf":"2026-09-08","days":20},{"id":"chan-zuckerberg-initiative","kind":"company","name":"Chan Zuckerberg Initiative (Biohub)","route":"/companies/chan-zuckerberg-initiative/","asOf":"2026-09-08","days":20},{"id":"tcia","kind":"collection","name":"The Cancer Imaging Archive (TCIA)","route":"/collections/tcia/","asOf":"2026-09-08","days":20},{"id":"imaging-data-commons","kind":"collection","name":"NCI Imaging Data Commons (IDC)","route":"/collections/imaging-data-commons/","asOf":"2026-09-08","days":20},{"id":"uk-biobank","kind":"collection","name":"UK Biobank","route":"/collections/uk-biobank/","asOf":"2026-09-08","days":20},{"id":"all-of-us","kind":"collection","name":"All of Us Research Program","route":"/collections/all-of-us/","asOf":"2026-09-08","days":20},{"id":"flatiron-foundation-cgdb","kind":"collection","name":"Flatiron Health and Foundation Medicine Clinico-Genomic Database","route":"/collections/flatiron-foundation-cgdb/","asOf":"2026-09-08","days":20},{"id":"cdas-nlst-plco","kind":"collection","name":"NCI CDAS: NLST and PLCO screening trial data","route":"/collections/cdas-nlst-plco/","asOf":"2026-09-08","days":20},{"id":"pathology-benchmarks","kind":"collection","name":"Pathology AI benchmarks (CAMELYON, PANDA, TCGA slide tasks)","route":"/collections/pathology-benchmarks/","asOf":"2026-09-08","days":20},{"id":"tahoe-100m","kind":"collection","name":"Tahoe-100M","route":"/collections/tahoe-100m/","asOf":"2026-09-08","days":20},{"id":"arc-virtual-cell-atlas","kind":"collection","name":"Arc Virtual Cell Atlas","route":"/collections/arc-virtual-cell-atlas/","asOf":"2026-09-08","days":20},{"id":"virchow","kind":"technology","name":"Virchow / Virchow2 (Paige, MSK)","route":"/technologies/virchow/","asOf":"2026-09-08","days":20},{"id":"uni-conch","kind":"technology","name":"UNI and CONCH (Harvard, Mahmood Lab)","route":"/technologies/uni-conch/","asOf":"2026-09-08","days":20},{"id":"titan","kind":"technology","name":"TITAN (whole-slide multimodal model)","route":"/technologies/titan/","asOf":"2026-09-08","days":20},{"id":"prov-gigapath","kind":"technology","name":"Prov-GigaPath (Microsoft, Providence)","route":"/technologies/prov-gigapath/","asOf":"2026-09-08","days":20},{"id":"chief","kind":"technology","name":"CHIEF (Harvard, Yu Lab)","route":"/technologies/chief/","asOf":"2026-09-08","days":20},{"id":"musk","kind":"technology","name":"MUSK (Stanford, vision-language pathology)","route":"/technologies/musk/","asOf":"2026-09-08","days":20},{"id":"h-optimus","kind":"technology","name":"H-optimus (Bioptimus)","route":"/technologies/h-optimus/","asOf":"2026-09-08","days":20},{"id":"pluto","kind":"technology","name":"PLUTO (PathAI)","route":"/technologies/pluto/","asOf":"2026-09-08","days":20},{"id":"hibou","kind":"technology","name":"Hibou (HistAI)","route":"/technologies/hibou/","asOf":"2026-09-08","days":20},{"id":"kaiko-midnight","kind":"technology","name":"Midnight (kaiko.ai)","route":"/technologies/kaiko-midnight/","asOf":"2026-09-08","days":20},{"id":"atlas-aignostics","kind":"technology","name":"Atlas (Aignostics, Mayo Clinic, Charité)","route":"/technologies/atlas-aignostics/","asOf":"2026-09-08","days":20},{"id":"phikon","kind":"technology","name":"Phikon / Phikon-v2 (Owkin)","route":"/technologies/phikon/","asOf":"2026-09-08","days":20},{"id":"merlin-ct","kind":"technology","name":"Merlin (Stanford abdominal CT vision-language model)","route":"/technologies/merlin-ct/","asOf":"2026-09-08","days":20},{"id":"radfm","kind":"technology","name":"RadFM (generalist radiology foundation model)","route":"/technologies/radfm/","asOf":"2026-09-08","days":20},{"id":"ct-fm","kind":"technology","name":"CT-FM (whole-body CT foundation model)","route":"/technologies/ct-fm/","asOf":"2026-09-08","days":20},{"id":"medsam","kind":"technology","name":"MedSAM / SAM-Med3D (segment anything for medicine)","route":"/technologies/medsam/","asOf":"2026-09-08","days":20},{"id":"sybil","kind":"technology","name":"Sybil (MIT/MGH lung cancer risk from CT)","route":"/technologies/sybil/","asOf":"2026-09-08","days":20},{"id":"mirai","kind":"technology","name":"Mirai (MIT breast cancer risk from mammograms)","route":"/technologies/mirai/","asOf":"2026-09-08","days":20},{"id":"med-gemini","kind":"technology","name":"Med-Gemini and MedLM (Google)","route":"/technologies/med-gemini/","asOf":"2026-09-08","days":20},{"id":"aidoc-care","kind":"technology","name":"Aidoc CARE (clinical radiology foundation model)","route":"/technologies/aidoc-care/","asOf":"2026-09-08","days":20},{"id":"geneformer","kind":"technology","name":"Geneformer","route":"/technologies/geneformer/","asOf":"2026-09-08","days":20},{"id":"scgpt","kind":"technology","name":"scGPT","route":"/technologies/scgpt/","asOf":"2026-09-08","days":20},{"id":"universal-cell-embedding","kind":"technology","name":"Universal Cell Embedding (UCE)","route":"/technologies/universal-cell-embedding/","asOf":"2026-09-08","days":20},{"id":"scfoundation","kind":"technology","name":"scFoundation (BioMap)","route":"/technologies/scfoundation/","asOf":"2026-09-08","days":20},{"id":"nicheformer","kind":"technology","name":"Nicheformer (spatial single-cell)","route":"/technologies/nicheformer/","asOf":"2026-09-08","days":20},{"id":"cellfm","kind":"technology","name":"CellFM","route":"/technologies/cellfm/","asOf":"2026-09-08","days":20},{"id":"genept","kind":"technology","name":"GenePT","route":"/technologies/genept/","asOf":"2026-09-08","days":20},{"id":"c2s-scale","kind":"technology","name":"Cell2Sentence / C2S-Scale (Yale, Google)","route":"/technologies/c2s-scale/","asOf":"2026-09-08","days":20},{"id":"state-arc","kind":"technology","name":"State (Arc Institute perturbation model)","route":"/technologies/state-arc/","asOf":"2026-09-08","days":20},{"id":"transcriptformer","kind":"technology","name":"TranscriptFormer and rBio (CZI virtual cell models)","route":"/technologies/transcriptformer/","asOf":"2026-09-08","days":20},{"id":"gears","kind":"technology","name":"GEARS and perturbation prediction benchmarks","route":"/technologies/gears/","asOf":"2026-09-08","days":20},{"id":"alphafold3","kind":"technology","name":"AlphaFold 3","route":"/technologies/alphafold3/","asOf":"2026-09-08","days":20},{"id":"boltz","kind":"technology","name":"Boltz-1 / Boltz-2 (MIT, open)","route":"/technologies/boltz/","asOf":"2026-09-08","days":20},{"id":"chai-1","kind":"technology","name":"Chai-1 / Chai-2","route":"/technologies/chai-1/","asOf":"2026-09-08","days":20},{"id":"esm3","kind":"technology","name":"ESM3 (EvolutionaryScale)","route":"/technologies/esm3/","asOf":"2026-09-08","days":20},{"id":"evo2","kind":"technology","name":"Evo 2 (Arc Institute, NVIDIA)","route":"/technologies/evo2/","asOf":"2026-09-08","days":20},{"id":"rfdiffusion","kind":"technology","name":"RFdiffusion / RFdiffusion2 and ProteinMPNN (Baker Lab)","route":"/technologies/rfdiffusion/","asOf":"2026-09-08","days":20},{"id":"bioemu","kind":"technology","name":"BioEmu (Microsoft)","route":"/technologies/bioemu/","asOf":"2026-09-08","days":20},{"id":"nucleotide-transformer","kind":"technology","name":"Nucleotide Transformer (InstaDeep)","route":"/technologies/nucleotide-transformer/","asOf":"2026-09-08","days":20},{"id":"enformer-borzoi","kind":"technology","name":"Enformer and Borzoi (DeepMind, Calico)","route":"/technologies/enformer-borzoi/","asOf":"2026-09-08","days":20},{"id":"alphamissense","kind":"technology","name":"AlphaMissense","route":"/technologies/alphamissense/","asOf":"2026-09-08","days":20},{"id":"alphagenome","kind":"technology","name":"AlphaGenome","route":"/technologies/alphagenome/","asOf":"2026-09-08","days":20},{"id":"foresight-ehr","kind":"technology","name":"Foresight (generative EHR model)","route":"/technologies/foresight-ehr/","asOf":"2026-09-08","days":20},{"id":"tempus-multimodal","kind":"technology","name":"Tempus multimodal models","route":"/technologies/tempus-multimodal/","asOf":"2026-09-08","days":20},{"id":"bionemo","kind":"technology","name":"NVIDIA BioNeMo","route":"/technologies/bionemo/","asOf":"2026-09-08","days":20},{"id":"phenom-2","kind":"technology","name":"Phenom-2 and Recursion OS","route":"/technologies/phenom-2/","asOf":"2026-09-08","days":20},{"id":"chemistry42","kind":"technology","name":"Chemistry42 and Pharma.AI (Insilico)","route":"/technologies/chemistry42/","asOf":"2026-09-08","days":20},{"id":"virtual-cell","kind":"roadmap","name":"Virtual cell roadmap: from bulk omics to a predictive model of a cancer cell","route":"/roadmaps/virtual-cell/","asOf":"2026-09-08","days":20},{"id":"ai-oncology-clinic","kind":"roadmap","name":"AI in the oncology clinic: from narrow cleared tools to multimodal decision support","route":"/roadmaps/ai-oncology-clinic/","asOf":"2026-09-08","days":20},{"id":"emily-whitehead","kind":"person","name":"Emily Whitehead","route":"/people/emily-whitehead/","asOf":"2026-09-09","days":19},{"id":"henrietta-lacks","kind":"person","name":"Henrietta Lacks","route":"/people/henrietta-lacks/","asOf":"2026-09-09","days":19},{"id":"einar-gustafson","kind":"person","name":"Einar \"Jimmy\" Gustafson","route":"/people/einar-gustafson/","asOf":"2026-09-09","days":19},{"id":"terry-fox","kind":"person","name":"Terry Fox","route":"/people/terry-fox/","asOf":"2026-09-09","days":19},{"id":"stephen-sutton","kind":"person","name":"Stephen Sutton","route":"/people/stephen-sutton/","asOf":"2026-09-09","days":19},{"id":"angelina-jolie","kind":"person","name":"Angelina Jolie","route":"/people/angelina-jolie/","asOf":"2026-09-09","days":19},{"id":"katie-couric","kind":"person","name":"Katie Couric","route":"/people/katie-couric/","asOf":"2026-09-09","days":19},{"id":"chadwick-boseman","kind":"person","name":"Chadwick Boseman","route":"/people/chadwick-boseman/","asOf":"2026-09-09","days":19},{"id":"jade-goody","kind":"person","name":"Jade Goody","route":"/people/jade-goody/","asOf":"2026-09-09","days":19},{"id":"lance-armstrong","kind":"person","name":"Lance Armstrong","route":"/people/lance-armstrong/","asOf":"2026-09-09","days":19},{"id":"steve-jobs","kind":"person","name":"Steve Jobs","route":"/people/steve-jobs/","asOf":"2026-09-09","days":19},{"id":"randy-pausch","kind":"person","name":"Randy Pausch","route":"/people/randy-pausch/","asOf":"2026-09-09","days":19},{"id":"deborah-james","kind":"person","name":"Dame Deborah James","route":"/people/deborah-james/","asOf":"2026-09-09","days":19},{"id":"kris-hallenga","kind":"person","name":"Kris Hallenga","route":"/people/kris-hallenga/","asOf":"2026-09-09","days":19},{"id":"ashya-king","kind":"person","name":"Ashya King","route":"/people/ashya-king/","asOf":"2026-09-09","days":19},{"id":"kate-granger","kind":"person","name":"Kate Granger","route":"/people/kate-granger/","asOf":"2026-09-09","days":19},{"id":"betty-ford","kind":"person","name":"Betty Ford","route":"/people/betty-ford/","asOf":"2026-09-09","days":19},{"id":"audre-lorde","kind":"person","name":"Audre Lorde","route":"/people/audre-lorde/","asOf":"2026-09-09","days":19},{"id":"rose-kushner","kind":"person","name":"Rose Kushner","route":"/people/rose-kushner/","asOf":"2026-09-09","days":19},{"id":"gilda-radner","kind":"person","name":"Gilda Radner","route":"/people/gilda-radner/","asOf":"2026-09-09","days":19},{"id":"jim-valvano","kind":"person","name":"Jim Valvano","route":"/people/jim-valvano/","asOf":"2026-09-09","days":19},{"id":"alex-scott","kind":"person","name":"Alexandra \"Alex\" Scott","route":"/people/alex-scott/","asOf":"2026-09-09","days":19},{"id":"barbara-bradfield","kind":"person","name":"Barbara Bradfield","route":"/people/barbara-bradfield/","asOf":"2026-09-09","days":19},{"id":"bud-romine","kind":"person","name":"Bud Romine","route":"/people/bud-romine/","asOf":"2026-09-09","days":19},{"id":"sharon-belvin","kind":"person","name":"Sharon Belvin","route":"/people/sharon-belvin/","asOf":"2026-09-09","days":19},{"id":"robert-sandler","kind":"person","name":"Robert Sandler","route":"/people/robert-sandler/","asOf":"2026-09-09","days":19},{"id":"mary-lasker","kind":"person","name":"Mary Lasker","route":"/people/mary-lasker/","asOf":"2026-09-09","days":19},{"id":"nancy-brinker","kind":"person","name":"Nancy Brinker","route":"/people/nancy-brinker/","asOf":"2026-09-09","days":19},{"id":"evelyn-lauder","kind":"person","name":"Evelyn Lauder","route":"/people/evelyn-lauder/","asOf":"2026-09-09","days":19},{"id":"fran-visco","kind":"person","name":"Fran Visco","route":"/people/fran-visco/","asOf":"2026-09-09","days":19},{"id":"susan-love","kind":"person","name":"Susan Love","route":"/people/susan-love/","asOf":"2026-09-09","days":19},{"id":"cicely-saunders","kind":"person","name":"Dame Cicely Saunders","route":"/people/cicely-saunders/","asOf":"2026-09-09","days":19},{"id":"elisabeth-kubler-ross","kind":"person","name":"Elisabeth Kübler-Ross","route":"/people/elisabeth-kubler-ross/","asOf":"2026-09-09","days":19},{"id":"sidney-farber","kind":"person","name":"Sidney Farber","route":"/people/sidney-farber/","asOf":"2026-09-09","days":19},{"id":"gertrude-elion","kind":"person","name":"Gertrude Elion","route":"/people/gertrude-elion/","asOf":"2026-09-09","days":19},{"id":"jane-cooke-wright","kind":"person","name":"Jane Cooke Wright","route":"/people/jane-cooke-wright/","asOf":"2026-09-09","days":19},{"id":"emil-freireich","kind":"person","name":"Emil J Freireich","route":"/people/emil-freireich/","asOf":"2026-09-09","days":19},{"id":"emil-frei","kind":"person","name":"Emil \"Tom\" Frei III","route":"/people/emil-frei/","asOf":"2026-09-09","days":19},{"id":"donald-pinkel","kind":"person","name":"Donald Pinkel","route":"/people/donald-pinkel/","asOf":"2026-09-09","days":19},{"id":"bernard-fisher","kind":"person","name":"Bernard Fisher","route":"/people/bernard-fisher/","asOf":"2026-09-09","days":19},{"id":"jimmie-holland","kind":"person","name":"Jimmie Holland","route":"/people/jimmie-holland/","asOf":"2026-09-09","days":19},{"id":"judah-folkman","kind":"person","name":"Judah Folkman","route":"/people/judah-folkman/","asOf":"2026-09-09","days":19},{"id":"brian-druker","kind":"person","name":"Brian Druker","route":"/people/brian-druker/","asOf":"2026-09-09","days":19},{"id":"tasuku-honjo","kind":"person","name":"Tasuku Honjo","route":"/people/tasuku-honjo/","asOf":"2026-09-09","days":19},{"id":"harald-zur-hausen","kind":"person","name":"Harald zur Hausen","route":"/people/harald-zur-hausen/","asOf":"2026-09-09","days":19},{"id":"ian-frazer","kind":"person","name":"Ian Frazer","route":"/people/ian-frazer/","asOf":"2026-09-09","days":19},{"id":"jian-zhou","kind":"person","name":"Jian Zhou","route":"/people/jian-zhou/","asOf":"2026-09-09","days":19},{"id":"mary-claire-king","kind":"person","name":"Mary-Claire King","route":"/people/mary-claire-king/","asOf":"2026-09-09","days":19},{"id":"janet-rowley","kind":"person","name":"Janet Rowley","route":"/people/janet-rowley/","asOf":"2026-09-09","days":19},{"id":"sid-sijbrandij","kind":"person","name":"Sid Sijbrandij","route":"/people/sid-sijbrandij/","asOf":"2026-09-09","days":19},{"id":"sn-38","kind":"term","name":"SN-38","route":"/terms/sn-38/","asOf":"2026-09-09","days":19},{"id":"dxd","kind":"term","name":"DXd","route":"/terms/dxd/","asOf":"2026-09-09","days":19},{"id":"exatecan","kind":"term","name":"Exatecan (and derivatives)","route":"/terms/exatecan/","asOf":"2026-09-09","days":19},{"id":"t030","kind":"term","name":"T030 (belotecan derivative)","route":"/terms/t030/","asOf":"2026-09-09","days":19},{"id":"mmae","kind":"term","name":"MMAE","route":"/terms/mmae/","asOf":"2026-09-09","days":19},{"id":"mmaf","kind":"term","name":"MMAF","route":"/terms/mmaf/","asOf":"2026-09-09","days":19},{"id":"dm1","kind":"term","name":"DM1","route":"/terms/dm1/","asOf":"2026-09-09","days":19},{"id":"dm4","kind":"term","name":"DM4","route":"/terms/dm4/","asOf":"2026-09-09","days":19},{"id":"pbd-sg3199","kind":"term","name":"PBD dimer (SG3199 / tesirine)","route":"/terms/pbd-sg3199/","asOf":"2026-09-09","days":19},{"id":"calicheamicin","kind":"term","name":"Calicheamicin","route":"/terms/calicheamicin/","asOf":"2026-09-09","days":19},{"id":"duocarmycin","kind":"term","name":"Duocarmycin (seco-DUBA)","route":"/terms/duocarmycin/","asOf":"2026-09-09","days":19},{"id":"topoisomerase-i-payloads","kind":"term","name":"Topoisomerase-I inhibitor payloads","route":"/terms/topoisomerase-i-payloads/","asOf":"2026-09-09","days":19},{"id":"tubulin-inhibitor-payloads","kind":"term","name":"Tubulin inhibitor payloads","route":"/terms/tubulin-inhibitor-payloads/","asOf":"2026-09-09","days":19},{"id":"pbd-dimer-payloads","kind":"term","name":"DNA crosslinker payloads (PBD dimers)","route":"/terms/pbd-dimer-payloads/","asOf":"2026-09-09","days":19},{"id":"dna-cleaver-payloads","kind":"term","name":"DNA cleaver payloads (enediynes)","route":"/terms/dna-cleaver-payloads/","asOf":"2026-09-09","days":19},{"id":"dna-alkylator-payloads","kind":"term","name":"DNA alkylator payloads","route":"/terms/dna-alkylator-payloads/","asOf":"2026-09-09","days":19},{"id":"cl2a","kind":"term","name":"CL2A","route":"/terms/cl2a/","asOf":"2026-09-09","days":19},{"id":"ggfg","kind":"term","name":"Tetrapeptide GGFG (maleimide-GGFG-aminomethyl)","route":"/terms/ggfg/","asOf":"2026-09-09","days":19},{"id":"mc-vc-pabc","kind":"term","name":"mc-Val-Cit-PABC","route":"/terms/mc-vc-pabc/","asOf":"2026-09-09","days":19},{"id":"smcc","kind":"term","name":"SMCC (thioether, non-cleavable)","route":"/terms/smcc/","asOf":"2026-09-09","days":19},{"id":"sulfo-spdb","kind":"term","name":"Sulfo-SPDB (disulfide)","route":"/terms/sulfo-spdb/","asOf":"2026-09-09","days":19},{"id":"hydrazone","kind":"term","name":"Acid-labile hydrazone (AcBut)","route":"/terms/hydrazone/","asOf":"2026-09-09","days":19},{"id":"val-ala","kind":"term","name":"Val-Ala dipeptide","route":"/terms/val-ala/","asOf":"2026-09-09","days":19},{"id":"mc-non-cleavable","kind":"term","name":"Maleimidocaproyl (mc), non-cleavable","route":"/terms/mc-non-cleavable/","asOf":"2026-09-09","days":19},{"id":"hydrophilic-next-gen","kind":"term","name":"Hydrophilic next-generation linkers (TMALIN, Dolaflexin, sulfonyl-pyrimidine, PEG-containing)","route":"/terms/hydrophilic-next-gen/","asOf":"2026-09-09","days":19},{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/","asOf":"2026-09-09","days":19},{"id":"lancet","kind":"journal","name":"The Lancet","route":"/journals/lancet/","asOf":"2026-09-09","days":19},{"id":"jama","kind":"journal","name":"JAMA","route":"/journals/jama/","asOf":"2026-09-09","days":19},{"id":"jama-internal-medicine","kind":"journal","name":"JAMA Internal Medicine","route":"/journals/jama-internal-medicine/","asOf":"2026-09-09","days":19},{"id":"bmj","kind":"journal","name":"BMJ","route":"/journals/bmj/","asOf":"2026-09-09","days":19},{"id":"annals-internal-medicine","kind":"journal","name":"Annals of Internal Medicine","route":"/journals/annals-internal-medicine/","asOf":"2026-09-09","days":19},{"id":"plos-medicine","kind":"journal","name":"PLOS Medicine","route":"/journals/plos-medicine/","asOf":"2026-09-09","days":19},{"id":"lancet-global-health","kind":"journal","name":"The Lancet Global Health","route":"/journals/lancet-global-health/","asOf":"2026-09-09","days":19},{"id":"lancet-oncology","kind":"journal","name":"The Lancet Oncology","route":"/journals/lancet-oncology/","asOf":"2026-09-09","days":19},{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/","asOf":"2026-09-09","days":19},{"id":"jco-precision-oncology","kind":"journal","name":"JCO Precision Oncology","route":"/journals/jco-precision-oncology/","asOf":"2026-09-09","days":19},{"id":"jco-oncology-practice","kind":"journal","name":"JCO Oncology Practice","route":"/journals/jco-oncology-practice/","asOf":"2026-09-09","days":19},{"id":"annals-of-oncology","kind":"journal","name":"Annals of Oncology","route":"/journals/annals-of-oncology/","asOf":"2026-09-09","days":19},{"id":"gut","kind":"journal","name":"Gut","route":"/journals/gut/","asOf":"2026-09-09","days":19},{"id":"gastroenterology","kind":"journal","name":"Gastroenterology","route":"/journals/gastroenterology/","asOf":"2026-09-09","days":19},{"id":"esmo-open","kind":"journal","name":"ESMO Open","route":"/journals/esmo-open/","asOf":"2026-09-09","days":19},{"id":"jama-oncology","kind":"journal","name":"JAMA Oncology","route":"/journals/jama-oncology/","asOf":"2026-09-09","days":19},{"id":"jnci","kind":"journal","name":"JNCI: Journal of the National Cancer Institute","route":"/journals/jnci/","asOf":"2026-09-09","days":19},{"id":"cancer-wiley","kind":"journal","name":"Cancer","route":"/journals/cancer-wiley/","asOf":"2026-09-09","days":19},{"id":"ca-cancer-journal","kind":"journal","name":"CA: A Cancer Journal for Clinicians","route":"/journals/ca-cancer-journal/","asOf":"2026-09-09","days":19},{"id":"british-journal-of-cancer","kind":"journal","name":"British Journal of Cancer","route":"/journals/british-journal-of-cancer/","asOf":"2026-09-09","days":19},{"id":"european-journal-of-cancer","kind":"journal","name":"European Journal of Cancer","route":"/journals/european-journal-of-cancer/","asOf":"2026-09-09","days":19},{"id":"jnccn","kind":"journal","name":"Journal of the National Comprehensive Cancer Network","route":"/journals/jnccn/","asOf":"2026-09-09","days":19},{"id":"journal-of-thoracic-oncology","kind":"journal","name":"Journal of Thoracic Oncology","route":"/journals/journal-of-thoracic-oncology/","asOf":"2026-09-09","days":19},{"id":"gynecologic-oncology","kind":"journal","name":"Gynecologic Oncology","route":"/journals/gynecologic-oncology/","asOf":"2026-09-09","days":19},{"id":"european-urology","kind":"journal","name":"European Urology","route":"/journals/european-urology/","asOf":"2026-09-09","days":19},{"id":"european-urology-oncology","kind":"journal","name":"European Urology Oncology","route":"/journals/european-urology-oncology/","asOf":"2026-09-09","days":19},{"id":"neuro-oncology","kind":"journal","name":"Neuro-Oncology","route":"/journals/neuro-oncology/","asOf":"2026-09-09","days":19},{"id":"radiotherapy-and-oncology","kind":"journal","name":"Radiotherapy and Oncology","route":"/journals/radiotherapy-and-oncology/","asOf":"2026-09-09","days":19},{"id":"ijrobp","kind":"journal","name":"International Journal of Radiation Oncology, Biology, Physics","route":"/journals/ijrobp/","asOf":"2026-09-09","days":19},{"id":"journal-of-nuclear-medicine","kind":"journal","name":"Journal of Nuclear Medicine","route":"/journals/journal-of-nuclear-medicine/","asOf":"2026-09-09","days":19},{"id":"radiology","kind":"journal","name":"Radiology","route":"/journals/radiology/","asOf":"2026-09-09","days":19},{"id":"pediatric-blood-and-cancer","kind":"journal","name":"Pediatric Blood & Cancer","route":"/journals/pediatric-blood-and-cancer/","asOf":"2026-09-09","days":19},{"id":"blood","kind":"journal","name":"Blood","route":"/journals/blood/","asOf":"2026-09-09","days":19},{"id":"blood-advances","kind":"journal","name":"Blood Advances","route":"/journals/blood-advances/","asOf":"2026-09-09","days":19},{"id":"leukemia","kind":"journal","name":"Leukemia","route":"/journals/leukemia/","asOf":"2026-09-09","days":19},{"id":"lancet-haematology","kind":"journal","name":"The Lancet Haematology","route":"/journals/lancet-haematology/","asOf":"2026-09-09","days":19},{"id":"haematologica","kind":"journal","name":"Haematologica","route":"/journals/haematologica/","asOf":"2026-09-09","days":19},{"id":"nature","kind":"journal","name":"Nature","route":"/journals/nature/","asOf":"2026-09-09","days":19},{"id":"science","kind":"journal","name":"Science","route":"/journals/science/","asOf":"2026-09-09","days":19},{"id":"cell","kind":"journal","name":"Cell","route":"/journals/cell/","asOf":"2026-09-09","days":19},{"id":"cancer-cell","kind":"journal","name":"Cancer Cell","route":"/journals/cancer-cell/","asOf":"2026-09-09","days":19},{"id":"cell-stem-cell","kind":"journal","name":"Cell Stem Cell","route":"/journals/cell-stem-cell/","asOf":"2026-09-09","days":19},{"id":"nature-medicine","kind":"journal","name":"Nature Medicine","route":"/journals/nature-medicine/","asOf":"2026-09-09","days":19},{"id":"nature-cancer","kind":"journal","name":"Nature Cancer","route":"/journals/nature-cancer/","asOf":"2026-09-09","days":19},{"id":"nature-reviews-cancer","kind":"journal","name":"Nature Reviews Cancer","route":"/journals/nature-reviews-cancer/","asOf":"2026-09-09","days":19},{"id":"nature-reviews-clinical-oncology","kind":"journal","name":"Nature Reviews Clinical Oncology","route":"/journals/nature-reviews-clinical-oncology/","asOf":"2026-09-09","days":19},{"id":"nature-reviews-drug-discovery","kind":"journal","name":"Nature Reviews Drug Discovery","route":"/journals/nature-reviews-drug-discovery/","asOf":"2026-09-09","days":19},{"id":"nature-genetics","kind":"journal","name":"Nature Genetics","route":"/journals/nature-genetics/","asOf":"2026-09-09","days":19},{"id":"nature-biotechnology","kind":"journal","name":"Nature Biotechnology","route":"/journals/nature-biotechnology/","asOf":"2026-09-09","days":19},{"id":"nature-communications","kind":"journal","name":"Nature Communications","route":"/journals/nature-communications/","asOf":"2026-09-09","days":19},{"id":"science-translational-medicine","kind":"journal","name":"Science Translational Medicine","route":"/journals/science-translational-medicine/","asOf":"2026-09-09","days":19},{"id":"cancer-discovery","kind":"journal","name":"Cancer Discovery","route":"/journals/cancer-discovery/","asOf":"2026-09-09","days":19},{"id":"cancer-research","kind":"journal","name":"Cancer Research","route":"/journals/cancer-research/","asOf":"2026-09-09","days":19},{"id":"clinical-cancer-research","kind":"journal","name":"Clinical Cancer Research","route":"/journals/clinical-cancer-research/","asOf":"2026-09-09","days":19},{"id":"cancer-immunology-research","kind":"journal","name":"Cancer Immunology Research","route":"/journals/cancer-immunology-research/","asOf":"2026-09-09","days":19},{"id":"molecular-cancer-therapeutics","kind":"journal","name":"Molecular Cancer Therapeutics","route":"/journals/molecular-cancer-therapeutics/","asOf":"2026-09-09","days":19},{"id":"cancer-epidemiology-biomarkers-prevention","kind":"journal","name":"Cancer Epidemiology, Biomarkers & Prevention","route":"/journals/cancer-epidemiology-biomarkers-prevention/","asOf":"2026-09-09","days":19},{"id":"jitc","kind":"journal","name":"Journal for ImmunoTherapy of Cancer","route":"/journals/jitc/","asOf":"2026-09-09","days":19},{"id":"jci","kind":"journal","name":"Journal of Clinical Investigation","route":"/journals/jci/","asOf":"2026-09-09","days":19},{"id":"genes-and-development","kind":"journal","name":"Genes & Development","route":"/journals/genes-and-development/","asOf":"2026-09-09","days":19},{"id":"pnas","kind":"journal","name":"Proceedings of the National Academy of Sciences","route":"/journals/pnas/","asOf":"2026-09-09","days":19},{"id":"elife","kind":"journal","name":"eLife","route":"/journals/elife/","asOf":"2026-09-09","days":19},{"id":"cancers-mdpi","kind":"journal","name":"Cancers","route":"/journals/cancers-mdpi/","asOf":"2026-09-09","days":19},{"id":"clinical-pharmacology-and-therapeutics","kind":"journal","name":"Clinical Pharmacology & Therapeutics","route":"/journals/clinical-pharmacology-and-therapeutics/","asOf":"2026-09-09","days":19},{"id":"lancet-digital-health","kind":"journal","name":"The Lancet Digital Health","route":"/journals/lancet-digital-health/","asOf":"2026-09-09","days":19},{"id":"nejm-evidence","kind":"journal","name":"NEJM Evidence","route":"/journals/nejm-evidence/","asOf":"2026-09-09","days":19},{"id":"medrxiv","kind":"journal","name":"medRxiv","route":"/journals/medrxiv/","asOf":"2026-09-09","days":19},{"id":"biorxiv","kind":"journal","name":"bioRxiv","route":"/journals/biorxiv/","asOf":"2026-09-09","days":19},{"id":"cell-term","kind":"term","name":"Cell","route":"/terms/cell-term/","asOf":"2026-09-09","days":19},{"id":"cell-membrane","kind":"term","name":"Cell membrane","route":"/terms/cell-membrane/","asOf":"2026-09-09","days":19},{"id":"nucleus","kind":"term","name":"Nucleus","route":"/terms/nucleus/","asOf":"2026-09-09","days":19},{"id":"dna-term","kind":"term","name":"DNA","route":"/terms/dna-term/","asOf":"2026-09-09","days":19},{"id":"rna","kind":"term","name":"RNA","route":"/terms/rna/","asOf":"2026-09-09","days":19},{"id":"gene","kind":"term","name":"Gene","route":"/terms/gene/","asOf":"2026-09-09","days":19},{"id":"chromosome","kind":"term","name":"Chromosome","route":"/terms/chromosome/","asOf":"2026-09-09","days":19},{"id":"protein","kind":"term","name":"Protein","route":"/terms/protein/","asOf":"2026-09-09","days":19},{"id":"enzyme","kind":"term","name":"Enzyme","route":"/terms/enzyme/","asOf":"2026-09-09","days":19},{"id":"gene-expression","kind":"term","name":"Gene expression","route":"/terms/gene-expression/","asOf":"2026-09-09","days":19},{"id":"mutation","kind":"term","name":"Mutation","route":"/terms/mutation/","asOf":"2026-09-09","days":19},{"id":"driver-mutation","kind":"term","name":"Driver mutation","route":"/terms/driver-mutation/","asOf":"2026-09-09","days":19},{"id":"amplification","kind":"term","name":"Amplification","route":"/terms/amplification/","asOf":"2026-09-09","days":19},{"id":"overexpression","kind":"term","name":"Overexpression","route":"/terms/overexpression/","asOf":"2026-09-09","days":19},{"id":"deletion","kind":"term","name":"Deletion","route":"/terms/deletion/","asOf":"2026-09-09","days":19},{"id":"oncogene","kind":"term","name":"Oncogene","route":"/terms/oncogene/","asOf":"2026-09-09","days":19},{"id":"tumour-suppressor-gene","kind":"term","name":"Tumour suppressor gene","route":"/terms/tumour-suppressor-gene/","asOf":"2026-09-09","days":19},{"id":"receptor","kind":"term","name":"Receptor","route":"/terms/receptor/","asOf":"2026-09-09","days":19},{"id":"ligand","kind":"term","name":"Ligand","route":"/terms/ligand/","asOf":"2026-09-09","days":19},{"id":"growth-factor","kind":"term","name":"Growth factor","route":"/terms/growth-factor/","asOf":"2026-09-09","days":19},{"id":"growth-signal","kind":"term","name":"Growth signal","route":"/terms/growth-signal/","asOf":"2026-09-09","days":19},{"id":"signalling-pathway","kind":"term","name":"Signalling pathway","route":"/terms/signalling-pathway/","asOf":"2026-09-09","days":19},{"id":"downstream","kind":"term","name":"Downstream and upstream","route":"/terms/downstream/","asOf":"2026-09-09","days":19},{"id":"kinase","kind":"term","name":"Kinase","route":"/terms/kinase/","asOf":"2026-09-09","days":19},{"id":"phosphorylation","kind":"term","name":"Phosphorylation","route":"/terms/phosphorylation/","asOf":"2026-09-09","days":19},{"id":"inhibitor","kind":"term","name":"Inhibitor","route":"/terms/inhibitor/","asOf":"2026-09-09","days":19},{"id":"agonist-antagonist","kind":"term","name":"Agonist and antagonist","route":"/terms/agonist-antagonist/","asOf":"2026-09-09","days":19},{"id":"antibody","kind":"term","name":"Antibody","route":"/terms/antibody/","asOf":"2026-09-09","days":19},{"id":"antigen","kind":"term","name":"Antigen","route":"/terms/antigen/","asOf":"2026-09-09","days":19},{"id":"epitope","kind":"term","name":"Epitope","route":"/terms/epitope/","asOf":"2026-09-09","days":19},{"id":"monoclonal","kind":"term","name":"Monoclonal","route":"/terms/monoclonal/","asOf":"2026-09-09","days":19},{"id":"cell-cycle","kind":"term","name":"Cell cycle","route":"/terms/cell-cycle/","asOf":"2026-09-09","days":19},{"id":"cell-division","kind":"term","name":"Cell division","route":"/terms/cell-division/","asOf":"2026-09-09","days":19},{"id":"proliferation","kind":"term","name":"Proliferation","route":"/terms/proliferation/","asOf":"2026-09-09","days":19},{"id":"differentiation","kind":"term","name":"Differentiation","route":"/terms/differentiation/","asOf":"2026-09-09","days":19},{"id":"stem-cell","kind":"term","name":"Stem cell","route":"/terms/stem-cell/","asOf":"2026-09-09","days":19},{"id":"apoptosis","kind":"term","name":"Apoptosis","route":"/terms/apoptosis/","asOf":"2026-09-09","days":19},{"id":"necrosis","kind":"term","name":"Necrosis","route":"/terms/necrosis/","asOf":"2026-09-09","days":19},{"id":"angiogenesis","kind":"term","name":"Angiogenesis","route":"/terms/angiogenesis/","asOf":"2026-09-09","days":19},{"id":"benign-vs-malignant","kind":"term","name":"Benign versus malignant","route":"/terms/benign-vs-malignant/","asOf":"2026-09-09","days":19},{"id":"primary-tumour","kind":"term","name":"Primary tumour","route":"/terms/primary-tumour/","asOf":"2026-09-09","days":19},{"id":"metastasis","kind":"term","name":"Metastasis","route":"/terms/metastasis/","asOf":"2026-09-09","days":19},{"id":"lesion","kind":"term","name":"Lesion","route":"/terms/lesion/","asOf":"2026-09-09","days":19},{"id":"carcinoma","kind":"term","name":"Carcinoma","route":"/terms/carcinoma/","asOf":"2026-09-09","days":19},{"id":"adenocarcinoma","kind":"term","name":"Adenocarcinoma","route":"/terms/adenocarcinoma/","asOf":"2026-09-09","days":19},{"id":"squamous-cell-carcinoma","kind":"term","name":"Squamous cell carcinoma","route":"/terms/squamous-cell-carcinoma/","asOf":"2026-09-09","days":19},{"id":"sarcoma-type","kind":"term","name":"Sarcoma (tissue type)","route":"/terms/sarcoma-type/","asOf":"2026-09-09","days":19},{"id":"lymphoma-type","kind":"term","name":"Lymphoma (tissue type)","route":"/terms/lymphoma-type/","asOf":"2026-09-09","days":19},{"id":"leukaemia-type","kind":"term","name":"Leukaemia (tissue type)","route":"/terms/leukaemia-type/","asOf":"2026-09-09","days":19},{"id":"bone-marrow","kind":"term","name":"Bone marrow","route":"/terms/bone-marrow/","asOf":"2026-09-09","days":19},{"id":"tumour-grade","kind":"term","name":"Grade","route":"/terms/tumour-grade/","asOf":"2026-09-09","days":19},{"id":"cancer-stage","kind":"term","name":"Stage","route":"/terms/cancer-stage/","asOf":"2026-09-09","days":19},{"id":"in-situ","kind":"term","name":"In situ","route":"/terms/in-situ/","asOf":"2026-09-09","days":19},{"id":"invasive-cancer","kind":"term","name":"Invasive","route":"/terms/invasive-cancer/","asOf":"2026-09-09","days":19},{"id":"lymph-node","kind":"term","name":"Lymph node","route":"/terms/lymph-node/","asOf":"2026-09-09","days":19},{"id":"biopsy","kind":"term","name":"Biopsy","route":"/terms/biopsy/","asOf":"2026-09-09","days":19},{"id":"histology","kind":"term","name":"Histology","route":"/terms/histology/","asOf":"2026-09-09","days":19},{"id":"biomarker","kind":"term","name":"Biomarker","route":"/terms/biomarker/","asOf":"2026-09-09","days":19},{"id":"tumour-marker","kind":"term","name":"Tumour marker","route":"/terms/tumour-marker/","asOf":"2026-09-09","days":19},{"id":"genomic-profiling","kind":"term","name":"Genomic profiling","route":"/terms/genomic-profiling/","asOf":"2026-09-09","days":19},{"id":"immune-system","kind":"term","name":"Immune system","route":"/terms/immune-system/","asOf":"2026-09-09","days":19},{"id":"t-cell","kind":"term","name":"T cell","route":"/terms/t-cell/","asOf":"2026-09-09","days":19},{"id":"b-cell","kind":"term","name":"B cell","route":"/terms/b-cell/","asOf":"2026-09-09","days":19},{"id":"nk-cell","kind":"term","name":"NK cell","route":"/terms/nk-cell/","asOf":"2026-09-09","days":19},{"id":"macrophage","kind":"term","name":"Macrophage","route":"/terms/macrophage/","asOf":"2026-09-09","days":19},{"id":"cytokine","kind":"term","name":"Cytokine","route":"/terms/cytokine/","asOf":"2026-09-09","days":19},{"id":"inflammation","kind":"term","name":"Inflammation","route":"/terms/inflammation/","asOf":"2026-09-09","days":19},{"id":"immune-checkpoint","kind":"term","name":"Immune checkpoint","route":"/terms/immune-checkpoint/","asOf":"2026-09-09","days":19},{"id":"immunotherapy-term","kind":"term","name":"Immunotherapy","route":"/terms/immunotherapy-term/","asOf":"2026-09-09","days":19},{"id":"chemotherapy-term","kind":"term","name":"Chemotherapy","route":"/terms/chemotherapy-term/","asOf":"2026-09-09","days":19},{"id":"targeted-therapy-term","kind":"term","name":"Targeted therapy","route":"/terms/targeted-therapy-term/","asOf":"2026-09-09","days":19},{"id":"hormone-therapy","kind":"term","name":"Hormone therapy","route":"/terms/hormone-therapy/","asOf":"2026-09-09","days":19},{"id":"radiotherapy","kind":"term","name":"Radiotherapy","route":"/terms/radiotherapy/","asOf":"2026-09-09","days":19},{"id":"systemic-vs-local-therapy","kind":"term","name":"Systemic versus local therapy","route":"/terms/systemic-vs-local-therapy/","asOf":"2026-09-09","days":19},{"id":"maintenance-therapy","kind":"term","name":"Maintenance therapy","route":"/terms/maintenance-therapy/","asOf":"2026-09-09","days":19},{"id":"palliative-treatment","kind":"term","name":"Palliative","route":"/terms/palliative-treatment/","asOf":"2026-09-09","days":19},{"id":"remission","kind":"term","name":"Remission","route":"/terms/remission/","asOf":"2026-09-09","days":19},{"id":"complete-response","kind":"term","name":"Complete response","route":"/terms/complete-response/","asOf":"2026-09-09","days":19},{"id":"partial-response","kind":"term","name":"Partial response","route":"/terms/partial-response/","asOf":"2026-09-09","days":19},{"id":"stable-disease","kind":"term","name":"Stable disease","route":"/terms/stable-disease/","asOf":"2026-09-09","days":19},{"id":"progression","kind":"term","name":"Progression","route":"/terms/progression/","asOf":"2026-09-09","days":19},{"id":"relapse-recurrence","kind":"term","name":"Recurrence and relapse","route":"/terms/relapse-recurrence/","asOf":"2026-09-09","days":19},{"id":"refractory","kind":"term","name":"Refractory","route":"/terms/refractory/","asOf":"2026-09-09","days":19},{"id":"duration-of-response","kind":"term","name":"Duration of response","route":"/terms/duration-of-response/","asOf":"2026-09-09","days":19},{"id":"prognosis","kind":"term","name":"Prognosis","route":"/terms/prognosis/","asOf":"2026-09-09","days":19},{"id":"clinical-trial","kind":"term","name":"Clinical trial","route":"/terms/clinical-trial/","asOf":"2026-09-09","days":19},{"id":"trial-phases","kind":"term","name":"Phase 1, 2 and 3 trials","route":"/terms/trial-phases/","asOf":"2026-09-09","days":19},{"id":"randomised-trial","kind":"term","name":"Randomised trial","route":"/terms/randomised-trial/","asOf":"2026-09-09","days":19},{"id":"placebo","kind":"term","name":"Placebo","route":"/terms/placebo/","asOf":"2026-09-09","days":19},{"id":"blinding","kind":"term","name":"Blinded trial","route":"/terms/blinding/","asOf":"2026-09-09","days":19},{"id":"endpoint","kind":"term","name":"Endpoint","route":"/terms/endpoint/","asOf":"2026-09-09","days":19},{"id":"surrogate-endpoint","kind":"term","name":"Surrogate endpoint","route":"/terms/surrogate-endpoint/","asOf":"2026-09-09","days":19},{"id":"hazard-ratio-basics","kind":"term","name":"Reading a hazard ratio","route":"/terms/hazard-ratio-basics/","asOf":"2026-09-09","days":19},{"id":"median-survival","kind":"term","name":"Median survival","route":"/terms/median-survival/","asOf":"2026-09-09","days":19},{"id":"confidence-interval","kind":"term","name":"Confidence interval","route":"/terms/confidence-interval/","asOf":"2026-09-09","days":19},{"id":"p-value","kind":"term","name":"P-value","route":"/terms/p-value/","asOf":"2026-09-09","days":19},{"id":"dose","kind":"term","name":"Dose","route":"/terms/dose/","asOf":"2026-09-09","days":19},{"id":"half-life","kind":"term","name":"Half-life","route":"/terms/half-life/","asOf":"2026-09-09","days":19},{"id":"toxicity-grade","kind":"term","name":"Toxicity grade","route":"/terms/toxicity-grade/","asOf":"2026-09-09","days":19},{"id":"side-effect-vs-adverse-event","kind":"term","name":"Side effect versus adverse event","route":"/terms/side-effect-vs-adverse-event/","asOf":"2026-09-09","days":19},{"id":"quality-of-life","kind":"term","name":"Quality of life","route":"/terms/quality-of-life/","asOf":"2026-09-09","days":19},{"id":"prodrug","kind":"term","name":"Prodrug","route":"/terms/prodrug/","asOf":"2026-09-09","days":19},{"id":"off-label","kind":"term","name":"Off-label","route":"/terms/off-label/","asOf":"2026-09-09","days":19},{"id":"orphan-drug","kind":"term","name":"Orphan drug","route":"/terms/orphan-drug/","asOf":"2026-09-09","days":19},{"id":"incidence-vs-prevalence","kind":"term","name":"Incidence versus prevalence","route":"/terms/incidence-vs-prevalence/","asOf":"2026-09-09","days":19},{"id":"mortality","kind":"term","name":"Mortality","route":"/terms/mortality/","asOf":"2026-09-09","days":19},{"id":"risk-factor","kind":"term","name":"Risk factor","route":"/terms/risk-factor/","asOf":"2026-09-09","days":19},{"id":"screening","kind":"term","name":"Screening","route":"/terms/screening/","asOf":"2026-09-09","days":19},{"id":"early-detection-term","kind":"term","name":"Early detection","route":"/terms/early-detection-term/","asOf":"2026-09-09","days":19},{"id":"in-vitro-in-vivo","kind":"term","name":"In vitro and in vivo","route":"/terms/in-vitro-in-vivo/","asOf":"2026-09-09","days":19},{"id":"preclinical","kind":"term","name":"Preclinical","route":"/terms/preclinical/","asOf":"2026-09-09","days":19},{"id":"model-organism","kind":"term","name":"Model organism","route":"/terms/model-organism/","asOf":"2026-09-09","days":19},{"id":"cell-line","kind":"term","name":"Cell line","route":"/terms/cell-line/","asOf":"2026-09-09","days":19},{"id":"organoid","kind":"term","name":"Organoid","route":"/terms/organoid/","asOf":"2026-09-09","days":19},{"id":"oesophagectomy","kind":"term","name":"Oesophagectomy","route":"/terms/oesophagectomy/","asOf":"2026-09-09","days":19},{"id":"whipple","kind":"term","name":"Whipple procedure (pancreaticoduodenectomy)","route":"/terms/whipple/","asOf":"2026-09-09","days":19},{"id":"lobectomy","kind":"term","name":"Lobectomy","route":"/terms/lobectomy/","asOf":"2026-09-09","days":19},{"id":"segmentectomy","kind":"term","name":"Segmentectomy (sublobar resection)","route":"/terms/segmentectomy/","asOf":"2026-09-09","days":19},{"id":"pneumonectomy","kind":"term","name":"Pneumonectomy","route":"/terms/pneumonectomy/","asOf":"2026-09-09","days":19},{"id":"cystectomy","kind":"term","name":"Radical cystectomy","route":"/terms/cystectomy/","asOf":"2026-09-09","days":19},{"id":"nephrectomy","kind":"term","name":"Nephrectomy","route":"/terms/nephrectomy/","asOf":"2026-09-09","days":19},{"id":"mastectomy","kind":"term","name":"Mastectomy","route":"/terms/mastectomy/","asOf":"2026-09-09","days":19},{"id":"lumpectomy","kind":"term","name":"Lumpectomy (breast-conserving surgery)","route":"/terms/lumpectomy/","asOf":"2026-09-09","days":19},{"id":"sentinel-lymph-node-biopsy","kind":"term","name":"Sentinel node biopsy","route":"/terms/sentinel-lymph-node-biopsy/","asOf":"2026-09-09","days":19},{"id":"lymphadenectomy","kind":"term","name":"Lymphadenectomy (lymph node dissection)","route":"/terms/lymphadenectomy/","asOf":"2026-09-09","days":19},{"id":"gastrectomy","kind":"term","name":"Gastrectomy","route":"/terms/gastrectomy/","asOf":"2026-09-09","days":19},{"id":"colectomy","kind":"term","name":"Colectomy","route":"/terms/colectomy/","asOf":"2026-09-09","days":19},{"id":"total-mesorectal-excision","kind":"term","name":"Total mesorectal excision (TME)","route":"/terms/total-mesorectal-excision/","asOf":"2026-09-09","days":19},{"id":"abdominoperineal-resection","kind":"term","name":"Abdominoperineal resection","route":"/terms/abdominoperineal-resection/","asOf":"2026-09-09","days":19},{"id":"hepatectomy","kind":"term","name":"Hepatectomy (liver resection)","route":"/terms/hepatectomy/","asOf":"2026-09-09","days":19},{"id":"prostatectomy","kind":"term","name":"Radical prostatectomy","route":"/terms/prostatectomy/","asOf":"2026-09-09","days":19},{"id":"orchiectomy","kind":"term","name":"Orchiectomy","route":"/terms/orchiectomy/","asOf":"2026-09-09","days":19},{"id":"hysterectomy","kind":"term","name":"Hysterectomy","route":"/terms/hysterectomy/","asOf":"2026-09-09","days":19},{"id":"salpingo-oophorectomy","kind":"term","name":"Salpingo-oophorectomy","route":"/terms/salpingo-oophorectomy/","asOf":"2026-09-09","days":19},{"id":"debulking","kind":"term","name":"Debulking (cytoreductive surgery)","route":"/terms/debulking/","asOf":"2026-09-09","days":19},{"id":"thyroidectomy","kind":"term","name":"Thyroidectomy","route":"/terms/thyroidectomy/","asOf":"2026-09-09","days":19},{"id":"adrenalectomy","kind":"term","name":"Adrenalectomy","route":"/terms/adrenalectomy/","asOf":"2026-09-09","days":19},{"id":"turbt","kind":"term","name":"Transurethral resection of bladder tumour (TURBT)","route":"/terms/turbt/","asOf":"2026-09-09","days":19},{"id":"limb-salvage-term","kind":"term","name":"Limb-salvage surgery","route":"/terms/limb-salvage-term/","asOf":"2026-09-09","days":19},{"id":"wide-local-excision","kind":"term","name":"Wide local excision","route":"/terms/wide-local-excision/","asOf":"2026-09-09","days":19},{"id":"mohs-surgery","kind":"term","name":"Mohs surgery","route":"/terms/mohs-surgery/","asOf":"2026-09-09","days":19},{"id":"endoscopic-resection-term","kind":"term","name":"EMR and ESD (endoscopic mucosal resection, endoscopic submucosal dissection)","route":"/terms/endoscopic-resection-term/","asOf":"2026-09-09","days":19},{"id":"colonoscopy","kind":"term","name":"Colonoscopy","route":"/terms/colonoscopy/","asOf":"2026-09-09","days":19},{"id":"endoscopy","kind":"term","name":"Endoscopy (EGD, EUS, ERCP)","route":"/terms/endoscopy/","asOf":"2026-09-09","days":19},{"id":"bronchoscopy","kind":"term","name":"Bronchoscopy (EBUS, robotic navigation)","route":"/terms/bronchoscopy/","asOf":"2026-09-09","days":19},{"id":"staging-laparoscopy","kind":"term","name":"Laparoscopy (keyhole surgery)","route":"/terms/staging-laparoscopy/","asOf":"2026-09-09","days":19},{"id":"minimally-invasive-surgery","kind":"term","name":"Minimally invasive surgery (laparoscopic, robotic, VATS)","route":"/terms/minimally-invasive-surgery/","asOf":"2026-09-09","days":19},{"id":"radiofrequency-ablation","kind":"term","name":"Radiofrequency ablation (RFA)","route":"/terms/radiofrequency-ablation/","asOf":"2026-09-09","days":19},{"id":"microwave-ablation","kind":"term","name":"Microwave ablation (MWA)","route":"/terms/microwave-ablation/","asOf":"2026-09-09","days":19},{"id":"cryoablation","kind":"term","name":"Cryoablation","route":"/terms/cryoablation/","asOf":"2026-09-09","days":19},{"id":"tace-term","kind":"term","name":"TACE (transarterial chemoembolisation)","route":"/terms/tace-term/","asOf":"2026-09-09","days":19},{"id":"tare","kind":"term","name":"TARE / SIRT (radioembolisation with yttrium-90)","route":"/terms/tare/","asOf":"2026-09-09","days":19},{"id":"stereotactic-radiosurgery","kind":"term","name":"Stereotactic radiosurgery (SRS)","route":"/terms/stereotactic-radiosurgery/","asOf":"2026-09-09","days":19},{"id":"wbrt","kind":"term","name":"Whole-brain radiotherapy (WBRT)","route":"/terms/wbrt/","asOf":"2026-09-09","days":19},{"id":"pci-term","kind":"term","name":"Prophylactic cranial irradiation (PCI)","route":"/terms/pci-term/","asOf":"2026-09-09","days":19},{"id":"biliary-stent","kind":"term","name":"Stenting (biliary, oesophageal, airway)","route":"/terms/biliary-stent/","asOf":"2026-09-09","days":19},{"id":"pleurodesis","kind":"term","name":"Pleurodesis and indwelling pleural catheter","route":"/terms/pleurodesis/","asOf":"2026-09-09","days":19},{"id":"apheresis","kind":"term","name":"Apheresis (leukapheresis)","route":"/terms/apheresis/","asOf":"2026-09-09","days":19},{"id":"intrathecal-therapy","kind":"term","name":"Intrathecal therapy (lumbar puncture, Ommaya reservoir)","route":"/terms/intrathecal-therapy/","asOf":"2026-09-09","days":19},{"id":"central-venous-access","kind":"term","name":"Central venous access (port, PICC line)","route":"/terms/central-venous-access/","asOf":"2026-09-09","days":19},{"id":"feeding-tube","kind":"term","name":"Feeding tube (gastrostomy, PEG, jejunostomy)","route":"/terms/feeding-tube/","asOf":"2026-09-09","days":19},{"id":"stoma","kind":"term","name":"Stoma (colostomy, ileostomy, urostomy)","route":"/terms/stoma/","asOf":"2026-09-09","days":19},{"id":"core-needle-biopsy","kind":"term","name":"Core needle biopsy and fine-needle aspiration (FNA)","route":"/terms/core-needle-biopsy/","asOf":"2026-09-09","days":19},{"id":"hipec-procedure","kind":"term","name":"HIPEC (hyperthermic intraperitoneal chemotherapy)","route":"/terms/hipec-procedure/","asOf":"2026-09-09","days":19},{"id":"brachytherapy-term","kind":"term","name":"Brachytherapy (internal radiotherapy)","route":"/terms/brachytherapy-term/","asOf":"2026-09-09","days":19},{"id":"sbrt-term","kind":"term","name":"Stereotactic body radiotherapy (SBRT / SABR)","route":"/terms/sbrt-term/","asOf":"2026-09-09","days":19},{"id":"imrt-term","kind":"term","name":"IMRT / IGRT / VMAT (modern external beam radiotherapy)","route":"/terms/imrt-term/","asOf":"2026-09-09","days":19},{"id":"mediastinum","kind":"term","name":"Mediastinum","route":"/terms/mediastinum/","asOf":"2026-09-09","days":19},{"id":"peritoneum","kind":"term","name":"Peritoneum and peritoneal metastases","route":"/terms/peritoneum/","asOf":"2026-09-09","days":19},{"id":"pleura","kind":"term","name":"Pleura","route":"/terms/pleura/","asOf":"2026-09-09","days":19},{"id":"pleural-effusion","kind":"term","name":"Malignant pleural effusion and ascites","route":"/terms/pleural-effusion/","asOf":"2026-09-09","days":19},{"id":"retroperitoneum","kind":"term","name":"Retroperitoneum","route":"/terms/retroperitoneum/","asOf":"2026-09-09","days":19},{"id":"lymph-node-status","kind":"term","name":"Lymph node status (node-positive / node-negative)","route":"/terms/lymph-node-status/","asOf":"2026-09-09","days":19},{"id":"gej","kind":"term","name":"Gastro-oesophageal junction (GEJ)","route":"/terms/gej/","asOf":"2026-09-09","days":19},{"id":"head-neck-subsites","kind":"term","name":"Head and neck subsites (oral cavity, oropharynx, larynx)","route":"/terms/head-neck-subsites/","asOf":"2026-09-09","days":19},{"id":"leptomeningeal-disease","kind":"term","name":"Leptomeningeal disease","route":"/terms/leptomeningeal-disease/","asOf":"2026-09-09","days":19},{"id":"brain-metastases","kind":"term","name":"Brain metastases (intracranial disease)","route":"/terms/brain-metastases/","asOf":"2026-09-09","days":19},{"id":"bone-metastases","kind":"term","name":"Bone metastases and skeletal-related events","route":"/terms/bone-metastases/","asOf":"2026-09-09","days":19},{"id":"portal-vein-tumour-thrombus","kind":"term","name":"Portal vein tumour thrombus (macrovascular invasion)","route":"/terms/portal-vein-tumour-thrombus/","asOf":"2026-09-09","days":19},{"id":"lymphovascular-invasion","kind":"term","name":"Lymphovascular invasion (LVI)","route":"/terms/lymphovascular-invasion/","asOf":"2026-09-09","days":19},{"id":"perineural-invasion","kind":"term","name":"Perineural invasion (PNI)","route":"/terms/perineural-invasion/","asOf":"2026-09-09","days":19},{"id":"resection-margins","kind":"term","name":"Resection margins (R0 / R1 / R2)","route":"/terms/resection-margins/","asOf":"2026-09-09","days":19},{"id":"tumour-differentiation","kind":"term","name":"Tumour differentiation (well / moderately / poorly differentiated)","route":"/terms/tumour-differentiation/","asOf":"2026-09-09","days":19},{"id":"dysplasia","kind":"term","name":"Dysplasia (pre-cancerous change)","route":"/terms/dysplasia/","asOf":"2026-09-09","days":19},{"id":"carcinoma-in-situ","kind":"term","name":"Carcinoma in situ (CIS)","route":"/terms/carcinoma-in-situ/","asOf":"2026-09-09","days":19},{"id":"dcis","kind":"term","name":"Ductal carcinoma in situ (DCIS)","route":"/terms/dcis/","asOf":"2026-09-09","days":19},{"id":"pd-l1-testing","kind":"term","name":"PD-L1 expression testing (22C3, SP142, SP263)","route":"/terms/pd-l1-testing/","asOf":"2026-09-09","days":19},{"id":"hormone-receptor-status","kind":"term","name":"Hormone receptor status (ER / PR)","route":"/terms/hormone-receptor-status/","asOf":"2026-09-09","days":19},{"id":"her2-positive","kind":"term","name":"HER2-positive (IHC 3+ or ISH-amplified)","route":"/terms/her2-positive/","asOf":"2026-09-09","days":19},{"id":"fish","kind":"term","name":"FISH / ISH (in situ hybridisation)","route":"/terms/fish/","asOf":"2026-09-09","days":19},{"id":"tumour-markers","kind":"term","name":"Tumour markers (CEA, LDH, chromogranin, thyroglobulin)","route":"/terms/tumour-markers/","asOf":"2026-09-09","days":19},{"id":"child-pugh","kind":"term","name":"Child-Pugh score","route":"/terms/child-pugh/","asOf":"2026-09-09","days":19},{"id":"cirrhosis","kind":"term","name":"Cirrhosis","route":"/terms/cirrhosis/","asOf":"2026-09-09","days":19},{"id":"hpv-status","kind":"term","name":"HPV status (HPV-positive / HPV-negative)","route":"/terms/hpv-status/","asOf":"2026-09-09","days":19},{"id":"ebv-term","kind":"term","name":"Epstein-Barr virus (EBV) in cancer","route":"/terms/ebv-term/","asOf":"2026-09-09","days":19},{"id":"mss-pmmr","kind":"term","name":"Microsatellite-stable (MSS) / mismatch-repair proficient (pMMR)","route":"/terms/mss-pmmr/","asOf":"2026-09-09","days":19},{"id":"gbrca-mutation","kind":"term","name":"Germline BRCA mutation (gBRCA)","route":"/terms/gbrca-mutation/","asOf":"2026-09-09","days":19},{"id":"wild-type","kind":"term","name":"Wild-type (WT)","route":"/terms/wild-type/","asOf":"2026-09-09","days":19},{"id":"gene-amplification","kind":"term","name":"Gene amplification and copy-number change","route":"/terms/gene-amplification/","asOf":"2026-09-09","days":19},{"id":"egfr-mutation-subtypes","kind":"term","name":"EGFR mutation subtypes (exon 19 deletion, L858R, exon 20 insertion, T790M)","route":"/terms/egfr-mutation-subtypes/","asOf":"2026-09-09","days":19},{"id":"kras-mutation-subtypes","kind":"term","name":"KRAS mutation subtypes (G12C, G12D, G12V)","route":"/terms/kras-mutation-subtypes/","asOf":"2026-09-09","days":19},{"id":"braf-v600-mutation","kind":"term","name":"BRAF V600E mutation","route":"/terms/braf-v600-mutation/","asOf":"2026-09-09","days":19},{"id":"gatekeeper-mutation","kind":"term","name":"On-target resistance mutations (gatekeeper, solvent-front, compound)","route":"/terms/gatekeeper-mutation/","asOf":"2026-09-09","days":19},{"id":"stk11-keap1","kind":"term","name":"STK11 / KEAP1 co-mutations","route":"/terms/stk11-keap1/","asOf":"2026-09-09","days":19},{"id":"tp53-mutated","kind":"term","name":"TP53-mutated (p53-abnormal)","route":"/terms/tp53-mutated/","asOf":"2026-09-09","days":19},{"id":"cytogenetics","kind":"term","name":"Cytogenetics and karyotype","route":"/terms/cytogenetics/","asOf":"2026-09-09","days":19},{"id":"flow-cytometry","kind":"term","name":"Flow cytometry (immunophenotyping)","route":"/terms/flow-cytometry/","asOf":"2026-09-09","days":19},{"id":"blasts","kind":"term","name":"Blasts (leukaemic blast cells)","route":"/terms/blasts/","asOf":"2026-09-09","days":19},{"id":"cfdna","kind":"term","name":"Cell-free DNA (cfDNA)","route":"/terms/cfdna/","asOf":"2026-09-09","days":19},{"id":"umrd","kind":"term","name":"Undetectable MRD (uMRD / MRD-negative)","route":"/terms/umrd/","asOf":"2026-09-09","days":19},{"id":"deauville","kind":"term","name":"Deauville score and PET-adapted therapy","route":"/terms/deauville/","asOf":"2026-09-09","days":19},{"id":"molecular-response","kind":"term","name":"Molecular response (MMR, MR4, treatment-free remission)","route":"/terms/molecular-response/","asOf":"2026-09-09","days":19},{"id":"philadelphia-chromosome","kind":"term","name":"Philadelphia chromosome (Ph+, BCR::ABL1)","route":"/terms/philadelphia-chromosome/","asOf":"2026-09-09","days":19},{"id":"staging-systems","kind":"term","name":"Disease-specific staging and risk systems (FIGO, Ann Arbor, IPI, R-ISS, ELN, IMDC)","route":"/terms/staging-systems/","asOf":"2026-09-09","days":19},{"id":"performance-status","kind":"term","name":"Performance status (ECOG, Karnofsky)","route":"/terms/performance-status/","asOf":"2026-09-09","days":19},{"id":"chemoradiation","kind":"term","name":"Chemoradiation (chemoradiotherapy, CRT)","route":"/terms/chemoradiation/","asOf":"2026-09-09","days":19},{"id":"induction-therapy","kind":"term","name":"Induction therapy","route":"/terms/induction-therapy/","asOf":"2026-09-09","days":19},{"id":"consolidation-therapy","kind":"term","name":"Consolidation therapy","route":"/terms/consolidation-therapy/","asOf":"2026-09-09","days":19},{"id":"salvage-therapy","kind":"term","name":"Salvage therapy","route":"/terms/salvage-therapy/","asOf":"2026-09-09","days":19},{"id":"relapsed-refractory","kind":"term","name":"Relapsed / refractory (R/R)","route":"/terms/relapsed-refractory/","asOf":"2026-09-09","days":19},{"id":"platinum-sensitivity","kind":"term","name":"Platinum-sensitive / platinum-resistant","route":"/terms/platinum-sensitivity/","asOf":"2026-09-09","days":19},{"id":"mcrpc-mhspc","kind":"term","name":"mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer)","route":"/terms/mcrpc-mhspc/","asOf":"2026-09-09","days":19},{"id":"adt","kind":"term","name":"Androgen deprivation therapy (ADT)","route":"/terms/adt/","asOf":"2026-09-09","days":19},{"id":"arpi","kind":"term","name":"Androgen receptor pathway inhibitor (ARPI)","route":"/terms/arpi/","asOf":"2026-09-09","days":19},{"id":"aromatase-inhibitor","kind":"term","name":"Aromatase inhibitor","route":"/terms/aromatase-inhibitor/","asOf":"2026-09-09","days":19},{"id":"serd","kind":"term","name":"Selective oestrogen receptor degrader (SERD)","route":"/terms/serd/","asOf":"2026-09-09","days":19},{"id":"hypofractionation","kind":"term","name":"Hypofractionation (fewer, larger radiotherapy doses)","route":"/terms/hypofractionation/","asOf":"2026-09-09","days":19},{"id":"gray-unit","kind":"term","name":"Gray unit (Gy)","route":"/terms/gray-unit/","asOf":"2026-09-09","days":19},{"id":"re-irradiation","kind":"term","name":"Re-irradiation","route":"/terms/re-irradiation/","asOf":"2026-09-09","days":19},{"id":"dose-dense-chemotherapy","kind":"term","name":"Dose-dense and metronomic chemotherapy","route":"/terms/dose-dense-chemotherapy/","asOf":"2026-09-09","days":19},{"id":"doublet-triplet","kind":"term","name":"Doublet, triplet and quadruplet regimens","route":"/terms/doublet-triplet/","asOf":"2026-09-09","days":19},{"id":"chemotherapy-regimen","kind":"term","name":"Regimen and cycles","route":"/terms/chemotherapy-regimen/","asOf":"2026-09-09","days":19},{"id":"anthracycline","kind":"term","name":"Anthracyclines (doxorubicin, epirubicin)","route":"/terms/anthracycline/","asOf":"2026-09-09","days":19},{"id":"taxane","kind":"term","name":"Taxanes (paclitaxel, docetaxel, nab-paclitaxel)","route":"/terms/taxane/","asOf":"2026-09-09","days":19},{"id":"alkylating-agent","kind":"term","name":"Alkylating agents and antimetabolites","route":"/terms/alkylating-agent/","asOf":"2026-09-09","days":19},{"id":"folfox-family","kind":"term","name":"FOLFOX, FOLFIRI, FOLFIRINOX and CAPOX","route":"/terms/folfox-family/","asOf":"2026-09-09","days":19},{"id":"flot-term","kind":"term","name":"FLOT regimen (perioperative chemotherapy for gastric cancer)","route":"/terms/flot-term/","asOf":"2026-09-09","days":19},{"id":"r-chop","kind":"term","name":"R-CHOP (lymphoma chemoimmunotherapy)","route":"/terms/r-chop/","asOf":"2026-09-09","days":19},{"id":"abvd-beacopp","kind":"term","name":"ABVD, BEACOPP and BrECADD (Hodgkin lymphoma regimens)","route":"/terms/abvd-beacopp/","asOf":"2026-09-09","days":19},{"id":"seven-plus-three","kind":"term","name":"7+3 induction chemotherapy","route":"/terms/seven-plus-three/","asOf":"2026-09-09","days":19},{"id":"vrd","kind":"term","name":"VRd and Dara-VRd (myeloma induction regimens)","route":"/terms/vrd/","asOf":"2026-09-09","days":19},{"id":"proteasome-inhibitor","kind":"term","name":"Proteasome inhibitor (bortezomib, carfilzomib, ixazomib)","route":"/terms/proteasome-inhibitor/","asOf":"2026-09-09","days":19},{"id":"imid","kind":"term","name":"Immunomodulatory drugs (IMiDs) and CELMoDs","route":"/terms/imid/","asOf":"2026-09-09","days":19},{"id":"hma","kind":"term","name":"Hypomethylating agents (azacitidine, decitabine)","route":"/terms/hma/","asOf":"2026-09-09","days":19},{"id":"tki-term","kind":"term","name":"Tyrosine kinase inhibitor (TKI)","route":"/terms/tki-term/","asOf":"2026-09-09","days":19},{"id":"immuno-oncology","kind":"term","name":"Immuno-oncology (IO) and checkpoint blockade","route":"/terms/immuno-oncology/","asOf":"2026-09-09","days":19},{"id":"backbone-add-on","kind":"term","name":"Backbone, add-on and monotherapy","route":"/terms/backbone-add-on/","asOf":"2026-09-09","days":19},{"id":"cross-resistance","kind":"term","name":"Cross-resistance","route":"/terms/cross-resistance/","asOf":"2026-09-09","days":19},{"id":"rechallenge","kind":"term","name":"Rechallenge and retreatment","route":"/terms/rechallenge/","asOf":"2026-09-09","days":19},{"id":"fixed-duration","kind":"term","name":"Fixed-duration vs continuous therapy","route":"/terms/fixed-duration/","asOf":"2026-09-09","days":19},{"id":"step-up-dosing","kind":"term","name":"Step-up dosing (T-cell engagers)","route":"/terms/step-up-dosing/","asOf":"2026-09-09","days":19},{"id":"de-escalation","kind":"term","name":"De-escalation, escalation and response-adapted therapy","route":"/terms/de-escalation/","asOf":"2026-09-09","days":19},{"id":"organ-preservation","kind":"term","name":"Organ preservation (watch-and-wait, bladder-sparing, larynx preservation)","route":"/terms/organ-preservation/","asOf":"2026-09-09","days":19},{"id":"active-surveillance-term","kind":"term","name":"Active surveillance and observation","route":"/terms/active-surveillance-term/","asOf":"2026-09-09","days":19},{"id":"curative-intent","kind":"term","name":"Curative intent vs palliative intent","route":"/terms/curative-intent/","asOf":"2026-09-09","days":19},{"id":"locally-advanced","kind":"term","name":"Locally advanced and locoregional disease","route":"/terms/locally-advanced/","asOf":"2026-09-09","days":19},{"id":"resectability","kind":"term","name":"Resectable, borderline resectable and unresectable","route":"/terms/resectability/","asOf":"2026-09-09","days":19},{"id":"limited-extensive-stage","kind":"term","name":"Limited-stage vs extensive-stage (small-cell lung cancer)","route":"/terms/limited-extensive-stage/","asOf":"2026-09-09","days":19},{"id":"intravesical-therapy","kind":"term","name":"Intravesical therapy (BCG and bladder instillations)","route":"/terms/intravesical-therapy/","asOf":"2026-09-09","days":19},{"id":"intraperitoneal-chemotherapy","kind":"term","name":"Intraperitoneal (IP) chemotherapy","route":"/terms/intraperitoneal-chemotherapy/","asOf":"2026-09-09","days":19},{"id":"liver-directed-therapy","kind":"term","name":"Liver-directed therapy (TACE, TARE, HAI, ablation)","route":"/terms/liver-directed-therapy/","asOf":"2026-09-09","days":19},{"id":"total-neoadjuvant-therapy","kind":"term","name":"Total neoadjuvant therapy (TNT, rectal cancer)","route":"/terms/total-neoadjuvant-therapy/","asOf":"2026-09-09","days":19},{"id":"downstaging","kind":"term","name":"Downstaging and conversion therapy","route":"/terms/downstaging/","asOf":"2026-09-09","days":19},{"id":"autologous-transplant","kind":"term","name":"Autologous stem cell transplant (ASCT)","route":"/terms/autologous-transplant/","asOf":"2026-09-09","days":19},{"id":"allogeneic-transplant","kind":"term","name":"Allogeneic stem cell transplant (allo-SCT)","route":"/terms/allogeneic-transplant/","asOf":"2026-09-09","days":19},{"id":"conditioning-regimen","kind":"term","name":"Conditioning regimen (myeloablative, reduced-intensity)","route":"/terms/conditioning-regimen/","asOf":"2026-09-09","days":19},{"id":"gvhd","kind":"term","name":"Graft-versus-host disease (GVHD) and graft-versus-leukaemia","route":"/terms/gvhd/","asOf":"2026-09-09","days":19},{"id":"lymphodepletion","kind":"term","name":"Lymphodepletion before CAR-T","route":"/terms/lymphodepletion/","asOf":"2026-09-09","days":19},{"id":"bridging-therapy","kind":"term","name":"Bridging therapy","route":"/terms/bridging-therapy/","asOf":"2026-09-09","days":19},{"id":"vein-to-vein-time","kind":"term","name":"Vein-to-vein time and manufacturing slots","route":"/terms/vein-to-vein-time/","asOf":"2026-09-09","days":19},{"id":"antigen-escape","kind":"term","name":"Antigen escape (antigen loss, lineage switch)","route":"/terms/antigen-escape/","asOf":"2026-09-09","days":19},{"id":"t-cell-exhaustion-term","kind":"term","name":"T-cell exhaustion and CAR-T persistence","route":"/terms/t-cell-exhaustion-term/","asOf":"2026-09-09","days":19},{"id":"prrt-term","kind":"term","name":"PRRT (peptide receptor radionuclide therapy)","route":"/terms/prrt-term/","asOf":"2026-09-09","days":19},{"id":"radioiodine-term","kind":"term","name":"Radioiodine therapy (I-131)","route":"/terms/radioiodine-term/","asOf":"2026-09-09","days":19},{"id":"cns-penetration","kind":"term","name":"CNS penetration (brain-penetrant drugs)","route":"/terms/cns-penetration/","asOf":"2026-09-09","days":19},{"id":"pharmacokinetics","kind":"term","name":"Pharmacokinetics (PK), half-life and exposure","route":"/terms/pharmacokinetics/","asOf":"2026-09-09","days":19},{"id":"therapeutic-index","kind":"term","name":"Therapeutic index (therapeutic window)","route":"/terms/therapeutic-index/","asOf":"2026-09-09","days":19},{"id":"centralisation","kind":"term","name":"Centralisation and high-volume centres","route":"/terms/centralisation/","asOf":"2026-09-09","days":19},{"id":"surgical-morbidity","kind":"term","name":"Surgical morbidity and postoperative complications","route":"/terms/surgical-morbidity/","asOf":"2026-09-09","days":19},{"id":"confirmatory-trial","kind":"term","name":"Confirmatory trial","route":"/terms/confirmatory-trial/","asOf":"2026-09-09","days":19},{"id":"complete-response-letter","kind":"term","name":"Complete response letter (CRL)","route":"/terms/complete-response-letter/","asOf":"2026-09-09","days":19},{"id":"label-indication","kind":"term","name":"Label, indication and label expansion","route":"/terms/label-indication/","asOf":"2026-09-09","days":19},{"id":"bla-nda","kind":"term","name":"BLA / NDA / MAA (marketing applications) and PDUFA dates","route":"/terms/bla-nda/","asOf":"2026-09-09","days":19},{"id":"orphan-designation","kind":"term","name":"Orphan drug designation","route":"/terms/orphan-designation/","asOf":"2026-09-09","days":19},{"id":"fast-track-rmat","kind":"term","name":"Fast Track and RMAT designations","route":"/terms/fast-track-rmat/","asOf":"2026-09-09","days":19},{"id":"conditional-approval","kind":"term","name":"Conditional marketing authorisation (EU)","route":"/terms/conditional-approval/","asOf":"2026-09-09","days":19},{"id":"full-approval","kind":"term","name":"Full (traditional, regular) approval","route":"/terms/full-approval/","asOf":"2026-09-09","days":19},{"id":"approval-withdrawal","kind":"term","name":"Indication withdrawal","route":"/terms/approval-withdrawal/","asOf":"2026-09-09","days":19},{"id":"odac","kind":"term","name":"ODAC (Oncologic Drugs Advisory Committee)","route":"/terms/odac/","asOf":"2026-09-09","days":19},{"id":"regulatory-agencies","kind":"term","name":"Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA)","route":"/terms/regulatory-agencies/","asOf":"2026-09-09","days":19},{"id":"hta","kind":"term","name":"Health technology assessment (HTA), reimbursement and QALYs","route":"/terms/hta/","asOf":"2026-09-09","days":19},{"id":"crossover","kind":"term","name":"Crossover in trials","route":"/terms/crossover/","asOf":"2026-09-09","days":19},{"id":"non-inferiority","kind":"term","name":"Non-inferiority trial","route":"/terms/non-inferiority/","asOf":"2026-09-09","days":19},{"id":"futility","kind":"term","name":"Futility analysis (stopped for futility)","route":"/terms/futility/","asOf":"2026-09-09","days":19},{"id":"interim-analysis","kind":"term","name":"Interim analysis, readout and data cut-off","route":"/terms/interim-analysis/","asOf":"2026-09-09","days":19},{"id":"primary-endpoint","kind":"term","name":"Primary, secondary and co-primary endpoints","route":"/terms/primary-endpoint/","asOf":"2026-09-09","days":19},{"id":"intention-to-treat","kind":"term","name":"Intention-to-treat (ITT) and per-protocol analysis","route":"/terms/intention-to-treat/","asOf":"2026-09-09","days":19},{"id":"prespecified-vs-post-hoc","kind":"term","name":"Pre-specified vs post-hoc analysis","route":"/terms/prespecified-vs-post-hoc/","asOf":"2026-09-09","days":19},{"id":"subgroup-analysis","kind":"term","name":"Subgroup analysis (forest plots)","route":"/terms/subgroup-analysis/","asOf":"2026-09-09","days":19},{"id":"statistical-significance","kind":"term","name":"Statistical significance (P values, alpha, multiplicity)","route":"/terms/statistical-significance/","asOf":"2026-09-09","days":19},{"id":"double-blind","kind":"term","name":"Blinding (double-blind, open-label, placebo-controlled)","route":"/terms/double-blind/","asOf":"2026-09-09","days":19},{"id":"single-arm","kind":"term","name":"Single-arm trial","route":"/terms/single-arm/","asOf":"2026-09-09","days":19},{"id":"external-control-arm","kind":"term","name":"External and synthetic control arms","route":"/terms/external-control-arm/","asOf":"2026-09-09","days":19},{"id":"control-arm","kind":"term","name":"Control arm and comparator (investigator's choice)","route":"/terms/control-arm/","asOf":"2026-09-09","days":19},{"id":"dose-limiting-toxicity","kind":"term","name":"Dose-limiting toxicity (DLT)","route":"/terms/dose-limiting-toxicity/","asOf":"2026-09-09","days":19},{"id":"mtd","kind":"term","name":"Maximum tolerated dose (MTD)","route":"/terms/mtd/","asOf":"2026-09-09","days":19},{"id":"rp2d","kind":"term","name":"Recommended phase 2 dose (RP2D)","route":"/terms/rp2d/","asOf":"2026-09-09","days":19},{"id":"dose-escalation-design","kind":"term","name":"Dose-escalation designs (3+3, BOIN, dose-expansion)","route":"/terms/dose-escalation-design/","asOf":"2026-09-09","days":19},{"id":"first-in-human","kind":"term","name":"First-in-human (FIH) trial","route":"/terms/first-in-human/","asOf":"2026-09-09","days":19},{"id":"window-of-opportunity-trial","kind":"term","name":"Window-of-opportunity trial","route":"/terms/window-of-opportunity-trial/","asOf":"2026-09-09","days":19},{"id":"pivotal-trial","kind":"term","name":"Pivotal (registrational) trial","route":"/terms/pivotal-trial/","asOf":"2026-09-09","days":19},{"id":"seamless-adaptive","kind":"term","name":"Seamless, adaptive and Bayesian trial designs","route":"/terms/seamless-adaptive/","asOf":"2026-09-09","days":19},{"id":"accrual","kind":"term","name":"Accrual and enrolment","route":"/terms/accrual/","asOf":"2026-09-09","days":19},{"id":"complete-response-term","kind":"term","name":"Complete response (CR) and partial response (PR)","route":"/terms/complete-response-term/","asOf":"2026-09-09","days":19},{"id":"progressive-disease","kind":"term","name":"Progressive disease and radiographic progression","route":"/terms/progressive-disease/","asOf":"2026-09-09","days":19},{"id":"duration-of-response-term","kind":"term","name":"Duration of response (DoR) and disease control rate (DCR)","route":"/terms/duration-of-response-term/","asOf":"2026-09-09","days":19},{"id":"ttp","kind":"term","name":"Time to progression (TTP) and time to next treatment (TTNT)","route":"/terms/ttp/","asOf":"2026-09-09","days":19},{"id":"landmark-survival","kind":"term","name":"Landmark and milestone survival (5-year survival, median follow-up)","route":"/terms/landmark-survival/","asOf":"2026-09-09","days":19},{"id":"data-maturity","kind":"term","name":"Data maturity (immature vs mature survival data)","route":"/terms/data-maturity/","asOf":"2026-09-09","days":19},{"id":"qol-pro","kind":"term","name":"Quality of life and patient-reported outcomes (QoL, PRO)","route":"/terms/qol-pro/","asOf":"2026-09-09","days":19},{"id":"ctcae-grading","kind":"term","name":"CTCAE toxicity grading (grade 3-4 adverse events)","route":"/terms/ctcae-grading/","asOf":"2026-09-09","days":19},{"id":"febrile-neutropenia","kind":"term","name":"Febrile neutropenia","route":"/terms/febrile-neutropenia/","asOf":"2026-09-09","days":19},{"id":"neutropenia","kind":"term","name":"Neutropenia","route":"/terms/neutropenia/","asOf":"2026-09-09","days":19},{"id":"thrombocytopenia","kind":"term","name":"Thrombocytopenia","route":"/terms/thrombocytopenia/","asOf":"2026-09-09","days":19},{"id":"anaemia","kind":"term","name":"Anaemia","route":"/terms/anaemia/","asOf":"2026-09-09","days":19},{"id":"cytopenias","kind":"term","name":"Cytopenias and myelosuppression","route":"/terms/cytopenias/","asOf":"2026-09-09","days":19},{"id":"mucositis","kind":"term","name":"Mucositis and stomatitis","route":"/terms/mucositis/","asOf":"2026-09-09","days":19},{"id":"hand-foot-syndrome","kind":"term","name":"Hand-foot syndrome and hand-foot skin reaction","route":"/terms/hand-foot-syndrome/","asOf":"2026-09-09","days":19},{"id":"peripheral-neuropathy","kind":"term","name":"Peripheral neuropathy (chemotherapy-induced)","route":"/terms/peripheral-neuropathy/","asOf":"2026-09-09","days":19},{"id":"cardiotoxicity","kind":"term","name":"Cardiotoxicity (LVEF decline, cardiomyopathy)","route":"/terms/cardiotoxicity/","asOf":"2026-09-09","days":19},{"id":"hepatotoxicity","kind":"term","name":"Hepatotoxicity (liver enzyme elevation)","route":"/terms/hepatotoxicity/","asOf":"2026-09-09","days":19},{"id":"immune-colitis","kind":"term","name":"Immune-mediated colitis and diarrhoea","route":"/terms/immune-colitis/","asOf":"2026-09-09","days":19},{"id":"immune-endocrinopathy","kind":"term","name":"Immune-related endocrinopathies (thyroiditis, hypophysitis)","route":"/terms/immune-endocrinopathy/","asOf":"2026-09-09","days":19},{"id":"myocarditis","kind":"term","name":"Immune-related myocarditis","route":"/terms/myocarditis/","asOf":"2026-09-09","days":19},{"id":"ocular-toxicity","kind":"term","name":"Ocular toxicity (keratopathy, blurred vision)","route":"/terms/ocular-toxicity/","asOf":"2026-09-09","days":19},{"id":"qt-prolongation","kind":"term","name":"QT prolongation","route":"/terms/qt-prolongation/","asOf":"2026-09-09","days":19},{"id":"hyperglycaemia","kind":"term","name":"Hyperglycaemia (PI3K/AKT inhibitor class effect)","route":"/terms/hyperglycaemia/","asOf":"2026-09-09","days":19},{"id":"rash-skin-toxicity","kind":"term","name":"Rash and skin toxicity (acneiform rash, paronychia)","route":"/terms/rash-skin-toxicity/","asOf":"2026-09-09","days":19},{"id":"extravasation-infusion-reaction","kind":"term","name":"Infusion reactions, hypersensitivity and extravasation","route":"/terms/extravasation-infusion-reaction/","asOf":"2026-09-09","days":19},{"id":"vte","kind":"term","name":"Venous thromboembolism (VTE)","route":"/terms/vte/","asOf":"2026-09-09","days":19},{"id":"antiangiogenic-toxicities","kind":"term","name":"Anti-VEGF class toxicities (hypertension, proteinuria, bleeding, perforation)","route":"/terms/antiangiogenic-toxicities/","asOf":"2026-09-09","days":19},{"id":"secondary-malignancy","kind":"term","name":"Secondary malignancy (therapy-related cancer)","route":"/terms/secondary-malignancy/","asOf":"2026-09-09","days":19},{"id":"late-effects","kind":"term","name":"Late effects and survivorship toxicity","route":"/terms/late-effects/","asOf":"2026-09-09","days":19},{"id":"hypogammaglobulinaemia","kind":"term","name":"Hypogammaglobulinaemia and infection risk after B-cell therapies","route":"/terms/hypogammaglobulinaemia/","asOf":"2026-09-09","days":19},{"id":"dose-modification","kind":"term","name":"Dose reduction, interruption and discontinuation","route":"/terms/dose-modification/","asOf":"2026-09-09","days":19},{"id":"obstructive-jaundice","kind":"term","name":"Obstructive jaundice and biliary obstruction","route":"/terms/obstructive-jaundice/","asOf":"2026-09-09","days":19},{"id":"dysphagia","kind":"term","name":"Dysphagia (difficulty swallowing)","route":"/terms/dysphagia/","asOf":"2026-09-09","days":19},{"id":"oneal-uab","kind":"institution","name":"O'Neal Comprehensive Cancer Center at UAB","route":"/institutions/oneal-uab/","asOf":"2026-09-09","days":19},{"id":"arizona-cancer-center","kind":"institution","name":"University of Arizona Cancer Center","route":"/institutions/arizona-cancer-center/","asOf":"2026-09-09","days":19},{"id":"uci-chao","kind":"institution","name":"Chao Family Comprehensive Cancer Center, UC Irvine","route":"/institutions/uci-chao/","asOf":"2026-09-09","days":19},{"id":"uc-davis-cancer","kind":"institution","name":"UC Davis Comprehensive Cancer Center","route":"/institutions/uc-davis-cancer/","asOf":"2026-09-09","days":19},{"id":"ucsd-moores","kind":"institution","name":"UC San Diego Moores Cancer Center","route":"/institutions/ucsd-moores/","asOf":"2026-09-09","days":19},{"id":"usc-norris","kind":"institution","name":"USC Norris Comprehensive Cancer Center","route":"/institutions/usc-norris/","asOf":"2026-09-09","days":19},{"id":"colorado-cancer-center","kind":"institution","name":"University of Colorado Cancer Center","route":"/institutions/colorado-cancer-center/","asOf":"2026-09-09","days":19},{"id":"georgetown-lombardi","kind":"institution","name":"Georgetown Lombardi Comprehensive Cancer Center","route":"/institutions/georgetown-lombardi/","asOf":"2026-09-09","days":19},{"id":"emory-winship","kind":"institution","name":"Winship Cancer Institute of Emory University","route":"/institutions/emory-winship/","asOf":"2026-09-09","days":19},{"id":"northwestern-lurie","kind":"institution","name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University","route":"/institutions/northwestern-lurie/","asOf":"2026-09-09","days":19},{"id":"uchicago-cancer","kind":"institution","name":"University of Chicago Medicine Comprehensive Cancer Center","route":"/institutions/uchicago-cancer/","asOf":"2026-09-09","days":19},{"id":"iu-simon","kind":"institution","name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center","route":"/institutions/iu-simon/","asOf":"2026-09-09","days":19},{"id":"iowa-holden","kind":"institution","name":"Holden Comprehensive Cancer Center, University of Iowa","route":"/institutions/iowa-holden/","asOf":"2026-09-09","days":19},{"id":"ku-cancer-center","kind":"institution","name":"The University of Kansas Cancer Center","route":"/institutions/ku-cancer-center/","asOf":"2026-09-09","days":19},{"id":"kentucky-markey","kind":"institution","name":"Markey Cancer Center, University of Kentucky","route":"/institutions/kentucky-markey/","asOf":"2026-09-09","days":19},{"id":"maryland-greenebaum","kind":"institution","name":"University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center","route":"/institutions/maryland-greenebaum/","asOf":"2026-09-09","days":19},{"id":"karmanos","kind":"institution","name":"Barbara Ann Karmanos Cancer Institute","route":"/institutions/karmanos/","asOf":"2026-09-09","days":19},{"id":"minnesota-masonic","kind":"institution","name":"Masonic Cancer Center, University of Minnesota","route":"/institutions/minnesota-masonic/","asOf":"2026-09-09","days":19},{"id":"dartmouth-cancer-center","kind":"institution","name":"Dartmouth Cancer Center","route":"/institutions/dartmouth-cancer-center/","asOf":"2026-09-09","days":19},{"id":"rutgers-cinj","kind":"institution","name":"Rutgers Cancer Institute of New Jersey","route":"/institutions/rutgers-cinj/","asOf":"2026-09-09","days":19},{"id":"unm-cancer-center","kind":"institution","name":"University of New Mexico Comprehensive Cancer Center","route":"/institutions/unm-cancer-center/","asOf":"2026-09-09","days":19},{"id":"montefiore-einstein","kind":"institution","name":"Montefiore Einstein Comprehensive Cancer Center","route":"/institutions/montefiore-einstein/","asOf":"2026-09-09","days":19},{"id":"columbia-hicc","kind":"institution","name":"Herbert Irving Comprehensive Cancer Center, Columbia University","route":"/institutions/columbia-hicc/","asOf":"2026-09-09","days":19},{"id":"nyu-perlmutter","kind":"institution","name":"Laura and Isaac Perlmutter Cancer Center at NYU Langone Health","route":"/institutions/nyu-perlmutter/","asOf":"2026-09-09","days":19},{"id":"duke-cancer-institute","kind":"institution","name":"Duke Cancer Institute","route":"/institutions/duke-cancer-institute/","asOf":"2026-09-09","days":19},{"id":"unc-lineberger","kind":"institution","name":"UNC Lineberger Comprehensive Cancer Center","route":"/institutions/unc-lineberger/","asOf":"2026-09-09","days":19},{"id":"wake-forest-cancer","kind":"institution","name":"Atrium Health Wake Forest Baptist Comprehensive Cancer Center","route":"/institutions/wake-forest-cancer/","asOf":"2026-09-09","days":19},{"id":"case-ccc","kind":"institution","name":"Case Comprehensive Cancer Center","route":"/institutions/case-ccc/","asOf":"2026-09-09","days":19},{"id":"osu-james","kind":"institution","name":"The Ohio State University Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute","route":"/institutions/osu-james/","asOf":"2026-09-09","days":19},{"id":"ohsu-knight","kind":"institution","name":"OHSU Knight Cancer Institute","route":"/institutions/ohsu-knight/","asOf":"2026-09-09","days":19},{"id":"fox-chase","kind":"institution","name":"Fox Chase Cancer Center","route":"/institutions/fox-chase/","asOf":"2026-09-09","days":19},{"id":"jefferson-kimmel","kind":"institution","name":"Sidney Kimmel Comprehensive Cancer Center at Jefferson Health","route":"/institutions/jefferson-kimmel/","asOf":"2026-09-09","days":19},{"id":"upmc-hillman","kind":"institution","name":"UPMC Hillman Cancer Center","route":"/institutions/upmc-hillman/","asOf":"2026-09-09","days":19},{"id":"vanderbilt-ingram","kind":"institution","name":"Vanderbilt-Ingram Cancer Center","route":"/institutions/vanderbilt-ingram/","asOf":"2026-09-09","days":19},{"id":"baylor-duncan","kind":"institution","name":"Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine","route":"/institutions/baylor-duncan/","asOf":"2026-09-09","days":19},{"id":"utsw-simmons","kind":"institution","name":"Harold C. Simmons Comprehensive Cancer Center, UT Southwestern","route":"/institutions/utsw-simmons/","asOf":"2026-09-09","days":19},{"id":"huntsman","kind":"institution","name":"Huntsman Cancer Institute, University of Utah","route":"/institutions/huntsman/","asOf":"2026-09-09","days":19},{"id":"vcu-massey","kind":"institution","name":"VCU Massey Comprehensive Cancer Center","route":"/institutions/vcu-massey/","asOf":"2026-09-09","days":19},{"id":"uva-cancer-center","kind":"institution","name":"UVA Comprehensive Cancer Center","route":"/institutions/uva-cancer-center/","asOf":"2026-09-09","days":19},{"id":"uw-carbone","kind":"institution","name":"University of Wisconsin Carbone Cancer Center","route":"/institutions/uw-carbone/","asOf":"2026-09-09","days":19},{"id":"st-jude","kind":"institution","name":"St. Jude Children's Research Hospital","route":"/institutions/st-jude/","asOf":"2026-09-09","days":19},{"id":"sylvester-miami","kind":"institution","name":"Sylvester Comprehensive Cancer Center, University of Miami","route":"/institutions/sylvester-miami/","asOf":"2026-09-09","days":19},{"id":"uf-health-cancer-center","kind":"institution","name":"University of Florida Health Cancer Center","route":"/institutions/uf-health-cancer-center/","asOf":"2026-09-09","days":19},{"id":"hawaii-cancer-center","kind":"institution","name":"University of Hawai'i Cancer Center","route":"/institutions/hawaii-cancer-center/","asOf":"2026-09-09","days":19},{"id":"nebraska-buffett","kind":"institution","name":"Fred & Pamela Buffett Cancer Center","route":"/institutions/nebraska-buffett/","asOf":"2026-09-09","days":19},{"id":"wilmot","kind":"institution","name":"Wilmot Cancer Institute, University of Rochester","route":"/institutions/wilmot/","asOf":"2026-09-09","days":19},{"id":"stephenson-oklahoma","kind":"institution","name":"Stephenson Cancer Center, OU Health","route":"/institutions/stephenson-oklahoma/","asOf":"2026-09-09","days":19},{"id":"musc-hollings","kind":"institution","name":"MUSC Hollings Cancer Center","route":"/institutions/musc-hollings/","asOf":"2026-09-09","days":19},{"id":"mays-cancer-center","kind":"institution","name":"Mays Cancer Center at UT Health San Antonio","route":"/institutions/mays-cancer-center/","asOf":"2026-09-09","days":19},{"id":"salk-institute","kind":"institution","name":"Salk Institute Cancer Center","route":"/institutions/salk-institute/","asOf":"2026-09-09","days":19},{"id":"sanford-burnham-prebys","kind":"institution","name":"Sanford Burnham Prebys Medical Discovery Institute","route":"/institutions/sanford-burnham-prebys/","asOf":"2026-09-09","days":19},{"id":"cancer-center-at-illinois","kind":"institution","name":"Cancer Center at Illinois","route":"/institutions/cancer-center-at-illinois/","asOf":"2026-09-09","days":19},{"id":"purdue-cancer-research","kind":"institution","name":"Purdue Institute for Cancer Research","route":"/institutions/purdue-cancer-research/","asOf":"2026-09-09","days":19},{"id":"jackson-laboratory","kind":"institution","name":"The Jackson Laboratory Cancer Center","route":"/institutions/jackson-laboratory/","asOf":"2026-09-09","days":19},{"id":"mit-koch","kind":"institution","name":"David H. Koch Institute for Integrative Cancer Research at MIT","route":"/institutions/mit-koch/","asOf":"2026-09-09","days":19},{"id":"wistar","kind":"institution","name":"The Wistar Institute","route":"/institutions/wistar/","asOf":"2026-09-09","days":19},{"id":"nci-ccr","kind":"institution","name":"NCI Center for Cancer Research (intramural programme)","route":"/institutions/nci-ccr/","asOf":"2026-09-09","days":19},{"id":"frederick-national-lab","kind":"institution","name":"Frederick National Laboratory for Cancer Research","route":"/institutions/frederick-national-lab/","asOf":"2026-09-09","days":19},{"id":"mayo-clinic-florida","kind":"institution","name":"Mayo Clinic Comprehensive Cancer Center in Florida","route":"/institutions/mayo-clinic-florida/","asOf":"2026-09-09","days":19},{"id":"mayo-clinic-arizona","kind":"institution","name":"Mayo Clinic Comprehensive Cancer Center in Arizona","route":"/institutions/mayo-clinic-arizona/","asOf":"2026-09-09","days":19},{"id":"city-of-hope-orange-county","kind":"institution","name":"City of Hope Orange County","route":"/institutions/city-of-hope-orange-county/","asOf":"2026-09-09","days":19},{"id":"cedars-sinai-cancer","kind":"institution","name":"Cedars-Sinai Cancer","route":"/institutions/cedars-sinai-cancer/","asOf":"2026-09-09","days":19},{"id":"northwell-cancer-institute","kind":"institution","name":"Northwell Health Cancer Institute","route":"/institutions/northwell-cancer-institute/","asOf":"2026-09-09","days":19},{"id":"intermountain-cancer","kind":"institution","name":"Intermountain Health Cancer Center","route":"/institutions/intermountain-cancer/","asOf":"2026-09-09","days":19},{"id":"kaiser-permanente-research","kind":"institution","name":"Kaiser Permanente Division of Research","route":"/institutions/kaiser-permanente-research/","asOf":"2026-09-09","days":19},{"id":"chop","kind":"institution","name":"Children's Hospital of Philadelphia","route":"/institutions/chop/","asOf":"2026-09-09","days":19},{"id":"texas-childrens","kind":"institution","name":"Texas Children's Cancer and Hematology Center","route":"/institutions/texas-childrens/","asOf":"2026-09-09","days":19},{"id":"nationwide-childrens","kind":"institution","name":"Nationwide Children's Hospital","route":"/institutions/nationwide-childrens/","asOf":"2026-09-09","days":19},{"id":"bc-cancer","kind":"institution","name":"BC Cancer","route":"/institutions/bc-cancer/","asOf":"2026-09-09","days":19},{"id":"cancer-care-alberta","kind":"institution","name":"Cancer Care Alberta (Alberta Health Services)","route":"/institutions/cancer-care-alberta/","asOf":"2026-09-09","days":19},{"id":"chum","kind":"institution","name":"Centre hospitalier de l'Université de Montréal (CHUM)","route":"/institutions/chum/","asOf":"2026-09-09","days":19},{"id":"mcgill-goodman","kind":"institution","name":"Rosalind and Morris Goodman Cancer Institute, McGill University","route":"/institutions/mcgill-goodman/","asOf":"2026-09-09","days":19},{"id":"ottawa-hospital","kind":"institution","name":"The Ottawa Hospital Cancer Centre / Ottawa Hospital Research Institute","route":"/institutions/ottawa-hospital/","asOf":"2026-09-09","days":19},{"id":"sunnybrook-odette","kind":"institution","name":"Sunnybrook Odette Cancer Centre","route":"/institutions/sunnybrook-odette/","asOf":"2026-09-09","days":19},{"id":"juravinski","kind":"institution","name":"Juravinski Cancer Centre / Escarpment Cancer Research Institute","route":"/institutions/juravinski/","asOf":"2026-09-09","days":19},{"id":"oicr","kind":"institution","name":"Ontario Institute for Cancer Research","route":"/institutions/oicr/","asOf":"2026-09-09","days":19},{"id":"sickkids","kind":"institution","name":"The Hospital for Sick Children (SickKids)","route":"/institutions/sickkids/","asOf":"2026-09-09","days":19},{"id":"pumch","kind":"institution","name":"Peking Union Medical College Hospital","route":"/institutions/pumch/","asOf":"2026-09-09","days":19},{"id":"pku-cancer-hospital","kind":"institution","name":"Peking University Cancer Hospital","route":"/institutions/pku-cancer-hospital/","asOf":"2026-09-09","days":19},{"id":"shanghai-chest-hospital","kind":"institution","name":"Shanghai Chest Hospital","route":"/institutions/shanghai-chest-hospital/","asOf":"2026-09-09","days":19},{"id":"shanghai-pulmonary-hospital","kind":"institution","name":"Shanghai Pulmonary Hospital","route":"/institutions/shanghai-pulmonary-hospital/","asOf":"2026-09-09","days":19},{"id":"zhongshan-hospital-fudan","kind":"institution","name":"Zhongshan Hospital, Fudan University","route":"/institutions/zhongshan-hospital-fudan/","asOf":"2026-09-09","days":19},{"id":"ruijin-hospital","kind":"institution","name":"Ruijin Hospital, Shanghai Jiao Tong University","route":"/institutions/ruijin-hospital/","asOf":"2026-09-09","days":19},{"id":"sysu-first-affiliated-hospital","kind":"institution","name":"First Affiliated Hospital of Sun Yat-sen University","route":"/institutions/sysu-first-affiliated-hospital/","asOf":"2026-09-09","days":19},{"id":"tmucih","kind":"institution","name":"Tianjin Medical University Cancer Institute and Hospital","route":"/institutions/tmucih/","asOf":"2026-09-09","days":19},{"id":"zhejiang-cancer-hospital","kind":"institution","name":"Zhejiang Cancer Hospital","route":"/institutions/zhejiang-cancer-hospital/","asOf":"2026-09-09","days":19},{"id":"hunan-cancer-hospital","kind":"institution","name":"Hunan Cancer Hospital","route":"/institutions/hunan-cancer-hospital/","asOf":"2026-09-09","days":19},{"id":"pla-general-hospital","kind":"institution","name":"Chinese PLA General Hospital","route":"/institutions/pla-general-hospital/","asOf":"2026-09-09","days":19},{"id":"henan-cancer-hospital","kind":"institution","name":"Henan Cancer Hospital","route":"/institutions/henan-cancer-hospital/","asOf":"2026-09-09","days":19},{"id":"shandong-cancer-hospital","kind":"institution","name":"Shandong Cancer Hospital and Institute","route":"/institutions/shandong-cancer-hospital/","asOf":"2026-09-09","days":19},{"id":"guangdong-provincial-peoples-hospital","kind":"institution","name":"Guangdong Provincial People's Hospital","route":"/institutions/guangdong-provincial-peoples-hospital/","asOf":"2026-09-09","days":19},{"id":"tongji-hospital-wuhan","kind":"institution","name":"Tongji Hospital, Huazhong University of Science and Technology","route":"/institutions/tongji-hospital-wuhan/","asOf":"2026-09-09","days":19},{"id":"union-hospital-wuhan","kind":"institution","name":"Union Hospital, Tongji Medical College","route":"/institutions/union-hospital-wuhan/","asOf":"2026-09-09","days":19},{"id":"queen-mary-hospital-hku","kind":"institution","name":"Queen Mary Hospital / University of Hong Kong","route":"/institutions/queen-mary-hospital-hku/","asOf":"2026-09-09","days":19},{"id":"prince-of-wales-hospital-cuhk","kind":"institution","name":"Prince of Wales Hospital / Chinese University of Hong Kong","route":"/institutions/prince-of-wales-hospital-cuhk/","asOf":"2026-09-09","days":19},{"id":"ntuh","kind":"institution","name":"National Taiwan University Hospital","route":"/institutions/ntuh/","asOf":"2026-09-09","days":19},{"id":"chang-gung-memorial-hospital","kind":"institution","name":"Chang Gung Memorial Hospital","route":"/institutions/chang-gung-memorial-hospital/","asOf":"2026-09-09","days":19},{"id":"taipei-veterans-general-hospital","kind":"institution","name":"Taipei Veterans General Hospital","route":"/institutions/taipei-veterans-general-hospital/","asOf":"2026-09-09","days":19},{"id":"koo-foundation-sun-yat-sen-cancer-center","kind":"institution","name":"Koo Foundation Sun Yat-Sen Cancer Center","route":"/institutions/koo-foundation-sun-yat-sen-cancer-center/","asOf":"2026-09-09","days":19},{"id":"kyoto-university-hospital","kind":"institution","name":"Kyoto University Hospital","route":"/institutions/kyoto-university-hospital/","asOf":"2026-09-09","days":19},{"id":"osaka-international-cancer-institute","kind":"institution","name":"Osaka International Cancer Institute","route":"/institutions/osaka-international-cancer-institute/","asOf":"2026-09-09","days":19},{"id":"aichi-cancer-center","kind":"institution","name":"Aichi Cancer Center","route":"/institutions/aichi-cancer-center/","asOf":"2026-09-09","days":19},{"id":"shizuoka-cancer-center","kind":"institution","name":"Shizuoka Cancer Center","route":"/institutions/shizuoka-cancer-center/","asOf":"2026-09-09","days":19},{"id":"kyushu-university-hospital","kind":"institution","name":"Kyushu University Hospital","route":"/institutions/kyushu-university-hospital/","asOf":"2026-09-09","days":19},{"id":"hokkaido-university-hospital","kind":"institution","name":"Hokkaido University Hospital","route":"/institutions/hokkaido-university-hospital/","asOf":"2026-09-09","days":19},{"id":"tohoku-university-hospital","kind":"institution","name":"Tohoku University Hospital","route":"/institutions/tohoku-university-hospital/","asOf":"2026-09-09","days":19},{"id":"keio-university-hospital","kind":"institution","name":"Keio University Hospital","route":"/institutions/keio-university-hospital/","asOf":"2026-09-09","days":19},{"id":"gunma-heavy-ion-medical-center","kind":"institution","name":"Gunma University Heavy Ion Medical Center","route":"/institutions/gunma-heavy-ion-medical-center/","asOf":"2026-09-09","days":19},{"id":"ncc-hospital-east","kind":"institution","name":"National Cancer Center Hospital East","route":"/institutions/ncc-hospital-east/","asOf":"2026-09-09","days":19},{"id":"qst-hospital","kind":"institution","name":"QST Hospital (National Institutes for Quantum Science and Technology)","route":"/institutions/qst-hospital/","asOf":"2026-09-09","days":19},{"id":"ncc-korea","kind":"institution","name":"National Cancer Center Korea","route":"/institutions/ncc-korea/","asOf":"2026-09-09","days":19},{"id":"seoul-st-marys-hospital","kind":"institution","name":"Seoul St. Mary's Hospital","route":"/institutions/seoul-st-marys-hospital/","asOf":"2026-09-09","days":19},{"id":"nccs","kind":"institution","name":"National Cancer Centre Singapore","route":"/institutions/nccs/","asOf":"2026-09-09","days":19},{"id":"nuh-ncis","kind":"institution","name":"National University Hospital / National University Cancer Institute, Singapore","route":"/institutions/nuh-ncis/","asOf":"2026-09-09","days":19},{"id":"aiims-delhi","kind":"institution","name":"All India Institute of Medical Sciences, New Delhi","route":"/institutions/aiims-delhi/","asOf":"2026-09-09","days":19},{"id":"rgci","kind":"institution","name":"Rajiv Gandhi Cancer Institute and Research Centre","route":"/institutions/rgci/","asOf":"2026-09-09","days":19},{"id":"kidwai-memorial-institute-of-oncology","kind":"institution","name":"Kidwai Memorial Institute of Oncology","route":"/institutions/kidwai-memorial-institute-of-oncology/","asOf":"2026-09-09","days":19},{"id":"cancer-institute-adyar","kind":"institution","name":"Cancer Institute (WIA), Adyar","route":"/institutions/cancer-institute-adyar/","asOf":"2026-09-09","days":19},{"id":"tata-medical-center-kolkata","kind":"institution","name":"Tata Medical Center, Kolkata","route":"/institutions/tata-medical-center-kolkata/","asOf":"2026-09-09","days":19},{"id":"hcg","kind":"institution","name":"HealthCare Global Enterprises","route":"/institutions/hcg/","asOf":"2026-09-09","days":19},{"id":"apollo-hospitals","kind":"institution","name":"Apollo Hospitals (Apollo Cancer Centres)","route":"/institutions/apollo-hospitals/","asOf":"2026-09-09","days":19},{"id":"cmc-vellore","kind":"institution","name":"Christian Medical College, Vellore","route":"/institutions/cmc-vellore/","asOf":"2026-09-09","days":19},{"id":"pgimer-chandigarh","kind":"institution","name":"Postgraduate Institute of Medical Education and Research, Chandigarh","route":"/institutions/pgimer-chandigarh/","asOf":"2026-09-09","days":19},{"id":"actrec","kind":"institution","name":"Advanced Centre for Treatment, Research and Education in Cancer","route":"/institutions/actrec/","asOf":"2026-09-09","days":19},{"id":"chris-obrien-lifehouse","kind":"institution","name":"Chris O'Brien Lifehouse","route":"/institutions/chris-obrien-lifehouse/","asOf":"2026-09-09","days":19},{"id":"onj-cancer-centre","kind":"institution","name":"Olivia Newton-John Cancer Wellness and Research Centre","route":"/institutions/onj-cancer-centre/","asOf":"2026-09-09","days":19},{"id":"garvan-institute","kind":"institution","name":"Garvan Institute of Medical Research / Kinghorn Cancer Centre","route":"/institutions/garvan-institute/","asOf":"2026-09-09","days":19},{"id":"wehi","kind":"institution","name":"Walter and Eliza Hall Institute of Medical Research","route":"/institutions/wehi/","asOf":"2026-09-09","days":19},{"id":"qimr-berghofer","kind":"institution","name":"QIMR Berghofer Medical Research Institute","route":"/institutions/qimr-berghofer/","asOf":"2026-09-09","days":19},{"id":"sydney-childrens-hospitals-network","kind":"institution","name":"Sydney Children's Hospitals Network / Children's Cancer Institute","route":"/institutions/sydney-childrens-hospitals-network/","asOf":"2026-09-09","days":19},{"id":"royal-adelaide-hospital","kind":"institution","name":"Royal Adelaide Hospital","route":"/institutions/royal-adelaide-hospital/","asOf":"2026-09-09","days":19},{"id":"auckland-city-hospital","kind":"institution","name":"Auckland City Hospital / Te Pūriri o Te Ora Cancer and Blood Service","route":"/institutions/auckland-city-hospital/","asOf":"2026-09-09","days":19},{"id":"siriraj-hospital","kind":"institution","name":"Siriraj Hospital, Mahidol University","route":"/institutions/siriraj-hospital/","asOf":"2026-09-09","days":19},{"id":"chulabhorn-hospital","kind":"institution","name":"Chulabhorn Hospital / Chulabhorn Royal Academy","route":"/institutions/chulabhorn-hospital/","asOf":"2026-09-09","days":19},{"id":"ramathibodi-hospital","kind":"institution","name":"Ramathibodi Hospital, Mahidol University","route":"/institutions/ramathibodi-hospital/","asOf":"2026-09-09","days":19},{"id":"dharmais-cancer-hospital","kind":"institution","name":"Dharmais National Cancer Center","route":"/institutions/dharmais-cancer-hospital/","asOf":"2026-09-09","days":19},{"id":"ummc-kuala-lumpur","kind":"institution","name":"University of Malaya Medical Centre","route":"/institutions/ummc-kuala-lumpur/","asOf":"2026-09-09","days":19},{"id":"philippine-general-hospital","kind":"institution","name":"Philippine General Hospital","route":"/institutions/philippine-general-hospital/","asOf":"2026-09-09","days":19},{"id":"k-hospital-hanoi","kind":"institution","name":"Vietnam National Cancer Hospital (K Hospital)","route":"/institutions/k-hospital-hanoi/","asOf":"2026-09-09","days":19},{"id":"hcmc-oncology-hospital","kind":"institution","name":"Ho Chi Minh City Oncology Hospital","route":"/institutions/hcmc-oncology-hospital/","asOf":"2026-09-09","days":19},{"id":"khcc","kind":"institution","name":"King Hussein Cancer Center","route":"/institutions/khcc/","asOf":"2026-09-09","days":19},{"id":"kfshrc","kind":"institution","name":"King Faisal Specialist Hospital and Research Centre","route":"/institutions/kfshrc/","asOf":"2026-09-09","days":19},{"id":"tawam-hospital","kind":"institution","name":"Tawam Hospital","route":"/institutions/tawam-hospital/","asOf":"2026-09-09","days":19},{"id":"cleveland-clinic-abu-dhabi","kind":"institution","name":"Cleveland Clinic Abu Dhabi","route":"/institutions/cleveland-clinic-abu-dhabi/","asOf":"2026-09-09","days":19},{"id":"hamad-medical-corporation","kind":"institution","name":"Hamad Medical Corporation / National Center for Cancer Care and Research","route":"/institutions/hamad-medical-corporation/","asOf":"2026-09-09","days":19},{"id":"tehran-cancer-institute","kind":"institution","name":"Cancer Institute of Iran, Imam Khomeini Hospital Complex","route":"/institutions/tehran-cancer-institute/","asOf":"2026-09-09","days":19},{"id":"inca-brazil","kind":"institution","name":"Instituto Nacional de Câncer (INCA)","route":"/institutions/inca-brazil/","asOf":"2026-09-09","days":19},{"id":"ac-camargo","kind":"institution","name":"A.C. Camargo Cancer Center","route":"/institutions/ac-camargo/","asOf":"2026-09-09","days":19},{"id":"hospital-de-amor-barretos","kind":"institution","name":"Hospital de Amor (Barretos Cancer Hospital)","route":"/institutions/hospital-de-amor-barretos/","asOf":"2026-09-09","days":19},{"id":"hcpa-porto-alegre","kind":"institution","name":"Hospital de Clínicas de Porto Alegre","route":"/institutions/hcpa-porto-alegre/","asOf":"2026-09-09","days":19},{"id":"incan-mexico","kind":"institution","name":"Instituto Nacional de Cancerología (Mexico)","route":"/institutions/incan-mexico/","asOf":"2026-09-09","days":19},{"id":"inc-colombia","kind":"institution","name":"Instituto Nacional de Cancerología (Colombia)","route":"/institutions/inc-colombia/","asOf":"2026-09-09","days":19},{"id":"inen-peru","kind":"institution","name":"Instituto Nacional de Enfermedades Neoplásicas","route":"/institutions/inen-peru/","asOf":"2026-09-09","days":19},{"id":"instituto-alexander-fleming","kind":"institution","name":"Instituto Alexander Fleming","route":"/institutions/instituto-alexander-fleming/","asOf":"2026-09-09","days":19},{"id":"falp-chile","kind":"institution","name":"Fundación Arturo López Pérez","route":"/institutions/falp-chile/","asOf":"2026-09-09","days":19},{"id":"groote-schuur-uct","kind":"institution","name":"Groote Schuur Hospital / University of Cape Town","route":"/institutions/groote-schuur-uct/","asOf":"2026-09-09","days":19},{"id":"wits-charlotte-maxeke","kind":"institution","name":"Charlotte Maxeke Johannesburg Academic Hospital / University of the Witwatersrand","route":"/institutions/wits-charlotte-maxeke/","asOf":"2026-09-09","days":19},{"id":"kenyatta-national-hospital","kind":"institution","name":"Kenyatta National Hospital","route":"/institutions/kenyatta-national-hospital/","asOf":"2026-09-09","days":19},{"id":"uganda-cancer-institute","kind":"institution","name":"Uganda Cancer Institute","route":"/institutions/uganda-cancer-institute/","asOf":"2026-09-09","days":19},{"id":"ocean-road-cancer-institute","kind":"institution","name":"Ocean Road Cancer Institute","route":"/institutions/ocean-road-cancer-institute/","asOf":"2026-09-09","days":19},{"id":"korle-bu-teaching-hospital","kind":"institution","name":"Korle Bu Teaching Hospital","route":"/institutions/korle-bu-teaching-hospital/","asOf":"2026-09-09","days":19},{"id":"luth-lagos","kind":"institution","name":"Lagos University Teaching Hospital","route":"/institutions/luth-lagos/","asOf":"2026-09-09","days":19},{"id":"nci-cairo","kind":"institution","name":"National Cancer Institute, Cairo University","route":"/institutions/nci-cairo/","asOf":"2026-09-09","days":19},{"id":"cche-57357","kind":"institution","name":"Children's Cancer Hospital Egypt 57357","route":"/institutions/cche-57357/","asOf":"2026-09-09","days":19},{"id":"institut-national-oncologie-rabat","kind":"institution","name":"Institut National d'Oncologie, Rabat","route":"/institutions/institut-national-oncologie-rabat/","asOf":"2026-09-09","days":19},{"id":"institut-salah-azaiez","kind":"institution","name":"Institut Salah Azaïez","route":"/institutions/institut-salah-azaiez/","asOf":"2026-09-09","days":19},{"id":"butaro-cancer-center","kind":"institution","name":"Butaro Cancer Center of Excellence","route":"/institutions/butaro-cancer-center/","asOf":"2026-09-09","days":19},{"id":"blida-anti-cancer-center","kind":"institution","name":"Anti-Cancer Center of Blida","route":"/institutions/blida-anti-cancer-center/","asOf":"2026-09-09","days":19},{"id":"jinshazhou-hospital","kind":"institution","name":"Jinshazhou Hospital of Guangzhou University of Chinese Medicine","route":"/institutions/jinshazhou-hospital/","asOf":"2026-09-09","days":19},{"id":"new-york-proton-center","kind":"institution","name":"New York Proton Center","route":"/institutions/new-york-proton-center/","asOf":"2026-09-09","days":19},{"id":"excel-diagnostics-nuclear-oncology","kind":"institution","name":"Excel Diagnostics and Nuclear Oncology Center","route":"/institutions/excel-diagnostics-nuclear-oncology/","asOf":"2026-09-09","days":19},{"id":"curanosticum","kind":"institution","name":"Curanosticum Wiesbaden-Frankfurt","route":"/institutions/curanosticum/","asOf":"2026-09-09","days":19},{"id":"cecurio","kind":"institution","name":"CeCurio (MVZ Tübingen oncology)","route":"/institutions/cecurio/","asOf":"2026-09-09","days":19},{"id":"immunocine","kind":"institution","name":"Immunocine","route":"/institutions/immunocine/","asOf":"2026-09-09","days":19},{"id":"houston-methodist-rna-therapeutics","kind":"institution","name":"Houston Methodist Center for RNA Therapeutics","route":"/institutions/houston-methodist-rna-therapeutics/","asOf":"2026-09-09","days":19},{"id":"center-for-metabolic-oncology","kind":"institution","name":"Center for Metabolic Oncology","route":"/institutions/center-for-metabolic-oncology/","asOf":"2026-09-09","days":19},{"id":"asthra-health","kind":"institution","name":"Asthra Health","route":"/institutions/asthra-health/","asOf":"2026-09-09","days":19},{"id":"sarcoma-oncology-center","kind":"institution","name":"Sarcoma Oncology Center","route":"/institutions/sarcoma-oncology-center/","asOf":"2026-09-09","days":19},{"id":"docrates","kind":"institution","name":"Docrates Cancer Center","route":"/institutions/docrates/","asOf":"2026-09-09","days":19},{"id":"siop-europe","kind":"institution","name":"SIOP Europe (European Society for Paediatric Oncology)","route":"/institutions/siop-europe/","asOf":"2026-09-09","days":19},{"id":"fondation-arc","kind":"institution","name":"Fondation ARC pour la recherche sur le cancer","route":"/institutions/fondation-arc/","asOf":"2026-09-09","days":19},{"id":"ligue-contre-le-cancer","kind":"institution","name":"Ligue nationale contre le cancer","route":"/institutions/ligue-contre-le-cancer/","asOf":"2026-09-09","days":19},{"id":"deutsche-krebshilfe","kind":"institution","name":"Deutsche Krebshilfe","route":"/institutions/deutsche-krebshilfe/","asOf":"2026-09-09","days":19},{"id":"kwf","kind":"institution","name":"KWF Dutch Cancer Society","route":"/institutions/kwf/","asOf":"2026-09-09","days":19},{"id":"airc","kind":"institution","name":"Fondazione AIRC per la ricerca sul cancro","route":"/institutions/airc/","asOf":"2026-09-09","days":19},{"id":"cancer-council-australia","kind":"institution","name":"Cancer Council Australia","route":"/institutions/cancer-council-australia/","asOf":"2026-09-09","days":19},{"id":"canadian-cancer-society","kind":"institution","name":"Canadian Cancer Society","route":"/institutions/canadian-cancer-society/","asOf":"2026-09-09","days":19},{"id":"irish-cancer-society","kind":"institution","name":"Irish Cancer Society","route":"/institutions/irish-cancer-society/","asOf":"2026-09-09","days":19},{"id":"worldwide-cancer-research","kind":"institution","name":"Worldwide Cancer Research","route":"/institutions/worldwide-cancer-research/","asOf":"2026-09-09","days":19},{"id":"wellcome","kind":"institution","name":"Wellcome","route":"/institutions/wellcome/","asOf":"2026-09-09","days":19},{"id":"hhmi","kind":"institution","name":"Howard Hughes Medical Institute","route":"/institutions/hhmi/","asOf":"2026-09-09","days":19},{"id":"damon-runyon","kind":"institution","name":"Damon Runyon Cancer Research Foundation","route":"/institutions/damon-runyon/","asOf":"2026-09-09","days":19},{"id":"v-foundation","kind":"institution","name":"The V Foundation for Cancer Research","route":"/institutions/v-foundation/","asOf":"2026-09-09","days":19},{"id":"stand-up-to-cancer","kind":"institution","name":"Stand Up To Cancer","route":"/institutions/stand-up-to-cancer/","asOf":"2026-09-09","days":19},{"id":"bcrf","kind":"institution","name":"Breast Cancer Research Foundation","route":"/institutions/bcrf/","asOf":"2026-09-09","days":19},{"id":"lustgarten-foundation","kind":"institution","name":"Lustgarten Foundation","route":"/institutions/lustgarten-foundation/","asOf":"2026-09-09","days":19},{"id":"cprit","kind":"institution","name":"Cancer Prevention and Research Institute of Texas","route":"/institutions/cprit/","asOf":"2026-09-09","days":19},{"id":"mark-foundation","kind":"institution","name":"The Mark Foundation for Cancer Research","route":"/institutions/mark-foundation/","asOf":"2026-09-09","days":19},{"id":"emerson-collective","kind":"institution","name":"Emerson Collective","route":"/institutions/emerson-collective/","asOf":"2026-09-09","days":19},{"id":"cz-biohub","kind":"institution","name":"Chan Zuckerberg Biohub","route":"/institutions/cz-biohub/","asOf":"2026-09-09","days":19},{"id":"gates-foundation","kind":"institution","name":"Gates Foundation","route":"/institutions/gates-foundation/","asOf":"2026-09-09","days":19},{"id":"cancer-grand-challenges","kind":"institution","name":"Cancer Grand Challenges","route":"/institutions/cancer-grand-challenges/","asOf":"2026-09-09","days":19},{"id":"arpa-h","kind":"institution","name":"Advanced Research Projects Agency for Health","route":"/institutions/arpa-h/","asOf":"2026-09-09","days":19},{"id":"movember","kind":"institution","name":"Movember","route":"/institutions/movember/","asOf":"2026-09-09","days":19},{"id":"macmillan-cancer-support","kind":"institution","name":"Macmillan Cancer Support","route":"/institutions/macmillan-cancer-support/","asOf":"2026-09-09","days":19},{"id":"marie-curie-uk","kind":"institution","name":"Marie Curie","route":"/institutions/marie-curie-uk/","asOf":"2026-09-09","days":19},{"id":"uicc","kind":"institution","name":"Union for International Cancer Control","route":"/institutions/uicc/","asOf":"2026-09-09","days":19},{"id":"who","kind":"institution","name":"World Health Organization Cancer Programme","route":"/institutions/who/","asOf":"2026-09-09","days":19},{"id":"iaea","kind":"institution","name":"International Atomic Energy Agency: Rays of Hope","route":"/institutions/iaea/","asOf":"2026-09-09","days":19},{"id":"fda-oce","kind":"institution","name":"FDA Oncology Center of Excellence","route":"/institutions/fda-oce/","asOf":"2026-09-09","days":19},{"id":"ema","kind":"institution","name":"European Medicines Agency","route":"/institutions/ema/","asOf":"2026-09-09","days":19},{"id":"mhra","kind":"institution","name":"Medicines and Healthcare products Regulatory Agency","route":"/institutions/mhra/","asOf":"2026-09-09","days":19},{"id":"nice","kind":"institution","name":"National Institute for Health and Care Excellence","route":"/institutions/nice/","asOf":"2026-09-09","days":19},{"id":"pmda","kind":"institution","name":"Pharmaceuticals and Medical Devices Agency","route":"/institutions/pmda/","asOf":"2026-09-09","days":19},{"id":"nmpa-cde","kind":"institution","name":"National Medical Products Administration / Center for Drug Evaluation","route":"/institutions/nmpa-cde/","asOf":"2026-09-09","days":19},{"id":"tga","kind":"institution","name":"Therapeutic Goods Administration","route":"/institutions/tga/","asOf":"2026-09-09","days":19},{"id":"health-canada","kind":"institution","name":"Health Canada","route":"/institutions/health-canada/","asOf":"2026-09-09","days":19},{"id":"swissmedic","kind":"institution","name":"Swissmedic","route":"/institutions/swissmedic/","asOf":"2026-09-09","days":19},{"id":"has-france","kind":"institution","name":"Haute Autorité de Santé","route":"/institutions/has-france/","asOf":"2026-09-09","days":19},{"id":"g-ba-iqwig","kind":"institution","name":"Gemeinsamer Bundesausschuss / IQWiG","route":"/institutions/g-ba-iqwig/","asOf":"2026-09-09","days":19},{"id":"smc","kind":"institution","name":"Scottish Medicines Consortium","route":"/institutions/smc/","asOf":"2026-09-09","days":19},{"id":"pbac","kind":"institution","name":"Pharmaceutical Benefits Advisory Committee","route":"/institutions/pbac/","asOf":"2026-09-09","days":19},{"id":"anvisa","kind":"institution","name":"Agência Nacional de Vigilância Sanitária","route":"/institutions/anvisa/","asOf":"2026-09-09","days":19},{"id":"cofepris","kind":"institution","name":"Comisión Federal para la Protección contra Riesgos Sanitarios","route":"/institutions/cofepris/","asOf":"2026-09-09","days":19},{"id":"cdsco","kind":"institution","name":"Central Drugs Standard Control Organization","route":"/institutions/cdsco/","asOf":"2026-09-09","days":19},{"id":"ash","kind":"institution","name":"American Society of Hematology","route":"/institutions/ash/","asOf":"2026-09-09","days":19},{"id":"astro","kind":"institution","name":"American Society for Radiation Oncology","route":"/institutions/astro/","asOf":"2026-09-09","days":19},{"id":"estro","kind":"institution","name":"European Society for Radiotherapy and Oncology","route":"/institutions/estro/","asOf":"2026-09-09","days":19},{"id":"snmmi","kind":"institution","name":"Society of Nuclear Medicine and Molecular Imaging","route":"/institutions/snmmi/","asOf":"2026-09-09","days":19},{"id":"eanm","kind":"institution","name":"European Association of Nuclear Medicine","route":"/institutions/eanm/","asOf":"2026-09-09","days":19},{"id":"sitc","kind":"institution","name":"Society for Immunotherapy of Cancer","route":"/institutions/sitc/","asOf":"2026-09-09","days":19},{"id":"sso","kind":"institution","name":"Society of Surgical Oncology","route":"/institutions/sso/","asOf":"2026-09-09","days":19},{"id":"esso","kind":"institution","name":"European Society of Surgical Oncology","route":"/institutions/esso/","asOf":"2026-09-09","days":19},{"id":"jsmo","kind":"institution","name":"Japanese Society of Medical Oncology","route":"/institutions/jsmo/","asOf":"2026-09-09","days":19},{"id":"csco","kind":"institution","name":"Chinese Society of Clinical Oncology","route":"/institutions/csco/","asOf":"2026-09-09","days":19},{"id":"ispor","kind":"institution","name":"ISPOR (The Professional Society for Health Economics and Outcomes Research)","route":"/institutions/ispor/","asOf":"2026-09-09","days":19},{"id":"iaslc","kind":"institution","name":"International Association for the Study of Lung Cancer","route":"/institutions/iaslc/","asOf":"2026-09-09","days":19},{"id":"sgo","kind":"institution","name":"Society of Gynecologic Oncology","route":"/institutions/sgo/","asOf":"2026-09-09","days":19},{"id":"esgo","kind":"institution","name":"European Society of Gynaecological Oncology","route":"/institutions/esgo/","asOf":"2026-09-09","days":19},{"id":"eha","kind":"institution","name":"European Hematology Association","route":"/institutions/eha/","asOf":"2026-09-09","days":19},{"id":"isoqol","kind":"institution","name":"International Society for Quality of Life Research","route":"/institutions/isoqol/","asOf":"2026-09-09","days":19},{"id":"mascc","kind":"institution","name":"Multinational Association of Supportive Care in Cancer","route":"/institutions/mascc/","asOf":"2026-09-09","days":19},{"id":"espen","kind":"institution","name":"European Society for Clinical Nutrition and Metabolism","route":"/institutions/espen/","asOf":"2026-09-09","days":19},{"id":"cdisc","kind":"institution","name":"Clinical Data Interchange Standards Consortium","route":"/institutions/cdisc/","asOf":"2026-09-09","days":19},{"id":"hl7","kind":"institution","name":"HL7 International","route":"/institutions/hl7/","asOf":"2026-09-09","days":19},{"id":"vivli","kind":"institution","name":"Vivli","route":"/institutions/vivli/","asOf":"2026-09-09","days":19},{"id":"yoda-project","kind":"institution","name":"Yale University Open Data Access (YODA) Project","route":"/institutions/yoda-project/","asOf":"2026-09-09","days":19},{"id":"institut-bergonie","kind":"institution","name":"Institut Bergonié","route":"/institutions/institut-bergonie/","asOf":"2026-09-09","days":19},{"id":"centre-leon-berard","kind":"institution","name":"Centre Léon Bérard","route":"/institutions/centre-leon-berard/","asOf":"2026-09-09","days":19},{"id":"institut-paoli-calmettes","kind":"institution","name":"Institut Paoli-Calmettes","route":"/institutions/institut-paoli-calmettes/","asOf":"2026-09-09","days":19},{"id":"iuct-oncopole","kind":"institution","name":"IUCT Oncopole (Institut Universitaire du Cancer de Toulouse)","route":"/institutions/iuct-oncopole/","asOf":"2026-09-09","days":19},{"id":"centre-oscar-lambret","kind":"institution","name":"Centre Oscar Lambret","route":"/institutions/centre-oscar-lambret/","asOf":"2026-09-09","days":19},{"id":"centre-antoine-lacassagne","kind":"institution","name":"Centre Antoine Lacassagne","route":"/institutions/centre-antoine-lacassagne/","asOf":"2026-09-09","days":19},{"id":"inca","kind":"institution","name":"Institut National du Cancer","route":"/institutions/inca/","asOf":"2026-09-09","days":19},{"id":"institut-pasteur","kind":"institution","name":"Institut Pasteur","route":"/institutions/institut-pasteur/","asOf":"2026-09-09","days":19},{"id":"tum-munich","kind":"institution","name":"TUM Klinikum rechts der Isar / CCC München","route":"/institutions/tum-munich/","asOf":"2026-09-09","days":19},{"id":"essen-wtz","kind":"institution","name":"West German Cancer Center (WTZ), University Hospital Essen","route":"/institutions/essen-wtz/","asOf":"2026-09-09","days":19},{"id":"nct-dresden","kind":"institution","name":"NCT/UCC Dresden, University Hospital Carl Gustav Carus","route":"/institutions/nct-dresden/","asOf":"2026-09-09","days":19},{"id":"uct-frankfurt","kind":"institution","name":"University Cancer Center Frankfurt (UCT)","route":"/institutions/uct-frankfurt/","asOf":"2026-09-09","days":19},{"id":"ccc-freiburg","kind":"institution","name":"Comprehensive Cancer Center Freiburg (CCCF)","route":"/institutions/ccc-freiburg/","asOf":"2026-09-09","days":19},{"id":"ccc-tuebingen","kind":"institution","name":"Comprehensive Cancer Center Tübingen-Stuttgart","route":"/institutions/ccc-tuebingen/","asOf":"2026-09-09","days":19},{"id":"ccc-wuerzburg","kind":"institution","name":"Comprehensive Cancer Center Mainfranken, University Hospital Würzburg","route":"/institutions/ccc-wuerzburg/","asOf":"2026-09-09","days":19},{"id":"uct-mainz","kind":"institution","name":"University Cancer Center Mainz (UCT Mainz) / Universitätsmedizin Mainz","route":"/institutions/uct-mainz/","asOf":"2026-09-09","days":19},{"id":"uk-duesseldorf","kind":"institution","name":"University Hospital Düsseldorf / CIO Düsseldorf","route":"/institutions/uk-duesseldorf/","asOf":"2026-09-09","days":19},{"id":"mdc-berlin","kind":"institution","name":"Max Delbrück Center for Molecular Medicine","route":"/institutions/mdc-berlin/","asOf":"2026-09-09","days":19},{"id":"barts-cancer-institute","kind":"institution","name":"Barts Cancer Institute / Barts Health NHS Trust","route":"/institutions/barts-cancer-institute/","asOf":"2026-09-09","days":19},{"id":"uclh","kind":"institution","name":"University College London Hospitals / UCL Cancer Institute","route":"/institutions/uclh/","asOf":"2026-09-09","days":19},{"id":"guys-st-thomas","kind":"institution","name":"Guy's and St Thomas' NHS Foundation Trust / King's Health Partners Cancer Centre","route":"/institutions/guys-st-thomas/","asOf":"2026-09-09","days":19},{"id":"leeds-cancer-centre","kind":"institution","name":"Leeds Cancer Centre, St James's University Hospital","route":"/institutions/leeds-cancer-centre/","asOf":"2026-09-09","days":19},{"id":"newcastle-cancer-centre","kind":"institution","name":"Newcastle Cancer Centre / Northern Centre for Cancer Care","route":"/institutions/newcastle-cancer-centre/","asOf":"2026-09-09","days":19},{"id":"beatson-glasgow","kind":"institution","name":"Beatson West of Scotland Cancer Centre / CRUK Scotland Institute","route":"/institutions/beatson-glasgow/","asOf":"2026-09-09","days":19},{"id":"edinburgh-cancer-centre","kind":"institution","name":"Edinburgh Cancer Centre / CRUK Scotland Centre","route":"/institutions/edinburgh-cancer-centre/","asOf":"2026-09-09","days":19},{"id":"velindre-cardiff","kind":"institution","name":"Velindre Cancer Centre","route":"/institutions/velindre-cardiff/","asOf":"2026-09-09","days":19},{"id":"oxford-cancer","kind":"institution","name":"Oxford Cancer (Oxford University Hospitals and University of Oxford)","route":"/institutions/oxford-cancer/","asOf":"2026-09-09","days":19},{"id":"cruk-cambridge-centre","kind":"institution","name":"Cancer Research UK Cambridge Centre / CRUK Cambridge Institute","route":"/institutions/cruk-cambridge-centre/","asOf":"2026-09-09","days":19},{"id":"southampton-cancer","kind":"institution","name":"University Hospital Southampton / Centre for Cancer Immunology","route":"/institutions/southampton-cancer/","asOf":"2026-09-09","days":19},{"id":"cruk-manchester-institute","kind":"institution","name":"Cancer Research UK Manchester Institute","route":"/institutions/cruk-manchester-institute/","asOf":"2026-09-09","days":19},{"id":"great-ormond-street","kind":"institution","name":"Great Ormond Street Hospital for Children","route":"/institutions/great-ormond-street/","asOf":"2026-09-09","days":19},{"id":"wellcome-sanger","kind":"institution","name":"Wellcome Sanger Institute","route":"/institutions/wellcome-sanger/","asOf":"2026-09-09","days":19},{"id":"embl-ebi","kind":"institution","name":"EMBL's European Bioinformatics Institute","route":"/institutions/embl-ebi/","asOf":"2026-09-09","days":19},{"id":"birmingham-cancer-centre","kind":"institution","name":"University Hospitals Birmingham / University of Birmingham Cancer Research Centre","route":"/institutions/birmingham-cancer-centre/","asOf":"2026-09-09","days":19},{"id":"erasmus-mc","kind":"institution","name":"Erasmus MC Cancer Institute","route":"/institutions/erasmus-mc/","asOf":"2026-09-09","days":19},{"id":"umc-utrecht","kind":"institution","name":"UMC Utrecht Cancer Center","route":"/institutions/umc-utrecht/","asOf":"2026-09-09","days":19},{"id":"princess-maxima","kind":"institution","name":"Princess Máxima Center for Pediatric Oncology","route":"/institutions/princess-maxima/","asOf":"2026-09-09","days":19},{"id":"lumc-leiden","kind":"institution","name":"Leiden University Medical Center","route":"/institutions/lumc-leiden/","asOf":"2026-09-09","days":19},{"id":"uz-leuven","kind":"institution","name":"UZ Leuven / Leuven Cancer Institute","route":"/institutions/uz-leuven/","asOf":"2026-09-09","days":19},{"id":"institut-jules-bordet","kind":"institution","name":"Institut Jules Bordet","route":"/institutions/institut-jules-bordet/","asOf":"2026-09-09","days":19},{"id":"uz-gent","kind":"institution","name":"Ghent University Hospital / Cancer Research Institute Ghent","route":"/institutions/uz-gent/","asOf":"2026-09-09","days":19},{"id":"hospital-clinic-barcelona","kind":"institution","name":"Hospital Clínic de Barcelona / IDIBAPS","route":"/institutions/hospital-clinic-barcelona/","asOf":"2026-09-09","days":19},{"id":"12-de-octubre","kind":"institution","name":"Hospital Universitario 12 de Octubre","route":"/institutions/12-de-octubre/","asOf":"2026-09-09","days":19},{"id":"la-fe-valencia","kind":"institution","name":"Hospital Universitari i Politècnic La Fe","route":"/institutions/la-fe-valencia/","asOf":"2026-09-09","days":19},{"id":"cun-navarra","kind":"institution","name":"Cancer Center Clínica Universidad de Navarra / CIMA","route":"/institutions/cun-navarra/","asOf":"2026-09-09","days":19},{"id":"cnio","kind":"institution","name":"Centro Nacional de Investigaciones Oncológicas (CNIO)","route":"/institutions/cnio/","asOf":"2026-09-09","days":19},{"id":"incliva-valencia","kind":"institution","name":"INCLIVA Biomedical Research Institute / Hospital Clínico Universitario de Valencia","route":"/institutions/incliva-valencia/","asOf":"2026-09-09","days":19},{"id":"hospital-del-mar","kind":"institution","name":"Hospital del Mar / Hospital del Mar Research Institute","route":"/institutions/hospital-del-mar/","asOf":"2026-09-09","days":19},{"id":"candiolo","kind":"institution","name":"Istituto di Candiolo IRCCS (FPO)","route":"/institutions/candiolo/","asOf":"2026-09-09","days":19},{"id":"pascale-naples","kind":"institution","name":"Istituto Nazionale Tumori IRCCS Fondazione G. Pascale","route":"/institutions/pascale-naples/","asOf":"2026-09-09","days":19},{"id":"regina-elena-rome","kind":"institution","name":"IRCCS Regina Elena National Cancer Institute","route":"/institutions/regina-elena-rome/","asOf":"2026-09-09","days":19},{"id":"humanitas","kind":"institution","name":"IRCCS Humanitas Research Hospital","route":"/institutions/humanitas/","asOf":"2026-09-09","days":19},{"id":"iov-veneto","kind":"institution","name":"Istituto Oncologico Veneto IRCCS","route":"/institutions/iov-veneto/","asOf":"2026-09-09","days":19},{"id":"sant-orsola-bologna","kind":"institution","name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola","route":"/institutions/sant-orsola-bologna/","asOf":"2026-09-09","days":19},{"id":"irst-meldola","kind":"institution","name":"IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)","route":"/institutions/irst-meldola/","asOf":"2026-09-09","days":19},{"id":"san-raffaele","kind":"institution","name":"IRCCS Ospedale San Raffaele","route":"/institutions/san-raffaele/","asOf":"2026-09-09","days":19},{"id":"rigshospitalet","kind":"institution","name":"Rigshospitalet, Copenhagen University Hospital","route":"/institutions/rigshospitalet/","asOf":"2026-09-09","days":19},{"id":"aarhus-university-hospital","kind":"institution","name":"Aarhus University Hospital","route":"/institutions/aarhus-university-hospital/","asOf":"2026-09-09","days":19},{"id":"oslo-radium-hospital","kind":"institution","name":"Oslo University Hospital, The Norwegian Radium Hospital","route":"/institutions/oslo-radium-hospital/","asOf":"2026-09-09","days":19},{"id":"helsinki-hus","kind":"institution","name":"HUS Comprehensive Cancer Center, Helsinki University Hospital","route":"/institutions/helsinki-hus/","asOf":"2026-09-09","days":19},{"id":"uppsala-akademiska","kind":"institution","name":"Uppsala University Hospital / Uppsala University","route":"/institutions/uppsala-akademiska/","asOf":"2026-09-09","days":19},{"id":"lund-skane","kind":"institution","name":"Skåne University Hospital / Lund University Cancer Centre","route":"/institutions/lund-skane/","asOf":"2026-09-09","days":19},{"id":"sahlgrenska","kind":"institution","name":"Sahlgrenska University Hospital / Sahlgrenska Center for Cancer Research","route":"/institutions/sahlgrenska/","asOf":"2026-09-09","days":19},{"id":"usz-zurich","kind":"institution","name":"University Hospital Zurich / Comprehensive Cancer Center Zurich","route":"/institutions/usz-zurich/","asOf":"2026-09-09","days":19},{"id":"chuv-lausanne","kind":"institution","name":"Lausanne University Hospital (CHUV) / Ludwig Institute Lausanne","route":"/institutions/chuv-lausanne/","asOf":"2026-09-09","days":19},{"id":"hug-geneva","kind":"institution","name":"Geneva University Hospitals (HUG)","route":"/institutions/hug-geneva/","asOf":"2026-09-09","days":19},{"id":"inselspital-bern","kind":"institution","name":"Inselspital, Bern University Hospital / University Cancer Center Inselspital","route":"/institutions/inselspital-bern/","asOf":"2026-09-09","days":19},{"id":"usb-basel","kind":"institution","name":"University Hospital Basel / Tumour Centre","route":"/institutions/usb-basel/","asOf":"2026-09-09","days":19},{"id":"ccc-vienna","kind":"institution","name":"Comprehensive Cancer Center Vienna, Medical University of Vienna / AKH","route":"/institutions/ccc-vienna/","asOf":"2026-09-09","days":19},{"id":"ipo-porto","kind":"institution","name":"Instituto Português de Oncologia do Porto Francisco Gentil","route":"/institutions/ipo-porto/","asOf":"2026-09-09","days":19},{"id":"ipo-lisboa","kind":"institution","name":"Instituto Português de Oncologia de Lisboa Francisco Gentil","route":"/institutions/ipo-lisboa/","asOf":"2026-09-09","days":19},{"id":"champalimaud","kind":"institution","name":"Champalimaud Foundation, Champalimaud Clinical Centre","route":"/institutions/champalimaud/","asOf":"2026-09-09","days":19},{"id":"nio-warsaw","kind":"institution","name":"Maria Skłodowska-Curie National Research Institute of Oncology","route":"/institutions/nio-warsaw/","asOf":"2026-09-09","days":19},{"id":"mou-brno","kind":"institution","name":"Masaryk Memorial Cancer Institute","route":"/institutions/mou-brno/","asOf":"2026-09-09","days":19},{"id":"noi-budapest","kind":"institution","name":"National Institute of Oncology, Hungary","route":"/institutions/noi-budapest/","asOf":"2026-09-09","days":19},{"id":"onkoloski-institut-ljubljana","kind":"institution","name":"Institute of Oncology Ljubljana","route":"/institutions/onkoloski-institut-ljubljana/","asOf":"2026-09-09","days":19},{"id":"sheba","kind":"institution","name":"Sheba Medical Center","route":"/institutions/sheba/","asOf":"2026-09-09","days":19},{"id":"hadassah","kind":"institution","name":"Hadassah Medical Center","route":"/institutions/hadassah/","asOf":"2026-09-09","days":19},{"id":"tel-aviv-sourasky","kind":"institution","name":"Tel Aviv Sourasky Medical Center","route":"/institutions/tel-aviv-sourasky/","asOf":"2026-09-09","days":19},{"id":"rambam","kind":"institution","name":"Rambam Health Care Campus","route":"/institutions/rambam/","asOf":"2026-09-09","days":19},{"id":"weizmann","kind":"institution","name":"Weizmann Institute of Science","route":"/institutions/weizmann/","asOf":"2026-09-09","days":19},{"id":"shaare-zedek","kind":"institution","name":"Shaare Zedek Medical Center","route":"/institutions/shaare-zedek/","asOf":"2026-09-09","days":19},{"id":"hacettepe-cancer-institute","kind":"institution","name":"Hacettepe University Cancer Institute","route":"/institutions/hacettepe-cancer-institute/","asOf":"2026-09-09","days":19},{"id":"istanbul-oncology-institute","kind":"institution","name":"Istanbul University Institute of Oncology","route":"/institutions/istanbul-oncology-institute/","asOf":"2026-09-09","days":19},{"id":"ecco","kind":"institution","name":"European Cancer Organisation","route":"/institutions/ecco/","asOf":"2026-09-09","days":19},{"id":"eacr","kind":"institution","name":"European Association for Cancer Research","route":"/institutions/eacr/","asOf":"2026-09-09","days":19},{"id":"oeci","kind":"institution","name":"Organisation of European Cancer Institutes","route":"/institutions/oeci/","asOf":"2026-09-09","days":19},{"id":"odense-university-hospital","kind":"institution","name":"Odense University Hospital","route":"/institutions/odense-university-hospital/","asOf":"2026-09-09","days":19},{"id":"aalborg-university-hospital","kind":"institution","name":"Aalborg University Hospital","route":"/institutions/aalborg-university-hospital/","asOf":"2026-09-09","days":19},{"id":"oulu-university-hospital","kind":"institution","name":"Oulu University Hospital","route":"/institutions/oulu-university-hospital/","asOf":"2026-09-09","days":19},{"id":"landspitali","kind":"institution","name":"Landspítali, the National University Hospital of Iceland","route":"/institutions/landspitali/","asOf":"2026-09-09","days":19},{"id":"motol-university-hospital","kind":"institution","name":"Motol University Hospital","route":"/institutions/motol-university-hospital/","asOf":"2026-09-09","days":19},{"id":"mater-misericordiae","kind":"institution","name":"Mater Misericordiae University Hospital","route":"/institutions/mater-misericordiae/","asOf":"2026-09-09","days":19},{"id":"institut-godinot","kind":"institution","name":"Institut Godinot","route":"/institutions/institut-godinot/","asOf":"2026-09-09","days":19},{"id":"centre-georges-francois-leclerc","kind":"institution","name":"Centre Georges-François Leclerc","route":"/institutions/centre-georges-francois-leclerc/","asOf":"2026-09-09","days":19},{"id":"institut-de-cancerologie-de-lorraine","kind":"institution","name":"Institut de Cancérologie de Lorraine","route":"/institutions/institut-de-cancerologie-de-lorraine/","asOf":"2026-09-09","days":19},{"id":"north-estonia-medical-centre","kind":"institution","name":"North Estonia Medical Centre","route":"/institutions/north-estonia-medical-centre/","asOf":"2026-09-09","days":19},{"id":"east-tallinn-central-hospital","kind":"institution","name":"East Tallinn Central Hospital","route":"/institutions/east-tallinn-central-hospital/","asOf":"2026-09-09","days":19},{"id":"fondazione-poliambulanza","kind":"institution","name":"Fondazione Poliambulanza","route":"/institutions/fondazione-poliambulanza/","asOf":"2026-09-09","days":19},{"id":"policlinico-san-matteo","kind":"institution","name":"Fondazione IRCCS Policlinico San Matteo","route":"/institutions/policlinico-san-matteo/","asOf":"2026-09-09","days":19},{"id":"haukeland-university-hospital","kind":"institution","name":"Haukeland University Hospital","route":"/institutions/haukeland-university-hospital/","asOf":"2026-09-09","days":19},{"id":"akershus-university-hospital","kind":"institution","name":"Akershus University Hospital","route":"/institutions/akershus-university-hospital/","asOf":"2026-09-09","days":19},{"id":"pauls-stradins-clinical-university-hospital","kind":"institution","name":"Pauls Stradiņš Clinical University Hospital","route":"/institutions/pauls-stradins-clinical-university-hospital/","asOf":"2026-09-09","days":19},{"id":"santaros-klinikos","kind":"institution","name":"Vilnius University Hospital Santaros Klinikos","route":"/institutions/santaros-klinikos/","asOf":"2026-09-09","days":19},{"id":"klaipeda-university-hospital","kind":"institution","name":"Klaipėda University Hospital","route":"/institutions/klaipeda-university-hospital/","asOf":"2026-09-09","days":19},{"id":"orebro-university-hospital","kind":"institution","name":"Örebro University Hospital","route":"/institutions/orebro-university-hospital/","asOf":"2026-09-09","days":19},{"id":"hospital-de-sant-pau","kind":"institution","name":"Hospital de la Santa Creu i Sant Pau","route":"/institutions/hospital-de-sant-pau/","asOf":"2026-09-09","days":19},{"id":"hospital-sant-joan-de-reus","kind":"institution","name":"Hospital Universitari Sant Joan de Reus","route":"/institutions/hospital-sant-joan-de-reus/","asOf":"2026-09-09","days":19},{"id":"uck-gdansk","kind":"institution","name":"University Clinical Centre, Gdańsk","route":"/institutions/uck-gdansk/","asOf":"2026-09-09","days":19},{"id":"polish-mothers-memorial-hospital","kind":"institution","name":"Polish Mother's Memorial Hospital Research Institute","route":"/institutions/polish-mothers-memorial-hospital/","asOf":"2026-09-09","days":19},{"id":"oncology-institute-of-vojvodina","kind":"institution","name":"Oncology Institute of Vojvodina","route":"/institutions/oncology-institute-of-vojvodina/","asOf":"2026-09-09","days":19},{"id":"mater-private","kind":"institution","name":"Mater Private Network","route":"/institutions/mater-private/","asOf":"2026-09-09","days":19},{"id":"iknl","kind":"institution","name":"Netherlands Comprehensive Cancer Organisation (IKNL)","route":"/institutions/iknl/","asOf":"2026-09-09","days":19},{"id":"bank-of-cyprus-oncology-centre","kind":"institution","name":"Bank of Cyprus Oncology Centre","route":"/institutions/bank-of-cyprus-oncology-centre/","asOf":"2026-09-09","days":19},{"id":"zealand-university-hospital","kind":"institution","name":"Zealand University Hospital","route":"/institutions/zealand-university-hospital/","asOf":"2026-09-09","days":19},{"id":"uz-brussel-cancer-centre","kind":"institution","name":"Brussels Cancer Centre (UZ Brussel)","route":"/institutions/uz-brussel-cancer-centre/","asOf":"2026-09-09","days":19},{"id":"sestre-milosrdnice-tumors","kind":"institution","name":"University Hospital for Tumors, Sestre milosrdnice University Hospital Centre","route":"/institutions/sestre-milosrdnice-tumors/","asOf":"2026-09-09","days":19},{"id":"german-oncology-center-limassol","kind":"institution","name":"German Oncology Center","route":"/institutions/german-oncology-center-limassol/","asOf":"2026-09-09","days":19},{"id":"metaxa-cancer-hospital","kind":"institution","name":"Metaxa Cancer Hospital, Piraeus","route":"/institutions/metaxa-cancer-hospital/","asOf":"2026-09-09","days":19},{"id":"university-hospital-waterford","kind":"institution","name":"University Hospital Waterford","route":"/institutions/university-hospital-waterford/","asOf":"2026-09-09","days":19},{"id":"mediterranean-institute-of-oncology","kind":"institution","name":"Mediterranean Institute of Oncology (IOM)","route":"/institutions/mediterranean-institute-of-oncology/","asOf":"2026-09-09","days":19},{"id":"kauno-klinikos","kind":"institution","name":"Hospital of the Lithuanian University of Health Sciences Kauno Klinikos","route":"/institutions/kauno-klinikos/","asOf":"2026-09-09","days":19},{"id":"oncological-institute-moldova","kind":"institution","name":"Oncological Institute of Moldova","route":"/institutions/oncological-institute-moldova/","asOf":"2026-09-09","days":19},{"id":"university-clinic-radiotherapy-oncology-skopje","kind":"institution","name":"University Clinic for Radiotherapy and Oncology, Skopje","route":"/institutions/university-clinic-radiotherapy-oncology-skopje/","asOf":"2026-09-09","days":19},{"id":"oncosalud-auna","kind":"institution","name":"Oncosalud (AUNA)","route":"/institutions/oncosalud-auna/","asOf":"2026-09-09","days":19},{"id":"iasi-regional-oncology-institute","kind":"institution","name":"Iași Regional Oncology Institute","route":"/institutions/iasi-regional-oncology-institute/","asOf":"2026-09-09","days":19},{"id":"clara-campal-oncology-centre","kind":"institution","name":"Centro Integral Oncológico Clara Campal (HM CIOCC)","route":"/institutions/clara-campal-oncology-centre/","asOf":"2026-09-09","days":19},{"id":"virgen-de-la-victoria-malaga","kind":"institution","name":"Hospital Universitario Virgen de la Victoria","route":"/institutions/virgen-de-la-victoria-malaga/","asOf":"2026-09-09","days":19},{"id":"doctor-peset-valencia","kind":"institution","name":"Hospital Universitario Doctor Peset","route":"/institutions/doctor-peset-valencia/","asOf":"2026-09-09","days":19},{"id":"umea-university-hospital","kind":"institution","name":"Umeå University Hospital (Norrland University Hospital)","route":"/institutions/umea-university-hospital/","asOf":"2026-09-09","days":19},{"id":"aga-khan-hospital-dar-es-salaam","kind":"institution","name":"The Aga Khan Hospital, Dar es Salaam","route":"/institutions/aga-khan-hospital-dar-es-salaam/","asOf":"2026-09-09","days":19},{"id":"dokuz-eylul-institute-of-oncology","kind":"institution","name":"Dokuz Eylül University Institute of Oncology","route":"/institutions/dokuz-eylul-institute-of-oncology/","asOf":"2026-09-09","days":19},{"id":"kavetsky-institute-kyiv","kind":"institution","name":"R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology","route":"/institutions/kavetsky-institute-kyiv/","asOf":"2026-09-09","days":19},{"id":"northern-cancer-alliance","kind":"institution","name":"Northern Cancer Alliance","route":"/institutions/northern-cancer-alliance/","asOf":"2026-09-09","days":19},{"id":"lancashire-south-cumbria-cancer-alliance","kind":"institution","name":"Lancashire and South Cumbria Cancer Alliance","route":"/institutions/lancashire-south-cumbria-cancer-alliance/","asOf":"2026-09-09","days":19},{"id":"west-yorkshire-harrogate-cancer-alliance","kind":"institution","name":"West Yorkshire and Harrogate Cancer Alliance","route":"/institutions/west-yorkshire-harrogate-cancer-alliance/","asOf":"2026-09-09","days":19},{"id":"humber-north-yorkshire-cancer-alliance","kind":"institution","name":"Humber & North Yorkshire Cancer Alliance","route":"/institutions/humber-north-yorkshire-cancer-alliance/","asOf":"2026-09-09","days":19},{"id":"cheshire-merseyside-cancer-alliance","kind":"institution","name":"Cheshire and Merseyside Cancer Alliance","route":"/institutions/cheshire-merseyside-cancer-alliance/","asOf":"2026-09-09","days":19},{"id":"greater-manchester-cancer-alliance","kind":"institution","name":"Greater Manchester Cancer Alliance","route":"/institutions/greater-manchester-cancer-alliance/","asOf":"2026-09-09","days":19},{"id":"south-yorkshire-bassetlaw-cancer-alliance","kind":"institution","name":"South Yorkshire and Bassetlaw Cancer Alliance","route":"/institutions/south-yorkshire-bassetlaw-cancer-alliance/","asOf":"2026-09-09","days":19},{"id":"west-midlands-cancer-alliance","kind":"institution","name":"West Midlands Cancer Alliance","route":"/institutions/west-midlands-cancer-alliance/","asOf":"2026-09-09","days":19},{"id":"east-midlands-cancer-alliance","kind":"institution","name":"East Midlands Cancer Alliance","route":"/institutions/east-midlands-cancer-alliance/","asOf":"2026-09-09","days":19},{"id":"east-of-england-cancer-alliance","kind":"institution","name":"East of England Cancer Alliance","route":"/institutions/east-of-england-cancer-alliance/","asOf":"2026-09-09","days":19},{"id":"north-central-london-cancer-alliance","kind":"institution","name":"North Central London Cancer Alliance","route":"/institutions/north-central-london-cancer-alliance/","asOf":"2026-09-09","days":19},{"id":"north-east-london-cancer-alliance","kind":"institution","name":"North East London Cancer Alliance","route":"/institutions/north-east-london-cancer-alliance/","asOf":"2026-09-09","days":19},{"id":"south-east-london-cancer-alliance","kind":"institution","name":"South East London Cancer Alliance","route":"/institutions/south-east-london-cancer-alliance/","asOf":"2026-09-09","days":19},{"id":"kent-medway-cancer-alliance","kind":"institution","name":"Kent and Medway Cancer Alliance","route":"/institutions/kent-medway-cancer-alliance/","asOf":"2026-09-09","days":19},{"id":"surrey-sussex-cancer-alliance","kind":"institution","name":"Surrey and Sussex Cancer Alliance","route":"/institutions/surrey-sussex-cancer-alliance/","asOf":"2026-09-09","days":19},{"id":"wessex-cancer-alliance","kind":"institution","name":"Wessex Cancer Alliance","route":"/institutions/wessex-cancer-alliance/","asOf":"2026-09-09","days":19},{"id":"thames-valley-cancer-alliance","kind":"institution","name":"Thames Valley Cancer Alliance","route":"/institutions/thames-valley-cancer-alliance/","asOf":"2026-09-09","days":19},{"id":"swag-cancer-alliance","kind":"institution","name":"Somerset, Wiltshire, Avon and Gloucestershire Cancer Alliance","route":"/institutions/swag-cancer-alliance/","asOf":"2026-09-09","days":19},{"id":"peninsula-cancer-alliance","kind":"institution","name":"Peninsula Cancer Alliance","route":"/institutions/peninsula-cancer-alliance/","asOf":"2026-09-09","days":19},{"id":"mother-teresa-hospital-tirana","kind":"institution","name":"University Hospital Center \"Mother Teresa\", Tirana","route":"/institutions/mother-teresa-hospital-tirana/","asOf":"2026-09-09","days":19},{"id":"institut-sainte-catherine","kind":"institution","name":"Institut Sainte Catherine","route":"/institutions/institut-sainte-catherine/","asOf":"2026-09-09","days":19},{"id":"hellenic-cancer-federation","kind":"institution","name":"Hellenic Cancer Federation (ELLOK)","route":"/institutions/hellenic-cancer-federation/","asOf":"2026-09-09","days":19},{"id":"koranyi-institute-budapest","kind":"institution","name":"National Korányi Institute for Pulmonology","route":"/institutions/koranyi-institute-budapest/","asOf":"2026-09-09","days":19},{"id":"favo","kind":"institution","name":"FAVO, Italian Federation of Voluntary Associations in Oncology","route":"/institutions/favo/","asOf":"2026-09-09","days":19},{"id":"nio-gliwice","kind":"institution","name":"National Institute of Oncology, Gliwice Branch","route":"/institutions/nio-gliwice/","asOf":"2026-09-09","days":19},{"id":"institute-of-mother-and-child","kind":"institution","name":"Institute of Mother and Child, Warsaw","route":"/institutions/institute-of-mother-and-child/","asOf":"2026-09-09","days":19},{"id":"biomedical-research-center-sas","kind":"institution","name":"Biomedical Research Center of the Slovak Academy of Sciences","route":"/institutions/biomedical-research-center-sas/","asOf":"2026-09-09","days":19},{"id":"aecc","kind":"institution","name":"Spanish Association Against Cancer (AECC)","route":"/institutions/aecc/","asOf":"2026-09-09","days":19},{"id":"tatarstan-cancer-center","kind":"institution","name":"Tatarstan Cancer Center, Kazan","route":"/institutions/tatarstan-cancer-center/","asOf":"2026-09-09","days":19},{"id":"mid-western-cancer-centre","kind":"institution","name":"Mid-Western Cancer Centre, University Hospital Limerick","route":"/institutions/mid-western-cancer-centre/","asOf":"2026-09-09","days":19},{"id":"nmrrc-moscow","kind":"institution","name":"National Medical Research Radiological Centre (NMRRC)","route":"/institutions/nmrrc-moscow/","asOf":"2026-09-09","days":19},{"id":"aidport","kind":"institution","name":"AidPort Clinical Trial Hospital","route":"/institutions/aidport/","asOf":"2026-09-09","days":19},{"id":"institut-strauss","kind":"institution","name":"Institut Strauss","route":"/institutions/institut-strauss/","asOf":"2026-09-09","days":19},{"id":"capio-st-goran","kind":"institution","name":"Capio S:t Göran's Hospital","route":"/institutions/capio-st-goran/","asOf":"2026-09-09","days":19},{"id":"heart-and-brain-pleven","kind":"institution","name":"Heart and Brain Hospital, Pleven","route":"/institutions/heart-and-brain-pleven/","asOf":"2026-09-09","days":19},{"id":"bjcn","kind":"institution","name":"Bulgarian Joint Cancer Network (BJCN)","route":"/institutions/bjcn/","asOf":"2026-09-09","days":19},{"id":"iba-masaryk","kind":"institution","name":"Institute of Biostatistics and Analyses, Masaryk University","route":"/institutions/iba-masaryk/","asOf":"2026-09-09","days":19},{"id":"fondazione-the-bridge","kind":"institution","name":"Fondazione The Bridge","route":"/institutions/fondazione-the-bridge/","asOf":"2026-09-09","days":19},{"id":"cancer-free-future-association","kind":"institution","name":"Cancer Free Future Association (CFFA)","route":"/institutions/cancer-free-future-association/","asOf":"2026-09-09","days":19},{"id":"sgccn","kind":"institution","name":"Stockholm Gotland Comprehensive Cancer Network (SGCCN)","route":"/institutions/sgccn/","asOf":"2026-09-09","days":19},{"id":"ramon-y-cajal","kind":"institution","name":"Hospital Universitario Ramón y Cajal","route":"/institutions/ramon-y-cajal/","asOf":"2026-09-09","days":19},{"id":"clinico-san-carlos","kind":"institution","name":"Hospital Clínico San Carlos","route":"/institutions/clinico-san-carlos/","asOf":"2026-09-09","days":19},{"id":"la-princesa","kind":"institution","name":"Hospital Universitario de La Princesa","route":"/institutions/la-princesa/","asOf":"2026-09-09","days":19},{"id":"puerta-de-hierro","kind":"institution","name":"Hospital Universitario Puerta de Hierro Majadahonda","route":"/institutions/puerta-de-hierro/","asOf":"2026-09-09","days":19},{"id":"herlev-hospital","kind":"institution","name":"Herlev Hospital, Copenhagen University Hospital","route":"/institutions/herlev-hospital/","asOf":"2026-09-09","days":19},{"id":"greater-poland-cancer-centre","kind":"institution","name":"Greater Poland Cancer Centre","route":"/institutions/greater-poland-cancer-centre/","asOf":"2026-09-09","days":19},{"id":"henri-mondor","kind":"institution","name":"AP-HP Henri-Mondor University Hospitals Cancer Institute","route":"/institutions/henri-mondor/","asOf":"2026-09-09","days":19},{"id":"king-albert-ii-cancer-institute","kind":"institution","name":"King Albert II Cancer Institute, Cliniques universitaires Saint-Luc","route":"/institutions/king-albert-ii-cancer-institute/","asOf":"2026-09-09","days":19},{"id":"blokhin-cancer-center","kind":"institution","name":"N. N. Blokhin National Medical Research Center of Oncology","route":"/institutions/blokhin-cancer-center/","asOf":"2026-09-09","days":19},{"id":"aphp-paris-saclay-cancer-institute","kind":"institution","name":"AP-HP Paris-Saclay University Hospitals Cancer Institute","route":"/institutions/aphp-paris-saclay-cancer-institute/","asOf":"2026-09-09","days":19},{"id":"inc-luxembourg","kind":"institution","name":"Institut National du Cancer, Luxembourg","route":"/institutions/inc-luxembourg/","asOf":"2026-09-09","days":19},{"id":"nci-ukraine","kind":"institution","name":"National Cancer Institute of Ukraine","route":"/institutions/nci-ukraine/","asOf":"2026-09-09","days":19},{"id":"fican","kind":"institution","name":"Finnish Cancer Center (FICAN)","route":"/institutions/fican/","asOf":"2026-09-09","days":19},{"id":"basement-membrane-tissue-barriers","kind":"pathway","name":"Basement membrane & tissue barriers","route":"/pathways/basement-membrane-tissue-barriers/","asOf":"2026-09-09","days":19},{"id":"cancer-immunity-cycle","kind":"pathway","name":"The cancer-immunity cycle","route":"/pathways/cancer-immunity-cycle/","asOf":"2026-09-09","days":19},{"id":"extrinsic-apoptosis-death-receptors","kind":"pathway","name":"Extrinsic apoptosis (death receptors)","route":"/pathways/extrinsic-apoptosis-death-receptors/","asOf":"2026-09-09","days":19},{"id":"p53-mdm2-axis","kind":"pathway","name":"The p53 network (guardian of the genome)","route":"/pathways/p53-mdm2-axis/","asOf":"2026-09-09","days":19},{"id":"mutagenesis-signatures","kind":"pathway","name":"Mutagenesis & mutational signatures","route":"/pathways/mutagenesis-signatures/","asOf":"2026-09-09","days":19},{"id":"oncogene-activation-two-hit","kind":"pathway","name":"Drivers, passengers & the two-hit model","route":"/pathways/oncogene-activation-two-hit/","asOf":"2026-09-09","days":19},{"id":"oncogenic-viruses","kind":"pathway","name":"Oncogenic viruses","route":"/pathways/oncogenic-viruses/","asOf":"2026-09-09","days":19},{"id":"cell-cycle-engine-cdks","kind":"pathway","name":"The cell-cycle engine (cyclins & CDKs)","route":"/pathways/cell-cycle-engine-cdks/","asOf":"2026-09-09","days":19},{"id":"dna-replication-licensing","kind":"pathway","name":"DNA replication & origin licensing","route":"/pathways/dna-replication-licensing/","asOf":"2026-09-09","days":19},{"id":"mitotic-spindle-checkpoint","kind":"pathway","name":"Mitosis & the spindle assembly checkpoint","route":"/pathways/mitotic-spindle-checkpoint/","asOf":"2026-09-09","days":19},{"id":"rtk-activation","kind":"pathway","name":"Receptor tyrosine kinase activation","route":"/pathways/rtk-activation/","asOf":"2026-09-09","days":19},{"id":"transcription-addiction","kind":"pathway","name":"Transcriptional machinery & addiction","route":"/pathways/transcription-addiction/","asOf":"2026-09-09","days":19},{"id":"ubiquitin-proteasome-system","kind":"pathway","name":"Ubiquitin-proteasome system & protein homeostasis","route":"/pathways/ubiquitin-proteasome-system/","asOf":"2026-09-09","days":19},{"id":"homologous-recombination-repair","kind":"pathway","name":"Double-strand break repair: HR versus end joining","route":"/pathways/homologous-recombination-repair/","asOf":"2026-09-09","days":19},{"id":"mismatch-repair-msi","kind":"pathway","name":"Mismatch repair & microsatellite instability","route":"/pathways/mismatch-repair-msi/","asOf":"2026-09-09","days":19},{"id":"base-excision-repair-parp","kind":"pathway","name":"Base excision repair, PARP & alkylation damage","route":"/pathways/base-excision-repair-parp/","asOf":"2026-09-09","days":19},{"id":"synthetic-lethality-map","kind":"pathway","name":"Synthetic lethality: paired dependencies","route":"/pathways/synthetic-lethality-map/","asOf":"2026-09-09","days":19},{"id":"glutamine-metabolism","kind":"pathway","name":"Glutamine addiction","route":"/pathways/glutamine-metabolism/","asOf":"2026-09-09","days":19},{"id":"lipid-metabolism-cancer","kind":"pathway","name":"Lipid synthesis, uptake & cholesterol","route":"/pathways/lipid-metabolism-cancer/","asOf":"2026-09-09","days":19},{"id":"angiogenic-switch","kind":"pathway","name":"The angiogenic switch & tumour vessels","route":"/pathways/angiogenic-switch/","asOf":"2026-09-09","days":19},{"id":"nutrient-competition-tme","kind":"pathway","name":"Nutrient competition & metabolic immunosuppression","route":"/pathways/nutrient-competition-tme/","asOf":"2026-09-09","days":19},{"id":"t-cell-exhaustion","kind":"pathway","name":"T-cell exhaustion","route":"/pathways/t-cell-exhaustion/","asOf":"2026-09-09","days":19},{"id":"immune-desert-exclusion","kind":"pathway","name":"Cold tumours: immune deserts and exclusion","route":"/pathways/immune-desert-exclusion/","asOf":"2026-09-09","days":19},{"id":"myeloid-suppression-axis","kind":"pathway","name":"Myeloid suppression: TAMs, MDSCs & don't-eat-me signals","route":"/pathways/myeloid-suppression-axis/","asOf":"2026-09-09","days":19},{"id":"complement-in-cancer","kind":"pathway","name":"Complement in cancer","route":"/pathways/complement-in-cancer/","asOf":"2026-09-09","days":19},{"id":"nk-cell-recognition","kind":"pathway","name":"NK-cell recognition: missing self & stress ligands","route":"/pathways/nk-cell-recognition/","asOf":"2026-09-09","days":19},{"id":"invasion-ecm-degradation","kind":"pathway","name":"Invasion: proteases, adhesion & the invasive front","route":"/pathways/invasion-ecm-degradation/","asOf":"2026-09-09","days":19},{"id":"intravasation-ctc-survival","kind":"pathway","name":"Intravasation & circulating tumour cells","route":"/pathways/intravasation-ctc-survival/","asOf":"2026-09-09","days":19},{"id":"pre-metastatic-niche","kind":"pathway","name":"The pre-metastatic niche","route":"/pathways/pre-metastatic-niche/","asOf":"2026-09-09","days":19},{"id":"organ-tropism-seed-soil","kind":"pathway","name":"Organ tropism: seed and soil","route":"/pathways/organ-tropism-seed-soil/","asOf":"2026-09-09","days":19},{"id":"blood-brain-barrier-metastasis","kind":"pathway","name":"The blood-brain barrier & brain metastasis","route":"/pathways/blood-brain-barrier-metastasis/","asOf":"2026-09-09","days":19},{"id":"caf-activation-desmoplasia","kind":"pathway","name":"Fibroblast activation, desmoplasia & matrix stiffness","route":"/pathways/caf-activation-desmoplasia/","asOf":"2026-09-09","days":19},{"id":"resistance-routes-map","kind":"pathway","name":"Resistance routes: how a blocked pathway comes back","route":"/pathways/resistance-routes-map/","asOf":"2026-09-09","days":19},{"id":"drug-tolerant-persisters","kind":"pathway","name":"Drug-tolerant persister cells","route":"/pathways/drug-tolerant-persisters/","asOf":"2026-09-09","days":19},{"id":"drug-efflux-pumps","kind":"pathway","name":"Drug efflux pumps (ABC transporters)","route":"/pathways/drug-efflux-pumps/","asOf":"2026-09-09","days":19},{"id":"lineage-plasticity-neuroendocrine","kind":"pathway","name":"Lineage plasticity & neuroendocrine transformation","route":"/pathways/lineage-plasticity-neuroendocrine/","asOf":"2026-09-09","days":19},{"id":"abcsg","kind":"company","name":"Austrian Breast & Colorectal Cancer Study Group","route":"/companies/abcsg/","asOf":"2026-09-09","days":19},{"id":"wjog","kind":"company","name":"West Japan Oncology Group","route":"/companies/wjog/","asOf":"2026-09-09","days":19},{"id":"kcsg","kind":"company","name":"Korean Cancer Study Group","route":"/companies/kcsg/","asOf":"2026-09-09","days":19},{"id":"trog","kind":"company","name":"TROG Cancer Research","route":"/companies/trog/","asOf":"2026-09-09","days":19},{"id":"anzup","kind":"company","name":"ANZUP Cancer Trials Group","route":"/companies/anzup/","asOf":"2026-09-09","days":19},{"id":"agitg","kind":"company","name":"Australasian Gastro-Intestinal Trials Group","route":"/companies/agitg/","asOf":"2026-09-09","days":19},{"id":"breast-cancer-trials","kind":"company","name":"Breast Cancer Trials","route":"/companies/breast-cancer-trials/","asOf":"2026-09-09","days":19},{"id":"geicam","kind":"company","name":"GEICAM Spanish Breast Cancer Group","route":"/companies/geicam/","asOf":"2026-09-09","days":19},{"id":"solti","kind":"company","name":"SOLTI Cancer Research Group","route":"/companies/solti/","asOf":"2026-09-09","days":19},{"id":"hovon","kind":"company","name":"HOVON","route":"/companies/hovon/","asOf":"2026-09-09","days":19},{"id":"gimema","kind":"company","name":"GIMEMA","route":"/companies/gimema/","asOf":"2026-09-09","days":19},{"id":"ielsg","kind":"company","name":"International Extranodal Lymphoma Study Group","route":"/companies/ielsg/","asOf":"2026-09-09","days":19},{"id":"lysa","kind":"company","name":"LYSA (The Lymphoma Study Association)","route":"/companies/lysa/","asOf":"2026-09-09","days":19},{"id":"german-lymphoma-alliance","kind":"company","name":"German Lymphoma Alliance","route":"/companies/german-lymphoma-alliance/","asOf":"2026-09-09","days":19},{"id":"ghsg","kind":"company","name":"German Hodgkin Study Group","route":"/companies/ghsg/","asOf":"2026-09-09","days":19},{"id":"nordic-lymphoma-group","kind":"company","name":"Nordic Lymphoma Group","route":"/companies/nordic-lymphoma-group/","asOf":"2026-09-09","days":19},{"id":"cclg","kind":"company","name":"Children's Cancer and Leukaemia Group","route":"/companies/cclg/","asOf":"2026-09-09","days":19},{"id":"etop-ibcsg","kind":"company","name":"ETOP IBCSG Partners Foundation","route":"/companies/etop-ibcsg/","asOf":"2026-09-09","days":19},{"id":"ifct","kind":"company","name":"Intergroupe Francophone de Cancérologie Thoracique","route":"/companies/ifct/","asOf":"2026-09-09","days":19},{"id":"arcagy-gineco","kind":"company","name":"ARCAGY-GINECO","route":"/companies/arcagy-gineco/","asOf":"2026-09-09","days":19},{"id":"gog-foundation","kind":"company","name":"GOG Foundation","route":"/companies/gog-foundation/","asOf":"2026-09-09","days":19},{"id":"nsabp-foundation","kind":"company","name":"NSABP Foundation","route":"/companies/nsabp-foundation/","asOf":"2026-09-09","days":19},{"id":"daniel-ludwig","kind":"person","name":"Daniel K. Ludwig","route":"/people/daniel-ludwig/","asOf":"2026-09-10","days":18},{"id":"sean-parker","kind":"person","name":"Sean Parker","route":"/people/sean-parker/","asOf":"2026-09-10","days":18},{"id":"michael-bloomberg","kind":"person","name":"Michael Bloomberg","route":"/people/michael-bloomberg/","asOf":"2026-09-10","days":18},{"id":"sidney-kimmel","kind":"person","name":"Sidney Kimmel","route":"/people/sidney-kimmel/","asOf":"2026-09-10","days":18},{"id":"david-koch","kind":"person","name":"David H. Koch","route":"/people/david-koch/","asOf":"2026-09-10","days":18},{"id":"eli-broad","kind":"person","name":"Eli Broad","route":"/people/eli-broad/","asOf":"2026-09-10","days":18},{"id":"jon-huntsman","kind":"person","name":"Jon M. Huntsman Sr.","route":"/people/jon-huntsman/","asOf":"2026-09-10","days":18},{"id":"phil-knight","kind":"person","name":"Phil Knight","route":"/people/phil-knight/","asOf":"2026-09-10","days":18},{"id":"gert-boyle","kind":"person","name":"Gert Boyle","route":"/people/gert-boyle/","asOf":"2026-09-10","days":18},{"id":"larry-ellison","kind":"person","name":"Larry Ellison","route":"/people/larry-ellison/","asOf":"2026-09-10","days":18},{"id":"herbert-irving","kind":"person","name":"Herbert Irving","route":"/people/herbert-irving/","asOf":"2026-09-10","days":18},{"id":"mortimer-zuckerman","kind":"person","name":"Mortimer Zuckerman","route":"/people/mortimer-zuckerman/","asOf":"2026-09-10","days":18},{"id":"helen-diller","kind":"person","name":"Helen Diller","route":"/people/helen-diller/","asOf":"2026-09-10","days":18},{"id":"leonard-abramson","kind":"person","name":"Leonard Abramson","route":"/people/leonard-abramson/","asOf":"2026-09-10","days":18},{"id":"richard-rogel","kind":"person","name":"Richard Rogel","route":"/people/richard-rogel/","asOf":"2026-09-10","days":18},{"id":"sanford-weill","kind":"person","name":"Sanford I. Weill","route":"/people/sanford-weill/","asOf":"2026-09-10","days":18},{"id":"john-jacob-astor-iii","kind":"person","name":"John Jacob Astor III","route":"/people/john-jacob-astor-iii/","asOf":"2026-09-10","days":18},{"id":"john-d-rockefeller-jr","kind":"person","name":"John D. Rockefeller Jr.","route":"/people/john-d-rockefeller-jr/","asOf":"2026-09-10","days":18},{"id":"alfred-sloan","kind":"person","name":"Alfred P. Sloan Jr.","route":"/people/alfred-sloan/","asOf":"2026-09-10","days":18},{"id":"charles-kettering","kind":"person","name":"Charles F. Kettering","route":"/people/charles-kettering/","asOf":"2026-09-10","days":18},{"id":"monroe-anderson","kind":"person","name":"Monroe Dunaway Anderson","route":"/people/monroe-anderson/","asOf":"2026-09-10","days":18},{"id":"robert-woodruff","kind":"person","name":"Robert W. Woodruff","route":"/people/robert-woodruff/","asOf":"2026-09-10","days":18},{"id":"lucille-markey","kind":"person","name":"Lucille P. Markey","route":"/people/lucille-markey/","asOf":"2026-09-10","days":18},{"id":"martha-ingram","kind":"person","name":"Martha Rivers Ingram","route":"/people/martha-ingram/","asOf":"2026-09-10","days":18},{"id":"ann-lurie","kind":"person","name":"Ann Lurie","route":"/people/ann-lurie/","asOf":"2026-09-10","days":18},{"id":"goh-cheng-liang","kind":"person","name":"Goh Cheng Liang","route":"/people/goh-cheng-liang/","asOf":"2026-09-10","days":18},{"id":"michael-milken","kind":"person","name":"Michael Milken","route":"/people/michael-milken/","asOf":"2026-09-10","days":18},{"id":"leon-black","kind":"person","name":"Leon Black","route":"/people/leon-black/","asOf":"2026-09-10","days":18},{"id":"debra-black","kind":"person","name":"Debra Black","route":"/people/debra-black/","asOf":"2026-09-10","days":18},{"id":"albert-lasker","kind":"person","name":"Albert Lasker","route":"/people/albert-lasker/","asOf":"2026-09-10","days":18},{"id":"walter-winchell","kind":"person","name":"Walter Winchell","route":"/people/walter-winchell/","asOf":"2026-09-10","days":18},{"id":"sherry-lansing","kind":"person","name":"Sherry Lansing","route":"/people/sherry-lansing/","asOf":"2026-09-10","days":18},{"id":"marc-lustgarten","kind":"person","name":"Marc Lustgarten","route":"/people/marc-lustgarten/","asOf":"2026-09-10","days":18},{"id":"priscilla-chan","kind":"person","name":"Priscilla Chan","route":"/people/priscilla-chan/","asOf":"2026-09-10","days":18},{"id":"bill-gates","kind":"person","name":"Bill Gates","route":"/people/bill-gates/","asOf":"2026-09-10","days":18},{"id":"li-ka-shing","kind":"person","name":"Li Ka-shing","route":"/people/li-ka-shing/","asOf":"2026-09-10","days":18},{"id":"dorabji-tata","kind":"person","name":"Sir Dorabji Tata","route":"/people/dorabji-tata/","asOf":"2026-09-10","days":18},{"id":"ratan-tata","kind":"person","name":"Ratan Tata","route":"/people/ratan-tata/","asOf":"2026-09-10","days":18},{"id":"ted-williams","kind":"person","name":"Ted Williams","route":"/people/ted-williams/","asOf":"2026-09-10","days":18},{"id":"billy-starr","kind":"person","name":"Billy Starr","route":"/people/billy-starr/","asOf":"2026-09-10","days":18},{"id":"chris-hoy","kind":"person","name":"Sir Chris Hoy","route":"/people/chris-hoy/","asOf":"2026-09-10","days":18},{"id":"iwona-lugowska","kind":"person","name":"Iwona Ługowska","route":"/people/iwona-lugowska/","asOf":"2026-09-10","days":18},{"id":"claudio-lombardo","kind":"person","name":"Claudio Lombardo","route":"/people/claudio-lombardo/","asOf":"2026-09-10","days":18},{"id":"matthew-hurles","kind":"person","name":"Matthew Hurles","route":"/people/matthew-hurles/","asOf":"2026-09-10","days":18},{"id":"michael-stratton","kind":"person","name":"Michael Stratton","route":"/people/michael-stratton/","asOf":"2026-09-10","days":18},{"id":"david-probert","kind":"person","name":"David Probert","route":"/people/david-probert/","asOf":"2026-09-10","days":18},{"id":"sandra-demaria","kind":"person","name":"Sandra Demaria","route":"/people/sandra-demaria/","asOf":"2026-09-10","days":18},{"id":"ziyu-li","kind":"person","name":"Ziyu Li","route":"/people/ziyu-li/","asOf":"2026-09-10","days":18},{"id":"yuqin-song","kind":"person","name":"Yuqin Song","route":"/people/yuqin-song/","asOf":"2026-09-10","days":18},{"id":"barbara-jereczek-fossa","kind":"person","name":"Barbara Jereczek-Fossa","route":"/people/barbara-jereczek-fossa/","asOf":"2026-09-10","days":18},{"id":"matthias-guckenberger","kind":"person","name":"Matthias Guckenberger","route":"/people/matthias-guckenberger/","asOf":"2026-09-10","days":18},{"id":"dirk-schadendorf","kind":"person","name":"Dirk Schadendorf","route":"/people/dirk-schadendorf/","asOf":"2026-09-10","days":18},{"id":"martin-schuler","kind":"person","name":"Martin Schuler","route":"/people/martin-schuler/","asOf":"2026-09-10","days":18},{"id":"emer-cooke","kind":"person","name":"Emer Cooke","route":"/people/emer-cooke/","asOf":"2026-09-10","days":18},{"id":"matthew-powell","kind":"person","name":"Matthew A. Powell","route":"/people/matthew-powell/","asOf":"2026-09-10","days":18},{"id":"karen-lu","kind":"person","name":"Karen H. Lu","route":"/people/karen-lu/","asOf":"2026-09-10","days":18},{"id":"josep-maria-campistol","kind":"person","name":"Josep Maria Campistol","route":"/people/josep-maria-campistol/","asOf":"2026-09-10","days":18},{"id":"susana-puig","kind":"person","name":"Susana Puig","route":"/people/susana-puig/","asOf":"2026-09-10","days":18},{"id":"thomas-herzog","kind":"person","name":"Thomas Herzog","route":"/people/thomas-herzog/","asOf":"2026-09-10","days":18},{"id":"robert-mannel","kind":"person","name":"Robert S. Mannel","route":"/people/robert-mannel/","asOf":"2026-09-10","days":18},{"id":"ian-davis","kind":"person","name":"Ian Davis","route":"/people/ian-davis/","asOf":"2026-09-10","days":18},{"id":"samantha-oakes","kind":"person","name":"Samantha Oakes","route":"/people/samantha-oakes/","asOf":"2026-09-10","days":18},{"id":"monika-janicke","kind":"person","name":"Monika Jänicke","route":"/people/monika-janicke/","asOf":"2026-09-10","days":18},{"id":"virginia-pappas","kind":"person","name":"Virginia Pappas","route":"/people/virginia-pappas/","asOf":"2026-09-10","days":18},{"id":"yitshak-kreiss","kind":"person","name":"Yitshak Kreiss","route":"/people/yitshak-kreiss/","asOf":"2026-09-10","days":18},{"id":"daniel-aebersold","kind":"person","name":"Daniel M. Aebersold","route":"/people/daniel-aebersold/","asOf":"2026-09-10","days":18},{"id":"adrian-ochsenbein","kind":"person","name":"Adrian Ochsenbein","route":"/people/adrian-ochsenbein/","asOf":"2026-09-10","days":18},{"id":"karen-kelly","kind":"person","name":"Karen Kelly","route":"/people/karen-kelly/","asOf":"2026-09-10","days":18},{"id":"nicolaas-schaap","kind":"person","name":"Nicolaas P.M. Schaap","route":"/people/nicolaas-schaap/","asOf":"2026-09-10","days":18},{"id":"marc-raaijmakers","kind":"person","name":"Marc H.G.P. Raaijmakers","route":"/people/marc-raaijmakers/","asOf":"2026-09-10","days":18},{"id":"paola-anna-erba","kind":"person","name":"Paola Anna Erba","route":"/people/paola-anna-erba/","asOf":"2026-09-10","days":18},{"id":"tedros-adhanom-ghebreyesus","kind":"person","name":"Tedros Adhanom Ghebreyesus","route":"/people/tedros-adhanom-ghebreyesus/","asOf":"2026-09-10","days":18},{"id":"yoram-weiss","kind":"person","name":"Yoram G. Weiss","route":"/people/yoram-weiss/","asOf":"2026-09-10","days":18},{"id":"konstanze-doehner","kind":"person","name":"Konstanze Döhner","route":"/people/konstanze-doehner/","asOf":"2026-09-10","days":18},{"id":"brian-huntly","kind":"person","name":"Brian Huntly","route":"/people/brian-huntly/","asOf":"2026-09-10","days":18},{"id":"anna-sapino","kind":"person","name":"Anna Sapino","route":"/people/anna-sapino/","asOf":"2026-09-10","days":18},{"id":"luis-paz-ares","kind":"person","name":"Luis Paz-Ares","route":"/people/luis-paz-ares/","asOf":"2026-09-10","days":18},{"id":"joaquin-martinez-lopez","kind":"person","name":"Joaquín Martínez-López","route":"/people/joaquin-martinez-lopez/","asOf":"2026-09-10","days":18},{"id":"alon-chen","kind":"person","name":"Alon Chen","route":"/people/alon-chen/","asOf":"2026-09-10","days":18},{"id":"wouter-de-laat","kind":"person","name":"Wouter de Laat","route":"/people/wouter-de-laat/","asOf":"2026-09-10","days":18},{"id":"jurgen-kuball","kind":"person","name":"Jürgen Kuball","route":"/people/jurgen-kuball/","asOf":"2026-09-10","days":18},{"id":"chong-jen-yu","kind":"person","name":"Chong-Jen Yu","route":"/people/chong-jen-yu/","asOf":"2026-09-10","days":18},{"id":"lawrence-tallon","kind":"person","name":"Lawrence Tallon","route":"/people/lawrence-tallon/","asOf":"2026-09-10","days":18},{"id":"linda-tantawi","kind":"person","name":"Linda Tantawi","route":"/people/linda-tantawi/","asOf":"2026-09-10","days":18},{"id":"jalid-sehouli","kind":"person","name":"Jalid Sehouli","route":"/people/jalid-sehouli/","asOf":"2026-09-10","days":18},{"id":"ane-gerda-eriksson","kind":"person","name":"Ane Gerda Eriksson","route":"/people/ane-gerda-eriksson/","asOf":"2026-09-10","days":18},{"id":"jason-carroll","kind":"person","name":"Jason Carroll","route":"/people/jason-carroll/","asOf":"2026-09-10","days":18},{"id":"james-brenton","kind":"person","name":"James Brenton","route":"/people/james-brenton/","asOf":"2026-09-10","days":18},{"id":"fernando-pelaez","kind":"person","name":"Fernando Peláez","route":"/people/fernando-pelaez/","asOf":"2026-09-10","days":18},{"id":"madeline-bell","kind":"person","name":"Madeline Bell","route":"/people/madeline-bell/","asOf":"2026-09-10","days":18},{"id":"susan-furth","kind":"person","name":"Susan Furth","route":"/people/susan-furth/","asOf":"2026-09-10","days":18},{"id":"sunil-lakhani","kind":"person","name":"Sunil Lakhani","route":"/people/sunil-lakhani/","asOf":"2026-09-10","days":18},{"id":"donna-mckay","kind":"person","name":"Donna McKay","route":"/people/donna-mckay/","asOf":"2026-09-10","days":18},{"id":"dorraya-el-ashry","kind":"person","name":"Dorraya El-Ashry","route":"/people/dorraya-el-ashry/","asOf":"2026-09-10","days":18},{"id":"kirsten-schmieder","kind":"person","name":"Kirsten Schmieder","route":"/people/kirsten-schmieder/","asOf":"2026-09-10","days":18},{"id":"sascha-dietrich","kind":"person","name":"Sascha Dietrich","route":"/people/sascha-dietrich/","asOf":"2026-09-10","days":18},{"id":"kenneth-tanabe","kind":"person","name":"Kenneth K. Tanabe","route":"/people/kenneth-tanabe/","asOf":"2026-09-10","days":18},{"id":"tari-king","kind":"person","name":"Tari A. King","route":"/people/tari-king/","asOf":"2026-09-10","days":18},{"id":"rasmus-mogelvang","kind":"person","name":"Rasmus Møgelvang","route":"/people/rasmus-mogelvang/","asOf":"2026-09-10","days":18},{"id":"kjetil-tasken","kind":"person","name":"Kjetil Taskén","route":"/people/kjetil-tasken/","asOf":"2026-09-10","days":18},{"id":"norman-wolmark","kind":"person","name":"Norman Wolmark","route":"/people/norman-wolmark/","asOf":"2026-09-10","days":18},{"id":"priya-rastogi","kind":"person","name":"Priya Rastogi","route":"/people/priya-rastogi/","asOf":"2026-09-10","days":18},{"id":"lim-soon-thye","kind":"person","name":"Lim Soon Thye","route":"/people/lim-soon-thye/","asOf":"2026-09-10","days":18},{"id":"rebecca-dent","kind":"person","name":"Rebecca Dent","route":"/people/rebecca-dent/","asOf":"2026-09-10","days":18},{"id":"alexandre-chan","kind":"person","name":"Alexandre Chan","route":"/people/alexandre-chan/","asOf":"2026-09-10","days":18},{"id":"franck-morschhauser","kind":"person","name":"Franck Morschhauser","route":"/people/franck-morschhauser/","asOf":"2026-09-10","days":18},{"id":"simona-sancini","kind":"person","name":"Simona Sancini","route":"/people/simona-sancini/","asOf":"2026-09-10","days":18},{"id":"armando-santoro","kind":"person","name":"Armando Santoro","route":"/people/armando-santoro/","asOf":"2026-09-10","days":18},{"id":"nu-zhang","kind":"person","name":"Nu Zhang","route":"/people/nu-zhang/","asOf":"2026-09-10","days":18},{"id":"wen-zhao-zhong","kind":"person","name":"Wen-Zhao Zhong","route":"/people/wen-zhao-zhong/","asOf":"2026-09-10","days":18},{"id":"samra-turajlic","kind":"person","name":"Samra Turajlić","route":"/people/samra-turajlic/","asOf":"2026-09-10","days":18},{"id":"tim-somervaille","kind":"person","name":"Tim Somervaille","route":"/people/tim-somervaille/","asOf":"2026-09-10","days":18},{"id":"geoff-parnell","kind":"person","name":"Geoff Parnell","route":"/people/geoff-parnell/","asOf":"2026-09-10","days":18},{"id":"christos-karapetis","kind":"person","name":"Christos Karapetis","route":"/people/christos-karapetis/","asOf":"2026-09-10","days":18},{"id":"rakesh-padiyath","kind":"person","name":"Rakesh Padiyath","route":"/people/rakesh-padiyath/","asOf":"2026-09-10","days":18},{"id":"astrid-beiglbock","kind":"person","name":"Astrid Beiglböck","route":"/people/astrid-beiglbock/","asOf":"2026-09-10","days":18},{"id":"benjamin-kasenda","kind":"person","name":"Benjamin Kasenda","route":"/people/benjamin-kasenda/","asOf":"2026-09-10","days":18},{"id":"martin-siess","kind":"person","name":"Martin Siess","route":"/people/martin-siess/","asOf":"2026-09-10","days":18},{"id":"julian-adams","kind":"person","name":"Julian Adams","route":"/people/julian-adams/","asOf":"2026-09-10","days":18},{"id":"chiara-gibertoni","kind":"person","name":"Chiara Gibertoni","route":"/people/chiara-gibertoni/","asOf":"2026-09-10","days":18},{"id":"gianvito-martino","kind":"person","name":"Gianvito Martino","route":"/people/gianvito-martino/","asOf":"2026-09-10","days":18},{"id":"beata-jagielska","kind":"person","name":"Beata Jagielska","route":"/people/beata-jagielska/","asOf":"2026-09-10","days":18},{"id":"michal-mikula","kind":"person","name":"Michał Mikula","route":"/people/michal-mikula/","asOf":"2026-09-10","days":18},{"id":"andrzej-kawecki","kind":"person","name":"Andrzej Kawecki","route":"/people/andrzej-kawecki/","asOf":"2026-09-10","days":18},{"id":"martin-jan-schalij","kind":"person","name":"Martin Jan Schalij","route":"/people/martin-jan-schalij/","asOf":"2026-09-10","days":18},{"id":"rafael-mariano-grossi","kind":"person","name":"Rafael Mariano Grossi","route":"/people/rafael-mariano-grossi/","asOf":"2026-09-10","days":18},{"id":"marco-vignetti","kind":"person","name":"Marco Vignetti","route":"/people/marco-vignetti/","asOf":"2026-09-10","days":18},{"id":"antonio-cuneo","kind":"person","name":"Antonio Cuneo","route":"/people/antonio-cuneo/","asOf":"2026-09-10","days":18},{"id":"shahrokh-f-shariat","kind":"person","name":"Shahrokh F. Shariat","route":"/people/shahrokh-f-shariat/","asOf":"2026-09-10","days":18},{"id":"nicole-concin","kind":"person","name":"Nicole Concin","route":"/people/nicole-concin/","asOf":"2026-09-10","days":18},{"id":"shane-degaris","kind":"person","name":"Shane DeGaris","route":"/people/shane-degaris/","asOf":"2026-09-10","days":18},{"id":"ken-smith","kind":"person","name":"Ken Smith","route":"/people/ken-smith/","asOf":"2026-09-10","days":18},{"id":"marianne-van-rooijen","kind":"person","name":"Marianne van Rooijen","route":"/people/marianne-van-rooijen/","asOf":"2026-09-10","days":18},{"id":"kunle-odunsi","kind":"person","name":"Kunle Odunsi","route":"/people/kunle-odunsi/","asOf":"2026-09-10","days":18},{"id":"ralph-weichselbaum","kind":"person","name":"Ralph Weichselbaum","route":"/people/ralph-weichselbaum/","asOf":"2026-09-10","days":18},{"id":"purnima-sundaresan","kind":"person","name":"Purnima Sundaresan","route":"/people/purnima-sundaresan/","asOf":"2026-09-10","days":18},{"id":"hien-le","kind":"person","name":"Hien Le","route":"/people/hien-le/","asOf":"2026-09-10","days":18},{"id":"tammy-kang","kind":"person","name":"Tammy Kang","route":"/people/tammy-kang/","asOf":"2026-09-10","days":18},{"id":"peter-johnson","kind":"person","name":"Peter Johnson","route":"/people/peter-johnson/","asOf":"2026-09-10","days":18},{"id":"mafalda-oliveira","kind":"person","name":"Mafalda Oliveira","route":"/people/mafalda-oliveira/","asOf":"2026-09-10","days":18},{"id":"eva-ciruelos","kind":"person","name":"Eva Ciruelos","route":"/people/eva-ciruelos/","asOf":"2026-09-10","days":18},{"id":"ofer-merin","kind":"person","name":"Ofer Merin","route":"/people/ofer-merin/","asOf":"2026-09-10","days":18},{"id":"giovanni-blandino","kind":"person","name":"Giovanni Blandino","route":"/people/giovanni-blandino/","asOf":"2026-09-10","days":18},{"id":"steven-clifford","kind":"person","name":"Steven Clifford","route":"/people/steven-clifford/","asOf":"2026-09-10","days":18},{"id":"martin-bornhauser","kind":"person","name":"Martin Bornhäuser","route":"/people/martin-bornhauser/","asOf":"2026-09-10","days":18},{"id":"hanno-glimm","kind":"person","name":"Hanno Glimm","route":"/people/hanno-glimm/","asOf":"2026-09-10","days":18},{"id":"jurgen-weitz","kind":"person","name":"Jürgen Weitz","route":"/people/jurgen-weitz/","asOf":"2026-09-10","days":18},{"id":"han-kwang-yang","kind":"person","name":"Han-Kwang Yang","route":"/people/han-kwang-yang/","asOf":"2026-09-10","days":18},{"id":"marek-svoboda","kind":"person","name":"Marek Svoboda","route":"/people/marek-svoboda/","asOf":"2026-09-10","days":18},{"id":"tomas-kazda","kind":"person","name":"Tomáš Kazda","route":"/people/tomas-kazda/","asOf":"2026-09-10","days":18},{"id":"igor-kiss","kind":"person","name":"Igor Kiss","route":"/people/igor-kiss/","asOf":"2026-09-10","days":18},{"id":"akifumi-takaori","kind":"person","name":"Akifumi Takaori","route":"/people/akifumi-takaori/","asOf":"2026-09-10","days":18},{"id":"hidetoshi-hayashi","kind":"person","name":"Hidetoshi Hayashi","route":"/people/hidetoshi-hayashi/","asOf":"2026-09-10","days":18},{"id":"alexis-cortot","kind":"person","name":"Alexis Cortot","route":"/people/alexis-cortot/","asOf":"2026-09-10","days":18},{"id":"david-planchard","kind":"person","name":"David Planchard","route":"/people/david-planchard/","asOf":"2026-09-10","days":18},{"id":"sonja-optendrenk","kind":"person","name":"Sonja Optendrenk","route":"/people/sonja-optendrenk/","asOf":"2026-09-10","days":18},{"id":"thomas-kaiser","kind":"person","name":"Thomas Kaiser","route":"/people/thomas-kaiser/","asOf":"2026-09-10","days":18},{"id":"geerard-beets","kind":"person","name":"Geerard Beets","route":"/people/geerard-beets/","asOf":"2026-09-10","days":18},{"id":"isabel-rubio","kind":"person","name":"Isabel T. Rubio","route":"/people/isabel-rubio/","asOf":"2026-09-10","days":18},{"id":"ewan-birney","kind":"person","name":"Ewan Birney","route":"/people/ewan-birney/","asOf":"2026-09-10","days":18},{"id":"julio-saez-rodriguez","kind":"person","name":"Julio Saez-Rodriguez","route":"/people/julio-saez-rodriguez/","asOf":"2026-09-10","days":18},{"id":"charlie-gourley","kind":"person","name":"Charlie Gourley","route":"/people/charlie-gourley/","asOf":"2026-09-10","days":18},{"id":"antonio-gonzalez-martin","kind":"person","name":"Antonio González-Martín","route":"/people/antonio-gonzalez-martin/","asOf":"2026-09-10","days":18},{"id":"bruno-sangro","kind":"person","name":"Bruno Sangro","route":"/people/bruno-sangro/","asOf":"2026-09-10","days":18},{"id":"jesus-san-miguel","kind":"person","name":"Jesús San Miguel","route":"/people/jesus-san-miguel/","asOf":"2026-09-10","days":18},{"id":"chris-decker","kind":"person","name":"Chris Decker","route":"/people/chris-decker/","asOf":"2026-09-10","days":18},{"id":"maximilian-niyazi","kind":"person","name":"Maximilian Niyazi","route":"/people/maximilian-niyazi/","asOf":"2026-09-10","days":18},{"id":"lars-zender","kind":"person","name":"Lars Zender","route":"/people/lars-zender/","asOf":"2026-09-10","days":18},{"id":"sara-brucker","kind":"person","name":"Sara Y. Brucker","route":"/people/sara-brucker/","asOf":"2026-09-10","days":18},{"id":"sharon-armstrong","kind":"person","name":"Sharon Armstrong","route":"/people/sharon-armstrong/","asOf":"2026-09-10","days":18},{"id":"owen-sansom","kind":"person","name":"Owen Sansom","route":"/people/owen-sansom/","asOf":"2026-09-10","days":18},{"id":"nikhil-tandon","kind":"person","name":"Nikhil Tandon","route":"/people/nikhil-tandon/","asOf":"2026-09-10","days":18},{"id":"rebecca-li","kind":"person","name":"Rebecca Li","route":"/people/rebecca-li/","asOf":"2026-09-10","days":18},{"id":"jackson-orem","kind":"person","name":"Jackson Orem","route":"/people/jackson-orem/","asOf":"2026-09-10","days":18},{"id":"diane-simeone","kind":"person","name":"Diane M. Simeone","route":"/people/diane-simeone/","asOf":"2026-09-10","days":18},{"id":"rana-mckay","kind":"person","name":"Rana McKay","route":"/people/rana-mckay/","asOf":"2026-09-10","days":18},{"id":"j-silvio-gutkind","kind":"person","name":"J. Silvio Gutkind","route":"/people/j-silvio-gutkind/","asOf":"2026-09-10","days":18},{"id":"cathryn-cox","kind":"person","name":"Cathryn Cox","route":"/people/cathryn-cox/","asOf":"2026-09-10","days":18},{"id":"louis-chesler","kind":"person","name":"Louis Chesler","route":"/people/louis-chesler/","asOf":"2026-09-10","days":18},{"id":"james-r-downing","kind":"person","name":"James R. Downing","route":"/people/james-r-downing/","asOf":"2026-09-10","days":18},{"id":"uta-dirksen","kind":"person","name":"Uta Dirksen","route":"/people/uta-dirksen/","asOf":"2026-09-10","days":18},{"id":"gilles-vassal","kind":"person","name":"Gilles Vassal","route":"/people/gilles-vassal/","asOf":"2026-09-10","days":18},{"id":"ronald-cohn","kind":"person","name":"Ronald Cohn","route":"/people/ronald-cohn/","asOf":"2026-09-10","days":18},{"id":"stephen-scherer","kind":"person","name":"Stephen Scherer","route":"/people/stephen-scherer/","asOf":"2026-09-10","days":18},{"id":"meredith-irwin","kind":"person","name":"Meredith Irwin","route":"/people/meredith-irwin/","asOf":"2026-09-10","days":18},{"id":"boubou-hallberg","kind":"person","name":"Boubou Hallberg","route":"/people/boubou-hallberg/","asOf":"2026-09-10","days":18},{"id":"vivek-lal","kind":"person","name":"Vivek Lal","route":"/people/vivek-lal/","asOf":"2026-09-10","days":18},{"id":"jin-seok-ahn","kind":"person","name":"Jin Seok Ahn","route":"/people/jin-seok-ahn/","asOf":"2026-09-10","days":18},{"id":"jean-pierre-delord","kind":"person","name":"Jean-Pierre Delord","route":"/people/jean-pierre-delord/","asOf":"2026-09-10","days":18},{"id":"beth-devine","kind":"person","name":"Beth Devine","route":"/people/beth-devine/","asOf":"2026-09-10","days":18},{"id":"rob-abbott","kind":"person","name":"Rob Abbott","route":"/people/rob-abbott/","asOf":"2026-09-10","days":18},{"id":"alfredo-addeo","kind":"person","name":"Alfredo Addeo","route":"/people/alfredo-addeo/","asOf":"2026-09-10","days":18},{"id":"jaume-raventos-i-monjo","kind":"person","name":"Jaume Raventós i Monjo","route":"/people/jaume-raventos-i-monjo/","asOf":"2026-09-10","days":18},{"id":"karl-munslow-ong","kind":"person","name":"Karl Munslow-Ong","route":"/people/karl-munslow-ong/","asOf":"2026-09-10","days":18},{"id":"sophia-varadkar","kind":"person","name":"Sophia Varadkar","route":"/people/sophia-varadkar/","asOf":"2026-09-10","days":18},{"id":"elisabetta-zanon","kind":"person","name":"Elisabetta Zanon","route":"/people/elisabetta-zanon/","asOf":"2026-09-10","days":18},{"id":"georges-pascal-haber","kind":"person","name":"Georges-Pascal Haber","route":"/people/georges-pascal-haber/","asOf":"2026-09-10","days":18},{"id":"florian-roser","kind":"person","name":"Florian Roser","route":"/people/florian-roser/","asOf":"2026-09-10","days":18},{"id":"leonor-beleza","kind":"person","name":"Leonor Beleza","route":"/people/leonor-beleza/","asOf":"2026-09-10","days":18},{"id":"teresa-cotta-dias","kind":"person","name":"Teresa Cotta-Dias","route":"/people/teresa-cotta-dias/","asOf":"2026-09-10","days":18},{"id":"patrick-mehlen","kind":"person","name":"Patrick Mehlen","route":"/people/patrick-mehlen/","asOf":"2026-09-10","days":18},{"id":"thomas-balle-kristensen","kind":"person","name":"Thomas Balle Kristensen","route":"/people/thomas-balle-kristensen/","asOf":"2026-09-10","days":18},{"id":"jens-overgaard","kind":"person","name":"Jens Overgaard","route":"/people/jens-overgaard/","asOf":"2026-09-10","days":18},{"id":"harlan-krumholz","kind":"person","name":"Harlan M. Krumholz","route":"/people/harlan-krumholz/","asOf":"2026-09-10","days":18},{"id":"joseph-ross","kind":"person","name":"Joseph S. Ross","route":"/people/joseph-ross/","asOf":"2026-09-10","days":18},{"id":"nobuyuki-yamamoto","kind":"person","name":"Nobuyuki Yamamoto","route":"/people/nobuyuki-yamamoto/","asOf":"2026-09-10","days":18},{"id":"shabir-madhi","kind":"person","name":"Shabir A. Madhi","route":"/people/shabir-madhi/","asOf":"2026-09-10","days":18},{"id":"karim-vermaelen","kind":"person","name":"Karim Vermaelen","route":"/people/karim-vermaelen/","asOf":"2026-09-10","days":18},{"id":"thomas-kindler","kind":"person","name":"Thomas Kindler","route":"/people/thomas-kindler/","asOf":"2026-09-10","days":18},{"id":"christian-brandts","kind":"person","name":"Christian Brandts","route":"/people/christian-brandts/","asOf":"2026-09-10","days":18},{"id":"florian-greten","kind":"person","name":"Florian R. Greten","route":"/people/florian-greten/","asOf":"2026-09-10","days":18},{"id":"hubert-serve","kind":"person","name":"Hubert Serve","route":"/people/hubert-serve/","asOf":"2026-09-10","days":18},{"id":"philip-chiu","kind":"person","name":"Philip Wai Yan Chiu","route":"/people/philip-chiu/","asOf":"2026-09-10","days":18},{"id":"tony-mok","kind":"person","name":"Tony S. K. Mok","route":"/people/tony-mok/","asOf":"2026-09-10","days":18},{"id":"anthony-chan","kind":"person","name":"Anthony T. C. Chan","route":"/people/anthony-chan/","asOf":"2026-09-10","days":18},{"id":"yasuhiro-fujiwara","kind":"person","name":"Yasuhiro Fujiwara","route":"/people/yasuhiro-fujiwara/","asOf":"2026-09-10","days":18},{"id":"zlata-stiblar-kisic","kind":"person","name":"Zlata Štiblar Kisić","route":"/people/zlata-stiblar-kisic/","asOf":"2026-09-10","days":18},{"id":"janja-ocvirk","kind":"person","name":"Janja Ocvirk","route":"/people/janja-ocvirk/","asOf":"2026-09-10","days":18},{"id":"shivaani-kummar","kind":"person","name":"Shivaani Kummar","route":"/people/shivaani-kummar/","asOf":"2026-09-10","days":18},{"id":"chee-cheng-ean","kind":"person","name":"Chee Cheng Ean","route":"/people/chee-cheng-ean/","asOf":"2026-09-10","days":18},{"id":"goh-boon-cher","kind":"person","name":"Goh Boon Cher","route":"/people/goh-boon-cher/","asOf":"2026-09-10","days":18},{"id":"jimmy-so","kind":"person","name":"Jimmy So","route":"/people/jimmy-so/","asOf":"2026-09-10","days":18},{"id":"matthew-vander-heiden","kind":"person","name":"Matthew Vander Heiden","route":"/people/matthew-vander-heiden/","asOf":"2026-09-10","days":18},{"id":"robert-langer","kind":"person","name":"Robert S. Langer","route":"/people/robert-langer/","asOf":"2026-09-10","days":18},{"id":"maike-sander","kind":"person","name":"Maike Sander","route":"/people/maike-sander/","asOf":"2026-09-10","days":18},{"id":"nikolaus-rajewsky","kind":"person","name":"Nikolaus Rajewsky","route":"/people/nikolaus-rajewsky/","asOf":"2026-09-10","days":18},{"id":"wasiu-lanre-adeyemo","kind":"person","name":"Wasiu Lanre Adeyemo","route":"/people/wasiu-lanre-adeyemo/","asOf":"2026-09-10","days":18},{"id":"carolina-samuelsson","kind":"person","name":"Carolina Samuelsson","route":"/people/carolina-samuelsson/","asOf":"2026-09-10","days":18},{"id":"asem-mansour","kind":"person","name":"Asem Mansour","route":"/people/asem-mansour/","asOf":"2026-09-10","days":18},{"id":"majid-alfayyadh","kind":"person","name":"Majid Ibrahim Alfayyadh","route":"/people/majid-alfayyadh/","asOf":"2026-09-10","days":18},{"id":"richard-lesiyampe","kind":"person","name":"Richard Lesiyampe","route":"/people/richard-lesiyampe/","asOf":"2026-09-10","days":18},{"id":"koichi-fukunaga","kind":"person","name":"Koichi Fukunaga","route":"/people/koichi-fukunaga/","asOf":"2026-09-10","days":18},{"id":"rachel-ramoni","kind":"person","name":"Rachel Ramoni","route":"/people/rachel-ramoni/","asOf":"2026-09-10","days":18},{"id":"theodore-levin","kind":"person","name":"Theodore R. Levin","route":"/people/theodore-levin/","asOf":"2026-09-10","days":18},{"id":"le-van-quang","kind":"person","name":"Lê Văn Quảng","route":"/people/le-van-quang/","asOf":"2026-09-10","days":18},{"id":"patrizia-simionato","kind":"person","name":"Patrizia Simionato","route":"/people/patrizia-simionato/","asOf":"2026-09-10","days":18},{"id":"antonio-rosato","kind":"person","name":"Antonio Rosato","route":"/people/antonio-rosato/","asOf":"2026-09-10","days":18},{"id":"roberto-de-almeida-gil","kind":"person","name":"Roberto de Almeida Gil","route":"/people/roberto-de-almeida-gil/","asOf":"2026-09-10","days":18},{"id":"suzette-delaloge","kind":"person","name":"Suzette Delaloge","route":"/people/suzette-delaloge/","asOf":"2026-09-10","days":18},{"id":"nicolas-scotte","kind":"person","name":"Nicolas Scotté","route":"/people/nicolas-scotte/","asOf":"2026-09-10","days":18},{"id":"bradley-cairns","kind":"person","name":"Bradley Cairns","route":"/people/bradley-cairns/","asOf":"2026-09-10","days":18},{"id":"erin-oshea","kind":"person","name":"Erin K. O'Shea","route":"/people/erin-oshea/","asOf":"2026-09-10","days":18},{"id":"brasil-silva-neto","kind":"person","name":"Brasil Silva Neto","route":"/people/brasil-silva-neto/","asOf":"2026-09-10","days":18},{"id":"lionel-collet","kind":"person","name":"Lionel Collet","route":"/people/lionel-collet/","asOf":"2026-09-10","days":18},{"id":"jean-lessi","kind":"person","name":"Jean Lessi","route":"/people/jean-lessi/","asOf":"2026-09-10","days":18},{"id":"mark-suzman","kind":"person","name":"Mark Suzman","route":"/people/mark-suzman/","asOf":"2026-09-10","days":18},{"id":"trevor-mundel","kind":"person","name":"Trevor Mundel","route":"/people/trevor-mundel/","asOf":"2026-09-10","days":18},{"id":"benjamin-kile","kind":"person","name":"Benjamin Kile","route":"/people/benjamin-kile/","asOf":"2026-09-10","days":18},{"id":"susan-clark","kind":"person","name":"Susan Clark","route":"/people/susan-clark/","asOf":"2026-09-10","days":18},{"id":"jay-schnitzer","kind":"person","name":"Jay Schnitzer","route":"/people/jay-schnitzer/","asOf":"2026-09-10","days":18},{"id":"suresh-ramalingam","kind":"person","name":"Suresh S. Ramalingam","route":"/people/suresh-ramalingam/","asOf":"2026-09-10","days":18},{"id":"richard-schulick","kind":"person","name":"Richard Schulick","route":"/people/richard-schulick/","asOf":"2026-09-10","days":18},{"id":"michael-gnant","kind":"person","name":"Michael Gnant","route":"/people/michael-gnant/","asOf":"2026-09-10","days":18},{"id":"christian-singer","kind":"person","name":"Christian Singer","route":"/people/christian-singer/","asOf":"2026-09-10","days":18},{"id":"john-arne-rottingen","kind":"person","name":"John-Arne Røttingen","route":"/people/john-arne-rottingen/","asOf":"2026-09-10","days":18},{"id":"shalene-curtis-micallef","kind":"person","name":"Shalene Curtis-Micallef","route":"/people/shalene-curtis-micallef/","asOf":"2026-09-10","days":18},{"id":"diep-bao-tuan","kind":"person","name":"Diệp Bảo Tuấn","route":"/people/diep-bao-tuan/","asOf":"2026-09-10","days":18},{"id":"yasuyuki-nasuhara","kind":"person","name":"Yasuyuki Nasuhara","route":"/people/yasuyuki-nasuhara/","asOf":"2026-09-10","days":18},{"id":"henrique-prata","kind":"person","name":"Henrique Prata","route":"/people/henrique-prata/","asOf":"2026-09-10","days":18},{"id":"johanna-mattson","kind":"person","name":"Johanna Mattson","route":"/people/johanna-mattson/","asOf":"2026-09-10","days":18},{"id":"nicolas-penel","kind":"person","name":"Nicolas Penel","route":"/people/nicolas-penel/","asOf":"2026-09-10","days":18},{"id":"renaud-witmeur","kind":"person","name":"Renaud Witmeur","route":"/people/renaud-witmeur/","asOf":"2026-09-10","days":18},{"id":"norbert-vey","kind":"person","name":"Norbert Vey","route":"/people/norbert-vey/","asOf":"2026-09-10","days":18},{"id":"yasmine-belkaid","kind":"person","name":"Yasmine Belkaid","route":"/people/yasmine-belkaid/","asOf":"2026-09-10","days":18},{"id":"senda-tounsi","kind":"person","name":"Senda Tounsi","route":"/people/senda-tounsi/","asOf":"2026-09-10","days":18},{"id":"david-baker","kind":"person","name":"David Baker","route":"/people/david-baker/","asOf":"2026-09-10","days":18},{"id":"bernardo-rubinstein","kind":"person","name":"Bernardo Rubinstein","route":"/people/bernardo-rubinstein/","asOf":"2026-09-10","days":18},{"id":"chen-wei-ming","kind":"person","name":"Chen Wei-ming","route":"/people/chen-wei-ming/","asOf":"2026-09-10","days":18},{"id":"sultan-mohamed-alkaram","kind":"person","name":"Sultan Mohamed Alkaram","route":"/people/sultan-mohamed-alkaram/","asOf":"2026-09-10","days":18},{"id":"eli-sprecher","kind":"person","name":"Eli Sprecher","route":"/people/eli-sprecher/","asOf":"2026-09-10","days":18},{"id":"ryan-schoenfeld","kind":"person","name":"Ryan Schoenfeld","route":"/people/ryan-schoenfeld/","asOf":"2026-09-10","days":18},{"id":"rebecca-auer","kind":"person","name":"Rebecca Auer","route":"/people/rebecca-auer/","asOf":"2026-09-10","days":18},{"id":"brandi-williams-broome","kind":"person","name":"Brandi Williams Broome","route":"/people/brandi-williams-broome/","asOf":"2026-09-10","days":18},{"id":"anthony-lawler","kind":"person","name":"Anthony Lawler","route":"/people/anthony-lawler/","asOf":"2026-09-10","days":18},{"id":"takashi-kamei","kind":"person","name":"Takashi Kamei","route":"/people/takashi-kamei/","asOf":"2026-09-10","days":18},{"id":"cary-adams","kind":"person","name":"Cary Adams","route":"/people/cary-adams/","asOf":"2026-09-10","days":18},{"id":"jonathan-brotherton","kind":"person","name":"Jonathan Brotherton","route":"/people/jonathan-brotherton/","asOf":"2026-09-10","days":18},{"id":"mohd-zukiflee-abu-bakar","kind":"person","name":"Mohd Zukiflee Abu Bakar","route":"/people/mohd-zukiflee-abu-bakar/","asOf":"2026-09-10","days":18},{"id":"paul-herijgers","kind":"person","name":"Paul Herijgers","route":"/people/paul-herijgers/","asOf":"2026-09-10","days":18},{"id":"carl-james","kind":"person","name":"Carl James","route":"/people/carl-james/","asOf":"2026-09-10","days":18},{"id":"laura-brady","kind":"person","name":"Laura Brady","route":"/people/laura-brady/","asOf":"2026-09-10","days":18},{"id":"laurene-powell-jobs","kind":"person","name":"Laurene Powell Jobs","route":"/people/laurene-powell-jobs/","asOf":"2026-09-10","days":18},{"id":"johanna-joyce","kind":"person","name":"Johanna Joyce","route":"/people/johanna-joyce/","asOf":"2026-09-10","days":18},{"id":"stanislaw-klek","kind":"person","name":"Stanislaw Klek","route":"/people/stanislaw-klek/","asOf":"2026-09-10","days":18},{"id":"r-angelo-de-claro","kind":"person","name":"R. Angelo de Claro","route":"/people/r-angelo-de-claro/","asOf":"2026-09-10","days":18},{"id":"dominique-bazy","kind":"person","name":"Dominique Bazy","route":"/people/dominique-bazy/","asOf":"2026-09-10","days":18},{"id":"andrea-sironi","kind":"person","name":"Andrea Sironi","route":"/people/andrea-sironi/","asOf":"2026-09-10","days":18},{"id":"cristian-ayala-munita","kind":"person","name":"Cristián Ayala Munita","route":"/people/cristian-ayala-munita/","asOf":"2026-09-10","days":18},{"id":"christiane-pott","kind":"person","name":"Christiane Pott","route":"/people/christiane-pott/","asOf":"2026-09-10","days":18},{"id":"tatsuya-ohno","kind":"person","name":"Tatsuya Ohno","route":"/people/tatsuya-ohno/","asOf":"2026-09-10","days":18},{"id":"amanda-pritchard","kind":"person","name":"Amanda Pritchard","route":"/people/amanda-pritchard/","asOf":"2026-09-10","days":18},{"id":"kadir-mutlu-hayran","kind":"person","name":"Kadir Mutlu Hayran","route":"/people/kadir-mutlu-hayran/","asOf":"2026-09-10","days":18},{"id":"robyn-ward","kind":"person","name":"Robyn Ward","route":"/people/robyn-ward/","asOf":"2026-09-10","days":18},{"id":"gerardo-legaspi","kind":"person","name":"Gerardo D. Legaspi","route":"/people/gerardo-legaspi/","asOf":"2026-09-10","days":18},{"id":"erik-wexler","kind":"person","name":"Erik G. Wexler","route":"/people/erik-wexler/","asOf":"2026-09-10","days":18},{"id":"brandon-wainwright","kind":"person","name":"Brandon Wainwright","route":"/people/brandon-wainwright/","asOf":"2026-09-10","days":18},{"id":"hitoshi-ishikawa","kind":"person","name":"Hitoshi Ishikawa","route":"/people/hitoshi-ishikawa/","asOf":"2026-09-10","days":18},{"id":"chak-sing-lau","kind":"person","name":"Chak-sing Lau","route":"/people/chak-sing-lau/","asOf":"2026-09-10","days":18},{"id":"atiporn-ingsathit","kind":"person","name":"Atiporn Ingsathit","route":"/people/atiporn-ingsathit/","asOf":"2026-09-10","days":18},{"id":"michal-mekel","kind":"person","name":"Michal Mekel","route":"/people/michal-mekel/","asOf":"2026-09-10","days":18},{"id":"john-stagg","kind":"person","name":"John Stagg","route":"/people/john-stagg/","asOf":"2026-09-10","days":18},{"id":"robert-peel","kind":"person","name":"Robert Peel","route":"/people/robert-peel/","asOf":"2026-09-10","days":18},{"id":"yoon-seung-kew","kind":"person","name":"Yoon Seung-kew","route":"/people/yoon-seung-kew/","asOf":"2026-09-10","days":18},{"id":"katsuhiko-uesaka","kind":"person","name":"Katsuhiko Uesaka","route":"/people/katsuhiko-uesaka/","asOf":"2026-09-10","days":18},{"id":"yongyut-sirivatanauksorn","kind":"person","name":"Yongyut Sirivatanauksorn","route":"/people/yongyut-sirivatanauksorn/","asOf":"2026-09-10","days":18},{"id":"monika-krzyzanowska","kind":"person","name":"Monika Krzyzanowska","route":"/people/monika-krzyzanowska/","asOf":"2026-09-10","days":18},{"id":"vincenza-trivigno","kind":"person","name":"Vincenza Trivigno","route":"/people/vincenza-trivigno/","asOf":"2026-09-10","days":18},{"id":"brendan-brown","kind":"person","name":"Brendan Brown","route":"/people/brendan-brown/","asOf":"2026-09-10","days":18},{"id":"philippe-bergerot","kind":"person","name":"Philippe Bergerot","route":"/people/philippe-bergerot/","asOf":"2026-09-10","days":18},{"id":"gemma-peters","kind":"person","name":"Gemma Peters","route":"/people/gemma-peters/","asOf":"2026-09-10","days":18},{"id":"matthew-reed","kind":"person","name":"Matthew Reed","route":"/people/matthew-reed/","asOf":"2026-09-10","days":18},{"id":"andrew-little","kind":"person","name":"Andrew Little","route":"/people/andrew-little/","asOf":"2026-09-10","days":18},{"id":"mohamed-abdel-moaty-samra","kind":"person","name":"Mohamed Abdel Moaty Samra","route":"/people/mohamed-abdel-moaty-samra/","asOf":"2026-09-10","days":18},{"id":"jonathan-benger","kind":"person","name":"Jonathan Benger","route":"/people/jonathan-benger/","asOf":"2026-09-10","days":18},{"id":"magdolna-dank","kind":"person","name":"Magdolna Dank","route":"/people/magdolna-dank/","asOf":"2026-09-10","days":18},{"id":"timothy-robinson","kind":"person","name":"Timothy Robinson","route":"/people/timothy-robinson/","asOf":"2026-09-10","days":18},{"id":"senthil-muthuswamy","kind":"person","name":"Senthil K. Muthuswamy","route":"/people/senthil-muthuswamy/","asOf":"2026-09-10","days":18},{"id":"sirpa-leppa","kind":"person","name":"Sirpa Leppä","route":"/people/sirpa-leppa/","asOf":"2026-09-10","days":18},{"id":"richard-barakat","kind":"person","name":"Richard Barakat","route":"/people/richard-barakat/","asOf":"2026-09-10","days":18},{"id":"diwani-msemo","kind":"person","name":"Diwani Msemo","route":"/people/diwani-msemo/","asOf":"2026-09-10","days":18},{"id":"marco-herold","kind":"person","name":"Marco Herold","route":"/people/marco-herold/","asOf":"2026-09-10","days":18},{"id":"nariaki-matsuura","kind":"person","name":"Nariaki Matsuura","route":"/people/nariaki-matsuura/","asOf":"2026-09-10","days":18},{"id":"mark-middleton","kind":"person","name":"Mark Middleton","route":"/people/mark-middleton/","asOf":"2026-09-10","days":18},{"id":"alicia-jackson","kind":"person","name":"Alicia Jackson","route":"/people/alicia-jackson/","asOf":"2026-09-10","days":18},{"id":"leandro-pinheiro-safatle","kind":"person","name":"Leandro Pinheiro Safatle","route":"/people/leandro-pinheiro-safatle/","asOf":"2026-09-10","days":18},{"id":"yasumasa-niwa","kind":"person","name":"Yasumasa Niwa","route":"/people/yasumasa-niwa/","asOf":"2026-09-10","days":18},{"id":"robert-negrin","kind":"person","name":"Robert Negrin","route":"/people/robert-negrin/","asOf":"2026-09-10","days":18},{"id":"silvana-konermann","kind":"person","name":"Silvana Konermann","route":"/people/silvana-konermann/","asOf":"2026-09-10","days":18},{"id":"sebastien-armanet","kind":"person","name":"Sébastien Armanet","route":"/people/sebastien-armanet/","asOf":"2026-09-10","days":18},{"id":"paris-ann-ingledew","kind":"person","name":"Paris-Ann Ingledew","route":"/people/paris-ann-ingledew/","asOf":"2026-09-10","days":18},{"id":"nadine-karema","kind":"person","name":"Nadine Karema","route":"/people/nadine-karema/","asOf":"2026-09-10","days":18},{"id":"andrea-seale","kind":"person","name":"Andrea Seale","route":"/people/andrea-seale/","asOf":"2026-09-10","days":18},{"id":"brenda-hubley","kind":"person","name":"Brenda Hubley","route":"/people/brenda-hubley/","asOf":"2026-09-10","days":18},{"id":"jacinta-reddan","kind":"person","name":"Jacinta Reddan","route":"/people/jacinta-reddan/","asOf":"2026-09-10","days":18},{"id":"seyed-rouhollah-miri","kind":"person","name":"Seyed Rouhollah Miri","route":"/people/seyed-rouhollah-miri/","asOf":"2026-09-10","days":18},{"id":"oscar-arrieta-rodriguez","kind":"person","name":"Óscar Gerardo Arrieta Rodríguez","route":"/people/oscar-arrieta-rodriguez/","asOf":"2026-09-10","days":18},{"id":"francisco-berrospi-espinoza","kind":"person","name":"Francisco Berrospi Espinoza","route":"/people/francisco-berrospi-espinoza/","asOf":"2026-09-10","days":18},{"id":"carla-goncalo","kind":"person","name":"Carla Gonçalo","route":"/people/carla-goncalo/","asOf":"2026-09-10","days":18},{"id":"julio-oliveira","kind":"person","name":"Júlio Oliveira","route":"/people/julio-oliveira/","asOf":"2026-09-10","days":18},{"id":"derrick-haslem","kind":"person","name":"Derrick S. Haslem","route":"/people/derrick-haslem/","asOf":"2026-09-10","days":18},{"id":"franco-cavalli","kind":"person","name":"Franco Cavalli","route":"/people/franco-cavalli/","asOf":"2026-09-10","days":18},{"id":"sandra-nolte","kind":"person","name":"Sandra Nolte","route":"/people/sandra-nolte/","asOf":"2026-09-10","days":18},{"id":"cristina-marchesi","kind":"person","name":"Cristina Marchesi","route":"/people/cristina-marchesi/","asOf":"2026-09-10","days":18},{"id":"nikki-gallagher","kind":"person","name":"Nikki Gallagher","route":"/people/nikki-gallagher/","asOf":"2026-09-10","days":18},{"id":"maurizio-di-mauro","kind":"person","name":"Maurizio Di Mauro","route":"/people/maurizio-di-mauro/","asOf":"2026-09-10","days":18},{"id":"chris-hillis","kind":"person","name":"Chris Hillis","route":"/people/chris-hillis/","asOf":"2026-09-10","days":18},{"id":"nei-min-chu","kind":"person","name":"Nei-Min Chu","route":"/people/nei-min-chu/","asOf":"2026-09-10","days":18},{"id":"yakubu-seidu-adam","kind":"person","name":"Yakubu Seidu Adam","route":"/people/yakubu-seidu-adam/","asOf":"2026-09-10","days":18},{"id":"carla-van-gils","kind":"person","name":"Carla van Gils","route":"/people/carla-van-gils/","asOf":"2026-09-10","days":18},{"id":"yasuharu-nakashima","kind":"person","name":"Yasuharu Nakashima","route":"/people/yasuharu-nakashima/","asOf":"2026-09-10","days":18},{"id":"robert-figlin","kind":"person","name":"Robert Figlin","route":"/people/robert-figlin/","asOf":"2026-09-10","days":18},{"id":"emmanuel-barranger","kind":"person","name":"Emmanuel Barranger","route":"/people/emmanuel-barranger/","asOf":"2026-09-10","days":18},{"id":"marie-eve-desrosiers","kind":"person","name":"Marie-Eve Desrosiers","route":"/people/marie-eve-desrosiers/","asOf":"2026-09-10","days":18},{"id":"ashley-ball-gamble","kind":"person","name":"Ashley Ball-Gamble","route":"/people/ashley-ball-gamble/","asOf":"2026-09-10","days":18},{"id":"michael-boyer","kind":"person","name":"Michael Boyer","route":"/people/michael-boyer/","asOf":"2026-09-10","days":18},{"id":"princess-chulabhorn","kind":"person","name":"Princess Chulabhorn","route":"/people/princess-chulabhorn/","asOf":"2026-09-10","days":18},{"id":"annette-walker","kind":"person","name":"Annette Walker","route":"/people/annette-walker/","asOf":"2026-09-10","days":18},{"id":"victor-hugo-borja-aburto","kind":"person","name":"Víctor Hugo Borja Aburto","route":"/people/victor-hugo-borja-aburto/","asOf":"2026-09-10","days":18},{"id":"elisabeth-schorb","kind":"person","name":"Elisabeth Schorb","route":"/people/elisabeth-schorb/","asOf":"2026-09-10","days":18},{"id":"ralf-c-bargou","kind":"person","name":"Ralf C. Bargou","route":"/people/ralf-c-bargou/","asOf":"2026-09-10","days":18},{"id":"yung-s-lie","kind":"person","name":"Yung S. Lie","route":"/people/yung-s-lie/","asOf":"2026-09-10","days":18},{"id":"rita-schmutzler","kind":"person","name":"Rita Schmutzler","route":"/people/rita-schmutzler/","asOf":"2026-09-10","days":18},{"id":"eniarti","kind":"person","name":"Eniarti","route":"/people/eniarti/","asOf":"2026-09-10","days":18},{"id":"wayne-roberts","kind":"person","name":"Wayne Roberts","route":"/people/wayne-roberts/","asOf":"2026-09-10","days":18},{"id":"tariq-enver","kind":"person","name":"Tariq Enver","route":"/people/tariq-enver/","asOf":"2026-09-10","days":18},{"id":"axel-behrens","kind":"person","name":"Axel Behrens","route":"/people/axel-behrens/","asOf":"2026-09-10","days":18},{"id":"kent-stobart","kind":"person","name":"Kent Stobart","route":"/people/kent-stobart/","asOf":"2026-09-10","days":18},{"id":"ramon-salazar-soler","kind":"person","name":"Ramon Salazar i Soler","route":"/people/ramon-salazar-soler/","asOf":"2026-09-10","days":18},{"id":"rajeev-singh-raghuvanshi","kind":"person","name":"Rajeev Singh Raghuvanshi","route":"/people/rajeev-singh-raghuvanshi/","asOf":"2026-09-10","days":18},{"id":"renaud-de-crevoisier","kind":"person","name":"Renaud de Crevoisier","route":"/people/renaud-de-crevoisier/","asOf":"2026-09-10","days":18},{"id":"roman-rouzier","kind":"person","name":"Roman Rouzier","route":"/people/roman-rouzier/","asOf":"2026-09-10","days":18},{"id":"pierre-vera","kind":"person","name":"Pierre Vera","route":"/people/pierre-vera/","asOf":"2026-09-10","days":18},{"id":"frederique-penault-llorca","kind":"person","name":"Frédérique Penault-Llorca","route":"/people/frederique-penault-llorca/","asOf":"2026-09-10","days":18},{"id":"giuseppe-tonutti","kind":"person","name":"Giuseppe Tonutti","route":"/people/giuseppe-tonutti/","asOf":"2026-09-10","days":18},{"id":"richard-van-etten","kind":"person","name":"Richard Van Etten","route":"/people/richard-van-etten/","asOf":"2026-09-10","days":18},{"id":"sandile-mfenyana","kind":"person","name":"Sandile Mfenyana","route":"/people/sandile-mfenyana/","asOf":"2026-09-10","days":18},{"id":"biju-george","kind":"person","name":"Biju George","route":"/people/biju-george/","asOf":"2026-09-10","days":18},{"id":"martin-beaumont","kind":"person","name":"Martin Beaumont","route":"/people/martin-beaumont/","asOf":"2026-09-10","days":18},{"id":"pavan-reddy","kind":"person","name":"Pavan Reddy","route":"/people/pavan-reddy/","asOf":"2026-09-10","days":18},{"id":"john-kennedy","kind":"person","name":"John Kennedy","route":"/people/john-kennedy/","asOf":"2026-09-10","days":18},{"id":"pia-vihinen","kind":"person","name":"Pia Vihinen","route":"/people/pia-vihinen/","asOf":"2026-09-10","days":18},{"id":"jesse-otegbayo","kind":"person","name":"Jesse Abiodun Otegbayo","route":"/people/jesse-otegbayo/","asOf":"2026-09-10","days":18},{"id":"ate-van-der-zee","kind":"person","name":"Ate van der Zee","route":"/people/ate-van-der-zee/","asOf":"2026-09-10","days":18},{"id":"dan-theodorescu","kind":"person","name":"Dan Theodorescu","route":"/people/dan-theodorescu/","asOf":"2026-09-10","days":18},{"id":"thomas-george","kind":"person","name":"Thomas J. George","route":"/people/thomas-george/","asOf":"2026-09-10","days":18},{"id":"michael-kerin","kind":"person","name":"Michael Kerin","route":"/people/michael-kerin/","asOf":"2026-09-10","days":18},{"id":"naoto-ueno","kind":"person","name":"Naoto T. Ueno","route":"/people/naoto-ueno/","asOf":"2026-09-10","days":18},{"id":"christian-capitini","kind":"person","name":"Christian Capitini","route":"/people/christian-capitini/","asOf":"2026-09-10","days":18},{"id":"thomas-loughran","kind":"person","name":"Thomas P. Loughran Jr.","route":"/people/thomas-loughran/","asOf":"2026-09-10","days":18},{"id":"robert-winn","kind":"person","name":"Robert A. Winn","route":"/people/robert-winn/","asOf":"2026-09-10","days":18},{"id":"christian-sauvr","kind":"person","name":"Christian Sauvr","route":"/people/christian-sauvr/","asOf":"2026-09-10","days":18},{"id":"tammy-quigley","kind":"person","name":"Tammy Quigley","route":"/people/tammy-quigley/","asOf":"2026-09-10","days":18},{"id":"kirsten-major","kind":"person","name":"Kirsten Major","route":"/people/kirsten-major/","asOf":"2026-09-10","days":18},{"id":"valdas-peceliunas","kind":"person","name":"Valdas Pečeliūnas","route":"/people/valdas-peceliunas/","asOf":"2026-09-10","days":18},{"id":"ls-shashidhara","kind":"person","name":"L. S. Shashidhara","route":"/people/ls-shashidhara/","asOf":"2026-09-10","days":18},{"id":"sunil-kumar-barnwal","kind":"person","name":"Sunil Kumar Barnwal","route":"/people/sunil-kumar-barnwal/","asOf":"2026-09-10","days":18},{"id":"mostafa-aziz-sumon","kind":"person","name":"Mostafa Aziz Sumon","route":"/people/mostafa-aziz-sumon/","asOf":"2026-09-10","days":18},{"id":"huang-guo","kind":"person","name":"Huang Guo","route":"/people/huang-guo/","asOf":"2026-09-10","days":18},{"id":"anthony-may","kind":"person","name":"Anthony May","route":"/people/anthony-may/","asOf":"2026-09-10","days":18},{"id":"nicole-boutilier","kind":"person","name":"Nicole Boutilier","route":"/people/nicole-boutilier/","asOf":"2026-09-10","days":18},{"id":"valery-lemmens","kind":"person","name":"Valery Lemmens","route":"/people/valery-lemmens/","asOf":"2026-09-10","days":18},{"id":"jon-irish","kind":"person","name":"Jon Irish","route":"/people/jon-irish/","asOf":"2026-09-10","days":18},{"id":"zhang-shuyang","kind":"person","name":"Zhang Shuyang","route":"/people/zhang-shuyang/","asOf":"2026-09-10","days":18},{"id":"lyn-simpson","kind":"person","name":"Lyn Simpson","route":"/people/lyn-simpson/","asOf":"2026-09-10","days":18},{"id":"bertine-lahuis","kind":"person","name":"Bertine Lahuis","route":"/people/bertine-lahuis/","asOf":"2026-09-10","days":18},{"id":"dharmendra-singh-gangwar","kind":"person","name":"Dharmendra Singh Gangwar","route":"/people/dharmendra-singh-gangwar/","asOf":"2026-09-10","days":18},{"id":"vadims-beluns","kind":"person","name":"Vadims Beļuns","route":"/people/vadims-beluns/","asOf":"2026-09-10","days":18},{"id":"steven-k-libutti","kind":"person","name":"Steven K. Libutti","route":"/people/steven-k-libutti/","asOf":"2026-09-10","days":18},{"id":"christos-fasianos","kind":"person","name":"Christos Fasianos","route":"/people/christos-fasianos/","asOf":"2026-09-10","days":18},{"id":"nicole-scobie","kind":"person","name":"Nicole Scobie","route":"/people/nicole-scobie/","asOf":"2026-09-10","days":18},{"id":"farhat-abbas","kind":"person","name":"Farhat Abbas","route":"/people/farhat-abbas/","asOf":"2026-09-10","days":18},{"id":"rashid-khalani","kind":"person","name":"Rashid Khalani","route":"/people/rashid-khalani/","asOf":"2026-09-10","days":18},{"id":"ali-taher","kind":"person","name":"Ali Taher","route":"/people/ali-taher/","asOf":"2026-09-10","days":18},{"id":"hans-van-goudoever","kind":"person","name":"Hans van Goudoever","route":"/people/hans-van-goudoever/","asOf":"2026-09-10","days":18},{"id":"timur-atsuren","kind":"person","name":"Timur Atsüren","route":"/people/timur-atsuren/","asOf":"2026-09-10","days":18},{"id":"luigi-cajazzo","kind":"person","name":"Luigi Cajazzo","route":"/people/luigi-cajazzo/","asOf":"2026-09-10","days":18},{"id":"ruben-mesa","kind":"person","name":"Ruben Mesa","route":"/people/ruben-mesa/","asOf":"2026-09-10","days":18},{"id":"dale-bramley","kind":"person","name":"Dale Bramley","route":"/people/dale-bramley/","asOf":"2026-09-10","days":18},{"id":"davide-fornaciari","kind":"person","name":"Davide Fornaciari","route":"/people/davide-fornaciari/","asOf":"2026-09-10","days":18},{"id":"inge-buyse","kind":"person","name":"Inge Buyse","route":"/people/inge-buyse/","asOf":"2026-09-10","days":18},{"id":"boris-pasche","kind":"person","name":"Boris C. Pasche","route":"/people/boris-pasche/","asOf":"2026-09-10","days":18},{"id":"patrick-morris","kind":"person","name":"Patrick G. Morris","route":"/people/patrick-morris/","asOf":"2026-09-10","days":18},{"id":"denise-soares-dos-santos","kind":"person","name":"Denise Soares dos Santos","route":"/people/denise-soares-dos-santos/","asOf":"2026-09-10","days":18},{"id":"maria-kane","kind":"person","name":"Maria Kane","route":"/people/maria-kane/","asOf":"2026-09-10","days":18},{"id":"rohit-bhargava","kind":"person","name":"Rohit Bhargava","route":"/people/rohit-bhargava/","asOf":"2026-09-10","days":18},{"id":"monica-calamai","kind":"person","name":"Monica Calamai","route":"/people/monica-calamai/","asOf":"2026-09-10","days":18},{"id":"claudio-cracco","kind":"person","name":"Claudio Cracco","route":"/people/claudio-cracco/","asOf":"2026-09-10","days":18},{"id":"paa-kwesi-baidoo","kind":"person","name":"Paa Kwesi Baidoo","route":"/people/paa-kwesi-baidoo/","asOf":"2026-09-10","days":18},{"id":"satu-tiainen","kind":"person","name":"Satu Tiainen","route":"/people/satu-tiainen/","asOf":"2026-09-10","days":18},{"id":"richard-mitchell","kind":"person","name":"Richard Mitchell","route":"/people/richard-mitchell/","asOf":"2026-09-10","days":18},{"id":"ida-danmark","kind":"person","name":"Ida Danmark","route":"/people/ida-danmark/","asOf":"2026-09-10","days":18},{"id":"helen-mertens","kind":"person","name":"Helen Mertens","route":"/people/helen-mertens/","asOf":"2026-09-10","days":18},{"id":"jeffrey-miller","kind":"person","name":"Jeffrey Miller","route":"/people/jeffrey-miller/","asOf":"2026-09-10","days":18},{"id":"abhay-soi","kind":"person","name":"Abhay Soi","route":"/people/abhay-soi/","asOf":"2026-09-10","days":18},{"id":"lei-zheng","kind":"person","name":"Lei Zheng","route":"/people/lei-zheng/","asOf":"2026-09-10","days":18},{"id":"lucie-opatrny","kind":"person","name":"Lucie Opatrny","route":"/people/lucie-opatrny/","asOf":"2026-09-10","days":18},{"id":"philip-kirwa","kind":"person","name":"Philip K. Kirwa","route":"/people/philip-kirwa/","asOf":"2026-09-10","days":18},{"id":"ulrich-steidl","kind":"person","name":"Ulrich G. Steidl","route":"/people/ulrich-steidl/","asOf":"2026-09-10","days":18},{"id":"martin-armstrong","kind":"person","name":"Martin Armstrong","route":"/people/martin-armstrong/","asOf":"2026-09-10","days":18},{"id":"raymond-dubois","kind":"person","name":"Raymond N. DuBois","route":"/people/raymond-dubois/","asOf":"2026-09-10","days":18},{"id":"erez-barenboim","kind":"person","name":"Erez Barenboim","route":"/people/erez-barenboim/","asOf":"2026-09-10","days":18},{"id":"rajesh-gokhale","kind":"person","name":"Rajesh S. Gokhale","route":"/people/rajesh-gokhale/","asOf":"2026-09-10","days":18},{"id":"xiao-haipeng","kind":"person","name":"Xiao Haipeng","route":"/people/xiao-haipeng/","asOf":"2026-09-10","days":18},{"id":"robert-uzzo","kind":"person","name":"Robert G. Uzzo","route":"/people/robert-uzzo/","asOf":"2026-09-10","days":18},{"id":"joann-sweasy","kind":"person","name":"Joann B. Sweasy","route":"/people/joann-sweasy/","asOf":"2026-09-10","days":18},{"id":"antonio-llombart-bosch","kind":"person","name":"Antonio Llombart Bosch","route":"/people/antonio-llombart-bosch/","asOf":"2026-09-10","days":18},{"id":"vicente-borrero","kind":"person","name":"Vicente Borrero","route":"/people/vicente-borrero/","asOf":"2026-09-10","days":18},{"id":"zhang-jiangong","kind":"person","name":"Zhang Jiangong","route":"/people/zhang-jiangong/","asOf":"2026-09-10","days":18},{"id":"vasanta-nanduri","kind":"person","name":"Vasanta Nanduri","route":"/people/vasanta-nanduri/","asOf":"2026-09-10","days":18},{"id":"mark-burkard","kind":"person","name":"Mark E. Burkard","route":"/people/mark-burkard/","asOf":"2026-09-10","days":18},{"id":"jean-francois-fortin-verreault","kind":"person","name":"Jean-François Fortin Verreault","route":"/people/jean-francois-fortin-verreault/","asOf":"2026-09-10","days":18},{"id":"flavio-tomasich","kind":"person","name":"Flávio Daniel Saavedra Tomasich","route":"/people/flavio-tomasich/","asOf":"2026-09-10","days":18},{"id":"reuben-shaw","kind":"person","name":"Reuben Shaw","route":"/people/reuben-shaw/","asOf":"2026-09-10","days":18},{"id":"paul-boutros","kind":"person","name":"Paul Boutros","route":"/people/paul-boutros/","asOf":"2026-09-10","days":18},{"id":"deb-bulych","kind":"person","name":"Deb Bulych","route":"/people/deb-bulych/","asOf":"2026-09-10","days":18},{"id":"yu-jinming","kind":"person","name":"Yu Jinming","route":"/people/yu-jinming/","asOf":"2026-09-10","days":18},{"id":"faisal-sultan","kind":"person","name":"Faisal Sultan","route":"/people/faisal-sultan/","asOf":"2026-09-10","days":18},{"id":"lin-tongyu","kind":"person","name":"Lin Tongyu","route":"/people/lin-tongyu/","asOf":"2026-09-10","days":18},{"id":"shlomi-codish","kind":"person","name":"Shlomi Codish","route":"/people/shlomi-codish/","asOf":"2026-09-10","days":18},{"id":"david-fennelly","kind":"person","name":"David Fennelly","route":"/people/david-fennelly/","asOf":"2026-09-10","days":18},{"id":"kathleen-ruddy","kind":"person","name":"Kathleen Ruddy","route":"/people/kathleen-ruddy/","asOf":"2026-09-10","days":18},{"id":"lehlohonolo-majake","kind":"person","name":"Lehlohonolo Majake","route":"/people/lehlohonolo-majake/","asOf":"2026-09-10","days":18},{"id":"priit-perens","kind":"person","name":"Priit Perens","route":"/people/priit-perens/","asOf":"2026-09-10","days":18},{"id":"annika-auranen","kind":"person","name":"Annika Auranen","route":"/people/annika-auranen/","asOf":"2026-09-10","days":18},{"id":"jim-woodgett","kind":"person","name":"Jim Woodgett","route":"/people/jim-woodgett/","asOf":"2026-09-10","days":18},{"id":"joan-spencer","kind":"person","name":"Joan Spencer","route":"/people/joan-spencer/","asOf":"2026-09-10","days":18},{"id":"karolina-palucka","kind":"person","name":"Karolina Palucka","route":"/people/karolina-palucka/","asOf":"2026-09-10","days":18},{"id":"ankita-mishra-bundela","kind":"person","name":"Ankita Mishra Bundela","route":"/people/ankita-mishra-bundela/","asOf":"2026-09-10","days":18},{"id":"dario-altieri","kind":"person","name":"Dario C. Altieri","route":"/people/dario-altieri/","asOf":"2026-09-10","days":18},{"id":"jihui-hao","kind":"person","name":"Jihui Hao","route":"/people/jihui-hao/","asOf":"2026-09-10","days":18},{"id":"hu-junbo","kind":"person","name":"Hu Junbo","route":"/people/hu-junbo/","asOf":"2026-09-10","days":18},{"id":"julian-redhead","kind":"person","name":"Julian Redhead","route":"/people/julian-redhead/","asOf":"2026-09-10","days":18},{"id":"govindan-rangarajan","kind":"person","name":"Govindan Rangarajan","route":"/people/govindan-rangarajan/","asOf":"2026-09-10","days":18},{"id":"d-wade-clapp","kind":"person","name":"D. Wade Clapp","route":"/people/d-wade-clapp/","asOf":"2026-09-10","days":18},{"id":"pamela-kearns","kind":"person","name":"Pamela Kearns","route":"/people/pamela-kearns/","asOf":"2026-09-10","days":18},{"id":"mario-campone","kind":"person","name":"Mario Campone","route":"/people/mario-campone/","asOf":"2026-09-10","days":18},{"id":"marc-ychou","kind":"person","name":"Marc Ychou","route":"/people/marc-ychou/","asOf":"2026-09-10","days":18},{"id":"pierre-laurent-puig","kind":"person","name":"Pierre Laurent-Puig","route":"/people/pierre-laurent-puig/","asOf":"2026-09-10","days":18},{"id":"brahim-lakhal","kind":"person","name":"Brahim Lakhal","route":"/people/brahim-lakhal/","asOf":"2026-09-10","days":18},{"id":"maneesha-inamdar","kind":"person","name":"Maneesha S Inamdar","route":"/people/maneesha-inamdar/","asOf":"2026-09-10","days":18},{"id":"tao-cheng","kind":"person","name":"Tao Cheng","route":"/people/tao-cheng/","asOf":"2026-09-10","days":18},{"id":"roxana-del-aguila","kind":"person","name":"Roxana del Águila","route":"/people/roxana-del-aguila/","asOf":"2026-09-10","days":18},{"id":"arthur-violante-sapia","kind":"person","name":"Arthur Violante Sapia","route":"/people/arthur-violante-sapia/","asOf":"2026-09-10","days":18},{"id":"susana-blanco","kind":"person","name":"Susana Blanco","route":"/people/susana-blanco/","asOf":"2026-09-10","days":18},{"id":"mauricio-cuello","kind":"person","name":"Mauricio Cuello","route":"/people/mauricio-cuello/","asOf":"2026-09-10","days":18},{"id":"ander-urruticoechea","kind":"person","name":"Ander Urruticoechea","route":"/people/ander-urruticoechea/","asOf":"2026-09-10","days":18},{"id":"mohammed-bin-khalifa-al-suwaidi","kind":"person","name":"Mohammed bin Khalifa Al Suwaidi","route":"/people/mohammed-bin-khalifa-al-suwaidi/","asOf":"2026-09-10","days":18},{"id":"rachel-dunscombe","kind":"person","name":"Rachel Dunscombe","route":"/people/rachel-dunscombe/","asOf":"2026-09-10","days":18},{"id":"zoe-robledo","kind":"person","name":"Zoé Robledo","route":"/people/zoe-robledo/","asOf":"2026-09-10","days":18},{"id":"esteban-langlois","kind":"person","name":"Esteban Langlois","route":"/people/esteban-langlois/","asOf":"2026-09-10","days":18},{"id":"jose-luis-poveda-andres","kind":"person","name":"José Luis Poveda Andrés","route":"/people/jose-luis-poveda-andres/","asOf":"2026-09-10","days":18},{"id":"javier-arcos","kind":"person","name":"Javier Arcos","route":"/people/javier-arcos/","asOf":"2026-09-10","days":18},{"id":"massimo-de-fino","kind":"person","name":"Massimo De Fino","route":"/people/massimo-de-fino/","asOf":"2026-09-10","days":18},{"id":"alessandro-delle-donne","kind":"person","name":"Alessandro Delle Donne","route":"/people/alessandro-delle-donne/","asOf":"2026-09-10","days":18},{"id":"t-naveen","kind":"person","name":"T. Naveen","route":"/people/t-naveen/","asOf":"2026-09-10","days":18},{"id":"shaheem-de-vries","kind":"person","name":"Shaheem de Vries","route":"/people/shaheem-de-vries/","asOf":"2026-09-10","days":18},{"id":"xiang-hua","kind":"person","name":"Xiang Hua","route":"/people/xiang-hua/","asOf":"2026-09-10","days":18},{"id":"shalini-singh","kind":"person","name":"Shalini Singh","route":"/people/shalini-singh/","asOf":"2026-09-10","days":18},{"id":"lp-mtshali","kind":"person","name":"L.P. Mtshali","route":"/people/lp-mtshali/","asOf":"2026-09-10","days":18},{"id":"joseph-gligorov","kind":"person","name":"Joseph Gligorov","route":"/people/joseph-gligorov/","asOf":"2026-09-10","days":18},{"id":"luis-eduardo-martin-rodriguez","kind":"person","name":"Luis Eduardo Martín Rodríguez","route":"/people/luis-eduardo-martin-rodriguez/","asOf":"2026-09-10","days":18},{"id":"berta-cerda-alvarez","kind":"person","name":"Berta Cerda Álvarez","route":"/people/berta-cerda-alvarez/","asOf":"2026-09-10","days":18},{"id":"maria-margarida-torres-de-ornelas","kind":"person","name":"Maria Margarida Torres de Ornelas","route":"/people/maria-margarida-torres-de-ornelas/","asOf":"2026-09-10","days":18},{"id":"victor-piana-de-andrade","kind":"person","name":"Victor Piana de Andrade","route":"/people/victor-piana-de-andrade/","asOf":"2026-09-10","days":18},{"id":"laura-skaife-knight","kind":"person","name":"Laura Skaife-Knight","route":"/people/laura-skaife-knight/","asOf":"2026-09-10","days":18},{"id":"shaikh-fahad-bin-khalifa-al-khalifa","kind":"person","name":"Shaikh Fahad bin Khalifa bin Salman Al Khalifa","route":"/people/shaikh-fahad-bin-khalifa-al-khalifa/","asOf":"2026-09-10","days":18},{"id":"susan-msadabwe","kind":"person","name":"Susan C. Msadabwe","route":"/people/susan-msadabwe/","asOf":"2026-09-10","days":18},{"id":"nicolas-revel","kind":"person","name":"Nicolas Revel","route":"/people/nicolas-revel/","asOf":"2026-09-10","days":18},{"id":"chen-chien-tzung","kind":"person","name":"Chen Chien-Tzung","route":"/people/chen-chien-tzung/","asOf":"2026-09-10","days":18},{"id":"sherif-abouel-naga","kind":"person","name":"Sherif Abouel Naga","route":"/people/sherif-abouel-naga/","asOf":"2026-09-10","days":18},{"id":"fan-daiming","kind":"person","name":"Fan Daiming","route":"/people/fan-daiming/","asOf":"2026-09-10","days":18},{"id":"wang-ying","kind":"person","name":"Wang Ying","route":"/people/wang-ying/","asOf":"2026-09-10","days":18},{"id":"dearbhaile-collins","kind":"person","name":"Dearbhaile Collins","route":"/people/dearbhaile-collins/","asOf":"2026-09-10","days":18},{"id":"jennifer-welsh","kind":"person","name":"Jennifer Welsh","route":"/people/jennifer-welsh/","asOf":"2026-09-10","days":18},{"id":"rene-medema","kind":"person","name":"René Medema","route":"/people/rene-medema/","asOf":"2026-09-10","days":18},{"id":"andrew-mesecar","kind":"person","name":"Andrew Mesecar","route":"/people/andrew-mesecar/","asOf":"2026-09-10","days":18},{"id":"geraline-leusink","kind":"person","name":"Geraline Leusink","route":"/people/geraline-leusink/","asOf":"2026-09-10","days":18},{"id":"xia-jiahong","kind":"person","name":"Xia Jiahong","route":"/people/xia-jiahong/","asOf":"2026-09-10","days":18},{"id":"taofeek-owonikoko","kind":"person","name":"Taofeek K. Owonikoko","route":"/people/taofeek-owonikoko/","asOf":"2026-09-10","days":18},{"id":"tan-weihong","kind":"person","name":"Tan Weihong","route":"/people/tan-weihong/","asOf":"2026-09-10","days":18},{"id":"niels-norgaard-pedersen","kind":"person","name":"Niels Nørgaard Pedersen","route":"/people/niels-norgaard-pedersen/","asOf":"2026-09-10","days":18},{"id":"lars-dahl-pedersen","kind":"person","name":"Lars Dahl Pedersen","route":"/people/lars-dahl-pedersen/","asOf":"2026-09-10","days":18},{"id":"ricco-norman-dyhr","kind":"person","name":"Ricco Norman Dyhr","route":"/people/ricco-norman-dyhr/","asOf":"2026-09-10","days":18},{"id":"kristo-erikson","kind":"person","name":"Kristo Erikson","route":"/people/kristo-erikson/","asOf":"2026-09-10","days":18},{"id":"tarmo-bakler","kind":"person","name":"Tarmo Bakler","route":"/people/tarmo-bakler/","asOf":"2026-09-10","days":18},{"id":"sirkku-jyrkkio","kind":"person","name":"Sirkku Jyrkkiö","route":"/people/sirkku-jyrkkio/","asOf":"2026-09-10","days":18},{"id":"juha-korpelainen","kind":"person","name":"Juha Korpelainen","route":"/people/juha-korpelainen/","asOf":"2026-09-10","days":18},{"id":"gerard-zalcman","kind":"person","name":"Gérard Zalcman","route":"/people/gerard-zalcman/","asOf":"2026-09-10","days":18},{"id":"jean-philippe-spano","kind":"person","name":"Jean-Philippe Spano","route":"/people/jean-philippe-spano/","asOf":"2026-09-10","days":18},{"id":"yacine-merrouche","kind":"person","name":"Yacine Merrouche","route":"/people/yacine-merrouche/","asOf":"2026-09-10","days":18},{"id":"didier-peiffert","kind":"person","name":"Didier Peiffert","route":"/people/didier-peiffert/","asOf":"2026-09-10","days":18},{"id":"vigdis-hallgrimsdottir","kind":"person","name":"Vigdís Hallgrímsdóttir","route":"/people/vigdis-hallgrimsdottir/","asOf":"2026-09-10","days":18},{"id":"maeve-lowery","kind":"person","name":"Maeve Lowery","route":"/people/maeve-lowery/","asOf":"2026-09-10","days":18},{"id":"anne-coyle","kind":"person","name":"Anne Coyle","route":"/people/anne-coyle/","asOf":"2026-09-10","days":18},{"id":"jerome-coffey","kind":"person","name":"Jerome Coffey","route":"/people/jerome-coffey/","asOf":"2026-09-10","days":18},{"id":"emma-browne","kind":"person","name":"Emma Browne","route":"/people/emma-browne/","asOf":"2026-09-10","days":18},{"id":"ilaria-panzini","kind":"person","name":"Ilaria Panzini","route":"/people/ilaria-panzini/","asOf":"2026-09-10","days":18},{"id":"carlo-cimbri","kind":"person","name":"Carlo Cimbri","route":"/people/carlo-cimbri/","asOf":"2026-09-10","days":18},{"id":"andrea-agnelli","kind":"person","name":"Andrea Agnelli","route":"/people/andrea-agnelli/","asOf":"2026-09-10","days":18},{"id":"mario-taccolini","kind":"person","name":"Mario Taccolini","route":"/people/mario-taccolini/","asOf":"2026-09-10","days":18},{"id":"alessandro-venturi","kind":"person","name":"Alessandro Venturi","route":"/people/alessandro-venturi/","asOf":"2026-09-10","days":18},{"id":"tomas-jovaisa","kind":"person","name":"Tomas Jovaiša","route":"/people/tomas-jovaisa/","asOf":"2026-09-10","days":18},{"id":"audrius-simaitis","kind":"person","name":"Audrius Šimaitis","route":"/people/audrius-simaitis/","asOf":"2026-09-10","days":18},{"id":"jakub-kraszewski","kind":"person","name":"Jakub Kraszewski","route":"/people/jakub-kraszewski/","asOf":"2026-09-10","days":18},{"id":"iwona-maroszynska","kind":"person","name":"Iwona Maroszyńska","route":"/people/iwona-maroszynska/","asOf":"2026-09-10","days":18},{"id":"jasna-trifunovic","kind":"person","name":"Jasna Trifunovic","route":"/people/jasna-trifunovic/","asOf":"2026-09-10","days":18},{"id":"albert-salazar-soler","kind":"person","name":"Albert Salazar Soler","route":"/people/albert-salazar-soler/","asOf":"2026-09-10","days":18},{"id":"anton-benet-catala","kind":"person","name":"Anton Benet Català","route":"/people/anton-benet-catala/","asOf":"2026-09-10","days":18},{"id":"adria-comella-carnice","kind":"person","name":"Adrià Comella Carnicé","route":"/people/adria-comella-carnice/","asOf":"2026-09-10","days":18},{"id":"mark-de-ridder","kind":"person","name":"Mark De Ridder","route":"/people/mark-de-ridder/","asOf":"2026-09-10","days":18},{"id":"nikolaos-zamboglou","kind":"person","name":"Nikolaos Zamboglou","route":"/people/nikolaos-zamboglou/","asOf":"2026-09-10","days":18},{"id":"ben-o-sullivan","kind":"person","name":"Ben O'Sullivan","route":"/people/ben-o-sullivan/","asOf":"2026-09-10","days":18},{"id":"renaldas-jurkevicius","kind":"person","name":"Renaldas Jurkevičius","route":"/people/renaldas-jurkevicius/","asOf":"2026-09-10","days":18},{"id":"ruslan-baltaga","kind":"person","name":"Ruslan Baltaga","route":"/people/ruslan-baltaga/","asOf":"2026-09-10","days":18},{"id":"igor-stojkovski","kind":"person","name":"Igor Stojkovski","route":"/people/igor-stojkovski/","asOf":"2026-09-10","days":18},{"id":"giuliana-cardenas-gamarra","kind":"person","name":"Giuliana Càrdenas Gamarra","route":"/people/giuliana-cardenas-gamarra/","asOf":"2026-09-10","days":18},{"id":"mirela-grosu","kind":"person","name":"Mirela Grosu","route":"/people/mirela-grosu/","asOf":"2026-09-10","days":18},{"id":"cesar-gregorio-munoz-sanchez-miguel","kind":"person","name":"César Gregorio Muñoz Sánchez-Miguel","route":"/people/cesar-gregorio-munoz-sanchez-miguel/","asOf":"2026-09-10","days":18},{"id":"jesus-fernandez-galan","kind":"person","name":"Jesús Fernández Galán","route":"/people/jesus-fernandez-galan/","asOf":"2026-09-10","days":18},{"id":"luis-ibanez-gadea","kind":"person","name":"Luis Ibáñez Gadea","route":"/people/luis-ibanez-gadea/","asOf":"2026-09-10","days":18},{"id":"patrik-rossi","kind":"person","name":"Patrik Rossi","route":"/people/patrik-rossi/","asOf":"2026-09-10","days":18},{"id":"jonas-claesson","kind":"person","name":"Jonas Claesson","route":"/people/jonas-claesson/","asOf":"2026-09-10","days":18},{"id":"pia-nasvall","kind":"person","name":"Pia Näsvall","route":"/people/pia-nasvall/","asOf":"2026-09-10","days":18},{"id":"rosaline-den-blanken","kind":"person","name":"Rosaline den Blanken","route":"/people/rosaline-den-blanken/","asOf":"2026-09-10","days":18},{"id":"haiko-bloemendal","kind":"person","name":"Haiko Bloemendal","route":"/people/haiko-bloemendal/","asOf":"2026-09-10","days":18},{"id":"ernst-j-kuipers","kind":"person","name":"Ernst J. Kuipers","route":"/people/ernst-j-kuipers/","asOf":"2026-09-10","days":18},{"id":"refik-emre-cecen","kind":"person","name":"Refik Emre Çeçen","route":"/people/refik-emre-cecen/","asOf":"2026-09-10","days":18},{"id":"rob-bristow","kind":"person","name":"Rob Bristow","route":"/people/rob-bristow/","asOf":"2026-09-10","days":18},{"id":"sacha-gougnard","kind":"person","name":"Sacha Gougnard","route":"/people/sacha-gougnard/","asOf":"2026-09-10","days":18},{"id":"frank-vermassen","kind":"person","name":"Frank Vermassen","route":"/people/frank-vermassen/","asOf":"2026-09-10","days":18},{"id":"rolando-medeiros","kind":"person","name":"Rolando Medeiros","route":"/people/rolando-medeiros/","asOf":"2026-09-10","days":18},{"id":"carolina-wiesner","kind":"person","name":"Carolina Wiesner","route":"/people/carolina-wiesner/","asOf":"2026-09-10","days":18},{"id":"robert-separovic","kind":"person","name":"Robert Šeparović","route":"/people/robert-separovic/","asOf":"2026-09-10","days":18},{"id":"panos-ergatoudes","kind":"person","name":"Panos Ergatoudes","route":"/people/panos-ergatoudes/","asOf":"2026-09-10","days":18},{"id":"petr-poloucek","kind":"person","name":"Petr Polouček","route":"/people/petr-poloucek/","asOf":"2026-09-10","days":18},{"id":"jannick-brennum","kind":"person","name":"Jannick Brennum","route":"/people/jannick-brennum/","asOf":"2026-09-10","days":18},{"id":"arto-mannermaa","kind":"person","name":"Arto Mannermaa","route":"/people/arto-mannermaa/","asOf":"2026-09-10","days":18},{"id":"eric-felix-lartigau","kind":"person","name":"Eric Felix Lartigau","route":"/people/eric-felix-lartigau/","asOf":"2026-09-10","days":18},{"id":"charles-coutant","kind":"person","name":"Charles Coutant","route":"/people/charles-coutant/","asOf":"2026-09-10","days":18},{"id":"panagiotis-klirides","kind":"person","name":"Panagiotis Klirides","route":"/people/panagiotis-klirides/","asOf":"2026-09-10","days":18},{"id":"sarantos-efstathopoulos","kind":"person","name":"Sarantos Efstathopoulos","route":"/people/sarantos-efstathopoulos/","asOf":"2026-09-10","days":18},{"id":"joseph-martin","kind":"person","name":"Joseph Martin","route":"/people/joseph-martin/","asOf":"2026-09-10","days":18},{"id":"tracey-fitzpatrick","kind":"person","name":"Tracey Fitzpatrick","route":"/people/tracey-fitzpatrick/","asOf":"2026-09-10","days":18},{"id":"gustavo-galmozzi","kind":"person","name":"Gustavo Galmozzi","route":"/people/gustavo-galmozzi/","asOf":"2026-09-10","days":18},{"id":"livio-de-angelis","kind":"person","name":"Livio De Angelis","route":"/people/livio-de-angelis/","asOf":"2026-09-10","days":18},{"id":"marco-centenari","kind":"person","name":"Marco Centenari","route":"/people/marco-centenari/","asOf":"2026-09-10","days":18},{"id":"riccardo-bui","kind":"person","name":"Riccardo Bui","route":"/people/riccardo-bui/","asOf":"2026-09-10","days":18},{"id":"roberto-cunsolo","kind":"person","name":"Roberto Cunsolo","route":"/people/roberto-cunsolo/","asOf":"2026-09-10","days":18},{"id":"nicola-normanno","kind":"person","name":"Nicola Normanno","route":"/people/nicola-normanno/","asOf":"2026-09-10","days":18},{"id":"daniele-piacentini","kind":"person","name":"Daniele Piacentini","route":"/people/daniele-piacentini/","asOf":"2026-09-10","days":18},{"id":"alinta-hegmane","kind":"person","name":"Alinta Hegmane","route":"/people/alinta-hegmane/","asOf":"2026-09-10","days":18},{"id":"lauris-vidzis","kind":"person","name":"Lauris Vidzis","route":"/people/lauris-vidzis/","asOf":"2026-09-10","days":18},{"id":"oddbjorn-straume","kind":"person","name":"Oddbjorn Straume","route":"/people/oddbjorn-straume/","asOf":"2026-09-10","days":18},{"id":"oystein-maeland","kind":"person","name":"Øystein Mæland","route":"/people/oystein-maeland/","asOf":"2026-09-10","days":18},{"id":"helena-isabal-roca","kind":"person","name":"Helena Isàbal Roca","route":"/people/helena-isabal-roca/","asOf":"2026-09-10","days":18},{"id":"manuel-llombart-fuertes","kind":"person","name":"Manuel Llombart Fuertes","route":"/people/manuel-llombart-fuertes/","asOf":"2026-09-10","days":18},{"id":"carmen-martinez-de-pancorbo-gonzalez","kind":"person","name":"Carmen Martínez de Pancorbo González","route":"/people/carmen-martinez-de-pancorbo-gonzalez/","asOf":"2026-09-10","days":18},{"id":"rafael-perez-santamarina","kind":"person","name":"Rafael Pérez-Santamarina","route":"/people/rafael-perez-santamarina/","asOf":"2026-09-10","days":18},{"id":"sonia-garcia-de-san-jose","kind":"person","name":"Sonia García de San José","route":"/people/sonia-garcia-de-san-jose/","asOf":"2026-09-10","days":18},{"id":"pamela-buchwald","kind":"person","name":"Pamela Buchwald","route":"/people/pamela-buchwald/","asOf":"2026-09-10","days":18},{"id":"erik-johnsson","kind":"person","name":"Erik Johnsson","route":"/people/erik-johnsson/","asOf":"2026-09-10","days":18},{"id":"karl-landergren","kind":"person","name":"Karl Landergren","route":"/people/karl-landergren/","asOf":"2026-09-10","days":18},{"id":"markus-g-manz","kind":"person","name":"Markus G. Manz","route":"/people/markus-g-manz/","asOf":"2026-09-10","days":18},{"id":"daniel-staub","kind":"person","name":"Daniel Staub","route":"/people/daniel-staub/","asOf":"2026-09-10","days":18},{"id":"sulaiman-shahabuddin","kind":"person","name":"Sulaiman Shahabuddin","route":"/people/sulaiman-shahabuddin/","asOf":"2026-09-10","days":18},{"id":"maurice-van-den-bosch","kind":"person","name":"Maurice van den Bosch","route":"/people/maurice-van-den-bosch/","asOf":"2026-09-10","days":18},{"id":"h-m-w-verheul","kind":"person","name":"H.M.W. Verheul","route":"/people/h-m-w-verheul/","asOf":"2026-09-10","days":18},{"id":"lukas-b-been","kind":"person","name":"Lukas B. Been","route":"/people/lukas-b-been/","asOf":"2026-09-10","days":18},{"id":"vasyl-f-chekhun","kind":"person","name":"Vasyl F. Chekhun","route":"/people/vasyl-f-chekhun/","asOf":"2026-09-10","days":18},{"id":"hugo-ford","kind":"person","name":"Hugo Ford","route":"/people/hugo-ford/","asOf":"2026-09-10","days":18},{"id":"jacinta-abraham","kind":"person","name":"Jacinta Abraham","route":"/people/jacinta-abraham/","asOf":"2026-09-10","days":18},{"id":"daniel-serin","kind":"person","name":"Daniel Serin","route":"/people/daniel-serin/","asOf":"2026-09-10","days":18},{"id":"georgios-kapetanakis","kind":"person","name":"Georgios Kapetanakis","route":"/people/georgios-kapetanakis/","asOf":"2026-09-10","days":18},{"id":"krisztina-bogos","kind":"person","name":"Krisztina Bogos","route":"/people/krisztina-bogos/","asOf":"2026-09-10","days":18},{"id":"francesco-de-lorenzo","kind":"person","name":"Francesco De Lorenzo","route":"/people/francesco-de-lorenzo/","asOf":"2026-09-10","days":18},{"id":"tomasz-maciejewski","kind":"person","name":"Tomasz Maciejewski","route":"/people/tomasz-maciejewski/","asOf":"2026-09-10","days":18},{"id":"miroslav-chovanec","kind":"person","name":"Miroslav Chovanec","route":"/people/miroslav-chovanec/","asOf":"2026-09-10","days":18},{"id":"ramon-reyes-bori","kind":"person","name":"Ramón Reyes Bori","route":"/people/ramon-reyes-bori/","asOf":"2026-09-10","days":18},{"id":"adda-bounedjar","kind":"person","name":"Adda Bounedjar","route":"/people/adda-bounedjar/","asOf":"2026-09-10","days":18},{"id":"toni-vekov","kind":"person","name":"Toni Vekov","route":"/people/toni-vekov/","asOf":"2026-09-10","days":18},{"id":"assia-konsoulova","kind":"person","name":"Assia Konsoulova","route":"/people/assia-konsoulova/","asOf":"2026-09-10","days":18},{"id":"wensheng-liu","kind":"person","name":"Wensheng Liu","route":"/people/wensheng-liu/","asOf":"2026-09-10","days":18},{"id":"ladislav-dusek","kind":"person","name":"Ladislav Dušek","route":"/people/ladislav-dusek/","asOf":"2026-09-10","days":18},{"id":"xavier-pivot","kind":"person","name":"Xavier Pivot","route":"/people/xavier-pivot/","asOf":"2026-09-10","days":18},{"id":"breda-duggan","kind":"person","name":"Breda Duggan","route":"/people/breda-duggan/","asOf":"2026-09-10","days":18},{"id":"maria-rosaria-iardino","kind":"person","name":"Maria Rosaria Iardino","route":"/people/maria-rosaria-iardino/","asOf":"2026-09-10","days":18},{"id":"joanna-lorenc","kind":"person","name":"Joanna Lorenc","route":"/people/joanna-lorenc/","asOf":"2026-09-10","days":18},{"id":"delia-nicoara","kind":"person","name":"Delia Nicoară","route":"/people/delia-nicoara/","asOf":"2026-09-10","days":18},{"id":"gustaf-storm","kind":"person","name":"Gustaf Storm","route":"/people/gustaf-storm/","asOf":"2026-09-10","days":18},{"id":"alvaro-bonet-pla","kind":"person","name":"Álvaro Bonet Pla","route":"/people/alvaro-bonet-pla/","asOf":"2026-09-10","days":18},{"id":"bjorn-atle-bjornbeth","kind":"person","name":"Bjørn Atle Bjørnbeth","route":"/people/bjorn-atle-bjornbeth/","asOf":"2026-09-10","days":18},{"id":"r-r-w-j-van-der-hulst","kind":"person","name":"R.R.W.J. van der Hulst","route":"/people/r-r-w-j-van-der-hulst/","asOf":"2026-09-10","days":18},{"id":"carlos-mingo-rodriguez","kind":"person","name":"Carlos Mingo Rodriguez","route":"/people/carlos-mingo-rodriguez/","asOf":"2026-09-10","days":18},{"id":"cesar-adolfo-gomez-derch","kind":"person","name":"César Adolfo Gómez Derch","route":"/people/cesar-adolfo-gomez-derch/","asOf":"2026-09-10","days":18},{"id":"jose-julian-diaz-melguizo","kind":"person","name":"Jose Julián Díaz Melguizo","route":"/people/jose-julian-diaz-melguizo/","asOf":"2026-09-10","days":18},{"id":"julio-garcia-pondal","kind":"person","name":"Julio García Pondal","route":"/people/julio-garcia-pondal/","asOf":"2026-09-10","days":18},{"id":"lisbet-isenbeg-ravn","kind":"person","name":"Lisbet Isenbeg Ravn","route":"/people/lisbet-isenbeg-ravn/","asOf":"2026-09-10","days":18},{"id":"julian-malicki","kind":"person","name":"Julian Malicki","route":"/people/julian-malicki/","asOf":"2026-09-10","days":18},{"id":"christophe-tournigand","kind":"person","name":"Christophe Tournigand","route":"/people/christophe-tournigand/","asOf":"2026-09-10","days":18},{"id":"philippe-leroy","kind":"person","name":"Philippe Leroy","route":"/people/philippe-leroy/","asOf":"2026-09-10","days":18},{"id":"ivan-s-stilidi","kind":"person","name":"Ivan S. Stilidi","route":"/people/ivan-s-stilidi/","asOf":"2026-09-10","days":18},{"id":"pascal-hammel","kind":"person","name":"Pascal Hammel","route":"/people/pascal-hammel/","asOf":"2026-09-10","days":18},{"id":"nikolai-goncharenko","kind":"person","name":"Nikolai Goncharenko","route":"/people/nikolai-goncharenko/","asOf":"2026-09-10","days":18},{"id":"olena-yefimenko","kind":"person","name":"Olena Yefimenko","route":"/people/olena-yefimenko/","asOf":"2026-09-10","days":18},{"id":"tomi-p-makela","kind":"person","name":"Tomi P. Mäkelä","route":"/people/tomi-p-makela/","asOf":"2026-09-10","days":18},{"id":"poornima-parameswaran","kind":"person","name":"Poornima Parameswaran","route":"/people/poornima-parameswaran/","asOf":"2026-09-10","days":18},{"id":"bayli-divita-dean","kind":"person","name":"Bayli DiVita Dean","route":"/people/bayli-divita-dean/","asOf":"2026-09-10","days":18},{"id":"pramesh-c-s","kind":"person","name":"C. S. Pramesh","route":"/people/pramesh-c-s/","asOf":"2026-09-10","days":18},{"id":"dcruz-anil","kind":"person","name":"Anil K. D'Cruz","route":"/people/dcruz-anil/","asOf":"2026-09-10","days":18},{"id":"raina-vinod","kind":"person","name":"Vinod Raina","route":"/people/raina-vinod/","asOf":"2026-09-10","days":18},{"id":"shanta-v","kind":"person","name":"V. Shanta","route":"/people/shanta-v/","asOf":"2026-09-10","days":18},{"id":"sankaranarayanan-rengaswamy","kind":"person","name":"Rengaswamy Sankaranarayanan","route":"/people/sankaranarayanan-rengaswamy/","asOf":"2026-09-10","days":18},{"id":"mazumdar-shaw-kiran","kind":"person","name":"Kiran Mazumdar-Shaw","route":"/people/mazumdar-shaw-kiran/","asOf":"2026-09-10","days":18},{"id":"purwar-rahul","kind":"person","name":"Rahul Purwar","route":"/people/purwar-rahul/","asOf":"2026-09-10","days":18},{"id":"jain-hasmukh","kind":"person","name":"Hasmukh Jain","route":"/people/jain-hasmukh/","asOf":"2026-09-10","days":18},{"id":"narula-gaurav","kind":"person","name":"Gaurav Narula","route":"/people/narula-gaurav/","asOf":"2026-09-10","days":18},{"id":"kapoor-akhil","kind":"person","name":"Akhil Kapoor","route":"/people/kapoor-akhil/","asOf":"2026-09-10","days":18},{"id":"mathur-prashant","kind":"person","name":"Prashant Mathur","route":"/people/mathur-prashant/","asOf":"2026-09-10","days":18},{"id":"shetty-devi","kind":"person","name":"Devi Shetty","route":"/people/shetty-devi/","asOf":"2026-09-10","days":18},{"id":"ajaikumar-b-s","kind":"person","name":"B. S. Ajaikumar","route":"/people/ajaikumar-b-s/","asOf":"2026-09-10","days":18},{"id":"huang-xiaojun","kind":"person","name":"Xiaojun Huang","route":"/people/huang-xiaojun/","asOf":"2026-09-10","days":18},{"id":"chen-saijuan","kind":"person","name":"Saijuan Chen","route":"/people/chen-saijuan/","asOf":"2026-09-10","days":18},{"id":"chen-zhu","kind":"person","name":"Zhu Chen","route":"/people/chen-zhu/","asOf":"2026-09-10","days":18},{"id":"qin-shukui","kind":"person","name":"Shukui Qin","route":"/people/qin-shukui/","asOf":"2026-09-10","days":18},{"id":"fan-jia","kind":"person","name":"Jia Fan","route":"/people/fan-jia/","asOf":"2026-09-10","days":18},{"id":"xu-jianming","kind":"person","name":"Jianming Xu","route":"/people/xu-jianming/","asOf":"2026-09-10","days":18},{"id":"cheng-ying","kind":"person","name":"Ying Cheng","route":"/people/cheng-ying/","asOf":"2026-09-10","days":18},{"id":"guo-jun","kind":"person","name":"Jun Guo","route":"/people/guo-jun/","asOf":"2026-09-10","days":18},{"id":"li-zonghai","kind":"person","name":"Zonghai Li","route":"/people/li-zonghai/","asOf":"2026-09-10","days":18},{"id":"oyler-john","kind":"person","name":"John Oyler","route":"/people/oyler-john/","asOf":"2026-09-10","days":18},{"id":"xia-michelle","kind":"person","name":"Michelle Xia (Xia Yu)","route":"/people/xia-michelle/","asOf":"2026-09-10","days":18},{"id":"yu-michael","kind":"person","name":"Michael Yu (Yu De-Chao)","route":"/people/yu-michael/","asOf":"2026-09-10","days":18},{"id":"sun-piaoyang","kind":"person","name":"Piaoyang Sun","route":"/people/sun-piaoyang/","asOf":"2026-09-10","days":18},{"id":"du-samantha","kind":"person","name":"Samantha Du (Du Ying)","route":"/people/du-samantha/","asOf":"2026-09-10","days":18},{"id":"li-ge","kind":"person","name":"Ge Li","route":"/people/li-ge/","asOf":"2026-09-10","days":18},{"id":"su-weiguo","kind":"person","name":"Weiguo Su","route":"/people/su-weiguo/","asOf":"2026-09-10","days":18},{"id":"zhang-fangliang","kind":"person","name":"Fangliang (Frank) Zhang","route":"/people/zhang-fangliang/","asOf":"2026-09-10","days":18},{"id":"richard-finn","kind":"person","name":"Richard S. Finn","route":"/people/richard-finn/","asOf":"2026-09-10","days":18},{"id":"massimo-cristofanilli","kind":"person","name":"Massimo Cristofanilli","route":"/people/massimo-cristofanilli/","asOf":"2026-09-10","days":18},{"id":"gabriel-hortobagyi","kind":"person","name":"Gabriel N. Hortobagyi","route":"/people/gabriel-hortobagyi/","asOf":"2026-09-10","days":18},{"id":"stephen-johnston","kind":"person","name":"Stephen Johnston","route":"/people/stephen-johnston/","asOf":"2026-09-10","days":18},{"id":"komal-jhaveri","kind":"person","name":"Komal Jhaveri","route":"/people/komal-jhaveri/","asOf":"2026-09-10","days":18},{"id":"joseph-sparano","kind":"person","name":"Joseph A. Sparano","route":"/people/joseph-sparano/","asOf":"2026-09-10","days":18},{"id":"kevin-kalinsky","kind":"person","name":"Kevin Kalinsky","route":"/people/kevin-kalinsky/","asOf":"2026-09-10","days":18},{"id":"prudence-francis","kind":"person","name":"Prudence A. Francis","route":"/people/prudence-francis/","asOf":"2026-09-10","days":18},{"id":"nadia-harbeck","kind":"person","name":"Nadia Harbeck","route":"/people/nadia-harbeck/","asOf":"2026-09-10","days":18},{"id":"mitch-dowsett","kind":"person","name":"Mitch Dowsett","route":"/people/mitch-dowsett/","asOf":"2026-09-10","days":18},{"id":"jack-cuzick","kind":"person","name":"Jack Cuzick","route":"/people/jack-cuzick/","asOf":"2026-09-10","days":18},{"id":"charles-perou","kind":"person","name":"Charles M. Perou","route":"/people/charles-perou/","asOf":"2026-09-10","days":18},{"id":"sandra-swain","kind":"person","name":"Sandra M. Swain","route":"/people/sandra-swain/","asOf":"2026-09-10","days":18},{"id":"ian-krop","kind":"person","name":"Ian E. Krop","route":"/people/ian-krop/","asOf":"2026-09-10","days":18},{"id":"shanu-modi","kind":"person","name":"Shanu Modi","route":"/people/shanu-modi/","asOf":"2026-09-10","days":18},{"id":"cristina-saura","kind":"person","name":"Cristina Saura","route":"/people/cristina-saura/","asOf":"2026-09-10","days":18},{"id":"helena-earl","kind":"person","name":"Helena Earl","route":"/people/helena-earl/","asOf":"2026-09-10","days":18},{"id":"aleix-prat","kind":"person","name":"Aleix Prat","route":"/people/aleix-prat/","asOf":"2026-09-10","days":18},{"id":"eleftherios-mamounas","kind":"person","name":"Eleftherios P. Mamounas","route":"/people/eleftherios-mamounas/","asOf":"2026-09-10","days":18},{"id":"peter-schmid","kind":"person","name":"Peter Schmid","route":"/people/peter-schmid/","asOf":"2026-09-10","days":18},{"id":"aditya-bardia","kind":"person","name":"Aditya Bardia","route":"/people/aditya-bardia/","asOf":"2026-09-10","days":18},{"id":"lajos-pusztai","kind":"person","name":"Lajos Pusztai","route":"/people/lajos-pusztai/","asOf":"2026-09-10","days":18},{"id":"elizabeth-mittendorf","kind":"person","name":"Elizabeth A. Mittendorf","route":"/people/elizabeth-mittendorf/","asOf":"2026-09-10","days":18},{"id":"monica-morrow","kind":"person","name":"Monica Morrow","route":"/people/monica-morrow/","asOf":"2026-09-10","days":18},{"id":"armando-giuliano","kind":"person","name":"Armando E. Giuliano","route":"/people/armando-giuliano/","asOf":"2026-09-10","days":18},{"id":"roy-herbst","kind":"person","name":"Roy S. Herbst","route":"/people/roy-herbst/","asOf":"2026-09-10","days":18},{"id":"martin-reck","kind":"person","name":"Martin Reck","route":"/people/martin-reck/","asOf":"2026-09-10","days":18},{"id":"scott-antonia","kind":"person","name":"Scott J. Antonia","route":"/people/scott-antonia/","asOf":"2026-09-10","days":18},{"id":"charles-rudin","kind":"person","name":"Charles M. Rudin","route":"/people/charles-rudin/","asOf":"2026-09-10","days":18},{"id":"ross-camidge","kind":"person","name":"D. Ross Camidge","route":"/people/ross-camidge/","asOf":"2026-09-10","days":18},{"id":"ferdinandos-skoulidis","kind":"person","name":"Ferdinandos Skoulidis","route":"/people/ferdinandos-skoulidis/","asOf":"2026-09-10","days":18},{"id":"tina-cascone","kind":"person","name":"Tina Cascone","route":"/people/tina-cascone/","asOf":"2026-09-10","days":18},{"id":"qing-zhou","kind":"person","name":"Qing Zhou","route":"/people/qing-zhou/","asOf":"2026-09-10","days":18},{"id":"jonathan-spicer","kind":"person","name":"Jonathan Spicer","route":"/people/jonathan-spicer/","asOf":"2026-09-10","days":18},{"id":"harry-de-koning","kind":"person","name":"Harry J. de Koning","route":"/people/harry-de-koning/","asOf":"2026-09-10","days":18},{"id":"denise-aberle","kind":"person","name":"Denise R. Aberle","route":"/people/denise-aberle/","asOf":"2026-09-10","days":18},{"id":"robert-timmerman","kind":"person","name":"Robert D. Timmerman","route":"/people/robert-timmerman/","asOf":"2026-09-10","days":18},{"id":"joe-chang","kind":"person","name":"Joe Y. Chang","route":"/people/joe-chang/","asOf":"2026-09-10","days":18},{"id":"david-palma","kind":"person","name":"David A. Palma","route":"/people/david-palma/","asOf":"2026-09-10","days":18},{"id":"jeffrey-bradley","kind":"person","name":"Jeffrey D. Bradley","route":"/people/jeffrey-bradley/","asOf":"2026-09-10","days":18},{"id":"corinne-faivre-finn","kind":"person","name":"Corinne Faivre-Finn","route":"/people/corinne-faivre-finn/","asOf":"2026-09-10","days":18},{"id":"thierry-andre","kind":"person","name":"Thierry André","route":"/people/thierry-andre/","asOf":"2026-09-10","days":18},{"id":"scott-kopetz","kind":"person","name":"Scott Kopetz","route":"/people/scott-kopetz/","asOf":"2026-09-10","days":18},{"id":"eric-van-cutsem","kind":"person","name":"Eric Van Cutsem","route":"/people/eric-van-cutsem/","asOf":"2026-09-10","days":18},{"id":"heinz-josef-lenz","kind":"person","name":"Heinz-Josef Lenz","route":"/people/heinz-josef-lenz/","asOf":"2026-09-10","days":18},{"id":"jeanne-tie","kind":"person","name":"Jeanne Tie","route":"/people/jeanne-tie/","asOf":"2026-09-10","days":18},{"id":"julio-garcia-aguilar","kind":"person","name":"Julio Garcia-Aguilar","route":"/people/julio-garcia-aguilar/","asOf":"2026-09-10","days":18},{"id":"angelita-habr-gama","kind":"person","name":"Angelita Habr-Gama","route":"/people/angelita-habr-gama/","asOf":"2026-09-10","days":18},{"id":"michael-bretthauer","kind":"person","name":"Michael Bretthauer","route":"/people/michael-bretthauer/","asOf":"2026-09-10","days":18},{"id":"aimery-de-gramont","kind":"person","name":"Aimery de Gramont","route":"/people/aimery-de-gramont/","asOf":"2026-09-10","days":18},{"id":"thierry-conroy","kind":"person","name":"Thierry Conroy","route":"/people/thierry-conroy/","asOf":"2026-09-10","days":18},{"id":"daniel-von-hoff","kind":"person","name":"Daniel D. Von Hoff","route":"/people/daniel-von-hoff/","asOf":"2026-09-10","days":18},{"id":"vinod-balachandran","kind":"person","name":"Vinod P. Balachandran","route":"/people/vinod-balachandran/","asOf":"2026-09-10","days":18},{"id":"talia-golan","kind":"person","name":"Talia Golan","route":"/people/talia-golan/","asOf":"2026-09-10","days":18},{"id":"hedy-kindler","kind":"person","name":"Hedy L. Kindler","route":"/people/hedy-kindler/","asOf":"2026-09-10","days":18},{"id":"zev-wainberg","kind":"person","name":"Zev A. Wainberg","route":"/people/zev-wainberg/","asOf":"2026-09-10","days":18},{"id":"marc-besselink","kind":"person","name":"Marc G. Besselink","route":"/people/marc-besselink/","asOf":"2026-09-10","days":18},{"id":"jaffer-ajani","kind":"person","name":"Jaffer A. Ajani","route":"/people/jaffer-ajani/","asOf":"2026-09-10","days":18},{"id":"florian-lordick","kind":"person","name":"Florian Lordick","route":"/people/florian-lordick/","asOf":"2026-09-10","days":18},{"id":"jan-van-lanschot","kind":"person","name":"J. Jan B. van Lanschot","route":"/people/jan-van-lanschot/","asOf":"2026-09-10","days":18},{"id":"ronan-kelly","kind":"person","name":"Ronan J. Kelly","route":"/people/ronan-kelly/","asOf":"2026-09-10","days":18},{"id":"ken-kato","kind":"person","name":"Ken Kato","route":"/people/ken-kato/","asOf":"2026-09-10","days":18},{"id":"mitsuru-sasako","kind":"person","name":"Mitsuru Sasako","route":"/people/mitsuru-sasako/","asOf":"2026-09-10","days":18},{"id":"josep-llovet","kind":"person","name":"Josep M. Llovet","route":"/people/josep-llovet/","asOf":"2026-09-10","days":18},{"id":"ann-lii-cheng","kind":"person","name":"Ann-Lii Cheng","route":"/people/ann-lii-cheng/","asOf":"2026-09-10","days":18},{"id":"masatoshi-kudo","kind":"person","name":"Masatoshi Kudo","route":"/people/masatoshi-kudo/","asOf":"2026-09-10","days":18},{"id":"ghassan-abou-alfa","kind":"person","name":"Ghassan K. Abou-Alfa","route":"/people/ghassan-abou-alfa/","asOf":"2026-09-10","days":18},{"id":"juan-valle","kind":"person","name":"Juan W. Valle","route":"/people/juan-valle/","asOf":"2026-09-10","days":18},{"id":"lipika-goyal","kind":"person","name":"Lipika Goyal","route":"/people/lipika-goyal/","asOf":"2026-09-10","days":18},{"id":"christopher-sweeney","kind":"person","name":"Christopher J. Sweeney","route":"/people/christopher-sweeney/","asOf":"2026-09-10","days":18},{"id":"oliver-sartor","kind":"person","name":"A. Oliver Sartor","route":"/people/oliver-sartor/","asOf":"2026-09-10","days":18},{"id":"matthew-smith","kind":"person","name":"Matthew R. Smith","route":"/people/matthew-smith/","asOf":"2026-09-10","days":18},{"id":"kim-chi","kind":"person","name":"Kim N. Chi","route":"/people/kim-chi/","asOf":"2026-09-10","days":18},{"id":"maha-hussain","kind":"person","name":"Maha Hussain","route":"/people/maha-hussain/","asOf":"2026-09-10","days":18},{"id":"andrew-armstrong","kind":"person","name":"Andrew J. Armstrong","route":"/people/andrew-armstrong/","asOf":"2026-09-10","days":18},{"id":"freddie-hamdy","kind":"person","name":"Freddie C. Hamdy","route":"/people/freddie-hamdy/","asOf":"2026-09-10","days":18},{"id":"mark-emberton","kind":"person","name":"Mark Emberton","route":"/people/mark-emberton/","asOf":"2026-09-10","days":18},{"id":"hashim-ahmed","kind":"person","name":"Hashim U. Ahmed","route":"/people/hashim-ahmed/","asOf":"2026-09-10","days":18},{"id":"anthony-damico","kind":"person","name":"Anthony V. D'Amico","route":"/people/anthony-damico/","asOf":"2026-09-10","days":18},{"id":"louise-emmett","kind":"person","name":"Louise Emmett","route":"/people/louise-emmett/","asOf":"2026-09-10","days":18},{"id":"declan-murphy","kind":"person","name":"Declan G. Murphy","route":"/people/declan-murphy/","asOf":"2026-09-10","days":18},{"id":"daniel-spratt","kind":"person","name":"Daniel E. Spratt","route":"/people/daniel-spratt/","asOf":"2026-09-10","days":18},{"id":"silke-gillessen","kind":"person","name":"Silke Gillessen","route":"/people/silke-gillessen/","asOf":"2026-09-10","days":18},{"id":"thomas-powles","kind":"person","name":"Thomas Powles","route":"/people/thomas-powles/","asOf":"2026-09-10","days":18},{"id":"jonathan-rosenberg","kind":"person","name":"Jonathan E. Rosenberg","route":"/people/jonathan-rosenberg/","asOf":"2026-09-10","days":18},{"id":"dean-bajorin","kind":"person","name":"Dean F. Bajorin","route":"/people/dean-bajorin/","asOf":"2026-09-10","days":18},{"id":"joaquim-bellmunt","kind":"person","name":"Joaquim Bellmunt","route":"/people/joaquim-bellmunt/","asOf":"2026-09-10","days":18},{"id":"arjun-balar","kind":"person","name":"Arjun V. Balar","route":"/people/arjun-balar/","asOf":"2026-09-10","days":18},{"id":"ashish-kamat","kind":"person","name":"Ashish M. Kamat","route":"/people/ashish-kamat/","asOf":"2026-09-10","days":18},{"id":"andrea-necchi","kind":"person","name":"Andrea Necchi","route":"/people/andrea-necchi/","asOf":"2026-09-10","days":18},{"id":"robert-motzer","kind":"person","name":"Robert J. Motzer","route":"/people/robert-motzer/","asOf":"2026-09-10","days":18},{"id":"brian-rini","kind":"person","name":"Brian I. Rini","route":"/people/brian-rini/","asOf":"2026-09-10","days":18},{"id":"laurence-albiges","kind":"person","name":"Laurence Albiges","route":"/people/laurence-albiges/","asOf":"2026-09-10","days":18},{"id":"sumanta-pal","kind":"person","name":"Sumanta K. Pal","route":"/people/sumanta-pal/","asOf":"2026-09-10","days":18},{"id":"arnaud-mejean","kind":"person","name":"Arnaud Méjean","route":"/people/arnaud-mejean/","asOf":"2026-09-10","days":18},{"id":"kathleen-moore","kind":"person","name":"Kathleen N. Moore","route":"/people/kathleen-moore/","asOf":"2026-09-10","days":18},{"id":"isabelle-ray-coquard","kind":"person","name":"Isabelle Ray-Coquard","route":"/people/isabelle-ray-coquard/","asOf":"2026-09-10","days":18},{"id":"jonathan-ledermann","kind":"person","name":"Jonathan A. Ledermann","route":"/people/jonathan-ledermann/","asOf":"2026-09-10","days":18},{"id":"robert-coleman","kind":"person","name":"Robert L. Coleman","route":"/people/robert-coleman/","asOf":"2026-09-10","days":18},{"id":"andreas-du-bois","kind":"person","name":"Andreas du Bois","route":"/people/andreas-du-bois/","asOf":"2026-09-10","days":18},{"id":"willemien-van-driel","kind":"person","name":"Willemien J. van Driel","route":"/people/willemien-van-driel/","asOf":"2026-09-10","days":18},{"id":"ignace-vergote","kind":"person","name":"Ignace Vergote","route":"/people/ignace-vergote/","asOf":"2026-09-10","days":18},{"id":"usha-menon","kind":"person","name":"Usha Menon","route":"/people/usha-menon/","asOf":"2026-09-10","days":18},{"id":"mansoor-raza-mirza","kind":"person","name":"Mansoor Raza Mirza","route":"/people/mansoor-raza-mirza/","asOf":"2026-09-10","days":18},{"id":"ramez-eskander","kind":"person","name":"Ramez N. Eskander","route":"/people/ramez-eskander/","asOf":"2026-09-10","days":18},{"id":"carien-creutzberg","kind":"person","name":"Carien L. Creutzberg","route":"/people/carien-creutzberg/","asOf":"2026-09-10","days":18},{"id":"douglas-levine","kind":"person","name":"Douglas A. Levine","route":"/people/douglas-levine/","asOf":"2026-09-10","days":18},{"id":"domenica-lorusso","kind":"person","name":"Domenica Lorusso","route":"/people/domenica-lorusso/","asOf":"2026-09-10","days":18},{"id":"nicoletta-colombo","kind":"person","name":"Nicoletta Colombo","route":"/people/nicoletta-colombo/","asOf":"2026-09-10","days":18},{"id":"bradley-monk","kind":"person","name":"Bradley J. Monk","route":"/people/bradley-monk/","asOf":"2026-09-10","days":18},{"id":"pedro-ramirez","kind":"person","name":"Pedro T. Ramirez","route":"/people/pedro-ramirez/","asOf":"2026-09-10","days":18},{"id":"mary-mccormack","kind":"person","name":"Mary McCormack","route":"/people/mary-mccormack/","asOf":"2026-09-10","days":18},{"id":"linda-mileshkin","kind":"person","name":"Linda Mileshkin","route":"/people/linda-mileshkin/","asOf":"2026-09-10","days":18},{"id":"georgina-long","kind":"person","name":"Georgina V. Long","route":"/people/georgina-long/","asOf":"2026-09-10","days":18},{"id":"jedd-wolchok","kind":"person","name":"Jedd D. Wolchok","route":"/people/jedd-wolchok/","asOf":"2026-09-10","days":18},{"id":"caroline-robert","kind":"person","name":"Caroline Robert","route":"/people/caroline-robert/","asOf":"2026-09-10","days":18},{"id":"hussein-tawbi","kind":"person","name":"Hussein A. Tawbi","route":"/people/hussein-tawbi/","asOf":"2026-09-10","days":18},{"id":"paolo-ascierto","kind":"person","name":"Paolo A. Ascierto","route":"/people/paolo-ascierto/","asOf":"2026-09-10","days":18},{"id":"michael-postow","kind":"person","name":"Michael A. Postow","route":"/people/michael-postow/","asOf":"2026-09-10","days":18},{"id":"jeffrey-weber","kind":"person","name":"Jeffrey S. Weber","route":"/people/jeffrey-weber/","asOf":"2026-09-10","days":18},{"id":"sapna-patel","kind":"person","name":"Sapna P. Patel","route":"/people/sapna-patel/","asOf":"2026-09-10","days":18},{"id":"jason-luke","kind":"person","name":"Jason J. Luke","route":"/people/jason-luke/","asOf":"2026-09-10","days":18},{"id":"mark-faries","kind":"person","name":"Mark B. Faries","route":"/people/mark-faries/","asOf":"2026-09-10","days":18},{"id":"reinhard-dummer","kind":"person","name":"Reinhard Dummer","route":"/people/reinhard-dummer/","asOf":"2026-09-10","days":18},{"id":"paul-nathan","kind":"person","name":"Paul Nathan","route":"/people/paul-nathan/","asOf":"2026-09-10","days":18},{"id":"richard-carvajal","kind":"person","name":"Richard D. Carvajal","route":"/people/richard-carvajal/","asOf":"2026-09-10","days":18},{"id":"jennifer-wargo","kind":"person","name":"Jennifer A. Wargo","route":"/people/jennifer-wargo/","asOf":"2026-09-10","days":18},{"id":"ingo-mellinghoff","kind":"person","name":"Ingo K. Mellinghoff","route":"/people/ingo-mellinghoff/","asOf":"2026-09-10","days":18},{"id":"patrick-wen","kind":"person","name":"Patrick Y. Wen","route":"/people/patrick-wen/","asOf":"2026-09-10","days":18},{"id":"martin-van-den-bent","kind":"person","name":"Martin J. van den Bent","route":"/people/martin-van-den-bent/","asOf":"2026-09-10","days":18},{"id":"monika-hegi","kind":"person","name":"Monika E. Hegi","route":"/people/monika-hegi/","asOf":"2026-09-10","days":18},{"id":"mitchel-berger","kind":"person","name":"Mitchel S. Berger","route":"/people/mitchel-berger/","asOf":"2026-09-10","days":18},{"id":"timothy-cloughesy","kind":"person","name":"Timothy F. Cloughesy","route":"/people/timothy-cloughesy/","asOf":"2026-09-10","days":18},{"id":"michelle-monje","kind":"person","name":"Michelle Monje","route":"/people/michelle-monje/","asOf":"2026-09-10","days":18},{"id":"michael-taylor","kind":"person","name":"Michael D. Taylor","route":"/people/michael-taylor/","asOf":"2026-09-10","days":18},{"id":"barbara-burtness","kind":"person","name":"Barbara Burtness","route":"/people/barbara-burtness/","asOf":"2026-09-10","days":18},{"id":"jan-vermorken","kind":"person","name":"Jan B. Vermorken","route":"/people/jan-vermorken/","asOf":"2026-09-10","days":18},{"id":"maura-gillison","kind":"person","name":"Maura L. Gillison","route":"/people/maura-gillison/","asOf":"2026-09-10","days":18},{"id":"hisham-mehanna","kind":"person","name":"Hisham Mehanna","route":"/people/hisham-mehanna/","asOf":"2026-09-10","days":18},{"id":"ezra-cohen","kind":"person","name":"Ezra E. W. Cohen","route":"/people/ezra-cohen/","asOf":"2026-09-10","days":18},{"id":"ravindra-uppaluri","kind":"person","name":"Ravindra Uppaluri","route":"/people/ravindra-uppaluri/","asOf":"2026-09-10","days":18},{"id":"jean-bourhis","kind":"person","name":"Jean Bourhis","route":"/people/jean-bourhis/","asOf":"2026-09-10","days":18},{"id":"george-demetri","kind":"person","name":"George D. Demetri","route":"/people/george-demetri/","asOf":"2026-09-10","days":18},{"id":"william-tap","kind":"person","name":"William D. Tap","route":"/people/william-tap/","asOf":"2026-09-10","days":18},{"id":"sandra-dangelo","kind":"person","name":"Sandra P. D'Angelo","route":"/people/sandra-dangelo/","asOf":"2026-09-10","days":18},{"id":"winette-van-der-graaf","kind":"person","name":"Winette T. A. van der Graaf","route":"/people/winette-van-der-graaf/","asOf":"2026-09-10","days":18},{"id":"silvia-stacchiotti","kind":"person","name":"Silvia Stacchiotti","route":"/people/silvia-stacchiotti/","asOf":"2026-09-10","days":18},{"id":"stefan-bielack","kind":"person","name":"Stefan S. Bielack","route":"/people/stefan-bielack/","asOf":"2026-09-10","days":18},{"id":"lori-wirth","kind":"person","name":"Lori J. Wirth","route":"/people/lori-wirth/","asOf":"2026-09-10","days":18},{"id":"martin-schlumberger","kind":"person","name":"Martin Schlumberger","route":"/people/martin-schlumberger/","asOf":"2026-09-10","days":18},{"id":"marcia-brose","kind":"person","name":"Marcia S. Brose","route":"/people/marcia-brose/","asOf":"2026-09-10","days":18},{"id":"maria-cabanillas","kind":"person","name":"Maria E. Cabanillas","route":"/people/maria-cabanillas/","asOf":"2026-09-10","days":18},{"id":"jonathan-strosberg","kind":"person","name":"Jonathan R. Strosberg","route":"/people/jonathan-strosberg/","asOf":"2026-09-10","days":18},{"id":"simron-singh","kind":"person","name":"Simron Singh","route":"/people/simron-singh/","asOf":"2026-09-10","days":18},{"id":"martyn-caplin","kind":"person","name":"Martyn E. Caplin","route":"/people/martyn-caplin/","asOf":"2026-09-10","days":18},{"id":"james-yao","kind":"person","name":"James C. Yao","route":"/people/james-yao/","asOf":"2026-09-10","days":18},{"id":"paul-baas","kind":"person","name":"Paul Baas","route":"/people/paul-baas/","asOf":"2026-09-10","days":18},{"id":"dean-fennell","kind":"person","name":"Dean A. Fennell","route":"/people/dean-fennell/","asOf":"2026-09-10","days":18},{"id":"anna-nowak","kind":"person","name":"Anna K. Nowak","route":"/people/anna-nowak/","asOf":"2026-09-10","days":18},{"id":"ruth-ladenstein","kind":"person","name":"Ruth Ladenstein","route":"/people/ruth-ladenstein/","asOf":"2026-09-10","days":18},{"id":"john-maris","kind":"person","name":"John M. Maris","route":"/people/john-maris/","asOf":"2026-09-10","days":18},{"id":"yael-mosse","kind":"person","name":"Yael P. Mossé","route":"/people/yael-mosse/","asOf":"2026-09-10","days":18},{"id":"nai-kong-cheung","kind":"person","name":"Nai-Kong V. Cheung","route":"/people/nai-kong-cheung/","asOf":"2026-09-10","days":18},{"id":"stephen-hunger","kind":"person","name":"Stephen P. Hunger","route":"/people/stephen-hunger/","asOf":"2026-09-10","days":18},{"id":"ching-hon-pui","kind":"person","name":"Ching-Hon Pui","route":"/people/ching-hon-pui/","asOf":"2026-09-10","days":18},{"id":"sumit-gupta","kind":"person","name":"Sumit Gupta","route":"/people/sumit-gupta/","asOf":"2026-09-10","days":18},{"id":"jeffrey-dome","kind":"person","name":"Jeffrey S. Dome","route":"/people/jeffrey-dome/","asOf":"2026-09-10","days":18},{"id":"amar-gajjar","kind":"person","name":"Amar Gajjar","route":"/people/amar-gajjar/","asOf":"2026-09-10","days":18},{"id":"courtney-dinardo","kind":"person","name":"Courtney D. DiNardo","route":"/people/courtney-dinardo/","asOf":"2026-09-10","days":18},{"id":"richard-stone","kind":"person","name":"Richard M. Stone","route":"/people/richard-stone/","asOf":"2026-09-10","days":18},{"id":"alexander-perl","kind":"person","name":"Alexander E. Perl","route":"/people/alexander-perl/","asOf":"2026-09-10","days":18},{"id":"hartmut-dohner","kind":"person","name":"Hartmut Döhner","route":"/people/hartmut-dohner/","asOf":"2026-09-10","days":18},{"id":"eytan-stein","kind":"person","name":"Eytan M. Stein","route":"/people/eytan-stein/","asOf":"2026-09-10","days":18},{"id":"ghayas-issa","kind":"person","name":"Ghayas C. Issa","route":"/people/ghayas-issa/","asOf":"2026-09-10","days":18},{"id":"andrew-wei","kind":"person","name":"Andrew H. Wei","route":"/people/andrew-wei/","asOf":"2026-09-10","days":18},{"id":"uwe-platzbecker","kind":"person","name":"Uwe Platzbecker","route":"/people/uwe-platzbecker/","asOf":"2026-09-10","days":18},{"id":"pierre-fenaux","kind":"person","name":"Pierre Fenaux","route":"/people/pierre-fenaux/","asOf":"2026-09-10","days":18},{"id":"claire-harrison","kind":"person","name":"Claire Harrison","route":"/people/claire-harrison/","asOf":"2026-09-10","days":18},{"id":"timothy-hughes","kind":"person","name":"Timothy P. Hughes","route":"/people/timothy-hughes/","asOf":"2026-09-10","days":18},{"id":"elias-jabbour","kind":"person","name":"Elias Jabbour","route":"/people/elias-jabbour/","asOf":"2026-09-10","days":18},{"id":"nicola-gokbuget","kind":"person","name":"Nicola Gökbuget","route":"/people/nicola-gokbuget/","asOf":"2026-09-10","days":18},{"id":"gilles-salles","kind":"person","name":"Gilles Salles","route":"/people/gilles-salles/","asOf":"2026-09-10","days":18},{"id":"herve-tilly","kind":"person","name":"Hervé Tilly","route":"/people/herve-tilly/","asOf":"2026-09-10","days":18},{"id":"laurie-sehn","kind":"person","name":"Laurie H. Sehn","route":"/people/laurie-sehn/","asOf":"2026-09-10","days":18},{"id":"sattva-neelapu","kind":"person","name":"Sattva S. Neelapu","route":"/people/sattva-neelapu/","asOf":"2026-09-10","days":18},{"id":"stephen-schuster","kind":"person","name":"Stephen J. Schuster","route":"/people/stephen-schuster/","asOf":"2026-09-10","days":18},{"id":"jason-westin","kind":"person","name":"Jason R. Westin","route":"/people/jason-westin/","asOf":"2026-09-10","days":18},{"id":"michael-dickinson","kind":"person","name":"Michael Dickinson","route":"/people/michael-dickinson/","asOf":"2026-09-10","days":18},{"id":"catherine-thieblemont","kind":"person","name":"Catherine Thieblemont","route":"/people/catherine-thieblemont/","asOf":"2026-09-10","days":18},{"id":"michael-wang","kind":"person","name":"Michael L. Wang","route":"/people/michael-wang/","asOf":"2026-09-10","days":18},{"id":"martin-dreyling","kind":"person","name":"Martin Dreyling","route":"/people/martin-dreyling/","asOf":"2026-09-10","days":18},{"id":"joseph-connors","kind":"person","name":"Joseph M. Connors","route":"/people/joseph-connors/","asOf":"2026-09-10","days":18},{"id":"peter-borchmann","kind":"person","name":"Peter Borchmann","route":"/people/peter-borchmann/","asOf":"2026-09-10","days":18},{"id":"andreas-engert","kind":"person","name":"Andreas Engert","route":"/people/andreas-engert/","asOf":"2026-09-10","days":18},{"id":"kara-kelly","kind":"person","name":"Kara M. Kelly","route":"/people/kara-kelly/","asOf":"2026-09-10","days":18},{"id":"wyndham-wilson","kind":"person","name":"Wyndham H. Wilson","route":"/people/wyndham-wilson/","asOf":"2026-09-10","days":18},{"id":"steven-treon","kind":"person","name":"Steven P. Treon","route":"/people/steven-treon/","asOf":"2026-09-10","days":18},{"id":"steven-horwitz","kind":"person","name":"Steven M. Horwitz","route":"/people/steven-horwitz/","asOf":"2026-09-10","days":18},{"id":"andres-ferreri","kind":"person","name":"Andrés J. M. Ferreri","route":"/people/andres-ferreri/","asOf":"2026-09-10","days":18},{"id":"john-byrd","kind":"person","name":"John C. Byrd","route":"/people/john-byrd/","asOf":"2026-09-10","days":18},{"id":"jennifer-woyach","kind":"person","name":"Jennifer A. Woyach","route":"/people/jennifer-woyach/","asOf":"2026-09-10","days":18},{"id":"jennifer-brown","kind":"person","name":"Jennifer R. Brown","route":"/people/jennifer-brown/","asOf":"2026-09-10","days":18},{"id":"kirsten-fischer","kind":"person","name":"Kirsten Fischer","route":"/people/kirsten-fischer/","asOf":"2026-09-10","days":18},{"id":"barbara-eichhorst","kind":"person","name":"Barbara Eichhorst","route":"/people/barbara-eichhorst/","asOf":"2026-09-10","days":18},{"id":"peter-hillmen","kind":"person","name":"Peter Hillmen","route":"/people/peter-hillmen/","asOf":"2026-09-10","days":18},{"id":"john-seymour","kind":"person","name":"John F. Seymour","route":"/people/john-seymour/","asOf":"2026-09-10","days":18},{"id":"william-wierda","kind":"person","name":"William G. Wierda","route":"/people/william-wierda/","asOf":"2026-09-10","days":18},{"id":"constantine-tam","kind":"person","name":"Constantine S. Tam","route":"/people/constantine-tam/","asOf":"2026-09-10","days":18},{"id":"philippe-moreau","kind":"person","name":"Philippe Moreau","route":"/people/philippe-moreau/","asOf":"2026-09-10","days":18},{"id":"thierry-facon","kind":"person","name":"Thierry Facon","route":"/people/thierry-facon/","asOf":"2026-09-10","days":18},{"id":"pieter-sonneveld","kind":"person","name":"Pieter Sonneveld","route":"/people/pieter-sonneveld/","asOf":"2026-09-10","days":18},{"id":"maria-victoria-mateos","kind":"person","name":"María-Victoria Mateos","route":"/people/maria-victoria-mateos/","asOf":"2026-09-10","days":18},{"id":"nikhil-munshi","kind":"person","name":"Nikhil C. Munshi","route":"/people/nikhil-munshi/","asOf":"2026-09-10","days":18},{"id":"jesus-berdeja","kind":"person","name":"Jesús G. Berdeja","route":"/people/jesus-berdeja/","asOf":"2026-09-10","days":18},{"id":"sagar-lonial","kind":"person","name":"Sagar Lonial","route":"/people/sagar-lonial/","asOf":"2026-09-10","days":18},{"id":"noopur-raje","kind":"person","name":"Noopur Raje","route":"/people/noopur-raje/","asOf":"2026-09-10","days":18},{"id":"ajai-chari","kind":"person","name":"Ajai Chari","route":"/people/ajai-chari/","asOf":"2026-09-10","days":18},{"id":"ola-landgren","kind":"person","name":"C. Ola Landgren","route":"/people/ola-landgren/","asOf":"2026-09-10","days":18},{"id":"sigurdur-kristinsson","kind":"person","name":"Sigurdur Y. Kristinsson","route":"/people/sigurdur-kristinsson/","asOf":"2026-09-10","days":18},{"id":"graham-jackson","kind":"person","name":"Graham H. Jackson","route":"/people/graham-jackson/","asOf":"2026-09-10","days":18},{"id":"meletios-dimopoulos","kind":"person","name":"Meletios A. Dimopoulos","route":"/people/meletios-dimopoulos/","asOf":"2026-09-10","days":18},{"id":"michel-sadelain","kind":"person","name":"Michel Sadelain","route":"/people/michel-sadelain/","asOf":"2026-09-10","days":18},{"id":"stephan-grupp","kind":"person","name":"Stephan A. Grupp","route":"/people/stephan-grupp/","asOf":"2026-09-10","days":18},{"id":"marcela-maus","kind":"person","name":"Marcela V. Maus","route":"/people/marcela-maus/","asOf":"2026-09-10","days":18},{"id":"waseem-qasim","kind":"person","name":"Waseem Qasim","route":"/people/waseem-qasim/","asOf":"2026-09-10","days":18},{"id":"katy-rezvani","kind":"person","name":"Katayoun Rezvani","route":"/people/katy-rezvani/","asOf":"2026-09-10","days":18},{"id":"inge-marie-svane","kind":"person","name":"Inge Marie Svane","route":"/people/inge-marie-svane/","asOf":"2026-09-10","days":18},{"id":"robbie-majzner","kind":"person","name":"Robbie G. Majzner","route":"/people/robbie-majzner/","asOf":"2026-09-10","days":18},{"id":"ken-herrmann","kind":"person","name":"Ken Herrmann","route":"/people/ken-herrmann/","asOf":"2026-09-10","days":18},{"id":"wolfgang-weber","kind":"person","name":"Wolfgang A. Weber","route":"/people/wolfgang-weber/","asOf":"2026-09-10","days":18},{"id":"jason-lewis","kind":"person","name":"Jason S. Lewis","route":"/people/jason-lewis/","asOf":"2026-09-10","days":18},{"id":"lieping-chen","kind":"person","name":"Lieping Chen","route":"/people/lieping-chen/","asOf":"2026-09-10","days":18},{"id":"gordon-freeman","kind":"person","name":"Gordon J. Freeman","route":"/people/gordon-freeman/","asOf":"2026-09-10","days":18},{"id":"thomas-gajewski","kind":"person","name":"Thomas F. Gajewski","route":"/people/thomas-gajewski/","asOf":"2026-09-10","days":18},{"id":"shimon-sakaguchi","kind":"person","name":"Shimon Sakaguchi","route":"/people/shimon-sakaguchi/","asOf":"2026-09-10","days":18},{"id":"ugur-sahin","kind":"person","name":"Uğur Şahin","route":"/people/ugur-sahin/","asOf":"2026-09-10","days":18},{"id":"catherine-wu","kind":"person","name":"Catherine J. Wu","route":"/people/catherine-wu/","asOf":"2026-09-10","days":18},{"id":"howard-kaufman","kind":"person","name":"Howard L. Kaufman","route":"/people/howard-kaufman/","asOf":"2026-09-10","days":18},{"id":"ignacio-melero","kind":"person","name":"Ignacio Melero","route":"/people/ignacio-melero/","asOf":"2026-09-10","days":18},{"id":"michael-berger","kind":"person","name":"Michael F. Berger","route":"/people/michael-berger/","asOf":"2026-09-10","days":18},{"id":"serena-nik-zainal","kind":"person","name":"Serena Nik-Zainal","route":"/people/serena-nik-zainal/","asOf":"2026-09-10","days":18},{"id":"ludmil-alexandrov","kind":"person","name":"Ludmil B. Alexandrov","route":"/people/ludmil-alexandrov/","asOf":"2026-09-10","days":18},{"id":"carlos-caldas","kind":"person","name":"Carlos Caldas","route":"/people/carlos-caldas/","asOf":"2026-09-10","days":18},{"id":"christina-curtis","kind":"person","name":"Christina Curtis","route":"/people/christina-curtis/","asOf":"2026-09-10","days":18},{"id":"nickolas-papadopoulos","kind":"person","name":"Nickolas Papadopoulos","route":"/people/nickolas-papadopoulos/","asOf":"2026-09-10","days":18},{"id":"alberto-bardelli","kind":"person","name":"Alberto Bardelli","route":"/people/alberto-bardelli/","asOf":"2026-09-10","days":18},{"id":"nitzan-rosenfeld","kind":"person","name":"Nitzan Rosenfeld","route":"/people/nitzan-rosenfeld/","asOf":"2026-09-10","days":18},{"id":"viktor-adalsteinsson","kind":"person","name":"Viktor A. Adalsteinsson","route":"/people/viktor-adalsteinsson/","asOf":"2026-09-10","days":18},{"id":"thomas-helleday","kind":"person","name":"Thomas Helleday","route":"/people/thomas-helleday/","asOf":"2026-09-10","days":18},{"id":"alan-dandrea","kind":"person","name":"Alan D. D'Andrea","route":"/people/alan-dandrea/","asOf":"2026-09-10","days":18},{"id":"razelle-kurzrock","kind":"person","name":"Razelle Kurzrock","route":"/people/razelle-kurzrock/","asOf":"2026-09-10","days":18},{"id":"charlotte-coles","kind":"person","name":"Charlotte E. Coles","route":"/people/charlotte-coles/","asOf":"2026-09-10","days":18},{"id":"murray-brunt","kind":"person","name":"A. Murray Brunt","route":"/people/murray-brunt/","asOf":"2026-09-10","days":18},{"id":"timothy-whelan","kind":"person","name":"Timothy J. Whelan","route":"/people/timothy-whelan/","asOf":"2026-09-10","days":18},{"id":"marie-catherine-vozenin","kind":"person","name":"Marie-Catherine Vozenin","route":"/people/marie-catherine-vozenin/","asOf":"2026-09-10","days":18},{"id":"bas-raaymakers","kind":"person","name":"Bas W. Raaymakers","route":"/people/bas-raaymakers/","asOf":"2026-09-10","days":18},{"id":"anthony-zietman","kind":"person","name":"Anthony L. Zietman","route":"/people/anthony-zietman/","asOf":"2026-09-10","days":18},{"id":"quynh-thu-le","kind":"person","name":"Quynh-Thu Le","route":"/people/quynh-thu-le/","asOf":"2026-09-10","days":18},{"id":"shankar-siva","kind":"person","name":"Shankar Siva","route":"/people/shankar-siva/","asOf":"2026-09-10","days":18},{"id":"cornelis-van-de-velde","kind":"person","name":"Cornelis J. H. van de Velde","route":"/people/cornelis-van-de-velde/","asOf":"2026-09-10","days":18},{"id":"yuman-fong","kind":"person","name":"Yuman Fong","route":"/people/yuman-fong/","asOf":"2026-09-10","days":18},{"id":"valerie-rusch","kind":"person","name":"Valerie W. Rusch","route":"/people/valerie-rusch/","asOf":"2026-09-10","days":18},{"id":"rebecca-fitzgerald","kind":"person","name":"Rebecca C. Fitzgerald","route":"/people/rebecca-fitzgerald/","asOf":"2026-09-10","days":18},{"id":"peter-sasieni","kind":"person","name":"Peter Sasieni","route":"/people/peter-sasieni/","asOf":"2026-09-10","days":18},{"id":"nubia-munoz","kind":"person","name":"Nubia Muñoz","route":"/people/nubia-munoz/","asOf":"2026-09-10","days":18},{"id":"mark-schiffman","kind":"person","name":"Mark Schiffman","route":"/people/mark-schiffman/","asOf":"2026-09-10","days":18},{"id":"kristina-lang","kind":"person","name":"Kristina Lång","route":"/people/kristina-lang/","asOf":"2026-09-10","days":18},{"id":"constance-lehman","kind":"person","name":"Constance D. Lehman","route":"/people/constance-lehman/","asOf":"2026-09-10","days":18},{"id":"eric-klein","kind":"person","name":"Eric A. Klein","route":"/people/eric-klein/","asOf":"2026-09-10","days":18},{"id":"deb-schrag","kind":"person","name":"Deborah Schrag","route":"/people/deb-schrag/","asOf":"2026-09-10","days":18},{"id":"faisal-mahmood","kind":"person","name":"Faisal Mahmood","route":"/people/faisal-mahmood/","asOf":"2026-09-10","days":18},{"id":"thomas-fuchs","kind":"person","name":"Thomas J. Fuchs","route":"/people/thomas-fuchs/","asOf":"2026-09-10","days":18},{"id":"jakob-nikolas-kather","kind":"person","name":"Jakob Nikolas Kather","route":"/people/jakob-nikolas-kather/","asOf":"2026-09-10","days":18},{"id":"regina-barzilay","kind":"person","name":"Regina Barzilay","route":"/people/regina-barzilay/","asOf":"2026-09-10","days":18},{"id":"jennifer-temel","kind":"person","name":"Jennifer S. Temel","route":"/people/jennifer-temel/","asOf":"2026-09-10","days":18},{"id":"ethan-basch","kind":"person","name":"Ethan Basch","route":"/people/ethan-basch/","asOf":"2026-09-10","days":18},{"id":"supriya-mohile","kind":"person","name":"Supriya G. Mohile","route":"/people/supriya-mohile/","asOf":"2026-09-10","days":18},{"id":"kerry-courneya","kind":"person","name":"Kerry S. Courneya","route":"/people/kerry-courneya/","asOf":"2026-09-10","days":18},{"id":"christopher-booth","kind":"person","name":"Christopher M. Booth","route":"/people/christopher-booth/","asOf":"2026-09-10","days":18},{"id":"ian-tannock","kind":"person","name":"Ian F. Tannock","route":"/people/ian-tannock/","asOf":"2026-09-10","days":18},{"id":"joseph-unger","kind":"person","name":"Joseph M. Unger","route":"/people/joseph-unger/","asOf":"2026-09-10","days":18},{"id":"richard-gray","kind":"person","name":"Richard Gray","route":"/people/richard-gray/","asOf":"2026-09-10","days":18},{"id":"richard-peto","kind":"person","name":"Sir Richard Peto","route":"/people/richard-peto/","asOf":"2026-09-10","days":18},{"id":"mahesh-parmar","kind":"person","name":"Mahesh K. B. Parmar","route":"/people/mahesh-parmar/","asOf":"2026-09-10","days":18},{"id":"judith-bliss","kind":"person","name":"Judith M. Bliss","route":"/people/judith-bliss/","asOf":"2026-09-10","days":18},{"id":"rolf-stahel","kind":"person","name":"Rolf A. Stahel","route":"/people/rolf-stahel/","asOf":"2026-09-10","days":18},{"id":"idea-cost-asp-flat-fee","kind":"idea","name":"Pay a flat fee for giving a Part B drug instead of 6% of its price","route":"/ideas/idea-cost-asp-flat-fee/","asOf":"2026-09-10","days":18},{"id":"idea-cost-site-neutral-infusion","kind":"idea","name":"Pay the same for an infusion whether it is given in a hospital or a clinic","route":"/ideas/idea-cost-site-neutral-infusion/","asOf":"2026-09-10","days":18},{"id":"idea-cost-340b-pass-through","kind":"idea","name":"Pass 340B discounts on cancer drugs through to the patient's bill","route":"/ideas/idea-cost-340b-pass-through/","asOf":"2026-09-10","days":18},{"id":"idea-cost-indication-based-pricing","kind":"idea","name":"Price a cancer drug by how well it works in each cancer","route":"/ideas/idea-cost-indication-based-pricing/","asOf":"2026-09-10","days":18},{"id":"idea-cost-inflation-rebates-commercial","kind":"idea","name":"Extend Medicare's inflation rebates to employer plans","route":"/ideas/idea-cost-inflation-rebates-commercial/","asOf":"2026-09-10","days":18},{"id":"idea-cost-part-b-cap","kind":"idea","name":"Cap what Original Medicare patients pay for Part B cancer drugs","route":"/ideas/idea-cost-part-b-cap/","asOf":"2026-09-10","days":18},{"id":"idea-cost-biosimilar-default-substitution","kind":"idea","name":"Make the biosimilar the default at the pharmacy for trastuzumab, bevacizumab and rituximab","route":"/ideas/idea-cost-biosimilar-default-substitution/","asOf":"2026-09-10","days":18},{"id":"idea-cost-interchangeable-oncology-biosimilars","kind":"idea","name":"Drop the extra switching studies for interchangeable oncology biosimilars","route":"/ideas/idea-cost-interchangeable-oncology-biosimilars/","asOf":"2026-09-10","days":18},{"id":"idea-cost-nonprofit-generic-oncology","kind":"idea","name":"A non-profit manufacturer for shortage-prone generic chemotherapy","route":"/ideas/idea-cost-nonprofit-generic-oncology/","asOf":"2026-09-10","days":18},{"id":"idea-cost-transparent-generic-pricing","kind":"idea","name":"Transparent cost-plus pricing for every oral oncology generic","route":"/ideas/idea-cost-transparent-generic-pricing/","asOf":"2026-09-10","days":18},{"id":"idea-cost-low-dose-abiraterone-food","kind":"idea","name":"Prescribe a quarter dose of abiraterone with breakfast","route":"/ideas/idea-cost-low-dose-abiraterone-food/","asOf":"2026-09-10","days":18},{"id":"idea-cost-low-dose-immunotherapy-trials","kind":"idea","name":"Test one-tenth-dose immunotherapy where the full dose is unaffordable","route":"/ideas/idea-cost-low-dose-immunotherapy-trials/","asOf":"2026-09-10","days":18},{"id":"idea-cost-optimus-legacy-drugs","kind":"idea","name":"Apply Project Optimus to drugs already on the market","route":"/ideas/idea-cost-optimus-legacy-drugs/","asOf":"2026-09-10","days":18},{"id":"idea-cost-extended-interval-default","kind":"idea","name":"Make six-weekly immunotherapy the default schedule","route":"/ideas/idea-cost-extended-interval-default/","asOf":"2026-09-10","days":18},{"id":"idea-cost-shorter-course-trials","kind":"idea","name":"Fund trials that test shorter courses of the most expensive adjuvant drugs","route":"/ideas/idea-cost-shorter-course-trials/","asOf":"2026-09-10","days":18},{"id":"idea-cost-hypofractionation-payment","kind":"idea","name":"Pay for a course of radiotherapy, not for each fraction","route":"/ideas/idea-cost-hypofractionation-payment/","asOf":"2026-09-10","days":18},{"id":"idea-cost-subcutaneous-community","kind":"idea","name":"Give subcutaneous immunotherapy in community clinics and at home","route":"/ideas/idea-cost-subcutaneous-community/","asOf":"2026-09-10","days":18},{"id":"idea-cost-vial-sharing-dose-rounding","kind":"idea","name":"Share vials and round doses to stop throwing away expensive drug","route":"/ideas/idea-cost-vial-sharing-dose-rounding/","asOf":"2026-09-10","days":18},{"id":"idea-cost-gold-card-oncology","kind":"idea","name":"Exempt oncologists who follow the pathway from prior authorisation","route":"/ideas/idea-cost-gold-card-oncology/","asOf":"2026-09-10","days":18},{"id":"idea-cost-real-time-pa-fhir","kind":"idea","name":"Answer prior authorisation requests in seconds from the medical record","route":"/ideas/idea-cost-real-time-pa-fhir/","asOf":"2026-09-10","days":18},{"id":"idea-cost-federal-oral-parity","kind":"idea","name":"Federal oral chemotherapy parity for self-funded employer plans","route":"/ideas/idea-cost-federal-oral-parity/","asOf":"2026-09-10","days":18},{"id":"idea-cost-financial-toxicity-screening","kind":"idea","name":"Screen every patient for money trouble the way we screen for pain","route":"/ideas/idea-cost-financial-toxicity-screening/","asOf":"2026-09-10","days":18},{"id":"idea-cost-travel-teleoncology","kind":"idea","name":"Bring the oncologist to the local clinic by video and the drug to the local pharmacy","route":"/ideas/idea-cost-travel-teleoncology/","asOf":"2026-09-10","days":18},{"id":"idea-cost-early-palliative-default","kind":"idea","name":"Make early palliative care and a goals conversation part of every advanced-cancer pathway","route":"/ideas/idea-cost-early-palliative-default/","asOf":"2026-09-10","days":18},{"id":"idea-cost-trial-enrolment-cost-lever","kind":"idea","name":"Treat trial enrolment as a cost lever: the sponsor pays for the drug","route":"/ideas/idea-cost-trial-enrolment-cost-lever/","asOf":"2026-09-10","days":18},{"id":"idea-cost-value-scale-in-coverage","kind":"idea","name":"Tie coverage and copays to the ESMO benefit scale","route":"/ideas/idea-cost-value-scale-in-coverage/","asOf":"2026-09-10","days":18},{"id":"idea-cost-managed-access-everywhere","kind":"idea","name":"Copy the Cancer Drugs Fund: pay for uncertain drugs while collecting the data","route":"/ideas/idea-cost-managed-access-everywhere/","asOf":"2026-09-10","days":18},{"id":"idea-cost-pooled-procurement-essential","kind":"idea","name":"Pool purchasing of essential cancer medicines across countries","route":"/ideas/idea-cost-pooled-procurement-essential/","asOf":"2026-09-10","days":18},{"id":"idea-cost-voluntary-licensing-oncology","kind":"idea","name":"Voluntary licences and price caps for patented cancer drugs in low-income countries","route":"/ideas/idea-cost-voluntary-licensing-oncology/","asOf":"2026-09-10","days":18},{"id":"yale-cancer-center","kind":"institution","name":"Yale Cancer Center / Smilow Cancer Hospital","route":"/institutions/yale-cancer-center/","asOf":"2026-09-10","days":18},{"id":"az-groeninge-kortrijk","kind":"institution","name":"AZ Groeninge Kortrijk Cancer Centre","route":"/institutions/az-groeninge-kortrijk/","asOf":"2026-09-10","days":18},{"id":"vejle-cancer-centre","kind":"institution","name":"Vejle Hospital Cancer Centre (Lillebaelt Hospital)","route":"/institutions/vejle-cancer-centre/","asOf":"2026-09-10","days":18},{"id":"tartu-university-hospital","kind":"institution","name":"Tartu University Hospital","route":"/institutions/tartu-university-hospital/","asOf":"2026-09-10","days":18},{"id":"kuopio-university-hospital","kind":"institution","name":"Kuopio University Hospital Cancer Center","route":"/institutions/kuopio-university-hospital/","asOf":"2026-09-10","days":18},{"id":"turku-university-hospital","kind":"institution","name":"Turku University Hospital Cancer Centre","route":"/institutions/turku-university-hospital/","asOf":"2026-09-10","days":18},{"id":"tays-cancer-centre","kind":"institution","name":"Tays Cancer Centre, Tampere University Hospital","route":"/institutions/tays-cancer-centre/","asOf":"2026-09-10","days":18},{"id":"linkoping-university-hospital","kind":"institution","name":"Linköping University Hospital Cancer Center","route":"/institutions/linkoping-university-hospital/","asOf":"2026-09-10","days":18},{"id":"riga-east-university-hospital","kind":"institution","name":"Riga East University Hospital / Oncology Centre of Latvia","route":"/institutions/riga-east-university-hospital/","asOf":"2026-09-10","days":18},{"id":"nci-vilnius","kind":"institution","name":"National Cancer Institute, Lithuania","route":"/institutions/nci-vilnius/","asOf":"2026-09-10","days":18},{"id":"icm-montpellier","kind":"institution","name":"Institut du Cancer de Montpellier (ICM)","route":"/institutions/icm-montpellier/","asOf":"2026-09-10","days":18},{"id":"centre-jean-perrin","kind":"institution","name":"Centre Jean Perrin","route":"/institutions/centre-jean-perrin/","asOf":"2026-09-10","days":18},{"id":"centre-henri-becquerel","kind":"institution","name":"Centre Henri Becquerel","route":"/institutions/centre-henri-becquerel/","asOf":"2026-09-10","days":18},{"id":"centre-eugene-marquis","kind":"institution","name":"Centre Eugène Marquis","route":"/institutions/centre-eugene-marquis/","asOf":"2026-09-10","days":18},{"id":"ico-angers-nantes","kind":"institution","name":"Institut de Cancérologie de l'Ouest (ICO)","route":"/institutions/ico-angers-nantes/","asOf":"2026-09-10","days":18},{"id":"centre-francois-baclesse","kind":"institution","name":"Centre François Baclesse","route":"/institutions/centre-francois-baclesse/","asOf":"2026-09-10","days":18},{"id":"aphp-nord-cancer-institute","kind":"institution","name":"Cancer Institute AP-HP Nord, Université Paris Cité","route":"/institutions/aphp-nord-cancer-institute/","asOf":"2026-09-10","days":18},{"id":"iuc-aphp-sorbonne","kind":"institution","name":"Institut Universitaire de Cancérologie AP-HP Sorbonne Université","route":"/institutions/iuc-aphp-sorbonne/","asOf":"2026-09-10","days":18},{"id":"carpem-aphp-centre","kind":"institution","name":"Institut du Cancer Paris CARPEM, AP-HP Centre","route":"/institutions/carpem-aphp-centre/","asOf":"2026-09-10","days":18},{"id":"trinity-st-jamess-cancer-institute","kind":"institution","name":"Trinity St James's Cancer Institute","route":"/institutions/trinity-st-jamess-cancer-institute/","asOf":"2026-09-10","days":18},{"id":"st-vincents-ucd-cancer-centre","kind":"institution","name":"St Vincent's University Hospital / UCD Cancer Centre","route":"/institutions/st-vincents-ucd-cancer-centre/","asOf":"2026-09-10","days":18},{"id":"cork-university-hospital","kind":"institution","name":"Cork University Hospital / UCC Cancer Centre","route":"/institutions/cork-university-hospital/","asOf":"2026-09-10","days":18},{"id":"galway-university-hospital-cancer-centre","kind":"institution","name":"University of Galway / Saolta Cancer Centre","route":"/institutions/galway-university-hospital-cancer-centre/","asOf":"2026-09-10","days":18},{"id":"beaumont-rcsi-cancer-centre","kind":"institution","name":"Beaumont RCSI Cancer Centre","route":"/institutions/beaumont-rcsi-cancer-centre/","asOf":"2026-09-10","days":18},{"id":"spedali-civili-brescia","kind":"institution","name":"ASST Spedali Civili di Brescia","route":"/institutions/spedali-civili-brescia/","asOf":"2026-09-10","days":18},{"id":"sacro-cuore-don-calabria","kind":"institution","name":"IRCCS Sacro Cuore Don Calabria Hospital","route":"/institutions/sacro-cuore-don-calabria/","asOf":"2026-09-10","days":18},{"id":"crob-rionero","kind":"institution","name":"IRCCS CROB, Centro di Riferimento Oncologico della Basilicata","route":"/institutions/crob-rionero/","asOf":"2026-09-10","days":18},{"id":"istituto-tumori-bari","kind":"institution","name":"IRCCS Istituto Tumori Giovanni Paolo II","route":"/institutions/istituto-tumori-bari/","asOf":"2026-09-10","days":18},{"id":"san-martino-genoa","kind":"institution","name":"IRCCS Ospedale Policlinico San Martino","route":"/institutions/san-martino-genoa/","asOf":"2026-09-10","days":18},{"id":"ausl-irccs-reggio-emilia","kind":"institution","name":"AUSL-IRCCS di Reggio Emilia","route":"/institutions/ausl-irccs-reggio-emilia/","asOf":"2026-09-10","days":18},{"id":"cro-aviano","kind":"institution","name":"Centro di Riferimento Oncologico di Aviano (CRO)","route":"/institutions/cro-aviano/","asOf":"2026-09-10","days":18},{"id":"ipo-coimbra","kind":"institution","name":"Instituto Português de Oncologia de Coimbra Francisco Gentil","route":"/institutions/ipo-coimbra/","asOf":"2026-09-10","days":18},{"id":"fundacion-jimenez-diaz","kind":"institution","name":"Hospital Universitario Fundación Jiménez Díaz","route":"/institutions/fundacion-jimenez-diaz/","asOf":"2026-09-10","days":18},{"id":"ico-catalonia","kind":"institution","name":"Catalan Institute of Oncology (ICO)","route":"/institutions/ico-catalonia/","asOf":"2026-09-10","days":18},{"id":"ivo-valencia","kind":"institution","name":"Fundación Instituto Valenciano de Oncología (IVO)","route":"/institutions/ivo-valencia/","asOf":"2026-09-10","days":18},{"id":"umcg-groningen","kind":"institution","name":"University Medical Center Groningen Comprehensive Cancer Center","route":"/institutions/umcg-groningen/","asOf":"2026-09-10","days":18},{"id":"maastricht-umc","kind":"institution","name":"Maastricht UMC+ Comprehensive Cancer Center","route":"/institutions/maastricht-umc/","asOf":"2026-09-10","days":18},{"id":"oncozon","kind":"institution","name":"OncoZON Comprehensive Cancer Network","route":"/institutions/oncozon/","asOf":"2026-09-10","days":18},{"id":"rijnstate-arnhem","kind":"institution","name":"Rijnstate","route":"/institutions/rijnstate-arnhem/","asOf":"2026-09-10","days":18},{"id":"radboudumc","kind":"institution","name":"Radboudumc Centre for Oncology","route":"/institutions/radboudumc/","asOf":"2026-09-10","days":18},{"id":"amsterdam-umc","kind":"institution","name":"Amsterdam UMC / Cancer Center Amsterdam","route":"/institutions/amsterdam-umc/","asOf":"2026-09-10","days":18},{"id":"anadolu-medical-center","kind":"institution","name":"Anadolu Medical Center","route":"/institutions/anadolu-medical-center/","asOf":"2026-09-10","days":18},{"id":"saint-savvas-athens","kind":"institution","name":"Saint Savvas General Oncology Hospital of Athens","route":"/institutions/saint-savvas-athens/","asOf":"2026-09-10","days":18},{"id":"clatterbridge","kind":"institution","name":"The Clatterbridge Cancer Centre NHS Foundation Trust","route":"/institutions/clatterbridge/","asOf":"2026-09-10","days":18},{"id":"weston-park-sheffield","kind":"institution","name":"Weston Park Cancer Centre, Sheffield Teaching Hospitals","route":"/institutions/weston-park-sheffield/","asOf":"2026-09-10","days":18},{"id":"mount-vernon-cancer-centre","kind":"institution","name":"Mount Vernon Cancer Centre","route":"/institutions/mount-vernon-cancer-centre/","asOf":"2026-09-10","days":18},{"id":"nottingham-cancer-centre","kind":"institution","name":"Nottingham University Hospitals Cancer Centre (City Hospital)","route":"/institutions/nottingham-cancer-centre/","asOf":"2026-09-10","days":18},{"id":"bristol-haematology-oncology-centre","kind":"institution","name":"Bristol Haematology and Oncology Centre","route":"/institutions/bristol-haematology-oncology-centre/","asOf":"2026-09-10","days":18},{"id":"northern-ireland-cancer-centre","kind":"institution","name":"Northern Ireland Cancer Centre, Belfast City Hospital","route":"/institutions/northern-ireland-cancer-centre/","asOf":"2026-09-10","days":18},{"id":"imperial-cancer-centre","kind":"institution","name":"Imperial College Healthcare NHS Trust / Imperial College London Cancer Research","route":"/institutions/imperial-cancer-centre/","asOf":"2026-09-10","days":18},{"id":"cruk-city-of-london-centre","kind":"institution","name":"Cancer Research UK City of London Centre","route":"/institutions/cruk-city-of-london-centre/","asOf":"2026-09-10","days":18},{"id":"cruk-convergence-science-centre","kind":"institution","name":"Cancer Research UK Convergence Science Centre","route":"/institutions/cruk-convergence-science-centre/","asOf":"2026-09-10","days":18},{"id":"queens-centre-hull","kind":"institution","name":"Queen's Centre for Oncology and Haematology, Castle Hill Hospital","route":"/institutions/queens-centre-hull/","asOf":"2026-09-10","days":18},{"id":"anchor-centre-aberdeen","kind":"institution","name":"ANCHOR Centre, Aberdeen Royal Infirmary","route":"/institutions/anchor-centre-aberdeen/","asOf":"2026-09-10","days":18},{"id":"leicester-cancer-research-centre","kind":"institution","name":"Leicester Cancer Research Centre / University Hospitals of Leicester","route":"/institutions/leicester-cancer-research-centre/","asOf":"2026-09-10","days":18},{"id":"cancercare-manitoba","kind":"institution","name":"CancerCare Manitoba","route":"/institutions/cancercare-manitoba/","asOf":"2026-09-10","days":18},{"id":"saskatchewan-cancer-agency","kind":"institution","name":"Saskatchewan Cancer Agency","route":"/institutions/saskatchewan-cancer-agency/","asOf":"2026-09-10","days":18},{"id":"ontario-health-cancer-care-ontario","kind":"institution","name":"Ontario Health (Cancer Care Ontario)","route":"/institutions/ontario-health-cancer-care-ontario/","asOf":"2026-09-10","days":18},{"id":"ciusss-emtl-maisonneuve-rosemont","kind":"institution","name":"Hôpital Maisonneuve-Rosemont / CIUSSS de l'Est-de-l'Île-de-Montréal","route":"/institutions/ciusss-emtl-maisonneuve-rosemont/","asOf":"2026-09-10","days":18},{"id":"muhc-cedars-cancer-centre","kind":"institution","name":"McGill University Health Centre / Cedars Cancer Centre","route":"/institutions/muhc-cedars-cancer-centre/","asOf":"2026-09-10","days":18},{"id":"lhsc-verspeeten","kind":"institution","name":"Verspeeten Family Cancer Centre, London Health Sciences Centre","route":"/institutions/lhsc-verspeeten/","asOf":"2026-09-10","days":18},{"id":"nova-scotia-cancer-care","kind":"institution","name":"Nova Scotia Health Cancer Care Program (QEII)","route":"/institutions/nova-scotia-cancer-care/","asOf":"2026-09-10","days":18},{"id":"chu-de-quebec","kind":"institution","name":"CHU de Québec - Université Laval","route":"/institutions/chu-de-quebec/","asOf":"2026-09-10","days":18},{"id":"terry-fox-research-institute","kind":"institution","name":"Terry Fox Research Institute","route":"/institutions/terry-fox-research-institute/","asOf":"2026-09-10","days":18},{"id":"aga-khan-university-hospital-nairobi","kind":"institution","name":"Aga Khan University Hospital, Nairobi","route":"/institutions/aga-khan-university-hospital-nairobi/","asOf":"2026-09-10","days":18},{"id":"tygerberg-hospital","kind":"institution","name":"Tygerberg Hospital / Stellenbosch University","route":"/institutions/tygerberg-hospital/","asOf":"2026-09-10","days":18},{"id":"cancer-diseases-hospital-lusaka","kind":"institution","name":"Cancer Diseases Hospital, Lusaka","route":"/institutions/cancer-diseases-hospital-lusaka/","asOf":"2026-09-10","days":18},{"id":"inkosi-albert-luthuli-hospital","kind":"institution","name":"Inkosi Albert Luthuli Central Hospital","route":"/institutions/inkosi-albert-luthuli-hospital/","asOf":"2026-09-10","days":18},{"id":"steve-biko-academic-hospital","kind":"institution","name":"Steve Biko Academic Hospital / University of Pretoria","route":"/institutions/steve-biko-academic-hospital/","asOf":"2026-09-10","days":18},{"id":"chris-hani-baragwanath","kind":"institution","name":"Chris Hani Baragwanath Academic Hospital","route":"/institutions/chris-hani-baragwanath/","asOf":"2026-09-10","days":18},{"id":"moi-teaching-referral-hospital","kind":"institution","name":"Moi Teaching and Referral Hospital / AMPATH Oncology","route":"/institutions/moi-teaching-referral-hospital/","asOf":"2026-09-10","days":18},{"id":"tikur-anbessa-hospital","kind":"institution","name":"Tikur Anbessa Specialized Hospital, Addis Ababa University","route":"/institutions/tikur-anbessa-hospital/","asOf":"2026-09-10","days":18},{"id":"komfo-anokye-teaching-hospital","kind":"institution","name":"Komfo Anokye Teaching Hospital","route":"/institutions/komfo-anokye-teaching-hospital/","asOf":"2026-09-10","days":18},{"id":"uch-ibadan","kind":"institution","name":"University College Hospital, Ibadan","route":"/institutions/uch-ibadan/","asOf":"2026-09-10","days":18},{"id":"aubmc-basile-cancer-institute","kind":"institution","name":"American University of Beirut Medical Center / Naef K. Basile Cancer Institute","route":"/institutions/aubmc-basile-cancer-institute/","asOf":"2026-09-10","days":18},{"id":"bahrain-oncology-centre","kind":"institution","name":"Bahrain Oncology Center, King Hamad University Hospital","route":"/institutions/bahrain-oncology-centre/","asOf":"2026-09-10","days":18},{"id":"sultan-qaboos-cccrc","kind":"institution","name":"Sultan Qaboos Comprehensive Cancer Care and Research Centre","route":"/institutions/sultan-qaboos-cccrc/","asOf":"2026-09-10","days":18},{"id":"rabin-davidoff-center","kind":"institution","name":"Davidoff Cancer Center, Rabin Medical Center","route":"/institutions/rabin-davidoff-center/","asOf":"2026-09-10","days":18},{"id":"soroka-medical-center","kind":"institution","name":"Soroka University Medical Center","route":"/institutions/soroka-medical-center/","asOf":"2026-09-10","days":18},{"id":"icesp","kind":"institution","name":"Instituto do Câncer do Estado de São Paulo (ICESP)","route":"/institutions/icesp/","asOf":"2026-09-10","days":18},{"id":"erasto-gaertner","kind":"institution","name":"Hospital Erasto Gaertner","route":"/institutions/erasto-gaertner/","asOf":"2026-09-10","days":18},{"id":"bp-beneficencia-portuguesa","kind":"institution","name":"BP - A Beneficência Portuguesa de São Paulo","route":"/institutions/bp-beneficencia-portuguesa/","asOf":"2026-09-10","days":18},{"id":"hospital-italiano-buenos-aires","kind":"institution","name":"Hospital Italiano de Buenos Aires","route":"/institutions/hospital-italiano-buenos-aires/","asOf":"2026-09-10","days":18},{"id":"instituto-roffo","kind":"institution","name":"Instituto de Oncología Ángel H. Roffo","route":"/institutions/instituto-roffo/","asOf":"2026-09-10","days":18},{"id":"inc-argentina","kind":"institution","name":"Instituto Nacional del Cáncer (Argentina)","route":"/institutions/inc-argentina/","asOf":"2026-09-10","days":18},{"id":"inca-uruguay","kind":"institution","name":"Instituto Nacional del Cáncer (Uruguay)","route":"/institutions/inca-uruguay/","asOf":"2026-09-10","days":18},{"id":"inc-chile","kind":"institution","name":"Instituto Nacional del Cáncer (Chile)","route":"/institutions/inc-chile/","asOf":"2026-09-10","days":18},{"id":"fundacion-valle-del-lili","kind":"institution","name":"Fundación Valle del Lili","route":"/institutions/fundacion-valle-del-lili/","asOf":"2026-09-10","days":18},{"id":"imss-oncologia-siglo-xxi","kind":"institution","name":"Hospital de Oncología, Centro Médico Nacional Siglo XXI (IMSS)","route":"/institutions/imss-oncologia-siglo-xxi/","asOf":"2026-09-10","days":18},{"id":"inor-cuba","kind":"institution","name":"Instituto Nacional de Oncología y Radiobiología (INOR)","route":"/institutions/inor-cuba/","asOf":"2026-09-10","days":18},{"id":"shaukat-khanum","kind":"institution","name":"Shaukat Khanum Memorial Cancer Hospital and Research Centre","route":"/institutions/shaukat-khanum/","asOf":"2026-09-10","days":18},{"id":"aku-karachi","kind":"institution","name":"Aga Khan University Hospital, Karachi","route":"/institutions/aku-karachi/","asOf":"2026-09-10","days":18},{"id":"nicrh-dhaka","kind":"institution","name":"National Institute of Cancer Research and Hospital","route":"/institutions/nicrh-dhaka/","asOf":"2026-09-10","days":18},{"id":"ludwig-cancer-research","kind":"institution","name":"Ludwig Cancer Research","route":"/institutions/ludwig-cancer-research/","asOf":"2026-09-10","days":18},{"id":"parker-institute","kind":"institution","name":"Parker Institute for Cancer Immunotherapy","route":"/institutions/parker-institute/","asOf":"2026-09-10","days":18},{"id":"pcf","kind":"institution","name":"Prostate Cancer Foundation","route":"/institutions/pcf/","asOf":"2026-09-10","days":18},{"id":"alsf","kind":"institution","name":"Alex's Lemonade Stand Foundation","route":"/institutions/alsf/","asOf":"2026-09-10","days":18},{"id":"st-baldricks-foundation","kind":"institution","name":"St. Baldrick's Foundation","route":"/institutions/st-baldricks-foundation/","asOf":"2026-09-10","days":18},{"id":"bowelbabe-fund","kind":"institution","name":"Bowelbabe Fund for Cancer Research UK","route":"/institutions/bowelbabe-fund/","asOf":"2026-09-10","days":18},{"id":"teenage-cancer-trust","kind":"institution","name":"Teenage Cancer Trust","route":"/institutions/teenage-cancer-trust/","asOf":"2026-09-10","days":18},{"id":"lasker-foundation","kind":"institution","name":"Lasker Foundation","route":"/institutions/lasker-foundation/","asOf":"2026-09-10","days":18},{"id":"terry-fox-foundation","kind":"institution","name":"Terry Fox Foundation","route":"/institutions/terry-fox-foundation/","asOf":"2026-09-10","days":18},{"id":"mra","kind":"institution","name":"Melanoma Research Alliance","route":"/institutions/mra/","asOf":"2026-09-10","days":18},{"id":"jimmy-fund","kind":"institution","name":"The Jimmy Fund","route":"/institutions/jimmy-fund/","asOf":"2026-09-10","days":18},{"id":"pan-mass-challenge","kind":"institution","name":"Pan-Mass Challenge","route":"/institutions/pan-mass-challenge/","asOf":"2026-09-10","days":18},{"id":"ellison-institute","kind":"institution","name":"Ellison Institute of Technology","route":"/institutions/ellison-institute/","asOf":"2026-09-10","days":18},{"id":"li-ka-shing-foundation","kind":"institution","name":"Li Ka Shing Foundation","route":"/institutions/li-ka-shing-foundation/","asOf":"2026-09-10","days":18},{"id":"tata-trusts","kind":"institution","name":"Tata Trusts","route":"/institutions/tata-trusts/","asOf":"2026-09-10","days":18},{"id":"acupuncture-nausea","kind":"technology","name":"Acupuncture and acupressure for chemotherapy nausea","route":"/technologies/acupuncture-nausea/","asOf":"2026-09-10","days":18},{"id":"acupuncture-aromatase-inhibitor-arthralgia","kind":"technology","name":"Acupuncture for aromatase-inhibitor joint pain","route":"/technologies/acupuncture-aromatase-inhibitor-arthralgia/","asOf":"2026-09-10","days":18},{"id":"acupuncture-hot-flushes","kind":"technology","name":"Acupuncture for hot flushes on endocrine therapy","route":"/technologies/acupuncture-hot-flushes/","asOf":"2026-09-10","days":18},{"id":"acupuncture-xerostomia","kind":"technology","name":"Acupuncture for dry mouth after head and neck radiotherapy","route":"/technologies/acupuncture-xerostomia/","asOf":"2026-09-10","days":18},{"id":"acupuncture-chemotherapy-neuropathy","kind":"technology","name":"Acupuncture for chemotherapy-induced neuropathy","route":"/technologies/acupuncture-chemotherapy-neuropathy/","asOf":"2026-09-10","days":18},{"id":"mindfulness-based-interventions","kind":"technology","name":"Mindfulness-based stress reduction and cognitive therapy","route":"/technologies/mindfulness-based-interventions/","asOf":"2026-09-10","days":18},{"id":"cbt-insomnia-cancer","kind":"technology","name":"Cognitive behavioural therapy for insomnia (CBT-I)","route":"/technologies/cbt-insomnia-cancer/","asOf":"2026-09-10","days":18},{"id":"cbt-fatigue-distress","kind":"technology","name":"Cognitive behavioural therapy for fatigue and distress","route":"/technologies/cbt-fatigue-distress/","asOf":"2026-09-10","days":18},{"id":"yoga-cancer","kind":"technology","name":"Yoga during and after cancer treatment","route":"/technologies/yoga-cancer/","asOf":"2026-09-10","days":18},{"id":"tai-chi-qigong","kind":"technology","name":"Tai chi and qigong","route":"/technologies/tai-chi-qigong/","asOf":"2026-09-10","days":18},{"id":"hypnosis-cancer-care","kind":"technology","name":"Clinical hypnosis for procedures, pain and hot flushes","route":"/technologies/hypnosis-cancer-care/","asOf":"2026-09-10","days":18},{"id":"relaxation-guided-imagery","kind":"technology","name":"Relaxation training and guided imagery","route":"/technologies/relaxation-guided-imagery/","asOf":"2026-09-10","days":18},{"id":"music-therapy-cancer","kind":"technology","name":"Music therapy and music medicine","route":"/technologies/music-therapy-cancer/","asOf":"2026-09-10","days":18},{"id":"dance-movement-therapy","kind":"technology","name":"Dance and movement therapy","route":"/technologies/dance-movement-therapy/","asOf":"2026-09-10","days":18},{"id":"peer-support-groups","kind":"technology","name":"Peer support and support groups","route":"/technologies/peer-support-groups/","asOf":"2026-09-10","days":18},{"id":"massage-therapy-cancer","kind":"technology","name":"Massage therapy in cancer care","route":"/technologies/massage-therapy-cancer/","asOf":"2026-09-10","days":18},{"id":"aromatherapy-cancer","kind":"technology","name":"Aromatherapy","route":"/technologies/aromatherapy-cancer/","asOf":"2026-09-10","days":18},{"id":"reflexology-cancer","kind":"technology","name":"Reflexology","route":"/technologies/reflexology-cancer/","asOf":"2026-09-10","days":18},{"id":"reiki-energy-therapies","kind":"technology","name":"Reiki, healing touch and other energy therapies","route":"/technologies/reiki-energy-therapies/","asOf":"2026-09-10","days":18},{"id":"ginger-nausea","kind":"technology","name":"Ginger for chemotherapy nausea","route":"/technologies/ginger-nausea/","asOf":"2026-09-10","days":18},{"id":"curcumin-turmeric","kind":"technology","name":"Curcumin and turmeric","route":"/technologies/curcumin-turmeric/","asOf":"2026-09-10","days":18},{"id":"green-tea-egcg","kind":"technology","name":"Green tea and EGCG extracts","route":"/technologies/green-tea-egcg/","asOf":"2026-09-10","days":18},{"id":"american-ginseng-fatigue","kind":"technology","name":"American ginseng for cancer-related fatigue","route":"/technologies/american-ginseng-fatigue/","asOf":"2026-09-10","days":18},{"id":"melatonin-cancer","kind":"technology","name":"Melatonin as a cancer adjunct","route":"/technologies/melatonin-cancer/","asOf":"2026-09-10","days":18},{"id":"omega3-epa-cachexia","kind":"technology","name":"Fish oil (EPA) for cancer weight loss","route":"/technologies/omega3-epa-cachexia/","asOf":"2026-09-10","days":18},{"id":"probiotics-treatment-diarrhoea","kind":"technology","name":"Probiotics for chemotherapy and radiotherapy diarrhoea","route":"/technologies/probiotics-treatment-diarrhoea/","asOf":"2026-09-10","days":18},{"id":"glutamine-mucositis-neuropathy","kind":"technology","name":"Glutamine for mucositis and neuropathy","route":"/technologies/glutamine-mucositis-neuropathy/","asOf":"2026-09-10","days":18},{"id":"honey-radiation-mucositis","kind":"technology","name":"Honey for radiation mucositis","route":"/technologies/honey-radiation-mucositis/","asOf":"2026-09-10","days":18},{"id":"mistletoe-extracts","kind":"technology","name":"Mistletoe extracts (Iscador, Helixor)","route":"/technologies/mistletoe-extracts/","asOf":"2026-09-10","days":18},{"id":"high-dose-vitamin-c","kind":"technology","name":"High-dose intravenous vitamin C","route":"/technologies/high-dose-vitamin-c/","asOf":"2026-09-10","days":18},{"id":"psk-krestin-adjuvant","kind":"technology","name":"PSK (Krestin) mushroom polysaccharide as adjuvant therapy","route":"/technologies/psk-krestin-adjuvant/","asOf":"2026-09-10","days":18},{"id":"medicinal-mushrooms-reishi-turkey-tail","kind":"technology","name":"Medicinal mushrooms: reishi, turkey tail, shiitake and others","route":"/technologies/medicinal-mushrooms-reishi-turkey-tail/","asOf":"2026-09-10","days":18},{"id":"traditional-chinese-herbal-medicine","kind":"technology","name":"Traditional Chinese herbal medicine alongside treatment","route":"/technologies/traditional-chinese-herbal-medicine/","asOf":"2026-09-10","days":18},{"id":"ayurvedic-medicine-cancer","kind":"technology","name":"Ayurvedic medicine and cancer","route":"/technologies/ayurvedic-medicine-cancer/","asOf":"2026-09-10","days":18},{"id":"homeopathy-cancer","kind":"technology","name":"Homeopathy","route":"/technologies/homeopathy-cancer/","asOf":"2026-09-10","days":18},{"id":"st-johns-wort-interaction","kind":"technology","name":"St John's wort: an interaction to avoid","route":"/technologies/st-johns-wort-interaction/","asOf":"2026-09-10","days":18},{"id":"cannabinoids-nausea","kind":"technology","name":"Cannabinoids for chemotherapy nausea (dronabinol, nabilone, medical cannabis)","route":"/technologies/cannabinoids-nausea/","asOf":"2026-09-10","days":18},{"id":"cannabinoids-pain-appetite","kind":"technology","name":"Cannabis and cannabinoids for pain, appetite and cancer control","route":"/technologies/cannabinoids-pain-appetite/","asOf":"2026-09-10","days":18},{"id":"oral-cryotherapy-mucositis","kind":"technology","name":"Oral cryotherapy (ice chips) to prevent mucositis","route":"/technologies/oral-cryotherapy-mucositis/","asOf":"2026-09-10","days":18},{"id":"frozen-gloves-compression-taxane","kind":"technology","name":"Frozen gloves, socks and compression for taxane nail and nerve damage","route":"/technologies/frozen-gloves-compression-taxane/","asOf":"2026-09-10","days":18},{"id":"photobiomodulation-mucositis","kind":"technology","name":"Photobiomodulation (low-level laser) for oral mucositis","route":"/technologies/photobiomodulation-mucositis/","asOf":"2026-09-10","days":18},{"id":"hyperbaric-oxygen-radiation-injury","kind":"technology","name":"Hyperbaric oxygen for late radiation injury","route":"/technologies/hyperbaric-oxygen-radiation-injury/","asOf":"2026-09-10","days":18},{"id":"lymphoedema-decongestive-therapy","kind":"technology","name":"Compression, decongestive therapy and exercise for lymphoedema","route":"/technologies/lymphoedema-decongestive-therapy/","asOf":"2026-09-10","days":18},{"id":"minoxidil-chemotherapy-alopecia","kind":"technology","name":"Minoxidil for persistent chemotherapy- and endocrine-therapy hair loss","route":"/technologies/minoxidil-chemotherapy-alopecia/","asOf":"2026-09-10","days":18},{"id":"bimatoprost-eyelash-regrowth","kind":"technology","name":"Bimatoprost for eyelash and eyebrow regrowth","route":"/technologies/bimatoprost-eyelash-regrowth/","asOf":"2026-09-10","days":18},{"id":"wigs-cranial-prosthesis","kind":"technology","name":"Wigs, cranial prostheses and head coverings","route":"/technologies/wigs-cranial-prosthesis/","asOf":"2026-09-10","days":18},{"id":"alternative-medicine-instead-of-treatment","kind":"technology","name":"Alternative medicine used instead of standard treatment","route":"/technologies/alternative-medicine-instead-of-treatment/","asOf":"2026-09-10","days":18},{"id":"laetrile-amygdalin","kind":"technology","name":"Laetrile (amygdalin, 'vitamin B17')","route":"/technologies/laetrile-amygdalin/","asOf":"2026-09-10","days":18},{"id":"gerson-therapy-detox-regimens","kind":"technology","name":"Gerson therapy, coffee enemas and 'detox' regimens","route":"/technologies/gerson-therapy-detox-regimens/","asOf":"2026-09-10","days":18},{"id":"shark-cartilage","kind":"technology","name":"Shark cartilage (AE-941, Neovastat)","route":"/technologies/shark-cartilage/","asOf":"2026-09-10","days":18},{"id":"hydrazine-sulfate","kind":"technology","name":"Hydrazine sulfate","route":"/technologies/hydrazine-sulfate/","asOf":"2026-09-10","days":18},{"id":"antineoplastons","kind":"technology","name":"Antineoplastons (Burzynski clinic)","route":"/technologies/antineoplastons/","asOf":"2026-09-10","days":18},{"id":"black-salve-escharotics","kind":"technology","name":"Black salve and other escharotic pastes","route":"/technologies/black-salve-escharotics/","asOf":"2026-09-10","days":18},{"id":"fenbendazole-ivermectin-repurposing-claims","kind":"technology","name":"Fenbendazole, ivermectin and other internet 'repurposed cures'","route":"/technologies/fenbendazole-ivermectin-repurposing-claims/","asOf":"2026-09-10","days":18},{"id":"essiac-herbal-cancer-cures","kind":"technology","name":"Essiac, Hoxsey and other 'herbal cancer cures'","route":"/technologies/essiac-herbal-cancer-cures/","asOf":"2026-09-10","days":18},{"id":"paper-johnson-alternative-medicine-jnci-2018","kind":"paper","name":"Use of alternative medicine for cancer and its impact on survival","route":"/key-papers/paper-johnson-alternative-medicine-jnci-2018/","asOf":"2026-09-10","days":18},{"id":"paper-scalp-trial-jama-2017","kind":"paper","name":"SCALP: scalp cooling to prevent hair loss during chemotherapy for early breast cancer","route":"/key-papers/paper-scalp-trial-jama-2017/","asOf":"2026-09-10","days":18},{"id":"guardant360-cdx","kind":"drug","name":"Guardant360 CDx","route":"/drugs/guardant360-cdx/","asOf":"2026-09-10","days":18},{"id":"oncomine-dx-target-test","kind":"drug","name":"Oncomine Dx Target Test","route":"/drugs/oncomine-dx-target-test/","asOf":"2026-09-10","days":18},{"id":"cobas-egfr-mutation-test","kind":"drug","name":"cobas EGFR Mutation Test v2","route":"/drugs/cobas-egfr-mutation-test/","asOf":"2026-09-10","days":18},{"id":"therascreen-cdx","kind":"drug","name":"therascreen companion diagnostic kits (KRAS, EGFR, PIK3CA, FGFR, BRAF)","route":"/drugs/therascreen-cdx/","asOf":"2026-09-10","days":18},{"id":"ventana-pd-l1-sp142","kind":"drug","name":"VENTANA PD-L1 (SP142) Assay","route":"/drugs/ventana-pd-l1-sp142/","asOf":"2026-09-10","days":18},{"id":"ventana-pd-l1-sp263","kind":"drug","name":"VENTANA PD-L1 (SP263) Assay","route":"/drugs/ventana-pd-l1-sp263/","asOf":"2026-09-10","days":18},{"id":"dako-pd-l1-22c3-pharmdx","kind":"drug","name":"PD-L1 IHC 22C3 pharmDx","route":"/drugs/dako-pd-l1-22c3-pharmdx/","asOf":"2026-09-10","days":18},{"id":"her2-testing-assays","kind":"drug","name":"HER2 IHC and ISH companion assays (HercepTest, PATHWAY 4B5, HER2 Dual ISH)","route":"/drugs/her2-testing-assays/","asOf":"2026-09-10","days":18},{"id":"ventana-mmr-rxdx","kind":"drug","name":"VENTANA MMR RxDx Panel","route":"/drugs/ventana-mmr-rxdx/","asOf":"2026-09-10","days":18},{"id":"bracanalysis-cdx","kind":"drug","name":"BRACAnalysis CDx","route":"/drugs/bracanalysis-cdx/","asOf":"2026-09-10","days":18},{"id":"mychoice-cdx","kind":"drug","name":"myChoice CDx","route":"/drugs/mychoice-cdx/","asOf":"2026-09-10","days":18},{"id":"trusight-oncology-comprehensive","kind":"drug","name":"TruSight Oncology Comprehensive","route":"/drugs/trusight-oncology-comprehensive/","asOf":"2026-09-10","days":18},{"id":"tempus-xt-cdx","kind":"drug","name":"Tempus xT CDx","route":"/drugs/tempus-xt-cdx/","asOf":"2026-09-10","days":18},{"id":"caris-mi-cancer-seek","kind":"drug","name":"MI Cancer Seek","route":"/drugs/caris-mi-cancer-seek/","asOf":"2026-09-10","days":18},{"id":"resolution-ctdx-first","kind":"drug","name":"Resolution ctDx FIRST","route":"/drugs/resolution-ctdx-first/","asOf":"2026-09-10","days":18},{"id":"cologuard","kind":"drug","name":"Cologuard","route":"/drugs/cologuard/","asOf":"2026-09-10","days":18},{"id":"cologuard-plus","kind":"drug","name":"Cologuard Plus","route":"/drugs/cologuard-plus/","asOf":"2026-09-10","days":18},{"id":"cancerguard","kind":"drug","name":"Cancerguard","route":"/drugs/cancerguard/","asOf":"2026-09-10","days":18},{"id":"clonoseq","kind":"drug","name":"clonoSEQ","route":"/drugs/clonoseq/","asOf":"2026-09-10","days":18},{"id":"guardant-reveal","kind":"drug","name":"Guardant Reveal","route":"/drugs/guardant-reveal/","asOf":"2026-09-10","days":18},{"id":"radar-mrd","kind":"drug","name":"RaDaR","route":"/drugs/radar-mrd/","asOf":"2026-09-10","days":18},{"id":"oncodetect","kind":"drug","name":"Oncodetect","route":"/drugs/oncodetect/","asOf":"2026-09-10","days":18},{"id":"prosigna","kind":"drug","name":"Prosigna (PAM50)","route":"/drugs/prosigna/","asOf":"2026-09-10","days":18},{"id":"endopredict","kind":"drug","name":"EndoPredict","route":"/drugs/endopredict/","asOf":"2026-09-10","days":18},{"id":"breast-cancer-index","kind":"drug","name":"Breast Cancer Index","route":"/drugs/breast-cancer-index/","asOf":"2026-09-10","days":18},{"id":"prolaris","kind":"drug","name":"Prolaris","route":"/drugs/prolaris/","asOf":"2026-09-10","days":18},{"id":"oncotype-dx-gps","kind":"drug","name":"Oncotype DX Genomic Prostate Score","route":"/drugs/oncotype-dx-gps/","asOf":"2026-09-10","days":18},{"id":"afirma","kind":"drug","name":"Afirma Genomic Sequencing Classifier","route":"/drugs/afirma/","asOf":"2026-09-10","days":18},{"id":"cxbladder","kind":"drug","name":"Cxbladder","route":"/drugs/cxbladder/","asOf":"2026-09-10","days":18},{"id":"urovysion","kind":"drug","name":"UroVysion Bladder Cancer Kit","route":"/drugs/urovysion/","asOf":"2026-09-10","days":18},{"id":"locametz","kind":"drug","name":"Locametz (kit for Ga-68 gozetotide)","route":"/drugs/locametz/","asOf":"2026-09-10","days":18},{"id":"fludeoxyglucose-f18","kind":"drug","name":"Fludeoxyglucose F-18 (FDG)","route":"/drugs/fludeoxyglucose-f18/","asOf":"2026-09-10","days":18},{"id":"paige-prostate","kind":"drug","name":"Paige Prostate Detect","route":"/drugs/paige-prostate/","asOf":"2026-09-10","days":18},{"id":"transpara","kind":"drug","name":"Transpara","route":"/drugs/transpara/","asOf":"2026-09-10","days":18},{"id":"optellum-virtual-nodule-clinic","kind":"drug","name":"Optellum Virtual Nodule Clinic","route":"/drugs/optellum-virtual-nodule-clinic/","asOf":"2026-09-10","days":18},{"id":"icad-profound-ai","kind":"drug","name":"ProFound AI (iCAD)","route":"/drugs/icad-profound-ai/","asOf":"2026-09-10","days":18},{"id":"kheiron-mia","kind":"drug","name":"Mia (Mammography Intelligent Assessment)","route":"/drugs/kheiron-mia/","asOf":"2026-09-10","days":18},{"id":"msi-mmr-testing","kind":"technology","name":"MSI and mismatch-repair testing","route":"/technologies/msi-mmr-testing/","asOf":"2026-09-10","days":18},{"id":"tmb-testing","kind":"technology","name":"Tumour mutational burden testing","route":"/technologies/tmb-testing/","asOf":"2026-09-10","days":18},{"id":"nhs-targeted-lung-health-check","kind":"technology","name":"NHS Targeted Lung Health Check (lung cancer screening programme)","route":"/technologies/nhs-targeted-lung-health-check/","asOf":"2026-09-10","days":18},{"id":"prostate-screening-psa-mri","kind":"technology","name":"PSA and MRI-first prostate cancer screening","route":"/technologies/prostate-screening-psa-mri/","asOf":"2026-09-10","days":18},{"id":"skin-cancer-screening","kind":"technology","name":"Skin cancer screening (visual skin examination)","route":"/technologies/skin-cancer-screening/","asOf":"2026-09-10","days":18},{"id":"oral-visual-screening","kind":"technology","name":"Oral cancer visual screening","route":"/technologies/oral-visual-screening/","asOf":"2026-09-10","days":18},{"id":"gastric-endoscopic-screening","kind":"technology","name":"Gastric cancer endoscopic screening (East Asia)","route":"/technologies/gastric-endoscopic-screening/","asOf":"2026-09-10","days":18},{"id":"polygenic-risk-scores","kind":"technology","name":"Polygenic risk scores for cancer","route":"/technologies/polygenic-risk-scores/","asOf":"2026-09-10","days":18},{"id":"mindact","kind":"trial","name":"MINDACT","route":"/trials/mindact/","asOf":"2026-09-10","days":18},{"id":"nordicc","kind":"trial","name":"NordICC (Nordic-European Initiative on Colorectal Cancer)","route":"/trials/nordicc/","asOf":"2026-09-10","days":18},{"id":"tmist","kind":"trial","name":"TMIST (Tomosynthesis Mammographic Imaging Screening Trial)","route":"/trials/tmist/","asOf":"2026-09-10","days":18},{"id":"masai","kind":"trial","name":"MASAI (Mammography Screening with Artificial Intelligence)","route":"/trials/masai/","asOf":"2026-09-10","days":18},{"id":"blue-c","kind":"trial","name":"BLUE-C","route":"/trials/blue-c/","asOf":"2026-09-10","days":18},{"id":"deep-c","kind":"trial","name":"DeeP-C","route":"/trials/deep-c/","asOf":"2026-09-10","days":18},{"id":"eclipse-shield","kind":"trial","name":"ECLIPSE (Shield blood test)","route":"/trials/eclipse-shield/","asOf":"2026-09-10","days":18},{"id":"goteborg-2","kind":"trial","name":"GÖTEBORG-2 (MRI-based prostate cancer screening)","route":"/trials/goteborg-2/","asOf":"2026-09-10","days":18},{"id":"myriad-genetics","kind":"company","name":"Myriad Genetics","route":"/companies/myriad-genetics/","asOf":"2026-09-10","days":18},{"id":"agendia","kind":"company","name":"Agendia","route":"/companies/agendia/","asOf":"2026-09-10","days":18},{"id":"hologic","kind":"company","name":"Hologic","route":"/companies/hologic/","asOf":"2026-09-10","days":18},{"id":"screenpoint-medical","kind":"company","name":"ScreenPoint Medical","route":"/companies/screenpoint-medical/","asOf":"2026-09-10","days":18},{"id":"optellum","kind":"company","name":"Optellum","route":"/companies/optellum/","asOf":"2026-09-10","days":18},{"id":"icad","kind":"company","name":"iCAD (RadNet)","route":"/companies/icad/","asOf":"2026-09-10","days":18},{"id":"advanced-accelerator-applications","kind":"company","name":"Advanced Accelerator Applications (Novartis)","route":"/companies/advanced-accelerator-applications/","asOf":"2026-09-10","days":18},{"id":"abbott","kind":"company","name":"Abbott Laboratories","route":"/companies/abbott/","asOf":"2026-09-10","days":18},{"id":"pacific-edge","kind":"company","name":"Pacific Edge","route":"/companies/pacific-edge/","asOf":"2026-09-10","days":18},{"id":"mdxhealth","kind":"company","name":"MDxHealth","route":"/companies/mdxhealth/","asOf":"2026-09-10","days":18},{"id":"on-target-laboratories","kind":"company","name":"On Target Laboratories","route":"/companies/on-target-laboratories/","asOf":"2026-09-10","days":18},{"id":"lumicell","kind":"company","name":"Lumicell","route":"/companies/lumicell/","asOf":"2026-09-10","days":18},{"id":"fda-ldt-rule","kind":"term","name":"FDA laboratory-developed test (LDT) rule","route":"/terms/fda-ldt-rule/","asOf":"2026-09-10","days":18},{"id":"ivdr","kind":"term","name":"IVDR (EU In Vitro Diagnostic Regulation 2017/746)","route":"/terms/ivdr/","asOf":"2026-09-10","days":18},{"id":"sensitivity-specificity","kind":"term","name":"Sensitivity and specificity","route":"/terms/sensitivity-specificity/","asOf":"2026-09-10","days":18},{"id":"overdiagnosis","kind":"term","name":"Overdiagnosis","route":"/terms/overdiagnosis/","asOf":"2026-09-10","days":18},{"id":"paediatric-low-grade-glioma","kind":"cancer","name":"Paediatric low-grade glioma","route":"/cancers/paediatric-low-grade-glioma/","asOf":"2026-09-10","days":18},{"id":"dipg-dmg","kind":"cancer","name":"Diffuse midline glioma, H3 K27-altered (including DIPG)","route":"/cancers/dipg-dmg/","asOf":"2026-09-10","days":18},{"id":"atrt","kind":"cancer","name":"Atypical teratoid/rhabdoid tumour (ATRT)","route":"/cancers/atrt/","asOf":"2026-09-10","days":18},{"id":"ependymoma","kind":"cancer","name":"Ependymoma","route":"/cancers/ependymoma/","asOf":"2026-09-10","days":18},{"id":"craniopharyngioma","kind":"cancer","name":"Craniopharyngioma","route":"/cancers/craniopharyngioma/","asOf":"2026-09-10","days":18},{"id":"pleuropulmonary-blastoma","kind":"cancer","name":"Childhood lung and airway tumours (pleuropulmonary blastoma, tracheobronchial tumours)","route":"/cancers/pleuropulmonary-blastoma/","asOf":"2026-09-10","days":18},{"id":"paediatric-germ-cell-tumours","kind":"cancer","name":"Germ cell tumours of childhood and adolescence (extracranial and CNS)","route":"/cancers/paediatric-germ-cell-tumours/","asOf":"2026-09-10","days":18},{"id":"langerhans-cell-histiocytosis","kind":"cancer","name":"Langerhans cell histiocytosis (LCH)","route":"/cancers/langerhans-cell-histiocytosis/","asOf":"2026-09-10","days":18},{"id":"burkitt-lymphoma","kind":"cancer","name":"Burkitt lymphoma","route":"/cancers/burkitt-lymphoma/","asOf":"2026-09-10","days":18},{"id":"rare-childhood-cancers","kind":"cancer","name":"Rare cancers of childhood (NCI PDQ umbrella)","route":"/cancers/rare-childhood-cancers/","asOf":"2026-09-10","days":18},{"id":"chordoma","kind":"cancer","name":"Chordoma","route":"/cancers/chordoma/","asOf":"2026-09-10","days":18},{"id":"desmoid-tumour","kind":"cancer","name":"Desmoid tumour","route":"/cancers/desmoid-tumour/","asOf":"2026-09-10","days":18},{"id":"tenosynovial-giant-cell-tumour","kind":"cancer","name":"Tenosynovial giant cell tumour (TGCT)","route":"/cancers/tenosynovial-giant-cell-tumour/","asOf":"2026-09-10","days":18},{"id":"epithelioid-sarcoma","kind":"cancer","name":"Epithelioid sarcoma","route":"/cancers/epithelioid-sarcoma/","asOf":"2026-09-10","days":18},{"id":"inflammatory-myofibroblastic-tumour","kind":"cancer","name":"Inflammatory myofibroblastic tumour (IMT)","route":"/cancers/inflammatory-myofibroblastic-tumour/","asOf":"2026-09-10","days":18},{"id":"vascular-tumours","kind":"cancer","name":"Vascular tumours (angiosarcoma, epithelioid haemangioendothelioma, kaposiform haemangioendothelioma)","route":"/cancers/vascular-tumours/","asOf":"2026-09-10","days":18},{"id":"uterine-sarcoma","kind":"cancer","name":"Uterine sarcoma","route":"/cancers/uterine-sarcoma/","asOf":"2026-09-10","days":18},{"id":"nut-carcinoma","kind":"cancer","name":"NUT carcinoma (midline carcinoma with NUTM1 rearrangement)","route":"/cancers/nut-carcinoma/","asOf":"2026-09-10","days":18},{"id":"sinonasal","kind":"cancer","name":"Nasal cavity and paranasal sinus cancers (including esthesioneuroblastoma)","route":"/cancers/sinonasal/","asOf":"2026-09-10","days":18},{"id":"pheochromocytoma-paraganglioma","kind":"cancer","name":"Pheochromocytoma and paraganglioma (PPGL)","route":"/cancers/pheochromocytoma-paraganglioma/","asOf":"2026-09-10","days":18},{"id":"parathyroid-carcinoma","kind":"cancer","name":"Parathyroid carcinoma","route":"/cancers/parathyroid-carcinoma/","asOf":"2026-09-10","days":18},{"id":"pituitary-tumours","kind":"cancer","name":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma","route":"/cancers/pituitary-tumours/","asOf":"2026-09-10","days":18},{"id":"multiple-endocrine-neoplasia","kind":"cancer","name":"Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)","route":"/cancers/multiple-endocrine-neoplasia/","asOf":"2026-09-10","days":18},{"id":"ampullary","kind":"cancer","name":"Ampullary cancer (ampulla of Vater)","route":"/cancers/ampullary/","asOf":"2026-09-10","days":18},{"id":"small-bowel","kind":"cancer","name":"Small intestine cancer (small bowel adenocarcinoma)","route":"/cancers/small-bowel/","asOf":"2026-09-10","days":18},{"id":"penile","kind":"cancer","name":"Penile cancer","route":"/cancers/penile/","asOf":"2026-09-10","days":18},{"id":"urethral","kind":"cancer","name":"Urethral cancer","route":"/cancers/urethral/","asOf":"2026-09-10","days":18},{"id":"vaginal","kind":"cancer","name":"Vaginal cancer","route":"/cancers/vaginal/","asOf":"2026-09-10","days":18},{"id":"male-breast-cancer","kind":"cancer","name":"Male breast cancer","route":"/cancers/male-breast-cancer/","asOf":"2026-09-10","days":18},{"id":"hiv-associated-lymphoma","kind":"cancer","name":"HIV-associated (AIDS-related) lymphomas","route":"/cancers/hiv-associated-lymphoma/","asOf":"2026-09-10","days":18},{"id":"cmml","kind":"cancer","name":"Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","route":"/cancers/cmml/","asOf":"2026-09-10","days":18},{"id":"systemic-mastocytosis","kind":"cancer","name":"Systemic mastocytosis","route":"/cancers/systemic-mastocytosis/","asOf":"2026-09-10","days":18},{"id":"histiocytoses","kind":"cancer","name":"Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms","route":"/cancers/histiocytoses/","asOf":"2026-09-10","days":18},{"id":"post-transplant-lymphoproliferative-disorder","kind":"cancer","name":"Post-transplant lymphoproliferative disorder (PTLD)","route":"/cancers/post-transplant-lymphoproliferative-disorder/","asOf":"2026-09-10","days":18},{"id":"firefly-1","kind":"trial","name":"FIREFLY-1","route":"/trials/firefly-1/","asOf":"2026-09-10","days":18},{"id":"tadpole","kind":"trial","name":"TADPOLE (CDRB436G2201)","route":"/trials/tadpole/","asOf":"2026-09-10","days":18},{"id":"action-dmg","kind":"trial","name":"ACTION","route":"/trials/action-dmg/","asOf":"2026-09-10","days":18},{"id":"pediatric-match","kind":"trial","name":"NCI-COG Pediatric MATCH (APEC1621)","route":"/trials/pediatric-match/","asOf":"2026-09-10","days":18},{"id":"acns0331","kind":"trial","name":"COG ACNS0331","route":"/trials/acns0331/","asOf":"2026-09-10","days":18},{"id":"aren0533","kind":"trial","name":"COG AREN0533","route":"/trials/aren0533/","asOf":"2026-09-10","days":18},{"id":"euramos-1","kind":"trial","name":"EURAMOS-1","route":"/trials/euramos-1/","asOf":"2026-09-10","days":18},{"id":"aaml0531","kind":"trial","name":"COG AAML0531","route":"/trials/aaml0531/","asOf":"2026-09-10","days":18},{"id":"inter-b-nhl-ritux-2010","kind":"trial","name":"Inter-B-NHL Ritux 2010","route":"/trials/inter-b-nhl-ritux-2010/","asOf":"2026-09-10","days":18},{"id":"lch-iii","kind":"trial","name":"LCH-III","route":"/trials/lch-iii/","asOf":"2026-09-10","days":18},{"id":"ccss","kind":"trial","name":"Childhood Cancer Survivor Study (CCSS)","route":"/trials/ccss/","asOf":"2026-09-10","days":18},{"id":"accelerate-platform","kind":"institution","name":"ACCELERATE","route":"/institutions/accelerate-platform/","asOf":"2026-09-10","days":18},{"id":"histiocyte-society","kind":"institution","name":"Histiocyte Society","route":"/institutions/histiocyte-society/","asOf":"2026-09-10","days":18},{"id":"race-for-children-act","kind":"term","name":"RACE for Children Act","route":"/terms/race-for-children-act/","asOf":"2026-09-10","days":18},{"id":"national-cancer-grid","kind":"institution","name":"National Cancer Grid of India","route":"/institutions/national-cancer-grid/","asOf":"2026-09-10","days":18},{"id":"homi-bhabha-cancer-hospital-varanasi","kind":"institution","name":"Homi Bhabha Cancer Hospital and Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Varanasi","route":"/institutions/homi-bhabha-cancer-hospital-varanasi/","asOf":"2026-09-10","days":18},{"id":"aiims-network","kind":"institution","name":"The new AIIMS network (PMSSY)","route":"/institutions/aiims-network/","asOf":"2026-09-10","days":18},{"id":"icmr","kind":"institution","name":"Indian Council of Medical Research","route":"/institutions/icmr/","asOf":"2026-09-10","days":18},{"id":"icmr-ncrp","kind":"institution","name":"National Cancer Registry Programme (ICMR-NINE, Bengaluru)","route":"/institutions/icmr-ncrp/","asOf":"2026-09-10","days":18},{"id":"icmr-nicpr","kind":"institution","name":"ICMR-National Institute of Cancer Prevention and Research","route":"/institutions/icmr-nicpr/","asOf":"2026-09-10","days":18},{"id":"dbt-india","kind":"institution","name":"Department of Biotechnology, Government of India","route":"/institutions/dbt-india/","asOf":"2026-09-10","days":18},{"id":"nha-pmjay","kind":"institution","name":"National Health Authority (Ayushman Bharat PM-JAY)","route":"/institutions/nha-pmjay/","asOf":"2026-09-10","days":18},{"id":"iit-bombay","kind":"institution","name":"Indian Institute of Technology Bombay","route":"/institutions/iit-bombay/","asOf":"2026-09-10","days":18},{"id":"iisc","kind":"institution","name":"Indian Institute of Science","route":"/institutions/iisc/","asOf":"2026-09-10","days":18},{"id":"ncbs","kind":"institution","name":"National Centre for Biological Sciences","route":"/institutions/ncbs/","asOf":"2026-09-10","days":18},{"id":"instem","kind":"institution","name":"Institute for Stem Cell Science and Regenerative Medicine","route":"/institutions/instem/","asOf":"2026-09-10","days":18},{"id":"max-healthcare","kind":"institution","name":"Max Healthcare (Max Institute of Cancer Care)","route":"/institutions/max-healthcare/","asOf":"2026-09-10","days":18},{"id":"narayana-health","kind":"institution","name":"Narayana Health (Mazumdar Shaw Medical Centre)","route":"/institutions/narayana-health/","asOf":"2026-09-10","days":18},{"id":"biocon","kind":"company","name":"Biocon","route":"/companies/biocon/","asOf":"2026-09-10","days":18},{"id":"biocon-biologics","kind":"company","name":"Biocon Biologics","route":"/companies/biocon-biologics/","asOf":"2026-09-10","days":18},{"id":"syngene","kind":"company","name":"Syngene International","route":"/companies/syngene/","asOf":"2026-09-10","days":18},{"id":"dr-reddys","kind":"company","name":"Dr. Reddy's Laboratories","route":"/companies/dr-reddys/","asOf":"2026-09-10","days":18},{"id":"aurigene","kind":"company","name":"Aurigene Oncology","route":"/companies/aurigene/","asOf":"2026-09-10","days":18},{"id":"sun-pharma","kind":"company","name":"Sun Pharmaceutical Industries","route":"/companies/sun-pharma/","asOf":"2026-09-10","days":18},{"id":"natco","kind":"company","name":"Natco Pharma","route":"/companies/natco/","asOf":"2026-09-10","days":18},{"id":"cipla","kind":"company","name":"Cipla","route":"/companies/cipla/","asOf":"2026-09-10","days":18},{"id":"zydus","kind":"company","name":"Zydus Lifesciences","route":"/companies/zydus/","asOf":"2026-09-10","days":18},{"id":"lupin","kind":"company","name":"Lupin","route":"/companies/lupin/","asOf":"2026-09-10","days":18},{"id":"intas","kind":"company","name":"Intas Pharmaceuticals (Accord Healthcare)","route":"/companies/intas/","asOf":"2026-09-10","days":18},{"id":"glenmark","kind":"company","name":"Glenmark Pharmaceuticals (Ichnos Glenmark Innovation)","route":"/companies/glenmark/","asOf":"2026-09-10","days":18},{"id":"immunoact","kind":"company","name":"ImmunoACT","route":"/companies/immunoact/","asOf":"2026-09-10","days":18},{"id":"immuneel","kind":"company","name":"Immuneel Therapeutics","route":"/companies/immuneel/","asOf":"2026-09-10","days":18},{"id":"cellogen","kind":"company","name":"Cellogen Therapeutics","route":"/companies/cellogen/","asOf":"2026-09-10","days":18},{"id":"hetero","kind":"company","name":"Hetero Drugs","route":"/companies/hetero/","asOf":"2026-09-10","days":18},{"id":"serum-institute-of-india","kind":"company","name":"Serum Institute of India","route":"/companies/serum-institute-of-india/","asOf":"2026-09-10","days":18},{"id":"talicabtagene-autoleucel","kind":"drug","name":"Talicabtagene autoleucel","route":"/drugs/talicabtagene-autoleucel/","asOf":"2026-09-10","days":18},{"id":"varnimcabtagene-autoleucel","kind":"drug","name":"Varnimcabtagene autoleucel","route":"/drugs/varnimcabtagene-autoleucel/","asOf":"2026-09-10","days":18},{"id":"cervavac","kind":"drug","name":"CERVAVAC (quadrivalent HPV vaccine, India)","route":"/drugs/cervavac/","asOf":"2026-09-10","days":18},{"id":"isb-2001","kind":"drug","name":"ISB 2001","route":"/drugs/isb-2001/","asOf":"2026-09-10","days":18},{"id":"low-dose-nivolumab-tmh","kind":"trial","name":"Low-dose nivolumab plus metronomic chemotherapy (Tata Memorial)","route":"/trials/low-dose-nivolumab-tmh/","asOf":"2026-09-10","days":18},{"id":"metronomic-vs-cisplatin-tmh","kind":"trial","name":"Oral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial)","route":"/trials/metronomic-vs-cisplatin-tmh/","asOf":"2026-09-10","days":18},{"id":"metro-plus-varanasi","kind":"trial","name":"METRO PLUS (Tata Memorial Centre, Varanasi)","route":"/trials/metro-plus-varanasi/","asOf":"2026-09-10","days":18},{"id":"gefitinib-chemo-tmh","kind":"trial","name":"Gefitinib vs gefitinib plus pemetrexed-carboplatin in EGFR-mutant lung cancer (Tata Memorial)","route":"/trials/gefitinib-chemo-tmh/","asOf":"2026-09-10","days":18},{"id":"progesterone-preop-tmh","kind":"trial","name":"Single-injection depot progesterone before breast surgery (Tata Memorial)","route":"/trials/progesterone-preop-tmh/","asOf":"2026-09-10","days":18},{"id":"lidocaine-peritumoral-tmh","kind":"trial","name":"Peritumoral lidocaine before breast cancer surgery (Tata Memorial)","route":"/trials/lidocaine-peritumoral-tmh/","asOf":"2026-09-10","days":18},{"id":"elective-neck-dissection-tmh","kind":"trial","name":"Elective vs therapeutic neck dissection in node-negative oral cancer (Tata Memorial)","route":"/trials/elective-neck-dissection-tmh/","asOf":"2026-09-10","days":18},{"id":"osmanabad-hpv-screening","kind":"trial","name":"Osmanabad cervical screening trial (HPV testing vs cytology vs VIA)","route":"/trials/osmanabad-hpv-screening/","asOf":"2026-09-10","days":18},{"id":"kerala-oral-screening","kind":"trial","name":"Kerala oral cancer visual screening trial (Trivandrum)","route":"/trials/kerala-oral-screening/","asOf":"2026-09-10","days":18},{"id":"mumbai-via-screening","kind":"trial","name":"Mumbai VIA cervical screening trial (Tata Memorial)","route":"/trials/mumbai-via-screening/","asOf":"2026-09-10","days":18},{"id":"iarc-india-hpv-dose-study","kind":"trial","name":"IARC India HPV vaccine dose study (one, two or three doses)","route":"/trials/iarc-india-hpv-dose-study/","asOf":"2026-09-10","days":18},{"id":"talicel-phase-1-2","kind":"trial","name":"Talicabtagene autoleucel (NexCAR19) phase 1/2","route":"/trials/talicel-phase-1-2/","asOf":"2026-09-10","days":18},{"id":"imagine-varnimcabtagene","kind":"trial","name":"IMAGINE (varnimcabtagene autoleucel, Immuneel)","route":"/trials/imagine-varnimcabtagene/","asOf":"2026-09-10","days":18},{"id":"paper-patil-low-dose-nivolumab-jco-2023","kind":"paper","name":"Low-dose immunotherapy in head and neck cancer: a randomised study (Tata Memorial)","route":"/key-papers/paper-patil-low-dose-nivolumab-jco-2023/","asOf":"2026-09-10","days":18},{"id":"paper-sankaranarayanan-hpv-screening-nejm-2009","kind":"paper","name":"HPV screening for cervical cancer in rural India (Osmanabad)","route":"/key-papers/paper-sankaranarayanan-hpv-screening-nejm-2009/","asOf":"2026-09-10","days":18},{"id":"paper-sankaranarayanan-oral-screening-lancet-2005","kind":"paper","name":"Effect of screening on oral cancer mortality in Kerala, India","route":"/key-papers/paper-sankaranarayanan-oral-screening-lancet-2005/","asOf":"2026-09-10","days":18},{"id":"paper-basu-single-dose-hpv-lancet-oncol-2021","kind":"paper","name":"Vaccine efficacy against persistent HPV 16/18 infection at 10 years after one, two and three doses of quadrivalent HPV vaccine in girls in India","route":"/key-papers/paper-basu-single-dose-hpv-lancet-oncol-2021/","asOf":"2026-09-10","days":18},{"id":"paper-badwe-progesterone-jco-2011","kind":"paper","name":"Single-injection depot progesterone before surgery and survival in operable breast cancer","route":"/key-papers/paper-badwe-progesterone-jco-2011/","asOf":"2026-09-10","days":18},{"id":"paper-dcruz-elective-neck-dissection-nejm-2015","kind":"paper","name":"Elective versus therapeutic neck dissection in node-negative oral cancer","route":"/key-papers/paper-dcruz-elective-neck-dissection-nejm-2015/","asOf":"2026-09-10","days":18},{"id":"paper-jain-talicabtagene-lancet-haem-2025","kind":"paper","name":"Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: an open-label, multicentre, phase 1/2 study","route":"/key-papers/paper-jain-talicabtagene-lancet-haem-2025/","asOf":"2026-09-10","days":18},{"id":"paper-mathur-ncrp-cancer-statistics-2020","kind":"paper","name":"Cancer Statistics, 2020: Report from National Cancer Registry Programme, India","route":"/key-papers/paper-mathur-ncrp-cancer-statistics-2020/","asOf":"2026-09-10","days":18},{"id":"paper-pramesh-ncg-pooled-procurement-2023","kind":"paper","name":"A National Cancer Grid pooled procurement initiative, India","route":"/key-papers/paper-pramesh-ncg-pooled-procurement-2023/","asOf":"2026-09-10","days":18},{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/","asOf":"2026-09-10","days":18},{"id":"sugemalimab","kind":"drug","name":"Sugemalimab","route":"/drugs/sugemalimab/","asOf":"2026-09-10","days":18},{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/","asOf":"2026-09-10","days":18},{"id":"envafolimab","kind":"drug","name":"Envafolimab","route":"/drugs/envafolimab/","asOf":"2026-09-10","days":18},{"id":"relmacabtagene-autoleucel","kind":"drug","name":"Relmacabtagene autoleucel","route":"/drugs/relmacabtagene-autoleucel/","asOf":"2026-09-10","days":18},{"id":"equecabtagene-autoleucel","kind":"drug","name":"Equecabtagene autoleucel","route":"/drugs/equecabtagene-autoleucel/","asOf":"2026-09-10","days":18},{"id":"zevorcabtagene-autoleucel","kind":"drug","name":"Zevorcabtagene autoleucel","route":"/drugs/zevorcabtagene-autoleucel/","asOf":"2026-09-10","days":18},{"id":"inaticabtagene-autoleucel","kind":"drug","name":"Inaticabtagene autoleucel","route":"/drugs/inaticabtagene-autoleucel/","asOf":"2026-09-10","days":18},{"id":"fulzerasib","kind":"drug","name":"Fulzerasib","route":"/drugs/fulzerasib/","asOf":"2026-09-10","days":18},{"id":"garsorasib","kind":"drug","name":"Garsorasib","route":"/drugs/garsorasib/","asOf":"2026-09-10","days":18},{"id":"furmonertinib","kind":"drug","name":"Furmonertinib","route":"/drugs/furmonertinib/","asOf":"2026-09-10","days":18},{"id":"aumolertinib","kind":"drug","name":"Aumolertinib","route":"/drugs/aumolertinib/","asOf":"2026-09-10","days":18},{"id":"icotinib","kind":"drug","name":"Icotinib","route":"/drugs/icotinib/","asOf":"2026-09-10","days":18},{"id":"savolitinib","kind":"drug","name":"Savolitinib","route":"/drugs/savolitinib/","asOf":"2026-09-10","days":18},{"id":"anlotinib","kind":"drug","name":"Anlotinib","route":"/drugs/anlotinib/","asOf":"2026-09-10","days":18},{"id":"rivoceranib","kind":"drug","name":"Rivoceranib (apatinib)","route":"/drugs/rivoceranib/","asOf":"2026-09-10","days":18},{"id":"donafenib","kind":"drug","name":"Donafenib","route":"/drugs/donafenib/","asOf":"2026-09-10","days":18},{"id":"orelabrutinib","kind":"drug","name":"Orelabrutinib","route":"/drugs/orelabrutinib/","asOf":"2026-09-10","days":18},{"id":"dalpiciclib","kind":"drug","name":"Dalpiciclib","route":"/drugs/dalpiciclib/","asOf":"2026-09-10","days":18},{"id":"tucidinostat","kind":"drug","name":"Tucidinostat (chidamide)","route":"/drugs/tucidinostat/","asOf":"2026-09-10","days":18},{"id":"innovent","kind":"company","name":"Innovent Biologics","route":"/companies/innovent/","asOf":"2026-09-10","days":18},{"id":"junshi","kind":"company","name":"Shanghai Junshi Biosciences","route":"/companies/junshi/","asOf":"2026-09-10","days":18},{"id":"zai-lab","kind":"company","name":"Zai Lab","route":"/companies/zai-lab/","asOf":"2026-09-10","days":18},{"id":"hutchmed","kind":"company","name":"Hutchmed","route":"/companies/hutchmed/","asOf":"2026-09-10","days":18},{"id":"cspc","kind":"company","name":"CSPC Pharmaceutical Group","route":"/companies/cspc/","asOf":"2026-09-10","days":18},{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","route":"/companies/sino-biopharm/","asOf":"2026-09-10","days":18},{"id":"wuxi-apptec","kind":"company","name":"WuXi AppTec","route":"/companies/wuxi-apptec/","asOf":"2026-09-10","days":18},{"id":"wuxi-biologics","kind":"company","name":"WuXi Biologics","route":"/companies/wuxi-biologics/","asOf":"2026-09-10","days":18},{"id":"jw-therapeutics","kind":"company","name":"JW Therapeutics","route":"/companies/jw-therapeutics/","asOf":"2026-09-10","days":18},{"id":"iaso-bio","kind":"company","name":"IASO Biotherapeutics","route":"/companies/iaso-bio/","asOf":"2026-09-10","days":18},{"id":"cstone","kind":"company","name":"CStone Pharmaceuticals","route":"/companies/cstone/","asOf":"2026-09-10","days":18},{"id":"allist","kind":"company","name":"Shanghai Allist Pharmaceuticals","route":"/companies/allist/","asOf":"2026-09-10","days":18},{"id":"genfleet","kind":"company","name":"GenFleet Therapeutics","route":"/companies/genfleet/","asOf":"2026-09-10","days":18},{"id":"inventisbio","kind":"company","name":"InventisBio","route":"/companies/inventisbio/","asOf":"2026-09-10","days":18},{"id":"alphamab","kind":"company","name":"Alphamab Oncology","route":"/companies/alphamab/","asOf":"2026-09-10","days":18},{"id":"zelgen","kind":"company","name":"Suzhou Zelgen Biopharmaceuticals","route":"/companies/zelgen/","asOf":"2026-09-10","days":18},{"id":"innocare","kind":"company","name":"InnoCare Pharma","route":"/companies/innocare/","asOf":"2026-09-10","days":18},{"id":"betta","kind":"company","name":"Betta Pharmaceuticals","route":"/companies/betta/","asOf":"2026-09-10","days":18},{"id":"chipscreen","kind":"company","name":"Chipscreen Biosciences","route":"/companies/chipscreen/","asOf":"2026-09-10","days":18},{"id":"ncc-china","kind":"institution","name":"National Cancer Center of China","route":"/institutions/ncc-china/","asOf":"2026-09-10","days":18},{"id":"nhsa","kind":"institution","name":"National Healthcare Security Administration","route":"/institutions/nhsa/","asOf":"2026-09-10","days":18},{"id":"caca","kind":"institution","name":"China Anti-Cancer Association","route":"/institutions/caca/","asOf":"2026-09-10","days":18},{"id":"pku-peoples-hospital","kind":"institution","name":"Peking University People's Hospital","route":"/institutions/pku-peoples-hospital/","asOf":"2026-09-10","days":18},{"id":"cams-hematology","kind":"institution","name":"Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences","route":"/institutions/cams-hematology/","asOf":"2026-09-10","days":18},{"id":"renji-hospital","kind":"institution","name":"Renji Hospital, Shanghai Jiao Tong University","route":"/institutions/renji-hospital/","asOf":"2026-09-10","days":18},{"id":"jilin-cancer-hospital","kind":"institution","name":"Jilin Cancer Hospital","route":"/institutions/jilin-cancer-hospital/","asOf":"2026-09-10","days":18},{"id":"jiangsu-cancer-hospital","kind":"institution","name":"Jiangsu Cancer Hospital","route":"/institutions/jiangsu-cancer-hospital/","asOf":"2026-09-10","days":18},{"id":"chongqing-university-cancer-hospital","kind":"institution","name":"Chongqing University Cancer Hospital","route":"/institutions/chongqing-university-cancer-hospital/","asOf":"2026-09-10","days":18},{"id":"sichuan-cancer-hospital","kind":"institution","name":"Sichuan Cancer Hospital","route":"/institutions/sichuan-cancer-hospital/","asOf":"2026-09-10","days":18},{"id":"orient-11","kind":"trial","name":"ORIENT-11","route":"/trials/orient-11/","asOf":"2026-09-10","days":18},{"id":"orient-32","kind":"trial","name":"ORIENT-32","route":"/trials/orient-32/","asOf":"2026-09-10","days":18},{"id":"orient-16","kind":"trial","name":"ORIENT-16","route":"/trials/orient-16/","asOf":"2026-09-10","days":18},{"id":"rationale-302","kind":"trial","name":"RATIONALE-302","route":"/trials/rationale-302/","asOf":"2026-09-10","days":18},{"id":"camel","kind":"trial","name":"CameL","route":"/trials/camel/","asOf":"2026-09-10","days":18},{"id":"jupiter-06","kind":"trial","name":"JUPITER-06","route":"/trials/jupiter-06/","asOf":"2026-09-10","days":18},{"id":"harmoni-a","kind":"trial","name":"HARMONi-A","route":"/trials/harmoni-a/","asOf":"2026-09-10","days":18},{"id":"capstone-1","kind":"trial","name":"CAPSTONE-1","route":"/trials/capstone-1/","asOf":"2026-09-10","days":18},{"id":"gemstone-302","kind":"trial","name":"GEMSTONE-302","route":"/trials/gemstone-302/","asOf":"2026-09-10","days":18},{"id":"furlong","kind":"trial","name":"FURLONG","route":"/trials/furlong/","asOf":"2026-09-10","days":18},{"id":"aeneas","kind":"trial","name":"AENEAS","route":"/trials/aeneas/","asOf":"2026-09-10","days":18},{"id":"alter-0303","kind":"trial","name":"ALTER 0303","route":"/trials/alter-0303/","asOf":"2026-09-10","days":18},{"id":"legend-2","kind":"trial","name":"LEGEND-2","route":"/trials/legend-2/","asOf":"2026-09-10","days":18},{"id":"fumanba-1","kind":"trial","name":"FUMANBA-1","route":"/trials/fumanba-1/","asOf":"2026-09-10","days":18},{"id":"lummicar-1","kind":"trial","name":"LUMMICAR STUDY 1","route":"/trials/lummicar-1/","asOf":"2026-09-10","days":18},{"id":"reliance","kind":"trial","name":"RELIANCE","route":"/trials/reliance/","asOf":"2026-09-10","days":18},{"id":"dawna-1","kind":"trial","name":"DAWNA-1","route":"/trials/dawna-1/","asOf":"2026-09-10","days":18},{"id":"zgdh3","kind":"trial","name":"ZGDH3 (donafenib vs sorafenib)","route":"/trials/zgdh3/","asOf":"2026-09-10","days":18},{"id":"alemtuzumab","kind":"drug","name":"Alemtuzumab","route":"/drugs/alemtuzumab/","asOf":"2026-09-10","days":18},{"id":"bexarotene","kind":"drug","name":"Bexarotene","route":"/drugs/bexarotene/","asOf":"2026-09-10","days":18},{"id":"busulfan","kind":"drug","name":"Busulfan","route":"/drugs/busulfan/","asOf":"2026-09-10","days":18},{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/","asOf":"2026-09-10","days":18},{"id":"carmustine","kind":"drug","name":"Carmustine","route":"/drugs/carmustine/","asOf":"2026-09-10","days":18},{"id":"chlorambucil","kind":"drug","name":"Chlorambucil","route":"/drugs/chlorambucil/","asOf":"2026-09-10","days":18},{"id":"clofarabine","kind":"drug","name":"Clofarabine","route":"/drugs/clofarabine/","asOf":"2026-09-10","days":18},{"id":"cytarabine","kind":"drug","name":"Cytarabine","route":"/drugs/cytarabine/","asOf":"2026-09-10","days":18},{"id":"dabrafenib","kind":"drug","name":"Dabrafenib","route":"/drugs/dabrafenib/","asOf":"2026-09-10","days":18},{"id":"dacarbazine","kind":"drug","name":"Dacarbazine","route":"/drugs/dacarbazine/","asOf":"2026-09-10","days":18},{"id":"daunorubicin","kind":"drug","name":"Daunorubicin","route":"/drugs/daunorubicin/","asOf":"2026-09-10","days":18},{"id":"decitabine","kind":"drug","name":"Decitabine","route":"/drugs/decitabine/","asOf":"2026-09-10","days":18},{"id":"epirubicin","kind":"drug","name":"Epirubicin","route":"/drugs/epirubicin/","asOf":"2026-09-10","days":18},{"id":"fludarabine","kind":"drug","name":"Fludarabine","route":"/drugs/fludarabine/","asOf":"2026-09-10","days":18},{"id":"flutamide","kind":"drug","name":"Flutamide","route":"/drugs/flutamide/","asOf":"2026-09-10","days":18},{"id":"idarubicin","kind":"drug","name":"Idarubicin","route":"/drugs/idarubicin/","asOf":"2026-09-10","days":18},{"id":"ixabepilone","kind":"drug","name":"Ixabepilone","route":"/drugs/ixabepilone/","asOf":"2026-09-10","days":18},{"id":"megestrol","kind":"drug","name":"Megestrol acetate","route":"/drugs/megestrol/","asOf":"2026-09-10","days":18},{"id":"mercaptopurine","kind":"drug","name":"Mercaptopurine","route":"/drugs/mercaptopurine/","asOf":"2026-09-10","days":18},{"id":"mitoxantrone","kind":"drug","name":"Mitoxantrone","route":"/drugs/mitoxantrone/","asOf":"2026-09-10","days":18},{"id":"nelarabine","kind":"drug","name":"Nelarabine","route":"/drugs/nelarabine/","asOf":"2026-09-10","days":18},{"id":"omacetaxine","kind":"drug","name":"Omacetaxine mepesuccinate","route":"/drugs/omacetaxine/","asOf":"2026-09-10","days":18},{"id":"procarbazine","kind":"drug","name":"Procarbazine","route":"/drugs/procarbazine/","asOf":"2026-09-10","days":18},{"id":"thioguanine","kind":"drug","name":"Thioguanine","route":"/drugs/thioguanine/","asOf":"2026-09-10","days":18},{"id":"thiotepa","kind":"drug","name":"Thiotepa","route":"/drugs/thiotepa/","asOf":"2026-09-10","days":18},{"id":"trametinib","kind":"drug","name":"Trametinib","route":"/drugs/trametinib/","asOf":"2026-09-10","days":18},{"id":"valrubicin","kind":"drug","name":"Valrubicin","route":"/drugs/valrubicin/","asOf":"2026-09-10","days":18},{"id":"vorinostat","kind":"drug","name":"Vorinostat","route":"/drugs/vorinostat/","asOf":"2026-09-10","days":18},{"id":"nilutamide","kind":"drug","name":"Nilutamide","route":"/drugs/nilutamide/","asOf":"2026-09-10","days":18},{"id":"toremifene","kind":"drug","name":"Toremifene","route":"/drugs/toremifene/","asOf":"2026-09-10","days":18},{"id":"raloxifene","kind":"drug","name":"Raloxifene","route":"/drugs/raloxifene/","asOf":"2026-09-10","days":18},{"id":"triptorelin","kind":"drug","name":"Triptorelin","route":"/drugs/triptorelin/","asOf":"2026-09-10","days":18},{"id":"dexamethasone","kind":"drug","name":"Dexamethasone","route":"/drugs/dexamethasone/","asOf":"2026-09-10","days":18},{"id":"prednisone","kind":"drug","name":"Prednisone","route":"/drugs/prednisone/","asOf":"2026-09-10","days":18},{"id":"imiquimod","kind":"drug","name":"Imiquimod","route":"/drugs/imiquimod/","asOf":"2026-09-10","days":18},{"id":"aminolevulinic-acid","kind":"drug","name":"Aminolevulinic acid (topical, for photodynamic therapy)","route":"/drugs/aminolevulinic-acid/","asOf":"2026-09-10","days":18},{"id":"denileukin-diftitox","kind":"drug","name":"Denileukin diftitox","route":"/drugs/denileukin-diftitox/","asOf":"2026-09-10","days":18},{"id":"ibritumomab-tiuxetan","kind":"drug","name":"Ibritumomab tiuxetan","route":"/drugs/ibritumomab-tiuxetan/","asOf":"2026-09-10","days":18},{"id":"necitumumab","kind":"drug","name":"Necitumumab","route":"/drugs/necitumumab/","asOf":"2026-09-10","days":18},{"id":"ofatumumab","kind":"drug","name":"Ofatumumab","route":"/drugs/ofatumumab/","asOf":"2026-09-10","days":18},{"id":"ziv-aflibercept","kind":"drug","name":"Ziv-aflibercept","route":"/drugs/ziv-aflibercept/","asOf":"2026-09-10","days":18},{"id":"selumetinib","kind":"drug","name":"Selumetinib","route":"/drugs/selumetinib/","asOf":"2026-09-10","days":18},{"id":"siltuximab","kind":"drug","name":"Siltuximab","route":"/drugs/siltuximab/","asOf":"2026-09-10","days":18},{"id":"sirolimus-albumin-bound","kind":"drug","name":"Sirolimus protein-bound particles","route":"/drugs/sirolimus-albumin-bound/","asOf":"2026-09-10","days":18},{"id":"denosumab","kind":"drug","name":"Denosumab","route":"/drugs/denosumab/","asOf":"2026-09-10","days":18},{"id":"zoledronic-acid","kind":"drug","name":"Zoledronic acid","route":"/drugs/zoledronic-acid/","asOf":"2026-09-10","days":18},{"id":"pamidronate","kind":"drug","name":"Pamidronate","route":"/drugs/pamidronate/","asOf":"2026-09-10","days":18},{"id":"tocilizumab","kind":"drug","name":"Tocilizumab","route":"/drugs/tocilizumab/","asOf":"2026-09-10","days":18},{"id":"amifostine","kind":"drug","name":"Amifostine","route":"/drugs/amifostine/","asOf":"2026-09-10","days":18},{"id":"aprepitant","kind":"drug","name":"Aprepitant (and fosaprepitant)","route":"/drugs/aprepitant/","asOf":"2026-09-10","days":18},{"id":"granisetron","kind":"drug","name":"Granisetron","route":"/drugs/granisetron/","asOf":"2026-09-10","days":18},{"id":"ondansetron","kind":"drug","name":"Ondansetron","route":"/drugs/ondansetron/","asOf":"2026-09-10","days":18},{"id":"palonosetron","kind":"drug","name":"Palonosetron","route":"/drugs/palonosetron/","asOf":"2026-09-10","days":18},{"id":"netupitant-palonosetron","kind":"drug","name":"Netupitant and palonosetron","route":"/drugs/netupitant-palonosetron/","asOf":"2026-09-10","days":18},{"id":"dexrazoxane","kind":"drug","name":"Dexrazoxane","route":"/drugs/dexrazoxane/","asOf":"2026-09-10","days":18},{"id":"mesna","kind":"drug","name":"Mesna","route":"/drugs/mesna/","asOf":"2026-09-10","days":18},{"id":"glucarpidase","kind":"drug","name":"Glucarpidase","route":"/drugs/glucarpidase/","asOf":"2026-09-10","days":18},{"id":"palifermin","kind":"drug","name":"Palifermin","route":"/drugs/palifermin/","asOf":"2026-09-10","days":18},{"id":"rasburicase","kind":"drug","name":"Rasburicase","route":"/drugs/rasburicase/","asOf":"2026-09-10","days":18},{"id":"plerixafor","kind":"drug","name":"Plerixafor","route":"/drugs/plerixafor/","asOf":"2026-09-10","days":18},{"id":"filgrastim","kind":"drug","name":"Filgrastim (G-CSF)","route":"/drugs/filgrastim/","asOf":"2026-09-10","days":18},{"id":"pegfilgrastim","kind":"drug","name":"Pegfilgrastim","route":"/drugs/pegfilgrastim/","asOf":"2026-09-10","days":18},{"id":"epoetin-alfa","kind":"drug","name":"Epoetin alfa","route":"/drugs/epoetin-alfa/","asOf":"2026-09-10","days":18},{"id":"darbepoetin-alfa","kind":"drug","name":"Darbepoetin alfa","route":"/drugs/darbepoetin-alfa/","asOf":"2026-09-10","days":18},{"id":"talc-sclerosant","kind":"drug","name":"Talc (intrapleural)","route":"/drugs/talc-sclerosant/","asOf":"2026-09-10","days":18},{"id":"hpv-quadrivalent-vaccine","kind":"drug","name":"HPV quadrivalent vaccine (types 6, 11, 16 and 18)","route":"/drugs/hpv-quadrivalent-vaccine/","asOf":"2026-09-10","days":18},{"id":"mirdametinib","kind":"drug","name":"Mirdametinib","route":"/drugs/mirdametinib/","asOf":"2026-09-10","days":18},{"id":"catumaxomab","kind":"drug","name":"Catumaxomab","route":"/drugs/catumaxomab/","asOf":"2026-09-10","days":18},{"id":"efbemalenograstim-alfa","kind":"drug","name":"Efbemalenograstim alfa","route":"/drugs/efbemalenograstim-alfa/","asOf":"2026-09-10","days":18},{"id":"padeliporfin","kind":"drug","name":"Padeliporfin","route":"/drugs/padeliporfin/","asOf":"2026-09-10","days":18},{"id":"telotristat-ethyl","kind":"drug","name":"Telotristat ethyl","route":"/drugs/telotristat-ethyl/","asOf":"2026-09-10","days":18},{"id":"tegafur-gimeracil-oteracil","kind":"drug","name":"Tegafur, gimeracil and oteracil (S-1)","route":"/drugs/tegafur-gimeracil-oteracil/","asOf":"2026-09-10","days":18},{"id":"vinflunine","kind":"drug","name":"Vinflunine","route":"/drugs/vinflunine/","asOf":"2026-09-10","days":18},{"id":"anagrelide","kind":"drug","name":"Anagrelide","route":"/drugs/anagrelide/","asOf":"2026-09-10","days":18},{"id":"temoporfin","kind":"drug","name":"Temoporfin","route":"/drugs/temoporfin/","asOf":"2026-09-10","days":18},{"id":"thyrotropin-alfa","kind":"drug","name":"Thyrotropin alfa","route":"/drugs/thyrotropin-alfa/","asOf":"2026-09-10","days":18},{"id":"tasonermin","kind":"drug","name":"Tasonermin","route":"/drugs/tasonermin/","asOf":"2026-09-10","days":18},{"id":"samarium-153-lexidronam","kind":"drug","name":"Samarium-153 lexidronam","route":"/drugs/samarium-153-lexidronam/","asOf":"2026-09-10","days":18},{"id":"ibandronic-acid","kind":"drug","name":"Ibandronic acid","route":"/drugs/ibandronic-acid/","asOf":"2026-09-10","days":18},{"id":"dorocubicel","kind":"drug","name":"Dorocubicel (UM171-expanded cord blood)","route":"/drugs/dorocubicel/","asOf":"2026-09-10","days":18},{"id":"mek","kind":"target","name":"MEK1/2","route":"/targets/mek/","asOf":"2026-09-10","days":18},{"id":"hdac","kind":"target","name":"Histone deacetylases (HDAC)","route":"/targets/hdac/","asOf":"2026-09-10","days":18},{"id":"rxr","kind":"target","name":"Retinoid X receptor (RXR)","route":"/targets/rxr/","asOf":"2026-09-10","days":18},{"id":"rankl","kind":"target","name":"RANK ligand (RANKL)","route":"/targets/rankl/","asOf":"2026-09-10","days":18},{"id":"il6","kind":"target","name":"Interleukin-6 and IL-6 receptor","route":"/targets/il6/","asOf":"2026-09-10","days":18},{"id":"cd25","kind":"target","name":"CD25 (IL-2 receptor alpha)","route":"/targets/cd25/","asOf":"2026-09-10","days":18},{"id":"mtor","kind":"target","name":"mTOR","route":"/targets/mtor/","asOf":"2026-09-10","days":18},{"id":"bausch-health","kind":"company","name":"Bausch Health","route":"/companies/bausch-health/","asOf":"2026-09-10","days":18},{"id":"otsuka","kind":"company","name":"Otsuka Pharmaceutical","route":"/companies/otsuka/","asOf":"2026-09-10","days":18},{"id":"helsinn","kind":"company","name":"Helsinn","route":"/companies/helsinn/","asOf":"2026-09-10","days":18},{"id":"recordati","kind":"company","name":"Recordati","route":"/companies/recordati/","asOf":"2026-09-10","days":18},{"id":"sandoz","kind":"company","name":"Sandoz","route":"/companies/sandoz/","asOf":"2026-09-10","days":18},{"id":"teva","kind":"company","name":"Teva Pharmaceuticals","route":"/companies/teva/","asOf":"2026-09-10","days":18},{"id":"leadiant","kind":"company","name":"Leadiant Biosciences","route":"/companies/leadiant/","asOf":"2026-09-10","days":18},{"id":"adienne","kind":"company","name":"Adienne Pharma & Biotech","route":"/companies/adienne/","asOf":"2026-09-10","days":18},{"id":"kyowa-kirin","kind":"company","name":"Kyowa Kirin","route":"/companies/kyowa-kirin/","asOf":"2026-09-10","days":18},{"id":"verity-pharma","kind":"company","name":"Verity Pharmaceuticals","route":"/companies/verity-pharma/","asOf":"2026-09-10","days":18},{"id":"biofrontera","kind":"company","name":"Biofrontera","route":"/companies/biofrontera/","asOf":"2026-09-10","days":18},{"id":"heron-therapeutics","kind":"company","name":"Heron Therapeutics","route":"/companies/heron-therapeutics/","asOf":"2026-09-10","days":18},{"id":"acrotech-biopharma","kind":"company","name":"Acrotech Biopharma","route":"/companies/acrotech-biopharma/","asOf":"2026-09-10","days":18},{"id":"citius-pharmaceuticals","kind":"company","name":"Citius Pharmaceuticals","route":"/companies/citius-pharmaceuticals/","asOf":"2026-09-10","days":18},{"id":"serb-pharmaceuticals","kind":"company","name":"SERB Pharmaceuticals","route":"/companies/serb-pharmaceuticals/","asOf":"2026-09-10","days":18},{"id":"tersera-therapeutics","kind":"company","name":"TerSera Therapeutics","route":"/companies/tersera-therapeutics/","asOf":"2026-09-10","days":18},{"id":"sobi","kind":"company","name":"Sobi (Swedish Orphan Biovitrum)","route":"/companies/sobi/","asOf":"2026-09-10","days":18},{"id":"hansoh-pharma","kind":"company","name":"Hansoh Pharmaceutical","route":"/companies/hansoh-pharma/","asOf":"2026-09-10","days":18},{"id":"evive-biotech","kind":"company","name":"Evive Biotech","route":"/companies/evive-biotech/","asOf":"2026-09-10","days":18},{"id":"pierre-fabre","kind":"company","name":"Pierre Fabre","route":"/companies/pierre-fabre/","asOf":"2026-09-10","days":18},{"id":"biolitec","kind":"company","name":"biolitec","route":"/companies/biolitec/","asOf":"2026-09-10","days":18},{"id":"bikanta","kind":"company","name":"Bikanta","route":"/companies/bikanta/","asOf":"2026-09-10","days":18},{"id":"notable-labs","kind":"company","name":"Notable Labs","route":"/companies/notable-labs/","asOf":"2026-09-10","days":18},{"id":"x-zell","kind":"company","name":"X-Zell","route":"/companies/x-zell/","asOf":"2026-09-10","days":18},{"id":"shasqi","kind":"company","name":"Shasqi","route":"/companies/shasqi/","asOf":"2026-09-10","days":18},{"id":"zpredicta","kind":"company","name":"zPREDICTA","route":"/companies/zpredicta/","asOf":"2026-09-10","days":18},{"id":"cofactor-genomics","kind":"company","name":"Cofactor Genomics","route":"/companies/cofactor-genomics/","asOf":"2026-09-10","days":18},{"id":"isono-health","kind":"company","name":"iSono Health","route":"/companies/isono-health/","asOf":"2026-09-10","days":18},{"id":"histowiz","kind":"company","name":"HistoWiz","route":"/companies/histowiz/","asOf":"2026-09-10","days":18},{"id":"billiontoone","kind":"company","name":"BillionToOne","route":"/companies/billiontoone/","asOf":"2026-09-10","days":18},{"id":"mednet","kind":"company","name":"Mednet (theMednet)","route":"/companies/mednet/","asOf":"2026-09-10","days":18},{"id":"delee","kind":"company","name":"Delee","route":"/companies/delee/","asOf":"2026-09-10","days":18},{"id":"oncobox","kind":"company","name":"Oncobox","route":"/companies/oncobox/","asOf":"2026-09-10","days":18},{"id":"cambridge-cancer-genomics","kind":"company","name":"Cambridge Cancer Genomics (CCG.ai)","route":"/companies/cambridge-cancer-genomics/","asOf":"2026-09-10","days":18},{"id":"tradewind-bioscience","kind":"company","name":"Tradewind BioScience","route":"/companies/tradewind-bioscience/","asOf":"2026-09-10","days":18},{"id":"persephone-biosciences","kind":"company","name":"Persephone Biosciences","route":"/companies/persephone-biosciences/","asOf":"2026-09-10","days":18},{"id":"reverie-labs","kind":"company","name":"Reverie Labs","route":"/companies/reverie-labs/","asOf":"2026-09-10","days":18},{"id":"fidocure","kind":"company","name":"FidoCure","route":"/companies/fidocure/","asOf":"2026-09-10","days":18},{"id":"data-driven-bioscience","kind":"company","name":"Data Driven Bioscience (Duoseq)","route":"/companies/data-driven-bioscience/","asOf":"2026-09-10","days":18},{"id":"clear-gene","kind":"company","name":"Clear Gene","route":"/companies/clear-gene/","asOf":"2026-09-10","days":18},{"id":"leah-labs","kind":"company","name":"LEAH Labs","route":"/companies/leah-labs/","asOf":"2026-09-10","days":18},{"id":"resistancebio","kind":"company","name":"ResistanceBio (Viosera Therapeutics)","route":"/companies/resistancebio/","asOf":"2026-09-10","days":18},{"id":"atomic-alchemy","kind":"company","name":"Atomic Alchemy","route":"/companies/atomic-alchemy/","asOf":"2026-09-10","days":18},{"id":"arpeggio-bio","kind":"company","name":"Arpeggio Bio","route":"/companies/arpeggio-bio/","asOf":"2026-09-10","days":18},{"id":"asher-bio","kind":"company","name":"Asher Biotherapeutics","route":"/companies/asher-bio/","asOf":"2026-09-10","days":18},{"id":"altay-therapeutics","kind":"company","name":"Altay Therapeutics","route":"/companies/altay-therapeutics/","asOf":"2026-09-10","days":18},{"id":"isabl","kind":"company","name":"Isabl","route":"/companies/isabl/","asOf":"2026-09-10","days":18},{"id":"algen-biotechnologies","kind":"company","name":"Algen Biotechnologies","route":"/companies/algen-biotechnologies/","asOf":"2026-09-10","days":18},{"id":"known-medicine","kind":"company","name":"Known Medicine","route":"/companies/known-medicine/","asOf":"2026-09-10","days":18},{"id":"kernal-biologics","kind":"company","name":"Kernal Biologics","route":"/companies/kernal-biologics/","asOf":"2026-09-10","days":18},{"id":"liyfe","kind":"company","name":"Liyfe","route":"/companies/liyfe/","asOf":"2026-09-10","days":18},{"id":"valink-therapeutics","kind":"company","name":"Valink Therapeutics","route":"/companies/valink-therapeutics/","asOf":"2026-09-10","days":18},{"id":"triomics","kind":"company","name":"Triomics","route":"/companies/triomics/","asOf":"2026-09-10","days":18},{"id":"aoa-dx","kind":"company","name":"AOA Dx","route":"/companies/aoa-dx/","asOf":"2026-09-10","days":18},{"id":"ananya-health","kind":"company","name":"Ananya Health","route":"/companies/ananya-health/","asOf":"2026-09-10","days":18},{"id":"reprosent","kind":"company","name":"REPROSENT","route":"/companies/reprosent/","asOf":"2026-09-10","days":18},{"id":"yemaachi-biotech","kind":"company","name":"Yemaachi Biotech","route":"/companies/yemaachi-biotech/","asOf":"2026-09-10","days":18},{"id":"digistain","kind":"company","name":"Digistain","route":"/companies/digistain/","asOf":"2026-09-10","days":18},{"id":"harmonic-discovery","kind":"company","name":"Harmonic Discovery","route":"/companies/harmonic-discovery/","asOf":"2026-09-10","days":18},{"id":"humane-genomics","kind":"company","name":"Humane Genomics","route":"/companies/humane-genomics/","asOf":"2026-09-10","days":18},{"id":"luminate-medical","kind":"company","name":"Luminate Medical","route":"/companies/luminate-medical/","asOf":"2026-09-10","days":18},{"id":"alixia","kind":"company","name":"Alixia","route":"/companies/alixia/","asOf":"2026-09-10","days":18},{"id":"nearwave","kind":"company","name":"NearWave","route":"/companies/nearwave/","asOf":"2026-09-10","days":18},{"id":"serinus-biosciences","kind":"company","name":"Serinus Biosciences","route":"/companies/serinus-biosciences/","asOf":"2026-09-10","days":18},{"id":"signatur-biosciences","kind":"company","name":"Signatur Biosciences","route":"/companies/signatur-biosciences/","asOf":"2026-09-10","days":18},{"id":"guardian-bio","kind":"company","name":"Guardian Bio","route":"/companies/guardian-bio/","asOf":"2026-09-10","days":18},{"id":"adventris-pharmaceuticals","kind":"company","name":"Adventris Pharmaceuticals","route":"/companies/adventris-pharmaceuticals/","asOf":"2026-09-10","days":18},{"id":"modulari-t","kind":"company","name":"Modulari-T","route":"/companies/modulari-t/","asOf":"2026-09-10","days":18},{"id":"numen","kind":"company","name":"Numen","route":"/companies/numen/","asOf":"2026-09-10","days":18},{"id":"synsorybio","kind":"company","name":"SynsoryBio","route":"/companies/synsorybio/","asOf":"2026-09-10","days":18},{"id":"velorum-therapeutics","kind":"company","name":"Velorum Therapeutics","route":"/companies/velorum-therapeutics/","asOf":"2026-09-10","days":18},{"id":"eris-biotech","kind":"company","name":"Eris Biotech","route":"/companies/eris-biotech/","asOf":"2026-09-10","days":18},{"id":"granza-bio","kind":"company","name":"Granza Bio","route":"/companies/granza-bio/","asOf":"2026-09-10","days":18},{"id":"kopra-bio","kind":"company","name":"Kopra Bio","route":"/companies/kopra-bio/","asOf":"2026-09-10","days":18},{"id":"aluna","kind":"company","name":"Aluna","route":"/companies/aluna/","asOf":"2026-09-10","days":18},{"id":"blank-bio","kind":"company","name":"Blank Bio","route":"/companies/blank-bio/","asOf":"2026-09-10","days":18},{"id":"nucleo-research","kind":"company","name":"Nucleo","route":"/companies/nucleo-research/","asOf":"2026-09-10","days":18},{"id":"origin-bio","kind":"company","name":"Origin Bio","route":"/companies/origin-bio/","asOf":"2026-09-10","days":18},{"id":"adialante","kind":"company","name":"Adialante","route":"/companies/adialante/","asOf":"2026-09-10","days":18},{"id":"tarebio","kind":"company","name":"TareBio","route":"/companies/tarebio/","asOf":"2026-09-10","days":18},{"id":"omanta","kind":"company","name":"Omanta","route":"/companies/omanta/","asOf":"2026-09-10","days":18},{"id":"gamgee","kind":"company","name":"Gamgee","route":"/companies/gamgee/","asOf":"2026-09-10","days":18},{"id":"abdera-therapeutics","kind":"company","name":"Abdera Therapeutics","route":"/companies/abdera-therapeutics/","asOf":"2026-09-10","days":18},{"id":"actinium-pharmaceuticals","kind":"company","name":"Actinium Pharmaceuticals","route":"/companies/actinium-pharmaceuticals/","asOf":"2026-09-10","days":18},{"id":"adcendo","kind":"company","name":"Adcendo","route":"/companies/adcendo/","asOf":"2026-09-10","days":18},{"id":"alentis-therapeutics","kind":"company","name":"Alentis Therapeutics","route":"/companies/alentis-therapeutics/","asOf":"2026-09-10","days":18},{"id":"alpha-tau-medical","kind":"company","name":"Alpha Tau Medical","route":"/companies/alpha-tau-medical/","asOf":"2026-09-10","days":18},{"id":"alpha-9-oncology","kind":"company","name":"Alpha-9 Oncology","route":"/companies/alpha-9-oncology/","asOf":"2026-09-10","days":18},{"id":"ariceum-therapeutics","kind":"company","name":"Ariceum Therapeutics","route":"/companies/ariceum-therapeutics/","asOf":"2026-09-10","days":18},{"id":"artbio","kind":"company","name":"ARTBIO","route":"/companies/artbio/","asOf":"2026-09-10","days":18},{"id":"callio-therapeutics","kind":"company","name":"Callio Therapeutics","route":"/companies/callio-therapeutics/","asOf":"2026-09-10","days":18},{"id":"convergent-therapeutics","kind":"company","name":"Convergent Therapeutics","route":"/companies/convergent-therapeutics/","asOf":"2026-09-10","days":18},{"id":"cytomx-therapeutics","kind":"company","name":"CytomX Therapeutics","route":"/companies/cytomx-therapeutics/","asOf":"2026-09-10","days":18},{"id":"dantari","kind":"company","name":"Dantari","route":"/companies/dantari/","asOf":"2026-09-10","days":18},{"id":"emergence-therapeutics","kind":"company","name":"Emergence Therapeutics","route":"/companies/emergence-therapeutics/","asOf":"2026-09-10","days":18},{"id":"enlaza-therapeutics","kind":"company","name":"Enlaza Therapeutics","route":"/companies/enlaza-therapeutics/","asOf":"2026-09-10","days":18},{"id":"evergreen-theragnostics","kind":"company","name":"Evergreen Theragnostics","route":"/companies/evergreen-theragnostics/","asOf":"2026-09-10","days":18},{"id":"firefly-bio","kind":"company","name":"Firefly Bio","route":"/companies/firefly-bio/","asOf":"2026-09-10","days":18},{"id":"iksuda-therapeutics","kind":"company","name":"Iksuda Therapeutics","route":"/companies/iksuda-therapeutics/","asOf":"2026-09-10","days":18},{"id":"mablink-bioscience","kind":"company","name":"Mablink Bioscience","route":"/companies/mablink-bioscience/","asOf":"2026-09-10","days":18},{"id":"mariana-oncology","kind":"company","name":"Mariana Oncology","route":"/companies/mariana-oncology/","asOf":"2026-09-10","days":18},{"id":"myricx-bio","kind":"company","name":"Myricx Bio","route":"/companies/myricx-bio/","asOf":"2026-09-10","days":18},{"id":"mythic-therapeutics","kind":"company","name":"Mythic Therapeutics","route":"/companies/mythic-therapeutics/","asOf":"2026-09-10","days":18},{"id":"nbe-therapeutics","kind":"company","name":"NBE-Therapeutics","route":"/companies/nbe-therapeutics/","asOf":"2026-09-10","days":18},{"id":"nucleus-radiopharma","kind":"company","name":"Nucleus RadioPharma","route":"/companies/nucleus-radiopharma/","asOf":"2026-09-10","days":18},{"id":"orum-therapeutics","kind":"company","name":"Orum Therapeutics","route":"/companies/orum-therapeutics/","asOf":"2026-09-10","days":18},{"id":"pheon-therapeutics","kind":"company","name":"Pheon Therapeutics","route":"/companies/pheon-therapeutics/","asOf":"2026-09-10","days":18},{"id":"point-biopharma","kind":"company","name":"POINT Biopharma","route":"/companies/point-biopharma/","asOf":"2026-09-10","days":18},{"id":"precirix","kind":"company","name":"Precirix","route":"/companies/precirix/","asOf":"2026-09-10","days":18},{"id":"profoundbio","kind":"company","name":"ProfoundBio","route":"/companies/profoundbio/","asOf":"2026-09-10","days":18},{"id":"radionetics-oncology","kind":"company","name":"Radionetics Oncology","route":"/companies/radionetics-oncology/","asOf":"2026-09-10","days":18},{"id":"ratio-therapeutics","kind":"company","name":"Ratio Therapeutics","route":"/companies/ratio-therapeutics/","asOf":"2026-09-10","days":18},{"id":"tallac-therapeutics","kind":"company","name":"Tallac Therapeutics","route":"/companies/tallac-therapeutics/","asOf":"2026-09-10","days":18},{"id":"adicet-bio","kind":"company","name":"Adicet Bio","route":"/companies/adicet-bio/","asOf":"2026-09-10","days":18},{"id":"affini-t-therapeutics","kind":"company","name":"Affini-T Therapeutics","route":"/companies/affini-t-therapeutics/","asOf":"2026-09-10","days":18},{"id":"allotera-therapeutics","kind":"company","name":"Allotera Therapeutics (formerly Wugen)","route":"/companies/allotera-therapeutics/","asOf":"2026-09-10","days":18},{"id":"amunix-pharmaceuticals","kind":"company","name":"Amunix Pharmaceuticals","route":"/companies/amunix-pharmaceuticals/","asOf":"2026-09-10","days":18},{"id":"arcellx","kind":"company","name":"Arcellx","route":"/companies/arcellx/","asOf":"2026-09-10","days":18},{"id":"bicara-therapeutics","kind":"company","name":"Bicara Therapeutics","route":"/companies/bicara-therapeutics/","asOf":"2026-09-10","days":18},{"id":"candel-therapeutics","kind":"company","name":"Candel Therapeutics","route":"/companies/candel-therapeutics/","asOf":"2026-09-10","days":18},{"id":"capstan-therapeutics","kind":"company","name":"Capstan Therapeutics","route":"/companies/capstan-therapeutics/","asOf":"2026-09-10","days":18},{"id":"cargo-therapeutics","kind":"company","name":"CARGO Therapeutics","route":"/companies/cargo-therapeutics/","asOf":"2026-09-10","days":18},{"id":"century-therapeutics","kind":"company","name":"Century Therapeutics","route":"/companies/century-therapeutics/","asOf":"2026-09-10","days":18},{"id":"compass-therapeutics","kind":"company","name":"Compass Therapeutics","route":"/companies/compass-therapeutics/","asOf":"2026-09-10","days":18},{"id":"cullinan-therapeutics","kind":"company","name":"Cullinan Therapeutics","route":"/companies/cullinan-therapeutics/","asOf":"2026-09-10","days":18},{"id":"harpoon-therapeutics","kind":"company","name":"Harpoon Therapeutics","route":"/companies/harpoon-therapeutics/","asOf":"2026-09-10","days":18},{"id":"igm-biosciences","kind":"company","name":"IGM Biosciences","route":"/companies/igm-biosciences/","asOf":"2026-09-10","days":18},{"id":"indapta-therapeutics","kind":"company","name":"Indapta Therapeutics","route":"/companies/indapta-therapeutics/","asOf":"2026-09-10","days":18},{"id":"janux-therapeutics","kind":"company","name":"Janux Therapeutics","route":"/companies/janux-therapeutics/","asOf":"2026-09-10","days":18},{"id":"kelonia-therapeutics","kind":"company","name":"Kelonia Therapeutics","route":"/companies/kelonia-therapeutics/","asOf":"2026-09-10","days":18},{"id":"lyell-immunopharma","kind":"company","name":"Lyell Immunopharma","route":"/companies/lyell-immunopharma/","asOf":"2026-09-10","days":18},{"id":"marengo-therapeutics","kind":"company","name":"Marengo Therapeutics","route":"/companies/marengo-therapeutics/","asOf":"2026-09-10","days":18},{"id":"marker-therapeutics","kind":"company","name":"Marker Therapeutics","route":"/companies/marker-therapeutics/","asOf":"2026-09-10","days":18},{"id":"neogene-therapeutics","kind":"company","name":"Neogene Therapeutics","route":"/companies/neogene-therapeutics/","asOf":"2026-09-10","days":18},{"id":"obsidian-therapeutics","kind":"company","name":"Obsidian Therapeutics","route":"/companies/obsidian-therapeutics/","asOf":"2026-09-10","days":18},{"id":"onk-therapeutics","kind":"company","name":"ONK Therapeutics","route":"/companies/onk-therapeutics/","asOf":"2026-09-10","days":18},{"id":"orca-bio","kind":"company","name":"Orca Bio","route":"/companies/orca-bio/","asOf":"2026-09-10","days":18},{"id":"poseida-therapeutics","kind":"company","name":"Poseida Therapeutics","route":"/companies/poseida-therapeutics/","asOf":"2026-09-10","days":18},{"id":"tmunity-therapeutics","kind":"company","name":"Tmunity Therapeutics","route":"/companies/tmunity-therapeutics/","asOf":"2026-09-10","days":18},{"id":"turnstone-biologics","kind":"company","name":"Turnstone Biologics","route":"/companies/turnstone-biologics/","asOf":"2026-09-10","days":18},{"id":"werewolf-therapeutics","kind":"company","name":"Werewolf Therapeutics","route":"/companies/werewolf-therapeutics/","asOf":"2026-09-10","days":18},{"id":"xilio-therapeutics","kind":"company","name":"Xilio Therapeutics","route":"/companies/xilio-therapeutics/","asOf":"2026-09-10","days":18},{"id":"belong-life","kind":"company","name":"Belong.Life","route":"/companies/belong-life/","asOf":"2026-09-10","days":18},{"id":"canopy","kind":"company","name":"Canopy","route":"/companies/canopy/","asOf":"2026-09-10","days":18},{"id":"careology","kind":"company","name":"Careology","route":"/companies/careology/","asOf":"2026-09-10","days":18},{"id":"carevive-systems","kind":"company","name":"Carevive Systems","route":"/companies/carevive-systems/","asOf":"2026-09-10","days":18},{"id":"carrum-health","kind":"company","name":"Carrum Health","route":"/companies/carrum-health/","asOf":"2026-09-10","days":18},{"id":"color-health","kind":"company","name":"Color Health","route":"/companies/color-health/","asOf":"2026-09-10","days":18},{"id":"deep-6-ai","kind":"company","name":"Deep 6 AI","route":"/companies/deep-6-ai/","asOf":"2026-09-10","days":18},{"id":"jasper-health","kind":"company","name":"Jasper Health","route":"/companies/jasper-health/","asOf":"2026-09-10","days":18},{"id":"massive-bio","kind":"company","name":"Massive Bio","route":"/companies/massive-bio/","asOf":"2026-09-10","days":18},{"id":"onc-ai","kind":"company","name":"Onc.AI","route":"/companies/onc-ai/","asOf":"2026-09-10","days":18},{"id":"oncohealth","kind":"company","name":"OncoHealth","route":"/companies/oncohealth/","asOf":"2026-09-10","days":18},{"id":"osara-health","kind":"company","name":"Osara Health","route":"/companies/osara-health/","asOf":"2026-09-10","days":18},{"id":"outcomes4me","kind":"company","name":"Outcomes4Me","route":"/companies/outcomes4me/","asOf":"2026-09-10","days":18},{"id":"perci-health","kind":"company","name":"Perci Health","route":"/companies/perci-health/","asOf":"2026-09-10","days":18},{"id":"radformation","kind":"company","name":"Radformation","route":"/companies/radformation/","asOf":"2026-09-10","days":18},{"id":"reimagine-care","kind":"company","name":"Reimagine Care","route":"/companies/reimagine-care/","asOf":"2026-09-10","days":18},{"id":"tailormed","kind":"company","name":"TailorMed","route":"/companies/tailormed/","asOf":"2026-09-10","days":18},{"id":"thyme-care","kind":"company","name":"Thyme Care","route":"/companies/thyme-care/","asOf":"2026-09-10","days":18},{"id":"trial-library","kind":"company","name":"Trial Library","route":"/companies/trial-library/","asOf":"2026-09-10","days":18},{"id":"adela","kind":"company","name":"Adela","route":"/companies/adela/","asOf":"2026-09-10","days":18},{"id":"ataraxis-ai","kind":"company","name":"Ataraxis AI","route":"/companies/ataraxis-ai/","asOf":"2026-09-10","days":18},{"id":"biodesix","kind":"company","name":"Biodesix","route":"/companies/biodesix/","asOf":"2026-09-10","days":18},{"id":"c2i-genomics","kind":"company","name":"C2i Genomics","route":"/companies/c2i-genomics/","asOf":"2026-09-10","days":18},{"id":"clearnote-health","kind":"company","name":"ClearNote Health","route":"/companies/clearnote-health/","asOf":"2026-09-10","days":18},{"id":"cyted-health","kind":"company","name":"Cyted Health","route":"/companies/cyted-health/","asOf":"2026-09-10","days":18},{"id":"elypta","kind":"company","name":"Elypta","route":"/companies/elypta/","asOf":"2026-09-10","days":18},{"id":"exai-bio","kind":"company","name":"Exai Bio","route":"/companies/exai-bio/","asOf":"2026-09-10","days":18},{"id":"haystack-oncology","kind":"company","name":"Haystack Oncology","route":"/companies/haystack-oncology/","asOf":"2026-09-10","days":18},{"id":"helio-genomics","kind":"company","name":"Helio Genomics","route":"/companies/helio-genomics/","asOf":"2026-09-10","days":18},{"id":"ibex-medical-analytics","kind":"company","name":"Ibex Medical Analytics","route":"/companies/ibex-medical-analytics/","asOf":"2026-09-10","days":18},{"id":"imagene-ai","kind":"company","name":"Imagene AI","route":"/companies/imagene-ai/","asOf":"2026-09-10","days":18},{"id":"inivata","kind":"company","name":"Inivata","route":"/companies/inivata/","asOf":"2026-09-10","days":18},{"id":"insight-molecular-diagnostics","kind":"company","name":"Insight Molecular Diagnostics (formerly Oncocyte)","route":"/companies/insight-molecular-diagnostics/","asOf":"2026-09-10","days":18},{"id":"kheiron-medical-technologies","kind":"company","name":"Kheiron Medical Technologies","route":"/companies/kheiron-medical-technologies/","asOf":"2026-09-10","days":18},{"id":"lucence","kind":"company","name":"Lucence","route":"/companies/lucence/","asOf":"2026-09-10","days":18},{"id":"naveris","kind":"company","name":"Naveris","route":"/companies/naveris/","asOf":"2026-09-10","days":18},{"id":"nonagen-bioscience","kind":"company","name":"Nonagen Bioscience","route":"/companies/nonagen-bioscience/","asOf":"2026-09-10","days":18},{"id":"nucleai","kind":"company","name":"Nucleai","route":"/companies/nucleai/","asOf":"2026-09-10","days":18},{"id":"nucleix","kind":"company","name":"Nucleix","route":"/companies/nucleix/","asOf":"2026-09-10","days":18},{"id":"owlstone-medical","kind":"company","name":"Owlstone Medical","route":"/companies/owlstone-medical/","asOf":"2026-09-10","days":18},{"id":"pathos-ai","kind":"company","name":"Pathos AI","route":"/companies/pathos-ai/","asOf":"2026-09-10","days":18},{"id":"therapixel","kind":"company","name":"Therapixel","route":"/companies/therapixel/","asOf":"2026-09-10","days":18},{"id":"universal-dx","kind":"company","name":"Universal DX","route":"/companies/universal-dx/","asOf":"2026-09-10","days":18},{"id":"valar-labs","kind":"company","name":"Valar Labs","route":"/companies/valar-labs/","asOf":"2026-09-10","days":18},{"id":"vara","kind":"company","name":"Vara","route":"/companies/vara/","asOf":"2026-09-10","days":18},{"id":"volitionrx","kind":"company","name":"VolitionRx","route":"/companies/volitionrx/","asOf":"2026-09-10","days":18},{"id":"volpara-health","kind":"company","name":"Volpara Health","route":"/companies/volpara-health/","asOf":"2026-09-10","days":18},{"id":"empyrean-medical-systems","kind":"company","name":"Empyrean Medical Systems","route":"/companies/empyrean-medical-systems/","asOf":"2026-09-10","days":18},{"id":"gt-medical-technologies","kind":"company","name":"GT Medical Technologies","route":"/companies/gt-medical-technologies/","asOf":"2026-09-10","days":18},{"id":"intraop-medical","kind":"company","name":"IntraOp Medical","route":"/companies/intraop-medical/","asOf":"2026-09-10","days":18},{"id":"leo-cancer-care","kind":"company","name":"Leo Cancer Care","route":"/companies/leo-cancer-care/","asOf":"2026-09-10","days":18},{"id":"monteris-medical","kind":"company","name":"Monteris Medical","route":"/companies/monteris-medical/","asOf":"2026-09-10","days":18},{"id":"neutron-therapeutics","kind":"company","name":"Neutron Therapeutics","route":"/companies/neutron-therapeutics/","asOf":"2026-09-10","days":18},{"id":"p-cure","kind":"company","name":"P-Cure","route":"/companies/p-cure/","asOf":"2026-09-10","days":18},{"id":"perimeter-medical-imaging-ai","kind":"company","name":"Perimeter Medical Imaging AI","route":"/companies/perimeter-medical-imaging-ai/","asOf":"2026-09-10","days":18},{"id":"quantum-surgical","kind":"company","name":"Quantum Surgical","route":"/companies/quantum-surgical/","asOf":"2026-09-10","days":18},{"id":"sonalasense","kind":"company","name":"SonALAsense","route":"/companies/sonalasense/","asOf":"2026-09-10","days":18},{"id":"tae-life-sciences","kind":"company","name":"TAE Life Sciences","route":"/companies/tae-life-sciences/","asOf":"2026-09-10","days":18},{"id":"theryq","kind":"company","name":"THERYQ","route":"/companies/theryq/","asOf":"2026-09-10","days":18},{"id":"vergent-bioscience","kind":"company","name":"Vergent Bioscience","route":"/companies/vergent-bioscience/","asOf":"2026-09-10","days":18},{"id":"xact-robotics","kind":"company","name":"XACT Robotics","route":"/companies/xact-robotics/","asOf":"2026-09-10","days":18},{"id":"xcision-medical-systems","kind":"company","name":"Xcision Medical Systems","route":"/companies/xcision-medical-systems/","asOf":"2026-09-10","days":18},{"id":"zap-surgical-systems","kind":"company","name":"ZAP Surgical Systems","route":"/companies/zap-surgical-systems/","asOf":"2026-09-10","days":18},{"id":"aqemia","kind":"company","name":"Aqemia","route":"/companies/aqemia/","asOf":"2026-09-10","days":18},{"id":"bighat-biosciences","kind":"company","name":"BigHat Biosciences","route":"/companies/bighat-biosciences/","asOf":"2026-09-10","days":18},{"id":"certis-oncology-solutions","kind":"company","name":"Certis Oncology Solutions","route":"/companies/certis-oncology-solutions/","asOf":"2026-09-10","days":18},{"id":"curevac","kind":"company","name":"CureVac","route":"/companies/curevac/","asOf":"2026-09-10","days":18},{"id":"cytoreason","kind":"company","name":"CytoReason","route":"/companies/cytoreason/","asOf":"2026-09-10","days":18},{"id":"evaxion","kind":"company","name":"Evaxion","route":"/companies/evaxion/","asOf":"2026-09-10","days":18},{"id":"exscientia","kind":"company","name":"Exscientia","route":"/companies/exscientia/","asOf":"2026-09-10","days":18},{"id":"geneos-therapeutics","kind":"company","name":"Geneos Therapeutics","route":"/companies/geneos-therapeutics/","asOf":"2026-09-10","days":18},{"id":"iktos","kind":"company","name":"Iktos","route":"/companies/iktos/","asOf":"2026-09-10","days":18},{"id":"immunai","kind":"company","name":"Immunai","route":"/companies/immunai/","asOf":"2026-09-10","days":18},{"id":"imugene","kind":"company","name":"Imugene","route":"/companies/imugene/","asOf":"2026-09-10","days":18},{"id":"io-biotech","kind":"company","name":"IO Biotech","route":"/companies/io-biotech/","asOf":"2026-09-10","days":18},{"id":"kanvas-biosciences","kind":"company","name":"Kanvas Biosciences","route":"/companies/kanvas-biosciences/","asOf":"2026-09-10","days":18},{"id":"maat-pharma","kind":"company","name":"MaaT Pharma","route":"/companies/maat-pharma/","asOf":"2026-09-10","days":18},{"id":"mendus","kind":"company","name":"Mendus","route":"/companies/mendus/","asOf":"2026-09-10","days":18},{"id":"microbiotica","kind":"company","name":"Microbiotica","route":"/companies/microbiotica/","asOf":"2026-09-10","days":18},{"id":"mission-bio","kind":"company","name":"Mission Bio","route":"/companies/mission-bio/","asOf":"2026-09-10","days":18},{"id":"noetik","kind":"company","name":"Noetik","route":"/companies/noetik/","asOf":"2026-09-10","days":18},{"id":"nykode-therapeutics","kind":"company","name":"Nykode Therapeutics","route":"/companies/nykode-therapeutics/","asOf":"2026-09-10","days":18},{"id":"oncohost","kind":"company","name":"OncoHost","route":"/companies/oncohost/","asOf":"2026-09-10","days":18},{"id":"ose-immunotherapeutics","kind":"company","name":"OSE Immunotherapeutics","route":"/companies/ose-immunotherapeutics/","asOf":"2026-09-10","days":18},{"id":"strand-therapeutics","kind":"company","name":"Strand Therapeutics","route":"/companies/strand-therapeutics/","asOf":"2026-09-10","days":18},{"id":"transgene","kind":"company","name":"Transgene","route":"/companies/transgene/","asOf":"2026-09-10","days":18},{"id":"turbine","kind":"company","name":"Turbine","route":"/companies/turbine/","asOf":"2026-09-10","days":18},{"id":"valo-health","kind":"company","name":"Valo Health","route":"/companies/valo-health/","asOf":"2026-09-10","days":18},{"id":"acrivon-therapeutics","kind":"company","name":"Acrivon Therapeutics","route":"/companies/acrivon-therapeutics/","asOf":"2026-09-10","days":18},{"id":"ambagon-therapeutics","kind":"company","name":"Ambagon Therapeutics","route":"/companies/ambagon-therapeutics/","asOf":"2026-09-10","days":18},{"id":"amphista-therapeutics","kind":"company","name":"Amphista Therapeutics","route":"/companies/amphista-therapeutics/","asOf":"2026-09-10","days":18},{"id":"black-diamond-therapeutics","kind":"company","name":"Black Diamond Therapeutics","route":"/companies/black-diamond-therapeutics/","asOf":"2026-09-10","days":18},{"id":"blueprint-medicines","kind":"company","name":"Blueprint Medicines","route":"/companies/blueprint-medicines/","asOf":"2026-09-10","days":18},{"id":"boundless-bio","kind":"company","name":"Boundless Bio","route":"/companies/boundless-bio/","asOf":"2026-09-10","days":18},{"id":"bridgebio-oncology-therapeutics","kind":"company","name":"BridgeBio Oncology Therapeutics","route":"/companies/bridgebio-oncology-therapeutics/","asOf":"2026-09-10","days":18},{"id":"captor-therapeutics","kind":"company","name":"Captor Therapeutics","route":"/companies/captor-therapeutics/","asOf":"2026-09-10","days":18},{"id":"cogent-biosciences","kind":"company","name":"Cogent Biosciences","route":"/companies/cogent-biosciences/","asOf":"2026-09-10","days":18},{"id":"cullgen","kind":"company","name":"Cullgen","route":"/companies/cullgen/","asOf":"2026-09-10","days":18},{"id":"enliven-therapeutics","kind":"company","name":"Enliven Therapeutics","route":"/companies/enliven-therapeutics/","asOf":"2026-09-10","days":18},{"id":"erasca","kind":"company","name":"Erasca","route":"/companies/erasca/","asOf":"2026-09-10","days":18},{"id":"foghorn-therapeutics","kind":"company","name":"Foghorn Therapeutics","route":"/companies/foghorn-therapeutics/","asOf":"2026-09-10","days":18},{"id":"halda-therapeutics","kind":"company","name":"Halda Therapeutics","route":"/companies/halda-therapeutics/","asOf":"2026-09-10","days":18},{"id":"ideaya-biosciences","kind":"company","name":"IDEAYA Biosciences","route":"/companies/ideaya-biosciences/","asOf":"2026-09-10","days":18},{"id":"inhibrx","kind":"company","name":"Inhibrx Biosciences","route":"/companies/inhibrx/","asOf":"2026-09-10","days":18},{"id":"k36-therapeutics","kind":"company","name":"K36 Therapeutics","route":"/companies/k36-therapeutics/","asOf":"2026-09-10","days":18},{"id":"kumquat-biosciences","kind":"company","name":"Kumquat Biosciences","route":"/companies/kumquat-biosciences/","asOf":"2026-09-10","days":18},{"id":"neomorph","kind":"company","name":"Neomorph","route":"/companies/neomorph/","asOf":"2026-09-10","days":18},{"id":"nested-therapeutics","kind":"company","name":"Nested Therapeutics","route":"/companies/nested-therapeutics/","asOf":"2026-09-10","days":18},{"id":"nimbus-therapeutics","kind":"company","name":"Nimbus Therapeutics","route":"/companies/nimbus-therapeutics/","asOf":"2026-09-10","days":18},{"id":"oric-pharmaceuticals","kind":"company","name":"ORIC Pharmaceuticals","route":"/companies/oric-pharmaceuticals/","asOf":"2026-09-10","days":18},{"id":"photys-therapeutics","kind":"company","name":"Photys Therapeutics","route":"/companies/photys-therapeutics/","asOf":"2026-09-10","days":18},{"id":"plexium","kind":"company","name":"Plexium","route":"/companies/plexium/","asOf":"2026-09-10","days":18},{"id":"prelude-therapeutics","kind":"company","name":"Prelude Therapeutics","route":"/companies/prelude-therapeutics/","asOf":"2026-09-10","days":18},{"id":"proxygen","kind":"company","name":"Proxygen","route":"/companies/proxygen/","asOf":"2026-09-10","days":18},{"id":"relay-therapeutics","kind":"company","name":"Relay Therapeutics","route":"/companies/relay-therapeutics/","asOf":"2026-09-10","days":18},{"id":"repare-therapeutics","kind":"company","name":"Repare Therapeutics","route":"/companies/repare-therapeutics/","asOf":"2026-09-10","days":18},{"id":"scorpion-therapeutics","kind":"company","name":"Scorpion Therapeutics","route":"/companies/scorpion-therapeutics/","asOf":"2026-09-10","days":18},{"id":"stablix","kind":"company","name":"Stablix","route":"/companies/stablix/","asOf":"2026-09-10","days":18},{"id":"tango-therapeutics","kind":"company","name":"Tango Therapeutics","route":"/companies/tango-therapeutics/","asOf":"2026-09-10","days":18},{"id":"treeline-biosciences","kind":"company","name":"Treeline Biosciences","route":"/companies/treeline-biosciences/","asOf":"2026-09-10","days":18},{"id":"triana-biomedicines","kind":"company","name":"Triana Biomedicines","route":"/companies/triana-biomedicines/","asOf":"2026-09-10","days":18},{"id":"tyra-biosciences","kind":"company","name":"Tyra Biosciences","route":"/companies/tyra-biosciences/","asOf":"2026-09-10","days":18},{"id":"zentalis-pharmaceuticals","kind":"company","name":"Zentalis Pharmaceuticals","route":"/companies/zentalis-pharmaceuticals/","asOf":"2026-09-10","days":18},{"id":"arden-bio","kind":"company","name":"Arden Bio","route":"/companies/arden-bio/","asOf":"2026-09-10","days":18},{"id":"echo-immune","kind":"company","name":"Echo Immune","route":"/companies/echo-immune/","asOf":"2026-09-10","days":18},{"id":"ignitus-bio","kind":"company","name":"Ignitus Bio","route":"/companies/ignitus-bio/","asOf":"2026-09-10","days":18},{"id":"invocata","kind":"company","name":"Invocata","route":"/companies/invocata/","asOf":"2026-09-10","days":18},{"id":"kernis-health","kind":"company","name":"Kernis Health","route":"/companies/kernis-health/","asOf":"2026-09-10","days":18},{"id":"minuteman-therapeutics","kind":"company","name":"Minuteman Therapeutics","route":"/companies/minuteman-therapeutics/","asOf":"2026-09-10","days":18},{"id":"palitra-bio","kind":"company","name":"Palitra Bio","route":"/companies/palitra-bio/","asOf":"2026-09-10","days":18},{"id":"perita-bio","kind":"company","name":"Perita Bio","route":"/companies/perita-bio/","asOf":"2026-09-10","days":18},{"id":"ranata-therapeutics","kind":"company","name":"Ranata Therapeutics","route":"/companies/ranata-therapeutics/","asOf":"2026-09-10","days":18},{"id":"rarivive","kind":"company","name":"Rarivive","route":"/companies/rarivive/","asOf":"2026-09-10","days":18},{"id":"relit-biosciences","kind":"company","name":"Relit Biosciences","route":"/companies/relit-biosciences/","asOf":"2026-09-10","days":18},{"id":"stitchpoint-bio","kind":"company","name":"Stitchpoint Bio","route":"/companies/stitchpoint-bio/","asOf":"2026-09-10","days":18},{"id":"yuga-bio","kind":"company","name":"Yuga Bio","route":"/companies/yuga-bio/","asOf":"2026-09-10","days":18},{"id":"y-combinator","kind":"company","name":"Y Combinator","route":"/companies/y-combinator/","asOf":"2026-09-10","days":18},{"id":"third-rock-ventures","kind":"company","name":"Third Rock Ventures","route":"/companies/third-rock-ventures/","asOf":"2026-09-10","days":18},{"id":"amgen-ventures","kind":"company","name":"Amgen Ventures","route":"/companies/amgen-ventures/","asOf":"2026-09-10","days":18},{"id":"a16z-bio-health","kind":"company","name":"Andreessen Horowitz Bio + Health","route":"/companies/a16z-bio-health/","asOf":"2026-09-10","days":18},{"id":"arch-venture-partners","kind":"company","name":"ARCH Venture Partners","route":"/companies/arch-venture-partners/","asOf":"2026-09-10","days":18},{"id":"flagship-pioneering","kind":"company","name":"Flagship Pioneering","route":"/companies/flagship-pioneering/","asOf":"2026-09-10","days":18},{"id":"atlas-venture","kind":"company","name":"Atlas Venture","route":"/companies/atlas-venture/","asOf":"2026-09-10","days":18},{"id":"versant-ventures","kind":"company","name":"Versant Ventures","route":"/companies/versant-ventures/","asOf":"2026-09-10","days":18},{"id":"orbimed","kind":"company","name":"OrbiMed","route":"/companies/orbimed/","asOf":"2026-09-10","days":18},{"id":"ra-capital","kind":"company","name":"RA Capital Management","route":"/companies/ra-capital/","asOf":"2026-09-10","days":18},{"id":"casdin-capital","kind":"company","name":"Casdin Capital","route":"/companies/casdin-capital/","asOf":"2026-09-10","days":18},{"id":"polaris-partners","kind":"company","name":"Polaris Partners","route":"/companies/polaris-partners/","asOf":"2026-09-10","days":18},{"id":"5am-ventures","kind":"company","name":"5AM Ventures","route":"/companies/5am-ventures/","asOf":"2026-09-10","days":18},{"id":"sofinnova-partners","kind":"company","name":"Sofinnova Partners","route":"/companies/sofinnova-partners/","asOf":"2026-09-10","days":18},{"id":"medicxi","kind":"company","name":"Medicxi","route":"/companies/medicxi/","asOf":"2026-09-10","days":18},{"id":"syncona","kind":"company","name":"Syncona","route":"/companies/syncona/","asOf":"2026-09-10","days":18},{"id":"forbion","kind":"company","name":"Forbion","route":"/companies/forbion/","asOf":"2026-09-10","days":18},{"id":"frazier-life-sciences","kind":"company","name":"Frazier Life Sciences","route":"/companies/frazier-life-sciences/","asOf":"2026-09-10","days":18},{"id":"bain-capital-life-sciences","kind":"company","name":"Bain Capital Life Sciences","route":"/companies/bain-capital-life-sciences/","asOf":"2026-09-10","days":18},{"id":"deerfield-management","kind":"company","name":"Deerfield Management","route":"/companies/deerfield-management/","asOf":"2026-09-10","days":18},{"id":"foresite-capital","kind":"company","name":"Foresite Capital","route":"/companies/foresite-capital/","asOf":"2026-09-10","days":18},{"id":"lux-capital","kind":"company","name":"Lux Capital","route":"/companies/lux-capital/","asOf":"2026-09-10","days":18},{"id":"khosla-ventures","kind":"company","name":"Khosla Ventures","route":"/companies/khosla-ventures/","asOf":"2026-09-10","days":18},{"id":"founders-fund","kind":"company","name":"Founders Fund","route":"/companies/founders-fund/","asOf":"2026-09-10","days":18},{"id":"general-catalyst","kind":"company","name":"General Catalyst","route":"/companies/general-catalyst/","asOf":"2026-09-10","days":18},{"id":"cancer-research-horizons","kind":"company","name":"Cancer Research Horizons","route":"/companies/cancer-research-horizons/","asOf":"2026-09-10","days":18},{"id":"mpm-bioimpact","kind":"company","name":"MPM BioImpact","route":"/companies/mpm-bioimpact/","asOf":"2026-09-10","days":18},{"id":"vida-ventures","kind":"company","name":"Vida Ventures","route":"/companies/vida-ventures/","asOf":"2026-09-10","days":18},{"id":"omega-funds","kind":"company","name":"Omega Funds","route":"/companies/omega-funds/","asOf":"2026-09-10","days":18},{"id":"samsara-biocapital","kind":"company","name":"Samsara BioCapital","route":"/companies/samsara-biocapital/","asOf":"2026-09-10","days":18},{"id":"cormorant-asset-management","kind":"company","name":"Cormorant Asset Management","route":"/companies/cormorant-asset-management/","asOf":"2026-09-10","days":18},{"id":"perceptive-advisors","kind":"company","name":"Perceptive Advisors","route":"/companies/perceptive-advisors/","asOf":"2026-09-10","days":18},{"id":"boxer-capital","kind":"company","name":"Boxer Capital","route":"/companies/boxer-capital/","asOf":"2026-09-10","days":18},{"id":"gv","kind":"company","name":"GV (Google Ventures)","route":"/companies/gv/","asOf":"2026-09-10","days":18},{"id":"novo-holdings","kind":"company","name":"Novo Holdings","route":"/companies/novo-holdings/","asOf":"2026-09-10","days":18},{"id":"sr-one","kind":"company","name":"SR One","route":"/companies/sr-one/","asOf":"2026-09-10","days":18},{"id":"pfizer-ventures","kind":"company","name":"Pfizer Ventures","route":"/companies/pfizer-ventures/","asOf":"2026-09-10","days":18},{"id":"novartis-venture-fund","kind":"company","name":"Novartis Venture Fund","route":"/companies/novartis-venture-fund/","asOf":"2026-09-10","days":18},{"id":"jjdc","kind":"company","name":"Johnson & Johnson Innovation - JJDC","route":"/companies/jjdc/","asOf":"2026-09-10","days":18},{"id":"roche-venture-fund","kind":"company","name":"Roche Venture Fund","route":"/companies/roche-venture-fund/","asOf":"2026-09-10","days":18},{"id":"msd-global-health-innovation-fund","kind":"company","name":"MSD Global Health Innovation Fund (Merck GHI)","route":"/companies/msd-global-health-innovation-fund/","asOf":"2026-09-10","days":18},{"id":"lilly-ventures","kind":"company","name":"Lilly Ventures","route":"/companies/lilly-ventures/","asOf":"2026-09-10","days":18},{"id":"abbvie-ventures","kind":"company","name":"AbbVie Ventures","route":"/companies/abbvie-ventures/","asOf":"2026-09-10","days":18},{"id":"leaps-by-bayer","kind":"company","name":"Leaps by Bayer","route":"/companies/leaps-by-bayer/","asOf":"2026-09-10","days":18},{"id":"sanofi-ventures","kind":"company","name":"Sanofi Ventures","route":"/companies/sanofi-ventures/","asOf":"2026-09-10","days":18},{"id":"takeda-ventures","kind":"company","name":"Takeda Ventures","route":"/companies/takeda-ventures/","asOf":"2026-09-10","days":18},{"id":"lls-therapy-acceleration-program","kind":"company","name":"Leukemia & Lymphoma Society Therapy Acceleration Program","route":"/companies/lls-therapy-acceleration-program/","asOf":"2026-09-10","days":18},{"id":"mmrf-myeloma-investment-fund","kind":"company","name":"Multiple Myeloma Research Foundation and Myeloma Investment Fund","route":"/companies/mmrf-myeloma-investment-fund/","asOf":"2026-09-10","days":18},{"id":"break-through-cancer","kind":"company","name":"Break Through Cancer","route":"/companies/break-through-cancer/","asOf":"2026-09-10","days":18},{"id":"venrock","kind":"company","name":"Venrock","route":"/companies/venrock/","asOf":"2026-09-10","days":18},{"id":"sv-health-investors","kind":"company","name":"SV Health Investors","route":"/companies/sv-health-investors/","asOf":"2026-09-10","days":18},{"id":"eqt-life-sciences","kind":"company","name":"EQT Life Sciences","route":"/companies/eqt-life-sciences/","asOf":"2026-09-10","days":18},{"id":"andera-partners","kind":"company","name":"Andera Partners","route":"/companies/andera-partners/","asOf":"2026-09-10","days":18},{"id":"illumina-ventures","kind":"company","name":"Illumina Ventures","route":"/companies/illumina-ventures/","asOf":"2026-09-10","days":18},{"id":"alexandria-venture-investments","kind":"company","name":"Alexandria Venture Investments","route":"/companies/alexandria-venture-investments/","asOf":"2026-09-10","days":18},{"id":"logos-capital","kind":"company","name":"Logos Capital","route":"/companies/logos-capital/","asOf":"2026-09-10","days":18},{"id":"jeito-capital","kind":"company","name":"Jeito Capital","route":"/companies/jeito-capital/","asOf":"2026-09-10","days":18},{"id":"tcgx","kind":"company","name":"TCGX (TCG Crossover)","route":"/companies/tcgx/","asOf":"2026-09-10","days":18},{"id":"ecor1-capital","kind":"company","name":"EcoR1 Capital","route":"/companies/ecor1-capital/","asOf":"2026-09-10","days":18},{"id":"gilde-healthcare","kind":"company","name":"Gilde Healthcare","route":"/companies/gilde-healthcare/","asOf":"2026-09-10","days":18},{"id":"lightspeed-venture-partners","kind":"company","name":"Lightspeed Venture Partners","route":"/companies/lightspeed-venture-partners/","asOf":"2026-09-10","days":18},{"id":"bpifrance","kind":"company","name":"Bpifrance","route":"/companies/bpifrance/","asOf":"2026-09-10","days":18},{"id":"f-prime-capital","kind":"company","name":"F-Prime Capital","route":"/companies/f-prime-capital/","asOf":"2026-09-10","days":18},{"id":"section-32","kind":"company","name":"Section 32 (S32)","route":"/companies/section-32/","asOf":"2026-09-10","days":18},{"id":"dcvc","kind":"company","name":"DCVC","route":"/companies/dcvc/","asOf":"2026-09-10","days":18},{"id":"longwood-fund","kind":"company","name":"Longwood Fund","route":"/companies/longwood-fund/","asOf":"2026-09-10","days":18},{"id":"mckesson-ventures","kind":"company","name":"McKesson Ventures","route":"/companies/mckesson-ventures/","asOf":"2026-09-10","days":18},{"id":"acs-brightedge","kind":"company","name":"ACS BrightEdge (American Cancer Society)","route":"/companies/acs-brightedge/","asOf":"2026-09-10","days":18},{"id":"sante-ventures","kind":"company","name":"Sante Ventures","route":"/companies/sante-ventures/","asOf":"2026-09-10","days":18},{"id":"evenone-ventures","kind":"company","name":"Even One Ventures","route":"/companies/evenone-ventures/","asOf":"2026-09-10","days":18},{"id":"diagnostics-roadmap","kind":"roadmap","name":"Diagnostics roadmap: stains → gene panels → blood tests that decide treatment","route":"/roadmaps/diagnostics-roadmap/","asOf":"2026-09-10","days":18},{"id":"surgery-roadmap","kind":"roadmap","name":"Surgery roadmap: radical operations → less surgery → no surgery when a drug has done the work","route":"/roadmaps/surgery-roadmap/","asOf":"2026-09-10","days":18},{"id":"chemotherapy-roadmap","kind":"roadmap","name":"Chemotherapy roadmap: mustard gas → curative combinations → the warhead inside smarter drugs","route":"/roadmaps/chemotherapy-roadmap/","asOf":"2026-09-10","days":18},{"id":"hormonal-therapy-roadmap","kind":"roadmap","name":"Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test","route":"/roadmaps/hormonal-therapy-roadmap/","asOf":"2026-09-10","days":18},{"id":"epigenetics-roadmap","kind":"roadmap","name":"Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome","route":"/roadmaps/epigenetics-roadmap/","asOf":"2026-09-10","days":18},{"id":"survivorship-roadmap","kind":"roadmap","name":"Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards","route":"/roadmaps/survivorship-roadmap/","asOf":"2026-09-10","days":18},{"id":"ai-oncology-roadmap","kind":"roadmap","name":"AI in oncology roadmap: pattern readers → foundation models → agents in the workflow","route":"/roadmaps/ai-oncology-roadmap/","asOf":"2026-09-10","days":18},{"id":"nutrition-lifestyle-roadmap","kind":"roadmap","name":"Diet, exercise and lifestyle roadmap: causes established → interventions that disappointed → exercise proven as treatment","route":"/roadmaps/nutrition-lifestyle-roadmap/","asOf":"2026-09-10","days":18},{"id":"devices-roadmap","kind":"roadmap","name":"Devices and physical therapies roadmap: heat and light → electric fields and focused sound → drug-releasing implants","route":"/roadmaps/devices-roadmap/","asOf":"2026-09-10","days":18},{"id":"radiation-roadmap","kind":"roadmap","name":"Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH","route":"/roadmaps/radiation-roadmap/","asOf":"2026-09-10","days":18},{"id":"targeted-therapy-roadmap","kind":"roadmap","name":"Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall","route":"/roadmaps/targeted-therapy-roadmap/","asOf":"2026-09-10","days":18},{"id":"drug-discovery-roadmap","kind":"roadmap","name":"Drug discovery roadmap: screening in mice → maps of dependency → designing in silico","route":"/roadmaps/drug-discovery-roadmap/","asOf":"2026-09-10","days":18},{"id":"prevention-roadmap","kind":"roadmap","name":"Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers","route":"/roadmaps/prevention-roadmap/","asOf":"2026-09-10","days":18},{"id":"paediatric-oncology-roadmap","kind":"roadmap","name":"Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first","route":"/roadmaps/paediatric-oncology-roadmap/","asOf":"2026-09-10","days":18},{"id":"global-access-roadmap","kind":"roadmap","name":"Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation","route":"/roadmaps/global-access-roadmap/","asOf":"2026-09-10","days":18},{"id":"trial-modernisation-roadmap","kind":"roadmap","name":"Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on","route":"/roadmaps/trial-modernisation-roadmap/","asOf":"2026-09-10","days":18},{"id":"micrornas-in-cancer","kind":"pathway","name":"MicroRNAs in cancer","route":"/pathways/micrornas-in-cancer/","asOf":"2026-09-10","days":18},{"id":"proteoglycans-in-cancer","kind":"pathway","name":"Proteoglycans in cancer","route":"/pathways/proteoglycans-in-cancer/","asOf":"2026-09-10","days":18},{"id":"chemical-carcinogenesis-receptor-activation","kind":"pathway","name":"Chemical carcinogenesis - receptor activation","route":"/pathways/chemical-carcinogenesis-receptor-activation/","asOf":"2026-09-10","days":18},{"id":"choline-metabolism-in-cancer","kind":"pathway","name":"Choline metabolism in cancer","route":"/pathways/choline-metabolism-in-cancer/","asOf":"2026-09-10","days":18},{"id":"colorectal-cancer-signalling","kind":"pathway","name":"Colorectal cancer (KEGG map)","route":"/pathways/colorectal-cancer-signalling/","asOf":"2026-09-10","days":18},{"id":"pancreatic-cancer-signalling","kind":"pathway","name":"Pancreatic cancer (KEGG map)","route":"/pathways/pancreatic-cancer-signalling/","asOf":"2026-09-10","days":18},{"id":"hepatocellular-carcinoma-signalling","kind":"pathway","name":"Hepatocellular carcinoma (KEGG map)","route":"/pathways/hepatocellular-carcinoma-signalling/","asOf":"2026-09-10","days":18},{"id":"gastric-cancer-signalling","kind":"pathway","name":"Gastric cancer (KEGG map)","route":"/pathways/gastric-cancer-signalling/","asOf":"2026-09-10","days":18},{"id":"glioma-signalling","kind":"pathway","name":"Glioma (KEGG map)","route":"/pathways/glioma-signalling/","asOf":"2026-09-10","days":18},{"id":"thyroid-cancer-signalling","kind":"pathway","name":"Thyroid cancer (KEGG map)","route":"/pathways/thyroid-cancer-signalling/","asOf":"2026-09-10","days":18},{"id":"aml-signalling","kind":"pathway","name":"Acute myeloid leukaemia (KEGG map)","route":"/pathways/aml-signalling/","asOf":"2026-09-10","days":18},{"id":"cml-signalling","kind":"pathway","name":"Chronic myeloid leukaemia (KEGG map)","route":"/pathways/cml-signalling/","asOf":"2026-09-10","days":18},{"id":"basal-cell-carcinoma-signalling","kind":"pathway","name":"Basal cell carcinoma (KEGG map)","route":"/pathways/basal-cell-carcinoma-signalling/","asOf":"2026-09-10","days":18},{"id":"melanoma-signalling","kind":"pathway","name":"Melanoma (KEGG map)","route":"/pathways/melanoma-signalling/","asOf":"2026-09-10","days":18},{"id":"renal-cell-carcinoma-signalling","kind":"pathway","name":"Renal cell carcinoma (KEGG map)","route":"/pathways/renal-cell-carcinoma-signalling/","asOf":"2026-09-10","days":18},{"id":"bladder-cancer-signalling","kind":"pathway","name":"Bladder cancer (KEGG map)","route":"/pathways/bladder-cancer-signalling/","asOf":"2026-09-10","days":18},{"id":"prostate-cancer-signalling","kind":"pathway","name":"Prostate cancer (KEGG map)","route":"/pathways/prostate-cancer-signalling/","asOf":"2026-09-10","days":18},{"id":"endometrial-cancer-signalling","kind":"pathway","name":"Endometrial cancer (KEGG map)","route":"/pathways/endometrial-cancer-signalling/","asOf":"2026-09-10","days":18},{"id":"breast-cancer-signalling","kind":"pathway","name":"Breast cancer (KEGG map)","route":"/pathways/breast-cancer-signalling/","asOf":"2026-09-10","days":18},{"id":"sclc-signalling","kind":"pathway","name":"Small cell lung cancer (KEGG map)","route":"/pathways/sclc-signalling/","asOf":"2026-09-10","days":18},{"id":"nsclc-signalling","kind":"pathway","name":"Non-small cell lung cancer (KEGG map)","route":"/pathways/nsclc-signalling/","asOf":"2026-09-10","days":18},{"id":"acta-oncologica","kind":"journal","name":"Acta oncologica","route":"/journals/acta-oncologica/","asOf":"2026-09-10","days":18},{"id":"advances-in-cancer-research","kind":"journal","name":"Advances in cancer research","route":"/journals/advances-in-cancer-research/","asOf":"2026-09-10","days":18},{"id":"american-journal-of-clinical-oncology","kind":"journal","name":"American journal of clinical oncology","route":"/journals/american-journal-of-clinical-oncology/","asOf":"2026-09-10","days":18},{"id":"asco-educational-book","kind":"journal","name":"American Society of Clinical Oncology educational book","route":"/journals/asco-educational-book/","asOf":"2026-09-10","days":18},{"id":"analytical-cellular-pathology","kind":"journal","name":"Analytical cellular pathology (Amsterdam)","route":"/journals/analytical-cellular-pathology/","asOf":"2026-09-10","days":18},{"id":"annals-of-surgical-oncology","kind":"journal","name":"Annals of surgical oncology","route":"/journals/annals-of-surgical-oncology/","asOf":"2026-09-10","days":18},{"id":"anticancer-research","kind":"journal","name":"Anticancer research","route":"/journals/anticancer-research/","asOf":"2026-09-10","days":18},{"id":"asia-pacific-journal-of-clinical-oncology","kind":"journal","name":"Asia-Pacific journal of clinical oncology","route":"/journals/asia-pacific-journal-of-clinical-oncology/","asOf":"2026-09-10","days":18},{"id":"asian-pacific-journal-of-cancer-prevention","kind":"journal","name":"Asian Pacific journal of cancer prevention","route":"/journals/asian-pacific-journal-of-cancer-prevention/","asOf":"2026-09-10","days":18},{"id":"bba-reviews-on-cancer","kind":"journal","name":"Biochimica et biophysica acta. Reviews on cancer","route":"/journals/bba-reviews-on-cancer/","asOf":"2026-09-10","days":18},{"id":"blood-cancer-discovery","kind":"journal","name":"Blood cancer discovery","route":"/journals/blood-cancer-discovery/","asOf":"2026-09-10","days":18},{"id":"blood-cancer-journal","kind":"journal","name":"Blood cancer journal","route":"/journals/blood-cancer-journal/","asOf":"2026-09-10","days":18},{"id":"bmc-cancer","kind":"journal","name":"BMC cancer","route":"/journals/bmc-cancer/","asOf":"2026-09-10","days":18},{"id":"brain-tumor-pathology","kind":"journal","name":"Brain tumor pathology","route":"/journals/brain-tumor-pathology/","asOf":"2026-09-10","days":18},{"id":"breast-cancer-jbcs","kind":"journal","name":"Breast cancer","route":"/journals/breast-cancer-jbcs/","asOf":"2026-09-10","days":18},{"id":"breast-cancer-research","kind":"journal","name":"Breast cancer research","route":"/journals/breast-cancer-research/","asOf":"2026-09-10","days":18},{"id":"breast-cancer-research-and-treatment","kind":"journal","name":"Breast cancer research and treatment","route":"/journals/breast-cancer-research-and-treatment/","asOf":"2026-09-10","days":18},{"id":"bulletin-du-cancer","kind":"journal","name":"Bulletin du cancer","route":"/journals/bulletin-du-cancer/","asOf":"2026-09-10","days":18},{"id":"cancer-biology-and-medicine","kind":"journal","name":"Cancer biology & medicine","route":"/journals/cancer-biology-and-medicine/","asOf":"2026-09-10","days":18},{"id":"cancer-biology-and-therapy","kind":"journal","name":"Cancer biology & therapy","route":"/journals/cancer-biology-and-therapy/","asOf":"2026-09-10","days":18},{"id":"cancer-biomarkers","kind":"journal","name":"Cancer biomarkers","route":"/journals/cancer-biomarkers/","asOf":"2026-09-10","days":18},{"id":"cancer-biotherapy-and-radiopharmaceuticals","kind":"journal","name":"Cancer biotherapy & radiopharmaceuticals","route":"/journals/cancer-biotherapy-and-radiopharmaceuticals/","asOf":"2026-09-10","days":18},{"id":"cancer-causes-and-control","kind":"journal","name":"Cancer causes & control","route":"/journals/cancer-causes-and-control/","asOf":"2026-09-10","days":18},{"id":"cancer-chemotherapy-and-pharmacology","kind":"journal","name":"Cancer chemotherapy and pharmacology","route":"/journals/cancer-chemotherapy-and-pharmacology/","asOf":"2026-09-10","days":18},{"id":"cancer-communications","kind":"journal","name":"Cancer communications","route":"/journals/cancer-communications/","asOf":"2026-09-10","days":18},{"id":"cancer-control","kind":"journal","name":"Cancer control","route":"/journals/cancer-control/","asOf":"2026-09-10","days":18},{"id":"cancer-cytopathology","kind":"journal","name":"Cancer cytopathology","route":"/journals/cancer-cytopathology/","asOf":"2026-09-10","days":18},{"id":"cancer-epidemiology","kind":"journal","name":"Cancer epidemiology","route":"/journals/cancer-epidemiology/","asOf":"2026-09-10","days":18},{"id":"cancer-gene-therapy","kind":"journal","name":"Cancer gene therapy","route":"/journals/cancer-gene-therapy/","asOf":"2026-09-10","days":18},{"id":"cancer-genetics","kind":"journal","name":"Cancer genetics","route":"/journals/cancer-genetics/","asOf":"2026-09-10","days":18},{"id":"cancer-genomics-and-proteomics","kind":"journal","name":"Cancer genomics & proteomics","route":"/journals/cancer-genomics-and-proteomics/","asOf":"2026-09-10","days":18},{"id":"cancer-imaging","kind":"journal","name":"Cancer imaging","route":"/journals/cancer-imaging/","asOf":"2026-09-10","days":18},{"id":"cancer-immunology-immunotherapy","kind":"journal","name":"Cancer immunology, immunotherapy","route":"/journals/cancer-immunology-immunotherapy/","asOf":"2026-09-10","days":18},{"id":"cancer-investigation","kind":"journal","name":"Cancer investigation","route":"/journals/cancer-investigation/","asOf":"2026-09-10","days":18},{"id":"cancer-letters","kind":"journal","name":"Cancer letters","route":"/journals/cancer-letters/","asOf":"2026-09-10","days":18},{"id":"cancer-medicine","kind":"journal","name":"Cancer medicine","route":"/journals/cancer-medicine/","asOf":"2026-09-10","days":18},{"id":"cancer-metastasis-reviews","kind":"journal","name":"Cancer metastasis reviews","route":"/journals/cancer-metastasis-reviews/","asOf":"2026-09-10","days":18},{"id":"cancer-nursing","kind":"journal","name":"Cancer nursing","route":"/journals/cancer-nursing/","asOf":"2026-09-10","days":18},{"id":"cancer-prevention-research","kind":"journal","name":"Cancer prevention research","route":"/journals/cancer-prevention-research/","asOf":"2026-09-10","days":18},{"id":"cancer-radiotherapie","kind":"journal","name":"Cancer radiothérapie","route":"/journals/cancer-radiotherapie/","asOf":"2026-09-10","days":18},{"id":"cancer-reports","kind":"journal","name":"Cancer reports","route":"/journals/cancer-reports/","asOf":"2026-09-10","days":18},{"id":"cancer-research-and-treatment","kind":"journal","name":"Cancer research and treatment","route":"/journals/cancer-research-and-treatment/","asOf":"2026-09-10","days":18},{"id":"cancer-research-communications","kind":"journal","name":"Cancer research communications","route":"/journals/cancer-research-communications/","asOf":"2026-09-10","days":18},{"id":"cancer-science","kind":"journal","name":"Cancer science","route":"/journals/cancer-science/","asOf":"2026-09-10","days":18},{"id":"cancer-treatment-and-research","kind":"journal","name":"Cancer treatment and research","route":"/journals/cancer-treatment-and-research/","asOf":"2026-09-10","days":18},{"id":"cancer-treatment-and-research-communications","kind":"journal","name":"Cancer treatment and research communications","route":"/journals/cancer-treatment-and-research-communications/","asOf":"2026-09-10","days":18},{"id":"cancer-treatment-reviews","kind":"journal","name":"Cancer treatment reviews","route":"/journals/cancer-treatment-reviews/","asOf":"2026-09-10","days":18},{"id":"carcinogenesis","kind":"journal","name":"Carcinogenesis","route":"/journals/carcinogenesis/","asOf":"2026-09-10","days":18},{"id":"cellular-oncology","kind":"journal","name":"Cellular oncology","route":"/journals/cellular-oncology/","asOf":"2026-09-10","days":18},{"id":"chinese-clinical-oncology","kind":"journal","name":"Chinese clinical oncology","route":"/journals/chinese-clinical-oncology/","asOf":"2026-09-10","days":18},{"id":"clinical-and-experimental-metastasis","kind":"journal","name":"Clinical & experimental metastasis","route":"/journals/clinical-and-experimental-metastasis/","asOf":"2026-09-10","days":18},{"id":"clinical-and-translational-oncology","kind":"journal","name":"Clinical & translational oncology","route":"/journals/clinical-and-translational-oncology/","asOf":"2026-09-10","days":18},{"id":"clinical-advances-in-hematology-and-oncology","kind":"journal","name":"Clinical advances in hematology & oncology","route":"/journals/clinical-advances-in-hematology-and-oncology/","asOf":"2026-09-10","days":18},{"id":"clinical-breast-cancer","kind":"journal","name":"Clinical breast cancer","route":"/journals/clinical-breast-cancer/","asOf":"2026-09-10","days":18},{"id":"clinical-colorectal-cancer","kind":"journal","name":"Clinical colorectal cancer","route":"/journals/clinical-colorectal-cancer/","asOf":"2026-09-10","days":18},{"id":"clinical-genitourinary-cancer","kind":"journal","name":"Clinical genitourinary cancer","route":"/journals/clinical-genitourinary-cancer/","asOf":"2026-09-10","days":18},{"id":"clinical-journal-of-oncology-nursing","kind":"journal","name":"Clinical journal of oncology nursing","route":"/journals/clinical-journal-of-oncology-nursing/","asOf":"2026-09-10","days":18},{"id":"clinical-lung-cancer","kind":"journal","name":"Clinical lung cancer","route":"/journals/clinical-lung-cancer/","asOf":"2026-09-10","days":18},{"id":"clinical-lymphoma-myeloma-and-leukemia","kind":"journal","name":"Clinical lymphoma, myeloma & leukemia","route":"/journals/clinical-lymphoma-myeloma-and-leukemia/","asOf":"2026-09-10","days":18},{"id":"clinical-oncology-rcr","kind":"journal","name":"Clinical oncology","route":"/journals/clinical-oncology-rcr/","asOf":"2026-09-10","days":18},{"id":"cns-oncology","kind":"journal","name":"CNS oncology","route":"/journals/cns-oncology/","asOf":"2026-09-10","days":18},{"id":"critical-reviews-in-oncogenesis","kind":"journal","name":"Critical reviews in oncogenesis","route":"/journals/critical-reviews-in-oncogenesis/","asOf":"2026-09-10","days":18},{"id":"critical-reviews-in-oncology-hematology","kind":"journal","name":"Critical reviews in oncology/hematology","route":"/journals/critical-reviews-in-oncology-hematology/","asOf":"2026-09-10","days":18},{"id":"current-cancer-drug-targets","kind":"journal","name":"Current cancer drug targets","route":"/journals/current-cancer-drug-targets/","asOf":"2026-09-10","days":18},{"id":"current-hematologic-malignancy-reports","kind":"journal","name":"Current hematologic malignancy reports","route":"/journals/current-hematologic-malignancy-reports/","asOf":"2026-09-10","days":18},{"id":"current-oncology-mdpi","kind":"journal","name":"Current oncology","route":"/journals/current-oncology-mdpi/","asOf":"2026-09-10","days":18},{"id":"current-oncology-reports","kind":"journal","name":"Current oncology reports","route":"/journals/current-oncology-reports/","asOf":"2026-09-10","days":18},{"id":"current-opinion-in-oncology","kind":"journal","name":"Current opinion in oncology","route":"/journals/current-opinion-in-oncology/","asOf":"2026-09-10","days":18},{"id":"current-problems-in-cancer","kind":"journal","name":"Current problems in cancer","route":"/journals/current-problems-in-cancer/","asOf":"2026-09-10","days":18},{"id":"current-treatment-options-in-oncology","kind":"journal","name":"Current treatment options in oncology","route":"/journals/current-treatment-options-in-oncology/","asOf":"2026-09-10","days":18},{"id":"endocrine-related-cancer","kind":"journal","name":"Endocrine-related cancer","route":"/journals/endocrine-related-cancer/","asOf":"2026-09-10","days":18},{"id":"esophagus-journal","kind":"journal","name":"Esophagus","route":"/journals/esophagus-journal/","asOf":"2026-09-10","days":18},{"id":"european-journal-of-cancer-prevention","kind":"journal","name":"European journal of cancer prevention","route":"/journals/european-journal-of-cancer-prevention/","asOf":"2026-09-10","days":18},{"id":"european-journal-of-oncology-nursing","kind":"journal","name":"European journal of oncology nursing","route":"/journals/european-journal-of-oncology-nursing/","asOf":"2026-09-10","days":18},{"id":"european-journal-of-surgical-oncology","kind":"journal","name":"European journal of surgical oncology","route":"/journals/european-journal-of-surgical-oncology/","asOf":"2026-09-10","days":18},{"id":"european-thyroid-journal","kind":"journal","name":"European thyroid journal","route":"/journals/european-thyroid-journal/","asOf":"2026-09-10","days":18},{"id":"experimental-oncology","kind":"journal","name":"Experimental oncology","route":"/journals/experimental-oncology/","asOf":"2026-09-10","days":18},{"id":"expert-review-of-anticancer-therapy","kind":"journal","name":"Expert review of anticancer therapy","route":"/journals/expert-review-of-anticancer-therapy/","asOf":"2026-09-10","days":18},{"id":"familial-cancer","kind":"journal","name":"Familial cancer","route":"/journals/familial-cancer/","asOf":"2026-09-10","days":18},{"id":"future-oncology","kind":"journal","name":"Future oncology","route":"/journals/future-oncology/","asOf":"2026-09-10","days":18},{"id":"gan-to-kagaku-ryoho","kind":"journal","name":"Gan to kagaku ryoho. Cancer & chemotherapy","route":"/journals/gan-to-kagaku-ryoho/","asOf":"2026-09-10","days":18},{"id":"gastric-cancer","kind":"journal","name":"Gastric cancer","route":"/journals/gastric-cancer/","asOf":"2026-09-10","days":18},{"id":"genes-chromosomes-and-cancer","kind":"journal","name":"Genes, chromosomes & cancer","route":"/journals/genes-chromosomes-and-cancer/","asOf":"2026-09-10","days":18},{"id":"head-and-neck-journal","kind":"journal","name":"Head & neck","route":"/journals/head-and-neck-journal/","asOf":"2026-09-10","days":18},{"id":"head-and-neck-pathology","kind":"journal","name":"Head and neck pathology","route":"/journals/head-and-neck-pathology/","asOf":"2026-09-10","days":18},{"id":"hematological-oncology","kind":"journal","name":"Hematological oncology","route":"/journals/hematological-oncology/","asOf":"2026-09-10","days":18},{"id":"hematology-oncology-and-stem-cell-therapy","kind":"journal","name":"Hematology/oncology and stem cell therapy","route":"/journals/hematology-oncology-and-stem-cell-therapy/","asOf":"2026-09-10","days":18},{"id":"hematology-oncology-clinics-of-north-america","kind":"journal","name":"Hematology/oncology clinics of North America","route":"/journals/hematology-oncology-clinics-of-north-america/","asOf":"2026-09-10","days":18},{"id":"in-vivo","kind":"journal","name":"In vivo","route":"/journals/in-vivo/","asOf":"2026-09-10","days":18},{"id":"indian-journal-of-cancer","kind":"journal","name":"Indian journal of cancer","route":"/journals/indian-journal-of-cancer/","asOf":"2026-09-10","days":18},{"id":"integrative-cancer-therapies","kind":"journal","name":"Integrative cancer therapies","route":"/journals/integrative-cancer-therapies/","asOf":"2026-09-10","days":18},{"id":"international-journal-of-cancer","kind":"journal","name":"International journal of cancer","route":"/journals/international-journal-of-cancer/","asOf":"2026-09-10","days":18},{"id":"international-journal-of-clinical-oncology","kind":"journal","name":"International journal of clinical oncology","route":"/journals/international-journal-of-clinical-oncology/","asOf":"2026-09-10","days":18},{"id":"international-journal-of-gynecological-cancer","kind":"journal","name":"International journal of gynecological cancer","route":"/journals/international-journal-of-gynecological-cancer/","asOf":"2026-09-10","days":18},{"id":"international-journal-of-hyperthermia","kind":"journal","name":"International journal of hyperthermia","route":"/journals/international-journal-of-hyperthermia/","asOf":"2026-09-10","days":18},{"id":"international-journal-of-oncology","kind":"journal","name":"International journal of oncology","route":"/journals/international-journal-of-oncology/","asOf":"2026-09-10","days":18},{"id":"japanese-journal-of-clinical-oncology","kind":"journal","name":"Japanese journal of clinical oncology","route":"/journals/japanese-journal-of-clinical-oncology/","asOf":"2026-09-10","days":18},{"id":"jco-clinical-cancer-informatics","kind":"journal","name":"JCO clinical cancer informatics","route":"/journals/jco-clinical-cancer-informatics/","asOf":"2026-09-10","days":18},{"id":"jco-global-oncology","kind":"journal","name":"JCO global oncology","route":"/journals/jco-global-oncology/","asOf":"2026-09-10","days":18},{"id":"jmir-cancer","kind":"journal","name":"JMIR cancer","route":"/journals/jmir-cancer/","asOf":"2026-09-10","days":18},{"id":"jnci-cancer-spectrum","kind":"journal","name":"JNCI cancer spectrum","route":"/journals/jnci-cancer-spectrum/","asOf":"2026-09-10","days":18},{"id":"journal-of-adolescent-and-young-adult-oncology","kind":"journal","name":"Journal of adolescent and young adult oncology","route":"/journals/journal-of-adolescent-and-young-adult-oncology/","asOf":"2026-09-10","days":18},{"id":"journal-of-breast-imaging","kind":"journal","name":"Journal of breast imaging","route":"/journals/journal-of-breast-imaging/","asOf":"2026-09-10","days":18},{"id":"journal-of-cachexia-sarcopenia-and-muscle","kind":"journal","name":"Journal of cachexia, sarcopenia and muscle","route":"/journals/journal-of-cachexia-sarcopenia-and-muscle/","asOf":"2026-09-10","days":18},{"id":"journal-of-cancer-education","kind":"journal","name":"Journal of cancer education","route":"/journals/journal-of-cancer-education/","asOf":"2026-09-10","days":18},{"id":"journal-of-cancer-policy","kind":"journal","name":"Journal of cancer policy","route":"/journals/journal-of-cancer-policy/","asOf":"2026-09-10","days":18},{"id":"journal-of-cancer-research-and-clinical-oncology","kind":"journal","name":"Journal of cancer research and clinical oncology","route":"/journals/journal-of-cancer-research-and-clinical-oncology/","asOf":"2026-09-10","days":18},{"id":"journal-of-cancer-research-and-therapeutics","kind":"journal","name":"Journal of cancer research and therapeutics","route":"/journals/journal-of-cancer-research-and-therapeutics/","asOf":"2026-09-10","days":18},{"id":"journal-of-cancer-survivorship","kind":"journal","name":"Journal of cancer survivorship","route":"/journals/journal-of-cancer-survivorship/","asOf":"2026-09-10","days":18},{"id":"journal-of-environmental-pathology-toxicology-and-oncology","kind":"journal","name":"Journal of environmental pathology, toxicology and oncology","route":"/journals/journal-of-environmental-pathology-toxicology-and-oncology/","asOf":"2026-09-10","days":18},{"id":"journal-of-experimental-and-clinical-cancer-research","kind":"journal","name":"Journal of experimental & clinical cancer research","route":"/journals/journal-of-experimental-and-clinical-cancer-research/","asOf":"2026-09-10","days":18},{"id":"journal-of-gastric-cancer","kind":"journal","name":"Journal of gastric cancer","route":"/journals/journal-of-gastric-cancer/","asOf":"2026-09-10","days":18},{"id":"journal-of-gastrointestinal-cancer","kind":"journal","name":"Journal of gastrointestinal cancer","route":"/journals/journal-of-gastrointestinal-cancer/","asOf":"2026-09-10","days":18},{"id":"journal-of-geriatric-oncology","kind":"journal","name":"Journal of geriatric oncology","route":"/journals/journal-of-geriatric-oncology/","asOf":"2026-09-10","days":18},{"id":"journal-of-gynecologic-oncology","kind":"journal","name":"Journal of gynecologic oncology","route":"/journals/journal-of-gynecologic-oncology/","asOf":"2026-09-10","days":18},{"id":"journal-of-hematology-and-oncology","kind":"journal","name":"Journal of hematology & oncology","route":"/journals/journal-of-hematology-and-oncology/","asOf":"2026-09-10","days":18},{"id":"journal-of-immunotherapy","kind":"journal","name":"Journal of immunotherapy","route":"/journals/journal-of-immunotherapy/","asOf":"2026-09-10","days":18},{"id":"journal-of-mammary-gland-biology-and-neoplasia","kind":"journal","name":"Journal of mammary gland biology and neoplasia","route":"/journals/journal-of-mammary-gland-biology-and-neoplasia/","asOf":"2026-09-10","days":18},{"id":"journal-of-medical-imaging-and-radiation-oncology","kind":"journal","name":"Journal of medical imaging and radiation oncology","route":"/journals/journal-of-medical-imaging-and-radiation-oncology/","asOf":"2026-09-10","days":18},{"id":"journal-of-neuro-oncology","kind":"journal","name":"Journal of neuro-oncology","route":"/journals/journal-of-neuro-oncology/","asOf":"2026-09-10","days":18},{"id":"journal-of-oncology-pharmacy-practice","kind":"journal","name":"Journal of oncology pharmacy practice","route":"/journals/journal-of-oncology-pharmacy-practice/","asOf":"2026-09-10","days":18},{"id":"journal-of-pediatric-hematology-oncology","kind":"journal","name":"Journal of pediatric hematology/oncology","route":"/journals/journal-of-pediatric-hematology-oncology/","asOf":"2026-09-10","days":18},{"id":"journal-of-pediatric-hematology-oncology-nursing","kind":"journal","name":"Journal of pediatric hematology/oncology nursing","route":"/journals/journal-of-pediatric-hematology-oncology-nursing/","asOf":"2026-09-10","days":18},{"id":"journal-of-psychosocial-oncology","kind":"journal","name":"Journal of psychosocial oncology","route":"/journals/journal-of-psychosocial-oncology/","asOf":"2026-09-10","days":18},{"id":"journal-of-radiation-research","kind":"journal","name":"Journal of radiation research","route":"/journals/journal-of-radiation-research/","asOf":"2026-09-10","days":18},{"id":"journal-of-registry-management","kind":"journal","name":"Journal of registry management","route":"/journals/journal-of-registry-management/","asOf":"2026-09-10","days":18},{"id":"journal-of-surgical-oncology","kind":"journal","name":"Journal of surgical oncology","route":"/journals/journal-of-surgical-oncology/","asOf":"2026-09-10","days":18},{"id":"journal-of-the-egyptian-national-cancer-institute","kind":"journal","name":"Journal of the Egyptian National Cancer Institute","route":"/journals/journal-of-the-egyptian-national-cancer-institute/","asOf":"2026-09-10","days":18},{"id":"jnci-monographs","kind":"journal","name":"Journal of the National Cancer Institute. Monographs","route":"/journals/jnci-monographs/","asOf":"2026-09-10","days":18},{"id":"klinicka-onkologie","kind":"journal","name":"Klinická onkologie","route":"/journals/klinicka-onkologie/","asOf":"2026-09-10","days":18},{"id":"leukemia-and-lymphoma","kind":"journal","name":"Leukemia & lymphoma","route":"/journals/leukemia-and-lymphoma/","asOf":"2026-09-10","days":18},{"id":"leukemia-research","kind":"journal","name":"Leukemia research","route":"/journals/leukemia-research/","asOf":"2026-09-10","days":18},{"id":"lung-cancer-journal","kind":"journal","name":"Lung cancer","route":"/journals/lung-cancer-journal/","asOf":"2026-09-10","days":18},{"id":"magyar-onkologia","kind":"journal","name":"Magyar onkologia","route":"/journals/magyar-onkologia/","asOf":"2026-09-10","days":18},{"id":"medical-oncology","kind":"journal","name":"Medical oncology","route":"/journals/medical-oncology/","asOf":"2026-09-10","days":18},{"id":"melanoma-research","kind":"journal","name":"Melanoma research","route":"/journals/melanoma-research/","asOf":"2026-09-10","days":18},{"id":"molecular-cancer","kind":"journal","name":"Molecular cancer","route":"/journals/molecular-cancer/","asOf":"2026-09-10","days":18},{"id":"molecular-cancer-research","kind":"journal","name":"Molecular cancer research","route":"/journals/molecular-cancer-research/","asOf":"2026-09-10","days":18},{"id":"molecular-carcinogenesis","kind":"journal","name":"Molecular carcinogenesis","route":"/journals/molecular-carcinogenesis/","asOf":"2026-09-10","days":18},{"id":"molecular-oncology","kind":"journal","name":"Molecular oncology","route":"/journals/molecular-oncology/","asOf":"2026-09-10","days":18},{"id":"nar-cancer","kind":"journal","name":"NAR cancer","route":"/journals/nar-cancer/","asOf":"2026-09-10","days":18},{"id":"neoplasia","kind":"journal","name":"Neoplasia","route":"/journals/neoplasia/","asOf":"2026-09-10","days":18},{"id":"neoplasma","kind":"journal","name":"Neoplasma","route":"/journals/neoplasma/","asOf":"2026-09-10","days":18},{"id":"nutrition-and-cancer","kind":"journal","name":"Nutrition and cancer","route":"/journals/nutrition-and-cancer/","asOf":"2026-09-10","days":18},{"id":"oncogene-journal","kind":"journal","name":"Oncogene","route":"/journals/oncogene-journal/","asOf":"2026-09-10","days":18},{"id":"oncoimmunology","kind":"journal","name":"Oncoimmunology","route":"/journals/oncoimmunology/","asOf":"2026-09-10","days":18},{"id":"oncology-williston-park","kind":"journal","name":"Oncology (Williston Park)","route":"/journals/oncology-williston-park/","asOf":"2026-09-10","days":18},{"id":"oncology-karger","kind":"journal","name":"Oncology","route":"/journals/oncology-karger/","asOf":"2026-09-10","days":18},{"id":"oncology-nursing-forum","kind":"journal","name":"Oncology nursing forum","route":"/journals/oncology-nursing-forum/","asOf":"2026-09-10","days":18},{"id":"oncology-reports","kind":"journal","name":"Oncology reports","route":"/journals/oncology-reports/","asOf":"2026-09-10","days":18},{"id":"oncology-research","kind":"journal","name":"Oncology research","route":"/journals/oncology-research/","asOf":"2026-09-10","days":18},{"id":"oncology-research-and-treatment","kind":"journal","name":"Oncology research and treatment","route":"/journals/oncology-research-and-treatment/","asOf":"2026-09-10","days":18},{"id":"oncotarget","kind":"journal","name":"Oncotarget","route":"/journals/oncotarget/","asOf":"2026-09-10","days":18},{"id":"oral-oncology","kind":"journal","name":"Oral oncology","route":"/journals/oral-oncology/","asOf":"2026-09-10","days":18},{"id":"pathology-and-oncology-research","kind":"journal","name":"Pathology oncology research","route":"/journals/pathology-and-oncology-research/","asOf":"2026-09-10","days":18},{"id":"pediatric-hematology-and-oncology","kind":"journal","name":"Pediatric hematology and oncology","route":"/journals/pediatric-hematology-and-oncology/","asOf":"2026-09-10","days":18},{"id":"pigment-cell-and-melanoma-research","kind":"journal","name":"Pigment cell & melanoma research","route":"/journals/pigment-cell-and-melanoma-research/","asOf":"2026-09-10","days":18},{"id":"practical-radiation-oncology","kind":"journal","name":"Practical radiation oncology","route":"/journals/practical-radiation-oncology/","asOf":"2026-09-10","days":18},{"id":"prostate-cancer-and-prostatic-diseases","kind":"journal","name":"Prostate cancer and prostatic diseases","route":"/journals/prostate-cancer-and-prostatic-diseases/","asOf":"2026-09-10","days":18},{"id":"psycho-oncology-journal","kind":"journal","name":"Psycho-oncology","route":"/journals/psycho-oncology-journal/","asOf":"2026-09-10","days":18},{"id":"radiation-and-environmental-biophysics","kind":"journal","name":"Radiation and environmental biophysics","route":"/journals/radiation-and-environmental-biophysics/","asOf":"2026-09-10","days":18},{"id":"radiation-oncology","kind":"journal","name":"Radiation oncology","route":"/journals/radiation-oncology/","asOf":"2026-09-10","days":18},{"id":"radiology-and-oncology","kind":"journal","name":"Radiology and oncology","route":"/journals/radiology-and-oncology/","asOf":"2026-09-10","days":18},{"id":"radiology-imaging-cancer","kind":"journal","name":"Radiology. Imaging cancer","route":"/journals/radiology-imaging-cancer/","asOf":"2026-09-10","days":18},{"id":"recent-patents-on-anti-cancer-drug-discovery","kind":"journal","name":"Recent patents on anti-cancer drug discovery","route":"/journals/recent-patents-on-anti-cancer-drug-discovery/","asOf":"2026-09-10","days":18},{"id":"recent-results-in-cancer-research","kind":"journal","name":"Recent results in cancer research","route":"/journals/recent-results-in-cancer-research/","asOf":"2026-09-10","days":18},{"id":"seminars-in-cancer-biology","kind":"journal","name":"Seminars in cancer biology","route":"/journals/seminars-in-cancer-biology/","asOf":"2026-09-10","days":18},{"id":"seminars-in-oncology","kind":"journal","name":"Seminars in oncology","route":"/journals/seminars-in-oncology/","asOf":"2026-09-10","days":18},{"id":"seminars-in-oncology-nursing","kind":"journal","name":"Seminars in oncology nursing","route":"/journals/seminars-in-oncology-nursing/","asOf":"2026-09-10","days":18},{"id":"seminars-in-radiation-oncology","kind":"journal","name":"Seminars in radiation oncology","route":"/journals/seminars-in-radiation-oncology/","asOf":"2026-09-10","days":18},{"id":"strahlentherapie-und-onkologie","kind":"journal","name":"Strahlentherapie und Onkologie","route":"/journals/strahlentherapie-und-onkologie/","asOf":"2026-09-10","days":18},{"id":"supportive-care-in-cancer","kind":"journal","name":"Supportive care in cancer","route":"/journals/supportive-care-in-cancer/","asOf":"2026-09-10","days":18},{"id":"surgical-oncology","kind":"journal","name":"Surgical oncology","route":"/journals/surgical-oncology/","asOf":"2026-09-10","days":18},{"id":"surgical-oncology-clinics-of-north-america","kind":"journal","name":"Surgical oncology clinics of North America","route":"/journals/surgical-oncology-clinics-of-north-america/","asOf":"2026-09-10","days":18},{"id":"targeted-oncology","kind":"journal","name":"Targeted oncology","route":"/journals/targeted-oncology/","asOf":"2026-09-10","days":18},{"id":"technology-in-cancer-research-and-treatment","kind":"journal","name":"Technology in cancer research & treatment","route":"/journals/technology-in-cancer-research-and-treatment/","asOf":"2026-09-10","days":18},{"id":"the-breast","kind":"journal","name":"The Breast","route":"/journals/the-breast/","asOf":"2026-09-10","days":18},{"id":"the-breast-journal","kind":"journal","name":"The breast journal","route":"/journals/the-breast-journal/","asOf":"2026-09-10","days":18},{"id":"the-cancer-journal","kind":"journal","name":"The cancer journal","route":"/journals/the-cancer-journal/","asOf":"2026-09-10","days":18},{"id":"gulf-journal-of-oncology","kind":"journal","name":"The Gulf journal of oncology","route":"/journals/gulf-journal-of-oncology/","asOf":"2026-09-10","days":18},{"id":"international-journal-of-biological-markers","kind":"journal","name":"The International journal of biological markers","route":"/journals/international-journal-of-biological-markers/","asOf":"2026-09-10","days":18},{"id":"the-oncologist","kind":"journal","name":"The oncologist","route":"/journals/the-oncologist/","asOf":"2026-09-10","days":18},{"id":"thoracic-cancer","kind":"journal","name":"Thoracic cancer","route":"/journals/thoracic-cancer/","asOf":"2026-09-10","days":18},{"id":"trends-in-cancer","kind":"journal","name":"Trends in cancer","route":"/journals/trends-in-cancer/","asOf":"2026-09-10","days":18},{"id":"tumori","kind":"journal","name":"Tumori","route":"/journals/tumori/","asOf":"2026-09-10","days":18},{"id":"tumour-biology","kind":"journal","name":"Tumour biology","route":"/journals/tumour-biology/","asOf":"2026-09-10","days":18},{"id":"tumour-virus-research","kind":"journal","name":"Tumour virus research","route":"/journals/tumour-virus-research/","asOf":"2026-09-10","days":18},{"id":"urologic-oncology","kind":"journal","name":"Urologic oncology","route":"/journals/urologic-oncology/","asOf":"2026-09-10","days":18},{"id":"veterinary-and-comparative-oncology","kind":"journal","name":"Veterinary and comparative oncology","route":"/journals/veterinary-and-comparative-oncology/","asOf":"2026-09-10","days":18},{"id":"world-journal-of-surgical-oncology","kind":"journal","name":"World journal of surgical oncology","route":"/journals/world-journal-of-surgical-oncology/","asOf":"2026-09-10","days":18},{"id":"chinese-journal-of-lung-cancer","kind":"journal","name":"Zhongguo fei ai za zhi","route":"/journals/chinese-journal-of-lung-cancer/","asOf":"2026-09-10","days":18},{"id":"chinese-journal-of-oncology","kind":"journal","name":"Zhonghua zhong liu za zhi","route":"/journals/chinese-journal-of-oncology/","asOf":"2026-09-10","days":18},{"id":"ctong","kind":"company","name":"Chinese Thoracic Oncology Group","route":"/companies/ctong/","asOf":"2026-09-10","days":18},{"id":"itcc","kind":"company","name":"Innovative Therapies for Children with Cancer (ITCC)","route":"/companies/itcc/","asOf":"2026-09-10","days":18},{"id":"qilu-pharmaceutical","kind":"company","name":"Qilu Pharmaceutical","route":"/companies/qilu-pharmaceutical/","asOf":"2026-09-11","days":17},{"id":"mabwell-shanghai-bioscience","kind":"company","name":"Mabwell (Shanghai) Bioscience","route":"/companies/mabwell-shanghai-bioscience/","asOf":"2026-09-11","days":17},{"id":"lanova-medicines","kind":"company","name":"LaNova Medicines","route":"/companies/lanova-medicines/","asOf":"2026-09-11","days":17},{"id":"lepu-biopharma","kind":"company","name":"Lepu Biopharma","route":"/companies/lepu-biopharma/","asOf":"2026-09-11","days":17},{"id":"nanjing-leads-biolabs","kind":"company","name":"Nanjing Leads Biolabs","route":"/companies/nanjing-leads-biolabs/","asOf":"2026-09-11","days":17},{"id":"philogen-s-p-a","kind":"company","name":"Philogen S.p.A.","route":"/companies/philogen-s-p-a/","asOf":"2026-09-11","days":17},{"id":"sinocelltech","kind":"company","name":"Sinocelltech","route":"/companies/sinocelltech/","asOf":"2026-09-11","days":17},{"id":"eikon-therapeutics","kind":"company","name":"Eikon Therapeutics","route":"/companies/eikon-therapeutics/","asOf":"2026-09-11","days":17},{"id":"evopoint-biosciences","kind":"company","name":"Evopoint Biosciences","route":"/companies/evopoint-biosciences/","asOf":"2026-09-11","days":17},{"id":"nuvation-bio","kind":"company","name":"Nuvation Bio","route":"/companies/nuvation-bio/","asOf":"2026-09-11","days":17},{"id":"avistone-biotechnology","kind":"company","name":"Avistone Biotechnology","route":"/companies/avistone-biotechnology/","asOf":"2026-09-11","days":17},{"id":"catalym","kind":"company","name":"CatalYm","route":"/companies/catalym/","asOf":"2026-09-11","days":17},{"id":"miltenyi-biomedicine","kind":"company","name":"Miltenyi Biomedicine","route":"/companies/miltenyi-biomedicine/","asOf":"2026-09-11","days":17},{"id":"oncoc4","kind":"company","name":"OncoC4","route":"/companies/oncoc4/","asOf":"2026-09-11","days":17},{"id":"ryvu-therapeutics","kind":"company","name":"Ryvu Therapeutics","route":"/companies/ryvu-therapeutics/","asOf":"2026-09-11","days":17},{"id":"shanghai-fosun-pharmaceutical-industrial-development","kind":"company","name":"Shanghai Fosun Pharmaceutical Industrial Development","route":"/companies/shanghai-fosun-pharmaceutical-industrial-development/","asOf":"2026-09-11","days":17},{"id":"arcus-biosciences","kind":"company","name":"Arcus Biosciences","route":"/companies/arcus-biosciences/","asOf":"2026-09-11","days":17},{"id":"bioinvent-international","kind":"company","name":"BioInvent International","route":"/companies/bioinvent-international/","asOf":"2026-09-11","days":17},{"id":"haihe-biopharma","kind":"company","name":"Haihe Biopharma","route":"/companies/haihe-biopharma/","asOf":"2026-09-11","days":17},{"id":"multitude-therapeutics","kind":"company","name":"Multitude Therapeutics","route":"/companies/multitude-therapeutics/","asOf":"2026-09-11","days":17},{"id":"orion-orion-pharma","kind":"company","name":"Orion, Orion Pharma","route":"/companies/orion-orion-pharma/","asOf":"2026-09-11","days":17},{"id":"shenzhen-targetrx","kind":"company","name":"Shenzhen TargetRx","route":"/companies/shenzhen-targetrx/","asOf":"2026-09-11","days":17},{"id":"bio-thera-solutions","kind":"company","name":"Bio-Thera Solutions","route":"/companies/bio-thera-solutions/","asOf":"2026-09-11","days":17},{"id":"crinetics-pharmaceuticals","kind":"company","name":"Crinetics Pharmaceuticals","route":"/companies/crinetics-pharmaceuticals/","asOf":"2026-09-11","days":17},{"id":"ellipses-pharma","kind":"company","name":"Ellipses Pharma","route":"/companies/ellipses-pharma/","asOf":"2026-09-11","days":17},{"id":"epicentrx","kind":"company","name":"EpicentRx","route":"/companies/epicentrx/","asOf":"2026-09-11","days":17},{"id":"intra-immusg","kind":"company","name":"Intra-IMMUSG","route":"/companies/intra-immusg/","asOf":"2026-09-11","days":17},{"id":"kartos-therapeutics","kind":"company","name":"Kartos Therapeutics","route":"/companies/kartos-therapeutics/","asOf":"2026-09-11","days":17},{"id":"neonc-technologies","kind":"company","name":"Neonc Technologies","route":"/companies/neonc-technologies/","asOf":"2026-09-11","days":17},{"id":"oncolytics-biotech","kind":"company","name":"Oncolytics Biotech","route":"/companies/oncolytics-biotech/","asOf":"2026-09-11","days":17},{"id":"rakuten-medical","kind":"company","name":"Rakuten Medical","route":"/companies/rakuten-medical/","asOf":"2026-09-11","days":17},{"id":"shanghai-kechow-pharma","kind":"company","name":"Shanghai Kechow Pharma","route":"/companies/shanghai-kechow-pharma/","asOf":"2026-09-11","days":17},{"id":"shenzhen-ionova-life-sciences","kind":"company","name":"Shenzhen Ionova Life Sciences","route":"/companies/shenzhen-ionova-life-sciences/","asOf":"2026-09-11","days":17},{"id":"treadwell-therapeutics","kind":"company","name":"Treadwell Therapeutics","route":"/companies/treadwell-therapeutics/","asOf":"2026-09-11","days":17},{"id":"urogen-pharma","kind":"company","name":"UroGen Pharma","route":"/companies/urogen-pharma/","asOf":"2026-09-11","days":17},{"id":"xuanzhu-biopharmaceutical","kind":"company","name":"Xuanzhu Biopharmaceutical","route":"/companies/xuanzhu-biopharmaceutical/","asOf":"2026-09-11","days":17},{"id":"ap-biosciences","kind":"company","name":"AP Biosciences","route":"/companies/ap-biosciences/","asOf":"2026-09-11","days":17},{"id":"ascentawits-pharmaceuticals","kind":"company","name":"Ascentawits Pharmaceuticals","route":"/companies/ascentawits-pharmaceuticals/","asOf":"2026-09-11","days":17},{"id":"askgene-pharma","kind":"company","name":"AskGene Pharma","route":"/companies/askgene-pharma/","asOf":"2026-09-11","days":17},{"id":"aura-biosciences","kind":"company","name":"Aura Biosciences","route":"/companies/aura-biosciences/","asOf":"2026-09-11","days":17},{"id":"aveta-biomics","kind":"company","name":"Aveta Biomics","route":"/companies/aveta-biomics/","asOf":"2026-09-11","days":17},{"id":"cebiotex","kind":"company","name":"CEBIOTEX","route":"/companies/cebiotex/","asOf":"2026-09-11","days":17},{"id":"celltrion","kind":"company","name":"Celltrion","route":"/companies/celltrion/","asOf":"2026-09-11","days":17},{"id":"chongqing-precision-biotech","kind":"company","name":"Chongqing Precision Biotech","route":"/companies/chongqing-precision-biotech/","asOf":"2026-09-11","days":17},{"id":"civatech-oncology","kind":"company","name":"CivaTech Oncology","route":"/companies/civatech-oncology/","asOf":"2026-09-11","days":17},{"id":"corbus-pharmaceuticals","kind":"company","name":"Corbus Pharmaceuticals","route":"/companies/corbus-pharmaceuticals/","asOf":"2026-09-11","days":17},{"id":"curis","kind":"company","name":"Curis","route":"/companies/curis/","asOf":"2026-09-11","days":17},{"id":"d3-bio-wuxi","kind":"company","name":"D3 Bio (Wuxi)","route":"/companies/d3-bio-wuxi/","asOf":"2026-09-11","days":17},{"id":"elpiscience-suzhou-biopharma","kind":"company","name":"Elpiscience (Suzhou) Biopharma","route":"/companies/elpiscience-suzhou-biopharma/","asOf":"2026-09-11","days":17},{"id":"forward-pharmaceuticals","kind":"company","name":"Forward Pharmaceuticals","route":"/companies/forward-pharmaceuticals/","asOf":"2026-09-11","days":17},{"id":"futurechem","kind":"company","name":"FutureChem","route":"/companies/futurechem/","asOf":"2026-09-11","days":17},{"id":"genelux","kind":"company","name":"Genelux","route":"/companies/genelux/","asOf":"2026-09-11","days":17},{"id":"genequantum-healthcare-suzhou","kind":"company","name":"GeneQuantum Healthcare (Suzhou)","route":"/companies/genequantum-healthcare-suzhou/","asOf":"2026-09-11","days":17},{"id":"genprex","kind":"company","name":"Genprex","route":"/companies/genprex/","asOf":"2026-09-11","days":17},{"id":"georgiamune","kind":"company","name":"Georgiamune","route":"/companies/georgiamune/","asOf":"2026-09-11","days":17},{"id":"hangzhou-hanx-biopharmaceuticals","kind":"company","name":"Hangzhou Hanx Biopharmaceuticals","route":"/companies/hangzhou-hanx-biopharmaceuticals/","asOf":"2026-09-11","days":17},{"id":"hangzhou-sumgen-biotech","kind":"company","name":"Hangzhou Sumgen Biotech","route":"/companies/hangzhou-sumgen-biotech/","asOf":"2026-09-11","days":17},{"id":"hinova-pharmaceuticals","kind":"company","name":"Hinova Pharmaceuticals","route":"/companies/hinova-pharmaceuticals/","asOf":"2026-09-11","days":17},{"id":"immuneering","kind":"company","name":"Immuneering","route":"/companies/immuneering/","asOf":"2026-09-11","days":17},{"id":"immuneoncia-therapeutics","kind":"company","name":"ImmuneOncia Therapeutics","route":"/companies/immuneoncia-therapeutics/","asOf":"2026-09-11","days":17},{"id":"ionctura","kind":"company","name":"iOnctura","route":"/companies/ionctura/","asOf":"2026-09-11","days":17},{"id":"italfarmaco","kind":"company","name":"Italfarmaco","route":"/companies/italfarmaco/","asOf":"2026-09-11","days":17},{"id":"krystal-biotech","kind":"company","name":"Krystal Biotech","route":"/companies/krystal-biotech/","asOf":"2026-09-11","days":17},{"id":"laminar-pharmaceuticals","kind":"company","name":"Laminar Pharmaceuticals","route":"/companies/laminar-pharmaceuticals/","asOf":"2026-09-11","days":17},{"id":"ligachem-biosciences","kind":"company","name":"LigaChem Biosciences","route":"/companies/ligachem-biosciences/","asOf":"2026-09-11","days":17},{"id":"mabxience-research-s-l","kind":"company","name":"mAbxience Research S.L.","route":"/companies/mabxience-research-s-l/","asOf":"2026-09-11","days":17},{"id":"maia-biotechnology","kind":"company","name":"Maia Biotechnology","route":"/companies/maia-biotechnology/","asOf":"2026-09-11","days":17},{"id":"mbrace-therapeutics","kind":"company","name":"MBrace Therapeutics","route":"/companies/mbrace-therapeutics/","asOf":"2026-09-11","days":17},{"id":"molecular-partners","kind":"company","name":"Molecular Partners","route":"/companies/molecular-partners/","asOf":"2026-09-11","days":17},{"id":"olema-pharmaceuticals","kind":"company","name":"Olema Pharmaceuticals","route":"/companies/olema-pharmaceuticals/","asOf":"2026-09-11","days":17},{"id":"oncoverity","kind":"company","name":"OncoVerity","route":"/companies/oncoverity/","asOf":"2026-09-11","days":17},{"id":"protara-therapeutics","kind":"company","name":"Protara Therapeutics","route":"/companies/protara-therapeutics/","asOf":"2026-09-11","days":17},{"id":"qbiotics","kind":"company","name":"QBiotics","route":"/companies/qbiotics/","asOf":"2026-09-11","days":17},{"id":"ranok-therapeutics-hangzhou","kind":"company","name":"Ranok Therapeutics (Hangzhou)","route":"/companies/ranok-therapeutics-hangzhou/","asOf":"2026-09-11","days":17},{"id":"scancell","kind":"company","name":"Scancell","route":"/companies/scancell/","asOf":"2026-09-11","days":17},{"id":"shanghai-abelzeta","kind":"company","name":"Shanghai AbelZeta","route":"/companies/shanghai-abelzeta/","asOf":"2026-09-11","days":17},{"id":"shanghai-juncell-therapeutics","kind":"company","name":"Shanghai Juncell Therapeutics","route":"/companies/shanghai-juncell-therapeutics/","asOf":"2026-09-11","days":17},{"id":"sinotau-pharmaceutical","kind":"company","name":"Sinotau Pharmaceutical","route":"/companies/sinotau-pharmaceutical/","asOf":"2026-09-11","days":17},{"id":"spectracure","kind":"company","name":"SpectraCure","route":"/companies/spectracure/","asOf":"2026-09-11","days":17},{"id":"stcube","kind":"company","name":"STCube","route":"/companies/stcube/","asOf":"2026-09-11","days":17},{"id":"suzhou-forlong-biotechnology","kind":"company","name":"Suzhou Forlong Biotechnology","route":"/companies/suzhou-forlong-biotechnology/","asOf":"2026-09-11","days":17},{"id":"tiumbio","kind":"company","name":"TiumBio","route":"/companies/tiumbio/","asOf":"2026-09-11","days":17},{"id":"vyriad","kind":"company","name":"Vyriad","route":"/companies/vyriad/","asOf":"2026-09-11","days":17},{"id":"wigen-biomedicine-technology-shanghai","kind":"company","name":"Wigen Biomedicine Technology (Shanghai)","route":"/companies/wigen-biomedicine-technology-shanghai/","asOf":"2026-09-11","days":17},{"id":"biocad","kind":"company","name":"Biocad","route":"/companies/biocad/","asOf":"2026-09-11","days":17},{"id":"simcere","kind":"company","name":"Simcere Pharmaceutical","route":"/companies/simcere/","asOf":"2026-09-11","days":17},{"id":"bebetter-med","kind":"company","name":"BeBetter Med","route":"/companies/bebetter-med/","asOf":"2026-09-11","days":17},{"id":"dizal","kind":"company","name":"Dizal Pharmaceutical","route":"/companies/dizal/","asOf":"2026-09-11","days":17},{"id":"alx-oncology","kind":"company","name":"ALX Oncology","route":"/companies/alx-oncology/","asOf":"2026-09-11","days":17},{"id":"immunome","kind":"company","name":"Immunome","route":"/companies/immunome/","asOf":"2026-09-11","days":17},{"id":"inxmed","kind":"company","name":"InxMed","route":"/companies/inxmed/","asOf":"2026-09-11","days":17},{"id":"coherus","kind":"company","name":"Coherus BioSciences","route":"/companies/coherus/","asOf":"2026-09-11","days":17},{"id":"geron","kind":"company","name":"Geron Corporation","route":"/companies/geron/","asOf":"2026-09-11","days":17},{"id":"checkpoint-therapeutics","kind":"company","name":"Checkpoint Therapeutics","route":"/companies/checkpoint-therapeutics/","asOf":"2026-09-11","days":17},{"id":"xcovery","kind":"company","name":"Xcovery","route":"/companies/xcovery/","asOf":"2026-09-11","days":17},{"id":"medac","kind":"company","name":"medac","route":"/companies/medac/","asOf":"2026-09-11","days":17},{"id":"gamida-cell","kind":"company","name":"Gamida Cell","route":"/companies/gamida-cell/","asOf":"2026-09-11","days":17},{"id":"mesoblast","kind":"company","name":"Mesoblast","route":"/companies/mesoblast/","asOf":"2026-09-11","days":17},{"id":"delcath","kind":"company","name":"Delcath Systems","route":"/companies/delcath/","asOf":"2026-09-11","days":17},{"id":"merck-kgaa","kind":"company","name":"Merck KGaA (EMD Serono)","route":"/companies/merck-kgaa/","asOf":"2026-09-11","days":17},{"id":"innopharmax","kind":"company","name":"InnoPharmax","route":"/companies/innopharmax/","asOf":"2026-09-11","days":17},{"id":"sunshine-lake-pharma","kind":"company","name":"Sunshine Lake Pharma (HEC)","route":"/companies/sunshine-lake-pharma/","asOf":"2026-09-11","days":17},{"id":"ab-science","kind":"company","name":"AB Science","route":"/companies/ab-science/","asOf":"2026-09-11","days":17},{"id":"ucb","kind":"company","name":"UCB","route":"/companies/ucb/","asOf":"2026-09-11","days":17},{"id":"leo-pharma","kind":"company","name":"LEO Pharma","route":"/companies/leo-pharma/","asOf":"2026-09-11","days":17},{"id":"galderma","kind":"company","name":"Galderma","route":"/companies/galderma/","asOf":"2026-09-11","days":17},{"id":"almirall","kind":"company","name":"Almirall","route":"/companies/almirall/","asOf":"2026-09-11","days":17},{"id":"argenx","kind":"company","name":"argenx","route":"/companies/argenx/","asOf":"2026-09-11","days":17},{"id":"nektar-therapeutics","kind":"company","name":"Nektar Therapeutics","route":"/companies/nektar-therapeutics/","asOf":"2026-09-11","days":17},{"id":"agenus","kind":"company","name":"Agenus","route":"/companies/agenus/","asOf":"2026-09-11","days":17},{"id":"ascentage-pharma","kind":"company","name":"Ascentage Pharma","route":"/companies/ascentage-pharma/","asOf":"2026-09-11","days":17},{"id":"beyondspring","kind":"company","name":"BeyondSpring Pharmaceuticals","route":"/companies/beyondspring/","asOf":"2026-09-11","days":17},{"id":"photocure","kind":"company","name":"Photocure","route":"/companies/photocure/","asOf":"2026-09-11","days":17},{"id":"luye-pharma","kind":"company","name":"Luye Pharma Group","route":"/companies/luye-pharma/","asOf":"2026-09-11","days":17},{"id":"r-pharm","kind":"company","name":"R-Pharm","route":"/companies/r-pharm/","asOf":"2026-09-11","days":17},{"id":"dendreon","kind":"company","name":"Dendreon","route":"/companies/dendreon/","asOf":"2026-09-11","days":17},{"id":"spectrum-pharmaceuticals","kind":"company","name":"Spectrum Pharmaceuticals","route":"/companies/spectrum-pharmaceuticals/","asOf":"2026-09-11","days":17},{"id":"chugai","kind":"company","name":"Chugai Pharmaceutical","route":"/companies/chugai/","asOf":"2026-09-11","days":17},{"id":"inovio","kind":"company","name":"Inovio Pharmaceuticals","route":"/companies/inovio/","asOf":"2026-09-11","days":17},{"id":"tg-therapeutics","kind":"company","name":"TG Therapeutics","route":"/companies/tg-therapeutics/","asOf":"2026-09-11","days":17},{"id":"pharmaessentia","kind":"company","name":"PharmaEssentia","route":"/companies/pharmaessentia/","asOf":"2026-09-11","days":17},{"id":"aop-health","kind":"company","name":"AOP Health","route":"/companies/aop-health/","asOf":"2026-09-11","days":17},{"id":"heidelberg-pharma","kind":"company","name":"Heidelberg Pharma","route":"/companies/heidelberg-pharma/","asOf":"2026-09-11","days":17},{"id":"imunon","kind":"company","name":"Imunon","route":"/companies/imunon/","asOf":"2026-09-11","days":17},{"id":"polaris-group","kind":"company","name":"Polaris Group","route":"/companies/polaris-group/","asOf":"2026-09-11","days":17},{"id":"securabio","kind":"company","name":"SecuraBio","route":"/companies/securabio/","asOf":"2026-09-11","days":17},{"id":"phaxiam","kind":"company","name":"Phaxiam Therapeutics (formerly ERYtech Pharma)","route":"/companies/phaxiam/","asOf":"2026-09-11","days":17},{"id":"navidea","kind":"company","name":"Navidea Biopharmaceuticals","route":"/companies/navidea/","asOf":"2026-09-11","days":17},{"id":"clovis-oncology","kind":"company","name":"Clovis Oncology","route":"/companies/clovis-oncology/","asOf":"2026-09-11","days":17},{"id":"soligenix","kind":"company","name":"Soligenix","route":"/companies/soligenix/","asOf":"2026-09-11","days":17},{"id":"veru","kind":"company","name":"Veru","route":"/companies/veru/","asOf":"2026-09-11","days":17},{"id":"cellectar","kind":"company","name":"Cellectar Biosciences","route":"/companies/cellectar/","asOf":"2026-09-11","days":17},{"id":"gc-cell","kind":"company","name":"GC Cell","route":"/companies/gc-cell/","asOf":"2026-09-11","days":17},{"id":"alaunos","kind":"company","name":"Alaunos Therapeutics (formerly Ziopharm Oncology)","route":"/companies/alaunos/","asOf":"2026-09-11","days":17},{"id":"3d-medicines","kind":"company","name":"3D Medicines","route":"/companies/3d-medicines/","asOf":"2026-09-11","days":17},{"id":"arrivent","kind":"company","name":"ArriVent BioPharma","route":"/companies/arrivent/","asOf":"2026-09-11","days":17},{"id":"oncopeptides","kind":"company","name":"Oncopeptides","route":"/companies/oncopeptides/","asOf":"2026-09-11","days":17},{"id":"mei-pharma","kind":"company","name":"MEI Pharma","route":"/companies/mei-pharma/","asOf":"2026-09-11","days":17},{"id":"protagonist-therapeutics","kind":"company","name":"Protagonist Therapeutics","route":"/companies/protagonist-therapeutics/","asOf":"2026-09-11","days":17},{"id":"basilea","kind":"company","name":"Basilea Pharmaceutica","route":"/companies/basilea/","asOf":"2026-09-11","days":17},{"id":"nippon-kayaku","kind":"company","name":"Nippon Kayaku","route":"/companies/nippon-kayaku/","asOf":"2026-09-11","days":17},{"id":"immutep","kind":"company","name":"Immutep","route":"/companies/immutep/","asOf":"2026-09-11","days":17},{"id":"g1-therapeutics","kind":"company","name":"G1 Therapeutics","route":"/companies/g1-therapeutics/","asOf":"2026-09-11","days":17},{"id":"antengene","kind":"company","name":"Antengene","route":"/companies/antengene/","asOf":"2026-09-11","days":17},{"id":"apollomics","kind":"company","name":"Apollomics","route":"/companies/apollomics/","asOf":"2026-09-11","days":17},{"id":"aprea-therapeutics","kind":"company","name":"Aprea Therapeutics","route":"/companies/aprea-therapeutics/","asOf":"2026-09-11","days":17},{"id":"aptose","kind":"company","name":"Aptose Biosciences","route":"/companies/aptose/","asOf":"2026-09-11","days":17},{"id":"bavarian-nordic","kind":"company","name":"Bavarian Nordic","route":"/companies/bavarian-nordic/","asOf":"2026-09-11","days":17},{"id":"accuray","kind":"company","name":"Accuray","route":"/companies/accuray/","asOf":"2026-09-11","days":17},{"id":"biolinerx","kind":"company","name":"BioLineRx","route":"/companies/biolinerx/","asOf":"2026-09-11","days":17},{"id":"sotio","kind":"company","name":"SOTIO Biotech","route":"/companies/sotio/","asOf":"2026-09-11","days":17},{"id":"tolmar","kind":"company","name":"Tolmar","route":"/companies/tolmar/","asOf":"2026-09-11","days":17},{"id":"partner-therapeutics","kind":"company","name":"Partner Therapeutics","route":"/companies/partner-therapeutics/","asOf":"2026-09-11","days":17},{"id":"pharmaand","kind":"company","name":"pharma&","route":"/companies/pharmaand/","asOf":"2026-09-11","days":17},{"id":"neovii","kind":"company","name":"Neovii","route":"/companies/neovii/","asOf":"2026-09-11","days":17},{"id":"abx-advanced-biochemical-compounds","kind":"company","name":"ABX advanced biochemical compounds","route":"/companies/abx-advanced-biochemical-compounds/","asOf":"2026-09-11","days":17},{"id":"lees-pharmaceutical","kind":"company","name":"Lee's Pharmaceutical","route":"/companies/lees-pharmaceutical/","asOf":"2026-09-11","days":17},{"id":"biogen","kind":"company","name":"Biogen","route":"/companies/biogen/","asOf":"2026-09-11","days":17},{"id":"norgine","kind":"company","name":"Norgine","route":"/companies/norgine/","asOf":"2026-09-11","days":17},{"id":"foresee-pharmaceuticals","kind":"company","name":"Foresee Pharmaceuticals","route":"/companies/foresee-pharmaceuticals/","asOf":"2026-09-11","days":17},{"id":"nobelpharma","kind":"company","name":"Nobelpharma","route":"/companies/nobelpharma/","asOf":"2026-09-11","days":17},{"id":"eurofarma","kind":"company","name":"Eurofarma","route":"/companies/eurofarma/","asOf":"2026-09-11","days":17},{"id":"changchun-genescience","kind":"company","name":"Changchun GeneScience Pharmaceutical","route":"/companies/changchun-genescience/","asOf":"2026-09-11","days":17},{"id":"endo","kind":"company","name":"Endo (now Keenova Therapeutics and Par Health)","route":"/companies/endo/","asOf":"2026-09-11","days":17},{"id":"aeterna-zentaris","kind":"company","name":"Aeterna Zentaris","route":"/companies/aeterna-zentaris/","asOf":"2026-09-11","days":17},{"id":"preglem","kind":"company","name":"PregLem","route":"/companies/preglem/","asOf":"2026-09-11","days":17},{"id":"telik","kind":"company","name":"Telik","route":"/companies/telik/","asOf":"2026-09-11","days":17},{"id":"agennix","kind":"company","name":"Agennix","route":"/companies/agennix/","asOf":"2026-09-11","days":17},{"id":"gtx","kind":"company","name":"GTx","route":"/companies/gtx/","asOf":"2026-09-11","days":17},{"id":"insys-therapeutics","kind":"company","name":"Insys Therapeutics","route":"/companies/insys-therapeutics/","asOf":"2026-09-11","days":17},{"id":"achieve-life-sciences","kind":"company","name":"Achieve Life Sciences (formerly OncoGenex)","route":"/companies/achieve-life-sciences/","asOf":"2026-09-11","days":17},{"id":"active-biotech","kind":"company","name":"Active Biotech","route":"/companies/active-biotech/","asOf":"2026-09-11","days":17},{"id":"advenchen-laboratories","kind":"company","name":"Advenchen Laboratories","route":"/companies/advenchen-laboratories/","asOf":"2026-09-11","days":17},{"id":"merrimack-pharmaceuticals","kind":"company","name":"Merrimack Pharmaceuticals","route":"/companies/merrimack-pharmaceuticals/","asOf":"2026-09-11","days":17},{"id":"threshold-pharmaceuticals","kind":"company","name":"Threshold Pharmaceuticals","route":"/companies/threshold-pharmaceuticals/","asOf":"2026-09-11","days":17},{"id":"peregrine-avid","kind":"company","name":"Peregrine Pharmaceuticals (now Avid Bioservices)","route":"/companies/peregrine-avid/","asOf":"2026-09-11","days":17},{"id":"sorrento-therapeutics","kind":"company","name":"Sorrento Therapeutics","route":"/companies/sorrento-therapeutics/","asOf":"2026-09-11","days":17},{"id":"dong-a-st","kind":"company","name":"Dong-A ST","route":"/companies/dong-a-st/","asOf":"2026-09-11","days":17},{"id":"harbour-biomed","kind":"company","name":"Harbour BioMed","route":"/companies/harbour-biomed/","asOf":"2026-09-11","days":17},{"id":"viatris","kind":"company","name":"Viatris","route":"/companies/viatris/","asOf":"2026-09-11","days":17},{"id":"organon","kind":"company","name":"Organon & Co.","route":"/companies/organon/","asOf":"2026-09-11","days":17},{"id":"csl","kind":"company","name":"CSL Limited","route":"/companies/csl/","asOf":"2026-09-11","days":17},{"id":"pharmacosmos","kind":"company","name":"Pharmacosmos","route":"/companies/pharmacosmos/","asOf":"2026-09-11","days":17},{"id":"kissei","kind":"company","name":"Kissei Pharmaceutical","route":"/companies/kissei/","asOf":"2026-09-11","days":17},{"id":"zeria","kind":"company","name":"Zeria Pharmaceutical","route":"/companies/zeria/","asOf":"2026-09-11","days":17},{"id":"rovi","kind":"company","name":"Rovi","route":"/companies/rovi/","asOf":"2026-09-11","days":17},{"id":"denovo-biopharma","kind":"company","name":"Denovo Biopharma","route":"/companies/denovo-biopharma/","asOf":"2026-09-11","days":17},{"id":"cancer-prevention-pharmaceuticals","kind":"company","name":"Cancer Prevention Pharmaceuticals","route":"/companies/cancer-prevention-pharmaceuticals/","asOf":"2026-09-11","days":17},{"id":"photonamic","kind":"company","name":"photonamic","route":"/companies/photonamic/","asOf":"2026-09-11","days":17},{"id":"oakwood-laboratories","kind":"company","name":"Oakwood Laboratories","route":"/companies/oakwood-laboratories/","asOf":"2026-09-11","days":17},{"id":"daehwa-pharmaceutical","kind":"company","name":"Daehwa Pharmaceutical","route":"/companies/daehwa-pharmaceutical/","asOf":"2026-09-11","days":17},{"id":"cellseed","kind":"company","name":"CellSeed","route":"/companies/cellseed/","asOf":"2026-09-11","days":17},{"id":"arog-pharmaceuticals","kind":"company","name":"Arog Pharmaceuticals","route":"/companies/arog-pharmaceuticals/","asOf":"2026-09-11","days":17},{"id":"cyclacel","kind":"company","name":"Cyclacel Pharmaceuticals","route":"/companies/cyclacel/","asOf":"2026-09-11","days":17},{"id":"galera-therapeutics","kind":"company","name":"Galera Therapeutics","route":"/companies/galera-therapeutics/","asOf":"2026-09-11","days":17},{"id":"idera-pharmaceuticals","kind":"company","name":"Idera Pharmaceuticals","route":"/companies/idera-pharmaceuticals/","asOf":"2026-09-11","days":17},{"id":"infinity-pharmaceuticals","kind":"company","name":"Infinity Pharmaceuticals","route":"/companies/infinity-pharmaceuticals/","asOf":"2026-09-11","days":17},{"id":"halozyme","kind":"company","name":"Halozyme Therapeutics","route":"/companies/halozyme/","asOf":"2026-09-11","days":17},{"id":"bellicum","kind":"company","name":"Bellicum Pharmaceuticals","route":"/companies/bellicum/","asOf":"2026-09-11","days":17},{"id":"can-fite","kind":"company","name":"Can-Fite BioPharma","route":"/companies/can-fite/","asOf":"2026-09-11","days":17},{"id":"cartesian-therapeutics","kind":"company","name":"Cartesian Therapeutics","route":"/companies/cartesian-therapeutics/","asOf":"2026-09-11","days":17},{"id":"atossa-therapeutics","kind":"company","name":"Atossa Therapeutics","route":"/companies/atossa-therapeutics/","asOf":"2026-09-11","days":17},{"id":"argos-therapeutics","kind":"company","name":"Argos Therapeutics","route":"/companies/argos-therapeutics/","asOf":"2026-09-11","days":17},{"id":"ascletis","kind":"company","name":"Ascletis Pharma","route":"/companies/ascletis/","asOf":"2026-09-11","days":17},{"id":"delta-fly-pharma","kind":"company","name":"Delta-Fly Pharma","route":"/companies/delta-fly-pharma/","asOf":"2026-09-11","days":17},{"id":"diffusion-pharmaceuticals","kind":"company","name":"Diffusion Pharmaceuticals","route":"/companies/diffusion-pharmaceuticals/","asOf":"2026-09-11","days":17},{"id":"galena-biopharma","kind":"company","name":"Galena Biopharma","route":"/companies/galena-biopharma/","asOf":"2026-09-11","days":17},{"id":"hibercell","kind":"company","name":"HiberCell","route":"/companies/hibercell/","asOf":"2026-09-11","days":17},{"id":"isarna-therapeutics","kind":"company","name":"Isarna Therapeutics","route":"/companies/isarna-therapeutics/","asOf":"2026-09-11","days":17},{"id":"medigene","kind":"company","name":"Medigene","route":"/companies/medigene/","asOf":"2026-09-11","days":17},{"id":"mundipharma","kind":"company","name":"Mundipharma","route":"/companies/mundipharma/","asOf":"2026-09-11","days":17},{"id":"abbisko","kind":"company","name":"Abbisko Therapeutics","route":"/companies/abbisko/","asOf":"2026-09-11","days":17},{"id":"acacia-pharma","kind":"company","name":"Acacia Pharma","route":"/companies/acacia-pharma/","asOf":"2026-09-11","days":17},{"id":"ionis","kind":"company","name":"Ionis Pharmaceuticals","route":"/companies/ionis/","asOf":"2026-09-11","days":17},{"id":"emergent-biosolutions","kind":"company","name":"Emergent BioSolutions","route":"/companies/emergent-biosolutions/","asOf":"2026-09-11","days":17},{"id":"grifols","kind":"company","name":"Grifols","route":"/companies/grifols/","asOf":"2026-09-11","days":17},{"id":"mabion","kind":"company","name":"Mabion","route":"/companies/mabion/","asOf":"2026-09-11","days":17},{"id":"impact-therapeutics","kind":"company","name":"IMPACT Therapeutics","route":"/companies/impact-therapeutics/","asOf":"2026-09-11","days":17},{"id":"blaze-bioscience","kind":"company","name":"Blaze Bioscience","route":"/companies/blaze-bioscience/","asOf":"2026-09-11","days":17},{"id":"jw-pharmaceutical","kind":"company","name":"JW Pharmaceutical","route":"/companies/jw-pharmaceutical/","asOf":"2026-09-11","days":17},{"id":"ptc-therapeutics","kind":"company","name":"PTC Therapeutics","route":"/companies/ptc-therapeutics/","asOf":"2026-09-11","days":17},{"id":"sunesis","kind":"company","name":"Sunesis Pharmaceuticals","route":"/companies/sunesis/","asOf":"2026-09-11","days":17},{"id":"symbio-pharmaceuticals","kind":"company","name":"SymBio Pharmaceuticals","route":"/companies/symbio-pharmaceuticals/","asOf":"2026-09-11","days":17},{"id":"takara-bio","kind":"company","name":"Takara Bio","route":"/companies/takara-bio/","asOf":"2026-09-11","days":17},{"id":"tracon","kind":"company","name":"Tracon Pharmaceuticals","route":"/companies/tracon/","asOf":"2026-09-11","days":17},{"id":"united-therapeutics","kind":"company","name":"United Therapeutics","route":"/companies/united-therapeutics/","asOf":"2026-09-11","days":17},{"id":"vion-pharmaceuticals","kind":"company","name":"Vion Pharmaceuticals","route":"/companies/vion-pharmaceuticals/","asOf":"2026-09-11","days":17},{"id":"vor-biopharma","kind":"company","name":"Vor Biopharma","route":"/companies/vor-biopharma/","asOf":"2026-09-11","days":17},{"id":"zhejiang-hisun","kind":"company","name":"Zhejiang Hisun Pharmaceutical","route":"/companies/zhejiang-hisun/","asOf":"2026-09-11","days":17},{"id":"mast-therapeutics","kind":"company","name":"Mast Therapeutics","route":"/companies/mast-therapeutics/","asOf":"2026-09-11","days":17},{"id":"sbi-pharmaceuticals","kind":"company","name":"SBI Pharmaceuticals","route":"/companies/sbi-pharmaceuticals/","asOf":"2026-09-11","days":17},{"id":"vasgene-therapeutics","kind":"company","name":"VasGene Therapeutics","route":"/companies/vasgene-therapeutics/","asOf":"2026-09-11","days":17},{"id":"angiocrine-bioscience","kind":"company","name":"Angiocrine Bioscience","route":"/companies/angiocrine-bioscience/","asOf":"2026-09-11","days":17},{"id":"wuhan-yzy-biopharma","kind":"company","name":"Wuhan YZY Biopharma","route":"/companies/wuhan-yzy-biopharma/","asOf":"2026-09-11","days":17},{"id":"huyabio","kind":"company","name":"HUYABIO International","route":"/companies/huyabio/","asOf":"2026-09-11","days":17},{"id":"immunitor","kind":"company","name":"Immunitor","route":"/companies/immunitor/","asOf":"2026-09-11","days":17},{"id":"moleculin","kind":"company","name":"Moleculin Biotech","route":"/companies/moleculin/","asOf":"2026-09-11","days":17},{"id":"lisata","kind":"company","name":"Lisata Therapeutics","route":"/companies/lisata/","asOf":"2026-09-11","days":17},{"id":"monopar","kind":"company","name":"Monopar Therapeutics","route":"/companies/monopar/","asOf":"2026-09-11","days":17},{"id":"gemini-therapeutics","kind":"company","name":"Gemini Therapeutics","route":"/companies/gemini-therapeutics/","asOf":"2026-09-11","days":17},{"id":"sijbrandij-foundation","kind":"company","name":"Sijbrandij Foundation","route":"/companies/sijbrandij-foundation/","asOf":"2026-09-11","days":17},{"id":"future-of-cancer-care-today","kind":"company","name":"Future of Cancer Care Today (FCCT)","route":"/companies/future-of-cancer-care-today/","asOf":"2026-09-11","days":17},{"id":"specicare","kind":"company","name":"SpeciCare","route":"/companies/specicare/","asOf":"2026-09-11","days":17},{"id":"storemytumor","kind":"company","name":"StoreMyTumor","route":"/companies/storemytumor/","asOf":"2026-09-11","days":17},{"id":"belay-diagnostics","kind":"company","name":"Belay Diagnostics","route":"/companies/belay-diagnostics/","asOf":"2026-09-11","days":17},{"id":"cnside-diagnostics","kind":"company","name":"CNSide Diagnostics","route":"/companies/cnside-diagnostics/","asOf":"2026-09-11","days":17},{"id":"rgcc-international","kind":"company","name":"RGCC International","route":"/companies/rgcc-international/","asOf":"2026-09-11","days":17},{"id":"navignostics","kind":"company","name":"Navignostics","route":"/companies/navignostics/","asOf":"2026-09-11","days":17},{"id":"cegat","kind":"company","name":"CeGaT","route":"/companies/cegat/","asOf":"2026-09-11","days":17},{"id":"oncodna","kind":"company","name":"OncoDNA","route":"/companies/oncodna/","asOf":"2026-09-11","days":17},{"id":"hartwig-medical-foundation","kind":"company","name":"Hartwig Medical Foundation","route":"/companies/hartwig-medical-foundation/","asOf":"2026-09-11","days":17},{"id":"vicinity-bio","kind":"company","name":"Vicinity Bio","route":"/companies/vicinity-bio/","asOf":"2026-09-11","days":17},{"id":"protean-biodiagnostics","kind":"company","name":"Protean BioDiagnostics","route":"/companies/protean-biodiagnostics/","asOf":"2026-09-11","days":17},{"id":"travera","kind":"company","name":"Travera","route":"/companies/travera/","asOf":"2026-09-11","days":17},{"id":"first-ascent-biomedical","kind":"company","name":"First Ascent Biomedical","route":"/companies/first-ascent-biomedical/","asOf":"2026-09-11","days":17},{"id":"kiyatec","kind":"company","name":"Kiyatec","route":"/companies/kiyatec/","asOf":"2026-09-11","days":17},{"id":"cure-first","kind":"company","name":"Cure-First","route":"/companies/cure-first/","asOf":"2026-09-11","days":17},{"id":"sagemedic","kind":"company","name":"SageMedic","route":"/companies/sagemedic/","asOf":"2026-09-11","days":17},{"id":"kyan-technologies","kind":"company","name":"KYAN Technologies","route":"/companies/kyan-technologies/","asOf":"2026-09-11","days":17},{"id":"cancertain","kind":"company","name":"CanCertain","route":"/companies/cancertain/","asOf":"2026-09-11","days":17},{"id":"2curex","kind":"company","name":"2cureX","route":"/companies/2curex/","asOf":"2026-09-11","days":17},{"id":"pathfinder-oncology","kind":"company","name":"Pathfinder Oncology","route":"/companies/pathfinder-oncology/","asOf":"2026-09-11","days":17},{"id":"jaime-leandro-foundation","kind":"company","name":"Jaime Leandro Foundation","route":"/companies/jaime-leandro-foundation/","asOf":"2026-09-11","days":17},{"id":"invoke-bio","kind":"company","name":"Invoke Bio","route":"/companies/invoke-bio/","asOf":"2026-09-11","days":17},{"id":"diakonos-oncology","kind":"company","name":"Diakonos Oncology","route":"/companies/diakonos-oncology/","asOf":"2026-09-11","days":17},{"id":"ubivac","kind":"company","name":"UbiVac","route":"/companies/ubivac/","asOf":"2026-09-11","days":17},{"id":"cartx-therapeutics","kind":"company","name":"CARTx Therapeutics","route":"/companies/cartx-therapeutics/","asOf":"2026-09-11","days":17},{"id":"picnic-health","kind":"company","name":"Picnic Health","route":"/companies/picnic-health/","asOf":"2026-09-11","days":17},{"id":"antidote","kind":"company","name":"Antidote","route":"/companies/antidote/","asOf":"2026-09-11","days":17},{"id":"mytomorrows","kind":"company","name":"myTomorrows","route":"/companies/mytomorrows/","asOf":"2026-09-11","days":17},{"id":"klineo","kind":"company","name":"Klineo","route":"/companies/klineo/","asOf":"2026-09-11","days":17},{"id":"galen","kind":"company","name":"Galen","route":"/companies/galen/","asOf":"2026-09-11","days":17},{"id":"opencancerai","kind":"company","name":"OpenCancerAI","route":"/companies/opencancerai/","asOf":"2026-09-11","days":17},{"id":"patient-advocators","kind":"company","name":"Patient Advocators","route":"/companies/patient-advocators/","asOf":"2026-09-11","days":17},{"id":"private-health-management","kind":"company","name":"Private Health Management","route":"/companies/private-health-management/","asOf":"2026-09-11","days":17},{"id":"sagely-health","kind":"company","name":"Sagely Health","route":"/companies/sagely-health/","asOf":"2026-09-11","days":17},{"id":"outperform-cancer","kind":"company","name":"Outperform Cancer","route":"/companies/outperform-cancer/","asOf":"2026-09-11","days":17},{"id":"epistamai-biotech","kind":"company","name":"Epistamai Biotech","route":"/companies/epistamai-biotech/","asOf":"2026-09-11","days":17},{"id":"private-medical","kind":"company","name":"Private Medical","route":"/companies/private-medical/","asOf":"2026-09-11","days":17},{"id":"biostar-pharmaceuticals","kind":"company","name":"Biostar Pharmaceuticals","route":"/companies/biostar-pharmaceuticals/","asOf":"2026-09-11","days":17},{"id":"3sbio","kind":"company","name":"3SBio","route":"/companies/3sbio/","asOf":"2026-09-11","days":17},{"id":"juventas-cell-therapy","kind":"company","name":"Juventas Cell Therapy","route":"/companies/juventas-cell-therapy/","asOf":"2026-09-11","days":17},{"id":"shanghai-yingli","kind":"company","name":"Shanghai Yingli Pharmaceutical","route":"/companies/shanghai-yingli/","asOf":"2026-09-11","days":17},{"id":"shanghai-sunway-biotech","kind":"company","name":"Shanghai Sunway Biotech","route":"/companies/shanghai-sunway-biotech/","asOf":"2026-09-11","days":17},{"id":"chengdu-zenitar-biomedical-technology","kind":"company","name":"Chengdu Zenitar Biomedical Technology","route":"/companies/chengdu-zenitar-biomedical-technology/","asOf":"2026-09-11","days":17},{"id":"jacobio-pharmaceuticals","kind":"company","name":"Jacobio Pharmaceuticals","route":"/companies/jacobio-pharmaceuticals/","asOf":"2026-09-11","days":17},{"id":"beijing-konruns-pharmaceutical","kind":"company","name":"Beijing Konruns Pharmaceutical","route":"/companies/beijing-konruns-pharmaceutical/","asOf":"2026-09-11","days":17},{"id":"beijing-mabworks-biotech","kind":"company","name":"Beijing Mabworks Biotech","route":"/companies/beijing-mabworks-biotech/","asOf":"2026-09-11","days":17},{"id":"binhui-biopharmaceutical","kind":"company","name":"Binhui Biopharmaceutical","route":"/companies/binhui-biopharmaceutical/","asOf":"2026-09-11","days":17},{"id":"beijing-pearl-biotechnology-limited-liability-company","kind":"company","name":"Beijing Pearl Biotechnology Limited Liability Company","route":"/companies/beijing-pearl-biotechnology-limited-liability-company/","asOf":"2026-09-11","days":17},{"id":"beijing-scitech-mq-pharmaceuticals","kind":"company","name":"Beijing Scitech-Mq Pharmaceuticals","route":"/companies/beijing-scitech-mq-pharmaceuticals/","asOf":"2026-09-11","days":17},{"id":"immvira-pharma","kind":"company","name":"ImmVira Pharma","route":"/companies/immvira-pharma/","asOf":"2026-09-11","days":17},{"id":"shandong-new-time-pharmaceutical","kind":"company","name":"Shandong New Time Pharmaceutical","route":"/companies/shandong-new-time-pharmaceutical/","asOf":"2026-09-11","days":17},{"id":"beijing-gene-key-life-technology","kind":"company","name":"Beijing Gene Key Life Technology","route":"/companies/beijing-gene-key-life-technology/","asOf":"2026-09-11","days":17},{"id":"beijing-tide-pharmaceutical","kind":"company","name":"Beijing Tide Pharmaceutical","route":"/companies/beijing-tide-pharmaceutical/","asOf":"2026-09-11","days":17},{"id":"henan-genuine-biotech","kind":"company","name":"Henan Genuine Biotech","route":"/companies/henan-genuine-biotech/","asOf":"2026-09-11","days":17},{"id":"nanjing-immunophage-biotech","kind":"company","name":"Nanjing Immunophage Biotech","route":"/companies/nanjing-immunophage-biotech/","asOf":"2026-09-11","days":17},{"id":"tj-biopharma","kind":"company","name":"TJ Biopharma","route":"/companies/tj-biopharma/","asOf":"2026-09-11","days":17},{"id":"zhuhai-yufan-biotechnologies","kind":"company","name":"Zhuhai Yufan Biotechnologies","route":"/companies/zhuhai-yufan-biotechnologies/","asOf":"2026-09-11","days":17},{"id":"scirouter","kind":"company","name":"SciRouter","route":"/companies/scirouter/","asOf":"2026-09-11","days":17},{"id":"anocca","kind":"company","name":"Anocca","route":"/companies/anocca/","asOf":"2026-09-11","days":17},{"id":"pf-08634404","kind":"drug","name":"PF-08634404","route":"/drugs/pf-08634404/","asOf":"2026-09-11","days":17},{"id":"shr-8068","kind":"drug","name":"SHR-8068","route":"/drugs/shr-8068/","asOf":"2026-09-11","days":17},{"id":"yl201","kind":"drug","name":"YL201","route":"/drugs/yl201/","asOf":"2026-09-11","days":17},{"id":"shr-a2102","kind":"drug","name":"SHR-A2102","route":"/drugs/shr-a2102/","asOf":"2026-09-11","days":17},{"id":"tqb2102","kind":"drug","name":"TQB2102","route":"/drugs/tqb2102/","asOf":"2026-09-11","days":17},{"id":"pm8002","kind":"drug","name":"PM8002","route":"/drugs/pm8002/","asOf":"2026-09-11","days":17},{"id":"in10018","kind":"drug","name":"IN10018","route":"/drugs/in10018/","asOf":"2026-09-11","days":17},{"id":"telisotuzumab-adizutecan","kind":"drug","name":"Telisotuzumab adizutecan","route":"/drugs/telisotuzumab-adizutecan/","asOf":"2026-09-11","days":17},{"id":"domvanalimab","kind":"drug","name":"Domvanalimab","route":"/drugs/domvanalimab/","asOf":"2026-09-11","days":17},{"id":"si-b001","kind":"drug","name":"SI-B001","route":"/drugs/si-b001/","asOf":"2026-09-11","days":17},{"id":"oleclumab","kind":"drug","name":"Oleclumab","route":"/drugs/oleclumab/","asOf":"2026-09-11","days":17},{"id":"cetrelimab","kind":"drug","name":"Cetrelimab","route":"/drugs/cetrelimab/","asOf":"2026-09-11","days":17},{"id":"hs-20093","kind":"drug","name":"HS-20093","route":"/drugs/hs-20093/","asOf":"2026-09-11","days":17},{"id":"zg006","kind":"drug","name":"ZG006","route":"/drugs/zg006/","asOf":"2026-09-11","days":17},{"id":"calderasib","kind":"drug","name":"Calderasib","route":"/drugs/calderasib/","asOf":"2026-09-11","days":17},{"id":"zanzalintinib","kind":"drug","name":"Zanzalintinib","route":"/drugs/zanzalintinib/","asOf":"2026-09-11","days":17},{"id":"ak117","kind":"drug","name":"AK117","route":"/drugs/ak117/","asOf":"2026-09-11","days":17},{"id":"qlc5508","kind":"drug","name":"QLC5508","route":"/drugs/qlc5508/","asOf":"2026-09-11","days":17},{"id":"kc1036","kind":"drug","name":"KC1036","route":"/drugs/kc1036/","asOf":"2026-09-11","days":17},{"id":"budigalimab","kind":"drug","name":"Budigalimab","route":"/drugs/budigalimab/","asOf":"2026-09-11","days":17},{"id":"ceralasertib","kind":"drug","name":"Ceralasertib","route":"/drugs/ceralasertib/","asOf":"2026-09-11","days":17},{"id":"abexinostat","kind":"drug","name":"Abexinostat","route":"/drugs/abexinostat/","asOf":"2026-09-11","days":17},{"id":"hrs-8080","kind":"drug","name":"HRS-8080","route":"/drugs/hrs-8080/","asOf":"2026-09-11","days":17},{"id":"ipatasertib","kind":"drug","name":"Ipatasertib","route":"/drugs/ipatasertib/","asOf":"2026-09-11","days":17},{"id":"opevesostat","kind":"drug","name":"Opevesostat","route":"/drugs/opevesostat/","asOf":"2026-09-11","days":17},{"id":"dzd8586","kind":"drug","name":"DZD8586","route":"/drugs/dzd8586/","asOf":"2026-09-11","days":17},{"id":"rc148","kind":"drug","name":"RC148","route":"/drugs/rc148/","asOf":"2026-09-11","days":17},{"id":"sph4336","kind":"drug","name":"SPH4336","route":"/drugs/sph4336/","asOf":"2026-09-11","days":17},{"id":"lm-108","kind":"drug","name":"LM-108","route":"/drugs/lm-108/","asOf":"2026-09-11","days":17},{"id":"yl202","kind":"drug","name":"YL202","route":"/drugs/yl202/","asOf":"2026-09-11","days":17},{"id":"livmoniplimab","kind":"drug","name":"Livmoniplimab","route":"/drugs/livmoniplimab/","asOf":"2026-09-11","days":17},{"id":"jdq443","kind":"drug","name":"JDQ443","route":"/drugs/jdq443/","asOf":"2026-09-11","days":17},{"id":"tqb3616","kind":"drug","name":"TQB3616","route":"/drugs/tqb3616/","asOf":"2026-09-11","days":17},{"id":"saruparib","kind":"drug","name":"Saruparib","route":"/drugs/saruparib/","asOf":"2026-09-11","days":17},{"id":"ql1706","kind":"drug","name":"QL1706","route":"/drugs/ql1706/","asOf":"2026-09-11","days":17},{"id":"rocbrutinib","kind":"drug","name":"Rocbrutinib","route":"/drugs/rocbrutinib/","asOf":"2026-09-11","days":17},{"id":"mk-1045","kind":"drug","name":"MK-1045","route":"/drugs/mk-1045/","asOf":"2026-09-11","days":17},{"id":"oregovomab","kind":"drug","name":"Oregovomab","route":"/drugs/oregovomab/","asOf":"2026-09-11","days":17},{"id":"monalizumab","kind":"drug","name":"Monalizumab","route":"/drugs/monalizumab/","asOf":"2026-09-11","days":17},{"id":"navlimetostat","kind":"drug","name":"Navlimetostat","route":"/drugs/navlimetostat/","asOf":"2026-09-11","days":17},{"id":"al8326","kind":"drug","name":"AL8326","route":"/drugs/al8326/","asOf":"2026-09-11","days":17},{"id":"hlx43","kind":"drug","name":"HLX43","route":"/drugs/hlx43/","asOf":"2026-09-11","days":17},{"id":"sys6010","kind":"drug","name":"SYS6010","route":"/drugs/sys6010/","asOf":"2026-09-11","days":17},{"id":"kl-a167","kind":"drug","name":"KL-A167","route":"/drugs/kl-a167/","asOf":"2026-09-11","days":17},{"id":"quemliclustat","kind":"drug","name":"Quemliclustat","route":"/drugs/quemliclustat/","asOf":"2026-09-11","days":17},{"id":"mrg003","kind":"drug","name":"MRG003","route":"/drugs/mrg003/","asOf":"2026-09-11","days":17},{"id":"shr-a1921","kind":"drug","name":"SHR-A1921","route":"/drugs/shr-a1921/","asOf":"2026-09-11","days":17},{"id":"shr-1501","kind":"drug","name":"SHR-1501","route":"/drugs/shr-1501/","asOf":"2026-09-11","days":17},{"id":"darovasertib","kind":"drug","name":"Darovasertib","route":"/drugs/darovasertib/","asOf":"2026-09-11","days":17},{"id":"cevostamab","kind":"drug","name":"Cevostamab","route":"/drugs/cevostamab/","asOf":"2026-09-11","days":17},{"id":"hb1801","kind":"drug","name":"HB1801","route":"/drugs/hb1801/","asOf":"2026-09-11","days":17},{"id":"jskn003","kind":"drug","name":"JSKN003","route":"/drugs/jskn003/","asOf":"2026-09-11","days":17},{"id":"eik1001","kind":"drug","name":"EIK1001","route":"/drugs/eik1001/","asOf":"2026-09-11","days":17},{"id":"kn026","kind":"drug","name":"KN026","route":"/drugs/kn026/","asOf":"2026-09-11","days":17},{"id":"bexobrutideg","kind":"drug","name":"Bexobrutideg","route":"/drugs/bexobrutideg/","asOf":"2026-09-11","days":17},{"id":"gfh375","kind":"drug","name":"GFH375","route":"/drugs/gfh375/","asOf":"2026-09-11","days":17},{"id":"zipalertinib","kind":"drug","name":"Zipalertinib","route":"/drugs/zipalertinib/","asOf":"2026-09-11","days":17},{"id":"aglatimagene-besadenovec","kind":"drug","name":"Aglatimagene besadenovec","route":"/drugs/aglatimagene-besadenovec/","asOf":"2026-09-11","days":17},{"id":"jnj-79635322","kind":"drug","name":"JNJ-79635322","route":"/drugs/jnj-79635322/","asOf":"2026-09-11","days":17},{"id":"ql2107","kind":"drug","name":"QL2107","route":"/drugs/ql2107/","asOf":"2026-09-11","days":17},{"id":"ibi354","kind":"drug","name":"IBI354","route":"/drugs/ibi354/","asOf":"2026-09-11","days":17},{"id":"gotistobart","kind":"drug","name":"Gotistobart","route":"/drugs/gotistobart/","asOf":"2026-09-11","days":17},{"id":"aaa817","kind":"drug","name":"AAA817","route":"/drugs/aaa817/","asOf":"2026-09-11","days":17},{"id":"purinostat","kind":"drug","name":"Purinostat","route":"/drugs/purinostat/","asOf":"2026-09-11","days":17},{"id":"tqb2450","kind":"drug","name":"TQB2450","route":"/drugs/tqb2450/","asOf":"2026-09-11","days":17},{"id":"xzp-3287","kind":"drug","name":"XZP-3287","route":"/drugs/xzp-3287/","asOf":"2026-09-11","days":17},{"id":"lam561","kind":"drug","name":"LAM561","route":"/drugs/lam561/","asOf":"2026-09-11","days":17},{"id":"zl-1310","kind":"drug","name":"ZL-1310","route":"/drugs/zl-1310/","asOf":"2026-09-11","days":17},{"id":"velzatinib","kind":"drug","name":"Velzatinib","route":"/drugs/velzatinib/","asOf":"2026-09-11","days":17},{"id":"a166","kind":"drug","name":"A166","route":"/drugs/a166/","asOf":"2026-09-11","days":17},{"id":"shr-a2009","kind":"drug","name":"SHR-A2009","route":"/drugs/shr-a2009/","asOf":"2026-09-11","days":17},{"id":"mrg002","kind":"drug","name":"MRG002","route":"/drugs/mrg002/","asOf":"2026-09-11","days":17},{"id":"lm-302","kind":"drug","name":"LM-302","route":"/drugs/lm-302/","asOf":"2026-09-11","days":17},{"id":"gr1803","kind":"drug","name":"GR1803","route":"/drugs/gr1803/","asOf":"2026-09-11","days":17},{"id":"io102-io103","kind":"drug","name":"IO102-IO103","route":"/drugs/io102-io103/","asOf":"2026-09-11","days":17},{"id":"pf-07248144","kind":"drug","name":"PF-07248144","route":"/drugs/pf-07248144/","asOf":"2026-09-11","days":17},{"id":"abbv-706","kind":"drug","name":"ABBV-706","route":"/drugs/abbv-706/","asOf":"2026-09-11","days":17},{"id":"esg401","kind":"drug","name":"ESG401","route":"/drugs/esg401/","asOf":"2026-09-11","days":17},{"id":"ty-9591","kind":"drug","name":"TY-9591","route":"/drugs/ty-9591/","asOf":"2026-09-11","days":17},{"id":"evorpacept","kind":"drug","name":"Evorpacept","route":"/drugs/evorpacept/","asOf":"2026-09-11","days":17},{"id":"bcd-217","kind":"drug","name":"BCD-217","route":"/drugs/bcd-217/","asOf":"2026-09-11","days":17},{"id":"tara-002","kind":"drug","name":"TARA-002","route":"/drugs/tara-002/","asOf":"2026-09-11","days":17},{"id":"tgrx-326","kind":"drug","name":"TGRX-326","route":"/drugs/tgrx-326/","asOf":"2026-09-11","days":17},{"id":"hs-20089","kind":"drug","name":"HS-20089","route":"/drugs/hs-20089/","asOf":"2026-09-11","days":17},{"id":"uliledlimab","kind":"drug","name":"Uliledlimab","route":"/drugs/uliledlimab/","asOf":"2026-09-11","days":17},{"id":"qls32015","kind":"drug","name":"QLS32015","route":"/drugs/qls32015/","asOf":"2026-09-11","days":17},{"id":"bebt-209","kind":"drug","name":"BEBT-209","route":"/drugs/bebt-209/","asOf":"2026-09-11","days":17},{"id":"givinostat","kind":"drug","name":"Givinostat","route":"/drugs/givinostat/","asOf":"2026-09-11","days":17},{"id":"sitneprotafib","kind":"drug","name":"Sitneprotafib","route":"/drugs/sitneprotafib/","asOf":"2026-09-11","days":17},{"id":"incb123667","kind":"drug","name":"INCB123667","route":"/drugs/incb123667/","asOf":"2026-09-11","days":17},{"id":"js105","kind":"drug","name":"JS105","route":"/drugs/js105/","asOf":"2026-09-11","days":17},{"id":"jmt101","kind":"drug","name":"JMT101","route":"/drugs/jmt101/","asOf":"2026-09-11","days":17},{"id":"jskn016","kind":"drug","name":"JSKN016","route":"/drugs/jskn016/","asOf":"2026-09-11","days":17},{"id":"acasunlimab","kind":"drug","name":"Acasunlimab","route":"/drugs/acasunlimab/","asOf":"2026-09-11","days":17},{"id":"bnt324","kind":"drug","name":"BNT324","route":"/drugs/bnt324/","asOf":"2026-09-11","days":17},{"id":"cobolimab","kind":"drug","name":"Cobolimab","route":"/drugs/cobolimab/","asOf":"2026-09-11","days":17},{"id":"icp-248","kind":"drug","name":"ICP-248","route":"/drugs/icp-248/","asOf":"2026-09-11","days":17},{"id":"emactuzumab","kind":"drug","name":"Emactuzumab","route":"/drugs/emactuzumab/","asOf":"2026-09-11","days":17},{"id":"azenosertib","kind":"drug","name":"Azenosertib","route":"/drugs/azenosertib/","asOf":"2026-09-11","days":17},{"id":"olvimulogene-nanivacirepvec","kind":"drug","name":"Olvimulogene nanivacirepvec","route":"/drugs/olvimulogene-nanivacirepvec/","asOf":"2026-09-11","days":17},{"id":"setidegrasib","kind":"drug","name":"Setidegrasib","route":"/drugs/setidegrasib/","asOf":"2026-09-11","days":17},{"id":"hlx22","kind":"drug","name":"HLX22","route":"/drugs/hlx22/","asOf":"2026-09-11","days":17},{"id":"sctb41","kind":"drug","name":"SCTB41","route":"/drugs/sctb41/","asOf":"2026-09-11","days":17},{"id":"d07001","kind":"drug","name":"D07001","route":"/drugs/d07001/","asOf":"2026-09-11","days":17},{"id":"sctb35","kind":"drug","name":"SCTB35","route":"/drugs/sctb35/","asOf":"2026-09-11","days":17},{"id":"tersolisib","kind":"drug","name":"Tersolisib","route":"/drugs/tersolisib/","asOf":"2026-09-11","days":17},{"id":"arlocabtagene-autoleucel","kind":"drug","name":"Arlocabtagene Autoleucel","route":"/drugs/arlocabtagene-autoleucel/","asOf":"2026-09-11","days":17},{"id":"bezuclastinib","kind":"drug","name":"Bezuclastinib","route":"/drugs/bezuclastinib/","asOf":"2026-09-11","days":17},{"id":"tqb3454","kind":"drug","name":"TQB3454","route":"/drugs/tqb3454/","asOf":"2026-09-11","days":17},{"id":"shr-a1912","kind":"drug","name":"SHR-A1912","route":"/drugs/shr-a1912/","asOf":"2026-09-11","days":17},{"id":"hmpl-306","kind":"drug","name":"HMPL-306","route":"/drugs/hmpl-306/","asOf":"2026-09-11","days":17},{"id":"tak-928","kind":"drug","name":"TAK-928","route":"/drugs/tak-928/","asOf":"2026-09-11","days":17},{"id":"clifutinib","kind":"drug","name":"Clifutinib","route":"/drugs/clifutinib/","asOf":"2026-09-11","days":17},{"id":"idrx-42","kind":"drug","name":"IDRX-42","route":"/drugs/idrx-42/","asOf":"2026-09-11","days":17},{"id":"elenestinib","kind":"drug","name":"Elenestinib","route":"/drugs/elenestinib/","asOf":"2026-09-11","days":17},{"id":"glsi-100","kind":"drug","name":"GLSI-100","route":"/drugs/glsi-100/","asOf":"2026-09-11","days":17},{"id":"int230-6","kind":"drug","name":"INT230-6","route":"/drugs/int230-6/","asOf":"2026-09-11","days":17},{"id":"grt-c901","kind":"drug","name":"GRT-C901","route":"/drugs/grt-c901/","asOf":"2026-09-11","days":17},{"id":"grt-r902","kind":"drug","name":"GRT-R902","route":"/drugs/grt-r902/","asOf":"2026-09-11","days":17},{"id":"imp4927","kind":"drug","name":"Senaparib (IMP4297)","route":"/drugs/imp4927/","asOf":"2026-09-11","days":17},{"id":"lerotinib","kind":"drug","name":"Lerotinib","route":"/drugs/lerotinib/","asOf":"2026-09-11","days":17},{"id":"azd5335","kind":"drug","name":"AZD5335","route":"/drugs/azd5335/","asOf":"2026-09-11","days":17},{"id":"tq-b3234","kind":"drug","name":"TQ-B3234","route":"/drugs/tq-b3234/","asOf":"2026-09-11","days":17},{"id":"ugn-103","kind":"drug","name":"UGN-103","route":"/drugs/ugn-103/","asOf":"2026-09-11","days":17},{"id":"hmpl-453","kind":"drug","name":"HMPL-453","route":"/drugs/hmpl-453/","asOf":"2026-09-11","days":17},{"id":"sctc21c","kind":"drug","name":"SCTC21C","route":"/drugs/sctc21c/","asOf":"2026-09-11","days":17},{"id":"bcd-100","kind":"drug","name":"BCD-100","route":"/drugs/bcd-100/","asOf":"2026-09-11","days":17},{"id":"hr070803","kind":"drug","name":"HR070803","route":"/drugs/hr070803/","asOf":"2026-09-11","days":17},{"id":"nb003","kind":"drug","name":"NB003","route":"/drugs/nb003/","asOf":"2026-09-11","days":17},{"id":"fda018-adc","kind":"drug","name":"FDA018-ADC","route":"/drugs/fda018-adc/","asOf":"2026-09-11","days":17},{"id":"tbi-1301","kind":"drug","name":"TBI-1301","route":"/drugs/tbi-1301/","asOf":"2026-09-11","days":17},{"id":"d-0502","kind":"drug","name":"D-0502","route":"/drugs/d-0502/","asOf":"2026-09-11","days":17},{"id":"incb161734","kind":"drug","name":"INCB161734","route":"/drugs/incb161734/","asOf":"2026-09-11","days":17},{"id":"tar-210","kind":"drug","name":"TAR-210","route":"/drugs/tar-210/","asOf":"2026-09-11","days":17},{"id":"hmpl-760","kind":"drug","name":"HMPL-760","route":"/drugs/hmpl-760/","asOf":"2026-09-11","days":17},{"id":"ima203","kind":"drug","name":"IMA203","route":"/drugs/ima203/","asOf":"2026-09-11","days":17},{"id":"sim0270","kind":"drug","name":"SIM0270","route":"/drugs/sim0270/","asOf":"2026-09-11","days":17},{"id":"asp2138","kind":"drug","name":"ASP2138","route":"/drugs/asp2138/","asOf":"2026-09-11","days":17},{"id":"f182112","kind":"drug","name":"F182112","route":"/drugs/f182112/","asOf":"2026-09-11","days":17},{"id":"zovegalisib","kind":"drug","name":"Zovegalisib","route":"/drugs/zovegalisib/","asOf":"2026-09-11","days":17},{"id":"vc004","kind":"drug","name":"VC004","route":"/drugs/vc004/","asOf":"2026-09-11","days":17},{"id":"hlx11","kind":"drug","name":"HLX11","route":"/drugs/hlx11/","asOf":"2026-09-11","days":17},{"id":"atigotatug","kind":"drug","name":"Atigotatug","route":"/drugs/atigotatug/","asOf":"2026-09-11","days":17},{"id":"sgm-101","kind":"drug","name":"SGM-101","route":"/drugs/sgm-101/","asOf":"2026-09-11","days":17},{"id":"precemtabart-tocentecan","kind":"drug","name":"Precemtabart tocentecan","route":"/drugs/precemtabart-tocentecan/","asOf":"2026-09-11","days":17},{"id":"al2846","kind":"drug","name":"AL2846","route":"/drugs/al2846/","asOf":"2026-09-11","days":17},{"id":"sasanlimab","kind":"drug","name":"Sasanlimab","route":"/drugs/sasanlimab/","asOf":"2026-09-11","days":17},{"id":"tovecimig","kind":"drug","name":"Tovecimig","route":"/drugs/tovecimig/","asOf":"2026-09-11","days":17},{"id":"inca33890","kind":"drug","name":"INCA33890","route":"/drugs/inca33890/","asOf":"2026-09-11","days":17},{"id":"rph-051","kind":"drug","name":"RPH-051","route":"/drugs/rph-051/","asOf":"2026-09-11","days":17},{"id":"bms-986365","kind":"drug","name":"BMS-986365","route":"/drugs/bms-986365/","asOf":"2026-09-11","days":17},{"id":"lns8801","kind":"drug","name":"LNS8801","route":"/drugs/lns8801/","asOf":"2026-09-11","days":17},{"id":"rondecabtagene-autoleucel","kind":"drug","name":"Rondecabtagene autoleucel","route":"/drugs/rondecabtagene-autoleucel/","asOf":"2026-09-11","days":17},{"id":"jnj-87189401","kind":"drug","name":"JNJ-87189401","route":"/drugs/jnj-87189401/","asOf":"2026-09-11","days":17},{"id":"inbrx-106","kind":"drug","name":"INBRX-106","route":"/drugs/inbrx-106/","asOf":"2026-09-11","days":17},{"id":"bomedemstat","kind":"drug","name":"Bomedemstat","route":"/drugs/bomedemstat/","asOf":"2026-09-11","days":17},{"id":"jnj-90301900","kind":"drug","name":"JNJ-90301900","route":"/drugs/jnj-90301900/","asOf":"2026-09-11","days":17},{"id":"m108","kind":"drug","name":"M108","route":"/drugs/m108/","asOf":"2026-09-11","days":17},{"id":"bgb-43395","kind":"drug","name":"BGB-43395","route":"/drugs/bgb-43395/","asOf":"2026-09-11","days":17},{"id":"soquelitinib","kind":"drug","name":"Soquelitinib","route":"/drugs/soquelitinib/","asOf":"2026-09-11","days":17},{"id":"vepugratinib","kind":"drug","name":"Vepugratinib","route":"/drugs/vepugratinib/","asOf":"2026-09-11","days":17},{"id":"pelabresib","kind":"drug","name":"Pelabresib","route":"/drugs/pelabresib/","asOf":"2026-09-11","days":17},{"id":"naporafenib","kind":"drug","name":"Naporafenib","route":"/drugs/naporafenib/","asOf":"2026-09-11","days":17},{"id":"asc40","kind":"drug","name":"ASC40","route":"/drugs/asc40/","asOf":"2026-09-11","days":17},{"id":"trabedersen","kind":"drug","name":"Trabedersen","route":"/drugs/trabedersen/","asOf":"2026-09-11","days":17},{"id":"adi-peg20","kind":"drug","name":"ADI-PEG20","route":"/drugs/adi-peg20/","asOf":"2026-09-11","days":17},{"id":"ro7771950","kind":"drug","name":"RO7771950","route":"/drugs/ro7771950/","asOf":"2026-09-11","days":17},{"id":"sctb14","kind":"drug","name":"SCTB14","route":"/drugs/sctb14/","asOf":"2026-09-11","days":17},{"id":"ose2101","kind":"drug","name":"OSE2101","route":"/drugs/ose2101/","asOf":"2026-09-11","days":17},{"id":"sg301","kind":"drug","name":"SG301","route":"/drugs/sg301/","asOf":"2026-09-11","days":17},{"id":"navitoclax","kind":"drug","name":"Navitoclax","route":"/drugs/navitoclax/","asOf":"2026-09-11","days":17},{"id":"pf-08046054","kind":"drug","name":"PF-08046054","route":"/drugs/pf-08046054/","asOf":"2026-09-11","days":17},{"id":"varegacestat","kind":"drug","name":"Varegacestat","route":"/drugs/varegacestat/","asOf":"2026-09-11","days":17},{"id":"hs-20117","kind":"drug","name":"HS-20117","route":"/drugs/hs-20117/","asOf":"2026-09-11","days":17},{"id":"gq1005","kind":"drug","name":"GQ1005","route":"/drugs/gq1005/","asOf":"2026-09-11","days":17},{"id":"ugn-104","kind":"drug","name":"UGN-104","route":"/drugs/ugn-104/","asOf":"2026-09-11","days":17},{"id":"qls31905","kind":"drug","name":"QLS31905","route":"/drugs/qls31905/","asOf":"2026-09-11","days":17},{"id":"sofetabart-mipitecan","kind":"drug","name":"Sofetabart Mipitecan","route":"/drugs/sofetabart-mipitecan/","asOf":"2026-09-11","days":17},{"id":"ivospemin","kind":"drug","name":"Ivospemin","route":"/drugs/ivospemin/","asOf":"2026-09-11","days":17},{"id":"bnt113","kind":"drug","name":"BNT113","route":"/drugs/bnt113/","asOf":"2026-09-11","days":17},{"id":"chiauranib","kind":"drug","name":"Chiauranib","route":"/drugs/chiauranib/","asOf":"2026-09-11","days":17},{"id":"rinzimetostat","kind":"drug","name":"Rinzimetostat","route":"/drugs/rinzimetostat/","asOf":"2026-09-11","days":17},{"id":"atebimetinib","kind":"drug","name":"Atebimetinib","route":"/drugs/atebimetinib/","asOf":"2026-09-11","days":17},{"id":"ibi343","kind":"drug","name":"IBI343","route":"/drugs/ibi343/","asOf":"2026-09-11","days":17},{"id":"bleximenib","kind":"drug","name":"Bleximenib","route":"/drugs/bleximenib/","asOf":"2026-09-11","days":17},{"id":"ibi310","kind":"drug","name":"IBI310","route":"/drugs/ibi310/","asOf":"2026-09-11","days":17},{"id":"ficlatuzumab","kind":"drug","name":"Ficlatuzumab","route":"/drugs/ficlatuzumab/","asOf":"2026-09-11","days":17},{"id":"azd0486","kind":"drug","name":"AZD0486","route":"/drugs/azd0486/","asOf":"2026-09-11","days":17},{"id":"ifupinostat","kind":"drug","name":"Ifupinostat","route":"/drugs/ifupinostat/","asOf":"2026-09-11","days":17},{"id":"hrs-4357","kind":"drug","name":"HRS-4357","route":"/drugs/hrs-4357/","asOf":"2026-09-11","days":17},{"id":"safusidenib","kind":"drug","name":"Safusidenib","route":"/drugs/safusidenib/","asOf":"2026-09-11","days":17},{"id":"iah0968","kind":"drug","name":"IAH0968","route":"/drugs/iah0968/","asOf":"2026-09-11","days":17},{"id":"ibi363","kind":"drug","name":"IBI363","route":"/drugs/ibi363/","asOf":"2026-09-11","days":17},{"id":"vs-7375","kind":"drug","name":"VS-7375","route":"/drugs/vs-7375/","asOf":"2026-09-11","days":17},{"id":"t3011","kind":"drug","name":"T3011","route":"/drugs/t3011/","asOf":"2026-09-11","days":17},{"id":"fpi-2265","kind":"drug","name":"FPI-2265","route":"/drugs/fpi-2265/","asOf":"2026-09-11","days":17},{"id":"adg126","kind":"drug","name":"ADG126","route":"/drugs/adg126/","asOf":"2026-09-11","days":17},{"id":"tng462","kind":"drug","name":"TNG462","route":"/drugs/tng462/","asOf":"2026-09-11","days":17},{"id":"mcla-129","kind":"drug","name":"MCLA-129","route":"/drugs/mcla-129/","asOf":"2026-09-11","days":17},{"id":"trk-950","kind":"drug","name":"TRK-950","route":"/drugs/trk-950/","asOf":"2026-09-11","days":17},{"id":"tqb2825","kind":"drug","name":"TQB2825","route":"/drugs/tqb2825/","asOf":"2026-09-11","days":17},{"id":"tyra-300","kind":"drug","name":"TYRA-300","route":"/drugs/tyra-300/","asOf":"2026-09-11","days":17},{"id":"tqb6411","kind":"drug","name":"TQB6411","route":"/drugs/tqb6411/","asOf":"2026-09-11","days":17},{"id":"tqb2930","kind":"drug","name":"TQB2930","route":"/drugs/tqb2930/","asOf":"2026-09-11","days":17},{"id":"krt-232","kind":"drug","name":"KRT-232","route":"/drugs/krt-232/","asOf":"2026-09-11","days":17},{"id":"azd3470","kind":"drug","name":"AZD3470","route":"/drugs/azd3470/","asOf":"2026-09-11","days":17},{"id":"ssgj-705","kind":"drug","name":"SSGJ-705","route":"/drugs/ssgj-705/","asOf":"2026-09-11","days":17},{"id":"avzo-021","kind":"drug","name":"AVZO-021","route":"/drugs/avzo-021/","asOf":"2026-09-11","days":17},{"id":"cusatuzumab","kind":"drug","name":"Cusatuzumab","route":"/drugs/cusatuzumab/","asOf":"2026-09-11","days":17},{"id":"xnw5004","kind":"drug","name":"XNW5004","route":"/drugs/xnw5004/","asOf":"2026-09-11","days":17},{"id":"serabelisib","kind":"drug","name":"Serabelisib","route":"/drugs/serabelisib/","asOf":"2026-09-11","days":17},{"id":"sapanisertib","kind":"drug","name":"Sapanisertib","route":"/drugs/sapanisertib/","asOf":"2026-09-11","days":17},{"id":"zamtocabtagene-autoleucel","kind":"drug","name":"Zamtocabtagene autoleucel","route":"/drugs/zamtocabtagene-autoleucel/","asOf":"2026-09-11","days":17},{"id":"ak119","kind":"drug","name":"AK119","route":"/drugs/ak119/","asOf":"2026-09-11","days":17},{"id":"anvumetostat","kind":"drug","name":"Anvumetostat","route":"/drugs/anvumetostat/","asOf":"2026-09-11","days":17},{"id":"xnw27011","kind":"drug","name":"XNW27011","route":"/drugs/xnw27011/","asOf":"2026-09-11","days":17},{"id":"azd9793","kind":"drug","name":"AZD9793","route":"/drugs/azd9793/","asOf":"2026-09-11","days":17},{"id":"tqb2922","kind":"drug","name":"TQB2922","route":"/drugs/tqb2922/","asOf":"2026-09-11","days":17},{"id":"cinrebafusp-alfa","kind":"drug","name":"Cinrebafusp alfa","route":"/drugs/cinrebafusp-alfa/","asOf":"2026-09-11","days":17},{"id":"e-edv-d682","kind":"drug","name":"E-EDV-D682","route":"/drugs/e-edv-d682/","asOf":"2026-09-11","days":17},{"id":"abt-301","kind":"drug","name":"ABT-301","route":"/drugs/abt-301/","asOf":"2026-09-11","days":17},{"id":"hmbd-001","kind":"drug","name":"HMBD-001","route":"/drugs/hmbd-001/","asOf":"2026-09-11","days":17},{"id":"tc011","kind":"drug","name":"TC011","route":"/drugs/tc011/","asOf":"2026-09-11","days":17},{"id":"englumafusp-alfa","kind":"drug","name":"Englumafusp alfa","route":"/drugs/englumafusp-alfa/","asOf":"2026-09-11","days":17},{"id":"azd4360","kind":"drug","name":"AZD4360","route":"/drugs/azd4360/","asOf":"2026-09-11","days":17},{"id":"ssgj-706","kind":"drug","name":"SSGJ-706","route":"/drugs/ssgj-706/","asOf":"2026-09-11","days":17},{"id":"ep0031","kind":"drug","name":"EP0031","route":"/drugs/ep0031/","asOf":"2026-09-11","days":17},{"id":"farletuzumab-exatecan","kind":"drug","name":"Farletuzumab-exatecan","route":"/drugs/farletuzumab-exatecan/","asOf":"2026-09-11","days":17},{"id":"absk061","kind":"drug","name":"ABSK061","route":"/drugs/absk061/","asOf":"2026-09-11","days":17},{"id":"rilvegostomig","kind":"drug","name":"Rilvegostomig","route":"/drugs/rilvegostomig/","asOf":"2026-09-11","days":17},{"id":"bio-106","kind":"drug","name":"BIO-106","route":"/drugs/bio-106/","asOf":"2026-09-11","days":17},{"id":"mavrostobart","kind":"drug","name":"Mavrostobart","route":"/drugs/mavrostobart/","asOf":"2026-09-11","days":17},{"id":"hb0036","kind":"drug","name":"HB0036","route":"/drugs/hb0036/","asOf":"2026-09-11","days":17},{"id":"botensilimab","kind":"drug","name":"Botensilimab","route":"/drugs/botensilimab/","asOf":"2026-09-11","days":17},{"id":"ndi-219216","kind":"drug","name":"NDI-219216","route":"/drugs/ndi-219216/","asOf":"2026-09-11","days":17},{"id":"crb-701","kind":"drug","name":"CRB-701","route":"/drugs/crb-701/","asOf":"2026-09-11","days":17},{"id":"ssgj-612","kind":"drug","name":"SSGJ-612","route":"/drugs/ssgj-612/","asOf":"2026-09-11","days":17},{"id":"jk08","kind":"drug","name":"JK08","route":"/drugs/jk08/","asOf":"2026-09-11","days":17},{"id":"ucart22","kind":"drug","name":"UCART22","route":"/drugs/ucart22/","asOf":"2026-09-11","days":17},{"id":"tri-611","kind":"drug","name":"TRI-611","route":"/drugs/tri-611/","asOf":"2026-09-11","days":17},{"id":"azd6621","kind":"drug","name":"AZD6621","route":"/drugs/azd6621/","asOf":"2026-09-11","days":17},{"id":"hdm2017","kind":"drug","name":"HDM2017","route":"/drugs/hdm2017/","asOf":"2026-09-11","days":17},{"id":"silevertinib","kind":"drug","name":"Silevertinib","route":"/drugs/silevertinib/","asOf":"2026-09-11","days":17},{"id":"crc01","kind":"drug","name":"CRC01","route":"/drugs/crc01/","asOf":"2026-09-11","days":17},{"id":"palacaparib","kind":"drug","name":"Palacaparib","route":"/drugs/palacaparib/","asOf":"2026-09-11","days":17},{"id":"tac01-cldn18-2","kind":"drug","name":"TAC01-CLDN18.2","route":"/drugs/tac01-cldn18-2/","asOf":"2026-09-11","days":17},{"id":"azd9750","kind":"drug","name":"AZD9750","route":"/drugs/azd9750/","asOf":"2026-09-11","days":17},{"id":"lorigerlimab","kind":"drug","name":"Lorigerlimab","route":"/drugs/lorigerlimab/","asOf":"2026-09-11","days":17},{"id":"ep0062","kind":"drug","name":"EP0062","route":"/drugs/ep0062/","asOf":"2026-09-11","days":17},{"id":"lcb02a","kind":"drug","name":"LCB02A","route":"/drugs/lcb02a/","asOf":"2026-09-11","days":17},{"id":"ai-081","kind":"drug","name":"AI-081","route":"/drugs/ai-081/","asOf":"2026-09-11","days":17},{"id":"ino-5401","kind":"drug","name":"INO-5401","route":"/drugs/ino-5401/","asOf":"2026-09-11","days":17},{"id":"rc118-adc","kind":"drug","name":"RC118-ADC","route":"/drugs/rc118-adc/","asOf":"2026-09-11","days":17},{"id":"adi-270","kind":"drug","name":"ADI-270","route":"/drugs/adi-270/","asOf":"2026-09-11","days":17},{"id":"gc101-til","kind":"drug","name":"GC101 TIL","route":"/drugs/gc101-til/","asOf":"2026-09-11","days":17},{"id":"qlh12016","kind":"drug","name":"QLH12016","route":"/drugs/qlh12016/","asOf":"2026-09-11","days":17},{"id":"peluntamig","kind":"drug","name":"Peluntamig","route":"/drugs/peluntamig/","asOf":"2026-09-11","days":17},{"id":"azd4512","kind":"drug","name":"AZD4512","route":"/drugs/azd4512/","asOf":"2026-09-11","days":17},{"id":"eb-nk-301","kind":"drug","name":"EB-NK-301","route":"/drugs/eb-nk-301/","asOf":"2026-09-11","days":17},{"id":"tng456","kind":"drug","name":"TNG456","route":"/drugs/tng456/","asOf":"2026-09-11","days":17},{"id":"bcb-276","kind":"drug","name":"BCB-276","route":"/drugs/bcb-276/","asOf":"2026-09-11","days":17},{"id":"azd5492","kind":"drug","name":"AZD5492","route":"/drugs/azd5492/","asOf":"2026-09-11","days":17},{"id":"jyp0015","kind":"drug","name":"JYP0015","route":"/drugs/jyp0015/","asOf":"2026-09-11","days":17},{"id":"bdc-4182","kind":"drug","name":"BDC-4182","route":"/drugs/bdc-4182/","asOf":"2026-09-11","days":17},{"id":"hlx26","kind":"drug","name":"HLX26","route":"/drugs/hlx26/","asOf":"2026-09-11","days":17},{"id":"ba3071","kind":"drug","name":"BA3071","route":"/drugs/ba3071/","asOf":"2026-09-11","days":17},{"id":"env-501","kind":"drug","name":"ENV-501","route":"/drugs/env-501/","asOf":"2026-09-11","days":17},{"id":"gc012f","kind":"drug","name":"GC012F","route":"/drugs/gc012f/","asOf":"2026-09-11","days":17},{"id":"azd4045","kind":"drug","name":"AZD4045","route":"/drugs/azd4045/","asOf":"2026-09-11","days":17},{"id":"azd7789","kind":"drug","name":"AZD7789","route":"/drugs/azd7789/","asOf":"2026-09-11","days":17},{"id":"vrn110755","kind":"drug","name":"VRN110755","route":"/drugs/vrn110755/","asOf":"2026-09-11","days":17},{"id":"cgt4859","kind":"drug","name":"CGT4859","route":"/drugs/cgt4859/","asOf":"2026-09-11","days":17},{"id":"jnj-90014496","kind":"drug","name":"JNJ-90014496","route":"/drugs/jnj-90014496/","asOf":"2026-09-11","days":17},{"id":"lcb84","kind":"drug","name":"LCB84","route":"/drugs/lcb84/","asOf":"2026-09-11","days":17},{"id":"eb-mf-car-nk-01","kind":"drug","name":"EB-MF-CAR-NK-01","route":"/drugs/eb-mf-car-nk-01/","asOf":"2026-09-11","days":17},{"id":"eb-car30-nk","kind":"drug","name":"EB-CAR30-NK","route":"/drugs/eb-car30-nk/","asOf":"2026-09-11","days":17},{"id":"ctx112","kind":"drug","name":"CTX112","route":"/drugs/ctx112/","asOf":"2026-09-11","days":17},{"id":"at101","kind":"drug","name":"AT101","route":"/drugs/at101/","asOf":"2026-09-11","days":17},{"id":"cart84","kind":"drug","name":"CART84","route":"/drugs/cart84/","asOf":"2026-09-11","days":17},{"id":"sys6023","kind":"drug","name":"SYS6023","route":"/drugs/sys6023/","asOf":"2026-09-11","days":17},{"id":"lirafugratinib","kind":"drug","name":"Lirafugratinib","route":"/drugs/lirafugratinib/","asOf":"2026-09-11","days":17},{"id":"sti-6129","kind":"drug","name":"STI-6129","route":"/drugs/sti-6129/","asOf":"2026-09-11","days":17},{"id":"men1703","kind":"drug","name":"MEN1703","route":"/drugs/men1703/","asOf":"2026-09-11","days":17},{"id":"allo-647","kind":"drug","name":"ALLO-647","route":"/drugs/allo-647/","asOf":"2026-09-11","days":17},{"id":"lb1410","kind":"drug","name":"LB1410","route":"/drugs/lb1410/","asOf":"2026-09-11","days":17},{"id":"lb4330","kind":"drug","name":"LB4330","route":"/drugs/lb4330/","asOf":"2026-09-11","days":17},{"id":"dji136","kind":"drug","name":"DJI136","route":"/drugs/dji136/","asOf":"2026-09-11","days":17},{"id":"cd19-t-hank","kind":"drug","name":"CD19 t-haNK","route":"/drugs/cd19-t-hank/","asOf":"2026-09-11","days":17},{"id":"spevatamig","kind":"drug","name":"Spevatamig","route":"/drugs/spevatamig/","asOf":"2026-09-11","days":17},{"id":"azd5863","kind":"drug","name":"AZD5863","route":"/drugs/azd5863/","asOf":"2026-09-11","days":17},{"id":"tbi-1501","kind":"drug","name":"TBI-1501","route":"/drugs/tbi-1501/","asOf":"2026-09-11","days":17},{"id":"js111","kind":"drug","name":"JS111","route":"/drugs/js111/","asOf":"2026-09-11","days":17},{"id":"symbiotic-gi-03","kind":"trial","name":"Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer","route":"/trials/symbiotic-gi-03/","asOf":"2026-09-11","days":17},{"id":"symbiotic-gi-16","kind":"trial","name":"Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer","route":"/trials/symbiotic-gi-16/","asOf":"2026-09-11","days":17},{"id":"symbiotic-lung-04","kind":"trial","name":"Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer","route":"/trials/symbiotic-lung-04/","asOf":"2026-09-11","days":17},{"id":"symbiotic-lung-01","kind":"trial","name":"Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","route":"/trials/symbiotic-lung-01/","asOf":"2026-09-11","days":17},{"id":"nct06980272","kind":"trial","name":"SSGJ-707 in Advanced Non-Small Cell Lung Cancer","route":"/trials/nct06980272/","asOf":"2026-09-11","days":17},{"id":"nct07229625","kind":"trial","name":"A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)","route":"/trials/nct07229625/","asOf":"2026-09-11","days":17},{"id":"taishan-301","kind":"trial","name":"A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma(TAISHAN-301)","route":"/trials/taishan-301/","asOf":"2026-09-11","days":17},{"id":"nct06612151","kind":"trial","name":"A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer（TAISHAN-302）","route":"/trials/nct06612151/","asOf":"2026-09-11","days":17},{"id":"nct07739758","kind":"trial","name":"A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer","route":"/trials/nct07739758/","asOf":"2026-09-11","days":17},{"id":"nct07418749","kind":"trial","name":"A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer","route":"/trials/nct07418749/","asOf":"2026-09-11","days":17},{"id":"nct07003074","kind":"trial","name":"A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer","route":"/trials/nct07003074/","asOf":"2026-09-11","days":17},{"id":"nct06561607","kind":"trial","name":"A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer","route":"/trials/nct06561607/","asOf":"2026-09-11","days":17},{"id":"nct07008976","kind":"trial","name":"Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer","route":"/trials/nct07008976/","asOf":"2026-09-11","days":17},{"id":"nct07043725","kind":"trial","name":"A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer","route":"/trials/nct07043725/","asOf":"2026-09-11","days":17},{"id":"nct06616532","kind":"trial","name":"PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer","route":"/trials/nct06616532/","asOf":"2026-09-11","days":17},{"id":"nct06419621","kind":"trial","name":"PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC","route":"/trials/nct06419621/","asOf":"2026-09-11","days":17},{"id":"nct07174908","kind":"trial","name":"A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation","route":"/trials/nct07174908/","asOf":"2026-09-11","days":17},{"id":"nct07525206","kind":"trial","name":"A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer","route":"/trials/nct07525206/","asOf":"2026-09-11","days":17},{"id":"nct06614192","kind":"trial","name":"A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer","route":"/trials/nct06614192/","asOf":"2026-09-11","days":17},{"id":"nct07155187","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer","route":"/trials/nct07155187/","asOf":"2026-09-11","days":17},{"id":"nct07005102","kind":"trial","name":"A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer","route":"/trials/nct07005102/","asOf":"2026-09-11","days":17},{"id":"nct05211895","kind":"trial","name":"A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC","route":"/trials/nct05211895/","asOf":"2026-09-11","days":17},{"id":"nct05502237","kind":"trial","name":"Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer","route":"/trials/nct05502237/","asOf":"2026-09-11","days":17},{"id":"nct05020769","kind":"trial","name":"SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer","route":"/trials/nct05020769/","asOf":"2026-09-11","days":17},{"id":"nct05221840","kind":"trial","name":"A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer","route":"/trials/nct05221840/","asOf":"2026-09-11","days":17},{"id":"nct04658862","kind":"trial","name":"A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder","route":"/trials/nct04658862/","asOf":"2026-09-11","days":17},{"id":"hr-nmibc","kind":"trial","name":"A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)","route":"/trials/hr-nmibc/","asOf":"2026-09-11","days":17},{"id":"nct06935409","kind":"trial","name":"Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure","route":"/trials/nct06935409/","asOf":"2026-09-11","days":17},{"id":"nct06498479","kind":"trial","name":"ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer","route":"/trials/nct06498479/","asOf":"2026-09-11","days":17},{"id":"nct07189455","kind":"trial","name":"Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer","route":"/trials/nct07189455/","asOf":"2026-09-11","days":17},{"id":"nct07554339","kind":"trial","name":"A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)","route":"/trials/nct07554339/","asOf":"2026-09-11","days":17},{"id":"nct06345729","kind":"trial","name":"A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)","route":"/trials/nct06345729/","asOf":"2026-09-11","days":17},{"id":"nct07431827","kind":"trial","name":"MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)","route":"/trials/nct07431827/","asOf":"2026-09-11","days":17},{"id":"nct06997497","kind":"trial","name":"A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)","route":"/trials/nct06997497/","asOf":"2026-09-11","days":17},{"id":"nct07190248","kind":"trial","name":"A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)","route":"/trials/nct07190248/","asOf":"2026-09-11","days":17},{"id":"nct06943755","kind":"trial","name":"Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors","route":"/trials/nct06943755/","asOf":"2026-09-11","days":17},{"id":"nct06082167","kind":"trial","name":"Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","route":"/trials/nct06082167/","asOf":"2026-09-11","days":17},{"id":"nct07227402","kind":"trial","name":"A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)","route":"/trials/nct07227402/","asOf":"2026-09-11","days":17},{"id":"nct07489495","kind":"trial","name":"A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)","route":"/trials/nct07489495/","asOf":"2026-09-11","days":17},{"id":"nct06601335","kind":"trial","name":"A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)","route":"/trials/nct06601335/","asOf":"2026-09-11","days":17},{"id":"nct07463573","kind":"trial","name":"QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma","route":"/trials/nct07463573/","asOf":"2026-09-11","days":17},{"id":"nct06954246","kind":"trial","name":"A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer","route":"/trials/nct06954246/","asOf":"2026-09-11","days":17},{"id":"nct06194734","kind":"trial","name":"A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer","route":"/trials/nct06194734/","asOf":"2026-09-11","days":17},{"id":"nsclc-2","kind":"trial","name":"Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nsclc-2/","asOf":"2026-09-11","days":17},{"id":"nct05450692","kind":"trial","name":"A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy","route":"/trials/nct05450692/","asOf":"2026-09-11","days":17},{"id":"renaviv","kind":"trial","name":"A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)","route":"/trials/renaviv/","asOf":"2026-09-11","days":17},{"id":"nct07354022","kind":"trial","name":"A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy","route":"/trials/nct07354022/","asOf":"2026-09-11","days":17},{"id":"nct07024173","kind":"trial","name":"A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer","route":"/trials/nct07024173/","asOf":"2026-09-11","days":17},{"id":"nct07349069","kind":"trial","name":"A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer","route":"/trials/nct07349069/","asOf":"2026-09-11","days":17},{"id":"nct05862285","kind":"trial","name":"A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study","route":"/trials/nct05862285/","asOf":"2026-09-11","days":17},{"id":"nct06136624","kind":"trial","name":"Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)","route":"/trials/nct06136624/","asOf":"2026-09-11","days":17},{"id":"nct06136650","kind":"trial","name":"A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)","route":"/trials/nct06136650/","asOf":"2026-09-11","days":17},{"id":"tai-shan6","kind":"trial","name":"A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)","route":"/trials/tai-shan6/","asOf":"2026-09-11","days":17},{"id":"sqnsclc","kind":"trial","name":"RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)","route":"/trials/sqnsclc/","asOf":"2026-09-11","days":17},{"id":"nct05744687","kind":"trial","name":"Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer","route":"/trials/nct05744687/","asOf":"2026-09-11","days":17},{"id":"nct05860465","kind":"trial","name":"Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer","route":"/trials/nct05860465/","asOf":"2026-09-11","days":17},{"id":"nct07362186","kind":"trial","name":"LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma","route":"/trials/nct07362186/","asOf":"2026-09-11","days":17},{"id":"nct07416994","kind":"trial","name":"Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer","route":"/trials/nct07416994/","asOf":"2026-09-11","days":17},{"id":"nct07461454","kind":"trial","name":"YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer","route":"/trials/nct07461454/","asOf":"2026-09-11","days":17},{"id":"nct05132075","kind":"trial","name":"Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer","route":"/trials/nct05132075/","asOf":"2026-09-11","days":17},{"id":"nct05780567","kind":"trial","name":"Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer","route":"/trials/nct05780567/","asOf":"2026-09-11","days":17},{"id":"nct05365178","kind":"trial","name":"To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer","route":"/trials/nct05365178/","asOf":"2026-09-11","days":17},{"id":"nct06952803","kind":"trial","name":"A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation","route":"/trials/nct06952803/","asOf":"2026-09-11","days":17},{"id":"nct06120491","kind":"trial","name":"Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents","route":"/trials/nct06120491/","asOf":"2026-09-11","days":17},{"id":"nct05487391","kind":"trial","name":"A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection","route":"/trials/nct05487391/","asOf":"2026-09-11","days":17},{"id":"nct06686576","kind":"trial","name":"A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer","route":"/trials/nct06686576/","asOf":"2026-09-11","days":17},{"id":"nct05690945","kind":"trial","name":"A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer","route":"/trials/nct05690945/","asOf":"2026-09-11","days":17},{"id":"nct07377578","kind":"trial","name":"A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma","route":"/trials/nct07377578/","asOf":"2026-09-11","days":17},{"id":"nct07342478","kind":"trial","name":"ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL","route":"/trials/nct07342478/","asOf":"2026-09-11","days":17},{"id":"nct07570173","kind":"trial","name":"A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)","route":"/trials/nct07570173/","asOf":"2026-09-11","days":17},{"id":"nct07634471","kind":"trial","name":"A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)","route":"/trials/nct07634471/","asOf":"2026-09-11","days":17},{"id":"nct04498117","kind":"trial","name":"Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery","route":"/trials/nct04498117/","asOf":"2026-09-11","days":17},{"id":"nct07063745","kind":"trial","name":"A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion","route":"/trials/nct07063745/","asOf":"2026-09-11","days":17},{"id":"mountaintap-30","kind":"trial","name":"A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)","route":"/trials/mountaintap-30/","asOf":"2026-09-11","days":17},{"id":"nct06247605","kind":"trial","name":"A Phase IIII Study of AL8326 in Small Cell Lung Cancer","route":"/trials/nct06247605/","asOf":"2026-09-11","days":17},{"id":"nct07459751","kind":"trial","name":"A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer","route":"/trials/nct07459751/","asOf":"2026-09-11","days":17},{"id":"nct06927986","kind":"trial","name":"Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）","route":"/trials/nct06927986/","asOf":"2026-09-11","days":17},{"id":"nct05294172","kind":"trial","name":"KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma","route":"/trials/nct05294172/","asOf":"2026-09-11","days":17},{"id":"nct06608927","kind":"trial","name":"Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma","route":"/trials/nct06608927/","asOf":"2026-09-11","days":17},{"id":"nct05751512","kind":"trial","name":"A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN","route":"/trials/nct05751512/","asOf":"2026-09-11","days":17},{"id":"nct06394492","kind":"trial","name":"SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer","route":"/trials/nct06394492/","asOf":"2026-09-11","days":17},{"id":"nct07424287","kind":"trial","name":"A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC","route":"/trials/nct07424287/","asOf":"2026-09-11","days":17},{"id":"nct07726992","kind":"trial","name":"A Study of SHR-1501 Combination With BCG Versus Placebo Combined With BCG in Subjects With Papillary-Only NMIBC","route":"/trials/nct07726992/","asOf":"2026-09-11","days":17},{"id":"nct07804186","kind":"trial","name":"Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma","route":"/trials/nct07804186/","asOf":"2026-09-11","days":17},{"id":"nct07015190","kind":"trial","name":"Neoadjuvant Darovasertib in Primary Uveal Melanoma","route":"/trials/nct07015190/","asOf":"2026-09-11","days":17},{"id":"nct07555938","kind":"trial","name":"Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma","route":"/trials/nct07555938/","asOf":"2026-09-11","days":17},{"id":"nct05838066","kind":"trial","name":"Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer","route":"/trials/nct05838066/","asOf":"2026-09-11","days":17},{"id":"nct07441460","kind":"trial","name":"A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer","route":"/trials/nct07441460/","asOf":"2026-09-11","days":17},{"id":"nct06747338","kind":"trial","name":"A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer","route":"/trials/nct06747338/","asOf":"2026-09-11","days":17},{"id":"nct06079983","kind":"trial","name":"JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects","route":"/trials/nct06079983/","asOf":"2026-09-11","days":17},{"id":"nct06846437","kind":"trial","name":"JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer","route":"/trials/nct06846437/","asOf":"2026-09-11","days":17},{"id":"nct06697301","kind":"trial","name":"Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma","route":"/trials/nct06697301/","asOf":"2026-09-11","days":17},{"id":"nct07365319","kind":"trial","name":"A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer","route":"/trials/nct07365319/","asOf":"2026-09-11","days":17},{"id":"nct07516093","kind":"trial","name":"Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL","route":"/trials/nct07516093/","asOf":"2026-09-11","days":17},{"id":"nct07262567","kind":"trial","name":"Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer","route":"/trials/nct07262567/","asOf":"2026-09-11","days":17},{"id":"nct07668752","kind":"trial","name":"A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation","route":"/trials/nct07668752/","asOf":"2026-09-11","days":17},{"id":"nct05973773","kind":"trial","name":"REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)","route":"/trials/nct05973773/","asOf":"2026-09-11","days":17},{"id":"nct07128199","kind":"trial","name":"A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection","route":"/trials/nct07128199/","asOf":"2026-09-11","days":17},{"id":"aurora","kind":"trial","name":"Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)","route":"/trials/aurora/","asOf":"2026-09-11","days":17},{"id":"nct07258511","kind":"trial","name":"A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07258511/","asOf":"2026-09-11","days":17},{"id":"nct07518186","kind":"trial","name":"A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07518186/","asOf":"2026-09-11","days":17},{"id":"nct06754644","kind":"trial","name":"A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC","route":"/trials/nct06754644/","asOf":"2026-09-11","days":17},{"id":"nct07377643","kind":"trial","name":"IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer","route":"/trials/nct07377643/","asOf":"2026-09-11","days":17},{"id":"nct06834672","kind":"trial","name":"Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","route":"/trials/nct06834672/","asOf":"2026-09-11","days":17},{"id":"nct05671510","kind":"trial","name":"ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors","route":"/trials/nct05671510/","asOf":"2026-09-11","days":17},{"id":"nct06855277","kind":"trial","name":"Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC","route":"/trials/nct06855277/","asOf":"2026-09-11","days":17},{"id":"nct06780670","kind":"trial","name":"Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy","route":"/trials/nct06780670/","asOf":"2026-09-11","days":17},{"id":"nct07011056","kind":"trial","name":"A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma","route":"/trials/nct07011056/","asOf":"2026-09-11","days":17},{"id":"nct04523272","kind":"trial","name":"A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer","route":"/trials/nct04523272/","asOf":"2026-09-11","days":17},{"id":"nct05077449","kind":"trial","name":"A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer","route":"/trials/nct05077449/","asOf":"2026-09-11","days":17},{"id":"nct04250922","kind":"trial","name":"LAM561 With RT and TMZ for Adults With Glioblastoma","route":"/trials/nct04250922/","asOf":"2026-09-11","days":17},{"id":"dllevate","kind":"trial","name":"A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)","route":"/trials/dllevate/","asOf":"2026-09-11","days":17},{"id":"nct07585266","kind":"trial","name":"A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)","route":"/trials/nct07585266/","asOf":"2026-09-11","days":17},{"id":"nct06968585","kind":"trial","name":"A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy","route":"/trials/nct06968585/","asOf":"2026-09-11","days":17},{"id":"nct06671379","kind":"trial","name":"A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC","route":"/trials/nct06671379/","asOf":"2026-09-11","days":17},{"id":"nct05754853","kind":"trial","name":"A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer","route":"/trials/nct05754853/","asOf":"2026-09-11","days":17},{"id":"nct07385703","kind":"trial","name":"Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma","route":"/trials/nct07385703/","asOf":"2026-09-11","days":17},{"id":"nct07452198","kind":"trial","name":"A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07452198/","asOf":"2026-09-11","days":17},{"id":"nct05155254","kind":"trial","name":"IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)","route":"/trials/nct05155254/","asOf":"2026-09-11","days":17},{"id":"nct07062965","kind":"trial","name":"A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment","route":"/trials/nct07062965/","asOf":"2026-09-11","days":17},{"id":"nct07365241","kind":"trial","name":"A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer","route":"/trials/nct07365241/","asOf":"2026-09-11","days":17},{"id":"nct06732323","kind":"trial","name":"A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer","route":"/trials/nct06732323/","asOf":"2026-09-11","days":17},{"id":"nct06383767","kind":"trial","name":"A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer","route":"/trials/nct06383767/","asOf":"2026-09-11","days":17},{"id":"fleteo","kind":"trial","name":"Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)","route":"/trials/fleteo/","asOf":"2026-09-11","days":17},{"id":"aspen-06","kind":"trial","name":"A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)","route":"/trials/aspen-06/","asOf":"2026-09-11","days":17},{"id":"nct05732805","kind":"trial","name":"A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma","route":"/trials/nct05732805/","asOf":"2026-09-11","days":17},{"id":"nct05751928","kind":"trial","name":"A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma","route":"/trials/nct05751928/","asOf":"2026-09-11","days":17},{"id":"nct07480356","kind":"trial","name":"Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer","route":"/trials/nct07480356/","asOf":"2026-09-11","days":17},{"id":"nsclc-3","kind":"trial","name":"TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nsclc-3/","asOf":"2026-09-11","days":17},{"id":"nct06855069","kind":"trial","name":"HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer","route":"/trials/nct06855069/","asOf":"2026-09-11","days":17},{"id":"nct06984588","kind":"trial","name":"A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer","route":"/trials/nct06984588/","asOf":"2026-09-11","days":17},{"id":"nct07138209","kind":"trial","name":"A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07138209/","asOf":"2026-09-11","days":17},{"id":"nct07544056","kind":"trial","name":"A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer","route":"/trials/nct07544056/","asOf":"2026-09-11","days":17},{"id":"nct06998108","kind":"trial","name":"Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy","route":"/trials/nct06998108/","asOf":"2026-09-11","days":17},{"id":"nct06093672","kind":"trial","name":"Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera","route":"/trials/nct06093672/","asOf":"2026-09-11","days":17},{"id":"nct06416410","kind":"trial","name":"JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation","route":"/trials/nct06416410/","asOf":"2026-09-11","days":17},{"id":"nct07214779","kind":"trial","name":"Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression","route":"/trials/nct07214779/","asOf":"2026-09-11","days":17},{"id":"nct07207070","kind":"trial","name":"A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer","route":"/trials/nct07207070/","asOf":"2026-09-11","days":17},{"id":"nct06735391","kind":"trial","name":"A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations","route":"/trials/nct06735391/","asOf":"2026-09-11","days":17},{"id":"nct07533123","kind":"trial","name":"A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care","route":"/trials/nct07533123/","asOf":"2026-09-11","days":17},{"id":"nct06635824","kind":"trial","name":"Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)","route":"/trials/nct06635824/","asOf":"2026-09-11","days":17},{"id":"nct07365995","kind":"trial","name":"A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer","route":"/trials/nct07365995/","asOf":"2026-09-11","days":17},{"id":"apex-03","kind":"trial","name":"ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)","route":"/trials/apex-03/","asOf":"2026-09-11","days":17},{"id":"nct05417789","kind":"trial","name":"Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)","route":"/trials/nct05417789/","asOf":"2026-09-11","days":17},{"id":"nct03768063","kind":"trial","name":"A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study","route":"/trials/nct03768063/","asOf":"2026-09-11","days":17},{"id":"nct07546500","kind":"trial","name":"A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression","route":"/trials/nct07546500/","asOf":"2026-09-11","days":17},{"id":"nct05281471","kind":"trial","name":"Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)","route":"/trials/nct05281471/","asOf":"2026-09-11","days":17},{"id":"nct07409272","kind":"trial","name":"A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer","route":"/trials/nct07409272/","asOf":"2026-09-11","days":17},{"id":"nct07566052","kind":"trial","name":"A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation","route":"/trials/nct07566052/","asOf":"2026-09-11","days":17},{"id":"nct06532006","kind":"trial","name":"A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer","route":"/trials/nct06532006/","asOf":"2026-09-11","days":17},{"id":"nct07662395","kind":"trial","name":"SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer","route":"/trials/nct07662395/","asOf":"2026-09-11","days":17},{"id":"nct05065957","kind":"trial","name":"Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer","route":"/trials/nct05065957/","asOf":"2026-09-11","days":17},{"id":"nct06622057","kind":"trial","name":"D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer","route":"/trials/nct06622057/","asOf":"2026-09-11","days":17},{"id":"nct07570823","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","route":"/trials/nct07570823/","asOf":"2026-09-11","days":17},{"id":"nct07562022","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma","route":"/trials/nct07562022/","asOf":"2026-09-11","days":17},{"id":"pik3ca-2","kind":"trial","name":"A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)","route":"/trials/pik3ca-2/","asOf":"2026-09-11","days":17},{"id":"quintessential-2","kind":"trial","name":"A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)","route":"/trials/quintessential-2/","asOf":"2026-09-11","days":17},{"id":"nct05987358","kind":"trial","name":"A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma","route":"/trials/nct05987358/","asOf":"2026-09-11","days":17},{"id":"nct06929624","kind":"trial","name":"A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma","route":"/trials/nct06929624/","asOf":"2026-09-11","days":17},{"id":"nct06387069","kind":"trial","name":"A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia","route":"/trials/nct06387069/","asOf":"2026-09-11","days":17},{"id":"nct07217301","kind":"trial","name":"A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer","route":"/trials/nct07217301/","asOf":"2026-09-11","days":17},{"id":"nct05586074","kind":"trial","name":"HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML","route":"/trials/nct05586074/","asOf":"2026-09-11","days":17},{"id":"nct07218926","kind":"trial","name":"A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy","route":"/trials/nct07218926/","asOf":"2026-09-11","days":17},{"id":"nct04910685","kind":"trial","name":"(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis","route":"/trials/nct04910685/","asOf":"2026-09-11","days":17},{"id":"nct05232916","kind":"trial","name":"Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects","route":"/trials/nct05232916/","asOf":"2026-09-11","days":17},{"id":"invincible-3","kind":"trial","name":"A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)","route":"/trials/invincible-3/","asOf":"2026-09-11","days":17},{"id":"nct05141721","kind":"trial","name":"A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer","route":"/trials/nct05141721/","asOf":"2026-09-11","days":17},{"id":"nct04169997","kind":"trial","name":"A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer","route":"/trials/nct04169997/","asOf":"2026-09-11","days":17},{"id":"nct04415853","kind":"trial","name":"Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer","route":"/trials/nct04415853/","asOf":"2026-09-11","days":17},{"id":"nct07218809","kind":"trial","name":"AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer","route":"/trials/nct07218809/","asOf":"2026-09-11","days":17},{"id":"nct07407803","kind":"trial","name":"Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas","route":"/trials/nct07407803/","asOf":"2026-09-11","days":17},{"id":"nct06331299","kind":"trial","name":"A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer","route":"/trials/nct06331299/","asOf":"2026-09-11","days":17},{"id":"nct04353375","kind":"trial","name":"HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma","route":"/trials/nct04353375/","asOf":"2026-09-11","days":17},{"id":"nct07297329","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant","route":"/trials/nct07297329/","asOf":"2026-09-11","days":17},{"id":"nct05945901","kind":"trial","name":"A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer","route":"/trials/nct05945901/","asOf":"2026-09-11","days":17},{"id":"nct07379047","kind":"trial","name":"Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)","route":"/trials/nct07379047/","asOf":"2026-09-11","days":17},{"id":"nct06519370","kind":"trial","name":"FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer","route":"/trials/nct06519370/","asOf":"2026-09-11","days":17},{"id":"nct07174427","kind":"trial","name":"Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma","route":"/trials/nct07174427/","asOf":"2026-09-11","days":17},{"id":"nct06954961","kind":"trial","name":"A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer","route":"/trials/nct06954961/","asOf":"2026-09-11","days":17},{"id":"nct07522073","kind":"trial","name":"A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma","route":"/trials/nct07522073/","asOf":"2026-09-11","days":17},{"id":"nct06919965","kind":"trial","name":"A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer","route":"/trials/nct06919965/","asOf":"2026-09-11","days":17},{"id":"nct07409428","kind":"trial","name":"A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL","route":"/trials/nct07409428/","asOf":"2026-09-11","days":17},{"id":"nct06743126","kind":"trial","name":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","route":"/trials/nct06743126/","asOf":"2026-09-11","days":17},{"id":"simrise","kind":"trial","name":"A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)","route":"/trials/simrise/","asOf":"2026-09-11","days":17},{"id":"nct07673887","kind":"trial","name":"A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer","route":"/trials/nct07673887/","asOf":"2026-09-11","days":17},{"id":"nct07579234","kind":"trial","name":"A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07579234/","asOf":"2026-09-11","days":17},{"id":"nct06982521","kind":"trial","name":"Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer","route":"/trials/nct06982521/","asOf":"2026-09-11","days":17},{"id":"nct06658353","kind":"trial","name":"Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors","route":"/trials/nct06658353/","asOf":"2026-09-11","days":17},{"id":"nct05346224","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer","route":"/trials/nct05346224/","asOf":"2026-09-11","days":17},{"id":"nct06646276","kind":"trial","name":"A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS)","route":"/trials/nct06646276/","asOf":"2026-09-11","days":17},{"id":"nct03659448","kind":"trial","name":"Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer","route":"/trials/nct03659448/","asOf":"2026-09-11","days":17},{"id":"proceade-crc-03","kind":"trial","name":"A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)","route":"/trials/proceade-crc-03/","asOf":"2026-09-11","days":17},{"id":"nct06860971","kind":"trial","name":"A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma","route":"/trials/nct06860971/","asOf":"2026-09-11","days":17},{"id":"nct04165317","kind":"trial","name":"A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer","route":"/trials/nct04165317/","asOf":"2026-09-11","days":17},{"id":"companion-002","kind":"trial","name":"A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)","route":"/trials/companion-002/","asOf":"2026-09-11","days":17},{"id":"nct07284849","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer","route":"/trials/nct07284849/","asOf":"2026-09-11","days":17},{"id":"nct07386938","kind":"trial","name":"A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer","route":"/trials/nct07386938/","asOf":"2026-09-11","days":17},{"id":"nct06764485","kind":"trial","name":"A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer","route":"/trials/nct06764485/","asOf":"2026-09-11","days":17},{"id":"nct06624644","kind":"trial","name":"A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma","route":"/trials/nct06624644/","asOf":"2026-09-11","days":17},{"id":"nct07188558","kind":"trial","name":"A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy","route":"/trials/nct07188558/","asOf":"2026-09-11","days":17},{"id":"mcrpc","kind":"trial","name":"A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)","route":"/trials/mcrpc/","asOf":"2026-09-11","days":17},{"id":"nct06295731","kind":"trial","name":"INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC","route":"/trials/nct06295731/","asOf":"2026-09-11","days":17},{"id":"nct06351631","kind":"trial","name":"A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)","route":"/trials/nct06351631/","asOf":"2026-09-11","days":17},{"id":"nct04892173","kind":"trial","name":"JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC","route":"/trials/nct04892173/","asOf":"2026-09-11","days":17},{"id":"nct06177041","kind":"trial","name":"M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma","route":"/trials/nct06177041/","asOf":"2026-09-11","days":17},{"id":"nct07492641","kind":"trial","name":"BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease","route":"/trials/nct07492641/","asOf":"2026-09-11","days":17},{"id":"nct06561048","kind":"trial","name":"Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma","route":"/trials/nct06561048/","asOf":"2026-09-11","days":17},{"id":"nct07218380","kind":"trial","name":"A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract","route":"/trials/nct07218380/","asOf":"2026-09-11","days":17},{"id":"nct06401356","kind":"trial","name":"An Extension Study for Patients Previously Enrolled in Studies With Pelabresib","route":"/trials/nct06401356/","asOf":"2026-09-11","days":17},{"id":"seacraft-2","kind":"trial","name":"A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)","route":"/trials/seacraft-2/","asOf":"2026-09-11","days":17},{"id":"nct05118776","kind":"trial","name":"Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM","route":"/trials/nct05118776/","asOf":"2026-09-11","days":17},{"id":"nct06079346","kind":"trial","name":"A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer","route":"/trials/nct06079346/","asOf":"2026-09-11","days":17},{"id":"nct05317819","kind":"trial","name":"Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma","route":"/trials/nct05317819/","asOf":"2026-09-11","days":17},{"id":"nct07413939","kind":"trial","name":"RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive","route":"/trials/nct07413939/","asOf":"2026-09-11","days":17},{"id":"nct07362459","kind":"trial","name":"A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer","route":"/trials/nct07362459/","asOf":"2026-09-11","days":17},{"id":"nct06472245","kind":"trial","name":"Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor","route":"/trials/nct06472245/","asOf":"2026-09-11","days":17},{"id":"nct06508983","kind":"trial","name":"A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients","route":"/trials/nct06508983/","asOf":"2026-09-11","days":17},{"id":"nct04468984","kind":"trial","name":"Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis","route":"/trials/nct04468984/","asOf":"2026-09-11","days":17},{"id":"nsclc-4","kind":"trial","name":"A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)","route":"/trials/nsclc-4/","asOf":"2026-09-11","days":17},{"id":"nct04871282","kind":"trial","name":"A Study of AL102 in Patients With Progressing Desmoid Tumors","route":"/trials/nct04871282/","asOf":"2026-09-11","days":17},{"id":"nct06417008","kind":"trial","name":"A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer","route":"/trials/nct06417008/","asOf":"2026-09-11","days":17},{"id":"nct07673029","kind":"trial","name":"A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer","route":"/trials/nct07673029/","asOf":"2026-09-11","days":17},{"id":"nct06774131","kind":"trial","name":"A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer","route":"/trials/nct06774131/","asOf":"2026-09-11","days":17},{"id":"nct07079228","kind":"trial","name":"A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer","route":"/trials/nct07079228/","asOf":"2026-09-11","days":17},{"id":"nct07213804","kind":"trial","name":"A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer","route":"/trials/nct07213804/","asOf":"2026-09-11","days":17},{"id":"nct05254171","kind":"trial","name":"Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer","route":"/trials/nct05254171/","asOf":"2026-09-11","days":17},{"id":"nct04534205","kind":"trial","name":"A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1","route":"/trials/nct04534205/","asOf":"2026-09-11","days":17},{"id":"nct04921527","kind":"trial","name":"Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer","route":"/trials/nct04921527/","asOf":"2026-09-11","days":17},{"id":"himalayas-1","kind":"trial","name":"A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)","route":"/trials/himalayas-1/","asOf":"2026-09-11","days":17},{"id":"nct07562152","kind":"trial","name":"Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","route":"/trials/nct07562152/","asOf":"2026-09-11","days":17},{"id":"g-hope-002","kind":"trial","name":"A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)","route":"/trials/g-hope-002/","asOf":"2026-09-11","days":17},{"id":"nct06852222","kind":"trial","name":"A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)","route":"/trials/nct06852222/","asOf":"2026-09-11","days":17},{"id":"nct07490262","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment","route":"/trials/nct07490262/","asOf":"2026-09-11","days":17},{"id":"nct06064877","kind":"trial","name":"A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma","route":"/trials/nct06064877/","asOf":"2026-09-11","days":17},{"id":"nct07215585","kind":"trial","name":"AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL","route":"/trials/nct07215585/","asOf":"2026-09-11","days":17},{"id":"nct06792253","kind":"trial","name":"Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","route":"/trials/nct06792253/","asOf":"2026-09-11","days":17},{"id":"nct07311694","kind":"trial","name":"A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct07311694/","asOf":"2026-09-11","days":17},{"id":"nct05303519","kind":"trial","name":"SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)","route":"/trials/nct05303519/","asOf":"2026-09-11","days":17},{"id":"nct06504732","kind":"trial","name":"To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer","route":"/trials/nct06504732/","asOf":"2026-09-11","days":17},{"id":"anetumab-vs-vinorelbine-mpm","kind":"trial","name":"Anetumab ravtansine versus vinorelbine in relapsed mesothelin-positive pleural mesothelioma","route":"/trials/anetumab-vs-vinorelbine-mpm/","asOf":"2026-09-11","days":17},{"id":"aldoxorubicin-phase-3-sts","kind":"trial","name":"Aldoxorubicin versus investigator's choice in relapsed or refractory soft tissue sarcoma","route":"/trials/aldoxorubicin-phase-3-sts/","asOf":"2026-09-11","days":17},{"id":"ucl-proton-hemithoracic-mpm","kind":"trial","name":"Hemithoracic irradiation with proton therapy in malignant pleural mesothelioma (UCL)","route":"/trials/ucl-proton-hemithoracic-mpm/","asOf":"2026-09-11","days":17},{"id":"tiger-trial","kind":"trial","name":"TIGER: standard-dose TIP versus high-dose TI-CE with stem cell transplant as first salvage for relapsed germ cell tumours","route":"/trials/tiger-trial/","asOf":"2026-09-16","days":12},{"id":"zen-3694-platinum-nut","kind":"trial","name":"ZEN-3694 with platinum chemotherapy in NUT carcinoma (NCI phase 1/2)","route":"/trials/zen-3694-platinum-nut/","asOf":"2026-09-16","days":12},{"id":"zen-3694-abemaciclib-nut","kind":"trial","name":"ZEN-3694 with abemaciclib in NUT carcinoma, breast cancer and other solid tumours (NCI phase 1)","route":"/trials/zen-3694-abemaciclib-nut/","asOf":"2026-09-16","days":12},{"id":"cemiplimab-nut","kind":"trial","name":"Cemiplimab in metastatic or unresectable NUT carcinoma (Northwestern pilot)","route":"/trials/cemiplimab-nut/","asOf":"2026-09-16","days":12},{"id":"sabr-comet","kind":"trial","name":"SABR-COMET: stereotactic ablative radiotherapy for oligometastatic cancer","route":"/trials/sabr-comet/","asOf":"2026-09-16","days":12},{"id":"olverembatinib","kind":"drug","name":"Olverembatinib","route":"/drugs/olverembatinib/","asOf":"2026-09-16","days":12},{"id":"trastuzumab-pamirtecan","kind":"drug","name":"Trastuzumab pamirtecan","route":"/drugs/trastuzumab-pamirtecan/","asOf":"2026-09-16","days":12},{"id":"florastamin-f18","kind":"drug","name":"Florastamin F-18","route":"/drugs/florastamin-f18/","asOf":"2026-09-16","days":12},{"id":"vebreltinib","kind":"drug","name":"Vebreltinib","route":"/drugs/vebreltinib/","asOf":"2026-09-16","days":12},{"id":"tunlametinib","kind":"drug","name":"Tunlametinib","route":"/drugs/tunlametinib/","asOf":"2026-09-16","days":12},{"id":"glecirasib","kind":"drug","name":"Glecirasib","route":"/drugs/glecirasib/","asOf":"2026-09-16","days":12},{"id":"glumetinib","kind":"drug","name":"Glumetinib","route":"/drugs/glumetinib/","asOf":"2026-09-16","days":12},{"id":"zimberelimab","kind":"drug","name":"Zimberelimab","route":"/drugs/zimberelimab/","asOf":"2026-09-16","days":12},{"id":"tabelecleucel","kind":"drug","name":"Tabelecleucel","route":"/drugs/tabelecleucel/","asOf":"2026-09-16","days":12},{"id":"rezvilutamide","kind":"drug","name":"Rezvilutamide","route":"/drugs/rezvilutamide/","asOf":"2026-09-16","days":12},{"id":"golidocitinib","kind":"drug","name":"Golidocitinib","route":"/drugs/golidocitinib/","asOf":"2026-09-16","days":12},{"id":"socazolimab","kind":"drug","name":"Socazolimab","route":"/drugs/socazolimab/","asOf":"2026-09-16","days":12},{"id":"pirarubicin","kind":"drug","name":"Pirarubicin","route":"/drugs/pirarubicin/","asOf":"2026-09-16","days":12},{"id":"girentuximab-zr89","kind":"drug","name":"Zirconium-89 girentuximab","route":"/drugs/girentuximab-zr89/","asOf":"2026-09-16","days":12},{"id":"psma-1007-f18","kind":"drug","name":"PSMA-1007 F-18","route":"/drugs/psma-1007-f18/","asOf":"2026-09-16","days":12},{"id":"favezelimab","kind":"drug","name":"Favezelimab","route":"/drugs/favezelimab/","asOf":"2026-09-16","days":12},{"id":"elritercept","kind":"drug","name":"Elritercept","route":"/drugs/elritercept/","asOf":"2026-09-16","days":12},{"id":"adagloxad-simolenin","kind":"drug","name":"Adagloxad simolenin","route":"/drugs/adagloxad-simolenin/","asOf":"2026-09-16","days":12},{"id":"retlirafusp-alfa","kind":"drug","name":"Retlirafusp alfa","route":"/drugs/retlirafusp-alfa/","asOf":"2026-09-16","days":12},{"id":"cam2029","kind":"drug","name":"CAM2029 (octreotide subcutaneous depot)","route":"/drugs/cam2029/","asOf":"2026-09-16","days":12},{"id":"m701","kind":"drug","name":"M701","route":"/drugs/m701/","asOf":"2026-09-16","days":12},{"id":"lerociclib","kind":"drug","name":"Lerociclib","route":"/drugs/lerociclib/","asOf":"2026-09-16","days":12},{"id":"limertinib","kind":"drug","name":"Limertinib","route":"/drugs/limertinib/","asOf":"2026-09-16","days":12},{"id":"iomab-b","kind":"drug","name":"Iomab-B","route":"/drugs/iomab-b/","asOf":"2026-09-16","days":12},{"id":"visugromab","kind":"drug","name":"Visugromab","route":"/drugs/visugromab/","asOf":"2026-09-16","days":12},{"id":"amrubicin","kind":"drug","name":"Amrubicin","route":"/drugs/amrubicin/","asOf":"2026-09-16","days":12},{"id":"pucotenlimab","kind":"drug","name":"Pucotenlimab","route":"/drugs/pucotenlimab/","asOf":"2026-09-16","days":12},{"id":"azd0120","kind":"drug","name":"AZD0120","route":"/drugs/azd0120/","asOf":"2026-09-16","days":12},{"id":"utomilumab","kind":"drug","name":"Utomilumab","route":"/drugs/utomilumab/","asOf":"2026-09-16","days":12},{"id":"alisertib","kind":"drug","name":"Alisertib","route":"/drugs/alisertib/","asOf":"2026-09-16","days":12},{"id":"roginolisib","kind":"drug","name":"Roginolisib","route":"/drugs/roginolisib/","asOf":"2026-09-16","days":12},{"id":"regn7075","kind":"drug","name":"REGN7075","route":"/drugs/regn7075/","asOf":"2026-09-16","days":12},{"id":"zalifrelimab","kind":"drug","name":"Zalifrelimab","route":"/drugs/zalifrelimab/","asOf":"2026-09-16","days":12},{"id":"balstilimab","kind":"drug","name":"Balstilimab","route":"/drugs/balstilimab/","asOf":"2026-09-16","days":12},{"id":"tst001","kind":"drug","name":"TST001","route":"/drugs/tst001/","asOf":"2026-09-16","days":12},{"id":"tno155","kind":"drug","name":"TNO155","route":"/drugs/tno155/","asOf":"2026-09-16","days":12},{"id":"parsaclisib","kind":"drug","name":"Parsaclisib","route":"/drugs/parsaclisib/","asOf":"2026-09-16","days":12},{"id":"feladilimab","kind":"drug","name":"Feladilimab","route":"/drugs/feladilimab/","asOf":"2026-09-16","days":12},{"id":"amt-116","kind":"drug","name":"AMT-116","route":"/drugs/amt-116/","asOf":"2026-09-16","days":12},{"id":"azd8421","kind":"drug","name":"AZD8421","route":"/drugs/azd8421/","asOf":"2026-09-16","days":12},{"id":"enb003","kind":"drug","name":"ENB003","route":"/drugs/enb003/","asOf":"2026-09-16","days":12},{"id":"eik1005","kind":"drug","name":"EIK1005","route":"/drugs/eik1005/","asOf":"2026-09-16","days":12},{"id":"gecacitinib","kind":"drug","name":"Gecacitinib","route":"/drugs/gecacitinib/","asOf":"2026-09-16","days":12},{"id":"tng260","kind":"drug","name":"TNG260","route":"/drugs/tng260/","asOf":"2026-09-16","days":12},{"id":"onvansertib","kind":"drug","name":"Onvansertib","route":"/drugs/onvansertib/","asOf":"2026-09-16","days":12},{"id":"vistusertib","kind":"drug","name":"Vistusertib","route":"/drugs/vistusertib/","asOf":"2026-09-16","days":12},{"id":"ct3001","kind":"drug","name":"CT3001","route":"/drugs/ct3001/","asOf":"2026-09-16","days":12},{"id":"prtx007","kind":"drug","name":"PRTX007","route":"/drugs/prtx007/","asOf":"2026-09-16","days":12},{"id":"merestinib","kind":"drug","name":"Merestinib","route":"/drugs/merestinib/","asOf":"2026-09-16","days":12},{"id":"lvgn6051","kind":"drug","name":"LVGN6051","route":"/drugs/lvgn6051/","asOf":"2026-09-16","days":12},{"id":"amo959","kind":"drug","name":"AMO959","route":"/drugs/amo959/","asOf":"2026-09-16","days":12},{"id":"sotevtamab","kind":"drug","name":"Sotevtamab","route":"/drugs/sotevtamab/","asOf":"2026-09-16","days":12},{"id":"tilt-123","kind":"drug","name":"TILT-123","route":"/drugs/tilt-123/","asOf":"2026-09-16","days":12},{"id":"au-007","kind":"drug","name":"AU-007","route":"/drugs/au-007/","asOf":"2026-09-16","days":12},{"id":"or502","kind":"drug","name":"OR502","route":"/drugs/or502/","asOf":"2026-09-16","days":12},{"id":"pamiparib","kind":"drug","name":"Pamiparib","route":"/drugs/pamiparib/","asOf":"2026-09-16","days":12},{"id":"radotinib","kind":"drug","name":"Radotinib","route":"/drugs/radotinib/","asOf":"2026-09-16","days":12},{"id":"ponsegromab","kind":"drug","name":"Ponsegromab","route":"/drugs/ponsegromab/","asOf":"2026-09-16","days":12},{"id":"wjb001","kind":"drug","name":"WJB001","route":"/drugs/wjb001/","asOf":"2026-09-16","days":12},{"id":"mhb039a","kind":"drug","name":"MHB039A","route":"/drugs/mhb039a/","asOf":"2026-09-16","days":12},{"id":"mhb036c","kind":"drug","name":"MHB036C","route":"/drugs/mhb036c/","asOf":"2026-09-16","days":12},{"id":"flonoltinib","kind":"drug","name":"Flonoltinib","route":"/drugs/flonoltinib/","asOf":"2026-09-16","days":12},{"id":"samuraciclib","kind":"drug","name":"Samuraciclib","route":"/drugs/samuraciclib/","asOf":"2026-09-16","days":12},{"id":"jmt203","kind":"drug","name":"JMT203","route":"/drugs/jmt203/","asOf":"2026-09-16","days":12},{"id":"emavusertib","kind":"drug","name":"Emavusertib","route":"/drugs/emavusertib/","asOf":"2026-09-16","days":12},{"id":"doc1021","kind":"drug","name":"DOC1021","route":"/drugs/doc1021/","asOf":"2026-09-16","days":12},{"id":"jbi-802","kind":"drug","name":"JBI-802","route":"/drugs/jbi-802/","asOf":"2026-09-16","days":12},{"id":"befotertinib","kind":"drug","name":"Befotertinib","route":"/drugs/befotertinib/","asOf":"2026-09-16","days":12},{"id":"camonsertib","kind":"drug","name":"Camonsertib","route":"/drugs/camonsertib/","asOf":"2026-09-16","days":12},{"id":"selicrelumab","kind":"drug","name":"Selicrelumab","route":"/drugs/selicrelumab/","asOf":"2026-09-16","days":12},{"id":"fluzoparib","kind":"drug","name":"Fluzoparib","route":"/drugs/fluzoparib/","asOf":"2026-09-16","days":12},{"id":"evexomostat","kind":"drug","name":"Evexomostat","route":"/drugs/evexomostat/","asOf":"2026-09-16","days":12},{"id":"tst003","kind":"drug","name":"TST003","route":"/drugs/tst003/","asOf":"2026-09-16","days":12},{"id":"obi-902","kind":"drug","name":"OBI-902","route":"/drugs/obi-902/","asOf":"2026-09-16","days":12},{"id":"cyh33","kind":"drug","name":"CYH33","route":"/drugs/cyh33/","asOf":"2026-09-16","days":12},{"id":"farletuzumab-ecteribulin","kind":"drug","name":"Farletuzumab ecteribulin","route":"/drugs/farletuzumab-ecteribulin/","asOf":"2026-09-16","days":12},{"id":"imp1734","kind":"drug","name":"IMP1734","route":"/drugs/imp1734/","asOf":"2026-09-16","days":12},{"id":"rv001v","kind":"drug","name":"RV001V","route":"/drugs/rv001v/","asOf":"2026-09-16","days":12},{"id":"dr-01","kind":"drug","name":"DR-01","route":"/drugs/dr-01/","asOf":"2026-09-16","days":12},{"id":"lp-184","kind":"drug","name":"LP-184","route":"/drugs/lp-184/","asOf":"2026-09-16","days":12},{"id":"skb105","kind":"drug","name":"SKB105","route":"/drugs/skb105/","asOf":"2026-09-16","days":12},{"id":"rvu120","kind":"drug","name":"RVU120","route":"/drugs/rvu120/","asOf":"2026-09-16","days":12},{"id":"tuspetinib","kind":"drug","name":"Tuspetinib","route":"/drugs/tuspetinib/","asOf":"2026-09-16","days":12},{"id":"avzo-023","kind":"drug","name":"AVZO-023","route":"/drugs/avzo-023/","asOf":"2026-09-16","days":12},{"id":"vudalimab","kind":"drug","name":"Vudalimab","route":"/drugs/vudalimab/","asOf":"2026-09-16","days":12},{"id":"np137","kind":"drug","name":"NP137","route":"/drugs/np137/","asOf":"2026-09-16","days":12},{"id":"tqb3702","kind":"drug","name":"TQB3702","route":"/drugs/tqb3702/","asOf":"2026-09-16","days":12},{"id":"rem-422","kind":"drug","name":"REM-422","route":"/drugs/rem-422/","asOf":"2026-09-16","days":12},{"id":"upifitamab-rilsodotin","kind":"drug","name":"Upifitamab rilsodotin","route":"/drugs/upifitamab-rilsodotin/","asOf":"2026-09-16","days":12},{"id":"stp938","kind":"drug","name":"STP938","route":"/drugs/stp938/","asOf":"2026-09-16","days":12},{"id":"tqb3909","kind":"drug","name":"TQB3909","route":"/drugs/tqb3909/","asOf":"2026-09-16","days":12},{"id":"obi-992","kind":"drug","name":"OBI-992","route":"/drugs/obi-992/","asOf":"2026-09-16","days":12},{"id":"theo-260","kind":"drug","name":"THEO-260","route":"/drugs/theo-260/","asOf":"2026-09-16","days":12},{"id":"pbp1510","kind":"drug","name":"PBP1510","route":"/drugs/pbp1510/","asOf":"2026-09-16","days":12},{"id":"rnk05047","kind":"drug","name":"RNK05047","route":"/drugs/rnk05047/","asOf":"2026-09-16","days":12},{"id":"bexmarilimab","kind":"drug","name":"Bexmarilimab","route":"/drugs/bexmarilimab/","asOf":"2026-09-16","days":12},{"id":"inlexisertib","kind":"drug","name":"Inlexisertib","route":"/drugs/inlexisertib/","asOf":"2026-09-16","days":12},{"id":"tenalisib","kind":"drug","name":"Tenalisib","route":"/drugs/tenalisib/","asOf":"2026-09-16","days":12},{"id":"mitazalimab","kind":"drug","name":"Mitazalimab","route":"/drugs/mitazalimab/","asOf":"2026-09-16","days":12},{"id":"ipg1094","kind":"drug","name":"IPG1094","route":"/drugs/ipg1094/","asOf":"2026-09-16","days":12},{"id":"vibostolimab","kind":"drug","name":"Vibostolimab","route":"/drugs/vibostolimab/","asOf":"2026-09-16","days":12},{"id":"boserolimab","kind":"drug","name":"Boserolimab","route":"/drugs/boserolimab/","asOf":"2026-09-16","days":12},{"id":"hst-1011","kind":"drug","name":"HST-1011","route":"/drugs/hst-1011/","asOf":"2026-09-16","days":12},{"id":"spartalizumab","kind":"drug","name":"Spartalizumab","route":"/drugs/spartalizumab/","asOf":"2026-09-16","days":12},{"id":"sabatolimab","kind":"drug","name":"Sabatolimab","route":"/drugs/sabatolimab/","asOf":"2026-09-16","days":12},{"id":"evm14","kind":"drug","name":"EVM14","route":"/drugs/evm14/","asOf":"2026-09-16","days":12},{"id":"pimicotinib","kind":"drug","name":"Pimicotinib","route":"/drugs/pimicotinib/","asOf":"2026-09-16","days":12},{"id":"vb15010","kind":"drug","name":"VB15010","route":"/drugs/vb15010/","asOf":"2026-09-16","days":12},{"id":"tqb2868","kind":"drug","name":"TQB2868","route":"/drugs/tqb2868/","asOf":"2026-09-16","days":12},{"id":"ard103","kind":"drug","name":"ARD103","route":"/drugs/ard103/","asOf":"2026-09-16","days":12},{"id":"vactosertib","kind":"drug","name":"Vactosertib","route":"/drugs/vactosertib/","asOf":"2026-09-16","days":12},{"id":"adavosertib","kind":"drug","name":"Adavosertib","route":"/drugs/adavosertib/","asOf":"2026-09-16","days":12},{"id":"nuv-1511","kind":"drug","name":"NUV-1511","route":"/drugs/nuv-1511/","asOf":"2026-09-16","days":12},{"id":"benmelstobart","kind":"drug","name":"Benmelstobart","route":"/drugs/benmelstobart/","asOf":"2026-09-16","days":12},{"id":"iruplinalkib","kind":"drug","name":"Iruplinalkib","route":"/drugs/iruplinalkib/","asOf":"2026-09-16","days":12},{"id":"flumatinib","kind":"drug","name":"Flumatinib","route":"/drugs/flumatinib/","asOf":"2026-09-16","days":12},{"id":"utidelone","kind":"drug","name":"Utidelone","route":"/drugs/utidelone/","asOf":"2026-09-16","days":12},{"id":"inetetamab","kind":"drug","name":"Inetetamab","route":"/drugs/inetetamab/","asOf":"2026-09-16","days":12},{"id":"linperlisib","kind":"drug","name":"Linperlisib","route":"/drugs/linperlisib/","asOf":"2026-09-16","days":12},{"id":"surufatinib","kind":"drug","name":"Surufatinib","route":"/drugs/surufatinib/","asOf":"2026-09-16","days":12},{"id":"recombinant-human-endostatin","kind":"drug","name":"Recombinant human endostatin","route":"/drugs/recombinant-human-endostatin/","asOf":"2026-09-16","days":12},{"id":"h101-oncolytic-adenovirus","kind":"drug","name":"H101 oncolytic adenovirus","route":"/drugs/h101-oncolytic-adenovirus/","asOf":"2026-09-16","days":12},{"id":"iparomlimab-tuvonralimab","kind":"drug","name":"Iparomlimab and tuvonralimab","route":"/drugs/iparomlimab-tuvonralimab/","asOf":"2026-09-16","days":12},{"id":"mecapegfilgrastim","kind":"drug","name":"Mecapegfilgrastim","route":"/drugs/mecapegfilgrastim/","asOf":"2026-09-16","days":12},{"id":"vorolanib","kind":"drug","name":"Vorolanib","route":"/drugs/vorolanib/","asOf":"2026-09-16","days":12},{"id":"polycythaemia-vera","kind":"cancer","name":"Polycythaemia vera (PV)","route":"/cancers/polycythaemia-vera/","asOf":"2026-09-16","days":12},{"id":"cyto-pv","kind":"trial","name":"CYTO-PV","route":"/trials/cyto-pv/","asOf":"2026-09-16","days":12},{"id":"response","kind":"trial","name":"RESPONSE","route":"/trials/response/","asOf":"2026-09-16","days":12},{"id":"response-2","kind":"trial","name":"RESPONSE-2","route":"/trials/response-2/","asOf":"2026-09-16","days":12},{"id":"proud-pv","kind":"trial","name":"PROUD-PV and CONTINUATION-PV","route":"/trials/proud-pv/","asOf":"2026-09-16","days":12},{"id":"low-pv","kind":"trial","name":"Low-PV","route":"/trials/low-pv/","asOf":"2026-09-16","days":12},{"id":"majic-pv","kind":"trial","name":"MAJIC-PV","route":"/trials/majic-pv/","asOf":"2026-09-16","days":12},{"id":"verify","kind":"trial","name":"VERIFY","route":"/trials/verify/","asOf":"2026-09-16","days":12},{"id":"jak2-v617f","kind":"term","name":"JAK2 V617F","route":"/terms/jak2-v617f/","asOf":"2026-09-16","days":12},{"id":"phlebotomy","kind":"term","name":"Phlebotomy (venesection)","route":"/terms/phlebotomy/","asOf":"2026-09-16","days":12},{"id":"haematocrit","kind":"term","name":"Haematocrit","route":"/terms/haematocrit/","asOf":"2026-09-16","days":12},{"id":"erythrocytosis","kind":"term","name":"Erythrocytosis (primary vs secondary)","route":"/terms/erythrocytosis/","asOf":"2026-09-16","days":12},{"id":"hepcidin","kind":"term","name":"Hepcidin","route":"/terms/hepcidin/","asOf":"2026-09-16","days":12},{"id":"aquagenic-pruritus","kind":"term","name":"Aquagenic pruritus","route":"/terms/aquagenic-pruritus/","asOf":"2026-09-16","days":12},{"id":"erythromelalgia","kind":"term","name":"Erythromelalgia","route":"/terms/erythromelalgia/","asOf":"2026-09-16","days":12},{"id":"post-pv-myelofibrosis","kind":"term","name":"Post-PV myelofibrosis (spent phase)","route":"/terms/post-pv-myelofibrosis/","asOf":"2026-09-16","days":12},{"id":"idea-pv-clone-directed-therapy","kind":"idea","name":"Clearing the JAK2 clone in polycythaemia vera: interferon plus mutant-selective inhibitors as a route to treatment-free remission","route":"/ideas/idea-pv-clone-directed-therapy/","asOf":"2026-09-16","days":12},{"id":"idea-pv-hepcidin-first","kind":"idea","name":"Hepcidin-based control as first-line treatment in low-risk polycythaemia vera","route":"/ideas/idea-pv-hepcidin-first/","asOf":"2026-09-16","days":12},{"id":"essential-thrombocythaemia","kind":"cancer","name":"Essential thrombocythaemia (ET)","route":"/cancers/essential-thrombocythaemia/","asOf":"2026-09-16","days":12},{"id":"pt-1","kind":"trial","name":"PT-1 (Primary Thrombocythaemia 1)","route":"/trials/pt-1/","asOf":"2026-09-16","days":12},{"id":"majic-et","kind":"trial","name":"MAJIC-ET","route":"/trials/majic-et/","asOf":"2026-09-16","days":12},{"id":"aspirin","kind":"drug","name":"Aspirin","route":"/drugs/aspirin/","asOf":"2026-09-16","days":12},{"id":"start-b","kind":"trial","name":"START-B (UK Standardisation of Breast Radiotherapy)","route":"/trials/start-b/","asOf":"2026-09-16","days":12},{"id":"fast-forward","kind":"trial","name":"FAST-Forward","route":"/trials/fast-forward/","asOf":"2026-09-16","days":12},{"id":"chhip","kind":"trial","name":"CHHiP","route":"/trials/chhip/","asOf":"2026-09-16","days":12},{"id":"pace-b","kind":"trial","name":"PACE-B","route":"/trials/pace-b/","asOf":"2026-09-16","days":12},{"id":"hypo-rt-pc","kind":"trial","name":"HYPO-RT-PC","route":"/trials/hypo-rt-pc/","asOf":"2026-09-16","days":12},{"id":"rtog-0617","kind":"trial","name":"RTOG 0617","route":"/trials/rtog-0617/","asOf":"2026-09-16","days":12},{"id":"calgb-9343","kind":"trial","name":"CALGB 9343","route":"/trials/calgb-9343/","asOf":"2026-09-16","days":12},{"id":"prime-ii","kind":"trial","name":"PRIME II","route":"/trials/prime-ii/","asOf":"2026-09-16","days":12},{"id":"lumina","kind":"trial","name":"LUMINA","route":"/trials/lumina/","asOf":"2026-09-16","days":12},{"id":"import-low","kind":"trial","name":"IMPORT LOW","route":"/trials/import-low/","asOf":"2026-09-16","days":12},{"id":"nsabp-b39","kind":"trial","name":"NSABP B-39/RTOG 0413","route":"/trials/nsabp-b39/","asOf":"2026-09-16","days":12},{"id":"chisel","kind":"trial","name":"CHISEL (TROG 09.02)","route":"/trials/chisel/","asOf":"2026-09-16","days":12},{"id":"jcog0403","kind":"trial","name":"JCOG0403","route":"/trials/jcog0403/","asOf":"2026-09-16","days":12},{"id":"alliance-n0574","kind":"trial","name":"Alliance N0574 (NCCTG N0574)","route":"/trials/alliance-n0574/","asOf":"2026-09-16","days":12},{"id":"nrg-cc001","kind":"trial","name":"NRG CC001","route":"/trials/nrg-cc001/","asOf":"2026-09-16","days":12},{"id":"quartz","kind":"trial","name":"QUARTZ","route":"/trials/quartz/","asOf":"2026-09-16","days":12},{"id":"catnon","kind":"trial","name":"CATNON (EORTC 26053-22054)","route":"/trials/catnon/","asOf":"2026-09-16","days":12},{"id":"dahanca-5","kind":"trial","name":"DAHANCA 5","route":"/trials/dahanca-5/","asOf":"2026-09-16","days":12},{"id":"pleural-mesothelioma","kind":"cancer","name":"Pleural mesothelioma","route":"/cancers/pleural-mesothelioma/","asOf":"2026-09-16","days":12},{"id":"peritoneal-mesothelioma","kind":"cancer","name":"Peritoneal mesothelioma","route":"/cancers/peritoneal-mesothelioma/","asOf":"2026-09-16","days":12},{"id":"nimorazole","kind":"drug","name":"Nimorazole","route":"/drugs/nimorazole/","asOf":"2026-09-16","days":12},{"id":"pilocarpine","kind":"drug","name":"Pilocarpine","route":"/drugs/pilocarpine/","asOf":"2026-09-16","days":12},{"id":"evofosfamide","kind":"drug","name":"Evofosfamide","route":"/drugs/evofosfamide/","asOf":"2026-09-16","days":12},{"id":"nanobiotix","kind":"company","name":"Nanobiotix","route":"/companies/nanobiotix/","asOf":"2026-09-16","days":12},{"id":"nct06423911","kind":"trial","name":"Study of Olverembatinib (HQP1351) in Patients With CML-CP","route":"/trials/nct06423911/","asOf":"2026-09-16","days":12},{"id":"nct06640361","kind":"trial","name":"A Study of Olverembatinib in SDH-deficient GIST.","route":"/trials/nct06640361/","asOf":"2026-09-16","days":12},{"id":"nct06051409","kind":"trial","name":"A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)","route":"/trials/nct06051409/","asOf":"2026-09-16","days":12},{"id":"nct06265428","kind":"trial","name":"A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer","route":"/trials/nct06265428/","asOf":"2026-09-16","days":12},{"id":"nct06018337","kind":"trial","name":"A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Bre","route":"/trials/nct06018337/","asOf":"2026-09-16","days":12},{"id":"nct05936658","kind":"trial","name":"[18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer","route":"/trials/nct05936658/","asOf":"2026-09-16","days":12},{"id":"nct05004285","kind":"trial","name":"Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis","route":"/trials/nct05004285/","asOf":"2026-09-16","days":12},{"id":"nct06105619","kind":"trial","name":"A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).","route":"/trials/nct06105619/","asOf":"2026-09-16","days":12},{"id":"nct05989542","kind":"trial","name":"A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)","route":"/trials/nct05989542/","asOf":"2026-09-16","days":12},{"id":"nct06008106","kind":"trial","name":"Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma","route":"/trials/nct06008106/","asOf":"2026-09-16","days":12},{"id":"nct06008119","kind":"trial","name":"Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer","route":"/trials/nct06008119/","asOf":"2026-09-16","days":12},{"id":"nct06829459","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in N","route":"/trials/nct06829459/","asOf":"2026-09-16","days":12},{"id":"nct05798819","kind":"trial","name":"A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervic","route":"/trials/nct05798819/","asOf":"2026-09-16","days":12},{"id":"nct03394365","kind":"trial","name":"A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failu","route":"/trials/nct03394365/","asOf":"2026-09-16","days":12},{"id":"nct07241416","kind":"trial","name":"A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer","route":"/trials/nct07241416/","asOf":"2026-09-16","days":12},{"id":"nct07234162","kind":"trial","name":"A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)","route":"/trials/nct07234162/","asOf":"2026-09-16","days":12},{"id":"nct06459687","kind":"trial","name":"Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer","route":"/trials/nct06459687/","asOf":"2026-09-16","days":12},{"id":"nct06750419","kind":"trial","name":"89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study","route":"/trials/nct06750419/","asOf":"2026-09-16","days":12},{"id":"nct06122584","kind":"trial","name":"Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer","route":"/trials/nct06122584/","asOf":"2026-09-16","days":12},{"id":"nct03486873","kind":"trial","name":"Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pemb","route":"/trials/nct03486873/","asOf":"2026-09-16","days":12},{"id":"nct06499285","kind":"trial","name":"A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular B","route":"/trials/nct06499285/","asOf":"2026-09-16","days":12},{"id":"nct03562637","kind":"trial","name":"Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC","route":"/trials/nct03562637/","asOf":"2026-09-16","days":12},{"id":"nct04950322","kind":"trial","name":"A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer","route":"/trials/nct04950322/","asOf":"2026-09-16","days":12},{"id":"nct05050942","kind":"trial","name":"A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET","route":"/trials/nct05050942/","asOf":"2026-09-16","days":12},{"id":"nct06432296","kind":"trial","name":"Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody","route":"/trials/nct06432296/","asOf":"2026-09-16","days":12},{"id":"nct05851014","kind":"trial","name":"A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer","route":"/trials/nct05851014/","asOf":"2026-09-16","days":12},{"id":"nct04143607","kind":"trial","name":"ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC","route":"/trials/nct04143607/","asOf":"2026-09-16","days":12},{"id":"nct02665065","kind":"trial","name":"Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia","route":"/trials/nct02665065/","asOf":"2026-09-16","days":12},{"id":"nct07112196","kind":"trial","name":"Visugromab in Cachexia International Trial","route":"/trials/nct07112196/","asOf":"2026-09-16","days":12},{"id":"nct05652894","kind":"trial","name":"A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer","route":"/trials/nct05652894/","asOf":"2026-09-16","days":12},{"id":"nct06097364","kind":"trial","name":"A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemo","route":"/trials/nct06097364/","asOf":"2026-09-16","days":12},{"id":"nct06199973","kind":"trial","name":"Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, ","route":"/trials/nct06199973/","asOf":"2026-09-16","days":12},{"id":"nct06828354","kind":"trial","name":"A Study of SHR-A1811 in Subjects With Ovarian Cancer","route":"/trials/nct06828354/","asOf":"2026-09-16","days":12},{"id":"nct05059522","kind":"trial","name":"Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing","route":"/trials/nct05059522/","asOf":"2026-09-16","days":12},{"id":"nct04639180","kind":"trial","name":"A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recur","route":"/trials/nct04639180/","asOf":"2026-09-16","days":12},{"id":"nct06350097","kind":"trial","name":"Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell L","route":"/trials/nct06350097/","asOf":"2026-09-16","days":12},{"id":"nct06348199","kind":"trial","name":"A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-s","route":"/trials/nct06348199/","asOf":"2026-09-16","days":12},{"id":"nct06712355","kind":"trial","name":"Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer","route":"/trials/nct06712355/","asOf":"2026-09-16","days":12},{"id":"nct04854668","kind":"trial","name":"A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Can","route":"/trials/nct04854668/","asOf":"2026-09-16","days":12},{"id":"nct07625644","kind":"trial","name":"BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)","route":"/trials/nct07625644/","asOf":"2026-09-16","days":12},{"id":"nct07010263","kind":"trial","name":"A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemor","route":"/trials/nct07010263/","asOf":"2026-09-16","days":12},{"id":"nct06758401","kind":"trial","name":"This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lu","route":"/trials/nct06758401/","asOf":"2026-09-16","days":12},{"id":"nct06216301","kind":"trial","name":"LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC","route":"/trials/nct06216301/","asOf":"2026-09-16","days":12},{"id":"nct04442022","kind":"trial","name":"A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Ly","route":"/trials/nct04442022/","asOf":"2026-09-16","days":12},{"id":"nct03873402","kind":"trial","name":"A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer","route":"/trials/nct03873402/","asOf":"2026-09-16","days":12},{"id":"nct04529772","kind":"trial","name":"A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)","route":"/trials/nct04529772/","asOf":"2026-09-16","days":12},{"id":"nct06838273","kind":"trial","name":"A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metas","route":"/trials/nct06838273/","asOf":"2026-09-16","days":12},{"id":"nct06767527","kind":"trial","name":"AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer","route":"/trials/nct06767527/","asOf":"2026-09-16","days":12},{"id":"nct06313086","kind":"trial","name":"DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer","route":"/trials/nct06313086/","asOf":"2026-09-16","days":12},{"id":"nct05920356","kind":"trial","name":"A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants Wi","route":"/trials/nct05920356/","asOf":"2026-09-16","days":12},{"id":"nct07502300","kind":"trial","name":"A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Pa","route":"/trials/nct07502300/","asOf":"2026-09-16","days":12},{"id":"nct04094311","kind":"trial","name":"Study of Out of Specification for Tisagenlecleucel","route":"/trials/nct04094311/","asOf":"2026-09-16","days":12},{"id":"nct07044336","kind":"trial","name":"Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)","route":"/trials/nct07044336/","asOf":"2026-09-16","days":12},{"id":"nct06717347","kind":"trial","name":"A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituxi","route":"/trials/nct06717347/","asOf":"2026-09-16","days":12},{"id":"nct06054555","kind":"trial","name":"A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma","route":"/trials/nct06054555/","asOf":"2026-09-16","days":12},{"id":"nct07226752","kind":"trial","name":"A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China","route":"/trials/nct07226752/","asOf":"2026-09-16","days":12},{"id":"nct05730036","kind":"trial","name":"A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Re","route":"/trials/nct05730036/","asOf":"2026-09-16","days":12},{"id":"nct06952478","kind":"trial","name":"A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone","route":"/trials/nct06952478/","asOf":"2026-09-16","days":12},{"id":"nct06340568","kind":"trial","name":"A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer","route":"/trials/nct06340568/","asOf":"2026-09-16","days":12},{"id":"nct05120349","kind":"trial","name":"A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection","route":"/trials/nct05120349/","asOf":"2026-09-16","days":12},{"id":"nct06464991","kind":"trial","name":"A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)","route":"/trials/nct06464991/","asOf":"2026-09-16","days":12},{"id":"nct06581406","kind":"trial","name":"A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult P","route":"/trials/nct06581406/","asOf":"2026-09-16","days":12},{"id":"nct03844048","kind":"trial","name":"An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial","route":"/trials/nct03844048/","asOf":"2026-09-16","days":12},{"id":"nct06629779","kind":"trial","name":"A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.","route":"/trials/nct06629779/","asOf":"2026-09-16","days":12},{"id":"nct06430866","kind":"trial","name":"Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)","route":"/trials/nct06430866/","asOf":"2026-09-16","days":12},{"id":"nct06670196","kind":"trial","name":"A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advan","route":"/trials/nct06670196/","asOf":"2026-09-16","days":12},{"id":"nct06788756","kind":"trial","name":"L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Re","route":"/trials/nct06788756/","asOf":"2026-09-16","days":12},{"id":"nct06382129","kind":"trial","name":"A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU","route":"/trials/nct06382129/","asOf":"2026-09-16","days":12},{"id":"nct06305754","kind":"trial","name":"Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, A","route":"/trials/nct06305754/","asOf":"2026-09-16","days":12},{"id":"nct05170204","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small C","route":"/trials/nct05170204/","asOf":"2026-09-16","days":12},{"id":"nct04842617","kind":"trial","name":"Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Ne","route":"/trials/nct04842617/","asOf":"2026-09-16","days":12},{"id":"nct06692738","kind":"trial","name":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-s","route":"/trials/nct06692738/","asOf":"2026-09-16","days":12},{"id":"nct06448312","kind":"trial","name":"A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","route":"/trials/nct06448312/","asOf":"2026-09-16","days":12},{"id":"nct05348577","kind":"trial","name":"Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)","route":"/trials/nct05348577/","asOf":"2026-09-16","days":12},{"id":"nct04384484","kind":"trial","name":"Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lym","route":"/trials/nct04384484/","asOf":"2026-09-16","days":12},{"id":"nct06801834","kind":"trial","name":"Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer","route":"/trials/nct06801834/","asOf":"2026-09-16","days":12},{"id":"nct04002297","kind":"trial","name":"A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantl","route":"/trials/nct04002297/","asOf":"2026-09-16","days":12},{"id":"nct05939414","kind":"trial","name":"An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.","route":"/trials/nct05939414/","asOf":"2026-09-16","days":12},{"id":"nct07154706","kind":"trial","name":"Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)","route":"/trials/nct07154706/","asOf":"2026-09-16","days":12},{"id":"nct05445778","kind":"trial","name":"Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal C","route":"/trials/nct05445778/","asOf":"2026-09-16","days":12},{"id":"nct06520345","kind":"trial","name":"The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)","route":"/trials/nct06520345/","asOf":"2026-09-16","days":12},{"id":"nct07221357","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Parti","route":"/trials/nct07221357/","asOf":"2026-09-16","days":12},{"id":"nct06899126","kind":"trial","name":"Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer","route":"/trials/nct06899126/","asOf":"2026-09-16","days":12},{"id":"nct05438043","kind":"trial","name":"A Study of Daratumumab","route":"/trials/nct05438043/","asOf":"2026-09-16","days":12},{"id":"nct05572515","kind":"trial","name":"A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With","route":"/trials/nct05572515/","asOf":"2026-09-16","days":12},{"id":"nct05320692","kind":"trial","name":"A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma","route":"/trials/nct05320692/","asOf":"2026-09-16","days":12},{"id":"nct06584032","kind":"trial","name":"Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer","route":"/trials/nct06584032/","asOf":"2026-09-16","days":12},{"id":"nct07775287","kind":"trial","name":"Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metast","route":"/trials/nct07775287/","asOf":"2026-09-16","days":12},{"id":"nct04379635","kind":"trial","name":"Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct04379635/","asOf":"2026-09-16","days":12},{"id":"nct06698042","kind":"trial","name":"A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)","route":"/trials/nct06698042/","asOf":"2026-09-16","days":12},{"id":"nct07216703","kind":"trial","name":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Canc","route":"/trials/nct07216703/","asOf":"2026-09-16","days":12},{"id":"nct04884360","kind":"trial","name":"D9319C00001- 1L OC Mono Global RCT","route":"/trials/nct04884360/","asOf":"2026-09-16","days":12},{"id":"nct07518173","kind":"trial","name":"A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or M","route":"/trials/nct07518173/","asOf":"2026-09-16","days":12},{"id":"nct06435429","kind":"trial","name":"A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment o","route":"/trials/nct06435429/","asOf":"2026-09-16","days":12},{"id":"nct04712097","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomi","route":"/trials/nct04712097/","asOf":"2026-09-16","days":12},{"id":"nct07028853","kind":"trial","name":"This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking En","route":"/trials/nct07028853/","asOf":"2026-09-16","days":12},{"id":"nct07491445","kind":"trial","name":"Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","route":"/trials/nct07491445/","asOf":"2026-09-16","days":12},{"id":"nct06246916","kind":"trial","name":"A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)","route":"/trials/nct06246916/","asOf":"2026-09-16","days":12},{"id":"nct07219238","kind":"trial","name":"Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, o","route":"/trials/nct07219238/","asOf":"2026-09-16","days":12},{"id":"nct06830889","kind":"trial","name":"A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy","route":"/trials/nct06830889/","asOf":"2026-09-16","days":12},{"id":"nct05429268","kind":"trial","name":"Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (","route":"/trials/nct05429268/","asOf":"2026-09-16","days":12},{"id":"nct06549595","kind":"trial","name":"A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients","route":"/trials/nct06549595/","asOf":"2026-09-16","days":12},{"id":"nct05353257","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage","route":"/trials/nct05353257/","asOf":"2026-09-16","days":12},{"id":"nct06699212","kind":"trial","name":"A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of ","route":"/trials/nct06699212/","asOf":"2026-09-16","days":12},{"id":"nct06041776","kind":"trial","name":"Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations","route":"/trials/nct06041776/","asOf":"2026-09-16","days":12},{"id":"nct05727904","kind":"trial","name":"Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.","route":"/trials/nct05727904/","asOf":"2026-09-16","days":12},{"id":"nct05800015","kind":"trial","name":"A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult ","route":"/trials/nct05800015/","asOf":"2026-09-16","days":12},{"id":"nct07318558","kind":"trial","name":"A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)","route":"/trials/nct07318558/","asOf":"2026-09-16","days":12},{"id":"nct04613596","kind":"trial","name":"Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G","route":"/trials/nct04613596/","asOf":"2026-09-16","days":12},{"id":"nct07805954","kind":"trial","name":"Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mut","route":"/trials/nct07805954/","asOf":"2026-09-16","days":12},{"id":"nct06149286","kind":"trial","name":"A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participant","route":"/trials/nct06149286/","asOf":"2026-09-16","days":12},{"id":"nct07183189","kind":"trial","name":"A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC","route":"/trials/nct07183189/","asOf":"2026-09-16","days":12},{"id":"nct06765109","kind":"trial","name":"Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC","route":"/trials/nct06765109/","asOf":"2026-09-16","days":12},{"id":"nct07640789","kind":"trial","name":"A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-s","route":"/trials/nct07640789/","asOf":"2026-09-16","days":12},{"id":"nct07541170","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Rese","route":"/trials/nct07541170/","asOf":"2026-09-16","days":12},{"id":"nct04674683","kind":"trial","name":"Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma","route":"/trials/nct04674683/","asOf":"2026-09-16","days":12},{"id":"nct06994195","kind":"trial","name":"A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANK","route":"/trials/nct06994195/","asOf":"2026-09-16","days":12},{"id":"nct05489289","kind":"trial","name":"A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection","route":"/trials/nct05489289/","asOf":"2026-09-16","days":12},{"id":"nct01436968","kind":"trial","name":"Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer","route":"/trials/nct01436968/","asOf":"2026-09-16","days":12},{"id":"nct06585410","kind":"trial","name":"Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma","route":"/trials/nct06585410/","asOf":"2026-09-16","days":12},{"id":"nct05623020","kind":"trial","name":"A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide","route":"/trials/nct05623020/","asOf":"2026-09-16","days":12},{"id":"nct05827016","kind":"trial","name":"A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly","route":"/trials/nct05827016/","asOf":"2026-09-16","days":12},{"id":"nct06956001","kind":"trial","name":"Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation","route":"/trials/nct06956001/","asOf":"2026-09-16","days":12},{"id":"nct04422366","kind":"trial","name":"Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females","route":"/trials/nct04422366/","asOf":"2026-09-16","days":12},{"id":"nct06152575","kind":"trial","name":"MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other","route":"/trials/nct06152575/","asOf":"2026-09-16","days":12},{"id":"nct07228832","kind":"trial","name":"Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer","route":"/trials/nct07228832/","asOf":"2026-09-16","days":12},{"id":"nct03539744","kind":"trial","name":"A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) ","route":"/trials/nct03539744/","asOf":"2026-09-16","days":12},{"id":"nct05519085","kind":"trial","name":"A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Re","route":"/trials/nct05519085/","asOf":"2026-09-16","days":12},{"id":"nct07412613","kind":"trial","name":"Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer","route":"/trials/nct07412613/","asOf":"2026-09-16","days":12},{"id":"nct06508658","kind":"trial","name":"A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcita","route":"/trials/nct06508658/","asOf":"2026-09-16","days":12},{"id":"nct06824467","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Pl","route":"/trials/nct06824467/","asOf":"2026-09-16","days":12},{"id":"nct06191744","kind":"trial","name":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease ","route":"/trials/nct06191744/","asOf":"2026-09-16","days":12},{"id":"nct06468033","kind":"trial","name":"P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk","route":"/trials/nct06468033/","asOf":"2026-09-16","days":12},{"id":"nct05009836","kind":"trial","name":"Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC","route":"/trials/nct05009836/","asOf":"2026-09-16","days":12},{"id":"nct06356311","kind":"trial","name":"A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)","route":"/trials/nct06356311/","asOf":"2026-09-16","days":12},{"id":"nct06564844","kind":"trial","name":"A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following C","route":"/trials/nct06564844/","asOf":"2026-09-16","days":12},{"id":"nct06417814","kind":"trial","name":"A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participan","route":"/trials/nct06417814/","asOf":"2026-09-16","days":12},{"id":"nct07168200","kind":"trial","name":"A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the","route":"/trials/nct07168200/","asOf":"2026-09-16","days":12},{"id":"nct07005128","kind":"trial","name":"A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small","route":"/trials/nct07005128/","asOf":"2026-09-16","days":12},{"id":"nct07509151","kind":"trial","name":"Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin He","route":"/trials/nct07509151/","asOf":"2026-09-16","days":12},{"id":"nct06514508","kind":"trial","name":"Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients","route":"/trials/nct06514508/","asOf":"2026-09-16","days":12},{"id":"nct07361510","kind":"trial","name":"A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and P","route":"/trials/nct07361510/","asOf":"2026-09-16","days":12},{"id":"nct06928389","kind":"trial","name":"Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer","route":"/trials/nct06928389/","asOf":"2026-09-16","days":12},{"id":"nct06170788","kind":"trial","name":"Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With P","route":"/trials/nct06170788/","asOf":"2026-09-16","days":12},{"id":"nct06459180","kind":"trial","name":"A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With","route":"/trials/nct06459180/","asOf":"2026-09-16","days":12},{"id":"nct06640530","kind":"trial","name":"Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin","route":"/trials/nct06640530/","asOf":"2026-09-16","days":12},{"id":"nct06072781","kind":"trial","name":"A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer","route":"/trials/nct06072781/","asOf":"2026-09-16","days":12},{"id":"nct06911502","kind":"trial","name":"A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Rela","route":"/trials/nct06911502/","asOf":"2026-09-16","days":12},{"id":"nct06452277","kind":"trial","name":"A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-sma","route":"/trials/nct06452277/","asOf":"2026-09-16","days":12},{"id":"nct06430437","kind":"trial","name":"A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations","route":"/trials/nct06430437/","asOf":"2026-09-16","days":12},{"id":"nct06316531","kind":"trial","name":"A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer","route":"/trials/nct06316531/","asOf":"2026-09-16","days":12},{"id":"nct03390686","kind":"trial","name":"A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer ","route":"/trials/nct03390686/","asOf":"2026-09-16","days":12},{"id":"nct05654454","kind":"trial","name":"A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer","route":"/trials/nct05654454/","asOf":"2026-09-16","days":12},{"id":"nct06311721","kind":"trial","name":"A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer","route":"/trials/nct06311721/","asOf":"2026-09-16","days":12},{"id":"nct05116462","kind":"trial","name":"Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer","route":"/trials/nct05116462/","asOf":"2026-09-16","days":12},{"id":"nct04975997","kind":"trial","name":"Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants ","route":"/trials/nct04975997/","asOf":"2026-09-16","days":12},{"id":"nct07252232","kind":"trial","name":"Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)","route":"/trials/nct07252232/","asOf":"2026-09-16","days":12},{"id":"nct06989112","kind":"trial","name":"DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC","route":"/trials/nct06989112/","asOf":"2026-09-16","days":12},{"id":"nct03800134","kind":"trial","name":"A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer","route":"/trials/nct03800134/","asOf":"2026-09-16","days":12},{"id":"nct05884398","kind":"trial","name":"A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC","route":"/trials/nct05884398/","asOf":"2026-09-16","days":12},{"id":"nct05804370","kind":"trial","name":"Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)","route":"/trials/nct05804370/","asOf":"2026-09-16","days":12},{"id":"nct06300177","kind":"trial","name":"D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standar","route":"/trials/nct06300177/","asOf":"2026-09-16","days":12},{"id":"nct07621718","kind":"trial","name":"Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-muta","route":"/trials/nct07621718/","asOf":"2026-09-16","days":12},{"id":"nct07170995","kind":"trial","name":"Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Adva","route":"/trials/nct07170995/","asOf":"2026-09-16","days":12},{"id":"nct06413498","kind":"trial","name":"A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma","route":"/trials/nct06413498/","asOf":"2026-09-16","days":12},{"id":"nct05425940","kind":"trial","name":"Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer","route":"/trials/nct05425940/","asOf":"2026-09-16","days":12},{"id":"nct06422143","kind":"trial","name":"Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287","route":"/trials/nct06422143/","asOf":"2026-09-16","days":12},{"id":"nct05607550","kind":"trial","name":"Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With","route":"/trials/nct05607550/","asOf":"2026-09-16","days":12},{"id":"nct07213674","kind":"trial","name":"A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate ","route":"/trials/nct07213674/","asOf":"2026-09-16","days":12},{"id":"nct05215340","kind":"trial","name":"Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionab","route":"/trials/nct05215340/","asOf":"2026-09-16","days":12},{"id":"nct06496178","kind":"trial","name":"A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma P","route":"/trials/nct06496178/","asOf":"2026-09-16","days":12},{"id":"nct06158841","kind":"trial","name":"Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refracto","route":"/trials/nct06158841/","asOf":"2026-09-16","days":12},{"id":"nct06230224","kind":"trial","name":"A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell ","route":"/trials/nct06230224/","asOf":"2026-09-16","days":12},{"id":"nct06976190","kind":"trial","name":"A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcin","route":"/trials/nct06976190/","asOf":"2026-09-16","days":12},{"id":"nct05317858","kind":"trial","name":"Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets","route":"/trials/nct05317858/","asOf":"2026-09-16","days":12},{"id":"nct05020236","kind":"trial","name":"A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments","route":"/trials/nct05020236/","asOf":"2026-09-16","days":12},{"id":"nct04224493","kind":"trial","name":"A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus ","route":"/trials/nct04224493/","asOf":"2026-09-16","days":12},{"id":"nct06711900","kind":"trial","name":"A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative P","route":"/trials/nct06711900/","asOf":"2026-09-16","days":12},{"id":"nct06252649","kind":"trial","name":"Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal","route":"/trials/nct06252649/","asOf":"2026-09-16","days":12},{"id":"nct04687241","kind":"trial","name":"Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations","route":"/trials/nct04687241/","asOf":"2026-09-16","days":12},{"id":"nct07473128","kind":"trial","name":"Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer","route":"/trials/nct07473128/","asOf":"2026-09-16","days":12},{"id":"nct04969731","kind":"trial","name":"Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer","route":"/trials/nct04969731/","asOf":"2026-09-16","days":12},{"id":"nct07391657","kind":"trial","name":"A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Rela","route":"/trials/nct07391657/","asOf":"2026-09-16","days":12},{"id":"nct06396065","kind":"trial","name":"Phase III Study of AK112 for NSCLC Patients","route":"/trials/nct06396065/","asOf":"2026-09-16","days":12},{"id":"nct04129502","kind":"trial","name":"TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations","route":"/trials/nct04129502/","asOf":"2026-09-16","days":12},{"id":"nct07095452","kind":"trial","name":"A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lena","route":"/trials/nct07095452/","asOf":"2026-09-16","days":12},{"id":"nct06712316","kind":"trial","name":"Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer","route":"/trials/nct06712316/","asOf":"2026-09-16","days":12},{"id":"nct06312137","kind":"trial","name":"A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Sm","route":"/trials/nct06312137/","asOf":"2026-09-16","days":12},{"id":"nct01804686","kind":"trial","name":"A Long-term Extension Study of PCI-32765 (Ibrutinib)","route":"/trials/nct01804686/","asOf":"2026-09-16","days":12},{"id":"nct07604766","kind":"trial","name":"An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Can","route":"/trials/nct07604766/","asOf":"2026-09-16","days":12},{"id":"nct06486441","kind":"trial","name":"Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Im","route":"/trials/nct06486441/","asOf":"2026-09-16","days":12},{"id":"nct07166094","kind":"trial","name":"Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer","route":"/trials/nct07166094/","asOf":"2026-09-16","days":12},{"id":"nct03246529","kind":"trial","name":"A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Pl","route":"/trials/nct03246529/","asOf":"2026-09-16","days":12},{"id":"nct06921785","kind":"trial","name":"Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma","route":"/trials/nct06921785/","asOf":"2026-09-16","days":12},{"id":"nct04951635","kind":"trial","name":"A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer","route":"/trials/nct04951635/","asOf":"2026-09-16","days":12},{"id":"nct05608291","kind":"trial","name":"A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back Af","route":"/trials/nct05608291/","asOf":"2026-09-16","days":12},{"id":"nct06947928","kind":"trial","name":"Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Car","route":"/trials/nct06947928/","asOf":"2026-09-16","days":12},{"id":"nct06952504","kind":"trial","name":"A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participan","route":"/trials/nct06952504/","asOf":"2026-09-16","days":12},{"id":"nct06496048","kind":"trial","name":"Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC","route":"/trials/nct06496048/","asOf":"2026-09-16","days":12},{"id":"nct05555732","kind":"trial","name":"Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)","route":"/trials/nct05555732/","asOf":"2026-09-16","days":12},{"id":"nct05785767","kind":"trial","name":"A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small","route":"/trials/nct05785767/","asOf":"2026-09-16","days":12},{"id":"nct04547166","kind":"trial","name":"A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Meta","route":"/trials/nct04547166/","asOf":"2026-09-16","days":12},{"id":"nct06208150","kind":"trial","name":"A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortez","route":"/trials/nct06208150/","asOf":"2026-09-16","days":12},{"id":"nct05797831","kind":"trial","name":"Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer","route":"/trials/nct05797831/","asOf":"2026-09-16","days":12},{"id":"nct05043090","kind":"trial","name":"Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC","route":"/trials/nct05043090/","asOf":"2026-09-16","days":12},{"id":"nct07185997","kind":"trial","name":"Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants W","route":"/trials/nct07185997/","asOf":"2026-09-16","days":12},{"id":"nct07361497","kind":"trial","name":"A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell","route":"/trials/nct07361497/","asOf":"2026-09-16","days":12},{"id":"nct05862337","kind":"trial","name":"Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.","route":"/trials/nct05862337/","asOf":"2026-09-16","days":12},{"id":"nct06679101","kind":"trial","name":"A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethas","route":"/trials/nct06679101/","asOf":"2026-09-16","days":12},{"id":"nct06819007","kind":"trial","name":"Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-","route":"/trials/nct06819007/","asOf":"2026-09-16","days":12},{"id":"nct06118333","kind":"trial","name":"A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)","route":"/trials/nct06118333/","asOf":"2026-09-16","days":12},{"id":"nct04421963","kind":"trial","name":"Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib","route":"/trials/nct04421963/","asOf":"2026-09-16","days":12},{"id":"nct03016819","kind":"trial","name":"Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)","route":"/trials/nct03016819/","asOf":"2026-09-16","days":12},{"id":"nct06132958","kind":"trial","name":"Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)","route":"/trials/nct06132958/","asOf":"2026-09-16","days":12},{"id":"nct05870319","kind":"trial","name":"A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients","route":"/trials/nct05870319/","asOf":"2026-09-16","days":12},{"id":"nct07764978","kind":"trial","name":"Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT","route":"/trials/nct07764978/","asOf":"2026-09-16","days":12},{"id":"nct06726265","kind":"trial","name":"Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy ","route":"/trials/nct06726265/","asOf":"2026-09-16","days":12},{"id":"nct07462143","kind":"trial","name":"A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer","route":"/trials/nct07462143/","asOf":"2026-09-16","days":12},{"id":"nct06746116","kind":"trial","name":"A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment","route":"/trials/nct06746116/","asOf":"2026-09-16","days":12},{"id":"nct07472517","kind":"trial","name":"DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment","route":"/trials/nct07472517/","asOf":"2026-09-16","days":12},{"id":"nct05468489","kind":"trial","name":"To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC","route":"/trials/nct05468489/","asOf":"2026-09-16","days":12},{"id":"nct06561386","kind":"trial","name":"A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous N","route":"/trials/nct06561386/","asOf":"2026-09-16","days":12},{"id":"nct04624204","kind":"trial","name":"Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-","route":"/trials/nct04624204/","asOf":"2026-09-16","days":12},{"id":"nct06091865","kind":"trial","name":"A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Pa","route":"/trials/nct06091865/","asOf":"2026-09-16","days":12},{"id":"nct06091254","kind":"trial","name":"A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy ","route":"/trials/nct06091254/","asOf":"2026-09-16","days":12},{"id":"nct07011719","kind":"trial","name":"Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma","route":"/trials/nct07011719/","asOf":"2026-09-16","days":12},{"id":"nct05883644","kind":"trial","name":"Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)","route":"/trials/nct05883644/","asOf":"2026-09-16","days":12},{"id":"nct06465914","kind":"trial","name":"A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males","route":"/trials/nct06465914/","asOf":"2026-09-16","days":12},{"id":"nct06767514","kind":"trial","name":"Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1","route":"/trials/nct06767514/","asOf":"2026-09-16","days":12},{"id":"nct03847428","kind":"trial","name":"Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment","route":"/trials/nct03847428/","asOf":"2026-09-16","days":12},{"id":"nct06619236","kind":"trial","name":"Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer","route":"/trials/nct06619236/","asOf":"2026-09-16","days":12},{"id":"nct06128837","kind":"trial","name":"Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer","route":"/trials/nct06128837/","asOf":"2026-09-16","days":12},{"id":"nct06925737","kind":"trial","name":"A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)","route":"/trials/nct06925737/","asOf":"2026-09-16","days":12},{"id":"nct05552976","kind":"trial","name":"A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants W","route":"/trials/nct05552976/","asOf":"2026-09-16","days":12},{"id":"nct07052214","kind":"trial","name":"PSMA PET Combined With MRI for the Detection of PCa","route":"/trials/nct07052214/","asOf":"2026-09-16","days":12},{"id":"nct02486718","kind":"trial","name":"Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [","route":"/trials/nct02486718/","asOf":"2026-09-16","days":12},{"id":"nct05047250","kind":"trial","name":"A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer","route":"/trials/nct05047250/","asOf":"2026-09-16","days":12},{"id":"nct06123884","kind":"trial","name":"BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer","route":"/trials/nct06123884/","asOf":"2026-09-16","days":12},{"id":"nct07642024","kind":"trial","name":"A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU","route":"/trials/nct07642024/","asOf":"2026-09-16","days":12},{"id":"nct06793215","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Particip","route":"/trials/nct06793215/","asOf":"2026-09-16","days":12},{"id":"nct06174987","kind":"trial","name":"A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)","route":"/trials/nct06174987/","asOf":"2026-09-16","days":12},{"id":"nct06506955","kind":"trial","name":"Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.","route":"/trials/nct06506955/","asOf":"2026-09-16","days":12},{"id":"nct07454720","kind":"trial","name":"A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer","route":"/trials/nct07454720/","asOf":"2026-09-16","days":12},{"id":"nct05270044","kind":"trial","name":"Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.","route":"/trials/nct05270044/","asOf":"2026-09-16","days":12},{"id":"nct06357533","kind":"trial","name":"Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥","route":"/trials/nct06357533/","asOf":"2026-09-16","days":12},{"id":"nct06687369","kind":"trial","name":"A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell L","route":"/trials/nct06687369/","asOf":"2026-09-16","days":12},{"id":"nct07722494","kind":"trial","name":"IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer","route":"/trials/nct07722494/","asOf":"2026-09-16","days":12},{"id":"nct04099251","kind":"trial","name":"Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma","route":"/trials/nct04099251/","asOf":"2026-09-16","days":12},{"id":"nct06074588","kind":"trial","name":"Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With","route":"/trials/nct06074588/","asOf":"2026-09-16","days":12},{"id":"nct05048797","kind":"trial","name":"A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic N","route":"/trials/nct05048797/","asOf":"2026-09-16","days":12},{"id":"nct06497985","kind":"trial","name":"A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients","route":"/trials/nct06497985/","asOf":"2026-09-16","days":12},{"id":"nct06117774","kind":"trial","name":"Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)","route":"/trials/nct06117774/","asOf":"2026-09-16","days":12},{"id":"nct07611110","kind":"trial","name":"AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)","route":"/trials/nct07611110/","asOf":"2026-09-16","days":12},{"id":"nct05317416","kind":"trial","name":"Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant","route":"/trials/nct05317416/","asOf":"2026-09-16","days":12},{"id":"nct05904886","kind":"trial","name":"A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocell","route":"/trials/nct05904886/","asOf":"2026-09-16","days":12},{"id":"nct05022901","kind":"trial","name":"An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma","route":"/trials/nct05022901/","asOf":"2026-09-16","days":12},{"id":"nct05552222","kind":"trial","name":"A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal","route":"/trials/nct05552222/","asOf":"2026-09-16","days":12},{"id":"nct06045806","kind":"trial","name":"A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alo","route":"/trials/nct06045806/","asOf":"2026-09-16","days":12},{"id":"nct04404283","kind":"trial","name":"Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL","route":"/trials/nct04404283/","asOf":"2026-09-16","days":12},{"id":"nct07778316","kind":"trial","name":"Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)","route":"/trials/nct07778316/","asOf":"2026-09-16","days":12},{"id":"nct03383458","kind":"trial","name":"A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation","route":"/trials/nct03383458/","asOf":"2026-09-16","days":12},{"id":"nct06617416","kind":"trial","name":"A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC","route":"/trials/nct06617416/","asOf":"2026-09-16","days":12},{"id":"nct06627647","kind":"trial","name":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous N","route":"/trials/nct06627647/","asOf":"2026-09-16","days":12},{"id":"nct06742996","kind":"trial","name":"A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refrac","route":"/trials/nct06742996/","asOf":"2026-09-16","days":12},{"id":"nct05549297","kind":"trial","name":"Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)","route":"/trials/nct05549297/","asOf":"2026-09-16","days":12},{"id":"nct06564324","kind":"trial","name":"A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients","route":"/trials/nct06564324/","asOf":"2026-09-16","days":12},{"id":"nct05100862","kind":"trial","name":"A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphom","route":"/trials/nct05100862/","asOf":"2026-09-16","days":12},{"id":"nct04657991","kind":"trial","name":"A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma","route":"/trials/nct04657991/","asOf":"2026-09-16","days":12},{"id":"nct07225270","kind":"trial","name":"Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Re","route":"/trials/nct07225270/","asOf":"2026-09-16","days":12},{"id":"nct06363994","kind":"trial","name":"A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL","route":"/trials/nct06363994/","asOf":"2026-09-16","days":12},{"id":"nct07291037","kind":"trial","name":"Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Acti","route":"/trials/nct07291037/","asOf":"2026-09-16","days":12},{"id":"nct07702032","kind":"trial","name":"Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorecta","route":"/trials/nct07702032/","asOf":"2026-09-16","days":12},{"id":"nct05888493","kind":"trial","name":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","route":"/trials/nct05888493/","asOf":"2026-09-16","days":12},{"id":"nct07182682","kind":"trial","name":"A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Ins","route":"/trials/nct07182682/","asOf":"2026-09-16","days":12},{"id":"nct07196774","kind":"trial","name":"A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer","route":"/trials/nct07196774/","asOf":"2026-09-16","days":12},{"id":"nct05984277","kind":"trial","name":"A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung","route":"/trials/nct05984277/","asOf":"2026-09-16","days":12},{"id":"nct05409066","kind":"trial","name":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease ","route":"/trials/nct05409066/","asOf":"2026-09-16","days":12},{"id":"nct07361003","kind":"trial","name":"A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer","route":"/trials/nct07361003/","asOf":"2026-09-16","days":12},{"id":"nct05455320","kind":"trial","name":"A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination Wi","route":"/trials/nct05455320/","asOf":"2026-09-16","days":12},{"id":"nct07393282","kind":"trial","name":"A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)","route":"/trials/nct07393282/","asOf":"2026-09-16","days":12},{"id":"nct07513376","kind":"trial","name":"A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I ","route":"/trials/nct07513376/","asOf":"2026-09-16","days":12},{"id":"nct06915025","kind":"trial","name":"Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Pat","route":"/trials/nct06915025/","asOf":"2026-09-16","days":12},{"id":"nct04793958","kind":"trial","name":"Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)","route":"/trials/nct04793958/","asOf":"2026-09-16","days":12},{"id":"nct04974398","kind":"trial","name":"A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma","route":"/trials/nct04974398/","asOf":"2026-09-16","days":12},{"id":"nct06881784","kind":"trial","name":"Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)","route":"/trials/nct06881784/","asOf":"2026-09-16","days":12},{"id":"nct03178552","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct03178552/","asOf":"2026-09-16","days":12},{"id":"nct04691804","kind":"trial","name":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Ver","route":"/trials/nct04691804/","asOf":"2026-09-16","days":12},{"id":"nct05557838","kind":"trial","name":"Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC","route":"/trials/nct05557838/","asOf":"2026-09-16","days":12},{"id":"nct05794906","kind":"trial","name":"A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer","route":"/trials/nct05794906/","asOf":"2026-09-16","days":12},{"id":"nct07777822","kind":"trial","name":"Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mu","route":"/trials/nct07777822/","asOf":"2026-09-16","days":12},{"id":"nct07178795","kind":"trial","name":"A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC","route":"/trials/nct07178795/","asOf":"2026-09-16","days":12},{"id":"nct06097728","kind":"trial","name":"MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma","route":"/trials/nct06097728/","asOf":"2026-09-16","days":12},{"id":"nct06371157","kind":"trial","name":"A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepat","route":"/trials/nct06371157/","asOf":"2026-09-16","days":12},{"id":"nct07100080","kind":"trial","name":"Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy","route":"/trials/nct07100080/","asOf":"2026-09-16","days":12},{"id":"nct07195695","kind":"trial","name":"Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutati","route":"/trials/nct07195695/","asOf":"2026-09-16","days":12},{"id":"nct06500026","kind":"trial","name":"A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)","route":"/trials/nct06500026/","asOf":"2026-09-16","days":12},{"id":"nct05668988","kind":"trial","name":"A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)","route":"/trials/nct05668988/","asOf":"2026-09-16","days":12},{"id":"nct02489318","kind":"trial","name":"A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC","route":"/trials/nct02489318/","asOf":"2026-09-16","days":12},{"id":"nct07564141","kind":"trial","name":"Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or","route":"/trials/nct07564141/","asOf":"2026-09-16","days":12},{"id":"nct07022483","kind":"trial","name":"Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer","route":"/trials/nct07022483/","asOf":"2026-09-16","days":12},{"id":"nct04712643","kind":"trial","name":"A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma","route":"/trials/nct04712643/","asOf":"2026-09-16","days":12},{"id":"nct06891833","kind":"trial","name":"A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Brea","route":"/trials/nct06891833/","asOf":"2026-09-16","days":12},{"id":"nct04316364","kind":"trial","name":"A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC","route":"/trials/nct04316364/","asOf":"2026-09-16","days":12},{"id":"nct07676162","kind":"trial","name":"A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal","route":"/trials/nct07676162/","asOf":"2026-09-16","days":12},{"id":"nct05371093","kind":"trial","name":"Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma","route":"/trials/nct05371093/","asOf":"2026-09-16","days":12},{"id":"nct05987332","kind":"trial","name":"IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma","route":"/trials/nct05987332/","asOf":"2026-09-16","days":12},{"id":"nct04923906","kind":"trial","name":"Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mut","route":"/trials/nct04923906/","asOf":"2026-09-16","days":12},{"id":"nct06382116","kind":"trial","name":"A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)","route":"/trials/nct06382116/","asOf":"2026-09-16","days":12},{"id":"nct05840016","kind":"trial","name":"AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer","route":"/trials/nct05840016/","asOf":"2026-09-16","days":12},{"id":"nct03556228","kind":"trial","name":"VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma","route":"/trials/nct03556228/","asOf":"2026-09-16","days":12},{"id":"nct07491497","kind":"trial","name":"A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC","route":"/trials/nct07491497/","asOf":"2026-09-16","days":12},{"id":"nct07258979","kind":"trial","name":"A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.","route":"/trials/nct07258979/","asOf":"2026-09-16","days":12},{"id":"nct06703398","kind":"trial","name":"A Study of GC101 TIL in Advanced Melanoma","route":"/trials/nct06703398/","asOf":"2026-09-16","days":12},{"id":"nct07527858","kind":"trial","name":"Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer","route":"/trials/nct07527858/","asOf":"2026-09-16","days":12},{"id":"nct05180799","kind":"trial","name":"A Phase 1/2 Study of BA3071 in Patients With Solid Tumors","route":"/trials/nct05180799/","asOf":"2026-09-16","days":12},{"id":"nct06475300","kind":"trial","name":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and ","route":"/trials/nct06475300/","asOf":"2026-09-16","days":12},{"id":"nct06445062","kind":"trial","name":"Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors","route":"/trials/nct06445062/","asOf":"2026-09-16","days":12},{"id":"nct06498986","kind":"trial","name":"A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct06498986/","asOf":"2026-09-16","days":12},{"id":"nct05652686","kind":"trial","name":"A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)","route":"/trials/nct05652686/","asOf":"2026-09-16","days":12},{"id":"nct02227251","kind":"trial","name":"Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","route":"/trials/nct02227251/","asOf":"2026-09-16","days":12},{"id":"nct06710288","kind":"trial","name":"A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In P","route":"/trials/nct06710288/","asOf":"2026-09-16","days":12},{"id":"nct06188520","kind":"trial","name":"A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With ","route":"/trials/nct06188520/","asOf":"2026-09-16","days":12},{"id":"nct05643742","kind":"trial","name":"A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies","route":"/trials/nct05643742/","asOf":"2026-09-16","days":12},{"id":"nct02343042","kind":"trial","name":"Selinexor and Backbone Treatments of Multiple Myeloma Patients","route":"/trials/nct02343042/","asOf":"2026-09-16","days":12},{"id":"nct05256290","kind":"trial","name":"Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations","route":"/trials/nct05256290/","asOf":"2026-09-16","days":12},{"id":"nct05422911","kind":"trial","name":"Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.","route":"/trials/nct05422911/","asOf":"2026-09-16","days":12},{"id":"nct06879717","kind":"trial","name":"A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients","route":"/trials/nct06879717/","asOf":"2026-09-16","days":12},{"id":"nct04205227","kind":"trial","name":"ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors","route":"/trials/nct04205227/","asOf":"2026-09-16","days":12},{"id":"nct06140524","kind":"trial","name":"A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With H","route":"/trials/nct06140524/","asOf":"2026-09-16","days":12},{"id":"nct05952024","kind":"trial","name":"Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL","route":"/trials/nct05952024/","asOf":"2026-09-16","days":12},{"id":"nct06589778","kind":"trial","name":"A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","route":"/trials/nct06589778/","asOf":"2026-09-16","days":12},{"id":"nct06601504","kind":"trial","name":"Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL","route":"/trials/nct06601504/","asOf":"2026-09-16","days":12},{"id":"nct05128825","kind":"trial","name":"A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer","route":"/trials/nct05128825/","asOf":"2026-09-16","days":12},{"id":"nct07059221","kind":"trial","name":"A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer","route":"/trials/nct07059221/","asOf":"2026-09-16","days":12},{"id":"nct05446298","kind":"trial","name":"ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer","route":"/trials/nct05446298/","asOf":"2026-09-16","days":12},{"id":"nct05784688","kind":"trial","name":"Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors","route":"/trials/nct05784688/","asOf":"2026-09-16","days":12},{"id":"nct07266441","kind":"trial","name":"A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07266441/","asOf":"2026-09-16","days":12},{"id":"nct06465329","kind":"trial","name":"A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Ce","route":"/trials/nct06465329/","asOf":"2026-09-16","days":12},{"id":"nct06535607","kind":"trial","name":"Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors","route":"/trials/nct06535607/","asOf":"2026-09-16","days":12},{"id":"nct06014528","kind":"trial","name":"IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurren","route":"/trials/nct06014528/","asOf":"2026-09-16","days":12},{"id":"nct06463028","kind":"trial","name":"Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial ","route":"/trials/nct06463028/","asOf":"2026-09-16","days":12},{"id":"nct03970746","kind":"trial","name":"Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC","route":"/trials/nct03970746/","asOf":"2026-09-16","days":12},{"id":"nct04986423","kind":"trial","name":"ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct04986423/","asOf":"2026-09-16","days":12},{"id":"nct02332668","kind":"trial","name":"A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)","route":"/trials/nct02332668/","asOf":"2026-09-16","days":12},{"id":"nct04152499","kind":"trial","name":"Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)","route":"/trials/nct04152499/","asOf":"2026-09-16","days":12},{"id":"nct07790510","kind":"trial","name":"HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer","route":"/trials/nct07790510/","asOf":"2026-09-16","days":12},{"id":"nct05658562","kind":"trial","name":"A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL","route":"/trials/nct05658562/","asOf":"2026-09-16","days":12},{"id":"nct06514027","kind":"trial","name":"Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations","route":"/trials/nct06514027/","asOf":"2026-09-16","days":12},{"id":"nct07545603","kind":"trial","name":"Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma","route":"/trials/nct07545603/","asOf":"2026-09-16","days":12},{"id":"nct06686030","kind":"trial","name":"Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer","route":"/trials/nct06686030/","asOf":"2026-09-16","days":12},{"id":"nct06134232","kind":"trial","name":"Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T","route":"/trials/nct06134232/","asOf":"2026-09-16","days":12},{"id":"nct02768363","kind":"trial","name":"Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)","route":"/trials/nct02768363/","asOf":"2026-09-16","days":12},{"id":"nct05751798","kind":"trial","name":"Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas","route":"/trials/nct05751798/","asOf":"2026-09-16","days":12},{"id":"nct05482893","kind":"trial","name":"Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junct","route":"/trials/nct05482893/","asOf":"2026-09-16","days":12},{"id":"nct05283226","kind":"trial","name":"Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck","route":"/trials/nct05283226/","asOf":"2026-09-16","days":12},{"id":"nct05822752","kind":"trial","name":"Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Bu","route":"/trials/nct05822752/","asOf":"2026-09-16","days":12},{"id":"nct07560111","kind":"trial","name":"A Phase II Study of GC101 in NSCLC","route":"/trials/nct07560111/","asOf":"2026-09-16","days":12},{"id":"nct07023289","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone o","route":"/trials/nct07023289/","asOf":"2026-09-16","days":12},{"id":"nct05775159","kind":"trial","name":"Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer","route":"/trials/nct05775159/","asOf":"2026-09-16","days":12},{"id":"nct07219459","kind":"trial","name":"Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)","route":"/trials/nct07219459/","asOf":"2026-09-16","days":12},{"id":"nct05955391","kind":"trial","name":"TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct05955391/","asOf":"2026-09-16","days":12},{"id":"nct07332000","kind":"trial","name":"A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec","route":"/trials/nct07332000/","asOf":"2026-09-16","days":12},{"id":"nct02213926","kind":"trial","name":"An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma","route":"/trials/nct02213926/","asOf":"2026-09-16","days":12},{"id":"nct07287150","kind":"trial","name":"A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct07287150/","asOf":"2026-09-16","days":12},{"id":"nct04140526","kind":"trial","name":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","route":"/trials/nct04140526/","asOf":"2026-09-16","days":12},{"id":"nct02568267","kind":"trial","name":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangeme","route":"/trials/nct02568267/","asOf":"2026-09-16","days":12},{"id":"nct07262619","kind":"trial","name":"EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Partic","route":"/trials/nct07262619/","asOf":"2026-09-16","days":12},{"id":"nct06668961","kind":"trial","name":"A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Sq","route":"/trials/nct06668961/","asOf":"2026-09-16","days":12},{"id":"nct06194656","kind":"trial","name":"Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma","route":"/trials/nct06194656/","asOf":"2026-09-16","days":12},{"id":"nct05830123","kind":"trial","name":"ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas","route":"/trials/nct05830123/","asOf":"2026-09-16","days":12},{"id":"nct06512051","kind":"trial","name":"A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct06512051/","asOf":"2026-09-16","days":12},{"id":"nct06550895","kind":"trial","name":"A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma","route":"/trials/nct06550895/","asOf":"2026-09-16","days":12},{"id":"nct04930432","kind":"trial","name":"Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors","route":"/trials/nct04930432/","asOf":"2026-09-16","days":12},{"id":"nct04843098","kind":"trial","name":"Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","route":"/trials/nct04843098/","asOf":"2026-09-16","days":12},{"id":"nct07024784","kind":"trial","name":"A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN1","route":"/trials/nct07024784/","asOf":"2026-09-16","days":12},{"id":"nct06769152","kind":"trial","name":"A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors","route":"/trials/nct06769152/","asOf":"2026-09-16","days":12},{"id":"nct07080216","kind":"trial","name":"Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer","route":"/trials/nct07080216/","asOf":"2026-09-16","days":12},{"id":"nct07306624","kind":"trial","name":"Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer","route":"/trials/nct07306624/","asOf":"2026-09-16","days":12},{"id":"nct07081633","kind":"trial","name":"Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma","route":"/trials/nct07081633/","asOf":"2026-09-16","days":12},{"id":"nct06780137","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensiv","route":"/trials/nct06780137/","asOf":"2026-09-16","days":12},{"id":"nct07446322","kind":"trial","name":"FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer","route":"/trials/nct07446322/","asOf":"2026-09-16","days":12},{"id":"nct03162536","kind":"trial","name":"A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)","route":"/trials/nct03162536/","asOf":"2026-09-16","days":12},{"id":"nct06437522","kind":"trial","name":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors","route":"/trials/nct06437522/","asOf":"2026-09-16","days":12},{"id":"nct05801029","kind":"trial","name":"A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth","route":"/trials/nct05801029/","asOf":"2026-09-16","days":12},{"id":"nct06448754","kind":"trial","name":"Volrustomig Priming Regimens Exploratory Phase II Platform Study","route":"/trials/nct06448754/","asOf":"2026-09-16","days":12},{"id":"nct07589634","kind":"trial","name":"A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relaps","route":"/trials/nct07589634/","asOf":"2026-09-16","days":12},{"id":"nct04083599","kind":"trial","name":"GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors","route":"/trials/nct04083599/","asOf":"2026-09-16","days":12},{"id":"nct06785636","kind":"trial","name":"A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC","route":"/trials/nct06785636/","asOf":"2026-09-16","days":12},{"id":"nct06228053","kind":"trial","name":"Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer","route":"/trials/nct06228053/","asOf":"2026-09-16","days":12},{"id":"nct06946797","kind":"trial","name":"A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Pre","route":"/trials/nct06946797/","asOf":"2026-09-16","days":12},{"id":"nct06107413","kind":"trial","name":"Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unrese","route":"/trials/nct06107413/","asOf":"2026-09-16","days":12},{"id":"nct07111520","kind":"trial","name":"A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced ","route":"/trials/nct07111520/","asOf":"2026-09-16","days":12},{"id":"nct05423262","kind":"trial","name":"A Study of TRK-950 in Patients With Advanced Solid Tumors","route":"/trials/nct05423262/","asOf":"2026-09-16","days":12},{"id":"nct03600441","kind":"trial","name":"Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma","route":"/trials/nct03600441/","asOf":"2026-09-16","days":12},{"id":"nct07054567","kind":"trial","name":"A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer","route":"/trials/nct07054567/","asOf":"2026-09-16","days":12},{"id":"nct04827953","kind":"trial","name":"Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic C","route":"/trials/nct04827953/","asOf":"2026-09-16","days":12},{"id":"nct03314181","kind":"trial","name":"A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractor","route":"/trials/nct03314181/","asOf":"2026-09-16","days":12},{"id":"nct05887492","kind":"trial","name":"Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors","route":"/trials/nct05887492/","asOf":"2026-09-16","days":12},{"id":"nct05372354","kind":"trial","name":"A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed ","route":"/trials/nct05372354/","asOf":"2026-09-16","days":12},{"id":"nct06235229","kind":"trial","name":"A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct06235229/","asOf":"2026-09-16","days":12},{"id":"nct03069469","kind":"trial","name":"Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor","route":"/trials/nct03069469/","asOf":"2026-09-16","days":12},{"id":"nct07519772","kind":"trial","name":"A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)","route":"/trials/nct07519772/","asOf":"2026-09-16","days":12},{"id":"nct06962865","kind":"trial","name":"A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Adv","route":"/trials/nct06962865/","asOf":"2026-09-16","days":12},{"id":"nct03228667","kind":"trial","name":"QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors","route":"/trials/nct03228667/","asOf":"2026-09-16","days":12},{"id":"nct06792695","kind":"trial","name":"A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer","route":"/trials/nct06792695/","asOf":"2026-09-16","days":12},{"id":"nct07805551","kind":"trial","name":"A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer","route":"/trials/nct07805551/","asOf":"2026-09-16","days":12},{"id":"nct04590326","kind":"trial","name":"A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamata","route":"/trials/nct04590326/","asOf":"2026-09-16","days":12},{"id":"nct07479485","kind":"trial","name":"MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)","route":"/trials/nct07479485/","asOf":"2026-09-16","days":12},{"id":"nct07659782","kind":"trial","name":"A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer","route":"/trials/nct07659782/","asOf":"2026-09-16","days":12},{"id":"nct04414475","kind":"trial","name":"A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refrac","route":"/trials/nct04414475/","asOf":"2026-09-16","days":12},{"id":"nct07079631","kind":"trial","name":"A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT3","route":"/trials/nct07079631/","asOf":"2026-09-16","days":12},{"id":"nct07253142","kind":"trial","name":"A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer","route":"/trials/nct07253142/","asOf":"2026-09-16","days":12},{"id":"nct06690775","kind":"trial","name":"CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.","route":"/trials/nct06690775/","asOf":"2026-09-16","days":12},{"id":"nct07049926","kind":"trial","name":"Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (","route":"/trials/nct07049926/","asOf":"2026-09-16","days":12},{"id":"nct05932212","kind":"trial","name":"AK104 for Recurrent or Metastatic Vulvar Cancer","route":"/trials/nct05932212/","asOf":"2026-09-16","days":12},{"id":"nct06114511","kind":"trial","name":"A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer","route":"/trials/nct06114511/","asOf":"2026-09-16","days":12},{"id":"nct07654400","kind":"trial","name":"A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer","route":"/trials/nct07654400/","asOf":"2026-09-16","days":12},{"id":"nct03972657","kind":"trial","name":"A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metasta","route":"/trials/nct03972657/","asOf":"2026-09-16","days":12},{"id":"nct05633667","kind":"trial","name":"Study of Novel Treatment Combinations in Patients With Lung Cancer","route":"/trials/nct05633667/","asOf":"2026-09-16","days":12},{"id":"nct07586124","kind":"trial","name":"Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma","route":"/trials/nct07586124/","asOf":"2026-09-16","days":12},{"id":"nct05009069","kind":"trial","name":"A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer","route":"/trials/nct05009069/","asOf":"2026-09-16","days":12},{"id":"nct06682988","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primar","route":"/trials/nct06682988/","asOf":"2026-09-16","days":12},{"id":"nct04501120","kind":"trial","name":"Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML","route":"/trials/nct04501120/","asOf":"2026-09-16","days":12},{"id":"nct06829771","kind":"trial","name":"Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma","route":"/trials/nct06829771/","asOf":"2026-09-16","days":12},{"id":"nct05846867","kind":"trial","name":"A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer","route":"/trials/nct05846867/","asOf":"2026-09-16","days":12},{"id":"nct06646055","kind":"trial","name":"AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer","route":"/trials/nct06646055/","asOf":"2026-09-16","days":12},{"id":"nct05925530","kind":"trial","name":"Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D,","route":"/trials/nct05925530/","asOf":"2026-09-16","days":12},{"id":"nct03407144","kind":"trial","name":"Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)","route":"/trials/nct03407144/","asOf":"2026-09-16","days":12},{"id":"nct06820463","kind":"trial","name":"A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil,","route":"/trials/nct06820463/","asOf":"2026-09-16","days":12},{"id":"nct07230106","kind":"trial","name":"A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer","route":"/trials/nct07230106/","asOf":"2026-09-16","days":12},{"id":"nct07284758","kind":"trial","name":"A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct07284758/","asOf":"2026-09-16","days":12},{"id":"nct04077723","kind":"trial","name":"A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combi","route":"/trials/nct04077723/","asOf":"2026-09-16","days":12},{"id":"nct07098988","kind":"trial","name":"Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC","route":"/trials/nct07098988/","asOf":"2026-09-16","days":12},{"id":"nct06797297","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastat","route":"/trials/nct06797297/","asOf":"2026-09-16","days":12},{"id":"nct05970497","kind":"trial","name":"A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct05970497/","asOf":"2026-09-16","days":12},{"id":"nct04663347","kind":"trial","name":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","route":"/trials/nct04663347/","asOf":"2026-09-16","days":12},{"id":"nct03564340","kind":"trial","name":"Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent","route":"/trials/nct03564340/","asOf":"2026-09-16","days":12},{"id":"nct06106308","kind":"trial","name":"Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab fo","route":"/trials/nct06106308/","asOf":"2026-09-16","days":12},{"id":"nct05676931","kind":"trial","name":"Study With Various Immunotherapy Treatments in Participants With Lung Cancer","route":"/trials/nct05676931/","asOf":"2026-09-16","days":12},{"id":"nct06689163","kind":"trial","name":"A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone","route":"/trials/nct06689163/","asOf":"2026-09-16","days":12},{"id":"nct07486089","kind":"trial","name":"Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)","route":"/trials/nct07486089/","asOf":"2026-09-16","days":12},{"id":"nct04050436","kind":"trial","name":"Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer","route":"/trials/nct04050436/","asOf":"2026-09-16","days":12},{"id":"nct07227012","kind":"trial","name":"Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a","route":"/trials/nct07227012/","asOf":"2026-09-16","days":12},{"id":"nct04133636","kind":"trial","name":"A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Mul","route":"/trials/nct04133636/","asOf":"2026-09-16","days":12},{"id":"nct03611868","kind":"trial","name":"A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors","route":"/trials/nct03611868/","asOf":"2026-09-16","days":12},{"id":"nct06172478","kind":"trial","name":"A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct06172478/","asOf":"2026-09-16","days":12},{"id":"nct05880706","kind":"trial","name":"A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung ","route":"/trials/nct05880706/","asOf":"2026-09-16","days":12},{"id":"nct06606847","kind":"trial","name":"A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small ","route":"/trials/nct06606847/","asOf":"2026-09-16","days":12},{"id":"nct07397338","kind":"trial","name":"Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors","route":"/trials/nct07397338/","asOf":"2026-09-16","days":12},{"id":"nct06090539","kind":"trial","name":"A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas","route":"/trials/nct06090539/","asOf":"2026-09-16","days":12},{"id":"nct07192614","kind":"trial","name":"A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Pr","route":"/trials/nct07192614/","asOf":"2026-09-16","days":12},{"id":"nct04895709","kind":"trial","name":"A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors","route":"/trials/nct04895709/","asOf":"2026-09-16","days":12},{"id":"nct05112991","kind":"trial","name":"Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer","route":"/trials/nct05112991/","asOf":"2026-09-16","days":12},{"id":"nct04644289","kind":"trial","name":"WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC","route":"/trials/nct04644289/","asOf":"2026-09-16","days":12},{"id":"nct06697184","kind":"trial","name":"A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.","route":"/trials/nct06697184/","asOf":"2026-09-16","days":12},{"id":"nct06344052","kind":"trial","name":"To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma","route":"/trials/nct06344052/","asOf":"2026-09-16","days":12},{"id":"nct07288177","kind":"trial","name":"Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer","route":"/trials/nct07288177/","asOf":"2026-09-16","days":12},{"id":"nct04440735","kind":"trial","name":"A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors","route":"/trials/nct04440735/","asOf":"2026-09-16","days":12},{"id":"nct05997017","kind":"trial","name":"Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer","route":"/trials/nct05997017/","asOf":"2026-09-16","days":12},{"id":"nct05583617","kind":"trial","name":"A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma","route":"/trials/nct05583617/","asOf":"2026-09-16","days":12},{"id":"nct05956587","kind":"trial","name":"A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other","route":"/trials/nct05956587/","asOf":"2026-09-16","days":12},{"id":"nct05601752","kind":"trial","name":"ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)","route":"/trials/nct05601752/","asOf":"2026-09-16","days":12},{"id":"nct06030258","kind":"trial","name":"IN10018 Combination Therapy in Treatment-naïve ES-SCLC","route":"/trials/nct06030258/","asOf":"2026-09-16","days":12},{"id":"nct06693336","kind":"trial","name":"An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer","route":"/trials/nct06693336/","asOf":"2026-09-16","days":12},{"id":"nct04586426","kind":"trial","name":"A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct04586426/","asOf":"2026-09-16","days":12},{"id":"nct05219500","kind":"trial","name":"Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).","route":"/trials/nct05219500/","asOf":"2026-09-16","days":12},{"id":"nct04752826","kind":"trial","name":"BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)","route":"/trials/nct04752826/","asOf":"2026-09-16","days":12},{"id":"nct06598007","kind":"trial","name":"A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors","route":"/trials/nct06598007/","asOf":"2026-09-16","days":12},{"id":"nct06948448","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard ","route":"/trials/nct06948448/","asOf":"2026-09-16","days":12},{"id":"nct06679985","kind":"trial","name":"A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepat","route":"/trials/nct06679985/","asOf":"2026-09-16","days":12},{"id":"nct04542824","kind":"trial","name":"Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)","route":"/trials/nct04542824/","asOf":"2026-09-16","days":12},{"id":"nct05593094","kind":"trial","name":"A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced So","route":"/trials/nct05593094/","asOf":"2026-09-16","days":12},{"id":"nct07208773","kind":"trial","name":"A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors","route":"/trials/nct07208773/","asOf":"2026-09-16","days":12},{"id":"nct06161974","kind":"trial","name":"Study of Olutasidenib and Temozolomide in HGG","route":"/trials/nct06161974/","asOf":"2026-09-16","days":12},{"id":"nct05338931","kind":"trial","name":"Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma","route":"/trials/nct05338931/","asOf":"2026-09-16","days":12},{"id":"nct02960022","kind":"trial","name":"A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study","route":"/trials/nct02960022/","asOf":"2026-09-16","days":12},{"id":"nct06480565","kind":"trial","name":"A Phase 1/2 Trial of ADI-270 in ccRCC","route":"/trials/nct06480565/","asOf":"2026-09-16","days":12},{"id":"nct04792489","kind":"trial","name":"DALY II USA/ MB-CART2019.1 for DLBCL","route":"/trials/nct04792489/","asOf":"2026-09-16","days":12},{"id":"nct07049055","kind":"trial","name":"A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer","route":"/trials/nct07049055/","asOf":"2026-09-16","days":12},{"id":"nct07659795","kind":"trial","name":"A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer","route":"/trials/nct07659795/","asOf":"2026-09-16","days":12},{"id":"nct06463665","kind":"trial","name":"Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL ","route":"/trials/nct06463665/","asOf":"2026-09-16","days":12},{"id":"nct07325136","kind":"trial","name":"A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung ","route":"/trials/nct07325136/","asOf":"2026-09-16","days":12},{"id":"nct06873763","kind":"trial","name":"Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer","route":"/trials/nct06873763/","asOf":"2026-09-16","days":12},{"id":"nct03989414","kind":"trial","name":"A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Tre","route":"/trials/nct03989414/","asOf":"2026-09-16","days":12},{"id":"nct07680764","kind":"trial","name":"A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pu","route":"/trials/nct07680764/","asOf":"2026-09-16","days":12},{"id":"nct05081609","kind":"trial","name":"A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other","route":"/trials/nct05081609/","asOf":"2026-09-16","days":12},{"id":"nct06731907","kind":"trial","name":"A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-34","route":"/trials/nct06731907/","asOf":"2026-09-16","days":12},{"id":"nct06784648","kind":"trial","name":"Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma","route":"/trials/nct06784648/","asOf":"2026-09-16","days":12},{"id":"nct04068597","kind":"trial","name":"Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies","route":"/trials/nct04068597/","asOf":"2026-09-16","days":12},{"id":"nct05990803","kind":"trial","name":"A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies","route":"/trials/nct05990803/","asOf":"2026-09-16","days":12},{"id":"nct05789082","kind":"trial","name":"A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Par","route":"/trials/nct05789082/","asOf":"2026-09-16","days":12},{"id":"nct07291076","kind":"trial","name":"A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unres","route":"/trials/nct07291076/","asOf":"2026-09-16","days":12},{"id":"nct07189065","kind":"trial","name":"A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma","route":"/trials/nct07189065/","asOf":"2026-09-16","days":12},{"id":"nct07235293","kind":"trial","name":"A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.","route":"/trials/nct07235293/","asOf":"2026-09-16","days":12},{"id":"nct05978284","kind":"trial","name":"Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma","route":"/trials/nct05978284/","asOf":"2026-09-16","days":12},{"id":"nct06253663","kind":"trial","name":"Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic L","route":"/trials/nct06253663/","asOf":"2026-09-16","days":12},{"id":"nct03634540","kind":"trial","name":"A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)","route":"/trials/nct03634540/","asOf":"2026-09-16","days":12},{"id":"nct06566547","kind":"trial","name":"GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct06566547/","asOf":"2026-09-16","days":12},{"id":"nct05605535","kind":"trial","name":"Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer","route":"/trials/nct05605535/","asOf":"2026-09-16","days":12},{"id":"nct07005336","kind":"trial","name":"A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untr","route":"/trials/nct07005336/","asOf":"2026-09-16","days":12},{"id":"nct05421663","kind":"trial","name":"A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma","route":"/trials/nct05421663/","asOf":"2026-09-16","days":12},{"id":"nct07071714","kind":"trial","name":"A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer","route":"/trials/nct07071714/","asOf":"2026-09-16","days":12},{"id":"nct05557591","kind":"trial","name":"A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small ","route":"/trials/nct05557591/","asOf":"2026-09-16","days":12},{"id":"nct05951959","kind":"trial","name":"A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma","route":"/trials/nct05951959/","asOf":"2026-09-16","days":12},{"id":"nct05608044","kind":"trial","name":"A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer","route":"/trials/nct05608044/","asOf":"2026-09-16","days":12},{"id":"nct06699836","kind":"trial","name":"CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen","route":"/trials/nct06699836/","asOf":"2026-09-16","days":12},{"id":"nct06219941","kind":"trial","name":"AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2","route":"/trials/nct06219941/","asOf":"2026-09-16","days":12},{"id":"nct04291105","kind":"trial","name":"Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients","route":"/trials/nct04291105/","asOf":"2026-09-16","days":12},{"id":"nct06922591","kind":"trial","name":"Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients","route":"/trials/nct06922591/","asOf":"2026-09-16","days":12},{"id":"nct06284590","kind":"trial","name":"Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients","route":"/trials/nct06284590/","asOf":"2026-09-16","days":12},{"id":"nct05458297","kind":"trial","name":"A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-","route":"/trials/nct05458297/","asOf":"2026-09-16","days":12},{"id":"nct05320588","kind":"trial","name":"A Study in Patients With Advanced Cancers","route":"/trials/nct05320588/","asOf":"2026-09-16","days":12},{"id":"nct05904379","kind":"trial","name":"AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer","route":"/trials/nct05904379/","asOf":"2026-09-16","days":12},{"id":"nct07133750","kind":"trial","name":"PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer","route":"/trials/nct07133750/","asOf":"2026-09-16","days":12},{"id":"nct03960840","kind":"trial","name":"Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL","route":"/trials/nct03960840/","asOf":"2026-09-16","days":12},{"id":"nct07255664","kind":"trial","name":"A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC","route":"/trials/nct07255664/","asOf":"2026-09-16","days":12},{"id":"nct05739981","kind":"trial","name":"Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer","route":"/trials/nct05739981/","asOf":"2026-09-16","days":12},{"id":"nct07387471","kind":"trial","name":"Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobu","route":"/trials/nct07387471/","asOf":"2026-09-16","days":12},{"id":"nct06521567","kind":"trial","name":"A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer","route":"/trials/nct06521567/","asOf":"2026-09-16","days":12},{"id":"nct05086692","kind":"trial","name":"A Beta-only IL-2 ImmunoTherapY Study","route":"/trials/nct05086692/","asOf":"2026-09-16","days":12},{"id":"nct07124936","kind":"trial","name":"A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma","route":"/trials/nct07124936/","asOf":"2026-09-16","days":12},{"id":"nct07052253","kind":"trial","name":"A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.","route":"/trials/nct07052253/","asOf":"2026-09-16","days":12},{"id":"nct07181161","kind":"trial","name":"Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer","route":"/trials/nct07181161/","asOf":"2026-09-16","days":12},{"id":"nct06522828","kind":"trial","name":"A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients","route":"/trials/nct06522828/","asOf":"2026-09-16","days":12},{"id":"nct05853575","kind":"trial","name":"Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)","route":"/trials/nct05853575/","asOf":"2026-09-16","days":12},{"id":"nct03775486","kind":"trial","name":"Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)","route":"/trials/nct03775486/","asOf":"2026-09-16","days":12},{"id":"nct07169994","kind":"trial","name":"A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors","route":"/trials/nct07169994/","asOf":"2026-09-16","days":12},{"id":"nct03709680","kind":"trial","name":"Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors","route":"/trials/nct03709680/","asOf":"2026-09-16","days":12},{"id":"nct07476287","kind":"trial","name":"Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed","route":"/trials/nct07476287/","asOf":"2026-09-16","days":12},{"id":"nct05826535","kind":"trial","name":"Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma","route":"/trials/nct05826535/","asOf":"2026-09-16","days":12},{"id":"nct06943820","kind":"trial","name":"AK129 Combination Therapy for Advanced Solid Tumors","route":"/trials/nct06943820/","asOf":"2026-09-16","days":12},{"id":"nct06577025","kind":"trial","name":"A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Ind","route":"/trials/nct06577025/","asOf":"2026-09-16","days":12},{"id":"nct04701476","kind":"trial","name":"TATE and Pembrolizumab (MK3475) in mCRC and NSCLC","route":"/trials/nct04701476/","asOf":"2026-09-16","days":12},{"id":"nct07162181","kind":"trial","name":"Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers","route":"/trials/nct07162181/","asOf":"2026-09-16","days":12},{"id":"nct04396821","kind":"trial","name":"A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors","route":"/trials/nct04396821/","asOf":"2026-09-16","days":12},{"id":"nct07807163","kind":"trial","name":"A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC","route":"/trials/nct07807163/","asOf":"2026-09-16","days":12},{"id":"nct03897881","kind":"trial","name":"An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYN","route":"/trials/nct03897881/","asOf":"2026-09-16","days":12},{"id":"nct07255404","kind":"trial","name":"A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have N","route":"/trials/nct07255404/","asOf":"2026-09-16","days":12},{"id":"nct05950165","kind":"trial","name":"A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Ly","route":"/trials/nct05950165/","asOf":"2026-09-16","days":12},{"id":"nct07296809","kind":"trial","name":"SKB500 Combinations in Patients With Small Cell Lung Cancer","route":"/trials/nct07296809/","asOf":"2026-09-16","days":12},{"id":"nct05919264","kind":"trial","name":"FOG-001 in Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct05919264/","asOf":"2026-09-16","days":12},{"id":"nct06283719","kind":"trial","name":"Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in P","route":"/trials/nct06283719/","asOf":"2026-09-16","days":12},{"id":"nct06241846","kind":"trial","name":"A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC","route":"/trials/nct06241846/","asOf":"2026-09-16","days":12},{"id":"nct07468071","kind":"trial","name":"Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other","route":"/trials/nct07468071/","asOf":"2026-09-16","days":12},{"id":"nct06526793","kind":"trial","name":"Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL","route":"/trials/nct06526793/","asOf":"2026-09-16","days":12},{"id":"nct05716087","kind":"trial","name":"A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma","route":"/trials/nct05716087/","asOf":"2026-09-16","days":12},{"id":"nct05712902","kind":"trial","name":"Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)","route":"/trials/nct05712902/","asOf":"2026-09-16","days":12},{"id":"nct06365853","kind":"trial","name":"A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer Wit","route":"/trials/nct06365853/","asOf":"2026-09-16","days":12},{"id":"nct05651022","kind":"trial","name":"Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors","route":"/trials/nct05651022/","asOf":"2026-09-16","days":12},{"id":"nct05413850","kind":"trial","name":"Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection","route":"/trials/nct05413850/","asOf":"2026-09-16","days":12},{"id":"nct04421820","kind":"trial","name":"BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours","route":"/trials/nct04421820/","asOf":"2026-09-16","days":12},{"id":"nct07227415","kind":"trial","name":"Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With ","route":"/trials/nct07227415/","asOf":"2026-09-16","days":12},{"id":"nct05797168","kind":"trial","name":"Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors","route":"/trials/nct05797168/","asOf":"2026-09-16","days":12},{"id":"nct07565285","kind":"trial","name":"The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma","route":"/trials/nct07565285/","asOf":"2026-09-16","days":12},{"id":"nct07714668","kind":"trial","name":"A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer","route":"/trials/nct07714668/","asOf":"2026-09-16","days":12},{"id":"nct04585750","kind":"trial","name":"The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","route":"/trials/nct04585750/","asOf":"2026-09-16","days":12},{"id":"nct05367440","kind":"trial","name":"Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer","route":"/trials/nct05367440/","asOf":"2026-09-16","days":12},{"id":"nct07269782","kind":"trial","name":"A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC","route":"/trials/nct07269782/","asOf":"2026-09-16","days":12},{"id":"nct07239596","kind":"trial","name":"Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom","route":"/trials/nct07239596/","asOf":"2026-09-16","days":12},{"id":"nct07609862","kind":"trial","name":"A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies","route":"/trials/nct07609862/","asOf":"2026-09-16","days":12},{"id":"nct05351788","kind":"trial","name":"SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.","route":"/trials/nct05351788/","asOf":"2026-09-16","days":12},{"id":"nct06991556","kind":"trial","name":"An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Canc","route":"/trials/nct06991556/","asOf":"2026-09-16","days":12},{"id":"nct06006169","kind":"trial","name":"A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumor","route":"/trials/nct06006169/","asOf":"2026-09-16","days":12},{"id":"nct06644768","kind":"trial","name":"A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations","route":"/trials/nct06644768/","asOf":"2026-09-16","days":12},{"id":"nct03785249","kind":"trial","name":"Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1","route":"/trials/nct03785249/","asOf":"2026-09-16","days":12},{"id":"nct04302025","kind":"trial","name":"A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct04302025/","asOf":"2026-09-16","days":12},{"id":"nct06081920","kind":"trial","name":"A Study of IBI363 in Subjects With Advanced Melanoma","route":"/trials/nct06081920/","asOf":"2026-09-16","days":12},{"id":"nct07452224","kind":"trial","name":"ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer","route":"/trials/nct07452224/","asOf":"2026-09-16","days":12},{"id":"nct07288203","kind":"trial","name":"A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma","route":"/trials/nct07288203/","asOf":"2026-09-16","days":12},{"id":"nct05280470","kind":"trial","name":"Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)","route":"/trials/nct05280470/","asOf":"2026-09-16","days":12},{"id":"nct07745361","kind":"trial","name":"Study of Oral MRT-2359 With Apalutamide in Prostate Cancer","route":"/trials/nct07745361/","asOf":"2026-09-16","days":12},{"id":"nct06915246","kind":"trial","name":"A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma","route":"/trials/nct06915246/","asOf":"2026-09-16","days":12},{"id":"nct07245446","kind":"trial","name":"A Study of Ivonescimab in First-Line ES-SCLC","route":"/trials/nct07245446/","asOf":"2026-09-16","days":12},{"id":"nct05535244","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multi","route":"/trials/nct05535244/","asOf":"2026-09-16","days":12},{"id":"nct05533775","kind":"trial","name":"A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Matu","route":"/trials/nct05533775/","asOf":"2026-09-16","days":12},{"id":"nct03915184","kind":"trial","name":"Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)","route":"/trials/nct03915184/","asOf":"2026-09-16","days":12},{"id":"nct05201248","kind":"trial","name":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Th","route":"/trials/nct05201248/","asOf":"2026-09-16","days":12},{"id":"nct07589543","kind":"trial","name":"Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer","route":"/trials/nct07589543/","asOf":"2026-09-16","days":12},{"id":"nct05551507","kind":"trial","name":"IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer","route":"/trials/nct05551507/","asOf":"2026-09-16","days":12},{"id":"nct05451810","kind":"trial","name":"A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refr","route":"/trials/nct05451810/","asOf":"2026-09-16","days":12},{"id":"nct06265025","kind":"trial","name":"GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors","route":"/trials/nct06265025/","asOf":"2026-09-16","days":12},{"id":"nct07221474","kind":"trial","name":"A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)","route":"/trials/nct07221474/","asOf":"2026-09-16","days":12},{"id":"nct05585320","kind":"trial","name":"A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors","route":"/trials/nct05585320/","asOf":"2026-09-16","days":12},{"id":"nct07098338","kind":"trial","name":"A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct07098338/","asOf":"2026-09-16","days":12},{"id":"nct05024214","kind":"trial","name":"Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors","route":"/trials/nct05024214/","asOf":"2026-09-16","days":12},{"id":"nct05431270","kind":"trial","name":"Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy","route":"/trials/nct05431270/","asOf":"2026-09-16","days":12},{"id":"nct07288879","kind":"trial","name":"DALY II Japan/MB-CART2019.1 for DLBCL","route":"/trials/nct07288879/","asOf":"2026-09-16","days":12},{"id":"nct07326566","kind":"trial","name":"Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII","route":"/trials/nct07326566/","asOf":"2026-09-16","days":12},{"id":"nct07450599","kind":"trial","name":"A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have Hi","route":"/trials/nct07450599/","asOf":"2026-09-16","days":12},{"id":"nct06988488","kind":"trial","name":"A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatama","route":"/trials/nct06988488/","asOf":"2026-09-16","days":12},{"id":"nct04787042","kind":"trial","name":"Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067","route":"/trials/nct04787042/","asOf":"2026-09-16","days":12},{"id":"nct06568094","kind":"trial","name":"A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer","route":"/trials/nct06568094/","asOf":"2026-09-16","days":12},{"id":"nct07432295","kind":"trial","name":"Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)","route":"/trials/nct07432295/","asOf":"2026-09-16","days":12},{"id":"nct07229729","kind":"trial","name":"A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer","route":"/trials/nct07229729/","asOf":"2026-09-16","days":12},{"id":"nct06362369","kind":"trial","name":"A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy","route":"/trials/nct06362369/","asOf":"2026-09-16","days":12},{"id":"nct04924075","kind":"trial","name":"Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL","route":"/trials/nct04924075/","asOf":"2026-09-16","days":12},{"id":"nct05949606","kind":"trial","name":"A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct05949606/","asOf":"2026-09-16","days":12},{"id":"nct06568939","kind":"trial","name":"A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult ","route":"/trials/nct06568939/","asOf":"2026-09-16","days":12},{"id":"nct05194995","kind":"trial","name":"JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation","route":"/trials/nct05194995/","asOf":"2026-09-16","days":12},{"id":"nct06087653","kind":"trial","name":"Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)","route":"/trials/nct06087653/","asOf":"2026-09-16","days":12},{"id":"nct06378177","kind":"trial","name":"A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)","route":"/trials/nct06378177/","asOf":"2026-09-16","days":12},{"id":"nct07483554","kind":"trial","name":"IBI343 in Combination Therapy for Advanced Malignant Solid Tumors","route":"/trials/nct07483554/","asOf":"2026-09-16","days":12},{"id":"nct06445400","kind":"trial","name":"A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive ","route":"/trials/nct06445400/","asOf":"2026-09-16","days":12},{"id":"nct04920617","kind":"trial","name":"DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymp","route":"/trials/nct04920617/","asOf":"2026-09-16","days":12},{"id":"nct05456685","kind":"trial","name":"Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ov","route":"/trials/nct05456685/","asOf":"2026-09-16","days":12},{"id":"nct07730515","kind":"trial","name":"Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma","route":"/trials/nct07730515/","asOf":"2026-09-16","days":12},{"id":"nct04616443","kind":"trial","name":"OH2 Injection in Combination With HX008 for Melanoma.","route":"/trials/nct04616443/","asOf":"2026-09-16","days":12},{"id":"nct07510815","kind":"trial","name":"Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma","route":"/trials/nct07510815/","asOf":"2026-09-16","days":12},{"id":"nct07170644","kind":"trial","name":"A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)","route":"/trials/nct07170644/","asOf":"2026-09-16","days":12},{"id":"nct05620134","kind":"trial","name":"Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer","route":"/trials/nct05620134/","asOf":"2026-09-16","days":12},{"id":"nct05635708","kind":"trial","name":"A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer","route":"/trials/nct05635708/","asOf":"2026-09-16","days":12},{"id":"nct05913089","kind":"trial","name":"A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer","route":"/trials/nct05913089/","asOf":"2026-09-16","days":12},{"id":"nct07293351","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal ","route":"/trials/nct07293351/","asOf":"2026-09-16","days":12},{"id":"nct07622186","kind":"trial","name":"A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct07622186/","asOf":"2026-09-16","days":12},{"id":"nct07123454","kind":"trial","name":"A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphom","route":"/trials/nct07123454/","asOf":"2026-09-16","days":12},{"id":"nct04675294","kind":"trial","name":"Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)","route":"/trials/nct04675294/","asOf":"2026-09-16","days":12},{"id":"nct03936153","kind":"trial","name":"Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)","route":"/trials/nct03936153/","asOf":"2026-09-16","days":12},{"id":"nct07680439","kind":"trial","name":"Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).","route":"/trials/nct07680439/","asOf":"2026-09-16","days":12},{"id":"nct06162572","kind":"trial","name":"Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct06162572/","asOf":"2026-09-16","days":12},{"id":"nct04471727","kind":"trial","name":"A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)","route":"/trials/nct04471727/","asOf":"2026-09-16","days":12},{"id":"nct06434610","kind":"trial","name":"A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.","route":"/trials/nct06434610/","asOf":"2026-09-16","days":12},{"id":"nct06996782","kind":"trial","name":"A Platform Study in Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct06996782/","asOf":"2026-09-16","days":12},{"id":"nct05123482","kind":"trial","name":"A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies","route":"/trials/nct05123482/","asOf":"2026-09-16","days":12},{"id":"nct06496490","kind":"trial","name":"A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality","route":"/trials/nct06496490/","asOf":"2026-09-16","days":12},{"id":"nct06706076","kind":"trial","name":"A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations","route":"/trials/nct06706076/","asOf":"2026-09-16","days":12},{"id":"nct05607420","kind":"trial","name":"Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma","route":"/trials/nct05607420/","asOf":"2026-09-16","days":12},{"id":"nct06161441","kind":"trial","name":"A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemoth","route":"/trials/nct06161441/","asOf":"2026-09-16","days":12},{"id":"nct05379985","kind":"trial","name":"Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","route":"/trials/nct05379985/","asOf":"2026-09-16","days":12},{"id":"nct05098132","kind":"trial","name":"Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers","route":"/trials/nct05098132/","asOf":"2026-09-16","days":12},{"id":"nct05060016","kind":"trial","name":"A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)","route":"/trials/nct05060016/","asOf":"2026-09-16","days":12},{"id":"nct05440708","kind":"trial","name":"A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma","route":"/trials/nct05440708/","asOf":"2026-09-16","days":12},{"id":"nct06281678","kind":"trial","name":"A Study of IBI363 in Subjects with Advanced Solid Malignancies","route":"/trials/nct06281678/","asOf":"2026-09-16","days":12},{"id":"nct07082686","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)","route":"/trials/nct07082686/","asOf":"2026-09-16","days":12},{"id":"nct06297226","kind":"trial","name":"Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct06297226/","asOf":"2026-09-16","days":12},{"id":"nct07617753","kind":"trial","name":"Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2","route":"/trials/nct07617753/","asOf":"2026-09-16","days":12},{"id":"nct07079475","kind":"trial","name":"Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)","route":"/trials/nct07079475/","asOf":"2026-09-16","days":12},{"id":"nct06534437","kind":"trial","name":"MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)","route":"/trials/nct06534437/","asOf":"2026-09-16","days":12},{"id":"nct05877430","kind":"trial","name":"Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer","route":"/trials/nct05877430/","asOf":"2026-09-16","days":12},{"id":"nct04782687","kind":"trial","name":"Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma","route":"/trials/nct04782687/","asOf":"2026-09-16","days":12},{"id":"nct05661955","kind":"trial","name":"A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants","route":"/trials/nct05661955/","asOf":"2026-09-16","days":12},{"id":"nct03907852","kind":"trial","name":"Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer","route":"/trials/nct03907852/","asOf":"2026-09-16","days":12},{"id":"nct06726148","kind":"trial","name":"Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors","route":"/trials/nct06726148/","asOf":"2026-09-16","days":12},{"id":"nct06560112","kind":"trial","name":"An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer","route":"/trials/nct06560112/","asOf":"2026-09-16","days":12},{"id":"nct03393884","kind":"trial","name":"Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)","route":"/trials/nct03393884/","asOf":"2026-09-16","days":12},{"id":"nct06500884","kind":"trial","name":"A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events","route":"/trials/nct06500884/","asOf":"2026-09-16","days":12},{"id":"nct06162221","kind":"trial","name":"Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC","route":"/trials/nct06162221/","asOf":"2026-09-16","days":12},{"id":"nct03526835","kind":"trial","name":"A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors","route":"/trials/nct03526835/","asOf":"2026-09-16","days":12},{"id":"nct04728893","kind":"trial","name":"Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)","route":"/trials/nct04728893/","asOf":"2026-09-16","days":12},{"id":"nct07264816","kind":"trial","name":"A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NS","route":"/trials/nct07264816/","asOf":"2026-09-16","days":12},{"id":"nct07590934","kind":"trial","name":"Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer","route":"/trials/nct07590934/","asOf":"2026-09-16","days":12},{"id":"nct05924841","kind":"trial","name":"A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer","route":"/trials/nct05924841/","asOf":"2026-09-16","days":12},{"id":"nct05186753","kind":"trial","name":"(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis","route":"/trials/nct05186753/","asOf":"2026-09-16","days":12},{"id":"nct07149857","kind":"trial","name":"A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel","route":"/trials/nct07149857/","asOf":"2026-09-16","days":12},{"id":"nct05565417","kind":"trial","name":"Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas","route":"/trials/nct05565417/","asOf":"2026-09-16","days":12},{"id":"nct06589440","kind":"trial","name":"Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Can","route":"/trials/nct06589440/","asOf":"2026-09-16","days":12},{"id":"nct05669482","kind":"trial","name":"Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer","route":"/trials/nct05669482/","asOf":"2026-09-16","days":12},{"id":"nct07226986","kind":"trial","name":"A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA","route":"/trials/nct07226986/","asOf":"2026-09-16","days":12},{"id":"nct04246086","kind":"trial","name":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokineti","route":"/trials/nct04246086/","asOf":"2026-09-16","days":12},{"id":"nct04657068","kind":"trial","name":"A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors","route":"/trials/nct04657068/","asOf":"2026-09-16","days":12},{"id":"nct07005154","kind":"trial","name":"A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer","route":"/trials/nct07005154/","asOf":"2026-09-16","days":12},{"id":"nct07246863","kind":"trial","name":"Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC","route":"/trials/nct07246863/","asOf":"2026-09-16","days":12},{"id":"nct05468697","kind":"trial","name":"A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6","route":"/trials/nct05468697/","asOf":"2026-09-16","days":12},{"id":"nct03916627","kind":"trial","name":"Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients","route":"/trials/nct03916627/","asOf":"2026-09-16","days":12},{"id":"nct04736173","kind":"trial","name":"Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer","route":"/trials/nct04736173/","asOf":"2026-09-16","days":12},{"id":"nct07042802","kind":"trial","name":"A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer","route":"/trials/nct07042802/","asOf":"2026-09-16","days":12},{"id":"nct04868877","kind":"trial","name":"Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combina","route":"/trials/nct04868877/","asOf":"2026-09-16","days":12},{"id":"nct04844866","kind":"trial","name":"Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients","route":"/trials/nct04844866/","asOf":"2026-09-16","days":12},{"id":"nct07244705","kind":"trial","name":"A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC","route":"/trials/nct07244705/","asOf":"2026-09-16","days":12},{"id":"nct06190951","kind":"trial","name":"A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma","route":"/trials/nct06190951/","asOf":"2026-09-16","days":12},{"id":"nct04733183","kind":"trial","name":"Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma","route":"/trials/nct04733183/","asOf":"2026-09-16","days":12},{"id":"nct05734066","kind":"trial","name":"Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma","route":"/trials/nct05734066/","asOf":"2026-09-16","days":12},{"id":"nct07594106","kind":"trial","name":"REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate ","route":"/trials/nct07594106/","asOf":"2026-09-16","days":12},{"id":"nct06115135","kind":"trial","name":"A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma","route":"/trials/nct06115135/","asOf":"2026-09-16","days":12},{"id":"nct07059650","kind":"trial","name":"DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)","route":"/trials/nct07059650/","asOf":"2026-09-16","days":12},{"id":"nct05735080","kind":"trial","name":"Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer","route":"/trials/nct05735080/","asOf":"2026-09-16","days":12},{"id":"nct07175220","kind":"trial","name":"Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects","route":"/trials/nct07175220/","asOf":"2026-09-16","days":12},{"id":"nct07336446","kind":"trial","name":"A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs","route":"/trials/nct07336446/","asOf":"2026-09-16","days":12},{"id":"nct04180371","kind":"trial","name":"Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression","route":"/trials/nct04180371/","asOf":"2026-09-16","days":12},{"id":"nct06792435","kind":"trial","name":"XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.","route":"/trials/nct06792435/","asOf":"2026-09-16","days":12},{"id":"nct05144698","kind":"trial","name":"RAPA-201 Therapy of Solid Tumors","route":"/trials/nct05144698/","asOf":"2026-09-16","days":12},{"id":"nct07521852","kind":"trial","name":"A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Part","route":"/trials/nct07521852/","asOf":"2026-09-16","days":12},{"id":"nct06128551","kind":"trial","name":"Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors","route":"/trials/nct06128551/","asOf":"2026-09-16","days":12},{"id":"nct06754930","kind":"trial","name":"A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC","route":"/trials/nct06754930/","asOf":"2026-09-16","days":12},{"id":"nct06008054","kind":"trial","name":"A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric ","route":"/trials/nct06008054/","asOf":"2026-09-16","days":12},{"id":"nct06727565","kind":"trial","name":"Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Subst","route":"/trials/nct06727565/","asOf":"2026-09-16","days":12},{"id":"nct06892522","kind":"trial","name":"A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-spe","route":"/trials/nct06892522/","asOf":"2026-09-16","days":12},{"id":"nct02861573","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)","route":"/trials/nct02861573/","asOf":"2026-09-16","days":12},{"id":"nct04938583","kind":"trial","name":"Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer","route":"/trials/nct04938583/","asOf":"2026-09-16","days":12},{"id":"nct06427941","kind":"trial","name":"A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Sol","route":"/trials/nct06427941/","asOf":"2026-09-16","days":12},{"id":"nct07051486","kind":"trial","name":"A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer","route":"/trials/nct07051486/","asOf":"2026-09-16","days":12},{"id":"nct06014190","kind":"trial","name":"HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer","route":"/trials/nct06014190/","asOf":"2026-09-16","days":12},{"id":"nct05394103","kind":"trial","name":"Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors","route":"/trials/nct05394103/","asOf":"2026-09-16","days":12},{"id":"nct07617805","kind":"trial","name":"EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC","route":"/trials/nct07617805/","asOf":"2026-09-16","days":12},{"id":"nct04557449","kind":"trial","name":"Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors","route":"/trials/nct04557449/","asOf":"2026-09-16","days":12},{"id":"nct06343064","kind":"trial","name":"Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI","route":"/trials/nct06343064/","asOf":"2026-09-16","days":12},{"id":"nct03647163","kind":"trial","name":"Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors","route":"/trials/nct03647163/","asOf":"2026-09-16","days":12},{"id":"nct06810544","kind":"trial","name":"Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss","route":"/trials/nct06810544/","asOf":"2026-09-16","days":12},{"id":"nct07227298","kind":"trial","name":"Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers","route":"/trials/nct07227298/","asOf":"2026-09-16","days":12},{"id":"nct06848699","kind":"trial","name":"A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors","route":"/trials/nct06848699/","asOf":"2026-09-16","days":12},{"id":"nct05805501","kind":"trial","name":"A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cel","route":"/trials/nct05805501/","asOf":"2026-09-16","days":12},{"id":"nct05126719","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma","route":"/trials/nct05126719/","asOf":"2026-09-16","days":12},{"id":"nct05067140","kind":"trial","name":"A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer","route":"/trials/nct05067140/","asOf":"2026-09-16","days":12},{"id":"nct06956690","kind":"trial","name":"A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing ","route":"/trials/nct06956690/","asOf":"2026-09-16","days":12},{"id":"nct06909825","kind":"trial","name":"FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","route":"/trials/nct06909825/","asOf":"2026-09-16","days":12},{"id":"nct05318573","kind":"trial","name":"A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer","route":"/trials/nct05318573/","asOf":"2026-09-16","days":12},{"id":"nct05816252","kind":"trial","name":"A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-","route":"/trials/nct05816252/","asOf":"2026-09-16","days":12},{"id":"nct07287917","kind":"trial","name":"Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors","route":"/trials/nct07287917/","asOf":"2026-09-16","days":12},{"id":"nct06307431","kind":"trial","name":"A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).","route":"/trials/nct06307431/","asOf":"2026-09-16","days":12},{"id":"nct05442060","kind":"trial","name":"To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic N","route":"/trials/nct05442060/","asOf":"2026-09-16","days":12},{"id":"nct06096779","kind":"trial","name":"A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirr","route":"/trials/nct06096779/","asOf":"2026-09-16","days":12},{"id":"nct07474727","kind":"trial","name":"A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer","route":"/trials/nct07474727/","asOf":"2026-09-16","days":12},{"id":"nct06225843","kind":"trial","name":"Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis","route":"/trials/nct06225843/","asOf":"2026-09-16","days":12},{"id":"nct03947385","kind":"trial","name":"Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions","route":"/trials/nct03947385/","asOf":"2026-09-16","days":12},{"id":"nct06607458","kind":"trial","name":"Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatme","route":"/trials/nct06607458/","asOf":"2026-09-16","days":12},{"id":"nct04988555","kind":"trial","name":"A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)","route":"/trials/nct04988555/","asOf":"2026-09-16","days":12},{"id":"nct05103358","kind":"trial","name":"Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)","route":"/trials/nct05103358/","asOf":"2026-09-16","days":12},{"id":"nct06437509","kind":"trial","name":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer","route":"/trials/nct06437509/","asOf":"2026-09-16","days":12},{"id":"nct04553133","kind":"trial","name":"PF-07104091 as a Single Agent and in Combination Therapy","route":"/trials/nct04553133/","asOf":"2026-09-16","days":12},{"id":"nct06890338","kind":"trial","name":"A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Fo","route":"/trials/nct06890338/","asOf":"2026-09-16","days":12},{"id":"nct04644068","kind":"trial","name":"Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies","route":"/trials/nct04644068/","asOf":"2026-09-16","days":12},{"id":"nct03767348","kind":"trial","name":"Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)","route":"/trials/nct03767348/","asOf":"2026-09-16","days":12},{"id":"nct06119685","kind":"trial","name":"IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers","route":"/trials/nct06119685/","asOf":"2026-09-16","days":12},{"id":"nct05271318","kind":"trial","name":"Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) ","route":"/trials/nct05271318/","asOf":"2026-09-16","days":12},{"id":"nct07044908","kind":"trial","name":"TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer","route":"/trials/nct07044908/","asOf":"2026-09-16","days":12},{"id":"nct06953960","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma ","route":"/trials/nct06953960/","asOf":"2026-09-16","days":12},{"id":"nct05267626","kind":"trial","name":"Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Ca","route":"/trials/nct05267626/","asOf":"2026-09-16","days":12},{"id":"nct05632939","kind":"trial","name":"ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.","route":"/trials/nct05632939/","asOf":"2026-09-16","days":12},{"id":"nct07465757","kind":"trial","name":"A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)","route":"/trials/nct07465757/","asOf":"2026-09-16","days":12},{"id":"nct05061550","kind":"trial","name":"Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer","route":"/trials/nct05061550/","asOf":"2026-09-16","days":12},{"id":"nct05207670","kind":"trial","name":"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies","route":"/trials/nct05207670/","asOf":"2026-09-16","days":12},{"id":"nct05006716","kind":"trial","name":"A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies","route":"/trials/nct05006716/","asOf":"2026-09-16","days":12},{"id":"nct06961006","kind":"trial","name":"A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)","route":"/trials/nct06961006/","asOf":"2026-09-16","days":12},{"id":"nct07310784","kind":"trial","name":"A Phase II Trial of LM103 in Advanced Melanoma","route":"/trials/nct07310784/","asOf":"2026-09-16","days":12},{"id":"nct07563738","kind":"trial","name":"A 2-part Phase 1/2 Open-label Trial on ODM-212","route":"/trials/nct07563738/","asOf":"2026-09-16","days":12},{"id":"nct07312188","kind":"trial","name":"A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07312188/","asOf":"2026-09-16","days":12},{"id":"nct06840002","kind":"trial","name":"A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer","route":"/trials/nct06840002/","asOf":"2026-09-16","days":12},{"id":"nct07623356","kind":"trial","name":"A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer","route":"/trials/nct07623356/","asOf":"2026-09-16","days":12},{"id":"nct06708663","kind":"trial","name":"HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours","route":"/trials/nct06708663/","asOf":"2026-09-16","days":12},{"id":"nct04996875","kind":"trial","name":"(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis","route":"/trials/nct04996875/","asOf":"2026-09-16","days":12},{"id":"nct06859775","kind":"trial","name":"SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer","route":"/trials/nct06859775/","asOf":"2026-09-16","days":12},{"id":"nct06324357","kind":"trial","name":"Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People Wit","route":"/trials/nct06324357/","asOf":"2026-09-16","days":12},{"id":"nct06481592","kind":"trial","name":"A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.","route":"/trials/nct06481592/","asOf":"2026-09-16","days":12},{"id":"nct05565807","kind":"trial","name":"Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma","route":"/trials/nct05565807/","asOf":"2026-09-16","days":12},{"id":"nct07480928","kind":"trial","name":"Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma","route":"/trials/nct07480928/","asOf":"2026-09-16","days":12},{"id":"nct07644559","kind":"trial","name":"A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer","route":"/trials/nct07644559/","asOf":"2026-09-16","days":12},{"id":"nct06228326","kind":"trial","name":"A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs","route":"/trials/nct06228326/","asOf":"2026-09-16","days":12},{"id":"nct07155174","kind":"trial","name":"A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus St","route":"/trials/nct07155174/","asOf":"2026-09-16","days":12},{"id":"nct04606446","kind":"trial","name":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors","route":"/trials/nct04606446/","asOf":"2026-09-16","days":12},{"id":"nct04495153","kind":"trial","name":"CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC","route":"/trials/nct04495153/","asOf":"2026-09-16","days":12},{"id":"nct07449754","kind":"trial","name":"Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma","route":"/trials/nct07449754/","asOf":"2026-09-16","days":12},{"id":"nct06090266","kind":"trial","name":"A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents","route":"/trials/nct06090266/","asOf":"2026-09-16","days":12},{"id":"nct05682443","kind":"trial","name":"ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC","route":"/trials/nct05682443/","asOf":"2026-09-16","days":12},{"id":"nct07288359","kind":"trial","name":"Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors","route":"/trials/nct07288359/","asOf":"2026-09-16","days":12},{"id":"nct07023627","kind":"trial","name":"A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression","route":"/trials/nct07023627/","asOf":"2026-09-16","days":12},{"id":"nct05382442","kind":"trial","name":"A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer","route":"/trials/nct05382442/","asOf":"2026-09-16","days":12},{"id":"nct02955940","kind":"trial","name":"An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib","route":"/trials/nct02955940/","asOf":"2026-09-16","days":12},{"id":"nct06730347","kind":"trial","name":"A Study of Lorigerlimab in Participants With Advanced Solid Tumors","route":"/trials/nct06730347/","asOf":"2026-09-16","days":12},{"id":"nct07202364","kind":"trial","name":"A Study of YL202 in Patients With Advanced Solid Tumors","route":"/trials/nct07202364/","asOf":"2026-09-16","days":12},{"id":"nct05257993","kind":"trial","name":"Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Adv","route":"/trials/nct05257993/","asOf":"2026-09-16","days":12},{"id":"nct06205706","kind":"trial","name":"BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors","route":"/trials/nct06205706/","asOf":"2026-09-16","days":12},{"id":"nct05704049","kind":"trial","name":"A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory","route":"/trials/nct05704049/","asOf":"2026-09-16","days":12},{"id":"nct07122687","kind":"trial","name":"IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small","route":"/trials/nct07122687/","asOf":"2026-09-16","days":12},{"id":"nct05074810","kind":"trial","name":"Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients","route":"/trials/nct05074810/","asOf":"2026-09-16","days":12},{"id":"nct07070440","kind":"trial","name":"DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)","route":"/trials/nct07070440/","asOf":"2026-09-16","days":12},{"id":"nct05283720","kind":"trial","name":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neopl","route":"/trials/nct05283720/","asOf":"2026-09-16","days":12},{"id":"nct03075696","kind":"trial","name":"A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treat","route":"/trials/nct03075696/","asOf":"2026-09-16","days":12},{"id":"nct03671018","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma","route":"/trials/nct03671018/","asOf":"2026-09-16","days":12},{"id":"nct04661007","kind":"trial","name":"To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL","route":"/trials/nct04661007/","asOf":"2026-09-16","days":12},{"id":"nct04245839","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)","route":"/trials/nct04245839/","asOf":"2026-09-16","days":12},{"id":"nct07473167","kind":"trial","name":"Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients","route":"/trials/nct07473167/","asOf":"2026-09-16","days":12},{"id":"nct04502394","kind":"trial","name":"Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL","route":"/trials/nct04502394/","asOf":"2026-09-16","days":12},{"id":"nct05020457","kind":"trial","name":"SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.","route":"/trials/nct05020457/","asOf":"2026-09-16","days":12},{"id":"nct07087158","kind":"trial","name":"A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma","route":"/trials/nct07087158/","asOf":"2026-09-16","days":12},{"id":"nct07329322","kind":"trial","name":"Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Facto","route":"/trials/nct07329322/","asOf":"2026-09-16","days":12},{"id":"nct07102381","kind":"trial","name":"A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer","route":"/trials/nct07102381/","asOf":"2026-09-16","days":12},{"id":"nct05546866","kind":"trial","name":"Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm","route":"/trials/nct05546866/","asOf":"2026-09-16","days":12},{"id":"nct07227311","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Mult","route":"/trials/nct07227311/","asOf":"2026-09-16","days":12},{"id":"nct07206498","kind":"trial","name":"A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC","route":"/trials/nct07206498/","asOf":"2026-09-16","days":12},{"id":"nct05063565","kind":"trial","name":"TheraSphere With Durvalumab and Tremelimumab for HCC","route":"/trials/nct05063565/","asOf":"2026-09-16","days":12},{"id":"nct04370587","kind":"trial","name":"A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Adva","route":"/trials/nct04370587/","asOf":"2026-09-16","days":12},{"id":"nct05733598","kind":"trial","name":"Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC","route":"/trials/nct05733598/","asOf":"2026-09-16","days":12},{"id":"nct04024696","kind":"trial","name":"A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients","route":"/trials/nct04024696/","asOf":"2026-09-16","days":12},{"id":"nct04669171","kind":"trial","name":"A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma","route":"/trials/nct04669171/","asOf":"2026-09-16","days":12},{"id":"nct07459634","kind":"trial","name":"A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC","route":"/trials/nct07459634/","asOf":"2026-09-16","days":12},{"id":"nct07020221","kind":"trial","name":"A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors","route":"/trials/nct07020221/","asOf":"2026-09-16","days":12},{"id":"nct06841055","kind":"trial","name":"Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Che","route":"/trials/nct06841055/","asOf":"2026-09-16","days":12},{"id":"nct04730258","kind":"trial","name":"A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML","route":"/trials/nct04730258/","asOf":"2026-09-16","days":12},{"id":"nct06449209","kind":"trial","name":"Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy","route":"/trials/nct06449209/","asOf":"2026-09-16","days":12},{"id":"nct06155396","kind":"trial","name":"A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent o","route":"/trials/nct06155396/","asOf":"2026-09-16","days":12},{"id":"nct06137144","kind":"trial","name":"AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.","route":"/trials/nct06137144/","asOf":"2026-09-16","days":12},{"id":"nct04665206","kind":"trial","name":"Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors","route":"/trials/nct04665206/","asOf":"2026-09-16","days":12},{"id":"nct05335993","kind":"trial","name":"A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.","route":"/trials/nct05335993/","asOf":"2026-09-16","days":12},{"id":"nct03836352","kind":"trial","name":"Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recur","route":"/trials/nct03836352/","asOf":"2026-09-16","days":12},{"id":"nct07018050","kind":"trial","name":"Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma","route":"/trials/nct07018050/","asOf":"2026-09-16","days":12},{"id":"nct07259590","kind":"trial","name":"A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation","route":"/trials/nct07259590/","asOf":"2026-09-16","days":12},{"id":"nct01843374","kind":"trial","name":"Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma","route":"/trials/nct01843374/","asOf":"2026-09-16","days":12},{"id":"nct06277154","kind":"trial","name":"MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma","route":"/trials/nct06277154/","asOf":"2026-09-16","days":12},{"id":"nct05867251","kind":"trial","name":"Study of AVZO-021 in Patients With Advanced Solid Tumors","route":"/trials/nct05867251/","asOf":"2026-09-16","days":12},{"id":"nct05379595","kind":"trial","name":"A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer","route":"/trials/nct05379595/","asOf":"2026-09-16","days":12},{"id":"nct06933329","kind":"trial","name":"Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct06933329/","asOf":"2026-09-16","days":12},{"id":"nct07198633","kind":"trial","name":"A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer","route":"/trials/nct07198633/","asOf":"2026-09-16","days":12},{"id":"nct06362252","kind":"trial","name":"A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-","route":"/trials/nct06362252/","asOf":"2026-09-16","days":12},{"id":"nct07254585","kind":"trial","name":"SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma","route":"/trials/nct07254585/","asOf":"2026-09-16","days":12},{"id":"nct07407283","kind":"trial","name":"A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer","route":"/trials/nct07407283/","asOf":"2026-09-16","days":12},{"id":"nct05910827","kind":"trial","name":"A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers","route":"/trials/nct05910827/","asOf":"2026-09-16","days":12},{"id":"nct03888105","kind":"trial","name":"A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treat","route":"/trials/nct03888105/","asOf":"2026-09-16","days":12},{"id":"nct05288205","kind":"trial","name":"Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation","route":"/trials/nct05288205/","asOf":"2026-09-16","days":12},{"id":"nct07590531","kind":"trial","name":"AMT-116 in Combination With AK112 in Patients With Lung Cancer","route":"/trials/nct07590531/","asOf":"2026-09-16","days":12},{"id":"nct05642455","kind":"trial","name":"SPEARHEAD-3 Pediatric Study","route":"/trials/nct05642455/","asOf":"2026-09-16","days":12},{"id":"nct05955508","kind":"trial","name":"A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Deve","route":"/trials/nct05955508/","asOf":"2026-09-16","days":12},{"id":"nct06669247","kind":"trial","name":"A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Mult","route":"/trials/nct06669247/","asOf":"2026-09-16","days":12},{"id":"nct06992258","kind":"trial","name":"A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer","route":"/trials/nct06992258/","asOf":"2026-09-16","days":12},{"id":"nct05703971","kind":"trial","name":"Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients","route":"/trials/nct05703971/","asOf":"2026-09-16","days":12},{"id":"nct05128487","kind":"trial","name":"A Study of NDI 1150-101 in Patients With Solid Tumors","route":"/trials/nct05128487/","asOf":"2026-09-16","days":12},{"id":"nct06093841","kind":"trial","name":"Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL","route":"/trials/nct06093841/","asOf":"2026-09-16","days":12},{"id":"nct05217446","kind":"trial","name":"A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic","route":"/trials/nct05217446/","asOf":"2026-09-16","days":12},{"id":"nct07489066","kind":"trial","name":"Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC","route":"/trials/nct07489066/","asOf":"2026-09-16","days":12},{"id":"nct04478279","kind":"trial","name":"A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors","route":"/trials/nct04478279/","asOf":"2026-09-16","days":12},{"id":"nct07310173","kind":"trial","name":"Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma","route":"/trials/nct07310173/","asOf":"2026-09-16","days":12},{"id":"nct06632262","kind":"trial","name":"A Phase 2 Clinical Study of ABSK061 and ABSK043","route":"/trials/nct06632262/","asOf":"2026-09-16","days":12},{"id":"nct05841472","kind":"trial","name":"Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metas","route":"/trials/nct05841472/","asOf":"2026-09-16","days":12},{"id":"nct06921928","kind":"trial","name":"Study for AZD4360 in Participants With Advanced Solid Tumours","route":"/trials/nct06921928/","asOf":"2026-09-16","days":12},{"id":"nct06295432","kind":"trial","name":"A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)","route":"/trials/nct06295432/","asOf":"2026-09-16","days":12},{"id":"nct04268706","kind":"trial","name":"Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)","route":"/trials/nct04268706/","asOf":"2026-09-16","days":12},{"id":"nct07564401","kind":"trial","name":"A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy","route":"/trials/nct07564401/","asOf":"2026-09-16","days":12},{"id":"nct06106945","kind":"trial","name":"AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma","route":"/trials/nct06106945/","asOf":"2026-09-16","days":12},{"id":"nct07699328","kind":"trial","name":"A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer","route":"/trials/nct07699328/","asOf":"2026-09-16","days":12},{"id":"nct02899052","kind":"trial","name":"Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)","route":"/trials/nct02899052/","asOf":"2026-09-16","days":12},{"id":"nct03436485","kind":"trial","name":"Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer","route":"/trials/nct03436485/","asOf":"2026-09-16","days":12},{"id":"nct07164170","kind":"trial","name":"A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib","route":"/trials/nct07164170/","asOf":"2026-09-16","days":12},{"id":"nct05828511","kind":"trial","name":"A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnose","route":"/trials/nct05828511/","asOf":"2026-09-16","days":12},{"id":"nct07627711","kind":"trial","name":"Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma","route":"/trials/nct07627711/","asOf":"2026-09-16","days":12},{"id":"nct06190899","kind":"trial","name":"Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct06190899/","asOf":"2026-09-16","days":12},{"id":"nct03259867","kind":"trial","name":"Combination of TATE and PD-1 Inhibitor in Liver Cancer","route":"/trials/nct03259867/","asOf":"2026-09-16","days":12},{"id":"nct05195632","kind":"trial","name":"Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung","route":"/trials/nct05195632/","asOf":"2026-09-16","days":12},{"id":"nct05093907","kind":"trial","name":"A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer","route":"/trials/nct05093907/","asOf":"2026-09-16","days":12},{"id":"nct05655312","kind":"trial","name":"MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma","route":"/trials/nct05655312/","asOf":"2026-09-16","days":12},{"id":"nct04836507","kind":"trial","name":"Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients","route":"/trials/nct04836507/","asOf":"2026-09-16","days":12},{"id":"nct06843447","kind":"trial","name":"A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)","route":"/trials/nct06843447/","asOf":"2026-09-16","days":12},{"id":"nct05358249","kind":"trial","name":"Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","route":"/trials/nct05358249/","asOf":"2026-09-16","days":12},{"id":"nct04417621","kind":"trial","name":"Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma","route":"/trials/nct04417621/","asOf":"2026-09-16","days":12},{"id":"nct06040099","kind":"trial","name":"A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepat","route":"/trials/nct06040099/","asOf":"2026-09-16","days":12},{"id":"nct06564038","kind":"trial","name":"A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies","route":"/trials/nct06564038/","asOf":"2026-09-16","days":12},{"id":"nct04675333","kind":"trial","name":"Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)","route":"/trials/nct04675333/","asOf":"2026-09-16","days":12},{"id":"nct07115043","kind":"trial","name":"A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors","route":"/trials/nct07115043/","asOf":"2026-09-16","days":12},{"id":"nct05247684","kind":"trial","name":"AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC","route":"/trials/nct05247684/","asOf":"2026-09-16","days":12},{"id":"nct05907954","kind":"trial","name":"(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma","route":"/trials/nct05907954/","asOf":"2026-09-16","days":12},{"id":"nct07029737","kind":"trial","name":"A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain","route":"/trials/nct07029737/","asOf":"2026-09-16","days":12},{"id":"nct07174583","kind":"trial","name":"A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer","route":"/trials/nct07174583/","asOf":"2026-09-16","days":12},{"id":"nct07322094","kind":"trial","name":"CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ov","route":"/trials/nct07322094/","asOf":"2026-09-16","days":12},{"id":"nct03930953","kind":"trial","name":"A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory No","route":"/trials/nct03930953/","asOf":"2026-09-16","days":12},{"id":"nct05714839","kind":"trial","name":"A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatme","route":"/trials/nct05714839/","asOf":"2026-09-16","days":12},{"id":"nct07190300","kind":"trial","name":"TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in ","route":"/trials/nct07190300/","asOf":"2026-09-16","days":12},{"id":"nct04126200","kind":"trial","name":"Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple","route":"/trials/nct04126200/","asOf":"2026-09-16","days":12},{"id":"nct06493760","kind":"trial","name":"A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients","route":"/trials/nct06493760/","asOf":"2026-09-16","days":12},{"id":"nct06413680","kind":"trial","name":"A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Hav","route":"/trials/nct06413680/","asOf":"2026-09-16","days":12},{"id":"nct04036682","kind":"trial","name":"A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer","route":"/trials/nct04036682/","asOf":"2026-09-16","days":12},{"id":"nct07553988","kind":"trial","name":"A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer","route":"/trials/nct07553988/","asOf":"2026-09-16","days":12},{"id":"nct05438420","kind":"trial","name":"Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors","route":"/trials/nct05438420/","asOf":"2026-09-16","days":12},{"id":"nct07227597","kind":"trial","name":"A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)","route":"/trials/nct07227597/","asOf":"2026-09-16","days":12},{"id":"nct06589830","kind":"trial","name":"TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer","route":"/trials/nct06589830/","asOf":"2026-09-16","days":12},{"id":"nct06758557","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor","route":"/trials/nct06758557/","asOf":"2026-09-16","days":12},{"id":"nct05824975","kind":"trial","name":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizu","route":"/trials/nct05824975/","asOf":"2026-09-16","days":12},{"id":"nct06005493","kind":"trial","name":"Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors","route":"/trials/nct06005493/","asOf":"2026-09-16","days":12},{"id":"nct06769698","kind":"trial","name":"A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous ","route":"/trials/nct06769698/","asOf":"2026-09-16","days":12},{"id":"nct07500220","kind":"trial","name":"Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC","route":"/trials/nct07500220/","asOf":"2026-09-16","days":12},{"id":"nct06895031","kind":"trial","name":"Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","route":"/trials/nct06895031/","asOf":"2026-09-16","days":12},{"id":"nct04110301","kind":"trial","name":"MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)","route":"/trials/nct04110301/","asOf":"2026-09-16","days":12},{"id":"nct07455851","kind":"trial","name":"A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct07455851/","asOf":"2026-09-16","days":12},{"id":"nct06894511","kind":"trial","name":"An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC","route":"/trials/nct06894511/","asOf":"2026-09-16","days":12},{"id":"nct05294731","kind":"trial","name":"Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader","route":"/trials/nct05294731/","asOf":"2026-09-16","days":12},{"id":"nct07681596","kind":"trial","name":"A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07681596/","asOf":"2026-09-16","days":12},{"id":"nct06047379","kind":"trial","name":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","route":"/trials/nct06047379/","asOf":"2026-09-16","days":12},{"id":"nct04495296","kind":"trial","name":"A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors","route":"/trials/nct04495296/","asOf":"2026-09-16","days":12},{"id":"nct05186974","kind":"trial","name":"Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)","route":"/trials/nct05186974/","asOf":"2026-09-16","days":12},{"id":"nct07669779","kind":"trial","name":"A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer","route":"/trials/nct07669779/","asOf":"2026-09-16","days":12},{"id":"nct07038096","kind":"trial","name":"ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma","route":"/trials/nct07038096/","asOf":"2026-09-16","days":12},{"id":"nct05044897","kind":"trial","name":"A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC","route":"/trials/nct05044897/","asOf":"2026-09-16","days":12},{"id":"nct06558227","kind":"trial","name":"Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma","route":"/trials/nct06558227/","asOf":"2026-09-16","days":12},{"id":"nct04104776","kind":"trial","name":"A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas","route":"/trials/nct04104776/","asOf":"2026-09-16","days":12},{"id":"nct05592626","kind":"trial","name":"A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors","route":"/trials/nct05592626/","asOf":"2026-09-16","days":12},{"id":"nct05403385","kind":"trial","name":"Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer","route":"/trials/nct05403385/","asOf":"2026-09-16","days":12},{"id":"nct07109726","kind":"trial","name":"A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations","route":"/trials/nct07109726/","asOf":"2026-09-16","days":12},{"id":"nct05903833","kind":"trial","name":"Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surge","route":"/trials/nct05903833/","asOf":"2026-09-16","days":12},{"id":"nct07406633","kind":"trial","name":"KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)","route":"/trials/nct07406633/","asOf":"2026-09-16","days":12},{"id":"nct06479356","kind":"trial","name":"CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma","route":"/trials/nct06479356/","asOf":"2026-09-16","days":12},{"id":"nct04919811","kind":"trial","name":"Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC","route":"/trials/nct04919811/","asOf":"2026-09-16","days":12},{"id":"nct05489211","kind":"trial","name":"Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)","route":"/trials/nct05489211/","asOf":"2026-09-16","days":12},{"id":"nct06787612","kind":"trial","name":"Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer","route":"/trials/nct06787612/","asOf":"2026-09-16","days":12},{"id":"nct04198766","kind":"trial","name":"Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalen","route":"/trials/nct04198766/","asOf":"2026-09-16","days":12},{"id":"nct06530251","kind":"trial","name":"A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)","route":"/trials/nct06530251/","asOf":"2026-09-16","days":12},{"id":"nct06007729","kind":"trial","name":"ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors","route":"/trials/nct06007729/","asOf":"2026-09-16","days":12},{"id":"nct05276726","kind":"trial","name":"A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1","route":"/trials/nct05276726/","asOf":"2026-09-16","days":12},{"id":"nct04977453","kind":"trial","name":"GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors","route":"/trials/nct04977453/","asOf":"2026-09-16","days":12},{"id":"nct06702995","kind":"trial","name":"Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct06702995/","asOf":"2026-09-16","days":12},{"id":"nct03944772","kind":"trial","name":"Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)","route":"/trials/nct03944772/","asOf":"2026-09-16","days":12},{"id":"nct03476681","kind":"trial","name":"Study of NEO-201 in Solid Tumors Expansion Cohorts","route":"/trials/nct03476681/","asOf":"2026-09-16","days":12},{"id":"nct05280314","kind":"trial","name":"Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors","route":"/trials/nct05280314/","asOf":"2026-09-16","days":12},{"id":"nct03175224","kind":"trial","name":"APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors","route":"/trials/nct03175224/","asOf":"2026-09-16","days":12},{"id":"nct03731260","kind":"trial","name":"(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo ","route":"/trials/nct03731260/","asOf":"2026-09-16","days":12},{"id":"nct05297890","kind":"trial","name":"A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer","route":"/trials/nct05297890/","asOf":"2026-09-16","days":12},{"id":"nct05257590","kind":"trial","name":"CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma","route":"/trials/nct05257590/","asOf":"2026-09-16","days":12},{"id":"nct06745323","kind":"trial","name":"A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC","route":"/trials/nct06745323/","asOf":"2026-09-16","days":12},{"id":"nct05309421","kind":"trial","name":"A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma","route":"/trials/nct05309421/","asOf":"2026-09-16","days":12},{"id":"nct06428409","kind":"trial","name":"A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)","route":"/trials/nct06428409/","asOf":"2026-09-16","days":12},{"id":"nct07627698","kind":"trial","name":"Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma","route":"/trials/nct07627698/","asOf":"2026-09-16","days":12},{"id":"nct04931342","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","route":"/trials/nct04931342/","asOf":"2026-09-16","days":12},{"id":"nct06395103","kind":"trial","name":"Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)","route":"/trials/nct06395103/","asOf":"2026-09-16","days":12},{"id":"nct07223047","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advance","route":"/trials/nct07223047/","asOf":"2026-09-16","days":12},{"id":"nct04973605","kind":"trial","name":"A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Darat","route":"/trials/nct04973605/","asOf":"2026-09-16","days":12},{"id":"nct06004661","kind":"trial","name":"Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function","route":"/trials/nct06004661/","asOf":"2026-09-16","days":12},{"id":"nct06695845","kind":"trial","name":"A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors","route":"/trials/nct06695845/","asOf":"2026-09-16","days":12},{"id":"nct05142696","kind":"trial","name":"A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab","route":"/trials/nct05142696/","asOf":"2026-09-16","days":12},{"id":"nct06710132","kind":"trial","name":"Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)","route":"/trials/nct06710132/","asOf":"2026-09-16","days":12},{"id":"nct06623136","kind":"trial","name":"A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer","route":"/trials/nct06623136/","asOf":"2026-09-16","days":12},{"id":"nct05742607","kind":"trial","name":"IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)","route":"/trials/nct05742607/","asOf":"2026-09-16","days":12},{"id":"nct07641036","kind":"trial","name":"Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer","route":"/trials/nct07641036/","asOf":"2026-09-16","days":12},{"id":"nct06787664","kind":"trial","name":"A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma","route":"/trials/nct06787664/","asOf":"2026-09-16","days":12},{"id":"nct05054439","kind":"trial","name":"A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC","route":"/trials/nct05054439/","asOf":"2026-09-16","days":12},{"id":"nct04524871","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Li","route":"/trials/nct04524871/","asOf":"2026-09-16","days":12},{"id":"nct07059845","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult","route":"/trials/nct07059845/","asOf":"2026-09-16","days":12},{"id":"nct06564272","kind":"trial","name":"A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma","route":"/trials/nct06564272/","asOf":"2026-09-16","days":12},{"id":"nct07551349","kind":"trial","name":"Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma","route":"/trials/nct07551349/","asOf":"2026-09-16","days":12},{"id":"nct06574347","kind":"trial","name":"Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.","route":"/trials/nct06574347/","asOf":"2026-09-16","days":12},{"id":"nct07610798","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations","route":"/trials/nct07610798/","asOf":"2026-09-16","days":12},{"id":"nct05125016","kind":"trial","name":"A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer","route":"/trials/nct05125016/","asOf":"2026-09-16","days":12},{"id":"nct05684965","kind":"trial","name":"XTX301 in Patients With Advanced Solid Tumors","route":"/trials/nct05684965/","asOf":"2026-09-16","days":12},{"id":"nct07100730","kind":"trial","name":"Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma","route":"/trials/nct07100730/","asOf":"2026-09-16","days":12},{"id":"nct07321574","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors","route":"/trials/nct07321574/","asOf":"2026-09-16","days":12},{"id":"nct04567420","kind":"trial","name":"DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)","route":"/trials/nct04567420/","asOf":"2026-09-16","days":12},{"id":"nct04165590","kind":"trial","name":"Plasmodium Immunotherapy for Advanced Malignant Solid Tumors","route":"/trials/nct04165590/","asOf":"2026-09-16","days":12},{"id":"nct02908906","kind":"trial","name":"A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers","route":"/trials/nct02908906/","asOf":"2026-09-16","days":12},{"id":"nct04914598","kind":"trial","name":"A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions","route":"/trials/nct04914598/","asOf":"2026-09-16","days":12},{"id":"nct06973187","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","route":"/trials/nct06973187/","asOf":"2026-09-16","days":12},{"id":"nct06373406","kind":"trial","name":"A Study of MHB036C for Advanced Solid Tumor","route":"/trials/nct06373406/","asOf":"2026-09-16","days":12},{"id":"nct04416984","kind":"trial","name":"Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)","route":"/trials/nct04416984/","asOf":"2026-09-16","days":12},{"id":"nct07567521","kind":"trial","name":"A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC","route":"/trials/nct07567521/","asOf":"2026-09-16","days":12},{"id":"nct04130516","kind":"trial","name":"Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab","route":"/trials/nct04130516/","asOf":"2026-09-16","days":12},{"id":"nct06483334","kind":"trial","name":"A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)","route":"/trials/nct06483334/","asOf":"2026-09-16","days":12},{"id":"nct05994131","kind":"trial","name":"IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC","route":"/trials/nct05994131/","asOf":"2026-09-16","days":12},{"id":"nct07227870","kind":"trial","name":"L19IL2/TNF in Patients With Basal Cell Carcinoma","route":"/trials/nct07227870/","asOf":"2026-09-16","days":12},{"id":"nct05615623","kind":"trial","name":"Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG","route":"/trials/nct05615623/","asOf":"2026-09-16","days":12},{"id":"nct07002203","kind":"trial","name":"Personalized Neoantigen Peptide Vaccines for Solid Tumors","route":"/trials/nct07002203/","asOf":"2026-09-16","days":12},{"id":"nct06595186","kind":"trial","name":"JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)","route":"/trials/nct06595186/","asOf":"2026-09-16","days":12},{"id":"nct06922383","kind":"trial","name":"A Clinical Study of Arfolitixorin in Patients With mCRC","route":"/trials/nct06922383/","asOf":"2026-09-16","days":12},{"id":"nct06650566","kind":"trial","name":"Study of LM-299 in Subjects Advanced Malignant Tumors","route":"/trials/nct06650566/","asOf":"2026-09-16","days":12},{"id":"nct06081959","kind":"trial","name":"Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer","route":"/trials/nct06081959/","asOf":"2026-09-16","days":12},{"id":"nct07326488","kind":"trial","name":"A Study of MHB009C in Patients With Advanced Solid Tumors","route":"/trials/nct07326488/","asOf":"2026-09-16","days":12},{"id":"nct07589569","kind":"trial","name":"An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer","route":"/trials/nct07589569/","asOf":"2026-09-16","days":12},{"id":"nct05120596","kind":"trial","name":"First in Human Study of T3P-Y058-739 (T3P)","route":"/trials/nct05120596/","asOf":"2026-09-16","days":12},{"id":"nct06386146","kind":"trial","name":"JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation","route":"/trials/nct06386146/","asOf":"2026-09-16","days":12},{"id":"nct05192486","kind":"trial","name":"A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)","route":"/trials/nct05192486/","asOf":"2026-09-16","days":12},{"id":"nct07459998","kind":"trial","name":"SKB103 for Injection in Advanced Solid Tumors","route":"/trials/nct07459998/","asOf":"2026-09-16","days":12},{"id":"nct04956640","kind":"trial","name":"Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)","route":"/trials/nct04956640/","asOf":"2026-09-16","days":12},{"id":"nct06043817","kind":"trial","name":"First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations","route":"/trials/nct06043817/","asOf":"2026-09-16","days":12},{"id":"nct07589517","kind":"trial","name":"Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer","route":"/trials/nct07589517/","asOf":"2026-09-16","days":12},{"id":"nct04077099","kind":"trial","name":"A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer","route":"/trials/nct04077099/","asOf":"2026-09-16","days":12},{"id":"nct03866525","kind":"trial","name":"OH2 Oncolytic Viral Therapy in Solid Tumors","route":"/trials/nct03866525/","asOf":"2026-09-16","days":12},{"id":"nct07441174","kind":"trial","name":"IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct07441174/","asOf":"2026-09-16","days":12},{"id":"nct06500676","kind":"trial","name":"A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations","route":"/trials/nct06500676/","asOf":"2026-09-16","days":12},{"id":"nct06581432","kind":"trial","name":"Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations","route":"/trials/nct06581432/","asOf":"2026-09-16","days":12},{"id":"nct03878849","kind":"trial","name":"Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer","route":"/trials/nct03878849/","asOf":"2026-09-16","days":12},{"id":"nct06393374","kind":"trial","name":"Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)","route":"/trials/nct06393374/","asOf":"2026-09-16","days":12},{"id":"nct07486817","kind":"trial","name":"Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab","route":"/trials/nct07486817/","asOf":"2026-09-16","days":12},{"id":"nct03301168","kind":"trial","name":"Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant","route":"/trials/nct03301168/","asOf":"2026-09-16","days":12},{"id":"nct07158918","kind":"trial","name":"ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors","route":"/trials/nct07158918/","asOf":"2026-09-16","days":12},{"id":"nct06112704","kind":"trial","name":"HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors","route":"/trials/nct06112704/","asOf":"2026-09-16","days":12},{"id":"nct03769506","kind":"trial","name":"ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy","route":"/trials/nct03769506/","asOf":"2026-09-16","days":12},{"id":"nct06496971","kind":"trial","name":"A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients","route":"/trials/nct06496971/","asOf":"2026-09-16","days":12},{"id":"nct05466799","kind":"trial","name":"FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma","route":"/trials/nct05466799/","asOf":"2026-09-16","days":12},{"id":"nct05235516","kind":"trial","name":"A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer","route":"/trials/nct05235516/","asOf":"2026-09-16","days":12},{"id":"nct05667506","kind":"trial","name":"A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)","route":"/trials/nct05667506/","asOf":"2026-09-16","days":12},{"id":"nct06750185","kind":"trial","name":"Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors","route":"/trials/nct06750185/","asOf":"2026-09-16","days":12},{"id":"nct06985147","kind":"trial","name":"A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)","route":"/trials/nct06985147/","asOf":"2026-09-16","days":12},{"id":"nct05565378","kind":"trial","name":"A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer","route":"/trials/nct05565378/","asOf":"2026-09-16","days":12},{"id":"nct06818643","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)","route":"/trials/nct06818643/","asOf":"2026-09-16","days":12},{"id":"nct02174549","kind":"trial","name":"Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer","route":"/trials/nct02174549/","asOf":"2026-09-16","days":12},{"id":"nct02704858","kind":"trial","name":"Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma","route":"/trials/nct02704858/","asOf":"2026-09-16","days":12},{"id":"nct07070349","kind":"trial","name":"A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors","route":"/trials/nct07070349/","asOf":"2026-09-16","days":12},{"id":"nct04464226","kind":"trial","name":"Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer","route":"/trials/nct04464226/","asOf":"2026-09-16","days":12},{"id":"nct06640049","kind":"trial","name":"A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China","route":"/trials/nct06640049/","asOf":"2026-09-16","days":12},{"id":"nct05609578","kind":"trial","name":"Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation","route":"/trials/nct05609578/","asOf":"2026-09-16","days":12},{"id":"nct05170958","kind":"trial","name":"A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors","route":"/trials/nct05170958/","asOf":"2026-09-16","days":12},{"id":"nct06382168","kind":"trial","name":"DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia","route":"/trials/nct06382168/","asOf":"2026-09-16","days":12},{"id":"nct06542250","kind":"trial","name":"A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.","route":"/trials/nct06542250/","asOf":"2026-09-16","days":12},{"id":"nct04752813","kind":"trial","name":"A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)","route":"/trials/nct04752813/","asOf":"2026-09-16","days":12},{"id":"nct05673057","kind":"trial","name":"Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome","route":"/trials/nct05673057/","asOf":"2026-09-16","days":12},{"id":"nct07700667","kind":"trial","name":"SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma","route":"/trials/nct07700667/","asOf":"2026-09-16","days":12},{"id":"nct06062420","kind":"trial","name":"A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202","route":"/trials/nct06062420/","asOf":"2026-09-16","days":12},{"id":"nct06123754","kind":"trial","name":"Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC","route":"/trials/nct06123754/","asOf":"2026-09-16","days":12},{"id":"nct06222879","kind":"trial","name":"Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer","route":"/trials/nct06222879/","asOf":"2026-09-16","days":12},{"id":"nct04853342","kind":"trial","name":"To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy","route":"/trials/nct04853342/","asOf":"2026-09-16","days":12},{"id":"nct05229497","kind":"trial","name":"A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors","route":"/trials/nct05229497/","asOf":"2026-09-16","days":12},{"id":"nct05427383","kind":"trial","name":"KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy","route":"/trials/nct05427383/","asOf":"2026-09-16","days":12},{"id":"nct05501886","kind":"trial","name":"Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)","route":"/trials/nct05501886/","asOf":"2026-09-16","days":12},{"id":"nct07701486","kind":"trial","name":"A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer","route":"/trials/nct07701486/","asOf":"2026-09-16","days":12},{"id":"nct06623422","kind":"trial","name":"A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)","route":"/trials/nct06623422/","asOf":"2026-09-16","days":12},{"id":"nct04145622","kind":"trial","name":"Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors","route":"/trials/nct04145622/","asOf":"2026-09-16","days":12},{"id":"nct07815665","kind":"trial","name":"A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma","route":"/trials/nct07815665/","asOf":"2026-09-16","days":12},{"id":"nct07196644","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan","route":"/trials/nct07196644/","asOf":"2026-09-16","days":12},{"id":"nct06460298","kind":"trial","name":"ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer","route":"/trials/nct06460298/","asOf":"2026-09-16","days":12},{"id":"nct07811037","kind":"trial","name":"A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, Immunogenicity, and Preliminary Efficacy of SGT003 in Patients With Advanced Solid Tumors","route":"/trials/nct07811037/","asOf":"2026-09-16","days":12},{"id":"nct07007312","kind":"trial","name":"Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML","route":"/trials/nct07007312/","asOf":"2026-09-16","days":12},{"id":"nct04807257","kind":"trial","name":"Auger Molecular Therapy (AMT) for Malignant Cutaneous Lesions Treatment","route":"/trials/nct04807257/","asOf":"2026-09-16","days":12},{"id":"nct06948981","kind":"trial","name":"GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies","route":"/trials/nct06948981/","asOf":"2026-09-16","days":12},{"id":"nct05898399","kind":"trial","name":"Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)","route":"/trials/nct05898399/","asOf":"2026-09-16","days":12},{"id":"nct05498428","kind":"trial","name":"A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer","route":"/trials/nct05498428/","asOf":"2026-09-16","days":12},{"id":"nct05304481","kind":"trial","name":"Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma","route":"/trials/nct05304481/","asOf":"2026-09-16","days":12},{"id":"nct06459973","kind":"trial","name":"A Clinical Study of YL205 in Patients With Advanced Solid Tumors","route":"/trials/nct06459973/","asOf":"2026-09-16","days":12},{"id":"nct07678957","kind":"trial","name":"A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer","route":"/trials/nct07678957/","asOf":"2026-09-16","days":12},{"id":"nct06943872","kind":"trial","name":"A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)","route":"/trials/nct06943872/","asOf":"2026-09-16","days":12},{"id":"nct06293651","kind":"trial","name":"Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct06293651/","asOf":"2026-09-16","days":12},{"id":"nct06267729","kind":"trial","name":"Study of AZD0754 in Participants With Metastatic Prostate Cancer","route":"/trials/nct06267729/","asOf":"2026-09-16","days":12},{"id":"nct04305795","kind":"trial","name":"An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors","route":"/trials/nct04305795/","asOf":"2026-09-16","days":12},{"id":"nct05768139","kind":"trial","name":"First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors","route":"/trials/nct05768139/","asOf":"2026-09-16","days":12},{"id":"nct05118789","kind":"trial","name":"A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)","route":"/trials/nct05118789/","asOf":"2026-09-16","days":12},{"id":"nct07209813","kind":"trial","name":"GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma","route":"/trials/nct07209813/","asOf":"2026-09-16","days":12},{"id":"nct07328217","kind":"trial","name":"A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors","route":"/trials/nct07328217/","asOf":"2026-09-16","days":12},{"id":"nct06131450","kind":"trial","name":"A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies","route":"/trials/nct06131450/","asOf":"2026-09-16","days":12},{"id":"nct04094610","kind":"trial","name":"A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations","route":"/trials/nct04094610/","asOf":"2026-09-16","days":12},{"id":"nct07026279","kind":"trial","name":"A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer","route":"/trials/nct07026279/","asOf":"2026-09-16","days":12},{"id":"nct07069062","kind":"trial","name":"A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors","route":"/trials/nct07069062/","asOf":"2026-09-16","days":12},{"id":"nct05688280","kind":"trial","name":"Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS","route":"/trials/nct05688280/","asOf":"2026-09-16","days":12},{"id":"nct07569042","kind":"trial","name":"A Rollover Study of NBM-BMX in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma","route":"/trials/nct07569042/","asOf":"2026-09-16","days":12},{"id":"nct04752722","kind":"trial","name":"LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve","route":"/trials/nct04752722/","asOf":"2026-09-16","days":12},{"id":"nct06361888","kind":"trial","name":"A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer","route":"/trials/nct06361888/","asOf":"2026-09-16","days":12},{"id":"nct06365840","kind":"trial","name":"A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor","route":"/trials/nct06365840/","asOf":"2026-09-16","days":12},{"id":"nct03945162","kind":"trial","name":"Intravesical Photodynamic Therapy (\"PDT\") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Patients","route":"/trials/nct03945162/","asOf":"2026-09-16","days":12},{"id":"nct06265727","kind":"trial","name":"A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors","route":"/trials/nct06265727/","asOf":"2026-09-16","days":12},{"id":"nct07192120","kind":"trial","name":"A Study of MHB048C in Patients With Advanced Solid Tumors","route":"/trials/nct07192120/","asOf":"2026-09-16","days":12},{"id":"nct07501559","kind":"trial","name":"A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)","route":"/trials/nct07501559/","asOf":"2026-09-16","days":12},{"id":"nct07450859","kind":"trial","name":"A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","route":"/trials/nct07450859/","asOf":"2026-09-16","days":12},{"id":"nct04233346","kind":"trial","name":"The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation","route":"/trials/nct04233346/","asOf":"2026-09-16","days":12},{"id":"nct05802225","kind":"trial","name":"Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer","route":"/trials/nct05802225/","asOf":"2026-09-16","days":12},{"id":"nct01761968","kind":"trial","name":"Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms","route":"/trials/nct01761968/","asOf":"2026-09-16","days":12},{"id":"nct04008797","kind":"trial","name":"A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor","route":"/trials/nct04008797/","asOf":"2026-09-16","days":12},{"id":"nct05636618","kind":"trial","name":"Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors","route":"/trials/nct05636618/","asOf":"2026-09-16","days":12},{"id":"nct07216560","kind":"trial","name":"First-in-human Study of 7MW4911 in GI Cancer","route":"/trials/nct07216560/","asOf":"2026-09-16","days":12},{"id":"nct07612280","kind":"trial","name":"Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis","route":"/trials/nct07612280/","asOf":"2026-09-16","days":12},{"id":"nct05532696","kind":"trial","name":"Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients","route":"/trials/nct05532696/","asOf":"2026-09-16","days":12},{"id":"nct06864169","kind":"trial","name":"A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)","route":"/trials/nct06864169/","asOf":"2026-09-16","days":12},{"id":"nct05300269","kind":"trial","name":"SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer","route":"/trials/nct05300269/","asOf":"2026-09-16","days":12},{"id":"nct03725059","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)","route":"/trials/nct03725059/","asOf":"2026-09-16","days":12},{"id":"nct04521231","kind":"trial","name":"A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL","route":"/trials/nct04521231/","asOf":"2026-09-16","days":12},{"id":"nct06125522","kind":"trial","name":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)","route":"/trials/nct06125522/","asOf":"2026-09-16","days":12},{"id":"nct04562389","kind":"trial","name":"Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis","route":"/trials/nct04562389/","asOf":"2026-09-16","days":12},{"id":"nct05909436","kind":"trial","name":"Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors","route":"/trials/nct05909436/","asOf":"2026-09-16","days":12},{"id":"nct06795412","kind":"trial","name":"Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors","route":"/trials/nct06795412/","asOf":"2026-09-16","days":12},{"id":"nct07213830","kind":"trial","name":"A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies","route":"/trials/nct07213830/","asOf":"2026-09-16","days":12},{"id":"nct06994507","kind":"trial","name":"GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer","route":"/trials/nct06994507/","asOf":"2026-09-16","days":12},{"id":"nct07181499","kind":"trial","name":"Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI","route":"/trials/nct07181499/","asOf":"2026-09-16","days":12},{"id":"nct03934567","kind":"trial","name":"A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma","route":"/trials/nct03934567/","asOf":"2026-09-16","days":12},{"id":"nct05458674","kind":"trial","name":"Tucatinib+Trastuzumab+Eribulin in HER2+ MBC","route":"/trials/nct05458674/","asOf":"2026-09-16","days":12},{"id":"nct06015048","kind":"trial","name":"A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.","route":"/trials/nct06015048/","asOf":"2026-09-16","days":12},{"id":"nct07211958","kind":"trial","name":"Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation","route":"/trials/nct07211958/","asOf":"2026-09-16","days":12},{"id":"nct07143604","kind":"trial","name":"A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2","route":"/trials/nct07143604/","asOf":"2026-09-16","days":12},{"id":"nct05435248","kind":"trial","name":"Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)","route":"/trials/nct05435248/","asOf":"2026-09-16","days":12},{"id":"nct05914116","kind":"trial","name":"A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors","route":"/trials/nct05914116/","asOf":"2026-09-16","days":12},{"id":"nct07554521","kind":"trial","name":"A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States","route":"/trials/nct07554521/","asOf":"2026-09-16","days":12},{"id":"nct04685226","kind":"trial","name":"A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors","route":"/trials/nct04685226/","asOf":"2026-09-16","days":12},{"id":"nct06244771","kind":"trial","name":"A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors","route":"/trials/nct06244771/","asOf":"2026-09-16","days":12},{"id":"nct06525298","kind":"trial","name":"EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors","route":"/trials/nct06525298/","asOf":"2026-09-16","days":12},{"id":"nct04616209","kind":"trial","name":"Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients","route":"/trials/nct04616209/","asOf":"2026-09-16","days":12},{"id":"nct03155191","kind":"trial","name":"Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia","route":"/trials/nct03155191/","asOf":"2026-09-16","days":12},{"id":"nct07362940","kind":"trial","name":"A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib","route":"/trials/nct07362940/","asOf":"2026-09-16","days":12},{"id":"nct07612891","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor","route":"/trials/nct07612891/","asOf":"2026-09-16","days":12},{"id":"nct07354074","kind":"trial","name":"Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP","route":"/trials/nct07354074/","asOf":"2026-09-16","days":12},{"id":"nct05980481","kind":"trial","name":"A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer","route":"/trials/nct05980481/","asOf":"2026-09-16","days":12},{"id":"nct06731478","kind":"trial","name":"Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer","route":"/trials/nct06731478/","asOf":"2026-09-16","days":12},{"id":"nct06246110","kind":"trial","name":"A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC","route":"/trials/nct06246110/","asOf":"2026-09-16","days":12},{"id":"nct07100106","kind":"trial","name":"A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer","route":"/trials/nct07100106/","asOf":"2026-09-16","days":12},{"id":"nct06155084","kind":"trial","name":"A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients","route":"/trials/nct06155084/","asOf":"2026-09-16","days":12},{"id":"nct06667076","kind":"trial","name":"A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct06667076/","asOf":"2026-09-16","days":12},{"id":"nct05491525","kind":"trial","name":"Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC","route":"/trials/nct05491525/","asOf":"2026-09-16","days":12},{"id":"nct06703255","kind":"trial","name":"A Phase 2 Study of HX301 in Patients with High-grade Giloma","route":"/trials/nct06703255/","asOf":"2026-09-16","days":12},{"id":"nct07232849","kind":"trial","name":"A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct07232849/","asOf":"2026-09-16","days":12},{"id":"nct06256588","kind":"trial","name":"A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma","route":"/trials/nct06256588/","asOf":"2026-09-16","days":12},{"id":"nct06631092","kind":"trial","name":"Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer","route":"/trials/nct06631092/","asOf":"2026-09-16","days":12},{"id":"nct04349436","kind":"trial","name":"Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies","route":"/trials/nct04349436/","asOf":"2026-09-16","days":12},{"id":"nct07669467","kind":"trial","name":"Nuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast Cancer","route":"/trials/nct07669467/","asOf":"2026-09-16","days":12},{"id":"nct07692204","kind":"trial","name":"A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer","route":"/trials/nct07692204/","asOf":"2026-09-16","days":12},{"id":"nct06668103","kind":"trial","name":"A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib","route":"/trials/nct06668103/","asOf":"2026-09-16","days":12},{"id":"nct06839066","kind":"trial","name":"A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy","route":"/trials/nct06839066/","asOf":"2026-09-16","days":12},{"id":"nct05888831","kind":"trial","name":"A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors","route":"/trials/nct05888831/","asOf":"2026-09-16","days":12},{"id":"nct07523529","kind":"trial","name":"Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors","route":"/trials/nct07523529/","asOf":"2026-09-16","days":12},{"id":"nct07765446","kind":"trial","name":"Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel","route":"/trials/nct07765446/","asOf":"2026-09-16","days":12},{"id":"nct06206837","kind":"trial","name":"A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.","route":"/trials/nct06206837/","asOf":"2026-09-16","days":12},{"id":"nct06979596","kind":"trial","name":"A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)","route":"/trials/nct06979596/","asOf":"2026-09-16","days":12},{"id":"nct07197827","kind":"trial","name":"A Study of YL242 in Subjects With Advanced Solid Tumors","route":"/trials/nct07197827/","asOf":"2026-09-16","days":12},{"id":"nct05991583","kind":"trial","name":"A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors","route":"/trials/nct05991583/","asOf":"2026-09-16","days":12},{"id":"nct06179524","kind":"trial","name":"CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL","route":"/trials/nct06179524/","asOf":"2026-09-16","days":12},{"id":"nct06022861","kind":"trial","name":"A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma","route":"/trials/nct06022861/","asOf":"2026-09-16","days":12},{"id":"nct06223841","kind":"trial","name":"A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors","route":"/trials/nct06223841/","asOf":"2026-09-16","days":12},{"id":"nct05287945","kind":"trial","name":"Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma","route":"/trials/nct05287945/","asOf":"2026-09-16","days":12},{"id":"nct05774951","kind":"trial","name":"A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy","route":"/trials/nct05774951/","asOf":"2026-09-16","days":12},{"id":"nct04589845","kind":"trial","name":"Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study","route":"/trials/nct04589845/","asOf":"2026-09-16","days":12},{"id":"nct04906395","kind":"trial","name":"Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer","route":"/trials/nct04906395/","asOf":"2026-09-16","days":12},{"id":"nct04588922","kind":"trial","name":"Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML","route":"/trials/nct04588922/","asOf":"2026-09-16","days":12},{"id":"nct06453902","kind":"trial","name":"TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients","route":"/trials/nct06453902/","asOf":"2026-09-16","days":12},{"id":"nct03379428","kind":"trial","name":"Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer","route":"/trials/nct03379428/","asOf":"2026-09-16","days":12},{"id":"nct07382531","kind":"trial","name":"OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors","route":"/trials/nct07382531/","asOf":"2026-09-16","days":12},{"id":"nct06465433","kind":"trial","name":"Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab","route":"/trials/nct06465433/","asOf":"2026-09-16","days":12},{"id":"nct05875168","kind":"trial","name":"First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors","route":"/trials/nct05875168/","asOf":"2026-09-16","days":12},{"id":"nct05302284","kind":"trial","name":"A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma","route":"/trials/nct05302284/","asOf":"2026-09-16","days":12},{"id":"nct07114315","kind":"trial","name":"A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer","route":"/trials/nct07114315/","asOf":"2026-09-16","days":12},{"id":"nct06567015","kind":"trial","name":"Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs","route":"/trials/nct06567015/","asOf":"2026-09-16","days":12},{"id":"nct06908304","kind":"trial","name":"A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC","route":"/trials/nct06908304/","asOf":"2026-09-16","days":12},{"id":"nct07129252","kind":"trial","name":"A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors","route":"/trials/nct07129252/","asOf":"2026-09-16","days":12},{"id":"nct04485949","kind":"trial","name":"A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma","route":"/trials/nct04485949/","asOf":"2026-09-16","days":12},{"id":"nct06245915","kind":"trial","name":"AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)","route":"/trials/nct06245915/","asOf":"2026-09-16","days":12},{"id":"nct06413706","kind":"trial","name":"A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy","route":"/trials/nct06413706/","asOf":"2026-09-16","days":12},{"id":"nct07720284","kind":"trial","name":"An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC","route":"/trials/nct07720284/","asOf":"2026-09-16","days":12},{"id":"nct06465563","kind":"trial","name":"SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer","route":"/trials/nct06465563/","asOf":"2026-09-16","days":12},{"id":"nct07108309","kind":"trial","name":"BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer","route":"/trials/nct07108309/","asOf":"2026-09-16","days":12},{"id":"nct04270409","kind":"trial","name":"Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma","route":"/trials/nct04270409/","asOf":"2026-09-16","days":12},{"id":"nct06609005","kind":"trial","name":"A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer","route":"/trials/nct06609005/","asOf":"2026-09-16","days":12},{"id":"nct05773820","kind":"trial","name":"A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors","route":"/trials/nct05773820/","asOf":"2026-09-16","days":12},{"id":"nct06578624","kind":"trial","name":"Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct06578624/","asOf":"2026-09-16","days":12},{"id":"nct01744223","kind":"trial","name":"Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant","route":"/trials/nct01744223/","asOf":"2026-09-16","days":12},{"id":"nct07263594","kind":"trial","name":"A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors","route":"/trials/nct07263594/","asOf":"2026-09-16","days":12},{"id":"nct05363280","kind":"trial","name":"Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment","route":"/trials/nct05363280/","asOf":"2026-09-16","days":12},{"id":"nct06202261","kind":"trial","name":"A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer","route":"/trials/nct06202261/","asOf":"2026-09-16","days":12},{"id":"nct07497386","kind":"trial","name":"A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer","route":"/trials/nct07497386/","asOf":"2026-09-16","days":12},{"id":"nct07130383","kind":"trial","name":"A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors","route":"/trials/nct07130383/","asOf":"2026-09-16","days":12},{"id":"nct06065748","kind":"trial","name":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","route":"/trials/nct06065748/","asOf":"2026-09-16","days":12},{"id":"nct07213817","kind":"trial","name":"A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours","route":"/trials/nct07213817/","asOf":"2026-09-16","days":12},{"id":"nct04486833","kind":"trial","name":"Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib","route":"/trials/nct04486833/","asOf":"2026-09-16","days":12},{"id":"nct06383052","kind":"trial","name":"A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC","route":"/trials/nct06383052/","asOf":"2026-09-16","days":12},{"id":"nct07488676","kind":"trial","name":"A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors","route":"/trials/nct07488676/","asOf":"2026-09-16","days":12},{"id":"nct06904235","kind":"trial","name":"Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)","route":"/trials/nct06904235/","asOf":"2026-09-16","days":12},{"id":"nct07023731","kind":"trial","name":"A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation","route":"/trials/nct07023731/","asOf":"2026-09-16","days":12},{"id":"nct05765812","kind":"trial","name":"A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma","route":"/trials/nct05765812/","asOf":"2026-09-16","days":12},{"id":"nct05944978","kind":"trial","name":"A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies","route":"/trials/nct05944978/","asOf":"2026-09-16","days":12},{"id":"nct03257033","kind":"trial","name":"Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC","route":"/trials/nct03257033/","asOf":"2026-09-16","days":12},{"id":"nct03899155","kind":"trial","name":"Pan Tumor Rollover Study","route":"/trials/nct03899155/","asOf":"2026-09-16","days":12},{"id":"nct06725758","kind":"trial","name":"A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours","route":"/trials/nct06725758/","asOf":"2026-09-16","days":12},{"id":"nct05319314","kind":"trial","name":"LYL273 for Patients With Relapsed or Refractory mCRC","route":"/trials/nct05319314/","asOf":"2026-09-16","days":12},{"id":"nct02912949","kind":"trial","name":"A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)","route":"/trials/nct02912949/","asOf":"2026-09-16","days":12},{"id":"nct06474455","kind":"trial","name":"A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors","route":"/trials/nct06474455/","asOf":"2026-09-16","days":12},{"id":"nct07280832","kind":"trial","name":"Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors","route":"/trials/nct07280832/","asOf":"2026-09-16","days":12},{"id":"nct06665100","kind":"trial","name":"PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)","route":"/trials/nct06665100/","asOf":"2026-09-16","days":12},{"id":"nct06953999","kind":"trial","name":"A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer","route":"/trials/nct06953999/","asOf":"2026-09-16","days":12},{"id":"nct07276399","kind":"trial","name":"A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer","route":"/trials/nct07276399/","asOf":"2026-09-16","days":12},{"id":"nct07070232","kind":"trial","name":"A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors","route":"/trials/nct07070232/","asOf":"2026-09-16","days":12},{"id":"nct06187402","kind":"trial","name":"A Study of LM-24C5 For Advanced Solid Tumors","route":"/trials/nct06187402/","asOf":"2026-09-16","days":12},{"id":"nct03067051","kind":"trial","name":"Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System","route":"/trials/nct03067051/","asOf":"2026-09-16","days":12},{"id":"nct05947851","kind":"trial","name":"A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).","route":"/trials/nct05947851/","asOf":"2026-09-16","days":12},{"id":"nct05702229","kind":"trial","name":"Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","route":"/trials/nct05702229/","asOf":"2026-09-16","days":12},{"id":"nct06938867","kind":"trial","name":"Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant","route":"/trials/nct06938867/","asOf":"2026-09-16","days":12},{"id":"nct06469944","kind":"trial","name":"Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)","route":"/trials/nct06469944/","asOf":"2026-09-16","days":12},{"id":"nct05296798","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","route":"/trials/nct05296798/","asOf":"2026-09-16","days":12},{"id":"nct07455734","kind":"trial","name":"Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors","route":"/trials/nct07455734/","asOf":"2026-09-16","days":12},{"id":"nct07502287","kind":"trial","name":"Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma","route":"/trials/nct07502287/","asOf":"2026-09-16","days":12},{"id":"nct06986811","kind":"trial","name":"CEB-01 in Paediatrics With Locally Resectable Abdominal Tumours","route":"/trials/nct06986811/","asOf":"2026-09-16","days":12},{"id":"nct07648264","kind":"trial","name":"Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies","route":"/trials/nct07648264/","asOf":"2026-09-16","days":12},{"id":"nct06514534","kind":"trial","name":"Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.","route":"/trials/nct06514534/","asOf":"2026-09-16","days":12},{"id":"nct05849298","kind":"trial","name":"A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC","route":"/trials/nct05849298/","asOf":"2026-09-16","days":12},{"id":"nct06422936","kind":"trial","name":"Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC)","route":"/trials/nct06422936/","asOf":"2026-09-16","days":12},{"id":"nct06330064","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)","route":"/trials/nct06330064/","asOf":"2026-09-16","days":12},{"id":"nct06234098","kind":"trial","name":"Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors","route":"/trials/nct06234098/","asOf":"2026-09-16","days":12},{"id":"nct07374419","kind":"trial","name":"Atamparib in Patients With Advanced Solid Tumors","route":"/trials/nct07374419/","asOf":"2026-09-16","days":12},{"id":"nct07589530","kind":"trial","name":"Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors","route":"/trials/nct07589530/","asOf":"2026-09-16","days":12},{"id":"nct06727630","kind":"trial","name":"A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma","route":"/trials/nct06727630/","asOf":"2026-09-16","days":12},{"id":"nct07108270","kind":"trial","name":"A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)","route":"/trials/nct07108270/","asOf":"2026-09-16","days":12},{"id":"nct07405151","kind":"trial","name":"A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)","route":"/trials/nct07405151/","asOf":"2026-09-16","days":12},{"id":"nct07510802","kind":"trial","name":"Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC","route":"/trials/nct07510802/","asOf":"2026-09-16","days":12},{"id":"nct06010342","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients","route":"/trials/nct06010342/","asOf":"2026-09-16","days":12},{"id":"nct06155383","kind":"trial","name":"Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.","route":"/trials/nct06155383/","asOf":"2026-09-16","days":12},{"id":"nct05814354","kind":"trial","name":"SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial","route":"/trials/nct05814354/","asOf":"2026-09-16","days":12},{"id":"nct04271644","kind":"trial","name":"BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease","route":"/trials/nct04271644/","asOf":"2026-09-16","days":12},{"id":"nct06049290","kind":"trial","name":"A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma","route":"/trials/nct06049290/","asOf":"2026-09-16","days":12},{"id":"nct06035497","kind":"trial","name":"A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)","route":"/trials/nct06035497/","asOf":"2026-09-16","days":12},{"id":"nct06515990","kind":"trial","name":"A Study of DM005 in Patients With Advanced Solid Tumors","route":"/trials/nct06515990/","asOf":"2026-09-16","days":12},{"id":"nct06975410","kind":"trial","name":"Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors","route":"/trials/nct06975410/","asOf":"2026-09-16","days":12},{"id":"nct06567782","kind":"trial","name":"A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer","route":"/trials/nct06567782/","asOf":"2026-09-16","days":12},{"id":"nct05037279","kind":"trial","name":"Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)","route":"/trials/nct05037279/","asOf":"2026-09-16","days":12},{"id":"nct07314294","kind":"trial","name":"Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients","route":"/trials/nct07314294/","asOf":"2026-09-16","days":12},{"id":"nct07429266","kind":"trial","name":"INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)","route":"/trials/nct07429266/","asOf":"2026-09-16","days":12},{"id":"nct06634875","kind":"trial","name":"Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)","route":"/trials/nct06634875/","asOf":"2026-09-16","days":12},{"id":"nct07266428","kind":"trial","name":"A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors","route":"/trials/nct07266428/","asOf":"2026-09-16","days":12},{"id":"nct04183166","kind":"trial","name":"A Clinical Trial Evaluating TG4050 in Head and Neck Cancer","route":"/trials/nct04183166/","asOf":"2026-09-16","days":12},{"id":"nct06163430","kind":"trial","name":"A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)","route":"/trials/nct06163430/","asOf":"2026-09-16","days":12},{"id":"nct07439094","kind":"trial","name":"A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer","route":"/trials/nct07439094/","asOf":"2026-09-16","days":12},{"id":"nct06868849","kind":"trial","name":"A Study of JMT203 in Patients With Cancer Cachexia","route":"/trials/nct06868849/","asOf":"2026-09-16","days":12},{"id":"nct05546268","kind":"trial","name":"Study of Oral MRT-2359 in Selected Cancer Patients","route":"/trials/nct05546268/","asOf":"2026-09-16","days":12},{"id":"nct06776952","kind":"trial","name":"A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma","route":"/trials/nct06776952/","asOf":"2026-09-16","days":12},{"id":"nct06693375","kind":"trial","name":"To Evaluate Dose and Safety of NanoEcho Particle-1 Using NanoEcho Imaging Device Examinations of Rectal Lymph Nodes in Healthy Volunteers and Rectal Cancer Patients.","route":"/trials/nct06693375/","asOf":"2026-09-16","days":12},{"id":"nct05120271","kind":"trial","name":"BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors","route":"/trials/nct05120271/","asOf":"2026-09-16","days":12},{"id":"nct06590857","kind":"trial","name":"Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.","route":"/trials/nct06590857/","asOf":"2026-09-16","days":12},{"id":"nct06679036","kind":"trial","name":"A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients","route":"/trials/nct06679036/","asOf":"2026-09-16","days":12},{"id":"nct06581419","kind":"trial","name":"A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors","route":"/trials/nct06581419/","asOf":"2026-09-16","days":12},{"id":"nct05941507","kind":"trial","name":"A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors","route":"/trials/nct05941507/","asOf":"2026-09-16","days":12},{"id":"nct06533644","kind":"trial","name":"A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct06533644/","asOf":"2026-09-16","days":12},{"id":"nct06795022","kind":"trial","name":"First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours","route":"/trials/nct06795022/","asOf":"2026-09-16","days":12},{"id":"nct05481151","kind":"trial","name":"A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV","route":"/trials/nct05481151/","asOf":"2026-09-16","days":12},{"id":"nct04557059","kind":"trial","name":"A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer","route":"/trials/nct04557059/","asOf":"2026-09-16","days":12},{"id":"nct01594723","kind":"trial","name":"A Study of LY2784544 in Participants With Myeloproliferative Neoplasms","route":"/trials/nct01594723/","asOf":"2026-09-16","days":12},{"id":"nct07744256","kind":"trial","name":"Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)","route":"/trials/nct07744256/","asOf":"2026-09-16","days":12},{"id":"nct05334823","kind":"trial","name":"A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents","route":"/trials/nct05334823/","asOf":"2026-09-16","days":12},{"id":"nct06732531","kind":"trial","name":"Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer","route":"/trials/nct06732531/","asOf":"2026-09-16","days":12},{"id":"nct06042894","kind":"trial","name":"A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer","route":"/trials/nct06042894/","asOf":"2026-09-16","days":12},{"id":"nct07512583","kind":"trial","name":"Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors","route":"/trials/nct07512583/","asOf":"2026-09-16","days":12},{"id":"nct07232602","kind":"trial","name":"KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)","route":"/trials/nct07232602/","asOf":"2026-09-16","days":12},{"id":"nct03424005","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","route":"/trials/nct03424005/","asOf":"2026-09-16","days":12},{"id":"nct07415031","kind":"trial","name":"A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies","route":"/trials/nct07415031/","asOf":"2026-09-16","days":12},{"id":"nct02503423","kind":"trial","name":"Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas","route":"/trials/nct02503423/","asOf":"2026-09-16","days":12},{"id":"nct06554795","kind":"trial","name":"First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors","route":"/trials/nct06554795/","asOf":"2026-09-16","days":12},{"id":"nct05624554","kind":"trial","name":"A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)","route":"/trials/nct05624554/","asOf":"2026-09-16","days":12},{"id":"nct06901531","kind":"trial","name":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","route":"/trials/nct06901531/","asOf":"2026-09-16","days":12},{"id":"nct02966756","kind":"trial","name":"A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","route":"/trials/nct02966756/","asOf":"2026-09-16","days":12},{"id":"nct07030257","kind":"trial","name":"Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors","route":"/trials/nct07030257/","asOf":"2026-09-16","days":12},{"id":"nct07648030","kind":"trial","name":"A Study of Rusfertide in Japanese Adults With Polycythemia Vera","route":"/trials/nct07648030/","asOf":"2026-09-16","days":12},{"id":"nct06084936","kind":"trial","name":"A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma","route":"/trials/nct06084936/","asOf":"2026-09-16","days":12},{"id":"nct07172802","kind":"trial","name":"A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors","route":"/trials/nct07172802/","asOf":"2026-09-16","days":12},{"id":"nct06209580","kind":"trial","name":"AMT-253 in Patients With Advanced Solid Tumours","route":"/trials/nct06209580/","asOf":"2026-09-16","days":12},{"id":"nct07283835","kind":"trial","name":"Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin","route":"/trials/nct07283835/","asOf":"2026-09-16","days":12},{"id":"nct06926920","kind":"trial","name":"A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer","route":"/trials/nct06926920/","asOf":"2026-09-16","days":12},{"id":"nct06208410","kind":"trial","name":"A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors","route":"/trials/nct06208410/","asOf":"2026-09-16","days":12},{"id":"nct07766018","kind":"trial","name":"A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer","route":"/trials/nct07766018/","asOf":"2026-09-16","days":12},{"id":"nct06359860","kind":"trial","name":"A Study of ST-1898 for Unresectable or Metastatic Melanoma","route":"/trials/nct06359860/","asOf":"2026-09-16","days":12},{"id":"nct05326243","kind":"trial","name":"Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma","route":"/trials/nct05326243/","asOf":"2026-09-16","days":12},{"id":"nct07229586","kind":"trial","name":"A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors","route":"/trials/nct07229586/","asOf":"2026-09-16","days":12},{"id":"nct06492005","kind":"trial","name":"A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer","route":"/trials/nct06492005/","asOf":"2026-09-16","days":12},{"id":"nct07496229","kind":"trial","name":"Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)","route":"/trials/nct07496229/","asOf":"2026-09-16","days":12},{"id":"nct07165886","kind":"trial","name":"Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors","route":"/trials/nct07165886/","asOf":"2026-09-16","days":12},{"id":"nct03348670","kind":"trial","name":"Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms","route":"/trials/nct03348670/","asOf":"2026-09-16","days":12},{"id":"nct06643754","kind":"trial","name":"A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors","route":"/trials/nct06643754/","asOf":"2026-09-16","days":12},{"id":"nct07249905","kind":"trial","name":"Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma","route":"/trials/nct07249905/","asOf":"2026-09-16","days":12},{"id":"nct05009329","kind":"trial","name":"A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China","route":"/trials/nct05009329/","asOf":"2026-09-16","days":12},{"id":"nct06737081","kind":"trial","name":"SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies","route":"/trials/nct06737081/","asOf":"2026-09-16","days":12},{"id":"nct05455619","kind":"trial","name":"Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer","route":"/trials/nct05455619/","asOf":"2026-09-16","days":12},{"id":"nct05883956","kind":"trial","name":"A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia","route":"/trials/nct05883956/","asOf":"2026-09-16","days":12},{"id":"nct05768529","kind":"trial","name":"Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","route":"/trials/nct05768529/","asOf":"2026-09-16","days":12},{"id":"nct04725474","kind":"trial","name":"First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)","route":"/trials/nct04725474/","asOf":"2026-09-16","days":12},{"id":"nct01872260","kind":"trial","name":"Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer","route":"/trials/nct01872260/","asOf":"2026-09-16","days":12},{"id":"nct06249048","kind":"trial","name":"Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab","route":"/trials/nct06249048/","asOf":"2026-09-16","days":12},{"id":"nct07294508","kind":"trial","name":"A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer","route":"/trials/nct07294508/","asOf":"2026-09-16","days":12},{"id":"nct07331155","kind":"trial","name":"A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]","route":"/trials/nct07331155/","asOf":"2026-09-16","days":12},{"id":"nct06227117","kind":"trial","name":"Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer","route":"/trials/nct06227117/","asOf":"2026-09-16","days":12},{"id":"nct07523555","kind":"trial","name":"Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies","route":"/trials/nct07523555/","asOf":"2026-09-16","days":12},{"id":"nct06038578","kind":"trial","name":"A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer","route":"/trials/nct06038578/","asOf":"2026-09-16","days":12},{"id":"nct06317311","kind":"trial","name":"A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer","route":"/trials/nct06317311/","asOf":"2026-09-16","days":12},{"id":"nct06011109","kind":"trial","name":"Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab","route":"/trials/nct06011109/","asOf":"2026-09-16","days":12},{"id":"nct06942234","kind":"trial","name":"Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer","route":"/trials/nct06942234/","asOf":"2026-09-16","days":12},{"id":"nct07672236","kind":"trial","name":"A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.","route":"/trials/nct07672236/","asOf":"2026-09-16","days":12},{"id":"nct05731271","kind":"trial","name":"A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors","route":"/trials/nct05731271/","asOf":"2026-09-16","days":12},{"id":"nct07102901","kind":"trial","name":"Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma","route":"/trials/nct07102901/","asOf":"2026-09-16","days":12},{"id":"nct07341100","kind":"trial","name":"Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC","route":"/trials/nct07341100/","asOf":"2026-09-16","days":12},{"id":"nct07346144","kind":"trial","name":"Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma","route":"/trials/nct07346144/","asOf":"2026-09-16","days":12},{"id":"nct05765032","kind":"trial","name":"Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors","route":"/trials/nct05765032/","asOf":"2026-09-16","days":12},{"id":"nct05413018","kind":"trial","name":"An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission","route":"/trials/nct05413018/","asOf":"2026-09-16","days":12},{"id":"nct07160725","kind":"trial","name":"A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors","route":"/trials/nct07160725/","asOf":"2026-09-16","days":12},{"id":"nct05381103","kind":"trial","name":"PSMA-PET to Guide Prostatectomy","route":"/trials/nct05381103/","asOf":"2026-09-16","days":12},{"id":"nct07391813","kind":"trial","name":"SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer","route":"/trials/nct07391813/","asOf":"2026-09-16","days":12},{"id":"nct06736704","kind":"trial","name":"SNV4818 in Participants With Advanced Solid Tumors","route":"/trials/nct06736704/","asOf":"2026-09-16","days":12},{"id":"nct06682793","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression","route":"/trials/nct06682793/","asOf":"2026-09-16","days":12},{"id":"nct06319963","kind":"trial","name":"A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer","route":"/trials/nct06319963/","asOf":"2026-09-16","days":12},{"id":"nct07122063","kind":"trial","name":"Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors","route":"/trials/nct07122063/","asOf":"2026-09-16","days":12},{"id":"nct03816163","kind":"trial","name":"A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer","route":"/trials/nct03816163/","asOf":"2026-09-16","days":12},{"id":"nct03579836","kind":"trial","name":"Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer","route":"/trials/nct03579836/","asOf":"2026-09-16","days":12},{"id":"nct07475806","kind":"trial","name":"A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder","route":"/trials/nct07475806/","asOf":"2026-09-16","days":12},{"id":"nct07710885","kind":"trial","name":"Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer","route":"/trials/nct07710885/","asOf":"2026-09-16","days":12},{"id":"nct06276283","kind":"trial","name":"DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)","route":"/trials/nct06276283/","asOf":"2026-09-16","days":12},{"id":"nct05263583","kind":"trial","name":"Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma","route":"/trials/nct05263583/","asOf":"2026-09-16","days":12},{"id":"nct05771480","kind":"trial","name":"Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)","route":"/trials/nct05771480/","asOf":"2026-09-16","days":12},{"id":"nct05785741","kind":"trial","name":"A Study of DB-1310 in Advanced/Metastatic Solid Tumors","route":"/trials/nct05785741/","asOf":"2026-09-16","days":12},{"id":"nct05133882","kind":"trial","name":"A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML","route":"/trials/nct05133882/","asOf":"2026-09-16","days":12},{"id":"nct07036250","kind":"trial","name":"Clinical Study of U32 in Patients With Acute Myeloid Leukemia","route":"/trials/nct07036250/","asOf":"2026-09-16","days":12},{"id":"nct06566079","kind":"trial","name":"Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors","route":"/trials/nct06566079/","asOf":"2026-09-16","days":12},{"id":"nct05890742","kind":"trial","name":"A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer","route":"/trials/nct05890742/","asOf":"2026-09-16","days":12},{"id":"nct04626479","kind":"trial","name":"Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)","route":"/trials/nct04626479/","asOf":"2026-09-16","days":12},{"id":"nct06631989","kind":"trial","name":"A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer","route":"/trials/nct06631989/","asOf":"2026-09-16","days":12},{"id":"nct07124117","kind":"trial","name":"A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors","route":"/trials/nct07124117/","asOf":"2026-09-16","days":12},{"id":"nct06057610","kind":"trial","name":"A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer","route":"/trials/nct06057610/","asOf":"2026-09-16","days":12},{"id":"nct07678684","kind":"trial","name":"A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma","route":"/trials/nct07678684/","asOf":"2026-09-16","days":12},{"id":"nct05394831","kind":"trial","name":"A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC","route":"/trials/nct05394831/","asOf":"2026-09-16","days":12},{"id":"nct07252739","kind":"trial","name":"KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)","route":"/trials/nct07252739/","asOf":"2026-09-16","days":12},{"id":"nct05043922","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma","route":"/trials/nct05043922/","asOf":"2026-09-16","days":12},{"id":"nct06157151","kind":"trial","name":"PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer","route":"/trials/nct06157151/","asOf":"2026-09-16","days":12},{"id":"nct03547973","kind":"trial","name":"Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread","route":"/trials/nct03547973/","asOf":"2026-09-16","days":12},{"id":"nct06921837","kind":"trial","name":"A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer","route":"/trials/nct06921837/","asOf":"2026-09-16","days":12},{"id":"nct05999994","kind":"trial","name":"A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer","route":"/trials/nct05999994/","asOf":"2026-09-16","days":12},{"id":"nct07427394","kind":"trial","name":"Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer","route":"/trials/nct07427394/","asOf":"2026-09-16","days":12},{"id":"nct06247956","kind":"trial","name":"Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer","route":"/trials/nct06247956/","asOf":"2026-09-16","days":12},{"id":"nct05142423","kind":"trial","name":"A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors","route":"/trials/nct05142423/","asOf":"2026-09-16","days":12},{"id":"nct06312176","kind":"trial","name":"A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)","route":"/trials/nct06312176/","asOf":"2026-09-16","days":12},{"id":"nct07047118","kind":"trial","name":"A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)","route":"/trials/nct07047118/","asOf":"2026-09-16","days":12},{"id":"nct06062810","kind":"trial","name":"Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms","route":"/trials/nct06062810/","asOf":"2026-09-16","days":12},{"id":"nct05168566","kind":"trial","name":"Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct05168566/","asOf":"2026-09-16","days":12},{"id":"nct07446153","kind":"trial","name":"A Clinical Study of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects","route":"/trials/nct07446153/","asOf":"2026-09-16","days":12},{"id":"nct06903377","kind":"trial","name":"Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer","route":"/trials/nct06903377/","asOf":"2026-09-16","days":12},{"id":"nct05490472","kind":"trial","name":"JAB-2485 Activity in Adult Patients With Advanced Solid Tumors","route":"/trials/nct05490472/","asOf":"2026-09-16","days":12},{"id":"nct06974812","kind":"trial","name":"IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct06974812/","asOf":"2026-09-16","days":12},{"id":"nct07286331","kind":"trial","name":"A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)","route":"/trials/nct07286331/","asOf":"2026-09-16","days":12},{"id":"nct07419295","kind":"trial","name":"A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)","route":"/trials/nct07419295/","asOf":"2026-09-16","days":12},{"id":"nct06764875","kind":"trial","name":"A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer","route":"/trials/nct06764875/","asOf":"2026-09-16","days":12},{"id":"nct05645692","kind":"trial","name":"A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer","route":"/trials/nct05645692/","asOf":"2026-09-16","days":12},{"id":"nct06061809","kind":"trial","name":"N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma","route":"/trials/nct06061809/","asOf":"2026-09-16","days":12},{"id":"nct05094336","kind":"trial","name":"A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)","route":"/trials/nct05094336/","asOf":"2026-09-16","days":12},{"id":"nct05405595","kind":"trial","name":"ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors","route":"/trials/nct05405595/","asOf":"2026-09-16","days":12},{"id":"nct05840211","kind":"trial","name":"Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy","route":"/trials/nct05840211/","asOf":"2026-09-16","days":12},{"id":"nct07630974","kind":"trial","name":"A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)","route":"/trials/nct07630974/","asOf":"2026-09-16","days":12},{"id":"nct06343948","kind":"trial","name":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)","route":"/trials/nct06343948/","asOf":"2026-09-16","days":12},{"id":"nct06084806","kind":"trial","name":"Test-retest Evaluation of [18F]F-AraG PET","route":"/trials/nct06084806/","asOf":"2026-09-16","days":12},{"id":"nct05985655","kind":"trial","name":"Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors","route":"/trials/nct05985655/","asOf":"2026-09-16","days":12},{"id":"nct07558733","kind":"trial","name":"Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer","route":"/trials/nct07558733/","asOf":"2026-09-16","days":12},{"id":"nct07432633","kind":"trial","name":"[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications","route":"/trials/nct07432633/","asOf":"2026-09-16","days":12},{"id":"nct06710847","kind":"trial","name":"A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors","route":"/trials/nct06710847/","asOf":"2026-09-16","days":12},{"id":"nct06016738","kind":"trial","name":"OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer","route":"/trials/nct06016738/","asOf":"2026-09-16","days":12},{"id":"nct04718883","kind":"trial","name":"CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma","route":"/trials/nct04718883/","asOf":"2026-09-16","days":12},{"id":"nct04300556","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types","route":"/trials/nct04300556/","asOf":"2026-09-16","days":12},{"id":"nct06977737","kind":"trial","name":"A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours","route":"/trials/nct06977737/","asOf":"2026-09-16","days":12},{"id":"nct06593522","kind":"trial","name":"A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)","route":"/trials/nct06593522/","asOf":"2026-09-16","days":12},{"id":"nct06253130","kind":"trial","name":"A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors","route":"/trials/nct06253130/","asOf":"2026-09-16","days":12},{"id":"nct04771130","kind":"trial","name":"A Study of BGB-11417 in Participants With Myeloid Malignancies","route":"/trials/nct04771130/","asOf":"2026-09-16","days":12},{"id":"nct05596409","kind":"trial","name":"ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study","route":"/trials/nct05596409/","asOf":"2026-09-16","days":12},{"id":"nct07129993","kind":"trial","name":"Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma","route":"/trials/nct07129993/","asOf":"2026-09-16","days":12},{"id":"nct07243340","kind":"trial","name":"A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor","route":"/trials/nct07243340/","asOf":"2026-09-16","days":12},{"id":"nct03682068","kind":"trial","name":"Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer","route":"/trials/nct03682068/","asOf":"2026-09-16","days":12},{"id":"nct06971614","kind":"trial","name":"A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC","route":"/trials/nct06971614/","asOf":"2026-09-16","days":12},{"id":"nct06783647","kind":"trial","name":"A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]","route":"/trials/nct06783647/","asOf":"2026-09-16","days":12},{"id":"nct06943833","kind":"trial","name":"A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)","route":"/trials/nct06943833/","asOf":"2026-09-16","days":12},{"id":"nct05696626","kind":"trial","name":"Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation","route":"/trials/nct05696626/","asOf":"2026-09-16","days":12},{"id":"nct06634849","kind":"trial","name":"An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1).","route":"/trials/nct06634849/","asOf":"2026-09-16","days":12},{"id":"nct05710848","kind":"trial","name":"A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer","route":"/trials/nct05710848/","asOf":"2026-09-16","days":12},{"id":"nct05768919","kind":"trial","name":"Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas","route":"/trials/nct05768919/","asOf":"2026-09-16","days":12},{"id":"nct06764628","kind":"trial","name":"A Study of SHR-4375 in Subjects With Solid Tumors","route":"/trials/nct06764628/","asOf":"2026-09-16","days":12},{"id":"nct06995677","kind":"trial","name":"Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer","route":"/trials/nct06995677/","asOf":"2026-09-16","days":12},{"id":"nct07280377","kind":"trial","name":"A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab","route":"/trials/nct07280377/","asOf":"2026-09-16","days":12},{"id":"nct07498478","kind":"trial","name":"Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment","route":"/trials/nct07498478/","asOf":"2026-09-16","days":12},{"id":"nct02952508","kind":"trial","name":"Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom","route":"/trials/nct02952508/","asOf":"2026-09-16","days":12},{"id":"nct05485948","kind":"trial","name":"A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU","route":"/trials/nct05485948/","asOf":"2026-09-16","days":12},{"id":"nct04208178","kind":"trial","name":"Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation","route":"/trials/nct04208178/","asOf":"2026-09-16","days":12},{"id":"nct05498155","kind":"trial","name":"Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer","route":"/trials/nct05498155/","asOf":"2026-09-16","days":12},{"id":"nct07302347","kind":"trial","name":"A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)","route":"/trials/nct07302347/","asOf":"2026-09-16","days":12},{"id":"nct05844150","kind":"trial","name":"A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC","route":"/trials/nct05844150/","asOf":"2026-09-16","days":12},{"id":"nct02584244","kind":"trial","name":"Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers","route":"/trials/nct02584244/","asOf":"2026-09-16","days":12},{"id":"nct07282587","kind":"trial","name":"Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma","route":"/trials/nct07282587/","asOf":"2026-09-16","days":12},{"id":"nct06008093","kind":"trial","name":"A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS","route":"/trials/nct06008093/","asOf":"2026-09-16","days":12},{"id":"nct06643884","kind":"trial","name":"Suprachoroidal Administration in Subjects With Metastases to the Choroid","route":"/trials/nct06643884/","asOf":"2026-09-16","days":12},{"id":"nct05459844","kind":"trial","name":"A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs","route":"/trials/nct05459844/","asOf":"2026-09-16","days":12},{"id":"nct05709249","kind":"trial","name":"Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer","route":"/trials/nct05709249/","asOf":"2026-09-16","days":12},{"id":"nct06504147","kind":"trial","name":"A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery","route":"/trials/nct06504147/","asOf":"2026-09-16","days":12},{"id":"nct04851717","kind":"trial","name":"Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures","route":"/trials/nct04851717/","asOf":"2026-09-16","days":12},{"id":"nct07629726","kind":"trial","name":"A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms","route":"/trials/nct07629726/","asOf":"2026-09-16","days":12},{"id":"nct04585035","kind":"trial","name":"Study to Evaluate D-1553 in Subjects With Solid Tumors","route":"/trials/nct04585035/","asOf":"2026-09-16","days":12},{"id":"nct07469774","kind":"trial","name":"BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct07469774/","asOf":"2026-09-16","days":12},{"id":"nct06206174","kind":"trial","name":"TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies","route":"/trials/nct06206174/","asOf":"2026-09-16","days":12},{"id":"nct06214143","kind":"trial","name":"A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors","route":"/trials/nct06214143/","asOf":"2026-09-16","days":12},{"id":"nct04969315","kind":"trial","name":"TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma","route":"/trials/nct04969315/","asOf":"2026-09-16","days":12},{"id":"nct07151040","kind":"trial","name":"Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors","route":"/trials/nct07151040/","asOf":"2026-09-16","days":12},{"id":"nct07489716","kind":"trial","name":"A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer","route":"/trials/nct07489716/","asOf":"2026-09-16","days":12},{"id":"nct05668858","kind":"trial","name":"A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma","route":"/trials/nct05668858/","asOf":"2026-09-16","days":12},{"id":"nct04114825","kind":"trial","name":"Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer","route":"/trials/nct04114825/","asOf":"2026-09-16","days":12},{"id":"nct07436728","kind":"trial","name":"A Study of TAK-505 in Adults With Solid Tumors","route":"/trials/nct07436728/","asOf":"2026-09-16","days":12},{"id":"nct05948943","kind":"trial","name":"Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.","route":"/trials/nct05948943/","asOf":"2026-09-16","days":12},{"id":"nct06951503","kind":"trial","name":"AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer","route":"/trials/nct06951503/","asOf":"2026-09-16","days":12},{"id":"nct04864054","kind":"trial","name":"GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC","route":"/trials/nct04864054/","asOf":"2026-09-16","days":12},{"id":"nct05687266","kind":"trial","name":"Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations","route":"/trials/nct05687266/","asOf":"2026-09-16","days":12},{"id":"nct06235151","kind":"trial","name":"Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer","route":"/trials/nct06235151/","asOf":"2026-09-16","days":12},{"id":"nct06118788","kind":"trial","name":"Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","route":"/trials/nct06118788/","asOf":"2026-09-16","days":12},{"id":"nct05862324","kind":"trial","name":"TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)","route":"/trials/nct05862324/","asOf":"2026-09-16","days":12},{"id":"nct06314373","kind":"trial","name":"A Study for HSK39775 in Participants With Solid Tumors","route":"/trials/nct06314373/","asOf":"2026-09-16","days":12},{"id":"nct06971523","kind":"trial","name":"A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies","route":"/trials/nct06971523/","asOf":"2026-09-16","days":12},{"id":"nct06771622","kind":"trial","name":"Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors","route":"/trials/nct06771622/","asOf":"2026-09-16","days":12},{"id":"nct06555068","kind":"trial","name":"A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients","route":"/trials/nct06555068/","asOf":"2026-09-16","days":12},{"id":"nct06151574","kind":"trial","name":"Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment","route":"/trials/nct06151574/","asOf":"2026-09-16","days":12},{"id":"nct06702618","kind":"trial","name":"Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer","route":"/trials/nct06702618/","asOf":"2026-09-16","days":12},{"id":"nct05475925","kind":"trial","name":"A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas","route":"/trials/nct05475925/","asOf":"2026-09-16","days":12},{"id":"nct04262466","kind":"trial","name":"Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors","route":"/trials/nct04262466/","asOf":"2026-09-16","days":12},{"id":"nct06895928","kind":"trial","name":"A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors","route":"/trials/nct06895928/","asOf":"2026-09-16","days":12},{"id":"nct04404595","kind":"trial","name":"Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers","route":"/trials/nct04404595/","asOf":"2026-09-16","days":12},{"id":"nct06399757","kind":"trial","name":"A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors","route":"/trials/nct06399757/","asOf":"2026-09-16","days":12},{"id":"nct03671044","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients","route":"/trials/nct03671044/","asOf":"2026-09-16","days":12},{"id":"nct04589234","kind":"trial","name":"Saltikva for Metastatic Pancreatic Cancer","route":"/trials/nct04589234/","asOf":"2026-09-16","days":12},{"id":"nct04587830","kind":"trial","name":"ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme","route":"/trials/nct04587830/","asOf":"2026-09-16","days":12},{"id":"nct07277231","kind":"trial","name":"A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia","route":"/trials/nct07277231/","asOf":"2026-09-16","days":12},{"id":"nct07586202","kind":"trial","name":"A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC","route":"/trials/nct07586202/","asOf":"2026-09-16","days":12},{"id":"nct05862272","kind":"trial","name":"A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis","route":"/trials/nct05862272/","asOf":"2026-09-16","days":12},{"id":"nct06687681","kind":"trial","name":"Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas","route":"/trials/nct06687681/","asOf":"2026-09-16","days":12},{"id":"nct04521413","kind":"trial","name":"Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies","route":"/trials/nct04521413/","asOf":"2026-09-16","days":12},{"id":"nct06730750","kind":"trial","name":"A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors","route":"/trials/nct06730750/","asOf":"2026-09-16","days":12},{"id":"nct05945823","kind":"trial","name":"Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors","route":"/trials/nct05945823/","asOf":"2026-09-16","days":12},{"id":"nct06414460","kind":"trial","name":"Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors","route":"/trials/nct06414460/","asOf":"2026-09-16","days":12},{"id":"nct06384807","kind":"trial","name":"A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors","route":"/trials/nct06384807/","asOf":"2026-09-16","days":12},{"id":"nct05261399","kind":"trial","name":"Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment","route":"/trials/nct05261399/","asOf":"2026-09-16","days":12},{"id":"nct05329532","kind":"trial","name":"Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer","route":"/trials/nct05329532/","asOf":"2026-09-16","days":12},{"id":"nct06568692","kind":"trial","name":"A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer","route":"/trials/nct06568692/","asOf":"2026-09-16","days":12},{"id":"nct07228247","kind":"trial","name":"A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors","route":"/trials/nct07228247/","asOf":"2026-09-16","days":12},{"id":"nct06119581","kind":"trial","name":"A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer","route":"/trials/nct06119581/","asOf":"2026-09-16","days":12},{"id":"nct06428019","kind":"trial","name":"A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)","route":"/trials/nct06428019/","asOf":"2026-09-16","days":12},{"id":"nct05933265","kind":"trial","name":"Study of LP-184 in Patients With Advanced Solid Tumors","route":"/trials/nct05933265/","asOf":"2026-09-16","days":12},{"id":"nct07192107","kind":"trial","name":"A Study of MHB042C in Patients With Advanced Solid Tumors","route":"/trials/nct07192107/","asOf":"2026-09-16","days":12},{"id":"nct07169851","kind":"trial","name":"A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer","route":"/trials/nct07169851/","asOf":"2026-09-16","days":12},{"id":"nct06538857","kind":"trial","name":"CEB-01 in Locally Resectable Pancreatic Cancer","route":"/trials/nct06538857/","asOf":"2026-09-16","days":12},{"id":"nct04762069","kind":"trial","name":"A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme","route":"/trials/nct04762069/","asOf":"2026-09-16","days":12},{"id":"nct07689201","kind":"trial","name":"A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib","route":"/trials/nct07689201/","asOf":"2026-09-16","days":12},{"id":"nct07126665","kind":"trial","name":"A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors","route":"/trials/nct07126665/","asOf":"2026-09-16","days":12},{"id":"nct07002177","kind":"trial","name":"A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC","route":"/trials/nct07002177/","asOf":"2026-09-16","days":12},{"id":"nct07229612","kind":"trial","name":"A Phase I/II Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors","route":"/trials/nct07229612/","asOf":"2026-09-16","days":12},{"id":"nct07547553","kind":"trial","name":"A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC","route":"/trials/nct07547553/","asOf":"2026-09-16","days":12},{"id":"nct07146672","kind":"trial","name":"Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for Tumors","route":"/trials/nct07146672/","asOf":"2026-09-16","days":12},{"id":"nct07380386","kind":"trial","name":"SKB105 for Injection in Advanced Solid Tumors","route":"/trials/nct07380386/","asOf":"2026-09-16","days":12},{"id":"nct06909877","kind":"trial","name":"Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma","route":"/trials/nct06909877/","asOf":"2026-09-16","days":12},{"id":"nct07415863","kind":"trial","name":"Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors","route":"/trials/nct07415863/","asOf":"2026-09-16","days":12},{"id":"nct06389006","kind":"trial","name":"To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer","route":"/trials/nct06389006/","asOf":"2026-09-16","days":12},{"id":"nct07258121","kind":"trial","name":"Study of ZGGS34 in Participants With Advanced Solid Tumors","route":"/trials/nct07258121/","asOf":"2026-09-16","days":12},{"id":"nct04634357","kind":"trial","name":"ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma","route":"/trials/nct04634357/","asOf":"2026-09-16","days":12},{"id":"nct06911333","kind":"trial","name":"AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct06911333/","asOf":"2026-09-16","days":12},{"id":"nct07111832","kind":"trial","name":"A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer","route":"/trials/nct07111832/","asOf":"2026-09-16","days":12},{"id":"nct07225621","kind":"trial","name":"Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma","route":"/trials/nct07225621/","asOf":"2026-09-16","days":12},{"id":"nct06966700","kind":"trial","name":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","route":"/trials/nct06966700/","asOf":"2026-09-16","days":12},{"id":"nct06232096","kind":"trial","name":"A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.","route":"/trials/nct06232096/","asOf":"2026-09-16","days":12},{"id":"nct06380660","kind":"trial","name":"Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors","route":"/trials/nct06380660/","asOf":"2026-09-16","days":12},{"id":"nct07480213","kind":"trial","name":"Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)","route":"/trials/nct07480213/","asOf":"2026-09-16","days":12},{"id":"nct06060613","kind":"trial","name":"Safety and Efficacy of OBX-115 in Advanced Solid Tumors","route":"/trials/nct06060613/","asOf":"2026-09-16","days":12},{"id":"nct07185880","kind":"trial","name":"A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients","route":"/trials/nct07185880/","asOf":"2026-09-16","days":12},{"id":"nct03148418","kind":"trial","name":"A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)","route":"/trials/nct03148418/","asOf":"2026-09-16","days":12},{"id":"nct05867420","kind":"trial","name":"A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.","route":"/trials/nct05867420/","asOf":"2026-09-16","days":12},{"id":"nct05833724","kind":"trial","name":"Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)","route":"/trials/nct05833724/","asOf":"2026-09-16","days":12},{"id":"nct06144671","kind":"trial","name":"Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors","route":"/trials/nct06144671/","asOf":"2026-09-16","days":12},{"id":"nct07795034","kind":"trial","name":"To Evaluate the Efficacy and Safety of Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) Combined With NBB-001 and NBB-002 for Patients With Recurrent Head and Neck Malignancies","route":"/trials/nct07795034/","asOf":"2026-09-16","days":12},{"id":"nct05434234","kind":"trial","name":"A Study of YL201 in Patients With Advanced Solid Tumors","route":"/trials/nct05434234/","asOf":"2026-09-16","days":12},{"id":"nct07169734","kind":"trial","name":"A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors","route":"/trials/nct07169734/","asOf":"2026-09-16","days":12},{"id":"nct06598787","kind":"trial","name":"A Study of BL-B01D1 in Patients With Recurrent Glioblastoma","route":"/trials/nct06598787/","asOf":"2026-09-16","days":12},{"id":"nct05748171","kind":"trial","name":"A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL","route":"/trials/nct05748171/","asOf":"2026-09-16","days":12},{"id":"nct02346747","kind":"trial","name":"A Trial of Vigil for Participants With Ovarian Cancer","route":"/trials/nct02346747/","asOf":"2026-09-16","days":12},{"id":"nct06191263","kind":"trial","name":"Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML","route":"/trials/nct06191263/","asOf":"2026-09-16","days":12},{"id":"nct07518147","kind":"trial","name":"A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment","route":"/trials/nct07518147/","asOf":"2026-09-16","days":12},{"id":"nct06588478","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","route":"/trials/nct06588478/","asOf":"2026-09-16","days":12},{"id":"nct06769113","kind":"trial","name":"A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy","route":"/trials/nct06769113/","asOf":"2026-09-16","days":12},{"id":"nct06111235","kind":"trial","name":"A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT","route":"/trials/nct06111235/","asOf":"2026-09-16","days":12},{"id":"nct07299747","kind":"trial","name":"Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors","route":"/trials/nct07299747/","asOf":"2026-09-16","days":12},{"id":"nct05601726","kind":"trial","name":"First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients","route":"/trials/nct05601726/","asOf":"2026-09-16","days":12},{"id":"nct07286149","kind":"trial","name":"A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)","route":"/trials/nct07286149/","asOf":"2026-09-16","days":12},{"id":"nct05523947","kind":"trial","name":"Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor","route":"/trials/nct05523947/","asOf":"2026-09-16","days":12},{"id":"nct07147348","kind":"trial","name":"A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors","route":"/trials/nct07147348/","asOf":"2026-09-16","days":12},{"id":"nct05700084","kind":"trial","name":"Phase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid Tumors","route":"/trials/nct05700084/","asOf":"2026-09-16","days":12},{"id":"nct05347134","kind":"trial","name":"SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer","route":"/trials/nct05347134/","asOf":"2026-09-16","days":12},{"id":"nct07448116","kind":"trial","name":"Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.","route":"/trials/nct07448116/","asOf":"2026-09-16","days":12},{"id":"nct04121455","kind":"trial","name":"Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients","route":"/trials/nct04121455/","asOf":"2026-09-16","days":12},{"id":"nct07278479","kind":"trial","name":"Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors","route":"/trials/nct07278479/","asOf":"2026-09-16","days":12},{"id":"nct06533579","kind":"trial","name":"Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)","route":"/trials/nct06533579/","asOf":"2026-09-16","days":12},{"id":"nct06712680","kind":"trial","name":"A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes","route":"/trials/nct06712680/","asOf":"2026-09-16","days":12},{"id":"nct03591510","kind":"trial","name":"A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML","route":"/trials/nct03591510/","asOf":"2026-09-16","days":12},{"id":"nct06857175","kind":"trial","name":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)","route":"/trials/nct06857175/","asOf":"2026-09-16","days":12},{"id":"nct05315167","kind":"trial","name":"A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors","route":"/trials/nct05315167/","asOf":"2026-09-16","days":12},{"id":"nct06846671","kind":"trial","name":"A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors","route":"/trials/nct06846671/","asOf":"2026-09-16","days":12},{"id":"nct06305767","kind":"trial","name":"A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)","route":"/trials/nct06305767/","asOf":"2026-09-16","days":12},{"id":"nct05645107","kind":"trial","name":"A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma","route":"/trials/nct05645107/","asOf":"2026-09-16","days":12},{"id":"nct07193511","kind":"trial","name":"BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)","route":"/trials/nct07193511/","asOf":"2026-09-16","days":12},{"id":"nct07060807","kind":"trial","name":"A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)","route":"/trials/nct07060807/","asOf":"2026-09-16","days":12},{"id":"nct07213609","kind":"trial","name":"A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors","route":"/trials/nct07213609/","asOf":"2026-09-16","days":12},{"id":"nct07327034","kind":"trial","name":"ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression","route":"/trials/nct07327034/","asOf":"2026-09-16","days":12},{"id":"nct07575191","kind":"trial","name":"Safety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer","route":"/trials/nct07575191/","asOf":"2026-09-16","days":12},{"id":"nct05262010","kind":"trial","name":"A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years","route":"/trials/nct05262010/","asOf":"2026-09-16","days":12},{"id":"nct05518045","kind":"trial","name":"A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors","route":"/trials/nct05518045/","asOf":"2026-09-16","days":12},{"id":"nct06116136","kind":"trial","name":"A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.","route":"/trials/nct06116136/","asOf":"2026-09-16","days":12},{"id":"nct06166836","kind":"trial","name":"a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors","route":"/trials/nct06166836/","asOf":"2026-09-16","days":12},{"id":"nct06940739","kind":"trial","name":"A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel","route":"/trials/nct06940739/","asOf":"2026-09-16","days":12},{"id":"nct03444844","kind":"trial","name":"Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer","route":"/trials/nct03444844/","asOf":"2026-09-16","days":12},{"id":"nct06083207","kind":"trial","name":"A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct06083207/","asOf":"2026-09-16","days":12},{"id":"nct06055439","kind":"trial","name":"A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy","route":"/trials/nct06055439/","asOf":"2026-09-16","days":12},{"id":"nct06973564","kind":"trial","name":"JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration","route":"/trials/nct06973564/","asOf":"2026-09-16","days":12},{"id":"nct02938299","kind":"trial","name":"Neoadjuvant L19IL2/L19TNF- Pivotal Study","route":"/trials/nct02938299/","asOf":"2026-09-16","days":12},{"id":"nct06990880","kind":"trial","name":"A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer","route":"/trials/nct06990880/","asOf":"2026-09-16","days":12},{"id":"nct05299424","kind":"trial","name":"A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct05299424/","asOf":"2026-09-16","days":12},{"id":"nct06038396","kind":"trial","name":"A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors","route":"/trials/nct06038396/","asOf":"2026-09-16","days":12},{"id":"nct07538804","kind":"trial","name":"A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer","route":"/trials/nct07538804/","asOf":"2026-09-16","days":12},{"id":"nct05544552","kind":"trial","name":"Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations","route":"/trials/nct05544552/","asOf":"2026-09-16","days":12},{"id":"nct06784752","kind":"trial","name":"Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET","route":"/trials/nct06784752/","asOf":"2026-09-16","days":12},{"id":"nct06635447","kind":"trial","name":"Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients","route":"/trials/nct06635447/","asOf":"2026-09-16","days":12},{"id":"nct07253116","kind":"trial","name":"A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors","route":"/trials/nct07253116/","asOf":"2026-09-16","days":12},{"id":"nct06431243","kind":"trial","name":"A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors","route":"/trials/nct06431243/","asOf":"2026-09-16","days":12},{"id":"nct04925479","kind":"trial","name":"Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia","route":"/trials/nct04925479/","asOf":"2026-09-16","days":12},{"id":"nct06807359","kind":"trial","name":"Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System","route":"/trials/nct06807359/","asOf":"2026-09-16","days":12},{"id":"nct05023980","kind":"trial","name":"A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","route":"/trials/nct05023980/","asOf":"2026-09-16","days":12},{"id":"nct06957379","kind":"trial","name":"Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy","route":"/trials/nct06957379/","asOf":"2026-09-16","days":12},{"id":"nct04538742","kind":"trial","name":"A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer","route":"/trials/nct04538742/","asOf":"2026-09-16","days":12},{"id":"nct04724980","kind":"trial","name":"Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis","route":"/trials/nct04724980/","asOf":"2026-09-16","days":12},{"id":"nct04229979","kind":"trial","name":"Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2","route":"/trials/nct04229979/","asOf":"2026-09-16","days":12},{"id":"nct03686124","kind":"trial","name":"ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors","route":"/trials/nct03686124/","asOf":"2026-09-16","days":12},{"id":"nct06669117","kind":"trial","name":"FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations","route":"/trials/nct06669117/","asOf":"2026-09-16","days":12},{"id":"nct06980480","kind":"trial","name":"A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma","route":"/trials/nct06980480/","asOf":"2026-09-16","days":12},{"id":"nct06349980","kind":"trial","name":"A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.","route":"/trials/nct06349980/","asOf":"2026-09-16","days":12},{"id":"nct06319820","kind":"trial","name":"A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer","route":"/trials/nct06319820/","asOf":"2026-09-16","days":12},{"id":"nct07008703","kind":"trial","name":"Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain","route":"/trials/nct07008703/","asOf":"2026-09-16","days":12},{"id":"nct07359066","kind":"trial","name":"An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors","route":"/trials/nct07359066/","asOf":"2026-09-16","days":12},{"id":"nct07070219","kind":"trial","name":"A Study of CTD402 in T-ALL/LBL Patients","route":"/trials/nct07070219/","asOf":"2026-09-16","days":12},{"id":"nct05562830","kind":"trial","name":"A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)","route":"/trials/nct05562830/","asOf":"2026-09-16","days":12},{"id":"nct07421700","kind":"trial","name":"Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer","route":"/trials/nct07421700/","asOf":"2026-09-16","days":12},{"id":"nct06211764","kind":"trial","name":"A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)","route":"/trials/nct06211764/","asOf":"2026-09-16","days":12},{"id":"nct05482971","kind":"trial","name":"A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET","route":"/trials/nct05482971/","asOf":"2026-09-16","days":12},{"id":"nct06467357","kind":"trial","name":"Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer","route":"/trials/nct06467357/","asOf":"2026-09-16","days":12},{"id":"nct07582432","kind":"trial","name":"A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma","route":"/trials/nct07582432/","asOf":"2026-09-16","days":12},{"id":"nct05429632","kind":"trial","name":"Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT","route":"/trials/nct05429632/","asOf":"2026-09-16","days":12},{"id":"nct06398444","kind":"trial","name":"A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms","route":"/trials/nct06398444/","asOf":"2026-09-16","days":12},{"id":"nct06449222","kind":"trial","name":"Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy","route":"/trials/nct06449222/","asOf":"2026-09-16","days":12},{"id":"nct07297212","kind":"trial","name":"A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma","route":"/trials/nct07297212/","asOf":"2026-09-16","days":12},{"id":"nct06778031","kind":"trial","name":"A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer","route":"/trials/nct06778031/","asOf":"2026-09-16","days":12},{"id":"nct06669975","kind":"trial","name":"A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors","route":"/trials/nct06669975/","asOf":"2026-09-16","days":12},{"id":"nct06906471","kind":"trial","name":"A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS","route":"/trials/nct06906471/","asOf":"2026-09-16","days":12},{"id":"nct06885281","kind":"trial","name":"A Study of ZL-1310 in Participants With Selected Solid Tumors","route":"/trials/nct06885281/","asOf":"2026-09-16","days":12},{"id":"nct07605728","kind":"trial","name":"Probiotics for Abemaciclib-Induced Abdominal Discomfort.","route":"/trials/nct07605728/","asOf":"2026-09-16","days":12},{"id":"nct05119907","kind":"trial","name":"Study of Sacituzumab Govitecan in Patients With Solid Tumor","route":"/trials/nct05119907/","asOf":"2026-09-16","days":12},{"id":"nct06003231","kind":"trial","name":"A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2","route":"/trials/nct06003231/","asOf":"2026-09-16","days":12},{"id":"nct07148128","kind":"trial","name":"Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.","route":"/trials/nct07148128/","asOf":"2026-09-16","days":12},{"id":"nct07341737","kind":"trial","name":"SL-28 for Advanced Solid Tumours","route":"/trials/nct07341737/","asOf":"2026-09-16","days":12},{"id":"nct05876754","kind":"trial","name":"An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma","route":"/trials/nct05876754/","asOf":"2026-09-16","days":12},{"id":"nct07112222","kind":"trial","name":"A Study of LM-350 in Subjects With Advanced Solid Tumours","route":"/trials/nct07112222/","asOf":"2026-09-16","days":12},{"id":"nct06622486","kind":"trial","name":"First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors","route":"/trials/nct06622486/","asOf":"2026-09-16","days":12},{"id":"nct06797986","kind":"trial","name":"A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC.","route":"/trials/nct06797986/","asOf":"2026-09-16","days":12},{"id":"nct07566156","kind":"trial","name":"Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)","route":"/trials/nct07566156/","asOf":"2026-09-16","days":12},{"id":"nct05827796","kind":"trial","name":"IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer","route":"/trials/nct05827796/","asOf":"2026-09-16","days":12},{"id":"nct06840483","kind":"trial","name":"Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer","route":"/trials/nct06840483/","asOf":"2026-09-16","days":12},{"id":"nct06033586","kind":"trial","name":"Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera","route":"/trials/nct06033586/","asOf":"2026-09-16","days":12},{"id":"nct06244992","kind":"trial","name":"PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct06244992/","asOf":"2026-09-16","days":12},{"id":"nct07617493","kind":"trial","name":"Evaluation of ICP-B208 in Patients With Advanced Solid Tumors","route":"/trials/nct07617493/","asOf":"2026-09-16","days":12},{"id":"nct05417321","kind":"trial","name":"A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors","route":"/trials/nct05417321/","asOf":"2026-09-16","days":12},{"id":"nct07093970","kind":"trial","name":"A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors","route":"/trials/nct07093970/","asOf":"2026-09-16","days":12},{"id":"nct05482568","kind":"trial","name":"A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer","route":"/trials/nct05482568/","asOf":"2026-09-16","days":12},{"id":"nct07492680","kind":"trial","name":"A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)","route":"/trials/nct07492680/","asOf":"2026-09-16","days":12},{"id":"nct06385925","kind":"trial","name":"A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","route":"/trials/nct06385925/","asOf":"2026-09-16","days":12},{"id":"nct04256317","kind":"trial","name":"A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)","route":"/trials/nct04256317/","asOf":"2026-09-16","days":12},{"id":"nct07268040","kind":"trial","name":"A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors","route":"/trials/nct07268040/","asOf":"2026-09-16","days":12},{"id":"nct06292208","kind":"trial","name":"A Clinical Trial to Evaluate Effect of IBD0333 in Patients With Advanced Malignant Tumors","route":"/trials/nct06292208/","asOf":"2026-09-16","days":12},{"id":"nct05563220","kind":"trial","name":"Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer","route":"/trials/nct05563220/","asOf":"2026-09-16","days":12},{"id":"nct07231068","kind":"trial","name":"A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation","route":"/trials/nct07231068/","asOf":"2026-09-16","days":12},{"id":"nct03850574","kind":"trial","name":"Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia","route":"/trials/nct03850574/","asOf":"2026-09-16","days":12},{"id":"nct06797635","kind":"trial","name":"Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)","route":"/trials/nct06797635/","asOf":"2026-09-16","days":12},{"id":"nct06898450","kind":"trial","name":"A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.","route":"/trials/nct06898450/","asOf":"2026-09-16","days":12},{"id":"nct07028268","kind":"trial","name":"A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors","route":"/trials/nct07028268/","asOf":"2026-09-16","days":12},{"id":"nct06877650","kind":"trial","name":"First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors","route":"/trials/nct06877650/","asOf":"2026-09-16","days":12},{"id":"nct04603807","kind":"trial","name":"A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases","route":"/trials/nct04603807/","asOf":"2026-09-16","days":12},{"id":"nct07171606","kind":"trial","name":"A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients","route":"/trials/nct07171606/","asOf":"2026-09-16","days":12},{"id":"nct05227664","kind":"trial","name":"A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer","route":"/trials/nct05227664/","asOf":"2026-09-16","days":12},{"id":"nct07033598","kind":"trial","name":"Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia","route":"/trials/nct07033598/","asOf":"2026-09-16","days":12},{"id":"nct06868199","kind":"trial","name":"A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours","route":"/trials/nct06868199/","asOf":"2026-09-16","days":12},{"id":"nct06824064","kind":"trial","name":"Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer","route":"/trials/nct06824064/","asOf":"2026-09-16","days":12},{"id":"nct06844357","kind":"trial","name":"A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.","route":"/trials/nct06844357/","asOf":"2026-09-16","days":12},{"id":"nct07392736","kind":"trial","name":"A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.","route":"/trials/nct07392736/","asOf":"2026-09-16","days":12},{"id":"nct06105021","kind":"trial","name":"Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor","route":"/trials/nct06105021/","asOf":"2026-09-16","days":12},{"id":"nct05704244","kind":"trial","name":"Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)","route":"/trials/nct05704244/","asOf":"2026-09-16","days":12},{"id":"nct06938321","kind":"trial","name":"A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer","route":"/trials/nct06938321/","asOf":"2026-09-16","days":12},{"id":"nct06440057","kind":"trial","name":"Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.","route":"/trials/nct06440057/","asOf":"2026-09-16","days":12},{"id":"nct06797999","kind":"trial","name":"First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma","route":"/trials/nct06797999/","asOf":"2026-09-16","days":12},{"id":"nct07743112","kind":"trial","name":"A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia","route":"/trials/nct07743112/","asOf":"2026-09-16","days":12},{"id":"nct03485209","kind":"trial","name":"Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors","route":"/trials/nct03485209/","asOf":"2026-09-16","days":12},{"id":"nct05205330","kind":"trial","name":"Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers","route":"/trials/nct05205330/","asOf":"2026-09-16","days":12},{"id":"nct06139575","kind":"trial","name":"Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer","route":"/trials/nct06139575/","asOf":"2026-09-16","days":12},{"id":"nct07615101","kind":"trial","name":"Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.","route":"/trials/nct07615101/","asOf":"2026-09-16","days":12},{"id":"nct05970016","kind":"trial","name":"A Phase I/II Clinical Study in Patients with Advanced Solid Tumor.","route":"/trials/nct05970016/","asOf":"2026-09-16","days":12},{"id":"nct06636682","kind":"trial","name":"FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer","route":"/trials/nct06636682/","asOf":"2026-09-16","days":12},{"id":"nct05678270","kind":"trial","name":"A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma","route":"/trials/nct05678270/","asOf":"2026-09-16","days":12},{"id":"nct07629960","kind":"trial","name":"A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations","route":"/trials/nct07629960/","asOf":"2026-09-16","days":12},{"id":"nct07102004","kind":"trial","name":"Study of MHB088C for Patients With Advanced Solid Malignant Tumors","route":"/trials/nct07102004/","asOf":"2026-09-16","days":12},{"id":"nct06431490","kind":"trial","name":"A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer","route":"/trials/nct06431490/","asOf":"2026-09-16","days":12},{"id":"nct07287098","kind":"trial","name":"A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer","route":"/trials/nct07287098/","asOf":"2026-09-16","days":12},{"id":"nct07109414","kind":"trial","name":"Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)","route":"/trials/nct07109414/","asOf":"2026-09-16","days":12},{"id":"nct07324304","kind":"trial","name":"NWRD06 DNA Plasmid for HCC After Curative Resection.","route":"/trials/nct07324304/","asOf":"2026-09-16","days":12},{"id":"nct06657222","kind":"trial","name":"First in Human Study of TUB-030 in Patients With Advanced Solid Tumors","route":"/trials/nct06657222/","asOf":"2026-09-16","days":12},{"id":"nct04078295","kind":"trial","name":"A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor","route":"/trials/nct04078295/","asOf":"2026-09-16","days":12},{"id":"nct07056777","kind":"trial","name":"Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer","route":"/trials/nct07056777/","asOf":"2026-09-16","days":12},{"id":"nct06998407","kind":"trial","name":"ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors","route":"/trials/nct06998407/","asOf":"2026-09-16","days":12},{"id":"nct07271667","kind":"trial","name":"A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies","route":"/trials/nct07271667/","asOf":"2026-09-16","days":12},{"id":"nct04509700","kind":"trial","name":"Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)","route":"/trials/nct04509700/","asOf":"2026-09-16","days":12},{"id":"nct06855771","kind":"trial","name":"A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)","route":"/trials/nct06855771/","asOf":"2026-09-16","days":12},{"id":"nct06245330","kind":"trial","name":"A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors","route":"/trials/nct06245330/","asOf":"2026-09-16","days":12},{"id":"nct06668792","kind":"trial","name":"An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct06668792/","asOf":"2026-09-16","days":12},{"id":"nct07106892","kind":"trial","name":"Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer","route":"/trials/nct07106892/","asOf":"2026-09-16","days":12},{"id":"nct07742215","kind":"trial","name":"A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)","route":"/trials/nct07742215/","asOf":"2026-09-16","days":12},{"id":"nct06220318","kind":"trial","name":"Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors","route":"/trials/nct06220318/","asOf":"2026-09-16","days":12},{"id":"nct04299191","kind":"trial","name":"Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors","route":"/trials/nct04299191/","asOf":"2026-09-16","days":12},{"id":"nct06510374","kind":"trial","name":"Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer","route":"/trials/nct06510374/","asOf":"2026-09-16","days":12},{"id":"nct07131202","kind":"trial","name":"A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors","route":"/trials/nct07131202/","asOf":"2026-09-16","days":12},{"id":"nct05934331","kind":"trial","name":"A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study","route":"/trials/nct05934331/","asOf":"2026-09-16","days":12},{"id":"nct06012695","kind":"trial","name":"NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma","route":"/trials/nct06012695/","asOf":"2026-09-16","days":12},{"id":"nct04554914","kind":"trial","name":"A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases","route":"/trials/nct04554914/","asOf":"2026-09-16","days":12},{"id":"nct06082102","kind":"trial","name":"Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma","route":"/trials/nct06082102/","asOf":"2026-09-16","days":12},{"id":"nct07548177","kind":"trial","name":"Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma","route":"/trials/nct07548177/","asOf":"2026-09-16","days":12},{"id":"nct06863272","kind":"trial","name":"A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)","route":"/trials/nct06863272/","asOf":"2026-09-16","days":12},{"id":"nct05943106","kind":"trial","name":"BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants","route":"/trials/nct05943106/","asOf":"2026-09-16","days":12},{"id":"nct05032040","kind":"trial","name":"A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies","route":"/trials/nct05032040/","asOf":"2026-09-16","days":12},{"id":"nct05944224","kind":"trial","name":"A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.","route":"/trials/nct05944224/","asOf":"2026-09-16","days":12},{"id":"nct05642780","kind":"trial","name":"SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors","route":"/trials/nct05642780/","asOf":"2026-09-16","days":12},{"id":"nct06745908","kind":"trial","name":"Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In","route":"/trials/nct06745908/","asOf":"2026-09-16","days":12},{"id":"nct07259317","kind":"trial","name":"Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma","route":"/trials/nct07259317/","asOf":"2026-09-16","days":12},{"id":"nct06120140","kind":"trial","name":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib","route":"/trials/nct06120140/","asOf":"2026-09-16","days":12},{"id":"nct04939610","kind":"trial","name":"A Study of 177Lu-FAP-2286 in Advanced Solid Tumors","route":"/trials/nct04939610/","asOf":"2026-09-16","days":12},{"id":"nct06468358","kind":"trial","name":"A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors","route":"/trials/nct06468358/","asOf":"2026-09-16","days":12},{"id":"nct07060989","kind":"trial","name":"A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation","route":"/trials/nct07060989/","asOf":"2026-09-16","days":12},{"id":"nct06126510","kind":"trial","name":"Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma","route":"/trials/nct06126510/","asOf":"2026-09-16","days":12},{"id":"nct07227350","kind":"trial","name":"L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)","route":"/trials/nct07227350/","asOf":"2026-09-16","days":12},{"id":"nct06662786","kind":"trial","name":"A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","route":"/trials/nct06662786/","asOf":"2026-09-16","days":12},{"id":"nct05261750","kind":"trial","name":"Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer","route":"/trials/nct05261750/","asOf":"2026-09-16","days":12},{"id":"nct06055959","kind":"trial","name":"A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis","route":"/trials/nct06055959/","asOf":"2026-09-16","days":12},{"id":"nct05322590","kind":"trial","name":"BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma","route":"/trials/nct05322590/","asOf":"2026-09-16","days":12},{"id":"nct05263960","kind":"trial","name":"A Study of CM350 in Patients With Advanced Solid Tumors","route":"/trials/nct05263960/","asOf":"2026-09-16","days":12},{"id":"nct04652076","kind":"trial","name":"GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab","route":"/trials/nct04652076/","asOf":"2026-09-16","days":12},{"id":"nct05923008","kind":"trial","name":"A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct05923008/","asOf":"2026-09-16","days":12},{"id":"nct05609968","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)","route":"/trials/nct05609968/","asOf":"2026-09-16","days":12},{"id":"nct05265091","kind":"trial","name":"A Study of KL590586 in Patients With Advanced Solid Tumors","route":"/trials/nct05265091/","asOf":"2026-09-16","days":12},{"id":"nct06639347","kind":"trial","name":"A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma","route":"/trials/nct06639347/","asOf":"2026-09-16","days":12},{"id":"nct04980885","kind":"trial","name":"A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia","route":"/trials/nct04980885/","asOf":"2026-09-16","days":12},{"id":"nct03897543","kind":"trial","name":"ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma","route":"/trials/nct03897543/","asOf":"2026-09-16","days":12},{"id":"nct07481058","kind":"trial","name":"KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer","route":"/trials/nct07481058/","asOf":"2026-09-16","days":12},{"id":"nct06221748","kind":"trial","name":"DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy","route":"/trials/nct06221748/","asOf":"2026-09-16","days":12},{"id":"nct06858618","kind":"trial","name":"FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms","route":"/trials/nct06858618/","asOf":"2026-09-16","days":12},{"id":"nct05658003","kind":"trial","name":"A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer","route":"/trials/nct05658003/","asOf":"2026-09-16","days":12},{"id":"nct05902169","kind":"trial","name":"Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM","route":"/trials/nct05902169/","asOf":"2026-09-16","days":12},{"id":"nct06953323","kind":"trial","name":"A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors","route":"/trials/nct06953323/","asOf":"2026-09-16","days":12},{"id":"nct06385080","kind":"trial","name":"A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer","route":"/trials/nct06385080/","asOf":"2026-09-16","days":12},{"id":"nct07192588","kind":"trial","name":"A Study of GR1014 Cutaneous Gel for the Prevention of Skin Reactions Caused by Radiation Therapy for Breast Cancer","route":"/trials/nct07192588/","asOf":"2026-09-16","days":12},{"id":"nct06566586","kind":"trial","name":"A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma","route":"/trials/nct06566586/","asOf":"2026-09-16","days":12},{"id":"nct06959082","kind":"trial","name":"Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer","route":"/trials/nct06959082/","asOf":"2026-09-16","days":12},{"id":"nct06008288","kind":"trial","name":"A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.","route":"/trials/nct06008288/","asOf":"2026-09-16","days":12},{"id":"nct05584670","kind":"trial","name":"A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors","route":"/trials/nct05584670/","asOf":"2026-09-16","days":12},{"id":"nct05646862","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy","route":"/trials/nct05646862/","asOf":"2026-09-16","days":12},{"id":"nct06109779","kind":"trial","name":"Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)","route":"/trials/nct06109779/","asOf":"2026-09-16","days":12},{"id":"nct06118086","kind":"trial","name":"Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma","route":"/trials/nct06118086/","asOf":"2026-09-16","days":12},{"id":"nct05479994","kind":"trial","name":"Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","route":"/trials/nct05479994/","asOf":"2026-09-16","days":12},{"id":"nct07110571","kind":"trial","name":"A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer","route":"/trials/nct07110571/","asOf":"2026-09-16","days":12},{"id":"nct04977024","kind":"trial","name":"SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer","route":"/trials/nct04977024/","asOf":"2026-09-16","days":12},{"id":"nct06667908","kind":"trial","name":"A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct06667908/","asOf":"2026-09-16","days":12},{"id":"nct07359820","kind":"trial","name":"A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement","route":"/trials/nct07359820/","asOf":"2026-09-16","days":12},{"id":"nct05548296","kind":"trial","name":"A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma","route":"/trials/nct05548296/","asOf":"2026-09-16","days":12},{"id":"nct06178159","kind":"trial","name":"DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer","route":"/trials/nct06178159/","asOf":"2026-09-16","days":12},{"id":"nct03812874","kind":"trial","name":"A Study of PTX-9908 Injection for Non-resectable HCC with TACE","route":"/trials/nct03812874/","asOf":"2026-09-16","days":12},{"id":"nct04774718","kind":"trial","name":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors","route":"/trials/nct04774718/","asOf":"2026-09-16","days":12},{"id":"nct06549946","kind":"trial","name":"Ixovex-1 Single Agent and Combination Therapy","route":"/trials/nct06549946/","asOf":"2026-09-16","days":12},{"id":"nct05732103","kind":"trial","name":"A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes","route":"/trials/nct05732103/","asOf":"2026-09-16","days":12},{"id":"nct05623982","kind":"trial","name":"A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","route":"/trials/nct05623982/","asOf":"2026-09-16","days":12},{"id":"nct06378242","kind":"trial","name":"To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2","route":"/trials/nct06378242/","asOf":"2026-09-16","days":12},{"id":"nct04873362","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy","route":"/trials/nct04873362/","asOf":"2026-09-16","days":12},{"id":"nct07644039","kind":"trial","name":"Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies","route":"/trials/nct07644039/","asOf":"2026-09-16","days":12},{"id":"nct03319628","kind":"trial","name":"First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b","route":"/trials/nct03319628/","asOf":"2026-09-16","days":12},{"id":"nct05112965","kind":"trial","name":"An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)","route":"/trials/nct05112965/","asOf":"2026-09-16","days":12},{"id":"nct06157892","kind":"trial","name":"A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors","route":"/trials/nct06157892/","asOf":"2026-09-16","days":12},{"id":"nct06962267","kind":"trial","name":"A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)","route":"/trials/nct06962267/","asOf":"2026-09-16","days":12},{"id":"nct07085767","kind":"trial","name":"Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer","route":"/trials/nct07085767/","asOf":"2026-09-16","days":12},{"id":"nct06960577","kind":"trial","name":"Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)","route":"/trials/nct06960577/","asOf":"2026-09-16","days":12},{"id":"nct06385678","kind":"trial","name":"A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","route":"/trials/nct06385678/","asOf":"2026-09-16","days":12},{"id":"nct06754085","kind":"trial","name":"Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer","route":"/trials/nct06754085/","asOf":"2026-09-16","days":12},{"id":"nct06545955","kind":"trial","name":"A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer","route":"/trials/nct06545955/","asOf":"2026-09-16","days":12},{"id":"nct04684147","kind":"trial","name":"Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia","route":"/trials/nct04684147/","asOf":"2026-09-16","days":12},{"id":"nct06634589","kind":"trial","name":"A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies","route":"/trials/nct06634589/","asOf":"2026-09-16","days":12},{"id":"nct05463263","kind":"trial","name":"A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas","route":"/trials/nct05463263/","asOf":"2026-09-16","days":12},{"id":"nct07221149","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)","route":"/trials/nct07221149/","asOf":"2026-09-16","days":12},{"id":"nct01906385","kind":"trial","name":"Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)","route":"/trials/nct01906385/","asOf":"2026-09-16","days":12},{"id":"nct07339176","kind":"trial","name":"Intratumoral N17350 in Advanced Solid Tumors","route":"/trials/nct07339176/","asOf":"2026-09-16","days":12},{"id":"nct06246643","kind":"trial","name":"A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies","route":"/trials/nct06246643/","asOf":"2026-09-16","days":12},{"id":"nct04683250","kind":"trial","name":"Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities","route":"/trials/nct04683250/","asOf":"2026-09-16","days":12},{"id":"nct06635785","kind":"trial","name":"Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors","route":"/trials/nct06635785/","asOf":"2026-09-16","days":12},{"id":"nct05664243","kind":"trial","name":"A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma","route":"/trials/nct05664243/","asOf":"2026-09-16","days":12},{"id":"nct06341114","kind":"trial","name":"A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors","route":"/trials/nct06341114/","asOf":"2026-09-16","days":12},{"id":"nct06781567","kind":"trial","name":"Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma","route":"/trials/nct06781567/","asOf":"2026-09-16","days":12},{"id":"nct07093814","kind":"trial","name":"A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma","route":"/trials/nct07093814/","asOf":"2026-09-16","days":12},{"id":"nct07011186","kind":"trial","name":"A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies","route":"/trials/nct07011186/","asOf":"2026-09-16","days":12},{"id":"nct07468851","kind":"trial","name":"A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy","route":"/trials/nct07468851/","asOf":"2026-09-16","days":12},{"id":"nct07109219","kind":"trial","name":"Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia","route":"/trials/nct07109219/","asOf":"2026-09-16","days":12},{"id":"nct07761533","kind":"trial","name":"PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS","route":"/trials/nct07761533/","asOf":"2026-09-16","days":12},{"id":"nct03600233","kind":"trial","name":"Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors","route":"/trials/nct03600233/","asOf":"2026-09-16","days":12},{"id":"nct05727176","kind":"trial","name":"Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement","route":"/trials/nct05727176/","asOf":"2026-09-16","days":12},{"id":"nct05803018","kind":"trial","name":"A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies","route":"/trials/nct05803018/","asOf":"2026-09-16","days":12},{"id":"nct06569420","kind":"trial","name":"Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC","route":"/trials/nct06569420/","asOf":"2026-09-16","days":12},{"id":"nct06970847","kind":"trial","name":"64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer","route":"/trials/nct06970847/","asOf":"2026-09-16","days":12},{"id":"nct06652633","kind":"trial","name":"Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies","route":"/trials/nct06652633/","asOf":"2026-09-16","days":12},{"id":"nct07217704","kind":"trial","name":"Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.","route":"/trials/nct07217704/","asOf":"2026-09-16","days":12},{"id":"nct06194448","kind":"trial","name":"To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations","route":"/trials/nct06194448/","asOf":"2026-09-16","days":12},{"id":"nct05320198","kind":"trial","name":"Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia","route":"/trials/nct05320198/","asOf":"2026-09-16","days":12},{"id":"nct04821622","kind":"trial","name":"Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC","route":"/trials/nct04821622/","asOf":"2026-09-16","days":12},{"id":"nct06737731","kind":"trial","name":"A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors","route":"/trials/nct06737731/","asOf":"2026-09-16","days":12},{"id":"nct07230405","kind":"trial","name":"A Phase II Study of SKB571 in Patients With Lung Cancer","route":"/trials/nct07230405/","asOf":"2026-09-16","days":12},{"id":"nct07541079","kind":"trial","name":"A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)","route":"/trials/nct07541079/","asOf":"2026-09-16","days":12},{"id":"nct02781883","kind":"trial","name":"Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML","route":"/trials/nct02781883/","asOf":"2026-09-16","days":12},{"id":"nct05653453","kind":"trial","name":"Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer","route":"/trials/nct05653453/","asOf":"2026-09-16","days":12},{"id":"nct05377996","kind":"trial","name":"A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors","route":"/trials/nct05377996/","asOf":"2026-09-16","days":12},{"id":"nct06726161","kind":"trial","name":"Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC","route":"/trials/nct06726161/","asOf":"2026-09-16","days":12},{"id":"nct05379946","kind":"trial","name":"Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors","route":"/trials/nct05379946/","asOf":"2026-09-16","days":12},{"id":"nct07134088","kind":"trial","name":"A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia","route":"/trials/nct07134088/","asOf":"2026-09-16","days":12},{"id":"nct06850623","kind":"trial","name":"Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer","route":"/trials/nct06850623/","asOf":"2026-09-16","days":12},{"id":"nct04699188","kind":"trial","name":"Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","route":"/trials/nct04699188/","asOf":"2026-09-16","days":12},{"id":"nct06914128","kind":"trial","name":"A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors","route":"/trials/nct06914128/","asOf":"2026-09-16","days":12},{"id":"nct06805305","kind":"trial","name":"DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)","route":"/trials/nct06805305/","asOf":"2026-09-16","days":12},{"id":"nct07047365","kind":"trial","name":"TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer","route":"/trials/nct07047365/","asOf":"2026-09-16","days":12},{"id":"nct03505320","kind":"trial","name":"A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer","route":"/trials/nct03505320/","asOf":"2026-09-16","days":12},{"id":"nct07669454","kind":"trial","name":"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300mg Capsule in Reducing Cancer-Tumor in Patients With Metastatic Colorectal Cancer Receiving Standard Chemotherapy.","route":"/trials/nct07669454/","asOf":"2026-09-16","days":12},{"id":"nct07724756","kind":"trial","name":"Phase II Study of QLC2519 in Pediatric Solid Tumor Participants","route":"/trials/nct07724756/","asOf":"2026-09-16","days":12},{"id":"nct00781612","kind":"trial","name":"A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies","route":"/trials/nct00781612/","asOf":"2026-09-16","days":12},{"id":"nct05319730","kind":"trial","name":"A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)","route":"/trials/nct05319730/","asOf":"2026-09-16","days":12},{"id":"nct05329766","kind":"trial","name":"A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies","route":"/trials/nct05329766/","asOf":"2026-09-16","days":12},{"id":"nct03040973","kind":"trial","name":"Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone","route":"/trials/nct03040973/","asOf":"2026-09-16","days":12},{"id":"nct07109531","kind":"trial","name":"ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy","route":"/trials/nct07109531/","asOf":"2026-09-16","days":12},{"id":"nct05688605","kind":"trial","name":"A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors","route":"/trials/nct05688605/","asOf":"2026-09-16","days":12},{"id":"nct05456256","kind":"trial","name":"A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma","route":"/trials/nct05456256/","asOf":"2026-09-16","days":12},{"id":"nct07736937","kind":"trial","name":"Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer","route":"/trials/nct07736937/","asOf":"2026-09-16","days":12},{"id":"nct04954001","kind":"trial","name":"Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1","route":"/trials/nct04954001/","asOf":"2026-09-16","days":12},{"id":"nct05211570","kind":"trial","name":"AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia","route":"/trials/nct05211570/","asOf":"2026-09-16","days":12},{"id":"nct06369831","kind":"trial","name":"HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011","route":"/trials/nct06369831/","asOf":"2026-09-16","days":12},{"id":"nct06193902","kind":"trial","name":"LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.","route":"/trials/nct06193902/","asOf":"2026-09-16","days":12},{"id":"nct06772623","kind":"trial","name":"Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations","route":"/trials/nct06772623/","asOf":"2026-09-16","days":12},{"id":"nct07572396","kind":"trial","name":"Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities","route":"/trials/nct07572396/","asOf":"2026-09-16","days":12},{"id":"nct07467863","kind":"trial","name":"Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC","route":"/trials/nct07467863/","asOf":"2026-09-16","days":12},{"id":"nct05907057","kind":"trial","name":"An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.","route":"/trials/nct05907057/","asOf":"2026-09-16","days":12},{"id":"nct05563844","kind":"trial","name":"Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)","route":"/trials/nct05563844/","asOf":"2026-09-16","days":12},{"id":"nct02138734","kind":"trial","name":"A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer","route":"/trials/nct02138734/","asOf":"2026-09-16","days":12},{"id":"nct07154264","kind":"trial","name":"A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)","route":"/trials/nct07154264/","asOf":"2026-09-16","days":12},{"id":"nct06760819","kind":"trial","name":"A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)","route":"/trials/nct06760819/","asOf":"2026-09-16","days":12},{"id":"nct04503265","kind":"trial","name":"A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies","route":"/trials/nct04503265/","asOf":"2026-09-16","days":12},{"id":"nct07136142","kind":"trial","name":"A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors","route":"/trials/nct07136142/","asOf":"2026-09-16","days":12},{"id":"nct06926075","kind":"trial","name":"Early Phase Study of KESONOTIDE™in Participants With Solid Tumours","route":"/trials/nct06926075/","asOf":"2026-09-16","days":12},{"id":"nct06596694","kind":"trial","name":"Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)","route":"/trials/nct06596694/","asOf":"2026-09-16","days":12},{"id":"nct06117566","kind":"trial","name":"A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors","route":"/trials/nct06117566/","asOf":"2026-09-16","days":12},{"id":"nct05584800","kind":"trial","name":"Study of ZGGS18 in Patients With Advanced Solid Tumors","route":"/trials/nct05584800/","asOf":"2026-09-16","days":12},{"id":"nct02650401","kind":"trial","name":"Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options","route":"/trials/nct02650401/","asOf":"2026-09-16","days":12},{"id":"nct06938880","kind":"trial","name":"Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors","route":"/trials/nct06938880/","asOf":"2026-09-16","days":12},{"id":"nct06616389","kind":"trial","name":"Study of ODX (OsteoDex) in Multiple Myeloma","route":"/trials/nct06616389/","asOf":"2026-09-16","days":12},{"id":"nct04711252","kind":"trial","name":"A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease","route":"/trials/nct04711252/","asOf":"2026-09-16","days":12},{"id":"nct03567889","kind":"trial","name":"Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients","route":"/trials/nct03567889/","asOf":"2026-09-16","days":12},{"id":"nct06188702","kind":"trial","name":"S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP","route":"/trials/nct06188702/","asOf":"2026-09-16","days":12},{"id":"nct05144854","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)","route":"/trials/nct05144854/","asOf":"2026-09-16","days":12},{"id":"nct05473156","kind":"trial","name":"A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies","route":"/trials/nct05473156/","asOf":"2026-09-16","days":12},{"id":"nct06072131","kind":"trial","name":"To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL","route":"/trials/nct06072131/","asOf":"2026-09-16","days":12},{"id":"nct07173751","kind":"trial","name":"ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer","route":"/trials/nct07173751/","asOf":"2026-09-16","days":12},{"id":"nct05804669","kind":"trial","name":"A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome","route":"/trials/nct05804669/","asOf":"2026-09-16","days":12},{"id":"nct06823427","kind":"trial","name":"9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma","route":"/trials/nct06823427/","asOf":"2026-09-16","days":12},{"id":"nct06637423","kind":"trial","name":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)","route":"/trials/nct06637423/","asOf":"2026-09-16","days":12},{"id":"nct05627856","kind":"trial","name":"A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL","route":"/trials/nct05627856/","asOf":"2026-09-16","days":12},{"id":"nct06041802","kind":"trial","name":"A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)","route":"/trials/nct06041802/","asOf":"2026-09-16","days":12},{"id":"nct03934372","kind":"trial","name":"Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors","route":"/trials/nct03934372/","asOf":"2026-09-16","days":12},{"id":"nct07387081","kind":"trial","name":"Phase II Study of LM-24C5","route":"/trials/nct07387081/","asOf":"2026-09-16","days":12},{"id":"nct05902988","kind":"trial","name":"A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer","route":"/trials/nct05902988/","asOf":"2026-09-16","days":12},{"id":"nct06015503","kind":"trial","name":"A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)","route":"/trials/nct06015503/","asOf":"2026-09-16","days":12},{"id":"nct06821503","kind":"trial","name":"Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C","route":"/trials/nct06821503/","asOf":"2026-09-16","days":12},{"id":"nct07007559","kind":"trial","name":"ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer","route":"/trials/nct07007559/","asOf":"2026-09-16","days":12},{"id":"nct04492488","kind":"trial","name":"A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer","route":"/trials/nct04492488/","asOf":"2026-09-16","days":12},{"id":"nct04686682","kind":"trial","name":"A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors","route":"/trials/nct04686682/","asOf":"2026-09-16","days":12},{"id":"nct07567846","kind":"trial","name":"A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer","route":"/trials/nct07567846/","asOf":"2026-09-16","days":12},{"id":"nct04581512","kind":"trial","name":"Study to Evaluate the Safety and Tolerability of EP0042","route":"/trials/nct04581512/","asOf":"2026-09-16","days":12},{"id":"nct06526819","kind":"trial","name":"SMP-3124LP in Adults With Advanced Solid Tumors","route":"/trials/nct06526819/","asOf":"2026-09-16","days":12},{"id":"nct05566795","kind":"trial","name":"DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)","route":"/trials/nct05566795/","asOf":"2026-09-16","days":12},{"id":"nct06126640","kind":"trial","name":"A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy","route":"/trials/nct06126640/","asOf":"2026-09-16","days":12},{"id":"nct05499013","kind":"trial","name":"Study to Assess SLN124 in Patients With Polycythemia Vera","route":"/trials/nct05499013/","asOf":"2026-09-16","days":12},{"id":"nct06686394","kind":"trial","name":"Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)","route":"/trials/nct06686394/","asOf":"2026-09-16","days":12},{"id":"nct07480954","kind":"trial","name":"Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)","route":"/trials/nct07480954/","asOf":"2026-09-16","days":12},{"id":"nct04219254","kind":"trial","name":"A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors","route":"/trials/nct04219254/","asOf":"2026-09-16","days":12},{"id":"nct07114861","kind":"trial","name":"The KN510713 Study in Combination With mFOLFIRINOX","route":"/trials/nct07114861/","asOf":"2026-09-16","days":12},{"id":"nct06480240","kind":"trial","name":"A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors","route":"/trials/nct06480240/","asOf":"2026-09-16","days":12},{"id":"nct07636785","kind":"trial","name":"A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors","route":"/trials/nct07636785/","asOf":"2026-09-16","days":12},{"id":"nct07389733","kind":"trial","name":"A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer","route":"/trials/nct07389733/","asOf":"2026-09-16","days":12},{"id":"nct05965856","kind":"trial","name":"A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors","route":"/trials/nct05965856/","asOf":"2026-09-16","days":12},{"id":"nct06130553","kind":"trial","name":"A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors","route":"/trials/nct06130553/","asOf":"2026-09-16","days":12},{"id":"nct07510828","kind":"trial","name":"PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors","route":"/trials/nct07510828/","asOf":"2026-09-16","days":12},{"id":"nct05308264","kind":"trial","name":"Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)","route":"/trials/nct05308264/","asOf":"2026-09-16","days":12},{"id":"nct06618235","kind":"trial","name":"Trial of THEO-260 in Ovarian Cancer Patients","route":"/trials/nct06618235/","asOf":"2026-09-16","days":12},{"id":"nct05732831","kind":"trial","name":"Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors","route":"/trials/nct05732831/","asOf":"2026-09-16","days":12},{"id":"nct05669430","kind":"trial","name":"A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies","route":"/trials/nct05669430/","asOf":"2026-09-16","days":12},{"id":"nct02320435","kind":"trial","name":"A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial","route":"/trials/nct02320435/","asOf":"2026-09-16","days":12},{"id":"nct04241185","kind":"trial","name":"Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)","route":"/trials/nct04241185/","asOf":"2026-09-16","days":12},{"id":"nct05899049","kind":"trial","name":"A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study","route":"/trials/nct05899049/","asOf":"2026-09-16","days":12},{"id":"nct06592326","kind":"trial","name":"9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer","route":"/trials/nct06592326/","asOf":"2026-09-16","days":12},{"id":"nct06947291","kind":"trial","name":"Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors","route":"/trials/nct06947291/","asOf":"2026-09-16","days":12},{"id":"nct06950086","kind":"trial","name":"Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors","route":"/trials/nct06950086/","asOf":"2026-09-16","days":12},{"id":"nct05548127","kind":"trial","name":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)","route":"/trials/nct05548127/","asOf":"2026-09-16","days":12},{"id":"nct07697586","kind":"trial","name":"SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer","route":"/trials/nct07697586/","asOf":"2026-09-16","days":12},{"id":"nct03533283","kind":"trial","name":"An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","route":"/trials/nct03533283/","asOf":"2026-09-16","days":12},{"id":"nct06095505","kind":"trial","name":"A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer","route":"/trials/nct06095505/","asOf":"2026-09-16","days":12},{"id":"nct07448922","kind":"trial","name":"A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors","route":"/trials/nct07448922/","asOf":"2026-09-16","days":12},{"id":"nct06600022","kind":"trial","name":"Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.","route":"/trials/nct06600022/","asOf":"2026-09-16","days":12},{"id":"nct07691775","kind":"trial","name":"A Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors","route":"/trials/nct07691775/","asOf":"2026-09-16","days":12},{"id":"nct06080776","kind":"trial","name":"SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations","route":"/trials/nct06080776/","asOf":"2026-09-16","days":12},{"id":"nct06764940","kind":"trial","name":"A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases","route":"/trials/nct06764940/","asOf":"2026-09-16","days":12},{"id":"nct05204862","kind":"trial","name":"Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors","route":"/trials/nct05204862/","asOf":"2026-09-16","days":12},{"id":"nct05254743","kind":"trial","name":"A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","route":"/trials/nct05254743/","asOf":"2026-09-16","days":12},{"id":"nct07582315","kind":"trial","name":"A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)","route":"/trials/nct07582315/","asOf":"2026-09-16","days":12},{"id":"nct04938817","kind":"trial","name":"Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)","route":"/trials/nct04938817/","asOf":"2026-09-16","days":12},{"id":"nct07335497","kind":"trial","name":"CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct07335497/","asOf":"2026-09-16","days":12},{"id":"nct06941272","kind":"trial","name":"A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)","route":"/trials/nct06941272/","asOf":"2026-09-16","days":12},{"id":"nct05101070","kind":"trial","name":"S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors","route":"/trials/nct05101070/","asOf":"2026-09-16","days":12},{"id":"nct05417594","kind":"trial","name":"Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies","route":"/trials/nct05417594/","asOf":"2026-09-16","days":12},{"id":"nct06888921","kind":"trial","name":"A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer","route":"/trials/nct06888921/","asOf":"2026-09-16","days":12},{"id":"nct06492616","kind":"trial","name":"A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence","route":"/trials/nct06492616/","asOf":"2026-09-16","days":12},{"id":"nct07805252","kind":"trial","name":"Trial to Study the Safety, Pharmacokinetics and Preliminary Antitumour Activity of ODM-216 in Patients With Cancer","route":"/trials/nct07805252/","asOf":"2026-09-16","days":12},{"id":"nct07606599","kind":"trial","name":"A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure","route":"/trials/nct07606599/","asOf":"2026-09-16","days":12},{"id":"nct06378593","kind":"trial","name":"A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations","route":"/trials/nct06378593/","asOf":"2026-09-16","days":12},{"id":"nct02716116","kind":"trial","name":"A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer","route":"/trials/nct02716116/","asOf":"2026-09-16","days":12},{"id":"nct07075328","kind":"trial","name":"A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma","route":"/trials/nct07075328/","asOf":"2026-09-16","days":12},{"id":"nct05949619","kind":"trial","name":"A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors","route":"/trials/nct05949619/","asOf":"2026-09-16","days":12},{"id":"nct06580301","kind":"trial","name":"Study of YK012 in B-cell Acute Lymphoblastic Leukemia","route":"/trials/nct06580301/","asOf":"2026-09-16","days":12},{"id":"nct05520567","kind":"trial","name":"A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia","route":"/trials/nct05520567/","asOf":"2026-09-16","days":12},{"id":"nct05141149","kind":"trial","name":"First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer","route":"/trials/nct05141149/","asOf":"2026-09-16","days":12},{"id":"nct04891198","kind":"trial","name":"ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors","route":"/trials/nct04891198/","asOf":"2026-09-16","days":12},{"id":"nct07216443","kind":"trial","name":"Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome","route":"/trials/nct07216443/","asOf":"2026-09-16","days":12},{"id":"nct06819735","kind":"trial","name":"Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors","route":"/trials/nct06819735/","asOf":"2026-09-16","days":12},{"id":"nct04976634","kind":"trial","name":"Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)","route":"/trials/nct04976634/","asOf":"2026-09-16","days":12},{"id":"nct04965493","kind":"trial","name":"A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)","route":"/trials/nct04965493/","asOf":"2026-09-16","days":12},{"id":"nct03459534","kind":"trial","name":"A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs","route":"/trials/nct03459534/","asOf":"2026-09-16","days":12},{"id":"nct01954992","kind":"trial","name":"Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer","route":"/trials/nct01954992/","asOf":"2026-09-16","days":12},{"id":"nct07125872","kind":"trial","name":"Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma","route":"/trials/nct07125872/","asOf":"2026-09-16","days":12},{"id":"nct07136181","kind":"trial","name":"Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma","route":"/trials/nct07136181/","asOf":"2026-09-16","days":12},{"id":"nct07431281","kind":"trial","name":"Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2","route":"/trials/nct07431281/","asOf":"2026-09-16","days":12},{"id":"nct05745623","kind":"trial","name":"Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors","route":"/trials/nct05745623/","asOf":"2026-09-16","days":12},{"id":"nct07332455","kind":"trial","name":"First-Time-in-Human Study of GSK5471713 in Adults With mCRPC","route":"/trials/nct07332455/","asOf":"2026-09-16","days":12},{"id":"nct04974008","kind":"trial","name":"Osteosarcoma Maintenance Therapy With OST31-164","route":"/trials/nct04974008/","asOf":"2026-09-16","days":12},{"id":"nct04895358","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)","route":"/trials/nct04895358/","asOf":"2026-09-16","days":12},{"id":"nct06861088","kind":"trial","name":"The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer","route":"/trials/nct06861088/","asOf":"2026-09-16","days":12},{"id":"nct07105215","kind":"trial","name":"A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors","route":"/trials/nct07105215/","asOf":"2026-09-16","days":12},{"id":"nct04626518","kind":"trial","name":"Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)","route":"/trials/nct04626518/","asOf":"2026-09-16","days":12},{"id":"nct06112379","kind":"trial","name":"A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer","route":"/trials/nct06112379/","asOf":"2026-09-16","days":12},{"id":"nct05886920","kind":"trial","name":"A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations","route":"/trials/nct05886920/","asOf":"2026-09-16","days":12},{"id":"nct07356973","kind":"trial","name":"Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma","route":"/trials/nct07356973/","asOf":"2026-09-16","days":12},{"id":"nct06590246","kind":"trial","name":"A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)","route":"/trials/nct06590246/","asOf":"2026-09-16","days":12},{"id":"nct07499674","kind":"trial","name":"Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung","route":"/trials/nct07499674/","asOf":"2026-09-16","days":12},{"id":"nct06387342","kind":"trial","name":"Namodenoson Treatment of Advanced Pancreatic Cancer","route":"/trials/nct06387342/","asOf":"2026-09-16","days":12},{"id":"nct07544654","kind":"trial","name":"DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy","route":"/trials/nct07544654/","asOf":"2026-09-16","days":12},{"id":"nct05101096","kind":"trial","name":"Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors","route":"/trials/nct05101096/","asOf":"2026-09-16","days":12},{"id":"nct03478488","kind":"trial","name":"Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC","route":"/trials/nct03478488/","asOf":"2026-09-16","days":12},{"id":"nct05487170","kind":"trial","name":"A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)","route":"/trials/nct05487170/","asOf":"2026-09-16","days":12},{"id":"nct06911827","kind":"trial","name":"A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients","route":"/trials/nct06911827/","asOf":"2026-09-16","days":12},{"id":"nct03833154","kind":"trial","name":"Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation","route":"/trials/nct03833154/","asOf":"2026-09-16","days":12},{"id":"nct06111274","kind":"trial","name":"A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer","route":"/trials/nct06111274/","asOf":"2026-09-16","days":12},{"id":"nct06812260","kind":"trial","name":"A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC","route":"/trials/nct06812260/","asOf":"2026-09-16","days":12},{"id":"nct06520488","kind":"trial","name":"A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors","route":"/trials/nct06520488/","asOf":"2026-09-16","days":12},{"id":"nct06934538","kind":"trial","name":"First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer","route":"/trials/nct06934538/","asOf":"2026-09-16","days":12},{"id":"nct06873555","kind":"trial","name":"A Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors","route":"/trials/nct06873555/","asOf":"2026-09-16","days":12},{"id":"nct05428969","kind":"trial","name":"A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies","route":"/trials/nct05428969/","asOf":"2026-09-16","days":12},{"id":"nct05288166","kind":"trial","name":"A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)","route":"/trials/nct05288166/","asOf":"2026-09-16","days":12},{"id":"nct03519230","kind":"trial","name":"Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer","route":"/trials/nct03519230/","asOf":"2026-09-16","days":12},{"id":"nct06616766","kind":"trial","name":"A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946","route":"/trials/nct06616766/","asOf":"2026-09-16","days":12},{"id":"nct07581002","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)","route":"/trials/nct07581002/","asOf":"2026-09-16","days":12},{"id":"nct06514794","kind":"trial","name":"A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)","route":"/trials/nct06514794/","asOf":"2026-09-16","days":12},{"id":"nct06107686","kind":"trial","name":"A Study of YL202 in Selected Patients With Advanced Solid Tumors","route":"/trials/nct06107686/","asOf":"2026-09-16","days":12},{"id":"nct06107374","kind":"trial","name":"Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG","route":"/trials/nct06107374/","asOf":"2026-09-16","days":12},{"id":"nct06957886","kind":"trial","name":"A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer","route":"/trials/nct06957886/","asOf":"2026-09-16","days":12},{"id":"nct06750094","kind":"trial","name":"A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy","route":"/trials/nct06750094/","asOf":"2026-09-16","days":12},{"id":"nct04959903","kind":"trial","name":"Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT","route":"/trials/nct04959903/","asOf":"2026-09-16","days":12},{"id":"nct04486378","kind":"trial","name":"A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer","route":"/trials/nct04486378/","asOf":"2026-09-16","days":12},{"id":"nct07169552","kind":"trial","name":"HC010 in First-line PD-L1 Positive Advanced NSCLC Patients","route":"/trials/nct07169552/","asOf":"2026-09-16","days":12},{"id":"nct03933735","kind":"trial","name":"A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct03933735/","asOf":"2026-09-16","days":12},{"id":"nct07023315","kind":"trial","name":"A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma","route":"/trials/nct07023315/","asOf":"2026-09-16","days":12},{"id":"nct06747585","kind":"trial","name":"A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors","route":"/trials/nct06747585/","asOf":"2026-09-16","days":12},{"id":"nct04365374","kind":"trial","name":"Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)","route":"/trials/nct04365374/","asOf":"2026-09-16","days":12},{"id":"nct07315750","kind":"trial","name":"A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.","route":"/trials/nct07315750/","asOf":"2026-09-16","days":12},{"id":"nct06405425","kind":"trial","name":"A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma","route":"/trials/nct06405425/","asOf":"2026-09-16","days":12},{"id":"nct06682780","kind":"trial","name":"A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours","route":"/trials/nct06682780/","asOf":"2026-09-16","days":12},{"id":"nct05587296","kind":"trial","name":"A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer","route":"/trials/nct05587296/","asOf":"2026-09-16","days":12},{"id":"nct06678659","kind":"trial","name":"A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer","route":"/trials/nct06678659/","asOf":"2026-09-16","days":12},{"id":"nct05761223","kind":"trial","name":"A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849","route":"/trials/nct05761223/","asOf":"2026-09-16","days":12},{"id":"nct05683886","kind":"trial","name":"A Study of KC1036 in Patients with Advanced Thymic Tumors","route":"/trials/nct05683886/","asOf":"2026-09-16","days":12},{"id":"nct07070518","kind":"trial","name":"Study of GV20-0251 in Participants With Solid Tumor Malignancies","route":"/trials/nct07070518/","asOf":"2026-09-16","days":12},{"id":"nct04379596","kind":"trial","name":"Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)","route":"/trials/nct04379596/","asOf":"2026-09-16","days":12},{"id":"nct07702292","kind":"trial","name":"[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications","route":"/trials/nct07702292/","asOf":"2026-09-16","days":12},{"id":"nct07069712","kind":"trial","name":"A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma","route":"/trials/nct07069712/","asOf":"2026-09-16","days":12},{"id":"nct05957367","kind":"trial","name":"A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies","route":"/trials/nct05957367/","asOf":"2026-09-16","days":12},{"id":"nct06332092","kind":"trial","name":"FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma","route":"/trials/nct06332092/","asOf":"2026-09-16","days":12},{"id":"nct05908734","kind":"trial","name":"A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer","route":"/trials/nct05908734/","asOf":"2026-09-16","days":12},{"id":"nct05406401","kind":"trial","name":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)","route":"/trials/nct05406401/","asOf":"2026-09-16","days":12},{"id":"nct07209111","kind":"trial","name":"A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)","route":"/trials/nct07209111/","asOf":"2026-09-16","days":12},{"id":"nct05850234","kind":"trial","name":"AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)","route":"/trials/nct05850234/","asOf":"2026-09-16","days":12},{"id":"nct03328078","kind":"trial","name":"CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)","route":"/trials/nct03328078/","asOf":"2026-09-16","days":12},{"id":"nct07024706","kind":"trial","name":"Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab","route":"/trials/nct07024706/","asOf":"2026-09-16","days":12},{"id":"nct05488314","kind":"trial","name":"A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer","route":"/trials/nct05488314/","asOf":"2026-09-16","days":12},{"id":"nct06298916","kind":"trial","name":"64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer","route":"/trials/nct06298916/","asOf":"2026-09-16","days":12},{"id":"nct07299825","kind":"trial","name":"A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer","route":"/trials/nct07299825/","asOf":"2026-09-16","days":12},{"id":"nct06780098","kind":"trial","name":"Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)","route":"/trials/nct06780098/","asOf":"2026-09-16","days":12},{"id":"nct04115306","kind":"trial","name":"Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer","route":"/trials/nct04115306/","asOf":"2026-09-16","days":12},{"id":"nct06806033","kind":"trial","name":"Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL","route":"/trials/nct06806033/","asOf":"2026-09-16","days":12},{"id":"nct05316155","kind":"trial","name":"Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer","route":"/trials/nct05316155/","asOf":"2026-09-16","days":12},{"id":"nct04586478","kind":"trial","name":"Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma","route":"/trials/nct04586478/","asOf":"2026-09-16","days":12},{"id":"nct05951608","kind":"trial","name":"A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors","route":"/trials/nct05951608/","asOf":"2026-09-16","days":12},{"id":"nct07598955","kind":"trial","name":"Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma","route":"/trials/nct07598955/","asOf":"2026-09-16","days":12},{"id":"nct07367516","kind":"trial","name":"Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer","route":"/trials/nct07367516/","asOf":"2026-09-16","days":12},{"id":"nct04454437","kind":"trial","name":"Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments","route":"/trials/nct04454437/","asOf":"2026-09-16","days":12},{"id":"nct05948475","kind":"trial","name":"Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma","route":"/trials/nct05948475/","asOf":"2026-09-16","days":12},{"id":"nct06842498","kind":"trial","name":"A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","route":"/trials/nct06842498/","asOf":"2026-09-16","days":12},{"id":"nct07232875","kind":"trial","name":"HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer","route":"/trials/nct07232875/","asOf":"2026-09-16","days":12},{"id":"nct06752811","kind":"trial","name":"Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer","route":"/trials/nct06752811/","asOf":"2026-09-16","days":12},{"id":"nct07099898","kind":"trial","name":"A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)","route":"/trials/nct07099898/","asOf":"2026-09-16","days":12},{"id":"nct06079671","kind":"trial","name":"Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)","route":"/trials/nct06079671/","asOf":"2026-09-16","days":12},{"id":"nct05262400","kind":"trial","name":"A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors","route":"/trials/nct05262400/","asOf":"2026-09-16","days":12},{"id":"nct04390737","kind":"trial","name":"Evaluate the Safety and Clinical Activity of HH2853","route":"/trials/nct04390737/","asOf":"2026-09-16","days":12},{"id":"nct06644781","kind":"trial","name":"A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)","route":"/trials/nct06644781/","asOf":"2026-09-16","days":12},{"id":"nct03937154","kind":"trial","name":"Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer","route":"/trials/nct03937154/","asOf":"2026-09-16","days":12},{"id":"nct03722420","kind":"trial","name":"Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)","route":"/trials/nct03722420/","asOf":"2026-09-16","days":12},{"id":"nct04170283","kind":"trial","name":"A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib","route":"/trials/nct04170283/","asOf":"2026-09-16","days":12},{"id":"nct07136779","kind":"trial","name":"First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies","route":"/trials/nct07136779/","asOf":"2026-09-16","days":12},{"id":"nct05230810","kind":"trial","name":"Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.","route":"/trials/nct05230810/","asOf":"2026-09-16","days":12},{"id":"nct06247995","kind":"trial","name":"A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.","route":"/trials/nct06247995/","asOf":"2026-09-16","days":12},{"id":"nct07055594","kind":"trial","name":"A Study to Investigate Safety and Preliminary Efficacy of SOA101 in Adult Subjects With Advanced Solid Tumors","route":"/trials/nct07055594/","asOf":"2026-09-16","days":12},{"id":"nct04614103","kind":"trial","name":"Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer","route":"/trials/nct04614103/","asOf":"2026-09-16","days":12},{"id":"nct06605222","kind":"trial","name":"A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors","route":"/trials/nct06605222/","asOf":"2026-09-16","days":12},{"id":"nct06428396","kind":"trial","name":"Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)","route":"/trials/nct06428396/","asOf":"2026-09-16","days":12},{"id":"nct07597629","kind":"trial","name":"A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer","route":"/trials/nct07597629/","asOf":"2026-09-16","days":12},{"id":"nct05689853","kind":"trial","name":"Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors","route":"/trials/nct05689853/","asOf":"2026-09-16","days":12},{"id":"nct06189209","kind":"trial","name":"Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)","route":"/trials/nct06189209/","asOf":"2026-09-16","days":12},{"id":"nct07646626","kind":"trial","name":"SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors","route":"/trials/nct07646626/","asOf":"2026-09-16","days":12},{"id":"nct06735144","kind":"trial","name":"Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors","route":"/trials/nct06735144/","asOf":"2026-09-16","days":12},{"id":"nct06757634","kind":"trial","name":"Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)","route":"/trials/nct06757634/","asOf":"2026-09-16","days":12},{"id":"nct04888312","kind":"trial","name":"Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients","route":"/trials/nct04888312/","asOf":"2026-09-16","days":12},{"id":"nct07288112","kind":"trial","name":"DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma","route":"/trials/nct07288112/","asOf":"2026-09-16","days":12},{"id":"nct05315700","kind":"trial","name":"Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration","route":"/trials/nct05315700/","asOf":"2026-09-16","days":12},{"id":"nct06439771","kind":"trial","name":"A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC","route":"/trials/nct06439771/","asOf":"2026-09-16","days":12},{"id":"nct06922357","kind":"trial","name":"A Phase I/II of HRS-6719 in Patients With Advanced/Metastatic Solid Tumors","route":"/trials/nct06922357/","asOf":"2026-09-16","days":12},{"id":"nct06827236","kind":"trial","name":"A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer","route":"/trials/nct06827236/","asOf":"2026-09-16","days":12},{"id":"nct07368998","kind":"trial","name":"To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer","route":"/trials/nct07368998/","asOf":"2026-09-16","days":12},{"id":"nct06630234","kind":"trial","name":"A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)","route":"/trials/nct06630234/","asOf":"2026-09-16","days":12},{"id":"nct05558007","kind":"trial","name":"Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients","route":"/trials/nct05558007/","asOf":"2026-09-16","days":12},{"id":"nct06127407","kind":"trial","name":"Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen","route":"/trials/nct06127407/","asOf":"2026-09-16","days":12},{"id":"nct04862663","kind":"trial","name":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)","route":"/trials/nct04862663/","asOf":"2026-09-16","days":12},{"id":"nct04086264","kind":"trial","name":"IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia","route":"/trials/nct04086264/","asOf":"2026-09-16","days":12},{"id":"nct05771584","kind":"trial","name":"Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer","route":"/trials/nct05771584/","asOf":"2026-09-16","days":12},{"id":"nct07229638","kind":"trial","name":"A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors","route":"/trials/nct07229638/","asOf":"2026-09-16","days":12},{"id":"nct06212076","kind":"trial","name":"Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients","route":"/trials/nct06212076/","asOf":"2026-09-16","days":12},{"id":"nct07168226","kind":"trial","name":"Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101","route":"/trials/nct07168226/","asOf":"2026-09-16","days":12},{"id":"nct04829604","kind":"trial","name":"ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)","route":"/trials/nct04829604/","asOf":"2026-09-16","days":12},{"id":"nct07586943","kind":"trial","name":"SKB118 Injection in Advanced Solid Tumors","route":"/trials/nct07586943/","asOf":"2026-09-16","days":12},{"id":"nct07508761","kind":"trial","name":"IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors","route":"/trials/nct07508761/","asOf":"2026-09-16","days":12},{"id":"nct05755113","kind":"trial","name":"A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma","route":"/trials/nct05755113/","asOf":"2026-09-16","days":12},{"id":"nct07679360","kind":"trial","name":"A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer","route":"/trials/nct07679360/","asOf":"2026-09-16","days":12},{"id":"nct07225946","kind":"trial","name":"A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct07225946/","asOf":"2026-09-16","days":12},{"id":"nct06631079","kind":"trial","name":"Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors","route":"/trials/nct06631079/","asOf":"2026-09-16","days":12},{"id":"nct05909397","kind":"trial","name":"Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer","route":"/trials/nct05909397/","asOf":"2026-09-16","days":12},{"id":"nct05514054","kind":"trial","name":"A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer","route":"/trials/nct05514054/","asOf":"2026-09-16","days":12},{"id":"nct03876769","kind":"trial","name":"Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients","route":"/trials/nct03876769/","asOf":"2026-09-16","days":12},{"id":"nct05163041","kind":"trial","name":"Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression","route":"/trials/nct05163041/","asOf":"2026-09-16","days":12},{"id":"nct07605962","kind":"trial","name":"Phase 1/2 Study of UI-102 in Selected Advanced Cancers","route":"/trials/nct07605962/","asOf":"2026-09-16","days":12},{"id":"nct06353386","kind":"trial","name":"Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)","route":"/trials/nct06353386/","asOf":"2026-09-16","days":12},{"id":"nct06692166","kind":"trial","name":"A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer","route":"/trials/nct06692166/","asOf":"2026-09-16","days":12},{"id":"nct04165070","kind":"trial","name":"KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)","route":"/trials/nct04165070/","asOf":"2026-09-16","days":12},{"id":"nct03949283","kind":"trial","name":"Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer","route":"/trials/nct03949283/","asOf":"2026-09-16","days":12},{"id":"nct06906341","kind":"trial","name":"Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers","route":"/trials/nct06906341/","asOf":"2026-09-16","days":12},{"id":"nct06184035","kind":"trial","name":"A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer","route":"/trials/nct06184035/","asOf":"2026-09-16","days":12},{"id":"nct06969430","kind":"trial","name":"A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)","route":"/trials/nct06969430/","asOf":"2026-09-16","days":12},{"id":"nct06508931","kind":"trial","name":"Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms","route":"/trials/nct06508931/","asOf":"2026-09-16","days":12},{"id":"nct05882058","kind":"trial","name":"DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers","route":"/trials/nct05882058/","asOf":"2026-09-16","days":12},{"id":"nct06505395","kind":"trial","name":"A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)","route":"/trials/nct06505395/","asOf":"2026-09-16","days":12},{"id":"nct07639450","kind":"trial","name":"N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors","route":"/trials/nct07639450/","asOf":"2026-09-16","days":12},{"id":"nct06915142","kind":"trial","name":"A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour","route":"/trials/nct06915142/","asOf":"2026-09-16","days":12},{"id":"nct05963074","kind":"trial","name":"A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia","route":"/trials/nct05963074/","asOf":"2026-09-16","days":12},{"id":"nct07276789","kind":"trial","name":"Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer","route":"/trials/nct07276789/","asOf":"2026-09-16","days":12},{"id":"nct07314723","kind":"trial","name":"9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer","route":"/trials/nct07314723/","asOf":"2026-09-16","days":12},{"id":"nct07295821","kind":"trial","name":"Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study","route":"/trials/nct07295821/","asOf":"2026-09-16","days":12},{"id":"nct06239155","kind":"trial","name":"A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors","route":"/trials/nct06239155/","asOf":"2026-09-16","days":12},{"id":"nct05173987","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)","route":"/trials/nct05173987/","asOf":"2026-09-16","days":12},{"id":"nct06375733","kind":"trial","name":"A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL","route":"/trials/nct06375733/","asOf":"2026-09-16","days":12},{"id":"nct07038343","kind":"trial","name":"AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)","route":"/trials/nct07038343/","asOf":"2026-09-16","days":12},{"id":"nct06117540","kind":"trial","name":"A Study of WX390 in Patients With Advanced Solid Tumors","route":"/trials/nct06117540/","asOf":"2026-09-16","days":12},{"id":"nct05662397","kind":"trial","name":"A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody","route":"/trials/nct05662397/","asOf":"2026-09-16","days":12},{"id":"nct02934568","kind":"trial","name":"Ribociclib (LEE011) Rollover Study for Continued Access","route":"/trials/nct02934568/","asOf":"2026-09-16","days":12},{"id":"nct05038735","kind":"trial","name":"Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.","route":"/trials/nct05038735/","asOf":"2026-09-16","days":12},{"id":"nct05361174","kind":"trial","name":"A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer","route":"/trials/nct05361174/","asOf":"2026-09-16","days":12},{"id":"nct04041310","kind":"trial","name":"Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors","route":"/trials/nct04041310/","asOf":"2026-09-16","days":12},{"id":"nct06875310","kind":"trial","name":"A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)","route":"/trials/nct06875310/","asOf":"2026-09-16","days":12},{"id":"nct07466160","kind":"trial","name":"A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors","route":"/trials/nct07466160/","asOf":"2026-09-16","days":12},{"id":"nct07471789","kind":"trial","name":"Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).","route":"/trials/nct07471789/","asOf":"2026-09-16","days":12},{"id":"nct06959615","kind":"trial","name":"A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration","route":"/trials/nct06959615/","asOf":"2026-09-16","days":12},{"id":"nct06833008","kind":"trial","name":"A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours","route":"/trials/nct06833008/","asOf":"2026-09-16","days":12},{"id":"nct05451602","kind":"trial","name":"HEC169096 in Participants With Advanced Solid Tumors","route":"/trials/nct05451602/","asOf":"2026-09-16","days":12},{"id":"nct03967977","kind":"trial","name":"Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma","route":"/trials/nct03967977/","asOf":"2026-09-16","days":12},{"id":"nct06799637","kind":"trial","name":"Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments","route":"/trials/nct06799637/","asOf":"2026-09-16","days":12},{"id":"nct07298772","kind":"trial","name":"A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors","route":"/trials/nct07298772/","asOf":"2026-09-16","days":12},{"id":"nct04623541","kind":"trial","name":"Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome","route":"/trials/nct04623541/","asOf":"2026-09-16","days":12},{"id":"nct06939283","kind":"trial","name":"A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma","route":"/trials/nct06939283/","asOf":"2026-09-16","days":12},{"id":"nct05023486","kind":"trial","name":"NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies","route":"/trials/nct05023486/","asOf":"2026-09-16","days":12},{"id":"nct05057494","kind":"trial","name":"A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","route":"/trials/nct05057494/","asOf":"2026-09-16","days":12},{"id":"nct05986851","kind":"trial","name":"Azeliragon in MGMT Unmethylated Glioblastoma","route":"/trials/nct05986851/","asOf":"2026-09-16","days":12},{"id":"nct07087054","kind":"trial","name":"Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen","route":"/trials/nct07087054/","asOf":"2026-09-16","days":12},{"id":"nct06896890","kind":"trial","name":"Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer","route":"/trials/nct06896890/","asOf":"2026-09-16","days":12},{"id":"nct07641023","kind":"trial","name":"Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC","route":"/trials/nct07641023/","asOf":"2026-09-16","days":12},{"id":"nct07256782","kind":"trial","name":"A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors","route":"/trials/nct07256782/","asOf":"2026-09-16","days":12},{"id":"nct07111546","kind":"trial","name":"A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]","route":"/trials/nct07111546/","asOf":"2026-09-16","days":12},{"id":"nct06016920","kind":"trial","name":"Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma","route":"/trials/nct06016920/","asOf":"2026-09-16","days":12},{"id":"nct06031584","kind":"trial","name":"A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors","route":"/trials/nct06031584/","asOf":"2026-09-16","days":12},{"id":"nct07744763","kind":"trial","name":"A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors","route":"/trials/nct07744763/","asOf":"2026-09-16","days":12},{"id":"nct06279364","kind":"trial","name":"A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer","route":"/trials/nct06279364/","asOf":"2026-09-16","days":12},{"id":"nct07308106","kind":"trial","name":"A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities","route":"/trials/nct07308106/","asOf":"2026-09-16","days":12},{"id":"nct07407933","kind":"trial","name":"A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors","route":"/trials/nct07407933/","asOf":"2026-09-16","days":12},{"id":"nct05384587","kind":"trial","name":"Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia","route":"/trials/nct05384587/","asOf":"2026-09-16","days":12},{"id":"nct07116616","kind":"trial","name":"A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07116616/","asOf":"2026-09-16","days":12},{"id":"nct06679634","kind":"trial","name":"Retinoblastoma Phase II Expanded Access Clinical Trial","route":"/trials/nct06679634/","asOf":"2026-09-16","days":12},{"id":"nct06305247","kind":"trial","name":"A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours","route":"/trials/nct06305247/","asOf":"2026-09-16","days":12},{"id":"nct05201066","kind":"trial","name":"Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.","route":"/trials/nct05201066/","asOf":"2026-09-16","days":12},{"id":"nct05190445","kind":"trial","name":"Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma","route":"/trials/nct05190445/","asOf":"2026-09-16","days":12},{"id":"nct07229599","kind":"trial","name":"A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer","route":"/trials/nct07229599/","asOf":"2026-09-16","days":12},{"id":"nct06890884","kind":"trial","name":"A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)","route":"/trials/nct06890884/","asOf":"2026-09-16","days":12},{"id":"nct06376136","kind":"trial","name":"A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors","route":"/trials/nct06376136/","asOf":"2026-09-16","days":12},{"id":"nct06667544","kind":"trial","name":"A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation","route":"/trials/nct06667544/","asOf":"2026-09-16","days":12},{"id":"nct05701306","kind":"trial","name":"APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors","route":"/trials/nct05701306/","asOf":"2026-09-16","days":12},{"id":"nct07324629","kind":"trial","name":"Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma","route":"/trials/nct07324629/","asOf":"2026-09-16","days":12},{"id":"nct05806099","kind":"trial","name":"A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL","route":"/trials/nct05806099/","asOf":"2026-09-16","days":12},{"id":"nct04414163","kind":"trial","name":"A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type","route":"/trials/nct04414163/","asOf":"2026-09-16","days":12},{"id":"nct06064812","kind":"trial","name":"A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.","route":"/trials/nct06064812/","asOf":"2026-09-16","days":12},{"id":"nct07028281","kind":"trial","name":"A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors","route":"/trials/nct07028281/","asOf":"2026-09-16","days":12},{"id":"nct06780111","kind":"trial","name":"Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)","route":"/trials/nct06780111/","asOf":"2026-09-16","days":12},{"id":"nct06742892","kind":"trial","name":"A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy","route":"/trials/nct06742892/","asOf":"2026-09-16","days":12},{"id":"nct07545265","kind":"trial","name":"SKB565 for Injection in Advanced Solid Tumors","route":"/trials/nct07545265/","asOf":"2026-09-16","days":12},{"id":"nct04895436","kind":"trial","name":"Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)","route":"/trials/nct04895436/","asOf":"2026-09-16","days":12},{"id":"nct05868707","kind":"trial","name":"OH2 Injection in Melanoma","route":"/trials/nct05868707/","asOf":"2026-09-16","days":12},{"id":"nct03315364","kind":"trial","name":"Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy","route":"/trials/nct03315364/","asOf":"2026-09-16","days":12},{"id":"nct05908409","kind":"trial","name":"A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies","route":"/trials/nct05908409/","asOf":"2026-09-16","days":12},{"id":"nct04817007","kind":"trial","name":"A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)","route":"/trials/nct04817007/","asOf":"2026-09-16","days":12},{"id":"nct07032077","kind":"trial","name":"A Clinical Trial of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid Tumors","route":"/trials/nct07032077/","asOf":"2026-09-16","days":12},{"id":"nct05911295","kind":"trial","name":"Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2","route":"/trials/nct05911295/","asOf":"2026-09-16","days":12},{"id":"nct05410145","kind":"trial","name":"A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation","route":"/trials/nct05410145/","asOf":"2026-09-16","days":12},{"id":"nct06854445","kind":"trial","name":"Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma","route":"/trials/nct06854445/","asOf":"2026-09-16","days":12},{"id":"nct05950945","kind":"trial","name":"Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer","route":"/trials/nct05950945/","asOf":"2026-09-16","days":12},{"id":"nct07591090","kind":"trial","name":"A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer","route":"/trials/nct07591090/","asOf":"2026-09-16","days":12},{"id":"nct06985355","kind":"trial","name":"A Study of MHB046C Injection in Patients With Advanced Solid Tumors","route":"/trials/nct06985355/","asOf":"2026-09-16","days":12},{"id":"nct05920135","kind":"trial","name":"First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI","route":"/trials/nct05920135/","asOf":"2026-09-16","days":12},{"id":"nct07462650","kind":"trial","name":"Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer","route":"/trials/nct07462650/","asOf":"2026-09-16","days":12},{"id":"nct06943521","kind":"trial","name":"A Study of MT-4561 in Patients With Various Advanced Solid Tumors","route":"/trials/nct06943521/","asOf":"2026-09-16","days":12},{"id":"nct06810804","kind":"trial","name":"A Phase IIa Study to Evaluate NBQ72S","route":"/trials/nct06810804/","asOf":"2026-09-16","days":12},{"id":"nct07446855","kind":"trial","name":"Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours","route":"/trials/nct07446855/","asOf":"2026-09-16","days":12},{"id":"nct07095868","kind":"trial","name":"Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors","route":"/trials/nct07095868/","asOf":"2026-09-16","days":12},{"id":"nct06717126","kind":"trial","name":"A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma","route":"/trials/nct06717126/","asOf":"2026-09-16","days":12},{"id":"nct05615974","kind":"trial","name":"A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors","route":"/trials/nct05615974/","asOf":"2026-09-16","days":12},{"id":"nct04668690","kind":"trial","name":"Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL","route":"/trials/nct04668690/","asOf":"2026-09-16","days":12},{"id":"nct04785196","kind":"trial","name":"APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors","route":"/trials/nct04785196/","asOf":"2026-09-16","days":12},{"id":"nct07222969","kind":"trial","name":"A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors","route":"/trials/nct07222969/","asOf":"2026-09-16","days":12},{"id":"nct05966194","kind":"trial","name":"RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer","route":"/trials/nct05966194/","asOf":"2026-09-16","days":12},{"id":"nct06271837","kind":"trial","name":"A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors","route":"/trials/nct06271837/","asOf":"2026-09-16","days":12},{"id":"nct06225596","kind":"trial","name":"Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)","route":"/trials/nct06225596/","asOf":"2026-09-16","days":12},{"id":"nct04494503","kind":"trial","name":"Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL","route":"/trials/nct04494503/","asOf":"2026-09-16","days":12},{"id":"nct06706713","kind":"trial","name":"Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer","route":"/trials/nct06706713/","asOf":"2026-09-16","days":12},{"id":"nct04802759","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","route":"/trials/nct04802759/","asOf":"2026-09-16","days":12},{"id":"nct05374603","kind":"trial","name":"Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC","route":"/trials/nct05374603/","asOf":"2026-09-16","days":12},{"id":"nct06867705","kind":"trial","name":"Randomized Controlled Trial of Remote Symptoms Monitoring With Resilience PRO Compared to Care As Usual Only","route":"/trials/nct06867705/","asOf":"2026-09-16","days":12},{"id":"nct07554456","kind":"trial","name":"A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)","route":"/trials/nct07554456/","asOf":"2026-09-16","days":12},{"id":"nct05893888","kind":"trial","name":"A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers","route":"/trials/nct05893888/","asOf":"2026-09-16","days":12},{"id":"nct06445972","kind":"trial","name":"Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)","route":"/trials/nct06445972/","asOf":"2026-09-16","days":12},{"id":"nct07015242","kind":"trial","name":"A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma","route":"/trials/nct07015242/","asOf":"2026-09-16","days":12},{"id":"nct07751042","kind":"trial","name":"Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab","route":"/trials/nct07751042/","asOf":"2026-09-16","days":12},{"id":"nct04443010","kind":"trial","name":"Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma","route":"/trials/nct04443010/","asOf":"2026-09-16","days":12},{"id":"nct06656390","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors","route":"/trials/nct06656390/","asOf":"2026-09-16","days":12},{"id":"nct06756269","kind":"trial","name":"To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years","route":"/trials/nct06756269/","asOf":"2026-09-16","days":12},{"id":"nct06303505","kind":"trial","name":"FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC","route":"/trials/nct06303505/","asOf":"2026-09-16","days":12},{"id":"nct06471205","kind":"trial","name":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer","route":"/trials/nct06471205/","asOf":"2026-09-16","days":12},{"id":"nct06506643","kind":"trial","name":"Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms","route":"/trials/nct06506643/","asOf":"2026-09-16","days":12},{"id":"nct05466149","kind":"trial","name":"Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion","route":"/trials/nct05466149/","asOf":"2026-09-16","days":12},{"id":"nct04274426","kind":"trial","name":"Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer","route":"/trials/nct04274426/","asOf":"2026-09-16","days":12},{"id":"nct07235176","kind":"trial","name":"Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients","route":"/trials/nct07235176/","asOf":"2026-09-16","days":12},{"id":"nct07498725","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors","route":"/trials/nct07498725/","asOf":"2026-09-16","days":12},{"id":"nct07265674","kind":"trial","name":"A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer","route":"/trials/nct07265674/","asOf":"2026-09-16","days":12},{"id":"nct07499362","kind":"trial","name":"Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)","route":"/trials/nct07499362/","asOf":"2026-09-16","days":12},{"id":"nct05885464","kind":"trial","name":"A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)","route":"/trials/nct05885464/","asOf":"2026-09-16","days":12},{"id":"nct03767244","kind":"trial","name":"A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy","route":"/trials/nct03767244/","asOf":"2026-09-16","days":12},{"id":"nct06992609","kind":"trial","name":"Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.","route":"/trials/nct06992609/","asOf":"2026-09-16","days":12},{"id":"nct04390399","kind":"trial","name":"Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer","route":"/trials/nct04390399/","asOf":"2026-09-16","days":12},{"id":"nct06975293","kind":"trial","name":"STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas","route":"/trials/nct06975293/","asOf":"2026-09-16","days":12},{"id":"nct05736406","kind":"trial","name":"A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma","route":"/trials/nct05736406/","asOf":"2026-09-16","days":12},{"id":"nct07003321","kind":"trial","name":"A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct07003321/","asOf":"2026-09-16","days":12},{"id":"nct06819215","kind":"trial","name":"Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors","route":"/trials/nct06819215/","asOf":"2026-09-16","days":12},{"id":"nct07529717","kind":"trial","name":"First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer","route":"/trials/nct07529717/","asOf":"2026-09-16","days":12},{"id":"nct06260774","kind":"trial","name":"Study of TTX-MC138 in Subjects With Advanced Solid Tumors","route":"/trials/nct06260774/","asOf":"2026-09-16","days":12},{"id":"nct07232290","kind":"trial","name":"Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera","route":"/trials/nct07232290/","asOf":"2026-09-16","days":12},{"id":"nct04632108","kind":"trial","name":"A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct04632108/","asOf":"2026-09-16","days":12},{"id":"nct05608876","kind":"trial","name":"A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer","route":"/trials/nct05608876/","asOf":"2026-09-16","days":12},{"id":"nct07227025","kind":"trial","name":"A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer","route":"/trials/nct07227025/","asOf":"2026-09-16","days":12},{"id":"nct06434597","kind":"trial","name":"A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.","route":"/trials/nct06434597/","asOf":"2026-09-16","days":12},{"id":"nct06499350","kind":"trial","name":"A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors","route":"/trials/nct06499350/","asOf":"2026-09-16","days":12},{"id":"nct03865082","kind":"trial","name":"Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)","route":"/trials/nct03865082/","asOf":"2026-09-16","days":12},{"id":"nct06016062","kind":"trial","name":"A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors","route":"/trials/nct06016062/","asOf":"2026-09-16","days":12},{"id":"nct05533697","kind":"trial","name":"Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors","route":"/trials/nct05533697/","asOf":"2026-09-16","days":12},{"id":"nct06154291","kind":"trial","name":"FIH XON7 in Advanced/Metastatic Solid Tumors","route":"/trials/nct06154291/","asOf":"2026-09-16","days":12},{"id":"nct05205850","kind":"trial","name":"A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors","route":"/trials/nct05205850/","asOf":"2026-09-16","days":12},{"id":"nct06137118","kind":"trial","name":"AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia","route":"/trials/nct06137118/","asOf":"2026-09-16","days":12},{"id":"nct05594797","kind":"trial","name":"Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM","route":"/trials/nct05594797/","asOf":"2026-09-16","days":12},{"id":"nct07393542","kind":"trial","name":"A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma","route":"/trials/nct07393542/","asOf":"2026-09-16","days":12},{"id":"nct07300943","kind":"trial","name":"Study in Advanced Solid Tumor Patients","route":"/trials/nct07300943/","asOf":"2026-09-16","days":12},{"id":"nct06667960","kind":"trial","name":"Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer","route":"/trials/nct06667960/","asOf":"2026-09-16","days":12},{"id":"nct04064060","kind":"trial","name":"A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials","route":"/trials/nct04064060/","asOf":"2026-09-16","days":12},{"id":"nct06767813","kind":"trial","name":"Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms","route":"/trials/nct06767813/","asOf":"2026-09-16","days":12},{"id":"nct05948813","kind":"trial","name":"TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases","route":"/trials/nct05948813/","asOf":"2026-09-16","days":12},{"id":"nct06868277","kind":"trial","name":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer","route":"/trials/nct06868277/","asOf":"2026-09-16","days":12},{"id":"nct07285694","kind":"trial","name":"AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)","route":"/trials/nct07285694/","asOf":"2026-09-16","days":12},{"id":"nct07255872","kind":"trial","name":"A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia","route":"/trials/nct07255872/","asOf":"2026-09-16","days":12},{"id":"nct04458272","kind":"trial","name":"A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma","route":"/trials/nct04458272/","asOf":"2026-09-16","days":12},{"id":"nct06680752","kind":"trial","name":"Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS","route":"/trials/nct06680752/","asOf":"2026-09-16","days":12},{"id":"nct06084884","kind":"trial","name":"A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma","route":"/trials/nct06084884/","asOf":"2026-09-16","days":12},{"id":"nct06452706","kind":"trial","name":"The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer","route":"/trials/nct06452706/","asOf":"2026-09-16","days":12},{"id":"nct07284433","kind":"trial","name":"Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies","route":"/trials/nct07284433/","asOf":"2026-09-16","days":12},{"id":"nct06824168","kind":"trial","name":"Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission","route":"/trials/nct06824168/","asOf":"2026-09-16","days":12},{"id":"nct04496349","kind":"trial","name":"A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL","route":"/trials/nct04496349/","asOf":"2026-09-16","days":12},{"id":"nct04868604","kind":"trial","name":"64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)","route":"/trials/nct04868604/","asOf":"2026-09-16","days":12},{"id":"nct07387926","kind":"trial","name":"Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)","route":"/trials/nct07387926/","asOf":"2026-09-16","days":12},{"id":"nct06243458","kind":"trial","name":"RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms","route":"/trials/nct06243458/","asOf":"2026-09-16","days":12},{"id":"nct06885034","kind":"trial","name":"A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)","route":"/trials/nct06885034/","asOf":"2026-09-16","days":12},{"id":"nct07602777","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)","route":"/trials/nct07602777/","asOf":"2026-09-16","days":12},{"id":"nct06500273","kind":"trial","name":"Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL","route":"/trials/nct06500273/","asOf":"2026-09-16","days":12},{"id":"nct06710756","kind":"trial","name":"Lead-212 PSV359 Therapy for Patients With Solid Tumors","route":"/trials/nct06710756/","asOf":"2026-09-16","days":12},{"id":"nct05987956","kind":"trial","name":"Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms","route":"/trials/nct05987956/","asOf":"2026-09-16","days":12},{"id":"nct07649122","kind":"trial","name":"This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.","route":"/trials/nct07649122/","asOf":"2026-09-16","days":12},{"id":"nct06632951","kind":"trial","name":"Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)","route":"/trials/nct06632951/","asOf":"2026-09-16","days":12},{"id":"nct05838729","kind":"trial","name":"Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer","route":"/trials/nct05838729/","asOf":"2026-09-16","days":12},{"id":"nct05438329","kind":"trial","name":"First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors","route":"/trials/nct05438329/","asOf":"2026-09-16","days":12},{"id":"nct06417554","kind":"trial","name":"A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors","route":"/trials/nct06417554/","asOf":"2026-09-16","days":12},{"id":"nct07398339","kind":"trial","name":"Cosiporfin Sodium for Injection Photodynamic Therapy","route":"/trials/nct07398339/","asOf":"2026-09-16","days":12},{"id":"nct05521802","kind":"trial","name":"A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct05521802/","asOf":"2026-09-16","days":12},{"id":"nct05720130","kind":"trial","name":"Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).","route":"/trials/nct05720130/","asOf":"2026-09-16","days":12},{"id":"nct03290534","kind":"trial","name":"Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®","route":"/trials/nct03290534/","asOf":"2026-09-16","days":12},{"id":"nct06413745","kind":"trial","name":"Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer","route":"/trials/nct06413745/","asOf":"2026-09-16","days":12},{"id":"nct06947967","kind":"trial","name":"Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype","route":"/trials/nct06947967/","asOf":"2026-09-16","days":12},{"id":"nct05607004","kind":"trial","name":"(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer","route":"/trials/nct05607004/","asOf":"2026-09-16","days":12},{"id":"nct06425926","kind":"trial","name":"Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors","route":"/trials/nct06425926/","asOf":"2026-09-16","days":12},{"id":"nct06978114","kind":"trial","name":"A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer","route":"/trials/nct06978114/","asOf":"2026-09-16","days":12},{"id":"nct06474806","kind":"trial","name":"Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer","route":"/trials/nct06474806/","asOf":"2026-09-16","days":12},{"id":"nct05872347","kind":"trial","name":"Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.","route":"/trials/nct05872347/","asOf":"2026-09-16","days":12},{"id":"nct07669519","kind":"trial","name":"Evaluation of NuvastaticTM in Reducing Cancer-Related Fatigue in Colon Cancer Patients Undergoing First-Line Chemotherapy","route":"/trials/nct07669519/","asOf":"2026-09-16","days":12},{"id":"nct06389292","kind":"trial","name":"A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia","route":"/trials/nct06389292/","asOf":"2026-09-16","days":12},{"id":"nct05629234","kind":"trial","name":"Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)","route":"/trials/nct05629234/","asOf":"2026-09-16","days":12},{"id":"nct06788912","kind":"trial","name":"Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)","route":"/trials/nct06788912/","asOf":"2026-09-16","days":12},{"id":"nct05251714","kind":"trial","name":"CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer","route":"/trials/nct05251714/","asOf":"2026-09-16","days":12},{"id":"nct07396584","kind":"trial","name":"HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor","route":"/trials/nct07396584/","asOf":"2026-09-16","days":12},{"id":"nct06127238","kind":"trial","name":"Study of ST-1898 in Advanced Renal Cell Carcinoma","route":"/trials/nct06127238/","asOf":"2026-09-16","days":12},{"id":"nct07220616","kind":"trial","name":"A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies","route":"/trials/nct07220616/","asOf":"2026-09-16","days":12},{"id":"nct04662255","kind":"trial","name":"Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)","route":"/trials/nct04662255/","asOf":"2026-09-16","days":12},{"id":"nct07150663","kind":"trial","name":"Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer","route":"/trials/nct07150663/","asOf":"2026-09-16","days":12},{"id":"nct05269316","kind":"trial","name":"Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors","route":"/trials/nct05269316/","asOf":"2026-09-16","days":12},{"id":"nct07823049","kind":"trial","name":"Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy","route":"/trials/nct07823049/","asOf":"2026-09-16","days":12},{"id":"nct03711032","kind":"trial","name":"Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)","route":"/trials/nct03711032/","asOf":"2026-09-16","days":12},{"id":"nct06777316","kind":"trial","name":"A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors","route":"/trials/nct06777316/","asOf":"2026-09-16","days":12},{"id":"nct04539496","kind":"trial","name":"A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors","route":"/trials/nct04539496/","asOf":"2026-09-16","days":12},{"id":"nct06782334","kind":"trial","name":"AMT-116 in Patients with Solid Tumors","route":"/trials/nct06782334/","asOf":"2026-09-16","days":12},{"id":"nct02637687","kind":"trial","name":"A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children","route":"/trials/nct02637687/","asOf":"2026-09-16","days":12},{"id":"nct05443126","kind":"trial","name":"A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies","route":"/trials/nct05443126/","asOf":"2026-09-16","days":12},{"id":"nct05630209","kind":"trial","name":"Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)","route":"/trials/nct05630209/","asOf":"2026-09-16","days":12},{"id":"nct07405164","kind":"trial","name":"Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)","route":"/trials/nct07405164/","asOf":"2026-09-16","days":12},{"id":"nct06534060","kind":"trial","name":"MB-105 in Patients With CD5 Positive T-cell Lymphoma","route":"/trials/nct06534060/","asOf":"2026-09-16","days":12},{"id":"nct07189871","kind":"trial","name":"177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors","route":"/trials/nct07189871/","asOf":"2026-09-16","days":12},{"id":"nct05573555","kind":"trial","name":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)","route":"/trials/nct05573555/","asOf":"2026-09-16","days":12},{"id":"nct05884255","kind":"trial","name":"An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.","route":"/trials/nct05884255/","asOf":"2026-09-16","days":12},{"id":"nct05150691","kind":"trial","name":"A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors","route":"/trials/nct05150691/","asOf":"2026-09-16","days":12},{"id":"nct06780085","kind":"trial","name":"A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)","route":"/trials/nct06780085/","asOf":"2026-09-16","days":12},{"id":"nct07195591","kind":"trial","name":"Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care","route":"/trials/nct07195591/","asOf":"2026-09-16","days":12},{"id":"nct07155226","kind":"trial","name":"Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression","route":"/trials/nct07155226/","asOf":"2026-09-16","days":12},{"id":"nct05367778","kind":"trial","name":"Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors","route":"/trials/nct05367778/","asOf":"2026-09-16","days":12},{"id":"nct07444437","kind":"trial","name":"A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer","route":"/trials/nct07444437/","asOf":"2026-09-16","days":12},{"id":"nct07006077","kind":"trial","name":"Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer","route":"/trials/nct07006077/","asOf":"2026-09-16","days":12},{"id":"nct06380751","kind":"trial","name":"Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer","route":"/trials/nct06380751/","asOf":"2026-09-16","days":12},{"id":"nct06522737","kind":"trial","name":"A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype","route":"/trials/nct06522737/","asOf":"2026-09-16","days":12},{"id":"nct06989437","kind":"trial","name":"A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue","route":"/trials/nct06989437/","asOf":"2026-09-16","days":12},{"id":"nct05415072","kind":"trial","name":"A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas","route":"/trials/nct05415072/","asOf":"2026-09-16","days":12},{"id":"nct07221253","kind":"trial","name":"A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)","route":"/trials/nct07221253/","asOf":"2026-09-16","days":12},{"id":"nct07589257","kind":"trial","name":"A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine Glioma","route":"/trials/nct07589257/","asOf":"2026-09-16","days":12},{"id":"nct06277219","kind":"trial","name":"A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)","route":"/trials/nct06277219/","asOf":"2026-09-16","days":12},{"id":"nct06660654","kind":"trial","name":"A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)","route":"/trials/nct06660654/","asOf":"2026-09-16","days":12},{"id":"nct07454187","kind":"trial","name":"To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma","route":"/trials/nct07454187/","asOf":"2026-09-16","days":12},{"id":"nct07145255","kind":"trial","name":"Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors","route":"/trials/nct07145255/","asOf":"2026-09-16","days":12},{"id":"nct06892548","kind":"trial","name":"A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer","route":"/trials/nct06892548/","asOf":"2026-09-16","days":12},{"id":"nct07390383","kind":"trial","name":"A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]","route":"/trials/nct07390383/","asOf":"2026-09-16","days":12},{"id":"nct06313983","kind":"trial","name":"A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer","route":"/trials/nct06313983/","asOf":"2026-09-16","days":12},{"id":"nct06825494","kind":"trial","name":"Clinical Studies for the Treatment of Advanced Solid Tumors","route":"/trials/nct06825494/","asOf":"2026-09-16","days":12},{"id":"nct07238283","kind":"trial","name":"Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer","route":"/trials/nct07238283/","asOf":"2026-09-16","days":12},{"id":"nct04928222","kind":"trial","name":"Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)","route":"/trials/nct04928222/","asOf":"2026-09-16","days":12},{"id":"nct06057922","kind":"trial","name":"A Study YL201 in Patients With Selected Advanced Solid Tumors","route":"/trials/nct06057922/","asOf":"2026-09-16","days":12},{"id":"nct06970639","kind":"trial","name":"A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases","route":"/trials/nct06970639/","asOf":"2026-09-16","days":12},{"id":"nct07522151","kind":"trial","name":"Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer","route":"/trials/nct07522151/","asOf":"2026-09-16","days":12},{"id":"nct06425302","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma","route":"/trials/nct06425302/","asOf":"2026-09-16","days":12},{"id":"nct07154290","kind":"trial","name":"A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct07154290/","asOf":"2026-09-16","days":12},{"id":"nct05852691","kind":"trial","name":"A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer","route":"/trials/nct05852691/","asOf":"2026-09-16","days":12},{"id":"nct06697197","kind":"trial","name":"A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors","route":"/trials/nct06697197/","asOf":"2026-09-16","days":12},{"id":"nct03093116","kind":"trial","name":"A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements","route":"/trials/nct03093116/","asOf":"2026-09-16","days":12},{"id":"nct05201404","kind":"trial","name":"Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis","route":"/trials/nct05201404/","asOf":"2026-09-16","days":12},{"id":"nct07222488","kind":"trial","name":"A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)","route":"/trials/nct07222488/","asOf":"2026-09-16","days":12},{"id":"nct05547061","kind":"trial","name":"A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy","route":"/trials/nct05547061/","asOf":"2026-09-16","days":12},{"id":"nct06764186","kind":"trial","name":"A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain","route":"/trials/nct06764186/","asOf":"2026-09-16","days":12},{"id":"nct06345482","kind":"trial","name":"A Study of MHB039A for Advanced Solid Tumor","route":"/trials/nct06345482/","asOf":"2026-09-16","days":12},{"id":"nct03997123","kind":"trial","name":"Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC","route":"/trials/nct03997123/","asOf":"2026-09-16","days":12},{"id":"nct05631262","kind":"trial","name":"SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors","route":"/trials/nct05631262/","asOf":"2026-09-16","days":12},{"id":"nct07290088","kind":"trial","name":"Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients","route":"/trials/nct07290088/","asOf":"2026-09-16","days":12},{"id":"nct05744427","kind":"trial","name":"Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors","route":"/trials/nct05744427/","asOf":"2026-09-16","days":12},{"id":"nct06940401","kind":"trial","name":"JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations","route":"/trials/nct06940401/","asOf":"2026-09-16","days":12},{"id":"nct05855200","kind":"trial","name":"Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer","route":"/trials/nct05855200/","asOf":"2026-09-16","days":12},{"id":"nct07730021","kind":"trial","name":"A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors","route":"/trials/nct07730021/","asOf":"2026-09-16","days":12},{"id":"nct04651634","kind":"trial","name":"MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients","route":"/trials/nct04651634/","asOf":"2026-09-16","days":12},{"id":"nct07283367","kind":"trial","name":"A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.","route":"/trials/nct07283367/","asOf":"2026-09-16","days":12},{"id":"nct06079112","kind":"trial","name":"9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer","route":"/trials/nct06079112/","asOf":"2026-09-16","days":12},{"id":"nct05759728","kind":"trial","name":"A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer","route":"/trials/nct05759728/","asOf":"2026-09-16","days":12},{"id":"nct07647328","kind":"trial","name":"A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer","route":"/trials/nct07647328/","asOf":"2026-09-16","days":12},{"id":"nct04524000","kind":"trial","name":"Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer","route":"/trials/nct04524000/","asOf":"2026-09-16","days":12},{"id":"nct06088004","kind":"trial","name":"Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors","route":"/trials/nct06088004/","asOf":"2026-09-16","days":12},{"id":"nct06868485","kind":"trial","name":"A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer","route":"/trials/nct06868485/","asOf":"2026-09-16","days":12},{"id":"nct04641247","kind":"trial","name":"A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study","route":"/trials/nct04641247/","asOf":"2026-09-16","days":12},{"id":"nct06591520","kind":"trial","name":"AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer","route":"/trials/nct06591520/","asOf":"2026-09-16","days":12},{"id":"nct07664150","kind":"trial","name":"CW-301 FIH Study of CAN016","route":"/trials/nct07664150/","asOf":"2026-09-16","days":12},{"id":"nct04098744","kind":"trial","name":"Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)","route":"/trials/nct04098744/","asOf":"2026-09-16","days":12},{"id":"nct05566041","kind":"trial","name":"A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer","route":"/trials/nct05566041/","asOf":"2026-09-16","days":12},{"id":"nct06937177","kind":"trial","name":"Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy","route":"/trials/nct06937177/","asOf":"2026-09-16","days":12},{"id":"nct06993844","kind":"trial","name":"Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors","route":"/trials/nct06993844/","asOf":"2026-09-16","days":12},{"id":"nct07241767","kind":"trial","name":"A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer","route":"/trials/nct07241767/","asOf":"2026-09-16","days":12},{"id":"nct07019675","kind":"trial","name":"A Study of SKB518 in Patients With Lung Cancer","route":"/trials/nct07019675/","asOf":"2026-09-16","days":12},{"id":"nct04906993","kind":"trial","name":"Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer","route":"/trials/nct04906993/","asOf":"2026-09-16","days":12},{"id":"nct05579132","kind":"trial","name":"A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)","route":"/trials/nct05579132/","asOf":"2026-09-16","days":12},{"id":"nct06879145","kind":"trial","name":"Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)","route":"/trials/nct06879145/","asOf":"2026-09-16","days":12},{"id":"nct06962787","kind":"trial","name":"A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer","route":"/trials/nct06962787/","asOf":"2026-09-16","days":12},{"id":"nct07140393","kind":"trial","name":"A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor","route":"/trials/nct07140393/","asOf":"2026-09-16","days":12},{"id":"nct06730009","kind":"trial","name":"Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients","route":"/trials/nct06730009/","asOf":"2026-09-16","days":12},{"id":"nct07033026","kind":"trial","name":"An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.","route":"/trials/nct07033026/","asOf":"2026-09-16","days":12},{"id":"nct06618287","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors","route":"/trials/nct06618287/","asOf":"2026-09-16","days":12},{"id":"nct07811193","kind":"trial","name":"A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum","route":"/trials/nct07811193/","asOf":"2026-09-16","days":12},{"id":"nct05918133","kind":"trial","name":"A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC","route":"/trials/nct05918133/","asOf":"2026-09-16","days":12},{"id":"nct06391944","kind":"trial","name":"JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations","route":"/trials/nct06391944/","asOf":"2026-09-16","days":12},{"id":"nct07122414","kind":"trial","name":"A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer","route":"/trials/nct07122414/","asOf":"2026-09-16","days":12},{"id":"nct04960709","kind":"trial","name":"Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin","route":"/trials/nct04960709/","asOf":"2026-09-16","days":12},{"id":"nct06359847","kind":"trial","name":"Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer","route":"/trials/nct06359847/","asOf":"2026-09-16","days":12},{"id":"nct07208149","kind":"trial","name":"A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)","route":"/trials/nct07208149/","asOf":"2026-09-16","days":12},{"id":"nct05990452","kind":"trial","name":"Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors","route":"/trials/nct05990452/","asOf":"2026-09-16","days":12},{"id":"nct07669415","kind":"trial","name":"A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors","route":"/trials/nct07669415/","asOf":"2026-09-16","days":12},{"id":"nct05636215","kind":"trial","name":"A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors","route":"/trials/nct05636215/","asOf":"2026-09-16","days":12},{"id":"nct07520006","kind":"trial","name":"Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies","route":"/trials/nct07520006/","asOf":"2026-09-16","days":12},{"id":"nct06150885","kind":"trial","name":"A Safety And Efficacy Study Of Allogeneic CAR Gamma-Delta T Cells in Subjects With Relapsed/Refractory Solid Tumors","route":"/trials/nct06150885/","asOf":"2026-09-16","days":12},{"id":"nct04626635","kind":"trial","name":"A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers","route":"/trials/nct04626635/","asOf":"2026-09-16","days":12},{"id":"nct05879055","kind":"trial","name":"A Study of PM8002 in Combination With Chemotherapy in Patients With NEN","route":"/trials/nct05879055/","asOf":"2026-09-16","days":12},{"id":"nct02531516","kind":"trial","name":"An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS","route":"/trials/nct02531516/","asOf":"2026-09-16","days":12},{"id":"nct05588648","kind":"trial","name":"Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma","route":"/trials/nct05588648/","asOf":"2026-09-16","days":12},{"id":"nct06472076","kind":"trial","name":"A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)","route":"/trials/nct06472076/","asOf":"2026-09-16","days":12},{"id":"nct06930794","kind":"trial","name":"A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive","route":"/trials/nct06930794/","asOf":"2026-09-16","days":12},{"id":"nct04079166","kind":"trial","name":"SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)","route":"/trials/nct04079166/","asOf":"2026-09-16","days":12},{"id":"nct07354711","kind":"trial","name":"A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors","route":"/trials/nct07354711/","asOf":"2026-09-16","days":12},{"id":"nct05257395","kind":"trial","name":"A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer","route":"/trials/nct05257395/","asOf":"2026-09-16","days":12},{"id":"nct07287995","kind":"trial","name":"A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors","route":"/trials/nct07287995/","asOf":"2026-09-16","days":12},{"id":"nct05543330","kind":"trial","name":"A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC","route":"/trials/nct05543330/","asOf":"2026-09-16","days":12},{"id":"nct07258407","kind":"trial","name":"A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer","route":"/trials/nct07258407/","asOf":"2026-09-16","days":12},{"id":"nct06241781","kind":"trial","name":"Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer","route":"/trials/nct06241781/","asOf":"2026-09-16","days":12},{"id":"nct06549465","kind":"trial","name":"Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)","route":"/trials/nct06549465/","asOf":"2026-09-16","days":12},{"id":"nct06474468","kind":"trial","name":"A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer","route":"/trials/nct06474468/","asOf":"2026-09-16","days":12},{"id":"nct05312710","kind":"trial","name":"Safety and Efficacy of APG-157 in Head and Neck Cancer","route":"/trials/nct05312710/","asOf":"2026-09-16","days":12},{"id":"nct05787613","kind":"trial","name":"A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients","route":"/trials/nct05787613/","asOf":"2026-09-16","days":12},{"id":"nct05951179","kind":"trial","name":"Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer","route":"/trials/nct05951179/","asOf":"2026-09-16","days":12},{"id":"nct04150497","kind":"trial","name":"Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)","route":"/trials/nct04150497/","asOf":"2026-09-16","days":12},{"id":"nct04561362","kind":"trial","name":"Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies","route":"/trials/nct04561362/","asOf":"2026-09-16","days":12},{"id":"nct03667170","kind":"trial","name":"KN035 for dMMR/MSI-H Advanced Solid Tumors","route":"/trials/nct03667170/","asOf":"2026-09-16","days":12},{"id":"nct07186842","kind":"trial","name":"A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9","route":"/trials/nct07186842/","asOf":"2026-09-16","days":12},{"id":"nct06041061","kind":"trial","name":"A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years","route":"/trials/nct06041061/","asOf":"2026-09-16","days":12},{"id":"nct06833073","kind":"trial","name":"A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)","route":"/trials/nct06833073/","asOf":"2026-09-16","days":12},{"id":"nct04879043","kind":"trial","name":"Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma","route":"/trials/nct04879043/","asOf":"2026-09-16","days":12},{"id":"nct06649708","kind":"trial","name":"HX044,FIH Study in Patients with Advanced Solid Tumor Malignancies","route":"/trials/nct06649708/","asOf":"2026-09-16","days":12},{"id":"nct04570423","kind":"trial","name":"A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy","route":"/trials/nct04570423/","asOf":"2026-09-16","days":12},{"id":"nct07259213","kind":"trial","name":"A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC","route":"/trials/nct07259213/","asOf":"2026-09-16","days":12},{"id":"nct07103668","kind":"trial","name":"A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients","route":"/trials/nct07103668/","asOf":"2026-09-16","days":12},{"id":"nct05941897","kind":"trial","name":"A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy","route":"/trials/nct05941897/","asOf":"2026-09-16","days":12},{"id":"nct04834024","kind":"trial","name":"MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma","route":"/trials/nct04834024/","asOf":"2026-09-16","days":12},{"id":"nct05239741","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)","route":"/trials/nct05239741/","asOf":"2026-09-16","days":12},{"id":"nct06637501","kind":"trial","name":"A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia","route":"/trials/nct06637501/","asOf":"2026-09-16","days":12},{"id":"nct06485219","kind":"trial","name":"A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma","route":"/trials/nct06485219/","asOf":"2026-09-16","days":12},{"id":"nct05801237","kind":"trial","name":"PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor","route":"/trials/nct05801237/","asOf":"2026-09-16","days":12},{"id":"nct07405801","kind":"trial","name":"A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer","route":"/trials/nct07405801/","asOf":"2026-09-16","days":12},{"id":"nct02340117","kind":"trial","name":"Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer","route":"/trials/nct02340117/","asOf":"2026-09-16","days":12},{"id":"nct06493552","kind":"trial","name":"Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors","route":"/trials/nct06493552/","asOf":"2026-09-16","days":12},{"id":"nct05027776","kind":"trial","name":"Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years","route":"/trials/nct05027776/","asOf":"2026-09-16","days":12},{"id":"nct06456463","kind":"trial","name":"A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy","route":"/trials/nct06456463/","asOf":"2026-09-16","days":12},{"id":"nct07371663","kind":"trial","name":"An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors","route":"/trials/nct07371663/","asOf":"2026-09-16","days":12},{"id":"nct01946204","kind":"trial","name":"A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct01946204/","asOf":"2026-09-16","days":12},{"id":"nct07281976","kind":"trial","name":"A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer","route":"/trials/nct07281976/","asOf":"2026-09-16","days":12},{"id":"nct06782555","kind":"trial","name":"A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab","route":"/trials/nct06782555/","asOf":"2026-09-16","days":12},{"id":"nct05864014","kind":"trial","name":"Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.","route":"/trials/nct05864014/","asOf":"2026-09-16","days":12},{"id":"nct07205718","kind":"trial","name":"A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors","route":"/trials/nct07205718/","asOf":"2026-09-16","days":12},{"id":"nct06012435","kind":"trial","name":"A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer","route":"/trials/nct06012435/","asOf":"2026-09-16","days":12},{"id":"nct04643418","kind":"trial","name":"Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors","route":"/trials/nct04643418/","asOf":"2026-09-16","days":12},{"id":"nct06600789","kind":"trial","name":"A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies","route":"/trials/nct06600789/","asOf":"2026-09-16","days":12},{"id":"nct03441113","kind":"trial","name":"Extended Access of Momelotinib in Adults With Myelofibrosis","route":"/trials/nct03441113/","asOf":"2026-09-16","days":12},{"id":"nct05967689","kind":"trial","name":"A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.","route":"/trials/nct05967689/","asOf":"2026-09-16","days":12},{"id":"nct05277168","kind":"trial","name":"A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS","route":"/trials/nct05277168/","asOf":"2026-09-16","days":12},{"id":"nct06970743","kind":"trial","name":"A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors","route":"/trials/nct06970743/","asOf":"2026-09-16","days":12},{"id":"nct05652920","kind":"trial","name":"Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC","route":"/trials/nct05652920/","asOf":"2026-09-16","days":12},{"id":"nct05827081","kind":"trial","name":"Phase IIIb Study of Ribociclib + ET in Early Breast Cancer","route":"/trials/nct05827081/","asOf":"2026-09-16","days":12},{"id":"nct06703177","kind":"trial","name":"A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors","route":"/trials/nct06703177/","asOf":"2026-09-16","days":12},{"id":"nct06966453","kind":"trial","name":"A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer","route":"/trials/nct06966453/","asOf":"2026-09-16","days":12},{"id":"nct04514419","kind":"trial","name":"Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel","route":"/trials/nct04514419/","asOf":"2026-09-16","days":12},{"id":"nct06642545","kind":"trial","name":"Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer","route":"/trials/nct06642545/","asOf":"2026-09-16","days":12},{"id":"nct06243354","kind":"trial","name":"Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation","route":"/trials/nct06243354/","asOf":"2026-09-16","days":12},{"id":"nct06123494","kind":"trial","name":"SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen","route":"/trials/nct06123494/","asOf":"2026-09-16","days":12},{"id":"nct07231211","kind":"trial","name":"A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors","route":"/trials/nct07231211/","asOf":"2026-09-16","days":12},{"id":"nct01064466","kind":"trial","name":"Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms","route":"/trials/nct01064466/","asOf":"2026-09-16","days":12},{"id":"nct06524375","kind":"trial","name":"A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period","route":"/trials/nct06524375/","asOf":"2026-09-16","days":12},{"id":"nct06484829","kind":"trial","name":"Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct06484829/","asOf":"2026-09-16","days":12},{"id":"nct07072728","kind":"trial","name":"Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder","route":"/trials/nct07072728/","asOf":"2026-09-16","days":12},{"id":"nct03862430","kind":"trial","name":"A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM","route":"/trials/nct03862430/","asOf":"2026-09-16","days":12},{"id":"nct05879822","kind":"trial","name":"A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive","route":"/trials/nct05879822/","asOf":"2026-09-16","days":12},{"id":"nct07700160","kind":"trial","name":"First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors","route":"/trials/nct07700160/","asOf":"2026-09-16","days":12},{"id":"nct03435796","kind":"trial","name":"Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells","route":"/trials/nct03435796/","asOf":"2026-09-16","days":12},{"id":"nct07019779","kind":"trial","name":"Study of CM518D1 in Patients With Advanced Solid Tumors","route":"/trials/nct07019779/","asOf":"2026-09-16","days":12},{"id":"nct04879329","kind":"trial","name":"A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2","route":"/trials/nct04879329/","asOf":"2026-09-16","days":12},{"id":"nct07106762","kind":"trial","name":"Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy","route":"/trials/nct07106762/","asOf":"2026-09-16","days":12},{"id":"nct04270591","kind":"trial","name":"Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer","route":"/trials/nct04270591/","asOf":"2026-09-16","days":12},{"id":"nct06147570","kind":"trial","name":"A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer","route":"/trials/nct06147570/","asOf":"2026-09-16","days":12},{"id":"nct05879068","kind":"trial","name":"A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC","route":"/trials/nct05879068/","asOf":"2026-09-16","days":12},{"id":"nct06336291","kind":"trial","name":"A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence","route":"/trials/nct06336291/","asOf":"2026-09-16","days":12},{"id":"nct05053880","kind":"trial","name":"A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme","route":"/trials/nct05053880/","asOf":"2026-09-16","days":12},{"id":"nct07444541","kind":"trial","name":"ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer","route":"/trials/nct07444541/","asOf":"2026-09-16","days":12},{"id":"nct06066203","kind":"trial","name":"A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies","route":"/trials/nct06066203/","asOf":"2026-09-16","days":12},{"id":"nct05589896","kind":"trial","name":"A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies","route":"/trials/nct05589896/","asOf":"2026-09-16","days":12},{"id":"nct02972840","kind":"trial","name":"A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL","route":"/trials/nct02972840/","asOf":"2026-09-16","days":12},{"id":"nct06654440","kind":"trial","name":"A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy","route":"/trials/nct06654440/","asOf":"2026-09-16","days":12},{"id":"nct04550260","kind":"trial","name":"Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC","route":"/trials/nct04550260/","asOf":"2026-09-16","days":12},{"id":"nct06619509","kind":"trial","name":"A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine","route":"/trials/nct06619509/","asOf":"2026-09-16","days":12},{"id":"nct06907043","kind":"trial","name":"A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.","route":"/trials/nct06907043/","asOf":"2026-09-16","days":12},{"id":"nct05526755","kind":"trial","name":"A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)","route":"/trials/nct05526755/","asOf":"2026-09-16","days":12},{"id":"nct06014658","kind":"trial","name":"Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors","route":"/trials/nct06014658/","asOf":"2026-09-16","days":12},{"id":"nct07648914","kind":"trial","name":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)","route":"/trials/nct07648914/","asOf":"2026-09-16","days":12},{"id":"nct06556563","kind":"trial","name":"EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma","route":"/trials/nct06556563/","asOf":"2026-09-16","days":12},{"id":"nct06296706","kind":"trial","name":"A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer","route":"/trials/nct06296706/","asOf":"2026-09-16","days":12},{"id":"nct07157033","kind":"trial","name":"A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.","route":"/trials/nct07157033/","asOf":"2026-09-16","days":12},{"id":"nct06760637","kind":"trial","name":"Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease","route":"/trials/nct06760637/","asOf":"2026-09-16","days":12},{"id":"nct06056830","kind":"trial","name":"Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy","route":"/trials/nct06056830/","asOf":"2026-09-16","days":12},{"id":"nct02843945","kind":"trial","name":"Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source","route":"/trials/nct02843945/","asOf":"2026-09-16","days":12},{"id":"nct07071337","kind":"trial","name":"A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy","route":"/trials/nct07071337/","asOf":"2026-09-16","days":12},{"id":"nct07460375","kind":"trial","name":"A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors","route":"/trials/nct07460375/","asOf":"2026-09-16","days":12},{"id":"nct06632912","kind":"trial","name":"Phase IIIb Clinical Trial of Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) for Age/Immunization Schedule Bridging","route":"/trials/nct06632912/","asOf":"2026-09-16","days":12},{"id":"nct06939595","kind":"trial","name":"A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer","route":"/trials/nct06939595/","asOf":"2026-09-16","days":12},{"id":"nct04014205","kind":"trial","name":"A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies","route":"/trials/nct04014205/","asOf":"2026-09-16","days":12},{"id":"nct04996121","kind":"trial","name":"A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct04996121/","asOf":"2026-09-16","days":12},{"id":"nct06464055","kind":"trial","name":"A Study of GQ1010 in Subjects With Advanced Solid Tumors","route":"/trials/nct06464055/","asOf":"2026-09-16","days":12},{"id":"nct07145333","kind":"trial","name":"Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms","route":"/trials/nct07145333/","asOf":"2026-09-16","days":12},{"id":"nct07022002","kind":"trial","name":"SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors","route":"/trials/nct07022002/","asOf":"2026-09-16","days":12},{"id":"nct05952037","kind":"trial","name":"A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia","route":"/trials/nct05952037/","asOf":"2026-09-16","days":12},{"id":"nct04725994","kind":"trial","name":"Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer","route":"/trials/nct04725994/","asOf":"2026-09-16","days":12},{"id":"nct06639256","kind":"trial","name":"Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors","route":"/trials/nct06639256/","asOf":"2026-09-16","days":12},{"id":"nct05918445","kind":"trial","name":"PM8002 in the Treatment of Patients With Advanced Solid Tumors","route":"/trials/nct05918445/","asOf":"2026-09-16","days":12},{"id":"nct03899636","kind":"trial","name":"A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer","route":"/trials/nct03899636/","asOf":"2026-09-16","days":12},{"id":"nct07541001","kind":"trial","name":"PRL3-Zumab in Patients With Advanced Solid Tumors","route":"/trials/nct07541001/","asOf":"2026-09-16","days":12},{"id":"nct06741644","kind":"trial","name":"A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors","route":"/trials/nct06741644/","asOf":"2026-09-16","days":12},{"id":"nct07221734","kind":"trial","name":"Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma","route":"/trials/nct07221734/","asOf":"2026-09-16","days":12},{"id":"nct05147467","kind":"trial","name":"Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL","route":"/trials/nct05147467/","asOf":"2026-09-16","days":12},{"id":"nct06987500","kind":"trial","name":"A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment","route":"/trials/nct06987500/","asOf":"2026-09-16","days":12},{"id":"nct06840119","kind":"trial","name":"Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers","route":"/trials/nct06840119/","asOf":"2026-09-16","days":12},{"id":"nct05208944","kind":"trial","name":"THIO Sequenced With Cemiplimab in Advanced NSCLC","route":"/trials/nct05208944/","asOf":"2026-09-16","days":12},{"id":"nct07357519","kind":"trial","name":"Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)","route":"/trials/nct07357519/","asOf":"2026-09-16","days":12},{"id":"nct07761429","kind":"trial","name":"A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP)","route":"/trials/nct07761429/","asOf":"2026-09-16","days":12},{"id":"nct07265622","kind":"trial","name":"First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors","route":"/trials/nct07265622/","asOf":"2026-09-16","days":12},{"id":"nct06751329","kind":"trial","name":"A Study of DM002 in Patients With Advanced Solid Tumors","route":"/trials/nct06751329/","asOf":"2026-09-16","days":12},{"id":"nct04910022","kind":"trial","name":"Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma","route":"/trials/nct04910022/","asOf":"2026-09-16","days":12},{"id":"nct05541822","kind":"trial","name":"To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation","route":"/trials/nct05541822/","asOf":"2026-09-16","days":12},{"id":"nct06603844","kind":"trial","name":"First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.","route":"/trials/nct06603844/","asOf":"2026-09-16","days":12},{"id":"nct06334432","kind":"trial","name":"Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors","route":"/trials/nct06334432/","asOf":"2026-09-16","days":12},{"id":"nct06149559","kind":"trial","name":"A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis","route":"/trials/nct06149559/","asOf":"2026-09-16","days":12},{"id":"nct07197580","kind":"trial","name":"Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC","route":"/trials/nct07197580/","asOf":"2026-09-16","days":12},{"id":"nct05706129","kind":"trial","name":"A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct05706129/","asOf":"2026-09-16","days":12},{"id":"nct06907615","kind":"trial","name":"A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct06907615/","asOf":"2026-09-16","days":12},{"id":"nct03815643","kind":"trial","name":"Avelumab Program Rollover Study","route":"/trials/nct03815643/","asOf":"2026-09-16","days":12},{"id":"nct05968326","kind":"trial","name":"A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC","route":"/trials/nct05968326/","asOf":"2026-09-16","days":12},{"id":"nct06682572","kind":"trial","name":"A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients","route":"/trials/nct06682572/","asOf":"2026-09-16","days":12},{"id":"nct05894239","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer","route":"/trials/nct05894239/","asOf":"2026-09-16","days":12},{"id":"nct07640295","kind":"trial","name":"Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations","route":"/trials/nct07640295/","asOf":"2026-09-16","days":12},{"id":"nct05845814","kind":"trial","name":"A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)","route":"/trials/nct05845814/","asOf":"2026-09-16","days":12},{"id":"nct06790693","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer","route":"/trials/nct06790693/","asOf":"2026-09-16","days":12},{"id":"nct07172919","kind":"trial","name":"A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation","route":"/trials/nct07172919/","asOf":"2026-09-16","days":12},{"id":"nct04639986","kind":"trial","name":"Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)","route":"/trials/nct04639986/","asOf":"2026-09-16","days":12},{"id":"nct05671822","kind":"trial","name":"Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer","route":"/trials/nct05671822/","asOf":"2026-09-16","days":12},{"id":"nct07206056","kind":"trial","name":"An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)","route":"/trials/nct07206056/","asOf":"2026-09-16","days":12},{"id":"nct04673942","kind":"trial","name":"A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors","route":"/trials/nct04673942/","asOf":"2026-09-16","days":12},{"id":"nct04452955","kind":"trial","name":"A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors","route":"/trials/nct04452955/","asOf":"2026-09-16","days":12},{"id":"nct07450976","kind":"trial","name":"A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer","route":"/trials/nct07450976/","asOf":"2026-09-16","days":12},{"id":"nct03851640","kind":"trial","name":"A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).","route":"/trials/nct03851640/","asOf":"2026-09-16","days":12},{"id":"nct03736889","kind":"trial","name":"Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors","route":"/trials/nct03736889/","asOf":"2026-09-16","days":12},{"id":"nct04995523","kind":"trial","name":"A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC","route":"/trials/nct04995523/","asOf":"2026-09-16","days":12},{"id":"nct03793478","kind":"trial","name":"Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood","route":"/trials/nct03793478/","asOf":"2026-09-16","days":12},{"id":"nct05859750","kind":"trial","name":"A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer","route":"/trials/nct05859750/","asOf":"2026-09-16","days":12},{"id":"nct07529808","kind":"trial","name":"Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma","route":"/trials/nct07529808/","asOf":"2026-09-16","days":12},{"id":"nct05386108","kind":"trial","name":"Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer","route":"/trials/nct05386108/","asOf":"2026-09-16","days":12},{"id":"nct07417189","kind":"trial","name":"A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )","route":"/trials/nct07417189/","asOf":"2026-09-16","days":12},{"id":"nct06007690","kind":"trial","name":"A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma","route":"/trials/nct06007690/","asOf":"2026-09-16","days":12},{"id":"nct07054190","kind":"trial","name":"A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer","route":"/trials/nct07054190/","asOf":"2026-09-16","days":12},{"id":"nct06343311","kind":"trial","name":"T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)","route":"/trials/nct06343311/","asOf":"2026-09-16","days":12},{"id":"nct07241936","kind":"trial","name":"A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors","route":"/trials/nct07241936/","asOf":"2026-09-16","days":12},{"id":"nct05874414","kind":"trial","name":"Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma","route":"/trials/nct05874414/","asOf":"2026-09-16","days":12},{"id":"nct04380636","kind":"trial","name":"Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)","route":"/trials/nct04380636/","asOf":"2026-09-16","days":12},{"id":"nct06196736","kind":"trial","name":"A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer","route":"/trials/nct06196736/","asOf":"2026-09-16","days":12},{"id":"nct06088290","kind":"trial","name":"Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)","route":"/trials/nct06088290/","asOf":"2026-09-16","days":12},{"id":"nct06539182","kind":"trial","name":"DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)","route":"/trials/nct06539182/","asOf":"2026-09-16","days":12},{"id":"nct05503797","kind":"trial","name":"A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations","route":"/trials/nct05503797/","asOf":"2026-09-16","days":12},{"id":"nct04342910","kind":"trial","name":"Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC","route":"/trials/nct04342910/","asOf":"2026-09-16","days":12},{"id":"nct07551362","kind":"trial","name":"Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer","route":"/trials/nct07551362/","asOf":"2026-09-16","days":12},{"id":"nct05934513","kind":"trial","name":"A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)","route":"/trials/nct05934513/","asOf":"2026-09-16","days":12},{"id":"nct06953089","kind":"trial","name":"DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors","route":"/trials/nct06953089/","asOf":"2026-09-16","days":12},{"id":"nct04544189","kind":"trial","name":"Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer","route":"/trials/nct04544189/","asOf":"2026-09-16","days":12},{"id":"nct04285086","kind":"trial","name":"Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance","route":"/trials/nct04285086/","asOf":"2026-09-16","days":12},{"id":"nct05736731","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression","route":"/trials/nct05736731/","asOf":"2026-09-16","days":12},{"id":"nct05958121","kind":"trial","name":"IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors","route":"/trials/nct05958121/","asOf":"2026-09-16","days":12},{"id":"nct04851613","kind":"trial","name":"Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer","route":"/trials/nct04851613/","asOf":"2026-09-16","days":12},{"id":"nct07286266","kind":"trial","name":"A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)","route":"/trials/nct07286266/","asOf":"2026-09-16","days":12},{"id":"nct03980054","kind":"trial","name":"A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer","route":"/trials/nct03980054/","asOf":"2026-09-16","days":12},{"id":"nct06841354","kind":"trial","name":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","route":"/trials/nct06841354/","asOf":"2026-09-16","days":12},{"id":"nct07050641","kind":"trial","name":"Phase I/II Study of SCTB39-1 in Advanced Solid Tumours","route":"/trials/nct07050641/","asOf":"2026-09-16","days":12},{"id":"nct07221500","kind":"trial","name":"A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)","route":"/trials/nct07221500/","asOf":"2026-09-16","days":12},{"id":"nct03669965","kind":"trial","name":"KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera","route":"/trials/nct03669965/","asOf":"2026-09-16","days":12},{"id":"nct04819100","kind":"trial","name":"A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct04819100/","asOf":"2026-09-16","days":12},{"id":"nct04931654","kind":"trial","name":"A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer","route":"/trials/nct04931654/","asOf":"2026-09-16","days":12},{"id":"nct03491683","kind":"trial","name":"INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)","route":"/trials/nct03491683/","asOf":"2026-09-16","days":12},{"id":"nct07293754","kind":"trial","name":"An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors","route":"/trials/nct07293754/","asOf":"2026-09-16","days":12},{"id":"nct07749586","kind":"trial","name":"A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors","route":"/trials/nct07749586/","asOf":"2026-09-16","days":12},{"id":"nct04592653","kind":"trial","name":"Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)","route":"/trials/nct04592653/","asOf":"2026-09-16","days":12},{"id":"nct06800313","kind":"trial","name":"Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer","route":"/trials/nct06800313/","asOf":"2026-09-16","days":12},{"id":"nct06239194","kind":"trial","name":"Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors","route":"/trials/nct06239194/","asOf":"2026-09-16","days":12},{"id":"nct06974929","kind":"trial","name":"A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer","route":"/trials/nct06974929/","asOf":"2026-09-16","days":12},{"id":"nct06369285","kind":"trial","name":"A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer","route":"/trials/nct06369285/","asOf":"2026-09-16","days":12},{"id":"nct06077877","kind":"trial","name":"A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors","route":"/trials/nct06077877/","asOf":"2026-09-16","days":12},{"id":"nct07296341","kind":"trial","name":"HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors","route":"/trials/nct07296341/","asOf":"2026-09-16","days":12},{"id":"nct06925581","kind":"trial","name":"A Trial of HRS-6768 in Patients With Advanced Solid Tumors","route":"/trials/nct06925581/","asOf":"2026-09-16","days":12},{"id":"nct07367529","kind":"trial","name":"A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection","route":"/trials/nct07367529/","asOf":"2026-09-16","days":12},{"id":"nct07439653","kind":"trial","name":"A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma","route":"/trials/nct07439653/","asOf":"2026-09-16","days":12},{"id":"nct06832202","kind":"trial","name":"A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients","route":"/trials/nct06832202/","asOf":"2026-09-16","days":12},{"id":"nct06262139","kind":"trial","name":"Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients","route":"/trials/nct06262139/","asOf":"2026-09-16","days":12},{"id":"nct07541430","kind":"trial","name":"A Study in Adults With Desmoid Tumors","route":"/trials/nct07541430/","asOf":"2026-09-16","days":12},{"id":"nct07276373","kind":"trial","name":"Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies","route":"/trials/nct07276373/","asOf":"2026-09-16","days":12},{"id":"nct06010329","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC","route":"/trials/nct06010329/","asOf":"2026-09-16","days":12},{"id":"nct04395677","kind":"trial","name":"A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene","route":"/trials/nct04395677/","asOf":"2026-09-16","days":12},{"id":"nct04634877","kind":"trial","name":"Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)","route":"/trials/nct04634877/","asOf":"2026-09-16","days":12},{"id":"nct06827613","kind":"trial","name":"A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors","route":"/trials/nct06827613/","asOf":"2026-09-16","days":12},{"id":"nct07073534","kind":"trial","name":"Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors","route":"/trials/nct07073534/","asOf":"2026-09-16","days":12},{"id":"nct06140836","kind":"trial","name":"A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)","route":"/trials/nct06140836/","asOf":"2026-09-16","days":12},{"id":"nct06075264","kind":"trial","name":"Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)","route":"/trials/nct06075264/","asOf":"2026-09-16","days":12},{"id":"nct07777211","kind":"trial","name":"A Phase I/IIa Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer","route":"/trials/nct07777211/","asOf":"2026-09-16","days":12},{"id":"nct07336732","kind":"trial","name":"Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations","route":"/trials/nct07336732/","asOf":"2026-09-16","days":12},{"id":"nct05355298","kind":"trial","name":"ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer","route":"/trials/nct05355298/","asOf":"2026-09-16","days":12},{"id":"nct04140500","kind":"trial","name":"Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors","route":"/trials/nct04140500/","asOf":"2026-09-16","days":12},{"id":"nct06968221","kind":"trial","name":"Bovine Reinforcement in Stomach, Colorectal and Lung Operation","route":"/trials/nct06968221/","asOf":"2026-09-16","days":12},{"id":"nct07623616","kind":"trial","name":"A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia","route":"/trials/nct07623616/","asOf":"2026-09-16","days":12},{"id":"nct06028074","kind":"trial","name":"Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies","route":"/trials/nct06028074/","asOf":"2026-09-16","days":12},{"id":"nct07083323","kind":"trial","name":"A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors","route":"/trials/nct07083323/","asOf":"2026-09-16","days":12},{"id":"nct07609823","kind":"trial","name":"A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL","route":"/trials/nct07609823/","asOf":"2026-09-16","days":12},{"id":"nct07602842","kind":"trial","name":"A Study of IDP-001 in Advanced or Metastatic Solid Tumors","route":"/trials/nct07602842/","asOf":"2026-09-16","days":12},{"id":"nct06883526","kind":"trial","name":"Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma","route":"/trials/nct06883526/","asOf":"2026-09-16","days":12},{"id":"nct05908643","kind":"trial","name":"A First-In-Human Trial of pTTL in Advanced Colorectal Cancer","route":"/trials/nct05908643/","asOf":"2026-09-16","days":12},{"id":"nct06927687","kind":"trial","name":"Study of ZG005 in Patients With Advanced Solid Tumors","route":"/trials/nct06927687/","asOf":"2026-09-16","days":12},{"id":"nct07192432","kind":"trial","name":"Gene Therapy for HER-Positive Cancer (SENTRY-HER2)","route":"/trials/nct07192432/","asOf":"2026-09-16","days":12},{"id":"nct04776330","kind":"trial","name":"a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease","route":"/trials/nct04776330/","asOf":"2026-09-16","days":12},{"id":"nct04329728","kind":"trial","name":"The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies","route":"/trials/nct04329728/","asOf":"2026-09-16","days":12},{"id":"nct06890598","kind":"trial","name":"Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer","route":"/trials/nct06890598/","asOf":"2026-09-16","days":12},{"id":"nct04243499","kind":"trial","name":"First-in-Human Study of ICT01 in Patients With Advanced Cancer","route":"/trials/nct04243499/","asOf":"2026-09-16","days":12},{"id":"nct07734116","kind":"trial","name":"A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma.","route":"/trials/nct07734116/","asOf":"2026-09-16","days":12},{"id":"nct06256328","kind":"trial","name":"A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)","route":"/trials/nct06256328/","asOf":"2026-09-16","days":12},{"id":"nct06796907","kind":"trial","name":"A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)","route":"/trials/nct06796907/","asOf":"2026-09-16","days":12},{"id":"nct05374915","kind":"trial","name":"Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)","route":"/trials/nct05374915/","asOf":"2026-09-16","days":12},{"id":"nct04919226","kind":"trial","name":"Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE","route":"/trials/nct04919226/","asOf":"2026-09-16","days":12},{"id":"nct05573126","kind":"trial","name":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer","route":"/trials/nct05573126/","asOf":"2026-09-16","days":12},{"id":"nct06777433","kind":"trial","name":"Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases","route":"/trials/nct06777433/","asOf":"2026-09-16","days":12},{"id":"nct06567743","kind":"trial","name":"Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC","route":"/trials/nct06567743/","asOf":"2026-09-16","days":12},{"id":"nct07205822","kind":"trial","name":"A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer","route":"/trials/nct07205822/","asOf":"2026-09-16","days":12},{"id":"nct05199272","kind":"trial","name":"A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies","route":"/trials/nct05199272/","asOf":"2026-09-16","days":12},{"id":"nct06051695","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression","route":"/trials/nct06051695/","asOf":"2026-09-16","days":12},{"id":"nct05785039","kind":"trial","name":"A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors","route":"/trials/nct05785039/","asOf":"2026-09-16","days":12},{"id":"nct06072612","kind":"trial","name":"Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.","route":"/trials/nct06072612/","asOf":"2026-09-16","days":12},{"id":"nct06612281","kind":"trial","name":"Evaluation of Gixam's Performance in a FIT Negative Population","route":"/trials/nct06612281/","asOf":"2026-09-16","days":12},{"id":"nct06478719","kind":"trial","name":"To Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization","route":"/trials/nct06478719/","asOf":"2026-09-16","days":12},{"id":"nct06395519","kind":"trial","name":"A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies","route":"/trials/nct06395519/","asOf":"2026-09-16","days":12},{"id":"nct06663137","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC","route":"/trials/nct06663137/","asOf":"2026-09-16","days":12},{"id":"nct07562581","kind":"trial","name":"A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC","route":"/trials/nct07562581/","asOf":"2026-09-16","days":12},{"id":"nct06198751","kind":"trial","name":"A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer","route":"/trials/nct06198751/","asOf":"2026-09-16","days":12},{"id":"nct06167694","kind":"trial","name":"Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer","route":"/trials/nct06167694/","asOf":"2026-09-16","days":12},{"id":"nct05226871","kind":"trial","name":"Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies","route":"/trials/nct05226871/","asOf":"2026-09-16","days":12},{"id":"nct04655092","kind":"trial","name":"Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients","route":"/trials/nct04655092/","asOf":"2026-09-16","days":12},{"id":"nct03096093","kind":"trial","name":"Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer","route":"/trials/nct03096093/","asOf":"2026-09-16","days":12},{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/","asOf":"2026-09-17","days":11},{"id":"checkmate-143","kind":"trial","name":"CheckMate 143","route":"/trials/checkmate-143/","asOf":"2026-09-17","days":11},{"id":"checkmate-498","kind":"trial","name":"CheckMate 498","route":"/trials/checkmate-498/","asOf":"2026-09-17","days":11},{"id":"checkmate-548","kind":"trial","name":"CheckMate 548","route":"/trials/checkmate-548/","asOf":"2026-09-17","days":11},{"id":"cctg-ce6","kind":"trial","name":"CCTG CE.6 / EORTC 26062-22061 (Perry trial)","route":"/trials/cctg-ce6/","asOf":"2026-09-17","days":11},{"id":"extent-of-resection","kind":"term","name":"Extent of resection (RANO resect classes)","route":"/terms/extent-of-resection/","asOf":"2026-09-17","days":11},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/","asOf":"2026-09-17","days":11},{"id":"proton-therapy","kind":"technology","name":"Proton therapy","route":"/technologies/proton-therapy/","asOf":"2026-09-17","days":11},{"id":"carbon-ion","kind":"technology","name":"Carbon-ion therapy","route":"/technologies/carbon-ion/","asOf":"2026-09-17","days":11},{"id":"tregzi","kind":"drug","name":"Allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq","route":"/drugs/tregzi/","asOf":"2026-09-17","days":11},{"id":"paper-paganetti-proton-rbe-ijrobp-2014","kind":"paper","name":"Paganetti 2014: proton RBE is not a fixed 1.1","route":"/key-papers/paper-paganetti-proton-rbe-ijrobp-2014/","asOf":"2026-09-17","days":11},{"id":"paper-swog-8710-neoadjuvant-mvac-nejm-2003","kind":"paper","name":"SWOG 8710: neoadjuvant MVAC chemotherapy before cystectomy for muscle-invasive bladder cancer","route":"/key-papers/paper-swog-8710-neoadjuvant-mvac-nejm-2003/","asOf":"2026-09-17","days":11},{"id":"paper-javelin-bladder-100-nejm-2020","kind":"paper","name":"JAVELIN Bladder 100: avelumab maintenance after first-line platinum chemotherapy in advanced urothelial cancer","route":"/key-papers/paper-javelin-bladder-100-nejm-2020/","asOf":"2026-09-17","days":11},{"id":"paper-keynote-057-lancet-oncol-2021","kind":"paper","name":"KEYNOTE-057: pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ","route":"/key-papers/paper-keynote-057-lancet-oncol-2021/","asOf":"2026-09-17","days":11},{"id":"paper-nadofaragene-firadenovec-lancet-oncol-2021","kind":"paper","name":"Nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer","route":"/key-papers/paper-nadofaragene-firadenovec-lancet-oncol-2021/","asOf":"2026-09-17","days":11},{"id":"paper-sylvester-eortc-risk-tables-eur-urol-2006","kind":"paper","name":"EORTC risk tables for recurrence and progression in Ta and T1 bladder cancer","route":"/key-papers/paper-sylvester-eortc-risk-tables-eur-urol-2006/","asOf":"2026-09-17","days":11},{"id":"paper-eau-nmibc-guideline-eur-urol-2022","kind":"paper","name":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1 and carcinoma in situ)","route":"/key-papers/paper-eau-nmibc-guideline-eur-urol-2022/","asOf":"2026-09-17","days":11},{"id":"paper-aza-aml-001-dombret-blood-2015","kind":"paper","name":"AZA-AML-001: azacitidine versus conventional care in older patients with acute myeloid leukaemia and more than 30 percent blasts","route":"/key-papers/paper-aza-aml-001-dombret-blood-2015/","asOf":"2026-09-17","days":11},{"id":"paper-eln-2022-aml-dohner-blood-2022","kind":"paper","name":"ELN 2022: diagnosis and management of acute myeloid leukaemia in adults","route":"/key-papers/paper-eln-2022-aml-dohner-blood-2022/","asOf":"2026-09-17","days":11},{"id":"paper-apl0406-lo-coco-nejm-2013","kind":"paper","name":"APL0406: retinoic acid plus arsenic trioxide without chemotherapy for low- and intermediate-risk acute promyelocytic leukaemia","route":"/key-papers/paper-apl0406-lo-coco-nejm-2013/","asOf":"2026-09-17","days":11},{"id":"paper-tallman-atra-apl-nejm-1997","kind":"paper","name":"North American Intergroup: all-trans retinoic acid in acute promyelocytic leukaemia","route":"/key-papers/paper-tallman-atra-apl-nejm-1997/","asOf":"2026-09-17","days":11},{"id":"paper-eln-apl-sanz-blood-2019","kind":"paper","name":"European LeukemiaNet recommendations for the management of acute promyelocytic leukaemia (2019 update)","route":"/key-papers/paper-eln-apl-sanz-blood-2019/","asOf":"2026-09-17","days":11},{"id":"paper-pace-ponatinib-nejm-2013","kind":"paper","name":"PACE: ponatinib in Philadelphia chromosome-positive leukaemias resistant to earlier tyrosine kinase inhibitors","route":"/key-papers/paper-pace-ponatinib-nejm-2013/","asOf":"2026-09-17","days":11},{"id":"paper-eln-2020-cml-hochhaus-leukemia-2020","kind":"paper","name":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukaemia","route":"/key-papers/paper-eln-2020-cml-hochhaus-leukemia-2020/","asOf":"2026-09-17","days":11},{"id":"paper-ratify-midostaurin-nejm-2017","kind":"paper","name":"RATIFY: midostaurin added to chemotherapy for acute myeloid leukaemia with a FLT3 mutation","route":"/key-papers/paper-ratify-midostaurin-nejm-2017/","asOf":"2026-09-17","days":11},{"id":"paper-aza-001-fenaux-lancet-oncol-2009","kind":"paper","name":"AZA-001: azacitidine versus conventional care in higher-risk myelodysplastic syndromes","route":"/key-papers/paper-aza-001-fenaux-lancet-oncol-2009/","asOf":"2026-09-17","days":11},{"id":"paper-ipss-m-bernard-nejm-evidence-2022","kind":"paper","name":"IPSS-M: the molecular international prognostic scoring system for myelodysplastic syndromes","route":"/key-papers/paper-ipss-m-bernard-nejm-evidence-2022/","asOf":"2026-09-17","days":11},{"id":"paper-who-2022-myeloid-khoury-leukemia-2022","kind":"paper","name":"WHO classification of haematolymphoid tumours, fifth edition: myeloid and histiocytic neoplasms","route":"/key-papers/paper-who-2022-myeloid-khoury-leukemia-2022/","asOf":"2026-09-17","days":11},{"id":"paper-icc-2022-arber-blood-2022","kind":"paper","name":"International Consensus Classification of myeloid neoplasms and acute leukaemias (2022)","route":"/key-papers/paper-icc-2022-arber-blood-2022/","asOf":"2026-09-17","days":11},{"id":"paper-ivosidenib-idh1-dinardo-nejm-2018","kind":"paper","name":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory acute myeloid leukaemia","route":"/key-papers/paper-ivosidenib-idh1-dinardo-nejm-2018/","asOf":"2026-09-17","days":11},{"id":"paper-enasidenib-idh2-stein-blood-2017","kind":"paper","name":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukaemia","route":"/key-papers/paper-enasidenib-idh2-stein-blood-2017/","asOf":"2026-09-17","days":11},{"id":"paper-cassiopeia-lancet-2019","kind":"paper","name":"CASSIOPEIA: daratumumab added to bortezomib, thalidomide and dexamethasone before and after transplant in newly diagnosed myeloma","route":"/key-papers/paper-cassiopeia-lancet-2019/","asOf":"2026-09-17","days":11},{"id":"paper-ifm-2009-attal-nejm-2017","kind":"paper","name":"IFM 2009: lenalidomide, bortezomib and dexamethasone with or without upfront transplantation for myeloma","route":"/key-papers/paper-ifm-2009-attal-nejm-2017/","asOf":"2026-09-17","days":11},{"id":"paper-r-iss-palumbo-jco-2015","kind":"paper","name":"Revised International Staging System (R-ISS) for multiple myeloma","route":"/key-papers/paper-r-iss-palumbo-jco-2015/","asOf":"2026-09-17","days":11},{"id":"paper-falini-npm1-nejm-2005","kind":"paper","name":"Cytoplasmic nucleophosmin in acute myeloid leukaemia with a normal karyotype","route":"/key-papers/paper-falini-npm1-nejm-2005/","asOf":"2026-09-17","days":11},{"id":"paper-ivey-npm1-mrd-nejm-2016","kind":"paper","name":"Molecular measurable residual disease in NPM1-mutated acute myeloid leukaemia (UK NCRI AML17)","route":"/key-papers/paper-ivey-npm1-mrd-nejm-2016/","asOf":"2026-09-17","days":11},{"id":"paper-imwg-plasma-cell-leukaemia-definition-bcj-2021","kind":"paper","name":"IMWG consensus definition of primary plasma cell leukaemia at 5 percent circulating plasma cells","route":"/key-papers/paper-imwg-plasma-cell-leukaemia-definition-bcj-2021/","asOf":"2026-09-17","days":11},{"id":"paper-royer-plasma-cell-leukaemia-ifm-jco-2016","kind":"paper","name":"IFM 2006 prospective trial: bortezomib-based induction and transplantation for primary plasma cell leukaemia","route":"/key-papers/paper-royer-plasma-cell-leukaemia-ifm-jco-2016/","asOf":"2026-09-17","days":11},{"id":"paper-monumental-1-talquetamab-nejm-2022","kind":"paper","name":"MonumenTAL-1: talquetamab, a GPRC5D-directed bispecific antibody for relapsed multiple myeloma","route":"/key-papers/paper-monumental-1-talquetamab-nejm-2022/","asOf":"2026-09-17","days":11},{"id":"paper-rossi-richter-syndrome-blood-2018","kind":"paper","name":"Biology and treatment of Richter syndrome","route":"/key-papers/paper-rossi-richter-syndrome-blood-2018/","asOf":"2026-09-17","days":11},{"id":"paper-who-2022-lymphoid-alaggio-leukemia-2022","kind":"paper","name":"WHO classification of haematolymphoid tumours, fifth edition: lymphoid neoplasms","route":"/key-papers/paper-who-2022-lymphoid-alaggio-leukemia-2022/","asOf":"2026-09-17","days":11},{"id":"paper-cpx-351-study-301-lancet-je-jco-2018","kind":"paper","name":"CPX-351 versus 7+3 chemotherapy in older adults with newly diagnosed secondary acute myeloid leukaemia","route":"/key-papers/paper-cpx-351-study-301-lancet-je-jco-2018/","asOf":"2026-09-17","days":11},{"id":"paper-aquila-daratumumab-smouldering-nejm-2025","kind":"paper","name":"AQUILA: daratumumab versus active monitoring in high-risk smouldering multiple myeloma","route":"/key-papers/paper-aquila-daratumumab-smouldering-nejm-2025/","asOf":"2026-09-17","days":11},{"id":"paper-e3a06-lenalidomide-smouldering-lonial-jco-2020","kind":"paper","name":"E3A06: lenalidomide versus observation in smouldering multiple myeloma","route":"/key-papers/paper-e3a06-lenalidomide-smouldering-lonial-jco-2020/","asOf":"2026-09-17","days":11},{"id":"paper-imwg-criteria-rajkumar-lancet-oncol-2014","kind":"paper","name":"IMWG updated criteria for the diagnosis of multiple myeloma (2014)","route":"/key-papers/paper-imwg-criteria-rajkumar-lancet-oncol-2014/","asOf":"2026-09-17","days":11},{"id":"paper-mateos-20-2-20-smouldering-bcj-2020","kind":"paper","name":"IMWG 20/2/20 risk stratification model for smouldering multiple myeloma","route":"/key-papers/paper-mateos-20-2-20-smouldering-bcj-2020/","asOf":"2026-09-17","days":11},{"id":"paper-aphinity-nejm-2017","kind":"paper","name":"APHINITY: adjuvant pertuzumab added to trastuzumab and chemotherapy in early HER2-positive breast cancer","route":"/key-papers/paper-aphinity-nejm-2017/","asOf":"2026-09-17","days":11},{"id":"paper-apt-tolaney-nejm-2015","kind":"paper","name":"APT: adjuvant paclitaxel and trastuzumab for small, node-negative HER2-positive breast cancer","route":"/key-papers/paper-apt-tolaney-nejm-2015/","asOf":"2026-09-17","days":11},{"id":"paper-train-2-lancet-oncol-2018","kind":"paper","name":"TRAIN-2: neoadjuvant chemotherapy with or without anthracyclines alongside dual HER2 blockade","route":"/key-papers/paper-train-2-lancet-oncol-2018/","asOf":"2026-09-17","days":11},{"id":"paper-her2climb-nejm-2020","kind":"paper","name":"HER2CLIMB: tucatinib with trastuzumab and capecitabine for HER2-positive metastatic breast cancer, including brain metastases","route":"/key-papers/paper-her2climb-nejm-2020/","asOf":"2026-09-17","days":11},{"id":"paper-her2climb-brain-lin-jco-2020","kind":"paper","name":"HER2CLIMB brain metastases analysis: intracranial efficacy and survival with tucatinib","route":"/key-papers/paper-her2climb-brain-lin-jco-2020/","asOf":"2026-09-17","days":11},{"id":"paper-tuxedo-1-trastuzumab-deruxtecan-brain-metastases-nat-med-2022","kind":"paper","name":"TUXEDO-1: trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastases","route":"/key-papers/paper-tuxedo-1-trastuzumab-deruxtecan-brain-metastases-nat-med-2022/","asOf":"2026-09-17","days":11},{"id":"paper-tailorx-nejm-2018","kind":"paper","name":"TAILORx: adjuvant chemotherapy guided by the 21-gene recurrence score in hormone receptor-positive, node-negative breast cancer","route":"/key-papers/paper-tailorx-nejm-2018/","asOf":"2026-09-17","days":11},{"id":"paper-emerald-elacestrant-jco-2022","kind":"paper","name":"EMERALD: elacestrant versus standard endocrine therapy after a CDK4/6 inhibitor","route":"/key-papers/paper-emerald-elacestrant-jco-2022/","asOf":"2026-09-17","days":11},{"id":"paper-capitello-291-nejm-2023","kind":"paper","name":"CAPItello-291: capivasertib plus fulvestrant in hormone receptor-positive advanced breast cancer","route":"/key-papers/paper-capitello-291-nejm-2023/","asOf":"2026-09-17","days":11},{"id":"paper-solar-1-alpelisib-nejm-2019","kind":"paper","name":"SOLAR-1: alpelisib plus fulvestrant for PIK3CA-mutated hormone receptor-positive advanced breast cancer","route":"/key-papers/paper-solar-1-alpelisib-nejm-2019/","asOf":"2026-09-17","days":11},{"id":"paper-dawood-inflammatory-breast-consensus-ann-oncol-2011","kind":"paper","name":"International expert panel consensus on the diagnosis and treatment of inflammatory breast cancer","route":"/key-papers/paper-dawood-inflammatory-breast-consensus-ann-oncol-2011/","asOf":"2026-09-17","days":11},{"id":"paper-rueth-inflammatory-breast-trimodality-jco-2014","kind":"paper","name":"Underuse of trimodality treatment and survival in inflammatory breast cancer (National Cancer Data Base)","route":"/key-papers/paper-rueth-inflammatory-breast-trimodality-jco-2014/","asOf":"2026-09-17","days":11},{"id":"paper-keynote-355-nejm-2022","kind":"paper","name":"KEYNOTE-355: pembrolizumab plus chemotherapy for PD-L1-positive advanced triple-negative breast cancer","route":"/key-papers/paper-keynote-355-nejm-2022/","asOf":"2026-09-17","days":11},{"id":"paper-olympiad-nejm-2017","kind":"paper","name":"OlympiAD: olaparib versus chemotherapy in metastatic breast cancer with a germline BRCA mutation","route":"/key-papers/paper-olympiad-nejm-2017/","asOf":"2026-09-17","days":11},{"id":"paper-kothari-paget-disease-nipple-multifocal-cancer-2002","kind":"paper","name":"Paget disease of the nipple as a marker of multifocal, higher-risk underlying breast cancer","route":"/key-papers/paper-kothari-paget-disease-nipple-multifocal-cancer-2002/","asOf":"2026-09-17","days":11},{"id":"paper-tan-phyllodes-consensus-histopathology-2016","kind":"paper","name":"Phyllodes tumours of the breast: a consensus review","route":"/key-papers/paper-tan-phyllodes-consensus-histopathology-2016/","asOf":"2026-09-17","days":11},{"id":"paper-barth-phyllodes-adjuvant-radiotherapy-ann-surg-oncol-2009","kind":"paper","name":"Prospective multi-institutional study of adjuvant radiotherapy after resection of borderline and malignant phyllodes tumours","route":"/key-papers/paper-barth-phyllodes-adjuvant-radiotherapy-ann-surg-oncol-2009/","asOf":"2026-09-17","days":11},{"id":"paper-yan-peritoneal-mesothelioma-crs-hipec-jco-2009","kind":"paper","name":"Cytoreductive surgery and HIPEC for malignant peritoneal mesothelioma: multi-institutional registry","route":"/key-papers/paper-yan-peritoneal-mesothelioma-crs-hipec-jco-2009/","asOf":"2026-09-17","days":11},{"id":"paper-raghav-atezolizumab-bevacizumab-peritoneal-mesothelioma-cancer-discov-2021","kind":"paper","name":"Atezolizumab plus bevacizumab in advanced malignant peritoneal mesothelioma","route":"/key-papers/paper-raghav-atezolizumab-bevacizumab-peritoneal-mesothelioma-cancer-discov-2021/","asOf":"2026-09-17","days":11},{"id":"paper-checkmate-743-lancet-2021","kind":"paper","name":"CheckMate 743: first-line nivolumab plus ipilimumab in unresectable pleural mesothelioma","route":"/key-papers/paper-checkmate-743-lancet-2021/","asOf":"2026-09-17","days":11},{"id":"paper-vogelzang-pemetrexed-mesothelioma-jco-2003","kind":"paper","name":"Phase 3 trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma","route":"/key-papers/paper-vogelzang-pemetrexed-mesothelioma-jco-2003/","asOf":"2026-09-17","days":11},{"id":"paper-mars-2-lancet-respir-med-2024","kind":"paper","name":"MARS 2: extended pleurectomy decortication plus chemotherapy versus chemotherapy alone for pleural mesothelioma","route":"/key-papers/paper-mars-2-lancet-respir-med-2024/","asOf":"2026-09-17","days":11},{"id":"paper-keynote-483-lancet-2023","kind":"paper","name":"KEYNOTE-483 (CCTG IND.227): pembrolizumab plus chemotherapy versus chemotherapy in untreated pleural mesothelioma","route":"/key-papers/paper-keynote-483-lancet-2023/","asOf":"2026-09-17","days":11},{"id":"paper-who-2021-cns-louis-neuro-oncology-2021","kind":"paper","name":"The 2021 WHO classification of tumours of the central nervous system: a summary","route":"/key-papers/paper-who-2021-cns-louis-neuro-oncology-2021/","asOf":"2026-09-17","days":11},{"id":"paper-rtog-9802-buckner-nejm-2016","kind":"paper","name":"RTOG 9802: radiation plus procarbazine, lomustine and vincristine in high-risk low-grade glioma","route":"/key-papers/paper-rtog-9802-buckner-nejm-2016/","asOf":"2026-09-17","days":11},{"id":"paper-catnon-lancet-2017","kind":"paper","name":"CATNON: concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion","route":"/key-papers/paper-catnon-lancet-2017/","asOf":"2026-09-17","days":11},{"id":"paper-alliance-n0574-brown-jama-2016","kind":"paper","name":"Alliance N0574: radiosurgery alone versus radiosurgery plus whole-brain radiotherapy for one to three brain metastases","route":"/key-papers/paper-alliance-n0574-brown-jama-2016/","asOf":"2026-09-17","days":11},{"id":"paper-n107c-brown-lancet-oncol-2017","kind":"paper","name":"N107C/CEC.3: postoperative radiosurgery versus whole-brain radiotherapy after resection of a brain metastasis","route":"/key-papers/paper-n107c-brown-lancet-oncol-2017/","asOf":"2026-09-17","days":11},{"id":"paper-nrg-cc001-brown-jco-2020","kind":"paper","name":"NRG CC001: hippocampal-avoidance whole-brain radiotherapy plus memantine for brain metastases","route":"/key-papers/paper-nrg-cc001-brown-jco-2020/","asOf":"2026-09-17","days":11},{"id":"paper-quartz-lancet-2016","kind":"paper","name":"QUARTZ: whole-brain radiotherapy versus supportive care alone for brain metastases from non-small-cell lung cancer","route":"/key-papers/paper-quartz-lancet-2016/","asOf":"2026-09-17","days":11},{"id":"paper-siop-cns-gct-96-calaminus-neuro-oncology-2013","kind":"paper","name":"SIOP CNS GCT 96: outcomes for children and adults with intracranial germinoma treated with radiotherapy alone or chemotherapy plus reduced radiotherapy","route":"/key-papers/paper-siop-cns-gct-96-calaminus-neuro-oncology-2013/","asOf":"2026-09-17","days":11},{"id":"paper-acns1123-germinoma-neuro-oncology-2022","kind":"paper","name":"ACNS1123: response-based reduced-dose whole-ventricular radiotherapy for localised germinoma","route":"/key-papers/paper-acns1123-germinoma-neuro-oncology-2022/","asOf":"2026-09-17","days":11},{"id":"paper-eano-meningioma-goldbrunner-neuro-oncology-2021","kind":"paper","name":"EANO guideline on the diagnosis and management of meningiomas (2021)","route":"/key-papers/paper-eano-meningioma-goldbrunner-neuro-oncology-2021/","asOf":"2026-09-17","days":11},{"id":"paper-sahm-meningioma-methylation-lancet-oncol-2017","kind":"paper","name":"DNA methylation-based classification and grading system for meningioma","route":"/key-papers/paper-sahm-meningioma-methylation-lancet-oncol-2017/","asOf":"2026-09-17","days":11},{"id":"paper-rtog-9402-cairncross-jco-2013","kind":"paper","name":"RTOG 9402: PCV chemotherapy before radiotherapy for anaplastic oligodendroglioma, long-term results","route":"/key-papers/paper-rtog-9402-cairncross-jco-2013/","asOf":"2026-09-17","days":11},{"id":"paper-eortc-26951-van-den-bent-jco-2013","kind":"paper","name":"EORTC 26951: adjuvant PCV after radiotherapy for anaplastic oligodendroglial tumours, long-term follow-up","route":"/key-papers/paper-eortc-26951-van-den-bent-jco-2013/","asOf":"2026-09-17","days":11},{"id":"paper-mackay-paediatric-hgg-cancer-cell-2017","kind":"paper","name":"Integrated molecular meta-analysis of 1,000 paediatric high-grade and diffuse intrinsic pontine gliomas","route":"/key-papers/paper-mackay-paediatric-hgg-cancer-cell-2017/","asOf":"2026-09-17","days":11},{"id":"paper-hargrave-dabrafenib-trametinib-paediatric-hgg-jco-2023","kind":"paper","name":"Dabrafenib plus trametinib in relapsed or refractory BRAF V600-mutant paediatric high-grade glioma","route":"/key-papers/paper-hargrave-dabrafenib-trametinib-paediatric-hgg-jco-2023/","asOf":"2026-09-17","days":11},{"id":"paper-belzutifan-vhl-jonasch-nejm-2021","kind":"paper","name":"Belzutifan for renal cell carcinoma and other tumours in von Hippel-Lindau disease","route":"/key-papers/paper-belzutifan-vhl-jonasch-nejm-2021/","asOf":"2026-09-17","days":11},{"id":"paper-plotkin-bevacizumab-nf2-nejm-2009","kind":"paper","name":"Hearing improvement after bevacizumab in patients with neurofibromatosis type 2","route":"/key-papers/paper-plotkin-bevacizumab-nf2-nejm-2009/","asOf":"2026-09-17","days":11},{"id":"paper-carlson-link-vestibular-schwannomas-nejm-2021","kind":"paper","name":"Vestibular schwannomas (review)","route":"/key-papers/paper-carlson-link-vestibular-schwannomas-nejm-2021/","asOf":"2026-09-17","days":11},{"id":"paper-cms-guinney-nat-med-2015","kind":"paper","name":"The consensus molecular subtypes of colorectal cancer","route":"/key-papers/paper-cms-guinney-nat-med-2015/","asOf":"2026-09-17","days":11},{"id":"paper-sinicrope-early-onset-crc-nejm-2022","kind":"paper","name":"Increasing incidence of early-onset colorectal cancer (review)","route":"/key-papers/paper-sinicrope-early-onset-crc-nejm-2022/","asOf":"2026-09-17","days":11},{"id":"paper-uspstf-crc-screening-45-jama-2021","kind":"paper","name":"US Preventive Services Task Force recommendation: colorectal cancer screening from age 45","route":"/key-papers/paper-uspstf-crc-screening-45-jama-2021/","asOf":"2026-09-17","days":11},{"id":"paper-krystal-1-crc-yaeger-nejm-2023","kind":"paper","name":"KRYSTAL-1: adagrasib with or without cetuximab in KRAS G12C-mutated colorectal cancer","route":"/key-papers/paper-krystal-1-crc-yaeger-nejm-2023/","asOf":"2026-09-17","days":11},{"id":"paper-checkmate-8hw-lancet-2025","kind":"paper","name":"CheckMate 8HW: nivolumab plus ipilimumab versus nivolumab alone in MSI-high metastatic colorectal cancer","route":"/key-papers/paper-checkmate-8hw-lancet-2025/","asOf":"2026-09-17","days":11},{"id":"paper-dunleavy-da-epoch-r-pmbcl-nejm-2013","kind":"paper","name":"Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma","route":"/key-papers/paper-dunleavy-da-epoch-r-pmbcl-nejm-2013/","asOf":"2026-09-17","days":11},{"id":"paper-ielsg37-pmbcl-martelli-jco-2024","kind":"paper","name":"IELSG37: omission of radiotherapy in primary mediastinal B-cell lymphoma after a negative PET scan","route":"/key-papers/paper-ielsg37-pmbcl-martelli-jco-2024/","asOf":"2026-09-17","days":11},{"id":"paper-keynote-170-pembrolizumab-pmbcl-armand-jco-2019","kind":"paper","name":"KEYNOTE-170: pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma","route":"/key-papers/paper-keynote-170-pembrolizumab-pmbcl-armand-jco-2019/","asOf":"2026-09-17","days":11},{"id":"paper-prospect-nejm-2023","kind":"paper","name":"PROSPECT: neoadjuvant FOLFOX with selective use of chemoradiotherapy for locally advanced rectal cancer","route":"/key-papers/paper-prospect-nejm-2023/","asOf":"2026-09-17","days":11},{"id":"paper-nrg-gy018-nejm-2023","kind":"paper","name":"NRG-GY018: pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer","route":"/key-papers/paper-nrg-gy018-nejm-2023/","asOf":"2026-09-17","days":11},{"id":"paper-keynote-775-nejm-2022","kind":"paper","name":"KEYNOTE-775: lenvatinib plus pembrolizumab versus chemotherapy for previously treated advanced endometrial cancer","route":"/key-papers/paper-keynote-775-nejm-2022/","asOf":"2026-09-17","days":11},{"id":"paper-duo-e-jco-2023","kind":"paper","name":"DUO-E: durvalumab with carboplatin-paclitaxel and maintenance durvalumab with or without olaparib in advanced endometrial cancer","route":"/key-papers/paper-duo-e-jco-2023/","asOf":"2026-09-17","days":11},{"id":"paper-lacc-nejm-2018","kind":"paper","name":"LACC: minimally invasive versus open radical hysterectomy for early cervical cancer","route":"/key-papers/paper-lacc-nejm-2018/","asOf":"2026-09-17","days":11},{"id":"paper-shape-nejm-2024","kind":"paper","name":"SHAPE: simple versus radical hysterectomy in low-risk early cervical cancer","route":"/key-papers/paper-shape-nejm-2024/","asOf":"2026-09-17","days":11},{"id":"paper-promise-talhouk-cancer-2017","kind":"paper","name":"Confirmation of ProMisE: a genomics-based clinical classifier for endometrial cancer","route":"/key-papers/paper-promise-talhouk-cancer-2017/","asOf":"2026-09-17","days":11},{"id":"paper-portec-2-lancet-2010","kind":"paper","name":"PORTEC-2: vaginal brachytherapy versus pelvic external beam radiotherapy for high-intermediate-risk endometrial cancer","route":"/key-papers/paper-portec-2-lancet-2010/","asOf":"2026-09-17","days":11},{"id":"paper-esgo-estro-esp-endometrial-concin-ijgc-2021","kind":"paper","name":"ESGO/ESTRO/ESP guidelines for the management of endometrial carcinoma (2021)","route":"/key-papers/paper-esgo-estro-esp-endometrial-concin-ijgc-2021/","asOf":"2026-09-17","days":11},{"id":"paper-tcga-endometrial-nature-2013","kind":"paper","name":"Integrated genomic characterisation of endometrial carcinoma (The Cancer Genome Atlas)","route":"/key-papers/paper-tcga-endometrial-nature-2013/","asOf":"2026-09-17","days":11},{"id":"paper-interlace-lancet-2024","kind":"paper","name":"INTERLACE: induction chemotherapy before chemoradiotherapy for locally advanced cervical cancer","route":"/key-papers/paper-interlace-lancet-2024/","asOf":"2026-09-17","days":11},{"id":"paper-outback-lancet-oncol-2023","kind":"paper","name":"OUTBACK: adjuvant carboplatin-paclitaxel after chemoradiotherapy for locally advanced cervical cancer","route":"/key-papers/paper-outback-lancet-oncol-2023/","asOf":"2026-09-17","days":11},{"id":"paper-rose-cisplatin-chemoradiation-cervical-nejm-1999","kind":"paper","name":"GOG 120: concurrent cisplatin-based chemotherapy with radiotherapy for locally advanced cervical cancer","route":"/key-papers/paper-rose-cisplatin-chemoradiation-cervical-nejm-1999/","asOf":"2026-09-17","days":11},{"id":"paper-garnet-dostarlimab-oaknin-jama-oncol-2020","kind":"paper","name":"GARNET: dostarlimab in mismatch repair-deficient recurrent or advanced endometrial cancer","route":"/key-papers/paper-garnet-dostarlimab-oaknin-jama-oncol-2020/","asOf":"2026-09-17","days":11},{"id":"paper-portec-3-molecular-leon-castillo-jco-2020","kind":"paper","name":"Molecular classification of the PORTEC-3 trial: prognosis and benefit from adjuvant chemotherapy by molecular group","route":"/key-papers/paper-portec-3-molecular-leon-castillo-jco-2020/","asOf":"2026-09-17","days":11},{"id":"paper-portec-3-lancet-oncol-2018","kind":"paper","name":"PORTEC-3: adjuvant chemoradiotherapy versus radiotherapy alone for high-risk endometrial cancer","route":"/key-papers/paper-portec-3-lancet-oncol-2018/","asOf":"2026-09-17","days":11},{"id":"paper-fader-trastuzumab-uterine-serous-jco-2018","kind":"paper","name":"Carboplatin-paclitaxel with or without trastuzumab in HER2-positive advanced or recurrent uterine serous carcinoma","route":"/key-papers/paper-fader-trastuzumab-uterine-serous-jco-2018/","asOf":"2026-09-17","days":11},{"id":"paper-destiny-pantumor02-jco-2024","kind":"paper","name":"DESTINY-PanTumor02: trastuzumab deruxtecan in HER2-expressing solid tumours","route":"/key-papers/paper-destiny-pantumor02-jco-2024/","asOf":"2026-09-17","days":11},{"id":"paper-mirasol-nejm-2023","kind":"paper","name":"MIRASOL: mirvetuximab soravtansine versus chemotherapy in folate receptor alpha-high platinum-resistant ovarian cancer","route":"/key-papers/paper-mirasol-nejm-2023/","asOf":"2026-09-17","days":11},{"id":"paper-rosella-relacorilant-lancet-2025","kind":"paper","name":"ROSELLA: relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer","route":"/key-papers/paper-rosella-relacorilant-lancet-2025/","asOf":"2026-09-17","days":11},{"id":"paper-prima-niraparib-nejm-2019","kind":"paper","name":"PRIMA: niraparib maintenance in newly diagnosed advanced ovarian cancer","route":"/key-papers/paper-prima-niraparib-nejm-2019/","asOf":"2026-09-17","days":11},{"id":"paper-desktop-iii-nejm-2021","kind":"paper","name":"DESKTOP III: secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer","route":"/key-papers/paper-desktop-iii-nejm-2021/","asOf":"2026-09-17","days":11},{"id":"paper-church-pole-endometrial-jnci-2015","kind":"paper","name":"Prognostic significance of POLE proofreading mutations in endometrial cancer","route":"/key-papers/paper-church-pole-endometrial-jnci-2015/","asOf":"2026-09-17","days":11},{"id":"paper-keynote-826-nejm-2021","kind":"paper","name":"KEYNOTE-826: pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer","route":"/key-papers/paper-keynote-826-nejm-2021/","asOf":"2026-09-17","days":11},{"id":"paper-innovatv-301-tisotumab-nejm-2024","kind":"paper","name":"innovaTV 301: tisotumab vedotin versus chemotherapy as second- or third-line therapy for recurrent cervical cancer","route":"/key-papers/paper-innovatv-301-tisotumab-nejm-2024/","asOf":"2026-09-17","days":11},{"id":"paper-empower-cervical-1-cemiplimab-nejm-2022","kind":"paper","name":"EMPOWER-Cervical 1: cemiplimab versus chemotherapy in recurrent cervical cancer after platinum","route":"/key-papers/paper-empower-cervical-1-cemiplimab-nejm-2022/","asOf":"2026-09-17","days":11},{"id":"paper-gog-240-bevacizumab-cervical-nejm-2014","kind":"paper","name":"GOG 240: bevacizumab added to chemotherapy for advanced cervical cancer","route":"/key-papers/paper-gog-240-bevacizumab-cervical-nejm-2014/","asOf":"2026-09-17","days":11},{"id":"paper-gog-0261-carcinosarcoma-powell-jco-2022","kind":"paper","name":"GOG-0261: paclitaxel-carboplatin versus paclitaxel-ifosfamide in uterine carcinosarcoma","route":"/key-papers/paper-gog-0261-carcinosarcoma-powell-jco-2022/","asOf":"2026-09-17","days":11},{"id":"paper-tchekmedyian-lenvatinib-adenoid-cystic-jco-2019","kind":"paper","name":"Phase 2 study of lenvatinib in progressive, recurrent or metastatic adenoid cystic carcinoma","route":"/key-papers/paper-tchekmedyian-lenvatinib-adenoid-cystic-jco-2019/","asOf":"2026-09-17","days":11},{"id":"paper-persson-myb-nfib-pnas-2009","kind":"paper","name":"Recurrent fusion of MYB and NFIB transcription factor genes in adenoid cystic carcinoma","route":"/key-papers/paper-persson-myb-nfib-pnas-2009/","asOf":"2026-09-17","days":11},{"id":"paper-bonner-cetuximab-radiotherapy-nejm-2006","kind":"paper","name":"Radiotherapy plus cetuximab for locoregionally advanced squamous cell carcinoma of the head and neck","route":"/key-papers/paper-bonner-cetuximab-radiotherapy-nejm-2006/","asOf":"2026-09-17","days":11},{"id":"paper-bernier-eortc-22931-nejm-2004","kind":"paper","name":"EORTC 22931: postoperative irradiation with or without concomitant cisplatin for locally advanced head and neck cancer","route":"/key-papers/paper-bernier-eortc-22931-nejm-2004/","asOf":"2026-09-17","days":11},{"id":"paper-cooper-rtog-9501-nejm-2004","kind":"paper","name":"RTOG 9501: postoperative concurrent radiotherapy and chemotherapy for high-risk head and neck squamous cell carcinoma","route":"/key-papers/paper-cooper-rtog-9501-nejm-2004/","asOf":"2026-09-17","days":11},{"id":"paper-keynote-689-nejm-2025","kind":"paper","name":"KEYNOTE-689: neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck cancer","route":"/key-papers/paper-keynote-689-nejm-2025/","asOf":"2026-09-17","days":11},{"id":"paper-ang-hpv-oropharyngeal-nejm-2010","kind":"paper","name":"Human papillomavirus and survival of patients with oropharyngeal cancer (RTOG 0129)","route":"/key-papers/paper-ang-hpv-oropharyngeal-nejm-2010/","asOf":"2026-09-17","days":11},{"id":"paper-rtog-1016-lancet-2019","kind":"paper","name":"NRG Oncology RTOG 1016: radiotherapy plus cetuximab versus cisplatin in HPV-positive oropharyngeal cancer","route":"/key-papers/paper-rtog-1016-lancet-2019/","asOf":"2026-09-17","days":11},{"id":"paper-de-escalate-lancet-2019","kind":"paper","name":"De-ESCALaTE HPV: radiotherapy plus cisplatin or cetuximab in low-risk HPV-positive oropharyngeal cancer","route":"/key-papers/paper-de-escalate-lancet-2019/","asOf":"2026-09-17","days":11},{"id":"paper-e3311-transoral-surgery-ferris-jco-2022","kind":"paper","name":"ECOG-ACRIN E3311: transoral surgery followed by reduced-dose radiotherapy for HPV-positive oropharyngeal cancer","route":"/key-papers/paper-e3311-transoral-surgery-ferris-jco-2022/","asOf":"2026-09-17","days":11},{"id":"paper-eortc-24891-larynx-preservation-lefebvre-jnci-1996","kind":"paper","name":"EORTC 24891: larynx preservation with induction chemotherapy in pyriform sinus (hypopharyngeal) cancer","route":"/key-papers/paper-eortc-24891-larynx-preservation-lefebvre-jnci-1996/","asOf":"2026-09-17","days":11},{"id":"paper-empower-cscc-1-cemiplimab-migden-nejm-2018","kind":"paper","name":"PD-1 blockade with cemiplimab in advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1)","route":"/key-papers/paper-empower-cscc-1-cemiplimab-migden-nejm-2018/","asOf":"2026-09-17","days":11},{"id":"paper-tonon-crtc1-maml2-nat-genet-2003","kind":"paper","name":"The t(11;19) translocation in mucoepidermoid carcinoma creates a CRTC1-MAML2 fusion","route":"/key-papers/paper-tonon-crtc1-maml2-nat-genet-2003/","asOf":"2026-09-17","days":11},{"id":"paper-laurie-licitra-salivary-systemic-jco-2006","kind":"paper","name":"Systemic therapy in the palliative management of advanced salivary gland cancers (review)","route":"/key-papers/paper-laurie-licitra-salivary-systemic-jco-2006/","asOf":"2026-09-17","days":11},{"id":"paper-extreme-vermorken-nejm-2008","kind":"paper","name":"EXTREME: platinum-based chemotherapy plus cetuximab in recurrent or metastatic head and neck cancer","route":"/key-papers/paper-extreme-vermorken-nejm-2008/","asOf":"2026-09-17","days":11},{"id":"paper-checkmate-141-ferris-nejm-2016","kind":"paper","name":"CheckMate 141: nivolumab for recurrent head and neck squamous cell carcinoma after platinum","route":"/key-papers/paper-checkmate-141-ferris-nejm-2016/","asOf":"2026-09-17","days":11},{"id":"paper-tpextreme-lancet-oncol-2021","kind":"paper","name":"TPExtreme (GORTEC 2014-01): docetaxel, cisplatin and cetuximab versus the EXTREME regimen in recurrent or metastatic head and neck cancer","route":"/key-papers/paper-tpextreme-lancet-oncol-2021/","asOf":"2026-09-17","days":11},{"id":"paper-takahashi-trastuzumab-docetaxel-salivary-duct-jco-2019","kind":"paper","name":"Phase 2 trial of trastuzumab and docetaxel in HER2-positive salivary duct carcinoma","route":"/key-papers/paper-takahashi-trastuzumab-docetaxel-salivary-duct-jco-2019/","asOf":"2026-09-17","days":11},{"id":"paper-fushimi-androgen-deprivation-salivary-duct-ann-oncol-2018","kind":"paper","name":"Combined androgen blockade in androgen receptor-positive salivary gland carcinoma","route":"/key-papers/paper-fushimi-androgen-deprivation-salivary-duct-ann-oncol-2018/","asOf":"2026-09-17","days":11},{"id":"paper-rtog-91-11-forastiere-nejm-2003","kind":"paper","name":"RTOG 91-11: concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer","route":"/key-papers/paper-rtog-91-11-forastiere-nejm-2003/","asOf":"2026-09-17","days":11},{"id":"paper-rtog-91-11-long-term-forastiere-jco-2013","kind":"paper","name":"Long-term results of RTOG 91-11: three non-surgical strategies to preserve the larynx","route":"/key-papers/paper-rtog-91-11-long-term-forastiere-jco-2013/","asOf":"2026-09-17","days":11},{"id":"paper-va-larynx-induction-chemotherapy-nejm-1991","kind":"paper","name":"Department of Veterans Affairs Laryngeal Cancer Study: induction chemotherapy plus radiation versus surgery plus radiation","route":"/key-papers/paper-va-larynx-induction-chemotherapy-nejm-1991/","asOf":"2026-09-17","days":11},{"id":"paper-who-2022-gu-moch-eur-urol-2022","kind":"paper","name":"WHO classification of tumours of the urinary system and male genital organs, 2022: renal, penile and testicular tumours","route":"/key-papers/paper-who-2022-gu-moch-eur-urol-2022/","asOf":"2026-09-17","days":11},{"id":"paper-tcga-chromophobe-davis-cancer-cell-2014","kind":"paper","name":"The somatic genomic landscape of chromophobe renal cell carcinoma (The Cancer Genome Atlas)","route":"/key-papers/paper-tcga-chromophobe-davis-cancer-cell-2014/","asOf":"2026-09-17","days":11},{"id":"paper-aspen-armstrong-lancet-oncol-2016","kind":"paper","name":"ASPEN: everolimus versus sunitinib in metastatic non-clear cell renal cell carcinoma","route":"/key-papers/paper-aspen-armstrong-lancet-oncol-2016/","asOf":"2026-09-17","days":11},{"id":"paper-keynote-426-nejm-2019","kind":"paper","name":"KEYNOTE-426: pembrolizumab plus axitinib versus sunitinib for advanced renal cell carcinoma","route":"/key-papers/paper-keynote-426-nejm-2019/","asOf":"2026-09-17","days":11},{"id":"paper-checkmate-214-nejm-2018","kind":"paper","name":"CheckMate 214: nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma","route":"/key-papers/paper-checkmate-214-nejm-2018/","asOf":"2026-09-17","days":11},{"id":"paper-papmet-pal-lancet-2021","kind":"paper","name":"PAPMET (SWOG 1500): cabozantinib versus sunitinib for metastatic papillary renal cell carcinoma","route":"/key-papers/paper-papmet-pal-lancet-2021/","asOf":"2026-09-17","days":11},{"id":"paper-tcga-papillary-rcc-nejm-2016","kind":"paper","name":"Comprehensive molecular characterisation of papillary renal cell carcinoma (The Cancer Genome Atlas)","route":"/key-papers/paper-tcga-papillary-rcc-nejm-2016/","asOf":"2026-09-17","days":11},{"id":"paper-planchard-dabrafenib-trametinib-braf-nsclc-lancet-oncol-2016","kind":"paper","name":"Dabrafenib plus trametinib in previously treated BRAF V600E-mutant metastatic non-small-cell lung cancer","route":"/key-papers/paper-planchard-dabrafenib-trametinib-braf-nsclc-lancet-oncol-2016/","asOf":"2026-09-17","days":11},{"id":"paper-planchard-dabrafenib-trametinib-first-line-lancet-oncol-2017","kind":"paper","name":"Dabrafenib plus trametinib in previously untreated BRAF V600E-mutant metastatic non-small-cell lung cancer","route":"/key-papers/paper-planchard-dabrafenib-trametinib-first-line-lancet-oncol-2017/","asOf":"2026-09-17","days":11},{"id":"paper-pharos-encorafenib-binimetinib-riely-jco-2023","kind":"paper","name":"PHAROS: encorafenib plus binimetinib in BRAF V600E-mutant metastatic non-small-cell lung cancer","route":"/key-papers/paper-pharos-encorafenib-binimetinib-riely-jco-2023/","asOf":"2026-09-17","days":11},{"id":"paper-destiny-lung01-nejm-2022","kind":"paper","name":"DESTINY-Lung01: trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","route":"/key-papers/paper-destiny-lung01-nejm-2022/","asOf":"2026-09-17","days":11},{"id":"paper-destiny-lung02-goto-jco-2023","kind":"paper","name":"DESTINY-Lung02: two doses of trastuzumab deruxtecan in HER2-mutant metastatic non-small-cell lung cancer","route":"/key-papers/paper-destiny-lung02-goto-jco-2023/","asOf":"2026-09-17","days":11},{"id":"paper-beamion-lung-1-zongertinib-nejm-2025","kind":"paper","name":"Beamion LUNG-1: zongertinib in previously treated HER2-mutant non-small-cell lung cancer","route":"/key-papers/paper-beamion-lung-1-zongertinib-nejm-2025/","asOf":"2026-09-17","days":11},{"id":"paper-vision-tepotinib-paik-nejm-2020","kind":"paper","name":"VISION: tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations","route":"/key-papers/paper-vision-tepotinib-paik-nejm-2020/","asOf":"2026-09-17","days":11},{"id":"paper-frampton-met-exon-14-cancer-discov-2015","kind":"paper","name":"MET exon 14 splicing alterations across tumour types and their sensitivity to MET inhibitors","route":"/key-papers/paper-frampton-met-exon-14-cancer-discov-2015/","asOf":"2026-09-17","days":11},{"id":"paper-drilon-larotrectinib-nejm-2018","kind":"paper","name":"Larotrectinib in TRK fusion-positive cancers in adults and children","route":"/key-papers/paper-drilon-larotrectinib-nejm-2018/","asOf":"2026-09-17","days":11},{"id":"paper-doebele-entrectinib-ntrk-lancet-oncol-2020","kind":"paper","name":"Entrectinib in NTRK fusion-positive solid tumours: integrated analysis of three trials","route":"/key-papers/paper-doebele-entrectinib-ntrk-lancet-oncol-2020/","asOf":"2026-09-17","days":11},{"id":"paper-trident-1-repotrectinib-nejm-2024","kind":"paper","name":"TRIDENT-1: repotrectinib in ROS1 fusion-positive non-small-cell lung cancer","route":"/key-papers/paper-trident-1-repotrectinib-nejm-2024/","asOf":"2026-09-17","days":11},{"id":"paper-libretto-001-selpercatinib-nsclc-nejm-2020","kind":"paper","name":"LIBRETTO-001: selpercatinib in RET fusion-positive non-small-cell lung cancer","route":"/key-papers/paper-libretto-001-selpercatinib-nsclc-nejm-2020/","asOf":"2026-09-17","days":11},{"id":"paper-libretto-431-nejm-2023","kind":"paper","name":"LIBRETTO-431: first-line selpercatinib versus chemotherapy with or without pembrolizumab in RET fusion-positive lung cancer","route":"/key-papers/paper-libretto-431-nejm-2023/","asOf":"2026-09-17","days":11},{"id":"paper-arrow-pralsetinib-gainor-lancet-oncol-2021","kind":"paper","name":"ARROW: pralsetinib for RET fusion-positive non-small-cell lung cancer","route":"/key-papers/paper-arrow-pralsetinib-gainor-lancet-oncol-2021/","asOf":"2026-09-17","days":11},{"id":"paper-shaw-crizotinib-ros1-nejm-2014","kind":"paper","name":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","route":"/key-papers/paper-shaw-crizotinib-ros1-nejm-2014/","asOf":"2026-09-17","days":11},{"id":"paper-drilon-entrectinib-ros1-lancet-oncol-2020","kind":"paper","name":"Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three trials","route":"/key-papers/paper-drilon-entrectinib-ros1-lancet-oncol-2020/","asOf":"2026-09-17","days":11},{"id":"paper-nordic-nec-sorbye-ann-oncol-2013","kind":"paper","name":"NORDIC NEC: predictive and prognostic factors in 305 patients with advanced gastrointestinal neuroendocrine carcinoma","route":"/key-papers/paper-nordic-nec-sorbye-ann-oncol-2013/","asOf":"2026-09-17","days":11},{"id":"paper-rindi-common-classification-framework-mod-pathol-2018","kind":"paper","name":"A common classification framework for neuroendocrine neoplasms (IARC and WHO expert consensus)","route":"/key-papers/paper-rindi-common-classification-framework-mod-pathol-2018/","asOf":"2026-09-17","days":11},{"id":"paper-dart-nivolumab-ipilimumab-nec-patel-ccr-2020","kind":"paper","name":"DART (SWOG 1609): nivolumab plus ipilimumab in rare tumours, non-pancreatic neuroendocrine neoplasms cohort","route":"/key-papers/paper-dart-nivolumab-ipilimumab-nec-patel-ccr-2020/","asOf":"2026-09-17","days":11},{"id":"paper-heetfeld-grade-3-net-erc-2015","kind":"paper","name":"Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms","route":"/key-papers/paper-heetfeld-grade-3-net-erc-2015/","asOf":"2026-09-17","days":11},{"id":"paper-radiant-4-everolimus-lancet-2016","kind":"paper","name":"RADIANT-4: everolimus for advanced non-functional neuroendocrine tumours of the lung or gastrointestinal tract","route":"/key-papers/paper-radiant-4-everolimus-lancet-2016/","asOf":"2026-09-17","days":11},{"id":"paper-cabinet-cabozantinib-nejm-2024","kind":"paper","name":"CABINET (Alliance A021602): cabozantinib for advanced neuroendocrine tumours","route":"/key-papers/paper-cabinet-cabozantinib-nejm-2024/","asOf":"2026-09-17","days":11},{"id":"paper-enets-lung-net-consensus-caplin-ann-oncol-2015","kind":"paper","name":"ENETS expert consensus on pulmonary neuroendocrine (carcinoid) tumours","route":"/key-papers/paper-enets-lung-net-consensus-caplin-ann-oncol-2015/","asOf":"2026-09-17","days":11},{"id":"paper-clarinet-lanreotide-nejm-2014","kind":"paper","name":"CLARINET: lanreotide in metastatic enteropancreatic neuroendocrine tumours","route":"/key-papers/paper-clarinet-lanreotide-nejm-2014/","asOf":"2026-09-17","days":11},{"id":"paper-radiant-3-everolimus-pnet-yao-nejm-2011","kind":"paper","name":"RADIANT-3: everolimus for advanced pancreatic neuroendocrine tumours","route":"/key-papers/paper-radiant-3-everolimus-pnet-yao-nejm-2011/","asOf":"2026-09-17","days":11},{"id":"paper-raymond-sunitinib-pnet-nejm-2011","kind":"paper","name":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumours","route":"/key-papers/paper-raymond-sunitinib-pnet-nejm-2011/","asOf":"2026-09-17","days":11},{"id":"paper-netter-1-nejm-2017","kind":"paper","name":"NETTER-1: 177Lu-Dotatate for midgut neuroendocrine tumours progressing on octreotide","route":"/key-papers/paper-netter-1-nejm-2017/","asOf":"2026-09-17","days":11},{"id":"paper-promid-rinke-jco-2009","kind":"paper","name":"PROMID: octreotide LAR in the control of tumour growth in metastatic midgut neuroendocrine tumours","route":"/key-papers/paper-promid-rinke-jco-2009/","asOf":"2026-09-17","days":11},{"id":"paper-shah-foxl2-granulosa-nejm-2009","kind":"paper","name":"Mutation of FOXL2 in granulosa cell tumours of the ovary","route":"/key-papers/paper-shah-foxl2-granulosa-nejm-2009/","asOf":"2026-09-17","days":11},{"id":"paper-esmo-non-epithelial-ovarian-ray-coquard-ann-oncol-2018","kind":"paper","name":"Non-epithelial ovarian cancer: ESMO clinical practice guidelines","route":"/key-papers/paper-esmo-non-epithelial-ovarian-ray-coquard-ann-oncol-2018/","asOf":"2026-09-17","days":11},{"id":"paper-wiegand-arid1a-clear-cell-nejm-2010","kind":"paper","name":"ARID1A mutations in endometriosis-associated ovarian carcinomas","route":"/key-papers/paper-wiegand-arid1a-clear-cell-nejm-2010/","asOf":"2026-09-17","days":11},{"id":"paper-jones-arid1a-clear-cell-science-2010","kind":"paper","name":"Frequent mutations of the chromatin remodelling gene ARID1A in ovarian clear cell carcinoma","route":"/key-papers/paper-jones-arid1a-clear-cell-science-2010/","asOf":"2026-09-17","days":11},{"id":"paper-tcga-ovarian-nature-2011","kind":"paper","name":"Integrated genomic analyses of ovarian carcinoma (The Cancer Genome Atlas)","route":"/key-papers/paper-tcga-ovarian-nature-2011/","asOf":"2026-09-17","days":11},{"id":"paper-gog-281-trametinib-lgsoc-gershenson-lancet-2022","kind":"paper","name":"GOG 281/LOGS: trametinib versus standard of care in recurrent low-grade serous ovarian cancer","route":"/key-papers/paper-gog-281-trametinib-lgsoc-gershenson-lancet-2022/","asOf":"2026-09-17","days":11},{"id":"paper-gershenson-hormonal-maintenance-lgsoc-jco-2017","kind":"paper","name":"Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum","route":"/key-papers/paper-gershenson-hormonal-maintenance-lgsoc-jco-2017/","asOf":"2026-09-17","days":11},{"id":"paper-ramp-201-avutometinib-defactinib-lgsoc-jco-2025","kind":"paper","name":"RAMP 201: avutometinib with or without defactinib in recurrent low-grade serous ovarian cancer","route":"/key-papers/paper-ramp-201-avutometinib-defactinib-lgsoc-jco-2025/","asOf":"2026-09-17","days":11},{"id":"paper-cheasley-mucinous-ovarian-genomics-nat-commun-2019","kind":"paper","name":"The molecular origin and taxonomy of mucinous ovarian carcinoma","route":"/key-papers/paper-cheasley-mucinous-ovarian-genomics-nat-commun-2019/","asOf":"2026-09-17","days":11},{"id":"paper-morice-mucinous-ovarian-carcinoma-nejm-2019","kind":"paper","name":"Mucinous ovarian carcinoma (review)","route":"/key-papers/paper-morice-mucinous-ovarian-carcinoma-nejm-2019/","asOf":"2026-09-17","days":11},{"id":"paper-aaml0531-gemtuzumab-gamis-jco-2014","kind":"paper","name":"AAML0531: gemtuzumab ozogamicin added to chemotherapy for children and adolescents with acute myeloid leukaemia","route":"/key-papers/paper-aaml0531-gemtuzumab-gamis-jco-2014/","asOf":"2026-09-17","days":11},{"id":"paper-aaml1031-sorafenib-flt3-pollard-jco-2022","kind":"paper","name":"AAML1031: sorafenib combined with chemotherapy for children with high allelic ratio FLT3-ITD acute myeloid leukaemia","route":"/key-papers/paper-aaml1031-sorafenib-flt3-pollard-jco-2022/","asOf":"2026-09-17","days":11},{"id":"paper-bolouri-paediatric-aml-genomics-nat-med-2018","kind":"paper","name":"The molecular landscape of paediatric acute myeloid leukaemia (TARGET)","route":"/key-papers/paper-bolouri-paediatric-aml-genomics-nat-med-2018/","asOf":"2026-09-17","days":11},{"id":"paper-taylor-medulloblastoma-consensus-acta-neuropathol-2012","kind":"paper","name":"Molecular subgroups of medulloblastoma: the current consensus","route":"/key-papers/paper-taylor-medulloblastoma-consensus-acta-neuropathol-2012/","asOf":"2026-09-17","days":11},{"id":"paper-cavalli-medulloblastoma-subtypes-cancer-cell-2017","kind":"paper","name":"Intertumoural heterogeneity within medulloblastoma subgroups","route":"/key-papers/paper-cavalli-medulloblastoma-subtypes-cancer-cell-2017/","asOf":"2026-09-17","days":11},{"id":"paper-acns0331-michalski-jco-2021","kind":"paper","name":"ACNS0331: reduced-dose and reduced-volume radiotherapy with chemotherapy for average-risk medulloblastoma","route":"/key-papers/paper-acns0331-michalski-jco-2021/","asOf":"2026-09-17","days":11},{"id":"paper-acns0332-leary-jama-oncol-2021","kind":"paper","name":"ACNS0332: carboplatin during radiotherapy and isotretinoin maintenance in high-risk medulloblastoma","route":"/key-papers/paper-acns0332-leary-jama-oncol-2021/","asOf":"2026-09-17","days":11},{"id":"paper-aall0232-larsen-jco-2016","kind":"paper","name":"AALL0232: dexamethasone and high-dose methotrexate improve outcome in high-risk B-cell acute lymphoblastic leukaemia in children and young adults","route":"/key-papers/paper-aall0232-larsen-jco-2016/","asOf":"2026-09-17","days":11},{"id":"paper-aall0434-nelarabine-t-all-dunsmore-jco-2020","kind":"paper","name":"AALL0434: nelarabine in newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults","route":"/key-papers/paper-aall0434-nelarabine-t-all-dunsmore-jco-2020/","asOf":"2026-09-17","days":11},{"id":"paper-hunger-mullighan-all-children-nejm-2015","kind":"paper","name":"Acute lymphoblastic leukaemia in children (review)","route":"/key-papers/paper-hunger-mullighan-all-children-nejm-2015/","asOf":"2026-09-17","days":11},{"id":"paper-inrg-cohn-jco-2009","kind":"paper","name":"The International Neuroblastoma Risk Group (INRG) classification system","route":"/key-papers/paper-inrg-cohn-jco-2009/","asOf":"2026-09-17","days":11},{"id":"paper-yu-anti-gd2-neuroblastoma-nejm-2010","kind":"paper","name":"Anti-GD2 antibody with GM-CSF, interleukin-2 and isotretinoin for high-risk neuroblastoma (COG ANBL0032)","route":"/key-papers/paper-yu-anti-gd2-neuroblastoma-nejm-2010/","asOf":"2026-09-17","days":11},{"id":"paper-hr-nbl1-busulfan-melphalan-ladenstein-lancet-oncol-2017","kind":"paper","name":"HR-NBL1/SIOPEN: busulfan-melphalan versus carboplatin-etoposide-melphalan high-dose chemotherapy for high-risk neuroblastoma","route":"/key-papers/paper-hr-nbl1-busulfan-melphalan-ladenstein-lancet-oncol-2017/","asOf":"2026-09-17","days":11},{"id":"paper-anbl0532-tandem-transplant-park-jama-2019","kind":"paper","name":"ANBL0532: tandem versus single autologous stem cell transplant for high-risk neuroblastoma","route":"/key-papers/paper-anbl0532-tandem-transplant-park-jama-2019/","asOf":"2026-09-17","days":11},{"id":"paper-interfant-06-pieters-jco-2019","kind":"paper","name":"Interfant-06: outcome of infants under one year with acute lymphoblastic leukaemia","route":"/key-papers/paper-interfant-06-pieters-jco-2019/","asOf":"2026-09-17","days":11},{"id":"paper-blinatumomab-infant-all-van-der-sluis-nejm-2023","kind":"paper","name":"Blinatumomab added to chemotherapy in infant KMT2A-rearranged acute lymphoblastic leukaemia","route":"/key-papers/paper-blinatumomab-infant-all-van-der-sluis-nejm-2023/","asOf":"2026-09-17","days":11},{"id":"paper-interfant-99-lancet-2007","kind":"paper","name":"Interfant-99: a treatment protocol for infants under one year with acute lymphoblastic leukaemia","route":"/key-papers/paper-interfant-99-lancet-2007/","asOf":"2026-09-17","days":11},{"id":"paper-a3961-intermediate-risk-neuroblastoma-baker-nejm-2010","kind":"paper","name":"A3961: outcome after reduced chemotherapy for intermediate-risk neuroblastoma","route":"/key-papers/paper-a3961-intermediate-risk-neuroblastoma-baker-nejm-2010/","asOf":"2026-09-17","days":11},{"id":"paper-anbl0531-twist-jco-2019","kind":"paper","name":"ANBL0531: response- and biology-based therapy for intermediate-risk neuroblastoma","route":"/key-papers/paper-anbl0531-twist-jco-2019/","asOf":"2026-09-17","days":11},{"id":"paper-anbl00p2-expectant-observation-nuchtern-ann-surg-2012","kind":"paper","name":"ANBL00P2: expectant observation as primary therapy for neuroblastoma in young infants","route":"/key-papers/paper-anbl00p2-expectant-observation-nuchtern-ann-surg-2012/","asOf":"2026-09-17","days":11},{"id":"paper-p9641-low-risk-neuroblastoma-strother-jco-2012","kind":"paper","name":"COG P9641: surgery alone or with restricted chemotherapy for low-risk neuroblastoma","route":"/key-papers/paper-p9641-low-risk-neuroblastoma-strother-jco-2012/","asOf":"2026-09-17","days":11},{"id":"paper-roberts-ph-like-all-nejm-2014","kind":"paper","name":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukaemia","route":"/key-papers/paper-roberts-ph-like-all-nejm-2014/","asOf":"2026-09-17","days":11},{"id":"paper-den-boer-bcr-abl1-like-all-lancet-oncol-2009","kind":"paper","name":"A subtype of childhood acute lymphoblastic leukaemia with poor outcome: genome-wide classification study (BCR-ABL1-like ALL)","route":"/key-papers/paper-den-boer-bcr-abl1-like-all-lancet-oncol-2009/","asOf":"2026-09-17","days":11},{"id":"paper-mullighan-ikzf1-nejm-2009","kind":"paper","name":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukaemia","route":"/key-papers/paper-mullighan-ikzf1-nejm-2009/","asOf":"2026-09-17","days":11},{"id":"paper-aall0031-imatinib-ph-positive-all-schultz-jco-2009","kind":"paper","name":"AALL0031: imatinib with intensive chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukaemia in children","route":"/key-papers/paper-aall0031-imatinib-ph-positive-all-schultz-jco-2009/","asOf":"2026-09-17","days":11},{"id":"paper-esphall-imatinib-biondi-lancet-oncol-2012","kind":"paper","name":"EsPhALL: imatinib after induction for children and adolescents with Philadelphia chromosome-positive acute lymphoblastic leukaemia","route":"/key-papers/paper-esphall-imatinib-biondi-lancet-oncol-2012/","asOf":"2026-09-17","days":11},{"id":"paper-dasatinib-vs-imatinib-ph-positive-all-shen-jama-oncol-2020","kind":"paper","name":"Dasatinib versus imatinib with chemotherapy for paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CCCG-ALL-2015)","route":"/key-papers/paper-dasatinib-vs-imatinib-ph-positive-all-shen-jama-oncol-2020/","asOf":"2026-09-17","days":11},{"id":"paper-robinson-vismodegib-shh-medulloblastoma-jco-2015","kind":"paper","name":"Vismodegib in recurrent sonic hedgehog-subgroup medulloblastoma (PBTC-025B and PBTC-032)","route":"/key-papers/paper-robinson-vismodegib-shh-medulloblastoma-jco-2015/","asOf":"2026-09-17","days":11},{"id":"paper-zhukova-tp53-medulloblastoma-jco-2013","kind":"paper","name":"Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma","route":"/key-papers/paper-zhukova-tp53-medulloblastoma-jco-2013/","asOf":"2026-09-17","days":11},{"id":"paper-embark-nejm-2023","kind":"paper","name":"EMBARK: enzalutamide with or without leuprolide in high-risk biochemically recurrent prostate cancer","route":"/key-papers/paper-embark-nejm-2023/","asOf":"2026-09-17","days":11},{"id":"paper-radicals-rt-lancet-2020","kind":"paper","name":"RADICALS-RT: timing of radiotherapy after radical prostatectomy","route":"/key-papers/paper-radicals-rt-lancet-2020/","asOf":"2026-09-17","days":11},{"id":"paper-propsma-hofman-lancet-2020","kind":"paper","name":"proPSMA: PSMA PET-CT versus conventional imaging for staging high-risk prostate cancer","route":"/key-papers/paper-propsma-hofman-lancet-2020/","asOf":"2026-09-17","days":11},{"id":"paper-stampede-abiraterone-high-risk-attard-lancet-2022","kind":"paper","name":"STAMPEDE: abiraterone with or without enzalutamide added to androgen deprivation for high-risk non-metastatic prostate cancer","route":"/key-papers/paper-stampede-abiraterone-high-risk-attard-lancet-2022/","asOf":"2026-09-17","days":11},{"id":"paper-bolla-eortc-22863-nejm-1997","kind":"paper","name":"EORTC 22863: improved survival with radiotherapy plus goserelin in locally advanced prostate cancer","route":"/key-papers/paper-bolla-eortc-22863-nejm-1997/","asOf":"2026-09-17","days":11},{"id":"paper-damico-risk-groups-jama-1998","kind":"paper","name":"D'Amico risk groups: biochemical outcome after radical prostatectomy, external beam radiotherapy or brachytherapy","route":"/key-papers/paper-damico-risk-groups-jama-1998/","asOf":"2026-09-17","days":11},{"id":"paper-protect-nejm-2016","kind":"paper","name":"ProtecT: 10-year outcomes after monitoring, surgery or radiotherapy for localised prostate cancer","route":"/key-papers/paper-protect-nejm-2016/","asOf":"2026-09-17","days":11},{"id":"paper-protect-15-year-nejm-2023","kind":"paper","name":"ProtecT: fifteen-year outcomes after monitoring, surgery or radiotherapy for prostate cancer","route":"/key-papers/paper-protect-15-year-nejm-2023/","asOf":"2026-09-17","days":11},{"id":"paper-chhip-lancet-oncol-2016","kind":"paper","name":"CHHiP: conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer","route":"/key-papers/paper-chhip-lancet-oncol-2016/","asOf":"2026-09-17","days":11},{"id":"paper-rtog-9408-short-term-adt-jones-nejm-2011","kind":"paper","name":"RTOG 9408: radiotherapy with short-term androgen deprivation for localised prostate cancer","route":"/key-papers/paper-rtog-9408-short-term-adt-jones-nejm-2011/","asOf":"2026-09-17","days":11},{"id":"paper-klotz-active-surveillance-jco-2015","kind":"paper","name":"Long-term follow-up of a large active surveillance cohort of patients with prostate cancer (Sunnybrook)","route":"/key-papers/paper-klotz-active-surveillance-jco-2015/","asOf":"2026-09-17","days":11},{"id":"paper-precision-mri-targeted-biopsy-nejm-2018","kind":"paper","name":"PRECISION: MRI-targeted or standard biopsy for prostate cancer diagnosis","route":"/key-papers/paper-precision-mri-targeted-biopsy-nejm-2018/","asOf":"2026-09-17","days":11},{"id":"paper-profound-nejm-2020","kind":"paper","name":"PROfound: olaparib for metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations","route":"/key-papers/paper-profound-nejm-2020/","asOf":"2026-09-17","days":11},{"id":"paper-cou-aa-301-abiraterone-de-bono-nejm-2011","kind":"paper","name":"COU-AA-301: abiraterone and increased survival in metastatic castration-resistant prostate cancer after docetaxel","route":"/key-papers/paper-cou-aa-301-abiraterone-de-bono-nejm-2011/","asOf":"2026-09-17","days":11},{"id":"paper-alsympca-radium-223-nejm-2013","kind":"paper","name":"ALSYMPCA: alpha emitter radium-223 and survival in metastatic prostate cancer with bone metastases","route":"/key-papers/paper-alsympca-radium-223-nejm-2013/","asOf":"2026-09-17","days":11},{"id":"paper-latitude-nejm-2017","kind":"paper","name":"LATITUDE: abiraterone plus prednisone in newly diagnosed high-risk metastatic castration-sensitive prostate cancer","route":"/key-papers/paper-latitude-nejm-2017/","asOf":"2026-09-17","days":11},{"id":"paper-arasens-nejm-2022","kind":"paper","name":"ARASENS: darolutamide added to androgen deprivation and docetaxel in metastatic hormone-sensitive prostate cancer","route":"/key-papers/paper-arasens-nejm-2022/","asOf":"2026-09-17","days":11},{"id":"paper-chaarted-nejm-2015","kind":"paper","name":"CHAARTED: chemohormonal therapy in metastatic hormone-sensitive prostate cancer","route":"/key-papers/paper-chaarted-nejm-2015/","asOf":"2026-09-17","days":11},{"id":"paper-beltran-nepc-divergent-evolution-nat-med-2016","kind":"paper","name":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","route":"/key-papers/paper-beltran-nepc-divergent-evolution-nat-med-2016/","asOf":"2026-09-17","days":11},{"id":"paper-aggarwal-t-sccpc-jco-2018","kind":"paper","name":"Clinical and genomic characterisation of treatment-emergent small-cell neuroendocrine prostate cancer","route":"/key-papers/paper-aggarwal-t-sccpc-jco-2018/","asOf":"2026-09-17","days":11},{"id":"paper-aparicio-aggressive-variant-ccr-2013","kind":"paper","name":"Platinum-based chemotherapy for variant castration-resistant prostate cancer (aggressive variant criteria)","route":"/key-papers/paper-aparicio-aggressive-variant-ccr-2013/","asOf":"2026-09-17","days":11},{"id":"paper-spartan-nejm-2018","kind":"paper","name":"SPARTAN: apalutamide for non-metastatic castration-resistant prostate cancer","route":"/key-papers/paper-spartan-nejm-2018/","asOf":"2026-09-17","days":11},{"id":"paper-prosper-nejm-2018","kind":"paper","name":"PROSPER: enzalutamide in men with non-metastatic castration-resistant prostate cancer","route":"/key-papers/paper-prosper-nejm-2018/","asOf":"2026-09-17","days":11},{"id":"paper-aramis-nejm-2019","kind":"paper","name":"ARAMIS: darolutamide in non-metastatic castration-resistant prostate cancer","route":"/key-papers/paper-aramis-nejm-2019/","asOf":"2026-09-17","days":11},{"id":"paper-atezolizumab-alveolar-soft-part-sarcoma-chen-nejm-2023","kind":"paper","name":"Atezolizumab for advanced alveolar soft part sarcoma","route":"/key-papers/paper-atezolizumab-alveolar-soft-part-sarcoma-chen-nejm-2023/","asOf":"2026-09-17","days":11},{"id":"paper-ladanyi-aspl-tfe3-oncogene-2001","kind":"paper","name":"The der(17)t(X;17) of alveolar soft part sarcoma fuses TFE3 to ASPL","route":"/key-papers/paper-ladanyi-aspl-tfe3-oncogene-2001/","asOf":"2026-09-17","days":11},{"id":"paper-angiotax-paclitaxel-angiosarcoma-penel-jco-2008","kind":"paper","name":"ANGIOTAX: phase 2 trial of weekly paclitaxel for unresectable angiosarcoma","route":"/key-papers/paper-angiotax-paclitaxel-angiosarcoma-penel-jco-2008/","asOf":"2026-09-17","days":11},{"id":"paper-young-angiosarcoma-review-lancet-oncol-2010","kind":"paper","name":"Angiosarcoma (review)","route":"/key-papers/paper-young-angiosarcoma-review-lancet-oncol-2010/","asOf":"2026-09-17","days":11},{"id":"paper-amary-idh-cartilaginous-tumours-j-pathol-2011","kind":"paper","name":"IDH1 and IDH2 mutations are frequent in central chondrosarcoma and central and periosteal chondromas","route":"/key-papers/paper-amary-idh-cartilaginous-tumours-j-pathol-2011/","asOf":"2026-09-17","days":11},{"id":"paper-esmo-bone-sarcoma-guideline-strauss-ann-oncol-2021","kind":"paper","name":"Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan clinical practice guideline","route":"/key-papers/paper-esmo-bone-sarcoma-guideline-strauss-ann-oncol-2021/","asOf":"2026-09-17","days":11},{"id":"paper-errani-wwtr1-camta1-ehe-gcc-2011","kind":"paper","name":"A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid haemangioendothelioma","route":"/key-papers/paper-errani-wwtr1-camta1-ehe-gcc-2011/","asOf":"2026-09-17","days":11},{"id":"paper-ehe-consensus-stacchiotti-esmo-open-2021","kind":"paper","name":"Epithelioid haemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts","route":"/key-papers/paper-ehe-consensus-stacchiotti-esmo-open-2021/","asOf":"2026-09-17","days":11},{"id":"paper-sirolimus-ehe-stacchiotti-cancer-2021","kind":"paper","name":"Activity of sirolimus in progressive epithelioid haemangioendothelioma (Italian Rare Cancer Network)","route":"/key-papers/paper-sirolimus-ehe-stacchiotti-cancer-2021/","asOf":"2026-09-17","days":11},{"id":"paper-kroep-mpnst-first-line-chemotherapy-ann-oncol-2011","kind":"paper","name":"First-line chemotherapy for malignant peripheral nerve sheath tumour versus other soft tissue sarcomas (EORTC pooled analysis)","route":"/key-papers/paper-kroep-mpnst-first-line-chemotherapy-ann-oncol-2011/","asOf":"2026-09-17","days":11},{"id":"paper-lee-prc2-mpnst-nat-genet-2014","kind":"paper","name":"PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumours","route":"/key-papers/paper-lee-prc2-mpnst-nat-genet-2014/","asOf":"2026-09-17","days":11},{"id":"paper-eortc-62012-doxorubicin-ifosfamide-judson-lancet-oncol-2014","kind":"paper","name":"EORTC 62012: doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced soft tissue sarcoma","route":"/key-papers/paper-eortc-62012-doxorubicin-ifosfamide-judson-lancet-oncol-2014/","asOf":"2026-09-17","days":11},{"id":"paper-esmo-sts-guideline-gronchi-ann-oncol-2021","kind":"paper","name":"Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guideline","route":"/key-papers/paper-esmo-sts-guideline-gronchi-ann-oncol-2021/","asOf":"2026-09-17","days":11},{"id":"paper-myxofibrosarcoma-mentzel-ajsp-1996","kind":"paper","name":"Myxofibrosarcoma: clinicopathological analysis of 75 cases with emphasis on the low-grade variant","route":"/key-papers/paper-myxofibrosarcoma-mentzel-ajsp-1996/","asOf":"2026-09-17","days":11},{"id":"paper-ampect-nab-sirolimus-pecoma-wagner-jco-2021","kind":"paper","name":"AMPECT: nab-sirolimus for malignant perivascular epithelioid cell tumours","route":"/key-papers/paper-ampect-nab-sirolimus-pecoma-wagner-jco-2021/","asOf":"2026-09-17","days":11},{"id":"paper-wagner-sirolimus-pecoma-jco-2010","kind":"paper","name":"Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumours","route":"/key-papers/paper-wagner-sirolimus-pecoma-jco-2010/","asOf":"2026-09-17","days":11},{"id":"paper-strass-lancet-oncol-2020","kind":"paper","name":"STRASS (EORTC 62092): preoperative radiotherapy plus surgery versus surgery alone for primary retroperitoneal sarcoma","route":"/key-papers/paper-strass-lancet-oncol-2020/","asOf":"2026-09-17","days":11},{"id":"paper-tarpswg-retroperitoneal-sarcoma-gronchi-ann-surg-2016","kind":"paper","name":"Variability in patterns of recurrence after resection of primary retroperitoneal sarcoma (TARPSWG)","route":"/key-papers/paper-tarpswg-retroperitoneal-sarcoma-gronchi-ann-surg-2016/","asOf":"2026-09-17","days":11},{"id":"paper-bonvalot-retroperitoneal-sarcoma-compartmental-jco-2009","kind":"paper","name":"Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control","route":"/key-papers/paper-bonvalot-retroperitoneal-sarcoma-compartmental-jco-2009/","asOf":"2026-09-17","days":11},{"id":"paper-ncic-sr2-preoperative-vs-postoperative-radiotherapy-osullivan-lancet-2002","kind":"paper","name":"NCIC SR2: preoperative versus postoperative radiotherapy in soft tissue sarcoma of the limbs","route":"/key-papers/paper-ncic-sr2-preoperative-vs-postoperative-radiotherapy-osullivan-lancet-2002/","asOf":"2026-09-17","days":11},{"id":"paper-isg-sts-1001-gronchi-lancet-oncol-2017","kind":"paper","name":"ISG-STS 1001: histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in high-risk soft tissue sarcoma","route":"/key-papers/paper-isg-sts-1001-gronchi-lancet-oncol-2017/","asOf":"2026-09-17","days":11},{"id":"paper-lms-04-doxorubicin-trabectedin-lancet-oncol-2022","kind":"paper","name":"LMS-04: doxorubicin plus trabectedin followed by trabectedin maintenance versus doxorubicin alone in metastatic leiomyosarcoma","route":"/key-papers/paper-lms-04-doxorubicin-trabectedin-lancet-oncol-2022/","asOf":"2026-09-17","days":11},{"id":"paper-sarc028-pembrolizumab-sarcoma-tawbi-lancet-oncol-2017","kind":"paper","name":"SARC028: pembrolizumab in advanced soft tissue and bone sarcoma","route":"/key-papers/paper-sarc028-pembrolizumab-sarcoma-tawbi-lancet-oncol-2017/","asOf":"2026-09-17","days":11},{"id":"paper-mavoric-mogamulizumab-lancet-oncol-2018","kind":"paper","name":"MAVORIC: mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma","route":"/key-papers/paper-mavoric-mogamulizumab-lancet-oncol-2018/","asOf":"2026-09-17","days":11},{"id":"paper-alcanza-brentuximab-vedotin-lancet-2017","kind":"paper","name":"ALCANZA: brentuximab vedotin versus physician's choice in CD30-positive cutaneous T-cell lymphoma","route":"/key-papers/paper-alcanza-brentuximab-vedotin-lancet-2017/","asOf":"2026-09-17","days":11},{"id":"paper-olsen-mycosis-fungoides-staging-blood-2007","kind":"paper","name":"Revisions to the staging and classification of mycosis fungoides and Sezary syndrome (ISCL/EORTC)","route":"/key-papers/paper-olsen-mycosis-fungoides-staging-blood-2007/","asOf":"2026-09-17","days":11},{"id":"paper-hensley-gemcitabine-docetaxel-leiomyosarcoma-jco-2002","kind":"paper","name":"Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase 2 trial","route":"/key-papers/paper-hensley-gemcitabine-docetaxel-leiomyosarcoma-jco-2002/","asOf":"2026-09-17","days":11},{"id":"paper-eribulin-liposarcoma-schoffski-lancet-2016","kind":"paper","name":"Eribulin versus dacarbazine in previously treated advanced liposarcoma or leiomyosarcoma","route":"/key-papers/paper-eribulin-liposarcoma-schoffski-lancet-2016/","asOf":"2026-09-17","days":11},{"id":"paper-trabectedin-vs-dacarbazine-demetri-jco-2016","kind":"paper","name":"Trabectedin versus dacarbazine for metastatic liposarcoma or leiomyosarcoma after anthracycline failure","route":"/key-papers/paper-trabectedin-vs-dacarbazine-demetri-jco-2016/","asOf":"2026-09-17","days":11},{"id":"paper-wotherspoon-h-pylori-malt-lancet-1993","kind":"paper","name":"Regression of primary low-grade gastric MALT lymphoma after eradication of Helicobacter pylori","route":"/key-papers/paper-wotherspoon-h-pylori-malt-lancet-1993/","asOf":"2026-09-17","days":11},{"id":"paper-esmo-marginal-zone-lymphoma-zucca-ann-oncol-2020","kind":"paper","name":"Marginal zone lymphomas: ESMO clinical practice guidelines","route":"/key-papers/paper-esmo-marginal-zone-lymphoma-zucca-ann-oncol-2020/","asOf":"2026-09-17","days":11},{"id":"paper-magnolia-zanubrutinib-mzl-ccr-2021","kind":"paper","name":"MAGNOLIA: zanubrutinib in relapsed or refractory marginal zone lymphoma","route":"/key-papers/paper-magnolia-zanubrutinib-mzl-ccr-2021/","asOf":"2026-09-17","days":11},{"id":"paper-augment-lenalidomide-rituximab-leonard-jco-2019","kind":"paper","name":"AUGMENT: lenalidomide plus rituximab versus rituximab alone in relapsed indolent lymphoma","route":"/key-papers/paper-augment-lenalidomide-rituximab-leonard-jco-2019/","asOf":"2026-09-17","days":11},{"id":"paper-clark-syt-ssx-synovial-sarcoma-nat-genet-1994","kind":"paper","name":"Identification of SYT and SSX, the genes fused by the t(X;18) translocation in synovial sarcoma","route":"/key-papers/paper-clark-syt-ssx-synovial-sarcoma-nat-genet-1994/","asOf":"2026-09-17","days":11},{"id":"paper-dangelo-ny-eso-1-tcr-synovial-sarcoma-cancer-discov-2018","kind":"paper","name":"NY-ESO-1 c259 T-cell receptor therapy in synovial sarcoma: prolonged persistence and antitumour activity","route":"/key-papers/paper-dangelo-ny-eso-1-tcr-synovial-sarcoma-cancer-discov-2018/","asOf":"2026-09-17","days":11},{"id":"paper-hayward-melanoma-whole-genome-nature-2017","kind":"paper","name":"Whole-genome landscapes of major melanoma subtypes","route":"/key-papers/paper-hayward-melanoma-whole-genome-nature-2017/","asOf":"2026-09-17","days":11},{"id":"paper-curtin-melanoma-genetic-alterations-nejm-2005","kind":"paper","name":"Distinct sets of genetic alterations in melanoma","route":"/key-papers/paper-curtin-melanoma-genetic-alterations-nejm-2005/","asOf":"2026-09-17","days":11},{"id":"paper-nakamura-anti-pd1-acral-melanoma-ann-oncol-2020","kind":"paper","name":"Anti-PD-1 checkpoint inhibitor therapy in acral melanoma: a multicentre study of 193 Japanese patients","route":"/key-papers/paper-nakamura-anti-pd1-acral-melanoma-ann-oncol-2020/","asOf":"2026-09-17","days":11},{"id":"paper-keynote-629-pembrolizumab-cscc-grob-jco-2020","kind":"paper","name":"KEYNOTE-629: pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma","route":"/key-papers/paper-keynote-629-pembrolizumab-cscc-grob-jco-2020/","asOf":"2026-09-17","days":11},{"id":"paper-c-post-adjuvant-cemiplimab-nejm-2025","kind":"paper","name":"C-POST: adjuvant cemiplimab versus placebo in high-risk cutaneous squamous cell carcinoma","route":"/key-papers/paper-c-post-adjuvant-cemiplimab-nejm-2025/","asOf":"2026-09-17","days":11},{"id":"paper-gross-neoadjuvant-cemiplimab-cscc-nejm-2022","kind":"paper","name":"Neoadjuvant cemiplimab for stage II to IV cutaneous squamous cell carcinoma","route":"/key-papers/paper-gross-neoadjuvant-cemiplimab-cscc-nejm-2022/","asOf":"2026-09-17","days":11},{"id":"paper-dreamseq-jco-2023","kind":"paper","name":"DREAMseq (ECOG-ACRIN EA6134): sequencing dabrafenib-trametinib and nivolumab-ipilimumab in BRAF-mutant metastatic melanoma","route":"/key-papers/paper-dreamseq-jco-2023/","asOf":"2026-09-17","days":11},{"id":"paper-combi-d-long-lancet-2015","kind":"paper","name":"COMBI-d: dabrafenib and trametinib versus dabrafenib alone for BRAF V600-mutant melanoma","route":"/key-papers/paper-combi-d-long-lancet-2015/","asOf":"2026-09-17","days":11},{"id":"paper-columbus-lancet-oncol-2018","kind":"paper","name":"COLUMBUS: encorafenib plus binimetinib versus vemurafenib or encorafenib in BRAF-mutant melanoma","route":"/key-papers/paper-columbus-lancet-oncol-2018/","asOf":"2026-09-17","days":11},{"id":"paper-combi-ad-nejm-2017","kind":"paper","name":"COMBI-AD: adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","route":"/key-papers/paper-combi-ad-nejm-2017/","asOf":"2026-09-17","days":11},{"id":"paper-chapman-vemurafenib-nejm-2011","kind":"paper","name":"BRIM-3: improved survival with vemurafenib in melanoma with BRAF V600E mutation","route":"/key-papers/paper-chapman-vemurafenib-nejm-2011/","asOf":"2026-09-17","days":11},{"id":"paper-imatinib-dfsp-eortc-swog-rutkowski-jco-2010","kind":"paper","name":"Imatinib in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase 2 trials (EORTC 62027 and SWOG S0345)","route":"/key-papers/paper-imatinib-dfsp-eortc-swog-rutkowski-jco-2010/","asOf":"2026-09-17","days":11},{"id":"paper-simon-col1a1-pdgfb-dfsp-nat-genet-1997","kind":"paper","name":"Deregulation of the platelet-derived growth factor B-chain gene via fusion with COL1A1 in dermatofibrosarcoma protuberans","route":"/key-papers/paper-simon-col1a1-pdgfb-dfsp-nat-genet-1997/","asOf":"2026-09-17","days":11},{"id":"paper-erivance-vismodegib-sekulic-nejm-2012","kind":"paper","name":"ERIVANCE BCC: efficacy and safety of vismodegib in advanced basal cell carcinoma","route":"/key-papers/paper-erivance-vismodegib-sekulic-nejm-2012/","asOf":"2026-09-17","days":11},{"id":"paper-bolt-sonidegib-migden-lancet-oncol-2015","kind":"paper","name":"BOLT: two doses of sonidegib in locally advanced or metastatic basal cell carcinoma","route":"/key-papers/paper-bolt-sonidegib-migden-lancet-oncol-2015/","asOf":"2026-09-17","days":11},{"id":"paper-cemiplimab-bcc-stratigos-lancet-oncol-2021","kind":"paper","name":"Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy","route":"/key-papers/paper-cemiplimab-bcc-stratigos-lancet-oncol-2021/","asOf":"2026-09-17","days":11},{"id":"paper-dangelo-mucosal-melanoma-pooled-jco-2017","kind":"paper","name":"Nivolumab alone or with ipilimumab in mucosal melanoma: pooled analysis","route":"/key-papers/paper-dangelo-mucosal-melanoma-pooled-jco-2017/","asOf":"2026-09-17","days":11},{"id":"paper-hodi-imatinib-kit-melanoma-jco-2013","kind":"paper","name":"Imatinib for melanomas harbouring mutationally activated or amplified KIT arising on mucosal, acral and chronically sun-damaged skin","route":"/key-papers/paper-hodi-imatinib-kit-melanoma-jco-2013/","asOf":"2026-09-17","days":11},{"id":"paper-curtin-kit-melanoma-jco-2006","kind":"paper","name":"Somatic activation of KIT in distinct subtypes of melanoma","route":"/key-papers/paper-curtin-kit-melanoma-jco-2006/","asOf":"2026-09-17","days":11},{"id":"paper-lian-adjuvant-temozolomide-cisplatin-mucosal-melanoma-ccr-2013","kind":"paper","name":"Adjuvant temozolomide plus cisplatin versus high-dose interferon versus observation in resected mucosal melanoma","route":"/key-papers/paper-lian-adjuvant-temozolomide-cisplatin-mucosal-melanoma-ccr-2013/","asOf":"2026-09-17","days":11},{"id":"paper-keynote-716-lancet-2022","kind":"paper","name":"KEYNOTE-716: adjuvant pembrolizumab versus placebo in completely resected stage IIB or IIC melanoma","route":"/key-papers/paper-keynote-716-lancet-2022/","asOf":"2026-09-17","days":11},{"id":"paper-checkmate-76k-nat-med-2023","kind":"paper","name":"CheckMate 76K: adjuvant nivolumab in resected stage IIB or IIC melanoma","route":"/key-papers/paper-checkmate-76k-nat-med-2023/","asOf":"2026-09-17","days":11},{"id":"paper-ajcc-8-melanoma-gershenwald-ca-2017","kind":"paper","name":"Melanoma staging: evidence-based changes in the AJCC eighth edition cancer staging manual","route":"/key-papers/paper-ajcc-8-melanoma-gershenwald-ca-2017/","asOf":"2026-09-17","days":11},{"id":"paper-mslt-ii-faries-nejm-2017","kind":"paper","name":"MSLT-II: completion lymph node dissection or observation for sentinel-node metastasis in melanoma","route":"/key-papers/paper-mslt-ii-faries-nejm-2017/","asOf":"2026-09-17","days":11},{"id":"paper-checkmate-238-nejm-2017","kind":"paper","name":"CheckMate 238: adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","route":"/key-papers/paper-checkmate-238-nejm-2017/","asOf":"2026-09-17","days":11},{"id":"paper-keynote-054-eggermont-nejm-2018","kind":"paper","name":"KEYNOTE-054 (EORTC 1325): adjuvant pembrolizumab versus placebo in resected stage III melanoma","route":"/key-papers/paper-keynote-054-eggermont-nejm-2018/","asOf":"2026-09-17","days":11},{"id":"paper-igcccg-classification-jco-1997","kind":"paper","name":"International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers","route":"/key-papers/paper-igcccg-classification-jco-1997/","asOf":"2026-09-17","days":11},{"id":"paper-igcccg-update-gillessen-jco-2021","kind":"paper","name":"IGCCCG Update Consortium: predicting outcomes in men with metastatic non-seminomatous germ cell tumours","route":"/key-papers/paper-igcccg-update-gillessen-jco-2021/","asOf":"2026-09-17","days":11},{"id":"paper-williams-bep-vs-pvb-nejm-1987","kind":"paper","name":"Treatment of disseminated germ cell tumours with cisplatin, bleomycin and either vinblastine or etoposide","route":"/key-papers/paper-williams-bep-vs-pvb-nejm-1987/","asOf":"2026-09-17","days":11},{"id":"paper-flot4-lancet-2019","kind":"paper","name":"FLOT4-AIO: perioperative FLOT versus ECF/ECX for resectable gastric or gastro-oesophageal junction adenocarcinoma","route":"/key-papers/paper-flot4-lancet-2019/","asOf":"2026-09-17","days":11},{"id":"paper-cross-nejm-2012","kind":"paper","name":"CROSS: preoperative chemoradiotherapy for oesophageal or junctional cancer","route":"/key-papers/paper-cross-nejm-2012/","asOf":"2026-09-17","days":11},{"id":"paper-checkmate-648-nejm-2022","kind":"paper","name":"CheckMate 648: nivolumab combination therapy in advanced oesophageal squamous cell carcinoma","route":"/key-papers/paper-checkmate-648-nejm-2022/","asOf":"2026-09-17","days":11},{"id":"paper-keynote-590-lancet-2021","kind":"paper","name":"KEYNOTE-590: pembrolizumab plus chemotherapy for first-line treatment of advanced oesophageal cancer","route":"/key-papers/paper-keynote-590-lancet-2021/","asOf":"2026-09-17","days":11},{"id":"paper-checkmate-577-nejm-2021","kind":"paper","name":"CheckMate 577: adjuvant nivolumab in resected oesophageal or gastro-oesophageal junction cancer","route":"/key-papers/paper-checkmate-577-nejm-2021/","asOf":"2026-09-17","days":11},{"id":"paper-mrc-te19-carboplatin-seminoma-oliver-lancet-2005","kind":"paper","name":"MRC TE19/EORTC 30982: radiotherapy versus single-dose carboplatin as adjuvant treatment for stage I seminoma","route":"/key-papers/paper-mrc-te19-carboplatin-seminoma-oliver-lancet-2005/","asOf":"2026-09-17","days":11},{"id":"paper-sempet-de-santis-jco-2004","kind":"paper","name":"SEMPET: FDG-PET as a predictor of viable tumour in post-chemotherapy seminoma residuals","route":"/key-papers/paper-sempet-de-santis-jco-2004/","asOf":"2026-09-17","days":11},{"id":"paper-subbiah-dabrafenib-trametinib-atc-jco-2018","kind":"paper","name":"Dabrafenib and trametinib in BRAF V600E-mutant anaplastic thyroid cancer (ROAR)","route":"/key-papers/paper-subbiah-dabrafenib-trametinib-atc-jco-2018/","asOf":"2026-09-17","days":11},{"id":"paper-ata-anaplastic-thyroid-guideline-bible-thyroid-2021","kind":"paper","name":"2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer","route":"/key-papers/paper-ata-anaplastic-thyroid-guideline-bible-thyroid-2021/","asOf":"2026-09-17","days":11},{"id":"paper-maniakas-neoadjuvant-braf-atc-jama-oncol-2020","kind":"paper","name":"Overall survival in anaplastic thyroid carcinoma 2000 to 2019: impact of targeted therapy and neoadjuvant BRAF-MEK inhibition","route":"/key-papers/paper-maniakas-neoadjuvant-braf-atc-jama-oncol-2020/","asOf":"2026-09-17","days":11},{"id":"paper-ata-2015-thyroid-nodules-dtc-haugen-thyroid-2016","kind":"paper","name":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer","route":"/key-papers/paper-ata-2015-thyroid-nodules-dtc-haugen-thyroid-2016/","asOf":"2026-09-17","days":11},{"id":"paper-select-lenvatinib-nejm-2015","kind":"paper","name":"SELECT: lenvatinib versus placebo in radioiodine-refractory differentiated thyroid cancer","route":"/key-papers/paper-select-lenvatinib-nejm-2015/","asOf":"2026-09-17","days":11},{"id":"paper-decision-sorafenib-lancet-2014","kind":"paper","name":"DECISION: sorafenib in radioactive iodine-refractory differentiated thyroid cancer","route":"/key-papers/paper-decision-sorafenib-lancet-2014/","asOf":"2026-09-17","days":11},{"id":"paper-libretto-531-nejm-2023","kind":"paper","name":"LIBRETTO-531: selpercatinib versus cabozantinib or vandetanib in advanced RET-mutant medullary thyroid cancer","route":"/key-papers/paper-libretto-531-nejm-2023/","asOf":"2026-09-17","days":11},{"id":"paper-ata-medullary-thyroid-guideline-wells-thyroid-2015","kind":"paper","name":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","route":"/key-papers/paper-ata-medullary-thyroid-guideline-wells-thyroid-2015/","asOf":"2026-09-17","days":11},{"id":"paper-exam-cabozantinib-mtc-elisei-jco-2013","kind":"paper","name":"EXAM: cabozantinib in progressive medullary thyroid cancer","route":"/key-papers/paper-exam-cabozantinib-mtc-elisei-jco-2013/","asOf":"2026-09-17","days":11},{"id":"paper-zeta-vandetanib-mtc-wells-jco-2012","kind":"paper","name":"ZETA: vandetanib in locally advanced or metastatic medullary thyroid cancer","route":"/key-papers/paper-zeta-vandetanib-mtc-wells-jco-2012/","asOf":"2026-09-17","days":11},{"id":"paper-estimabl2-leboulleux-nejm-2022","kind":"paper","name":"ESTIMABL2: thyroidectomy without radioiodine in patients with low-risk thyroid cancer","route":"/key-papers/paper-estimabl2-leboulleux-nejm-2022/","asOf":"2026-09-17","days":11},{"id":"paper-ito-kuma-active-surveillance-microcarcinoma-thyroid-2014","kind":"paper","name":"Active surveillance of papillary thyroid microcarcinoma at Kuma Hospital: patient age and progression","route":"/key-papers/paper-ito-kuma-active-surveillance-microcarcinoma-thyroid-2014/","asOf":"2026-09-17","days":11},{"id":"paper-himalaya-nejm-evidence-2022","kind":"paper","name":"HIMALAYA: tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","route":"/key-papers/paper-himalaya-nejm-evidence-2022/","asOf":"2026-09-17","days":11},{"id":"paper-sharp-sorafenib-nejm-2008","kind":"paper","name":"SHARP: sorafenib in advanced hepatocellular carcinoma","route":"/key-papers/paper-sharp-sorafenib-nejm-2008/","asOf":"2026-09-17","days":11},{"id":"paper-reflect-lenvatinib-lancet-2018","kind":"paper","name":"REFLECT: lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma","route":"/key-papers/paper-reflect-lenvatinib-lancet-2018/","asOf":"2026-09-17","days":11},{"id":"paper-glow-zolbetuximab-nat-med-2023","kind":"paper","name":"GLOW: zolbetuximab plus CAPOX in claudin 18.2-positive, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma","route":"/key-papers/paper-glow-zolbetuximab-nat-med-2023/","asOf":"2026-09-17","days":11},{"id":"paper-gotoda-endoscopic-resection-criteria-gastric-cancer-2000","kind":"paper","name":"Incidence of lymph node metastasis from early gastric cancer: estimation from 5,265 patients at two large centres","route":"/key-papers/paper-gotoda-endoscopic-resection-criteria-gastric-cancer-2000/","asOf":"2026-09-17","days":11},{"id":"paper-klass-01-kim-jama-oncol-2019","kind":"paper","name":"KLASS-01: laparoscopic versus open distal gastrectomy for stage I gastric cancer, long-term survival","route":"/key-papers/paper-klass-01-kim-jama-oncol-2019/","asOf":"2026-09-17","days":11},{"id":"paper-jcog0912-katai-lancet-gastroenterol-hepatol-2020","kind":"paper","name":"JCOG0912: laparoscopy-assisted versus open distal gastrectomy for clinical stage IA or IB gastric cancer","route":"/key-papers/paper-jcog0912-katai-lancet-gastroenterol-hepatol-2020/","asOf":"2026-09-17","days":11},{"id":"paper-japanese-gastric-cancer-treatment-guidelines-2021-gastric-cancer-2023","kind":"paper","name":"Japanese gastric cancer treatment guidelines 2021 (6th edition)","route":"/key-papers/paper-japanese-gastric-cancer-treatment-guidelines-2021-gastric-cancer-2023/","asOf":"2026-09-17","days":11},{"id":"paper-mazzaferro-milan-criteria-nejm-1996","kind":"paper","name":"Liver transplantation for small hepatocellular carcinomas in patients with cirrhosis (the Milan criteria)","route":"/key-papers/paper-mazzaferro-milan-criteria-nejm-1996/","asOf":"2026-09-17","days":11},{"id":"paper-bclc-2022-reig-j-hepatol-2022","kind":"paper","name":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","route":"/key-papers/paper-bclc-2022-reig-j-hepatol-2022/","asOf":"2026-09-17","days":11},{"id":"paper-imbrave050-lancet-2023","kind":"paper","name":"IMbrave050: adjuvant atezolizumab plus bevacizumab versus active surveillance after resection or ablation of high-risk hepatocellular carcinoma","route":"/key-papers/paper-imbrave050-lancet-2023/","asOf":"2026-09-17","days":11},{"id":"paper-storm-adjuvant-sorafenib-bruix-lancet-oncol-2015","kind":"paper","name":"STORM: adjuvant sorafenib after resection or ablation of hepatocellular carcinoma","route":"/key-papers/paper-storm-adjuvant-sorafenib-bruix-lancet-oncol-2015/","asOf":"2026-09-17","days":11},{"id":"paper-bilcap-lancet-oncol-2019","kind":"paper","name":"BILCAP: capecitabine compared with observation in resected biliary tract cancer","route":"/key-papers/paper-bilcap-lancet-oncol-2019/","asOf":"2026-09-17","days":11},{"id":"paper-abc-02-gemcitabine-cisplatin-nejm-2010","kind":"paper","name":"ABC-02: cisplatin plus gemcitabine versus gemcitabine alone for biliary tract cancer","route":"/key-papers/paper-abc-02-gemcitabine-cisplatin-nejm-2010/","asOf":"2026-09-17","days":11},{"id":"paper-topaz-1-nejm-evidence-2022","kind":"paper","name":"TOPAZ-1: durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","route":"/key-papers/paper-topaz-1-nejm-evidence-2022/","asOf":"2026-09-17","days":11},{"id":"paper-keynote-966-lancet-2023","kind":"paper","name":"KEYNOTE-966: pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer","route":"/key-papers/paper-keynote-966-lancet-2023/","asOf":"2026-09-17","days":11},{"id":"paper-fight-202-pemigatinib-lancet-oncol-2020","kind":"paper","name":"FIGHT-202: pemigatinib for previously treated cholangiocarcinoma with FGFR2 fusions or rearrangements","route":"/key-papers/paper-fight-202-pemigatinib-lancet-oncol-2020/","asOf":"2026-09-17","days":11},{"id":"paper-keynote-811-janjigian-lancet-2023","kind":"paper","name":"KEYNOTE-811: pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma","route":"/key-papers/paper-keynote-811-janjigian-lancet-2023/","asOf":"2026-09-17","days":11},{"id":"paper-destiny-gastric01-nejm-2020","kind":"paper","name":"DESTINY-Gastric01: trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","route":"/key-papers/paper-destiny-gastric01-nejm-2020/","asOf":"2026-09-17","days":11},{"id":"paper-demetri-sunitinib-gist-lancet-2006","kind":"paper","name":"Sunitinib in advanced gastrointestinal stromal tumour after failure of imatinib","route":"/key-papers/paper-demetri-sunitinib-gist-lancet-2006/","asOf":"2026-09-17","days":11},{"id":"paper-grid-regorafenib-gist-lancet-2013","kind":"paper","name":"GRID: regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib","route":"/key-papers/paper-grid-regorafenib-gist-lancet-2013/","asOf":"2026-09-17","days":11},{"id":"paper-invictus-ripretinib-lancet-oncol-2020","kind":"paper","name":"INVICTUS: ripretinib in advanced gastrointestinal stromal tumours after three or more prior kinase inhibitors","route":"/key-papers/paper-invictus-ripretinib-lancet-oncol-2020/","asOf":"2026-09-17","days":11},{"id":"paper-intrigue-ripretinib-vs-sunitinib-jco-2022","kind":"paper","name":"INTRIGUE: ripretinib versus sunitinib in advanced gastrointestinal stromal tumour after imatinib","route":"/key-papers/paper-intrigue-ripretinib-vs-sunitinib-jco-2022/","asOf":"2026-09-17","days":11},{"id":"paper-llovet-tace-lancet-2002","kind":"paper","name":"Arterial embolisation or chemoembolisation versus symptomatic treatment in unresectable hepatocellular carcinoma","route":"/key-papers/paper-llovet-tace-lancet-2002/","asOf":"2026-09-17","days":11},{"id":"paper-emerald-1-lancet-2025","kind":"paper","name":"EMERALD-1: durvalumab with or without bevacizumab added to transarterial chemoembolisation for embolisation-eligible hepatocellular carcinoma","route":"/key-papers/paper-emerald-1-lancet-2025/","asOf":"2026-09-17","days":11},{"id":"paper-leap-012-lancet-2025","kind":"paper","name":"LEAP-012: transarterial chemoembolisation with lenvatinib plus pembrolizumab versus placebo for unresectable non-metastatic hepatocellular carcinoma","route":"/key-papers/paper-leap-012-lancet-2025/","asOf":"2026-09-17","days":11},{"id":"paper-demetri-imatinib-gist-nejm-2002","kind":"paper","name":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumours","route":"/key-papers/paper-demetri-imatinib-gist-nejm-2002/","asOf":"2026-09-17","days":11},{"id":"paper-hirota-kit-gist-science-1998","kind":"paper","name":"Gain-of-function mutations of c-kit in human gastrointestinal stromal tumours","route":"/key-papers/paper-hirota-kit-gist-science-1998/","asOf":"2026-09-17","days":11},{"id":"paper-ssg-xviii-adjuvant-imatinib-joensuu-jama-2012","kind":"paper","name":"SSG XVIII/AIO: one versus three years of adjuvant imatinib for operable gastrointestinal stromal tumour","route":"/key-papers/paper-ssg-xviii-adjuvant-imatinib-joensuu-jama-2012/","asOf":"2026-09-17","days":11},{"id":"paper-heinrich-kit-mutation-imatinib-response-jco-2003","kind":"paper","name":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumour","route":"/key-papers/paper-heinrich-kit-mutation-imatinib-response-jco-2003/","asOf":"2026-09-17","days":11},{"id":"paper-keynote-062-shitara-jama-oncol-2020","kind":"paper","name":"KEYNOTE-062: pembrolizumab or pembrolizumab plus chemotherapy versus chemotherapy in PD-L1-positive advanced gastric cancer","route":"/key-papers/paper-keynote-062-shitara-jama-oncol-2020/","asOf":"2026-09-17","days":11},{"id":"paper-pietrantonio-msi-gastric-meta-analysis-jco-2019","kind":"paper","name":"Individual patient data meta-analysis of microsatellite instability as a biomarker in gastric cancer (MAGIC, CLASSIC, ARTIST, ITACA-S)","route":"/key-papers/paper-pietrantonio-msi-gastric-meta-analysis-jco-2019/","asOf":"2026-09-17","days":11},{"id":"paper-tcga-gastric-nature-2014","kind":"paper","name":"Comprehensive molecular characterisation of gastric adenocarcinoma (The Cancer Genome Atlas)","route":"/key-papers/paper-tcga-gastric-nature-2014/","asOf":"2026-09-17","days":11},{"id":"paper-keynote-859-lancet-oncol-2023","kind":"paper","name":"KEYNOTE-859: pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer","route":"/key-papers/paper-keynote-859-lancet-oncol-2023/","asOf":"2026-09-17","days":11},{"id":"paper-matterhorn-nejm-2025","kind":"paper","name":"MATTERHORN: perioperative durvalumab with FLOT chemotherapy for resectable gastric and gastro-oesophageal junction cancer","route":"/key-papers/paper-matterhorn-nejm-2025/","asOf":"2026-09-17","days":11},{"id":"paper-rainbow-ramucirumab-paclitaxel-lancet-oncol-2014","kind":"paper","name":"RAINBOW: ramucirumab plus paclitaxel versus placebo plus paclitaxel in previously treated advanced gastric cancer","route":"/key-papers/paper-rainbow-ramucirumab-paclitaxel-lancet-oncol-2014/","asOf":"2026-09-17","days":11},{"id":"paper-navigator-avapritinib-heinrich-lancet-oncol-2020","kind":"paper","name":"NAVIGATOR: avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour","route":"/key-papers/paper-navigator-avapritinib-heinrich-lancet-oncol-2020/","asOf":"2026-09-17","days":11},{"id":"paper-heinrich-pdgfra-gist-science-2003","kind":"paper","name":"PDGFRA activating mutations in gastrointestinal stromal tumours","route":"/key-papers/paper-heinrich-pdgfra-gist-science-2003/","asOf":"2026-09-17","days":11},{"id":"small-molecule","kind":"term","name":"Small molecule drug","route":"/terms/small-molecule/","asOf":"2026-09-17","days":11},{"id":"vaccines-and-oncolytic-viruses","kind":"term","name":"Cancer vaccines and oncolytic viruses","route":"/terms/vaccines-and-oncolytic-viruses/","asOf":"2026-09-17","days":11},{"id":"non-inferiority-margin","kind":"term","name":"Non-inferiority margin and equivalence trials","route":"/terms/non-inferiority-margin/","asOf":"2026-09-17","days":11},{"id":"stratified-randomisation","kind":"term","name":"Stratified randomisation, allocation concealment and minimisation","route":"/terms/stratified-randomisation/","asOf":"2026-09-17","days":11},{"id":"clinical-equipoise","kind":"term","name":"Clinical equipoise","route":"/terms/clinical-equipoise/","asOf":"2026-09-17","days":11},{"id":"basket-trial","kind":"term","name":"Basket trial","route":"/terms/basket-trial/","asOf":"2026-09-17","days":11},{"id":"umbrella-trial","kind":"term","name":"Umbrella trial","route":"/terms/umbrella-trial/","asOf":"2026-09-17","days":11},{"id":"sample-size-re-estimation","kind":"term","name":"Statistical power, sample size and re-estimation","route":"/terms/sample-size-re-estimation/","asOf":"2026-09-17","days":11},{"id":"response-adaptive-randomisation","kind":"term","name":"Response-adaptive randomisation","route":"/terms/response-adaptive-randomisation/","asOf":"2026-09-17","days":11},{"id":"bayesian-trial-design","kind":"term","name":"Bayesian trial design","route":"/terms/bayesian-trial-design/","asOf":"2026-09-17","days":11},{"id":"smart-design","kind":"term","name":"SMART design (sequential multiple assignment randomised trial)","route":"/terms/smart-design/","asOf":"2026-09-17","days":11},{"id":"biomarker-stratified-design","kind":"term","name":"Enrichment and biomarker-stratified designs","route":"/terms/biomarker-stratified-design/","asOf":"2026-09-17","days":11},{"id":"pragmatic-trial","kind":"term","name":"Pragmatic trial","route":"/terms/pragmatic-trial/","asOf":"2026-09-17","days":11},{"id":"registry-based-trial","kind":"term","name":"Registry-based randomised trial","route":"/terms/registry-based-trial/","asOf":"2026-09-17","days":11},{"id":"decentralised-trial","kind":"term","name":"Decentralised trial","route":"/terms/decentralised-trial/","asOf":"2026-09-17","days":11},{"id":"n-of-1-trial","kind":"term","name":"N-of-1 trial","route":"/terms/n-of-1-trial/","asOf":"2026-09-17","days":11},{"id":"cluster-randomised-trial","kind":"term","name":"Cluster-randomised trial","route":"/terms/cluster-randomised-trial/","asOf":"2026-09-17","days":11},{"id":"stepped-wedge-design","kind":"term","name":"Stepped-wedge design","route":"/terms/stepped-wedge-design/","asOf":"2026-09-17","days":11},{"id":"kaplan-meier-curve","kind":"term","name":"Kaplan-Meier curve, censoring and proportional hazards","route":"/terms/kaplan-meier-curve/","asOf":"2026-09-17","days":11},{"id":"group-sequential-design","kind":"term","name":"Group sequential design, stopping rules and alpha spending","route":"/terms/group-sequential-design/","asOf":"2026-09-17","days":11},{"id":"absolute-benefit","kind":"term","name":"Absolute versus relative benefit (number needed to treat)","route":"/terms/absolute-benefit/","asOf":"2026-09-17","days":11},{"id":"estimand","kind":"term","name":"Estimands and intercurrent events (ICH E9(R1))","route":"/terms/estimand/","asOf":"2026-09-17","days":11},{"id":"surrogate-validation","kind":"term","name":"Surrogate endpoint validation: which stand-ins have earned trust","route":"/terms/surrogate-validation/","asOf":"2026-09-17","days":11},{"id":"quality-adjusted-survival","kind":"term","name":"Quality-adjusted survival (QALYs and Q-TWiST)","route":"/terms/quality-adjusted-survival/","asOf":"2026-09-17","days":11},{"id":"data-monitoring-committee","kind":"term","name":"Data monitoring committee (DSMB, IDMC)","route":"/terms/data-monitoring-committee/","asOf":"2026-09-17","days":11},{"id":"ethics-review","kind":"term","name":"Ethics review (IRB, research ethics committee)","route":"/terms/ethics-review/","asOf":"2026-09-17","days":11},{"id":"informed-consent","kind":"term","name":"Informed consent","route":"/terms/informed-consent/","asOf":"2026-09-17","days":11},{"id":"trial-registration","kind":"term","name":"Trial registration and results reporting (ClinicalTrials.gov, EU CTR)","route":"/terms/trial-registration/","asOf":"2026-09-17","days":11},{"id":"trial-protocol","kind":"term","name":"Trial protocol and statistical analysis plan","route":"/terms/trial-protocol/","asOf":"2026-09-17","days":11},{"id":"trial-lifecycle","kind":"term","name":"Trial lifecycle: from protocol to label","route":"/terms/trial-lifecycle/","asOf":"2026-09-17","days":11},{"id":"trial-failure-modes","kind":"term","name":"Why trials fail: underpowered, wrong endpoint, control arm drift, subgroup fishing, crossover","route":"/terms/trial-failure-modes/","asOf":"2026-09-17","days":11},{"id":"fdca","kind":"term","name":"Federal Food, Drug, and Cosmetic Act and the Kefauver-Harris Amendments","route":"/terms/fdca/","asOf":"2026-09-17","days":11},{"id":"fdora-2022","kind":"term","name":"FDORA 2022 accelerated approval reforms","route":"/terms/fdora-2022/","asOf":"2026-09-17","days":11},{"id":"fdasia-2012","kind":"term","name":"FDASIA 2012 and the origins of the expedited programmes","route":"/terms/fdasia-2012/","asOf":"2026-09-17","days":11},{"id":"21st-century-cures-act","kind":"term","name":"21st Century Cures Act","route":"/terms/21st-century-cures-act/","asOf":"2026-09-17","days":11},{"id":"orphan-drug-act","kind":"term","name":"Orphan Drug Act 1983","route":"/terms/orphan-drug-act/","asOf":"2026-09-17","days":11},{"id":"bpca-prea","kind":"term","name":"Paediatric drug laws: BPCA and PREA","route":"/terms/bpca-prea/","asOf":"2026-09-17","days":11},{"id":"right-to-try","kind":"term","name":"Right to Try Act 2018 and state right-to-try laws","route":"/terms/right-to-try/","asOf":"2026-09-17","days":11},{"id":"expanded-access","kind":"term","name":"Expanded access (compassionate use)","route":"/terms/expanded-access/","asOf":"2026-09-17","days":11},{"id":"abigail-alliance","kind":"term","name":"Abigail Alliance v. von Eschenbach (2007)","route":"/terms/abigail-alliance/","asOf":"2026-09-17","days":11},{"id":"hatch-waxman","kind":"term","name":"Hatch-Waxman Act 1984","route":"/terms/hatch-waxman/","asOf":"2026-09-17","days":11},{"id":"bpcia","kind":"term","name":"Biologics Price Competition and Innovation Act 2010","route":"/terms/bpcia/","asOf":"2026-09-17","days":11},{"id":"us-regulatory-exclusivity","kind":"term","name":"US regulatory exclusivity periods","route":"/terms/us-regulatory-exclusivity/","asOf":"2026-09-17","days":11},{"id":"inflation-reduction-act","kind":"term","name":"Inflation Reduction Act 2022: Medicare drug price negotiation","route":"/terms/inflation-reduction-act/","asOf":"2026-09-17","days":11},{"id":"medicare-ced","kind":"term","name":"Medicare coverage with evidence development","route":"/terms/medicare-ced/","asOf":"2026-09-17","days":11},{"id":"hipaa","kind":"term","name":"HIPAA (Health Insurance Portability and Accountability Act)","route":"/terms/hipaa/","asOf":"2026-09-17","days":11},{"id":"gina","kind":"term","name":"GINA (Genetic Information Nondiscrimination Act 2008)","route":"/terms/gina/","asOf":"2026-09-17","days":11},{"id":"common-rule","kind":"term","name":"The Common Rule (45 CFR 46)","route":"/terms/common-rule/","asOf":"2026-09-17","days":11},{"id":"myriad-ruling","kind":"term","name":"Association for Molecular Pathology v. Myriad Genetics (2013)","route":"/terms/myriad-ruling/","asOf":"2026-09-17","days":11},{"id":"state-biomarker-testing-laws","kind":"term","name":"State biomarker testing coverage laws","route":"/terms/state-biomarker-testing-laws/","asOf":"2026-09-17","days":11},{"id":"tobacco-control-act","kind":"term","name":"Family Smoking Prevention and Tobacco Control Act 2009","route":"/terms/tobacco-control-act/","asOf":"2026-09-17","days":11},{"id":"tobacco-21","kind":"term","name":"Tobacco 21","route":"/terms/tobacco-21/","asOf":"2026-09-17","days":11},{"id":"eu-regulation-726-2004","kind":"term","name":"Regulation (EC) No 726/2004: the EU centralised procedure","route":"/terms/eu-regulation-726-2004/","asOf":"2026-09-17","days":11},{"id":"eu-orphan-regulation","kind":"term","name":"Regulation (EC) No 141/2000: EU orphan medicines","route":"/terms/eu-orphan-regulation/","asOf":"2026-09-17","days":11},{"id":"eu-paediatric-regulation","kind":"term","name":"Regulation (EC) No 1901/2006: EU paediatric medicines","route":"/terms/eu-paediatric-regulation/","asOf":"2026-09-17","days":11},{"id":"eu-clinical-trials-regulation","kind":"term","name":"Clinical Trials Regulation (EU) No 536/2014 and CTIS","route":"/terms/eu-clinical-trials-regulation/","asOf":"2026-09-17","days":11},{"id":"gdpr","kind":"term","name":"GDPR and health data (Regulation (EU) 2016/679)","route":"/terms/gdpr/","asOf":"2026-09-17","days":11},{"id":"european-health-data-space","kind":"term","name":"European Health Data Space Regulation (EU) 2025/327","route":"/terms/european-health-data-space/","asOf":"2026-09-17","days":11},{"id":"eu-hta-regulation","kind":"term","name":"EU HTA Regulation (EU) 2021/2282: joint clinical assessments","route":"/terms/eu-hta-regulation/","asOf":"2026-09-17","days":11},{"id":"eu-pharma-package","kind":"term","name":"EU pharmaceutical package reform (2023 proposal)","route":"/terms/eu-pharma-package/","asOf":"2026-09-17","days":11},{"id":"spc","kind":"term","name":"Supplementary protection certificate (EU)","route":"/terms/spc/","asOf":"2026-09-17","days":11},{"id":"eu-data-exclusivity","kind":"term","name":"EU data and market protection (8+2+1)","route":"/terms/eu-data-exclusivity/","asOf":"2026-09-17","days":11},{"id":"ilap","kind":"term","name":"ILAP (Innovative Licensing and Access Pathway)","route":"/terms/ilap/","asOf":"2026-09-17","days":11},{"id":"cancer-drugs-fund","kind":"term","name":"Cancer Drugs Fund (England)","route":"/terms/cancer-drugs-fund/","asOf":"2026-09-17","days":11},{"id":"nice-methods","kind":"term","name":"NICE technology appraisal methods (2022)","route":"/terms/nice-methods/","asOf":"2026-09-17","days":11},{"id":"innovative-medicines-fund","kind":"term","name":"Innovative Medicines Fund (England)","route":"/terms/innovative-medicines-fund/","asOf":"2026-09-17","days":11},{"id":"medicines-medical-devices-act-2021","kind":"term","name":"Medicines and Medical Devices Act 2021","route":"/terms/medicines-medical-devices-act-2021/","asOf":"2026-09-17","days":11},{"id":"uk-data-protection-act","kind":"term","name":"UK Data Protection Act 2018 and health data law","route":"/terms/uk-data-protection-act/","asOf":"2026-09-17","days":11},{"id":"amnog","kind":"term","name":"AMNOG (Germany, 2011)","route":"/terms/amnog/","asOf":"2026-09-17","days":11},{"id":"france-early-access","kind":"term","name":"France: early access (accès précoce), formerly ATU","route":"/terms/france-early-access/","asOf":"2026-09-17","days":11},{"id":"sakigake","kind":"term","name":"Sakigake designation (Japan)","route":"/terms/sakigake/","asOf":"2026-09-17","days":11},{"id":"japan-conditional-early-approval","kind":"term","name":"Japan conditional early approval and time-limited approval","route":"/terms/japan-conditional-early-approval/","asOf":"2026-09-17","days":11},{"id":"china-drug-administration-law","kind":"term","name":"China Drug Administration Law (2019) and expedited pathways","route":"/terms/china-drug-administration-law/","asOf":"2026-09-17","days":11},{"id":"pipl","kind":"term","name":"PIPL (China Personal Information Protection Law 2021)","route":"/terms/pipl/","asOf":"2026-09-17","days":11},{"id":"china-hgr-rules","kind":"term","name":"China Human Genetic Resources rules (2019, 2023)","route":"/terms/china-hgr-rules/","asOf":"2026-09-17","days":11},{"id":"china-vbp-nrdl","kind":"term","name":"China National Reimbursement Drug List negotiation and volume-based procurement","route":"/terms/china-vbp-nrdl/","asOf":"2026-09-17","days":11},{"id":"india-new-drugs-rules-2019","kind":"term","name":"India New Drugs and Clinical Trials Rules 2019","route":"/terms/india-new-drugs-rules-2019/","asOf":"2026-09-17","days":11},{"id":"nexavar-compulsory-licence","kind":"term","name":"Nexavar compulsory licence (India, 2012)","route":"/terms/nexavar-compulsory-licence/","asOf":"2026-09-17","days":11},{"id":"novartis-glivec-ruling","kind":"term","name":"Novartis v. Union of India (Glivec, 2013)","route":"/terms/novartis-glivec-ruling/","asOf":"2026-09-17","days":11},{"id":"trips-doha","kind":"term","name":"TRIPS Agreement and the Doha Declaration","route":"/terms/trips-doha/","asOf":"2026-09-17","days":11},{"id":"declaration-of-helsinki","kind":"term","name":"Declaration of Helsinki","route":"/terms/declaration-of-helsinki/","asOf":"2026-09-17","days":11},{"id":"ich-gcp","kind":"term","name":"ICH good clinical practice (E6)","route":"/terms/ich-gcp/","asOf":"2026-09-17","days":11},{"id":"medulloblastoma-molecular-groups","kind":"term","name":"Medulloblastoma molecular groups (WNT, SHH, group 3, group 4)","route":"/terms/medulloblastoma-molecular-groups/","asOf":"2026-09-17","days":11},{"id":"pole-ultramutation","kind":"term","name":"POLE ultramutation (POLEmut)","route":"/terms/pole-ultramutation/","asOf":"2026-09-17","days":11},{"id":"nsmp","kind":"term","name":"No specific molecular profile (NSMP) endometrial cancer","route":"/terms/nsmp/","asOf":"2026-09-17","days":11},{"id":"ependymoma-molecular-groups","kind":"term","name":"Ependymoma molecular groups (PF-A, PF-B, ZFTA, YAP1, MYCN)","route":"/terms/ependymoma-molecular-groups/","asOf":"2026-09-17","days":11},{"id":"sclc-molecular-subtypes","kind":"term","name":"Small-cell lung cancer transcription-factor subtypes (SCLC-A, SCLC-N, SCLC-P, SCLC-I) and SLFN11","route":"/terms/sclc-molecular-subtypes/","asOf":"2026-09-17","days":11},{"id":"uveal-melanoma-prognostic-markers","kind":"term","name":"Uveal melanoma prognostic markers (GNAQ/GNA11, monosomy 3, gene-expression class)","route":"/terms/uveal-melanoma-prognostic-markers/","asOf":"2026-09-17","days":11},{"id":"interferon-gamma-signature","kind":"term","name":"Interferon-gamma gene signature (T-cell-inflamed signature)","route":"/terms/interferon-gamma-signature/","asOf":"2026-09-17","days":11},{"id":"ipss-m-ipss-r","kind":"term","name":"IPSS-R and IPSS-M (myelodysplastic syndrome risk scores)","route":"/terms/ipss-m-ipss-r/","asOf":"2026-09-17","days":11},{"id":"sokal-elts-scores","kind":"term","name":"Sokal and ELTS risk scores (chronic myeloid leukaemia)","route":"/terms/sokal-elts-scores/","asOf":"2026-09-17","days":11},{"id":"flipi","kind":"term","name":"FLIPI, FLIPI2 and POD24 (follicular lymphoma risk)","route":"/terms/flipi/","asOf":"2026-09-17","days":11},{"id":"mipi","kind":"term","name":"MIPI (Mantle Cell Lymphoma International Prognostic Index)","route":"/terms/mipi/","asOf":"2026-09-17","days":11},{"id":"cll-ipi","kind":"term","name":"CLL-IPI (chronic lymphocytic leukaemia prognostic index)","route":"/terms/cll-ipi/","asOf":"2026-09-17","days":11},{"id":"dipss-mipss70","kind":"term","name":"DIPSS, DIPSS-plus and MIPSS70 (myelofibrosis risk scores)","route":"/terms/dipss-mipss70/","asOf":"2026-09-17","days":11},{"id":"ipset-thrombosis","kind":"term","name":"IPSET-thrombosis score (essential thrombocythaemia)","route":"/terms/ipset-thrombosis/","asOf":"2026-09-17","days":11},{"id":"li-rads","kind":"term","name":"LI-RADS (Liver Imaging Reporting and Data System)","route":"/terms/li-rads/","asOf":"2026-09-17","days":11},{"id":"pretext-chic","kind":"term","name":"PRETEXT and CHIC risk groups (hepatoblastoma)","route":"/terms/pretext-chic/","asOf":"2026-09-17","days":11},{"id":"wilms-risk-markers","kind":"term","name":"Wilms tumour risk markers (anaplasia, 1p/16q loss, 1q gain, SIOP and COG risk groups)","route":"/terms/wilms-risk-markers/","asOf":"2026-09-17","days":11},{"id":"b-all-cytogenetic-risk","kind":"term","name":"B-ALL risk groups (NCI criteria, ETV6::RUNX1, hyperdiploidy, hypodiploidy, iAMP21, IKZF1, CNS status)","route":"/terms/b-all-cytogenetic-risk/","asOf":"2026-09-17","days":11},{"id":"disease-volume-chaarted","kind":"term","name":"Disease volume (CHAARTED high-volume versus low-volume) and LATITUDE risk","route":"/terms/disease-volume-chaarted/","asOf":"2026-09-17","days":11},{"id":"graded-prognostic-assessment","kind":"term","name":"Graded Prognostic Assessment (GPA) for brain metastases","route":"/terms/graded-prognostic-assessment/","asOf":"2026-09-17","days":11},{"id":"ph-like-all","kind":"term","name":"Ph-like (BCR::ABL1-like) acute lymphoblastic leukaemia","route":"/terms/ph-like-all/","asOf":"2026-09-17","days":11},{"id":"abl1-kinase-domain-mutations","kind":"term","name":"BCR::ABL1 kinase domain mutations (T315I and others)","route":"/terms/abl1-kinase-domain-mutations/","asOf":"2026-09-17","days":11},{"id":"mpn-driver-mutations","kind":"term","name":"MPN driver mutations (JAK2 V617F, CALR, MPL) and allele burden","route":"/terms/mpn-driver-mutations/","asOf":"2026-09-17","days":11},{"id":"aml-myelodysplasia-related","kind":"term","name":"AML with myelodysplasia-related gene mutations (AML-MR)","route":"/terms/aml-myelodysplasia-related/","asOf":"2026-09-17","days":11},{"id":"sf3b1-mutation","kind":"term","name":"SF3B1 mutation","route":"/terms/sf3b1-mutation/","asOf":"2026-09-17","days":11},{"id":"del5q","kind":"term","name":"del(5q) (5q- syndrome and lenalidomide response)","route":"/terms/del5q/","asOf":"2026-09-17","days":11},{"id":"myd88-l265p","kind":"term","name":"MYD88 L265P and CXCR4 mutations","route":"/terms/myd88-l265p/","asOf":"2026-09-17","days":11},{"id":"cyclin-d1-t11-14","kind":"term","name":"t(11;14), cyclin D1 and SOX11","route":"/terms/cyclin-d1-t11-14/","asOf":"2026-09-17","days":11},{"id":"btki-bcl2i-resistance-mutations","kind":"term","name":"BTK C481S, PLCG2 and BCL2 G101V resistance mutations","route":"/terms/btki-bcl2i-resistance-mutations/","asOf":"2026-09-17","days":11},{"id":"brca-reversion-mutations","kind":"term","name":"BRCA reversion mutations","route":"/terms/brca-reversion-mutations/","asOf":"2026-09-17","days":11},{"id":"met-exon-14-skipping","kind":"term","name":"MET exon 14 skipping mutation","route":"/terms/met-exon-14-skipping/","asOf":"2026-09-17","days":11},{"id":"mlh1-promoter-methylation","kind":"term","name":"MLH1 promoter methylation (sporadic versus Lynch mismatch repair loss)","route":"/terms/mlh1-promoter-methylation/","asOf":"2026-09-17","days":11},{"id":"1p19q-codeletion","kind":"term","name":"1p/19q codeletion","route":"/terms/1p19q-codeletion/","asOf":"2026-09-17","days":11},{"id":"cdkn2a-homozygous-deletion","kind":"term","name":"CDKN2A/B homozygous deletion","route":"/terms/cdkn2a-homozygous-deletion/","asOf":"2026-09-17","days":11},{"id":"pten-loss","kind":"term","name":"PTEN loss","route":"/terms/pten-loss/","asOf":"2026-09-17","days":11},{"id":"bap1-loss","kind":"term","name":"BAP1 loss","route":"/terms/bap1-loss/","asOf":"2026-09-17","days":11},{"id":"sdh-deficiency","kind":"term","name":"SDH deficiency (SDHB immunohistochemistry loss)","route":"/terms/sdh-deficiency/","asOf":"2026-09-17","days":11},{"id":"foxo1-fusion-status","kind":"term","name":"FOXO1 fusion status and IRS group (rhabdomyosarcoma)","route":"/terms/foxo1-fusion-status/","asOf":"2026-09-17","days":11},{"id":"ss18-ssx-fusion","kind":"term","name":"SS18::SSX fusion (synovial sarcoma)","route":"/terms/ss18-ssx-fusion/","asOf":"2026-09-17","days":11},{"id":"mcpyv-status","kind":"term","name":"Merkel cell polyomavirus (MCPyV) status","route":"/terms/mcpyv-status/","asOf":"2026-09-17","days":11},{"id":"hhv8-kshv","kind":"term","name":"HHV-8 (KSHV) status and LANA-1 immunohistochemistry","route":"/terms/hhv8-kshv/","asOf":"2026-09-17","days":11},{"id":"gist-risk-stratification","kind":"term","name":"GIST risk stratification (mitotic count, size, site; Miettinen and modified NIH criteria)","route":"/terms/gist-risk-stratification/","asOf":"2026-09-17","days":11},{"id":"histological-response-induction","kind":"term","name":"Histological response to induction chemotherapy (osteosarcoma and Ewing sarcoma)","route":"/terms/histological-response-induction/","asOf":"2026-09-17","days":11},{"id":"extranodal-extension","kind":"term","name":"Extranodal extension (ENE)","route":"/terms/extranodal-extension/","asOf":"2026-09-17","days":11},{"id":"depth-of-invasion","kind":"term","name":"Depth of invasion (DOI)","route":"/terms/depth-of-invasion/","asOf":"2026-09-17","days":11},{"id":"segmental-chromosomal-aberrations","kind":"term","name":"Segmental chromosomal aberrations and ploidy (neuroblastoma)","route":"/terms/segmental-chromosomal-aberrations/","asOf":"2026-09-17","days":11},{"id":"urinary-catecholamines","kind":"term","name":"Urinary catecholamine metabolites (VMA and HVA)","route":"/terms/urinary-catecholamines/","asOf":"2026-09-17","days":11},{"id":"curie-siopen-score","kind":"term","name":"MIBG Curie and SIOPEN scores","route":"/terms/curie-siopen-score/","asOf":"2026-09-17","days":11},{"id":"psa-kinetics","kind":"term","name":"PSA kinetics: PSA doubling time and PSA density","route":"/terms/psa-kinetics/","asOf":"2026-09-17","days":11},{"id":"m-protein-free-light-chains","kind":"term","name":"M-protein, immunofixation and serum free light chains","route":"/terms/m-protein-free-light-chains/","asOf":"2026-09-17","days":11},{"id":"dktk","kind":"institution","name":"German Cancer Consortium (DKTK)","route":"/institutions/dktk/","asOf":"2026-09-17","days":11},{"id":"jeffrey-bluestone","kind":"person","name":"Jeffrey A. Bluestone","route":"/people/jeffrey-bluestone/","asOf":"2026-09-17","days":11},{"id":"karen-knudsen","kind":"person","name":"Karen E. Knudsen","route":"/people/karen-knudsen/","asOf":"2026-09-17","days":11},{"id":"santosh-kesari","kind":"person","name":"Santosh Kesari","route":"/people/santosh-kesari/","asOf":"2026-09-17","days":11},{"id":"richard-baum","kind":"person","name":"Richard P. Baum","route":"/people/richard-baum/","asOf":"2026-09-17","days":11},{"id":"ebrahim-delpassand","kind":"person","name":"Ebrahim S. Delpassand","route":"/people/ebrahim-delpassand/","asOf":"2026-09-17","days":11},{"id":"sant-chawla","kind":"person","name":"Sant P. Chawla","route":"/people/sant-chawla/","asOf":"2026-09-17","days":11},{"id":"charles-simone","kind":"person","name":"Charles B. Simone II","route":"/people/charles-simone/","asOf":"2026-09-17","days":11},{"id":"minghui-pharmaceutical","kind":"company","name":"Minghui Pharmaceutical","route":"/companies/minghui-pharmaceutical/","asOf":"2026-09-17","days":11},{"id":"disc-medicine","kind":"company","name":"Disc Medicine","route":"/companies/disc-medicine/","asOf":"2026-09-17","days":11},{"id":"teclison","kind":"company","name":"Teclison","route":"/companies/teclison/","asOf":"2026-09-17","days":11},{"id":"grit-bio","kind":"company","name":"Grit Bio","route":"/companies/grit-bio/","asOf":"2026-09-17","days":11},{"id":"amplia-therapeutics","kind":"company","name":"Amplia Therapeutics","route":"/companies/amplia-therapeutics/","asOf":"2026-09-17","days":11},{"id":"sichuan-huiyu-pharmaceutical","kind":"company","name":"Sichuan Huiyu Pharmaceutical","route":"/companies/sichuan-huiyu-pharmaceutical/","asOf":"2026-09-17","days":11},{"id":"anbogen-therapeutics","kind":"company","name":"Anbogen Therapeutics","route":"/companies/anbogen-therapeutics/","asOf":"2026-09-17","days":11},{"id":"nec-bio","kind":"company","name":"NEC Bio","route":"/companies/nec-bio/","asOf":"2026-09-17","days":11},{"id":"natureceuticals","kind":"company","name":"NatureCeuticals","route":"/companies/natureceuticals/","asOf":"2026-09-17","days":11},{"id":"sunho-biopharmaceutical","kind":"company","name":"SunHo Biopharmaceutical","route":"/companies/sunho-biopharmaceutical/","asOf":"2026-09-17","days":11},{"id":"norroy-bioscience","kind":"company","name":"Norroy Bioscience","route":"/companies/norroy-bioscience/","asOf":"2026-09-17","days":11},{"id":"yuhan","kind":"company","name":"Yuhan Corporation","route":"/companies/yuhan/","asOf":"2026-09-17","days":11},{"id":"gi-innovation","kind":"company","name":"GI Innovation","route":"/companies/gi-innovation/","asOf":"2026-09-17","days":11},{"id":"modex-therapeutics","kind":"company","name":"ModeX Therapeutics","route":"/companies/modex-therapeutics/","asOf":"2026-09-17","days":11},{"id":"unicar-therapy","kind":"company","name":"Unicar-Therapy","route":"/companies/unicar-therapy/","asOf":"2026-09-17","days":11},{"id":"a2-biotherapeutics","kind":"company","name":"A2 Biotherapeutics","route":"/companies/a2-biotherapeutics/","asOf":"2026-09-17","days":11},{"id":"wayshine-biopharm","kind":"company","name":"Wayshine Biopharm","route":"/companies/wayshine-biopharm/","asOf":"2026-09-17","days":11},{"id":"cellsight-technologies","kind":"company","name":"CellSight Technologies","route":"/companies/cellsight-technologies/","asOf":"2026-09-17","days":11},{"id":"eureka-therapeutics","kind":"company","name":"Eureka Therapeutics","route":"/companies/eureka-therapeutics/","asOf":"2026-09-17","days":11},{"id":"velavigo","kind":"company","name":"VelaVigo","route":"/companies/velavigo/","asOf":"2026-09-17","days":11},{"id":"vironexis-biotherapeutics","kind":"company","name":"Vironexis Biotherapeutics","route":"/companies/vironexis-biotherapeutics/","asOf":"2026-09-17","days":11},{"id":"precigen","kind":"company","name":"Precigen","route":"/companies/precigen/","asOf":"2026-09-17","days":11},{"id":"guangzhou-virotech","kind":"company","name":"Guangzhou Virotech Pharmaceutical","route":"/companies/guangzhou-virotech/","asOf":"2026-09-17","days":11},{"id":"tairx","kind":"company","name":"TaiRx","route":"/companies/tairx/","asOf":"2026-09-17","days":11},{"id":"tyk-medicines","kind":"company","name":"TYK Medicines","route":"/companies/tyk-medicines/","asOf":"2026-09-17","days":11},{"id":"il-yang-pharmaceutical","kind":"company","name":"Il-Yang Pharmaceutical","route":"/companies/il-yang-pharmaceutical/","asOf":"2026-09-17","days":11},{"id":"gv20-therapeutics","kind":"company","name":"GV20 Therapeutics","route":"/companies/gv20-therapeutics/","asOf":"2026-09-17","days":11},{"id":"shanghai-jiatan-pharmatech","kind":"company","name":"Shanghai Jiatan Pharmatech","route":"/companies/shanghai-jiatan-pharmatech/","asOf":"2026-09-17","days":11},{"id":"shanghai-bovax-biotechnology","kind":"company","name":"Shanghai Bovax Biotechnology","route":"/companies/shanghai-bovax-biotechnology/","asOf":"2026-09-17","days":11},{"id":"aosaikang-pharmaceutical","kind":"company","name":"Aosaikang Pharmaceutical","route":"/companies/aosaikang-pharmaceutical/","asOf":"2026-09-17","days":11},{"id":"salubris-biotherapeutics","kind":"company","name":"Salubris Biotherapeutics","route":"/companies/salubris-biotherapeutics/","asOf":"2026-09-17","days":11},{"id":"suzhou-bluehorse-therapeutics","kind":"company","name":"Suzhou BlueHorse Therapeutics","route":"/companies/suzhou-bluehorse-therapeutics/","asOf":"2026-09-17","days":11},{"id":"frantz-viral-therapeutics","kind":"company","name":"Frantz Viral Therapeutics","route":"/companies/frantz-viral-therapeutics/","asOf":"2026-09-17","days":11},{"id":"radiopharm-theranostics","kind":"company","name":"Radiopharm Theranostics","route":"/companies/radiopharm-theranostics/","asOf":"2026-09-17","days":11},{"id":"torl-biotherapeutics","kind":"company","name":"TORL BioTherapeutics","route":"/companies/torl-biotherapeutics/","asOf":"2026-09-17","days":11},{"id":"lupeng-pharmaceuticals","kind":"company","name":"Lupeng Pharmaceuticals","route":"/companies/lupeng-pharmaceuticals/","asOf":"2026-09-17","days":11},{"id":"xynomic-pharmaceuticals","kind":"company","name":"Xynomic Pharmaceuticals","route":"/companies/xynomic-pharmaceuticals/","asOf":"2026-09-17","days":11},{"id":"obi-pharma","kind":"company","name":"OBI Pharma","route":"/companies/obi-pharma/","asOf":"2026-09-17","days":11},{"id":"aulos-bioscience","kind":"company","name":"Aulos Bioscience","route":"/companies/aulos-bioscience/","asOf":"2026-09-17","days":11},{"id":"bioatla","kind":"company","name":"BioAtla","route":"/companies/bioatla/","asOf":"2026-09-17","days":11},{"id":"bolt-biotherapeutics","kind":"company","name":"Bolt Biotherapeutics","route":"/companies/bolt-biotherapeutics/","asOf":"2026-09-17","days":11},{"id":"faron-pharmaceuticals","kind":"company","name":"Faron Pharmaceuticals","route":"/companies/faron-pharmaceuticals/","asOf":"2026-09-17","days":11},{"id":"camurus","kind":"company","name":"Camurus","route":"/companies/camurus/","asOf":"2026-09-17","days":11},{"id":"lindis-biotech","kind":"company","name":"Lindis Biotech","route":"/companies/lindis-biotech/","asOf":"2026-09-17","days":11},{"id":"pieris-pharmaceuticals","kind":"company","name":"Pieris Pharmaceuticals","route":"/companies/pieris-pharmaceuticals/","asOf":"2026-09-17","days":11},{"id":"crispr-therapeutics","kind":"company","name":"CRISPR Therapeutics","route":"/companies/crispr-therapeutics/","asOf":"2026-09-17","days":11},{"id":"excellthera","kind":"company","name":"ExCellThera","route":"/companies/excellthera/","asOf":"2026-09-17","days":11},{"id":"dren-bio","kind":"company","name":"Dren Bio","route":"/companies/dren-bio/","asOf":"2026-09-17","days":11},{"id":"engeneic","kind":"company","name":"EnGeneIC","route":"/companies/engeneic/","asOf":"2026-09-17","days":11},{"id":"keros-therapeutics","kind":"company","name":"Keros Therapeutics","route":"/companies/keros-therapeutics/","asOf":"2026-09-17","days":11},{"id":"enb-therapeutics","kind":"company","name":"ENB Therapeutics","route":"/companies/enb-therapeutics/","asOf":"2026-09-17","days":11},{"id":"guerbet","kind":"company","name":"Guerbet","route":"/companies/guerbet/","asOf":"2026-09-17","days":11},{"id":"syndevrx","kind":"company","name":"SynDevRx","route":"/companies/syndevrx/","asOf":"2026-09-17","days":11},{"id":"everest-medicines","kind":"company","name":"Everest Medicines","route":"/companies/everest-medicines/","asOf":"2026-09-17","days":11},{"id":"gracell-biotechnologies","kind":"company","name":"Gracell Biotechnologies","route":"/companies/gracell-biotechnologies/","asOf":"2026-09-17","days":11},{"id":"globeimmune","kind":"company","name":"GlobeImmune","route":"/companies/globeimmune/","asOf":"2026-09-17","days":11},{"id":"greenwich-lifesciences","kind":"company","name":"Greenwich LifeSciences","route":"/companies/greenwich-lifesciences/","asOf":"2026-09-17","days":11},{"id":"genrix-bio","kind":"company","name":"Genrix Bio","route":"/companies/genrix-bio/","asOf":"2026-09-17","days":11},{"id":"hookipa-pharma","kind":"company","name":"Hookipa Pharma","route":"/companies/hookipa-pharma/","asOf":"2026-09-17","days":11},{"id":"huabo-biopharm","kind":"company","name":"Huabo Biopharm","route":"/companies/huabo-biopharm/","asOf":"2026-09-17","days":11},{"id":"hummingbird-bioscience","kind":"company","name":"Hummingbird Bioscience","route":"/companies/hummingbird-bioscience/","asOf":"2026-09-17","days":11},{"id":"hotspot-therapeutics","kind":"company","name":"HotSpot Therapeutics","route":"/companies/hotspot-therapeutics/","asOf":"2026-09-17","days":11},{"id":"intensity-therapeutics","kind":"company","name":"Intensity Therapeutics","route":"/companies/intensity-therapeutics/","asOf":"2026-09-17","days":11},{"id":"panbela-therapeutics","kind":"company","name":"Panbela Therapeutics","route":"/companies/panbela-therapeutics/","asOf":"2026-09-17","days":11},{"id":"jubilant-therapeutics","kind":"company","name":"Jubilant Therapeutics","route":"/companies/jubilant-therapeutics/","asOf":"2026-09-17","days":11},{"id":"humanigen","kind":"company","name":"Humanigen","route":"/companies/humanigen/","asOf":"2026-09-17","days":11},{"id":"linnaeus-therapeutics","kind":"company","name":"Linnaeus Therapeutics","route":"/companies/linnaeus-therapeutics/","asOf":"2026-09-17","days":11},{"id":"nextsource-biotechnology","kind":"company","name":"NextSource Biotechnology","route":"/companies/nextsource-biotechnology/","asOf":"2026-09-17","days":11},{"id":"lantern-pharma","kind":"company","name":"Lantern Pharma","route":"/companies/lantern-pharma/","asOf":"2026-09-17","days":11},{"id":"lyvgen-biopharma","kind":"company","name":"Lyvgen Biopharma","route":"/companies/lyvgen-biopharma/","asOf":"2026-09-17","days":11},{"id":"x4-pharmaceuticals","kind":"company","name":"X4 Pharmaceuticals","route":"/companies/x4-pharmaceuticals/","asOf":"2026-09-17","days":11},{"id":"phanes-therapeutics","kind":"company","name":"Phanes Therapeutics","route":"/companies/phanes-therapeutics/","asOf":"2026-09-17","days":11},{"id":"alligator-bioscience","kind":"company","name":"Alligator Bioscience","route":"/companies/alligator-bioscience/","asOf":"2026-09-17","days":11},{"id":"shanghai-miracogen","kind":"company","name":"Shanghai Miracogen","route":"/companies/shanghai-miracogen/","asOf":"2026-09-17","days":11},{"id":"shionogi","kind":"company","name":"Shionogi","route":"/companies/shionogi/","asOf":"2026-09-17","days":11},{"id":"cimab","kind":"company","name":"CIMAB","route":"/companies/cimab/","asOf":"2026-09-17","days":11},{"id":"netris-pharma","kind":"company","name":"Netris Pharma","route":"/companies/netris-pharma/","asOf":"2026-09-17","days":11},{"id":"immix-biopharma","kind":"company","name":"Immix Biopharma","route":"/companies/immix-biopharma/","asOf":"2026-09-17","days":11},{"id":"hanmi-pharmaceutical","kind":"company","name":"Hanmi Pharmaceutical","route":"/companies/hanmi-pharmaceutical/","asOf":"2026-09-17","days":11},{"id":"cardiff-oncology","kind":"company","name":"Cardiff Oncology","route":"/companies/cardiff-oncology/","asOf":"2026-09-17","days":11},{"id":"oncoresponse","kind":"company","name":"OncoResponse","route":"/companies/oncoresponse/","asOf":"2026-09-17","days":11},{"id":"canariabio","kind":"company","name":"CanariaBio","route":"/companies/canariabio/","asOf":"2026-09-17","days":11},{"id":"steba-biotech","kind":"company","name":"Steba Biotech","route":"/companies/steba-biotech/","asOf":"2026-09-17","days":11},{"id":"pellepharm","kind":"company","name":"PellePharm","route":"/companies/pellepharm/","asOf":"2026-09-17","days":11},{"id":"prestige-biopharma","kind":"company","name":"Prestige Biopharma","route":"/companies/prestige-biopharma/","asOf":"2026-09-17","days":11},{"id":"pinnacle-biologics","kind":"company","name":"Pinnacle Biologics","route":"/companies/pinnacle-biologics/","asOf":"2026-09-17","days":11},{"id":"primmune-therapeutics","kind":"company","name":"Primmune Therapeutics","route":"/companies/primmune-therapeutics/","asOf":"2026-09-17","days":11},{"id":"remix-therapeutics","kind":"company","name":"Remix Therapeutics","route":"/companies/remix-therapeutics/","asOf":"2026-09-17","days":11},{"id":"rhovac","kind":"company","name":"RhoVac","route":"/companies/rhovac/","asOf":"2026-09-17","days":11},{"id":"rhythm-pharmaceuticals","kind":"company","name":"Rhythm Pharmaceuticals","route":"/companies/rhythm-pharmaceuticals/","asOf":"2026-09-17","days":11},{"id":"surgimab","kind":"company","name":"Surgimab","route":"/companies/surgimab/","asOf":"2026-09-17","days":11},{"id":"aadi-bioscience","kind":"company","name":"Aadi Bioscience","route":"/companies/aadi-bioscience/","asOf":"2026-09-17","days":11},{"id":"fennec-pharmaceuticals","kind":"company","name":"Fennec Pharmaceuticals","route":"/companies/fennec-pharmaceuticals/","asOf":"2026-09-17","days":11},{"id":"corvus-pharmaceuticals","kind":"company","name":"Corvus Pharmaceuticals","route":"/companies/corvus-pharmaceuticals/","asOf":"2026-09-17","days":11},{"id":"alethia-biotherapeutics","kind":"company","name":"Alethia Biotherapeutics","route":"/companies/alethia-biotherapeutics/","asOf":"2026-09-17","days":11},{"id":"shanghai-pharmaceuticals","kind":"company","name":"Shanghai Pharmaceuticals","route":"/companies/shanghai-pharmaceuticals/","asOf":"2026-09-17","days":11},{"id":"step-pharma","kind":"company","name":"Step Pharma","route":"/companies/step-pharma/","asOf":"2026-09-17","days":11},{"id":"atara-biotherapeutics","kind":"company","name":"Atara Biotherapeutics","route":"/companies/atara-biotherapeutics/","asOf":"2026-09-17","days":11},{"id":"triumvira-immunologics","kind":"company","name":"Triumvira Immunologics","route":"/companies/triumvira-immunologics/","asOf":"2026-09-17","days":11},{"id":"rhizen-pharmaceuticals","kind":"company","name":"Rhizen Pharmaceuticals","route":"/companies/rhizen-pharmaceuticals/","asOf":"2026-09-17","days":11},{"id":"theolytics","kind":"company","name":"Theolytics","route":"/companies/theolytics/","asOf":"2026-09-17","days":11},{"id":"tilt-biotherapeutics","kind":"company","name":"TILT Biotherapeutics","route":"/companies/tilt-biotherapeutics/","asOf":"2026-09-17","days":11},{"id":"oncternal-therapeutics","kind":"company","name":"Oncternal Therapeutics","route":"/companies/oncternal-therapeutics/","asOf":"2026-09-17","days":11},{"id":"byondis","kind":"company","name":"Byondis","route":"/companies/byondis/","asOf":"2026-09-17","days":11},{"id":"toray-industries","kind":"company","name":"Toray Industries","route":"/companies/toray-industries/","asOf":"2026-09-17","days":11},{"id":"transcenta","kind":"company","name":"Transcenta","route":"/companies/transcenta/","asOf":"2026-09-17","days":11},{"id":"i-mab","kind":"company","name":"I-Mab","route":"/companies/i-mab/","asOf":"2026-09-17","days":11},{"id":"medpacto","kind":"company","name":"MedPacto","route":"/companies/medpacto/","asOf":"2026-09-17","days":11},{"id":"zenith-epigenetics","kind":"company","name":"Zenith Epigenetics","route":"/companies/zenith-epigenetics/","asOf":"2026-09-17","days":11},{"id":"abclon","kind":"company","name":"AbClon","route":"/companies/abclon/","asOf":"2026-09-17","days":11},{"id":"devimistat","kind":"drug","name":"Devimistat","route":"/drugs/devimistat/","asOf":"2026-09-17","days":11},{"id":"pamrevlumab","kind":"drug","name":"Pamrevlumab","route":"/drugs/pamrevlumab/","asOf":"2026-09-17","days":11},{"id":"eryaspase","kind":"drug","name":"Eryaspase","route":"/drugs/eryaspase/","asOf":"2026-09-17","days":11},{"id":"algenpantucel-l","kind":"drug","name":"Algenpantucel-L","route":"/drugs/algenpantucel-l/","asOf":"2026-09-17","days":11},{"id":"elraglusib","kind":"drug","name":"Elraglusib","route":"/drugs/elraglusib/","asOf":"2026-09-17","days":11},{"id":"avenger-500","kind":"trial","name":"AVENGER 500","route":"/trials/avenger-500/","asOf":"2026-09-17","days":11},{"id":"lapis-trial","kind":"trial","name":"LAPIS","route":"/trials/lapis-trial/","asOf":"2026-09-17","days":11},{"id":"trybeca-1","kind":"trial","name":"TRYbeCA-1","route":"/trials/trybeca-1/","asOf":"2026-09-17","days":11},{"id":"impress-trial","kind":"trial","name":"IMPRESS (algenpantucel-L)","route":"/trials/impress-trial/","asOf":"2026-09-17","days":11},{"id":"notable-trial","kind":"trial","name":"NOTABLE (nimotuzumab, KRAS wild-type pancreatic cancer)","route":"/trials/notable-trial/","asOf":"2026-09-17","days":11},{"id":"actuate-1801","kind":"trial","name":"Actuate 1801 Part 3B (elraglusib)","route":"/trials/actuate-1801/","asOf":"2026-09-17","days":11},{"id":"cornerstone-pharmaceuticals","kind":"company","name":"Cornerstone Pharmaceuticals (formerly Rafael Pharmaceuticals)","route":"/companies/cornerstone-pharmaceuticals/","asOf":"2026-09-17","days":11},{"id":"fibrogen","kind":"company","name":"FibroGen","route":"/companies/fibrogen/","asOf":"2026-09-17","days":11},{"id":"newlink-genetics","kind":"company","name":"NewLink Genetics (now Lumos Pharma)","route":"/companies/newlink-genetics/","asOf":"2026-09-17","days":11},{"id":"actuate-therapeutics","kind":"company","name":"Actuate Therapeutics","route":"/companies/actuate-therapeutics/","asOf":"2026-09-17","days":11},{"id":"anastrozole","kind":"drug","name":"Anastrozole","route":"/drugs/anastrozole/","asOf":"2026-09-17","days":11},{"id":"zanidatamab-zovodotin","kind":"drug","name":"Zanidatamab zovodotin","route":"/drugs/zanidatamab-zovodotin/","asOf":"2026-09-17","days":11},{"id":"acitretin","kind":"drug","name":"Acitretin","route":"/drugs/acitretin/","asOf":"2026-09-17","days":11},{"id":"nicotinamide","kind":"drug","name":"Nicotinamide","route":"/drugs/nicotinamide/","asOf":"2026-09-17","days":11},{"id":"patidegib","kind":"drug","name":"Patidegib","route":"/drugs/patidegib/","asOf":"2026-09-17","days":11},{"id":"hypericin-sgx301","kind":"drug","name":"Synthetic hypericin","route":"/drugs/hypericin-sgx301/","asOf":"2026-09-17","days":11},{"id":"daromun","kind":"drug","name":"Daromun","route":"/drugs/daromun/","asOf":"2026-09-17","days":11},{"id":"celecoxib","kind":"drug","name":"Celecoxib","route":"/drugs/celecoxib/","asOf":"2026-09-17","days":11},{"id":"xevinapant","kind":"drug","name":"Xevinapant","route":"/drugs/xevinapant/","asOf":"2026-09-17","days":11},{"id":"hb-200","kind":"drug","name":"HB-200","route":"/drugs/hb-200/","asOf":"2026-09-17","days":11},{"id":"depatuxizumab-mafodotin","kind":"drug","name":"Depatuxizumab mafodotin","route":"/drugs/depatuxizumab-mafodotin/","asOf":"2026-09-17","days":11},{"id":"neovax","kind":"drug","name":"NeoVax","route":"/drugs/neovax/","asOf":"2026-09-17","days":11},{"id":"mifepristone","kind":"drug","name":"Mifepristone","route":"/drugs/mifepristone/","asOf":"2026-09-17","days":11},{"id":"memantine","kind":"drug","name":"Memantine","route":"/drugs/memantine/","asOf":"2026-09-17","days":11},{"id":"bromocriptine","kind":"drug","name":"Bromocriptine","route":"/drugs/bromocriptine/","asOf":"2026-09-17","days":11},{"id":"cabergoline","kind":"drug","name":"Cabergoline","route":"/drugs/cabergoline/","asOf":"2026-09-17","days":11},{"id":"pasireotide","kind":"drug","name":"Pasireotide","route":"/drugs/pasireotide/","asOf":"2026-09-17","days":11},{"id":"pegvisomant","kind":"drug","name":"Pegvisomant","route":"/drugs/pegvisomant/","asOf":"2026-09-17","days":11},{"id":"osilodrostat","kind":"drug","name":"Osilodrostat","route":"/drugs/osilodrostat/","asOf":"2026-09-17","days":11},{"id":"metyrapone","kind":"drug","name":"Metyrapone","route":"/drugs/metyrapone/","asOf":"2026-09-17","days":11},{"id":"paltusotine","kind":"drug","name":"Paltusotine","route":"/drugs/paltusotine/","asOf":"2026-09-17","days":11},{"id":"obrixtamig","kind":"drug","name":"Obrixtamig","route":"/drugs/obrixtamig/","asOf":"2026-09-17","days":11},{"id":"diazoxide","kind":"drug","name":"Diazoxide","route":"/drugs/diazoxide/","asOf":"2026-09-17","days":11},{"id":"brigimadlin","kind":"drug","name":"Brigimadlin","route":"/drugs/brigimadlin/","asOf":"2026-09-17","days":11},{"id":"cediranib","kind":"drug","name":"Cediranib","route":"/drugs/cediranib/","asOf":"2026-09-17","days":11},{"id":"carotuximab","kind":"drug","name":"Carotuximab","route":"/drugs/carotuximab/","asOf":"2026-09-17","days":11},{"id":"tk216","kind":"drug","name":"TK216","route":"/drugs/tk216/","asOf":"2026-09-17","days":11},{"id":"gi-6301","kind":"drug","name":"GI-6301","route":"/drugs/gi-6301/","asOf":"2026-09-17","days":11},{"id":"poziotinib","kind":"drug","name":"Poziotinib","route":"/drugs/poziotinib/","asOf":"2026-09-17","days":11},{"id":"aminopterin","kind":"drug","name":"Aminopterin","route":"/drugs/aminopterin/","asOf":"2026-09-17","days":11},{"id":"pevonedistat","kind":"drug","name":"Pevonedistat","route":"/drugs/pevonedistat/","asOf":"2026-09-17","days":11},{"id":"lenzilumab","kind":"drug","name":"Lenzilumab","route":"/drugs/lenzilumab/","asOf":"2026-09-17","days":11},{"id":"inca033989","kind":"drug","name":"INCA033989","route":"/drugs/inca033989/","asOf":"2026-09-17","days":11},{"id":"danazol","kind":"drug","name":"Danazol","route":"/drugs/danazol/","asOf":"2026-09-17","days":11},{"id":"phosphorus-32","kind":"drug","name":"Phosphorus-32 (radiophosphorus)","route":"/drugs/phosphorus-32/","asOf":"2026-09-17","days":11},{"id":"mavorixafor","kind":"drug","name":"Mavorixafor","route":"/drugs/mavorixafor/","asOf":"2026-09-17","days":11},{"id":"isotretinoin","kind":"drug","name":"Isotretinoin","route":"/drugs/isotretinoin/","asOf":"2026-09-17","days":11},{"id":"stride-dna-break-detection","kind":"technology","name":"STRIDE DNA break detection (intoDNA)","route":"/technologies/stride-dna-break-detection/","asOf":"2026-09-17","days":11},{"id":"intodna","kind":"company","name":"intoDNA","route":"/companies/intodna/","asOf":"2026-09-17","days":11},{"id":"strata-oncology","kind":"company","name":"Strata Oncology","route":"/companies/strata-oncology/","asOf":"2026-09-17","days":11},{"id":"rad51-foci-assay","kind":"technology","name":"RAD51 foci assay (functional HRD test)","route":"/technologies/rad51-foci-assay/","asOf":"2026-09-17","days":11},{"id":"hrd-genomic-scar-scores","kind":"technology","name":"HRD genomic scar scores (GIS, LOH, HRDetect)","route":"/technologies/hrd-genomic-scar-scores/","asOf":"2026-09-17","days":11},{"id":"cellsearch-ctc-count","kind":"technology","name":"CellSearch circulating tumour cell count","route":"/technologies/cellsearch-ctc-count/","asOf":"2026-09-17","days":11},{"id":"parsortix-ctc-harvest","kind":"technology","name":"Parsortix label-free circulating tumour cell harvest","route":"/technologies/parsortix-ctc-harvest/","asOf":"2026-09-17","days":11},{"id":"functional-precision-medicine-haematology","kind":"technology","name":"Ex vivo drug sensitivity screening in blood cancers (EXALT)","route":"/technologies/functional-precision-medicine-haematology/","asOf":"2026-09-17","days":11},{"id":"sarcoma-methylation-classifier","kind":"technology","name":"Methylation classifier for sarcomas","route":"/technologies/sarcoma-methylation-classifier/","asOf":"2026-09-17","days":11},{"id":"urine-bladder-cancer-tests","kind":"technology","name":"Urine tests for bladder cancer (cytology, FISH, RNA and methylation)","route":"/technologies/urine-bladder-cancer-tests/","asOf":"2026-09-17","days":11},{"id":"bladder-epicheck","kind":"technology","name":"Bladder EpiCheck urine methylation test","route":"/technologies/bladder-epicheck/","asOf":"2026-09-17","days":11},{"id":"multitarget-stool-rna-test","kind":"technology","name":"Multitarget stool RNA test (ColoSense)","route":"/technologies/multitarget-stool-rna-test/","asOf":"2026-09-17","days":11},{"id":"fes-pet","kind":"technology","name":"FES PET (oestrogen receptor imaging)","route":"/technologies/fes-pet/","asOf":"2026-09-17","days":11},{"id":"quantitative-imaging-biomarkers","kind":"technology","name":"Quantitative imaging biomarkers (RECIST, PERCIST, SUV, ADC)","route":"/technologies/quantitative-imaging-biomarkers/","asOf":"2026-09-17","days":11},{"id":"ct-body-composition-sarcopenia","kind":"technology","name":"CT body composition and sarcopenia measurement","route":"/technologies/ct-body-composition-sarcopenia/","asOf":"2026-09-17","days":11},{"id":"dpyd-genotyping","kind":"technology","name":"DPYD genotyping and DPD phenotyping before fluoropyrimidines","route":"/technologies/dpyd-genotyping/","asOf":"2026-09-17","days":11},{"id":"ugt1a1-genotyping","kind":"technology","name":"UGT1A1 genotyping before irinotecan","route":"/technologies/ugt1a1-genotyping/","asOf":"2026-09-17","days":11},{"id":"tpmt-nudt15-genotyping","kind":"technology","name":"TPMT and NUDT15 genotyping before thiopurines","route":"/technologies/tpmt-nudt15-genotyping/","asOf":"2026-09-17","days":11},{"id":"cardiac-biomarker-monitoring","kind":"technology","name":"Troponin and natriuretic peptide monitoring during cancer treatment","route":"/technologies/cardiac-biomarker-monitoring/","asOf":"2026-09-17","days":11},{"id":"strain-echocardiography-gls","kind":"technology","name":"Strain echocardiography (global longitudinal strain)","route":"/technologies/strain-echocardiography-gls/","asOf":"2026-09-17","days":11},{"id":"g8-geriatric-screening","kind":"technology","name":"G8 geriatric screening tool","route":"/technologies/g8-geriatric-screening/","asOf":"2026-09-17","days":11},{"id":"via-cervical-screening","kind":"technology","name":"Visual inspection with acetic acid (VIA) for cervical screening","route":"/technologies/via-cervical-screening/","asOf":"2026-09-17","days":11},{"id":"hand-held-ultrasound","kind":"technology","name":"Hand-held and point-of-care ultrasound","route":"/technologies/hand-held-ultrasound/","asOf":"2026-09-17","days":11},{"id":"serum-tumour-markers","kind":"technology","name":"Serum tumour markers: proper use and misuse","route":"/technologies/serum-tumour-markers/","asOf":"2026-09-17","days":11},{"id":"germ-cell-tumour-markers","kind":"technology","name":"AFP, hCG and LDH in germ cell tumours (IGCCCG risk groups)","route":"/technologies/germ-cell-tumour-markers/","asOf":"2026-09-17","days":11},{"id":"thyroid-cancer-markers","kind":"technology","name":"Thyroglobulin, calcitonin and CEA in thyroid cancer follow-up","route":"/technologies/thyroid-cancer-markers/","asOf":"2026-09-17","days":11},{"id":"cea-surveillance-colorectal","kind":"technology","name":"CEA surveillance after colorectal cancer surgery","route":"/technologies/cea-surveillance-colorectal/","asOf":"2026-09-17","days":11},{"id":"menarini-silicon-biosystems","kind":"company","name":"Menarini Silicon Biosystems","route":"/companies/menarini-silicon-biosystems/","asOf":"2026-09-17","days":11},{"id":"angle-plc","kind":"company","name":"ANGLE plc","route":"/companies/angle-plc/","asOf":"2026-09-17","days":11},{"id":"geneoscopy","kind":"company","name":"Geneoscopy","route":"/companies/geneoscopy/","asOf":"2026-09-17","days":11},{"id":"butterfly-network","kind":"company","name":"Butterfly Network","route":"/companies/butterfly-network/","asOf":"2026-09-17","days":11},{"id":"fujirebio","kind":"company","name":"Fujirebio","route":"/companies/fujirebio/","asOf":"2026-09-17","days":11},{"id":"i-spy-1","kind":"trial","name":"I-SPY 1 (CALGB 150007/150012, ACRIN 6657)","route":"/trials/i-spy-1/","asOf":"2026-09-17","days":11},{"id":"i-spy-2","kind":"trial","name":"I-SPY 2","route":"/trials/i-spy-2/","asOf":"2026-09-17","days":11},{"id":"i-spy-2-2","kind":"trial","name":"I-SPY 2.2","route":"/trials/i-spy-2-2/","asOf":"2026-09-17","days":11},{"id":"quantum-leap-healthcare-collaborative","kind":"company","name":"Quantum Leap Healthcare Collaborative","route":"/companies/quantum-leap-healthcare-collaborative/","asOf":"2026-09-17","days":11},{"id":"vmat","kind":"technology","name":"Volumetric modulated arc therapy (VMAT)","route":"/technologies/vmat/","asOf":"2026-09-17","days":11},{"id":"radiosurgery-srs","kind":"technology","name":"Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS)","route":"/technologies/radiosurgery-srs/","asOf":"2026-09-17","days":11},{"id":"adaptive-radiotherapy","kind":"technology","name":"Adaptive radiotherapy (online replanning)","route":"/technologies/adaptive-radiotherapy/","asOf":"2026-09-17","days":11},{"id":"surface-guided-radiotherapy","kind":"technology","name":"Surface-guided radiotherapy (SGRT)","route":"/technologies/surface-guided-radiotherapy/","asOf":"2026-09-17","days":11},{"id":"respiratory-motion-management","kind":"technology","name":"Respiratory motion management (4D-CT, gating, breath-hold, tracking)","route":"/technologies/respiratory-motion-management/","asOf":"2026-09-17","days":11},{"id":"hypofractionated-radiotherapy","kind":"technology","name":"Hypofractionated radiotherapy","route":"/technologies/hypofractionated-radiotherapy/","asOf":"2026-09-17","days":11},{"id":"sabr-oligometastases","kind":"technology","name":"Stereotactic ablative radiotherapy for oligometastatic disease","route":"/technologies/sabr-oligometastases/","asOf":"2026-09-17","days":11},{"id":"hdr-brachytherapy","kind":"technology","name":"High-dose-rate brachytherapy","route":"/technologies/hdr-brachytherapy/","asOf":"2026-09-17","days":11},{"id":"ldr-seed-brachytherapy","kind":"technology","name":"Low-dose-rate seed brachytherapy","route":"/technologies/ldr-seed-brachytherapy/","asOf":"2026-09-17","days":11},{"id":"intensity-modulated-proton-therapy","kind":"technology","name":"Pencil-beam scanning and intensity-modulated proton therapy","route":"/technologies/intensity-modulated-proton-therapy/","asOf":"2026-09-17","days":11},{"id":"total-body-irradiation","kind":"technology","name":"Total body and total marrow irradiation","route":"/technologies/total-body-irradiation/","asOf":"2026-09-17","days":11},{"id":"total-skin-electron-therapy","kind":"technology","name":"Total skin electron beam therapy","route":"/technologies/total-skin-electron-therapy/","asOf":"2026-09-17","days":11},{"id":"superficial-radiotherapy","kind":"technology","name":"Superficial and orthovoltage radiotherapy for skin cancer","route":"/technologies/superficial-radiotherapy/","asOf":"2026-09-17","days":11},{"id":"cobalt-60-teletherapy","kind":"technology","name":"Cobalt-60 teletherapy","route":"/technologies/cobalt-60-teletherapy/","asOf":"2026-09-17","days":11},{"id":"radiotherapy-access-gap","kind":"technology","name":"Radiotherapy access and the global machine gap","route":"/technologies/radiotherapy-access-gap/","asOf":"2026-09-17","days":11},{"id":"radiosensitisers","kind":"technology","name":"Radiosensitisers","route":"/technologies/radiosensitisers/","asOf":"2026-09-17","days":11},{"id":"radioprotectors","kind":"technology","name":"Radioprotectors and normal-tissue sparing drugs","route":"/technologies/radioprotectors/","asOf":"2026-09-17","days":11},{"id":"linear-quadratic-model","kind":"technology","name":"The linear-quadratic model and fractionation","route":"/technologies/linear-quadratic-model/","asOf":"2026-09-17","days":11},{"id":"tumour-hypoxia-modification","kind":"technology","name":"Tumour hypoxia: imaging and modification","route":"/technologies/tumour-hypoxia-modification/","asOf":"2026-09-17","days":11},{"id":"dose-painting","kind":"technology","name":"Dose painting and biologically guided radiotherapy","route":"/technologies/dose-painting/","asOf":"2026-09-17","days":11},{"id":"knowledge-based-planning","kind":"technology","name":"Knowledge-based and automated treatment planning","route":"/technologies/knowledge-based-planning/","asOf":"2026-09-17","days":11},{"id":"in-vivo-dosimetry","kind":"technology","name":"In vivo dosimetry and patient-specific quality assurance","route":"/technologies/in-vivo-dosimetry/","asOf":"2026-09-17","days":11},{"id":"radiogenomics","kind":"technology","name":"Radiogenomics: predicting radiation sensitivity from genes","route":"/technologies/radiogenomics/","asOf":"2026-09-17","days":11},{"id":"alpha-beta-ratio","kind":"term","name":"Alpha/beta ratio","route":"/terms/alpha-beta-ratio/","asOf":"2026-09-17","days":11},{"id":"biologically-effective-dose","kind":"term","name":"Biologically effective dose (BED) and EQD2","route":"/terms/biologically-effective-dose/","asOf":"2026-09-17","days":11},{"id":"planning-target-volume","kind":"term","name":"GTV, CTV and PTV (target volumes)","route":"/terms/planning-target-volume/","asOf":"2026-09-17","days":11},{"id":"organs-at-risk","kind":"term","name":"Organs at risk and dose constraints","route":"/terms/organs-at-risk/","asOf":"2026-09-17","days":11},{"id":"deep-inspiration-breath-hold","kind":"term","name":"Deep inspiration breath-hold (DIBH)","route":"/terms/deep-inspiration-breath-hold/","asOf":"2026-09-17","days":11},{"id":"fiducial-markers","kind":"term","name":"Fiducial markers","route":"/terms/fiducial-markers/","asOf":"2026-09-17","days":11},{"id":"tumour-hypoxia","kind":"term","name":"Tumour hypoxia","route":"/terms/tumour-hypoxia/","asOf":"2026-09-17","days":11},{"id":"oxygen-enhancement-ratio","kind":"term","name":"Oxygen enhancement ratio","route":"/terms/oxygen-enhancement-ratio/","asOf":"2026-09-17","days":11},{"id":"radiation-dermatitis","kind":"term","name":"Radiation dermatitis (skin reaction)","route":"/terms/radiation-dermatitis/","asOf":"2026-09-17","days":11},{"id":"radiation-pneumonitis","kind":"term","name":"Radiation pneumonitis and lung fibrosis","route":"/terms/radiation-pneumonitis/","asOf":"2026-09-17","days":11},{"id":"radiation-necrosis","kind":"term","name":"Radiation necrosis (brain)","route":"/terms/radiation-necrosis/","asOf":"2026-09-17","days":11},{"id":"second-cancers-after-radiotherapy","kind":"term","name":"Second cancers after radiotherapy","route":"/terms/second-cancers-after-radiotherapy/","asOf":"2026-09-17","days":11},{"id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/","asOf":"2026-09-17","days":11},{"id":"biliary-tract-cancer","kind":"cancer","name":"Biliary tract cancer (all types)","route":"/cancers/biliary-tract-cancer/","asOf":"2026-09-17","days":11},{"id":"int-0116","kind":"trial","name":"INT-0116 (Macdonald trial)","route":"/trials/int-0116/","asOf":"2026-09-17","days":11},{"id":"cao-aro-aio-94","kind":"trial","name":"CAO/ARO/AIO-94 (German Rectal Cancer Study)","route":"/trials/cao-aro-aio-94/","asOf":"2026-09-17","days":11},{"id":"rapido","kind":"trial","name":"RAPIDO","route":"/trials/rapido/","asOf":"2026-09-17","days":11},{"id":"prodige-23","kind":"trial","name":"PRODIGE 23","route":"/trials/prodige-23/","asOf":"2026-09-17","days":11},{"id":"act-ii","kind":"trial","name":"ACT II","route":"/trials/act-ii/","asOf":"2026-09-17","days":11},{"id":"rtog-91-11","kind":"trial","name":"RTOG 91-11","route":"/trials/rtog-91-11/","asOf":"2026-09-17","days":11},{"id":"bonner-cetuximab-rt","kind":"trial","name":"Bonner trial (cetuximab plus radiotherapy)","route":"/trials/bonner-cetuximab-rt/","asOf":"2026-09-17","days":11},{"id":"rtog-1016","kind":"trial","name":"RTOG 1016","route":"/trials/rtog-1016/","asOf":"2026-09-17","days":11},{"id":"de-escalate","kind":"trial","name":"De-ESCALaTE HPV","route":"/trials/de-escalate/","asOf":"2026-09-17","days":11},{"id":"rtog-9601","kind":"trial","name":"RTOG 9601","route":"/trials/rtog-9601/","asOf":"2026-09-17","days":11},{"id":"horrad","kind":"trial","name":"HORRAD","route":"/trials/horrad/","asOf":"2026-09-17","days":11},{"id":"pop-rt","kind":"trial","name":"POP-RT","route":"/trials/pop-rt/","asOf":"2026-09-17","days":11},{"id":"slotman-pci-es-sclc","kind":"trial","name":"EORTC 08993 (Slotman): prophylactic cranial irradiation in extensive-stage small-cell lung cancer","route":"/trials/slotman-pci-es-sclc/","asOf":"2026-09-17","days":11},{"id":"takahashi-pci","kind":"trial","name":"Takahashi trial: prophylactic cranial irradiation with MRI surveillance in extensive-stage small-cell lung cancer","route":"/trials/takahashi-pci/","asOf":"2026-09-17","days":11},{"id":"eortc-22922","kind":"trial","name":"EORTC 22922/10925","route":"/trials/eortc-22922/","asOf":"2026-09-17","days":11},{"id":"ma-20","kind":"trial","name":"NCIC MA.20","route":"/trials/ma-20/","asOf":"2026-09-17","days":11},{"id":"dbcg-82bc","kind":"trial","name":"DBCG 82b and 82c","route":"/trials/dbcg-82bc/","asOf":"2026-09-17","days":11},{"id":"rtog-9402","kind":"trial","name":"RTOG 9402","route":"/trials/rtog-9402/","asOf":"2026-09-17","days":11},{"id":"eortc-26951","kind":"trial","name":"EORTC 26951","route":"/trials/eortc-26951/","asOf":"2026-09-17","days":11},{"id":"eortc-22033","kind":"trial","name":"EORTC 22033-26033","route":"/trials/eortc-22033/","asOf":"2026-09-17","days":11},{"id":"linear-energy-transfer","kind":"term","name":"Linear energy transfer (LET)","route":"/terms/linear-energy-transfer/","asOf":"2026-09-17","days":11},{"id":"relative-biological-effectiveness","kind":"term","name":"Relative biological effectiveness (RBE)","route":"/terms/relative-biological-effectiveness/","asOf":"2026-09-17","days":11},{"id":"bragg-peak","kind":"term","name":"Bragg peak","route":"/terms/bragg-peak/","asOf":"2026-09-17","days":11},{"id":"partiqol","kind":"trial","name":"PARTIQoL","route":"/trials/partiqol/","asOf":"2026-09-17","days":11},{"id":"radcomp","kind":"trial","name":"RADCOMP","route":"/trials/radcomp/","asOf":"2026-09-17","days":11},{"id":"papillary-thyroid-cancer","kind":"cancer","name":"Papillary thyroid cancer","route":"/cancers/papillary-thyroid-cancer/","asOf":"2026-09-17","days":11},{"id":"follicular-thyroid-cancer","kind":"cancer","name":"Follicular thyroid cancer","route":"/cancers/follicular-thyroid-cancer/","asOf":"2026-09-17","days":11},{"id":"medullary-thyroid-cancer","kind":"cancer","name":"Medullary thyroid cancer","route":"/cancers/medullary-thyroid-cancer/","asOf":"2026-09-17","days":11},{"id":"anaplastic-thyroid-cancer","kind":"cancer","name":"Anaplastic thyroid cancer","route":"/cancers/anaplastic-thyroid-cancer/","asOf":"2026-09-17","days":11},{"id":"oropharyngeal-cancer","kind":"cancer","name":"Oropharyngeal cancer (tonsil and base of tongue)","route":"/cancers/oropharyngeal-cancer/","asOf":"2026-09-17","days":11},{"id":"laryngeal-cancer","kind":"cancer","name":"Laryngeal and hypopharyngeal cancer","route":"/cancers/laryngeal-cancer/","asOf":"2026-09-17","days":11},{"id":"oral-cavity-cancer","kind":"cancer","name":"Oral cavity cancer (mouth and tongue)","route":"/cancers/oral-cavity-cancer/","asOf":"2026-09-17","days":11},{"id":"high-grade-serous-ovarian-cancer","kind":"cancer","name":"High-grade serous ovarian cancer","route":"/cancers/high-grade-serous-ovarian-cancer/","asOf":"2026-09-17","days":11},{"id":"low-grade-serous-ovarian-cancer","kind":"cancer","name":"Low-grade serous ovarian cancer","route":"/cancers/low-grade-serous-ovarian-cancer/","asOf":"2026-09-17","days":11},{"id":"clear-cell-ovarian-cancer","kind":"cancer","name":"Clear cell ovarian cancer","route":"/cancers/clear-cell-ovarian-cancer/","asOf":"2026-09-17","days":11},{"id":"mucinous-ovarian-cancer","kind":"cancer","name":"Mucinous ovarian cancer","route":"/cancers/mucinous-ovarian-cancer/","asOf":"2026-09-17","days":11},{"id":"granulosa-cell-tumour","kind":"cancer","name":"Adult granulosa cell tumour of the ovary","route":"/cancers/granulosa-cell-tumour/","asOf":"2026-09-17","days":11},{"id":"clear-cell-rcc","kind":"cancer","name":"Clear cell renal cell carcinoma","route":"/cancers/clear-cell-rcc/","asOf":"2026-09-17","days":11},{"id":"papillary-rcc","kind":"cancer","name":"Papillary renal cell carcinoma","route":"/cancers/papillary-rcc/","asOf":"2026-09-17","days":11},{"id":"chromophobe-rcc","kind":"cancer","name":"Chromophobe renal cell carcinoma","route":"/cancers/chromophobe-rcc/","asOf":"2026-09-17","days":11},{"id":"seminoma","kind":"cancer","name":"Seminoma","route":"/cancers/seminoma/","asOf":"2026-09-17","days":11},{"id":"non-seminoma","kind":"cancer","name":"Non-seminomatous germ cell tumour","route":"/cancers/non-seminoma/","asOf":"2026-09-17","days":11},{"id":"oesophageal-squamous-cell-carcinoma","kind":"cancer","name":"Oesophageal squamous cell carcinoma","route":"/cancers/oesophageal-squamous-cell-carcinoma/","asOf":"2026-09-17","days":11},{"id":"oesophageal-adenocarcinoma","kind":"cancer","name":"Oesophageal and junctional adenocarcinoma","route":"/cancers/oesophageal-adenocarcinoma/","asOf":"2026-09-17","days":11},{"id":"non-muscle-invasive-bladder-cancer","kind":"cancer","name":"Non-muscle-invasive bladder cancer","route":"/cancers/non-muscle-invasive-bladder-cancer/","asOf":"2026-09-17","days":11},{"id":"muscle-invasive-bladder-cancer","kind":"cancer","name":"Muscle-invasive and advanced bladder cancer","route":"/cancers/muscle-invasive-bladder-cancer/","asOf":"2026-09-17","days":11},{"id":"leiomyosarcoma","kind":"cancer","name":"Leiomyosarcoma","route":"/cancers/leiomyosarcoma/","asOf":"2026-09-17","days":11},{"id":"liposarcoma","kind":"cancer","name":"Liposarcoma","route":"/cancers/liposarcoma/","asOf":"2026-09-17","days":11},{"id":"synovial-sarcoma","kind":"cancer","name":"Synovial sarcoma","route":"/cancers/synovial-sarcoma/","asOf":"2026-09-17","days":11},{"id":"marginal-zone-lymphoma","kind":"cancer","name":"Marginal zone lymphoma","route":"/cancers/marginal-zone-lymphoma/","asOf":"2026-09-17","days":11},{"id":"cutaneous-t-cell-lymphoma","kind":"cancer","name":"Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)","route":"/cancers/cutaneous-t-cell-lymphoma/","asOf":"2026-09-17","days":11},{"id":"gompertzian-growth-model","kind":"technology","name":"Gompertzian tumour growth","route":"/technologies/gompertzian-growth-model/","asOf":"2026-09-17","days":11},{"id":"log-kill-hypothesis","kind":"technology","name":"Log-kill hypothesis (Skipper)","route":"/technologies/log-kill-hypothesis/","asOf":"2026-09-17","days":11},{"id":"norton-simon-hypothesis","kind":"technology","name":"Norton-Simon hypothesis and dose-dense chemotherapy","route":"/technologies/norton-simon-hypothesis/","asOf":"2026-09-17","days":11},{"id":"goldie-coldman-model","kind":"technology","name":"Goldie-Coldman model of resistance","route":"/technologies/goldie-coldman-model/","asOf":"2026-09-17","days":11},{"id":"drug-resistance-dynamics","kind":"technology","name":"Evolutionary dynamics of drug resistance","route":"/technologies/drug-resistance-dynamics/","asOf":"2026-09-17","days":11},{"id":"adaptive-therapy-dynamics","kind":"technology","name":"Adaptive therapy (evolution-based dosing)","route":"/technologies/adaptive-therapy-dynamics/","asOf":"2026-09-17","days":11},{"id":"evolutionary-game-theory-cancer","kind":"technology","name":"Evolutionary game theory in cancer","route":"/technologies/evolutionary-game-theory-cancer/","asOf":"2026-09-17","days":11},{"id":"clonal-evolution-models","kind":"technology","name":"Clonal evolution and branching models","route":"/technologies/clonal-evolution-models/","asOf":"2026-09-17","days":11},{"id":"reaction-diffusion-glioma-model","kind":"technology","name":"Proliferation-invasion (reaction-diffusion) models of glioma","route":"/technologies/reaction-diffusion-glioma-model/","asOf":"2026-09-17","days":11},{"id":"agent-based-tumour-models","kind":"technology","name":"Agent-based and multicellular simulations","route":"/technologies/agent-based-tumour-models/","asOf":"2026-09-17","days":11},{"id":"immune-tumour-dynamics-models","kind":"technology","name":"Tumour-immune dynamics models","route":"/technologies/immune-tumour-dynamics-models/","asOf":"2026-09-17","days":11},{"id":"quantitative-systems-pharmacology","kind":"technology","name":"Quantitative systems pharmacology (QSP)","route":"/technologies/quantitative-systems-pharmacology/","asOf":"2026-09-17","days":11},{"id":"pkpd-modelling","kind":"technology","name":"Pharmacokinetic and pharmacodynamic modelling","route":"/technologies/pkpd-modelling/","asOf":"2026-09-17","days":11},{"id":"body-surface-area-dosing","kind":"technology","name":"Body-surface-area dosing","route":"/technologies/body-surface-area-dosing/","asOf":"2026-09-17","days":11},{"id":"tumour-control-probability-models","kind":"technology","name":"Tumour control and normal tissue complication probability (TCP and NTCP)","route":"/technologies/tumour-control-probability-models/","asOf":"2026-09-17","days":11},{"id":"fractionation-repopulation-models","kind":"technology","name":"The four Rs and accelerated repopulation","route":"/technologies/fractionation-repopulation-models/","asOf":"2026-09-17","days":11},{"id":"tumour-doubling-time","kind":"technology","name":"Tumour volume doubling time","route":"/technologies/tumour-doubling-time/","asOf":"2026-09-17","days":11},{"id":"angiogenesis-models","kind":"technology","name":"Angiogenesis and vascular normalisation models","route":"/technologies/angiogenesis-models/","asOf":"2026-09-17","days":11},{"id":"tumour-mechanics-models","kind":"technology","name":"Solid stress and tumour mechanobiology models","route":"/technologies/tumour-mechanics-models/","asOf":"2026-09-17","days":11},{"id":"metastasis-seeding-models","kind":"technology","name":"Metastatic seeding and dormancy models","route":"/technologies/metastasis-seeding-models/","asOf":"2026-09-17","days":11},{"id":"mrd-kinetics-models","kind":"technology","name":"Residual disease kinetics (BCR-ABL halving and ctDNA slopes)","route":"/technologies/mrd-kinetics-models/","asOf":"2026-09-17","days":11},{"id":"digital-twin-patient-models","kind":"technology","name":"Patient digital twins","route":"/technologies/digital-twin-patient-models/","asOf":"2026-09-17","days":11},{"id":"mathematical-oncology","kind":"technology","name":"Mathematical models of cancer (mathematical oncology)","route":"/technologies/mathematical-oncology/","asOf":"2026-09-17","days":11},{"id":"x-ray-radiography-fluoroscopy","kind":"technology","name":"X-ray radiography and fluoroscopy","route":"/technologies/x-ray-radiography-fluoroscopy/","asOf":"2026-09-17","days":11},{"id":"photon-counting-ct","kind":"technology","name":"Photon-counting CT","route":"/technologies/photon-counting-ct/","asOf":"2026-09-17","days":11},{"id":"dual-energy-spectral-ct","kind":"technology","name":"Dual-energy and spectral CT","route":"/technologies/dual-energy-spectral-ct/","asOf":"2026-09-17","days":11},{"id":"ultrasound-elastography-ceus","kind":"technology","name":"Elastography and contrast-enhanced ultrasound","route":"/technologies/ultrasound-elastography-ceus/","asOf":"2026-09-17","days":11},{"id":"mri-field-strengths","kind":"technology","name":"MRI field strengths: 1.5 T, 3 T and 7 T","route":"/technologies/mri-field-strengths/","asOf":"2026-09-17","days":11},{"id":"spect-ct","kind":"technology","name":"SPECT/CT","route":"/technologies/spect-ct/","asOf":"2026-09-17","days":11},{"id":"intraoperative-mri-ct","kind":"technology","name":"Intraoperative MRI and CT","route":"/technologies/intraoperative-mri-ct/","asOf":"2026-09-17","days":11},{"id":"c-arm-linac","kind":"technology","name":"C-arm medical linear accelerators (TrueBeam, Versa HD and others)","route":"/technologies/c-arm-linac/","asOf":"2026-09-17","days":11},{"id":"ring-gantry-linac","kind":"technology","name":"Ring-gantry linacs (Halcyon, Ethos)","route":"/technologies/ring-gantry-linac/","asOf":"2026-09-17","days":11},{"id":"tomotherapy","kind":"technology","name":"TomoTherapy and Radixact (helical radiotherapy)","route":"/technologies/tomotherapy/","asOf":"2026-09-17","days":11},{"id":"cyberknife","kind":"technology","name":"CyberKnife robotic radiosurgery","route":"/technologies/cyberknife/","asOf":"2026-09-17","days":11},{"id":"gamma-knife","kind":"technology","name":"Gamma Knife","route":"/technologies/gamma-knife/","asOf":"2026-09-17","days":11},{"id":"zap-x","kind":"technology","name":"ZAP-X gyroscopic radiosurgery","route":"/technologies/zap-x/","asOf":"2026-09-17","days":11},{"id":"biology-guided-radiotherapy","kind":"technology","name":"Biology-guided radiotherapy (RefleXion X1, SCINTIX)","route":"/technologies/biology-guided-radiotherapy/","asOf":"2026-09-17","days":11},{"id":"brachytherapy-afterloaders","kind":"technology","name":"Remote afterloaders for HDR brachytherapy","route":"/technologies/brachytherapy-afterloaders/","asOf":"2026-09-17","days":11},{"id":"proton-therapy-systems","kind":"technology","name":"Proton therapy machines: cyclotrons, synchrotrons and single-room systems","route":"/technologies/proton-therapy-systems/","asOf":"2026-09-17","days":11},{"id":"carbon-ion-synchrotrons","kind":"technology","name":"Carbon-ion synchrotrons and facilities","route":"/technologies/carbon-ion-synchrotrons/","asOf":"2026-09-17","days":11},{"id":"cryoablation-systems","kind":"technology","name":"Cryoablation systems","route":"/technologies/cryoablation-systems/","asOf":"2026-09-17","days":11},{"id":"microwave-rf-ablation","kind":"technology","name":"Microwave and radiofrequency ablation systems","route":"/technologies/microwave-rf-ablation/","asOf":"2026-09-17","days":11},{"id":"surgical-robot-platforms","kind":"technology","name":"Surgical robots: da Vinci, Hugo, Versius and single-port systems","route":"/technologies/surgical-robot-platforms/","asOf":"2026-09-17","days":11},{"id":"flow-cytometers","kind":"technology","name":"Flow cytometers","route":"/technologies/flow-cytometers/","asOf":"2026-09-17","days":11},{"id":"hitachi","kind":"company","name":"Hitachi (particle therapy)","route":"/companies/hitachi/","asOf":"2026-09-17","days":11},{"id":"viewray","kind":"company","name":"ViewRay (MRIdian)","route":"/companies/viewray/","asOf":"2026-09-17","days":11},{"id":"medtronic","kind":"company","name":"Medtronic","route":"/companies/medtronic/","asOf":"2026-09-17","days":11},{"id":"cmr-surgical","kind":"company","name":"CMR Surgical","route":"/companies/cmr-surgical/","asOf":"2026-09-17","days":11},{"id":"angiodynamics","kind":"company","name":"AngioDynamics","route":"/companies/angiodynamics/","asOf":"2026-09-17","days":11},{"id":"fujifilm","kind":"company","name":"FUJIFILM Healthcare","route":"/companies/fujifilm/","asOf":"2026-09-17","days":11},{"id":"shimadzu","kind":"company","name":"Shimadzu","route":"/companies/shimadzu/","asOf":"2026-09-17","days":11},{"id":"sumitomo-heavy-industries","kind":"company","name":"Sumitomo Heavy Industries","route":"/companies/sumitomo-heavy-industries/","asOf":"2026-09-17","days":11},{"id":"toshiba-energy-systems","kind":"company","name":"Toshiba Energy Systems & Solutions","route":"/companies/toshiba-energy-systems/","asOf":"2026-09-17","days":11},{"id":"mediso","kind":"company","name":"Mediso","route":"/companies/mediso/","asOf":"2026-09-17","days":11},{"id":"carl-zeiss-meditec","kind":"company","name":"Carl Zeiss Meditec","route":"/companies/carl-zeiss-meditec/","asOf":"2026-09-17","days":11},{"id":"profound-medical","kind":"company","name":"Profound Medical","route":"/companies/profound-medical/","asOf":"2026-09-17","days":11},{"id":"icecure-medical","kind":"company","name":"IceCure Medical","route":"/companies/icecure-medical/","asOf":"2026-09-17","days":11},{"id":"beckman-coulter","kind":"company","name":"Beckman Coulter","route":"/companies/beckman-coulter/","asOf":"2026-09-17","days":11},{"id":"cytek-biosciences","kind":"company","name":"Cytek Biosciences","route":"/companies/cytek-biosciences/","asOf":"2026-09-17","days":11},{"id":"mindray","kind":"company","name":"Mindray","route":"/companies/mindray/","asOf":"2026-09-17","days":11},{"id":"protom","kind":"company","name":"ProTom International","route":"/companies/protom/","asOf":"2026-09-17","days":11},{"id":"small-molecule-api-synthesis","kind":"technology","name":"Small-molecule API synthesis","route":"/technologies/small-molecule-api-synthesis/","asOf":"2026-09-17","days":11},{"id":"oral-solid-dose-manufacturing","kind":"technology","name":"Oral solid dose manufacturing (tablets and capsules)","route":"/technologies/oral-solid-dose-manufacturing/","asOf":"2026-09-17","days":11},{"id":"sterile-injectable-generics-manufacturing","kind":"technology","name":"Generic sterile injectables (the 2023 platinum shortage)","route":"/technologies/sterile-injectable-generics-manufacturing/","asOf":"2026-09-17","days":11},{"id":"bcg-vaccine-manufacturing","kind":"technology","name":"BCG manufacturing and the bladder cancer BCG shortage","route":"/technologies/bcg-vaccine-manufacturing/","asOf":"2026-09-17","days":11},{"id":"downstream-purification-chromatography","kind":"technology","name":"Downstream purification (Protein A capture, viral clearance, polishing)","route":"/technologies/downstream-purification-chromatography/","asOf":"2026-09-17","days":11},{"id":"single-use-bioprocessing","kind":"technology","name":"Single-use bioprocessing systems","route":"/technologies/single-use-bioprocessing/","asOf":"2026-09-17","days":11},{"id":"biosimilar-manufacturing","kind":"technology","name":"Biosimilar manufacturing and comparability","route":"/technologies/biosimilar-manufacturing/","asOf":"2026-09-17","days":11},{"id":"pharmaceutical-gmp-inspections","kind":"technology","name":"GMP, inspections, Form 483s and warning letters","route":"/technologies/pharmaceutical-gmp-inspections/","asOf":"2026-09-17","days":11},{"id":"adc-supply-chain","kind":"technology","name":"The ADC supply chain (antibody, payload-linker, conjugation, fill)","route":"/technologies/adc-supply-chain/","asOf":"2026-09-17","days":11},{"id":"car-t-manufacturing-process","kind":"technology","name":"Autologous CAR-T manufacturing, batch by batch","route":"/technologies/car-t-manufacturing-process/","asOf":"2026-09-17","days":11},{"id":"allogeneic-cell-banks","kind":"technology","name":"Allogeneic cell banks: one donor, hundreds of doses","route":"/technologies/allogeneic-cell-banks/","asOf":"2026-09-17","days":11},{"id":"mrna-lnp-manufacturing","kind":"technology","name":"mRNA and lipid nanoparticle manufacturing","route":"/technologies/mrna-lnp-manufacturing/","asOf":"2026-09-17","days":11},{"id":"research-reactor-isotope-production","kind":"technology","name":"Research reactors for medical isotopes (Mo-99, Lu-177, I-131)","route":"/technologies/research-reactor-isotope-production/","asOf":"2026-09-17","days":11},{"id":"cyclotron-isotope-production","kind":"technology","name":"Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211)","route":"/technologies/cyclotron-isotope-production/","asOf":"2026-09-17","days":11},{"id":"actinium-225-supply","kind":"technology","name":"Actinium-225 supply: thorium stocks, accelerators and radium targets","route":"/technologies/actinium-225-supply/","asOf":"2026-09-17","days":11},{"id":"radiopharmaceutical-gmp-release","kind":"technology","name":"Radiopharmaceutical GMP and releasing a drug that decays","route":"/technologies/radiopharmaceutical-gmp-release/","asOf":"2026-09-17","days":11},{"id":"radiotherapy-equipment-manufacturing","kind":"technology","name":"Linac, proton system and brachytherapy machine manufacturing","route":"/technologies/radiotherapy-equipment-manufacturing/","asOf":"2026-09-17","days":11},{"id":"medical-imaging-scanner-manufacturing","kind":"technology","name":"CT, MRI and PET scanner manufacturing","route":"/technologies/medical-imaging-scanner-manufacturing/","asOf":"2026-09-17","days":11},{"id":"sterling-pharma-solutions","kind":"company","name":"Sterling Pharma Solutions","route":"/companies/sterling-pharma-solutions/","asOf":"2026-09-17","days":11},{"id":"sartorius","kind":"company","name":"Sartorius","route":"/companies/sartorius/","asOf":"2026-09-17","days":11},{"id":"hikma","kind":"company","name":"Hikma Pharmaceuticals","route":"/companies/hikma/","asOf":"2026-09-17","days":11},{"id":"amneal","kind":"company","name":"Amneal Pharmaceuticals","route":"/companies/amneal/","asOf":"2026-09-17","days":11},{"id":"samsung-bioepis","kind":"company","name":"Samsung Bioepis","route":"/companies/samsung-bioepis/","asOf":"2026-09-17","days":11},{"id":"cellectis","kind":"company","name":"Cellectis","route":"/companies/cellectis/","asOf":"2026-09-17","days":11},{"id":"ntp-radioisotopes","kind":"company","name":"NTP Radioisotopes","route":"/companies/ntp-radioisotopes/","asOf":"2026-09-17","days":11},{"id":"ansto","kind":"company","name":"ANSTO (Australian Nuclear Science and Technology Organisation)","route":"/companies/ansto/","asOf":"2026-09-17","days":11},{"id":"ire","kind":"company","name":"IRE (Institut national des Radioéléments)","route":"/companies/ire/","asOf":"2026-09-17","days":11},{"id":"nordion","kind":"company","name":"Nordion (Sotera Health)","route":"/companies/nordion/","asOf":"2026-09-17","days":11},{"id":"bruce-power","kind":"company","name":"Bruce Power","route":"/companies/bruce-power/","asOf":"2026-09-17","days":11},{"id":"nusano","kind":"company","name":"Nusano","route":"/companies/nusano/","asOf":"2026-09-17","days":11},{"id":"isotopia","kind":"company","name":"Isotopia Molecular Imaging","route":"/companies/isotopia/","asOf":"2026-09-17","days":11},{"id":"theories-of-cancer","kind":"pathway","name":"Theories of cancer: how the ideas connect","route":"/pathways/theories-of-cancer/","asOf":"2026-09-17","days":11},{"id":"somatic-mutation-theory","kind":"term","name":"Somatic mutation theory of cancer","route":"/terms/somatic-mutation-theory/","asOf":"2026-09-17","days":11},{"id":"driver-passenger-model","kind":"term","name":"Driver and passenger mutations: the refined somatic mutation theory","route":"/terms/driver-passenger-model/","asOf":"2026-09-17","days":11},{"id":"clonal-evolution-theory","kind":"term","name":"Clonal evolution and the ecological view of cancer","route":"/terms/clonal-evolution-theory/","asOf":"2026-09-17","days":11},{"id":"hallmarks-synthesis","kind":"term","name":"Hallmarks of cancer as a synthesis of the theories","route":"/terms/hallmarks-synthesis/","asOf":"2026-09-17","days":11},{"id":"cancer-stem-cell-theory","kind":"term","name":"Cancer stem cell theory and phenotypic plasticity","route":"/terms/cancer-stem-cell-theory/","asOf":"2026-09-17","days":11},{"id":"epigenetic-progenitor-theory","kind":"term","name":"Epigenetic progenitor theory: cancer without a first mutation","route":"/terms/epigenetic-progenitor-theory/","asOf":"2026-09-17","days":11},{"id":"aneuploidy-theory-of-cancer","kind":"term","name":"Aneuploidy and chromosomal instability as the cause of cancer","route":"/terms/aneuploidy-theory-of-cancer/","asOf":"2026-09-17","days":11},{"id":"metabolic-theory-of-cancer","kind":"term","name":"Metabolic theory of cancer: from Warburg to oncometabolites","route":"/terms/metabolic-theory-of-cancer/","asOf":"2026-09-17","days":11},{"id":"tissue-organisation-field-theory","kind":"term","name":"Tissue organisation field theory (Sonnenschein and Soto)","route":"/terms/tissue-organisation-field-theory/","asOf":"2026-09-17","days":11},{"id":"microenvironment-inflammation-theory","kind":"term","name":"Microenvironment and inflammation: tumours as wounds that do not heal","route":"/terms/microenvironment-inflammation-theory/","asOf":"2026-09-17","days":11},{"id":"seed-and-soil-hypothesis","kind":"term","name":"Seed and soil hypothesis of metastasis (Paget)","route":"/terms/seed-and-soil-hypothesis/","asOf":"2026-09-17","days":11},{"id":"immune-surveillance-immunoediting","kind":"term","name":"Immune surveillance and cancer immunoediting","route":"/terms/immune-surveillance-immunoediting/","asOf":"2026-09-17","days":11},{"id":"ageing-tissue-field-theory","kind":"term","name":"Ageing tissue and clonal fields: cancer as a disease of old tissue","route":"/terms/ageing-tissue-field-theory/","asOf":"2026-09-17","days":11},{"id":"atavistic-theory-of-cancer","kind":"term","name":"Atavistic theory: cancer as a reversion to an ancient programme","route":"/terms/atavistic-theory-of-cancer/","asOf":"2026-09-17","days":11},{"id":"mechanical-theory-of-cancer","kind":"term","name":"Mechanical theory: stiffness, pressure and force as causes","route":"/terms/mechanical-theory-of-cancer/","asOf":"2026-09-17","days":11},{"id":"bioelectric-theory-of-cancer","kind":"term","name":"Bioelectric theory of cancer (Levin)","route":"/terms/bioelectric-theory-of-cancer/","asOf":"2026-09-17","days":11},{"id":"master-protocol","kind":"term","name":"Master protocol (platform, basket and umbrella trials)","route":"/terms/master-protocol/","asOf":"2026-09-17","days":11},{"id":"lung-map-s1400i","kind":"trial","name":"Lung-MAP S1400I: nivolumab with or without ipilimumab","route":"/trials/lung-map-s1400i/","asOf":"2026-09-17","days":11},{"id":"lung-map-s1800a","kind":"trial","name":"Lung-MAP S1800A: ramucirumab plus pembrolizumab","route":"/trials/lung-map-s1800a/","asOf":"2026-09-17","days":11},{"id":"national-lung-matrix-trial","kind":"trial","name":"National Lung Matrix Trial","route":"/trials/national-lung-matrix-trial/","asOf":"2026-09-17","days":11},{"id":"alchemist","kind":"trial","name":"ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)","route":"/trials/alchemist/","asOf":"2026-09-17","days":11},{"id":"nci-match","kind":"trial","name":"NCI-MATCH (EAY131)","route":"/trials/nci-match/","asOf":"2026-09-17","days":11},{"id":"combomatch","kind":"trial","name":"ComboMATCH (EAY191)","route":"/trials/combomatch/","asOf":"2026-09-17","days":11},{"id":"tapur","kind":"trial","name":"TAPUR (Targeted Agent and Profiling Utilization Registry)","route":"/trials/tapur/","asOf":"2026-09-17","days":11},{"id":"dart-s1609","kind":"trial","name":"DART (SWOG S1609): nivolumab plus ipilimumab in rare tumours","route":"/trials/dart-s1609/","asOf":"2026-09-17","days":11},{"id":"mypathway","kind":"trial","name":"MyPathway","route":"/trials/mypathway/","asOf":"2026-09-17","days":11},{"id":"i-predict","kind":"trial","name":"I-PREDICT","route":"/trials/i-predict/","asOf":"2026-09-17","days":11},{"id":"winther","kind":"trial","name":"WINTHER","route":"/trials/winther/","asOf":"2026-09-17","days":11},{"id":"cupisco","kind":"trial","name":"CUPISCO","route":"/trials/cupisco/","asOf":"2026-09-17","days":11},{"id":"plasmamatch","kind":"trial","name":"plasmaMATCH","route":"/trials/plasmamatch/","asOf":"2026-09-17","days":11},{"id":"target-national","kind":"trial","name":"TARGET National","route":"/trials/target-national/","asOf":"2026-09-17","days":11},{"id":"determine-trial","kind":"trial","name":"DETERMINE","route":"/trials/determine-trial/","asOf":"2026-09-17","days":11},{"id":"focus4","kind":"trial","name":"FOCUS4","route":"/trials/focus4/","asOf":"2026-09-17","days":11},{"id":"gbm-agile","kind":"trial","name":"GBM AGILE","route":"/trials/gbm-agile/","asOf":"2026-09-17","days":11},{"id":"precision-promise","kind":"trial","name":"Precision Promise","route":"/trials/precision-promise/","asOf":"2026-09-17","days":11},{"id":"beat-aml-master-trial","kind":"trial","name":"Beat AML Master Trial","route":"/trials/beat-aml-master-trial/","asOf":"2026-09-17","days":11},{"id":"idh-mutant-astrocytoma","kind":"cancer","name":"Astrocytoma, IDH-mutant (grades 2 to 4)","route":"/cancers/idh-mutant-astrocytoma/","asOf":"2026-09-17","days":11},{"id":"oligodendroglioma","kind":"cancer","name":"Oligodendroglioma, IDH-mutant and 1p/19q-codeleted","route":"/cancers/oligodendroglioma/","asOf":"2026-09-17","days":11},{"id":"meningioma","kind":"cancer","name":"Meningioma","route":"/cancers/meningioma/","asOf":"2026-09-17","days":11},{"id":"secondary-brain-tumours","kind":"cancer","name":"Brain metastases (secondary brain tumours)","route":"/cancers/secondary-brain-tumours/","asOf":"2026-09-17","days":11},{"id":"paediatric-high-grade-glioma","kind":"cancer","name":"Paediatric high-grade glioma (excluding diffuse midline glioma)","route":"/cancers/paediatric-high-grade-glioma/","asOf":"2026-09-17","days":11},{"id":"spinal-cord-tumours","kind":"cancer","name":"Spinal cord tumours (intramedullary and intradural)","route":"/cancers/spinal-cord-tumours/","asOf":"2026-09-17","days":11},{"id":"vestibular-schwannoma","kind":"cancer","name":"Vestibular schwannoma (acoustic neuroma)","route":"/cancers/vestibular-schwannoma/","asOf":"2026-09-17","days":11},{"id":"cns-germ-cell-tumours","kind":"cancer","name":"Central nervous system germ cell tumours (germinoma and non-germinomatous)","route":"/cancers/cns-germ-cell-tumours/","asOf":"2026-09-17","days":11},{"id":"bnct-accelerator-systems","kind":"technology","name":"Accelerator-based BNCT systems (NeuCure, nuBeam, NeuPex)","route":"/technologies/bnct-accelerator-systems/","asOf":"2026-09-17","days":11},{"id":"flash-research-accelerators","kind":"technology","name":"FLASH research accelerators (Oriatron, Mobetron FLASH, ProBeam FLASH)","route":"/technologies/flash-research-accelerators/","asOf":"2026-09-17","days":11},{"id":"electron-beam-therapy-systems","kind":"technology","name":"Electron beam therapy systems (linac electrons, total skin electron units, mobile electron IORT)","route":"/technologies/electron-beam-therapy-systems/","asOf":"2026-09-17","days":11},{"id":"oncology-information-systems","kind":"technology","name":"Oncology information and record-and-verify systems (ARIA, MOSAIQ)","route":"/technologies/oncology-information-systems/","asOf":"2026-09-17","days":11},{"id":"patient-positioning-surface-guidance-systems","kind":"technology","name":"Patient positioning and surface guidance systems (AlignRT, Catalyst, ExacTrac Dynamic)","route":"/technologies/patient-positioning-surface-guidance-systems/","asOf":"2026-09-17","days":11},{"id":"respiratory-gating-tumour-tracking-systems","kind":"technology","name":"Respiratory gating and tumour tracking systems (RPM, ABC, Calypso, Synchrony)","route":"/technologies/respiratory-gating-tumour-tracking-systems/","asOf":"2026-09-17","days":11},{"id":"in-room-imaging-systems","kind":"technology","name":"In-room imaging for radiotherapy (cone-beam CT, ExacTrac, CT-on-rails, HyperSight)","route":"/technologies/in-room-imaging-systems/","asOf":"2026-09-17","days":11},{"id":"radiotherapy-qa-phantoms-dosimeters","kind":"technology","name":"Radiotherapy QA phantoms and dosimeters (Sun Nuclear, IBA Dosimetry, PTW)","route":"/technologies/radiotherapy-qa-phantoms-dosimeters/","asOf":"2026-09-17","days":11},{"id":"hyperthermia-systems","kind":"technology","name":"Hyperthermia systems (BSD-2000, EHY-2000, superficial and interstitial applicators)","route":"/technologies/hyperthermia-systems/","asOf":"2026-09-17","days":11},{"id":"photodynamic-therapy-lasers","kind":"technology","name":"Photodynamic therapy lasers and light sources","route":"/technologies/photodynamic-therapy-lasers/","asOf":"2026-09-17","days":11},{"id":"litt-systems","kind":"technology","name":"Laser interstitial thermal therapy systems (NeuroBlate, Visualase)","route":"/technologies/litt-systems/","asOf":"2026-09-17","days":11},{"id":"transcranial-focused-ultrasound-systems","kind":"technology","name":"Transcranial focused ultrasound systems (Exablate Neuro, SonoCloud)","route":"/technologies/transcranial-focused-ultrasound-systems/","asOf":"2026-09-17","days":11},{"id":"electrochemotherapy-devices","kind":"technology","name":"Electrochemotherapy devices (Cliniporator)","route":"/technologies/electrochemotherapy-devices/","asOf":"2026-09-17","days":11},{"id":"hipec-pipac-devices","kind":"technology","name":"HIPEC perfusion pumps and PIPAC nebulisers","route":"/technologies/hipec-pipac-devices/","asOf":"2026-09-17","days":11},{"id":"intraoperative-fluorescence-imaging-systems","kind":"technology","name":"Intraoperative fluorescence and Cerenkov imaging systems (SPY, Firefly, LumiSystem, LightPath)","route":"/technologies/intraoperative-fluorescence-imaging-systems/","asOf":"2026-09-17","days":11},{"id":"gamma-probes-dose-calibrators","kind":"technology","name":"Gamma probes, handheld gamma cameras and dose calibrators","route":"/technologies/gamma-probes-dose-calibrators/","asOf":"2026-09-17","days":11},{"id":"endoscopic-ultrasound-systems","kind":"technology","name":"Endoscopic ultrasound and EBUS systems","route":"/technologies/endoscopic-ultrasound-systems/","asOf":"2026-09-17","days":11},{"id":"capsule-endoscopy-systems","kind":"technology","name":"Capsule endoscopy (PillCam, EndoCapsule, CapsoCam)","route":"/technologies/capsule-endoscopy-systems/","asOf":"2026-09-17","days":11},{"id":"colposcopes-digital-cervical-screening","kind":"technology","name":"Colposcopes and digital cervical screening devices (DYSIS, EVA System, AVE)","route":"/technologies/colposcopes-digital-cervical-screening/","asOf":"2026-09-17","days":11},{"id":"confocal-oct-skin-imaging","kind":"technology","name":"Confocal microscopy and optical coherence tomography for skin (VivaScope, VivoSight, deepLive)","route":"/technologies/confocal-oct-skin-imaging/","asOf":"2026-09-17","days":11},{"id":"contrast-enhanced-mammography","kind":"technology","name":"Contrast-enhanced mammography","route":"/technologies/contrast-enhanced-mammography/","asOf":"2026-09-17","days":11},{"id":"breast-mri-coils-abbreviated-mri","kind":"technology","name":"Breast MRI coils and abbreviated breast MRI","route":"/technologies/breast-mri-coils-abbreviated-mri/","asOf":"2026-09-17","days":11},{"id":"closed-system-transfer-devices","kind":"technology","name":"Closed-system transfer devices for hazardous drugs (PhaSeal, ChemoLock, Equashield)","route":"/technologies/closed-system-transfer-devices/","asOf":"2026-09-17","days":11},{"id":"stella-pharma","kind":"company","name":"Stella Pharma","route":"/companies/stella-pharma/","asOf":"2026-09-17","days":11},{"id":"neuboron-medtech","kind":"company","name":"Neuboron Medtech","route":"/companies/neuboron-medtech/","asOf":"2026-09-17","days":11},{"id":"pyrexar-medical","kind":"company","name":"Pyrexar Medical","route":"/companies/pyrexar-medical/","asOf":"2026-09-17","days":11},{"id":"oncotherm","kind":"company","name":"Oncotherm","route":"/companies/oncotherm/","asOf":"2026-09-17","days":11},{"id":"modulight","kind":"company","name":"Modulight","route":"/companies/modulight/","asOf":"2026-09-17","days":11},{"id":"carthera","kind":"company","name":"Carthera","route":"/companies/carthera/","asOf":"2026-09-17","days":11},{"id":"igea","kind":"company","name":"IGEA","route":"/companies/igea/","asOf":"2026-09-17","days":11},{"id":"belmont-medical-technologies","kind":"company","name":"Belmont Medical Technologies","route":"/companies/belmont-medical-technologies/","asOf":"2026-09-17","days":11},{"id":"capnomed","kind":"company","name":"Capnomed (Reger Medizintechnik)","route":"/companies/capnomed/","asOf":"2026-09-17","days":11},{"id":"stryker","kind":"company","name":"Stryker","route":"/companies/stryker/","asOf":"2026-09-17","days":11},{"id":"karl-storz","kind":"company","name":"Karl Storz","route":"/companies/karl-storz/","asOf":"2026-09-17","days":11},{"id":"olympus","kind":"company","name":"Olympus","route":"/companies/olympus/","asOf":"2026-09-17","days":11},{"id":"pentax-medical","kind":"company","name":"Pentax Medical (HOYA)","route":"/companies/pentax-medical/","asOf":"2026-09-17","days":11},{"id":"cook-medical","kind":"company","name":"Cook Medical","route":"/companies/cook-medical/","asOf":"2026-09-17","days":11},{"id":"capsovision","kind":"company","name":"CapsoVision","route":"/companies/capsovision/","asOf":"2026-09-17","days":11},{"id":"lightpoint-medical","kind":"company","name":"Lightpoint Medical","route":"/companies/lightpoint-medical/","asOf":"2026-09-17","days":11},{"id":"mammotome","kind":"company","name":"Mammotome (Danaher)","route":"/companies/mammotome/","asOf":"2026-09-17","days":11},{"id":"dysis-medical","kind":"company","name":"DYSIS Medical","route":"/companies/dysis-medical/","asOf":"2026-09-17","days":11},{"id":"mobileodt","kind":"company","name":"MobileODT","route":"/companies/mobileodt/","asOf":"2026-09-17","days":11},{"id":"canfield-scientific","kind":"company","name":"Canfield Scientific","route":"/companies/canfield-scientific/","asOf":"2026-09-17","days":11},{"id":"fotofinder","kind":"company","name":"FotoFinder Systems","route":"/companies/fotofinder/","asOf":"2026-09-17","days":11},{"id":"caliber-imaging-diagnostics","kind":"company","name":"Caliber Imaging and Diagnostics","route":"/companies/caliber-imaging-diagnostics/","asOf":"2026-09-17","days":11},{"id":"michelson-diagnostics","kind":"company","name":"Michelson Diagnostics","route":"/companies/michelson-diagnostics/","asOf":"2026-09-17","days":11},{"id":"damae-medical","kind":"company","name":"DAMAE Medical","route":"/companies/damae-medical/","asOf":"2026-09-17","days":11},{"id":"vision-rt","kind":"company","name":"Vision RT","route":"/companies/vision-rt/","asOf":"2026-09-17","days":11},{"id":"c-rad","kind":"company","name":"C-RAD","route":"/companies/c-rad/","asOf":"2026-09-17","days":11},{"id":"ptw-freiburg","kind":"company","name":"PTW Freiburg","route":"/companies/ptw-freiburg/","asOf":"2026-09-17","days":11},{"id":"standard-imaging","kind":"company","name":"Standard Imaging","route":"/companies/standard-imaging/","asOf":"2026-09-17","days":11},{"id":"icu-medical","kind":"company","name":"ICU Medical","route":"/companies/icu-medical/","asOf":"2026-09-17","days":11},{"id":"equashield","kind":"company","name":"Equashield","route":"/companies/equashield/","asOf":"2026-09-17","days":11},{"id":"loccioni","kind":"company","name":"Loccioni","route":"/companies/loccioni/","asOf":"2026-09-17","days":11},{"id":"paxman","kind":"company","name":"Paxman","route":"/companies/paxman/","asOf":"2026-09-17","days":11},{"id":"dignitana","kind":"company","name":"Dignitana","route":"/companies/dignitana/","asOf":"2026-09-17","days":11},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/","asOf":"2026-09-17","days":11},{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/","asOf":"2026-09-17","days":11},{"id":"braf-v600e-colorectal","kind":"cancer","name":"BRAF V600E-mutant colorectal cancer","route":"/cancers/braf-v600e-colorectal/","asOf":"2026-09-17","days":11},{"id":"her2-amplified-colorectal","kind":"cancer","name":"HER2-amplified colorectal cancer","route":"/cancers/her2-amplified-colorectal/","asOf":"2026-09-17","days":11},{"id":"kras-g12c-colorectal","kind":"cancer","name":"KRAS G12C-mutant colorectal cancer","route":"/cancers/kras-g12c-colorectal/","asOf":"2026-09-17","days":11},{"id":"early-onset-colorectal","kind":"cancer","name":"Early-onset colorectal cancer (under 50)","route":"/cancers/early-onset-colorectal/","asOf":"2026-09-17","days":11},{"id":"primary-mediastinal-b-cell-lymphoma","kind":"cancer","name":"Primary mediastinal (thymic) large B-cell lymphoma","route":"/cancers/primary-mediastinal-b-cell-lymphoma/","asOf":"2026-09-17","days":11},{"id":"opra","kind":"trial","name":"OPRA","route":"/trials/opra/","asOf":"2026-09-17","days":11},{"id":"prospect","kind":"trial","name":"PROSPECT (Alliance N1048)","route":"/trials/prospect/","asOf":"2026-09-17","days":11},{"id":"beacon-crc","kind":"trial","name":"BEACON CRC","route":"/trials/beacon-crc/","asOf":"2026-09-17","days":11},{"id":"keynote-170","kind":"trial","name":"KEYNOTE-170","route":"/trials/keynote-170/","asOf":"2026-09-17","days":11},{"id":"ielsg37","kind":"trial","name":"IELSG37","route":"/trials/ielsg37/","asOf":"2026-09-17","days":11},{"id":"gastric-her2-positive","kind":"cancer","name":"HER2-positive gastric cancer","route":"/cancers/gastric-her2-positive/","asOf":"2026-09-17","days":11},{"id":"gastric-cldn18-2-positive","kind":"cancer","name":"Claudin 18.2-positive gastric cancer","route":"/cancers/gastric-cldn18-2-positive/","asOf":"2026-09-17","days":11},{"id":"gastric-pdl1-high","kind":"cancer","name":"PD-L1-high gastric cancer","route":"/cancers/gastric-pdl1-high/","asOf":"2026-09-17","days":11},{"id":"gastric-msi-high","kind":"cancer","name":"Microsatellite-unstable (MSI-high) gastric cancer","route":"/cancers/gastric-msi-high/","asOf":"2026-09-17","days":11},{"id":"early-gastric-cancer","kind":"cancer","name":"Early gastric cancer","route":"/cancers/early-gastric-cancer/","asOf":"2026-09-17","days":11},{"id":"hcc-early","kind":"cancer","name":"Early hepatocellular carcinoma (BCLC 0 and A)","route":"/cancers/hcc-early/","asOf":"2026-09-17","days":11},{"id":"hcc-intermediate","kind":"cancer","name":"Intermediate hepatocellular carcinoma (BCLC B)","route":"/cancers/hcc-intermediate/","asOf":"2026-09-17","days":11},{"id":"hcc-advanced","kind":"cancer","name":"Advanced hepatocellular carcinoma (BCLC C)","route":"/cancers/hcc-advanced/","asOf":"2026-09-17","days":11},{"id":"intrahepatic-cholangiocarcinoma","kind":"cancer","name":"Intrahepatic cholangiocarcinoma","route":"/cancers/intrahepatic-cholangiocarcinoma/","asOf":"2026-09-17","days":11},{"id":"extrahepatic-cholangiocarcinoma","kind":"cancer","name":"Extrahepatic cholangiocarcinoma (perihilar and distal)","route":"/cancers/extrahepatic-cholangiocarcinoma/","asOf":"2026-09-17","days":11},{"id":"gist-kit-exon-11","kind":"cancer","name":"KIT exon 11-mutant GIST","route":"/cancers/gist-kit-exon-11/","asOf":"2026-09-17","days":11},{"id":"gist-pdgfra-d842v","kind":"cancer","name":"PDGFRA D842V-mutant GIST","route":"/cancers/gist-pdgfra-d842v/","asOf":"2026-09-17","days":11},{"id":"gist-imatinib-resistant","kind":"cancer","name":"Imatinib-resistant GIST","route":"/cancers/gist-imatinib-resistant/","asOf":"2026-09-17","days":11},{"id":"aml-flt3","kind":"cancer","name":"FLT3-mutated acute myeloid leukaemia","route":"/cancers/aml-flt3/","asOf":"2026-09-17","days":11},{"id":"aml-idh","kind":"cancer","name":"IDH1- and IDH2-mutated acute myeloid leukaemia","route":"/cancers/aml-idh/","asOf":"2026-09-17","days":11},{"id":"aml-npm1-kmt2a","kind":"cancer","name":"NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia","route":"/cancers/aml-npm1-kmt2a/","asOf":"2026-09-17","days":11},{"id":"aml-secondary","kind":"cancer","name":"Secondary and therapy-related acute myeloid leukaemia","route":"/cancers/aml-secondary/","asOf":"2026-09-17","days":11},{"id":"apl","kind":"cancer","name":"Acute promyelocytic leukaemia","route":"/cancers/apl/","asOf":"2026-09-17","days":11},{"id":"aml-older-unfit","kind":"cancer","name":"Acute myeloid leukaemia in older or unfit patients","route":"/cancers/aml-older-unfit/","asOf":"2026-09-17","days":11},{"id":"smouldering-myeloma","kind":"cancer","name":"Smouldering multiple myeloma","route":"/cancers/smouldering-myeloma/","asOf":"2026-09-17","days":11},{"id":"myeloma-transplant-eligible","kind":"cancer","name":"Newly diagnosed multiple myeloma, transplant-eligible","route":"/cancers/myeloma-transplant-eligible/","asOf":"2026-09-17","days":11},{"id":"myeloma-transplant-ineligible","kind":"cancer","name":"Newly diagnosed multiple myeloma, transplant-ineligible","route":"/cancers/myeloma-transplant-ineligible/","asOf":"2026-09-17","days":11},{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/","asOf":"2026-09-17","days":11},{"id":"plasma-cell-leukaemia","kind":"cancer","name":"Plasma cell leukaemia","route":"/cancers/plasma-cell-leukaemia/","asOf":"2026-09-17","days":11},{"id":"mds-lower-risk","kind":"cancer","name":"Lower-risk myelodysplastic syndromes","route":"/cancers/mds-lower-risk/","asOf":"2026-09-17","days":11},{"id":"mds-higher-risk","kind":"cancer","name":"Higher-risk myelodysplastic syndromes","route":"/cancers/mds-higher-risk/","asOf":"2026-09-17","days":11},{"id":"cll-treatment-naive","kind":"cancer","name":"Chronic lymphocytic leukaemia, first treatment","route":"/cancers/cll-treatment-naive/","asOf":"2026-09-17","days":11},{"id":"cll-relapsed","kind":"cancer","name":"Relapsed or refractory chronic lymphocytic leukaemia","route":"/cancers/cll-relapsed/","asOf":"2026-09-17","days":11},{"id":"richter-transformation-cll","kind":"cancer","name":"Richter transformation of chronic lymphocytic leukaemia","route":"/cancers/richter-transformation-cll/","asOf":"2026-09-17","days":11},{"id":"cml-chronic-phase","kind":"cancer","name":"Chronic myeloid leukaemia, chronic phase","route":"/cancers/cml-chronic-phase/","asOf":"2026-09-17","days":11},{"id":"cml-advanced-phase","kind":"cancer","name":"Chronic myeloid leukaemia, accelerated and blast phase","route":"/cancers/cml-advanced-phase/","asOf":"2026-09-17","days":11},{"id":"primary-myelofibrosis","kind":"cancer","name":"Primary myelofibrosis","route":"/cancers/primary-myelofibrosis/","asOf":"2026-09-17","days":11},{"id":"endometrial-pole-ultramutated","kind":"cancer","name":"POLE-ultramutated endometrial cancer","route":"/cancers/endometrial-pole-ultramutated/","asOf":"2026-09-17","days":11},{"id":"endometrial-mmr-deficient","kind":"cancer","name":"Mismatch-repair-deficient endometrial cancer","route":"/cancers/endometrial-mmr-deficient/","asOf":"2026-09-17","days":11},{"id":"endometrial-p53-abnormal","kind":"cancer","name":"p53-abnormal endometrial cancer, including uterine serous carcinoma","route":"/cancers/endometrial-p53-abnormal/","asOf":"2026-09-17","days":11},{"id":"endometrial-nsmp","kind":"cancer","name":"Endometrial cancer with no specific molecular profile","route":"/cancers/endometrial-nsmp/","asOf":"2026-09-17","days":11},{"id":"advanced-recurrent-endometrial-cancer","kind":"cancer","name":"Advanced or recurrent endometrial cancer","route":"/cancers/advanced-recurrent-endometrial-cancer/","asOf":"2026-09-17","days":11},{"id":"uterine-carcinosarcoma","kind":"cancer","name":"Uterine carcinosarcoma","route":"/cancers/uterine-carcinosarcoma/","asOf":"2026-09-17","days":11},{"id":"early-cervical-cancer","kind":"cancer","name":"Early cervical cancer and fertility-sparing surgery","route":"/cancers/early-cervical-cancer/","asOf":"2026-09-17","days":11},{"id":"locally-advanced-cervical-cancer","kind":"cancer","name":"Locally advanced cervical cancer","route":"/cancers/locally-advanced-cervical-cancer/","asOf":"2026-09-17","days":11},{"id":"recurrent-metastatic-cervical-cancer","kind":"cancer","name":"Recurrent or metastatic cervical cancer","route":"/cancers/recurrent-metastatic-cervical-cancer/","asOf":"2026-09-17","days":11},{"id":"platinum-sensitive-ovarian-cancer","kind":"cancer","name":"Platinum-sensitive ovarian cancer","route":"/cancers/platinum-sensitive-ovarian-cancer/","asOf":"2026-09-17","days":11},{"id":"platinum-resistant-ovarian-cancer","kind":"cancer","name":"Platinum-resistant ovarian cancer","route":"/cancers/platinum-resistant-ovarian-cancer/","asOf":"2026-09-17","days":11},{"id":"braf-v600-melanoma","kind":"cancer","name":"BRAF V600-mutant melanoma","route":"/cancers/braf-v600-melanoma/","asOf":"2026-09-17","days":11},{"id":"stage-iii-melanoma","kind":"cancer","name":"Stage III melanoma (after surgery)","route":"/cancers/stage-iii-melanoma/","asOf":"2026-09-17","days":11},{"id":"stage-ii-melanoma","kind":"cancer","name":"Stage IIB and IIC melanoma","route":"/cancers/stage-ii-melanoma/","asOf":"2026-09-17","days":11},{"id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/","asOf":"2026-09-17","days":11},{"id":"mucosal-melanoma","kind":"cancer","name":"Mucosal melanoma","route":"/cancers/mucosal-melanoma/","asOf":"2026-09-17","days":11},{"id":"acral-melanoma","kind":"cancer","name":"Acral melanoma","route":"/cancers/acral-melanoma/","asOf":"2026-09-17","days":11},{"id":"dermatofibrosarcoma-protuberans","kind":"cancer","name":"Dermatofibrosarcoma protuberans","route":"/cancers/dermatofibrosarcoma-protuberans/","asOf":"2026-09-17","days":11},{"id":"combi-d","kind":"trial","name":"COMBI-d","route":"/trials/combi-d/","asOf":"2026-09-17","days":11},{"id":"cobrim","kind":"trial","name":"coBRIM","route":"/trials/cobrim/","asOf":"2026-09-17","days":11},{"id":"checkmate-238","kind":"trial","name":"CheckMate 238","route":"/trials/checkmate-238/","asOf":"2026-09-17","days":11},{"id":"checkmate-204","kind":"trial","name":"CheckMate 204","route":"/trials/checkmate-204/","asOf":"2026-09-17","days":11},{"id":"empower-cscc-1","kind":"trial","name":"EMPOWER-CSCC-1","route":"/trials/empower-cscc-1/","asOf":"2026-09-17","days":11},{"id":"keynote-629","kind":"trial","name":"KEYNOTE-629","route":"/trials/keynote-629/","asOf":"2026-09-17","days":11},{"id":"erivance","kind":"trial","name":"ERIVANCE BCC","route":"/trials/erivance/","asOf":"2026-09-17","days":11},{"id":"bolt","kind":"trial","name":"BOLT","route":"/trials/bolt/","asOf":"2026-09-17","days":11},{"id":"javelin-merkel-200","kind":"trial","name":"JAVELIN Merkel 200","route":"/trials/javelin-merkel-200/","asOf":"2026-09-17","days":11},{"id":"keynote-017","kind":"trial","name":"KEYNOTE-017 (Cancer Immunotherapy Trials Network 09)","route":"/trials/keynote-017/","asOf":"2026-09-17","days":11},{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/","asOf":"2026-09-17","days":11},{"id":"alk-positive-nsclc","kind":"cancer","name":"ALK-positive non-small-cell lung cancer","route":"/cancers/alk-positive-nsclc/","asOf":"2026-09-17","days":11},{"id":"kras-g12c-nsclc","kind":"cancer","name":"KRAS G12C-mutant non-small-cell lung cancer","route":"/cancers/kras-g12c-nsclc/","asOf":"2026-09-17","days":11},{"id":"ros1-positive-nsclc","kind":"cancer","name":"ROS1-positive non-small-cell lung cancer","route":"/cancers/ros1-positive-nsclc/","asOf":"2026-09-17","days":11},{"id":"met-altered-nsclc","kind":"cancer","name":"MET exon 14 and MET-amplified non-small-cell lung cancer","route":"/cancers/met-altered-nsclc/","asOf":"2026-09-17","days":11},{"id":"ret-fusion-nsclc","kind":"cancer","name":"RET fusion-positive non-small-cell lung cancer","route":"/cancers/ret-fusion-nsclc/","asOf":"2026-09-17","days":11},{"id":"braf-v600e-nsclc","kind":"cancer","name":"BRAF V600E-mutant non-small-cell lung cancer","route":"/cancers/braf-v600e-nsclc/","asOf":"2026-09-17","days":11},{"id":"her2-mutant-nsclc","kind":"cancer","name":"HER2-mutant non-small-cell lung cancer","route":"/cancers/her2-mutant-nsclc/","asOf":"2026-09-17","days":11},{"id":"ntrk-fusion-nsclc","kind":"cancer","name":"NTRK fusion-positive non-small-cell lung cancer","route":"/cancers/ntrk-fusion-nsclc/","asOf":"2026-09-17","days":11},{"id":"pdl1-high-nsclc","kind":"cancer","name":"PD-L1-high non-small-cell lung cancer without a driver mutation","route":"/cancers/pdl1-high-nsclc/","asOf":"2026-09-17","days":11},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/","asOf":"2026-09-17","days":11},{"id":"stage-iii-unresectable-nsclc","kind":"cancer","name":"Unresectable stage III non-small-cell lung cancer","route":"/cancers/stage-iii-unresectable-nsclc/","asOf":"2026-09-17","days":11},{"id":"limited-stage-sclc","kind":"cancer","name":"Limited-stage small-cell lung cancer","route":"/cancers/limited-stage-sclc/","asOf":"2026-09-17","days":11},{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/","asOf":"2026-09-17","days":11},{"id":"flaura","kind":"trial","name":"FLAURA","route":"/trials/flaura/","asOf":"2026-09-17","days":11},{"id":"alex","kind":"trial","name":"ALEX","route":"/trials/alex/","asOf":"2026-09-17","days":11},{"id":"alta-1l","kind":"trial","name":"ALTA-1L","route":"/trials/alta-1l/","asOf":"2026-09-17","days":11},{"id":"keynote-042","kind":"trial","name":"KEYNOTE-042","route":"/trials/keynote-042/","asOf":"2026-09-17","days":11},{"id":"empower-lung-1","kind":"trial","name":"EMPOWER-Lung 1","route":"/trials/empower-lung-1/","asOf":"2026-09-17","days":11},{"id":"geometry-mono-1","kind":"trial","name":"GEOMETRY mono-1","route":"/trials/geometry-mono-1/","asOf":"2026-09-17","days":11},{"id":"pharos","kind":"trial","name":"PHAROS","route":"/trials/pharos/","asOf":"2026-09-17","days":11},{"id":"destiny-lung02","kind":"trial","name":"DESTINY-Lung02","route":"/trials/destiny-lung02/","asOf":"2026-09-17","days":11},{"id":"beamion-lung-1","kind":"trial","name":"Beamion LUNG-1","route":"/trials/beamion-lung-1/","asOf":"2026-09-17","days":11},{"id":"calgb-140503","kind":"trial","name":"CALGB 140503 (Alliance)","route":"/trials/calgb-140503/","asOf":"2026-09-17","days":11},{"id":"hr-positive-early-high-risk","kind":"cancer","name":"High-risk early HR-positive breast cancer","route":"/cancers/hr-positive-early-high-risk/","asOf":"2026-09-17","days":11},{"id":"hr-positive-metastatic-post-cdk46","kind":"cancer","name":"HR-positive metastatic breast cancer after CDK4/6 inhibitors","route":"/cancers/hr-positive-metastatic-post-cdk46/","asOf":"2026-09-17","days":11},{"id":"her2-low-metastatic-breast-cancer","kind":"cancer","name":"HER2-low and HER2-ultralow metastatic breast cancer","route":"/cancers/her2-low-metastatic-breast-cancer/","asOf":"2026-09-17","days":11},{"id":"her2-positive-early-breast-cancer","kind":"cancer","name":"Early HER2-positive breast cancer","route":"/cancers/her2-positive-early-breast-cancer/","asOf":"2026-09-17","days":11},{"id":"her2-positive-breast-brain-metastases","kind":"cancer","name":"HER2-positive breast cancer with brain metastases","route":"/cancers/her2-positive-breast-brain-metastases/","asOf":"2026-09-17","days":11},{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/","asOf":"2026-09-17","days":11},{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/","asOf":"2026-09-17","days":11},{"id":"inflammatory-breast-cancer","kind":"cancer","name":"Inflammatory breast cancer","route":"/cancers/inflammatory-breast-cancer/","asOf":"2026-09-17","days":11},{"id":"paget-disease-of-the-nipple","kind":"cancer","name":"Paget disease of the nipple","route":"/cancers/paget-disease-of-the-nipple/","asOf":"2026-09-17","days":11},{"id":"phyllodes-tumour","kind":"cancer","name":"Phyllodes tumour of the breast","route":"/cancers/phyllodes-tumour/","asOf":"2026-09-17","days":11},{"id":"train-2","kind":"trial","name":"TRAIN-2","route":"/trials/train-2/","asOf":"2026-09-17","days":11},{"id":"kristine","kind":"trial","name":"KRISTINE","route":"/trials/kristine/","asOf":"2026-09-17","days":11},{"id":"olympiad","kind":"trial","name":"OlympiAD","route":"/trials/olympiad/","asOf":"2026-09-17","days":11},{"id":"embraca","kind":"trial","name":"EMBRACA","route":"/trials/embraca/","asOf":"2026-09-17","days":11},{"id":"impassion031","kind":"trial","name":"IMpassion031","route":"/trials/impassion031/","asOf":"2026-09-17","days":11},{"id":"chondrosarcoma","kind":"cancer","name":"Chondrosarcoma","route":"/cancers/chondrosarcoma/","asOf":"2026-09-17","days":11},{"id":"angiosarcoma","kind":"cancer","name":"Angiosarcoma","route":"/cancers/angiosarcoma/","asOf":"2026-09-17","days":11},{"id":"undifferentiated-pleomorphic-sarcoma","kind":"cancer","name":"Undifferentiated pleomorphic sarcoma (UPS)","route":"/cancers/undifferentiated-pleomorphic-sarcoma/","asOf":"2026-09-17","days":11},{"id":"myxofibrosarcoma","kind":"cancer","name":"Myxofibrosarcoma","route":"/cancers/myxofibrosarcoma/","asOf":"2026-09-17","days":11},{"id":"alveolar-soft-part-sarcoma","kind":"cancer","name":"Alveolar soft part sarcoma","route":"/cancers/alveolar-soft-part-sarcoma/","asOf":"2026-09-17","days":11},{"id":"pecoma","kind":"cancer","name":"Perivascular epithelioid cell tumour (PEComa)","route":"/cancers/pecoma/","asOf":"2026-09-17","days":11},{"id":"epithelioid-haemangioendothelioma","kind":"cancer","name":"Epithelioid haemangioendothelioma","route":"/cancers/epithelioid-haemangioendothelioma/","asOf":"2026-09-17","days":11},{"id":"malignant-peripheral-nerve-sheath-tumour","kind":"cancer","name":"Malignant peripheral nerve sheath tumour (MPNST)","route":"/cancers/malignant-peripheral-nerve-sheath-tumour/","asOf":"2026-09-17","days":11},{"id":"retroperitoneal-sarcoma","kind":"cancer","name":"Retroperitoneal sarcoma","route":"/cancers/retroperitoneal-sarcoma/","asOf":"2026-09-17","days":11},{"id":"extremity-soft-tissue-sarcoma","kind":"cancer","name":"Soft tissue sarcoma of the extremity (localised and advanced)","route":"/cancers/extremity-soft-tissue-sarcoma/","asOf":"2026-09-17","days":11},{"id":"strass","kind":"trial","name":"STRASS (EORTC 62092)","route":"/trials/strass/","asOf":"2026-09-17","days":11},{"id":"eortc-62012","kind":"trial","name":"EORTC 62012","route":"/trials/eortc-62012/","asOf":"2026-09-17","days":11},{"id":"lms-04","kind":"trial","name":"LMS-04","route":"/trials/lms-04/","asOf":"2026-09-17","days":11},{"id":"angiotax","kind":"trial","name":"ANGIOTAX","route":"/trials/angiotax/","asOf":"2026-09-17","days":11},{"id":"enliven","kind":"trial","name":"ENLIVEN","route":"/trials/enliven/","asOf":"2026-09-17","days":11},{"id":"ampect","kind":"trial","name":"AMPECT","route":"/trials/ampect/","asOf":"2026-09-17","days":11},{"id":"all-paediatric-standard-risk","kind":"cancer","name":"Standard-risk B-cell acute lymphoblastic leukaemia in children","route":"/cancers/all-paediatric-standard-risk/","asOf":"2026-09-17","days":11},{"id":"all-paediatric-high-risk","kind":"cancer","name":"High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL)","route":"/cancers/all-paediatric-high-risk/","asOf":"2026-09-17","days":11},{"id":"all-paediatric-ph-positive","kind":"cancer","name":"Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL)","route":"/cancers/all-paediatric-ph-positive/","asOf":"2026-09-17","days":11},{"id":"all-ph-like","kind":"cancer","name":"Philadelphia chromosome-like acute lymphoblastic leukaemia (Ph-like or BCR::ABL1-like ALL)","route":"/cancers/all-ph-like/","asOf":"2026-09-17","days":11},{"id":"all-infant","kind":"cancer","name":"Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year)","route":"/cancers/all-infant/","asOf":"2026-09-17","days":11},{"id":"all-paediatric-relapsed","kind":"cancer","name":"Relapsed and refractory acute lymphoblastic leukaemia in children","route":"/cancers/all-paediatric-relapsed/","asOf":"2026-09-17","days":11},{"id":"aml-paediatric","kind":"cancer","name":"Acute myeloid leukaemia in children","route":"/cancers/aml-paediatric/","asOf":"2026-09-17","days":11},{"id":"neuroblastoma-low-risk","kind":"cancer","name":"Low-risk neuroblastoma (INRG very low and low risk, including stage MS)","route":"/cancers/neuroblastoma-low-risk/","asOf":"2026-09-17","days":11},{"id":"neuroblastoma-intermediate-risk","kind":"cancer","name":"Intermediate-risk neuroblastoma","route":"/cancers/neuroblastoma-intermediate-risk/","asOf":"2026-09-17","days":11},{"id":"neuroblastoma-high-risk","kind":"cancer","name":"High-risk neuroblastoma","route":"/cancers/neuroblastoma-high-risk/","asOf":"2026-09-17","days":11},{"id":"medulloblastoma-wnt","kind":"cancer","name":"WNT-activated medulloblastoma","route":"/cancers/medulloblastoma-wnt/","asOf":"2026-09-17","days":11},{"id":"medulloblastoma-shh","kind":"cancer","name":"SHH-activated medulloblastoma","route":"/cancers/medulloblastoma-shh/","asOf":"2026-09-17","days":11},{"id":"medulloblastoma-group-3-4","kind":"cancer","name":"Group 3 and group 4 medulloblastoma (non-WNT/non-SHH)","route":"/cancers/medulloblastoma-group-3-4/","asOf":"2026-09-17","days":11},{"id":"aya-cancers","kind":"cancer","name":"Adolescent and young adult cancers (ages 15 to 39)","route":"/cancers/aya-cancers/","asOf":"2026-09-17","days":11},{"id":"small-intestinal-net","kind":"cancer","name":"Small intestinal neuroendocrine tumours","route":"/cancers/small-intestinal-net/","asOf":"2026-09-17","days":11},{"id":"pancreatic-net","kind":"cancer","name":"Pancreatic neuroendocrine tumours","route":"/cancers/pancreatic-net/","asOf":"2026-09-17","days":11},{"id":"lung-net","kind":"cancer","name":"Lung neuroendocrine tumours (typical and atypical carcinoid)","route":"/cancers/lung-net/","asOf":"2026-09-17","days":11},{"id":"extrapulmonary-nec","kind":"cancer","name":"Extrapulmonary neuroendocrine carcinoma","route":"/cancers/extrapulmonary-nec/","asOf":"2026-09-17","days":11},{"id":"grade-3-net","kind":"cancer","name":"Grade 3 well-differentiated neuroendocrine tumour","route":"/cancers/grade-3-net/","asOf":"2026-09-17","days":11},{"id":"hpv-positive-oropharyngeal-cancer","kind":"cancer","name":"HPV-positive oropharyngeal cancer","route":"/cancers/hpv-positive-oropharyngeal-cancer/","asOf":"2026-09-17","days":11},{"id":"hpv-negative-head-and-neck-cancer","kind":"cancer","name":"HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)","route":"/cancers/hpv-negative-head-and-neck-cancer/","asOf":"2026-09-17","days":11},{"id":"recurrent-metastatic-hnscc","kind":"cancer","name":"Recurrent or metastatic head and neck squamous cell carcinoma","route":"/cancers/recurrent-metastatic-hnscc/","asOf":"2026-09-17","days":11},{"id":"hypopharyngeal-cancer","kind":"cancer","name":"Hypopharyngeal cancer","route":"/cancers/hypopharyngeal-cancer/","asOf":"2026-09-17","days":11},{"id":"adenoid-cystic-carcinoma","kind":"cancer","name":"Adenoid cystic carcinoma","route":"/cancers/adenoid-cystic-carcinoma/","asOf":"2026-09-17","days":11},{"id":"salivary-duct-carcinoma","kind":"cancer","name":"Salivary duct carcinoma","route":"/cancers/salivary-duct-carcinoma/","asOf":"2026-09-17","days":11},{"id":"mucoepidermoid-carcinoma","kind":"cancer","name":"Mucoepidermoid carcinoma","route":"/cancers/mucoepidermoid-carcinoma/","asOf":"2026-09-17","days":11},{"id":"oral-tongue-cancer","kind":"cancer","name":"Oral tongue and floor of mouth cancer","route":"/cancers/oral-tongue-cancer/","asOf":"2026-09-17","days":11},{"id":"buccal-mucosa-cancer","kind":"cancer","name":"Buccal mucosa and gingivobuccal cancer (oral cancer in India)","route":"/cancers/buccal-mucosa-cancer/","asOf":"2026-09-17","days":11},{"id":"lip-cancer","kind":"cancer","name":"Lip cancer","route":"/cancers/lip-cancer/","asOf":"2026-09-17","days":11},{"id":"nivopostop","kind":"trial","name":"NIVOPOSTOP (GORTEC 2018-01)","route":"/trials/nivopostop/","asOf":"2026-09-17","days":11},{"id":"ecog-e3311","kind":"trial","name":"ECOG-ACRIN E3311","route":"/trials/ecog-e3311/","asOf":"2026-09-17","days":11},{"id":"pathos","kind":"trial","name":"PATHOS","route":"/trials/pathos/","asOf":"2026-09-17","days":11},{"id":"captain-1st","kind":"trial","name":"CAPTAIN-1st","route":"/trials/captain-1st/","asOf":"2026-09-17","days":11},{"id":"checkmate-227","kind":"trial","name":"CheckMate 227","route":"/trials/checkmate-227/","asOf":"2026-09-17","days":11},{"id":"keynote-407","kind":"trial","name":"KEYNOTE-407","route":"/trials/keynote-407/","asOf":"2026-09-17","days":11},{"id":"destiny-lung01","kind":"trial","name":"DESTINY-Lung01","route":"/trials/destiny-lung01/","asOf":"2026-09-17","days":11},{"id":"pacific-2","kind":"trial","name":"PACIFIC-2","route":"/trials/pacific-2/","asOf":"2026-09-17","days":11},{"id":"chrysalis","kind":"trial","name":"CHRYSALIS","route":"/trials/chrysalis/","asOf":"2026-09-17","days":11},{"id":"destiny-gastric01","kind":"trial","name":"DESTINY-Gastric01","route":"/trials/destiny-gastric01/","asOf":"2026-09-17","days":11},{"id":"destiny-gastric02","kind":"trial","name":"DESTINY-Gastric02","route":"/trials/destiny-gastric02/","asOf":"2026-09-17","days":11},{"id":"keynote-811","kind":"trial","name":"KEYNOTE-811","route":"/trials/keynote-811/","asOf":"2026-09-17","days":11},{"id":"keynote-062","kind":"trial","name":"KEYNOTE-062","route":"/trials/keynote-062/","asOf":"2026-09-17","days":11},{"id":"flot4","kind":"trial","name":"FLOT4-AIO","route":"/trials/flot4/","asOf":"2026-09-17","days":11},{"id":"esopec","kind":"trial","name":"ESOPEC","route":"/trials/esopec/","asOf":"2026-09-17","days":11},{"id":"abc-06","kind":"trial","name":"ABC-06","route":"/trials/abc-06/","asOf":"2026-09-17","days":11},{"id":"reach-2","kind":"trial","name":"REACH-2","route":"/trials/reach-2/","asOf":"2026-09-17","days":11},{"id":"heracles","kind":"trial","name":"HERACLES","route":"/trials/heracles/","asOf":"2026-09-17","days":11},{"id":"spinet","kind":"trial","name":"SPINET","route":"/trials/spinet/","asOf":"2026-09-17","days":11},{"id":"ifm-2009","kind":"trial","name":"IFM 2009","route":"/trials/ifm-2009/","asOf":"2026-09-17","days":11},{"id":"cassiopeia","kind":"trial","name":"CASSIOPEIA","route":"/trials/cassiopeia/","asOf":"2026-09-17","days":11},{"id":"cartitude-6","kind":"trial","name":"CARTITUDE-6","route":"/trials/cartitude-6/","asOf":"2026-09-17","days":11},{"id":"apl0406","kind":"trial","name":"APL0406","route":"/trials/apl0406/","asOf":"2026-09-17","days":11},{"id":"commands","kind":"trial","name":"COMMANDS","route":"/trials/commands/","asOf":"2026-09-17","days":11},{"id":"medalist","kind":"trial","name":"MEDALIST","route":"/trials/medalist/","asOf":"2026-09-17","days":11},{"id":"imerge","kind":"trial","name":"IMerge","route":"/trials/imerge/","asOf":"2026-09-17","days":11},{"id":"verona","kind":"trial","name":"VERONA","route":"/trials/verona/","asOf":"2026-09-17","days":11},{"id":"momentum","kind":"trial","name":"MOMENTUM","route":"/trials/momentum/","asOf":"2026-09-17","days":11},{"id":"manifest-2","kind":"trial","name":"MANIFEST-2","route":"/trials/manifest-2/","asOf":"2026-09-17","days":11},{"id":"dasision","kind":"trial","name":"DASISION","route":"/trials/dasision/","asOf":"2026-09-17","days":11},{"id":"murano","kind":"trial","name":"MURANO","route":"/trials/murano/","asOf":"2026-09-17","days":11},{"id":"augment","kind":"trial","name":"AUGMENT","route":"/trials/augment/","asOf":"2026-09-17","days":11},{"id":"zuma-5","kind":"trial","name":"ZUMA-5","route":"/trials/zuma-5/","asOf":"2026-09-17","days":11},{"id":"zuma-1","kind":"trial","name":"ZUMA-1","route":"/trials/zuma-1/","asOf":"2026-09-17","days":11},{"id":"zuma-2","kind":"trial","name":"ZUMA-2","route":"/trials/zuma-2/","asOf":"2026-09-17","days":11},{"id":"aspen-wm","kind":"trial","name":"ASPEN (Waldenström macroglobulinaemia)","route":"/trials/aspen-wm/","asOf":"2026-09-17","days":11},{"id":"echelon-2","kind":"trial","name":"ECHELON-2","route":"/trials/echelon-2/","asOf":"2026-09-17","days":11},{"id":"alcanza","kind":"trial","name":"ALCANZA","route":"/trials/alcanza/","asOf":"2026-09-17","days":11},{"id":"aall0434","kind":"trial","name":"COG AALL0434","route":"/trials/aall0434/","asOf":"2026-09-17","days":11},{"id":"aren0532","kind":"trial","name":"COG AREN0532","route":"/trials/aren0532/","asOf":"2026-09-17","days":11},{"id":"acns0332","kind":"trial","name":"COG ACNS0332","route":"/trials/acns0332/","asOf":"2026-09-17","days":11},{"id":"cabone","kind":"trial","name":"CABONE","route":"/trials/cabone/","asOf":"2026-09-17","days":11},{"id":"sarc028","kind":"trial","name":"SARC028","route":"/trials/sarc028/","asOf":"2026-09-17","days":11},{"id":"regobone","kind":"trial","name":"REGOBONE","route":"/trials/regobone/","asOf":"2026-09-17","days":11},{"id":"tappas","kind":"trial","name":"TAPPAS","route":"/trials/tappas/","asOf":"2026-09-17","days":11},{"id":"navigator","kind":"trial","name":"NAVIGATOR","route":"/trials/navigator/","asOf":"2026-09-17","days":11},{"id":"grid","kind":"trial","name":"GRID","route":"/trials/grid/","asOf":"2026-09-17","days":11},{"id":"tam-01","kind":"trial","name":"TAM-01","route":"/trials/tam-01/","asOf":"2026-09-17","days":11},{"id":"comet-dcis","kind":"trial","name":"COMET (Comparison of Operative versus Monitoring and Endocrine Therapy)","route":"/trials/comet-dcis/","asOf":"2026-09-17","days":11},{"id":"penelope-b","kind":"trial","name":"PENELOPE-B","route":"/trials/penelope-b/","asOf":"2026-09-17","days":11},{"id":"bolero-2","kind":"trial","name":"BOLERO-2","route":"/trials/bolero-2/","asOf":"2026-09-17","days":11},{"id":"nala","kind":"trial","name":"NALA","route":"/trials/nala/","asOf":"2026-09-17","days":11},{"id":"patina","kind":"trial","name":"PATINA","route":"/trials/patina/","asOf":"2026-09-17","days":11},{"id":"atempt","kind":"trial","name":"ATEMPT","route":"/trials/atempt/","asOf":"2026-09-17","days":11},{"id":"tuxedo-1","kind":"trial","name":"TUXEDO-1","route":"/trials/tuxedo-1/","asOf":"2026-09-17","days":11},{"id":"geparsixto","kind":"trial","name":"GeparSixto","route":"/trials/geparsixto/","asOf":"2026-09-17","days":11},{"id":"checkmate-915","kind":"trial","name":"CheckMate 915","route":"/trials/checkmate-915/","asOf":"2026-09-17","days":11},{"id":"stamp-merkel","kind":"trial","name":"STAMP (EA6174)","route":"/trials/stamp-merkel/","asOf":"2026-09-17","days":11},{"id":"keynote-412","kind":"trial","name":"KEYNOTE-412","route":"/trials/keynote-412/","asOf":"2026-09-17","days":11},{"id":"tpextreme","kind":"trial","name":"TPExtreme (GORTEC 2014-01)","route":"/trials/tpextreme/","asOf":"2026-09-17","days":11},{"id":"orator","kind":"trial","name":"ORATOR","route":"/trials/orator/","asOf":"2026-09-17","days":11},{"id":"exam","kind":"trial","name":"EXAM","route":"/trials/exam/","asOf":"2026-09-17","days":11},{"id":"prosper","kind":"trial","name":"PROSPER","route":"/trials/prosper/","asOf":"2026-09-17","days":11},{"id":"aramis","kind":"trial","name":"ARAMIS","route":"/trials/aramis/","asOf":"2026-09-17","days":11},{"id":"enzamet","kind":"trial","name":"ENZAMET","route":"/trials/enzamet/","asOf":"2026-09-17","days":11},{"id":"aranote","kind":"trial","name":"ARANOTE","route":"/trials/aranote/","asOf":"2026-09-17","days":11},{"id":"checkmate-025","kind":"trial","name":"CheckMate 025","route":"/trials/checkmate-025/","asOf":"2026-09-17","days":11},{"id":"carmena","kind":"trial","name":"CARMENA","route":"/trials/carmena/","asOf":"2026-09-17","days":11},{"id":"papmet","kind":"trial","name":"PAPMET (SWOG S1500)","route":"/trials/papmet/","asOf":"2026-09-17","days":11},{"id":"keynote-057","kind":"trial","name":"KEYNOTE-057","route":"/trials/keynote-057/","asOf":"2026-09-17","days":11},{"id":"calla","kind":"trial","name":"CALLA","route":"/trials/calla/","asOf":"2026-09-17","days":11},{"id":"shape","kind":"trial","name":"SHAPE (CCTG CX.5)","route":"/trials/shape/","asOf":"2026-09-17","days":11},{"id":"garnet","kind":"trial","name":"GARNET","route":"/trials/garnet/","asOf":"2026-09-17","days":11},{"id":"soraya","kind":"trial","name":"SORAYA","route":"/trials/soraya/","asOf":"2026-09-17","days":11},{"id":"portec-2","kind":"trial","name":"PORTEC-2","route":"/trials/portec-2/","asOf":"2026-09-17","days":11},{"id":"intellance-1","kind":"trial","name":"INTELLANCE-1","route":"/trials/intellance-1/","asOf":"2026-09-17","days":11},{"id":"attraction-2","kind":"trial","name":"ATTRACTION-2","route":"/trials/attraction-2/","asOf":"2026-09-17","days":11},{"id":"gatsby","kind":"trial","name":"GATSBY","route":"/trials/gatsby/","asOf":"2026-09-17","days":11},{"id":"klass-01","kind":"trial","name":"KLASS-01","route":"/trials/klass-01/","asOf":"2026-09-17","days":11},{"id":"aza-001","kind":"trial","name":"AZA-001","route":"/trials/aza-001/","asOf":"2026-09-17","days":11},{"id":"maia","kind":"trial","name":"MAIA","route":"/trials/maia/","asOf":"2026-09-17","days":11},{"id":"determination","kind":"trial","name":"DETERMINATION","route":"/trials/determination/","asOf":"2026-09-17","days":11},{"id":"aquila","kind":"trial","name":"AQUILA","route":"/trials/aquila/","asOf":"2026-09-17","days":11},{"id":"resonate-2","kind":"trial","name":"RESONATE-2","route":"/trials/resonate-2/","asOf":"2026-09-17","days":11},{"id":"mavoric","kind":"trial","name":"MAVORIC","route":"/trials/mavoric/","asOf":"2026-09-17","days":11},{"id":"herby","kind":"trial","name":"HERBY","route":"/trials/herby/","asOf":"2026-09-17","days":11},{"id":"avaglio","kind":"trial","name":"AVAglio","route":"/trials/avaglio/","asOf":"2026-09-17","days":11},{"id":"codel","kind":"trial","name":"CODEL","route":"/trials/codel/","asOf":"2026-09-17","days":11},{"id":"neosphere","kind":"trial","name":"NeoSphere","route":"/trials/neosphere/","asOf":"2026-09-17","days":11},{"id":"brightness","kind":"trial","name":"BrighTNess","route":"/trials/brightness/","asOf":"2026-09-17","days":11},{"id":"imspire150","kind":"trial","name":"IMspire150","route":"/trials/imspire150/","asOf":"2026-09-17","days":11},{"id":"checkmate-358","kind":"trial","name":"CheckMate 358","route":"/trials/checkmate-358/","asOf":"2026-09-17","days":11},{"id":"zeta","kind":"trial","name":"ZETA","route":"/trials/zeta/","asOf":"2026-09-17","days":11},{"id":"pancan-know-your-tumor","kind":"collection","name":"PanCAN Know Your Tumor","route":"/collections/pancan-know-your-tumor/","asOf":"2026-09-17","days":11},{"id":"prostate-cancer-promise","kind":"collection","name":"PROMISE registry: free germline testing in prostate cancer","route":"/collections/prostate-cancer-promise/","asOf":"2026-09-17","days":11},{"id":"nhs-genomic-medicine-service","kind":"collection","name":"NHS Genomic Medicine Service","route":"/collections/nhs-genomic-medicine-service/","asOf":"2026-09-17","days":11},{"id":"nhs-jewish-brca-testing","kind":"collection","name":"NHS Jewish BRCA Testing Programme","route":"/collections/nhs-jewish-brca-testing/","asOf":"2026-09-17","days":11},{"id":"nhs-cancer-screening-programmes","kind":"collection","name":"NHS cancer screening programmes","route":"/collections/nhs-cancer-screening-programmes/","asOf":"2026-09-17","days":11},{"id":"australia-cancer-screening-programs","kind":"collection","name":"Australia's national cancer screening programs","route":"/collections/australia-cancer-screening-programs/","asOf":"2026-09-17","days":11},{"id":"ireland-national-screening-service","kind":"collection","name":"Ireland's National Screening Service","route":"/collections/ireland-national-screening-service/","asOf":"2026-09-17","days":11},{"id":"nz-time-to-screen","kind":"collection","name":"Time to Screen (New Zealand national screening)","route":"/collections/nz-time-to-screen/","asOf":"2026-09-17","days":11},{"id":"cdc-nbccedp","kind":"collection","name":"CDC National Breast and Cervical Cancer Early Detection Program","route":"/collections/cdc-nbccedp/","asOf":"2026-09-17","days":11},{"id":"nhs-hpv-vaccination","kind":"collection","name":"NHS HPV vaccination programme","route":"/collections/nhs-hpv-vaccination/","asOf":"2026-09-17","days":11},{"id":"us-vaccines-for-children","kind":"collection","name":"Vaccines for Children program (US)","route":"/collections/us-vaccines-for-children/","asOf":"2026-09-17","days":11},{"id":"gavi-hpv-programme","kind":"collection","name":"Gavi HPV vaccine support","route":"/collections/gavi-hpv-programme/","asOf":"2026-09-17","days":11},{"id":"nci-cancer-information-service","kind":"collection","name":"NCI Cancer Information Service","route":"/collections/nci-cancer-information-service/","asOf":"2026-09-17","days":11},{"id":"macmillan-support-line","kind":"collection","name":"Macmillan Support Line","route":"/collections/macmillan-support-line/","asOf":"2026-09-17","days":11},{"id":"cruk-nurse-helpline","kind":"collection","name":"Cancer Research UK nurse helpline","route":"/collections/cruk-nurse-helpline/","asOf":"2026-09-17","days":11},{"id":"acs-cancer-helpline","kind":"collection","name":"American Cancer Society helpline","route":"/collections/acs-cancer-helpline/","asOf":"2026-09-17","days":11},{"id":"cancercare","kind":"collection","name":"CancerCare","route":"/collections/cancercare/","asOf":"2026-09-17","days":11},{"id":"cancer-support-community","kind":"collection","name":"Cancer Support Community","route":"/collections/cancer-support-community/","asOf":"2026-09-17","days":11},{"id":"krebsinformationsdienst","kind":"collection","name":"Krebsinformationsdienst (KID)","route":"/collections/krebsinformationsdienst/","asOf":"2026-09-17","days":11},{"id":"breast-cancer-now-helpline","kind":"collection","name":"Breast Cancer Now helpline","route":"/collections/breast-cancer-now-helpline/","asOf":"2026-09-17","days":11},{"id":"acs-road-to-recovery","kind":"collection","name":"ACS Road To Recovery","route":"/collections/acs-road-to-recovery/","asOf":"2026-09-17","days":11},{"id":"acs-hope-lodge","kind":"collection","name":"ACS Hope Lodge","route":"/collections/acs-hope-lodge/","asOf":"2026-09-17","days":11},{"id":"corporate-angel-network","kind":"collection","name":"Corporate Angel Network","route":"/collections/corporate-angel-network/","asOf":"2026-09-17","days":11},{"id":"ronald-mcdonald-house-charities","kind":"collection","name":"Ronald McDonald House Charities","route":"/collections/ronald-mcdonald-house-charities/","asOf":"2026-09-17","days":11},{"id":"nhs-healthcare-travel-costs-scheme","kind":"collection","name":"NHS Healthcare Travel Costs Scheme","route":"/collections/nhs-healthcare-travel-costs-scheme/","asOf":"2026-09-17","days":11},{"id":"young-lives-vs-cancer","kind":"collection","name":"Young Lives vs Cancer","route":"/collections/young-lives-vs-cancer/","asOf":"2026-09-17","days":11},{"id":"thesecondopinion","kind":"collection","name":"thesecondopinion","route":"/collections/thesecondopinion/","asOf":"2026-09-17","days":11},{"id":"lazarex-cancer-foundation","kind":"collection","name":"Lazarex Cancer Foundation","route":"/collections/lazarex-cancer-foundation/","asOf":"2026-09-17","days":11},{"id":"nihr-be-part-of-research","kind":"collection","name":"Be Part of Research (NIHR)","route":"/collections/nihr-be-part-of-research/","asOf":"2026-09-17","days":11},{"id":"force-facing-our-risk","kind":"collection","name":"FORCE: Facing Our Risk of Cancer Empowered","route":"/collections/force-facing-our-risk/","asOf":"2026-09-17","days":11},{"id":"sharsheret","kind":"collection","name":"Sharsheret","route":"/collections/sharsheret/","asOf":"2026-09-17","days":11},{"id":"maggies-centres","kind":"collection","name":"Maggie's","route":"/collections/maggies-centres/","asOf":"2026-09-17","days":11},{"id":"penny-brohn-uk","kind":"collection","name":"Penny Brohn UK","route":"/collections/penny-brohn-uk/","asOf":"2026-09-17","days":11},{"id":"livestrong-at-the-ymca","kind":"collection","name":"LIVESTRONG at the YMCA","route":"/collections/livestrong-at-the-ymca/","asOf":"2026-09-17","days":11},{"id":"look-good-feel-better","kind":"collection","name":"Look Good Feel Better","route":"/collections/look-good-feel-better/","asOf":"2026-09-17","days":11},{"id":"imerman-angels","kind":"collection","name":"Imerman Angels","route":"/collections/imerman-angels/","asOf":"2026-09-17","days":11},{"id":"first-descents","kind":"collection","name":"First Descents","route":"/collections/first-descents/","asOf":"2026-09-17","days":11},{"id":"kesem","kind":"collection","name":"Kesem","route":"/collections/kesem/","asOf":"2026-09-17","days":11},{"id":"little-princess-trust","kind":"collection","name":"The Little Princess Trust","route":"/collections/little-princess-trust/","asOf":"2026-09-17","days":11},{"id":"knitted-knockers","kind":"collection","name":"Knitted Knockers","route":"/collections/knitted-knockers/","asOf":"2026-09-17","days":11},{"id":"wigs-for-kids","kind":"collection","name":"Wigs for Kids","route":"/collections/wigs-for-kids/","asOf":"2026-09-17","days":11},{"id":"matthew-hellmann","kind":"person","name":"Matthew D. Hellmann","route":"/people/matthew-hellmann/","asOf":"2026-09-18","days":10},{"id":"keunchil-park","kind":"person","name":"Keunchil Park","route":"/people/keunchil-park/","asOf":"2026-09-18","days":10},{"id":"alice-shaw","kind":"person","name":"Alice T. Shaw","route":"/people/alice-shaw/","asOf":"2026-09-18","days":10},{"id":"robert-doebele","kind":"person","name":"Robert C. Doebele","route":"/people/robert-doebele/","asOf":"2026-09-18","days":10},{"id":"gregory-riely","kind":"person","name":"Gregory J. Riely","route":"/people/gregory-riely/","asOf":"2026-09-18","days":10},{"id":"paul-paik","kind":"person","name":"Paul K. Paik","route":"/people/paul-paik/","asOf":"2026-09-18","days":10},{"id":"salah-eddin-al-batran","kind":"person","name":"Salah-Eddin Al-Batran","route":"/people/salah-eddin-al-batran/","asOf":"2026-09-18","days":10},{"id":"yuichiro-doki","kind":"person","name":"Yuichiro Doki","route":"/people/yuichiro-doki/","asOf":"2026-09-18","days":10},{"id":"jong-mu-sun","kind":"person","name":"Jong-Mu Sun","route":"/people/jong-mu-sun/","asOf":"2026-09-18","days":10},{"id":"peter-thuss-patience","kind":"person","name":"Peter Thuss-Patience","route":"/people/peter-thuss-patience/","asOf":"2026-09-18","days":10},{"id":"jens-hoeppner","kind":"person","name":"Jens Höppner","route":"/people/jens-hoeppner/","asOf":"2026-09-18","days":10},{"id":"hyung-ho-kim","kind":"person","name":"Hyung-Ho Kim","route":"/people/hyung-ho-kim/","asOf":"2026-09-18","days":10},{"id":"hitoshi-katai","kind":"person","name":"Hitoshi Katai","route":"/people/hitoshi-katai/","asOf":"2026-09-18","days":10},{"id":"manish-shah","kind":"person","name":"Manish A. Shah","route":"/people/manish-shah/","asOf":"2026-09-18","days":10},{"id":"hansjochen-wilke","kind":"person","name":"Hansjochen Wilke","route":"/people/hansjochen-wilke/","asOf":"2026-09-18","days":10},{"id":"jordi-bruix","kind":"person","name":"Jordi Bruix","route":"/people/jordi-bruix/","asOf":"2026-09-18","days":10},{"id":"john-primrose","kind":"person","name":"John N. Primrose","route":"/people/john-primrose/","asOf":"2026-09-18","days":10},{"id":"robin-kate-kelley","kind":"person","name":"Robin Kate Kelley","route":"/people/robin-kate-kelley/","asOf":"2026-09-18","days":10},{"id":"angela-lamarca","kind":"person","name":"Angela Lamarca","route":"/people/angela-lamarca/","asOf":"2026-09-18","days":10},{"id":"andrew-zhu","kind":"person","name":"Andrew X. Zhu","route":"/people/andrew-zhu/","asOf":"2026-09-18","days":10},{"id":"michael-heinrich","kind":"person","name":"Michael C. Heinrich","route":"/people/michael-heinrich/","asOf":"2026-09-18","days":10},{"id":"sebastian-bauer","kind":"person","name":"Sebastian Bauer","route":"/people/sebastian-bauer/","asOf":"2026-09-18","days":10},{"id":"heikki-joensuu","kind":"person","name":"Heikki Joensuu","route":"/people/heikki-joensuu/","asOf":"2026-09-18","days":10},{"id":"herve-dombret","kind":"person","name":"Hervé Dombret","route":"/people/herve-dombret/","asOf":"2026-09-18","days":10},{"id":"francesco-lo-coco","kind":"person","name":"Francesco Lo-Coco","route":"/people/francesco-lo-coco/","asOf":"2026-09-18","days":10},{"id":"miguel-sanz","kind":"person","name":"Miguel A. Sanz","route":"/people/miguel-sanz/","asOf":"2026-09-18","days":10},{"id":"michel-attal","kind":"person","name":"Michel Attal","route":"/people/michel-attal/","asOf":"2026-09-18","days":10},{"id":"jeffrey-lancet","kind":"person","name":"Jeffrey E. Lancet","route":"/people/jeffrey-lancet/","asOf":"2026-09-18","days":10},{"id":"jan-burger","kind":"person","name":"Jan A. Burger","route":"/people/jan-burger/","asOf":"2026-09-18","days":10},{"id":"srdan-verstovsek","kind":"person","name":"Srdan Verstovsek","route":"/people/srdan-verstovsek/","asOf":"2026-09-18","days":10},{"id":"raajit-rampal","kind":"person","name":"Raajit K. Rampal","route":"/people/raajit-rampal/","asOf":"2026-09-18","days":10},{"id":"amer-zeidan","kind":"person","name":"Amer M. Zeidan","route":"/people/amer-zeidan/","asOf":"2026-09-18","days":10},{"id":"john-leonard","kind":"person","name":"John P. Leonard","route":"/people/john-leonard/","asOf":"2026-09-18","days":10},{"id":"philippe-armand","kind":"person","name":"Philippe Armand","route":"/people/philippe-armand/","asOf":"2026-09-18","days":10},{"id":"caron-jacobson","kind":"person","name":"Caron A. Jacobson","route":"/people/caron-jacobson/","asOf":"2026-09-18","days":10},{"id":"miles-prince","kind":"person","name":"H. Miles Prince","route":"/people/miles-prince/","asOf":"2026-09-18","days":10},{"id":"youn-kim","kind":"person","name":"Youn H. Kim","route":"/people/youn-kim/","asOf":"2026-09-18","days":10},{"id":"rashmi-murthy","kind":"person","name":"Rashmi K. Murthy","route":"/people/rashmi-murthy/","asOf":"2026-09-18","days":10},{"id":"rupert-bartsch","kind":"person","name":"Rupert Bartsch","route":"/people/rupert-bartsch/","asOf":"2026-09-18","days":10},{"id":"mark-robson","kind":"person","name":"Mark E. Robson","route":"/people/mark-robson/","asOf":"2026-09-18","days":10},{"id":"andrea-decensi","kind":"person","name":"Andrea DeCensi","route":"/people/andrea-decensi/","asOf":"2026-09-18","days":10},{"id":"shelley-hwang","kind":"person","name":"E. Shelley Hwang","route":"/people/shelley-hwang/","asOf":"2026-09-18","days":10},{"id":"luca-gianni","kind":"person","name":"Luca Gianni","route":"/people/luca-gianni/","asOf":"2026-09-18","days":10},{"id":"jose-baselga","kind":"person","name":"José Baselga","route":"/people/jose-baselga/","asOf":"2026-09-18","days":10},{"id":"paul-chapman","kind":"person","name":"Paul B. Chapman","route":"/people/paul-chapman/","asOf":"2026-09-18","days":10},{"id":"michael-atkins","kind":"person","name":"Michael B. Atkins","route":"/people/michael-atkins/","asOf":"2026-09-18","days":10},{"id":"john-kirkwood","kind":"person","name":"John M. Kirkwood","route":"/people/john-kirkwood/","asOf":"2026-09-18","days":10},{"id":"jeffrey-gershenwald","kind":"person","name":"Jeffrey E. Gershenwald","route":"/people/jeffrey-gershenwald/","asOf":"2026-09-18","days":10},{"id":"piotr-rutkowski","kind":"person","name":"Piotr Rutkowski","route":"/people/piotr-rutkowski/","asOf":"2026-09-18","days":10},{"id":"aleksandar-sekulic","kind":"person","name":"Aleksandar Sekulic","route":"/people/aleksandar-sekulic/","asOf":"2026-09-18","days":10},{"id":"alexander-stratigos","kind":"person","name":"Alexander J. Stratigos","route":"/people/alexander-stratigos/","asOf":"2026-09-18","days":10},{"id":"michael-migden","kind":"person","name":"Michael R. Migden","route":"/people/michael-migden/","asOf":"2026-09-18","days":10},{"id":"jean-jacques-grob","kind":"person","name":"Jean-Jacques Grob","route":"/people/jean-jacques-grob/","asOf":"2026-09-18","days":10},{"id":"danny-rischin","kind":"person","name":"Danny Rischin","route":"/people/danny-rischin/","asOf":"2026-09-18","days":10},{"id":"neil-gross","kind":"person","name":"Neil D. Gross","route":"/people/neil-gross/","asOf":"2026-09-18","days":10},{"id":"ralf-gutzmer","kind":"person","name":"Ralf Gutzmer","route":"/people/ralf-gutzmer/","asOf":"2026-09-18","days":10},{"id":"shailender-bhatia","kind":"person","name":"Shailender Bhatia","route":"/people/shailender-bhatia/","asOf":"2026-09-18","days":10},{"id":"robert-ferris","kind":"person","name":"Robert L. Ferris","route":"/people/robert-ferris/","asOf":"2026-09-18","days":10},{"id":"joel-guigay","kind":"person","name":"Joël Guigay","route":"/people/joel-guigay/","asOf":"2026-09-18","days":10},{"id":"jean-pascal-machiels","kind":"person","name":"Jean-Pascal Machiels","route":"/people/jean-pascal-machiels/","asOf":"2026-09-18","days":10},{"id":"anthony-nichols","kind":"person","name":"Anthony C. Nichols","route":"/people/anthony-nichols/","asOf":"2026-09-18","days":10},{"id":"rossella-elisei","kind":"person","name":"Rossella Elisei","route":"/people/rossella-elisei/","asOf":"2026-09-18","days":10},{"id":"samuel-wells","kind":"person","name":"Samuel A. Wells Jr.","route":"/people/samuel-wells/","asOf":"2026-09-18","days":10},{"id":"bryan-haugen","kind":"person","name":"Bryan R. Haugen","route":"/people/bryan-haugen/","asOf":"2026-09-18","days":10},{"id":"keith-bible","kind":"person","name":"Keith C. Bible","route":"/people/keith-bible/","asOf":"2026-09-18","days":10},{"id":"julien-hadoux","kind":"person","name":"Julien Hadoux","route":"/people/julien-hadoux/","asOf":"2026-09-18","days":10},{"id":"vivek-subbiah","kind":"person","name":"Vivek Subbiah","route":"/people/vivek-subbiah/","asOf":"2026-09-18","days":10},{"id":"stephen-freedland","kind":"person","name":"Stephen J. Freedland","route":"/people/stephen-freedland/","asOf":"2026-09-18","days":10},{"id":"chris-parker","kind":"person","name":"Chris C. Parker","route":"/people/chris-parker/","asOf":"2026-09-18","days":10},{"id":"gerhardt-attard","kind":"person","name":"Gerhardt Attard","route":"/people/gerhardt-attard/","asOf":"2026-09-18","days":10},{"id":"david-dearnaley","kind":"person","name":"David Dearnaley","route":"/people/david-dearnaley/","asOf":"2026-09-18","days":10},{"id":"fred-saad","kind":"person","name":"Fred Saad","route":"/people/fred-saad/","asOf":"2026-09-18","days":10},{"id":"stephen-boorjian","kind":"person","name":"Stephen A. Boorjian","route":"/people/stephen-boorjian/","asOf":"2026-09-18","days":10},{"id":"krishnansu-tewari","kind":"person","name":"Krishnansu S. Tewari","route":"/people/krishnansu-tewari/","asOf":"2026-09-18","days":10},{"id":"david-gershenson","kind":"person","name":"David M. Gershenson","route":"/people/david-gershenson/","asOf":"2026-09-18","days":10},{"id":"vicky-makker","kind":"person","name":"Vicky Makker","route":"/people/vicky-makker/","asOf":"2026-09-18","days":10},{"id":"shannon-westin","kind":"person","name":"Shannon N. Westin","route":"/people/shannon-westin/","asOf":"2026-09-18","days":10},{"id":"marie-plante","kind":"person","name":"Marie Plante","route":"/people/marie-plante/","asOf":"2026-09-18","days":10},{"id":"remi-nout","kind":"person","name":"Remi A. Nout","route":"/people/remi-nout/","asOf":"2026-09-18","days":10},{"id":"ana-oaknin","kind":"person","name":"Ana Oaknin","route":"/people/ana-oaknin/","asOf":"2026-09-18","days":10},{"id":"amanda-fader","kind":"person","name":"Amanda Nickles Fader","route":"/people/amanda-fader/","asOf":"2026-09-18","days":10},{"id":"susana-banerjee","kind":"person","name":"Susana Banerjee","route":"/people/susana-banerjee/","asOf":"2026-09-18","days":10},{"id":"paul-brown","kind":"person","name":"Paul D. Brown","route":"/people/paul-brown/","asOf":"2026-09-18","days":10},{"id":"jan-buckner","kind":"person","name":"Jan C. Buckner","route":"/people/jan-buckner/","asOf":"2026-09-18","days":10},{"id":"eric-jonasch","kind":"person","name":"Eric Jonasch","route":"/people/eric-jonasch/","asOf":"2026-09-18","days":10},{"id":"scott-plotkin","kind":"person","name":"Scott R. Plotkin","route":"/people/scott-plotkin/","asOf":"2026-09-18","days":10},{"id":"andrew-lassman","kind":"person","name":"Andrew B. Lassman","route":"/people/andrew-lassman/","asOf":"2026-09-18","days":10},{"id":"olivier-chinot","kind":"person","name":"Olivier L. Chinot","route":"/people/olivier-chinot/","asOf":"2026-09-18","days":10},{"id":"jacques-grill","kind":"person","name":"Jacques Grill","route":"/people/jacques-grill/","asOf":"2026-09-18","days":10},{"id":"darren-hargrave","kind":"person","name":"Darren R. Hargrave","route":"/people/darren-hargrave/","asOf":"2026-09-18","days":10},{"id":"giles-robinson","kind":"person","name":"Giles W. Robinson","route":"/people/giles-robinson/","asOf":"2026-09-18","days":10},{"id":"sarah-leary","kind":"person","name":"Sarah E. S. Leary","route":"/people/sarah-leary/","asOf":"2026-09-18","days":10},{"id":"kimberly-dunsmore","kind":"person","name":"Kimberly P. Dunsmore","route":"/people/kimberly-dunsmore/","asOf":"2026-09-18","days":10},{"id":"rob-pieters","kind":"person","name":"Rob Pieters","route":"/people/rob-pieters/","asOf":"2026-09-18","days":10},{"id":"inge-van-der-sluis","kind":"person","name":"Inge M. van der Sluis","route":"/people/inge-van-der-sluis/","asOf":"2026-09-18","days":10},{"id":"sylvie-bonvalot","kind":"person","name":"Sylvie Bonvalot","route":"/people/sylvie-bonvalot/","asOf":"2026-09-18","days":10},{"id":"andrew-wagner","kind":"person","name":"Andrew J. Wagner","route":"/people/andrew-wagner/","asOf":"2026-09-18","days":10},{"id":"patricia-pautier","kind":"person","name":"Patricia Pautier","route":"/people/patricia-pautier/","asOf":"2026-09-18","days":10},{"id":"patrick-schoffski","kind":"person","name":"Patrick Schöffski","route":"/people/patrick-schoffski/","asOf":"2026-09-18","days":10},{"id":"alice-chen","kind":"person","name":"Alice P. Chen","route":"/people/alice-chen/","asOf":"2026-09-18","days":10},{"id":"antoine-italiano","kind":"person","name":"Antoine Italiano","route":"/people/antoine-italiano/","asOf":"2026-09-18","days":10},{"id":"florence-duffaud","kind":"person","name":"Florence Duffaud","route":"/people/florence-duffaud/","asOf":"2026-09-18","days":10},{"id":"robin-jones","kind":"person","name":"Robin L. Jones","route":"/people/robin-jones/","asOf":"2026-09-18","days":10},{"id":"jennifer-chan","kind":"person","name":"Jennifer A. Chan","route":"/people/jennifer-chan/","asOf":"2026-09-18","days":10},{"id":"john-strickler","kind":"person","name":"John H. Strickler","route":"/people/john-strickler/","asOf":"2026-09-18","days":10},{"id":"andrea-sartore-bianchi","kind":"person","name":"Andrea Sartore-Bianchi","route":"/people/andrea-sartore-bianchi/","asOf":"2026-09-18","days":10},{"id":"salvatore-siena","kind":"person","name":"Salvatore Siena","route":"/people/salvatore-siena/","asOf":"2026-09-18","days":10},{"id":"rona-yaeger","kind":"person","name":"Rona Yaeger","route":"/people/rona-yaeger/","asOf":"2026-09-18","days":10},{"id":"gerald-prager","kind":"person","name":"Gerald W. Prager","route":"/people/gerald-prager/","asOf":"2026-09-18","days":10},{"id":"quincy-chu","kind":"person","name":"Quincy Chu","route":"/people/quincy-chu/","asOf":"2026-09-18","days":10},{"id":"maria-de-santis","kind":"person","name":"Maria De Santis","route":"/people/maria-de-santis/","asOf":"2026-09-18","days":10},{"id":"paper-anchor-anal-hsil-treatment-nejm-2022","kind":"paper","name":"ANCHOR: treating anal high-grade squamous intraepithelial lesions to prevent anal cancer in people living with HIV","route":"/key-papers/paper-anchor-anal-hsil-treatment-nejm-2022/","asOf":"2026-09-18","days":10},{"id":"paper-ians-anal-cancer-screening-guidelines-ijc-2024","kind":"paper","name":"International Anal Neoplasia Society consensus guidelines for anal cancer screening","route":"/key-papers/paper-ians-anal-cancer-screening-guidelines-ijc-2024/","asOf":"2026-09-18","days":10},{"id":"paper-act-ii-anal-cancer-chemoradiation-lancet-oncol-2013","kind":"paper","name":"ACT II: mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for squamous cell carcinoma of the anus","route":"/key-papers/paper-act-ii-anal-cancer-chemoradiation-lancet-oncol-2013/","asOf":"2026-09-18","days":10},{"id":"paper-esmo-anal-cancer-guideline-ann-oncol-2021","kind":"paper","name":"ESMO Clinical Practice Guideline on anal cancer: diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-anal-cancer-guideline-ann-oncol-2021/","asOf":"2026-09-18","days":10},{"id":"paper-eau-asco-penile-cancer-guideline-eur-urol-2023","kind":"paper","name":"EAU-ASCO collaborative guideline on penile cancer, 2023 update","route":"/key-papers/paper-eau-asco-penile-cancer-guideline-eur-urol-2023/","asOf":"2026-09-18","days":10},{"id":"paper-pagliaro-neoadjuvant-tip-penile-cancer-jco-2010","kind":"paper","name":"Neoadjuvant paclitaxel, ifosfamide and cisplatin (TIP) for penile cancer with bulky lymph node metastases","route":"/key-papers/paper-pagliaro-neoadjuvant-tip-penile-cancer-jco-2010/","asOf":"2026-09-18","days":10},{"id":"paper-groinss-v-sentinel-node-vulvar-cancer-jco-2008","kind":"paper","name":"GROINSS-V: sentinel node dissection is safe in early-stage vulvar cancer","route":"/key-papers/paper-groinss-v-sentinel-node-vulvar-cancer-jco-2008/","asOf":"2026-09-18","days":10},{"id":"paper-groinss-v-ii-radiotherapy-vulvar-micrometastases-jco-2021","kind":"paper","name":"GROINSS-V II: radiotherapy versus inguinofemoral lymphadenectomy for vulvar cancer with sentinel node micrometastases","route":"/key-papers/paper-groinss-v-ii-radiotherapy-vulvar-micrometastases-jco-2021/","asOf":"2026-09-18","days":10},{"id":"paper-figo-annual-report-carcinoma-of-the-vagina-ijgo-2006","kind":"paper","name":"Carcinoma of the vagina: FIGO 26th Annual Report on the results of treatment in gynecological cancer","route":"/key-papers/paper-figo-annual-report-carcinoma-of-the-vagina-ijgo-2006/","asOf":"2026-09-18","days":10},{"id":"paper-figo-cancer-report-cancer-of-the-vagina-ijgo-2018","kind":"paper","name":"FIGO Cancer Report 2018: cancer of the vagina","route":"/key-papers/paper-figo-cancer-report-cancer-of-the-vagina-ijgo-2018/","asOf":"2026-09-18","days":10},{"id":"paper-herbst-diethylstilbestrol-vaginal-adenocarcinoma-nejm-1971","kind":"paper","name":"Adenocarcinoma of the vagina: association of maternal stilbestrol therapy with tumour appearance in young women","route":"/key-papers/paper-herbst-diethylstilbestrol-vaginal-adenocarcinoma-nejm-1971/","asOf":"2026-09-18","days":10},{"id":"paper-esmo-thymic-epithelial-tumours-guideline-ann-oncol-2015","kind":"paper","name":"Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-thymic-epithelial-tumours-guideline-ann-oncol-2015/","asOf":"2026-09-18","days":10},{"id":"paper-masaoka-thymoma-clinical-staging-cancer-1981","kind":"paper","name":"Masaoka staging: follow-up study of thymomas with special reference to their clinical stages","route":"/key-papers/paper-masaoka-thymoma-clinical-staging-cancer-1981/","asOf":"2026-09-18","days":10},{"id":"paper-who-2021-thymus-mediastinum-classification-marx-jto-2022","kind":"paper","name":"The 2021 WHO classification of tumours of the thymus and mediastinum: what is new in thymic epithelial, germ cell and mesenchymal tumours","route":"/key-papers/paper-who-2021-thymus-mediastinum-classification-marx-jto-2022/","asOf":"2026-09-18","days":10},{"id":"paper-remora-lenvatinib-thymic-carcinoma-lancet-oncol-2020","kind":"paper","name":"REMORA: lenvatinib in advanced or metastatic thymic carcinoma","route":"/key-papers/paper-remora-lenvatinib-thymic-carcinoma-lancet-oncol-2020/","asOf":"2026-09-18","days":10},{"id":"paper-giaccone-pembrolizumab-thymic-carcinoma-lancet-oncol-2018","kind":"paper","name":"Pembrolizumab in patients with thymic carcinoma: a single-arm phase 2 study","route":"/key-papers/paper-giaccone-pembrolizumab-thymic-carcinoma-lancet-oncol-2018/","asOf":"2026-09-18","days":10},{"id":"paper-ese-ensat-adrenocortical-carcinoma-guideline-eur-j-endocrinol-2018","kind":"paper","name":"European Society of Endocrinology and ENSAT clinical practice guidelines on the management of adrenocortical carcinoma in adults","route":"/key-papers/paper-ese-ensat-adrenocortical-carcinoma-guideline-eur-j-endocrinol-2018/","asOf":"2026-09-18","days":10},{"id":"paper-firm-act-edp-mitotane-adrenocortical-carcinoma-nejm-2012","kind":"paper","name":"FIRM-ACT: combination chemotherapy in advanced adrenocortical carcinoma","route":"/key-papers/paper-firm-act-edp-mitotane-adrenocortical-carcinoma-nejm-2012/","asOf":"2026-09-18","days":10},{"id":"paper-psogi-pseudomyxoma-appendiceal-classification-am-j-surg-pathol-2016","kind":"paper","name":"PSOGI consensus for classification and pathological reporting of pseudomyxoma peritonei and associated appendiceal neoplasia","route":"/key-papers/paper-psogi-pseudomyxoma-appendiceal-classification-am-j-surg-pathol-2016/","asOf":"2026-09-18","days":10},{"id":"paper-who-2019-digestive-system-tumours-nagtegaal-histopathology-2020","kind":"paper","name":"The 2019 WHO classification of tumours of the digestive system","route":"/key-papers/paper-who-2019-digestive-system-tumours-nagtegaal-histopathology-2020/","asOf":"2026-09-18","days":10},{"id":"paper-chicago-consensus-appendiceal-neoplasms-cancer-2020","kind":"paper","name":"The Chicago Consensus on peritoneal surface malignancies: management of appendiceal neoplasms","route":"/key-papers/paper-chicago-consensus-appendiceal-neoplasms-cancer-2020/","asOf":"2026-09-18","days":10},{"id":"paper-overman-capox-small-bowel-adenocarcinoma-jco-2009","kind":"paper","name":"Phase 2 study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater","route":"/key-papers/paper-overman-capox-small-bowel-adenocarcinoma-jco-2009/","asOf":"2026-09-18","days":10},{"id":"paper-zebra-pembrolizumab-small-bowel-adenocarcinoma-ccr-2021","kind":"paper","name":"ZEBRA: pembrolizumab in advanced small bowel adenocarcinoma","route":"/key-papers/paper-zebra-pembrolizumab-small-bowel-adenocarcinoma-ccr-2021/","asOf":"2026-09-18","days":10},{"id":"paper-esmo-cancer-of-unknown-primary-guideline-ann-oncol-2023","kind":"paper","name":"Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-cancer-of-unknown-primary-guideline-ann-oncol-2023/","asOf":"2026-09-18","days":10},{"id":"paper-cupisco-molecularly-guided-therapy-cup-lancet-2024","kind":"paper","name":"CUPISCO: molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary","route":"/key-papers/paper-cupisco-molecularly-guided-therapy-cup-lancet-2024/","asOf":"2026-09-18","days":10},{"id":"paper-hayashi-site-specific-vs-empirical-chemotherapy-cup-jco-2019","kind":"paper","name":"Randomised phase 2 trial of site-specific treatment based on gene expression profiling versus carboplatin and paclitaxel in cancer of unknown primary","route":"/key-papers/paper-hayashi-site-specific-vs-empirical-chemotherapy-cup-jco-2019/","asOf":"2026-09-18","days":10},{"id":"paper-ve-basket-vemurafenib-erdheim-chester-lch-jama-oncol-2018","kind":"paper","name":"VE-BASKET: vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis","route":"/key-papers/paper-ve-basket-vemurafenib-erdheim-chester-lch-jama-oncol-2018/","asOf":"2026-09-18","days":10},{"id":"paper-erdheim-chester-disease-consensus-recommendations-blood-2020","kind":"paper","name":"Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis and treatment in the molecular era","route":"/key-papers/paper-erdheim-chester-disease-consensus-recommendations-blood-2020/","asOf":"2026-09-18","days":10},{"id":"paper-emile-revised-classification-of-histiocytoses-blood-2016","kind":"paper","name":"Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages","route":"/key-papers/paper-emile-revised-classification-of-histiocytoses-blood-2016/","asOf":"2026-09-18","days":10},{"id":"paper-rosai-dorfman-destombes-consensus-recommendations-blood-2018","kind":"paper","name":"Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease","route":"/key-papers/paper-rosai-dorfman-destombes-consensus-recommendations-blood-2018/","asOf":"2026-09-18","days":10},{"id":"paper-lch-iii-therapy-prolongation-multisystem-lch-blood-2013","kind":"paper","name":"LCH-III: therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis","route":"/key-papers/paper-lch-iii-therapy-prolongation-multisystem-lch-blood-2013/","asOf":"2026-09-18","days":10},{"id":"paper-badalian-very-braf-mutations-lch-blood-2010","kind":"paper","name":"Recurrent BRAF mutations in Langerhans cell histiocytosis","route":"/key-papers/paper-badalian-very-braf-mutations-lch-blood-2010/","asOf":"2026-09-18","days":10},{"id":"paper-donadieu-vemurafenib-refractory-multisystem-lch-jco-2019","kind":"paper","name":"Vemurafenib for refractory multisystem Langerhans cell histiocytosis in children: an international observational study","route":"/key-papers/paper-donadieu-vemurafenib-refractory-multisystem-lch-jco-2019/","asOf":"2026-09-18","days":10},{"id":"paper-pioneer-avapritinib-indolent-systemic-mastocytosis-nejm-evid-2023","kind":"paper","name":"PIONEER: avapritinib versus placebo in indolent systemic mastocytosis","route":"/key-papers/paper-pioneer-avapritinib-indolent-systemic-mastocytosis-nejm-evid-2023/","asOf":"2026-09-18","days":10},{"id":"paper-gotlib-midostaurin-advanced-systemic-mastocytosis-nejm-2016","kind":"paper","name":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","route":"/key-papers/paper-gotlib-midostaurin-advanced-systemic-mastocytosis-nejm-2016/","asOf":"2026-09-18","days":10},{"id":"paper-explorer-avapritinib-advanced-systemic-mastocytosis-nat-med-2021","kind":"paper","name":"EXPLORER: safety and efficacy of avapritinib in advanced systemic mastocytosis (phase 1)","route":"/key-papers/paper-explorer-avapritinib-advanced-systemic-mastocytosis-nat-med-2021/","asOf":"2026-09-18","days":10},{"id":"paper-pathfinder-avapritinib-advanced-systemic-mastocytosis-nat-med-2021","kind":"paper","name":"PATHFINDER: efficacy and safety of avapritinib in advanced systemic mastocytosis (phase 2 interim analysis)","route":"/key-papers/paper-pathfinder-avapritinib-advanced-systemic-mastocytosis-nat-med-2021/","asOf":"2026-09-18","days":10},{"id":"paper-ghsg-hd10-reduced-intensity-early-hodgkin-nejm-2010","kind":"paper","name":"GHSG HD10: reduced treatment intensity in early-stage favourable Hodgkin lymphoma","route":"/key-papers/paper-ghsg-hd10-reduced-intensity-early-hodgkin-nejm-2010/","asOf":"2026-09-18","days":10},{"id":"paper-rapid-pet-directed-therapy-early-hodgkin-nejm-2015","kind":"paper","name":"RAPID: PET-directed therapy for early-stage Hodgkin lymphoma","route":"/key-papers/paper-rapid-pet-directed-therapy-early-hodgkin-nejm-2015/","asOf":"2026-09-18","days":10},{"id":"paper-rathl-interim-pet-adapted-abvd-advanced-hodgkin-nejm-2016","kind":"paper","name":"RATHL: adapted treatment guided by interim PET-CT in advanced Hodgkin lymphoma","route":"/key-papers/paper-rathl-interim-pet-adapted-abvd-advanced-hodgkin-nejm-2016/","asOf":"2026-09-18","days":10},{"id":"paper-ghsg-hd21-brecadd-vs-ebeacopp-advanced-hodgkin-lancet-2024","kind":"paper","name":"GHSG HD21: PET-guided BrECADD versus escalated BEACOPP in advanced-stage classical Hodgkin lymphoma","route":"/key-papers/paper-ghsg-hd21-brecadd-vs-ebeacopp-advanced-hodgkin-lancet-2024/","asOf":"2026-09-18","days":10},{"id":"paper-aethera-brentuximab-consolidation-after-asct-hodgkin-lancet-2015","kind":"paper","name":"AETHERA: brentuximab vedotin consolidation after autologous stem cell transplantation in Hodgkin lymphoma at risk of relapse","route":"/key-papers/paper-aethera-brentuximab-consolidation-after-asct-hodgkin-lancet-2015/","asOf":"2026-09-18","days":10},{"id":"paper-keynote-204-pembrolizumab-vs-brentuximab-rr-hodgkin-lancet-oncol-2021","kind":"paper","name":"KEYNOTE-204: pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma","route":"/key-papers/paper-keynote-204-pembrolizumab-vs-brentuximab-rr-hodgkin-lancet-oncol-2021/","asOf":"2026-09-18","days":10},{"id":"paper-checkmate-205-nivolumab-rr-hodgkin-extended-follow-up-jco-2018","kind":"paper","name":"CheckMate 205: nivolumab for relapsed or refractory classical Hodgkin lymphoma after autologous transplant failure, extended follow-up","route":"/key-papers/paper-checkmate-205-nivolumab-rr-hodgkin-extended-follow-up-jco-2018/","asOf":"2026-09-18","days":10},{"id":"paper-eichenauer-nlphl-ghsg-hd7-hd15-long-term-jco-2020","kind":"paper","name":"Long-term follow-up of nodular lymphocyte-predominant Hodgkin lymphoma treated in the GHSG HD7 to HD15 trials","route":"/key-papers/paper-eichenauer-nlphl-ghsg-hd7-hd15-long-term-jco-2020/","asOf":"2026-09-18","days":10},{"id":"paper-figo-2000-staging-gestational-trophoblastic-neoplasia-ijgo-2002","kind":"paper","name":"FIGO staging for gestational trophoblastic neoplasia 2000","route":"/key-papers/paper-figo-2000-staging-gestational-trophoblastic-neoplasia-ijgo-2002/","asOf":"2026-09-18","days":10},{"id":"paper-gog-174-methotrexate-vs-dactinomycin-low-risk-gtn-jco-2011","kind":"paper","name":"GOG 174: weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia","route":"/key-papers/paper-gog-174-methotrexate-vs-dactinomycin-low-risk-gtn-jco-2011/","asOf":"2026-09-18","days":10},{"id":"paper-bower-ema-co-high-risk-gtn-charing-cross-jco-1997","kind":"paper","name":"EMA/CO for high-risk gestational trophoblastic tumours: results from a cohort of 272 patients","route":"/key-papers/paper-bower-ema-co-high-risk-gtn-charing-cross-jco-1997/","asOf":"2026-09-18","days":10},{"id":"paper-figo-cancer-report-gestational-trophoblastic-disease-ijgo-2021","kind":"paper","name":"FIGO Cancer Report 2021: diagnosis and management of gestational trophoblastic disease","route":"/key-papers/paper-figo-cancer-report-gestational-trophoblastic-disease-ijgo-2021/","asOf":"2026-09-18","days":10},{"id":"paper-schmid-placental-site-trophoblastic-tumour-outcomes-lancet-2009","kind":"paper","name":"Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study","route":"/key-papers/paper-schmid-placental-site-trophoblastic-tumour-outcomes-lancet-2009/","asOf":"2026-09-18","days":10},{"id":"paper-froeling-pstt-ett-intensified-therapy-bjc-2019","kind":"paper","name":"Intensified therapies improve survival and identification of novel prognostic factors for placental-site and epithelioid trophoblastic tumours","route":"/key-papers/paper-froeling-pstt-ett-intensified-therapy-bjc-2019/","asOf":"2026-09-18","days":10},{"id":"paper-neumann-germline-mutations-nonsyndromic-pheochromocytoma-nejm-2002","kind":"paper","name":"Germline mutations in nonsyndromic pheochromocytoma","route":"/key-papers/paper-neumann-germline-mutations-nonsyndromic-pheochromocytoma-nejm-2002/","asOf":"2026-09-18","days":10},{"id":"paper-endocrine-society-pheochromocytoma-paraganglioma-guideline-jcem-2014","kind":"paper","name":"Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline","route":"/key-papers/paper-endocrine-society-pheochromocytoma-paraganglioma-guideline-jcem-2014/","asOf":"2026-09-18","days":10},{"id":"paper-pryma-high-specific-activity-i131-mibg-ppgl-jnm-2019","kind":"paper","name":"Efficacy and safety of high-specific-activity 131I-MIBG therapy in advanced pheochromocytoma or paraganglioma","route":"/key-papers/paper-pryma-high-specific-activity-i131-mibg-ppgl-jnm-2019/","asOf":"2026-09-18","days":10},{"id":"paper-intergroup-0099-chemoradiotherapy-nasopharyngeal-jco-1998","kind":"paper","name":"Intergroup 0099: chemoradiotherapy versus radiotherapy in advanced nasopharyngeal cancer","route":"/key-papers/paper-intergroup-0099-chemoradiotherapy-nasopharyngeal-jco-1998/","asOf":"2026-09-18","days":10},{"id":"paper-zhang-gemcitabine-cisplatin-induction-nasopharyngeal-nejm-2019","kind":"paper","name":"Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma","route":"/key-papers/paper-zhang-gemcitabine-cisplatin-induction-nasopharyngeal-nejm-2019/","asOf":"2026-09-18","days":10},{"id":"paper-csco-asco-nasopharyngeal-carcinoma-guideline-jco-2021","kind":"paper","name":"CSCO and ASCO guideline: chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II to IVA nasopharyngeal carcinoma","route":"/key-papers/paper-csco-asco-nasopharyngeal-carcinoma-guideline-jco-2021/","asOf":"2026-09-18","days":10},{"id":"paper-zhang-gemcitabine-cisplatin-vs-fluorouracil-cisplatin-rm-npc-lancet-2016","kind":"paper","name":"Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma","route":"/key-papers/paper-zhang-gemcitabine-cisplatin-vs-fluorouracil-cisplatin-rm-npc-lancet-2016/","asOf":"2026-09-18","days":10},{"id":"paper-jupiter-02-toripalimab-chemotherapy-npc-nat-med-2021","kind":"paper","name":"JUPITER-02: toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma","route":"/key-papers/paper-jupiter-02-toripalimab-chemotherapy-npc-nat-med-2021/","asOf":"2026-09-18","days":10},{"id":"paper-captain-1st-camrelizumab-chemotherapy-npc-lancet-oncol-2021","kind":"paper","name":"CAPTAIN-1st: camrelizumab versus placebo with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma","route":"/key-papers/paper-captain-1st-camrelizumab-chemotherapy-npc-lancet-oncol-2021/","asOf":"2026-09-18","days":10},{"id":"paper-kadish-olfactory-neuroblastoma-staging-cancer-1976","kind":"paper","name":"Kadish staging: olfactory neuroblastoma, a clinical analysis of 17 cases","route":"/key-papers/paper-kadish-olfactory-neuroblastoma-staging-cancer-1976/","asOf":"2026-09-18","days":10},{"id":"paper-dulguerov-esthesioneuroblastoma-meta-analysis-lancet-oncol-2001","kind":"paper","name":"Esthesioneuroblastoma: a meta-analysis and review","route":"/key-papers/paper-dulguerov-esthesioneuroblastoma-meta-analysis-lancet-oncol-2001/","asOf":"2026-09-18","days":10},{"id":"paper-amit-induction-chemotherapy-response-snuc-jco-2019","kind":"paper","name":"Induction chemotherapy response as a guide to treatment optimisation in sinonasal undifferentiated carcinoma","route":"/key-papers/paper-amit-induction-chemotherapy-response-snuc-jco-2019/","asOf":"2026-09-18","days":10},{"id":"paper-jo-idh2-r172-mutations-snuc-mod-pathol-2017","kind":"paper","name":"Recurrent IDH2 R172X mutations in sinonasal undifferentiated carcinoma","route":"/key-papers/paper-jo-idh2-r172-mutations-snuc-mod-pathol-2017/","asOf":"2026-09-18","days":10},{"id":"krankenhaus-nordwest","kind":"institution","name":"Krankenhaus Nordwest / Institute of Clinical Cancer Research (IKF)","route":"/institutions/krankenhaus-nordwest/","asOf":"2026-09-18","days":10},{"id":"kliniken-essen-mitte","kind":"institution","name":"Kliniken Essen-Mitte","route":"/institutions/kliniken-essen-mitte/","asOf":"2026-09-18","days":10},{"id":"lungenclinic-grosshansdorf","kind":"institution","name":"LungenClinic Grosshansdorf","route":"/institutions/lungenclinic-grosshansdorf/","asOf":"2026-09-18","days":10},{"id":"university-hospital-leipzig","kind":"institution","name":"Leipzig University Hospital / University Cancer Center Leipzig (UCCL)","route":"/institutions/university-hospital-leipzig/","asOf":"2026-09-18","days":10},{"id":"klinikum-stuttgart-olgahospital","kind":"institution","name":"Klinikum Stuttgart / Olgahospital","route":"/institutions/klinikum-stuttgart-olgahospital/","asOf":"2026-09-18","days":10},{"id":"ulm-university-hospital","kind":"institution","name":"Ulm University Hospital / Comprehensive Cancer Center Ulm","route":"/institutions/ulm-university-hospital/","asOf":"2026-09-18","days":10},{"id":"st-anna-ccri-vienna","kind":"institution","name":"St. Anna Children's Hospital and Children's Cancer Research Institute (CCRI)","route":"/institutions/st-anna-ccri-vienna/","asOf":"2026-09-18","days":10},{"id":"iosi-bellinzona","kind":"institution","name":"Oncology Institute of Southern Switzerland (IOSI)","route":"/institutions/iosi-bellinzona/","asOf":"2026-09-18","days":10},{"id":"ap-hm-timone","kind":"institution","name":"Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille","route":"/institutions/ap-hm-timone/","asOf":"2026-09-18","days":10},{"id":"chu-nantes","kind":"institution","name":"Nantes University Hospital (CHU de Nantes)","route":"/institutions/chu-nantes/","asOf":"2026-09-18","days":10},{"id":"chu-lille","kind":"institution","name":"Lille University Hospital (CHU de Lille)","route":"/institutions/chu-lille/","asOf":"2026-09-18","days":10},{"id":"antwerp-university-hospital","kind":"institution","name":"Antwerp University Hospital (UZA)","route":"/institutions/antwerp-university-hospital/","asOf":"2026-09-18","days":10},{"id":"niguarda-cancer-center","kind":"institution","name":"Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda","route":"/institutions/niguarda-cancer-center/","asOf":"2026-09-18","days":10},{"id":"fondazione-michelangelo","kind":"institution","name":"Fondazione Michelangelo","route":"/institutions/fondazione-michelangelo/","asOf":"2026-09-18","days":10},{"id":"ospedali-galliera","kind":"institution","name":"E.O. Ospedali Galliera","route":"/institutions/ospedali-galliera/","asOf":"2026-09-18","days":10},{"id":"university-of-pisa","kind":"institution","name":"University of Pisa / Azienda Ospedaliero-Universitaria Pisana","route":"/institutions/university-of-pisa/","asOf":"2026-09-18","days":10},{"id":"hospital-universitario-salamanca","kind":"institution","name":"University Hospital of Salamanca / IBSAL","route":"/institutions/hospital-universitario-salamanca/","asOf":"2026-09-18","days":10},{"id":"nkua-athens","kind":"institution","name":"National and Kapodistrian University of Athens, School of Medicine","route":"/institutions/nkua-athens/","asOf":"2026-09-18","days":10},{"id":"royal-free-hospital","kind":"institution","name":"Royal Free Hospital, Royal Free London NHS Foundation Trust","route":"/institutions/royal-free-hospital/","asOf":"2026-09-18","days":10},{"id":"weill-cornell-meyer-cancer-center","kind":"institution","name":"Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine","route":"/institutions/weill-cornell-meyer-cancer-center/","asOf":"2026-09-18","days":10},{"id":"seattle-childrens","kind":"institution","name":"Seattle Children's Hospital","route":"/institutions/seattle-childrens/","asOf":"2026-09-18","days":10},{"id":"carilion-clinic","kind":"institution","name":"Carilion Clinic / Virginia Tech Carilion School of Medicine","route":"/institutions/carilion-clinic/","asOf":"2026-09-18","days":10},{"id":"tennessee-oncology","kind":"institution","name":"Tennessee Oncology / Greco-Hainsworth Centers for Research","route":"/institutions/tennessee-oncology/","asOf":"2026-09-18","days":10},{"id":"us-oncology-network","kind":"institution","name":"The US Oncology Network / US Oncology Research","route":"/institutions/us-oncology-network/","asOf":"2026-09-18","days":10},{"id":"orlando-health-cancer-institute","kind":"institution","name":"Orlando Health Cancer Institute","route":"/institutions/orlando-health-cancer-institute/","asOf":"2026-09-18","days":10},{"id":"baylor-sammons-dallas","kind":"institution","name":"Charles A. Sammons Cancer Center, Baylor University Medical Center","route":"/institutions/baylor-sammons-dallas/","asOf":"2026-09-18","days":10},{"id":"tgen","kind":"institution","name":"Translational Genomics Research Institute (TGen)","route":"/institutions/tgen/","asOf":"2026-09-18","days":10},{"id":"houston-methodist-neal-cancer-center","kind":"institution","name":"Houston Methodist Dr. Mary and Ron Neal Cancer Center","route":"/institutions/houston-methodist-neal-cancer-center/","asOf":"2026-09-18","days":10},{"id":"childrens-national-hospital","kind":"institution","name":"Children's National Hospital","route":"/institutions/childrens-national-hospital/","asOf":"2026-09-18","days":10},{"id":"cincinnati-cancer-center","kind":"institution","name":"University of Cincinnati Cancer Center","route":"/institutions/cincinnati-cancer-center/","asOf":"2026-09-18","days":10},{"id":"mcw-cancer-center","kind":"institution","name":"Medical College of Wisconsin Cancer Center","route":"/institutions/mcw-cancer-center/","asOf":"2026-09-18","days":10},{"id":"university-of-alberta","kind":"institution","name":"University of Alberta","route":"/institutions/university-of-alberta/","asOf":"2026-09-18","days":10},{"id":"queens-university-kingston","kind":"institution","name":"Queen's University / Kingston Health Sciences Centre","route":"/institutions/queens-university-kingston/","asOf":"2026-09-18","days":10},{"id":"osaka-university","kind":"institution","name":"Osaka University Graduate School of Medicine / Osaka University Hospital","route":"/institutions/osaka-university/","asOf":"2026-09-18","days":10},{"id":"kindai-university-hospital","kind":"institution","name":"Kindai University Faculty of Medicine and Hospital","route":"/institutions/kindai-university-hospital/","asOf":"2026-09-18","days":10},{"id":"snu-bundang-hospital","kind":"institution","name":"Seoul National University Bundang Hospital","route":"/institutions/snu-bundang-hospital/","asOf":"2026-09-18","days":10},{"id":"melanoma-institute-australia","kind":"institution","name":"Melanoma Institute Australia","route":"/institutions/melanoma-institute-australia/","asOf":"2026-09-18","days":10},{"id":"saigenci-adelaide","kind":"institution","name":"South Australian immunoGENomics Cancer Institute (SAiGENCI), University of Adelaide","route":"/institutions/saigenci-adelaide/","asOf":"2026-09-18","days":10},{"id":"alfred-health-monash","kind":"institution","name":"Alfred Health / Monash University","route":"/institutions/alfred-health-monash/","asOf":"2026-09-18","days":10},{"id":"university-of-western-australia","kind":"institution","name":"University of Western Australia","route":"/institutions/university-of-western-australia/","asOf":"2026-09-18","days":10},{"id":"uq-frazer-institute","kind":"institution","name":"The University of Queensland Frazer Institute","route":"/institutions/uq-frazer-institute/","asOf":"2026-09-18","days":10},{"id":"strand-ai","kind":"company","name":"Strand AI","route":"/companies/strand-ai/","asOf":"2026-09-18","days":10},{"id":"anal-hsil-precursor","kind":"cancer","name":"Anal high-grade squamous intraepithelial lesions (precursor)","route":"/cancers/anal-hsil-precursor/","asOf":"2026-09-18","days":10},{"id":"localised-anal-cancer","kind":"cancer","name":"Localised anal squamous cell carcinoma (stage I to III)","route":"/cancers/localised-anal-cancer/","asOf":"2026-09-18","days":10},{"id":"metastatic-anal-cancer","kind":"cancer","name":"Metastatic and recurrent anal squamous cell carcinoma","route":"/cancers/metastatic-anal-cancer/","asOf":"2026-09-18","days":10},{"id":"localised-penile-cancer","kind":"cancer","name":"Localised penile cancer (organ-confined, node-negative)","route":"/cancers/localised-penile-cancer/","asOf":"2026-09-18","days":10},{"id":"node-positive-penile-cancer","kind":"cancer","name":"Node-positive and metastatic penile cancer","route":"/cancers/node-positive-penile-cancer/","asOf":"2026-09-18","days":10},{"id":"hpv-associated-vulvar-cancer","kind":"cancer","name":"HPV-associated vulvar squamous cell carcinoma","route":"/cancers/hpv-associated-vulvar-cancer/","asOf":"2026-09-18","days":10},{"id":"hpv-independent-vulvar-cancer","kind":"cancer","name":"HPV-independent vulvar squamous cell carcinoma (p53-mutant)","route":"/cancers/hpv-independent-vulvar-cancer/","asOf":"2026-09-18","days":10},{"id":"vaginal-squamous-cell-carcinoma","kind":"cancer","name":"Vaginal squamous cell carcinoma (HPV-associated)","route":"/cancers/vaginal-squamous-cell-carcinoma/","asOf":"2026-09-18","days":10},{"id":"vaginal-adenocarcinoma","kind":"cancer","name":"Vaginal adenocarcinoma (including DES-associated clear cell adenocarcinoma)","route":"/cancers/vaginal-adenocarcinoma/","asOf":"2026-09-18","days":10},{"id":"thymoma","kind":"cancer","name":"Thymoma (WHO types A, AB, B1, B2 and B3)","route":"/cancers/thymoma/","asOf":"2026-09-18","days":10},{"id":"thymic-carcinoma","kind":"cancer","name":"Thymic carcinoma","route":"/cancers/thymic-carcinoma/","asOf":"2026-09-18","days":10},{"id":"localised-adrenocortical-carcinoma","kind":"cancer","name":"Localised adrenocortical carcinoma (ENSAT stage I to III, resectable)","route":"/cancers/localised-adrenocortical-carcinoma/","asOf":"2026-09-18","days":10},{"id":"advanced-adrenocortical-carcinoma","kind":"cancer","name":"Advanced and metastatic adrenocortical carcinoma (ENSAT stage IV or unresectable)","route":"/cancers/advanced-adrenocortical-carcinoma/","asOf":"2026-09-18","days":10},{"id":"low-grade-appendiceal-mucinous-neoplasm","kind":"cancer","name":"Low-grade appendiceal mucinous neoplasm and pseudomyxoma peritonei","route":"/cancers/low-grade-appendiceal-mucinous-neoplasm/","asOf":"2026-09-18","days":10},{"id":"appendiceal-adenocarcinoma","kind":"cancer","name":"Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell)","route":"/cancers/appendiceal-adenocarcinoma/","asOf":"2026-09-18","days":10},{"id":"goblet-cell-adenocarcinoma","kind":"cancer","name":"Goblet cell adenocarcinoma of the appendix","route":"/cancers/goblet-cell-adenocarcinoma/","asOf":"2026-09-18","days":10},{"id":"localised-small-bowel-adenocarcinoma","kind":"cancer","name":"Localised small bowel adenocarcinoma (stage I to III, resected)","route":"/cancers/localised-small-bowel-adenocarcinoma/","asOf":"2026-09-18","days":10},{"id":"advanced-small-bowel-adenocarcinoma","kind":"cancer","name":"Advanced and metastatic small bowel adenocarcinoma","route":"/cancers/advanced-small-bowel-adenocarcinoma/","asOf":"2026-09-18","days":10},{"id":"cup-favourable-subsets","kind":"cancer","name":"Cancer of unknown primary, favourable subsets","route":"/cancers/cup-favourable-subsets/","asOf":"2026-09-18","days":10},{"id":"cup-unfavourable","kind":"cancer","name":"Cancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma)","route":"/cancers/cup-unfavourable/","asOf":"2026-09-18","days":10},{"id":"erdheim-chester-disease","kind":"cancer","name":"Erdheim-Chester disease","route":"/cancers/erdheim-chester-disease/","asOf":"2026-09-18","days":10},{"id":"rosai-dorfman-disease","kind":"cancer","name":"Rosai-Dorfman-Destombes disease","route":"/cancers/rosai-dorfman-disease/","asOf":"2026-09-18","days":10},{"id":"lch-single-system","kind":"cancer","name":"Single-system Langerhans cell histiocytosis (bone, skin or one other organ)","route":"/cancers/lch-single-system/","asOf":"2026-09-18","days":10},{"id":"lch-multisystem","kind":"cancer","name":"Multisystem Langerhans cell histiocytosis (with or without risk-organ involvement)","route":"/cancers/lch-multisystem/","asOf":"2026-09-18","days":10},{"id":"indolent-systemic-mastocytosis","kind":"cancer","name":"Indolent and smouldering systemic mastocytosis","route":"/cancers/indolent-systemic-mastocytosis/","asOf":"2026-09-18","days":10},{"id":"advanced-systemic-mastocytosis","kind":"cancer","name":"Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia)","route":"/cancers/advanced-systemic-mastocytosis/","asOf":"2026-09-18","days":10},{"id":"early-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Early-stage classical Hodgkin lymphoma (stage I to II)","route":"/cancers/early-stage-classical-hodgkin-lymphoma/","asOf":"2026-09-18","days":10},{"id":"advanced-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Advanced-stage classical Hodgkin lymphoma (stage III to IV)","route":"/cancers/advanced-stage-classical-hodgkin-lymphoma/","asOf":"2026-09-18","days":10},{"id":"nodular-lymphocyte-predominant-hodgkin-lymphoma","kind":"cancer","name":"Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma)","route":"/cancers/nodular-lymphocyte-predominant-hodgkin-lymphoma/","asOf":"2026-09-18","days":10},{"id":"relapsed-refractory-hodgkin-lymphoma","kind":"cancer","name":"Relapsed and refractory classical Hodgkin lymphoma","route":"/cancers/relapsed-refractory-hodgkin-lymphoma/","asOf":"2026-09-18","days":10},{"id":"low-risk-gtn","kind":"cancer","name":"Low-risk gestational trophoblastic neoplasia (FIGO score 0 to 6)","route":"/cancers/low-risk-gtn/","asOf":"2026-09-18","days":10},{"id":"high-risk-gtn","kind":"cancer","name":"High-risk gestational trophoblastic neoplasia (FIGO score 7 or more, including ultra-high-risk)","route":"/cancers/high-risk-gtn/","asOf":"2026-09-18","days":10},{"id":"placental-site-trophoblastic-tumour","kind":"cancer","name":"Placental-site trophoblastic tumour and epithelioid trophoblastic tumour","route":"/cancers/placental-site-trophoblastic-tumour/","asOf":"2026-09-18","days":10},{"id":"hereditary-ppgl","kind":"cancer","name":"Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)","route":"/cancers/hereditary-ppgl/","asOf":"2026-09-18","days":10},{"id":"metastatic-ppgl","kind":"cancer","name":"Metastatic pheochromocytoma and paraganglioma","route":"/cancers/metastatic-ppgl/","asOf":"2026-09-18","days":10},{"id":"locoregionally-advanced-nasopharyngeal-carcinoma","kind":"cancer","name":"Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA)","route":"/cancers/locoregionally-advanced-nasopharyngeal-carcinoma/","asOf":"2026-09-18","days":10},{"id":"recurrent-metastatic-nasopharyngeal-carcinoma","kind":"cancer","name":"Recurrent and metastatic nasopharyngeal carcinoma","route":"/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/","asOf":"2026-09-18","days":10},{"id":"esthesioneuroblastoma","kind":"cancer","name":"Esthesioneuroblastoma (olfactory neuroblastoma)","route":"/cancers/esthesioneuroblastoma/","asOf":"2026-09-18","days":10},{"id":"sinonasal-undifferentiated-carcinoma","kind":"cancer","name":"Sinonasal undifferentiated carcinoma (SNUC) and SWI/SNF-deficient sinonasal carcinoma","route":"/cancers/sinonasal-undifferentiated-carcinoma/","asOf":"2026-09-18","days":10},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/","asOf":"2026-09-18","days":10},{"id":"borderline-resectable-pdac","kind":"cancer","name":"Borderline resectable pancreatic ductal adenocarcinoma","route":"/cancers/borderline-resectable-pdac/","asOf":"2026-09-18","days":10},{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/","asOf":"2026-09-18","days":10},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/","asOf":"2026-09-18","days":10},{"id":"kras-g12c-pdac","kind":"cancer","name":"KRAS G12C-mutant pancreatic ductal adenocarcinoma","route":"/cancers/kras-g12c-pdac/","asOf":"2026-09-18","days":10},{"id":"kras-wild-type-pdac","kind":"cancer","name":"KRAS wild-type pancreatic ductal adenocarcinoma","route":"/cancers/kras-wild-type-pdac/","asOf":"2026-09-18","days":10},{"id":"brca-palb2-pdac","kind":"cancer","name":"BRCA or PALB2-mutant pancreatic ductal adenocarcinoma","route":"/cancers/brca-palb2-pdac/","asOf":"2026-09-18","days":10},{"id":"msi-high-pdac","kind":"cancer","name":"Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma","route":"/cancers/msi-high-pdac/","asOf":"2026-09-18","days":10},{"id":"pancreatic-acinar-cell-carcinoma","kind":"cancer","name":"Pancreatic acinar cell carcinoma","route":"/cancers/pancreatic-acinar-cell-carcinoma/","asOf":"2026-09-18","days":10},{"id":"ipmn-cystic-precursors","kind":"cancer","name":"Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors","route":"/cancers/ipmn-cystic-precursors/","asOf":"2026-09-18","days":10},{"id":"pancreatoblastoma","kind":"cancer","name":"Pancreatoblastoma","route":"/cancers/pancreatoblastoma/","asOf":"2026-09-18","days":10},{"id":"g12d-plus-pan-ras","kind":"pairing","name":"G12D-selective + pan-RAS(ON) inhibitor (zoldonrasib + daraxonrasib)","route":"/pairings/g12d-plus-pan-ras/","asOf":"2026-09-21","days":7},{"id":"muc16","kind":"target","name":"MUC16 (CA-125)","route":"/targets/muc16/","asOf":"2026-09-21","days":7},{"id":"paper-partiqol-astro-2024","kind":"paper","name":"PARTIQoL: phase 3 randomised trial of proton therapy versus IMRT for localised prostate cancer (ASTRO 2024 late-breaking abstract)","route":"/key-papers/paper-partiqol-astro-2024/","asOf":"2026-09-21","days":7},{"id":"paper-prodige-24-adjuvant-mfolfirinox-pancreatic-nejm-2018","kind":"paper","name":"PRODIGE 24/CCTG PA6: adjuvant modified FOLFIRINOX versus gemcitabine after resection of pancreatic cancer","route":"/key-papers/paper-prodige-24-adjuvant-mfolfirinox-pancreatic-nejm-2018/","asOf":"2026-09-21","days":7},{"id":"paper-espac-4-gemcitabine-capecitabine-adjuvant-pancreatic-lancet-2017","kind":"paper","name":"ESPAC-4: adjuvant gemcitabine plus capecitabine versus gemcitabine alone after resection of pancreatic cancer","route":"/key-papers/paper-espac-4-gemcitabine-capecitabine-adjuvant-pancreatic-lancet-2017/","asOf":"2026-09-21","days":7},{"id":"paper-preopanc-neoadjuvant-chemoradiotherapy-long-term-jco-2022","kind":"paper","name":"PREOPANC long-term results: neoadjuvant gemcitabine-based chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer","route":"/key-papers/paper-preopanc-neoadjuvant-chemoradiotherapy-long-term-jco-2022/","asOf":"2026-09-21","days":7},{"id":"paper-espac-5-neoadjuvant-borderline-resectable-pancreatic-lancet-gastro-hep-2023","kind":"paper","name":"ESPAC5: immediate surgery versus short-course neoadjuvant chemotherapy or chemoradiotherapy for borderline resectable pancreatic cancer","route":"/key-papers/paper-espac-5-neoadjuvant-borderline-resectable-pancreatic-lancet-gastro-hep-2023/","asOf":"2026-09-21","days":7},{"id":"paper-alliance-a021501-mfolfirinox-radiotherapy-borderline-resectable-jama-oncol-2022","kind":"paper","name":"Alliance A021501: preoperative modified FOLFIRINOX with or without hypofractionated radiotherapy for borderline resectable pancreatic cancer","route":"/key-papers/paper-alliance-a021501-mfolfirinox-radiotherapy-borderline-resectable-jama-oncol-2022/","asOf":"2026-09-21","days":7},{"id":"paper-lap07-chemoradiotherapy-locally-advanced-pancreatic-jama-2016","kind":"paper","name":"LAP07: chemoradiotherapy versus continued chemotherapy for locally advanced pancreatic cancer controlled after four months of gemcitabine","route":"/key-papers/paper-lap07-chemoradiotherapy-locally-advanced-pancreatic-jama-2016/","asOf":"2026-09-21","days":7},{"id":"paper-codebreak-100-sotorasib-kras-g12c-pancreatic-nejm-2023","kind":"paper","name":"CodeBreaK 100: sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer","route":"/key-papers/paper-codebreak-100-sotorasib-kras-g12c-pancreatic-nejm-2023/","asOf":"2026-09-21","days":7},{"id":"paper-krystal-1-adagrasib-kras-g12c-solid-tumours-jco-2023","kind":"paper","name":"KRYSTAL-1: adagrasib in advanced solid tumours harbouring a KRAS G12C mutation, including pancreatic cancer","route":"/key-papers/paper-krystal-1-adagrasib-kras-g12c-solid-tumours-jco-2023/","asOf":"2026-09-21","days":7},{"id":"paper-heining-nrg1-fusions-kras-wild-type-pancreatic-cancer-discov-2018","kind":"paper","name":"Heining 2018: NRG1 fusions in KRAS wild-type pancreatic cancer","route":"/key-papers/paper-heining-nrg1-fusions-kras-wild-type-pancreatic-cancer-discov-2018/","asOf":"2026-09-21","days":7},{"id":"paper-jones-nrg1-fusions-recurrent-actionable-kras-wild-type-pdac-ccr-2019","kind":"paper","name":"Jones 2019: NRG1 gene fusions are recurrent, clinically actionable rearrangements in KRAS wild-type pancreatic ductal adenocarcinoma","route":"/key-papers/paper-jones-nrg1-fusions-recurrent-actionable-kras-wild-type-pdac-ccr-2019/","asOf":"2026-09-21","days":7},{"id":"paper-enrgy-zenocutuzumab-nrg1-fusion-positive-cancer-nejm-2025","kind":"paper","name":"eNRGy: efficacy of zenocutuzumab in NRG1 fusion-positive cancer","route":"/key-papers/paper-enrgy-zenocutuzumab-nrg1-fusion-positive-cancer-nejm-2025/","asOf":"2026-09-21","days":7},{"id":"paper-polo-olaparib-maintenance-gbrca-pancreatic-nejm-2019","kind":"paper","name":"POLO: maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","route":"/key-papers/paper-polo-olaparib-maintenance-gbrca-pancreatic-nejm-2019/","asOf":"2026-09-21","days":7},{"id":"paper-polo-overall-survival-olaparib-gbrca-pancreatic-jco-2022","kind":"paper","name":"POLO final overall survival: maintenance olaparib versus placebo in germline BRCA-mutated metastatic pancreatic cancer","route":"/key-papers/paper-polo-overall-survival-olaparib-gbrca-pancreatic-jco-2022/","asOf":"2026-09-21","days":7},{"id":"paper-oreilly-gemcitabine-cisplatin-veliparib-gbrca-palb2-pancreatic-jco-2020","kind":"paper","name":"O'Reilly 2020: gemcitabine and cisplatin with or without veliparib in pancreatic cancer with a germline BRCA or PALB2 mutation","route":"/key-papers/paper-oreilly-gemcitabine-cisplatin-veliparib-gbrca-palb2-pancreatic-jco-2020/","asOf":"2026-09-21","days":7},{"id":"paper-keynote-158-pembrolizumab-msi-high-noncolorectal-jco-2020","kind":"paper","name":"KEYNOTE-158: pembrolizumab in non-colorectal high microsatellite instability or mismatch repair-deficient cancer","route":"/key-papers/paper-keynote-158-pembrolizumab-msi-high-noncolorectal-jco-2020/","asOf":"2026-09-21","days":7},{"id":"paper-hu-mismatch-repair-deficiency-pancreatic-adenocarcinoma-ccr-2018","kind":"paper","name":"Hu 2018: evaluating mismatch repair deficiency in pancreatic adenocarcinoma, challenges and recommendations","route":"/key-papers/paper-hu-mismatch-repair-deficiency-pancreatic-adenocarcinoma-ccr-2018/","asOf":"2026-09-21","days":7},{"id":"paper-klimstra-acinar-cell-carcinoma-pancreas-28-cases-ajsp-1992","kind":"paper","name":"Klimstra 1992: acinar cell carcinoma of the pancreas, a clinicopathologic study of 28 cases","route":"/key-papers/paper-klimstra-acinar-cell-carcinoma-pancreas-28-cases-ajsp-1992/","asOf":"2026-09-21","days":7},{"id":"paper-la-rosa-acinar-cell-carcinoma-62-cases-ajsp-2012","kind":"paper","name":"La Rosa 2012: clinicopathologic study of 62 acinar cell carcinomas of the pancreas","route":"/key-papers/paper-la-rosa-acinar-cell-carcinoma-62-cases-ajsp-2012/","asOf":"2026-09-21","days":7},{"id":"paper-chmielecki-acinar-cell-carcinoma-raf-fusions-dna-repair-cancer-discov-2014","kind":"paper","name":"Chmielecki 2014: comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes","route":"/key-papers/paper-chmielecki-acinar-cell-carcinoma-raf-fusions-dna-repair-cancer-discov-2014/","asOf":"2026-09-21","days":7},{"id":"paper-wisnoski-acinar-cell-carcinoma-672-patients-seer-surgery-2008","kind":"paper","name":"Wisnoski 2008: 672 patients with acinar cell carcinoma of the pancreas, a population-based comparison to pancreatic adenocarcinoma","route":"/key-papers/paper-wisnoski-acinar-cell-carcinoma-672-patients-seer-surgery-2008/","asOf":"2026-09-21","days":7},{"id":"paper-fukuoka-2017-consensus-guidelines-ipmn-pancreatology-2017","kind":"paper","name":"Revised international consensus Fukuoka guidelines for the management of IPMN of the pancreas (2017)","route":"/key-papers/paper-fukuoka-2017-consensus-guidelines-ipmn-pancreatology-2017/","asOf":"2026-09-21","days":7},{"id":"paper-kyoto-2024-evidence-based-guidelines-ipmn-pancreatology-2024","kind":"paper","name":"International evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas (2024)","route":"/key-papers/paper-kyoto-2024-evidence-based-guidelines-ipmn-pancreatology-2024/","asOf":"2026-09-21","days":7},{"id":"paper-european-evidence-based-guidelines-pancreatic-cystic-neoplasms-gut-2018","kind":"paper","name":"European evidence-based guidelines on pancreatic cystic neoplasms (2018)","route":"/key-papers/paper-european-evidence-based-guidelines-pancreatic-cystic-neoplasms-gut-2018/","asOf":"2026-09-21","days":7},{"id":"paper-klimstra-pancreatoblastoma-clinicopathologic-study-ajsp-1995","kind":"paper","name":"Klimstra 1995: pancreatoblastoma, a clinicopathologic study and review of the literature","route":"/key-papers/paper-klimstra-pancreatoblastoma-clinicopathologic-study-ajsp-1995/","asOf":"2026-09-21","days":7},{"id":"paper-bien-pancreatoblastoma-expert-european-cooperative-ejc-2011","kind":"paper","name":"Bien 2011: pancreatoblastoma, a report from the European cooperative study group for paediatric rare tumours (EXPeRT)","route":"/key-papers/paper-bien-pancreatoblastoma-expert-european-cooperative-ejc-2011/","asOf":"2026-09-21","days":7},{"id":"paper-dhebri-pancreatoblastoma-diagnosis-treatment-outcome-pancreatology-2004","kind":"paper","name":"Dhebri 2004: diagnosis, treatment and outcome of pancreatoblastoma","route":"/key-papers/paper-dhebri-pancreatoblastoma-diagnosis-treatment-outcome-pancreatology-2004/","asOf":"2026-09-21","days":7},{"id":"paper-adaura-8-year-os-jto-2026","kind":"paper","name":"ADAURA: exploratory eight-year overall survival update for adjuvant osimertinib in resected EGFR-mutated stage IB to IIIA lung cancer","route":"/key-papers/paper-adaura-8-year-os-jto-2026/","asOf":"2026-09-21","days":7},{"id":"paper-flaura2-long-term-safety-lung-cancer-2026","kind":"paper","name":"FLAURA2: long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced lung cancer","route":"/key-papers/paper-flaura2-long-term-safety-lung-cancer-2026/","asOf":"2026-09-21","days":7},{"id":"paper-krystal-12-plain-language-summary-future-oncol-2026","kind":"paper","name":"KRYSTAL-12 plain language summary: adagrasib for non-small-cell lung cancer with KRAS G12C mutations","route":"/key-papers/paper-krystal-12-plain-language-summary-future-oncol-2026/","asOf":"2026-09-21","days":7},{"id":"paper-tropion-breast01-china-cohort-esmo-open-2026","kind":"paper","name":"TROPION-Breast01 China cohort: datopotamab deruxtecan versus chemotherapy in previously treated HR-positive, HER2-negative breast cancer","route":"/key-papers/paper-tropion-breast01-china-cohort-esmo-open-2026/","asOf":"2026-09-21","days":7},{"id":"paper-ctrak-tn-tissue-free-mrd-jamaoncol-2026","kind":"paper","name":"c-TRAK TN analysis: tissue-free versus tumour-informed ctDNA assays for residual disease in early triple-negative breast cancer","route":"/key-papers/paper-ctrak-tn-tissue-free-mrd-jamaoncol-2026/","asOf":"2026-09-21","days":7},{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/","asOf":"2026-09-21","days":7},{"id":"tracc","kind":"trial","name":"TRACC","route":"/trials/tracc/","asOf":"2026-09-21","days":7},{"id":"bespoke-crc","kind":"trial","name":"BESPOKE CRC","route":"/trials/bespoke-crc/","asOf":"2026-09-21","days":7},{"id":"mermaid-1","kind":"trial","name":"MERMAID-1","route":"/trials/mermaid-1/","asOf":"2026-09-21","days":7},{"id":"circulate-us","kind":"trial","name":"CIRCULATE-US","route":"/trials/circulate-us/","asOf":"2026-09-21","days":7},{"id":"vanguard-study","kind":"trial","name":"Vanguard Study (NCI Cancer Screening Research Network)","route":"/trials/vanguard-study/","asOf":"2026-09-21","days":7},{"id":"tumour-informed-assay","kind":"term","name":"Tumour-informed versus tumour-naive ctDNA assays","route":"/terms/tumour-informed-assay/","asOf":"2026-09-21","days":7},{"id":"ubamatamab","kind":"drug","name":"Ubamatamab","route":"/drugs/ubamatamab/","asOf":"2026-09-21","days":7},{"id":"nct06040541","kind":"trial","name":"Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors","route":"/trials/nct06040541/","asOf":"2026-09-21","days":7},{"id":"paper-haslam-jama-netw-open","kind":"paper","name":"Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs","route":"/key-papers/paper-haslam-jama-netw-open/","asOf":"2026-09-22","days":6},{"id":"paper-crosby-science","kind":"paper","name":"Early detection of cancer","route":"/key-papers/paper-crosby-science/","asOf":"2026-09-22","days":6},{"id":"paper-islami-ca-cancer-j-clin","kind":"paper","name":"Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States","route":"/key-papers/paper-islami-ca-cancer-j-clin/","asOf":"2026-09-22","days":6},{"id":"paper-dang-nat-rev-cancer","kind":"paper","name":"Drugging the 'undruggable' cancer targets","route":"/key-papers/paper-dang-nat-rev-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-wu-nat-med","kind":"paper","name":"How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals","route":"/key-papers/paper-wu-nat-med/","asOf":"2026-09-22","days":6},{"id":"paper-wong-biostatistics","kind":"paper","name":"Estimation of clinical trial success rates and related parameters","route":"/key-papers/paper-wong-biostatistics/","asOf":"2026-09-22","days":6},{"id":"paper-hernandez-jama-oncol","kind":"paper","name":"Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy","route":"/key-papers/paper-hernandez-jama-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-welch-j-natl-cancer-inst","kind":"paper","name":"Overdiagnosis in cancer","route":"/key-papers/paper-welch-j-natl-cancer-inst/","asOf":"2026-09-22","days":6},{"id":"paper-pantziarka-ecancermedicalscience","kind":"paper","name":"The Repurposing Drugs in Oncology (ReDO) Project","route":"/key-papers/paper-pantziarka-ecancermedicalscience/","asOf":"2026-09-22","days":6},{"id":"paper-prasad-nat-rev-clin-oncol","kind":"paper","name":"The high price of anticancer drugs: origins, implications, barriers, solutions","route":"/key-papers/paper-prasad-nat-rev-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-palmer-cell","kind":"paper","name":"Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy","route":"/key-papers/paper-palmer-cell/","asOf":"2026-09-22","days":6},{"id":"paper-hanna-bmj","kind":"paper","name":"Mortality due to cancer treatment delay: systematic review and meta-analysis","route":"/key-papers/paper-hanna-bmj/","asOf":"2026-09-22","days":6},{"id":"paper-morris-j-r-soc-med","kind":"paper","name":"The answer is 17 years, what is the question: understanding time lags in translational research","route":"/key-papers/paper-morris-j-r-soc-med/","asOf":"2026-09-22","days":6},{"id":"paper-fernandez-jama-oncol","kind":"paper","name":"Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue","route":"/key-papers/paper-fernandez-jama-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-dillekas-cancer-med","kind":"paper","name":"Are 90% of deaths from cancer caused by metastases?","route":"/key-papers/paper-dillekas-cancer-med/","asOf":"2026-09-22","days":6},{"id":"paper-davis-bmj","kind":"paper","name":"Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13","route":"/key-papers/paper-davis-bmj/","asOf":"2026-09-22","days":6},{"id":"paper-johnson-j-natl-cancer-inst","kind":"paper","name":"Cancer Misinformation and Harmful Information on Facebook and Other Social Media: A Brief Report","route":"/key-papers/paper-johnson-j-natl-cancer-inst/","asOf":"2026-09-22","days":6},{"id":"paper-di-maio-j-clin-oncol","kind":"paper","name":"Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials","route":"/key-papers/paper-di-maio-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-childers-j-clin-oncol","kind":"paper","name":"National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer","route":"/key-papers/paper-childers-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-yang-j-oncol-pract","kind":"paper","name":"Projected supply of and demand for oncologists and radiation oncologists through 2025: an aging, better-insured population will result in shortage","route":"/key-papers/paper-yang-j-oncol-pract/","asOf":"2026-09-22","days":6},{"id":"paper-gyawali-jama-intern-med","kind":"paper","name":"Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval","route":"/key-papers/paper-gyawali-jama-intern-med/","asOf":"2026-09-22","days":6},{"id":"paper-loree-jama-oncol","kind":"paper","name":"Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018","route":"/key-papers/paper-loree-jama-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-sullivan-lancet-oncol","kind":"paper","name":"Global cancer surgery: delivering safe, affordable, and timely cancer surgery","route":"/key-papers/paper-sullivan-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-anderson-n-engl-j-med","kind":"paper","name":"Compliance with results reporting at ClinicalTrials.gov","route":"/key-papers/paper-anderson-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-fearon-lancet-oncol","kind":"paper","name":"Definition and classification of cancer cachexia: an international consensus","route":"/key-papers/paper-fearon-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-upadhaya-nat-rev-drug-discov","kind":"paper","name":"Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape","route":"/key-papers/paper-upadhaya-nat-rev-drug-discov/","asOf":"2026-09-22","days":6},{"id":"paper-gatta-eur-j-cancer","kind":"paper","name":"Rare cancers are not so rare: the rare cancer burden in Europe","route":"/key-papers/paper-gatta-eur-j-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-butler-nature","kind":"paper","name":"Translational research: crossing the valley of death","route":"/key-papers/paper-butler-nature/","asOf":"2026-09-22","days":6},{"id":"paper-sun-bmc-cancer","kind":"paper","name":"Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials","route":"/key-papers/paper-sun-bmc-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-mao-j-clin-oncol","kind":"paper","name":"Integrative Medicine for Pain Management in Oncology: Society for Integrative Oncology-ASCO Guideline","route":"/key-papers/paper-mao-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-danchev-jama-netw-open","kind":"paper","name":"Evaluation of Data Sharing After Implementation of the International Committee of Medical Journal Editors Data Sharing Statement Requirement","route":"/key-papers/paper-danchev-jama-netw-open/","asOf":"2026-09-22","days":6},{"id":"paper-carlson-j-clin-oncol","kind":"paper","name":"Integrative Oncology Care of Symptoms of Anxiety and Depression in Adults With Cancer: Society for Integrative Oncology-ASCO Guideline","route":"/key-papers/paper-carlson-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-muscaritoli-clin-nutr","kind":"paper","name":"ESPEN practical guideline: Clinical Nutrition in cancer","route":"/key-papers/paper-muscaritoli-clin-nutr/","asOf":"2026-09-22","days":6},{"id":"paper-atun-lancet-oncol","kind":"paper","name":"Expanding global access to radiotherapy","route":"/key-papers/paper-atun-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-davar-science","kind":"paper","name":"Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients","route":"/key-papers/paper-davar-science/","asOf":"2026-09-22","days":6},{"id":"paper-greenlee-ca-cancer-j-clin","kind":"paper","name":"Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment","route":"/key-papers/paper-greenlee-ca-cancer-j-clin/","asOf":"2026-09-22","days":6},{"id":"paper-elad-cancer","kind":"paper","name":"MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy","route":"/key-papers/paper-elad-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-tap-lancet","kind":"paper","name":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial","route":"/key-papers/paper-tap-lancet/","asOf":"2026-09-22","days":6},{"id":"paper-vokinger-lancet-oncol","kind":"paper","name":"Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis","route":"/key-papers/paper-vokinger-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-zhang-nat-commun","kind":"paper","name":"Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer","route":"/key-papers/paper-zhang-nat-commun/","asOf":"2026-09-22","days":6},{"id":"paper-murray-brunt-lancet","kind":"paper","name":"Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial","route":"/key-papers/paper-murray-brunt-lancet/","asOf":"2026-09-22","days":6},{"id":"paper-massague-nature","kind":"paper","name":"Metastatic colonization by circulating tumour cells","route":"/key-papers/paper-massague-nature/","asOf":"2026-09-22","days":6},{"id":"paper-chen-nature","kind":"paper","name":"Elements of cancer immunity and the cancer-immune set point","route":"/key-papers/paper-chen-nature/","asOf":"2026-09-22","days":6},{"id":"paper-lord-science","kind":"paper","name":"PARP inhibitors: Synthetic lethality in the clinic","route":"/key-papers/paper-lord-science/","asOf":"2026-09-22","days":6},{"id":"paper-kindler-lancet-oncol","kind":"paper","name":"Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial","route":"/key-papers/paper-kindler-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-brock-n-engl-j-med","kind":"paper","name":"Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss","route":"/key-papers/paper-brock-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-chen-nat-med","kind":"paper","name":"Towards a general-purpose foundation model for computational pathology","route":"/key-papers/paper-chen-nat-med/","asOf":"2026-09-22","days":6},{"id":"paper-xu-jama","kind":"paper","name":"Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial","route":"/key-papers/paper-xu-jama/","asOf":"2026-09-22","days":6},{"id":"paper-molenaar-jama-surg","kind":"paper","name":"Effect of Multimodal Prehabilitation on Reducing Postoperative Complications and Enhancing Functional Capacity Following Colorectal Cancer Surgery: The PREHAB Randomized Clinical Trial","route":"/key-papers/paper-molenaar-jama-surg/","asOf":"2026-09-22","days":6},{"id":"paper-hirsch-j-thorac-oncol","kind":"paper","name":"PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project","route":"/key-papers/paper-hirsch-j-thorac-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-independent-uk-panel-on-breast-cancer-lancet","kind":"paper","name":"The benefits and harms of breast cancer screening: an independent review","route":"/key-papers/paper-independent-uk-panel-on-breast-cancer-lancet/","asOf":"2026-09-22","days":6},{"id":"paper-early-breast-cancer-trialists-collaborative-group-ebctcg-lancet","kind":"paper","name":"Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials","route":"/key-papers/paper-early-breast-cancer-trialists-collaborative-group-ebctcg-lancet/","asOf":"2026-09-22","days":6},{"id":"paper-knaul-lancet","kind":"paper","name":"Alleviating the access abyss in palliative care and pain relief-an imperative of universal health coverage: the Lancet Commission report","route":"/key-papers/paper-knaul-lancet/","asOf":"2026-09-22","days":6},{"id":"paper-takahashi-lancet-oncol","kind":"paper","name":"Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial","route":"/key-papers/paper-takahashi-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-ren-lancet-oncol","kind":"paper","name":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study","route":"/key-papers/paper-ren-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-qian-lancet-oncol","kind":"paper","name":"Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study","route":"/key-papers/paper-qian-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-greaves-nature","kind":"paper","name":"Clonal evolution in cancer","route":"/key-papers/paper-greaves-nature/","asOf":"2026-09-22","days":6},{"id":"paper-phan-nat-rev-cancer","kind":"paper","name":"The dormant cancer cell life cycle","route":"/key-papers/paper-phan-nat-rev-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-vasan-nature","kind":"paper","name":"A view on drug resistance in cancer","route":"/key-papers/paper-vasan-nature/","asOf":"2026-09-22","days":6},{"id":"paper-pan-n-engl-j-med","kind":"paper","name":"20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years","route":"/key-papers/paper-pan-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-ahn-n-engl-j-med","kind":"paper","name":"Korea's thyroid-cancer \"epidemic\"--screening and overdiagnosis","route":"/key-papers/paper-ahn-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-lyon-eur-heart-j","kind":"paper","name":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","route":"/key-papers/paper-lyon-eur-heart-j/","asOf":"2026-09-22","days":6},{"id":"paper-nowell-science","kind":"paper","name":"The clonal evolution of tumor cell populations","route":"/key-papers/paper-nowell-science/","asOf":"2026-09-22","days":6},{"id":"paper-martincorena-science","kind":"paper","name":"Somatic mutant clones colonize the human esophagus with age","route":"/key-papers/paper-martincorena-science/","asOf":"2026-09-22","days":6},{"id":"paper-baruch-science","kind":"paper","name":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients","route":"/key-papers/paper-baruch-science/","asOf":"2026-09-22","days":6},{"id":"paper-gatenby-cancer-res","kind":"paper","name":"Adaptive therapy","route":"/key-papers/paper-gatenby-cancer-res/","asOf":"2026-09-22","days":6},{"id":"paper-roeland-j-clin-oncol","kind":"paper","name":"Management of Cancer Cachexia: ASCO Guideline","route":"/key-papers/paper-roeland-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-sandhya-j-clin-oncol","kind":"paper","name":"Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer","route":"/key-papers/paper-sandhya-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-yamazaki-nat-commun","kind":"paper","name":"Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance","route":"/key-papers/paper-yamazaki-nat-commun/","asOf":"2026-09-22","days":6},{"id":"paper-ligibel-npj-breast-cancer","kind":"paper","name":"Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design","route":"/key-papers/paper-ligibel-npj-breast-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-mcneil-n-engl-j-med","kind":"paper","name":"Effect of Aspirin on All-Cause Mortality in the Healthy Elderly","route":"/key-papers/paper-mcneil-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-manson-n-engl-j-med","kind":"paper","name":"Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease","route":"/key-papers/paper-manson-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-weaver-j-cell-biol","kind":"paper","name":"Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies","route":"/key-papers/paper-weaver-j-cell-biol/","asOf":"2026-09-22","days":6},{"id":"paper-cheson-j-clin-oncol","kind":"paper","name":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","route":"/key-papers/paper-cheson-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-kinzler-nature","kind":"paper","name":"Cancer-susceptibility genes. Gatekeepers and caretakers","route":"/key-papers/paper-kinzler-nature/","asOf":"2026-09-22","days":6},{"id":"paper-begley-nature","kind":"paper","name":"Drug development: Raise standards for preclinical cancer research","route":"/key-papers/paper-begley-nature/","asOf":"2026-09-22","days":6},{"id":"paper-venkatesh-nature","kind":"paper","name":"Electrical and synaptic integration of glioma into neural circuits","route":"/key-papers/paper-venkatesh-nature/","asOf":"2026-09-22","days":6},{"id":"paper-malouff-front-oncol","kind":"paper","name":"Carbon Ion Therapy: A Modern Review of an Emerging Technology","route":"/key-papers/paper-malouff-front-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-pfeiffer-embo-mol-med","kind":"paper","name":"In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome","route":"/key-papers/paper-pfeiffer-embo-mol-med/","asOf":"2026-09-22","days":6},{"id":"paper-kapoor-jco-glob-oncol","kind":"paper","name":"Integrating Metronomic Therapy With Standard Chemotherapy in Advanced Unresectable Head and Neck Cancer: A Randomized Trial Addressing Global Cancer Care Equity (METRO PLUS)","route":"/key-papers/paper-kapoor-jco-glob-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-gordan-j-clin-oncol","kind":"paper","name":"Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline","route":"/key-papers/paper-gordan-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-ali-thyroid","kind":"paper","name":"The 2023 Bethesda System for Reporting Thyroid Cytopathology","route":"/key-papers/paper-ali-thyroid/","asOf":"2026-09-22","days":6},{"id":"paper-ying-cancer-med","kind":"paper","name":"Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China","route":"/key-papers/paper-ying-cancer-med/","asOf":"2026-09-22","days":6},{"id":"paper-minard-colin-n-engl-j-med","kind":"paper","name":"Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children","route":"/key-papers/paper-minard-colin-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-kurtz-j-clin-oncol","kind":"paper","name":"Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma","route":"/key-papers/paper-kurtz-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-chawla-jama-oncol","kind":"paper","name":"First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial","route":"/key-papers/paper-chawla-jama-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-zhu-clin-transl-sci","kind":"paper","name":"Translational findings support regimen selection for first-in-human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer","route":"/key-papers/paper-zhu-clin-transl-sci/","asOf":"2026-09-22","days":6},{"id":"paper-burd-nat-med","kind":"paper","name":"Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial","route":"/key-papers/paper-burd-nat-med/","asOf":"2026-09-22","days":6},{"id":"paper-shuch-lancet-oncol","kind":"paper","name":"[ 89 Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial","route":"/key-papers/paper-shuch-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-voss-int-j-radiat-oncol-biol-phys","kind":"paper","name":"ERGO2: A Prospective, Randomized Trial of Calorie-Restricted Ketogenic Diet and Fasting in Addition to Reirradiation for Malignant Glioma","route":"/key-papers/paper-voss-int-j-radiat-oncol-biol-phys/","asOf":"2026-09-22","days":6},{"id":"paper-stummer-lancet-oncol","kind":"paper","name":"Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial","route":"/key-papers/paper-stummer-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-majzner-nature","kind":"paper","name":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","route":"/key-papers/paper-majzner-nature/","asOf":"2026-09-22","days":6},{"id":"paper-kilburn-nat-med","kind":"paper","name":"The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial","route":"/key-papers/paper-kilburn-nat-med/","asOf":"2026-09-22","days":6},{"id":"paper-mainprize-sci-rep","kind":"paper","name":"Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study","route":"/key-papers/paper-mainprize-sci-rep/","asOf":"2026-09-22","days":6},{"id":"paper-bouffet-n-engl-j-med","kind":"paper","name":"Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations","route":"/key-papers/paper-bouffet-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-braun-j-clin-oncol","kind":"paper","name":"Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline","route":"/key-papers/paper-braun-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-li-jama-oncol","kind":"paper","name":"Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma: The FUMANBA-1 Nonrandomized Clinical Trial","route":"/key-papers/paper-li-jama-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-chen-exp-hematol-oncol","kind":"paper","name":"Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma","route":"/key-papers/paper-chen-exp-hematol-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-marina-lancet-oncol","kind":"paper","name":"Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial","route":"/key-papers/paper-marina-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-gounder-lancet-oncol","kind":"paper","name":"Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study","route":"/key-papers/paper-gounder-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-haanen-ann-oncol","kind":"paper","name":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-haanen-ann-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-sonnenschein-semin-cancer-biol","kind":"paper","name":"Theories of carcinogenesis: an emerging perspective","route":"/key-papers/paper-sonnenschein-semin-cancer-biol/","asOf":"2026-09-22","days":6},{"id":"paper-mariathasan-nature","kind":"paper","name":"TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","route":"/key-papers/paper-mariathasan-nature/","asOf":"2026-09-22","days":6},{"id":"paper-abramson-nature","kind":"paper","name":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","route":"/key-papers/paper-abramson-nature/","asOf":"2026-09-22","days":6},{"id":"paper-vorontsov-nat-med","kind":"paper","name":"A foundation model for clinical-grade computational pathology and rare cancers detection","route":"/key-papers/paper-vorontsov-nat-med/","asOf":"2026-09-22","days":6},{"id":"paper-chan-n-engl-j-med","kind":"paper","name":"Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer","route":"/key-papers/paper-chan-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-woodcock-n-engl-j-med","kind":"paper","name":"Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both","route":"/key-papers/paper-woodcock-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-paganetti-phys-med-biol","kind":"paper","name":"Relative biological effectiveness (RBE) values for proton beam therapy. Variations as a function of biological endpoint, dose, and linear energy transfer","route":"/key-papers/paper-paganetti-phys-med-biol/","asOf":"2026-09-22","days":6},{"id":"paper-baylin-cold-spring-harb-perspect-biol","kind":"paper","name":"Epigenetic Determinants of Cancer","route":"/key-papers/paper-baylin-cold-spring-harb-perspect-biol/","asOf":"2026-09-22","days":6},{"id":"paper-irwin-j-clin-oncol","kind":"paper","name":"Tai Chi Chih Compared With Cognitive Behavioral Therapy for the Treatment of Insomnia in Survivors of Breast Cancer: A Randomized, Partially Blinded, Noninferiority Trial","route":"/key-papers/paper-irwin-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-zon-jco-oncol-pract","kind":"paper","name":"Telehealth in Oncology: ASCO Standards and Practice Recommendations","route":"/key-papers/paper-zon-jco-oncol-pract/","asOf":"2026-09-22","days":6},{"id":"paper-ramsey-health-aff-millwood","kind":"paper","name":"Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis","route":"/key-papers/paper-ramsey-health-aff-millwood/","asOf":"2026-09-22","days":6},{"id":"paper-annema-jama","kind":"paper","name":"Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial","route":"/key-papers/paper-annema-jama/","asOf":"2026-09-22","days":6},{"id":"paper-hoskin-jama","kind":"paper","name":"Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer: The SCORAD Randomized Clinical Trial","route":"/key-papers/paper-hoskin-jama/","asOf":"2026-09-22","days":6},{"id":"paper-mailankody-jama-oncol","kind":"paper","name":"Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs","route":"/key-papers/paper-mailankody-jama-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-dewey-cochrane-database-syst-rev","kind":"paper","name":"Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia","route":"/key-papers/paper-dewey-cochrane-database-syst-rev/","asOf":"2026-09-22","days":6},{"id":"paper-miften-med-phys","kind":"paper","name":"Tolerance limits and methodologies for IMRT measurement-based verification QA: Recommendations of AAPM Task Group No. 218","route":"/key-papers/paper-miften-med-phys/","asOf":"2026-09-22","days":6},{"id":"paper-al-hallaq-med-phys","kind":"paper","name":"AAPM task group report 302: Surface-guided radiotherapy","route":"/key-papers/paper-al-hallaq-med-phys/","asOf":"2026-09-22","days":6},{"id":"paper-mcgranahan-cell","kind":"paper","name":"Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future","route":"/key-papers/paper-mcgranahan-cell/","asOf":"2026-09-22","days":6},{"id":"paper-faubert-cell","kind":"paper","name":"Lactate Metabolism in Human Lung Tumors","route":"/key-papers/paper-faubert-cell/","asOf":"2026-09-22","days":6},{"id":"paper-nagata-int-j-radiat-oncol-biol-phys","kind":"paper","name":"Prospective Trial of Stereotactic Body Radiation Therapy for Both Operable and Inoperable T1N0M0 Non-Small Cell Lung Cancer: Japan Clinical Oncology Group Study JCOG0403","route":"/key-papers/paper-nagata-int-j-radiat-oncol-biol-phys/","asOf":"2026-09-22","days":6},{"id":"paper-camidge-j-thorac-oncol","kind":"paper","name":"Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial","route":"/key-papers/paper-camidge-j-thorac-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-li-j-thorac-oncol","kind":"paper","name":"D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRAS G12C in Patients With NSCLC: Phase 1 Study Results","route":"/key-papers/paper-li-j-thorac-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-kozono-j-thorac-oncol","kind":"paper","name":"Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400)","route":"/key-papers/paper-kozono-j-thorac-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-zhou-j-thorac-oncol","kind":"paper","name":"Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study","route":"/key-papers/paper-zhou-j-thorac-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-lutz-pract-radiat-oncol","kind":"paper","name":"Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based Guideline","route":"/key-papers/paper-lutz-pract-radiat-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-centore-trends-genet","kind":"paper","name":"Mammalian SWI/SNF Chromatin Remodeling Complexes: Emerging Mechanisms and Therapeutic Strategies","route":"/key-papers/paper-centore-trends-genet/","asOf":"2026-09-22","days":6},{"id":"paper-schuetz-lancet","kind":"paper","name":"Individualised nutritional support in medical inpatients at nutritional risk: a randomised clinical trial","route":"/key-papers/paper-schuetz-lancet/","asOf":"2026-09-22","days":6},{"id":"paper-menon-lancet","kind":"paper","name":"Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial","route":"/key-papers/paper-menon-lancet/","asOf":"2026-09-22","days":6},{"id":"paper-jaffray-int-j-radiat-oncol-biol-phys","kind":"paper","name":"Flat-panel cone-beam computed tomography for image-guided radiation therapy","route":"/key-papers/paper-jaffray-int-j-radiat-oncol-biol-phys/","asOf":"2026-09-22","days":6},{"id":"paper-prado-lancet-oncol","kind":"paper","name":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study","route":"/key-papers/paper-prado-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-shi-lancet-oncol","kind":"paper","name":"Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial","route":"/key-papers/paper-shi-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-iarc-monographs-vol-124-group-lancet-oncol","kind":"paper","name":"Carcinogenicity of night shift work","route":"/key-papers/paper-iarc-monographs-vol-124-group-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-guckenberger-lancet-oncol","kind":"paper","name":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","route":"/key-papers/paper-guckenberger-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-redman-lancet-oncol","kind":"paper","name":"Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol","route":"/key-papers/paper-redman-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-cho-lancet-oncol","kind":"paper","name":"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study","route":"/key-papers/paper-cho-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-zeidan-lancet-haematol","kind":"paper","name":"Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial","route":"/key-papers/paper-zeidan-lancet-haematol/","asOf":"2026-09-22","days":6},{"id":"paper-shankaran-nature","kind":"paper","name":"IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity","route":"/key-papers/paper-shankaran-nature/","asOf":"2026-09-22","days":6},{"id":"paper-michor-nature","kind":"paper","name":"Dynamics of chronic myeloid leukaemia","route":"/key-papers/paper-michor-nature/","asOf":"2026-09-22","days":6},{"id":"paper-chen-nature-2016","kind":"paper","name":"Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer","route":"/key-papers/paper-chen-nature-2016/","asOf":"2026-09-22","days":6},{"id":"paper-hangauer-nature","kind":"paper","name":"Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition","route":"/key-papers/paper-hangauer-nature/","asOf":"2026-09-22","days":6},{"id":"paper-herbst-nature","kind":"paper","name":"The biology and management of non-small cell lung cancer","route":"/key-papers/paper-herbst-nature/","asOf":"2026-09-22","days":6},{"id":"paper-sottoriva-nat-genet","kind":"paper","name":"A Big Bang model of human colorectal tumor growth","route":"/key-papers/paper-sottoriva-nat-genet/","asOf":"2026-09-22","days":6},{"id":"paper-dunn-nat-immunol","kind":"paper","name":"Cancer immunoediting: from immunosurveillance to tumor escape","route":"/key-papers/paper-dunn-nat-immunol/","asOf":"2026-09-22","days":6},{"id":"paper-thress-nat-med","kind":"paper","name":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M","route":"/key-papers/paper-thress-nat-med/","asOf":"2026-09-22","days":6},{"id":"paper-romero-nat-med","kind":"paper","name":"Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis","route":"/key-papers/paper-romero-nat-med/","asOf":"2026-09-22","days":6},{"id":"paper-steeg-nat-rev-cancer","kind":"paper","name":"Targeting metastasis","route":"/key-papers/paper-steeg-nat-rev-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-merlo-nat-rev-cancer","kind":"paper","name":"Cancer as an evolutionary and ecological process","route":"/key-papers/paper-merlo-nat-rev-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-malumbres-nat-rev-cancer","kind":"paper","name":"Cell cycle, CDKs and cancer: a changing paradigm","route":"/key-papers/paper-malumbres-nat-rev-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-menden-nat-commun","kind":"paper","name":"Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen","route":"/key-papers/paper-menden-nat-commun/","asOf":"2026-09-22","days":6},{"id":"paper-arvanitis-nat-rev-cancer","kind":"paper","name":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","route":"/key-papers/paper-arvanitis-nat-rev-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-achrol-nat-rev-dis-primers","kind":"paper","name":"Brain metastases","route":"/key-papers/paper-achrol-nat-rev-dis-primers/","asOf":"2026-09-22","days":6},{"id":"paper-rudin-nat-rev-dis-primers","kind":"paper","name":"Small-cell lung cancer","route":"/key-papers/paper-rudin-nat-rev-dis-primers/","asOf":"2026-09-22","days":6},{"id":"paper-johnston-nature","kind":"paper","name":"VISTA is an acidic pH-selective ligand for PSGL-1","route":"/key-papers/paper-johnston-nature/","asOf":"2026-09-22","days":6},{"id":"paper-middleton-nature","kind":"paper","name":"The National Lung Matrix Trial of personalized therapy in lung cancer","route":"/key-papers/paper-middleton-nature/","asOf":"2026-09-22","days":6},{"id":"paper-xiang-nature","kind":"paper","name":"A vision-language foundation model for precision oncology","route":"/key-papers/paper-xiang-nature/","asOf":"2026-09-22","days":6},{"id":"paper-dizman-nat-med","kind":"paper","name":"Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial","route":"/key-papers/paper-dizman-nat-med/","asOf":"2026-09-22","days":6},{"id":"paper-mackensen-nat-med","kind":"paper","name":"CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial","route":"/key-papers/paper-mackensen-nat-med/","asOf":"2026-09-22","days":6},{"id":"paper-hutchins-n-engl-j-med","kind":"paper","name":"Underrepresentation of patients 65 years of age or older in cancer-treatment trials","route":"/key-papers/paper-hutchins-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-slotman-n-engl-j-med","kind":"paper","name":"Prophylactic cranial irradiation in extensive small-cell lung cancer","route":"/key-papers/paper-slotman-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-van-klaveren-n-engl-j-med","kind":"paper","name":"Management of lung nodules detected by volume CT scanning","route":"/key-papers/paper-van-klaveren-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-solomon-n-engl-j-med","kind":"paper","name":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","route":"/key-papers/paper-solomon-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-bellera-ann-oncol","kind":"paper","name":"Screening older cancer patients: first evaluation of the G-8 geriatric screening tool","route":"/key-papers/paper-bellera-ann-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-lu-j-natl-cancer-inst","kind":"paper","name":"Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial","route":"/key-papers/paper-lu-j-natl-cancer-inst/","asOf":"2026-09-22","days":6},{"id":"paper-keall-med-phys","kind":"paper","name":"The management of respiratory motion in radiation oncology report of AAPM Task Group 76","route":"/key-papers/paper-keall-med-phys/","asOf":"2026-09-22","days":6},{"id":"paper-stutman-science","kind":"paper","name":"Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice","route":"/key-papers/paper-stutman-science/","asOf":"2026-09-22","days":6},{"id":"paper-cristescu-science","kind":"paper","name":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","route":"/key-papers/paper-cristescu-science/","asOf":"2026-09-22","days":6},{"id":"paper-spencer-science","kind":"paper","name":"Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response","route":"/key-papers/paper-spencer-science/","asOf":"2026-09-22","days":6},{"id":"paper-burnet-br-med-j","kind":"paper","name":"Cancer; a biological approach. I. The processes of control","route":"/key-papers/paper-burnet-br-med-j/","asOf":"2026-09-22","days":6},{"id":"paper-nagendran-bmj","kind":"paper","name":"Artificial intelligence versus clinicians: systematic review of design, reporting standards, and claims of deep learning studies","route":"/key-papers/paper-nagendran-bmj/","asOf":"2026-09-22","days":6},{"id":"paper-solheim-bmj-support-palliat-care","kind":"paper","name":"Cancer cachexia: rationale for the MENAC (Multimodal-Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial","route":"/key-papers/paper-solheim-bmj-support-palliat-care/","asOf":"2026-09-22","days":6},{"id":"paper-merino-j-immunother-cancer","kind":"paper","name":"Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project","route":"/key-papers/paper-merino-j-immunother-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-aster-annu-rev-pathol","kind":"paper","name":"The Varied Roles of Notch in Cancer","route":"/key-papers/paper-aster-annu-rev-pathol/","asOf":"2026-09-22","days":6},{"id":"paper-prior-cancer-res","kind":"paper","name":"The Frequency of Ras Mutations in Cancer","route":"/key-papers/paper-prior-cancer-res/","asOf":"2026-09-22","days":6},{"id":"paper-herbst-clin-cancer-res","kind":"paper","name":"Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400","route":"/key-papers/paper-herbst-clin-cancer-res/","asOf":"2026-09-22","days":6},{"id":"paper-engstrom-cancer-discov","kind":"paper","name":"MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer","route":"/key-papers/paper-engstrom-cancer-discov/","asOf":"2026-09-22","days":6},{"id":"paper-burnet-prog-exp-tumor-res","kind":"paper","name":"The concept of immunological surveillance","route":"/key-papers/paper-burnet-prog-exp-tumor-res/","asOf":"2026-09-22","days":6},{"id":"paper-khorana-blood","kind":"paper","name":"Development and validation of a predictive model for chemotherapy-associated thrombosis","route":"/key-papers/paper-khorana-blood/","asOf":"2026-09-22","days":6},{"id":"paper-peters-j-clin-oncol","kind":"paper","name":"SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer","route":"/key-papers/paper-peters-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-noronha-j-clin-oncol","kind":"paper","name":"Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR -Mutated Lung Cancer","route":"/key-papers/paper-noronha-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-ambrosone-j-clin-oncol","kind":"paper","name":"Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221)","route":"/key-papers/paper-ambrosone-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-palma-j-clin-oncol","kind":"paper","name":"Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial","route":"/key-papers/paper-palma-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-van-waart-j-clin-oncol","kind":"paper","name":"Effect of Low-Intensity Physical Activity and Moderate- to High-Intensity Physical Exercise During Adjuvant Chemotherapy on Physical Fitness, Fatigue, and Chemotherapy Completion Rates: Results of the PACES Randomized Clinical Trial","route":"/key-papers/paper-van-waart-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-ferrell-j-clin-oncol","kind":"paper","name":"Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update","route":"/key-papers/paper-ferrell-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-van-poznak-j-clin-oncol","kind":"paper","name":"Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update","route":"/key-papers/paper-van-poznak-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-mohile-j-clin-oncol","kind":"paper","name":"Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology","route":"/key-papers/paper-mohile-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-park-j-clin-oncol","kind":"paper","name":"Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study","route":"/key-papers/paper-park-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-herbst-j-clin-oncol","kind":"paper","name":"COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer","route":"/key-papers/paper-herbst-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-reckamp-j-clin-oncol","kind":"paper","name":"Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A","route":"/key-papers/paper-reckamp-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-mikhael-j-clin-oncol","kind":"paper","name":"Sybil: A Validated Deep Learning Model to Predict Future Lung Cancer Risk From a Single Low-Dose Chest Computed Tomography","route":"/key-papers/paper-mikhael-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-key-j-clin-oncol","kind":"paper","name":"Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update","route":"/key-papers/paper-key-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-sanders-j-clin-oncol","kind":"paper","name":"Palliative Care for Patients With Cancer: ASCO Guideline Update","route":"/key-papers/paper-sanders-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-ahn-jco-precis-oncol","kind":"paper","name":"Palbociclib in Patients With Non-Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study","route":"/key-papers/paper-ahn-jco-precis-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-gupta-jco-precis-oncol","kind":"paper","name":"Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study","route":"/key-papers/paper-gupta-jco-precis-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-perez-jco-precis-oncol","kind":"paper","name":"Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study","route":"/key-papers/paper-perez-jco-precis-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-campbell-med-sci-sports-exerc","kind":"paper","name":"Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable","route":"/key-papers/paper-campbell-med-sci-sports-exerc/","asOf":"2026-09-22","days":6},{"id":"paper-farwell-j-nucl-med","kind":"paper","name":"CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89 Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody","route":"/key-papers/paper-farwell-j-nucl-med/","asOf":"2026-09-22","days":6},{"id":"paper-withers-acta-oncol","kind":"paper","name":"The hazard of accelerated tumor clonogen repopulation during radiotherapy","route":"/key-papers/paper-withers-acta-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-agostinis-ca-cancer-j-clin","kind":"paper","name":"Photodynamic therapy of cancer: an update","route":"/key-papers/paper-agostinis-ca-cancer-j-clin/","asOf":"2026-09-22","days":6},{"id":"paper-sedrak-ca-cancer-j-clin","kind":"paper","name":"Older adult participation in cancer clinical trials: A systematic review of barriers and interventions","route":"/key-papers/paper-sedrak-ca-cancer-j-clin/","asOf":"2026-09-22","days":6},{"id":"paper-sheikh-ann-intern-med","kind":"paper","name":"Postdiagnosis Smoking Cessation and Reduced Risk for Lung Cancer Progression and Mortality: A Prospective Cohort Study","route":"/key-papers/paper-sheikh-ann-intern-med/","asOf":"2026-09-22","days":6},{"id":"paper-ng-jama","kind":"paper","name":"Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial","route":"/key-papers/paper-ng-jama/","asOf":"2026-09-22","days":6},{"id":"paper-comstock-jama","kind":"paper","name":"Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening","route":"/key-papers/paper-comstock-jama/","asOf":"2026-09-22","days":6},{"id":"paper-wouters-jama","kind":"paper","name":"Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018","route":"/key-papers/paper-wouters-jama/","asOf":"2026-09-22","days":6},{"id":"paper-goodwin-jama","kind":"paper","name":"Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial","route":"/key-papers/paper-goodwin-jama/","asOf":"2026-09-22","days":6},{"id":"paper-aminian-jama","kind":"paper","name":"Association of Bariatric Surgery With Cancer Risk and Mortality in Adults With Obesity","route":"/key-papers/paper-aminian-jama/","asOf":"2026-09-22","days":6},{"id":"paper-freites-martinez-jama-dermatol","kind":"paper","name":"Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer","route":"/key-papers/paper-freites-martinez-jama-dermatol/","asOf":"2026-09-22","days":6},{"id":"paper-marinac-jama-oncol","kind":"paper","name":"Prolonged Nightly Fasting and Breast Cancer Prognosis","route":"/key-papers/paper-marinac-jama-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-murphy-jama-oncol","kind":"paper","name":"Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial","route":"/key-papers/paper-murphy-jama-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-horneber-cochrane-database-syst-rev","kind":"paper","name":"Mistletoe therapy in oncology","route":"/key-papers/paper-horneber-cochrane-database-syst-rev/","asOf":"2026-09-22","days":6},{"id":"paper-bradt-cochrane-database-syst-rev","kind":"paper","name":"Dance/movement therapy for improving psychological and physical outcomes in cancer patients","route":"/key-papers/paper-bradt-cochrane-database-syst-rev/","asOf":"2026-09-22","days":6},{"id":"paper-cramer-cochrane-database-syst-rev","kind":"paper","name":"Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer","route":"/key-papers/paper-cramer-cochrane-database-syst-rev/","asOf":"2026-09-22","days":6},{"id":"paper-swain-cancer","kind":"paper","name":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","route":"/key-papers/paper-swain-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-langley-int-j-cancer","kind":"paper","name":"The seed and soil hypothesis revisited--the role of tumor-stroma interactions in metastasis to different organs","route":"/key-papers/paper-langley-int-j-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-mavaddat-am-j-hum-genet","kind":"paper","name":"Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes","route":"/key-papers/paper-mavaddat-am-j-hum-genet/","asOf":"2026-09-22","days":6},{"id":"paper-jain-cancer-cell","kind":"paper","name":"Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia","route":"/key-papers/paper-jain-cancer-cell/","asOf":"2026-09-22","days":6},{"id":"paper-paszek-cancer-cell","kind":"paper","name":"Tensional homeostasis and the malignant phenotype","route":"/key-papers/paper-paszek-cancer-cell/","asOf":"2026-09-22","days":6},{"id":"paper-levental-cell","kind":"paper","name":"Matrix crosslinking forces tumor progression by enhancing integrin signaling","route":"/key-papers/paper-levental-cell/","asOf":"2026-09-22","days":6},{"id":"paper-bradner-cell","kind":"paper","name":"Transcriptional Addiction in Cancer","route":"/key-papers/paper-bradner-cell/","asOf":"2026-09-22","days":6},{"id":"paper-freites-martinez-j-am-acad-dermatol","kind":"paper","name":"Hair disorders in cancer survivors","route":"/key-papers/paper-freites-martinez-j-am-acad-dermatol/","asOf":"2026-09-22","days":6},{"id":"paper-obenauf-trends-cancer","kind":"paper","name":"Surviving at a Distance: Organ-Specific Metastasis","route":"/key-papers/paper-obenauf-trends-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-van-der-zee-lancet","kind":"paper","name":"Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group","route":"/key-papers/paper-van-der-zee-lancet/","asOf":"2026-09-22","days":6},{"id":"paper-paget-cancer-metastasis-rev","kind":"paper","name":"The distribution of secondary growths in cancer of the breast. 1889","route":"/key-papers/paper-paget-cancer-metastasis-rev/","asOf":"2026-09-22","days":6},{"id":"paper-rustin-lancet","kind":"paper","name":"Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial","route":"/key-papers/paper-rustin-lancet/","asOf":"2026-09-22","days":6},{"id":"paper-cortes-lancet","kind":"paper","name":"Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","route":"/key-papers/paper-cortes-lancet/","asOf":"2026-09-22","days":6},{"id":"paper-coles-lancet","kind":"paper","name":"Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial","route":"/key-papers/paper-coles-lancet/","asOf":"2026-09-22","days":6},{"id":"paper-early-breast-cancer-trialists-collaborative-group-ebctcg-lancet-2019","kind":"paper","name":"Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials","route":"/key-papers/paper-early-breast-cancer-trialists-collaborative-group-ebctcg-lancet-2019/","asOf":"2026-09-22","days":6},{"id":"paper-duvic-j-am-acad-dermatol","kind":"paper","name":"A randomized trial of minoxidil in chemotherapy-induced alopecia","route":"/key-papers/paper-duvic-j-am-acad-dermatol/","asOf":"2026-09-22","days":6},{"id":"paper-sjostrom-lancet-oncol","kind":"paper","name":"Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial","route":"/key-papers/paper-sjostrom-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-issels-lancet-oncol","kind":"paper","name":"Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study","route":"/key-papers/paper-issels-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-haviland-lancet-oncol","kind":"paper","name":"The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials","route":"/key-papers/paper-haviland-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-henricks-lancet-oncol","kind":"paper","name":"DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis","route":"/key-papers/paper-henricks-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-jiang-lancet-oncol","kind":"paper","name":"Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-jiang-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-piccart-lancet-oncol","kind":"paper","name":"70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age","route":"/key-papers/paper-piccart-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-orecchia-lancet-oncol","kind":"paper","name":"Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial","route":"/key-papers/paper-orecchia-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-cowan-lancet-oncol","kind":"paper","name":"γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial","route":"/key-papers/paper-cowan-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-minn-nature","kind":"paper","name":"Genes that mediate breast cancer metastasis to lung","route":"/key-papers/paper-minn-nature/","asOf":"2026-09-22","days":6},{"id":"paper-kaplan-nature","kind":"paper","name":"VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche","route":"/key-papers/paper-kaplan-nature/","asOf":"2026-09-22","days":6},{"id":"paper-davies-nat-med","kind":"paper","name":"HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures","route":"/key-papers/paper-davies-nat-med/","asOf":"2026-09-22","days":6},{"id":"paper-kalluri-nat-rev-cancer","kind":"paper","name":"The biology and function of fibroblasts in cancer","route":"/key-papers/paper-kalluri-nat-rev-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-rohrig-nat-rev-cancer","kind":"paper","name":"The multifaceted roles of fatty acid synthesis in cancer","route":"/key-papers/paper-rohrig-nat-rev-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-fidler-nat-rev-cancer","kind":"paper","name":"The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited","route":"/key-papers/paper-fidler-nat-rev-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-sosa-nat-rev-cancer","kind":"paper","name":"Mechanisms of disseminated cancer cell dormancy: an awakening field","route":"/key-papers/paper-sosa-nat-rev-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-caldecott-nat-rev-genet","kind":"paper","name":"Single-strand break repair and genetic disease","route":"/key-papers/paper-caldecott-nat-rev-genet/","asOf":"2026-09-22","days":6},{"id":"paper-chang-nat-rev-mol-cell-biol","kind":"paper","name":"Non-homologous DNA end joining and alternative pathways to double-strand break repair","route":"/key-papers/paper-chang-nat-rev-mol-cell-biol/","asOf":"2026-09-22","days":6},{"id":"paper-de-groot-nat-commun","kind":"paper","name":"Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial","route":"/key-papers/paper-de-groot-nat-commun/","asOf":"2026-09-22","days":6},{"id":"paper-sahai-nat-rev-cancer","kind":"paper","name":"A framework for advancing our understanding of cancer-associated fibroblasts","route":"/key-papers/paper-sahai-nat-rev-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-harbeck-nat-rev-dis-primers","kind":"paper","name":"Breast cancer","route":"/key-papers/paper-harbeck-nat-rev-dis-primers/","asOf":"2026-09-22","days":6},{"id":"paper-bekes-nat-rev-drug-discov","kind":"paper","name":"PROTAC targeted protein degraders: the past is prologue","route":"/key-papers/paper-bekes-nat-rev-drug-discov/","asOf":"2026-09-22","days":6},{"id":"paper-ben-david-nat-rev-genet","kind":"paper","name":"Context is everything: aneuploidy in cancer","route":"/key-papers/paper-ben-david-nat-rev-genet/","asOf":"2026-09-22","days":6},{"id":"paper-hu-nat-genet","kind":"paper","name":"Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases","route":"/key-papers/paper-hu-nat-genet/","asOf":"2026-09-22","days":6},{"id":"paper-tutt-nat-med","kind":"paper","name":"Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial","route":"/key-papers/paper-tutt-nat-med/","asOf":"2026-09-22","days":6},{"id":"paper-garralda-nat-med","kind":"paper","name":"MYC targeting by OMO-103 in solid tumors: a phase 1 trial","route":"/key-papers/paper-garralda-nat-med/","asOf":"2026-09-22","days":6},{"id":"paper-smith-nejm-evid","kind":"paper","name":"Intraoperative Fluorescence Guidance for Breast Cancer Lumpectomy Surgery","route":"/key-papers/paper-smith-nejm-evid/","asOf":"2026-09-22","days":6},{"id":"paper-overgaard-n-engl-j-med","kind":"paper","name":"Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial","route":"/key-papers/paper-overgaard-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-goodwin-n-engl-j-med","kind":"paper","name":"The effect of group psychosocial support on survival in metastatic breast cancer","route":"/key-papers/paper-goodwin-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-hughes-n-engl-j-med","kind":"paper","name":"Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer","route":"/key-papers/paper-hughes-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-cristofanilli-n-engl-j-med","kind":"paper","name":"Circulating tumor cells, disease progression, and survival in metastatic breast cancer","route":"/key-papers/paper-cristofanilli-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-schmitz-n-engl-j-med","kind":"paper","name":"Weight lifting in women with breast-cancer-related lymphedema","route":"/key-papers/paper-schmitz-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-cardoso-n-engl-j-med","kind":"paper","name":"70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer","route":"/key-papers/paper-cardoso-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-bakker-n-engl-j-med","kind":"paper","name":"Supplemental MRI Screening for Women with Extremely Dense Breast Tissue","route":"/key-papers/paper-bakker-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-kunkler-n-engl-j-med","kind":"paper","name":"Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer","route":"/key-papers/paper-kunkler-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-partridge-n-engl-j-med","kind":"paper","name":"Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer","route":"/key-papers/paper-partridge-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-lincoff-n-engl-j-med","kind":"paper","name":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","route":"/key-papers/paper-lincoff-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-oeffinger-n-engl-j-med","kind":"paper","name":"Chronic health conditions in adult survivors of childhood cancer","route":"/key-papers/paper-oeffinger-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-gehl-acta-oncol","kind":"paper","name":"Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases","route":"/key-papers/paper-gehl-acta-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-kelley-j-cell-biol","kind":"paper","name":"Traversing the basement membrane in vivo: a diversity of strategies","route":"/key-papers/paper-kelley-j-cell-biol/","asOf":"2026-09-22","days":6},{"id":"paper-gebhart-ann-oncol","kind":"paper","name":"Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial","route":"/key-papers/paper-gebhart-ann-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-cardoso-ann-oncol","kind":"paper","name":"Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program","route":"/key-papers/paper-cardoso-ann-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-montgomery-j-natl-cancer-inst","kind":"paper","name":"A randomized clinical trial of a brief hypnosis intervention to control side effects in breast surgery patients","route":"/key-papers/paper-montgomery-j-natl-cancer-inst/","asOf":"2026-09-22","days":6},{"id":"paper-albrengues-science","kind":"paper","name":"Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice","route":"/key-papers/paper-albrengues-science/","asOf":"2026-09-22","days":6},{"id":"paper-nia-science","kind":"paper","name":"Physical traits of cancer","route":"/key-papers/paper-nia-science/","asOf":"2026-09-22","days":6},{"id":"paper-yala-sci-transl-med","kind":"paper","name":"Toward robust mammography-based models for breast cancer risk","route":"/key-papers/paper-yala-sci-transl-med/","asOf":"2026-09-22","days":6},{"id":"paper-lane-bmj","kind":"paper","name":"Ultra-processed food exposure and adverse health outcomes: umbrella review of epidemiological meta-analyses","route":"/key-papers/paper-lane-bmj/","asOf":"2026-09-22","days":6},{"id":"paper-fiolet-bmj","kind":"paper","name":"Consumption of ultra-processed foods and cancer risk: results from NutriNet-Santé prospective cohort","route":"/key-papers/paper-fiolet-bmj/","asOf":"2026-09-22","days":6},{"id":"paper-vaidya-bmj","kind":"paper","name":"Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial","route":"/key-papers/paper-vaidya-bmj/","asOf":"2026-09-22","days":6},{"id":"paper-jochelson-radiology","kind":"paper","name":"Contrast-enhanced Mammography: State of the Art","route":"/key-papers/paper-jochelson-radiology/","asOf":"2026-09-22","days":6},{"id":"paper-win-cancer-epidemiol-biomarkers-prev","kind":"paper","name":"Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer","route":"/key-papers/paper-win-cancer-epidemiol-biomarkers-prev/","asOf":"2026-09-22","days":6},{"id":"paper-ring-clin-cancer-res","kind":"paper","name":"Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)","route":"/key-papers/paper-ring-clin-cancer-res/","asOf":"2026-09-22","days":6},{"id":"paper-browne-clin-cancer-res","kind":"paper","name":"The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial","route":"/key-papers/paper-browne-clin-cancer-res/","asOf":"2026-09-22","days":6},{"id":"paper-demaria-cancer-discov","kind":"paper","name":"Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse","route":"/key-papers/paper-demaria-cancer-discov/","asOf":"2026-09-22","days":6},{"id":"paper-makvandi-j-clin-invest","kind":"paper","name":"A PET imaging agent for evaluating PARP-1 expression in ovarian cancer","route":"/key-papers/paper-makvandi-j-clin-invest/","asOf":"2026-09-22","days":6},{"id":"paper-hassett-j-clin-oncol","kind":"paper","name":"Management of Male Breast Cancer: ASCO Guideline","route":"/key-papers/paper-hassett-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-citron-j-clin-oncol","kind":"paper","name":"Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741","route":"/key-papers/paper-citron-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-symmans-j-clin-oncol","kind":"paper","name":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","route":"/key-papers/paper-symmans-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-elkins-j-clin-oncol","kind":"paper","name":"Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors","route":"/key-papers/paper-elkins-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-parker-j-clin-oncol","kind":"paper","name":"Supervised risk predictor of breast cancer based on intrinsic subtypes","route":"/key-papers/paper-parker-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-hughes-j-clin-oncol","kind":"paper","name":"Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343","route":"/key-papers/paper-hughes-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-kuhl-j-clin-oncol","kind":"paper","name":"Abbreviated breast magnetic resonance imaging (MRI): first postcontrast subtracted images and maximum-intensity projection-a novel approach to breast cancer screening with MRI","route":"/key-papers/paper-kuhl-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-mao-j-clin-oncol-2015","kind":"paper","name":"Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial","route":"/key-papers/paper-mao-j-clin-oncol-2015/","asOf":"2026-09-22","days":6},{"id":"paper-morrow-j-clin-oncol","kind":"paper","name":"Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ","route":"/key-papers/paper-morrow-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-oktay-j-clin-oncol","kind":"paper","name":"Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update","route":"/key-papers/paper-oktay-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-andre-j-clin-oncol","kind":"paper","name":"Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update","route":"/key-papers/paper-andre-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-badwe-j-clin-oncol","kind":"paper","name":"Effect of Peritumoral Infiltration of Local Anesthetic Before Surgery on Survival in Early Breast Cancer","route":"/key-papers/paper-badwe-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-wolff-j-clin-oncol","kind":"paper","name":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update","route":"/key-papers/paper-wolff-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-castroviejo-bermejo-embo-mol-med","kind":"paper","name":"A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation","route":"/key-papers/paper-castroviejo-bermejo-embo-mol-med/","asOf":"2026-09-22","days":6},{"id":"paper-rock-ca-cancer-j-clin","kind":"paper","name":"American Cancer Society guideline for diet and physical activity for cancer prevention","route":"/key-papers/paper-rock-ca-cancer-j-clin/","asOf":"2026-09-22","days":6},{"id":"paper-nechuta-am-j-clin-nutr","kind":"paper","name":"Soy food intake after diagnosis of breast cancer and survival: an in-depth analysis of combined evidence from cohort studies of US and Chinese women","route":"/key-papers/paper-nechuta-am-j-clin-nutr/","asOf":"2026-09-22","days":6},{"id":"paper-primrose-jama","kind":"paper","name":"Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial","route":"/key-papers/paper-primrose-jama/","asOf":"2026-09-22","days":6},{"id":"paper-wei-cochrane-database-syst-rev","kind":"paper","name":"Probiotics for the prevention or treatment of chemotherapy- or radiotherapy-related diarrhoea in people with cancer","route":"/key-papers/paper-wei-cochrane-database-syst-rev/","asOf":"2026-09-22","days":6},{"id":"paper-burden-cochrane-database-syst-rev","kind":"paper","name":"Pre-operative nutrition support in patients undergoing gastrointestinal surgery","route":"/key-papers/paper-burden-cochrane-database-syst-rev/","asOf":"2026-09-22","days":6},{"id":"paper-sakamoto-cancer-immunol-immunother","kind":"paper","name":"Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials","route":"/key-papers/paper-sakamoto-cancer-immunol-immunother/","asOf":"2026-09-22","days":6},{"id":"paper-oba-cancer-immunol-immunother","kind":"paper","name":"Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer","route":"/key-papers/paper-oba-cancer-immunol-immunother/","asOf":"2026-09-22","days":6},{"id":"paper-fearon-cell","kind":"paper","name":"A genetic model for colorectal tumorigenesis","route":"/key-papers/paper-fearon-cell/","asOf":"2026-09-22","days":6},{"id":"paper-hanahan-cancer-cell","kind":"paper","name":"Accessories to the crime: functions of cells recruited to the tumor microenvironment","route":"/key-papers/paper-hanahan-cancer-cell/","asOf":"2026-09-22","days":6},{"id":"paper-rothwell-lancet","kind":"paper","name":"Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials","route":"/key-papers/paper-rothwell-lancet/","asOf":"2026-09-22","days":6},{"id":"paper-ridker-lancet","kind":"paper","name":"Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial","route":"/key-papers/paper-ridker-lancet/","asOf":"2026-09-22","days":6},{"id":"paper-dekker-lancet","kind":"paper","name":"Colorectal cancer","route":"/key-papers/paper-dekker-lancet/","asOf":"2026-09-22","days":6},{"id":"paper-bouvard-lancet-oncol","kind":"paper","name":"Carcinogenicity of consumption of red and processed meat","route":"/key-papers/paper-bouvard-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-loomis-lancet-oncol","kind":"paper","name":"Carcinogenicity of drinking coffee, mate, and very hot beverages","route":"/key-papers/paper-loomis-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-alyami-lancet-oncol","kind":"paper","name":"Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications","route":"/key-papers/paper-alyami-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-armitage-br-j-cancer","kind":"paper","name":"The age distribution of cancer and a multi-stage theory of carcinogenesis","route":"/key-papers/paper-armitage-br-j-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-bergers-nat-rev-cancer","kind":"paper","name":"Tumorigenesis and the angiogenic switch","route":"/key-papers/paper-bergers-nat-rev-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-schafer-nat-rev-mol-cell-biol","kind":"paper","name":"Cancer as an overhealing wound: an old hypothesis revisited","route":"/key-papers/paper-schafer-nat-rev-mol-cell-biol/","asOf":"2026-09-22","days":6},{"id":"paper-chan-nature","kind":"paper","name":"WRN helicase is a synthetic lethal target in microsatellite unstable cancers","route":"/key-papers/paper-chan-nature/","asOf":"2026-09-22","days":6},{"id":"paper-pant-nat-med","kind":"paper","name":"Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial","route":"/key-papers/paper-pant-nat-med/","asOf":"2026-09-22","days":6},{"id":"paper-dvorak-n-engl-j-med","kind":"paper","name":"Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing","route":"/key-papers/paper-dvorak-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-knudson-proc-natl-acad-sci-u-s-a","kind":"paper","name":"Mutation and cancer: statistical study of retinoblastoma","route":"/key-papers/paper-knudson-proc-natl-acad-sci-u-s-a/","asOf":"2026-09-22","days":6},{"id":"paper-mintz-proc-natl-acad-sci-u-s-a","kind":"paper","name":"Normal genetically mosaic mice produced from malignant teratocarcinoma cells","route":"/key-papers/paper-mintz-proc-natl-acad-sci-u-s-a/","asOf":"2026-09-22","days":6},{"id":"paper-mcneil-j-natl-cancer-inst","kind":"paper","name":"Effect of Aspirin on Cancer Incidence and Mortality in Older Adults","route":"/key-papers/paper-mcneil-j-natl-cancer-inst/","asOf":"2026-09-22","days":6},{"id":"paper-tomasetti-science","kind":"paper","name":"Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions","route":"/key-papers/paper-tomasetti-science/","asOf":"2026-09-22","days":6},{"id":"paper-poole-bmj","kind":"paper","name":"Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes","route":"/key-papers/paper-poole-bmj/","asOf":"2026-09-22","days":6},{"id":"paper-friedman-cancer-discov","kind":"paper","name":"Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study","route":"/key-papers/paper-friedman-cancer-discov/","asOf":"2026-09-22","days":6},{"id":"paper-brown-clin-trials","kind":"paper","name":"Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer","route":"/key-papers/paper-brown-clin-trials/","asOf":"2026-09-22","days":6},{"id":"paper-tabernero-j-clin-oncol","kind":"paper","name":"Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study","route":"/key-papers/paper-tabernero-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-hainsworth-j-clin-oncol","kind":"paper","name":"Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study","route":"/key-papers/paper-hainsworth-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-seligmann-j-clin-oncol","kind":"paper","name":"Inhibition of WEE1 Is Effective in TP53 - and RAS -Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring","route":"/key-papers/paper-seligmann-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-adams-j-clin-oncol","kind":"paper","name":"Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial","route":"/key-papers/paper-adams-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-pellacani-jama-dermatol","kind":"paper","name":"Effect of Reflectance Confocal Microscopy for Suspect Lesions on Diagnostic Accuracy in Melanoma: A Randomized Clinical Trial","route":"/key-papers/paper-pellacani-jama-dermatol/","asOf":"2026-09-22","days":6},{"id":"paper-mascia-jama-oncol","kind":"paper","name":"Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases: The FAST-01 Nonrandomized Trial","route":"/key-papers/paper-mascia-jama-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-kahles-cancer-cell","kind":"paper","name":"Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients","route":"/key-papers/paper-kahles-cancer-cell/","asOf":"2026-09-22","days":6},{"id":"paper-monje-cell","kind":"paper","name":"Roadmap for the Emerging Field of Cancer Neuroscience","route":"/key-papers/paper-monje-cell/","asOf":"2026-09-22","days":6},{"id":"paper-levin-cell","kind":"paper","name":"Bioelectric signaling: Reprogrammable circuits underlying embryogenesis, regeneration, and cancer","route":"/key-papers/paper-levin-cell/","asOf":"2026-09-22","days":6},{"id":"paper-mesri-cell-host-microbe","kind":"paper","name":"Human viral oncogenesis: a cancer hallmarks analysis","route":"/key-papers/paper-mesri-cell-host-microbe/","asOf":"2026-09-22","days":6},{"id":"paper-clover-eur-j-cancer","kind":"paper","name":"Electrochemotherapy in the treatment of cutaneous malignancy: Outcomes and subgroup analysis from the cumulative results from the pan-European International Network for Sharing Practice in Electrochemotherapy database for 2482 lesions in 987 patients (2008-2019)","route":"/key-papers/paper-clover-eur-j-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-barton-radiother-oncol","kind":"paper","name":"Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012","route":"/key-papers/paper-barton-radiother-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-bourhis-radiother-oncol","kind":"paper","name":"Treatment of a first patient with FLASH-radiotherapy","route":"/key-papers/paper-bourhis-radiother-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-hirose-radiother-oncol","kind":"paper","name":"Boron neutron capture therapy using cyclotron-based epithermal neutron source and borofalan ( 10 B) for recurrent or locally advanced head and neck cancer (JHN002): An open-label phase II trial","route":"/key-papers/paper-hirose-radiother-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-mcculloch-lancet","kind":"paper","name":"No surgical innovation without evaluation: the IDEAL recommendations","route":"/key-papers/paper-mcculloch-lancet/","asOf":"2026-09-22","days":6},{"id":"paper-lapidot-nature","kind":"paper","name":"A cell initiating human acute myeloid leukaemia after transplantation into SCID mice","route":"/key-papers/paper-lapidot-nature/","asOf":"2026-09-22","days":6},{"id":"paper-quintana-nature","kind":"paper","name":"Efficient tumour formation by single human melanoma cells","route":"/key-papers/paper-quintana-nature/","asOf":"2026-09-22","days":6},{"id":"paper-bonilla-nat-genet","kind":"paper","name":"Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma","route":"/key-papers/paper-bonilla-nat-genet/","asOf":"2026-09-22","days":6},{"id":"paper-batlle-nat-med","kind":"paper","name":"Cancer stem cells revisited","route":"/key-papers/paper-batlle-nat-med/","asOf":"2026-09-22","days":6},{"id":"paper-bonnet-nat-med","kind":"paper","name":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell","route":"/key-papers/paper-bonnet-nat-med/","asOf":"2026-09-22","days":6},{"id":"paper-gupta-nat-med","kind":"paper","name":"Cancer stem cells: mirage or reality?","route":"/key-papers/paper-gupta-nat-med/","asOf":"2026-09-22","days":6},{"id":"paper-shain-nat-rev-cancer","kind":"paper","name":"From melanocytes to melanomas","route":"/key-papers/paper-shain-nat-rev-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-epstein-nat-rev-cancer","kind":"paper","name":"Basal cell carcinomas: attack of the hedgehog","route":"/key-papers/paper-epstein-nat-rev-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-bradley-nat-rev-cancer","kind":"paper","name":"RNA splicing dysregulation and the hallmarks of cancer","route":"/key-papers/paper-bradley-nat-rev-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-venkataramani-nature","kind":"paper","name":"Glutamatergic synaptic input to glioma cells drives brain tumour progression","route":"/key-papers/paper-venkataramani-nature/","asOf":"2026-09-22","days":6},{"id":"paper-tetzlaff-ann-oncol","kind":"paper","name":"Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma","route":"/key-papers/paper-tetzlaff-ann-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-chesney-j-clin-oncol","kind":"paper","name":"Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma","route":"/key-papers/paper-chesney-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-landa-j-clin-endocrinol-metab","kind":"paper","name":"Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease","route":"/key-papers/paper-landa-j-clin-endocrinol-metab/","asOf":"2026-09-22","days":6},{"id":"paper-chernet-dis-model-mech","kind":"paper","name":"Transmembrane voltage potential is an essential cellular parameter for the detection and control of tumor development in a Xenopus model","route":"/key-papers/paper-chernet-dis-model-mech/","asOf":"2026-09-22","days":6},{"id":"paper-zager-ann-surg-oncol","kind":"paper","name":"Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study","route":"/key-papers/paper-zager-ann-surg-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-chernet-oncotarget","kind":"paper","name":"Use of genetically encoded, light-gated ion translocators to control tumorigenesis","route":"/key-papers/paper-chernet-oncotarget/","asOf":"2026-09-22","days":6},{"id":"paper-martin-jama","kind":"paper","name":"Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial","route":"/key-papers/paper-martin-jama/","asOf":"2026-09-22","days":6},{"id":"paper-phillips-jama-oncol","kind":"paper","name":"Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial","route":"/key-papers/paper-phillips-jama-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-kishan-jama-oncol","kind":"paper","name":"Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial","route":"/key-papers/paper-kishan-jama-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-bennett-cochrane-database-syst-rev","kind":"paper","name":"Hyperbaric oxygen therapy for late radiation tissue injury","route":"/key-papers/paper-bennett-cochrane-database-syst-rev/","asOf":"2026-09-22","days":6},{"id":"paper-boeve-eur-urol","kind":"paper","name":"Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial","route":"/key-papers/paper-boeve-eur-urol/","asOf":"2026-09-22","days":6},{"id":"paper-hugosson-eur-urol","kind":"paper","name":"A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer","route":"/key-papers/paper-hugosson-eur-urol/","asOf":"2026-09-22","days":6},{"id":"paper-parker-lancet","kind":"paper","name":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","route":"/key-papers/paper-parker-lancet/","asOf":"2026-09-22","days":6},{"id":"paper-widmark-lancet","kind":"paper","name":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","route":"/key-papers/paper-widmark-lancet/","asOf":"2026-09-22","days":6},{"id":"paper-langley-lancet","kind":"paper","name":"Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme","route":"/key-papers/paper-langley-lancet/","asOf":"2026-09-22","days":6},{"id":"paper-attard-lancet-oncol","kind":"paper","name":"Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol","route":"/key-papers/paper-attard-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-esteva-npj-digit-med","kind":"paper","name":"Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials","route":"/key-papers/paper-esteva-npj-digit-med/","asOf":"2026-09-22","days":6},{"id":"paper-clarke-nejm-evid","kind":"paper","name":"Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer","route":"/key-papers/paper-clarke-nejm-evid/","asOf":"2026-09-22","days":6},{"id":"paper-kantoff-n-engl-j-med","kind":"paper","name":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","route":"/key-papers/paper-kantoff-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-van-as-n-engl-j-med","kind":"paper","name":"Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer","route":"/key-papers/paper-van-as-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-zahalka-science","kind":"paper","name":"Adrenergic nerves activate an angio-metabolic switch in prostate cancer","route":"/key-papers/paper-zahalka-science/","asOf":"2026-09-22","days":6},{"id":"paper-murthy-j-clin-oncol","kind":"paper","name":"Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial","route":"/key-papers/paper-murthy-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-scher-j-clin-oncol","kind":"paper","name":"Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3","route":"/key-papers/paper-scher-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-szmulewitz-j-clin-oncol","kind":"paper","name":"Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer","route":"/key-papers/paper-szmulewitz-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-arends-clin-nutr","kind":"paper","name":"ESPEN guidelines on nutrition in cancer patients","route":"/key-papers/paper-arends-clin-nutr/","asOf":"2026-09-22","days":6},{"id":"paper-smyth-lancet","kind":"paper","name":"Gastric cancer","route":"/key-papers/paper-smyth-lancet/","asOf":"2026-09-22","days":6},{"id":"paper-qin-lancet","kind":"paper","name":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","route":"/key-papers/paper-qin-lancet/","asOf":"2026-09-22","days":6},{"id":"paper-turner-nature","kind":"paper","name":"Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity","route":"/key-papers/paper-turner-nature/","asOf":"2026-09-22","days":6},{"id":"paper-jun-gastroenterology","kind":"paper","name":"Effectiveness of the Korean National Cancer Screening Program in Reducing Gastric Cancer Mortality","route":"/key-papers/paper-jun-gastroenterology/","asOf":"2026-09-22","days":6},{"id":"paper-macdonald-n-engl-j-med","kind":"paper","name":"Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction","route":"/key-papers/paper-macdonald-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-ishigami-j-clin-oncol","kind":"paper","name":"Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial","route":"/key-papers/paper-ishigami-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-kratochwil-j-nucl-med","kind":"paper","name":"68 Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer","route":"/key-papers/paper-kratochwil-j-nucl-med/","asOf":"2026-09-22","days":6},{"id":"paper-garcia-jama-netw-open","kind":"paper","name":"Effect of True and Sham Acupuncture on Radiation-Induced Xerostomia Among Patients With Head and Neck Cancer: A Randomized Clinical Trial","route":"/key-papers/paper-garcia-jama-netw-open/","asOf":"2026-09-22","days":6},{"id":"paper-tamrakar-cancer","kind":"paper","name":"Cervical cancer elimination in India: Repurposing diagnostics, vaccination, and accelerating policy for the 2030 target","route":"/key-papers/paper-tamrakar-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-zadik-support-care-cancer","kind":"paper","name":"Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines","route":"/key-papers/paper-zadik-support-care-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-friedl-cell","kind":"paper","name":"Cancer invasion and the microenvironment: plasticity and reciprocity","route":"/key-papers/paper-friedl-cell/","asOf":"2026-09-22","days":6},{"id":"paper-overgaard-radiother-oncol","kind":"paper","name":"A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85","route":"/key-papers/paper-overgaard-radiother-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-patil-lancet-glob-health","kind":"paper","name":"Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial","route":"/key-papers/paper-patil-lancet-glob-health/","asOf":"2026-09-22","days":6},{"id":"paper-mitsunaga-nat-med","kind":"paper","name":"Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules","route":"/key-papers/paper-mitsunaga-nat-med/","asOf":"2026-09-22","days":6},{"id":"paper-chera-j-clin-oncol","kind":"paper","name":"Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer","route":"/key-papers/paper-chera-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-akgor-vaccines-basel","kind":"paper","name":"New HPV Vaccines on the Market and Future Trends: A State-of-the-Art Review","route":"/key-papers/paper-akgor-vaccines-basel/","asOf":"2026-09-22","days":6},{"id":"paper-chalasani-clin-gastroenterol-hepatol","kind":"paper","name":"Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma","route":"/key-papers/paper-chalasani-clin-gastroenterol-hepatol/","asOf":"2026-09-22","days":6},{"id":"paper-llovet-nat-rev-dis-primers","kind":"paper","name":"Hepatocellular carcinoma","route":"/key-papers/paper-llovet-nat-rev-dis-primers/","asOf":"2026-09-22","days":6},{"id":"paper-tabrizian-am-j-transplant","kind":"paper","name":"PD-1 inhibitor as bridge therapy to liver transplantation?","route":"/key-papers/paper-tabrizian-am-j-transplant/","asOf":"2026-09-22","days":6},{"id":"paper-mccollough-radiology","kind":"paper","name":"Dual- and Multi-Energy CT: Principles, Technical Approaches, and Clinical Applications","route":"/key-papers/paper-mccollough-radiology/","asOf":"2026-09-22","days":6},{"id":"paper-patel-jama-surg","kind":"paper","name":"Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules","route":"/key-papers/paper-patel-jama-surg/","asOf":"2026-09-22","days":6},{"id":"paper-cabanillas-lancet","kind":"paper","name":"Thyroid cancer","route":"/key-papers/paper-cabanillas-lancet/","asOf":"2026-09-22","days":6},{"id":"paper-sankaranarayanan-lancet","kind":"paper","name":"Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial","route":"/key-papers/paper-sankaranarayanan-lancet/","asOf":"2026-09-22","days":6},{"id":"paper-sankaranarayanan-lancet-oncol","kind":"paper","name":"Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study","route":"/key-papers/paper-sankaranarayanan-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-shastri-j-natl-cancer-inst","kind":"paper","name":"Effect of VIA screening by primary health workers: randomized controlled study in Mumbai, India","route":"/key-papers/paper-shastri-j-natl-cancer-inst/","asOf":"2026-09-22","days":6},{"id":"paper-hu-j-natl-cancer-inst","kind":"paper","name":"An Observational Study of Deep Learning and Automated Evaluation of Cervical Images for Cancer Screening","route":"/key-papers/paper-hu-j-natl-cancer-inst/","asOf":"2026-09-22","days":6},{"id":"paper-knowles-nat-rev-cancer","kind":"paper","name":"Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity","route":"/key-papers/paper-knowles-nat-rev-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-chamie-nejm-evid","kind":"paper","name":"IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer","route":"/key-papers/paper-chamie-nejm-evid/","asOf":"2026-09-22","days":6},{"id":"paper-dudley-cancer-discov","kind":"paper","name":"Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA","route":"/key-papers/paper-dudley-cancer-discov/","asOf":"2026-09-22","days":6},{"id":"paper-hesseling-pediatr-blood-cancer","kind":"paper","name":"Practical recommendations for the management of children with endemic Burkitt lymphoma (BL) in a resource limited setting","route":"/key-papers/paper-hesseling-pediatr-blood-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-rummel-lancet","kind":"paper","name":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","route":"/key-papers/paper-rummel-lancet/","asOf":"2026-09-22","days":6},{"id":"paper-horwitz-lancet","kind":"paper","name":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","route":"/key-papers/paper-horwitz-lancet/","asOf":"2026-09-22","days":6},{"id":"paper-trappe-lancet-oncol","kind":"paper","name":"Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial","route":"/key-papers/paper-trappe-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-alizadeh-nature","kind":"paper","name":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","route":"/key-papers/paper-alizadeh-nature/","asOf":"2026-09-22","days":6},{"id":"paper-ferreri-leukemia","kind":"paper","name":"Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial","route":"/key-papers/paper-ferreri-leukemia/","asOf":"2026-09-22","days":6},{"id":"paper-roumenina-nat-rev-cancer","kind":"paper","name":"Context-dependent roles of complement in cancer","route":"/key-papers/paper-roumenina-nat-rev-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-dhanasekaran-nat-rev-clin-oncol","kind":"paper","name":"The MYC oncogene - the grand orchestrator of cancer growth and immune evasion","route":"/key-papers/paper-dhanasekaran-nat-rev-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-kurtz-nat-biotechnol","kind":"paper","name":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","route":"/key-papers/paper-kurtz-nat-biotechnol/","asOf":"2026-09-22","days":6},{"id":"paper-brown-nat-med","kind":"paper","name":"Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","route":"/key-papers/paper-brown-nat-med/","asOf":"2026-09-22","days":6},{"id":"paper-shah-br-j-haematol","kind":"paper","name":"Front-line management of post-transplantation lymphoproliferative disorder in adult solid organ recipient patients - A British Society for Haematology Guideline","route":"/key-papers/paper-shah-br-j-haematol/","asOf":"2026-09-22","days":6},{"id":"paper-martinez-cibrian-br-j-haematol","kind":"paper","name":"The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma","route":"/key-papers/paper-martinez-cibrian-br-j-haematol/","asOf":"2026-09-22","days":6},{"id":"paper-kornauth-cancer-discov","kind":"paper","name":"Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders","route":"/key-papers/paper-kornauth-cancer-discov/","asOf":"2026-09-22","days":6},{"id":"paper-sparano-blood","kind":"paper","name":"Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma","route":"/key-papers/paper-sparano-blood/","asOf":"2026-09-22","days":6},{"id":"paper-treon-blood","kind":"paper","name":"Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia","route":"/key-papers/paper-treon-blood/","asOf":"2026-09-22","days":6},{"id":"paper-viardot-blood","kind":"paper","name":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma","route":"/key-papers/paper-viardot-blood/","asOf":"2026-09-22","days":6},{"id":"paper-tam-blood","kind":"paper","name":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study","route":"/key-papers/paper-tam-blood/","asOf":"2026-09-22","days":6},{"id":"paper-hillmen-j-clin-oncol","kind":"paper","name":"Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia","route":"/key-papers/paper-hillmen-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-wang-cancer-cell","kind":"paper","name":"Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial","route":"/key-papers/paper-wang-cancer-cell/","asOf":"2026-09-22","days":6},{"id":"paper-fitzgerald-lancet","kind":"paper","name":"Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial","route":"/key-papers/paper-fitzgerald-lancet/","asOf":"2026-09-22","days":6},{"id":"paper-cancer-genome-atlas-research-nature","kind":"paper","name":"Integrated genomic characterization of oesophageal carcinoma","route":"/key-papers/paper-cancer-genome-atlas-research-nature/","asOf":"2026-09-22","days":6},{"id":"paper-laconi-br-j-cancer","kind":"paper","name":"Cancer as a disease of old age: changing mutational and microenvironmental landscapes","route":"/key-papers/paper-laconi-br-j-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-kakiuchi-nat-rev-cancer","kind":"paper","name":"Clonal expansion in non-cancer tissues","route":"/key-papers/paper-kakiuchi-nat-rev-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-yoshida-nature","kind":"paper","name":"Tobacco smoking and somatic mutations in human bronchial epithelium","route":"/key-papers/paper-yoshida-nature/","asOf":"2026-09-22","days":6},{"id":"paper-rozhok-proc-natl-acad-sci-u-s-a","kind":"paper","name":"Toward an evolutionary model of cancer: Considering the mechanisms that govern the fate of somatic mutations","route":"/key-papers/paper-rozhok-proc-natl-acad-sci-u-s-a/","asOf":"2026-09-22","days":6},{"id":"paper-jaiswal-science","kind":"paper","name":"Clonal hematopoiesis in human aging and disease","route":"/key-papers/paper-jaiswal-science/","asOf":"2026-09-22","days":6},{"id":"paper-shen-j-clin-oncol","kind":"paper","name":"Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study","route":"/key-papers/paper-shen-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-bien-pediatr-blood-cancer","kind":"paper","name":"Pancreatoblastoma in children: EXPeRT/PARTNER diagnostic and therapeutic recommendations","route":"/key-papers/paper-bien-pediatr-blood-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-altman-nat-rev-cancer","kind":"paper","name":"From Krebs to clinic: glutamine metabolism to cancer therapy","route":"/key-papers/paper-altman-nat-rev-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-kleeff-nat-rev-dis-primers","kind":"paper","name":"Pancreatic cancer","route":"/key-papers/paper-kleeff-nat-rev-dis-primers/","asOf":"2026-09-22","days":6},{"id":"paper-yamamoto-nature","kind":"paper","name":"Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I","route":"/key-papers/paper-yamamoto-nature/","asOf":"2026-09-22","days":6},{"id":"paper-mahalingam-nat-med","kind":"paper","name":"Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial","route":"/key-papers/paper-mahalingam-nat-med/","asOf":"2026-09-22","days":6},{"id":"paper-moertel-n-engl-j-med","kind":"paper","name":"High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison","route":"/key-papers/paper-moertel-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-stylianopoulos-proc-natl-acad-sci-u-s-a","kind":"paper","name":"Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors","route":"/key-papers/paper-stylianopoulos-proc-natl-acad-sci-u-s-a/","asOf":"2026-09-22","days":6},{"id":"paper-golfier-mol-cancer-ther","kind":"paper","name":"Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect","route":"/key-papers/paper-golfier-mol-cancer-ther/","asOf":"2026-09-22","days":6},{"id":"paper-tiriac-cancer-discov","kind":"paper","name":"Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer","route":"/key-papers/paper-tiriac-cancer-discov/","asOf":"2026-09-22","days":6},{"id":"paper-hammel-j-clin-oncol","kind":"paper","name":"TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma","route":"/key-papers/paper-hammel-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-hassan-j-clin-oncol","kind":"paper","name":"First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors","route":"/key-papers/paper-hassan-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-qin-j-clin-oncol","kind":"paper","name":"Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer","route":"/key-papers/paper-qin-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-philip-j-clin-oncol","kind":"paper","name":"Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study","route":"/key-papers/paper-philip-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-carson-jama","kind":"paper","name":"Red Blood Cell Transfusion: 2023 AABB International Guidelines","route":"/key-papers/paper-carson-jama/","asOf":"2026-09-22","days":6},{"id":"paper-weaver-cancer-cell","kind":"paper","name":"Aneuploidy acts both oncogenically and as a tumor suppressor","route":"/key-papers/paper-weaver-cancer-cell/","asOf":"2026-09-22","days":6},{"id":"paper-stephens-cell","kind":"paper","name":"Massive genomic rearrangement acquired in a single catastrophic event during cancer development","route":"/key-papers/paper-stephens-cell/","asOf":"2026-09-22","days":6},{"id":"paper-kastenhuber-cell","kind":"paper","name":"Putting p53 in Context","route":"/key-papers/paper-kastenhuber-cell/","asOf":"2026-09-22","days":6},{"id":"paper-bakhoum-cell","kind":"paper","name":"The Multifaceted Role of Chromosomal Instability in Cancer and Its Microenvironment","route":"/key-papers/paper-bakhoum-cell/","asOf":"2026-09-22","days":6},{"id":"paper-pavlova-cell-metab","kind":"paper","name":"The Emerging Hallmarks of Cancer Metabolism","route":"/key-papers/paper-pavlova-cell-metab/","asOf":"2026-09-22","days":6},{"id":"paper-feinberg-nature","kind":"paper","name":"Hypomethylation distinguishes genes of some human cancers from their normal counterparts","route":"/key-papers/paper-feinberg-nature/","asOf":"2026-09-22","days":6},{"id":"paper-mack-nature","kind":"paper","name":"Epigenomic alterations define lethal CIMP-positive ependymomas of infancy","route":"/key-papers/paper-mack-nature/","asOf":"2026-09-22","days":6},{"id":"paper-barretina-nat-genet","kind":"paper","name":"Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy","route":"/key-papers/paper-barretina-nat-genet/","asOf":"2026-09-22","days":6},{"id":"paper-ren-nat-rev-cancer","kind":"paper","name":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","route":"/key-papers/paper-ren-nat-rev-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-feinberg-nat-rev-genet","kind":"paper","name":"Epigenetic modulators, modifiers and mediators in cancer aetiology and progression","route":"/key-papers/paper-feinberg-nat-rev-genet/","asOf":"2026-09-22","days":6},{"id":"paper-feinberg-nat-rev-genet-2006","kind":"paper","name":"The epigenetic progenitor origin of human cancer","route":"/key-papers/paper-feinberg-nat-rev-genet-2006/","asOf":"2026-09-22","days":6},{"id":"paper-cortes-ciriano-nat-genet","kind":"paper","name":"Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing","route":"/key-papers/paper-cortes-ciriano-nat-genet/","asOf":"2026-09-22","days":6},{"id":"paper-bolton-nat-genet","kind":"paper","name":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","route":"/key-papers/paper-bolton-nat-genet/","asOf":"2026-09-22","days":6},{"id":"paper-huang-bone-marrow-transplant","kind":"paper","name":"Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies","route":"/key-papers/paper-huang-bone-marrow-transplant/","asOf":"2026-09-22","days":6},{"id":"paper-kralovics-n-engl-j-med","kind":"paper","name":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","route":"/key-papers/paper-kralovics-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-tiacci-n-engl-j-med","kind":"paper","name":"BRAF mutations in hairy-cell leukemia","route":"/key-papers/paper-tiacci-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-armstrong-n-engl-j-med","kind":"paper","name":"Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer","route":"/key-papers/paper-armstrong-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-pemmaraju-n-engl-j-med","kind":"paper","name":"Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm","route":"/key-papers/paper-pemmaraju-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-dohner-n-engl-j-med","kind":"paper","name":"Acute Myeloid Leukemia","route":"/key-papers/paper-dohner-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-duesberg-proc-natl-acad-sci-u-s-a","kind":"paper","name":"Genetic instability of cancer cells is proportional to their degree of aneuploidy","route":"/key-papers/paper-duesberg-proc-natl-acad-sci-u-s-a/","asOf":"2026-09-22","days":6},{"id":"paper-vander-heiden-science","kind":"paper","name":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","route":"/key-papers/paper-vander-heiden-science/","asOf":"2026-09-22","days":6},{"id":"paper-warburg-science","kind":"paper","name":"On the origin of cancer cells","route":"/key-papers/paper-warburg-science/","asOf":"2026-09-22","days":6},{"id":"paper-flavahan-science","kind":"paper","name":"Epigenetic plasticity and the hallmarks of cancer","route":"/key-papers/paper-flavahan-science/","asOf":"2026-09-22","days":6},{"id":"paper-montoya-science","kind":"paper","name":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127","route":"/key-papers/paper-montoya-science/","asOf":"2026-09-22","days":6},{"id":"paper-heuser-blood","kind":"paper","name":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","route":"/key-papers/paper-heuser-blood/","asOf":"2026-09-22","days":6},{"id":"paper-wattel-blood","kind":"paper","name":"A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group","route":"/key-papers/paper-wattel-blood/","asOf":"2026-09-22","days":6},{"id":"paper-seyfried-nutr-metab-lond","kind":"paper","name":"Cancer as a metabolic disease","route":"/key-papers/paper-seyfried-nutr-metab-lond/","asOf":"2026-09-22","days":6},{"id":"paper-bohlius-j-clin-oncol","kind":"paper","name":"Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update","route":"/key-papers/paper-bohlius-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-grever-j-clin-oncol","kind":"paper","name":"Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study","route":"/key-papers/paper-grever-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-boveri-j-cell-sci","kind":"paper","name":"Concerning the origin of malignant tumours by Theodor Boveri. Translated and annotated by Henry Harris","route":"/key-papers/paper-boveri-j-cell-sci/","asOf":"2026-09-22","days":6},{"id":"paper-hsieh-nat-rev-dis-primers","kind":"paper","name":"Renal cell carcinoma","route":"/key-papers/paper-hsieh-nat-rev-dis-primers/","asOf":"2026-09-22","days":6},{"id":"paper-heng-j-clin-oncol","kind":"paper","name":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","route":"/key-papers/paper-heng-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-crosbie-lancet","kind":"paper","name":"Endometrial cancer","route":"/key-papers/paper-crosbie-lancet/","asOf":"2026-09-22","days":6},{"id":"paper-rodolakis-int-j-gynecol-cancer","kind":"paper","name":"ESGO/ESHRE/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma","route":"/key-papers/paper-rodolakis-int-j-gynecol-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-brown-jama-oncol","kind":"paper","name":"Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis","route":"/key-papers/paper-brown-jama-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-molinaro-jama-oncol","kind":"paper","name":"Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma","route":"/key-papers/paper-molinaro-jama-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-reardon-jama-oncol","kind":"paper","name":"Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial","route":"/key-papers/paper-reardon-jama-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-pajtler-cancer-cell","kind":"paper","name":"Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups","route":"/key-papers/paper-pajtler-cancer-cell/","asOf":"2026-09-22","days":6},{"id":"paper-lichtman-j-pain-symptom-manage","kind":"paper","name":"Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain","route":"/key-papers/paper-lichtman-j-pain-symptom-manage/","asOf":"2026-09-22","days":6},{"id":"paper-senft-lancet-oncol","kind":"paper","name":"Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial","route":"/key-papers/paper-senft-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-malmstrom-lancet-oncol","kind":"paper","name":"Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial","route":"/key-papers/paper-malmstrom-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-baumert-lancet-oncol","kind":"paper","name":"Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study","route":"/key-papers/paper-baumert-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-sonabend-lancet-oncol","kind":"paper","name":"Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial","route":"/key-papers/paper-sonabend-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-brastianos-nat-genet","kind":"paper","name":"Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas","route":"/key-papers/paper-brastianos-nat-genet/","asOf":"2026-09-22","days":6},{"id":"paper-weller-nat-rev-dis-primers","kind":"paper","name":"Glioma","route":"/key-papers/paper-weller-nat-rev-dis-primers/","asOf":"2026-09-22","days":6},{"id":"paper-petersenn-nat-rev-endocrinol","kind":"paper","name":"Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement","route":"/key-papers/paper-petersenn-nat-rev-endocrinol/","asOf":"2026-09-22","days":6},{"id":"paper-swanson-cell-prolif","kind":"paper","name":"A quantitative model for differential motility of gliomas in grey and white matter","route":"/key-papers/paper-swanson-cell-prolif/","asOf":"2026-09-22","days":6},{"id":"paper-brown-n-engl-j-med","kind":"paper","name":"Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy","route":"/key-papers/paper-brown-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-perry-n-engl-j-med","kind":"paper","name":"Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma","route":"/key-papers/paper-perry-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-omuro-neuro-oncol","kind":"paper","name":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial","route":"/key-papers/paper-omuro-neuro-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-lim-neuro-oncol","kind":"paper","name":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter","route":"/key-papers/paper-lim-neuro-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-karschnia-neuro-oncol","kind":"paper","name":"Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group","route":"/key-papers/paper-karschnia-neuro-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-fruhwald-neuro-oncol","kind":"paper","name":"Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors","route":"/key-papers/paper-fruhwald-neuro-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-kamath-neurosurgery","kind":"paper","name":"Glioblastoma Treated With Magnetic Resonance Imaging-Guided Laser Interstitial Thermal Therapy: Safety, Efficacy, and Outcomes","route":"/key-papers/paper-kamath-neurosurgery/","asOf":"2026-09-22","days":6},{"id":"paper-rennert-neurosurgery","kind":"paper","name":"Laser Ablation of Abnormal Neurological Tissue Using Robotic Neuroblate System (LAANTERN): Procedural Safety and Hospitalization","route":"/key-papers/paper-rennert-neurosurgery/","asOf":"2026-09-22","days":6},{"id":"paper-alexander-clin-cancer-res","kind":"paper","name":"Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE","route":"/key-papers/paper-alexander-clin-cancer-res/","asOf":"2026-09-22","days":6},{"id":"paper-idbaih-clin-cancer-res","kind":"paper","name":"Safety and Feasibility of Repeated and Transient Blood-Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma","route":"/key-papers/paper-idbaih-clin-cancer-res/","asOf":"2026-09-22","days":6},{"id":"paper-wen-j-clin-oncol","kind":"paper","name":"Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial","route":"/key-papers/paper-wen-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-ballman-j-clin-oncol","kind":"paper","name":"Lessons From GBM AGILE's Regorafenib Experience in Newly Diagnosed and Recurrent Glioblastoma","route":"/key-papers/paper-ballman-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-arrillaga-romany-j-clin-oncol","kind":"paper","name":"ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma","route":"/key-papers/paper-arrillaga-romany-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-raverot-eur-j-endocrinol","kind":"paper","name":"European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas","route":"/key-papers/paper-raverot-eur-j-endocrinol/","asOf":"2026-09-22","days":6},{"id":"paper-taha-oncologist","kind":"paper","name":"Cannabis Impacts Tumor Response Rate to Nivolumab in Patients with Advanced Malignancies","route":"/key-papers/paper-taha-oncologist/","asOf":"2026-09-22","days":6},{"id":"paper-sanai-j-neurosurg","kind":"paper","name":"An extent of resection threshold for newly diagnosed glioblastomas","route":"/key-papers/paper-sanai-j-neurosurg/","asOf":"2026-09-22","days":6},{"id":"paper-keam-mol-diagn-ther","kind":"paper","name":"Equecabtagene Autoleucel: First Approval","route":"/key-papers/paper-keam-mol-diagn-ther/","asOf":"2026-09-22","days":6},{"id":"paper-dhillon-mol-diagn-ther","kind":"paper","name":"Zevorcabtagene Autoleucel: First Approval","route":"/key-papers/paper-dhillon-mol-diagn-ther/","asOf":"2026-09-22","days":6},{"id":"paper-kumar-lancet-oncol","kind":"paper","name":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","route":"/key-papers/paper-kumar-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-zhao-j-hematol-oncol","kind":"paper","name":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","route":"/key-papers/paper-zhao-j-hematol-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-neoptolemos-jama","kind":"paper","name":"Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial","route":"/key-papers/paper-neoptolemos-jama/","asOf":"2026-09-22","days":6},{"id":"paper-harding-lancet-oncol","kind":"paper","name":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","route":"/key-papers/paper-harding-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-kelly-jama-oncol","kind":"paper","name":"Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial","route":"/key-papers/paper-kelly-jama-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-trojani-int-j-cancer","kind":"paper","name":"Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system","route":"/key-papers/paper-trojani-int-j-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-casali-ann-oncol","kind":"paper","name":"Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up","route":"/key-papers/paper-casali-ann-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-timbergen-eur-j-cancer","kind":"paper","name":"Active surveillance in desmoid-type fibromatosis: A systematic literature review","route":"/key-papers/paper-timbergen-eur-j-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-gelderblom-lancet","kind":"paper","name":"Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-gelderblom-lancet/","asOf":"2026-09-22","days":6},{"id":"paper-stacchiotti-lancet-oncol","kind":"paper","name":"Building a global consensus approach to chordoma: a position paper from the medical and patient community","route":"/key-papers/paper-stacchiotti-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-seddon-lancet-oncol","kind":"paper","name":"Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial","route":"/key-papers/paper-seddon-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-bisogno-lancet-oncol","kind":"paper","name":"Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial","route":"/key-papers/paper-bisogno-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-blay-lancet-oncol","kind":"paper","name":"Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial","route":"/key-papers/paper-blay-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-schoffski-lancet-respir-med","kind":"paper","name":"Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial","route":"/key-papers/paper-schoffski-lancet-respir-med/","asOf":"2026-09-22","days":6},{"id":"paper-delattre-nature","kind":"paper","name":"Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours","route":"/key-papers/paper-delattre-nature/","asOf":"2026-09-22","days":6},{"id":"paper-koelsche-nat-commun","kind":"paper","name":"Sarcoma classification by DNA methylation profiling","route":"/key-papers/paper-koelsche-nat-commun/","asOf":"2026-09-22","days":6},{"id":"paper-gounder-n-engl-j-med","kind":"paper","name":"Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors","route":"/key-papers/paper-gounder-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-wagner-j-immunother-cancer","kind":"paper","name":"Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)","route":"/key-papers/paper-wagner-j-immunother-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-bielack-j-clin-oncol","kind":"paper","name":"Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial","route":"/key-papers/paper-bielack-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-franklin-nat-rev-cancer","kind":"paper","name":"Insights into recent findings and clinical application of YAP and TAZ in cancer","route":"/key-papers/paper-franklin-nat-rev-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-adusumilli-cancer-discov","kind":"paper","name":"A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab","route":"/key-papers/paper-adusumilli-cancer-discov/","asOf":"2026-09-22","days":6},{"id":"paper-karius-radiother-oncol","kind":"paper","name":"Seed-displacements in the immediate post-implant phase in permanent prostate brachytherapy","route":"/key-papers/paper-karius-radiother-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-stupp-jama","kind":"paper","name":"Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial","route":"/key-papers/paper-stupp-jama/","asOf":"2026-09-22","days":6},{"id":"paper-basch-jama","kind":"paper","name":"Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial","route":"/key-papers/paper-basch-jama/","asOf":"2026-09-22","days":6},{"id":"paper-mai-jama","kind":"paper","name":"Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial","route":"/key-papers/paper-mai-jama/","asOf":"2026-09-22","days":6},{"id":"paper-greer-jama","kind":"paper","name":"Telehealth vs In-Person Early Palliative Care for Patients With Advanced Lung Cancer: A Multisite Randomized Clinical Trial","route":"/key-papers/paper-greer-jama/","asOf":"2026-09-22","days":6},{"id":"paper-saper-jama","kind":"paper","name":"Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the Internet","route":"/key-papers/paper-saper-jama/","asOf":"2026-09-22","days":6},{"id":"paper-metter-jama-netw-open","kind":"paper","name":"Trends in the US and Canadian Pathologist Workforces From 2007 to 2017","route":"/key-papers/paper-metter-jama-netw-open/","asOf":"2026-09-22","days":6},{"id":"paper-chen-jama-oncol","kind":"paper","name":"Anlotinib for Refractory Advanced Non-Small Cell Lung Cancer in China","route":"/key-papers/paper-chen-jama-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-global-retinoblastoma-study-jama-oncol","kind":"paper","name":"Global Retinoblastoma Presentation and Analysis by National Income Level","route":"/key-papers/paper-global-retinoblastoma-study-jama-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-ezzo-cochrane-database-syst-rev","kind":"paper","name":"Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting","route":"/key-papers/paper-ezzo-cochrane-database-syst-rev/","asOf":"2026-09-22","days":6},{"id":"paper-taixiang-cochrane-database-syst-rev","kind":"paper","name":"Chinese medical herbs for chemotherapy side effects in colorectal cancer patients","route":"/key-papers/paper-taixiang-cochrane-database-syst-rev/","asOf":"2026-09-22","days":6},{"id":"paper-kassab-cochrane-database-syst-rev","kind":"paper","name":"Homeopathic medicines for adverse effects of cancer treatments","route":"/key-papers/paper-kassab-cochrane-database-syst-rev/","asOf":"2026-09-22","days":6},{"id":"paper-filippini-cochrane-database-syst-rev","kind":"paper","name":"Green tea (Camellia sinensis) for the prevention of cancer","route":"/key-papers/paper-filippini-cochrane-database-syst-rev/","asOf":"2026-09-22","days":6},{"id":"paper-milazzo-cochrane-database-syst-rev","kind":"paper","name":"Laetrile treatment for cancer","route":"/key-papers/paper-milazzo-cochrane-database-syst-rev/","asOf":"2026-09-22","days":6},{"id":"paper-bradt-cochrane-database-syst-rev-2021","kind":"paper","name":"Music interventions for improving psychological and physical outcomes in people with cancer","route":"/key-papers/paper-bradt-cochrane-database-syst-rev-2021/","asOf":"2026-09-22","days":6},{"id":"paper-jin-cochrane-database-syst-rev","kind":"paper","name":"Ganoderma lucidum (Reishi mushroom) for cancer treatment","route":"/key-papers/paper-jin-cochrane-database-syst-rev/","asOf":"2026-09-22","days":6},{"id":"paper-shin-cochrane-database-syst-rev","kind":"paper","name":"Massage with or without aromatherapy for symptom relief in people with cancer","route":"/key-papers/paper-shin-cochrane-database-syst-rev/","asOf":"2026-09-22","days":6},{"id":"paper-riley-cochrane-database-syst-rev","kind":"paper","name":"Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy","route":"/key-papers/paper-riley-cochrane-database-syst-rev/","asOf":"2026-09-22","days":6},{"id":"paper-soto-bioessays","kind":"paper","name":"The tissue organization field theory of cancer: a testable replacement for the somatic mutation theory","route":"/key-papers/paper-soto-bioessays/","asOf":"2026-09-22","days":6},{"id":"paper-vincent-bioessays","kind":"paper","name":"Cancer: a de-repression of a default survival program common to all cells?: a life-history perspective on the nature of cancer","route":"/key-papers/paper-vincent-bioessays/","asOf":"2026-09-22","days":6},{"id":"paper-lineweaver-bioessays","kind":"paper","name":"Targeting cancer's weaknesses (not its strengths): Therapeutic strategies suggested by the atavistic model","route":"/key-papers/paper-lineweaver-bioessays/","asOf":"2026-09-22","days":6},{"id":"paper-english-cancer","kind":"paper","name":"Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo","route":"/key-papers/paper-english-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-cillessen-psychooncology","kind":"paper","name":"Mindfulness-based interventions for psychological and physical health outcomes in cancer patients and survivors: A systematic review and meta-analysis of randomized controlled trials","route":"/key-papers/paper-cillessen-psychooncology/","asOf":"2026-09-22","days":6},{"id":"paper-kuznetsov-bull-math-biol","kind":"paper","name":"Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis","route":"/key-papers/paper-kuznetsov-bull-math-biol/","asOf":"2026-09-22","days":6},{"id":"paper-ryan-support-care-cancer","kind":"paper","name":"Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients","route":"/key-papers/paper-ryan-support-care-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-gilligan-am-j-med","kind":"paper","name":"Death or Debt? National Estimates of Financial Toxicity in Persons with Newly-Diagnosed Cancer","route":"/key-papers/paper-gilligan-am-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-lee-biol-blood-marrow-transplant","kind":"paper","name":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","route":"/key-papers/paper-lee-biol-blood-marrow-transplant/","asOf":"2026-09-22","days":6},{"id":"paper-de-visser-cancer-cell","kind":"paper","name":"The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth","route":"/key-papers/paper-de-visser-cancer-cell/","asOf":"2026-09-22","days":6},{"id":"paper-sharma-cell","kind":"paper","name":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","route":"/key-papers/paper-sharma-cell/","asOf":"2026-09-22","days":6},{"id":"paper-aceto-cell","kind":"paper","name":"Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis","route":"/key-papers/paper-aceto-cell/","asOf":"2026-09-22","days":6},{"id":"paper-chang-cell","kind":"paper","name":"Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression","route":"/key-papers/paper-chang-cell/","asOf":"2026-09-22","days":6},{"id":"paper-martincorena-cell","kind":"paper","name":"Universal Patterns of Selection in Cancer and Somatic Tissues","route":"/key-papers/paper-martincorena-cell/","asOf":"2026-09-22","days":6},{"id":"paper-wells-cell","kind":"paper","name":"Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction","route":"/key-papers/paper-wells-cell/","asOf":"2026-09-22","days":6},{"id":"paper-shen-cell","kind":"paper","name":"Persistent Cancer Cells: The Deadly Survivors","route":"/key-papers/paper-shen-cell/","asOf":"2026-09-22","days":6},{"id":"paper-stockwell-cell","kind":"paper","name":"Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications","route":"/key-papers/paper-stockwell-cell/","asOf":"2026-09-22","days":6},{"id":"paper-gerstberger-cell","kind":"paper","name":"Metastasis","route":"/key-papers/paper-gerstberger-cell/","asOf":"2026-09-22","days":6},{"id":"paper-pavlova-cell-metab-2022","kind":"paper","name":"The hallmarks of cancer metabolism: Still emerging","route":"/key-papers/paper-pavlova-cell-metab-2022/","asOf":"2026-09-22","days":6},{"id":"paper-powell-esmo-open","kind":"paper","name":"Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","route":"/key-papers/paper-powell-esmo-open/","asOf":"2026-09-22","days":6},{"id":"paper-van-herpen-esmo-open","kind":"paper","name":"Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-van-herpen-esmo-open/","asOf":"2026-09-22","days":6},{"id":"paper-bentzen-int-j-radiat-oncol-biol-phys","kind":"paper","name":"Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues","route":"/key-papers/paper-bentzen-int-j-radiat-oncol-biol-phys/","asOf":"2026-09-22","days":6},{"id":"paper-greten-immunity","kind":"paper","name":"Inflammation and Cancer: Triggers, Mechanisms, and Consequences","route":"/key-papers/paper-greten-immunity/","asOf":"2026-09-22","days":6},{"id":"paper-li-j-mol-diagn","kind":"paper","name":"Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","route":"/key-papers/paper-li-j-mol-diagn/","asOf":"2026-09-22","days":6},{"id":"paper-han-j-natl-cancer-cent","kind":"paper","name":"Cancer incidence and mortality in China, 2022","route":"/key-papers/paper-han-j-natl-cancer-cent/","asOf":"2026-09-22","days":6},{"id":"paper-halder-lancet-reg-health-southeast-asia","kind":"paper","name":"Access to timely cancer treatment initiation in India: extent, determinants and trends","route":"/key-papers/paper-halder-lancet-reg-health-southeast-asia/","asOf":"2026-09-22","days":6},{"id":"paper-rubin-mol-cell","kind":"paper","name":"Impact of Lineage Plasticity to and from a Neuroendocrine Phenotype on Progression and Response in Prostate and Lung Cancers","route":"/key-papers/paper-rubin-mol-cell/","asOf":"2026-09-22","days":6},{"id":"paper-saxena-mol-cell","kind":"paper","name":"Hallmarks of DNA replication stress","route":"/key-papers/paper-saxena-mol-cell/","asOf":"2026-09-22","days":6},{"id":"paper-lievens-radiother-oncol","kind":"paper","name":"Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document","route":"/key-papers/paper-lievens-radiother-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-cardenas-semin-radiat-oncol","kind":"paper","name":"Advances in Auto-Segmentation","route":"/key-papers/paper-cardenas-semin-radiat-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-johnson-sleep-med-rev","kind":"paper","name":"A systematic review and meta-analysis of randomized controlled trials of cognitive behavior therapy for insomnia (CBT-I) in cancer survivors","route":"/key-papers/paper-johnson-sleep-med-rev/","asOf":"2026-09-22","days":6},{"id":"paper-contopoulos-ioannidis-am-j-med","kind":"paper","name":"Translation of highly promising basic science research into clinical applications","route":"/key-papers/paper-contopoulos-ioannidis-am-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-sharpe-lancet","kind":"paper","name":"Integrated collaborative care for comorbid major depression in patients with cancer (SMaRT Oncology-2): a multicentre randomised controlled effectiveness trial","route":"/key-papers/paper-sharpe-lancet/","asOf":"2026-09-22","days":6},{"id":"paper-wilson-lancet","kind":"paper","name":"Access to pathology and laboratory medicine services: a crucial gap","route":"/key-papers/paper-wilson-lancet/","asOf":"2026-09-22","days":6},{"id":"paper-pramesh-lancet-oncol","kind":"paper","name":"Delivery of affordable and equitable cancer care in India","route":"/key-papers/paper-pramesh-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-villani-lancet-oncol","kind":"paper","name":"Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study","route":"/key-papers/paper-villani-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-pishvaian-lancet-oncol","kind":"paper","name":"Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial","route":"/key-papers/paper-pishvaian-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-ranganathan-lancet-oncol","kind":"paper","name":"The International Collaboration for Research methods Development in Oncology (CReDO) workshops: shaping the future of global oncology research","route":"/key-papers/paper-ranganathan-lancet-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-gisslinger-lancet-haematol","kind":"paper","name":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","route":"/key-papers/paper-gisslinger-lancet-haematol/","asOf":"2026-09-22","days":6},{"id":"paper-kraljevic-lancet-digit-health","kind":"paper","name":"Foresight-a generative pretrained transformer for modelling of patient timelines using electronic health records: a retrospective modelling study","route":"/key-papers/paper-kraljevic-lancet-digit-health/","asOf":"2026-09-22","days":6},{"id":"paper-nelson-j-med-chem","kind":"paper","name":"The Essential Medicinal Chemistry of Curcumin","route":"/key-papers/paper-nelson-j-med-chem/","asOf":"2026-09-22","days":6},{"id":"paper-doronina-bioconjug-chem","kind":"paper","name":"Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity","route":"/key-papers/paper-doronina-bioconjug-chem/","asOf":"2026-09-22","days":6},{"id":"paper-kellogg-bioconjug-chem","kind":"paper","name":"Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage","route":"/key-papers/paper-kellogg-bioconjug-chem/","asOf":"2026-09-22","days":6},{"id":"paper-widdison-j-med-chem","kind":"paper","name":"Semisynthetic maytansine analogues for the targeted treatment of cancer","route":"/key-papers/paper-widdison-j-med-chem/","asOf":"2026-09-22","days":6},{"id":"paper-laird-br-j-cancer","kind":"paper","name":"DYNAMICS OF TUMOR GROWTH","route":"/key-papers/paper-laird-br-j-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-stratton-nature","kind":"paper","name":"The cancer genome","route":"/key-papers/paper-stratton-nature/","asOf":"2026-09-22","days":6},{"id":"paper-filippakopoulos-nature","kind":"paper","name":"Selective inhibition of BET bromodomains","route":"/key-papers/paper-filippakopoulos-nature/","asOf":"2026-09-22","days":6},{"id":"paper-spranger-nature","kind":"paper","name":"Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity","route":"/key-papers/paper-spranger-nature/","asOf":"2026-09-22","days":6},{"id":"paper-viswanathan-nature","kind":"paper","name":"Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway","route":"/key-papers/paper-viswanathan-nature/","asOf":"2026-09-22","days":6},{"id":"paper-bakhoum-nature","kind":"paper","name":"Chromosomal instability drives metastasis through a cytosolic DNA response","route":"/key-papers/paper-bakhoum-nature/","asOf":"2026-09-22","days":6},{"id":"paper-doronina-nat-biotechnol","kind":"paper","name":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy","route":"/key-papers/paper-doronina-nat-biotechnol/","asOf":"2026-09-22","days":6},{"id":"paper-griffith-nat-genet","kind":"paper","name":"CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer","route":"/key-papers/paper-griffith-nat-genet/","asOf":"2026-09-22","days":6},{"id":"paper-bissell-nat-med","kind":"paper","name":"Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression","route":"/key-papers/paper-bissell-nat-med/","asOf":"2026-09-22","days":6},{"id":"paper-authors-nat-methods","kind":"paper","name":"Method of the Year 2012","route":"/key-papers/paper-authors-nat-methods/","asOf":"2026-09-22","days":6},{"id":"paper-morvan-nat-rev-cancer","kind":"paper","name":"NK cells and cancer: you can teach innate cells new tricks","route":"/key-papers/paper-morvan-nat-rev-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-peinado-nat-rev-cancer","kind":"paper","name":"Pre-metastatic niches: organ-specific homes for metastases","route":"/key-papers/paper-peinado-nat-rev-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-calin-nat-rev-cancer","kind":"paper","name":"MicroRNA signatures in human cancers","route":"/key-papers/paper-calin-nat-rev-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-lazebnik-nat-rev-cancer","kind":"paper","name":"What are the hallmarks of cancer?","route":"/key-papers/paper-lazebnik-nat-rev-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-glunde-nat-rev-cancer","kind":"paper","name":"Choline metabolism in malignant transformation","route":"/key-papers/paper-glunde-nat-rev-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-korolev-nat-rev-cancer","kind":"paper","name":"Turning ecology and evolution against cancer","route":"/key-papers/paper-korolev-nat-rev-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-murray-nat-rev-cancer","kind":"paper","name":"Aryl hydrocarbon receptor ligands in cancer: friend and foe","route":"/key-papers/paper-murray-nat-rev-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-goodnow-nat-rev-drug-discov","kind":"paper","name":"DNA-encoded chemistry: enabling the deeper sampling of chemical space","route":"/key-papers/paper-goodnow-nat-rev-drug-discov/","asOf":"2026-09-22","days":6},{"id":"paper-wherry-nat-rev-immunol","kind":"paper","name":"Molecular and cellular insights into T cell exhaustion","route":"/key-papers/paper-wherry-nat-rev-immunol/","asOf":"2026-09-22","days":6},{"id":"paper-musacchio-nat-rev-mol-cell-biol","kind":"paper","name":"The spindle-assembly checkpoint in space and time","route":"/key-papers/paper-musacchio-nat-rev-mol-cell-biol/","asOf":"2026-09-22","days":6},{"id":"paper-van-den-heuvel-eibrink-nat-rev-urol","kind":"paper","name":"Position paper: Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP-RTSG 2016 protocol","route":"/key-papers/paper-van-den-heuvel-eibrink-nat-rev-urol/","asOf":"2026-09-22","days":6},{"id":"paper-hu-signal-transduct-target-ther","kind":"paper","name":"The JAK/STAT signaling pathway: from bench to clinic","route":"/key-papers/paper-hu-signal-transduct-target-ther/","asOf":"2026-09-22","days":6},{"id":"paper-ma-nat-commun","kind":"paper","name":"Segment anything in medical images","route":"/key-papers/paper-ma-nat-commun/","asOf":"2026-09-22","days":6},{"id":"paper-robey-nat-rev-cancer","kind":"paper","name":"Revisiting the role of ABC transporters in multidrug-resistant cancer","route":"/key-papers/paper-robey-nat-rev-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-fabbri-nat-rev-cancer","kind":"paper","name":"The plasticity of mRNA translation during cancer progression and therapy resistance","route":"/key-papers/paper-fabbri-nat-rev-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-schmitt-nat-rev-clin-oncol","kind":"paper","name":"Senescence and cancer - role and therapeutic opportunities","route":"/key-papers/paper-schmitt-nat-rev-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-depil-nat-rev-drug-discov","kind":"paper","name":"'Off-the-shelf' allogeneic CAR T cells: development and challenges","route":"/key-papers/paper-depil-nat-rev-drug-discov/","asOf":"2026-09-22","days":6},{"id":"paper-shay-nat-rev-genet","kind":"paper","name":"Telomeres and telomerase: three decades of progress","route":"/key-papers/paper-shay-nat-rev-genet/","asOf":"2026-09-22","days":6},{"id":"paper-logsdon-nat-rev-genet","kind":"paper","name":"Long-read human genome sequencing and its applications","route":"/key-papers/paper-logsdon-nat-rev-genet/","asOf":"2026-09-22","days":6},{"id":"paper-denardo-nat-rev-immunol","kind":"paper","name":"Macrophages as regulators of tumour immunity and immunotherapy","route":"/key-papers/paper-denardo-nat-rev-immunol/","asOf":"2026-09-22","days":6},{"id":"paper-diamond-nature","kind":"paper","name":"Efficacy of MEK inhibition in patients with histiocytic neoplasms","route":"/key-papers/paper-diamond-nature/","asOf":"2026-09-22","days":6},{"id":"paper-alexandrov-nature","kind":"paper","name":"The repertoire of mutational signatures in human cancer","route":"/key-papers/paper-alexandrov-nature/","asOf":"2026-09-22","days":6},{"id":"paper-theodoris-nature","kind":"paper","name":"Transfer learning enables predictions in network biology","route":"/key-papers/paper-theodoris-nature/","asOf":"2026-09-22","days":6},{"id":"paper-watson-nature","kind":"paper","name":"De novo design of protein structure and function with RFdiffusion","route":"/key-papers/paper-watson-nature/","asOf":"2026-09-22","days":6},{"id":"paper-xu-nature","kind":"paper","name":"A whole-slide foundation model for digital pathology from real-world data","route":"/key-papers/paper-xu-nature/","asOf":"2026-09-22","days":6},{"id":"paper-wang-nature","kind":"paper","name":"A pathology foundation model for cancer diagnosis and prognosis prediction","route":"/key-papers/paper-wang-nature/","asOf":"2026-09-22","days":6},{"id":"paper-klichinsky-nat-biotechnol","kind":"paper","name":"Human chimeric antigen receptor macrophages for cancer immunotherapy","route":"/key-papers/paper-klichinsky-nat-biotechnol/","asOf":"2026-09-22","days":6},{"id":"paper-roohani-nat-biotechnol","kind":"paper","name":"Predicting transcriptional outcomes of novel multigene perturbations with GEARS","route":"/key-papers/paper-roohani-nat-biotechnol/","asOf":"2026-09-22","days":6},{"id":"paper-bielski-nat-genet","kind":"paper","name":"Genome doubling shapes the evolution and prognosis of advanced cancers","route":"/key-papers/paper-bielski-nat-genet/","asOf":"2026-09-22","days":6},{"id":"paper-linder-nat-genet","kind":"paper","name":"Predicting RNA-seq coverage from DNA sequence as a unifying model of gene regulation","route":"/key-papers/paper-linder-nat-genet/","asOf":"2026-09-22","days":6},{"id":"paper-bensch-nat-med","kind":"paper","name":"89 Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer","route":"/key-papers/paper-bensch-nat-med/","asOf":"2026-09-22","days":6},{"id":"paper-rothwell-nat-med","kind":"paper","name":"Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study","route":"/key-papers/paper-rothwell-nat-med/","asOf":"2026-09-22","days":6},{"id":"paper-sicklick-nat-med","kind":"paper","name":"Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study","route":"/key-papers/paper-sicklick-nat-med/","asOf":"2026-09-22","days":6},{"id":"paper-rodon-nat-med","kind":"paper","name":"Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial","route":"/key-papers/paper-rodon-nat-med/","asOf":"2026-09-22","days":6},{"id":"paper-durham-nat-med","kind":"paper","name":"Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms","route":"/key-papers/paper-durham-nat-med/","asOf":"2026-09-22","days":6},{"id":"paper-o-dwyer-nat-med","kind":"paper","name":"The NCI-MATCH trial: lessons for precision oncology","route":"/key-papers/paper-o-dwyer-nat-med/","asOf":"2026-09-22","days":6},{"id":"paper-lu-nat-med","kind":"paper","name":"A visual-language foundation model for computational pathology","route":"/key-papers/paper-lu-nat-med/","asOf":"2026-09-22","days":6},{"id":"paper-authors-nat-methods-2021","kind":"paper","name":"Method of the Year 2020: spatially resolved transcriptomics","route":"/key-papers/paper-authors-nat-methods-2021/","asOf":"2026-09-22","days":6},{"id":"paper-avsec-z-nat-methods","kind":"paper","name":"Effective gene expression prediction from sequence by integrating long-range interactions","route":"/key-papers/paper-avsec-z-nat-methods/","asOf":"2026-09-22","days":6},{"id":"paper-cui-nat-methods","kind":"paper","name":"scGPT: toward building a foundation model for single-cell multi-omics using generative AI","route":"/key-papers/paper-cui-nat-methods/","asOf":"2026-09-22","days":6},{"id":"paper-hao-nat-methods","kind":"paper","name":"Large-scale foundation model on single-cell transcriptomics","route":"/key-papers/paper-hao-nat-methods/","asOf":"2026-09-22","days":6},{"id":"paper-dalla-torre-nat-methods","kind":"paper","name":"Nucleotide Transformer: building and evaluating robust foundation models for human genomics","route":"/key-papers/paper-dalla-torre-nat-methods/","asOf":"2026-09-22","days":6},{"id":"paper-rieke-npj-digit-med","kind":"paper","name":"The future of digital health with federated learning","route":"/key-papers/paper-rieke-npj-digit-med/","asOf":"2026-09-22","days":6},{"id":"paper-ackerman-nat-cancer","kind":"paper","name":"Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity","route":"/key-papers/paper-ackerman-nat-cancer/","asOf":"2026-09-22","days":6},{"id":"paper-cooper-chem-soc-rev","kind":"paper","name":"Peptides as a platform for targeted therapeutics for cancer: peptide-drug conjugates (PDCs)","route":"/key-papers/paper-cooper-chem-soc-rev/","asOf":"2026-09-22","days":6},{"id":"paper-barnabas-nejm-evid","kind":"paper","name":"Efficacy of single-dose HPV vaccination among young African women","route":"/key-papers/paper-barnabas-nejm-evid/","asOf":"2026-09-22","days":6},{"id":"paper-shattuck-n-engl-j-med","kind":"paper","name":"Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma","route":"/key-papers/paper-shattuck-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-braun-n-engl-j-med","kind":"paper","name":"A pooled analysis of bone marrow micrometastasis in breast cancer","route":"/key-papers/paper-braun-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-amant-n-engl-j-med","kind":"paper","name":"Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy","route":"/key-papers/paper-amant-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-navari-n-engl-j-med","kind":"paper","name":"Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting","route":"/key-papers/paper-navari-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-zaretsky-n-engl-j-med","kind":"paper","name":"Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma","route":"/key-papers/paper-zaretsky-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-liu-n-engl-j-med","kind":"paper","name":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","route":"/key-papers/paper-liu-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-birkmeyer-n-engl-j-med","kind":"paper","name":"Hospital volume and surgical mortality in the United States","route":"/key-papers/paper-birkmeyer-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-downing-n-engl-j-med","kind":"paper","name":"Regulatory review of novel therapeutics--comparison of three regulatory agencies","route":"/key-papers/paper-downing-n-engl-j-med/","asOf":"2026-09-22","days":6},{"id":"paper-mcfarland-proc-natl-acad-sci-u-s-a","kind":"paper","name":"Impact of deleterious passenger mutations on cancer progression","route":"/key-papers/paper-mcfarland-proc-natl-acad-sci-u-s-a/","asOf":"2026-09-22","days":6},{"id":"paper-trigos-proc-natl-acad-sci-u-s-a","kind":"paper","name":"Altered interactions between unicellular and multicellular genes drive hallmarks of transformation in a diverse range of solid tumors","route":"/key-papers/paper-trigos-proc-natl-acad-sci-u-s-a/","asOf":"2026-09-22","days":6},{"id":"paper-bussey-proc-natl-acad-sci-u-s-a","kind":"paper","name":"Ancestral gene regulatory networks drive cancer","route":"/key-papers/paper-bussey-proc-natl-acad-sci-u-s-a/","asOf":"2026-09-22","days":6},{"id":"paper-davies-phys-biol","kind":"paper","name":"Cancer tumors as Metazoa 1.0: tapping genes of ancient ancestors","route":"/key-papers/paper-davies-phys-biol/","asOf":"2026-09-22","days":6},{"id":"paper-peccatori-ann-oncol","kind":"paper","name":"Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","route":"/key-papers/paper-peccatori-ann-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-mathijssen-j-natl-cancer-inst","kind":"paper","name":"Effects of St. John's wort on irinotecan metabolism","route":"/key-papers/paper-mathijssen-j-natl-cancer-inst/","asOf":"2026-09-22","days":6},{"id":"paper-barton-j-natl-cancer-inst","kind":"paper","name":"Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2","route":"/key-papers/paper-barton-j-natl-cancer-inst/","asOf":"2026-09-22","days":6},{"id":"paper-hanai-j-natl-cancer-inst","kind":"paper","name":"Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial","route":"/key-papers/paper-hanai-j-natl-cancer-inst/","asOf":"2026-09-22","days":6},{"id":"paper-aktipis-philos-trans-r-soc-lond-b-biol-sci","kind":"paper","name":"Cancer across the tree of life: cooperation and cheating in multicellularity","route":"/key-papers/paper-aktipis-philos-trans-r-soc-lond-b-biol-sci/","asOf":"2026-09-22","days":6},{"id":"paper-almogy-biorxiv","kind":"paper","name":"Cost-efficient whole genome-sequencing using novel mostly natural sequencing-by-synthesis chemistry and open fluidics platform","route":"/key-papers/paper-almogy-biorxiv/","asOf":"2026-09-22","days":6},{"id":"paper-glaser-br-j-dermatol","kind":"paper","name":"Long-term safety and efficacy of bimatoprost solution 0·03% application to the eyelid margin for the treatment of idiopathic and chemotherapy-induced eyelash hypotrichosis: a randomized controlled trial","route":"/key-papers/paper-glaser-br-j-dermatol/","asOf":"2026-09-22","days":6},{"id":"paper-ogitani-cancer-sci","kind":"paper","name":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","route":"/key-papers/paper-ogitani-cancer-sci/","asOf":"2026-09-22","days":6},{"id":"paper-iozzo-j-cell-mol-med","kind":"paper","name":"Proteoglycans in cancer biology, tumour microenvironment and angiogenesis","route":"/key-papers/paper-iozzo-j-cell-mol-med/","asOf":"2026-09-22","days":6},{"id":"paper-fraass-med-phys","kind":"paper","name":"American Association of Physicists in Medicine Radiation Therapy Committee Task Group 53: quality assurance for clinical radiotherapy treatment planning","route":"/key-papers/paper-fraass-med-phys/","asOf":"2026-09-22","days":6},{"id":"paper-jain-science","kind":"paper","name":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","route":"/key-papers/paper-jain-science/","asOf":"2026-09-22","days":6},{"id":"paper-cheng-science","kind":"paper","name":"Accurate proteome-wide missense variant effect prediction with AlphaMissense","route":"/key-papers/paper-cheng-science/","asOf":"2026-09-22","days":6},{"id":"paper-hayes-science","kind":"paper","name":"Simulating 500 million years of evolution with a language model","route":"/key-papers/paper-hayes-science/","asOf":"2026-09-22","days":6},{"id":"paper-lewis-science","kind":"paper","name":"Scalable emulation of protein equilibrium ensembles with generative deep learning","route":"/key-papers/paper-lewis-science/","asOf":"2026-09-22","days":6},{"id":"paper-taylor-bmj","kind":"paper","name":"Multidisciplinary team working in cancer: what is the evidence?","route":"/key-papers/paper-taylor-bmj/","asOf":"2026-09-22","days":6},{"id":"paper-ross-bmj","kind":"paper","name":"Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis","route":"/key-papers/paper-ross-bmj/","asOf":"2026-09-22","days":6},{"id":"paper-zhang-bmj-glob-health","kind":"paper","name":"The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China","route":"/key-papers/paper-zhang-bmj-glob-health/","asOf":"2026-09-22","days":6},{"id":"paper-bell-annu-rev-biochem","kind":"paper","name":"DNA replication in eukaryotic cells","route":"/key-papers/paper-bell-annu-rev-biochem/","asOf":"2026-09-22","days":6},{"id":"paper-devita-cancer-res","kind":"paper","name":"A history of cancer chemotherapy","route":"/key-papers/paper-devita-cancer-res/","asOf":"2026-09-22","days":6},{"id":"paper-yurkovetskiy-cancer-res","kind":"paper","name":"A Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy","route":"/key-papers/paper-yurkovetskiy-cancer-res/","asOf":"2026-09-22","days":6},{"id":"paper-cardillo-clin-cancer-res","kind":"paper","name":"Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys","route":"/key-papers/paper-cardillo-clin-cancer-res/","asOf":"2026-09-22","days":6},{"id":"paper-ogitani-clin-cancer-res","kind":"paper","name":"DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1","route":"/key-papers/paper-ogitani-clin-cancer-res/","asOf":"2026-09-22","days":6},{"id":"paper-schultz-clin-cancer-res","kind":"paper","name":"DICER1 and Associated Conditions: Identification of At-risk Individuals and Recommended Surveillance Strategies","route":"/key-papers/paper-schultz-clin-cancer-res/","asOf":"2026-09-22","days":6},{"id":"paper-reidy-lagunes-clin-cancer-res","kind":"paper","name":"Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177 Lu-Satoreotide Tetraxetan","route":"/key-papers/paper-reidy-lagunes-clin-cancer-res/","asOf":"2026-09-22","days":6},{"id":"paper-autio-clin-cancer-res","kind":"paper","name":"Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology","route":"/key-papers/paper-autio-clin-cancer-res/","asOf":"2026-09-22","days":6},{"id":"paper-zhou-clin-cancer-res","kind":"paper","name":"Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial","route":"/key-papers/paper-zhou-clin-cancer-res/","asOf":"2026-09-22","days":6},{"id":"paper-ashkenazi-j-clin-invest","kind":"paper","name":"Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions","route":"/key-papers/paper-ashkenazi-j-clin-invest/","asOf":"2026-09-22","days":6},{"id":"paper-seely-integr-cancer-ther","kind":"paper","name":"Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials","route":"/key-papers/paper-seely-integr-cancer-ther/","asOf":"2026-09-22","days":6},{"id":"paper-zammarchi-blood","kind":"paper","name":"ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies","route":"/key-papers/paper-zammarchi-blood/","asOf":"2026-09-22","days":6},{"id":"paper-stock-blood","kind":"paper","name":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","route":"/key-papers/paper-stock-blood/","asOf":"2026-09-22","days":6},{"id":"paper-dix-j-clin-oncol","kind":"paper","name":"Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report","route":"/key-papers/paper-dix-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-azad-j-clin-oncol","kind":"paper","name":"Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study","route":"/key-papers/paper-azad-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-flaherty-j-clin-oncol","kind":"paper","name":"Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)","route":"/key-papers/paper-flaherty-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-calvert-j-clin-oncol","kind":"paper","name":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","route":"/key-papers/paper-calvert-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-salama-j-clin-oncol","kind":"paper","name":"Dabrafenib and Trametinib in Patients With Tumors With BRAF V600E Mutations: Results of the NCI-MATCH Trial Subprotocol H","route":"/key-papers/paper-salama-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-chua-j-clin-oncol","kind":"paper","name":"Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","route":"/key-papers/paper-chua-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-frazier-j-clin-oncol","kind":"paper","name":"Revised risk classification for pediatric extracranial germ cell tumors based on 25 years of clinical trial data from the United Kingdom and United States","route":"/key-papers/paper-frazier-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-smith-j-clin-oncol","kind":"paper","name":"Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update","route":"/key-papers/paper-smith-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-ramsey-j-clin-oncol","kind":"paper","name":"Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer","route":"/key-papers/paper-ramsey-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-schnipper-j-clin-oncol","kind":"paper","name":"Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received","route":"/key-papers/paper-schnipper-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-paice-j-clin-oncol","kind":"paper","name":"Management of Chronic Pain in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline","route":"/key-papers/paper-paice-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-kim-j-clin-oncol","kind":"paper","name":"Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement","route":"/key-papers/paper-kim-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-dix-j-clin-oncol-2018","kind":"paper","name":"Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study","route":"/key-papers/paper-dix-j-clin-oncol-2018/","asOf":"2026-09-22","days":6},{"id":"paper-wolff-j-clin-oncol-2018","kind":"paper","name":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update","route":"/key-papers/paper-wolff-j-clin-oncol-2018/","asOf":"2026-09-22","days":6},{"id":"paper-lyman-j-clin-oncol","kind":"paper","name":"Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline","route":"/key-papers/paper-lyman-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-parsons-j-clin-oncol","kind":"paper","name":"Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial","route":"/key-papers/paper-parsons-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-eckstein-j-clin-oncol","kind":"paper","name":"Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial","route":"/key-papers/paper-eckstein-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-harrison-j-clin-oncol","kind":"paper","name":"Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial","route":"/key-papers/paper-harrison-j-clin-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-chakravarty-jco-precis-oncol","kind":"paper","name":"OncoKB: A Precision Oncology Knowledge Base","route":"/key-papers/paper-chakravarty-jco-precis-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-larson-jco-precis-oncol","kind":"paper","name":"Clinical Outcomes of Molecular Tumor Boards: A Systematic Review","route":"/key-papers/paper-larson-jco-precis-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-thakker-j-clin-endocrinol-metab","kind":"paper","name":"Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)","route":"/key-papers/paper-thakker-j-clin-endocrinol-metab/","asOf":"2026-09-22","days":6},{"id":"paper-maffini-j-cell-sci","kind":"paper","name":"The stroma as a crucial target in rat mammary gland carcinogenesis","route":"/key-papers/paper-maffini-j-cell-sci/","asOf":"2026-09-22","days":6},{"id":"paper-freedman-plos-biol","kind":"paper","name":"The Economics of Reproducibility in Preclinical Research","route":"/key-papers/paper-freedman-plos-biol/","asOf":"2026-09-22","days":6},{"id":"paper-ghaffarizadeh-plos-comput-biol","kind":"paper","name":"PhysiCell: An open source physics-based cell simulator for 3-D multicellular systems","route":"/key-papers/paper-ghaffarizadeh-plos-comput-biol/","asOf":"2026-09-22","days":6},{"id":"paper-zafar-oncologist","kind":"paper","name":"The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience","route":"/key-papers/paper-zafar-oncologist/","asOf":"2026-09-22","days":6},{"id":"paper-pramesh-bull-world-health-organ","kind":"paper","name":"National Cancer Grid initiative for electronic medical records, India","route":"/key-papers/paper-pramesh-bull-world-health-organ/","asOf":"2026-09-22","days":6},{"id":"paper-pandit-taskar-j-nucl-med","kind":"paper","name":"Biodistribution and Dosimetry of 18 F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies","route":"/key-papers/paper-pandit-taskar-j-nucl-med/","asOf":"2026-09-22","days":6},{"id":"paper-badawi-j-nucl-med","kind":"paper","name":"First Human Imaging Studies with the EXPLORER Total-Body PET Scanner","route":"/key-papers/paper-badawi-j-nucl-med/","asOf":"2026-09-22","days":6},{"id":"paper-paskett-ca-cancer-j-clin","kind":"paper","name":"Patient navigation: an update on the state of the science","route":"/key-papers/paper-paskett-ca-cancer-j-clin/","asOf":"2026-09-22","days":6},{"id":"paper-bar-j-pers-med","kind":"paper","name":"Clinical Utility of an Ex Vivo Functional Test in Personalized Cancer Treatment","route":"/key-papers/paper-bar-j-pers-med/","asOf":"2026-09-22","days":6},{"id":"paper-pramesh-indian-j-med-paediatr-oncol","kind":"paper","name":"The national cancer grid of India","route":"/key-papers/paper-pramesh-indian-j-med-paediatr-oncol/","asOf":"2026-09-22","days":6},{"id":"paper-cai-j-glob-health","kind":"paper","name":"Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: A controlled interrupted time series study","route":"/key-papers/paper-cai-j-glob-health/","asOf":"2026-09-22","days":6},{"id":"paper-kutner-ann-intern-med","kind":"paper","name":"Massage therapy versus simple touch to improve pain and mood in patients with advanced cancer: a randomized trial","route":"/key-papers/paper-kutner-ann-intern-med/","asOf":"2026-09-22","days":6},{"id":"paper-bozic-elife","kind":"paper","name":"Evolutionary dynamics of cancer in response to targeted combination therapy","route":"/key-papers/paper-bozic-elife/","asOf":"2026-09-22","days":6},{"id":"paper-amer-zeidan-n-engl-j-med-2020","kind":"paper","name":"Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes","route":"/key-papers/paper-amer-zeidan-n-engl-j-med-2020/","asOf":"2026-09-22","days":6},{"id":"paper-amer-zeidan-j-clin-oncol-2021","kind":"paper","name":"Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia","route":"/key-papers/paper-amer-zeidan-j-clin-oncol-2021/","asOf":"2026-09-22","days":6},{"id":"paper-andrea-decensi-cancer-prev-res-phila-2014","kind":"paper","name":"Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders","route":"/key-papers/paper-andrea-decensi-cancer-prev-res-phila-2014/","asOf":"2026-09-22","days":6},{"id":"paper-andrea-decensi-diabetologia-2017","kind":"paper","name":"Repurposing metformin for the prevention of cancer and cancer recurrence","route":"/key-papers/paper-andrea-decensi-diabetologia-2017/","asOf":"2026-09-22","days":6},{"id":"paper-andrea-decensi-j-clin-oncol-2019","kind":"paper","name":"Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update","route":"/key-papers/paper-andrea-decensi-j-clin-oncol-2019/","asOf":"2026-09-22","days":6},{"id":"paper-andrew-lassman-neuro-oncol-2020","kind":"paper","name":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions","route":"/key-papers/paper-andrew-lassman-neuro-oncol-2020/","asOf":"2026-09-22","days":6},{"id":"paper-andrew-lassman-j-clin-oncol-2022","kind":"paper","name":"Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline","route":"/key-papers/paper-andrew-lassman-j-clin-oncol-2022/","asOf":"2026-09-22","days":6},{"id":"paper-andrew-lassman-j-clin-oncol-2023","kind":"paper","name":"RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults","route":"/key-papers/paper-andrew-lassman-j-clin-oncol-2023/","asOf":"2026-09-22","days":6},{"id":"paper-anthony-nichols-lancet-oncol-2019","kind":"paper","name":"Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial","route":"/key-papers/paper-anthony-nichols-lancet-oncol-2019/","asOf":"2026-09-22","days":6},{"id":"paper-anthony-nichols-nat-genet-2017","kind":"paper","name":"Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas","route":"/key-papers/paper-anthony-nichols-nat-genet-2017/","asOf":"2026-09-22","days":6},{"id":"paper-anthony-nichols-nat-genet-2014","kind":"paper","name":"Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands","route":"/key-papers/paper-anthony-nichols-nat-genet-2014/","asOf":"2026-09-22","days":6},{"id":"paper-antoine-italiano-nature-2020","kind":"paper","name":"B cells are associated with survival and immunotherapy response in sarcoma","route":"/key-papers/paper-antoine-italiano-nature-2020/","asOf":"2026-09-22","days":6},{"id":"paper-antoine-italiano-nat-cancer-2021","kind":"paper","name":"Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression","route":"/key-papers/paper-antoine-italiano-nat-cancer-2021/","asOf":"2026-09-22","days":6},{"id":"paper-antoine-italiano-j-clin-oncol-2022","kind":"paper","name":"Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study","route":"/key-papers/paper-antoine-italiano-j-clin-oncol-2022/","asOf":"2026-09-22","days":6},{"id":"paper-florence-duffaud-ann-oncol-2017","kind":"paper","name":"Improved survival using specialized multidisciplinary board in sarcoma patients","route":"/key-papers/paper-florence-duffaud-ann-oncol-2017/","asOf":"2026-09-22","days":6},{"id":"paper-florence-duffaud-lancet-oncol-2020","kind":"paper","name":"Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial","route":"/key-papers/paper-florence-duffaud-lancet-oncol-2020/","asOf":"2026-09-22","days":6},{"id":"paper-florence-duffaud-lancet-oncol-2019","kind":"paper","name":"Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study","route":"/key-papers/paper-florence-duffaud-lancet-oncol-2019/","asOf":"2026-09-22","days":6},{"id":"paper-jacques-grill-cell-2016","kind":"paper","name":"New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs","route":"/key-papers/paper-jacques-grill-cell-2016/","asOf":"2026-09-22","days":6},{"id":"paper-jacques-grill-acta-neuropathol-2015","kind":"paper","name":"Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes","route":"/key-papers/paper-jacques-grill-acta-neuropathol-2015/","asOf":"2026-09-22","days":6},{"id":"paper-jan-burger-n-engl-j-med-2015","kind":"paper","name":"Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia","route":"/key-papers/paper-jan-burger-n-engl-j-med-2015/","asOf":"2026-09-22","days":6},{"id":"paper-jan-burger-blood-2015","kind":"paper","name":"Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","route":"/key-papers/paper-jan-burger-blood-2015/","asOf":"2026-09-22","days":6},{"id":"paper-jan-burger-blood-2009","kind":"paper","name":"The microenvironment in mature B-cell malignancies: a target for new treatment strategies","route":"/key-papers/paper-jan-burger-blood-2009/","asOf":"2026-09-22","days":6},{"id":"paper-jean-pascal-machiels-lancet-2019","kind":"paper","name":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","route":"/key-papers/paper-jean-pascal-machiels-lancet-2019/","asOf":"2026-09-22","days":6},{"id":"paper-jean-pascal-machiels-ann-oncol-2020","kind":"paper","name":"Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up","route":"/key-papers/paper-jean-pascal-machiels-ann-oncol-2020/","asOf":"2026-09-22","days":6},{"id":"paper-jean-pascal-machiels-ann-oncol-2021","kind":"paper","name":"Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up †","route":"/key-papers/paper-jean-pascal-machiels-ann-oncol-2021/","asOf":"2026-09-22","days":6},{"id":"paper-keunchil-park-lancet-2017","kind":"paper","name":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","route":"/key-papers/paper-keunchil-park-lancet-2017/","asOf":"2026-09-22","days":6},{"id":"paper-keunchil-park-lancet-2016","kind":"paper","name":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","route":"/key-papers/paper-keunchil-park-lancet-2016/","asOf":"2026-09-22","days":6},{"id":"paper-keunchil-park-n-engl-j-med-2019","kind":"paper","name":"Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer","route":"/key-papers/paper-keunchil-park-n-engl-j-med-2019/","asOf":"2026-09-22","days":6},{"id":"paper-luca-gianni-j-clin-oncol-2022","kind":"paper","name":"Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study","route":"/key-papers/paper-luca-gianni-j-clin-oncol-2022/","asOf":"2026-09-22","days":6},{"id":"paper-luca-gianni-cancer-med-2023","kind":"paper","name":"Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma","route":"/key-papers/paper-luca-gianni-cancer-med-2023/","asOf":"2026-09-22","days":6},{"id":"paper-luca-gianni-j-natl-cancer-inst-2022","kind":"paper","name":"Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab","route":"/key-papers/paper-luca-gianni-j-natl-cancer-inst-2022/","asOf":"2026-09-22","days":6},{"id":"paper-olivier-chinot-n-engl-j-med-2014","kind":"paper","name":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","route":"/key-papers/paper-olivier-chinot-n-engl-j-med-2014/","asOf":"2026-09-22","days":6},{"id":"paper-olivier-chinot-nat-rev-clin-oncol-2021","kind":"paper","name":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","route":"/key-papers/paper-olivier-chinot-nat-rev-clin-oncol-2021/","asOf":"2026-09-22","days":6},{"id":"paper-olivier-chinot-cancer-treat-rev-2020","kind":"paper","name":"Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook","route":"/key-papers/paper-olivier-chinot-cancer-treat-rev-2020/","asOf":"2026-09-22","days":6},{"id":"paper-peter-thuss-patience-eur-j-cancer-2011","kind":"paper","name":"Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)","route":"/key-papers/paper-peter-thuss-patience-eur-j-cancer-2011/","asOf":"2026-09-22","days":6},{"id":"paper-peter-thuss-patience-ann-oncol-2019","kind":"paper","name":"A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study","route":"/key-papers/paper-peter-thuss-patience-ann-oncol-2019/","asOf":"2026-09-22","days":6},{"id":"paper-raajit-rampal-nature-2020","kind":"paper","name":"Single-cell mutation analysis of clonal evolution in myeloid malignancies","route":"/key-papers/paper-raajit-rampal-nature-2020/","asOf":"2026-09-22","days":6},{"id":"paper-raajit-rampal-blood-2014","kind":"paper","name":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","route":"/key-papers/paper-raajit-rampal-blood-2014/","asOf":"2026-09-22","days":6},{"id":"paper-raajit-rampal-cancer-discov-2015","kind":"paper","name":"JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response","route":"/key-papers/paper-raajit-rampal-cancer-discov-2015/","asOf":"2026-09-22","days":6},{"id":"paper-robin-jones-ann-oncol-2018","kind":"paper","name":"Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","route":"/key-papers/paper-robin-jones-ann-oncol-2018/","asOf":"2026-09-22","days":6},{"id":"paper-robin-jones-lancet-2016","kind":"paper","name":"Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial","route":"/key-papers/paper-robin-jones-lancet-2016/","asOf":"2026-09-22","days":6},{"id":"paper-santosh-kesari-nat-commun-2026","kind":"paper","name":"Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations","route":"/key-papers/paper-santosh-kesari-nat-commun-2026/","asOf":"2026-09-22","days":6},{"id":"paper-shailender-bhatia-cell-2017","kind":"paper","name":"Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab","route":"/key-papers/paper-shailender-bhatia-cell-2017/","asOf":"2026-09-22","days":6},{"id":"paper-shelley-hwang-cancer-cell-2014","kind":"paper","name":"Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells","route":"/key-papers/paper-shelley-hwang-cancer-cell-2014/","asOf":"2026-09-22","days":6},{"id":"paper-shelley-hwang-cancer-cell-2019","kind":"paper","name":"Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets","route":"/key-papers/paper-shelley-hwang-cancer-cell-2019/","asOf":"2026-09-22","days":6},{"id":"paper-trastuzumab-deruxtecan-breast-hr-positive-ann-oncol-2026","kind":"paper","name":"Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial","route":"/key-papers/paper-trastuzumab-deruxtecan-breast-hr-positive-ann-oncol-2026/","asOf":"2026-09-22","days":6},{"id":"paper-trastuzumab-deruxtecan-tnbc-esmo-open-2021","kind":"paper","name":"Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape","route":"/key-papers/paper-trastuzumab-deruxtecan-tnbc-esmo-open-2021/","asOf":"2026-09-22","days":6},{"id":"paper-trastuzumab-deruxtecan-tnbc-expert-opin-biol-ther-2021","kind":"paper","name":"Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan","route":"/key-papers/paper-trastuzumab-deruxtecan-tnbc-expert-opin-biol-ther-2021/","asOf":"2026-09-22","days":6},{"id":"paper-egfr-nsclc-lancet-oncol-2012","kind":"paper","name":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","route":"/key-papers/paper-egfr-nsclc-lancet-oncol-2012/","asOf":"2026-09-22","days":6},{"id":"paper-egfr-nsclc-n-engl-j-med-2010","kind":"paper","name":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","route":"/key-papers/paper-egfr-nsclc-n-engl-j-med-2010/","asOf":"2026-09-22","days":6},{"id":"paper-palbociclib-breast-hr-positive-lancet-oncol-2015","kind":"paper","name":"The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study","route":"/key-papers/paper-palbociclib-breast-hr-positive-lancet-oncol-2015/","asOf":"2026-09-22","days":6},{"id":"paper-trastuzumab-deruxtecan-breast-her2-positive-n-engl-j-med-2020","kind":"paper","name":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer","route":"/key-papers/paper-trastuzumab-deruxtecan-breast-her2-positive-n-engl-j-med-2020/","asOf":"2026-09-22","days":6},{"id":"paper-capivasertib-breast-hr-positive-lancet-oncol-2022","kind":"paper","name":"Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial","route":"/key-papers/paper-capivasertib-breast-hr-positive-lancet-oncol-2022/","asOf":"2026-09-22","days":6},{"id":"paper-capivasertib-breast-hr-positive-breast-2022","kind":"paper","name":"\"The emerging role of capivasertib in breast cancer\"","route":"/key-papers/paper-capivasertib-breast-hr-positive-breast-2022/","asOf":"2026-09-22","days":6},{"id":"paper-capivasertib-breast-hr-positive-drugs-2024","kind":"paper","name":"Capivasertib: First Approval","route":"/key-papers/paper-capivasertib-breast-hr-positive-drugs-2024/","asOf":"2026-09-22","days":6},{"id":"paper-cd47-pancreatic-pharmacol-res-2022","kind":"paper","name":"Overcoming immunotherapeutic resistance in PDAC: SIRPα-CD47 blockade","route":"/key-papers/paper-cd47-pancreatic-pharmacol-res-2022/","asOf":"2026-09-22","days":6},{"id":"paper-cd47-neuroblastoma-curr-oncol-2024","kind":"paper","name":"A Perspective on the CD47-SIRPA Axis in High-Risk Neuroblastoma","route":"/key-papers/paper-cd47-neuroblastoma-curr-oncol-2024/","asOf":"2026-09-22","days":6},{"id":"paper-osimertinib-nsclc-n-engl-j-med-2017","kind":"paper","name":"Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer","route":"/key-papers/paper-osimertinib-nsclc-n-engl-j-med-2017/","asOf":"2026-09-22","days":6},{"id":"paper-osimertinib-nsclc-n-engl-j-med-2020","kind":"paper","name":"Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC","route":"/key-papers/paper-osimertinib-nsclc-n-engl-j-med-2020/","asOf":"2026-09-22","days":6},{"id":"paper-trastuzumab-breast-her2-positive-n-engl-j-med-2005","kind":"paper","name":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","route":"/key-papers/paper-trastuzumab-breast-her2-positive-n-engl-j-med-2005/","asOf":"2026-09-22","days":6},{"id":"paper-trastuzumab-breast-her2-positive-n-engl-j-med-2011","kind":"paper","name":"Adjuvant trastuzumab in HER2-positive breast cancer","route":"/key-papers/paper-trastuzumab-breast-her2-positive-n-engl-j-med-2011/","asOf":"2026-09-22","days":6},{"id":"paper-sacituzumab-govitecan-tnbc-n-engl-j-med-2019","kind":"paper","name":"Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer","route":"/key-papers/paper-sacituzumab-govitecan-tnbc-n-engl-j-med-2019/","asOf":"2026-09-22","days":6},{"id":"paper-sacituzumab-govitecan-tnbc-j-clin-oncol-2017","kind":"paper","name":"Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer","route":"/key-papers/paper-sacituzumab-govitecan-tnbc-j-clin-oncol-2017/","asOf":"2026-09-22","days":6},{"id":"paper-kras-nsclc-n-engl-j-med-2021","kind":"paper","name":"Sotorasib for Lung Cancers with KRAS p.G12C Mutation","route":"/key-papers/paper-kras-nsclc-n-engl-j-med-2021/","asOf":"2026-09-22","days":6},{"id":"paper-kras-nsclc-cancer-discov-2018","kind":"paper","name":"STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma","route":"/key-papers/paper-kras-nsclc-cancer-discov-2018/","asOf":"2026-09-22","days":6},{"id":"paper-kras-nsclc-j-clin-oncol-2005","kind":"paper","name":"Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib","route":"/key-papers/paper-kras-nsclc-j-clin-oncol-2005/","asOf":"2026-09-22","days":6},{"id":"paper-ezh2-colorectal-br-j-cancer-2009","kind":"paper","name":"Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis","route":"/key-papers/paper-ezh2-colorectal-br-j-cancer-2009/","asOf":"2026-09-22","days":6},{"id":"paper-pd-1-nsclc-am-j-clin-oncol-2016","kind":"paper","name":"CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition","route":"/key-papers/paper-pd-1-nsclc-am-j-clin-oncol-2016/","asOf":"2026-09-22","days":6},{"id":"paper-dll3-sclc-clin-cancer-res-2019","kind":"paper","name":"Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study","route":"/key-papers/paper-dll3-sclc-clin-cancer-res-2019/","asOf":"2026-09-22","days":6},{"id":"paper-tarlatamab-sclc-n-engl-j-med-2025","kind":"paper","name":"Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy","route":"/key-papers/paper-tarlatamab-sclc-n-engl-j-med-2025/","asOf":"2026-09-22","days":6},{"id":"paper-braf-melanoma-n-engl-j-med-2015","kind":"paper","name":"Nivolumab in previously untreated melanoma without BRAF mutation","route":"/key-papers/paper-braf-melanoma-n-engl-j-med-2015/","asOf":"2026-09-22","days":6},{"id":"paper-alk-nsclc-n-engl-j-med-2013","kind":"paper","name":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","route":"/key-papers/paper-alk-nsclc-n-engl-j-med-2013/","asOf":"2026-09-22","days":6},{"id":"paper-kras-colorectal-j-clin-oncol-2008","kind":"paper","name":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","route":"/key-papers/paper-kras-colorectal-j-clin-oncol-2008/","asOf":"2026-09-22","days":6},{"id":"paper-kras-colorectal-j-clin-oncol-2011","kind":"paper","name":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status","route":"/key-papers/paper-kras-colorectal-j-clin-oncol-2011/","asOf":"2026-09-22","days":6},{"id":"paper-kras-colorectal-j-clin-oncol-2010","kind":"paper","name":"Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial","route":"/key-papers/paper-kras-colorectal-j-clin-oncol-2010/","asOf":"2026-09-22","days":6},{"id":"paper-cd47-colorectal-cancers-basel-2025","kind":"paper","name":"Expression and Clinical Significance of CD47 in Colorectal Cancer: A Review","route":"/key-papers/paper-cd47-colorectal-cancers-basel-2025/","asOf":"2026-09-22","days":6},{"id":"paper-cd47-colorectal-cancer-res-commun-2025","kind":"paper","name":"Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer","route":"/key-papers/paper-cd47-colorectal-cancer-res-commun-2025/","asOf":"2026-09-22","days":6},{"id":"paper-ctla-4-colorectal-j-exp-clin-cancer-res-2019","kind":"paper","name":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","route":"/key-papers/paper-ctla-4-colorectal-j-exp-clin-cancer-res-2019/","asOf":"2026-09-22","days":6},{"id":"paper-pik3ca-colorectal-lancet-oncol-2011","kind":"paper","name":"KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer","route":"/key-papers/paper-pik3ca-colorectal-lancet-oncol-2011/","asOf":"2026-09-22","days":6},{"id":"paper-pik3ca-colorectal-acta-oncol-2014","kind":"paper","name":"The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis","route":"/key-papers/paper-pik3ca-colorectal-acta-oncol-2014/","asOf":"2026-09-22","days":6},{"id":"paper-pik3ca-colorectal-j-clin-oncol-2013","kind":"paper","name":"Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer","route":"/key-papers/paper-pik3ca-colorectal-j-clin-oncol-2013/","asOf":"2026-09-22","days":6},{"id":"paper-pd-l1-urothelial-mol-cancer-ther-2015","kind":"paper","name":"PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy","route":"/key-papers/paper-pd-l1-urothelial-mol-cancer-ther-2015/","asOf":"2026-09-22","days":6},{"id":"paper-pd-l1-urothelial-trends-mol-med-2015","kind":"paper","name":"Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway","route":"/key-papers/paper-pd-l1-urothelial-trends-mol-med-2015/","asOf":"2026-09-22","days":6},{"id":"paper-pd-l1-urothelial-onco-targets-ther-2016","kind":"paper","name":"PD-L1 expression in human cancers and its association with clinical outcomes","route":"/key-papers/paper-pd-l1-urothelial-onco-targets-ther-2016/","asOf":"2026-09-22","days":6},{"id":"paper-gpc3-hcc-oncoimmunology-2016","kind":"paper","name":"Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients","route":"/key-papers/paper-gpc3-hcc-oncoimmunology-2016/","asOf":"2026-09-22","days":6},{"id":"paper-cldn18-gastric-front-oncol-2020","kind":"paper","name":"The Significance of the CLDN18-ARHGAP Fusion Gene in Gastric Cancer: A Systematic Review and Meta-Analysis","route":"/key-papers/paper-cldn18-gastric-front-oncol-2020/","asOf":"2026-09-22","days":6},{"id":"paper-gpc3-gastric-pathol-res-pract-2026","kind":"paper","name":"Research progress of GPC3 and gastric cancer: Clinicopathologic characteristics and application prospects","route":"/key-papers/paper-gpc3-gastric-pathol-res-pract-2026/","asOf":"2026-09-22","days":6},{"id":"paper-daraxonrasib-pancreatic-n-engl-j-med-2026","kind":"paper","name":"Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer","route":"/key-papers/paper-daraxonrasib-pancreatic-n-engl-j-med-2026/","asOf":"2026-09-22","days":6},{"id":"paper-daraxonrasib-pancreatic-cureus-2026","kind":"paper","name":"Daraxonrasib: A Breakthrough in Pancreatic Ductal Adenocarcinoma","route":"/key-papers/paper-daraxonrasib-pancreatic-cureus-2026/","asOf":"2026-09-22","days":6},{"id":"paper-lutetium-177-vipivotide-tetrax-prostate-oncol-ther-2025","kind":"paper","name":"Sequencing of Radium-223 and Lutetium-177 Vipivotide Tetraxetan: Maximizing the Benefit of Systemic Targeted Radiation Therapy in Metastatic Castration-Resistant Prostate Cancer","route":"/key-papers/paper-lutetium-177-vipivotide-tetrax-prostate-oncol-ther-2025/","asOf":"2026-09-22","days":6},{"id":"paper-lutetium-177-vipivotide-tetrax-prostate-journal-2023","kind":"paper","name":"Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments","route":"/key-papers/paper-lutetium-177-vipivotide-tetrax-prostate-journal-2023/","asOf":"2026-09-22","days":6},{"id":"paper-androgen-receptor-prostate-endocr-rev-2004","kind":"paper","name":"Androgen receptor in prostate cancer","route":"/key-papers/paper-androgen-receptor-prostate-endocr-rev-2004/","asOf":"2026-09-22","days":6},{"id":"paper-androgen-receptor-prostate-nat-rev-cancer-2015","kind":"paper","name":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","route":"/key-papers/paper-androgen-receptor-prostate-nat-rev-cancer-2015/","asOf":"2026-09-22","days":6},{"id":"paper-androgen-receptor-prostate-acta-pharmacol-sin-2015","kind":"paper","name":"Androgen receptor: structure, role in prostate cancer and drug discovery","route":"/key-papers/paper-androgen-receptor-prostate-acta-pharmacol-sin-2015/","asOf":"2026-09-22","days":6},{"id":"paper-abiraterone-acetate-prostate-n-engl-j-med-2013","kind":"paper","name":"Abiraterone in metastatic prostate cancer without previous chemotherapy","route":"/key-papers/paper-abiraterone-acetate-prostate-n-engl-j-med-2013/","asOf":"2026-09-22","days":6},{"id":"paper-abiraterone-acetate-prostate-lancet-oncol-2015","kind":"paper","name":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","route":"/key-papers/paper-abiraterone-acetate-prostate-lancet-oncol-2015/","asOf":"2026-09-22","days":6},{"id":"paper-abiraterone-acetate-prostate-lancet-oncol-2012","kind":"paper","name":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","route":"/key-papers/paper-abiraterone-acetate-prostate-lancet-oncol-2012/","asOf":"2026-09-22","days":6},{"id":"paper-nivolumab-melanoma-n-engl-j-med-2015","kind":"paper","name":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","route":"/key-papers/paper-nivolumab-melanoma-n-engl-j-med-2015/","asOf":"2026-09-22","days":6},{"id":"paper-tebentafusp-melanoma-cancers-basel-2019","kind":"paper","name":"Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma","route":"/key-papers/paper-tebentafusp-melanoma-cancers-basel-2019/","asOf":"2026-09-22","days":6},{"id":"paper-mesothelin-mesothelioma-cancer-discov-2016","kind":"paper","name":"Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors","route":"/key-papers/paper-mesothelin-mesothelioma-cancer-discov-2016/","asOf":"2026-09-22","days":6},{"id":"paper-mesothelin-mesothelioma-clin-cancer-res-2004","kind":"paper","name":"Mesothelin: a new target for immunotherapy","route":"/key-papers/paper-mesothelin-mesothelioma-clin-cancer-res-2004/","asOf":"2026-09-22","days":6},{"id":"paper-mesothelin-mesothelioma-j-clin-oncol-2016","kind":"paper","name":"Mesothelin Immunotherapy for Cancer: Ready for Prime Time?","route":"/key-papers/paper-mesothelin-mesothelioma-j-clin-oncol-2016/","asOf":"2026-09-22","days":6},{"id":"paper-egfr-gastric-eur-j-cancer-2001","kind":"paper","name":"EGFR and cancer prognosis","route":"/key-papers/paper-egfr-gastric-eur-j-cancer-2001/","asOf":"2026-09-22","days":6},{"id":"paper-egfr-glioblastoma-mol-oncol-2018","kind":"paper","name":"Emerging functions of the EGFR in cancer","route":"/key-papers/paper-egfr-glioblastoma-mol-oncol-2018/","asOf":"2026-09-22","days":6},{"id":"paper-egfr-glioblastoma-sci-signal-2009","kind":"paper","name":"Oncogenic EGFR signaling networks in glioma","route":"/key-papers/paper-egfr-glioblastoma-sci-signal-2009/","asOf":"2026-09-22","days":6},{"id":"paper-ezh2-ovarian-mol-cancer-ther-2018","kind":"paper","name":"Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer","route":"/key-papers/paper-ezh2-ovarian-mol-cancer-ther-2018/","asOf":"2026-09-22","days":6},{"id":"paper-ezh2-sarcoma-bmc-med-2011","kind":"paper","name":"Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications","route":"/key-papers/paper-ezh2-sarcoma-bmc-med-2011/","asOf":"2026-09-22","days":6},{"id":"paper-ezh2-sarcoma-biochem-pharmacol-2023","kind":"paper","name":"Targeting EZH2 in SMARCB1-deficient sarcomas: Advances and opportunities to potentiate the efficacy of EZH2 inhibitors","route":"/key-papers/paper-ezh2-sarcoma-biochem-pharmacol-2023/","asOf":"2026-09-22","days":6},{"id":"paper-niraparib-ovarian-n-engl-j-med-2016","kind":"paper","name":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer","route":"/key-papers/paper-niraparib-ovarian-n-engl-j-med-2016/","asOf":"2026-09-22","days":6},{"id":"paper-mirvetuximab-soravtansine-ovarian-j-clin-oncol-2023","kind":"paper","name":"Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study","route":"/key-papers/paper-mirvetuximab-soravtansine-ovarian-j-clin-oncol-2023/","asOf":"2026-09-22","days":6},{"id":"paper-mirvetuximab-soravtansine-ovarian-ann-oncol-2021","kind":"paper","name":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I","route":"/key-papers/paper-mirvetuximab-soravtansine-ovarian-ann-oncol-2021/","asOf":"2026-09-22","days":6},{"id":"paper-braf-thyroid-n-engl-j-med-2015","kind":"paper","name":"Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations","route":"/key-papers/paper-braf-thyroid-n-engl-j-med-2015/","asOf":"2026-09-22","days":6},{"id":"paper-braf-thyroid-endocr-relat-cancer-2005","kind":"paper","name":"BRAF mutation in thyroid cancer","route":"/key-papers/paper-braf-thyroid-endocr-relat-cancer-2005/","asOf":"2026-09-22","days":6},{"id":"paper-braf-thyroid-endocr-rev-2007","kind":"paper","name":"BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications","route":"/key-papers/paper-braf-thyroid-endocr-rev-2007/","asOf":"2026-09-22","days":6},{"id":"paper-carboplatin-glioblastoma-neuro-oncol-2003","kind":"paper","name":"A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma","route":"/key-papers/paper-carboplatin-glioblastoma-neuro-oncol-2003/","asOf":"2026-09-22","days":6},{"id":"paper-carboplatin-glioblastoma-neuro-oncol-2015","kind":"paper","name":"Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma","route":"/key-papers/paper-carboplatin-glioblastoma-neuro-oncol-2015/","asOf":"2026-09-22","days":6},{"id":"paper-carboplatin-glioblastoma-eur-j-cancer-2017","kind":"paper","name":"A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma - A final report","route":"/key-papers/paper-carboplatin-glioblastoma-eur-j-cancer-2017/","asOf":"2026-09-22","days":6},{"id":"paper-glofitamab-dlbcl-n-engl-j-med-2022","kind":"paper","name":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","route":"/key-papers/paper-glofitamab-dlbcl-n-engl-j-med-2022/","asOf":"2026-09-22","days":6},{"id":"paper-glofitamab-dlbcl-lancet-2024","kind":"paper","name":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial","route":"/key-papers/paper-glofitamab-dlbcl-lancet-2024/","asOf":"2026-09-22","days":6},{"id":"paper-pembrolizumab-urothelial-n-engl-j-med-2017","kind":"paper","name":"Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma","route":"/key-papers/paper-pembrolizumab-urothelial-n-engl-j-med-2017/","asOf":"2026-09-22","days":6},{"id":"paper-pembrolizumab-urothelial-lancet-oncol-2017","kind":"paper","name":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","route":"/key-papers/paper-pembrolizumab-urothelial-lancet-oncol-2017/","asOf":"2026-09-22","days":6},{"id":"paper-fgfr2-cholangiocarcinoma-annu-rev-med-2023","kind":"paper","name":"FGFR2 Inhibition in Cholangiocarcinoma","route":"/key-papers/paper-fgfr2-cholangiocarcinoma-annu-rev-med-2023/","asOf":"2026-09-22","days":6},{"id":"paper-fgfr2-cholangiocarcinoma-cancers-basel-2026","kind":"paper","name":"FGFR2-Rearranged Biliary Tract Cancer: Biology, Resistance Mechanisms, and Emerging Therapeutic Strategies","route":"/key-papers/paper-fgfr2-cholangiocarcinoma-cancers-basel-2026/","asOf":"2026-09-22","days":6},{"id":"paper-fgfr2-cholangiocarcinoma-int-j-mol-sci-2025","kind":"paper","name":"Expanding Horizons in Cholangiocarcinoma: Emerging Targets Beyond FGFR2 and IDH1","route":"/key-papers/paper-fgfr2-cholangiocarcinoma-int-j-mol-sci-2025/","asOf":"2026-09-22","days":6},{"id":"paper-acalabrutinib-cll-n-engl-j-med-2016","kind":"paper","name":"Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia","route":"/key-papers/paper-acalabrutinib-cll-n-engl-j-med-2016/","asOf":"2026-09-22","days":6},{"id":"paper-bcl-2-cll-nat-rev-drug-discov-2017","kind":"paper","name":"From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors","route":"/key-papers/paper-bcl-2-cll-nat-rev-drug-discov-2017/","asOf":"2026-09-22","days":6},{"id":"paper-acalabrutinib-cll-j-clin-oncol-2021","kind":"paper","name":"Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial","route":"/key-papers/paper-acalabrutinib-cll-j-clin-oncol-2021/","asOf":"2026-09-22","days":6},{"id":"paper-ciltacabtagene-autoleucel-multiple-myeloma-front-immunol-2022","kind":"paper","name":"Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma","route":"/key-papers/paper-ciltacabtagene-autoleucel-multiple-myeloma-front-immunol-2022/","asOf":"2026-09-22","days":6},{"id":"paper-ciltacabtagene-autoleucel-multiple-myeloma-j-clin-oncol-2023","kind":"paper","name":"Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1)","route":"/key-papers/paper-ciltacabtagene-autoleucel-multiple-myeloma-j-clin-oncol-2023/","asOf":"2026-09-22","days":6},{"id":"paper-ciltacabtagene-autoleucel-multiple-myeloma-clin-cancer-res-2024","kind":"paper","name":"FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma","route":"/key-papers/paper-ciltacabtagene-autoleucel-multiple-myeloma-clin-cancer-res-2024/","asOf":"2026-09-22","days":6},{"id":"paper-cd30-hodgkin-lymphoma-j-clin-oncol-2020","kind":"paper","name":"Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma","route":"/key-papers/paper-cd30-hodgkin-lymphoma-j-clin-oncol-2020/","asOf":"2026-09-22","days":6},{"id":"paper-cd30-hodgkin-lymphoma-blood-cancer-j-2017","kind":"paper","name":"Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions","route":"/key-papers/paper-cd30-hodgkin-lymphoma-blood-cancer-j-2017/","asOf":"2026-09-22","days":6},{"id":"paper-cd30-hodgkin-lymphoma-j-clin-oncol-2015","kind":"paper","name":"Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project","route":"/key-papers/paper-cd30-hodgkin-lymphoma-j-clin-oncol-2015/","asOf":"2026-09-22","days":6},{"id":"paper-brentuximab-vedotin-hodgkin-lymphoma-lancet-oncol-2016","kind":"paper","name":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","route":"/key-papers/paper-brentuximab-vedotin-hodgkin-lymphoma-lancet-oncol-2016/","asOf":"2026-09-22","days":6},{"id":"paper-brentuximab-vedotin-hodgkin-lymphoma-blood-2018","kind":"paper","name":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","route":"/key-papers/paper-brentuximab-vedotin-hodgkin-lymphoma-blood-2018/","asOf":"2026-09-22","days":6},{"id":"paper-pembrolizumab-head-and-neck-j-clin-oncol-2017","kind":"paper","name":"Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study","route":"/key-papers/paper-pembrolizumab-head-and-neck-j-clin-oncol-2017/","asOf":"2026-09-22","days":6},{"id":"paper-epcoritamab-dlbcl-drugs-2023","kind":"paper","name":"Epcoritamab: First Approval","route":"/key-papers/paper-epcoritamab-dlbcl-drugs-2023/","asOf":"2026-09-22","days":6},{"id":"paper-epcoritamab-dlbcl-blood-2025","kind":"paper","name":"Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial","route":"/key-papers/paper-epcoritamab-dlbcl-blood-2025/","asOf":"2026-09-22","days":6},{"id":"paper-cd19-all-leukemia-j-clin-invest-2016","kind":"paper","name":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","route":"/key-papers/paper-cd19-all-leukemia-j-clin-invest-2016/","asOf":"2026-09-22","days":6},{"id":"paper-cd19-all-leukemia-j-clin-oncol-2014","kind":"paper","name":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","route":"/key-papers/paper-cd19-all-leukemia-j-clin-oncol-2014/","asOf":"2026-09-22","days":6},{"id":"paper-cd19-all-leukemia-blood-2015","kind":"paper","name":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","route":"/key-papers/paper-cd19-all-leukemia-blood-2015/","asOf":"2026-09-22","days":6},{"id":"paper-b7-h3-glioblastoma-int-j-biol-sci-2023","kind":"paper","name":"B7-H3 in Brain Malignancies: Immunology and Immunotherapy","route":"/key-papers/paper-b7-h3-glioblastoma-int-j-biol-sci-2023/","asOf":"2026-09-22","days":6},{"id":"paper-atezolizumab-hcc-j-hepatol-2022","kind":"paper","name":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","route":"/key-papers/paper-atezolizumab-hcc-j-hepatol-2022/","asOf":"2026-09-22","days":6},{"id":"paper-nivolumab-hcc-jama-oncol-2020","kind":"paper","name":"Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial","route":"/key-papers/paper-nivolumab-hcc-jama-oncol-2020/","asOf":"2026-09-22","days":6},{"id":"paper-blinatumomab-all-leukemia-n-engl-j-med-2017","kind":"paper","name":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","route":"/key-papers/paper-blinatumomab-all-leukemia-n-engl-j-med-2017/","asOf":"2026-09-22","days":6},{"id":"paper-blinatumomab-all-leukemia-lancet-oncol-2015","kind":"paper","name":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","route":"/key-papers/paper-blinatumomab-all-leukemia-lancet-oncol-2015/","asOf":"2026-09-22","days":6},{"id":"paper-blinatumomab-all-leukemia-j-clin-oncol-2011","kind":"paper","name":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","route":"/key-papers/paper-blinatumomab-all-leukemia-j-clin-oncol-2011/","asOf":"2026-09-22","days":6},{"id":"paper-durvalumab-endometrial-j-immunother-cancer-2021","kind":"paper","name":"Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial","route":"/key-papers/paper-durvalumab-endometrial-j-immunother-cancer-2021/","asOf":"2026-09-22","days":6},{"id":"paper-durvalumab-endometrial-gynecol-oncol-2022","kind":"paper","name":"Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial)","route":"/key-papers/paper-durvalumab-endometrial-gynecol-oncol-2022/","asOf":"2026-09-22","days":6},{"id":"paper-bcma-multiple-myeloma-leukemia-2020","kind":"paper","name":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","route":"/key-papers/paper-bcma-multiple-myeloma-leukemia-2020/","asOf":"2026-09-22","days":6},{"id":"paper-cd19-multiple-myeloma-lancet-haematol-2019","kind":"paper","name":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","route":"/key-papers/paper-cd19-multiple-myeloma-lancet-haematol-2019/","asOf":"2026-09-22","days":6},{"id":"paper-cd19-multiple-myeloma-blood-2020","kind":"paper","name":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","route":"/key-papers/paper-cd19-multiple-myeloma-blood-2020/","asOf":"2026-09-22","days":6},{"id":"paper-zanubrutinib-cll-n-engl-j-med-2023","kind":"paper","name":"Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia","route":"/key-papers/paper-zanubrutinib-cll-n-engl-j-med-2023/","asOf":"2026-09-22","days":6},{"id":"paper-zanubrutinib-cll-lancet-oncol-2022","kind":"paper","name":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","route":"/key-papers/paper-zanubrutinib-cll-lancet-oncol-2022/","asOf":"2026-09-22","days":6},{"id":"paper-zanubrutinib-cll-lancet-haematol-2021","kind":"paper","name":"Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial","route":"/key-papers/paper-zanubrutinib-cll-lancet-haematol-2021/","asOf":"2026-09-22","days":6},{"id":"paper-lenalidomide-multiple-myeloma-n-engl-j-med-2016","kind":"paper","name":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","route":"/key-papers/paper-lenalidomide-multiple-myeloma-n-engl-j-med-2016/","asOf":"2026-09-22","days":6},{"id":"paper-lenalidomide-multiple-myeloma-n-engl-j-med-2007","kind":"paper","name":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","route":"/key-papers/paper-lenalidomide-multiple-myeloma-n-engl-j-med-2007/","asOf":"2026-09-22","days":6},{"id":"paper-lenalidomide-multiple-myeloma-n-engl-j-med-2015","kind":"paper","name":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","route":"/key-papers/paper-lenalidomide-multiple-myeloma-n-engl-j-med-2015/","asOf":"2026-09-22","days":6},{"id":"paper-pembrolizumab-glioblastoma-clin-cancer-res-2021","kind":"paper","name":"Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma","route":"/key-papers/paper-pembrolizumab-glioblastoma-clin-cancer-res-2021/","asOf":"2026-09-22","days":6},{"id":"paper-pembrolizumab-glioblastoma-med-2025","kind":"paper","name":"Efficacy and safety of adjuvant TTFields plus pembrolizumab and temozolomide in newly diagnosed glioblastoma: A phase 2 study","route":"/key-papers/paper-pembrolizumab-glioblastoma-med-2025/","asOf":"2026-09-22","days":6},{"id":"paper-pembrolizumab-glioblastoma-clin-cancer-res-2025","kind":"paper","name":"Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma","route":"/key-papers/paper-pembrolizumab-glioblastoma-clin-cancer-res-2025/","asOf":"2026-09-22","days":6},{"id":"paper-lutetium-177-dotatate-neuroendocrine-pract-radiat-oncol-2022","kind":"paper","name":"Lutetium-177 DOTATATE: A Practical Review","route":"/key-papers/paper-lutetium-177-dotatate-neuroendocrine-pract-radiat-oncol-2022/","asOf":"2026-09-22","days":6},{"id":"paper-jak2-polycythaemia-vera-lancet-2005","kind":"paper","name":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","route":"/key-papers/paper-jak2-polycythaemia-vera-lancet-2005/","asOf":"2026-09-22","days":6},{"id":"paper-jak2-polycythaemia-vera-nat-rev-cancer-2007","kind":"paper","name":"Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders","route":"/key-papers/paper-jak2-polycythaemia-vera-nat-rev-cancer-2007/","asOf":"2026-09-22","days":6},{"id":"paper-jak2-myeloproliferative-neoplasms-leukemia-2010","kind":"paper","name":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1","route":"/key-papers/paper-jak2-myeloproliferative-neoplasms-leukemia-2010/","asOf":"2026-09-22","days":6},{"id":"paper-cd19-dlbcl-am-j-hematol-2021","kind":"paper","name":"Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials","route":"/key-papers/paper-cd19-dlbcl-am-j-hematol-2021/","asOf":"2026-09-22","days":6},{"id":"paper-cd19-dlbcl-clin-cancer-res-2011","kind":"paper","name":"SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies","route":"/key-papers/paper-cd19-dlbcl-clin-cancer-res-2011/","asOf":"2026-09-22","days":6},{"id":"paper-cd19-dlbcl-cytotherapy-2020","kind":"paper","name":"The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19","route":"/key-papers/paper-cd19-dlbcl-cytotherapy-2020/","asOf":"2026-09-22","days":6},{"id":"paper-azacitidine-aml-j-clin-oncol-2010","kind":"paper","name":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","route":"/key-papers/paper-azacitidine-aml-j-clin-oncol-2010/","asOf":"2026-09-22","days":6},{"id":"nct03268382","kind":"trial","name":"p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246","route":"/trials/nct03268382/","asOf":"2026-09-22","days":6},{"id":"nct03777982","kind":"trial","name":"Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT","route":"/trials/nct03777982/","asOf":"2026-09-22","days":6},{"id":"nct00841113","kind":"trial","name":"Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer","route":"/trials/nct00841113/","asOf":"2026-09-22","days":6},{"id":"nct00100243","kind":"trial","name":"Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy","route":"/trials/nct00100243/","asOf":"2026-09-22","days":6},{"id":"nct02050321","kind":"trial","name":"A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma","route":"/trials/nct02050321/","asOf":"2026-09-22","days":6},{"id":"nct03937141","kind":"trial","name":"Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer","route":"/trials/nct03937141/","asOf":"2026-09-22","days":6},{"id":"nct05016349","kind":"trial","name":"Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer","route":"/trials/nct05016349/","asOf":"2026-09-22","days":6},{"id":"nct00006371","kind":"trial","name":"A Phase II Trial of Early Medical Adrenalectomy for \"D0.5\" Prostate Cancer","route":"/trials/nct00006371/","asOf":"2026-09-22","days":6},{"id":"nct00002658","kind":"trial","name":"Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia","route":"/trials/nct00002658/","asOf":"2026-09-22","days":6},{"id":"nct00003436","kind":"trial","name":"Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia","route":"/trials/nct00003436/","asOf":"2026-09-22","days":6},{"id":"nct00002719","kind":"trial","name":"Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia","route":"/trials/nct00002719/","asOf":"2026-09-22","days":6},{"id":"nct04410445","kind":"trial","name":"Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence","route":"/trials/nct04410445/","asOf":"2026-09-22","days":6},{"id":"nct03729245","kind":"trial","name":"A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)","route":"/trials/nct03729245/","asOf":"2026-09-22","days":6},{"id":"nct04513717","kind":"trial","name":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial","route":"/trials/nct04513717/","asOf":"2026-09-22","days":6},{"id":"nct00567580","kind":"trial","name":"Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer","route":"/trials/nct00567580/","asOf":"2026-09-22","days":6},{"id":"nct07463235","kind":"trial","name":"Safety and Potency of a High Cabergoline Dosage in Microprolactinomas","route":"/trials/nct07463235/","asOf":"2026-09-22","days":6},{"id":"nct03271918","kind":"trial","name":"Cabergoline in Nonfunctioning Pituitary Adenomas","route":"/trials/nct03271918/","asOf":"2026-09-22","days":6},{"id":"nct00889525","kind":"trial","name":"Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor","route":"/trials/nct00889525/","asOf":"2026-09-22","days":6},{"id":"nct00189345","kind":"trial","name":"Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients","route":"/trials/nct00189345/","asOf":"2026-09-22","days":6},{"id":"nct00563836","kind":"trial","name":"Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer","route":"/trials/nct00563836/","asOf":"2026-09-22","days":6},{"id":"nct00532194","kind":"trial","name":"An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer","route":"/trials/nct00532194/","asOf":"2026-09-22","days":6},{"id":"nct03784014","kind":"trial","name":"Molecular Profiling of Advanced Soft-tissue Sarcomas","route":"/trials/nct03784014/","asOf":"2026-09-22","days":6},{"id":"nct01377220","kind":"trial","name":"Evaluation of 11 C-Choline PET-CT for Detection of Hepatocellular Carcinoma","route":"/trials/nct01377220/","asOf":"2026-09-22","days":6},{"id":"nct00136084","kind":"trial","name":"Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia","route":"/trials/nct00136084/","asOf":"2026-09-22","days":6},{"id":"nct02072811","kind":"trial","name":"Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia","route":"/trials/nct02072811/","asOf":"2026-09-22","days":6},{"id":"nct00703820","kind":"trial","name":"Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia","route":"/trials/nct00703820/","asOf":"2026-09-22","days":6},{"id":"nct05917405","kind":"trial","name":"Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT","route":"/trials/nct05917405/","asOf":"2026-09-22","days":6},{"id":"nct06483100","kind":"trial","name":"Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance","route":"/trials/nct06483100/","asOf":"2026-09-22","days":6},{"id":"nct06828991","kind":"trial","name":"A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP","route":"/trials/nct06828991/","asOf":"2026-09-22","days":6},{"id":"nct06252675","kind":"trial","name":"Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma","route":"/trials/nct06252675/","asOf":"2026-09-22","days":6},{"id":"nct04786964","kind":"trial","name":"Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC","route":"/trials/nct04786964/","asOf":"2026-09-22","days":6},{"id":"nct04293562","kind":"trial","name":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","route":"/trials/nct04293562/","asOf":"2026-09-22","days":6},{"id":"nct06486142","kind":"trial","name":"EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study","route":"/trials/nct06486142/","asOf":"2026-09-22","days":6},{"id":"nct00261313","kind":"trial","name":"ACCELERATE: Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Pegfilgrastim and Darbepoetin Alfa Support for the Treatment of Women With Breast Cancer","route":"/trials/nct00261313/","asOf":"2026-09-22","days":6},{"id":"nct00077311","kind":"trial","name":"Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer","route":"/trials/nct00077311/","asOf":"2026-09-22","days":6},{"id":"nct02890602","kind":"trial","name":"Erythropoietin for Management of Anemia Caused by Chemotherapy","route":"/trials/nct02890602/","asOf":"2026-09-22","days":6},{"id":"nct00045968","kind":"trial","name":"Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer","route":"/trials/nct00045968/","asOf":"2026-09-22","days":6},{"id":"nct06220032","kind":"trial","name":"Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma","route":"/trials/nct06220032/","asOf":"2026-09-22","days":6},{"id":"nct00016276","kind":"trial","name":"Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer","route":"/trials/nct00016276/","asOf":"2026-09-22","days":6},{"id":"nct00316927","kind":"trial","name":"Dexamethasone, Aspirin, and Diethylstilbestrol in Treating Patients With Locally Advanced or Metastatic Prostate Cancer","route":"/trials/nct00316927/","asOf":"2026-09-22","days":6},{"id":"nct00858429","kind":"trial","name":"Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases","route":"/trials/nct00858429/","asOf":"2026-09-22","days":6},{"id":"nct06731894","kind":"trial","name":"Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors","route":"/trials/nct06731894/","asOf":"2026-09-22","days":6},{"id":"nct03603795","kind":"trial","name":"Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy","route":"/trials/nct03603795/","asOf":"2026-09-22","days":6},{"id":"nct06550141","kind":"trial","name":"Emapalumab Prevention of CAR-T Cell Associated Toxicities","route":"/trials/nct06550141/","asOf":"2026-09-22","days":6},{"id":"nct07567014","kind":"trial","name":"Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS","route":"/trials/nct07567014/","asOf":"2026-09-22","days":6},{"id":"nct03348904","kind":"trial","name":"Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer","route":"/trials/nct03348904/","asOf":"2026-09-22","days":6},{"id":"nct00055731","kind":"trial","name":"Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse","route":"/trials/nct00055731/","asOf":"2026-09-22","days":6},{"id":"nct02971345","kind":"trial","name":"Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus","route":"/trials/nct02971345/","asOf":"2026-09-22","days":6},{"id":"nct02755311","kind":"trial","name":"Liver Resection Versus Transarterial Chemoembolization for the Treatment of Intermediate-stage Hepatocellular Carcinoma","route":"/trials/nct02755311/","asOf":"2026-09-22","days":6},{"id":"nct00542542","kind":"trial","name":"Evaluate the Use of Paravertebral Block in Reconstructive Breast Surgery","route":"/trials/nct00542542/","asOf":"2026-09-22","days":6},{"id":"nct07285057","kind":"trial","name":"Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance","route":"/trials/nct07285057/","asOf":"2026-09-22","days":6},{"id":"nct07455903","kind":"trial","name":"Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT","route":"/trials/nct07455903/","asOf":"2026-09-22","days":6},{"id":"nct06617481","kind":"trial","name":"PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence","route":"/trials/nct06617481/","asOf":"2026-09-22","days":6},{"id":"nct00268463","kind":"trial","name":"Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer","route":"/trials/nct00268463/","asOf":"2026-09-22","days":6},{"id":"nct03678428","kind":"trial","name":"FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM","route":"/trials/nct03678428/","asOf":"2026-09-22","days":6},{"id":"nct05863195","kind":"trial","name":"Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial","route":"/trials/nct05863195/","asOf":"2026-09-22","days":6},{"id":"nct04423211","kind":"trial","name":"Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging","route":"/trials/nct04423211/","asOf":"2026-09-22","days":6},{"id":"nct05479136","kind":"trial","name":"18F-Fluciclovine PET Imaging for Detecting High Grade Glioma Recurrence After Radiochemotherapy","route":"/trials/nct05479136/","asOf":"2026-09-22","days":6},{"id":"nct04333537","kind":"trial","name":"Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer","route":"/trials/nct04333537/","asOf":"2026-09-22","days":6},{"id":"nct04375683","kind":"trial","name":"Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL","route":"/trials/nct04375683/","asOf":"2026-09-22","days":6},{"id":"nct01503502","kind":"trial","name":"A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia","route":"/trials/nct01503502/","asOf":"2026-09-22","days":6},{"id":"nct05433532","kind":"trial","name":"Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients","route":"/trials/nct05433532/","asOf":"2026-09-22","days":6},{"id":"nct02398773","kind":"trial","name":"FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy","route":"/trials/nct02398773/","asOf":"2026-09-22","days":6},{"id":"nct06260033","kind":"trial","name":"Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer","route":"/trials/nct06260033/","asOf":"2026-09-22","days":6},{"id":"nct00104741","kind":"trial","name":"Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer","route":"/trials/nct00104741/","asOf":"2026-09-22","days":6},{"id":"nct00002881","kind":"trial","name":"Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer","route":"/trials/nct00002881/","asOf":"2026-09-22","days":6},{"id":"nct03678025","kind":"trial","name":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer","route":"/trials/nct03678025/","asOf":"2026-09-22","days":6},{"id":"nct00923481","kind":"trial","name":"A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H..","route":"/trials/nct00923481/","asOf":"2026-09-22","days":6},{"id":"nct07601048","kind":"trial","name":"A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment","route":"/trials/nct07601048/","asOf":"2026-09-22","days":6},{"id":"nct07581912","kind":"trial","name":"Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases","route":"/trials/nct07581912/","asOf":"2026-09-22","days":6},{"id":"nct06936644","kind":"trial","name":"A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation","route":"/trials/nct06936644/","asOf":"2026-09-22","days":6},{"id":"nct04847505","kind":"trial","name":"68Ga-DOTA-TATE PET/CT Imaging in NETs","route":"/trials/nct04847505/","asOf":"2026-09-22","days":6},{"id":"nct05880394","kind":"trial","name":"Study of Dotatate Imaging in Breast Cancer","route":"/trials/nct05880394/","asOf":"2026-09-22","days":6},{"id":"nct04842604","kind":"trial","name":"Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML","route":"/trials/nct04842604/","asOf":"2026-09-22","days":6},{"id":"nct04093505","kind":"trial","name":"Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)","route":"/trials/nct04093505/","asOf":"2026-09-22","days":6},{"id":"nct00634322","kind":"trial","name":"High Dose Methotrexate With Leucovorin Rescue With or Without Glucarpidase in Osteosarcoma","route":"/trials/nct00634322/","asOf":"2026-09-22","days":6},{"id":"nct02022358","kind":"trial","name":"Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays?","route":"/trials/nct02022358/","asOf":"2026-09-22","days":6},{"id":"nct07802626","kind":"trial","name":"Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing","route":"/trials/nct07802626/","asOf":"2026-09-22","days":6},{"id":"nct03780049","kind":"trial","name":"HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B","route":"/trials/nct03780049/","asOf":"2026-09-22","days":6},{"id":"nct02579564","kind":"trial","name":"Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients","route":"/trials/nct02579564/","asOf":"2026-09-22","days":6},{"id":"nct07398664","kind":"trial","name":"H101 Plus TACE for r/m HNSCC","route":"/trials/nct07398664/","asOf":"2026-09-22","days":6},{"id":"nct01697384","kind":"trial","name":"Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer","route":"/trials/nct01697384/","asOf":"2026-09-22","days":6},{"id":"nct01394263","kind":"trial","name":"Study of Histrelin Subdermal Implant in Patients With Prostate Cancer","route":"/trials/nct01394263/","asOf":"2026-09-22","days":6},{"id":"nct02205762","kind":"trial","name":"LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis","route":"/trials/nct02205762/","asOf":"2026-09-22","days":6},{"id":"nct06470451","kind":"trial","name":"Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL","route":"/trials/nct06470451/","asOf":"2026-09-22","days":6},{"id":"nct00326820","kind":"trial","name":"Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer","route":"/trials/nct00326820/","asOf":"2026-09-22","days":6},{"id":"nct00082927","kind":"trial","name":"Single-Dose Local Radiation Therapy Compared With Ibandronate in Treating Patients With Localized Metastatic Bone Pain","route":"/trials/nct00082927/","asOf":"2026-09-22","days":6},{"id":"nct01827605","kind":"trial","name":"A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)","route":"/trials/nct01827605/","asOf":"2026-09-22","days":6},{"id":"nct04736589","kind":"trial","name":"Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway","route":"/trials/nct04736589/","asOf":"2026-09-22","days":6},{"id":"nct07366840","kind":"trial","name":"RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure","route":"/trials/nct07366840/","asOf":"2026-09-22","days":6},{"id":"nct04963595","kind":"trial","name":"Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer","route":"/trials/nct04963595/","asOf":"2026-09-22","days":6},{"id":"nct02706691","kind":"trial","name":"BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer","route":"/trials/nct02706691/","asOf":"2026-09-22","days":6},{"id":"nct00938652","kind":"trial","name":"A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer","route":"/trials/nct00938652/","asOf":"2026-09-22","days":6},{"id":"nct01045304","kind":"trial","name":"Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer","route":"/trials/nct01045304/","asOf":"2026-09-22","days":6},{"id":"nct01204125","kind":"trial","name":"Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients","route":"/trials/nct01204125/","asOf":"2026-09-22","days":6},{"id":"nct06789796","kind":"trial","name":"a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy","route":"/trials/nct06789796/","asOf":"2026-09-22","days":6},{"id":"nct07447570","kind":"trial","name":"Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC","route":"/trials/nct07447570/","asOf":"2026-09-22","days":6},{"id":"nct07446387","kind":"trial","name":"A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer","route":"/trials/nct07446387/","asOf":"2026-09-22","days":6},{"id":"nct04632758","kind":"trial","name":"Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients","route":"/trials/nct04632758/","asOf":"2026-09-22","days":6},{"id":"nct05765877","kind":"trial","name":"Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer","route":"/trials/nct05765877/","asOf":"2026-09-22","days":6},{"id":"nct04641754","kind":"trial","name":"A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer","route":"/trials/nct04641754/","asOf":"2026-09-22","days":6},{"id":"nct05862012","kind":"trial","name":"Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)","route":"/trials/nct05862012/","asOf":"2026-09-22","days":6},{"id":"nct00998738","kind":"trial","name":"Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer","route":"/trials/nct00998738/","asOf":"2026-09-22","days":6},{"id":"nct01985724","kind":"trial","name":"Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer","route":"/trials/nct01985724/","asOf":"2026-09-22","days":6},{"id":"nct00615602","kind":"trial","name":"Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer","route":"/trials/nct00615602/","asOf":"2026-09-22","days":6},{"id":"nct00431080","kind":"trial","name":"Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer","route":"/trials/nct00431080/","asOf":"2026-09-22","days":6},{"id":"nct06224257","kind":"trial","name":"Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia","route":"/trials/nct06224257/","asOf":"2026-09-22","days":6},{"id":"nct04379167","kind":"trial","name":"A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma","route":"/trials/nct04379167/","asOf":"2026-09-22","days":6},{"id":"nct05870748","kind":"trial","name":"REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1","route":"/trials/nct05870748/","asOf":"2026-09-22","days":6},{"id":"nct04425018","kind":"trial","name":"MARGetuximab Or Trastuzumab (MARGOT)","route":"/trials/nct04425018/","asOf":"2026-09-22","days":6},{"id":"nct06312670","kind":"trial","name":"Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer","route":"/trials/nct06312670/","asOf":"2026-09-22","days":6},{"id":"nct02823405","kind":"trial","name":"X4P-001 and Pembrolizumab in Patients With Advanced Melanoma","route":"/trials/nct02823405/","asOf":"2026-09-22","days":6},{"id":"nct04274738","kind":"trial","name":"A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4","route":"/trials/nct04274738/","asOf":"2026-09-22","days":6},{"id":"nct05463601","kind":"trial","name":"Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer","route":"/trials/nct05463601/","asOf":"2026-09-22","days":6},{"id":"nct05076682","kind":"trial","name":"Reverse Triple Negative Immune Resistant Breast Cancer","route":"/trials/nct05076682/","asOf":"2026-09-22","days":6},{"id":"nct03463252","kind":"trial","name":"Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC","route":"/trials/nct03463252/","asOf":"2026-09-22","days":6},{"id":"nct02990728","kind":"trial","name":"Mirena® ± Metformin as Fertility-preserving Treatment for Young Asian Women With Early Endometrial Cancer","route":"/trials/nct02990728/","asOf":"2026-09-22","days":6},{"id":"nct01594879","kind":"trial","name":"Treatment With Medroxyprogesterone Acetate Plus LNG-IUS in Young Women With Early Stage Endometrial Cancer","route":"/trials/nct01594879/","asOf":"2026-09-22","days":6},{"id":"nct03150693","kind":"trial","name":"Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia","route":"/trials/nct03150693/","asOf":"2026-09-22","days":6},{"id":"nct01686594","kind":"trial","name":"PUVA Maintenance Therapy in Mycosis Fungoides","route":"/trials/nct01686594/","asOf":"2026-09-22","days":6},{"id":"nct04930653","kind":"trial","name":"Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma","route":"/trials/nct04930653/","asOf":"2026-09-22","days":6},{"id":"nct07619898","kind":"trial","name":"PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure","route":"/trials/nct07619898/","asOf":"2026-09-22","days":6},{"id":"nct03643133","kind":"trial","name":"Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients","route":"/trials/nct03643133/","asOf":"2026-09-22","days":6},{"id":"nct07787429","kind":"trial","name":"Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma","route":"/trials/nct07787429/","asOf":"2026-09-22","days":6},{"id":"nct06099769","kind":"trial","name":"A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer","route":"/trials/nct06099769/","asOf":"2026-09-22","days":6},{"id":"nct06153173","kind":"trial","name":"Mirdametinib in Histiocytic Disorders","route":"/trials/nct06153173/","asOf":"2026-09-22","days":6},{"id":"nct07061951","kind":"trial","name":"Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia","route":"/trials/nct07061951/","asOf":"2026-09-22","days":6},{"id":"nct07237100","kind":"trial","name":"Mirdametinib in Patients With Advanced NF1-mutant Melanoma","route":"/trials/nct07237100/","asOf":"2026-09-22","days":6},{"id":"nct02338050","kind":"trial","name":"Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation","route":"/trials/nct02338050/","asOf":"2026-09-22","days":6},{"id":"nct05737706","kind":"trial","name":"Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation","route":"/trials/nct05737706/","asOf":"2026-09-22","days":6},{"id":"nct02802540","kind":"trial","name":"Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Lung Cancer Patients","route":"/trials/nct02802540/","asOf":"2026-09-22","days":6},{"id":"nct03367572","kind":"trial","name":"Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer","route":"/trials/nct03367572/","asOf":"2026-09-22","days":6},{"id":"nct03668639","kind":"trial","name":"Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin","route":"/trials/nct03668639/","asOf":"2026-09-22","days":6},{"id":"nct03386617","kind":"trial","name":"AKY15-HK-301_NEPA Study","route":"/trials/nct03386617/","asOf":"2026-09-22","days":6},{"id":"nct00003653","kind":"trial","name":"Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer","route":"/trials/nct00003653/","asOf":"2026-09-22","days":6},{"id":"nct00002633","kind":"trial","name":"Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer","route":"/trials/nct00002633/","asOf":"2026-09-22","days":6},{"id":"nct02485652","kind":"trial","name":"Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung","route":"/trials/nct02485652/","asOf":"2026-09-22","days":6},{"id":"nct02444819","kind":"trial","name":"Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy","route":"/trials/nct02444819/","asOf":"2026-09-22","days":6},{"id":"nct03228277","kind":"trial","name":"Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA","route":"/trials/nct03228277/","asOf":"2026-09-22","days":6},{"id":"nct00004157","kind":"trial","name":"Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors","route":"/trials/nct00004157/","asOf":"2026-09-22","days":6},{"id":"nct01310894","kind":"trial","name":"Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance","route":"/trials/nct01310894/","asOf":"2026-09-22","days":6},{"id":"nct01875393","kind":"trial","name":"Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer","route":"/trials/nct01875393/","asOf":"2026-09-22","days":6},{"id":"nct04241315","kind":"trial","name":"ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting","route":"/trials/nct04241315/","asOf":"2026-09-22","days":6},{"id":"nct07039526","kind":"trial","name":"Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer","route":"/trials/nct07039526/","asOf":"2026-09-22","days":6},{"id":"nct06434909","kind":"trial","name":"CYTALUX™for the Intraoperative Imaging of Prostate Cancer","route":"/trials/nct06434909/","asOf":"2026-09-22","days":6},{"id":"nct00376883","kind":"trial","name":"Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month","route":"/trials/nct00376883/","asOf":"2026-09-22","days":6},{"id":"nct00033332","kind":"trial","name":"Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma","route":"/trials/nct00033332/","asOf":"2026-09-22","days":6},{"id":"nct00083382","kind":"trial","name":"Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide","route":"/trials/nct00083382/","asOf":"2026-09-22","days":6},{"id":"nct00880269","kind":"trial","name":"Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)","route":"/trials/nct00880269/","asOf":"2026-09-22","days":6},{"id":"nct01387763","kind":"trial","name":"A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms","route":"/trials/nct01387763/","asOf":"2026-09-22","days":6},{"id":"nct00143416","kind":"trial","name":"Long Term Study With B2036-PEG","route":"/trials/nct00143416/","asOf":"2026-09-22","days":6},{"id":"nct02952885","kind":"trial","name":"Strict IGF-1 Control in Acromegaly","route":"/trials/nct02952885/","asOf":"2026-09-22","days":6},{"id":"nct01188798","kind":"trial","name":"Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies","route":"/trials/nct01188798/","asOf":"2026-09-22","days":6},{"id":"nct01059786","kind":"trial","name":"Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia","route":"/trials/nct01059786/","asOf":"2026-09-22","days":6},{"id":"nct04090736","kind":"trial","name":"Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy","route":"/trials/nct04090736/","asOf":"2026-09-22","days":6},{"id":"nct00003139","kind":"trial","name":"Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer","route":"/trials/nct00003139/","asOf":"2026-09-22","days":6},{"id":"nct00168181","kind":"trial","name":"Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients","route":"/trials/nct00168181/","asOf":"2026-09-22","days":6},{"id":"nct03458260","kind":"trial","name":"Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma","route":"/trials/nct03458260/","asOf":"2026-09-22","days":6},{"id":"nct00103662","kind":"trial","name":"Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients","route":"/trials/nct00103662/","asOf":"2026-09-22","days":6},{"id":"nct01301963","kind":"trial","name":"Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide","route":"/trials/nct01301963/","asOf":"2026-09-22","days":6},{"id":"nct01767714","kind":"trial","name":"Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation","route":"/trials/nct01767714/","asOf":"2026-09-22","days":6},{"id":"nct01624090","kind":"trial","name":"Mithramycin for Lung, Esophagus, and Other Chest Cancers","route":"/trials/nct01624090/","asOf":"2026-09-22","days":6},{"id":"nct00003788","kind":"trial","name":"Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas","route":"/trials/nct00003788/","asOf":"2026-09-22","days":6},{"id":"nct00513539","kind":"trial","name":"Biliary Stenting With or Without Photodynamic Therapy in Treating Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors That Cannot Be Removed by Surgery","route":"/trials/nct00513539/","asOf":"2026-09-22","days":6},{"id":"nct02628665","kind":"trial","name":"Clinical Study of Time Optimizing of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer","route":"/trials/nct02628665/","asOf":"2026-09-22","days":6},{"id":"nct07125391","kind":"trial","name":"Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer","route":"/trials/nct07125391/","asOf":"2026-09-22","days":6},{"id":"nct05741164","kind":"trial","name":"Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer","route":"/trials/nct05741164/","asOf":"2026-09-22","days":6},{"id":"nct02653755","kind":"trial","name":"The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer","route":"/trials/nct02653755/","asOf":"2026-09-22","days":6},{"id":"nct03739684","kind":"trial","name":"Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer","route":"/trials/nct03739684/","asOf":"2026-09-22","days":6},{"id":"nct04457245","kind":"trial","name":"Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer","route":"/trials/nct04457245/","asOf":"2026-09-22","days":6},{"id":"nct02981368","kind":"trial","name":"Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer","route":"/trials/nct02981368/","asOf":"2026-09-22","days":6},{"id":"nct00002893","kind":"trial","name":"Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer","route":"/trials/nct00002893/","asOf":"2026-09-22","days":6},{"id":"nct05701436","kind":"trial","name":"Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial","route":"/trials/nct05701436/","asOf":"2026-09-22","days":6},{"id":"nct05766605","kind":"trial","name":"Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial","route":"/trials/nct05766605/","asOf":"2026-09-22","days":6},{"id":"nct00199043","kind":"trial","name":"Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma","route":"/trials/nct00199043/","asOf":"2026-09-22","days":6},{"id":"nct00576914","kind":"trial","name":"Adjuvant Vinorelbine Plus Cisplatin (NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer","route":"/trials/nct00576914/","asOf":"2026-09-22","days":6},{"id":"nct01124253","kind":"trial","name":"Adjuvant Vinorelbine Plus Cisplatin(NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer(NSCLC)","route":"/trials/nct01124253/","asOf":"2026-09-22","days":6},{"id":"nct02953301","kind":"trial","name":"Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)","route":"/trials/nct02953301/","asOf":"2026-09-22","days":6},{"id":"nct00943449","kind":"trial","name":"4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma","route":"/trials/nct00943449/","asOf":"2026-09-22","days":6},{"id":"nct01037478","kind":"trial","name":"Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma","route":"/trials/nct01037478/","asOf":"2026-09-22","days":6},{"id":"nct04747236","kind":"trial","name":"Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL","route":"/trials/nct04747236/","asOf":"2026-09-22","days":6},{"id":"nct06679829","kind":"trial","name":"A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant","route":"/trials/nct06679829/","asOf":"2026-09-22","days":6},{"id":"nct03315026","kind":"trial","name":"Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis","route":"/trials/nct03315026/","asOf":"2026-09-22","days":6},{"id":"nct05382338","kind":"trial","name":"A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss","route":"/trials/nct05382338/","asOf":"2026-09-22","days":6},{"id":"nct00652132","kind":"trial","name":"Cisplatin With or Without Sodium Thiosulfate in Treating Young Patients With Stage I, II, or III Childhood Liver Cancer","route":"/trials/nct00652132/","asOf":"2026-09-22","days":6},{"id":"nct00602082","kind":"trial","name":"Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors","route":"/trials/nct00602082/","asOf":"2026-09-22","days":6},{"id":"nct00004688","kind":"trial","name":"Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms","route":"/trials/nct00004688/","asOf":"2026-09-22","days":6},{"id":"nct00002622","kind":"trial","name":"Talc in Treating Patients With Malignant Pleural Effusion","route":"/trials/nct00002622/","asOf":"2026-09-22","days":6},{"id":"nct00002872","kind":"trial","name":"Bleomycin, Doxycycline, or Talc in Treating Patients With Malignant Pleural Effusions","route":"/trials/nct00002872/","asOf":"2026-09-22","days":6},{"id":"nct00821860","kind":"trial","name":"Video-Assisted Surgery or Talc Pleurodesis in Treating Patients With Malignant Mesothelioma","route":"/trials/nct00821860/","asOf":"2026-09-22","days":6},{"id":"nct07764653","kind":"trial","name":"Technetium Tc 99m Sulfur Colloid Injection for Tracing Sentinel Nodes in Breast Cancer","route":"/trials/nct07764653/","asOf":"2026-09-22","days":6},{"id":"nct07121595","kind":"trial","name":"Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial","route":"/trials/nct07121595/","asOf":"2026-09-22","days":6},{"id":"nct01276054","kind":"trial","name":"Sentinel and/or Axillary Lymph Node Biopsy With or Without Axillary Reverse Mapping in Reducing Incidence and Severity of Arm Lymphedema in Stage 0-2 Patients","route":"/trials/nct01276054/","asOf":"2026-09-22","days":6},{"id":"nct00660894","kind":"trial","name":"Tegafur-Uracil and Leucovorin or S-1 in Treating Patients With Stage III Colon Cancer That Has Been Completely Removed by Surgery","route":"/trials/nct00660894/","asOf":"2026-09-22","days":6},{"id":"nct03448549","kind":"trial","name":"SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients","route":"/trials/nct03448549/","asOf":"2026-09-22","days":6},{"id":"nct04543955","kind":"trial","name":"Telotristat With Lutathera in Neuroendocrine Tumors","route":"/trials/nct04543955/","asOf":"2026-09-22","days":6},{"id":"nct01415986","kind":"trial","name":"Interstitial Photodynamic Therapy (PDT) With Temoporfin for Advanced Head and Neck Cancers","route":"/trials/nct01415986/","asOf":"2026-09-22","days":6},{"id":"nct01086488","kind":"trial","name":"Foscan®-Mediated Photodynamic Therapy Versus Brachytherapy in Patients With Nasopharyngeal Carcinoma","route":"/trials/nct01086488/","asOf":"2026-09-22","days":6},{"id":"nct03003065","kind":"trial","name":"Safety and Tumoricidal Effect of Low Dose Foscan PDT in Patients With Inoperable Bile Duct Cancers","route":"/trials/nct03003065/","asOf":"2026-09-22","days":6},{"id":"nct07583511","kind":"trial","name":"Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study","route":"/trials/nct07583511/","asOf":"2026-09-22","days":6},{"id":"nct07188441","kind":"trial","name":"Treatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Injection Combined With Cisplatin","route":"/trials/nct07188441/","asOf":"2026-09-22","days":6},{"id":"nct04964284","kind":"trial","name":"rhTSH for Radioactive Iodine Remnant Ablation in Participants With Differentiated Thyroid Cancer (DTC)","route":"/trials/nct04964284/","asOf":"2026-09-22","days":6},{"id":"nct04971473","kind":"trial","name":"Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal","route":"/trials/nct04971473/","asOf":"2026-09-22","days":6},{"id":"nct00295763","kind":"trial","name":"A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen","route":"/trials/nct00295763/","asOf":"2026-09-22","days":6},{"id":"nct05647122","kind":"trial","name":"First in Human Study of AZD9592 in Solid Tumors","route":"/trials/nct05647122/","asOf":"2026-09-22","days":6},{"id":"nct00129142","kind":"trial","name":"Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy","route":"/trials/nct00129142/","asOf":"2026-09-22","days":6},{"id":"nct03351062","kind":"trial","name":"Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer","route":"/trials/nct03351062/","asOf":"2026-09-22","days":6},{"id":"nct02132390","kind":"trial","name":"Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea","route":"/trials/nct02132390/","asOf":"2026-09-22","days":6},{"id":"nct00822393","kind":"trial","name":"Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)","route":"/trials/nct00822393/","asOf":"2026-09-22","days":6},{"id":"nct01423500","kind":"trial","name":"ALL-SCT BFM International- HSCT in Children and Adolescents With ALL","route":"/trials/nct01423500/","asOf":"2026-09-22","days":6},{"id":"nct01020448","kind":"trial","name":"Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer","route":"/trials/nct01020448/","asOf":"2026-09-22","days":6},{"id":"nct00412022","kind":"trial","name":"HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer","route":"/trials/nct00412022/","asOf":"2026-09-22","days":6},{"id":"nct02793583","kind":"trial","name":"Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma","route":"/trials/nct02793583/","asOf":"2026-09-22","days":6},{"id":"nct01310803","kind":"trial","name":"Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder","route":"/trials/nct01310803/","asOf":"2026-09-22","days":6},{"id":"nct04221035","kind":"trial","name":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","route":"/trials/nct04221035/","asOf":"2026-09-22","days":6},{"id":"nct03206671","kind":"trial","name":"Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents","route":"/trials/nct03206671/","asOf":"2026-09-22","days":6},{"id":"nct01117441","kind":"trial","name":"International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia","route":"/trials/nct01117441/","asOf":"2026-09-22","days":6},{"id":"nct07047001","kind":"trial","name":"Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma","route":"/trials/nct07047001/","asOf":"2026-09-22","days":6},{"id":"nct06523049","kind":"trial","name":"Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy","route":"/trials/nct06523049/","asOf":"2026-09-22","days":6},{"id":"nct06264180","kind":"trial","name":"VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]","route":"/trials/nct06264180/","asOf":"2026-09-22","days":6},{"id":"nct06898970","kind":"trial","name":"Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma","route":"/trials/nct06898970/","asOf":"2026-09-22","days":6},{"id":"nct03172299","kind":"trial","name":"Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated with Proton Therapy for a Large Choroidal Melanoma","route":"/trials/nct03172299/","asOf":"2026-09-22","days":6},{"id":"nct06641635","kind":"trial","name":"Moderated Hypofractionated Online Adaptive Radiotherapy in Cervical Cancer","route":"/trials/nct06641635/","asOf":"2026-09-22","days":6},{"id":"nct06246344","kind":"trial","name":"Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer","route":"/trials/nct06246344/","asOf":"2026-09-22","days":6},{"id":"nct06345287","kind":"trial","name":"Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC","route":"/trials/nct06345287/","asOf":"2026-09-22","days":6},{"id":"nct02887040","kind":"trial","name":"Study of Antineoplaston Therapy + Radiation vs. Radiation Only in Diffuse, Intrinsic, Brainstem Glioma","route":"/trials/nct02887040/","asOf":"2026-09-22","days":6},{"id":"nct00003456","kind":"trial","name":"Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma Multiforme","route":"/trials/nct00003456/","asOf":"2026-09-22","days":6},{"id":"nct00003475","kind":"trial","name":"Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors","route":"/trials/nct00003475/","asOf":"2026-09-22","days":6},{"id":"nct03223662","kind":"trial","name":"Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy","route":"/trials/nct03223662/","asOf":"2026-09-22","days":6},{"id":"nct05796375","kind":"trial","name":"Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance","route":"/trials/nct05796375/","asOf":"2026-09-22","days":6},{"id":"nct03849118","kind":"trial","name":"89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study","route":"/trials/nct03849118/","asOf":"2026-09-22","days":6},{"id":"nct06447103","kind":"trial","name":"An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer","route":"/trials/nct06447103/","asOf":"2026-09-22","days":6},{"id":"nct02219529","kind":"trial","name":"Magnetic-controlled Capsule Endoscopy vs. Gastroscopy for Detection of Gastric Diseases","route":"/trials/nct02219529/","asOf":"2026-09-22","days":6},{"id":"nct06311695","kind":"trial","name":"Contrast-Enhanced Spectral Mammography (CESM)","route":"/trials/nct06311695/","asOf":"2026-09-22","days":6},{"id":"nct05395962","kind":"trial","name":"Electrochemotherapy With Carboplatinum Plus Bleomycin Versus Bleomycin Alone in Vulvar Cancer","route":"/trials/nct05395962/","asOf":"2026-09-22","days":6},{"id":"nct07443475","kind":"trial","name":"Electrochemotherapy for Recurrent Vulvar Cancer","route":"/trials/nct07443475/","asOf":"2026-09-22","days":6},{"id":"nct04275986","kind":"trial","name":"Concurrent Chemoradiotherapy After Endoscopic Resection for Stage I Esophageal Carcinoma","route":"/trials/nct04275986/","asOf":"2026-09-22","days":6},{"id":"nct03274414","kind":"trial","name":"A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages","route":"/trials/nct03274414/","asOf":"2026-09-22","days":6},{"id":"nct06599775","kind":"trial","name":"Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer","route":"/trials/nct06599775/","asOf":"2026-09-22","days":6},{"id":"nct01986569","kind":"trial","name":"Diagnostic Accuracy and Safety Study of FES PET/CT in Assessment of ER Status of Recurrent or Metastatic Breast Cancer","route":"/trials/nct01986569/","asOf":"2026-09-22","days":6},{"id":"nct04883814","kind":"trial","name":"18F-fluoroestradiol (FES) PET/CT for Breast Cancer","route":"/trials/nct04883814/","asOf":"2026-09-22","days":6},{"id":"nct07455331","kind":"trial","name":"Flash Radiotherapy for Skin Cancer","route":"/trials/nct07455331/","asOf":"2026-09-22","days":6},{"id":"nct03439709","kind":"trial","name":"Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma","route":"/trials/nct03439709/","asOf":"2026-09-22","days":6},{"id":"nct01011231","kind":"trial","name":"Study of Gamma-Knife Radiosurgery Using Magnetic Resonance Imaging (MRI) Spectroscopy for Recurrent Glioma","route":"/trials/nct01011231/","asOf":"2026-09-22","days":6},{"id":"nct06044623","kind":"trial","name":"Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients","route":"/trials/nct06044623/","asOf":"2026-09-22","days":6},{"id":"nct06052826","kind":"trial","name":"Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study","route":"/trials/nct06052826/","asOf":"2026-09-22","days":6},{"id":"nct06835530","kind":"trial","name":"A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)","route":"/trials/nct06835530/","asOf":"2026-09-22","days":6},{"id":"nct07527806","kind":"trial","name":"Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging","route":"/trials/nct07527806/","asOf":"2026-09-22","days":6},{"id":"nct05619016","kind":"trial","name":"[68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors","route":"/trials/nct05619016/","asOf":"2026-09-22","days":6},{"id":"nct00626444","kind":"trial","name":"Pilot Trial of Intravenous Vitamin C in Refractory Non-Hodgkin Lymphoma (NHL)","route":"/trials/nct00626444/","asOf":"2026-09-22","days":6},{"id":"nct07765667","kind":"trial","name":"NCT + PD1 + Ketogenic Diet and/or Vitamin C for LARC","route":"/trials/nct07765667/","asOf":"2026-09-22","days":6},{"id":"nct04801511","kind":"trial","name":"Preoperative IMRT With Concurrent High-dose Vitamin C and mFOLFOX6 in Locally Advanced Rectal Cancer","route":"/trials/nct04801511/","asOf":"2026-09-22","days":6},{"id":"nct05946603","kind":"trial","name":"IS-002 Phase 2 Prostate Cancer Study","route":"/trials/nct05946603/","asOf":"2026-09-22","days":6},{"id":"nct02685605","kind":"trial","name":"Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme","route":"/trials/nct02685605/","asOf":"2026-09-22","days":6},{"id":"nct02213991","kind":"trial","name":"Intraoperative Radiotherapy for Korean Patients With Breast Cancer","route":"/trials/nct02213991/","asOf":"2026-09-22","days":6},{"id":"nct05498311","kind":"trial","name":"Breast Cancer With Intraoperative Radiotherapy Followed by Hypofractionated External Beam Radiotherapy","route":"/trials/nct05498311/","asOf":"2026-09-22","days":6},{"id":"nct06558214","kind":"trial","name":"OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial","route":"/trials/nct06558214/","asOf":"2026-09-22","days":6},{"id":"nct01377753","kind":"trial","name":"MR Image Guided Therapy in Prostate Cancer","route":"/trials/nct01377753/","asOf":"2026-09-22","days":6},{"id":"nct07620548","kind":"trial","name":"Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas","route":"/trials/nct07620548/","asOf":"2026-09-22","days":6},{"id":"nct07337876","kind":"trial","name":"Organ Preservation in Rectal Cancer by Dose Escalated MR Guided Adaptive Radiotherapy","route":"/trials/nct07337876/","asOf":"2026-09-22","days":6},{"id":"nct06840665","kind":"trial","name":"MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer","route":"/trials/nct06840665/","asOf":"2026-09-22","days":6},{"id":"nct06227065","kind":"trial","name":"Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids","route":"/trials/nct06227065/","asOf":"2026-09-22","days":6},{"id":"nct05725200","kind":"trial","name":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer","route":"/trials/nct05725200/","asOf":"2026-09-22","days":6},{"id":"nct06519266","kind":"trial","name":"PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases","route":"/trials/nct06519266/","asOf":"2026-09-22","days":6},{"id":"nct03711877","kind":"trial","name":"Comparative Study of Scalp Cooling System and Chemical Cold Cap (COHAIR Study)","route":"/trials/nct03711877/","asOf":"2026-09-22","days":6},{"id":"nct04986579","kind":"trial","name":"Scalp Cooling in MBC","route":"/trials/nct04986579/","asOf":"2026-09-22","days":6},{"id":"nct00515762","kind":"trial","name":"Prevention of Persistent Alopecia Following Docetaxel by Means of Scalp Cooling","route":"/trials/nct00515762/","asOf":"2026-09-22","days":6},{"id":"nct00005838","kind":"trial","name":"Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery","route":"/trials/nct00005838/","asOf":"2026-09-22","days":6},{"id":"nct00026117","kind":"trial","name":"Shark Cartilage in Treating Patients With Advanced Colorectal or Breast Cancer","route":"/trials/nct00026117/","asOf":"2026-09-22","days":6},{"id":"nct00022282","kind":"trial","name":"AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct00022282/","asOf":"2026-09-22","days":6},{"id":"nct03673943","kind":"trial","name":"Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE","route":"/trials/nct03673943/","asOf":"2026-09-22","days":6},{"id":"nct05709171","kind":"trial","name":"Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms","route":"/trials/nct05709171/","asOf":"2026-09-22","days":6},{"id":"nct04665609","kind":"trial","name":"Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC","route":"/trials/nct04665609/","asOf":"2026-09-22","days":6},{"id":"nct07483996","kind":"trial","name":"Cryoablation Versus Lumpectomy in Early-Stage Breast Cancer","route":"/trials/nct07483996/","asOf":"2026-09-22","days":6},{"id":"nct05864534","kind":"trial","name":"Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma","route":"/trials/nct05864534/","asOf":"2026-09-22","days":6},{"id":"nct07471776","kind":"trial","name":"Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer","route":"/trials/nct07471776/","asOf":"2026-09-22","days":6},{"id":"nct03329183","kind":"trial","name":"High-dose FOLFIRI in Advanced Colorectal Cancer Patients With Wild-type UGT1A1*6 and *28","route":"/trials/nct03329183/","asOf":"2026-09-22","days":6},{"id":"nct00628810","kind":"trial","name":"Combination Chemotherapy and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","route":"/trials/nct00628810/","asOf":"2026-09-22","days":6},{"id":"nct00541125","kind":"trial","name":"G-CSF in Preventing Neutropenia During First-Line Treatment With Chemotherapy and Bevacizumab in Patients With Metastatic Colorectal Cancer","route":"/trials/nct00541125/","asOf":"2026-09-22","days":6},{"id":"nct01883128","kind":"trial","name":"FOcal RECurrent Assessment and Salvage Treatment","route":"/trials/nct01883128/","asOf":"2026-09-22","days":6},{"id":"nct02814968","kind":"trial","name":"PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide","route":"/trials/nct02814968/","asOf":"2026-09-22","days":6},{"id":"nct02815033","kind":"trial","name":"Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide","route":"/trials/nct02815033/","asOf":"2026-09-22","days":6},{"id":"nras","kind":"target","name":"NRAS","route":"/targets/nras/","asOf":"2026-09-22","days":6},{"id":"cd28","kind":"target","name":"CD28","route":"/targets/cd28/","asOf":"2026-09-22","days":6},{"id":"hla-a","kind":"target","name":"HLA-A","route":"/targets/hla-a/","asOf":"2026-09-22","days":6},{"id":"mpl","kind":"target","name":"MPL (thrombopoietin receptor)","route":"/targets/mpl/","asOf":"2026-09-22","days":6},{"id":"shp2","kind":"target","name":"SHP2 (PTPN11)","route":"/targets/shp2/","asOf":"2026-09-22","days":6},{"id":"stat5","kind":"target","name":"STAT5 (STAT5A, STAT5B)","route":"/targets/stat5/","asOf":"2026-09-22","days":6},{"id":"ikzf1","kind":"target","name":"IKZF1 (Ikaros)","route":"/targets/ikzf1/","asOf":"2026-09-22","days":6},{"id":"jak1","kind":"target","name":"JAK1","route":"/targets/jak1/","asOf":"2026-09-22","days":6},{"id":"cd80","kind":"target","name":"CD80 (B7-1)","route":"/targets/cd80/","asOf":"2026-09-22","days":6},{"id":"abl1","kind":"target","name":"ABL1","route":"/targets/abl1/","asOf":"2026-09-22","days":6},{"id":"fak","kind":"target","name":"FAK (PTK2)","route":"/targets/fak/","asOf":"2026-09-22","days":6},{"id":"ikzf3","kind":"target","name":"IKZF3 (Aiolos)","route":"/targets/ikzf3/","asOf":"2026-09-22","days":6},{"id":"ptch1","kind":"target","name":"PTCH1 (Patched 1)","route":"/targets/ptch1/","asOf":"2026-09-22","days":6},{"id":"cd137","kind":"target","name":"CD137 (4-1BB, TNFRSF9)","route":"/targets/cd137/","asOf":"2026-09-22","days":6},{"id":"hif1a","kind":"target","name":"HIF-1α (HIF1A)","route":"/targets/hif1a/","asOf":"2026-09-22","days":6},{"id":"ido1","kind":"target","name":"IDO1","route":"/targets/ido1/","asOf":"2026-09-22","days":6},{"id":"brd4","kind":"target","name":"BRD4","route":"/targets/brd4/","asOf":"2026-09-22","days":6},{"id":"irf4","kind":"target","name":"IRF4","route":"/targets/irf4/","asOf":"2026-09-22","days":6},{"id":"b7h4","kind":"target","name":"B7-H4 (VTCN1)","route":"/targets/b7h4/","asOf":"2026-09-22","days":6},{"id":"tet2","kind":"target","name":"TET2","route":"/targets/tet2/","asOf":"2026-09-22","days":6},{"id":"nf1","kind":"target","name":"NF1 (neurofibromin)","route":"/targets/nf1/","asOf":"2026-09-22","days":6},{"id":"acvr1","kind":"target","name":"ACVR1 (ALK2)","route":"/targets/acvr1/","asOf":"2026-09-22","days":6},{"id":"hoxa9","kind":"target","name":"HOXA9","route":"/targets/hoxa9/","asOf":"2026-09-22","days":6},{"id":"meis1","kind":"target","name":"MEIS1","route":"/targets/meis1/","asOf":"2026-09-22","days":6},{"id":"bim","kind":"target","name":"BIM (BCL2L11)","route":"/targets/bim/","asOf":"2026-09-22","days":6},{"id":"bax","kind":"target","name":"BAX","route":"/targets/bax/","asOf":"2026-09-22","days":6},{"id":"crisantaspase","kind":"drug","name":"Crisantaspase (recombinant Erwinia asparaginase)","route":"/drugs/crisantaspase/","asOf":"2026-09-22","days":6},{"id":"human-normal-immunoglobulin","kind":"drug","name":"Human normal immunoglobulin (IVIg)","route":"/drugs/human-normal-immunoglobulin/","asOf":"2026-09-22","days":6},{"id":"fentanyl","kind":"drug","name":"Fentanyl (transmucosal, for breakthrough cancer pain)","route":"/drugs/fentanyl/","asOf":"2026-09-22","days":6},{"id":"resminostat","kind":"drug","name":"Resminostat","route":"/drugs/resminostat/","asOf":"2026-09-22","days":6},{"id":"tacquell","kind":"drug","name":"Tacquell (autologous melanoma-derived tumour-infiltrating lymphocytes)","route":"/drugs/tacquell/","asOf":"2026-09-22","days":6},{"id":"criterium","kind":"company","name":"Criterium","route":"/companies/criterium/","asOf":"2026-09-22","days":6},{"id":"artios-pharma","kind":"company","name":"Artios Pharma","route":"/companies/artios-pharma/","asOf":"2026-09-22","days":6},{"id":"ambrx","kind":"company","name":"Ambrx","route":"/companies/ambrx/","asOf":"2026-09-22","days":6},{"id":"nerviano-medical-sciences","kind":"company","name":"Nerviano Medical Sciences","route":"/companies/nerviano-medical-sciences/","asOf":"2026-09-22","days":6},{"id":"qurient","kind":"company","name":"Qurient","route":"/companies/qurient/","asOf":"2026-09-22","days":6},{"id":"immunovaccine","kind":"company","name":"Immunovaccine (IMV)","route":"/companies/immunovaccine/","asOf":"2026-09-22","days":6},{"id":"gruenenthal","kind":"company","name":"Grünenthal","route":"/companies/gruenenthal/","asOf":"2026-09-22","days":6},{"id":"4sc","kind":"company","name":"4SC","route":"/companies/4sc/","asOf":"2026-09-22","days":6},{"id":"nct06109272","kind":"trial","name":"A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)","route":"/trials/nct06109272/","asOf":"2026-09-22","days":6},{"id":"nct04590963","kind":"trial","name":"Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer","route":"/trials/nct04590963/","asOf":"2026-09-22","days":6},{"id":"nct04655976","kind":"trial","name":"Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy","route":"/trials/nct04655976/","asOf":"2026-09-22","days":6},{"id":"nct05208047","kind":"trial","name":"(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors","route":"/trials/nct05208047/","asOf":"2026-09-22","days":6},{"id":"fight-302","kind":"trial","name":"FIGHT-302","route":"/trials/fight-302/","asOf":"2026-09-22","days":6},{"id":"aall1331","kind":"trial","name":"AALL1331","route":"/trials/aall1331/","asOf":"2026-09-22","days":6},{"id":"graall-2005","kind":"trial","name":"GRAALL-2005","route":"/trials/graall-2005/","asOf":"2026-09-22","days":6},{"id":"quazar-aml-001","kind":"trial","name":"QUAZAR AML-001","route":"/trials/quazar-aml-001/","asOf":"2026-09-22","days":6},{"id":"morpho","kind":"trial","name":"MORPHO","route":"/trials/morpho/","asOf":"2026-09-22","days":6},{"id":"aaml1031","kind":"trial","name":"AAML1031","route":"/trials/aaml1031/","asOf":"2026-09-22","days":6},{"id":"cll12","kind":"trial","name":"CLL12","route":"/trials/cll12/","asOf":"2026-09-22","days":6},{"id":"aall0232","kind":"trial","name":"AALL0232","route":"/trials/aall0232/","asOf":"2026-09-22","days":6},{"id":"aall1231","kind":"trial","name":"AALL1231","route":"/trials/aall1231/","asOf":"2026-09-22","days":6},{"id":"aall1521","kind":"trial","name":"AALL1521","route":"/trials/aall1521/","asOf":"2026-09-22","days":6},{"id":"esphall","kind":"trial","name":"EsPhALL (EsPhALL2004 and EsPhALL2010)","route":"/trials/esphall/","asOf":"2026-09-22","days":6},{"id":"ukallr3","kind":"trial","name":"ALL R3 (UKALLR3)","route":"/trials/ukallr3/","asOf":"2026-09-22","days":6},{"id":"intreall-sr-2010","kind":"trial","name":"IntReALL SR 2010","route":"/trials/intreall-sr-2010/","asOf":"2026-09-22","days":6},{"id":"comfort-i","kind":"trial","name":"COMFORT-I","route":"/trials/comfort-i/","asOf":"2026-09-22","days":6},{"id":"comfort-ii","kind":"trial","name":"COMFORT-II","route":"/trials/comfort-ii/","asOf":"2026-09-22","days":6},{"id":"explorer","kind":"trial","name":"EXPLORER","route":"/trials/explorer/","asOf":"2026-09-22","days":6},{"id":"bmt-ctn-1102","kind":"trial","name":"BMT CTN 1102","route":"/trials/bmt-ctn-1102/","asOf":"2026-09-22","days":6},{"id":"telesto","kind":"trial","name":"TELESTO","route":"/trials/telesto/","asOf":"2026-09-22","days":6},{"id":"impactmf","kind":"trial","name":"IMpactMF","route":"/trials/impactmf/","asOf":"2026-09-22","days":6},{"id":"acns1123","kind":"trial","name":"ACNS1123","route":"/trials/acns1123/","asOf":"2026-09-22","days":6},{"id":"acns0122","kind":"trial","name":"ACNS0122","route":"/trials/acns0122/","asOf":"2026-09-22","days":6},{"id":"acns0333","kind":"trial","name":"ACNS0333","route":"/trials/acns0333/","asOf":"2026-09-22","days":6},{"id":"acns0121","kind":"trial","name":"ACNS0121","route":"/trials/acns0121/","asOf":"2026-09-22","days":6},{"id":"noa-08","kind":"trial","name":"NOA-08","route":"/trials/noa-08/","asOf":"2026-09-22","days":6},{"id":"sjmb12","kind":"trial","name":"SJMB12","route":"/trials/sjmb12/","asOf":"2026-09-22","days":6},{"id":"acns1422","kind":"trial","name":"ACNS1422","route":"/trials/acns1422/","asOf":"2026-09-22","days":6},{"id":"ielsg32","kind":"trial","name":"IELSG32","route":"/trials/ielsg32/","asOf":"2026-09-22","days":6},{"id":"ielsg43","kind":"trial","name":"MATRix/IELSG43","route":"/trials/ielsg43/","asOf":"2026-09-22","days":6},{"id":"intuitt-nf2","kind":"trial","name":"INTUITT-NF2","route":"/trials/intuitt-nf2/","asOf":"2026-09-22","days":6},{"id":"anbl1221","kind":"trial","name":"ANBL1221","route":"/trials/anbl1221/","asOf":"2026-09-22","days":6},{"id":"anbl0531","kind":"trial","name":"ANBL0531","route":"/trials/anbl0531/","asOf":"2026-09-22","days":6},{"id":"anbl17p1","kind":"trial","name":"ANBL17P1","route":"/trials/anbl17p1/","asOf":"2026-09-22","days":6},{"id":"aews0031","kind":"trial","name":"AEWS0031","route":"/trials/aews0031/","asOf":"2026-09-22","days":6},{"id":"siopel-3","kind":"trial","name":"SIOPEL-3","route":"/trials/siopel-3/","asOf":"2026-09-22","days":6},{"id":"siopel-4","kind":"trial","name":"SIOPEL-4","route":"/trials/siopel-4/","asOf":"2026-09-22","days":6},{"id":"agct1531","kind":"trial","name":"AGCT1531","route":"/trials/agct1531/","asOf":"2026-09-22","days":6},{"id":"ahod1331","kind":"trial","name":"AHOD1331","route":"/trials/ahod1331/","asOf":"2026-09-22","days":6},{"id":"euronet-phl-c2","kind":"trial","name":"EuroNet-PHL-C2","route":"/trials/euronet-phl-c2/","asOf":"2026-09-22","days":6},{"id":"fort","kind":"trial","name":"FoRT","route":"/trials/fort/","asOf":"2026-09-22","days":6},{"id":"gallium","kind":"trial","name":"GALLIUM","route":"/trials/gallium/","asOf":"2026-09-22","days":6},{"id":"relevance","kind":"trial","name":"RELEVANCE","route":"/trials/relevance/","asOf":"2026-09-22","days":6},{"id":"triangle","kind":"trial","name":"TRIANGLE","route":"/trials/triangle/","asOf":"2026-09-22","days":6},{"id":"sympatico","kind":"trial","name":"SYMPATICO","route":"/trials/sympatico/","asOf":"2026-09-22","days":6},{"id":"bmt-ctn-0803","kind":"trial","name":"BMT CTN 0803","route":"/trials/bmt-ctn-0803/","asOf":"2026-09-22","days":6},{"id":"ptld-1","kind":"trial","name":"PTLD-1","route":"/trials/ptld-1/","asOf":"2026-09-22","days":6},{"id":"classic","kind":"trial","name":"CLASSIC","route":"/trials/classic/","asOf":"2026-09-22","days":6},{"id":"espac-3","kind":"trial","name":"ESPAC-3","route":"/trials/espac-3/","asOf":"2026-09-22","days":6},{"id":"espac-4","kind":"trial","name":"ESPAC-4","route":"/trials/espac-4/","asOf":"2026-09-22","days":6},{"id":"conko-001","kind":"trial","name":"CONKO-001","route":"/trials/conko-001/","asOf":"2026-09-22","days":6},{"id":"norpact-1","kind":"trial","name":"NORPACT-1","route":"/trials/norpact-1/","asOf":"2026-09-22","days":6},{"id":"lap07","kind":"trial","name":"LAP07","route":"/trials/lap07/","asOf":"2026-09-22","days":6},{"id":"espac-5","kind":"trial","name":"ESPAC-5","route":"/trials/espac-5/","asOf":"2026-09-22","days":6},{"id":"precede","kind":"trial","name":"PRECEDE","route":"/trials/precede/","asOf":"2026-09-22","days":6},{"id":"actg-a5263","kind":"trial","name":"ACTG A5263/AMC 066","route":"/trials/actg-a5263/","asOf":"2026-09-22","days":6},{"id":"anchor","kind":"trial","name":"ANCHOR","route":"/trials/anchor/","asOf":"2026-09-22","days":6},{"id":"pod1um-303","kind":"trial","name":"POD1UM-303/InterAACT-2","route":"/trials/pod1um-303/","asOf":"2026-09-22","days":6},{"id":"interaact","kind":"trial","name":"InterAACT","route":"/trials/interaact/","asOf":"2026-09-22","days":6},{"id":"nci9673","kind":"trial","name":"NCI9673","route":"/trials/nci9673/","asOf":"2026-09-22","days":6},{"id":"capp2","kind":"trial","name":"CAPP2","route":"/trials/capp2/","asOf":"2026-09-22","days":6},{"id":"continuum","kind":"trial","name":"CONTINUUM","route":"/trials/continuum/","asOf":"2026-09-22","days":6},{"id":"aurelia","kind":"trial","name":"AURELIA","route":"/trials/aurelia/","asOf":"2026-09-22","days":6},{"id":"rainbo","kind":"trial","name":"RAINBO","route":"/trials/rainbo/","asOf":"2026-09-22","days":6},{"id":"drammatic","kind":"trial","name":"DRAMMATIC","route":"/trials/drammatic/","asOf":"2026-09-22","days":6},{"id":"firstmappp","kind":"trial","name":"FIRSTMAPPP","route":"/trials/firstmappp/","asOf":"2026-09-22","days":6},{"id":"inpact","kind":"trial","name":"InPACT","route":"/trials/inpact/","asOf":"2026-09-22","days":6},{"id":"getug-13","kind":"trial","name":"GETUG 13","route":"/trials/getug-13/","asOf":"2026-09-22","days":6},{"id":"adiuvo","kind":"trial","name":"ADIUVO","route":"/trials/adiuvo/","asOf":"2026-09-22","days":6},{"id":"adiuvo-2","kind":"trial","name":"ADIUVO-2","route":"/trials/adiuvo-2/","asOf":"2026-09-22","days":6},{"id":"trophimmun","kind":"trial","name":"TROPHIMMUN","route":"/trials/trophimmun/","asOf":"2026-09-22","days":6},{"id":"ballad","kind":"trial","name":"BALLAD","route":"/trials/ballad/","asOf":"2026-09-22","days":6},{"id":"paper-aall1331-brown-jama-2021","kind":"paper","name":"AALL1331: blinatumomab versus chemotherapy consolidation in high- and intermediate-risk first relapse of childhood B-ALL","route":"/key-papers/paper-aall1331-brown-jama-2021/","asOf":"2026-09-22","days":6},{"id":"paper-aall1331-low-risk-hogan-jco-2023","kind":"paper","name":"AALL1331: blinatumomab added to chemotherapy in low-risk first relapse of childhood B-ALL","route":"/key-papers/paper-aall1331-low-risk-hogan-jco-2023/","asOf":"2026-09-22","days":6},{"id":"paper-graall-2005-huguet-jco-2018","kind":"paper","name":"GRAALL-2005: randomised hyperfractionated cyclophosphamide in a paediatric-inspired adult ALL protocol","route":"/key-papers/paper-graall-2005-huguet-jco-2018/","asOf":"2026-09-22","days":6},{"id":"paper-quazar-aml-001-wei-nejm-2020","kind":"paper","name":"QUAZAR AML-001: oral azacitidine maintenance for acute myeloid leukaemia in first remission","route":"/key-papers/paper-quazar-aml-001-wei-nejm-2020/","asOf":"2026-09-22","days":6},{"id":"paper-morpho-gilteritinib-levis-jco-2024","kind":"paper","name":"MORPHO: gilteritinib as post-transplant maintenance for FLT3-ITD acute myeloid leukaemia","route":"/key-papers/paper-morpho-gilteritinib-levis-jco-2024/","asOf":"2026-09-22","days":6},{"id":"paper-aaml1031-bortezomib-aplenc-haematologica-2020","kind":"paper","name":"AAML1031: bortezomib with standard chemotherapy for children with acute myeloid leukaemia does not improve outcomes","route":"/key-papers/paper-aaml1031-bortezomib-aplenc-haematologica-2020/","asOf":"2026-09-22","days":6},{"id":"paper-cll12-ibrutinib-early-stage-langerbeins-jco-2025","kind":"paper","name":"CLL12: ibrutinib in early-stage chronic lymphocytic leukaemia, a randomised placebo-controlled phase 3 trial","route":"/key-papers/paper-cll12-ibrutinib-early-stage-langerbeins-jco-2025/","asOf":"2026-09-22","days":6},{"id":"paper-aall1231-bortezomib-t-all-teachey-jco-2022","kind":"paper","name":"AALL1231: bortezomib in newly diagnosed T-cell acute lymphoblastic leukaemia and lymphoma, with cranial radiotherapy removed","route":"/key-papers/paper-aall1231-bortezomib-t-all-teachey-jco-2022/","asOf":"2026-09-22","days":6},{"id":"paper-esphall2010-continuous-imatinib-biondi-lancet-haematol-2018","kind":"paper","name":"EsPhALL2010: continuous imatinib with chemotherapy in paediatric Philadelphia chromosome-positive ALL","route":"/key-papers/paper-esphall2010-continuous-imatinib-biondi-lancet-haematol-2018/","asOf":"2026-09-22","days":6},{"id":"paper-all-r3-mitoxantrone-relapsed-childhood-all-parker-lancet-2010","kind":"paper","name":"ALL R3: mitoxantrone versus idarubicin in first relapse of childhood acute lymphoblastic leukaemia","route":"/key-papers/paper-all-r3-mitoxantrone-relapsed-childhood-all-parker-lancet-2010/","asOf":"2026-09-22","days":6},{"id":"paper-comfort-ii-ruxolitinib-best-available-therapy-harrison-nejm-2012","kind":"paper","name":"COMFORT-II: JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","route":"/key-papers/paper-comfort-ii-ruxolitinib-best-available-therapy-harrison-nejm-2012/","asOf":"2026-09-22","days":6},{"id":"paper-bmt-ctn-1102-transplant-older-mds-nakamura-jco-2021","kind":"paper","name":"BMT CTN 1102: biologic assignment trial of reduced-intensity transplant by donor availability in patients aged 50 to 75 with advanced myelodysplastic syndrome","route":"/key-papers/paper-bmt-ctn-1102-transplant-older-mds-nakamura-jco-2021/","asOf":"2026-09-22","days":6},{"id":"paper-acns1123-nggct-reduced-radiotherapy-fangusaro-jco-2019","kind":"paper","name":"ACNS1123: response-based reduced radiotherapy for localised CNS non-germinomatous germ cell tumours","route":"/key-papers/paper-acns1123-nggct-reduced-radiotherapy-fangusaro-jco-2019/","asOf":"2026-09-22","days":6},{"id":"paper-acns0333-atrt-high-dose-chemotherapy-reddy-jco-2020","kind":"paper","name":"ACNS0333: high-dose chemotherapy and three-dimensional conformal radiation for atypical teratoid/rhabdoid tumour","route":"/key-papers/paper-acns0333-atrt-high-dose-chemotherapy-reddy-jco-2020/","asOf":"2026-09-22","days":6},{"id":"paper-acns0121-ependymoma-conformal-radiotherapy-merchant-jco-2019","kind":"paper","name":"ACNS0121: conformal radiotherapy for paediatric ependymoma, chemotherapy for incompletely resected tumours and observation after complete resection","route":"/key-papers/paper-acns0121-ependymoma-conformal-radiotherapy-merchant-jco-2019/","asOf":"2026-09-22","days":6},{"id":"paper-noa-08-temozolomide-vs-radiotherapy-elderly-wick-lancet-oncol-2012","kind":"paper","name":"NOA-08: temozolomide alone versus radiotherapy alone for malignant astrocytoma in the elderly","route":"/key-papers/paper-noa-08-temozolomide-vs-radiotherapy-elderly-wick-lancet-oncol-2012/","asOf":"2026-09-22","days":6},{"id":"paper-ielsg32-matrix-induction-ferreri-lancet-haematol-2016","kind":"paper","name":"IELSG32 first randomisation: the MATRix regimen (methotrexate, cytarabine, thiotepa, rituximab) in primary CNS lymphoma","route":"/key-papers/paper-ielsg32-matrix-induction-ferreri-lancet-haematol-2016/","asOf":"2026-09-22","days":6},{"id":"paper-ielsg32-wbrt-vs-asct-consolidation-ferreri-lancet-haematol-2017","kind":"paper","name":"IELSG32 second randomisation: whole-brain radiotherapy or autologous stem cell transplant as consolidation in primary CNS lymphoma","route":"/key-papers/paper-ielsg32-wbrt-vs-asct-consolidation-ferreri-lancet-haematol-2017/","asOf":"2026-09-22","days":6},{"id":"paper-matrix-ielsg43-asct-consolidation-pcnsl-illerhaus-lancet-2026","kind":"paper","name":"MATRix/IELSG43: high-dose chemotherapy and autologous stem cell transplant versus non-myeloablative consolidation in primary CNS lymphoma","route":"/key-papers/paper-matrix-ielsg43-asct-consolidation-pcnsl-illerhaus-lancet-2026/","asOf":"2026-09-22","days":6},{"id":"paper-intuitt-nf2-brigatinib-plotkin-nejm-2024","kind":"paper","name":"INTUITT-NF2: brigatinib in NF2-related schwannomatosis with progressive tumours","route":"/key-papers/paper-intuitt-nf2-brigatinib-plotkin-nejm-2024/","asOf":"2026-09-22","days":6},{"id":"paper-anbl1221-irinotecan-temozolomide-dinutuximab-mody-lancet-oncol-2017","kind":"paper","name":"ANBL1221: irinotecan-temozolomide with temsirolimus or dinutuximab in relapsed or refractory neuroblastoma","route":"/key-papers/paper-anbl1221-irinotecan-temozolomide-dinutuximab-mody-lancet-oncol-2017/","asOf":"2026-09-22","days":6},{"id":"paper-anbl1221-expansion-dinutuximab-gm-csf-mody-jco-2020","kind":"paper","name":"ANBL1221 expansion: irinotecan, temozolomide and dinutuximab with GM-CSF in refractory or relapsed neuroblastoma","route":"/key-papers/paper-anbl1221-expansion-dinutuximab-gm-csf-mody-jco-2020/","asOf":"2026-09-22","days":6},{"id":"paper-aews0031-interval-compressed-chemotherapy-ewing-womer-jco-2012","kind":"paper","name":"AEWS0031: randomised trial of interval-compressed chemotherapy for localised Ewing sarcoma","route":"/key-papers/paper-aews0031-interval-compressed-chemotherapy-ewing-womer-jco-2012/","asOf":"2026-09-22","days":6},{"id":"paper-siopel-3-cisplatin-vs-plado-standard-risk-hepatoblastoma-perilongo-nejm-2009","kind":"paper","name":"SIOPEL-3: cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma","route":"/key-papers/paper-siopel-3-cisplatin-vs-plado-standard-risk-hepatoblastoma-perilongo-nejm-2009/","asOf":"2026-09-22","days":6},{"id":"paper-siopel-4-dose-dense-cisplatin-high-risk-hepatoblastoma-zsiros-lancet-oncol-2013","kind":"paper","name":"SIOPEL-4: dose-dense cisplatin-based chemotherapy and surgery for high-risk hepatoblastoma","route":"/key-papers/paper-siopel-4-dose-dense-cisplatin-high-risk-hepatoblastoma-zsiros-lancet-oncol-2013/","asOf":"2026-09-22","days":6},{"id":"paper-ahod1331-brentuximab-vedotin-paediatric-hodgkin-castellino-nejm-2022","kind":"paper","name":"AHOD1331: brentuximab vedotin with chemotherapy in paediatric high-risk Hodgkin lymphoma","route":"/key-papers/paper-ahod1331-brentuximab-vedotin-paediatric-hodgkin-castellino-nejm-2022/","asOf":"2026-09-22","days":6},{"id":"paper-fort-4gy-vs-24gy-indolent-lymphoma-hoskin-lancet-oncol-2014","kind":"paper","name":"FoRT: 4 Gy versus 24 Gy radiotherapy for indolent lymphoma, a randomised phase 3 non-inferiority trial","route":"/key-papers/paper-fort-4gy-vs-24gy-indolent-lymphoma-hoskin-lancet-oncol-2014/","asOf":"2026-09-22","days":6},{"id":"paper-fort-long-term-follow-up-hoskin-lancet-oncol-2021","kind":"paper","name":"FoRT long-term follow-up: 4 Gy versus 24 Gy for follicular and marginal zone lymphoma","route":"/key-papers/paper-fort-long-term-follow-up-hoskin-lancet-oncol-2021/","asOf":"2026-09-22","days":6},{"id":"paper-gallium-obinutuzumab-first-line-follicular-lymphoma-marcus-nejm-2017","kind":"paper","name":"GALLIUM: obinutuzumab for the first-line treatment of follicular lymphoma","route":"/key-papers/paper-gallium-obinutuzumab-first-line-follicular-lymphoma-marcus-nejm-2017/","asOf":"2026-09-22","days":6},{"id":"paper-relevance-rituximab-lenalidomide-follicular-lymphoma-morschhauser-nejm-2018","kind":"paper","name":"RELEVANCE: rituximab plus lenalidomide in advanced untreated follicular lymphoma","route":"/key-papers/paper-relevance-rituximab-lenalidomide-follicular-lymphoma-morschhauser-nejm-2018/","asOf":"2026-09-22","days":6},{"id":"paper-triangle-ibrutinib-mantle-cell-lymphoma-dreyling-lancet-2024","kind":"paper","name":"TRIANGLE: ibrutinib with immunochemotherapy with or without autologous transplant versus immunochemotherapy and transplant in untreated mantle cell lymphoma","route":"/key-papers/paper-triangle-ibrutinib-mantle-cell-lymphoma-dreyling-lancet-2024/","asOf":"2026-09-22","days":6},{"id":"paper-bmt-ctn-0803-autologous-transplant-hiv-lymphoma-alvarnas-blood-2016","kind":"paper","name":"BMT CTN 0803/AMC 071: autologous haematopoietic cell transplantation for HIV-related lymphoma","route":"/key-papers/paper-bmt-ctn-0803-autologous-transplant-hiv-lymphoma-alvarnas-blood-2016/","asOf":"2026-09-22","days":6},{"id":"paper-ptld-1-risk-stratified-sequential-treatment-trappe-jco-2017","kind":"paper","name":"PTLD-1: response to rituximab induction as a predictive marker allowing stratification into rituximab or R-CHOP consolidation in B-cell post-transplant lymphoproliferative disorder","route":"/key-papers/paper-ptld-1-risk-stratified-sequential-treatment-trappe-jco-2017/","asOf":"2026-09-22","days":6},{"id":"paper-classic-adjuvant-capox-gastric-bang-lancet-2012","kind":"paper","name":"CLASSIC: adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy","route":"/key-papers/paper-classic-adjuvant-capox-gastric-bang-lancet-2012/","asOf":"2026-09-22","days":6},{"id":"paper-classic-5-year-follow-up-noh-lancet-oncol-2014","kind":"paper","name":"CLASSIC 5-year follow-up: adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy","route":"/key-papers/paper-classic-5-year-follow-up-noh-lancet-oncol-2014/","asOf":"2026-09-22","days":6},{"id":"paper-espac-3-fluorouracil-vs-gemcitabine-adjuvant-neoptolemos-jama-2010","kind":"paper","name":"ESPAC-3: adjuvant fluorouracil plus folinic acid versus gemcitabine after pancreatic cancer resection","route":"/key-papers/paper-espac-3-fluorouracil-vs-gemcitabine-adjuvant-neoptolemos-jama-2010/","asOf":"2026-09-22","days":6},{"id":"paper-conko-001-adjuvant-gemcitabine-long-term-oettle-jama-2013","kind":"paper","name":"CONKO-001: adjuvant gemcitabine and long-term outcomes after resected pancreatic cancer","route":"/key-papers/paper-conko-001-adjuvant-gemcitabine-long-term-oettle-jama-2013/","asOf":"2026-09-22","days":6},{"id":"paper-norpact-1-neoadjuvant-folfirinox-labori-lancet-gastroenterol-hepatol-2024","kind":"paper","name":"NORPACT-1: neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer","route":"/key-papers/paper-norpact-1-neoadjuvant-folfirinox-labori-lancet-gastroenterol-hepatol-2024/","asOf":"2026-09-22","days":6},{"id":"paper-actg-a5263-kaposi-sarcoma-resource-limited-krown-lancet-2020","kind":"paper","name":"ACTG A5263/AMC 066: three chemotherapy regimens with antiretroviral therapy for advanced AIDS-associated Kaposi sarcoma in resource-limited settings","route":"/key-papers/paper-actg-a5263-kaposi-sarcoma-resource-limited-krown-lancet-2020/","asOf":"2026-09-22","days":6},{"id":"paper-pod1um-303-retifanlimab-anal-cancer-rao-lancet-2025","kind":"paper","name":"POD1UM-303/InterAACT-2: retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic anal squamous cell carcinoma","route":"/key-papers/paper-pod1um-303-retifanlimab-anal-cancer-rao-lancet-2025/","asOf":"2026-09-22","days":6},{"id":"paper-interaact-carboplatin-paclitaxel-advanced-anal-cancer-rao-jco-2020","kind":"paper","name":"InterAACT: cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer","route":"/key-papers/paper-interaact-carboplatin-paclitaxel-advanced-anal-cancer-rao-jco-2020/","asOf":"2026-09-22","days":6},{"id":"paper-nci9673-nivolumab-metastatic-anal-cancer-morris-lancet-oncol-2017","kind":"paper","name":"NCI9673: nivolumab for previously treated unresectable metastatic anal cancer","route":"/key-papers/paper-nci9673-nivolumab-metastatic-anal-cancer-morris-lancet-oncol-2017/","asOf":"2026-09-22","days":6},{"id":"paper-nci9673-part-b-nivolumab-ipilimumab-anal-cancer-morris-jco-2026","kind":"paper","name":"NCI9673 part B: randomised phase 2 study of nivolumab with or without ipilimumab in refractory metastatic anal cancer","route":"/key-papers/paper-nci9673-part-b-nivolumab-ipilimumab-anal-cancer-morris-jco-2026/","asOf":"2026-09-22","days":6},{"id":"paper-continuum-sintilimab-nasopharyngeal-liu-lancet-2024","kind":"paper","name":"CONTINUUM: induction-concurrent chemoradiotherapy with or without sintilimab in locoregionally advanced nasopharyngeal carcinoma","route":"/key-papers/paper-continuum-sintilimab-nasopharyngeal-liu-lancet-2024/","asOf":"2026-09-22","days":6},{"id":"paper-aurelia-bevacizumab-platinum-resistant-ovarian-pujade-lauraine-jco-2014","kind":"paper","name":"AURELIA: bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer","route":"/key-papers/paper-aurelia-bevacizumab-platinum-resistant-ovarian-pujade-lauraine-jco-2014/","asOf":"2026-09-22","days":6},{"id":"paper-firstmappp-sunitinib-metastatic-ppgl-baudin-lancet-2024","kind":"paper","name":"FIRSTMAPPP: sunitinib for metastatic progressive phaeochromocytomas and paragangliomas","route":"/key-papers/paper-firstmappp-sunitinib-metastatic-ppgl-baudin-lancet-2024/","asOf":"2026-09-22","days":6},{"id":"paper-getug-13-marker-guided-dose-dense-chemotherapy-fizazi-lancet-oncol-2014","kind":"paper","name":"GETUG 13: personalised chemotherapy based on tumour marker decline in poor-prognosis germ cell tumours","route":"/key-papers/paper-getug-13-marker-guided-dose-dense-chemotherapy-fizazi-lancet-oncol-2014/","asOf":"2026-09-22","days":6},{"id":"paper-adiuvo-adjuvant-mitotane-low-grade-acc-terzolo-lancet-diabetes-endocrinol-2023","kind":"paper","name":"ADIUVO: adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma","route":"/key-papers/paper-adiuvo-adjuvant-mitotane-low-grade-acc-terzolo-lancet-diabetes-endocrinol-2023/","asOf":"2026-09-22","days":6},{"id":"paper-trophimmun-avelumab-chemoresistant-gtn-you-jco-2020","kind":"paper","name":"TROPHIMMUN cohort A: avelumab in gestational trophoblastic tumours resistant to single-agent chemotherapy","route":"/key-papers/paper-trophimmun-avelumab-chemoresistant-gtn-you-jco-2020/","asOf":"2026-09-22","days":6},{"id":"nct06212752","kind":"trial","name":"A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension","route":"/trials/nct06212752/","asOf":"2026-09-22","days":6},{"id":"nct05089734","kind":"trial","name":"Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct05089734/","asOf":"2026-09-22","days":6},{"id":"nct04351555","kind":"trial","name":"A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-S","route":"/trials/nct04351555/","asOf":"2026-09-22","days":6},{"id":"nct06868654","kind":"trial","name":"China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexame","route":"/trials/nct06868654/","asOf":"2026-09-22","days":6},{"id":"nct04940052","kind":"trial","name":"Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refracto","route":"/trials/nct04940052/","asOf":"2026-09-22","days":6},{"id":"nct02152631","kind":"trial","name":"A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer","route":"/trials/nct02152631/","asOf":"2026-09-22","days":6},{"id":"nct04810078","kind":"trial","name":"A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advance","route":"/trials/nct04810078/","asOf":"2026-09-22","days":6},{"id":"nct06956170","kind":"trial","name":"All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myelo","route":"/trials/nct06956170/","asOf":"2026-09-22","days":6},{"id":"nct04194775","kind":"trial","name":"A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma","route":"/trials/nct04194775/","asOf":"2026-09-22","days":6},{"id":"nct02411448","kind":"trial","name":"A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RE","route":"/trials/nct02411448/","asOf":"2026-09-22","days":6},{"id":"nct03755791","kind":"trial","name":"Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Rece","route":"/trials/nct03755791/","asOf":"2026-09-22","days":6},{"id":"nct04717414","kind":"trial","name":"An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomi","route":"/trials/nct04717414/","asOf":"2026-09-22","days":6},{"id":"nct03706365","kind":"trial","name":"A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer","route":"/trials/nct03706365/","asOf":"2026-09-22","days":6},{"id":"nct04076059","kind":"trial","name":"An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormo","route":"/trials/nct04076059/","asOf":"2026-09-22","days":6},{"id":"nct04162210","kind":"trial","name":"Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple","route":"/trials/nct04162210/","asOf":"2026-09-22","days":6},{"id":"nct04446117","kind":"trial","name":"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC","route":"/trials/nct04446117/","asOf":"2026-09-22","days":6},{"id":"nct05625399","kind":"trial","name":"A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma","route":"/trials/nct05625399/","asOf":"2026-09-22","days":6},{"id":"nct06077760","kind":"trial","name":"A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (","route":"/trials/nct06077760/","asOf":"2026-09-22","days":6},{"id":"nct01933932","kind":"trial","name":"Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral","route":"/trials/nct01933932/","asOf":"2026-09-22","days":6},{"id":"nct06868667","kind":"trial","name":"Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dex","route":"/trials/nct06868667/","asOf":"2026-09-22","days":6},{"id":"nct04680052","kind":"trial","name":"A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Pa","route":"/trials/nct04680052/","asOf":"2026-09-22","days":6},{"id":"nct03164616","kind":"trial","name":"Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).","route":"/trials/nct03164616/","asOf":"2026-09-22","days":6},{"id":"nct02362594","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)","route":"/trials/nct02362594/","asOf":"2026-09-22","days":6},{"id":"nct03690388","kind":"trial","name":"A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Va","route":"/trials/nct03690388/","asOf":"2026-09-22","days":6},{"id":"nct05722015","kind":"trial","name":"A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)","route":"/trials/nct05722015/","asOf":"2026-09-22","days":6},{"id":"nct05171816","kind":"trial","name":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)","route":"/trials/nct05171816/","asOf":"2026-09-22","days":6},{"id":"nct05388669","kind":"trial","name":"A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)","route":"/trials/nct05388669/","asOf":"2026-09-22","days":6},{"id":"nct04956692","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participan","route":"/trials/nct04956692/","asOf":"2026-09-22","days":6},{"id":"nct04765059","kind":"trial","name":"A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct04765059/","asOf":"2026-09-22","days":6},{"id":"nct04619004","kind":"trial","name":"HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer","route":"/trials/nct04619004/","asOf":"2026-09-22","days":6},{"id":"nct05222555","kind":"trial","name":"Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients","route":"/trials/nct05222555/","asOf":"2026-09-22","days":6},{"id":"nct04606771","kind":"trial","name":"A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC","route":"/trials/nct04606771/","asOf":"2026-09-22","days":6},{"id":"nct07084896","kind":"trial","name":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM","route":"/trials/nct07084896/","asOf":"2026-09-22","days":6},{"id":"nct01081951","kind":"trial","name":"Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitax","route":"/trials/nct01081951/","asOf":"2026-09-22","days":6},{"id":"nct04430738","kind":"trial","name":"Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers","route":"/trials/nct04430738/","asOf":"2026-09-22","days":6},{"id":"nct06502977","kind":"trial","name":"Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment","route":"/trials/nct06502977/","asOf":"2026-09-22","days":6},{"id":"nct06101134","kind":"trial","name":"A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed","route":"/trials/nct06101134/","asOf":"2026-09-22","days":6},{"id":"nct06099782","kind":"trial","name":"A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrol","route":"/trials/nct06099782/","asOf":"2026-09-22","days":6},{"id":"nct04745689","kind":"trial","name":"Study of AZD2811 + Durvalumab in ES-SCLC","route":"/trials/nct04745689/","asOf":"2026-09-22","days":6},{"id":"nct03334617","kind":"trial","name":"Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy","route":"/trials/nct03334617/","asOf":"2026-09-22","days":6},{"id":"nct04895722","kind":"trial","name":"Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) ","route":"/trials/nct04895722/","asOf":"2026-09-22","days":6},{"id":"nct03157128","kind":"trial","name":"A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRET","route":"/trials/nct03157128/","asOf":"2026-09-22","days":6},{"id":"nct04068610","kind":"trial","name":"COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC","route":"/trials/nct04068610/","asOf":"2026-09-22","days":6},{"id":"nct05471843","kind":"trial","name":"Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma","route":"/trials/nct05471843/","asOf":"2026-09-22","days":6},{"id":"nct03974022","kind":"trial","name":"Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)","route":"/trials/nct03974022/","asOf":"2026-09-22","days":6},{"id":"nct05609370","kind":"trial","name":"A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus ","route":"/trials/nct05609370/","asOf":"2026-09-22","days":6},{"id":"nct02711553","kind":"trial","name":"A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer","route":"/trials/nct02711553/","asOf":"2026-09-22","days":6},{"id":"nct02180711","kind":"trial","name":"Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma","route":"/trials/nct02180711/","asOf":"2026-09-22","days":6},{"id":"nct07150091","kind":"trial","name":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM","route":"/trials/nct07150091/","asOf":"2026-09-22","days":6},{"id":"nct04639219","kind":"trial","name":"A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations","route":"/trials/nct04639219/","asOf":"2026-09-22","days":6},{"id":"nct04280081","kind":"trial","name":"A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer a","route":"/trials/nct04280081/","asOf":"2026-09-22","days":6},{"id":"nct04711135","kind":"trial","name":"Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs","route":"/trials/nct04711135/","asOf":"2026-09-22","days":6},{"id":"nct03932331","kind":"trial","name":"Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malign","route":"/trials/nct03932331/","asOf":"2026-09-22","days":6},{"id":"nct07217119","kind":"trial","name":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM","route":"/trials/nct07217119/","asOf":"2026-09-22","days":6},{"id":"nct03260023","kind":"trial","name":"Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers","route":"/trials/nct03260023/","asOf":"2026-09-22","days":6},{"id":"nct06390995","kind":"trial","name":"A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors","route":"/trials/nct06390995/","asOf":"2026-09-22","days":6},{"id":"nct05246514","kind":"trial","name":"A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC","route":"/trials/nct05246514/","asOf":"2026-09-22","days":6},{"id":"nct07217184","kind":"trial","name":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM","route":"/trials/nct07217184/","asOf":"2026-09-22","days":6},{"id":"nct03899792","kind":"trial","name":"A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors","route":"/trials/nct03899792/","asOf":"2026-09-22","days":6},{"id":"nct05061134","kind":"trial","name":"A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition","route":"/trials/nct05061134/","asOf":"2026-09-22","days":6},{"id":"nct05117242","kind":"trial","name":"Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer","route":"/trials/nct05117242/","asOf":"2026-09-22","days":6},{"id":"nct02519348","kind":"trial","name":"A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma","route":"/trials/nct02519348/","asOf":"2026-09-22","days":6},{"id":"nct02773030","kind":"trial","name":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple","route":"/trials/nct02773030/","asOf":"2026-09-22","days":6},{"id":"nct07150104","kind":"trial","name":"Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants Wi","route":"/trials/nct07150104/","asOf":"2026-09-22","days":6},{"id":"nct05287113","kind":"trial","name":"Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck","route":"/trials/nct05287113/","asOf":"2026-09-22","days":6},{"id":"nct05243550","kind":"trial","name":"A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer","route":"/trials/nct05243550/","asOf":"2026-09-22","days":6},{"id":"nct05663866","kind":"trial","name":"Premedication to Reduce Amivantamab Associated Infusion Related Reactions","route":"/trials/nct05663866/","asOf":"2026-09-22","days":6},{"id":"nct05020015","kind":"trial","name":"A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)","route":"/trials/nct05020015/","asOf":"2026-09-22","days":6},{"id":"nct02677922","kind":"trial","name":"A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy","route":"/trials/nct02677922/","asOf":"2026-09-22","days":6},{"id":"nct02979522","kind":"trial","name":"A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma","route":"/trials/nct02979522/","asOf":"2026-09-22","days":6},{"id":"nct05316701","kind":"trial","name":"Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies","route":"/trials/nct05316701/","asOf":"2026-09-22","days":6},{"id":"nct05804045","kind":"trial","name":"Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)","route":"/trials/nct05804045/","asOf":"2026-09-22","days":6},{"id":"nct03706690","kind":"trial","name":"A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients","route":"/trials/nct03706690/","asOf":"2026-09-22","days":6},{"id":"nct03091192","kind":"trial","name":"Savolitinib vs. Sunitinib in MET-driven PRCC.","route":"/trials/nct03091192/","asOf":"2026-09-22","days":6},{"id":"nct04075292","kind":"trial","name":"Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia","route":"/trials/nct04075292/","asOf":"2026-09-22","days":6},{"id":"nct05224141","kind":"trial","name":"Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)","route":"/trials/nct05224141/","asOf":"2026-09-22","days":6},{"id":"nct03778229","kind":"trial","name":"Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib","route":"/trials/nct03778229/","asOf":"2026-09-22","days":6},{"id":"nct05440786","kind":"trial","name":"CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma","route":"/trials/nct05440786/","asOf":"2026-09-22","days":6},{"id":"nct02763566","kind":"trial","name":"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer","route":"/trials/nct02763566/","asOf":"2026-09-22","days":6},{"id":"nct04488822","kind":"trial","name":"A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT","route":"/trials/nct04488822/","asOf":"2026-09-22","days":6},{"id":"nct04538664","kind":"trial","name":"A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions","route":"/trials/nct04538664/","asOf":"2026-09-22","days":6},{"id":"nct04025879","kind":"trial","name":"A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer","route":"/trials/nct04025879/","asOf":"2026-09-22","days":6},{"id":"nct04971226","kind":"trial","name":"A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP","route":"/trials/nct04971226/","asOf":"2026-09-22","days":6},{"id":"nct02477696","kind":"trial","name":"Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)","route":"/trials/nct02477696/","asOf":"2026-09-22","days":6},{"id":"nct02257736","kind":"trial","name":"An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)","route":"/trials/nct02257736/","asOf":"2026-09-22","days":6},{"id":"nct02107703","kind":"trial","name":"A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer","route":"/trials/nct02107703/","asOf":"2026-09-22","days":6},{"id":"nct04665856","kind":"trial","name":"Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer","route":"/trials/nct04665856/","asOf":"2026-09-22","days":6},{"id":"nct03036098","kind":"trial","name":"Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer","route":"/trials/nct03036098/","asOf":"2026-09-22","days":6},{"id":"nct02671435","kind":"trial","name":"A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors","route":"/trials/nct02671435/","asOf":"2026-09-22","days":6},{"id":"nct02970318","kind":"trial","name":"A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL","route":"/trials/nct02970318/","asOf":"2026-09-22","days":6},{"id":"nct02516241","kind":"trial","name":"Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer","route":"/trials/nct02516241/","asOf":"2026-09-22","days":6},{"id":"nct03381274","kind":"trial","name":"Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study","route":"/trials/nct03381274/","asOf":"2026-09-22","days":6},{"id":"nct01874353","kind":"trial","name":"Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy","route":"/trials/nct01874353/","asOf":"2026-09-22","days":6},{"id":"nct03386513","kind":"trial","name":"Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN","route":"/trials/nct03386513/","asOf":"2026-09-22","days":6},{"id":"nct04044768","kind":"trial","name":"Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma","route":"/trials/nct04044768/","asOf":"2026-09-22","days":6},{"id":"nct05445843","kind":"trial","name":"Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.","route":"/trials/nct05445843/","asOf":"2026-09-22","days":6},{"id":"nct02453282","kind":"trial","name":"Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)","route":"/trials/nct02453282/","asOf":"2026-09-22","days":6},{"id":"nct04915755","kind":"trial","name":"Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease","route":"/trials/nct04915755/","asOf":"2026-09-22","days":6},{"id":"nct02734004","kind":"trial","name":"A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.","route":"/trials/nct02734004/","asOf":"2026-09-22","days":6},{"id":"nct02586857","kind":"trial","name":"A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)","route":"/trials/nct02586857/","asOf":"2026-09-22","days":6},{"id":"nct00099437","kind":"trial","name":"Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.","route":"/trials/nct00099437/","asOf":"2026-09-22","days":6},{"id":"nct03673501","kind":"trial","name":"A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib","route":"/trials/nct03673501/","asOf":"2026-09-22","days":6},{"id":"nct03837899","kind":"trial","name":"Durvalumab and Tremelimumab for Pediatric Malignancies","route":"/trials/nct03837899/","asOf":"2026-09-22","days":6},{"id":"nct03972488","kind":"trial","name":"Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET","route":"/trials/nct03972488/","asOf":"2026-09-22","days":6},{"id":"nct04214288","kind":"trial","name":"A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer","route":"/trials/nct04214288/","asOf":"2026-09-22","days":6},{"id":"nct04225117","kind":"trial","name":"A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)","route":"/trials/nct04225117/","asOf":"2026-09-22","days":6},{"id":"nct04724369","kind":"trial","name":"Open-Label Study of 18F-mFBG for Imaging Neuroblastoma","route":"/trials/nct04724369/","asOf":"2026-09-22","days":6},{"id":"nct02747004","kind":"trial","name":"A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer","route":"/trials/nct02747004/","asOf":"2026-09-22","days":6},{"id":"nct05583552","kind":"trial","name":"Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy","route":"/trials/nct05583552/","asOf":"2026-09-22","days":6},{"id":"nct04703192","kind":"trial","name":"Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)","route":"/trials/nct04703192/","asOf":"2026-09-22","days":6},{"id":"nct02542293","kind":"trial","name":"Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)","route":"/trials/nct02542293/","asOf":"2026-09-22","days":6},{"id":"nct04999969","kind":"trial","name":"Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours","route":"/trials/nct04999969/","asOf":"2026-09-22","days":6},{"id":"nct03431350","kind":"trial","name":"A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct03431350/","asOf":"2026-09-22","days":6},{"id":"nct03742895","kind":"trial","name":"Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)","route":"/trials/nct03742895/","asOf":"2026-09-22","days":6},{"id":"nct03003962","kind":"trial","name":"Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)","route":"/trials/nct03003962/","asOf":"2026-09-22","days":6},{"id":"nct04576455","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)","route":"/trials/nct04576455/","asOf":"2026-09-22","days":6},{"id":"nct02180724","kind":"trial","name":"An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia","route":"/trials/nct02180724/","asOf":"2026-09-22","days":6},{"id":"nct03964727","kind":"trial","name":"Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors","route":"/trials/nct03964727/","asOf":"2026-09-22","days":6},{"id":"nct04023526","kind":"trial","name":"A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy","route":"/trials/nct04023526/","asOf":"2026-09-22","days":6},{"id":"nct04497844","kind":"trial","name":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)","route":"/trials/nct04497844/","asOf":"2026-09-22","days":6},{"id":"nct04721977","kind":"trial","name":"A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)","route":"/trials/nct04721977/","asOf":"2026-09-22","days":6},{"id":"nct05456191","kind":"trial","name":"A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)","route":"/trials/nct05456191/","asOf":"2026-09-22","days":6},{"id":"nct05673785","kind":"trial","name":"A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)","route":"/trials/nct05673785/","asOf":"2026-09-22","days":6},{"id":"nct04980222","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma","route":"/trials/nct04980222/","asOf":"2026-09-22","days":6},{"id":"nct03459846","kind":"trial","name":"A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)","route":"/trials/nct03459846/","asOf":"2026-09-22","days":6},{"id":"nct03602859","kind":"trial","name":"A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer","route":"/trials/nct03602859/","asOf":"2026-09-22","days":6},{"id":"nct04579380","kind":"trial","name":"Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations","route":"/trials/nct04579380/","asOf":"2026-09-22","days":6},{"id":"nct04988295","kind":"trial","name":"A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure","route":"/trials/nct04988295/","asOf":"2026-09-22","days":6},{"id":"nct05460273","kind":"trial","name":"A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)","route":"/trials/nct05460273/","asOf":"2026-09-22","days":6},{"id":"nct06050122","kind":"trial","name":"Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome","route":"/trials/nct06050122/","asOf":"2026-09-22","days":6},{"id":"nct02717611","kind":"trial","name":"A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy","route":"/trials/nct02717611/","asOf":"2026-09-22","days":6},{"id":"nct03742102","kind":"trial","name":"A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer","route":"/trials/nct03742102/","asOf":"2026-09-22","days":6},{"id":"nct04489771","kind":"trial","name":"A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)","route":"/trials/nct04489771/","asOf":"2026-09-22","days":6},{"id":"nct03182244","kind":"trial","name":"A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation","route":"/trials/nct03182244/","asOf":"2026-09-22","days":6},{"id":"nct02029443","kind":"trial","name":"ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia","route":"/trials/nct02029443/","asOf":"2026-09-22","days":6},{"id":"nct02365597","kind":"trial","name":"An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer","route":"/trials/nct02365597/","asOf":"2026-09-22","days":6},{"id":"nct03473743","kind":"trial","name":"A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer","route":"/trials/nct03473743/","asOf":"2026-09-22","days":6},{"id":"nct03330847","kind":"trial","name":"To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.","route":"/trials/nct03330847/","asOf":"2026-09-22","days":6},{"id":"nct05197426","kind":"trial","name":"A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission","route":"/trials/nct05197426/","asOf":"2026-09-22","days":6},{"id":"nct00248287","kind":"trial","name":"PhII ICb With/Without Erbitux in MBC Pts","route":"/trials/nct00248287/","asOf":"2026-09-22","days":6},{"id":"nct05327530","kind":"trial","name":"A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)","route":"/trials/nct05327530/","asOf":"2026-09-22","days":6},{"id":"nct04325828","kind":"trial","name":"A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma","route":"/trials/nct04325828/","asOf":"2026-09-22","days":6},{"id":"paper-nhs-galleri-performance-nat-med-2026","kind":"paper","name":"Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial","route":"/key-papers/paper-nhs-galleri-performance-nat-med-2026/","asOf":"2026-09-23","days":5},{"id":"mki67","kind":"target","name":"Ki-67 (MKI67)","route":"/targets/mki67/","asOf":"2026-09-23","days":5},{"id":"mgmt-protein","kind":"target","name":"MGMT (O6-methylguanine-DNA methyltransferase)","route":"/targets/mgmt-protein/","asOf":"2026-09-23","days":5},{"id":"mycn","kind":"target","name":"MYCN (N-myc)","route":"/targets/mycn/","asOf":"2026-09-23","days":5},{"id":"h3-3a","kind":"target","name":"Histone H3.3 (H3-3A)","route":"/targets/h3-3a/","asOf":"2026-09-23","days":5},{"id":"fcrh5","kind":"target","name":"FcRH5 (FCRL5)","route":"/targets/fcrh5/","asOf":"2026-09-23","days":5},{"id":"pten","kind":"target","name":"PTEN","route":"/targets/pten/","asOf":"2026-09-23","days":5},{"id":"mmr","kind":"target","name":"Mismatch repair proteins (MLH1, MSH2, MSH6, PMS2)","route":"/targets/mmr/","asOf":"2026-09-23","days":5},{"id":"pd-l1-cps","kind":"biomarker","name":"PD-L1 CPS (combined positive score)","route":"/biomarkers/pd-l1-cps/","asOf":"2026-09-23","days":5},{"id":"pd-l1-tps","kind":"biomarker","name":"PD-L1 TPS (tumour proportion score)","route":"/biomarkers/pd-l1-tps/","asOf":"2026-09-23","days":5},{"id":"pd-l1-ic-score","kind":"biomarker","name":"PD-L1 IC score (immune-cell score, SP142)","route":"/biomarkers/pd-l1-ic-score/","asOf":"2026-09-23","days":5},{"id":"pd-l1-tc-score","kind":"biomarker","name":"PD-L1 TC score (tumour-cell score, SP263 and 28-8)","route":"/biomarkers/pd-l1-tc-score/","asOf":"2026-09-23","days":5},{"id":"her2-ihc-3-plus","kind":"biomarker","name":"HER2 IHC 3+ (HER2-positive by immunohistochemistry)","route":"/biomarkers/her2-ihc-3-plus/","asOf":"2026-09-23","days":5},{"id":"her2-ihc-2-plus","kind":"biomarker","name":"HER2 IHC 2+ (equivocal, reflex to ISH)","route":"/biomarkers/her2-ihc-2-plus/","asOf":"2026-09-23","days":5},{"id":"her2-ihc-1-plus","kind":"biomarker","name":"HER2 IHC 1+","route":"/biomarkers/her2-ihc-1-plus/","asOf":"2026-09-23","days":5},{"id":"her2-ihc-0","kind":"biomarker","name":"HER2 IHC 0 (HER2-negative, including ultralow)","route":"/biomarkers/her2-ihc-0/","asOf":"2026-09-23","days":5},{"id":"her2-low-ihc","kind":"biomarker","name":"HER2-low (IHC 1+ or IHC 2+/ISH-negative)","route":"/biomarkers/her2-low-ihc/","asOf":"2026-09-23","days":5},{"id":"her2-ultralow","kind":"biomarker","name":"HER2-ultralow (IHC 0 with membrane staining)","route":"/biomarkers/her2-ultralow/","asOf":"2026-09-23","days":5},{"id":"her2-ish-amplified","kind":"biomarker","name":"HER2 ISH amplified (ERBB2 gene amplification)","route":"/biomarkers/her2-ish-amplified/","asOf":"2026-09-23","days":5},{"id":"her2-mutation","kind":"biomarker","name":"HER2 (ERBB2) activating mutation","route":"/biomarkers/her2-mutation/","asOf":"2026-09-23","days":5},{"id":"er-status","kind":"biomarker","name":"ER status (oestrogen receptor by IHC)","route":"/biomarkers/er-status/","asOf":"2026-09-23","days":5},{"id":"pr-status","kind":"biomarker","name":"PR status (progesterone receptor by IHC)","route":"/biomarkers/pr-status/","asOf":"2026-09-23","days":5},{"id":"ki-67-index","kind":"biomarker","name":"Ki-67 index (proliferation by IHC)","route":"/biomarkers/ki-67-index/","asOf":"2026-09-23","days":5},{"id":"dmmr-ihc","kind":"biomarker","name":"dMMR (mismatch repair deficiency by IHC)","route":"/biomarkers/dmmr-ihc/","asOf":"2026-09-23","days":5},{"id":"msi-high","kind":"biomarker","name":"MSI-high (microsatellite instability by PCR or sequencing)","route":"/biomarkers/msi-high/","asOf":"2026-09-23","days":5},{"id":"tmb-high","kind":"biomarker","name":"TMB-high (tumour mutational burden >= 10 mutations per megabase)","route":"/biomarkers/tmb-high/","asOf":"2026-09-23","days":5},{"id":"brca-germline","kind":"biomarker","name":"Germline BRCA1/2 pathogenic variant (gBRCAm)","route":"/biomarkers/brca-germline/","asOf":"2026-09-23","days":5},{"id":"brca-somatic","kind":"biomarker","name":"Tumour (somatic or germline) BRCA1/2 mutation and HRR gene alterations","route":"/biomarkers/brca-somatic/","asOf":"2026-09-23","days":5},{"id":"hrd-positive","kind":"biomarker","name":"HRD-positive (genomic instability score)","route":"/biomarkers/hrd-positive/","asOf":"2026-09-23","days":5},{"id":"egfr-exon-19-deletion","kind":"biomarker","name":"EGFR exon 19 deletion","route":"/biomarkers/egfr-exon-19-deletion/","asOf":"2026-09-23","days":5},{"id":"egfr-l858r","kind":"biomarker","name":"EGFR L858R","route":"/biomarkers/egfr-l858r/","asOf":"2026-09-23","days":5},{"id":"egfr-t790m","kind":"biomarker","name":"EGFR T790M","route":"/biomarkers/egfr-t790m/","asOf":"2026-09-23","days":5},{"id":"egfr-exon-20-insertion","kind":"biomarker","name":"EGFR exon 20 insertion","route":"/biomarkers/egfr-exon-20-insertion/","asOf":"2026-09-23","days":5},{"id":"kras-g12c","kind":"biomarker","name":"KRAS G12C","route":"/biomarkers/kras-g12c/","asOf":"2026-09-23","days":5},{"id":"ras-wild-type","kind":"biomarker","name":"RAS wild-type (extended KRAS and NRAS testing)","route":"/biomarkers/ras-wild-type/","asOf":"2026-09-23","days":5},{"id":"kras-g12d","kind":"biomarker","name":"KRAS G12D (and other non-G12C KRAS mutations)","route":"/biomarkers/kras-g12d/","asOf":"2026-09-23","days":5},{"id":"braf-v600e","kind":"biomarker","name":"BRAF V600E (and V600K)","route":"/biomarkers/braf-v600e/","asOf":"2026-09-23","days":5},{"id":"braf-class-ii-iii","kind":"biomarker","name":"BRAF class II and class III mutations (non-V600)","route":"/biomarkers/braf-class-ii-iii/","asOf":"2026-09-23","days":5},{"id":"braf-fusion","kind":"biomarker","name":"BRAF fusion or rearrangement","route":"/biomarkers/braf-fusion/","asOf":"2026-09-23","days":5},{"id":"alk-fusion","kind":"biomarker","name":"ALK fusion (ALK-positive)","route":"/biomarkers/alk-fusion/","asOf":"2026-09-23","days":5},{"id":"ros1-fusion","kind":"biomarker","name":"ROS1 fusion (ROS1-positive)","route":"/biomarkers/ros1-fusion/","asOf":"2026-09-23","days":5},{"id":"ret-fusion","kind":"biomarker","name":"RET fusion and RET mutation","route":"/biomarkers/ret-fusion/","asOf":"2026-09-23","days":5},{"id":"ntrk-fusion","kind":"biomarker","name":"NTRK1/2/3 gene fusion","route":"/biomarkers/ntrk-fusion/","asOf":"2026-09-23","days":5},{"id":"nrg1-fusion","kind":"biomarker","name":"NRG1 gene fusion","route":"/biomarkers/nrg1-fusion/","asOf":"2026-09-23","days":5},{"id":"met-ex14","kind":"biomarker","name":"MET exon 14 skipping mutation","route":"/biomarkers/met-ex14/","asOf":"2026-09-23","days":5},{"id":"met-amplification-readout","kind":"biomarker","name":"MET amplification (gene copy number)","route":"/biomarkers/met-amplification-readout/","asOf":"2026-09-23","days":5},{"id":"met-overexpression","kind":"biomarker","name":"c-Met protein overexpression (IHC 3+ in >= 50% of tumour cells)","route":"/biomarkers/met-overexpression/","asOf":"2026-09-23","days":5},{"id":"fgfr2-fusion-rearrangement","kind":"biomarker","name":"FGFR2 fusion or rearrangement","route":"/biomarkers/fgfr2-fusion-rearrangement/","asOf":"2026-09-23","days":5},{"id":"fgfr3-alteration","kind":"biomarker","name":"FGFR3 alteration (mutation or fusion)","route":"/biomarkers/fgfr3-alteration/","asOf":"2026-09-23","days":5},{"id":"idh1-r132","kind":"biomarker","name":"IDH1 R132 mutation","route":"/biomarkers/idh1-r132/","asOf":"2026-09-23","days":5},{"id":"idh2-mutation","kind":"biomarker","name":"IDH2 mutation (R140 and R172)","route":"/biomarkers/idh2-mutation/","asOf":"2026-09-23","days":5},{"id":"flt3-itd","kind":"biomarker","name":"FLT3-ITD (internal tandem duplication)","route":"/biomarkers/flt3-itd/","asOf":"2026-09-23","days":5},{"id":"flt3-tkd","kind":"biomarker","name":"FLT3-TKD (D835 and I836 tyrosine kinase domain mutations)","route":"/biomarkers/flt3-tkd/","asOf":"2026-09-23","days":5},{"id":"npm1-mutation","kind":"biomarker","name":"NPM1 mutation","route":"/biomarkers/npm1-mutation/","asOf":"2026-09-23","days":5},{"id":"kit-d816v","kind":"biomarker","name":"KIT D816V","route":"/biomarkers/kit-d816v/","asOf":"2026-09-23","days":5},{"id":"pdgfra-exon-18-d842v","kind":"biomarker","name":"PDGFRA exon 18 mutation (D842V)","route":"/biomarkers/pdgfra-exon-18-d842v/","asOf":"2026-09-23","days":5},{"id":"bcr-abl1-transcript","kind":"biomarker","name":"BCR::ABL1 transcript (Philadelphia chromosome, quantitative PCR)","route":"/biomarkers/bcr-abl1-transcript/","asOf":"2026-09-23","days":5},{"id":"bcr-abl1-t315i","kind":"biomarker","name":"BCR::ABL1 T315I","route":"/biomarkers/bcr-abl1-t315i/","asOf":"2026-09-23","days":5},{"id":"pik3ca-hotspot-mutation","kind":"biomarker","name":"PIK3CA mutation","route":"/biomarkers/pik3ca-hotspot-mutation/","asOf":"2026-09-23","days":5},{"id":"akt1-e17k","kind":"biomarker","name":"AKT1 E17K mutation","route":"/biomarkers/akt1-e17k/","asOf":"2026-09-23","days":5},{"id":"pten-alteration","kind":"biomarker","name":"PTEN alteration (sequencing) and PTEN loss (IHC)","route":"/biomarkers/pten-alteration/","asOf":"2026-09-23","days":5},{"id":"esr1-mutation-ctdna","kind":"biomarker","name":"ESR1 mutation (ligand-binding domain, usually in ctDNA)","route":"/biomarkers/esr1-mutation-ctdna/","asOf":"2026-09-23","days":5},{"id":"ar-v7-splice-variant","kind":"biomarker","name":"AR-V7 splice variant","route":"/biomarkers/ar-v7-splice-variant/","asOf":"2026-09-23","days":5},{"id":"psma-pet-expression","kind":"biomarker","name":"PSMA expression by PET (PSMA-positive)","route":"/biomarkers/psma-pet-expression/","asOf":"2026-09-23","days":5},{"id":"sstr-pet-expression","kind":"biomarker","name":"Somatostatin receptor expression by PET (SSTR-positive)","route":"/biomarkers/sstr-pet-expression/","asOf":"2026-09-23","days":5},{"id":"cd19-expression","kind":"biomarker","name":"CD19 expression (CD19-positive)","route":"/biomarkers/cd19-expression/","asOf":"2026-09-23","days":5},{"id":"cd20-expression","kind":"biomarker","name":"CD20 expression (CD20-positive)","route":"/biomarkers/cd20-expression/","asOf":"2026-09-23","days":5},{"id":"cd22-expression","kind":"biomarker","name":"CD22 expression (CD22-positive)","route":"/biomarkers/cd22-expression/","asOf":"2026-09-23","days":5},{"id":"cd30-expression","kind":"biomarker","name":"CD30 expression (CD30-positive)","route":"/biomarkers/cd30-expression/","asOf":"2026-09-23","days":5},{"id":"cd33-expression","kind":"biomarker","name":"CD33 expression (CD33-positive)","route":"/biomarkers/cd33-expression/","asOf":"2026-09-23","days":5},{"id":"cd38-expression","kind":"biomarker","name":"CD38 expression","route":"/biomarkers/cd38-expression/","asOf":"2026-09-23","days":5},{"id":"bcma-expression","kind":"biomarker","name":"BCMA expression","route":"/biomarkers/bcma-expression/","asOf":"2026-09-23","days":5},{"id":"gprc5d-expression","kind":"biomarker","name":"GPRC5D expression","route":"/biomarkers/gprc5d-expression/","asOf":"2026-09-23","days":5},{"id":"fcrh5-expression","kind":"biomarker","name":"FcRH5 expression","route":"/biomarkers/fcrh5-expression/","asOf":"2026-09-23","days":5},{"id":"cldn18-2-expression","kind":"biomarker","name":"Claudin 18.2 expression (>= 75% of tumour cells, moderate to strong)","route":"/biomarkers/cldn18-2-expression/","asOf":"2026-09-23","days":5},{"id":"folr1-expression","kind":"biomarker","name":"Folate receptor alpha expression (FRα-positive, PS2+ >= 75%)","route":"/biomarkers/folr1-expression/","asOf":"2026-09-23","days":5},{"id":"trop2-expression","kind":"biomarker","name":"TROP2 expression","route":"/biomarkers/trop2-expression/","asOf":"2026-09-23","days":5},{"id":"nectin-4-expression","kind":"biomarker","name":"Nectin-4 expression","route":"/biomarkers/nectin-4-expression/","asOf":"2026-09-23","days":5},{"id":"her3-expression","kind":"biomarker","name":"HER3 expression","route":"/biomarkers/her3-expression/","asOf":"2026-09-23","days":5},{"id":"b7-h3-expression","kind":"biomarker","name":"B7-H3 (CD276) expression","route":"/biomarkers/b7-h3-expression/","asOf":"2026-09-23","days":5},{"id":"dll3-expression","kind":"biomarker","name":"DLL3 expression","route":"/biomarkers/dll3-expression/","asOf":"2026-09-23","days":5},{"id":"tissue-factor-expression","kind":"biomarker","name":"Tissue factor expression","route":"/biomarkers/tissue-factor-expression/","asOf":"2026-09-23","days":5},{"id":"ceacam5-expression","kind":"biomarker","name":"CEACAM5 expression","route":"/biomarkers/ceacam5-expression/","asOf":"2026-09-23","days":5},{"id":"tp53-del17p","kind":"biomarker","name":"TP53 mutation and del(17p)","route":"/biomarkers/tp53-del17p/","asOf":"2026-09-23","days":5},{"id":"mycn-amp","kind":"biomarker","name":"MYCN amplification","route":"/biomarkers/mycn-amp/","asOf":"2026-09-23","days":5},{"id":"mgmt-promoter-methylation","kind":"biomarker","name":"MGMT promoter methylation","route":"/biomarkers/mgmt-promoter-methylation/","asOf":"2026-09-23","days":5},{"id":"1p19q-codeletion-readout","kind":"biomarker","name":"1p/19q codeletion","route":"/biomarkers/1p19q-codeletion-readout/","asOf":"2026-09-23","days":5},{"id":"h3-k27m","kind":"biomarker","name":"H3 K27M mutation","route":"/biomarkers/h3-k27m/","asOf":"2026-09-23","days":5},{"id":"ctdna-mrd-positive","kind":"biomarker","name":"ctDNA MRD positivity (molecular residual disease after curative treatment)","route":"/biomarkers/ctdna-mrd-positive/","asOf":"2026-09-23","days":5},{"id":"hla-a-02-01","kind":"biomarker","name":"HLA-A*02:01 (HLA typing for TCR therapies)","route":"/biomarkers/hla-a-02-01/","asOf":"2026-09-23","days":5},{"id":"ctnnb1","kind":"target","name":"CTNNB1","route":"/targets/ctnnb1/","asOf":"2026-09-23","days":5},{"id":"ccnd1","kind":"target","name":"CCND1","route":"/targets/ccnd1/","asOf":"2026-09-23","days":5},{"id":"tert","kind":"target","name":"TERT","route":"/targets/tert/","asOf":"2026-09-23","days":5},{"id":"pole","kind":"target","name":"POLE","route":"/targets/pole/","asOf":"2026-09-23","days":5},{"id":"apc","kind":"target","name":"APC","route":"/targets/apc/","asOf":"2026-09-23","days":5},{"id":"fgfr4","kind":"target","name":"FGFR4","route":"/targets/fgfr4/","asOf":"2026-09-23","days":5},{"id":"pold1","kind":"target","name":"POLD1","route":"/targets/pold1/","asOf":"2026-09-23","days":5},{"id":"nrg1","kind":"target","name":"NRG1","route":"/targets/nrg1/","asOf":"2026-09-23","days":5},{"id":"tsc1","kind":"target","name":"TSC1","route":"/targets/tsc1/","asOf":"2026-09-23","days":5},{"id":"setd2","kind":"target","name":"SETD2","route":"/targets/setd2/","asOf":"2026-09-23","days":5},{"id":"tsc2","kind":"target","name":"TSC2","route":"/targets/tsc2/","asOf":"2026-09-23","days":5},{"id":"calr","kind":"target","name":"CALR","route":"/targets/calr/","asOf":"2026-09-23","days":5},{"id":"eml4","kind":"target","name":"EML4","route":"/targets/eml4/","asOf":"2026-09-23","days":5},{"id":"esr2","kind":"target","name":"ESR2","route":"/targets/esr2/","asOf":"2026-09-23","days":5},{"id":"pml","kind":"target","name":"PML","route":"/targets/pml/","asOf":"2026-09-23","days":5},{"id":"kif5b","kind":"target","name":"KIF5B","route":"/targets/kif5b/","asOf":"2026-09-23","days":5},{"id":"lck","kind":"target","name":"LCK","route":"/targets/lck/","asOf":"2026-09-23","days":5},{"id":"smad2","kind":"target","name":"SMAD2","route":"/targets/smad2/","asOf":"2026-09-23","days":5},{"id":"jak3","kind":"target","name":"JAK3","route":"/targets/jak3/","asOf":"2026-09-23","days":5},{"id":"yes1","kind":"target","name":"YES1","route":"/targets/yes1/","asOf":"2026-09-23","days":5},{"id":"ccdc6","kind":"target","name":"CCDC6","route":"/targets/ccdc6/","asOf":"2026-09-23","days":5},{"id":"sem1","kind":"target","name":"SEM1","route":"/targets/sem1/","asOf":"2026-09-23","days":5},{"id":"rbx1","kind":"target","name":"RBX1","route":"/targets/rbx1/","asOf":"2026-09-23","days":5},{"id":"fyn","kind":"target","name":"FYN","route":"/targets/fyn/","asOf":"2026-09-23","days":5},{"id":"prim1","kind":"target","name":"PRIM1","route":"/targets/prim1/","asOf":"2026-09-23","days":5},{"id":"tyk2","kind":"target","name":"TYK2","route":"/targets/tyk2/","asOf":"2026-09-23","days":5},{"id":"cd74","kind":"target","name":"CD74","route":"/targets/cd74/","asOf":"2026-09-23","days":5},{"id":"ephb2","kind":"target","name":"EPHB2","route":"/targets/ephb2/","asOf":"2026-09-23","days":5},{"id":"syk","kind":"target","name":"SYK","route":"/targets/syk/","asOf":"2026-09-23","days":5},{"id":"dpyd","kind":"target","name":"DPYD","route":"/targets/dpyd/","asOf":"2026-09-23","days":5},{"id":"sdc4","kind":"target","name":"SDC4","route":"/targets/sdc4/","asOf":"2026-09-23","days":5},{"id":"tubb3","kind":"target","name":"TUBB3","route":"/targets/tubb3/","asOf":"2026-09-23","days":5},{"id":"pola2","kind":"target","name":"POLA2","route":"/targets/pola2/","asOf":"2026-09-23","days":5},{"id":"prim2","kind":"target","name":"PRIM2","route":"/targets/prim2/","asOf":"2026-09-23","days":5},{"id":"psma4","kind":"target","name":"PSMA4","route":"/targets/psma4/","asOf":"2026-09-23","days":5},{"id":"pde3a","kind":"target","name":"PDE3A","route":"/targets/pde3a/","asOf":"2026-09-23","days":5},{"id":"pold3","kind":"target","name":"POLD3","route":"/targets/pold3/","asOf":"2026-09-23","days":5},{"id":"tuba1c","kind":"target","name":"TUBA1C","route":"/targets/tuba1c/","asOf":"2026-09-23","days":5},{"id":"epha3","kind":"target","name":"EPHA3","route":"/targets/epha3/","asOf":"2026-09-23","days":5},{"id":"epha7","kind":"target","name":"EPHA7","route":"/targets/epha7/","asOf":"2026-09-23","days":5},{"id":"hdac4","kind":"target","name":"HDAC4","route":"/targets/hdac4/","asOf":"2026-09-23","days":5},{"id":"top2b","kind":"target","name":"TOP2B","route":"/targets/top2b/","asOf":"2026-09-23","days":5},{"id":"blk","kind":"target","name":"BLK","route":"/targets/blk/","asOf":"2026-09-23","days":5},{"id":"fgf7","kind":"target","name":"FGF7","route":"/targets/fgf7/","asOf":"2026-09-23","days":5},{"id":"prkcb","kind":"target","name":"PRKCB","route":"/targets/prkcb/","asOf":"2026-09-23","days":5},{"id":"psmd7","kind":"target","name":"PSMD7","route":"/targets/psmd7/","asOf":"2026-09-23","days":5},{"id":"prkd1","kind":"target","name":"PRKD1","route":"/targets/prkd1/","asOf":"2026-09-23","days":5},{"id":"hdac9","kind":"target","name":"HDAC9","route":"/targets/hdac9/","asOf":"2026-09-23","days":5},{"id":"itk","kind":"target","name":"ITK","route":"/targets/itk/","asOf":"2026-09-23","days":5},{"id":"psmb7","kind":"target","name":"PSMB7","route":"/targets/psmb7/","asOf":"2026-09-23","days":5},{"id":"prkci","kind":"target","name":"PRKCI","route":"/targets/prkci/","asOf":"2026-09-23","days":5},{"id":"tymp","kind":"target","name":"TYMP","route":"/targets/tymp/","asOf":"2026-09-23","days":5},{"id":"hdac11","kind":"target","name":"HDAC11","route":"/targets/hdac11/","asOf":"2026-09-23","days":5},{"id":"psmd6","kind":"target","name":"PSMD6","route":"/targets/psmd6/","asOf":"2026-09-23","days":5},{"id":"irak1","kind":"target","name":"IRAK1","route":"/targets/irak1/","asOf":"2026-09-23","days":5},{"id":"psma6","kind":"target","name":"PSMA6","route":"/targets/psma6/","asOf":"2026-09-23","days":5},{"id":"epha4","kind":"target","name":"EPHA4","route":"/targets/epha4/","asOf":"2026-09-23","days":5},{"id":"thrb","kind":"target","name":"THRB","route":"/targets/thrb/","asOf":"2026-09-23","days":5},{"id":"psmd4","kind":"target","name":"PSMD4","route":"/targets/psmd4/","asOf":"2026-09-23","days":5},{"id":"prkce","kind":"target","name":"PRKCE","route":"/targets/prkce/","asOf":"2026-09-23","days":5},{"id":"epha5","kind":"target","name":"EPHA5","route":"/targets/epha5/","asOf":"2026-09-23","days":5},{"id":"arnt","kind":"target","name":"ARNT","route":"/targets/arnt/","asOf":"2026-09-23","days":5},{"id":"adrm1","kind":"target","name":"ADRM1","route":"/targets/adrm1/","asOf":"2026-09-23","days":5},{"id":"tubb4b","kind":"target","name":"TUBB4B","route":"/targets/tubb4b/","asOf":"2026-09-23","days":5},{"id":"ephb1","kind":"target","name":"EPHB1","route":"/targets/ephb1/","asOf":"2026-09-23","days":5},{"id":"tuba3c","kind":"target","name":"TUBA3C","route":"/targets/tuba3c/","asOf":"2026-09-23","days":5},{"id":"psmc1","kind":"target","name":"PSMC1","route":"/targets/psmc1/","asOf":"2026-09-23","days":5},{"id":"psmd11","kind":"target","name":"PSMD11","route":"/targets/psmd11/","asOf":"2026-09-23","days":5},{"id":"pdcd1lg2","kind":"target","name":"PDCD1LG2","route":"/targets/pdcd1lg2/","asOf":"2026-09-23","days":5},{"id":"rrm2","kind":"target","name":"RRM2","route":"/targets/rrm2/","asOf":"2026-09-23","days":5},{"id":"psmb8","kind":"target","name":"PSMB8","route":"/targets/psmb8/","asOf":"2026-09-23","days":5},{"id":"rrm2b","kind":"target","name":"RRM2B","route":"/targets/rrm2b/","asOf":"2026-09-23","days":5},{"id":"tubb2b","kind":"target","name":"TUBB2B","route":"/targets/tubb2b/","asOf":"2026-09-23","days":5},{"id":"prkcz","kind":"target","name":"PRKCZ","route":"/targets/prkcz/","asOf":"2026-09-23","days":5},{"id":"psma2","kind":"target","name":"PSMA2","route":"/targets/psma2/","asOf":"2026-09-23","days":5},{"id":"rarg","kind":"target","name":"RARG","route":"/targets/rarg/","asOf":"2026-09-23","days":5},{"id":"tubb4a","kind":"target","name":"TUBB4A","route":"/targets/tubb4a/","asOf":"2026-09-23","days":5},{"id":"epha6","kind":"target","name":"EPHA6","route":"/targets/epha6/","asOf":"2026-09-23","days":5},{"id":"hdac7","kind":"target","name":"HDAC7","route":"/targets/hdac7/","asOf":"2026-09-23","days":5},{"id":"psmd12","kind":"target","name":"PSMD12","route":"/targets/psmd12/","asOf":"2026-09-23","days":5},{"id":"pole2","kind":"target","name":"POLE2","route":"/targets/pole2/","asOf":"2026-09-23","days":5},{"id":"psma5","kind":"target","name":"PSMA5","route":"/targets/psma5/","asOf":"2026-09-23","days":5},{"id":"psmd14","kind":"target","name":"PSMD14","route":"/targets/psmd14/","asOf":"2026-09-23","days":5},{"id":"tuba1b","kind":"target","name":"TUBA1B","route":"/targets/tuba1b/","asOf":"2026-09-23","days":5},{"id":"psma7","kind":"target","name":"PSMA7","route":"/targets/psma7/","asOf":"2026-09-23","days":5},{"id":"cul4a","kind":"target","name":"CUL4A","route":"/targets/cul4a/","asOf":"2026-09-23","days":5},{"id":"tubb6","kind":"target","name":"TUBB6","route":"/targets/tubb6/","asOf":"2026-09-23","days":5},{"id":"parp2","kind":"target","name":"PARP2","route":"/targets/parp2/","asOf":"2026-09-23","days":5},{"id":"psmc2","kind":"target","name":"PSMC2","route":"/targets/psmc2/","asOf":"2026-09-23","days":5},{"id":"psma3","kind":"target","name":"PSMA3","route":"/targets/psma3/","asOf":"2026-09-23","days":5},{"id":"psmb9","kind":"target","name":"PSMB9","route":"/targets/psmb9/","asOf":"2026-09-23","days":5},{"id":"fgf23","kind":"target","name":"FGF23","route":"/targets/fgf23/","asOf":"2026-09-23","days":5},{"id":"tubb2a","kind":"target","name":"TUBB2A","route":"/targets/tubb2a/","asOf":"2026-09-23","days":5},{"id":"psmb10","kind":"target","name":"PSMB10","route":"/targets/psmb10/","asOf":"2026-09-23","days":5},{"id":"prkch","kind":"target","name":"PRKCH","route":"/targets/prkch/","asOf":"2026-09-23","days":5},{"id":"psmd2","kind":"target","name":"PSMD2","route":"/targets/psmd2/","asOf":"2026-09-23","days":5},{"id":"psmd1","kind":"target","name":"PSMD1","route":"/targets/psmd1/","asOf":"2026-09-23","days":5},{"id":"ddb1","kind":"target","name":"DDB1","route":"/targets/ddb1/","asOf":"2026-09-23","days":5},{"id":"tuba1a","kind":"target","name":"TUBA1A","route":"/targets/tuba1a/","asOf":"2026-09-23","days":5},{"id":"psmd3","kind":"target","name":"PSMD3","route":"/targets/psmd3/","asOf":"2026-09-23","days":5},{"id":"pold4","kind":"target","name":"POLD4","route":"/targets/pold4/","asOf":"2026-09-23","days":5},{"id":"tuba4a","kind":"target","name":"TUBA4A","route":"/targets/tuba4a/","asOf":"2026-09-23","days":5},{"id":"fdps","kind":"target","name":"FDPS","route":"/targets/fdps/","asOf":"2026-09-23","days":5},{"id":"psmb4","kind":"target","name":"PSMB4","route":"/targets/psmb4/","asOf":"2026-09-23","days":5},{"id":"psmc5","kind":"target","name":"PSMC5","route":"/targets/psmc5/","asOf":"2026-09-23","days":5},{"id":"psmd8","kind":"target","name":"PSMD8","route":"/targets/psmd8/","asOf":"2026-09-23","days":5},{"id":"psma1","kind":"target","name":"PSMA1","route":"/targets/psma1/","asOf":"2026-09-23","days":5},{"id":"rarb","kind":"target","name":"RARB","route":"/targets/rarb/","asOf":"2026-09-23","days":5},{"id":"psmb2","kind":"target","name":"PSMB2","route":"/targets/psmb2/","asOf":"2026-09-23","days":5},{"id":"pold2","kind":"target","name":"POLD2","route":"/targets/pold2/","asOf":"2026-09-23","days":5},{"id":"psmd13","kind":"target","name":"PSMD13","route":"/targets/psmd13/","asOf":"2026-09-23","days":5},{"id":"cd3d","kind":"target","name":"CD3D","route":"/targets/cd3d/","asOf":"2026-09-23","days":5},{"id":"pde3b","kind":"target","name":"PDE3B","route":"/targets/pde3b/","asOf":"2026-09-23","days":5},{"id":"psmb6","kind":"target","name":"PSMB6","route":"/targets/psmb6/","asOf":"2026-09-23","days":5},{"id":"psmc4","kind":"target","name":"PSMC4","route":"/targets/psmc4/","asOf":"2026-09-23","days":5},{"id":"parp3","kind":"target","name":"PARP3","route":"/targets/parp3/","asOf":"2026-09-23","days":5},{"id":"ptgs1","kind":"target","name":"PTGS1","route":"/targets/ptgs1/","asOf":"2026-09-23","days":5},{"id":"tubb1","kind":"target","name":"TUBB1","route":"/targets/tubb1/","asOf":"2026-09-23","days":5},{"id":"psmb3","kind":"target","name":"PSMB3","route":"/targets/psmb3/","asOf":"2026-09-23","days":5},{"id":"psmb1","kind":"target","name":"PSMB1","route":"/targets/psmb1/","asOf":"2026-09-23","days":5},{"id":"psma8","kind":"target","name":"PSMA8","route":"/targets/psma8/","asOf":"2026-09-23","days":5},{"id":"ephb4","kind":"target","name":"EPHB4","route":"/targets/ephb4/","asOf":"2026-09-23","days":5},{"id":"il2rg","kind":"target","name":"IL2RG","route":"/targets/il2rg/","asOf":"2026-09-23","days":5},{"id":"psmc6","kind":"target","name":"PSMC6","route":"/targets/psmc6/","asOf":"2026-09-23","days":5},{"id":"psmc3","kind":"target","name":"PSMC3","route":"/targets/psmc3/","asOf":"2026-09-23","days":5},{"id":"psmb11","kind":"target","name":"PSMB11","route":"/targets/psmb11/","asOf":"2026-09-23","days":5},{"id":"il2rb","kind":"target","name":"IL2RB","route":"/targets/il2rb/","asOf":"2026-09-23","days":5},{"id":"scn3a","kind":"target","name":"SCN3A","route":"/targets/scn3a/","asOf":"2026-09-23","days":5},{"id":"tgfb1","kind":"target","name":"TGFB1","route":"/targets/tgfb1/","asOf":"2026-09-23","days":5},{"id":"fgr","kind":"target","name":"FGR","route":"/targets/fgr/","asOf":"2026-09-23","days":5},{"id":"srd5a3","kind":"target","name":"SRD5A3","route":"/targets/srd5a3/","asOf":"2026-09-23","days":5},{"id":"mapk11","kind":"target","name":"MAPK11","route":"/targets/mapk11/","asOf":"2026-09-23","days":5},{"id":"ifnar2","kind":"target","name":"IFNAR2","route":"/targets/ifnar2/","asOf":"2026-09-23","days":5},{"id":"tuba3e","kind":"target","name":"TUBA3E","route":"/targets/tuba3e/","asOf":"2026-09-23","days":5},{"id":"srd5a1","kind":"target","name":"SRD5A1","route":"/targets/srd5a1/","asOf":"2026-09-23","days":5},{"id":"cd3g","kind":"target","name":"CD3G","route":"/targets/cd3g/","asOf":"2026-09-23","days":5},{"id":"pole3","kind":"target","name":"POLE3","route":"/targets/pole3/","asOf":"2026-09-23","days":5},{"id":"tubb8","kind":"target","name":"TUBB8","route":"/targets/tubb8/","asOf":"2026-09-23","days":5},{"id":"hdac5","kind":"target","name":"HDAC5","route":"/targets/hdac5/","asOf":"2026-09-23","days":5},{"id":"hdac8","kind":"target","name":"HDAC8","route":"/targets/hdac8/","asOf":"2026-09-23","days":5},{"id":"hdac10","kind":"target","name":"HDAC10","route":"/targets/hdac10/","asOf":"2026-09-23","days":5},{"id":"prkcq","kind":"target","name":"PRKCQ","route":"/targets/prkcq/","asOf":"2026-09-23","days":5},{"id":"casr","kind":"target","name":"CASR","route":"/targets/casr/","asOf":"2026-09-23","days":5},{"id":"epha1","kind":"target","name":"EPHA1","route":"/targets/epha1/","asOf":"2026-09-23","days":5},{"id":"ephb3","kind":"target","name":"EPHB3","route":"/targets/ephb3/","asOf":"2026-09-23","days":5},{"id":"epha10","kind":"target","name":"EPHA10","route":"/targets/epha10/","asOf":"2026-09-23","days":5},{"id":"ghsr","kind":"target","name":"GHSR","route":"/targets/ghsr/","asOf":"2026-09-23","days":5},{"id":"srms","kind":"target","name":"SRMS","route":"/targets/srms/","asOf":"2026-09-23","days":5},{"id":"kcnq1","kind":"target","name":"KCNQ1","route":"/targets/kcnq1/","asOf":"2026-09-23","days":5},{"id":"prkd3","kind":"target","name":"PRKD3","route":"/targets/prkd3/","asOf":"2026-09-23","days":5},{"id":"prkcg","kind":"target","name":"PRKCG","route":"/targets/prkcg/","asOf":"2026-09-23","days":5},{"id":"impdh1","kind":"target","name":"IMPDH1","route":"/targets/impdh1/","asOf":"2026-09-23","days":5},{"id":"thra","kind":"target","name":"THRA","route":"/targets/thra/","asOf":"2026-09-23","days":5},{"id":"prkcd","kind":"target","name":"PRKCD","route":"/targets/prkcd/","asOf":"2026-09-23","days":5},{"id":"atp4b","kind":"target","name":"ATP4B","route":"/targets/atp4b/","asOf":"2026-09-23","days":5},{"id":"epha8","kind":"target","name":"EPHA8","route":"/targets/epha8/","asOf":"2026-09-23","days":5},{"id":"sstr5","kind":"target","name":"SSTR5","route":"/targets/sstr5/","asOf":"2026-09-23","days":5},{"id":"adra1a","kind":"target","name":"ADRA1A","route":"/targets/adra1a/","asOf":"2026-09-23","days":5},{"id":"atp4a","kind":"target","name":"ATP4A","route":"/targets/atp4a/","asOf":"2026-09-23","days":5},{"id":"sstr1","kind":"target","name":"SSTR1","route":"/targets/sstr1/","asOf":"2026-09-23","days":5},{"id":"ppat","kind":"target","name":"PPAT","route":"/targets/ppat/","asOf":"2026-09-23","days":5},{"id":"kcnb2","kind":"target","name":"KCNB2","route":"/targets/kcnb2/","asOf":"2026-09-23","days":5},{"id":"kcnq5","kind":"target","name":"KCNQ5","route":"/targets/kcnq5/","asOf":"2026-09-23","days":5},{"id":"cacna1h","kind":"target","name":"CACNA1H","route":"/targets/cacna1h/","asOf":"2026-09-23","days":5},{"id":"adra2c","kind":"target","name":"ADRA2C","route":"/targets/adra2c/","asOf":"2026-09-23","days":5},{"id":"tgfb2","kind":"target","name":"TGFB2","route":"/targets/tgfb2/","asOf":"2026-09-23","days":5},{"id":"scn2a","kind":"target","name":"SCN2A","route":"/targets/scn2a/","asOf":"2026-09-23","days":5},{"id":"scn8a","kind":"target","name":"SCN8A","route":"/targets/scn8a/","asOf":"2026-09-23","days":5},{"id":"sstr4","kind":"target","name":"SSTR4","route":"/targets/sstr4/","asOf":"2026-09-23","days":5},{"id":"slc6a3","kind":"target","name":"SLC6A3","route":"/targets/slc6a3/","asOf":"2026-09-23","days":5},{"id":"sstr3","kind":"target","name":"SSTR3","route":"/targets/sstr3/","asOf":"2026-09-23","days":5},{"id":"kcnh8","kind":"target","name":"KCNH8","route":"/targets/kcnh8/","asOf":"2026-09-23","days":5},{"id":"csf2rb","kind":"target","name":"CSF2RB","route":"/targets/csf2rb/","asOf":"2026-09-23","days":5},{"id":"scn4a","kind":"target","name":"SCN4A","route":"/targets/scn4a/","asOf":"2026-09-23","days":5},{"id":"kcnq3","kind":"target","name":"KCNQ3","route":"/targets/kcnq3/","asOf":"2026-09-23","days":5},{"id":"scn5a","kind":"target","name":"SCN5A","route":"/targets/scn5a/","asOf":"2026-09-23","days":5},{"id":"adra1b","kind":"target","name":"ADRA1B","route":"/targets/adra1b/","asOf":"2026-09-23","days":5},{"id":"cacna1g","kind":"target","name":"CACNA1G","route":"/targets/cacna1g/","asOf":"2026-09-23","days":5},{"id":"ednra","kind":"target","name":"EDNRA","route":"/targets/ednra/","asOf":"2026-09-23","days":5},{"id":"scn9a","kind":"target","name":"SCN9A","route":"/targets/scn9a/","asOf":"2026-09-23","days":5},{"id":"kcna3","kind":"target","name":"KCNA3","route":"/targets/kcna3/","asOf":"2026-09-23","days":5},{"id":"scn7a","kind":"target","name":"SCN7A","route":"/targets/scn7a/","asOf":"2026-09-23","days":5},{"id":"scn10a","kind":"target","name":"SCN10A","route":"/targets/scn10a/","asOf":"2026-09-23","days":5},{"id":"scn1a","kind":"target","name":"SCN1A","route":"/targets/scn1a/","asOf":"2026-09-23","days":5},{"id":"kcnd3","kind":"target","name":"KCND3","route":"/targets/kcnd3/","asOf":"2026-09-23","days":5},{"id":"cacna1i","kind":"target","name":"CACNA1I","route":"/targets/cacna1i/","asOf":"2026-09-23","days":5},{"id":"adra1d","kind":"target","name":"ADRA1D","route":"/targets/adra1d/","asOf":"2026-09-23","days":5},{"id":"kcnh1","kind":"target","name":"KCNH1","route":"/targets/kcnh1/","asOf":"2026-09-23","days":5},{"id":"pik3cg","kind":"target","name":"PIK3CG","route":"/targets/pik3cg/","asOf":"2026-09-23","days":5},{"id":"cda","kind":"target","name":"CDA","route":"/targets/cda/","asOf":"2026-09-23","days":5},{"id":"slc6a2","kind":"target","name":"SLC6A2","route":"/targets/slc6a2/","asOf":"2026-09-23","days":5},{"id":"scn11a","kind":"target","name":"SCN11A","route":"/targets/scn11a/","asOf":"2026-09-23","days":5},{"id":"slc6a4","kind":"target","name":"SLC6A4","route":"/targets/slc6a4/","asOf":"2026-09-23","days":5},{"id":"kcnd2","kind":"target","name":"KCND2","route":"/targets/kcnd2/","asOf":"2026-09-23","days":5},{"id":"ifna2","kind":"target","name":"IFNA2","route":"/targets/ifna2/","asOf":"2026-09-23","days":5},{"id":"adra2a","kind":"target","name":"ADRA2A","route":"/targets/adra2a/","asOf":"2026-09-23","days":5},{"id":"cyp11b1","kind":"target","name":"CYP11B1","route":"/targets/cyp11b1/","asOf":"2026-09-23","days":5},{"id":"kcnh7","kind":"target","name":"KCNH7","route":"/targets/kcnh7/","asOf":"2026-09-23","days":5},{"id":"adra2b","kind":"target","name":"ADRA2B","route":"/targets/adra2b/","asOf":"2026-09-23","days":5},{"id":"kcna4","kind":"target","name":"KCNA4","route":"/targets/kcna4/","asOf":"2026-09-23","days":5},{"id":"snap25","kind":"target","name":"SNAP25","route":"/targets/snap25/","asOf":"2026-09-23","days":5},{"id":"kcnf1","kind":"target","name":"KCNF1","route":"/targets/kcnf1/","asOf":"2026-09-23","days":5},{"id":"kcnc2","kind":"target","name":"KCNC2","route":"/targets/kcnc2/","asOf":"2026-09-23","days":5},{"id":"tgfb3","kind":"target","name":"TGFB3","route":"/targets/tgfb3/","asOf":"2026-09-23","days":5},{"id":"ugt1a1","kind":"target","name":"UGT1A1","route":"/targets/ugt1a1/","asOf":"2026-09-23","days":5},{"id":"csf1","kind":"target","name":"CSF1","route":"/targets/csf1/","asOf":"2026-09-23","days":5},{"id":"mcl1","kind":"target","name":"MCL1","route":"/targets/mcl1/","asOf":"2026-09-23","days":5},{"id":"nudt15","kind":"target","name":"NUDT15","route":"/targets/nudt15/","asOf":"2026-09-23","days":5},{"id":"col6a3","kind":"target","name":"COL6A3","route":"/targets/col6a3/","asOf":"2026-09-23","days":5},{"id":"tec","kind":"target","name":"TEC","route":"/targets/tec/","asOf":"2026-09-23","days":5},{"id":"aph1a","kind":"target","name":"APH1A","route":"/targets/aph1a/","asOf":"2026-09-23","days":5},{"id":"aph1b","kind":"target","name":"APH1B","route":"/targets/aph1b/","asOf":"2026-09-23","days":5},{"id":"csnk1e","kind":"target","name":"CSNK1E","route":"/targets/csnk1e/","asOf":"2026-09-23","days":5},{"id":"ncstn","kind":"target","name":"NCSTN","route":"/targets/ncstn/","asOf":"2026-09-23","days":5},{"id":"psen2","kind":"target","name":"PSEN2","route":"/targets/psen2/","asOf":"2026-09-23","days":5},{"id":"psenen","kind":"target","name":"PSENEN","route":"/targets/psenen/","asOf":"2026-09-23","days":5},{"id":"tph2","kind":"target","name":"TPH2","route":"/targets/tph2/","asOf":"2026-09-23","days":5},{"id":"vhl","kind":"target","name":"VHL","route":"/targets/vhl/","asOf":"2026-09-23","days":5},{"id":"atm","kind":"target","name":"ATM","route":"/targets/atm/","asOf":"2026-09-23","days":5},{"id":"cdkn2a","kind":"target","name":"CDKN2A","route":"/targets/cdkn2a/","asOf":"2026-09-23","days":5},{"id":"notch1","kind":"target","name":"NOTCH1","route":"/targets/notch1/","asOf":"2026-09-23","days":5},{"id":"smad4","kind":"target","name":"SMAD4","route":"/targets/smad4/","asOf":"2026-09-23","days":5},{"id":"mlh1","kind":"target","name":"MLH1","route":"/targets/mlh1/","asOf":"2026-09-23","days":5},{"id":"dicer1","kind":"target","name":"DICER1","route":"/targets/dicer1/","asOf":"2026-09-23","days":5},{"id":"rb1","kind":"target","name":"RB1","route":"/targets/rb1/","asOf":"2026-09-23","days":5},{"id":"hras","kind":"target","name":"HRAS","route":"/targets/hras/","asOf":"2026-09-23","days":5},{"id":"smarcb1","kind":"target","name":"SMARCB1","route":"/targets/smarcb1/","asOf":"2026-09-23","days":5},{"id":"smarca4","kind":"target","name":"SMARCA4","route":"/targets/smarca4/","asOf":"2026-09-23","days":5},{"id":"stk11","kind":"target","name":"STK11","route":"/targets/stk11/","asOf":"2026-09-23","days":5},{"id":"bap1","kind":"target","name":"BAP1","route":"/targets/bap1/","asOf":"2026-09-23","days":5},{"id":"arid1a","kind":"target","name":"ARID1A","route":"/targets/arid1a/","asOf":"2026-09-23","days":5},{"id":"ercc2","kind":"target","name":"ERCC2","route":"/targets/ercc2/","asOf":"2026-09-23","days":5},{"id":"kmt2d","kind":"target","name":"KMT2D","route":"/targets/kmt2d/","asOf":"2026-09-23","days":5},{"id":"runx1","kind":"target","name":"RUNX1","route":"/targets/runx1/","asOf":"2026-09-23","days":5},{"id":"palb2","kind":"target","name":"PALB2","route":"/targets/palb2/","asOf":"2026-09-23","days":5},{"id":"wt1","kind":"target","name":"WT1","route":"/targets/wt1/","asOf":"2026-09-23","days":5},{"id":"cebpa","kind":"target","name":"CEBPA","route":"/targets/cebpa/","asOf":"2026-09-23","days":5},{"id":"fbxw7","kind":"target","name":"FBXW7","route":"/targets/fbxw7/","asOf":"2026-09-23","days":5},{"id":"msh2","kind":"target","name":"MSH2","route":"/targets/msh2/","asOf":"2026-09-23","days":5},{"id":"chek2","kind":"target","name":"CHEK2","route":"/targets/chek2/","asOf":"2026-09-23","days":5},{"id":"msh6","kind":"target","name":"MSH6","route":"/targets/msh6/","asOf":"2026-09-23","days":5},{"id":"cdh1","kind":"target","name":"CDH1","route":"/targets/cdh1/","asOf":"2026-09-23","days":5},{"id":"bcor","kind":"target","name":"BCOR","route":"/targets/bcor/","asOf":"2026-09-23","days":5},{"id":"atrx","kind":"target","name":"ATRX","route":"/targets/atrx/","asOf":"2026-09-23","days":5},{"id":"gnas","kind":"target","name":"GNAS","route":"/targets/gnas/","asOf":"2026-09-23","days":5},{"id":"sf3b1","kind":"target","name":"SF3B1","route":"/targets/sf3b1/","asOf":"2026-09-23","days":5},{"id":"asxl1","kind":"target","name":"ASXL1","route":"/targets/asxl1/","asOf":"2026-09-23","days":5},{"id":"etv6","kind":"target","name":"ETV6","route":"/targets/etv6/","asOf":"2026-09-23","days":5},{"id":"cbl","kind":"target","name":"CBL","route":"/targets/cbl/","asOf":"2026-09-23","days":5},{"id":"pik3r1","kind":"target","name":"PIK3R1","route":"/targets/pik3r1/","asOf":"2026-09-23","days":5},{"id":"kmt2c","kind":"target","name":"KMT2C","route":"/targets/kmt2c/","asOf":"2026-09-23","days":5},{"id":"kdm6a","kind":"target","name":"KDM6A","route":"/targets/kdm6a/","asOf":"2026-09-23","days":5},{"id":"pbrm1","kind":"target","name":"PBRM1","route":"/targets/pbrm1/","asOf":"2026-09-23","days":5},{"id":"pms2","kind":"target","name":"PMS2","route":"/targets/pms2/","asOf":"2026-09-23","days":5},{"id":"crebbp","kind":"target","name":"CREBBP","route":"/targets/crebbp/","asOf":"2026-09-23","days":5},{"id":"nfe2l2","kind":"target","name":"NFE2L2","route":"/targets/nfe2l2/","asOf":"2026-09-23","days":5},{"id":"ep300","kind":"target","name":"EP300","route":"/targets/ep300/","asOf":"2026-09-23","days":5},{"id":"cdk12","kind":"target","name":"CDK12","route":"/targets/cdk12/","asOf":"2026-09-23","days":5},{"id":"ccne1","kind":"target","name":"CCNE1","route":"/targets/ccne1/","asOf":"2026-09-23","days":5},{"id":"bard1","kind":"target","name":"BARD1","route":"/targets/bard1/","asOf":"2026-09-23","days":5},{"id":"brip1","kind":"target","name":"BRIP1","route":"/targets/brip1/","asOf":"2026-09-23","days":5},{"id":"rad51c","kind":"target","name":"RAD51C","route":"/targets/rad51c/","asOf":"2026-09-23","days":5},{"id":"ddx41","kind":"target","name":"DDX41","route":"/targets/ddx41/","asOf":"2026-09-23","days":5},{"id":"lrp1b","kind":"target","name":"LRP1B","route":"/targets/lrp1b/","asOf":"2026-09-23","days":5},{"id":"rad51d","kind":"target","name":"RAD51D","route":"/targets/rad51d/","asOf":"2026-09-23","days":5},{"id":"mapk1","kind":"target","name":"MAPK1","route":"/targets/mapk1/","asOf":"2026-09-23","days":5},{"id":"flcn","kind":"target","name":"FLCN","route":"/targets/flcn/","asOf":"2026-09-23","days":5},{"id":"nbn","kind":"target","name":"NBN","route":"/targets/nbn/","asOf":"2026-09-23","days":5},{"id":"srsf2","kind":"target","name":"SRSF2","route":"/targets/srsf2/","asOf":"2026-09-23","days":5},{"id":"spop","kind":"target","name":"SPOP","route":"/targets/spop/","asOf":"2026-09-23","days":5},{"id":"u2af1","kind":"target","name":"U2AF1","route":"/targets/u2af1/","asOf":"2026-09-23","days":5},{"id":"myc-gene","kind":"target","name":"MYC","route":"/targets/myc-gene/","asOf":"2026-09-23","days":5},{"id":"setbp1","kind":"target","name":"SETBP1","route":"/targets/setbp1/","asOf":"2026-09-23","days":5},{"id":"gata2","kind":"target","name":"GATA2","route":"/targets/gata2/","asOf":"2026-09-23","days":5},{"id":"map3k1","kind":"target","name":"MAP3K1","route":"/targets/map3k1/","asOf":"2026-09-23","days":5},{"id":"casp8","kind":"target","name":"CASP8","route":"/targets/casp8/","asOf":"2026-09-23","days":5},{"id":"gnaq","kind":"target","name":"GNAQ","route":"/targets/gnaq/","asOf":"2026-09-23","days":5},{"id":"sdha","kind":"target","name":"SDHA","route":"/targets/sdha/","asOf":"2026-09-23","days":5},{"id":"fbxo11","kind":"target","name":"FBXO11","route":"/targets/fbxo11/","asOf":"2026-09-23","days":5},{"id":"cdkn1b","kind":"target","name":"CDKN1B","route":"/targets/cdkn1b/","asOf":"2026-09-23","days":5},{"id":"pik3cb","kind":"target","name":"PIK3CB","route":"/targets/pik3cb/","asOf":"2026-09-23","days":5},{"id":"nf2","kind":"target","name":"NF2","route":"/targets/nf2/","asOf":"2026-09-23","days":5},{"id":"fat1","kind":"target","name":"FAT1","route":"/targets/fat1/","asOf":"2026-09-23","days":5},{"id":"ppp2r1a","kind":"target","name":"PPP2R1A","route":"/targets/ppp2r1a/","asOf":"2026-09-23","days":5},{"id":"smad3","kind":"target","name":"SMAD3","route":"/targets/smad3/","asOf":"2026-09-23","days":5},{"id":"ccnd2","kind":"target","name":"CCND2","route":"/targets/ccnd2/","asOf":"2026-09-23","days":5},{"id":"keap1","kind":"target","name":"KEAP1","route":"/targets/keap1/","asOf":"2026-09-23","days":5},{"id":"stag2","kind":"target","name":"STAG2","route":"/targets/stag2/","asOf":"2026-09-23","days":5},{"id":"sh2b3","kind":"target","name":"SH2B3","route":"/targets/sh2b3/","asOf":"2026-09-23","days":5},{"id":"rad50","kind":"target","name":"RAD50","route":"/targets/rad50/","asOf":"2026-09-23","days":5},{"id":"axin2","kind":"target","name":"AXIN2","route":"/targets/axin2/","asOf":"2026-09-23","days":5},{"id":"prkar1a","kind":"target","name":"PRKAR1A","route":"/targets/prkar1a/","asOf":"2026-09-23","days":5},{"id":"notch2","kind":"target","name":"NOTCH2","route":"/targets/notch2/","asOf":"2026-09-23","days":5},{"id":"rad51b","kind":"target","name":"RAD51B","route":"/targets/rad51b/","asOf":"2026-09-23","days":5},{"id":"rac1","kind":"target","name":"RAC1","route":"/targets/rac1/","asOf":"2026-09-23","days":5},{"id":"gna11","kind":"target","name":"GNA11","route":"/targets/gna11/","asOf":"2026-09-23","days":5},{"id":"foxa1","kind":"target","name":"FOXA1","route":"/targets/foxa1/","asOf":"2026-09-23","days":5},{"id":"sos1","kind":"target","name":"SOS1","route":"/targets/sos1/","asOf":"2026-09-23","days":5},{"id":"pot1","kind":"target","name":"POT1","route":"/targets/pot1/","asOf":"2026-09-23","days":5},{"id":"gata1","kind":"target","name":"GATA1","route":"/targets/gata1/","asOf":"2026-09-23","days":5},{"id":"mitf","kind":"target","name":"MITF","route":"/targets/mitf/","asOf":"2026-09-23","days":5},{"id":"fancc","kind":"target","name":"FANCC","route":"/targets/fancc/","asOf":"2026-09-23","days":5},{"id":"mecom","kind":"target","name":"MECOM","route":"/targets/mecom/","asOf":"2026-09-23","days":5},{"id":"fanca","kind":"target","name":"FANCA","route":"/targets/fanca/","asOf":"2026-09-23","days":5},{"id":"h3c2","kind":"target","name":"H3C2","route":"/targets/h3c2/","asOf":"2026-09-23","days":5},{"id":"plcg1","kind":"target","name":"PLCG1","route":"/targets/plcg1/","asOf":"2026-09-23","days":5},{"id":"arhgap35","kind":"target","name":"ARHGAP35","route":"/targets/arhgap35/","asOf":"2026-09-23","days":5},{"id":"arid2","kind":"target","name":"ARID2","route":"/targets/arid2/","asOf":"2026-09-23","days":5},{"id":"map2k4","kind":"target","name":"MAP2K4","route":"/targets/map2k4/","asOf":"2026-09-23","days":5},{"id":"stat3","kind":"target","name":"STAT3","route":"/targets/stat3/","asOf":"2026-09-23","days":5},{"id":"lztr1","kind":"target","name":"LZTR1","route":"/targets/lztr1/","asOf":"2026-09-23","days":5},{"id":"ercc4","kind":"target","name":"ERCC4","route":"/targets/ercc4/","asOf":"2026-09-23","days":5},{"id":"ctcf","kind":"target","name":"CTCF","route":"/targets/ctcf/","asOf":"2026-09-23","days":5},{"id":"myod1","kind":"target","name":"MYOD1","route":"/targets/myod1/","asOf":"2026-09-23","days":5},{"id":"rhoa","kind":"target","name":"RHOA","route":"/targets/rhoa/","asOf":"2026-09-23","days":5},{"id":"arid1b","kind":"target","name":"ARID1B","route":"/targets/arid1b/","asOf":"2026-09-23","days":5},{"id":"gata3","kind":"target","name":"GATA3","route":"/targets/gata3/","asOf":"2026-09-23","days":5},{"id":"nt5c2","kind":"target","name":"NT5C2","route":"/targets/nt5c2/","asOf":"2026-09-23","days":5},{"id":"drosha","kind":"target","name":"DROSHA","route":"/targets/drosha/","asOf":"2026-09-23","days":5},{"id":"pparg","kind":"target","name":"PPARG","route":"/targets/pparg/","asOf":"2026-09-23","days":5},{"id":"hgf","kind":"target","name":"HGF","route":"/targets/hgf/","asOf":"2026-09-23","days":5},{"id":"bcl11a","kind":"target","name":"BCL11A","route":"/targets/bcl11a/","asOf":"2026-09-23","days":5},{"id":"rasa1","kind":"target","name":"RASA1","route":"/targets/rasa1/","asOf":"2026-09-23","days":5},{"id":"hoxb13","kind":"target","name":"HOXB13","route":"/targets/hoxb13/","asOf":"2026-09-23","days":5},{"id":"fh","kind":"target","name":"FH","route":"/targets/fh/","asOf":"2026-09-23","days":5},{"id":"b2m","kind":"target","name":"B2M","route":"/targets/b2m/","asOf":"2026-09-23","days":5},{"id":"kdm5c","kind":"target","name":"KDM5C","route":"/targets/kdm5c/","asOf":"2026-09-23","days":5},{"id":"cic","kind":"target","name":"CIC","route":"/targets/cic/","asOf":"2026-09-23","days":5},{"id":"mdm4","kind":"target","name":"MDM4","route":"/targets/mdm4/","asOf":"2026-09-23","days":5},{"id":"cdkn1a","kind":"target","name":"CDKN1A","route":"/targets/cdkn1a/","asOf":"2026-09-23","days":5},{"id":"mbd4","kind":"target","name":"MBD4","route":"/targets/mbd4/","asOf":"2026-09-23","days":5},{"id":"fhit","kind":"target","name":"FHIT","route":"/targets/fhit/","asOf":"2026-09-23","days":5},{"id":"foxp1","kind":"target","name":"FOXP1","route":"/targets/foxp1/","asOf":"2026-09-23","days":5},{"id":"rras2","kind":"target","name":"RRAS2","route":"/targets/rras2/","asOf":"2026-09-23","days":5},{"id":"araf","kind":"target","name":"ARAF","route":"/targets/araf/","asOf":"2026-09-23","days":5},{"id":"etv1","kind":"target","name":"ETV1","route":"/targets/etv1/","asOf":"2026-09-23","days":5},{"id":"rpl5","kind":"target","name":"RPL5","route":"/targets/rpl5/","asOf":"2026-09-23","days":5},{"id":"pax5","kind":"target","name":"PAX5","route":"/targets/pax5/","asOf":"2026-09-23","days":5},{"id":"spen","kind":"target","name":"SPEN","route":"/targets/spen/","asOf":"2026-09-23","days":5},{"id":"grin2a","kind":"target","name":"GRIN2A","route":"/targets/grin2a/","asOf":"2026-09-23","days":5},{"id":"ptprb","kind":"target","name":"PTPRB","route":"/targets/ptprb/","asOf":"2026-09-23","days":5},{"id":"jun","kind":"target","name":"JUN","route":"/targets/jun/","asOf":"2026-09-23","days":5},{"id":"ebf1","kind":"target","name":"EBF1","route":"/targets/ebf1/","asOf":"2026-09-23","days":5},{"id":"myb","kind":"target","name":"MYB","route":"/targets/myb/","asOf":"2026-09-23","days":5},{"id":"pim1","kind":"target","name":"PIM1","route":"/targets/pim1/","asOf":"2026-09-23","days":5},{"id":"ercc5","kind":"target","name":"ERCC5","route":"/targets/ercc5/","asOf":"2026-09-23","days":5},{"id":"prex2","kind":"target","name":"PREX2","route":"/targets/prex2/","asOf":"2026-09-23","days":5},{"id":"pdgfb","kind":"target","name":"PDGFB","route":"/targets/pdgfb/","asOf":"2026-09-23","days":5},{"id":"cdkn2b","kind":"target","name":"CDKN2B","route":"/targets/cdkn2b/","asOf":"2026-09-23","days":5},{"id":"hsp90aa1","kind":"target","name":"HSP90AA1","route":"/targets/hsp90aa1/","asOf":"2026-09-23","days":5},{"id":"mn1","kind":"target","name":"MN1","route":"/targets/mn1/","asOf":"2026-09-23","days":5},{"id":"cacna1d","kind":"target","name":"CACNA1D","route":"/targets/cacna1d/","asOf":"2026-09-23","days":5},{"id":"ptprt","kind":"target","name":"PTPRT","route":"/targets/ptprt/","asOf":"2026-09-23","days":5},{"id":"pik3r2","kind":"target","name":"PIK3R2","route":"/targets/pik3r2/","asOf":"2026-09-23","days":5},{"id":"nr4a3","kind":"target","name":"NR4A3","route":"/targets/nr4a3/","asOf":"2026-09-23","days":5},{"id":"fubp1","kind":"target","name":"FUBP1","route":"/targets/fubp1/","asOf":"2026-09-23","days":5},{"id":"foxo1","kind":"target","name":"FOXO1","route":"/targets/foxo1/","asOf":"2026-09-23","days":5},{"id":"sdhb","kind":"target","name":"SDHB","route":"/targets/sdhb/","asOf":"2026-09-23","days":5},{"id":"il7r","kind":"target","name":"IL7R","route":"/targets/il7r/","asOf":"2026-09-23","days":5},{"id":"erg","kind":"target","name":"ERG","route":"/targets/erg/","asOf":"2026-09-23","days":5},{"id":"ercc3","kind":"target","name":"ERCC3","route":"/targets/ercc3/","asOf":"2026-09-23","days":5},{"id":"fgf2","kind":"target","name":"FGF2","route":"/targets/fgf2/","asOf":"2026-09-23","days":5},{"id":"msh3","kind":"target","name":"MSH3","route":"/targets/msh3/","asOf":"2026-09-23","days":5},{"id":"sufu","kind":"target","name":"SUFU","route":"/targets/sufu/","asOf":"2026-09-23","days":5},{"id":"pax8","kind":"target","name":"PAX8","route":"/targets/pax8/","asOf":"2026-09-23","days":5},{"id":"h3-3b","kind":"target","name":"H3-3B","route":"/targets/h3-3b/","asOf":"2026-09-23","days":5},{"id":"prdm1","kind":"target","name":"PRDM1","route":"/targets/prdm1/","asOf":"2026-09-23","days":5},{"id":"ubr5","kind":"target","name":"UBR5","route":"/targets/ubr5/","asOf":"2026-09-23","days":5},{"id":"klf5","kind":"target","name":"KLF5","route":"/targets/klf5/","asOf":"2026-09-23","days":5},{"id":"slc34a2","kind":"target","name":"SLC34A2","route":"/targets/slc34a2/","asOf":"2026-09-23","days":5},{"id":"ddx3x","kind":"target","name":"DDX3X","route":"/targets/ddx3x/","asOf":"2026-09-23","days":5},{"id":"fgf1","kind":"target","name":"FGF1","route":"/targets/fgf1/","asOf":"2026-09-23","days":5},{"id":"klf4","kind":"target","name":"KLF4","route":"/targets/klf4/","asOf":"2026-09-23","days":5},{"id":"card11","kind":"target","name":"CARD11","route":"/targets/card11/","asOf":"2026-09-23","days":5},{"id":"tet1","kind":"target","name":"TET1","route":"/targets/tet1/","asOf":"2026-09-23","days":5},{"id":"cblb","kind":"target","name":"CBLB","route":"/targets/cblb/","asOf":"2026-09-23","days":5},{"id":"ccnd3","kind":"target","name":"CCND3","route":"/targets/ccnd3/","asOf":"2026-09-23","days":5},{"id":"ikbkb","kind":"target","name":"IKBKB","route":"/targets/ikbkb/","asOf":"2026-09-23","days":5},{"id":"fgf4","kind":"target","name":"FGF4","route":"/targets/fgf4/","asOf":"2026-09-23","days":5},{"id":"tbl1xr1","kind":"target","name":"TBL1XR1","route":"/targets/tbl1xr1/","asOf":"2026-09-23","days":5},{"id":"bcl10","kind":"target","name":"BCL10","route":"/targets/bcl10/","asOf":"2026-09-23","days":5},{"id":"rictor","kind":"target","name":"RICTOR","route":"/targets/rictor/","asOf":"2026-09-23","days":5},{"id":"abl2","kind":"target","name":"ABL2","route":"/targets/abl2/","asOf":"2026-09-23","days":5},{"id":"mre11","kind":"target","name":"MRE11","route":"/targets/mre11/","asOf":"2026-09-23","days":5},{"id":"fgf3","kind":"target","name":"FGF3","route":"/targets/fgf3/","asOf":"2026-09-23","days":5},{"id":"etv5","kind":"target","name":"ETV5","route":"/targets/etv5/","asOf":"2026-09-23","days":5},{"id":"grb2","kind":"target","name":"GRB2","route":"/targets/grb2/","asOf":"2026-09-23","days":5},{"id":"etv4","kind":"target","name":"ETV4","route":"/targets/etv4/","asOf":"2026-09-23","days":5},{"id":"itgb3","kind":"target","name":"ITGB3","route":"/targets/itgb3/","asOf":"2026-09-23","days":5},{"id":"yap1","kind":"target","name":"YAP1","route":"/targets/yap1/","asOf":"2026-09-23","days":5},{"id":"fgg","kind":"target","name":"FGG","route":"/targets/fgg/","asOf":"2026-09-23","days":5},{"id":"tfeb","kind":"target","name":"TFEB","route":"/targets/tfeb/","asOf":"2026-09-23","days":5},{"id":"prkn","kind":"target","name":"PRKN","route":"/targets/prkn/","asOf":"2026-09-23","days":5},{"id":"crlf2","kind":"target","name":"CRLF2","route":"/targets/crlf2/","asOf":"2026-09-23","days":5},{"id":"fcgr2b","kind":"target","name":"FCGR2B","route":"/targets/fcgr2b/","asOf":"2026-09-23","days":5},{"id":"klk3","kind":"target","name":"KLK3","route":"/targets/klk3/","asOf":"2026-09-23","days":5},{"id":"fn1","kind":"target","name":"FN1","route":"/targets/fn1/","asOf":"2026-09-23","days":5},{"id":"atp1a1","kind":"target","name":"ATP1A1","route":"/targets/atp1a1/","asOf":"2026-09-23","days":5},{"id":"cdx2","kind":"target","name":"CDX2","route":"/targets/cdx2/","asOf":"2026-09-23","days":5},{"id":"ereg","kind":"target","name":"EREG","route":"/targets/ereg/","asOf":"2026-09-23","days":5},{"id":"gsk3b","kind":"target","name":"GSK3B","route":"/targets/gsk3b/","asOf":"2026-09-23","days":5},{"id":"fga","kind":"target","name":"FGA","route":"/targets/fga/","asOf":"2026-09-23","days":5},{"id":"myd88","kind":"target","name":"MYD88","route":"/targets/myd88/","asOf":"2026-09-23","days":5},{"id":"birc6","kind":"target","name":"BIRC6","route":"/targets/birc6/","asOf":"2026-09-23","days":5},{"id":"btg1","kind":"target","name":"BTG1","route":"/targets/btg1/","asOf":"2026-09-23","days":5},{"id":"fgb","kind":"target","name":"FGB","route":"/targets/fgb/","asOf":"2026-09-23","days":5},{"id":"mycl","kind":"target","name":"MYCL","route":"/targets/mycl/","asOf":"2026-09-23","days":5},{"id":"egf","kind":"target","name":"EGF","route":"/targets/egf/","asOf":"2026-09-23","days":5},{"id":"nsd2","kind":"target","name":"NSD2","route":"/targets/nsd2/","asOf":"2026-09-23","days":5},{"id":"tcf3","kind":"target","name":"TCF3","route":"/targets/tcf3/","asOf":"2026-09-23","days":5},{"id":"ciita","kind":"target","name":"CIITA","route":"/targets/ciita/","asOf":"2026-09-23","days":5},{"id":"birc3","kind":"target","name":"BIRC3","route":"/targets/birc3/","asOf":"2026-09-23","days":5},{"id":"bcl6","kind":"target","name":"BCL6","route":"/targets/bcl6/","asOf":"2026-09-23","days":5},{"id":"rpl10","kind":"target","name":"RPL10","route":"/targets/rpl10/","asOf":"2026-09-23","days":5},{"id":"nfkbie","kind":"target","name":"NFKBIE","route":"/targets/nfkbie/","asOf":"2026-09-23","days":5},{"id":"atg7","kind":"target","name":"ATG7","route":"/targets/atg7/","asOf":"2026-09-23","days":5},{"id":"rpl22","kind":"target","name":"RPL22","route":"/targets/rpl22/","asOf":"2026-09-23","days":5},{"id":"pou5f1","kind":"target","name":"POU5F1","route":"/targets/pou5f1/","asOf":"2026-09-23","days":5},{"id":"rspo3","kind":"target","name":"RSPO3","route":"/targets/rspo3/","asOf":"2026-09-23","days":5},{"id":"zrsr2","kind":"target","name":"ZRSR2","route":"/targets/zrsr2/","asOf":"2026-09-23","days":5},{"id":"tgfbr1","kind":"target","name":"TGFBR1","route":"/targets/tgfbr1/","asOf":"2026-09-23","days":5},{"id":"rps27a","kind":"target","name":"RPS27A","route":"/targets/rps27a/","asOf":"2026-09-23","days":5},{"id":"tnfrsf10b","kind":"target","name":"TNFRSF10B","route":"/targets/tnfrsf10b/","asOf":"2026-09-23","days":5},{"id":"mapk3","kind":"target","name":"MAPK3","route":"/targets/mapk3/","asOf":"2026-09-23","days":5},{"id":"pcbp1","kind":"target","name":"PCBP1","route":"/targets/pcbp1/","asOf":"2026-09-23","days":5},{"id":"fas","kind":"target","name":"FAS","route":"/targets/fas/","asOf":"2026-09-23","days":5},{"id":"tnfaip3","kind":"target","name":"TNFAIP3","route":"/targets/tnfaip3/","asOf":"2026-09-23","days":5},{"id":"pik3r3","kind":"target","name":"PIK3R3","route":"/targets/pik3r3/","asOf":"2026-09-23","days":5},{"id":"fto","kind":"target","name":"FTO","route":"/targets/fto/","asOf":"2026-09-23","days":5},{"id":"actb","kind":"target","name":"ACTB","route":"/targets/actb/","asOf":"2026-09-23","days":5},{"id":"rel","kind":"target","name":"REL","route":"/targets/rel/","asOf":"2026-09-23","days":5},{"id":"ercc6","kind":"target","name":"ERCC6","route":"/targets/ercc6/","asOf":"2026-09-23","days":5},{"id":"tnfrsf14","kind":"target","name":"TNFRSF14","route":"/targets/tnfrsf14/","asOf":"2026-09-23","days":5},{"id":"ppp2ca","kind":"target","name":"PPP2CA","route":"/targets/ppp2ca/","asOf":"2026-09-23","days":5},{"id":"p2ry8","kind":"target","name":"P2RY8","route":"/targets/p2ry8/","asOf":"2026-09-23","days":5},{"id":"hbegf","kind":"target","name":"HBEGF","route":"/targets/hbegf/","asOf":"2026-09-23","days":5},{"id":"rabl3","kind":"target","name":"RABL3","route":"/targets/rabl3/","asOf":"2026-09-23","days":5},{"id":"icos","kind":"target","name":"ICOS","route":"/targets/icos/","asOf":"2026-09-23","days":5},{"id":"bach2","kind":"target","name":"BACH2","route":"/targets/bach2/","asOf":"2026-09-23","days":5},{"id":"dcc","kind":"target","name":"DCC","route":"/targets/dcc/","asOf":"2026-09-23","days":5},{"id":"pou2af1","kind":"target","name":"POU2AF1","route":"/targets/pou2af1/","asOf":"2026-09-23","days":5},{"id":"stat6","kind":"target","name":"STAT6","route":"/targets/stat6/","asOf":"2026-09-23","days":5},{"id":"dll4","kind":"target","name":"DLL4","route":"/targets/dll4/","asOf":"2026-09-23","days":5},{"id":"eif1ax","kind":"target","name":"EIF1AX","route":"/targets/eif1ax/","asOf":"2026-09-23","days":5},{"id":"pdpk1","kind":"target","name":"PDPK1","route":"/targets/pdpk1/","asOf":"2026-09-23","days":5},{"id":"stat1","kind":"target","name":"STAT1","route":"/targets/stat1/","asOf":"2026-09-23","days":5},{"id":"ndufa13","kind":"target","name":"NDUFA13","route":"/targets/ndufa13/","asOf":"2026-09-23","days":5},{"id":"irs2","kind":"target","name":"IRS2","route":"/targets/irs2/","asOf":"2026-09-23","days":5},{"id":"mapk8","kind":"target","name":"MAPK8","route":"/targets/mapk8/","asOf":"2026-09-23","days":5},{"id":"aldh2","kind":"target","name":"ALDH2","route":"/targets/aldh2/","asOf":"2026-09-23","days":5},{"id":"mapk9","kind":"target","name":"MAPK9","route":"/targets/mapk9/","asOf":"2026-09-23","days":5},{"id":"mmp7","kind":"target","name":"MMP7","route":"/targets/mmp7/","asOf":"2026-09-23","days":5},{"id":"znf217","kind":"target","name":"ZNF217","route":"/targets/znf217/","asOf":"2026-09-23","days":5},{"id":"areg","kind":"target","name":"AREG","route":"/targets/areg/","asOf":"2026-09-23","days":5},{"id":"ppp2cb","kind":"target","name":"PPP2CB","route":"/targets/ppp2cb/","asOf":"2026-09-23","days":5},{"id":"rad54l","kind":"target","name":"RAD54L","route":"/targets/rad54l/","asOf":"2026-09-23","days":5},{"id":"fancl","kind":"target","name":"FANCL","route":"/targets/fancl/","asOf":"2026-09-23","days":5},{"id":"cul3","kind":"target","name":"CUL3","route":"/targets/cul3/","asOf":"2026-09-23","days":5},{"id":"nox4","kind":"target","name":"NOX4","route":"/targets/nox4/","asOf":"2026-09-23","days":5},{"id":"psca","kind":"target","name":"PSCA","route":"/targets/psca/","asOf":"2026-09-23","days":5},{"id":"flt3lg","kind":"target","name":"FLT3LG","route":"/targets/flt3lg/","asOf":"2026-09-23","days":5},{"id":"rfx7","kind":"target","name":"RFX7","route":"/targets/rfx7/","asOf":"2026-09-23","days":5},{"id":"chrna4","kind":"target","name":"CHRNA4","route":"/targets/chrna4/","asOf":"2026-09-23","days":5},{"id":"abcc1","kind":"target","name":"ABCC1","route":"/targets/abcc1/","asOf":"2026-09-23","days":5},{"id":"klf2","kind":"target","name":"KLF2","route":"/targets/klf2/","asOf":"2026-09-23","days":5},{"id":"hla-b","kind":"target","name":"HLA-B","route":"/targets/hla-b/","asOf":"2026-09-23","days":5},{"id":"xrcc1","kind":"target","name":"XRCC1","route":"/targets/xrcc1/","asOf":"2026-09-23","days":5},{"id":"rps24","kind":"target","name":"RPS24","route":"/targets/rps24/","asOf":"2026-09-23","days":5},{"id":"zfp36l1","kind":"target","name":"ZFP36L1","route":"/targets/zfp36l1/","asOf":"2026-09-23","days":5},{"id":"rps29","kind":"target","name":"RPS29","route":"/targets/rps29/","asOf":"2026-09-23","days":5},{"id":"mmp2","kind":"target","name":"MMP2","route":"/targets/mmp2/","asOf":"2026-09-23","days":5},{"id":"rps26","kind":"target","name":"RPS26","route":"/targets/rps26/","asOf":"2026-09-23","days":5},{"id":"mt-nd6","kind":"target","name":"MT-ND6","route":"/targets/mt-nd6/","asOf":"2026-09-23","days":5},{"id":"vdr","kind":"target","name":"VDR","route":"/targets/vdr/","asOf":"2026-09-23","days":5},{"id":"tgfa","kind":"target","name":"TGFA","route":"/targets/tgfa/","asOf":"2026-09-23","days":5},{"id":"angpt1","kind":"target","name":"ANGPT1","route":"/targets/angpt1/","asOf":"2026-09-23","days":5},{"id":"pik3r5","kind":"target","name":"PIK3R5","route":"/targets/pik3r5/","asOf":"2026-09-23","days":5},{"id":"hmgcr","kind":"target","name":"HMGCR","route":"/targets/hmgcr/","asOf":"2026-09-23","days":5},{"id":"rps19","kind":"target","name":"RPS19","route":"/targets/rps19/","asOf":"2026-09-23","days":5},{"id":"socs1","kind":"target","name":"SOCS1","route":"/targets/socs1/","asOf":"2026-09-23","days":5},{"id":"cd200","kind":"target","name":"CD200","route":"/targets/cd200/","asOf":"2026-09-23","days":5},{"id":"mt-nd1","kind":"target","name":"MT-ND1","route":"/targets/mt-nd1/","asOf":"2026-09-23","days":5},{"id":"rps27","kind":"target","name":"RPS27","route":"/targets/rps27/","asOf":"2026-09-23","days":5},{"id":"gabrg3","kind":"target","name":"GABRG3","route":"/targets/gabrg3/","asOf":"2026-09-23","days":5},{"id":"rps7","kind":"target","name":"RPS7","route":"/targets/rps7/","asOf":"2026-09-23","days":5},{"id":"prps1","kind":"target","name":"PRPS1","route":"/targets/prps1/","asOf":"2026-09-23","days":5},{"id":"cd44","kind":"target","name":"CD44","route":"/targets/cd44/","asOf":"2026-09-23","days":5},{"id":"rit1","kind":"target","name":"RIT1","route":"/targets/rit1/","asOf":"2026-09-23","days":5},{"id":"ercc1","kind":"target","name":"ERCC1","route":"/targets/ercc1/","asOf":"2026-09-23","days":5},{"id":"zeb1","kind":"target","name":"ZEB1","route":"/targets/zeb1/","asOf":"2026-09-23","days":5},{"id":"abcb1","kind":"target","name":"ABCB1","route":"/targets/abcb1/","asOf":"2026-09-23","days":5},{"id":"aurka","kind":"target","name":"AURKA","route":"/targets/aurka/","asOf":"2026-09-23","days":5},{"id":"ptprd","kind":"target","name":"PTPRD","route":"/targets/ptprd/","asOf":"2026-09-23","days":5},{"id":"fgf19","kind":"target","name":"FGF19","route":"/targets/fgf19/","asOf":"2026-09-23","days":5},{"id":"igf2","kind":"target","name":"IGF2","route":"/targets/igf2/","asOf":"2026-09-23","days":5},{"id":"tbxt","kind":"target","name":"TBXT","route":"/targets/tbxt/","asOf":"2026-09-23","days":5},{"id":"sgk1","kind":"target","name":"SGK1","route":"/targets/sgk1/","asOf":"2026-09-23","days":5},{"id":"foxl2","kind":"target","name":"FOXL2","route":"/targets/foxl2/","asOf":"2026-09-23","days":5},{"id":"map2k7","kind":"target","name":"MAP2K7","route":"/targets/map2k7/","asOf":"2026-09-23","days":5},{"id":"atp7b","kind":"target","name":"ATP7B","route":"/targets/atp7b/","asOf":"2026-09-23","days":5},{"id":"atxn7","kind":"target","name":"ATXN7","route":"/targets/atxn7/","asOf":"2026-09-23","days":5},{"id":"mir21","kind":"target","name":"MIR21","route":"/targets/mir21/","asOf":"2026-09-23","days":5},{"id":"gna13","kind":"target","name":"GNA13","route":"/targets/gna13/","asOf":"2026-09-23","days":5},{"id":"actl6a","kind":"target","name":"ACTL6A","route":"/targets/actl6a/","asOf":"2026-09-23","days":5},{"id":"aldh1a2","kind":"target","name":"ALDH1A2","route":"/targets/aldh1a2/","asOf":"2026-09-23","days":5},{"id":"cdk9","kind":"target","name":"CDK9","route":"/targets/cdk9/","asOf":"2026-09-23","days":5},{"id":"ceacam1","kind":"target","name":"CEACAM1","route":"/targets/ceacam1/","asOf":"2026-09-23","days":5},{"id":"fos","kind":"target","name":"FOS","route":"/targets/fos/","asOf":"2026-09-23","days":5},{"id":"foxr2","kind":"target","name":"FOXR2","route":"/targets/foxr2/","asOf":"2026-09-23","days":5},{"id":"hsph1","kind":"target","name":"HSPH1","route":"/targets/hsph1/","asOf":"2026-09-23","days":5},{"id":"lgr5-gene","kind":"target","name":"LGR5","route":"/targets/lgr5-gene/","asOf":"2026-09-23","days":5},{"id":"mir218-1","kind":"target","name":"MIR218-1","route":"/targets/mir218-1/","asOf":"2026-09-23","days":5},{"id":"mthfr","kind":"target","name":"MTHFR","route":"/targets/mthfr/","asOf":"2026-09-23","days":5},{"id":"mybl1","kind":"target","name":"MYBL1","route":"/targets/mybl1/","asOf":"2026-09-23","days":5},{"id":"ncoa3","kind":"target","name":"NCOA3","route":"/targets/ncoa3/","asOf":"2026-09-23","days":5},{"id":"nqo1","kind":"target","name":"NQO1","route":"/targets/nqo1/","asOf":"2026-09-23","days":5},{"id":"nr4a2","kind":"target","name":"NR4A2","route":"/targets/nr4a2/","asOf":"2026-09-23","days":5},{"id":"plcg2","kind":"target","name":"PLCG2","route":"/targets/plcg2/","asOf":"2026-09-23","days":5},{"id":"prkdc","kind":"target","name":"PRKDC","route":"/targets/prkdc/","asOf":"2026-09-23","days":5},{"id":"slfn11","kind":"target","name":"SLFN11","route":"/targets/slfn11/","asOf":"2026-09-23","days":5},{"id":"tnc","kind":"target","name":"TNC","route":"/targets/tnc/","asOf":"2026-09-23","days":5},{"id":"mef2b","kind":"target","name":"MEF2B","route":"/targets/mef2b/","asOf":"2026-09-23","days":5},{"id":"bcl7a","kind":"target","name":"BCL7A","route":"/targets/bcl7a/","asOf":"2026-09-23","days":5},{"id":"kmt2b","kind":"target","name":"KMT2B","route":"/targets/kmt2b/","asOf":"2026-09-23","days":5},{"id":"sin3a","kind":"target","name":"SIN3A","route":"/targets/sin3a/","asOf":"2026-09-23","days":5},{"id":"gnai2","kind":"target","name":"GNAI2","route":"/targets/gnai2/","asOf":"2026-09-23","days":5},{"id":"hla-c","kind":"target","name":"HLA-C","route":"/targets/hla-c/","asOf":"2026-09-23","days":5},{"id":"smarca2","kind":"target","name":"SMARCA2","route":"/targets/smarca2/","asOf":"2026-09-23","days":5},{"id":"ass1","kind":"target","name":"ASS1","route":"/targets/ass1/","asOf":"2026-09-23","days":5},{"id":"atxn1l","kind":"target","name":"ATXN1L","route":"/targets/atxn1l/","asOf":"2026-09-23","days":5},{"id":"birc5","kind":"target","name":"BIRC5","route":"/targets/birc5/","asOf":"2026-09-23","days":5},{"id":"birc7","kind":"target","name":"BIRC7","route":"/targets/birc7/","asOf":"2026-09-23","days":5},{"id":"ccne2","kind":"target","name":"CCNE2","route":"/targets/ccne2/","asOf":"2026-09-23","days":5},{"id":"cdc50a","kind":"target","name":"CDC50A","route":"/targets/cdc50a/","asOf":"2026-09-23","days":5},{"id":"chek1","kind":"target","name":"CHEK1","route":"/targets/chek1/","asOf":"2026-09-23","days":5},{"id":"cip2a","kind":"target","name":"CIP2A","route":"/targets/cip2a/","asOf":"2026-09-23","days":5},{"id":"crkl","kind":"target","name":"CRKL","route":"/targets/crkl/","asOf":"2026-09-23","days":5},{"id":"ctag1b","kind":"target","name":"CTAG1B","route":"/targets/ctag1b/","asOf":"2026-09-23","days":5},{"id":"cul7","kind":"target","name":"CUL7","route":"/targets/cul7/","asOf":"2026-09-23","days":5},{"id":"eif4ebp1","kind":"target","name":"EIF4EBP1","route":"/targets/eif4ebp1/","asOf":"2026-09-23","days":5},{"id":"emsy","kind":"target","name":"EMSY","route":"/targets/emsy/","asOf":"2026-09-23","days":5},{"id":"errfi1","kind":"target","name":"ERRFI1","route":"/targets/errfi1/","asOf":"2026-09-23","days":5},{"id":"faap20","kind":"target","name":"FAAP20","route":"/targets/faap20/","asOf":"2026-09-23","days":5},{"id":"fcgr2a","kind":"target","name":"FCGR2A","route":"/targets/fcgr2a/","asOf":"2026-09-23","days":5},{"id":"fcgr3a","kind":"target","name":"FCGR3A","route":"/targets/fcgr3a/","asOf":"2026-09-23","days":5},{"id":"gas6","kind":"target","name":"GAS6","route":"/targets/gas6/","asOf":"2026-09-23","days":5},{"id":"gstp1","kind":"target","name":"GSTP1","route":"/targets/gstp1/","asOf":"2026-09-23","days":5},{"id":"hnrnph1","kind":"target","name":"HNRNPH1","route":"/targets/hnrnph1/","asOf":"2026-09-23","days":5},{"id":"hoxc10","kind":"target","name":"HOXC10","route":"/targets/hoxc10/","asOf":"2026-09-23","days":5},{"id":"klln","kind":"target","name":"KLLN","route":"/targets/klln/","asOf":"2026-09-23","days":5},{"id":"notch3","kind":"target","name":"NOTCH3","route":"/targets/notch3/","asOf":"2026-09-23","days":5},{"id":"pbk","kind":"target","name":"PBK","route":"/targets/pbk/","asOf":"2026-09-23","days":5},{"id":"ppp2r2a","kind":"target","name":"PPP2R2A","route":"/targets/ppp2r2a/","asOf":"2026-09-23","days":5},{"id":"ptprf","kind":"target","name":"PTPRF","route":"/targets/ptprf/","asOf":"2026-09-23","days":5},{"id":"sirt1","kind":"target","name":"SIRT1","route":"/targets/sirt1/","asOf":"2026-09-23","days":5},{"id":"slc12a2","kind":"target","name":"SLC12A2","route":"/targets/slc12a2/","asOf":"2026-09-23","days":5},{"id":"slco1b1","kind":"target","name":"SLCO1B1","route":"/targets/slco1b1/","asOf":"2026-09-23","days":5},{"id":"timp1","kind":"target","name":"TIMP1","route":"/targets/timp1/","asOf":"2026-09-23","days":5},{"id":"tspyl1","kind":"target","name":"TSPYL1","route":"/targets/tspyl1/","asOf":"2026-09-23","days":5},{"id":"setd1b","kind":"target","name":"SETD1B","route":"/targets/setd1b/","asOf":"2026-09-23","days":5},{"id":"btg2","kind":"target","name":"BTG2","route":"/targets/btg2/","asOf":"2026-09-23","days":5},{"id":"tmsb4x","kind":"target","name":"TMSB4X","route":"/targets/tmsb4x/","asOf":"2026-09-23","days":5},{"id":"id3","kind":"target","name":"ID3","route":"/targets/id3/","asOf":"2026-09-23","days":5},{"id":"mga","kind":"target","name":"MGA","route":"/targets/mga/","asOf":"2026-09-23","days":5},{"id":"nfkbia","kind":"target","name":"NFKBIA","route":"/targets/nfkbia/","asOf":"2026-09-23","days":5},{"id":"pou2f2","kind":"target","name":"POU2F2","route":"/targets/pou2f2/","asOf":"2026-09-23","days":5},{"id":"ptpn6","kind":"target","name":"PTPN6","route":"/targets/ptpn6/","asOf":"2026-09-23","days":5},{"id":"tfap4","kind":"target","name":"TFAP4","route":"/targets/tfap4/","asOf":"2026-09-23","days":5},{"id":"cd58","kind":"target","name":"CD58","route":"/targets/cd58/","asOf":"2026-09-23","days":5},{"id":"cysltr2","kind":"target","name":"CYSLTR2","route":"/targets/cysltr2/","asOf":"2026-09-23","days":5},{"id":"klhl6","kind":"target","name":"KLHL6","route":"/targets/klhl6/","asOf":"2026-09-23","days":5},{"id":"usp7","kind":"target","name":"USP7","route":"/targets/usp7/","asOf":"2026-09-23","days":5},{"id":"dtx1","kind":"target","name":"DTX1","route":"/targets/dtx1/","asOf":"2026-09-23","days":5},{"id":"sp140","kind":"target","name":"SP140","route":"/targets/sp140/","asOf":"2026-09-23","days":5},{"id":"ube2a","kind":"target","name":"UBE2A","route":"/targets/ube2a/","asOf":"2026-09-23","days":5},{"id":"abcc10","kind":"target","name":"ABCC10","route":"/targets/abcc10/","asOf":"2026-09-23","days":5},{"id":"abcc3","kind":"target","name":"ABCC3","route":"/targets/abcc3/","asOf":"2026-09-23","days":5},{"id":"abcg2","kind":"target","name":"ABCG2","route":"/targets/abcg2/","asOf":"2026-09-23","days":5},{"id":"acta1","kind":"target","name":"ACTA1","route":"/targets/acta1/","asOf":"2026-09-23","days":5},{"id":"aebp1","kind":"target","name":"AEBP1","route":"/targets/aebp1/","asOf":"2026-09-23","days":5},{"id":"agr2","kind":"target","name":"AGR2","route":"/targets/agr2/","asOf":"2026-09-23","days":5},{"id":"aimp2","kind":"target","name":"AIMP2","route":"/targets/aimp2/","asOf":"2026-09-23","days":5},{"id":"alcam","kind":"target","name":"ALCAM","route":"/targets/alcam/","asOf":"2026-09-23","days":5},{"id":"ascl1","kind":"target","name":"ASCL1","route":"/targets/ascl1/","asOf":"2026-09-23","days":5},{"id":"asns","kind":"target","name":"ASNS","route":"/targets/asns/","asOf":"2026-09-23","days":5},{"id":"atg12","kind":"target","name":"ATG12","route":"/targets/atg12/","asOf":"2026-09-23","days":5},{"id":"aurkb","kind":"target","name":"AURKB","route":"/targets/aurkb/","asOf":"2026-09-23","days":5},{"id":"b4galt1","kind":"target","name":"B4GALT1","route":"/targets/b4galt1/","asOf":"2026-09-23","days":5},{"id":"bmp7","kind":"target","name":"BMP7","route":"/targets/bmp7/","asOf":"2026-09-23","days":5},{"id":"cblc","kind":"target","name":"CBLC","route":"/targets/cblc/","asOf":"2026-09-23","days":5},{"id":"ccn2","kind":"target","name":"CCN2","route":"/targets/ccn2/","asOf":"2026-09-23","days":5},{"id":"cd83","kind":"target","name":"CD83","route":"/targets/cd83/","asOf":"2026-09-23","days":5},{"id":"cdk2","kind":"target","name":"CDK2","route":"/targets/cdk2/","asOf":"2026-09-23","days":5},{"id":"cdk5","kind":"target","name":"CDK5","route":"/targets/cdk5/","asOf":"2026-09-23","days":5},{"id":"cflar","kind":"target","name":"CFLAR","route":"/targets/cflar/","asOf":"2026-09-23","days":5},{"id":"chd8","kind":"target","name":"CHD8","route":"/targets/chd8/","asOf":"2026-09-23","days":5},{"id":"ctag2","kind":"target","name":"CTAG2","route":"/targets/ctag2/","asOf":"2026-09-23","days":5},{"id":"cx3cl1","kind":"target","name":"CX3CL1","route":"/targets/cx3cl1/","asOf":"2026-09-23","days":5},{"id":"cxcl10","kind":"target","name":"CXCL10","route":"/targets/cxcl10/","asOf":"2026-09-23","days":5},{"id":"cyp2d6","kind":"target","name":"CYP2D6","route":"/targets/cyp2d6/","asOf":"2026-09-23","days":5},{"id":"dazap1","kind":"target","name":"DAZAP1","route":"/targets/dazap1/","asOf":"2026-09-23","days":5},{"id":"ddx43","kind":"target","name":"DDX43","route":"/targets/ddx43/","asOf":"2026-09-23","days":5},{"id":"defa1","kind":"target","name":"DEFA1","route":"/targets/defa1/","asOf":"2026-09-23","days":5},{"id":"dkk1","kind":"target","name":"DKK1","route":"/targets/dkk1/","asOf":"2026-09-23","days":5},{"id":"drd5","kind":"target","name":"DRD5","route":"/targets/drd5/","asOf":"2026-09-23","days":5},{"id":"dusp2","kind":"target","name":"DUSP2","route":"/targets/dusp2/","asOf":"2026-09-23","days":5},{"id":"dusp6","kind":"target","name":"DUSP6","route":"/targets/dusp6/","asOf":"2026-09-23","days":5},{"id":"ecscr","kind":"target","name":"ECSCR","route":"/targets/ecscr/","asOf":"2026-09-23","days":5},{"id":"eif4a1","kind":"target","name":"EIF4A1","route":"/targets/eif4a1/","asOf":"2026-09-23","days":5},{"id":"ets1","kind":"target","name":"ETS1","route":"/targets/ets1/","asOf":"2026-09-23","days":5},{"id":"ets2","kind":"target","name":"ETS2","route":"/targets/ets2/","asOf":"2026-09-23","days":5},{"id":"fbxw11","kind":"target","name":"FBXW11","route":"/targets/fbxw11/","asOf":"2026-09-23","days":5},{"id":"fgf13","kind":"target","name":"FGF13","route":"/targets/fgf13/","asOf":"2026-09-23","days":5},{"id":"fntb","kind":"target","name":"FNTB","route":"/targets/fntb/","asOf":"2026-09-23","days":5},{"id":"fosb","kind":"target","name":"FOSB","route":"/targets/fosb/","asOf":"2026-09-23","days":5},{"id":"foxc2","kind":"target","name":"FOXC2","route":"/targets/foxc2/","asOf":"2026-09-23","days":5},{"id":"foxf1","kind":"target","name":"FOXF1","route":"/targets/foxf1/","asOf":"2026-09-23","days":5},{"id":"foxp3","kind":"target","name":"FOXP3","route":"/targets/foxp3/","asOf":"2026-09-23","days":5},{"id":"gadd45a","kind":"target","name":"GADD45A","route":"/targets/gadd45a/","asOf":"2026-09-23","days":5},{"id":"galnt14","kind":"target","name":"GALNT14","route":"/targets/galnt14/","asOf":"2026-09-23","days":5},{"id":"grhpr","kind":"target","name":"GRHPR","route":"/targets/grhpr/","asOf":"2026-09-23","days":5},{"id":"h1-2","kind":"target","name":"H1-2","route":"/targets/h1-2/","asOf":"2026-09-23","days":5},{"id":"h1-3","kind":"target","name":"H1-3","route":"/targets/h1-3/","asOf":"2026-09-23","days":5},{"id":"h1-5","kind":"target","name":"H1-5","route":"/targets/h1-5/","asOf":"2026-09-23","days":5},{"id":"h2ac17","kind":"target","name":"H2AC17","route":"/targets/h2ac17/","asOf":"2026-09-23","days":5},{"id":"h2ac6","kind":"target","name":"H2AC6","route":"/targets/h2ac6/","asOf":"2026-09-23","days":5},{"id":"h2bc12","kind":"target","name":"H2BC12","route":"/targets/h2bc12/","asOf":"2026-09-23","days":5},{"id":"h2bc5","kind":"target","name":"H2BC5","route":"/targets/h2bc5/","asOf":"2026-09-23","days":5},{"id":"h3c14","kind":"target","name":"H3C14","route":"/targets/h3c14/","asOf":"2026-09-23","days":5},{"id":"h3c4","kind":"target","name":"H3C4","route":"/targets/h3c4/","asOf":"2026-09-23","days":5},{"id":"hbb","kind":"target","name":"HBB","route":"/targets/hbb/","asOf":"2026-09-23","days":5},{"id":"hla-dra","kind":"target","name":"HLA-DRA","route":"/targets/hla-dra/","asOf":"2026-09-23","days":5},{"id":"hmox1","kind":"target","name":"HMOX1","route":"/targets/hmox1/","asOf":"2026-09-23","days":5},{"id":"hnrnpu","kind":"target","name":"HNRNPU","route":"/targets/hnrnpu/","asOf":"2026-09-23","days":5},{"id":"hoxd8","kind":"target","name":"HOXD8","route":"/targets/hoxd8/","asOf":"2026-09-23","days":5},{"id":"hsp90b1","kind":"target","name":"HSP90B1","route":"/targets/hsp90b1/","asOf":"2026-09-23","days":5},{"id":"hspa5","kind":"target","name":"HSPA5","route":"/targets/hspa5/","asOf":"2026-09-23","days":5},{"id":"hspb1","kind":"target","name":"HSPB1","route":"/targets/hspb1/","asOf":"2026-09-23","days":5},{"id":"hvcn1","kind":"target","name":"HVCN1","route":"/targets/hvcn1/","asOf":"2026-09-23","days":5},{"id":"ifngr1","kind":"target","name":"IFNGR1","route":"/targets/ifngr1/","asOf":"2026-09-23","days":5},{"id":"il33","kind":"target","name":"IL33","route":"/targets/il33/","asOf":"2026-09-23","days":5},{"id":"il4r","kind":"target","name":"IL4R","route":"/targets/il4r/","asOf":"2026-09-23","days":5},{"id":"irf8","kind":"target","name":"IRF8","route":"/targets/irf8/","asOf":"2026-09-23","days":5},{"id":"itpkb","kind":"target","name":"ITPKB","route":"/targets/itpkb/","asOf":"2026-09-23","days":5},{"id":"kdm5d","kind":"target","name":"KDM5D","route":"/targets/kdm5d/","asOf":"2026-09-23","days":5},{"id":"kif23","kind":"target","name":"KIF23","route":"/targets/kif23/","asOf":"2026-09-23","days":5},{"id":"klhl14","kind":"target","name":"KLHL14","route":"/targets/klhl14/","asOf":"2026-09-23","days":5},{"id":"krt18","kind":"target","name":"KRT18","route":"/targets/krt18/","asOf":"2026-09-23","days":5},{"id":"lepr","kind":"target","name":"LEPR","route":"/targets/lepr/","asOf":"2026-09-23","days":5},{"id":"ltb","kind":"target","name":"LTB","route":"/targets/ltb/","asOf":"2026-09-23","days":5},{"id":"mageh1","kind":"target","name":"MAGEH1","route":"/targets/mageh1/","asOf":"2026-09-23","days":5},{"id":"mef2c","kind":"target","name":"MEF2C","route":"/targets/mef2c/","asOf":"2026-09-23","days":5},{"id":"mef2d","kind":"target","name":"MEF2D","route":"/targets/mef2d/","asOf":"2026-09-23","days":5},{"id":"mertk","kind":"target","name":"MERTK","route":"/targets/mertk/","asOf":"2026-09-23","days":5},{"id":"mmp1","kind":"target","name":"MMP1","route":"/targets/mmp1/","asOf":"2026-09-23","days":5},{"id":"mmp9","kind":"target","name":"MMP9","route":"/targets/mmp9/","asOf":"2026-09-23","days":5},{"id":"mpeg1","kind":"target","name":"MPEG1","route":"/targets/mpeg1/","asOf":"2026-09-23","days":5},{"id":"mus81","kind":"target","name":"MUS81","route":"/targets/mus81/","asOf":"2026-09-23","days":5},{"id":"naprt","kind":"target","name":"NAPRT","route":"/targets/naprt/","asOf":"2026-09-23","days":5},{"id":"nedd9","kind":"target","name":"NEDD9","route":"/targets/nedd9/","asOf":"2026-09-23","days":5},{"id":"nfkbiz","kind":"target","name":"NFKBIZ","route":"/targets/nfkbiz/","asOf":"2026-09-23","days":5},{"id":"nol9","kind":"target","name":"NOL9","route":"/targets/nol9/","asOf":"2026-09-23","days":5},{"id":"nptxr","kind":"target","name":"NPTXR","route":"/targets/nptxr/","asOf":"2026-09-23","days":5},{"id":"nr2f2","kind":"target","name":"NR2F2","route":"/targets/nr2f2/","asOf":"2026-09-23","days":5},{"id":"orc1","kind":"target","name":"ORC1","route":"/targets/orc1/","asOf":"2026-09-23","days":5},{"id":"osbpl10","kind":"target","name":"OSBPL10","route":"/targets/osbpl10/","asOf":"2026-09-23","days":5},{"id":"ovol2","kind":"target","name":"OVOL2","route":"/targets/ovol2/","asOf":"2026-09-23","days":5},{"id":"pappa2","kind":"target","name":"PAPPA2","route":"/targets/pappa2/","asOf":"2026-09-23","days":5},{"id":"pbld","kind":"target","name":"PBLD","route":"/targets/pbld/","asOf":"2026-09-23","days":5},{"id":"pcna","kind":"target","name":"PCNA","route":"/targets/pcna/","asOf":"2026-09-23","days":5},{"id":"pdcd4","kind":"target","name":"PDCD4","route":"/targets/pdcd4/","asOf":"2026-09-23","days":5},{"id":"pim2","kind":"target","name":"PIM2","route":"/targets/pim2/","asOf":"2026-09-23","days":5},{"id":"plk1","kind":"target","name":"PLK1","route":"/targets/plk1/","asOf":"2026-09-23","days":5},{"id":"pole4","kind":"target","name":"POLE4","route":"/targets/pole4/","asOf":"2026-09-23","days":5},{"id":"ppp1r15a","kind":"target","name":"PPP1R15A","route":"/targets/ppp1r15a/","asOf":"2026-09-23","days":5},{"id":"prkaa2","kind":"target","name":"PRKAA2","route":"/targets/prkaa2/","asOf":"2026-09-23","days":5},{"id":"prncr1","kind":"target","name":"PRNCR1","route":"/targets/prncr1/","asOf":"2026-09-23","days":5},{"id":"prom1","kind":"target","name":"PROM1","route":"/targets/prom1/","asOf":"2026-09-23","days":5},{"id":"ptp4a3","kind":"target","name":"PTP4A3","route":"/targets/ptp4a3/","asOf":"2026-09-23","days":5},{"id":"ptpn12","kind":"target","name":"PTPN12","route":"/targets/ptpn12/","asOf":"2026-09-23","days":5},{"id":"pttg1","kind":"target","name":"PTTG1","route":"/targets/pttg1/","asOf":"2026-09-23","days":5},{"id":"pxdnl","kind":"target","name":"PXDNL","route":"/targets/pxdnl/","asOf":"2026-09-23","days":5},{"id":"rad23b","kind":"target","name":"RAD23B","route":"/targets/rad23b/","asOf":"2026-09-23","days":5},{"id":"rheb","kind":"target","name":"RHEB","route":"/targets/rheb/","asOf":"2026-09-23","days":5},{"id":"robo4","kind":"target","name":"ROBO4","route":"/targets/robo4/","asOf":"2026-09-23","days":5},{"id":"rps6","kind":"target","name":"RPS6","route":"/targets/rps6/","asOf":"2026-09-23","days":5},{"id":"rsf1","kind":"target","name":"RSF1","route":"/targets/rsf1/","asOf":"2026-09-23","days":5},{"id":"s100b","kind":"target","name":"S100B","route":"/targets/s100b/","asOf":"2026-09-23","days":5},{"id":"s1pr1","kind":"target","name":"S1PR1","route":"/targets/s1pr1/","asOf":"2026-09-23","days":5},{"id":"s1pr2","kind":"target","name":"S1PR2","route":"/targets/s1pr2/","asOf":"2026-09-23","days":5},{"id":"slc29a1","kind":"target","name":"SLC29A1","route":"/targets/slc29a1/","asOf":"2026-09-23","days":5},{"id":"sncaip","kind":"target","name":"SNCAIP","route":"/targets/sncaip/","asOf":"2026-09-23","days":5},{"id":"sox10","kind":"target","name":"SOX10","route":"/targets/sox10/","asOf":"2026-09-23","days":5},{"id":"sphk1","kind":"target","name":"SPHK1","route":"/targets/sphk1/","asOf":"2026-09-23","days":5},{"id":"spry2","kind":"target","name":"SPRY2","route":"/targets/spry2/","asOf":"2026-09-23","days":5},{"id":"stag2-as1","kind":"target","name":"STAG2-AS1","route":"/targets/stag2-as1/","asOf":"2026-09-23","days":5},{"id":"stag3","kind":"target","name":"STAG3","route":"/targets/stag3/","asOf":"2026-09-23","days":5},{"id":"stmn1","kind":"target","name":"STMN1","route":"/targets/stmn1/","asOf":"2026-09-23","days":5},{"id":"tbk1","kind":"target","name":"TBK1","route":"/targets/tbk1/","asOf":"2026-09-23","days":5},{"id":"tcf19","kind":"target","name":"TCF19","route":"/targets/tcf19/","asOf":"2026-09-23","days":5},{"id":"tf","kind":"target","name":"TF","route":"/targets/tf/","asOf":"2026-09-23","days":5},{"id":"tff3","kind":"target","name":"TFF3","route":"/targets/tff3/","asOf":"2026-09-23","days":5},{"id":"tgfbr3","kind":"target","name":"TGFBR3","route":"/targets/tgfbr3/","asOf":"2026-09-23","days":5},{"id":"thbs2","kind":"target","name":"THBS2","route":"/targets/thbs2/","asOf":"2026-09-23","days":5},{"id":"tlk2","kind":"target","name":"TLK2","route":"/targets/tlk2/","asOf":"2026-09-23","days":5},{"id":"tox","kind":"target","name":"TOX","route":"/targets/tox/","asOf":"2026-09-23","days":5},{"id":"tp53bp1","kind":"target","name":"TP53BP1","route":"/targets/tp53bp1/","asOf":"2026-09-23","days":5},{"id":"tpt1","kind":"target","name":"TPT1","route":"/targets/tpt1/","asOf":"2026-09-23","days":5},{"id":"ttf1","kind":"target","name":"TTF1","route":"/targets/ttf1/","asOf":"2026-09-23","days":5},{"id":"ubtf","kind":"target","name":"UBTF","route":"/targets/ubtf/","asOf":"2026-09-23","days":5},{"id":"ugt1a","kind":"target","name":"UGT1A","route":"/targets/ugt1a/","asOf":"2026-09-23","days":5},{"id":"vegfc","kind":"target","name":"VEGFC","route":"/targets/vegfc/","asOf":"2026-09-23","days":5},{"id":"vps37a","kind":"target","name":"VPS37A","route":"/targets/vps37a/","asOf":"2026-09-23","days":5},{"id":"wdr12","kind":"target","name":"WDR12","route":"/targets/wdr12/","asOf":"2026-09-23","days":5},{"id":"wnk1","kind":"target","name":"WNK1","route":"/targets/wnk1/","asOf":"2026-09-23","days":5},{"id":"wnt11","kind":"target","name":"WNT11","route":"/targets/wnt11/","asOf":"2026-09-23","days":5},{"id":"wnt6","kind":"target","name":"WNT6","route":"/targets/wnt6/","asOf":"2026-09-23","days":5},{"id":"xrcc3","kind":"target","name":"XRCC3","route":"/targets/xrcc3/","asOf":"2026-09-23","days":5},{"id":"zhx2","kind":"target","name":"ZHX2","route":"/targets/zhx2/","asOf":"2026-09-23","days":5},{"id":"znf292","kind":"target","name":"ZNF292","route":"/targets/znf292/","asOf":"2026-09-23","days":5},{"id":"znf703","kind":"target","name":"ZNF703","route":"/targets/znf703/","asOf":"2026-09-23","days":5},{"id":"tgfbr2","kind":"target","name":"TGFBR2","route":"/targets/tgfbr2/","asOf":"2026-09-23","days":5},{"id":"axin1","kind":"target","name":"AXIN1","route":"/targets/axin1/","asOf":"2026-09-23","days":5},{"id":"cdc73","kind":"target","name":"CDC73","route":"/targets/cdc73/","asOf":"2026-09-23","days":5},{"id":"rnf43","kind":"target","name":"RNF43","route":"/targets/rnf43/","asOf":"2026-09-23","days":5},{"id":"amer1","kind":"target","name":"AMER1","route":"/targets/amer1/","asOf":"2026-09-23","days":5},{"id":"tcf7l2","kind":"target","name":"TCF7L2","route":"/targets/tcf7l2/","asOf":"2026-09-23","days":5},{"id":"cux1","kind":"target","name":"CUX1","route":"/targets/cux1/","asOf":"2026-09-23","days":5},{"id":"hnf1a","kind":"target","name":"HNF1A","route":"/targets/hnf1a/","asOf":"2026-09-23","days":5},{"id":"zfhx3","kind":"target","name":"ZFHX3","route":"/targets/zfhx3/","asOf":"2026-09-23","days":5},{"id":"ppm1d","kind":"target","name":"PPM1D","route":"/targets/ppm1d/","asOf":"2026-09-23","days":5},{"id":"tbx3","kind":"target","name":"TBX3","route":"/targets/tbx3/","asOf":"2026-09-23","days":5},{"id":"tp63","kind":"target","name":"TP63","route":"/targets/tp63/","asOf":"2026-09-23","days":5},{"id":"maml2","kind":"target","name":"MAML2","route":"/targets/maml2/","asOf":"2026-09-23","days":5},{"id":"suz12","kind":"target","name":"SUZ12","route":"/targets/suz12/","asOf":"2026-09-23","days":5},{"id":"recql4","kind":"target","name":"RECQL4","route":"/targets/recql4/","asOf":"2026-09-23","days":5},{"id":"trim24","kind":"target","name":"TRIM24","route":"/targets/trim24/","asOf":"2026-09-23","days":5},{"id":"ranbp2","kind":"target","name":"RANBP2","route":"/targets/ranbp2/","asOf":"2026-09-23","days":5},{"id":"klf6","kind":"target","name":"KLF6","route":"/targets/klf6/","asOf":"2026-09-23","days":5},{"id":"acvr1b","kind":"target","name":"ACVR1B","route":"/targets/acvr1b/","asOf":"2026-09-23","days":5},{"id":"bmpr1a","kind":"target","name":"BMPR1A","route":"/targets/bmpr1a/","asOf":"2026-09-23","days":5},{"id":"ncor1","kind":"target","name":"NCOR1","route":"/targets/ncor1/","asOf":"2026-09-23","days":5},{"id":"acvr2a","kind":"target","name":"ACVR2A","route":"/targets/acvr2a/","asOf":"2026-09-23","days":5},{"id":"cltc","kind":"target","name":"CLTC","route":"/targets/cltc/","asOf":"2026-09-23","days":5},{"id":"rbm10","kind":"target","name":"RBM10","route":"/targets/rbm10/","asOf":"2026-09-23","days":5},{"id":"nkx2-1","kind":"target","name":"NKX2-1","route":"/targets/nkx2-1/","asOf":"2026-09-23","days":5},{"id":"qki","kind":"target","name":"QKI","route":"/targets/qki/","asOf":"2026-09-23","days":5},{"id":"fat4","kind":"target","name":"FAT4","route":"/targets/fat4/","asOf":"2026-09-23","days":5},{"id":"snd1","kind":"target","name":"SND1","route":"/targets/snd1/","asOf":"2026-09-23","days":5},{"id":"chd4","kind":"target","name":"CHD4","route":"/targets/chd4/","asOf":"2026-09-23","days":5},{"id":"trrap","kind":"target","name":"TRRAP","route":"/targets/trrap/","asOf":"2026-09-23","days":5},{"id":"tmprss2","kind":"target","name":"TMPRSS2","route":"/targets/tmprss2/","asOf":"2026-09-23","days":5},{"id":"myh9","kind":"target","name":"MYH9","route":"/targets/myh9/","asOf":"2026-09-23","days":5},{"id":"cbfb","kind":"target","name":"CBFB","route":"/targets/cbfb/","asOf":"2026-09-23","days":5},{"id":"max","kind":"target","name":"MAX","route":"/targets/max/","asOf":"2026-09-23","days":5},{"id":"usp6","kind":"target","name":"USP6","route":"/targets/usp6/","asOf":"2026-09-23","days":5},{"id":"hip1","kind":"target","name":"HIP1","route":"/targets/hip1/","asOf":"2026-09-23","days":5},{"id":"nsd1","kind":"target","name":"NSD1","route":"/targets/nsd1/","asOf":"2026-09-23","days":5},{"id":"cdh11","kind":"target","name":"CDH11","route":"/targets/cdh11/","asOf":"2026-09-23","days":5},{"id":"daxx","kind":"target","name":"DAXX","route":"/targets/daxx/","asOf":"2026-09-23","days":5},{"id":"cyld","kind":"target","name":"CYLD","route":"/targets/cyld/","asOf":"2026-09-23","days":5},{"id":"tfg","kind":"target","name":"TFG","route":"/targets/tfg/","asOf":"2026-09-23","days":5},{"id":"rspo2","kind":"target","name":"RSPO2","route":"/targets/rspo2/","asOf":"2026-09-23","days":5},{"id":"bcl11b","kind":"target","name":"BCL11B","route":"/targets/bcl11b/","asOf":"2026-09-23","days":5},{"id":"lats1","kind":"target","name":"LATS1","route":"/targets/lats1/","asOf":"2026-09-23","days":5},{"id":"six1","kind":"target","name":"SIX1","route":"/targets/six1/","asOf":"2026-09-23","days":5},{"id":"bcl9l","kind":"target","name":"BCL9L","route":"/targets/bcl9l/","asOf":"2026-09-23","days":5},{"id":"rad21","kind":"target","name":"RAD21","route":"/targets/rad21/","asOf":"2026-09-23","days":5},{"id":"prdm16","kind":"target","name":"PRDM16","route":"/targets/prdm16/","asOf":"2026-09-23","days":5},{"id":"ncor2","kind":"target","name":"NCOR2","route":"/targets/ncor2/","asOf":"2026-09-23","days":5},{"id":"maf","kind":"target","name":"MAF","route":"/targets/maf/","asOf":"2026-09-23","days":5},{"id":"ptprk","kind":"target","name":"PTPRK","route":"/targets/ptprk/","asOf":"2026-09-23","days":5},{"id":"tent5c","kind":"target","name":"TENT5C","route":"/targets/tent5c/","asOf":"2026-09-23","days":5},{"id":"zbtb16","kind":"target","name":"ZBTB16","route":"/targets/zbtb16/","asOf":"2026-09-23","days":5},{"id":"phf6","kind":"target","name":"PHF6","route":"/targets/phf6/","asOf":"2026-09-23","days":5},{"id":"msi2","kind":"target","name":"MSI2","route":"/targets/msi2/","asOf":"2026-09-23","days":5},{"id":"tpr","kind":"target","name":"TPR","route":"/targets/tpr/","asOf":"2026-09-23","days":5},{"id":"med12","kind":"target","name":"MED12","route":"/targets/med12/","asOf":"2026-09-23","days":5},{"id":"bcorl1","kind":"target","name":"BCORL1","route":"/targets/bcorl1/","asOf":"2026-09-23","days":5},{"id":"ppp6c","kind":"target","name":"PPP6C","route":"/targets/ppp6c/","asOf":"2026-09-23","days":5},{"id":"ncoa2","kind":"target","name":"NCOA2","route":"/targets/ncoa2/","asOf":"2026-09-23","days":5},{"id":"zmym2","kind":"target","name":"ZMYM2","route":"/targets/zmym2/","asOf":"2026-09-23","days":5},{"id":"runx1t1","kind":"target","name":"RUNX1T1","route":"/targets/runx1t1/","asOf":"2026-09-23","days":5},{"id":"znf521","kind":"target","name":"ZNF521","route":"/targets/znf521/","asOf":"2026-09-23","days":5},{"id":"plag1","kind":"target","name":"PLAG1","route":"/targets/plag1/","asOf":"2026-09-23","days":5},{"id":"lats2","kind":"target","name":"LATS2","route":"/targets/lats2/","asOf":"2026-09-23","days":5},{"id":"psip1","kind":"target","name":"PSIP1","route":"/targets/psip1/","asOf":"2026-09-23","days":5},{"id":"sall4","kind":"target","name":"SALL4","route":"/targets/sall4/","asOf":"2026-09-23","days":5},{"id":"rap1b","kind":"target","name":"RAP1B","route":"/targets/rap1b/","asOf":"2026-09-23","days":5},{"id":"ackr3","kind":"target","name":"ACKR3","route":"/targets/ackr3/","asOf":"2026-09-23","days":5},{"id":"sox9","kind":"target","name":"SOX9","route":"/targets/sox9/","asOf":"2026-09-23","days":5},{"id":"akap9","kind":"target","name":"AKAP9","route":"/targets/akap9/","asOf":"2026-09-23","days":5},{"id":"rap1gds1","kind":"target","name":"RAP1GDS1","route":"/targets/rap1gds1/","asOf":"2026-09-23","days":5},{"id":"kat6b","kind":"target","name":"KAT6B","route":"/targets/kat6b/","asOf":"2026-09-23","days":5},{"id":"polq","kind":"target","name":"POLQ","route":"/targets/polq/","asOf":"2026-09-23","days":5},{"id":"ctnna1","kind":"target","name":"CTNNA1","route":"/targets/ctnna1/","asOf":"2026-09-23","days":5},{"id":"csmd3","kind":"target","name":"CSMD3","route":"/targets/csmd3/","asOf":"2026-09-23","days":5},{"id":"il6st","kind":"target","name":"IL6ST","route":"/targets/il6st/","asOf":"2026-09-23","days":5},{"id":"cdkn2c","kind":"target","name":"CDKN2C","route":"/targets/cdkn2c/","asOf":"2026-09-23","days":5},{"id":"cntrl","kind":"target","name":"CNTRL","route":"/targets/cntrl/","asOf":"2026-09-23","days":5},{"id":"cnot3","kind":"target","name":"CNOT3","route":"/targets/cnot3/","asOf":"2026-09-23","days":5},{"id":"trip11","kind":"target","name":"TRIP11","route":"/targets/trip11/","asOf":"2026-09-23","days":5},{"id":"aff4","kind":"target","name":"AFF4","route":"/targets/aff4/","asOf":"2026-09-23","days":5},{"id":"ptpn13","kind":"target","name":"PTPN13","route":"/targets/ptpn13/","asOf":"2026-09-23","days":5},{"id":"crtc1","kind":"target","name":"CRTC1","route":"/targets/crtc1/","asOf":"2026-09-23","days":5},{"id":"ptprc","kind":"target","name":"PTPRC","route":"/targets/ptprc/","asOf":"2026-09-23","days":5},{"id":"col1a1","kind":"target","name":"COL1A1","route":"/targets/col1a1/","asOf":"2026-09-23","days":5},{"id":"kat6a","kind":"target","name":"KAT6A","route":"/targets/kat6a/","asOf":"2026-09-23","days":5},{"id":"afdn","kind":"target","name":"AFDN","route":"/targets/afdn/","asOf":"2026-09-23","days":5},{"id":"clip1","kind":"target","name":"CLIP1","route":"/targets/clip1/","asOf":"2026-09-23","days":5},{"id":"nutm1","kind":"target","name":"NUTM1","route":"/targets/nutm1/","asOf":"2026-09-23","days":5},{"id":"knl1","kind":"target","name":"KNL1","route":"/targets/knl1/","asOf":"2026-09-23","days":5},{"id":"irf1","kind":"target","name":"IRF1","route":"/targets/irf1/","asOf":"2026-09-23","days":5},{"id":"bcl9","kind":"target","name":"BCL9","route":"/targets/bcl9/","asOf":"2026-09-23","days":5},{"id":"elf4","kind":"target","name":"ELF4","route":"/targets/elf4/","asOf":"2026-09-23","days":5},{"id":"usp8","kind":"target","name":"USP8","route":"/targets/usp8/","asOf":"2026-09-23","days":5},{"id":"nbea","kind":"target","name":"NBEA","route":"/targets/nbea/","asOf":"2026-09-23","days":5},{"id":"arhgef12","kind":"target","name":"ARHGEF12","route":"/targets/arhgef12/","asOf":"2026-09-23","days":5},{"id":"ddb2","kind":"target","name":"DDB2","route":"/targets/ddb2/","asOf":"2026-09-23","days":5},{"id":"camta1","kind":"target","name":"CAMTA1","route":"/targets/camta1/","asOf":"2026-09-23","days":5},{"id":"aff3","kind":"target","name":"AFF3","route":"/targets/aff3/","asOf":"2026-09-23","days":5},{"id":"ell","kind":"target","name":"ELL","route":"/targets/ell/","asOf":"2026-09-23","days":5},{"id":"foxo3","kind":"target","name":"FOXO3","route":"/targets/foxo3/","asOf":"2026-09-23","days":5},{"id":"atp2b3","kind":"target","name":"ATP2B3","route":"/targets/atp2b3/","asOf":"2026-09-23","days":5},{"id":"wwtr1","kind":"target","name":"WWTR1","route":"/targets/wwtr1/","asOf":"2026-09-23","days":5},{"id":"flg","kind":"target","name":"FLG","route":"/targets/flg/","asOf":"2026-09-23","days":5},{"id":"ddx6","kind":"target","name":"DDX6","route":"/targets/ddx6/","asOf":"2026-09-23","days":5},{"id":"cltcl1","kind":"target","name":"CLTCL1","route":"/targets/cltcl1/","asOf":"2026-09-23","days":5},{"id":"nsd3","kind":"target","name":"NSD3","route":"/targets/nsd3/","asOf":"2026-09-23","days":5},{"id":"nfatc2","kind":"target","name":"NFATC2","route":"/targets/nfatc2/","asOf":"2026-09-23","days":5},{"id":"eif3e","kind":"target","name":"EIF3E","route":"/targets/eif3e/","asOf":"2026-09-23","days":5},{"id":"lef1","kind":"target","name":"LEF1","route":"/targets/lef1/","asOf":"2026-09-23","days":5},{"id":"irs4","kind":"target","name":"IRS4","route":"/targets/irs4/","asOf":"2026-09-23","days":5},{"id":"hnrnpa2b1","kind":"target","name":"HNRNPA2B1","route":"/targets/hnrnpa2b1/","asOf":"2026-09-23","days":5},{"id":"fus","kind":"target","name":"FUS","route":"/targets/fus/","asOf":"2026-09-23","days":5},{"id":"nfkb2","kind":"target","name":"NFKB2","route":"/targets/nfkb2/","asOf":"2026-09-23","days":5},{"id":"nup98","kind":"target","name":"NUP98","route":"/targets/nup98/","asOf":"2026-09-23","days":5},{"id":"pcm1","kind":"target","name":"PCM1","route":"/targets/pcm1/","asOf":"2026-09-23","days":5},{"id":"fcrl4","kind":"target","name":"FCRL4","route":"/targets/fcrl4/","asOf":"2026-09-23","days":5},{"id":"lrig3","kind":"target","name":"LRIG3","route":"/targets/lrig3/","asOf":"2026-09-23","days":5},{"id":"trim33","kind":"target","name":"TRIM33","route":"/targets/trim33/","asOf":"2026-09-23","days":5},{"id":"rest","kind":"target","name":"REST","route":"/targets/rest/","asOf":"2026-09-23","days":5},{"id":"znf331","kind":"target","name":"ZNF331","route":"/targets/znf331/","asOf":"2026-09-23","days":5},{"id":"eps15","kind":"target","name":"EPS15","route":"/targets/eps15/","asOf":"2026-09-23","days":5},{"id":"elk4","kind":"target","name":"ELK4","route":"/targets/elk4/","asOf":"2026-09-23","days":5},{"id":"kdm5a","kind":"target","name":"KDM5A","route":"/targets/kdm5a/","asOf":"2026-09-23","days":5},{"id":"ing1","kind":"target","name":"ING1","route":"/targets/ing1/","asOf":"2026-09-23","days":5},{"id":"zmym3","kind":"target","name":"ZMYM3","route":"/targets/zmym3/","asOf":"2026-09-23","days":5},{"id":"tcl1a","kind":"target","name":"TCL1A","route":"/targets/tcl1a/","asOf":"2026-09-23","days":5},{"id":"rhpn2","kind":"target","name":"RHPN2","route":"/targets/rhpn2/","asOf":"2026-09-23","days":5},{"id":"malt1","kind":"target","name":"MALT1","route":"/targets/malt1/","asOf":"2026-09-23","days":5},{"id":"elf3","kind":"target","name":"ELF3","route":"/targets/elf3/","asOf":"2026-09-23","days":5},{"id":"tal2","kind":"target","name":"TAL2","route":"/targets/tal2/","asOf":"2026-09-23","days":5},{"id":"traf7","kind":"target","name":"TRAF7","route":"/targets/traf7/","asOf":"2026-09-23","days":5},{"id":"was","kind":"target","name":"WAS","route":"/targets/was/","asOf":"2026-09-23","days":5},{"id":"nup214","kind":"target","name":"NUP214","route":"/targets/nup214/","asOf":"2026-09-23","days":5},{"id":"hoxc13","kind":"target","name":"HOXC13","route":"/targets/hoxc13/","asOf":"2026-09-23","days":5},{"id":"pabpc1","kind":"target","name":"PABPC1","route":"/targets/pabpc1/","asOf":"2026-09-23","days":5},{"id":"tal1","kind":"target","name":"TAL1","route":"/targets/tal1/","asOf":"2026-09-23","days":5},{"id":"lifr","kind":"target","name":"LIFR","route":"/targets/lifr/","asOf":"2026-09-23","days":5},{"id":"msn","kind":"target","name":"MSN","route":"/targets/msn/","asOf":"2026-09-23","days":5},{"id":"brd7","kind":"target","name":"BRD7","route":"/targets/brd7/","asOf":"2026-09-23","days":5},{"id":"acsl3","kind":"target","name":"ACSL3","route":"/targets/acsl3/","asOf":"2026-09-23","days":5},{"id":"mllt1","kind":"target","name":"MLLT1","route":"/targets/mllt1/","asOf":"2026-09-23","days":5},{"id":"atf7ip","kind":"target","name":"ATF7IP","route":"/targets/atf7ip/","asOf":"2026-09-23","days":5},{"id":"asxl2","kind":"target","name":"ASXL2","route":"/targets/asxl2/","asOf":"2026-09-23","days":5},{"id":"znrf3","kind":"target","name":"ZNRF3","route":"/targets/znrf3/","asOf":"2026-09-23","days":5},{"id":"ptpn14","kind":"target","name":"PTPN14","route":"/targets/ptpn14/","asOf":"2026-09-23","days":5},{"id":"rps6ka3","kind":"target","name":"RPS6KA3","route":"/targets/rps6ka3/","asOf":"2026-09-23","days":5},{"id":"lpa","kind":"target","name":"LPA","route":"/targets/lpa/","asOf":"2026-09-23","days":5},{"id":"h4c9","kind":"target","name":"H4C9","route":"/targets/h4c9/","asOf":"2026-09-23","days":5},{"id":"adamts9","kind":"target","name":"ADAMTS9","route":"/targets/adamts9/","asOf":"2026-09-23","days":5},{"id":"znf750","kind":"target","name":"ZNF750","route":"/targets/znf750/","asOf":"2026-09-23","days":5},{"id":"rnf6","kind":"target","name":"RNF6","route":"/targets/rnf6/","asOf":"2026-09-23","days":5},{"id":"ncoa1","kind":"target","name":"NCOA1","route":"/targets/ncoa1/","asOf":"2026-09-23","days":5},{"id":"rbfox1","kind":"target","name":"RBFOX1","route":"/targets/rbfox1/","asOf":"2026-09-23","days":5},{"id":"fmn2","kind":"target","name":"FMN2","route":"/targets/fmn2/","asOf":"2026-09-23","days":5},{"id":"myeov","kind":"target","name":"MYEOV","route":"/targets/myeov/","asOf":"2026-09-23","days":5},{"id":"znf429","kind":"target","name":"ZNF429","route":"/targets/znf429/","asOf":"2026-09-23","days":5},{"id":"gpc5","kind":"target","name":"GPC5","route":"/targets/gpc5/","asOf":"2026-09-23","days":5},{"id":"baz1a","kind":"target","name":"BAZ1A","route":"/targets/baz1a/","asOf":"2026-09-23","days":5},{"id":"mllt3","kind":"target","name":"MLLT3","route":"/targets/mllt3/","asOf":"2026-09-23","days":5},{"id":"aff1","kind":"target","name":"AFF1","route":"/targets/aff1/","asOf":"2026-09-23","days":5},{"id":"fat3","kind":"target","name":"FAT3","route":"/targets/fat3/","asOf":"2026-09-23","days":5},{"id":"robo2","kind":"target","name":"ROBO2","route":"/targets/robo2/","asOf":"2026-09-23","days":5},{"id":"ctnna2","kind":"target","name":"CTNNA2","route":"/targets/ctnna2/","asOf":"2026-09-23","days":5},{"id":"rnf213","kind":"target","name":"RNF213","route":"/targets/rnf213/","asOf":"2026-09-23","days":5},{"id":"myh11","kind":"target","name":"MYH11","route":"/targets/myh11/","asOf":"2026-09-23","days":5},{"id":"fam135b","kind":"target","name":"FAM135B","route":"/targets/fam135b/","asOf":"2026-09-23","days":5},{"id":"fbln2","kind":"target","name":"FBLN2","route":"/targets/fbln2/","asOf":"2026-09-23","days":5},{"id":"setdb1","kind":"target","name":"SETDB1","route":"/targets/setdb1/","asOf":"2026-09-23","days":5},{"id":"ank1","kind":"target","name":"ANK1","route":"/targets/ank1/","asOf":"2026-09-23","days":5},{"id":"arhgap5","kind":"target","name":"ARHGAP5","route":"/targets/arhgap5/","asOf":"2026-09-23","days":5},{"id":"chd2","kind":"target","name":"CHD2","route":"/targets/chd2/","asOf":"2026-09-23","days":5},{"id":"ctnnd2","kind":"target","name":"CTNND2","route":"/targets/ctnnd2/","asOf":"2026-09-23","days":5},{"id":"usp9x","kind":"target","name":"USP9X","route":"/targets/usp9x/","asOf":"2026-09-23","days":5},{"id":"cdh10","kind":"target","name":"CDH10","route":"/targets/cdh10/","asOf":"2026-09-23","days":5},{"id":"rgs7","kind":"target","name":"RGS7","route":"/targets/rgs7/","asOf":"2026-09-23","days":5},{"id":"bclaf1","kind":"target","name":"BCLAF1","route":"/targets/bclaf1/","asOf":"2026-09-23","days":5},{"id":"sirpa","kind":"target","name":"SIRPA","route":"/targets/sirpa/","asOf":"2026-09-23","days":5},{"id":"arhgef10","kind":"target","name":"ARHGEF10","route":"/targets/arhgef10/","asOf":"2026-09-23","days":5},{"id":"dcaf12l2","kind":"target","name":"DCAF12L2","route":"/targets/dcaf12l2/","asOf":"2026-09-23","days":5},{"id":"dgcr8","kind":"target","name":"DGCR8","route":"/targets/dgcr8/","asOf":"2026-09-23","days":5},{"id":"mb21d2","kind":"target","name":"MB21D2","route":"/targets/mb21d2/","asOf":"2026-09-23","days":5},{"id":"myo5a","kind":"target","name":"MYO5A","route":"/targets/myo5a/","asOf":"2026-09-23","days":5},{"id":"naca","kind":"target","name":"NACA","route":"/targets/naca/","asOf":"2026-09-23","days":5},{"id":"wnk2","kind":"target","name":"WNK2","route":"/targets/wnk2/","asOf":"2026-09-23","days":5},{"id":"cd209","kind":"target","name":"CD209","route":"/targets/cd209/","asOf":"2026-09-23","days":5},{"id":"fam174b","kind":"target","name":"FAM174B","route":"/targets/fam174b/","asOf":"2026-09-23","days":5},{"id":"grm3","kind":"target","name":"GRM3","route":"/targets/grm3/","asOf":"2026-09-23","days":5},{"id":"ldb1","kind":"target","name":"LDB1","route":"/targets/ldb1/","asOf":"2026-09-23","days":5},{"id":"muc6","kind":"target","name":"MUC6","route":"/targets/muc6/","asOf":"2026-09-23","days":5},{"id":"n4bp2","kind":"target","name":"N4BP2","route":"/targets/n4bp2/","asOf":"2026-09-23","days":5},{"id":"nin","kind":"target","name":"NIN","route":"/targets/nin/","asOf":"2026-09-23","days":5},{"id":"parp4","kind":"target","name":"PARP4","route":"/targets/parp4/","asOf":"2026-09-23","days":5},{"id":"prdm2","kind":"target","name":"PRDM2","route":"/targets/prdm2/","asOf":"2026-09-23","days":5},{"id":"rgpd3","kind":"target","name":"RGPD3","route":"/targets/rgpd3/","asOf":"2026-09-23","days":5},{"id":"arhgef10l","kind":"target","name":"ARHGEF10L","route":"/targets/arhgef10l/","asOf":"2026-09-23","days":5},{"id":"cnot9","kind":"target","name":"CNOT9","route":"/targets/cnot9/","asOf":"2026-09-23","days":5},{"id":"cyp2c8","kind":"target","name":"CYP2C8","route":"/targets/cyp2c8/","asOf":"2026-09-23","days":5},{"id":"dot1l","kind":"target","name":"DOT1L","route":"/targets/dot1l/","asOf":"2026-09-23","days":5},{"id":"dusp16","kind":"target","name":"DUSP16","route":"/targets/dusp16/","asOf":"2026-09-23","days":5},{"id":"eln","kind":"target","name":"ELN","route":"/targets/eln/","asOf":"2026-09-23","days":5},{"id":"foxa2","kind":"target","name":"FOXA2","route":"/targets/foxa2/","asOf":"2026-09-23","days":5},{"id":"kdm3b","kind":"target","name":"KDM3B","route":"/targets/kdm3b/","asOf":"2026-09-23","days":5},{"id":"mllt6","kind":"target","name":"MLLT6","route":"/targets/mllt6/","asOf":"2026-09-23","days":5},{"id":"nipbl","kind":"target","name":"NIPBL","route":"/targets/nipbl/","asOf":"2026-09-23","days":5},{"id":"numa1","kind":"target","name":"NUMA1","route":"/targets/numa1/","asOf":"2026-09-23","days":5},{"id":"nxf1","kind":"target","name":"NXF1","route":"/targets/nxf1/","asOf":"2026-09-23","days":5},{"id":"smarcd1","kind":"target","name":"SMARCD1","route":"/targets/smarcd1/","asOf":"2026-09-23","days":5},{"id":"smc1a","kind":"target","name":"SMC1A","route":"/targets/smc1a/","asOf":"2026-09-23","days":5},{"id":"snx29","kind":"target","name":"SNX29","route":"/targets/snx29/","asOf":"2026-09-23","days":5},{"id":"taf15","kind":"target","name":"TAF15","route":"/targets/taf15/","asOf":"2026-09-23","days":5},{"id":"tcf12","kind":"target","name":"TCF12","route":"/targets/tcf12/","asOf":"2026-09-23","days":5},{"id":"tcf4","kind":"target","name":"TCF4","route":"/targets/tcf4/","asOf":"2026-09-23","days":5},{"id":"tfrc","kind":"target","name":"TFRC","route":"/targets/tfrc/","asOf":"2026-09-23","days":5},{"id":"abcc4","kind":"target","name":"ABCC4","route":"/targets/abcc4/","asOf":"2026-09-23","days":5},{"id":"acsl6","kind":"target","name":"ACSL6","route":"/targets/acsl6/","asOf":"2026-09-23","days":5},{"id":"acsm3","kind":"target","name":"ACSM3","route":"/targets/acsm3/","asOf":"2026-09-23","days":5},{"id":"ajuba","kind":"target","name":"AJUBA","route":"/targets/ajuba/","asOf":"2026-09-23","days":5},{"id":"alpk1","kind":"target","name":"ALPK1","route":"/targets/alpk1/","asOf":"2026-09-23","days":5},{"id":"ankrd11","kind":"target","name":"ANKRD11","route":"/targets/ankrd11/","asOf":"2026-09-23","days":5},{"id":"bmp6","kind":"target","name":"BMP6","route":"/targets/bmp6/","asOf":"2026-09-23","days":5},{"id":"cadm2","kind":"target","name":"CADM2","route":"/targets/cadm2/","asOf":"2026-09-23","days":5},{"id":"cant1","kind":"target","name":"CANT1","route":"/targets/cant1/","asOf":"2026-09-23","days":5},{"id":"casz1","kind":"target","name":"CASZ1","route":"/targets/casz1/","asOf":"2026-09-23","days":5},{"id":"ccar1","kind":"target","name":"CCAR1","route":"/targets/ccar1/","asOf":"2026-09-23","days":5},{"id":"ccnt1","kind":"target","name":"CCNT1","route":"/targets/ccnt1/","asOf":"2026-09-23","days":5},{"id":"ccr7","kind":"target","name":"CCR7","route":"/targets/ccr7/","asOf":"2026-09-23","days":5},{"id":"cep89","kind":"target","name":"CEP89","route":"/targets/cep89/","asOf":"2026-09-23","days":5},{"id":"chd7","kind":"target","name":"CHD7","route":"/targets/chd7/","asOf":"2026-09-23","days":5},{"id":"chrdl1","kind":"target","name":"CHRDL1","route":"/targets/chrdl1/","asOf":"2026-09-23","days":5},{"id":"cmtr2","kind":"target","name":"CMTR2","route":"/targets/cmtr2/","asOf":"2026-09-23","days":5},{"id":"col2a1","kind":"target","name":"COL2A1","route":"/targets/col2a1/","asOf":"2026-09-23","days":5},{"id":"col6a6","kind":"target","name":"COL6A6","route":"/targets/col6a6/","asOf":"2026-09-23","days":5},{"id":"cpeb3","kind":"target","name":"CPEB3","route":"/targets/cpeb3/","asOf":"2026-09-23","days":5},{"id":"cspg4","kind":"target","name":"CSPG4","route":"/targets/cspg4/","asOf":"2026-09-23","days":5},{"id":"dhx9","kind":"target","name":"DHX9","route":"/targets/dhx9/","asOf":"2026-09-23","days":5},{"id":"dis3","kind":"target","name":"DIS3","route":"/targets/dis3/","asOf":"2026-09-23","days":5},{"id":"dsp","kind":"target","name":"DSP","route":"/targets/dsp/","asOf":"2026-09-23","days":5},{"id":"eftud2","kind":"target","name":"EFTUD2","route":"/targets/eftud2/","asOf":"2026-09-23","days":5},{"id":"egr2","kind":"target","name":"EGR2","route":"/targets/egr2/","asOf":"2026-09-23","days":5},{"id":"eif4a2","kind":"target","name":"EIF4A2","route":"/targets/eif4a2/","asOf":"2026-09-23","days":5},{"id":"esrra","kind":"target","name":"ESRRA","route":"/targets/esrra/","asOf":"2026-09-23","days":5},{"id":"fat2","kind":"target","name":"FAT2","route":"/targets/fat2/","asOf":"2026-09-23","days":5},{"id":"fbn2","kind":"target","name":"FBN2","route":"/targets/fbn2/","asOf":"2026-09-23","days":5},{"id":"fgd1","kind":"target","name":"FGD1","route":"/targets/fgd1/","asOf":"2026-09-23","days":5},{"id":"fgd5","kind":"target","name":"FGD5","route":"/targets/fgd5/","asOf":"2026-09-23","days":5},{"id":"fndc3b","kind":"target","name":"FNDC3B","route":"/targets/fndc3b/","asOf":"2026-09-23","days":5},{"id":"gli1","kind":"target","name":"GLI1","route":"/targets/gli1/","asOf":"2026-09-23","days":5},{"id":"gmps","kind":"target","name":"GMPS","route":"/targets/gmps/","asOf":"2026-09-23","days":5},{"id":"gpaa1","kind":"target","name":"GPAA1","route":"/targets/gpaa1/","asOf":"2026-09-23","days":5},{"id":"gtf2i","kind":"target","name":"GTF2I","route":"/targets/gtf2i/","asOf":"2026-09-23","days":5},{"id":"hcar3","kind":"target","name":"HCAR3","route":"/targets/hcar3/","asOf":"2026-09-23","days":5},{"id":"hla-dqa1","kind":"target","name":"HLA-DQA1","route":"/targets/hla-dqa1/","asOf":"2026-09-23","days":5},{"id":"hsp90ab1","kind":"target","name":"HSP90AB1","route":"/targets/hsp90ab1/","asOf":"2026-09-23","days":5},{"id":"hspg2","kind":"target","name":"HSPG2","route":"/targets/hspg2/","asOf":"2026-09-23","days":5},{"id":"inppl1","kind":"target","name":"INPPL1","route":"/targets/inppl1/","asOf":"2026-09-23","days":5},{"id":"itgav","kind":"target","name":"ITGAV","route":"/targets/itgav/","asOf":"2026-09-23","days":5},{"id":"kat7","kind":"target","name":"KAT7","route":"/targets/kat7/","asOf":"2026-09-23","days":5},{"id":"kmt5a","kind":"target","name":"KMT5A","route":"/targets/kmt5a/","asOf":"2026-09-23","days":5},{"id":"knstrn","kind":"target","name":"KNSTRN","route":"/targets/knstrn/","asOf":"2026-09-23","days":5},{"id":"lsm14a","kind":"target","name":"LSM14A","route":"/targets/lsm14a/","asOf":"2026-09-23","days":5},{"id":"macc1","kind":"target","name":"MACC1","route":"/targets/macc1/","asOf":"2026-09-23","days":5},{"id":"mark2","kind":"target","name":"MARK2","route":"/targets/mark2/","asOf":"2026-09-23","days":5},{"id":"mcm7","kind":"target","name":"MCM7","route":"/targets/mcm7/","asOf":"2026-09-23","days":5},{"id":"mdga2","kind":"target","name":"MDGA2","route":"/targets/mdga2/","asOf":"2026-09-23","days":5},{"id":"med23","kind":"target","name":"MED23","route":"/targets/med23/","asOf":"2026-09-23","days":5},{"id":"mib2","kind":"target","name":"MIB2","route":"/targets/mib2/","asOf":"2026-09-23","days":5},{"id":"ncaph","kind":"target","name":"NCAPH","route":"/targets/ncaph/","asOf":"2026-09-23","days":5},{"id":"nckipsd","kind":"target","name":"NCKIPSD","route":"/targets/nckipsd/","asOf":"2026-09-23","days":5},{"id":"nktr","kind":"target","name":"NKTR","route":"/targets/nktr/","asOf":"2026-09-23","days":5},{"id":"nprl2","kind":"target","name":"NPRL2","route":"/targets/nprl2/","asOf":"2026-09-23","days":5},{"id":"nrk","kind":"target","name":"NRK","route":"/targets/nrk/","asOf":"2026-09-23","days":5},{"id":"nt5c3a","kind":"target","name":"NT5C3A","route":"/targets/nt5c3a/","asOf":"2026-09-23","days":5},{"id":"nutm2d","kind":"target","name":"NUTM2D","route":"/targets/nutm2d/","asOf":"2026-09-23","days":5},{"id":"nvl","kind":"target","name":"NVL","route":"/targets/nvl/","asOf":"2026-09-23","days":5},{"id":"pcmtd1","kind":"target","name":"PCMTD1","route":"/targets/pcmtd1/","asOf":"2026-09-23","days":5},{"id":"pdzd2","kind":"target","name":"PDZD2","route":"/targets/pdzd2/","asOf":"2026-09-23","days":5},{"id":"peg3","kind":"target","name":"PEG3","route":"/targets/peg3/","asOf":"2026-09-23","days":5},{"id":"per3","kind":"target","name":"PER3","route":"/targets/per3/","asOf":"2026-09-23","days":5},{"id":"pi4ka","kind":"target","name":"PI4KA","route":"/targets/pi4ka/","asOf":"2026-09-23","days":5},{"id":"picalm","kind":"target","name":"PICALM","route":"/targets/picalm/","asOf":"2026-09-23","days":5},{"id":"plxnc1","kind":"target","name":"PLXNC1","route":"/targets/plxnc1/","asOf":"2026-09-23","days":5},{"id":"ppp3ca","kind":"target","name":"PPP3CA","route":"/targets/ppp3ca/","asOf":"2026-09-23","days":5},{"id":"prkd2","kind":"target","name":"PRKD2","route":"/targets/prkd2/","asOf":"2026-09-23","days":5},{"id":"prune2","kind":"target","name":"PRUNE2","route":"/targets/prune2/","asOf":"2026-09-23","days":5},{"id":"pspc1","kind":"target","name":"PSPC1","route":"/targets/pspc1/","asOf":"2026-09-23","days":5},{"id":"ptma","kind":"target","name":"PTMA","route":"/targets/ptma/","asOf":"2026-09-23","days":5},{"id":"ptpn3","kind":"target","name":"PTPN3","route":"/targets/ptpn3/","asOf":"2026-09-23","days":5},{"id":"pwwp2a","kind":"target","name":"PWWP2A","route":"/targets/pwwp2a/","asOf":"2026-09-23","days":5},{"id":"rasa2","kind":"target","name":"RASA2","route":"/targets/rasa2/","asOf":"2026-09-23","days":5},{"id":"rbm15","kind":"target","name":"RBM15","route":"/targets/rbm15/","asOf":"2026-09-23","days":5},{"id":"rbm38","kind":"target","name":"RBM38","route":"/targets/rbm38/","asOf":"2026-09-23","days":5},{"id":"rbm39","kind":"target","name":"RBM39","route":"/targets/rbm39/","asOf":"2026-09-23","days":5},{"id":"rela","kind":"target","name":"RELA","route":"/targets/rela/","asOf":"2026-09-23","days":5},{"id":"ripk1","kind":"target","name":"RIPK1","route":"/targets/ripk1/","asOf":"2026-09-23","days":5},{"id":"rps3a","kind":"target","name":"RPS3A","route":"/targets/rps3a/","asOf":"2026-09-23","days":5},{"id":"rragc","kind":"target","name":"RRAGC","route":"/targets/rragc/","asOf":"2026-09-23","days":5},{"id":"rrn3","kind":"target","name":"RRN3","route":"/targets/rrn3/","asOf":"2026-09-23","days":5},{"id":"samhd1","kind":"target","name":"SAMHD1","route":"/targets/samhd1/","asOf":"2026-09-23","days":5},{"id":"sdcbp","kind":"target","name":"SDCBP","route":"/targets/sdcbp/","asOf":"2026-09-23","days":5},{"id":"shtn1","kind":"target","name":"SHTN1","route":"/targets/shtn1/","asOf":"2026-09-23","days":5},{"id":"sox17","kind":"target","name":"SOX17","route":"/targets/sox17/","asOf":"2026-09-23","days":5},{"id":"sox21","kind":"target","name":"SOX21","route":"/targets/sox21/","asOf":"2026-09-23","days":5},{"id":"srgap3","kind":"target","name":"SRGAP3","route":"/targets/srgap3/","asOf":"2026-09-23","days":5},{"id":"susd2","kind":"target","name":"SUSD2","route":"/targets/susd2/","asOf":"2026-09-23","days":5},{"id":"taf1l","kind":"target","name":"TAF1L","route":"/targets/taf1l/","asOf":"2026-09-23","days":5},{"id":"tgif1","kind":"target","name":"TGIF1","route":"/targets/tgif1/","asOf":"2026-09-23","days":5},{"id":"thrap3","kind":"target","name":"THRAP3","route":"/targets/thrap3/","asOf":"2026-09-23","days":5},{"id":"traf3","kind":"target","name":"TRAF3","route":"/targets/traf3/","asOf":"2026-09-23","days":5},{"id":"trim49c","kind":"target","name":"TRIM49C","route":"/targets/trim49c/","asOf":"2026-09-23","days":5},{"id":"tyw2","kind":"target","name":"TYW2","route":"/targets/tyw2/","asOf":"2026-09-23","days":5},{"id":"u2af2","kind":"target","name":"U2AF2","route":"/targets/u2af2/","asOf":"2026-09-23","days":5},{"id":"ubxn11","kind":"target","name":"UBXN11","route":"/targets/ubxn11/","asOf":"2026-09-23","days":5},{"id":"vav1","kind":"target","name":"VAV1","route":"/targets/vav1/","asOf":"2026-09-23","days":5},{"id":"wnt1","kind":"target","name":"WNT1","route":"/targets/wnt1/","asOf":"2026-09-23","days":5},{"id":"zbtb20","kind":"target","name":"ZBTB20","route":"/targets/zbtb20/","asOf":"2026-09-23","days":5},{"id":"zbtb48","kind":"target","name":"ZBTB48","route":"/targets/zbtb48/","asOf":"2026-09-23","days":5},{"id":"zbtb7b","kind":"target","name":"ZBTB7B","route":"/targets/zbtb7b/","asOf":"2026-09-23","days":5},{"id":"zcchc8","kind":"target","name":"ZCCHC8","route":"/targets/zcchc8/","asOf":"2026-09-23","days":5},{"id":"zcrb1","kind":"target","name":"ZCRB1","route":"/targets/zcrb1/","asOf":"2026-09-23","days":5},{"id":"znf208","kind":"target","name":"ZNF208","route":"/targets/znf208/","asOf":"2026-09-23","days":5},{"id":"znf274","kind":"target","name":"ZNF274","route":"/targets/znf274/","asOf":"2026-09-23","days":5},{"id":"znf395","kind":"target","name":"ZNF395","route":"/targets/znf395/","asOf":"2026-09-23","days":5},{"id":"znf626","kind":"target","name":"ZNF626","route":"/targets/znf626/","asOf":"2026-09-23","days":5},{"id":"znf680","kind":"target","name":"ZNF680","route":"/targets/znf680/","asOf":"2026-09-23","days":5},{"id":"znf721","kind":"target","name":"ZNF721","route":"/targets/znf721/","asOf":"2026-09-23","days":5},{"id":"znf780a","kind":"target","name":"ZNF780A","route":"/targets/znf780a/","asOf":"2026-09-23","days":5},{"id":"znf814","kind":"target","name":"ZNF814","route":"/targets/znf814/","asOf":"2026-09-23","days":5},{"id":"znf90","kind":"target","name":"ZNF90","route":"/targets/znf90/","asOf":"2026-09-23","days":5},{"id":"znf93","kind":"target","name":"ZNF93","route":"/targets/znf93/","asOf":"2026-09-23","days":5},{"id":"zxdb","kind":"target","name":"ZXDB","route":"/targets/zxdb/","asOf":"2026-09-23","days":5},{"id":"mutyh","kind":"target","name":"MUTYH","route":"/targets/mutyh/","asOf":"2026-09-23","days":5},{"id":"ext1","kind":"target","name":"EXT1","route":"/targets/ext1/","asOf":"2026-09-23","days":5},{"id":"fancd2","kind":"target","name":"FANCD2","route":"/targets/fancd2/","asOf":"2026-09-23","days":5},{"id":"pax6","kind":"target","name":"PAX6","route":"/targets/pax6/","asOf":"2026-09-23","days":5},{"id":"blm","kind":"target","name":"BLM","route":"/targets/blm/","asOf":"2026-09-23","days":5},{"id":"xpa","kind":"target","name":"XPA","route":"/targets/xpa/","asOf":"2026-09-23","days":5},{"id":"sdhaf2","kind":"target","name":"SDHAF2","route":"/targets/sdhaf2/","asOf":"2026-09-23","days":5},{"id":"pax3","kind":"target","name":"PAX3","route":"/targets/pax3/","asOf":"2026-09-23","days":5},{"id":"lpp","kind":"target","name":"LPP","route":"/targets/lpp/","asOf":"2026-09-23","days":5},{"id":"strn","kind":"target","name":"STRN","route":"/targets/strn/","asOf":"2026-09-23","days":5},{"id":"bub1b","kind":"target","name":"BUB1B","route":"/targets/bub1b/","asOf":"2026-09-23","days":5},{"id":"hnf1b","kind":"target","name":"HNF1B","route":"/targets/hnf1b/","asOf":"2026-09-23","days":5},{"id":"c11orf65","kind":"target","name":"C11orf65","route":"/targets/c11orf65/","asOf":"2026-09-23","days":5},{"id":"arhgap26","kind":"target","name":"ARHGAP26","route":"/targets/arhgap26/","asOf":"2026-09-23","days":5},{"id":"fgf10","kind":"target","name":"FGF10","route":"/targets/fgf10/","asOf":"2026-09-23","days":5},{"id":"rmi2","kind":"target","name":"RMI2","route":"/targets/rmi2/","asOf":"2026-09-23","days":5},{"id":"tfe3","kind":"target","name":"TFE3","route":"/targets/tfe3/","asOf":"2026-09-23","days":5},{"id":"fance","kind":"target","name":"FANCE","route":"/targets/fance/","asOf":"2026-09-23","days":5},{"id":"fancg","kind":"target","name":"FANCG","route":"/targets/fancg/","asOf":"2026-09-23","days":5},{"id":"sdhc","kind":"target","name":"SDHC","route":"/targets/sdhc/","asOf":"2026-09-23","days":5},{"id":"elac2","kind":"target","name":"ELAC2","route":"/targets/elac2/","asOf":"2026-09-23","days":5},{"id":"mprip","kind":"target","name":"MPRIP","route":"/targets/mprip/","asOf":"2026-09-23","days":5},{"id":"mllt10","kind":"target","name":"MLLT10","route":"/targets/mllt10/","asOf":"2026-09-23","days":5},{"id":"nthl1","kind":"target","name":"NTHL1","route":"/targets/nthl1/","asOf":"2026-09-23","days":5},{"id":"tmem127","kind":"target","name":"TMEM127","route":"/targets/tmem127/","asOf":"2026-09-23","days":5},{"id":"fancf","kind":"target","name":"FANCF","route":"/targets/fancf/","asOf":"2026-09-23","days":5},{"id":"rad51","kind":"target","name":"RAD51","route":"/targets/rad51/","asOf":"2026-09-23","days":5},{"id":"pax7","kind":"target","name":"PAX7","route":"/targets/pax7/","asOf":"2026-09-23","days":5},{"id":"tpm3","kind":"target","name":"TPM3","route":"/targets/tpm3/","asOf":"2026-09-23","days":5},{"id":"ext2","kind":"target","name":"EXT2","route":"/targets/ext2/","asOf":"2026-09-23","days":5},{"id":"sdhd","kind":"target","name":"SDHD","route":"/targets/sdhd/","asOf":"2026-09-23","days":5},{"id":"cars1","kind":"target","name":"CARS1","route":"/targets/cars1/","asOf":"2026-09-23","days":5},{"id":"atic","kind":"target","name":"ATIC","route":"/targets/atic/","asOf":"2026-09-23","days":5},{"id":"cep43","kind":"target","name":"CEP43","route":"/targets/cep43/","asOf":"2026-09-23","days":5},{"id":"gab2","kind":"target","name":"GAB2","route":"/targets/gab2/","asOf":"2026-09-23","days":5},{"id":"mrtfa","kind":"target","name":"MRTFA","route":"/targets/mrtfa/","asOf":"2026-09-23","days":5},{"id":"srgap1","kind":"target","name":"SRGAP1","route":"/targets/srgap1/","asOf":"2026-09-23","days":5},{"id":"atf1","kind":"target","name":"ATF1","route":"/targets/atf1/","asOf":"2026-09-23","days":5},{"id":"cbfa2t3","kind":"target","name":"CBFA2T3","route":"/targets/cbfa2t3/","asOf":"2026-09-23","days":5},{"id":"trim28","kind":"target","name":"TRIM28","route":"/targets/trim28/","asOf":"2026-09-23","days":5},{"id":"hmga2","kind":"target","name":"HMGA2","route":"/targets/hmga2/","asOf":"2026-09-23","days":5},{"id":"xpc","kind":"target","name":"XPC","route":"/targets/xpc/","asOf":"2026-09-23","days":5},{"id":"xrcc2","kind":"target","name":"XRCC2","route":"/targets/xrcc2/","asOf":"2026-09-23","days":5},{"id":"sox2","kind":"target","name":"SOX2","route":"/targets/sox2/","asOf":"2026-09-23","days":5},{"id":"fes","kind":"target","name":"FES","route":"/targets/fes/","asOf":"2026-09-23","days":5},{"id":"dnm2","kind":"target","name":"DNM2","route":"/targets/dnm2/","asOf":"2026-09-23","days":5},{"id":"ssx1","kind":"target","name":"SSX1","route":"/targets/ssx1/","asOf":"2026-09-23","days":5},{"id":"mlh3","kind":"target","name":"MLH3","route":"/targets/mlh3/","asOf":"2026-09-23","days":5},{"id":"ksr2","kind":"target","name":"KSR2","route":"/targets/ksr2/","asOf":"2026-09-23","days":5},{"id":"nrg3","kind":"target","name":"NRG3","route":"/targets/nrg3/","asOf":"2026-09-23","days":5},{"id":"exo1","kind":"target","name":"EXO1","route":"/targets/exo1/","asOf":"2026-09-23","days":5},{"id":"jag1","kind":"target","name":"JAG1","route":"/targets/jag1/","asOf":"2026-09-23","days":5},{"id":"prf1","kind":"target","name":"PRF1","route":"/targets/prf1/","asOf":"2026-09-23","days":5},{"id":"maml3","kind":"target","name":"MAML3","route":"/targets/maml3/","asOf":"2026-09-23","days":5},{"id":"ppp2r1b","kind":"target","name":"PPP2R1B","route":"/targets/ppp2r1b/","asOf":"2026-09-23","days":5},{"id":"fgf9","kind":"target","name":"FGF9","route":"/targets/fgf9/","asOf":"2026-09-23","days":5},{"id":"nfib","kind":"target","name":"NFIB","route":"/targets/nfib/","asOf":"2026-09-23","days":5},{"id":"lmo1","kind":"target","name":"LMO1","route":"/targets/lmo1/","asOf":"2026-09-23","days":5},{"id":"stn1","kind":"target","name":"STN1","route":"/targets/stn1/","asOf":"2026-09-23","days":5},{"id":"iqgap1","kind":"target","name":"IQGAP1","route":"/targets/iqgap1/","asOf":"2026-09-23","days":5},{"id":"vwf","kind":"target","name":"VWF","route":"/targets/vwf/","asOf":"2026-09-23","days":5},{"id":"rbbp8","kind":"target","name":"RBBP8","route":"/targets/rbbp8/","asOf":"2026-09-23","days":5},{"id":"kdm7a","kind":"target","name":"KDM7A","route":"/targets/kdm7a/","asOf":"2026-09-23","days":5},{"id":"hoxd11","kind":"target","name":"HOXD11","route":"/targets/hoxd11/","asOf":"2026-09-23","days":5},{"id":"ogg1","kind":"target","name":"OGG1","route":"/targets/ogg1/","asOf":"2026-09-23","days":5},{"id":"shc1","kind":"target","name":"SHC1","route":"/targets/shc1/","asOf":"2026-09-23","days":5},{"id":"lmo2","kind":"target","name":"LMO2","route":"/targets/lmo2/","asOf":"2026-09-23","days":5},{"id":"pou5f1b","kind":"target","name":"POU5F1B","route":"/targets/pou5f1b/","asOf":"2026-09-23","days":5},{"id":"lrrfip1","kind":"target","name":"LRRFIP1","route":"/targets/lrrfip1/","asOf":"2026-09-23","days":5},{"id":"lmna","kind":"target","name":"LMNA","route":"/targets/lmna/","asOf":"2026-09-23","days":5},{"id":"ctr9","kind":"target","name":"CTR9","route":"/targets/ctr9/","asOf":"2026-09-23","days":5},{"id":"btc","kind":"target","name":"BTC","route":"/targets/btc/","asOf":"2026-09-23","days":5},{"id":"frs2","kind":"target","name":"FRS2","route":"/targets/frs2/","asOf":"2026-09-23","days":5},{"id":"hmga1","kind":"target","name":"HMGA1","route":"/targets/hmga1/","asOf":"2026-09-23","days":5},{"id":"ddit3","kind":"target","name":"DDIT3","route":"/targets/ddit3/","asOf":"2026-09-23","days":5},{"id":"sbds","kind":"target","name":"SBDS","route":"/targets/sbds/","asOf":"2026-09-23","days":5},{"id":"hlf","kind":"target","name":"HLF","route":"/targets/hlf/","asOf":"2026-09-23","days":5},{"id":"gab1","kind":"target","name":"GAB1","route":"/targets/gab1/","asOf":"2026-09-23","days":5},{"id":"sptbn1","kind":"target","name":"SPTBN1","route":"/targets/sptbn1/","asOf":"2026-09-23","days":5},{"id":"wwox","kind":"target","name":"WWOX","route":"/targets/wwox/","asOf":"2026-09-23","days":5},{"id":"kat2b","kind":"target","name":"KAT2B","route":"/targets/kat2b/","asOf":"2026-09-23","days":5},{"id":"ss18","kind":"target","name":"SS18","route":"/targets/ss18/","asOf":"2026-09-23","days":5},{"id":"foxe1","kind":"target","name":"FOXE1","route":"/targets/foxe1/","asOf":"2026-09-23","days":5},{"id":"oca2","kind":"target","name":"OCA2","route":"/targets/oca2/","asOf":"2026-09-23","days":5},{"id":"erbin","kind":"target","name":"ERBIN","route":"/targets/erbin/","asOf":"2026-09-23","days":5},{"id":"tln1","kind":"target","name":"TLN1","route":"/targets/tln1/","asOf":"2026-09-23","days":5},{"id":"mark3","kind":"target","name":"MARK3","route":"/targets/mark3/","asOf":"2026-09-23","days":5},{"id":"mxi1","kind":"target","name":"MXI1","route":"/targets/mxi1/","asOf":"2026-09-23","days":5},{"id":"crtc3","kind":"target","name":"CRTC3","route":"/targets/crtc3/","asOf":"2026-09-23","days":5},{"id":"etnk1","kind":"target","name":"ETNK1","route":"/targets/etnk1/","asOf":"2026-09-23","days":5},{"id":"sfrp4","kind":"target","name":"SFRP4","route":"/targets/sfrp4/","asOf":"2026-09-23","days":5},{"id":"erlin2","kind":"target","name":"ERLIN2","route":"/targets/erlin2/","asOf":"2026-09-23","days":5},{"id":"myo18a","kind":"target","name":"MYO18A","route":"/targets/myo18a/","asOf":"2026-09-23","days":5},{"id":"fgf5","kind":"target","name":"FGF5","route":"/targets/fgf5/","asOf":"2026-09-23","days":5},{"id":"csk","kind":"target","name":"CSK","route":"/targets/csk/","asOf":"2026-09-23","days":5},{"id":"wif1","kind":"target","name":"WIF1","route":"/targets/wif1/","asOf":"2026-09-23","days":5},{"id":"minpp1","kind":"target","name":"MINPP1","route":"/targets/minpp1/","asOf":"2026-09-23","days":5},{"id":"msmb","kind":"target","name":"MSMB","route":"/targets/msmb/","asOf":"2026-09-23","days":5},{"id":"fmn1","kind":"target","name":"FMN1","route":"/targets/fmn1/","asOf":"2026-09-23","days":5},{"id":"creb3l2","kind":"target","name":"CREB3L2","route":"/targets/creb3l2/","asOf":"2026-09-23","days":5},{"id":"cdc37","kind":"target","name":"CDC37","route":"/targets/cdc37/","asOf":"2026-09-23","days":5},{"id":"creb1","kind":"target","name":"CREB1","route":"/targets/creb1/","asOf":"2026-09-23","days":5},{"id":"fgf8","kind":"target","name":"FGF8","route":"/targets/fgf8/","asOf":"2026-09-23","days":5},{"id":"ndrg1","kind":"target","name":"NDRG1","route":"/targets/ndrg1/","asOf":"2026-09-23","days":5},{"id":"hoxa13","kind":"target","name":"HOXA13","route":"/targets/hoxa13/","asOf":"2026-09-23","days":5},{"id":"dll1","kind":"target","name":"DLL1","route":"/targets/dll1/","asOf":"2026-09-23","days":5},{"id":"fgf18","kind":"target","name":"FGF18","route":"/targets/fgf18/","asOf":"2026-09-23","days":5},{"id":"ddx10","kind":"target","name":"DDX10","route":"/targets/ddx10/","asOf":"2026-09-23","days":5},{"id":"kitlg","kind":"target","name":"KITLG","route":"/targets/kitlg/","asOf":"2026-09-23","days":5},{"id":"creb3l1","kind":"target","name":"CREB3L1","route":"/targets/creb3l1/","asOf":"2026-09-23","days":5},{"id":"kat2a","kind":"target","name":"KAT2A","route":"/targets/kat2a/","asOf":"2026-09-23","days":5},{"id":"ksr1","kind":"target","name":"KSR1","route":"/targets/ksr1/","asOf":"2026-09-23","days":5},{"id":"apobec3b","kind":"target","name":"APOBEC3B","route":"/targets/apobec3b/","asOf":"2026-09-23","days":5},{"id":"ywhae","kind":"target","name":"YWHAE","route":"/targets/ywhae/","asOf":"2026-09-23","days":5},{"id":"papss1","kind":"target","name":"PAPSS1","route":"/targets/papss1/","asOf":"2026-09-23","days":5},{"id":"per1","kind":"target","name":"PER1","route":"/targets/per1/","asOf":"2026-09-23","days":5},{"id":"map3k13","kind":"target","name":"MAP3K13","route":"/targets/map3k13/","asOf":"2026-09-23","days":5},{"id":"fancm","kind":"target","name":"FANCM","route":"/targets/fancm/","asOf":"2026-09-23","days":5},{"id":"fgf20","kind":"target","name":"FGF20","route":"/targets/fgf20/","asOf":"2026-09-23","days":5},{"id":"ncoa4","kind":"target","name":"NCOA4","route":"/targets/ncoa4/","asOf":"2026-09-23","days":5},{"id":"tpm4","kind":"target","name":"TPM4","route":"/targets/tpm4/","asOf":"2026-09-23","days":5},{"id":"pbx1","kind":"target","name":"PBX1","route":"/targets/pbx1/","asOf":"2026-09-23","days":5},{"id":"arrb1","kind":"target","name":"ARRB1","route":"/targets/arrb1/","asOf":"2026-09-23","days":5},{"id":"itga2b","kind":"target","name":"ITGA2B","route":"/targets/itga2b/","asOf":"2026-09-23","days":5},{"id":"fanci","kind":"target","name":"FANCI","route":"/targets/fanci/","asOf":"2026-09-23","days":5},{"id":"abi1","kind":"target","name":"ABI1","route":"/targets/abi1/","asOf":"2026-09-23","days":5},{"id":"ywhab","kind":"target","name":"YWHAB","route":"/targets/ywhab/","asOf":"2026-09-23","days":5},{"id":"fgf17","kind":"target","name":"FGF17","route":"/targets/fgf17/","asOf":"2026-09-23","days":5},{"id":"dek","kind":"target","name":"DEK","route":"/targets/dek/","asOf":"2026-09-23","days":5},{"id":"fgf16","kind":"target","name":"FGF16","route":"/targets/fgf16/","asOf":"2026-09-23","days":5},{"id":"kiaa1549","kind":"target","name":"KIAA1549","route":"/targets/kiaa1549/","asOf":"2026-09-23","days":5},{"id":"dctn1","kind":"target","name":"DCTN1","route":"/targets/dctn1/","asOf":"2026-09-23","days":5},{"id":"mafb","kind":"target","name":"MAFB","route":"/targets/mafb/","asOf":"2026-09-23","days":5},{"id":"maml1","kind":"target","name":"MAML1","route":"/targets/maml1/","asOf":"2026-09-23","days":5},{"id":"vcl","kind":"target","name":"VCL","route":"/targets/vcl/","asOf":"2026-09-23","days":5},{"id":"sqstm1","kind":"target","name":"SQSTM1","route":"/targets/sqstm1/","asOf":"2026-09-23","days":5},{"id":"phox2b","kind":"target","name":"PHOX2B","route":"/targets/phox2b/","asOf":"2026-09-23","days":5},{"id":"apbb1ip","kind":"target","name":"APBB1IP","route":"/targets/apbb1ip/","asOf":"2026-09-23","days":5},{"id":"fam131b","kind":"target","name":"FAM131B","route":"/targets/fam131b/","asOf":"2026-09-23","days":5},{"id":"ssx2","kind":"target","name":"SSX2","route":"/targets/ssx2/","asOf":"2026-09-23","days":5},{"id":"rap1a","kind":"target","name":"RAP1A","route":"/targets/rap1a/","asOf":"2026-09-23","days":5},{"id":"actg1","kind":"target","name":"ACTG1","route":"/targets/actg1/","asOf":"2026-09-23","days":5},{"id":"arrb2","kind":"target","name":"ARRB2","route":"/targets/arrb2/","asOf":"2026-09-23","days":5},{"id":"ddx5","kind":"target","name":"DDX5","route":"/targets/ddx5/","asOf":"2026-09-23","days":5},{"id":"cnksr2","kind":"target","name":"CNKSR2","route":"/targets/cnksr2/","asOf":"2026-09-23","days":5},{"id":"lyl1","kind":"target","name":"LYL1","route":"/targets/lyl1/","asOf":"2026-09-23","days":5},{"id":"aspscr1","kind":"target","name":"ASPSCR1","route":"/targets/aspscr1/","asOf":"2026-09-23","days":5},{"id":"bcl3","kind":"target","name":"BCL3","route":"/targets/bcl3/","asOf":"2026-09-23","days":5},{"id":"mamld1","kind":"target","name":"MAMLD1","route":"/targets/mamld1/","asOf":"2026-09-23","days":5},{"id":"patz1","kind":"target","name":"PATZ1","route":"/targets/patz1/","asOf":"2026-09-23","days":5},{"id":"trim27","kind":"target","name":"TRIM27","route":"/targets/trim27/","asOf":"2026-09-23","days":5},{"id":"smarce1","kind":"target","name":"SMARCE1","route":"/targets/smarce1/","asOf":"2026-09-23","days":5},{"id":"rmi1","kind":"target","name":"RMI1","route":"/targets/rmi1/","asOf":"2026-09-23","days":5},{"id":"trak1","kind":"target","name":"TRAK1","route":"/targets/trak1/","asOf":"2026-09-23","days":5},{"id":"nutm2b","kind":"target","name":"NUTM2B","route":"/targets/nutm2b/","asOf":"2026-09-23","days":5},{"id":"rbpj","kind":"target","name":"RBPJ","route":"/targets/rbpj/","asOf":"2026-09-23","days":5},{"id":"olig2","kind":"target","name":"OLIG2","route":"/targets/olig2/","asOf":"2026-09-23","days":5},{"id":"cnksr1","kind":"target","name":"CNKSR1","route":"/targets/cnksr1/","asOf":"2026-09-23","days":5},{"id":"slc45a2","kind":"target","name":"SLC45A2","route":"/targets/slc45a2/","asOf":"2026-09-23","days":5},{"id":"mlf1","kind":"target","name":"MLF1","route":"/targets/mlf1/","asOf":"2026-09-23","days":5},{"id":"fgf6","kind":"target","name":"FGF6","route":"/targets/fgf6/","asOf":"2026-09-23","days":5},{"id":"cpvl","kind":"target","name":"CPVL","route":"/targets/cpvl/","asOf":"2026-09-23","days":5},{"id":"hoxd13","kind":"target","name":"HOXD13","route":"/targets/hoxd13/","asOf":"2026-09-23","days":5},{"id":"hoxa11","kind":"target","name":"HOXA11","route":"/targets/hoxa11/","asOf":"2026-09-23","days":5},{"id":"cd79a","kind":"target","name":"CD79A","route":"/targets/cd79a/","asOf":"2026-09-23","days":5},{"id":"slc67a1","kind":"target","name":"SLC67A1","route":"/targets/slc67a1/","asOf":"2026-09-23","days":5},{"id":"srsf3","kind":"target","name":"SRSF3","route":"/targets/srsf3/","asOf":"2026-09-23","days":5},{"id":"tlx3","kind":"target","name":"TLX3","route":"/targets/tlx3/","asOf":"2026-09-23","days":5},{"id":"bag4","kind":"target","name":"BAG4","route":"/targets/bag4/","asOf":"2026-09-23","days":5},{"id":"kank1","kind":"target","name":"KANK1","route":"/targets/kank1/","asOf":"2026-09-23","days":5},{"id":"jazf1","kind":"target","name":"JAZF1","route":"/targets/jazf1/","asOf":"2026-09-23","days":5},{"id":"hey1","kind":"target","name":"HEY1","route":"/targets/hey1/","asOf":"2026-09-23","days":5},{"id":"nrg2","kind":"target","name":"NRG2","route":"/targets/nrg2/","asOf":"2026-09-23","days":5},{"id":"cyp1b1","kind":"target","name":"CYP1B1","route":"/targets/cyp1b1/","asOf":"2026-09-23","days":5},{"id":"rhoh","kind":"target","name":"RHOH","route":"/targets/rhoh/","asOf":"2026-09-23","days":5},{"id":"mtcp1","kind":"target","name":"MTCP1","route":"/targets/mtcp1/","asOf":"2026-09-23","days":5},{"id":"cpsf6","kind":"target","name":"CPSF6","route":"/targets/cpsf6/","asOf":"2026-09-23","days":5},{"id":"tlx1","kind":"target","name":"TLX1","route":"/targets/tlx1/","asOf":"2026-09-23","days":5},{"id":"smad7","kind":"target","name":"SMAD7","route":"/targets/smad7/","asOf":"2026-09-23","days":5},{"id":"hoxc11","kind":"target","name":"HOXC11","route":"/targets/hoxc11/","asOf":"2026-09-23","days":5},{"id":"golgb1","kind":"target","name":"GOLGB1","route":"/targets/golgb1/","asOf":"2026-09-23","days":5},{"id":"nrg4","kind":"target","name":"NRG4","route":"/targets/nrg4/","asOf":"2026-09-23","days":5},{"id":"habp2","kind":"target","name":"HABP2","route":"/targets/habp2/","asOf":"2026-09-23","days":5},{"id":"sh3gl1","kind":"target","name":"SH3GL1","route":"/targets/sh3gl1/","asOf":"2026-09-23","days":5},{"id":"fgf22","kind":"target","name":"FGF22","route":"/targets/fgf22/","asOf":"2026-09-23","days":5},{"id":"fgfr1op2","kind":"target","name":"FGFR1OP2","route":"/targets/fgfr1op2/","asOf":"2026-09-23","days":5},{"id":"cnbp","kind":"target","name":"CNBP","route":"/targets/cnbp/","asOf":"2026-09-23","days":5},{"id":"mc1r","kind":"target","name":"MC1R","route":"/targets/mc1r/","asOf":"2026-09-23","days":5},{"id":"prkaca","kind":"target","name":"PRKACA","route":"/targets/prkaca/","asOf":"2026-09-23","days":5},{"id":"slx4","kind":"target","name":"SLX4","route":"/targets/slx4/","asOf":"2026-09-23","days":5},{"id":"ezr","kind":"target","name":"EZR","route":"/targets/ezr/","asOf":"2026-09-23","days":5},{"id":"otx1","kind":"target","name":"OTX1","route":"/targets/otx1/","asOf":"2026-09-23","days":5},{"id":"ppp2r5a","kind":"target","name":"PPP2R5A","route":"/targets/ppp2r5a/","asOf":"2026-09-23","days":5},{"id":"ktn1","kind":"target","name":"KTN1","route":"/targets/ktn1/","asOf":"2026-09-23","days":5},{"id":"snw1","kind":"target","name":"SNW1","route":"/targets/snw1/","asOf":"2026-09-23","days":5},{"id":"znf462","kind":"target","name":"ZNF462","route":"/targets/znf462/","asOf":"2026-09-23","days":5},{"id":"prc1","kind":"target","name":"PRC1","route":"/targets/prc1/","asOf":"2026-09-23","days":5},{"id":"ppp2r5c","kind":"target","name":"PPP2R5C","route":"/targets/ppp2r5c/","asOf":"2026-09-23","days":5},{"id":"adh1b","kind":"target","name":"ADH1B","route":"/targets/adh1b/","asOf":"2026-09-23","days":5},{"id":"krt5","kind":"target","name":"KRT5","route":"/targets/krt5/","asOf":"2026-09-23","days":5},{"id":"jag2","kind":"target","name":"JAG2","route":"/targets/jag2/","asOf":"2026-09-23","days":5},{"id":"tyr","kind":"target","name":"TYR","route":"/targets/tyr/","asOf":"2026-09-23","days":5},{"id":"csnk1a1","kind":"target","name":"CSNK1A1","route":"/targets/csnk1a1/","asOf":"2026-09-23","days":5},{"id":"spdl1","kind":"target","name":"SPDL1","route":"/targets/spdl1/","asOf":"2026-09-23","days":5},{"id":"rtel1","kind":"target","name":"RTEL1","route":"/targets/rtel1/","asOf":"2026-09-23","days":5},{"id":"ap3b1","kind":"target","name":"AP3B1","route":"/targets/ap3b1/","asOf":"2026-09-23","days":5},{"id":"ppp1r14a","kind":"target","name":"PPP1R14A","route":"/targets/ppp1r14a/","asOf":"2026-09-23","days":5},{"id":"erc1","kind":"target","name":"ERC1","route":"/targets/erc1/","asOf":"2026-09-23","days":5},{"id":"fev","kind":"target","name":"FEV","route":"/targets/fev/","asOf":"2026-09-23","days":5},{"id":"ccnb1ip1","kind":"target","name":"CCNB1IP1","route":"/targets/ccnb1ip1/","asOf":"2026-09-23","days":5},{"id":"ano7","kind":"target","name":"ANO7","route":"/targets/ano7/","asOf":"2026-09-23","days":5},{"id":"rnasel","kind":"target","name":"RNASEL","route":"/targets/rnasel/","asOf":"2026-09-23","days":5},{"id":"msr1","kind":"target","name":"MSR1","route":"/targets/msr1/","asOf":"2026-09-23","days":5},{"id":"esrp1","kind":"target","name":"ESRP1","route":"/targets/esrp1/","asOf":"2026-09-23","days":5},{"id":"zmiz1","kind":"target","name":"ZMIZ1","route":"/targets/zmiz1/","asOf":"2026-09-23","days":5},{"id":"gopc","kind":"target","name":"GOPC","route":"/targets/gopc/","asOf":"2026-09-23","days":5},{"id":"trps1","kind":"target","name":"TRPS1","route":"/targets/trps1/","asOf":"2026-09-23","days":5},{"id":"tg","kind":"target","name":"TG","route":"/targets/tg/","asOf":"2026-09-23","days":5},{"id":"dnmt3b","kind":"target","name":"DNMT3B","route":"/targets/dnmt3b/","asOf":"2026-09-23","days":5},{"id":"tnfrsf13b","kind":"target","name":"TNFRSF13B","route":"/targets/tnfrsf13b/","asOf":"2026-09-23","days":5},{"id":"polk","kind":"target","name":"POLK","route":"/targets/polk/","asOf":"2026-09-23","days":5},{"id":"neil1","kind":"target","name":"NEIL1","route":"/targets/neil1/","asOf":"2026-09-23","days":5},{"id":"tox3","kind":"target","name":"TOX3","route":"/targets/tox3/","asOf":"2026-09-23","days":5},{"id":"aggf1","kind":"target","name":"AGGF1","route":"/targets/aggf1/","asOf":"2026-09-23","days":5},{"id":"usp28","kind":"target","name":"USP28","route":"/targets/usp28/","asOf":"2026-09-23","days":5},{"id":"dock8","kind":"target","name":"DOCK8","route":"/targets/dock8/","asOf":"2026-09-23","days":5},{"id":"stil","kind":"target","name":"STIL","route":"/targets/stil/","asOf":"2026-09-23","days":5},{"id":"tns3","kind":"target","name":"TNS3","route":"/targets/tns3/","asOf":"2026-09-23","days":5},{"id":"ppfibp1","kind":"target","name":"PPFIBP1","route":"/targets/ppfibp1/","asOf":"2026-09-23","days":5},{"id":"dnajb1","kind":"target","name":"DNAJB1","route":"/targets/dnajb1/","asOf":"2026-09-23","days":5},{"id":"agtrap","kind":"target","name":"AGTRAP","route":"/targets/agtrap/","asOf":"2026-09-23","days":5},{"id":"foxo4","kind":"target","name":"FOXO4","route":"/targets/foxo4/","asOf":"2026-09-23","days":5},{"id":"ppp2r5e","kind":"target","name":"PPP2R5E","route":"/targets/ppp2r5e/","asOf":"2026-09-23","days":5},{"id":"sfpq","kind":"target","name":"SFPQ","route":"/targets/sfpq/","asOf":"2026-09-23","days":5},{"id":"fxr1","kind":"target","name":"FXR1","route":"/targets/fxr1/","asOf":"2026-09-23","days":5},{"id":"bnc2","kind":"target","name":"BNC2","route":"/targets/bnc2/","asOf":"2026-09-23","days":5},{"id":"ctsh","kind":"target","name":"CTSH","route":"/targets/ctsh/","asOf":"2026-09-23","days":5},{"id":"eed","kind":"target","name":"EED","route":"/targets/eed/","asOf":"2026-09-23","days":5},{"id":"agk","kind":"target","name":"AGK","route":"/targets/agk/","asOf":"2026-09-23","days":5},{"id":"lmo7","kind":"target","name":"LMO7","route":"/targets/lmo7/","asOf":"2026-09-23","days":5},{"id":"ctss","kind":"target","name":"CTSS","route":"/targets/ctss/","asOf":"2026-09-23","days":5},{"id":"casp10","kind":"target","name":"CASP10","route":"/targets/casp10/","asOf":"2026-09-23","days":5},{"id":"tent4a","kind":"target","name":"TENT4A","route":"/targets/tent4a/","asOf":"2026-09-23","days":5},{"id":"poglut3","kind":"target","name":"POGLUT3","route":"/targets/poglut3/","asOf":"2026-09-23","days":5},{"id":"cdca7","kind":"target","name":"CDCA7","route":"/targets/cdca7/","asOf":"2026-09-23","days":5},{"id":"tgm3","kind":"target","name":"TGM3","route":"/targets/tgm3/","asOf":"2026-09-23","days":5},{"id":"grem1","kind":"target","name":"GREM1","route":"/targets/grem1/","asOf":"2026-09-23","days":5},{"id":"inhbb","kind":"target","name":"INHBB","route":"/targets/inhbb/","asOf":"2026-09-23","days":5},{"id":"lamc1","kind":"target","name":"LAMC1","route":"/targets/lamc1/","asOf":"2026-09-23","days":5},{"id":"rnaset2","kind":"target","name":"RNASET2","route":"/targets/rnaset2/","asOf":"2026-09-23","days":5},{"id":"golga5","kind":"target","name":"GOLGA5","route":"/targets/golga5/","asOf":"2026-09-23","days":5},{"id":"ppp2r5d","kind":"target","name":"PPP2R5D","route":"/targets/ppp2r5d/","asOf":"2026-09-23","days":5},{"id":"wdcp","kind":"target","name":"WDCP","route":"/targets/wdcp/","asOf":"2026-09-23","days":5},{"id":"rassf6","kind":"target","name":"RASSF6","route":"/targets/rassf6/","asOf":"2026-09-23","days":5},{"id":"zc3hav1","kind":"target","name":"ZC3HAV1","route":"/targets/zc3hav1/","asOf":"2026-09-23","days":5},{"id":"pnpla3","kind":"target","name":"PNPLA3","route":"/targets/pnpla3/","asOf":"2026-09-23","days":5},{"id":"nab2","kind":"target","name":"NAB2","route":"/targets/nab2/","asOf":"2026-09-23","days":5},{"id":"chchd7","kind":"target","name":"CHCHD7","route":"/targets/chchd7/","asOf":"2026-09-23","days":5},{"id":"rhobtb2","kind":"target","name":"RHOBTB2","route":"/targets/rhobtb2/","asOf":"2026-09-23","days":5},{"id":"tyrp1","kind":"target","name":"TYRP1","route":"/targets/tyrp1/","asOf":"2026-09-23","days":5},{"id":"dna2","kind":"target","name":"DNA2","route":"/targets/dna2/","asOf":"2026-09-23","days":5},{"id":"bmp4","kind":"target","name":"BMP4","route":"/targets/bmp4/","asOf":"2026-09-23","days":5},{"id":"sdccag8","kind":"target","name":"SDCCAG8","route":"/targets/sdccag8/","asOf":"2026-09-23","days":5},{"id":"naf1","kind":"target","name":"NAF1","route":"/targets/naf1/","asOf":"2026-09-23","days":5},{"id":"kat5","kind":"target","name":"KAT5","route":"/targets/kat5/","asOf":"2026-09-23","days":5},{"id":"dclre1b","kind":"target","name":"DCLRE1B","route":"/targets/dclre1b/","asOf":"2026-09-23","days":5},{"id":"clcn6","kind":"target","name":"CLCN6","route":"/targets/clcn6/","asOf":"2026-09-23","days":5},{"id":"vps53","kind":"target","name":"VPS53","route":"/targets/vps53/","asOf":"2026-09-23","days":5},{"id":"top3a","kind":"target","name":"TOP3A","route":"/targets/top3a/","asOf":"2026-09-23","days":5},{"id":"fip1l1","kind":"target","name":"FIP1L1","route":"/targets/fip1l1/","asOf":"2026-09-23","days":5},{"id":"irs1","kind":"target","name":"IRS1","route":"/targets/irs1/","asOf":"2026-09-23","days":5},{"id":"ppp2r5b","kind":"target","name":"PPP2R5B","route":"/targets/ppp2r5b/","asOf":"2026-09-23","days":5},{"id":"sntb1","kind":"target","name":"SNTB1","route":"/targets/sntb1/","asOf":"2026-09-23","days":5},{"id":"fam114a2","kind":"target","name":"FAM114A2","route":"/targets/fam114a2/","asOf":"2026-09-23","days":5},{"id":"tcea1","kind":"target","name":"TCEA1","route":"/targets/tcea1/","asOf":"2026-09-23","days":5},{"id":"slc22a3","kind":"target","name":"SLC22A3","route":"/targets/slc22a3/","asOf":"2026-09-23","days":5},{"id":"apoe","kind":"target","name":"APOE","route":"/targets/apoe/","asOf":"2026-09-23","days":5},{"id":"slc24a5","kind":"target","name":"SLC24A5","route":"/targets/slc24a5/","asOf":"2026-09-23","days":5},{"id":"hook3","kind":"target","name":"HOOK3","route":"/targets/hook3/","asOf":"2026-09-23","days":5},{"id":"zbtb10","kind":"target","name":"ZBTB10","route":"/targets/zbtb10/","asOf":"2026-09-23","days":5},{"id":"abo","kind":"target","name":"ABO","route":"/targets/abo/","asOf":"2026-09-23","days":5},{"id":"ccdc170","kind":"target","name":"CCDC170","route":"/targets/ccdc170/","asOf":"2026-09-23","days":5},{"id":"hhip","kind":"target","name":"HHIP","route":"/targets/hhip/","asOf":"2026-09-23","days":5},{"id":"lig4","kind":"target","name":"LIG4","route":"/targets/lig4/","asOf":"2026-09-23","days":5},{"id":"chrna5","kind":"target","name":"CHRNA5","route":"/targets/chrna5/","asOf":"2026-09-23","days":5},{"id":"eif2ak3","kind":"target","name":"EIF2AK3","route":"/targets/eif2ak3/","asOf":"2026-09-23","days":5},{"id":"golga4","kind":"target","name":"GOLGA4","route":"/targets/golga4/","asOf":"2026-09-23","days":5},{"id":"fermt2","kind":"target","name":"FERMT2","route":"/targets/fermt2/","asOf":"2026-09-23","days":5},{"id":"pms1","kind":"target","name":"PMS1","route":"/targets/pms1/","asOf":"2026-09-23","days":5},{"id":"prcc","kind":"target","name":"PRCC","route":"/targets/prcc/","asOf":"2026-09-23","days":5},{"id":"tmem17","kind":"target","name":"TMEM17","route":"/targets/tmem17/","asOf":"2026-09-23","days":5},{"id":"tpcn2","kind":"target","name":"TPCN2","route":"/targets/tpcn2/","asOf":"2026-09-23","days":5},{"id":"ehbp1","kind":"target","name":"EHBP1","route":"/targets/ehbp1/","asOf":"2026-09-23","days":5},{"id":"fancb","kind":"target","name":"FANCB","route":"/targets/fancb/","asOf":"2026-09-23","days":5},{"id":"dlc1","kind":"target","name":"DLC1","route":"/targets/dlc1/","asOf":"2026-09-23","days":5},{"id":"lrp5","kind":"target","name":"LRP5","route":"/targets/lrp5/","asOf":"2026-09-23","days":5},{"id":"plxnb2","kind":"target","name":"PLXNB2","route":"/targets/plxnb2/","asOf":"2026-09-23","days":5},{"id":"ubc","kind":"target","name":"UBC","route":"/targets/ubc/","asOf":"2026-09-23","days":5},{"id":"nr5a2","kind":"target","name":"NR5A2","route":"/targets/nr5a2/","asOf":"2026-09-23","days":5},{"id":"tmem238l","kind":"target","name":"TMEM238L","route":"/targets/tmem238l/","asOf":"2026-09-23","days":5},{"id":"arhgef5","kind":"target","name":"ARHGEF5","route":"/targets/arhgef5/","asOf":"2026-09-23","days":5},{"id":"ubb","kind":"target","name":"UBB","route":"/targets/ubb/","asOf":"2026-09-23","days":5},{"id":"l3mbtl3","kind":"target","name":"L3MBTL3","route":"/targets/l3mbtl3/","asOf":"2026-09-23","days":5},{"id":"itga6","kind":"target","name":"ITGA6","route":"/targets/itga6/","asOf":"2026-09-23","days":5},{"id":"ptpn22","kind":"target","name":"PTPN22","route":"/targets/ptpn22/","asOf":"2026-09-23","days":5},{"id":"lama5","kind":"target","name":"LAMA5","route":"/targets/lama5/","asOf":"2026-09-23","days":5},{"id":"lsp1","kind":"target","name":"LSP1","route":"/targets/lsp1/","asOf":"2026-09-23","days":5},{"id":"bmp5","kind":"target","name":"BMP5","route":"/targets/bmp5/","asOf":"2026-09-23","days":5},{"id":"sim2","kind":"target","name":"SIM2","route":"/targets/sim2/","asOf":"2026-09-23","days":5},{"id":"ccnh","kind":"target","name":"CCNH","route":"/targets/ccnh/","asOf":"2026-09-23","days":5},{"id":"irf5","kind":"target","name":"IRF5","route":"/targets/irf5/","asOf":"2026-09-23","days":5},{"id":"klc1","kind":"target","name":"KLC1","route":"/targets/klc1/","asOf":"2026-09-23","days":5},{"id":"skp1","kind":"target","name":"SKP1","route":"/targets/skp1/","asOf":"2026-09-23","days":5},{"id":"uba52","kind":"target","name":"UBA52","route":"/targets/uba52/","asOf":"2026-09-23","days":5},{"id":"cul1","kind":"target","name":"CUL1","route":"/targets/cul1/","asOf":"2026-09-23","days":5},{"id":"chmp4c","kind":"target","name":"CHMP4C","route":"/targets/chmp4c/","asOf":"2026-09-23","days":5},{"id":"mov10","kind":"target","name":"MOV10","route":"/targets/mov10/","asOf":"2026-09-23","days":5},{"id":"igf2r","kind":"target","name":"IGF2R","route":"/targets/igf2r/","asOf":"2026-09-23","days":5},{"id":"rgs17","kind":"target","name":"RGS17","route":"/targets/rgs17/","asOf":"2026-09-23","days":5},{"id":"clptm1l","kind":"target","name":"CLPTM1L","route":"/targets/clptm1l/","asOf":"2026-09-23","days":5},{"id":"zfpm2","kind":"target","name":"ZFPM2","route":"/targets/zfpm2/","asOf":"2026-09-23","days":5},{"id":"incenp","kind":"target","name":"INCENP","route":"/targets/incenp/","asOf":"2026-09-23","days":5},{"id":"lrfn2","kind":"target","name":"LRFN2","route":"/targets/lrfn2/","asOf":"2026-09-23","days":5},{"id":"ppm1b","kind":"target","name":"PPM1B","route":"/targets/ppm1b/","asOf":"2026-09-23","days":5},{"id":"tnfsf10","kind":"target","name":"TNFSF10","route":"/targets/tnfsf10/","asOf":"2026-09-23","days":5},{"id":"pax9","kind":"target","name":"PAX9","route":"/targets/pax9/","asOf":"2026-09-23","days":5},{"id":"rcc2","kind":"target","name":"RCC2","route":"/targets/rcc2/","asOf":"2026-09-23","days":5},{"id":"nrip1","kind":"target","name":"NRIP1","route":"/targets/nrip1/","asOf":"2026-09-23","days":5},{"id":"tns1","kind":"target","name":"TNS1","route":"/targets/tns1/","asOf":"2026-09-23","days":5},{"id":"irx4","kind":"target","name":"IRX4","route":"/targets/irx4/","asOf":"2026-09-23","days":5},{"id":"mx2","kind":"target","name":"MX2","route":"/targets/mx2/","asOf":"2026-09-23","days":5},{"id":"adam29","kind":"target","name":"ADAM29","route":"/targets/adam29/","asOf":"2026-09-23","days":5},{"id":"mt-cyb","kind":"target","name":"MT-CYB","route":"/targets/mt-cyb/","asOf":"2026-09-23","days":5},{"id":"tbx1","kind":"target","name":"TBX1","route":"/targets/tbx1/","asOf":"2026-09-23","days":5},{"id":"ccdc88c","kind":"target","name":"CCDC88C","route":"/targets/ccdc88c/","asOf":"2026-09-23","days":5},{"id":"rbbp7","kind":"target","name":"RBBP7","route":"/targets/rbbp7/","asOf":"2026-09-23","days":5},{"id":"foxp4","kind":"target","name":"FOXP4","route":"/targets/foxp4/","asOf":"2026-09-23","days":5},{"id":"itpr1","kind":"target","name":"ITPR1","route":"/targets/itpr1/","asOf":"2026-09-23","days":5},{"id":"skil","kind":"target","name":"SKIL","route":"/targets/skil/","asOf":"2026-09-23","days":5},{"id":"nek10","kind":"target","name":"NEK10","route":"/targets/nek10/","asOf":"2026-09-23","days":5},{"id":"celf2","kind":"target","name":"CELF2","route":"/targets/celf2/","asOf":"2026-09-23","days":5},{"id":"toe1","kind":"target","name":"TOE1","route":"/targets/toe1/","asOf":"2026-09-23","days":5},{"id":"bik","kind":"target","name":"BIK","route":"/targets/bik/","asOf":"2026-09-23","days":5},{"id":"sidt1","kind":"target","name":"SIDT1","route":"/targets/sidt1/","asOf":"2026-09-23","days":5},{"id":"grhl2","kind":"target","name":"GRHL2","route":"/targets/grhl2/","asOf":"2026-09-23","days":5},{"id":"frs3","kind":"target","name":"FRS3","route":"/targets/frs3/","asOf":"2026-09-23","days":5},{"id":"gdf7","kind":"target","name":"GDF7","route":"/targets/gdf7/","asOf":"2026-09-23","days":5},{"id":"vti1a","kind":"target","name":"VTI1A","route":"/targets/vti1a/","asOf":"2026-09-23","days":5},{"id":"bmp2","kind":"target","name":"BMP2","route":"/targets/bmp2/","asOf":"2026-09-23","days":5},{"id":"dnah11","kind":"target","name":"DNAH11","route":"/targets/dnah11/","asOf":"2026-09-23","days":5},{"id":"chrna3","kind":"target","name":"CHRNA3","route":"/targets/chrna3/","asOf":"2026-09-23","days":5},{"id":"herpud1","kind":"target","name":"HERPUD1","route":"/targets/herpud1/","asOf":"2026-09-23","days":5},{"id":"dnajc1","kind":"target","name":"DNAJC1","route":"/targets/dnajc1/","asOf":"2026-09-23","days":5},{"id":"pcnx2","kind":"target","name":"PCNX2","route":"/targets/pcnx2/","asOf":"2026-09-23","days":5},{"id":"wrap53","kind":"target","name":"WRAP53","route":"/targets/wrap53/","asOf":"2026-09-23","days":5},{"id":"samd9l","kind":"target","name":"SAMD9L","route":"/targets/samd9l/","asOf":"2026-09-23","days":5},{"id":"slc14a1","kind":"target","name":"SLC14A1","route":"/targets/slc14a1/","asOf":"2026-09-23","days":5},{"id":"zfhx4","kind":"target","name":"ZFHX4","route":"/targets/zfhx4/","asOf":"2026-09-23","days":5},{"id":"mlph","kind":"target","name":"MLPH","route":"/targets/mlph/","asOf":"2026-09-23","days":5},{"id":"rfwd3","kind":"target","name":"RFWD3","route":"/targets/rfwd3/","asOf":"2026-09-23","days":5},{"id":"cdkal1","kind":"target","name":"CDKAL1","route":"/targets/cdkal1/","asOf":"2026-09-23","days":5},{"id":"ebf2","kind":"target","name":"EBF2","route":"/targets/ebf2/","asOf":"2026-09-23","days":5},{"id":"hnf4g","kind":"target","name":"HNF4G","route":"/targets/hnf4g/","asOf":"2026-09-23","days":5},{"id":"elp4","kind":"target","name":"ELP4","route":"/targets/elp4/","asOf":"2026-09-23","days":5},{"id":"sorcs3","kind":"target","name":"SORCS3","route":"/targets/sorcs3/","asOf":"2026-09-23","days":5},{"id":"mcm8","kind":"target","name":"MCM8","route":"/targets/mcm8/","asOf":"2026-09-23","days":5},{"id":"tbpl1","kind":"target","name":"TBPL1","route":"/targets/tbpl1/","asOf":"2026-09-23","days":5},{"id":"pdgfrl","kind":"target","name":"PDGFRL","route":"/targets/pdgfrl/","asOf":"2026-09-23","days":5},{"id":"pdlim5","kind":"target","name":"PDLIM5","route":"/targets/pdlim5/","asOf":"2026-09-23","days":5},{"id":"lmx1b","kind":"target","name":"LMX1B","route":"/targets/lmx1b/","asOf":"2026-09-23","days":5},{"id":"mt-co1","kind":"target","name":"MT-CO1","route":"/targets/mt-co1/","asOf":"2026-09-23","days":5},{"id":"nkx3-1","kind":"target","name":"NKX3-1","route":"/targets/nkx3-1/","asOf":"2026-09-23","days":5},{"id":"a1cf","kind":"target","name":"A1CF","route":"/targets/a1cf/","asOf":"2026-09-23","days":5},{"id":"lratd2","kind":"target","name":"LRATD2","route":"/targets/lratd2/","asOf":"2026-09-23","days":5},{"id":"eomes","kind":"target","name":"EOMES","route":"/targets/eomes/","asOf":"2026-09-23","days":5},{"id":"bak1","kind":"target","name":"BAK1","route":"/targets/bak1/","asOf":"2026-09-23","days":5},{"id":"set","kind":"target","name":"SET","route":"/targets/set/","asOf":"2026-09-23","days":5},{"id":"arid5b","kind":"target","name":"ARID5B","route":"/targets/arid5b/","asOf":"2026-09-23","days":5},{"id":"acoxl","kind":"target","name":"ACOXL","route":"/targets/acoxl/","asOf":"2026-09-23","days":5},{"id":"acta2","kind":"target","name":"ACTA2","route":"/targets/acta2/","asOf":"2026-09-23","days":5},{"id":"dlst","kind":"target","name":"DLST","route":"/targets/dlst/","asOf":"2026-09-23","days":5},{"id":"elp1","kind":"target","name":"ELP1","route":"/targets/elp1/","asOf":"2026-09-23","days":5},{"id":"gnb1","kind":"target","name":"GNB1","route":"/targets/gnb1/","asOf":"2026-09-23","days":5},{"id":"gpr161","kind":"target","name":"GPR161","route":"/targets/gpr161/","asOf":"2026-09-23","days":5},{"id":"klhdc8b","kind":"target","name":"KLHDC8B","route":"/targets/klhdc8b/","asOf":"2026-09-23","days":5},{"id":"mysm1","kind":"target","name":"MYSM1","route":"/targets/mysm1/","asOf":"2026-09-23","days":5},{"id":"samd9","kind":"target","name":"SAMD9","route":"/targets/samd9/","asOf":"2026-09-23","days":5},{"id":"slc25a11","kind":"target","name":"SLC25A11","route":"/targets/slc25a11/","asOf":"2026-09-23","days":5},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/","asOf":"2026-09-24","days":4},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/","asOf":"2026-09-24","days":4},{"id":"pancreatic-adenosquamous-carcinoma","kind":"cancer","name":"Adenosquamous carcinoma of the pancreas","route":"/cancers/pancreatic-adenosquamous-carcinoma/","asOf":"2026-09-24","days":4},{"id":"pancreatic-colloid-carcinoma","kind":"cancer","name":"Colloid (mucinous non-cystic) carcinoma of the pancreas","route":"/cancers/pancreatic-colloid-carcinoma/","asOf":"2026-09-24","days":4},{"id":"pancreatic-undifferentiated-carcinoma-ogc","kind":"cancer","name":"Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells","route":"/cancers/pancreatic-undifferentiated-carcinoma-ogc/","asOf":"2026-09-24","days":4},{"id":"ipmn-associated-carcinoma","kind":"cancer","name":"Invasive carcinoma arising in an intraductal papillary mucinous neoplasm (IPMN-associated carcinoma)","route":"/cancers/ipmn-associated-carcinoma/","asOf":"2026-09-24","days":4},{"id":"mcn-associated-carcinoma","kind":"cancer","name":"Mucinous cystic neoplasm of the pancreas with associated invasive carcinoma (MCN-associated carcinoma)","route":"/cancers/mcn-associated-carcinoma/","asOf":"2026-09-24","days":4},{"id":"solid-pseudopapillary-neoplasm","kind":"cancer","name":"Solid pseudopapillary neoplasm of the pancreas","route":"/cancers/solid-pseudopapillary-neoplasm/","asOf":"2026-09-24","days":4},{"id":"nccn-resectability-criteria-pancreatic","kind":"term","name":"Resectability classes for pancreatic cancer (NCCN anatomical criteria and the 2017 international consensus)","route":"/terms/nccn-resectability-criteria-pancreatic/","asOf":"2026-09-24","days":4},{"id":"pancreas-protocol-ct","kind":"term","name":"Pancreas protocol CT (pancreatic protocol CT, dual-phase thin-slice CT with structured reporting)","route":"/terms/pancreas-protocol-ct/","asOf":"2026-09-24","days":4},{"id":"distal-pancreatectomy","kind":"term","name":"Distal pancreatectomy (removal of the body and tail of the pancreas, usually with the spleen)","route":"/terms/distal-pancreatectomy/","asOf":"2026-09-24","days":4},{"id":"vascular-resection-pancreatic","kind":"term","name":"Vascular resection in pancreatic cancer surgery (portal and superior mesenteric vein resection; arterial resection)","route":"/terms/vascular-resection-pancreatic/","asOf":"2026-09-24","days":4},{"id":"pancreatic-enzyme-replacement","kind":"term","name":"Pancreatic enzyme replacement therapy (PERT, pancreatin, Creon) for pancreatic exocrine insufficiency: why and how to take it","route":"/terms/pancreatic-enzyme-replacement/","asOf":"2026-09-24","days":4},{"id":"lewis-negative","kind":"term","name":"Lewis-negative (Lewis antigen-negative, CA 19-9 non-secretor) status","route":"/terms/lewis-negative/","asOf":"2026-09-24","days":4},{"id":"panin","kind":"term","name":"Pancreatic intraepithelial neoplasia (PanIN), the microscopic precursor of pancreatic cancer","route":"/terms/panin/","asOf":"2026-09-24","days":4},{"id":"pancreatic-cyst-high-risk-stigmata","kind":"term","name":"High-risk stigmata and worrisome features of pancreatic cysts (IPMN and MCN surgical criteria)","route":"/terms/pancreatic-cyst-high-risk-stigmata/","asOf":"2026-09-24","days":4},{"id":"new-onset-diabetes-pancreatic-cancer","kind":"term","name":"New-onset diabetes as a signal of pancreatic cancer (and the ENDPAC score)","route":"/terms/new-onset-diabetes-pancreatic-cancer/","asOf":"2026-09-24","days":4},{"id":"r0-r1-margin-pancreatic","kind":"term","name":"R0 and R1 margins in pancreatic cancer: the 1 mm rule and standardised specimen reporting","route":"/terms/r0-r1-margin-pancreatic/","asOf":"2026-09-24","days":4},{"id":"neoadjuvant-versus-upfront-surgery-pancreatic","kind":"term","name":"Neoadjuvant therapy versus surgery first for resectable and borderline resectable pancreatic cancer","route":"/terms/neoadjuvant-versus-upfront-surgery-pancreatic/","asOf":"2026-09-24","days":4},{"id":"emergency-presentation","kind":"term","name":"Emergency presentation (route to diagnosis)","route":"/terms/emergency-presentation/","asOf":"2026-09-24","days":4},{"id":"familial-pancreatic-cancer","kind":"term","name":"Familial pancreatic cancer and inherited risk (who qualifies for surveillance)","route":"/terms/familial-pancreatic-cancer/","asOf":"2026-09-24","days":4},{"id":"classical-vs-basal-like","kind":"term","name":"Classical versus basal-like (squamous) subtypes of pancreatic cancer, and GATA6","route":"/terms/classical-vs-basal-like/","asOf":"2026-09-24","days":4},{"id":"clinical-benefit-response","kind":"term","name":"Clinical benefit response (the gemcitabine trial endpoint)","route":"/terms/clinical-benefit-response/","asOf":"2026-09-24","days":4},{"id":"type-3c-diabetes-pancreatic-cancer","kind":"term","name":"Type 3c diabetes with pancreatic cancer","route":"/terms/type-3c-diabetes-pancreatic-cancer/","asOf":"2026-09-24","days":4},{"id":"coeliac-plexus-block","kind":"term","name":"Coeliac plexus block for pancreatic cancer pain","route":"/terms/coeliac-plexus-block/","asOf":"2026-09-24","days":4},{"id":"eating-after-whipple","kind":"term","name":"Eating after a Whipple operation: slow stomach emptying, dumping and bowel changes","route":"/terms/eating-after-whipple/","asOf":"2026-09-24","days":4},{"id":"chemotherapy-side-effects-pancreatic","kind":"term","name":"Living with FOLFIRINOX, NALIRIFOX and gemcitabine with nab-paclitaxel","route":"/terms/chemotherapy-side-effects-pancreatic/","asOf":"2026-09-24","days":4},{"id":"urgent-help-pancreatic-cancer","kind":"term","name":"When to seek urgent help with pancreatic cancer (NHS 111 and 999)","route":"/terms/urgent-help-pancreatic-cancer/","asOf":"2026-09-24","days":4},{"id":"work-and-money-pancreatic-cancer-uk","kind":"term","name":"Work and money with pancreatic cancer (UK)","route":"/terms/work-and-money-pancreatic-cancer-uk/","asOf":"2026-09-24","days":4},{"id":"carers-pancreatic-cancer-uk","kind":"term","name":"Carers: what you can do and UK carer support (pancreatic cancer)","route":"/terms/carers-pancreatic-cancer-uk/","asOf":"2026-09-24","days":4},{"id":"pancreatic-cancer-uk","kind":"institution","name":"Pancreatic Cancer UK","route":"/institutions/pancreatic-cancer-uk/","asOf":"2026-09-24","days":4},{"id":"pancreatic-cancer-action","kind":"institution","name":"Pancreatic Cancer Action","route":"/institutions/pancreatic-cancer-action/","asOf":"2026-09-24","days":4},{"id":"wolfson-wohl-cancer-research-centre","kind":"institution","name":"Wolfson Wohl Cancer Research Centre, University of Glasgow","route":"/institutions/wolfson-wohl-cancer-research-centre/","asOf":"2026-09-24","days":4},{"id":"hull-castle-hill","kind":"institution","name":"Castle Hill Hospital, Hull (Queen's Centre)","route":"/institutions/hull-castle-hill/","asOf":"2026-09-24","days":4},{"id":"royal-stoke-uhnm","kind":"institution","name":"Royal Stoke University Hospital","route":"/institutions/royal-stoke-uhnm/","asOf":"2026-09-24","days":4},{"id":"uhcw-coventry","kind":"institution","name":"University Hospital Coventry","route":"/institutions/uhcw-coventry/","asOf":"2026-09-24","days":4},{"id":"royal-surrey-guildford","kind":"institution","name":"Royal Surrey County Hospital, Guildford","route":"/institutions/royal-surrey-guildford/","asOf":"2026-09-24","days":4},{"id":"royal-blackburn-elht","kind":"institution","name":"Royal Blackburn Hospital (East Lancashire HPB MDT)","route":"/institutions/royal-blackburn-elht/","asOf":"2026-09-24","days":4},{"id":"ninewells-dundee","kind":"institution","name":"Ninewells Hospital, Dundee","route":"/institutions/ninewells-dundee/","asOf":"2026-09-24","days":4},{"id":"aberdeen-royal-infirmary","kind":"institution","name":"Aberdeen Royal Infirmary","route":"/institutions/aberdeen-royal-infirmary/","asOf":"2026-09-24","days":4},{"id":"raigmore-inverness","kind":"institution","name":"Raigmore Hospital, Inverness","route":"/institutions/raigmore-inverness/","asOf":"2026-09-24","days":4},{"id":"andrew-biankin","kind":"person","name":"Andrew Biankin","route":"/people/andrew-biankin/","asOf":"2026-09-24","days":4},{"id":"paula-ghaneh","kind":"person","name":"Paula Ghaneh","route":"/people/paula-ghaneh/","asOf":"2026-09-24","days":4},{"id":"daniel-palmer","kind":"person","name":"Daniel Palmer","route":"/people/daniel-palmer/","asOf":"2026-09-24","days":4},{"id":"chris-halloran","kind":"person","name":"Chris Halloran","route":"/people/chris-halloran/","asOf":"2026-09-24","days":4},{"id":"bill-greenhalf","kind":"person","name":"Bill Greenhalf","route":"/people/bill-greenhalf/","asOf":"2026-09-24","days":4},{"id":"europac","kind":"trial","name":"EUROPAC","route":"/trials/europac/","asOf":"2026-09-24","days":4},{"id":"precision-panc","kind":"trial","name":"Precision-Panc","route":"/trials/precision-panc/","asOf":"2026-09-24","days":4},{"id":"tnbc-basal-like-1","kind":"cancer","name":"Basal-like 1 triple-negative breast cancer (BL1)","route":"/cancers/tnbc-basal-like-1/","asOf":"2026-09-24","days":4},{"id":"tnbc-basal-like-2","kind":"cancer","name":"Basal-like 2 triple-negative breast cancer (BL2)","route":"/cancers/tnbc-basal-like-2/","asOf":"2026-09-24","days":4},{"id":"tnbc-mesenchymal","kind":"cancer","name":"Mesenchymal triple-negative breast cancer (M)","route":"/cancers/tnbc-mesenchymal/","asOf":"2026-09-24","days":4},{"id":"tnbc-mesenchymal-stem-like","kind":"cancer","name":"Mesenchymal stem-like triple-negative breast cancer (MSL)","route":"/cancers/tnbc-mesenchymal-stem-like/","asOf":"2026-09-24","days":4},{"id":"tnbc-luminal-androgen-receptor","kind":"cancer","name":"Luminal androgen receptor triple-negative breast cancer (LAR)","route":"/cancers/tnbc-luminal-androgen-receptor/","asOf":"2026-09-24","days":4},{"id":"tnbc-immunomodulatory","kind":"cancer","name":"Immunomodulatory triple-negative breast cancer (IM)","route":"/cancers/tnbc-immunomodulatory/","asOf":"2026-09-24","days":4},{"id":"metaplastic-breast-carcinoma","kind":"cancer","name":"Metaplastic breast carcinoma","route":"/cancers/metaplastic-breast-carcinoma/","asOf":"2026-09-24","days":4},{"id":"medullary-pattern-breast-carcinoma","kind":"cancer","name":"Carcinoma with medullary pattern (medullary breast cancer)","route":"/cancers/medullary-pattern-breast-carcinoma/","asOf":"2026-09-24","days":4},{"id":"adenoid-cystic-carcinoma-breast","kind":"cancer","name":"Adenoid cystic carcinoma of the breast","route":"/cancers/adenoid-cystic-carcinoma-breast/","asOf":"2026-09-24","days":4},{"id":"apocrine-carcinoma-breast","kind":"cancer","name":"Apocrine carcinoma of the breast","route":"/cancers/apocrine-carcinoma-breast/","asOf":"2026-09-24","days":4},{"id":"secretory-carcinoma-breast","kind":"cancer","name":"Secretory carcinoma of the breast","route":"/cancers/secretory-carcinoma-breast/","asOf":"2026-09-24","days":4},{"id":"brca-associated-tnbc","kind":"cancer","name":"BRCA-associated triple-negative breast cancer","route":"/cancers/brca-associated-tnbc/","asOf":"2026-09-24","days":4},{"id":"er-pr-negative-threshold","kind":"term","name":"ER and PR negative under 1 percent (the triple-negative threshold, and ER-low)","route":"/terms/er-pr-negative-threshold/","asOf":"2026-09-24","days":4},{"id":"her2-low-and-trop2-adc-eligibility-tnbc","kind":"term","name":"HER2-low eligibility for trastuzumab deruxtecan, and TROP2 ADCs without a test (triple-negative disease)","route":"/terms/her2-low-and-trop2-adc-eligibility-tnbc/","asOf":"2026-09-24","days":4},{"id":"pd-l1-cps-10-tnbc","kind":"term","name":"PD-L1 combined positive score 10 in triple-negative breast cancer","route":"/terms/pd-l1-cps-10-tnbc/","asOf":"2026-09-24","days":4},{"id":"hrd-in-breast-cancer","kind":"term","name":"Homologous recombination deficiency (HRD) in breast cancer","route":"/terms/hrd-in-breast-cancer/","asOf":"2026-09-24","days":4},{"id":"germline-brca-testing-criteria-tnbc","kind":"term","name":"Germline BRCA testing criteria for triple-negative breast cancer (UK)","route":"/terms/germline-brca-testing-criteria-tnbc/","asOf":"2026-09-24","days":4},{"id":"ki-67-in-tnbc","kind":"term","name":"Ki-67 in triple-negative breast cancer","route":"/terms/ki-67-in-tnbc/","asOf":"2026-09-24","days":4},{"id":"basal-like","kind":"term","name":"Basal-like breast cancer","route":"/terms/basal-like/","asOf":"2026-09-24","days":4},{"id":"claudin-low","kind":"term","name":"Claudin-low breast cancer","route":"/terms/claudin-low/","asOf":"2026-09-24","days":4},{"id":"androgen-receptor-positive-tnbc","kind":"term","name":"Androgen receptor-positive triple-negative breast cancer","route":"/terms/androgen-receptor-positive-tnbc/","asOf":"2026-09-24","days":4},{"id":"ajcc-prognostic-stage-breast","kind":"term","name":"AJCC 8th edition prognostic stage for breast cancer","route":"/terms/ajcc-prognostic-stage-breast/","asOf":"2026-09-24","days":4},{"id":"interval-breast-cancer","kind":"term","name":"Interval breast cancer (a cancer found between screening rounds)","route":"/terms/interval-breast-cancer/","asOf":"2026-09-24","days":4},{"id":"risk-reducing-surgery-brca-carriers","kind":"term","name":"Risk-reducing surgery for BRCA carriers (bilateral and contralateral mastectomy, salpingo-oophorectomy)","route":"/terms/risk-reducing-surgery-brca-carriers/","asOf":"2026-09-24","days":4},{"id":"chemoprevention-and-er-negative-breast-cancer","kind":"term","name":"Chemoprevention (tamoxifen, anastrozole, raloxifene) and ER-negative breast cancer","route":"/terms/chemoprevention-and-er-negative-breast-cancer/","asOf":"2026-09-24","days":4},{"id":"founder-mutation","kind":"term","name":"Founder mutation (BRCA1 185delAG and 5382insC, BRCA2 6174delT)","route":"/terms/founder-mutation/","asOf":"2026-09-24","days":4},{"id":"idfs","kind":"term","name":"Invasive disease-free survival (iDFS)","route":"/terms/idfs/","asOf":"2026-09-24","days":4},{"id":"luminal-androgen-receptor","kind":"term","name":"Luminal androgen receptor (LAR) subtype","route":"/terms/luminal-androgen-receptor/","asOf":"2026-09-24","days":4},{"id":"pd-l1-assay-discordance","kind":"term","name":"PD-L1 assay discordance (SP142, SP263 and 22C3 in breast cancer)","route":"/terms/pd-l1-assay-discordance/","asOf":"2026-09-24","days":4},{"id":"exceptional-responder","kind":"term","name":"Exceptional responder","route":"/terms/exceptional-responder/","asOf":"2026-09-24","days":4},{"id":"health-disparities","kind":"term","name":"Health disparities in cancer outcomes (ethnicity, deprivation and access)","route":"/terms/health-disparities/","asOf":"2026-09-24","days":4},{"id":"hair-loss-and-scalp-cooling-breast","kind":"term","name":"Hair loss and scalp cooling with breast cancer chemotherapy","route":"/terms/hair-loss-and-scalp-cooling-breast/","asOf":"2026-09-24","days":4},{"id":"menopause-after-chemotherapy-breast","kind":"term","name":"Menopause symptoms after chemotherapy for breast cancer","route":"/terms/menopause-after-chemotherapy-breast/","asOf":"2026-09-24","days":4},{"id":"body-image-after-breast-surgery","kind":"term","name":"Body image after breast surgery and reconstruction","route":"/terms/body-image-after-breast-surgery/","asOf":"2026-09-24","days":4},{"id":"neutropenic-sepsis-breast-chemotherapy","kind":"term","name":"Neutropenic sepsis: the temperature rule and the 999 signs","route":"/terms/neutropenic-sepsis-breast-chemotherapy/","asOf":"2026-09-24","days":4},{"id":"adc-side-effects-breast","kind":"term","name":"Living with an antibody-drug conjugate: diarrhoea, blood counts, eyes and lungs","route":"/terms/adc-side-effects-breast/","asOf":"2026-09-24","days":4},{"id":"urgent-help-tnbc","kind":"term","name":"When to seek urgent help with triple-negative breast cancer (NHS 111 and 999)","route":"/terms/urgent-help-tnbc/","asOf":"2026-09-24","days":4},{"id":"work-and-money-breast-cancer-uk","kind":"term","name":"Work and money during breast cancer treatment (UK)","route":"/terms/work-and-money-breast-cancer-uk/","asOf":"2026-09-24","days":4},{"id":"carers-breast-cancer-uk","kind":"term","name":"Carers: what you can do and UK carer support (breast cancer)","route":"/terms/carers-breast-cancer-uk/","asOf":"2026-09-24","days":4},{"id":"paper-esmo-early-breast-cancer-guideline-ann-oncol-2024","kind":"paper","name":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-early-breast-cancer-guideline-ann-oncol-2024/","asOf":"2026-09-24","days":4},{"id":"paper-esmo-metastatic-breast-cancer-guideline-ann-oncol-2021","kind":"paper","name":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","route":"/key-papers/paper-esmo-metastatic-breast-cancer-guideline-ann-oncol-2021/","asOf":"2026-09-24","days":4},{"id":"paper-esmo-mbc-living-guideline-update-ann-oncol-2025","kind":"paper","name":"Updated treatment recommendations for systemic treatment: from the ESMO Metastatic Breast Cancer Living Guideline","route":"/key-papers/paper-esmo-mbc-living-guideline-update-ann-oncol-2025/","asOf":"2026-09-24","days":4},{"id":"paper-nccn-breast-cancer-v4-2026-jnccn-2026","kind":"paper","name":"Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology","route":"/key-papers/paper-nccn-breast-cancer-v4-2026-jnccn-2026/","asOf":"2026-09-24","days":4},{"id":"paper-st-gallen-2023-consensus-ann-oncol-2023","kind":"paper","name":"Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023","route":"/key-papers/paper-st-gallen-2023-consensus-ann-oncol-2023/","asOf":"2026-09-24","days":4},{"id":"paper-st-gallen-2025-consensus-ann-oncol-2025","kind":"paper","name":"Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer","route":"/key-papers/paper-st-gallen-2025-consensus-ann-oncol-2025/","asOf":"2026-09-24","days":4},{"id":"paper-asco-neoadjuvant-therapy-breast-guideline-jco-2021","kind":"paper","name":"Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline","route":"/key-papers/paper-asco-neoadjuvant-therapy-breast-guideline-jco-2021/","asOf":"2026-09-24","days":4},{"id":"paper-asco-pembrolizumab-early-tnbc-rapid-update-jco-2022","kind":"paper","name":"Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update","route":"/key-papers/paper-asco-pembrolizumab-early-tnbc-rapid-update-jco-2022/","asOf":"2026-09-24","days":4},{"id":"paper-asco-hereditary-breast-cancer-guideline-jco-2020","kind":"paper","name":"Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline","route":"/key-papers/paper-asco-hereditary-breast-cancer-guideline-jco-2020/","asOf":"2026-09-24","days":4},{"id":"paper-asco-biomarkers-metastatic-breast-cancer-guideline-jco-2022","kind":"paper","name":"Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update","route":"/key-papers/paper-asco-biomarkers-metastatic-breast-cancer-guideline-jco-2022/","asOf":"2026-09-24","days":4},{"id":"paper-asco-cap-er-pr-testing-guideline-jco-2010","kind":"paper","name":"American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","route":"/key-papers/paper-asco-cap-er-pr-testing-guideline-jco-2010/","asOf":"2026-09-24","days":4},{"id":"paper-perou-molecular-portraits-breast-tumours-nature-2000","kind":"paper","name":"Molecular portraits of human breast tumours","route":"/key-papers/paper-perou-molecular-portraits-breast-tumours-nature-2000/","asOf":"2026-09-24","days":4},{"id":"paper-sorlie-breast-carcinoma-subclasses-pnas-2001","kind":"paper","name":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","route":"/key-papers/paper-sorlie-breast-carcinoma-subclasses-pnas-2001/","asOf":"2026-09-24","days":4},{"id":"paper-sorlie-repeated-observation-subtypes-brca1-basal-pnas-2003","kind":"paper","name":"Repeated observation of breast tumor subtypes in independent gene expression data sets","route":"/key-papers/paper-sorlie-repeated-observation-subtypes-brca1-basal-pnas-2003/","asOf":"2026-09-24","days":4},{"id":"paper-foulkes-brca1-basal-phenotype-jnci-2003","kind":"paper","name":"Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer","route":"/key-papers/paper-foulkes-brca1-basal-phenotype-jnci-2003/","asOf":"2026-09-24","days":4},{"id":"paper-struewing-brca-founder-mutations-ashkenazi-nejm-1997","kind":"paper","name":"The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews","route":"/key-papers/paper-struewing-brca-founder-mutations-ashkenazi-nejm-1997/","asOf":"2026-09-24","days":4},{"id":"paper-gorski-brca1-founder-mutations-poland-ajhg-2000","kind":"paper","name":"Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer","route":"/key-papers/paper-gorski-brca1-founder-mutations-poland-ajhg-2000/","asOf":"2026-09-24","days":4},{"id":"paper-atchley-brca-status-triple-negative-jco-2008","kind":"paper","name":"Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer","route":"/key-papers/paper-atchley-brca-status-triple-negative-jco-2008/","asOf":"2026-09-24","days":4},{"id":"paper-dent-tnbc-clinical-features-recurrence-ccr-2007","kind":"paper","name":"Triple-negative breast cancer: clinical features and patterns of recurrence","route":"/key-papers/paper-dent-tnbc-clinical-features-recurrence-ccr-2007/","asOf":"2026-09-24","days":4},{"id":"paper-bauer-triple-negative-california-registry-cancer-2007","kind":"paper","name":"Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry","route":"/key-papers/paper-bauer-triple-negative-california-registry-cancer-2007/","asOf":"2026-09-24","days":4},{"id":"paper-carey-race-breast-cancer-subtypes-cbcs-jama-2006","kind":"paper","name":"Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study","route":"/key-papers/paper-carey-race-breast-cancer-subtypes-cbcs-jama-2006/","asOf":"2026-09-24","days":4},{"id":"paper-howlader-us-incidence-breast-subtypes-jnci-2014","kind":"paper","name":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","route":"/key-papers/paper-howlader-us-incidence-breast-subtypes-jnci-2014/","asOf":"2026-09-24","days":4},{"id":"paper-scott-tnbc-disparities-uscs-cancer-2019","kind":"paper","name":"Update on triple-negative breast cancer disparities for the United States: A population-based study from the United States Cancer Statistics database, 2010 through 2014","route":"/key-papers/paper-scott-tnbc-disparities-uscs-cancer-2019/","asOf":"2026-09-24","days":4},{"id":"paper-copson-posh-ethnicity-young-breast-cancer-uk-bjc-2014","kind":"paper","name":"Ethnicity and outcome of young breast cancer patients in the United Kingdom: the POSH study","route":"/key-papers/paper-copson-posh-ethnicity-young-breast-cancer-uk-bjc-2014/","asOf":"2026-09-24","days":4},{"id":"paper-lin-tnbc-cns-metastases-dfci-cancer-2008","kind":"paper","name":"Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases","route":"/key-papers/paper-lin-tnbc-cns-metastases-dfci-cancer-2008/","asOf":"2026-09-24","days":4},{"id":"paper-lehmann-tnbc-subtypes-jci-2011","kind":"paper","name":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","route":"/key-papers/paper-lehmann-tnbc-subtypes-jci-2011/","asOf":"2026-09-24","days":4},{"id":"paper-lehmann-tnbctype-4-refinement-plos-one-2016","kind":"paper","name":"Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection","route":"/key-papers/paper-lehmann-tnbctype-4-refinement-plos-one-2016/","asOf":"2026-09-24","days":4},{"id":"paper-burstein-tnbc-genomic-subtypes-ccr-2015","kind":"paper","name":"Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer","route":"/key-papers/paper-burstein-tnbc-genomic-subtypes-ccr-2015/","asOf":"2026-09-24","days":4},{"id":"paper-ebctcg-polychemotherapy-regimens-meta-analysis-lancet-2012","kind":"paper","name":"Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials","route":"/key-papers/paper-ebctcg-polychemotherapy-regimens-meta-analysis-lancet-2012/","asOf":"2026-09-24","days":4},{"id":"paper-liedtke-neoadjuvant-response-survival-tnbc-jco-2008","kind":"paper","name":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","route":"/key-papers/paper-liedtke-neoadjuvant-response-survival-tnbc-jco-2008/","asOf":"2026-09-24","days":4},{"id":"paper-cortazar-ctneobc-pcr-pooled-analysis-lancet-2014","kind":"paper","name":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","route":"/key-papers/paper-cortazar-ctneobc-pcr-pooled-analysis-lancet-2014/","asOf":"2026-09-24","days":4},{"id":"paper-symmans-rcb-long-term-prognosis-subtype-jco-2017","kind":"paper","name":"Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype","route":"/key-papers/paper-symmans-rcb-long-term-prognosis-subtype-jco-2017/","asOf":"2026-09-24","days":4},{"id":"paper-yau-rcb-pooled-analysis-5161-lancet-oncol-2022","kind":"paper","name":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients","route":"/key-papers/paper-yau-rcb-pooled-analysis-5161-lancet-oncol-2022/","asOf":"2026-09-24","days":4},{"id":"paper-sikov-calgb-40603-carboplatin-bevacizumab-jco-2015","kind":"paper","name":"Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)","route":"/key-papers/paper-sikov-calgb-40603-carboplatin-bevacizumab-jco-2015/","asOf":"2026-09-24","days":4},{"id":"paper-loibl-geparsixto-survival-hrd-ann-oncol-2018","kind":"paper","name":"Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto","route":"/key-papers/paper-loibl-geparsixto-survival-hrd-ann-oncol-2018/","asOf":"2026-09-24","days":4},{"id":"paper-geyer-brightness-4-year-follow-up-ann-oncol-2022","kind":"paper","name":"Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial","route":"/key-papers/paper-geyer-brightness-4-year-follow-up-ann-oncol-2022/","asOf":"2026-09-24","days":4},{"id":"paper-create-x-adjuvant-capecitabine-nejm-2017","kind":"paper","name":"Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy","route":"/key-papers/paper-create-x-adjuvant-capecitabine-nejm-2017/","asOf":"2026-09-24","days":4},{"id":"paper-olympia-overall-survival-ann-oncol-2022","kind":"paper","name":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer","route":"/key-papers/paper-olympia-overall-survival-ann-oncol-2022/","asOf":"2026-09-24","days":4},{"id":"paper-olympia-6-year-update-ann-oncol-2026","kind":"paper","name":"Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial","route":"/key-papers/paper-olympia-6-year-update-ann-oncol-2026/","asOf":"2026-09-24","days":4},{"id":"paper-rugo-pd-l1-assay-comparison-impassion130-jnci-2021","kind":"paper","name":"PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer","route":"/key-papers/paper-rugo-pd-l1-assay-comparison-impassion130-jnci-2021/","asOf":"2026-09-24","days":4},{"id":"paper-leon-ferre-tils-tnbc-no-chemotherapy-jama-2024","kind":"paper","name":"Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer","route":"/key-papers/paper-leon-ferre-tils-tnbc-no-chemotherapy-jama-2024/","asOf":"2026-09-24","days":4},{"id":"paper-tropion-breast02-ann-oncol-2026","kind":"paper","name":"Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial","route":"/key-papers/paper-tropion-breast02-ann-oncol-2026/","asOf":"2026-09-24","days":4},{"id":"paper-capitello-290-capivasertib-paclitaxel-ann-oncol-2026","kind":"paper","name":"Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trial","route":"/key-papers/paper-capitello-290-capivasertib-paclitaxel-ann-oncol-2026/","asOf":"2026-09-24","days":4},{"id":"paper-schettini-her2-low-features-npj-breast-cancer-2021","kind":"paper","name":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","route":"/key-papers/paper-schettini-her2-low-features-npj-breast-cancer-2021/","asOf":"2026-09-24","days":4},{"id":"paper-radovich-ctdna-ctc-bre12-158-jama-oncol-2020","kind":"paper","name":"Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial","route":"/key-papers/paper-radovich-ctdna-ctc-bre12-158-jama-oncol-2020/","asOf":"2026-09-24","days":4},{"id":"paper-turner-c-trak-tn-ctdna-pembrolizumab-ann-oncol-2023","kind":"paper","name":"Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer","route":"/key-papers/paper-turner-c-trak-tn-ctdna-pembrolizumab-ann-oncol-2023/","asOf":"2026-09-24","days":4},{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/","asOf":"2026-09-24","days":4},{"id":"idea-tnbc-de-escalation-for-exceptional-responders","kind":"idea","name":"Give exceptional responders less: pembrolizumab omission after complete response, anthracycline-free regimens and chemotherapy omission in lymphocyte-rich stage I disease","route":"/ideas/idea-tnbc-de-escalation-for-exceptional-responders/","asOf":"2026-09-24","days":4},{"id":"idea-tnbc-ctdna-guided-adjuvant-decisions","kind":"idea","name":"ctDNA-guided adjuvant decisions after residual disease: escalate the positive, spare the negative","route":"/ideas/idea-tnbc-ctdna-guided-adjuvant-decisions/","asOf":"2026-09-24","days":4},{"id":"idea-tnbc-disparities-in-access-and-outcomes","kind":"idea","name":"Close the gap between who gets triple-negative breast cancer and who is in its trials","route":"/ideas/idea-tnbc-disparities-in-access-and-outcomes/","asOf":"2026-09-24","days":4},{"id":"idea-tnbc-pd-l1-assay-harmonisation","kind":"idea","name":"Harmonise PD-L1 testing for triple-negative breast cancer around one scored assay, with external quality assurance","route":"/ideas/idea-tnbc-pd-l1-assay-harmonisation/","asOf":"2026-09-24","days":4},{"id":"idea-tnbc-adc-sequencing-trial","kind":"idea","name":"A randomised trial of antibody-drug conjugate sequence in metastatic triple-negative breast cancer","route":"/ideas/idea-tnbc-adc-sequencing-trial/","asOf":"2026-09-24","days":4},{"id":"idea-tnbc-brain-metastasis-trials","kind":"idea","name":"Trials that include, and report, brain metastases in triple-negative breast cancer","route":"/ideas/idea-tnbc-brain-metastasis-trials/","asOf":"2026-09-24","days":4},{"id":"idea-tnbc-her2-ultralow-testing-uptake","kind":"idea","name":"Reflex re-scoring of HER2 0 versus 1+ with digital assistance so every eligible triple-negative patient reaches trastuzumab deruxtecan","route":"/ideas/idea-tnbc-her2-ultralow-testing-uptake/","asOf":"2026-09-24","days":4},{"id":"idea-tnbc-uk-trial-access-and-germline-testing-audit","kind":"idea","name":"A UK audit of trial access and germline testing uptake in triple-negative breast cancer","route":"/ideas/idea-tnbc-uk-trial-access-and-germline-testing-audit/","asOf":"2026-09-24","days":4},{"id":"idea-tnbc-uk-ethnicity-stratified-outcome-reporting","kind":"idea","name":"Ethnicity-stratified outcome reporting for triple-negative breast cancer in NHS cancer statistics","route":"/ideas/idea-tnbc-uk-ethnicity-stratified-outcome-reporting/","asOf":"2026-09-24","days":4},{"id":"breast-cancer-now","kind":"institution","name":"Breast Cancer Now","route":"/institutions/breast-cancer-now/","asOf":"2026-09-24","days":4},{"id":"jean-abraham","kind":"person","name":"Jean Abraham","route":"/people/jean-abraham/","asOf":"2026-09-24","days":4},{"id":"ellen-copson","kind":"person","name":"Ellen Copson","route":"/people/ellen-copson/","asOf":"2026-09-24","days":4},{"id":"anne-armstrong","kind":"person","name":"Anne Armstrong","route":"/people/anne-armstrong/","asOf":"2026-09-24","days":4},{"id":"tnt","kind":"trial","name":"TNT (Triple Negative Trial)","route":"/trials/tnt/","asOf":"2026-09-24","days":4},{"id":"partner","kind":"trial","name":"PARTNER","route":"/trials/partner/","asOf":"2026-09-24","days":4},{"id":"paper-shah-tnbc-clonal-evolution-nature-2012","kind":"paper","name":"The clonal and mutational evolution spectrum of primary triple-negative breast cancers","route":"/key-papers/paper-shah-tnbc-clonal-evolution-nature-2012/","asOf":"2026-09-24","days":4},{"id":"paper-tcga-breast-molecular-portraits-nature-2012","kind":"paper","name":"Comprehensive molecular portraits of human breast tumours","route":"/key-papers/paper-tcga-breast-molecular-portraits-nature-2012/","asOf":"2026-09-24","days":4},{"id":"paper-lehmann-tnbc-subtype-multiomics-nat-commun-2021","kind":"paper","name":"Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes","route":"/key-papers/paper-lehmann-tnbc-subtype-multiomics-nat-commun-2021/","asOf":"2026-09-24","days":4},{"id":"paper-bareche-tnbc-multiomic-heterogeneity-ann-oncol-2018","kind":"paper","name":"Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis","route":"/key-papers/paper-bareche-tnbc-multiomic-heterogeneity-ann-oncol-2018/","asOf":"2026-09-24","days":4},{"id":"paper-bareche-tnbc-microenvironment-jnci-2020","kind":"paper","name":"Unraveling triple-negative breast cancer tumor microenvironment heterogeneity: towards an optimized treatment approach","route":"/key-papers/paper-bareche-tnbc-microenvironment-jnci-2020/","asOf":"2026-09-24","days":4},{"id":"paper-jiang-fuscc-tnbc-landscape-cancer-cell-2019","kind":"paper","name":"Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies","route":"/key-papers/paper-jiang-fuscc-tnbc-landscape-cancer-cell-2019/","asOf":"2026-09-24","days":4},{"id":"paper-staaf-tnbc-whole-genome-scan-b-nat-med-2019","kind":"paper","name":"Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study","route":"/key-papers/paper-staaf-tnbc-whole-genome-scan-b-nat-med-2019/","asOf":"2026-09-24","days":4},{"id":"paper-bertucci-metastatic-breast-genomics-nature-2019","kind":"paper","name":"Genomic characterization of metastatic breast cancers","route":"/key-papers/paper-bertucci-metastatic-breast-genomics-nature-2019/","asOf":"2026-09-24","days":4},{"id":"paper-couch-tnbc-germline-17-genes-jco-2015","kind":"paper","name":"Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer","route":"/key-papers/paper-couch-tnbc-germline-17-genes-jco-2015/","asOf":"2026-09-24","days":4},{"id":"paper-hahnen-geparsixto-germline-brca-jama-oncol-2017","kind":"paper","name":"Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial","route":"/key-papers/paper-hahnen-geparsixto-germline-brca-jama-oncol-2017/","asOf":"2026-09-24","days":4},{"id":"paper-shimelis-tnbc-risk-genes-jnci-2018","kind":"paper","name":"Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing","route":"/key-papers/paper-shimelis-tnbc-risk-genes-jnci-2018/","asOf":"2026-09-24","days":4},{"id":"paper-sharma-tnbc-registry-germline-brca-bcrt-2014","kind":"paper","name":"Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing","route":"/key-papers/paper-sharma-tnbc-registry-germline-brca-bcrt-2014/","asOf":"2026-09-24","days":4},{"id":"paper-telli-hrd-score-platinum-tnbc-ccr-2016","kind":"paper","name":"Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer","route":"/key-papers/paper-telli-hrd-score-platinum-tnbc-ccr-2016/","asOf":"2026-09-24","days":4},{"id":"paper-zheng-nigerian-inherited-breast-cancer-jco-2018","kind":"paper","name":"Inherited breast cancer in Nigerian women","route":"/key-papers/paper-zheng-nigerian-inherited-breast-cancer-jco-2018/","asOf":"2026-09-24","days":4},{"id":"paper-huo-tcga-ancestry-breast-jama-oncol-2017","kind":"paper","name":"Comparison of breast cancer molecular features and survival by African and European ancestry in The Cancer Genome Atlas","route":"/key-papers/paper-huo-tcga-ancestry-breast-jama-oncol-2017/","asOf":"2026-09-24","days":4},{"id":"paper-martini-african-ancestry-tnbc-cancer-discov-2022","kind":"paper","name":"African ancestry-associated gene expression profiles in triple-negative breast cancer underlie altered tumor biology and clinical outcome in women of African descent","route":"/key-papers/paper-martini-african-ancestry-tnbc-cancer-discov-2022/","asOf":"2026-09-24","days":4},{"id":"paper-donenberg-bahamas-brca1-founder-bcrt-2011","kind":"paper","name":"A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas","route":"/key-papers/paper-donenberg-bahamas-brca1-founder-bcrt-2011/","asOf":"2026-09-24","days":4},{"id":"paper-villarreal-garza-mexican-tnbc-brca-bcrt-2015","kind":"paper","name":"The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer","route":"/key-papers/paper-villarreal-garza-mexican-tnbc-brca-bcrt-2015/","asOf":"2026-09-24","days":4},{"id":"paper-sigurjonsdottir-sp142-22c3-tnbc-bcr-2023","kind":"paper","name":"Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms","route":"/key-papers/paper-sigurjonsdottir-sp142-22c3-tnbc-bcr-2023/","asOf":"2026-09-24","days":4},{"id":"paper-barroso-sousa-breast-tmb-prevalence-ann-oncol-2020","kind":"paper","name":"Prevalence and mutational determinants of high tumor mutation burden in breast cancer","route":"/key-papers/paper-barroso-sousa-breast-tmb-prevalence-ann-oncol-2020/","asOf":"2026-09-24","days":4},{"id":"paper-barroso-sousa-tmb-pten-ici-mtnbc-ccr-2020","kind":"paper","name":"Tumor mutational burden and PTEN alterations as molecular correlates of response to PD-1/L1 blockade in metastatic triple-negative breast cancer","route":"/key-papers/paper-barroso-sousa-tmb-pten-ici-mtnbc-ccr-2020/","asOf":"2026-09-24","days":4},{"id":"paper-ren-tnbc-mmr-msi-440-front-oncol-2021","kind":"paper","name":"Mismatch repair deficiency and microsatellite instability in triple-negative breast cancer: a retrospective study of 440 patients","route":"/key-papers/paper-ren-tnbc-mmr-msi-440-front-oncol-2021/","asOf":"2026-09-24","days":4},{"id":"paper-kurata-japanese-tnbc-msi-breast-cancer-2020","kind":"paper","name":"Microsatellite instability in Japanese female patients with triple-negative breast cancer","route":"/key-papers/paper-kurata-japanese-tnbc-msi-breast-cancer-2020/","asOf":"2026-09-24","days":4},{"id":"paper-loi-tils-pooled-early-tnbc-jco-2019","kind":"paper","name":"Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers","route":"/key-papers/paper-loi-tils-pooled-early-tnbc-jco-2019/","asOf":"2026-09-24","days":4},{"id":"paper-denkert-tils-neoadjuvant-pooled-lancet-oncol-2018","kind":"paper","name":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","route":"/key-papers/paper-denkert-tils-neoadjuvant-pooled-lancet-oncol-2018/","asOf":"2026-09-24","days":4},{"id":"paper-gruosso-tnbc-spatial-immune-microenvironments-jci-2019","kind":"paper","name":"Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers","route":"/key-papers/paper-gruosso-tnbc-spatial-immune-microenvironments-jci-2019/","asOf":"2026-09-24","days":4},{"id":"paper-park-tils-untreated-early-tnbc-ann-oncol-2019","kind":"paper","name":"Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy","route":"/key-papers/paper-park-tils-untreated-early-tnbc-ann-oncol-2019/","asOf":"2026-09-24","days":4},{"id":"paper-denkert-her2-low-pooled-neoadjuvant-lancet-oncol-2021","kind":"paper","name":"Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials","route":"/key-papers/paper-denkert-her2-low-pooled-neoadjuvant-lancet-oncol-2021/","asOf":"2026-09-24","days":4},{"id":"paper-boissiere-michot-her2-ultralow-tnbc-virchows-arch-2026","kind":"paper","name":"Exploring the spectrum of HER2 in non-metastatic triple negative breast cancer: from HER2-null to HER2-low, including HER2-ultralow status","route":"/key-papers/paper-boissiere-michot-her2-ultralow-tnbc-virchows-arch-2026/","asOf":"2026-09-24","days":4},{"id":"paper-bardia-ascent-trop2-biomarker-ann-oncol-2021","kind":"paper","name":"Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer","route":"/key-papers/paper-bardia-ascent-trop2-biomarker-ann-oncol-2021/","asOf":"2026-09-24","days":4},{"id":"paper-gucalp-bicalutamide-ar-positive-tbcrc011-ccr-2013","kind":"paper","name":"Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer","route":"/key-papers/paper-gucalp-bicalutamide-ar-positive-tbcrc011-ccr-2013/","asOf":"2026-09-24","days":4},{"id":"paper-traina-enzalutamide-ar-tnbc-jco-2018","kind":"paper","name":"Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer","route":"/key-papers/paper-traina-enzalutamide-ar-tnbc-jco-2018/","asOf":"2026-09-24","days":4},{"id":"paper-kim-lotus-ipatasertib-tnbc-lancet-oncol-2017","kind":"paper","name":"Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","route":"/key-papers/paper-kim-lotus-ipatasertib-tnbc-lancet-oncol-2017/","asOf":"2026-09-24","days":4},{"id":"paper-schmid-pakt-capivasertib-tnbc-jco-2020","kind":"paper","name":"Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial","route":"/key-papers/paper-schmid-pakt-capivasertib-tnbc-jco-2020/","asOf":"2026-09-24","days":4},{"id":"paper-stoeck-notch-rearrangements-tnbc-cancer-discov-2014","kind":"paper","name":"Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma","route":"/key-papers/paper-stoeck-notch-rearrangements-tnbc-cancer-discov-2014/","asOf":"2026-09-24","days":4},{"id":"paper-wang-notch-pest-mutations-tnbc-ccr-2015","kind":"paper","name":"PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a gamma-secretase inhibitor","route":"/key-papers/paper-wang-notch-pest-mutations-tnbc-ccr-2015/","asOf":"2026-09-24","days":4},{"id":"paper-horiuchi-myc-tnbc-cdk-synthetic-lethal-jem-2012","kind":"paper","name":"MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition","route":"/key-papers/paper-horiuchi-myc-tnbc-cdk-synthetic-lethal-jem-2012/","asOf":"2026-09-24","days":4},{"id":"paper-herschkowitz-rb1-loss-basal-like-bcr-2008","kind":"paper","name":"The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas","route":"/key-papers/paper-herschkowitz-rb1-loss-basal-like-bcr-2008/","asOf":"2026-09-24","days":4},{"id":"paper-magbanua-ispy2-ctdna-neoadjuvant-ann-oncol-2021","kind":"paper","name":"Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival","route":"/key-papers/paper-magbanua-ispy2-ctdna-neoadjuvant-ann-oncol-2021/","asOf":"2026-09-24","days":4},{"id":"paper-stecklein-ctdna-rcb-tnbc-residual-disease-npj-2023","kind":"paper","name":"ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease","route":"/key-papers/paper-stecklein-ctdna-rcb-tnbc-residual-disease-npj-2023/","asOf":"2026-09-24","days":4},{"id":"paper-garcia-murillas-ctdna-mutation-tracking-stm-2015","kind":"paper","name":"Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer","route":"/key-papers/paper-garcia-murillas-ctdna-mutation-tracking-stm-2015/","asOf":"2026-09-24","days":4},{"id":"paper-garcia-murillas-molecular-relapse-detection-jama-oncol-2019","kind":"paper","name":"Assessment of molecular relapse detection in early-stage breast cancer","route":"/key-papers/paper-garcia-murillas-molecular-relapse-detection-jama-oncol-2019/","asOf":"2026-09-24","days":4},{"id":"paper-cavallone-tnbc-ctdna-neoadjuvant-sci-rep-2020","kind":"paper","name":"Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer","route":"/key-papers/paper-cavallone-tnbc-ctdna-neoadjuvant-sci-rep-2020/","asOf":"2026-09-24","days":4},{"id":"paper-bedrosian-asco-sso-germline-testing-breast-jco-2024","kind":"paper","name":"Germline testing in patients with breast cancer: ASCO-Society of Surgical Oncology guideline","route":"/key-papers/paper-bedrosian-asco-sso-germline-testing-breast-jco-2024/","asOf":"2026-09-24","days":4},{"id":"paper-conroy-nhs-r208-mainstream-testing-audit-breast-j-2026","kind":"paper","name":"Implementation and audit of mainstream genetic testing within a high-volume UK breast unit for pathogenic variations associated with breast cancer using the R208 and R444.1 National Test Directory criterion","route":"/key-papers/paper-conroy-nhs-r208-mainstream-testing-audit-breast-j-2026/","asOf":"2026-09-24","days":4},{"id":"paper-hudson-phillips-expanded-germline-testing-clin-breast-cancer-2026","kind":"paper","name":"The impact of expanded access to germline high penetrance genetic testing for women with a new diagnosis of invasive breast cancer or high-grade DCIS","route":"/key-papers/paper-hudson-phillips-expanded-germline-testing-clin-breast-cancer-2026/","asOf":"2026-09-24","days":4},{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/","asOf":"2026-09-24","days":4},{"id":"tnbc-residual-disease-decision","kind":"term","name":"Residual disease after neoadjuvant therapy in triple-negative breast cancer: the decision point","route":"/terms/tnbc-residual-disease-decision/","asOf":"2026-09-24","days":4},{"id":"tnbc-symptom-control-palliation","kind":"term","name":"Palliation in advanced triple-negative breast cancer: brain, bone, pleura, skin and end of life","route":"/terms/tnbc-symptom-control-palliation/","asOf":"2026-09-24","days":4},{"id":"veliparib","kind":"drug","name":"Veliparib","route":"/drugs/veliparib/","asOf":"2026-09-24","days":4},{"id":"create-x","kind":"trial","name":"CREATE-X","route":"/trials/create-x/","asOf":"2026-09-24","days":4},{"id":"calgb-40603","kind":"trial","name":"CALGB 40603 (Alliance)","route":"/trials/calgb-40603/","asOf":"2026-09-24","days":4},{"id":"neotrip","kind":"trial","name":"NeoTRIP (NeoTRIPaPDL1)","route":"/trials/neotrip/","asOf":"2026-09-24","days":4},{"id":"gepardouze","kind":"trial","name":"GeparDouze / NSABP B-59","route":"/trials/gepardouze/","asOf":"2026-09-24","days":4},{"id":"impassion030","kind":"trial","name":"ALEXANDRA / IMpassion030","route":"/trials/impassion030/","asOf":"2026-09-24","days":4},{"id":"a-brave","kind":"trial","name":"A-BRAVE","route":"/trials/a-brave/","asOf":"2026-09-24","days":4},{"id":"neopact","kind":"trial","name":"NeoPACT","route":"/trials/neopact/","asOf":"2026-09-24","days":4},{"id":"sysucc-001","kind":"trial","name":"SYSUCC-001","route":"/trials/sysucc-001/","asOf":"2026-09-24","days":4},{"id":"geicam-ciboma","kind":"trial","name":"GEICAM/2003-11_CIBOMA/2004-01","route":"/trials/geicam-ciboma/","asOf":"2026-09-24","days":4},{"id":"bre12-158","kind":"trial","name":"BRE12-158 (Hoosier Oncology Group)","route":"/trials/bre12-158/","asOf":"2026-09-24","days":4},{"id":"c-trak-tn","kind":"trial","name":"c-TRAK TN","route":"/trials/c-trak-tn/","asOf":"2026-09-24","days":4},{"id":"swog-s1418","kind":"trial","name":"SWOG S1418 / NRG BR006","route":"/trials/swog-s1418/","asOf":"2026-09-24","days":4},{"id":"phoenix","kind":"trial","name":"PHOENIX DDR/Anti-PD-L1","route":"/trials/phoenix/","asOf":"2026-09-24","days":4},{"id":"barbican","kind":"trial","name":"BARBICAN","route":"/trials/barbican/","asOf":"2026-09-24","days":4},{"id":"keynote-119","kind":"trial","name":"KEYNOTE-119","route":"/trials/keynote-119/","asOf":"2026-09-24","days":4},{"id":"ipatunity130","kind":"trial","name":"IPATunity130","route":"/trials/ipatunity130/","asOf":"2026-09-24","days":4},{"id":"brocade3","kind":"trial","name":"BROCADE3","route":"/trials/brocade3/","asOf":"2026-09-24","days":4},{"id":"diamond","kind":"trial","name":"DIAMOND","route":"/trials/diamond/","asOf":"2026-09-24","days":4},{"id":"lotus","kind":"trial","name":"LOTUS","route":"/trials/lotus/","asOf":"2026-09-24","days":4},{"id":"pakt","kind":"trial","name":"PAKT","route":"/trials/pakt/","asOf":"2026-09-24","days":4},{"id":"scan-b","kind":"trial","name":"SCAN-B (Sweden Cancerome Analysis Network - Breast)","route":"/trials/scan-b/","asOf":"2026-09-24","days":4},{"id":"nct02641847","kind":"trial","name":"TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature","route":"/trials/nct02641847/","asOf":"2026-09-24","days":4},{"id":"nct01057069","kind":"trial","name":"Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer","route":"/trials/nct01057069/","asOf":"2026-09-24","days":4},{"id":"nct03168880","kind":"trial","name":"A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced","route":"/trials/nct03168880/","asOf":"2026-09-24","days":4},{"id":"nct02488967","kind":"trial","name":"Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer","route":"/trials/nct02488967/","asOf":"2026-09-24","days":4},{"id":"nct02455141","kind":"trial","name":"Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer","route":"/trials/nct02455141/","asOf":"2026-09-24","days":4},{"id":"nct05552001","kind":"trial","name":"Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer","route":"/trials/nct05552001/","asOf":"2026-09-24","days":4},{"id":"nct04335669","kind":"trial","name":"NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC","route":"/trials/nct04335669/","asOf":"2026-09-24","days":4},{"id":"nct04595565","kind":"trial","name":"Sacituzumab Govitecan in Primary HER2-negative Breast Cancer","route":"/trials/nct04595565/","asOf":"2026-09-24","days":4},{"id":"nct05078047","kind":"trial","name":"Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO","route":"/trials/nct05078047/","asOf":"2026-09-24","days":4},{"id":"nct04296175","kind":"trial","name":"Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)","route":"/trials/nct04296175/","asOf":"2026-09-24","days":4},{"id":"nct06910072","kind":"trial","name":"Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer（UPGRADE-TN","route":"/trials/nct06910072/","asOf":"2026-09-24","days":4},{"id":"nct07359404","kind":"trial","name":"Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC","route":"/trials/nct07359404/","asOf":"2026-09-24","days":4},{"id":"nct07376629","kind":"trial","name":"A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC","route":"/trials/nct07376629/","asOf":"2026-09-24","days":4},{"id":"nct05821686","kind":"trial","name":"Efficacy of Interleukin-2 in Triple Negative Breast Cancer","route":"/trials/nct05821686/","asOf":"2026-09-24","days":4},{"id":"nct07107217","kind":"trial","name":"Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer","route":"/trials/nct07107217/","asOf":"2026-09-24","days":4},{"id":"nct06977542","kind":"trial","name":"Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer","route":"/trials/nct06977542/","asOf":"2026-09-24","days":4},{"id":"nct07413601","kind":"trial","name":"Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Secon","route":"/trials/nct07413601/","asOf":"2026-09-24","days":4},{"id":"nct07681297","kind":"trial","name":"Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Dis","route":"/trials/nct07681297/","asOf":"2026-09-24","days":4},{"id":"nct04301739","kind":"trial","name":"to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versu","route":"/trials/nct04301739/","asOf":"2026-09-24","days":4},{"id":"nct07721259","kind":"trial","name":"A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden","route":"/trials/nct07721259/","asOf":"2026-09-24","days":4},{"id":"nct07788222","kind":"trial","name":"Sacituzumab Govitecan and Q901 in Advanced TNBC","route":"/trials/nct07788222/","asOf":"2026-09-24","days":4},{"id":"nct07021261","kind":"trial","name":"Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients","route":"/trials/nct07021261/","asOf":"2026-09-24","days":4},{"id":"nct07743723","kind":"trial","name":"A Study of IOV-5001 in Adults With Advanced Solid Tumors","route":"/trials/nct07743723/","asOf":"2026-09-24","days":4},{"id":"nct07011823","kind":"trial","name":"Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC","route":"/trials/nct07011823/","asOf":"2026-09-24","days":4},{"id":"nct07407517","kind":"trial","name":"Adjuvant Intensification for LAR","route":"/trials/nct07407517/","asOf":"2026-09-24","days":4},{"id":"nct07299409","kind":"trial","name":"First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.","route":"/trials/nct07299409/","asOf":"2026-09-24","days":4},{"id":"nct07487519","kind":"trial","name":"Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Br","route":"/trials/nct07487519/","asOf":"2026-09-24","days":4},{"id":"nct07486687","kind":"trial","name":"Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy","route":"/trials/nct07486687/","asOf":"2026-09-24","days":4},{"id":"nct07372079","kind":"trial","name":"Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemoth","route":"/trials/nct07372079/","asOf":"2026-09-24","days":4},{"id":"nct06731153","kind":"trial","name":"JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC","route":"/trials/nct06731153/","asOf":"2026-09-24","days":4},{"id":"nct07441512","kind":"trial","name":"A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer","route":"/trials/nct07441512/","asOf":"2026-09-24","days":4},{"id":"nct07743632","kind":"trial","name":"Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC","route":"/trials/nct07743632/","asOf":"2026-09-24","days":4},{"id":"nct07458204","kind":"trial","name":"Peritumoral and Periganglionic Infiltration of Levobupivacaine Prior to Conservative Surgery for Triple-negative Breast Cancer","route":"/trials/nct07458204/","asOf":"2026-09-24","days":4},{"id":"nct05862610","kind":"trial","name":"The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC","route":"/trials/nct05862610/","asOf":"2026-09-24","days":4},{"id":"nct07752550","kind":"trial","name":"Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer","route":"/trials/nct07752550/","asOf":"2026-09-24","days":4},{"id":"nct05522491","kind":"trial","name":"Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer","route":"/trials/nct05522491/","asOf":"2026-09-24","days":4},{"id":"nct06404736","kind":"trial","name":"QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer","route":"/trials/nct06404736/","asOf":"2026-09-24","days":4},{"id":"nct07509515","kind":"trial","name":"QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC.","route":"/trials/nct07509515/","asOf":"2026-09-24","days":4},{"id":"nct07015853","kind":"trial","name":"ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation","route":"/trials/nct07015853/","asOf":"2026-09-24","days":4},{"id":"nct07151586","kind":"trial","name":"Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Lo","route":"/trials/nct07151586/","asOf":"2026-09-24","days":4},{"id":"nct06371807","kind":"trial","name":"Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab","route":"/trials/nct06371807/","asOf":"2026-09-24","days":4},{"id":"nct07552181","kind":"trial","name":"Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer","route":"/trials/nct07552181/","asOf":"2026-09-24","days":4},{"id":"nct07762703","kind":"trial","name":"Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Incl","route":"/trials/nct07762703/","asOf":"2026-09-24","days":4},{"id":"nct07292142","kind":"trial","name":"FMT in Triple Negative Breast Cancer Guided by ctDNA","route":"/trials/nct07292142/","asOf":"2026-09-24","days":4},{"id":"nct07244874","kind":"trial","name":"Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC","route":"/trials/nct07244874/","asOf":"2026-09-24","days":4},{"id":"nct02802423","kind":"trial","name":"Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.","route":"/trials/nct02802423/","asOf":"2026-09-24","days":4},{"id":"nct06202313","kind":"trial","name":"Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer","route":"/trials/nct06202313/","asOf":"2026-09-24","days":4},{"id":"nct07040644","kind":"trial","name":"A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC","route":"/trials/nct07040644/","asOf":"2026-09-24","days":4},{"id":"nct06724263","kind":"trial","name":"A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors","route":"/trials/nct06724263/","asOf":"2026-09-24","days":4},{"id":"nct06632405","kind":"trial","name":"A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC","route":"/trials/nct06632405/","asOf":"2026-09-24","days":4},{"id":"nct06849492","kind":"trial","name":"HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer","route":"/trials/nct06849492/","asOf":"2026-09-24","days":4},{"id":"nct07054242","kind":"trial","name":"A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Ca","route":"/trials/nct07054242/","asOf":"2026-09-24","days":4},{"id":"nct06746870","kind":"trial","name":"A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Tr","route":"/trials/nct06746870/","asOf":"2026-09-24","days":4},{"id":"nct05128734","kind":"trial","name":"Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)","route":"/trials/nct05128734/","asOf":"2026-09-24","days":4},{"id":"nct07256964","kind":"trial","name":"Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer","route":"/trials/nct07256964/","asOf":"2026-09-24","days":4},{"id":"nct07628504","kind":"trial","name":"Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations","route":"/trials/nct07628504/","asOf":"2026-09-24","days":4},{"id":"nct07101614","kind":"trial","name":"A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy fo","route":"/trials/nct07101614/","asOf":"2026-09-24","days":4},{"id":"nct07103447","kind":"trial","name":"Prospective Multicenter Single-arm Trial: AK112 + Nab-paclitaxel/Carboplatin Neoadjuvant for TNBC","route":"/trials/nct07103447/","asOf":"2026-09-24","days":4},{"id":"nct06819319","kind":"trial","name":"SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer","route":"/trials/nct06819319/","asOf":"2026-09-24","days":4},{"id":"nct07161791","kind":"trial","name":"Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer","route":"/trials/nct07161791/","asOf":"2026-09-24","days":4},{"id":"nct07581314","kind":"trial","name":"Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)","route":"/trials/nct07581314/","asOf":"2026-09-24","days":4},{"id":"nct06691594","kind":"trial","name":"Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy","route":"/trials/nct06691594/","asOf":"2026-09-24","days":4},{"id":"nct07271992","kind":"trial","name":"TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer","route":"/trials/nct07271992/","asOf":"2026-09-24","days":4},{"id":"nct07153965","kind":"trial","name":"Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer","route":"/trials/nct07153965/","asOf":"2026-09-24","days":4},{"id":"nct07255612","kind":"trial","name":"Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)","route":"/trials/nct07255612/","asOf":"2026-09-24","days":4},{"id":"nct07730125","kind":"trial","name":"Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies","route":"/trials/nct07730125/","asOf":"2026-09-24","days":4},{"id":"nct06140576","kind":"trial","name":"The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breas","route":"/trials/nct06140576/","asOf":"2026-09-24","days":4},{"id":"nct06229067","kind":"trial","name":"Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer","route":"/trials/nct06229067/","asOf":"2026-09-24","days":4},{"id":"nct06787339","kind":"trial","name":"Capecitabine in Low Risk Triple Negative Breast Cancer","route":"/trials/nct06787339/","asOf":"2026-09-24","days":4},{"id":"nct07005583","kind":"trial","name":"Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent","route":"/trials/nct07005583/","asOf":"2026-09-24","days":4},{"id":"nct07723469","kind":"trial","name":"Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery","route":"/trials/nct07723469/","asOf":"2026-09-24","days":4},{"id":"nct05067530","kind":"trial","name":"Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a \"Window of Opportunity\" Study","route":"/trials/nct05067530/","asOf":"2026-09-24","days":4},{"id":"nct06795503","kind":"trial","name":"Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients","route":"/trials/nct06795503/","asOf":"2026-09-24","days":4},{"id":"nct06586866","kind":"trial","name":"JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases","route":"/trials/nct06586866/","asOf":"2026-09-24","days":4},{"id":"nct07786428","kind":"trial","name":"Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC","route":"/trials/nct07786428/","asOf":"2026-09-24","days":4},{"id":"nct07419880","kind":"trial","name":"Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer","route":"/trials/nct07419880/","asOf":"2026-09-24","days":4},{"id":"nct07610525","kind":"trial","name":"Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial","route":"/trials/nct07610525/","asOf":"2026-09-24","days":4},{"id":"nct07729956","kind":"trial","name":"A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inopera","route":"/trials/nct07729956/","asOf":"2026-09-24","days":4},{"id":"nct05806385","kind":"trial","name":"Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers","route":"/trials/nct05806385/","asOf":"2026-09-24","days":4},{"id":"nct07528768","kind":"trial","name":"HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry.","route":"/trials/nct07528768/","asOf":"2026-09-24","days":4},{"id":"nct06268327","kind":"trial","name":"Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy","route":"/trials/nct06268327/","asOf":"2026-09-24","days":4},{"id":"nct07007780","kind":"trial","name":"Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC","route":"/trials/nct07007780/","asOf":"2026-09-24","days":4},{"id":"nct07139470","kind":"trial","name":"Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer","route":"/trials/nct07139470/","asOf":"2026-09-24","days":4},{"id":"nct07458113","kind":"trial","name":"Sac-TMT for Active TNBC Brain Metastases","route":"/trials/nct07458113/","asOf":"2026-09-24","days":4},{"id":"nct07556848","kind":"trial","name":"A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer","route":"/trials/nct07556848/","asOf":"2026-09-24","days":4},{"id":"nct06407310","kind":"trial","name":"Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer","route":"/trials/nct06407310/","asOf":"2026-09-24","days":4},{"id":"nct07178730","kind":"trial","name":"NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer","route":"/trials/nct07178730/","asOf":"2026-09-24","days":4},{"id":"nct07698106","kind":"trial","name":"Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC","route":"/trials/nct07698106/","asOf":"2026-09-24","days":4},{"id":"nct06176261","kind":"trial","name":"DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs","route":"/trials/nct06176261/","asOf":"2026-09-24","days":4},{"id":"nct04468061","kind":"trial","name":"Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC","route":"/trials/nct04468061/","asOf":"2026-09-24","days":4},{"id":"nct06627712","kind":"trial","name":"SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC","route":"/trials/nct06627712/","asOf":"2026-09-24","days":4},{"id":"nct05447702","kind":"trial","name":"Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)","route":"/trials/nct05447702/","asOf":"2026-09-24","days":4},{"id":"nct07064018","kind":"trial","name":"Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies","route":"/trials/nct07064018/","asOf":"2026-09-24","days":4},{"id":"nct07378306","kind":"trial","name":"FMD and Neoadjuvant Chemo-immunotherapy in TNBC","route":"/trials/nct07378306/","asOf":"2026-09-24","days":4},{"id":"nct07601178","kind":"trial","name":"QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride","route":"/trials/nct07601178/","asOf":"2026-09-24","days":4},{"id":"nct06793332","kind":"trial","name":"BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC","route":"/trials/nct06793332/","asOf":"2026-09-24","days":4},{"id":"nct06245889","kind":"trial","name":"PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC","route":"/trials/nct06245889/","asOf":"2026-09-24","days":4},{"id":"nct04768426","kind":"trial","name":"Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer","route":"/trials/nct04768426/","asOf":"2026-09-24","days":4},{"id":"nct06793553","kind":"trial","name":"Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC","route":"/trials/nct06793553/","asOf":"2026-09-24","days":4},{"id":"nct06963905","kind":"trial","name":"Saci Nivo Rela for TNBC","route":"/trials/nct06963905/","asOf":"2026-09-24","days":4},{"id":"nct06682195","kind":"trial","name":"Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)","route":"/trials/nct06682195/","asOf":"2026-09-24","days":4},{"id":"nct04683679","kind":"trial","name":"A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negat","route":"/trials/nct04683679/","asOf":"2026-09-24","days":4},{"id":"nct06353997","kind":"trial","name":"Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients","route":"/trials/nct06353997/","asOf":"2026-09-24","days":4},{"id":"nct04230109","kind":"trial","name":"Sacituzumab Govitecan In TNBC","route":"/trials/nct04230109/","asOf":"2026-09-24","days":4},{"id":"nct06134375","kind":"trial","name":"A Study of Tetrathiomolybdate (TM) Plus Capecitabine","route":"/trials/nct06134375/","asOf":"2026-09-24","days":4},{"id":"nct06616987","kind":"trial","name":"Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer","route":"/trials/nct06616987/","asOf":"2026-09-24","days":4},{"id":"nct06385990","kind":"trial","name":"Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy","route":"/trials/nct06385990/","asOf":"2026-09-24","days":4},{"id":"nct06367088","kind":"trial","name":"Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer","route":"/trials/nct06367088/","asOf":"2026-09-24","days":4},{"id":"nct06831955","kind":"trial","name":"LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer","route":"/trials/nct06831955/","asOf":"2026-09-24","days":4},{"id":"nct07371208","kind":"trial","name":"Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer","route":"/trials/nct07371208/","asOf":"2026-09-24","days":4},{"id":"nct06817525","kind":"trial","name":"Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC","route":"/trials/nct06817525/","asOf":"2026-09-24","days":4},{"id":"nct07342283","kind":"trial","name":"QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer","route":"/trials/nct07342283/","asOf":"2026-09-24","days":4},{"id":"nct06878625","kind":"trial","name":"A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer","route":"/trials/nct06878625/","asOf":"2026-09-24","days":4},{"id":"nct06636981","kind":"trial","name":"All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi","route":"/trials/nct06636981/","asOf":"2026-09-24","days":4},{"id":"nct07739485","kind":"trial","name":"Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study","route":"/trials/nct07739485/","asOf":"2026-09-24","days":4},{"id":"nct05550415","kind":"trial","name":"The Role of Simvastatin in The Epithelial-Mesenchymal Transition Process of Breast Cancer","route":"/trials/nct05550415/","asOf":"2026-09-24","days":4},{"id":"nct06078384","kind":"trial","name":"Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC","route":"/trials/nct06078384/","asOf":"2026-09-24","days":4},{"id":"nct05866432","kind":"trial","name":"Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases","route":"/trials/nct05866432/","asOf":"2026-09-24","days":4},{"id":"nct06851299","kind":"trial","name":"The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast","route":"/trials/nct06851299/","asOf":"2026-09-24","days":4},{"id":"nct05570253","kind":"trial","name":"A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer","route":"/trials/nct05570253/","asOf":"2026-09-24","days":4},{"id":"nct07078604","kind":"trial","name":"A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer","route":"/trials/nct07078604/","asOf":"2026-09-24","days":4},{"id":"nct04722978","kind":"trial","name":"Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer","route":"/trials/nct04722978/","asOf":"2026-09-24","days":4},{"id":"nct04437160","kind":"trial","name":"Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy","route":"/trials/nct04437160/","asOf":"2026-09-24","days":4},{"id":"nct05806060","kind":"trial","name":"Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer","route":"/trials/nct05806060/","asOf":"2026-09-24","days":4},{"id":"nct05660083","kind":"trial","name":"Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)","route":"/trials/nct05660083/","asOf":"2026-09-24","days":4},{"id":"nct06358573","kind":"trial","name":"Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK","route":"/trials/nct06358573/","asOf":"2026-09-24","days":4},{"id":"nct07276880","kind":"trial","name":"Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer","route":"/trials/nct07276880/","asOf":"2026-09-24","days":4},{"id":"nct06081244","kind":"trial","name":"NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)","route":"/trials/nct06081244/","asOf":"2026-09-24","days":4},{"id":"nct07394387","kind":"trial","name":"Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.","route":"/trials/nct07394387/","asOf":"2026-09-24","days":4},{"id":"nct07045311","kind":"trial","name":"JS207 Combination Therapy in Triple-negative Breast Cancer","route":"/trials/nct07045311/","asOf":"2026-09-24","days":4},{"id":"nct07768436","kind":"trial","name":"A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer","route":"/trials/nct07768436/","asOf":"2026-09-24","days":4},{"id":"nct05475678","kind":"trial","name":"Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer","route":"/trials/nct05475678/","asOf":"2026-09-24","days":4},{"id":"nct06976944","kind":"trial","name":"Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer","route":"/trials/nct06976944/","asOf":"2026-09-24","days":4},{"id":"nct04481763","kind":"trial","name":"A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast","route":"/trials/nct04481763/","asOf":"2026-09-24","days":4},{"id":"nct05999149","kind":"trial","name":"A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BC","route":"/trials/nct05999149/","asOf":"2026-09-24","days":4},{"id":"nct07743190","kind":"trial","name":"A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) P","route":"/trials/nct07743190/","asOf":"2026-09-24","days":4},{"id":"nct05035745","kind":"trial","name":"Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)","route":"/trials/nct05035745/","asOf":"2026-09-24","days":4},{"id":"nct04159818","kind":"trial","name":"Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients","route":"/trials/nct04159818/","asOf":"2026-09-24","days":4},{"id":"nct05192798","kind":"trial","name":"Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC","route":"/trials/nct05192798/","asOf":"2026-09-24","days":4},{"id":"nct06313463","kind":"trial","name":"Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy","route":"/trials/nct06313463/","asOf":"2026-09-24","days":4},{"id":"nct06538896","kind":"trial","name":"Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Mu","route":"/trials/nct06538896/","asOf":"2026-09-24","days":4},{"id":"nct05749588","kind":"trial","name":"FUSCC Refractory TNBC Platform Study (FUTURE2.0)","route":"/trials/nct05749588/","asOf":"2026-09-24","days":4},{"id":"nct07321015","kind":"trial","name":"A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance","route":"/trials/nct07321015/","asOf":"2026-09-24","days":4},{"id":"nct06786026","kind":"trial","name":"QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC","route":"/trials/nct06786026/","asOf":"2026-09-24","days":4},{"id":"nct06238921","kind":"trial","name":"Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases","route":"/trials/nct06238921/","asOf":"2026-09-24","days":4},{"id":"nct04677816","kind":"trial","name":"Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients","route":"/trials/nct04677816/","asOf":"2026-09-24","days":4},{"id":"nct07069595","kind":"trial","name":"PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease","route":"/trials/nct07069595/","asOf":"2026-09-24","days":4},{"id":"nct06532812","kind":"trial","name":"TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer","route":"/trials/nct06532812/","asOf":"2026-09-24","days":4},{"id":"nct06387628","kind":"trial","name":"LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer","route":"/trials/nct06387628/","asOf":"2026-09-24","days":4},{"id":"nct05528133","kind":"trial","name":"Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer","route":"/trials/nct05528133/","asOf":"2026-09-24","days":4},{"id":"nct07401537","kind":"trial","name":"Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer","route":"/trials/nct07401537/","asOf":"2026-09-24","days":4},{"id":"nct05296564","kind":"trial","name":"Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers","route":"/trials/nct05296564/","asOf":"2026-09-24","days":4},{"id":"nct06845319","kind":"trial","name":"NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients","route":"/trials/nct06845319/","asOf":"2026-09-24","days":4},{"id":"nct03606967","kind":"trial","name":"Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer","route":"/trials/nct03606967/","asOf":"2026-09-24","days":4},{"id":"nct04138719","kind":"trial","name":"Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer","route":"/trials/nct04138719/","asOf":"2026-09-24","days":4},{"id":"nct06678048","kind":"trial","name":"Arsenous Acid for Refractory Triple-Negative Breast Cancer","route":"/trials/nct06678048/","asOf":"2026-09-24","days":4},{"id":"nct05491226","kind":"trial","name":"Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation","route":"/trials/nct05491226/","asOf":"2026-09-24","days":4},{"id":"nct05582538","kind":"trial","name":"Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel","route":"/trials/nct05582538/","asOf":"2026-09-24","days":4},{"id":"nct06840821","kind":"trial","name":"Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptor","route":"/trials/nct06840821/","asOf":"2026-09-24","days":4},{"id":"nct07623577","kind":"trial","name":"Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases","route":"/trials/nct07623577/","asOf":"2026-09-24","days":4},{"id":"nct06690840","kind":"trial","name":"Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients","route":"/trials/nct06690840/","asOf":"2026-09-24","days":4},{"id":"nct06125080","kind":"trial","name":"The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospec","route":"/trials/nct06125080/","asOf":"2026-09-24","days":4},{"id":"nct05485766","kind":"trial","name":"Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer","route":"/trials/nct05485766/","asOf":"2026-09-24","days":4},{"id":"nct07340541","kind":"trial","name":"Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies","route":"/trials/nct07340541/","asOf":"2026-09-24","days":4},{"id":"nct06365788","kind":"trial","name":"Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer","route":"/trials/nct06365788/","asOf":"2026-09-24","days":4},{"id":"nct07017673","kind":"trial","name":"Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer","route":"/trials/nct07017673/","asOf":"2026-09-24","days":4},{"id":"nct07638852","kind":"trial","name":"Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.","route":"/trials/nct07638852/","asOf":"2026-09-24","days":4},{"id":"nct04333706","kind":"trial","name":"A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of S","route":"/trials/nct04333706/","asOf":"2026-09-24","days":4},{"id":"nct06165900","kind":"trial","name":"Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC","route":"/trials/nct06165900/","asOf":"2026-09-24","days":4},{"id":"nct06508216","kind":"trial","name":"A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negat","route":"/trials/nct06508216/","asOf":"2026-09-24","days":4},{"id":"nct06225284","kind":"trial","name":"Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients","route":"/trials/nct06225284/","asOf":"2026-09-24","days":4},{"id":"nct06889688","kind":"trial","name":"Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer","route":"/trials/nct06889688/","asOf":"2026-09-24","days":4},{"id":"nct05019690","kind":"trial","name":"Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer","route":"/trials/nct05019690/","asOf":"2026-09-24","days":4},{"id":"nct04137653","kind":"trial","name":"Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT","route":"/trials/nct04137653/","asOf":"2026-09-24","days":4},{"id":"nct06380816","kind":"trial","name":"A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer","route":"/trials/nct06380816/","asOf":"2026-09-24","days":4},{"id":"nct05973864","kind":"trial","name":"Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery","route":"/trials/nct05973864/","asOf":"2026-09-24","days":4},{"id":"nct05862064","kind":"trial","name":"A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chem","route":"/trials/nct05862064/","asOf":"2026-09-24","days":4},{"id":"nct06492759","kind":"trial","name":"High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer","route":"/trials/nct06492759/","asOf":"2026-09-24","days":4},{"id":"nct05846789","kind":"trial","name":"Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers","route":"/trials/nct05846789/","asOf":"2026-09-24","days":4},{"id":"nct06889610","kind":"trial","name":"A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.","route":"/trials/nct06889610/","asOf":"2026-09-24","days":4},{"id":"nct06318897","kind":"trial","name":"Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T","route":"/trials/nct06318897/","asOf":"2026-09-24","days":4},{"id":"nct06534762","kind":"trial","name":"Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study","route":"/trials/nct06534762/","asOf":"2026-09-24","days":4},{"id":"nct05909332","kind":"trial","name":"Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)","route":"/trials/nct05909332/","asOf":"2026-09-24","days":4},{"id":"nct06771609","kind":"trial","name":"Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy fo","route":"/trials/nct06771609/","asOf":"2026-09-24","days":4},{"id":"nct06434064","kind":"trial","name":"Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer","route":"/trials/nct06434064/","asOf":"2026-09-24","days":4},{"id":"nct06606730","kind":"trial","name":"Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer","route":"/trials/nct06606730/","asOf":"2026-09-24","days":4},{"id":"nct05770531","kind":"trial","name":"Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy","route":"/trials/nct05770531/","asOf":"2026-09-24","days":4},{"id":"nct06291064","kind":"trial","name":"Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer","route":"/trials/nct06291064/","asOf":"2026-09-24","days":4},{"id":"nct07351487","kind":"trial","name":"Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)","route":"/trials/nct07351487/","asOf":"2026-09-24","days":4},{"id":"nct06401005","kind":"trial","name":"SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)","route":"/trials/nct06401005/","asOf":"2026-09-24","days":4},{"id":"nct07016399","kind":"trial","name":"Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC","route":"/trials/nct07016399/","asOf":"2026-09-24","days":4},{"id":"nct07457359","kind":"trial","name":"Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer","route":"/trials/nct07457359/","asOf":"2026-09-24","days":4},{"id":"nct06735131","kind":"trial","name":"The Optimal Radioimmunotherapy Combinations for Advanced TNBC","route":"/trials/nct06735131/","asOf":"2026-09-24","days":4},{"id":"nct06992336","kind":"trial","name":"Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy","route":"/trials/nct06992336/","asOf":"2026-09-24","days":4},{"id":"nct07011654","kind":"trial","name":"Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)","route":"/trials/nct07011654/","asOf":"2026-09-24","days":4},{"id":"nct06533384","kind":"trial","name":"PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC","route":"/trials/nct06533384/","asOf":"2026-09-24","days":4},{"id":"nct05760378","kind":"trial","name":"Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.","route":"/trials/nct05760378/","asOf":"2026-09-24","days":4},{"id":"nct07074106","kind":"trial","name":"TIL-Driven De-escalated Chemotherapy in Stage I-II TNBC","route":"/trials/nct07074106/","asOf":"2026-09-24","days":4},{"id":"nct04434040","kind":"trial","name":"Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)","route":"/trials/nct04434040/","asOf":"2026-09-24","days":4},{"id":"nct04501523","kind":"trial","name":"A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC","route":"/trials/nct04501523/","asOf":"2026-09-24","days":4},{"id":"nct03808337","kind":"trial","name":"Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Origina","route":"/trials/nct03808337/","asOf":"2026-09-24","days":4},{"id":"nct07283692","kind":"trial","name":"Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)","route":"/trials/nct07283692/","asOf":"2026-09-24","days":4},{"id":"nct06342037","kind":"trial","name":"NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial","route":"/trials/nct06342037/","asOf":"2026-09-24","days":4},{"id":"nct07188246","kind":"trial","name":"Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer","route":"/trials/nct07188246/","asOf":"2026-09-24","days":4},{"id":"nct06802757","kind":"trial","name":"Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer","route":"/trials/nct06802757/","asOf":"2026-09-24","days":4},{"id":"nct05451784","kind":"trial","name":"Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS","route":"/trials/nct05451784/","asOf":"2026-09-24","days":4},{"id":"nct05491083","kind":"trial","name":"Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer","route":"/trials/nct05491083/","asOf":"2026-09-24","days":4},{"id":"nct07104266","kind":"trial","name":"Triple Negative Breast Cancer and Celecoxib. Pilot Study","route":"/trials/nct07104266/","asOf":"2026-09-24","days":4},{"id":"nct05269381","kind":"trial","name":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","route":"/trials/nct05269381/","asOf":"2026-09-24","days":4},{"id":"nct04159142","kind":"trial","name":"Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer","route":"/trials/nct04159142/","asOf":"2026-09-24","days":4},{"id":"nct04947189","kind":"trial","name":"Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer","route":"/trials/nct04947189/","asOf":"2026-09-24","days":4},{"id":"nct06635980","kind":"trial","name":"Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer","route":"/trials/nct06635980/","asOf":"2026-09-24","days":4},{"id":"nct04771871","kind":"trial","name":"MicroRNA Profiles in Triple Negative Breast Cancer","route":"/trials/nct04771871/","asOf":"2026-09-24","days":4},{"id":"paper-esmo-pancreatic-cancer-guideline-ann-oncol-2023","kind":"paper","name":"Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-pancreatic-cancer-guideline-ann-oncol-2023/","asOf":"2026-09-24","days":4},{"id":"paper-nccn-pancreatic-adenocarcinoma-v2-2021-jnccn-2021","kind":"paper","name":"Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","route":"/key-papers/paper-nccn-pancreatic-adenocarcinoma-v2-2021-jnccn-2021/","asOf":"2026-09-24","days":4},{"id":"paper-asco-metastatic-pancreatic-cancer-guideline-update-jco-2020","kind":"paper","name":"Metastatic Pancreatic Cancer: ASCO Guideline Update","route":"/key-papers/paper-asco-metastatic-pancreatic-cancer-guideline-update-jco-2020/","asOf":"2026-09-24","days":4},{"id":"paper-asco-potentially-curable-pancreatic-guideline-update-jco-2019","kind":"paper","name":"Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update","route":"/key-papers/paper-asco-potentially-curable-pancreatic-guideline-update-jco-2019/","asOf":"2026-09-24","days":4},{"id":"paper-caps-consortium-surveillance-recommendations-gut-2020","kind":"paper","name":"Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium","route":"/key-papers/paper-caps-consortium-surveillance-recommendations-gut-2020/","asOf":"2026-09-24","days":4},{"id":"paper-whipple-carcinoma-ampulla-of-vater-ann-surg-1935","kind":"paper","name":"Treatment of carcinoma of the ampulla of Vater","route":"/key-papers/paper-whipple-carcinoma-ampulla-of-vater-ann-surg-1935/","asOf":"2026-09-24","days":4},{"id":"paper-traverso-longmire-pylorus-preservation-pancreaticoduodenectomy-sgo-1978","kind":"paper","name":"Preservation of the pylorus in pancreaticoduodenectomy","route":"/key-papers/paper-traverso-longmire-pylorus-preservation-pancreaticoduodenectomy-sgo-1978/","asOf":"2026-09-24","days":4},{"id":"paper-hidalgo-pancreatic-cancer-review-nejm-2010","kind":"paper","name":"Pancreatic cancer","route":"/key-papers/paper-hidalgo-pancreatic-cancer-review-nejm-2010/","asOf":"2026-09-24","days":4},{"id":"paper-almoguera-kras-codon-12-pancreatic-cell-1988","kind":"paper","name":"Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes","route":"/key-papers/paper-almoguera-kras-codon-12-pancreatic-cell-1988/","asOf":"2026-09-24","days":4},{"id":"paper-holderfield-ras-on-multi-selective-inhibitor-nature-2024","kind":"paper","name":"Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy","route":"/key-papers/paper-holderfield-ras-on-multi-selective-inhibitor-nature-2024/","asOf":"2026-09-24","days":4},{"id":"paper-waddell-whole-genomes-pancreatic-nature-2015","kind":"paper","name":"Whole genomes redefine the mutational landscape of pancreatic cancer","route":"/key-papers/paper-waddell-whole-genomes-pancreatic-nature-2015/","asOf":"2026-09-24","days":4},{"id":"paper-moffitt-virtual-microdissection-subtypes-nat-genet-2015","kind":"paper","name":"Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma","route":"/key-papers/paper-moffitt-virtual-microdissection-subtypes-nat-genet-2015/","asOf":"2026-09-24","days":4},{"id":"paper-bailey-molecular-subtypes-pancreatic-nature-2016","kind":"paper","name":"Genomic analyses identify molecular subtypes of pancreatic cancer","route":"/key-papers/paper-bailey-molecular-subtypes-pancreatic-nature-2016/","asOf":"2026-09-24","days":4},{"id":"paper-hu-germline-mutations-pancreatic-cancer-risk-jama-2018","kind":"paper","name":"Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer","route":"/key-papers/paper-hu-germline-mutations-pancreatic-cancer-risk-jama-2018/","asOf":"2026-09-24","days":4},{"id":"paper-ozdemir-caf-depletion-accelerates-pancreatic-cancer-cancer-cell-2014","kind":"paper","name":"Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival","route":"/key-papers/paper-ozdemir-caf-depletion-accelerates-pancreatic-cancer-cancer-cell-2014/","asOf":"2026-09-24","days":4},{"id":"paper-espac-1-chemoradiotherapy-chemotherapy-resected-pancreatic-nejm-2004","kind":"paper","name":"A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer","route":"/key-papers/paper-espac-1-chemoradiotherapy-chemotherapy-resected-pancreatic-nejm-2004/","asOf":"2026-09-24","days":4},{"id":"paper-conko-001-adjuvant-gemcitabine-observation-jama-2007","kind":"paper","name":"Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial","route":"/key-papers/paper-conko-001-adjuvant-gemcitabine-observation-jama-2007/","asOf":"2026-09-24","days":4},{"id":"paper-napoli-1-nanoliposomal-irinotecan-lancet-2016","kind":"paper","name":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","route":"/key-papers/paper-napoli-1-nanoliposomal-irinotecan-lancet-2016/","asOf":"2026-09-24","days":4},{"id":"paper-prodige-24-five-year-outcomes-jama-oncol-2022","kind":"paper","name":"Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial","route":"/key-papers/paper-prodige-24-five-year-outcomes-jama-oncol-2022/","asOf":"2026-09-24","days":4},{"id":"paper-preopanc-preoperative-chemoradiotherapy-jco-2020","kind":"paper","name":"Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial","route":"/key-papers/paper-preopanc-preoperative-chemoradiotherapy-jco-2020/","asOf":"2026-09-24","days":4},{"id":"paper-preopanc-2-neoadjuvant-folfirinox-vs-chemoradiotherapy-lancet-oncol-2025","kind":"paper","name":"Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial","route":"/key-papers/paper-preopanc-2-neoadjuvant-folfirinox-vs-chemoradiotherapy-lancet-oncol-2025/","asOf":"2026-09-24","days":4},{"id":"paper-halo-301-pegvorhyaluronidase-jco-2020","kind":"paper","name":"Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma","route":"/key-papers/paper-halo-301-pegvorhyaluronidase-jco-2020/","asOf":"2026-09-24","days":4},{"id":"paper-panova-3-ttfields-locally-advanced-pancreatic-jco-2025","kind":"paper","name":"Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study","route":"/key-papers/paper-panova-3-ttfields-locally-advanced-pancreatic-jco-2025/","asOf":"2026-09-24","days":4},{"id":"paper-sethna-rna-neoantigen-vaccine-long-lived-t-cells-nature-2025","kind":"paper","name":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","route":"/key-papers/paper-sethna-rna-neoantigen-vaccine-long-lived-t-cells-nature-2025/","asOf":"2026-09-24","days":4},{"id":"paper-tempero-ca19-9-lewis-antigens-cancer-res-1987","kind":"paper","name":"Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer","route":"/key-papers/paper-tempero-ca19-9-lewis-antigens-cancer-res-1987/","asOf":"2026-09-24","days":4},{"id":"paper-fahrmann-ca19-9-lead-time-gastroenterology-2021","kind":"paper","name":"Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection","route":"/key-papers/paper-fahrmann-ca19-9-lead-time-gastroenterology-2021/","asOf":"2026-09-24","days":4},{"id":"paper-chari-pancreatic-cancer-following-diabetes-gastroenterology-2005","kind":"paper","name":"Probability of pancreatic cancer following diabetes: a population-based study","route":"/key-papers/paper-chari-pancreatic-cancer-following-diabetes-gastroenterology-2005/","asOf":"2026-09-24","days":4},{"id":"paper-sharma-endpac-model-new-onset-diabetes-gastroenterology-2018","kind":"paper","name":"Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes","route":"/key-papers/paper-sharma-endpac-model-new-onset-diabetes-gastroenterology-2018/","asOf":"2026-09-24","days":4},{"id":"paper-canto-caps-long-term-surveillance-gastroenterology-2018","kind":"paper","name":"Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance","route":"/key-papers/paper-canto-caps-long-term-surveillance-gastroenterology-2018/","asOf":"2026-09-24","days":4},{"id":"paper-dbouk-caps5-stage-survival-jco-2022","kind":"paper","name":"The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival","route":"/key-papers/paper-dbouk-caps5-stage-survival-jco-2022/","asOf":"2026-09-24","days":4},{"id":"paper-rahib-projection-us-cancer-2040-jama-netw-open-2021","kind":"paper","name":"Estimated Projection of US Cancer Incidence and Death to 2040","route":"/key-papers/paper-rahib-projection-us-cancer-2040-jama-netw-open-2021/","asOf":"2026-09-24","days":4},{"id":"paper-roberts-pert-survival-pancreatic-cancer-pancreatology-2019","kind":"paper","name":"Enzyme replacement improves survival among patients with pancreatic cancer: Results of a population based study","route":"/key-papers/paper-roberts-pert-survival-pancreatic-cancer-pancreatology-2019/","asOf":"2026-09-24","days":4},{"id":"paper-groarke-ponsegromab-cancer-cachexia-nejm-2024","kind":"paper","name":"Ponsegromab for the Treatment of Cancer Cachexia","route":"/key-papers/paper-groarke-ponsegromab-cancer-cachexia-nejm-2024/","asOf":"2026-09-24","days":4},{"id":"pancreatic-roadmap","kind":"roadmap","name":"Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question","route":"/roadmaps/pancreatic-roadmap/","asOf":"2026-09-24","days":4},{"id":"idea-pdac-new-onset-diabetes-risk-score-pathway","kind":"idea","name":"Run the ENDPAC score on every new diabetes diagnosis after 50 and scan the high scorers","route":"/ideas/idea-pdac-new-onset-diabetes-risk-score-pathway/","asOf":"2026-09-24","days":4},{"id":"idea-pdac-surveillance-for-every-germline-carrier","kind":"idea","name":"Surveillance for every germline carrier found by universal testing, inside a registry rather than a research exception","route":"/ideas/idea-pdac-surveillance-for-every-germline-carrier/","asOf":"2026-09-24","days":4},{"id":"idea-pdac-neoadjuvant-chemotherapy-for-all-resectable-disease","kind":"idea","name":"Chemotherapy before surgery for every resectable pancreatic cancer, settled by the two perioperative trials rather than assumed","route":"/ideas/idea-pdac-neoadjuvant-chemotherapy-for-all-resectable-disease/","asOf":"2026-09-24","days":4},{"id":"idea-pdac-stromal-reprogramming-not-depletion","kind":"idea","name":"Reprogramme the stroma rather than remove it: second-generation stromal trials with a stromal biomarker and a survival endpoint","route":"/ideas/idea-pdac-stromal-reprogramming-not-depletion/","asOf":"2026-09-24","days":4},{"id":"idea-pdac-ras-inhibitor-combinations-and-sequencing","kind":"idea","name":"RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression","route":"/ideas/idea-pdac-ras-inhibitor-combinations-and-sequencing/","asOf":"2026-09-24","days":4},{"id":"idea-pdac-cachexia-trials-embedded-in-chemotherapy-trials","kind":"idea","name":"Embed cachexia treatment in chemotherapy trials: weight, muscle and treatment delivery as co-primary endpoints","route":"/ideas/idea-pdac-cachexia-trials-embedded-in-chemotherapy-trials/","asOf":"2026-09-24","days":4},{"id":"idea-pdac-enzyme-replacement-prescribing-by-default","kind":"idea","name":"Pancreatic enzyme replacement by default: prescribe at diagnosis, audit the rate, and run the trial that settles survival","route":"/ideas/idea-pdac-enzyme-replacement-prescribing-by-default/","asOf":"2026-09-24","days":4},{"id":"idea-pdac-uk-active-treatment-rate-audit-and-target","kind":"idea","name":"Raise the share of UK patients who receive any active treatment, and publish it by trust","route":"/ideas/idea-pdac-uk-active-treatment-rate-audit-and-target/","asOf":"2026-09-24","days":4},{"id":"idea-pdac-uk-fast-track-diagnosis-to-treatment-pathway","kind":"idea","name":"A fast-track pathway from suspicion to treatment for pancreatic cancer in the NHS, measured from first scan to first treatment","route":"/ideas/idea-pdac-uk-fast-track-diagnosis-to-treatment-pathway/","asOf":"2026-09-24","days":4},{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/","asOf":"2026-09-24","days":4},{"id":"pancreatic-palliation-obstruction-pain-nutrition","kind":"term","name":"Palliation in pancreatic cancer: biliary and duodenal stents, coeliac plexus block, enzymes and cachexia","route":"/terms/pancreatic-palliation-obstruction-pain-nutrition/","asOf":"2026-09-24","days":4},{"id":"pancreatic-cancer-uk-drug-access","kind":"term","name":"Pancreatic cancer drugs in England: NICE appraisals and the Cancer Drugs Fund (September 2026)","route":"/terms/pancreatic-cancer-uk-drug-access/","asOf":"2026-09-24","days":4},{"id":"pancreatic-failed-programmes","kind":"term","name":"Pancreatic cancer: the failed and stopped programmes and why","route":"/terms/pancreatic-failed-programmes/","asOf":"2026-09-24","days":4},{"id":"pancrelipase","kind":"drug","name":"Pancrelipase (pancreatic enzyme replacement therapy)","route":"/drugs/pancrelipase/","asOf":"2026-09-24","days":4},{"id":"pegvorhyaluronidase-alfa","kind":"drug","name":"Pegvorhyaluronidase alfa","route":"/drugs/pegvorhyaluronidase-alfa/","asOf":"2026-09-24","days":4},{"id":"pegilodecakin","kind":"drug","name":"Pegilodecakin","route":"/drugs/pegilodecakin/","asOf":"2026-09-24","days":4},{"id":"napabucasin","kind":"drug","name":"Napabucasin","route":"/drugs/napabucasin/","asOf":"2026-09-24","days":4},{"id":"espac-1","kind":"trial","name":"ESPAC-1","route":"/trials/espac-1/","asOf":"2026-09-24","days":4},{"id":"jaspac-01","kind":"trial","name":"JASPAC 01","route":"/trials/jaspac-01/","asOf":"2026-09-24","days":4},{"id":"apact","kind":"trial","name":"APACT","route":"/trials/apact/","asOf":"2026-09-24","days":4},{"id":"swog-s1505","kind":"trial","name":"SWOG S1505","route":"/trials/swog-s1505/","asOf":"2026-09-24","days":4},{"id":"neonax","kind":"trial","name":"NEONAX","route":"/trials/neonax/","asOf":"2026-09-24","days":4},{"id":"preopanc-2","kind":"trial","name":"PREOPANC-2","route":"/trials/preopanc-2/","asOf":"2026-09-24","days":4},{"id":"alliance-a021806","kind":"trial","name":"Alliance A021806","route":"/trials/alliance-a021806/","asOf":"2026-09-24","days":4},{"id":"preopanc-3","kind":"trial","name":"PREOPANC-3","route":"/trials/preopanc-3/","asOf":"2026-09-24","days":4},{"id":"alliance-a021501","kind":"trial","name":"Alliance A021501","route":"/trials/alliance-a021501/","asOf":"2026-09-24","days":4},{"id":"conko-005","kind":"trial","name":"CONKO-005","route":"/trials/conko-005/","asOf":"2026-09-24","days":4},{"id":"autogene-cevumeran-phase-1","kind":"trial","name":"Autogene cevumeran phase 1 in resected pancreatic cancer (Memorial Sloan Kettering)","route":"/trials/autogene-cevumeran-phase-1/","asOf":"2026-09-24","days":4},{"id":"starpac2","kind":"trial","name":"STARPAC2","route":"/trials/starpac2/","asOf":"2026-09-24","days":4},{"id":"primus-001","kind":"trial","name":"PRIMUS 001","route":"/trials/primus-001/","asOf":"2026-09-24","days":4},{"id":"prodige-4-accord-11","kind":"trial","name":"PRODIGE 4 / ACCORD 11","route":"/trials/prodige-4-accord-11/","asOf":"2026-09-24","days":4},{"id":"mpact","kind":"trial","name":"MPACT","route":"/trials/mpact/","asOf":"2026-09-24","days":4},{"id":"napoli-1","kind":"trial","name":"NAPOLI-1","route":"/trials/napoli-1/","asOf":"2026-09-24","days":4},{"id":"conko-003","kind":"trial","name":"CONKO-003 (OFF)","route":"/trials/conko-003/","asOf":"2026-09-24","days":4},{"id":"panoptimox-prodige-35","kind":"trial","name":"PANOPTIMOX-PRODIGE 35","route":"/trials/panoptimox-prodige-35/","asOf":"2026-09-24","days":4},{"id":"conko-007","kind":"trial","name":"CONKO-007","route":"/trials/conko-007/","asOf":"2026-09-24","days":4},{"id":"neolap","kind":"trial","name":"NEOLAP","route":"/trials/neolap/","asOf":"2026-09-24","days":4},{"id":"scalop","kind":"trial","name":"SCALOP","route":"/trials/scalop/","asOf":"2026-09-24","days":4},{"id":"scalop-2","kind":"trial","name":"SCALOP-2","route":"/trials/scalop-2/","asOf":"2026-09-24","days":4},{"id":"crossfire","kind":"trial","name":"CROSSFIRE","route":"/trials/crossfire/","asOf":"2026-09-24","days":4},{"id":"panfire-2","kind":"trial","name":"PANFIRE-2","route":"/trials/panfire-2/","asOf":"2026-09-24","days":4},{"id":"halo-301","kind":"trial","name":"HALO 109-301","route":"/trials/halo-301/","asOf":"2026-09-24","days":4},{"id":"canstem111p","kind":"trial","name":"CanStem111P","route":"/trials/canstem111p/","asOf":"2026-09-24","days":4},{"id":"resolve","kind":"trial","name":"RESOLVE","route":"/trials/resolve/","asOf":"2026-09-24","days":4},{"id":"codebreak-100","kind":"trial","name":"CodeBreaK 100 (pancreatic cancer cohort)","route":"/trials/codebreak-100/","asOf":"2026-09-24","days":4},{"id":"eclipse","kind":"trial","name":"ECLIPSE (GVAX pancreas and CRS-207)","route":"/trials/eclipse/","asOf":"2026-09-24","days":4},{"id":"nct06783140","kind":"trial","name":"Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer","route":"/trials/nct06783140/","asOf":"2026-09-24","days":4},{"id":"nct06946420","kind":"trial","name":"SENECA: First Line metaStatic pancrEatic caNcer Primary and Distant (if Oligometastatic) lEsion direCted rAdiotherapy","route":"/trials/nct06946420/","asOf":"2026-09-24","days":4},{"id":"nct05836870","kind":"trial","name":"Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer","route":"/trials/nct05836870/","asOf":"2026-09-24","days":4},{"id":"nct06115499","kind":"trial","name":"The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer","route":"/trials/nct06115499/","asOf":"2026-09-24","days":4},{"id":"nct07386704","kind":"trial","name":"Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer","route":"/trials/nct07386704/","asOf":"2026-09-24","days":4},{"id":"nct07344220","kind":"trial","name":"Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate","route":"/trials/nct07344220/","asOf":"2026-09-24","days":4},{"id":"nct06866977","kind":"trial","name":"A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Advanced Pancreatic Cancer","route":"/trials/nct06866977/","asOf":"2026-09-24","days":4},{"id":"nct07469956","kind":"trial","name":"Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer","route":"/trials/nct07469956/","asOf":"2026-09-24","days":4},{"id":"nct07138846","kind":"trial","name":"A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer","route":"/trials/nct07138846/","asOf":"2026-09-24","days":4},{"id":"nct07153289","kind":"trial","name":"CD318-targeted CAR-T Cell Therapy in Patients With Pancreatic Cancer (ResCPa)","route":"/trials/nct07153289/","asOf":"2026-09-24","days":4},{"id":"nct07415525","kind":"trial","name":"IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer","route":"/trials/nct07415525/","asOf":"2026-09-24","days":4},{"id":"nct06991491","kind":"trial","name":"Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer (WGOG-PAN 004)","route":"/trials/nct06991491/","asOf":"2026-09-24","days":4},{"id":"nct07745790","kind":"trial","name":"Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer","route":"/trials/nct07745790/","asOf":"2026-09-24","days":4},{"id":"nct04901741","kind":"trial","name":"Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer","route":"/trials/nct04901741/","asOf":"2026-09-24","days":4},{"id":"nct07814066","kind":"trial","name":"A Multicenter, Open-label, Phase II Umbrella Study to Evaluate the Efficacy and Safety of the Investigational Product in Participants With Advanced or Metastati","route":"/trials/nct07814066/","asOf":"2026-09-24","days":4},{"id":"nct07705074","kind":"trial","name":"FAPI PET Imaging - An Exploratory Study","route":"/trials/nct07705074/","asOf":"2026-09-24","days":4},{"id":"nct07028424","kind":"trial","name":"PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment","route":"/trials/nct07028424/","asOf":"2026-09-24","days":4},{"id":"nct06383078","kind":"trial","name":"HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer","route":"/trials/nct06383078/","asOf":"2026-09-24","days":4},{"id":"nct07277452","kind":"trial","name":"Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer","route":"/trials/nct07277452/","asOf":"2026-09-24","days":4},{"id":"nct07477418","kind":"trial","name":"PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)","route":"/trials/nct07477418/","asOf":"2026-09-24","days":4},{"id":"nct06759090","kind":"trial","name":"Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer","route":"/trials/nct06759090/","asOf":"2026-09-24","days":4},{"id":"nct06513455","kind":"trial","name":"Irinotecan Liposome，Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer","route":"/trials/nct06513455/","asOf":"2026-09-24","days":4},{"id":"nct05810792","kind":"trial","name":"Histamine Dihydrochloride and Interleukin-2 in Primary Resectable Pancreatic Cancer","route":"/trials/nct05810792/","asOf":"2026-09-24","days":4},{"id":"nct07765836","kind":"trial","name":"Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC","route":"/trials/nct07765836/","asOf":"2026-09-24","days":4},{"id":"nct07230301","kind":"trial","name":"Adebrelimab Infusion Plus Standard Care for Pancreatic Cancer With Pleural or Peritoneal Effusions","route":"/trials/nct07230301/","asOf":"2026-09-24","days":4},{"id":"nct07773363","kind":"trial","name":"Retlirafusp Alfa Plus Apatinib and Chemotherapy as Second-Line Treatment for Pancreatic Cancer","route":"/trials/nct07773363/","asOf":"2026-09-24","days":4},{"id":"nct06573398","kind":"trial","name":"Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC","route":"/trials/nct06573398/","asOf":"2026-09-24","days":4},{"id":"nct07691593","kind":"trial","name":"Neoadjuvant HRS-4642 Plus Chemotherapy With or Without Immunotherapy for Pancreatic Cancer","route":"/trials/nct07691593/","asOf":"2026-09-24","days":4},{"id":"nct06233877","kind":"trial","name":"Clinical Trial Evaluating Low Dose G-FLIP Plus Mitomycin C for Stage IV Pancreatic Cancer","route":"/trials/nct06233877/","asOf":"2026-09-24","days":4},{"id":"nct06750861","kind":"trial","name":"QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDAC","route":"/trials/nct06750861/","asOf":"2026-09-24","days":4},{"id":"nct07689539","kind":"trial","name":"Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation","route":"/trials/nct07689539/","asOf":"2026-09-24","days":4},{"id":"nct06370754","kind":"trial","name":"Newly Emerging Immunotherapy for Pancreatic Cancer Treatment","route":"/trials/nct06370754/","asOf":"2026-09-24","days":4},{"id":"nct07578337","kind":"trial","name":"A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease.","route":"/trials/nct07578337/","asOf":"2026-09-24","days":4},{"id":"nct06621095","kind":"trial","name":"Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)","route":"/trials/nct06621095/","asOf":"2026-09-24","days":4},{"id":"nct06009029","kind":"trial","name":"SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)","route":"/trials/nct06009029/","asOf":"2026-09-24","days":4},{"id":"nct03301805","kind":"trial","name":"A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer","route":"/trials/nct03301805/","asOf":"2026-09-24","days":4},{"id":"nct06166589","kind":"trial","name":"Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer","route":"/trials/nct06166589/","asOf":"2026-09-24","days":4},{"id":"nct06255912","kind":"trial","name":"Clinical Trial for Advanced or Metastatic Pancreatic Cancer","route":"/trials/nct06255912/","asOf":"2026-09-24","days":4},{"id":"nct07705919","kind":"trial","name":"DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer","route":"/trials/nct07705919/","asOf":"2026-09-24","days":4},{"id":"nct06361030","kind":"trial","name":"Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer","route":"/trials/nct06361030/","asOf":"2026-09-24","days":4},{"id":"nct07711067","kind":"trial","name":"A Study Comparing Whole-Body Heat Treatment Plus Systemic Therapy to Systemic Therapy Alone, for Advanced Pancreatic Cancer","route":"/trials/nct07711067/","asOf":"2026-09-24","days":4},{"id":"nct07670312","kind":"trial","name":"Evaluation of XYA02 in Patients With Advanced Solid Tumors","route":"/trials/nct07670312/","asOf":"2026-09-24","days":4},{"id":"nct07336953","kind":"trial","name":"A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic P","route":"/trials/nct07336953/","asOf":"2026-09-24","days":4},{"id":"nct07678593","kind":"trial","name":"A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation","route":"/trials/nct07678593/","asOf":"2026-09-24","days":4},{"id":"nct07802184","kind":"trial","name":"GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC","route":"/trials/nct07802184/","asOf":"2026-09-24","days":4},{"id":"nct07333287","kind":"trial","name":"A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With Arterial Infusion Chemotherapy and Emboli","route":"/trials/nct07333287/","asOf":"2026-09-24","days":4},{"id":"nct07824960","kind":"trial","name":"Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma","route":"/trials/nct07824960/","asOf":"2026-09-24","days":4},{"id":"nct07175389","kind":"trial","name":"JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure","route":"/trials/nct07175389/","asOf":"2026-09-24","days":4},{"id":"nct07342725","kind":"trial","name":"Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Met","route":"/trials/nct07342725/","asOf":"2026-09-24","days":4},{"id":"nct05637567","kind":"trial","name":"Perioperative Platelet Inhibition With Acetylsalicylic Acid in Patients With Resectable Tumors of the Pancreatic Head","route":"/trials/nct05637567/","asOf":"2026-09-24","days":4},{"id":"nct06888648","kind":"trial","name":"Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.","route":"/trials/nct06888648/","asOf":"2026-09-24","days":4},{"id":"nct06571461","kind":"trial","name":"Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Canc","route":"/trials/nct06571461/","asOf":"2026-09-24","days":4},{"id":"nct06662669","kind":"trial","name":"YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer","route":"/trials/nct06662669/","asOf":"2026-09-24","days":4},{"id":"nct05562297","kind":"trial","name":"Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer","route":"/trials/nct05562297/","asOf":"2026-09-24","days":4},{"id":"nct06999512","kind":"trial","name":"Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing Major Hepatectomy and Pancreaticoduodenectomy for C","route":"/trials/nct06999512/","asOf":"2026-09-24","days":4},{"id":"nct05988372","kind":"trial","name":"Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)","route":"/trials/nct05988372/","asOf":"2026-09-24","days":4},{"id":"nct07827053","kind":"trial","name":"Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer","route":"/trials/nct07827053/","asOf":"2026-09-24","days":4},{"id":"nct07748611","kind":"trial","name":"SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial","route":"/trials/nct07748611/","asOf":"2026-09-24","days":4},{"id":"nct07689955","kind":"trial","name":"A Phase-II Clinical Trial of Radiotherapy to the Coeliac Plexus to Help Pain in Advanced Pancreatic Cancer","route":"/trials/nct07689955/","asOf":"2026-09-24","days":4},{"id":"nct07698613","kind":"trial","name":"EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer","route":"/trials/nct07698613/","asOf":"2026-09-24","days":4},{"id":"nct07561463","kind":"trial","name":"Sacituzumab Tirumotecan for Pancreatic Cancer","route":"/trials/nct07561463/","asOf":"2026-09-24","days":4},{"id":"nct07504263","kind":"trial","name":"Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies","route":"/trials/nct07504263/","asOf":"2026-09-24","days":4},{"id":"nct07631871","kind":"trial","name":"An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy","route":"/trials/nct07631871/","asOf":"2026-09-24","days":4},{"id":"nct06329947","kind":"trial","name":"A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD","route":"/trials/nct06329947/","asOf":"2026-09-24","days":4},{"id":"nct07155629","kind":"trial","name":"Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer","route":"/trials/nct07155629/","asOf":"2026-09-24","days":4},{"id":"nct06259058","kind":"trial","name":"Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer","route":"/trials/nct06259058/","asOf":"2026-09-24","days":4},{"id":"nct06172036","kind":"trial","name":"Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab","route":"/trials/nct06172036/","asOf":"2026-09-24","days":4},{"id":"nct06492941","kind":"trial","name":"A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic Cancer","route":"/trials/nct06492941/","asOf":"2026-09-24","days":4},{"id":"nct04381130","kind":"trial","name":"A Phase I/IIa Study of EF-009 in Patients With Pancreatic Cancer","route":"/trials/nct04381130/","asOf":"2026-09-24","days":4},{"id":"nct06916975","kind":"trial","name":"Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer","route":"/trials/nct06916975/","asOf":"2026-09-24","days":4},{"id":"nct06217042","kind":"trial","name":"HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer","route":"/trials/nct06217042/","asOf":"2026-09-24","days":4},{"id":"nct06210360","kind":"trial","name":"Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX","route":"/trials/nct06210360/","asOf":"2026-09-24","days":4},{"id":"nct06669078","kind":"trial","name":"NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX as Conversion Therapy of Locally Advanced Pancreatic Cancer","route":"/trials/nct06669078/","asOf":"2026-09-24","days":4},{"id":"nct07683221","kind":"trial","name":"SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer","route":"/trials/nct07683221/","asOf":"2026-09-24","days":4},{"id":"nct06234072","kind":"trial","name":"Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients","route":"/trials/nct06234072/","asOf":"2026-09-24","days":4},{"id":"nct06177522","kind":"trial","name":"Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer","route":"/trials/nct06177522/","asOf":"2026-09-24","days":4},{"id":"nct07806058","kind":"trial","name":"An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors","route":"/trials/nct07806058/","asOf":"2026-09-24","days":4},{"id":"nct06700603","kind":"trial","name":"Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer","route":"/trials/nct06700603/","asOf":"2026-09-24","days":4},{"id":"nct07814859","kind":"trial","name":"Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic Cancer","route":"/trials/nct07814859/","asOf":"2026-09-24","days":4},{"id":"nct07097064","kind":"trial","name":"Evaluation of the Stereotactic MR-guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancers","route":"/trials/nct07097064/","asOf":"2026-09-24","days":4},{"id":"nct07233850","kind":"trial","name":"A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers","route":"/trials/nct07233850/","asOf":"2026-09-24","days":4},{"id":"nct07825753","kind":"trial","name":"Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer","route":"/trials/nct07825753/","asOf":"2026-09-24","days":4},{"id":"nct07752875","kind":"trial","name":"A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation","route":"/trials/nct07752875/","asOf":"2026-09-24","days":4},{"id":"nct06938503","kind":"trial","name":"AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer","route":"/trials/nct06938503/","asOf":"2026-09-24","days":4},{"id":"nct07446270","kind":"trial","name":"Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies","route":"/trials/nct07446270/","asOf":"2026-09-24","days":4},{"id":"nct07108504","kind":"trial","name":"Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer","route":"/trials/nct07108504/","asOf":"2026-09-24","days":4},{"id":"nct06888674","kind":"trial","name":"Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.","route":"/trials/nct06888674/","asOf":"2026-09-24","days":4},{"id":"nct07208539","kind":"trial","name":"AG Followed by FOLFIRINOX Both Combined With PD-L1 Antibodies as a Conversion Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer.","route":"/trials/nct07208539/","asOf":"2026-09-24","days":4},{"id":"nct06409429","kind":"trial","name":"Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer","route":"/trials/nct06409429/","asOf":"2026-09-24","days":4},{"id":"nct07736612","kind":"trial","name":"A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer","route":"/trials/nct07736612/","asOf":"2026-09-24","days":4},{"id":"nct07784374","kind":"trial","name":"A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 Monotherapy in Patients With Previously Treated Locally Advanced Unresectable or Metast","route":"/trials/nct07784374/","asOf":"2026-09-24","days":4},{"id":"nct07802418","kind":"trial","name":"Molecularly Tailored Therapy in Advanced Pancreatic Cancer","route":"/trials/nct07802418/","asOf":"2026-09-24","days":4},{"id":"nct07803783","kind":"trial","name":"A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based","route":"/trials/nct07803783/","asOf":"2026-09-24","days":4},{"id":"nct07665684","kind":"trial","name":"Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer","route":"/trials/nct07665684/","asOf":"2026-09-24","days":4},{"id":"nct07828756","kind":"trial","name":"Albumin-bound Paclitaxel (II)-Combined Regimens for Pancreatic Cancer","route":"/trials/nct07828756/","asOf":"2026-09-24","days":4},{"id":"nct07383922","kind":"trial","name":"A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer","route":"/trials/nct07383922/","asOf":"2026-09-24","days":4},{"id":"nct07429643","kind":"trial","name":"Endoscopic Ultrasound-Guided Loco-regional Chemotherapy Injection as Adjuvant Therapy for Locally Advanced Pancreatic Cancer.","route":"/trials/nct07429643/","asOf":"2026-09-24","days":4},{"id":"nct07831330","kind":"trial","name":"Albumin-bound Paclitaxel (II) in Combination With Gemcitabine as First Line Therapy for Metastatic Pancreatic Cancer","route":"/trials/nct07831330/","asOf":"2026-09-24","days":4},{"id":"nct07656376","kind":"trial","name":"Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation","route":"/trials/nct07656376/","asOf":"2026-09-24","days":4},{"id":"nct07301229","kind":"trial","name":"A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic Cancer","route":"/trials/nct07301229/","asOf":"2026-09-24","days":4},{"id":"nct07833241","kind":"trial","name":"Surufatinib in Combination With Iparomlimab and Tuvonralimab Injection and AG Chemotherapy for Neoadjuvant Therapy of HRPC or BRPC","route":"/trials/nct07833241/","asOf":"2026-09-24","days":4},{"id":"nct07272109","kind":"trial","name":"Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes","route":"/trials/nct07272109/","asOf":"2026-09-24","days":4},{"id":"nct06196671","kind":"trial","name":"Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer","route":"/trials/nct06196671/","asOf":"2026-09-24","days":4},{"id":"nct06587061","kind":"trial","name":"HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer","route":"/trials/nct06587061/","asOf":"2026-09-24","days":4},{"id":"nct06423326","kind":"trial","name":"Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer","route":"/trials/nct06423326/","asOf":"2026-09-24","days":4},{"id":"nct06483555","kind":"trial","name":"Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel","route":"/trials/nct06483555/","asOf":"2026-09-24","days":4},{"id":"nct07043270","kind":"trial","name":"24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC","route":"/trials/nct07043270/","asOf":"2026-09-24","days":4},{"id":"nct06938282","kind":"trial","name":"An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer","route":"/trials/nct06938282/","asOf":"2026-09-24","days":4},{"id":"nct04084496","kind":"trial","name":"mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients","route":"/trials/nct04084496/","asOf":"2026-09-24","days":4},{"id":"nct06411795","kind":"trial","name":"Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy","route":"/trials/nct06411795/","asOf":"2026-09-24","days":4},{"id":"nct07235930","kind":"trial","name":"Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer","route":"/trials/nct07235930/","asOf":"2026-09-24","days":4},{"id":"nct07542002","kind":"trial","name":"Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pan","route":"/trials/nct07542002/","asOf":"2026-09-24","days":4},{"id":"nct03322995","kind":"trial","name":"Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial","route":"/trials/nct03322995/","asOf":"2026-09-24","days":4},{"id":"nct06782932","kind":"trial","name":"Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer","route":"/trials/nct06782932/","asOf":"2026-09-24","days":4},{"id":"nct07155525","kind":"trial","name":"Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas","route":"/trials/nct07155525/","asOf":"2026-09-24","days":4},{"id":"nct04683315","kind":"trial","name":"PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples","route":"/trials/nct04683315/","asOf":"2026-09-24","days":4},{"id":"nct07769502","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatob","route":"/trials/nct07769502/","asOf":"2026-09-24","days":4},{"id":"nct07632118","kind":"trial","name":"Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery","route":"/trials/nct07632118/","asOf":"2026-09-24","days":4},{"id":"nct05841420","kind":"trial","name":"Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer","route":"/trials/nct05841420/","asOf":"2026-09-24","days":4},{"id":"nct07595835","kind":"trial","name":"CT-guided Percutaneous Radionuclide Therapy With 32P Microparticles in Patients With Non-progressive Locally Advanced Pancreatic Cancer","route":"/trials/nct07595835/","asOf":"2026-09-24","days":4},{"id":"nct04172532","kind":"trial","name":"Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer","route":"/trials/nct04172532/","asOf":"2026-09-24","days":4},{"id":"nct05438459","kind":"trial","name":"GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites","route":"/trials/nct05438459/","asOf":"2026-09-24","days":4},{"id":"nct07410676","kind":"trial","name":"EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors","route":"/trials/nct07410676/","asOf":"2026-09-24","days":4},{"id":"nct05679583","kind":"trial","name":"Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer","route":"/trials/nct05679583/","asOf":"2026-09-24","days":4},{"id":"nct07483983","kind":"trial","name":"Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Bi","route":"/trials/nct07483983/","asOf":"2026-09-24","days":4},{"id":"nct07066995","kind":"trial","name":"Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer","route":"/trials/nct07066995/","asOf":"2026-09-24","days":4},{"id":"nct07440290","kind":"trial","name":"DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positi","route":"/trials/nct07440290/","asOf":"2026-09-24","days":4},{"id":"nct06906562","kind":"trial","name":"A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic","route":"/trials/nct06906562/","asOf":"2026-09-24","days":4},{"id":"nct07353645","kind":"trial","name":"KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer","route":"/trials/nct07353645/","asOf":"2026-09-24","days":4},{"id":"nct06843551","kind":"trial","name":"The Miami \"EMPIRE\" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation","route":"/trials/nct06843551/","asOf":"2026-09-24","days":4},{"id":"nct06790602","kind":"trial","name":"Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma","route":"/trials/nct06790602/","asOf":"2026-09-24","days":4},{"id":"nct07312422","kind":"trial","name":"LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study","route":"/trials/nct07312422/","asOf":"2026-09-24","days":4},{"id":"nct06427239","kind":"trial","name":"Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma","route":"/trials/nct06427239/","asOf":"2026-09-24","days":4},{"id":"nct06782412","kind":"trial","name":"Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Dif","route":"/trials/nct06782412/","asOf":"2026-09-24","days":4},{"id":"nct06391892","kind":"trial","name":"Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery","route":"/trials/nct06391892/","asOf":"2026-09-24","days":4},{"id":"nct06095141","kind":"trial","name":"Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency","route":"/trials/nct06095141/","asOf":"2026-09-24","days":4},{"id":"nct06861452","kind":"trial","name":"Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients With Locally Advanced Pancreatic Carcinoma","route":"/trials/nct06861452/","asOf":"2026-09-24","days":4},{"id":"nct05187338","kind":"trial","name":"Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors","route":"/trials/nct05187338/","asOf":"2026-09-24","days":4},{"id":"nct06159478","kind":"trial","name":"Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)","route":"/trials/nct06159478/","asOf":"2026-09-24","days":4},{"id":"nct05821556","kind":"trial","name":"Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients","route":"/trials/nct05821556/","asOf":"2026-09-24","days":4},{"id":"nct06736717","kind":"trial","name":"Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer","route":"/trials/nct06736717/","asOf":"2026-09-24","days":4},{"id":"nct06844422","kind":"trial","name":"Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)","route":"/trials/nct06844422/","asOf":"2026-09-24","days":4},{"id":"nct05218889","kind":"trial","name":"Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer","route":"/trials/nct05218889/","asOf":"2026-09-24","days":4},{"id":"nct07436741","kind":"trial","name":"Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable P","route":"/trials/nct07436741/","asOf":"2026-09-24","days":4},{"id":"nct06384560","kind":"trial","name":"Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)","route":"/trials/nct06384560/","asOf":"2026-09-24","days":4},{"id":"nct06199895","kind":"trial","name":"Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholan","route":"/trials/nct06199895/","asOf":"2026-09-24","days":4},{"id":"nct06580002","kind":"trial","name":"Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial","route":"/trials/nct06580002/","asOf":"2026-09-24","days":4},{"id":"nct07285044","kind":"trial","name":"The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients","route":"/trials/nct07285044/","asOf":"2026-09-24","days":4},{"id":"nct06479239","kind":"trial","name":"Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer","route":"/trials/nct06479239/","asOf":"2026-09-24","days":4},{"id":"nct07040228","kind":"trial","name":"A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer","route":"/trials/nct07040228/","asOf":"2026-09-24","days":4},{"id":"nct06831136","kind":"trial","name":"Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma","route":"/trials/nct06831136/","asOf":"2026-09-24","days":4},{"id":"nct06453486","kind":"trial","name":"A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment","route":"/trials/nct06453486/","asOf":"2026-09-24","days":4},{"id":"nct05988814","kind":"trial","name":"Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Li","route":"/trials/nct05988814/","asOf":"2026-09-24","days":4},{"id":"nct07269626","kind":"trial","name":"PULSAR in Systemic Therapy for Pancreatic Cancer","route":"/trials/nct07269626/","asOf":"2026-09-24","days":4},{"id":"nct07199764","kind":"trial","name":"Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer","route":"/trials/nct07199764/","asOf":"2026-09-24","days":4},{"id":"nct07098598","kind":"trial","name":"Pancreatic Cancer Diagnosis With FAPI-PET Imaging","route":"/trials/nct07098598/","asOf":"2026-09-24","days":4},{"id":"nct05929885","kind":"trial","name":"Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients","route":"/trials/nct05929885/","asOf":"2026-09-24","days":4},{"id":"nct07306286","kind":"trial","name":"Cryoablation Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy","route":"/trials/nct07306286/","asOf":"2026-09-24","days":4},{"id":"nct06722911","kind":"trial","name":"Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer","route":"/trials/nct06722911/","asOf":"2026-09-24","days":4},{"id":"nct06584227","kind":"trial","name":"Adebrelimab and Chidamide for Pancreatic Cancer","route":"/trials/nct06584227/","asOf":"2026-09-24","days":4},{"id":"nct06332274","kind":"trial","name":"tislelizUMaB in canceR Patients With molEcuLar residuaL Disease","route":"/trials/nct06332274/","asOf":"2026-09-24","days":4},{"id":"nct05944237","kind":"trial","name":"HTL0039732 in Participants With Advanced Solid Tumours","route":"/trials/nct05944237/","asOf":"2026-09-24","days":4},{"id":"nct07595172","kind":"trial","name":"NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer","route":"/trials/nct07595172/","asOf":"2026-09-24","days":4},{"id":"nct06030622","kind":"trial","name":"Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer","route":"/trials/nct06030622/","asOf":"2026-09-24","days":4},{"id":"nct06662006","kind":"trial","name":"Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic","route":"/trials/nct06662006/","asOf":"2026-09-24","days":4},{"id":"nct05518903","kind":"trial","name":"Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma","route":"/trials/nct05518903/","asOf":"2026-09-24","days":4},{"id":"nct06601283","kind":"trial","name":"Vitamin C Plus Cordyceps to Chemotherapy Related Anemia in Pancreatic Cancer","route":"/trials/nct06601283/","asOf":"2026-09-24","days":4},{"id":"nct06756074","kind":"trial","name":"Reinforced Pancreaticojejunostomy With or Without glubran2","route":"/trials/nct06756074/","asOf":"2026-09-24","days":4},{"id":"nct05969860","kind":"trial","name":"At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer","route":"/trials/nct05969860/","asOf":"2026-09-24","days":4},{"id":"nct06435260","kind":"trial","name":"Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer","route":"/trials/nct06435260/","asOf":"2026-09-24","days":4},{"id":"nct07600268","kind":"trial","name":"Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Maintenance Therapy Compared to Maintenance Therapy Alone in Advanced Pancreatic Cancer","route":"/trials/nct07600268/","asOf":"2026-09-24","days":4},{"id":"nct07435038","kind":"trial","name":"Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","route":"/trials/nct07435038/","asOf":"2026-09-24","days":4},{"id":"nct06714604","kind":"trial","name":"Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC","route":"/trials/nct06714604/","asOf":"2026-09-24","days":4},{"id":"nct06503146","kind":"trial","name":"18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection","route":"/trials/nct06503146/","asOf":"2026-09-24","days":4},{"id":"nct07110064","kind":"trial","name":"QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer","route":"/trials/nct07110064/","asOf":"2026-09-24","days":4},{"id":"nct07716228","kind":"trial","name":"Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Gemcitabine Combined With Paclitaxel Protein","route":"/trials/nct07716228/","asOf":"2026-09-24","days":4},{"id":"nct05744219","kind":"trial","name":"Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial","route":"/trials/nct05744219/","asOf":"2026-09-24","days":4},{"id":"nct05093231","kind":"trial","name":"Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer","route":"/trials/nct05093231/","asOf":"2026-09-24","days":4},{"id":"nct05065801","kind":"trial","name":"Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients","route":"/trials/nct05065801/","asOf":"2026-09-24","days":4},{"id":"nct05268692","kind":"trial","name":"Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP","route":"/trials/nct05268692/","asOf":"2026-09-24","days":4},{"id":"nct04990609","kind":"trial","name":"EUS-RFA PANCARDINAL-1 Trial","route":"/trials/nct04990609/","asOf":"2026-09-24","days":4},{"id":"nct07131514","kind":"trial","name":"HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer","route":"/trials/nct07131514/","asOf":"2026-09-24","days":4},{"id":"nct03492671","kind":"trial","name":"Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer","route":"/trials/nct03492671/","asOf":"2026-09-24","days":4},{"id":"nct06758544","kind":"trial","name":"A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer","route":"/trials/nct06758544/","asOf":"2026-09-24","days":4},{"id":"nct05969171","kind":"trial","name":"A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Ca","route":"/trials/nct05969171/","asOf":"2026-09-24","days":4},{"id":"nct06944106","kind":"trial","name":"A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer","route":"/trials/nct06944106/","asOf":"2026-09-24","days":4},{"id":"nct06946901","kind":"trial","name":"The Safety and Effectiveness of Hyperthermic Intraperitoneal Chemotherapy Combined With Intravenous Chemotherapy for Peritoneal Metastatic Pancreatic Cancer, a","route":"/trials/nct06946901/","asOf":"2026-09-24","days":4},{"id":"nct03977233","kind":"trial","name":"Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer","route":"/trials/nct03977233/","asOf":"2026-09-24","days":4},{"id":"nct07504471","kind":"trial","name":"Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metast","route":"/trials/nct07504471/","asOf":"2026-09-24","days":4},{"id":"nct06782685","kind":"trial","name":"Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV","route":"/trials/nct06782685/","asOf":"2026-09-24","days":4},{"id":"nct06017284","kind":"trial","name":"Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer","route":"/trials/nct06017284/","asOf":"2026-09-24","days":4},{"id":"nct05053971","kind":"trial","name":"Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors","route":"/trials/nct05053971/","asOf":"2026-09-24","days":4},{"id":"nct03498326","kind":"trial","name":"Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer","route":"/trials/nct03498326/","asOf":"2026-09-24","days":4},{"id":"nct06998940","kind":"trial","name":"Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations","route":"/trials/nct06998940/","asOf":"2026-09-24","days":4},{"id":"nct07410494","kind":"trial","name":"Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors","route":"/trials/nct07410494/","asOf":"2026-09-24","days":4},{"id":"nct04485286","kind":"trial","name":"Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury","route":"/trials/nct04485286/","asOf":"2026-09-24","days":4},{"id":"nct03608631","kind":"trial","name":"iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation","route":"/trials/nct03608631/","asOf":"2026-09-24","days":4},{"id":"nct07306273","kind":"trial","name":"IRE Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy","route":"/trials/nct07306273/","asOf":"2026-09-24","days":4},{"id":"nct06598033","kind":"trial","name":"Vitamin C Plus Cordyceps to Quality of Life in Patients With Terminal Stage Pancreatic Cancer","route":"/trials/nct06598033/","asOf":"2026-09-24","days":4},{"id":"nct06770452","kind":"trial","name":"HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients","route":"/trials/nct06770452/","asOf":"2026-09-24","days":4},{"id":"nct06405490","kind":"trial","name":"NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC","route":"/trials/nct06405490/","asOf":"2026-09-24","days":4},{"id":"nct07230509","kind":"trial","name":"Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate","route":"/trials/nct07230509/","asOf":"2026-09-24","days":4},{"id":"nct04858334","kind":"trial","name":"APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a","route":"/trials/nct04858334/","asOf":"2026-09-24","days":4},{"id":"nct06958328","kind":"trial","name":"Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer","route":"/trials/nct06958328/","asOf":"2026-09-24","days":4},{"id":"nct06250972","kind":"trial","name":"Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer","route":"/trials/nct06250972/","asOf":"2026-09-24","days":4},{"id":"nct07283705","kind":"trial","name":"A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer","route":"/trials/nct07283705/","asOf":"2026-09-24","days":4},{"id":"nct04146298","kind":"trial","name":"Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer","route":"/trials/nct04146298/","asOf":"2026-09-24","days":4},{"id":"nct06605430","kind":"trial","name":"Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer","route":"/trials/nct06605430/","asOf":"2026-09-24","days":4},{"id":"nct05083247","kind":"trial","name":"Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma","route":"/trials/nct05083247/","asOf":"2026-09-24","days":4},{"id":"nct04570943","kind":"trial","name":"Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer","route":"/trials/nct04570943/","asOf":"2026-09-24","days":4},{"id":"nct07354919","kind":"trial","name":"Axelopran for Advanced Cancer in Patients Receiving Opioids","route":"/trials/nct07354919/","asOf":"2026-09-24","days":4},{"id":"nct06770439","kind":"trial","name":"IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer","route":"/trials/nct06770439/","asOf":"2026-09-24","days":4},{"id":"nct06145074","kind":"trial","name":"Examining Safety, Efficacy and Feasibility of Preoperative Propranolol in Patients With PDAC.","route":"/trials/nct06145074/","asOf":"2026-09-24","days":4},{"id":"nct06789679","kind":"trial","name":"Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer","route":"/trials/nct06789679/","asOf":"2026-09-24","days":4},{"id":"nct05624918","kind":"trial","name":"A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma","route":"/trials/nct05624918/","asOf":"2026-09-24","days":4},{"id":"nct06914674","kind":"trial","name":"Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas","route":"/trials/nct06914674/","asOf":"2026-09-24","days":4},{"id":"nct06690528","kind":"trial","name":"Conversion Surgery Vs. Palliative Care in Pancreatic Cancer Oligometastatic to the Liver","route":"/trials/nct06690528/","asOf":"2026-09-24","days":4},{"id":"nct06807437","kind":"trial","name":"Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula","route":"/trials/nct06807437/","asOf":"2026-09-24","days":4},{"id":"nct06757244","kind":"trial","name":"DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer","route":"/trials/nct06757244/","asOf":"2026-09-24","days":4},{"id":"nct07619521","kind":"trial","name":"Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma","route":"/trials/nct07619521/","asOf":"2026-09-24","days":4},{"id":"nct06149689","kind":"trial","name":"mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer","route":"/trials/nct06149689/","asOf":"2026-09-24","days":4},{"id":"nct05529940","kind":"trial","name":"NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)","route":"/trials/nct05529940/","asOf":"2026-09-24","days":4},{"id":"nct05984810","kind":"trial","name":"NIR-Fluorescence Guided Surgical Resection of Neoadjuvant Treated Localized Pancreatic Cancer Using SGM-101","route":"/trials/nct05984810/","asOf":"2026-09-24","days":4},{"id":"nct06593431","kind":"trial","name":"Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial","route":"/trials/nct06593431/","asOf":"2026-09-24","days":4},{"id":"nct05927142","kind":"trial","name":"Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for The","route":"/trials/nct05927142/","asOf":"2026-09-24","days":4},{"id":"nct07629609","kind":"trial","name":"BEFAST Study, [68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer","route":"/trials/nct07629609/","asOf":"2026-09-24","days":4},{"id":"nct05720338","kind":"trial","name":"Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy?","route":"/trials/nct05720338/","asOf":"2026-09-24","days":4},{"id":"nct06196788","kind":"trial","name":"Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer","route":"/trials/nct06196788/","asOf":"2026-09-24","days":4},{"id":"nct06454448","kind":"trial","name":"Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic P","route":"/trials/nct06454448/","asOf":"2026-09-24","days":4},{"id":"nct07539155","kind":"trial","name":"Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer","route":"/trials/nct07539155/","asOf":"2026-09-24","days":4},{"id":"nct07126158","kind":"trial","name":"Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma","route":"/trials/nct07126158/","asOf":"2026-09-24","days":4},{"id":"nct07284277","kind":"trial","name":"TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)","route":"/trials/nct07284277/","asOf":"2026-09-24","days":4},{"id":"nct05776524","kind":"trial","name":"Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer","route":"/trials/nct05776524/","asOf":"2026-09-24","days":4},{"id":"nct05462496","kind":"trial","name":"Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer","route":"/trials/nct05462496/","asOf":"2026-09-24","days":4},{"id":"nct05241249","kind":"trial","name":"Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma","route":"/trials/nct05241249/","asOf":"2026-09-24","days":4},{"id":"nct04605913","kind":"trial","name":"Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC","route":"/trials/nct04605913/","asOf":"2026-09-24","days":4},{"id":"nct06427460","kind":"trial","name":"Central-boost Ablative Radiation Therapy for Solid Tumors (CBART)","route":"/trials/nct06427460/","asOf":"2026-09-24","days":4},{"id":"nct06951997","kind":"trial","name":"QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer","route":"/trials/nct06951997/","asOf":"2026-09-24","days":4},{"id":"nct06761027","kind":"trial","name":"mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer","route":"/trials/nct06761027/","asOf":"2026-09-24","days":4},{"id":"nct03190941","kind":"trial","name":"Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients","route":"/trials/nct03190941/","asOf":"2026-09-24","days":4},{"id":"nct07101679","kind":"trial","name":"A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer","route":"/trials/nct07101679/","asOf":"2026-09-24","days":4},{"id":"nct06813079","kind":"trial","name":"Using Tumor Models to Determine Treatments","route":"/trials/nct06813079/","asOf":"2026-09-24","days":4},{"id":"nct04195347","kind":"trial","name":"Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase","route":"/trials/nct04195347/","asOf":"2026-09-24","days":4},{"id":"nct06747845","kind":"trial","name":"Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy","route":"/trials/nct06747845/","asOf":"2026-09-24","days":4},{"id":"nct07240766","kind":"trial","name":"HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation","route":"/trials/nct07240766/","asOf":"2026-09-24","days":4},{"id":"nct06491472","kind":"trial","name":"Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer","route":"/trials/nct06491472/","asOf":"2026-09-24","days":4},{"id":"nct03755739","kind":"trial","name":"Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors","route":"/trials/nct03755739/","asOf":"2026-09-24","days":4},{"id":"nct06941857","kind":"trial","name":"NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer","route":"/trials/nct06941857/","asOf":"2026-09-24","days":4},{"id":"nct06904378","kind":"trial","name":"ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma","route":"/trials/nct06904378/","asOf":"2026-09-24","days":4},{"id":"nct06050317","kind":"trial","name":"Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer","route":"/trials/nct06050317/","asOf":"2026-09-24","days":4},{"id":"nct07537660","kind":"trial","name":"Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Gemcitabine Plus Paclitaxel","route":"/trials/nct07537660/","asOf":"2026-09-24","days":4},{"id":"nct06897644","kind":"trial","name":"Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic C","route":"/trials/nct06897644/","asOf":"2026-09-24","days":4},{"id":"nct07214298","kind":"trial","name":"Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma","route":"/trials/nct07214298/","asOf":"2026-09-24","days":4},{"id":"nct02000089","kind":"trial","name":"The Cancer of the Pancreas Screening-5 CAPS5)Study","route":"/trials/nct02000089/","asOf":"2026-09-24","days":4},{"id":"nct06576115","kind":"trial","name":"Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer","route":"/trials/nct06576115/","asOf":"2026-09-24","days":4},{"id":"nct06532617","kind":"trial","name":"Cadonilimab Combined With S-1 or Capecitabine as Second-line Treatment for Advanced Pancreatic Cancer","route":"/trials/nct06532617/","asOf":"2026-09-24","days":4},{"id":"nct07226856","kind":"trial","name":"BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma","route":"/trials/nct07226856/","asOf":"2026-09-24","days":4},{"id":"nct07257523","kind":"trial","name":"Carbon Ion Radiotherapy in Frail Patients With Pancreatic Cancer","route":"/trials/nct07257523/","asOf":"2026-09-24","days":4},{"id":"nct07692750","kind":"trial","name":"IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer","route":"/trials/nct07692750/","asOf":"2026-09-24","days":4},{"id":"nct06229340","kind":"trial","name":"Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations","route":"/trials/nct06229340/","asOf":"2026-09-24","days":4},{"id":"nct06359275","kind":"trial","name":"PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients","route":"/trials/nct06359275/","asOf":"2026-09-24","days":4},{"id":"nct06389760","kind":"trial","name":"Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer","route":"/trials/nct06389760/","asOf":"2026-09-24","days":4},{"id":"nct05116072","kind":"trial","name":"Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula","route":"/trials/nct05116072/","asOf":"2026-09-24","days":4},{"id":"nct06249321","kind":"trial","name":"mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy","route":"/trials/nct06249321/","asOf":"2026-09-24","days":4},{"id":"nct06572813","kind":"trial","name":"Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer","route":"/trials/nct06572813/","asOf":"2026-09-24","days":4},{"id":"nct06531278","kind":"trial","name":"Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cance","route":"/trials/nct06531278/","asOf":"2026-09-24","days":4},{"id":"nct03384238","kind":"trial","name":"Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery","route":"/trials/nct03384238/","asOf":"2026-09-24","days":4},{"id":"nct06659705","kind":"trial","name":"Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)","route":"/trials/nct06659705/","asOf":"2026-09-24","days":4},{"id":"nct06427447","kind":"trial","name":"Adjuvant Chemoradiotherapy Versus Chemotherapy for Pancreatic Cancer (ADJUPANC)","route":"/trials/nct06427447/","asOf":"2026-09-24","days":4},{"id":"nct05132504","kind":"trial","name":"Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer","route":"/trials/nct05132504/","asOf":"2026-09-24","days":4},{"id":"nct06333314","kind":"trial","name":"Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI","route":"/trials/nct06333314/","asOf":"2026-09-24","days":4},{"id":"nct04851119","kind":"trial","name":"Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors","route":"/trials/nct04851119/","asOf":"2026-09-24","days":4},{"id":"nct06547736","kind":"trial","name":"Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer","route":"/trials/nct06547736/","asOf":"2026-09-24","days":4},{"id":"nct07438106","kind":"trial","name":"A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer","route":"/trials/nct07438106/","asOf":"2026-09-24","days":4},{"id":"nct07081360","kind":"trial","name":"Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer","route":"/trials/nct07081360/","asOf":"2026-09-24","days":4},{"id":"nct02830724","kind":"trial","name":"Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers","route":"/trials/nct02830724/","asOf":"2026-09-24","days":4},{"id":"nct07433283","kind":"trial","name":"Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor","route":"/trials/nct07433283/","asOf":"2026-09-24","days":4},{"id":"nct04789486","kind":"trial","name":"Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer","route":"/trials/nct04789486/","asOf":"2026-09-24","days":4},{"id":"nct03093688","kind":"trial","name":"Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor","route":"/trials/nct03093688/","asOf":"2026-09-24","days":4},{"id":"nct07586813","kind":"trial","name":"Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gastrointestinal Solid Tumors","route":"/trials/nct07586813/","asOf":"2026-09-24","days":4},{"id":"nct06151262","kind":"trial","name":"A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer","route":"/trials/nct06151262/","asOf":"2026-09-24","days":4},{"id":"nct02598349","kind":"trial","name":"Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas","route":"/trials/nct02598349/","asOf":"2026-09-24","days":4},{"id":"nct04858009","kind":"trial","name":"Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis","route":"/trials/nct04858009/","asOf":"2026-09-24","days":4},{"id":"nct07044453","kind":"trial","name":"Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX","route":"/trials/nct07044453/","asOf":"2026-09-24","days":4},{"id":"paper-jones-pancreatic-core-pathways-science-2008","kind":"paper","name":"Core signaling pathways in human pancreatic cancers revealed by global genomic analyses","route":"/key-papers/paper-jones-pancreatic-core-pathways-science-2008/","asOf":"2026-09-24","days":4},{"id":"paper-biankin-pancreatic-exomes-axon-guidance-nature-2012","kind":"paper","name":"Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes","route":"/key-papers/paper-biankin-pancreatic-exomes-axon-guidance-nature-2012/","asOf":"2026-09-24","days":4},{"id":"paper-witkiewicz-pancreatic-exomes-utsw-nat-commun-2015","kind":"paper","name":"Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets","route":"/key-papers/paper-witkiewicz-pancreatic-exomes-utsw-nat-commun-2015/","asOf":"2026-09-24","days":4},{"id":"paper-tcga-pancreatic-integrated-characterisation-cancer-cell-2017","kind":"paper","name":"Integrated genomic characterization of pancreatic ductal adenocarcinoma","route":"/key-papers/paper-tcga-pancreatic-integrated-characterisation-cancer-cell-2017/","asOf":"2026-09-24","days":4},{"id":"paper-collisson-pancreatic-subtypes-nat-med-2011","kind":"paper","name":"Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy","route":"/key-papers/paper-collisson-pancreatic-subtypes-nat-med-2011/","asOf":"2026-09-24","days":4},{"id":"paper-aung-compass-early-results-ccr-2018","kind":"paper","name":"Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial","route":"/key-papers/paper-aung-compass-early-results-ccr-2018/","asOf":"2026-09-24","days":4},{"id":"paper-okane-gata6-basal-like-compass-ccr-2020","kind":"paper","name":"GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer","route":"/key-papers/paper-okane-gata6-basal-like-compass-ccr-2020/","asOf":"2026-09-24","days":4},{"id":"paper-chan-seng-yue-pancreatic-transcription-phenotypes-nat-genet-2020","kind":"paper","name":"Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution","route":"/key-papers/paper-chan-seng-yue-pancreatic-transcription-phenotypes-nat-genet-2020/","asOf":"2026-09-24","days":4},{"id":"paper-rashid-purist-pancreatic-subtype-classifier-ccr-2020","kind":"paper","name":"Purity Independent Subtyping of Tumors (PurIST), a clinically robust, single-sample classifier for tumor subtyping in pancreatic cancer","route":"/key-papers/paper-rashid-purist-pancreatic-subtype-classifier-ccr-2020/","asOf":"2026-09-24","days":4},{"id":"paper-puleo-pancreatic-tumour-microenvironment-subtypes-gastroenterology-2018","kind":"paper","name":"Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features","route":"/key-papers/paper-puleo-pancreatic-tumour-microenvironment-subtypes-gastroenterology-2018/","asOf":"2026-09-24","days":4},{"id":"paper-topham-subtype-discordant-pancreatic-ccr-2021","kind":"paper","name":"Subtype-discordant pancreatic ductal adenocarcinoma tumors show intermediate clinical and molecular characteristics","route":"/key-papers/paper-topham-subtype-discordant-pancreatic-ccr-2021/","asOf":"2026-09-24","days":4},{"id":"paper-hayashi-squamous-basal-like-pancreatic-nat-cancer-2020","kind":"paper","name":"A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma","route":"/key-papers/paper-hayashi-squamous-basal-like-pancreatic-nat-cancer-2020/","asOf":"2026-09-24","days":4},{"id":"paper-andricovich-kdm6a-squamous-pancreatic-cancer-cell-2018","kind":"paper","name":"Loss of KDM6A activates super-enhancers to induce gender-specific squamous-like pancreatic cancer and confers sensitivity to BET inhibitors","route":"/key-papers/paper-andricovich-kdm6a-squamous-pancreatic-cancer-cell-2018/","asOf":"2026-09-24","days":4},{"id":"paper-aguirre-real-time-genomic-characterisation-pancreatic-cancer-discov-2018","kind":"paper","name":"Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine","route":"/key-papers/paper-aguirre-real-time-genomic-characterisation-pancreatic-cancer-discov-2018/","asOf":"2026-09-24","days":4},{"id":"paper-singhi-targeted-genome-profiling-3594-pdac-gastroenterology-2019","kind":"paper","name":"Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers","route":"/key-papers/paper-singhi-targeted-genome-profiling-3594-pdac-gastroenterology-2019/","asOf":"2026-09-24","days":4},{"id":"paper-philip-kras-wild-type-pancreatic-ccr-2022","kind":"paper","name":"Molecular characterization of KRAS wild-type tumors in patients with pancreatic adenocarcinoma","route":"/key-papers/paper-philip-kras-wild-type-pancreatic-ccr-2022/","asOf":"2026-09-24","days":4},{"id":"paper-singhi-alk-rearrangements-pancreatic-jnccn-2017","kind":"paper","name":"Identification of targetable ALK rearrangements in pancreatic ductal adenocarcinoma","route":"/key-papers/paper-singhi-alk-rearrangements-pancreatic-jnccn-2017/","asOf":"2026-09-24","days":4},{"id":"paper-oreilly-hechtman-ntrk-fusion-pancreatic-larotrectinib-ann-oncol-2019","kind":"paper","name":"Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion","route":"/key-papers/paper-oreilly-hechtman-ntrk-fusion-pancreatic-larotrectinib-ann-oncol-2019/","asOf":"2026-09-24","days":4},{"id":"paper-luchini-msi-dmmr-pancreatic-systematic-review-gut-2021","kind":"paper","name":"Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications","route":"/key-papers/paper-luchini-msi-dmmr-pancreatic-systematic-review-gut-2021/","asOf":"2026-09-24","days":4},{"id":"paper-shindo-germline-sporadic-pancreatic-jco-2017","kind":"paper","name":"Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma","route":"/key-papers/paper-shindo-germline-sporadic-pancreatic-jco-2017/","asOf":"2026-09-24","days":4},{"id":"paper-yurgelun-germline-second-hits-resected-pancreatic-genet-med-2019","kind":"paper","name":"Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer","route":"/key-papers/paper-yurgelun-germline-second-hits-resected-pancreatic-genet-med-2019/","asOf":"2026-09-24","days":4},{"id":"paper-lowery-prospective-germline-exocrine-pancreatic-jnci-2018","kind":"paper","name":"Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms","route":"/key-papers/paper-lowery-prospective-germline-exocrine-pancreatic-jnci-2018/","asOf":"2026-09-24","days":4},{"id":"paper-roberts-familial-pancreatic-whole-genome-cancer-discov-2016","kind":"paper","name":"Whole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer","route":"/key-papers/paper-roberts-familial-pancreatic-whole-genome-cancer-discov-2016/","asOf":"2026-09-24","days":4},{"id":"paper-golan-brca-pancreatic-platinum-survival-bjc-2014","kind":"paper","name":"Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers","route":"/key-papers/paper-golan-brca-pancreatic-platinum-survival-bjc-2014/","asOf":"2026-09-24","days":4},{"id":"paper-park-hrd-pancreatic-platinum-ccr-2020","kind":"paper","name":"Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection","route":"/key-papers/paper-park-hrd-pancreatic-platinum-ccr-2020/","asOf":"2026-09-24","days":4},{"id":"paper-reiss-rucaparib-maintenance-brca-palb2-pancreatic-jco-2021","kind":"paper","name":"Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2","route":"/key-papers/paper-reiss-rucaparib-maintenance-brca-palb2-pancreatic-jco-2021/","asOf":"2026-09-24","days":4},{"id":"paper-connor-mutational-signatures-immune-pancreatic-jama-oncol-2017","kind":"paper","name":"Association of distinct mutational signatures with correlates of increased immune activity in pancreatic ductal adenocarcinoma","route":"/key-papers/paper-connor-mutational-signatures-immune-pancreatic-jama-oncol-2017/","asOf":"2026-09-24","days":4},{"id":"paper-qian-driver-genes-outcomes-resected-pancreatic-jama-oncol-2018","kind":"paper","name":"Association of alterations in main driver genes with outcomes of patients with resected pancreatic ductal adenocarcinoma","route":"/key-papers/paper-qian-driver-genes-outcomes-resected-pancreatic-jama-oncol-2018/","asOf":"2026-09-24","days":4},{"id":"paper-bournet-kras-g12d-prognosis-pancreatic-ctg-2016","kind":"paper","name":"KRAS G12D mutation subtype is a prognostic factor for advanced pancreatic adenocarcinoma","route":"/key-papers/paper-bournet-kras-g12d-prognosis-pancreatic-ctg-2016/","asOf":"2026-09-24","days":4},{"id":"paper-iacobuzio-donahue-dpc4-failure-pattern-autopsy-jco-2009","kind":"paper","name":"DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer","route":"/key-papers/paper-iacobuzio-donahue-dpc4-failure-pattern-autopsy-jco-2009/","asOf":"2026-09-24","days":4},{"id":"paper-crane-smad4-progression-pattern-locally-advanced-jco-2011","kind":"paper","name":"Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression","route":"/key-papers/paper-crane-smad4-progression-pattern-locally-advanced-jco-2011/","asOf":"2026-09-24","days":4},{"id":"paper-yachida-metastasis-late-genetic-evolution-pancreatic-nature-2010","kind":"paper","name":"Distant metastasis occurs late during the genetic evolution of pancreatic cancer","route":"/key-papers/paper-yachida-metastasis-late-genetic-evolution-pancreatic-nature-2010/","asOf":"2026-09-24","days":4},{"id":"paper-notta-punctuated-evolution-pancreatic-nature-2016","kind":"paper","name":"A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns","route":"/key-papers/paper-notta-punctuated-evolution-pancreatic-nature-2016/","asOf":"2026-09-24","days":4},{"id":"paper-makohon-moore-metastases-driver-homogeneity-nat-genet-2017","kind":"paper","name":"Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer","route":"/key-papers/paper-makohon-moore-metastases-driver-homogeneity-nat-genet-2017/","asOf":"2026-09-24","days":4},{"id":"paper-makohon-moore-precursor-cells-ductal-system-nature-2018","kind":"paper","name":"Precancerous neoplastic cells can move through the pancreatic ductal system","route":"/key-papers/paper-makohon-moore-precursor-cells-ductal-system-nature-2018/","asOf":"2026-09-24","days":4},{"id":"paper-hruban-panin-nomenclature-ajsp-2001","kind":"paper","name":"Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions","route":"/key-papers/paper-hruban-panin-nomenclature-ajsp-2001/","asOf":"2026-09-24","days":4},{"id":"paper-basturk-baltimore-consensus-precursor-lesions-ajsp-2015","kind":"paper","name":"A revised classification system and recommendations from the Baltimore consensus meeting for neoplastic precursor lesions in the pancreas","route":"/key-papers/paper-basturk-baltimore-consensus-precursor-lesions-ajsp-2015/","asOf":"2026-09-24","days":4},{"id":"paper-kanda-panin-1-somatic-mutations-gastroenterology-2012","kind":"paper","name":"Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia","route":"/key-papers/paper-kanda-panin-1-somatic-mutations-gastroenterology-2012/","asOf":"2026-09-24","days":4},{"id":"paper-wu-gnas-ipmn-sci-transl-med-2011","kind":"paper","name":"Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development","route":"/key-papers/paper-wu-gnas-ipmn-sci-transl-med-2011/","asOf":"2026-09-24","days":4},{"id":"paper-wu-pancreatic-cyst-exomes-rnf43-pnas-2011","kind":"paper","name":"Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways","route":"/key-papers/paper-wu-pancreatic-cyst-exomes-rnf43-pnas-2011/","asOf":"2026-09-24","days":4},{"id":"paper-springer-pancreatic-cyst-molecular-classification-gastroenterology-2015","kind":"paper","name":"A combination of molecular markers and clinical features improve the classification of pancreatic cysts","route":"/key-papers/paper-springer-pancreatic-cyst-molecular-classification-gastroenterology-2015/","asOf":"2026-09-24","days":4},{"id":"paper-omori-ipmn-progression-pathways-gastroenterology-2019","kind":"paper","name":"Pathways of progression from intraductal papillary mucinous neoplasm to pancreatic ductal adenocarcinoma based on molecular features","route":"/key-papers/paper-omori-ipmn-progression-pathways-gastroenterology-2019/","asOf":"2026-09-24","days":4},{"id":"paper-felsenstein-ipmn-cooccurring-cancer-relatedness-gut-2018","kind":"paper","name":"IPMNs with co-occurring invasive cancers: neighbours but not always relatives","route":"/key-papers/paper-felsenstein-ipmn-cooccurring-cancer-relatedness-gut-2018/","asOf":"2026-09-24","days":4},{"id":"paper-noe-cyst-malignant-progression-genomics-nat-commun-2020","kind":"paper","name":"Genomic characterization of malignant progression in neoplastic pancreatic cysts","route":"/key-papers/paper-noe-cyst-malignant-progression-genomics-nat-commun-2020/","asOf":"2026-09-24","days":4},{"id":"paper-olive-hedgehog-stroma-gemcitabine-delivery-science-2009","kind":"paper","name":"Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer","route":"/key-papers/paper-olive-hedgehog-stroma-gemcitabine-delivery-science-2009/","asOf":"2026-09-24","days":4},{"id":"paper-rhim-stroma-restrains-pancreatic-cancer-cell-2014","kind":"paper","name":"Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma","route":"/key-papers/paper-rhim-stroma-restrains-pancreatic-cancer-cell-2014/","asOf":"2026-09-24","days":4},{"id":"paper-ohlund-caf-subtypes-mycaf-icaf-jem-2017","kind":"paper","name":"Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer","route":"/key-papers/paper-ohlund-caf-subtypes-mycaf-icaf-jem-2017/","asOf":"2026-09-24","days":4},{"id":"paper-elyada-antigen-presenting-cafs-single-cell-cancer-discov-2019","kind":"paper","name":"Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts","route":"/key-papers/paper-elyada-antigen-presenting-cafs-single-cell-cancer-discov-2019/","asOf":"2026-09-24","days":4},{"id":"paper-feig-cxcl12-fap-cafs-t-cell-exclusion-pnas-2013","kind":"paper","name":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","route":"/key-papers/paper-feig-cxcl12-fap-cafs-t-cell-exclusion-pnas-2013/","asOf":"2026-09-24","days":4},{"id":"paper-grunwald-subtme-pancreatic-cell-2021","kind":"paper","name":"Spatially confined sub-tumor microenvironments in pancreatic cancer","route":"/key-papers/paper-grunwald-subtme-pancreatic-cell-2021/","asOf":"2026-09-24","days":4},{"id":"paper-royal-ipilimumab-pancreatic-j-immunother-2010","kind":"paper","name":"Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","route":"/key-papers/paper-royal-ipilimumab-pancreatic-j-immunother-2010/","asOf":"2026-09-24","days":4},{"id":"paper-brahmer-anti-pd-l1-phase-1-nejm-2012","kind":"paper","name":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","route":"/key-papers/paper-brahmer-anti-pd-l1-phase-1-nejm-2012/","asOf":"2026-09-24","days":4},{"id":"paper-oreilly-durvalumab-tremelimumab-pancreatic-jama-oncol-2019","kind":"paper","name":"Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial","route":"/key-papers/paper-oreilly-durvalumab-tremelimumab-pancreatic-jama-oncol-2019/","asOf":"2026-09-24","days":4},{"id":"paper-balachandran-neoantigen-quality-long-term-survivors-nature-2017","kind":"paper","name":"Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer","route":"/key-papers/paper-balachandran-neoantigen-quality-long-term-survivors-nature-2017/","asOf":"2026-09-24","days":4},{"id":"paper-bear-pancreatic-immunotherapy-review-cancer-cell-2020","kind":"paper","name":"Challenges and opportunities for pancreatic cancer immunotherapy","route":"/key-papers/paper-bear-pancreatic-immunotherapy-review-cancer-cell-2020/","asOf":"2026-09-24","days":4},{"id":"paper-ho-pancreatic-tumour-microenvironment-review-nrco-2020","kind":"paper","name":"The tumour microenvironment in pancreatic cancer: clinical challenges and opportunities","route":"/key-papers/paper-ho-pancreatic-tumour-microenvironment-review-nrco-2020/","asOf":"2026-09-24","days":4},{"id":"paper-goonetilleke-ca19-9-systematic-review-ejso-2007","kind":"paper","name":"Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer","route":"/key-papers/paper-goonetilleke-ca19-9-systematic-review-ejso-2007/","asOf":"2026-09-24","days":4},{"id":"paper-hess-ca19-9-response-chemotherapy-lancet-oncol-2008","kind":"paper","name":"CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial","route":"/key-papers/paper-hess-ca19-9-response-chemotherapy-lancet-oncol-2008/","asOf":"2026-09-24","days":4},{"id":"paper-yeh-ca19-9-lewis-negative-fut3-cutoff-ccr-2026","kind":"paper","name":"A new CA19-9 cutoff value identifies Lewis antigen status and refines prognostic stratification in PDAC","route":"/key-papers/paper-yeh-ca19-9-lewis-negative-fut3-cutoff-ccr-2026/","asOf":"2026-09-24","days":4},{"id":"paper-sausen-ctdna-pancreatic-resection-nat-commun-2015","kind":"paper","name":"Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients","route":"/key-papers/paper-sausen-ctdna-pancreatic-resection-nat-commun-2015/","asOf":"2026-09-24","days":4},{"id":"paper-pietrasz-ctdna-prognostic-pancreatic-ccr-2017","kind":"paper","name":"Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker","route":"/key-papers/paper-pietrasz-ctdna-prognostic-pancreatic-ccr-2017/","asOf":"2026-09-24","days":4},{"id":"paper-bernard-ctdna-exodna-pancreatic-gastroenterology-2019","kind":"paper","name":"Circulating nucleic acids are associated with outcomes of patients with pancreatic cancer","route":"/key-papers/paper-bernard-ctdna-exodna-pancreatic-gastroenterology-2019/","asOf":"2026-09-24","days":4},{"id":"paper-groot-kras-ctdna-clinical-test-resected-pancreatic-ccr-2019","kind":"paper","name":"Circulating tumor DNA as a clinical test in resected pancreatic cancer","route":"/key-papers/paper-groot-kras-ctdna-clinical-test-resected-pancreatic-ccr-2019/","asOf":"2026-09-24","days":4},{"id":"paper-lee-ctdna-adjuvant-benefit-localized-pancreatic-ann-oncol-2019","kind":"paper","name":"Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer","route":"/key-papers/paper-lee-ctdna-adjuvant-benefit-localized-pancreatic-ann-oncol-2019/","asOf":"2026-09-24","days":4},{"id":"paper-cohen-ctdna-protein-liquid-biopsy-pancreatic-pnas-2017","kind":"paper","name":"Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers","route":"/key-papers/paper-cohen-ctdna-protein-liquid-biopsy-pancreatic-pnas-2017/","asOf":"2026-09-24","days":4},{"id":"paper-cohen-cancerseek-multi-analyte-blood-test-science-2018","kind":"paper","name":"Detection and localization of surgically resectable cancers with a multi-analyte blood test","route":"/key-papers/paper-cohen-cancerseek-multi-analyte-blood-test-science-2018/","asOf":"2026-09-24","days":4},{"id":"paper-klein-ccga3-mced-validation-ann-oncol-2021","kind":"paper","name":"Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set","route":"/key-papers/paper-klein-ccga3-mced-validation-ann-oncol-2021/","asOf":"2026-09-24","days":4},{"id":"paper-gonda-precede-consortium-recommendations-gastroenterology-2021","kind":"paper","name":"Recommendations for a more organized and effective approach to the early detection of pancreatic cancer from the PRECEDE (Pancreatic Cancer Early Detection) consortium","route":"/key-papers/paper-gonda-precede-consortium-recommendations-gastroenterology-2021/","asOf":"2026-09-24","days":4},{"id":"paper-worthington-precede-early-detection-biomarkers-ijc-2026","kind":"paper","name":"Pancreatic cancer early detection biomarkers for high-risk individuals: insights from the PRECEDE consortium","route":"/key-papers/paper-worthington-precede-early-detection-biomarkers-ijc-2026/","asOf":"2026-09-24","days":4},{"id":"gata6-classical-basal-marker","kind":"term","name":"GATA6 as the marker of classical versus basal-like pancreatic cancer","route":"/terms/gata6-classical-basal-marker/","asOf":"2026-09-24","days":4},{"id":"kras-allelic-imbalance","kind":"term","name":"KRAS allelic imbalance and mutant KRAS dosage in pancreatic cancer","route":"/terms/kras-allelic-imbalance/","asOf":"2026-09-24","days":4},{"id":"caf-subtypes-pancreatic","kind":"term","name":"Fibroblast subtypes in the pancreatic cancer stroma (myCAF, iCAF and apCAF)","route":"/terms/caf-subtypes-pancreatic/","asOf":"2026-09-24","days":4},{"id":"compass-study-pancreatic","kind":"term","name":"COMPASS: real-time sequencing of advanced pancreatic cancer for treatment selection","route":"/terms/compass-study-pancreatic/","asOf":"2026-09-24","days":4},{"id":"caps-consortium-pancreatic-screening","kind":"term","name":"CAPS: the Cancer of the Pancreas Screening consortium and its surveillance studies (CAPS1 to CAPS5)","route":"/terms/caps-consortium-pancreatic-screening/","asOf":"2026-09-24","days":4},{"id":"detect-a-study","kind":"term","name":"DETECT-A: a blood test plus PET-CT to screen 10,006 women with no symptoms","route":"/terms/detect-a-study/","asOf":"2026-09-24","days":4},{"id":"ccga-study","kind":"term","name":"CCGA: the Circulating Cell-free Genome Atlas behind the Galleri methylation test","route":"/terms/ccga-study/","asOf":"2026-09-24","days":4},{"id":"bowel-cancer-uk","kind":"institution","name":"Bowel Cancer UK","route":"/institutions/bowel-cancer-uk/","asOf":"2026-09-24","days":4},{"id":"bowel-research-uk","kind":"institution","name":"Bowel Research UK","route":"/institutions/bowel-research-uk/","asOf":"2026-09-24","days":4},{"id":"david-sebag-montefiore","kind":"person","name":"David Sebag-Montefiore","route":"/people/david-sebag-montefiore/","asOf":"2026-09-24","days":4},{"id":"matt-seymour","kind":"person","name":"Matt Seymour","route":"/people/matt-seymour/","asOf":"2026-09-24","days":4},{"id":"dion-morton","kind":"person","name":"Dion Morton","route":"/people/dion-morton/","asOf":"2026-09-24","days":4},{"id":"john-burn","kind":"person","name":"John Burn","route":"/people/john-burn/","asOf":"2026-09-24","days":4},{"id":"rachel-kerr","kind":"person","name":"Rachel Kerr","route":"/people/rachel-kerr/","asOf":"2026-09-24","days":4},{"id":"tim-maughan","kind":"person","name":"Tim Maughan","route":"/people/tim-maughan/","asOf":"2026-09-24","days":4},{"id":"naureen-starling","kind":"person","name":"Naureen Starling","route":"/people/naureen-starling/","asOf":"2026-09-24","days":4},{"id":"ian-chau","kind":"person","name":"Ian Chau","route":"/people/ian-chau/","asOf":"2026-09-24","days":4},{"id":"quasar","kind":"trial","name":"QUASAR","route":"/trials/quasar/","asOf":"2026-09-24","days":4},{"id":"scot","kind":"trial","name":"SCOT","route":"/trials/scot/","asOf":"2026-09-24","days":4},{"id":"cr07","kind":"trial","name":"MRC CR07","route":"/trials/cr07/","asOf":"2026-09-24","days":4},{"id":"foxtrot","kind":"trial","name":"FOxTROT","route":"/trials/foxtrot/","asOf":"2026-09-24","days":4},{"id":"coin","kind":"trial","name":"MRC COIN","route":"/trials/coin/","asOf":"2026-09-24","days":4},{"id":"mercury","kind":"trial","name":"MERCURY","route":"/trials/mercury/","asOf":"2026-09-24","days":4},{"id":"star-trec","kind":"trial","name":"STAR-TREC","route":"/trials/star-trec/","asOf":"2026-09-24","days":4},{"id":"nottingham-fob","kind":"trial","name":"Nottingham faecal occult blood screening trial","route":"/trials/nottingham-fob/","asOf":"2026-09-24","days":4},{"id":"ukfss","kind":"trial","name":"UK Flexible Sigmoidoscopy Screening Trial","route":"/trials/ukfss/","asOf":"2026-09-24","days":4},{"id":"paper-lengauer-genetic-instability-colorectal-nature-1997","kind":"paper","name":"Genetic instability in colorectal cancers","route":"/key-papers/paper-lengauer-genetic-instability-colorectal-nature-1997/","asOf":"2026-09-24","days":4},{"id":"paper-markowitz-tgfbr2-inactivation-msi-colon-science-1995","kind":"paper","name":"Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability","route":"/key-papers/paper-markowitz-tgfbr2-inactivation-msi-colon-science-1995/","asOf":"2026-09-24","days":4},{"id":"paper-tcga-colorectal-comprehensive-characterization-nature-2012","kind":"paper","name":"Comprehensive molecular characterization of human colon and rectal cancer","route":"/key-papers/paper-tcga-colorectal-comprehensive-characterization-nature-2012/","asOf":"2026-09-24","days":4},{"id":"paper-seshagiri-rspo-fusions-colon-nature-2012","kind":"paper","name":"Recurrent R-spondin fusions in colon cancer","route":"/key-papers/paper-seshagiri-rspo-fusions-colon-nature-2012/","asOf":"2026-09-24","days":4},{"id":"paper-giannakis-genomic-correlates-immune-colorectal-cell-rep-2016","kind":"paper","name":"Genomic correlates of immune-cell infiltrates in colorectal carcinoma","route":"/key-papers/paper-giannakis-genomic-correlates-immune-colorectal-cell-rep-2016/","asOf":"2026-09-24","days":4},{"id":"paper-yaeger-metastatic-colorectal-genomic-landscape-cancer-cell-2018","kind":"paper","name":"Clinical sequencing defines the genomic landscape of metastatic colorectal cancer","route":"/key-papers/paper-yaeger-metastatic-colorectal-genomic-landscape-cancer-cell-2018/","asOf":"2026-09-24","days":4},{"id":"paper-grasso-immune-evasion-colorectal-cancer-discov-2018","kind":"paper","name":"Genetic mechanisms of immune evasion in colorectal cancer","route":"/key-papers/paper-grasso-immune-evasion-colorectal-cancer-discov-2018/","asOf":"2026-09-24","days":4},{"id":"paper-herman-mlh1-promoter-hypermethylation-colorectal-pnas-1998","kind":"paper","name":"Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma","route":"/key-papers/paper-herman-mlh1-promoter-hypermethylation-colorectal-pnas-1998/","asOf":"2026-09-24","days":4},{"id":"paper-weisenberger-cimp-braf-mlh1-colorectal-nat-genet-2006","kind":"paper","name":"CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer","route":"/key-papers/paper-weisenberger-cimp-braf-mlh1-colorectal-nat-genet-2006/","asOf":"2026-09-24","days":4},{"id":"paper-ligtenberg-epcam-deletion-msh2-silencing-nat-genet-2009","kind":"paper","name":"Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1","route":"/key-papers/paper-ligtenberg-epcam-deletion-msh2-silencing-nat-genet-2009/","asOf":"2026-09-24","days":4},{"id":"paper-moreira-lynch-syndrome-identification-jama-2012","kind":"paper","name":"Identification of Lynch syndrome among patients with colorectal cancer","route":"/key-papers/paper-moreira-lynch-syndrome-identification-jama-2012/","asOf":"2026-09-24","days":4},{"id":"paper-koopman-deficient-mismatch-repair-advanced-colorectal-bjc-2009","kind":"paper","name":"Deficient mismatch repair system in patients with sporadic advanced colorectal cancer","route":"/key-papers/paper-koopman-deficient-mismatch-repair-advanced-colorectal-bjc-2009/","asOf":"2026-09-24","days":4},{"id":"paper-venderbosch-mmr-braf-metastatic-colorectal-pooled-ccr-2014","kind":"paper","name":"Mismatch repair status and BRAF mutation status in metastatic colorectal cancer: a pooled analysis of the CAIRO, CAIRO2, COIN and FOCUS studies","route":"/key-papers/paper-venderbosch-mmr-braf-metastatic-colorectal-pooled-ccr-2014/","asOf":"2026-09-24","days":4},{"id":"paper-palles-germline-pole-pold1-proofreading-nat-genet-2013","kind":"paper","name":"Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas","route":"/key-papers/paper-palles-germline-pole-pold1-proofreading-nat-genet-2013/","asOf":"2026-09-24","days":4},{"id":"paper-domingo-somatic-pole-proofreading-colorectal-lancet-gastro-2016","kind":"paper","name":"Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer","route":"/key-papers/paper-domingo-somatic-pole-proofreading-colorectal-lancet-gastro-2016/","asOf":"2026-09-24","days":4},{"id":"paper-bettington-serrated-pathway-colorectal-histopathology-2013","kind":"paper","name":"The serrated pathway to colorectal carcinoma: current concepts and challenges","route":"/key-papers/paper-bettington-serrated-pathway-colorectal-histopathology-2013/","asOf":"2026-09-24","days":4},{"id":"paper-crockett-nagtegaal-serrated-neoplasia-gastroenterology-2019","kind":"paper","name":"Terminology, molecular features, epidemiology, and management of serrated colorectal neoplasia","route":"/key-papers/paper-crockett-nagtegaal-serrated-neoplasia-gastroenterology-2019/","asOf":"2026-09-24","days":4},{"id":"paper-lee-six-somatic-mutation-normal-colorectal-crypts-nature-2019","kind":"paper","name":"The landscape of somatic mutation in normal colorectal epithelial cells","route":"/key-papers/paper-lee-six-somatic-mutation-normal-colorectal-crypts-nature-2019/","asOf":"2026-09-24","days":4},{"id":"paper-isella-stromal-contribution-colorectal-transcriptome-nat-genet-2015","kind":"paper","name":"Stromal contribution to the colorectal cancer transcriptome","route":"/key-papers/paper-isella-stromal-contribution-colorectal-transcriptome-nat-genet-2015/","asOf":"2026-09-24","days":4},{"id":"paper-calon-stromal-gene-expression-poor-prognosis-colorectal-nat-genet-2015","kind":"paper","name":"Stromal gene expression defines poor-prognosis subtypes in colorectal cancer","route":"/key-papers/paper-calon-stromal-gene-expression-poor-prognosis-colorectal-nat-genet-2015/","asOf":"2026-09-24","days":4},{"id":"paper-tauriello-tgfbeta-immune-evasion-colorectal-nature-2018","kind":"paper","name":"TGF-beta drives immune evasion in genetically reconstituted colon cancer metastasis","route":"/key-papers/paper-tauriello-tgfbeta-immune-evasion-colorectal-nature-2018/","asOf":"2026-09-24","days":4},{"id":"paper-lenz-cms-calgb-swog-80405-jco-2019","kind":"paper","name":"Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: results from CALGB/SWOG 80405","route":"/key-papers/paper-lenz-cms-calgb-swog-80405-jco-2019/","asOf":"2026-09-24","days":4},{"id":"paper-missiaglia-distal-proximal-colon-cancers-ann-oncol-2014","kind":"paper","name":"Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features","route":"/key-papers/paper-missiaglia-distal-proximal-colon-cancers-ann-oncol-2014/","asOf":"2026-09-24","days":4},{"id":"paper-tejpar-tumour-location-crystal-fire3-jama-oncol-2017","kind":"paper","name":"Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials","route":"/key-papers/paper-tejpar-tumour-location-crystal-fire3-jama-oncol-2017/","asOf":"2026-09-24","days":4},{"id":"paper-loree-tumour-location-continuum-colorectal-ccr-2018","kind":"paper","name":"Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes","route":"/key-papers/paper-loree-tumour-location-continuum-colorectal-ccr-2018/","asOf":"2026-09-24","days":4},{"id":"paper-karapetis-kras-cetuximab-colorectal-nejm-2008","kind":"paper","name":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","route":"/key-papers/paper-karapetis-kras-cetuximab-colorectal-nejm-2008/","asOf":"2026-09-24","days":4},{"id":"paper-jones-non-v600-braf-colorectal-jco-2017","kind":"paper","name":"Non-V600 BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer","route":"/key-papers/paper-jones-non-v600-braf-colorectal-jco-2017/","asOf":"2026-09-24","days":4},{"id":"paper-schirripa-kras-g12c-metastatic-colorectal-clin-colorectal-cancer-2020","kind":"paper","name":"KRAS G12C metastatic colorectal cancer: specific features of a new emerging target population","route":"/key-papers/paper-schirripa-kras-g12c-metastatic-colorectal-clin-colorectal-cancer-2020/","asOf":"2026-09-24","days":4},{"id":"paper-misale-kras-acquired-resistance-anti-egfr-colorectal-nature-2012","kind":"paper","name":"Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer","route":"/key-papers/paper-misale-kras-acquired-resistance-anti-egfr-colorectal-nature-2012/","asOf":"2026-09-24","days":4},{"id":"paper-diaz-molecular-evolution-egfr-resistance-colorectal-nature-2012","kind":"paper","name":"The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers","route":"/key-papers/paper-diaz-molecular-evolution-egfr-resistance-colorectal-nature-2012/","asOf":"2026-09-24","days":4},{"id":"paper-bertotti-xenopatients-her2-cetuximab-resistant-colorectal-cancer-discov-2011","kind":"paper","name":"A molecularly annotated platform of patient-derived xenografts identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer","route":"/key-papers/paper-bertotti-xenopatients-her2-cetuximab-resistant-colorectal-cancer-discov-2011/","asOf":"2026-09-24","days":4},{"id":"paper-valtorta-her2-scoring-colorectal-heracles-mod-pathol-2015","kind":"paper","name":"Assessment of a HER2 scoring system for colorectal cancer: results from a validation study","route":"/key-papers/paper-valtorta-her2-scoring-colorectal-heracles-mod-pathol-2015/","asOf":"2026-09-24","days":4},{"id":"paper-richman-her2-amplification-quasar-focus-piccolo-j-pathol-2016","kind":"paper","name":"HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials","route":"/key-papers/paper-richman-her2-amplification-quasar-focus-piccolo-j-pathol-2016/","asOf":"2026-09-24","days":4},{"id":"paper-nakamura-triumph-ctdna-pertuzumab-trastuzumab-her2-colorectal-nat-med-2021","kind":"paper","name":"Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial (TRIUMPH)","route":"/key-papers/paper-nakamura-triumph-ctdna-pertuzumab-trastuzumab-her2-colorectal-nat-med-2021/","asOf":"2026-09-24","days":4},{"id":"paper-overman-checkmate-142-nivolumab-dmmr-colorectal-lancet-oncol-2017","kind":"paper","name":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142)","route":"/key-papers/paper-overman-checkmate-142-nivolumab-dmmr-colorectal-lancet-oncol-2017/","asOf":"2026-09-24","days":4},{"id":"paper-eng-imblaze370-atezolizumab-cobimetinib-colorectal-lancet-oncol-2019","kind":"paper","name":"Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370)","route":"/key-papers/paper-eng-imblaze370-atezolizumab-cobimetinib-colorectal-lancet-oncol-2019/","asOf":"2026-09-24","days":4},{"id":"paper-mlecnik-immunoscore-msi-colorectal-immunity-2016","kind":"paper","name":"Integrative analyses of colorectal cancer show Immunoscore is a stronger predictor of patient survival than microsatellite instability","route":"/key-papers/paper-mlecnik-immunoscore-msi-colorectal-immunity-2016/","asOf":"2026-09-24","days":4},{"id":"paper-pages-immunoscore-international-validation-lancet-2018","kind":"paper","name":"International validation of the consensus Immunoscore for the classification of colon cancer","route":"/key-papers/paper-pages-immunoscore-international-validation-lancet-2018/","asOf":"2026-09-24","days":4},{"id":"paper-reinert-ctdna-ultradeep-sequencing-colorectal-jama-oncol-2019","kind":"paper","name":"Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer","route":"/key-papers/paper-reinert-ctdna-ultradeep-sequencing-colorectal-jama-oncol-2019/","asOf":"2026-09-24","days":4},{"id":"paper-henriksen-ctdna-stage-iii-colorectal-improve-it-ccr-2022","kind":"paper","name":"Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences","route":"/key-papers/paper-henriksen-ctdna-stage-iii-colorectal-improve-it-ccr-2022/","asOf":"2026-09-24","days":4},{"id":"paper-sepulveda-molecular-biomarkers-colorectal-guideline-jco-2017","kind":"paper","name":"Molecular biomarkers for the evaluation of colorectal cancer: guideline from ASCP, CAP, AMP and ASCO","route":"/key-papers/paper-sepulveda-molecular-biomarkers-colorectal-guideline-jco-2017/","asOf":"2026-09-24","days":4},{"id":"paper-esmo-metastatic-colorectal-cancer-guideline-ann-oncol-2023","kind":"paper","name":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-metastatic-colorectal-cancer-guideline-ann-oncol-2023/","asOf":"2026-09-24","days":4},{"id":"paper-esmo-localised-colon-cancer-guideline-ann-oncol-2020","kind":"paper","name":"Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-localised-colon-cancer-guideline-ann-oncol-2020/","asOf":"2026-09-24","days":4},{"id":"paper-esmo-rectal-cancer-guideline-ann-oncol-2017","kind":"paper","name":"Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-rectal-cancer-guideline-ann-oncol-2017/","asOf":"2026-09-24","days":4},{"id":"paper-vogelstein-genetic-alterations-colorectal-tumor-development-nejm-1988","kind":"paper","name":"Genetic alterations during colorectal-tumor development","route":"/key-papers/paper-vogelstein-genetic-alterations-colorectal-tumor-development-nejm-1988/","asOf":"2026-09-24","days":4},{"id":"paper-diaz-gay-colibactin-geographic-age-mutational-processes-nature-2025","kind":"paper","name":"Geographic and age variations in mutational processes in colorectal cancer","route":"/key-papers/paper-diaz-gay-colibactin-geographic-age-mutational-processes-nature-2025/","asOf":"2026-09-24","days":4},{"id":"paper-hardcastle-nottingham-faecal-occult-blood-lancet-1996","kind":"paper","name":"Randomised controlled trial of faecal-occult-blood screening for colorectal cancer (Nottingham)","route":"/key-papers/paper-hardcastle-nottingham-faecal-occult-blood-lancet-1996/","asOf":"2026-09-24","days":4},{"id":"paper-kronborg-funen-faecal-occult-blood-lancet-1996","kind":"paper","name":"Randomised study of screening for colorectal cancer with faecal-occult-blood test (Funen)","route":"/key-papers/paper-kronborg-funen-faecal-occult-blood-lancet-1996/","asOf":"2026-09-24","days":4},{"id":"paper-zauber-national-polyp-study-colonoscopic-polypectomy-nejm-2012","kind":"paper","name":"Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths (National Polyp Study)","route":"/key-papers/paper-zauber-national-polyp-study-colonoscopic-polypectomy-nejm-2012/","asOf":"2026-09-24","days":4},{"id":"paper-atkin-once-only-flexible-sigmoidoscopy-lancet-2010","kind":"paper","name":"Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial","route":"/key-papers/paper-atkin-once-only-flexible-sigmoidoscopy-lancet-2010/","asOf":"2026-09-24","days":4},{"id":"paper-atkin-flexible-sigmoidoscopy-17-year-follow-up-lancet-2017","kind":"paper","name":"Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up","route":"/key-papers/paper-atkin-flexible-sigmoidoscopy-17-year-follow-up-lancet-2017/","asOf":"2026-09-24","days":4},{"id":"paper-imperiale-multitarget-stool-dna-screening-nejm-2014","kind":"paper","name":"Multitarget stool DNA testing for colorectal-cancer screening","route":"/key-papers/paper-imperiale-multitarget-stool-dna-screening-nejm-2014/","asOf":"2026-09-24","days":4},{"id":"paper-kaminski-adenoma-detection-rate-interval-cancer-nejm-2010","kind":"paper","name":"Quality indicators for colonoscopy and the risk of interval cancer","route":"/key-papers/paper-kaminski-adenoma-detection-rate-interval-cancer-nejm-2010/","asOf":"2026-09-24","days":4},{"id":"paper-siegel-colorectal-incidence-birth-cohort-jnci-2017","kind":"paper","name":"Colorectal cancer incidence patterns in the United States, 1974-2013","route":"/key-papers/paper-siegel-colorectal-incidence-birth-cohort-jnci-2017/","asOf":"2026-09-24","days":4},{"id":"paper-vuik-early-onset-colorectal-europe-gut-2019","kind":"paper","name":"Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years","route":"/key-papers/paper-vuik-early-onset-colorectal-europe-gut-2019/","asOf":"2026-09-24","days":4},{"id":"paper-siegel-colorectal-cancer-statistics-ca-2023","kind":"paper","name":"Colorectal cancer statistics, 2023","route":"/key-papers/paper-siegel-colorectal-cancer-statistics-ca-2023/","asOf":"2026-09-24","days":4},{"id":"paper-hur-sugar-sweetened-beverages-early-onset-colorectal-gut-2021","kind":"paper","name":"Sugar-sweetened beverage intake in adulthood and adolescence and risk of early-onset colorectal cancer among women","route":"/key-papers/paper-hur-sugar-sweetened-beverages-early-onset-colorectal-gut-2021/","asOf":"2026-09-24","days":4},{"id":"paper-moertel-levamisole-fluorouracil-adjuvant-colon-nejm-1990","kind":"paper","name":"Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma","route":"/key-papers/paper-moertel-levamisole-fluorouracil-adjuvant-colon-nejm-1990/","asOf":"2026-09-24","days":4},{"id":"paper-quasar-adjuvant-chemotherapy-vs-observation-lancet-2007","kind":"paper","name":"Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study (QUASAR)","route":"/key-papers/paper-quasar-adjuvant-chemotherapy-vs-observation-lancet-2007/","asOf":"2026-09-24","days":4},{"id":"paper-mosaic-oxaliplatin-adjuvant-colon-nejm-2004","kind":"paper","name":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer (MOSAIC)","route":"/key-papers/paper-mosaic-oxaliplatin-adjuvant-colon-nejm-2004/","asOf":"2026-09-24","days":4},{"id":"paper-idea-duration-adjuvant-stage-iii-colon-nejm-2018","kind":"paper","name":"Duration of adjuvant chemotherapy for stage III colon cancer (the IDEA collaboration)","route":"/key-papers/paper-idea-duration-adjuvant-stage-iii-colon-nejm-2018/","asOf":"2026-09-24","days":4},{"id":"paper-foxtrot-preoperative-chemotherapy-colon-jco-2023","kind":"paper","name":"Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial (FOxTROT)","route":"/key-papers/paper-foxtrot-preoperative-chemotherapy-colon-jco-2023/","asOf":"2026-09-24","days":4},{"id":"paper-heald-mesorectum-rectal-cancer-surgery-br-j-surg-1982","kind":"paper","name":"The mesorectum in rectal cancer surgery: the clue to pelvic recurrence?","route":"/key-papers/paper-heald-mesorectum-rectal-cancer-surgery-br-j-surg-1982/","asOf":"2026-09-24","days":4},{"id":"paper-swedish-rectal-cancer-trial-preoperative-radiotherapy-nejm-1997","kind":"paper","name":"Improved survival with preoperative radiotherapy in resectable rectal cancer (Swedish Rectal Cancer Trial)","route":"/key-papers/paper-swedish-rectal-cancer-trial-preoperative-radiotherapy-nejm-1997/","asOf":"2026-09-24","days":4},{"id":"paper-kapiteijn-dutch-tme-preoperative-radiotherapy-nejm-2001","kind":"paper","name":"Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer (Dutch TME trial)","route":"/key-papers/paper-kapiteijn-dutch-tme-preoperative-radiotherapy-nejm-2001/","asOf":"2026-09-24","days":4},{"id":"paper-sebag-montefiore-cr07-preoperative-radiotherapy-lancet-2009","kind":"paper","name":"Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016)","route":"/key-papers/paper-sebag-montefiore-cr07-preoperative-radiotherapy-lancet-2009/","asOf":"2026-09-24","days":4},{"id":"paper-bahadoer-rapido-short-course-radiotherapy-lancet-oncol-2021","kind":"paper","name":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision versus preoperative chemoradiotherapy in locally advanced rectal cancer (RAPIDO)","route":"/key-papers/paper-bahadoer-rapido-short-course-radiotherapy-lancet-oncol-2021/","asOf":"2026-09-24","days":4},{"id":"paper-conroy-prodige-23-neoadjuvant-folfirinox-rectal-lancet-oncol-2021","kind":"paper","name":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23)","route":"/key-papers/paper-conroy-prodige-23-neoadjuvant-folfirinox-rectal-lancet-oncol-2021/","asOf":"2026-09-24","days":4},{"id":"paper-habr-gama-nonoperative-stage-0-rectal-ann-surg-2004","kind":"paper","name":"Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results","route":"/key-papers/paper-habr-gama-nonoperative-stage-0-rectal-ann-surg-2004/","asOf":"2026-09-24","days":4},{"id":"paper-garcia-aguilar-opra-organ-preservation-jco-2022","kind":"paper","name":"Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy (OPRA)","route":"/key-papers/paper-garcia-aguilar-opra-organ-preservation-jco-2022/","asOf":"2026-09-24","days":4},{"id":"paper-van-cutsem-crystal-cetuximab-folfiri-nejm-2009","kind":"paper","name":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer (CRYSTAL)","route":"/key-papers/paper-van-cutsem-crystal-cetuximab-folfiri-nejm-2009/","asOf":"2026-09-24","days":4},{"id":"paper-douillard-prime-panitumumab-ras-nejm-2013","kind":"paper","name":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer (PRIME)","route":"/key-papers/paper-douillard-prime-panitumumab-ras-nejm-2013/","asOf":"2026-09-24","days":4},{"id":"paper-heinemann-fire-3-cetuximab-vs-bevacizumab-lancet-oncol-2014","kind":"paper","name":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3)","route":"/key-papers/paper-heinemann-fire-3-cetuximab-vs-bevacizumab-lancet-oncol-2014/","asOf":"2026-09-24","days":4},{"id":"paper-venook-calgb-80405-cetuximab-vs-bevacizumab-jama-2017","kind":"paper","name":"Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in KRAS wild-type advanced or metastatic colorectal cancer (CALGB/SWOG 80405)","route":"/key-papers/paper-venook-calgb-80405-cetuximab-vs-bevacizumab-jama-2017/","asOf":"2026-09-24","days":4},{"id":"paper-arnold-primary-tumour-side-ras-wild-type-ann-oncol-2017","kind":"paper","name":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials","route":"/key-papers/paper-arnold-primary-tumour-side-ras-wild-type-ann-oncol-2017/","asOf":"2026-09-24","days":4},{"id":"paper-cremolini-tribe-folfoxiri-bevacizumab-lancet-oncol-2015","kind":"paper","name":"FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of TRIBE","route":"/key-papers/paper-cremolini-tribe-folfoxiri-bevacizumab-lancet-oncol-2015/","asOf":"2026-09-24","days":4},{"id":"paper-grothey-correct-regorafenib-lancet-2013","kind":"paper","name":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT)","route":"/key-papers/paper-grothey-correct-regorafenib-lancet-2013/","asOf":"2026-09-24","days":4},{"id":"paper-mayer-recourse-tas-102-nejm-2015","kind":"paper","name":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer (RECOURSE)","route":"/key-papers/paper-mayer-recourse-tas-102-nejm-2015/","asOf":"2026-09-24","days":4},{"id":"paper-prager-sunlight-trifluridine-tipiracil-bevacizumab-nejm-2023","kind":"paper","name":"Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer (SUNLIGHT)","route":"/key-papers/paper-prager-sunlight-trifluridine-tipiracil-bevacizumab-nejm-2023/","asOf":"2026-09-24","days":4},{"id":"paper-dasari-fresco-2-fruquintinib-lancet-2023","kind":"paper","name":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2)","route":"/key-papers/paper-dasari-fresco-2-fruquintinib-lancet-2023/","asOf":"2026-09-24","days":4},{"id":"paper-andre-checkmate-8hw-nivolumab-ipilimumab-nejm-2024","kind":"paper","name":"Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer (CheckMate 8HW)","route":"/key-papers/paper-andre-checkmate-8hw-nivolumab-ipilimumab-nejm-2024/","asOf":"2026-09-24","days":4},{"id":"paper-cercek-nonoperative-management-mismatch-repair-deficient-tumours-nejm-2025","kind":"paper","name":"Nonoperative management of mismatch repair-deficient tumors","route":"/key-papers/paper-cercek-nonoperative-management-mismatch-repair-deficient-tumours-nejm-2025/","asOf":"2026-09-24","days":4},{"id":"paper-bullock-botensilimab-balstilimab-mss-colorectal-nat-med-2024","kind":"paper","name":"Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial","route":"/key-papers/paper-bullock-botensilimab-balstilimab-mss-colorectal-nat-med-2024/","asOf":"2026-09-24","days":4},{"id":"paper-kopetz-beacon-encorafenib-braf-colorectal-nejm-2019","kind":"paper","name":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer (BEACON CRC)","route":"/key-papers/paper-kopetz-beacon-encorafenib-braf-colorectal-nejm-2019/","asOf":"2026-09-24","days":4},{"id":"paper-sartore-bianchi-heracles-trastuzumab-lapatinib-lancet-oncol-2016","kind":"paper","name":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES)","route":"/key-papers/paper-sartore-bianchi-heracles-trastuzumab-lapatinib-lancet-oncol-2016/","asOf":"2026-09-24","days":4},{"id":"paper-siena-destiny-crc01-trastuzumab-deruxtecan-lancet-oncol-2021","kind":"paper","name":"Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01)","route":"/key-papers/paper-siena-destiny-crc01-trastuzumab-deruxtecan-lancet-oncol-2021/","asOf":"2026-09-24","days":4},{"id":"paper-strickler-mountaineer-tucatinib-trastuzumab-lancet-oncol-2023","kind":"paper","name":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER)","route":"/key-papers/paper-strickler-mountaineer-tucatinib-trastuzumab-lancet-oncol-2023/","asOf":"2026-09-24","days":4},{"id":"paper-tie-ctdna-minimal-residual-disease-stage-ii-colon-sci-transl-med-2016","kind":"paper","name":"Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer","route":"/key-papers/paper-tie-ctdna-minimal-residual-disease-stage-ii-colon-sci-transl-med-2016/","asOf":"2026-09-24","days":4},{"id":"paper-verwaal-cytoreduction-hipec-peritoneal-colorectal-jco-2003","kind":"paper","name":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer","route":"/key-papers/paper-verwaal-cytoreduction-hipec-peritoneal-colorectal-jco-2003/","asOf":"2026-09-24","days":4},{"id":"paper-quenet-prodige-7-hipec-peritoneal-colorectal-lancet-oncol-2021","kind":"paper","name":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7)","route":"/key-papers/paper-quenet-prodige-7-hipec-peritoneal-colorectal-lancet-oncol-2021/","asOf":"2026-09-24","days":4},{"id":"colorectal-roadmap","kind":"roadmap","name":"Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation","route":"/roadmaps/colorectal-roadmap/","asOf":"2026-09-24","days":4},{"id":"idea-crc-early-onset-cause-hunt","kind":"idea","name":"Find out what is driving early-onset bowel cancer, starting with colibactin, before extending screening any further","route":"/ideas/idea-crc-early-onset-cause-hunt/","asOf":"2026-09-24","days":4},{"id":"idea-crc-screening-uptake-and-age-extension","kind":"idea","name":"Treat screening uptake, not test sensitivity, as the thing to optimise, and settle the age extension with a trial rather than a model","route":"/ideas/idea-crc-screening-uptake-and-age-extension/","asOf":"2026-09-24","days":4},{"id":"idea-crc-ctdna-de-escalation-beyond-stage-ii","kind":"idea","name":"Take ctDNA-guided de-escalation beyond stage II, and stop escalating on a positive result until a trial says it helps","route":"/ideas/idea-crc-ctdna-de-escalation-beyond-stage-ii/","asOf":"2026-09-24","days":4},{"id":"idea-crc-organ-preservation-randomised-in-pmmr-rectal","kind":"idea","name":"Randomise organ preservation against surgery in mismatch repair-proficient rectal cancer, with bowel function as a co-primary endpoint","route":"/ideas/idea-crc-organ-preservation-randomised-in-pmmr-rectal/","asOf":"2026-09-24","days":4},{"id":"idea-crc-mss-immunotherapy-by-biomarker-not-by-line","kind":"idea","name":"Select microsatellite stable patients for immunotherapy by a measured immune biomarker, not by how many treatments they have already failed","route":"/ideas/idea-crc-mss-immunotherapy-by-biomarker-not-by-line/","asOf":"2026-09-24","days":4},{"id":"idea-crc-peritoneal-disease-found-early-and-treated-in-networks","kind":"idea","name":"Find peritoneal spread while it is still small, and run complete cytoreduction through networks rather than adding heated chemotherapy","route":"/ideas/idea-crc-peritoneal-disease-found-early-and-treated-in-networks/","asOf":"2026-09-24","days":4},{"id":"idea-crc-exercise-as-a-funded-treatment","kind":"idea","name":"Fund structured exercise after colon cancer surgery as a treatment, because a randomised trial says it works as well as a drug","route":"/ideas/idea-crc-exercise-as-a-funded-treatment/","asOf":"2026-09-24","days":4},{"id":"idea-crc-uk-colonoscopy-capacity-and-fit-threshold","kind":"idea","name":"UK gap: match endoscopy capacity and quality to the faecal immunochemical test thresholds the NHS has already set","route":"/ideas/idea-crc-uk-colonoscopy-capacity-and-fit-threshold/","asOf":"2026-09-24","days":4},{"id":"idea-crc-uk-young-patient-referral-and-diagnostic-interval","kind":"idea","name":"UK gap: shorten the route to diagnosis for patients below the screening age, where the rise in incidence is","route":"/ideas/idea-crc-uk-young-patient-referral-and-diagnostic-interval/","asOf":"2026-09-24","days":4},{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/","asOf":"2026-09-24","days":4},{"id":"colorectal-palliation-obstruction-pain","kind":"term","name":"Palliation in colorectal cancer: obstruction, stents, stomas and liver capsule pain","route":"/terms/colorectal-palliation-obstruction-pain/","asOf":"2026-09-24","days":4},{"id":"colorectal-failed-programmes","kind":"term","name":"Colorectal cancer: the failed and stopped programmes, and why","route":"/terms/colorectal-failed-programmes/","asOf":"2026-09-24","days":4},{"id":"colorectal-uk-drug-access","kind":"term","name":"Colorectal cancer drugs in England: what NICE has recommended","route":"/terms/colorectal-uk-drug-access/","asOf":"2026-09-24","days":4},{"id":"folfoxiri","kind":"drug","name":"FOLFOXIRI (5-FU, leucovorin, oxaliplatin, irinotecan)","route":"/drugs/folfoxiri/","asOf":"2026-09-24","days":4},{"id":"mosaic","kind":"trial","name":"MOSAIC","route":"/trials/mosaic/","asOf":"2026-09-24","days":4},{"id":"idea-collaboration","kind":"trial","name":"IDEA collaboration","route":"/trials/idea-collaboration/","asOf":"2026-09-24","days":4},{"id":"tosca","kind":"trial","name":"TOSCA","route":"/trials/tosca/","asOf":"2026-09-24","days":4},{"id":"petacc-8","kind":"trial","name":"PETACC-8","route":"/trials/petacc-8/","asOf":"2026-09-24","days":4},{"id":"n0147","kind":"trial","name":"Alliance N0147","route":"/trials/n0147/","asOf":"2026-09-24","days":4},{"id":"dutch-tme-trial","kind":"trial","name":"Dutch TME trial","route":"/trials/dutch-tme-trial/","asOf":"2026-09-24","days":4},{"id":"stockholm-iii","kind":"trial","name":"Stockholm III","route":"/trials/stockholm-iii/","asOf":"2026-09-24","days":4},{"id":"stellar-rectal","kind":"trial","name":"STELLAR (rectal cancer)","route":"/trials/stellar-rectal/","asOf":"2026-09-24","days":4},{"id":"cao-aro-aio-12","kind":"trial","name":"CAO/ARO/AIO-12","route":"/trials/cao-aro-aio-12/","asOf":"2026-09-24","days":4},{"id":"iwwd","kind":"trial","name":"International Watch & Wait Database","route":"/trials/iwwd/","asOf":"2026-09-24","days":4},{"id":"avf2107g","kind":"trial","name":"AVF2107g","route":"/trials/avf2107g/","asOf":"2026-09-24","days":4},{"id":"prime","kind":"trial","name":"PRIME","route":"/trials/prime/","asOf":"2026-09-24","days":4},{"id":"opus","kind":"trial","name":"OPUS","route":"/trials/opus/","asOf":"2026-09-24","days":4},{"id":"calgb-80405","kind":"trial","name":"CALGB/SWOG 80405","route":"/trials/calgb-80405/","asOf":"2026-09-24","days":4},{"id":"tribe","kind":"trial","name":"TRIBE","route":"/trials/tribe/","asOf":"2026-09-24","days":4},{"id":"tribe2","kind":"trial","name":"TRIBE2","route":"/trials/tribe2/","asOf":"2026-09-24","days":4},{"id":"velour","kind":"trial","name":"VELOUR","route":"/trials/velour/","asOf":"2026-09-24","days":4},{"id":"raise","kind":"trial","name":"RAISE","route":"/trials/raise/","asOf":"2026-09-24","days":4},{"id":"correct","kind":"trial","name":"CORRECT","route":"/trials/correct/","asOf":"2026-09-24","days":4},{"id":"concur","kind":"trial","name":"CONCUR","route":"/trials/concur/","asOf":"2026-09-24","days":4},{"id":"recourse","kind":"trial","name":"RECOURSE","route":"/trials/recourse/","asOf":"2026-09-24","days":4},{"id":"fresco","kind":"trial","name":"FRESCO","route":"/trials/fresco/","asOf":"2026-09-24","days":4},{"id":"cairo3","kind":"trial","name":"CAIRO3","route":"/trials/cairo3/","asOf":"2026-09-24","days":4},{"id":"cairo5","kind":"trial","name":"CAIRO5","route":"/trials/cairo5/","asOf":"2026-09-24","days":4},{"id":"swog-s1406","kind":"trial","name":"SWOG S1406","route":"/trials/swog-s1406/","asOf":"2026-09-24","days":4},{"id":"destiny-crc01","kind":"trial","name":"DESTINY-CRC01","route":"/trials/destiny-crc01/","asOf":"2026-09-24","days":4},{"id":"mountaineer-03","kind":"trial","name":"MOUNTAINEER-03","route":"/trials/mountaineer-03/","asOf":"2026-09-24","days":4},{"id":"imblaze370","kind":"trial","name":"IMblaze370","route":"/trials/imblaze370/","asOf":"2026-09-24","days":4},{"id":"eortc-40983","kind":"trial","name":"EORTC 40983","route":"/trials/eortc-40983/","asOf":"2026-09-24","days":4},{"id":"new-epoc","kind":"trial","name":"New EPOC","route":"/trials/new-epoc/","asOf":"2026-09-24","days":4},{"id":"clocc","kind":"trial","name":"CLOCC","route":"/trials/clocc/","asOf":"2026-09-24","days":4},{"id":"prodige-7","kind":"trial","name":"PRODIGE 7","route":"/trials/prodige-7/","asOf":"2026-09-24","days":4},{"id":"colopec","kind":"trial","name":"COLOPEC","route":"/trials/colopec/","asOf":"2026-09-24","days":4},{"id":"prophylochip","kind":"trial","name":"PROPHYLOCHIP-PRODIGE 15","route":"/trials/prophylochip/","asOf":"2026-09-24","days":4},{"id":"dynamic-iii","kind":"trial","name":"DYNAMIC-III","route":"/trials/dynamic-iii/","asOf":"2026-09-24","days":4},{"id":"altair","kind":"trial","name":"ALTAIR","route":"/trials/altair/","asOf":"2026-09-24","days":4},{"id":"chronos","kind":"trial","name":"CHRONOS","route":"/trials/chronos/","asOf":"2026-09-24","days":4},{"id":"cave","kind":"trial","name":"CAVE mCRC","route":"/trials/cave/","asOf":"2026-09-24","days":4},{"id":"swedish-rectal-cancer-trial","kind":"trial","name":"Swedish Rectal Cancer Trial","route":"/trials/swedish-rectal-cancer-trial/","asOf":"2026-09-24","days":4},{"id":"minnesota-fob","kind":"trial","name":"Minnesota Colon Cancer Control Study","route":"/trials/minnesota-fob/","asOf":"2026-09-24","days":4},{"id":"funen-fob","kind":"trial","name":"Funen faecal occult blood screening trial","route":"/trials/funen-fob/","asOf":"2026-09-24","days":4},{"id":"national-polyp-study","kind":"trial","name":"National Polyp Study","route":"/trials/national-polyp-study/","asOf":"2026-09-24","days":4},{"id":"netherlands-hipec","kind":"trial","name":"Netherlands Cancer Institute HIPEC trial","route":"/trials/netherlands-hipec/","asOf":"2026-09-24","days":4},{"id":"checkmate-142","kind":"trial","name":"CheckMate 142","route":"/trials/checkmate-142/","asOf":"2026-09-24","days":4},{"id":"co-17","kind":"trial","name":"NCIC CO.17","route":"/trials/co-17/","asOf":"2026-09-24","days":4},{"id":"petacc-3","kind":"trial","name":"PETACC-3","route":"/trials/petacc-3/","asOf":"2026-09-24","days":4},{"id":"triumph","kind":"trial","name":"TRIUMPH","route":"/trials/triumph/","asOf":"2026-09-24","days":4},{"id":"nct04776655","kind":"trial","name":"Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB","route":"/trials/nct04776655/","asOf":"2026-09-24","days":4},{"id":"nct04230187","kind":"trial","name":"Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer","route":"/trials/nct04230187/","asOf":"2026-09-24","days":4},{"id":"nct03635021","kind":"trial","name":"Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumu","route":"/trials/nct03635021/","asOf":"2026-09-24","days":4},{"id":"nct03869892","kind":"trial","name":"Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.","route":"/trials/nct03869892/","asOf":"2026-09-24","days":4},{"id":"nct03426904","kind":"trial","name":"Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer","route":"/trials/nct03426904/","asOf":"2026-09-24","days":4},{"id":"nct04137107","kind":"trial","name":"Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer","route":"/trials/nct04137107/","asOf":"2026-09-24","days":4},{"id":"nct02572141","kind":"trial","name":"FOLFOX or CAPOX Perioperative Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Colon Cancer (OPTICAL)","route":"/trials/nct02572141/","asOf":"2026-09-24","days":4},{"id":"nct02758951","kind":"trial","name":"Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases","route":"/trials/nct02758951/","asOf":"2026-09-24","days":4},{"id":"nct02813824","kind":"trial","name":"Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome","route":"/trials/nct02813824/","asOf":"2026-09-24","days":4},{"id":"nct02945033","kind":"trial","name":"Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk","route":"/trials/nct02945033/","asOf":"2026-09-24","days":4},{"id":"nct02997228","kind":"trial","name":"Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study","route":"/trials/nct02997228/","asOf":"2026-09-24","days":4},{"id":"nct02301286","kind":"trial","name":"A Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients","route":"/trials/nct02301286/","asOf":"2026-09-24","days":4},{"id":"nct03828227","kind":"trial","name":"QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters.","route":"/trials/nct03828227/","asOf":"2026-09-24","days":4},{"id":"nct04068103","kind":"trial","name":"Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery","route":"/trials/nct04068103/","asOf":"2026-09-24","days":4},{"id":"nct01460589","kind":"trial","name":"Early Commencement of Adjuvant Chemotherapy for Colon Cancer","route":"/trials/nct01460589/","asOf":"2026-09-24","days":4},{"id":"nct05710406","kind":"trial","name":"Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer","route":"/trials/nct05710406/","asOf":"2026-09-24","days":4},{"id":"nct04188145","kind":"trial","name":"A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Meta","route":"/trials/nct04188145/","asOf":"2026-09-24","days":4},{"id":"nct05171660","kind":"trial","name":"Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer","route":"/trials/nct05171660/","asOf":"2026-09-24","days":4},{"id":"nct03326791","kind":"trial","name":"Aspirin in Colorectal Cancer Liver Metastases","route":"/trials/nct03326791/","asOf":"2026-09-24","days":4},{"id":"nct03428477","kind":"trial","name":"EPA for Metastasis Trial 2","route":"/trials/nct03428477/","asOf":"2026-09-24","days":4},{"id":"nct04428905","kind":"trial","name":"Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer","route":"/trials/nct04428905/","asOf":"2026-09-24","days":4},{"id":"nct03464305","kind":"trial","name":"ASPIRIN Trial Belgium","route":"/trials/nct03464305/","asOf":"2026-09-24","days":4},{"id":"nct03413254","kind":"trial","name":"Second and Third Look Laparoscopy in pT4 Colon Cancer Patients for Early Detection of Peritoneal Metastases","route":"/trials/nct03413254/","asOf":"2026-09-24","days":4},{"id":"nct06709144","kind":"trial","name":"Borderline of CME/D3 Dissection for Local Advanced Right-sided Colon Cancer","route":"/trials/nct06709144/","asOf":"2026-09-24","days":4},{"id":"nct03803553","kind":"trial","name":"Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer","route":"/trials/nct03803553/","asOf":"2026-09-24","days":4},{"id":"nct01349881","kind":"trial","name":"S0820, Adenoma and Second Primary Prevention Trial","route":"/trials/nct01349881/","asOf":"2026-09-24","days":4},{"id":"nct07340567","kind":"trial","name":"Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test","route":"/trials/nct07340567/","asOf":"2026-09-24","days":4},{"id":"nct06936527","kind":"trial","name":"XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation","route":"/trials/nct06936527/","asOf":"2026-09-24","days":4},{"id":"nct07542262","kind":"trial","name":"Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR Cancers","route":"/trials/nct07542262/","asOf":"2026-09-24","days":4},{"id":"nct07620574","kind":"trial","name":"Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study","route":"/trials/nct07620574/","asOf":"2026-09-24","days":4},{"id":"nct05220800","kind":"trial","name":"Effects of Intravenous Administered Iron in Non-anemic Iron Deficient Patients With Colorectal Cancer","route":"/trials/nct05220800/","asOf":"2026-09-24","days":4},{"id":"nct02448173","kind":"trial","name":"A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer","route":"/trials/nct02448173/","asOf":"2026-09-24","days":4},{"id":"nct07649473","kind":"trial","name":"QL1706 Combined With Standard Therapy for Conversion Therapy of Synchronous Liver Metastases From Colon Cancer: a Multicenter, Single-arm, Exploratory Study","route":"/trials/nct07649473/","asOf":"2026-09-24","days":4},{"id":"nct06192680","kind":"trial","name":"Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer","route":"/trials/nct06192680/","asOf":"2026-09-24","days":4},{"id":"nct07585279","kind":"trial","name":"A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer","route":"/trials/nct07585279/","asOf":"2026-09-24","days":4},{"id":"nct07683403","kind":"trial","name":"Savolitinib Plus Cetuximab and FOLFOX Chemotherapy for RAS/BRAF Wild-type Metastatic Colorectal Cancer","route":"/trials/nct07683403/","asOf":"2026-09-24","days":4},{"id":"nct07467590","kind":"trial","name":"Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Study","route":"/trials/nct07467590/","asOf":"2026-09-24","days":4},{"id":"nct07405736","kind":"trial","name":"Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer","route":"/trials/nct07405736/","asOf":"2026-09-24","days":4},{"id":"nct07178717","kind":"trial","name":"A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy W","route":"/trials/nct07178717/","asOf":"2026-09-24","days":4},{"id":"nct07337551","kind":"trial","name":"Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive","route":"/trials/nct07337551/","asOf":"2026-09-24","days":4},{"id":"nct05231850","kind":"trial","name":"A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With Stage II and Stage III Colon Cancer and dMMR/MSI.","route":"/trials/nct05231850/","asOf":"2026-09-24","days":4},{"id":"nct05794750","kind":"trial","name":"Assess the Efficacy of Radiotherapy and Sequential Chemotherapy and AK104 Before TME Surgery for Local CRC（AK104-IIT-13）","route":"/trials/nct05794750/","asOf":"2026-09-24","days":4},{"id":"nct07156682","kind":"trial","name":"QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer","route":"/trials/nct07156682/","asOf":"2026-09-24","days":4},{"id":"nct07515820","kind":"trial","name":"SHR-3821 in Advanced Colorectal Cancer: an Exploratory Study","route":"/trials/nct07515820/","asOf":"2026-09-24","days":4},{"id":"nct07021950","kind":"trial","name":"AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer","route":"/trials/nct07021950/","asOf":"2026-09-24","days":4},{"id":"nct07823322","kind":"trial","name":"A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection a","route":"/trials/nct07823322/","asOf":"2026-09-24","days":4},{"id":"nct07025850","kind":"trial","name":"Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer","route":"/trials/nct07025850/","asOf":"2026-09-24","days":4},{"id":"nct05275374","kind":"trial","name":"XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation","route":"/trials/nct05275374/","asOf":"2026-09-24","days":4},{"id":"nct06899477","kind":"trial","name":"Pre-Operative Treatment in REseCTable COlon CanceR","route":"/trials/nct06899477/","asOf":"2026-09-24","days":4},{"id":"nct07025239","kind":"trial","name":"QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer","route":"/trials/nct07025239/","asOf":"2026-09-24","days":4},{"id":"nct06423937","kind":"trial","name":"Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer","route":"/trials/nct06423937/","asOf":"2026-09-24","days":4},{"id":"nct06959693","kind":"trial","name":"A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Col","route":"/trials/nct06959693/","asOf":"2026-09-24","days":4},{"id":"nct07134205","kind":"trial","name":"The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer","route":"/trials/nct07134205/","asOf":"2026-09-24","days":4},{"id":"nct07260058","kind":"trial","name":"Immune Cell Therapy for Advanced Solid Tumors","route":"/trials/nct07260058/","asOf":"2026-09-24","days":4},{"id":"nct07656766","kind":"trial","name":"Sintilimab Plus Gossypol Acetate in Advanced Colorectal Cancer","route":"/trials/nct07656766/","asOf":"2026-09-24","days":4},{"id":"nct07150403","kind":"trial","name":"Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal","route":"/trials/nct07150403/","asOf":"2026-09-24","days":4},{"id":"nct07134101","kind":"trial","name":"Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)","route":"/trials/nct07134101/","asOf":"2026-09-24","days":4},{"id":"nct06513221","kind":"trial","name":"A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab","route":"/trials/nct06513221/","asOf":"2026-09-24","days":4},{"id":"nct06446557","kind":"trial","name":"De-scalation or swItch of Treatment According to Circulating tuMOr DNA Variation After 2 Cycles of Doublet Chemotherapy Plus Targeted Agent in Metastatic Unrese","route":"/trials/nct06446557/","asOf":"2026-09-24","days":4},{"id":"nct07808151","kind":"trial","name":"Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer","route":"/trials/nct07808151/","asOf":"2026-09-24","days":4},{"id":"nct06343116","kind":"trial","name":"Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer","route":"/trials/nct06343116/","asOf":"2026-09-24","days":4},{"id":"nct07059338","kind":"trial","name":"Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer","route":"/trials/nct07059338/","asOf":"2026-09-24","days":4},{"id":"nct07549906","kind":"trial","name":"Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospecti","route":"/trials/nct07549906/","asOf":"2026-09-24","days":4},{"id":"nct07677579","kind":"trial","name":"NIMBLE-CRC: NeoImmunoModulation Before Leveraging Excision in Colorectal Rectal Cancer","route":"/trials/nct07677579/","asOf":"2026-09-24","days":4},{"id":"nct02497820","kind":"trial","name":"Finding the Best Dose of Aspirin to Prevent Lynch Syndrome Cancers","route":"/trials/nct02497820/","asOf":"2026-09-24","days":4},{"id":"nct07714447","kind":"trial","name":"Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer","route":"/trials/nct07714447/","asOf":"2026-09-24","days":4},{"id":"nct07359456","kind":"trial","name":"Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases","route":"/trials/nct07359456/","asOf":"2026-09-24","days":4},{"id":"nct07004413","kind":"trial","name":"Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients","route":"/trials/nct07004413/","asOf":"2026-09-24","days":4},{"id":"nct07807800","kind":"trial","name":"A Study of DES-1357 in People With Deficient Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer (mCRC)","route":"/trials/nct07807800/","asOf":"2026-09-24","days":4},{"id":"nct06391905","kind":"trial","name":"PCSK9 Inhibitors in Combination With Advanced Treatment Strategies for the Treatment of Advanced Colorectal Cancer With pMMR/MSS","route":"/trials/nct06391905/","asOf":"2026-09-24","days":4},{"id":"nct07268677","kind":"trial","name":"A Single-arm Clinical Study Evaluating Pirfenidone and Sintilimab in Combination With Standard Neoadjuvant Chemotherapy for Colorectal Cancer Patients With Peri","route":"/trials/nct07268677/","asOf":"2026-09-24","days":4},{"id":"nct07224022","kind":"trial","name":"Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer","route":"/trials/nct07224022/","asOf":"2026-09-24","days":4},{"id":"nct06652412","kind":"trial","name":"CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC","route":"/trials/nct06652412/","asOf":"2026-09-24","days":4},{"id":"nct07381309","kind":"trial","name":"Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM","route":"/trials/nct07381309/","asOf":"2026-09-24","days":4},{"id":"nct07535632","kind":"trial","name":"SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer","route":"/trials/nct07535632/","asOf":"2026-09-24","days":4},{"id":"nct05699746","kind":"trial","name":"CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD","route":"/trials/nct05699746/","asOf":"2026-09-24","days":4},{"id":"nct06092242","kind":"trial","name":"The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer","route":"/trials/nct06092242/","asOf":"2026-09-24","days":4},{"id":"nct07284394","kind":"trial","name":"Liver-directed Chemotherapy After Surgery of Liver Metastases of Colorectal Cancer in Patients With High Risk of Recurrence of Their Disease","route":"/trials/nct07284394/","asOf":"2026-09-24","days":4},{"id":"nct06400160","kind":"trial","name":"Clinical Trial of TB511 in Advanced Solid Tumors","route":"/trials/nct06400160/","asOf":"2026-09-24","days":4},{"id":"nct07391566","kind":"trial","name":"LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation","route":"/trials/nct07391566/","asOf":"2026-09-24","days":4},{"id":"nct07395063","kind":"trial","name":"A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.","route":"/trials/nct07395063/","asOf":"2026-09-24","days":4},{"id":"nct07595276","kind":"trial","name":"Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Stat","route":"/trials/nct07595276/","asOf":"2026-09-24","days":4},{"id":"nct07815834","kind":"trial","name":"FAPI-Guided Radiotherapy With Cadonilimab and Standard Chemotherapy for Colorectal Peritoneal Metastasis: A Phase III Randomized Controlled Trial (TORHC-PM02)","route":"/trials/nct07815834/","asOf":"2026-09-24","days":4},{"id":"nct07612007","kind":"trial","name":"HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization","route":"/trials/nct07612007/","asOf":"2026-09-24","days":4},{"id":"nct07515963","kind":"trial","name":"FULIRI Plus Targeted Therapy for First-line Conversion Therapy of Colorectal Cancer Liver Metastases.","route":"/trials/nct07515963/","asOf":"2026-09-24","days":4},{"id":"nct07691489","kind":"trial","name":"A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer","route":"/trials/nct07691489/","asOf":"2026-09-24","days":4},{"id":"nct07243938","kind":"trial","name":"Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)","route":"/trials/nct07243938/","asOf":"2026-09-24","days":4},{"id":"nct05776381","kind":"trial","name":"The Impact of a Patient Decision Aid on Treatment Choices for Patients With an Unexpected Malignant Colorectal Polyp","route":"/trials/nct05776381/","asOf":"2026-09-24","days":4},{"id":"nct07409844","kind":"trial","name":"Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer","route":"/trials/nct07409844/","asOf":"2026-09-24","days":4},{"id":"nct06099951","kind":"trial","name":"Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer: Anti-PD-1 Antibody With FOLFOXIRI and Preoperative Radiation Therapy","route":"/trials/nct06099951/","asOf":"2026-09-24","days":4},{"id":"nct07662031","kind":"trial","name":"Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer","route":"/trials/nct07662031/","asOf":"2026-09-24","days":4},{"id":"nct07071844","kind":"trial","name":"BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients","route":"/trials/nct07071844/","asOf":"2026-09-24","days":4},{"id":"nct07791758","kind":"trial","name":"A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma","route":"/trials/nct07791758/","asOf":"2026-09-24","days":4},{"id":"nct06845306","kind":"trial","name":"The Use of Indocyanine Green Near-infrared Fluorescence for Bowel Perfusion Quantitative Assessment in Order to Prevent Anastomotic Leakage in Colorectal Surger","route":"/trials/nct06845306/","asOf":"2026-09-24","days":4},{"id":"nct07622550","kind":"trial","name":"A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated A","route":"/trials/nct07622550/","asOf":"2026-09-24","days":4},{"id":"nct06255379","kind":"trial","name":"Study of Fruquintinib Combined With Tegafur Gimeracil Oteracil in Patients With Metastatic Colorectal Cancer","route":"/trials/nct06255379/","asOf":"2026-09-24","days":4},{"id":"nct07621497","kind":"trial","name":"FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)","route":"/trials/nct07621497/","asOf":"2026-09-24","days":4},{"id":"nct06835179","kind":"trial","name":"SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.","route":"/trials/nct06835179/","asOf":"2026-09-24","days":4},{"id":"nct06646445","kind":"trial","name":"Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study.","route":"/trials/nct06646445/","asOf":"2026-09-24","days":4},{"id":"nct07271355","kind":"trial","name":"Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases,","route":"/trials/nct07271355/","asOf":"2026-09-24","days":4},{"id":"nct07051785","kind":"trial","name":"Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer","route":"/trials/nct07051785/","asOf":"2026-09-24","days":4},{"id":"nct07551778","kind":"trial","name":"Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors","route":"/trials/nct07551778/","asOf":"2026-09-24","days":4},{"id":"nct06594692","kind":"trial","name":"Node-Sparing Short-Course Radiation With CAPOX and Sintilimab for MSS Locally Advanced Colon Cancer: A Randomized, Prospective, Multicenter Study","route":"/trials/nct06594692/","asOf":"2026-09-24","days":4},{"id":"nct06790212","kind":"trial","name":"Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer","route":"/trials/nct06790212/","asOf":"2026-09-24","days":4},{"id":"nct06839092","kind":"trial","name":"Prophylactic PIPAC in Patients With High-risk Colorectal Cancer","route":"/trials/nct06839092/","asOf":"2026-09-24","days":4},{"id":"nct07095309","kind":"trial","name":"Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/ III Colorectal Cancer","route":"/trials/nct07095309/","asOf":"2026-09-24","days":4},{"id":"nct06195670","kind":"trial","name":"Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC","route":"/trials/nct06195670/","asOf":"2026-09-24","days":4},{"id":"nct07007728","kind":"trial","name":"Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis","route":"/trials/nct07007728/","asOf":"2026-09-24","days":4},{"id":"nct07729605","kind":"trial","name":"FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC","route":"/trials/nct07729605/","asOf":"2026-09-24","days":4},{"id":"nct07435584","kind":"trial","name":"Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)","route":"/trials/nct07435584/","asOf":"2026-09-24","days":4},{"id":"nct06860685","kind":"trial","name":"Trial of Gum Chewing to Enhance the Restoration of Intestinal Motility in Colorectal Cancer Surgery","route":"/trials/nct06860685/","asOf":"2026-09-24","days":4},{"id":"nct07570914","kind":"trial","name":"Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases","route":"/trials/nct07570914/","asOf":"2026-09-24","days":4},{"id":"nct07132008","kind":"trial","name":"Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer","route":"/trials/nct07132008/","asOf":"2026-09-24","days":4},{"id":"nct06665087","kind":"trial","name":"CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC","route":"/trials/nct06665087/","asOf":"2026-09-24","days":4},{"id":"nct07730489","kind":"trial","name":"A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, F","route":"/trials/nct07730489/","asOf":"2026-09-24","days":4},{"id":"nct07124884","kind":"trial","name":"5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemother","route":"/trials/nct07124884/","asOf":"2026-09-24","days":4},{"id":"nct06301386","kind":"trial","name":"Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients","route":"/trials/nct06301386/","asOf":"2026-09-24","days":4},{"id":"nct06944548","kind":"trial","name":"Evaluation of the Effect of Adapted Physical Activity on the Modification of Lipid Metabolism During Chemotherapy for Metastatic COLorectal Cancer","route":"/trials/nct06944548/","asOf":"2026-09-24","days":4},{"id":"nct07123441","kind":"trial","name":"A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer","route":"/trials/nct07123441/","asOf":"2026-09-24","days":4},{"id":"nct07229872","kind":"trial","name":"A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer","route":"/trials/nct07229872/","asOf":"2026-09-24","days":4},{"id":"nct07261709","kind":"trial","name":"Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-","route":"/trials/nct07261709/","asOf":"2026-09-24","days":4},{"id":"nct07229846","kind":"trial","name":"A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatme","route":"/trials/nct07229846/","asOf":"2026-09-24","days":4},{"id":"nct07403877","kind":"trial","name":"Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer","route":"/trials/nct07403877/","asOf":"2026-09-24","days":4},{"id":"nct06258525","kind":"trial","name":"SAMe in Prevention of Oxaliplatin-associated Liver Injury","route":"/trials/nct06258525/","asOf":"2026-09-24","days":4},{"id":"nct07814417","kind":"trial","name":"A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation","route":"/trials/nct07814417/","asOf":"2026-09-24","days":4},{"id":"nct06681038","kind":"trial","name":"Systemic Antitumor Treatment with or Without Pressurized Intraperitoneal Aerosol Chemotherapy for Colon Peritoneal Metastases (PIPOX02)","route":"/trials/nct06681038/","asOf":"2026-09-24","days":4},{"id":"nct07286695","kind":"trial","name":"Fruquintinib Combined With Trifluridine/Tipiracil Versus Bevacizumab Combined With Trifluridine/Tipiracil for Advanced Metastatic Colorectal Cancer","route":"/trials/nct07286695/","asOf":"2026-09-24","days":4},{"id":"nct06746545","kind":"trial","name":"A Prospective, Open-label, Single-arm Phase II Clinical Study of Fruquintinib Combined With S-1 for the Treatment of Metastatic Colorectal Cancer.","route":"/trials/nct06746545/","asOf":"2026-09-24","days":4},{"id":"nct07591597","kind":"trial","name":"A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus F","route":"/trials/nct07591597/","asOf":"2026-09-24","days":4},{"id":"nct05427669","kind":"trial","name":"Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD)","route":"/trials/nct05427669/","asOf":"2026-09-24","days":4},{"id":"nct05747716","kind":"trial","name":"SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC","route":"/trials/nct05747716/","asOf":"2026-09-24","days":4},{"id":"nct07509398","kind":"trial","name":"FMT Combined With Standard First-Line Therapy in Initially Unresectable Colorectal Cancer","route":"/trials/nct07509398/","asOf":"2026-09-24","days":4},{"id":"nct07321847","kind":"trial","name":"Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases","route":"/trials/nct07321847/","asOf":"2026-09-24","days":4},{"id":"nct06218888","kind":"trial","name":"A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Micro","route":"/trials/nct06218888/","asOf":"2026-09-24","days":4},{"id":"nct06890624","kind":"trial","name":"mFOLFOXIRI Plus PD-1 Inhibitor vs mFOLFOX6 as Neoadjuvant Therapy for Locally Advanced Colon Cancer","route":"/trials/nct06890624/","asOf":"2026-09-24","days":4},{"id":"nct06047015","kind":"trial","name":"Irreversible Electroporation (NanoKnife ®) and Immunotherapy for the Treatment of Stage IV Colorectal Cancer","route":"/trials/nct06047015/","asOf":"2026-09-24","days":4},{"id":"nct06858969","kind":"trial","name":"Chidamide in Combination With PD-1 Inhibitor, Bevacizumab, and XELOX for Metastatic Colorectal Cancer","route":"/trials/nct06858969/","asOf":"2026-09-24","days":4},{"id":"nct06373133","kind":"trial","name":"SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer","route":"/trials/nct06373133/","asOf":"2026-09-24","days":4},{"id":"nct07358585","kind":"trial","name":"A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal Cancer","route":"/trials/nct07358585/","asOf":"2026-09-24","days":4},{"id":"nct07576725","kind":"trial","name":"Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial","route":"/trials/nct07576725/","asOf":"2026-09-24","days":4},{"id":"nct07353268","kind":"trial","name":"Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerabil","route":"/trials/nct07353268/","asOf":"2026-09-24","days":4},{"id":"nct07502014","kind":"trial","name":"A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line","route":"/trials/nct07502014/","asOf":"2026-09-24","days":4},{"id":"nct07198321","kind":"trial","name":"A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors","route":"/trials/nct07198321/","asOf":"2026-09-24","days":4},{"id":"nct07750041","kind":"trial","name":"A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer","route":"/trials/nct07750041/","asOf":"2026-09-24","days":4},{"id":"nct06616259","kind":"trial","name":"First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Contro","route":"/trials/nct06616259/","asOf":"2026-09-24","days":4},{"id":"nct05909423","kind":"trial","name":"Combining Intratumoral Flu Vaccine and Systemic Pembrolizumab in Patients With Early pMMR Colorectal Cancer","route":"/trials/nct05909423/","asOf":"2026-09-24","days":4},{"id":"nct07510932","kind":"trial","name":"Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients (FIRST-K)","route":"/trials/nct07510932/","asOf":"2026-09-24","days":4},{"id":"nct07362836","kind":"trial","name":"Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS)","route":"/trials/nct07362836/","asOf":"2026-09-24","days":4},{"id":"nct06999252","kind":"trial","name":"Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer Patients","route":"/trials/nct06999252/","asOf":"2026-09-24","days":4},{"id":"nct07333651","kind":"trial","name":"125I Seed Implantation Plus Systemic Therapy for Oligoprogressive NSCLC or Colorectal Cancer","route":"/trials/nct07333651/","asOf":"2026-09-24","days":4},{"id":"nct07009145","kind":"trial","name":"QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC","route":"/trials/nct07009145/","asOf":"2026-09-24","days":4},{"id":"nct07559760","kind":"trial","name":"New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer","route":"/trials/nct07559760/","asOf":"2026-09-24","days":4},{"id":"nct06130280","kind":"trial","name":"A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal","route":"/trials/nct06130280/","asOf":"2026-09-24","days":4},{"id":"nct06609551","kind":"trial","name":"ctDNA-guided Selection of Adjuvant Chemotherapy Regimens for Elderly Colon Cancer Patients After Surgery: A Single-center, Randomized, Controlled Study","route":"/trials/nct06609551/","asOf":"2026-09-24","days":4},{"id":"nct06293625","kind":"trial","name":"Personalising and Refining Neo-adjuvant Chemotherapy in Locally Advanced but Resecable Colon Cancer in the Elderly of 70 Years Old or More","route":"/trials/nct06293625/","asOf":"2026-09-24","days":4},{"id":"nct06979908","kind":"trial","name":"A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal C","route":"/trials/nct06979908/","asOf":"2026-09-24","days":4},{"id":"nct04120701","kind":"trial","name":"CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II","route":"/trials/nct04120701/","asOf":"2026-09-24","days":4},{"id":"nct06490536","kind":"trial","name":"The Sagittarius Trial","route":"/trials/nct06490536/","asOf":"2026-09-24","days":4},{"id":"nct05310643","kind":"trial","name":"Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC","route":"/trials/nct05310643/","asOf":"2026-09-24","days":4},{"id":"nct06509126","kind":"trial","name":"Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer","route":"/trials/nct06509126/","asOf":"2026-09-24","days":4},{"id":"nct06553885","kind":"trial","name":"Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC","route":"/trials/nct06553885/","asOf":"2026-09-24","days":4},{"id":"nct05672108","kind":"trial","name":"Phase II Trial of Lung Chemoemobolization","route":"/trials/nct05672108/","asOf":"2026-09-24","days":4},{"id":"nct06197425","kind":"trial","name":"Investigate the Efficacy of Chemotherapy in Patients With Positive ctDNA After Surgery and Adjuvant Chemotherapy for a Stage III Colorectal Cancer","route":"/trials/nct06197425/","asOf":"2026-09-24","days":4},{"id":"nct06530303","kind":"trial","name":"Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer","route":"/trials/nct06530303/","asOf":"2026-09-24","days":4},{"id":"nct05845450","kind":"trial","name":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","route":"/trials/nct05845450/","asOf":"2026-09-24","days":4},{"id":"nct05797467","kind":"trial","name":"Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients","route":"/trials/nct05797467/","asOf":"2026-09-24","days":4},{"id":"nct06356714","kind":"trial","name":"Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens for the Treatment of Potentially Hazardous Colorectal Cancer SD Statu","route":"/trials/nct06356714/","asOf":"2026-09-24","days":4},{"id":"nct06566755","kind":"trial","name":"Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer","route":"/trials/nct06566755/","asOf":"2026-09-24","days":4},{"id":"nct06176885","kind":"trial","name":"Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite","route":"/trials/nct06176885/","asOf":"2026-09-24","days":4},{"id":"nct04235114","kind":"trial","name":"Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET)","route":"/trials/nct04235114/","asOf":"2026-09-24","days":4},{"id":"nct07405476","kind":"trial","name":"Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment","route":"/trials/nct07405476/","asOf":"2026-09-24","days":4},{"id":"nct05168839","kind":"trial","name":"Intraoperative Indocyanine Green Fluorescence Angiography in Colorectal Surgery to Prevent Anastomotic Leakage","route":"/trials/nct05168839/","asOf":"2026-09-24","days":4},{"id":"nct06242067","kind":"trial","name":"Second-line Treatment of Metastatic Colorectal Cancer","route":"/trials/nct06242067/","asOf":"2026-09-24","days":4},{"id":"nct06936774","kind":"trial","name":"Improving Functional Outcomes and Quality of Life in Patients With Rectal Cancer After Surgery With Intensified Follow-up & Surveillance","route":"/trials/nct06936774/","asOf":"2026-09-24","days":4},{"id":"nct06528990","kind":"trial","name":"Telehealth Intervention for Ostomy Self-Management","route":"/trials/nct06528990/","asOf":"2026-09-24","days":4},{"id":"nct07003022","kind":"trial","name":"Phase II Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC","route":"/trials/nct07003022/","asOf":"2026-09-24","days":4},{"id":"nct06207656","kind":"trial","name":"Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initial","route":"/trials/nct06207656/","asOf":"2026-09-24","days":4},{"id":"nct06776757","kind":"trial","name":"Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer","route":"/trials/nct06776757/","asOf":"2026-09-24","days":4},{"id":"nct06557733","kind":"trial","name":"An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis","route":"/trials/nct06557733/","asOf":"2026-09-24","days":4},{"id":"nct06856837","kind":"trial","name":"- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorec","route":"/trials/nct06856837/","asOf":"2026-09-24","days":4},{"id":"nct06185556","kind":"trial","name":"COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases","route":"/trials/nct06185556/","asOf":"2026-09-24","days":4},{"id":"nct07562503","kind":"trial","name":"Randomized Trial of Plasma ctDNA Methylation-Guided Adjuvant Therapy in T4N0 and Low-Risk Stage III Colorectal Cancer","route":"/trials/nct07562503/","asOf":"2026-09-24","days":4},{"id":"nct07537998","kind":"trial","name":"Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a Single-Center, Prospective Randomized Co","route":"/trials/nct07537998/","asOf":"2026-09-24","days":4},{"id":"nct06791512","kind":"trial","name":"mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC","route":"/trials/nct06791512/","asOf":"2026-09-24","days":4},{"id":"nct06763029","kind":"trial","name":"Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer","route":"/trials/nct06763029/","asOf":"2026-09-24","days":4},{"id":"nct05727163","kind":"trial","name":"FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutat","route":"/trials/nct05727163/","asOf":"2026-09-24","days":4},{"id":"nct05534087","kind":"trial","name":"Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)","route":"/trials/nct05534087/","asOf":"2026-09-24","days":4},{"id":"nct06265285","kind":"trial","name":"Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW)","route":"/trials/nct06265285/","asOf":"2026-09-24","days":4},{"id":"nct05286814","kind":"trial","name":"PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarc","route":"/trials/nct05286814/","asOf":"2026-09-24","days":4},{"id":"nct06270017","kind":"trial","name":"Evaluation of Metastatic Disease and Oncological Treatment in Patients With Colon Cancer Using Zebra Fish Avatars","route":"/trials/nct06270017/","asOf":"2026-09-24","days":4},{"id":"nct07147231","kind":"trial","name":"Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refracto","route":"/trials/nct07147231/","asOf":"2026-09-24","days":4},{"id":"nct06226857","kind":"trial","name":"Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer","route":"/trials/nct06226857/","asOf":"2026-09-24","days":4},{"id":"nct05646511","kind":"trial","name":"TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer","route":"/trials/nct05646511/","asOf":"2026-09-24","days":4},{"id":"nct07789210","kind":"trial","name":"A Single-Arm, Phase II, Multicenter Clinical Study of Neoadjuvant Encorafenib Plus Cetuximab N01 and mFOLFOX6 in Patients With Locally Advanced BRAF V600E-Mutan","route":"/trials/nct07789210/","asOf":"2026-09-24","days":4},{"id":"nct06794086","kind":"trial","name":"SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases","route":"/trials/nct06794086/","asOf":"2026-09-24","days":4},{"id":"nct05954429","kind":"trial","name":"A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-cente","route":"/trials/nct05954429/","asOf":"2026-09-24","days":4},{"id":"nct06275958","kind":"trial","name":"DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer","route":"/trials/nct06275958/","asOf":"2026-09-24","days":4},{"id":"nct05775146","kind":"trial","name":"SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases","route":"/trials/nct05775146/","asOf":"2026-09-24","days":4},{"id":"nct06280495","kind":"trial","name":"Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients","route":"/trials/nct06280495/","asOf":"2026-09-24","days":4},{"id":"nct06698757","kind":"trial","name":"Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instability-high, Locally Advanced Colorectal Cancer","route":"/trials/nct06698757/","asOf":"2026-09-24","days":4},{"id":"nct07407465","kind":"trial","name":"Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.","route":"/trials/nct07407465/","asOf":"2026-09-24","days":4},{"id":"nct06441565","kind":"trial","name":"Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer","route":"/trials/nct06441565/","asOf":"2026-09-24","days":4},{"id":"nct07468630","kind":"trial","name":"Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma","route":"/trials/nct07468630/","asOf":"2026-09-24","days":4},{"id":"nct07736495","kind":"trial","name":"Protective Role of Alpha-Lipoic Acid in Chemotherapy-Induced Mucositis","route":"/trials/nct07736495/","asOf":"2026-09-24","days":4},{"id":"nct07463599","kind":"trial","name":"Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma","route":"/trials/nct07463599/","asOf":"2026-09-24","days":4},{"id":"nct03401294","kind":"trial","name":"Conversion From Unresectable To Resectable Metastatic Colorectal Cancer.","route":"/trials/nct03401294/","asOf":"2026-09-24","days":4},{"id":"nct07192068","kind":"trial","name":"Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.","route":"/trials/nct07192068/","asOf":"2026-09-24","days":4},{"id":"nct07411599","kind":"trial","name":"Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Rela","route":"/trials/nct07411599/","asOf":"2026-09-24","days":4},{"id":"nct06184698","kind":"trial","name":"Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer","route":"/trials/nct06184698/","asOf":"2026-09-24","days":4},{"id":"nct03874026","kind":"trial","name":"Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients","route":"/trials/nct03874026/","asOf":"2026-09-24","days":4},{"id":"nct02185443","kind":"trial","name":"Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases","route":"/trials/nct02185443/","asOf":"2026-09-24","days":4},{"id":"nct06733038","kind":"trial","name":"FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.","route":"/trials/nct06733038/","asOf":"2026-09-24","days":4},{"id":"nct06638502","kind":"trial","name":"Safety of HRX215 in Patients After Minor and Major Liver Resection","route":"/trials/nct06638502/","asOf":"2026-09-24","days":4},{"id":"nct07018869","kind":"trial","name":"Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors","route":"/trials/nct07018869/","asOf":"2026-09-24","days":4},{"id":"nct06522919","kind":"trial","name":"Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mi","route":"/trials/nct06522919/","asOf":"2026-09-24","days":4},{"id":"nct01174121","kind":"trial","name":"Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer","route":"/trials/nct01174121/","asOf":"2026-09-24","days":4},{"id":"nct06119867","kind":"trial","name":"CompariSon Between the EuroPeAn and Japanese pathologiCal InvEstigation for Colon Cancer (SPACE)","route":"/trials/nct06119867/","asOf":"2026-09-24","days":4},{"id":"nct06547203","kind":"trial","name":"Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study","route":"/trials/nct06547203/","asOf":"2026-09-24","days":4},{"id":"nct06245356","kind":"trial","name":"Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer","route":"/trials/nct06245356/","asOf":"2026-09-24","days":4},{"id":"nct06411600","kind":"trial","name":"Combination Therapy for BRAF-V600E Metastatic CRCm","route":"/trials/nct06411600/","asOf":"2026-09-24","days":4},{"id":"nct06907342","kind":"trial","name":"Testing a Functional Precision Medicine Approach to Select Chemotherapy for Metastatic Colorectal Cancer (COSENSE-1)","route":"/trials/nct06907342/","asOf":"2026-09-24","days":4},{"id":"nct07085169","kind":"trial","name":"Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC","route":"/trials/nct07085169/","asOf":"2026-09-24","days":4},{"id":"nct07277322","kind":"trial","name":"Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases","route":"/trials/nct07277322/","asOf":"2026-09-24","days":4},{"id":"nct06778382","kind":"trial","name":"Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer.","route":"/trials/nct06778382/","asOf":"2026-09-24","days":4},{"id":"nct06949982","kind":"trial","name":"Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Co","route":"/trials/nct06949982/","asOf":"2026-09-24","days":4},{"id":"nct07644286","kind":"trial","name":"A Phase II Study of Pirfenidone Plus PD-1 Inhibitor With or Without Hypofractionated Radiotherapy for Refractory pMMR/MSS Colorectal Cancer","route":"/trials/nct07644286/","asOf":"2026-09-24","days":4},{"id":"nct06728072","kind":"trial","name":"Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer","route":"/trials/nct06728072/","asOf":"2026-09-24","days":4},{"id":"nct07562711","kind":"trial","name":"Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer","route":"/trials/nct07562711/","asOf":"2026-09-24","days":4},{"id":"nct07389265","kind":"trial","name":"Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer","route":"/trials/nct07389265/","asOf":"2026-09-24","days":4},{"id":"nct06830239","kind":"trial","name":"Phase II Study of Neoadjuvant Dostarlimab in Patients With Untreated T3-4N0-2 or Stage III pMMR/MSS Resectable Colon Cancer","route":"/trials/nct06830239/","asOf":"2026-09-24","days":4},{"id":"nct00722228","kind":"trial","name":"Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors","route":"/trials/nct00722228/","asOf":"2026-09-24","days":4},{"id":"nct06980532","kind":"trial","name":"Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer","route":"/trials/nct06980532/","asOf":"2026-09-24","days":4},{"id":"nct07693751","kind":"trial","name":"A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer","route":"/trials/nct07693751/","asOf":"2026-09-24","days":4},{"id":"nct07562659","kind":"trial","name":"Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer","route":"/trials/nct07562659/","asOf":"2026-09-24","days":4},{"id":"nct06341296","kind":"trial","name":"Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer","route":"/trials/nct06341296/","asOf":"2026-09-24","days":4},{"id":"nct05815082","kind":"trial","name":"ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer","route":"/trials/nct05815082/","asOf":"2026-09-24","days":4},{"id":"nct07595874","kind":"trial","name":"Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3","route":"/trials/nct07595874/","asOf":"2026-09-24","days":4},{"id":"nct05462613","kind":"trial","name":"Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer","route":"/trials/nct05462613/","asOf":"2026-09-24","days":4},{"id":"nct05692024","kind":"trial","name":"COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER","route":"/trials/nct05692024/","asOf":"2026-09-24","days":4},{"id":"nct07253896","kind":"trial","name":"Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab","route":"/trials/nct07253896/","asOf":"2026-09-24","days":4},{"id":"nct06134388","kind":"trial","name":"Sulfasalazine in Patients With Metastatic Colorectal Cancer","route":"/trials/nct06134388/","asOf":"2026-09-24","days":4},{"id":"nct05008809","kind":"trial","name":"Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)","route":"/trials/nct05008809/","asOf":"2026-09-24","days":4},{"id":"nct05768178","kind":"trial","name":"DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.","route":"/trials/nct05768178/","asOf":"2026-09-24","days":4},{"id":"nct06709885","kind":"trial","name":"HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer","route":"/trials/nct06709885/","asOf":"2026-09-24","days":4},{"id":"nct06168786","kind":"trial","name":"Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC","route":"/trials/nct06168786/","asOf":"2026-09-24","days":4},{"id":"nct05868226","kind":"trial","name":"PRE-ISPY Phase I/II Oncology Platform Program","route":"/trials/nct05868226/","asOf":"2026-09-24","days":4},{"id":"nct06243393","kind":"trial","name":"Sacituzumab Govitecan in Metastatic Colorectal Cancer","route":"/trials/nct06243393/","asOf":"2026-09-24","days":4},{"id":"nct07506109","kind":"trial","name":"A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colo","route":"/trials/nct07506109/","asOf":"2026-09-24","days":4},{"id":"nct06643793","kind":"trial","name":"Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC","route":"/trials/nct06643793/","asOf":"2026-09-24","days":4},{"id":"nct06349590","kind":"trial","name":"Manipulation of the Gut Microbiome by a Standardized Preoperative Diet to Prevent Colorectal Cancer Recurrence and Metastasis Following Surgery","route":"/trials/nct06349590/","asOf":"2026-09-24","days":4},{"id":"nct07432399","kind":"trial","name":"Effect of Perioperative Lidocaine or High-Dose Dexamethasone on Immune Response in Colon Cancer Surgery (PILDI Study)","route":"/trials/nct07432399/","asOf":"2026-09-24","days":4},{"id":"nct07281768","kind":"trial","name":"Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer","route":"/trials/nct07281768/","asOf":"2026-09-24","days":4},{"id":"nct05806931","kind":"trial","name":"Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer","route":"/trials/nct05806931/","asOf":"2026-09-24","days":4},{"id":"nct06617858","kind":"trial","name":"Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment","route":"/trials/nct06617858/","asOf":"2026-09-24","days":4},{"id":"nct05007132","kind":"trial","name":"Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer","route":"/trials/nct05007132/","asOf":"2026-09-24","days":4},{"id":"nct07230639","kind":"trial","name":"Node-Sparing Hypofractionated Radiotherapy Plus Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A Prospective, Randomized,","route":"/trials/nct07230639/","asOf":"2026-09-24","days":4},{"id":"nct03303495","kind":"trial","name":"A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC","route":"/trials/nct03303495/","asOf":"2026-09-24","days":4},{"id":"nct05748145","kind":"trial","name":"Metronidazole as Preoperative Therapy in CRC / FusoMetro-001","route":"/trials/nct05748145/","asOf":"2026-09-24","days":4},{"id":"nct07604909","kind":"trial","name":"A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy","route":"/trials/nct07604909/","asOf":"2026-09-24","days":4},{"id":"nct06856187","kind":"trial","name":"Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer","route":"/trials/nct06856187/","asOf":"2026-09-24","days":4},{"id":"nct06887218","kind":"trial","name":"5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer","route":"/trials/nct06887218/","asOf":"2026-09-24","days":4},{"id":"nct05462236","kind":"trial","name":"MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer","route":"/trials/nct05462236/","asOf":"2026-09-24","days":4},{"id":"nct06680739","kind":"trial","name":"Single cEll pRofiling PErsistaNce To ImmuNothErapy","route":"/trials/nct06680739/","asOf":"2026-09-24","days":4},{"id":"nct06714357","kind":"trial","name":"ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer","route":"/trials/nct06714357/","asOf":"2026-09-24","days":4},{"id":"nct04516681","kind":"trial","name":"Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer","route":"/trials/nct04516681/","asOf":"2026-09-24","days":4},{"id":"nct03957902","kind":"trial","name":"Assessment of Direct Biomarkers of Aspirin Action to Develop a Precision Chemoprevention Therapy of Colorectal Cancer","route":"/trials/nct03957902/","asOf":"2026-09-24","days":4},{"id":"nct06758830","kind":"trial","name":"Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.","route":"/trials/nct06758830/","asOf":"2026-09-24","days":4},{"id":"nct05797077","kind":"trial","name":"Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA","route":"/trials/nct05797077/","asOf":"2026-09-24","days":4},{"id":"nct06425133","kind":"trial","name":"Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers","route":"/trials/nct06425133/","asOf":"2026-09-24","days":4},{"id":"nct06321081","kind":"trial","name":"ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC","route":"/trials/nct06321081/","asOf":"2026-09-24","days":4},{"id":"nct04689347","kind":"trial","name":"5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.","route":"/trials/nct04689347/","asOf":"2026-09-24","days":4},{"id":"nct06949111","kind":"trial","name":"Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）","route":"/trials/nct06949111/","asOf":"2026-09-24","days":4},{"id":"nct06307548","kind":"trial","name":"Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurre","route":"/trials/nct06307548/","asOf":"2026-09-24","days":4},{"id":"nct03925662","kind":"trial","name":"Mebendazole as Adjuvant Treatment for Colon Cancer","route":"/trials/nct03925662/","asOf":"2026-09-24","days":4},{"id":"nct02885753","kind":"trial","name":"Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal C","route":"/trials/nct02885753/","asOf":"2026-09-24","days":4},{"id":"nct05870800","kind":"trial","name":"Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER","route":"/trials/nct05870800/","asOf":"2026-09-24","days":4},{"id":"nct07060443","kind":"trial","name":"Fluorescence Lymph Node Mapping for Colon Cancer Surgery","route":"/trials/nct07060443/","asOf":"2026-09-24","days":4},{"id":"nct07047560","kind":"trial","name":"Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Si","route":"/trials/nct07047560/","asOf":"2026-09-24","days":4},{"id":"nct05343013","kind":"trial","name":"TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy","route":"/trials/nct05343013/","asOf":"2026-09-24","days":4},{"id":"nct05914389","kind":"trial","name":"Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer","route":"/trials/nct05914389/","asOf":"2026-09-24","days":4},{"id":"nct03965234","kind":"trial","name":"Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases","route":"/trials/nct03965234/","asOf":"2026-09-24","days":4},{"id":"nct06475352","kind":"trial","name":"Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme","route":"/trials/nct06475352/","asOf":"2026-09-24","days":4},{"id":"nct06978400","kind":"trial","name":"A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer","route":"/trials/nct06978400/","asOf":"2026-09-24","days":4},{"id":"nct03919461","kind":"trial","name":"Colorectal Metastasis Prevention International Trial 2","route":"/trials/nct03919461/","asOf":"2026-09-24","days":4},{"id":"nct04687631","kind":"trial","name":"Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases","route":"/trials/nct04687631/","asOf":"2026-09-24","days":4},{"id":"nct07722754","kind":"trial","name":"Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial","route":"/trials/nct07722754/","asOf":"2026-09-24","days":4},{"id":"nct05854498","kind":"trial","name":"Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer","route":"/trials/nct05854498/","asOf":"2026-09-24","days":4},{"id":"nct06205836","kind":"trial","name":"Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer","route":"/trials/nct06205836/","asOf":"2026-09-24","days":4},{"id":"nct05086614","kind":"trial","name":"Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer","route":"/trials/nct05086614/","asOf":"2026-09-24","days":4},{"id":"nct05239546","kind":"trial","name":"Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers","route":"/trials/nct05239546/","asOf":"2026-09-24","days":4},{"id":"nct07724223","kind":"trial","name":"Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC","route":"/trials/nct07724223/","asOf":"2026-09-24","days":4},{"id":"nct06356584","kind":"trial","name":"Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases","route":"/trials/nct06356584/","asOf":"2026-09-24","days":4},{"id":"nct07106034","kind":"trial","name":"Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial","route":"/trials/nct07106034/","asOf":"2026-09-24","days":4},{"id":"nct06888843","kind":"trial","name":"Study to Evaluate the Use of Capecitabine in Monotherapy and in Combination With Oxaliplatin in Elderly Patients as Adjuvant Chemotherapy for Locally Advanced C","route":"/trials/nct06888843/","asOf":"2026-09-24","days":4},{"id":"nct07653685","kind":"trial","name":"A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advan","route":"/trials/nct07653685/","asOf":"2026-09-24","days":4},{"id":"nct07447050","kind":"trial","name":"Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial","route":"/trials/nct07447050/","asOf":"2026-09-24","days":4},{"id":"nct06580574","kind":"trial","name":"Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers","route":"/trials/nct06580574/","asOf":"2026-09-24","days":4},{"id":"nct06923787","kind":"trial","name":"Effect of Perioperative Intravenous Infusion of Lidocaine on the Postoperative Course and the Immune Response in Patients Undergoing Surgery for Colon Cancer -","route":"/trials/nct06923787/","asOf":"2026-09-24","days":4},{"id":"nct07071961","kind":"trial","name":"Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Di","route":"/trials/nct07071961/","asOf":"2026-09-24","days":4},{"id":"nct06850103","kind":"trial","name":"SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases","route":"/trials/nct06850103/","asOf":"2026-09-24","days":4},{"id":"nct07503756","kind":"trial","name":"JS212 Combination Therapies in Metastatic Colorectal Cancer","route":"/trials/nct07503756/","asOf":"2026-09-24","days":4},{"id":"nct06202001","kind":"trial","name":"Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients","route":"/trials/nct06202001/","asOf":"2026-09-24","days":4},{"id":"nct07371273","kind":"trial","name":"Comparative Study on the Short- and Long-term Efficacy of Q-ISR, Traditional Sub-ISR, and t-ISR","route":"/trials/nct07371273/","asOf":"2026-09-24","days":4},{"id":"nct06558773","kind":"trial","name":"GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.","route":"/trials/nct06558773/","asOf":"2026-09-24","days":4},{"id":"nct07272772","kind":"trial","name":"Colon Cancer Diagnosis With FAPI-PET Imaging","route":"/trials/nct07272772/","asOf":"2026-09-24","days":4},{"id":"nct06563986","kind":"trial","name":"FTD-TPI, Bevacizumab, and Radioembolization With 166Ho-microspheres in Refractory Metastatic Colorectal Cancer","route":"/trials/nct06563986/","asOf":"2026-09-24","days":4},{"id":"nct05673148","kind":"trial","name":"Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial","route":"/trials/nct05673148/","asOf":"2026-09-24","days":4},{"id":"nct05742425","kind":"trial","name":"Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases","route":"/trials/nct05742425/","asOf":"2026-09-24","days":4},{"id":"nct07011576","kind":"trial","name":"A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)","route":"/trials/nct07011576/","asOf":"2026-09-24","days":4},{"id":"nct06520683","kind":"trial","name":"Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer","route":"/trials/nct06520683/","asOf":"2026-09-24","days":4},{"id":"nct06529523","kind":"trial","name":"Tislelizumab in People With Colorectal Cancer","route":"/trials/nct06529523/","asOf":"2026-09-24","days":4},{"id":"nct07478731","kind":"trial","name":"Neoadjuvant SHR-1701 Plus Chemoradiotherapy for Locally Advanced Rectal Cancer","route":"/trials/nct07478731/","asOf":"2026-09-24","days":4},{"id":"nct07365592","kind":"trial","name":"Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC","route":"/trials/nct07365592/","asOf":"2026-09-24","days":4},{"id":"nct05985109","kind":"trial","name":"KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer","route":"/trials/nct05985109/","asOf":"2026-09-24","days":4},{"id":"nct07213570","kind":"trial","name":"STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer","route":"/trials/nct07213570/","asOf":"2026-09-24","days":4},{"id":"nct07381764","kind":"trial","name":"ROMANCE: \"Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer\"","route":"/trials/nct07381764/","asOf":"2026-09-24","days":4},{"id":"nct05194878","kind":"trial","name":"Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers","route":"/trials/nct05194878/","asOf":"2026-09-24","days":4},{"id":"nct05954078","kind":"trial","name":"Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer","route":"/trials/nct05954078/","asOf":"2026-09-24","days":4},{"id":"nct07042685","kind":"trial","name":"Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer","route":"/trials/nct07042685/","asOf":"2026-09-24","days":4},{"id":"nct05706779","kind":"trial","name":"Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer","route":"/trials/nct05706779/","asOf":"2026-09-24","days":4},{"id":"nct07809893","kind":"trial","name":"Ivosidenib Plus mFOLFOXIRI and Celecoxib for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer Patients","route":"/trials/nct07809893/","asOf":"2026-09-24","days":4},{"id":"nct06405139","kind":"trial","name":"Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal Cancer","route":"/trials/nct06405139/","asOf":"2026-09-24","days":4},{"id":"nct06218810","kind":"trial","name":"Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal","route":"/trials/nct06218810/","asOf":"2026-09-24","days":4},{"id":"nct06385418","kind":"trial","name":"Fluorouracil Treatment Via Colon for Colorectal Cancer","route":"/trials/nct06385418/","asOf":"2026-09-24","days":4},{"id":"nct06959550","kind":"trial","name":"Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer","route":"/trials/nct06959550/","asOf":"2026-09-24","days":4},{"id":"nct06149481","kind":"trial","name":"Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Can","route":"/trials/nct06149481/","asOf":"2026-09-24","days":4},{"id":"nct07728019","kind":"trial","name":"Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM","route":"/trials/nct07728019/","asOf":"2026-09-24","days":4},{"id":"nct06208371","kind":"trial","name":"Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM","route":"/trials/nct06208371/","asOf":"2026-09-24","days":4},{"id":"nct06107920","kind":"trial","name":"Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy","route":"/trials/nct06107920/","asOf":"2026-09-24","days":4},{"id":"nct07750158","kind":"trial","name":"Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease","route":"/trials/nct07750158/","asOf":"2026-09-24","days":4},{"id":"nct04861558","kind":"trial","name":"Efficacy of Hyperthermic Intraperitoneal Chemotherapy","route":"/trials/nct04861558/","asOf":"2026-09-24","days":4},{"id":"nct06002789","kind":"trial","name":"Safety and Efficacy of PD-1 ± mFOLFOX6 Neoadjuvant Therapy in Local Advanced sMPCC","route":"/trials/nct06002789/","asOf":"2026-09-24","days":4},{"id":"nct07140679","kind":"trial","name":"Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer","route":"/trials/nct07140679/","asOf":"2026-09-24","days":4},{"id":"nct03539822","kind":"trial","name":"Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies","route":"/trials/nct03539822/","asOf":"2026-09-24","days":4},{"id":"nct05411718","kind":"trial","name":"A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome","route":"/trials/nct05411718/","asOf":"2026-09-24","days":4},{"id":"nct05691491","kind":"trial","name":"Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness","route":"/trials/nct05691491/","asOf":"2026-09-24","days":4},{"id":"nct03280511","kind":"trial","name":"Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients","route":"/trials/nct03280511/","asOf":"2026-09-24","days":4},{"id":"nct06992648","kind":"trial","name":"Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer","route":"/trials/nct06992648/","asOf":"2026-09-24","days":4},{"id":"nct06300463","kind":"trial","name":"Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases","route":"/trials/nct06300463/","asOf":"2026-09-24","days":4},{"id":"nct05236972","kind":"trial","name":"PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer","route":"/trials/nct05236972/","asOf":"2026-09-24","days":4},{"id":"nct07398326","kind":"trial","name":"Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer","route":"/trials/nct07398326/","asOf":"2026-09-24","days":4},{"id":"nct05768503","kind":"trial","name":"Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC","route":"/trials/nct05768503/","asOf":"2026-09-24","days":4},{"id":"nct06857773","kind":"trial","name":"Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy With Systemic Therapy","route":"/trials/nct06857773/","asOf":"2026-09-24","days":4},{"id":"nct07279077","kind":"trial","name":"Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A Prospective, Single-Ar","route":"/trials/nct07279077/","asOf":"2026-09-24","days":4},{"id":"nct04912765","kind":"trial","name":"Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC","route":"/trials/nct04912765/","asOf":"2026-09-24","days":4},{"id":"nct03926338","kind":"trial","name":"Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer","route":"/trials/nct03926338/","asOf":"2026-09-24","days":4},{"id":"nct04680260","kind":"trial","name":"OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer","route":"/trials/nct04680260/","asOf":"2026-09-24","days":4},{"id":"nct07562490","kind":"trial","name":"A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer","route":"/trials/nct07562490/","asOf":"2026-09-24","days":4},{"id":"nct05861505","kind":"trial","name":"COLLISION RELAPSE Trial","route":"/trials/nct05861505/","asOf":"2026-09-24","days":4},{"id":"nct04920149","kind":"trial","name":"Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome","route":"/trials/nct04920149/","asOf":"2026-09-24","days":4},{"id":"nct05571644","kind":"trial","name":"Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer","route":"/trials/nct05571644/","asOf":"2026-09-24","days":4},{"id":"nct07058012","kind":"trial","name":"A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal","route":"/trials/nct07058012/","asOf":"2026-09-24","days":4},{"id":"nct04771520","kind":"trial","name":"Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors","route":"/trials/nct04771520/","asOf":"2026-09-24","days":4},{"id":"nct06603376","kind":"trial","name":"Irinotecan Hydrochloride Liposome Injection (II) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated","route":"/trials/nct06603376/","asOf":"2026-09-24","days":4},{"id":"nct06783491","kind":"trial","name":"Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer","route":"/trials/nct06783491/","asOf":"2026-09-24","days":4},{"id":"nct03516708","kind":"trial","name":"Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer","route":"/trials/nct03516708/","asOf":"2026-09-24","days":4},{"id":"nct06846268","kind":"trial","name":"Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer","route":"/trials/nct06846268/","asOf":"2026-09-24","days":4},{"id":"nct07309289","kind":"trial","name":"NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer","route":"/trials/nct07309289/","asOf":"2026-09-24","days":4},{"id":"nct02215889","kind":"trial","name":"Partial Liver Segment 2/3 Transplantation Study","route":"/trials/nct02215889/","asOf":"2026-09-24","days":4},{"id":"nct06722183","kind":"trial","name":"Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities","route":"/trials/nct06722183/","asOf":"2026-09-24","days":4},{"id":"nct07281716","kind":"trial","name":"Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC","route":"/trials/nct07281716/","asOf":"2026-09-24","days":4},{"id":"nct07154316","kind":"trial","name":"Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer","route":"/trials/nct07154316/","asOf":"2026-09-24","days":4},{"id":"nct06293014","kind":"trial","name":"TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer","route":"/trials/nct06293014/","asOf":"2026-09-24","days":4},{"id":"nct05179889","kind":"trial","name":"Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer","route":"/trials/nct05179889/","asOf":"2026-09-24","days":4},{"id":"nct06991465","kind":"trial","name":"Organ Preservation in Rectal AdenoCa Using Hypofractionated Pelvic RT(Hypo-OPRA)","route":"/trials/nct06991465/","asOf":"2026-09-24","days":4},{"id":"nct05962502","kind":"trial","name":"Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy","route":"/trials/nct05962502/","asOf":"2026-09-24","days":4},{"id":"nct05771181","kind":"trial","name":"Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients","route":"/trials/nct05771181/","asOf":"2026-09-24","days":4},{"id":"nct03125980","kind":"trial","name":"Perioperative Versus Postoperative CapOX Chemotherapy for Locally Advanced Colon Cancer","route":"/trials/nct03125980/","asOf":"2026-09-24","days":4},{"id":"nct07550088","kind":"trial","name":"BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases","route":"/trials/nct07550088/","asOf":"2026-09-24","days":4},{"id":"nct07448142","kind":"trial","name":"Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer","route":"/trials/nct07448142/","asOf":"2026-09-24","days":4},{"id":"nct05770102","kind":"trial","name":"DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Mi","route":"/trials/nct05770102/","asOf":"2026-09-24","days":4},{"id":"nct06368141","kind":"trial","name":"Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer","route":"/trials/nct06368141/","asOf":"2026-09-24","days":4},{"id":"nct07764497","kind":"trial","name":"Hepatic Arterial Infusion Chemotherapy in Patients With Inoperable Colorectal Cancer Liver Metastasis","route":"/trials/nct07764497/","asOf":"2026-09-24","days":4},{"id":"nct05786924","kind":"trial","name":"Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies","route":"/trials/nct05786924/","asOf":"2026-09-24","days":4},{"id":"nct04899908","kind":"trial","name":"Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases","route":"/trials/nct04899908/","asOf":"2026-09-24","days":4},{"id":"nct06242418","kind":"trial","name":"CtDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial)","route":"/trials/nct06242418/","asOf":"2026-09-24","days":4},{"id":"nct06412198","kind":"trial","name":"A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations","route":"/trials/nct06412198/","asOf":"2026-09-24","days":4},{"id":"nct04087421","kind":"trial","name":"Comparison of Transanal Irrigation and Glycerol Suppositories in Treatment of Low Anterior Resection Syndrome","route":"/trials/nct04087421/","asOf":"2026-09-24","days":4},{"id":"nct06958419","kind":"trial","name":"Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorectal Cancer (MODIFI-CRC)","route":"/trials/nct06958419/","asOf":"2026-09-24","days":4},{"id":"nct06630624","kind":"trial","name":"Dose Finding, Efficacy and Immunological Response of IP-001 Following MWA or IRE for CRLM","route":"/trials/nct06630624/","asOf":"2026-09-24","days":4},{"id":"nct06640166","kind":"trial","name":"Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafen","route":"/trials/nct06640166/","asOf":"2026-09-24","days":4},{"id":"nct07257653","kind":"trial","name":"The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresect","route":"/trials/nct07257653/","asOf":"2026-09-24","days":4},{"id":"nct05296681","kind":"trial","name":"Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery","route":"/trials/nct05296681/","asOf":"2026-09-24","days":4},{"id":"nct06940947","kind":"trial","name":"Endoscopic Therapy Or Surgery for Early Colon Cancer","route":"/trials/nct06940947/","asOf":"2026-09-24","days":4},{"id":"nct02919644","kind":"trial","name":"Vaccination with Autologous Dendritic Cells Loaded with Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.","route":"/trials/nct02919644/","asOf":"2026-09-24","days":4},{"id":"nct06903858","kind":"trial","name":"Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer","route":"/trials/nct06903858/","asOf":"2026-09-24","days":4},{"id":"nct07718490","kind":"trial","name":"Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancer","route":"/trials/nct07718490/","asOf":"2026-09-24","days":4},{"id":"nct07551596","kind":"trial","name":"Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial","route":"/trials/nct07551596/","asOf":"2026-09-24","days":4},{"id":"nct06501482","kind":"trial","name":"Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI","route":"/trials/nct06501482/","asOf":"2026-09-24","days":4},{"id":"nct06563388","kind":"trial","name":"Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial","route":"/trials/nct06563388/","asOf":"2026-09-24","days":4},{"id":"nct07223424","kind":"trial","name":"Patient Preference for Subcutaneous vs. Intravenous Immune Therapy","route":"/trials/nct07223424/","asOf":"2026-09-24","days":4},{"id":"nct05959356","kind":"trial","name":"Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer","route":"/trials/nct05959356/","asOf":"2026-09-24","days":4},{"id":"nct07227636","kind":"trial","name":"A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy","route":"/trials/nct07227636/","asOf":"2026-09-24","days":4},{"id":"nct04014530","kind":"trial","name":"Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study","route":"/trials/nct04014530/","asOf":"2026-09-24","days":4},{"id":"nct06234007","kind":"trial","name":"Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Mult","route":"/trials/nct06234007/","asOf":"2026-09-24","days":4},{"id":"nct02505750","kind":"trial","name":"Safety of a Boost (CXB or EBRT) in Combination With Neoadjuvant Chemoradiotherapy for Early Rectal Adenocarcinoma","route":"/trials/nct02505750/","asOf":"2026-09-24","days":4},{"id":"nct02945566","kind":"trial","name":"Can we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer?","route":"/trials/nct02945566/","asOf":"2026-09-24","days":4},{"id":"nct06507371","kind":"trial","name":"Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer","route":"/trials/nct06507371/","asOf":"2026-09-24","days":4},{"id":"nct04928807","kind":"trial","name":"Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION)","route":"/trials/nct04928807/","asOf":"2026-09-24","days":4},{"id":"nct04922853","kind":"trial","name":"Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer","route":"/trials/nct04922853/","asOf":"2026-09-24","days":4},{"id":"nct05610163","kind":"trial","name":"Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage","route":"/trials/nct05610163/","asOf":"2026-09-24","days":4},{"id":"nct04246684","kind":"trial","name":"Short RT Versus RCT,Followed by Chemo and Organ Preservation for Interm and High-risk Rectal Cancer Patients","route":"/trials/nct04246684/","asOf":"2026-09-24","days":4},{"id":"nct02843191","kind":"trial","name":"Consolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After Neoadjuvant Concurrent Chemoradiotherapy","route":"/trials/nct02843191/","asOf":"2026-09-24","days":4},{"id":"nct07441369","kind":"trial","name":"Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer","route":"/trials/nct07441369/","asOf":"2026-09-24","days":4},{"id":"nct07683949","kind":"trial","name":"Clinical Trial Evaluating the Efficacy of Capecitabine Plus Lenvatinib in Patients With Advanced Colorectal Cancer Refractory to Irinotecan, Oxaliplatin, and Fl","route":"/trials/nct07683949/","asOf":"2026-09-24","days":4},{"id":"nct06959589","kind":"trial","name":"The Efficacy and Safety of IBI351, Cetuximab β Combined With FOLFIRI as First-line /IBI351, Cetuximab β as Second-line in the Treatment of KRAS G12C-mutated Met","route":"/trials/nct06959589/","asOf":"2026-09-24","days":4},{"id":"nct07357220","kind":"trial","name":"A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases","route":"/trials/nct07357220/","asOf":"2026-09-24","days":4},{"id":"nct07134218","kind":"trial","name":"Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer","route":"/trials/nct07134218/","asOf":"2026-09-24","days":4},{"id":"nct07700719","kind":"trial","name":"SHR-A1904 in Advanced Colorectal Cancer: an Exploratory Study","route":"/trials/nct07700719/","asOf":"2026-09-24","days":4},{"id":"nct07007767","kind":"trial","name":"Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）","route":"/trials/nct07007767/","asOf":"2026-09-24","days":4},{"id":"nct07504198","kind":"trial","name":"Neuroprotection of Memantine and Rosuvastatin","route":"/trials/nct07504198/","asOf":"2026-09-24","days":4},{"id":"nct07116577","kind":"trial","name":"Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC","route":"/trials/nct07116577/","asOf":"2026-09-24","days":4},{"id":"nct07740720","kind":"trial","name":"A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer","route":"/trials/nct07740720/","asOf":"2026-09-24","days":4},{"id":"nct06666166","kind":"trial","name":"SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer","route":"/trials/nct06666166/","asOf":"2026-09-24","days":4},{"id":"nct06872606","kind":"trial","name":"Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for","route":"/trials/nct06872606/","asOf":"2026-09-24","days":4},{"id":"nct06788171","kind":"trial","name":"PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM","route":"/trials/nct06788171/","asOf":"2026-09-24","days":4},{"id":"nct07796763","kind":"trial","name":"A Global Trial of Trastuzumab Rezetecan (SHR-A1811) in Combination With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Colorecta","route":"/trials/nct07796763/","asOf":"2026-09-24","days":4},{"id":"nct07302126","kind":"trial","name":"Preventive Efficacy of Bergmann Enema for Acute Radiation-induced Rectal Injury in Rectal Cancer Patients Undergoing Short-course Radiotherapy","route":"/trials/nct07302126/","asOf":"2026-09-24","days":4},{"id":"nct07248020","kind":"trial","name":"A Phase II Single-Arm Study of High-Bioavailability Curcumin as Neoadjuvant Chemoradiotherapy in Mid-to-Low Rectal Cancer: Integrated Clinical and Translational","route":"/trials/nct07248020/","asOf":"2026-09-24","days":4},{"id":"nct07774754","kind":"trial","name":"Radiotherapy Combined With Capeox Chemotherapy, Sintilimab and Suvemcitug in Locally Advanced pMMR Rectal Cancer:a Prospective Clinical Trial","route":"/trials/nct07774754/","asOf":"2026-09-24","days":4},{"id":"nct03975049","kind":"trial","name":"Triplet Combination or Doublet Regimen Versus Chemoradiation as Neoadjuvant Therapy for Locally Advanced Rectal Cancer","route":"/trials/nct03975049/","asOf":"2026-09-24","days":4},{"id":"nct07755124","kind":"trial","name":"Dietary Arginine Deprivation Combined With Chemoradiotherapy for Neoadjuvant Treatment of Rectal Cancer: A Randomized Controlled Trial","route":"/trials/nct07755124/","asOf":"2026-09-24","days":4},{"id":"nct07815288","kind":"trial","name":"Retlirafusp Alfa Plus Targeted Therapy and Chemotherapy for Unresectable Colorectal Liver-Limited Metastases","route":"/trials/nct07815288/","asOf":"2026-09-24","days":4},{"id":"nct06838546","kind":"trial","name":"A Multicenter, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Colorectal Cancer","route":"/trials/nct06838546/","asOf":"2026-09-24","days":4},{"id":"nct07297030","kind":"trial","name":"SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal Cancer","route":"/trials/nct07297030/","asOf":"2026-09-24","days":4},{"id":"nct07580339","kind":"trial","name":"Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer","route":"/trials/nct07580339/","asOf":"2026-09-24","days":4},{"id":"nct04889742","kind":"trial","name":"Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors","route":"/trials/nct04889742/","asOf":"2026-09-24","days":4},{"id":"nct07402486","kind":"trial","name":"A Phase II Prospective Study of Maastro Applicator Brachytherapy for Rectal Cancer","route":"/trials/nct07402486/","asOf":"2026-09-24","days":4},{"id":"nct06057831","kind":"trial","name":"PET/MRI in Rectal Cancer","route":"/trials/nct06057831/","asOf":"2026-09-24","days":4},{"id":"nct07817888","kind":"trial","name":"mFOLFOXIRI Plus Bevacizumab for Organ Preservation in Locally Advanced Rectal Cancer","route":"/trials/nct07817888/","asOf":"2026-09-24","days":4},{"id":"nct07061210","kind":"trial","name":"An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer","route":"/trials/nct07061210/","asOf":"2026-09-24","days":4},{"id":"nct04443543","kind":"trial","name":"An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer","route":"/trials/nct04443543/","asOf":"2026-09-24","days":4},{"id":"nct06751394","kind":"trial","name":"Preoperative Chemoradiotherapy and Toripalimab in Locally Recurrent Rectal Cancer","route":"/trials/nct06751394/","asOf":"2026-09-24","days":4},{"id":"nct06596343","kind":"trial","name":"Evaluating the Benefits of Personalized Traditional Chinese Medicine in Postoperative Treatment for Locally Advanced Colorectal Cancer","route":"/trials/nct06596343/","asOf":"2026-09-24","days":4},{"id":"nct07737600","kind":"trial","name":"A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer","route":"/trials/nct07737600/","asOf":"2026-09-24","days":4},{"id":"nct07483684","kind":"trial","name":"A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxal","route":"/trials/nct07483684/","asOf":"2026-09-24","days":4},{"id":"nct05969847","kind":"trial","name":"Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer","route":"/trials/nct05969847/","asOf":"2026-09-24","days":4},{"id":"nct05841134","kind":"trial","name":"Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer","route":"/trials/nct05841134/","asOf":"2026-09-24","days":4},{"id":"nct06014944","kind":"trial","name":"Short-course Radiotherapy Combined With Furoquintinib and PD-1 Monoclonal Antibody","route":"/trials/nct06014944/","asOf":"2026-09-24","days":4},{"id":"nct07691632","kind":"trial","name":"Serplulimab Plus Decitabine and CAPOX Before Surgery for Locally Advanced Colorectal Cancer","route":"/trials/nct07691632/","asOf":"2026-09-24","days":4},{"id":"nct06855849","kind":"trial","name":"An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients","route":"/trials/nct06855849/","asOf":"2026-09-24","days":4},{"id":"nct07503639","kind":"trial","name":"Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer","route":"/trials/nct07503639/","asOf":"2026-09-24","days":4},{"id":"nct07381400","kind":"trial","name":"Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Study)","route":"/trials/nct07381400/","asOf":"2026-09-24","days":4},{"id":"nct07490119","kind":"trial","name":"Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer","route":"/trials/nct07490119/","asOf":"2026-09-24","days":4},{"id":"nct07548736","kind":"trial","name":"Improvement Effect of Dexamethasone Enema for Acute Radiation-induced Rectal Injury","route":"/trials/nct07548736/","asOf":"2026-09-24","days":4},{"id":"nct07819604","kind":"trial","name":"Serplulimab Combined With CAPOX and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer","route":"/trials/nct07819604/","asOf":"2026-09-24","days":4},{"id":"nct07000305","kind":"trial","name":"A Study of Cetuximabβ Combined With Envolimab and mFOLFOX6 in Subjects With Advanced Colorectal Cancer","route":"/trials/nct07000305/","asOf":"2026-09-24","days":4},{"id":"nct06097416","kind":"trial","name":"Neoadjuvant Chemoradiotherapy Versus Total Neoadjuvant Therapy in the Treatment of T3 Rectal Cancer","route":"/trials/nct06097416/","asOf":"2026-09-24","days":4},{"id":"nct07543848","kind":"trial","name":"A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemot","route":"/trials/nct07543848/","asOf":"2026-09-24","days":4},{"id":"nct06832917","kind":"trial","name":"Short-course Radiation (SCRT) Followed by 6 Cycles of Cadonilimab Plus MFOLFOX6 As Neoadjuvant Therapy for Patients with Locally Advanced Rectal Cancer (LARC):","route":"/trials/nct06832917/","asOf":"2026-09-24","days":4},{"id":"nct06599827","kind":"trial","name":"Neoadjuvant Moderately Hypofractionated Radiotherapy Combined with Chemotherapy and Immunotherapy for High-risk LARC","route":"/trials/nct06599827/","asOf":"2026-09-24","days":4},{"id":"nct06973343","kind":"trial","name":"Sintilimab Plus Bevacizumab and Chemotherapy in MSS/pMMR Colorectal With no Liver Metastasis","route":"/trials/nct06973343/","asOf":"2026-09-24","days":4},{"id":"nct06972498","kind":"trial","name":"A Prospective Multicenter Study: Ivosimab + Chemotherapy as Neoadjuvant for Resectable pMMR/MSS CRC Liver Mets","route":"/trials/nct06972498/","asOf":"2026-09-24","days":4},{"id":"nct06593548","kind":"trial","name":"Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer","route":"/trials/nct06593548/","asOf":"2026-09-24","days":4},{"id":"nct07621159","kind":"trial","name":"A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal Cancer","route":"/trials/nct07621159/","asOf":"2026-09-24","days":4},{"id":"nct06919510","kind":"trial","name":"A Phase ll Study of Neoadjuvant Short-course Radiotherapy Followed by Ivonescimab and Chemotherapy in pMMR/MSS Locally Advanced Rectal Cancer","route":"/trials/nct06919510/","asOf":"2026-09-24","days":4},{"id":"nct06450574","kind":"trial","name":"Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery Versus Ttransanal Endoscopic Microsurgery in T1 N0, M0 Rectal Cancer (TAUTEM-T1 Study)","route":"/trials/nct06450574/","asOf":"2026-09-24","days":4},{"id":"nct07161115","kind":"trial","name":"Involve-site Radiotherapy Combined With Chemotherapy and Immunotherapy as Neoadjuvant Treatment for Locally Advanced Rectal Cancer","route":"/trials/nct07161115/","asOf":"2026-09-24","days":4},{"id":"nct07622017","kind":"trial","name":"KORTUC (KRC-01) Plus Radiotherapy for Organ Preservation in Rectal Cancer","route":"/trials/nct07622017/","asOf":"2026-09-24","days":4},{"id":"nct06304545","kind":"trial","name":"Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab","route":"/trials/nct06304545/","asOf":"2026-09-24","days":4},{"id":"nct07394192","kind":"trial","name":"Short-Course Radiotherapy With Tumor-Draining Lymph Node Preservation Followed by PD-1 Inhibitors in pMMR/MSS Stage II-III Rectal Cancer","route":"/trials/nct07394192/","asOf":"2026-09-24","days":4},{"id":"nct07797244","kind":"trial","name":"A Single-Arm, Phase II Study of Retlirafusp Alfa in Combination With XELOX and Bevacizumab for the First-Line Treatment of Advanced RAS-Mutated Colorectal Cance","route":"/trials/nct07797244/","asOf":"2026-09-24","days":4},{"id":"nct05364489","kind":"trial","name":"Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First-line Treatment of Advanced Colorectal Cancer","route":"/trials/nct05364489/","asOf":"2026-09-24","days":4},{"id":"nct07209384","kind":"trial","name":"Clinical Efficacy of Transarterial Chemoembolization in Elderly Patients With Advanced Unresectable Colorectal Cancer","route":"/trials/nct07209384/","asOf":"2026-09-24","days":4},{"id":"nct07509424","kind":"trial","name":"Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Ca","route":"/trials/nct07509424/","asOf":"2026-09-24","days":4},{"id":"nct07527520","kind":"trial","name":"Neoadjuvant Moderately Hypofractionated Radiotherapy Combined With Chemotherapy and Immunotherapy for High-risk pMMR/MSS Locally Advanced Rectal Cancer: A Prosp","route":"/trials/nct07527520/","asOf":"2026-09-24","days":4},{"id":"nct07175636","kind":"trial","name":"QL1706 With Short-Course Radiotherapy and Chemotherapy for MSS Rectal Cancer","route":"/trials/nct07175636/","asOf":"2026-09-24","days":4},{"id":"nct07779694","kind":"trial","name":"16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal Cancer","route":"/trials/nct07779694/","asOf":"2026-09-24","days":4},{"id":"nct05359393","kind":"trial","name":"A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis","route":"/trials/nct05359393/","asOf":"2026-09-24","days":4},{"id":"nct05807984","kind":"trial","name":"Re-irradiation Therapy of Locally Recurrent Rectal Cancer With Carbon Ion","route":"/trials/nct05807984/","asOf":"2026-09-24","days":4},{"id":"nct05484024","kind":"trial","name":"Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer","route":"/trials/nct05484024/","asOf":"2026-09-24","days":4},{"id":"nct07209215","kind":"trial","name":"ctDNA-Informed Management of Early-Stage Rectal Cancer","route":"/trials/nct07209215/","asOf":"2026-09-24","days":4},{"id":"nct07070713","kind":"trial","name":"Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC","route":"/trials/nct07070713/","asOf":"2026-09-24","days":4},{"id":"nct05239650","kind":"trial","name":"Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC","route":"/trials/nct05239650/","asOf":"2026-09-24","days":4},{"id":"nct07384377","kind":"trial","name":"JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Iri","route":"/trials/nct07384377/","asOf":"2026-09-24","days":4},{"id":"nct06390982","kind":"trial","name":"Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study","route":"/trials/nct06390982/","asOf":"2026-09-24","days":4},{"id":"nct07397442","kind":"trial","name":"Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer","route":"/trials/nct07397442/","asOf":"2026-09-24","days":4},{"id":"nct07516210","kind":"trial","name":"Adaptive Radiotherapy for Safe Hypofractionation","route":"/trials/nct07516210/","asOf":"2026-09-24","days":4},{"id":"nct06443671","kind":"trial","name":"Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer","route":"/trials/nct06443671/","asOf":"2026-09-24","days":4},{"id":"nct06679673","kind":"trial","name":"SHR-1701 Combined with SHR2554 and BP102 for MCRC","route":"/trials/nct06679673/","asOf":"2026-09-24","days":4},{"id":"nct07810114","kind":"trial","name":"Total Neoadjuvant mFOLFOX6 Plus Suvemcitug and Enlonstobart With Selective Omission of Pelvic Radiotherapy for High-Risk Mid-Rectal Locally Advanced Rectal Canc","route":"/trials/nct07810114/","asOf":"2026-09-24","days":4},{"id":"nct06521866","kind":"trial","name":"Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer","route":"/trials/nct06521866/","asOf":"2026-09-24","days":4},{"id":"nct05731726","kind":"trial","name":"Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer","route":"/trials/nct05731726/","asOf":"2026-09-24","days":4},{"id":"nct06205485","kind":"trial","name":"Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer","route":"/trials/nct06205485/","asOf":"2026-09-24","days":4},{"id":"nct05913674","kind":"trial","name":"Technical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC)","route":"/trials/nct05913674/","asOf":"2026-09-24","days":4},{"id":"nct07528209","kind":"trial","name":"Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer","route":"/trials/nct07528209/","asOf":"2026-09-24","days":4},{"id":"nct06154538","kind":"trial","name":"Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer","route":"/trials/nct06154538/","asOf":"2026-09-24","days":4},{"id":"nct06542588","kind":"trial","name":"Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC","route":"/trials/nct06542588/","asOf":"2026-09-24","days":4},{"id":"nct06764680","kind":"trial","name":"Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer","route":"/trials/nct06764680/","asOf":"2026-09-24","days":4},{"id":"nct05450029","kind":"trial","name":"Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer","route":"/trials/nct05450029/","asOf":"2026-09-24","days":4},{"id":"nct06440902","kind":"trial","name":"Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNA","route":"/trials/nct06440902/","asOf":"2026-09-24","days":4},{"id":"nct03875781","kind":"trial","name":"Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer","route":"/trials/nct03875781/","asOf":"2026-09-24","days":4},{"id":"nct06685276","kind":"trial","name":"Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer","route":"/trials/nct06685276/","asOf":"2026-09-24","days":4},{"id":"nct05984485","kind":"trial","name":"The Efficacy of Primary Total Mesorectal Excision (TME) Surgery Versus Neoadjuvant Chemotherapy Combined With TME Surgery in Low-risk Locally Advanced Rectal Ca","route":"/trials/nct05984485/","asOf":"2026-09-24","days":4},{"id":"nct05628038","kind":"trial","name":"The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer","route":"/trials/nct05628038/","asOf":"2026-09-24","days":4},{"id":"nct06780787","kind":"trial","name":"FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery","route":"/trials/nct06780787/","asOf":"2026-09-24","days":4},{"id":"nct07132463","kind":"trial","name":"Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study","route":"/trials/nct07132463/","asOf":"2026-09-24","days":4},{"id":"nct06642844","kind":"trial","name":"Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment","route":"/trials/nct06642844/","asOf":"2026-09-24","days":4},{"id":"nct07044921","kind":"trial","name":"Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer.","route":"/trials/nct07044921/","asOf":"2026-09-24","days":4},{"id":"nct06848842","kind":"trial","name":"Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases","route":"/trials/nct06848842/","asOf":"2026-09-24","days":4},{"id":"nct06204094","kind":"trial","name":"Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer","route":"/trials/nct06204094/","asOf":"2026-09-24","days":4},{"id":"nct07070622","kind":"trial","name":"Planed Organ Preservation for Low Rectal Cancer After Neoadjuvant Chemotherapy (OPLAR)","route":"/trials/nct07070622/","asOf":"2026-09-24","days":4},{"id":"nct07239466","kind":"trial","name":"A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant T","route":"/trials/nct07239466/","asOf":"2026-09-24","days":4},{"id":"nct06484153","kind":"trial","name":"Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma","route":"/trials/nct06484153/","asOf":"2026-09-24","days":4},{"id":"nct05794971","kind":"trial","name":"Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases","route":"/trials/nct05794971/","asOf":"2026-09-24","days":4},{"id":"nct03051464","kind":"trial","name":"Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery","route":"/trials/nct03051464/","asOf":"2026-09-24","days":4},{"id":"nct06930118","kind":"trial","name":"The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advan","route":"/trials/nct06930118/","asOf":"2026-09-24","days":4},{"id":"nct07130903","kind":"trial","name":"Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer","route":"/trials/nct07130903/","asOf":"2026-09-24","days":4},{"id":"nct07198165","kind":"trial","name":"SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC","route":"/trials/nct07198165/","asOf":"2026-09-24","days":4},{"id":"nct06647680","kind":"trial","name":"Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）","route":"/trials/nct06647680/","asOf":"2026-09-24","days":4},{"id":"nct07150247","kind":"trial","name":"Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer","route":"/trials/nct07150247/","asOf":"2026-09-24","days":4},{"id":"nct07558083","kind":"trial","name":"FOLICOLOR TRIAL: Following Therapy Response Through Liquid Biopsy in Metatstatic Colorectal Cancer Patients","route":"/trials/nct07558083/","asOf":"2026-09-24","days":4},{"id":"nct05752136","kind":"trial","name":"Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma","route":"/trials/nct05752136/","asOf":"2026-09-24","days":4},{"id":"nct04109755","kind":"trial","name":"Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer","route":"/trials/nct04109755/","asOf":"2026-09-24","days":4},{"id":"nct06369259","kind":"trial","name":"Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-R","route":"/trials/nct06369259/","asOf":"2026-09-24","days":4},{"id":"nct07505472","kind":"trial","name":"Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuva","route":"/trials/nct07505472/","asOf":"2026-09-24","days":4},{"id":"nct07095439","kind":"trial","name":"Efficacy and Toxicity of Total Neoadjuvant Sandwich Treatment Via Short Course Radiotherapy in the Treatment of Stage II and III Rectal Cancer Patients","route":"/trials/nct07095439/","asOf":"2026-09-24","days":4},{"id":"nct07176182","kind":"trial","name":"Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression","route":"/trials/nct07176182/","asOf":"2026-09-24","days":4},{"id":"nct07561060","kind":"trial","name":"Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy","route":"/trials/nct07561060/","asOf":"2026-09-24","days":4},{"id":"nct05672524","kind":"trial","name":"A Study of Tucatinib and Trastuzumab in People With Rectal Cancer","route":"/trials/nct05672524/","asOf":"2026-09-24","days":4},{"id":"nct06123156","kind":"trial","name":"Interest of Early Erectile Rehabilitation With Sildenafil After Radiotherapy and Proctectomy for Rectal Cancer","route":"/trials/nct06123156/","asOf":"2026-09-24","days":4},{"id":"nct07735624","kind":"trial","name":"RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer","route":"/trials/nct07735624/","asOf":"2026-09-24","days":4},{"id":"nct07833319","kind":"trial","name":"Local Methylene Blue Injection for Prevention of Anastomotic Leakage and Permanent Stoma After Low Anterior Resection for Rectal Cancer","route":"/trials/nct07833319/","asOf":"2026-09-24","days":4},{"id":"nct06885385","kind":"trial","name":"A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer","route":"/trials/nct06885385/","asOf":"2026-09-24","days":4},{"id":"nct06555133","kind":"trial","name":"Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC","route":"/trials/nct06555133/","asOf":"2026-09-24","days":4},{"id":"nct04288999","kind":"trial","name":"Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer","route":"/trials/nct04288999/","asOf":"2026-09-24","days":4},{"id":"nct07520578","kind":"trial","name":"EFFECTIVENESS OF EARLY INFORMATION AND ENDORSMENT BY GP TO INCREASE COLONOSCOPY FOLLOW-UP AND REDUCE DELAYS IN PEOPLE WITH A POSITIVE COLORECTAL CANCER SCREENIN","route":"/trials/nct07520578/","asOf":"2026-09-24","days":4},{"id":"nct04215731","kind":"trial","name":"Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer","route":"/trials/nct04215731/","asOf":"2026-09-24","days":4},{"id":"nct07284992","kind":"trial","name":"SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC","route":"/trials/nct07284992/","asOf":"2026-09-24","days":4},{"id":"nct07162714","kind":"trial","name":"SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer","route":"/trials/nct07162714/","asOf":"2026-09-24","days":4},{"id":"nct06940388","kind":"trial","name":"Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer.","route":"/trials/nct06940388/","asOf":"2026-09-24","days":4},{"id":"nct04643366","kind":"trial","name":"Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer","route":"/trials/nct04643366/","asOf":"2026-09-24","days":4},{"id":"nct07068763","kind":"trial","name":"Node-Sparing Short-Course Radiation Combined With Capecitabine and PD-1/CTLA-4 for MSS Early Rectal Cancer","route":"/trials/nct07068763/","asOf":"2026-09-24","days":4},{"id":"nct07549399","kind":"trial","name":"SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC","route":"/trials/nct07549399/","asOf":"2026-09-24","days":4},{"id":"nct07201519","kind":"trial","name":"Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy","route":"/trials/nct07201519/","asOf":"2026-09-24","days":4},{"id":"nct04095299","kind":"trial","name":"Standard Dose Versus High Dose of Radiotherapy in Rectal Preservation With Chemo-radiotherapy in Rectal Cancer Patients","route":"/trials/nct04095299/","asOf":"2026-09-24","days":4},{"id":"nct07622771","kind":"trial","name":"Neoadjuvant Radiotherapy Combined With NALIRIFOX and Adebrelimab in pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Randomized, Phase II Clinical Trial","route":"/trials/nct07622771/","asOf":"2026-09-24","days":4},{"id":"nct05732389","kind":"trial","name":"Immunotherapy in Patients With Early dMMR Rectal Cancer","route":"/trials/nct05732389/","asOf":"2026-09-24","days":4},{"id":"nct05965531","kind":"trial","name":"Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy","route":"/trials/nct05965531/","asOf":"2026-09-24","days":4},{"id":"nct05939687","kind":"trial","name":"Prophylactic Mesh Placement During Stoma Closure After Low Anterior Resection","route":"/trials/nct05939687/","asOf":"2026-09-24","days":4},{"id":"nct06801665","kind":"trial","name":"FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colorectal Cancer With Liver Metastasis","route":"/trials/nct06801665/","asOf":"2026-09-24","days":4},{"id":"nct07544784","kind":"trial","name":"AK104 Plus Radiotherapy Combined With Standard Therapy Versus Standard Therapy as First-Line Treatment for pMMR/MSS CRLM (APSOC)","route":"/trials/nct07544784/","asOf":"2026-09-24","days":4},{"id":"nct06540326","kind":"trial","name":"Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab","route":"/trials/nct06540326/","asOf":"2026-09-24","days":4},{"id":"nct07407647","kind":"trial","name":"Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer","route":"/trials/nct07407647/","asOf":"2026-09-24","days":4},{"id":"nct05939661","kind":"trial","name":"A Multicenter Single-arm P2 to Evaluate Safety and Efficacy of the Total Neoadjuvant Therapy for cT2 Rectal Cancer","route":"/trials/nct05939661/","asOf":"2026-09-24","days":4},{"id":"nct06923345","kind":"trial","name":"Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I)","route":"/trials/nct06923345/","asOf":"2026-09-24","days":4},{"id":"nct06229041","kind":"trial","name":"Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi)","route":"/trials/nct06229041/","asOf":"2026-09-24","days":4},{"id":"nct06911684","kind":"trial","name":"Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.","route":"/trials/nct06911684/","asOf":"2026-09-24","days":4},{"id":"nct06949098","kind":"trial","name":"Tumor Local Excision +Postoperative Adjuvant Chemoradiotherapy for T1-2N0M0 Low/Ultra-Low Rectal Cancer","route":"/trials/nct06949098/","asOf":"2026-09-24","days":4},{"id":"nct07646639","kind":"trial","name":"Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC","route":"/trials/nct07646639/","asOf":"2026-09-24","days":4},{"id":"nct07347951","kind":"trial","name":"A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer","route":"/trials/nct07347951/","asOf":"2026-09-24","days":4},{"id":"nct07372300","kind":"trial","name":"Modulated Electro-Hyperthermia in Combination With Multimodal Therapy for Locally Advanced Rectal Cancer","route":"/trials/nct07372300/","asOf":"2026-09-24","days":4},{"id":"nct06254521","kind":"trial","name":"The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer","route":"/trials/nct06254521/","asOf":"2026-09-24","days":4},{"id":"nct05136326","kind":"trial","name":"Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer","route":"/trials/nct05136326/","asOf":"2026-09-24","days":4},{"id":"nct05563922","kind":"trial","name":"Organ Preservation Strategy of Total Neoadjuvant Chemoradiotherapy for Low Rectal Carcinoma","route":"/trials/nct05563922/","asOf":"2026-09-24","days":4},{"id":"nct06829355","kind":"trial","name":"\"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer\"","route":"/trials/nct06829355/","asOf":"2026-09-24","days":4},{"id":"nct07113275","kind":"trial","name":"A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course R","route":"/trials/nct07113275/","asOf":"2026-09-24","days":4},{"id":"nct07012954","kind":"trial","name":"ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC","route":"/trials/nct07012954/","asOf":"2026-09-24","days":4},{"id":"nct07458529","kind":"trial","name":"Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer","route":"/trials/nct07458529/","asOf":"2026-09-24","days":4},{"id":"nct06266832","kind":"trial","name":"The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra","route":"/trials/nct06266832/","asOf":"2026-09-24","days":4},{"id":"nct05228431","kind":"trial","name":"Modified Sandwich Therapeutic Regimen for Locally Advanced Rectal Cancer","route":"/trials/nct05228431/","asOf":"2026-09-24","days":4},{"id":"nct04389086","kind":"trial","name":"Induction Chemotherapy for Locally Recurrent Rectal Cancer","route":"/trials/nct04389086/","asOf":"2026-09-24","days":4},{"id":"nct07204574","kind":"trial","name":"The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuxi","route":"/trials/nct07204574/","asOf":"2026-09-24","days":4},{"id":"nct06812728","kind":"trial","name":"Neoadjuvant FOLFIRINOX and Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer Patients","route":"/trials/nct06812728/","asOf":"2026-09-24","days":4},{"id":"nct05360277","kind":"trial","name":"Maintenance Tislelizumab + Capecitabine to Treat Metastatic Colorectal Cancer","route":"/trials/nct05360277/","asOf":"2026-09-24","days":4},{"id":"nct07292298","kind":"trial","name":"Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation","route":"/trials/nct07292298/","asOf":"2026-09-24","days":4},{"id":"nct03671252","kind":"trial","name":"Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Co","route":"/trials/nct03671252/","asOf":"2026-09-24","days":4},{"id":"nct07104604","kind":"trial","name":"Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Tislelizumab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally","route":"/trials/nct07104604/","asOf":"2026-09-24","days":4},{"id":"nct06793137","kind":"trial","name":"Intestinal Microbiome Modulation With Antibiotics in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer","route":"/trials/nct06793137/","asOf":"2026-09-24","days":4},{"id":"nct07188025","kind":"trial","name":"ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer","route":"/trials/nct07188025/","asOf":"2026-09-24","days":4},{"id":"nct06279351","kind":"trial","name":"Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer","route":"/trials/nct06279351/","asOf":"2026-09-24","days":4},{"id":"nct04495088","kind":"trial","name":"Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer","route":"/trials/nct04495088/","asOf":"2026-09-24","days":4},{"id":"nct06525428","kind":"trial","name":"Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer","route":"/trials/nct06525428/","asOf":"2026-09-24","days":4},{"id":"nct05378919","kind":"trial","name":"Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer","route":"/trials/nct05378919/","asOf":"2026-09-24","days":4},{"id":"nct05254327","kind":"trial","name":"Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001","route":"/trials/nct05254327/","asOf":"2026-09-24","days":4},{"id":"nct07795749","kind":"trial","name":"Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B)","route":"/trials/nct07795749/","asOf":"2026-09-24","days":4},{"id":"nct05201430","kind":"trial","name":"Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer","route":"/trials/nct05201430/","asOf":"2026-09-24","days":4},{"id":"nct06555003","kind":"trial","name":"DEBIRI Plus Chemotherapy vs. Chemotherapy Alone in Colorectal Cancer Liver Metastases","route":"/trials/nct06555003/","asOf":"2026-09-24","days":4},{"id":"nct06455124","kind":"trial","name":"Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)","route":"/trials/nct06455124/","asOf":"2026-09-24","days":4},{"id":"nct06282445","kind":"trial","name":"Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsate","route":"/trials/nct06282445/","asOf":"2026-09-24","days":4},{"id":"nct06881537","kind":"trial","name":"CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer","route":"/trials/nct06881537/","asOf":"2026-09-24","days":4},{"id":"nct06569368","kind":"trial","name":"Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy","route":"/trials/nct06569368/","asOf":"2026-09-24","days":4},{"id":"nct06850090","kind":"trial","name":"Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial","route":"/trials/nct06850090/","asOf":"2026-09-24","days":4},{"id":"nct06826092","kind":"trial","name":"Metformin for the Treatment of mCRC Patients Undergoing FOLFIRI Plus Target Therapy","route":"/trials/nct06826092/","asOf":"2026-09-24","days":4},{"id":"nct05024097","kind":"trial","name":"A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for","route":"/trials/nct05024097/","asOf":"2026-09-24","days":4},{"id":"nct07391618","kind":"trial","name":"Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU","route":"/trials/nct07391618/","asOf":"2026-09-24","days":4},{"id":"nct07669220","kind":"trial","name":"A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Cours","route":"/trials/nct07669220/","asOf":"2026-09-24","days":4},{"id":"nct06162650","kind":"trial","name":"Total Neoadjuvant Therapy in Rectal Cancer","route":"/trials/nct06162650/","asOf":"2026-09-24","days":4},{"id":"nct07594925","kind":"trial","name":"Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer: A Prospective, Randomiz","route":"/trials/nct07594925/","asOf":"2026-09-24","days":4},{"id":"nct06590259","kind":"trial","name":"A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM","route":"/trials/nct06590259/","asOf":"2026-09-24","days":4},{"id":"nct07108127","kind":"trial","name":"Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced","route":"/trials/nct07108127/","asOf":"2026-09-24","days":4},{"id":"nct06770270","kind":"trial","name":"Pucotenlimab Plus Radiotherapy and Chemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cance(PUCRT)","route":"/trials/nct06770270/","asOf":"2026-09-24","days":4},{"id":"nct06765616","kind":"trial","name":"Adebrelimab Injection (PD-L1) Combined With Short Course Radiotherapy and Chemotherapy for Neoadjuvant Therapy of Locally Advanced Rectal Cancer","route":"/trials/nct06765616/","asOf":"2026-09-24","days":4},{"id":"nct06718543","kind":"trial","name":"Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal Cancer","route":"/trials/nct06718543/","asOf":"2026-09-24","days":4},{"id":"nct05057052","kind":"trial","name":"Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis","route":"/trials/nct05057052/","asOf":"2026-09-24","days":4},{"id":"nct05963490","kind":"trial","name":"Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer","route":"/trials/nct05963490/","asOf":"2026-09-24","days":4},{"id":"nct04749108","kind":"trial","name":"Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma","route":"/trials/nct04749108/","asOf":"2026-09-24","days":4},{"id":"nct05624138","kind":"trial","name":"The Possible Protective Role of Ketotifen Against Oxaliplatin Induced Peripheral Neuropathy","route":"/trials/nct05624138/","asOf":"2026-09-24","days":4},{"id":"nct06998758","kind":"trial","name":"Megestrol Acetate in Improving Neoadjuvant Chemotherapy-Related Weight Loss in Locally Advanced CRC","route":"/trials/nct06998758/","asOf":"2026-09-24","days":4},{"id":"nct06841159","kind":"trial","name":"Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Can","route":"/trials/nct06841159/","asOf":"2026-09-24","days":4},{"id":"nct05576480","kind":"trial","name":"SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer","route":"/trials/nct05576480/","asOf":"2026-09-24","days":4},{"id":"nct06958432","kind":"trial","name":"Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II)","route":"/trials/nct06958432/","asOf":"2026-09-24","days":4},{"id":"nct07686796","kind":"trial","name":"Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A P","route":"/trials/nct07686796/","asOf":"2026-09-24","days":4},{"id":"nct07469306","kind":"trial","name":"Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer","route":"/trials/nct07469306/","asOf":"2026-09-24","days":4},{"id":"nct07314528","kind":"trial","name":"Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal Cancer","route":"/trials/nct07314528/","asOf":"2026-09-24","days":4},{"id":"nct07551479","kind":"trial","name":"SCRT Based iTNT vs. LCRT Based TNT for MSS Locally Advanced Rectal Cancer","route":"/trials/nct07551479/","asOf":"2026-09-24","days":4},{"id":"nct07645118","kind":"trial","name":"Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer","route":"/trials/nct07645118/","asOf":"2026-09-24","days":4},{"id":"nct07118800","kind":"trial","name":"Study Evaluating Two Treatment Strategies for Rectal Cancer in Patients ≥75 Years Old","route":"/trials/nct07118800/","asOf":"2026-09-24","days":4},{"id":"nct07430696","kind":"trial","name":"INVESTIGATION OF THE ANTI-NEOPLASTIC EFFECT OF TRISHUL (AYURVEDIC AGENT) ON TUMOUR REGRESSION OF RECTAL CANCER- A PILOT STUDY","route":"/trials/nct07430696/","asOf":"2026-09-24","days":4},{"id":"nct07277842","kind":"trial","name":"PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer","route":"/trials/nct07277842/","asOf":"2026-09-24","days":4},{"id":"nct07596290","kind":"trial","name":"Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC","route":"/trials/nct07596290/","asOf":"2026-09-24","days":4},{"id":"nct07662278","kind":"trial","name":"rSIFN-co in Combination With Total Neo-adjuvant Therapy in Subjects With Mid-low Locally Advanced Rectal Cancer","route":"/trials/nct07662278/","asOf":"2026-09-24","days":4},{"id":"nct07383285","kind":"trial","name":"CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal C","route":"/trials/nct07383285/","asOf":"2026-09-24","days":4},{"id":"nct07381777","kind":"trial","name":"XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC)","route":"/trials/nct07381777/","asOf":"2026-09-24","days":4},{"id":"nct07472868","kind":"trial","name":"Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk","route":"/trials/nct07472868/","asOf":"2026-09-24","days":4},{"id":"nct05998122","kind":"trial","name":"Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A","route":"/trials/nct05998122/","asOf":"2026-09-24","days":4},{"id":"nct07811076","kind":"trial","name":"Serine/Glycine-Restricted Diet With Chemoradiotherapy for Rectal Cancer","route":"/trials/nct07811076/","asOf":"2026-09-24","days":4},{"id":"nct07074353","kind":"trial","name":"Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer","route":"/trials/nct07074353/","asOf":"2026-09-24","days":4},{"id":"nct07059949","kind":"trial","name":"Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer","route":"/trials/nct07059949/","asOf":"2026-09-24","days":4},{"id":"nct05479240","kind":"trial","name":"Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer","route":"/trials/nct05479240/","asOf":"2026-09-24","days":4},{"id":"nct07837362","kind":"trial","name":"SCRT Combined With CAPOX and PD-1/CTLA4 Antibody for Early-stage Low Rectal Cancer","route":"/trials/nct07837362/","asOf":"2026-09-24","days":4},{"id":"nct07521605","kind":"trial","name":"Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer","route":"/trials/nct07521605/","asOf":"2026-09-24","days":4},{"id":"nct06760520","kind":"trial","name":"Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer","route":"/trials/nct06760520/","asOf":"2026-09-24","days":4},{"id":"nct07581626","kind":"trial","name":"Short-Course Online Adaptive Radiotherapy Combined With Chemotherapy, Targeted Therapy and Immunotherapy as Total Neoadjuvant Therapy (TNT) for Locally Advanced","route":"/trials/nct07581626/","asOf":"2026-09-24","days":4},{"id":"nct07214142","kind":"trial","name":"Total Neoadjuvant Therapy With PD-1 for Locally Advcancer Rectal Cancer","route":"/trials/nct07214142/","asOf":"2026-09-24","days":4},{"id":"nct07651007","kind":"trial","name":"Short-course RT Followed by NALIRIFOX Plus Pucotenlimab as Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer With MSS/pMMR","route":"/trials/nct07651007/","asOf":"2026-09-24","days":4},{"id":"nct05601505","kind":"trial","name":"Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer","route":"/trials/nct05601505/","asOf":"2026-09-24","days":4},{"id":"nct05245474","kind":"trial","name":"Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer","route":"/trials/nct05245474/","asOf":"2026-09-24","days":4},{"id":"nct06312982","kind":"trial","name":"A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer","route":"/trials/nct06312982/","asOf":"2026-09-24","days":4},{"id":"nct06767007","kind":"trial","name":"SBRT + PD-1 Antibody in Unresectable Locally Recurrent Rectal Cancer（SPARKLE）","route":"/trials/nct06767007/","asOf":"2026-09-24","days":4},{"id":"nct06762405","kind":"trial","name":"PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-defi","route":"/trials/nct06762405/","asOf":"2026-09-24","days":4},{"id":"nct07750951","kind":"trial","name":"Single-arm, Phase II Clinical Study Evaluating the Safety and Efficacy of Sintilimab Combined With IBI-310 and Chemotherapy as Neoadjuvant Therapy for Locally A","route":"/trials/nct07750951/","asOf":"2026-09-24","days":4},{"id":"nct07026422","kind":"trial","name":"Iparomlimab/Tuvonralimab Integrating With Total Neoadjuvant Therapy for pMMR/MSS Locally Advanced Rectal Cancer (IT-TNT)","route":"/trials/nct07026422/","asOf":"2026-09-24","days":4},{"id":"nct07291401","kind":"trial","name":"Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARC","route":"/trials/nct07291401/","asOf":"2026-09-24","days":4},{"id":"nct07183865","kind":"trial","name":"Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)","route":"/trials/nct07183865/","asOf":"2026-09-24","days":4},{"id":"nct07020247","kind":"trial","name":"Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study","route":"/trials/nct07020247/","asOf":"2026-09-24","days":4},{"id":"nct06843434","kind":"trial","name":"A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma","route":"/trials/nct06843434/","asOf":"2026-09-24","days":4},{"id":"nct04695782","kind":"trial","name":"Pencil Beam Proton Therapy for Pelvic Recurrences in Rectal Cancer Patients Previously Treated With Radiotherapy","route":"/trials/nct04695782/","asOf":"2026-09-24","days":4},{"id":"nct07150949","kind":"trial","name":"Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC","route":"/trials/nct07150949/","asOf":"2026-09-24","days":4},{"id":"nct06928584","kind":"trial","name":"Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer","route":"/trials/nct06928584/","asOf":"2026-09-24","days":4},{"id":"nct05972655","kind":"trial","name":"Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer","route":"/trials/nct05972655/","asOf":"2026-09-24","days":4},{"id":"nct07040098","kind":"trial","name":"Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer","route":"/trials/nct07040098/","asOf":"2026-09-24","days":4},{"id":"nct05555888","kind":"trial","name":"The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer","route":"/trials/nct05555888/","asOf":"2026-09-24","days":4},{"id":"nct05663775","kind":"trial","name":"Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)","route":"/trials/nct05663775/","asOf":"2026-09-24","days":4},{"id":"nct06808412","kind":"trial","name":"To Explore the Efficacy of Sintilimab Combined With Bevacizumab in Rectal Cancer","route":"/trials/nct06808412/","asOf":"2026-09-24","days":4},{"id":"nct07200141","kind":"trial","name":"Simultaneous Boost in Neoadjuvant Radiotherapy for Rectal Cancer","route":"/trials/nct07200141/","asOf":"2026-09-24","days":4},{"id":"nct06802666","kind":"trial","name":"Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer","route":"/trials/nct06802666/","asOf":"2026-09-24","days":4},{"id":"nct07448077","kind":"trial","name":"Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC","route":"/trials/nct07448077/","asOf":"2026-09-24","days":4},{"id":"nct07281157","kind":"trial","name":"Liposomal Irinotecan, Capecitabine and Enlonstobart With Short-Course Radiotherapy for Locally Advanced Rectal Cancer","route":"/trials/nct07281157/","asOf":"2026-09-24","days":4},{"id":"nct07005570","kind":"trial","name":"Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS","route":"/trials/nct07005570/","asOf":"2026-09-24","days":4},{"id":"nct06462053","kind":"trial","name":"Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined With CAPOX for Early Low-lying Rectal Cancer","route":"/trials/nct06462053/","asOf":"2026-09-24","days":4},{"id":"nct06864013","kind":"trial","name":"SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer","route":"/trials/nct06864013/","asOf":"2026-09-24","days":4},{"id":"nct07297004","kind":"trial","name":"Stereotactic Body Radiation Therapy for Unresectable Locally Recurrent Rectal Cancer","route":"/trials/nct07297004/","asOf":"2026-09-24","days":4},{"id":"nct06281405","kind":"trial","name":"CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer","route":"/trials/nct06281405/","asOf":"2026-09-24","days":4},{"id":"nct07686640","kind":"trial","name":"Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR/MSS Locally Advanced Rectal Cancer","route":"/trials/nct07686640/","asOf":"2026-09-24","days":4},{"id":"nct07527026","kind":"trial","name":"A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS","route":"/trials/nct07527026/","asOf":"2026-09-24","days":4},{"id":"nct06787183","kind":"trial","name":"SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases","route":"/trials/nct06787183/","asOf":"2026-09-24","days":4},{"id":"nct07674732","kind":"trial","name":"Nodal-Region Sparing Short-Course RT With Chemo-PD-1/Bevacizumab vs. Short-Course RT With Chemotherapy as TNT in pMMR/MSS Locally Advanced Rectal Cancer","route":"/trials/nct07674732/","asOf":"2026-09-24","days":4},{"id":"colorectal-micropapillary-carcinoma","kind":"cancer","name":"Micropapillary adenocarcinoma of the colon and rectum","route":"/cancers/colorectal-micropapillary-carcinoma/","asOf":"2026-09-24","days":4},{"id":"colorectal-adenoma-like-adenocarcinoma","kind":"cancer","name":"Adenoma-like adenocarcinoma of the colon and rectum","route":"/cancers/colorectal-adenoma-like-adenocarcinoma/","asOf":"2026-09-24","days":4},{"id":"lynch-associated-colorectal-cancer","kind":"cancer","name":"Lynch syndrome-associated colorectal cancer","route":"/cancers/lynch-associated-colorectal-cancer/","asOf":"2026-09-24","days":4},{"id":"fap-associated-colorectal-cancer","kind":"cancer","name":"Familial adenomatous polyposis-associated colorectal cancer","route":"/cancers/fap-associated-colorectal-cancer/","asOf":"2026-09-24","days":4},{"id":"adenoma-carcinoma-sequence","kind":"term","name":"Adenoma-carcinoma sequence","route":"/terms/adenoma-carcinoma-sequence/","asOf":"2026-09-24","days":4},{"id":"serrated-pathway","kind":"term","name":"Serrated pathway","route":"/terms/serrated-pathway/","asOf":"2026-09-24","days":4},{"id":"colorectal-polyp-types","kind":"term","name":"Polyp types in the bowel","route":"/terms/colorectal-polyp-types/","asOf":"2026-09-24","days":4},{"id":"bowel-cancer-screening-uk","kind":"term","name":"NHS bowel cancer screening programme","route":"/terms/bowel-cancer-screening-uk/","asOf":"2026-09-24","days":4},{"id":"colonoscopy-surveillance-intervals","kind":"term","name":"Surveillance intervals after polypectomy","route":"/terms/colonoscopy-surveillance-intervals/","asOf":"2026-09-24","days":4},{"id":"watch-and-wait-rectal-cancer","kind":"term","name":"Watch and wait after chemoradiotherapy for rectal cancer","route":"/terms/watch-and-wait-rectal-cancer/","asOf":"2026-09-24","days":4},{"id":"circumferential-resection-margin","kind":"term","name":"Circumferential resection margin (rectal cancer)","route":"/terms/circumferential-resection-margin/","asOf":"2026-09-24","days":4},{"id":"obstructing-colorectal-cancer","kind":"term","name":"Obstruction and T4 disease in bowel cancer","route":"/terms/obstructing-colorectal-cancer/","asOf":"2026-09-24","days":4},{"id":"liver-limited-metastatic-colorectal","kind":"term","name":"Liver-limited metastatic bowel cancer","route":"/terms/liver-limited-metastatic-colorectal/","asOf":"2026-09-24","days":4},{"id":"conversion-therapy-colorectal","kind":"term","name":"Conversion therapy in bowel cancer","route":"/terms/conversion-therapy-colorectal/","asOf":"2026-09-24","days":4},{"id":"colorectal-peritoneal-metastases","kind":"term","name":"Peritoneal metastases from bowel cancer","route":"/terms/colorectal-peritoneal-metastases/","asOf":"2026-09-24","days":4},{"id":"adenoma-detection-rate","kind":"term","name":"Adenoma detection rate","route":"/terms/adenoma-detection-rate/","asOf":"2026-09-24","days":4},{"id":"interval-cancer","kind":"term","name":"Interval cancer","route":"/terms/interval-cancer/","asOf":"2026-09-24","days":4},{"id":"screening-uptake","kind":"term","name":"Screening uptake","route":"/terms/screening-uptake/","asOf":"2026-09-24","days":4},{"id":"faecal-occult-blood-test","kind":"term","name":"Faecal occult blood test (guaiac)","route":"/terms/faecal-occult-blood-test/","asOf":"2026-09-24","days":4},{"id":"cytoreductive-surgery","kind":"term","name":"Cytoreductive surgery","route":"/terms/cytoreductive-surgery/","asOf":"2026-09-24","days":4},{"id":"peritoneal-carcinomatosis-index","kind":"term","name":"Peritoneal cancer index","route":"/terms/peritoneal-carcinomatosis-index/","asOf":"2026-09-24","days":4},{"id":"colibactin","kind":"term","name":"Colibactin","route":"/terms/colibactin/","asOf":"2026-09-24","days":4},{"id":"extended-ras-testing","kind":"term","name":"Extended RAS testing","route":"/terms/extended-ras-testing/","asOf":"2026-09-24","days":4},{"id":"anti-egfr-rechallenge","kind":"term","name":"Anti-EGFR rechallenge","route":"/terms/anti-egfr-rechallenge/","asOf":"2026-09-24","days":4},{"id":"cimp","kind":"term","name":"CpG island methylator phenotype (CIMP)","route":"/terms/cimp/","asOf":"2026-09-24","days":4},{"id":"immunoscore","kind":"term","name":"Immunoscore","route":"/terms/immunoscore/","asOf":"2026-09-24","days":4},{"id":"heracles-criteria","kind":"term","name":"HERACLES criteria (HER2 in bowel cancer)","route":"/terms/heracles-criteria/","asOf":"2026-09-24","days":4},{"id":"rspo-fusion","kind":"term","name":"R-spondin fusion","route":"/terms/rspo-fusion/","asOf":"2026-09-24","days":4},{"id":"low-anterior-resection-syndrome","kind":"term","name":"Low anterior resection syndrome (LARS)","route":"/terms/low-anterior-resection-syndrome/","asOf":"2026-09-24","days":4},{"id":"living-with-a-stoma-bowel-cancer","kind":"term","name":"Living with a stoma after bowel cancer surgery","route":"/terms/living-with-a-stoma-bowel-cancer/","asOf":"2026-09-24","days":4},{"id":"chemotherapy-side-effects-colorectal","kind":"term","name":"Living with FOLFOX, CAPOX, FOLFIRI and the EGFR antibodies","route":"/terms/chemotherapy-side-effects-colorectal/","asOf":"2026-09-24","days":4},{"id":"urgent-help-bowel-cancer","kind":"term","name":"When to seek urgent help with bowel cancer (NHS 111 and 999)","route":"/terms/urgent-help-bowel-cancer/","asOf":"2026-09-24","days":4},{"id":"lynch-syndrome-testing-uk","kind":"term","name":"Lynch syndrome testing after bowel cancer, and what it means for the family","route":"/terms/lynch-syndrome-testing-uk/","asOf":"2026-09-24","days":4},{"id":"sex-fertility-after-bowel-cancer","kind":"term","name":"Sexual function, fertility and body image after bowel cancer","route":"/terms/sex-fertility-after-bowel-cancer/","asOf":"2026-09-24","days":4},{"id":"work-and-money-bowel-cancer-uk","kind":"term","name":"Work and money with bowel cancer (UK)","route":"/terms/work-and-money-bowel-cancer-uk/","asOf":"2026-09-24","days":4},{"id":"carers-bowel-cancer-uk","kind":"term","name":"Carers: what you can do and UK carer support (bowel cancer)","route":"/terms/carers-bowel-cancer-uk/","asOf":"2026-09-24","days":4},{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/","asOf":"2026-09-24","days":4},{"id":"gallbladder-adenocarcinoma","kind":"cancer","name":"Gallbladder adenocarcinoma","route":"/cancers/gallbladder-adenocarcinoma/","asOf":"2026-09-24","days":4},{"id":"gallbladder-papillary-carcinoma","kind":"cancer","name":"Papillary carcinoma of the gallbladder","route":"/cancers/gallbladder-papillary-carcinoma/","asOf":"2026-09-24","days":4},{"id":"gallbladder-mucinous-carcinoma","kind":"cancer","name":"Mucinous carcinoma of the gallbladder","route":"/cancers/gallbladder-mucinous-carcinoma/","asOf":"2026-09-24","days":4},{"id":"gallbladder-adenosquamous-squamous-carcinoma","kind":"cancer","name":"Adenosquamous and squamous carcinoma of the gallbladder","route":"/cancers/gallbladder-adenosquamous-squamous-carcinoma/","asOf":"2026-09-24","days":4},{"id":"gallbladder-neuroendocrine-carcinoma","kind":"cancer","name":"Neuroendocrine carcinoma of the gallbladder","route":"/cancers/gallbladder-neuroendocrine-carcinoma/","asOf":"2026-09-24","days":4},{"id":"incidental-gallbladder-cancer","kind":"cancer","name":"Incidental gallbladder cancer (found after cholecystectomy)","route":"/cancers/incidental-gallbladder-cancer/","asOf":"2026-09-24","days":4},{"id":"gallbladder-carcinoma-in-situ-and-dysplasia","kind":"cancer","name":"Carcinoma in situ and dysplasia of the gallbladder","route":"/cancers/gallbladder-carcinoma-in-situ-and-dysplasia/","asOf":"2026-09-24","days":4},{"id":"cystic-duct-carcinoma","kind":"cancer","name":"Cystic duct carcinoma","route":"/cancers/cystic-duct-carcinoma/","asOf":"2026-09-24","days":4},{"id":"porcelain-gallbladder","kind":"term","name":"Porcelain gallbladder","route":"/terms/porcelain-gallbladder/","asOf":"2026-09-24","days":4},{"id":"gallbladder-polyp","kind":"term","name":"Gallbladder polyp (polypoid lesion)","route":"/terms/gallbladder-polyp/","asOf":"2026-09-24","days":4},{"id":"simple-cholecystectomy","kind":"term","name":"Simple cholecystectomy","route":"/terms/simple-cholecystectomy/","asOf":"2026-09-24","days":4},{"id":"radical-cholecystectomy","kind":"term","name":"Radical (extended) cholecystectomy","route":"/terms/radical-cholecystectomy/","asOf":"2026-09-24","days":4},{"id":"segment-ivb-v-resection","kind":"term","name":"Segment IVb and V liver resection (versus wedge resection)","route":"/terms/segment-ivb-v-resection/","asOf":"2026-09-24","days":4},{"id":"port-site-metastasis","kind":"term","name":"Port-site metastasis","route":"/terms/port-site-metastasis/","asOf":"2026-09-24","days":4},{"id":"t2a-versus-t2b","kind":"term","name":"T2a versus T2b gallbladder cancer (peritoneal side versus hepatic side)","route":"/terms/t2a-versus-t2b/","asOf":"2026-09-24","days":4},{"id":"rokitansky-aschoff-sinus","kind":"term","name":"Rokitansky-Aschoff sinus","route":"/terms/rokitansky-aschoff-sinus/","asOf":"2026-09-24","days":4},{"id":"anomalous-pancreaticobiliary-junction","kind":"term","name":"Anomalous pancreaticobiliary junction (pancreaticobiliary maljunction)","route":"/terms/anomalous-pancreaticobiliary-junction/","asOf":"2026-09-24","days":4},{"id":"cystic-duct-margin","kind":"term","name":"Cystic duct margin","route":"/terms/cystic-duct-margin/","asOf":"2026-09-24","days":4},{"id":"stent-or-bypass-for-jaundice","kind":"term","name":"Stent or bypass for jaundice: the choice","route":"/terms/stent-or-bypass-for-jaundice/","asOf":"2026-09-24","days":4},{"id":"genomic-testing-biliary-uk","kind":"term","name":"HER2 and genomic testing for biliary cancer on the NHS","route":"/terms/genomic-testing-biliary-uk/","asOf":"2026-09-24","days":4},{"id":"trial-or-standard-treatment-biliary","kind":"term","name":"A clinical trial or standard treatment for gallbladder cancer","route":"/terms/trial-or-standard-treatment-biliary/","asOf":"2026-09-24","days":4},{"id":"jaundice-and-itch-biliary","kind":"term","name":"Living with jaundice and itching (biliary cancer)","route":"/terms/jaundice-and-itch-biliary/","asOf":"2026-09-24","days":4},{"id":"biliary-stent-problems","kind":"term","name":"Biliary stent problems: blockage and infection","route":"/terms/biliary-stent-problems/","asOf":"2026-09-24","days":4},{"id":"acute-cholangitis","kind":"term","name":"Cholangitis: infection of a blocked bile duct","route":"/terms/acute-cholangitis/","asOf":"2026-09-24","days":4},{"id":"pain-with-biliary-cancer","kind":"term","name":"Pain with gallbladder and bile duct cancer","route":"/terms/pain-with-biliary-cancer/","asOf":"2026-09-24","days":4},{"id":"weight-loss-and-fat-digestion-biliary","kind":"term","name":"Weight loss, fat digestion and enzymes with gallbladder cancer","route":"/terms/weight-loss-and-fat-digestion-biliary/","asOf":"2026-09-24","days":4},{"id":"cancer-related-fatigue","kind":"term","name":"Cancer-related fatigue (tiredness)","route":"/terms/cancer-related-fatigue/","asOf":"2026-09-24","days":4},{"id":"eating-after-gallbladder-removal","kind":"term","name":"Eating after gallbladder removal","route":"/terms/eating-after-gallbladder-removal/","asOf":"2026-09-24","days":4},{"id":"urgent-help-gallbladder-cancer","kind":"term","name":"When to seek urgent help with gallbladder cancer (NHS 111 and 999)","route":"/terms/urgent-help-gallbladder-cancer/","asOf":"2026-09-24","days":4},{"id":"emotional-support-cancer-uk","kind":"term","name":"Emotional support and helplines (UK)","route":"/terms/emotional-support-cancer-uk/","asOf":"2026-09-24","days":4},{"id":"carers-gallbladder-cancer-uk","kind":"term","name":"Carers: what you can do and UK carer support","route":"/terms/carers-gallbladder-cancer-uk/","asOf":"2026-09-24","days":4},{"id":"metaplasia-dysplasia-carcinoma-sequence","kind":"term","name":"Metaplasia, dysplasia, carcinoma in situ: the flat route to gallbladder cancer","route":"/terms/metaplasia-dysplasia-carcinoma-sequence/","asOf":"2026-09-24","days":4},{"id":"intracholecystic-papillary-tubular-neoplasm","kind":"term","name":"Intracholecystic papillary-tubular neoplasm (ICPN)","route":"/terms/intracholecystic-papillary-tubular-neoplasm/","asOf":"2026-09-24","days":4},{"id":"salmonella-typhi-gallbladder-cancer","kind":"term","name":"Salmonella Typhi carriage and gallbladder cancer","route":"/terms/salmonella-typhi-gallbladder-cancer/","asOf":"2026-09-24","days":4},{"id":"her2-testing-in-biliary-cancer","kind":"term","name":"HER2 testing in biliary tract cancer (IHC, ISH and NGS)","route":"/terms/her2-testing-in-biliary-cancer/","asOf":"2026-09-24","days":4},{"id":"paper-li-gallbladder-exome-erbb-nat-genet-2014","kind":"paper","name":"Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway","route":"/key-papers/paper-li-gallbladder-exome-erbb-nat-genet-2014/","asOf":"2026-09-24","days":4},{"id":"paper-nakamura-biliary-genomic-spectra-nat-genet-2015","kind":"paper","name":"Genomic spectra of biliary tract cancer","route":"/key-papers/paper-nakamura-biliary-genomic-spectra-nat-genet-2015/","asOf":"2026-09-24","days":4},{"id":"paper-javle-biliary-ngs-cancer-2016","kind":"paper","name":"Biliary cancer: utility of next-generation sequencing for clinical management","route":"/key-papers/paper-javle-biliary-ngs-cancer-2016/","asOf":"2026-09-24","days":4},{"id":"paper-wardell-biliary-drivers-germline-j-hepatol-2018","kind":"paper","name":"Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations","route":"/key-papers/paper-wardell-biliary-drivers-germline-j-hepatol-2018/","asOf":"2026-09-24","days":4},{"id":"paper-narayan-gallbladder-regional-mutations-cancer-2019","kind":"paper","name":"Regional differences in gallbladder cancer pathogenesis: insights from a multi-institutional comparison of tumor mutations","route":"/key-papers/paper-narayan-gallbladder-regional-mutations-cancer-2019/","asOf":"2026-09-24","days":4},{"id":"paper-weinberg-biliary-profiling-jgo-2019","kind":"paper","name":"Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets","route":"/key-papers/paper-weinberg-biliary-profiling-jgo-2019/","asOf":"2026-09-24","days":4},{"id":"paper-pandey-gallbladder-elf3-nat-commun-2020","kind":"paper","name":"Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate","route":"/key-papers/paper-pandey-gallbladder-elf3-nat-commun-2020/","asOf":"2026-09-24","days":4},{"id":"paper-nepal-gallbladder-microenvironment-subtypes-j-hepatol-2021","kind":"paper","name":"Integrative molecular characterisation of gallbladder cancer reveals micro-environment-associated subtypes","route":"/key-papers/paper-nepal-gallbladder-microenvironment-subtypes-j-hepatol-2021/","asOf":"2026-09-24","days":4},{"id":"paper-giraldo-gallbladder-msk-impact-ccr-2022","kind":"paper","name":"Comprehensive molecular characterization of gallbladder carcinoma and potential targets for intervention","route":"/key-papers/paper-giraldo-gallbladder-msk-impact-ccr-2022/","asOf":"2026-09-24","days":4},{"id":"paper-mondaca-erbb2-gallbladder-us-chile-jco-go-2024","kind":"paper","name":"Clinical and genomic characterization of ERBB2-altered gallbladder cancer: exploring differences between an American and a Chilean cohort","route":"/key-papers/paper-mondaca-erbb2-gallbladder-us-chile-jco-go-2024/","asOf":"2026-09-24","days":4},{"id":"paper-suryavanshi-indian-gallbladder-genomics-jco-go-2025","kind":"paper","name":"Genomic profiling of Indian gallbladder carcinoma: mutational insights in a high-incidence population","route":"/key-papers/paper-suryavanshi-indian-gallbladder-genomics-jco-go-2025/","asOf":"2026-09-24","days":4},{"id":"paper-erices-chilean-gallbladder-landscape-front-oncol-2025","kind":"paper","name":"The mutational landscape and actionable targets of gallbladder cancer: an ancestry-informed and comparative analysis of a Chilean population","route":"/key-papers/paper-erices-chilean-gallbladder-landscape-front-oncol-2025/","asOf":"2026-09-24","days":4},{"id":"paper-cowzer-biliary-targeted-therapy-determinants-ccr-2026","kind":"paper","name":"Molecular and clinical determinants of targeted therapy treatment in biliary tract cancer","route":"/key-papers/paper-cowzer-biliary-targeted-therapy-determinants-ccr-2026/","asOf":"2026-09-24","days":4},{"id":"paper-goeppert-cholangiocarcinoma-mmr-deficiency-bjc-2019","kind":"paper","name":"Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma","route":"/key-papers/paper-goeppert-cholangiocarcinoma-mmr-deficiency-bjc-2019/","asOf":"2026-09-24","days":4},{"id":"paper-hiraoka-her2-status-biliary-hum-pathol-2020","kind":"paper","name":"Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer","route":"/key-papers/paper-hiraoka-her2-status-biliary-hum-pathol-2020/","asOf":"2026-09-24","days":4},{"id":"paper-roa-her2-overexpression-gallbladder-gcr-2014","kind":"paper","name":"Overexpression of the HER2/neu gene: a new therapeutic possibility for patients with advanced gallbladder cancer","route":"/key-papers/paper-roa-her2-overexpression-gallbladder-gcr-2014/","asOf":"2026-09-24","days":4},{"id":"paper-angerilli-her2-ihc-cish-biliary-hum-pathol-2026","kind":"paper","name":"HER2 status in extrahepatic cholangiocarcinoma and gallbladder carcinoma: concordance between immunohistochemistry and chromogenic in situ hybridization in 140 cases","route":"/key-papers/paper-angerilli-her2-ihc-cish-biliary-hum-pathol-2026/","asOf":"2026-09-24","days":4},{"id":"paper-neyaz-pdl1-gallbladder-histopathology-2018","kind":"paper","name":"Clinical relevance of PD-L1 expression in gallbladder cancer: a potential target for therapy","route":"/key-papers/paper-neyaz-pdl1-gallbladder-histopathology-2018/","asOf":"2026-09-24","days":4},{"id":"paper-albrecht-pdl1-western-gallbladder-cancers-2021","kind":"paper","name":"Programmed death ligand-1 (PD-L1) is an independent negative prognosticator in Western-world gallbladder cancer","route":"/key-papers/paper-albrecht-pdl1-western-gallbladder-cancers-2021/","asOf":"2026-09-24","days":4},{"id":"paper-patil-gallbladder-immune-microenvironment-aimm-2021","kind":"paper","name":"Immune microenvironment in gallbladder adenocarcinomas","route":"/key-papers/paper-patil-gallbladder-immune-microenvironment-aimm-2021/","asOf":"2026-09-24","days":4},{"id":"paper-scanu-salmonella-gallbladder-transformation-cell-host-microbe-2015","kind":"paper","name":"Salmonella manipulation of host signaling pathways provokes cellular transformation associated with gallbladder carcinoma","route":"/key-papers/paper-scanu-salmonella-gallbladder-transformation-cell-host-microbe-2015/","asOf":"2026-09-24","days":4},{"id":"paper-roa-gallbladder-preneoplastic-lesions-jso-2006","kind":"paper","name":"Preneoplastic lesions in gallbladder cancer","route":"/key-papers/paper-roa-gallbladder-preneoplastic-lesions-jso-2006/","asOf":"2026-09-24","days":4},{"id":"paper-roa-dysplasia-to-carcinoma-interval-gastroenterology-1996","kind":"paper","name":"Preneoplastic lesions and gallbladder cancer: an estimate of the period required for progression","route":"/key-papers/paper-roa-dysplasia-to-carcinoma-interval-gastroenterology-1996/","asOf":"2026-09-24","days":4},{"id":"paper-adsay-icpn-gallbladder-ajsp-2012","kind":"paper","name":"Intracholecystic papillary-tubular neoplasms (ICPN) of the gallbladder (neoplastic polyps, adenomas, and papillary neoplasms that are at least 1.0 cm): clinicopathologic and immunohistochemical analysis of 123 cases","route":"/key-papers/paper-adsay-icpn-gallbladder-ajsp-2012/","asOf":"2026-09-24","days":4},{"id":"paper-lin-gallbladder-neoplasia-carcinoma-evolution-nat-commun-2021","kind":"paper","name":"Genomic characterization of co-existing neoplasia and carcinoma lesions reveals distinct evolutionary paths of gallbladder cancer","route":"/key-papers/paper-lin-gallbladder-neoplasia-carcinoma-evolution-nat-commun-2021/","asOf":"2026-09-24","days":4},{"id":"paper-mody-biliary-ctdna-profiling-jco-po-2019","kind":"paper","name":"Circulating tumor DNA profiling of advanced biliary tract cancers","route":"/key-papers/paper-mody-biliary-ctdna-profiling-jco-po-2019/","asOf":"2026-09-24","days":4},{"id":"paper-ettrich-cholangiocarcinoma-ctdna-genotyping-sci-rep-2019","kind":"paper","name":"Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information","route":"/key-papers/paper-ettrich-cholangiocarcinoma-ctdna-genotyping-sci-rep-2019/","asOf":"2026-09-24","days":4},{"id":"paper-javle-mypathway-her2-biliary-lancet-oncol-2021","kind":"paper","name":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","route":"/key-papers/paper-javle-mypathway-her2-biliary-lancet-oncol-2021/","asOf":"2026-09-24","days":4},{"id":"paper-ohba-herb-trastuzumab-deruxtecan-biliary-jco-2024","kind":"paper","name":"Trastuzumab deruxtecan in human epidermal growth factor receptor 2-expressing biliary tract cancer (HERB; NCCH1805): a multicenter, single-arm, phase II trial","route":"/key-papers/paper-ohba-herb-trastuzumab-deruxtecan-biliary-jco-2024/","asOf":"2026-09-24","days":4},{"id":"paper-oh-destiny-pantumor02-biliary-pancreatic-esmo-open-2026","kind":"paper","name":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing biliary tract or pancreatic tumors: a subgroup analysis of DESTINY-PanTumor02","route":"/key-papers/paper-oh-destiny-pantumor02-biliary-pancreatic-esmo-open-2026/","asOf":"2026-09-24","days":4},{"id":"ammf","kind":"institution","name":"AMMF, the Cholangiocarcinoma Charity","route":"/institutions/ammf/","asOf":"2026-09-24","days":4},{"id":"kings-college-hospital-london","kind":"institution","name":"King's College Hospital, London","route":"/institutions/kings-college-hospital-london/","asOf":"2026-09-24","days":4},{"id":"addenbrookes-cambridge","kind":"institution","name":"Addenbrooke's Hospital, Cambridge University Hospitals","route":"/institutions/addenbrookes-cambridge/","asOf":"2026-09-24","days":4},{"id":"manchester-royal-infirmary","kind":"institution","name":"Manchester Royal Infirmary HPB Unit","route":"/institutions/manchester-royal-infirmary/","asOf":"2026-09-24","days":4},{"id":"liverpool-hpb-centre","kind":"institution","name":"Liverpool University Hospitals HPB centre (Aintree)","route":"/institutions/liverpool-hpb-centre/","asOf":"2026-09-24","days":4},{"id":"derriford-plymouth","kind":"institution","name":"Derriford Hospital, University Hospitals Plymouth","route":"/institutions/derriford-plymouth/","asOf":"2026-09-24","days":4},{"id":"glasgow-royal-infirmary","kind":"institution","name":"Glasgow Royal Infirmary","route":"/institutions/glasgow-royal-infirmary/","asOf":"2026-09-24","days":4},{"id":"royal-infirmary-edinburgh","kind":"institution","name":"Royal Infirmary of Edinburgh","route":"/institutions/royal-infirmary-edinburgh/","asOf":"2026-09-24","days":4},{"id":"morriston-swansea","kind":"institution","name":"Morriston Hospital, Swansea","route":"/institutions/morriston-swansea/","asOf":"2026-09-24","days":4},{"id":"university-hospital-wales-cardiff","kind":"institution","name":"University Hospital of Wales, Cardiff","route":"/institutions/university-hospital-wales-cardiff/","asOf":"2026-09-24","days":4},{"id":"belfast-trust-hpb","kind":"institution","name":"Belfast Health and Social Care Trust HPB service","route":"/institutions/belfast-trust-hpb/","asOf":"2026-09-24","days":4},{"id":"john-bridgewater","kind":"person","name":"John Bridgewater","route":"/people/john-bridgewater/","asOf":"2026-09-24","days":4},{"id":"mairead-mcnamara","kind":"person","name":"Mairéad McNamara","route":"/people/mairead-mcnamara/","asOf":"2026-09-24","days":4},{"id":"shahid-khan","kind":"person","name":"Shahid A. Khan","route":"/people/shahid-khan/","asOf":"2026-09-24","days":4},{"id":"hassan-malik","kind":"person","name":"Hassan Malik","route":"/people/hassan-malik/","asOf":"2026-09-24","days":4},{"id":"uk-hpb-specialist-centres","kind":"collection","name":"UK specialist HPB cancer centres","route":"/collections/uk-hpb-specialist-centres/","asOf":"2026-09-24","days":4},{"id":"gallbladder-cancer-surgery","kind":"technology","name":"Surgery for gallbladder cancer: simple versus radical cholecystectomy, re-resection and lymphadenectomy","route":"/technologies/gallbladder-cancer-surgery/","asOf":"2026-09-24","days":4},{"id":"gallbladder-cancer-in-biliary-trials","kind":"term","name":"Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)","route":"/terms/gallbladder-cancer-in-biliary-trials/","asOf":"2026-09-24","days":4},{"id":"biliary-drainage-routes","kind":"term","name":"Biliary drainage routes: ERCP stent, percutaneous (PTC) and EUS-guided","route":"/terms/biliary-drainage-routes/","asOf":"2026-09-24","days":4},{"id":"duodenal-stenting-gastric-outlet","kind":"term","name":"Duodenal stenting and gastrojejunostomy for malignant gastric outlet obstruction","route":"/terms/duodenal-stenting-gastric-outlet/","asOf":"2026-09-24","days":4},{"id":"gallbladder-cancer-symptom-control","kind":"term","name":"Symptom control in advanced gallbladder cancer: pain, ascites and nutrition","route":"/terms/gallbladder-cancer-symptom-control/","asOf":"2026-09-24","days":4},{"id":"liposomal-irinotecan","kind":"drug","name":"Liposomal irinotecan","route":"/drugs/liposomal-irinotecan/","asOf":"2026-09-24","days":4},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/","asOf":"2026-09-24","days":4},{"id":"varlitinib","kind":"drug","name":"Varlitinib","route":"/drugs/varlitinib/","asOf":"2026-09-24","days":4},{"id":"acticca-1","kind":"trial","name":"ACTICCA-1","route":"/trials/acticca-1/","asOf":"2026-09-24","days":4},{"id":"ascot-jcog1202","kind":"trial","name":"ASCOT (JCOG1202)","route":"/trials/ascot-jcog1202/","asOf":"2026-09-24","days":4},{"id":"swog-s0809","kind":"trial","name":"SWOG S0809","route":"/trials/swog-s0809/","asOf":"2026-09-24","days":4},{"id":"opt-in","kind":"trial","name":"OPT-IN (EA2197)","route":"/trials/opt-in/","asOf":"2026-09-24","days":4},{"id":"gain-igbc","kind":"trial","name":"GAIN (AIO/CALGP/ACO)","route":"/trials/gain-igbc/","asOf":"2026-09-24","days":4},{"id":"polcagb","kind":"trial","name":"POLCAGB","route":"/trials/polcagb/","asOf":"2026-09-24","days":4},{"id":"neogb","kind":"trial","name":"NEOGB","route":"/trials/neogb/","asOf":"2026-09-24","days":4},{"id":"rugb","kind":"trial","name":"RUGB","route":"/trials/rugb/","asOf":"2026-09-24","days":4},{"id":"debate","kind":"trial","name":"DEBATE","route":"/trials/debate/","asOf":"2026-09-24","days":4},{"id":"swog-s1815","kind":"trial","name":"SWOG S1815","route":"/trials/swog-s1815/","asOf":"2026-09-24","days":4},{"id":"gap-phase2-mdacc","kind":"trial","name":"Gemcitabine, cisplatin and nab-paclitaxel phase 2 (MD Anderson and Mayo)","route":"/trials/gap-phase2-mdacc/","asOf":"2026-09-24","days":4},{"id":"nifty","kind":"trial","name":"NIFTY","route":"/trials/nifty/","asOf":"2026-09-24","days":4},{"id":"nife","kind":"trial","name":"NIFE (AIO-YMO HEP-0315)","route":"/trials/nife/","asOf":"2026-09-24","days":4},{"id":"treetopp","kind":"trial","name":"TreeTopp","route":"/trials/treetopp/","asOf":"2026-09-24","days":4},{"id":"eortc-1607-pembro-cisgem","kind":"trial","name":"EORTC 1607: pembrolizumab with cisplatin and gemcitabine in biliary tract cancer","route":"/trials/eortc-1607-pembro-cisgem/","asOf":"2026-09-24","days":4},{"id":"sevilla","kind":"trial","name":"SEVILLA","route":"/trials/sevilla/","asOf":"2026-09-24","days":4},{"id":"safir-abc10","kind":"trial","name":"SAFIR-ABC10","route":"/trials/safir-abc10/","asOf":"2026-09-24","days":4},{"id":"determine-arm04","kind":"trial","name":"DETERMINE arm 04: trastuzumab with pertuzumab in HER2-amplified or mutated rare cancers","route":"/trials/determine-arm04/","asOf":"2026-09-24","days":4},{"id":"abc-07","kind":"trial","name":"ABC-07","route":"/trials/abc-07/","asOf":"2026-09-24","days":4},{"id":"abc-12","kind":"trial","name":"ABC-12","route":"/trials/abc-12/","asOf":"2026-09-24","days":4},{"id":"ea2197-ivonescimab","kind":"trial","name":"EA2197 ivonescimab: ivonescimab with gemcitabine and cisplatin versus standard chemo-immunotherapy in advanced biliary tract cancer","route":"/trials/ea2197-ivonescimab/","asOf":"2026-09-24","days":4},{"id":"combomatch-binimetinib-folfox","kind":"trial","name":"ComboMATCH: FOLFOX with or without binimetinib in second-line biliary tract cancer with MAPK pathway alterations","route":"/trials/combomatch-binimetinib-folfox/","asOf":"2026-09-24","days":4},{"id":"trap-btc","kind":"trial","name":"TRAP-BTC","route":"/trials/trap-btc/","asOf":"2026-09-24","days":4},{"id":"tesla-rct","kind":"trial","name":"TESLA RCT","route":"/trials/tesla-rct/","asOf":"2026-09-24","days":4},{"id":"herizon-btc-01","kind":"trial","name":"HERIZON-BTC-01","route":"/trials/herizon-btc-01/","asOf":"2026-09-24","days":4},{"id":"roar","kind":"trial","name":"ROAR (Rare Oncology Agnostic Research) basket: BRAF V600E biliary tract cancer cohort","route":"/trials/roar/","asOf":"2026-09-24","days":4},{"id":"keynote-158","kind":"trial","name":"KEYNOTE-158","route":"/trials/keynote-158/","asOf":"2026-09-24","days":4},{"id":"nct05482516","kind":"trial","name":"Evaluating Novel Therapies in ctDNA Positive GI Cancers","route":"/trials/nct05482516/","asOf":"2026-09-24","days":4},{"id":"nct07062263","kind":"trial","name":"Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients","route":"/trials/nct07062263/","asOf":"2026-09-24","days":4},{"id":"nct07745296","kind":"trial","name":"Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer","route":"/trials/nct07745296/","asOf":"2026-09-24","days":4},{"id":"nct06037980","kind":"trial","name":"CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence","route":"/trials/nct06037980/","asOf":"2026-09-24","days":4},{"id":"nct06355427","kind":"trial","name":"The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma","route":"/trials/nct06355427/","asOf":"2026-09-24","days":4},{"id":"nct06662877","kind":"trial","name":"Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment","route":"/trials/nct06662877/","asOf":"2026-09-24","days":4},{"id":"nct07437287","kind":"trial","name":"Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers","route":"/trials/nct07437287/","asOf":"2026-09-24","days":4},{"id":"nct07598318","kind":"trial","name":"Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations","route":"/trials/nct07598318/","asOf":"2026-09-24","days":4},{"id":"nct02151084","kind":"trial","name":"A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer","route":"/trials/nct02151084/","asOf":"2026-09-24","days":4},{"id":"nct02632305","kind":"trial","name":"A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer","route":"/trials/nct02632305/","asOf":"2026-09-24","days":4},{"id":"nct03364530","kind":"trial","name":"Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma","route":"/trials/nct03364530/","asOf":"2026-09-24","days":4},{"id":"nct03482102","kind":"trial","name":"Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer","route":"/trials/nct03482102/","asOf":"2026-09-24","days":4},{"id":"nct03801083","kind":"trial","name":"Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers","route":"/trials/nct03801083/","asOf":"2026-09-24","days":4},{"id":"nct03937830","kind":"trial","name":"Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma","route":"/trials/nct03937830/","asOf":"2026-09-24","days":4},{"id":"nct04005339","kind":"trial","name":"NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer","route":"/trials/nct04005339/","asOf":"2026-09-24","days":4},{"id":"nct04042831","kind":"trial","name":"Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations","route":"/trials/nct04042831/","asOf":"2026-09-24","days":4},{"id":"nct04183712","kind":"trial","name":"Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA","route":"/trials/nct04183712/","asOf":"2026-09-24","days":4},{"id":"nct04238637","kind":"trial","name":"Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)","route":"/trials/nct04238637/","asOf":"2026-09-24","days":4},{"id":"nct04634058","kind":"trial","name":"PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment","route":"/trials/nct04634058/","asOf":"2026-09-24","days":4},{"id":"nct04910386","kind":"trial","name":"Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers","route":"/trials/nct04910386/","asOf":"2026-09-24","days":4},{"id":"nct04941287","kind":"trial","name":"Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer","route":"/trials/nct04941287/","asOf":"2026-09-24","days":4},{"id":"nct04969887","kind":"trial","name":"Combination Immunotherapy in Rare Cancers Under InvesTigation","route":"/trials/nct04969887/","asOf":"2026-09-24","days":4},{"id":"nct05170438","kind":"trial","name":"Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment","route":"/trials/nct05170438/","asOf":"2026-09-24","days":4},{"id":"nct05222971","kind":"trial","name":"Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy","route":"/trials/nct05222971/","asOf":"2026-09-24","days":4},{"id":"nct05422690","kind":"trial","name":"The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer","route":"/trials/nct05422690/","asOf":"2026-09-24","days":4},{"id":"nct05451043","kind":"trial","name":"Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)","route":"/trials/nct05451043/","asOf":"2026-09-24","days":4},{"id":"nct05451290","kind":"trial","name":"Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer","route":"/trials/nct05451290/","asOf":"2026-09-24","days":4},{"id":"nct05640791","kind":"trial","name":"Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer","route":"/trials/nct05640791/","asOf":"2026-09-24","days":4},{"id":"nct05705492","kind":"trial","name":"Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer","route":"/trials/nct05705492/","asOf":"2026-09-24","days":4},{"id":"nct05724563","kind":"trial","name":"Domvanalimab and Zimberelimab in Advanced Liver Cancers","route":"/trials/nct05724563/","asOf":"2026-09-24","days":4},{"id":"nct05733000","kind":"trial","name":"CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors","route":"/trials/nct05733000/","asOf":"2026-09-24","days":4},{"id":"nct05757336","kind":"trial","name":"Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer","route":"/trials/nct05757336/","asOf":"2026-09-24","days":4},{"id":"nct05985707","kind":"trial","name":"KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma","route":"/trials/nct05985707/","asOf":"2026-09-24","days":4},{"id":"nct06001658","kind":"trial","name":"Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers","route":"/trials/nct06001658/","asOf":"2026-09-24","days":4},{"id":"nct06037655","kind":"trial","name":"Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC","route":"/trials/nct06037655/","asOf":"2026-09-24","days":4},{"id":"nct06048133","kind":"trial","name":"Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)","route":"/trials/nct06048133/","asOf":"2026-09-24","days":4},{"id":"nct06135896","kind":"trial","name":"Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers","route":"/trials/nct06135896/","asOf":"2026-09-24","days":4},{"id":"nct06230471","kind":"trial","name":"Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer","route":"/trials/nct06230471/","asOf":"2026-09-24","days":4},{"id":"nct06274879","kind":"trial","name":"Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer","route":"/trials/nct06274879/","asOf":"2026-09-24","days":4},{"id":"nct06280508","kind":"trial","name":"Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer","route":"/trials/nct06280508/","asOf":"2026-09-24","days":4},{"id":"nct06389500","kind":"trial","name":"HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer","route":"/trials/nct06389500/","asOf":"2026-09-24","days":4},{"id":"nct06423170","kind":"trial","name":"A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs","route":"/trials/nct06423170/","asOf":"2026-09-24","days":4},{"id":"nct06438822","kind":"trial","name":"Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma","route":"/trials/nct06438822/","asOf":"2026-09-24","days":4},{"id":"nct06490107","kind":"trial","name":"Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC","route":"/trials/nct06490107/","asOf":"2026-09-24","days":4},{"id":"nct06502080","kind":"trial","name":"Consolidative Radiotherapy (CSRT) in Patients With Oligometastatic/Locally Advanced Unresectable Bilary Tract Cancer (BTC)","route":"/trials/nct06502080/","asOf":"2026-09-24","days":4},{"id":"nct06530823","kind":"trial","name":"Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma","route":"/trials/nct06530823/","asOf":"2026-09-24","days":4},{"id":"nct06531291","kind":"trial","name":"Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation","route":"/trials/nct06531291/","asOf":"2026-09-24","days":4},{"id":"nct06591650","kind":"trial","name":"Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer","route":"/trials/nct06591650/","asOf":"2026-09-24","days":4},{"id":"nct06620848","kind":"trial","name":"A Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors.","route":"/trials/nct06620848/","asOf":"2026-09-24","days":4},{"id":"nct06638931","kind":"trial","name":"Agnostic Therapy in Rare Solid Tumors","route":"/trials/nct06638931/","asOf":"2026-09-24","days":4},{"id":"nct06654947","kind":"trial","name":"A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.","route":"/trials/nct06654947/","asOf":"2026-09-24","days":4},{"id":"nct06708858","kind":"trial","name":"Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer","route":"/trials/nct06708858/","asOf":"2026-09-24","days":4},{"id":"nct06717464","kind":"trial","name":"Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer","route":"/trials/nct06717464/","asOf":"2026-09-24","days":4},{"id":"nct06728410","kind":"trial","name":"A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement","route":"/trials/nct06728410/","asOf":"2026-09-24","days":4},{"id":"nct06789848","kind":"trial","name":"Ligufalimab and Cadonilimab in Advanced Liver Cancers","route":"/trials/nct06789848/","asOf":"2026-09-24","days":4},{"id":"nct06852287","kind":"trial","name":"Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer","route":"/trials/nct06852287/","asOf":"2026-09-24","days":4},{"id":"nct06892925","kind":"trial","name":"QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors","route":"/trials/nct06892925/","asOf":"2026-09-24","days":4},{"id":"nct06901622","kind":"trial","name":"Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma","route":"/trials/nct06901622/","asOf":"2026-09-24","days":4},{"id":"nct06903273","kind":"trial","name":"Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma","route":"/trials/nct06903273/","asOf":"2026-09-24","days":4},{"id":"nct06919848","kind":"trial","name":"Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)","route":"/trials/nct06919848/","asOf":"2026-09-24","days":4},{"id":"nct06963060","kind":"trial","name":"Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)","route":"/trials/nct06963060/","asOf":"2026-09-24","days":4},{"id":"nct06993025","kind":"trial","name":"Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies","route":"/trials/nct06993025/","asOf":"2026-09-24","days":4},{"id":"nct07003815","kind":"trial","name":"Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer","route":"/trials/nct07003815/","asOf":"2026-09-24","days":4},{"id":"nct07025174","kind":"trial","name":"Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer","route":"/trials/nct07025174/","asOf":"2026-09-24","days":4},{"id":"nct07036380","kind":"trial","name":"MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma","route":"/trials/nct07036380/","asOf":"2026-09-24","days":4},{"id":"nct07062536","kind":"trial","name":"mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line","route":"/trials/nct07062536/","asOf":"2026-09-24","days":4},{"id":"nct07099794","kind":"trial","name":"A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen","route":"/trials/nct07099794/","asOf":"2026-09-24","days":4},{"id":"nct07105852","kind":"trial","name":"Exploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Advanced Cholangiocarcinoma","route":"/trials/nct07105852/","asOf":"2026-09-24","days":4},{"id":"nct07109167","kind":"trial","name":"The Safety and Efficacy of Benmelstobart Injection in Patients With Advanced Biliary Tract Malignant Tumors","route":"/trials/nct07109167/","asOf":"2026-09-24","days":4},{"id":"nct07129018","kind":"trial","name":"Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer","route":"/trials/nct07129018/","asOf":"2026-09-24","days":4},{"id":"nct07135544","kind":"trial","name":"A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer","route":"/trials/nct07135544/","asOf":"2026-09-24","days":4},{"id":"nct07146646","kind":"trial","name":"Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer","route":"/trials/nct07146646/","asOf":"2026-09-24","days":4},{"id":"nct07151872","kind":"trial","name":"Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer","route":"/trials/nct07151872/","asOf":"2026-09-24","days":4},{"id":"nct07159204","kind":"trial","name":"Polymeric Micellar Paclitaxel-Based Combination Therapy for Advanced Biliary Tract Cancer","route":"/trials/nct07159204/","asOf":"2026-09-24","days":4},{"id":"nct07159217","kind":"trial","name":"Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer","route":"/trials/nct07159217/","asOf":"2026-09-24","days":4},{"id":"nct07160283","kind":"trial","name":"The Efficacy and Safety of Trilaciclib in Bone Marrow Protection Before Chemotherapy for Advanced Bile Duct Cancer and Pancreatic Cancer","route":"/trials/nct07160283/","asOf":"2026-09-24","days":4},{"id":"nct07263360","kind":"trial","name":"Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer","route":"/trials/nct07263360/","asOf":"2026-09-24","days":4},{"id":"nct07267078","kind":"trial","name":"Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer","route":"/trials/nct07267078/","asOf":"2026-09-24","days":4},{"id":"nct07282262","kind":"trial","name":"An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.","route":"/trials/nct07282262/","asOf":"2026-09-24","days":4},{"id":"nct07282912","kind":"trial","name":"Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels","route":"/trials/nct07282912/","asOf":"2026-09-24","days":4},{"id":"nct07296666","kind":"trial","name":"Adjuvant Chemotherapy for BTC Based on 3D-PTA","route":"/trials/nct07296666/","asOf":"2026-09-24","days":4},{"id":"nct07310069","kind":"trial","name":"Gemcitabine and Nab-Paclitaxel Combined With Iparomlimab and Tuvorilimab for Advanced Gallbladder Cancer","route":"/trials/nct07310069/","asOf":"2026-09-24","days":4},{"id":"nct07351591","kind":"trial","name":"A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Biliary Tract Cancers","route":"/trials/nct07351591/","asOf":"2026-09-24","days":4},{"id":"nct07433673","kind":"trial","name":"Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)","route":"/trials/nct07433673/","asOf":"2026-09-24","days":4},{"id":"nct07471165","kind":"trial","name":"A Prospective, Single-Arm, Phase II Study: PD-L1 Monoclonal Antibody + Chemoradiotherapy as Bridge Therapy to Liver Transplantation for Locally Advanced Perihilar Cholangiocarcinoma (ACHIEVE-LT)","route":"/trials/nct07471165/","asOf":"2026-09-24","days":4},{"id":"nct07472933","kind":"trial","name":"Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies","route":"/trials/nct07472933/","asOf":"2026-09-24","days":4},{"id":"nct07478523","kind":"trial","name":"FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers","route":"/trials/nct07478523/","asOf":"2026-09-24","days":4},{"id":"nct07506057","kind":"trial","name":"Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy","route":"/trials/nct07506057/","asOf":"2026-09-24","days":4},{"id":"nct07514533","kind":"trial","name":"The Efficacy and Safety of Pucotenlimab (PD-1) Combined With Becotatugvedotin (EGFR-ADC) in Advanced Cholangiocarcinoma","route":"/trials/nct07514533/","asOf":"2026-09-24","days":4},{"id":"nct07530445","kind":"trial","name":"Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer","route":"/trials/nct07530445/","asOf":"2026-09-24","days":4},{"id":"nct07561775","kind":"trial","name":"Adebrelimab Plus S-1 for Resected Cholangiocarcinoma","route":"/trials/nct07561775/","asOf":"2026-09-24","days":4},{"id":"nct07569679","kind":"trial","name":"Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer","route":"/trials/nct07569679/","asOf":"2026-09-24","days":4},{"id":"nct07570849","kind":"trial","name":"Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma","route":"/trials/nct07570849/","asOf":"2026-09-24","days":4},{"id":"nct07599995","kind":"trial","name":"Gemcitabine-Cisplatin Plus Envafolimab in Resectable Biliary Tract Malignancies","route":"/trials/nct07599995/","asOf":"2026-09-24","days":4},{"id":"nct07623642","kind":"trial","name":"A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.","route":"/trials/nct07623642/","asOf":"2026-09-24","days":4},{"id":"nct07631884","kind":"trial","name":"Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor","route":"/trials/nct07631884/","asOf":"2026-09-24","days":4},{"id":"nct07635290","kind":"trial","name":"Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer","route":"/trials/nct07635290/","asOf":"2026-09-24","days":4},{"id":"nct07636824","kind":"trial","name":"Efficacy and Safety of Postoperative Concurrent Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma: A Multicenter Prospective Phase II Study","route":"/trials/nct07636824/","asOf":"2026-09-24","days":4},{"id":"nct07638501","kind":"trial","name":"Efficacy and Safety of SBRT Plus Gemcitabine, Cisplatin, and Sintilimab as First-Line Treatment for Unresectable Biliary Tract Cancer","route":"/trials/nct07638501/","asOf":"2026-09-24","days":4},{"id":"nct07649980","kind":"trial","name":"Becotatug Vedotin Plus Pucotenlimab for Advanced Biliary Tract Cancer, Phase II","route":"/trials/nct07649980/","asOf":"2026-09-24","days":4},{"id":"nct07654530","kind":"trial","name":"Sintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC.","route":"/trials/nct07654530/","asOf":"2026-09-24","days":4},{"id":"nct07668453","kind":"trial","name":"An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies","route":"/trials/nct07668453/","asOf":"2026-09-24","days":4},{"id":"nct07670273","kind":"trial","name":"Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer","route":"/trials/nct07670273/","asOf":"2026-09-24","days":4},{"id":"nct07679399","kind":"trial","name":"A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.","route":"/trials/nct07679399/","asOf":"2026-09-24","days":4},{"id":"nct07701122","kind":"trial","name":"Sacituzumab Tirumotecan in Previously Treated TROP2-Positive Advanced Biliary Tract Cancer","route":"/trials/nct07701122/","asOf":"2026-09-24","days":4},{"id":"nct07704177","kind":"trial","name":"Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer","route":"/trials/nct07704177/","asOf":"2026-09-24","days":4},{"id":"nct07723534","kind":"trial","name":"Zolbetuximab With mFOLFOX6 or CAPOX in Claudin 18.2 Overexpressed Advanced or Metastatic Biliary Tract Cancers","route":"/trials/nct07723534/","asOf":"2026-09-24","days":4},{"id":"nct07726446","kind":"trial","name":"Study on Sequential Cryoablation, Relaforp Alpha, and Chemotherapy for Bile Duct Tumors","route":"/trials/nct07726446/","asOf":"2026-09-24","days":4},{"id":"nct07729033","kind":"trial","name":"A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy.","route":"/trials/nct07729033/","asOf":"2026-09-24","days":4},{"id":"nct07729917","kind":"trial","name":"Precision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform Study","route":"/trials/nct07729917/","asOf":"2026-09-24","days":4},{"id":"nct07733115","kind":"trial","name":"QL1706（Iparomlimab/Tuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line Treatment for PD-L1-Positive Biliary Tract Cancer","route":"/trials/nct07733115/","asOf":"2026-09-24","days":4},{"id":"nct07767994","kind":"trial","name":"AK112 Combined With GAP Conversion Therapy for Locally Advanced Gallbladder Cancer","route":"/trials/nct07767994/","asOf":"2026-09-24","days":4},{"id":"nct07780838","kind":"trial","name":"Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma","route":"/trials/nct07780838/","asOf":"2026-09-24","days":4},{"id":"nct07786766","kind":"trial","name":"Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive Cholangiocarcinoma","route":"/trials/nct07786766/","asOf":"2026-09-24","days":4},{"id":"nct07793253","kind":"trial","name":"Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer","route":"/trials/nct07793253/","asOf":"2026-09-24","days":4},{"id":"nct07797816","kind":"trial","name":"Liposomal Irinotecan Plus 5-FU/LV and Sintilimab With Sequential SBRT for Locally Advanced Biliary Tract Cancer","route":"/trials/nct07797816/","asOf":"2026-09-24","days":4},{"id":"nct07829874","kind":"trial","name":"Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer.","route":"/trials/nct07829874/","asOf":"2026-09-24","days":4},{"id":"nct07831993","kind":"trial","name":"Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer","route":"/trials/nct07831993/","asOf":"2026-09-24","days":4},{"id":"nct04068194","kind":"trial","name":"Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies","route":"/trials/nct04068194/","asOf":"2026-09-24","days":4},{"id":"nct04645160","kind":"trial","name":"Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers","route":"/trials/nct04645160/","asOf":"2026-09-24","days":4},{"id":"nct04781192","kind":"trial","name":"The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers","route":"/trials/nct04781192/","asOf":"2026-09-24","days":4},{"id":"nct05000294","kind":"trial","name":"Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types","route":"/trials/nct05000294/","asOf":"2026-09-24","days":4},{"id":"nct05749900","kind":"trial","name":"First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)","route":"/trials/nct05749900/","asOf":"2026-09-24","days":4},{"id":"nct05849480","kind":"trial","name":"A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)","route":"/trials/nct05849480/","asOf":"2026-09-24","days":4},{"id":"nct05994001","kind":"trial","name":"Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody","route":"/trials/nct05994001/","asOf":"2026-09-24","days":4},{"id":"nct06548412","kind":"trial","name":"CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers","route":"/trials/nct06548412/","asOf":"2026-09-24","days":4},{"id":"nct07269158","kind":"trial","name":"A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer","route":"/trials/nct07269158/","asOf":"2026-09-24","days":4},{"id":"nct07392541","kind":"trial","name":"Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer","route":"/trials/nct07392541/","asOf":"2026-09-24","days":4},{"id":"nct07594626","kind":"trial","name":"BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion","route":"/trials/nct07594626/","asOf":"2026-09-24","days":4},{"id":"nct07632235","kind":"trial","name":"A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma","route":"/trials/nct07632235/","asOf":"2026-09-24","days":4},{"id":"nct07636798","kind":"trial","name":"Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer","route":"/trials/nct07636798/","asOf":"2026-09-24","days":4},{"id":"prophylactic-cholecystectomy","kind":"term","name":"Prophylactic (preventive) cholecystectomy","route":"/terms/prophylactic-cholecystectomy/","asOf":"2026-09-24","days":4},{"id":"paper-esmo-biliary-tract-cancer-guideline-ann-oncol-2023","kind":"paper","name":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","route":"/key-papers/paper-esmo-biliary-tract-cancer-guideline-ann-oncol-2023/","asOf":"2026-09-24","days":4},{"id":"paper-nccn-biliary-tract-cancers-v2-2025-jnccn-2025","kind":"paper","name":"Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology","route":"/key-papers/paper-nccn-biliary-tract-cancers-v2-2025-jnccn-2025/","asOf":"2026-09-24","days":4},{"id":"paper-bsg-cholangiocarcinoma-guideline-gut-2023","kind":"paper","name":"British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma","route":"/key-papers/paper-bsg-cholangiocarcinoma-guideline-gut-2023/","asOf":"2026-09-24","days":4},{"id":"paper-gallbladder-polyp-joint-guideline-eur-radiol-2022","kind":"paper","name":"Management and follow-up of gallbladder polyps: updated joint guidelines between the ESGAR, EAES, EFISDS and ESGE","route":"/key-papers/paper-gallbladder-polyp-joint-guideline-eur-radiol-2022/","asOf":"2026-09-24","days":4},{"id":"paper-jshbps-biliary-tract-cancer-guidelines-2019-jhbps-2021","kind":"paper","name":"Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd English edition","route":"/key-papers/paper-jshbps-biliary-tract-cancer-guidelines-2019-jhbps-2021/","asOf":"2026-09-24","days":4},{"id":"paper-abc-06-folfox-second-line-lancet-oncol-2021","kind":"paper","name":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","route":"/key-papers/paper-abc-06-folfox-second-line-lancet-oncol-2021/","asOf":"2026-09-24","days":4},{"id":"paper-nifty-liposomal-irinotecan-lancet-oncol-2021","kind":"paper","name":"Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study","route":"/key-papers/paper-nifty-liposomal-irinotecan-lancet-oncol-2021/","asOf":"2026-09-24","days":4},{"id":"paper-swog-s0809-adjuvant-chemoradiation-jco-2015","kind":"paper","name":"SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma","route":"/key-papers/paper-swog-s0809-adjuvant-chemoradiation-jco-2015/","asOf":"2026-09-24","days":4},{"id":"paper-topaz-1-three-year-survival-j-hepatol-2025","kind":"paper","name":"Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study","route":"/key-papers/paper-topaz-1-three-year-survival-j-hepatol-2025/","asOf":"2026-09-24","days":4},{"id":"paper-polcagb-protocol-bmj-open-2019","kind":"paper","name":"A phase III randomised clinical trial of perioperative therapy (neoadjuvant chemotherapy versus chemoradiotherapy) in locally advanced gallbladder cancers (POLCAGB): study protocol","route":"/key-papers/paper-polcagb-protocol-bmj-open-2019/","asOf":"2026-09-24","days":4},{"id":"paper-gain-trial-protocol-bmc-cancer-2020","kind":"paper","name":"Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) - a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)- the AIO/ CALGP/ ACO- GAIN-trial","route":"/key-papers/paper-gain-trial-protocol-bmc-cancer-2020/","asOf":"2026-09-24","days":4},{"id":"paper-pawlik-incidental-gallbladder-cancer-residual-disease-jgs-2007","kind":"paper","name":"Incidence of finding residual disease for incidental gallbladder carcinoma: implications for re-resection","route":"/key-papers/paper-pawlik-incidental-gallbladder-cancer-residual-disease-jgs-2007/","asOf":"2026-09-24","days":4},{"id":"paper-ethun-re-resection-timing-incidental-gallbladder-cancer-jama-surg-2017","kind":"paper","name":"Association of Optimal Time Interval to Re-resection for Incidental Gallbladder Cancer With Overall Survival: A Multi-Institution Analysis From the US Extrahepatic Biliary Malignancy Consortium","route":"/key-papers/paper-ethun-re-resection-timing-incidental-gallbladder-cancer-jama-surg-2017/","asOf":"2026-09-24","days":4},{"id":"paper-soreide-incidental-gallbladder-cancer-review-bjs-2019","kind":"paper","name":"Systematic review of management of incidental gallbladder cancer after cholecystectomy","route":"/key-papers/paper-soreide-incidental-gallbladder-cancer-review-bjs-2019/","asOf":"2026-09-24","days":4},{"id":"paper-pyo-incidental-gallbladder-cancer-meta-analysis-jcm-2020","kind":"paper","name":"Incidental Carcinoma after Cholecystectomy for Benign Disease of the Gallbladder: A Meta-Analysis","route":"/key-papers/paper-pyo-incidental-gallbladder-cancer-meta-analysis-jcm-2020/","asOf":"2026-09-24","days":4},{"id":"paper-de-savornin-lohman-re-resection-incidental-gallbladder-cancer-aso-2020","kind":"paper","name":"Re-resection in Incidental Gallbladder Cancer: Survival and the Incidence of Residual Disease","route":"/key-papers/paper-de-savornin-lohman-re-resection-incidental-gallbladder-cancer-aso-2020/","asOf":"2026-09-24","days":4},{"id":"paper-selvakumar-revision-surgery-timing-ipd-meta-analysis-hpb-2026","kind":"paper","name":"Timing of revision surgery for incidental gallbladder cancer: a systematic review and individual patient data meta-analysis","route":"/key-papers/paper-selvakumar-revision-surgery-timing-ipd-meta-analysis-hpb-2026/","asOf":"2026-09-24","days":4},{"id":"paper-kim-t1b-gallbladder-cancer-international-jhbps-2018","kind":"paper","name":"Optimal surgical treatment in patients with T1b gallbladder cancer: An international multicenter study","route":"/key-papers/paper-kim-t1b-gallbladder-cancer-international-jhbps-2018/","asOf":"2026-09-24","days":4},{"id":"paper-shindoh-t2-gallbladder-cancer-tumour-location-ann-surg-2015","kind":"paper","name":"Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: an international multicenter study","route":"/key-papers/paper-shindoh-t2-gallbladder-cancer-tumour-location-ann-surg-2015/","asOf":"2026-09-24","days":4},{"id":"paper-lee-t2-gallbladder-cancer-surgical-strategy-aso-2015","kind":"paper","name":"Surgical Strategy for T2 Gallbladder Cancer According to Tumor Location","route":"/key-papers/paper-lee-t2-gallbladder-cancer-surgical-strategy-aso-2015/","asOf":"2026-09-24","days":4},{"id":"paper-kang-t2-gallbladder-cancer-location-meta-analysis-jcm-2021","kind":"paper","name":"Prognostic Significance of Tumor Location in T2 Gallbladder Cancer: A Systematic Review and Meta-Analysis","route":"/key-papers/paper-kang-t2-gallbladder-cancer-location-meta-analysis-jcm-2021/","asOf":"2026-09-24","days":4},{"id":"paper-khan-t2-gallbladder-cancer-liver-resection-meta-analysis-updates-surg-2021","kind":"paper","name":"Tumor location and concurrent liver resection, impact survival in T2 gallbladder cancer: a meta-analysis of the literature","route":"/key-papers/paper-khan-t2-gallbladder-cancer-liver-resection-meta-analysis-updates-surg-2021/","asOf":"2026-09-24","days":4},{"id":"paper-nevin-gallbladder-carcinoma-staging-cancer-1976","kind":"paper","name":"Carcinoma of the gallbladder: staging, treatment, and prognosis","route":"/key-papers/paper-nevin-gallbladder-carcinoma-staging-cancer-1976/","asOf":"2026-09-24","days":4},{"id":"paper-chun-ajcc-8th-edition-hepatobiliary-aso-2018","kind":"paper","name":"8th Edition of the AJCC Cancer Staging Manual: Pancreas and Hepatobiliary Cancers","route":"/key-papers/paper-chun-ajcc-8th-edition-hepatobiliary-aso-2018/","asOf":"2026-09-24","days":4},{"id":"paper-giannis-ajcc8-gallbladder-staging-validation-cancers-2021","kind":"paper","name":"Validation of the 8th Edition American Joint Commission on Cancer (AJCC) Gallbladder Cancer Staging System: Prognostic Discrimination and Identification of Key Predictive Factors","route":"/key-papers/paper-giannis-ajcc8-gallbladder-staging-validation-cancers-2021/","asOf":"2026-09-24","days":4},{"id":"paper-mcclements-capbil-incidental-gallbladder-cancer-bjs-2026","kind":"paper","name":"Management of incidental gallbladder cancer in the nationwide CAPBIL study","route":"/key-papers/paper-mcclements-capbil-incidental-gallbladder-cancer-bjs-2026/","asOf":"2026-09-24","days":4},{"id":"paper-mcclements-capbil-surgical-outcomes-gallbladder-cancer-hpb-2026","kind":"paper","name":"Surgical outcomes in gallbladder cancer: evidence from the UK nationwide CAPBIL study","route":"/key-papers/paper-mcclements-capbil-surgical-outcomes-gallbladder-cancer-hpb-2026/","asOf":"2026-09-24","days":4},{"id":"paper-szpakowski-gallbladder-polyps-20-year-cohort-jama-netw-open-2020","kind":"paper","name":"Outcomes of Gallbladder Polyps and Their Association With Gallbladder Cancer in a 20-Year Cohort","route":"/key-papers/paper-szpakowski-gallbladder-polyps-20-year-cohort-jama-netw-open-2020/","asOf":"2026-09-24","days":4},{"id":"paper-wennmacker-gallbladder-polyp-size-threshold-surg-endosc-2019","kind":"paper","name":"Polyp size of 1 cm is insufficient to discriminate neoplastic and non-neoplastic gallbladder polyps","route":"/key-papers/paper-wennmacker-gallbladder-polyp-size-threshold-surg-endosc-2019/","asOf":"2026-09-24","days":4},{"id":"paper-elmasry-gallbladder-polyp-malignancy-systematic-review-int-j-surg-2016","kind":"paper","name":"The risk of malignancy in ultrasound detected gallbladder polyps: A systematic review","route":"/key-papers/paper-elmasry-gallbladder-polyp-malignancy-systematic-review-int-j-surg-2016/","asOf":"2026-09-24","days":4},{"id":"paper-roa-gallbladder-cancer-primer-nat-rev-dis-primers-2022","kind":"paper","name":"Gallbladder cancer","route":"/key-papers/paper-roa-gallbladder-cancer-primer-nat-rev-dis-primers-2022/","asOf":"2026-09-24","days":4},{"id":"paper-wistuba-gazdar-gallbladder-cancer-lessons-nat-rev-cancer-2004","kind":"paper","name":"Gallbladder cancer: lessons from a rare tumour","route":"/key-papers/paper-wistuba-gazdar-gallbladder-cancer-lessons-nat-rev-cancer-2004/","asOf":"2026-09-24","days":4},{"id":"paper-samaniego-chile-ges-programme-evaluation-rev-med-chile-2024","kind":"paper","name":"Gallbladder Cancer: Is It Time to Modify the Explicit Health Guarantees (GES) Program?","route":"/key-papers/paper-samaniego-chile-ges-programme-evaluation-rev-med-chile-2024/","asOf":"2026-09-24","days":4},{"id":"paper-mardones-frenz-chile-ges-mortality-rev-med-chile-2019","kind":"paper","name":"Changes in gallbladder cancer mortality and hospital discharges due to preventive cholecystectomy in Chile","route":"/key-papers/paper-mardones-frenz-chile-ges-mortality-rev-med-chile-2019/","asOf":"2026-09-24","days":4},{"id":"paper-cid-chile-programme-gallbladder-cancer-mortality-am-j-epidemiol-2024","kind":"paper","name":"Gallbladder cancer mortality in Chile: has the government program targeting young gallstone patients had an impact?","route":"/key-papers/paper-cid-chile-programme-gallbladder-cancer-mortality-am-j-epidemiol-2024/","asOf":"2026-09-24","days":4},{"id":"paper-dutta-gallbladder-cancer-epidemiology-india-chin-clin-oncol-2019","kind":"paper","name":"Epidemiology of gallbladder cancer in India","route":"/key-papers/paper-dutta-gallbladder-cancer-epidemiology-india-chin-clin-oncol-2019/","asOf":"2026-09-24","days":4},{"id":"paper-patkar-tata-memorial-gallbladder-cancer-registry-cancer-epidemiol-2025","kind":"paper","name":"Hospital-based gallbladder cancer registry from a high-volume referral cancer centre in India: Insights into epidemiology and roadmap for enhancing cancer care","route":"/key-papers/paper-patkar-tata-memorial-gallbladder-cancer-registry-cancer-epidemiol-2025/","asOf":"2026-09-24","days":4},{"id":"paper-koshiol-salmonella-typhi-gallbladder-cancer-cancer-med-2016","kind":"paper","name":"Salmonella enterica serovar Typhi and gallbladder cancer: a case-control study and meta-analysis","route":"/key-papers/paper-koshiol-salmonella-typhi-gallbladder-cancer-cancer-med-2016/","asOf":"2026-09-24","days":4},{"id":"paper-nagaraja-eslick-typhi-carrier-gallbladder-cancer-meta-analysis-apt-2014","kind":"paper","name":"Systematic review with meta-analysis: the relationship between chronic Salmonella typhi carrier status and gall-bladder cancer","route":"/key-papers/paper-nagaraja-eslick-typhi-carrier-gallbladder-cancer-meta-analysis-apt-2014/","asOf":"2026-09-24","days":4},{"id":"paper-galdy-her2-biliary-tract-meta-analysis-cancer-metastasis-rev-2017","kind":"paper","name":"HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?","route":"/key-papers/paper-galdy-her2-biliary-tract-meta-analysis-cancer-metastasis-rev-2017/","asOf":"2026-09-24","days":4},{"id":"paper-malla-ctdna-resected-biliary-tract-cancer-esmo-gi-onc-2026","kind":"paper","name":"Real-world analysis of ctDNA and other biomarkers in patients with curatively resected stage I-III biliary tract cancer","route":"/key-papers/paper-malla-ctdna-resected-biliary-tract-cancer-esmo-gi-onc-2026/","asOf":"2026-09-24","days":4},{"id":"paper-yu-ctdna-early-recurrence-biliary-tract-cancer-jco-po-2025","kind":"paper","name":"Detecting Early Recurrence With Circulating Tumor DNA in Stage I-III Biliary Tract Cancer After Curative Resection","route":"/key-papers/paper-yu-ctdna-early-recurrence-biliary-tract-cancer-jco-po-2025/","asOf":"2026-09-24","days":4},{"id":"paper-wang-adjuvant-chemoradiotherapy-nomogram-gallbladder-cancer-jco-2011","kind":"paper","name":"Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer","route":"/key-papers/paper-wang-adjuvant-chemoradiotherapy-nomogram-gallbladder-cancer-jco-2011/","asOf":"2026-09-24","days":4},{"id":"paper-varshney-neoadjuvant-incidental-gallbladder-cancer-systematic-review-ahbps-2025","kind":"paper","name":"Neoadjuvant treatment for incidental gallbladder cancer: A systematic review","route":"/key-papers/paper-varshney-neoadjuvant-incidental-gallbladder-cancer-systematic-review-ahbps-2025/","asOf":"2026-09-24","days":4},{"id":"paper-garate-calderon-gallbladder-cancer-worldwide-exome-ebiomedicine-2026","kind":"paper","name":"Geographic and genetic diversity in gallbladder cancer mutation profiles: insights from a worldwide exome analysis","route":"/key-papers/paper-garate-calderon-gallbladder-cancer-worldwide-exome-ebiomedicine-2026/","asOf":"2026-09-24","days":4},{"id":"paper-zhu-population-specific-immunogenomics-gallbladder-cancer-mod-pathol-2025","kind":"paper","name":"Population-Specific Immunogenomic Alterations in Gallbladder Cancer and Prognostic Significance","route":"/key-papers/paper-zhu-population-specific-immunogenomics-gallbladder-cancer-mod-pathol-2025/","asOf":"2026-09-24","days":4},{"id":"gallbladder-cancer-roadmap","kind":"roadmap","name":"Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials","route":"/roadmaps/gallbladder-cancer-roadmap/","asOf":"2026-09-24","days":4},{"id":"idea-gbc-report-gallbladder-separately-in-biliary-trials","kind":"idea","name":"Report gallbladder cancer as its own population in every biliary trial","route":"/ideas/idea-gbc-report-gallbladder-separately-in-biliary-trials/","asOf":"2026-09-24","days":4},{"id":"idea-gbc-national-incidental-cancer-pathway","kind":"idea","name":"A national incidental gallbladder cancer pathway: histology for every gallbladder, referral within two weeks, re-resection by eight","route":"/ideas/idea-gbc-national-incidental-cancer-pathway/","asOf":"2026-09-24","days":4},{"id":"idea-gbc-t1b-simple-cholecystectomy-prospective-study","kind":"idea","name":"Test whether T1b gallbladder cancer needs the second operation at all","route":"/ideas/idea-gbc-t1b-simple-cholecystectomy-prospective-study/","asOf":"2026-09-24","days":4},{"id":"idea-gbc-t2a-spare-liver-resection-trial","kind":"idea","name":"A trial of sparing the liver resection in peritoneal-side (T2a) gallbladder cancer","route":"/ideas/idea-gbc-t2a-spare-liver-resection-trial/","asOf":"2026-09-24","days":4},{"id":"idea-gbc-reflex-her2-testing-advanced-biliary","kind":"idea","name":"Reflex HER2 testing of every advanced gallbladder and extrahepatic biliary cancer","route":"/ideas/idea-gbc-reflex-her2-testing-advanced-biliary/","asOf":"2026-09-24","days":4},{"id":"idea-gbc-risk-targeted-ultrasound-in-high-incidence-regions","kind":"idea","name":"Risk-targeted ultrasound screening in high-incidence regions, tested against usual care","route":"/ideas/idea-gbc-risk-targeted-ultrasound-in-high-incidence-regions/","asOf":"2026-09-24","days":4},{"id":"idea-gbc-prophylactic-cholecystectomy-targeted-and-evaluated","kind":"idea","name":"Redesign Chile's prophylactic cholecystectomy programme around risk, and evaluate it properly","route":"/ideas/idea-gbc-prophylactic-cholecystectomy-targeted-and-evaluated/","asOf":"2026-09-24","days":4},{"id":"idea-gbc-typhoid-carrier-cholecystectomy-or-surveillance","kind":"idea","name":"Cholecystectomy or ultrasound surveillance for chronic typhoid carriers in endemic regions","route":"/ideas/idea-gbc-typhoid-carrier-cholecystectomy-or-surveillance/","asOf":"2026-09-24","days":4},{"id":"idea-gbc-ctdna-residual-disease-guided-adjuvant-trial","kind":"idea","name":"A ctDNA residual disease-guided adjuvant trial after gallbladder cancer resection","route":"/ideas/idea-gbc-ctdna-residual-disease-guided-adjuvant-trial/","asOf":"2026-09-24","days":4},{"id":"idea-gbc-neoadjuvant-for-high-risk-incidental-cancer","kind":"idea","name":"Chemotherapy before the second operation for high-risk incidental gallbladder cancer","route":"/ideas/idea-gbc-neoadjuvant-for-high-risk-incidental-cancer/","asOf":"2026-09-24","days":4},{"id":"idea-gbc-randomised-adjuvant-chemoradiation-r1-node-positive","kind":"idea","name":"A randomised trial of adjuvant chemoradiation after margin-positive or node-positive gallbladder cancer resection","route":"/ideas/idea-gbc-randomised-adjuvant-chemoradiation-r1-node-positive/","asOf":"2026-09-24","days":4},{"id":"idea-gbc-burden-to-funding-audit-and-dedicated-call","kind":"idea","name":"A burden-to-funding audit for gallbladder cancer and a dedicated research call","route":"/ideas/idea-gbc-burden-to-funding-audit-and-dedicated-call/","asOf":"2026-09-24","days":4},{"id":"satricabtagene-autoleucel","kind":"drug","name":"Satricabtagene autoleucel","route":"/drugs/satricabtagene-autoleucel/","asOf":"2026-09-24","days":4},{"id":"remestemcel-l","kind":"drug","name":"Remestemcel-L","route":"/drugs/remestemcel-l/","asOf":"2026-09-24","days":4},{"id":"hepzato","kind":"drug","name":"Melphalan hepatic delivery system","route":"/drugs/hepzato/","asOf":"2026-09-24","days":4},{"id":"ascent-05","kind":"trial","name":"ASCENT-05 / OptimICE-RD (AFT-65, GBG 119, NSABP B-63)","route":"/trials/ascent-05/","asOf":"2026-09-24","days":4},{"id":"belumosudil","kind":"drug","name":"Belumosudil","route":"/drugs/belumosudil/","asOf":"2026-09-24","days":4},{"id":"cosibelimab","kind":"drug","name":"Cosibelimab","route":"/drugs/cosibelimab/","asOf":"2026-09-24","days":4},{"id":"dacomitinib","kind":"drug","name":"Dacomitinib","route":"/drugs/dacomitinib/","asOf":"2026-09-24","days":4},{"id":"ceritinib","kind":"drug","name":"Ceritinib","route":"/drugs/ceritinib/","asOf":"2026-09-24","days":4},{"id":"brigatinib","kind":"drug","name":"Brigatinib","route":"/drugs/brigatinib/","asOf":"2026-09-24","days":4},{"id":"ensartinib","kind":"drug","name":"Ensartinib","route":"/drugs/ensartinib/","asOf":"2026-09-24","days":4},{"id":"pegulicianine","kind":"drug","name":"Pegulicianine","route":"/drugs/pegulicianine/","asOf":"2026-09-24","days":4},{"id":"ivermectin","kind":"drug","name":"Ivermectin","route":"/drugs/ivermectin/","asOf":"2026-09-24","days":4},{"id":"fenbendazole","kind":"drug","name":"Fenbendazole (veterinary anthelmintic)","route":"/drugs/fenbendazole/","asOf":"2026-09-24","days":4},{"id":"mebendazole","kind":"drug","name":"Mebendazole","route":"/drugs/mebendazole/","asOf":"2026-09-24","days":4},{"id":"nct05318469","kind":"trial","name":"Ivermectin with balstilimab or pembrolizumab in metastatic triple-negative breast cancer (Cedars-Sinai phase 1/2)","route":"/trials/nct05318469/","asOf":"2026-09-24","days":4},{"id":"nct07487805","kind":"trial","name":"ICONIC: ivermectin combined with immune checkpoint inhibition in cancer (University of Florida phase 2)","route":"/trials/nct07487805/","asOf":"2026-09-24","days":4},{"id":"nct04447235","kind":"trial","name":"Ivermectin plus losartan for COVID-19 in cancer patients (ICESP phase 2, terminated)","route":"/trials/nct04447235/","asOf":"2026-09-24","days":4},{"id":"nct02366884","kind":"trial","name":"Atavistic chemotherapy: combinations of antibacterial, antifungal and antiprotozoal drugs in advanced cancer (Arguello clinic, status unknown)","route":"/trials/nct02366884/","asOf":"2026-09-24","days":4},{"id":"paper-juarez-ivermectin-repositioned-cancer-drug-2018","kind":"paper","name":"The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug","route":"/key-papers/paper-juarez-ivermectin-repositioned-cancer-drug-2018/","asOf":"2026-09-24","days":4},{"id":"paper-tang-ivermectin-potential-anticancer-pharmacol-res-2021","kind":"paper","name":"Ivermectin, a potential anticancer drug derived from an antiparasitic drug","route":"/key-papers/paper-tang-ivermectin-potential-anticancer-pharmacol-res-2021/","asOf":"2026-09-24","days":4},{"id":"paper-patel-ivermectin-cancer-curr-oncol-rep-2025","kind":"paper","name":"Ivermectin in cancer treatment: should healthcare providers caution or explore its therapeutic potential?","route":"/key-papers/paper-patel-ivermectin-cancer-curr-oncol-rep-2025/","asOf":"2026-09-24","days":4},{"id":"paper-mujumdar-ivermectin-gynaecological-cancer-2025","kind":"paper","name":"Ivermectin and gynecologic cancer: what's the data?","route":"/key-papers/paper-mujumdar-ivermectin-gynaecological-cancer-2025/","asOf":"2026-09-24","days":4},{"id":"paper-straughn-ivermectin-hope-versus-hype-2025","kind":"paper","name":"Ivermectin treatment for gynecologic cancers: hope versus hype","route":"/key-papers/paper-straughn-ivermectin-hope-versus-hype-2025/","asOf":"2026-09-24","days":4},{"id":"paper-yilmaz-ivermectin-toxicity-j-appl-toxicol-2026","kind":"paper","name":"Ivermectin toxicity in humans and animals: clinical spectrum, mechanisms, and management","route":"/key-papers/paper-yilmaz-ivermectin-toxicity-j-appl-toxicol-2026/","asOf":"2026-09-24","days":4},{"id":"paper-draganov-ivermectin-cold-tumours-npj-breast-cancer-2021","kind":"paper","name":"Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer (with 2026 expression of concern)","route":"/key-papers/paper-draganov-ivermectin-cold-tumours-npj-breast-cancer-2021/","asOf":"2026-09-24","days":4},{"id":"paper-hulscher-ivermectin-mebendazole-cohort-anticancer-res-2026","kind":"paper","name":"Real-world clinical outcomes of ivermectin and mebendazole in cancer patients: results from a prospective observational cohort (with 2026 expression of concern)","route":"/key-papers/paper-hulscher-ivermectin-mebendazole-cohort-anticancer-res-2026/","asOf":"2026-09-24","days":4},{"id":"paper-jimenez-gaona-ivermectin-loja-ecuador-2023","kind":"paper","name":"Outcome of ivermectin in cancer treatment: an experience in Loja, Ecuador","route":"/key-papers/paper-jimenez-gaona-ivermectin-loja-ecuador-2023/","asOf":"2026-09-24","days":4},{"id":"paper-rockwell-ivermectin-benzimidazole-prescribing-jama-netw-open-2026","kind":"paper","name":"Ivermectin-benzimidazole prescribing following celebrity endorsement","route":"/key-papers/paper-rockwell-ivermectin-benzimidazole-prescribing-jama-netw-open-2026/","asOf":"2026-09-24","days":4},{"id":"paper-saperstein-ivermectin-neurotoxicity-breast-cancer-2026","kind":"paper","name":"Life-threatening neurotoxicity following off-label ivermectin use in metastatic breast cancer: a case report","route":"/key-papers/paper-saperstein-ivermectin-neurotoxicity-breast-cancer-2026/","asOf":"2026-09-24","days":4},{"id":"paper-powderly-fenbendazole-ivermectin-liver-injury-2026","kind":"paper","name":"Drug-induced liver injury following co-ingestion of veterinary fenbendazole and ivermectin for prostate cancer: a case report","route":"/key-papers/paper-powderly-fenbendazole-ivermectin-liver-injury-2026/","asOf":"2026-09-24","days":4},{"id":"paper-gilene-ivermectin-toxicity-paediatric-oncology-2025","kind":"paper","name":"The threat of medical misinformation: a case of ivermectin toxicity in a pediatric oncology patient","route":"/key-papers/paper-gilene-ivermectin-toxicity-paediatric-oncology-2025/","asOf":"2026-09-24","days":4},{"id":"paper-hoang-ivermectin-toxicity-clin-toxicol-2022","kind":"paper","name":"Characteristics of ivermectin toxicity in patients taking veterinary and human formulations for the prevention and treatment of COVID-19","route":"/key-papers/paper-hoang-ivermectin-toxicity-clin-toxicol-2022/","asOf":"2026-09-24","days":4},{"id":"paper-ghai-california-poison-control-ivermectin-2024","kind":"paper","name":"Exposures to bleach, peroxide, disinfectants, antimalarials, and ivermectin reported to the California Poison Control System before and during the COVID-19 pandemic, 2015 to 2021","route":"/key-papers/paper-ghai-california-poison-control-ivermectin-2024/","asOf":"2026-09-24","days":4},{"id":"paper-cheng-melanoma-ctdna-antiparasitic-front-oncol-2026","kind":"paper","name":"Metastatic melanoma with initial ctDNA decline and radiographic response during self-directed antiparasitic use: treatment effect or spontaneous regression?","route":"/key-papers/paper-cheng-melanoma-ctdna-antiparasitic-front-oncol-2026/","asOf":"2026-09-24","days":4},{"id":"paper-ishiguro-dichloroacetate-ivermectin-cureus-2022","kind":"paper","name":"Synergistic anti-tumor effect of dichloroacetate and ivermectin","route":"/key-papers/paper-ishiguro-dichloroacetate-ivermectin-cureus-2022/","asOf":"2026-09-24","days":4},{"id":"paper-guilford-antiparasitic-acupuncture-meridian-case-series-2026","kind":"paper","name":"Cancer therapy using antiparasitic medications guided by acupuncture meridian assessment: a case series of six patients","route":"/key-papers/paper-guilford-antiparasitic-acupuncture-meridian-case-series-2026/","asOf":"2026-09-24","days":4},{"id":"paper-thakurdesai-fenbendazole-liver-injury-2024","kind":"paper","name":"Severe drug-induced liver injury due to self-administration of the veterinary anthelmintic medication fenbendazole","route":"/key-papers/paper-thakurdesai-fenbendazole-liver-injury-2024/","asOf":"2026-09-24","days":4},{"id":"paper-makis-fenbendazole-case-series-retracted-2025","kind":"paper","name":"RETRACTED: Fenbendazole as an anticancer agent? A case series of self-administration in three patients","route":"/key-papers/paper-makis-fenbendazole-case-series-retracted-2025/","asOf":"2026-09-24","days":4},{"id":"paper-patil-mebendazole-glioma-phase-1-cancer-med-2020","kind":"paper","name":"Reverse swing-M, phase 1 study of repurposing mebendazole in recurrent high-grade glioma","route":"/key-papers/paper-patil-mebendazole-glioma-phase-1-cancer-med-2020/","asOf":"2026-09-24","days":4},{"id":"paper-mansoori-mebendazole-gi-cancer-phase-2a-sci-rep-2021","kind":"paper","name":"A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer","route":"/key-papers/paper-mansoori-mebendazole-gi-cancer-phase-2a-sci-rep-2021/","asOf":"2026-09-24","days":4},{"id":"paper-aeneas-j-clin-oncol-2022","kind":"paper","name":"AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations","route":"/key-papers/paper-aeneas-j-clin-oncol-2022/","asOf":"2026-09-24","days":4},{"id":"paper-alex-ann-oncol-2020-update","kind":"paper","name":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","route":"/key-papers/paper-alex-ann-oncol-2020-update/","asOf":"2026-09-24","days":4},{"id":"paper-alta-1l-n-engl-j-med-2018","kind":"paper","name":"Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer","route":"/key-papers/paper-alta-1l-n-engl-j-med-2018/","asOf":"2026-09-24","days":4},{"id":"paper-alter-0303-jama-oncol-2018","kind":"paper","name":"Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial","route":"/key-papers/paper-alter-0303-jama-oncol-2018/","asOf":"2026-09-24","days":4},{"id":"paper-astrum-005-jama-2022","kind":"paper","name":"Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial","route":"/key-papers/paper-astrum-005-jama-2022/","asOf":"2026-09-24","days":4},{"id":"paper-atlantis-lancet-respir-med-2023","kind":"paper","name":"Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial","route":"/key-papers/paper-atlantis-lancet-respir-med-2023/","asOf":"2026-09-24","days":4},{"id":"paper-calgb-140503-n-engl-j-med-2023","kind":"paper","name":"Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer","route":"/key-papers/paper-calgb-140503-n-engl-j-med-2023/","asOf":"2026-09-24","days":4},{"id":"paper-camel-lancet-respir-med-2021","kind":"paper","name":"Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial","route":"/key-papers/paper-camel-lancet-respir-med-2021/","asOf":"2026-09-24","days":4},{"id":"paper-camel-j-thorac-oncol-2023-update","kind":"paper","name":"Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial","route":"/key-papers/paper-camel-j-thorac-oncol-2023-update/","asOf":"2026-09-24","days":4},{"id":"paper-capstone-1-lancet-oncol-2022","kind":"paper","name":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-capstone-1-lancet-oncol-2022/","asOf":"2026-09-24","days":4},{"id":"paper-caspian-lancet-oncol-2021-update","kind":"paper","name":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial","route":"/key-papers/paper-caspian-lancet-oncol-2021-update/","asOf":"2026-09-24","days":4},{"id":"paper-checkmate-227-n-engl-j-med-2018","kind":"paper","name":"Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden","route":"/key-papers/paper-checkmate-227-n-engl-j-med-2018/","asOf":"2026-09-24","days":4},{"id":"paper-checkmate-227-int-j-clin-oncol-2023-update","kind":"paper","name":"First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1","route":"/key-papers/paper-checkmate-227-int-j-clin-oncol-2023-update/","asOf":"2026-09-24","days":4},{"id":"paper-checkmate-816-n-engl-j-med-2025-update","kind":"paper","name":"Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer","route":"/key-papers/paper-checkmate-816-n-engl-j-med-2025-update/","asOf":"2026-09-24","days":4},{"id":"paper-chisel-lancet-oncol-2019","kind":"paper","name":"Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial","route":"/key-papers/paper-chisel-lancet-oncol-2019/","asOf":"2026-09-24","days":4},{"id":"paper-convert-lancet-oncol-2017","kind":"paper","name":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial","route":"/key-papers/paper-convert-lancet-oncol-2017/","asOf":"2026-09-24","days":4},{"id":"paper-convert-int-j-radiat-oncol-biol-phys-2024-update","kind":"paper","name":"Long-Term Outcomes After Concurrent Once- or Twice-Daily Chemoradiation in Limited-Stage Small Cell Lung Cancer: A Brief Report From the CONVERT Trial","route":"/key-papers/paper-convert-int-j-radiat-oncol-biol-phys-2024-update/","asOf":"2026-09-24","days":4},{"id":"paper-crown-lancet-respir-med-2023-update","kind":"paper","name":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study","route":"/key-papers/paper-crown-lancet-respir-med-2023-update/","asOf":"2026-09-24","days":4},{"id":"paper-destiny-lung02-j-thorac-oncol-2025","kind":"paper","name":"Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC","route":"/key-papers/paper-destiny-lung02-j-thorac-oncol-2025/","asOf":"2026-09-24","days":4},{"id":"paper-empower-lung-1-lancet-2021","kind":"paper","name":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial","route":"/key-papers/paper-empower-lung-1-lancet-2021/","asOf":"2026-09-24","days":4},{"id":"paper-empower-lung-1-lancet-oncol-2023-update","kind":"paper","name":"First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial","route":"/key-papers/paper-empower-lung-1-lancet-oncol-2023-update/","asOf":"2026-09-24","days":4},{"id":"paper-furlong-lancet-respir-med-2022","kind":"paper","name":"Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study","route":"/key-papers/paper-furlong-lancet-respir-med-2022/","asOf":"2026-09-24","days":4},{"id":"paper-gemstone-302-lancet-oncol-2022","kind":"paper","name":"Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial","route":"/key-papers/paper-gemstone-302-lancet-oncol-2022/","asOf":"2026-09-24","days":4},{"id":"paper-gemstone-302-nat-cancer-2023-update","kind":"paper","name":"Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC","route":"/key-papers/paper-gemstone-302-nat-cancer-2023-update/","asOf":"2026-09-24","days":4},{"id":"paper-geometry-mono-1-lancet-oncol-2024-update","kind":"paper","name":"Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial","route":"/key-papers/paper-geometry-mono-1-lancet-oncol-2024-update/","asOf":"2026-09-24","days":4},{"id":"paper-harmoni-a-jama-2024","kind":"paper","name":"Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial","route":"/key-papers/paper-harmoni-a-jama-2024/","asOf":"2026-09-24","days":4},{"id":"paper-imforte-lancet-2025","kind":"paper","name":"Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial","route":"/key-papers/paper-imforte-lancet-2025/","asOf":"2026-09-24","days":4},{"id":"paper-impower133-n-engl-j-med-2018","kind":"paper","name":"First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer","route":"/key-papers/paper-impower133-n-engl-j-med-2018/","asOf":"2026-09-24","days":4},{"id":"paper-keynote-024-189-j-clin-oncol-2021-update","kind":"paper","name":"Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50","route":"/key-papers/paper-keynote-024-189-j-clin-oncol-2021-update/","asOf":"2026-09-24","days":4},{"id":"paper-keynote-042-lancet-2019","kind":"paper","name":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","route":"/key-papers/paper-keynote-042-lancet-2019/","asOf":"2026-09-24","days":4},{"id":"paper-keynote-042-j-clin-oncol-2023-update","kind":"paper","name":"Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study","route":"/key-papers/paper-keynote-042-j-clin-oncol-2023-update/","asOf":"2026-09-24","days":4},{"id":"paper-keynote-407-n-engl-j-med-2018","kind":"paper","name":"Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer","route":"/key-papers/paper-keynote-407-n-engl-j-med-2018/","asOf":"2026-09-24","days":4},{"id":"paper-keynote-407-j-clin-oncol-2023-update","kind":"paper","name":"Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study","route":"/key-papers/paper-keynote-407-j-clin-oncol-2023-update/","asOf":"2026-09-24","days":4},{"id":"paper-keynote-671-n-engl-j-med-2023","kind":"paper","name":"Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer","route":"/key-papers/paper-keynote-671-n-engl-j-med-2023/","asOf":"2026-09-24","days":4},{"id":"paper-keynote-671-ann-oncol-2026-update","kind":"paper","name":"Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study","route":"/key-papers/paper-keynote-671-ann-oncol-2026-update/","asOf":"2026-09-24","days":4},{"id":"paper-luminosity-j-clin-oncol-2024","kind":"paper","name":"Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR -Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial","route":"/key-papers/paper-luminosity-j-clin-oncol-2024/","asOf":"2026-09-24","days":4},{"id":"paper-luminosity-jto-clin-res-rep-2026-update","kind":"paper","name":"Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial","route":"/key-papers/paper-luminosity-jto-clin-res-rep-2026-update/","asOf":"2026-09-24","days":4},{"id":"paper-lung-map-s1400i-jama-oncol-2021","kind":"paper","name":"Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial","route":"/key-papers/paper-lung-map-s1400i-jama-oncol-2021/","asOf":"2026-09-24","days":4},{"id":"paper-navigate-j-clin-invest-2021","kind":"paper","name":"NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake","route":"/key-papers/paper-navigate-j-clin-invest-2021/","asOf":"2026-09-24","days":4},{"id":"paper-orient-11-j-thorac-oncol-2020","kind":"paper","name":"Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)","route":"/key-papers/paper-orient-11-j-thorac-oncol-2020/","asOf":"2026-09-24","days":4},{"id":"paper-orient-11-lung-cancer-2022-update","kind":"paper","name":"Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study","route":"/key-papers/paper-orient-11-lung-cancer-2022-update/","asOf":"2026-09-24","days":4},{"id":"paper-pacific-n-engl-j-med-2018-update","kind":"paper","name":"Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC","route":"/key-papers/paper-pacific-n-engl-j-med-2018-update/","asOf":"2026-09-24","days":4},{"id":"paper-pharos-j-thorac-oncol-2025","kind":"paper","name":"Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report","route":"/key-papers/paper-pharos-j-thorac-oncol-2025/","asOf":"2026-09-24","days":4},{"id":"paper-romana-1-2-lancet-oncol-2016","kind":"paper","name":"Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials","route":"/key-papers/paper-romana-1-2-lancet-oncol-2016/","asOf":"2026-09-24","days":4},{"id":"paper-rtog-0617-lancet-oncol-2015","kind":"paper","name":"Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study","route":"/key-papers/paper-rtog-0617-lancet-oncol-2015/","asOf":"2026-09-24","days":4},{"id":"paper-sabr-comet-lancet-2019","kind":"paper","name":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","route":"/key-papers/paper-sabr-comet-lancet-2019/","asOf":"2026-09-24","days":4},{"id":"paper-soho-01-n-engl-j-med-2025","kind":"paper","name":"Sevabertinib in Advanced HER2 -Mutant Non-Small-Cell Lung Cancer","route":"/key-papers/paper-soho-01-n-engl-j-med-2025/","asOf":"2026-09-24","days":4},{"id":"paper-tropion-lung05-j-clin-oncol-2025","kind":"paper","name":"Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study","route":"/key-papers/paper-tropion-lung05-j-clin-oncol-2025/","asOf":"2026-09-24","days":4},{"id":"paper-alchemist-jama-oncol-2022","kind":"paper","name":"Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216)","route":"/key-papers/paper-alchemist-jama-oncol-2022/","asOf":"2026-09-24","days":4},{"id":"paper-chrysalis-nat-med-2023","kind":"paper","name":"Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial","route":"/key-papers/paper-chrysalis-nat-med-2023/","asOf":"2026-09-24","days":4},{"id":"paper-lung-map-j-thorac-oncol-2019","kind":"paper","name":"SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)","route":"/key-papers/paper-lung-map-j-thorac-oncol-2019/","asOf":"2026-09-24","days":4},{"id":"paper-nct01933932-jama-2017","kind":"paper","name":"Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial","route":"/key-papers/paper-nct01933932-jama-2017/","asOf":"2026-09-24","days":4},{"id":"paper-nct02152631-front-oncol-2020","kind":"paper","name":"A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER","route":"/key-papers/paper-nct02152631-front-oncol-2020/","asOf":"2026-09-24","days":4},{"id":"paper-nct02411448-lancet-oncol-2019","kind":"paper","name":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-nct02411448-lancet-oncol-2019/","asOf":"2026-09-24","days":4},{"id":"paper-nct02411448-j-thorac-oncol-2025-update","kind":"paper","name":"RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC","route":"/key-papers/paper-nct02411448-j-thorac-oncol-2025-update/","asOf":"2026-09-24","days":4},{"id":"paper-nct02453282-jama-oncol-2020","kind":"paper","name":"Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial","route":"/key-papers/paper-nct02453282-jama-oncol-2020/","asOf":"2026-09-24","days":4},{"id":"paper-nct02486718-ann-oncol-2023-update","kind":"paper","name":"Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial","route":"/key-papers/paper-nct02486718-ann-oncol-2023-update/","asOf":"2026-09-24","days":4},{"id":"paper-nct02716116-jama-oncol-2021","kind":"paper","name":"Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial","route":"/key-papers/paper-nct02716116-jama-oncol-2021/","asOf":"2026-09-24","days":4},{"id":"paper-nct02734004-lancet-oncol-2020","kind":"paper","name":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study","route":"/key-papers/paper-nct02734004-lancet-oncol-2020/","asOf":"2026-09-24","days":4},{"id":"paper-nct02767804-jama-oncol-2021","kind":"paper","name":"Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial","route":"/key-papers/paper-nct02767804-jama-oncol-2021/","asOf":"2026-09-24","days":4},{"id":"paper-nct02864992-jama-oncol-2023-update","kind":"paper","name":"Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial","route":"/key-papers/paper-nct02864992-jama-oncol-2023-update/","asOf":"2026-09-24","days":4},{"id":"paper-nct03003962-j-thorac-oncol-2025","kind":"paper","name":"Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study","route":"/key-papers/paper-nct03003962-j-thorac-oncol-2025/","asOf":"2026-09-24","days":4},{"id":"paper-nct03157128-j-clin-oncol-2024-update","kind":"paper","name":"Durability of Response With Selpercatinib in Patients With RET -Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001","route":"/key-papers/paper-nct03157128-j-clin-oncol-2024-update/","asOf":"2026-09-24","days":4},{"id":"paper-nct03178552-nat-med-2022","kind":"paper","name":"Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial","route":"/key-papers/paper-nct03178552-nat-med-2022/","asOf":"2026-09-24","days":4},{"id":"paper-nct03334617-nat-med-2024","kind":"paper","name":"Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial","route":"/key-papers/paper-nct03334617-nat-med-2024/","asOf":"2026-09-24","days":4},{"id":"paper-nct03381274-j-thorac-oncol-2023","kind":"paper","name":"CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report","route":"/key-papers/paper-nct03381274-j-thorac-oncol-2023/","asOf":"2026-09-24","days":4},{"id":"paper-nct03476681-j-exp-clin-cancer-res-2023","kind":"paper","name":"First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors","route":"/key-papers/paper-nct03476681-j-exp-clin-cancer-res-2023/","asOf":"2026-09-24","days":4},{"id":"paper-nct03706690-j-hematol-oncol-2025","kind":"paper","name":"PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy","route":"/key-papers/paper-nct03706690-j-hematol-oncol-2025/","asOf":"2026-09-24","days":4},{"id":"paper-nct03775486-j-thorac-oncol-2023","kind":"paper","name":"Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study","route":"/key-papers/paper-nct03775486-j-thorac-oncol-2023/","asOf":"2026-09-24","days":4},{"id":"paper-nct03778229-ann-oncol-2025","kind":"paper","name":"Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study","route":"/key-papers/paper-nct03778229-ann-oncol-2025/","asOf":"2026-09-24","days":4},{"id":"paper-nct03907852-nat-med-2023","kind":"paper","name":"Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results","route":"/key-papers/paper-nct03907852-nat-med-2023/","asOf":"2026-09-24","days":4},{"id":"paper-nct03916627-lancet-gastroenterol-hepatol-2022","kind":"paper","name":"Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial","route":"/key-papers/paper-nct03916627-lancet-gastroenterol-hepatol-2022/","asOf":"2026-09-24","days":4},{"id":"paper-nct03944772-jco-precis-oncol-2025","kind":"paper","name":"ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib","route":"/key-papers/paper-nct03944772-jco-precis-oncol-2025/","asOf":"2026-09-24","days":4},{"id":"paper-nct03974022-j-clin-oncol-2025","kind":"paper","name":"Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)","route":"/key-papers/paper-nct03974022-j-clin-oncol-2025/","asOf":"2026-09-24","days":4},{"id":"paper-nct04025879-n-engl-j-med-2024","kind":"paper","name":"Perioperative Nivolumab in Resectable Lung Cancer","route":"/key-papers/paper-nct04025879-n-engl-j-med-2024/","asOf":"2026-09-24","days":4},{"id":"paper-nct04036682-j-clin-oncol-2025","kind":"paper","name":"Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab","route":"/key-papers/paper-nct04036682-j-clin-oncol-2025/","asOf":"2026-09-24","days":4},{"id":"paper-nct04129502-j-clin-oncol-2025","kind":"paper","name":"First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial","route":"/key-papers/paper-nct04129502-j-clin-oncol-2025/","asOf":"2026-09-24","days":4},{"id":"paper-nct04143607-lancet-respir-med-2025","kind":"paper","name":"Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial","route":"/key-papers/paper-nct04143607-lancet-respir-med-2025/","asOf":"2026-09-24","days":4},{"id":"paper-nct04152499-j-hematol-oncol-2025","kind":"paper","name":"Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies","route":"/key-papers/paper-nct04152499-j-hematol-oncol-2025/","asOf":"2026-09-24","days":4},{"id":"paper-nct04379635-lancet-respir-med-2025","kind":"paper","name":"Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial","route":"/key-papers/paper-nct04379635-lancet-respir-med-2025/","asOf":"2026-09-24","days":4},{"id":"paper-nct04379635-ann-oncol-2026-update","kind":"paper","name":"Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer: final analysis of the randomized RATIONALE-315 trial","route":"/key-papers/paper-nct04379635-ann-oncol-2026-update/","asOf":"2026-09-24","days":4},{"id":"paper-nct04395677-j-clin-oncol-2024","kind":"paper","name":"Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non-Small Cell Lung Cancer: The Phase II TRUST-I Study","route":"/key-papers/paper-nct04395677-j-clin-oncol-2024/","asOf":"2026-09-24","days":4},{"id":"paper-nct04395677-j-clin-oncol-2026-update","kind":"paper","name":"Long-Term Efficacy and Safety of Taletrectinib in Patients With ROS1 + Non-Small Cell Lung Cancer: Results From the Phase II TRUST-I Study","route":"/key-papers/paper-nct04395677-j-clin-oncol-2026-update/","asOf":"2026-09-24","days":4},{"id":"paper-nct04538664-n-engl-j-med-2023","kind":"paper","name":"Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions","route":"/key-papers/paper-nct04538664-n-engl-j-med-2023/","asOf":"2026-09-24","days":4},{"id":"paper-nct04561362-j-clin-oncol-2025","kind":"paper","name":"First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation","route":"/key-papers/paper-nct04561362-j-clin-oncol-2025/","asOf":"2026-09-24","days":4},{"id":"paper-nct04579380-j-clin-oncol-2023","kind":"paper","name":"Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study","route":"/key-papers/paper-nct04579380-j-clin-oncol-2023/","asOf":"2026-09-24","days":4},{"id":"paper-nct04585035-signal-transduct-target-ther-2025","kind":"paper","name":"Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation","route":"/key-papers/paper-nct04585035-signal-transduct-target-ther-2025/","asOf":"2026-09-24","days":4},{"id":"paper-nct04619004-j-clin-oncol-2023","kind":"paper","name":"HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy","route":"/key-papers/paper-nct04619004-j-clin-oncol-2023/","asOf":"2026-09-24","days":4},{"id":"paper-nct04665856-j-thorac-oncol-2026","kind":"paper","name":"SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage SCLC in China","route":"/key-papers/paper-nct04665856-j-thorac-oncol-2026/","asOf":"2026-09-24","days":4},{"id":"paper-nct04687241-lancet-oncol-2026","kind":"paper","name":"Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial","route":"/key-papers/paper-nct04687241-lancet-oncol-2026/","asOf":"2026-09-24","days":4},{"id":"paper-nct04765059-esmo-open-2025","kind":"paper","name":"COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib","route":"/key-papers/paper-nct04765059-esmo-open-2025/","asOf":"2026-09-24","days":4},{"id":"paper-nct04819100-n-engl-j-med-2026","kind":"paper","name":"Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer","route":"/key-papers/paper-nct04819100-n-engl-j-med-2026/","asOf":"2026-09-24","days":4},{"id":"paper-nct04923906-lancet-oncol-2026","kind":"paper","name":"Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial","route":"/key-papers/paper-nct04923906-lancet-oncol-2026/","asOf":"2026-09-24","days":4},{"id":"paper-nct04956640-nat-commun-2026","kind":"paper","name":"Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study","route":"/key-papers/paper-nct04956640-nat-commun-2026/","asOf":"2026-09-24","days":4},{"id":"paper-nct05009329-nat-med-2025","kind":"paper","name":"Glecirasib in KRAS G12C -mutated nonsmall-cell lung cancer: a phase 2b trial","route":"/key-papers/paper-nct05009329-nat-med-2025/","asOf":"2026-09-24","days":4},{"id":"paper-nct05081609-j-immunother-cancer-2022","kind":"paper","name":"TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer","route":"/key-papers/paper-nct05081609-j-immunother-cancer-2022/","asOf":"2026-09-24","days":4},{"id":"paper-nct05128487-cell-rep-med-2026","kind":"paper","name":"HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results","route":"/key-papers/paper-nct05128487-cell-rep-med-2026/","asOf":"2026-09-24","days":4},{"id":"paper-nct05186974-j-thorac-oncol-2026","kind":"paper","name":"First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study","route":"/key-papers/paper-nct05186974-j-thorac-oncol-2026/","asOf":"2026-09-24","days":4},{"id":"paper-nct05195632-lung-cancer-2026","kind":"paper","name":"A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAF V600E mutated metastatic non-small cell lung cancer: Results from the OCEAN II study","route":"/key-papers/paper-nct05195632-lung-cancer-2026/","asOf":"2026-09-24","days":4},{"id":"paper-nct05199272-cancer-res-commun-2025","kind":"paper","name":"First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies","route":"/key-papers/paper-nct05199272-cancer-res-commun-2025/","asOf":"2026-09-24","days":4},{"id":"paper-nct05246514-clin-lung-cancer-2026","kind":"paper","name":"Trastuzumab Deruxtecan in Patients From China With Pretreated HER2-Mutant Non-Small Cell Lung Cancer: Final Analysis of the Phase 2, Single-Arm DESTINY-Lung05 Trial","route":"/key-papers/paper-nct05246514-clin-lung-cancer-2026/","asOf":"2026-09-24","days":4},{"id":"paper-nct05663866-j-thorac-oncol-2025","kind":"paper","name":"Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr, a Phase 2 Study: A Brief Report","route":"/key-papers/paper-nct05663866-j-thorac-oncol-2025/","asOf":"2026-09-24","days":4},{"id":"paper-nct05668988-n-engl-j-med-2026","kind":"paper","name":"First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations","route":"/key-papers/paper-nct05668988-n-engl-j-med-2026/","asOf":"2026-09-24","days":4},{"id":"paper-nct05671510-nat-med-2026","kind":"paper","name":"Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial","route":"/key-papers/paper-nct05671510-nat-med-2026/","asOf":"2026-09-24","days":4},{"id":"paper-nct05712902-lancet-respir-med-2024","kind":"paper","name":"Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial","route":"/key-papers/paper-nct05712902-lancet-respir-med-2024/","asOf":"2026-09-24","days":4},{"id":"paper-nct05722015-ann-oncol-2025","kind":"paper","name":"Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial","route":"/key-papers/paper-nct05722015-ann-oncol-2025/","asOf":"2026-09-24","days":4},{"id":"paper-nct05840016-lancet-2025","kind":"paper","name":"Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial","route":"/key-papers/paper-nct05840016-lancet-2025/","asOf":"2026-09-24","days":4},{"id":"paper-nct05840016-lancet-2026-update","kind":"paper","name":"Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China","route":"/key-papers/paper-nct05840016-lancet-2026-update/","asOf":"2026-09-24","days":4},{"id":"paper-nct05870319-n-engl-j-med-2026","kind":"paper","name":"Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR -Mutated Advanced NSCLC","route":"/key-papers/paper-nct05870319-n-engl-j-med-2026/","asOf":"2026-09-24","days":4},{"id":"paper-nct05933265-invest-new-drugs-2026","kind":"paper","name":"A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors","route":"/key-papers/paper-nct05933265-invest-new-drugs-2026/","asOf":"2026-09-24","days":4},{"id":"paper-nct05955391-j-thorac-oncol-2026","kind":"paper","name":"Deulorlatinib (TGRX-326) in ALK Gene Fusion Positive NSCLC After Failure of Second-Generation Inhibitors: A Single-Arm, Multicenter, Phase 2 Trial","route":"/key-papers/paper-nct05955391-j-thorac-oncol-2026/","asOf":"2026-09-24","days":4},{"id":"paper-nct06015503-j-thorac-oncol-2026","kind":"paper","name":"Andamertinib in Advanced NSCLC With EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results From the Phase 2 KANNON Study","route":"/key-papers/paper-nct06015503-j-thorac-oncol-2026/","asOf":"2026-09-24","days":4},{"id":"paper-nct06099782-jco-oncol-pract-2026","kind":"paper","name":"Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized, Open-Label, Phase II Study","route":"/key-papers/paper-nct06099782-jco-oncol-pract-2026/","asOf":"2026-09-24","days":4},{"id":"paper-nct06120140-j-thorac-oncol-2025","kind":"paper","name":"Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial","route":"/key-papers/paper-nct06120140-j-thorac-oncol-2025/","asOf":"2026-09-24","days":4},{"id":"paper-nct06396065-lancet-oncol-2026","kind":"paper","name":"Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial","route":"/key-papers/paper-nct06396065-lancet-oncol-2026/","asOf":"2026-09-24","days":4},{"id":"paper-nct06448312-lancet-2026","kind":"paper","name":"Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial","route":"/key-papers/paper-nct06448312-lancet-2026/","asOf":"2026-09-24","days":4},{"id":"paper-nct06612151-n-engl-j-med-2026","kind":"paper","name":"Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy","route":"/key-papers/paper-nct06612151-n-engl-j-med-2026/","asOf":"2026-09-24","days":4},{"id":"paper-nct04270591-eclinicalmedicine-2023","kind":"paper","name":"Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial","route":"/key-papers/paper-nct04270591-eclinicalmedicine-2023/","asOf":"2026-09-24","days":4},{"id":"paper-nct04270591-transl-lung-cancer-res-2025-update","kind":"paper","name":"Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with MET exon 14 skipping mutated non-small cell lung cancer","route":"/key-papers/paper-nct04270591-transl-lung-cancer-res-2025-update/","asOf":"2026-09-24","days":4},{"id":"paper-nct04606446-nat-med-2024","kind":"paper","name":"Inhibition of lysine acetyltransferase KAT6 in ER + HER2 - metastatic breast cancer: a phase 1 trial","route":"/key-papers/paper-nct04606446-nat-med-2024/","asOf":"2026-09-24","days":4},{"id":"paper-nct05061550-nat-med-2025","kind":"paper","name":"Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial","route":"/key-papers/paper-nct05061550-nat-med-2025/","asOf":"2026-09-24","days":4},{"id":"paper-nct05168566-j-thorac-oncol-2026","kind":"paper","name":"Sutetinib for Patients with Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial","route":"/key-papers/paper-nct05168566-j-thorac-oncol-2026/","asOf":"2026-09-24","days":4},{"id":"paper-nct05288205-lancet-respir-med-2026","kind":"paper","name":"Glecirasib plus sitneprotafib in patients with KRAS G12C -mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial","route":"/key-papers/paper-nct05288205-lancet-respir-med-2026/","asOf":"2026-09-24","days":4},{"id":"paper-nct05351788-nat-med-2025","kind":"paper","name":"First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial","route":"/key-papers/paper-nct05351788-nat-med-2025/","asOf":"2026-09-24","days":4},{"id":"paper-nct05379985-n-engl-j-med-2026","kind":"paper","name":"Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer","route":"/key-papers/paper-nct05379985-n-engl-j-med-2026/","asOf":"2026-09-24","days":4},{"id":"paper-nct05435248-j-transl-med-2025","kind":"paper","name":"HS-10375, a selective EGFR C797S tyrosine kinase inhibitor, in advanced non-small cell lung cancer","route":"/key-papers/paper-nct05435248-j-transl-med-2025/","asOf":"2026-09-24","days":4},{"id":"paper-nct05751798-eur-j-cancer-2026","kind":"paper","name":"A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours","route":"/key-papers/paper-nct05751798-eur-j-cancer-2026/","asOf":"2026-09-24","days":4},{"id":"paper-aphinity-j-clin-oncol-2024-update","kind":"paper","name":"Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update","route":"/key-papers/paper-aphinity-j-clin-oncol-2024-update/","asOf":"2026-09-24","days":4},{"id":"paper-apt-trial-lancet-oncol-2023-update","kind":"paper","name":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial","route":"/key-papers/paper-apt-trial-lancet-oncol-2023-update/","asOf":"2026-09-24","days":4},{"id":"paper-ascent-03-n-engl-j-med-2025","kind":"paper","name":"Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer","route":"/key-papers/paper-ascent-03-n-engl-j-med-2025/","asOf":"2026-09-24","days":4},{"id":"paper-ascent-04-n-engl-j-med-2026","kind":"paper","name":"Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer","route":"/key-papers/paper-ascent-04-n-engl-j-med-2026/","asOf":"2026-09-24","days":4},{"id":"paper-bolero-2-n-engl-j-med-2012","kind":"paper","name":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","route":"/key-papers/paper-bolero-2-n-engl-j-med-2012/","asOf":"2026-09-24","days":4},{"id":"paper-bolero-2-ann-oncol-2014-update","kind":"paper","name":"Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†","route":"/key-papers/paper-bolero-2-ann-oncol-2014-update/","asOf":"2026-09-24","days":4},{"id":"paper-cleopatra-n-engl-j-med-2012","kind":"paper","name":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","route":"/key-papers/paper-cleopatra-n-engl-j-med-2012/","asOf":"2026-09-24","days":4},{"id":"paper-cleopatra-lancet-oncol-2013-update","kind":"paper","name":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study","route":"/key-papers/paper-cleopatra-lancet-oncol-2013-update/","asOf":"2026-09-24","days":4},{"id":"paper-comet-dcis-jama-2025","kind":"paper","name":"Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial","route":"/key-papers/paper-comet-dcis-jama-2025/","asOf":"2026-09-24","days":4},{"id":"paper-dawna-1-nat-med-2021","kind":"paper","name":"Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial","route":"/key-papers/paper-dawna-1-nat-med-2021/","asOf":"2026-09-24","days":4},{"id":"paper-destiny-breast03-lancet-2023-update","kind":"paper","name":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","route":"/key-papers/paper-destiny-breast03-lancet-2023-update/","asOf":"2026-09-24","days":4},{"id":"paper-destiny-breast04-nat-med-2025-update","kind":"paper","name":"Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial","route":"/key-papers/paper-destiny-breast04-nat-med-2025-update/","asOf":"2026-09-24","days":4},{"id":"paper-destiny-breast05-n-engl-j-med-2026","kind":"paper","name":"Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer","route":"/key-papers/paper-destiny-breast05-n-engl-j-med-2026/","asOf":"2026-09-24","days":4},{"id":"paper-destiny-breast09-n-engl-j-med-2026","kind":"paper","name":"Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer","route":"/key-papers/paper-destiny-breast09-n-engl-j-med-2026/","asOf":"2026-09-24","days":4},{"id":"paper-destiny-breast12-nat-med-2024","kind":"paper","name":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial","route":"/key-papers/paper-destiny-breast12-nat-med-2024/","asOf":"2026-09-24","days":4},{"id":"paper-ember-3-n-engl-j-med-2025","kind":"paper","name":"Imlunestrant with or without Abemaciclib in Advanced Breast Cancer","route":"/key-papers/paper-ember-3-n-engl-j-med-2025/","asOf":"2026-09-24","days":4},{"id":"paper-embraca-n-engl-j-med-2018","kind":"paper","name":"Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation","route":"/key-papers/paper-embraca-n-engl-j-med-2018/","asOf":"2026-09-24","days":4},{"id":"paper-eortc-22922-n-engl-j-med-2015","kind":"paper","name":"Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer","route":"/key-papers/paper-eortc-22922-n-engl-j-med-2015/","asOf":"2026-09-24","days":4},{"id":"paper-eortc-22922-lancet-oncol-2020-update","kind":"paper","name":"Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial","route":"/key-papers/paper-eortc-22922-lancet-oncol-2020-update/","asOf":"2026-09-24","days":4},{"id":"paper-geparsixto-lancet-oncol-2014","kind":"paper","name":"Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial","route":"/key-papers/paper-geparsixto-lancet-oncol-2014/","asOf":"2026-09-24","days":4},{"id":"paper-her2climb-02-ann-oncol-2026","kind":"paper","name":"Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02","route":"/key-papers/paper-her2climb-02-ann-oncol-2026/","asOf":"2026-09-24","days":4},{"id":"paper-her2climb-05-j-clin-oncol-2026","kind":"paper","name":"HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer","route":"/key-papers/paper-her2climb-05-j-clin-oncol-2026/","asOf":"2026-09-24","days":4},{"id":"paper-hera-b31-n9831-n-engl-j-med-2005","kind":"paper","name":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","route":"/key-papers/paper-hera-b31-n9831-n-engl-j-med-2005/","asOf":"2026-09-24","days":4},{"id":"paper-hera-b31-n9831-lancet-2017-update","kind":"paper","name":"11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial","route":"/key-papers/paper-hera-b31-n9831-lancet-2017-update/","asOf":"2026-09-24","days":4},{"id":"paper-horizon-breast01-lancet-oncol-2026","kind":"paper","name":"Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial","route":"/key-papers/paper-horizon-breast01-lancet-oncol-2026/","asOf":"2026-09-24","days":4},{"id":"paper-impassion031-lancet-2020","kind":"paper","name":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","route":"/key-papers/paper-impassion031-lancet-2020/","asOf":"2026-09-24","days":4},{"id":"paper-impassion031-nat-med-2025-update","kind":"paper","name":"Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial","route":"/key-papers/paper-impassion031-nat-med-2025-update/","asOf":"2026-09-24","days":4},{"id":"paper-impassion130-n-engl-j-med-2018","kind":"paper","name":"Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer","route":"/key-papers/paper-impassion130-n-engl-j-med-2018/","asOf":"2026-09-24","days":4},{"id":"paper-impassion130-lancet-oncol-2020-update","kind":"paper","name":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-impassion130-lancet-oncol-2020-update/","asOf":"2026-09-24","days":4},{"id":"paper-impassion131-ann-oncol-2021","kind":"paper","name":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer","route":"/key-papers/paper-impassion131-ann-oncol-2021/","asOf":"2026-09-24","days":4},{"id":"paper-inavo120-n-engl-j-med-2024","kind":"paper","name":"Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer","route":"/key-papers/paper-inavo120-n-engl-j-med-2024/","asOf":"2026-09-24","days":4},{"id":"paper-inavo120-n-engl-j-med-2025-update","kind":"paper","name":"Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer","route":"/key-papers/paper-inavo120-n-engl-j-med-2025-update/","asOf":"2026-09-24","days":4},{"id":"paper-keynote-355-lancet-2020","kind":"paper","name":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","route":"/key-papers/paper-keynote-355-lancet-2020/","asOf":"2026-09-24","days":4},{"id":"paper-keynote-522-n-engl-j-med-2020","kind":"paper","name":"Pembrolizumab for Early Triple-Negative Breast Cancer","route":"/key-papers/paper-keynote-522-n-engl-j-med-2020/","asOf":"2026-09-24","days":4},{"id":"paper-keynote-522-n-engl-j-med-2024-update","kind":"paper","name":"Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer","route":"/key-papers/paper-keynote-522-n-engl-j-med-2024-update/","asOf":"2026-09-24","days":4},{"id":"paper-kristine-lancet-oncol-2018","kind":"paper","name":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial","route":"/key-papers/paper-kristine-lancet-oncol-2018/","asOf":"2026-09-24","days":4},{"id":"paper-lumina-n-engl-j-med-2023","kind":"paper","name":"Omitting Radiotherapy after Breast-Conserving Surgery in Luminal A Breast Cancer","route":"/key-papers/paper-lumina-n-engl-j-med-2023/","asOf":"2026-09-24","days":4},{"id":"paper-ma-20-n-engl-j-med-2015","kind":"paper","name":"Regional Nodal Irradiation in Early-Stage Breast Cancer","route":"/key-papers/paper-ma-20-n-engl-j-med-2015/","asOf":"2026-09-24","days":4},{"id":"paper-masai-lancet-digit-health-2025","kind":"paper","name":"Screening performance and characteristics of breast cancer detected in the Mammography Screening with Artificial Intelligence trial (MASAI): a randomised, controlled, parallel-group, non-inferiority, single-blinded, screening accuracy study","route":"/key-papers/paper-masai-lancet-digit-health-2025/","asOf":"2026-09-24","days":4},{"id":"paper-mindact-ann-oncol-2014","kind":"paper","name":"High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial","route":"/key-papers/paper-mindact-ann-oncol-2014/","asOf":"2026-09-24","days":4},{"id":"paper-monaleesa-2-n-engl-j-med-2016","kind":"paper","name":"Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer","route":"/key-papers/paper-monaleesa-2-n-engl-j-med-2016/","asOf":"2026-09-24","days":4},{"id":"paper-monaleesa-2-n-engl-j-med-2022-update","kind":"paper","name":"Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer","route":"/key-papers/paper-monaleesa-2-n-engl-j-med-2022-update/","asOf":"2026-09-24","days":4},{"id":"paper-monarche-lancet-oncol-2023","kind":"paper","name":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","route":"/key-papers/paper-monarche-lancet-oncol-2023/","asOf":"2026-09-24","days":4},{"id":"paper-monarche-ann-oncol-2026-update","kind":"paper","name":"Overall survival with abemaciclib in early breast cancer","route":"/key-papers/paper-monarche-ann-oncol-2026-update/","asOf":"2026-09-24","days":4},{"id":"paper-nala-j-clin-oncol-2020","kind":"paper","name":"Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial","route":"/key-papers/paper-nala-j-clin-oncol-2020/","asOf":"2026-09-24","days":4},{"id":"paper-natalee-jama-oncol-2025-update","kind":"paper","name":"Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial","route":"/key-papers/paper-natalee-jama-oncol-2025-update/","asOf":"2026-09-24","days":4},{"id":"paper-neosphere-lancet-oncol-2012","kind":"paper","name":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","route":"/key-papers/paper-neosphere-lancet-oncol-2012/","asOf":"2026-09-24","days":4},{"id":"paper-neosphere-lancet-oncol-2016-update","kind":"paper","name":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial","route":"/key-papers/paper-neosphere-lancet-oncol-2016-update/","asOf":"2026-09-24","days":4},{"id":"paper-nsabp-b39-lancet-2019","kind":"paper","name":"Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial","route":"/key-papers/paper-nsabp-b39-lancet-2019/","asOf":"2026-09-24","days":4},{"id":"paper-olympiad-ann-oncol-2019-update","kind":"paper","name":"OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","route":"/key-papers/paper-olympiad-ann-oncol-2019-update/","asOf":"2026-09-24","days":4},{"id":"paper-pallas-penelope-b-lancet-oncol-2021","kind":"paper","name":"Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study","route":"/key-papers/paper-pallas-penelope-b-lancet-oncol-2021/","asOf":"2026-09-24","days":4},{"id":"paper-paloma-2-n-engl-j-med-2016","kind":"paper","name":"Palbociclib and Letrozole in Advanced Breast Cancer","route":"/key-papers/paper-paloma-2-n-engl-j-med-2016/","asOf":"2026-09-24","days":4},{"id":"paper-paloma-2-breast-cancer-res-treat-2019-update","kind":"paper","name":"Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up","route":"/key-papers/paper-paloma-2-breast-cancer-res-treat-2019-update/","asOf":"2026-09-24","days":4},{"id":"paper-patina-n-engl-j-med-2026","kind":"paper","name":"Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer","route":"/key-papers/paper-patina-n-engl-j-med-2026/","asOf":"2026-09-24","days":4},{"id":"paper-penelope-b-j-clin-oncol-2021","kind":"paper","name":"Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial","route":"/key-papers/paper-penelope-b-j-clin-oncol-2021/","asOf":"2026-09-24","days":4},{"id":"paper-persephone-lancet-2019","kind":"paper","name":"6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial","route":"/key-papers/paper-persephone-lancet-2019/","asOf":"2026-09-24","days":4},{"id":"paper-phergain-lancet-oncol-2021","kind":"paper","name":"Chemotherapy de-escalation using an 18 F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial","route":"/key-papers/paper-phergain-lancet-oncol-2021/","asOf":"2026-09-24","days":4},{"id":"paper-phergain-lancet-2024-update","kind":"paper","name":"3-year invasive disease-free survival with chemotherapy de-escalation using an 18 F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial","route":"/key-papers/paper-phergain-lancet-2024-update/","asOf":"2026-09-24","days":4},{"id":"paper-rxponder-n-engl-j-med-2021","kind":"paper","name":"21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer","route":"/key-papers/paper-rxponder-n-engl-j-med-2021/","asOf":"2026-09-24","days":4},{"id":"paper-serena-6-n-engl-j-med-2025","kind":"paper","name":"First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer","route":"/key-papers/paper-serena-6-n-engl-j-med-2025/","asOf":"2026-09-24","days":4},{"id":"paper-soft-text-n-engl-j-med-2015","kind":"paper","name":"Adjuvant ovarian suppression in premenopausal breast cancer","route":"/key-papers/paper-soft-text-n-engl-j-med-2015/","asOf":"2026-09-24","days":4},{"id":"paper-soft-text-j-clin-oncol-2023-update","kind":"paper","name":"Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT","route":"/key-papers/paper-soft-text-j-clin-oncol-2023-update/","asOf":"2026-09-24","days":4},{"id":"paper-solar-1-ann-oncol-2021-update","kind":"paper","name":"Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1","route":"/key-papers/paper-solar-1-ann-oncol-2021-update/","asOf":"2026-09-24","days":4},{"id":"paper-tropics-02-lancet-2023","kind":"paper","name":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","route":"/key-papers/paper-tropics-02-lancet-2023/","asOf":"2026-09-24","days":4},{"id":"paper-whel-jama-2007","kind":"paper","name":"Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial","route":"/key-papers/paper-whel-jama-2007/","asOf":"2026-09-24","days":4},{"id":"paper-brightness-lancet-oncol-2018","kind":"paper","name":"Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial","route":"/key-papers/paper-brightness-lancet-oncol-2018/","asOf":"2026-09-24","days":4},{"id":"paper-plasmamatch-lancet-oncol-2020","kind":"paper","name":"Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial","route":"/key-papers/paper-plasmamatch-lancet-oncol-2020/","asOf":"2026-09-24","days":4},{"id":"paper-i-spy-2-jama-oncol-2020","kind":"paper","name":"Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial","route":"/key-papers/paper-i-spy-2-jama-oncol-2020/","asOf":"2026-09-24","days":4},{"id":"paper-nct02107703-j-clin-oncol-2017","kind":"paper","name":"MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy","route":"/key-papers/paper-nct02107703-j-clin-oncol-2017/","asOf":"2026-09-24","days":4},{"id":"paper-nct02107703-jama-oncol-2020-update","kind":"paper","name":"The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial","route":"/key-papers/paper-nct02107703-jama-oncol-2020-update/","asOf":"2026-09-24","days":4},{"id":"paper-nct03330847-clin-cancer-res-2026","kind":"paper","name":"Safety and Efficacy of Ceralasertib plus Olaparib for Advanced/Metastatic Triple-Negative Breast Cancer in Three Molecular Strata: The Phase II VIOLETTE Study","route":"/key-papers/paper-nct03330847-clin-cancer-res-2026/","asOf":"2026-09-24","days":4},{"id":"paper-nct03725059-nat-med-2025","kind":"paper","name":"Pembrolizumab and chemotherapy in high-risk, early-stage, ER + /HER2 - breast cancer: a randomized phase 3 trial","route":"/key-papers/paper-nct03725059-nat-med-2025/","asOf":"2026-09-24","days":4},{"id":"paper-nct03742102-ann-oncol-2026","kind":"paper","name":"Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study","route":"/key-papers/paper-nct03742102-ann-oncol-2026/","asOf":"2026-09-24","days":4},{"id":"paper-nct04214288-lancet-oncol-2024","kind":"paper","name":"Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial","route":"/key-papers/paper-nct04214288-lancet-oncol-2024/","asOf":"2026-09-24","days":4},{"id":"paper-nct04454437-int-j-cancer-2023","kind":"paper","name":"A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments","route":"/key-papers/paper-nct04454437-int-j-cancer-2023/","asOf":"2026-09-24","days":4},{"id":"paper-nct04576455-j-clin-oncol-2024","kind":"paper","name":"Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study","route":"/key-papers/paper-nct04576455-j-clin-oncol-2024/","asOf":"2026-09-24","days":4},{"id":"paper-nct05077449-nat-commun-2025","kind":"paper","name":"Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis","route":"/key-papers/paper-nct05077449-nat-commun-2025/","asOf":"2026-09-24","days":4},{"id":"paper-nct05101096-int-j-clin-oncol-2024","kind":"paper","name":"Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors","route":"/key-papers/paper-nct05101096-int-j-clin-oncol-2024/","asOf":"2026-09-24","days":4},{"id":"paper-nct05227664-nat-med-2026","kind":"paper","name":"First-line PD-1/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial","route":"/key-papers/paper-nct05227664-nat-med-2026/","asOf":"2026-09-24","days":4},{"id":"paper-nct05347134-nat-med-2025","kind":"paper","name":"Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial","route":"/key-papers/paper-nct05347134-nat-med-2025/","asOf":"2026-09-24","days":4},{"id":"paper-nct05587296-n-engl-j-med-2025","kind":"paper","name":"Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer","route":"/key-papers/paper-nct05587296-n-engl-j-med-2025/","asOf":"2026-09-24","days":4},{"id":"paper-nct06198751-j-clin-oncol-2026","kind":"paper","name":"Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial","route":"/key-papers/paper-nct06198751-j-clin-oncol-2026/","asOf":"2026-09-24","days":4},{"id":"paper-nct06747338-jama-oncol-2026","kind":"paper","name":"Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial","route":"/key-papers/paper-nct06747338-jama-oncol-2026/","asOf":"2026-09-24","days":4},{"id":"paper-nct06968585-j-clin-oncol-2026","kind":"paper","name":"Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial","route":"/key-papers/paper-nct06968585-j-clin-oncol-2026/","asOf":"2026-09-24","days":4},{"id":"paper-wisdom-trial-jama-2026","kind":"paper","name":"Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial","route":"/key-papers/paper-wisdom-trial-jama-2026/","asOf":"2026-09-24","days":4},{"id":"paper-alascca-n-engl-j-med-2025","kind":"paper","name":"Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer","route":"/key-papers/paper-alascca-n-engl-j-med-2025/","asOf":"2026-09-24","days":4},{"id":"paper-atomic-n-engl-j-med-2026","kind":"paper","name":"Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer","route":"/key-papers/paper-atomic-n-engl-j-med-2026/","asOf":"2026-09-24","days":4},{"id":"paper-blue-c-n-engl-j-med-2024","kind":"paper","name":"Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening","route":"/key-papers/paper-blue-c-n-engl-j-med-2024/","asOf":"2026-09-24","days":4},{"id":"paper-breakwater-nat-med-2025","kind":"paper","name":"Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial","route":"/key-papers/paper-breakwater-nat-med-2025/","asOf":"2026-09-24","days":4},{"id":"paper-destiny-crc02-lancet-oncol-2024","kind":"paper","name":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial","route":"/key-papers/paper-destiny-crc02-lancet-oncol-2024/","asOf":"2026-09-24","days":4},{"id":"paper-dynamic-nat-med-2025-update","kind":"paper","name":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial","route":"/key-papers/paper-dynamic-nat-med-2025-update/","asOf":"2026-09-24","days":4},{"id":"paper-eclipse-shield-n-engl-j-med-2024","kind":"paper","name":"A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening","route":"/key-papers/paper-eclipse-shield-n-engl-j-med-2024/","asOf":"2026-09-24","days":4},{"id":"paper-keynote-177-lancet-oncol-2022-update","kind":"paper","name":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","route":"/key-papers/paper-keynote-177-lancet-oncol-2022-update/","asOf":"2026-09-24","days":4},{"id":"paper-niche-2-nat-med-2020","kind":"paper","name":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","route":"/key-papers/paper-niche-2-nat-med-2020/","asOf":"2026-09-24","days":4},{"id":"paper-nordicc-lancet-2026-update","kind":"paper","name":"Long-term effects of colonoscopy screening on colorectal cancer incidence and mortality: a multicountry, population-based randomised controlled trial","route":"/key-papers/paper-nordicc-lancet-2026-update/","asOf":"2026-09-24","days":4},{"id":"paper-opra-j-clin-oncol-2024","kind":"paper","name":"Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial","route":"/key-papers/paper-opra-j-clin-oncol-2024/","asOf":"2026-09-24","days":4},{"id":"paper-paradigm-jama-2023","kind":"paper","name":"Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial","route":"/key-papers/paper-paradigm-jama-2023/","asOf":"2026-09-24","days":4},{"id":"paper-mountaineer-nat-commun-2026-update","kind":"paper","name":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 +, RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis","route":"/key-papers/paper-mountaineer-nat-commun-2026-update/","asOf":"2026-09-24","days":4},{"id":"paper-mypathway-lancet-oncol-2019","kind":"paper","name":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study","route":"/key-papers/paper-mypathway-lancet-oncol-2019/","asOf":"2026-09-24","days":4},{"id":"paper-nct03785249-n-engl-j-med-2022","kind":"paper","name":"Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS G12C Mutation","route":"/key-papers/paper-nct03785249-n-engl-j-med-2022/","asOf":"2026-09-24","days":4},{"id":"paper-nct04068610-br-j-cancer-2024","kind":"paper","name":"COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer","route":"/key-papers/paper-nct04068610-br-j-cancer-2024/","asOf":"2026-09-24","days":4},{"id":"paper-nct04854668-signal-transduct-target-ther-2026","kind":"paper","name":"First-line anlotinib versus bevacizumab plus CapeOX in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ANCHOR): a multicenter, prospective, randomized, phase 3 trial","route":"/key-papers/paper-nct04854668-signal-transduct-target-ther-2026/","asOf":"2026-09-24","days":4},{"id":"paper-nct05425940-lancet-2025","kind":"paper","name":"Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial","route":"/key-papers/paper-nct05425940-lancet-2025/","asOf":"2026-09-24","days":4},{"id":"paper-nct05890742-cancer-cell-2025","kind":"paper","name":"Neoadjuvant treatment of IBI310 plus sintilimab in locally advanced MSI-H/dMMR colon cancer: A randomized phase 1b study","route":"/key-papers/paper-nct05890742-cancer-cell-2025/","asOf":"2026-09-24","days":4},{"id":"paper-nct06106308-j-clin-oncol-2025","kind":"paper","name":"Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS -Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial","route":"/key-papers/paper-nct06106308-j-clin-oncol-2025/","asOf":"2026-09-24","days":4},{"id":"paper-nct04547166-med-2024","kind":"paper","name":"First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial","route":"/key-papers/paper-nct04547166-med-2024/","asOf":"2026-09-24","days":4},{"id":"paper-nct04585750-n-engl-j-med-2026","kind":"paper","name":"Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors","route":"/key-papers/paper-nct04585750-n-engl-j-med-2026/","asOf":"2026-09-24","days":4},{"id":"paper-nct05300269-cancer-lett-2026","kind":"paper","name":"Efficacy and safety of SHR-1701 combined with chemoradiotherapy as neoadjuvant treatment for locally advanced rectal cancer","route":"/key-papers/paper-nct05300269-cancer-lett-2026/","asOf":"2026-09-24","days":4},{"id":"paper-nct05379595-j-clin-oncol-2026","kind":"paper","name":"Amivantamab Monotherapy in Chemorefractory RAS / BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study","route":"/key-papers/paper-nct05379595-j-clin-oncol-2026/","asOf":"2026-09-24","days":4},{"id":"paper-tracc-clin-cancer-res-2024","kind":"paper","name":"Tissue-Free Liquid Biopsies Combining Genomic and Methylation Signals for Minimal Residual Disease Detection in Patients with Early Colorectal Cancer from the UK TRACC Part B Study","route":"/key-papers/paper-tracc-clin-cancer-res-2024/","asOf":"2026-09-24","days":4},{"id":"paper-bolt-j-eur-acad-dermatol-venereol-2018-update","kind":"paper","name":"Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study","route":"/key-papers/paper-bolt-j-eur-acad-dermatol-venereol-2018-update/","asOf":"2026-09-24","days":4},{"id":"paper-checkmate-204-n-engl-j-med-2018","kind":"paper","name":"Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain","route":"/key-papers/paper-checkmate-204-n-engl-j-med-2018/","asOf":"2026-09-24","days":4},{"id":"paper-checkmate-204-lancet-oncol-2021-update","kind":"paper","name":"Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study","route":"/key-papers/paper-checkmate-204-lancet-oncol-2021-update/","asOf":"2026-09-24","days":4},{"id":"paper-checkmate-238-lancet-oncol-2020-update","kind":"paper","name":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","route":"/key-papers/paper-checkmate-238-lancet-oncol-2020-update/","asOf":"2026-09-24","days":4},{"id":"paper-checkmate-915-j-immunother-cancer-2025","kind":"paper","name":"Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915","route":"/key-papers/paper-checkmate-915-j-immunother-cancer-2025/","asOf":"2026-09-24","days":4},{"id":"paper-cobrim-n-engl-j-med-2014","kind":"paper","name":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","route":"/key-papers/paper-cobrim-n-engl-j-med-2014/","asOf":"2026-09-24","days":4},{"id":"paper-cobrim-lancet-oncol-2016-update","kind":"paper","name":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","route":"/key-papers/paper-cobrim-lancet-oncol-2016-update/","asOf":"2026-09-24","days":4},{"id":"paper-columbus-lancet-oncol-2018-update","kind":"paper","name":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial","route":"/key-papers/paper-columbus-lancet-oncol-2018-update/","asOf":"2026-09-24","days":4},{"id":"paper-combi-ad-n-engl-j-med-2020-update","kind":"paper","name":"Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma","route":"/key-papers/paper-combi-ad-n-engl-j-med-2020-update/","asOf":"2026-09-24","days":4},{"id":"paper-combi-d-n-engl-j-med-2014","kind":"paper","name":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","route":"/key-papers/paper-combi-d-n-engl-j-med-2014/","asOf":"2026-09-24","days":4},{"id":"paper-empower-cscc-1-lancet-oncol-2020","kind":"paper","name":"Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial","route":"/key-papers/paper-empower-cscc-1-lancet-oncol-2020/","asOf":"2026-09-24","days":4},{"id":"paper-empower-cscc-1-j-am-acad-dermatol-2025-update","kind":"paper","name":"A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6","route":"/key-papers/paper-empower-cscc-1-j-am-acad-dermatol-2025-update/","asOf":"2026-09-24","days":4},{"id":"paper-erivance-bmc-cancer-2017-update","kind":"paper","name":"Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study","route":"/key-papers/paper-erivance-bmc-cancer-2017-update/","asOf":"2026-09-24","days":4},{"id":"paper-imcgp100-202-n-engl-j-med-2021","kind":"paper","name":"Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma","route":"/key-papers/paper-imcgp100-202-n-engl-j-med-2021/","asOf":"2026-09-24","days":4},{"id":"paper-imcgp100-202-n-engl-j-med-2023-update","kind":"paper","name":"Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma","route":"/key-papers/paper-imcgp100-202-n-engl-j-med-2023-update/","asOf":"2026-09-24","days":4},{"id":"paper-imspire150-lancet-2020","kind":"paper","name":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF V600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-imspire150-lancet-2020/","asOf":"2026-09-24","days":4},{"id":"paper-imspire150-lancet-oncol-2023-update","kind":"paper","name":"Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF V600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study","route":"/key-papers/paper-imspire150-lancet-oncol-2023-update/","asOf":"2026-09-24","days":4},{"id":"paper-javelin-merkel-200-lancet-oncol-2016","kind":"paper","name":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial","route":"/key-papers/paper-javelin-merkel-200-lancet-oncol-2016/","asOf":"2026-09-24","days":4},{"id":"paper-javelin-merkel-200-j-immunother-cancer-2018-update","kind":"paper","name":"Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial","route":"/key-papers/paper-javelin-merkel-200-j-immunother-cancer-2018-update/","asOf":"2026-09-24","days":4},{"id":"paper-keynote-017-n-engl-j-med-2016","kind":"paper","name":"PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma","route":"/key-papers/paper-keynote-017-n-engl-j-med-2016/","asOf":"2026-09-24","days":4},{"id":"paper-keynote-017-j-immunother-cancer-2021-update","kind":"paper","name":"Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma","route":"/key-papers/paper-keynote-017-j-immunother-cancer-2021-update/","asOf":"2026-09-24","days":4},{"id":"paper-keynote-716-lancet-oncol-2022-update","kind":"paper","name":"Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial","route":"/key-papers/paper-keynote-716-lancet-oncol-2022-update/","asOf":"2026-09-24","days":4},{"id":"paper-relativity-047-nejm-evid-2023-update","kind":"paper","name":"Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma","route":"/key-papers/paper-relativity-047-nejm-evid-2023-update/","asOf":"2026-09-24","days":4},{"id":"paper-relativity-098-nat-med-2025","kind":"paper","name":"Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial","route":"/key-papers/paper-relativity-098-nat-med-2025/","asOf":"2026-09-24","days":4},{"id":"paper-swog-s1801-n-engl-j-med-2023","kind":"paper","name":"Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma","route":"/key-papers/paper-swog-s1801-n-engl-j-med-2023/","asOf":"2026-09-24","days":4},{"id":"paper-checkmate-358-j-clin-oncol-2019","kind":"paper","name":"Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial","route":"/key-papers/paper-checkmate-358-j-clin-oncol-2019/","asOf":"2026-09-24","days":4},{"id":"paper-mimic-01-nat-med-2023","kind":"paper","name":"Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial","route":"/key-papers/paper-mimic-01-nat-med-2023/","asOf":"2026-09-24","days":4},{"id":"paper-nct02362594-lancet-oncol-2021-update","kind":"paper","name":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","route":"/key-papers/paper-nct02362594-lancet-oncol-2021-update/","asOf":"2026-09-24","days":4},{"id":"paper-nct02938299-ann-oncol-2025","kind":"paper","name":"Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma","route":"/key-papers/paper-nct02938299-ann-oncol-2025/","asOf":"2026-09-24","days":4},{"id":"paper-nct02938299-j-clin-oncol-2026-update","kind":"paper","name":"Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial","route":"/key-papers/paper-nct02938299-j-clin-oncol-2026-update/","asOf":"2026-09-24","days":4},{"id":"paper-nct03897881-j-clin-oncol-2026-update","kind":"paper","name":"Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study","route":"/key-papers/paper-nct03897881-j-clin-oncol-2026-update/","asOf":"2026-09-24","days":4},{"id":"paper-nct04639219-lancet-oncol-2024","kind":"paper","name":"Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study","route":"/key-papers/paper-nct04639219-lancet-oncol-2024/","asOf":"2026-09-24","days":4},{"id":"paper-nct04657991-eur-j-cancer-2024","kind":"paper","name":"First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study","route":"/key-papers/paper-nct04657991-eur-j-cancer-2024/","asOf":"2026-09-24","days":4},{"id":"paper-nct05415072-nat-med-2026","kind":"paper","name":"An anti-PMEL antibody-drug conjugate with a G q/1 1 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial","route":"/key-papers/paper-nct05415072-nat-med-2026/","asOf":"2026-09-24","days":4},{"id":"paper-nct05732805-eur-j-cancer-2025","kind":"paper","name":"Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial","route":"/key-papers/paper-nct05732805-eur-j-cancer-2025/","asOf":"2026-09-24","days":4},{"id":"paper-nct02332668-lancet-oncol-2020","kind":"paper","name":"Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial","route":"/key-papers/paper-nct02332668-lancet-oncol-2020/","asOf":"2026-09-24","days":4},{"id":"paper-nct05877430-j-immunother-cancer-2026","kind":"paper","name":"Phase I trial of CJRB-101 plus pembrolizumab in patients with metastatic non-small cell lung cancer, head and neck squamous cell carcinoma and melanoma","route":"/key-papers/paper-nct05877430-j-immunother-cancer-2026/","asOf":"2026-09-24","days":4},{"id":"paper-aranote-eur-urol-2026","kind":"paper","name":"Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial","route":"/key-papers/paper-aranote-eur-urol-2026/","asOf":"2026-09-24","days":4},{"id":"paper-arches-j-clin-oncol-2019","kind":"paper","name":"ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer","route":"/key-papers/paper-arches-j-clin-oncol-2019/","asOf":"2026-09-24","days":4},{"id":"paper-arches-eur-urol-2026-update","kind":"paper","name":"ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients","route":"/key-papers/paper-arches-eur-urol-2026-update/","asOf":"2026-09-24","days":4},{"id":"paper-capitello-281-ann-oncol-2026","kind":"paper","name":"Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study","route":"/key-papers/paper-capitello-281-ann-oncol-2026/","asOf":"2026-09-24","days":4},{"id":"paper-enzamet-n-engl-j-med-2019","kind":"paper","name":"Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer","route":"/key-papers/paper-enzamet-n-engl-j-med-2019/","asOf":"2026-09-24","days":4},{"id":"paper-goteborg-2-n-engl-j-med-2022","kind":"paper","name":"Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only","route":"/key-papers/paper-goteborg-2-n-engl-j-med-2022/","asOf":"2026-09-24","days":4},{"id":"paper-latitude-lancet-oncol-2019-update","kind":"paper","name":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","route":"/key-papers/paper-latitude-lancet-oncol-2019-update/","asOf":"2026-09-24","days":4},{"id":"paper-magnitude-j-clin-oncol-2023","kind":"paper","name":"Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer","route":"/key-papers/paper-magnitude-j-clin-oncol-2023/","asOf":"2026-09-24","days":4},{"id":"paper-pace-b-lancet-oncol-2019","kind":"paper","name":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","route":"/key-papers/paper-pace-b-lancet-oncol-2019/","asOf":"2026-09-24","days":4},{"id":"paper-pace-b-lancet-oncol-2022-update","kind":"paper","name":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","route":"/key-papers/paper-pace-b-lancet-oncol-2022-update/","asOf":"2026-09-24","days":4},{"id":"paper-peace-1-lancet-2022","kind":"paper","name":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design","route":"/key-papers/paper-peace-1-lancet-2022/","asOf":"2026-09-24","days":4},{"id":"paper-propel-lancet-oncol-2023","kind":"paper","name":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","route":"/key-papers/paper-propel-lancet-oncol-2023/","asOf":"2026-09-24","days":4},{"id":"paper-psmaddition-lancet-2026","kind":"paper","name":"[ 177 Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial","route":"/key-papers/paper-psmaddition-lancet-2026/","asOf":"2026-09-24","days":4},{"id":"paper-psmafore-lancet-2024","kind":"paper","name":"177 Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","route":"/key-papers/paper-psmafore-lancet-2024/","asOf":"2026-09-24","days":4},{"id":"paper-rtog-9601-n-engl-j-med-2017","kind":"paper","name":"Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer","route":"/key-papers/paper-rtog-9601-n-engl-j-med-2017/","asOf":"2026-09-24","days":4},{"id":"paper-splash-front-oncol-2024","kind":"paper","name":"Initial clinical experience with [ 177 Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial","route":"/key-papers/paper-splash-front-oncol-2024/","asOf":"2026-09-24","days":4},{"id":"paper-stampede-lancet-2016","kind":"paper","name":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","route":"/key-papers/paper-stampede-lancet-2016/","asOf":"2026-09-24","days":4},{"id":"paper-stampede-plos-med-2022-update","kind":"paper","name":"Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial","route":"/key-papers/paper-stampede-plos-med-2022-update/","asOf":"2026-09-24","days":4},{"id":"paper-talapro-2-lancet-2023","kind":"paper","name":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","route":"/key-papers/paper-talapro-2-lancet-2023/","asOf":"2026-09-24","days":4},{"id":"paper-talapro-2-lancet-2025-update","kind":"paper","name":"Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial","route":"/key-papers/paper-talapro-2-lancet-2025-update/","asOf":"2026-09-24","days":4},{"id":"paper-therap-lancet-2021","kind":"paper","name":"[ 177 Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","route":"/key-papers/paper-therap-lancet-2021/","asOf":"2026-09-24","days":4},{"id":"paper-therap-lancet-oncol-2024-update","kind":"paper","name":"Overall survival with [ 177 Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","route":"/key-papers/paper-therap-lancet-oncol-2024-update/","asOf":"2026-09-24","days":4},{"id":"paper-protect-bju-int-2026-update","kind":"paper","name":"Long-term outcomes of cribriform-positive and cribriform-negative prostate cancer treated with radical prostatectomy in the ProtecT trial","route":"/key-papers/paper-protect-bju-int-2026-update/","asOf":"2026-09-24","days":4},{"id":"paper-nct01436968-lancet-oncol-2026","kind":"paper","name":"Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial","route":"/key-papers/paper-nct01436968-lancet-oncol-2026/","asOf":"2026-09-24","days":4},{"id":"paper-nct02257736-lancet-oncol-2021","kind":"paper","name":"Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study","route":"/key-papers/paper-nct02257736-lancet-oncol-2021/","asOf":"2026-09-24","days":4},{"id":"paper-nct02489318-n-engl-j-med-2019","kind":"paper","name":"Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer","route":"/key-papers/paper-nct02489318-n-engl-j-med-2019/","asOf":"2026-09-24","days":4},{"id":"paper-nct02861573-eur-urol-2022","kind":"paper","name":"Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study","route":"/key-papers/paper-nct02861573-eur-urol-2022/","asOf":"2026-09-24","days":4},{"id":"paper-nct03436485-nejm-evid-2024","kind":"paper","name":"Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer","route":"/key-papers/paper-nct03436485-nejm-evid-2024/","asOf":"2026-09-24","days":4},{"id":"paper-nct03706365-lancet-oncol-2025","kind":"paper","name":"Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","route":"/key-papers/paper-nct03706365-lancet-oncol-2025/","asOf":"2026-09-24","days":4},{"id":"paper-nct03767244-n-engl-j-med-2026","kind":"paper","name":"Perioperative Apalutamide in High-Risk Localized Prostate Cancer","route":"/key-papers/paper-nct03767244-n-engl-j-med-2026/","asOf":"2026-09-24","days":4},{"id":"paper-nct04446117-lancet-oncol-2025","kind":"paper","name":"Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial","route":"/key-papers/paper-nct04446117-lancet-oncol-2025/","asOf":"2026-09-24","days":4},{"id":"paper-nct04497844-nat-med-2025","kind":"paper","name":"Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial","route":"/key-papers/paper-nct04497844-nat-med-2025/","asOf":"2026-09-24","days":4},{"id":"paper-nct04821622-n-engl-j-med-2026","kind":"paper","name":"PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer","route":"/key-papers/paper-nct04821622-n-engl-j-med-2026/","asOf":"2026-09-24","days":4},{"id":"paper-nct03851640-signal-transduct-target-ther-2026","kind":"paper","name":"Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial","route":"/key-papers/paper-nct03851640-signal-transduct-target-ther-2026/","asOf":"2026-09-24","days":4},{"id":"paper-nct05413850-j-nucl-med-2024","kind":"paper","name":"First Safety and Efficacy Data with the Radiohybrid 177 Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer","route":"/key-papers/paper-nct05413850-j-nucl-med-2024/","asOf":"2026-09-24","days":4},{"id":"paper-naliricc-lancet-gastroenterol-hepatol-2024","kind":"paper","name":"Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial","route":"/key-papers/paper-naliricc-lancet-gastroenterol-hepatol-2024/","asOf":"2026-09-24","days":4},{"id":"paper-roar-lancet-oncol-2020","kind":"paper","name":"Dabrafenib plus trametinib in patients with BRAF V600E -mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","route":"/key-papers/paper-roar-lancet-oncol-2020/","asOf":"2026-09-24","days":4},{"id":"paper-roar-ann-oncol-2022-update","kind":"paper","name":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study","route":"/key-papers/paper-roar-ann-oncol-2022-update/","asOf":"2026-09-24","days":4},{"id":"paper-topaz-1-lancet-gastroenterol-hepatol-2024-update","kind":"paper","name":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","route":"/key-papers/paper-topaz-1-lancet-gastroenterol-hepatol-2024-update/","asOf":"2026-09-24","days":4},{"id":"paper-gap-phase2-mdacc-jama-oncol-2019","kind":"paper","name":"Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial","route":"/key-papers/paper-gap-phase2-mdacc-jama-oncol-2019/","asOf":"2026-09-24","days":4},{"id":"paper-keynote-158-j-clin-oncol-2019","kind":"paper","name":"Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study","route":"/key-papers/paper-keynote-158-j-clin-oncol-2019/","asOf":"2026-09-24","days":4},{"id":"paper-keynote-158-ann-oncol-2022-update","kind":"paper","name":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","route":"/key-papers/paper-keynote-158-ann-oncol-2022-update/","asOf":"2026-09-24","days":4},{"id":"paper-nct04969887-jama-oncol-2025","kind":"paper","name":"Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers: A Nonrandomized Clinical Trial","route":"/key-papers/paper-nct04969887-jama-oncol-2025/","asOf":"2026-09-24","days":4},{"id":"paper-nct05724563-nat-commun-2025","kind":"paper","name":"Dual TIGIT and PD-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-PD-1 therapies: the phase 2 LIVERTI trial","route":"/key-papers/paper-nct05724563-nat-commun-2025/","asOf":"2026-09-24","days":4},{"id":"nct01517802","kind":"trial","name":"A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate","route":"/trials/nct01517802/","asOf":"2026-09-24","days":4},{"id":"nct03213665","kind":"trial","name":"Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)","route":"/trials/nct03213665/","asOf":"2026-09-24","days":4},{"id":"nct03635983","kind":"trial","name":"A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma","route":"/trials/nct03635983/","asOf":"2026-09-24","days":4},{"id":"nct00936390","kind":"trial","name":"Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer","route":"/trials/nct00936390/","asOf":"2026-09-24","days":4},{"id":"nct00377429","kind":"trial","name":"Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy","route":"/trials/nct00377429/","asOf":"2026-09-24","days":4},{"id":"nct00399035","kind":"trial","name":"Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer","route":"/trials/nct00399035/","asOf":"2026-09-24","days":4},{"id":"nct00777153","kind":"trial","name":"Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma","route":"/trials/nct00777153/","asOf":"2026-09-24","days":4},{"id":"nct01828112","kind":"trial","name":"LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib","route":"/trials/nct01828112/","asOf":"2026-09-24","days":4},{"id":"nct02260817","kind":"trial","name":"Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer","route":"/trials/nct02260817/","asOf":"2026-09-24","days":4},{"id":"nct01054079","kind":"trial","name":"Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer","route":"/trials/nct01054079/","asOf":"2026-09-24","days":4},{"id":"nct00718549","kind":"trial","name":"A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)","route":"/trials/nct00718549/","asOf":"2026-09-24","days":4},{"id":"nct02883049","kind":"trial","name":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","route":"/trials/nct02883049/","asOf":"2026-09-24","days":4},{"id":"nct02521493","kind":"trial","name":"Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome","route":"/trials/nct02521493/","asOf":"2026-09-24","days":4},{"id":"nct01360554","kind":"trial","name":"ARCHER 1009: A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer","route":"/trials/nct01360554/","asOf":"2026-09-24","days":4},{"id":"nct02663908","kind":"trial","name":"A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease","route":"/trials/nct02663908/","asOf":"2026-09-24","days":4},{"id":"nct00833248","kind":"trial","name":"Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer","route":"/trials/nct00833248/","asOf":"2026-09-24","days":4},{"id":"nct00884273","kind":"trial","name":"Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients","route":"/trials/nct00884273/","asOf":"2026-09-24","days":4},{"id":"nct01127451","kind":"trial","name":"Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma","route":"/trials/nct01127451/","asOf":"2026-09-24","days":4},{"id":"nct00299689","kind":"trial","name":"Phase II Trial of Ontak With Metastatic Melanoma","route":"/trials/nct00299689/","asOf":"2026-09-24","days":4},{"id":"nct00880360","kind":"trial","name":"A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer","route":"/trials/nct00880360/","asOf":"2026-09-24","days":4},{"id":"nct03252431","kind":"trial","name":"Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy","route":"/trials/nct03252431/","asOf":"2026-09-24","days":4},{"id":"nct04174599","kind":"trial","name":"Study to Compare the Efficacy and Safety of F-627 and GRAN®","route":"/trials/nct04174599/","asOf":"2026-09-24","days":4},{"id":"nct02872103","kind":"trial","name":"Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy","route":"/trials/nct02872103/","asOf":"2026-09-24","days":4},{"id":"nct01890746","kind":"trial","name":"A Safety and Efficacy Study of Eltrombopag in Subjects With AML","route":"/trials/nct01890746/","asOf":"2026-09-24","days":4},{"id":"nct01772420","kind":"trial","name":"Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia","route":"/trials/nct01772420/","asOf":"2026-09-24","days":4},{"id":"nct03260894","kind":"trial","name":"Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)","route":"/trials/nct03260894/","asOf":"2026-09-24","days":4},{"id":"nct03358472","kind":"trial","name":"Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)","route":"/trials/nct03358472/","asOf":"2026-09-24","days":4},{"id":"nct00004054","kind":"trial","name":"Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer","route":"/trials/nct00004054/","asOf":"2026-09-24","days":4},{"id":"nct00024167","kind":"trial","name":"Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer","route":"/trials/nct00024167/","asOf":"2026-09-24","days":4},{"id":"nct02762266","kind":"trial","name":"Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization","route":"/trials/nct02762266/","asOf":"2026-09-24","days":4},{"id":"nct04410133","kind":"trial","name":"Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases","route":"/trials/nct04410133/","asOf":"2026-09-24","days":4},{"id":"nct04692103","kind":"trial","name":"Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy","route":"/trials/nct04692103/","asOf":"2026-09-24","days":4},{"id":"nct01499303","kind":"trial","name":"Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer","route":"/trials/nct01499303/","asOf":"2026-09-24","days":4},{"id":"nct04543279","kind":"trial","name":"Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia","route":"/trials/nct04543279/","asOf":"2026-09-24","days":4},{"id":"nct03416179","kind":"trial","name":"A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia","route":"/trials/nct03416179/","asOf":"2026-09-24","days":4},{"id":"nct01305655","kind":"trial","name":"Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL","route":"/trials/nct01305655/","asOf":"2026-09-24","days":4},{"id":"nct00186628","kind":"trial","name":"Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD","route":"/trials/nct00186628/","asOf":"2026-09-24","days":4},{"id":"nct02448381","kind":"trial","name":"FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)","route":"/trials/nct02448381/","asOf":"2026-09-24","days":4},{"id":"nct06149247","kind":"trial","name":"HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL","route":"/trials/nct06149247/","asOf":"2026-09-24","days":4},{"id":"nct02739594","kind":"trial","name":"Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma","route":"/trials/nct02739594/","asOf":"2026-09-24","days":4},{"id":"nct00582166","kind":"trial","name":"Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance","route":"/trials/nct00582166/","asOf":"2026-09-24","days":4},{"id":"nct01497275","kind":"trial","name":"Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma","route":"/trials/nct01497275/","asOf":"2026-09-24","days":4},{"id":"nct02159066","kind":"trial","name":"LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma","route":"/trials/nct02159066/","asOf":"2026-09-24","days":4},{"id":"nct01975701","kind":"trial","name":"A Phase 2 Study of BGJ398 in Patients With Recurrent GBM","route":"/trials/nct01975701/","asOf":"2026-09-24","days":4},{"id":"nct00630032","kind":"trial","name":"Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer","route":"/trials/nct00630032/","asOf":"2026-09-24","days":4},{"id":"nct00883116","kind":"trial","name":"A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer","route":"/trials/nct00883116/","asOf":"2026-09-24","days":4},{"id":"nct04313881","kind":"trial","name":"Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)","route":"/trials/nct04313881/","asOf":"2026-09-24","days":4},{"id":"nct05079230","kind":"trial","name":"Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia","route":"/trials/nct05079230/","asOf":"2026-09-24","days":4},{"id":"nct04778397","kind":"trial","name":"Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated","route":"/trials/nct04778397/","asOf":"2026-09-24","days":4},{"id":"nct02492711","kind":"trial","name":"Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer","route":"/trials/nct02492711/","asOf":"2026-09-24","days":4},{"id":"nct04082364","kind":"trial","name":"Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer","route":"/trials/nct04082364/","asOf":"2026-09-24","days":4},{"id":"nct03151811","kind":"trial","name":"A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide","route":"/trials/nct03151811/","asOf":"2026-09-24","days":4},{"id":"nct04649060","kind":"trial","name":"Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma","route":"/trials/nct04649060/","asOf":"2026-09-24","days":4},{"id":"nct02963493","kind":"trial","name":"A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct02963493/","asOf":"2026-09-24","days":4},{"id":"nct00557193","kind":"trial","name":"Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","route":"/trials/nct00557193/","asOf":"2026-09-24","days":4},{"id":"nct02144077","kind":"trial","name":"Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy","route":"/trials/nct02144077/","asOf":"2026-09-24","days":4},{"id":"nct02441309","kind":"trial","name":"A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS)","route":"/trials/nct02441309/","asOf":"2026-09-24","days":4},{"id":"nct02788981","kind":"trial","name":"Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer","route":"/trials/nct02788981/","asOf":"2026-09-24","days":4},{"id":"nct01829711","kind":"trial","name":"Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia","route":"/trials/nct01829711/","asOf":"2026-09-24","days":4},{"id":"nct02730299","kind":"trial","name":"Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS","route":"/trials/nct02730299/","asOf":"2026-09-24","days":4},{"id":"nct00493181","kind":"trial","name":"Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients","route":"/trials/nct00493181/","asOf":"2026-09-24","days":4},{"id":"nct02697734","kind":"trial","name":"Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease","route":"/trials/nct02697734/","asOf":"2026-09-24","days":4},{"id":"nct01331239","kind":"trial","name":"Safety and Efficacy of LCI699 in Cushing's Disease Patients","route":"/trials/nct01331239/","asOf":"2026-09-24","days":4},{"id":"nct03315754","kind":"trial","name":"Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer","route":"/trials/nct03315754/","asOf":"2026-09-24","days":4},{"id":"nct00434161","kind":"trial","name":"A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma","route":"/trials/nct00434161/","asOf":"2026-09-24","days":4},{"id":"nct00101582","kind":"trial","name":"Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer","route":"/trials/nct00101582/","asOf":"2026-09-24","days":4},{"id":"nct00109031","kind":"trial","name":"Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)","route":"/trials/nct00109031/","asOf":"2026-09-24","days":4},{"id":"nct00742027","kind":"trial","name":"Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma","route":"/trials/nct00742027/","asOf":"2026-09-24","days":4},{"id":"nct02506959","kind":"trial","name":"Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma","route":"/trials/nct02506959/","asOf":"2026-09-24","days":4},{"id":"nct00600886","kind":"trial","name":"Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly","route":"/trials/nct00600886/","asOf":"2026-09-24","days":4},{"id":"nct01137682","kind":"trial","name":"Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly","route":"/trials/nct01137682/","asOf":"2026-09-24","days":4},{"id":"nct00434148","kind":"trial","name":"Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease","route":"/trials/nct00434148/","asOf":"2026-09-24","days":4},{"id":"nct00539591","kind":"trial","name":"Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma","route":"/trials/nct00539591/","asOf":"2026-09-24","days":4},{"id":"nct00383708","kind":"trial","name":"Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients","route":"/trials/nct00383708/","asOf":"2026-09-24","days":4},{"id":"nct00254163","kind":"trial","name":"Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients","route":"/trials/nct00254163/","asOf":"2026-09-24","days":4},{"id":"nct03268954","kind":"trial","name":"Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)","route":"/trials/nct03268954/","asOf":"2026-09-24","days":4},{"id":"nct00343382","kind":"trial","name":"Pilocarpine in Treating Vaginal Dryness in Patients With Breast Cancer","route":"/trials/nct00343382/","asOf":"2026-09-24","days":4},{"id":"nct01086605","kind":"trial","name":"Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer","route":"/trials/nct01086605/","asOf":"2026-09-24","days":4},{"id":"nct01102426","kind":"trial","name":"Aplidin - Dexamethasone in Relapsed/Refractory Myeloma","route":"/trials/nct01102426/","asOf":"2026-09-24","days":4},{"id":"nct00229203","kind":"trial","name":"A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma","route":"/trials/nct00229203/","asOf":"2026-09-24","days":4},{"id":"nct01876043","kind":"trial","name":"Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial","route":"/trials/nct01876043/","asOf":"2026-09-24","days":4},{"id":"nct02659514","kind":"trial","name":"Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer","route":"/trials/nct02659514/","asOf":"2026-09-24","days":4},{"id":"nct03744715","kind":"trial","name":"A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib","route":"/trials/nct03744715/","asOf":"2026-09-24","days":4},{"id":"nct04172597","kind":"trial","name":"A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies","route":"/trials/nct04172597/","asOf":"2026-09-24","days":4},{"id":"nct00057811","kind":"trial","name":"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma","route":"/trials/nct00057811/","asOf":"2026-09-24","days":4},{"id":"nct01200485","kind":"trial","name":"Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2","route":"/trials/nct01200485/","asOf":"2026-09-24","days":4},{"id":"nct00106431","kind":"trial","name":"A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)","route":"/trials/nct00106431/","asOf":"2026-09-24","days":4},{"id":"nct00112463","kind":"trial","name":"Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma","route":"/trials/nct00112463/","asOf":"2026-09-24","days":4},{"id":"nct03033511","kind":"trial","name":"A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)","route":"/trials/nct03033511/","asOf":"2026-09-24","days":4},{"id":"nct03061812","kind":"trial","name":"Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)","route":"/trials/nct03061812/","asOf":"2026-09-24","days":4},{"id":"nct02674568","kind":"trial","name":"Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer","route":"/trials/nct02674568/","asOf":"2026-09-24","days":4},{"id":"nct00551525","kind":"trial","name":"Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer","route":"/trials/nct00551525/","asOf":"2026-09-24","days":4},{"id":"nct00450619","kind":"trial","name":"153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer","route":"/trials/nct00450619/","asOf":"2026-09-24","days":4},{"id":"nct01886105","kind":"trial","name":"Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma","route":"/trials/nct01886105/","asOf":"2026-09-24","days":4},{"id":"nct00716976","kind":"trial","name":"Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy","route":"/trials/nct00716976/","asOf":"2026-09-24","days":4},{"id":"nct02263508","kind":"trial","name":"Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma","route":"/trials/nct02263508/","asOf":"2026-09-24","days":4},{"id":"nct00769704","kind":"trial","name":"Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma","route":"/trials/nct00769704/","asOf":"2026-09-24","days":4},{"id":"nct01368276","kind":"trial","name":"An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma","route":"/trials/nct01368276/","asOf":"2026-09-24","days":4},{"id":"nct03790111","kind":"trial","name":"A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer","route":"/trials/nct03790111/","asOf":"2026-09-24","days":4},{"id":"nct01700946","kind":"trial","name":"Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma","route":"/trials/nct01700946/","asOf":"2026-09-24","days":4},{"id":"nct00671918","kind":"trial","name":"Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma","route":"/trials/nct00671918/","asOf":"2026-09-24","days":4},{"id":"nct01106040","kind":"trial","name":"Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes","route":"/trials/nct01106040/","asOf":"2026-09-24","days":4},{"id":"nct00911326","kind":"trial","name":"Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma","route":"/trials/nct00911326/","asOf":"2026-09-24","days":4},{"id":"nct01275677","kind":"trial","name":"Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer","route":"/trials/nct01275677/","asOf":"2026-09-24","days":4},{"id":"nct00769379","kind":"trial","name":"Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy","route":"/trials/nct00769379/","asOf":"2026-09-24","days":4},{"id":"nct02003209","kind":"trial","name":"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer","route":"/trials/nct02003209/","asOf":"2026-09-24","days":4},{"id":"nct03262935","kind":"trial","name":"SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer","route":"/trials/nct03262935/","asOf":"2026-09-24","days":4},{"id":"nct04205630","kind":"trial","name":"SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma","route":"/trials/nct04205630/","asOf":"2026-09-24","days":4},{"id":"nct00066703","kind":"trial","name":"Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer","route":"/trials/nct00066703/","asOf":"2026-09-24","days":4},{"id":"nct04154956","kind":"trial","name":"SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients","route":"/trials/nct04154956/","asOf":"2026-09-24","days":4},{"id":"nct04524689","kind":"trial","name":"Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC","route":"/trials/nct04524689/","asOf":"2026-09-24","days":4},{"id":"nct04659603","kind":"trial","name":"Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors","route":"/trials/nct04659603/","asOf":"2026-09-24","days":4},{"id":"nct03801525","kind":"trial","name":"Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)","route":"/trials/nct03801525/","asOf":"2026-09-24","days":4},{"id":"nct04624633","kind":"trial","name":"Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL","route":"/trials/nct04624633/","asOf":"2026-09-24","days":4},{"id":"nct04373369","kind":"trial","name":"Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer","route":"/trials/nct04373369/","asOf":"2026-09-24","days":4},{"id":"nct00390234","kind":"trial","name":"Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma","route":"/trials/nct00390234/","asOf":"2026-09-24","days":4},{"id":"nct01882868","kind":"trial","name":"A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan","route":"/trials/nct01882868/","asOf":"2026-09-24","days":4},{"id":"nct01091974","kind":"trial","name":"Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy","route":"/trials/nct01091974/","asOf":"2026-09-24","days":4},{"id":"nct00744653","kind":"trial","name":"Electrochemotherapy for Chest Wall Recurrence af Breast Cancer: Present Challenges and Future Prospects","route":"/trials/nct00744653/","asOf":"2026-09-24","days":4},{"id":"nct04252859","kind":"trial","name":"[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma","route":"/trials/nct04252859/","asOf":"2026-09-24","days":4},{"id":"nct00582075","kind":"trial","name":"Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases","route":"/trials/nct00582075/","asOf":"2026-09-24","days":4},{"id":"alta","kind":"trial","name":"ALTA","route":"/trials/alta/","asOf":"2026-09-24","days":4},{"id":"ck-301-101","kind":"trial","name":"CK-301-101","route":"/trials/ck-301-101/","asOf":"2026-09-24","days":4},{"id":"nct01828099","kind":"trial","name":"ASCEND-4","route":"/trials/nct01828099/","asOf":"2026-09-24","days":4},{"id":"nct01774721","kind":"trial","name":"ARCHER 1050","route":"/trials/nct01774721/","asOf":"2026-09-24","days":4},{"id":"rockstar","kind":"trial","name":"ROCKstar","route":"/trials/rockstar/","asOf":"2026-09-24","days":4},{"id":"act-in-sarc","kind":"trial","name":"Act.In.Sarc","route":"/trials/act-in-sarc/","asOf":"2026-09-24","days":4},{"id":"nct02767804","kind":"trial","name":"eXalt3","route":"/trials/nct02767804/","asOf":"2026-09-24","days":4},{"id":"nct02678572","kind":"trial","name":"FOCUS","route":"/trials/nct02678572/","asOf":"2026-09-24","days":4},{"id":"msb-gvhd001","kind":"trial","name":"MSB-GVHD001","route":"/trials/msb-gvhd001/","asOf":"2026-09-24","days":4},{"id":"nct04581473","kind":"trial","name":"CT041-ST-01","route":"/trials/nct04581473/","asOf":"2026-09-24","days":4},{"id":"study-2005-01","kind":"trial","name":"Study 2005-01","route":"/trials/study-2005-01/","asOf":"2026-09-24","days":4},{"id":"study-201","kind":"trial","name":"Study 201","route":"/trials/study-201/","asOf":"2026-09-24","days":4},{"id":"study-0201","kind":"trial","name":"Study 0201","route":"/trials/study-0201/","asOf":"2026-09-24","days":4},{"id":"vistogard-studies-1-2","kind":"trial","name":"Vistogard Studies 1 and 2","route":"/trials/vistogard-studies-1-2/","asOf":"2026-09-24","days":4},{"id":"paper-alta-jco-2017","kind":"paper","name":"Brigatinib in patients with crizotinib-refractory ALK-positive non-small-cell lung cancer: a randomized, multicenter phase II trial (ALTA)","route":"/key-papers/paper-alta-jco-2017/","asOf":"2026-09-24","days":4},{"id":"paper-ck-301-101-jitc-2023","kind":"paper","name":"Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma","route":"/key-papers/paper-ck-301-101-jitc-2023/","asOf":"2026-09-24","days":4},{"id":"paper-ascend-4-lancet-2017","kind":"paper","name":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","route":"/key-papers/paper-ascend-4-lancet-2017/","asOf":"2026-09-24","days":4},{"id":"paper-archer-1050-lancet-oncol-2017","kind":"paper","name":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","route":"/key-papers/paper-archer-1050-lancet-oncol-2017/","asOf":"2026-09-24","days":4},{"id":"paper-archer-1050-os-jco-2018","kind":"paper","name":"Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations","route":"/key-papers/paper-archer-1050-os-jco-2018/","asOf":"2026-09-24","days":4},{"id":"paper-rockstar-blood-2021","kind":"paper","name":"Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study","route":"/key-papers/paper-rockstar-blood-2021/","asOf":"2026-09-24","days":4},{"id":"paper-act-in-sarc-lancet-oncol-2019","kind":"paper","name":"NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial","route":"/key-papers/paper-act-in-sarc-lancet-oncol-2019/","asOf":"2026-09-24","days":4},{"id":"paper-msb-gvhd001-bbmt-2020","kind":"paper","name":"A phase 3, single-arm, prospective study of remestemcel-L, ex vivo culture-expanded adult human mesenchymal stromal cells for the treatment of pediatric patients who failed to respond to steroid treatment for acute graft-versus-host disease","route":"/key-papers/paper-msb-gvhd001-bbmt-2020/","asOf":"2026-09-24","days":4},{"id":"paper-ct041-st-01-lancet-2025","kind":"paper","name":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial","route":"/key-papers/paper-ct041-st-01-lancet-2025/","asOf":"2026-09-24","days":4},{"id":"paper-defibrotide-2005-01-blood-2016","kind":"paper","name":"Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure","route":"/key-papers/paper-defibrotide-2005-01-blood-2016/","asOf":"2026-09-24","days":4},{"id":"paper-study-201-jama-dermatol-2013","kind":"paper","name":"Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides","route":"/key-papers/paper-study-201-jama-dermatol-2013/","asOf":"2026-09-24","days":4},{"id":"paper-study-0201-blood-2006","kind":"paper","name":"Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial","route":"/key-papers/paper-study-0201-blood-2006/","asOf":"2026-09-24","days":4},{"id":"paper-vistogard-cancer-2017","kind":"paper","name":"Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity","route":"/key-papers/paper-vistogard-cancer-2017/","asOf":"2026-09-24","days":4},{"id":"mermaid-2","kind":"trial","name":"MERMAID-2","route":"/trials/mermaid-2/","asOf":"2026-09-24","days":4},{"id":"simplescreen-crc","kind":"drug","name":"SimpleScreen CRC","route":"/drugs/simplescreen-crc/","asOf":"2026-09-24","days":4},{"id":"illuccix","kind":"drug","name":"Illuccix (kit for Ga-68 gozetotide)","route":"/drugs/illuccix/","asOf":"2026-09-24","days":4},{"id":"lunit-insight-mmg","kind":"drug","name":"Lunit INSIGHT MMG","route":"/drugs/lunit-insight-mmg/","asOf":"2026-09-24","days":4},{"id":"mechlorethamine","kind":"drug","name":"Mechlorethamine (chlormethine)","route":"/drugs/mechlorethamine/","asOf":"2026-09-24","days":4},{"id":"rolapitant","kind":"drug","name":"Rolapitant","route":"/drugs/rolapitant/","asOf":"2026-09-24","days":4},{"id":"uridine-triacetate","kind":"drug","name":"Uridine triacetate","route":"/drugs/uridine-triacetate/","asOf":"2026-09-24","days":4},{"id":"defibrotide","kind":"drug","name":"Defibrotide","route":"/drugs/defibrotide/","asOf":"2026-09-24","days":4},{"id":"methylnaltrexone","kind":"drug","name":"Methylnaltrexone","route":"/drugs/methylnaltrexone/","asOf":"2026-09-24","days":4},{"id":"hpv-bivalent-vaccine","kind":"drug","name":"HPV bivalent vaccine (types 16 and 18)","route":"/drugs/hpv-bivalent-vaccine/","asOf":"2026-09-24","days":4},{"id":"lipegfilgrastim","kind":"drug","name":"Lipegfilgrastim","route":"/drugs/lipegfilgrastim/","asOf":"2026-09-24","days":4},{"id":"histamine-dihydrochloride","kind":"drug","name":"Histamine dihydrochloride","route":"/drugs/histamine-dihydrochloride/","asOf":"2026-09-24","days":4},{"id":"pald1","kind":"target","name":"PALD1 (paladin)","route":"/targets/pald1/","asOf":"2026-09-24","days":4},{"id":"burosumab","kind":"drug","name":"Burosumab","route":"/drugs/burosumab/","asOf":"2026-09-24","days":4},{"id":"epoetin-theta","kind":"drug","name":"Epoetin theta","route":"/drugs/epoetin-theta/","asOf":"2026-09-24","days":4},{"id":"nxc-201-car-t","kind":"drug","name":"NXC-201 CAR-T","route":"/drugs/nxc-201-car-t/","asOf":"2026-09-24","days":4},{"id":"nci-anetumab-pembrolizumab-mpm","kind":"trial","name":"Pembrolizumab with or without anetumab ravtansine in mesothelin-positive pleural mesothelioma (NCI)","route":"/trials/nci-anetumab-pembrolizumab-mpm/","asOf":"2026-09-24","days":4},{"id":"tazemetostat-doxorubicin-es","kind":"trial","name":"Tazemetostat with doxorubicin as front-line therapy for advanced epithelioid sarcoma (EZH-301 run-in)","route":"/trials/tazemetostat-doxorubicin-es/","asOf":"2026-09-24","days":4},{"id":"gsk2256098","kind":"drug","name":"GSK2256098","route":"/drugs/gsk2256098/","asOf":"2026-09-24","days":4},{"id":"setmelanotide","kind":"drug","name":"Setmelanotide","route":"/drugs/setmelanotide/","asOf":"2026-09-24","days":4},{"id":"wisdom-trial","kind":"trial","name":"WISDOM (Women Informed to Screen Depending on Measures of Risk)","route":"/trials/wisdom-trial/","asOf":"2026-09-24","days":4},{"id":"nbtxr3","kind":"drug","name":"NBTXR3 (hafnium oxide nanoparticles)","route":"/drugs/nbtxr3/","asOf":"2026-09-24","days":4},{"id":"avasopasem-manganese","kind":"drug","name":"Avasopasem manganese","route":"/drugs/avasopasem-manganese/","asOf":"2026-09-24","days":4},{"id":"lung-map","kind":"trial","name":"Lung-MAP (SWOG S1400 and S1900)","route":"/trials/lung-map/","asOf":"2026-09-24","days":4},{"id":"mediastinal-germ-cell-tumour","kind":"cancer","name":"Mediastinal germ cell tumour","route":"/cancers/mediastinal-germ-cell-tumour/","asOf":"2026-09-24","days":4},{"id":"retroperitoneal-germ-cell-tumour","kind":"cancer","name":"Retroperitoneal germ cell tumour","route":"/cancers/retroperitoneal-germ-cell-tumour/","asOf":"2026-09-24","days":4},{"id":"men1-syndrome","kind":"cancer","name":"Multiple endocrine neoplasia type 1 (MEN1)","route":"/cancers/men1-syndrome/","asOf":"2026-09-24","days":4},{"id":"men2-syndrome","kind":"cancer","name":"Multiple endocrine neoplasia type 2 (MEN2A and MEN2B)","route":"/cancers/men2-syndrome/","asOf":"2026-09-24","days":4},{"id":"hyperparathyroidism-jaw-tumour-syndrome","kind":"cancer","name":"Hyperparathyroidism-jaw tumour syndrome (CDC73-related parathyroid carcinoma)","route":"/cancers/hyperparathyroidism-jaw-tumour-syndrome/","asOf":"2026-09-24","days":4},{"id":"urethral-urothelial-carcinoma","kind":"cancer","name":"Urothelial carcinoma of the urethra","route":"/cancers/urethral-urothelial-carcinoma/","asOf":"2026-09-24","days":4},{"id":"urethral-squamous-cell-carcinoma","kind":"cancer","name":"Squamous cell carcinoma of the urethra","route":"/cancers/urethral-squamous-cell-carcinoma/","asOf":"2026-09-24","days":4},{"id":"urethral-adenocarcinoma","kind":"cancer","name":"Adenocarcinoma of the urethra (including clear cell adenocarcinoma)","route":"/cancers/urethral-adenocarcinoma/","asOf":"2026-09-24","days":4},{"id":"urethral-melanoma","kind":"cancer","name":"Melanoma of the urethra","route":"/cancers/urethral-melanoma/","asOf":"2026-09-24","days":4},{"id":"lung-adenocarcinoma","kind":"cancer","name":"Adenocarcinoma of the lung","route":"/cancers/lung-adenocarcinoma/","asOf":"2026-09-24","days":4},{"id":"lung-squamous-cell-carcinoma","kind":"cancer","name":"Squamous cell carcinoma of the lung","route":"/cancers/lung-squamous-cell-carcinoma/","asOf":"2026-09-24","days":4},{"id":"large-cell-lung-carcinoma","kind":"cancer","name":"Large cell carcinoma of the lung","route":"/cancers/large-cell-lung-carcinoma/","asOf":"2026-09-24","days":4},{"id":"pulmonary-sarcomatoid-carcinoma","kind":"cancer","name":"Sarcomatoid carcinoma of the lung","route":"/cancers/pulmonary-sarcomatoid-carcinoma/","asOf":"2026-09-24","days":4},{"id":"lung-adenosquamous-carcinoma","kind":"cancer","name":"Adenosquamous carcinoma of the lung","route":"/cancers/lung-adenosquamous-carcinoma/","asOf":"2026-09-24","days":4},{"id":"invasive-mucinous-adenocarcinoma-lung","kind":"cancer","name":"Invasive mucinous adenocarcinoma of the lung","route":"/cancers/invasive-mucinous-adenocarcinoma-lung/","asOf":"2026-09-24","days":4},{"id":"lung-adenocarcinoma-in-situ-and-minimally-invasive","kind":"cancer","name":"Adenocarcinoma in situ and minimally invasive adenocarcinoma of the lung","route":"/cancers/lung-adenocarcinoma-in-situ-and-minimally-invasive/","asOf":"2026-09-24","days":4},{"id":"basaloid-squamous-cell-carcinoma-lung","kind":"cancer","name":"Basaloid squamous cell carcinoma of the lung","route":"/cancers/basaloid-squamous-cell-carcinoma-lung/","asOf":"2026-09-24","days":4},{"id":"lymphoepithelial-carcinoma-lung","kind":"cancer","name":"Lymphoepithelial carcinoma of the lung","route":"/cancers/lymphoepithelial-carcinoma-lung/","asOf":"2026-09-24","days":4},{"id":"pulmonary-blastoma","kind":"cancer","name":"Pulmonary blastoma (adult)","route":"/cancers/pulmonary-blastoma/","asOf":"2026-09-24","days":4},{"id":"invasive-lobular-carcinoma","kind":"cancer","name":"Invasive lobular carcinoma of the breast","route":"/cancers/invasive-lobular-carcinoma/","asOf":"2026-09-24","days":4},{"id":"tubular-carcinoma-breast","kind":"cancer","name":"Tubular carcinoma of the breast","route":"/cancers/tubular-carcinoma-breast/","asOf":"2026-09-24","days":4},{"id":"mucinous-carcinoma-breast","kind":"cancer","name":"Mucinous carcinoma of the breast","route":"/cancers/mucinous-carcinoma-breast/","asOf":"2026-09-24","days":4},{"id":"papillary-carcinoma-breast","kind":"cancer","name":"Papillary carcinomas of the breast (encapsulated, solid and invasive papillary)","route":"/cancers/papillary-carcinoma-breast/","asOf":"2026-09-24","days":4},{"id":"invasive-cribriform-carcinoma-breast","kind":"cancer","name":"Invasive cribriform carcinoma of the breast","route":"/cancers/invasive-cribriform-carcinoma-breast/","asOf":"2026-09-24","days":4},{"id":"invasive-micropapillary-carcinoma-breast","kind":"cancer","name":"Invasive micropapillary carcinoma of the breast","route":"/cancers/invasive-micropapillary-carcinoma-breast/","asOf":"2026-09-24","days":4},{"id":"neuroendocrine-neoplasms-breast","kind":"cancer","name":"Neuroendocrine neoplasms of the breast","route":"/cancers/neuroendocrine-neoplasms-breast/","asOf":"2026-09-24","days":4},{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/","asOf":"2026-09-24","days":4},{"id":"colorectal-mucinous-adenocarcinoma","kind":"cancer","name":"Mucinous adenocarcinoma of the colon and rectum","route":"/cancers/colorectal-mucinous-adenocarcinoma/","asOf":"2026-09-24","days":4},{"id":"colorectal-signet-ring-cell-carcinoma","kind":"cancer","name":"Signet ring cell carcinoma of the colon and rectum","route":"/cancers/colorectal-signet-ring-cell-carcinoma/","asOf":"2026-09-24","days":4},{"id":"colorectal-medullary-carcinoma","kind":"cancer","name":"Medullary carcinoma of the colon","route":"/cancers/colorectal-medullary-carcinoma/","asOf":"2026-09-24","days":4},{"id":"colorectal-serrated-adenocarcinoma","kind":"cancer","name":"Serrated adenocarcinoma of the colon and rectum","route":"/cancers/colorectal-serrated-adenocarcinoma/","asOf":"2026-09-24","days":4},{"id":"collecting-duct-carcinoma","kind":"cancer","name":"Collecting duct carcinoma of the kidney","route":"/cancers/collecting-duct-carcinoma/","asOf":"2026-09-24","days":4},{"id":"renal-medullary-carcinoma","kind":"cancer","name":"Renal medullary carcinoma (SMARCB1-deficient)","route":"/cancers/renal-medullary-carcinoma/","asOf":"2026-09-24","days":4},{"id":"tfe3-rearranged-renal-cell-carcinoma","kind":"cancer","name":"TFE3-rearranged (translocation) renal cell carcinoma","route":"/cancers/tfe3-rearranged-renal-cell-carcinoma/","asOf":"2026-09-24","days":4},{"id":"fh-deficient-renal-cell-carcinoma","kind":"cancer","name":"Fumarate hydratase-deficient renal cell carcinoma (HLRCC-associated)","route":"/cancers/fh-deficient-renal-cell-carcinoma/","asOf":"2026-09-24","days":4},{"id":"sdh-deficient-renal-cell-carcinoma","kind":"cancer","name":"Succinate dehydrogenase-deficient renal cell carcinoma","route":"/cancers/sdh-deficient-renal-cell-carcinoma/","asOf":"2026-09-24","days":4},{"id":"mucinous-tubular-spindle-cell-carcinoma","kind":"cancer","name":"Mucinous tubular and spindle cell carcinoma of the kidney","route":"/cancers/mucinous-tubular-spindle-cell-carcinoma/","asOf":"2026-09-24","days":4},{"id":"eosinophilic-solid-cystic-renal-cell-carcinoma","kind":"cancer","name":"Eosinophilic solid and cystic renal cell carcinoma","route":"/cancers/eosinophilic-solid-cystic-renal-cell-carcinoma/","asOf":"2026-09-24","days":4},{"id":"clear-cell-papillary-renal-cell-tumour","kind":"cancer","name":"Clear cell papillary renal cell tumour","route":"/cancers/clear-cell-papillary-renal-cell-tumour/","asOf":"2026-09-24","days":4},{"id":"leydig-cell-tumour","kind":"cancer","name":"Leydig cell tumour of the testis","route":"/cancers/leydig-cell-tumour/","asOf":"2026-09-24","days":4},{"id":"sertoli-cell-tumour","kind":"cancer","name":"Sertoli cell tumour of the testis","route":"/cancers/sertoli-cell-tumour/","asOf":"2026-09-24","days":4},{"id":"spermatocytic-tumour","kind":"cancer","name":"Spermatocytic tumour of the testis","route":"/cancers/spermatocytic-tumour/","asOf":"2026-09-24","days":4},{"id":"germ-cell-neoplasia-in-situ","kind":"cancer","name":"Germ cell neoplasia in situ (GCNIS)","route":"/cancers/germ-cell-neoplasia-in-situ/","asOf":"2026-09-24","days":4},{"id":"embryonal-carcinoma-testis","kind":"cancer","name":"Embryonal carcinoma of the testis","route":"/cancers/embryonal-carcinoma-testis/","asOf":"2026-09-24","days":4},{"id":"yolk-sac-tumour-postpubertal","kind":"cancer","name":"Yolk sac tumour of the testis, postpubertal type","route":"/cancers/yolk-sac-tumour-postpubertal/","asOf":"2026-09-24","days":4},{"id":"testicular-choriocarcinoma","kind":"cancer","name":"Choriocarcinoma of the testis","route":"/cancers/testicular-choriocarcinoma/","asOf":"2026-09-24","days":4},{"id":"malt-lymphoma","kind":"cancer","name":"Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)","route":"/cancers/malt-lymphoma/","asOf":"2026-09-24","days":4},{"id":"splenic-marginal-zone-lymphoma","kind":"cancer","name":"Splenic marginal zone lymphoma","route":"/cancers/splenic-marginal-zone-lymphoma/","asOf":"2026-09-24","days":4},{"id":"nodal-marginal-zone-lymphoma","kind":"cancer","name":"Nodal marginal zone lymphoma","route":"/cancers/nodal-marginal-zone-lymphoma/","asOf":"2026-09-24","days":4},{"id":"primary-cutaneous-marginal-zone-lymphoma","kind":"cancer","name":"Primary cutaneous marginal zone lymphoma","route":"/cancers/primary-cutaneous-marginal-zone-lymphoma/","asOf":"2026-09-24","days":4},{"id":"primary-cutaneous-follicle-centre-lymphoma","kind":"cancer","name":"Primary cutaneous follicle centre lymphoma","route":"/cancers/primary-cutaneous-follicle-centre-lymphoma/","asOf":"2026-09-24","days":4},{"id":"sezary-syndrome","kind":"cancer","name":"Sezary syndrome","route":"/cancers/sezary-syndrome/","asOf":"2026-09-24","days":4},{"id":"angioimmunoblastic-t-cell-lymphoma","kind":"cancer","name":"Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma)","route":"/cancers/angioimmunoblastic-t-cell-lymphoma/","asOf":"2026-09-24","days":4},{"id":"hepatosplenic-t-cell-lymphoma","kind":"cancer","name":"Hepatosplenic T-cell lymphoma","route":"/cancers/hepatosplenic-t-cell-lymphoma/","asOf":"2026-09-24","days":4},{"id":"intravascular-large-b-cell-lymphoma","kind":"cancer","name":"Intravascular large B-cell lymphoma","route":"/cancers/intravascular-large-b-cell-lymphoma/","asOf":"2026-09-24","days":4},{"id":"lymphomatoid-granulomatosis","kind":"cancer","name":"Lymphomatoid granulomatosis","route":"/cancers/lymphomatoid-granulomatosis/","asOf":"2026-09-24","days":4},{"id":"t-cell-prolymphocytic-leukaemia","kind":"cancer","name":"T-cell prolymphocytic leukaemia","route":"/cancers/t-cell-prolymphocytic-leukaemia/","asOf":"2026-09-24","days":4},{"id":"splenic-b-cell-lymphoma-leukaemia-prominent-nucleoli","kind":"cancer","name":"Splenic B-cell lymphoma/leukaemia with prominent nucleoli (formerly B-cell prolymphocytic leukaemia and hairy cell leukaemia variant)","route":"/cancers/splenic-b-cell-lymphoma-leukaemia-prominent-nucleoli/","asOf":"2026-09-24","days":4},{"id":"t-large-granular-lymphocytic-leukaemia","kind":"cancer","name":"T-cell large granular lymphocytic leukaemia","route":"/cancers/t-large-granular-lymphocytic-leukaemia/","asOf":"2026-09-24","days":4},{"id":"mixed-phenotype-acute-leukaemia","kind":"cancer","name":"Mixed-phenotype acute leukaemia","route":"/cancers/mixed-phenotype-acute-leukaemia/","asOf":"2026-09-24","days":4},{"id":"myeloid-leukaemia-of-down-syndrome","kind":"cancer","name":"Myeloid leukaemia of Down syndrome","route":"/cancers/myeloid-leukaemia-of-down-syndrome/","asOf":"2026-09-24","days":4},{"id":"burkitt-leukaemia","kind":"cancer","name":"Burkitt leukaemia","route":"/cancers/burkitt-leukaemia/","asOf":"2026-09-24","days":4},{"id":"adamantinoma","kind":"cancer","name":"Adamantinoma of bone","route":"/cancers/adamantinoma/","asOf":"2026-09-24","days":4},{"id":"dedifferentiated-chordoma","kind":"cancer","name":"Dedifferentiated chordoma","route":"/cancers/dedifferentiated-chordoma/","asOf":"2026-09-24","days":4},{"id":"poorly-differentiated-chordoma","kind":"cancer","name":"Poorly differentiated chordoma (SMARCB1-deficient)","route":"/cancers/poorly-differentiated-chordoma/","asOf":"2026-09-24","days":4},{"id":"pineal-parenchymal-tumours","kind":"cancer","name":"Pineocytoma and pineal parenchymal tumour of intermediate differentiation","route":"/cancers/pineal-parenchymal-tumours/","asOf":"2026-09-24","days":4},{"id":"pineoblastoma","kind":"cancer","name":"Pineoblastoma","route":"/cancers/pineoblastoma/","asOf":"2026-09-24","days":4},{"id":"papillary-tumour-pineal-region","kind":"cancer","name":"Papillary tumour of the pineal region","route":"/cancers/papillary-tumour-pineal-region/","asOf":"2026-09-24","days":4},{"id":"choroid-plexus-carcinoma","kind":"cancer","name":"Choroid plexus carcinoma","route":"/cancers/choroid-plexus-carcinoma/","asOf":"2026-09-24","days":4},{"id":"optic-pathway-glioma","kind":"cancer","name":"Optic pathway glioma","route":"/cancers/optic-pathway-glioma/","asOf":"2026-09-24","days":4},{"id":"pleuropulmonary-blastoma-dicer1","kind":"cancer","name":"Pleuropulmonary blastoma (types I, Ir, II and III)","route":"/cancers/pleuropulmonary-blastoma-dicer1/","asOf":"2026-09-24","days":4},{"id":"glucagonoma","kind":"cancer","name":"Glucagonoma","route":"/cancers/glucagonoma/","asOf":"2026-09-24","days":4},{"id":"vipoma","kind":"cancer","name":"VIPoma","route":"/cancers/vipoma/","asOf":"2026-09-24","days":4},{"id":"somatostatinoma","kind":"cancer","name":"Somatostatinoma","route":"/cancers/somatostatinoma/","asOf":"2026-09-24","days":4},{"id":"conjunctival-melanoma","kind":"cancer","name":"Conjunctival melanoma","route":"/cancers/conjunctival-melanoma/","asOf":"2026-09-24","days":4},{"id":"desmoplastic-small-round-cell-tumour","kind":"cancer","name":"Desmoplastic small round cell tumour","route":"/cancers/desmoplastic-small-round-cell-tumour/","asOf":"2026-09-24","days":4},{"id":"lactotroph-pitnet","kind":"cancer","name":"Lactotroph pituitary neuroendocrine tumour (prolactinoma)","route":"/cancers/lactotroph-pitnet/","asOf":"2026-09-24","days":4},{"id":"somatotroph-pitnet","kind":"cancer","name":"Somatotroph pituitary neuroendocrine tumour (acromegaly)","route":"/cancers/somatotroph-pitnet/","asOf":"2026-09-24","days":4},{"id":"corticotroph-pitnet","kind":"cancer","name":"Corticotroph pituitary neuroendocrine tumour (Cushing disease and silent corticotroph tumour)","route":"/cancers/corticotroph-pitnet/","asOf":"2026-09-24","days":4},{"id":"gonadotroph-pitnet","kind":"cancer","name":"Gonadotroph pituitary neuroendocrine tumour (non-functioning adenoma)","route":"/cancers/gonadotroph-pitnet/","asOf":"2026-09-24","days":4},{"id":"thyrotroph-pitnet","kind":"cancer","name":"Thyrotroph pituitary neuroendocrine tumour (TSH-secreting)","route":"/cancers/thyrotroph-pitnet/","asOf":"2026-09-24","days":4},{"id":"thymoma-type-a-ab","kind":"cancer","name":"Type A and type AB thymoma","route":"/cancers/thymoma-type-a-ab/","asOf":"2026-09-24","days":4},{"id":"thymoma-type-b1-b2","kind":"cancer","name":"Type B1 and type B2 thymoma","route":"/cancers/thymoma-type-b1-b2/","asOf":"2026-09-24","days":4},{"id":"thymoma-type-b3","kind":"cancer","name":"Type B3 thymoma","route":"/cancers/thymoma-type-b3/","asOf":"2026-09-24","days":4},{"id":"micronodular-thymoma","kind":"cancer","name":"Micronodular thymoma with lymphoid stroma","route":"/cancers/micronodular-thymoma/","asOf":"2026-09-24","days":4},{"id":"acinic-cell-carcinoma-salivary","kind":"cancer","name":"Acinic cell carcinoma of the salivary glands","route":"/cancers/acinic-cell-carcinoma-salivary/","asOf":"2026-09-24","days":4},{"id":"carcinoma-ex-pleomorphic-adenoma","kind":"cancer","name":"Carcinoma ex pleomorphic adenoma","route":"/cancers/carcinoma-ex-pleomorphic-adenoma/","asOf":"2026-09-24","days":4},{"id":"cervical-adenosquamous-carcinoma","kind":"cancer","name":"Adenosquamous carcinoma of the cervix","route":"/cancers/cervical-adenosquamous-carcinoma/","asOf":"2026-09-24","days":4},{"id":"cervical-small-cell-neuroendocrine-carcinoma","kind":"cancer","name":"Small cell neuroendocrine carcinoma of the cervix","route":"/cancers/cervical-small-cell-neuroendocrine-carcinoma/","asOf":"2026-09-24","days":4},{"id":"bartholin-gland-carcinoma","kind":"cancer","name":"Bartholin gland carcinoma","route":"/cancers/bartholin-gland-carcinoma/","asOf":"2026-09-24","days":4},{"id":"vulvar-melanoma","kind":"cancer","name":"Vulvar melanoma","route":"/cancers/vulvar-melanoma/","asOf":"2026-09-24","days":4},{"id":"vaginal-melanoma","kind":"cancer","name":"Vaginal melanoma","route":"/cancers/vaginal-melanoma/","asOf":"2026-09-24","days":4},{"id":"nct02864992","kind":"trial","name":"VISION (tepotinib)","route":"/trials/nct02864992/","asOf":"2026-09-24","days":4},{"id":"nct04586231","kind":"trial","name":"LITESPARK-011","route":"/trials/nct04586231/","asOf":"2026-09-24","days":4},{"id":"mntx-302","kind":"trial","name":"MNTX 302","route":"/trials/mntx-302/","asOf":"2026-09-24","days":4},{"id":"paper-mntx-302-thomas-nejm-2008","kind":"paper","name":"Methylnaltrexone for opioid-induced constipation in advanced illness (MNTX 302)","route":"/key-papers/paper-mntx-302-thomas-nejm-2008/","asOf":"2026-09-24","days":4},{"id":"xm22-03","kind":"trial","name":"XM22-03","route":"/trials/xm22-03/","asOf":"2026-09-24","days":4},{"id":"paper-xm22-03-bondarenko-bmc-cancer-2013","kind":"paper","name":"Efficacy and safety of lipegfilgrastim versus pegfilgrastim in breast cancer patients receiving doxorubicin and docetaxel (XM22-03)","route":"/key-papers/paper-xm22-03-bondarenko-bmc-cancer-2013/","asOf":"2026-09-24","days":4},{"id":"ts-p04834","kind":"trial","name":"Study 3 (rolapitant, moderately emetogenic chemotherapy)","route":"/trials/ts-p04834/","asOf":"2026-09-24","days":4},{"id":"paper-rolapitant-study-3-schwartzberg-lancet-oncol-2015","kind":"paper","name":"Rolapitant for prevention of chemotherapy-induced nausea and vomiting after moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens: a randomised, active-controlled, double-blind, phase 3 trial","route":"/key-papers/paper-rolapitant-study-3-schwartzberg-lancet-oncol-2015/","asOf":"2026-09-24","days":4},{"id":"xm01-22","kind":"trial","name":"XM01-22","route":"/trials/xm01-22/","asOf":"2026-09-24","days":4},{"id":"paper-xm01-22-tjulandin-arch-drug-inf-2011","kind":"paper","name":"Epoetin theta with a new dosing schedule in anaemic cancer patients receiving nonplatinum-based chemotherapy: a randomised controlled trial (XM01-22)","route":"/key-papers/paper-xm01-22-tjulandin-arch-drug-inf-2011/","asOf":"2026-09-24","days":4},{"id":"patricia","kind":"trial","name":"PATRICIA","route":"/trials/patricia/","asOf":"2026-09-24","days":4},{"id":"paper-patricia-paavonen-lancet-2009","kind":"paper","name":"Efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis","route":"/key-papers/paper-patricia-paavonen-lancet-2009/","asOf":"2026-09-24","days":4},{"id":"ux023t-cl201","kind":"trial","name":"UX023T-CL201","route":"/trials/ux023t-cl201/","asOf":"2026-09-24","days":4},{"id":"paper-ux023t-cl201-jan-de-beur-jbmr-2021","kind":"paper","name":"Burosumab for the treatment of tumor-induced osteomalacia (UX023T-CL201)","route":"/key-papers/paper-ux023t-cl201-jan-de-beur-jbmr-2021/","asOf":"2026-09-24","days":4},{"id":"transcend","kind":"trial","name":"TRANSCEND","route":"/trials/transcend/","asOf":"2026-09-24","days":4},{"id":"paper-transcend-miller-nejm-2026","kind":"paper","name":"Setmelanotide for the treatment of acquired hypothalamic obesity (TRANSCEND)","route":"/key-papers/paper-transcend-miller-nejm-2026/","asOf":"2026-09-24","days":4},{"id":"preempt-crc","kind":"trial","name":"PREEMPT CRC","route":"/trials/preempt-crc/","asOf":"2026-09-24","days":4},{"id":"paper-preempt-crc-shaukat-jama-2025","kind":"paper","name":"Clinical validation of a circulating tumor DNA-based blood test to screen for colorectal cancer (PREEMPT CRC)","route":"/key-papers/paper-preempt-crc-shaukat-jama-2025/","asOf":"2026-09-24","days":4},{"id":"a071401","kind":"trial","name":"Alliance A071401","route":"/trials/a071401/","asOf":"2026-09-24","days":4},{"id":"paper-a071401-brastianos-jco-2023","kind":"paper","name":"Alliance A071401: phase II trial of focal adhesion kinase inhibition in meningiomas with somatic NF2 mutations","route":"/key-papers/paper-a071401-brastianos-jco-2023/","asOf":"2026-09-24","days":4},{"id":"roman","kind":"trial","name":"ROMAN","route":"/trials/roman/","asOf":"2026-09-24","days":4},{"id":"paper-roman-anderson-eclinicalmedicine-2025","kind":"paper","name":"Avasopasem manganese treatment for severe oral mucositis from chemoradiotherapy for locally advanced head and neck cancer: phase 3 randomized controlled trial (ROMAN)","route":"/key-papers/paper-roman-anderson-eclinicalmedicine-2025/","asOf":"2026-09-24","days":4},{"id":"psma-prerp","kind":"trial","name":"PSMA-PreRP","route":"/trials/psma-prerp/","asOf":"2026-09-24","days":4},{"id":"paper-psma-prerp-hope-jama-oncol-2021","kind":"paper","name":"Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial","route":"/key-papers/paper-psma-prerp-hope-jama-oncol-2021/","asOf":"2026-09-24","days":4},{"id":"screentrustcad","kind":"trial","name":"ScreenTrustCAD","route":"/trials/screentrustcad/","asOf":"2026-09-24","days":4},{"id":"paper-screentrustcad-dembrower-lancet-digit-health-2023","kind":"paper","name":"Artificial intelligence for breast cancer detection in screening mammography in Sweden: a prospective, population-based, paired-reader, non-inferiority study (ScreenTrustCAD)","route":"/key-papers/paper-screentrustcad-dembrower-lancet-digit-health-2023/","asOf":"2026-09-24","days":4},{"id":"nxc-201-mm","kind":"trial","name":"HBI0101 (NXC-201) multiple myeloma phase 1","route":"/trials/nxc-201-mm/","asOf":"2026-09-24","days":4},{"id":"paper-nxc-201-hbi0101-asherie-haematologica-2023","kind":"paper","name":"Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial (HBI0101)","route":"/key-papers/paper-nxc-201-hbi0101-asherie-haematologica-2023/","asOf":"2026-09-24","days":4},{"id":"insite","kind":"trial","name":"INSITE","route":"/trials/insite/","asOf":"2026-09-24","days":4},{"id":"paper-litespark-011-motzer-lancet-2026","kind":"paper","name":"Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial","route":"/key-papers/paper-litespark-011-motzer-lancet-2026/","asOf":"2026-09-24","days":4},{"id":"btla","kind":"target","name":"BTLA","route":"/targets/btla/","asOf":"2026-09-24","days":4},{"id":"klrc1","kind":"target","name":"NKG2A (KLRC1)","route":"/targets/klrc1/","asOf":"2026-09-24","days":4},{"id":"kir2dl1","kind":"target","name":"KIR2DL1 (inhibitory KIR)","route":"/targets/kir2dl1/","asOf":"2026-09-24","days":4},{"id":"cd96","kind":"target","name":"CD96","route":"/targets/cd96/","asOf":"2026-09-24","days":4},{"id":"pvrig","kind":"target","name":"PVRIG (CD112R)","route":"/targets/pvrig/","asOf":"2026-09-24","days":4},{"id":"cd86","kind":"target","name":"CD86 (B7-2)","route":"/targets/cd86/","asOf":"2026-09-24","days":4},{"id":"fgl1","kind":"target","name":"FGL1","route":"/targets/fgl1/","asOf":"2026-09-24","days":4},{"id":"lgals9","kind":"target","name":"Galectin-9 (LGALS9)","route":"/targets/lgals9/","asOf":"2026-09-24","days":4},{"id":"pvr","kind":"target","name":"CD155 (PVR)","route":"/targets/pvr/","asOf":"2026-09-24","days":4},{"id":"nectin2","kind":"target","name":"CD112 (nectin-2)","route":"/targets/nectin2/","asOf":"2026-09-24","days":4},{"id":"hla-e","kind":"target","name":"HLA-E","route":"/targets/hla-e/","asOf":"2026-09-24","days":4},{"id":"cd24","kind":"target","name":"CD24","route":"/targets/cd24/","asOf":"2026-09-24","days":4},{"id":"siglec10","kind":"target","name":"Siglec-10","route":"/targets/siglec10/","asOf":"2026-09-24","days":4},{"id":"lilrb1","kind":"target","name":"LILRB1 (ILT2)","route":"/targets/lilrb1/","asOf":"2026-09-24","days":4},{"id":"lilrb2","kind":"target","name":"LILRB2 (ILT4)","route":"/targets/lilrb2/","asOf":"2026-09-24","days":4},{"id":"tnfrsf4","kind":"target","name":"OX40 (TNFRSF4)","route":"/targets/tnfrsf4/","asOf":"2026-09-24","days":4},{"id":"tnfrsf18","kind":"target","name":"GITR (TNFRSF18)","route":"/targets/tnfrsf18/","asOf":"2026-09-24","days":4},{"id":"cd27","kind":"target","name":"CD27","route":"/targets/cd27/","asOf":"2026-09-24","days":4},{"id":"cd40","kind":"target","name":"CD40","route":"/targets/cd40/","asOf":"2026-09-24","days":4},{"id":"tdo2","kind":"target","name":"TDO2","route":"/targets/tdo2/","asOf":"2026-09-24","days":4},{"id":"entpd1","kind":"target","name":"CD39 (ENTPD1)","route":"/targets/entpd1/","asOf":"2026-09-24","days":4},{"id":"adora2a","kind":"target","name":"Adenosine A2A receptor (ADORA2A)","route":"/targets/adora2a/","asOf":"2026-09-24","days":4},{"id":"hhla2","kind":"target","name":"HHLA2 (B7-H7)","route":"/targets/hhla2/","asOf":"2026-09-24","days":4},{"id":"il10","kind":"target","name":"Interleukin-10 (IL10)","route":"/targets/il10/","asOf":"2026-09-24","days":4},{"id":"bub1","kind":"target","name":"BUB1","route":"/targets/bub1/","asOf":"2026-09-24","days":4},{"id":"ttk","kind":"target","name":"MPS1 (TTK)","route":"/targets/ttk/","asOf":"2026-09-24","days":4},{"id":"checkpoint","kind":"term","name":"Checkpoint (two meanings)","route":"/terms/checkpoint/","asOf":"2026-09-24","days":4},{"id":"tumour-board","kind":"term","name":"Tumour board (multidisciplinary team meeting)","route":"/terms/tumour-board/","asOf":"2026-09-24","days":4},{"id":"grade-vs-stage","kind":"term","name":"Grade versus stage","route":"/terms/grade-vs-stage/","asOf":"2026-09-24","days":4},{"id":"tumour-purity","kind":"term","name":"Tumour purity","route":"/terms/tumour-purity/","asOf":"2026-09-24","days":4},{"id":"cell-composition-confound","kind":"term","name":"Cell composition confound (tumour versus stroma and immune cells)","route":"/terms/cell-composition-confound/","asOf":"2026-09-24","days":4},{"id":"intra-tumour-heterogeneity","kind":"term","name":"Intra-tumour heterogeneity","route":"/terms/intra-tumour-heterogeneity/","asOf":"2026-09-24","days":4},{"id":"tumour-evolution","kind":"term","name":"Tumour evolution (somatic evolution)","route":"/terms/tumour-evolution/","asOf":"2026-09-24","days":4},{"id":"censoring-and-events","kind":"term","name":"Censoring and events in survival data","route":"/terms/censoring-and-events/","asOf":"2026-09-24","days":4},{"id":"prognosis-risk-percentile","kind":"term","name":"Risk score and risk percentile","route":"/terms/prognosis-risk-percentile/","asOf":"2026-09-24","days":4},{"id":"clinical-covariates","kind":"term","name":"Clinical covariates (age, stage, nodes, treatment flags)","route":"/terms/clinical-covariates/","asOf":"2026-09-24","days":4},{"id":"endocrine-therapy-resistance","kind":"term","name":"Endocrine therapy and endocrine resistance","route":"/terms/endocrine-therapy-resistance/","asOf":"2026-09-24","days":4},{"id":"immunotherapy-response","kind":"term","name":"Immunotherapy response and its prediction","route":"/terms/immunotherapy-response/","asOf":"2026-09-24","days":4},{"id":"tertiary-lymphoid-structures","kind":"term","name":"Tertiary lymphoid structures (TLS)","route":"/terms/tertiary-lymphoid-structures/","asOf":"2026-09-24","days":4},{"id":"pharmacogenomics-term","kind":"term","name":"Pharmacogenomics","route":"/terms/pharmacogenomics-term/","asOf":"2026-09-24","days":4},{"id":"drug-response-sensitivity","kind":"term","name":"Drug response and drug sensitivity (IC50, AUC)","route":"/terms/drug-response-sensitivity/","asOf":"2026-09-24","days":4},{"id":"cell-lines-as-proxy","kind":"term","name":"Cell lines as a proxy for patients","route":"/terms/cell-lines-as-proxy/","asOf":"2026-09-24","days":4},{"id":"co-amplification","kind":"term","name":"Co-amplification and the 17q12 HER2 amplicon","route":"/terms/co-amplification/","asOf":"2026-09-24","days":4},{"id":"copy-number-variation-term","kind":"term","name":"Copy number alteration (CNA)","route":"/terms/copy-number-variation-term/","asOf":"2026-09-24","days":4},{"id":"cancer-drivers-vs-actionable","kind":"term","name":"Actionable genomic biomarkers","route":"/terms/cancer-drivers-vs-actionable/","asOf":"2026-09-24","days":4},{"id":"mrna-protein-concordance","kind":"term","name":"mRNA to protein concordance","route":"/terms/mrna-protein-concordance/","asOf":"2026-09-24","days":4},{"id":"post-transcriptional-regulation-term","kind":"term","name":"Post-transcriptional and post-translational regulation","route":"/terms/post-transcriptional-regulation-term/","asOf":"2026-09-24","days":4},{"id":"pathway-activation-state","kind":"term","name":"Pathway activation state (phosphosignalling)","route":"/terms/pathway-activation-state/","asOf":"2026-09-24","days":4},{"id":"gene-co-expression","kind":"term","name":"Gene co-expression structure","route":"/terms/gene-co-expression/","asOf":"2026-09-24","days":4},{"id":"organ-of-origin-signal","kind":"term","name":"Tissue-of-origin signal in tumour data","route":"/terms/organ-of-origin-signal/","asOf":"2026-09-24","days":4},{"id":"spatial-autocorrelation","kind":"term","name":"Spatial autocorrelation (Moran's I)","route":"/terms/spatial-autocorrelation/","asOf":"2026-09-24","days":4},{"id":"variant-effect-prediction","kind":"term","name":"Variant effect prediction","route":"/terms/variant-effect-prediction/","asOf":"2026-09-24","days":4},{"id":"bulk-rna-seq","kind":"term","name":"Bulk RNA sequencing (RNA-seq) and the full transcriptome","route":"/terms/bulk-rna-seq/","asOf":"2026-09-24","days":4},{"id":"tpm-fpkm-counts","kind":"term","name":"TPM, FPKM and raw counts (expression units)","route":"/terms/tpm-fpkm-counts/","asOf":"2026-09-24","days":4},{"id":"star-salmon","kind":"term","name":"STAR and Salmon (RNA-seq alignment and quantification)","route":"/terms/star-salmon/","asOf":"2026-09-24","days":4},{"id":"variant-calling","kind":"term","name":"Variant calling","route":"/terms/variant-calling/","asOf":"2026-09-24","days":4},{"id":"somatic-mutations-wxs-wgs","kind":"term","name":"Somatic mutations from exome and genome sequencing (WXS, WGS)","route":"/terms/somatic-mutations-wxs-wgs/","asOf":"2026-09-24","days":4},{"id":"targeted-panel-sequencing","kind":"term","name":"Targeted panel sequencing","route":"/terms/targeted-panel-sequencing/","asOf":"2026-09-24","days":4},{"id":"gistic","kind":"term","name":"GISTIC (copy number driver detection)","route":"/terms/gistic/","asOf":"2026-09-24","days":4},{"id":"mutsig","kind":"term","name":"MutSig (significantly mutated gene detection)","route":"/terms/mutsig/","asOf":"2026-09-24","days":4},{"id":"batch-effects","kind":"term","name":"Batch effects and harmonisation","route":"/terms/batch-effects/","asOf":"2026-09-24","days":4},{"id":"gsea","kind":"term","name":"Gene set enrichment analysis (GSEA and ssGSEA)","route":"/terms/gsea/","asOf":"2026-09-24","days":4},{"id":"single-cell-rna-seq","kind":"term","name":"Single-cell RNA sequencing (scRNA-seq, 10x Chromium)","route":"/terms/single-cell-rna-seq/","asOf":"2026-09-24","days":4},{"id":"spatial-transcriptomics-platforms","kind":"term","name":"Spatial transcriptomics platforms (Visium HD, Xenium, MERFISH, CosMx, CODEX)","route":"/terms/spatial-transcriptomics-platforms/","asOf":"2026-09-24","days":4},{"id":"h-and-e-staining","kind":"term","name":"H&E staining (haematoxylin and eosin)","route":"/terms/h-and-e-staining/","asOf":"2026-09-24","days":4},{"id":"digital-pathology-wsi","kind":"term","name":"Digital pathology and whole-slide images (WSI)","route":"/terms/digital-pathology-wsi/","asOf":"2026-09-24","days":4},{"id":"tile-patch-encoding","kind":"term","name":"Tile and patch encoding of slides","route":"/terms/tile-patch-encoding/","asOf":"2026-09-24","days":4},{"id":"magnification","kind":"term","name":"Magnification (20x, 40x) and microns per pixel","route":"/terms/magnification/","asOf":"2026-09-24","days":4},{"id":"methylation-arrays","kind":"term","name":"DNA methylation arrays and beta values (450k, EPIC)","route":"/terms/methylation-arrays/","asOf":"2026-09-24","days":4},{"id":"microarray-expression","kind":"term","name":"Microarray expression data","route":"/terms/microarray-expression/","asOf":"2026-09-24","days":4},{"id":"rppa","kind":"term","name":"Reverse-phase protein array (RPPA)","route":"/terms/rppa/","asOf":"2026-09-24","days":4},{"id":"mass-spec-proteome","kind":"term","name":"Deep mass-spectrometry proteome (CPTAC)","route":"/terms/mass-spec-proteome/","asOf":"2026-09-24","days":4},{"id":"ehr-text-pathology-reports","kind":"term","name":"Clinical text: EHR notes and pathology reports","route":"/terms/ehr-text-pathology-reports/","asOf":"2026-09-24","days":4},{"id":"radiology-imaging-modality","kind":"term","name":"Radiology imaging as a data modality (CT, MRI, TCIA)","route":"/terms/radiology-imaging-modality/","asOf":"2026-09-24","days":4},{"id":"os-pfs-time-event","kind":"term","name":"Survival outcomes as time plus event (OS, PFS)","route":"/terms/os-pfs-time-event/","asOf":"2026-09-24","days":4},{"id":"controlled-access-data","kind":"term","name":"Controlled-access genomic data (dbGaP, EGA)","route":"/terms/controlled-access-data/","asOf":"2026-09-24","days":4},{"id":"tcga-tiers","kind":"term","name":"TCGA open versus controlled data tiers","route":"/terms/tcga-tiers/","asOf":"2026-09-24","days":4},{"id":"data-use-agreements","kind":"term","name":"Data use agreements and consent for research use","route":"/terms/data-use-agreements/","asOf":"2026-09-24","days":4},{"id":"samd","kind":"term","name":"Software as a medical device (SaMD)","route":"/terms/samd/","asOf":"2026-09-24","days":4},{"id":"research-use-only","kind":"term","name":"Research use only (RUO)","route":"/terms/research-use-only/","asOf":"2026-09-24","days":4},{"id":"analytical-vs-clinical-validation","kind":"term","name":"Analytical versus clinical validation","route":"/terms/analytical-vs-clinical-validation/","asOf":"2026-09-24","days":4},{"id":"hgnc-symbol","kind":"term","name":"HGNC gene symbol","route":"/terms/hgnc-symbol/","asOf":"2026-09-24","days":4},{"id":"ensembl-gene-id","kind":"term","name":"Ensembl gene ID","route":"/terms/ensembl-gene-id/","asOf":"2026-09-24","days":4},{"id":"genome-builds","kind":"term","name":"Genome builds: GRCh38 versus hg19 (GRCh37)","route":"/terms/genome-builds/","asOf":"2026-09-24","days":4},{"id":"hgvs","kind":"term","name":"HGVS variant nomenclature","route":"/terms/hgvs/","asOf":"2026-09-24","days":4},{"id":"icd-o-3","kind":"term","name":"ICD-O-3 (International Classification of Diseases for Oncology)","route":"/terms/icd-o-3/","asOf":"2026-09-24","days":4},{"id":"oncotree-term","kind":"term","name":"OncoTree cancer classification","route":"/terms/oncotree-term/","asOf":"2026-09-24","days":4},{"id":"ncit","kind":"term","name":"NCI Thesaurus (NCIt)","route":"/terms/ncit/","asOf":"2026-09-24","days":4},{"id":"mondo","kind":"term","name":"Mondo disease ontology","route":"/terms/mondo/","asOf":"2026-09-24","days":4},{"id":"hpo","kind":"term","name":"Human Phenotype Ontology (HPO)","route":"/terms/hpo/","asOf":"2026-09-24","days":4},{"id":"uberon","kind":"term","name":"Uberon anatomy ontology and the Cell Ontology","route":"/terms/uberon/","asOf":"2026-09-24","days":4},{"id":"units-ontology","kind":"term","name":"Units of measurement ontology (UO)","route":"/terms/units-ontology/","asOf":"2026-09-24","days":4},{"id":"rxnorm","kind":"term","name":"RxNorm drug nomenclature","route":"/terms/rxnorm/","asOf":"2026-09-24","days":4},{"id":"ajcc-stage","kind":"term","name":"AJCC stage (TNM staging manual)","route":"/terms/ajcc-stage/","asOf":"2026-09-24","days":4},{"id":"tcga-barcode","kind":"term","name":"TCGA barcode","route":"/terms/tcga-barcode/","asOf":"2026-09-24","days":4},{"id":"provenance-fields","kind":"term","name":"Provenance fields for research data","route":"/terms/provenance-fields/","asOf":"2026-09-24","days":4},{"id":"desmoplastic-stroma-rich","kind":"term","name":"Stroma-rich and desmoplastic tumours in molecular data","route":"/terms/desmoplastic-stroma-rich/","asOf":"2026-09-24","days":4},{"id":"cancer-ai-vocabulary","kind":"term","name":"Cancer AI vocabulary (CanSim terms map)","route":"/terms/cancer-ai-vocabulary/","asOf":"2026-09-24","days":4},{"id":"foundation-model","kind":"term","name":"Foundation model","route":"/terms/foundation-model/","asOf":"2026-09-24","days":4},{"id":"self-supervised-pretraining","kind":"term","name":"Self-supervised pretraining (SSL)","route":"/terms/self-supervised-pretraining/","asOf":"2026-09-24","days":4},{"id":"masked-modelling","kind":"term","name":"Masked autoencoders and masked gene modelling","route":"/terms/masked-modelling/","asOf":"2026-09-24","days":4},{"id":"contrastive-learning","kind":"term","name":"Contrastive learning (InfoNCE)","route":"/terms/contrastive-learning/","asOf":"2026-09-24","days":4},{"id":"transformer-architecture","kind":"term","name":"Transformer and attention","route":"/terms/transformer-architecture/","asOf":"2026-09-24","days":4},{"id":"tokenisation","kind":"term","name":"Tokenisation (genes, tiles and sequence as tokens)","route":"/terms/tokenisation/","asOf":"2026-09-24","days":4},{"id":"embedding","kind":"term","name":"Embedding (learned representation)","route":"/terms/embedding/","asOf":"2026-09-24","days":4},{"id":"fine-tuning-vs-frozen","kind":"term","name":"Fine-tuning versus frozen features, and LoRA","route":"/terms/fine-tuning-vs-frozen/","asOf":"2026-09-24","days":4},{"id":"linear-probe","kind":"term","name":"Linear probe","route":"/terms/linear-probe/","asOf":"2026-09-24","days":4},{"id":"transfer-learning","kind":"term","name":"Transfer learning and the low-label regime","route":"/terms/transfer-learning/","asOf":"2026-09-24","days":4},{"id":"zero-shot","kind":"term","name":"Zero-shot prediction","route":"/terms/zero-shot/","asOf":"2026-09-24","days":4},{"id":"autoregressive-modelling","kind":"term","name":"Autoregressive (next-token) modelling","route":"/terms/autoregressive-modelling/","asOf":"2026-09-24","days":4},{"id":"multimodal-fusion","kind":"term","name":"Multimodal fusion (early, late, modality dropout)","route":"/terms/multimodal-fusion/","asOf":"2026-09-24","days":4},{"id":"abmil","kind":"term","name":"Attention-based multiple-instance learning (ABMIL, CLAM)","route":"/terms/abmil/","asOf":"2026-09-24","days":4},{"id":"pathology-foundation-models","kind":"term","name":"Pathology foundation models: UNI, UNI2, Virchow2, CTransPath, CONCH, TITAN","route":"/terms/pathology-foundation-models/","asOf":"2026-09-24","days":4},{"id":"single-cell-foundation-models","kind":"term","name":"Single-cell and transcriptome foundation models: UCE, GeneCompass, BulkFormer, BulkRNABert","route":"/terms/single-cell-foundation-models/","asOf":"2026-09-24","days":4},{"id":"genomic-and-protein-language-models","kind":"term","name":"Genomic and protein language models: Evo 2, Enformer, ESM","route":"/terms/genomic-and-protein-language-models/","asOf":"2026-09-24","days":4},{"id":"spagcn","kind":"term","name":"Spatially aware clustering (SpaGCN, KNN smoothing)","route":"/terms/spagcn/","asOf":"2026-09-24","days":4},{"id":"virtual-cell-models","kind":"term","name":"Virtual cell models and in-silico perturbation screens","route":"/terms/virtual-cell-models/","asOf":"2026-09-24","days":4},{"id":"drug-response-splits","kind":"term","name":"Drug-response data splits: leave-cell-line-out, leave-drug-out, leave-tissue-out","route":"/terms/drug-response-splits/","asOf":"2026-09-24","days":4},{"id":"drug-response-baselines","kind":"term","name":"Drug-response baselines and frameworks: mean-drug floor, LightGBM, DrEval, IMPROVE, DeepTTA","route":"/terms/drug-response-baselines/","asOf":"2026-09-24","days":4},{"id":"domain-adaptation","kind":"term","name":"Domain shift and domain adaptation (cell line to patient)","route":"/terms/domain-adaptation/","asOf":"2026-09-24","days":4},{"id":"mechanism-of-action-recovery","kind":"term","name":"Mechanism-of-action recovery and known-biology probes","route":"/terms/mechanism-of-action-recovery/","asOf":"2026-09-24","days":4},{"id":"cross-validation","kind":"term","name":"Cross-validation and stratified k-fold","route":"/terms/cross-validation/","asOf":"2026-09-24","days":4},{"id":"train-test-discipline","kind":"term","name":"Train, validation and test split discipline","route":"/terms/train-test-discipline/","asOf":"2026-09-24","days":4},{"id":"data-leakage","kind":"term","name":"Data leakage in model evaluation","route":"/terms/data-leakage/","asOf":"2026-09-24","days":4},{"id":"external-validation","kind":"term","name":"External validation","route":"/terms/external-validation/","asOf":"2026-09-24","days":4},{"id":"concordance-index","kind":"term","name":"C-index (concordance index), Harrell's and Uno's","route":"/terms/concordance-index/","asOf":"2026-09-24","days":4},{"id":"calibration","kind":"term","name":"Calibration: reliability diagrams and the Brier score","route":"/terms/calibration/","asOf":"2026-09-24","days":4},{"id":"roc-auc","kind":"term","name":"ROC-AUC, PR-AUC and time-dependent AUC","route":"/terms/roc-auc/","asOf":"2026-09-24","days":4},{"id":"accuracy-f1","kind":"term","name":"Accuracy, macro-F1 and confusion matrices","route":"/terms/accuracy-f1/","asOf":"2026-09-24","days":4},{"id":"time-dependent-auc","kind":"term","name":"Univariate Cox scores and time-dependent metrics","route":"/terms/time-dependent-auc/","asOf":"2026-09-24","days":4},{"id":"bootstrap","kind":"term","name":"Bootstrap resampling","route":"/terms/bootstrap/","asOf":"2026-09-24","days":4},{"id":"permutation-test","kind":"term","name":"Permutation test and the Mann-Whitney U test","route":"/terms/permutation-test/","asOf":"2026-09-24","days":4},{"id":"spearman-correlation","kind":"term","name":"Spearman rank correlation","route":"/terms/spearman-correlation/","asOf":"2026-09-24","days":4},{"id":"logistic-regression-term","kind":"term","name":"Logistic regression and nearest-centroid classifiers","route":"/terms/logistic-regression-term/","asOf":"2026-09-24","days":4},{"id":"ridge-regression","kind":"term","name":"Ridge regression and the multilayer perceptron","route":"/terms/ridge-regression/","asOf":"2026-09-24","days":4},{"id":"pca","kind":"term","name":"Principal component analysis (PCA) as a feature compressor","route":"/terms/pca/","asOf":"2026-09-24","days":4},{"id":"quantile-normalisation","kind":"term","name":"Quantile normalisation, rank transforms and z-scores","route":"/terms/quantile-normalisation/","asOf":"2026-09-24","days":4},{"id":"cross-entropy-mse","kind":"term","name":"Loss functions: cross-entropy and mean squared error","route":"/terms/cross-entropy-mse/","asOf":"2026-09-24","days":4},{"id":"ablation-study","kind":"term","name":"Ablation study and multi-task heads","route":"/terms/ablation-study/","asOf":"2026-09-24","days":4},{"id":"ood-detection","kind":"term","name":"Out-of-distribution detection (Mahalanobis guard)","route":"/terms/ood-detection/","asOf":"2026-09-24","days":4},{"id":"uncertainty-quantification","kind":"term","name":"Uncertainty quantification and confidence gates","route":"/terms/uncertainty-quantification/","asOf":"2026-09-24","days":4},{"id":"conformal-prediction","kind":"term","name":"Conformal prediction","route":"/terms/conformal-prediction/","asOf":"2026-09-24","days":4},{"id":"model-card","kind":"term","name":"Model cards and datasheets for datasets","route":"/terms/model-card/","asOf":"2026-09-24","days":4},{"id":"leaderboard-benchmark","kind":"term","name":"Benchmarks, leaderboards and contamination","route":"/terms/leaderboard-benchmark/","asOf":"2026-09-24","days":4},{"id":"reproducibility","kind":"term","name":"Reproducibility and negative results","route":"/terms/reproducibility/","asOf":"2026-09-24","days":4},{"id":"pre-registered-experiment","kind":"term","name":"Pre-registered experiment","route":"/terms/pre-registered-experiment/","asOf":"2026-09-24","days":4},{"id":"open-weights","kind":"term","name":"Open weights, open code and gated models","route":"/terms/open-weights/","asOf":"2026-09-24","days":4},{"id":"open-licences","kind":"term","name":"Open licences: Apache-2.0, MIT and CC BY 4.0","route":"/terms/open-licences/","asOf":"2026-09-24","days":4},{"id":"hugging-face-hub","kind":"term","name":"Hugging Face Hub","route":"/terms/hugging-face-hub/","asOf":"2026-09-24","days":4},{"id":"zenodo-doi","kind":"term","name":"Zenodo DOIs for data and code","route":"/terms/zenodo-doi/","asOf":"2026-09-24","days":4},{"id":"citation-cff","kind":"term","name":"CITATION.cff (Citation File Format)","route":"/terms/citation-cff/","asOf":"2026-09-24","days":4},{"id":"anndata-h5ad","kind":"term","name":"AnnData and h5ad files","route":"/terms/anndata-h5ad/","asOf":"2026-09-24","days":4},{"id":"hdf5-zarr-parquet","kind":"term","name":"Array and table formats: HDF5, Zarr, OME-Zarr, Parquet","route":"/terms/hdf5-zarr-parquet/","asOf":"2026-09-24","days":4},{"id":"duckdb-catalog","kind":"term","name":"Analytical databases as a data catalogue (DuckDB, PostgreSQL)","route":"/terms/duckdb-catalog/","asOf":"2026-09-24","days":4},{"id":"mixed-precision-gpu","kind":"term","name":"GPU training and mixed precision","route":"/terms/mixed-precision-gpu/","asOf":"2026-09-24","days":4},{"id":"local-llm-reasoning-layer","kind":"term","name":"Local-only language models over patient data (privacy by architecture)","route":"/terms/local-llm-reasoning-layer/","asOf":"2026-09-24","days":4},{"id":"grb7","kind":"target","name":"GRB7","route":"/targets/grb7/","asOf":"2026-09-24","days":4},{"id":"stard3","kind":"target","name":"STARD3","route":"/targets/stard3/","asOf":"2026-09-24","days":4},{"id":"pgap3","kind":"target","name":"PGAP3","route":"/targets/pgap3/","asOf":"2026-09-24","days":4},{"id":"mien1","kind":"target","name":"MIEN1","route":"/targets/mien1/","asOf":"2026-09-24","days":4},{"id":"pnmt","kind":"target","name":"PNMT","route":"/targets/pnmt/","asOf":"2026-09-24","days":4},{"id":"spry4","kind":"target","name":"SPRY4","route":"/targets/spry4/","asOf":"2026-09-24","days":4},{"id":"phlpp2","kind":"target","name":"PHLPP2","route":"/targets/phlpp2/","asOf":"2026-09-24","days":4},{"id":"phlda1","kind":"target","name":"PHLDA1","route":"/targets/phlda1/","asOf":"2026-09-24","days":4},{"id":"e2f7","kind":"target","name":"E2F7","route":"/targets/e2f7/","asOf":"2026-09-24","days":4},{"id":"dclk1","kind":"target","name":"DCLK1","route":"/targets/dclk1/","asOf":"2026-09-24","days":4},{"id":"dnajc12","kind":"target","name":"DNAJC12","route":"/targets/dnajc12/","asOf":"2026-09-24","days":4},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/","asOf":"2026-09-25","days":3},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/","asOf":"2026-09-25","days":3},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/","asOf":"2026-09-25","days":3},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/","asOf":"2026-09-25","days":3},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/","asOf":"2026-09-25","days":3},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/","asOf":"2026-09-25","days":3},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/","asOf":"2026-09-25","days":3},{"id":"ea1131","kind":"trial","name":"ECOG-ACRIN EA1131","route":"/trials/ea1131/","asOf":"2026-09-25","days":3},{"id":"nct03829462","kind":"trial","name":"Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients","route":"/trials/nct03829462/","asOf":"2026-09-25","days":3},{"id":"nct04094688","kind":"trial","name":"Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer","route":"/trials/nct04094688/","asOf":"2026-09-25","days":3},{"id":"nct00569127","kind":"trial","name":"Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor","route":"/trials/nct00569127/","asOf":"2026-09-25","days":3},{"id":"lung-lcnec","kind":"cancer","name":"Large cell neuroendocrine carcinoma of the lung","route":"/cancers/lung-lcnec/","asOf":"2026-09-25","days":3},{"id":"targeted-lung-health-check","kind":"term","name":"Targeted lung health check","route":"/terms/targeted-lung-health-check/","asOf":"2026-09-25","days":3},{"id":"pack-year","kind":"term","name":"Pack-year","route":"/terms/pack-year/","asOf":"2026-09-25","days":3},{"id":"never-smoker-lung-cancer","kind":"term","name":"Lung cancer in never-smokers","route":"/terms/never-smoker-lung-cancer/","asOf":"2026-09-25","days":3},{"id":"ebus-tbna","kind":"term","name":"Endobronchial ultrasound (EBUS-TBNA)","route":"/terms/ebus-tbna/","asOf":"2026-09-25","days":3},{"id":"tnm-9-lung-cancer","kind":"term","name":"TNM 9: what changed in lung cancer staging","route":"/terms/tnm-9-lung-cancer/","asOf":"2026-09-25","days":3},{"id":"resectability-lung-cancer","kind":"term","name":"Resectability in lung cancer","route":"/terms/resectability-lung-cancer/","asOf":"2026-09-25","days":3},{"id":"pneumonitis","kind":"term","name":"Pneumonitis","route":"/terms/pneumonitis/","asOf":"2026-09-25","days":3},{"id":"pulmonary-nodule","kind":"term","name":"Pulmonary nodule","route":"/terms/pulmonary-nodule/","asOf":"2026-09-25","days":3},{"id":"lung-rads","kind":"term","name":"Lung-RADS and nodule reporting","route":"/terms/lung-rads/","asOf":"2026-09-25","days":3},{"id":"radon","kind":"term","name":"Radon","route":"/terms/radon/","asOf":"2026-09-25","days":3},{"id":"asbestos","kind":"term","name":"Asbestos","route":"/terms/asbestos/","asOf":"2026-09-25","days":3},{"id":"smoking-cessation","kind":"term","name":"Stopping smoking","route":"/terms/smoking-cessation/","asOf":"2026-09-25","days":3},{"id":"haemoptysis","kind":"term","name":"Haemoptysis (coughing up blood)","route":"/terms/haemoptysis/","asOf":"2026-09-25","days":3},{"id":"pancoast-tumour","kind":"term","name":"Pancoast (superior sulcus) tumour","route":"/terms/pancoast-tumour/","asOf":"2026-09-25","days":3},{"id":"spread-through-air-spaces","kind":"term","name":"Spread through air spaces (STAS)","route":"/terms/spread-through-air-spaces/","asOf":"2026-09-25","days":3},{"id":"ttf1-p40","kind":"term","name":"TTF-1 and p40 (how lung histology is decided)","route":"/terms/ttf1-p40/","asOf":"2026-09-25","days":3},{"id":"mediastinal-lymph-node-stations","kind":"term","name":"Mediastinal lymph node stations","route":"/terms/mediastinal-lymph-node-stations/","asOf":"2026-09-25","days":3},{"id":"malignant-pleural-effusion","kind":"term","name":"Malignant pleural effusion","route":"/terms/malignant-pleural-effusion/","asOf":"2026-09-25","days":3},{"id":"superior-vena-cava-obstruction","kind":"term","name":"Superior vena cava obstruction","route":"/terms/superior-vena-cava-obstruction/","asOf":"2026-09-25","days":3},{"id":"sublobar-resection","kind":"term","name":"Sublobar resection (segmentectomy and wedge)","route":"/terms/sublobar-resection/","asOf":"2026-09-25","days":3},{"id":"paper-wynder-graham-tobacco-bronchiogenic-carcinoma-jama-1950","kind":"paper","name":"Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma; a study of 684 proved cases","route":"/key-papers/paper-wynder-graham-tobacco-bronchiogenic-carcinoma-jama-1950/","asOf":"2026-09-25","days":3},{"id":"paper-doll-hill-mortality-of-doctors-smoking-bmj-1954","kind":"paper","name":"The mortality of doctors in relation to their smoking habits; a preliminary report","route":"/key-papers/paper-doll-hill-mortality-of-doctors-smoking-bmj-1954/","asOf":"2026-09-25","days":3},{"id":"paper-peto-smoking-cessation-lung-cancer-uk-bmj-2000","kind":"paper","name":"Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies","route":"/key-papers/paper-peto-smoking-cessation-lung-cancer-uk-bmj-2000/","asOf":"2026-09-25","days":3},{"id":"paper-caret-beta-carotene-retinol-lung-cancer-nejm-1996","kind":"paper","name":"Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease","route":"/key-papers/paper-caret-beta-carotene-retinol-lung-cancer-nejm-1996/","asOf":"2026-09-25","days":3},{"id":"paper-hill-lung-adenocarcinoma-air-pollutants-nature-2023","kind":"paper","name":"Lung adenocarcinoma promotion by air pollutants","route":"/key-papers/paper-hill-lung-adenocarcinoma-air-pollutants-nature-2023/","asOf":"2026-09-25","days":3},{"id":"paper-zhang-lung-cancer-never-smokers-nat-genet-2021","kind":"paper","name":"Genomic and evolutionary classification of lung cancer in never smokers","route":"/key-papers/paper-zhang-lung-cancer-never-smokers-nat-genet-2021/","asOf":"2026-09-25","days":3},{"id":"paper-plco-chest-radiograph-lung-cancer-mortality-jama-2011","kind":"paper","name":"Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial","route":"/key-papers/paper-plco-chest-radiograph-lung-cancer-mortality-jama-2011/","asOf":"2026-09-25","days":3},{"id":"paper-uspstf-lung-cancer-screening-jama-2021","kind":"paper","name":"Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement","route":"/key-papers/paper-uspstf-lung-cancer-screening-jama-2021/","asOf":"2026-09-25","days":3},{"id":"paper-aldrich-uspstf-screening-african-american-smokers-jama-oncol-2019","kind":"paper","name":"Evaluation of USPSTF Lung Cancer Screening Guidelines Among African American Adult Smokers","route":"/key-papers/paper-aldrich-uspstf-screening-african-american-smokers-jama-oncol-2019/","asOf":"2026-09-25","days":3},{"id":"paper-forrest-socioeconomic-inequalities-lung-cancer-treatment-plos-med-2013","kind":"paper","name":"Socioeconomic inequalities in lung cancer treatment: systematic review and meta-analysis","route":"/key-papers/paper-forrest-socioeconomic-inequalities-lung-cancer-treatment-plos-med-2013/","asOf":"2026-09-25","days":3},{"id":"paper-nsclc-collaborative-group-chemotherapy-meta-analysis-bmj-1995","kind":"paper","name":"Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials","route":"/key-papers/paper-nsclc-collaborative-group-chemotherapy-meta-analysis-bmj-1995/","asOf":"2026-09-25","days":3},{"id":"paper-schiller-ecog-1594-four-chemotherapy-regimens-nejm-2002","kind":"paper","name":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","route":"/key-papers/paper-schiller-ecog-1594-four-chemotherapy-regimens-nejm-2002/","asOf":"2026-09-25","days":3},{"id":"paper-scagliotti-cisplatin-pemetrexed-histology-jco-2008","kind":"paper","name":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","route":"/key-papers/paper-scagliotti-cisplatin-pemetrexed-histology-jco-2008/","asOf":"2026-09-25","days":3},{"id":"paper-sandler-ecog-4599-bevacizumab-nsclc-nejm-2006","kind":"paper","name":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","route":"/key-papers/paper-sandler-ecog-4599-bevacizumab-nsclc-nejm-2006/","asOf":"2026-09-25","days":3},{"id":"paper-lace-adjuvant-cisplatin-pooled-analysis-jco-2008","kind":"paper","name":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group","route":"/key-papers/paper-lace-adjuvant-cisplatin-pooled-analysis-jco-2008/","asOf":"2026-09-25","days":3},{"id":"paper-lynch-egfr-activating-mutations-gefitinib-nejm-2004","kind":"paper","name":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","route":"/key-papers/paper-lynch-egfr-activating-mutations-gefitinib-nejm-2004/","asOf":"2026-09-25","days":3},{"id":"paper-paez-egfr-mutations-gefitinib-science-2004","kind":"paper","name":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","route":"/key-papers/paper-paez-egfr-mutations-gefitinib-science-2004/","asOf":"2026-09-25","days":3},{"id":"paper-mok-ipass-gefitinib-pulmonary-adenocarcinoma-nejm-2009","kind":"paper","name":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","route":"/key-papers/paper-mok-ipass-gefitinib-pulmonary-adenocarcinoma-nejm-2009/","asOf":"2026-09-25","days":3},{"id":"paper-planchard-flaura2-osimertinib-chemotherapy-nejm-2023","kind":"paper","name":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","route":"/key-papers/paper-planchard-flaura2-osimertinib-chemotherapy-nejm-2023/","asOf":"2026-09-25","days":3},{"id":"paper-lu-laura-osimertinib-stage-iii-nejm-2024","kind":"paper","name":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","route":"/key-papers/paper-lu-laura-osimertinib-stage-iii-nejm-2024/","asOf":"2026-09-25","days":3},{"id":"paper-soda-eml4-alk-fusion-nature-2007","kind":"paper","name":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","route":"/key-papers/paper-soda-eml4-alk-fusion-nature-2007/","asOf":"2026-09-25","days":3},{"id":"paper-kwak-crizotinib-alk-nsclc-nejm-2010","kind":"paper","name":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","route":"/key-papers/paper-kwak-crizotinib-alk-nsclc-nejm-2010/","asOf":"2026-09-25","days":3},{"id":"paper-peters-alex-alectinib-crizotinib-nejm-2017","kind":"paper","name":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","route":"/key-papers/paper-peters-alex-alectinib-crizotinib-nejm-2017/","asOf":"2026-09-25","days":3},{"id":"paper-shaw-crown-lorlatinib-crizotinib-nejm-2020","kind":"paper","name":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","route":"/key-papers/paper-shaw-crown-lorlatinib-crizotinib-nejm-2020/","asOf":"2026-09-25","days":3},{"id":"paper-wu-alina-adjuvant-alectinib-nejm-2024","kind":"paper","name":"Alectinib in resected ALK-positive non-small-cell lung cancer","route":"/key-papers/paper-wu-alina-adjuvant-alectinib-nejm-2024/","asOf":"2026-09-25","days":3},{"id":"paper-wolf-geometry-mono-1-capmatinib-nejm-2020","kind":"paper","name":"Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer","route":"/key-papers/paper-wolf-geometry-mono-1-capmatinib-nejm-2020/","asOf":"2026-09-25","days":3},{"id":"paper-kobayashi-egfr-t790m-gefitinib-resistance-nejm-2005","kind":"paper","name":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","route":"/key-papers/paper-kobayashi-egfr-t790m-gefitinib-resistance-nejm-2005/","asOf":"2026-09-25","days":3},{"id":"paper-sequist-genotypic-histological-evolution-egfr-resistance-sci-transl-med-2011","kind":"paper","name":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","route":"/key-papers/paper-sequist-genotypic-histological-evolution-egfr-resistance-sci-transl-med-2011/","asOf":"2026-09-25","days":3},{"id":"paper-abbosh-phylogenetic-ctdna-lung-cancer-nature-2017","kind":"paper","name":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","route":"/key-papers/paper-abbosh-phylogenetic-ctdna-lung-cancer-nature-2017/","asOf":"2026-09-25","days":3},{"id":"paper-herbst-impower110-atezolizumab-pd-l1-nejm-2020","kind":"paper","name":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","route":"/key-papers/paper-herbst-impower110-atezolizumab-pd-l1-nejm-2020/","asOf":"2026-09-25","days":3},{"id":"paper-felip-impower010-adjuvant-atezolizumab-lancet-2021","kind":"paper","name":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010)","route":"/key-papers/paper-felip-impower010-adjuvant-atezolizumab-lancet-2021/","asOf":"2026-09-25","days":3},{"id":"paper-heymach-aegean-perioperative-durvalumab-nejm-2023","kind":"paper","name":"Perioperative durvalumab for resectable non-small-cell lung cancer","route":"/key-papers/paper-heymach-aegean-perioperative-durvalumab-nejm-2023/","asOf":"2026-09-25","days":3},{"id":"paper-provencio-nadim-ii-perioperative-nivolumab-stage-iii-nejm-2023","kind":"paper","name":"Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer","route":"/key-papers/paper-provencio-nadim-ii-perioperative-nivolumab-stage-iii-nejm-2023/","asOf":"2026-09-25","days":3},{"id":"paper-spigel-pacific-five-year-survival-jco-2022","kind":"paper","name":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","route":"/key-papers/paper-spigel-pacific-five-year-survival-jco-2022/","asOf":"2026-09-25","days":3},{"id":"paper-turrisi-twice-daily-thoracic-radiotherapy-limited-sclc-nejm-1999","kind":"paper","name":"Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide","route":"/key-papers/paper-turrisi-twice-daily-thoracic-radiotherapy-limited-sclc-nejm-1999/","asOf":"2026-09-25","days":3},{"id":"paper-auperin-prophylactic-cranial-irradiation-sclc-nejm-1999","kind":"paper","name":"Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission","route":"/key-papers/paper-auperin-prophylactic-cranial-irradiation-sclc-nejm-1999/","asOf":"2026-09-25","days":3},{"id":"paper-paz-ares-caspian-durvalumab-es-sclc-lancet-2019","kind":"paper","name":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN)","route":"/key-papers/paper-paz-ares-caspian-durvalumab-es-sclc-lancet-2019/","asOf":"2026-09-25","days":3},{"id":"paper-george-sclc-genomic-profiles-nature-2015","kind":"paper","name":"Comprehensive genomic profiles of small cell lung cancer","route":"/key-papers/paper-george-sclc-genomic-profiles-nature-2015/","asOf":"2026-09-25","days":3},{"id":"paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019","kind":"paper","name":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","route":"/key-papers/paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019/","asOf":"2026-09-25","days":3},{"id":"lung-cancer-evidence-roadmap","kind":"roadmap","name":"Lung cancer roadmap: from Doll and Hill and the naming of tobacco, through the cytotoxic plateau, computed tomography screening, EGFR and ALK, immunotherapy by PD-L1, the perioperative trials and PACIFIC, to DLL3 in small-cell disease and a 2032 registry watch","route":"/roadmaps/lung-cancer-evidence-roadmap/","asOf":"2026-09-25","days":3},{"id":"idea-lung-screening-eligibility-by-risk-not-pack-years","kind":"idea","name":"Decide who is screened for lung cancer by individual risk, not by pack-years","route":"/ideas/idea-lung-screening-eligibility-by-risk-not-pack-years/","asOf":"2026-09-25","days":3},{"id":"idea-lung-never-smoker-disease-its-own-programme","kind":"idea","name":"Treat lung cancer in never-smokers as its own disease, with its own detection programme","route":"/ideas/idea-lung-never-smoker-disease-its-own-programme/","asOf":"2026-09-25","days":3},{"id":"idea-lung-resistance-directed-sequencing-at-every-progression","kind":"idea","name":"Make resistance a diagnosis: sequence at every progression and choose the next line from what the tumour became","route":"/ideas/idea-lung-resistance-directed-sequencing-at-every-progression/","asOf":"2026-09-25","days":3},{"id":"idea-lung-brain-metastasis-prevention-as-a-primary-endpoint","kind":"idea","name":"Measure brain metastasis prevention as a primary endpoint, not as a secondary one","route":"/ideas/idea-lung-brain-metastasis-prevention-as-a-primary-endpoint/","asOf":"2026-09-25","days":3},{"id":"idea-lung-deprivation-gradient-treated-as-a-defect-in-delivery","kind":"idea","name":"Treat the deprivation gradient in lung cancer as a defect in delivery that can be fixed and measured","route":"/ideas/idea-lung-deprivation-gradient-treated-as-a-defect-in-delivery/","asOf":"2026-09-25","days":3},{"id":"idea-lung-small-cell-platform-with-shared-controls-and-subtypes","kind":"idea","name":"Run small-cell lung cancer as one platform with shared controls and subtype stratification","route":"/ideas/idea-lung-small-cell-platform-with-shared-controls-and-subtypes/","asOf":"2026-09-25","days":3},{"id":"idea-lung-uk-screening-testing-and-access-gaps","kind":"idea","name":"Publish the four numbers the NHS lung cancer pathway does not currently measure: reflex testing rate, genomic turnaround, surgical access and a lung-specific waiting time in every nation","route":"/ideas/idea-lung-uk-screening-testing-and-access-gaps/","asOf":"2026-09-25","days":3},{"id":"paper-tcga-lung-adenocarcinoma-nature-2014","kind":"paper","name":"Comprehensive molecular profiling of lung adenocarcinoma","route":"/key-papers/paper-tcga-lung-adenocarcinoma-nature-2014/","asOf":"2026-09-25","days":3},{"id":"paper-tcga-lung-squamous-nature-2012","kind":"paper","name":"Comprehensive genomic characterization of squamous cell lung cancers","route":"/key-papers/paper-tcga-lung-squamous-nature-2012/","asOf":"2026-09-25","days":3},{"id":"paper-campbell-pan-lung-somatic-alterations-nat-genet-2016","kind":"paper","name":"Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas","route":"/key-papers/paper-campbell-pan-lung-somatic-alterations-nat-genet-2016/","asOf":"2026-09-25","days":3},{"id":"paper-jordan-prospective-lung-adenocarcinoma-msk-cancer-discov-2017","kind":"paper","name":"Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies","route":"/key-papers/paper-jordan-prospective-lung-adenocarcinoma-msk-cancer-discov-2017/","asOf":"2026-09-25","days":3},{"id":"paper-chen-east-asian-lung-adenocarcinoma-nat-genet-2020","kind":"paper","name":"Genomic landscape of lung adenocarcinoma in East Asians","route":"/key-papers/paper-chen-east-asian-lung-adenocarcinoma-nat-genet-2020/","asOf":"2026-09-25","days":3},{"id":"paper-kris-lung-cancer-mutation-consortium-jama-2014","kind":"paper","name":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","route":"/key-papers/paper-kris-lung-cancer-mutation-consortium-jama-2014/","asOf":"2026-09-25","days":3},{"id":"paper-alexandrov-tobacco-smoking-mutational-signatures-science-2016","kind":"paper","name":"Mutational signatures associated with tobacco smoking in human cancer","route":"/key-papers/paper-alexandrov-tobacco-smoking-mutational-signatures-science-2016/","asOf":"2026-09-25","days":3},{"id":"paper-bergethon-ros1-rearrangements-lung-jco-2012","kind":"paper","name":"ROS1 rearrangements define a unique molecular class of lung cancers","route":"/key-papers/paper-bergethon-ros1-rearrangements-lung-jco-2012/","asOf":"2026-09-25","days":3},{"id":"paper-awad-met-exon-14-mutations-lung-jco-2016","kind":"paper","name":"MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression","route":"/key-papers/paper-awad-met-exon-14-mutations-lung-jco-2016/","asOf":"2026-09-25","days":3},{"id":"paper-weiss-fgfr1-amplification-squamous-lung-sci-transl-med-2010","kind":"paper","name":"Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer","route":"/key-papers/paper-weiss-fgfr1-amplification-squamous-lung-sci-transl-med-2010/","asOf":"2026-09-25","days":3},{"id":"paper-fernandez-cuesta-cd74-nrg1-fusion-lung-cancer-discov-2014","kind":"paper","name":"CD74-NRG1 fusions in lung adenocarcinoma","route":"/key-papers/paper-fernandez-cuesta-cd74-nrg1-fusion-lung-cancer-discov-2014/","asOf":"2026-09-25","days":3},{"id":"paper-jonna-nrg1-fusions-solid-tumours-ccr-2019","kind":"paper","name":"Detection of NRG1 gene fusions in solid tumors","route":"/key-papers/paper-jonna-nrg1-fusions-solid-tumours-ccr-2019/","asOf":"2026-09-25","days":3},{"id":"paper-schoenfeld-smarca4-alterations-lung-ccr-2020","kind":"paper","name":"The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancer","route":"/key-papers/paper-schoenfeld-smarca4-alterations-lung-ccr-2020/","asOf":"2026-09-25","days":3},{"id":"paper-skoulidis-kras-co-mutation-subsets-cancer-discov-2015","kind":"paper","name":"Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities","route":"/key-papers/paper-skoulidis-kras-co-mutation-subsets-cancer-discov-2015/","asOf":"2026-09-25","days":3},{"id":"paper-arbour-kras-co-mutation-outcomes-ccr-2018","kind":"paper","name":"Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer","route":"/key-papers/paper-arbour-kras-co-mutation-outcomes-ccr-2018/","asOf":"2026-09-25","days":3},{"id":"paper-ricciuti-stk11-keap1-kras-immunotherapy-jto-2022","kind":"paper","name":"Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status","route":"/key-papers/paper-ricciuti-stk11-keap1-kras-immunotherapy-jto-2022/","asOf":"2026-09-25","days":3},{"id":"paper-blueprint-phase-2-pd-l1-assays-jto-2018","kind":"paper","name":"PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of Blueprint phase 2 project","route":"/key-papers/paper-blueprint-phase-2-pd-l1-assays-jto-2018/","asOf":"2026-09-25","days":3},{"id":"paper-rimm-pd-l1-assay-comparison-jama-oncol-2017","kind":"paper","name":"A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer","route":"/key-papers/paper-rimm-pd-l1-assay-comparison-jama-oncol-2017/","asOf":"2026-09-25","days":3},{"id":"paper-rizvi-targeted-ngs-immunotherapy-determinants-jco-2018","kind":"paper","name":"Molecular determinants of response to anti-PD-1 and anti-PD-L1 blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing","route":"/key-papers/paper-rizvi-targeted-ngs-immunotherapy-determinants-jco-2018/","asOf":"2026-09-25","days":3},{"id":"paper-checkmate-026-first-line-nivolumab-nejm-2017","kind":"paper","name":"CheckMate 026: first-line nivolumab in stage IV or recurrent non-small-cell lung cancer","route":"/key-papers/paper-checkmate-026-first-line-nivolumab-nejm-2017/","asOf":"2026-09-25","days":3},{"id":"paper-ricciuti-tmb-pd-l1-levels-jama-oncol-2022","kind":"paper","name":"Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels","route":"/key-papers/paper-ricciuti-tmb-pd-l1-levels-jama-oncol-2022/","asOf":"2026-09-25","days":3},{"id":"paper-keynote-042-tmb-mutations-ann-oncol-2023","kind":"paper","name":"Associations of tissue tumour mutational burden and mutational status with clinical outcomes in KEYNOTE-042","route":"/key-papers/paper-keynote-042-tmb-mutations-ann-oncol-2023/","asOf":"2026-09-25","days":3},{"id":"paper-keynote-189-407-tmb-jtocrr-2023","kind":"paper","name":"Associations of tissue tumour mutational burden and mutational status with clinical outcomes with pembrolizumab plus chemotherapy versus chemotherapy for metastatic non-small-cell lung cancer","route":"/key-papers/paper-keynote-189-407-tmb-jtocrr-2023/","asOf":"2026-09-25","days":3},{"id":"paper-gandara-blood-tmb-atezolizumab-nat-med-2018","kind":"paper","name":"Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab","route":"/key-papers/paper-gandara-blood-tmb-atezolizumab-nat-med-2018/","asOf":"2026-09-25","days":3},{"id":"paper-pao-egfr-t790m-acquired-resistance-plos-med-2005","kind":"paper","name":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","route":"/key-papers/paper-pao-egfr-t790m-acquired-resistance-plos-med-2005/","asOf":"2026-09-25","days":3},{"id":"paper-engelman-met-amplification-gefitinib-resistance-science-2007","kind":"paper","name":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","route":"/key-papers/paper-engelman-met-amplification-gefitinib-resistance-science-2007/","asOf":"2026-09-25","days":3},{"id":"paper-yu-acquired-resistance-rebiopsy-egfr-ccr-2013","kind":"paper","name":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","route":"/key-papers/paper-yu-acquired-resistance-rebiopsy-egfr-ccr-2013/","asOf":"2026-09-25","days":3},{"id":"paper-oxnard-osimertinib-resistance-mechanisms-jama-oncol-2018","kind":"paper","name":"Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib","route":"/key-papers/paper-oxnard-osimertinib-resistance-mechanisms-jama-oncol-2018/","asOf":"2026-09-25","days":3},{"id":"paper-gainor-alk-resistance-mutations-cancer-discov-2016","kind":"paper","name":"Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer","route":"/key-papers/paper-gainor-alk-resistance-mutations-cancer-discov-2016/","asOf":"2026-09-25","days":3},{"id":"paper-shaw-alk-resistance-mutations-lorlatinib-jco-2019","kind":"paper","name":"ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer","route":"/key-papers/paper-shaw-alk-resistance-mutations-lorlatinib-jco-2019/","asOf":"2026-09-25","days":3},{"id":"paper-shaw-alk-l1198f-resensitisation-nejm-2016","kind":"paper","name":"Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F","route":"/key-papers/paper-shaw-alk-l1198f-resensitisation-nejm-2016/","asOf":"2026-09-25","days":3},{"id":"paper-lee-clonal-history-small-cell-transformation-jco-2017","kind":"paper","name":"Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas","route":"/key-papers/paper-lee-clonal-history-small-cell-transformation-jco-2017/","asOf":"2026-09-25","days":3},{"id":"paper-offin-rb1-tp53-transformation-risk-jto-2019","kind":"paper","name":"Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes","route":"/key-papers/paper-offin-rb1-tp53-transformation-risk-jto-2019/","asOf":"2026-09-25","days":3},{"id":"paper-marcoux-egfr-small-cell-transformation-outcomes-jco-2019","kind":"paper","name":"EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes","route":"/key-papers/paper-marcoux-egfr-small-cell-transformation-outcomes-jco-2019/","asOf":"2026-09-25","days":3},{"id":"paper-lindeman-lung-molecular-testing-guideline-jto-2018","kind":"paper","name":"Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors","route":"/key-papers/paper-lindeman-lung-molecular-testing-guideline-jto-2018/","asOf":"2026-09-25","days":3},{"id":"paper-leighl-nile-cfdna-tissue-genotyping-ccr-2019","kind":"paper","name":"NILE: clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer","route":"/key-papers/paper-leighl-nile-cfdna-tissue-genotyping-ccr-2019/","asOf":"2026-09-25","days":3},{"id":"paper-aggarwal-plasma-genotyping-personalised-therapy-jama-oncol-2019","kind":"paper","name":"Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer","route":"/key-papers/paper-aggarwal-plasma-genotyping-personalised-therapy-jama-oncol-2019/","asOf":"2026-09-25","days":3},{"id":"paper-gay-sclc-subtypes-inflamed-cancer-cell-2021","kind":"paper","name":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities","route":"/key-papers/paper-gay-sclc-subtypes-inflamed-cancer-cell-2021/","asOf":"2026-09-25","days":3},{"id":"paper-baine-sclc-subtype-immunohistochemistry-jto-2020","kind":"paper","name":"SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization","route":"/key-papers/paper-baine-sclc-subtype-immunohistochemistry-jto-2020/","asOf":"2026-09-25","days":3},{"id":"egfr-c797s","kind":"biomarker","name":"EGFR C797S (and its phase with T790M)","route":"/biomarkers/egfr-c797s/","asOf":"2026-09-25","days":3},{"id":"alk-resistance-mutation","kind":"biomarker","name":"ALK kinase-domain resistance mutation (G1202R and the rest)","route":"/biomarkers/alk-resistance-mutation/","asOf":"2026-09-25","days":3},{"id":"stk11-keap1-loss","kind":"biomarker","name":"STK11 or KEAP1 loss in KRAS-mutant lung adenocarcinoma","route":"/biomarkers/stk11-keap1-loss/","asOf":"2026-09-25","days":3},{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/","asOf":"2026-09-25","days":3},{"id":"lung-palliation-breathlessness-effusion-obstruction","kind":"term","name":"Palliation in lung cancer: breathlessness, pleural effusion, blocked airway, bone and brain","route":"/terms/lung-palliation-breathlessness-effusion-obstruction/","asOf":"2026-09-25","days":3},{"id":"lung-failed-programmes","kind":"term","name":"Lung cancer: the failed and stopped programmes, and why","route":"/terms/lung-failed-programmes/","asOf":"2026-09-25","days":3},{"id":"lung-uk-drug-access","kind":"term","name":"Lung cancer drugs in England: what NICE has recommended","route":"/terms/lung-uk-drug-access/","asOf":"2026-09-25","days":3},{"id":"jcog0802","kind":"trial","name":"JCOG0802 / WJOG4607L","route":"/trials/jcog0802/","asOf":"2026-09-25","days":3},{"id":"ialt","kind":"trial","name":"IALT (International Adjuvant Lung Cancer Trial)","route":"/trials/ialt/","asOf":"2026-09-25","days":3},{"id":"jbr-10","kind":"trial","name":"JBR.10 (NCIC CTG)","route":"/trials/jbr-10/","asOf":"2026-09-25","days":3},{"id":"anita","kind":"trial","name":"ANITA (Adjuvant Navelbine International Trialist Association)","route":"/trials/anita/","asOf":"2026-09-25","days":3},{"id":"lace-pooled-analysis","kind":"trial","name":"LACE (Lung Adjuvant Cisplatin Evaluation) pooled analysis","route":"/trials/lace-pooled-analysis/","asOf":"2026-09-25","days":3},{"id":"lung-art","kind":"trial","name":"Lung ART","route":"/trials/lung-art/","asOf":"2026-09-25","days":3},{"id":"stars-rosel","kind":"trial","name":"STARS and ROSEL pooled analysis","route":"/trials/stars-rosel/","asOf":"2026-09-25","days":3},{"id":"keynote-091","kind":"trial","name":"KEYNOTE-091 (PEARLS)","route":"/trials/keynote-091/","asOf":"2026-09-25","days":3},{"id":"neotorch","kind":"trial","name":"Neotorch","route":"/trials/neotorch/","asOf":"2026-09-25","days":3},{"id":"gemstone-301","kind":"trial","name":"GEMSTONE-301","route":"/trials/gemstone-301/","asOf":"2026-09-25","days":3},{"id":"lux-lung-3","kind":"trial","name":"LUX-Lung 3","route":"/trials/lux-lung-3/","asOf":"2026-09-25","days":3},{"id":"aura3","kind":"trial","name":"AURA3","route":"/trials/aura3/","asOf":"2026-09-25","days":3},{"id":"profile-1014","kind":"trial","name":"PROFILE 1014","route":"/trials/profile-1014/","asOf":"2026-09-25","days":3},{"id":"alesia","kind":"trial","name":"ALESIA","route":"/trials/alesia/","asOf":"2026-09-25","days":3},{"id":"profile-1001-ros1","kind":"trial","name":"PROFILE 1001 ROS1 expansion cohort","route":"/trials/profile-1001-ros1/","asOf":"2026-09-25","days":3},{"id":"brf113928","kind":"trial","name":"BRF113928 cohort C (dabrafenib with trametinib, untreated BRAF V600E)","route":"/trials/brf113928/","asOf":"2026-09-25","days":3},{"id":"checkmate-017","kind":"trial","name":"CheckMate 017","route":"/trials/checkmate-017/","asOf":"2026-09-25","days":3},{"id":"checkmate-057","kind":"trial","name":"CheckMate 057","route":"/trials/checkmate-057/","asOf":"2026-09-25","days":3},{"id":"oak","kind":"trial","name":"OAK","route":"/trials/oak/","asOf":"2026-09-25","days":3},{"id":"impower110","kind":"trial","name":"IMpower110","route":"/trials/impower110/","asOf":"2026-09-25","days":3},{"id":"impower150","kind":"trial","name":"IMpower150","route":"/trials/impower150/","asOf":"2026-09-25","days":3},{"id":"checkmate-9la","kind":"trial","name":"CheckMate 9LA","route":"/trials/checkmate-9la/","asOf":"2026-09-25","days":3},{"id":"checkmate-026","kind":"trial","name":"CheckMate 026","route":"/trials/checkmate-026/","asOf":"2026-09-25","days":3},{"id":"keynote-010","kind":"trial","name":"KEYNOTE-010","route":"/trials/keynote-010/","asOf":"2026-09-25","days":3},{"id":"revel","kind":"trial","name":"REVEL","route":"/trials/revel/","asOf":"2026-09-25","days":3},{"id":"lume-lung-1","kind":"trial","name":"LUME-Lung 1","route":"/trials/lume-lung-1/","asOf":"2026-09-25","days":3},{"id":"squire","kind":"trial","name":"SQUIRE","route":"/trials/squire/","asOf":"2026-09-25","days":3},{"id":"j-alex","kind":"trial","name":"J-ALEX","route":"/trials/j-alex/","asOf":"2026-09-25","days":3},{"id":"lurbinectedin-basket-sclc","kind":"trial","name":"Lurbinectedin basket trial, small-cell lung cancer cohort","route":"/trials/lurbinectedin-basket-sclc/","asOf":"2026-09-25","days":3},{"id":"turrisi-intergroup-0096","kind":"trial","name":"Intergroup 0096 (Turrisi): twice-daily versus once-daily thoracic radiotherapy","route":"/trials/turrisi-intergroup-0096/","asOf":"2026-09-25","days":3},{"id":"crest-thoracic-rt","kind":"trial","name":"CREST: consolidation thoracic radiotherapy in extensive-stage small-cell lung cancer","route":"/trials/crest-thoracic-rt/","asOf":"2026-09-25","days":3},{"id":"pci-overview-1999","kind":"trial","name":"Prophylactic Cranial Irradiation Overview (Auperin meta-analysis)","route":"/trials/pci-overview-1999/","asOf":"2026-09-25","days":3},{"id":"time2","kind":"trial","name":"TIME2","route":"/trials/time2/","asOf":"2026-09-25","days":3},{"id":"ample","kind":"trial","name":"AMPLE","route":"/trials/ample/","asOf":"2026-09-25","days":3},{"id":"dutch-bone-metastasis-study","kind":"trial","name":"Dutch Bone Metastasis Study","route":"/trials/dutch-bone-metastasis-study/","asOf":"2026-09-25","days":3},{"id":"jrosg-99-1","kind":"trial","name":"JROSG 99-1 (Aoyama): stereotactic radiosurgery with or without whole-brain radiotherapy","route":"/trials/jrosg-99-1/","asOf":"2026-09-25","days":3},{"id":"nct04695925","kind":"trial","name":"Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations","route":"/trials/nct04695925/","asOf":"2026-09-25","days":3},{"id":"nct06031558","kind":"trial","name":"Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC","route":"/trials/nct06031558/","asOf":"2026-09-25","days":3},{"id":"nct05943795","kind":"trial","name":"A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma","route":"/trials/nct05943795/","asOf":"2026-09-25","days":3},{"id":"nct03811002","kind":"trial","name":"Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lun","route":"/trials/nct03811002/","asOf":"2026-09-25","days":3},{"id":"nct06872541","kind":"trial","name":"Evaluation of Platelet Aggregability in Patients with Non-small Cell Lung Carcinomas","route":"/trials/nct06872541/","asOf":"2026-09-25","days":3},{"id":"nct01993810","kind":"trial","name":"Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer","route":"/trials/nct01993810/","asOf":"2026-09-25","days":3},{"id":"nct03391869","kind":"trial","name":"Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer","route":"/trials/nct03391869/","asOf":"2026-09-25","days":3},{"id":"nct03774732","kind":"trial","name":"PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer","route":"/trials/nct03774732/","asOf":"2026-09-25","days":3},{"id":"nct04597671","kind":"trial","name":"Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28)","route":"/trials/nct04597671/","asOf":"2026-09-25","days":3},{"id":"nct07076693","kind":"trial","name":"Standard-of-care Systemic Therapy With or Without Local Therapy in Patients With Oligoprogressive Non-Small Cell Lung Cancer(NSCLC）","route":"/trials/nct07076693/","asOf":"2026-09-25","days":3},{"id":"nct04804644","kind":"trial","name":"Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of M","route":"/trials/nct04804644/","asOf":"2026-09-25","days":3},{"id":"nct04536675","kind":"trial","name":"Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery","route":"/trials/nct04536675/","asOf":"2026-09-25","days":3},{"id":"nct04929041","kind":"trial","name":"Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Pati","route":"/trials/nct04929041/","asOf":"2026-09-25","days":3},{"id":"nct06632327","kind":"trial","name":"Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer","route":"/trials/nct06632327/","asOf":"2026-09-25","days":3},{"id":"nct04214262","kind":"trial","name":"Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer","route":"/trials/nct04214262/","asOf":"2026-09-25","days":3},{"id":"nct05096663","kind":"trial","name":"Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer","route":"/trials/nct05096663/","asOf":"2026-09-25","days":3},{"id":"nct04547504","kind":"trial","name":"PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %","route":"/trials/nct04547504/","asOf":"2026-09-25","days":3},{"id":"nct04155034","kind":"trial","name":"S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cel","route":"/trials/nct04155034/","asOf":"2026-09-25","days":3},{"id":"nct03637816","kind":"trial","name":"Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer","route":"/trials/nct03637816/","asOf":"2026-09-25","days":3},{"id":"nct04093167","kind":"trial","name":"Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer","route":"/trials/nct04093167/","asOf":"2026-09-25","days":3},{"id":"nct04564157","kind":"trial","name":"New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy","route":"/trials/nct04564157/","asOf":"2026-09-25","days":3},{"id":"nct06505837","kind":"trial","name":"JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC）","route":"/trials/nct06505837/","asOf":"2026-09-25","days":3},{"id":"nct03977194","kind":"trial","name":"Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy","route":"/trials/nct03977194/","asOf":"2026-09-25","days":3},{"id":"nct03793179","kind":"trial","name":"Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer","route":"/trials/nct03793179/","asOf":"2026-09-25","days":3},{"id":"nct04841811","kind":"trial","name":"MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH)","route":"/trials/nct04841811/","asOf":"2026-09-25","days":3},{"id":"nct04092283","kind":"trial","name":"Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Anti","route":"/trials/nct04092283/","asOf":"2026-09-25","days":3},{"id":"nct06732401","kind":"trial","name":"Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer","route":"/trials/nct06732401/","asOf":"2026-09-25","days":3},{"id":"nct06500455","kind":"trial","name":"Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain","route":"/trials/nct06500455/","asOf":"2026-09-25","days":3},{"id":"nct06281964","kind":"trial","name":"Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.","route":"/trials/nct06281964/","asOf":"2026-09-25","days":3},{"id":"nct06370416","kind":"trial","name":"the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib","route":"/trials/nct06370416/","asOf":"2026-09-25","days":3},{"id":"nct06759857","kind":"trial","name":"FHND9041 Versus Afatinib for Non-small Cell Lung Cancer","route":"/trials/nct06759857/","asOf":"2026-09-25","days":3},{"id":"nct04762459","kind":"trial","name":"Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Com","route":"/trials/nct04762459/","asOf":"2026-09-25","days":3},{"id":"nct06419179","kind":"trial","name":"Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extens","route":"/trials/nct06419179/","asOf":"2026-09-25","days":3},{"id":"nct07710612","kind":"trial","name":"A Phase 2 Study of ABSK043 Combined With Osimertinib","route":"/trials/nct07710612/","asOf":"2026-09-25","days":3},{"id":"nct07355231","kind":"trial","name":"Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI","route":"/trials/nct07355231/","asOf":"2026-09-25","days":3},{"id":"nct07796100","kind":"trial","name":"A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Ther","route":"/trials/nct07796100/","asOf":"2026-09-25","days":3},{"id":"nct07477808","kind":"trial","name":"Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer","route":"/trials/nct07477808/","asOf":"2026-09-25","days":3},{"id":"nct07234877","kind":"trial","name":"Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets","route":"/trials/nct07234877/","asOf":"2026-09-25","days":3},{"id":"nct07169903","kind":"trial","name":"Segmentectomy vs Lobectomy for 2 - 3cm IASLC Grade 1-2 Lung Adenocarcinoma: A Multi-center RCT","route":"/trials/nct07169903/","asOf":"2026-09-25","days":3},{"id":"nct05496166","kind":"trial","name":"The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Canc","route":"/trials/nct05496166/","asOf":"2026-09-25","days":3},{"id":"nct05186506","kind":"trial","name":"A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer","route":"/trials/nct05186506/","asOf":"2026-09-25","days":3},{"id":"nct07637513","kind":"trial","name":"Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer","route":"/trials/nct07637513/","asOf":"2026-09-25","days":3},{"id":"nct07285148","kind":"trial","name":"A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer","route":"/trials/nct07285148/","asOf":"2026-09-25","days":3},{"id":"nct07742956","kind":"trial","name":"Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab In","route":"/trials/nct07742956/","asOf":"2026-09-25","days":3},{"id":"nct07063329","kind":"trial","name":"Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive","route":"/trials/nct07063329/","asOf":"2026-09-25","days":3},{"id":"nct06970782","kind":"trial","name":"Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failur","route":"/trials/nct06970782/","asOf":"2026-09-25","days":3},{"id":"nct07360132","kind":"trial","name":"Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous","route":"/trials/nct07360132/","asOf":"2026-09-25","days":3},{"id":"nct07289646","kind":"trial","name":"Functional Lung Avoidance Planning Guided by Lung Perfusion PET/CT Versus Anatomical Planning for Lung Stereotactic Body Radiotherapy","route":"/trials/nct07289646/","asOf":"2026-09-25","days":3},{"id":"nct05859217","kind":"trial","name":"A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)","route":"/trials/nct05859217/","asOf":"2026-09-25","days":3},{"id":"nct07739199","kind":"trial","name":"A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line","route":"/trials/nct07739199/","asOf":"2026-09-25","days":3},{"id":"nct07808138","kind":"trial","name":"RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung Cancer","route":"/trials/nct07808138/","asOf":"2026-09-25","days":3},{"id":"nct07501169","kind":"trial","name":"Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)","route":"/trials/nct07501169/","asOf":"2026-09-25","days":3},{"id":"nct05764928","kind":"trial","name":"Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin Therapy","route":"/trials/nct05764928/","asOf":"2026-09-25","days":3},{"id":"nct07704645","kind":"trial","name":"The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer","route":"/trials/nct07704645/","asOf":"2026-09-25","days":3},{"id":"nct05767892","kind":"trial","name":"YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations","route":"/trials/nct05767892/","asOf":"2026-09-25","days":3},{"id":"nct04153734","kind":"trial","name":"Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC","route":"/trials/nct04153734/","asOf":"2026-09-25","days":3},{"id":"nct06526624","kind":"trial","name":"A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer","route":"/trials/nct06526624/","asOf":"2026-09-25","days":3},{"id":"nct06908772","kind":"trial","name":"Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients","route":"/trials/nct06908772/","asOf":"2026-09-25","days":3},{"id":"nct07718737","kind":"trial","name":"Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Can","route":"/trials/nct07718737/","asOf":"2026-09-25","days":3},{"id":"nct06456138","kind":"trial","name":"Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC","route":"/trials/nct06456138/","asOf":"2026-09-25","days":3},{"id":"nct06847334","kind":"trial","name":"A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in the First-Line Treatment of Advanced Non-squamous","route":"/trials/nct06847334/","asOf":"2026-09-25","days":3},{"id":"nct07798947","kind":"trial","name":"A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC","route":"/trials/nct07798947/","asOf":"2026-09-25","days":3},{"id":"nct06045767","kind":"trial","name":"T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer","route":"/trials/nct06045767/","asOf":"2026-09-25","days":3},{"id":"nct07560358","kind":"trial","name":"Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer","route":"/trials/nct07560358/","asOf":"2026-09-25","days":3},{"id":"nct07076095","kind":"trial","name":"A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer","route":"/trials/nct07076095/","asOf":"2026-09-25","days":3},{"id":"nct07256509","kind":"trial","name":"A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous No","route":"/trials/nct07256509/","asOf":"2026-09-25","days":3},{"id":"nct06955325","kind":"trial","name":"Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations","route":"/trials/nct06955325/","asOf":"2026-09-25","days":3},{"id":"nct07416058","kind":"trial","name":"PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC","route":"/trials/nct07416058/","asOf":"2026-09-25","days":3},{"id":"nct07135882","kind":"trial","name":"Primary Radiotherapy In MEtastatic Lung Cancer","route":"/trials/nct07135882/","asOf":"2026-09-25","days":3},{"id":"nct07402070","kind":"trial","name":"IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer","route":"/trials/nct07402070/","asOf":"2026-09-25","days":3},{"id":"nct07545213","kind":"trial","name":"Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis","route":"/trials/nct07545213/","asOf":"2026-09-25","days":3},{"id":"nct07723482","kind":"trial","name":"ML-016 in Advanced Cancer With Lung and/or Liver Involvement","route":"/trials/nct07723482/","asOf":"2026-09-25","days":3},{"id":"nct07318883","kind":"trial","name":"A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab","route":"/trials/nct07318883/","asOf":"2026-09-25","days":3},{"id":"nct07739966","kind":"trial","name":"A Study of DS-3939a in Participants With Solid Tumors","route":"/trials/nct07739966/","asOf":"2026-09-25","days":3},{"id":"nct06581380","kind":"trial","name":"JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer","route":"/trials/nct06581380/","asOf":"2026-09-25","days":3},{"id":"nct07728955","kind":"trial","name":"A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as First-line Therapy for","route":"/trials/nct07728955/","asOf":"2026-09-25","days":3},{"id":"nct07242274","kind":"trial","name":"Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC","route":"/trials/nct07242274/","asOf":"2026-09-25","days":3},{"id":"nct06672068","kind":"trial","name":"A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC","route":"/trials/nct06672068/","asOf":"2026-09-25","days":3},{"id":"nct07453394","kind":"trial","name":"QLS5132 Combination Therapy in Advanced Solid Tumors","route":"/trials/nct07453394/","asOf":"2026-09-25","days":3},{"id":"nct06683703","kind":"trial","name":"Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases","route":"/trials/nct06683703/","asOf":"2026-09-25","days":3},{"id":"nct07633873","kind":"trial","name":"SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNST","route":"/trials/nct07633873/","asOf":"2026-09-25","days":3},{"id":"nct07816380","kind":"trial","name":"A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer","route":"/trials/nct07816380/","asOf":"2026-09-25","days":3},{"id":"nct06704620","kind":"trial","name":"Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Can","route":"/trials/nct06704620/","asOf":"2026-09-25","days":3},{"id":"nct06469879","kind":"trial","name":"A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients","route":"/trials/nct06469879/","asOf":"2026-09-25","days":3},{"id":"nct07343479","kind":"trial","name":"Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases","route":"/trials/nct07343479/","asOf":"2026-09-25","days":3},{"id":"nct07162883","kind":"trial","name":"Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct07162883/","asOf":"2026-09-25","days":3},{"id":"nct06961188","kind":"trial","name":"Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis","route":"/trials/nct06961188/","asOf":"2026-09-25","days":3},{"id":"nct06319313","kind":"trial","name":"Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer","route":"/trials/nct06319313/","asOf":"2026-09-25","days":3},{"id":"nct07383116","kind":"trial","name":"Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous No","route":"/trials/nct07383116/","asOf":"2026-09-25","days":3},{"id":"nct07158840","kind":"trial","name":"AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor","route":"/trials/nct07158840/","asOf":"2026-09-25","days":3},{"id":"nct07551635","kind":"trial","name":"SMARCA4/2 Inhibitor for POU2F3-Positive SCLC","route":"/trials/nct07551635/","asOf":"2026-09-25","days":3},{"id":"nct07146230","kind":"trial","name":"The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2","route":"/trials/nct07146230/","asOf":"2026-09-25","days":3},{"id":"nct07551414","kind":"trial","name":"Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI","route":"/trials/nct07551414/","asOf":"2026-09-25","days":3},{"id":"nct07819591","kind":"trial","name":"Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC","route":"/trials/nct07819591/","asOf":"2026-09-25","days":3},{"id":"nct07636226","kind":"trial","name":"QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer","route":"/trials/nct07636226/","asOf":"2026-09-25","days":3},{"id":"nct07739186","kind":"trial","name":"A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment f","route":"/trials/nct07739186/","asOf":"2026-09-25","days":3},{"id":"nct07101627","kind":"trial","name":"A Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer Therapy","route":"/trials/nct07101627/","asOf":"2026-09-25","days":3},{"id":"nct07829549","kind":"trial","name":"Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Act","route":"/trials/nct07829549/","asOf":"2026-09-25","days":3},{"id":"nct07819578","kind":"trial","name":"Toripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable NSCLC","route":"/trials/nct07819578/","asOf":"2026-09-25","days":3},{"id":"nct06323148","kind":"trial","name":"Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)","route":"/trials/nct06323148/","asOf":"2026-09-25","days":3},{"id":"nct04846634","kind":"trial","name":"Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (A","route":"/trials/nct04846634/","asOf":"2026-09-25","days":3},{"id":"nct06780839","kind":"trial","name":"Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD","route":"/trials/nct06780839/","asOf":"2026-09-25","days":3},{"id":"nct07680790","kind":"trial","name":"Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based C","route":"/trials/nct07680790/","asOf":"2026-09-25","days":3},{"id":"nct07802821","kind":"trial","name":"A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Sm","route":"/trials/nct07802821/","asOf":"2026-09-25","days":3},{"id":"nct07802834","kind":"trial","name":"Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC","route":"/trials/nct07802834/","asOf":"2026-09-25","days":3},{"id":"nct07603791","kind":"trial","name":"Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC","route":"/trials/nct07603791/","asOf":"2026-09-25","days":3},{"id":"nct06028633","kind":"trial","name":"Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients","route":"/trials/nct06028633/","asOf":"2026-09-25","days":3},{"id":"nct07450183","kind":"trial","name":"Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1","route":"/trials/nct07450183/","asOf":"2026-09-25","days":3},{"id":"nct01394679","kind":"trial","name":"A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer","route":"/trials/nct01394679/","asOf":"2026-09-25","days":3},{"id":"nct07707895","kind":"trial","name":"DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers","route":"/trials/nct07707895/","asOf":"2026-09-25","days":3},{"id":"nct07608159","kind":"trial","name":"Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC.","route":"/trials/nct07608159/","asOf":"2026-09-25","days":3},{"id":"nct07754123","kind":"trial","name":"Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC","route":"/trials/nct07754123/","asOf":"2026-09-25","days":3},{"id":"nct07746388","kind":"trial","name":"Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial","route":"/trials/nct07746388/","asOf":"2026-09-25","days":3},{"id":"nct06858410","kind":"trial","name":"Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma","route":"/trials/nct06858410/","asOf":"2026-09-25","days":3},{"id":"nct05745740","kind":"trial","name":"A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation","route":"/trials/nct05745740/","asOf":"2026-09-25","days":3},{"id":"nct04465968","kind":"trial","name":"Efficacy and Safety of CRT, Durvalumab and Surgery for SST","route":"/trials/nct04465968/","asOf":"2026-09-25","days":3},{"id":"nct06198907","kind":"trial","name":"Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)","route":"/trials/nct06198907/","asOf":"2026-09-25","days":3},{"id":"nct07283198","kind":"trial","name":"A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer","route":"/trials/nct07283198/","asOf":"2026-09-25","days":3},{"id":"nct07756645","kind":"trial","name":"A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advan","route":"/trials/nct07756645/","asOf":"2026-09-25","days":3},{"id":"nct07688577","kind":"trial","name":"XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors","route":"/trials/nct07688577/","asOf":"2026-09-25","days":3},{"id":"nct07154368","kind":"trial","name":"JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs.","route":"/trials/nct07154368/","asOf":"2026-09-25","days":3},{"id":"nct05393466","kind":"trial","name":"BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct05393466/","asOf":"2026-09-25","days":3},{"id":"nct06961201","kind":"trial","name":"Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cache","route":"/trials/nct06961201/","asOf":"2026-09-25","days":3},{"id":"nct07821684","kind":"trial","name":"A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanc","route":"/trials/nct07821684/","asOf":"2026-09-25","days":3},{"id":"nct06102161","kind":"trial","name":"Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020)","route":"/trials/nct06102161/","asOf":"2026-09-25","days":3},{"id":"nct06775483","kind":"trial","name":"Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study","route":"/trials/nct06775483/","asOf":"2026-09-25","days":3},{"id":"nct05503888","kind":"trial","name":"Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer","route":"/trials/nct05503888/","asOf":"2026-09-25","days":3},{"id":"nct07043907","kind":"trial","name":"PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA NSCLC","route":"/trials/nct07043907/","asOf":"2026-09-25","days":3},{"id":"nct06380348","kind":"trial","name":"JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Chara","route":"/trials/nct06380348/","asOf":"2026-09-25","days":3},{"id":"nct07827261","kind":"trial","name":"A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer","route":"/trials/nct07827261/","asOf":"2026-09-25","days":3},{"id":"nct06416852","kind":"trial","name":"Clinical Study of 18F-Alfatide Injection PET/CT","route":"/trials/nct06416852/","asOf":"2026-09-25","days":3},{"id":"nct06951399","kind":"trial","name":"Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer","route":"/trials/nct06951399/","asOf":"2026-09-25","days":3},{"id":"nct05990127","kind":"trial","name":"A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer","route":"/trials/nct05990127/","asOf":"2026-09-25","days":3},{"id":"nct07617389","kind":"trial","name":"Selective Mediastinal Lymph Node Sampling Versus Systematic medIastinal Lymph Node Dissection After Neoadjuvant Chemoimmunotherapy for Non-small Cell Lung Cance","route":"/trials/nct07617389/","asOf":"2026-09-25","days":3},{"id":"nct07464327","kind":"trial","name":"A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-S","route":"/trials/nct07464327/","asOf":"2026-09-25","days":3},{"id":"nct07294261","kind":"trial","name":"Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC","route":"/trials/nct07294261/","asOf":"2026-09-25","days":3},{"id":"nct07414927","kind":"trial","name":"A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following E","route":"/trials/nct07414927/","asOf":"2026-09-25","days":3},{"id":"nct07472647","kind":"trial","name":"SYS6090 Combination Therapy in Advanced Lung Cancer","route":"/trials/nct07472647/","asOf":"2026-09-25","days":3},{"id":"nct07106528","kind":"trial","name":"Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer","route":"/trials/nct07106528/","asOf":"2026-09-25","days":3},{"id":"nct06719336","kind":"trial","name":"Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001)","route":"/trials/nct06719336/","asOf":"2026-09-25","days":3},{"id":"nct07197853","kind":"trial","name":"Clinical Efficacy and Safety of Microwave Ablation Combined With Huaier Granules in Patients With Inoperable Stage IA Non-Small Cell Lung Cancer: A Prospective,","route":"/trials/nct07197853/","asOf":"2026-09-25","days":3},{"id":"nct07831863","kind":"trial","name":"A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy","route":"/trials/nct07831863/","asOf":"2026-09-25","days":3},{"id":"nct07442565","kind":"trial","name":"SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase III","route":"/trials/nct07442565/","asOf":"2026-09-25","days":3},{"id":"nct06982924","kind":"trial","name":"A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.","route":"/trials/nct06982924/","asOf":"2026-09-25","days":3},{"id":"nct07806773","kind":"trial","name":"Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer","route":"/trials/nct07806773/","asOf":"2026-09-25","days":3},{"id":"nct06048315","kind":"trial","name":"A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs W","route":"/trials/nct06048315/","asOf":"2026-09-25","days":3},{"id":"nct07609251","kind":"trial","name":"A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study","route":"/trials/nct07609251/","asOf":"2026-09-25","days":3},{"id":"nct07361484","kind":"trial","name":"Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)","route":"/trials/nct07361484/","asOf":"2026-09-25","days":3},{"id":"nct06254599","kind":"trial","name":"A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC","route":"/trials/nct06254599/","asOf":"2026-09-25","days":3},{"id":"nct07672223","kind":"trial","name":"A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct07672223/","asOf":"2026-09-25","days":3},{"id":"nct06885840","kind":"trial","name":"Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.","route":"/trials/nct06885840/","asOf":"2026-09-25","days":3},{"id":"nct07833202","kind":"trial","name":"A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutatio","route":"/trials/nct07833202/","asOf":"2026-09-25","days":3},{"id":"nct06525350","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed","route":"/trials/nct06525350/","asOf":"2026-09-25","days":3},{"id":"nct07538271","kind":"trial","name":"A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer","route":"/trials/nct07538271/","asOf":"2026-09-25","days":3},{"id":"nct07376382","kind":"trial","name":"A Phase III Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC","route":"/trials/nct07376382/","asOf":"2026-09-25","days":3},{"id":"nct07229339","kind":"trial","name":"Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer","route":"/trials/nct07229339/","asOf":"2026-09-25","days":3},{"id":"nct04772287","kind":"trial","name":"Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)","route":"/trials/nct04772287/","asOf":"2026-09-25","days":3},{"id":"nct06335355","kind":"trial","name":"A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients","route":"/trials/nct06335355/","asOf":"2026-09-25","days":3},{"id":"nct07160686","kind":"trial","name":"Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment","route":"/trials/nct07160686/","asOf":"2026-09-25","days":3},{"id":"nct07554859","kind":"trial","name":"GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer","route":"/trials/nct07554859/","asOf":"2026-09-25","days":3},{"id":"nct07715396","kind":"trial","name":"Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden","route":"/trials/nct07715396/","asOf":"2026-09-25","days":3},{"id":"nct07824882","kind":"trial","name":"A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamo","route":"/trials/nct07824882/","asOf":"2026-09-25","days":3},{"id":"nct07822542","kind":"trial","name":"A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Pat","route":"/trials/nct07822542/","asOf":"2026-09-25","days":3},{"id":"nct07150416","kind":"trial","name":"Nebulized Inhalation of Recombinant Human p53 Adenovirus Injection for Treatment of Multiple Ground-Glass Lung Nodules: A Single-Arm Clinical Study","route":"/trials/nct07150416/","asOf":"2026-09-25","days":3},{"id":"nct06828757","kind":"trial","name":"Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cancer","route":"/trials/nct06828757/","asOf":"2026-09-25","days":3},{"id":"nct07662811","kind":"trial","name":"SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer","route":"/trials/nct07662811/","asOf":"2026-09-25","days":3},{"id":"nct07323641","kind":"trial","name":"Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer","route":"/trials/nct07323641/","asOf":"2026-09-25","days":3},{"id":"nct05085028","kind":"trial","name":"A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung","route":"/trials/nct05085028/","asOf":"2026-09-25","days":3},{"id":"nct07057791","kind":"trial","name":"Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer","route":"/trials/nct07057791/","asOf":"2026-09-25","days":3},{"id":"nct06315010","kind":"trial","name":"Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis","route":"/trials/nct06315010/","asOf":"2026-09-25","days":3},{"id":"nct05825443","kind":"trial","name":"Adjuvant Chemotherapy Combined With Camrelizumab for IIA -IIIA NSCLC Patients","route":"/trials/nct05825443/","asOf":"2026-09-25","days":3},{"id":"nct07153055","kind":"trial","name":"Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer","route":"/trials/nct07153055/","asOf":"2026-09-25","days":3},{"id":"nct07034326","kind":"trial","name":"Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer","route":"/trials/nct07034326/","asOf":"2026-09-25","days":3},{"id":"nct05607108","kind":"trial","name":"A Study of ZEN003694 in People With Squamous Cell Lung Cancer","route":"/trials/nct05607108/","asOf":"2026-09-25","days":3},{"id":"nct07149363","kind":"trial","name":"Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer","route":"/trials/nct07149363/","asOf":"2026-09-25","days":3},{"id":"nct04691817","kind":"trial","name":"Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based T","route":"/trials/nct04691817/","asOf":"2026-09-25","days":3},{"id":"nct07559929","kind":"trial","name":"A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.","route":"/trials/nct07559929/","asOf":"2026-09-25","days":3},{"id":"nct06478108","kind":"trial","name":"Interventional Software for Multi-immunotherapy of Solid Tumors","route":"/trials/nct06478108/","asOf":"2026-09-25","days":3},{"id":"nct06814496","kind":"trial","name":"Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors","route":"/trials/nct06814496/","asOf":"2026-09-25","days":3},{"id":"nct05718323","kind":"trial","name":"Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC","route":"/trials/nct05718323/","asOf":"2026-09-25","days":3},{"id":"nct06177925","kind":"trial","name":"A Phase II Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC","route":"/trials/nct06177925/","asOf":"2026-09-25","days":3},{"id":"nct05903092","kind":"trial","name":"MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer","route":"/trials/nct05903092/","asOf":"2026-09-25","days":3},{"id":"nct07149649","kind":"trial","name":"Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)","route":"/trials/nct07149649/","asOf":"2026-09-25","days":3},{"id":"nct07132190","kind":"trial","name":"Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction","route":"/trials/nct07132190/","asOf":"2026-09-25","days":3},{"id":"nct07219576","kind":"trial","name":"Retifanlimab and Ruxolitinib In Solid Malignancies","route":"/trials/nct07219576/","asOf":"2026-09-25","days":3},{"id":"nct01639508","kind":"trial","name":"Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or A","route":"/trials/nct01639508/","asOf":"2026-09-25","days":3},{"id":"nct04585490","kind":"trial","name":"Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC","route":"/trials/nct04585490/","asOf":"2026-09-25","days":3},{"id":"nct06284317","kind":"trial","name":"A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Canc","route":"/trials/nct06284317/","asOf":"2026-09-25","days":3},{"id":"nct07251582","kind":"trial","name":"Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer","route":"/trials/nct07251582/","asOf":"2026-09-25","days":3},{"id":"nct07535463","kind":"trial","name":"A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer","route":"/trials/nct07535463/","asOf":"2026-09-25","days":3},{"id":"nct06616584","kind":"trial","name":"Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemoth","route":"/trials/nct06616584/","asOf":"2026-09-25","days":3},{"id":"nct05852990","kind":"trial","name":"Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC","route":"/trials/nct05852990/","asOf":"2026-09-25","days":3},{"id":"nct07213375","kind":"trial","name":"High Dose Dexamethasone to Reduce Postoperative Pain After Video-Assisted Thoracoscopic Surgery Lobectomy /Segmentectomy","route":"/trials/nct07213375/","asOf":"2026-09-25","days":3},{"id":"nct06674343","kind":"trial","name":"Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations","route":"/trials/nct06674343/","asOf":"2026-09-25","days":3},{"id":"nct05469022","kind":"trial","name":"Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy","route":"/trials/nct05469022/","asOf":"2026-09-25","days":3},{"id":"nct05624996","kind":"trial","name":"Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer","route":"/trials/nct05624996/","asOf":"2026-09-25","days":3},{"id":"nct06110572","kind":"trial","name":"Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation","route":"/trials/nct06110572/","asOf":"2026-09-25","days":3},{"id":"nct06698965","kind":"trial","name":"Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and C","route":"/trials/nct06698965/","asOf":"2026-09-25","days":3},{"id":"nct06663098","kind":"trial","name":"Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).","route":"/trials/nct06663098/","asOf":"2026-09-25","days":3},{"id":"nct05987644","kind":"trial","name":"Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements","route":"/trials/nct05987644/","asOf":"2026-09-25","days":3},{"id":"nct05623319","kind":"trial","name":"Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)","route":"/trials/nct05623319/","asOf":"2026-09-25","days":3},{"id":"nct05450965","kind":"trial","name":"Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer","route":"/trials/nct05450965/","asOf":"2026-09-25","days":3},{"id":"nct06931717","kind":"trial","name":"A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Re","route":"/trials/nct06931717/","asOf":"2026-09-25","days":3},{"id":"nct05918302","kind":"trial","name":"Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.","route":"/trials/nct05918302/","asOf":"2026-09-25","days":3},{"id":"nct06810375","kind":"trial","name":"Erector Spinae Versus Intercostal Nerve Blocks With Liposomal Bupivacaine for Analgesia in Thoracic Surgery","route":"/trials/nct06810375/","asOf":"2026-09-25","days":3},{"id":"nct05692999","kind":"trial","name":"Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study","route":"/trials/nct05692999/","asOf":"2026-09-25","days":3},{"id":"nct07718243","kind":"trial","name":"Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC","route":"/trials/nct07718243/","asOf":"2026-09-25","days":3},{"id":"nct06498635","kind":"trial","name":"Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial","route":"/trials/nct06498635/","asOf":"2026-09-25","days":3},{"id":"nct05502913","kind":"trial","name":"Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer","route":"/trials/nct05502913/","asOf":"2026-09-25","days":3},{"id":"nct05950139","kind":"trial","name":"Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC","route":"/trials/nct05950139/","asOf":"2026-09-25","days":3},{"id":"nct04335292","kind":"trial","name":"Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge","route":"/trials/nct04335292/","asOf":"2026-09-25","days":3},{"id":"nct02468024","kind":"trial","name":"JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer","route":"/trials/nct02468024/","asOf":"2026-09-25","days":3},{"id":"nct05445791","kind":"trial","name":"Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations","route":"/trials/nct05445791/","asOf":"2026-09-25","days":3},{"id":"nct06686771","kind":"trial","name":"Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer","route":"/trials/nct06686771/","asOf":"2026-09-25","days":3},{"id":"nct06623656","kind":"trial","name":"Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC","route":"/trials/nct06623656/","asOf":"2026-09-25","days":3},{"id":"nct06987734","kind":"trial","name":"Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients","route":"/trials/nct06987734/","asOf":"2026-09-25","days":3},{"id":"nct07339059","kind":"trial","name":"Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer","route":"/trials/nct07339059/","asOf":"2026-09-25","days":3},{"id":"nct06864624","kind":"trial","name":"Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC","route":"/trials/nct06864624/","asOf":"2026-09-25","days":3},{"id":"nct04499053","kind":"trial","name":"Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer","route":"/trials/nct04499053/","asOf":"2026-09-25","days":3},{"id":"nct05623267","kind":"trial","name":"Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT","route":"/trials/nct05623267/","asOf":"2026-09-25","days":3},{"id":"nct06457906","kind":"trial","name":"SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC","route":"/trials/nct06457906/","asOf":"2026-09-25","days":3},{"id":"nct07355205","kind":"trial","name":"First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer","route":"/trials/nct07355205/","asOf":"2026-09-25","days":3},{"id":"nct06230445","kind":"trial","name":"Effects of Digital Therapeutic in Whole Process Management of Lung Cancer","route":"/trials/nct06230445/","asOf":"2026-09-25","days":3},{"id":"nct05522660","kind":"trial","name":"Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer","route":"/trials/nct05522660/","asOf":"2026-09-25","days":3},{"id":"nct04339218","kind":"trial","name":"Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma","route":"/trials/nct04339218/","asOf":"2026-09-25","days":3},{"id":"nct06908993","kind":"trial","name":"Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated","route":"/trials/nct06908993/","asOf":"2026-09-25","days":3},{"id":"nct04317534","kind":"trial","name":"Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm","route":"/trials/nct04317534/","asOf":"2026-09-25","days":3},{"id":"nct07001618","kind":"trial","name":"Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiot","route":"/trials/nct07001618/","asOf":"2026-09-25","days":3},{"id":"nct07423585","kind":"trial","name":"Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer","route":"/trials/nct07423585/","asOf":"2026-09-25","days":3},{"id":"nct05055908","kind":"trial","name":"Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors","route":"/trials/nct05055908/","asOf":"2026-09-25","days":3},{"id":"nct06043973","kind":"trial","name":"Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance","route":"/trials/nct06043973/","asOf":"2026-09-25","days":3},{"id":"nct05632809","kind":"trial","name":"REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)","route":"/trials/nct05632809/","asOf":"2026-09-25","days":3},{"id":"nct07481786","kind":"trial","name":"Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases","route":"/trials/nct07481786/","asOf":"2026-09-25","days":3},{"id":"nct06840782","kind":"trial","name":"First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.","route":"/trials/nct06840782/","asOf":"2026-09-25","days":3},{"id":"nct07428044","kind":"trial","name":"A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer","route":"/trials/nct07428044/","asOf":"2026-09-25","days":3},{"id":"nct07443397","kind":"trial","name":"Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.","route":"/trials/nct07443397/","asOf":"2026-09-25","days":3},{"id":"nct07016126","kind":"trial","name":"D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC","route":"/trials/nct07016126/","asOf":"2026-09-25","days":3},{"id":"nct04875585","kind":"trial","name":"Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC","route":"/trials/nct04875585/","asOf":"2026-09-25","days":3},{"id":"nct06448572","kind":"trial","name":"EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy.","route":"/trials/nct06448572/","asOf":"2026-09-25","days":3},{"id":"nct06634966","kind":"trial","name":"Segmentectomy for Solid-dominant Lung Cancer","route":"/trials/nct06634966/","asOf":"2026-09-25","days":3},{"id":"nct04871412","kind":"trial","name":"The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial - Stage III","route":"/trials/nct04871412/","asOf":"2026-09-25","days":3},{"id":"nct06290869","kind":"trial","name":"Tobacco Education and Lung Health Study (TEAL)","route":"/trials/nct06290869/","asOf":"2026-09-25","days":3},{"id":"nct06500481","kind":"trial","name":"Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial","route":"/trials/nct06500481/","asOf":"2026-09-25","days":3},{"id":"nct05570825","kind":"trial","name":"SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer","route":"/trials/nct05570825/","asOf":"2026-09-25","days":3},{"id":"nct05236946","kind":"trial","name":"Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT","route":"/trials/nct05236946/","asOf":"2026-09-25","days":3},{"id":"nct06865339","kind":"trial","name":"Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer","route":"/trials/nct06865339/","asOf":"2026-09-25","days":3},{"id":"nct05800223","kind":"trial","name":"Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer","route":"/trials/nct05800223/","asOf":"2026-09-25","days":3},{"id":"nct05501665","kind":"trial","name":"Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer","route":"/trials/nct05501665/","asOf":"2026-09-25","days":3},{"id":"nct06523673","kind":"trial","name":"Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer","route":"/trials/nct06523673/","asOf":"2026-09-25","days":3},{"id":"nct06031181","kind":"trial","name":"Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019)","route":"/trials/nct06031181/","asOf":"2026-09-25","days":3},{"id":"nct06248606","kind":"trial","name":"Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases","route":"/trials/nct06248606/","asOf":"2026-09-25","days":3},{"id":"nct06822543","kind":"trial","name":"A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cance","route":"/trials/nct06822543/","asOf":"2026-09-25","days":3},{"id":"nct07133425","kind":"trial","name":"A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer","route":"/trials/nct07133425/","asOf":"2026-09-25","days":3},{"id":"nct06475209","kind":"trial","name":"Adebrelimab + Apatinib in SCLC Maintenance Therapy","route":"/trials/nct06475209/","asOf":"2026-09-25","days":3},{"id":"nct04267848","kind":"trial","name":"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Ch","route":"/trials/nct04267848/","asOf":"2026-09-25","days":3},{"id":"nct05286957","kind":"trial","name":"MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC","route":"/trials/nct05286957/","asOf":"2026-09-25","days":3},{"id":"nct07602855","kind":"trial","name":"A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)","route":"/trials/nct07602855/","asOf":"2026-09-25","days":3},{"id":"nct05429463","kind":"trial","name":"Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE II）","route":"/trials/nct05429463/","asOf":"2026-09-25","days":3},{"id":"nct07224152","kind":"trial","name":"NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer","route":"/trials/nct07224152/","asOf":"2026-09-25","days":3},{"id":"nct07485452","kind":"trial","name":"Boosting Osimertinib Blood Brain Barrier Penetration","route":"/trials/nct07485452/","asOf":"2026-09-25","days":3},{"id":"nct05255302","kind":"trial","name":"De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction","route":"/trials/nct05255302/","asOf":"2026-09-25","days":3},{"id":"nct04410796","kind":"trial","name":"Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers","route":"/trials/nct04410796/","asOf":"2026-09-25","days":3},{"id":"nct06607796","kind":"trial","name":"Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy","route":"/trials/nct06607796/","asOf":"2026-09-25","days":3},{"id":"nct06096844","kind":"trial","name":"Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial","route":"/trials/nct06096844/","asOf":"2026-09-25","days":3},{"id":"nct05588388","kind":"trial","name":"Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases","route":"/trials/nct05588388/","asOf":"2026-09-25","days":3},{"id":"nct07131319","kind":"trial","name":"SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC","route":"/trials/nct07131319/","asOf":"2026-09-25","days":3},{"id":"nct06102057","kind":"trial","name":"PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC","route":"/trials/nct06102057/","asOf":"2026-09-25","days":3},{"id":"nct06610734","kind":"trial","name":"Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Ext","route":"/trials/nct06610734/","asOf":"2026-09-25","days":3},{"id":"nct04322617","kind":"trial","name":"Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer","route":"/trials/nct04322617/","asOf":"2026-09-25","days":3},{"id":"nct04966663","kind":"trial","name":"Using ctDNA to Determine Therapies for Lung Cancer","route":"/trials/nct04966663/","asOf":"2026-09-25","days":3},{"id":"nct07052669","kind":"trial","name":"Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC","route":"/trials/nct07052669/","asOf":"2026-09-25","days":3},{"id":"nct07388524","kind":"trial","name":"Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial","route":"/trials/nct07388524/","asOf":"2026-09-25","days":3},{"id":"nct06031246","kind":"trial","name":"Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018)","route":"/trials/nct06031246/","asOf":"2026-09-25","days":3},{"id":"nct06338683","kind":"trial","name":"Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer","route":"/trials/nct06338683/","asOf":"2026-09-25","days":3},{"id":"nct07050043","kind":"trial","name":"Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC","route":"/trials/nct07050043/","asOf":"2026-09-25","days":3},{"id":"nct06222489","kind":"trial","name":"Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT","route":"/trials/nct06222489/","asOf":"2026-09-25","days":3},{"id":"nct07535437","kind":"trial","name":"A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer","route":"/trials/nct07535437/","asOf":"2026-09-25","days":3},{"id":"nct07809256","kind":"trial","name":"A Prospective, Single-center, Non-randomized, Interventional Study on the Effectiveness and Safety of Combined Immunotargeted Therapy in Patients With Metastati","route":"/trials/nct07809256/","asOf":"2026-09-25","days":3},{"id":"nct07058519","kind":"trial","name":"A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC","route":"/trials/nct07058519/","asOf":"2026-09-25","days":3},{"id":"nct05334277","kind":"trial","name":"Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA","route":"/trials/nct05334277/","asOf":"2026-09-25","days":3},{"id":"nct06840704","kind":"trial","name":"Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer","route":"/trials/nct06840704/","asOf":"2026-09-25","days":3},{"id":"nct06951646","kind":"trial","name":"ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)","route":"/trials/nct06951646/","asOf":"2026-09-25","days":3},{"id":"nct04980716","kind":"trial","name":"Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients","route":"/trials/nct04980716/","asOf":"2026-09-25","days":3},{"id":"nct07008716","kind":"trial","name":"Omitting CTV for Primary Tumor in LS-SCLC","route":"/trials/nct07008716/","asOf":"2026-09-25","days":3},{"id":"nct05278052","kind":"trial","name":"Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC","route":"/trials/nct05278052/","asOf":"2026-09-25","days":3},{"id":"nct07016230","kind":"trial","name":"Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocri","route":"/trials/nct07016230/","asOf":"2026-09-25","days":3},{"id":"nct06851663","kind":"trial","name":"Trop2-targeted immunoPET Imaging of Solid Tumors","route":"/trials/nct06851663/","asOf":"2026-09-25","days":3},{"id":"nct06449313","kind":"trial","name":"Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features","route":"/trials/nct06449313/","asOf":"2026-09-25","days":3},{"id":"nct07554846","kind":"trial","name":"Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC","route":"/trials/nct07554846/","asOf":"2026-09-25","days":3},{"id":"nct07198841","kind":"trial","name":"IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation","route":"/trials/nct07198841/","asOf":"2026-09-25","days":3},{"id":"nct06545747","kind":"trial","name":"Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI","route":"/trials/nct06545747/","asOf":"2026-09-25","days":3},{"id":"nct06127654","kind":"trial","name":"Ventilation Imaging to Improve the Quality of Life for Patients With Lung Cancer Treated With Radiation Therapy","route":"/trials/nct06127654/","asOf":"2026-09-25","days":3},{"id":"nct06437977","kind":"trial","name":"Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)","route":"/trials/nct06437977/","asOf":"2026-09-25","days":3},{"id":"nct07738172","kind":"trial","name":"Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung Cancer","route":"/trials/nct07738172/","asOf":"2026-09-25","days":3},{"id":"nct06734702","kind":"trial","name":"Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Ca","route":"/trials/nct06734702/","asOf":"2026-09-25","days":3},{"id":"nct07110103","kind":"trial","name":"Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC","route":"/trials/nct07110103/","asOf":"2026-09-25","days":3},{"id":"nct07155200","kind":"trial","name":"Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)","route":"/trials/nct07155200/","asOf":"2026-09-25","days":3},{"id":"nct05578326","kind":"trial","name":"Study of Trilaciclib and Lurbinectidin","route":"/trials/nct05578326/","asOf":"2026-09-25","days":3},{"id":"nct07412262","kind":"trial","name":"A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and Hig","route":"/trials/nct07412262/","asOf":"2026-09-25","days":3},{"id":"nct06401824","kind":"trial","name":"Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases","route":"/trials/nct06401824/","asOf":"2026-09-25","days":3},{"id":"nct06745882","kind":"trial","name":"Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC","route":"/trials/nct06745882/","asOf":"2026-09-25","days":3},{"id":"nct07322341","kind":"trial","name":"SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer","route":"/trials/nct07322341/","asOf":"2026-09-25","days":3},{"id":"nct06784791","kind":"trial","name":"Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mut","route":"/trials/nct06784791/","asOf":"2026-09-25","days":3},{"id":"nct06634056","kind":"trial","name":"Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation","route":"/trials/nct06634056/","asOf":"2026-09-25","days":3},{"id":"nct04181060","kind":"trial","name":"Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer","route":"/trials/nct04181060/","asOf":"2026-09-25","days":3},{"id":"nct07405190","kind":"trial","name":"Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC","route":"/trials/nct07405190/","asOf":"2026-09-25","days":3},{"id":"nct04829708","kind":"trial","name":"Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission Aft","route":"/trials/nct04829708/","asOf":"2026-09-25","days":3},{"id":"nct04933903","kind":"trial","name":"BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab","route":"/trials/nct04933903/","asOf":"2026-09-25","days":3},{"id":"nct07203053","kind":"trial","name":"A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2","route":"/trials/nct07203053/","asOf":"2026-09-25","days":3},{"id":"nct06598527","kind":"trial","name":"Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant The","route":"/trials/nct06598527/","asOf":"2026-09-25","days":3},{"id":"nct07655622","kind":"trial","name":"Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression","route":"/trials/nct07655622/","asOf":"2026-09-25","days":3},{"id":"nct07492342","kind":"trial","name":"Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC","route":"/trials/nct07492342/","asOf":"2026-09-25","days":3},{"id":"nct06431633","kind":"trial","name":"Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.","route":"/trials/nct06431633/","asOf":"2026-09-25","days":3},{"id":"nct02448992","kind":"trial","name":"Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer","route":"/trials/nct02448992/","asOf":"2026-09-25","days":3},{"id":"nct07815223","kind":"trial","name":"A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC","route":"/trials/nct07815223/","asOf":"2026-09-25","days":3},{"id":"nct04273061","kind":"trial","name":"Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity","route":"/trials/nct04273061/","asOf":"2026-09-25","days":3},{"id":"nct06121505","kind":"trial","name":"Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer","route":"/trials/nct06121505/","asOf":"2026-09-25","days":3},{"id":"nct04919382","kind":"trial","name":"Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer","route":"/trials/nct04919382/","asOf":"2026-09-25","days":3},{"id":"nct06141070","kind":"trial","name":"Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease","route":"/trials/nct06141070/","asOf":"2026-09-25","days":3},{"id":"nct07015892","kind":"trial","name":"Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized Trial","route":"/trials/nct07015892/","asOf":"2026-09-25","days":3},{"id":"nct05717803","kind":"trial","name":"Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012)","route":"/trials/nct05717803/","asOf":"2026-09-25","days":3},{"id":"nct06672133","kind":"trial","name":"Adebrelimab Combined with Chemotherapy and Thoracic Radiotherapy for First-line Treatment of ES-SCLC","route":"/trials/nct06672133/","asOf":"2026-09-25","days":3},{"id":"nct06441344","kind":"trial","name":"Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell","route":"/trials/nct06441344/","asOf":"2026-09-25","days":3},{"id":"roy-castle-lung-cancer-foundation","kind":"institution","name":"Roy Castle Lung Cancer Foundation","route":"/institutions/roy-castle-lung-cancer-foundation/","asOf":"2026-09-25","days":3},{"id":"royal-papworth","kind":"institution","name":"Royal Papworth Hospital NHS Foundation Trust","route":"/institutions/royal-papworth/","asOf":"2026-09-25","days":3},{"id":"liverpool-heart-and-chest","kind":"institution","name":"Liverpool Heart and Chest Hospital NHS Foundation Trust","route":"/institutions/liverpool-heart-and-chest/","asOf":"2026-09-25","days":3},{"id":"philip-crosbie","kind":"person","name":"Philip Crosbie","route":"/people/philip-crosbie/","asOf":"2026-09-25","days":3},{"id":"matthew-callister","kind":"person","name":"Matthew Callister","route":"/people/matthew-callister/","asOf":"2026-09-25","days":3},{"id":"john-field","kind":"person","name":"John Field","route":"/people/john-field/","asOf":"2026-09-25","days":3},{"id":"david-baldwin","kind":"person","name":"David Baldwin","route":"/people/david-baldwin/","asOf":"2026-09-25","days":3},{"id":"gary-middleton","kind":"person","name":"Gary Middleton","route":"/people/gary-middleton/","asOf":"2026-09-25","days":3},{"id":"sanjay-popat","kind":"person","name":"Sanjay Popat","route":"/people/sanjay-popat/","asOf":"2026-09-25","days":3},{"id":"alastair-greystoke","kind":"person","name":"Alastair Greystoke","route":"/people/alastair-greystoke/","asOf":"2026-09-25","days":3},{"id":"ukls","kind":"trial","name":"UKLS","route":"/trials/ukls/","asOf":"2026-09-25","days":3},{"id":"ylst","kind":"trial","name":"YLST","route":"/trials/ylst/","asOf":"2026-09-25","days":3},{"id":"summit-lung","kind":"trial","name":"SUMMIT (lung health check study)","route":"/trials/summit-lung/","asOf":"2026-09-25","days":3},{"id":"lungsearch","kind":"trial","name":"Lung-SEARCH","route":"/trials/lungsearch/","asOf":"2026-09-25","days":3},{"id":"chart-lung","kind":"trial","name":"CHART","route":"/trials/chart-lung/","asOf":"2026-09-25","days":3},{"id":"big-lung-trial","kind":"trial","name":"Big Lung Trial","route":"/trials/big-lung-trial/","asOf":"2026-09-25","days":3},{"id":"violet","kind":"trial","name":"VIOLET","route":"/trials/violet/","asOf":"2026-09-25","days":3},{"id":"tracerx","kind":"trial","name":"TRACERx","route":"/trials/tracerx/","asOf":"2026-09-25","days":3},{"id":"prostate-ductal-adenocarcinoma","kind":"cancer","name":"Ductal adenocarcinoma of the prostate","route":"/cancers/prostate-ductal-adenocarcinoma/","asOf":"2026-09-25","days":3},{"id":"cambridge-prognostic-group","kind":"term","name":"Cambridge Prognostic Group (CPG 1 to 5)","route":"/terms/cambridge-prognostic-group/","asOf":"2026-09-25","days":3},{"id":"tnm-prostate-cancer","kind":"term","name":"TNM staging for prostate cancer, and what changed in the 9th edition","route":"/terms/tnm-prostate-cancer/","asOf":"2026-09-25","days":3},{"id":"prostate-acinar-adenocarcinoma","kind":"term","name":"Acinar adenocarcinoma of the prostate","route":"/terms/prostate-acinar-adenocarcinoma/","asOf":"2026-09-25","days":3},{"id":"intraductal-carcinoma-prostate","kind":"term","name":"Intraductal carcinoma of the prostate (IDC-P)","route":"/terms/intraductal-carcinoma-prostate/","asOf":"2026-09-25","days":3},{"id":"cribriform-prostate-cancer","kind":"term","name":"Cribriform growth pattern in prostate cancer","route":"/terms/cribriform-prostate-cancer/","asOf":"2026-09-25","days":3},{"id":"percentage-gleason-pattern-4","kind":"term","name":"Percentage of Gleason pattern 4","route":"/terms/percentage-gleason-pattern-4/","asOf":"2026-09-25","days":3},{"id":"psa-density","kind":"term","name":"PSA density","route":"/terms/psa-density/","asOf":"2026-09-25","days":3},{"id":"extraprostatic-extension","kind":"term","name":"Extraprostatic extension and seminal vesicle invasion","route":"/terms/extraprostatic-extension/","asOf":"2026-09-25","days":3},{"id":"high-grade-pin","kind":"term","name":"High-grade prostatic intraepithelial neoplasia (HGPIN)","route":"/terms/high-grade-pin/","asOf":"2026-09-25","days":3},{"id":"watchful-waiting","kind":"term","name":"Watchful waiting, and how it differs from active surveillance","route":"/terms/watchful-waiting/","asOf":"2026-09-25","days":3},{"id":"psa-doubling-time","kind":"term","name":"PSA doubling time","route":"/terms/psa-doubling-time/","asOf":"2026-09-25","days":3},{"id":"metastatic-spinal-cord-compression","kind":"term","name":"Metastatic spinal cord compression (MSCC)","route":"/terms/metastatic-spinal-cord-compression/","asOf":"2026-09-25","days":3},{"id":"acute-urinary-retention","kind":"term","name":"Acute urinary retention","route":"/terms/acute-urinary-retention/","asOf":"2026-09-25","days":3},{"id":"stress-urinary-incontinence","kind":"term","name":"Stress urinary incontinence","route":"/terms/stress-urinary-incontinence/","asOf":"2026-09-25","days":3},{"id":"pelvic-floor-muscle-exercises","kind":"term","name":"Pelvic floor muscle exercises","route":"/terms/pelvic-floor-muscle-exercises/","asOf":"2026-09-25","days":3},{"id":"artificial-urinary-sphincter","kind":"term","name":"Artificial urinary sphincter","route":"/terms/artificial-urinary-sphincter/","asOf":"2026-09-25","days":3},{"id":"erectile-dysfunction-after-prostate-cancer","kind":"term","name":"Erectile dysfunction after prostate cancer treatment","route":"/terms/erectile-dysfunction-after-prostate-cancer/","asOf":"2026-09-25","days":3},{"id":"priapism","kind":"term","name":"Priapism","route":"/terms/priapism/","asOf":"2026-09-25","days":3},{"id":"treatment-induced-bone-loss","kind":"term","name":"Treatment-induced bone loss","route":"/terms/treatment-induced-bone-loss/","asOf":"2026-09-25","days":3},{"id":"hot-flushes-on-hormone-therapy","kind":"term","name":"Hot flushes on hormone therapy","route":"/terms/hot-flushes-on-hormone-therapy/","asOf":"2026-09-25","days":3},{"id":"gynaecomastia","kind":"term","name":"Gynaecomastia","route":"/terms/gynaecomastia/","asOf":"2026-09-25","days":3},{"id":"paper-huggins-hodges-castration-serum-phosphatases-prostate-1941","kind":"paper","name":"Huggins and Hodges 1941: the effect of castration, of oestrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate","route":"/key-papers/paper-huggins-hodges-castration-serum-phosphatases-prostate-1941/","asOf":"2026-09-25","days":3},{"id":"paper-visakorpi-androgen-receptor-amplification-nat-genet-1995","kind":"paper","name":"In vivo amplification of the androgen receptor gene and progression of human prostate cancer","route":"/key-papers/paper-visakorpi-androgen-receptor-amplification-nat-genet-1995/","asOf":"2026-09-25","days":3},{"id":"paper-chen-androgen-receptor-overexpression-antiandrogen-resistance-nat-med-2004","kind":"paper","name":"Molecular determinants of resistance to antiandrogen therapy","route":"/key-papers/paper-chen-androgen-receptor-overexpression-antiandrogen-resistance-nat-med-2004/","asOf":"2026-09-25","days":3},{"id":"paper-attard-abiraterone-phase-1-cyp17-jco-2008","kind":"paper","name":"Phase 1 trial of abiraterone acetate confirms that castration-resistant prostate cancer commonly remains hormone driven","route":"/key-papers/paper-attard-abiraterone-phase-1-cyp17-jco-2008/","asOf":"2026-09-25","days":3},{"id":"paper-tannock-tax-327-docetaxel-prednisone-nejm-2004","kind":"paper","name":"TAX 327: docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","route":"/key-papers/paper-tannock-tax-327-docetaxel-prednisone-nejm-2004/","asOf":"2026-09-25","days":3},{"id":"paper-petrylak-swog-9916-docetaxel-estramustine-nejm-2004","kind":"paper","name":"SWOG 9916: docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","route":"/key-papers/paper-petrylak-swog-9916-docetaxel-estramustine-nejm-2004/","asOf":"2026-09-25","days":3},{"id":"paper-de-bono-tropic-cabazitaxel-lancet-2010","kind":"paper","name":"TROPIC: prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel","route":"/key-papers/paper-de-bono-tropic-cabazitaxel-lancet-2010/","asOf":"2026-09-25","days":3},{"id":"paper-scher-affirm-enzalutamide-nejm-2012","kind":"paper","name":"AFFIRM: increased survival with enzalutamide in prostate cancer after chemotherapy","route":"/key-papers/paper-scher-affirm-enzalutamide-nejm-2012/","asOf":"2026-09-25","days":3},{"id":"paper-beer-prevail-enzalutamide-nejm-2014","kind":"paper","name":"PREVAIL: enzalutamide in metastatic prostate cancer before chemotherapy","route":"/key-papers/paper-beer-prevail-enzalutamide-nejm-2014/","asOf":"2026-09-25","days":3},{"id":"paper-gravis-getug-afu-15-docetaxel-lancet-oncol-2013","kind":"paper","name":"GETUG-AFU 15: androgen deprivation alone or with docetaxel in non-castrate metastatic prostate cancer","route":"/key-papers/paper-gravis-getug-afu-15-docetaxel-lancet-oncol-2013/","asOf":"2026-09-25","days":3},{"id":"paper-vale-stopcap-docetaxel-bisphosphonates-lancet-oncol-2016","kind":"paper","name":"STOpCaP: docetaxel or bisphosphonates added to standard of care in hormone-sensitive prostate cancer, a systematic review and meta-analysis","route":"/key-papers/paper-vale-stopcap-docetaxel-bisphosphonates-lancet-oncol-2016/","asOf":"2026-09-25","days":3},{"id":"paper-hussain-swog-9346-intermittent-androgen-deprivation-nejm-2013","kind":"paper","name":"SWOG 9346: intermittent versus continuous androgen deprivation in metastatic prostate cancer","route":"/key-papers/paper-hussain-swog-9346-intermittent-androgen-deprivation-nejm-2013/","asOf":"2026-09-25","days":3},{"id":"paper-teply-restore-bipolar-androgen-therapy-lancet-oncol-2018","kind":"paper","name":"RESTORE: bipolar androgen therapy after progression on enzalutamide in metastatic castration-resistant prostate cancer","route":"/key-papers/paper-teply-restore-bipolar-androgen-therapy-lancet-oncol-2018/","asOf":"2026-09-25","days":3},{"id":"paper-denmeade-transformer-bipolar-androgen-therapy-jco-2021","kind":"paper","name":"TRANSFORMER: bipolar androgen therapy versus enzalutamide in asymptomatic metastatic castration-resistant prostate cancer","route":"/key-papers/paper-denmeade-transformer-bipolar-androgen-therapy-jco-2021/","asOf":"2026-09-25","days":3},{"id":"paper-stamey-psa-serum-marker-nejm-1987","kind":"paper","name":"Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate","route":"/key-papers/paper-stamey-psa-serum-marker-nejm-1987/","asOf":"2026-09-25","days":3},{"id":"paper-catalona-psa-screening-test-nejm-1991","kind":"paper","name":"Measurement of prostate-specific antigen in serum as a screening test for prostate cancer","route":"/key-papers/paper-catalona-psa-screening-test-nejm-1991/","asOf":"2026-09-25","days":3},{"id":"paper-schroder-erspc-screening-mortality-nejm-2009","kind":"paper","name":"ERSPC: screening and prostate cancer mortality in a randomised European study","route":"/key-papers/paper-schroder-erspc-screening-mortality-nejm-2009/","asOf":"2026-09-25","days":3},{"id":"paper-andriole-plco-prostate-screening-nejm-2009","kind":"paper","name":"PLCO: mortality results from a randomised prostate cancer screening trial","route":"/key-papers/paper-andriole-plco-prostate-screening-nejm-2009/","asOf":"2026-09-25","days":3},{"id":"paper-welch-albertsen-psa-era-diagnosis-treatment-jnci-2009","kind":"paper","name":"Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening, 1986 to 2005","route":"/key-papers/paper-welch-albertsen-psa-era-diagnosis-treatment-jnci-2009/","asOf":"2026-09-25","days":3},{"id":"paper-draisma-lead-time-overdiagnosis-psa-jnci-2009","kind":"paper","name":"Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context","route":"/key-papers/paper-draisma-lead-time-overdiagnosis-psa-jnci-2009/","asOf":"2026-09-25","days":3},{"id":"paper-loeb-overdiagnosis-overtreatment-prostate-eur-urol-2014","kind":"paper","name":"Overdiagnosis and overtreatment of prostate cancer","route":"/key-papers/paper-loeb-overdiagnosis-overtreatment-prostate-eur-urol-2014/","asOf":"2026-09-25","days":3},{"id":"paper-moyer-uspstf-prostate-screening-ann-intern-med-2012","kind":"paper","name":"USPSTF 2012: screening for prostate cancer, recommendation statement (grade D)","route":"/key-papers/paper-moyer-uspstf-prostate-screening-ann-intern-med-2012/","asOf":"2026-09-25","days":3},{"id":"paper-uspstf-prostate-screening-jama-2018","kind":"paper","name":"USPSTF 2018: screening for prostate cancer, recommendation statement (grade C at 55 to 69, grade D at 70 and over)","route":"/key-papers/paper-uspstf-prostate-screening-jama-2018/","asOf":"2026-09-25","days":3},{"id":"paper-bill-axelson-spcg-4-29-year-nejm-2018","kind":"paper","name":"SPCG-4: radical prostatectomy or watchful waiting in prostate cancer, 29-year follow-up","route":"/key-papers/paper-bill-axelson-spcg-4-29-year-nejm-2018/","asOf":"2026-09-25","days":3},{"id":"paper-wilt-pivot-prostatectomy-observation-nejm-2017","kind":"paper","name":"PIVOT: follow-up of prostatectomy versus observation for early prostate cancer","route":"/key-papers/paper-wilt-pivot-prostatectomy-observation-nejm-2017/","asOf":"2026-09-25","days":3},{"id":"paper-ahmed-promis-multiparametric-mri-lancet-2017","kind":"paper","name":"PROMIS: diagnostic accuracy of multiparametric MRI and TRUS biopsy in prostate cancer","route":"/key-papers/paper-ahmed-promis-multiparametric-mri-lancet-2017/","asOf":"2026-09-25","days":3},{"id":"paper-johnson-mpmri-individual-foci-eur-urol-2019","kind":"paper","name":"Detection of individual prostate cancer foci via multiparametric magnetic resonance imaging","route":"/key-papers/paper-johnson-mpmri-individual-foci-eur-urol-2019/","asOf":"2026-09-25","days":3},{"id":"paper-conti-trans-ancestry-gwas-prostate-nat-genet-2021","kind":"paper","name":"Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction","route":"/key-papers/paper-conti-trans-ancestry-gwas-prostate-nat-genet-2021/","asOf":"2026-09-25","days":3},{"id":"paper-dess-black-race-prostate-mortality-jama-oncol-2019","kind":"paper","name":"Association of Black race with prostate cancer-specific and other-cause mortality","route":"/key-papers/paper-dess-black-race-prostate-mortality-jama-oncol-2019/","asOf":"2026-09-25","days":3},{"id":"paper-tomlins-tmprss2-ets-fusion-science-2005","kind":"paper","name":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","route":"/key-papers/paper-tomlins-tmprss2-ets-fusion-science-2005/","asOf":"2026-09-25","days":3},{"id":"paper-taylor-integrative-genomic-profiling-cancer-cell-2010","kind":"paper","name":"Integrative genomic profiling of human prostate cancer","route":"/key-papers/paper-taylor-integrative-genomic-profiling-cancer-cell-2010/","asOf":"2026-09-25","days":3},{"id":"paper-grasso-mutational-landscape-lethal-crpc-nature-2012","kind":"paper","name":"The mutational landscape of lethal castration-resistant prostate cancer","route":"/key-papers/paper-grasso-mutational-landscape-lethal-crpc-nature-2012/","asOf":"2026-09-25","days":3},{"id":"paper-baca-punctuated-evolution-chromoplexy-cell-2013","kind":"paper","name":"Punctuated evolution of prostate cancer genomes","route":"/key-papers/paper-baca-punctuated-evolution-chromoplexy-cell-2013/","asOf":"2026-09-25","days":3},{"id":"paper-tcga-molecular-taxonomy-primary-prostate-cell-2015","kind":"paper","name":"TCGA: the molecular taxonomy of primary prostate cancer","route":"/key-papers/paper-tcga-molecular-taxonomy-primary-prostate-cell-2015/","asOf":"2026-09-25","days":3},{"id":"paper-robinson-integrative-clinical-genomics-advanced-prostate-cell-2015","kind":"paper","name":"SU2C-PCF: integrative clinical genomics of advanced prostate cancer","route":"/key-papers/paper-robinson-integrative-clinical-genomics-advanced-prostate-cell-2015/","asOf":"2026-09-25","days":3},{"id":"paper-gundem-evolutionary-history-lethal-metastatic-prostate-nature-2015","kind":"paper","name":"The evolutionary history of lethal metastatic prostate cancer","route":"/key-papers/paper-gundem-evolutionary-history-lethal-metastatic-prostate-nature-2015/","asOf":"2026-09-25","days":3},{"id":"paper-pritchard-inherited-dna-repair-metastatic-prostate-nejm-2016","kind":"paper","name":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","route":"/key-papers/paper-pritchard-inherited-dna-repair-metastatic-prostate-nejm-2016/","asOf":"2026-09-25","days":3},{"id":"paper-mateo-toparp-a-olaparib-dna-repair-nejm-2015","kind":"paper","name":"TOPARP-A: DNA-repair defects and olaparib in metastatic prostate cancer","route":"/key-papers/paper-mateo-toparp-a-olaparib-dna-repair-nejm-2015/","asOf":"2026-09-25","days":3},{"id":"paper-abida-triton2-rucaparib-brca-jco-2020","kind":"paper","name":"TRITON2: rucaparib in men with metastatic castration-resistant prostate cancer harbouring a BRCA1 or BRCA2 alteration","route":"/key-papers/paper-abida-triton2-rucaparib-brca-jco-2020/","asOf":"2026-09-25","days":3},{"id":"paper-fizazi-triton3-rucaparib-nejm-2023","kind":"paper","name":"TRITON3: rucaparib or physician's choice in metastatic castration-resistant prostate cancer","route":"/key-papers/paper-fizazi-triton3-rucaparib-nejm-2023/","asOf":"2026-09-25","days":3},{"id":"paper-chung-comprehensive-genomic-profiling-prostate-jco-po-2019","kind":"paper","name":"Prospective comprehensive genomic profiling of 3,476 primary and metastatic prostate tumours","route":"/key-papers/paper-chung-comprehensive-genomic-profiling-prostate-jco-po-2019/","asOf":"2026-09-25","days":3},{"id":"paper-antonarakis-ar-v7-resistance-nejm-2014","kind":"paper","name":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","route":"/key-papers/paper-antonarakis-ar-v7-resistance-nejm-2014/","asOf":"2026-09-25","days":3},{"id":"paper-mu-sox2-lineage-plasticity-science-2017","kind":"paper","name":"SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer","route":"/key-papers/paper-mu-sox2-lineage-plasticity-science-2017/","asOf":"2026-09-25","days":3},{"id":"paper-antonarakis-keynote-199-pembrolizumab-jco-2020","kind":"paper","name":"KEYNOTE-199: pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer","route":"/key-papers/paper-antonarakis-keynote-199-pembrolizumab-jco-2020/","asOf":"2026-09-25","days":3},{"id":"prostate-roadmap","kind":"roadmap","name":"Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch","route":"/roadmaps/prostate-roadmap/","asOf":"2026-09-25","days":3},{"id":"idea-prostate-hrr-testing-at-metastatic-diagnosis","kind":"idea","name":"Test every man for DNA repair faults on the day his prostate cancer is found to have spread, not three treatments later","route":"/ideas/idea-prostate-hrr-testing-at-metastatic-diagnosis/","asOf":"2026-09-25","days":3},{"id":"idea-prostate-randomise-the-sequence-not-only-the-drugs","kind":"idea","name":"Randomise the order of treatment, not only the drugs: a strategy platform for metastatic prostate cancer","route":"/ideas/idea-prostate-randomise-the-sequence-not-only-the-drugs/","asOf":"2026-09-25","days":3},{"id":"idea-prostate-plasticity-surveillance-before-it-is-neuroendocrine","kind":"idea","name":"Watch for the cancer changing cell type before the biopsy says neuroendocrine, and act on it","route":"/ideas/idea-prostate-plasticity-surveillance-before-it-is-neuroendocrine/","asOf":"2026-09-25","days":3},{"id":"idea-prostate-bipolar-androgen-therapy-phase-3-on-pfs2","kind":"idea","name":"Take high-dose testosterone to phase 3, with progression-free survival through the second line as the primary endpoint","route":"/ideas/idea-prostate-bipolar-androgen-therapy-phase-3-on-pfs2/","asOf":"2026-09-25","days":3},{"id":"idea-prostate-metastatic-presentation-as-the-screening-endpoint","kind":"idea","name":"Judge a prostate screening programme on metastatic presentation, not on incidence or mortality","route":"/ideas/idea-prostate-metastatic-presentation-as-the-screening-endpoint/","asOf":"2026-09-25","days":3},{"id":"idea-prostate-other-cause-mortality-as-a-reported-service-outcome","kind":"idea","name":"Report death from other causes as an outcome of the prostate cancer service, split by deprivation and ethnicity","route":"/ideas/idea-prostate-other-cause-mortality-as-a-reported-service-outcome/","asOf":"2026-09-25","days":3},{"id":"idea-prostate-per-lesion-mri-audit-before-focal-treatment","kind":"idea","name":"Publish a per-lesion miss rate for every prostate MRI service before it is allowed to guide focal treatment","route":"/ideas/idea-prostate-per-lesion-mri-audit-before-focal-treatment/","asOf":"2026-09-25","days":3},{"id":"prostate-treatment-choice-localised","kind":"term","name":"Choosing treatment for localised prostate cancer: what each option costs","route":"/terms/prostate-treatment-choice-localised/","asOf":"2026-09-25","days":3},{"id":"prostate-radiotherapy-fractionation","kind":"term","name":"How many radiotherapy visits: the prostate fractionation trials","route":"/terms/prostate-radiotherapy-fractionation/","asOf":"2026-09-25","days":3},{"id":"prostate-stampede-arms","kind":"term","name":"STAMPEDE's arms, and what each one answered","route":"/terms/prostate-stampede-arms/","asOf":"2026-09-25","days":3},{"id":"prostate-adt-burden","kind":"term","name":"What androgen deprivation costs: the side of hormone therapy the survival curves do not show","route":"/terms/prostate-adt-burden/","asOf":"2026-09-25","days":3},{"id":"prostate-crpc-sequencing","kind":"term","name":"What follows what in castration-resistant prostate cancer","route":"/terms/prostate-crpc-sequencing/","asOf":"2026-09-25","days":3},{"id":"prostate-hrr-eligibility","kind":"term","name":"Who is eligible for a PARP inhibitor in prostate cancer, and why the gene matters","route":"/terms/prostate-hrr-eligibility/","asOf":"2026-09-25","days":3},{"id":"prostate-failed-programmes","kind":"term","name":"Prostate cancer programmes that failed, and what each failure taught","route":"/terms/prostate-failed-programmes/","asOf":"2026-09-25","days":3},{"id":"prostate-uk-drug-approvals","kind":"term","name":"Prostate cancer drugs in England: what NICE recommends, and what it refuses","route":"/terms/prostate-uk-drug-approvals/","asOf":"2026-09-25","days":3},{"id":"prostate-focal-therapy","kind":"term","name":"Focal and tissue-preserving treatment of prostate cancer","route":"/terms/prostate-focal-therapy/","asOf":"2026-09-25","days":3},{"id":"galeterone","kind":"drug","name":"Galeterone","route":"/drugs/galeterone/","asOf":"2026-09-25","days":3},{"id":"custirsen","kind":"drug","name":"Custirsen","route":"/drugs/custirsen/","asOf":"2026-09-25","days":3},{"id":"orteronel","kind":"drug","name":"Orteronel","route":"/drugs/orteronel/","asOf":"2026-09-25","days":3},{"id":"tasquinimod","kind":"drug","name":"Tasquinimod","route":"/drugs/tasquinimod/","asOf":"2026-09-25","days":3},{"id":"zibotentan","kind":"drug","name":"Zibotentan","route":"/drugs/zibotentan/","asOf":"2026-09-25","days":3},{"id":"atrasentan","kind":"drug","name":"Atrasentan","route":"/drugs/atrasentan/","asOf":"2026-09-25","days":3},{"id":"prostvac","kind":"drug","name":"PROSTVAC","route":"/drugs/prostvac/","asOf":"2026-09-25","days":3},{"id":"erspc","kind":"trial","name":"ERSPC (European Randomized Study of Screening for Prostate Cancer)","route":"/trials/erspc/","asOf":"2026-09-25","days":3},{"id":"plco-prostate","kind":"trial","name":"PLCO, prostate component (Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial)","route":"/trials/plco-prostate/","asOf":"2026-09-25","days":3},{"id":"spcg-4","kind":"trial","name":"SPCG-4 (Scandinavian Prostate Cancer Group Study 4)","route":"/trials/spcg-4/","asOf":"2026-09-25","days":3},{"id":"pivot","kind":"trial","name":"PIVOT (Prostate Cancer Intervention Versus Observation Trial)","route":"/trials/pivot/","asOf":"2026-09-25","days":3},{"id":"rtog-0415","kind":"trial","name":"RTOG 0415","route":"/trials/rtog-0415/","asOf":"2026-09-25","days":3},{"id":"profit-trial","kind":"trial","name":"PROFIT (Prostate Fractionated Irradiation Trial)","route":"/trials/profit-trial/","asOf":"2026-09-25","days":3},{"id":"ascende-rt","kind":"trial","name":"ASCENDE-RT","route":"/trials/ascende-rt/","asOf":"2026-09-25","days":3},{"id":"eortc-22863","kind":"trial","name":"EORTC 22863","route":"/trials/eortc-22863/","asOf":"2026-09-25","days":3},{"id":"eortc-22961","kind":"trial","name":"EORTC 22961","route":"/trials/eortc-22961/","asOf":"2026-09-25","days":3},{"id":"rtog-9202","kind":"trial","name":"RTOG 92-02","route":"/trials/rtog-9202/","asOf":"2026-09-25","days":3},{"id":"rtog-9408","kind":"trial","name":"RTOG 94-08","route":"/trials/rtog-9408/","asOf":"2026-09-25","days":3},{"id":"eortc-22991","kind":"trial","name":"EORTC 22991","route":"/trials/eortc-22991/","asOf":"2026-09-25","days":3},{"id":"dart-01-05-gicor","kind":"trial","name":"DART 01/05 GICOR","route":"/trials/dart-01-05-gicor/","asOf":"2026-09-25","days":3},{"id":"spcg-7","kind":"trial","name":"SPCG-7/SFUO-3","route":"/trials/spcg-7/","asOf":"2026-09-25","days":3},{"id":"rtog-0521","kind":"trial","name":"NRG Oncology RTOG 0521","route":"/trials/rtog-0521/","asOf":"2026-09-25","days":3},{"id":"swog-8794","kind":"trial","name":"SWOG 8794","route":"/trials/swog-8794/","asOf":"2026-09-25","days":3},{"id":"eortc-22911","kind":"trial","name":"EORTC 22911","route":"/trials/eortc-22911/","asOf":"2026-09-25","days":3},{"id":"radicals-rt","kind":"trial","name":"RADICALS-RT","route":"/trials/radicals-rt/","asOf":"2026-09-25","days":3},{"id":"raves","kind":"trial","name":"RAVES (TROG 08.03/ANZUP)","route":"/trials/raves/","asOf":"2026-09-25","days":3},{"id":"getug-afu-17","kind":"trial","name":"GETUG-AFU 17","route":"/trials/getug-afu-17/","asOf":"2026-09-25","days":3},{"id":"artistic-meta-analysis","kind":"trial","name":"ARTISTIC meta-analysis","route":"/trials/artistic-meta-analysis/","asOf":"2026-09-25","days":3},{"id":"radicals-hd","kind":"trial","name":"RADICALS-HD","route":"/trials/radicals-hd/","asOf":"2026-09-25","days":3},{"id":"getug-afu-16","kind":"trial","name":"GETUG-AFU 16","route":"/trials/getug-afu-16/","asOf":"2026-09-25","days":3},{"id":"getug-afu-15","kind":"trial","name":"GETUG-AFU 15","route":"/trials/getug-afu-15/","asOf":"2026-09-25","days":3},{"id":"swog-9346","kind":"trial","name":"SWOG 9346 (intermittent androgen deprivation)","route":"/trials/swog-9346/","asOf":"2026-09-25","days":3},{"id":"patch-transdermal-oestradiol","kind":"trial","name":"PATCH (Prostate Adenocarcinoma Transcutaneous Hormone)","route":"/trials/patch-transdermal-oestradiol/","asOf":"2026-09-25","days":3},{"id":"hero","kind":"trial","name":"HERO","route":"/trials/hero/","asOf":"2026-09-25","days":3},{"id":"stomp-oligorecurrence","kind":"trial","name":"STOMP","route":"/trials/stomp-oligorecurrence/","asOf":"2026-09-25","days":3},{"id":"oriole","kind":"trial","name":"ORIOLE","route":"/trials/oriole/","asOf":"2026-09-25","days":3},{"id":"tax-327","kind":"trial","name":"TAX 327","route":"/trials/tax-327/","asOf":"2026-09-25","days":3},{"id":"swog-9916","kind":"trial","name":"SWOG 9916","route":"/trials/swog-9916/","asOf":"2026-09-25","days":3},{"id":"tropic","kind":"trial","name":"TROPIC","route":"/trials/tropic/","asOf":"2026-09-25","days":3},{"id":"proselica","kind":"trial","name":"PROSELICA","route":"/trials/proselica/","asOf":"2026-09-25","days":3},{"id":"firstana","kind":"trial","name":"FIRSTANA","route":"/trials/firstana/","asOf":"2026-09-25","days":3},{"id":"cou-aa-301","kind":"trial","name":"COU-AA-301","route":"/trials/cou-aa-301/","asOf":"2026-09-25","days":3},{"id":"cou-aa-302","kind":"trial","name":"COU-AA-302","route":"/trials/cou-aa-302/","asOf":"2026-09-25","days":3},{"id":"affirm","kind":"trial","name":"AFFIRM","route":"/trials/affirm/","asOf":"2026-09-25","days":3},{"id":"prevail","kind":"trial","name":"PREVAIL","route":"/trials/prevail/","asOf":"2026-09-25","days":3},{"id":"card","kind":"trial","name":"CARD","route":"/trials/card/","asOf":"2026-09-25","days":3},{"id":"impact-sipuleucel-t","kind":"trial","name":"IMPACT (sipuleucel-T)","route":"/trials/impact-sipuleucel-t/","asOf":"2026-09-25","days":3},{"id":"triton3","kind":"trial","name":"TRITON3","route":"/trials/triton3/","asOf":"2026-09-25","days":3},{"id":"peace-3","kind":"trial","name":"PEACE-3 (EORTC 1333)","route":"/trials/peace-3/","asOf":"2026-09-25","days":3},{"id":"era-223","kind":"trial","name":"ERA 223","route":"/trials/era-223/","asOf":"2026-09-25","days":3},{"id":"imbassador250","kind":"trial","name":"IMbassador250","route":"/trials/imbassador250/","asOf":"2026-09-25","days":3},{"id":"keynote-921","kind":"trial","name":"KEYNOTE-921","route":"/trials/keynote-921/","asOf":"2026-09-25","days":3},{"id":"keynote-641","kind":"trial","name":"KEYNOTE-641","route":"/trials/keynote-641/","asOf":"2026-09-25","days":3},{"id":"keynote-991","kind":"trial","name":"KEYNOTE-991","route":"/trials/keynote-991/","asOf":"2026-09-25","days":3},{"id":"ca184-043-ipilimumab","kind":"trial","name":"CA184-043","route":"/trials/ca184-043-ipilimumab/","asOf":"2026-09-25","days":3},{"id":"armor3-sv","kind":"trial","name":"ARMOR3-SV","route":"/trials/armor3-sv/","asOf":"2026-09-25","days":3},{"id":"synergy-custirsen","kind":"trial","name":"SYNERGY","route":"/trials/synergy-custirsen/","asOf":"2026-09-25","days":3},{"id":"affinity-custirsen","kind":"trial","name":"AFFINITY","route":"/trials/affinity-custirsen/","asOf":"2026-09-25","days":3},{"id":"elm-pc-4-orteronel","kind":"trial","name":"ELM-PC 4","route":"/trials/elm-pc-4-orteronel/","asOf":"2026-09-25","days":3},{"id":"tasquinimod-10tasq10","kind":"trial","name":"10TASQ10","route":"/trials/tasquinimod-10tasq10/","asOf":"2026-09-25","days":3},{"id":"comet-1","kind":"trial","name":"COMET-1","route":"/trials/comet-1/","asOf":"2026-09-25","days":3},{"id":"swog-s0421-atrasentan","kind":"trial","name":"SWOG S0421","route":"/trials/swog-s0421-atrasentan/","asOf":"2026-09-25","days":3},{"id":"enthuse-m1-zibotentan","kind":"trial","name":"ENTHUSE M1","route":"/trials/enthuse-m1-zibotentan/","asOf":"2026-09-25","days":3},{"id":"prospect-prostvac","kind":"trial","name":"PROSPECT","route":"/trials/prospect-prostvac/","asOf":"2026-09-25","days":3},{"id":"ready-dasatinib","kind":"trial","name":"READY","route":"/trials/ready-dasatinib/","asOf":"2026-09-25","days":3},{"id":"calgb-90401","kind":"trial","name":"CALGB 90401","route":"/trials/calgb-90401/","asOf":"2026-09-25","days":3},{"id":"prostate-cancer-uk","kind":"institution","name":"Prostate Cancer UK","route":"/institutions/prostate-cancer-uk/","asOf":"2026-09-25","days":3},{"id":"jenny-donovan","kind":"person","name":"Jenny Donovan","route":"/people/jenny-donovan/","asOf":"2026-09-25","days":3},{"id":"caroline-moore","kind":"person","name":"Caroline Moore","route":"/people/caroline-moore/","asOf":"2026-09-25","days":3},{"id":"nicholas-van-as","kind":"person","name":"Nicholas van As","route":"/people/nicholas-van-as/","asOf":"2026-09-25","days":3},{"id":"ros-eeles","kind":"person","name":"Rosalind Eeles","route":"/people/ros-eeles/","asOf":"2026-09-25","days":3},{"id":"rakesh-heer","kind":"person","name":"Rakesh Heer","route":"/people/rakesh-heer/","asOf":"2026-09-25","days":3},{"id":"promis","kind":"trial","name":"PROMIS","route":"/trials/promis/","asOf":"2026-09-25","days":3},{"id":"transform-prostate","kind":"trial","name":"TRANSFORM","route":"/trials/transform-prostate/","asOf":"2026-09-25","days":3},{"id":"lead-time-bias","kind":"term","name":"Lead time, and lead-time bias","route":"/terms/lead-time-bias/","asOf":"2026-09-25","days":3},{"id":"overtreatment","kind":"term","name":"Overtreatment","route":"/terms/overtreatment/","asOf":"2026-09-25","days":3},{"id":"number-needed-to-screen","kind":"term","name":"Number needed to screen (and number needed to diagnose)","route":"/terms/number-needed-to-screen/","asOf":"2026-09-25","days":3},{"id":"other-cause-mortality","kind":"term","name":"Other-cause mortality","route":"/terms/other-cause-mortality/","asOf":"2026-09-25","days":3},{"id":"metastasis-free-survival","kind":"term","name":"Metastasis-free survival (MFS)","route":"/terms/metastasis-free-survival/","asOf":"2026-09-25","days":3},{"id":"radiographic-progression-free-survival","kind":"term","name":"Radiographic progression-free survival (rPFS)","route":"/terms/radiographic-progression-free-survival/","asOf":"2026-09-25","days":3},{"id":"chromoplexy","kind":"term","name":"Chromoplexy","route":"/terms/chromoplexy/","asOf":"2026-09-25","days":3},{"id":"genome-wide-loss-of-heterozygosity","kind":"term","name":"Genome-wide loss of heterozygosity (gLOH)","route":"/terms/genome-wide-loss-of-heterozygosity/","asOf":"2026-09-25","days":3},{"id":"polygenic-risk-score","kind":"term","name":"Polygenic risk score (PRS)","route":"/terms/polygenic-risk-score/","asOf":"2026-09-25","days":3},{"id":"neuroendocrine-differentiation","kind":"term","name":"Neuroendocrine differentiation in prostate cancer","route":"/terms/neuroendocrine-differentiation/","asOf":"2026-09-25","days":3},{"id":"whole-mount-pathology","kind":"term","name":"Whole-mount pathology","route":"/terms/whole-mount-pathology/","asOf":"2026-09-25","days":3},{"id":"pi-rads","kind":"term","name":"PI-RADS (Prostate Imaging Reporting and Data System)","route":"/terms/pi-rads/","asOf":"2026-09-25","days":3},{"id":"template-mapping-biopsy","kind":"term","name":"Template mapping biopsy (transperineal template prostate mapping)","route":"/terms/template-mapping-biopsy/","asOf":"2026-09-25","days":3},{"id":"bipolar-androgen-therapy","kind":"term","name":"Bipolar androgen therapy (BAT)","route":"/terms/bipolar-androgen-therapy/","asOf":"2026-09-25","days":3},{"id":"intermittent-androgen-deprivation","kind":"term","name":"Intermittent androgen deprivation (IAD)","route":"/terms/intermittent-androgen-deprivation/","asOf":"2026-09-25","days":3},{"id":"paper-taplin-ar-mutation-androgen-independent-prostate-nejm-1995","kind":"paper","name":"Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer","route":"/key-papers/paper-taplin-ar-mutation-androgen-independent-prostate-nejm-1995/","asOf":"2026-09-25","days":3},{"id":"paper-quigley-structural-variation-mcrpc-cell-2018","kind":"paper","name":"Genomic hallmarks and structural variation in metastatic prostate cancer","route":"/key-papers/paper-quigley-structural-variation-mcrpc-cell-2018/","asOf":"2026-09-25","days":3},{"id":"paper-prophecy-arv7-validation-jco-2019","kind":"paper","name":"PROPHECY: prospective multicentre validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer","route":"/key-papers/paper-prophecy-arv7-validation-jco-2019/","asOf":"2026-09-25","days":3},{"id":"paper-scher-nuclear-arv7-taxane-vs-arsi-jama-oncol-2018","kind":"paper","name":"Nuclear-localised androgen receptor splice variant 7 in circulating tumour cells as a predictive biomarker in castration-resistant prostate cancer","route":"/key-papers/paper-scher-nuclear-arv7-taxane-vs-arsi-jama-oncol-2018/","asOf":"2026-09-25","days":3},{"id":"paper-barbieri-spop-foxa1-med12-prostate-nat-genet-2012","kind":"paper","name":"Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer","route":"/key-papers/paper-barbieri-spop-foxa1-med12-prostate-nat-genet-2012/","asOf":"2026-09-25","days":3},{"id":"paper-abida-genomic-correlates-outcome-mcrpc-pnas-2019","kind":"paper","name":"Genomic correlates of clinical outcome in advanced prostate cancer","route":"/key-papers/paper-abida-genomic-correlates-outcome-mcrpc-pnas-2019/","asOf":"2026-09-25","days":3},{"id":"paper-armenia-long-tail-oncogenic-drivers-prostate-nat-genet-2018","kind":"paper","name":"The long tail of oncogenic drivers in prostate cancer","route":"/key-papers/paper-armenia-long-tail-oncogenic-drivers-prostate-nat-genet-2018/","asOf":"2026-09-25","days":3},{"id":"paper-kumar-interindividual-genomic-diversity-metastatic-prostate-nat-med-2016","kind":"paper","name":"Substantial interindividual and limited intraindividual genomic diversity among tumours from men with metastatic prostate cancer","route":"/key-papers/paper-kumar-interindividual-genomic-diversity-metastatic-prostate-nat-med-2016/","asOf":"2026-09-25","days":3},{"id":"paper-stopsack-mcspc-genomic-alterations-outcomes-ccr-2020","kind":"paper","name":"Oncogenic genomic alterations, clinical phenotypes and outcomes in metastatic castration-sensitive prostate cancer","route":"/key-papers/paper-stopsack-mcspc-genomic-alterations-outcomes-ccr-2020/","asOf":"2026-09-25","days":3},{"id":"paper-stopsack-prostate-genomes-by-race-ccr-2022","kind":"paper","name":"Differences in prostate cancer genomes by self-reported race","route":"/key-papers/paper-stopsack-prostate-genomes-by-race-ccr-2022/","asOf":"2026-09-25","days":3},{"id":"paper-ren-chinese-prostate-whole-genome-eur-urol-2018","kind":"paper","name":"Whole-genome and transcriptome sequencing of prostate cancer identifies new genetic alterations driving disease progression","route":"/key-papers/paper-ren-chinese-prostate-whole-genome-eur-urol-2018/","asOf":"2026-09-25","days":3},{"id":"paper-mateo-genomics-lethal-prostate-diagnosis-castration-resistance-jci-2020","kind":"paper","name":"Genomics of lethal prostate cancer at diagnosis and castration resistance","route":"/key-papers/paper-mateo-genomics-lethal-prostate-diagnosis-castration-resistance-jci-2020/","asOf":"2026-09-25","days":3},{"id":"paper-nicolosi-germline-variants-prostate-testing-guidelines-jama-oncol-2019","kind":"paper","name":"Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines","route":"/key-papers/paper-nicolosi-germline-variants-prostate-testing-guidelines-jama-oncol-2019/","asOf":"2026-09-25","days":3},{"id":"paper-castro-germline-brca-prostate-outcomes-jco-2013","kind":"paper","name":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis and poor survival outcomes in prostate cancer","route":"/key-papers/paper-castro-germline-brca-prostate-outcomes-jco-2013/","asOf":"2026-09-25","days":3},{"id":"paper-isaacsson-velho-intraductal-germline-dna-repair-prostate-2018","kind":"paper","name":"Intraductal and ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer","route":"/key-papers/paper-isaacsson-velho-intraductal-germline-dna-repair-prostate-2018/","asOf":"2026-09-25","days":3},{"id":"paper-taylor-germline-brca2-evolutionary-trajectories-nat-commun-2017","kind":"paper","name":"Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories","route":"/key-papers/paper-taylor-germline-brca2-evolutionary-trajectories-nat-commun-2017/","asOf":"2026-09-25","days":3},{"id":"paper-quigley-brca2-reversion-cfdna-parp-resistance-cancer-discov-2017","kind":"paper","name":"Analysis of circulating cell-free DNA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors","route":"/key-papers/paper-quigley-brca2-reversion-cfdna-parp-resistance-cancer-discov-2017/","asOf":"2026-09-25","days":3},{"id":"paper-jensen-clonal-haematopoiesis-cfdna-interference-prostate-jama-oncol-2021","kind":"paper","name":"Association of clonal haematopoiesis in DNA repair genes with prostate cancer plasma cell-free DNA testing interference","route":"/key-papers/paper-jensen-clonal-haematopoiesis-cfdna-interference-prostate-jama-oncol-2021/","asOf":"2026-09-25","days":3},{"id":"paper-carver-pi3k-ar-reciprocal-feedback-prostate-cancer-cell-2011","kind":"paper","name":"Reciprocal feedback regulation of PI3K and androgen receptor signalling in PTEN-deficient prostate cancer","route":"/key-papers/paper-carver-pi3k-ar-reciprocal-feedback-prostate-cancer-cell-2011/","asOf":"2026-09-25","days":3},{"id":"paper-ferraldeschi-pten-protein-loss-abiraterone-eur-urol-2015","kind":"paper","name":"PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate","route":"/key-papers/paper-ferraldeschi-pten-protein-loss-abiraterone-eur-urol-2015/","asOf":"2026-09-25","days":3},{"id":"paper-ipatential150-ipatasertib-abiraterone-pten-lancet-2021","kind":"paper","name":"IPATential150: ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer","route":"/key-papers/paper-ipatential150-ipatasertib-abiraterone-pten-lancet-2021/","asOf":"2026-09-25","days":3},{"id":"paper-pettersson-tmprss2-erg-outcome-meta-analysis-cebp-2012","kind":"paper","name":"The TMPRSS2-ERG rearrangement, ERG expression and prostate cancer outcomes: a cohort study and meta-analysis","route":"/key-papers/paper-pettersson-tmprss2-erg-outcome-meta-analysis-cebp-2012/","asOf":"2026-09-25","days":3},{"id":"paper-abida-msi-prostate-checkpoint-blockade-jama-oncol-2019","kind":"paper","name":"Prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade","route":"/key-papers/paper-abida-msi-prostate-checkpoint-blockade-jama-oncol-2019/","asOf":"2026-09-25","days":3},{"id":"paper-pritchard-complex-msh2-msh6-hypermutated-prostate-nat-commun-2014","kind":"paper","name":"Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer","route":"/key-papers/paper-pritchard-complex-msh2-msh6-hypermutated-prostate-nat-commun-2014/","asOf":"2026-09-25","days":3},{"id":"paper-guedes-msh2-loss-primary-prostate-ccr-2017","kind":"paper","name":"MSH2 loss in primary prostate cancer","route":"/key-papers/paper-guedes-msh2-loss-primary-prostate-ccr-2017/","asOf":"2026-09-25","days":3},{"id":"paper-silver-psma-expression-normal-malignant-tissues-ccr-1997","kind":"paper","name":"Prostate-specific membrane antigen expression in normal and malignant human tissues","route":"/key-papers/paper-silver-psma-expression-normal-malignant-tissues-ccr-1997/","asOf":"2026-09-25","days":3},{"id":"paper-fendler-psma-pet-biochemical-recurrence-jama-oncol-2019","kind":"paper","name":"Accuracy of gallium-68 PSMA-11 PET in localising recurrent prostate cancer: a prospective single-arm clinical trial","route":"/key-papers/paper-fendler-psma-pet-biochemical-recurrence-jama-oncol-2019/","asOf":"2026-09-25","days":3},{"id":"paper-epstein-neuroendocrine-prostate-morphologic-classification-ajsp-2014","kind":"paper","name":"Proposed morphologic classification of prostate cancer with neuroendocrine differentiation","route":"/key-papers/paper-epstein-neuroendocrine-prostate-morphologic-classification-ajsp-2014/","asOf":"2026-09-25","days":3},{"id":"paper-beltran-nepc-aurka-mycn-cancer-discov-2011","kind":"paper","name":"Molecular characterisation of neuroendocrine prostate cancer and identification of new drug targets","route":"/key-papers/paper-beltran-nepc-aurka-mycn-cancer-discov-2011/","asOf":"2026-09-25","days":3},{"id":"paper-ku-rb1-trp53-lineage-plasticity-science-2017","kind":"paper","name":"Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis and antiandrogen resistance","route":"/key-papers/paper-ku-rb1-trp53-lineage-plasticity-science-2017/","asOf":"2026-09-25","days":3},{"id":"paper-bluemn-double-negative-prostate-fgf-mapk-cancer-cell-2017","kind":"paper","name":"Androgen receptor pathway-independent prostate cancer is sustained through FGF signalling","route":"/key-papers/paper-bluemn-double-negative-prostate-fgf-mapk-cancer-cell-2017/","asOf":"2026-09-25","days":3},{"id":"paper-labrecque-mcrpc-phenotypes-jci-2019","kind":"paper","name":"Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer","route":"/key-papers/paper-labrecque-mcrpc-phenotypes-jci-2019/","asOf":"2026-09-25","days":3},{"id":"paper-aparicio-aggressive-variant-prostate-tumour-suppressors-ccr-2016","kind":"paper","name":"Combined tumour suppressor defects characterise clinically defined aggressive variant prostate cancers","route":"/key-papers/paper-aparicio-aggressive-variant-prostate-tumour-suppressors-ccr-2016/","asOf":"2026-09-25","days":3},{"id":"paper-berchuck-cfdna-methylation-nepc-detection-ccr-2022","kind":"paper","name":"Detecting neuroendocrine prostate cancer through tissue-informed cell-free DNA methylation analysis","route":"/key-papers/paper-berchuck-cfdna-methylation-nepc-detection-ccr-2022/","asOf":"2026-09-25","days":3},{"id":"paper-wyatt-ctdna-tissue-concordance-mcrpc-jnci-2017","kind":"paper","name":"Concordance of circulating tumour DNA and matched metastatic tissue biopsy in prostate cancer","route":"/key-papers/paper-wyatt-ctdna-tissue-concordance-mcrpc-jnci-2017/","asOf":"2026-09-25","days":3},{"id":"paper-annala-ctdna-resistance-abiraterone-enzalutamide-cancer-discov-2018","kind":"paper","name":"Circulating tumour DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer","route":"/key-papers/paper-annala-ctdna-resistance-abiraterone-enzalutamide-cancer-discov-2018/","asOf":"2026-09-25","days":3},{"id":"paper-tukachinsky-ctdna-3334-advanced-prostate-ccr-2021","kind":"paper","name":"Genomic analysis of circulating tumour DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms","route":"/key-papers/paper-tukachinsky-ctdna-3334-advanced-prostate-ccr-2021/","asOf":"2026-09-25","days":3},{"id":"ar-amplification","kind":"biomarker","name":"AR amplification (gene and upstream enhancer)","route":"/biomarkers/ar-amplification/","asOf":"2026-09-25","days":3},{"id":"ar-ligand-binding-domain-mutation","kind":"biomarker","name":"AR ligand-binding-domain mutation (L702H, W742C, H875Y, T878A, F877L)","route":"/biomarkers/ar-ligand-binding-domain-mutation/","asOf":"2026-09-25","days":3},{"id":"hrr-gene-mutation","kind":"biomarker","name":"Homologous recombination repair gene mutation in prostate cancer","route":"/biomarkers/hrr-gene-mutation/","asOf":"2026-09-25","days":3},{"id":"tmprss2-erg-fusion","kind":"biomarker","name":"TMPRSS2-ERG fusion (and the other ETS rearrangements)","route":"/biomarkers/tmprss2-erg-fusion/","asOf":"2026-09-25","days":3},{"id":"spop-mutation","kind":"biomarker","name":"SPOP mutation","route":"/biomarkers/spop-mutation/","asOf":"2026-09-25","days":3},{"id":"nepc-transformation","kind":"biomarker","name":"Treatment-emergent neuroendocrine transformation (recognising it)","route":"/biomarkers/nepc-transformation/","asOf":"2026-09-25","days":3},{"id":"ctdna-tumour-fraction","kind":"biomarker","name":"Circulating tumour DNA fraction (and what a negative plasma result means)","route":"/biomarkers/ctdna-tumour-fraction/","asOf":"2026-09-25","days":3},{"id":"terminal-duct-lobular-unit","kind":"term","name":"Ducts, lobules and the terminal duct lobular unit","route":"/terms/terminal-duct-lobular-unit/","asOf":"2026-09-25","days":3},{"id":"who-breast-classification","kind":"term","name":"The WHO classification of breast tumours, and what the 6th edition changed","route":"/terms/who-breast-classification/","asOf":"2026-09-25","days":3},{"id":"nottingham-grade","kind":"term","name":"Nottingham grade (breast cancer grade 1, 2 and 3)","route":"/terms/nottingham-grade/","asOf":"2026-09-25","days":3},{"id":"nottingham-prognostic-index","kind":"term","name":"Nottingham Prognostic Index (NPI), and PREDICT","route":"/terms/nottingham-prognostic-index/","asOf":"2026-09-25","days":3},{"id":"tnm-breast-cancer-editions","kind":"term","name":"Which staging edition a breast report uses: UICC TNM 8, TNM 9 and the AJCC prognostic stage","route":"/terms/tnm-breast-cancer-editions/","asOf":"2026-09-25","days":3},{"id":"grade-stage-receptor-breast","kind":"term","name":"Grade, stage and receptor status: three different things on one breast report","route":"/terms/grade-stage-receptor-breast/","asOf":"2026-09-25","days":3},{"id":"er-pr-scoring-breast","kind":"term","name":"How ER and PR are scored on a breast report (Allred score, H score, and why PR is not a UK core item)","route":"/terms/er-pr-scoring-breast/","asOf":"2026-09-25","days":3},{"id":"her2-testing-uk-breast","kind":"term","name":"HER2 testing in the UK: reflex ISH, the ratio against the copy number, and where the UK differs from ASCO/CAP","route":"/terms/her2-testing-uk-breast/","asOf":"2026-09-25","days":3},{"id":"receptor-conversion-breast","kind":"term","name":"Receptor conversion: when the receptors change between the primary and a recurrence","route":"/terms/receptor-conversion-breast/","asOf":"2026-09-25","days":3},{"id":"breast-tumour-size-on-the-report","kind":"term","name":"Tumour size on a breast report, and why it differs from the scan","route":"/terms/breast-tumour-size-on-the-report/","asOf":"2026-09-25","days":3},{"id":"breast-conserving-surgery-versus-mastectomy","kind":"term","name":"Breast conservation or mastectomy","route":"/terms/breast-conserving-surgery-versus-mastectomy/","asOf":"2026-09-25","days":3},{"id":"oncoplastic-breast-surgery","kind":"term","name":"Oncoplastic breast surgery","route":"/terms/oncoplastic-breast-surgery/","asOf":"2026-09-25","days":3},{"id":"axillary-surgery-de-escalation","kind":"term","name":"Doing less to the armpit","route":"/terms/axillary-surgery-de-escalation/","asOf":"2026-09-25","days":3},{"id":"targeted-axillary-dissection","kind":"term","name":"Targeted axillary dissection","route":"/terms/targeted-axillary-dissection/","asOf":"2026-09-25","days":3},{"id":"breast-cancer-related-lymphoedema","kind":"term","name":"Lymphoedema after breast cancer treatment","route":"/terms/breast-cancer-related-lymphoedema/","asOf":"2026-09-25","days":3},{"id":"breast-reconstruction","kind":"term","name":"Breast reconstruction","route":"/terms/breast-reconstruction/","asOf":"2026-09-25","days":3},{"id":"bia-alcl","kind":"term","name":"Breast implant-associated anaplastic large cell lymphoma","route":"/terms/bia-alcl/","asOf":"2026-09-25","days":3},{"id":"radiotherapy-omission-early-breast-cancer","kind":"term","name":"Leaving radiotherapy out","route":"/terms/radiotherapy-omission-early-breast-cancer/","asOf":"2026-09-25","days":3},{"id":"partial-breast-irradiation","kind":"term","name":"Partial-breast irradiation","route":"/terms/partial-breast-irradiation/","asOf":"2026-09-25","days":3},{"id":"tumour-bed-boost","kind":"term","name":"Tumour bed boost","route":"/terms/tumour-bed-boost/","asOf":"2026-09-25","days":3},{"id":"post-mastectomy-radiotherapy","kind":"term","name":"Radiotherapy after mastectomy","route":"/terms/post-mastectomy-radiotherapy/","asOf":"2026-09-25","days":3},{"id":"neoadjuvant-versus-adjuvant-breast","kind":"term","name":"Drugs before or after the operation","route":"/terms/neoadjuvant-versus-adjuvant-breast/","asOf":"2026-09-25","days":3},{"id":"nsabp-b06","kind":"trial","name":"NSABP B-06","route":"/trials/nsabp-b06/","asOf":"2026-09-25","days":3},{"id":"milan-i","kind":"trial","name":"Milan I (quadrantectomy against radical mastectomy)","route":"/trials/milan-i/","asOf":"2026-09-25","days":3},{"id":"eortc-10801","kind":"trial","name":"EORTC 10801","route":"/trials/eortc-10801/","asOf":"2026-09-25","days":3},{"id":"nsabp-b04","kind":"trial","name":"NSABP B-04","route":"/trials/nsabp-b04/","asOf":"2026-09-25","days":3},{"id":"nsabp-b32","kind":"trial","name":"NSABP B-32","route":"/trials/nsabp-b32/","asOf":"2026-09-25","days":3},{"id":"almanac","kind":"trial","name":"ALMANAC (Axillary Lymphatic Mapping Against Nodal Axillary Clearance)","route":"/trials/almanac/","asOf":"2026-09-25","days":3},{"id":"acosog-z0011","kind":"trial","name":"ACOSOG Z0011 (Alliance)","route":"/trials/acosog-z0011/","asOf":"2026-09-25","days":3},{"id":"amaros","kind":"trial","name":"AMAROS (EORTC 10981-22023)","route":"/trials/amaros/","asOf":"2026-09-25","days":3},{"id":"ibcsg-23-01","kind":"trial","name":"IBCSG 23-01","route":"/trials/ibcsg-23-01/","asOf":"2026-09-25","days":3},{"id":"senomac","kind":"trial","name":"SENOMAC","route":"/trials/senomac/","asOf":"2026-09-25","days":3},{"id":"posnoc","kind":"trial","name":"POSNOC","route":"/trials/posnoc/","asOf":"2026-09-25","days":3},{"id":"sound","kind":"trial","name":"SOUND (Sentinel Node vs Observation After Axillary Ultra-Sound)","route":"/trials/sound/","asOf":"2026-09-25","days":3},{"id":"insema","kind":"trial","name":"INSEMA (Intergroup Sentinel Mamma)","route":"/trials/insema/","asOf":"2026-09-25","days":3},{"id":"acosog-z1071","kind":"trial","name":"ACOSOG Z1071 (Alliance)","route":"/trials/acosog-z1071/","asOf":"2026-09-25","days":3},{"id":"targeted-axillary-dissection-md-anderson","kind":"trial","name":"Targeted axillary dissection (MD Anderson prospective study)","route":"/trials/targeted-axillary-dissection-md-anderson/","asOf":"2026-09-25","days":3},{"id":"atnec","kind":"trial","name":"ATNEC","route":"/trials/atnec/","asOf":"2026-09-25","days":3},{"id":"start-a","kind":"trial","name":"START-A (UK Standardisation of Breast Radiotherapy, trial A)","route":"/trials/start-a/","asOf":"2026-09-25","days":3},{"id":"fast-trial","kind":"trial","name":"FAST (5-fraction whole-breast radiotherapy)","route":"/trials/fast-trial/","asOf":"2026-09-25","days":3},{"id":"eortc-22881-boost","kind":"trial","name":"EORTC 22881-10882 (boost against no boost)","route":"/trials/eortc-22881-boost/","asOf":"2026-09-25","days":3},{"id":"rapid","kind":"trial","name":"RAPID (accelerated partial-breast irradiation)","route":"/trials/rapid/","asOf":"2026-09-25","days":3},{"id":"targit-a","kind":"trial","name":"TARGIT-A (targeted intraoperative radiotherapy)","route":"/trials/targit-a/","asOf":"2026-09-25","days":3},{"id":"supremo","kind":"trial","name":"SUPREMO (BIG 2-04)","route":"/trials/supremo/","asOf":"2026-09-25","days":3},{"id":"nsabp-b51","kind":"trial","name":"NSABP B-51 / RTOG 1304","route":"/trials/nsabp-b51/","asOf":"2026-09-25","days":3},{"id":"ibra-study","kind":"trial","name":"iBRA (implant Breast Reconstruction evAluation)","route":"/trials/ibra-study/","asOf":"2026-09-25","days":3},{"id":"pre-bra","kind":"trial","name":"Pre-BRA (pre-pectoral breast reconstruction evaluation)","route":"/trials/pre-bra/","asOf":"2026-09-25","days":3},{"id":"best-bra","kind":"trial","name":"Best-BRA","route":"/trials/best-bra/","asOf":"2026-09-25","days":3},{"id":"mroc","kind":"trial","name":"Mastectomy Reconstruction Outcomes Consortium (MROC)","route":"/trials/mroc/","asOf":"2026-09-25","days":3},{"id":"lymphoedema-after-breast-cancer","kind":"term","name":"Lymphoedema after breast cancer treatment","route":"/terms/lymphoedema-after-breast-cancer/","asOf":"2026-09-25","days":3},{"id":"numbness-after-breast-surgery","kind":"term","name":"Numbness and nerve pain after breast surgery","route":"/terms/numbness-after-breast-surgery/","asOf":"2026-09-25","days":3},{"id":"cording-axillary-web-syndrome","kind":"term","name":"Cording (axillary web syndrome)","route":"/terms/cording-axillary-web-syndrome/","asOf":"2026-09-25","days":3},{"id":"seroma-after-breast-surgery","kind":"term","name":"Seroma after breast surgery","route":"/terms/seroma-after-breast-surgery/","asOf":"2026-09-25","days":3},{"id":"breast-margins-and-re-excision","kind":"term","name":"Margins after breast-conserving surgery, and second operations","route":"/terms/breast-margins-and-re-excision/","asOf":"2026-09-25","days":3},{"id":"ibis-i","kind":"trial","name":"IBIS-I (International Breast Intervention Study I)","route":"/trials/ibis-i/","asOf":"2026-09-25","days":3},{"id":"ibis-ii","kind":"trial","name":"IBIS-II (International Breast Intervention Study II)","route":"/trials/ibis-ii/","asOf":"2026-09-25","days":3},{"id":"agex","kind":"trial","name":"AgeX","route":"/trials/agex/","asOf":"2026-09-25","days":3},{"id":"curettage-and-cautery","kind":"term","name":"Curettage and cautery","route":"/terms/curettage-and-cautery/","asOf":"2026-09-25","days":3},{"id":"skin-graft-and-flap-reconstruction","kind":"term","name":"Skin grafts and flaps after skin cancer surgery","route":"/terms/skin-graft-and-flap-reconstruction/","asOf":"2026-09-25","days":3},{"id":"facial-scar-after-skin-cancer","kind":"term","name":"The scar on the face after skin cancer surgery","route":"/terms/facial-scar-after-skin-cancer/","asOf":"2026-09-25","days":3},{"id":"second-primary-skin-cancer","kind":"term","name":"The next skin cancer: second primaries after a keratinocyte cancer","route":"/terms/second-primary-skin-cancer/","asOf":"2026-09-25","days":3},{"id":"sun-protection-after-skin-cancer","kind":"term","name":"Sun protection after a skin cancer diagnosis","route":"/terms/sun-protection-after-skin-cancer/","asOf":"2026-09-25","days":3},{"id":"bowens-disease","kind":"cancer","name":"Bowen's disease (squamous cell carcinoma in situ)","route":"/cancers/bowens-disease/","asOf":"2026-09-25","days":3},{"id":"keratinocyte-cancer","kind":"term","name":"Keratinocyte cancer (and why 'non-melanoma skin cancer' is being retired)","route":"/terms/keratinocyte-cancer/","asOf":"2026-09-25","days":3},{"id":"keratinocyte-cancer-counting","kind":"term","name":"Why nobody knows how many skin cancers there are: the counting rule behind every figure","route":"/terms/keratinocyte-cancer-counting/","asOf":"2026-09-25","days":3},{"id":"bcc-growth-pattern","kind":"term","name":"The growth pattern on a basal cell carcinoma report: nodular, superficial, infiltrative, basosquamous","route":"/terms/bcc-growth-pattern/","asOf":"2026-09-25","days":3},{"id":"cscc-subtype-and-grade","kind":"term","name":"The subtype and grade on a cutaneous squamous cell carcinoma report","route":"/terms/cscc-subtype-and-grade/","asOf":"2026-09-25","days":3},{"id":"tnm-skin-carcinoma","kind":"term","name":"How skin carcinoma is staged in Britain: UICC TNM, and why it is not the American system","route":"/terms/tnm-skin-carcinoma/","asOf":"2026-09-25","days":3},{"id":"bwh-staging-cscc","kind":"term","name":"The Brigham and Women's Hospital staging system, and why squamous cell carcinoma has two","route":"/terms/bwh-staging-cscc/","asOf":"2026-09-25","days":3},{"id":"skin-cancer-high-risk-features","kind":"term","name":"What makes a skin cancer high risk: the UK feature lists","route":"/terms/skin-cancer-high-risk-features/","asOf":"2026-09-25","days":3},{"id":"actinic-keratosis","kind":"term","name":"Actinic keratosis (solar keratosis): sun damage, not cancer","route":"/terms/actinic-keratosis/","asOf":"2026-09-25","days":3},{"id":"keratoacanthoma","kind":"term","name":"Keratoacanthoma: the tumour that may be a squamous cell carcinoma","route":"/terms/keratoacanthoma/","asOf":"2026-09-25","days":3},{"id":"inherited-skin-cancer-syndromes","kind":"term","name":"Inherited syndromes that cause skin cancer: Gorlin syndrome and xeroderma pigmentosum","route":"/terms/inherited-skin-cancer-syndromes/","asOf":"2026-09-25","days":3},{"id":"surgical-margins-keratinocyte-cancer","kind":"term","name":"The margin in skin cancer surgery","route":"/terms/surgical-margins-keratinocyte-cancer/","asOf":"2026-09-25","days":3},{"id":"topical-and-destructive-treatment-bcc","kind":"term","name":"Creams, light and cold for basal cell carcinoma","route":"/terms/topical-and-destructive-treatment-bcc/","asOf":"2026-09-25","days":3},{"id":"radiotherapy-for-skin-cancer","kind":"term","name":"Radiotherapy for skin cancer","route":"/terms/radiotherapy-for-skin-cancer/","asOf":"2026-09-25","days":3},{"id":"hedgehog-inhibitor-tolerability","kind":"term","name":"Why people stop taking hedgehog inhibitors","route":"/terms/hedgehog-inhibitor-tolerability/","asOf":"2026-09-25","days":3},{"id":"skin-cancer-after-organ-transplant","kind":"term","name":"Skin cancer after an organ transplant","route":"/terms/skin-cancer-after-organ-transplant/","asOf":"2026-09-25","days":3},{"id":"sirolimus","kind":"drug","name":"Sirolimus","route":"/drugs/sirolimus/","asOf":"2026-09-25","days":3},{"id":"mohs-versus-excision-facial-bcc","kind":"trial","name":"Mohs surgery against ordinary excision for facial basal cell carcinoma (Maastricht trial)","route":"/trials/mohs-versus-excision-facial-bcc/","asOf":"2026-09-25","days":3},{"id":"sins-trial","kind":"trial","name":"SINS (surgical excision against imiquimod cream for basal cell carcinoma)","route":"/trials/sins-trial/","asOf":"2026-09-25","days":3},{"id":"mal-pdt-imiquimod-fluorouracil-superficial-bcc","kind":"trial","name":"Photodynamic therapy against imiquimod against fluorouracil for superficial basal cell carcinoma","route":"/trials/mal-pdt-imiquimod-fluorouracil-superficial-bcc/","asOf":"2026-09-25","days":3},{"id":"scin-trial","kind":"trial","name":"SCIN (curettage then imiquimod against excision for nodular basal cell carcinoma)","route":"/trials/scin-trial/","asOf":"2026-09-25","days":3},{"id":"mal-pdt-versus-surgery-nodular-bcc","kind":"trial","name":"Photodynamic therapy against surgery for nodular basal cell carcinoma","route":"/trials/mal-pdt-versus-surgery-nodular-bcc/","asOf":"2026-09-25","days":3},{"id":"mal-pdt-versus-cryotherapy-superficial-bcc","kind":"trial","name":"Photodynamic therapy against cryotherapy for superficial basal cell carcinoma","route":"/trials/mal-pdt-versus-cryotherapy-superficial-bcc/","asOf":"2026-09-25","days":3},{"id":"avril-surgery-versus-radiotherapy-bcc","kind":"trial","name":"Surgery against radiotherapy for basal cell carcinoma of the face","route":"/trials/avril-surgery-versus-radiotherapy-bcc/","asOf":"2026-09-25","days":3},{"id":"trog-05-01","kind":"trial","name":"TROG 05.01 (chemotherapy added to radiotherapy after surgery for high-risk skin squamous cell carcinoma)","route":"/trials/trog-05-01/","asOf":"2026-09-25","days":3},{"id":"stevie","kind":"trial","name":"STEVIE (vismodegib in ordinary practice)","route":"/trials/stevie/","asOf":"2026-09-25","days":3},{"id":"vismoneo","kind":"trial","name":"VISMONEO (vismodegib before surgery for locally advanced basal cell carcinoma)","route":"/trials/vismoneo/","asOf":"2026-09-25","days":3},{"id":"cemiplimab-advanced-bcc","kind":"trial","name":"Cemiplimab in basal cell carcinoma after a hedgehog inhibitor","route":"/trials/cemiplimab-advanced-bcc/","asOf":"2026-09-25","days":3},{"id":"c-post","kind":"trial","name":"C-POST (cemiplimab after surgery and radiotherapy for high-risk skin squamous cell carcinoma)","route":"/trials/c-post/","asOf":"2026-09-25","days":3},{"id":"neoadjuvant-cemiplimab-cscc","kind":"trial","name":"Neoadjuvant cemiplimab for resectable stage II to IV skin squamous cell carcinoma","route":"/trials/neoadjuvant-cemiplimab-cscc/","asOf":"2026-09-25","days":3},{"id":"admec-o","kind":"trial","name":"ADMEC-O (adjuvant nivolumab in completely resected Merkel cell carcinoma)","route":"/trials/admec-o/","asOf":"2026-09-25","days":3},{"id":"pod1um-201","kind":"trial","name":"POD1UM-201 (retifanlimab in advanced Merkel cell carcinoma)","route":"/trials/pod1um-201/","asOf":"2026-09-25","days":3},{"id":"tumorapa","kind":"trial","name":"TUMORAPA (switching from a calcineurin inhibitor to sirolimus after a transplant skin cancer)","route":"/trials/tumorapa/","asOf":"2026-09-25","days":3},{"id":"cemiplimab-kidney-transplant-cscc","kind":"trial","name":"Cemiplimab for kidney transplant recipients with advanced skin squamous cell carcinoma","route":"/trials/cemiplimab-kidney-transplant-cscc/","asOf":"2026-09-25","days":3},{"id":"patidegib-gel-gorlin-phase-2","kind":"trial","name":"Patidegib gel in Gorlin syndrome (phase 2A)","route":"/trials/patidegib-gel-gorlin-phase-2/","asOf":"2026-09-25","days":3},{"id":"melanoma-focus","kind":"institution","name":"Melanoma Focus","route":"/institutions/melanoma-focus/","asOf":"2026-09-25","days":3},{"id":"skcin","kind":"institution","name":"Skcin (the Karen Clifford Skin Cancer Charity)","route":"/institutions/skcin/","asOf":"2026-09-25","days":3},{"id":"british-association-of-dermatologists","kind":"institution","name":"British Association of Dermatologists","route":"/institutions/british-association-of-dermatologists/","asOf":"2026-09-25","days":3},{"id":"hywel-williams","kind":"person","name":"Hywel Williams","route":"/people/hywel-williams/","asOf":"2026-09-25","days":3},{"id":"nick-levell","kind":"person","name":"Nick Levell","route":"/people/nick-levell/","asOf":"2026-09-25","days":3},{"id":"molemate","kind":"trial","name":"MoleMate UK Trial","route":"/trials/molemate/","asOf":"2026-09-25","days":3},{"id":"mcc-rational-treatment","kind":"trial","name":"Rational treatment selection for Merkel cell carcinoma","route":"/trials/mcc-rational-treatment/","asOf":"2026-09-25","days":3},{"id":"impact-bcc","kind":"trial","name":"IMPACT (cemiplimab in advanced basal cell carcinoma)","route":"/trials/impact-bcc/","asOf":"2026-09-25","days":3},{"id":"spot-it","kind":"trial","name":"SPOT-IT","route":"/trials/spot-it/","asOf":"2026-09-25","days":3},{"id":"scc-after","kind":"trial","name":"SCC-AFTER","route":"/trials/scc-after/","asOf":"2026-09-25","days":3},{"id":"zelig-eshhar","kind":"person","name":"Zelig Eshhar","route":"/people/zelig-eshhar/","asOf":"2026-09-25","days":3},{"id":"yardena-samuels","kind":"person","name":"Yardena Samuels","route":"/people/yardena-samuels/","asOf":"2026-09-25","days":3},{"id":"yosef-yarden","kind":"person","name":"Yosef Yarden","route":"/people/yosef-yarden/","asOf":"2026-09-25","days":3},{"id":"moshe-oren","kind":"person","name":"Moshe Oren","route":"/people/moshe-oren/","asOf":"2026-09-25","days":3},{"id":"aaron-ciechanover","kind":"person","name":"Aaron Ciechanover","route":"/people/aaron-ciechanover/","asOf":"2026-09-25","days":3},{"id":"avram-hershko","kind":"person","name":"Avram Hershko","route":"/people/avram-hershko/","asOf":"2026-09-25","days":3},{"id":"yechezkel-barenholz","kind":"person","name":"Yechezkel Barenholz","route":"/people/yechezkel-barenholz/","asOf":"2026-09-25","days":3},{"id":"ephrat-levy-lahad","kind":"person","name":"Ephrat Levy-Lahad","route":"/people/ephrat-levy-lahad/","asOf":"2026-09-25","days":3},{"id":"rachel-michaelson-cohen","kind":"person","name":"Rachel Michaelson-Cohen","route":"/people/rachel-michaelson-cohen/","asOf":"2026-09-25","days":3},{"id":"eitan-friedman","kind":"person","name":"Eitan Friedman","route":"/people/eitan-friedman/","asOf":"2026-09-25","days":3},{"id":"jacob-schachter","kind":"person","name":"Jacob Schachter","route":"/people/jacob-schachter/","asOf":"2026-09-25","days":3},{"id":"michal-besser","kind":"person","name":"Michal Besser","route":"/people/michal-besser/","asOf":"2026-09-25","days":3},{"id":"gal-markel","kind":"person","name":"Gal Markel","route":"/people/gal-markel/","asOf":"2026-09-25","days":3},{"id":"polina-stepensky","kind":"person","name":"Polina Stepensky","route":"/people/polina-stepensky/","asOf":"2026-09-25","days":3},{"id":"alberto-gabizon","kind":"person","name":"Alberto Gabizon","route":"/people/alberto-gabizon/","asOf":"2026-09-25","days":3},{"id":"beata-halassy","kind":"person","name":"Beata Halassy","route":"/people/beata-halassy/","asOf":"2026-09-25","days":3},{"id":"dubravko-forcic","kind":"person","name":"Dubravko Forcic","route":"/people/dubravko-forcic/","asOf":"2026-09-25","days":3},{"id":"stephen-russell","kind":"person","name":"Stephen J. Russell","route":"/people/stephen-russell/","asOf":"2026-09-25","days":3},{"id":"john-bell","kind":"person","name":"John C. Bell","route":"/people/john-bell/","asOf":"2026-09-25","days":3},{"id":"robert-martuza","kind":"person","name":"Robert L. Martuza","route":"/people/robert-martuza/","asOf":"2026-09-25","days":3},{"id":"tomoki-todo","kind":"person","name":"Tomoki Todo","route":"/people/tomoki-todo/","asOf":"2026-09-25","days":3},{"id":"merkel-cell-carcinoma","kind":"cancer","name":"Merkel cell carcinoma","route":"/cancers/merkel-cell-carcinoma/","asOf":"2026-09-25","days":3},{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/","asOf":"2026-09-25","days":3},{"id":"basal-cell-carcinoma","kind":"cancer","name":"Basal cell carcinoma","route":"/cancers/basal-cell-carcinoma/","asOf":"2026-09-25","days":3},{"id":"paper-stojdl-vsv-interferon-defect-natmed-2000","kind":"paper","name":"Stojdl 2000: cancer cells that stopped answering interferon cannot stop a virus either","route":"/key-papers/paper-stojdl-vsv-interferon-defect-natmed-2000/","asOf":"2026-09-25","days":3},{"id":"paper-coffey-reovirus-ras-science-1998","kind":"paper","name":"Coffey 1998: reovirus grows in cells with an activated Ras pathway, which describes a great many cancers","route":"/key-papers/paper-coffey-reovirus-ras-science-1998/","asOf":"2026-09-25","days":3},{"id":"paper-martuza-engineered-hsv-glioma-science-1991","kind":"paper","name":"Martuza 1991: the first genetically engineered virus built to treat a cancer","route":"/key-papers/paper-martuza-engineered-hsv-glioma-science-1991/","asOf":"2026-09-25","days":3},{"id":"paper-bischoff-onyx-015-science-1996","kind":"paper","name":"Bischoff 1996: the adenovirus that was said to replicate only where p53 was lost","route":"/key-papers/paper-bischoff-onyx-015-science-1996/","asOf":"2026-09-25","days":3},{"id":"paper-kelly-russell-oncolytic-history-moltherapy-2007","kind":"paper","name":"Kelly and Russell 2007: a century of trying to treat cancer with viruses, and why it kept stopping","route":"/key-papers/paper-kelly-russell-oncolytic-history-moltherapy-2007/","asOf":"2026-09-25","days":3},{"id":"paper-russell-peng-bell-oncolytic-virotherapy-natbiotech-2012","kind":"paper","name":"Russell, Peng and Bell 2012: the field states its own problems","route":"/key-papers/paper-russell-peng-bell-oncolytic-virotherapy-natbiotech-2012/","asOf":"2026-09-25","days":3},{"id":"paper-shalhout-oncolytic-progress-challenges-natrevclinonc-2023","kind":"paper","name":"Shalhout 2023: what the approved oncolytic viruses actually do in practice","route":"/key-papers/paper-shalhout-oncolytic-progress-challenges-natrevclinonc-2023/","asOf":"2026-09-25","days":3},{"id":"paper-andtbacka-optim-talimogene-jco-2015","kind":"paper","name":"OPTiM: the trial that made talimogene laherparepvec the first approved oncolytic virus","route":"/key-papers/paper-andtbacka-optim-talimogene-jco-2015/","asOf":"2026-09-25","days":3},{"id":"paper-todo-g47delta-glioblastoma-natmed-2022","kind":"paper","name":"Todo 2022: the triple-mutated herpes virus that became Japan's first approved oncolytic virus","route":"/key-papers/paper-todo-g47delta-glioblastoma-natmed-2022/","asOf":"2026-09-25","days":3},{"id":"paper-xia-h101-head-neck-aizheng-2004","kind":"paper","name":"Xia 2004: the randomised trial behind China's approval of the oncolytic adenovirus H101","route":"/key-papers/paper-xia-h101-head-neck-aizheng-2004/","asOf":"2026-09-25","days":3},{"id":"paper-wong-ignyte-rp1-nivolumab-jco-2025","kind":"paper","name":"IGNYTE: an engineered herpes virus with nivolumab in melanoma that had already failed anti-PD-1 therapy","route":"/key-papers/paper-wong-ignyte-rp1-nivolumab-jco-2025/","asOf":"2026-09-25","days":3},{"id":"paper-russell-mv-nis-myeloma-mayo-2014","kind":"paper","name":"Russell 2014: a measles virus given into the vein put one patient's myeloma into complete remission","route":"/key-papers/paper-russell-mv-nis-myeloma-mayo-2014/","asOf":"2026-09-25","days":3},{"id":"paper-cloughesy-toca5-glioma-jamaoncol-2020","kind":"paper","name":"Toca 5: a virus plus a prodrug in recurrent brain cancer, tested properly, and it did not work","route":"/key-papers/paper-cloughesy-toca5-glioma-jamaoncol-2020/","asOf":"2026-09-25","days":3},{"id":"paper-abou-alfa-phocus-pexa-vec-liver-cancer-2024","kind":"paper","name":"PHOCUS: an oncolytic vaccinia virus before sorafenib in liver cancer did worse than sorafenib alone","route":"/key-papers/paper-abou-alfa-phocus-pexa-vec-liver-cancer-2024/","asOf":"2026-09-25","days":3},{"id":"paper-hietanen-rigvir-echovirus-viruses-2022","kind":"paper","name":"Hietanen 2022: the marketed oncolytic virus Rigvir was no more oncolytic than any other echovirus isolate","route":"/key-papers/paper-hietanen-rigvir-echovirus-viruses-2022/","asOf":"2026-09-25","days":3},{"id":"paper-bourgeois-daigneault-neoadjuvant-ovt-tnbc-scitranslmed-2018","kind":"paper","name":"Bourgeois-Daigneault 2018: giving the virus before surgery, not after everything else has failed","route":"/key-papers/paper-bourgeois-daigneault-neoadjuvant-ovt-tnbc-scitranslmed-2018/","asOf":"2026-09-25","days":3},{"id":"paper-halassy-self-experiment-ovt-vaccines-2024","kind":"paper","name":"The self-experiment: a virologist treated her own recurrent breast cancer with two viruses she made in her own laboratory","route":"/key-papers/paper-halassy-self-experiment-ovt-vaccines-2024/","asOf":"2026-09-25","days":3},{"id":"paper-pugh-self-experimentation-publication-jme-2026","kind":"paper","name":"Pugh 2026: should a journal publish a scientist's experiment on herself?","route":"/key-papers/paper-pugh-self-experimentation-publication-jme-2026/","asOf":"2026-09-25","days":3},{"id":"petrov-institute","kind":"institution","name":"N. N. Petrov National Medical Research Centre of Oncology","route":"/institutions/petrov-institute/","asOf":"2026-09-25","days":3},{"id":"rogachev-centre","kind":"institution","name":"Dmitry Rogachev National Medical Research Centre of Paediatric Haematology, Oncology and Immunology","route":"/institutions/rogachev-centre/","asOf":"2026-09-25","days":3},{"id":"tomsk-cancer-research-institute","kind":"institution","name":"Cancer Research Institute, Tomsk National Research Medical Centre","route":"/institutions/tomsk-cancer-research-institute/","asOf":"2026-09-25","days":3},{"id":"russco","kind":"institution","name":"Russian Society of Clinical Oncology (RUSSCO)","route":"/institutions/russco/","asOf":"2026-09-25","days":3},{"id":"paper-barchuk-registry-validity-acta-oncol-2021","kind":"paper","name":"Comparability and validity of cancer registry data in the north-west of Russia","route":"/key-papers/paper-barchuk-registry-validity-acta-oncol-2021/","asOf":"2026-09-25","days":3},{"id":"paper-barchuk-registry-completeness-bmc-cancer-2023","kind":"paper","name":"Completeness of regional cancer registry data in north-west Russia, 2008 to 2017","route":"/key-papers/paper-barchuk-registry-completeness-bmc-cancer-2023/","asOf":"2026-09-25","days":3},{"id":"paper-tjulandin-prolgolimab-miraculum-ejc-2021","kind":"paper","name":"MIRACULUM: prolgolimab, the first Russian-developed anti-PD-1 antibody, in advanced melanoma","route":"/key-papers/paper-tjulandin-prolgolimab-miraculum-ejc-2021/","asOf":"2026-09-25","days":3},{"id":"paper-laktionov-prolgolimab-domajor-ejc-2025","kind":"paper","name":"DOMAJOR: prolgolimab with chemotherapy first line in advanced non-squamous lung cancer","route":"/key-papers/paper-laktionov-prolgolimab-domajor-ejc-2025/","asOf":"2026-09-25","days":3},{"id":"ductal-carcinoma-in-situ","kind":"cancer","name":"Ductal carcinoma in situ (DCIS)","route":"/cancers/ductal-carcinoma-in-situ/","asOf":"2026-09-25","days":3},{"id":"bfarm","kind":"institution","name":"Bundesinstitut für Arzneimittel und Medizinprodukte","route":"/institutions/bfarm/","asOf":"2026-09-25","days":3},{"id":"paul-ehrlich-institut","kind":"institution","name":"Paul-Ehrlich-Institut","route":"/institutions/paul-ehrlich-institut/","asOf":"2026-09-25","days":3},{"id":"zfkd-rki","kind":"institution","name":"Zentrum für Krebsregisterdaten am Robert Koch-Institut","route":"/institutions/zfkd-rki/","asOf":"2026-09-25","days":3},{"id":"deutsche-krebsgesellschaft","kind":"institution","name":"Deutsche Krebsgesellschaft","route":"/institutions/deutsche-krebsgesellschaft/","asOf":"2026-09-25","days":3},{"id":"nngm","kind":"institution","name":"nationales Netzwerk Genomische Medizin Lungenkrebs","route":"/institutions/nngm/","asOf":"2026-09-25","days":3},{"id":"dnpm","kind":"institution","name":"Deutsches Netzwerk für Personalisierte Medizin","route":"/institutions/dnpm/","asOf":"2026-09-25","days":3},{"id":"technion","kind":"institution","name":"Technion, Israel Institute of Technology","route":"/institutions/technion/","asOf":"2026-09-25","days":3},{"id":"hebrew-university-of-jerusalem","kind":"institution","name":"Hebrew University of Jerusalem","route":"/institutions/hebrew-university-of-jerusalem/","asOf":"2026-09-25","days":3},{"id":"israel-cancer-association","kind":"institution","name":"Israel Cancer Association","route":"/institutions/israel-cancer-association/","asOf":"2026-09-25","days":3},{"id":"iscort","kind":"institution","name":"Israel Society of Clinical Oncology and Radiation Therapy","route":"/institutions/iscort/","asOf":"2026-09-25","days":3},{"id":"israel-national-cancer-registry","kind":"institution","name":"Israel National Cancer Registry","route":"/institutions/israel-national-cancer-registry/","asOf":"2026-09-25","days":3},{"id":"tel-aviv-university","kind":"institution","name":"Tel Aviv University","route":"/institutions/tel-aviv-university/","asOf":"2026-09-25","days":3},{"id":"paper-gross-eshhar-chimeric-receptor-pnas-1989","kind":"paper","name":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","route":"/key-papers/paper-gross-eshhar-chimeric-receptor-pnas-1989/","asOf":"2026-09-25","days":3},{"id":"paper-gabai-kapara-population-brca-screening-pnas-2014","kind":"paper","name":"Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2","route":"/key-papers/paper-gabai-kapara-population-brca-screening-pnas-2014/","asOf":"2026-09-25","days":3},{"id":"paper-besser-til-melanoma-intent-to-treat-ccr-2013","kind":"paper","name":"Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies","route":"/key-papers/paper-besser-til-melanoma-intent-to-treat-ccr-2013/","asOf":"2026-09-25","days":3},{"id":"paper-moore-israel-cancer-registry-completeness-imaj-2021","kind":"paper","name":"An assessment of the completeness and timeliness of the Israel National Cancer Registry","route":"/key-papers/paper-moore-israel-cancer-registry-completeness-imaj-2021/","asOf":"2026-09-25","days":3},{"id":"gortec","kind":"company","name":"GORTEC","route":"/companies/gortec/","asOf":"2026-09-25","days":3},{"id":"german-cll-study-group","kind":"company","name":"German CLL Study Group","route":"/companies/german-cll-study-group/","asOf":"2026-09-25","days":3},{"id":"french-sarcoma-group","kind":"company","name":"French Sarcoma Group","route":"/companies/french-sarcoma-group/","asOf":"2026-09-25","days":3},{"id":"ago-study-group","kind":"company","name":"AGO Study Group","route":"/companies/ago-study-group/","asOf":"2026-09-25","days":3},{"id":"aio","kind":"company","name":"AIO (Arbeitsgemeinschaft Internistische Onkologie)","route":"/companies/aio/","asOf":"2026-09-25","days":3},{"id":"mrc-ctu","kind":"company","name":"MRC Clinical Trials Unit at UCL","route":"/companies/mrc-ctu/","asOf":"2026-09-25","days":3},{"id":"horg","kind":"company","name":"Hellenic Oncology Research Group","route":"/companies/horg/","asOf":"2026-09-25","days":3},{"id":"dpcg","kind":"company","name":"Dutch Pancreatic Cancer Group","route":"/companies/dpcg/","asOf":"2026-09-25","days":3},{"id":"dbcg","kind":"company","name":"Danish Breast Cancer Group","route":"/companies/dbcg/","asOf":"2026-09-25","days":3},{"id":"dahanca","kind":"company","name":"DAHANCA","route":"/companies/dahanca/","asOf":"2026-09-25","days":3},{"id":"gercor","kind":"company","name":"GERCOR","route":"/companies/gercor/","asOf":"2026-09-25","days":3},{"id":"italian-sarcoma-group","kind":"company","name":"Italian Sarcoma Group","route":"/companies/italian-sarcoma-group/","asOf":"2026-09-25","days":3},{"id":"scandinavian-sarcoma-group","kind":"company","name":"Scandinavian Sarcoma Group","route":"/companies/scandinavian-sarcoma-group/","asOf":"2026-09-25","days":3},{"id":"european-myeloma-network","kind":"company","name":"European Myeloma Network","route":"/companies/european-myeloma-network/","asOf":"2026-09-25","days":3},{"id":"ifm","kind":"company","name":"Intergroupe Francophone du Myélome (IFM)","route":"/companies/ifm/","asOf":"2026-09-25","days":3},{"id":"alfa","kind":"company","name":"ALFA (Acute Leukemia French Association)","route":"/companies/alfa/","asOf":"2026-09-25","days":3},{"id":"aids-malignancy-consortium","kind":"company","name":"AIDS Malignancy Consortium","route":"/companies/aids-malignancy-consortium/","asOf":"2026-09-25","days":3},{"id":"ocog","kind":"company","name":"Ontario Clinical Oncology Group","route":"/companies/ocog/","asOf":"2026-09-25","days":3},{"id":"kgog","kind":"company","name":"Korean Gynecologic Oncology Group","route":"/companies/kgog/","asOf":"2026-09-25","days":3},{"id":"sarc","kind":"company","name":"SARC (Sarcoma Alliance for Research through Collaboration)","route":"/companies/sarc/","asOf":"2026-09-25","days":3},{"id":"fondazione-italiana-linfomi","kind":"company","name":"Fondazione Italiana Linfomi","route":"/companies/fondazione-italiana-linfomi/","asOf":"2026-09-25","days":3},{"id":"filo","kind":"company","name":"FILO (French Innovative Leukemia Organisation)","route":"/companies/filo/","asOf":"2026-09-25","days":3},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/","asOf":"2026-09-25","days":3},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/","asOf":"2026-09-25","days":3},{"id":"prostate-low-risk","kind":"cancer","name":"Localised prostate cancer, very low and low risk","route":"/cancers/prostate-low-risk/","asOf":"2026-09-25","days":3},{"id":"prostate-intermediate-risk","kind":"cancer","name":"Localised prostate cancer, intermediate risk","route":"/cancers/prostate-intermediate-risk/","asOf":"2026-09-25","days":3},{"id":"prostate-high-risk","kind":"cancer","name":"Localised prostate cancer, high and very high risk","route":"/cancers/prostate-high-risk/","asOf":"2026-09-25","days":3},{"id":"prostate-bcr","kind":"cancer","name":"Biochemical recurrence of prostate cancer","route":"/cancers/prostate-bcr/","asOf":"2026-09-25","days":3},{"id":"prostate-mhspc","kind":"cancer","name":"Metastatic hormone-sensitive prostate cancer","route":"/cancers/prostate-mhspc/","asOf":"2026-09-25","days":3},{"id":"prostate-nmcrpc","kind":"cancer","name":"Non-metastatic castration-resistant prostate cancer","route":"/cancers/prostate-nmcrpc/","asOf":"2026-09-25","days":3},{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/","asOf":"2026-09-25","days":3},{"id":"prostate-nepc","kind":"cancer","name":"Neuroendocrine and small-cell prostate cancer","route":"/cancers/prostate-nepc/","asOf":"2026-09-25","days":3},{"id":"advanced-cutaneous-scc","kind":"cancer","name":"Advanced cutaneous squamous cell carcinoma","route":"/cancers/advanced-cutaneous-scc/","asOf":"2026-09-25","days":3},{"id":"locally-advanced-bcc","kind":"cancer","name":"Locally advanced and metastatic basal cell carcinoma","route":"/cancers/locally-advanced-bcc/","asOf":"2026-09-25","days":3},{"id":"invasive-breast-carcinoma-no-special-type","kind":"cancer","name":"Invasive breast carcinoma of no special type (invasive ductal carcinoma)","route":"/cancers/invasive-breast-carcinoma-no-special-type/","asOf":"2026-09-25","days":3},{"id":"lobular-carcinoma-in-situ","kind":"cancer","name":"Lobular carcinoma in situ (LCIS)","route":"/cancers/lobular-carcinoma-in-situ/","asOf":"2026-09-25","days":3},{"id":"1746","kind":"year","name":"1746 in oncology","route":"/years/1746/","asOf":"2026-09-25","days":3},{"id":"1775","kind":"year","name":"1775 in oncology","route":"/years/1775/","asOf":"2026-09-25","days":3},{"id":"1777","kind":"year","name":"1777 in oncology","route":"/years/1777/","asOf":"2026-09-25","days":3},{"id":"1806","kind":"year","name":"1806 in oncology","route":"/years/1806/","asOf":"2026-09-25","days":3},{"id":"1809","kind":"year","name":"1809 in oncology","route":"/years/1809/","asOf":"2026-09-25","days":3},{"id":"1812","kind":"year","name":"1812 in oncology","route":"/years/1812/","asOf":"2026-09-25","days":3},{"id":"1814","kind":"year","name":"1814 in oncology","route":"/years/1814/","asOf":"2026-09-25","days":3},{"id":"1823","kind":"year","name":"1823 in oncology","route":"/years/1823/","asOf":"2026-09-25","days":3},{"id":"1832","kind":"year","name":"1832 in oncology","route":"/years/1832/","asOf":"2026-09-25","days":3},{"id":"1834","kind":"year","name":"1834 in oncology","route":"/years/1834/","asOf":"2026-09-25","days":3},{"id":"1838","kind":"year","name":"1838 in oncology","route":"/years/1838/","asOf":"2026-09-25","days":3},{"id":"1840","kind":"year","name":"1840 in oncology","route":"/years/1840/","asOf":"2026-09-25","days":3},{"id":"1842","kind":"year","name":"1842 in oncology","route":"/years/1842/","asOf":"2026-09-25","days":3},{"id":"1844","kind":"year","name":"1844 in oncology","route":"/years/1844/","asOf":"2026-09-25","days":3},{"id":"1845","kind":"year","name":"1845 in oncology","route":"/years/1845/","asOf":"2026-09-25","days":3},{"id":"1855","kind":"year","name":"1855 in oncology","route":"/years/1855/","asOf":"2026-09-25","days":3},{"id":"1857","kind":"year","name":"1857 in oncology","route":"/years/1857/","asOf":"2026-09-25","days":3},{"id":"1859","kind":"year","name":"1859 in oncology","route":"/years/1859/","asOf":"2026-09-25","days":3},{"id":"1869","kind":"year","name":"1869 in oncology","route":"/years/1869/","asOf":"2026-09-25","days":3},{"id":"1870","kind":"year","name":"1870 in oncology","route":"/years/1870/","asOf":"2026-09-25","days":3},{"id":"1872","kind":"year","name":"1872 in oncology","route":"/years/1872/","asOf":"2026-09-25","days":3},{"id":"1873","kind":"year","name":"1873 in oncology","route":"/years/1873/","asOf":"2026-09-25","days":3},{"id":"1874","kind":"year","name":"1874 in oncology","route":"/years/1874/","asOf":"2026-09-25","days":3},{"id":"1875","kind":"year","name":"1875 in oncology","route":"/years/1875/","asOf":"2026-09-25","days":3},{"id":"1878","kind":"year","name":"1878 in oncology","route":"/years/1878/","asOf":"2026-09-25","days":3},{"id":"1879","kind":"year","name":"1879 in oncology","route":"/years/1879/","asOf":"2026-09-25","days":3},{"id":"1880","kind":"year","name":"1880 in oncology","route":"/years/1880/","asOf":"2026-09-25","days":3},{"id":"1881","kind":"year","name":"1881 in oncology","route":"/years/1881/","asOf":"2026-09-25","days":3},{"id":"1882","kind":"year","name":"1882 in oncology","route":"/years/1882/","asOf":"2026-09-25","days":3},{"id":"1883","kind":"year","name":"1883 in oncology","route":"/years/1883/","asOf":"2026-09-25","days":3},{"id":"1884","kind":"year","name":"1884 in oncology","route":"/years/1884/","asOf":"2026-09-25","days":3},{"id":"1886","kind":"year","name":"1886 in oncology","route":"/years/1886/","asOf":"2026-09-25","days":3},{"id":"1887","kind":"year","name":"1887 in oncology","route":"/years/1887/","asOf":"2026-09-25","days":3},{"id":"1888","kind":"year","name":"1888 in oncology","route":"/years/1888/","asOf":"2026-09-25","days":3},{"id":"1889","kind":"year","name":"1889 in oncology","route":"/years/1889/","asOf":"2026-09-25","days":3},{"id":"1892","kind":"year","name":"1892 in oncology","route":"/years/1892/","asOf":"2026-09-25","days":3},{"id":"1894","kind":"year","name":"1894 in oncology","route":"/years/1894/","asOf":"2026-09-25","days":3},{"id":"1896","kind":"year","name":"1896 in oncology","route":"/years/1896/","asOf":"2026-09-25","days":3},{"id":"1898","kind":"year","name":"1898 in oncology","route":"/years/1898/","asOf":"2026-09-25","days":3},{"id":"1899","kind":"year","name":"1899 in oncology","route":"/years/1899/","asOf":"2026-09-25","days":3},{"id":"1900","kind":"year","name":"1900 in oncology","route":"/years/1900/","asOf":"2026-09-25","days":3},{"id":"1901","kind":"year","name":"1901 in oncology","route":"/years/1901/","asOf":"2026-09-25","days":3},{"id":"1902","kind":"year","name":"1902 in oncology","route":"/years/1902/","asOf":"2026-09-25","days":3},{"id":"1903","kind":"year","name":"1903 in oncology","route":"/years/1903/","asOf":"2026-09-25","days":3},{"id":"1904","kind":"year","name":"1904 in oncology","route":"/years/1904/","asOf":"2026-09-25","days":3},{"id":"1905","kind":"year","name":"1905 in oncology","route":"/years/1905/","asOf":"2026-09-25","days":3},{"id":"1906","kind":"year","name":"1906 in oncology","route":"/years/1906/","asOf":"2026-09-25","days":3},{"id":"1907","kind":"year","name":"1907 in oncology","route":"/years/1907/","asOf":"2026-09-25","days":3},{"id":"1908","kind":"year","name":"1908 in oncology","route":"/years/1908/","asOf":"2026-09-25","days":3},{"id":"1909","kind":"year","name":"1909 in oncology","route":"/years/1909/","asOf":"2026-09-25","days":3},{"id":"1910","kind":"year","name":"1910 in oncology","route":"/years/1910/","asOf":"2026-09-25","days":3},{"id":"1911","kind":"year","name":"1911 in oncology","route":"/years/1911/","asOf":"2026-09-25","days":3},{"id":"1912","kind":"year","name":"1912 in oncology","route":"/years/1912/","asOf":"2026-09-25","days":3},{"id":"1913","kind":"year","name":"1913 in oncology","route":"/years/1913/","asOf":"2026-09-25","days":3},{"id":"1914","kind":"year","name":"1914 in oncology","route":"/years/1914/","asOf":"2026-09-25","days":3},{"id":"1915","kind":"year","name":"1915 in oncology","route":"/years/1915/","asOf":"2026-09-25","days":3},{"id":"1916","kind":"year","name":"1916 in oncology","route":"/years/1916/","asOf":"2026-09-25","days":3},{"id":"1917","kind":"year","name":"1917 in oncology","route":"/years/1917/","asOf":"2026-09-25","days":3},{"id":"1918","kind":"year","name":"1918 in oncology","route":"/years/1918/","asOf":"2026-09-25","days":3},{"id":"1919","kind":"year","name":"1919 in oncology","route":"/years/1919/","asOf":"2026-09-25","days":3},{"id":"1920","kind":"year","name":"1920 in oncology","route":"/years/1920/","asOf":"2026-09-25","days":3},{"id":"1921","kind":"year","name":"1921 in oncology","route":"/years/1921/","asOf":"2026-09-25","days":3},{"id":"1922","kind":"year","name":"1922 in oncology","route":"/years/1922/","asOf":"2026-09-25","days":3},{"id":"1923","kind":"year","name":"1923 in oncology","route":"/years/1923/","asOf":"2026-09-25","days":3},{"id":"1924","kind":"year","name":"1924 in oncology","route":"/years/1924/","asOf":"2026-09-25","days":3},{"id":"1925","kind":"year","name":"1925 in oncology","route":"/years/1925/","asOf":"2026-09-25","days":3},{"id":"1926","kind":"year","name":"1926 in oncology","route":"/years/1926/","asOf":"2026-09-25","days":3},{"id":"1927","kind":"year","name":"1927 in oncology","route":"/years/1927/","asOf":"2026-09-25","days":3},{"id":"1928","kind":"year","name":"1928 in oncology","route":"/years/1928/","asOf":"2026-09-25","days":3},{"id":"1929","kind":"year","name":"1929 in oncology","route":"/years/1929/","asOf":"2026-09-25","days":3},{"id":"1930","kind":"year","name":"1930 in oncology","route":"/years/1930/","asOf":"2026-09-25","days":3},{"id":"1931","kind":"year","name":"1931 in oncology","route":"/years/1931/","asOf":"2026-09-25","days":3},{"id":"1932","kind":"year","name":"1932 in oncology","route":"/years/1932/","asOf":"2026-09-25","days":3},{"id":"1933","kind":"year","name":"1933 in oncology","route":"/years/1933/","asOf":"2026-09-25","days":3},{"id":"1934","kind":"year","name":"1934 in oncology","route":"/years/1934/","asOf":"2026-09-25","days":3},{"id":"1935","kind":"year","name":"1935 in oncology","route":"/years/1935/","asOf":"2026-09-25","days":3},{"id":"1936","kind":"year","name":"1936 in oncology","route":"/years/1936/","asOf":"2026-09-25","days":3},{"id":"1937","kind":"year","name":"1937 in oncology","route":"/years/1937/","asOf":"2026-09-25","days":3},{"id":"1938","kind":"year","name":"1938 in oncology","route":"/years/1938/","asOf":"2026-09-25","days":3},{"id":"1939","kind":"year","name":"1939 in oncology","route":"/years/1939/","asOf":"2026-09-25","days":3},{"id":"1940","kind":"year","name":"1940 in oncology","route":"/years/1940/","asOf":"2026-09-25","days":3},{"id":"1941","kind":"year","name":"1941 in oncology","route":"/years/1941/","asOf":"2026-09-25","days":3},{"id":"1942","kind":"year","name":"1942 in oncology","route":"/years/1942/","asOf":"2026-09-25","days":3},{"id":"1943","kind":"year","name":"1943 in oncology","route":"/years/1943/","asOf":"2026-09-25","days":3},{"id":"1944","kind":"year","name":"1944 in oncology","route":"/years/1944/","asOf":"2026-09-25","days":3},{"id":"1945","kind":"year","name":"1945 in oncology","route":"/years/1945/","asOf":"2026-09-25","days":3},{"id":"1946","kind":"year","name":"1946 in oncology","route":"/years/1946/","asOf":"2026-09-25","days":3},{"id":"1947","kind":"year","name":"1947 in oncology","route":"/years/1947/","asOf":"2026-09-25","days":3},{"id":"1948","kind":"year","name":"1948 in oncology","route":"/years/1948/","asOf":"2026-09-25","days":3},{"id":"1949","kind":"year","name":"1949 in oncology","route":"/years/1949/","asOf":"2026-09-25","days":3},{"id":"1950","kind":"year","name":"1950 in oncology","route":"/years/1950/","asOf":"2026-09-25","days":3},{"id":"1951","kind":"year","name":"1951 in oncology","route":"/years/1951/","asOf":"2026-09-25","days":3},{"id":"1952","kind":"year","name":"1952 in oncology","route":"/years/1952/","asOf":"2026-09-25","days":3},{"id":"1953","kind":"year","name":"1953 in oncology","route":"/years/1953/","asOf":"2026-09-25","days":3},{"id":"1954","kind":"year","name":"1954 in oncology","route":"/years/1954/","asOf":"2026-09-25","days":3},{"id":"1955","kind":"year","name":"1955 in oncology","route":"/years/1955/","asOf":"2026-09-25","days":3},{"id":"1956","kind":"year","name":"1956 in oncology","route":"/years/1956/","asOf":"2026-09-25","days":3},{"id":"1957","kind":"year","name":"1957 in oncology","route":"/years/1957/","asOf":"2026-09-25","days":3},{"id":"1958","kind":"year","name":"1958 in oncology","route":"/years/1958/","asOf":"2026-09-25","days":3},{"id":"1959","kind":"year","name":"1959 in oncology","route":"/years/1959/","asOf":"2026-09-25","days":3},{"id":"1960","kind":"year","name":"1960 in oncology","route":"/years/1960/","asOf":"2026-09-25","days":3},{"id":"1961","kind":"year","name":"1961 in oncology","route":"/years/1961/","asOf":"2026-09-25","days":3},{"id":"1962","kind":"year","name":"1962 in oncology","route":"/years/1962/","asOf":"2026-09-25","days":3},{"id":"1963","kind":"year","name":"1963 in oncology","route":"/years/1963/","asOf":"2026-09-25","days":3},{"id":"1964","kind":"year","name":"1964 in oncology","route":"/years/1964/","asOf":"2026-09-25","days":3},{"id":"1965","kind":"year","name":"1965 in oncology","route":"/years/1965/","asOf":"2026-09-25","days":3},{"id":"1966","kind":"year","name":"1966 in oncology","route":"/years/1966/","asOf":"2026-09-25","days":3},{"id":"1967","kind":"year","name":"1967 in oncology","route":"/years/1967/","asOf":"2026-09-25","days":3},{"id":"1968","kind":"year","name":"1968 in oncology","route":"/years/1968/","asOf":"2026-09-25","days":3},{"id":"1969","kind":"year","name":"1969 in oncology","route":"/years/1969/","asOf":"2026-09-25","days":3},{"id":"1970","kind":"year","name":"1970 in oncology","route":"/years/1970/","asOf":"2026-09-25","days":3},{"id":"1971","kind":"year","name":"1971 in oncology","route":"/years/1971/","asOf":"2026-09-25","days":3},{"id":"1972","kind":"year","name":"1972 in oncology","route":"/years/1972/","asOf":"2026-09-25","days":3},{"id":"1973","kind":"year","name":"1973 in oncology","route":"/years/1973/","asOf":"2026-09-25","days":3},{"id":"1974","kind":"year","name":"1974 in oncology","route":"/years/1974/","asOf":"2026-09-25","days":3},{"id":"1975","kind":"year","name":"1975 in oncology","route":"/years/1975/","asOf":"2026-09-25","days":3},{"id":"1976","kind":"year","name":"1976 in oncology","route":"/years/1976/","asOf":"2026-09-25","days":3},{"id":"1977","kind":"year","name":"1977 in oncology","route":"/years/1977/","asOf":"2026-09-25","days":3},{"id":"1978","kind":"year","name":"1978 in oncology","route":"/years/1978/","asOf":"2026-09-25","days":3},{"id":"1979","kind":"year","name":"1979 in oncology","route":"/years/1979/","asOf":"2026-09-25","days":3},{"id":"1980","kind":"year","name":"1980 in oncology","route":"/years/1980/","asOf":"2026-09-25","days":3},{"id":"1981","kind":"year","name":"1981 in oncology","route":"/years/1981/","asOf":"2026-09-25","days":3},{"id":"1982","kind":"year","name":"1982 in oncology","route":"/years/1982/","asOf":"2026-09-25","days":3},{"id":"1983","kind":"year","name":"1983 in oncology","route":"/years/1983/","asOf":"2026-09-25","days":3},{"id":"1984","kind":"year","name":"1984 in oncology","route":"/years/1984/","asOf":"2026-09-25","days":3},{"id":"1985","kind":"year","name":"1985 in oncology","route":"/years/1985/","asOf":"2026-09-25","days":3},{"id":"1986","kind":"year","name":"1986 in oncology","route":"/years/1986/","asOf":"2026-09-25","days":3},{"id":"1987","kind":"year","name":"1987 in oncology","route":"/years/1987/","asOf":"2026-09-25","days":3},{"id":"1988","kind":"year","name":"1988 in oncology","route":"/years/1988/","asOf":"2026-09-25","days":3},{"id":"1989","kind":"year","name":"1989 in oncology","route":"/years/1989/","asOf":"2026-09-25","days":3},{"id":"1990","kind":"year","name":"1990 in oncology","route":"/years/1990/","asOf":"2026-09-25","days":3},{"id":"1991","kind":"year","name":"1991 in oncology","route":"/years/1991/","asOf":"2026-09-25","days":3},{"id":"1992","kind":"year","name":"1992 in oncology","route":"/years/1992/","asOf":"2026-09-25","days":3},{"id":"1993","kind":"year","name":"1993 in oncology","route":"/years/1993/","asOf":"2026-09-25","days":3},{"id":"1994","kind":"year","name":"1994 in oncology","route":"/years/1994/","asOf":"2026-09-25","days":3},{"id":"1995","kind":"year","name":"1995 in oncology","route":"/years/1995/","asOf":"2026-09-25","days":3},{"id":"1996","kind":"year","name":"1996 in oncology","route":"/years/1996/","asOf":"2026-09-25","days":3},{"id":"1997","kind":"year","name":"1997 in oncology","route":"/years/1997/","asOf":"2026-09-25","days":3},{"id":"1998","kind":"year","name":"1998 in oncology","route":"/years/1998/","asOf":"2026-09-25","days":3},{"id":"1999","kind":"year","name":"1999 in oncology","route":"/years/1999/","asOf":"2026-09-25","days":3},{"id":"2000","kind":"year","name":"2000 in oncology","route":"/years/2000/","asOf":"2026-09-25","days":3},{"id":"2001","kind":"year","name":"2001 in oncology","route":"/years/2001/","asOf":"2026-09-25","days":3},{"id":"2002","kind":"year","name":"2002 in oncology","route":"/years/2002/","asOf":"2026-09-25","days":3},{"id":"2003","kind":"year","name":"2003 in oncology","route":"/years/2003/","asOf":"2026-09-25","days":3},{"id":"2004","kind":"year","name":"2004 in oncology","route":"/years/2004/","asOf":"2026-09-25","days":3},{"id":"2005","kind":"year","name":"2005 in oncology","route":"/years/2005/","asOf":"2026-09-25","days":3},{"id":"2006","kind":"year","name":"2006 in oncology","route":"/years/2006/","asOf":"2026-09-25","days":3},{"id":"2007","kind":"year","name":"2007 in oncology","route":"/years/2007/","asOf":"2026-09-25","days":3},{"id":"2008","kind":"year","name":"2008 in oncology","route":"/years/2008/","asOf":"2026-09-25","days":3},{"id":"2009","kind":"year","name":"2009 in oncology","route":"/years/2009/","asOf":"2026-09-25","days":3},{"id":"2010","kind":"year","name":"2010 in oncology","route":"/years/2010/","asOf":"2026-09-25","days":3},{"id":"2011","kind":"year","name":"2011 in oncology","route":"/years/2011/","asOf":"2026-09-25","days":3},{"id":"2012","kind":"year","name":"2012 in oncology","route":"/years/2012/","asOf":"2026-09-25","days":3},{"id":"2013","kind":"year","name":"2013 in oncology","route":"/years/2013/","asOf":"2026-09-25","days":3},{"id":"2014","kind":"year","name":"2014 in oncology","route":"/years/2014/","asOf":"2026-09-25","days":3},{"id":"2015","kind":"year","name":"2015 in oncology","route":"/years/2015/","asOf":"2026-09-25","days":3},{"id":"2016","kind":"year","name":"2016 in oncology","route":"/years/2016/","asOf":"2026-09-25","days":3},{"id":"2017","kind":"year","name":"2017 in oncology","route":"/years/2017/","asOf":"2026-09-25","days":3},{"id":"2018","kind":"year","name":"2018 in oncology","route":"/years/2018/","asOf":"2026-09-25","days":3},{"id":"2019","kind":"year","name":"2019 in oncology","route":"/years/2019/","asOf":"2026-09-25","days":3},{"id":"2020","kind":"year","name":"2020 in oncology","route":"/years/2020/","asOf":"2026-09-25","days":3},{"id":"2021","kind":"year","name":"2021 in oncology","route":"/years/2021/","asOf":"2026-09-25","days":3},{"id":"2022","kind":"year","name":"2022 in oncology","route":"/years/2022/","asOf":"2026-09-25","days":3},{"id":"2023","kind":"year","name":"2023 in oncology","route":"/years/2023/","asOf":"2026-09-25","days":3},{"id":"2024","kind":"year","name":"2024 in oncology","route":"/years/2024/","asOf":"2026-09-25","days":3},{"id":"2025","kind":"year","name":"2025 in oncology","route":"/years/2025/","asOf":"2026-09-25","days":3},{"id":"2026","kind":"year","name":"2026 in oncology","route":"/years/2026/","asOf":"2026-09-25","days":3},{"id":"2027","kind":"year","name":"2027 in oncology","route":"/years/2027/","asOf":"2026-09-25","days":3},{"id":"2028","kind":"year","name":"2028 in oncology","route":"/years/2028/","asOf":"2026-09-25","days":3},{"id":"2029","kind":"year","name":"2029 in oncology","route":"/years/2029/","asOf":"2026-09-25","days":3},{"id":"2030","kind":"year","name":"2030 in oncology","route":"/years/2030/","asOf":"2026-09-25","days":3},{"id":"2031","kind":"year","name":"2031 in oncology","route":"/years/2031/","asOf":"2026-09-25","days":3},{"id":"2032","kind":"year","name":"2032 in oncology","route":"/years/2032/","asOf":"2026-09-25","days":3},{"id":"2033","kind":"year","name":"2033 in oncology","route":"/years/2033/","asOf":"2026-09-25","days":3}],"summary":{"future-year":1,"soc-cites-dead":18,"approvals-vs-regional":125,"asof-before-regulatory-event":2,"duplicate-name":174,"future-year-in-text":3313,"near-duplicate-levenshtein":27,"outcome-no-source":47,"pipeline-cites-dead":10,"positive-hr-ge-1":5,"spike-scalar-divergence":6,"status-vs-approvals":25,"text-vs-structured":13,"unsourced-numbers":37,"approved-only-live-trials":79,"name-collision-across-kinds":342,"near-duplicate-name":8,"orphan":112,"regional-approval-only":1,"text-says-approved":29,"unsourced":358}}